data_1xsf_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 1xsf _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.484 ' O ' HG13 ' A' ' 30' ' ' ILE . 14.0 m-20 . . . . . 0 N--CA 1.445 -0.687 0 CA-C-O 121.73 0.776 . . . . 0.0 109.009 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . 0.401 ' HA2' ' HB2' ' A' ' 31' ' ' TRP . . . -64.27 -10.51 41.96 Favored Glycine 0 N--CA 1.441 -1.008 0 CA-C-N 114.572 -1.194 . . . . 0.0 110.55 174.198 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 47.0 m -76.32 -37.44 57.38 Favored 'General case' 0 N--CA 1.45 -0.464 0 CA-C-O 121.268 0.556 . . . . 0.0 109.867 175.363 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.599 ' HA ' ' HB1' ' A' ' 105' ' ' ALA . 0.2 OUTLIER -69.23 -36.27 71.93 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 N-CA-C 107.718 -1.216 . . . . 0.0 107.718 175.468 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' TRP . . . . . 0.528 ' CH2' ' HB2' ' A' ' 86' ' ' ALA . 42.1 m95 -70.55 -36.31 73.6 Favored 'General case' 0 C--N 1.318 -0.786 0 CA-C-N 114.401 -1.272 . . . . 0.0 110.487 -179.226 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.848 ' HB2' HH21 ' A' ' 79' ' ' ARG . 23.6 t70 -76.43 -37.66 56.67 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.583 179.271 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . 0.504 ' HB2' ' CB ' ' A' ' 105' ' ' ALA . . . -69.58 -33.98 73.5 Favored 'General case' 0 N--CA 1.447 -0.599 0 C-N-CA 120.852 -0.339 . . . . 0.0 110.62 178.331 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . 0.542 HG13 ' O ' ' A' ' 30' ' ' ILE . 78.0 mt -64.29 -47.48 89.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-O 121.009 0.433 . . . . 0.0 110.001 172.443 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . 0.41 ' HA ' ' O ' ' A' ' 54' ' ' GLY . . . -57.87 -39.79 78.64 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.681 -0.69 . . . . 0.0 110.169 177.446 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . 0.517 ' HA2' ' N ' ' A' ' 41' ' ' GLY . . . -70.26 -18.14 74.76 Favored Glycine 0 N--CA 1.453 -0.202 0 CA-C-N 115.501 -0.772 . . . . 0.0 112.135 179.496 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 26.4 t -90.94 -53.04 4.56 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-O 120.931 0.396 . . . . 0.0 111.419 -178.402 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 6.9 tp10 -87.23 -33.2 19.39 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.289 -170.747 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -105.5 -10.63 16.79 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.809 -0.632 . . . . 0.0 111.606 -177.528 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 78.95 14.68 81.72 Favored Glycine 0 CA--C 1.504 -0.598 0 N-CA-C 109.75 -1.34 . . . . 0.0 109.75 -175.206 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . 0.517 ' N ' ' HA2' ' A' ' 36' ' ' GLY . . . 78.49 63.25 2.15 Favored Glycine 0 N--CA 1.434 -1.481 0 CA-C-N 114.019 -1.091 . . . . 0.0 111.514 -175.571 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 2.4 t-20 -145.91 96.81 2.86 Favored 'General case' 0 N--CA 1.447 -0.576 0 N-CA-C 109.442 -0.577 . . . . 0.0 109.442 -177.451 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' TRP . . . . . 0.707 ' CE3' ' HA ' ' A' ' 79' ' ' ARG . 29.9 m95 -83.65 -4.1 58.31 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-N 115.561 -0.745 . . . . 0.0 110.385 -175.145 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -109.26 14.65 23.67 Favored 'General case' 0 C--N 1.315 -0.925 0 CA-C-N 114.805 -1.089 . . . . 0.0 110.282 178.017 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.951 HG21 ' HA2' ' A' ' 53' ' ' GLY . 8.9 tt -78.02 139.08 19.14 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.038 0 CA-C-O 121.509 0.671 . . . . 0.0 110.197 -179.148 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 13.1 t-20 -139.86 76.58 1.57 Allowed 'General case' 0 C--N 1.308 -1.2 0 N-CA-C 108.593 -0.892 . . . . 0.0 108.593 177.865 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 5.1 p -57.6 -29.2 64.3 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 114.366 -1.288 . . . . 0.0 110.997 -178.982 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 96.06 22.81 19.11 Favored Glycine 0 N--CA 1.437 -1.252 0 N-CA-C 110.922 -0.871 . . . . 0.0 110.922 178.552 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 39.0 p-10 -102.8 4.25 37.65 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 120.881 0.372 . . . . 0.0 111.015 -177.085 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . 0.431 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 94.82 -8.09 70.63 Favored Glycine 0 N--CA 1.448 -0.55 0 N-CA-C 111.535 -0.626 . . . . 0.0 111.535 178.639 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' TYR . . . . . 0.505 ' HA ' ' HA ' ' A' ' 58' ' ' ASP . 0.5 OUTLIER -112.64 132.94 54.93 Favored 'General case' 0 N--CA 1.446 -0.65 0 N-CA-C 106.71 -1.589 . . . . 0.0 106.71 -179.094 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' TYR . . . . . 0.533 ' O ' ' HA ' ' A' ' 56' ' ' GLN . 50.6 m-85 -104.64 171.36 7.37 Favored 'General case' 0 C--N 1.304 -1.375 0 N-CA-C 113.225 0.824 . . . . 0.0 113.225 -165.747 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.951 ' HA2' HG21 ' A' ' 45' ' ' ILE . . . -48.46 155.33 1.47 Allowed Glycine 0 N--CA 1.45 -0.373 0 CA-C-N 114.783 -1.099 . . . . 0.0 115.833 -170.204 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . 0.701 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 94.13 -106.41 3.41 Favored Glycine 0 N--CA 1.438 -1.172 0 CA-C-N 114.706 -0.747 . . . . 0.0 112.179 174.756 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -84.29 -1.52 6.44 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 CA-C-O 121.246 0.546 . . . . 0.0 111.534 -178.812 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' GLN . . . . . 0.533 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 5.4 mm-40 59.21 50.39 8.01 Favored 'General case' 0 N--CA 1.467 0.409 0 CA-C-N 114.502 -1.227 . . . . 0.0 113.965 167.059 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -116.23 160.07 20.94 Favored 'General case' 0 C--N 1.326 -0.431 0 C-N-CA 119.804 -0.758 . . . . 0.0 111.569 173.693 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.505 ' HA ' ' HA ' ' A' ' 51' ' ' TYR . 7.3 p-10 -71.11 160.78 32.27 Favored 'General case' 0 C--N 1.324 -0.506 0 N-CA-C 113.797 1.036 . . . . 0.0 113.797 -163.451 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . 0.729 ' HA ' HE21 ' A' ' 59' ' ' GLN . 0.0 OUTLIER -55.36 -39.96 70.71 Favored 'General case' 0 N--CA 1.446 -0.65 0 CA-C-N 113.987 -1.46 . . . . 0.0 111.438 178.056 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -67.65 -48.66 54.98 Favored Glycine 0 C--O 1.225 -0.467 0 CA-C-N 115.417 -0.81 . . . . 0.0 112.042 -175.816 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 89.0 m -66.4 -40.63 89.74 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-O 121.067 0.46 . . . . 0.0 110.641 177.226 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' TRP . . . . . 0.488 ' HZ3' ' HG3' ' A' ' 82' ' ' GLN . 56.9 t-105 -56.48 -48.98 75.98 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-O 121.622 0.725 . . . . 0.0 109.5 175.407 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . 0.775 ' HG3' HD11 ' A' ' 68' ' ' LEU . 27.9 tt0 -66.85 -34.33 77.56 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 115.015 -0.993 . . . . 0.0 110.985 179.845 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -63.96 -41.86 97.44 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.968 -0.56 . . . . 0.0 111.454 -177.441 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 36.5 m-80 -81.52 -7.86 59.64 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.079 -0.51 . . . . 0.0 109.983 175.618 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . 0.452 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 83.29 48.34 5.39 Favored Glycine 0 N--CA 1.45 -0.413 0 CA-C-N 115.507 -0.769 . . . . 0.0 112.647 174.975 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . 0.64 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -79.68 -15.98 78.43 Favored Glycine 0 CA--C 1.504 -0.649 0 C-N-CA 120.87 -0.681 . . . . 0.0 111.904 -176.352 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 0.775 HD11 ' HG3' ' A' ' 63' ' ' GLU . 19.2 mt -61.72 -28.83 69.7 Favored 'General case' 0 C--N 1.314 -0.97 0 C-N-CA 123.346 0.659 . . . . 0.0 111.956 -172.953 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . 0.452 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 5.6 ptp180 -68.05 -28.45 67.39 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-O 121.557 0.694 . . . . 0.0 109.789 178.861 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 70' ' ' TYR . . . . . 0.728 ' HB3' ' HG2' ' A' ' 81' ' ' GLU . 89.0 m-85 -81.47 -34.66 31.26 Favored 'General case' 0 N--CA 1.439 -0.983 0 N-CA-C 107.872 -1.158 . . . . 0.0 107.872 176.848 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.571 ' HB2' ' HB3' ' A' ' 77' ' ' ALA . . . 165.33 125.22 0.02 OUTLIER Pre-proline 0 N--CA 1.445 -0.687 0 CA-C-N 112.336 -2.211 . . . . 0.0 107.115 -179.296 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 72' ' ' PRO . . . . . 0.552 ' HA ' ' HA ' ' A' ' 68' ' ' LEU . 26.8 Cg_exo -53.71 -5.97 0.36 Allowed 'Trans proline' 0 C--N 1.334 -0.232 0 C-N-CA 123.14 2.56 . . . . 0.0 114.169 -178.745 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 11.2 ptm180 -148.28 141.0 24.57 Favored 'General case' 0 C--N 1.314 -0.966 0 N-CA-C 109.231 -0.655 . . . . 0.0 109.231 175.387 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -60.72 -27.01 67.59 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.674 -0.694 . . . . 0.0 112.65 -176.39 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . 0.58 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 3.5 p30 -80.08 -5.95 56.81 Favored 'General case' 0 C--N 1.322 -0.618 0 C-N-CA 120.007 -0.677 . . . . 0.0 110.921 -177.785 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.53 ' HB3' ' HB1' ' A' ' 71' ' ' ALA . 59.2 tp -97.89 -32.72 11.54 Favored 'General case' 0 C--N 1.321 -0.66 0 N-CA-C 109.113 -0.699 . . . . 0.0 109.113 174.815 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . 0.686 ' HB1' ' CB ' ' A' ' 81' ' ' GLU . . . -79.68 164.29 23.87 Favored 'General case' 0 N--CA 1.447 -0.586 0 CA-C-N 115.243 -0.889 . . . . 0.0 109.911 174.485 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 42.8 p -101.13 -173.89 2.48 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 116.573 -0.285 . . . . 0.0 110.801 -177.879 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . 0.848 HH21 ' HB2' ' A' ' 32' ' ' ASP . 41.2 mtp180 -50.42 -52.58 36.38 Favored 'General case' 0 CA--C 1.515 -0.402 0 CA-C-O 121.218 0.532 . . . . 0.0 111.295 -178.137 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 80' ' ' GLU . . . . . 0.692 ' HA ' HD13 ' A' ' 83' ' ' ILE . 6.9 pt-20 -66.0 -27.77 68.38 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-N 115.139 -0.937 . . . . 0.0 112.061 -173.873 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 81' ' ' GLU . . . . . 0.728 ' HG2' ' HB3' ' A' ' 70' ' ' TYR . 3.2 mp0 -72.83 -46.26 54.03 Favored 'General case' 0 C--N 1.324 -0.507 0 C-N-CA 120.762 -0.375 . . . . 0.0 111.758 174.239 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 82' ' ' GLN . . . . . 0.613 ' HB2' ' HZ3' ' A' ' 43' ' ' TRP . 0.1 OUTLIER -58.96 -34.72 72.12 Favored 'General case' 0 CA--C 1.506 -0.735 0 N-CA-C 109.108 -0.701 . . . . 0.0 109.108 175.125 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . 0.692 HD13 ' HA ' ' A' ' 80' ' ' GLU . 60.3 mt -60.62 -48.75 87.28 Favored 'Isoleucine or valine' 0 C--O 1.211 -0.957 0 CA-C-N 114.731 -1.122 . . . . 0.0 110.022 173.636 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 84' ' ' ALA . . . . . 0.62 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -63.67 -45.26 90.91 Favored 'General case' 0 C--O 1.238 0.452 0 CA-C-O 121.439 0.637 . . . . 0.0 111.897 -174.98 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . 0.477 HG22 ' HA2' ' A' ' 67' ' ' GLY . 34.8 t -66.52 -48.1 81.58 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.775 0 CA-C-N 115.756 -0.656 . . . . 0.0 110.651 -179.206 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 86' ' ' ALA . . . . . 0.528 ' HB2' ' CH2' ' A' ' 31' ' ' TRP . . . -61.46 -28.08 69.03 Favored 'General case' 0 N--CA 1.45 -0.45 0 CA-C-N 115.468 -0.787 . . . . 0.0 110.415 174.976 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 87' ' ' GLU . . . . . 0.678 ' HG2' ' O ' ' A' ' 83' ' ' ILE . 36.0 mm-40 -59.09 -43.37 91.84 Favored 'General case' 0 CA--C 1.513 -0.457 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.63 179.78 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.512 ' O ' ' HG3' ' A' ' 92' ' ' ARG . 48.8 t -65.27 -42.8 94.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 C-N-CA 120.385 -0.526 . . . . 0.0 109.893 175.851 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 89' ' ' THR . . . . . 0.743 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 0.2 OUTLIER -66.82 -46.88 73.75 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 115.956 -0.565 . . . . 0.0 111.465 -175.271 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 90' ' ' ARG . . . . . 0.474 ' HG3' ' N ' ' A' ' 91' ' ' LEU . 4.9 ptt180 -66.09 -31.18 71.9 Favored 'General case' 0 C--O 1.218 -0.577 0 CA-C-O 122.042 0.925 . . . . 0.0 109.083 -179.018 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 91' ' ' LEU . . . . . 0.474 ' N ' ' HG3' ' A' ' 90' ' ' ARG . 56.3 tp -61.84 -30.5 70.89 Favored 'General case' 0 C--N 1.308 -1.211 0 CA-C-N 114.494 -1.23 . . . . 0.0 111.509 -175.633 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . 0.512 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 7.6 mtm180 -90.68 -45.73 8.69 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-N 115.559 -0.746 . . . . 0.0 110.205 -175.402 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 93' ' ' GLN . . . . . 0.475 ' NE2' HG22 ' A' ' 89' ' ' THR . 21.1 pt20 -104.03 -27.32 12.2 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 114.897 -1.047 . . . . 0.0 113.039 -169.923 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 106.75 -107.71 2.74 Favored Glycine 0 N--CA 1.44 -1.034 0 N-CA-C 109.134 -1.586 . . . . 0.0 109.134 -175.214 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 95' ' ' TRP . . . . . 0.546 ' CZ2' HD12 ' A' ' 30' ' ' ILE . 29.7 m95 -138.51 21.56 2.73 Favored 'General case' 0 C--N 1.308 -1.21 0 N-CA-C 106.348 -1.723 . . . . 0.0 106.348 172.995 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -56.26 -35.16 64.31 Favored Glycine 0 C--N 1.335 0.514 0 CA-C-N 114.706 -1.134 . . . . 0.0 112.901 179.752 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . 0.401 ' HB1' ' OE1' ' A' ' 93' ' ' GLN . . . -79.25 -15.38 58.1 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.78 0.324 . . . . 0.0 110.533 178.092 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 98' ' ' TRP . . . . . 0.743 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 24.7 m-90 -104.92 107.81 59.59 Favored Pre-proline 0 C--N 1.323 -0.572 0 CA-C-O 121.459 0.647 . . . . 0.0 110.019 178.722 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 99' ' ' PRO . . . . . 0.419 ' HD3' ' HA ' ' A' ' 98' ' ' TRP . 37.6 Cg_exo -64.73 -139.39 0.01 OUTLIER 'Trans proline' 0 CA--C 1.534 0.52 0 C-N-CA 123.764 2.976 . . . . 0.0 114.762 -174.102 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . 0.567 ' O ' ' HD2' ' A' ' 104' ' ' ARG . 23.8 t -55.89 -25.84 19.67 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.266 0 CA-C-N 115.441 -0.8 . . . . 0.0 110.746 -178.126 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 89.9 m -60.12 -38.73 83.91 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.321 176.907 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 102' ' ' ALA . . . . . 0.541 ' HB2' ' HB3' ' A' ' 98' ' ' TRP . . . -70.48 -41.2 73.02 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.686 0.279 . . . . 0.0 110.452 178.434 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -59.63 -44.81 93.33 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 121.189 0.519 . . . . 0.0 110.025 178.208 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 104' ' ' ARG . . . . . 0.567 ' HD2' ' O ' ' A' ' 100' ' ' VAL . 0.0 OUTLIER -62.52 -37.01 84.42 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.393 -0.821 . . . . 0.0 111.052 176.787 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 105' ' ' ALA . . . . . 0.599 ' HB1' ' HA ' ' A' ' 30' ' ' ILE . . . -78.77 -22.45 46.36 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 115.624 -0.716 . . . . 0.0 111.905 -176.165 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 114.56 62.13 0.39 Allowed Glycine 0 CA--C 1.519 0.325 0 C-N-CA 121.143 -0.551 . . . . 0.0 112.392 -178.185 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -61.47 140.61 58.04 Favored 'General case' 0 C--O 1.236 0.343 0 C-N-CA 122.789 0.435 . . . . 0.0 110.799 -179.331 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 8.7 ptm180 . . . . . 0 C--O 1.245 0.858 0 CA-C-O 118.556 -0.735 . . . . 0.0 110.555 -172.452 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 . . . . . 0 CA--C 1.503 -0.846 0 CA-C-O 121.449 0.642 . . . . 0.0 109.904 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -61.21 -15.22 43.57 Favored Glycine 0 CA--C 1.505 -0.565 0 CA-C-N 114.904 -1.043 . . . . 0.0 110.543 177.646 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 23.2 m -77.28 -37.23 53.28 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 114.666 -0.767 . . . . 0.0 110.068 177.598 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.554 ' O ' HG13 ' A' ' 34' ' ' ILE . 1.1 mm -71.38 -39.08 71.36 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.751 0 N-CA-C 107.029 -1.471 . . . . 0.0 107.029 178.693 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' TRP . . . . . 0.621 ' HZ2' ' HD3' ' A' ' 90' ' ' ARG . 24.3 m95 -68.54 -36.91 79.48 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-N 114.054 -1.43 . . . . 0.0 110.793 -176.154 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 7.8 t70 -74.92 -36.2 62.17 Favored 'General case' 0 N--CA 1.444 -0.743 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.587 177.203 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . 0.489 ' HB1' ' HB3' ' A' ' 105' ' ' ALA . . . -70.92 -35.52 72.29 Favored 'General case' 0 N--CA 1.448 -0.533 0 C-N-CA 120.736 -0.386 . . . . 0.0 110.846 178.937 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . 0.554 HG13 ' O ' ' A' ' 30' ' ' ILE . 75.8 mt -66.96 -46.07 85.75 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.222 0 CA-C-O 120.987 0.423 . . . . 0.0 110.002 174.662 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -57.61 -38.22 74.57 Favored 'General case' 0 CA--C 1.515 -0.373 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.297 176.92 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . 0.54 ' HA2' ' CA ' ' A' ' 41' ' ' GLY . . . -77.96 -1.64 79.69 Favored Glycine 0 N--CA 1.449 -0.436 0 CA-C-N 115.421 -0.809 . . . . 0.0 112.028 179.341 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 38.5 t -106.61 -57.09 2.1 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 115.825 -0.187 . . . . 0.0 111.361 -177.319 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . 0.815 ' HG3' ' SG ' ' A' ' 101' ' ' CYS . 9.9 mt-10 -88.09 -30.83 19.58 Favored 'General case' 0 CA--C 1.514 -0.422 0 C-N-CA 120.949 -0.301 . . . . 0.0 111.101 -175.207 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -96.68 -7.44 34.07 Favored 'General case' 0 N--CA 1.449 -0.488 0 C-N-CA 120.765 -0.374 . . . . 0.0 111.527 -179.079 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 82.09 2.6 90.61 Favored Glycine 0 CA--C 1.505 -0.575 0 N-CA-C 110.0 -1.24 . . . . 0.0 110.0 -177.962 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . 0.54 ' CA ' ' HA2' ' A' ' 36' ' ' GLY . . . 89.76 54.62 2.17 Favored Glycine 0 N--CA 1.433 -1.511 0 CA-C-N 114.208 -0.996 . . . . 0.0 111.807 -178.043 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 53.0 t30 -147.82 124.57 11.18 Favored 'General case' 0 N--CA 1.443 -0.793 0 N-CA-C 109.147 -0.686 . . . . 0.0 109.147 -178.983 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' TRP . . . . . 0.775 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 20.5 m95 -99.44 1.61 44.32 Favored 'General case' 0 C--N 1.301 -1.527 0 CA-C-N 115.132 -0.94 . . . . 0.0 110.004 -174.467 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -111.59 5.48 19.42 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.088 -0.96 . . . . 0.0 111.102 177.188 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 13.0 tt -75.26 143.32 13.42 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.769 0 CA-C-O 120.946 0.403 . . . . 0.0 110.196 -178.927 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 40.7 t-20 -156.46 96.62 1.68 Allowed 'General case' 0 C--N 1.311 -1.089 0 CA-C-O 121.154 0.502 . . . . 0.0 109.826 179.399 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 20.5 p -76.72 -22.0 54.5 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 115.782 -0.645 . . . . 0.0 111.262 -177.154 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 98.33 21.73 16.62 Favored Glycine 0 N--CA 1.442 -0.902 0 CA-C-N 115.549 -0.751 . . . . 0.0 111.272 -179.016 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 66.3 t30 -91.16 11.89 21.8 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 121.59 0.71 . . . . 0.0 110.934 -177.358 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 84.58 -14.41 46.92 Favored Glycine 0 N--CA 1.453 -0.224 0 N-CA-C 111.234 -0.746 . . . . 0.0 111.234 -178.281 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' TYR . . . . . 0.612 ' CE1' ' HB2' ' A' ' 58' ' ' ASP . 0.5 OUTLIER -98.07 142.4 29.81 Favored 'General case' 0 N--CA 1.445 -0.693 0 N-CA-C 108.174 -1.047 . . . . 0.0 108.174 173.226 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' TYR . . . . . 0.8 ' CE1' ' HB2' ' A' ' 59' ' ' GLN . 4.7 m-85 -108.56 170.28 8.12 Favored 'General case' 0 C--N 1.311 -1.097 0 CA-C-N 116.019 -0.537 . . . . 0.0 111.456 -174.323 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -58.89 172.56 4.07 Favored Glycine 0 N--CA 1.452 -0.286 0 N-CA-C 115.123 0.809 . . . . 0.0 115.123 -170.202 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . 0.751 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 87.01 -111.73 3.7 Favored Glycine 0 N--CA 1.443 -0.865 0 C-N-CA 120.962 -0.637 . . . . 0.0 111.577 -179.607 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.436 HG11 ' CE3' ' A' ' 31' ' ' TRP . 6.2 t -84.28 6.43 2.02 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.74 0 CA-C-O 121.736 0.779 . . . . 0.0 109.778 179.959 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' GLN . . . . . 0.702 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 8.4 tp-100 53.54 51.91 14.31 Favored 'General case' 0 C--O 1.236 0.366 0 CA-C-N 114.427 -1.26 . . . . 0.0 112.872 164.816 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 6.9 p90 -120.15 167.94 11.72 Favored 'General case' 0 N--CA 1.443 -0.801 0 C-N-CA 119.555 -0.858 . . . . 0.0 111.897 174.245 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.612 ' HB2' ' CE1' ' A' ' 51' ' ' TYR . 0.6 OUTLIER -71.09 141.81 50.82 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 114.242 -1.345 . . . . 0.0 113.062 -165.636 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . 0.8 ' HB2' ' CE1' ' A' ' 52' ' ' TYR . 0.0 OUTLIER -56.2 -38.12 70.56 Favored 'General case' 0 N--CA 1.446 -0.628 0 CA-C-N 113.389 -1.732 . . . . 0.0 111.522 178.074 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -63.89 -48.93 71.5 Favored Glycine 0 N--CA 1.441 -1.006 0 CA-C-N 115.938 -0.573 . . . . 0.0 112.019 178.102 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 68.8 m -61.47 -42.21 98.43 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 121.279 0.561 . . . . 0.0 110.4 175.076 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' TRP . . . . . 0.443 ' CZ3' ' HA ' ' A' ' 82' ' ' GLN . 43.4 t-105 -56.13 -49.83 72.81 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.055 -0.975 . . . . 0.0 109.981 175.635 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . 0.655 ' HG3' HD12 ' A' ' 68' ' ' LEU . 29.3 tt0 -66.8 -39.36 87.71 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 115.195 -0.912 . . . . 0.0 110.756 -178.663 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -62.25 -39.5 93.07 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.553 -0.749 . . . . 0.0 110.92 -176.922 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . 0.572 ' OD1' ' HB ' ' A' ' 89' ' ' THR . 10.7 m120 -75.59 -21.14 58.08 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.198 177.014 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 101.7 39.36 2.97 Favored Glycine 0 N--CA 1.449 -0.493 0 C-N-CA 120.957 -0.64 . . . . 0.0 112.28 178.317 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . 0.652 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -79.25 -16.66 77.99 Favored Glycine 0 N--CA 1.44 -1.048 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.073 -173.915 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 0.655 HD12 ' HG3' ' A' ' 63' ' ' GLU . 26.4 mt -63.55 -23.76 67.52 Favored 'General case' 0 N--CA 1.442 -0.828 0 CA-C-N 115.502 -0.349 . . . . 0.0 111.566 -172.932 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . 0.564 ' HG3' ' N ' ' A' ' 70' ' ' TYR . 0.0 OUTLIER -70.77 -32.68 69.89 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 121.186 0.517 . . . . 0.0 110.068 176.165 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 70' ' ' TYR . . . . . 0.68 ' HB3' ' CG ' ' A' ' 81' ' ' GLU . 86.9 m-85 -76.13 -33.17 59.43 Favored 'General case' 0 CA--C 1.503 -0.852 0 N-CA-C 107.574 -1.269 . . . . 0.0 107.574 -179.934 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.738 ' HB2' ' HB3' ' A' ' 77' ' ' ALA . . . 163.26 125.48 0.01 OUTLIER Pre-proline 0 C--N 1.321 -0.654 0 CA-C-N 111.903 -2.408 . . . . 0.0 106.688 179.293 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 72' ' ' PRO . . . . . 0.567 ' HA ' ' HA ' ' A' ' 68' ' ' LEU . 17.3 Cg_exo -55.16 -4.0 0.37 Allowed 'Trans proline' 0 C--N 1.331 -0.342 0 C-N-CA 122.85 2.366 . . . . 0.0 113.633 -179.799 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 73' ' ' ARG . . . . . 0.418 ' H ' ' C ' ' A' ' 71' ' ' ALA . 14.8 ptm180 -145.83 136.94 24.7 Favored 'General case' 0 C--N 1.317 -0.836 0 CA-C-O 121.269 0.557 . . . . 0.0 109.657 176.6 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -63.43 -25.49 68.3 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 115.455 -0.793 . . . . 0.0 111.914 -177.467 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . 0.485 ' OD1' ' HD2' ' A' ' 52' ' ' TYR . 26.9 p-10 -88.16 10.0 20.88 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-O 121.292 0.568 . . . . 0.0 110.847 -177.714 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 68.7 tp -113.0 -34.43 5.74 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.46 -0.791 . . . . 0.0 109.048 168.121 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . 0.738 ' HB3' ' HB2' ' A' ' 71' ' ' ALA . . . -78.31 153.43 31.75 Favored 'General case' 0 N--CA 1.443 -0.799 0 CA-C-N 115.357 -0.838 . . . . 0.0 109.851 177.687 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 33.5 p -96.54 -173.98 2.91 Favored 'General case' 0 C--N 1.317 -0.84 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.35 -176.951 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . 0.775 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 49.1 mtt85 -50.63 -52.56 38.43 Favored 'General case' 0 CA--C 1.513 -0.46 0 O-C-N 123.519 0.512 . . . . 0.0 111.549 -178.06 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 80' ' ' GLU . . . . . 0.543 ' HG3' ' OE2' ' A' ' 81' ' ' GLU . 9.3 pt-20 -59.28 -42.96 92.5 Favored 'General case' 0 C--N 1.318 -0.786 0 CA-C-N 116.026 -0.534 . . . . 0.0 111.962 -176.627 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 81' ' ' GLU . . . . . 0.68 ' CG ' ' HB3' ' A' ' 70' ' ' TYR . 4.9 mp0 -63.68 -51.99 62.64 Favored 'General case' 0 N--CA 1.454 -0.229 0 N-CA-C 112.094 0.405 . . . . 0.0 112.094 173.987 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 82' ' ' GLN . . . . . 0.455 ' NE2' ' HE3' ' A' ' 43' ' ' TRP . 51.4 mt-30 -59.16 -43.35 92.07 Favored 'General case' 0 CA--C 1.509 -0.611 0 CA-C-O 121.067 0.461 . . . . 0.0 110.459 -176.303 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . 0.662 ' O ' ' HG2' ' A' ' 87' ' ' GLU . 34.3 mt -59.53 -41.88 86.23 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.793 0 CA-C-N 115.157 -0.928 . . . . 0.0 110.006 -178.886 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 84' ' ' ALA . . . . . 0.607 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -64.52 -42.8 95.55 Favored 'General case' 0 C--O 1.236 0.394 0 CA-C-O 121.705 0.764 . . . . 0.0 111.043 -177.793 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . 0.414 HG21 ' HA2' ' A' ' 67' ' ' GLY . 48.3 t -65.53 -49.12 80.01 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 CA-C-N 115.539 -0.755 . . . . 0.0 110.906 178.188 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -58.48 -30.47 67.01 Favored 'General case' 0 N--CA 1.452 -0.362 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.534 173.965 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 87' ' ' GLU . . . . . 0.662 ' HG2' ' O ' ' A' ' 83' ' ' ILE . 26.4 mm-40 -58.99 -44.06 91.56 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.45 -178.749 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.567 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 98.1 t -64.18 -50.68 75.71 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 C-N-CA 120.555 -0.458 . . . . 0.0 110.622 -179.799 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 89' ' ' THR . . . . . 0.572 ' HB ' ' OD1' ' A' ' 65' ' ' ASN . 12.5 t -73.59 -35.63 65.44 Favored 'General case' 0 C--N 1.318 -0.793 0 C-N-CA 120.796 -0.362 . . . . 0.0 111.66 -174.612 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 90' ' ' ARG . . . . . 0.636 ' HG3' ' N ' ' A' ' 91' ' ' LEU . 10.9 ptt85 -60.77 -41.6 95.82 Favored 'General case' 0 N--CA 1.471 0.597 0 CA-C-N 117.919 0.327 . . . . 0.0 110.783 -179.194 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 91' ' ' LEU . . . . . 0.636 ' N ' ' HG3' ' A' ' 90' ' ' ARG . 4.5 pp -69.8 -23.83 63.39 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.845 -0.616 . . . . 0.0 111.419 -172.43 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . 0.528 ' NE ' ' HA ' ' A' ' 89' ' ' THR . 1.9 mtm180 -81.22 -47.96 12.71 Favored 'General case' 0 N--CA 1.447 -0.606 0 CA-C-O 121.576 0.703 . . . . 0.0 109.468 -178.948 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 93' ' ' GLN . . . . . 0.477 ' OE1' ' HB1' ' A' ' 97' ' ' ALA . 17.6 pt20 -95.94 -27.14 15.3 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 114.731 -1.122 . . . . 0.0 112.872 -167.633 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 91.76 39.86 5.43 Favored Glycine 0 CA--C 1.504 -0.615 0 C-N-CA 120.344 -0.931 . . . . 0.0 111.985 170.441 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 95' ' ' TRP . . . . . 0.45 ' HA ' ' HE3' ' A' ' 98' ' ' TRP . 6.9 m95 63.74 17.27 10.35 Favored 'General case' 0 C--O 1.22 -0.474 0 N-CA-C 109.255 -0.646 . . . . 0.0 109.255 -179.231 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -70.47 -30.29 69.12 Favored Glycine 0 N--CA 1.451 -0.344 0 CA-C-N 115.504 -0.771 . . . . 0.0 112.598 177.989 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . 0.477 ' HB1' ' OE1' ' A' ' 93' ' ' GLN . . . -69.99 -30.11 67.36 Favored 'General case' 0 CA--C 1.514 -0.439 0 CA-C-O 120.924 0.392 . . . . 0.0 110.21 177.488 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 98' ' ' TRP . . . . . 0.487 ' CZ3' ' HH2' ' A' ' 31' ' ' TRP . 25.6 m-90 -98.47 104.55 24.45 Favored Pre-proline 0 C--N 1.323 -0.571 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 177.353 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 99' ' ' PRO . . . . . 0.405 ' HD3' ' O ' ' A' ' 97' ' ' ALA . 20.2 Cg_exo -70.99 -94.2 0.01 OUTLIER 'Trans proline' 0 CA--C 1.534 0.505 0 C-N-CA 122.889 2.393 . . . . 0.0 114.734 -172.22 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 60.6 t -70.99 -31.95 46.84 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 CA-C-O 121.822 0.82 . . . . 0.0 110.19 -173.98 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 101' ' ' CYS . . . . . 0.815 ' SG ' ' HG3' ' A' ' 38' ' ' GLU . 75.6 m -78.26 -26.1 47.05 Favored 'General case' 0 C--N 1.315 -0.932 0 CA-C-N 114.772 -1.104 . . . . 0.0 112.27 -168.832 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 102' ' ' ALA . . . . . 0.478 ' HB3' ' HB2' ' A' ' 98' ' ' TRP . . . -69.93 -46.19 65.89 Favored 'General case' 0 C--N 1.326 -0.444 0 C-N-CA 120.549 -0.461 . . . . 0.0 110.23 176.249 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -65.33 -35.92 82.46 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.699 -179.358 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 104' ' ' ARG . . . . . 0.414 ' HG2' ' HA ' ' A' ' 101' ' ' CYS . 0.0 OUTLIER -73.41 -21.45 60.48 Favored 'General case' 0 N--CA 1.444 -0.725 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.425 179.785 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 105' ' ' ALA . . . . . 0.489 ' HB3' ' HB1' ' A' ' 33' ' ' ALA . . . -96.08 -22.82 17.1 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.821 -0.627 . . . . 0.0 111.581 -178.157 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 119.02 63.66 0.29 Allowed Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 121.236 -0.507 . . . . 0.0 112.236 -176.86 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -64.09 145.15 56.42 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.776 0.322 . . . . 0.0 110.782 179.36 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 51.8 mtp180 . . . . . 0 C--O 1.249 1.06 0 CA-C-O 118.395 -0.812 . . . . 0.0 110.332 -173.293 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 15.0 m-20 . . . . . 0 CA--C 1.507 -0.706 0 CA-C-O 121.865 0.84 . . . . 0.0 109.532 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . 0.466 ' HA2' ' HB2' ' A' ' 31' ' ' TRP . . . -70.23 -6.32 56.98 Favored Glycine 0 N--CA 1.44 -1.057 0 CA-C-N 114.481 -1.236 . . . . 0.0 110.38 176.526 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 9.6 m -76.96 -39.4 50.71 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-O 121.659 0.742 . . . . 0.0 109.087 174.661 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.498 ' O ' HG13 ' A' ' 34' ' ' ILE . 1.0 OUTLIER -69.65 -38.1 75.64 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.576 0 N-CA-C 107.492 -1.299 . . . . 0.0 107.492 177.366 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' TRP . . . . . 0.503 ' CD1' HG22 ' A' ' 83' ' ' ILE . 43.2 m95 -71.41 -35.91 71.16 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 114.262 -1.336 . . . . 0.0 110.487 -177.857 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.505 ' HB2' HH21 ' A' ' 79' ' ' ARG . 15.5 t70 -74.28 -34.56 63.6 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.385 178.328 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -69.89 -34.47 73.59 Favored 'General case' 0 N--CA 1.446 -0.629 0 C-N-CA 120.756 -0.377 . . . . 0.0 110.12 177.705 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . 0.557 ' HA ' ' HB3' ' A' ' 101' ' ' CYS . 61.9 mt -67.33 -47.44 81.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.312 174.399 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . 0.442 ' HA ' ' O ' ' A' ' 54' ' ' GLY . . . -58.76 -39.14 80.12 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.501 177.554 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -76.13 -8.79 85.42 Favored Glycine 0 N--CA 1.451 -0.337 0 CA-C-N 115.559 -0.746 . . . . 0.0 112.081 179.603 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 1.7 t -97.16 -57.96 2.13 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-O 120.678 0.275 . . . . 0.0 111.417 -178.6 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . 0.542 ' HB2' ' SG ' ' A' ' 101' ' ' CYS . 8.0 tp10 -87.97 -33.02 18.57 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 121.207 0.527 . . . . 0.0 109.999 -171.315 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -95.71 -13.05 24.52 Favored 'General case' 0 N--CA 1.448 -0.538 0 CA-C-N 115.631 -0.713 . . . . 0.0 111.197 -178.749 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 82.52 1.34 90.47 Favored Glycine 0 N--CA 1.448 -0.505 0 N-CA-C 109.983 -1.247 . . . . 0.0 109.983 -177.04 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 93.65 55.63 1.52 Allowed Glycine 0 N--CA 1.436 -1.327 0 CA-C-N 114.372 -0.914 . . . . 0.0 111.61 -176.543 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' ASN . . . . . 0.559 ' HB3' ' HB ' ' A' ' 45' ' ' ILE . 0.3 OUTLIER -142.93 94.6 2.65 Favored 'General case' 0 N--CA 1.447 -0.606 0 N-CA-C 108.704 -0.85 . . . . 0.0 108.704 -177.689 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' TRP . . . . . 0.75 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 38.3 m95 -76.65 -10.71 59.58 Favored 'General case' 0 C--N 1.317 -0.844 0 CA-C-O 121.384 0.611 . . . . 0.0 110.423 -175.385 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -107.73 15.38 24.66 Favored 'General case' 0 C--N 1.318 -0.795 0 CA-C-N 114.981 -1.009 . . . . 0.0 111.731 -178.624 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.726 HG21 ' HA2' ' A' ' 53' ' ' GLY . 9.9 tt -83.21 142.42 13.56 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.619 0 CA-C-O 121.432 0.634 . . . . 0.0 111.344 -175.639 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 9.7 m120 -133.53 88.19 2.46 Favored 'General case' 0 C--N 1.316 -0.873 0 N-CA-C 108.539 -0.911 . . . . 0.0 108.539 176.663 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 1.2 p -69.31 -24.09 63.89 Favored 'General case' 0 C--N 1.315 -0.934 0 CA-C-N 115.769 -0.651 . . . . 0.0 110.603 179.708 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 94.57 19.0 33.51 Favored Glycine 0 N--CA 1.444 -0.795 0 N-CA-C 111.272 -0.731 . . . . 0.0 111.272 176.412 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 30.7 p-10 -94.7 11.62 30.64 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.141 0.496 . . . . 0.0 111.134 -175.301 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . 0.469 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 89.9 -11.59 70.07 Favored Glycine 0 N--CA 1.445 -0.724 0 N-CA-C 110.823 -0.911 . . . . 0.0 110.823 -178.243 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' TYR . . . . . 0.588 ' CE1' ' HB3' ' A' ' 58' ' ' ASP . 0.8 OUTLIER -109.94 151.64 26.85 Favored 'General case' 0 CA--C 1.512 -0.488 0 N-CA-C 107.827 -1.175 . . . . 0.0 107.827 178.722 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' TYR . . . . . 0.612 ' CE1' ' HB2' ' A' ' 59' ' ' GLN . 24.2 m-85 -115.36 170.4 8.43 Favored 'General case' 0 C--N 1.313 -0.995 0 C-N-CA 120.647 -0.421 . . . . 0.0 111.316 -170.294 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.726 ' HA2' HG21 ' A' ' 45' ' ' ILE . . . -56.92 166.72 4.72 Favored Glycine 0 N--CA 1.451 -0.354 0 N-CA-C 114.818 0.687 . . . . 0.0 114.818 -169.744 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . 0.671 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 88.19 -103.78 2.97 Favored Glycine 0 N--CA 1.444 -0.791 0 C-N-CA 121.253 -0.499 . . . . 0.0 112.237 177.305 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.48 ' HB ' ' CD1' ' A' ' 57' ' ' PHE . 2.5 t -83.27 -2.82 6.95 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 CA-C-O 121.445 0.64 . . . . 0.0 109.785 -177.873 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' GLN . . . . . 0.598 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 2.0 mm-40 55.91 42.33 28.94 Favored 'General case' 0 N--CA 1.462 0.139 0 CA-C-N 114.747 -1.115 . . . . 0.0 113.102 169.727 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . 0.48 ' CD1' ' HB ' ' A' ' 55' ' ' VAL . 1.5 p90 -114.88 165.63 12.64 Favored 'General case' 0 C--N 1.322 -0.616 0 C-N-CA 119.912 -0.715 . . . . 0.0 111.041 175.253 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.588 ' HB3' ' CE1' ' A' ' 51' ' ' TYR . 8.1 p-10 -76.02 155.56 34.82 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 122.075 0.941 . . . . 0.0 112.619 -164.238 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . 0.612 ' HB2' ' CE1' ' A' ' 52' ' ' TYR . 3.6 tp-100 -61.42 -32.11 72.06 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 113.414 -1.721 . . . . 0.0 111.14 179.767 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -65.94 -49.5 58.26 Favored Glycine 0 C--N 1.316 -0.553 0 CA-C-N 115.48 -0.782 . . . . 0.0 111.786 -179.862 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 90.9 m -66.67 -40.75 88.75 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-O 120.787 0.327 . . . . 0.0 110.996 175.979 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' TRP . . . . . 0.484 ' CH2' ' HA ' ' A' ' 74' ' ' ALA . 46.2 t-105 -56.38 -49.53 74.18 Favored 'General case' 0 N--CA 1.45 -0.462 0 CA-C-O 121.656 0.741 . . . . 0.0 109.293 176.137 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . 0.427 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 33.6 tt0 -68.11 -32.28 72.47 Favored 'General case' 0 N--CA 1.444 -0.763 0 CA-C-N 115.022 -0.99 . . . . 0.0 110.855 179.857 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -64.26 -39.03 93.11 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.891 -179.588 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . 0.573 ' HB2' HG13 ' A' ' 85' ' ' VAL . 5.5 m120 -78.76 -14.05 59.48 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 121.597 0.713 . . . . 0.0 109.485 175.134 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . 0.565 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 82.68 49.15 5.25 Favored Glycine 0 N--CA 1.445 -0.702 0 CA-C-N 115.061 -0.972 . . . . 0.0 111.608 -179.924 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . 0.618 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -78.67 -15.39 80.86 Favored Glycine 0 N--CA 1.442 -0.96 0 C-N-CA 121.273 -0.489 . . . . 0.0 112.432 -174.765 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 0.866 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 6.8 mp -59.21 -27.27 65.57 Favored 'General case' 0 C--N 1.323 -0.575 0 N-CA-C 111.872 0.323 . . . . 0.0 111.872 -175.568 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . 0.565 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 9.1 ptp180 -65.33 -30.12 70.93 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 121.353 0.597 . . . . 0.0 110.046 177.182 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 70' ' ' TYR . . . . . 0.978 ' HB3' ' HB3' ' A' ' 81' ' ' GLU . 75.0 m-85 -81.49 -34.3 31.39 Favored 'General case' 0 N--CA 1.441 -0.905 0 N-CA-C 107.638 -1.245 . . . . 0.0 107.638 176.405 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.681 ' HB1' ' HB2' ' A' ' 77' ' ' ALA . . . 162.67 128.92 0.01 OUTLIER Pre-proline 0 CA--C 1.513 -0.465 0 CA-C-N 112.653 -2.067 . . . . 0.0 107.009 -179.568 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 72' ' ' PRO . . . . . 0.866 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 20.4 Cg_exo -57.35 -4.93 1.3 Allowed 'Trans proline' 0 C--N 1.333 -0.26 0 C-N-CA 122.77 2.313 . . . . 0.0 113.767 -177.17 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 73' ' ' ARG . . . . . 0.409 ' HE ' ' CG ' ' A' ' 75' ' ' ASP . 10.7 ptm180 -147.86 139.01 23.45 Favored 'General case' 0 C--N 1.317 -0.805 0 N-CA-C 109.367 -0.605 . . . . 0.0 109.367 176.526 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . 0.484 ' HA ' ' CH2' ' A' ' 62' ' ' TRP . . . -55.95 -29.84 60.77 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 114.941 -1.027 . . . . 0.0 112.52 -177.193 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . 0.531 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 4.6 p-10 -83.97 -4.68 58.9 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 120.967 0.413 . . . . 0.0 111.256 -176.037 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 68.1 tp -100.0 -29.74 12.37 Favored 'General case' 0 C--N 1.322 -0.59 0 N-CA-C 108.46 -0.941 . . . . 0.0 108.46 172.549 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . 0.782 ' HB3' ' HB2' ' A' ' 81' ' ' GLU . . . -79.28 159.16 27.36 Favored 'General case' 0 N--CA 1.44 -0.968 0 CA-C-N 114.78 -1.1 . . . . 0.0 109.795 175.113 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 61.9 p -100.35 -175.19 2.85 Favored 'General case' 0 C--N 1.309 -1.188 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.355 -176.974 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . 0.75 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 77.7 mtp180 -50.01 -52.93 30.11 Favored 'General case' 0 C--N 1.329 -0.293 0 O-C-N 123.416 0.447 . . . . 0.0 111.265 178.819 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 80' ' ' GLU . . . . . 0.436 ' HA ' HD11 ' A' ' 83' ' ' ILE . 17.0 pt-20 -60.8 -37.23 81.24 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.873 -0.603 . . . . 0.0 111.434 -174.43 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 81' ' ' GLU . . . . . 0.978 ' HB3' ' HB3' ' A' ' 70' ' ' TYR . 4.2 mm-40 -70.22 -50.32 41.05 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 121.031 0.443 . . . . 0.0 109.959 -179.465 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 82' ' ' GLN . . . . . 0.553 ' HB2' ' HZ3' ' A' ' 43' ' ' TRP . 41.7 mt-30 -60.03 -34.45 73.4 Favored 'General case' 0 CA--C 1.513 -0.465 0 CA-C-N 115.515 -0.766 . . . . 0.0 110.201 -179.319 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . 0.68 ' O ' ' HG2' ' A' ' 87' ' ' GLU . 40.3 mt -60.77 -49.1 85.91 Favored 'Isoleucine or valine' 0 C--O 1.212 -0.883 0 N-CA-C 109.084 -0.71 . . . . 0.0 109.084 175.855 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 84' ' ' ALA . . . . . 0.578 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -62.1 -44.09 97.4 Favored 'General case' 0 C--O 1.237 0.414 0 CA-C-O 121.277 0.56 . . . . 0.0 111.867 -176.353 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . 0.573 HG13 ' HB2' ' A' ' 65' ' ' ASN . 40.0 t -66.24 -49.32 76.86 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.609 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.862 179.432 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 86' ' ' ALA . . . . . 0.458 ' HB1' ' CH2' ' A' ' 31' ' ' TRP . . . -59.11 -29.54 67.45 Favored 'General case' 0 N--CA 1.447 -0.592 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.404 174.572 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 87' ' ' GLU . . . . . 0.849 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 15.7 mm-40 -59.46 -44.3 93.0 Favored 'General case' 0 C--O 1.222 -0.386 0 CA-C-N 115.846 -0.616 . . . . 0.0 110.492 -178.599 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.438 ' O ' ' HG3' ' A' ' 92' ' ' ARG . 70.6 t -60.52 -49.3 84.93 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.303 0 C-N-CA 120.288 -0.565 . . . . 0.0 110.091 179.747 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 89' ' ' THR . . . . . 0.565 HG22 ' NE2' ' A' ' 93' ' ' GLN . 24.0 m -66.24 -43.8 85.57 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-N 115.683 -0.69 . . . . 0.0 111.437 -177.155 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 90' ' ' ARG . . . . . 0.647 ' HA ' ' OE1' ' A' ' 93' ' ' GLN . 3.2 ppt_? -60.96 -34.34 74.59 Favored 'General case' 0 N--CA 1.467 0.4 0 N-CA-C 112.073 0.397 . . . . 0.0 112.073 -176.48 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 91' ' ' LEU . . . . . 0.849 ' HG ' ' O ' ' A' ' 87' ' ' GLU . 46.5 mt -62.87 -33.25 74.88 Favored 'General case' 0 N--CA 1.471 0.587 0 CA-C-O 121.47 0.652 . . . . 0.0 110.152 -177.998 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . 0.438 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 6.5 mtm180 -81.57 -50.57 9.21 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-N 114.818 -1.083 . . . . 0.0 110.103 -169.85 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 93' ' ' GLN . . . . . 0.647 ' OE1' ' HA ' ' A' ' 90' ' ' ARG . 0.0 OUTLIER -96.13 -23.55 16.7 Favored 'General case' 0 C--N 1.318 -0.785 0 C-N-CA 119.733 -0.787 . . . . 0.0 113.045 -171.682 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 88.48 40.41 6.42 Favored Glycine 0 CA--C 1.508 -0.345 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.156 172.466 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 95' ' ' TRP . . . . . 0.521 ' CZ2' ' HD3' ' A' ' 90' ' ' ARG . 22.1 m95 67.16 9.09 6.68 Favored 'General case' 0 C--O 1.221 -0.423 0 C-N-CA 123.6 0.76 . . . . 0.0 110.033 -179.124 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -71.97 -23.48 77.93 Favored Glycine 0 N--CA 1.451 -0.305 0 CA-C-N 115.891 -0.595 . . . . 0.0 112.444 178.155 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . 0.411 ' HB3' ' HG3' ' A' ' 93' ' ' GLN . . . -72.7 -28.1 62.47 Favored 'General case' 0 CA--C 1.516 -0.337 0 CA-C-O 121.046 0.451 . . . . 0.0 109.988 177.641 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 98' ' ' TRP . . . . . 0.517 ' HZ3' ' HA ' ' A' ' 90' ' ' ARG . 28.6 m-90 -101.02 104.16 30.31 Favored Pre-proline 0 N--CA 1.448 -0.567 0 CA-C-N 115.146 -0.934 . . . . 0.0 108.966 176.528 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 99' ' ' PRO . . . . . 0.409 ' HD3' ' HA ' ' A' ' 98' ' ' TRP . 15.7 Cg_exo -73.95 -88.38 0.0 OUTLIER 'Trans proline' 0 CA--C 1.53 0.32 0 C-N-CA 123.182 2.588 . . . . 0.0 114.993 -171.127 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . 0.416 ' HA ' HH21 ' A' ' 104' ' ' ARG . 80.5 t -69.45 -30.08 44.24 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-O 121.142 0.496 . . . . 0.0 110.693 -172.393 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 101' ' ' CYS . . . . . 0.557 ' HB3' ' HA ' ' A' ' 34' ' ' ILE . 87.1 m -79.79 -37.64 34.84 Favored 'General case' 0 C--N 1.317 -0.812 0 CA-C-N 115.7 -0.682 . . . . 0.0 112.403 -170.102 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 102' ' ' ALA . . . . . 0.435 ' HB2' ' HB3' ' A' ' 95' ' ' TRP . . . -69.62 -40.33 76.66 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.828 0.347 . . . . 0.0 110.912 -178.556 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -61.48 -38.55 87.71 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-O 121.318 0.58 . . . . 0.0 110.588 177.127 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 104' ' ' ARG . . . . . 0.416 HH21 ' HA ' ' A' ' 100' ' ' VAL . 1.4 mpp_? -74.58 -18.45 60.57 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.371 -0.831 . . . . 0.0 111.618 176.77 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -96.49 -22.8 16.89 Favored 'General case' 0 C--N 1.327 -0.399 0 N-CA-C 112.659 0.615 . . . . 0.0 112.659 -173.638 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 106.11 64.21 0.62 Allowed Glycine 0 CA--C 1.52 0.4 0 C-N-CA 120.793 -0.718 . . . . 0.0 112.252 -177.582 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -72.24 149.14 44.83 Favored 'General case' 0 C--N 1.326 -0.436 0 C-N-CA 122.906 0.483 . . . . 0.0 111.28 -174.867 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.245 0.819 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.619 -175.403 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.447 ' O ' HG12 ' A' ' 30' ' ' ILE . 18.4 m-20 . . . . . 0 CA--C 1.511 -0.53 0 CA-C-O 121.42 0.628 . . . . 0.0 109.784 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . 0.403 ' HA2' ' HB2' ' A' ' 31' ' ' TRP . . . -69.91 -8.36 60.88 Favored Glycine 0 CA--C 1.5 -0.874 0 N-CA-C 110.343 -1.103 . . . . 0.0 110.343 177.921 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 16.4 m -76.55 -35.04 58.47 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 114.591 -0.805 . . . . 0.0 109.197 175.857 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.613 ' HA ' ' HB1' ' A' ' 105' ' ' ALA . 1.1 mm -71.46 -36.95 62.62 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.645 0 N-CA-C 107.245 -1.391 . . . . 0.0 107.245 177.105 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' TRP . . . . . 0.545 ' CH2' ' HB2' ' A' ' 86' ' ' ALA . 34.6 m95 -71.15 -36.3 72.0 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 114.089 -1.414 . . . . 0.0 111.012 -177.259 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.752 ' HB2' HH21 ' A' ' 79' ' ' ARG . 17.5 t70 -74.79 -36.7 62.51 Favored 'General case' 0 N--CA 1.445 -0.694 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.477 179.119 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . 0.464 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -70.47 -34.19 72.12 Favored 'General case' 0 N--CA 1.448 -0.537 0 C-N-CA 120.817 -0.353 . . . . 0.0 110.695 178.687 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . 0.548 HG13 ' O ' ' A' ' 30' ' ' ILE . 65.9 mt -64.73 -44.67 96.51 Favored 'Isoleucine or valine' 0 C--O 1.235 0.327 0 CA-C-O 121.286 0.565 . . . . 0.0 109.988 173.914 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . 0.436 ' HA ' ' O ' ' A' ' 54' ' ' GLY . . . -59.59 -35.03 73.51 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.511 -0.768 . . . . 0.0 110.261 176.245 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . 0.509 ' HA2' ' N ' ' A' ' 41' ' ' GLY . . . -78.94 4.37 61.82 Favored Glycine 0 N--CA 1.452 -0.293 0 CA-C-N 115.368 -0.833 . . . . 0.0 112.341 179.643 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 27.0 t -108.15 -53.84 2.58 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 120.576 0.227 . . . . 0.0 111.114 -179.499 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . 0.436 ' HG2' ' SG ' ' A' ' 101' ' ' CYS . 36.7 mm-40 -87.86 -33.1 18.67 Favored 'General case' 0 CA--C 1.515 -0.39 0 CA-C-O 121.093 0.473 . . . . 0.0 110.552 -176.547 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -105.1 -9.71 17.62 Favored 'General case' 0 N--CA 1.447 -0.587 0 CA-C-N 116.044 -0.525 . . . . 0.0 112.124 -175.201 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 75.11 17.51 80.23 Favored Glycine 0 CA--C 1.505 -0.577 0 N-CA-C 109.635 -1.386 . . . . 0.0 109.635 -177.199 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . 0.509 ' N ' ' HA2' ' A' ' 36' ' ' GLY . . . 75.24 61.51 2.99 Favored Glycine 0 N--CA 1.432 -1.598 0 CA-C-N 114.019 -1.091 . . . . 0.0 111.455 -174.953 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' ASN . . . . . 0.495 HD21 ' HB ' ' A' ' 45' ' ' ILE . 3.7 t30 -145.84 100.16 3.37 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 108.332 -0.988 . . . . 0.0 108.332 -177.251 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' TRP . . . . . 0.8 ' HA ' ' N ' ' A' ' 54' ' ' GLY . 30.2 m95 -84.47 -3.82 58.59 Favored 'General case' 0 C--N 1.317 -0.833 0 CA-C-O 121.605 0.717 . . . . 0.0 110.664 -170.785 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -111.64 15.69 20.93 Favored 'General case' 0 C--N 1.311 -1.091 0 CA-C-N 114.806 -1.088 . . . . 0.0 110.86 178.768 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.789 HG22 ' HA2' ' A' ' 53' ' ' GLY . 10.5 tt -79.38 137.63 21.4 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.733 0 CA-C-O 121.163 0.506 . . . . 0.0 110.508 -177.85 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 46.4 t30 -171.24 103.72 0.21 Allowed 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 115.956 -0.566 . . . . 0.0 110.379 178.948 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 25.3 p -82.63 -11.51 58.33 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 115.767 -0.651 . . . . 0.0 111.09 177.586 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 104.07 21.28 9.64 Favored Glycine 0 N--CA 1.449 -0.483 0 C-N-CA 120.808 -0.711 . . . . 0.0 111.386 -175.348 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 8.6 p30 -82.15 -4.86 57.84 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 115.623 -0.288 . . . . 0.0 111.161 -178.335 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . 0.546 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 96.3 -11.95 66.88 Favored Glycine 0 N--CA 1.448 -0.525 0 C-N-CA 121.305 -0.474 . . . . 0.0 112.039 177.755 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' TYR . . . . . 0.569 ' HA ' ' HA ' ' A' ' 58' ' ' ASP . 0.6 OUTLIER -112.37 151.61 29.59 Favored 'General case' 0 CA--C 1.514 -0.412 0 N-CA-C 107.834 -1.173 . . . . 0.0 107.834 176.349 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' TYR . . . . . 0.68 ' O ' ' HA ' ' A' ' 56' ' ' GLN . 42.9 m-85 -116.61 170.39 8.62 Favored 'General case' 0 C--N 1.313 -0.984 0 C-N-CA 120.4 -0.52 . . . . 0.0 112.203 -166.242 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.789 ' HA2' HG22 ' A' ' 45' ' ' ILE . . . -60.12 172.18 5.83 Favored Glycine 0 N--CA 1.446 -0.658 0 N-CA-C 115.548 0.979 . . . . 0.0 115.548 -167.653 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . 0.8 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 87.53 -109.35 3.46 Favored Glycine 0 N--CA 1.437 -1.234 0 CA-C-N 114.486 -0.857 . . . . 0.0 111.636 177.557 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.513 HG12 ' CE3' ' A' ' 31' ' ' TRP . 0.5 OUTLIER -84.16 2.21 3.93 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.594 0 CA-C-O 121.351 0.596 . . . . 0.0 110.868 178.793 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' GLN . . . . . 0.755 ' HA ' HE21 ' A' ' 56' ' ' GLN . 0.0 OUTLIER 59.5 51.36 6.6 Favored 'General case' 0 CA--C 1.532 0.271 0 CA-C-N 114.207 -1.361 . . . . 0.0 113.316 164.952 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -119.12 168.37 10.91 Favored 'General case' 0 C--N 1.326 -0.454 0 C-N-CA 119.465 -0.894 . . . . 0.0 111.865 174.215 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.569 ' HA ' ' HA ' ' A' ' 51' ' ' TYR . 7.4 p-10 -78.53 166.11 22.95 Favored 'General case' 0 C--N 1.327 -0.383 0 N-CA-C 113.724 1.009 . . . . 0.0 113.724 -163.459 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . 0.452 ' HB2' ' HE1' ' A' ' 52' ' ' TYR . 5.6 tp-100 -61.08 -39.96 91.87 Favored 'General case' 0 N--CA 1.446 -0.667 0 CA-C-N 114.775 -1.102 . . . . 0.0 111.244 177.601 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -64.32 -49.55 65.16 Favored Glycine 0 C--N 1.317 -0.483 0 CA-C-N 115.665 -0.698 . . . . 0.0 111.572 -175.185 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 87.9 m -66.77 -41.58 87.5 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-N 115.612 -0.294 . . . . 0.0 111.167 176.591 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' TRP . . . . . 0.437 ' CE2' ' HA3' ' A' ' 67' ' ' GLY . 57.2 t-105 -56.48 -48.4 77.19 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 121.773 0.796 . . . . 0.0 109.437 177.0 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . 0.459 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 29.3 tt0 -67.44 -34.22 76.76 Favored 'General case' 0 C--N 1.317 -0.833 0 CA-C-N 114.8 -1.091 . . . . 0.0 111.131 -179.655 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -65.14 -41.36 94.87 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.899 -0.592 . . . . 0.0 111.129 -177.166 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . 0.563 ' HB2' HG11 ' A' ' 85' ' ' VAL . 31.4 m-80 -82.94 -9.2 59.41 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.715 0.293 . . . . 0.0 110.502 177.232 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . 0.504 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 91.46 49.79 2.91 Favored Glycine 0 C--N 1.334 0.433 0 C-N-CA 121.181 -0.533 . . . . 0.0 113.168 173.218 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . 0.483 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -80.61 -28.2 48.29 Favored Glycine 0 N--CA 1.439 -1.127 0 C-N-CA 121.041 -0.6 . . . . 0.0 113.107 -177.391 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 0.895 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 7.2 mp -57.4 -23.58 50.2 Favored 'General case' 0 N--CA 1.452 -0.355 0 N-CA-C 112.2 0.445 . . . . 0.0 112.2 -173.032 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . 0.504 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 1.5 ptm180 -67.56 -31.67 71.91 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-O 121.043 0.449 . . . . 0.0 109.971 178.529 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 70' ' ' TYR . . . . . 1.049 ' HB3' ' HG2' ' A' ' 81' ' ' GLU . 63.5 m-85 -83.99 -36.63 23.04 Favored 'General case' 0 N--CA 1.44 -0.946 0 N-CA-C 107.327 -1.36 . . . . 0.0 107.327 177.218 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.64 ' HB1' ' HB1' ' A' ' 77' ' ' ALA . . . 169.1 126.96 0.04 OUTLIER Pre-proline 0 N--CA 1.443 -0.784 0 CA-C-N 112.899 -1.955 . . . . 0.0 107.406 -175.89 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 72' ' ' PRO . . . . . 0.895 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 21.5 Cg_exo -56.85 -5.9 1.48 Allowed 'Trans proline' 0 C--N 1.33 -0.417 0 C-N-CA 122.982 2.454 . . . . 0.0 113.705 -177.542 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 73' ' ' ARG . . . . . 0.615 ' HB2' ' CD2' ' A' ' 52' ' ' TYR . 28.3 ptt-85 -149.74 140.32 22.53 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-O 121.188 0.518 . . . . 0.0 110.356 176.756 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -57.65 -22.83 48.04 Favored 'General case' 0 C--O 1.217 -0.645 0 CA-C-N 114.851 -1.068 . . . . 0.0 113.189 -178.98 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . 0.564 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 0.0 OUTLIER -76.76 -23.15 52.95 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 121.227 0.537 . . . . 0.0 110.921 -179.159 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.497 ' HB3' ' HB3' ' A' ' 71' ' ' ALA . 54.9 tp -87.68 -33.19 18.86 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 115.567 -0.742 . . . . 0.0 109.191 176.034 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . 0.73 ' HB2' ' CB ' ' A' ' 81' ' ' GLU . . . -79.15 158.47 27.71 Favored 'General case' 0 N--CA 1.445 -0.723 0 CA-C-N 115.344 -0.844 . . . . 0.0 110.97 176.1 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 47.5 p -101.5 -172.48 2.17 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.231 -178.444 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . 0.752 HH21 ' HB2' ' A' ' 32' ' ' ASP . 66.8 mtp180 -49.52 -52.55 28.85 Favored 'General case' 0 N--CA 1.466 0.325 0 CA-C-N 116.433 -0.349 . . . . 0.0 111.521 -177.955 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 10.2 pt-20 -62.69 -33.07 74.33 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 116.023 -0.535 . . . . 0.0 111.365 -174.977 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 81' ' ' GLU . . . . . 1.049 ' HG2' ' HB3' ' A' ' 70' ' ' TYR . 5.9 mt-10 -71.9 -47.53 52.03 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.532 -0.304 . . . . 0.0 111.235 178.43 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 82' ' ' GLN . . . . . 0.568 ' NE2' ' HE3' ' A' ' 43' ' ' TRP . 0.1 OUTLIER -59.5 -39.61 84.38 Favored 'General case' 0 CA--C 1.505 -0.752 0 N-CA-C 109.509 -0.552 . . . . 0.0 109.509 174.551 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . 0.676 ' O ' ' HG2' ' A' ' 87' ' ' GLU . 27.2 mt -60.1 -49.75 82.87 Favored 'Isoleucine or valine' 0 C--O 1.209 -1.03 0 CA-C-N 114.848 -1.069 . . . . 0.0 110.591 177.471 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 84' ' ' ALA . . . . . 0.615 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -60.8 -46.02 92.14 Favored 'General case' 0 C--O 1.242 0.664 0 CA-C-O 121.409 0.623 . . . . 0.0 111.973 -177.176 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . 0.563 HG11 ' HB2' ' A' ' 65' ' ' ASN . 58.6 t -66.51 -48.27 81.07 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.737 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.448 -179.525 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 86' ' ' ALA . . . . . 0.545 ' HB2' ' CH2' ' A' ' 31' ' ' TRP . . . -59.95 -28.49 67.69 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.584 -0.735 . . . . 0.0 110.793 174.065 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 87' ' ' GLU . . . . . 0.676 ' HG2' ' O ' ' A' ' 83' ' ' ILE . 10.9 mm-40 -59.26 -45.0 92.38 Favored 'General case' 0 N--CA 1.468 0.434 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.166 -179.17 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.65 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 62.1 t -65.95 -42.49 91.93 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.295 0 C-N-CA 120.115 -0.634 . . . . 0.0 109.594 175.933 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 89' ' ' THR . . . . . 0.89 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 1.1 m -64.0 -45.28 89.69 Favored 'General case' 0 C--N 1.319 -0.758 0 CA-C-N 115.613 -0.721 . . . . 0.0 111.498 -176.136 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 90' ' ' ARG . . . . . 0.534 ' HA ' ' HZ3' ' A' ' 98' ' ' TRP . 5.0 ptt180 -69.29 -33.17 72.79 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.679 -175.559 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 91' ' ' LEU . . . . . 0.65 ' HG ' ' O ' ' A' ' 88' ' ' VAL . 4.6 pp -68.59 -24.46 64.6 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 121.368 0.604 . . . . 0.0 110.309 -173.4 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . 0.46 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 4.2 mtm180 -84.36 -43.87 14.32 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-O 122.14 0.972 . . . . 0.0 109.163 176.451 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 93' ' ' GLN . . . . . 0.697 ' NE2' HG23 ' A' ' 89' ' ' THR . 21.9 mt-30 -87.84 -28.23 21.75 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 113.746 -1.57 . . . . 0.0 114.329 -167.43 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 74.89 32.63 56.65 Favored Glycine 0 CA--C 1.51 -0.245 0 N-CA-C 111.858 -0.497 . . . . 0.0 111.858 179.894 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 95' ' ' TRP . . . . . 0.431 ' CH2' ' HB ' ' A' ' 30' ' ' ILE . 28.6 m95 67.05 5.02 3.86 Favored 'General case' 0 C--O 1.216 -0.678 0 C-N-CA 123.451 0.701 . . . . 0.0 110.082 -177.151 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -59.39 -43.8 97.12 Favored Glycine 0 CA--C 1.518 0.233 0 CA-C-N 116.125 -0.489 . . . . 0.0 113.327 -178.557 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -69.67 -21.15 63.54 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.826 0.346 . . . . 0.0 110.971 -179.371 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 98' ' ' TRP . . . . . 0.89 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 21.6 m-90 -90.31 108.93 29.97 Favored Pre-proline 0 N--CA 1.445 -0.681 0 N-CA-C 108.127 -1.064 . . . . 0.0 108.127 174.303 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 99' ' ' PRO . . . . . 0.451 ' HD3' ' HA ' ' A' ' 98' ' ' TRP . 46.9 Cg_exo -62.97 -138.89 0.0 OUTLIER 'Trans proline' 0 CA--C 1.533 0.44 0 C-N-CA 123.616 2.877 . . . . 0.0 114.45 -171.828 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 4.2 p -55.38 -25.92 18.1 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.195 0 CA-C-O 121.427 0.632 . . . . 0.0 110.759 -176.939 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 101' ' ' CYS . . . . . 0.436 ' SG ' ' HG2' ' A' ' 38' ' ' GLU . 39.9 m -55.98 -39.16 71.43 Favored 'General case' 0 C--N 1.317 -0.844 0 CA-C-N 114.896 -1.047 . . . . 0.0 111.427 177.703 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -70.86 -41.42 71.44 Favored 'General case' 0 CA--C 1.519 -0.219 0 CA-C-O 120.877 0.37 . . . . 0.0 110.722 179.609 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -64.34 -43.02 95.91 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 121.074 0.464 . . . . 0.0 110.274 178.171 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 60.1 mtp180 -62.92 -30.82 71.84 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 115.51 -0.768 . . . . 0.0 110.897 176.696 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 105' ' ' ALA . . . . . 0.613 ' HB1' ' HA ' ' A' ' 30' ' ' ILE . . . -85.23 -21.27 29.16 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.72 -0.673 . . . . 0.0 111.456 -177.966 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . 0.466 ' O ' ' HG2' ' A' ' 108' ' ' ARG . . . 102.55 67.71 0.78 Allowed Glycine 0 CA--C 1.52 0.393 0 CA-C-N 115.892 -0.595 . . . . 0.0 112.288 -178.636 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -57.54 147.63 26.32 Favored 'General case' 0 C--O 1.236 0.362 0 C-N-CA 122.895 0.478 . . . . 0.0 111.6 -177.609 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 108' ' ' ARG . . . . . 0.466 ' HG2' ' O ' ' A' ' 106' ' ' GLY . 3.6 ptp180 . . . . . 0 C--O 1.251 1.149 0 CA-C-O 118.496 -0.764 . . . . 0.0 110.582 -171.575 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.538 ' O ' HG12 ' A' ' 30' ' ' ILE . 26.3 m-20 . . . . . 0 CA--C 1.5 -0.946 0 CA-C-O 121.744 0.783 . . . . 0.0 109.688 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . 0.533 ' HA3' HD13 ' A' ' 83' ' ' ILE . . . -72.36 -1.03 49.72 Favored Glycine 0 N--CA 1.434 -1.462 0 CA-C-N 114.596 -1.184 . . . . 0.0 111.091 178.403 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 14.9 m -73.8 -40.96 63.02 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-O 121.744 0.783 . . . . 0.0 109.293 175.089 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.538 HG12 ' O ' ' A' ' 27' ' ' ASP . 0.0 OUTLIER -70.99 -36.33 63.13 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.633 0 CA-C-N 114.548 -1.205 . . . . 0.0 107.78 177.218 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' TRP . . . . . 0.625 ' CD1' HG22 ' A' ' 83' ' ' ILE . 49.1 m95 -72.34 -35.96 68.7 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 114.781 -1.1 . . . . 0.0 111.075 -178.32 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.444 ' HB3' ' O ' ' A' ' 28' ' ' GLY . 0.0 OUTLIER -71.0 -35.88 72.24 Favored 'General case' 0 N--CA 1.45 -0.449 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.115 177.395 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . 0.444 ' HB2' ' CB ' ' A' ' 105' ' ' ALA . . . -70.38 -37.19 74.49 Favored 'General case' 0 N--CA 1.446 -0.65 0 C-N-CA 120.869 -0.332 . . . . 0.0 110.944 177.816 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . 0.517 HG13 ' O ' ' A' ' 30' ' ' ILE . 72.6 mt -67.04 -46.97 83.44 Favored 'Isoleucine or valine' 0 C--O 1.234 0.238 0 CA-C-O 121.036 0.446 . . . . 0.0 110.215 174.949 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -57.96 -38.31 75.77 Favored 'General case' 0 N--CA 1.451 -0.386 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.445 176.833 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -72.71 -13.31 78.29 Favored Glycine 0 N--CA 1.451 -0.352 0 CA-C-N 115.683 -0.689 . . . . 0.0 111.838 179.824 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 53.1 t -95.9 -59.09 1.93 Allowed 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.639 -0.28 . . . . 0.0 111.413 -177.092 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . 0.854 ' HG3' ' SG ' ' A' ' 101' ' ' CYS . 26.5 mt-10 -88.93 -22.95 22.84 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 120.651 0.263 . . . . 0.0 111.619 -173.536 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -106.26 -12.13 15.81 Favored 'General case' 0 N--CA 1.447 -0.58 0 C-N-CA 120.184 -0.607 . . . . 0.0 111.717 -179.208 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 77.99 15.98 80.45 Favored Glycine 0 CA--C 1.507 -0.459 0 N-CA-C 109.935 -1.266 . . . . 0.0 109.935 -176.861 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 73.07 57.03 5.43 Favored Glycine 0 N--CA 1.435 -1.416 0 CA-C-N 114.072 -1.064 . . . . 0.0 111.516 -175.334 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 2.6 t-20 -140.19 98.55 3.47 Favored 'General case' 0 N--CA 1.447 -0.609 0 N-CA-C 109.194 -0.669 . . . . 0.0 109.194 -177.713 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' TRP . . . . . 0.767 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 32.3 m95 -84.07 2.37 39.6 Favored 'General case' 0 C--N 1.319 -0.758 0 CA-C-N 115.485 -0.78 . . . . 0.0 109.973 -174.799 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -111.15 1.76 17.46 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-N 114.903 -1.044 . . . . 0.0 111.488 177.41 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.858 HG23 ' HA2' ' A' ' 53' ' ' GLY . 6.4 tt -66.91 143.91 15.13 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.677 0 CA-C-O 121.268 0.556 . . . . 0.0 110.358 -177.34 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . 0.441 ' ND2' ' HD1' ' A' ' 52' ' ' TYR . 9.4 t-20 -152.08 98.67 2.46 Favored 'General case' 0 C--N 1.309 -1.179 0 CA-C-O 121.234 0.54 . . . . 0.0 109.67 -178.49 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 21.1 p -75.38 -21.33 58.36 Favored 'General case' 0 C--N 1.317 -0.817 0 CA-C-N 115.362 -0.835 . . . . 0.0 110.292 179.259 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 91.04 18.53 46.46 Favored Glycine 0 N--CA 1.443 -0.848 0 CA-C-N 115.339 -0.846 . . . . 0.0 111.038 178.272 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 28.5 p-10 -95.44 4.47 53.26 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.891 0.377 . . . . 0.0 111.647 -174.407 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . 0.453 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 95.47 -8.22 68.96 Favored Glycine 0 N--CA 1.45 -0.424 0 C-N-CA 120.49 -0.862 . . . . 0.0 111.832 -178.055 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' TYR . . . . . 0.562 ' CE1' ' HB3' ' A' ' 58' ' ' ASP . 0.2 OUTLIER -112.89 144.65 42.08 Favored 'General case' 0 CA--C 1.511 -0.544 0 N-CA-C 106.826 -1.546 . . . . 0.0 106.826 176.131 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' TYR . . . . . 0.611 ' O ' ' HA ' ' A' ' 56' ' ' GLN . 53.6 m-85 -117.38 169.05 9.8 Favored 'General case' 0 C--N 1.306 -1.307 0 N-CA-C 113.488 0.922 . . . . 0.0 113.488 -165.388 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.858 ' HA2' HG23 ' A' ' 45' ' ' ILE . . . -62.89 159.05 36.36 Favored Glycine 0 CA--C 1.501 -0.797 0 CA-C-N 114.845 -1.071 . . . . 0.0 114.018 -171.991 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . 0.578 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 101.72 -103.73 2.56 Favored Glycine 0 N--CA 1.437 -1.249 0 N-CA-C 111.402 -0.679 . . . . 0.0 111.402 -177.212 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.55 HG23 ' HG2' ' A' ' 82' ' ' GLN . 2.8 t -92.05 0.78 9.23 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 CA-C-O 121.652 0.739 . . . . 0.0 109.898 -178.61 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' GLN . . . . . 0.611 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 8.3 mm-40 59.51 50.37 7.55 Favored 'General case' 0 N--CA 1.464 0.269 0 CA-C-N 114.644 -1.162 . . . . 0.0 113.901 167.92 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 17.8 p90 -120.91 171.45 8.62 Favored 'General case' 0 C--N 1.325 -0.478 0 C-N-CA 119.833 -0.747 . . . . 0.0 112.092 175.112 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.562 ' HB3' ' CE1' ' A' ' 51' ' ' TYR . 6.4 p-10 -82.37 158.6 23.29 Favored 'General case' 0 CA--C 1.516 -0.356 0 N-CA-C 113.686 0.995 . . . . 0.0 113.686 -163.417 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . 0.431 ' HB2' ' CE2' ' A' ' 52' ' ' TYR . 20.6 tp60 -57.84 -39.79 78.53 Favored 'General case' 0 N--CA 1.442 -0.828 0 CA-C-N 113.279 -1.782 . . . . 0.0 111.714 179.229 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -67.47 -49.46 50.9 Favored Glycine 0 N--CA 1.45 -0.404 0 CA-C-N 115.603 -0.726 . . . . 0.0 112.034 -175.303 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 83.2 m -62.87 -41.05 99.25 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 121.252 0.548 . . . . 0.0 110.389 176.57 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' TRP . . . . . 0.438 ' CH2' ' HA ' ' A' ' 74' ' ' ALA . 54.1 t-105 -56.99 -50.1 73.74 Favored 'General case' 0 N--CA 1.444 -0.737 0 CA-C-N 115.265 -0.88 . . . . 0.0 109.687 176.734 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . 0.463 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 36.7 tt0 -67.1 -39.28 86.7 Favored 'General case' 0 N--CA 1.445 -0.683 0 CA-C-N 114.918 -1.037 . . . . 0.0 110.91 -178.183 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -62.11 -40.95 97.62 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.539 -0.755 . . . . 0.0 111.109 -176.682 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 9.3 m120 -82.3 -9.61 59.41 Favored 'General case' 0 N--CA 1.45 -0.461 0 CA-C-O 120.908 0.385 . . . . 0.0 110.768 178.521 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 93.23 47.57 3.03 Favored Glycine 0 C--N 1.333 0.373 0 CA-C-N 116.089 -0.505 . . . . 0.0 112.659 173.784 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . 0.587 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -80.2 -22.92 62.1 Favored Glycine 0 N--CA 1.44 -1.045 0 C-N-CA 120.966 -0.635 . . . . 0.0 112.868 -174.621 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 0.871 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 6.8 mp -61.51 -23.48 65.95 Favored 'General case' 0 N--CA 1.447 -0.595 0 N-CA-C 112.483 0.549 . . . . 0.0 112.483 -172.569 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . 0.435 ' HG3' ' N ' ' A' ' 70' ' ' TYR . 3.8 ptm180 -69.02 -30.96 69.44 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 121.19 0.519 . . . . 0.0 110.145 176.041 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 70' ' ' TYR . . . . . 0.791 ' HB3' ' HG3' ' A' ' 81' ' ' GLU . 79.5 m-85 -79.71 -34.8 39.78 Favored 'General case' 0 N--CA 1.446 -0.674 0 N-CA-C 107.679 -1.23 . . . . 0.0 107.679 177.144 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.688 ' HB1' ' HB2' ' A' ' 77' ' ' ALA . . . 161.57 128.73 0.01 OUTLIER Pre-proline 0 CA--C 1.509 -0.602 0 CA-C-N 112.609 -2.087 . . . . 0.0 106.689 -178.452 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 72' ' ' PRO . . . . . 0.871 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 32.3 Cg_exo -54.9 -6.68 0.7 Allowed 'Trans proline' 0 C--N 1.33 -0.416 0 C-N-CA 123.171 2.581 . . . . 0.0 114.246 -177.08 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 73' ' ' ARG . . . . . 0.421 ' HE ' ' CG ' ' A' ' 75' ' ' ASP . 12.4 ptm180 -149.59 142.77 25.06 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-O 121.095 0.474 . . . . 0.0 109.794 176.515 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . 0.438 ' HA ' ' CH2' ' A' ' 62' ' ' TRP . . . -61.06 -23.48 65.49 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.267 -0.879 . . . . 0.0 113.017 -175.159 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . 0.481 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 9.4 p-10 -88.21 -0.57 57.26 Favored 'General case' 0 C--N 1.33 -0.262 0 C-N-CA 120.544 -0.462 . . . . 0.0 110.905 -179.54 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 62.0 tp -103.75 -31.11 10.0 Favored 'General case' 0 C--N 1.323 -0.584 0 N-CA-C 109.026 -0.731 . . . . 0.0 109.026 172.641 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . 0.688 ' HB2' ' HB1' ' A' ' 71' ' ' ALA . . . -79.81 162.05 25.32 Favored 'General case' 0 N--CA 1.446 -0.631 0 CA-C-N 115.142 -0.935 . . . . 0.0 109.426 174.262 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 61.7 p -100.66 -175.0 2.78 Favored 'General case' 0 C--N 1.312 -1.046 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.874 -176.688 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . 0.767 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 11.9 mtp180 -50.92 -55.24 18.11 Favored 'General case' 0 C--O 1.222 -0.383 0 O-C-N 123.406 0.441 . . . . 0.0 110.594 179.518 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 11.3 pt-20 -61.76 -41.88 98.27 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 115.893 -0.594 . . . . 0.0 111.501 -174.326 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 81' ' ' GLU . . . . . 0.791 ' HG3' ' HB3' ' A' ' 70' ' ' TYR . 0.2 OUTLIER -64.2 -52.05 60.73 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 115.405 -0.816 . . . . 0.0 112.138 177.457 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 82' ' ' GLN . . . . . 0.55 ' HG2' HG23 ' A' ' 55' ' ' VAL . 5.7 tt0 -68.1 -31.34 70.89 Favored 'General case' 0 C--N 1.317 -0.805 0 CA-C-N 115.364 -0.835 . . . . 0.0 110.409 -176.759 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . 0.625 HG22 ' CD1' ' A' ' 31' ' ' TRP . 25.0 mt -59.83 -44.54 94.33 Favored 'Isoleucine or valine' 0 C--O 1.216 -0.691 0 CA-C-N 115.471 -0.786 . . . . 0.0 109.563 173.524 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 84' ' ' ALA . . . . . 0.585 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -63.22 -40.64 98.04 Favored 'General case' 0 C--O 1.236 0.371 0 CA-C-O 121.352 0.596 . . . . 0.0 111.16 -175.632 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 44.2 t -69.02 -48.04 72.09 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 CA-C-N 115.685 -0.688 . . . . 0.0 110.919 177.758 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -57.05 -30.43 64.25 Favored 'General case' 0 N--CA 1.449 -0.48 0 CA-C-O 120.895 0.378 . . . . 0.0 110.401 172.796 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 87' ' ' GLU . . . . . 0.809 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 8.1 mm-40 -60.48 -44.58 95.78 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.196 -179.178 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 83.4 t -62.23 -44.91 99.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 C-N-CA 120.407 -0.517 . . . . 0.0 109.857 178.864 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 89' ' ' THR . . . . . 0.684 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 1.2 m -61.92 -47.78 83.4 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 115.504 -0.771 . . . . 0.0 111.478 -178.896 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 90' ' ' ARG . . . . . 0.733 ' HA ' ' OE1' ' A' ' 93' ' ' GLN . 2.5 ptt180 -62.02 -32.66 73.17 Favored 'General case' 0 CA--C 1.52 -0.176 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.361 -174.992 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 91' ' ' LEU . . . . . 0.809 ' HG ' ' O ' ' A' ' 87' ' ' GLU . 45.6 mt -61.06 -33.9 74.04 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-O 121.358 0.599 . . . . 0.0 110.529 -176.965 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 1.3 mtm180 -86.75 -45.36 11.01 Favored 'General case' 0 N--CA 1.443 -0.788 0 CA-C-N 115.221 -0.9 . . . . 0.0 110.589 -169.707 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 93' ' ' GLN . . . . . 0.733 ' OE1' ' HA ' ' A' ' 90' ' ' ARG . 0.0 OUTLIER -99.55 -21.32 15.95 Favored 'General case' 0 C--N 1.323 -0.572 0 N-CA-C 113.13 0.789 . . . . 0.0 113.13 -172.376 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 82.93 38.86 10.82 Favored Glycine 0 C--N 1.333 0.39 0 C-N-CA 120.926 -0.654 . . . . 0.0 112.523 171.441 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 95' ' ' TRP . . . . . 0.593 ' CZ2' ' HD3' ' A' ' 90' ' ' ARG . 20.7 m95 66.6 11.06 7.89 Favored 'General case' 0 C--O 1.221 -0.4 0 C-N-CA 123.445 0.698 . . . . 0.0 110.247 -179.212 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -68.7 -35.22 79.89 Favored Glycine 0 N--CA 1.453 -0.226 0 C-N-CA 121.236 -0.507 . . . . 0.0 112.352 176.817 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . 0.442 ' O ' ' HD3' ' A' ' 99' ' ' PRO . . . -66.85 -29.63 69.59 Favored 'General case' 0 CA--C 1.517 -0.294 0 CA-C-O 121.051 0.453 . . . . 0.0 110.577 178.857 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 98' ' ' TRP . . . . . 0.684 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 24.3 m-90 -92.72 108.41 31.57 Favored Pre-proline 0 N--CA 1.445 -0.722 0 N-CA-C 108.438 -0.949 . . . . 0.0 108.438 177.52 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 99' ' ' PRO . . . . . 0.442 ' HD3' ' O ' ' A' ' 97' ' ' ALA . 45.7 Cg_exo -63.08 -131.3 0.0 OUTLIER 'Trans proline' 0 CA--C 1.541 0.854 0 C-N-CA 123.492 2.794 . . . . 0.0 114.5 -175.06 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 39.2 t -55.65 -29.41 24.97 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.146 0 O-C-N 122.081 -0.387 . . . . 0.0 111.612 -174.662 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 101' ' ' CYS . . . . . 0.854 ' SG ' ' HG3' ' A' ' 38' ' ' GLU . 71.1 m -68.4 -31.97 71.69 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 116.56 -0.291 . . . . 0.0 111.604 -174.87 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 102' ' ' ALA . . . . . 0.554 ' HB2' ' CB ' ' A' ' 98' ' ' TRP . . . -70.36 -43.66 69.72 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.033 0.444 . . . . 0.0 110.335 176.185 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -62.08 -40.21 95.06 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.267 178.583 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 104' ' ' ARG . . . . . 0.627 ' HA ' ' NE ' ' A' ' 104' ' ' ARG . 1.9 mmp_? -69.16 -25.72 64.51 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.408 -0.814 . . . . 0.0 111.45 177.68 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 105' ' ' ALA . . . . . 0.444 ' CB ' ' HB2' ' A' ' 33' ' ' ALA . . . -83.38 -21.6 33.0 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.911 -177.477 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 105.38 47.75 1.11 Allowed Glycine 0 CA--C 1.521 0.456 0 C-N-CA 120.88 -0.676 . . . . 0.0 111.98 -176.599 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -57.74 149.45 22.06 Favored 'General case' 0 C--N 1.327 -0.395 0 C-N-CA 123.636 0.774 . . . . 0.0 112.23 -178.858 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 108' ' ' ARG . . . . . 0.459 ' O ' ' HD3' ' A' ' 108' ' ' ARG . 0.0 OUTLIER . . . . . 0 C--O 1.246 0.899 0 CA-C-N 115.771 -0.649 . . . . 0.0 110.373 -177.095 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.48 ' O ' HG12 ' A' ' 30' ' ' ILE . 27.5 m-20 . . . . . 0 CA--C 1.507 -0.708 0 CA-C-O 121.41 0.624 . . . . 0.0 110.092 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -63.4 -12.19 44.34 Favored Glycine 0 CA--C 1.504 -0.614 0 CA-C-N 114.977 -1.01 . . . . 0.0 111.206 -177.726 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 19.3 m -76.24 -43.35 42.4 Favored 'General case' 0 C--N 1.317 -0.809 0 CA-C-O 121.914 0.864 . . . . 0.0 109.477 177.95 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.523 HG22 ' HB1' ' A' ' 105' ' ' ALA . 0.1 OUTLIER -68.9 -38.85 79.15 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.802 0 CA-C-N 114.178 -1.373 . . . . 0.0 107.871 179.775 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' TRP . . . . . 0.455 ' CD1' HG21 ' A' ' 83' ' ' ILE . 17.1 m95 -67.48 -36.96 82.14 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 114.735 -1.121 . . . . 0.0 110.511 -177.627 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 9.7 t70 -75.2 -38.86 60.57 Favored 'General case' 0 N--CA 1.444 -0.759 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.692 179.017 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . 0.529 ' HB3' ' HB3' ' A' ' 105' ' ' ALA . . . -70.82 -35.79 72.64 Favored 'General case' 0 N--CA 1.448 -0.548 0 C-N-CA 120.78 -0.368 . . . . 0.0 110.903 178.737 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . 0.489 HG13 ' O ' ' A' ' 30' ' ' ILE . 64.8 mt -62.33 -45.6 98.38 Favored 'Isoleucine or valine' 0 C--O 1.234 0.247 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 173.646 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . 0.553 ' HA ' ' O ' ' A' ' 54' ' ' GLY . . . -57.62 -38.52 75.1 Favored 'General case' 0 N--CA 1.451 -0.404 0 CA-C-N 115.506 -0.77 . . . . 0.0 110.056 176.734 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . 0.444 ' HA2' ' N ' ' A' ' 41' ' ' GLY . . . -73.6 -22.06 78.81 Favored Glycine 0 N--CA 1.451 -0.338 0 CA-C-N 115.467 -0.788 . . . . 0.0 111.944 -179.814 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 6.3 t -84.53 -56.65 3.5 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-O 120.831 0.348 . . . . 0.0 111.608 -178.704 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . 0.405 ' HB2' ' SG ' ' A' ' 101' ' ' CYS . 11.4 tp10 -87.61 -30.53 20.41 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 121.063 0.459 . . . . 0.0 110.511 -170.453 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -107.59 -8.01 16.31 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.956 -0.566 . . . . 0.0 111.871 -176.565 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 80.23 4.06 89.79 Favored Glycine 0 CA--C 1.507 -0.408 0 N-CA-C 110.239 -1.144 . . . . 0.0 110.239 -177.535 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . 0.444 ' N ' ' HA2' ' A' ' 36' ' ' GLY . . . 89.95 56.41 1.85 Allowed Glycine 0 N--CA 1.432 -1.568 0 CA-C-N 114.006 -1.097 . . . . 0.0 111.302 -175.986 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 2.4 t-20 -141.71 99.48 3.56 Favored 'General case' 0 N--CA 1.447 -0.596 0 N-CA-C 108.732 -0.84 . . . . 0.0 108.732 -175.655 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' TRP . . . . . 0.757 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 23.4 m95 -83.81 -4.33 58.57 Favored 'General case' 0 C--N 1.313 -1.005 0 CA-C-N 115.723 -0.672 . . . . 0.0 110.158 -173.39 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . 0.423 ' HA ' ' HB2' ' A' ' 75' ' ' ASP . . . -109.3 10.74 25.57 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 115.183 -0.917 . . . . 0.0 111.06 179.351 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.72 HG21 ' HA2' ' A' ' 53' ' ' GLY . 9.0 tt -76.09 144.57 11.71 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.792 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.31 179.892 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 10.3 t-20 -142.46 97.96 3.21 Favored 'General case' 0 C--N 1.31 -1.111 0 N-CA-C 108.995 -0.743 . . . . 0.0 108.995 177.393 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 10.0 p -70.08 -22.28 63.06 Favored 'General case' 0 N--CA 1.445 -0.715 0 CA-C-N 114.819 -1.082 . . . . 0.0 111.345 -173.753 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 90.39 17.2 53.66 Favored Glycine 0 N--CA 1.44 -1.066 0 N-CA-C 110.094 -1.202 . . . . 0.0 110.094 -176.773 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 5.1 m-20 -91.34 -5.91 53.85 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.169 -0.516 . . . . 0.0 111.01 -175.183 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . 0.418 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 94.25 -5.1 71.16 Favored Glycine 0 N--CA 1.444 -0.77 0 N-CA-C 110.081 -1.208 . . . . 0.0 110.081 -172.676 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' TYR . . . . . 0.546 ' HA ' ' HA ' ' A' ' 58' ' ' ASP . 0.4 OUTLIER -111.61 149.15 31.91 Favored 'General case' 0 N--CA 1.446 -0.664 0 N-CA-C 106.976 -1.491 . . . . 0.0 106.976 177.916 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' TYR . . . . . 0.686 ' O ' ' HA ' ' A' ' 56' ' ' GLN . 71.0 m-85 -114.59 170.37 8.36 Favored 'General case' 0 C--N 1.307 -1.245 0 C-N-CA 120.432 -0.507 . . . . 0.0 111.908 -168.655 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.72 ' HA2' HG21 ' A' ' 45' ' ' ILE . . . -57.94 171.91 3.45 Favored Glycine 0 C--O 1.227 -0.321 0 N-CA-C 115.072 0.789 . . . . 0.0 115.072 -168.919 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . 0.669 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 80.4 -101.76 2.02 Favored Glycine 0 N--CA 1.442 -0.924 0 C-N-CA 120.955 -0.641 . . . . 0.0 112.148 177.367 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.485 ' HB ' ' CD1' ' A' ' 57' ' ' PHE . 2.4 t -83.3 -3.04 7.13 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-O 121.646 0.736 . . . . 0.0 110.296 -176.68 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' GLN . . . . . 0.686 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 7.7 tp-100 54.83 50.47 15.6 Favored 'General case' 0 CA--C 1.53 0.186 0 CA-C-N 114.034 -1.439 . . . . 0.0 112.852 169.203 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . 0.485 ' CD1' ' HB ' ' A' ' 55' ' ' VAL . 2.0 p90 -121.54 163.32 19.05 Favored 'General case' 0 C--N 1.325 -0.474 0 C-N-CA 120.213 -0.595 . . . . 0.0 111.532 176.995 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.546 ' HA ' ' HA ' ' A' ' 51' ' ' TYR . 7.8 p-10 -72.29 162.3 29.65 Favored 'General case' 0 CA--C 1.514 -0.419 0 N-CA-C 113.76 1.022 . . . . 0.0 113.76 -163.511 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . 0.433 ' HB2' ' HE1' ' A' ' 52' ' ' TYR . 17.7 tp60 -55.15 -42.2 72.76 Favored 'General case' 0 N--CA 1.441 -0.878 0 CA-C-N 114.327 -1.306 . . . . 0.0 110.969 177.206 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -67.84 -50.44 41.63 Favored Glycine 0 C--O 1.224 -0.481 0 CA-C-N 115.183 -0.917 . . . . 0.0 112.584 -172.819 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 97.1 m -61.67 -41.46 97.57 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 121.177 0.513 . . . . 0.0 110.8 177.139 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' TRP . . . . . 0.451 ' CH2' ' HA ' ' A' ' 74' ' ' ALA . 52.4 t-105 -58.23 -49.11 78.23 Favored 'General case' 0 N--CA 1.446 -0.671 0 CA-C-N 115.467 -0.788 . . . . 0.0 109.691 175.786 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . 0.483 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 36.2 tt0 -67.13 -36.75 82.55 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.193 -0.912 . . . . 0.0 110.801 -178.205 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -63.53 -41.49 98.47 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.591 -0.731 . . . . 0.0 111.195 -176.882 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . 0.641 HD21 ' N ' ' A' ' 65' ' ' ASN . 0.7 OUTLIER -81.09 -8.74 59.83 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 121.1 0.476 . . . . 0.0 110.22 177.632 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . 0.455 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 89.35 48.6 3.71 Favored Glycine 0 C--N 1.334 0.433 0 CA-C-N 115.746 -0.661 . . . . 0.0 112.271 174.678 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . 0.482 ' HA2' ' HD1' ' A' ' 70' ' ' TYR . . . -79.36 -22.91 64.02 Favored Glycine 0 N--CA 1.439 -1.121 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.838 -175.051 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 0.82 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 6.9 mp -58.89 -25.95 63.84 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 112.893 0.701 . . . . 0.0 112.893 -172.945 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . 0.455 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 14.9 ptp180 -70.5 -29.24 65.7 Favored 'General case' 0 C--N 1.318 -0.772 0 CA-C-O 121.079 0.466 . . . . 0.0 110.553 176.643 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 70' ' ' TYR . . . . . 0.611 ' HB3' ' CG ' ' A' ' 81' ' ' GLU . 74.2 m-85 -79.32 -34.25 42.46 Favored 'General case' 0 N--CA 1.444 -0.749 0 N-CA-C 107.05 -1.463 . . . . 0.0 107.05 175.764 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.702 ' HB2' ' HB3' ' A' ' 77' ' ' ALA . . . 161.81 130.27 0.01 OUTLIER Pre-proline 0 CA--C 1.511 -0.524 0 CA-C-N 112.037 -2.347 . . . . 0.0 106.817 -179.117 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 72' ' ' PRO . . . . . 0.82 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 13.5 Cg_exo -58.33 -2.13 0.85 Allowed 'Trans proline' 0 C--N 1.33 -0.415 0 C-N-CA 122.837 2.358 . . . . 0.0 113.965 -177.083 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 73' ' ' ARG . . . . . 0.44 ' HB2' ' CD2' ' A' ' 52' ' ' TYR . 0.0 OUTLIER -153.3 142.56 21.52 Favored 'General case' 0 C--N 1.316 -0.85 0 N-CA-C 109.211 -0.663 . . . . 0.0 109.211 177.695 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . 0.451 ' HA ' ' CH2' ' A' ' 62' ' ' TRP . . . -60.2 -27.94 67.57 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.32 -0.855 . . . . 0.0 112.721 -175.464 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . 0.553 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 6.7 p-10 -86.87 3.2 46.44 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 121.246 0.546 . . . . 0.0 110.824 -176.6 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.526 ' HB3' ' HB1' ' A' ' 71' ' ' ALA . 50.7 tp -103.68 -34.12 8.72 Favored 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 171.155 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . 0.702 ' HB3' ' HB2' ' A' ' 71' ' ' ALA . . . -79.86 161.51 25.56 Favored 'General case' 0 N--CA 1.448 -0.568 0 CA-C-N 115.1 -0.955 . . . . 0.0 109.93 175.621 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 36.1 p -101.2 -173.19 2.31 Favored 'General case' 0 C--N 1.318 -0.796 0 C-N-CA 120.788 -0.365 . . . . 0.0 110.74 179.874 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . 0.757 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 9.0 mtp85 -52.59 -51.98 57.34 Favored 'General case' 0 CA--C 1.513 -0.46 0 O-C-N 123.592 0.558 . . . . 0.0 110.953 -174.789 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 1.3 pm0 -59.71 -41.67 91.34 Favored 'General case' 0 C--N 1.317 -0.836 0 CA-C-N 115.319 -0.855 . . . . 0.0 112.131 -176.504 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 81' ' ' GLU . . . . . 0.632 ' CB ' ' HB1' ' A' ' 77' ' ' ALA . 2.3 mp0 -62.26 -51.23 68.57 Favored 'General case' 0 C--O 1.234 0.254 0 O-C-N 122.352 -0.218 . . . . 0.0 111.322 174.377 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 82' ' ' GLN . . . . . 0.43 ' HB2' ' HZ3' ' A' ' 43' ' ' TRP . 50.3 mt-30 -60.9 -37.01 80.74 Favored 'General case' 0 CA--C 1.514 -0.413 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.66 -177.9 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . 0.495 ' O ' ' HB3' ' A' ' 87' ' ' GLU . 42.1 mt -59.28 -45.51 93.06 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.777 0 CA-C-N 115.139 -0.937 . . . . 0.0 109.801 176.742 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 84' ' ' ALA . . . . . 0.632 ' O ' ' HG3' ' A' ' 87' ' ' GLU . . . -66.35 -45.98 78.32 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.621 -177.908 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . 0.416 HG22 ' O ' ' A' ' 81' ' ' GLU . 44.0 t -66.06 -49.01 79.61 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-O 120.779 0.323 . . . . 0.0 111.631 -179.926 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -67.02 -31.3 71.75 Favored 'General case' 0 CA--C 1.516 -0.359 0 CA-C-O 121.147 0.498 . . . . 0.0 110.498 -179.719 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 87' ' ' GLU . . . . . 0.757 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 0.1 OUTLIER -69.69 -31.5 69.58 Favored 'General case' 0 C--N 1.322 -0.604 0 C-N-CA 120.149 -0.62 . . . . 0.0 110.325 -176.455 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.574 ' O ' ' HG3' ' A' ' 92' ' ' ARG . 69.1 t -61.43 -40.77 87.47 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.224 0 N-CA-C 108.839 -0.8 . . . . 0.0 108.839 172.89 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 89' ' ' THR . . . . . 0.892 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 4.3 m -64.8 -43.32 93.54 Favored 'General case' 0 N--CA 1.447 -0.597 0 CA-C-N 115.648 -0.706 . . . . 0.0 110.388 179.367 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 90' ' ' ARG . . . . . 0.522 ' HG3' ' O ' ' A' ' 87' ' ' GLU . 1.2 ppt_? -61.53 -31.24 71.24 Favored 'General case' 0 C--O 1.223 -0.336 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.561 179.907 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 91' ' ' LEU . . . . . 0.757 ' HG ' ' O ' ' A' ' 87' ' ' GLU . 28.8 mt -64.07 -33.56 76.03 Favored 'General case' 0 C--N 1.318 -0.801 0 CA-C-O 121.63 0.729 . . . . 0.0 109.88 -179.872 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . 0.574 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 7.6 mtm180 -91.62 -51.58 5.18 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 115.058 -0.974 . . . . 0.0 110.618 -169.925 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 93' ' ' GLN . . . . . 0.558 HE22 ' HZ3' ' A' ' 98' ' ' TRP . 0.0 OUTLIER -106.49 -14.51 15.05 Favored 'General case' 0 N--CA 1.443 -0.786 0 CA-C-N 115.446 -0.797 . . . . 0.0 112.016 -175.293 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . 0.415 ' O ' ' HA ' ' A' ' 90' ' ' ARG . . . 86.74 -109.14 3.39 Favored Glycine 0 CA--C 1.496 -1.116 0 N-CA-C 110.797 -0.921 . . . . 0.0 110.797 178.813 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 95' ' ' TRP . . . . . 0.452 ' HA ' ' HE3' ' A' ' 98' ' ' TRP . 6.6 m95 -141.17 24.39 2.14 Favored 'General case' 0 C--N 1.311 -1.103 0 N-CA-C 107.207 -1.405 . . . . 0.0 107.207 -179.794 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -77.29 -20.76 74.57 Favored Glycine 0 N--CA 1.447 -0.594 0 CA-C-N 114.381 -1.281 . . . . 0.0 111.831 175.616 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . 0.436 ' O ' ' HD3' ' A' ' 99' ' ' PRO . . . -90.35 -24.04 20.95 Favored 'General case' 0 CA--C 1.516 -0.364 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 176.248 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 98' ' ' TRP . . . . . 0.892 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 24.3 m-90 -96.59 104.69 18.88 Favored Pre-proline 0 N--CA 1.451 -0.42 0 N-CA-C 108.811 -0.811 . . . . 0.0 108.811 173.643 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 99' ' ' PRO . . . . . 0.462 ' HD3' ' HA ' ' A' ' 98' ' ' TRP . 28.9 Cg_exo -67.34 -110.1 0.0 OUTLIER 'Trans proline' 0 CA--C 1.538 0.719 0 C-N-CA 123.49 2.793 . . . . 0.0 114.757 -171.826 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . 0.491 ' O ' ' HG2' ' A' ' 104' ' ' ARG . 40.8 t -67.41 -31.5 53.09 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-O 121.305 0.574 . . . . 0.0 110.432 -174.506 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 101' ' ' CYS . . . . . 0.405 ' SG ' ' HB2' ' A' ' 38' ' ' GLU . 98.5 m -68.71 -32.78 72.82 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 115.28 -0.873 . . . . 0.0 111.92 -171.82 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 102' ' ' ALA . . . . . 0.444 ' HB2' ' CB ' ' A' ' 98' ' ' TRP . . . -69.65 -44.63 70.16 Favored 'General case' 0 C--N 1.324 -0.513 0 C-N-CA 120.651 -0.419 . . . . 0.0 110.202 178.822 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -65.66 -34.28 77.85 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 121.172 0.511 . . . . 0.0 110.406 178.5 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 104' ' ' ARG . . . . . 0.491 ' HG2' ' O ' ' A' ' 100' ' ' VAL . 3.4 mmp_? -70.3 -28.5 65.23 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.129 176.544 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 105' ' ' ALA . . . . . 0.529 ' HB3' ' HB3' ' A' ' 33' ' ' ALA . . . -89.43 -20.82 23.46 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.808 -0.633 . . . . 0.0 112.114 -175.549 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 110.4 64.35 0.52 Allowed Glycine 0 N--CA 1.447 -0.61 0 C-N-CA 120.95 -0.643 . . . . 0.0 111.681 -177.155 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -63.53 149.25 46.67 Favored 'General case' 0 C--N 1.328 -0.337 0 C-N-CA 122.848 0.459 . . . . 0.0 110.824 -176.823 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 108' ' ' ARG . . . . . 0.405 ' CZ ' HD12 ' A' ' 30' ' ' ILE . 91.2 mtt180 . . . . . 0 C--O 1.247 0.944 0 CA-C-O 118.368 -0.825 . . . . 0.0 109.756 -173.016 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 . . . . . 0 CA--C 1.507 -0.679 0 CA-C-O 121.742 0.782 . . . . 0.0 109.605 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -65.84 -9.54 46.57 Favored Glycine 0 N--CA 1.441 -0.969 0 CA-C-N 114.868 -1.06 . . . . 0.0 110.721 177.381 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 21.8 m -76.93 -41.5 43.16 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-O 121.571 0.7 . . . . 0.0 109.387 175.181 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.543 ' HA ' ' HB1' ' A' ' 105' ' ' ALA . 0.8 OUTLIER -66.68 -38.81 82.34 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.64 0 N-CA-C 107.645 -1.243 . . . . 0.0 107.645 177.223 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' TRP . . . . . 0.473 ' CD1' HG22 ' A' ' 83' ' ' ILE . 36.8 m95 -70.91 -35.75 72.42 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 114.627 -1.169 . . . . 0.0 110.894 -177.922 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.41 ' HB2' HH21 ' A' ' 79' ' ' ARG . 1.9 t70 -72.53 -36.76 68.4 Favored 'General case' 0 N--CA 1.449 -0.509 0 CA-C-N 116.387 -0.37 . . . . 0.0 110.338 177.771 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . 0.493 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -70.19 -35.36 73.9 Favored 'General case' 0 N--CA 1.448 -0.552 0 C-N-CA 120.627 -0.429 . . . . 0.0 110.392 177.96 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . 0.443 HG13 ' O ' ' A' ' 30' ' ' ILE . 64.5 mt -67.13 -43.54 88.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.312 174.05 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . 0.513 ' HA ' ' O ' ' A' ' 54' ' ' GLY . . . -59.59 -35.02 73.47 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 121.313 0.578 . . . . 0.0 110.15 175.973 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . 0.418 ' HA2' ' N ' ' A' ' 41' ' ' GLY . . . -77.62 -14.97 81.88 Favored Glycine 0 N--CA 1.448 -0.564 0 CA-C-N 115.497 -0.774 . . . . 0.0 111.873 178.409 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 36.8 t -95.92 -48.01 5.89 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-O 120.737 0.303 . . . . 0.0 111.387 -177.032 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . 0.483 ' HG2' ' SG ' ' A' ' 101' ' ' CYS . 8.5 mm-40 -86.91 -34.2 19.46 Favored 'General case' 0 CA--C 1.511 -0.541 0 CA-C-O 121.077 0.465 . . . . 0.0 110.17 -175.538 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -107.94 -12.47 15.16 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.613 -0.721 . . . . 0.0 112.064 -174.089 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 76.31 16.65 80.55 Favored Glycine 0 N--CA 1.449 -0.461 0 N-CA-C 109.957 -1.257 . . . . 0.0 109.957 -176.767 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . 0.418 ' N ' ' HA2' ' A' ' 36' ' ' GLY . . . 82.98 59.91 2.12 Favored Glycine 0 N--CA 1.434 -1.475 0 CA-C-N 113.944 -1.128 . . . . 0.0 111.807 -176.904 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' ASN . . . . . 0.823 ' HB3' ' HB ' ' A' ' 45' ' ' ILE . 3.4 m120 -146.1 96.02 2.72 Favored 'General case' 0 C--N 1.324 -0.515 0 N-CA-C 109.223 -0.658 . . . . 0.0 109.223 -178.893 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' TRP . . . . . 0.685 ' CE2' ' HG2' ' A' ' 79' ' ' ARG . 52.5 m95 -78.88 -14.39 59.26 Favored 'General case' 0 C--N 1.314 -0.975 0 CA-C-N 115.711 -0.677 . . . . 0.0 109.803 -177.941 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -102.48 7.97 40.12 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 115.271 -0.877 . . . . 0.0 111.289 -179.692 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.823 ' HB ' ' HB3' ' A' ' 42' ' ' ASN . 8.2 tt -74.18 145.16 11.62 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.708 0 CA-C-O 121.401 0.619 . . . . 0.0 110.984 -177.182 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 17.4 t-20 -141.5 96.19 2.94 Favored 'General case' 0 C--N 1.309 -1.183 0 N-CA-C 109.099 -0.704 . . . . 0.0 109.099 178.953 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 19.7 p -68.61 -21.3 64.51 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 115.029 -0.987 . . . . 0.0 111.058 -177.486 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 88.06 18.22 56.27 Favored Glycine 0 N--CA 1.441 -1.001 0 N-CA-C 110.373 -1.091 . . . . 0.0 110.373 179.44 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 92.2 m-20 -97.37 10.23 40.2 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 121.092 0.472 . . . . 0.0 111.347 -174.621 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . 0.422 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 90.96 -11.6 71.59 Favored Glycine 0 N--CA 1.443 -0.842 0 N-CA-C 110.853 -0.899 . . . . 0.0 110.853 -178.003 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 51' ' ' TYR . . . . . 0.568 ' HA ' ' HA ' ' A' ' 58' ' ' ASP . 0.7 OUTLIER -109.58 152.36 25.61 Favored 'General case' 0 CA--C 1.509 -0.624 0 N-CA-C 108.092 -1.077 . . . . 0.0 108.092 178.026 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 52' ' ' TYR . . . . . 0.754 ' O ' ' HA ' ' A' ' 56' ' ' GLN . 18.4 m-85 -112.81 169.93 8.56 Favored 'General case' 0 C--N 1.31 -1.12 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.698 -169.763 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.435 ' CA ' HG22 ' A' ' 45' ' ' ILE . . . -66.08 -171.79 4.07 Favored Glycine 0 N--CA 1.451 -0.361 0 N-CA-C 115.025 0.77 . . . . 0.0 115.025 -168.353 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . 0.624 ' CA ' ' HA ' ' A' ' 43' ' ' TRP . . . 75.27 -101.97 1.42 Allowed Glycine 0 N--CA 1.443 -0.847 0 CA-C-N 114.738 -0.731 . . . . 0.0 112.177 178.475 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.496 ' HB ' ' CE1' ' A' ' 57' ' ' PHE . 2.3 t -84.3 -3.54 7.95 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 CA-C-O 121.606 0.717 . . . . 0.0 109.541 179.409 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' GLN . . . . . 0.754 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 0.0 OUTLIER 57.93 46.83 16.04 Favored 'General case' 0 N--CA 1.463 0.179 0 CA-C-N 114.432 -1.258 . . . . 0.0 113.556 170.256 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . 0.496 ' CE1' ' HB ' ' A' ' 55' ' ' VAL . 0.3 OUTLIER -117.15 166.61 12.03 Favored 'General case' 0 C--N 1.323 -0.581 0 C-N-CA 119.597 -0.841 . . . . 0.0 111.956 175.069 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.568 ' HA ' ' HA ' ' A' ' 51' ' ' TYR . 7.2 p-10 -74.8 162.89 28.25 Favored 'General case' 0 CA--C 1.514 -0.411 0 CA-C-N 115.444 -0.798 . . . . 0.0 113.071 -167.055 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . 0.506 ' HB2' ' CE1' ' A' ' 52' ' ' TYR . 4.5 tp-100 -63.06 -35.36 79.99 Favored 'General case' 0 N--CA 1.448 -0.567 0 CA-C-N 114.318 -1.31 . . . . 0.0 111.069 179.623 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -65.15 -49.69 60.75 Favored Glycine 0 C--N 1.312 -0.756 0 CA-C-N 115.368 -0.833 . . . . 0.0 111.437 -178.067 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 91.5 m -65.9 -42.6 90.01 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-O 120.757 0.313 . . . . 0.0 110.986 176.375 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 62' ' ' TRP . . . . . 0.474 ' CH2' ' HA ' ' A' ' 74' ' ' ALA . 60.3 t-105 -56.26 -47.72 77.98 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 121.549 0.69 . . . . 0.0 109.656 177.353 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . 0.417 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 5.1 tp10 -66.13 -34.78 78.83 Favored 'General case' 0 C--N 1.318 -0.802 0 CA-C-N 114.818 -1.083 . . . . 0.0 110.505 179.002 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -63.58 -42.54 98.29 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.17 -177.439 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . 0.714 ' HB2' HG12 ' A' ' 85' ' ' VAL . 27.4 m-80 -81.09 -9.99 59.74 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.927 0.394 . . . . 0.0 110.313 176.872 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . 0.467 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 87.69 51.83 3.15 Favored Glycine 0 C--O 1.225 -0.447 0 CA-C-N 115.888 -0.596 . . . . 0.0 112.429 175.357 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . 0.572 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -80.14 -23.77 60.68 Favored Glycine 0 N--CA 1.442 -0.956 0 C-N-CA 120.946 -0.645 . . . . 0.0 112.666 -176.604 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 1.058 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 7.2 mp -61.25 -17.66 54.48 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 112.877 0.695 . . . . 0.0 112.877 -172.751 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . 0.467 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 17.5 ptp180 -70.59 -34.75 72.5 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-O 121.154 0.502 . . . . 0.0 109.775 174.724 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 70' ' ' TYR . . . . . 0.666 ' HB3' ' HB3' ' A' ' 81' ' ' GLU . 54.1 m-85 -80.94 -34.59 33.18 Favored 'General case' 0 N--CA 1.444 -0.77 0 N-CA-C 107.551 -1.278 . . . . 0.0 107.551 179.221 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.613 ' HB1' ' HB2' ' A' ' 77' ' ' ALA . . . 166.32 127.14 0.03 OUTLIER Pre-proline 0 N--CA 1.445 -0.722 0 CA-C-N 112.755 -2.02 . . . . 0.0 106.995 -178.096 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 72' ' ' PRO . . . . . 1.058 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 24.4 Cg_exo -55.91 -7.18 1.49 Allowed 'Trans proline' 0 C--N 1.334 -0.227 0 C-N-CA 122.958 2.439 . . . . 0.0 113.821 -177.68 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 73' ' ' ARG . . . . . 0.489 ' HB2' ' CD2' ' A' ' 52' ' ' TYR . 11.4 ptm180 -144.58 137.12 26.53 Favored 'General case' 0 C--N 1.314 -0.935 0 N-CA-C 108.987 -0.746 . . . . 0.0 108.987 178.059 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . 0.474 ' HA ' ' CH2' ' A' ' 62' ' ' TRP . . . -55.78 -31.45 62.63 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 114.935 -1.029 . . . . 0.0 112.614 -175.993 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . 0.617 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 6.4 p-10 -81.2 -10.02 59.69 Favored 'General case' 0 C--N 1.328 -0.34 0 C-N-CA 120.426 -0.51 . . . . 0.0 111.312 -174.443 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 67.9 tp -93.94 -27.7 16.22 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-O 121.798 0.808 . . . . 0.0 108.921 172.801 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . 0.751 ' HB3' ' HB2' ' A' ' 81' ' ' GLU . . . -79.16 159.38 27.44 Favored 'General case' 0 N--CA 1.441 -0.909 0 CA-C-N 114.723 -1.126 . . . . 0.0 109.863 174.779 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 78' ' ' THR . . . . . 0.414 ' HG1' ' CD ' ' A' ' 80' ' ' GLU . 70.6 p -100.91 -174.59 2.66 Favored 'General case' 0 C--N 1.313 -0.983 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.932 -176.818 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . 0.685 ' HG2' ' CE2' ' A' ' 43' ' ' TRP . 77.0 mtp180 -51.02 -53.53 32.65 Favored 'General case' 0 CA--C 1.514 -0.419 0 CA-C-O 120.893 0.378 . . . . 0.0 110.702 -178.675 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 80' ' ' GLU . . . . . 0.414 ' CD ' ' HG1' ' A' ' 78' ' ' THR . 1.7 pm0 -63.18 -36.11 82.53 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-N 115.463 -0.789 . . . . 0.0 111.804 -175.016 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 81' ' ' GLU . . . . . 0.751 ' HB2' ' HB3' ' A' ' 77' ' ' ALA . 3.5 mm-40 -66.75 -50.7 61.88 Favored 'General case' 0 CA--C 1.516 -0.356 0 CA-C-O 121.041 0.448 . . . . 0.0 110.104 178.827 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 82' ' ' GLN . . . . . 0.572 ' HB2' ' HZ3' ' A' ' 43' ' ' TRP . 48.0 mt-30 -64.68 -35.81 82.23 Favored 'General case' 0 CA--C 1.511 -0.541 0 CA-C-N 115.685 -0.688 . . . . 0.0 110.062 -178.452 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . 0.659 ' O ' ' HG2' ' A' ' 87' ' ' GLU . 53.1 mt -59.23 -48.87 85.44 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.812 0 CA-C-N 115.45 -0.796 . . . . 0.0 109.265 174.199 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 84' ' ' ALA . . . . . 0.526 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -61.51 -42.24 98.52 Favored 'General case' 0 C--O 1.239 0.517 0 CA-C-O 121.083 0.468 . . . . 0.0 111.615 -177.682 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . 0.714 HG12 ' HB2' ' A' ' 65' ' ' ASN . 69.5 t -67.85 -48.5 75.17 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.85 179.494 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 86' ' ' ALA . . . . . 0.406 ' HB1' ' CH2' ' A' ' 31' ' ' TRP . . . -60.74 -29.12 69.19 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.543 174.594 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 87' ' ' GLU . . . . . 0.659 ' HG2' ' O ' ' A' ' 83' ' ' ILE . 14.8 mm-40 -59.75 -44.31 93.87 Favored 'General case' 0 N--CA 1.469 0.477 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.494 -179.797 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.574 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 61.7 t -62.94 -40.49 89.12 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.44 0 N-CA-C 109.712 -0.477 . . . . 0.0 109.712 176.641 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 89' ' ' THR . . . . . 0.842 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 1.0 OUTLIER -70.03 -48.9 56.1 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.958 -0.565 . . . . 0.0 111.484 -175.89 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 90' ' ' ARG . . . . . 0.615 ' HA ' ' OE1' ' A' ' 93' ' ' GLN . 2.3 ptt180 -60.86 -33.63 73.38 Favored 'General case' 0 CA--C 1.519 -0.24 0 CA-C-N 116.025 -0.534 . . . . 0.0 111.638 -173.539 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 91' ' ' LEU . . . . . 0.574 ' HG ' ' O ' ' A' ' 88' ' ' VAL . 4.7 pp -71.42 -21.84 61.93 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.588 -175.188 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . 0.564 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 22.0 mtm180 -88.02 -52.39 5.28 Favored 'General case' 0 CA--C 1.509 -0.615 0 CA-C-O 121.247 0.546 . . . . 0.0 110.689 -175.8 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 93' ' ' GLN . . . . . 0.615 ' OE1' ' HA ' ' A' ' 90' ' ' ARG . 0.0 OUTLIER -95.3 -21.83 18.16 Favored 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 113.048 0.758 . . . . 0.0 113.048 -171.356 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 88.1 42.34 5.97 Favored Glycine 0 CA--C 1.506 -0.492 0 C-N-CA 120.488 -0.863 . . . . 0.0 111.97 172.251 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 95' ' ' TRP . . . . . 0.43 ' HA ' ' HE3' ' A' ' 98' ' ' TRP . 6.7 m95 62.7 12.15 5.4 Favored 'General case' 0 C--O 1.22 -0.489 0 C-N-CA 123.587 0.755 . . . . 0.0 109.801 -179.347 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -74.14 -20.0 79.73 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 121.172 -0.537 . . . . 0.0 112.458 179.46 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -78.58 -27.23 45.68 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 121.157 0.503 . . . . 0.0 109.872 176.628 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 98' ' ' TRP . . . . . 0.842 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 27.0 m-90 -101.04 103.65 26.9 Favored Pre-proline 0 C--N 1.324 -0.53 0 N-CA-C 108.86 -0.793 . . . . 0.0 108.86 176.399 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 14.7 Cg_exo -74.77 -88.54 0.0 OUTLIER 'Trans proline' 0 CA--C 1.53 0.28 0 C-N-CA 123.034 2.489 . . . . 0.0 114.872 -170.894 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 61.1 t -70.59 -29.91 40.29 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 CA-C-O 121.555 0.693 . . . . 0.0 110.565 -171.966 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 101' ' ' CYS . . . . . 0.483 ' SG ' ' HG2' ' A' ' 38' ' ' GLU . 85.0 m -83.29 -32.48 26.33 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-N 115.14 -0.936 . . . . 0.0 112.021 -169.012 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -68.11 -43.01 79.42 Favored 'General case' 0 C--N 1.327 -0.393 0 C-N-CA 120.47 -0.492 . . . . 0.0 110.098 177.493 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -60.58 -36.12 77.74 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 121.194 0.521 . . . . 0.0 110.739 177.515 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 35.5 mtp180 -73.03 -38.83 66.41 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.702 -0.681 . . . . 0.0 111.183 177.379 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 105' ' ' ALA . . . . . 0.543 ' HB1' ' HA ' ' A' ' 30' ' ' ILE . . . -80.79 -22.42 40.1 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 115.632 -0.713 . . . . 0.0 112.567 -173.69 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 116.57 62.44 0.33 Allowed Glycine 0 CA--C 1.521 0.415 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.31 -178.623 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -63.25 149.46 45.51 Favored 'General case' 0 C--N 1.328 -0.337 0 C-N-CA 122.927 0.491 . . . . 0.0 110.748 179.417 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 72.0 mtp180 . . . . . 0 C--O 1.247 0.937 0 CA-C-O 118.247 -0.882 . . . . 0.0 111.089 -170.546 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.57 ' O ' HG12 ' A' ' 30' ' ' ILE . 6.2 m-20 . . . . . 0 CA--C 1.499 -1.006 0 CA-C-O 121.909 0.861 . . . . 0.0 110.057 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . 0.577 ' HA2' ' HB2' ' A' ' 31' ' ' TRP . . . -72.52 0.94 39.28 Favored Glycine 0 N--CA 1.436 -1.319 0 CA-C-N 114.464 -1.244 . . . . 0.0 111.053 178.77 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 13.8 m -76.41 -39.13 54.45 Favored 'General case' 0 C--N 1.32 -0.716 0 N-CA-C 108.892 -0.781 . . . . 0.0 108.892 173.458 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.57 HG12 ' O ' ' A' ' 27' ' ' ASP . 0.2 OUTLIER -71.99 -39.1 66.01 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 CA-C-N 114.327 -1.306 . . . . 0.0 107.527 176.317 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' TRP . . . . . 0.577 ' HB2' ' HA2' ' A' ' 28' ' ' GLY . 22.9 m95 -70.69 -35.56 72.84 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-N 114.483 -1.235 . . . . 0.0 110.333 -176.443 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.695 ' HB2' HH21 ' A' ' 79' ' ' ARG . 7.0 t70 -76.87 -32.24 57.34 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.458 179.7 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -70.45 -37.73 74.36 Favored 'General case' 0 N--CA 1.447 -0.601 0 C-N-CA 120.729 -0.388 . . . . 0.0 110.27 175.051 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . 0.471 HG13 ' O ' ' A' ' 30' ' ' ILE . 62.0 mt -64.89 -44.4 96.22 Favored 'Isoleucine or valine' 0 C--O 1.235 0.293 0 CA-C-O 120.954 0.407 . . . . 0.0 110.324 174.535 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . 0.482 ' O ' ' HB3' ' A' ' 39' ' ' ALA . . . -57.84 -39.25 77.27 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.236 0.541 . . . . 0.0 110.032 175.127 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -74.07 -9.01 79.85 Favored Glycine 0 N--CA 1.452 -0.299 0 CA-C-N 115.568 -0.742 . . . . 0.0 111.761 179.736 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 44.8 t -97.22 -62.85 1.19 Allowed 'General case' 0 N--CA 1.446 -0.648 0 CA-C-N 115.554 -0.323 . . . . 0.0 111.077 -178.068 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . 0.871 ' HG3' ' SG ' ' A' ' 101' ' ' CYS . 27.3 mt-10 -89.36 -27.32 20.56 Favored 'General case' 0 C--N 1.328 -0.357 0 N-CA-C 111.778 0.288 . . . . 0.0 111.778 -174.181 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . 0.482 ' HB3' ' O ' ' A' ' 35' ' ' ALA . . . -95.14 -17.11 22.08 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 121.015 0.435 . . . . 0.0 112.021 -176.457 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 81.54 14.05 78.99 Favored Glycine 0 N--CA 1.447 -0.599 0 N-CA-C 109.709 -1.357 . . . . 0.0 109.709 -174.622 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 77.52 57.2 3.66 Favored Glycine 0 N--CA 1.438 -1.203 0 CA-C-N 114.236 -0.982 . . . . 0.0 112.656 179.874 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 55.9 t30 -150.73 127.5 10.96 Favored 'General case' 0 CA--C 1.503 -0.853 0 N-CA-C 109.201 -0.666 . . . . 0.0 109.201 178.19 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' TRP . . . . . 0.752 ' HA ' ' N ' ' A' ' 54' ' ' GLY . 26.2 m95 -100.28 -2.02 34.79 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-N 115.437 -0.801 . . . . 0.0 110.099 -174.167 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -112.19 8.77 19.98 Favored 'General case' 0 C--N 1.318 -0.772 0 CA-C-N 115.052 -0.977 . . . . 0.0 111.021 178.574 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.57 HG23 ' HA2' ' A' ' 53' ' ' GLY . 12.5 tt -74.3 143.89 13.01 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.76 0 CA-C-O 120.988 0.423 . . . . 0.0 110.176 -178.784 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 13.3 t-20 -149.63 85.21 1.43 Allowed 'General case' 0 C--N 1.314 -0.939 0 CA-C-O 121.299 0.571 . . . . 0.0 110.302 -177.793 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -69.89 -20.03 63.4 Favored 'General case' 0 N--CA 1.445 -0.7 0 CA-C-N 115.476 -0.784 . . . . 0.0 111.058 177.88 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 92.05 21.56 32.74 Favored Glycine 0 N--CA 1.444 -0.795 0 C-N-CA 120.909 -0.662 . . . . 0.0 111.698 174.578 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 4.2 p-10 -94.97 14.38 21.91 Favored 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 112.082 0.401 . . . . 0.0 112.082 -175.275 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . 0.52 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 92.39 -13.92 66.01 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 121.32 -0.467 . . . . 0.0 112.171 176.5 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 51' ' ' TYR . . . . . 0.612 ' CE1' ' HB2' ' A' ' 58' ' ' ASP . 0.3 OUTLIER -110.0 155.29 22.0 Favored 'General case' 0 C--N 1.323 -0.546 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 173.505 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 52' ' ' TYR . . . . . 0.719 ' O ' ' HA ' ' A' ' 56' ' ' GLN . 63.5 m-85 -119.38 171.05 8.6 Favored 'General case' 0 C--N 1.312 -1.06 0 N-CA-C 112.657 0.614 . . . . 0.0 112.657 -168.467 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.57 ' HA2' HG23 ' A' ' 45' ' ' ILE . . . -53.87 163.19 3.07 Favored Glycine 0 N--CA 1.449 -0.44 0 CA-C-N 115.356 -0.838 . . . . 0.0 114.09 -175.527 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . 0.752 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 90.27 -109.51 3.66 Favored Glycine 0 N--CA 1.442 -0.921 0 C-N-CA 121.05 -0.595 . . . . 0.0 112.397 178.738 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.436 ' HB ' ' CD1' ' A' ' 57' ' ' PHE . 2.5 t -83.63 0.7 4.58 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-O 121.968 0.89 . . . . 0.0 109.784 -177.065 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' GLN . . . . . 0.719 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 0.0 OUTLIER 53.97 50.18 17.32 Favored 'General case' 0 N--CA 1.449 -0.495 0 CA-C-N 113.826 -1.534 . . . . 0.0 112.729 170.679 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . 0.436 ' CD1' ' HB ' ' A' ' 55' ' ' VAL . 2.5 p90 -119.04 166.63 12.65 Favored 'General case' 0 C--N 1.323 -0.564 0 C-N-CA 119.304 -0.958 . . . . 0.0 111.914 174.837 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.612 ' HB2' ' CE1' ' A' ' 51' ' ' TYR . 0.0 OUTLIER -75.75 157.46 33.49 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 114.32 -1.309 . . . . 0.0 113.777 -162.071 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . 0.47 ' HB2' ' HE1' ' A' ' 52' ' ' TYR . 22.1 tp60 -53.34 -44.25 68.33 Favored 'General case' 0 N--CA 1.441 -0.9 0 CA-C-N 114.171 -1.377 . . . . 0.0 111.463 179.243 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -68.49 -49.05 47.16 Favored Glycine 0 C--O 1.22 -0.735 0 CA-C-N 115.325 -0.852 . . . . 0.0 112.396 -176.106 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 46.3 m -60.77 -40.61 93.15 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-O 121.552 0.691 . . . . 0.0 110.519 179.098 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 62' ' ' TRP . . . . . 0.468 ' CZ3' ' HA ' ' A' ' 82' ' ' GLN . 50.6 t-105 -61.98 -48.86 78.45 Favored 'General case' 0 C--N 1.318 -0.794 0 CA-C-N 114.845 -1.071 . . . . 0.0 109.863 175.279 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . 0.596 ' HB2' HD12 ' A' ' 68' ' ' LEU . 0.0 OUTLIER -67.97 -36.39 79.97 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.733 -0.667 . . . . 0.0 110.353 -176.801 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . 0.482 ' N ' ' HG3' ' A' ' 63' ' ' GLU . . . -66.16 -41.05 90.89 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.433 -0.803 . . . . 0.0 111.28 -175.972 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . 0.455 ' HB3' ' HB ' ' A' ' 88' ' ' VAL . 84.5 m-20 -84.09 -3.61 58.2 Favored 'General case' 0 N--CA 1.446 -0.669 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.61 176.906 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . 0.482 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 85.74 46.92 5.27 Favored Glycine 0 N--CA 1.448 -0.532 0 CA-C-N 115.573 -0.74 . . . . 0.0 113.107 171.11 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . 0.618 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -80.28 -16.46 76.23 Favored Glycine 0 N--CA 1.443 -0.899 0 C-N-CA 120.672 -0.775 . . . . 0.0 111.828 179.918 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 0.616 ' HA ' ' HA ' ' A' ' 72' ' ' PRO . 14.6 mt -64.74 -22.74 67.05 Favored 'General case' 0 C--N 1.32 -0.707 0 C-N-CA 122.817 0.447 . . . . 0.0 111.363 -171.332 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . 0.482 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 14.9 ptm180 -70.85 -32.49 69.53 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.311 176.138 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 70' ' ' TYR . . . . . 0.675 ' HB3' ' HB3' ' A' ' 81' ' ' GLU . 58.9 m-85 -80.09 -33.33 38.88 Favored 'General case' 0 N--CA 1.445 -0.697 0 N-CA-C 107.217 -1.401 . . . . 0.0 107.217 178.19 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.653 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 165.94 127.12 0.03 OUTLIER Pre-proline 0 CA--C 1.511 -0.538 0 CA-C-N 112.447 -2.161 . . . . 0.0 107.122 178.693 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 72' ' ' PRO . . . . . 0.616 ' HA ' ' HA ' ' A' ' 68' ' ' LEU . 15.5 Cg_exo -56.2 -0.8 0.23 Allowed 'Trans proline' 0 CA--C 1.531 0.369 0 C-N-CA 122.961 2.441 . . . . 0.0 114.231 -177.849 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 13.0 ptm180 -150.82 142.46 23.62 Favored 'General case' 0 C--N 1.317 -0.839 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 172.776 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . 0.426 ' HA ' ' CH2' ' A' ' 62' ' ' TRP . . . -58.69 -30.34 67.33 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.332 -0.849 . . . . 0.0 112.89 -175.899 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . 0.438 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 15.7 p-10 -87.33 5.54 37.98 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 121.269 0.557 . . . . 0.0 111.129 -176.232 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.425 ' HB3' ' HB2' ' A' ' 71' ' ' ALA . 65.2 tp -105.67 -30.17 9.64 Favored 'General case' 0 C--N 1.319 -0.72 0 N-CA-C 108.359 -0.978 . . . . 0.0 108.359 168.967 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . 0.671 ' HB3' ' HB2' ' A' ' 81' ' ' GLU . . . -79.47 164.48 23.91 Favored 'General case' 0 N--CA 1.444 -0.739 0 CA-C-N 114.446 -1.252 . . . . 0.0 110.183 175.933 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 78' ' ' THR . . . . . 0.443 ' OG1' ' HG2' ' A' ' 81' ' ' GLU . 65.9 p -99.97 -178.89 3.99 Favored 'General case' 0 C--N 1.313 -0.994 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.414 -177.042 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . 0.695 HH21 ' HB2' ' A' ' 32' ' ' ASP . 47.2 mtp180 -52.71 -53.67 44.32 Favored 'General case' 0 CA--C 1.516 -0.342 0 CA-C-O 121.045 0.45 . . . . 0.0 110.374 -178.536 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 80' ' ' GLU . . . . . 0.591 ' HA ' HD11 ' A' ' 83' ' ' ILE . 2.7 pm0 -60.51 -32.64 71.65 Favored 'General case' 0 C--N 1.317 -0.816 0 CA-C-N 115.083 -0.962 . . . . 0.0 112.254 -176.818 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 81' ' ' GLU . . . . . 0.675 ' HB3' ' HB3' ' A' ' 70' ' ' TYR . 5.4 mm-40 -70.64 -50.41 37.13 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-O 120.877 0.37 . . . . 0.0 110.031 177.477 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 82' ' ' GLN . . . . . 0.468 ' HA ' ' CZ3' ' A' ' 62' ' ' TRP . 51.2 mt-30 -61.11 -35.61 77.49 Favored 'General case' 0 CA--C 1.507 -0.69 0 CA-C-N 115.582 -0.736 . . . . 0.0 109.631 179.833 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . 0.682 ' O ' ' HG2' ' A' ' 87' ' ' GLU . 39.2 mt -59.55 -49.16 84.69 Favored 'Isoleucine or valine' 0 C--O 1.211 -0.952 0 CA-C-N 114.714 -1.13 . . . . 0.0 109.763 174.829 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 84' ' ' ALA . . . . . 0.607 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -61.25 -41.58 97.15 Favored 'General case' 0 C--O 1.236 0.365 0 CA-C-O 121.403 0.62 . . . . 0.0 111.579 -177.606 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . 0.449 HG21 ' O ' ' A' ' 81' ' ' GLU . 34.7 t -69.2 -47.85 71.89 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.794 178.528 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -58.22 -29.44 65.72 Favored 'General case' 0 N--CA 1.45 -0.446 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.364 172.99 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 87' ' ' GLU . . . . . 0.682 ' HG2' ' O ' ' A' ' 83' ' ' ILE . 14.5 mm-40 -60.03 -44.62 94.5 Favored 'General case' 0 N--CA 1.469 0.497 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.111 179.277 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.636 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 60.8 t -63.56 -47.71 90.21 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.437 0 N-CA-C 109.473 -0.566 . . . . 0.0 109.473 174.243 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 89' ' ' THR . . . . . 0.904 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 0.7 OUTLIER -59.21 -49.86 76.22 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-N 115.696 -0.684 . . . . 0.0 111.387 -176.508 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 90' ' ' ARG . . . . . 0.498 ' HA ' ' HZ3' ' A' ' 98' ' ' TRP . 27.0 ptt85 -60.51 -34.97 74.87 Favored 'General case' 0 C--O 1.223 -0.314 0 CA-C-N 116.723 -0.217 . . . . 0.0 111.232 -172.477 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 91' ' ' LEU . . . . . 0.636 ' HG ' ' O ' ' A' ' 88' ' ' VAL . 4.5 pp -74.71 -22.82 58.63 Favored 'General case' 0 C--N 1.318 -0.798 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.52 -173.488 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . 0.591 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 15.6 mtm180 -80.82 -52.71 7.19 Favored 'General case' 0 CA--C 1.505 -0.773 0 CA-C-O 121.13 0.491 . . . . 0.0 109.877 -176.04 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 4.9 pm0 -103.75 -15.36 15.76 Favored 'General case' 0 N--CA 1.445 -0.681 0 C-N-CA 119.645 -0.822 . . . . 0.0 113.022 -173.411 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 87.33 45.12 5.39 Favored Glycine 0 CA--C 1.498 -1.03 0 C-N-CA 120.732 -0.747 . . . . 0.0 111.88 168.424 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 95' ' ' TRP . . . . . 0.476 ' HA ' ' HE3' ' A' ' 98' ' ' TRP . 15.7 m95 66.47 2.23 2.39 Favored 'General case' 0 C--O 1.216 -0.669 0 C-N-CA 123.236 0.614 . . . . 0.0 109.979 -178.276 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -70.35 -13.01 70.23 Favored Glycine 0 C--N 1.335 0.517 0 C-N-CA 121.447 -0.406 . . . . 0.0 112.792 -178.108 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -81.93 -23.66 36.06 Favored 'General case' 0 C--N 1.325 -0.471 0 N-CA-C 109.525 -0.546 . . . . 0.0 109.525 175.159 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 98' ' ' TRP . . . . . 0.904 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 29.0 m-90 -103.16 104.95 43.59 Favored Pre-proline 0 N--CA 1.45 -0.444 0 N-CA-C 108.745 -0.835 . . . . 0.0 108.745 175.146 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 99' ' ' PRO . . . . . 0.403 ' HD3' ' HA ' ' A' ' 98' ' ' TRP . 15.0 Cg_exo -74.43 -87.09 0.0 OUTLIER 'Trans proline' 0 CA--C 1.53 0.305 0 C-N-CA 122.902 2.401 . . . . 0.0 114.673 -172.666 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 48.4 t -71.25 -27.92 30.83 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-O 121.322 0.582 . . . . 0.0 111.086 -170.949 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 101' ' ' CYS . . . . . 0.871 ' SG ' ' HG3' ' A' ' 38' ' ' GLU . 64.2 m -90.99 -27.55 18.59 Favored 'General case' 0 C--N 1.314 -0.946 0 CA-C-N 115.915 -0.584 . . . . 0.0 112.545 -168.772 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 102' ' ' ALA . . . . . 0.573 ' HB2' ' HB2' ' A' ' 98' ' ' TRP . . . -67.54 -46.43 72.82 Favored 'General case' 0 C--N 1.33 -0.268 0 C-N-CA 120.515 -0.474 . . . . 0.0 110.928 -178.719 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -61.22 -39.09 88.95 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-O 121.097 0.475 . . . . 0.0 110.634 179.25 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -66.56 -39.77 88.68 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.469 -0.787 . . . . 0.0 111.548 176.655 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 105' ' ' ALA . . . . . 0.41 ' HB3' HG21 ' A' ' 30' ' ' ILE . . . -77.56 -22.51 50.89 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.929 -175.933 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 116.02 55.83 0.34 Allowed Glycine 0 N--CA 1.452 -0.236 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.528 -178.942 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -57.52 149.2 21.67 Favored 'General case' 0 CA--C 1.517 -0.305 0 C-N-CA 123.049 0.54 . . . . 0.0 110.572 179.149 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 69.9 mtp180 . . . . . 0 C--O 1.249 1.04 0 CA-C-O 118.202 -0.904 . . . . 0.0 110.465 -170.19 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.607 ' O ' HG12 ' A' ' 30' ' ' ILE . 13.0 m-20 . . . . . 0 CA--C 1.502 -0.899 0 CA-C-O 121.891 0.853 . . . . 0.0 109.208 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . 0.721 ' HA2' ' HB2' ' A' ' 31' ' ' TRP . . . -77.75 2.7 62.91 Favored Glycine 0 N--CA 1.433 -1.534 0 CA-C-N 114.583 -1.19 . . . . 0.0 110.611 -177.76 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 17.0 m -76.23 -40.36 52.26 Favored 'General case' 0 C--N 1.318 -0.794 0 N-CA-C 108.77 -0.826 . . . . 0.0 108.77 173.626 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.666 ' HA ' ' HB2' ' A' ' 105' ' ' ALA . 0.0 OUTLIER -71.52 -38.03 66.32 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.679 0 N-CA-C 107.348 -1.353 . . . . 0.0 107.348 176.573 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' TRP . . . . . 0.721 ' HB2' ' HA2' ' A' ' 28' ' ' GLY . 14.6 m95 -71.85 -36.29 70.11 Favored 'General case' 0 N--CA 1.438 -1.054 0 CA-C-N 114.251 -1.34 . . . . 0.0 110.601 -176.188 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 31.7 t70 -77.23 -34.31 56.01 Favored 'General case' 0 N--CA 1.446 -0.66 0 CA-C-N 116.529 -0.305 . . . . 0.0 110.931 178.082 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . 0.495 ' HB2' ' CB ' ' A' ' 105' ' ' ALA . . . -70.16 -34.08 72.56 Favored 'General case' 0 N--CA 1.448 -0.532 0 C-N-CA 120.288 -0.565 . . . . 0.0 110.278 177.523 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . 0.507 HG13 ' O ' ' A' ' 30' ' ' ILE . 68.3 mt -67.88 -46.55 81.92 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-O 121.07 0.462 . . . . 0.0 110.176 172.298 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -58.72 -38.91 79.36 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.277 176.89 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . 0.507 ' HA2' ' N ' ' A' ' 41' ' ' GLY . . . -74.88 -12.97 82.84 Favored Glycine 0 C--O 1.228 -0.26 0 CA-C-N 115.618 -0.719 . . . . 0.0 111.535 178.699 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 40.8 t -89.5 -60.94 1.81 Allowed 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 115.356 -0.422 . . . . 0.0 110.93 -177.748 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . 0.821 ' HG3' ' SG ' ' A' ' 101' ' ' CYS . 34.3 mt-10 -89.55 -28.37 19.64 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 120.687 0.28 . . . . 0.0 111.534 -174.441 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -101.49 -12.01 18.87 Favored 'General case' 0 C--N 1.326 -0.452 0 C-N-CA 120.43 -0.508 . . . . 0.0 111.785 -178.14 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 81.03 6.52 89.4 Favored Glycine 0 N--CA 1.45 -0.371 0 N-CA-C 110.027 -1.229 . . . . 0.0 110.027 -177.846 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . 0.507 ' N ' ' HA2' ' A' ' 36' ' ' GLY . . . 85.35 53.88 2.98 Favored Glycine 0 N--CA 1.437 -1.274 0 CA-C-N 114.148 -1.026 . . . . 0.0 111.942 -177.71 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' ASN . . . . . 0.416 ' OD1' ' HB ' ' A' ' 45' ' ' ILE . 2.3 t-20 -138.71 99.32 3.77 Favored 'General case' 0 N--CA 1.447 -0.58 0 N-CA-C 108.829 -0.804 . . . . 0.0 108.829 -175.84 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' TRP . . . . . 0.663 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 37.1 m95 -81.48 -10.32 59.51 Favored 'General case' 0 C--N 1.312 -1.026 0 CA-C-N 115.389 -0.823 . . . . 0.0 110.805 -172.664 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -107.0 8.71 30.56 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 115.504 -0.771 . . . . 0.0 110.829 -179.492 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.416 ' HB ' ' OD1' ' A' ' 42' ' ' ASN . 9.3 tt -72.56 144.27 13.17 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.916 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 179.578 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 22.4 t-20 -154.22 98.47 2.14 Favored 'General case' 0 C--N 1.309 -1.183 0 CA-C-O 121.384 0.612 . . . . 0.0 109.372 -179.956 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 17.5 p -72.51 -24.05 61.1 Favored 'General case' 0 C--N 1.317 -0.819 0 CA-C-N 114.76 -1.109 . . . . 0.0 110.919 -177.376 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 93.48 20.64 31.56 Favored Glycine 0 N--CA 1.441 -0.981 0 N-CA-C 110.722 -0.951 . . . . 0.0 110.722 -178.698 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 82.8 m-20 -93.18 12.8 23.14 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.877 0.37 . . . . 0.0 111.415 -176.234 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . 0.527 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 85.29 -11.73 60.18 Favored Glycine 0 N--CA 1.449 -0.46 0 N-CA-C 111.209 -0.757 . . . . 0.0 111.209 -177.883 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 51' ' ' TYR . . . . . 0.559 ' HA ' ' HA ' ' A' ' 58' ' ' ASP . 0.3 OUTLIER -112.22 146.37 38.25 Favored 'General case' 0 CA--C 1.51 -0.562 0 N-CA-C 107.197 -1.408 . . . . 0.0 107.197 177.214 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 52' ' ' TYR . . . . . 0.818 ' O ' ' HA ' ' A' ' 56' ' ' GLN . 32.8 m-85 -110.73 170.5 8.05 Favored 'General case' 0 C--N 1.309 -1.154 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.697 -165.96 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -69.06 -174.37 9.98 Favored Glycine 0 C--O 1.228 -0.223 0 N-CA-C 114.907 0.723 . . . . 0.0 114.907 -169.761 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . 0.599 ' CA ' ' HA ' ' A' ' 43' ' ' TRP . . . 80.0 -107.53 2.62 Favored Glycine 0 N--CA 1.442 -0.942 0 C-N-CA 120.859 -0.686 . . . . 0.0 111.457 -178.349 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.419 HG12 ' HE1' ' A' ' 98' ' ' TRP . 3.4 t -88.21 4.22 4.84 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 CA-C-O 121.554 0.692 . . . . 0.0 109.618 179.016 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' GLN . . . . . 0.818 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 7.0 tt0 54.5 53.82 10.22 Favored 'General case' 0 CA--C 1.535 0.379 0 N-CA-C 114.854 1.427 . . . . 0.0 114.854 164.887 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -121.15 170.26 9.73 Favored 'General case' 0 C--N 1.326 -0.418 0 C-N-CA 119.447 -0.901 . . . . 0.0 112.018 171.652 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.559 ' HA ' ' HA ' ' A' ' 51' ' ' TYR . 6.9 p-10 -76.25 165.22 25.18 Favored 'General case' 0 C--N 1.331 -0.219 0 N-CA-C 113.311 0.856 . . . . 0.0 113.311 -166.809 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . 0.478 ' HB2' ' HE1' ' A' ' 52' ' ' TYR . 5.9 tp-100 -63.15 -37.99 89.4 Favored 'General case' 0 N--CA 1.448 -0.568 0 CA-C-N 114.881 -1.054 . . . . 0.0 110.827 179.127 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -63.46 -49.78 67.28 Favored Glycine 0 C--N 1.314 -0.68 0 CA-C-N 115.551 -0.75 . . . . 0.0 111.777 -175.643 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 86.4 m -63.91 -44.19 93.7 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-O 120.954 0.407 . . . . 0.0 111.201 176.414 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 62' ' ' TRP . . . . . 0.451 ' CZ3' ' HA ' ' A' ' 82' ' ' GLN . 54.4 t-105 -56.86 -48.95 76.93 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 121.84 0.828 . . . . 0.0 109.967 177.546 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . 0.519 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 36.0 tt0 -67.39 -34.68 77.76 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-N 114.611 -1.177 . . . . 0.0 110.471 -178.426 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -64.85 -41.9 95.32 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.645 -0.707 . . . . 0.0 110.993 -178.711 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . 0.565 ' HB2' HG11 ' A' ' 85' ' ' VAL . 7.9 m120 -82.06 -2.85 53.19 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.459 177.144 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . 0.563 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 83.57 47.62 5.6 Favored Glycine 0 C--O 1.225 -0.467 0 CA-C-N 115.782 -0.645 . . . . 0.0 112.587 173.245 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . 0.602 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -80.03 -21.96 64.43 Favored Glycine 0 N--CA 1.438 -1.197 0 C-N-CA 120.956 -0.64 . . . . 0.0 112.934 -175.107 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 0.878 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 6.8 mp -61.61 -22.73 65.49 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 112.048 0.388 . . . . 0.0 112.048 -172.43 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . 0.563 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 9.6 ptm180 -67.74 -33.68 75.33 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 121.254 0.549 . . . . 0.0 109.963 176.522 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 70' ' ' TYR . . . . . 0.788 ' HB3' ' HG3' ' A' ' 81' ' ' GLU . 63.5 m-85 -79.91 -34.51 38.92 Favored 'General case' 0 N--CA 1.444 -0.772 0 N-CA-C 107.499 -1.297 . . . . 0.0 107.499 178.159 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.697 ' HB2' ' HB3' ' A' ' 77' ' ' ALA . . . 163.99 129.05 0.02 OUTLIER Pre-proline 0 CA--C 1.51 -0.568 0 CA-C-N 112.595 -2.093 . . . . 0.0 107.198 -179.888 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 72' ' ' PRO . . . . . 0.878 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 16.9 Cg_exo -58.46 -3.02 1.15 Allowed 'Trans proline' 0 C--N 1.332 -0.299 0 C-N-CA 122.622 2.215 . . . . 0.0 113.559 -177.911 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 73' ' ' ARG . . . . . 0.405 ' HB2' ' CD2' ' A' ' 52' ' ' TYR . 13.5 ptm180 -146.63 137.36 23.99 Favored 'General case' 0 C--N 1.319 -0.731 0 N-CA-C 109.289 -0.634 . . . . 0.0 109.289 177.342 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . 0.424 ' HA ' ' CH2' ' A' ' 62' ' ' TRP . . . -58.11 -29.52 65.56 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.312 -0.858 . . . . 0.0 112.611 -178.066 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 14.7 p-10 -87.84 9.19 22.72 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 121.364 0.602 . . . . 0.0 110.852 -176.092 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.416 ' HB3' ' HB1' ' A' ' 71' ' ' ALA . 58.6 tp -110.07 -33.63 6.63 Favored 'General case' 0 C--N 1.322 -0.627 0 N-CA-C 108.322 -0.992 . . . . 0.0 108.322 169.81 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . 0.712 ' HB1' ' HB3' ' A' ' 81' ' ' GLU . . . -78.39 163.36 25.72 Favored 'General case' 0 N--CA 1.445 -0.691 0 CA-C-N 114.771 -1.104 . . . . 0.0 110.393 177.084 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 71.5 p -99.36 -174.49 2.75 Favored 'General case' 0 C--N 1.315 -0.931 0 CA-C-N 115.656 -0.702 . . . . 0.0 110.337 -174.532 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . 0.663 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 23.7 mtt85 -53.93 -56.81 14.33 Favored 'General case' 0 CA--C 1.512 -0.509 0 CA-C-O 120.988 0.423 . . . . 0.0 110.772 178.848 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 1.8 pm0 -58.22 -41.18 83.51 Favored 'General case' 0 C--N 1.314 -0.937 0 CA-C-N 115.043 -0.981 . . . . 0.0 111.262 -176.391 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 81' ' ' GLU . . . . . 0.788 ' HG3' ' HB3' ' A' ' 70' ' ' TYR . 0.4 OUTLIER -63.18 -52.72 61.21 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 115.5 -0.773 . . . . 0.0 112.161 175.835 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 82' ' ' GLN . . . . . 0.451 ' HA ' ' CZ3' ' A' ' 62' ' ' TRP . 53.4 mt-30 -60.66 -43.09 98.04 Favored 'General case' 0 CA--C 1.509 -0.613 0 CA-C-O 121.762 0.791 . . . . 0.0 109.833 -178.972 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . 0.6 HG22 ' CD1' ' A' ' 31' ' ' TRP . 10.8 mt -59.5 -39.74 80.07 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.993 0 CA-C-N 114.276 -1.329 . . . . 0.0 110.303 -177.822 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 84' ' ' ALA . . . . . 0.426 ' O ' HG23 ' A' ' 88' ' ' VAL . . . -62.1 -42.46 99.24 Favored 'General case' 0 C--N 1.319 -0.752 0 CA-C-O 121.273 0.559 . . . . 0.0 110.476 -179.181 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . 0.565 HG11 ' HB2' ' A' ' 65' ' ' ASN . 43.0 t -70.05 -50.77 45.26 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 CA-C-N 115.764 -0.653 . . . . 0.0 111.741 -179.569 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -65.69 -31.49 72.52 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 121.489 0.662 . . . . 0.0 110.858 -179.6 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 87' ' ' GLU . . . . . 0.773 ' HA ' ' HG2' ' A' ' 90' ' ' ARG . 0.7 OUTLIER -71.16 -28.41 64.24 Favored 'General case' 0 C--N 1.316 -0.855 0 CA-C-N 115.716 -0.674 . . . . 0.0 110.436 -178.348 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.666 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 88.1 t -61.86 -46.47 96.43 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.26 0 N-CA-C 109.299 -0.63 . . . . 0.0 109.299 168.54 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 89' ' ' THR . . . . . 0.483 ' O ' ' HG2' ' A' ' 93' ' ' GLN . 0.1 OUTLIER -64.64 -45.71 85.63 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 115.697 -0.683 . . . . 0.0 111.866 -177.48 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 90' ' ' ARG . . . . . 0.773 ' HG2' ' HA ' ' A' ' 87' ' ' GLU . 22.5 ptt180 -58.91 -35.36 72.94 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.98 -0.555 . . . . 0.0 111.048 -175.799 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 91' ' ' LEU . . . . . 0.666 ' HG ' ' O ' ' A' ' 88' ' ' VAL . 4.6 pp -74.69 -24.39 58.76 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.022 -0.536 . . . . 0.0 110.827 -169.536 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . 0.452 ' NH2' HG22 ' A' ' 89' ' ' THR . 3.9 mtm180 -85.59 -45.56 11.63 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.783 -0.644 . . . . 0.0 109.686 -177.948 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 93' ' ' GLN . . . . . 0.483 ' HG2' ' O ' ' A' ' 89' ' ' THR . 24.0 pt20 -98.6 -29.12 13.24 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.192 -0.913 . . . . 0.0 113.188 -169.715 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 87.42 46.67 4.88 Favored Glycine 0 CA--C 1.505 -0.58 0 C-N-CA 120.426 -0.893 . . . . 0.0 111.06 176.463 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 95' ' ' TRP . . . . . 0.494 ' HA ' ' HE3' ' A' ' 98' ' ' TRP . 1.9 m95 58.59 27.0 15.12 Favored 'General case' 0 C--O 1.223 -0.34 0 CA-C-O 121.484 0.659 . . . . 0.0 109.687 177.457 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -70.83 -30.5 68.12 Favored Glycine 0 N--CA 1.449 -0.445 0 CA-C-N 115.349 -0.841 . . . . 0.0 112.245 176.618 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . 0.42 ' O ' ' HD3' ' A' ' 99' ' ' PRO . . . -79.46 -24.84 42.13 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 120.66 0.267 . . . . 0.0 110.57 177.114 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 98' ' ' TRP . . . . . 0.494 ' HE3' ' HA ' ' A' ' 95' ' ' TRP . 23.8 m-90 -101.96 103.25 28.17 Favored Pre-proline 0 C--N 1.327 -0.389 0 N-CA-C 109.406 -0.59 . . . . 0.0 109.406 175.897 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 99' ' ' PRO . . . . . 0.43 ' HB2' ' H ' ' A' ' 100' ' ' VAL . 22.0 Cg_exo -70.52 -101.7 0.01 OUTLIER 'Trans proline' 0 CA--C 1.539 0.746 0 C-N-CA 123.242 2.628 . . . . 0.0 114.991 -173.013 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . 0.476 ' O ' ' HD2' ' A' ' 104' ' ' ARG . 41.0 t -69.82 -27.94 35.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 121.596 0.712 . . . . 0.0 110.452 -171.598 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 101' ' ' CYS . . . . . 0.821 ' SG ' ' HG3' ' A' ' 38' ' ' GLU . 79.1 m -73.07 -32.38 64.97 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-N 115.228 -0.896 . . . . 0.0 111.511 -171.416 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -70.0 -46.18 65.69 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 120.757 0.313 . . . . 0.0 110.953 -179.892 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -62.25 -37.28 84.83 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 121.097 0.475 . . . . 0.0 110.773 179.514 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 104' ' ' ARG . . . . . 0.476 ' HD2' ' O ' ' A' ' 100' ' ' VAL . 0.0 OUTLIER -73.02 -30.47 63.78 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.627 -0.715 . . . . 0.0 111.583 178.566 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 105' ' ' ALA . . . . . 0.666 ' HB2' ' HA ' ' A' ' 30' ' ' ILE . . . -82.17 -21.38 36.57 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.692 -176.997 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 109.39 60.93 0.52 Allowed Glycine 0 CA--C 1.518 0.25 0 C-N-CA 121.011 -0.614 . . . . 0.0 112.158 -178.122 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -66.41 152.67 44.62 Favored 'General case' 0 N--CA 1.45 -0.442 0 C-N-CA 122.642 0.377 . . . . 0.0 111.013 -176.562 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 20.7 mmt180 . . . . . 0 C--O 1.244 0.814 0 CA-C-O 118.404 -0.808 . . . . 0.0 110.959 176.677 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.515 ' O ' HG12 ' A' ' 30' ' ' ILE . 11.2 m-20 . . . . . 0 CA--C 1.504 -0.805 0 CA-C-O 121.364 0.602 . . . . 0.0 110.931 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . 0.697 ' HA3' ' CD1' ' A' ' 83' ' ' ILE . . . -76.05 1.65 58.75 Favored Glycine 0 CA--C 1.498 -0.998 0 N-CA-C 110.715 -0.954 . . . . 0.0 110.715 -179.336 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 19.1 m -76.99 -40.86 45.22 Favored 'General case' 0 C--N 1.322 -0.628 0 N-CA-C 108.497 -0.927 . . . . 0.0 108.497 171.381 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.515 HG12 ' O ' ' A' ' 27' ' ' ASP . 0.7 OUTLIER -67.29 -40.21 84.43 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.457 0 CA-C-N 114.399 -1.273 . . . . 0.0 107.724 175.946 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' TRP . . . . . 0.559 ' HB2' ' HA2' ' A' ' 28' ' ' GLY . 36.5 m95 -67.41 -36.68 81.76 Favored 'General case' 0 C--N 1.318 -0.776 0 CA-C-N 114.17 -1.377 . . . . 0.0 110.378 -177.826 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.415 ' CB ' HH21 ' A' ' 79' ' ' ARG . 4.6 t70 -77.19 -33.34 56.38 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 115.748 -0.66 . . . . 0.0 110.62 -179.5 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . 0.422 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -70.13 -34.07 72.61 Favored 'General case' 0 N--CA 1.447 -0.575 0 C-N-CA 120.506 -0.478 . . . . 0.0 109.977 176.159 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . 0.513 HG13 ' O ' ' A' ' 30' ' ' ILE . 74.2 mt -65.52 -43.45 94.32 Favored 'Isoleucine or valine' 0 C--O 1.234 0.268 0 CA-C-N 116.057 -0.519 . . . . 0.0 109.865 172.23 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . 0.448 ' HA ' ' O ' ' A' ' 54' ' ' GLY . . . -57.57 -37.4 73.09 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.059 175.211 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . 0.401 ' HA2' ' N ' ' A' ' 41' ' ' GLY . . . -70.89 -15.98 74.31 Favored Glycine 0 N--CA 1.449 -0.45 0 CA-C-N 115.27 -0.877 . . . . 0.0 112.181 179.299 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 44.1 t -85.19 -58.87 2.51 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 120.611 0.243 . . . . 0.0 111.186 -177.256 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 8.6 tp10 -89.09 -34.04 16.89 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-O 121.074 0.464 . . . . 0.0 110.877 -172.693 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -97.63 -14.66 20.83 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.029 -0.532 . . . . 0.0 111.511 -175.427 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 86.31 -4.51 85.99 Favored Glycine 0 N--CA 1.448 -0.523 0 N-CA-C 109.847 -1.301 . . . . 0.0 109.847 -174.408 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . 0.401 ' N ' ' HA2' ' A' ' 36' ' ' GLY . . . 102.04 56.06 0.85 Allowed Glycine 0 N--CA 1.435 -1.37 0 CA-C-N 114.213 -0.993 . . . . 0.0 112.058 -179.235 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 43.8 t-20 -144.33 127.25 16.38 Favored 'General case' 0 N--CA 1.44 -0.968 0 N-CA-C 108.263 -1.014 . . . . 0.0 108.263 -179.602 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' TRP . . . . . 0.677 ' HZ3' ' HB2' ' A' ' 82' ' ' GLN . 40.5 m95 -99.28 -13.27 19.74 Favored 'General case' 0 C--N 1.305 -1.351 0 CA-C-N 115.398 -0.819 . . . . 0.0 110.935 -173.385 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -100.53 -6.77 24.94 Favored 'General case' 0 C--N 1.316 -0.881 0 CA-C-N 115.199 -0.909 . . . . 0.0 110.479 -177.889 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 10.0 tt -62.33 141.58 17.67 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.996 0 CA-C-N 115.474 -0.784 . . . . 0.0 109.921 178.556 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 43.3 t-20 -158.73 103.52 1.73 Allowed 'General case' 0 C--N 1.312 -1.025 0 CA-C-O 121.03 0.443 . . . . 0.0 110.112 -177.655 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 11.2 p -82.75 -15.01 53.46 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 115.718 -0.674 . . . . 0.0 111.923 -177.56 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 90.47 25.23 26.4 Favored Glycine 0 N--CA 1.446 -0.662 0 N-CA-C 110.943 -0.863 . . . . 0.0 110.943 -177.743 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 65.0 t30 -83.63 -1.76 54.63 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 121.222 0.534 . . . . 0.0 111.222 -175.352 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . 0.482 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 95.19 -9.34 69.89 Favored Glycine 0 CA--C 1.505 -0.539 0 N-CA-C 110.093 -1.203 . . . . 0.0 110.093 -175.734 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 51' ' ' TYR . . . . . 0.555 ' HA ' ' HA ' ' A' ' 58' ' ' ASP . 0.5 OUTLIER -117.98 158.2 25.36 Favored 'General case' 0 N--CA 1.441 -0.923 0 N-CA-C 106.118 -1.808 . . . . 0.0 106.118 177.998 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 52' ' ' TYR . . . . . 0.703 ' O ' ' HA ' ' A' ' 56' ' ' GLN . 35.1 m-85 -118.41 169.59 9.63 Favored 'General case' 0 C--N 1.303 -1.447 0 C-N-CA 120.222 -0.591 . . . . 0.0 110.851 -172.241 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -65.14 -173.26 3.81 Favored Glycine 0 N--CA 1.448 -0.515 0 C-N-CA 121.173 -0.537 . . . . 0.0 114.362 -170.019 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . 0.582 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 77.39 -104.97 2.01 Favored Glycine 0 N--CA 1.439 -1.157 0 N-CA-C 111.346 -0.702 . . . . 0.0 111.346 -179.635 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.407 HG11 ' HE1' ' A' ' 98' ' ' TRP . 2.2 t -83.41 -1.83 6.25 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 CA-C-O 121.503 0.668 . . . . 0.0 109.676 -179.122 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' GLN . . . . . 0.803 ' HA ' HE21 ' A' ' 56' ' ' GLN . 0.0 OUTLIER 57.34 45.18 20.52 Favored 'General case' 0 N--CA 1.464 0.249 0 CA-C-N 114.541 -1.209 . . . . 0.0 113.444 169.584 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 1.1 p90 -117.89 168.53 10.41 Favored 'General case' 0 C--N 1.328 -0.357 0 C-N-CA 119.582 -0.847 . . . . 0.0 112.035 176.476 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.555 ' HA ' ' HA ' ' A' ' 51' ' ' TYR . 7.5 p-10 -79.33 164.15 24.31 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.141 -0.936 . . . . 0.0 113.419 -164.39 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . 0.682 ' HA ' HE21 ' A' ' 59' ' ' GLN . 0.0 OUTLIER -63.25 -36.63 84.3 Favored 'General case' 0 N--CA 1.449 -0.487 0 CA-C-N 114.101 -1.409 . . . . 0.0 111.578 179.188 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -68.0 -50.33 41.4 Favored Glycine 0 C--N 1.32 -0.324 0 C-N-CA 121.2 -0.524 . . . . 0.0 112.303 -175.703 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 88.5 m -61.7 -42.16 98.56 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 121.157 0.503 . . . . 0.0 110.113 175.689 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 62' ' ' TRP . . . . . 0.595 ' HH2' ' CD ' ' A' ' 81' ' ' GLU . 59.3 t-105 -56.85 -49.68 74.73 Favored 'General case' 0 N--CA 1.447 -0.623 0 CA-C-N 114.985 -1.007 . . . . 0.0 110.209 177.264 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . 0.909 ' HG3' HD12 ' A' ' 68' ' ' LEU . 29.1 tt0 -67.15 -34.38 77.44 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 115.026 -0.988 . . . . 0.0 110.773 -177.18 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -67.91 -41.58 82.45 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.897 -0.592 . . . . 0.0 111.082 -178.44 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . 0.661 ' HB2' HG11 ' A' ' 85' ' ' VAL . 4.8 m120 -71.8 -15.79 62.16 Favored 'General case' 0 C--N 1.332 -0.154 0 CA-C-O 121.349 0.595 . . . . 0.0 109.773 174.99 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 88.32 44.74 5.21 Favored Glycine 0 N--CA 1.446 -0.7 0 CA-C-N 115.208 -0.906 . . . . 0.0 111.752 178.422 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . 0.587 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -78.5 -19.58 73.53 Favored Glycine 0 CA--C 1.5 -0.865 0 C-N-CA 120.612 -0.804 . . . . 0.0 111.123 -173.818 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 0.909 HD12 ' HG3' ' A' ' 63' ' ' GLU . 11.8 mt -61.32 -24.86 66.74 Favored 'General case' 0 C--N 1.317 -0.807 0 CA-C-N 114.664 -0.768 . . . . 0.0 110.806 -174.667 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 12.1 ptm180 -70.34 -28.61 65.27 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.461 -0.79 . . . . 0.0 109.856 179.664 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 70' ' ' TYR . . . . . 0.587 ' HD2' ' HA2' ' A' ' 67' ' ' GLY . 47.7 m-85 -85.49 -34.47 21.58 Favored 'General case' 0 N--CA 1.439 -1.007 0 N-CA-C 107.143 -1.428 . . . . 0.0 107.143 176.201 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.769 ' HB2' ' HB3' ' A' ' 76' ' ' LEU . . . 170.22 127.27 0.05 OUTLIER Pre-proline 0 C--O 1.217 -0.617 0 CA-C-N 112.729 -2.032 . . . . 0.0 107.712 -178.029 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 72' ' ' PRO . . . . . 0.556 ' HA ' ' HA ' ' A' ' 68' ' ' LEU . 17.2 Cg_exo -58.32 -0.96 0.54 Allowed 'Trans proline' 0 C--N 1.331 -0.39 0 C-N-CA 122.968 2.445 . . . . 0.0 113.8 -179.455 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 73' ' ' ARG . . . . . 0.41 ' HE ' ' CG ' ' A' ' 75' ' ' ASP . 13.4 ptm180 -152.85 143.04 22.43 Favored 'General case' 0 C--N 1.318 -0.799 0 N-CA-C 109.232 -0.655 . . . . 0.0 109.232 174.059 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . 0.469 ' HA ' ' CH2' ' A' ' 62' ' ' TRP . . . -61.7 -25.48 67.44 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.574 -0.739 . . . . 0.0 112.359 -174.381 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . 0.41 ' CG ' ' HE ' ' A' ' 73' ' ' ARG . 17.2 p-10 -89.36 10.91 20.7 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-O 121.049 0.452 . . . . 0.0 111.363 -178.041 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.769 ' HB3' ' HB2' ' A' ' 71' ' ' ALA . 42.0 tp -104.29 -42.71 5.42 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.345 177.207 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . 0.711 ' HB1' ' OE2' ' A' ' 81' ' ' GLU . . . -100.73 170.47 8.32 Favored 'General case' 0 N--CA 1.45 -0.473 0 CA-C-O 121.136 0.493 . . . . 0.0 109.932 177.826 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 78' ' ' THR . . . . . 0.549 ' OG1' ' HG2' ' A' ' 80' ' ' GLU . 41.3 p -85.06 168.71 14.63 Favored 'General case' 0 C--N 1.312 -1.063 0 N-CA-C 113.2 0.815 . . . . 0.0 113.2 -167.775 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . 0.626 ' HA ' ' CE3' ' A' ' 43' ' ' TRP . 7.1 ptm180 -47.4 -36.09 9.29 Favored 'General case' 0 N--CA 1.466 0.352 0 C-N-CA 122.724 0.41 . . . . 0.0 112.087 -175.238 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 80' ' ' GLU . . . . . 0.903 ' HA ' HD11 ' A' ' 83' ' ' ILE . 16.1 pt-20 -62.36 -31.22 71.83 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.407 -178.556 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 81' ' ' GLU . . . . . 0.711 ' OE2' ' HB1' ' A' ' 77' ' ' ALA . 0.0 OUTLIER -72.53 -48.86 36.99 Favored 'General case' 0 N--CA 1.428 -1.545 0 N-CA-C 110.075 -0.343 . . . . 0.0 110.075 177.163 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 82' ' ' GLN . . . . . 0.677 ' HB2' ' HZ3' ' A' ' 43' ' ' TRP . 67.1 mt-30 -59.82 -31.8 70.06 Favored 'General case' 0 CA--C 1.511 -0.521 0 C-N-CA 120.874 -0.331 . . . . 0.0 110.225 178.245 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . 0.903 HD11 ' HA ' ' A' ' 80' ' ' GLU . 79.7 mt -59.32 -51.5 71.92 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.782 0 CA-C-N 115.892 -0.594 . . . . 0.0 109.626 173.328 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 84' ' ' ALA . . . . . 0.476 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -62.36 -44.42 96.51 Favored 'General case' 0 C--O 1.238 0.459 0 CA-C-O 121.635 0.731 . . . . 0.0 111.285 -175.081 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . 0.661 HG11 ' HB2' ' A' ' 65' ' ' ASN . 48.9 t -67.97 -49.17 71.0 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.635 0 CA-C-N 115.388 -0.823 . . . . 0.0 111.107 -177.876 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -60.61 -29.7 69.38 Favored 'General case' 0 N--CA 1.451 -0.416 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.175 175.581 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 87' ' ' GLU . . . . . 0.77 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 28.7 mt-10 -60.31 -42.86 96.46 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.59 179.885 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.418 ' O ' ' HG3' ' A' ' 92' ' ' ARG . 75.6 t -60.67 -50.0 82.22 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.284 0 C-N-CA 120.37 -0.532 . . . . 0.0 110.189 178.943 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 89' ' ' THR . . . . . 0.485 ' HA ' ' NE ' ' A' ' 92' ' ' ARG . 97.0 m -64.11 -38.82 92.45 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-N 115.524 -0.762 . . . . 0.0 111.252 -178.442 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 90' ' ' ARG . . . . . 0.654 HH11 ' HG2' ' A' ' 87' ' ' GLU . 1.4 ptt180 -60.52 -35.88 77.04 Favored 'General case' 0 N--CA 1.464 0.258 0 CA-C-N 116.613 -0.267 . . . . 0.0 111.387 -179.674 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 91' ' ' LEU . . . . . 0.77 ' HG ' ' O ' ' A' ' 87' ' ' GLU . 32.1 mt -64.18 -29.02 70.16 Favored 'General case' 0 N--CA 1.47 0.534 0 CA-C-O 121.708 0.766 . . . . 0.0 110.15 -174.821 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . 0.485 ' NE ' ' HA ' ' A' ' 89' ' ' THR . 9.8 mtm180 -87.65 -43.89 11.61 Favored 'General case' 0 C--N 1.314 -0.956 0 CA-C-N 114.541 -1.209 . . . . 0.0 110.516 -169.573 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 93' ' ' GLN . . . . . 0.529 ' OE1' ' HA ' ' A' ' 90' ' ' ARG . 0.0 OUTLIER -105.79 -17.74 14.28 Favored 'General case' 0 CA--C 1.545 0.769 0 N-CA-C 113.956 1.095 . . . . 0.0 113.956 -173.965 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 79.86 44.34 9.23 Favored Glycine 0 C--N 1.335 0.513 0 C-N-CA 121.312 -0.47 . . . . 0.0 112.983 171.929 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 95' ' ' TRP . . . . . 0.402 ' CZ2' ' HD2' ' A' ' 90' ' ' ARG . 13.4 m95 61.62 19.94 10.87 Favored 'General case' 0 C--O 1.223 -0.338 0 C-N-CA 123.483 0.713 . . . . 0.0 109.618 -179.059 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -77.42 -32.98 45.23 Favored Glycine 0 N--CA 1.453 -0.189 0 CA-C-N 115.381 -0.827 . . . . 0.0 112.385 176.348 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -72.66 -24.85 61.09 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 121.338 0.589 . . . . 0.0 109.781 178.953 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 98' ' ' TRP . . . . . 0.448 ' HZ3' ' HA ' ' A' ' 90' ' ' ARG . 25.0 m-90 -95.33 108.22 37.69 Favored Pre-proline 0 N--CA 1.441 -0.88 0 N-CA-C 108.358 -0.979 . . . . 0.0 108.358 175.001 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 45.4 Cg_exo -64.14 -141.76 0.01 OUTLIER 'Trans proline' 0 CA--C 1.532 0.394 0 C-N-CA 123.466 2.777 . . . . 0.0 113.906 -174.189 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 4.3 t -56.21 -21.79 12.67 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.425 0 CA-C-O 120.928 0.394 . . . . 0.0 111.176 -175.542 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 77.5 m -56.87 -39.18 73.86 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-N 116.573 -0.285 . . . . 0.0 111.04 175.09 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -71.27 -37.96 71.88 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-O 120.905 0.383 . . . . 0.0 110.351 177.572 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -61.19 -41.64 97.18 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.638 177.44 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -67.59 -30.29 69.86 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.833 -0.621 . . . . 0.0 111.131 175.531 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 105' ' ' ALA . . . . . 0.422 ' CB ' ' HB3' ' A' ' 33' ' ' ALA . . . -86.28 -22.8 26.6 Favored 'General case' 0 C--N 1.326 -0.428 0 N-CA-C 112.709 0.633 . . . . 0.0 112.709 -172.812 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 104.16 65.74 0.7 Allowed Glycine 0 CA--C 1.521 0.447 0 C-N-CA 120.795 -0.716 . . . . 0.0 112.5 -178.182 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -70.28 148.59 48.36 Favored 'General case' 0 C--N 1.324 -0.525 0 C-N-CA 122.905 0.482 . . . . 0.0 110.773 -176.699 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 108' ' ' ARG . . . . . 0.44 ' O ' ' HD3' ' A' ' 108' ' ' ARG . 0.0 OUTLIER . . . . . 0 C--O 1.247 0.96 0 CA-C-O 119.069 -0.491 . . . . 0.0 111.181 -174.505 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.43 ' O ' HG12 ' A' ' 30' ' ' ILE . 6.3 m-20 . . . . . 0 CA--C 1.503 -0.83 0 CA-C-O 121.548 0.69 . . . . 0.0 109.833 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . 0.577 ' HA3' HD12 ' A' ' 83' ' ' ILE . . . -63.51 -9.05 29.4 Favored Glycine 0 N--CA 1.436 -1.343 0 CA-C-N 114.909 -1.041 . . . . 0.0 110.905 174.506 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 8.4 m -71.34 -44.25 65.44 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-O 121.681 0.753 . . . . 0.0 109.293 175.195 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.505 ' O ' HG13 ' A' ' 34' ' ' ILE . 0.4 OUTLIER -69.15 -39.45 79.37 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.604 0 CA-C-N 114.576 -1.193 . . . . 0.0 107.881 178.533 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' TRP . . . . . 0.688 ' CD1' HG22 ' A' ' 83' ' ' ILE . 39.5 m95 -67.95 -35.93 79.24 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 114.493 -1.231 . . . . 0.0 110.528 -177.15 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.432 ' CG ' HH21 ' A' ' 79' ' ' ARG . 3.9 t70 -71.23 -42.25 69.12 Favored 'General case' 0 N--CA 1.447 -0.621 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.256 177.665 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . 0.437 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -67.33 -33.77 75.95 Favored 'General case' 0 N--CA 1.446 -0.662 0 CA-C-N 116.44 -0.345 . . . . 0.0 110.511 -179.665 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . 0.505 HG13 ' O ' ' A' ' 30' ' ' ILE . 65.7 mt -64.41 -46.14 93.82 Favored 'Isoleucine or valine' 0 C--O 1.234 0.255 0 CA-C-O 121.046 0.45 . . . . 0.0 109.865 172.457 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . 0.477 ' HA ' ' NE2' ' A' ' 56' ' ' GLN . . . -57.99 -38.85 76.86 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.133 176.065 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . 0.414 ' HA2' ' N ' ' A' ' 41' ' ' GLY . . . -65.44 -28.83 74.01 Favored Glycine 0 N--CA 1.451 -0.329 0 CA-C-N 115.588 -0.733 . . . . 0.0 111.97 179.248 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 6.7 t -76.25 -64.49 1.09 Allowed 'General case' 0 C--N 1.318 -0.764 0 N-CA-C 111.926 0.343 . . . . 0.0 111.926 -178.823 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . 0.501 ' HB3' ' CD ' ' A' ' 56' ' ' GLN . 11.2 tp10 -88.19 -31.79 18.93 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 121.062 0.458 . . . . 0.0 110.692 -168.939 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -96.89 -9.15 29.11 Favored 'General case' 0 N--CA 1.45 -0.436 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.764 -175.348 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 78.57 16.66 78.96 Favored Glycine 0 CA--C 1.503 -0.685 0 N-CA-C 109.848 -1.301 . . . . 0.0 109.848 -177.929 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . 0.414 ' N ' ' HA2' ' A' ' 36' ' ' GLY . . . 69.19 59.69 5.67 Favored Glycine 0 N--CA 1.432 -1.606 0 CA-C-N 113.992 -1.104 . . . . 0.0 111.928 -177.179 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 62.2 t30 -147.12 122.17 10.09 Favored 'General case' 0 CA--C 1.505 -0.77 0 N-CA-C 109.134 -0.691 . . . . 0.0 109.134 179.346 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 43' ' ' TRP . . . . . 0.71 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 33.9 m95 -97.5 -6.25 34.1 Favored 'General case' 0 C--N 1.306 -1.315 0 CA-C-N 114.956 -1.02 . . . . 0.0 109.935 -173.168 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -110.51 9.93 23.17 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-N 114.907 -1.042 . . . . 0.0 111.183 -179.073 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.74 HG23 ' HA2' ' A' ' 53' ' ' GLY . 3.2 tt -71.09 143.21 14.66 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.615 0 N-CA-C 109.477 -0.564 . . . . 0.0 109.477 179.099 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 45.0 t-20 -165.2 96.05 0.68 Allowed 'General case' 0 C--N 1.312 -1.041 0 CA-C-O 121.047 0.451 . . . . 0.0 110.132 -176.577 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 17.8 p -82.32 -12.06 58.22 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.392 179.832 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 89.29 22.15 38.8 Favored Glycine 0 N--CA 1.446 -0.697 0 N-CA-C 111.275 -0.73 . . . . 0.0 111.275 178.985 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 8.6 p30 -88.36 5.86 40.05 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 121.03 0.443 . . . . 0.0 110.99 -176.031 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . 0.496 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 95.77 -12.22 67.53 Favored Glycine 0 N--CA 1.448 -0.536 0 CA-C-N 115.913 -0.585 . . . . 0.0 112.117 -178.234 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 51' ' ' TYR . . . . . 0.544 ' HA ' ' HA ' ' A' ' 58' ' ' ASP . 0.1 OUTLIER -112.99 161.29 17.2 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 108.026 -1.102 . . . . 0.0 108.026 173.494 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 52' ' ' TYR . . . . . 0.406 ' HE1' ' HB2' ' A' ' 59' ' ' GLN . 42.7 m-85 -125.62 170.26 11.67 Favored 'General case' 0 C--N 1.313 -0.982 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.686 -170.752 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.74 ' HA2' HG23 ' A' ' 45' ' ' ILE . . . -70.36 -172.59 11.31 Favored Glycine 0 N--CA 1.446 -0.678 0 CA-C-N 116.177 -0.465 . . . . 0.0 114.23 -171.69 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . 0.626 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 81.91 -111.03 3.27 Favored Glycine 0 N--CA 1.443 -0.888 0 C-N-CA 121.011 -0.614 . . . . 0.0 111.76 -179.154 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.529 ' HB ' ' CE2' ' A' ' 57' ' ' PHE . 1.8 t -91.69 19.96 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-O 121.183 0.516 . . . . 0.0 110.53 -178.488 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 56' ' ' GLN . . . . . 0.501 ' CD ' ' HB3' ' A' ' 38' ' ' GLU . 7.0 mp0 59.51 50.31 7.6 Favored 'General case' 0 N--CA 1.47 0.547 0 CA-C-N 115.168 -0.924 . . . . 0.0 111.704 171.496 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . 0.529 ' CE2' ' HB ' ' A' ' 55' ' ' VAL . 57.3 m-85 -81.45 138.07 35.57 Favored 'General case' 0 CA--C 1.504 -0.804 0 CA-C-N 115.77 -0.65 . . . . 0.0 112.266 178.345 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.544 ' HA ' ' HA ' ' A' ' 51' ' ' TYR . 7.9 p-10 -79.45 155.96 28.08 Favored 'General case' 0 C--N 1.313 -1.003 0 N-CA-C 108.535 -0.913 . . . . 0.0 108.535 163.631 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . 0.406 ' HB2' ' HE1' ' A' ' 52' ' ' TYR . 19.0 tp60 -54.63 -36.47 64.56 Favored 'General case' 0 N--CA 1.445 -0.701 0 CA-C-O 121.188 0.518 . . . . 0.0 110.352 -179.026 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -68.51 -50.5 37.13 Favored Glycine 0 C--O 1.225 -0.428 0 CA-C-N 114.795 -1.093 . . . . 0.0 113.041 -173.557 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 99.1 m -67.51 -40.32 85.12 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 121.082 0.468 . . . . 0.0 110.299 -179.197 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 62' ' ' TRP . . . . . 0.503 ' CZ3' ' HA ' ' A' ' 82' ' ' GLN . 53.5 t-105 -57.82 -48.72 78.93 Favored 'General case' 0 N--CA 1.443 -0.789 0 CA-C-N 115.468 -0.787 . . . . 0.0 109.367 176.586 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . 0.503 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 44.9 tt0 -67.93 -33.97 75.71 Favored 'General case' 0 N--CA 1.444 -0.738 0 CA-C-N 115.07 -0.968 . . . . 0.0 110.695 -179.431 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -63.09 -41.49 99.42 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.839 -178.75 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . 0.654 ' HB2' HG11 ' A' ' 85' ' ' VAL . 7.5 m120 -73.92 -19.55 60.66 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 121.438 0.637 . . . . 0.0 110.054 176.41 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . 0.594 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 90.13 45.72 4.36 Favored Glycine 0 N--CA 1.446 -0.674 0 CA-C-N 115.148 -0.933 . . . . 0.0 111.534 -178.55 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . 0.724 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -78.59 -15.7 80.42 Favored Glycine 0 N--CA 1.445 -0.744 0 C-N-CA 120.998 -0.62 . . . . 0.0 112.359 -172.806 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 0.866 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 7.1 mp -60.27 -27.54 67.34 Favored 'General case' 0 C--N 1.316 -0.865 0 N-CA-C 112.875 0.694 . . . . 0.0 112.875 -175.918 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . 0.594 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 17.1 ptm180 -65.25 -32.44 74.1 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 121.602 0.715 . . . . 0.0 109.748 175.545 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 70' ' ' TYR . . . . . 0.724 ' HD2' ' HA2' ' A' ' 67' ' ' GLY . 93.1 m-85 -77.78 -34.55 52.23 Favored 'General case' 0 N--CA 1.439 -0.988 0 N-CA-C 107.877 -1.157 . . . . 0.0 107.877 177.388 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.657 ' HB1' ' HB2' ' A' ' 77' ' ' ALA . . . 160.42 129.56 0.0 OUTLIER Pre-proline 0 CA--C 1.513 -0.48 0 CA-C-N 112.21 -2.268 . . . . 0.0 106.738 179.308 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 72' ' ' PRO . . . . . 0.866 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 17.4 Cg_exo -58.18 -4.12 1.49 Allowed 'Trans proline' 0 CA--C 1.53 0.278 0 C-N-CA 122.582 2.188 . . . . 0.0 113.506 -176.919 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 13.2 ptm180 -145.29 136.29 24.72 Favored 'General case' 0 C--N 1.321 -0.647 0 N-CA-C 108.99 -0.745 . . . . 0.0 108.99 175.801 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . 0.474 ' HA ' ' CH2' ' A' ' 62' ' ' TRP . . . -55.87 -30.7 61.92 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 114.873 -1.058 . . . . 0.0 112.772 -177.763 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . 0.424 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 20.8 p-10 -88.27 9.55 22.74 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 120.907 0.384 . . . . 0.0 111.362 -176.314 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 60.7 tp -109.98 -33.14 6.79 Favored 'General case' 0 C--N 1.323 -0.56 0 N-CA-C 108.783 -0.821 . . . . 0.0 108.783 170.246 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . 0.657 ' HB2' ' HB1' ' A' ' 71' ' ' ALA . . . -79.85 163.17 24.59 Favored 'General case' 0 N--CA 1.444 -0.759 0 CA-C-N 115.061 -0.972 . . . . 0.0 109.272 174.143 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 32.0 p -99.39 -173.91 2.6 Favored 'General case' 0 C--N 1.315 -0.927 0 C-N-CA 120.799 -0.36 . . . . 0.0 110.385 -178.497 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . 0.71 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 20.7 mtp180 -51.0 -54.34 25.39 Favored 'General case' 0 C--O 1.22 -0.452 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.99 -177.378 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 80' ' ' GLU . . . . . 0.452 ' HA ' HD13 ' A' ' 83' ' ' ILE . 9.0 pt-20 -61.41 -41.42 97.12 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.829 -172.683 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 81' ' ' GLU . . . . . 0.706 ' HB3' ' HB3' ' A' ' 70' ' ' TYR . 3.6 mp0 -59.24 -51.77 68.53 Favored 'General case' 0 C--N 1.323 -0.551 0 N-CA-C 112.016 0.376 . . . . 0.0 112.016 172.74 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 82' ' ' GLN . . . . . 0.503 ' HA ' ' CZ3' ' A' ' 62' ' ' TRP . 34.8 mt-30 -59.67 -39.07 83.25 Favored 'General case' 0 CA--C 1.51 -0.561 0 CA-C-O 121.719 0.771 . . . . 0.0 109.681 179.903 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . 0.688 HG22 ' CD1' ' A' ' 31' ' ' TRP . 34.8 mt -60.85 -44.42 97.66 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.903 0 CA-C-N 114.112 -1.404 . . . . 0.0 110.61 179.557 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 84' ' ' ALA . . . . . 0.603 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -66.34 -35.76 81.18 Favored 'General case' 0 C--O 1.236 0.37 0 CA-C-O 121.559 0.695 . . . . 0.0 110.939 -178.613 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . 0.654 HG11 ' HB2' ' A' ' 65' ' ' ASN . 57.4 t -66.15 -48.18 82.25 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.65 0 CA-C-N 115.595 -0.73 . . . . 0.0 110.082 174.672 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -58.76 -30.65 67.68 Favored 'General case' 0 CA--C 1.518 -0.284 0 CA-C-N 115.766 -0.652 . . . . 0.0 110.567 173.551 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 87' ' ' GLU . . . . . 0.664 ' HG2' ' O ' ' A' ' 83' ' ' ILE . 30.9 mm-40 -59.06 -43.32 91.7 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.735 -0.666 . . . . 0.0 110.368 179.754 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.504 ' O ' ' HG3' ' A' ' 92' ' ' ARG . 91.1 t -62.9 -49.49 83.42 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-O 120.851 0.357 . . . . 0.0 110.446 177.901 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 89' ' ' THR . . . . . 0.573 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 23.8 m -66.17 -42.16 89.31 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.936 -0.574 . . . . 0.0 111.312 -176.479 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 90' ' ' ARG . . . . . 0.649 ' HA ' ' OE1' ' A' ' 93' ' ' GLN . 8.1 ptt180 -69.17 -32.76 72.3 Favored 'General case' 0 CA--C 1.515 -0.392 0 CA-C-O 121.729 0.776 . . . . 0.0 109.435 -179.255 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 91' ' ' LEU . . . . . 0.447 ' HB2' ' O ' ' A' ' 87' ' ' GLU . 49.4 tp -57.14 -27.44 61.85 Favored 'General case' 0 C--N 1.315 -0.92 0 CA-C-N 114.762 -1.108 . . . . 0.0 111.09 -179.179 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . 0.504 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 6.7 mtm180 -92.14 -50.97 5.41 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 115.407 -0.815 . . . . 0.0 110.581 -175.846 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 93' ' ' GLN . . . . . 0.649 ' OE1' ' HA ' ' A' ' 90' ' ' ARG . 0.0 OUTLIER -104.93 -15.1 15.24 Favored 'General case' 0 CA--C 1.539 0.531 0 N-CA-C 113.44 0.904 . . . . 0.0 113.44 -170.151 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . 0.475 ' O ' ' HB2' ' A' ' 90' ' ' ARG . . . 101.32 -97.55 1.67 Allowed Glycine 0 CA--C 1.498 -0.996 0 N-CA-C 110.096 -1.202 . . . . 0.0 110.096 -179.631 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 95' ' ' TRP . . . . . . . . . . . . . 25.3 m95 -145.89 19.45 1.45 Allowed 'General case' 0 C--N 1.315 -0.895 0 N-CA-C 106.246 -1.761 . . . . 0.0 106.246 171.867 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -66.03 -26.59 72.4 Favored Glycine 0 N--CA 1.451 -0.325 0 CA-C-N 114.581 -1.191 . . . . 0.0 112.833 -177.181 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -81.36 -15.19 56.04 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 121.272 0.558 . . . . 0.0 109.966 177.341 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 98' ' ' TRP . . . . . 0.573 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 28.3 m-90 -106.7 107.95 61.09 Favored Pre-proline 0 N--CA 1.445 -0.685 0 CA-C-N 115.472 -0.785 . . . . 0.0 109.42 177.657 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 99' ' ' PRO . . . . . 0.445 ' HD3' ' HA ' ' A' ' 98' ' ' TRP . 50.6 Cg_exo -61.99 -138.17 0.0 OUTLIER 'Trans proline' 0 CA--C 1.534 0.495 0 C-N-CA 123.876 3.051 . . . . 0.0 114.1 -174.628 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 15.0 m -54.97 -26.49 17.62 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.292 0 CA-C-O 121.166 0.507 . . . . 0.0 111.731 -176.468 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 101' ' ' CYS . . . . . 0.441 ' SG ' ' HB2' ' A' ' 38' ' ' GLU . 83.0 m -56.38 -35.3 67.56 Favored 'General case' 0 C--N 1.313 -0.985 0 CA-C-N 115.195 -0.911 . . . . 0.0 111.553 177.72 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -70.88 -45.83 63.68 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.768 0.318 . . . . 0.0 110.934 178.479 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -59.46 -42.69 92.57 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 121.086 0.469 . . . . 0.0 110.621 177.256 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 49.3 mtp180 -67.14 -19.46 65.61 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.348 -0.842 . . . . 0.0 111.14 178.199 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 105' ' ' ALA . . . . . 0.437 ' CB ' ' HB3' ' A' ' 33' ' ' ALA . . . -96.43 -20.39 18.47 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.938 -0.573 . . . . 0.0 112.109 -176.489 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 102.29 55.28 0.86 Allowed Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.887 -0.673 . . . . 0.0 111.802 -175.996 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -57.58 149.74 20.74 Favored 'General case' 0 C--N 1.329 -0.29 0 C-N-CA 123.224 0.61 . . . . 0.0 111.352 -179.639 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 28.0 mtp180 . . . . . 0 C--O 1.25 1.118 0 CA-C-O 118.317 -0.849 . . . . 0.0 109.49 -171.547 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.516 ' HB2' ' OE1' ' A' ' 87' ' ' GLU . 31.1 m-20 . . . . . 0 CA--C 1.511 -0.556 0 CA-C-O 121.059 0.457 . . . . 0.0 110.286 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . 0.58 ' HA2' ' HD1' ' A' ' 31' ' ' TRP . . . -60.55 -14.07 33.67 Favored Glycine 0 N--CA 1.448 -0.516 0 CA-C-N 115.631 -0.713 . . . . 0.0 111.683 -177.816 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 3.6 m -76.65 -41.9 44.04 Favored 'General case' 0 C--N 1.318 -0.772 0 CA-C-O 121.901 0.857 . . . . 0.0 109.576 178.263 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.524 ' O ' HG13 ' A' ' 34' ' ' ILE . 0.5 OUTLIER -66.95 -38.21 80.93 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.696 0 CA-C-N 114.263 -1.335 . . . . 0.0 107.891 -179.66 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' TRP . . . . . 0.58 ' HD1' ' HA2' ' A' ' 28' ' ' GLY . 38.2 m95 -66.33 -35.99 81.77 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 114.852 -1.067 . . . . 0.0 110.519 -177.215 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 5.4 t0 -70.1 -42.88 72.12 Favored 'General case' 0 N--CA 1.442 -0.86 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.138 178.621 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . 0.441 ' HB1' ' HB3' ' A' ' 105' ' ' ALA . . . -69.35 -34.22 74.28 Favored 'General case' 0 N--CA 1.445 -0.704 0 C-N-CA 120.39 -0.524 . . . . 0.0 110.683 179.457 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . 0.524 HG13 ' O ' ' A' ' 30' ' ' ILE . 51.9 mt -62.61 -43.65 98.69 Favored 'Isoleucine or valine' 0 C--O 1.235 0.295 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.429 174.692 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . 0.535 ' HA ' ' O ' ' A' ' 54' ' ' GLY . . . -61.84 -34.94 76.88 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.285 176.349 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . 0.435 ' HA2' ' N ' ' A' ' 41' ' ' GLY . . . -72.46 -16.9 77.51 Favored Glycine 0 N--CA 1.451 -0.328 0 CA-C-N 115.503 -0.771 . . . . 0.0 111.902 179.332 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 7.1 t -81.62 -61.88 1.8 Allowed 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.575 -0.313 . . . . 0.0 111.78 -177.388 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 14.0 tp10 -88.76 -33.73 17.37 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-O 121.109 0.48 . . . . 0.0 110.714 -172.641 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -99.13 -10.53 22.4 Favored 'General case' 0 N--CA 1.446 -0.626 0 CA-C-N 115.986 -0.552 . . . . 0.0 111.797 -173.817 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 75.13 15.9 80.87 Favored Glycine 0 N--CA 1.448 -0.522 0 N-CA-C 109.666 -1.374 . . . . 0.0 109.666 -177.041 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . 0.435 ' N ' ' HA2' ' A' ' 36' ' ' GLY . . . 79.18 61.73 2.31 Favored Glycine 0 N--CA 1.434 -1.478 0 CA-C-N 114.045 -1.077 . . . . 0.0 111.465 -174.64 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 2.4 t-20 -142.91 95.63 2.8 Favored 'General case' 0 C--N 1.323 -0.581 0 N-CA-C 108.799 -0.815 . . . . 0.0 108.799 -179.46 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 43' ' ' TRP . . . . . 0.758 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 18.2 m95 -78.29 -3.23 41.87 Favored 'General case' 0 C--N 1.314 -0.944 0 CA-C-N 115.413 -0.812 . . . . 0.0 110.122 -174.269 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -112.58 14.21 20.11 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.273 -0.876 . . . . 0.0 111.7 -179.111 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.926 HG23 ' HA2' ' A' ' 53' ' ' GLY . 2.9 tt -75.61 145.08 11.2 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.45 0 CA-C-O 121.24 0.543 . . . . 0.0 110.214 179.435 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 14.1 t-20 -146.88 87.62 1.7 Allowed 'General case' 0 C--N 1.312 -1.028 0 N-CA-C 109.649 -0.5 . . . . 0.0 109.649 179.188 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 22.4 p -68.6 -28.16 66.68 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.657 -0.701 . . . . 0.0 110.268 179.72 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 100.01 18.09 23.34 Favored Glycine 0 N--CA 1.444 -0.785 0 CA-C-N 115.382 -0.827 . . . . 0.0 111.162 179.474 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 32.9 p-10 -92.85 10.63 30.24 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 120.878 0.37 . . . . 0.0 111.419 -175.147 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . 0.537 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 90.51 -11.66 70.78 Favored Glycine 0 N--CA 1.449 -0.433 0 N-CA-C 111.707 -0.557 . . . . 0.0 111.707 179.715 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 51' ' ' TYR . . . . . 0.561 ' CE1' ' HB3' ' A' ' 58' ' ' ASP . 0.6 OUTLIER -111.9 162.07 15.72 Favored 'General case' 0 N--CA 1.446 -0.644 0 N-CA-C 106.541 -1.652 . . . . 0.0 106.541 177.671 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 52' ' ' TYR . . . . . 0.444 ' O ' ' HA ' ' A' ' 56' ' ' GLN . 39.3 m-85 -125.85 169.68 12.38 Favored 'General case' 0 C--N 1.31 -1.114 0 C-N-CA 119.82 -0.752 . . . . 0.0 112.028 -168.313 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.926 ' HA2' HG23 ' A' ' 45' ' ' ILE . . . -60.52 160.04 24.59 Favored Glycine 0 CA--C 1.5 -0.893 0 CA-C-N 115.121 -0.945 . . . . 0.0 113.54 -175.045 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . 0.626 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 92.15 -109.55 3.77 Favored Glycine 0 N--CA 1.437 -1.267 0 C-N-CA 120.515 -0.85 . . . . 0.0 111.615 -177.751 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.554 HG12 ' NE1' ' A' ' 98' ' ' TRP . 3.9 t -87.15 13.18 1.03 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-O 121.378 0.609 . . . . 0.0 110.466 -174.266 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 56' ' ' GLN . . . . . 0.446 ' HG2' ' O ' ' A' ' 55' ' ' VAL . 0.0 OUTLIER 51.07 33.85 9.88 Favored 'General case' 0 N--CA 1.473 0.689 0 N-CA-C 114.454 1.279 . . . . 0.0 114.454 164.975 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 4.7 p90 -113.77 168.95 9.35 Favored 'General case' 0 C--N 1.325 -0.475 0 C-N-CA 119.348 -0.941 . . . . 0.0 112.169 178.593 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.561 ' HB3' ' CE1' ' A' ' 51' ' ' TYR . 5.5 p-10 -83.83 164.53 19.44 Favored 'General case' 0 CA--C 1.517 -0.311 0 N-CA-C 113.887 1.069 . . . . 0.0 113.887 -163.379 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . 0.402 ' HB2' ' HE1' ' A' ' 52' ' ' TYR . 5.2 tp-100 -63.38 -39.58 94.92 Favored 'General case' 0 N--CA 1.449 -0.481 0 CA-C-N 113.553 -1.658 . . . . 0.0 111.969 179.695 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -65.52 -48.03 72.25 Favored Glycine 0 C--N 1.317 -0.504 0 C-N-CA 121.124 -0.56 . . . . 0.0 111.991 -176.217 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 98.4 m -64.85 -42.05 95.21 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-O 120.936 0.398 . . . . 0.0 110.85 176.052 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 62' ' ' TRP . . . . . 0.439 ' CH2' ' HA ' ' A' ' 82' ' ' GLN . 53.4 t-105 -56.91 -49.76 74.6 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 121.733 0.778 . . . . 0.0 109.871 176.764 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . 0.516 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 1.8 tm-20 -67.68 -33.48 75.0 Favored 'General case' 0 C--N 1.318 -0.802 0 CA-C-N 114.677 -1.147 . . . . 0.0 110.656 -178.246 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -66.86 -40.8 87.98 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.923 -179.581 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 8.2 m120 -82.93 -1.78 53.22 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 121.056 0.455 . . . . 0.0 110.328 177.163 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 80.17 48.93 6.18 Favored Glycine 0 C--N 1.334 0.446 0 CA-C-N 115.6 -0.727 . . . . 0.0 112.413 173.686 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . 0.54 ' HA2' ' HD1' ' A' ' 70' ' ' TYR . . . -80.25 -18.71 71.01 Favored Glycine 0 N--CA 1.442 -0.953 0 C-N-CA 120.828 -0.701 . . . . 0.0 112.959 -176.338 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 0.735 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 6.5 mp -60.84 -28.47 68.85 Favored 'General case' 0 C--N 1.322 -0.616 0 N-CA-C 112.379 0.511 . . . . 0.0 112.379 -172.364 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 16.3 ptm180 -67.85 -28.79 67.85 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 121.457 0.646 . . . . 0.0 110.188 176.206 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 70' ' ' TYR . . . . . 0.62 ' HB3' ' HG3' ' A' ' 81' ' ' GLU . 86.4 m-85 -79.4 -34.11 42.12 Favored 'General case' 0 N--CA 1.442 -0.838 0 N-CA-C 107.419 -1.326 . . . . 0.0 107.419 175.708 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.679 ' HB2' ' HB2' ' A' ' 77' ' ' ALA . . . 159.13 128.39 0.0 OUTLIER Pre-proline 0 CA--C 1.51 -0.589 0 CA-C-N 112.473 -2.149 . . . . 0.0 106.539 -179.474 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 72' ' ' PRO . . . . . 0.735 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 23.3 Cg_exo -55.64 -6.08 0.94 Allowed 'Trans proline' 0 CA--C 1.527 0.166 0 C-N-CA 122.829 2.353 . . . . 0.0 113.808 -176.824 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 12.8 ptm180 -146.84 138.49 24.38 Favored 'General case' 0 C--N 1.322 -0.597 0 N-CA-C 109.521 -0.548 . . . . 0.0 109.521 177.927 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . 0.419 ' HA ' ' CH2' ' A' ' 62' ' ' TRP . . . -61.7 -23.0 65.82 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 113.052 0.76 . . . . 0.0 113.052 -176.168 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . 0.66 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 5.5 p-10 -84.86 -7.68 59.08 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 121.191 0.52 . . . . 0.0 110.65 -179.051 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 54.6 tp -97.68 -31.47 12.25 Favored 'General case' 0 C--N 1.322 -0.623 0 N-CA-C 109.249 -0.648 . . . . 0.0 109.249 173.591 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . 0.712 ' HB3' ' HB3' ' A' ' 81' ' ' GLU . . . -78.55 155.22 29.82 Favored 'General case' 0 N--CA 1.444 -0.757 0 CA-C-N 115.267 -0.879 . . . . 0.0 109.562 176.277 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 48.0 p -97.86 -173.9 2.74 Favored 'General case' 0 C--N 1.311 -1.093 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.539 -176.766 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . 0.758 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 2.1 mtp180 -51.44 -53.62 35.19 Favored 'General case' 0 C--O 1.219 -0.518 0 O-C-N 123.184 0.302 . . . . 0.0 111.073 -178.044 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 80' ' ' GLU . . . . . 0.462 ' HG2' ' H ' ' A' ' 81' ' ' GLU . 1.6 pm0 -62.47 -45.47 92.89 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-O 120.949 0.404 . . . . 0.0 111.6 -176.5 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 81' ' ' GLU . . . . . 0.712 ' HB3' ' HB3' ' A' ' 77' ' ' ALA . 0.4 OUTLIER -60.88 -52.3 65.66 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 121.204 0.526 . . . . 0.0 112.332 178.194 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 82' ' ' GLN . . . . . 0.501 ' HG2' HG21 ' A' ' 55' ' ' VAL . 6.0 tt0 -69.84 -33.94 72.97 Favored 'General case' 0 C--N 1.316 -0.876 0 CA-C-N 115.449 -0.796 . . . . 0.0 110.735 -175.305 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . 0.553 ' O ' ' HG2' ' A' ' 87' ' ' GLU . 24.3 mt -60.52 -43.18 93.82 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.638 0 CA-C-N 115.535 -0.757 . . . . 0.0 109.905 174.155 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 84' ' ' ALA . . . . . 0.568 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -64.51 -39.29 93.51 Favored 'General case' 0 C--O 1.237 0.411 0 CA-C-O 121.421 0.629 . . . . 0.0 111.076 -174.867 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 51.5 t -68.29 -49.28 68.2 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 CA-C-N 115.645 -0.707 . . . . 0.0 111.162 177.761 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -58.69 -29.82 66.93 Favored 'General case' 0 C--O 1.234 0.267 0 CA-C-O 120.955 0.407 . . . . 0.0 110.532 174.232 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 87' ' ' GLU . . . . . 0.718 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 8.8 mm-40 -59.36 -44.42 92.69 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.467 -0.788 . . . . 0.0 109.766 179.279 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.436 ' O ' ' HG3' ' A' ' 92' ' ' ARG . 70.4 t -62.03 -46.26 96.89 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.209 0 CA-C-O 120.933 0.397 . . . . 0.0 109.938 176.473 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 89' ' ' THR . . . . . 0.94 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 0.2 OUTLIER -60.03 -48.61 81.02 Favored 'General case' 0 N--CA 1.447 -0.59 0 CA-C-N 115.67 -0.695 . . . . 0.0 112.004 -175.141 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 90' ' ' ARG . . . . . 0.68 ' HA ' ' OE1' ' A' ' 93' ' ' GLN . 0.2 OUTLIER -60.46 -33.41 72.51 Favored 'General case' 0 CA--C 1.518 -0.28 0 CA-C-N 116.036 -0.529 . . . . 0.0 111.349 -173.433 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 91' ' ' LEU . . . . . 0.718 ' HG ' ' O ' ' A' ' 87' ' ' GLU . 24.4 mt -66.53 -26.26 67.07 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 121.364 0.602 . . . . 0.0 110.139 -175.039 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . 0.436 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 10.3 mtm180 -89.13 -49.94 6.45 Favored 'General case' 0 C--N 1.317 -0.84 0 CA-C-N 114.957 -1.02 . . . . 0.0 110.377 -172.18 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 93' ' ' GLN . . . . . 0.68 ' OE1' ' HA ' ' A' ' 90' ' ' ARG . 0.0 OUTLIER -99.05 -22.94 15.46 Favored 'General case' 0 CA--C 1.54 0.582 0 N-CA-C 113.457 0.91 . . . . 0.0 113.457 -171.599 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 81.7 47.19 6.42 Favored Glycine 0 C--N 1.335 0.522 0 C-N-CA 120.81 -0.709 . . . . 0.0 111.921 173.225 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 95' ' ' TRP . . . . . 0.434 ' HH2' ' HB3' ' A' ' 27' ' ' ASP . 4.9 m95 59.34 21.15 9.4 Favored 'General case' 0 C--O 1.221 -0.404 0 CA-C-O 121.567 0.698 . . . . 0.0 109.674 -179.02 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 0.441 ' H ' ' HG2' ' A' ' 93' ' ' GLN . . . -78.09 -18.62 76.3 Favored Glycine 0 N--CA 1.452 -0.262 0 CA-C-N 115.4 -0.818 . . . . 0.0 112.11 174.645 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -81.79 -31.84 31.65 Favored 'General case' 0 C--N 1.326 -0.421 0 N-CA-C 109.541 -0.54 . . . . 0.0 109.541 176.421 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 98' ' ' TRP . . . . . 0.94 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 17.2 m-90 -105.68 103.9 45.88 Favored Pre-proline 0 C--N 1.323 -0.577 0 CA-C-N 115.286 -0.87 . . . . 0.0 109.143 177.265 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 99' ' ' PRO . . . . . 0.417 ' HD3' ' HA ' ' A' ' 98' ' ' TRP . 11.3 Cg_exo -77.2 -90.85 0.0 OUTLIER 'Trans proline' 0 CA--C 1.536 0.589 0 C-N-CA 122.789 2.326 . . . . 0.0 114.543 -173.467 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . 0.474 ' O ' ' HD2' ' A' ' 104' ' ' ARG . 4.5 p -69.77 -29.37 40.6 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.349 0 CA-C-O 121.962 0.887 . . . . 0.0 110.196 -172.525 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 78.0 m -73.39 -38.8 65.52 Favored 'General case' 0 C--N 1.312 -1.061 0 CA-C-N 114.281 -1.327 . . . . 0.0 111.564 -174.05 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 102' ' ' ALA . . . . . 0.421 ' HB1' ' HB2' ' A' ' 98' ' ' TRP . . . -70.27 -42.37 72.22 Favored 'General case' 0 C--N 1.326 -0.441 0 C-N-CA 120.761 -0.376 . . . . 0.0 110.499 178.494 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -59.3 -45.47 91.19 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 121.2 0.524 . . . . 0.0 110.59 178.552 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 104' ' ' ARG . . . . . 0.474 ' HD2' ' O ' ' A' ' 100' ' ' VAL . 0.0 OUTLIER -71.82 -18.5 62.08 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 115.566 -0.743 . . . . 0.0 111.888 179.512 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 105' ' ' ALA . . . . . 0.455 ' HB1' HG22 ' A' ' 30' ' ' ILE . . . -92.16 -21.35 20.45 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 121.001 0.429 . . . . 0.0 111.45 179.508 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 110.5 63.06 0.51 Allowed Glycine 0 N--CA 1.451 -0.353 0 CA-C-N 116.005 -0.543 . . . . 0.0 112.018 -177.885 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -65.13 149.39 49.99 Favored 'General case' 0 C--N 1.33 -0.244 0 C-N-CA 122.806 0.442 . . . . 0.0 110.908 -178.25 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 71.7 mtp180 . . . . . 0 C--O 1.246 0.884 0 CA-C-O 118.638 -0.696 . . . . 0.0 110.195 -170.995 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.414 ' O ' HG13 ' A' ' 30' ' ' ILE . 15.0 m-20 . . . . . 0 CA--C 1.498 -1.036 0 CA-C-O 121.88 0.848 . . . . 0.0 109.791 . . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . 0.619 ' HA2' ' HB2' ' A' ' 31' ' ' TRP . . . -70.66 -7.44 61.36 Favored Glycine 0 N--CA 1.438 -1.228 0 CA-C-N 114.659 -1.155 . . . . 0.0 110.295 -179.12 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 41.7 m -77.05 -38.35 52.9 Favored 'General case' 0 C--N 1.32 -0.717 0 N-CA-C 109.029 -0.73 . . . . 0.0 109.029 173.997 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.568 ' HA ' ' HB3' ' A' ' 105' ' ' ALA . 0.2 OUTLIER -71.92 -37.1 60.07 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.692 0 N-CA-C 107.844 -1.169 . . . . 0.0 107.844 175.929 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' TRP . . . . . 0.619 ' HB2' ' HA2' ' A' ' 28' ' ' GLY . 38.9 m95 -71.38 -38.29 71.55 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 114.611 -1.177 . . . . 0.0 110.391 -178.377 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 28.3 t70 -78.31 -30.14 48.17 Favored 'General case' 0 N--CA 1.442 -0.846 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.041 178.599 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . 0.497 ' HB1' ' CB ' ' A' ' 105' ' ' ALA . . . -70.6 -33.78 71.43 Favored 'General case' 0 N--CA 1.452 -0.371 0 O-C-N 122.012 -0.43 . . . . 0.0 110.177 176.389 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . 0.521 HG13 ' O ' ' A' ' 30' ' ' ILE . 70.3 mt -64.73 -46.14 93.07 Favored 'Isoleucine or valine' 0 C--O 1.234 0.239 0 CA-C-O 121.241 0.544 . . . . 0.0 109.804 171.473 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . 0.488 ' HA ' ' O ' ' A' ' 54' ' ' GLY . . . -58.61 -39.45 80.48 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.547 -0.751 . . . . 0.0 110.453 176.177 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -76.51 -7.25 85.33 Favored Glycine 0 C--N 1.319 -0.363 0 CA-C-N 115.462 -0.79 . . . . 0.0 111.763 179.923 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 9.3 t -92.47 -64.78 1.06 Allowed 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 115.428 -0.386 . . . . 0.0 110.972 -178.981 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . 0.8 ' HG3' ' SG ' ' A' ' 101' ' ' CYS . 25.7 mt-10 -90.49 -33.64 15.87 Favored 'General case' 0 C--N 1.325 -0.473 0 C-N-CA 120.522 -0.471 . . . . 0.0 111.419 -175.684 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . 0.416 ' HB2' ' O ' ' A' ' 35' ' ' ALA . . . -89.62 -11.86 41.37 Favored 'General case' 0 C--N 1.325 -0.495 0 C-N-CA 120.697 -0.401 . . . . 0.0 111.641 -176.033 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 76.32 13.36 83.41 Favored Glycine 0 CA--C 1.505 -0.556 0 N-CA-C 110.225 -1.15 . . . . 0.0 110.225 -179.672 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 79.64 57.45 3.1 Favored Glycine 0 N--CA 1.433 -1.549 0 CA-C-N 113.915 -1.143 . . . . 0.0 111.759 -176.038 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 42' ' ' ASN . . . . . 0.414 ' OD1' ' HB ' ' A' ' 45' ' ' ILE . 2.4 t-20 -147.8 106.12 3.77 Favored 'General case' 0 N--CA 1.448 -0.548 0 N-CA-C 108.76 -0.83 . . . . 0.0 108.76 -177.752 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 43' ' ' TRP . . . . . 0.747 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 35.2 m95 -83.92 -12.38 55.49 Favored 'General case' 0 C--N 1.311 -1.07 0 CA-C-N 115.643 -0.708 . . . . 0.0 110.315 -174.031 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -106.67 13.98 27.46 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 115.346 -0.843 . . . . 0.0 110.895 -179.508 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.525 HG22 ' HA3' ' A' ' 53' ' ' GLY . 7.0 tt -77.51 144.38 11.56 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.01 0 N-CA-C 109.239 -0.652 . . . . 0.0 109.239 177.412 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 41.1 t-20 -156.59 100.67 1.96 Allowed 'General case' 0 C--N 1.313 -1.022 0 CA-C-O 121.213 0.53 . . . . 0.0 109.614 -177.625 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 14.6 p -72.59 -24.75 61.13 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.298 -0.864 . . . . 0.0 110.383 179.527 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 96.12 17.77 33.65 Favored Glycine 0 N--CA 1.441 -1.013 0 CA-C-N 115.413 -0.812 . . . . 0.0 111.181 178.537 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 1.6 p-10 -90.34 9.47 28.76 Favored 'General case' 0 C--N 1.329 -0.32 0 C-N-CA 120.56 -0.456 . . . . 0.0 111.356 -173.141 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . 0.465 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 95.42 -11.55 68.66 Favored Glycine 0 N--CA 1.454 -0.154 0 C-N-CA 120.88 -0.676 . . . . 0.0 111.774 -179.194 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 51' ' ' TYR . . . . . 0.559 ' HA ' ' HA ' ' A' ' 58' ' ' ASP . 0.1 OUTLIER -113.67 159.82 19.28 Favored 'General case' 0 N--CA 1.447 -0.62 0 N-CA-C 106.655 -1.609 . . . . 0.0 106.655 174.186 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 52' ' ' TYR . . . . . 0.807 ' O ' ' HA ' ' A' ' 56' ' ' GLN . 50.8 m-85 -123.67 170.67 10.24 Favored 'General case' 0 C--N 1.311 -1.104 0 C-N-CA 120.639 -0.425 . . . . 0.0 111.116 -169.336 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.525 ' HA3' HG22 ' A' ' 45' ' ' ILE . . . -69.88 -168.27 6.56 Favored Glycine 0 N--CA 1.445 -0.753 0 N-CA-C 114.373 0.509 . . . . 0.0 114.373 -172.851 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . 0.645 ' CA ' ' HA ' ' A' ' 43' ' ' TRP . . . 73.46 -107.84 2.34 Favored Glycine 0 N--CA 1.441 -0.977 0 N-CA-C 111.335 -0.706 . . . . 0.0 111.335 -179.466 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.554 HG21 ' HB3' ' A' ' 82' ' ' GLN . 1.7 m -83.73 -0.43 5.39 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-O 121.464 0.649 . . . . 0.0 110.702 179.413 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 56' ' ' GLN . . . . . 0.807 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 7.8 tp-100 57.97 52.98 7.22 Favored 'General case' 0 CA--C 1.535 0.393 0 CA-C-N 114.157 -1.383 . . . . 0.0 114.546 164.404 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -126.73 171.92 10.78 Favored 'General case' 0 C--O 1.233 0.233 0 C-N-CA 118.969 -1.092 . . . . 0.0 112.806 172.512 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.559 ' HA ' ' HA ' ' A' ' 51' ' ' TYR . 7.9 p-10 -77.72 162.34 27.05 Favored 'General case' 0 CA--C 1.515 -0.393 0 N-CA-C 113.945 1.091 . . . . 0.0 113.945 -163.756 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . 0.757 ' HA ' HE21 ' A' ' 59' ' ' GLN . 0.0 OUTLIER -57.67 -41.98 82.62 Favored 'General case' 0 N--CA 1.445 -0.719 0 CA-C-N 114.367 -1.288 . . . . 0.0 111.137 177.194 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -67.61 -49.44 50.16 Favored Glycine 0 CA--C 1.507 -0.431 0 C-N-CA 120.993 -0.622 . . . . 0.0 112.22 -171.787 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 38.8 m -64.97 -42.03 94.92 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-O 120.904 0.383 . . . . 0.0 111.029 177.804 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 62' ' ' TRP . . . . . 0.473 ' CZ3' ' HA ' ' A' ' 82' ' ' GLN . 47.7 t-105 -56.63 -48.2 78.03 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 121.775 0.798 . . . . 0.0 109.514 175.29 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . 0.662 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 36.9 tt0 -65.74 -37.56 86.72 Favored 'General case' 0 N--CA 1.443 -0.791 0 CA-C-N 114.738 -1.119 . . . . 0.0 110.892 -179.151 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -66.02 -41.39 91.04 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.857 -177.941 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . 0.415 ' HB2' HG13 ' A' ' 85' ' ' VAL . 9.4 m120 -76.8 -13.04 60.05 Favored 'General case' 0 N--CA 1.45 -0.445 0 CA-C-O 120.883 0.373 . . . . 0.0 110.261 177.493 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . 0.525 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 92.11 45.43 3.85 Favored Glycine 0 C--N 1.333 0.393 0 CA-C-N 115.846 -0.616 . . . . 0.0 112.642 175.327 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . 0.571 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -79.91 -20.31 68.26 Favored Glycine 0 N--CA 1.443 -0.89 0 C-N-CA 120.807 -0.711 . . . . 0.0 112.848 -174.495 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 0.96 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 6.7 mp -64.37 -23.47 67.3 Favored 'General case' 0 C--N 1.319 -0.756 0 N-CA-C 112.424 0.527 . . . . 0.0 112.424 -172.933 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . 0.525 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 13.2 ptp180 -65.26 -31.16 72.17 Favored 'General case' 0 C--N 1.324 -0.509 0 N-CA-C 109.113 -0.699 . . . . 0.0 109.113 175.884 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 70' ' ' TYR . . . . . 0.601 ' HB3' ' HB3' ' A' ' 81' ' ' GLU . 92.4 m-85 -81.12 -36.05 30.82 Favored 'General case' 0 N--CA 1.439 -0.992 0 CA-C-N 114.683 -1.144 . . . . 0.0 107.94 177.394 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.499 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 164.72 127.55 0.02 OUTLIER Pre-proline 0 N--CA 1.448 -0.567 0 CA-C-N 112.626 -2.079 . . . . 0.0 107.342 -178.364 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 72' ' ' PRO . . . . . 0.96 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 17.4 Cg_exo -59.03 -3.44 1.6 Allowed 'Trans proline' 0 C--N 1.334 -0.217 0 C-N-CA 122.724 2.282 . . . . 0.0 113.586 -178.557 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 13.0 ptm180 -144.05 133.74 23.66 Favored 'General case' 0 C--N 1.315 -0.913 0 N-CA-C 108.127 -1.064 . . . . 0.0 108.127 175.986 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . 0.446 ' HA ' ' CH2' ' A' ' 62' ' ' TRP . . . -57.99 -28.8 64.74 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 115.578 -0.737 . . . . 0.0 112.372 -175.897 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 20.9 p-10 -84.24 -2.86 57.68 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 121.111 0.481 . . . . 0.0 111.499 -175.944 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.468 ' HB3' ' HB2' ' A' ' 71' ' ' ALA . 62.5 tp -96.38 -28.01 14.66 Favored 'General case' 0 C--N 1.322 -0.624 0 N-CA-C 108.413 -0.958 . . . . 0.0 108.413 170.342 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . 0.729 ' HB3' ' HB2' ' A' ' 81' ' ' GLU . . . -80.18 154.4 28.0 Favored 'General case' 0 N--CA 1.444 -0.77 0 CA-C-N 114.413 -1.267 . . . . 0.0 110.093 173.443 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 44.6 p -100.03 -172.5 2.24 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-N 116.392 -0.367 . . . . 0.0 110.136 179.291 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . 0.747 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 19.2 mtt180 -48.73 -53.28 19.59 Favored 'General case' 0 CA--C 1.509 -0.605 0 CA-C-O 121.205 0.526 . . . . 0.0 111.277 -177.924 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 80' ' ' GLU . . . . . 0.568 ' HG3' ' OE2' ' A' ' 81' ' ' GLU . 3.4 pt-20 -59.88 -41.04 90.68 Favored 'General case' 0 C--N 1.312 -1.04 0 CA-C-N 114.958 -1.019 . . . . 0.0 112.086 -175.553 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 81' ' ' GLU . . . . . 0.729 ' HB2' ' HB3' ' A' ' 77' ' ' ALA . 4.6 mp0 -67.46 -51.99 44.8 Favored 'General case' 0 C--O 1.232 0.181 0 N-CA-C 112.132 0.419 . . . . 0.0 112.132 174.444 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 82' ' ' GLN . . . . . 0.554 ' HB3' HG21 ' A' ' 55' ' ' VAL . 54.3 mt-30 -59.98 -43.44 95.12 Favored 'General case' 0 CA--C 1.512 -0.501 0 CA-C-O 121.116 0.484 . . . . 0.0 110.54 -175.73 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . 0.622 ' O ' ' HG2' ' A' ' 87' ' ' GLU . 15.4 mt -60.69 -40.81 85.98 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.787 0 CA-C-N 114.947 -1.024 . . . . 0.0 110.568 178.851 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 84' ' ' ALA . . . . . 0.577 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -63.6 -42.13 98.26 Favored 'General case' 0 C--O 1.239 0.524 0 CA-C-O 121.428 0.632 . . . . 0.0 111.366 -177.917 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . 0.415 HG13 ' HB2' ' A' ' 65' ' ' ASN . 44.5 t -69.05 -48.01 72.05 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.675 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.243 178.99 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 86' ' ' ALA . . . . . 0.435 ' HB2' ' CH2' ' A' ' 31' ' ' TRP . . . -57.85 -29.69 65.19 Favored 'General case' 0 N--CA 1.452 -0.34 0 CA-C-N 115.603 -0.726 . . . . 0.0 110.594 174.062 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 87' ' ' GLU . . . . . 0.622 ' HG2' ' O ' ' A' ' 83' ' ' ILE . 15.9 mm-40 -60.81 -40.64 93.5 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.193 178.738 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.499 ' O ' ' HG3' ' A' ' 92' ' ' ARG . 59.0 t -63.08 -48.06 89.61 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-O 121.276 0.56 . . . . 0.0 109.716 173.546 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 89' ' ' THR . . . . . 0.738 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 0.3 OUTLIER -63.41 -47.47 81.85 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 115.559 -0.746 . . . . 0.0 112.224 -174.832 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 90' ' ' ARG . . . . . 0.536 ' HB3' ' CH2' ' A' ' 31' ' ' TRP . 4.8 ptt180 -62.54 -32.82 73.84 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 121.519 0.676 . . . . 0.0 109.216 -176.276 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 91' ' ' LEU . . . . . 0.535 ' N ' ' HG3' ' A' ' 90' ' ' ARG . 64.3 tp -66.09 -32.18 73.5 Favored 'General case' 0 C--N 1.313 -1.01 0 CA-C-N 114.029 -1.441 . . . . 0.0 111.622 -173.236 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . 0.499 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 3.5 mtm180 -84.98 -46.46 11.2 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-O 121.507 0.67 . . . . 0.0 110.077 -175.116 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 93' ' ' GLN . . . . . 0.406 ' OE1' ' HB2' ' A' ' 97' ' ' ALA . 4.5 pt20 -101.89 -27.31 13.06 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 115.218 -0.901 . . . . 0.0 113.155 -168.5 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 92.3 39.62 5.33 Favored Glycine 0 CA--C 1.505 -0.555 0 C-N-CA 120.416 -0.897 . . . . 0.0 111.926 174.547 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 95' ' ' TRP . . . . . 0.499 ' CH2' ' HB ' ' A' ' 30' ' ' ILE . 38.7 m95 71.37 6.91 5.92 Favored 'General case' 0 C--O 1.218 -0.589 0 C-N-CA 123.399 0.68 . . . . 0.0 109.6 -178.462 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -58.46 -37.56 88.58 Favored Glycine 0 CA--C 1.521 0.44 0 CA-C-N 115.595 -0.73 . . . . 0.0 113.741 -179.826 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . 0.406 ' HB2' ' OE1' ' A' ' 93' ' ' GLN . . . -68.92 -22.2 64.16 Favored 'General case' 0 CA--C 1.519 -0.241 0 CA-C-N 117.219 0.51 . . . . 0.0 110.657 179.139 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 98' ' ' TRP . . . . . 0.738 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 27.7 m-90 -100.9 104.09 29.45 Favored Pre-proline 0 N--CA 1.449 -0.483 0 N-CA-C 109.05 -0.722 . . . . 0.0 109.05 175.918 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 16.5 Cg_exo -72.85 -89.96 0.01 OUTLIER 'Trans proline' 0 CA--C 1.533 0.427 0 C-N-CA 122.872 2.382 . . . . 0.0 114.738 -171.509 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 49.0 t -71.68 -30.28 37.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-O 121.811 0.815 . . . . 0.0 110.103 -173.122 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 101' ' ' CYS . . . . . 0.8 ' SG ' ' HG3' ' A' ' 38' ' ' GLU . 70.4 m -76.77 -27.57 55.36 Favored 'General case' 0 C--N 1.317 -0.835 0 CA-C-N 115.099 -0.955 . . . . 0.0 111.869 -169.713 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -69.68 -46.0 67.05 Favored 'General case' 0 C--N 1.329 -0.317 0 C-N-CA 120.75 -0.38 . . . . 0.0 110.753 -179.628 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -67.62 -32.12 72.61 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 120.856 0.36 . . . . 0.0 110.647 -179.946 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -74.1 -21.94 59.69 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.85 177.261 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 105' ' ' ALA . . . . . 0.568 ' HB3' ' HA ' ' A' ' 30' ' ' ILE . . . -96.17 -22.07 17.51 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.815 -0.629 . . . . 0.0 112.057 -176.26 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 108.62 57.08 0.56 Allowed Glycine 0 CA--C 1.522 0.492 0 C-N-CA 120.871 -0.681 . . . . 0.0 112.186 -177.517 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -61.54 149.73 38.09 Favored 'General case' 0 C--N 1.329 -0.321 0 C-N-CA 123.253 0.621 . . . . 0.0 111.551 -175.674 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 72.9 mtp180 . . . . . 0 C--O 1.245 0.859 0 CA-C-O 118.686 -0.673 . . . . 0.0 110.419 -173.855 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 8.7 m-20 . . . . . 0 CA--C 1.502 -0.889 0 CA-C-O 121.511 0.672 . . . . 0.0 109.774 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . 0.484 ' HA2' ' HB2' ' A' ' 31' ' ' TRP . . . -64.62 -11.62 49.48 Favored Glycine 0 N--CA 1.44 -1.073 0 CA-C-N 114.893 -1.049 . . . . 0.0 110.64 176.536 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 11.9 m -76.92 -36.88 56.3 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-O 121.854 0.835 . . . . 0.0 109.592 176.511 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.548 ' HA ' ' HB1' ' A' ' 105' ' ' ALA . 1.2 mm -71.34 -40.79 73.71 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 N-CA-C 107.088 -1.449 . . . . 0.0 107.088 176.701 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' TRP . . . . . 0.554 ' HA ' ' CE3' ' A' ' 31' ' ' TRP . 14.3 m95 -67.93 -35.83 79.09 Favored 'General case' 0 C--N 1.315 -0.898 0 CA-C-N 113.711 -1.586 . . . . 0.0 110.536 -175.528 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.572 ' HB2' HH21 ' A' ' 79' ' ' ARG . 12.4 t70 -77.18 -36.6 54.91 Favored 'General case' 0 N--CA 1.44 -0.937 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.712 -179.532 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . 0.519 ' HB2' ' CB ' ' A' ' 105' ' ' ALA . . . -70.65 -34.02 71.59 Favored 'General case' 0 N--CA 1.448 -0.558 0 C-N-CA 120.692 -0.403 . . . . 0.0 110.789 177.124 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . 0.529 HG13 ' O ' ' A' ' 30' ' ' ILE . 60.5 mt -64.94 -46.83 90.48 Favored 'Isoleucine or valine' 0 C--O 1.234 0.25 0 CA-C-O 120.889 0.376 . . . . 0.0 110.559 175.359 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . 0.423 ' O ' ' HB3' ' A' ' 39' ' ' ALA . . . -61.75 -34.67 76.25 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 121.328 0.585 . . . . 0.0 110.285 176.761 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . 0.467 ' HA2' ' N ' ' A' ' 41' ' ' GLY . . . -75.58 -9.47 84.69 Favored Glycine 0 N--CA 1.449 -0.462 0 CA-C-N 115.525 -0.762 . . . . 0.0 111.47 178.117 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.451 ' HB3' ' O ' ' A' ' 34' ' ' ILE . 1.7 t -91.03 -63.13 1.31 Allowed 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 115.399 -0.401 . . . . 0.0 111.409 -177.508 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . 0.733 ' HG3' ' SG ' ' A' ' 101' ' ' CYS . 13.9 mt-10 -89.27 -33.9 16.8 Favored 'General case' 0 C--N 1.327 -0.381 0 C-N-CA 120.405 -0.518 . . . . 0.0 111.39 -175.262 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . 0.423 ' HB3' ' O ' ' A' ' 35' ' ' ALA . . . -88.93 -9.02 53.06 Favored 'General case' 0 C--N 1.323 -0.567 0 C-N-CA 120.706 -0.398 . . . . 0.0 111.367 -177.335 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 75.5 15.92 80.94 Favored Glycine 0 CA--C 1.504 -0.637 0 N-CA-C 110.033 -1.227 . . . . 0.0 110.033 -178.689 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . 0.467 ' N ' ' HA2' ' A' ' 36' ' ' GLY . . . 75.76 60.39 3.19 Favored Glycine 0 N--CA 1.434 -1.491 0 CA-C-N 114.047 -1.076 . . . . 0.0 111.25 -174.273 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 2.1 t-20 -142.71 95.42 2.78 Favored 'General case' 0 N--CA 1.448 -0.538 0 N-CA-C 109.242 -0.651 . . . . 0.0 109.242 -178.759 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 43' ' ' TRP . . . . . 0.687 ' HA ' ' N ' ' A' ' 54' ' ' GLY . 36.8 m95 -79.96 -4.03 50.78 Favored 'General case' 0 C--N 1.317 -0.824 0 CA-C-N 115.516 -0.765 . . . . 0.0 110.319 -176.465 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -111.78 15.07 21.07 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 114.893 -1.049 . . . . 0.0 111.416 179.548 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.814 HG23 ' HA2' ' A' ' 53' ' ' GLY . 10.8 tt -76.64 141.44 15.67 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.719 0 CA-C-O 121.297 0.57 . . . . 0.0 110.398 179.612 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 19.1 m120 -142.01 95.93 2.88 Favored 'General case' 0 C--N 1.312 -1.053 0 CA-C-O 121.34 0.59 . . . . 0.0 109.513 -177.927 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 34.3 p -66.47 -23.7 66.31 Favored 'General case' 0 C--N 1.318 -0.791 0 CA-C-N 114.959 -1.019 . . . . 0.0 110.52 -179.097 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 88.55 14.54 61.44 Favored Glycine 0 N--CA 1.441 -0.989 0 N-CA-C 110.135 -1.186 . . . . 0.0 110.135 -178.408 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 2.6 t30 -96.16 5.25 51.49 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.423 0.63 . . . . 0.0 110.67 -173.229 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 95.53 -1.34 64.0 Favored Glycine 0 N--CA 1.447 -0.618 0 C-N-CA 120.612 -0.804 . . . . 0.0 111.103 -176.223 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 51' ' ' TYR . . . . . 0.529 ' HA ' ' O ' ' A' ' 57' ' ' PHE . 0.7 OUTLIER -110.88 161.36 15.9 Favored 'General case' 0 N--CA 1.444 -0.77 0 N-CA-C 107.724 -1.213 . . . . 0.0 107.724 179.077 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 52' ' ' TYR . . . . . 0.413 ' CD1' ' HB2' ' A' ' 73' ' ' ARG . 43.8 m-85 -129.62 170.05 14.27 Favored 'General case' 0 C--N 1.313 -1.013 0 CA-C-O 120.877 0.37 . . . . 0.0 111.823 -170.092 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.814 ' HA2' HG23 ' A' ' 45' ' ' ILE . . . -60.61 164.8 15.32 Favored Glycine 0 N--CA 1.448 -0.562 0 N-CA-C 115.127 0.811 . . . . 0.0 115.127 -168.663 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . 0.687 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 90.22 -96.29 2.19 Favored Glycine 0 N--CA 1.439 -1.152 0 CA-C-N 114.659 -0.77 . . . . 0.0 112.258 177.652 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -102.21 12.46 7.09 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.672 0 CA-C-O 120.77 0.319 . . . . 0.0 111.49 -175.803 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 56' ' ' GLN . . . . . . . . . . . . . 21.4 mm-40 60.24 43.64 13.6 Favored 'General case' 0 N--CA 1.47 0.557 0 CA-C-N 115.427 -0.806 . . . . 0.0 112.417 173.903 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . 0.529 ' O ' ' HA ' ' A' ' 51' ' ' TYR . 24.3 m-85 -63.38 127.09 29.72 Favored 'General case' 0 CA--C 1.505 -0.757 0 CA-C-N 115.306 -0.861 . . . . 0.0 112.173 172.847 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.475 ' HA ' ' HA ' ' A' ' 51' ' ' TYR . 6.7 p-10 -72.62 156.77 38.63 Favored 'General case' 0 C--N 1.317 -0.84 0 N-CA-C 108.414 -0.958 . . . . 0.0 108.414 163.522 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . 0.826 ' HA ' HE21 ' A' ' 59' ' ' GLN . 0.0 OUTLIER -58.44 -35.2 71.76 Favored 'General case' 0 C--N 1.316 -0.89 0 CA-C-O 120.733 0.301 . . . . 0.0 111.039 -177.221 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -68.13 -49.69 45.08 Favored Glycine 0 N--CA 1.451 -0.349 0 CA-C-N 116.045 -0.525 . . . . 0.0 112.494 -175.945 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 82.0 m -67.7 -40.97 84.28 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 120.933 0.397 . . . . 0.0 110.735 178.767 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 62' ' ' TRP . . . . . 0.506 ' CE2' ' HA3' ' A' ' 67' ' ' GLY . 65.6 t-105 -58.05 -47.56 82.77 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-O 121.547 0.689 . . . . 0.0 109.416 176.436 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . 0.41 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 33.8 tt0 -67.4 -32.51 73.45 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 115.182 -0.917 . . . . 0.0 110.924 -179.979 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -66.42 -42.37 87.85 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.71 -175.832 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . 0.782 ' HB2' HG12 ' A' ' 85' ' ' VAL . 26.1 m-80 -82.86 -5.9 59.2 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.874 0.368 . . . . 0.0 110.292 176.031 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . 0.584 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 90.61 48.15 3.53 Favored Glycine 0 C--N 1.332 0.327 0 CA-C-N 115.928 -0.578 . . . . 0.0 112.931 171.056 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . 0.576 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -79.8 -29.48 47.33 Favored Glycine 0 N--CA 1.438 -1.203 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.43 -176.053 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 1.008 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 8.2 mp -56.78 -22.0 32.71 Favored 'General case' 0 N--CA 1.447 -0.605 0 N-CA-C 112.997 0.74 . . . . 0.0 112.997 -175.189 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . 0.584 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 12.3 ptm180 -70.76 -30.26 66.71 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-O 121.431 0.634 . . . . 0.0 110.076 177.744 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 70' ' ' TYR . . . . . 1.016 ' HB3' ' HG2' ' A' ' 81' ' ' GLU . 46.7 m-85 -85.41 -36.0 20.95 Favored 'General case' 0 N--CA 1.443 -0.817 0 N-CA-C 107.447 -1.316 . . . . 0.0 107.447 177.037 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.639 ' HB1' ' HB1' ' A' ' 77' ' ' ALA . . . 170.74 126.23 0.05 OUTLIER Pre-proline 0 N--CA 1.445 -0.722 0 CA-C-N 112.863 -1.972 . . . . 0.0 107.522 -176.24 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 72' ' ' PRO . . . . . 1.008 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 26.4 Cg_exo -56.43 -6.15 1.37 Allowed 'Trans proline' 0 C--N 1.333 -0.28 0 C-N-CA 123.005 2.47 . . . . 0.0 113.785 -178.289 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 73' ' ' ARG . . . . . 0.413 ' HB2' ' CD1' ' A' ' 52' ' ' TYR . 13.5 ptm180 -147.53 138.67 23.64 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-O 121.28 0.562 . . . . 0.0 109.559 176.155 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -56.33 -30.22 62.31 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 114.861 -1.063 . . . . 0.0 113.307 -176.289 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 5.4 p-10 -80.47 -11.82 59.63 Favored 'General case' 0 C--N 1.327 -0.379 0 C-N-CA 120.428 -0.509 . . . . 0.0 110.899 -176.988 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.535 ' HB3' ' HB3' ' A' ' 71' ' ' ALA . 46.4 tp -90.16 -31.8 16.92 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-O 121.937 0.875 . . . . 0.0 108.76 173.621 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . 0.639 ' HB1' ' HB1' ' A' ' 71' ' ' ALA . . . -79.68 162.98 24.9 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 114.489 -1.232 . . . . 0.0 110.255 174.122 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 64.1 p -102.11 176.59 5.15 Favored 'General case' 0 C--N 1.318 -0.782 0 CA-C-N 116.399 -0.364 . . . . 0.0 110.721 179.155 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . 0.641 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 41.8 mtp180 -47.37 -50.84 21.35 Favored 'General case' 0 CA--C 1.511 -0.549 0 C-N-CA 123.103 0.561 . . . . 0.0 111.255 -174.75 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 80' ' ' GLU . . . . . 0.534 ' HA ' HD11 ' A' ' 83' ' ' ILE . 3.4 pm0 -60.01 -31.78 70.26 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-N 115.729 -0.669 . . . . 0.0 111.52 -176.815 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 81' ' ' GLU . . . . . 1.016 ' HG2' ' HB3' ' A' ' 70' ' ' TYR . 5.4 mt-10 -71.72 -47.4 54.16 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 116.619 -0.264 . . . . 0.0 111.524 176.302 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 82' ' ' GLN . . . . . 0.569 ' HB2' ' HZ3' ' A' ' 43' ' ' TRP . 5.9 mp0 -60.78 -36.52 79.18 Favored 'General case' 0 CA--C 1.514 -0.428 0 C-N-CA 120.213 -0.595 . . . . 0.0 109.447 175.466 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . 0.534 HD11 ' HA ' ' A' ' 80' ' ' GLU . 53.7 mt -60.7 -49.28 85.15 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.635 0 CA-C-N 115.104 -0.953 . . . . 0.0 110.47 178.111 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 84' ' ' ALA . . . . . 0.473 ' O ' ' HG3' ' A' ' 87' ' ' GLU . . . -60.35 -45.76 92.32 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-O 120.957 0.408 . . . . 0.0 111.517 -179.53 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . 0.782 HG12 ' HB2' ' A' ' 65' ' ' ASN . 63.6 t -69.1 -49.26 63.87 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.554 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.551 -178.588 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 86' ' ' ALA . . . . . 0.524 ' CA ' ' HZ ' ' A' ' 57' ' ' PHE . . . -64.56 -32.05 73.53 Favored 'General case' 0 CA--C 1.509 -0.619 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.897 179.645 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 87' ' ' GLU . . . . . 0.566 ' O ' ' HG3' ' A' ' 90' ' ' ARG . 1.3 pp20? -70.83 -29.65 65.85 Favored 'General case' 0 C--N 1.321 -0.665 0 C-N-CA 120.271 -0.572 . . . . 0.0 110.117 -177.624 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.716 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 61.2 t -64.74 -41.47 92.28 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.285 0 N-CA-C 109.136 -0.69 . . . . 0.0 109.136 168.093 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 89' ' ' THR . . . . . 0.943 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 1.8 m -65.02 -47.01 78.98 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 115.66 -0.7 . . . . 0.0 111.166 -177.906 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 90' ' ' ARG . . . . . 0.672 ' HA ' ' OE1' ' A' ' 93' ' ' GLN . 3.0 ppt_? -60.69 -34.1 73.85 Favored 'General case' 0 CA--C 1.516 -0.365 0 CA-C-N 115.801 -0.636 . . . . 0.0 111.598 -175.774 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 91' ' ' LEU . . . . . 0.716 ' HG ' ' O ' ' A' ' 88' ' ' VAL . 4.5 pp -72.51 -22.22 61.07 Favored 'General case' 0 C--N 1.319 -0.758 0 CA-C-O 121.222 0.534 . . . . 0.0 110.185 -175.035 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . 0.579 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 10.4 mtm180 -84.57 -51.59 6.76 Favored 'General case' 0 CA--C 1.51 -0.574 0 CA-C-N 115.699 -0.682 . . . . 0.0 110.069 -177.713 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 93' ' ' GLN . . . . . 0.672 ' OE1' ' HA ' ' A' ' 90' ' ' ARG . 0.0 OUTLIER -99.17 -22.91 15.43 Favored 'General case' 0 C--N 1.325 -0.474 0 N-CA-C 113.148 0.795 . . . . 0.0 113.148 -171.127 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 94.52 35.04 6.07 Favored Glycine 0 CA--C 1.508 -0.397 0 C-N-CA 120.849 -0.691 . . . . 0.0 112.439 171.254 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 95' ' ' TRP . . . . . 0.421 ' HA ' ' HE3' ' A' ' 98' ' ' TRP . 20.1 m95 66.27 7.87 5.2 Favored 'General case' 0 C--O 1.22 -0.472 0 C-N-CA 123.602 0.761 . . . . 0.0 109.542 -177.146 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -65.55 -32.55 83.66 Favored Glycine 0 C--N 1.332 0.337 0 C-N-CA 121.083 -0.58 . . . . 0.0 112.169 -179.996 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -67.44 -28.92 68.29 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.792 0.329 . . . . 0.0 110.639 178.998 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 98' ' ' TRP . . . . . 0.943 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 26.5 m-90 -100.1 104.44 29.25 Favored Pre-proline 0 N--CA 1.448 -0.55 0 N-CA-C 108.923 -0.769 . . . . 0.0 108.923 176.246 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 99' ' ' PRO . . . . . 0.424 ' HD3' ' HA ' ' A' ' 98' ' ' TRP . 17.0 Cg_exo -72.53 -91.29 0.01 OUTLIER 'Trans proline' 0 CA--C 1.533 0.434 0 C-N-CA 123.101 2.534 . . . . 0.0 114.682 -171.884 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . 0.41 ' H ' ' HB2' ' A' ' 99' ' ' PRO . 41.5 t -70.67 -28.05 32.98 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-O 121.764 0.792 . . . . 0.0 110.234 -172.938 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 101' ' ' CYS . . . . . 0.733 ' SG ' ' HG3' ' A' ' 38' ' ' GLU . 84.7 m -75.66 -38.4 58.81 Favored 'General case' 0 C--N 1.315 -0.906 0 CA-C-N 115.063 -0.971 . . . . 0.0 111.881 -171.588 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -68.05 -44.48 76.28 Favored 'General case' 0 C--N 1.327 -0.398 0 C-N-CA 120.591 -0.444 . . . . 0.0 110.309 -179.861 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -59.49 -37.44 78.25 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 121.081 0.467 . . . . 0.0 111.053 179.075 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 15.9 tpp180 -73.98 -34.33 64.17 Favored 'General case' 0 N--CA 1.431 -1.398 0 CA-C-N 115.578 -0.737 . . . . 0.0 111.429 179.323 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 105' ' ' ALA . . . . . 0.548 ' HB1' ' HA ' ' A' ' 30' ' ' ILE . . . -88.12 -22.65 23.98 Favored 'General case' 0 C--N 1.326 -0.416 0 N-CA-C 112.667 0.617 . . . . 0.0 112.667 -172.878 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 120.33 58.42 0.24 Allowed Glycine 0 CA--C 1.521 0.415 0 C-N-CA 120.661 -0.781 . . . . 0.0 112.527 -177.927 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -66.68 148.8 51.42 Favored 'General case' 0 C--N 1.325 -0.478 0 C-N-CA 122.771 0.428 . . . . 0.0 110.519 -179.355 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 72.3 mtp180 . . . . . 0 C--O 1.247 0.949 0 CA-C-O 117.946 -1.026 . . . . 0.0 110.777 -171.924 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.593 ' O ' HG12 ' A' ' 30' ' ' ILE . 16.1 m-20 . . . . . 0 CA--C 1.499 -1.006 0 CA-C-O 121.998 0.904 . . . . 0.0 108.919 . . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . 0.737 ' HA3' HD12 ' A' ' 83' ' ' ILE . . . -67.55 -1.25 15.12 Favored Glycine 0 N--CA 1.433 -1.534 0 CA-C-N 114.143 -1.39 . . . . 0.0 110.844 172.693 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' SER . . . . . 0.401 ' H ' ' C ' ' A' ' 27' ' ' ASP . 19.0 m -73.71 -38.31 64.89 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-O 121.46 0.648 . . . . 0.0 109.405 173.203 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.593 HG12 ' O ' ' A' ' 27' ' ' ASP . 0.3 OUTLIER -71.69 -38.84 67.93 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.551 0 N-CA-C 107.179 -1.415 . . . . 0.0 107.179 175.595 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' TRP . . . . . 0.671 ' CD1' HG21 ' A' ' 83' ' ' ILE . 38.8 m95 -69.2 -36.69 77.56 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 114.359 -1.292 . . . . 0.0 110.667 -176.828 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 18.1 t70 -75.33 -33.93 61.17 Favored 'General case' 0 N--CA 1.444 -0.726 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.444 179.775 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . 0.48 ' HB1' ' CB ' ' A' ' 105' ' ' ALA . . . -70.42 -35.26 73.31 Favored 'General case' 0 N--CA 1.444 -0.739 0 C-N-CA 120.441 -0.503 . . . . 0.0 109.965 175.307 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . 0.553 HG13 ' O ' ' A' ' 30' ' ' ILE . 64.6 mt -64.59 -42.59 95.55 Favored 'Isoleucine or valine' 0 C--O 1.234 0.243 0 CA-C-O 120.996 0.427 . . . . 0.0 109.949 172.947 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . 0.428 ' HA ' ' O ' ' A' ' 54' ' ' GLY . . . -57.22 -38.02 73.11 Favored 'General case' 0 N--CA 1.451 -0.418 0 CA-C-N 115.78 -0.646 . . . . 0.0 109.997 174.608 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -73.49 -13.39 80.08 Favored Glycine 0 N--CA 1.45 -0.431 0 CA-C-N 115.375 -0.829 . . . . 0.0 112.051 179.456 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 37.3 t -94.19 -60.11 1.81 Allowed 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 120.702 0.286 . . . . 0.0 111.291 -178.999 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 9.0 tp10 -88.04 -34.32 18.03 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 121.099 0.476 . . . . 0.0 110.223 -170.972 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -92.76 -16.28 25.6 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.99 -0.55 . . . . 0.0 111.268 -177.528 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 83.52 5.33 88.57 Favored Glycine 0 CA--C 1.507 -0.461 0 N-CA-C 110.118 -1.193 . . . . 0.0 110.118 -176.124 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 90.28 59.23 1.48 Allowed Glycine 0 N--CA 1.434 -1.44 0 CA-C-N 114.095 -1.053 . . . . 0.0 112.034 -178.912 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 42' ' ' ASN . . . . . 0.477 HD21 ' HB ' ' A' ' 45' ' ' ILE . 66.0 t30 -152.44 126.32 9.01 Favored 'General case' 0 CA--C 1.507 -0.674 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 178.12 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 43' ' ' TRP . . . . . 0.751 ' HA ' ' N ' ' A' ' 54' ' ' GLY . 37.4 m95 -98.16 -12.89 21.25 Favored 'General case' 0 C--N 1.307 -1.263 0 CA-C-N 115.769 -0.65 . . . . 0.0 110.475 -174.171 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -102.95 5.23 38.24 Favored 'General case' 0 C--N 1.316 -0.875 0 CA-C-N 114.922 -1.036 . . . . 0.0 110.729 -179.113 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.477 ' HB ' HD21 ' A' ' 42' ' ' ASN . 9.8 tt -73.57 142.15 15.3 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.981 0 CA-C-N 115.921 -0.581 . . . . 0.0 109.876 -178.55 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 40.3 t-20 -154.63 99.15 2.14 Favored 'General case' 0 C--N 1.307 -1.281 0 N-CA-C 109.446 -0.576 . . . . 0.0 109.446 179.611 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 34.8 p -74.58 -15.79 60.83 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 115.626 -0.716 . . . . 0.0 110.937 -177.33 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 94.84 19.76 30.57 Favored Glycine 0 N--CA 1.448 -0.559 0 N-CA-C 111.431 -0.668 . . . . 0.0 111.431 178.932 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 32.5 p-10 -95.64 2.68 54.23 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-O 120.987 0.423 . . . . 0.0 111.421 -176.374 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 95.49 -11.33 68.72 Favored Glycine 0 N--CA 1.448 -0.553 0 N-CA-C 111.425 -0.67 . . . . 0.0 111.425 179.108 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 51' ' ' TYR . . . . . 0.608 ' CD1' ' HB2' ' A' ' 58' ' ' ASP . 0.5 OUTLIER -106.69 132.64 52.45 Favored 'General case' 0 CA--C 1.505 -0.752 0 N-CA-C 107.283 -1.377 . . . . 0.0 107.283 178.46 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 52' ' ' TYR . . . . . 0.659 ' O ' ' HA ' ' A' ' 56' ' ' GLN . 30.9 m-85 -103.07 169.44 8.56 Favored 'General case' 0 C--N 1.304 -1.371 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.972 -168.433 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -59.53 173.54 4.34 Favored Glycine 0 N--CA 1.448 -0.526 0 N-CA-C 115.086 0.794 . . . . 0.0 115.086 -169.151 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . 0.751 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 82.13 -99.58 2.04 Favored Glycine 0 N--CA 1.436 -1.329 0 CA-C-N 114.872 -0.664 . . . . 0.0 111.698 178.944 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.565 ' HB ' ' CD1' ' A' ' 57' ' ' PHE . 2.0 t -84.25 -3.41 7.83 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-O 121.774 0.797 . . . . 0.0 109.938 -177.511 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 56' ' ' GLN . . . . . 0.851 ' HA ' HE21 ' A' ' 56' ' ' GLN . 0.0 OUTLIER 55.81 50.36 14.27 Favored 'General case' 0 N--CA 1.46 0.04 0 CA-C-N 114.058 -1.428 . . . . 0.0 112.479 171.429 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . 0.565 ' CD1' ' HB ' ' A' ' 55' ' ' VAL . 3.8 p90 -124.62 165.36 18.01 Favored 'General case' 0 C--N 1.323 -0.546 0 C-N-CA 119.912 -0.715 . . . . 0.0 111.859 177.453 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.608 ' HB2' ' CD1' ' A' ' 51' ' ' TYR . 0.0 OUTLIER -77.12 152.04 35.11 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 114.382 -1.281 . . . . 0.0 113.758 -163.169 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . 0.664 ' HA ' HE21 ' A' ' 59' ' ' GLN . 0.0 OUTLIER -50.82 -41.55 57.57 Favored 'General case' 0 N--CA 1.451 -0.393 0 CA-C-N 113.225 -1.807 . . . . 0.0 112.122 177.699 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -67.6 -49.1 52.67 Favored Glycine 0 C--N 1.315 -0.616 0 CA-C-N 115.507 -0.769 . . . . 0.0 112.013 -176.38 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 89.0 m -64.88 -41.16 95.87 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-O 120.919 0.39 . . . . 0.0 110.631 176.99 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 62' ' ' TRP . . . . . 0.509 ' CZ3' ' HA ' ' A' ' 82' ' ' GLN . 40.9 t-105 -57.0 -47.79 79.99 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 121.622 0.725 . . . . 0.0 109.617 174.725 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . 0.523 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 20.2 tt0 -65.28 -36.79 85.16 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-N 114.872 -1.058 . . . . 0.0 110.792 -179.932 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -67.57 -35.47 79.07 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 115.427 -0.806 . . . . 0.0 110.518 -177.672 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . 0.513 ' HB2' HG13 ' A' ' 85' ' ' VAL . 10.7 m120 -78.51 -12.9 60.04 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.249 175.823 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . 0.561 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 87.81 44.11 5.54 Favored Glycine 0 N--CA 1.447 -0.569 0 CA-C-N 115.411 -0.813 . . . . 0.0 112.035 177.345 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . 0.601 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -78.74 -22.04 67.48 Favored Glycine 0 N--CA 1.439 -1.117 0 C-N-CA 120.595 -0.812 . . . . 0.0 112.361 -173.52 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 0.932 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 7.1 mp -60.68 -21.25 62.64 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 112.592 0.59 . . . . 0.0 112.592 -174.334 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . 0.561 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 10.0 ptp180 -70.56 -32.9 70.49 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-O 121.253 0.549 . . . . 0.0 109.835 175.185 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 70' ' ' TYR . . . . . 0.65 ' HB3' ' CG ' ' A' ' 81' ' ' GLU . 73.2 m-85 -80.53 -34.59 35.42 Favored 'General case' 0 N--CA 1.443 -0.812 0 N-CA-C 107.47 -1.308 . . . . 0.0 107.47 178.502 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.698 ' HB1' ' HB1' ' A' ' 77' ' ' ALA . . . 164.12 129.12 0.02 OUTLIER Pre-proline 0 CA--C 1.511 -0.551 0 CA-C-N 112.616 -2.084 . . . . 0.0 106.759 -179.49 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 72' ' ' PRO . . . . . 0.932 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 20.4 Cg_exo -57.14 -4.75 1.12 Allowed 'Trans proline' 0 C--N 1.333 -0.244 0 C-N-CA 122.84 2.36 . . . . 0.0 113.932 -177.2 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 13.8 ptm180 -148.11 141.09 24.86 Favored 'General case' 0 C--N 1.317 -0.815 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 176.259 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . 0.507 ' HA ' ' CH2' ' A' ' 62' ' ' TRP . . . -59.12 -31.7 69.17 Favored 'General case' 0 C--O 1.219 -0.509 0 CA-C-N 115.615 -0.72 . . . . 0.0 112.298 -177.109 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 8.4 p-10 -85.17 9.68 14.35 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 121.282 0.563 . . . . 0.0 111.263 -174.673 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 50.2 tp -112.13 -33.01 6.37 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.519 -0.764 . . . . 0.0 109.182 173.667 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . 0.698 ' HB1' ' HB1' ' A' ' 71' ' ' ALA . . . -79.6 164.71 23.61 Favored 'General case' 0 N--CA 1.448 -0.548 0 CA-C-N 115.065 -0.97 . . . . 0.0 109.449 173.029 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 19.4 p -100.5 -176.99 3.36 Favored 'General case' 0 C--N 1.322 -0.626 0 C-N-CA 120.429 -0.509 . . . . 0.0 110.292 -179.997 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . 0.611 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 2.5 mtp180 -49.3 -52.63 26.47 Favored 'General case' 0 CA--C 1.512 -0.517 0 O-C-N 123.403 0.439 . . . . 0.0 111.178 -174.505 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 80' ' ' GLU . . . . . 0.55 ' HG3' ' OE2' ' A' ' 81' ' ' GLU . 11.7 pt-20 -58.39 -42.26 86.67 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.892 -174.806 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 81' ' ' GLU . . . . . 0.65 ' CG ' ' HB3' ' A' ' 70' ' ' TYR . 5.2 mp0 -63.5 -52.71 60.08 Favored 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 111.956 0.354 . . . . 0.0 111.956 174.186 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 82' ' ' GLN . . . . . 0.509 ' HA ' ' CZ3' ' A' ' 62' ' ' TRP . 40.7 mt-30 -59.7 -38.11 80.69 Favored 'General case' 0 CA--C 1.518 -0.268 0 CA-C-O 121.54 0.686 . . . . 0.0 110.097 -176.577 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . 0.737 HD12 ' HA3' ' A' ' 28' ' ' GLY . 31.7 mt -61.57 -49.51 84.09 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.843 0 CA-C-N 114.276 -1.329 . . . . 0.0 111.082 173.832 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 84' ' ' ALA . . . . . 0.637 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -62.67 -38.79 91.72 Favored 'General case' 0 N--CA 1.466 0.342 0 CA-C-O 121.195 0.522 . . . . 0.0 111.886 -176.08 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . 0.513 HG13 ' HB2' ' A' ' 65' ' ' ASN . 60.5 t -64.45 -47.73 88.13 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.495 175.853 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -59.44 -30.86 68.79 Favored 'General case' 0 N--CA 1.453 -0.282 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.051 174.497 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 87' ' ' GLU . . . . . 0.793 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 14.4 mm-40 -59.51 -44.31 93.17 Favored 'General case' 0 C--O 1.219 -0.51 0 CA-C-N 115.344 -0.844 . . . . 0.0 110.484 179.736 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.468 ' HB ' ' HB3' ' A' ' 65' ' ' ASN . 70.7 t -61.48 -49.92 82.46 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.404 0 CA-C-O 121.049 0.452 . . . . 0.0 110.574 -176.414 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 89' ' ' THR . . . . . 0.509 HG23 ' CH2' ' A' ' 98' ' ' TRP . 13.7 t -72.64 -33.76 66.82 Favored 'General case' 0 N--CA 1.438 -1.027 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.074 -176.482 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 90' ' ' ARG . . . . . 0.563 ' HG2' ' HA ' ' A' ' 87' ' ' GLU . 0.8 OUTLIER -60.33 -32.1 70.93 Favored 'General case' 0 N--CA 1.472 0.644 0 CA-C-O 121.176 0.512 . . . . 0.0 110.229 175.982 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 91' ' ' LEU . . . . . 0.793 ' HG ' ' O ' ' A' ' 87' ' ' GLU . 19.4 mt -62.51 -33.08 74.17 Favored 'General case' 0 C--N 1.317 -0.805 0 CA-C-O 121.428 0.632 . . . . 0.0 109.733 177.312 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . 0.46 ' NE ' ' HA ' ' A' ' 89' ' ' THR . 2.8 mtm180 -86.29 -52.63 5.51 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-N 115.068 -0.969 . . . . 0.0 110.911 -172.975 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -117.05 2.95 12.73 Favored 'General case' 0 N--CA 1.448 -0.533 0 C-N-CA 119.862 -0.735 . . . . 0.0 112.461 -174.076 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . 0.434 ' HA2' ' O ' ' A' ' 90' ' ' ARG . . . 74.64 -119.98 6.27 Favored Glycine 0 CA--C 1.485 -1.786 0 N-CA-C 111.02 -0.832 . . . . 0.0 111.02 171.943 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 95' ' ' TRP . . . . . 0.445 ' HB3' ' CB ' ' A' ' 102' ' ' ALA . 3.4 m95 -127.57 31.65 5.13 Favored 'General case' 0 C--N 1.299 -1.62 0 N-CA-C 106.338 -1.727 . . . . 0.0 106.338 179.834 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -82.17 -25.92 50.15 Favored Glycine 0 N--CA 1.446 -0.666 0 CA-C-N 114.027 -1.442 . . . . 0.0 110.915 171.539 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -81.14 -23.3 38.41 Favored 'General case' 0 CA--C 1.515 -0.372 0 N-CA-C 109.663 -0.495 . . . . 0.0 109.663 174.352 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 98' ' ' TRP . . . . . 0.509 ' CH2' HG23 ' A' ' 89' ' ' THR . 23.7 m-90 -107.93 107.35 60.17 Favored Pre-proline 0 N--CA 1.448 -0.547 0 CA-C-N 115.776 -0.647 . . . . 0.0 109.909 177.071 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_exo -62.34 -137.01 0.0 OUTLIER 'Trans proline' 0 CA--C 1.535 0.526 0 C-N-CA 123.647 2.898 . . . . 0.0 114.119 -177.044 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 2.9 m -54.54 -28.24 18.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 115.88 -0.6 . . . . 0.0 112.152 -177.787 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 82.5 m -56.8 -39.23 73.75 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.263 178.933 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 102' ' ' ALA . . . . . 0.445 ' CB ' ' HB3' ' A' ' 95' ' ' TRP . . . -71.41 -43.94 65.84 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.845 0.355 . . . . 0.0 111.008 178.118 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -61.54 -44.57 96.8 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.851 -179.649 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -67.33 -19.41 65.45 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.728 -0.669 . . . . 0.0 111.159 177.279 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 105' ' ' ALA . . . . . 0.48 ' CB ' ' HB1' ' A' ' 33' ' ' ALA . . . -91.03 -21.15 21.4 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.913 -0.585 . . . . 0.0 111.606 -178.547 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 111.37 61.52 0.47 Allowed Glycine 0 CA--C 1.519 0.344 0 C-N-CA 121.087 -0.577 . . . . 0.0 111.967 -176.481 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -64.11 149.42 47.69 Favored 'General case' 0 C--N 1.328 -0.355 0 C-N-CA 122.878 0.471 . . . . 0.0 111.006 -176.716 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 74.0 mtp180 . . . . . 0 C--O 1.247 0.946 0 CA-C-O 118.503 -0.761 . . . . 0.0 109.912 -173.899 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.582 ' O ' HG12 ' A' ' 30' ' ' ILE . 4.5 m-20 . . . . . 0 CA--C 1.507 -0.711 0 CA-C-O 121.62 0.724 . . . . 0.0 109.745 . . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . 0.704 ' HA2' ' HB2' ' A' ' 31' ' ' TRP . . . -81.24 3.45 77.19 Favored Glycine 0 CA--C 1.494 -1.259 0 N-CA-C 110.863 -0.895 . . . . 0.0 110.863 -174.504 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 5.8 m -76.39 -48.2 20.65 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-O 121.727 0.775 . . . . 0.0 109.069 176.864 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.786 HG22 ' O ' ' A' ' 105' ' ' ALA . 4.0 pt -71.77 -34.78 52.92 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.182 0 CA-C-N 114.626 -1.17 . . . . 0.0 109.675 175.807 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' TRP . . . . . 0.704 ' HB2' ' HA2' ' A' ' 28' ' ' GLY . 6.5 m95 -66.26 -35.46 80.46 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.311 -0.858 . . . . 0.0 110.085 177.54 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.727 ' HB2' HH21 ' A' ' 79' ' ' ARG . 13.9 t70 -76.37 -34.42 58.92 Favored 'General case' 0 N--CA 1.449 -0.496 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.215 177.135 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . 0.413 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -65.67 -36.0 82.4 Favored 'General case' 0 N--CA 1.445 -0.683 0 C-N-CA 120.775 -0.37 . . . . 0.0 110.328 176.794 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . 0.492 ' HA ' ' HB3' ' A' ' 101' ' ' CYS . 10.0 mt -67.4 -44.09 87.24 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-O 120.895 0.379 . . . . 0.0 110.706 174.28 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . 0.479 ' HA ' ' O ' ' A' ' 54' ' ' GLY . . . -60.22 -34.13 73.23 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-O 121.464 0.65 . . . . 0.0 110.334 177.023 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -76.35 -18.97 78.81 Favored Glycine 0 N--CA 1.448 -0.551 0 CA-C-N 115.306 -0.861 . . . . 0.0 111.231 177.117 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 7.9 t -86.72 -57.1 3.11 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.238 -0.481 . . . . 0.0 111.536 -176.743 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . 0.868 ' HG2' ' SG ' ' A' ' 101' ' ' CYS . 15.6 mm-40 -87.77 -33.61 18.6 Favored 'General case' 0 CA--C 1.515 -0.39 0 CA-C-O 120.821 0.343 . . . . 0.0 111.078 -174.933 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . 0.476 ' HB1' ' O ' ' A' ' 35' ' ' ALA . . . -96.66 -11.31 25.37 Favored 'General case' 0 C--N 1.324 -0.511 0 C-N-CA 120.424 -0.511 . . . . 0.0 112.124 -173.891 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 80.3 8.28 87.73 Favored Glycine 0 CA--C 1.506 -0.53 0 N-CA-C 110.125 -1.19 . . . . 0.0 110.125 -177.291 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 87.62 56.24 2.16 Favored Glycine 0 N--CA 1.434 -1.455 0 CA-C-N 114.129 -1.036 . . . . 0.0 112.595 179.706 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 50.7 t30 -154.44 122.77 6.06 Favored 'General case' 0 CA--C 1.507 -0.71 0 N-CA-C 109.413 -0.588 . . . . 0.0 109.413 176.993 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 43' ' ' TRP . . . . . 0.713 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 26.3 m95 -96.25 -12.64 24.25 Favored 'General case' 0 C--N 1.308 -1.231 0 CA-C-N 115.055 -0.975 . . . . 0.0 110.415 -173.298 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -101.95 8.97 40.91 Favored 'General case' 0 C--N 1.318 -0.782 0 CA-C-N 115.367 -0.833 . . . . 0.0 110.786 -178.36 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.726 HG21 ' CA ' ' A' ' 53' ' ' GLY . 2.0 tt -72.87 144.22 13.12 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.769 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.006 179.249 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 47.6 t-20 -160.42 101.37 1.36 Allowed 'General case' 0 C--N 1.314 -0.972 0 N-CA-C 109.432 -0.581 . . . . 0.0 109.432 -179.525 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 23.4 p -82.89 -17.13 44.85 Favored 'General case' 0 N--CA 1.445 -0.724 0 CA-C-N 115.559 -0.746 . . . . 0.0 111.222 -178.974 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 91.33 22.19 32.77 Favored Glycine 0 N--CA 1.445 -0.745 0 N-CA-C 111.141 -0.784 . . . . 0.0 111.141 178.398 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 28.7 p-10 -93.67 11.38 29.18 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 121.2 0.524 . . . . 0.0 111.385 -175.904 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . 0.464 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 94.36 -11.38 70.41 Favored Glycine 0 N--CA 1.447 -0.576 0 C-N-CA 120.874 -0.679 . . . . 0.0 111.524 -178.486 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 51' ' ' TYR . . . . . 0.544 ' HA ' ' HA ' ' A' ' 58' ' ' ASP . 0.2 OUTLIER -114.64 162.62 16.54 Favored 'General case' 0 N--CA 1.447 -0.591 0 N-CA-C 107.787 -1.19 . . . . 0.0 107.787 176.94 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 52' ' ' TYR . . . . . 0.517 ' HB2' ' HB3' ' A' ' 74' ' ' ALA . 26.9 m-85 -127.9 169.68 13.67 Favored 'General case' 0 C--N 1.309 -1.191 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.046 -172.717 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.726 ' CA ' HG21 ' A' ' 45' ' ' ILE . . . -68.85 -170.68 6.56 Favored Glycine 0 N--CA 1.445 -0.719 0 N-CA-C 114.342 0.497 . . . . 0.0 114.342 -170.944 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . 0.675 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 75.49 -107.3 2.28 Favored Glycine 0 N--CA 1.44 -1.057 0 C-N-CA 120.984 -0.627 . . . . 0.0 111.856 179.248 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 2.1 t -88.56 9.61 2.29 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.655 0 CA-C-O 121.203 0.525 . . . . 0.0 110.357 -177.403 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 56' ' ' GLN . . . . . 0.63 ' HG3' ' HB3' ' A' ' 38' ' ' GLU . 7.7 mm-40 60.02 50.42 6.66 Favored 'General case' 0 N--CA 1.468 0.426 0 CA-C-N 115.197 -0.911 . . . . 0.0 112.66 174.513 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . 0.501 ' HZ ' ' CA ' ' A' ' 86' ' ' ALA . 49.9 m-85 -76.2 132.24 39.82 Favored 'General case' 0 CA--C 1.503 -0.861 0 CA-C-N 115.126 -0.943 . . . . 0.0 112.301 176.345 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.544 ' HA ' ' HA ' ' A' ' 51' ' ' TYR . 5.6 p-10 -72.54 153.76 41.15 Favored 'General case' 0 C--N 1.315 -0.897 0 C-N-CA 119.542 -0.863 . . . . 0.0 108.707 159.644 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . 0.702 ' HA ' HE21 ' A' ' 59' ' ' GLN . 0.0 OUTLIER -54.92 -36.33 65.13 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-O 120.67 0.271 . . . . 0.0 111.482 -178.187 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -67.63 -49.67 48.33 Favored Glycine 0 C--O 1.226 -0.372 0 CA-C-N 116.046 -0.525 . . . . 0.0 112.445 -174.289 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 88.4 m -65.68 -41.4 92.46 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 121.366 0.603 . . . . 0.0 110.894 179.084 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 62' ' ' TRP . . . . . 0.455 ' CE2' ' HA3' ' A' ' 67' ' ' GLY . 56.5 t-105 -59.07 -48.91 79.87 Favored 'General case' 0 N--CA 1.444 -0.762 0 CA-C-N 115.104 -0.953 . . . . 0.0 109.467 177.144 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . 0.444 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 34.8 tt0 -68.18 -34.64 76.68 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 115.051 -0.977 . . . . 0.0 111.05 -178.604 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -64.43 -41.34 96.64 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.942 -0.572 . . . . 0.0 111.394 -175.914 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . 0.63 HD21 ' N ' ' A' ' 65' ' ' ASN . 0.7 OUTLIER -84.99 -8.63 58.65 Favored 'General case' 0 N--CA 1.451 -0.384 0 CA-C-O 121.109 0.48 . . . . 0.0 110.21 177.394 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 91.76 52.85 2.2 Favored Glycine 0 N--CA 1.451 -0.36 0 CA-C-N 115.762 -0.653 . . . . 0.0 113.15 172.627 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . 0.537 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -80.02 -26.46 55.57 Favored Glycine 0 N--CA 1.439 -1.121 0 C-N-CA 120.669 -0.777 . . . . 0.0 112.338 -178.599 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 0.992 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 7.6 mp -57.56 -23.0 48.14 Favored 'General case' 0 N--CA 1.45 -0.463 0 N-CA-C 113.272 0.841 . . . . 0.0 113.272 -173.256 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . 0.439 ' HG3' ' N ' ' A' ' 70' ' ' TYR . 1.1 ptp180 -70.39 -31.89 69.31 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-O 121.005 0.431 . . . . 0.0 110.044 176.829 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 70' ' ' TYR . . . . . 1.013 ' HB3' ' HG3' ' A' ' 81' ' ' GLU . 67.5 m-85 -81.39 -34.53 31.58 Favored 'General case' 0 CA--C 1.505 -0.766 0 N-CA-C 107.457 -1.312 . . . . 0.0 107.457 177.274 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.581 ' HB1' ' HB1' ' A' ' 77' ' ' ALA . . . 165.77 129.6 0.03 OUTLIER Pre-proline 0 C--O 1.218 -0.572 0 CA-C-N 112.272 -2.24 . . . . 0.0 107.259 -178.225 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 72' ' ' PRO . . . . . 0.992 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 7.0 Cg_exo -61.02 0.22 0.96 Allowed 'Trans proline' 0 C--N 1.331 -0.367 0 C-N-CA 122.786 2.324 . . . . 0.0 113.536 -177.318 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 73' ' ' ARG . . . . . 0.461 ' HB2' ' CD2' ' A' ' 52' ' ' TYR . 3.4 ptt180 -151.79 136.65 17.19 Favored 'General case' 0 N--CA 1.441 -0.923 0 N-CA-C 108.968 -0.753 . . . . 0.0 108.968 178.817 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . 0.517 ' HB3' ' HB2' ' A' ' 52' ' ' TYR . . . -56.05 -29.55 60.65 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 115.064 -0.971 . . . . 0.0 113.136 -177.081 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . 0.531 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 11.6 p-10 -83.54 -2.26 55.59 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 121.014 0.435 . . . . 0.0 111.205 -175.729 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.477 ' HB3' ' HB3' ' A' ' 71' ' ' ALA . 61.6 tp -101.51 -31.48 10.86 Favored 'General case' 0 C--N 1.322 -0.604 0 N-CA-C 108.536 -0.913 . . . . 0.0 108.536 172.103 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . 0.669 ' HB2' ' HB3' ' A' ' 81' ' ' GLU . . . -78.82 163.26 25.48 Favored 'General case' 0 N--CA 1.443 -0.825 0 CA-C-N 114.739 -1.118 . . . . 0.0 109.86 174.963 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 61.2 p -101.33 -174.59 2.64 Favored 'General case' 0 C--N 1.31 -1.149 0 CA-C-N 115.934 -0.575 . . . . 0.0 111.072 -176.956 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . 0.727 HH21 ' HB2' ' A' ' 32' ' ' ASP . 46.2 mtp180 -54.07 -54.44 39.29 Favored 'General case' 0 CA--C 1.515 -0.374 0 CA-C-O 120.759 0.314 . . . . 0.0 110.437 179.256 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 1.9 pm0 -60.19 -40.37 89.81 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.275 -0.875 . . . . 0.0 111.289 -176.52 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 81' ' ' GLU . . . . . 1.013 ' HG3' ' HB3' ' A' ' 70' ' ' TYR . 0.3 OUTLIER -62.62 -51.19 68.28 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.921 -0.582 . . . . 0.0 112.272 175.94 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 82' ' ' GLN . . . . . 0.607 ' HB2' ' HZ3' ' A' ' 43' ' ' TRP . 53.4 mt-30 -64.07 -35.83 82.01 Favored 'General case' 0 CA--C 1.515 -0.4 0 CA-C-O 121.103 0.478 . . . . 0.0 109.715 179.973 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . 0.581 HG22 ' CD1' ' A' ' 31' ' ' TRP . 14.7 mt -59.8 -45.43 94.79 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 CA-C-N 115.239 -0.891 . . . . 0.0 110.526 176.636 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 84' ' ' ALA . . . . . 0.473 ' O ' HG21 ' A' ' 88' ' ' VAL . . . -60.15 -44.29 95.08 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-O 121.209 0.528 . . . . 0.0 110.511 -178.449 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 67.5 t -69.1 -48.58 68.53 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.604 0 CA-C-N 115.428 -0.806 . . . . 0.0 111.493 179.341 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 86' ' ' ALA . . . . . 0.501 ' CA ' ' HZ ' ' A' ' 57' ' ' PHE . . . -62.6 -34.63 77.4 Favored 'General case' 0 CA--C 1.51 -0.584 0 CA-C-O 121.378 0.608 . . . . 0.0 110.536 179.891 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 87' ' ' GLU . . . . . 0.638 ' HA ' ' HG2' ' A' ' 90' ' ' ARG . 0.7 OUTLIER -71.49 -28.99 64.3 Favored 'General case' 0 C--N 1.315 -0.892 0 CA-C-N 115.525 -0.761 . . . . 0.0 109.965 -176.46 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.642 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 59.9 t -62.47 -42.56 96.19 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.191 0 N-CA-C 109.212 -0.662 . . . . 0.0 109.212 168.969 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 89' ' ' THR . . . . . 0.7 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 0.2 OUTLIER -71.96 -41.23 68.0 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 115.869 -0.605 . . . . 0.0 111.54 -174.445 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 90' ' ' ARG . . . . . 0.638 ' HG2' ' HA ' ' A' ' 87' ' ' GLU . 30.3 ptt180 -59.27 -36.87 76.3 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.657 -175.775 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 91' ' ' LEU . . . . . 0.642 ' HG ' ' O ' ' A' ' 88' ' ' VAL . 4.6 pp -74.88 -25.25 58.82 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.616 -0.72 . . . . 0.0 111.388 -170.087 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . 0.45 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 1.7 mtm180 -85.01 -46.24 11.38 Favored 'General case' 0 CA--C 1.511 -0.533 0 CA-C-O 121.513 0.673 . . . . 0.0 109.796 -176.113 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 16.6 pt20 -98.71 -29.45 13.01 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.15 -0.932 . . . . 0.0 113.01 -168.592 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 91.86 35.85 6.64 Favored Glycine 0 N--CA 1.446 -0.637 0 C-N-CA 120.167 -1.016 . . . . 0.0 111.355 175.459 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 95' ' ' TRP . . . . . 0.492 ' HA ' ' HE3' ' A' ' 98' ' ' TRP . 31.2 m95 68.3 22.66 7.97 Favored 'General case' 0 C--O 1.222 -0.378 0 CA-C-O 121.486 0.66 . . . . 0.0 110.027 177.186 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -70.11 -27.15 73.32 Favored Glycine 0 N--CA 1.449 -0.454 0 CA-C-N 115.135 -0.938 . . . . 0.0 112.35 175.519 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -75.45 -30.49 59.98 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.782 0.325 . . . . 0.0 110.58 177.242 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 98' ' ' TRP . . . . . 0.7 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 16.5 m-90 -103.8 104.76 44.55 Favored Pre-proline 0 C--N 1.324 -0.527 0 N-CA-C 109.706 -0.479 . . . . 0.0 109.706 179.972 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 17.5 Cg_exo -71.09 -93.12 0.01 OUTLIER 'Trans proline' 0 CA--C 1.537 0.645 0 C-N-CA 123.192 2.594 . . . . 0.0 114.523 -173.341 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . 0.468 ' O ' ' HD2' ' A' ' 104' ' ' ARG . 1.3 p -71.68 -27.57 28.54 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.391 0 CA-C-O 121.89 0.852 . . . . 0.0 109.781 -172.686 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 101' ' ' CYS . . . . . 0.868 ' SG ' ' HG2' ' A' ' 38' ' ' GLU . 33.2 m -65.74 -34.76 78.92 Favored 'General case' 0 C--N 1.318 -0.772 0 CA-C-N 114.313 -1.312 . . . . 0.0 111.056 -175.712 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 102' ' ' ALA . . . . . 0.589 ' HB2' ' HB3' ' A' ' 107' ' ' ALA . . . -65.53 -46.55 79.16 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-O 120.945 0.403 . . . . 0.0 110.146 -179.782 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -63.7 -40.59 97.16 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.282 0.563 . . . . 0.0 110.545 179.352 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 104' ' ' ARG . . . . . 0.468 ' HD2' ' O ' ' A' ' 100' ' ' VAL . 0.0 OUTLIER -71.9 -37.89 70.02 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.661 -0.7 . . . . 0.0 111.918 -179.346 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 105' ' ' ALA . . . . . 0.786 ' O ' HG22 ' A' ' 30' ' ' ILE . . . -82.37 -27.84 31.88 Favored 'General case' 0 C--N 1.329 -0.313 0 N-CA-C 112.009 0.374 . . . . 0.0 112.009 -176.166 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 109.4 67.02 0.58 Allowed Glycine 0 CA--C 1.522 0.486 0 C-N-CA 120.64 -0.791 . . . . 0.0 112.277 -173.741 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 107' ' ' ALA . . . . . 0.589 ' HB3' ' HB2' ' A' ' 102' ' ' ALA . . . -58.4 149.81 23.92 Favored 'General case' 0 C--N 1.324 -0.516 0 C-N-CA 123.586 0.754 . . . . 0.0 111.664 178.808 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 8.9 ptm180 . . . . . 0 C--O 1.247 0.945 0 CA-C-N 115.476 -0.783 . . . . 0.0 110.165 -173.168 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.638 ' O ' HG12 ' A' ' 30' ' ' ILE . 2.5 m-20 . . . . . 0 CA--C 1.506 -0.737 0 CA-C-O 121.86 0.838 . . . . 0.0 109.297 . . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . 0.557 ' HA2' ' HB2' ' A' ' 31' ' ' TRP . . . -79.81 3.81 68.12 Favored Glycine 0 N--CA 1.434 -1.45 0 CA-C-N 114.841 -1.072 . . . . 0.0 110.496 -174.829 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 19.9 t -77.06 -38.86 51.77 Favored 'General case' 0 C--N 1.318 -0.798 0 N-CA-C 108.701 -0.851 . . . . 0.0 108.701 173.456 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.813 ' HA ' ' HB2' ' A' ' 105' ' ' ALA . 0.0 OUTLIER -71.48 -36.66 61.39 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.669 0 N-CA-C 107.166 -1.42 . . . . 0.0 107.166 177.167 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' TRP . . . . . 0.557 ' HB2' ' HA2' ' A' ' 28' ' ' GLY . 14.6 m95 -75.05 -37.91 61.55 Favored 'General case' 0 N--CA 1.442 -0.826 0 CA-C-N 114.447 -1.252 . . . . 0.0 110.726 -176.863 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 23.2 t70 -78.44 -33.28 48.62 Favored 'General case' 0 N--CA 1.442 -0.846 0 CA-C-N 116.445 -0.343 . . . . 0.0 110.933 178.365 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . 0.454 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -68.52 -36.74 79.28 Favored 'General case' 0 N--CA 1.454 -0.26 0 C-N-CA 120.18 -0.608 . . . . 0.0 110.561 176.37 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . 0.491 HG23 ' CD1' ' A' ' 98' ' ' TRP . 79.7 mt -66.63 -46.22 86.54 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-O 120.761 0.315 . . . . 0.0 110.169 174.494 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . 0.413 ' O ' ' HB2' ' A' ' 39' ' ' ALA . . . -58.05 -34.62 70.29 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 121.292 0.568 . . . . 0.0 110.448 176.13 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . 0.518 ' HA2' ' N ' ' A' ' 41' ' ' GLY . . . -80.47 -11.23 84.38 Favored Glycine 0 N--CA 1.45 -0.429 0 CA-C-N 115.616 -0.72 . . . . 0.0 111.975 179.27 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 44.3 t -97.96 -50.75 4.29 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 120.643 0.259 . . . . 0.0 111.309 -176.991 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . 0.577 ' HG2' ' SG ' ' A' ' 101' ' ' CYS . 13.7 mt-10 -88.02 -31.85 19.1 Favored 'General case' 0 CA--C 1.513 -0.474 0 CA-C-O 120.906 0.384 . . . . 0.0 110.346 -175.403 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . 0.413 ' HB2' ' O ' ' A' ' 35' ' ' ALA . . . -103.17 -9.18 19.85 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.828 -177.904 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 77.97 9.92 86.59 Favored Glycine 0 CA--C 1.507 -0.432 0 N-CA-C 110.011 -1.236 . . . . 0.0 110.011 -177.586 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . 0.518 ' N ' ' HA2' ' A' ' 36' ' ' GLY . . . 85.9 59.25 1.9 Allowed Glycine 0 N--CA 1.435 -1.384 0 CA-C-N 114.049 -1.076 . . . . 0.0 111.337 -176.398 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 42' ' ' ASN . . . . . 0.594 ' HB3' ' HB ' ' A' ' 45' ' ' ILE . 1.8 t30 -140.46 89.3 2.27 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 109.215 -0.661 . . . . 0.0 109.215 -176.105 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 43' ' ' TRP . . . . . 0.62 ' HA ' ' N ' ' A' ' 54' ' ' GLY . 50.0 m95 -75.19 -7.83 54.92 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-O 121.563 0.697 . . . . 0.0 110.135 -176.506 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -104.73 9.51 35.01 Favored 'General case' 0 C--N 1.316 -0.867 0 CA-C-N 114.851 -1.068 . . . . 0.0 111.473 -179.637 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.899 HG23 ' HA2' ' A' ' 53' ' ' GLY . 9.7 tt -74.41 143.21 13.74 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.794 0 CA-C-O 121.194 0.521 . . . . 0.0 110.699 -176.862 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 15.3 t-20 -148.37 88.07 1.62 Allowed 'General case' 0 C--N 1.314 -0.958 0 CA-C-O 121.145 0.497 . . . . 0.0 109.681 179.177 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 5.1 p -72.45 -23.95 61.13 Favored 'General case' 0 C--N 1.319 -0.752 0 CA-C-N 115.297 -0.865 . . . . 0.0 111.129 -179.342 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 96.8 16.71 35.26 Favored Glycine 0 N--CA 1.448 -0.513 0 C-N-CA 120.951 -0.642 . . . . 0.0 111.552 178.79 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 12.0 m120 -79.93 2.72 22.36 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.807 0.337 . . . . 0.0 111.006 -175.397 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . 0.459 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 85.7 -3.87 86.55 Favored Glycine 0 N--CA 1.446 -0.678 0 N-CA-C 109.905 -1.278 . . . . 0.0 109.905 -168.396 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 51' ' ' TYR . . . . . 0.488 ' CE1' ' HB3' ' A' ' 58' ' ' ASP . 0.4 OUTLIER -109.09 155.72 20.64 Favored 'General case' 0 N--CA 1.45 -0.453 0 N-CA-C 107.036 -1.468 . . . . 0.0 107.036 177.94 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 52' ' ' TYR . . . . . 0.821 ' O ' ' HA ' ' A' ' 56' ' ' GLN . 47.3 m-85 -129.55 171.32 12.71 Favored 'General case' 0 C--N 1.317 -0.823 0 C-N-CA 120.266 -0.574 . . . . 0.0 112.536 -170.303 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.899 ' HA2' HG23 ' A' ' 45' ' ' ILE . . . -47.97 154.69 1.4 Allowed Glycine 0 N--CA 1.453 -0.172 0 N-CA-C 115.583 0.993 . . . . 0.0 115.583 -171.459 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . 0.62 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 97.79 -109.8 3.89 Favored Glycine 0 N--CA 1.442 -0.923 0 CA-C-N 114.653 -0.774 . . . . 0.0 111.708 176.631 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 1.9 m -84.58 -3.22 7.82 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 CA-C-O 121.681 0.753 . . . . 0.0 110.924 178.403 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 56' ' ' GLN . . . . . 0.821 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 6.1 tt0 55.29 51.4 13.14 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 113.855 -1.521 . . . . 0.0 113.803 168.12 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 1.6 p90 -109.85 172.53 6.8 Favored 'General case' 0 C--O 1.236 0.349 0 C-N-CA 119.731 -0.787 . . . . 0.0 111.533 173.928 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.488 ' HB3' ' CE1' ' A' ' 51' ' ' TYR . 6.8 p-10 -79.0 156.48 28.42 Favored 'General case' 0 C--N 1.329 -0.308 0 N-CA-C 113.733 1.012 . . . . 0.0 113.733 -161.499 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . 0.668 ' HA ' HE21 ' A' ' 59' ' ' GLN . 0.0 OUTLIER -57.03 -38.58 73.38 Favored 'General case' 0 N--CA 1.449 -0.48 0 CA-C-N 113.492 -1.685 . . . . 0.0 111.579 178.805 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -67.38 -49.67 50.02 Favored Glycine 0 N--CA 1.44 -1.089 0 CA-C-N 115.881 -0.6 . . . . 0.0 112.182 -174.256 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 61' ' ' THR . . . . . 0.439 HG23 HG22 ' A' ' 89' ' ' THR . 91.6 m -65.8 -41.64 91.67 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 121.37 0.605 . . . . 0.0 110.425 176.405 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 62' ' ' TRP . . . . . 0.6 ' CH2' ' HA ' ' A' ' 74' ' ' ALA . 44.8 t-105 -56.27 -49.49 74.07 Favored 'General case' 0 N--CA 1.447 -0.615 0 CA-C-N 115.129 -0.941 . . . . 0.0 109.958 177.485 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . 0.64 ' HG3' HD11 ' A' ' 68' ' ' LEU . 18.3 tt0 -67.45 -36.47 81.25 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-N 114.907 -1.042 . . . . 0.0 110.77 -179.226 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -64.95 -41.52 95.41 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.657 -0.701 . . . . 0.0 111.059 -177.578 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . 0.617 ' HB2' HG12 ' A' ' 85' ' ' VAL . 8.4 m120 -81.68 -16.44 51.28 Favored 'General case' 0 C--N 1.325 -0.473 0 N-CA-C 109.557 -0.534 . . . . 0.0 109.557 177.991 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 97.01 45.48 2.61 Favored Glycine 0 N--CA 1.449 -0.442 0 CA-C-N 115.784 -0.643 . . . . 0.0 113.538 170.648 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -79.42 -24.47 60.85 Favored Glycine 0 N--CA 1.44 -1.037 0 N-CA-C 110.762 -0.935 . . . . 0.0 110.762 -179.543 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 0.642 ' HA ' ' HA ' ' A' ' 72' ' ' PRO . 19.1 mt -54.63 -25.77 28.75 Favored 'General case' 0 N--CA 1.449 -0.503 0 CA-C-O 121.365 0.602 . . . . 0.0 110.728 -176.3 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 8.4 ptm180 -71.98 -27.79 63.0 Favored 'General case' 0 N--CA 1.439 -0.996 0 CA-C-N 115.132 -0.94 . . . . 0.0 109.922 -175.835 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 70' ' ' TYR . . . . . 0.768 ' HB2' ' OE2' ' A' ' 81' ' ' GLU . 10.4 m-85 -94.13 -33.25 13.41 Favored 'General case' 0 N--CA 1.433 -1.308 0 N-CA-C 106.625 -1.62 . . . . 0.0 106.625 177.566 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.915 ' HB1' ' HB3' ' A' ' 76' ' ' LEU . . . 179.16 122.38 0.21 Allowed Pre-proline 0 N--CA 1.447 -0.621 0 CA-C-N 113.422 -1.717 . . . . 0.0 108.754 -178.589 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 72' ' ' PRO . . . . . 0.642 ' HA ' ' HA ' ' A' ' 68' ' ' LEU . 11.9 Cg_exo -61.2 1.58 0.62 Allowed 'Trans proline' 0 CA--C 1.528 0.216 0 C-N-CA 122.683 2.255 . . . . 0.0 113.293 179.417 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 73' ' ' ARG . . . . . 0.506 ' HB2' ' CD2' ' A' ' 52' ' ' TYR . 15.1 ptm180 -151.28 138.2 19.02 Favored 'General case' 0 C--N 1.316 -0.889 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 175.236 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . 0.6 ' HA ' ' CH2' ' A' ' 62' ' ' TRP . . . -58.36 -28.53 65.22 Favored 'General case' 0 C--O 1.218 -0.561 0 CA-C-N 115.543 -0.753 . . . . 0.0 112.584 -174.082 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 11.3 p-10 -87.95 10.15 19.81 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-O 121.062 0.458 . . . . 0.0 111.009 -176.393 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.915 ' HB3' ' HB1' ' A' ' 71' ' ' ALA . 41.6 tp -101.03 -40.16 7.36 Favored 'General case' 0 N--CA 1.45 -0.447 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.121 176.352 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . 0.856 ' HB2' ' HG2' ' A' ' 81' ' ' GLU . . . -103.84 168.81 8.89 Favored 'General case' 0 N--CA 1.447 -0.596 0 CA-C-O 121.108 0.48 . . . . 0.0 110.467 176.757 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 78' ' ' THR . . . . . 0.541 ' HG1' ' CD ' ' A' ' 80' ' ' GLU . 43.6 p -90.17 -177.96 5.28 Favored 'General case' 0 C--N 1.315 -0.918 0 CA-C-N 115.676 -0.693 . . . . 0.0 112.785 -167.303 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . 0.589 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 5.0 mtp180 -49.27 -48.83 45.68 Favored 'General case' 0 CA--C 1.513 -0.457 0 C-N-CA 123.94 0.896 . . . . 0.0 111.782 -171.899 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 80' ' ' GLU . . . . . 0.541 ' CD ' ' HG1' ' A' ' 78' ' ' THR . 2.3 pm0 -60.53 -30.31 69.67 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.567 -0.742 . . . . 0.0 111.74 -175.957 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 81' ' ' GLU . . . . . 0.856 ' HG2' ' HB2' ' A' ' 77' ' ' ALA . 0.0 OUTLIER -71.71 -50.38 30.8 Favored 'General case' 0 N--CA 1.449 -0.485 0 C-N-CA 120.934 -0.306 . . . . 0.0 110.311 176.011 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 82' ' ' GLN . . . . . 0.739 ' N ' ' HG3' ' A' ' 81' ' ' GLU . 4.6 mt-30 -59.64 -35.47 74.47 Favored 'General case' 0 CA--C 1.508 -0.661 0 N-CA-C 109.336 -0.616 . . . . 0.0 109.336 -179.851 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . 0.669 ' O ' ' HG2' ' A' ' 87' ' ' GLU . 21.8 mt -61.37 -47.2 94.53 Favored 'Isoleucine or valine' 0 C--O 1.212 -0.92 0 CA-C-N 114.824 -1.08 . . . . 0.0 110.527 175.755 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 84' ' ' ALA . . . . . 0.635 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -61.03 -43.92 98.17 Favored 'General case' 0 C--O 1.239 0.527 0 CA-C-O 121.378 0.608 . . . . 0.0 111.462 -176.555 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . 0.617 HG12 ' HB2' ' A' ' 65' ' ' ASN . 22.1 t -69.1 -48.47 69.06 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-N 115.927 -0.578 . . . . 0.0 110.549 179.551 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -57.66 -28.68 63.96 Favored 'General case' 0 C--O 1.223 -0.311 0 CA-C-N 115.868 -0.606 . . . . 0.0 110.618 173.925 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 87' ' ' GLU . . . . . 0.669 ' HG2' ' O ' ' A' ' 83' ' ' ILE . 6.6 mm-40 -59.76 -44.87 93.65 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.955 -0.566 . . . . 0.0 109.65 178.166 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.707 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 46.4 t -69.59 -42.34 80.57 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 C-N-CA 120.573 -0.451 . . . . 0.0 110.02 175.58 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 89' ' ' THR . . . . . 0.834 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 2.6 m -59.81 -48.09 83.07 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 116.43 -0.35 . . . . 0.0 111.443 -178.898 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 90' ' ' ARG . . . . . 0.648 ' HA ' ' OE1' ' A' ' 93' ' ' GLN . 7.9 ptt180 -65.67 -34.19 77.64 Favored 'General case' 0 CA--C 1.517 -0.31 0 CA-C-O 120.941 0.4 . . . . 0.0 111.421 -174.874 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 91' ' ' LEU . . . . . 0.707 ' HG ' ' O ' ' A' ' 88' ' ' VAL . 4.6 pp -70.52 -22.26 62.65 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.892 -174.143 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . 0.555 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 9.8 mtm180 -84.98 -52.28 6.09 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -178.698 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 93' ' ' GLN . . . . . 0.648 ' OE1' ' HA ' ' A' ' 90' ' ' ARG . 0.0 OUTLIER -96.78 -24.75 15.77 Favored 'General case' 0 CA--C 1.539 0.53 0 N-CA-C 113.602 0.964 . . . . 0.0 113.602 -169.275 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 80.51 50.83 5.17 Favored Glycine 0 CA--C 1.507 -0.414 0 C-N-CA 120.728 -0.749 . . . . 0.0 111.783 176.762 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 95' ' ' TRP . . . . . 0.452 ' HA ' ' HE3' ' A' ' 98' ' ' TRP . 1.4 m95 56.61 29.2 15.21 Favored 'General case' 0 C--O 1.223 -0.3 0 CA-C-O 121.582 0.706 . . . . 0.0 109.754 177.355 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 0.638 ' H ' ' HG2' ' A' ' 93' ' ' GLN . . . -83.93 -24.78 47.74 Favored Glycine 0 N--CA 1.449 -0.439 0 CA-C-N 115.314 -0.857 . . . . 0.0 111.87 174.912 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -80.9 -23.88 38.65 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 121.238 0.542 . . . . 0.0 109.685 176.423 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 98' ' ' TRP . . . . . 0.834 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 23.4 m-90 -101.01 108.01 52.52 Favored Pre-proline 0 N--CA 1.445 -0.708 0 N-CA-C 108.59 -0.893 . . . . 0.0 108.59 175.63 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 99' ' ' PRO . . . . . 0.433 ' HD3' ' HA ' ' A' ' 98' ' ' TRP . 45.0 Cg_exo -63.7 -133.68 0.0 OUTLIER 'Trans proline' 0 CA--C 1.541 0.828 0 C-N-CA 123.654 2.903 . . . . 0.0 113.991 -175.928 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 41.8 t -55.22 -25.56 16.99 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.287 0 CA-C-O 120.886 0.374 . . . . 0.0 111.637 -175.116 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 101' ' ' CYS . . . . . 0.577 ' SG ' ' HG2' ' A' ' 38' ' ' GLU . 85.1 m -63.99 -25.66 68.23 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 116.315 -0.402 . . . . 0.0 111.686 -178.25 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -69.36 -44.63 71.17 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.922 0.392 . . . . 0.0 110.368 177.704 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -67.42 -36.63 81.63 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 121.19 0.519 . . . . 0.0 110.142 178.554 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 9.8 mmm180 -64.73 -32.56 74.29 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.352 -0.84 . . . . 0.0 110.937 176.844 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 105' ' ' ALA . . . . . 0.813 ' HB2' ' HA ' ' A' ' 30' ' ' ILE . . . -89.01 -22.46 22.97 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 116.136 -0.484 . . . . 0.0 112.085 -176.076 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 103.18 68.04 0.77 Allowed Glycine 0 CA--C 1.521 0.445 0 C-N-CA 120.97 -0.633 . . . . 0.0 112.313 -177.794 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -64.45 152.71 40.88 Favored 'General case' 0 N--CA 1.45 -0.452 0 C-N-CA 122.856 0.462 . . . . 0.0 111.256 -176.063 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 25.5 mmt180 . . . . . 0 C--O 1.248 0.987 0 CA-C-O 118.289 -0.862 . . . . 0.0 111.56 177.64 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.441 ' O ' HG13 ' A' ' 30' ' ' ILE . 48.6 m-20 . . . . . 0 CA--C 1.503 -0.838 0 CA-C-O 122.316 1.055 . . . . 0.0 108.817 . . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . 0.625 ' HA2' ' HB2' ' A' ' 31' ' ' TRP . . . -72.15 -2.7 54.29 Favored Glycine 0 N--CA 1.442 -0.923 0 CA-C-N 113.677 -1.602 . . . . 0.0 111.555 -176.637 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 6.3 p -78.02 -48.09 16.96 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-O 122.049 0.928 . . . . 0.0 109.568 174.677 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.736 ' HA ' ' HB2' ' A' ' 105' ' ' ALA . 0.1 OUTLIER -62.89 -35.64 72.11 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.971 0 CA-C-N 113.392 -1.731 . . . . 0.0 107.713 175.691 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' TRP . . . . . 0.625 ' HB2' ' HA2' ' A' ' 28' ' ' GLY . 18.5 m95 -73.58 -36.91 65.61 Favored 'General case' 0 C--N 1.317 -0.817 0 CA-C-N 114.301 -1.318 . . . . 0.0 110.821 -178.092 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 1.6 t70 -77.92 -34.39 51.37 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.596 179.671 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . 0.45 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -70.07 -34.28 72.98 Favored 'General case' 0 N--CA 1.45 -0.474 0 C-N-CA 120.877 -0.329 . . . . 0.0 110.339 176.584 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . 0.51 HG13 ' O ' ' A' ' 30' ' ' ILE . 54.0 mt -65.12 -45.1 95.19 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.225 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 172.311 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . 0.544 ' HA ' ' O ' ' A' ' 54' ' ' GLY . . . -57.59 -36.41 71.68 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.228 176.613 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -73.92 -21.12 79.57 Favored Glycine 0 N--CA 1.451 -0.328 0 CA-C-N 115.574 -0.739 . . . . 0.0 112.237 178.886 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 18.5 t -93.75 -52.9 4.24 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-O 121.038 0.447 . . . . 0.0 111.811 -176.593 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 9.3 tp10 -87.58 -32.3 19.41 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 121.399 0.619 . . . . 0.0 110.107 -171.667 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . 0.417 ' HB3' ' O ' ' A' ' 35' ' ' ALA . . . -101.51 -13.57 17.85 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 115.644 -0.707 . . . . 0.0 111.616 -177.805 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 80.1 13.08 82.54 Favored Glycine 0 CA--C 1.505 -0.555 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 -176.808 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 81.03 58.83 2.55 Favored Glycine 0 N--CA 1.436 -1.319 0 CA-C-N 114.143 -1.028 . . . . 0.0 111.965 -177.569 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 42' ' ' ASN . . . . . 0.798 ' HB3' ' HB ' ' A' ' 45' ' ' ILE . 2.0 t30 -151.44 97.34 2.39 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 108.73 -0.841 . . . . 0.0 108.73 -178.229 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 43' ' ' TRP . . . . . 0.716 ' HZ3' ' HB2' ' A' ' 82' ' ' GLN . 49.8 m95 -75.51 -17.03 60.22 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-O 121.49 0.662 . . . . 0.0 110.495 -176.348 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -101.2 14.31 32.36 Favored 'General case' 0 C--N 1.313 -0.995 0 CA-C-N 115.007 -0.997 . . . . 0.0 110.693 -179.451 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.798 ' HB ' ' HB3' ' A' ' 42' ' ' ASN . 6.2 tt -77.44 143.26 13.1 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.951 0 CA-C-O 121.083 0.468 . . . . 0.0 109.759 -178.487 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . 0.576 ' ND2' HH21 ' A' ' 73' ' ' ARG . 29.3 t-20 -145.54 89.1 1.89 Allowed 'General case' 0 C--N 1.304 -1.399 0 CA-C-O 121.814 0.816 . . . . 0.0 108.994 179.369 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 2.6 p -67.98 -22.03 65.03 Favored 'General case' 0 N--CA 1.443 -0.81 0 CA-C-N 114.091 -1.413 . . . . 0.0 111.142 -178.418 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 90.03 23.45 32.45 Favored Glycine 0 N--CA 1.441 -0.984 0 N-CA-C 111.112 -0.795 . . . . 0.0 111.112 178.109 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 49' ' ' ASN . . . . . 0.482 HD21 ' H ' ' A' ' 51' ' ' TYR . 0.3 OUTLIER -101.58 15.42 28.95 Favored 'General case' 0 C--N 1.326 -0.426 0 N-CA-C 112.384 0.513 . . . . 0.0 112.384 -177.214 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . 0.411 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 93.48 -10.91 72.39 Favored Glycine 0 CA--C 1.509 -0.309 0 N-CA-C 111.401 -0.68 . . . . 0.0 111.401 177.608 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 51' ' ' TYR . . . . . 0.543 ' CD1' ' HB2' ' A' ' 58' ' ' ASP . 0.1 OUTLIER -118.79 149.28 41.76 Favored 'General case' 0 N--CA 1.445 -0.713 0 N-CA-C 106.434 -1.691 . . . . 0.0 106.434 -177.566 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 52' ' ' TYR . . . . . 0.649 ' O ' ' HA ' ' A' ' 56' ' ' GLN . 22.4 m-85 -119.56 170.9 8.76 Favored 'General case' 0 C--N 1.309 -1.18 0 C-N-CA 119.921 -0.711 . . . . 0.0 112.183 -169.298 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.757 ' HA2' HG22 ' A' ' 45' ' ' ILE . . . -57.56 167.64 5.07 Favored Glycine 0 N--CA 1.449 -0.493 0 N-CA-C 115.939 1.136 . . . . 0.0 115.939 -166.115 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . 0.64 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 86.62 -102.08 2.7 Favored Glycine 0 N--CA 1.437 -1.296 0 CA-C-N 114.202 -0.999 . . . . 0.0 111.541 178.247 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.684 HG22 ' HB3' ' A' ' 82' ' ' GLN . 3.1 m -85.4 -2.85 7.91 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.737 0 CA-C-O 120.434 0.159 . . . . 0.0 111.329 -179.586 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 56' ' ' GLN . . . . . 0.649 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 8.9 tp-100 52.78 52.94 12.96 Favored 'General case' 0 CA--C 1.534 0.339 0 N-CA-C 113.481 0.919 . . . . 0.0 113.481 166.17 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -120.57 163.33 18.16 Favored 'General case' 0 C--N 1.327 -0.379 0 C-N-CA 119.862 -0.735 . . . . 0.0 111.366 170.996 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.543 ' HB2' ' CD1' ' A' ' 51' ' ' TYR . 0.0 OUTLIER -73.6 155.1 39.44 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 114.799 -1.092 . . . . 0.0 113.365 -164.565 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . 0.737 ' HA ' HE21 ' A' ' 59' ' ' GLN . 0.0 OUTLIER -53.3 -39.98 64.4 Favored 'General case' 0 N--CA 1.451 -0.402 0 CA-C-N 114.078 -1.419 . . . . 0.0 112.303 -179.905 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -68.39 -49.45 45.04 Favored Glycine 0 C--O 1.225 -0.441 0 CA-C-N 115.921 -0.582 . . . . 0.0 112.03 -177.264 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 32.8 m -65.64 -38.18 88.63 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-O 121.461 0.648 . . . . 0.0 110.26 176.105 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 62' ' ' TRP . . . . . 0.571 ' CH2' ' HA ' ' A' ' 74' ' ' ALA . 39.1 t-105 -56.67 -48.89 76.61 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 115.32 -0.854 . . . . 0.0 109.643 173.9 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . 0.563 ' CB ' HD11 ' A' ' 68' ' ' LEU . 60.6 tt0 -67.07 -33.97 76.66 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-N 114.876 -1.056 . . . . 0.0 110.943 179.359 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -63.04 -42.03 99.65 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.796 -0.638 . . . . 0.0 111.366 -177.81 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 33.0 m-80 -86.64 -11.76 50.44 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.977 0.418 . . . . 0.0 110.303 177.809 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . 0.413 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 92.93 52.38 2.1 Favored Glycine 0 C--O 1.22 -0.743 0 CA-C-N 115.858 -0.61 . . . . 0.0 114.043 170.533 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . 0.47 ' HA3' ' CE2' ' A' ' 62' ' ' TRP . . . -80.28 -27.95 50.43 Favored Glycine 0 N--CA 1.441 -0.967 0 C-N-CA 120.666 -0.778 . . . . 0.0 112.629 179.694 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 0.637 ' HA ' ' HA ' ' A' ' 72' ' ' PRO . 2.4 mp -59.3 -20.51 55.04 Favored 'General case' 0 CA--C 1.519 -0.241 0 CA-C-O 120.864 0.364 . . . . 0.0 111.923 -170.084 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . 0.413 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 9.1 ptp180 -72.55 -28.1 62.63 Favored 'General case' 0 N--CA 1.44 -0.944 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.225 -179.155 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 70' ' ' TYR . . . . . 0.699 ' HB2' ' CD ' ' A' ' 81' ' ' GLU . 10.5 m-85 -92.26 -33.29 14.71 Favored 'General case' 0 N--CA 1.433 -1.316 0 N-CA-C 106.683 -1.599 . . . . 0.0 106.683 176.894 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.651 ' HB2' ' HB3' ' A' ' 76' ' ' LEU . . . 175.34 126.86 0.13 Allowed Pre-proline 0 N--CA 1.45 -0.443 0 CA-C-N 113.005 -1.907 . . . . 0.0 108.494 179.107 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 72' ' ' PRO . . . . . 0.637 ' HA ' ' HA ' ' A' ' 68' ' ' LEU . 6.1 Cg_exo -62.46 3.86 0.42 Allowed 'Trans proline' 0 C--N 1.333 -0.272 0 C-N-CA 122.717 2.278 . . . . 0.0 113.709 -178.987 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 73' ' ' ARG . . . . . 0.576 HH21 ' ND2' ' A' ' 46' ' ' ASN . 11.0 ptm180 -154.53 142.51 20.17 Favored 'General case' 0 C--N 1.316 -0.877 0 N-CA-C 108.988 -0.745 . . . . 0.0 108.988 177.302 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . 0.571 ' HA ' ' CH2' ' A' ' 62' ' ' TRP . . . -61.69 -29.45 70.1 Favored 'General case' 0 C--O 1.219 -0.508 0 CA-C-N 115.935 -0.575 . . . . 0.0 112.284 -176.675 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 18.6 p-10 -86.44 12.01 11.2 Favored 'General case' 0 C--N 1.317 -0.836 0 CA-C-O 121.168 0.508 . . . . 0.0 111.032 -175.091 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.651 ' HB3' ' HB2' ' A' ' 71' ' ' ALA . 39.6 tp -108.38 -43.58 4.3 Favored 'General case' 0 N--CA 1.449 -0.5 0 CA-C-N 115.586 -0.734 . . . . 0.0 110.429 175.39 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . 0.67 ' HB1' ' HG2' ' A' ' 81' ' ' GLU . . . -99.06 167.85 10.45 Favored 'General case' 0 N--CA 1.449 -0.475 0 CA-C-O 121.58 0.705 . . . . 0.0 111.079 178.767 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 78' ' ' THR . . . . . 0.417 ' OG1' ' HG2' ' A' ' 80' ' ' GLU . 27.6 p -91.78 178.73 5.82 Favored 'General case' 0 C--N 1.316 -0.877 0 CA-C-N 115.002 -0.999 . . . . 0.0 112.69 -167.564 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . 0.659 ' HG2' ' CE2' ' A' ' 43' ' ' TRP . 64.5 mtp180 -45.89 -42.9 13.2 Favored 'General case' 0 N--CA 1.469 0.501 0 C-N-CA 123.523 0.729 . . . . 0.0 111.88 -174.779 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 80' ' ' GLU . . . . . 0.421 ' HG3' ' N ' ' A' ' 81' ' ' GLU . 7.4 pt-20 -57.19 -37.57 72.37 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 115.738 -0.665 . . . . 0.0 111.002 -177.423 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 81' ' ' GLU . . . . . 0.699 ' CD ' ' HB2' ' A' ' 70' ' ' TYR . 0.0 OUTLIER -72.03 -49.48 36.49 Favored 'General case' 0 N--CA 1.444 -0.731 0 CA-C-N 116.665 -0.243 . . . . 0.0 110.65 -179.238 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 82' ' ' GLN . . . . . 0.716 ' HB2' ' HZ3' ' A' ' 43' ' ' TRP . 9.4 mp0 -61.97 -32.38 72.82 Favored 'General case' 0 CA--C 1.509 -0.61 0 C-N-CA 120.343 -0.543 . . . . 0.0 110.198 -179.276 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . 0.681 ' O ' ' HB3' ' A' ' 87' ' ' GLU . 40.7 mt -64.37 -46.05 94.17 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.753 0 CA-C-N 115.459 -0.791 . . . . 0.0 109.788 176.598 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 84' ' ' ALA . . . . . 0.466 ' O ' ' HG3' ' A' ' 87' ' ' GLU . . . -66.12 -48.22 71.57 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 121.038 0.447 . . . . 0.0 111.649 -176.7 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 47.2 t -69.58 -48.35 66.42 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.577 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.874 -175.414 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 86' ' ' ALA . . . . . 0.448 ' HB1' ' CZ2' ' A' ' 98' ' ' TRP . . . -66.56 -30.15 70.38 Favored 'General case' 0 N--CA 1.444 -0.728 0 CA-C-O 121.026 0.441 . . . . 0.0 110.234 179.682 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 87' ' ' GLU . . . . . 0.681 ' HB3' ' O ' ' A' ' 83' ' ' ILE . 0.4 OUTLIER -70.44 -30.19 66.97 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.774 -177.138 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.665 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 59.1 t -61.29 -42.38 93.34 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.284 0 N-CA-C 108.812 -0.81 . . . . 0.0 108.812 170.732 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 89' ' ' THR . . . . . 0.849 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 0.2 OUTLIER -67.25 -43.83 80.91 Favored 'General case' 0 C--N 1.316 -0.872 0 CA-C-N 115.517 -0.765 . . . . 0.0 110.631 -179.45 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 90' ' ' ARG . . . . . 0.582 ' HG3' ' O ' ' A' ' 87' ' ' GLU . 3.0 ppt_? -63.25 -34.37 77.52 Favored 'General case' 0 CA--C 1.517 -0.295 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.764 -177.512 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 91' ' ' LEU . . . . . 0.665 ' HG ' ' O ' ' A' ' 88' ' ' VAL . 4.4 pp -73.5 -23.7 60.08 Favored 'General case' 0 C--N 1.322 -0.588 0 O-C-N 123.312 0.383 . . . . 0.0 110.949 -171.387 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . 0.533 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 4.6 mtm180 -84.3 -48.5 9.66 Favored 'General case' 0 CA--C 1.512 -0.511 0 CA-C-O 121.516 0.674 . . . . 0.0 109.628 -178.386 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 93' ' ' GLN . . . . . 0.538 ' NE2' HG21 ' A' ' 89' ' ' THR . 21.7 pt20 -98.47 -28.47 13.59 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 114.967 -1.015 . . . . 0.0 113.285 -169.1 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 92.54 40.1 5.13 Favored Glycine 0 CA--C 1.509 -0.323 0 C-N-CA 120.504 -0.855 . . . . 0.0 111.759 176.013 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 95' ' ' TRP . . . . . 0.566 ' CZ2' HD12 ' A' ' 30' ' ' ILE . 34.4 m95 68.7 11.53 8.38 Favored 'General case' 0 C--O 1.216 -0.671 0 C-N-CA 123.316 0.646 . . . . 0.0 110.165 178.536 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -58.85 -29.51 64.82 Favored Glycine 0 CA--C 1.522 0.49 0 CA-C-N 115.523 -0.762 . . . . 0.0 113.463 178.795 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -80.83 -17.64 50.12 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.938 0.399 . . . . 0.0 110.884 178.031 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 98' ' ' TRP . . . . . 0.849 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 30.0 m-90 -104.93 108.02 60.13 Favored Pre-proline 0 C--N 1.324 -0.51 0 CA-C-N 116.052 -0.522 . . . . 0.0 109.736 178.517 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 39.5 Cg_exo -64.43 -134.63 0.0 OUTLIER 'Trans proline' 0 CA--C 1.537 0.631 0 C-N-CA 123.95 3.1 . . . . 0.0 114.148 -175.845 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 3.8 m -54.14 -27.48 16.55 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.229 0 N-CA-C 112.442 0.534 . . . . 0.0 112.442 -176.813 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 77.1 m -60.81 -40.36 92.41 Favored 'General case' 0 C--N 1.317 -0.847 0 CA-C-N 115.887 -0.597 . . . . 0.0 111.37 179.183 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 102' ' ' ALA . . . . . 0.432 ' HB3' ' CB ' ' A' ' 98' ' ' TRP . . . -72.03 -41.6 67.31 Favored 'General case' 0 CA--C 1.517 -0.295 0 CA-C-O 121.092 0.473 . . . . 0.0 110.26 177.302 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -59.27 -46.21 89.15 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.577 -0.738 . . . . 0.0 110.917 179.128 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 3.0 mpp_? -73.71 -22.08 60.03 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.816 -0.629 . . . . 0.0 111.423 179.854 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 105' ' ' ALA . . . . . 0.736 ' HB2' ' HA ' ' A' ' 30' ' ' ILE . . . -83.06 -20.89 34.09 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.397 179.433 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 104.52 60.72 0.66 Allowed Glycine 0 CA--C 1.519 0.305 0 C-N-CA 121.111 -0.566 . . . . 0.0 112.142 -179.178 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -64.11 141.53 58.74 Favored 'General case' 0 C--O 1.235 0.295 0 C-N-CA 122.659 0.384 . . . . 0.0 111.939 -176.574 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 108' ' ' ARG . . . . . 0.654 ' OXT' ' HD3' ' A' ' 108' ' ' ARG . 0.0 OUTLIER . . . . . 0 C--O 1.246 0.903 0 CA-C-O 118.567 -0.73 . . . . 0.0 110.726 -177.491 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.71 ' O ' HG12 ' A' ' 30' ' ' ILE . 33.5 m-20 . . . . . 0 N--CA 1.448 -0.557 0 N-CA-C 108.553 -0.906 . . . . 0.0 108.553 . . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . 0.482 ' HA2' ' CD1' ' A' ' 31' ' ' TRP . . . -72.22 -2.6 54.33 Favored Glycine 0 CA--C 1.5 -0.856 0 N-CA-C 110.605 -0.998 . . . . 0.0 110.605 177.482 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 16.4 m -69.63 -37.41 76.8 Favored 'General case' 0 C--N 1.317 -0.828 0 CA-C-O 121.499 0.666 . . . . 0.0 109.352 173.564 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.71 HG12 ' O ' ' A' ' 27' ' ' ASP . 0.3 OUTLIER -69.55 -35.97 68.9 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.672 0 N-CA-C 107.159 -1.422 . . . . 0.0 107.159 176.364 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 31' ' ' TRP . . . . . 0.541 ' CZ2' ' HD3' ' A' ' 90' ' ' ARG . 21.7 m95 -71.45 -36.45 71.23 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 114.255 -1.339 . . . . 0.0 110.776 -177.394 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 27.1 t70 -76.82 -33.39 57.96 Favored 'General case' 0 N--CA 1.445 -0.713 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.167 177.904 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . 0.488 ' HB1' ' CB ' ' A' ' 105' ' ' ALA . . . -70.69 -34.07 71.58 Favored 'General case' 0 N--CA 1.447 -0.592 0 C-N-CA 120.432 -0.507 . . . . 0.0 110.138 176.529 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . 0.515 ' HA ' ' HB3' ' A' ' 101' ' ' CYS . 56.9 mt -67.38 -41.7 86.58 Favored 'Isoleucine or valine' 0 C--O 1.234 0.28 0 CA-C-N 115.851 -0.613 . . . . 0.0 109.99 172.647 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . 0.497 ' HA ' ' O ' ' A' ' 54' ' ' GLY . . . -58.75 -38.68 78.97 Favored 'General case' 0 CA--C 1.515 -0.379 0 CA-C-O 121.448 0.642 . . . . 0.0 110.112 174.045 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -75.29 -10.1 84.34 Favored Glycine 0 N--CA 1.449 -0.443 0 CA-C-N 115.192 -0.913 . . . . 0.0 111.343 179.22 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.416 ' HB3' ' O ' ' A' ' 34' ' ' ILE . 14.4 t -90.87 -66.72 0.9 Allowed 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.174 -0.513 . . . . 0.0 111.327 -178.607 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . 0.857 ' HG3' ' SG ' ' A' ' 101' ' ' CYS . 53.7 mt-10 -89.7 -34.48 16.22 Favored 'General case' 0 CA--C 1.513 -0.45 0 C-N-CA 120.399 -0.521 . . . . 0.0 110.918 -174.023 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . 0.47 ' HB1' ' O ' ' A' ' 35' ' ' ALA . . . -84.15 -18.32 37.12 Favored 'General case' 0 N--CA 1.445 -0.685 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.227 -176.363 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 80.35 12.57 82.96 Favored Glycine 0 CA--C 1.503 -0.701 0 N-CA-C 109.991 -1.243 . . . . 0.0 109.991 -177.351 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 82.81 61.47 1.94 Allowed Glycine 0 N--CA 1.434 -1.44 0 CA-C-N 114.066 -1.067 . . . . 0.0 111.866 -176.689 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 42' ' ' ASN . . . . . 0.48 ' HB3' ' HB ' ' A' ' 45' ' ' ILE . 52.8 t-20 -155.1 124.37 6.32 Favored 'General case' 0 N--CA 1.442 -0.835 0 N-CA-C 108.624 -0.88 . . . . 0.0 108.624 -179.215 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 43' ' ' TRP . . . . . 0.76 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 44.9 m95 -97.27 -10.41 25.78 Favored 'General case' 0 C--N 1.308 -1.217 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.9 -174.207 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -110.16 9.34 23.95 Favored 'General case' 0 C--N 1.315 -0.91 0 CA-C-N 115.115 -0.948 . . . . 0.0 110.982 179.938 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.48 ' HB ' ' HB3' ' A' ' 42' ' ' ASN . 11.5 tt -73.78 143.27 13.84 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.875 0 CA-C-O 121.462 0.649 . . . . 0.0 110.959 -178.438 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -135.11 94.71 3.18 Favored 'General case' 0 C--N 1.311 -1.097 0 N-CA-C 109.028 -0.73 . . . . 0.0 109.028 179.46 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 1.7 p -73.79 -12.19 60.62 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-N 115.628 -0.714 . . . . 0.0 110.933 -178.269 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 85.29 21.84 53.42 Favored Glycine 0 N--CA 1.443 -0.878 0 N-CA-C 111.179 -0.769 . . . . 0.0 111.179 174.1 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 33.4 p-10 -103.44 10.17 37.4 Favored 'General case' 0 C--N 1.322 -0.612 0 C-N-CA 120.894 -0.322 . . . . 0.0 111.562 -174.944 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . 0.532 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 87.32 -2.66 86.68 Favored Glycine 0 N--CA 1.454 -0.149 0 C-N-CA 120.87 -0.681 . . . . 0.0 111.658 -178.252 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 51' ' ' TYR . . . . . 0.549 ' HA ' ' HA ' ' A' ' 58' ' ' ASP . 0.3 OUTLIER -116.51 147.7 41.52 Favored 'General case' 0 CA--C 1.508 -0.643 0 N-CA-C 106.5 -1.667 . . . . 0.0 106.5 178.649 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 52' ' ' TYR . . . . . 0.713 ' O ' ' HA ' ' A' ' 56' ' ' GLN . 47.9 m-85 -114.7 163.79 14.97 Favored 'General case' 0 C--N 1.304 -1.376 0 C-N-CA 119.821 -0.751 . . . . 0.0 111.688 -170.247 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.418 ' CA ' HG23 ' A' ' 45' ' ' ILE . . . -60.56 177.95 3.41 Favored Glycine 0 N--CA 1.448 -0.54 0 O-C-N 124.047 0.842 . . . . 0.0 114.849 -167.801 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . 0.662 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 85.87 -108.7 3.27 Favored Glycine 0 N--CA 1.436 -1.359 0 N-CA-C 111.121 -0.792 . . . . 0.0 111.121 -178.417 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.478 HG22 ' HB3' ' A' ' 82' ' ' GLN . 0.2 OUTLIER -83.2 -1.03 5.54 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.69 0 CA-C-O 121.437 0.637 . . . . 0.0 110.067 178.713 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 56' ' ' GLN . . . . . 0.713 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 20.0 tp60 56.12 50.43 13.61 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 114.265 -1.334 . . . . 0.0 113.28 164.678 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -118.72 169.5 9.78 Favored 'General case' 0 C--N 1.329 -0.317 0 C-N-CA 119.44 -0.904 . . . . 0.0 111.478 172.209 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.549 ' HA ' ' HA ' ' A' ' 51' ' ' TYR . 8.3 p-10 -74.38 162.13 29.17 Favored 'General case' 0 C--N 1.327 -0.382 0 N-CA-C 113.995 1.109 . . . . 0.0 113.995 -163.992 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . 0.428 ' HB2' ' CE2' ' A' ' 52' ' ' TYR . 20.6 tp60 -56.06 -42.61 76.89 Favored 'General case' 0 N--CA 1.443 -0.813 0 CA-C-N 114.085 -1.416 . . . . 0.0 111.084 177.256 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -67.77 -49.68 47.44 Favored Glycine 0 N--CA 1.451 -0.365 0 CA-C-N 115.056 -0.974 . . . . 0.0 112.667 -173.896 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 92.3 m -64.63 -40.24 95.12 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-O 120.644 0.259 . . . . 0.0 110.958 177.91 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 62' ' ' TRP . . . . . 0.459 ' CZ3' ' HA ' ' A' ' 82' ' ' GLN . 54.4 t-105 -56.64 -49.3 75.41 Favored 'General case' 0 N--CA 1.45 -0.454 0 CA-C-O 121.809 0.814 . . . . 0.0 109.102 175.008 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . 0.545 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 29.5 tt0 -64.83 -35.67 81.85 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 114.653 -1.158 . . . . 0.0 111.319 -179.979 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -64.93 -42.4 94.72 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.976 -0.556 . . . . 0.0 111.335 -174.606 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 33.8 m-80 -81.49 -9.24 59.75 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.981 0.42 . . . . 0.0 110.369 176.815 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . 0.557 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 92.29 50.38 2.61 Favored Glycine 0 C--N 1.332 0.309 0 CA-C-N 115.865 -0.607 . . . . 0.0 112.658 173.288 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . 0.559 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -80.03 -23.59 61.24 Favored Glycine 0 N--CA 1.438 -1.205 0 C-N-CA 120.887 -0.673 . . . . 0.0 112.781 -176.48 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 0.891 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 6.9 mp -60.87 -22.9 64.73 Favored 'General case' 0 N--CA 1.448 -0.552 0 N-CA-C 112.139 0.422 . . . . 0.0 112.139 -172.893 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . 0.557 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 3.7 ptp180 -68.37 -32.81 73.16 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-O 121.12 0.486 . . . . 0.0 109.928 177.002 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 70' ' ' TYR . . . . . 0.608 ' HB3' ' CG ' ' A' ' 81' ' ' GLU . 65.6 m-85 -82.26 -34.23 28.85 Favored 'General case' 0 N--CA 1.44 -0.948 0 N-CA-C 107.564 -1.273 . . . . 0.0 107.564 178.915 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.651 ' HB2' ' HB3' ' A' ' 77' ' ' ALA . . . 168.35 124.35 0.04 OUTLIER Pre-proline 0 N--CA 1.448 -0.528 0 CA-C-N 112.868 -1.969 . . . . 0.0 107.319 -178.835 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 72' ' ' PRO . . . . . 0.891 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 24.8 Cg_exo -54.98 -7.38 0.95 Allowed 'Trans proline' 0 C--N 1.335 -0.174 0 C-N-CA 123.003 2.468 . . . . 0.0 114.11 -177.534 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 12.8 ptm180 -146.42 137.16 24.13 Favored 'General case' 0 C--N 1.319 -0.754 0 N-CA-C 108.853 -0.795 . . . . 0.0 108.853 176.472 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . 0.432 ' HA ' ' CH2' ' A' ' 62' ' ' TRP . . . -56.26 -32.0 64.11 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.151 -0.931 . . . . 0.0 112.574 -176.992 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . 0.591 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 4.9 p-10 -78.81 -8.14 58.51 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 121.108 0.48 . . . . 0.0 110.93 -175.312 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 64.5 tp -93.61 -32.04 14.26 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 108.781 -0.822 . . . . 0.0 108.781 173.605 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . 0.765 ' HB1' ' HB2' ' A' ' 81' ' ' GLU . . . -79.68 157.96 27.1 Favored 'General case' 0 N--CA 1.445 -0.713 0 CA-C-N 114.964 -1.016 . . . . 0.0 110.487 176.092 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 40.6 p -100.62 -172.48 2.2 Favored 'General case' 0 C--N 1.315 -0.906 0 CA-C-N 115.937 -0.574 . . . . 0.0 109.918 179.698 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . 0.76 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 10.9 mtt180 -51.14 -52.71 41.33 Favored 'General case' 0 CA--C 1.51 -0.579 0 O-C-N 123.432 0.457 . . . . 0.0 111.029 -175.433 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 1.3 pm0 -57.71 -48.31 79.93 Favored 'General case' 0 C--N 1.314 -0.943 0 CA-C-N 115.135 -0.938 . . . . 0.0 112.142 -176.374 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 81' ' ' GLU . . . . . 0.765 ' HB2' ' HB1' ' A' ' 77' ' ' ALA . 6.5 mp0 -61.31 -50.48 72.79 Favored 'General case' 0 C--O 1.233 0.221 0 N-CA-C 111.9 0.333 . . . . 0.0 111.9 176.491 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 82' ' ' GLN . . . . . 0.478 ' HB3' HG22 ' A' ' 55' ' ' VAL . 51.4 mt-30 -59.93 -39.94 87.22 Favored 'General case' 0 CA--C 1.516 -0.355 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.229 -177.819 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . 0.676 ' O ' ' HG2' ' A' ' 87' ' ' GLU . 28.3 mt -61.78 -45.54 98.46 Favored 'Isoleucine or valine' 0 C--O 1.212 -0.886 0 CA-C-N 115.36 -0.836 . . . . 0.0 110.151 178.601 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 84' ' ' ALA . . . . . 0.537 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -59.48 -43.4 93.28 Favored 'General case' 0 C--O 1.239 0.509 0 CA-C-O 121.154 0.502 . . . . 0.0 111.336 -178.347 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 60.5 t -68.66 -48.11 73.28 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.649 179.517 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -59.8 -30.08 68.66 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.63 -0.714 . . . . 0.0 110.518 176.08 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 87' ' ' GLU . . . . . 0.676 ' HG2' ' O ' ' A' ' 83' ' ' ILE . 40.1 mm-40 -60.22 -45.81 91.92 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.371 -0.831 . . . . 0.0 110.396 -179.998 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.569 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 24.6 t -64.58 -41.74 93.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 121.392 0.615 . . . . 0.0 109.645 177.823 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 89' ' ' THR . . . . . 0.78 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 0.5 OUTLIER -67.56 -46.7 71.95 Favored 'General case' 0 C--N 1.318 -0.791 0 CA-C-N 115.635 -0.711 . . . . 0.0 111.581 -175.662 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 90' ' ' ARG . . . . . 0.541 ' HD3' ' CZ2' ' A' ' 31' ' ' TRP . 13.8 ptt180 -64.55 -34.16 77.59 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.494 -0.321 . . . . 0.0 111.192 -175.247 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 91' ' ' LEU . . . . . 0.569 ' HG ' ' O ' ' A' ' 88' ' ' VAL . 4.4 pp -72.63 -23.74 60.96 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.289 -171.92 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . 0.523 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 6.6 mtm180 -83.93 -48.53 9.89 Favored 'General case' 0 CA--C 1.511 -0.53 0 CA-C-O 121.437 0.636 . . . . 0.0 109.734 -178.638 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 93' ' ' GLN . . . . . 0.621 ' NE2' HG23 ' A' ' 89' ' ' THR . 28.9 pt20 -98.44 -28.98 13.38 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 114.773 -1.103 . . . . 0.0 113.741 -168.135 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 82.99 48.5 5.41 Favored Glycine 0 N--CA 1.448 -0.502 0 C-N-CA 120.11 -1.043 . . . . 0.0 111.357 178.784 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 95' ' ' TRP . . . . . 0.498 ' HA ' ' HE3' ' A' ' 98' ' ' TRP . 2.4 m95 62.59 24.12 14.35 Favored 'General case' 0 C--O 1.224 -0.274 0 C-N-CA 123.176 0.591 . . . . 0.0 110.288 176.103 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -69.19 -24.51 75.93 Favored Glycine 0 CA--C 1.52 0.359 0 CA-C-N 115.706 -0.679 . . . . 0.0 112.433 175.977 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . 0.429 ' O ' ' HD3' ' A' ' 99' ' ' PRO . . . -82.05 -34.14 29.61 Favored 'General case' 0 CA--C 1.516 -0.355 0 CA-C-O 120.888 0.375 . . . . 0.0 110.474 176.289 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 98' ' ' TRP . . . . . 0.78 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 22.4 m-90 -96.37 103.55 14.41 Favored Pre-proline 0 N--CA 1.451 -0.414 0 CA-C-N 115.713 -0.676 . . . . 0.0 109.202 -179.62 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 99' ' ' PRO . . . . . 0.429 ' HD3' ' O ' ' A' ' 97' ' ' ALA . 16.4 Cg_exo -73.44 -98.72 0.01 OUTLIER 'Trans proline' 0 CA--C 1.537 0.656 0 C-N-CA 123.27 2.646 . . . . 0.0 114.869 -170.682 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 32.8 t -70.22 -27.27 31.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-O 121.702 0.763 . . . . 0.0 110.01 -172.853 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 101' ' ' CYS . . . . . 0.857 ' SG ' ' HG3' ' A' ' 38' ' ' GLU . 38.7 m -67.08 -33.98 76.66 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-N 114.755 -1.111 . . . . 0.0 111.13 -174.77 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 102' ' ' ALA . . . . . 0.437 ' HB1' ' HB3' ' A' ' 107' ' ' ALA . . . -65.38 -45.44 84.03 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.817 0.342 . . . . 0.0 110.69 179.839 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -64.76 -36.28 83.79 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 121.102 0.477 . . . . 0.0 110.545 178.824 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 21.1 mmm180 -74.03 -23.35 59.39 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.553 -0.749 . . . . 0.0 111.693 179.057 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 105' ' ' ALA . . . . . 0.615 ' HB1' ' HA ' ' A' ' 30' ' ' ILE . . . -96.91 -21.53 17.41 Favored 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 112.496 0.554 . . . . 0.0 112.496 -174.472 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 103.94 65.15 0.69 Allowed Glycine 0 CA--C 1.518 0.253 0 C-N-CA 120.827 -0.702 . . . . 0.0 111.919 -177.753 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 107' ' ' ALA . . . . . 0.437 ' HB3' ' HB1' ' A' ' 102' ' ' ALA . . . -71.93 152.75 42.3 Favored 'General case' 0 C--N 1.326 -0.433 0 C-N-CA 122.877 0.471 . . . . 0.0 111.674 -174.912 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 10.7 mmm180 . . . . . 0 C--O 1.25 1.081 0 CA-C-O 117.926 -1.035 . . . . 0.0 111.408 175.043 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.523 ' O ' HG12 ' A' ' 30' ' ' ILE . 7.3 m-20 . . . . . 0 CA--C 1.504 -0.794 0 CA-C-O 121.669 0.747 . . . . 0.0 109.498 . . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . 0.555 ' HA2' ' HD1' ' A' ' 31' ' ' TRP . . . -67.49 -8.02 49.46 Favored Glycine 0 N--CA 1.445 -0.748 0 CA-C-N 114.786 -1.097 . . . . 0.0 110.715 179.484 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 6.1 m -76.72 -39.05 53.13 Favored 'General case' 0 C--N 1.318 -0.779 0 CA-C-O 121.652 0.739 . . . . 0.0 109.239 176.388 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.591 ' HA ' ' HB3' ' A' ' 105' ' ' ALA . 0.7 OUTLIER -68.58 -38.49 79.15 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.592 0 N-CA-C 107.35 -1.352 . . . . 0.0 107.35 177.429 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 31' ' ' TRP . . . . . 0.555 ' HD1' ' HA2' ' A' ' 28' ' ' GLY . 34.8 m95 -68.52 -36.68 79.2 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 114.535 -1.212 . . . . 0.0 110.378 -177.296 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.688 ' HB2' HH21 ' A' ' 79' ' ' ARG . 33.5 t70 -73.77 -41.23 62.74 Favored 'General case' 0 N--CA 1.445 -0.703 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.1 179.043 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . 0.486 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -70.1 -33.11 71.45 Favored 'General case' 0 N--CA 1.448 -0.55 0 CA-C-N 116.405 -0.361 . . . . 0.0 110.912 -179.966 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . 0.609 ' HA ' ' HB3' ' A' ' 101' ' ' CYS . 50.9 mt -64.23 -49.28 81.88 Favored 'Isoleucine or valine' 0 C--O 1.234 0.256 0 CA-C-O 120.777 0.322 . . . . 0.0 110.56 174.893 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . 0.509 ' O ' ' HB3' ' A' ' 39' ' ' ALA . . . -66.02 -33.7 76.4 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 121.296 0.57 . . . . 0.0 110.218 178.528 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . 0.426 ' HA2' ' N ' ' A' ' 41' ' ' GLY . . . -71.61 -21.98 78.72 Favored Glycine 0 N--CA 1.448 -0.526 0 N-CA-C 111.101 -0.799 . . . . 0.0 111.101 176.892 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -76.19 -69.33 0.51 Allowed 'General case' 0 N--CA 1.448 -0.551 0 CA-C-N 115.291 -0.455 . . . . 0.0 111.536 -178.574 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . 0.667 ' HB2' ' SG ' ' A' ' 101' ' ' CYS . 15.3 tt0 -90.9 -32.99 15.79 Favored 'General case' 0 C--N 1.323 -0.572 0 C-N-CA 119.743 -0.783 . . . . 0.0 110.871 -171.455 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . 0.509 ' HB3' ' O ' ' A' ' 35' ' ' ALA . . . -84.46 -13.85 50.87 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.996 -178.855 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 74.89 20.5 79.44 Favored Glycine 0 CA--C 1.501 -0.839 0 N-CA-C 109.853 -1.299 . . . . 0.0 109.853 -179.472 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . 0.426 ' N ' ' HA2' ' A' ' 36' ' ' GLY . . . 72.2 64.03 2.77 Favored Glycine 0 N--CA 1.433 -1.564 0 CA-C-N 114.108 -1.046 . . . . 0.0 111.093 -172.837 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 42' ' ' ASN . . . . . 0.702 ' HB3' ' HB ' ' A' ' 45' ' ' ILE . 0.2 OUTLIER -140.99 84.21 1.92 Allowed 'General case' 0 C--N 1.322 -0.595 0 N-CA-C 108.815 -0.809 . . . . 0.0 108.815 -177.193 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 43' ' ' TRP . . . . . 0.756 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 37.0 m95 -73.65 -11.59 60.46 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 115.741 -0.663 . . . . 0.0 109.973 -177.922 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -106.6 14.38 27.08 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 115.37 -0.832 . . . . 0.0 111.406 179.583 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.721 HG22 ' HA2' ' A' ' 53' ' ' GLY . 9.0 tt -75.86 144.62 11.7 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.812 0 N-CA-C 109.695 -0.483 . . . . 0.0 109.695 179.83 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 21.7 t-20 -153.99 94.65 1.77 Allowed 'General case' 0 C--N 1.308 -1.208 0 CA-C-O 121.302 0.572 . . . . 0.0 110.38 -178.867 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 16.3 p -76.57 -19.56 57.76 Favored 'General case' 0 N--CA 1.445 -0.709 0 CA-C-N 115.225 -0.898 . . . . 0.0 110.718 178.925 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 87.85 24.02 36.78 Favored Glycine 0 N--CA 1.445 -0.759 0 N-CA-C 110.954 -0.859 . . . . 0.0 110.954 179.256 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 3.8 m-20 -97.54 14.4 26.66 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 121.065 0.459 . . . . 0.0 111.52 -174.259 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . 0.463 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 87.46 -16.03 51.4 Favored Glycine 0 N--CA 1.452 -0.28 0 CA-C-N 115.717 -0.674 . . . . 0.0 111.772 179.631 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 51' ' ' TYR . . . . . 0.741 ' CE1' ' HB2' ' A' ' 58' ' ' ASP . 0.3 OUTLIER -102.72 131.89 49.23 Favored 'General case' 0 N--CA 1.446 -0.66 0 N-CA-C 107.805 -1.183 . . . . 0.0 107.805 169.623 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 52' ' ' TYR . . . . . 0.71 ' CE1' ' HB2' ' A' ' 59' ' ' GLN . 15.0 m-85 -104.26 169.64 8.37 Favored 'General case' 0 C--N 1.311 -1.096 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.85 -173.184 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.721 ' HA2' HG22 ' A' ' 45' ' ' ILE . . . -51.91 158.09 3.1 Favored Glycine 0 CA--C 1.509 -0.326 0 N-CA-C 115.613 1.005 . . . . 0.0 115.613 -169.361 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . 0.57 ' CA ' ' HA ' ' A' ' 43' ' ' TRP . . . 98.49 -113.05 4.62 Favored Glycine 0 N--CA 1.438 -1.168 0 CA-C-N 114.486 -0.857 . . . . 0.0 111.369 175.444 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 1.3 m -86.91 -6.09 10.45 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.73 0 CA-C-O 120.442 0.163 . . . . 0.0 110.82 178.38 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 56' ' ' GLN . . . . . 0.597 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 10.5 pt20 45.52 51.71 9.64 Favored 'General case' 0 N--CA 1.479 1.003 0 N-CA-C 114.502 1.297 . . . . 0.0 114.502 167.483 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . 0.569 ' O ' ' HB ' ' A' ' 61' ' ' THR . 19.7 p90 -103.67 21.62 15.84 Favored 'General case' 0 C--N 1.328 -0.344 0 N-CA-C 113.25 0.833 . . . . 0.0 113.25 -176.071 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.741 ' HB2' ' CE1' ' A' ' 51' ' ' TYR . 0.4 OUTLIER 89.06 135.82 0.04 OUTLIER 'General case' 0 C--N 1.317 -0.838 0 C-N-CA 124.615 1.166 . . . . 0.0 111.953 168.399 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . 0.71 ' HB2' ' CE1' ' A' ' 52' ' ' TYR . 0.0 OUTLIER -58.81 -34.23 71.27 Favored 'General case' 0 CA--C 1.512 -0.493 0 CA-C-N 114.195 -1.366 . . . . 0.0 110.932 -179.332 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -67.06 -44.05 89.05 Favored Glycine 0 N--CA 1.449 -0.463 0 C-N-CA 120.717 -0.754 . . . . 0.0 111.619 177.667 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 61' ' ' THR . . . . . 0.569 ' HB ' ' O ' ' A' ' 57' ' ' PHE . 89.5 m -71.02 -41.2 71.16 Favored 'General case' 0 N--CA 1.445 -0.685 0 CA-C-O 121.048 0.452 . . . . 0.0 110.324 178.023 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 62' ' ' TRP . . . . . 0.455 ' CH2' ' HA ' ' A' ' 74' ' ' ALA . 41.1 t-105 -55.57 -49.98 71.27 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.455 -0.793 . . . . 0.0 110.215 172.71 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . 0.487 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 3.7 tp10 -63.54 -40.34 96.75 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 115.437 -0.801 . . . . 0.0 110.555 179.512 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -61.39 -41.37 97.02 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.753 -0.658 . . . . 0.0 110.804 -177.486 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . 0.435 ' HB3' ' HB ' ' A' ' 88' ' ' VAL . 9.3 m120 -80.55 -9.6 59.77 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.439 178.358 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . 0.485 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 85.32 46.8 5.43 Favored Glycine 0 N--CA 1.449 -0.445 0 CA-C-N 115.736 -0.665 . . . . 0.0 112.689 175.716 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . 0.607 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -78.95 -18.53 74.78 Favored Glycine 0 N--CA 1.442 -0.961 0 C-N-CA 120.868 -0.682 . . . . 0.0 112.429 -174.668 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 0.972 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 7.0 mp -60.12 -24.11 64.41 Favored 'General case' 0 N--CA 1.445 -0.688 0 N-CA-C 112.545 0.572 . . . . 0.0 112.545 -175.0 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . 0.485 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 9.1 ptp180 -67.2 -31.85 72.52 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 121.405 0.622 . . . . 0.0 109.771 175.933 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 70' ' ' TYR . . . . . 0.83 ' HB3' ' HB3' ' A' ' 81' ' ' GLU . 74.5 m-85 -81.47 -33.91 31.72 Favored 'General case' 0 N--CA 1.443 -0.814 0 N-CA-C 107.728 -1.212 . . . . 0.0 107.728 178.199 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.548 ' HB1' ' HB3' ' A' ' 77' ' ' ALA . . . 165.9 126.01 0.03 OUTLIER Pre-proline 0 CA--C 1.512 -0.517 0 CA-C-N 112.897 -1.956 . . . . 0.0 107.325 -179.011 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 72' ' ' PRO . . . . . 0.972 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 21.2 Cg_exo -56.91 -6.66 1.87 Allowed 'Trans proline' 0 C--N 1.333 -0.242 0 C-N-CA 122.495 2.13 . . . . 0.0 113.587 -179.412 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 13.9 ptm180 -143.85 137.49 27.97 Favored 'General case' 0 C--N 1.321 -0.671 0 N-CA-C 109.228 -0.656 . . . . 0.0 109.228 177.752 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . 0.455 ' HA ' ' CH2' ' A' ' 62' ' ' TRP . . . -60.14 -28.06 67.58 Favored 'General case' 0 C--O 1.218 -0.569 0 CA-C-N 114.999 -1.0 . . . . 0.0 111.916 -176.96 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . 0.519 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 20.7 p-10 -88.13 3.56 48.69 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 121.186 0.517 . . . . 0.0 111.761 -176.449 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 66.9 tp -100.57 -30.67 11.65 Favored 'General case' 0 C--N 1.321 -0.64 0 N-CA-C 108.29 -1.004 . . . . 0.0 108.29 168.637 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . 0.907 ' HB1' ' HB2' ' A' ' 81' ' ' GLU . . . -78.89 143.87 35.48 Favored 'General case' 0 N--CA 1.441 -0.914 0 CA-C-N 114.617 -1.174 . . . . 0.0 110.704 176.486 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 27.7 p -93.88 -170.55 2.35 Favored 'General case' 0 C--N 1.314 -0.969 0 CA-C-N 115.417 -0.811 . . . . 0.0 109.117 178.93 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . 0.756 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 57.0 mtp180 -48.53 -51.38 27.79 Favored 'General case' 0 C--N 1.33 -0.262 0 O-C-N 123.196 0.31 . . . . 0.0 111.001 -178.512 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 10.2 pt-20 -57.64 -48.28 79.9 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.856 -0.611 . . . . 0.0 112.264 -173.776 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 81' ' ' GLU . . . . . 0.907 ' HB2' ' HB1' ' A' ' 77' ' ' ALA . 16.9 mp0 -65.25 -51.09 63.04 Favored 'General case' 0 N--CA 1.452 -0.358 0 N-CA-C 112.056 0.391 . . . . 0.0 112.056 177.339 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 82' ' ' GLN . . . . . 0.645 ' HB2' ' HZ3' ' A' ' 43' ' ' TRP . 46.0 mt-30 -61.6 -38.64 88.34 Favored 'General case' 0 CA--C 1.51 -0.561 0 CA-C-O 120.754 0.312 . . . . 0.0 110.833 -175.426 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . 0.636 ' O ' ' HG2' ' A' ' 87' ' ' GLU . 50.2 mt -59.34 -44.46 92.43 Favored 'Isoleucine or valine' 0 C--O 1.215 -0.715 0 CA-C-N 115.512 -0.767 . . . . 0.0 109.865 176.889 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 84' ' ' ALA . . . . . 0.674 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -66.01 -41.92 90.4 Favored 'General case' 0 C--O 1.237 0.441 0 CA-C-O 121.29 0.567 . . . . 0.0 111.571 -176.841 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . 0.526 HG22 ' O ' ' A' ' 81' ' ' GLU . 14.8 t -69.12 -47.94 71.89 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.696 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.454 178.969 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -58.23 -28.67 65.09 Favored 'General case' 0 C--O 1.232 0.143 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.431 173.389 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 87' ' ' GLU . . . . . 0.766 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 20.2 mm-40 -59.15 -43.87 92.07 Favored 'General case' 0 CA--C 1.51 -0.589 0 CA-C-N 115.32 -0.855 . . . . 0.0 109.619 178.926 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.575 ' O ' ' HG3' ' A' ' 92' ' ' ARG . 40.6 t -63.1 -43.55 99.0 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 CA-C-O 121.293 0.568 . . . . 0.0 109.933 175.572 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 89' ' ' THR . . . . . 1.007 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 0.2 OUTLIER -62.61 -47.12 85.16 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.746 -0.661 . . . . 0.0 111.982 -176.016 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 90' ' ' ARG . . . . . 0.482 ' HB3' ' CZ2' ' A' ' 31' ' ' TRP . 30.4 ptt85 -60.16 -29.39 68.63 Favored 'General case' 0 N--CA 1.467 0.381 0 CA-C-O 121.313 0.578 . . . . 0.0 110.448 -178.996 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 91' ' ' LEU . . . . . 0.766 ' HG ' ' O ' ' A' ' 87' ' ' GLU . 33.4 mt -66.97 -35.01 79.01 Favored 'General case' 0 C--N 1.314 -0.948 0 CA-C-O 121.406 0.622 . . . . 0.0 109.885 -179.918 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . 0.575 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 4.7 mtm180 -89.11 -51.54 5.54 Favored 'General case' 0 N--CA 1.443 -0.78 0 CA-C-N 115.348 -0.842 . . . . 0.0 110.13 -171.807 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 93' ' ' GLN . . . . . 0.488 HE22 ' HZ3' ' A' ' 98' ' ' TRP . 0.0 OUTLIER -108.72 -15.85 14.31 Favored 'General case' 0 N--CA 1.44 -0.946 0 CA-C-N 115.087 -0.96 . . . . 0.0 111.942 -173.151 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . 0.478 ' HA2' ' O ' ' A' ' 90' ' ' ARG . . . 83.6 -107.41 2.93 Favored Glycine 0 CA--C 1.494 -1.232 0 N-CA-C 111.082 -0.807 . . . . 0.0 111.082 177.911 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 95' ' ' TRP . . . . . . . . . . . . . 3.5 m95 -142.81 27.32 1.66 Allowed 'General case' 0 C--N 1.313 -0.994 0 N-CA-C 106.901 -1.518 . . . . 0.0 106.901 179.813 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -79.19 -22.46 65.38 Favored Glycine 0 N--CA 1.448 -0.546 0 CA-C-N 114.457 -1.247 . . . . 0.0 111.079 173.195 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . 0.433 ' O ' ' HD3' ' A' ' 99' ' ' PRO . . . -85.12 -32.16 22.92 Favored 'General case' 0 C--N 1.327 -0.373 0 N-CA-C 109.378 -0.601 . . . . 0.0 109.378 174.419 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 98' ' ' TRP . . . . . 1.007 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 16.9 m-90 -101.14 100.72 13.94 Favored Pre-proline 0 C--O 1.221 -0.441 0 N-CA-C 109.009 -0.737 . . . . 0.0 109.009 174.027 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 99' ' ' PRO . . . . . 0.433 ' HD3' ' O ' ' A' ' 97' ' ' ALA . 10.3 Cg_exo -79.33 -88.49 0.0 OUTLIER 'Trans proline' 0 CA--C 1.532 0.411 0 C-N-CA 122.848 2.365 . . . . 0.0 115.085 -171.828 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . 0.401 ' H ' ' HB2' ' A' ' 99' ' ' PRO . 63.3 t -69.96 -28.32 36.06 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.349 0 CA-C-O 121.679 0.752 . . . . 0.0 110.047 -172.461 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 101' ' ' CYS . . . . . 0.667 ' SG ' ' HB2' ' A' ' 38' ' ' GLU . 87.4 m -72.21 -27.25 62.42 Favored 'General case' 0 C--N 1.317 -0.84 0 CA-C-N 115.25 -0.887 . . . . 0.0 111.084 -176.759 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 102' ' ' ALA . . . . . 0.58 ' HB1' ' HB1' ' A' ' 107' ' ' ALA . . . -69.93 -40.41 75.55 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.808 0.337 . . . . 0.0 110.333 175.658 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -63.08 -37.81 88.68 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 121.432 0.634 . . . . 0.0 110.336 177.591 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -72.88 -30.62 64.1 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.243 -0.89 . . . . 0.0 111.686 177.363 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 105' ' ' ALA . . . . . 0.591 ' HB3' ' HA ' ' A' ' 30' ' ' ILE . . . -96.32 -22.58 17.11 Favored 'General case' 0 C--N 1.325 -0.457 0 N-CA-C 113.001 0.741 . . . . 0.0 113.001 -172.271 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 104.13 69.85 0.8 Allowed Glycine 0 CA--C 1.52 0.376 0 C-N-CA 120.832 -0.699 . . . . 0.0 112.134 -177.302 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 107' ' ' ALA . . . . . 0.58 ' HB1' ' HB1' ' A' ' 102' ' ' ALA . . . -60.02 146.7 41.78 Favored 'General case' 0 CA--C 1.517 -0.325 0 C-N-CA 122.709 0.403 . . . . 0.0 110.912 -179.899 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 97.3 mtt180 . . . . . 0 C--O 1.248 1.013 0 CA-C-O 118.323 -0.846 . . . . 0.0 111.021 -170.482 . . . . . . . . 0 0 . 1 . 021 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.435 ' O ' HG12 ' A' ' 30' ' ' ILE . 19.4 m-20 . . . . . 0 CA--C 1.508 -0.643 0 CA-C-O 121.441 0.639 . . . . 0.0 109.791 . . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -64.3 -11.54 47.05 Favored Glycine 0 CA--C 1.503 -0.656 0 CA-C-N 114.961 -1.018 . . . . 0.0 111.051 179.635 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 4.4 m -75.73 -41.27 53.85 Favored 'General case' 0 C--N 1.318 -0.794 0 CA-C-O 121.956 0.884 . . . . 0.0 109.116 177.225 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.554 ' HA ' ' HB1' ' A' ' 105' ' ' ALA . 0.9 OUTLIER -67.91 -38.99 80.94 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.726 0 CA-C-N 113.898 -1.501 . . . . 0.0 107.735 178.423 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 31' ' ' TRP . . . . . 0.494 ' HB2' HG12 ' A' ' 83' ' ' ILE . 32.6 m95 -67.98 -35.96 79.23 Favored 'General case' 0 C--N 1.317 -0.845 0 CA-C-N 114.472 -1.24 . . . . 0.0 110.619 -177.684 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.817 ' HB2' HH21 ' A' ' 79' ' ' ARG . 23.3 t70 -73.07 -37.59 66.74 Favored 'General case' 0 N--CA 1.446 -0.654 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.44 -179.349 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . 0.542 ' HB1' ' CB ' ' A' ' 105' ' ' ALA . . . -70.99 -34.15 71.1 Favored 'General case' 0 N--CA 1.446 -0.632 0 C-N-CA 120.707 -0.397 . . . . 0.0 110.787 176.494 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . 0.531 HG13 ' O ' ' A' ' 30' ' ' ILE . 61.1 mt -67.34 -46.89 82.76 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.283 0 CA-C-O 121.108 0.48 . . . . 0.0 110.701 175.201 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . 0.455 ' O ' ' HB3' ' A' ' 39' ' ' ALA . . . -63.19 -34.39 77.54 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.408 178.108 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -72.63 -15.01 77.67 Favored Glycine 0 N--CA 1.449 -0.491 0 N-CA-C 111.181 -0.768 . . . . 0.0 111.181 176.729 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.436 ' HB3' ' O ' ' A' ' 34' ' ' ILE . 41.3 t -87.18 -64.5 1.14 Allowed 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.296 -0.452 . . . . 0.0 111.292 -176.702 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . 0.784 ' HG3' ' SG ' ' A' ' 101' ' ' CYS . 40.8 mt-10 -88.94 -29.62 19.42 Favored 'General case' 0 CA--C 1.516 -0.357 0 CA-C-O 120.813 0.34 . . . . 0.0 111.784 -173.277 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . 0.455 ' HB3' ' O ' ' A' ' 35' ' ' ALA . . . -92.72 -11.33 34.26 Favored 'General case' 0 C--N 1.322 -0.619 0 C-N-CA 120.455 -0.498 . . . . 0.0 111.316 -176.956 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 76.24 15.52 81.39 Favored Glycine 0 N--CA 1.446 -0.664 0 N-CA-C 109.782 -1.327 . . . . 0.0 109.782 -176.229 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 75.11 51.68 7.4 Favored Glycine 0 N--CA 1.436 -1.339 0 CA-C-N 114.268 -0.966 . . . . 0.0 111.939 -176.449 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 2.2 t-20 -140.67 100.1 3.78 Favored 'General case' 0 N--CA 1.448 -0.542 0 N-CA-C 108.855 -0.795 . . . . 0.0 108.855 179.947 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 43' ' ' TRP . . . . . 0.715 ' CE3' ' HA ' ' A' ' 79' ' ' ARG . 30.9 m95 -82.78 -12.69 57.31 Favored 'General case' 0 C--N 1.313 -1.009 0 CA-C-N 115.241 -0.891 . . . . 0.0 110.529 -172.846 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -104.61 10.99 34.7 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 115.455 -0.793 . . . . 0.0 111.272 -178.145 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.682 HG23 ' CA ' ' A' ' 53' ' ' GLY . 4.0 tt -74.04 143.72 13.28 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.655 0 CA-C-O 121.0 0.429 . . . . 0.0 109.915 179.507 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 17.6 t-20 -142.75 87.22 1.98 Allowed 'General case' 0 C--N 1.313 -0.989 0 CA-C-O 121.286 0.565 . . . . 0.0 109.567 -179.171 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 22.7 p -74.12 -24.57 59.47 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.648 179.983 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 92.43 19.57 37.94 Favored Glycine 0 N--CA 1.445 -0.709 0 N-CA-C 110.824 -0.91 . . . . 0.0 110.824 -177.913 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 64.8 t30 -74.94 -7.31 53.19 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 121.384 0.611 . . . . 0.0 111.12 -174.635 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . 0.515 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 95.73 -12.94 67.03 Favored Glycine 0 CA--C 1.504 -0.643 0 N-CA-C 109.47 -1.452 . . . . 0.0 109.47 -173.252 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 51' ' ' TYR . . . . . 0.534 ' HA ' ' HA ' ' A' ' 58' ' ' ASP . 0.5 OUTLIER -114.74 160.9 18.86 Favored 'General case' 0 N--CA 1.439 -0.984 0 N-CA-C 106.132 -1.803 . . . . 0.0 106.132 173.187 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 52' ' ' TYR . . . . . 0.563 ' O ' ' HA ' ' A' ' 56' ' ' GLN . 55.5 m-85 -123.51 169.4 11.44 Favored 'General case' 0 C--N 1.308 -1.207 0 C-N-CA 120.085 -0.646 . . . . 0.0 111.403 -169.702 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.682 ' CA ' HG23 ' A' ' 45' ' ' ILE . . . -59.31 171.34 5.25 Favored Glycine 0 N--CA 1.445 -0.724 0 O-C-N 123.778 0.674 . . . . 0.0 113.821 -173.212 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . 0.695 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 87.79 -107.78 3.33 Favored Glycine 0 N--CA 1.44 -1.09 0 C-N-CA 120.708 -0.758 . . . . 0.0 111.77 -179.391 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.513 ' HB ' ' CD1' ' A' ' 57' ' ' PHE . 2.0 t -84.6 0.58 5.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.542 0 CA-C-O 121.276 0.56 . . . . 0.0 110.277 -177.555 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 56' ' ' GLN . . . . . 0.563 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 79.3 mm-40 58.05 44.59 19.16 Favored 'General case' 0 N--CA 1.462 0.164 0 CA-C-N 114.971 -1.013 . . . . 0.0 113.169 170.886 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . 0.513 ' CD1' ' HB ' ' A' ' 55' ' ' VAL . 1.6 p90 -118.98 164.26 15.72 Favored 'General case' 0 C--N 1.325 -0.472 0 C-N-CA 119.435 -0.906 . . . . 0.0 111.914 177.301 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.534 ' HA ' ' HA ' ' A' ' 51' ' ' TYR . 7.9 p-10 -74.81 165.57 25.03 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 114.985 -1.007 . . . . 0.0 113.685 -163.512 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . 0.424 ' HB2' ' HE1' ' A' ' 52' ' ' TYR . 19.5 tp60 -59.26 -41.95 90.04 Favored 'General case' 0 N--CA 1.438 -1.044 0 CA-C-N 114.538 -1.21 . . . . 0.0 110.945 178.184 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -68.1 -49.45 46.89 Favored Glycine 0 C--O 1.225 -0.45 0 CA-C-N 115.617 -0.719 . . . . 0.0 112.614 -172.35 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 86.7 m -62.25 -42.37 99.26 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-O 121.098 0.475 . . . . 0.0 110.761 178.624 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 62' ' ' TRP . . . . . 0.503 ' CH2' ' HA ' ' A' ' 74' ' ' ALA . 53.4 t-105 -56.62 -51.25 69.41 Favored 'General case' 0 N--CA 1.448 -0.565 0 CA-C-N 115.133 -0.94 . . . . 0.0 109.39 175.323 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . 1.021 ' HG3' HD13 ' A' ' 68' ' ' LEU . 24.0 tt0 -64.43 -38.36 90.75 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-N 114.544 -1.207 . . . . 0.0 111.275 -177.606 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -67.71 -42.39 82.03 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.935 -0.575 . . . . 0.0 111.424 -175.027 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . 0.62 HD21 ' N ' ' A' ' 65' ' ' ASN . 0.7 OUTLIER -77.96 -8.85 58.69 Favored 'General case' 0 N--CA 1.451 -0.405 0 CA-C-O 121.316 0.579 . . . . 0.0 109.672 176.812 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . 0.509 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 90.17 47.71 3.76 Favored Glycine 0 N--CA 1.449 -0.498 0 CA-C-N 115.438 -0.801 . . . . 0.0 112.417 173.386 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . 0.549 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -80.47 -16.39 76.01 Favored Glycine 0 N--CA 1.444 -0.813 0 C-N-CA 120.876 -0.678 . . . . 0.0 112.065 -177.14 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 1.021 HD13 ' HG3' ' A' ' 63' ' ' GLU . 20.8 mt -65.53 -28.58 69.27 Favored 'General case' 0 C--N 1.314 -0.937 0 CA-C-O 120.999 0.428 . . . . 0.0 111.351 -171.06 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . 0.509 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 11.7 ptm180 -65.04 -31.69 73.04 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.217 175.379 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 70' ' ' TYR . . . . . 0.803 ' HB3' ' HB3' ' A' ' 81' ' ' GLU . 89.9 m-85 -77.4 -34.61 54.79 Favored 'General case' 0 CA--C 1.505 -0.755 0 N-CA-C 107.723 -1.214 . . . . 0.0 107.723 178.328 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.559 ' HB2' ' HB3' ' A' ' 77' ' ' ALA . . . 164.65 123.57 0.02 OUTLIER Pre-proline 0 C--N 1.319 -0.724 0 CA-C-N 112.125 -2.307 . . . . 0.0 106.859 -178.232 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 72' ' ' PRO . . . . . 0.53 ' HA ' ' HA ' ' A' ' 68' ' ' LEU . 38.6 Cg_exo -51.76 -6.48 0.17 Allowed 'Trans proline' 0 CA--C 1.53 0.282 0 C-N-CA 123.16 2.573 . . . . 0.0 114.393 -178.513 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 9.2 ptm180 -146.85 142.67 27.91 Favored 'General case' 0 C--N 1.315 -0.91 0 N-CA-C 108.825 -0.805 . . . . 0.0 108.825 174.905 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . 0.503 ' HA ' ' CH2' ' A' ' 62' ' ' TRP . . . -58.35 -33.08 69.15 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.679 -0.691 . . . . 0.0 112.753 -177.129 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . 0.557 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 4.3 p-10 -80.28 -10.22 59.75 Favored 'General case' 0 C--N 1.331 -0.231 0 C-N-CA 120.668 -0.413 . . . . 0.0 111.247 -173.931 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.466 ' HB3' ' HB1' ' A' ' 71' ' ' ALA . 62.5 tp -87.23 -32.49 19.74 Favored 'General case' 0 C--N 1.323 -0.552 0 N-CA-C 108.869 -0.789 . . . . 0.0 108.869 173.66 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . 0.815 ' HB1' ' HB2' ' A' ' 81' ' ' GLU . . . -82.22 161.08 22.84 Favored 'General case' 0 N--CA 1.442 -0.853 0 CA-C-N 114.98 -1.009 . . . . 0.0 110.371 176.171 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 20.0 p -100.59 -170.59 1.88 Allowed 'General case' 0 C--N 1.316 -0.876 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.088 179.127 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . 0.817 HH21 ' HB2' ' A' ' 32' ' ' ASP . 39.1 mtp180 -48.98 -53.48 19.66 Favored 'General case' 0 CA--C 1.515 -0.391 0 O-C-N 123.498 0.499 . . . . 0.0 111.005 -177.044 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 2.5 pt-20 -60.91 -42.47 98.16 Favored 'General case' 0 C--N 1.315 -0.928 0 CA-C-N 114.972 -1.013 . . . . 0.0 112.895 -171.486 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 81' ' ' GLU . . . . . 0.815 ' HB2' ' HB1' ' A' ' 77' ' ' ALA . 9.1 mp0 -63.38 -50.67 68.99 Favored 'General case' 0 N--CA 1.455 -0.196 0 CA-C-N 118.194 0.452 . . . . 0.0 111.491 175.163 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 82' ' ' GLN . . . . . 0.58 ' HB2' ' HZ3' ' A' ' 43' ' ' TRP . 48.0 mt-30 -61.87 -36.79 82.3 Favored 'General case' 0 CA--C 1.515 -0.369 0 CA-C-O 121.122 0.487 . . . . 0.0 110.309 -177.673 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . 0.57 ' O ' ' HB3' ' A' ' 87' ' ' GLU . 33.8 mt -59.4 -44.0 91.61 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.686 0 CA-C-N 114.982 -1.008 . . . . 0.0 109.973 177.119 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 84' ' ' ALA . . . . . 0.604 ' O ' ' HG3' ' A' ' 87' ' ' GLU . . . -66.57 -45.38 79.49 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 116.038 -0.528 . . . . 0.0 111.47 -179.503 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . 0.509 HG21 ' O ' ' A' ' 81' ' ' GLU . 40.1 t -67.73 -50.21 62.56 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-N 116.305 -0.407 . . . . 0.0 112.018 -179.343 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -63.67 -30.96 71.99 Favored 'General case' 0 N--CA 1.449 -0.502 0 CA-C-O 121.002 0.43 . . . . 0.0 110.542 178.962 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 87' ' ' GLU . . . . . 0.604 ' HG3' ' O ' ' A' ' 84' ' ' ALA . 0.1 OUTLIER -70.36 -29.97 66.78 Favored 'General case' 0 C--N 1.325 -0.489 0 C-N-CA 120.418 -0.513 . . . . 0.0 110.438 -177.788 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 53.8 t -62.31 -43.31 97.92 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.258 0 N-CA-C 108.831 -0.803 . . . . 0.0 108.831 170.479 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 89' ' ' THR . . . . . 0.706 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 0.6 OUTLIER -65.67 -43.22 89.98 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 115.232 -0.895 . . . . 0.0 110.689 -177.971 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 90' ' ' ARG . . . . . 0.586 ' HG3' ' O ' ' A' ' 87' ' ' GLU . 4.2 ppt_? -66.37 -33.52 75.89 Favored 'General case' 0 CA--C 1.513 -0.47 0 N-CA-C 109.213 -0.662 . . . . 0.0 109.213 -178.929 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 91' ' ' LEU . . . . . 0.456 ' O ' HD11 ' A' ' 91' ' ' LEU . 2.2 tm? -57.21 -34.8 68.91 Favored 'General case' 0 C--N 1.318 -0.786 0 CA-C-N 114.386 -1.279 . . . . 0.0 110.095 -174.931 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 3.4 mtm180 -92.49 -39.9 11.13 Favored 'General case' 0 C--N 1.315 -0.934 0 CA-C-N 115.18 -0.918 . . . . 0.0 109.91 -172.227 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 93' ' ' GLN . . . . . 0.479 ' NE2' ' CZ3' ' A' ' 98' ' ' TRP . 7.5 pt20 -94.63 -30.73 14.18 Favored 'General case' 0 C--N 1.316 -0.871 0 CA-C-N 114.27 -1.332 . . . . 0.0 113.777 -169.335 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 86.17 32.46 17.03 Favored Glycine 0 CA--C 1.52 0.345 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.619 178.207 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 95' ' ' TRP . . . . . 0.453 ' CE2' ' HD3' ' A' ' 90' ' ' ARG . 13.5 m95 66.82 16.27 10.33 Favored 'General case' 0 N--CA 1.466 0.355 0 C-N-CA 123.395 0.678 . . . . 0.0 110.085 178.095 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -63.94 -41.69 98.59 Favored Glycine 0 CA--C 1.519 0.326 0 CA-C-N 115.461 -0.79 . . . . 0.0 113.65 -179.852 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . 0.492 ' O ' ' HD3' ' A' ' 99' ' ' PRO . . . -78.59 -21.62 48.3 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 117.072 0.436 . . . . 0.0 111.259 -178.456 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 98' ' ' TRP . . . . . 0.706 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 16.3 m-90 -85.54 104.53 5.2 Favored Pre-proline 0 C--O 1.225 -0.226 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 170.118 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 99' ' ' PRO . . . . . 0.492 ' HD3' ' O ' ' A' ' 97' ' ' ALA . 11.7 Cg_exo -76.28 -95.59 0.01 OUTLIER 'Trans proline' 0 N--CA 1.457 -0.648 0 C-N-CA 122.435 2.09 . . . . 0.0 115.087 -171.275 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 38.3 t -71.32 -30.09 38.49 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.445 0 CA-C-O 121.72 0.771 . . . . 0.0 110.411 -169.07 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 101' ' ' CYS . . . . . 0.784 ' SG ' ' HG3' ' A' ' 38' ' ' GLU . 60.8 m -81.8 -25.66 35.04 Favored 'General case' 0 C--N 1.316 -0.855 0 CA-C-N 115.193 -0.912 . . . . 0.0 111.363 -169.722 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -69.82 -45.21 68.39 Favored 'General case' 0 C--N 1.33 -0.276 0 N-CA-C 110.04 -0.355 . . . . 0.0 110.04 176.502 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -61.96 -39.34 91.78 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 121.307 0.575 . . . . 0.0 110.63 177.512 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 12.5 mtp180 -66.09 -39.02 89.66 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.438 -0.801 . . . . 0.0 111.476 177.405 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 105' ' ' ALA . . . . . 0.554 ' HB1' ' HA ' ' A' ' 30' ' ' ILE . . . -83.56 -22.07 32.47 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 112.583 0.586 . . . . 0.0 112.583 -174.026 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 107.71 61.05 0.56 Allowed Glycine 0 CA--C 1.521 0.459 0 C-N-CA 121.035 -0.602 . . . . 0.0 112.506 -179.56 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -62.45 149.22 43.28 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 121.037 0.446 . . . . 0.0 111.528 -176.342 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 92.6 mtt180 . . . . . 0 C--O 1.249 1.067 0 CA-C-N 115.628 -0.715 . . . . 0.0 110.57 -172.596 . . . . . . . . 0 0 . 1 . 022 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.464 ' O ' HG12 ' A' ' 30' ' ' ILE . 7.6 m-20 . . . . . 0 CA--C 1.507 -0.677 0 CA-C-O 121.749 0.785 . . . . 0.0 109.397 . . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -69.92 -5.31 51.9 Favored Glycine 0 N--CA 1.441 -1.004 0 CA-C-N 114.702 -1.136 . . . . 0.0 110.802 178.701 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 12.5 m -76.86 -42.95 38.0 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-O 121.813 0.816 . . . . 0.0 109.11 174.512 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.713 ' HA ' ' HB3' ' A' ' 105' ' ' ALA . 0.4 OUTLIER -66.58 -38.75 82.3 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-N 114.274 -1.33 . . . . 0.0 107.728 178.426 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 31' ' ' TRP . . . . . 0.459 ' CZ2' ' HD3' ' A' ' 90' ' ' ARG . 26.3 m95 -70.05 -35.0 73.94 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 114.572 -1.195 . . . . 0.0 110.516 -178.395 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 32.5 t70 -76.14 -37.63 57.77 Favored 'General case' 0 N--CA 1.449 -0.518 0 CA-C-N 116.024 -0.534 . . . . 0.0 110.349 -179.095 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . 0.524 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -70.59 -34.06 71.75 Favored 'General case' 0 N--CA 1.45 -0.441 0 C-N-CA 120.792 -0.363 . . . . 0.0 110.647 177.417 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . 0.498 HG13 ' O ' ' A' ' 30' ' ' ILE . 74.6 mt -65.55 -45.11 93.48 Favored 'Isoleucine or valine' 0 C--O 1.234 0.252 0 CA-C-O 121.168 0.509 . . . . 0.0 109.841 173.113 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -58.45 -38.3 77.22 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.611 -0.722 . . . . 0.0 110.014 175.074 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . 0.406 ' HA2' ' N ' ' A' ' 41' ' ' GLY . . . -72.2 -12.31 76.0 Favored Glycine 0 N--CA 1.449 -0.456 0 CA-C-N 115.399 -0.819 . . . . 0.0 111.835 179.139 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 46.8 t -88.78 -62.77 1.41 Allowed 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 115.614 -0.293 . . . . 0.0 111.118 -178.249 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 34.2 mt-10 -90.0 -33.37 16.39 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 120.969 0.414 . . . . 0.0 111.185 -174.107 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -93.78 -8.57 40.24 Favored 'General case' 0 N--CA 1.45 -0.471 0 C-N-CA 120.547 -0.461 . . . . 0.0 111.763 -174.755 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 79.71 7.16 88.71 Favored Glycine 0 CA--C 1.505 -0.579 0 N-CA-C 110.26 -1.136 . . . . 0.0 110.26 -178.106 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . 0.406 ' N ' ' HA2' ' A' ' 36' ' ' GLY . . . 81.76 50.78 4.81 Favored Glycine 0 N--CA 1.435 -1.374 0 CA-C-N 114.324 -0.938 . . . . 0.0 112.656 -178.537 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 44.7 t-20 -144.26 128.56 17.82 Favored 'General case' 0 N--CA 1.441 -0.9 0 N-CA-C 107.871 -1.159 . . . . 0.0 107.871 178.256 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 43' ' ' TRP . . . . . 0.785 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 17.6 m95 -103.38 0.41 31.25 Favored 'General case' 0 C--N 1.306 -1.304 0 CA-C-N 115.589 -0.732 . . . . 0.0 110.313 -173.549 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -112.55 -2.47 14.61 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-N 115.4 -0.818 . . . . 0.0 111.011 178.396 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 10.0 tt -66.6 143.4 15.63 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.79 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.078 177.991 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 17.7 t-20 -143.59 91.68 2.27 Favored 'General case' 0 C--N 1.317 -0.83 0 CA-C-O 121.471 0.653 . . . . 0.0 109.334 -179.077 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -73.69 -19.17 60.9 Favored 'General case' 0 N--CA 1.437 -1.085 0 CA-C-N 115.065 -0.971 . . . . 0.0 110.555 177.51 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 82.88 23.01 56.82 Favored Glycine 0 N--CA 1.445 -0.732 0 CA-C-N 115.51 -0.768 . . . . 0.0 111.247 174.315 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 4.6 p-10 -93.5 15.38 16.11 Favored 'General case' 0 C--N 1.325 -0.5 0 N-CA-C 112.247 0.462 . . . . 0.0 112.247 -172.073 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . 0.517 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 95.06 -13.51 66.91 Favored Glycine 0 CA--C 1.508 -0.358 0 N-CA-C 110.789 -0.925 . . . . 0.0 110.789 178.859 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 51' ' ' TYR . . . . . 0.517 ' HD1' ' C ' ' A' ' 50' ' ' GLY . 0.1 OUTLIER -121.52 161.58 22.06 Favored 'General case' 0 N--CA 1.441 -0.881 0 N-CA-C 105.286 -2.116 . . . . 0.0 105.286 174.483 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 52' ' ' TYR . . . . . 0.729 ' O ' ' HA ' ' A' ' 56' ' ' GLN . 20.8 m-85 -126.97 167.85 15.33 Favored 'General case' 0 C--N 1.302 -1.487 0 C-N-CA 119.621 -0.832 . . . . 0.0 111.231 -169.827 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -55.31 164.18 4.1 Favored Glycine 0 N--CA 1.446 -0.689 0 O-C-N 123.881 0.738 . . . . 0.0 114.105 -175.852 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . 0.604 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 97.1 -112.99 4.59 Favored Glycine 0 N--CA 1.439 -1.155 0 N-CA-C 111.421 -0.672 . . . . 0.0 111.421 -176.423 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.48 HG22 ' HB3' ' A' ' 82' ' ' GLN . 2.2 t -84.81 -3.5 8.13 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 CA-C-O 121.826 0.822 . . . . 0.0 109.783 -178.418 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 56' ' ' GLN . . . . . 0.729 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 6.4 tt0 50.36 50.57 18.47 Favored 'General case' 0 N--CA 1.463 0.213 0 CA-C-N 113.774 -1.557 . . . . 0.0 113.498 173.314 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . 0.45 ' CD1' ' HB ' ' A' ' 55' ' ' VAL . 2.8 p90 -113.41 159.35 19.55 Favored 'General case' 0 C--N 1.321 -0.64 0 C-N-CA 119.925 -0.71 . . . . 0.0 110.684 171.668 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.415 ' HB3' ' CD1' ' A' ' 51' ' ' TYR . 5.9 p-10 -71.29 157.75 37.57 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-O 121.75 0.786 . . . . 0.0 112.869 -163.922 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . 0.669 ' HA ' HE21 ' A' ' 59' ' ' GLN . 0.0 OUTLIER -55.8 -35.75 66.65 Favored 'General case' 0 N--CA 1.447 -0.603 0 CA-C-N 114.193 -1.367 . . . . 0.0 111.371 178.944 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -68.12 -49.75 44.7 Favored Glycine 0 N--CA 1.45 -0.407 0 CA-C-N 115.572 -0.74 . . . . 0.0 112.155 -175.896 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 51.3 m -65.19 -41.23 94.76 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-O 121.113 0.482 . . . . 0.0 110.595 176.447 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 62' ' ' TRP . . . . . 0.595 ' CZ3' ' HG2' ' A' ' 82' ' ' GLN . 54.5 t-105 -56.5 -48.89 76.23 Favored 'General case' 0 N--CA 1.448 -0.531 0 CA-C-N 115.493 -0.776 . . . . 0.0 109.389 175.833 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . 0.468 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 34.9 tt0 -68.25 -32.49 72.71 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 115.105 -0.952 . . . . 0.0 111.217 -179.505 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -65.53 -41.21 93.34 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.991 -0.549 . . . . 0.0 110.711 -178.552 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . 0.502 ' HB2' HG13 ' A' ' 85' ' ' VAL . 5.9 m120 -81.13 -8.07 59.69 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.45 0.643 . . . . 0.0 109.862 175.239 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . 0.416 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 80.74 50.26 5.34 Favored Glycine 0 N--CA 1.449 -0.454 0 CA-C-N 115.031 -0.986 . . . . 0.0 112.828 174.903 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . 0.595 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -78.58 -18.55 75.46 Favored Glycine 0 N--CA 1.442 -0.966 0 C-N-CA 120.957 -0.64 . . . . 0.0 112.086 -176.499 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 0.893 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 7.0 mp -60.34 -20.2 58.4 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 111.994 0.368 . . . . 0.0 111.994 -176.09 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . 0.416 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 9.9 ptm180 -70.57 -31.86 69.05 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-O 121.253 0.549 . . . . 0.0 109.823 177.238 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 70' ' ' TYR . . . . . 0.595 ' HD2' ' HA2' ' A' ' 67' ' ' GLY . 43.8 m-85 -85.3 -34.0 21.99 Favored 'General case' 0 N--CA 1.438 -1.04 0 N-CA-C 107.71 -1.218 . . . . 0.0 107.71 178.239 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.495 ' HB3' ' HB3' ' A' ' 76' ' ' LEU . . . 170.69 122.06 0.05 OUTLIER Pre-proline 0 N--CA 1.45 -0.454 0 CA-C-N 113.247 -1.797 . . . . 0.0 107.83 -177.301 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 72' ' ' PRO . . . . . 0.893 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 25.1 Cg_exo -55.34 -7.94 1.48 Allowed 'Trans proline' 0 C--N 1.334 -0.192 0 C-N-CA 123.01 2.473 . . . . 0.0 113.789 -178.737 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 13.4 ptm180 -142.99 136.86 28.88 Favored 'General case' 0 C--N 1.317 -0.825 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 177.461 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . 0.471 ' HA ' ' CH2' ' A' ' 62' ' ' TRP . . . -60.22 -28.11 67.74 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.199 -0.91 . . . . 0.0 112.238 -175.351 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . 0.565 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 19.5 p-10 -84.79 -8.99 58.6 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 121.072 0.463 . . . . 0.0 111.344 -176.712 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.495 ' HB3' ' HB3' ' A' ' 71' ' ' ALA . 57.2 tp -84.96 -32.36 23.07 Favored 'General case' 0 C--N 1.32 -0.682 0 N-CA-C 108.107 -1.071 . . . . 0.0 108.107 169.361 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . 0.938 ' HB3' ' HB2' ' A' ' 81' ' ' GLU . . . -77.93 154.23 31.82 Favored 'General case' 0 N--CA 1.44 -0.935 0 CA-C-N 114.953 -1.021 . . . . 0.0 110.851 177.071 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 78' ' ' THR . . . . . 0.529 ' H ' ' CD ' ' A' ' 81' ' ' GLU . 19.5 p -99.91 -169.89 1.81 Allowed 'General case' 0 C--N 1.315 -0.895 0 CA-C-N 115.656 -0.702 . . . . 0.0 109.552 176.786 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . 0.785 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 79.8 mtp180 -49.66 -51.41 38.22 Favored 'General case' 0 C--N 1.329 -0.31 0 O-C-N 123.418 0.449 . . . . 0.0 111.305 -176.974 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 80' ' ' GLU . . . . . 0.439 ' HG3' ' N ' ' A' ' 81' ' ' GLU . 10.0 pt-20 -60.87 -47.56 85.82 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 112.457 0.54 . . . . 0.0 112.457 -173.361 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 81' ' ' GLU . . . . . 0.938 ' HB2' ' HB3' ' A' ' 77' ' ' ALA . 4.4 mp0 -60.96 -50.64 72.59 Favored 'General case' 0 CA--C 1.518 -0.26 0 CA-C-O 121.064 0.459 . . . . 0.0 111.03 178.382 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 82' ' ' GLN . . . . . 0.595 ' HG2' ' CZ3' ' A' ' 62' ' ' TRP . 34.2 mt-30 -63.65 -37.05 85.88 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.789 -0.641 . . . . 0.0 111.421 -176.682 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . 0.68 ' O ' ' HG2' ' A' ' 87' ' ' GLU . 40.0 mt -60.14 -44.47 95.27 Favored 'Isoleucine or valine' 0 C--O 1.213 -0.841 0 N-CA-C 109.461 -0.57 . . . . 0.0 109.461 174.211 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 84' ' ' ALA . . . . . 0.602 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -62.7 -43.6 98.39 Favored 'General case' 0 C--O 1.236 0.346 0 CA-C-O 121.208 0.528 . . . . 0.0 111.792 -177.023 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . 0.502 HG13 ' HB2' ' A' ' 65' ' ' ASN . 32.4 t -67.5 -47.86 79.07 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.332 178.845 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -59.07 -29.75 67.56 Favored 'General case' 0 N--CA 1.455 -0.225 0 CA-C-N 115.531 -0.759 . . . . 0.0 110.468 174.859 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 87' ' ' GLU . . . . . 0.68 ' HG2' ' O ' ' A' ' 83' ' ' ILE . 25.9 mm-40 -59.51 -43.42 93.38 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.605 -0.725 . . . . 0.0 110.115 178.649 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.681 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 96.9 t -62.64 -48.47 88.04 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.322 0 CA-C-O 121.127 0.489 . . . . 0.0 110.124 176.454 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 89' ' ' THR . . . . . 0.76 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 0.2 OUTLIER -64.56 -47.62 78.07 Favored 'General case' 0 C--N 1.317 -0.84 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.989 -175.433 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 90' ' ' ARG . . . . . 0.459 ' HD3' ' CZ2' ' A' ' 31' ' ' TRP . 7.9 ptt180 -62.52 -33.06 74.14 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.858 -175.84 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 91' ' ' LEU . . . . . 0.681 ' HG ' ' O ' ' A' ' 88' ' ' VAL . 4.4 pp -73.57 -23.45 59.95 Favored 'General case' 0 C--N 1.321 -0.637 0 C-N-CA 120.623 -0.431 . . . . 0.0 111.069 -172.013 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . 0.547 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 6.1 mtm180 -84.2 -45.86 12.48 Favored 'General case' 0 N--CA 1.45 -0.468 0 CA-C-O 121.369 0.605 . . . . 0.0 109.654 -178.487 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 9.1 pt20 -102.89 -27.98 12.32 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 113.924 1.083 . . . . 0.0 113.924 -169.603 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 83.68 50.95 4.23 Favored Glycine 0 CA--C 1.507 -0.448 0 C-N-CA 120.699 -0.762 . . . . 0.0 111.834 178.735 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 95' ' ' TRP . . . . . 0.485 ' HA ' ' HE3' ' A' ' 98' ' ' TRP . 2.5 m95 60.47 22.77 12.41 Favored 'General case' 0 C--O 1.224 -0.251 0 CA-C-O 121.282 0.563 . . . . 0.0 109.674 177.098 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -75.53 -20.77 78.23 Favored Glycine 0 N--CA 1.447 -0.586 0 CA-C-N 115.368 -0.833 . . . . 0.0 112.569 178.454 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -89.77 -17.49 28.12 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 121.096 0.475 . . . . 0.0 110.173 176.253 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 98' ' ' TRP . . . . . 0.76 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 23.3 m-90 -100.09 113.14 65.14 Favored Pre-proline 0 N--CA 1.444 -0.738 0 CA-C-N 115.73 -0.668 . . . . 0.0 109.433 178.748 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 99' ' ' PRO . . . . . 0.431 ' HD3' ' HA ' ' A' ' 98' ' ' TRP . 52.8 Cg_exo -61.93 -145.33 0.01 OUTLIER 'Trans proline' 0 CA--C 1.535 0.542 0 C-N-CA 123.954 3.103 . . . . 0.0 114.315 -173.738 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . 0.406 HG13 ' HG3' ' A' ' 104' ' ' ARG . 58.5 t -55.84 -24.4 16.88 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.307 0 CA-C-N 115.919 -0.582 . . . . 0.0 111.032 -179.791 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 56.6 m -56.44 -36.36 68.91 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.003 177.436 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -69.77 -42.88 73.23 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.834 0.349 . . . . 0.0 110.639 178.891 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -64.37 -42.78 96.0 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.51 178.837 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 104' ' ' ARG . . . . . 0.406 ' HG3' HG13 ' A' ' 100' ' ' VAL . 68.4 mtp180 -60.14 -39.49 86.5 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.389 -0.823 . . . . 0.0 110.916 176.262 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 105' ' ' ALA . . . . . 0.713 ' HB3' ' HA ' ' A' ' 30' ' ' ILE . . . -78.07 -22.05 49.63 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.628 -0.714 . . . . 0.0 112.114 -175.997 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 102.51 64.41 0.73 Allowed Glycine 0 CA--C 1.519 0.318 0 C-N-CA 120.935 -0.65 . . . . 0.0 112.188 -178.23 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -71.1 152.34 43.57 Favored 'General case' 0 C--N 1.324 -0.527 0 C-N-CA 122.649 0.379 . . . . 0.0 111.491 -175.29 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 27.6 mtt180 . . . . . 0 C--O 1.247 0.971 0 CA-C-O 117.702 -1.142 . . . . 0.0 112.464 174.618 . . . . . . . . 0 0 . 1 . 023 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.642 ' O ' HG12 ' A' ' 30' ' ' ILE . 26.0 t0 . . . . . 0 CA--C 1.498 -1.037 0 CA-C-O 122.725 1.25 . . . . 0.0 108.8 . . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . 0.801 ' HA2' ' HB2' ' A' ' 31' ' ' TRP . . . -75.02 6.58 26.64 Favored Glycine 0 N--CA 1.435 -1.418 0 CA-C-N 113.081 -1.872 . . . . 0.0 111.638 -178.162 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 59.6 m -76.69 -42.3 42.09 Favored 'General case' 0 C--N 1.315 -0.904 0 CA-C-O 121.508 0.67 . . . . 0.0 109.346 172.941 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.642 HG12 ' O ' ' A' ' 27' ' ' ASP . 0.0 OUTLIER -71.23 -38.85 71.87 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 N-CA-C 107.517 -1.29 . . . . 0.0 107.517 174.939 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 31' ' ' TRP . . . . . 0.801 ' HB2' ' HA2' ' A' ' 28' ' ' GLY . 20.8 m95 -67.91 -35.15 77.96 Favored 'General case' 0 N--CA 1.445 -0.714 0 CA-C-N 114.543 -1.208 . . . . 0.0 110.686 -177.231 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 6.3 t70 -73.62 -43.12 60.42 Favored 'General case' 0 N--CA 1.446 -0.627 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.951 177.531 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . 0.545 ' HB2' ' CB ' ' A' ' 105' ' ' ALA . . . -68.82 -33.56 74.04 Favored 'General case' 0 N--CA 1.446 -0.639 0 C-N-CA 120.331 -0.548 . . . . 0.0 110.394 -179.497 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . 0.447 HG13 ' O ' ' A' ' 30' ' ' ILE . 65.1 mt -66.89 -43.89 89.19 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.172 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.128 173.066 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -58.04 -35.76 71.78 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 121.299 0.571 . . . . 0.0 110.288 176.375 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . 0.432 ' HA2' ' N ' ' A' ' 41' ' ' GLY . . . -74.02 -22.21 78.19 Favored Glycine 0 N--CA 1.45 -0.383 0 CA-C-N 115.52 -0.764 . . . . 0.0 111.725 178.617 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 11.9 t -87.41 -52.82 5.16 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 115.377 -0.411 . . . . 0.0 111.87 -176.939 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 10.2 tp10 -87.77 -34.01 18.46 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-O 121.071 0.462 . . . . 0.0 110.161 -172.955 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -103.76 -7.81 20.32 Favored 'General case' 0 C--N 1.323 -0.544 0 C-N-CA 120.437 -0.505 . . . . 0.0 112.186 -175.099 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 77.75 13.26 83.64 Favored Glycine 0 CA--C 1.505 -0.58 0 N-CA-C 109.985 -1.246 . . . . 0.0 109.985 -177.666 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . 0.432 ' N ' ' HA2' ' A' ' 36' ' ' GLY . . . 76.74 58.28 3.55 Favored Glycine 0 N--CA 1.434 -1.488 0 CA-C-N 114.236 -0.982 . . . . 0.0 111.975 -177.236 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 42' ' ' ASN . . . . . 0.57 ' HB3' ' HB ' ' A' ' 45' ' ' ILE . 2.9 t30 -145.88 103.37 3.75 Favored 'General case' 0 N--CA 1.447 -0.593 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 179.901 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 43' ' ' TRP . . . . . 0.758 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 35.6 m95 -82.63 -6.58 59.44 Favored 'General case' 0 C--N 1.314 -0.972 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.649 -172.887 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -111.86 14.7 20.99 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 115.259 -0.882 . . . . 0.0 111.33 179.417 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.57 ' HB ' ' HB3' ' A' ' 42' ' ' ASN . 10.2 tt -79.93 140.54 16.59 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.773 0 N-CA-C 109.138 -0.69 . . . . 0.0 109.138 -179.599 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 10.0 t-20 -149.14 107.22 3.72 Favored 'General case' 0 C--N 1.307 -1.281 0 CA-C-O 121.289 0.566 . . . . 0.0 109.716 -174.861 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 24.5 p -82.45 -22.96 35.02 Favored 'General case' 0 N--CA 1.437 -1.109 0 CA-C-N 115.185 -0.916 . . . . 0.0 109.997 178.946 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 90.63 20.57 40.12 Favored Glycine 0 N--CA 1.443 -0.88 0 N-CA-C 110.902 -0.879 . . . . 0.0 110.902 178.702 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 27.5 p-10 -93.64 11.39 29.06 Favored 'General case' 0 C--N 1.327 -0.379 0 C-N-CA 120.656 -0.418 . . . . 0.0 111.684 -173.359 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 93.97 -12.31 69.44 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.699 -0.763 . . . . 0.0 111.431 -177.95 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 51' ' ' TYR . . . . . 0.755 ' CE1' ' HB2' ' A' ' 58' ' ' ASP . 0.2 OUTLIER -108.02 160.66 15.62 Favored 'General case' 0 N--CA 1.446 -0.673 0 N-CA-C 106.982 -1.488 . . . . 0.0 106.982 172.811 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 52' ' ' TYR . . . . . 0.864 ' O ' ' HA ' ' A' ' 56' ' ' GLN . 31.6 m-85 -130.35 170.57 13.98 Favored 'General case' 0 C--N 1.318 -0.783 0 C-N-CA 120.668 -0.413 . . . . 0.0 111.045 -171.298 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.484 ' HA2' HG23 ' A' ' 45' ' ' ILE . . . -61.63 177.91 4.61 Favored Glycine 0 N--CA 1.452 -0.28 0 N-CA-C 114.833 0.693 . . . . 0.0 114.833 -171.717 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . 0.675 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 82.61 -104.96 2.57 Favored Glycine 0 N--CA 1.445 -0.702 0 C-N-CA 121.039 -0.6 . . . . 0.0 111.718 -179.877 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.424 ' HB ' ' CD1' ' A' ' 57' ' ' PHE . 2.1 t -83.84 -2.66 7.08 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.657 0 CA-C-O 121.902 0.858 . . . . 0.0 109.616 -179.385 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 56' ' ' GLN . . . . . 0.864 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 5.7 tt0 53.3 52.54 13.35 Favored 'General case' 0 N--CA 1.462 0.149 0 CA-C-N 113.681 -1.599 . . . . 0.0 113.3 171.981 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . 0.501 ' CZ ' ' HE3' ' A' ' 62' ' ' TRP . 16.5 p90 -121.13 173.34 7.35 Favored 'General case' 0 C--N 1.324 -0.519 0 C-N-CA 119.849 -0.74 . . . . 0.0 112.657 176.09 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.755 ' HB2' ' CE1' ' A' ' 51' ' ' TYR . 0.0 OUTLIER -83.97 153.63 23.79 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 114.534 -1.212 . . . . 0.0 114.091 -161.854 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . 0.435 ' HB2' ' HE1' ' A' ' 52' ' ' TYR . 6.3 tp-100 -56.38 -41.91 76.99 Favored 'General case' 0 N--CA 1.447 -0.597 0 CA-C-N 113.656 -1.611 . . . . 0.0 111.985 178.973 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -64.97 -48.42 71.39 Favored Glycine 0 N--CA 1.445 -0.747 0 C-N-CA 120.944 -0.645 . . . . 0.0 111.574 -176.747 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 67.6 m -65.89 -43.83 87.09 Favored 'General case' 0 C--N 1.318 -0.779 0 C-N-CA 122.696 0.398 . . . . 0.0 111.069 176.443 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 62' ' ' TRP . . . . . 0.501 ' HE3' ' CZ ' ' A' ' 57' ' ' PHE . 45.5 t-105 -56.98 -48.21 78.93 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 121.397 0.618 . . . . 0.0 109.729 177.008 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . 0.425 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 3.6 tm-20 -68.05 -32.82 73.44 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 115.143 -0.935 . . . . 0.0 110.39 -178.401 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -66.62 -41.81 87.77 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.717 -0.674 . . . . 0.0 111.493 -178.009 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . 0.638 ' HB2' HG12 ' A' ' 85' ' ' VAL . 50.6 m-20 -76.43 -15.41 59.93 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.002 0.429 . . . . 0.0 110.511 175.839 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . 0.518 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 94.36 48.09 2.66 Favored Glycine 0 C--N 1.333 0.379 0 CA-C-N 115.735 -0.666 . . . . 0.0 112.199 176.966 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . 0.597 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -79.98 -26.24 56.13 Favored Glycine 0 N--CA 1.44 -1.081 0 C-N-CA 121.12 -0.562 . . . . 0.0 112.907 -174.699 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 0.988 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 7.5 mp -60.5 -25.44 66.08 Favored 'General case' 0 N--CA 1.445 -0.705 0 N-CA-C 112.814 0.672 . . . . 0.0 112.814 -173.761 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . 0.527 ' HG3' ' N ' ' A' ' 70' ' ' TYR . 1.3 ptm180 -65.07 -33.64 76.52 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 121.35 0.595 . . . . 0.0 109.615 175.242 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 70' ' ' TYR . . . . . 0.602 ' HB3' ' CG ' ' A' ' 81' ' ' GLU . 84.3 m-85 -78.08 -35.43 49.4 Favored 'General case' 0 N--CA 1.438 -1.059 0 N-CA-C 107.483 -1.303 . . . . 0.0 107.483 178.159 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.596 ' HB1' ' HB2' ' A' ' 77' ' ' ALA . . . 162.03 130.15 0.01 OUTLIER Pre-proline 0 N--CA 1.447 -0.588 0 CA-C-N 112.676 -2.057 . . . . 0.0 106.756 -179.106 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 72' ' ' PRO . . . . . 0.988 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 26.5 Cg_exo -56.41 -6.54 1.52 Allowed 'Trans proline' 0 C--N 1.334 -0.226 0 C-N-CA 122.955 2.436 . . . . 0.0 113.862 -176.894 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 73' ' ' ARG . . . . . 0.474 ' HB2' ' CD2' ' A' ' 52' ' ' TYR . 0.2 OUTLIER -147.0 143.08 28.15 Favored 'General case' 0 C--N 1.317 -0.811 0 N-CA-C 109.533 -0.543 . . . . 0.0 109.533 176.523 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . 0.446 ' HA ' ' CH2' ' A' ' 62' ' ' TRP . . . -58.94 -26.5 64.44 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.413 -0.812 . . . . 0.0 112.722 -177.05 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . 0.465 ' HB2' ' NH2' ' A' ' 73' ' ' ARG . 0.0 OUTLIER -74.27 -25.43 59.61 Favored 'General case' 0 CA--C 1.518 -0.265 0 CA-C-O 121.096 0.474 . . . . 0.0 110.704 -177.258 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.524 ' HB3' ' HB3' ' A' ' 71' ' ' ALA . 55.3 tp -86.76 -30.22 21.76 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-O 121.342 0.591 . . . . 0.0 109.972 -178.635 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . 0.654 ' HB3' ' CB ' ' A' ' 81' ' ' GLU . . . -82.97 161.05 21.9 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 115.383 -0.826 . . . . 0.0 109.66 172.992 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 18.7 p -101.32 -171.78 2.05 Favored 'General case' 0 C--N 1.32 -0.714 0 C-N-CA 120.611 -0.435 . . . . 0.0 110.054 -179.359 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . 0.758 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 2.8 mtt85 -49.36 -53.12 23.99 Favored 'General case' 0 C--N 1.326 -0.436 0 O-C-N 123.487 0.492 . . . . 0.0 111.916 -177.69 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 80' ' ' GLU . . . . . 0.779 ' HA ' HD12 ' A' ' 83' ' ' ILE . 0.0 OUTLIER -61.4 -40.35 94.05 Favored 'General case' 0 C--N 1.324 -0.534 0 O-C-N 123.206 0.316 . . . . 0.0 111.578 -172.275 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 81' ' ' GLU . . . . . 0.654 ' CB ' ' HB3' ' A' ' 77' ' ' ALA . 47.0 mp0 -61.9 -51.48 67.97 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.724 0.297 . . . . 0.0 111.343 175.505 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 82' ' ' GLN . . . . . 0.416 ' HB2' ' HZ3' ' A' ' 43' ' ' TRP . 46.7 mt-30 -59.71 -35.51 74.66 Favored 'General case' 0 CA--C 1.513 -0.473 0 CA-C-O 121.141 0.496 . . . . 0.0 110.198 -178.83 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . 0.779 HD12 ' HA ' ' A' ' 80' ' ' GLU . 35.4 mt -59.47 -49.53 83.27 Favored 'Isoleucine or valine' 0 C--O 1.212 -0.896 0 CA-C-N 114.95 -1.023 . . . . 0.0 109.955 176.905 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 84' ' ' ALA . . . . . 0.56 ' O ' ' HG3' ' A' ' 87' ' ' GLU . . . -61.27 -44.26 97.52 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-O 121.199 0.523 . . . . 0.0 111.162 -176.188 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . 0.638 HG12 ' HB2' ' A' ' 65' ' ' ASN . 21.8 t -69.33 -49.02 64.34 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.823 179.776 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -66.2 -32.15 73.42 Favored 'General case' 0 CA--C 1.515 -0.379 0 CA-C-O 121.137 0.494 . . . . 0.0 110.888 -179.912 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 87' ' ' GLU . . . . . 0.748 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 0.0 OUTLIER -70.5 -31.52 68.66 Favored 'General case' 0 C--N 1.317 -0.817 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.255 -176.054 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.452 ' O ' ' HG3' ' A' ' 92' ' ' ARG . 71.8 t -60.63 -42.51 92.02 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.373 0 N-CA-C 108.892 -0.781 . . . . 0.0 108.892 172.399 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 89' ' ' THR . . . . . 0.82 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 1.1 m -67.42 -43.7 80.57 Favored 'General case' 0 N--CA 1.441 -0.879 0 CA-C-N 114.766 -1.106 . . . . 0.0 111.023 -176.139 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 90' ' ' ARG . . . . . 0.644 ' HA ' ' OE1' ' A' ' 93' ' ' GLN . 36.2 ptt85 -60.51 -32.46 71.47 Favored 'General case' 0 N--CA 1.461 0.102 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.472 -174.677 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 91' ' ' LEU . . . . . 0.748 ' HG ' ' O ' ' A' ' 87' ' ' GLU . 18.4 mt -67.7 -25.42 65.66 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-O 121.559 0.695 . . . . 0.0 110.197 -176.804 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . 0.452 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 11.4 mtm180 -90.15 -51.48 5.43 Favored 'General case' 0 C--N 1.317 -0.838 0 CA-C-N 114.992 -1.004 . . . . 0.0 110.44 -171.253 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 93' ' ' GLN . . . . . 0.644 ' OE1' ' HA ' ' A' ' 90' ' ' ARG . 0.0 OUTLIER -96.52 -23.59 16.47 Favored 'General case' 0 C--N 1.32 -0.689 0 N-CA-C 113.047 0.758 . . . . 0.0 113.047 -172.088 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 78.38 51.29 5.72 Favored Glycine 0 CA--C 1.506 -0.53 0 C-N-CA 120.507 -0.854 . . . . 0.0 111.565 176.695 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 95' ' ' TRP . . . . . 0.553 ' CZ2' ' HD2' ' A' ' 90' ' ' ARG . 2.6 m95 59.79 23.5 12.44 Favored 'General case' 0 C--N 1.329 -0.317 0 C-N-CA 123.361 0.665 . . . . 0.0 110.685 175.217 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 0.537 ' H ' ' HG2' ' A' ' 93' ' ' GLN . . . -77.75 -17.73 78.33 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.935 -0.65 . . . . 0.0 111.682 173.64 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -87.52 -23.09 24.5 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 121.301 0.572 . . . . 0.0 110.137 176.618 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 98' ' ' TRP . . . . . 0.82 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 20.8 m-90 -110.44 108.68 58.43 Favored Pre-proline 0 N--CA 1.448 -0.55 0 CA-C-N 115.417 -0.811 . . . . 0.0 109.797 179.315 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 99' ' ' PRO . . . . . 0.414 ' HD3' ' HA ' ' A' ' 98' ' ' TRP . 52.6 Cg_exo -61.48 -135.43 0.0 OUTLIER 'Trans proline' 0 CA--C 1.538 0.711 0 C-N-CA 124.083 3.189 . . . . 0.0 114.16 -175.151 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 21.2 t -56.42 -23.21 16.23 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.249 0 CA-C-N 116.397 -0.365 . . . . 0.0 110.95 -178.409 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 68.5 m -54.79 -38.12 66.9 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.013 -0.54 . . . . 0.0 111.024 178.011 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -69.44 -45.89 68.06 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.827 0.346 . . . . 0.0 110.757 -179.163 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -63.56 -35.82 81.77 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.514 179.365 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 4.7 mmp_? -70.79 -31.56 68.37 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.561 -0.745 . . . . 0.0 111.356 177.821 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 105' ' ' ALA . . . . . 0.641 ' HB1' ' HA ' ' A' ' 30' ' ' ILE . . . -89.0 -22.51 22.96 Favored 'General case' 0 C--N 1.326 -0.438 0 N-CA-C 112.664 0.616 . . . . 0.0 112.664 -173.079 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 113.23 58.52 0.41 Allowed Glycine 0 CA--C 1.521 0.437 0 C-N-CA 120.569 -0.824 . . . . 0.0 112.473 -178.333 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -66.69 154.36 40.83 Favored 'General case' 0 C--N 1.325 -0.472 0 C-N-CA 123.402 0.681 . . . . 0.0 111.775 -175.763 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 23.5 mmt180 . . . . . 0 C--O 1.247 0.95 0 CA-C-O 118.09 -0.957 . . . . 0.0 111.346 177.353 . . . . . . . . 0 0 . 1 . 024 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.502 ' O ' HG12 ' A' ' 30' ' ' ILE . 46.5 m-20 . . . . . 0 CA--C 1.507 -0.673 0 CA-C-O 121.542 0.687 . . . . 0.0 109.741 . . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . 0.65 ' HA2' HG12 ' A' ' 83' ' ' ILE . . . -68.24 -6.51 47.49 Favored Glycine 0 N--CA 1.438 -1.203 0 CA-C-N 115.029 -0.987 . . . . 0.0 111.896 -178.878 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 4.9 m -74.47 -46.27 40.78 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-O 122.064 0.935 . . . . 0.0 109.105 176.623 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.595 ' HA ' ' HB3' ' A' ' 105' ' ' ALA . 0.0 OUTLIER -69.77 -38.47 76.11 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.777 0 CA-C-N 114.129 -1.396 . . . . 0.0 108.263 179.242 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 31' ' ' TRP . . . . . 0.545 ' HA ' ' CE3' ' A' ' 31' ' ' TRP . 9.0 m95 -70.55 -36.29 73.57 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 114.86 -1.063 . . . . 0.0 110.861 -177.589 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 4.4 t70 -72.79 -39.37 66.78 Favored 'General case' 0 N--CA 1.446 -0.663 0 CA-C-N 116.481 -0.327 . . . . 0.0 110.521 178.174 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . 0.454 ' HB2' ' CB ' ' A' ' 105' ' ' ALA . . . -69.54 -37.43 77.08 Favored 'General case' 0 N--CA 1.445 -0.69 0 C-N-CA 120.637 -0.425 . . . . 0.0 110.782 179.294 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . 0.482 HG13 ' O ' ' A' ' 30' ' ' ILE . 75.5 mt -67.46 -44.42 86.79 Favored 'Isoleucine or valine' 0 C--O 1.232 0.177 0 CA-C-O 120.809 0.338 . . . . 0.0 110.454 175.524 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -60.86 -31.83 71.28 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 121.252 0.549 . . . . 0.0 110.229 176.907 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -77.42 -22.78 69.52 Favored Glycine 0 N--CA 1.45 -0.395 0 CA-C-N 115.596 -0.729 . . . . 0.0 111.516 177.54 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 40.9 t -76.83 -58.36 3.32 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 115.367 -0.417 . . . . 0.0 111.041 -179.055 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 17.5 mt-10 -89.1 -32.9 17.31 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 116.353 -0.385 . . . . 0.0 111.3 -171.365 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -102.05 -17.61 15.98 Favored 'General case' 0 C--N 1.323 -0.576 0 C-N-CA 120.507 -0.477 . . . . 0.0 112.183 -177.562 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 81.36 9.99 85.2 Favored Glycine 0 N--CA 1.448 -0.535 0 N-CA-C 109.805 -1.318 . . . . 0.0 109.805 -175.709 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 88.39 62.71 1.39 Allowed Glycine 0 N--CA 1.438 -1.199 0 CA-C-N 114.156 -1.022 . . . . 0.0 111.713 -176.931 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 42' ' ' ASN . . . . . 0.697 HD21 ' HB ' ' A' ' 45' ' ' ILE . 3.3 t30 -139.31 87.98 2.23 Favored 'General case' 0 C--N 1.326 -0.418 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 -177.142 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 43' ' ' TRP . . . . . 0.771 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 37.9 m95 -76.41 -11.47 59.9 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-O 121.171 0.51 . . . . 0.0 111.259 -172.669 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -102.66 15.56 28.95 Favored 'General case' 0 C--N 1.314 -0.955 0 CA-C-N 115.793 -0.64 . . . . 0.0 110.447 -179.94 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.697 ' HB ' HD21 ' A' ' 42' ' ' ASN . 10.1 tt -77.53 139.94 17.86 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.003 0 CA-C-N 115.861 -0.609 . . . . 0.0 110.799 -177.771 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 34.1 t-20 -150.59 92.35 1.84 Allowed 'General case' 0 C--N 1.314 -0.957 0 CA-C-N 115.522 -0.763 . . . . 0.0 109.363 179.578 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 8.9 p -76.19 -15.67 60.0 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 115.581 -0.736 . . . . 0.0 111.668 -176.279 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 93.43 21.95 28.07 Favored Glycine 0 N--CA 1.448 -0.561 0 N-CA-C 111.149 -0.78 . . . . 0.0 111.149 -179.904 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 4.9 m-20 -90.7 -0.57 57.74 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 120.857 0.361 . . . . 0.0 111.434 -177.005 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . 0.506 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 86.53 -8.42 75.01 Favored Glycine 0 N--CA 1.449 -0.478 0 N-CA-C 110.888 -0.885 . . . . 0.0 110.888 -172.775 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 51' ' ' TYR . . . . . 0.566 ' N ' ' HD1' ' A' ' 51' ' ' TYR . 0.1 OUTLIER -114.27 140.47 48.57 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 107.459 -1.312 . . . . 0.0 107.459 175.434 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 52' ' ' TYR . . . . . 0.477 ' O ' ' HA ' ' A' ' 56' ' ' GLN . 0.1 OUTLIER -140.33 163.82 31.75 Favored 'General case' 0 C--N 1.319 -0.748 0 N-CA-C 112.7 0.63 . . . . 0.0 112.7 -170.991 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 65.45 105.66 0.01 OUTLIER Glycine 0 C--O 1.221 -0.684 0 N-CA-C 116.287 1.275 . . . . 0.0 116.287 164.198 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . 0.466 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 57.99 -83.45 0.01 OUTLIER Glycine 0 C--N 1.339 0.696 0 N-CA-C 114.579 0.591 . . . . 0.0 114.579 165.226 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 3.7 m -83.16 -6.29 9.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-O 120.932 0.396 . . . . 0.0 110.282 178.337 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 56' ' ' GLN . . . . . 0.477 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 9.8 mt-30 50.19 51.84 15.93 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 114.934 -1.03 . . . . 0.0 113.203 166.788 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 5.5 p90 -102.13 166.68 10.47 Favored 'General case' 0 C--N 1.323 -0.572 0 C-N-CA 119.382 -0.927 . . . . 0.0 110.705 174.926 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.55 ' HB3' ' CE1' ' A' ' 51' ' ' TYR . 4.9 p-10 -74.48 155.99 37.41 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 122.223 1.011 . . . . 0.0 113.548 -163.276 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . 0.414 ' HB2' ' CE1' ' A' ' 52' ' ' TYR . 23.3 tp60 -57.06 -39.58 75.17 Favored 'General case' 0 N--CA 1.441 -0.877 0 CA-C-N 113.175 -1.829 . . . . 0.0 111.633 179.813 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -67.74 -49.29 50.41 Favored Glycine 0 N--CA 1.451 -0.352 0 CA-C-N 115.422 -0.808 . . . . 0.0 112.248 -176.332 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 97.8 m -64.15 -40.83 96.98 Favored 'General case' 0 C--N 1.322 -0.602 0 C-N-CA 122.829 0.451 . . . . 0.0 110.827 176.761 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 62' ' ' TRP . . . . . 0.545 ' CH2' ' HA ' ' A' ' 74' ' ' ALA . 45.6 t-105 -55.92 -48.58 75.42 Favored 'General case' 0 N--CA 1.45 -0.471 0 CA-C-O 121.71 0.767 . . . . 0.0 109.221 174.859 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . 0.521 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 33.2 tt0 -64.64 -36.57 84.67 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-N 114.821 -1.081 . . . . 0.0 110.989 179.187 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -65.47 -41.16 93.64 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.75 -0.659 . . . . 0.0 110.948 -177.282 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . 0.443 ' HB3' ' HB ' ' A' ' 88' ' ' VAL . 8.2 m120 -80.79 -7.76 59.49 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 121.043 0.449 . . . . 0.0 110.339 177.968 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . 0.586 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 87.64 46.8 4.77 Favored Glycine 0 N--CA 1.447 -0.582 0 CA-C-N 115.622 -0.717 . . . . 0.0 112.511 174.207 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . 0.582 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -78.68 -25.05 61.28 Favored Glycine 0 N--CA 1.44 -1.095 0 C-N-CA 120.579 -0.819 . . . . 0.0 112.007 -175.435 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 0.906 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 7.3 mp -57.78 -23.27 51.46 Favored 'General case' 0 N--CA 1.446 -0.628 0 N-CA-C 112.671 0.619 . . . . 0.0 112.671 -175.38 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . 0.586 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 5.6 ptp180 -70.74 -29.39 65.63 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-O 121.327 0.584 . . . . 0.0 109.761 178.281 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 70' ' ' TYR . . . . . 0.739 ' HB3' ' CG ' ' A' ' 81' ' ' GLU . 43.5 m-85 -87.24 -34.62 18.89 Favored 'General case' 0 N--CA 1.439 -1.005 0 N-CA-C 107.373 -1.343 . . . . 0.0 107.373 177.724 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.531 ' HB1' ' HB2' ' A' ' 77' ' ' ALA . . . 170.12 125.31 0.05 OUTLIER Pre-proline 0 N--CA 1.449 -0.51 0 CA-C-N 113.198 -1.819 . . . . 0.0 107.89 -177.39 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 72' ' ' PRO . . . . . 0.906 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 15.9 Cg_exo -59.79 -2.8 1.73 Allowed 'Trans proline' 0 C--N 1.333 -0.27 0 C-N-CA 122.803 2.335 . . . . 0.0 113.562 -179.044 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 15.5 ptm180 -143.48 138.19 29.07 Favored 'General case' 0 C--N 1.316 -0.851 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 176.614 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . 0.568 ' HB1' ' OE1' ' A' ' 82' ' ' GLN . . . -59.09 -31.24 68.73 Favored 'General case' 0 C--N 1.316 -0.863 0 CA-C-N 114.952 -1.022 . . . . 0.0 112.393 -176.206 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 20.7 p-10 -88.93 9.0 26.51 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 120.961 0.41 . . . . 0.0 112.014 -175.956 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.493 ' HB3' ' HB3' ' A' ' 71' ' ' ALA . 68.3 tp -103.79 -28.93 11.34 Favored 'General case' 0 C--N 1.321 -0.634 0 N-CA-C 108.614 -0.884 . . . . 0.0 108.614 169.974 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . 0.716 ' HB3' ' CB ' ' A' ' 81' ' ' GLU . . . -79.91 153.68 28.82 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-N 114.545 -1.207 . . . . 0.0 110.39 176.553 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 21.9 p -99.79 -171.81 2.12 Favored 'General case' 0 C--N 1.32 -0.712 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.854 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . 0.771 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 4.0 mtp180 -50.65 -52.91 35.29 Favored 'General case' 0 C--O 1.222 -0.367 0 O-C-N 123.356 0.41 . . . . 0.0 110.779 -175.999 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 80' ' ' GLU . . . . . 0.428 ' HG3' ' OE2' ' A' ' 81' ' ' GLU . 10.5 pt-20 -58.92 -40.03 83.32 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.726 -0.67 . . . . 0.0 111.688 -174.154 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 81' ' ' GLU . . . . . 0.739 ' CG ' ' HB3' ' A' ' 70' ' ' TYR . 8.8 mp0 -67.8 -52.36 37.95 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 120.815 0.34 . . . . 0.0 111.812 176.397 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 82' ' ' GLN . . . . . 0.568 ' OE1' ' HB1' ' A' ' 74' ' ' ALA . 31.3 mt-30 -64.37 -31.28 72.43 Favored 'General case' 0 CA--C 1.514 -0.434 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.724 -175.7 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . 0.65 HG12 ' HA2' ' A' ' 28' ' ' GLY . 27.9 mt -59.58 -48.16 88.37 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 CA-C-N 115.413 -0.812 . . . . 0.0 109.771 172.66 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 84' ' ' ALA . . . . . 0.506 ' HA ' ' HG2' ' A' ' 87' ' ' GLU . . . -62.57 -43.27 99.24 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.989 -0.55 . . . . 0.0 112.056 -177.465 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . 0.411 HG23 ' O ' ' A' ' 81' ' ' GLU . 21.3 t -69.85 -49.76 54.57 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.69 0 O-C-N 122.112 -0.368 . . . . 0.0 111.346 -178.939 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -66.77 -31.17 71.63 Favored 'General case' 0 N--CA 1.446 -0.632 0 CA-C-N 115.947 -0.569 . . . . 0.0 110.403 -179.463 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 87' ' ' GLU . . . . . 0.808 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 6.5 pt-20 -67.62 -32.2 72.74 Favored 'General case' 0 C--O 1.219 -0.551 0 C-N-CA 120.272 -0.571 . . . . 0.0 109.72 -177.637 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.446 ' O ' ' HG3' ' A' ' 92' ' ' ARG . 87.3 t -61.77 -46.95 95.42 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.273 0 CA-C-O 121.421 0.629 . . . . 0.0 109.394 172.625 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 89' ' ' THR . . . . . 0.697 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 0.2 OUTLIER -60.8 -45.43 94.44 Favored 'General case' 0 N--CA 1.443 -0.794 0 CA-C-N 115.289 -0.869 . . . . 0.0 111.377 -178.184 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 90' ' ' ARG . . . . . 0.666 ' HG3' ' O ' ' A' ' 87' ' ' GLU . 5.6 ppt_? -60.35 -32.63 71.44 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.478 -177.095 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 91' ' ' LEU . . . . . 0.808 ' HG ' ' O ' ' A' ' 87' ' ' GLU . 38.6 mt -61.88 -43.01 99.72 Favored 'General case' 0 N--CA 1.473 0.676 0 CA-C-O 122.165 0.983 . . . . 0.0 110.047 -176.706 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . 0.446 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 4.4 mtm180 -78.24 -45.17 23.62 Favored 'General case' 0 C--N 1.316 -0.864 0 CA-C-N 113.828 -1.533 . . . . 0.0 110.083 -167.327 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 13.9 pt20 -100.99 -26.74 13.62 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-N 114.605 -1.179 . . . . 0.0 112.857 -170.094 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 87.56 40.19 6.91 Favored Glycine 0 CA--C 1.508 -0.378 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.176 174.775 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 95' ' ' TRP . . . . . 0.499 ' CZ2' ' HD3' ' A' ' 90' ' ' ARG . 18.5 m95 64.54 18.66 11.49 Favored 'General case' 0 C--O 1.219 -0.527 0 CA-C-O 121.455 0.645 . . . . 0.0 109.815 179.912 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -66.41 -29.8 75.46 Favored Glycine 0 CA--C 1.519 0.299 0 CA-C-N 115.163 -0.926 . . . . 0.0 112.862 175.462 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -81.83 -21.21 37.75 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.879 0.371 . . . . 0.0 110.625 178.692 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 98' ' ' TRP . . . . . 0.697 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 24.6 m-90 -99.3 109.06 53.31 Favored Pre-proline 0 N--CA 1.446 -0.625 0 N-CA-C 109.245 -0.65 . . . . 0.0 109.245 177.637 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 99' ' ' PRO . . . . . 0.425 ' HD3' ' HA ' ' A' ' 98' ' ' TRP . 44.8 Cg_exo -63.24 -139.48 0.0 OUTLIER 'Trans proline' 0 CA--C 1.535 0.541 0 C-N-CA 123.578 2.852 . . . . 0.0 114.331 -174.909 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . 0.416 ' O ' ' HD2' ' A' ' 104' ' ' ARG . 45.0 t -54.98 -23.98 13.64 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.315 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.682 -174.185 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 60.7 m -63.42 -31.66 72.88 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.549 -179.847 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -69.72 -46.03 66.88 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.617 0.246 . . . . 0.0 111.124 -177.364 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -66.09 -36.56 83.52 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 121.019 0.438 . . . . 0.0 110.652 179.896 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 104' ' ' ARG . . . . . 0.416 ' HD2' ' O ' ' A' ' 100' ' ' VAL . 0.0 OUTLIER -70.78 -24.13 62.52 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.78 -0.646 . . . . 0.0 111.23 177.194 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 105' ' ' ALA . . . . . 0.595 ' HB3' ' HA ' ' A' ' 30' ' ' ILE . . . -88.83 -21.46 23.71 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.583 -178.386 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . 0.46 ' O ' ' HG2' ' A' ' 108' ' ' ARG . . . 112.29 63.09 0.46 Allowed Glycine 0 CA--C 1.52 0.354 0 C-N-CA 120.996 -0.621 . . . . 0.0 112.129 -178.0 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -57.91 142.06 47.35 Favored 'General case' 0 C--N 1.329 -0.321 0 C-N-CA 122.679 0.392 . . . . 0.0 111.084 -179.321 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 108' ' ' ARG . . . . . 0.46 ' HG2' ' O ' ' A' ' 106' ' ' GLY . 4.6 ptp180 . . . . . 0 C--O 1.247 0.961 0 CA-C-O 118.484 -0.769 . . . . 0.0 111.093 -170.195 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.435 ' O ' HG12 ' A' ' 30' ' ' ILE . 50.0 m-20 . . . . . 0 CA--C 1.506 -0.713 0 CA-C-O 121.392 0.615 . . . . 0.0 109.693 . . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -70.34 -7.84 61.19 Favored Glycine 0 N--CA 1.44 -1.066 0 N-CA-C 110.024 -1.231 . . . . 0.0 110.024 176.577 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 8.7 m -74.39 -39.42 62.7 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 114.644 -0.778 . . . . 0.0 109.122 174.621 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.634 ' HA ' ' HB1' ' A' ' 105' ' ' ALA . 1.0 OUTLIER -68.18 -39.58 81.45 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 N-CA-C 107.402 -1.333 . . . . 0.0 107.402 177.771 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 31' ' ' TRP . . . . . 0.589 ' CZ2' ' HD3' ' A' ' 90' ' ' ARG . 27.2 m95 -70.61 -37.35 73.85 Favored 'General case' 0 N--CA 1.443 -0.795 0 CA-C-N 114.301 -1.318 . . . . 0.0 110.345 -177.051 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.626 ' HB2' HH21 ' A' ' 79' ' ' ARG . 21.8 t70 -79.34 -33.85 42.69 Favored 'General case' 0 N--CA 1.448 -0.549 0 CA-C-N 115.965 -0.561 . . . . 0.0 111.258 -179.55 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . 0.47 ' HB2' ' CB ' ' A' ' 105' ' ' ALA . . . -68.63 -32.97 73.21 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 176.713 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . 0.544 HG13 ' O ' ' A' ' 30' ' ' ILE . 66.3 mt -61.07 -45.39 98.66 Favored 'Isoleucine or valine' 0 C--O 1.234 0.289 0 CA-C-N 116.172 -0.467 . . . . 0.0 109.85 171.315 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . 0.754 ' HA ' ' NE2' ' A' ' 56' ' ' GLN . . . -61.34 -36.03 79.05 Favored 'General case' 0 CA--C 1.513 -0.475 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.684 177.6 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -73.56 -18.13 79.32 Favored Glycine 0 N--CA 1.448 -0.509 0 N-CA-C 111.025 -0.83 . . . . 0.0 111.025 179.44 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . 0.496 ' HB3' ' O ' ' A' ' 34' ' ' ILE . 8.3 t -77.14 -70.64 0.45 Allowed 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 115.102 -0.549 . . . . 0.0 111.587 -178.065 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . 0.707 ' HG2' ' SG ' ' A' ' 101' ' ' CYS . 4.5 mm-40 -90.44 -33.54 15.96 Favored 'General case' 0 CA--C 1.511 -0.554 0 C-N-CA 120.435 -0.506 . . . . 0.0 111.133 -172.65 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . 0.477 ' HB1' ' O ' ' A' ' 35' ' ' ALA . . . -84.57 -15.69 44.79 Favored 'General case' 0 N--CA 1.443 -0.8 0 CA-C-N 115.997 -0.547 . . . . 0.0 111.125 -177.182 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 75.84 13.29 83.23 Favored Glycine 0 CA--C 1.504 -0.607 0 N-CA-C 109.687 -1.365 . . . . 0.0 109.687 -177.456 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 88.62 63.33 1.35 Allowed Glycine 0 N--CA 1.432 -1.583 0 CA-C-N 113.957 -1.121 . . . . 0.0 111.436 -175.424 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 42' ' ' ASN . . . . . 0.79 ' HB3' ' HB ' ' A' ' 45' ' ' ILE . 6.6 m120 -146.59 103.32 3.65 Favored 'General case' 0 CA--C 1.513 -0.456 0 CA-C-O 121.125 0.488 . . . . 0.0 110.003 -177.962 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 43' ' ' TRP . . . . . 0.688 ' HA ' ' N ' ' A' ' 54' ' ' GLY . 44.5 m95 -84.97 -6.87 59.33 Favored 'General case' 0 C--N 1.311 -1.066 0 CA-C-O 121.642 0.734 . . . . 0.0 110.128 178.155 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -109.72 13.96 23.51 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-N 114.924 -1.034 . . . . 0.0 111.546 178.449 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.79 ' HB ' ' HB3' ' A' ' 42' ' ' ASN . 11.2 tt -87.23 143.67 10.85 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.712 0 CA-C-O 120.85 0.357 . . . . 0.0 110.595 -177.833 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 4.8 p30 -161.71 113.55 1.75 Allowed 'General case' 0 C--N 1.315 -0.916 0 CA-C-O 121.375 0.607 . . . . 0.0 110.482 175.974 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 30.5 p -82.32 -20.17 37.91 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 115.739 -0.664 . . . . 0.0 111.684 -175.22 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 102.66 25.01 7.87 Favored Glycine 0 N--CA 1.445 -0.757 0 N-CA-C 110.703 -0.959 . . . . 0.0 110.703 -175.204 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 3.4 t30 -95.01 -2.91 49.36 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 121.533 0.682 . . . . 0.0 110.346 -178.64 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 96.3 -13.81 65.23 Favored Glycine 0 C--O 1.227 -0.314 0 CA-C-N 115.548 -0.751 . . . . 0.0 111.526 179.202 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 51' ' ' TYR . . . . . 0.57 ' N ' ' CD1' ' A' ' 51' ' ' TYR . 0.3 OUTLIER -99.55 137.94 37.33 Favored 'General case' 0 CA--C 1.511 -0.541 0 N-CA-C 108.234 -1.024 . . . . 0.0 108.234 174.543 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 52' ' ' TYR . . . . . 0.646 ' CE1' ' HB2' ' A' ' 59' ' ' GLN . 15.9 m-85 -107.62 169.5 8.55 Favored 'General case' 0 C--N 1.312 -1.065 0 C-N-CA 120.685 -0.406 . . . . 0.0 111.698 -172.199 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -63.01 169.59 16.49 Favored Glycine 0 N--CA 1.449 -0.484 0 N-CA-C 115.256 0.862 . . . . 0.0 115.256 -166.613 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . 0.688 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 85.11 -93.17 1.81 Allowed Glycine 0 N--CA 1.44 -1.086 0 CA-C-N 114.508 -0.846 . . . . 0.0 112.01 177.983 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.59 HG21 ' HB3' ' A' ' 82' ' ' GLN . 0.4 OUTLIER -90.95 -2.15 10.14 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.764 0 CA-C-O 121.017 0.437 . . . . 0.0 111.403 -177.447 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 56' ' ' GLN . . . . . 0.754 ' NE2' ' HA ' ' A' ' 35' ' ' ALA . 9.2 mt-30 58.02 46.94 15.58 Favored 'General case' 0 N--CA 1.472 0.625 0 N-CA-C 113.849 1.055 . . . . 0.0 113.849 164.645 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -125.3 157.77 35.83 Favored 'General case' 0 C--N 1.318 -0.765 0 C-N-CA 119.221 -0.992 . . . . 0.0 111.296 174.87 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.569 ' HA ' ' HA ' ' A' ' 51' ' ' TYR . 24.1 t70 -65.21 144.12 57.39 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 114.33 -1.304 . . . . 0.0 112.052 -167.709 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . 0.646 ' HB2' ' CE1' ' A' ' 52' ' ' TYR . 0.0 OUTLIER -51.87 -36.15 47.5 Favored 'General case' 0 N--CA 1.448 -0.562 0 CA-C-N 114.131 -1.395 . . . . 0.0 111.807 179.017 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -67.43 -41.98 90.04 Favored Glycine 0 N--CA 1.449 -0.438 0 N-CA-C 111.453 -0.659 . . . . 0.0 111.453 179.386 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 64.1 m -71.47 -38.69 71.23 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 120.759 0.314 . . . . 0.0 110.434 176.368 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 62' ' ' TRP . . . . . 0.568 ' CH2' ' HA ' ' A' ' 74' ' ' ALA . 43.3 t-105 -55.59 -47.57 76.26 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 121.64 0.733 . . . . 0.0 109.089 172.571 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . 0.507 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 27.6 tt0 -64.67 -33.53 76.16 Favored 'General case' 0 N--CA 1.443 -0.775 0 CA-C-N 114.784 -1.098 . . . . 0.0 110.711 178.127 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -64.36 -42.84 96.0 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 115.928 -0.578 . . . . 0.0 111.624 -176.598 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . 0.412 ' HB2' HG13 ' A' ' 85' ' ' VAL . 10.2 m-80 -74.16 -19.31 60.6 Favored 'General case' 0 N--CA 1.462 0.173 0 CA-C-O 121.254 0.549 . . . . 0.0 109.892 174.01 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . 0.4 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 94.02 48.12 2.73 Favored Glycine 0 N--CA 1.448 -0.514 0 CA-C-N 115.536 -0.756 . . . . 0.0 111.814 179.309 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . 0.524 ' HA2' ' HD1' ' A' ' 70' ' ' TYR . . . -79.59 -17.37 75.76 Favored Glycine 0 N--CA 1.44 -1.068 0 C-N-CA 120.992 -0.623 . . . . 0.0 113.044 -173.377 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 0.783 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 6.5 mp -61.68 -23.3 66.0 Favored 'General case' 0 N--CA 1.45 -0.441 0 N-CA-C 112.179 0.437 . . . . 0.0 112.179 -173.372 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . 0.4 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 4.8 ptt180 -70.52 -29.49 66.0 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 121.04 0.448 . . . . 0.0 110.604 175.552 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 70' ' ' TYR . . . . . 0.572 ' HB3' ' HB3' ' A' ' 81' ' ' GLU . 74.7 m-85 -79.27 -33.65 43.25 Favored 'General case' 0 N--CA 1.446 -0.642 0 N-CA-C 107.185 -1.413 . . . . 0.0 107.185 175.891 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.615 ' HB2' ' HB1' ' A' ' 77' ' ' ALA . . . 163.02 127.69 0.01 OUTLIER Pre-proline 0 C--O 1.22 -0.452 0 CA-C-N 112.662 -2.063 . . . . 0.0 107.044 -179.709 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 72' ' ' PRO . . . . . 0.783 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 16.6 Cg_exo -56.92 -4.77 1.02 Allowed 'Trans proline' 0 C--N 1.334 -0.194 0 C-N-CA 122.605 2.203 . . . . 0.0 113.774 -177.97 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 14.4 ptm180 -145.38 140.19 27.5 Favored 'General case' 0 C--N 1.318 -0.798 0 N-CA-C 108.501 -0.925 . . . . 0.0 108.501 175.888 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . 0.568 ' HA ' ' CH2' ' A' ' 62' ' ' TRP . . . -57.68 -36.03 71.38 Favored 'General case' 0 C--O 1.219 -0.535 0 CA-C-N 115.448 -0.796 . . . . 0.0 111.691 -176.77 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . 0.458 ' OD1' ' HD2' ' A' ' 52' ' ' TYR . 11.6 p-10 -84.03 2.58 38.43 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 120.935 0.398 . . . . 0.0 111.455 -173.08 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.461 ' HB3' ' HB1' ' A' ' 71' ' ' ALA . 49.2 tp -98.13 -33.96 10.94 Favored 'General case' 0 C--N 1.323 -0.568 0 N-CA-C 108.419 -0.956 . . . . 0.0 108.419 170.893 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . 0.765 ' HB2' ' HB2' ' A' ' 81' ' ' GLU . . . -79.32 163.27 25.02 Favored 'General case' 0 N--CA 1.444 -0.768 0 CA-C-N 114.785 -1.098 . . . . 0.0 109.959 175.242 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 38.3 p -101.0 178.23 4.73 Favored 'General case' 0 C--N 1.316 -0.887 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.121 179.491 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . 0.64 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 60.4 mtp180 -46.1 -48.37 17.18 Favored 'General case' 0 N--CA 1.467 0.399 0 O-C-N 123.693 0.621 . . . . 0.0 111.32 -176.06 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 6.0 pt-20 -61.7 -42.03 98.4 Favored 'General case' 0 C--N 1.315 -0.915 0 CA-C-N 115.756 -0.656 . . . . 0.0 112.659 -177.375 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 81' ' ' GLU . . . . . 0.765 ' HB2' ' HB2' ' A' ' 77' ' ' ALA . 5.7 mp0 -65.68 -50.48 64.74 Favored 'General case' 0 C--O 1.231 0.121 0 CA-C-N 118.369 0.531 . . . . 0.0 111.824 172.936 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 82' ' ' GLN . . . . . 0.59 ' HB3' HG21 ' A' ' 55' ' ' VAL . 4.0 mt-30 -57.76 -40.78 80.55 Favored 'General case' 0 CA--C 1.515 -0.379 0 CA-C-O 121.217 0.532 . . . . 0.0 110.26 -177.707 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . 0.485 HG12 ' CB ' ' A' ' 31' ' ' TRP . 11.6 mt -61.82 -45.49 98.59 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.696 0 CA-C-N 114.898 -1.047 . . . . 0.0 110.593 178.045 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 84' ' ' ALA . . . . . 0.554 ' O ' ' HG3' ' A' ' 87' ' ' GLU . . . -62.33 -44.49 96.37 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.911 0.386 . . . . 0.0 111.513 -177.575 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . 0.475 HG21 ' O ' ' A' ' 81' ' ' GLU . 21.7 t -67.27 -48.84 76.88 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 CA-C-N 116.535 -0.302 . . . . 0.0 111.457 179.291 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -65.04 -30.97 71.98 Favored 'General case' 0 N--CA 1.451 -0.423 0 CA-C-O 121.148 0.499 . . . . 0.0 110.558 179.145 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 87' ' ' GLU . . . . . 0.636 ' O ' ' HG2' ' A' ' 90' ' ' ARG . 0.7 OUTLIER -71.86 -27.71 63.05 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.876 -177.526 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.719 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 88.8 t -62.21 -40.1 86.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 N-CA-C 108.805 -0.813 . . . . 0.0 108.805 166.805 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 89' ' ' THR . . . . . 0.781 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 2.7 m -67.86 -43.05 80.33 Favored 'General case' 0 C--N 1.318 -0.772 0 CA-C-N 115.524 -0.762 . . . . 0.0 111.005 -178.89 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 90' ' ' ARG . . . . . 0.636 ' HG2' ' O ' ' A' ' 87' ' ' GLU . 26.3 ptt180 -60.08 -34.34 73.31 Favored 'General case' 0 N--CA 1.47 0.54 0 C-N-CA 122.761 0.424 . . . . 0.0 111.447 -175.906 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 91' ' ' LEU . . . . . 0.719 ' HG ' ' O ' ' A' ' 88' ' ' VAL . 4.3 pp -73.15 -21.83 60.63 Favored 'General case' 0 C--N 1.318 -0.774 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.588 -174.361 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . 0.466 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 6.7 mtm180 -86.61 -51.1 6.35 Favored 'General case' 0 CA--C 1.511 -0.538 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.135 -176.607 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 93' ' ' GLN . . . . . 0.612 ' OE1' ' HA ' ' A' ' 90' ' ' ARG . 0.0 OUTLIER -98.03 -25.43 14.96 Favored 'General case' 0 CA--C 1.538 0.487 0 N-CA-C 113.311 0.856 . . . . 0.0 113.311 -170.779 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 90.47 40.1 5.79 Favored Glycine 0 CA--C 1.507 -0.447 0 C-N-CA 120.672 -0.775 . . . . 0.0 111.99 173.462 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 95' ' ' TRP . . . . . 0.456 ' HB3' ' HB2' ' A' ' 102' ' ' ALA . 10.2 m95 64.35 11.71 6.66 Favored 'General case' 0 C--O 1.223 -0.328 0 C-N-CA 123.678 0.791 . . . . 0.0 110.142 -179.131 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -71.66 -28.33 69.43 Favored Glycine 0 C--N 1.33 0.2 0 C-N-CA 121.114 -0.565 . . . . 0.0 112.433 177.982 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -70.0 -29.2 66.23 Favored 'General case' 0 CA--C 1.516 -0.334 0 CA-C-O 121.183 0.516 . . . . 0.0 110.2 178.667 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 98' ' ' TRP . . . . . 0.781 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 26.2 m-90 -98.74 103.84 21.35 Favored Pre-proline 0 N--CA 1.446 -0.638 0 N-CA-C 108.299 -1.0 . . . . 0.0 108.299 174.948 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 22.9 Cg_exo -69.25 -94.23 0.01 OUTLIER 'Trans proline' 0 CA--C 1.532 0.424 0 C-N-CA 123.176 2.584 . . . . 0.0 114.727 -170.438 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 47.9 t -70.92 -29.74 38.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-O 121.702 0.763 . . . . 0.0 110.013 -174.385 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 101' ' ' CYS . . . . . 0.707 ' SG ' ' HG2' ' A' ' 38' ' ' GLU . 64.0 m -71.13 -38.41 72.27 Favored 'General case' 0 C--N 1.317 -0.807 0 CA-C-N 114.789 -1.096 . . . . 0.0 111.794 -170.895 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 102' ' ' ALA . . . . . 0.456 ' HB2' ' HB3' ' A' ' 95' ' ' TRP . . . -69.99 -43.14 72.06 Favored 'General case' 0 C--N 1.327 -0.401 0 C-N-CA 120.698 -0.401 . . . . 0.0 110.704 179.86 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -61.67 -37.19 83.18 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 121.355 0.598 . . . . 0.0 110.464 178.42 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 104' ' ' ARG . . . . . 0.58 ' HA ' ' NE ' ' A' ' 104' ' ' ARG . 4.8 mmp_? -71.33 -34.84 70.91 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.495 -0.775 . . . . 0.0 111.563 176.323 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 105' ' ' ALA . . . . . 0.634 ' HB1' ' HA ' ' A' ' 30' ' ' ILE . . . -83.4 -22.33 32.77 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.158 -0.474 . . . . 0.0 112.208 -174.775 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 114.81 59.23 0.36 Allowed Glycine 0 CA--C 1.521 0.425 0 C-N-CA 120.818 -0.706 . . . . 0.0 112.37 -178.611 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -61.65 148.03 43.9 Favored 'General case' 0 CA--C 1.515 -0.367 0 C-N-CA 122.91 0.484 . . . . 0.0 110.635 179.478 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.245 0.845 0 CA-C-O 118.29 -0.862 . . . . 0.0 110.059 -173.013 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 7.9 m-20 . . . . . 0 CA--C 1.503 -0.856 0 CA-C-O 121.656 0.741 . . . . 0.0 109.395 . . . . . . . . . 0 0 . 1 . 026 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . 0.527 ' HA2' ' HB2' ' A' ' 31' ' ' TRP . . . -66.83 -5.78 33.59 Favored Glycine 0 N--CA 1.439 -1.131 0 CA-C-N 114.229 -1.35 . . . . 0.0 110.902 179.94 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 12.7 m -76.38 -44.66 35.27 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-O 121.419 0.628 . . . . 0.0 109.813 175.792 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.582 ' HB ' ' CH2' ' A' ' 95' ' ' TRP . 0.1 OUTLIER -71.01 -35.94 61.39 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.594 0 N-CA-C 108.113 -1.069 . . . . 0.0 108.113 178.078 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 31' ' ' TRP . . . . . 0.688 ' CD1' HG13 ' A' ' 83' ' ' ILE . 48.9 m95 -71.75 -35.64 70.18 Favored 'General case' 0 N--CA 1.442 -0.865 0 CA-C-N 114.658 -1.156 . . . . 0.0 110.19 -178.975 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 20.4 t70 -77.0 -29.31 55.41 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.342 178.908 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -68.55 -35.06 76.9 Favored 'General case' 0 N--CA 1.444 -0.732 0 N-CA-C 109.671 -0.492 . . . . 0.0 109.671 175.215 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . 0.572 ' HA ' ' HB3' ' A' ' 101' ' ' CYS . 58.0 mt -67.64 -49.34 71.15 Favored 'Isoleucine or valine' 0 C--O 1.233 0.199 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.402 173.908 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . 0.443 ' O ' ' HB2' ' A' ' 39' ' ' ALA . . . -59.08 -41.26 87.6 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.778 -0.646 . . . . 0.0 110.454 178.951 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . 0.402 ' HA2' ' N ' ' A' ' 41' ' ' GLY . . . -72.09 -18.95 78.2 Favored Glycine 0 N--CA 1.449 -0.484 0 CA-C-N 115.453 -0.794 . . . . 0.0 111.649 179.069 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 3.6 t -84.24 -62.93 1.44 Allowed 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.433 -0.383 . . . . 0.0 111.463 -178.088 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . 0.575 ' HB2' ' SG ' ' A' ' 101' ' ' CYS . 15.9 tt0 -89.06 -33.2 17.21 Favored 'General case' 0 C--N 1.324 -0.517 0 C-N-CA 120.532 -0.467 . . . . 0.0 110.602 -170.908 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . 0.443 ' HB2' ' O ' ' A' ' 35' ' ' ALA . . . -91.18 -12.36 35.62 Favored 'General case' 0 N--CA 1.453 -0.286 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.301 -178.857 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 82.0 4.93 90.11 Favored Glycine 0 CA--C 1.505 -0.552 0 N-CA-C 109.923 -1.271 . . . . 0.0 109.923 -178.857 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . 0.402 ' N ' ' HA2' ' A' ' 36' ' ' GLY . . . 87.3 61.56 1.55 Allowed Glycine 0 N--CA 1.434 -1.482 0 CA-C-N 113.946 -1.127 . . . . 0.0 111.369 -175.291 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 42' ' ' ASN . . . . . 0.634 ' HB3' ' HB ' ' A' ' 45' ' ' ILE . 0.3 OUTLIER -144.96 96.57 2.88 Favored 'General case' 0 N--CA 1.448 -0.559 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 -177.217 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 43' ' ' TRP . . . . . 0.744 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 46.3 m95 -79.04 -14.1 59.37 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.968 -175.223 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -107.49 14.24 26.03 Favored 'General case' 0 C--N 1.316 -0.861 0 CA-C-N 115.525 -0.761 . . . . 0.0 111.399 179.962 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.634 ' HB ' ' HB3' ' A' ' 42' ' ' ASN . 8.6 tt -78.13 144.56 11.11 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.738 0 CA-C-O 120.994 0.426 . . . . 0.0 110.181 -178.612 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 29.0 t-20 -150.26 86.74 1.43 Allowed 'General case' 0 C--N 1.31 -1.141 0 CA-C-O 121.437 0.637 . . . . 0.0 109.664 178.952 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 6.1 p -68.7 -25.79 64.96 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.122 -0.945 . . . . 0.0 111.464 -178.342 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 100.98 21.01 12.44 Favored Glycine 0 N--CA 1.445 -0.712 0 C-N-CA 120.985 -0.626 . . . . 0.0 111.545 -179.652 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 4.3 m-20 -81.42 -4.05 54.67 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 121.229 0.538 . . . . 0.0 111.029 -179.243 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 95.91 -13.6 65.9 Favored Glycine 0 N--CA 1.446 -0.635 0 N-CA-C 110.038 -1.225 . . . . 0.0 110.038 -176.592 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 51' ' ' TYR . . . . . 0.669 ' CD1' ' HB2' ' A' ' 58' ' ' ASP . 0.1 OUTLIER -102.81 144.99 30.43 Favored 'General case' 0 N--CA 1.446 -0.643 0 N-CA-C 107.631 -1.248 . . . . 0.0 107.631 174.048 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 52' ' ' TYR . . . . . 0.825 ' O ' ' HA ' ' A' ' 56' ' ' GLN . 10.3 m-85 -108.61 164.81 12.03 Favored 'General case' 0 C--N 1.308 -1.205 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.717 -172.147 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.451 ' HA2' HG22 ' A' ' 45' ' ' ILE . . . -58.13 172.73 3.27 Favored Glycine 0 C--O 1.229 -0.182 0 N-CA-C 115.702 1.041 . . . . 0.0 115.702 -166.107 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . 0.631 ' CA ' ' HA ' ' A' ' 43' ' ' TRP . . . 91.55 -111.02 3.93 Favored Glycine 0 N--CA 1.446 -0.671 0 CA-C-N 114.86 -0.67 . . . . 0.0 111.509 -178.799 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 1.9 m -83.23 -2.64 6.79 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 CA-C-O 122.077 0.942 . . . . 0.0 110.454 176.22 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 56' ' ' GLN . . . . . 0.825 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 5.9 tt0 50.49 52.1 15.51 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 113.436 -1.711 . . . . 0.0 114.18 168.921 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . 0.415 ' HZ ' HG13 ' A' ' 85' ' ' VAL . 7.2 p90 -105.74 158.49 16.69 Favored 'General case' 0 C--N 1.321 -0.652 0 C-N-CA 119.123 -1.031 . . . . 0.0 110.368 170.788 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.669 ' HB2' ' CD1' ' A' ' 51' ' ' TYR . 0.5 OUTLIER -64.54 144.19 57.38 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 114.888 -1.051 . . . . 0.0 112.016 -168.793 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . 0.694 ' HB2' ' CE1' ' A' ' 52' ' ' TYR . 4.6 tp-100 -63.1 -30.29 71.48 Favored 'General case' 0 C--O 1.218 -0.555 0 CA-C-N 114.841 -1.072 . . . . 0.0 111.54 -178.562 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -64.83 -44.17 95.08 Favored Glycine 0 C--N 1.316 -0.529 0 N-CA-C 110.84 -0.904 . . . . 0.0 110.84 174.949 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 88.6 m -71.36 -40.18 70.82 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-O 121.093 0.473 . . . . 0.0 111.207 175.299 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 62' ' ' TRP . . . . . 0.757 ' CZ3' HG12 ' A' ' 85' ' ' VAL . 29.5 t-105 -55.12 -46.59 75.62 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-O 121.492 0.663 . . . . 0.0 109.694 173.229 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . 0.562 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 32.0 tt0 -67.24 -35.2 79.05 Favored 'General case' 0 C--N 1.316 -0.876 0 CA-C-N 114.957 -1.019 . . . . 0.0 111.01 179.305 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -64.89 -40.85 95.74 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.936 -0.574 . . . . 0.0 110.958 -178.509 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . 0.432 ' HB3' ' HB ' ' A' ' 88' ' ' VAL . 34.8 m-80 -81.68 -7.29 59.58 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.045 -0.525 . . . . 0.0 111.085 177.039 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 87.14 45.1 5.45 Favored Glycine 0 C--N 1.331 0.269 0 C-N-CA 121.022 -0.609 . . . . 0.0 112.812 173.639 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . 0.574 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -79.67 -22.34 64.49 Favored Glycine 0 N--CA 1.441 -0.973 0 C-N-CA 121.184 -0.532 . . . . 0.0 112.783 -175.861 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 0.821 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 6.7 mp -60.66 -23.67 64.98 Favored 'General case' 0 C--N 1.328 -0.341 0 N-CA-C 112.345 0.498 . . . . 0.0 112.345 -172.338 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 35.7 ptt180 -71.56 -27.02 62.87 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-O 120.933 0.397 . . . . 0.0 110.374 178.882 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 70' ' ' TYR . . . . . 0.98 ' HB3' ' HG2' ' A' ' 81' ' ' GLU . 51.8 m-85 -82.98 -34.41 26.38 Favored 'General case' 0 N--CA 1.444 -0.746 0 N-CA-C 107.09 -1.448 . . . . 0.0 107.09 174.056 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.522 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 167.25 130.12 0.04 OUTLIER Pre-proline 0 C--N 1.327 -0.397 0 CA-C-N 112.456 -2.157 . . . . 0.0 108.866 -178.783 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 72' ' ' PRO . . . . . 0.821 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 36.6 Cg_endo -67.97 29.58 0.14 Allowed 'Trans proline' 0 N--CA 1.476 0.487 0 C-N-CA 122.862 2.374 . . . . 0.0 113.877 179.311 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 73' ' ' ARG . . . . . 0.496 ' H ' ' C ' ' A' ' 71' ' ' ALA . 14.7 ptm180 -176.27 140.15 0.38 Allowed 'General case' 0 C--N 1.321 -0.66 0 N-CA-C 108.665 -0.865 . . . . 0.0 108.665 178.136 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . 0.543 ' HA ' ' CH2' ' A' ' 62' ' ' TRP . . . -66.47 -27.15 67.57 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.788 -0.642 . . . . 0.0 111.795 -174.949 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . 0.442 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 21.1 p-10 -86.57 -4.92 59.24 Favored 'General case' 0 C--N 1.324 -0.532 0 C-N-CA 120.832 -0.347 . . . . 0.0 111.61 -174.825 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 65.2 tp -97.85 -28.61 13.77 Favored 'General case' 0 C--N 1.322 -0.604 0 N-CA-C 108.97 -0.752 . . . . 0.0 108.97 171.31 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . 0.66 ' HB3' ' HB3' ' A' ' 81' ' ' GLU . . . -78.05 148.54 34.24 Favored 'General case' 0 N--CA 1.441 -0.919 0 CA-C-N 115.12 -0.946 . . . . 0.0 109.934 175.309 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 47.0 p -91.79 -175.61 4.2 Favored 'General case' 0 C--N 1.31 -1.135 0 CA-C-N 115.608 -0.724 . . . . 0.0 109.982 -178.617 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . 0.744 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 43.1 mtp-105 -53.7 -54.84 32.2 Favored 'General case' 0 CA--C 1.515 -0.382 0 CA-C-O 120.979 0.419 . . . . 0.0 110.167 -178.31 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 2.6 pm0 -56.85 -39.02 73.52 Favored 'General case' 0 C--N 1.318 -0.787 0 CA-C-N 115.454 -0.794 . . . . 0.0 111.486 -176.362 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 81' ' ' GLU . . . . . 0.98 ' HG2' ' HB3' ' A' ' 70' ' ' TYR . 1.0 OUTLIER -66.93 -50.8 61.23 Favored 'General case' 0 C--N 1.323 -0.582 0 N-CA-C 112.419 0.526 . . . . 0.0 112.419 175.188 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 82' ' ' GLN . . . . . 0.604 ' HB2' ' HZ3' ' A' ' 43' ' ' TRP . 56.1 mt-30 -61.45 -34.89 76.18 Favored 'General case' 0 CA--C 1.514 -0.417 0 C-N-CA 121.023 -0.271 . . . . 0.0 110.318 -178.402 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . 0.688 HG13 ' CD1' ' A' ' 31' ' ' TRP . 1.4 mp -60.12 -46.19 94.78 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.089 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.76 173.518 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 84' ' ' ALA . . . . . 0.609 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -62.6 -44.75 95.53 Favored 'General case' 0 C--O 1.238 0.498 0 CA-C-O 121.533 0.683 . . . . 0.0 111.663 -172.813 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . 0.757 HG12 ' CZ3' ' A' ' 62' ' ' TRP . 2.7 p -70.68 -43.66 77.24 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.721 0 CA-C-N 115.949 -0.569 . . . . 0.0 111.027 -179.91 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 86' ' ' ALA . . . . . 0.44 ' HB3' ' CH2' ' A' ' 31' ' ' TRP . . . -61.04 -28.4 69.03 Favored 'General case' 0 N--CA 1.451 -0.415 0 CA-C-N 115.764 -0.653 . . . . 0.0 109.69 174.396 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 87' ' ' GLU . . . . . 0.685 ' HG3' ' O ' ' A' ' 83' ' ' ILE . 30.6 mt-10 -61.18 -43.84 98.25 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.398 -0.819 . . . . 0.0 109.888 179.203 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.669 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 41.2 t -61.81 -46.08 97.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-O 121.178 0.513 . . . . 0.0 109.799 176.244 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 89' ' ' THR . . . . . 0.805 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 0.2 OUTLIER -67.42 -45.95 74.6 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 115.961 -0.563 . . . . 0.0 111.499 -175.25 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 90' ' ' ARG . . . . . 0.629 ' HD3' ' HZ2' ' A' ' 31' ' ' TRP . 23.2 ptt180 -62.87 -34.23 76.94 Favored 'General case' 0 C--O 1.221 -0.418 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.742 -177.259 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 91' ' ' LEU . . . . . 0.669 ' HG ' ' O ' ' A' ' 88' ' ' VAL . 4.2 pp -73.55 -23.78 60.02 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-O 120.951 0.405 . . . . 0.0 110.904 -171.82 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . 0.566 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 4.7 mtm180 -82.06 -46.91 13.26 Favored 'General case' 0 CA--C 1.51 -0.588 0 CA-C-O 121.426 0.632 . . . . 0.0 109.608 -179.11 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 93' ' ' GLN . . . . . 0.475 ' NE2' HG21 ' A' ' 89' ' ' THR . 13.2 pt20 -103.42 -27.95 12.1 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 114.759 -1.109 . . . . 0.0 113.965 -168.344 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 92.02 39.98 5.32 Favored Glycine 0 C--N 1.332 0.338 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.436 175.983 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 95' ' ' TRP . . . . . 0.606 ' HZ2' HH11 ' A' ' 90' ' ' ARG . 33.2 m95 70.06 9.62 7.13 Favored 'General case' 0 C--O 1.219 -0.55 0 C-N-CA 123.338 0.655 . . . . 0.0 109.609 -179.933 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -59.44 -41.78 97.23 Favored Glycine 0 N--CA 1.453 -0.223 0 CA-C-N 115.28 -0.873 . . . . 0.0 113.476 -178.68 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . 0.413 ' O ' ' HD3' ' A' ' 99' ' ' PRO . . . -70.03 -17.87 63.28 Favored 'General case' 0 N--CA 1.464 0.275 0 CA-C-N 117.117 0.459 . . . . 0.0 110.793 179.772 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 98' ' ' TRP . . . . . 0.805 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 24.6 m-90 -95.65 107.84 36.12 Favored Pre-proline 0 N--CA 1.448 -0.564 0 N-CA-C 108.794 -0.817 . . . . 0.0 108.794 176.171 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 99' ' ' PRO . . . . . 0.427 ' HD3' ' HA ' ' A' ' 98' ' ' TRP . 41.7 Cg_exo -63.77 -132.46 0.0 OUTLIER 'Trans proline' 0 CA--C 1.539 0.746 0 C-N-CA 123.857 3.038 . . . . 0.0 114.408 -173.804 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 18.3 t -55.48 -26.24 19.0 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.252 0 CA-C-O 120.82 0.343 . . . . 0.0 111.497 -174.623 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 101' ' ' CYS . . . . . 0.575 ' SG ' ' HB2' ' A' ' 38' ' ' GLU . 75.0 m -64.75 -34.41 78.27 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 116.339 -0.392 . . . . 0.0 111.528 -178.553 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -70.03 -40.78 74.97 Favored 'General case' 0 CA--C 1.519 -0.232 0 CA-C-O 120.971 0.415 . . . . 0.0 110.226 177.642 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -63.09 -39.38 94.52 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.353 176.904 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 104' ' ' ARG . . . . . 0.444 ' HA ' ' NE ' ' A' ' 104' ' ' ARG . 14.9 mmp_? -71.69 -31.49 66.82 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.605 -0.725 . . . . 0.0 111.003 178.844 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 105' ' ' ALA . . . . . 0.473 ' CB ' HG22 ' A' ' 30' ' ' ILE . . . -80.71 -23.95 39.14 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 120.989 0.423 . . . . 0.0 111.735 -177.356 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 97.98 59.3 0.95 Allowed Glycine 0 CA--C 1.522 0.471 0 C-N-CA 120.983 -0.627 . . . . 0.0 112.096 -176.707 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -57.62 146.72 29.56 Favored 'General case' 0 C--N 1.329 -0.311 0 C-N-CA 123.274 0.629 . . . . 0.0 112.356 -177.612 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 108' ' ' ARG . . . . . 0.693 ' O ' ' HD3' ' A' ' 108' ' ' ARG . 0.0 OUTLIER . . . . . 0 C--O 1.25 1.09 0 CA-C-O 118.545 -0.74 . . . . 0.0 110.594 -175.899 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.46 ' O ' HG12 ' A' ' 30' ' ' ILE . 5.8 m-20 . . . . . 0 CA--C 1.504 -0.804 0 CA-C-O 121.874 0.845 . . . . 0.0 109.523 . . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . 0.579 ' HA2' ' HB2' ' A' ' 31' ' ' TRP . . . -69.1 -9.31 60.01 Favored Glycine 0 N--CA 1.437 -1.266 0 N-CA-C 110.302 -1.119 . . . . 0.0 110.302 176.222 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 17.6 m -76.97 -47.83 19.72 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 121.405 0.622 . . . . 0.0 110.073 177.12 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.766 HG21 ' O ' ' A' ' 105' ' ' ALA . 4.2 pt -71.67 -34.64 52.9 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.923 0 CA-C-N 115.087 -0.96 . . . . 0.0 109.641 176.844 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 31' ' ' TRP . . . . . 0.667 ' CZ2' ' HD3' ' A' ' 90' ' ' ARG . 12.1 m95 -63.75 -37.18 86.41 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 115.334 -0.848 . . . . 0.0 109.528 175.652 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 36.2 t70 -77.63 -31.32 52.7 Favored 'General case' 0 N--CA 1.448 -0.54 0 CA-C-N 115.837 -0.62 . . . . 0.0 111.133 179.793 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . 0.514 ' HB1' ' HB3' ' A' ' 105' ' ' ALA . . . -69.0 -33.75 74.17 Favored 'General case' 0 N--CA 1.446 -0.642 0 C-N-CA 120.409 -0.516 . . . . 0.0 109.727 176.706 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . 0.469 HG13 ' O ' ' A' ' 30' ' ' ILE . 74.1 mt -67.43 -42.81 87.66 Favored 'Isoleucine or valine' 0 C--O 1.233 0.215 0 CA-C-O 121.132 0.491 . . . . 0.0 109.722 171.72 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . 0.597 ' HA ' ' O ' ' A' ' 54' ' ' GLY . . . -57.76 -35.25 70.48 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.574 -0.739 . . . . 0.0 110.452 175.917 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . 0.493 ' HA2' ' N ' ' A' ' 41' ' ' GLY . . . -78.67 -5.44 88.29 Favored Glycine 0 N--CA 1.449 -0.46 0 CA-C-N 115.267 -0.879 . . . . 0.0 112.138 179.412 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 42.6 t -103.07 -54.17 2.67 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 120.742 0.306 . . . . 0.0 110.892 -178.483 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . 0.454 ' HG2' ' SG ' ' A' ' 101' ' ' CYS . 30.1 mm-40 -87.06 -31.05 20.72 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 121.162 0.506 . . . . 0.0 110.758 -174.717 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -103.22 -10.51 18.71 Favored 'General case' 0 N--CA 1.447 -0.6 0 CA-C-N 116.029 -0.532 . . . . 0.0 111.262 -179.043 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 76.22 14.23 82.52 Favored Glycine 0 CA--C 1.503 -0.7 0 N-CA-C 109.864 -1.294 . . . . 0.0 109.864 -178.455 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . 0.493 ' N ' ' HA2' ' A' ' 36' ' ' GLY . . . 81.66 62.53 1.93 Allowed Glycine 0 N--CA 1.432 -1.596 0 CA-C-N 113.94 -1.13 . . . . 0.0 111.82 -176.568 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 42' ' ' ASN . . . . . 0.559 ' HB3' ' HB ' ' A' ' 45' ' ' ILE . 3.4 t30 -155.87 96.97 1.78 Allowed 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 109.136 -0.69 . . . . 0.0 109.136 -178.557 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 43' ' ' TRP . . . . . 0.719 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 33.0 m95 -73.35 -11.04 60.35 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-O 121.285 0.564 . . . . 0.0 111.007 -175.319 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -106.25 14.91 26.91 Favored 'General case' 0 C--N 1.314 -0.952 0 CA-C-N 115.575 -0.739 . . . . 0.0 111.432 -179.059 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.823 HG21 ' HA2' ' A' ' 53' ' ' GLY . 7.0 tt -78.86 142.92 13.39 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.793 0 CA-C-O 121.138 0.494 . . . . 0.0 110.121 -178.106 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . 0.545 ' ND2' HH21 ' A' ' 73' ' ' ARG . 9.3 t-20 -148.29 90.05 1.77 Allowed 'General case' 0 C--N 1.312 -1.027 0 CA-C-O 121.114 0.483 . . . . 0.0 109.958 178.923 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 13.9 p -76.48 -16.65 59.6 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 115.87 -0.605 . . . . 0.0 111.724 -176.92 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 94.93 21.99 24.31 Favored Glycine 0 N--CA 1.447 -0.625 0 N-CA-C 110.942 -0.863 . . . . 0.0 110.942 -177.931 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 10.4 t-20 -86.1 -12.27 50.48 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 121.302 0.573 . . . . 0.0 110.964 -175.098 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . 0.415 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 95.21 -9.47 69.83 Favored Glycine 0 N--CA 1.448 -0.517 0 N-CA-C 110.184 -1.166 . . . . 0.0 110.184 -175.386 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 51' ' ' TYR . . . . . 0.482 ' N ' ' CD1' ' A' ' 51' ' ' TYR . 0.5 OUTLIER -110.73 146.68 35.87 Favored 'General case' 0 CA--C 1.505 -0.777 0 N-CA-C 105.914 -1.884 . . . . 0.0 105.914 175.373 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 52' ' ' TYR . . . . . 0.574 ' O ' ' HA ' ' A' ' 56' ' ' GLN . 45.0 m-85 -112.9 167.58 10.39 Favored 'General case' 0 C--N 1.304 -1.412 0 C-N-CA 119.623 -0.831 . . . . 0.0 112.905 -167.835 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.823 ' HA2' HG21 ' A' ' 45' ' ' ILE . . . -54.86 157.15 7.19 Favored Glycine 0 N--CA 1.446 -0.682 0 CA-C-N 114.787 -1.097 . . . . 0.0 114.105 -171.698 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . 0.676 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 97.03 -109.86 3.93 Favored Glycine 0 N--CA 1.437 -1.244 0 C-N-CA 120.803 -0.713 . . . . 0.0 111.72 -178.411 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.524 HG21 ' HG2' ' A' ' 82' ' ' GLN . 3.1 t -84.83 -0.46 5.94 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 CA-C-O 121.771 0.796 . . . . 0.0 110.354 -176.344 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 56' ' ' GLN . . . . . 0.574 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 8.1 tp-100 56.66 50.49 12.61 Favored 'General case' 0 C--N 1.339 0.141 0 CA-C-N 114.195 -1.366 . . . . 0.0 112.685 168.289 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . 0.445 ' CE1' ' HB2' ' A' ' 86' ' ' ALA . 7.8 p90 -116.98 162.76 17.26 Favored 'General case' 0 C--N 1.321 -0.659 0 C-N-CA 120.105 -0.638 . . . . 0.0 111.083 175.287 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.481 ' HB3' ' CE1' ' A' ' 51' ' ' TYR . 6.4 p-10 -76.28 160.17 29.9 Favored 'General case' 0 C--N 1.324 -0.511 0 N-CA-C 113.594 0.961 . . . . 0.0 113.594 -162.957 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . 0.403 ' HB2' ' CE2' ' A' ' 52' ' ' TYR . 13.1 tp60 -57.24 -39.45 75.59 Favored 'General case' 0 N--CA 1.443 -0.808 0 CA-C-N 114.036 -1.438 . . . . 0.0 111.563 178.888 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -66.74 -49.89 51.99 Favored Glycine 0 C--O 1.225 -0.436 0 CA-C-N 115.653 -0.703 . . . . 0.0 112.468 -175.746 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 93.6 m -60.68 -44.06 96.96 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 121.15 0.5 . . . . 0.0 110.681 176.051 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 62' ' ' TRP . . . . . 0.438 ' HE3' ' CZ ' ' A' ' 57' ' ' PHE . 52.3 t-105 -57.05 -48.61 78.11 Favored 'General case' 0 N--CA 1.445 -0.68 0 CA-C-N 115.331 -0.849 . . . . 0.0 109.895 176.667 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . 0.505 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 31.4 tt0 -67.48 -35.09 78.48 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-N 115.141 -0.936 . . . . 0.0 110.875 -177.593 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -67.03 -41.67 86.16 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.76 -0.655 . . . . 0.0 111.04 -176.639 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . 0.401 ' HB2' HG12 ' A' ' 85' ' ' VAL . 8.1 m120 -77.69 -9.06 58.78 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 121.112 0.482 . . . . 0.0 110.156 176.137 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 88.35 45.2 5.07 Favored Glycine 0 C--N 1.332 0.341 0 CA-C-N 115.734 -0.666 . . . . 0.0 112.395 174.05 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . 0.514 ' HA2' ' CD1' ' A' ' 70' ' ' TYR . . . -79.02 -20.28 70.62 Favored Glycine 0 N--CA 1.442 -0.964 0 C-N-CA 120.883 -0.675 . . . . 0.0 112.879 -172.937 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 0.828 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 6.7 mp -61.27 -24.05 66.12 Favored 'General case' 0 N--CA 1.45 -0.434 0 N-CA-C 112.281 0.475 . . . . 0.0 112.281 -173.72 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . 0.5 ' HG3' ' N ' ' A' ' 70' ' ' TYR . 0.7 OUTLIER -70.62 -29.42 65.8 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 121.206 0.527 . . . . 0.0 110.135 176.143 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 70' ' ' TYR . . . . . 0.839 ' HB3' ' HB3' ' A' ' 81' ' ' GLU . 71.7 m-85 -79.7 -34.35 40.23 Favored 'General case' 0 N--CA 1.446 -0.655 0 N-CA-C 107.329 -1.36 . . . . 0.0 107.329 176.449 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.695 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 162.51 127.57 0.01 OUTLIER Pre-proline 0 C--O 1.218 -0.558 0 CA-C-N 112.401 -2.182 . . . . 0.0 107.098 -178.286 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 72' ' ' PRO . . . . . 0.828 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 17.9 Cg_exo -57.13 -1.97 0.47 Allowed 'Trans proline' 0 C--N 1.332 -0.34 0 C-N-CA 122.991 2.46 . . . . 0.0 114.058 -177.453 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 73' ' ' ARG . . . . . 0.545 HH21 ' ND2' ' A' ' 46' ' ' ASN . 12.5 ptm180 -152.56 141.89 21.55 Favored 'General case' 0 C--N 1.319 -0.726 0 N-CA-C 109.64 -0.504 . . . . 0.0 109.64 176.998 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . 0.556 ' HB3' ' HB2' ' A' ' 52' ' ' TYR . . . -63.44 -22.07 66.67 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.509 -0.769 . . . . 0.0 113.028 -176.798 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . 0.496 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 5.2 p-10 -88.29 2.92 51.38 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 121.328 0.585 . . . . 0.0 110.847 -179.781 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.443 ' HB3' ' HB2' ' A' ' 71' ' ' ALA . 53.5 tp -106.27 -34.86 7.35 Favored 'General case' 0 C--N 1.321 -0.654 0 N-CA-C 108.858 -0.793 . . . . 0.0 108.858 174.246 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . 0.783 ' HB3' ' HB2' ' A' ' 81' ' ' GLU . . . -79.83 158.12 26.85 Favored 'General case' 0 N--CA 1.446 -0.627 0 CA-C-N 114.99 -1.005 . . . . 0.0 110.057 174.512 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 25.4 p -100.77 -171.64 2.04 Favored 'General case' 0 C--N 1.314 -0.965 0 CA-C-N 116.2 -0.455 . . . . 0.0 109.8 -179.435 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . 0.719 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 35.9 mtt85 -49.21 -51.95 29.91 Favored 'General case' 0 C--O 1.218 -0.559 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.79 -179.959 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -57.45 -47.61 81.35 Favored 'General case' 0 C--N 1.321 -0.666 0 N-CA-C 112.148 0.425 . . . . 0.0 112.148 -174.854 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 81' ' ' GLU . . . . . 0.839 ' HB3' ' HB3' ' A' ' 70' ' ' TYR . 60.6 mp0 -65.6 -51.23 61.28 Favored 'General case' 0 CA--C 1.517 -0.318 0 CA-C-O 120.983 0.421 . . . . 0.0 111.403 177.228 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 82' ' ' GLN . . . . . 0.524 ' HG2' HG21 ' A' ' 55' ' ' VAL . 4.2 tt0 -65.0 -34.35 78.24 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.606 -0.724 . . . . 0.0 111.361 -173.657 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . 0.583 ' O ' ' HB3' ' A' ' 87' ' ' GLU . 8.1 mt -61.63 -46.13 97.2 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 N-CA-C 109.471 -0.566 . . . . 0.0 109.471 174.193 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 84' ' ' ALA . . . . . . . . . . . . . . . -61.37 -47.48 85.68 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.205 -176.825 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . 0.401 HG12 ' HB2' ' A' ' 65' ' ' ASN . 46.5 t -65.97 -50.28 70.85 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-N 116.137 -0.483 . . . . 0.0 112.207 -179.997 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 86' ' ' ALA . . . . . 0.445 ' HB2' ' CE1' ' A' ' 57' ' ' PHE . . . -63.87 -32.05 73.44 Favored 'General case' 0 CA--C 1.515 -0.394 0 CA-C-O 121.397 0.618 . . . . 0.0 110.437 179.702 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 87' ' ' GLU . . . . . 0.653 ' HA ' ' HG2' ' A' ' 90' ' ' ARG . 0.4 OUTLIER -71.32 -27.28 63.28 Favored 'General case' 0 C--N 1.317 -0.844 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.871 -178.136 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.678 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 94.6 t -61.22 -44.17 97.85 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.254 0 N-CA-C 108.701 -0.852 . . . . 0.0 108.701 169.295 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 89' ' ' THR . . . . . 0.665 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 0.3 OUTLIER -66.81 -43.81 82.87 Favored 'General case' 0 C--N 1.316 -0.852 0 CA-C-N 115.582 -0.735 . . . . 0.0 111.375 -179.778 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 90' ' ' ARG . . . . . 0.667 ' HD3' ' CZ2' ' A' ' 31' ' ' TRP . 20.7 ptt180 -59.88 -35.11 74.13 Favored 'General case' 0 C--O 1.222 -0.392 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.707 -176.197 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 91' ' ' LEU . . . . . 0.678 ' HG ' ' O ' ' A' ' 88' ' ' VAL . 4.6 pp -74.44 -24.77 59.12 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 121.042 0.448 . . . . 0.0 111.102 -171.678 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . 0.492 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 2.5 mtm180 -81.79 -45.24 15.87 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-O 121.568 0.699 . . . . 0.0 109.514 -178.044 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 6.6 pt20 -104.27 -28.06 11.63 Favored 'General case' 0 C--N 1.322 -0.618 0 N-CA-C 113.59 0.959 . . . . 0.0 113.59 -169.696 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 88.35 44.23 5.35 Favored Glycine 0 CA--C 1.507 -0.419 0 C-N-CA 120.625 -0.797 . . . . 0.0 112.136 176.195 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 95' ' ' TRP . . . . . 0.522 ' HZ2' HH11 ' A' ' 90' ' ' ARG . 23.6 m95 66.87 13.63 9.5 Favored 'General case' 0 C--O 1.218 -0.6 0 CA-C-O 121.173 0.511 . . . . 0.0 109.812 178.396 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -65.53 -31.62 80.74 Favored Glycine 0 N--CA 1.451 -0.304 0 CA-C-N 115.588 -0.733 . . . . 0.0 113.132 177.289 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -76.49 -21.52 55.72 Favored 'General case' 0 CA--C 1.515 -0.385 0 CA-C-O 121.152 0.501 . . . . 0.0 110.411 178.508 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 98' ' ' TRP . . . . . 0.665 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 25.1 m-90 -100.26 108.62 53.41 Favored Pre-proline 0 N--CA 1.443 -0.803 0 CA-C-N 115.521 -0.763 . . . . 0.0 109.202 178.42 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 99' ' ' PRO . . . . . 0.446 ' HD3' ' HA ' ' A' ' 98' ' ' TRP . 52.5 Cg_exo -62.25 -138.46 0.0 OUTLIER 'Trans proline' 0 CA--C 1.535 0.56 0 C-N-CA 123.831 3.021 . . . . 0.0 114.265 -174.026 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 3.4 m -54.11 -26.3 14.6 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.915 -177.882 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 101' ' ' CYS . . . . . 0.454 ' SG ' ' HG2' ' A' ' 38' ' ' GLU . 62.0 m -56.69 -39.64 74.16 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-N 115.75 -0.659 . . . . 0.0 111.525 178.035 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -70.8 -44.24 67.0 Favored 'General case' 0 CA--C 1.519 -0.23 0 CA-C-O 121.008 0.432 . . . . 0.0 110.716 179.871 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -60.68 -44.15 96.85 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.634 179.724 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -66.87 -34.03 76.91 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.712 -0.676 . . . . 0.0 111.049 176.957 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 105' ' ' ALA . . . . . 0.766 ' O ' HG21 ' A' ' 30' ' ' ILE . . . -76.51 -26.77 55.6 Favored 'General case' 0 C--N 1.331 -0.238 0 N-CA-C 111.895 0.332 . . . . 0.0 111.895 -175.285 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 111.62 60.28 0.46 Allowed Glycine 0 CA--C 1.521 0.415 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.234 -175.31 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -70.11 148.61 48.52 Favored 'General case' 0 C--N 1.327 -0.375 0 C-N-CA 122.579 0.351 . . . . 0.0 110.891 -178.94 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 108' ' ' ARG . . . . . 0.439 ' O ' ' HD3' ' A' ' 108' ' ' ARG . 0.0 OUTLIER . . . . . 0 C--O 1.245 0.825 0 CA-C-O 118.559 -0.734 . . . . 0.0 110.318 -177.082 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.498 ' O ' HG12 ' A' ' 30' ' ' ILE . 7.0 m-20 . . . . . 0 CA--C 1.504 -0.803 0 CA-C-O 121.791 0.805 . . . . 0.0 108.849 . . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . 0.597 ' HA2' ' HB2' ' A' ' 31' ' ' TRP . . . -66.25 -5.05 25.93 Favored Glycine 0 N--CA 1.44 -1.092 0 CA-C-N 114.488 -1.233 . . . . 0.0 110.581 176.721 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 22.3 m -77.2 -40.44 45.15 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 120.989 0.423 . . . . 0.0 109.98 174.053 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.507 ' O ' HG13 ' A' ' 34' ' ' ILE . 0.6 OUTLIER -65.25 -38.92 83.82 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.513 0 N-CA-C 107.038 -1.467 . . . . 0.0 107.038 174.108 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 31' ' ' TRP . . . . . 0.672 ' CD1' HG13 ' A' ' 83' ' ' ILE . 31.7 m95 -72.1 -36.49 69.48 Favored 'General case' 0 N--CA 1.438 -1.075 0 CA-C-N 113.598 -1.637 . . . . 0.0 111.031 -175.998 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 6.6 t70 -72.63 -34.65 67.46 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.016 178.203 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -67.3 -37.01 82.67 Favored 'General case' 0 N--CA 1.445 -0.685 0 C-N-CA 120.64 -0.424 . . . . 0.0 109.923 177.119 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . 0.507 HG13 ' O ' ' A' ' 30' ' ' ILE . 74.2 mt -67.66 -46.43 82.79 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.171 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.523 174.491 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -58.91 -34.22 71.45 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 121.215 0.531 . . . . 0.0 110.516 177.563 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . 0.528 ' HA2' ' N ' ' A' ' 41' ' ' GLY . . . -78.83 -7.03 88.51 Favored Glycine 0 N--CA 1.45 -0.418 0 CA-C-N 115.617 -0.72 . . . . 0.0 111.719 178.616 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 46.0 t -94.81 -58.1 2.27 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-O 120.775 0.321 . . . . 0.0 110.607 -179.221 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . 0.416 ' HG3' ' SG ' ' A' ' 101' ' ' CYS . 40.2 mt-10 -89.29 -25.61 21.58 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.379 -0.373 . . . . 0.0 111.345 -173.52 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -107.53 -12.95 15.18 Favored 'General case' 0 C--N 1.324 -0.527 0 C-N-CA 120.444 -0.502 . . . . 0.0 111.869 -179.011 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 78.72 13.57 83.01 Favored Glycine 0 CA--C 1.503 -0.665 0 N-CA-C 109.789 -1.324 . . . . 0.0 109.789 -177.371 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . 0.528 ' N ' ' HA2' ' A' ' 36' ' ' GLY . . . 78.87 61.52 2.39 Favored Glycine 0 N--CA 1.435 -1.391 0 CA-C-N 114.069 -1.066 . . . . 0.0 111.855 -177.053 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 42' ' ' ASN . . . . . 0.583 HD21 ' HB ' ' A' ' 45' ' ' ILE . 4.1 t30 -145.66 96.98 2.9 Favored 'General case' 0 N--CA 1.45 -0.449 0 N-CA-C 109.044 -0.724 . . . . 0.0 109.044 -177.968 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 43' ' ' TRP . . . . . 0.852 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 16.1 m95 -82.72 -1.42 51.34 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-O 121.554 0.692 . . . . 0.0 111.156 -170.412 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -113.62 9.55 17.89 Favored 'General case' 0 C--N 1.314 -0.967 0 CA-C-N 115.039 -0.982 . . . . 0.0 111.095 178.713 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.94 HG23 ' HA2' ' A' ' 53' ' ' GLY . 9.5 tt -72.65 143.22 14.2 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.68 0 CA-C-O 121.177 0.513 . . . . 0.0 110.654 -175.603 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 15.3 t-20 -150.8 97.05 2.43 Favored 'General case' 0 C--N 1.311 -1.1 0 N-CA-C 109.399 -0.593 . . . . 0.0 109.399 177.732 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 11.1 p -74.89 -16.67 60.66 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 115.798 -0.637 . . . . 0.0 111.006 -177.7 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 101.4 13.03 34.09 Favored Glycine 0 N--CA 1.445 -0.705 0 CA-C-N 115.818 -0.628 . . . . 0.0 111.612 178.059 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 31.7 p-10 -91.65 3.01 56.07 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.801 0.334 . . . . 0.0 111.4 -176.381 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . 0.403 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 94.9 -2.54 66.55 Favored Glycine 0 N--CA 1.449 -0.494 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.265 179.909 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 51' ' ' TYR . . . . . 0.526 ' HA ' ' HA ' ' A' ' 58' ' ' ASP . 0.4 OUTLIER -108.59 162.6 13.99 Favored 'General case' 0 CA--C 1.515 -0.374 0 N-CA-C 108.464 -0.939 . . . . 0.0 108.464 176.874 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 52' ' ' TYR . . . . . 0.616 ' O ' ' HA ' ' A' ' 56' ' ' GLN . 61.6 m-85 -123.32 169.73 11.03 Favored 'General case' 0 C--N 1.315 -0.927 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.617 -170.874 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.94 ' HA2' HG23 ' A' ' 45' ' ' ILE . . . -64.58 157.89 44.24 Favored Glycine 0 N--CA 1.445 -0.765 0 CA-C-N 115.585 -0.734 . . . . 0.0 114.105 -169.913 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . 0.657 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 107.1 -111.73 3.57 Favored Glycine 0 N--CA 1.442 -0.964 0 N-CA-C 111.653 -0.579 . . . . 0.0 111.653 179.3 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 3.1 m -93.42 12.9 2.75 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 CA-C-O 121.906 0.86 . . . . 0.0 110.385 176.69 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 56' ' ' GLN . . . . . 0.616 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 4.1 tt0 60.8 49.85 5.83 Favored 'General case' 0 C--N 1.317 -0.845 0 CA-C-N 113.673 -1.603 . . . . 0.0 112.178 172.652 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . 0.415 ' HZ ' ' CA ' ' A' ' 86' ' ' ALA . 27.3 m-85 -60.97 133.93 56.59 Favored 'General case' 0 CA--C 1.506 -0.717 0 CA-C-N 115.35 -0.841 . . . . 0.0 111.547 169.626 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.526 ' HA ' ' HA ' ' A' ' 51' ' ' TYR . 6.2 p-10 -74.01 156.13 37.85 Favored 'General case' 0 C--N 1.315 -0.932 0 C-N-CA 119.509 -0.877 . . . . 0.0 108.831 163.928 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 21.0 tp60 -52.52 -39.06 60.93 Favored 'General case' 0 N--CA 1.443 -0.778 0 CA-C-O 121.098 0.475 . . . . 0.0 111.039 -179.082 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -69.7 -50.95 27.62 Favored Glycine 0 C--O 1.222 -0.599 0 CA-C-N 115.127 -0.942 . . . . 0.0 113.237 -174.005 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 95.6 m -64.8 -35.24 80.46 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 121.201 0.524 . . . . 0.0 110.771 179.369 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 62' ' ' TRP . . . . . 0.674 ' CZ3' ' HA ' ' A' ' 82' ' ' GLN . 59.8 t-105 -60.99 -49.04 79.07 Favored 'General case' 0 N--CA 1.443 -0.779 0 CA-C-O 121.579 0.704 . . . . 0.0 109.258 174.768 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . 0.479 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 40.8 tt0 -67.24 -33.96 76.44 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-N 114.858 -1.064 . . . . 0.0 110.858 -179.017 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -63.36 -42.65 98.89 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.815 -0.63 . . . . 0.0 112.057 -175.341 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . 0.636 ' HB2' HG13 ' A' ' 85' ' ' VAL . 37.1 m-80 -83.43 -10.41 58.41 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.826 0.346 . . . . 0.0 110.409 176.209 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . 0.447 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 94.09 51.44 2.08 Favored Glycine 0 C--N 1.332 0.35 0 C-N-CA 121.007 -0.616 . . . . 0.0 112.839 173.831 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . 0.591 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -79.73 -23.96 61.19 Favored Glycine 0 N--CA 1.439 -1.116 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.821 -176.49 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 0.842 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 6.9 mp -59.47 -26.8 65.54 Favored 'General case' 0 C--N 1.323 -0.545 0 N-CA-C 112.553 0.575 . . . . 0.0 112.553 -172.748 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . 0.447 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 3.4 ptm180 -65.5 -33.15 75.27 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 121.36 0.6 . . . . 0.0 109.877 177.335 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 70' ' ' TYR . . . . . 1.07 ' HB3' ' HG2' ' A' ' 81' ' ' GLU . 74.1 m-85 -81.26 -34.79 31.83 Favored 'General case' 0 N--CA 1.439 -0.98 0 N-CA-C 107.956 -1.127 . . . . 0.0 107.956 179.389 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.676 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 164.63 126.12 0.02 OUTLIER Pre-proline 0 N--CA 1.448 -0.552 0 CA-C-N 112.63 -2.077 . . . . 0.0 106.989 -178.766 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 72' ' ' PRO . . . . . 0.842 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 26.5 Cg_exo -55.17 -5.88 0.66 Allowed 'Trans proline' 0 C--N 1.332 -0.3 0 C-N-CA 123.216 2.61 . . . . 0.0 114.076 -177.808 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 73' ' ' ARG . . . . . 0.414 HH11 ' HD2' ' A' ' 73' ' ' ARG . 9.9 ptm180 -146.97 138.37 24.14 Favored 'General case' 0 C--N 1.318 -0.795 0 CA-C-O 121.459 0.647 . . . . 0.0 110.402 175.776 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -60.12 -20.68 59.46 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 114.839 -1.073 . . . . 0.0 112.6 -178.889 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . 0.598 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 0.0 OUTLIER -76.83 -22.17 53.97 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 121.262 0.553 . . . . 0.0 110.602 -178.536 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 57.9 tp -92.66 -33.36 14.4 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.643 -0.708 . . . . 0.0 110.022 177.766 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . 0.692 ' HB3' ' HB3' ' A' ' 81' ' ' GLU . . . -77.8 154.84 31.51 Favored 'General case' 0 N--CA 1.447 -0.581 0 CA-C-N 115.48 -0.782 . . . . 0.0 110.66 178.657 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 72.9 p -96.41 -174.39 3.04 Favored 'General case' 0 C--N 1.314 -0.955 0 CA-C-N 115.214 -0.903 . . . . 0.0 110.84 -176.65 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . 0.852 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 0.1 OUTLIER -50.9 -54.75 21.35 Favored 'General case' 0 C--O 1.216 -0.668 0 CA-C-O 120.699 0.285 . . . . 0.0 110.376 -179.093 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -60.35 -38.22 83.14 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-O 121.261 0.553 . . . . 0.0 111.289 -174.086 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 81' ' ' GLU . . . . . 1.07 ' HG2' ' HB3' ' A' ' 70' ' ' TYR . 2.9 mt-10 -72.32 -52.99 13.7 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 115.505 -0.771 . . . . 0.0 112.297 -179.98 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 82' ' ' GLN . . . . . 0.674 ' HA ' ' CZ3' ' A' ' 62' ' ' TRP . 3.7 tt0 -63.78 -34.47 77.97 Favored 'General case' 0 C--N 1.317 -0.841 0 CA-C-N 115.28 -0.873 . . . . 0.0 109.621 -178.441 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . 0.672 HG13 ' CD1' ' A' ' 31' ' ' TRP . 0.5 OUTLIER -70.02 -39.56 77.47 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.235 0 CA-C-N 114.632 -1.167 . . . . 0.0 110.965 177.907 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 84' ' ' ALA . . . . . 0.421 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -58.98 -36.19 74.46 Favored 'General case' 0 C--O 1.237 0.418 0 CA-C-O 121.587 0.708 . . . . 0.0 110.321 -178.272 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . 0.636 HG13 ' HB2' ' A' ' 65' ' ' ASN . 44.6 t -67.21 -46.89 83.14 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-N 115.173 -0.921 . . . . 0.0 110.187 176.57 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 86' ' ' ALA . . . . . 0.415 ' CA ' ' HZ ' ' A' ' 57' ' ' PHE . . . -61.67 -31.92 72.07 Favored 'General case' 0 N--CA 1.451 -0.378 0 CA-C-N 115.465 -0.789 . . . . 0.0 110.641 175.813 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 87' ' ' GLU . . . . . 0.622 ' HA ' ' HG2' ' A' ' 90' ' ' ARG . 21.4 mm-40 -60.53 -44.29 96.22 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.616 -177.809 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.575 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 96.8 t -62.52 -51.78 68.03 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.425 0 C-N-CA 120.431 -0.508 . . . . 0.0 110.553 -179.13 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 89' ' ' THR . . . . . 0.541 ' HA ' ' NE ' ' A' ' 92' ' ' ARG . 14.8 t -74.09 -35.08 64.17 Favored 'General case' 0 N--CA 1.439 -0.99 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.505 -175.278 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 90' ' ' ARG . . . . . 0.622 ' HG2' ' HA ' ' A' ' 87' ' ' GLU . 3.3 ptt180 -62.26 -36.84 83.3 Favored 'General case' 0 N--CA 1.471 0.595 0 O-C-N 122.252 -0.28 . . . . 0.0 111.165 -178.337 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 91' ' ' LEU . . . . . 0.596 ' N ' ' HG3' ' A' ' 90' ' ' ARG . 4.5 pp -73.03 -23.75 60.63 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.311 -172.964 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . 0.541 ' NE ' ' HA ' ' A' ' 89' ' ' THR . 4.4 mtm180 -82.08 -43.09 18.31 Favored 'General case' 0 CA--C 1.51 -0.581 0 CA-C-O 121.797 0.808 . . . . 0.0 109.652 -178.274 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 93' ' ' GLN . . . . . 0.474 ' OE1' ' HB2' ' A' ' 97' ' ' ALA . 19.0 pt20 -99.98 -27.35 13.62 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 114.764 -1.107 . . . . 0.0 113.111 -170.485 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 84.14 47.75 5.39 Favored Glycine 0 CA--C 1.502 -0.772 0 C-N-CA 120.698 -0.763 . . . . 0.0 111.616 174.795 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 95' ' ' TRP . . . . . 0.503 ' HA ' ' HE3' ' A' ' 98' ' ' TRP . 2.9 m95 63.27 17.4 10.21 Favored 'General case' 0 C--O 1.219 -0.512 0 C-N-CA 123.148 0.579 . . . . 0.0 109.647 177.71 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -66.79 -36.64 91.47 Favored Glycine 0 C--N 1.333 0.372 0 CA-C-N 115.896 -0.593 . . . . 0.0 112.253 179.586 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . 0.474 ' HB2' ' OE1' ' A' ' 93' ' ' GLN . . . -69.94 -23.45 63.2 Favored 'General case' 0 CA--C 1.517 -0.296 0 CA-C-O 120.709 0.29 . . . . 0.0 110.577 177.768 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 98' ' ' TRP . . . . . 0.503 ' HE3' ' HA ' ' A' ' 95' ' ' TRP . 25.1 m-90 -98.94 108.11 47.4 Favored Pre-proline 0 N--CA 1.447 -0.6 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 179.095 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 43.6 Cg_exo -63.36 -136.13 0.0 OUTLIER 'Trans proline' 0 CA--C 1.537 0.665 0 C-N-CA 123.671 2.914 . . . . 0.0 114.083 -174.275 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 44.3 t -55.19 -24.77 15.61 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.259 0 CA-C-O 121.241 0.543 . . . . 0.0 111.49 -176.106 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 101' ' ' CYS . . . . . 0.416 ' SG ' ' HG3' ' A' ' 38' ' ' GLU . 61.0 m -62.84 -34.81 78.12 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 116.064 -0.516 . . . . 0.0 111.502 -179.217 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -70.34 -41.05 73.71 Favored 'General case' 0 C--N 1.333 -0.136 0 CA-C-O 121.014 0.435 . . . . 0.0 110.775 177.975 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -64.72 -34.74 79.02 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.002 -0.544 . . . . 0.0 110.272 178.235 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 55.7 mtp180 -73.87 -19.08 60.83 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.505 -0.77 . . . . 0.0 111.864 176.468 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -95.76 -21.69 17.99 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 116.094 -0.503 . . . . 0.0 112.096 -172.951 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 99.93 67.13 0.84 Allowed Glycine 0 N--CA 1.454 -0.161 0 C-N-CA 120.777 -0.725 . . . . 0.0 111.88 -177.03 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -64.67 152.02 43.42 Favored 'General case' 0 N--CA 1.45 -0.468 0 C-N-CA 122.67 0.388 . . . . 0.0 111.022 -174.147 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 18.0 mmt180 . . . . . 0 C--O 1.241 0.656 0 O-C-N 124.019 0.824 . . . . 0.0 111.416 177.948 . . . . . . . . 0 0 . 1 . 029 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.408 ' O ' HG12 ' A' ' 30' ' ' ILE . 14.2 m-20 . . . . . 0 CA--C 1.498 -1.049 0 CA-C-O 121.729 0.776 . . . . 0.0 109.598 . . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -63.09 -16.52 57.75 Favored Glycine 0 C--N 1.309 -0.963 0 CA-C-N 114.321 -1.309 . . . . 0.0 111.247 -177.047 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 15.5 m -77.66 -39.84 43.67 Favored 'General case' 0 C--N 1.315 -0.909 0 CA-C-O 121.811 0.815 . . . . 0.0 109.359 178.397 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.572 ' O ' HG13 ' A' ' 34' ' ' ILE . 0.5 OUTLIER -69.76 -39.73 78.29 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.706 0 CA-C-N 114.111 -1.404 . . . . 0.0 107.497 179.194 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 31' ' ' TRP . . . . . 0.476 ' CZ2' ' HB3' ' A' ' 90' ' ' ARG . 18.1 m95 -68.35 -37.42 80.48 Favored 'General case' 0 C--N 1.317 -0.828 0 CA-C-N 114.195 -1.366 . . . . 0.0 110.809 -177.017 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 7.7 t70 -76.38 -32.32 58.52 Favored 'General case' 0 N--CA 1.447 -0.621 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.74 179.335 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . 0.498 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -71.05 -37.19 72.52 Favored 'General case' 0 N--CA 1.448 -0.527 0 C-N-CA 120.684 -0.406 . . . . 0.0 110.691 176.48 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . 0.572 HG13 ' O ' ' A' ' 30' ' ' ILE . 82.3 mt -67.16 -41.81 87.37 Favored 'Isoleucine or valine' 0 C--O 1.234 0.262 0 CA-C-O 121.212 0.53 . . . . 0.0 109.892 175.032 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . 0.642 ' HA ' ' O ' ' A' ' 54' ' ' GLY . . . -57.44 -37.91 73.58 Favored 'General case' 0 CA--C 1.515 -0.382 0 CA-C-N 115.511 -0.768 . . . . 0.0 110.317 175.997 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -78.38 -3.91 86.47 Favored Glycine 0 N--CA 1.45 -0.374 0 CA-C-N 115.246 -0.888 . . . . 0.0 111.638 179.883 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 41.0 t -97.51 -60.14 1.63 Allowed 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 115.689 -0.256 . . . . 0.0 111.055 -178.415 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . 0.616 ' HG3' ' SG ' ' A' ' 101' ' ' CYS . 39.2 mt-10 -89.28 -33.78 16.83 Favored 'General case' 0 CA--C 1.516 -0.356 0 CA-C-O 120.715 0.293 . . . . 0.0 111.388 -173.418 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -95.42 -14.06 24.11 Favored 'General case' 0 C--N 1.324 -0.534 0 C-N-CA 120.676 -0.409 . . . . 0.0 111.693 -176.819 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 77.97 20.22 73.63 Favored Glycine 0 N--CA 1.445 -0.745 0 N-CA-C 109.754 -1.338 . . . . 0.0 109.754 -175.799 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 71.07 56.47 7.0 Favored Glycine 0 N--CA 1.437 -1.28 0 CA-C-N 114.185 -1.008 . . . . 0.0 112.036 -176.412 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 42' ' ' ASN . . . . . 0.599 HD21 ' HB ' ' A' ' 45' ' ' ILE . 3.7 t30 -141.23 88.03 2.13 Favored 'General case' 0 N--CA 1.447 -0.597 0 N-CA-C 108.89 -0.782 . . . . 0.0 108.89 -177.592 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 43' ' ' TRP . . . . . 0.737 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 22.1 m95 -70.37 -13.03 61.97 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.515 -0.766 . . . . 0.0 111.176 -173.31 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -102.94 14.05 32.87 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 115.959 -0.564 . . . . 0.0 111.543 -177.624 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.789 HG23 ' HA2' ' A' ' 53' ' ' GLY . 3.6 tt -82.82 144.29 10.44 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.598 0 CA-C-O 120.915 0.388 . . . . 0.0 110.171 -177.955 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 44.5 t-20 -158.24 90.51 1.04 Allowed 'General case' 0 C--N 1.314 -0.95 0 N-CA-C 109.67 -0.493 . . . . 0.0 109.67 178.708 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 35.2 p -76.8 -24.05 52.81 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.622 -0.717 . . . . 0.0 110.92 -179.849 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 99.36 23.94 10.72 Favored Glycine 0 N--CA 1.442 -0.921 0 CA-C-N 115.458 -0.792 . . . . 0.0 111.377 -179.346 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 35.2 p30 -85.4 5.41 31.04 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.986 0.422 . . . . 0.0 111.559 179.656 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . 0.45 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 96.28 -10.63 67.42 Favored Glycine 0 N--CA 1.446 -0.653 0 N-CA-C 111.625 -0.59 . . . . 0.0 111.625 179.153 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 51' ' ' TYR . . . . . 0.521 ' HA ' ' HA ' ' A' ' 58' ' ' ASP . 0.2 OUTLIER -117.84 156.2 28.8 Favored 'General case' 0 CA--C 1.505 -0.75 0 N-CA-C 106.593 -1.632 . . . . 0.0 106.593 179.393 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 52' ' ' TYR . . . . . 0.562 ' O ' ' HA ' ' A' ' 56' ' ' GLN . 46.2 m-85 -120.35 165.44 14.88 Favored 'General case' 0 C--N 1.307 -1.258 0 C-N-CA 119.69 -0.804 . . . . 0.0 112.466 -170.415 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.789 ' HA2' HG23 ' A' ' 45' ' ' ILE . . . -57.93 157.81 16.14 Favored Glycine 0 CA--C 1.502 -0.752 0 CA-C-N 114.854 -1.067 . . . . 0.0 114.41 -169.901 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . 0.653 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 99.52 -109.23 3.7 Favored Glycine 0 N--CA 1.436 -1.314 0 N-CA-C 111.246 -0.741 . . . . 0.0 111.246 -178.693 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.448 HG13 ' CE3' ' A' ' 31' ' ' TRP . 3.2 t -84.31 -2.11 6.88 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.67 0 CA-C-O 121.791 0.805 . . . . 0.0 110.025 -177.151 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 56' ' ' GLN . . . . . 0.797 ' HA ' HE21 ' A' ' 56' ' ' GLN . 0.0 OUTLIER 57.97 50.51 10.17 Favored 'General case' 0 N--CA 1.461 0.088 0 CA-C-N 114.141 -1.391 . . . . 0.0 112.833 166.598 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 10.3 p90 -117.34 162.38 18.01 Favored 'General case' 0 C--N 1.324 -0.511 0 C-N-CA 120.443 -0.503 . . . . 0.0 111.071 175.166 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.521 ' HA ' ' HA ' ' A' ' 51' ' ' TYR . 5.0 p-10 -77.01 163.19 26.92 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 113.667 0.988 . . . . 0.0 113.667 -163.733 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . 0.769 ' HA ' HE21 ' A' ' 59' ' ' GLN . 0.0 OUTLIER -60.57 -40.45 91.71 Favored 'General case' 0 N--CA 1.446 -0.653 0 CA-C-N 113.714 -1.585 . . . . 0.0 111.883 -179.934 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -65.41 -45.2 91.45 Favored Glycine 0 C--N 1.321 -0.286 0 C-N-CA 121.077 -0.582 . . . . 0.0 111.953 -176.952 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 61' ' ' THR . . . . . 0.503 ' CG2' HG23 ' A' ' 89' ' ' THR . 95.0 m -66.61 -43.98 83.31 Favored 'General case' 0 C--N 1.32 -0.701 0 C-N-CA 122.558 0.343 . . . . 0.0 111.077 176.524 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 62' ' ' TRP . . . . . . . . . . . . . 50.3 t-105 -57.63 -47.3 82.6 Favored 'General case' 0 N--CA 1.45 -0.426 0 CA-C-O 121.62 0.724 . . . . 0.0 109.876 176.539 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . 0.449 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 29.2 tt0 -67.31 -33.35 75.09 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 115.09 -0.959 . . . . 0.0 110.614 -178.336 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -66.54 -42.87 86.51 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.76 -0.655 . . . . 0.0 110.745 -176.806 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . 0.495 ' HB2' HG13 ' A' ' 85' ' ' VAL . 7.2 m120 -75.22 -13.97 60.49 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 121.041 0.448 . . . . 0.0 110.387 176.655 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 91.98 46.64 3.57 Favored Glycine 0 N--CA 1.448 -0.533 0 CA-C-N 115.675 -0.693 . . . . 0.0 111.855 176.114 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . 0.521 ' O ' ' HB2' ' A' ' 70' ' ' TYR . . . -79.52 -21.81 65.97 Favored Glycine 0 N--CA 1.439 -1.142 0 C-N-CA 120.882 -0.675 . . . . 0.0 112.835 -172.648 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 0.872 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 7.4 mp -58.98 -29.93 67.57 Favored 'General case' 0 C--N 1.319 -0.73 0 N-CA-C 112.764 0.653 . . . . 0.0 112.764 -173.191 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 12.3 ptm180 -66.02 -29.36 69.72 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-O 121.491 0.662 . . . . 0.0 110.105 176.324 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 70' ' ' TYR . . . . . 0.815 ' HB3' ' HG2' ' A' ' 81' ' ' GLU . 86.8 m-85 -78.14 -36.2 48.02 Favored 'General case' 0 N--CA 1.445 -0.717 0 N-CA-C 107.366 -1.346 . . . . 0.0 107.366 175.493 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.65 ' HB2' ' HB1' ' A' ' 77' ' ' ALA . . . 158.26 130.67 0.0 OUTLIER Pre-proline 0 CA--C 1.508 -0.659 0 CA-C-N 112.096 -2.32 . . . . 0.0 106.262 -177.949 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 72' ' ' PRO . . . . . 0.872 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 18.4 Cg_exo -56.89 -4.45 0.92 Allowed 'Trans proline' 0 C--N 1.331 -0.343 0 C-N-CA 122.988 2.459 . . . . 0.0 114.103 -174.655 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 3.4 ptt180 -154.48 143.78 21.29 Favored 'General case' 0 C--N 1.318 -0.766 0 CA-C-O 121.308 0.575 . . . . 0.0 110.759 176.894 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . 0.535 ' HB2' ' HB2' ' A' ' 52' ' ' TYR . . . -57.95 -21.97 46.68 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.635 -175.514 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . 0.641 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 5.0 p-10 -87.57 -9.88 53.14 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 121.357 0.598 . . . . 0.0 110.672 -178.642 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.517 HD21 ' HD2' ' A' ' 72' ' ' PRO . 57.6 tp -99.86 -30.5 12.0 Favored 'General case' 0 C--N 1.319 -0.73 0 N-CA-C 108.846 -0.798 . . . . 0.0 108.846 175.301 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . 0.65 ' HB1' ' HB2' ' A' ' 71' ' ' ALA . . . -79.63 160.71 26.27 Favored 'General case' 0 N--CA 1.442 -0.846 0 CA-C-N 115.041 -0.982 . . . . 0.0 109.789 173.118 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 36.0 p -100.48 -178.92 3.95 Favored 'General case' 0 C--N 1.309 -1.188 0 CA-C-N 115.564 -0.744 . . . . 0.0 110.914 -178.023 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . 0.737 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 5.5 mtt180 -51.17 -53.75 31.8 Favored 'General case' 0 CA--C 1.511 -0.525 0 CA-C-O 120.871 0.367 . . . . 0.0 111.031 -179.516 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 1.9 pm0 -58.36 -39.65 80.1 Favored 'General case' 0 C--N 1.314 -0.938 0 CA-C-N 115.393 -0.821 . . . . 0.0 111.602 -177.888 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 81' ' ' GLU . . . . . 0.815 ' HG2' ' HB3' ' A' ' 70' ' ' TYR . 4.1 mt-10 -70.01 -51.54 31.48 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 121.13 0.49 . . . . 0.0 111.923 178.014 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 82' ' ' GLN . . . . . 0.451 ' CD ' ' HB1' ' A' ' 74' ' ' ALA . 5.3 tt0 -65.69 -33.9 76.94 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-N 115.377 -0.829 . . . . 0.0 110.591 -176.904 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . 0.431 HG21 ' CD1' ' A' ' 31' ' ' TRP . 24.4 mt -61.56 -45.06 99.44 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.678 0 CA-C-N 115.708 -0.678 . . . . 0.0 109.849 174.073 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 84' ' ' ALA . . . . . 0.643 ' O ' ' HG3' ' A' ' 87' ' ' GLU . . . -64.54 -41.1 96.56 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.945 0.403 . . . . 0.0 111.59 -176.804 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . 0.495 HG13 ' HB2' ' A' ' 65' ' ' ASN . 50.2 t -69.05 -48.99 66.58 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-O 120.968 0.413 . . . . 0.0 111.127 179.255 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -65.7 -31.79 72.99 Favored 'General case' 0 N--CA 1.449 -0.484 0 CA-C-N 115.914 -0.584 . . . . 0.0 110.76 -179.893 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 87' ' ' GLU . . . . . 0.643 ' HG3' ' O ' ' A' ' 84' ' ' ALA . 0.1 OUTLIER -70.1 -28.93 65.8 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.228 -177.373 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.552 ' O ' ' HG3' ' A' ' 92' ' ' ARG . 85.9 t -61.11 -48.64 88.11 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.177 0 N-CA-C 109.241 -0.651 . . . . 0.0 109.241 169.703 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 89' ' ' THR . . . . . 0.547 ' HB ' ' CH2' ' A' ' 98' ' ' TRP . 0.1 OUTLIER -64.9 -44.18 90.43 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 115.647 -0.706 . . . . 0.0 112.143 -176.257 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 90' ' ' ARG . . . . . 0.476 ' HB3' ' CZ2' ' A' ' 31' ' ' TRP . 0.0 OUTLIER -61.2 -32.23 71.99 Favored 'General case' 0 CA--C 1.511 -0.535 0 CA-C-O 121.727 0.775 . . . . 0.0 108.974 -177.068 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 91' ' ' LEU . . . . . 0.411 HD11 HH12 ' A' ' 90' ' ' ARG . 48.4 tp -69.48 -27.42 65.2 Favored 'General case' 0 C--N 1.313 -0.984 0 CA-C-N 113.966 -1.47 . . . . 0.0 111.276 -174.418 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . 0.552 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 4.1 mtm180 -90.59 -48.29 7.17 Favored 'General case' 0 C--N 1.317 -0.805 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.293 -175.832 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 93' ' ' GLN . . . . . 0.411 HE21 ' HZ3' ' A' ' 98' ' ' TRP . 15.3 pt20 -99.07 -27.78 13.68 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-N 114.965 -1.016 . . . . 0.0 113.006 -168.995 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 89.17 41.15 5.92 Favored Glycine 0 CA--C 1.501 -0.842 0 C-N-CA 119.971 -1.109 . . . . 0.0 110.796 178.926 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 95' ' ' TRP . . . . . 0.517 ' HA ' ' HE3' ' A' ' 98' ' ' TRP . 6.1 m95 67.16 19.8 10.33 Favored 'General case' 0 C--O 1.216 -0.674 0 CA-C-N 114.893 -0.654 . . . . 0.0 109.288 176.455 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . 0.406 ' H ' ' HG3' ' A' ' 93' ' ' GLN . . . -64.1 -30.44 77.77 Favored Glycine 0 N--CA 1.452 -0.286 0 CA-C-N 115.465 -0.789 . . . . 0.0 112.886 178.462 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -75.14 -20.68 59.28 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 121.006 0.431 . . . . 0.0 110.142 176.584 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 98' ' ' TRP . . . . . 0.547 ' CH2' ' HB ' ' A' ' 89' ' ' THR . 22.3 m-90 -104.31 111.67 65.24 Favored Pre-proline 0 N--CA 1.446 -0.631 0 CA-C-N 115.72 -0.673 . . . . 0.0 110.335 -177.905 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 99' ' ' PRO . . . . . 0.41 ' HD3' ' HA ' ' A' ' 98' ' ' TRP . 52.5 Cg_exo -61.48 -140.2 0.0 OUTLIER 'Trans proline' 0 CA--C 1.534 0.487 0 C-N-CA 123.644 2.896 . . . . 0.0 114.444 -175.31 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . 0.482 ' O ' ' HD2' ' A' ' 104' ' ' ARG . 12.6 m -54.7 -29.52 21.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.654 -0.703 . . . . 0.0 111.26 -178.363 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 101' ' ' CYS . . . . . 0.616 ' SG ' ' HG3' ' A' ' 38' ' ' GLU . 59.3 m -56.34 -35.56 67.76 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-N 115.205 -0.907 . . . . 0.0 111.706 -179.591 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -69.62 -42.56 74.19 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 121.072 0.463 . . . . 0.0 110.51 179.117 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -66.76 -37.72 85.18 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.656 179.42 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 104' ' ' ARG . . . . . 0.482 ' HD2' ' O ' ' A' ' 100' ' ' VAL . 0.0 OUTLIER -72.6 -20.54 61.28 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.804 -0.635 . . . . 0.0 111.009 178.373 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 105' ' ' ALA . . . . . 0.552 ' HB3' ' HA ' ' A' ' 30' ' ' ILE . . . -91.38 -20.91 21.31 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 115.821 -0.627 . . . . 0.0 111.694 -177.392 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 103.82 54.46 0.81 Allowed Glycine 0 CA--C 1.518 0.244 0 C-N-CA 121.005 -0.617 . . . . 0.0 112.188 179.987 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -67.74 151.25 47.54 Favored 'General case' 0 N--CA 1.449 -0.522 0 C-N-CA 122.385 0.274 . . . . 0.0 111.691 -175.44 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 14.5 mtt180 . . . . . 0 C--O 1.252 1.2 0 O-C-N 124.211 0.944 . . . . 0.0 111.673 174.85 . . . . . . . . 0 0 . 1 . 030 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.52 ' O ' HG12 ' A' ' 30' ' ' ILE . 71.8 m-20 . . . . . 0 CA--C 1.505 -0.767 0 CA-C-O 122.075 0.941 . . . . 0.0 108.869 . . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . 0.58 ' HA2' ' HB2' ' A' ' 31' ' ' TRP . . . -71.58 -3.0 52.89 Favored Glycine 0 N--CA 1.439 -1.123 0 CA-C-N 113.899 -1.5 . . . . 0.0 110.219 174.958 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 5.6 m -76.34 -37.57 57.15 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 108.655 -0.868 . . . . 0.0 108.655 174.086 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.52 HG12 ' O ' ' A' ' 27' ' ' ASP . 0.9 OUTLIER -70.15 -37.99 73.47 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 N-CA-C 106.943 -1.503 . . . . 0.0 106.943 175.683 . . . . . . . . 3 3 . 1 . 030 nuclear orig core ' A' A ' 31' ' ' TRP . . . . . 0.58 ' HB2' ' HA2' ' A' ' 28' ' ' GLY . 22.8 m95 -70.27 -36.41 74.41 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 114.122 -1.399 . . . . 0.0 110.754 -177.079 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.709 ' HB2' HH21 ' A' ' 79' ' ' ARG . 26.5 t70 -76.8 -36.17 57.13 Favored 'General case' 0 N--CA 1.444 -0.73 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.385 179.643 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . 0.435 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -70.77 -36.66 73.17 Favored 'General case' 0 N--CA 1.448 -0.526 0 CA-C-O 120.768 0.318 . . . . 0.0 110.809 176.944 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 34' ' ' ILE . . . . . 0.496 HG13 ' O ' ' A' ' 30' ' ' ILE . 59.3 mt -63.97 -43.91 97.78 Favored 'Isoleucine or valine' 0 C--O 1.234 0.267 0 CA-C-O 121.041 0.448 . . . . 0.0 110.006 173.789 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . 0.457 ' HA ' ' O ' ' A' ' 54' ' ' GLY . . . -57.1 -39.39 74.96 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.551 -0.75 . . . . 0.0 110.151 176.584 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -73.0 -17.68 78.73 Favored Glycine 0 N--CA 1.452 -0.283 0 CA-C-N 115.299 -0.864 . . . . 0.0 111.813 -179.528 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 11.1 t -88.24 -60.9 1.84 Allowed 'General case' 0 C--N 1.322 -0.63 0 CA-C-O 120.778 0.323 . . . . 0.0 111.404 -178.783 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 38' ' ' GLU . . . . . 0.777 ' HG3' ' HG2' ' A' ' 56' ' ' GLN . 8.8 tp10 -88.06 -33.49 18.3 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-O 121.009 0.433 . . . . 0.0 110.509 -169.513 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -96.85 -7.46 33.45 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.086 -0.506 . . . . 0.0 111.605 -176.468 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 76.2 17.2 80.16 Favored Glycine 0 N--CA 1.448 -0.523 0 N-CA-C 109.987 -1.245 . . . . 0.0 109.987 -177.322 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 72.81 55.29 6.6 Favored Glycine 0 N--CA 1.436 -1.306 0 CA-C-N 114.084 -1.058 . . . . 0.0 112.034 -177.334 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 42' ' ' ASN . . . . . 0.726 ' HB3' ' HB ' ' A' ' 45' ' ' ILE . 2.2 t30 -148.17 105.83 3.68 Favored 'General case' 0 CA--C 1.511 -0.521 0 N-CA-C 108.396 -0.964 . . . . 0.0 108.396 -176.444 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 43' ' ' TRP . . . . . 0.869 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 30.4 m95 -83.26 -6.87 59.62 Favored 'General case' 0 C--N 1.309 -1.161 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.551 -173.125 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -111.08 15.03 21.84 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.594 -0.73 . . . . 0.0 111.698 177.792 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.726 ' HB ' ' HB3' ' A' ' 42' ' ' ASN . 11.0 tt -86.73 144.78 8.66 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.624 0 CA-C-O 120.835 0.35 . . . . 0.0 110.868 -176.545 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 45.6 t30 -153.62 111.29 3.52 Favored 'General case' 0 C--N 1.316 -0.89 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 174.178 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 6.9 p -82.4 -15.81 51.33 Favored 'General case' 0 C--N 1.315 -0.896 0 CA-C-N 115.809 -0.632 . . . . 0.0 111.342 -179.679 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 95.92 20.53 25.89 Favored Glycine 0 N--CA 1.446 -0.673 0 N-CA-C 111.174 -0.77 . . . . 0.0 111.174 -177.555 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 8.8 p30 -85.73 -5.29 59.28 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 121.136 0.493 . . . . 0.0 111.221 -176.16 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . 0.47 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 96.87 -12.99 65.61 Favored Glycine 0 N--CA 1.448 -0.5 0 CA-C-N 115.945 -0.57 . . . . 0.0 111.832 178.411 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 51' ' ' TYR . . . . . 0.535 ' HA ' ' HA ' ' A' ' 58' ' ' ASP . 0.9 OUTLIER -108.82 137.19 47.14 Favored 'General case' 0 CA--C 1.511 -0.529 0 N-CA-C 107.376 -1.342 . . . . 0.0 107.376 172.609 . . . . . . . . 3 3 . 1 . 030 nuclear orig core ' A' A ' 52' ' ' TYR . . . . . 0.674 ' CE1' ' HB2' ' A' ' 59' ' ' GLN . 26.6 m-85 -99.83 156.54 17.06 Favored 'General case' 0 C--N 1.307 -1.243 0 C-N-CA 120.607 -0.437 . . . . 0.0 111.255 -167.892 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -61.16 -176.07 1.74 Allowed Glycine 0 C--N 1.329 0.19 0 N-CA-C 115.387 0.915 . . . . 0.0 115.387 -167.632 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . 0.72 ' CA ' ' HA ' ' A' ' 43' ' ' TRP . . . 86.84 -105.12 3.0 Favored Glycine 0 N--CA 1.446 -0.646 0 N-CA-C 111.318 -0.713 . . . . 0.0 111.318 -174.768 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.509 ' HB ' ' CD1' ' A' ' 57' ' ' PHE . 3.1 t -83.58 -4.47 8.44 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.751 0 N-CA-C 108.53 -0.915 . . . . 0.0 108.53 176.857 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 56' ' ' GLN . . . . . 0.777 ' HG2' ' HG3' ' A' ' 38' ' ' GLU . 14.8 tp60 58.38 43.56 19.64 Favored 'General case' 0 C--O 1.231 0.115 0 CA-C-N 114.021 -1.445 . . . . 0.0 112.377 169.651 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 57' ' ' PHE . . . . . 0.509 ' CD1' ' HB ' ' A' ' 55' ' ' VAL . 3.7 p90 -111.44 168.92 9.16 Favored 'General case' 0 C--N 1.323 -0.546 0 C-N-CA 120.181 -0.608 . . . . 0.0 110.888 174.829 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.535 ' HA ' ' HA ' ' A' ' 51' ' ' TYR . 7.7 p-10 -78.07 153.77 31.96 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 122.014 0.912 . . . . 0.0 112.38 -165.514 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . 0.674 ' HB2' ' CE1' ' A' ' 52' ' ' TYR . 4.9 tp-100 -63.77 -30.69 71.75 Favored 'General case' 0 N--CA 1.444 -0.737 0 CA-C-N 113.827 -1.533 . . . . 0.0 111.098 -179.804 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -62.96 -50.29 64.88 Favored Glycine 0 C--N 1.314 -0.689 0 C-N-CA 120.743 -0.741 . . . . 0.0 111.676 178.195 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 99.4 m -65.85 -41.86 91.17 Favored 'General case' 0 C--N 1.321 -0.674 0 C-N-CA 122.707 0.403 . . . . 0.0 111.065 175.697 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 62' ' ' TRP . . . . . 0.529 ' CH2' ' HA ' ' A' ' 74' ' ' ALA . 50.0 t-105 -56.33 -48.74 76.14 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-O 121.617 0.722 . . . . 0.0 109.546 177.487 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . 0.54 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 55.7 tt0 -67.76 -34.78 77.49 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 114.901 -1.045 . . . . 0.0 110.712 -179.76 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -62.66 -41.09 98.88 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.773 -179.398 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . 0.644 ' OD1' ' HB ' ' A' ' 89' ' ' THR . 7.9 m120 -79.96 -11.16 59.81 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.536 177.9 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . 0.551 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 84.03 49.0 4.93 Favored Glycine 0 N--CA 1.448 -0.528 0 CA-C-N 115.47 -0.786 . . . . 0.0 112.105 178.485 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 67' ' ' GLY . . . . . 0.594 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -80.17 -18.93 70.7 Favored Glycine 0 N--CA 1.439 -1.124 0 C-N-CA 121.104 -0.57 . . . . 0.0 112.725 -176.214 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 0.667 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 6.4 mp -62.31 -23.1 66.55 Favored 'General case' 0 N--CA 1.45 -0.425 0 N-CA-C 112.035 0.383 . . . . 0.0 112.035 -172.578 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . 0.551 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 13.9 ptp180 -68.69 -32.19 71.83 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-O 121.259 0.552 . . . . 0.0 110.118 176.84 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 70' ' ' TYR . . . . . 0.67 ' HB3' ' HB3' ' A' ' 81' ' ' GLU . 67.7 m-85 -82.18 -33.99 29.22 Favored 'General case' 0 N--CA 1.442 -0.834 0 N-CA-C 107.436 -1.32 . . . . 0.0 107.436 178.443 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 71' ' ' ALA . . . . . 0.544 ' HB2' ' HB1' ' A' ' 77' ' ' ALA . . . 169.14 122.86 0.04 OUTLIER Pre-proline 0 N--CA 1.447 -0.61 0 CA-C-N 112.654 -2.066 . . . . 0.0 107.445 -178.423 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 72' ' ' PRO . . . . . 0.667 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 20.9 Cg_exo -55.28 -7.02 0.98 Allowed 'Trans proline' 0 CA--C 1.527 0.138 0 C-N-CA 122.807 2.338 . . . . 0.0 113.76 -178.81 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 73' ' ' ARG . . . . . 0.411 ' HE ' ' CG ' ' A' ' 75' ' ' ASP . 12.1 ptm180 -145.39 137.98 25.96 Favored 'General case' 0 C--N 1.318 -0.772 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 177.491 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . 0.529 ' HA ' ' CH2' ' A' ' 62' ' ' TRP . . . -55.76 -35.43 66.19 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 114.802 -1.09 . . . . 0.0 112.248 -176.005 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . 0.651 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 14.9 p-10 -80.95 -7.35 59.49 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 121.092 0.472 . . . . 0.0 111.531 -173.782 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.505 ' HB3' ' HB1' ' A' ' 71' ' ' ALA . 60.2 tp -87.7 -33.06 18.87 Favored 'General case' 0 C--N 1.318 -0.773 0 N-CA-C 108.688 -0.856 . . . . 0.0 108.688 171.776 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 77' ' ' ALA . . . . . 0.931 ' HB2' ' HB2' ' A' ' 81' ' ' GLU . . . -79.29 153.37 29.92 Favored 'General case' 0 N--CA 1.446 -0.659 0 CA-C-N 115.01 -0.995 . . . . 0.0 111.012 176.444 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 22.8 p -101.16 -170.3 1.82 Allowed 'General case' 0 C--N 1.315 -0.929 0 CA-C-N 115.77 -0.65 . . . . 0.0 109.517 179.131 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . 0.869 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 53.1 mtp180 -50.67 -48.66 58.35 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.903 0.382 . . . . 0.0 111.341 -176.808 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 7.3 pt-20 -57.88 -49.29 77.21 Favored 'General case' 0 C--N 1.319 -0.75 0 CA-C-N 115.391 -0.822 . . . . 0.0 112.432 -175.517 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 81' ' ' GLU . . . . . 0.931 ' HB2' ' HB2' ' A' ' 77' ' ' ALA . 26.1 mp0 -66.29 -50.46 63.58 Favored 'General case' 0 CA--C 1.52 -0.208 0 O-C-N 122.06 -0.4 . . . . 0.0 111.559 178.0 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 82' ' ' GLN . . . . . 0.666 ' HB2' ' HZ3' ' A' ' 43' ' ' TRP . 52.0 mt-30 -62.44 -33.67 75.27 Favored 'General case' 0 CA--C 1.513 -0.448 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.003 -174.576 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . 0.641 ' O ' ' HG2' ' A' ' 87' ' ' GLU . 27.2 mt -60.53 -49.11 85.67 Favored 'Isoleucine or valine' 0 C--O 1.216 -0.663 0 N-CA-C 109.188 -0.671 . . . . 0.0 109.188 174.986 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 84' ' ' ALA . . . . . 0.59 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -57.12 -47.68 80.51 Favored 'General case' 0 C--O 1.239 0.53 0 CA-C-O 121.522 0.677 . . . . 0.0 111.821 -178.281 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . 0.42 HG11 ' HB2' ' A' ' 65' ' ' ASN . 45.7 t -65.97 -48.82 80.48 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.587 0 CA-C-N 115.827 -0.624 . . . . 0.0 111.284 -179.458 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -59.21 -30.31 68.14 Favored 'General case' 0 N--CA 1.45 -0.468 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.439 175.572 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 87' ' ' GLU . . . . . 0.641 ' HG2' ' O ' ' A' ' 83' ' ' ILE . 21.1 mm-40 -59.58 -43.97 93.48 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.957 -179.111 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.631 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 94.2 t -64.9 -50.98 72.52 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 C-N-CA 120.56 -0.456 . . . . 0.0 110.915 179.289 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 89' ' ' THR . . . . . 0.644 ' HB ' ' OD1' ' A' ' 65' ' ' ASN . 14.7 t -72.8 -34.89 67.2 Favored 'General case' 0 C--N 1.317 -0.843 0 C-N-CA 120.495 -0.482 . . . . 0.0 111.499 -173.599 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 90' ' ' ARG . . . . . 0.621 ' HG3' ' N ' ' A' ' 91' ' ' LEU . 4.3 ptt180 -60.45 -39.31 87.08 Favored 'General case' 0 N--CA 1.466 0.338 0 O-C-N 122.291 -0.256 . . . . 0.0 110.978 -178.267 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 91' ' ' LEU . . . . . 0.631 ' HG ' ' O ' ' A' ' 88' ' ' VAL . 4.5 pp -72.72 -23.91 60.91 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 115.956 -0.566 . . . . 0.0 111.479 -173.28 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . 0.549 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 10.8 mtm180 -79.28 -48.17 14.61 Favored 'General case' 0 CA--C 1.509 -0.61 0 CA-C-O 121.803 0.811 . . . . 0.0 109.456 -176.882 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 93' ' ' GLN . . . . . 0.51 ' OE1' ' HB3' ' A' ' 97' ' ' ALA . 14.8 pt20 -97.37 -28.38 14.05 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 114.413 -1.267 . . . . 0.0 113.149 -169.773 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 96.89 39.92 3.96 Favored Glycine 0 CA--C 1.503 -0.682 0 C-N-CA 120.215 -0.993 . . . . 0.0 111.119 172.892 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 95' ' ' TRP . . . . . 0.52 ' HA ' ' HE3' ' A' ' 98' ' ' TRP . 12.3 m95 68.11 9.3 7.1 Favored 'General case' 0 C--O 1.218 -0.592 0 N-CA-C 108.953 -0.758 . . . . 0.0 108.953 -178.151 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -62.39 -32.13 81.86 Favored Glycine 0 C--N 1.334 0.451 0 CA-C-N 115.592 -0.731 . . . . 0.0 113.14 -177.814 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . 0.51 ' HB3' ' OE1' ' A' ' 93' ' ' GLN . . . -64.45 -24.26 67.56 Favored 'General case' 0 CA--C 1.514 -0.406 0 CA-C-O 120.902 0.382 . . . . 0.0 110.073 176.312 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 98' ' ' TRP . . . . . 0.554 ' HB2' ' HB3' ' A' ' 102' ' ' ALA . 19.6 m-90 -108.63 105.07 56.25 Favored Pre-proline 0 C--N 1.324 -0.522 0 CA-C-N 115.829 -0.623 . . . . 0.0 109.976 178.893 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 19.1 Cg_exo -72.14 -94.08 0.01 OUTLIER 'Trans proline' 0 CA--C 1.536 0.604 0 C-N-CA 122.888 2.392 . . . . 0.0 113.851 -175.59 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 46.5 t -71.44 -26.78 27.1 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.176 0 CA-C-O 121.637 0.732 . . . . 0.0 110.324 -174.799 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 101' ' ' CYS . . . . . 0.44 ' SG ' ' HB2' ' A' ' 38' ' ' GLU . 80.2 m -73.02 -37.48 66.91 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 115.217 -0.901 . . . . 0.0 111.742 -172.987 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 102' ' ' ALA . . . . . 0.554 ' HB3' ' HB2' ' A' ' 98' ' ' TRP . . . -69.7 -44.14 71.01 Favored 'General case' 0 C--N 1.327 -0.382 0 C-N-CA 120.811 -0.356 . . . . 0.0 110.267 179.258 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -61.27 -37.41 83.03 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 121.193 0.521 . . . . 0.0 110.92 179.715 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -72.11 -23.84 61.38 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.731 -0.668 . . . . 0.0 111.818 177.526 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 105' ' ' ALA . . . . . 0.486 ' HB1' ' HA ' ' A' ' 30' ' ' ILE . . . -95.63 -22.78 17.37 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 116.1 -0.5 . . . . 0.0 112.154 -174.619 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 121.55 58.47 0.22 Allowed Glycine 0 CA--C 1.521 0.437 0 C-N-CA 121.05 -0.595 . . . . 0.0 112.189 -176.765 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -72.21 150.4 43.73 Favored 'General case' 0 C--N 1.327 -0.386 0 C-N-CA 122.871 0.469 . . . . 0.0 111.079 -176.494 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 108' ' ' ARG . . . . . 0.454 ' HB2' ' HE1' ' A' ' 95' ' ' TRP . 93.1 mtt180 . . . . . 0 C--O 1.25 1.09 0 CA-C-O 118.303 -0.855 . . . . 0.0 110.636 -174.644 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 94.8 m-20 . . . . . 0 N--CA 1.477 0.921 0 CA-C-O 120.835 0.35 . . . . 0.0 110.318 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 13.0 p -69.29 -16.18 20.39 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.331 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.589 178.426 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 60.9 t -61.26 107.61 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.472 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.397 176.102 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 4.7 p -73.86 141.04 16.71 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 CA-C-O 121.814 0.816 . . . . 0.0 111.446 -177.654 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 1.5 p -110.5 114.56 54.95 Favored Pre-proline 0 C--N 1.311 -1.07 0 CA-C-N 114.456 -1.247 . . . . 0.0 110.915 -176.932 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 7.8 Cg_endo -88.58 168.82 5.9 Favored 'Trans proline' 0 N--CA 1.449 -1.102 0 C-N-CA 123.327 2.685 . . . . 0.0 111.686 177.991 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -76.87 88.59 3.46 Favored 'General case' 0 C--N 1.311 -1.071 0 CA-C-N 114.607 -1.179 . . . . 0.0 110.621 179.03 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 29.6 m170 -82.85 -11.48 58.19 Favored 'General case' 0 C--N 1.312 -1.036 0 CA-C-N 114.344 -1.298 . . . . 0.0 108.332 172.368 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 11.7 pt-20 -78.85 139.15 38.39 Favored 'General case' 0 N--CA 1.452 -0.371 0 CA-C-N 115.568 -0.742 . . . . 0.0 110.645 -178.566 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -147.95 77.03 1.4 Allowed 'General case' 0 C--N 1.319 -0.756 0 CA-C-N 115.448 -0.796 . . . . 0.0 109.609 179.226 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 62.7 t -66.92 -71.72 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.63 0 CA-C-N 115.004 -0.998 . . . . 0.0 110.496 -178.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 5.9 p 25.73 77.79 0.01 OUTLIER 'Isoleucine or valine' 0 C--O 1.237 0.434 0 CA-C-O 122.842 1.306 . . . . 0.0 112.641 179.64 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 64.3 mtm180 -78.56 109.11 12.46 Favored 'General case' 0 N--CA 1.434 -1.267 0 CA-C-N 113.939 -1.482 . . . . 0.0 111.655 -173.328 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.8 t -96.36 154.44 3.57 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.426 0 CA-C-N 113.996 -1.456 . . . . 0.0 107.702 172.074 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -102.66 -63.91 0.72 Allowed Glycine 0 C--N 1.301 -1.373 0 CA-C-N 115.366 -0.834 . . . . 0.0 111.411 -173.642 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' THR . . . . . 0.4 ' O ' ' HD3' ' A' ' 18' ' ' PRO . 24.2 m -147.87 -46.48 0.16 Allowed 'General case' 0 N--CA 1.429 -1.492 0 CA-C-N 114.583 -0.809 . . . . 0.0 110.371 178.803 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 66.8 mmtt -66.0 108.66 2.39 Favored Pre-proline 0 C--N 1.317 -0.841 0 CA-C-N 114.89 -1.05 . . . . 0.0 109.461 179.653 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . 0.4 ' HD3' ' O ' ' A' ' 16' ' ' THR . 97.7 Cg_endo -71.81 106.44 1.99 Allowed 'Trans proline' 0 N--CA 1.452 -0.922 0 C-N-CA 122.853 2.368 . . . . 0.0 111.113 -178.998 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 82.99 56.97 2.61 Favored Glycine 0 C--N 1.294 -1.789 0 CA-C-N 113.259 -1.791 . . . . 0.0 110.428 -173.096 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 1.4 m -56.44 -53.06 61.88 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.364 -0.418 . . . . 0.0 110.136 179.216 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -145.96 110.34 5.05 Favored 'General case' 0 N--CA 1.451 -0.411 0 CA-C-N 115.848 -0.614 . . . . 0.0 110.446 174.617 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 64.7 t -109.31 112.92 59.07 Favored Pre-proline 0 C--N 1.316 -0.853 0 N-CA-C 109.117 -0.697 . . . . 0.0 109.117 175.044 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . 0.46 ' HA ' ' HD2' ' A' ' 24' ' ' PRO . 48.1 Cg_exo -55.71 128.65 31.23 Favored 'Trans proline' 0 N--CA 1.462 -0.358 0 C-N-CA 122.616 2.211 . . . . 0.0 112.145 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . 0.46 ' HD2' ' HA ' ' A' ' 23' ' ' PRO . 11.0 Cg_endo -56.28 140.68 88.39 Favored 'Trans proline' 0 N--CA 1.453 -0.901 0 C-N-CA 123.132 2.554 . . . . 0.0 111.862 176.384 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.546 ' HB ' HG23 ' A' ' 83' ' ' ILE . 85.9 t -116.76 126.38 74.17 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.162 0 CA-C-N 114.96 -1.018 . . . . 0.0 110.01 -178.46 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 43.4 mm -68.92 -23.21 27.1 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-N 115.531 -0.759 . . . . 0.0 111.152 -174.204 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.484 ' O ' HG13 ' A' ' 30' ' ' ILE . 14.0 m-20 -91.68 6.44 45.85 Favored 'General case' 0 N--CA 1.445 -0.687 0 CA-C-O 121.73 0.776 . . . . 0.0 109.009 -177.663 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . 0.401 ' HA2' ' HB2' ' A' ' 31' ' ' TRP . . . -64.27 -10.51 41.96 Favored Glycine 0 N--CA 1.441 -1.008 0 CA-C-N 114.572 -1.194 . . . . 0.0 110.55 174.198 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 47.0 m -76.32 -37.44 57.38 Favored 'General case' 0 N--CA 1.45 -0.464 0 CA-C-O 121.268 0.556 . . . . 0.0 109.867 175.363 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.599 ' HA ' ' HB1' ' A' ' 105' ' ' ALA . 0.2 OUTLIER -69.23 -36.27 71.93 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 N-CA-C 107.718 -1.216 . . . . 0.0 107.718 175.468 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' TRP . . . . . 0.528 ' CH2' ' HB2' ' A' ' 86' ' ' ALA . 42.1 m95 -70.55 -36.31 73.6 Favored 'General case' 0 C--N 1.318 -0.786 0 CA-C-N 114.401 -1.272 . . . . 0.0 110.487 -179.226 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.848 ' HB2' HH21 ' A' ' 79' ' ' ARG . 23.6 t70 -76.43 -37.66 56.67 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.583 179.271 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . 0.504 ' HB2' ' CB ' ' A' ' 105' ' ' ALA . . . -69.58 -33.98 73.5 Favored 'General case' 0 N--CA 1.447 -0.599 0 C-N-CA 120.852 -0.339 . . . . 0.0 110.62 178.331 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . 0.542 HG13 ' O ' ' A' ' 30' ' ' ILE . 78.0 mt -64.29 -47.48 89.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-O 121.009 0.433 . . . . 0.0 110.001 172.443 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . 0.41 ' HA ' ' O ' ' A' ' 54' ' ' GLY . . . -57.87 -39.79 78.64 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.681 -0.69 . . . . 0.0 110.169 177.446 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . 0.517 ' HA2' ' N ' ' A' ' 41' ' ' GLY . . . -70.26 -18.14 74.76 Favored Glycine 0 N--CA 1.453 -0.202 0 CA-C-N 115.501 -0.772 . . . . 0.0 112.135 179.496 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 26.4 t -90.94 -53.04 4.56 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-O 120.931 0.396 . . . . 0.0 111.419 -178.402 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 6.9 tp10 -87.23 -33.2 19.39 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.289 -170.747 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -105.5 -10.63 16.79 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.809 -0.632 . . . . 0.0 111.606 -177.528 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 78.95 14.68 81.72 Favored Glycine 0 CA--C 1.504 -0.598 0 N-CA-C 109.75 -1.34 . . . . 0.0 109.75 -175.206 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . 0.517 ' N ' ' HA2' ' A' ' 36' ' ' GLY . . . 78.49 63.25 2.15 Favored Glycine 0 N--CA 1.434 -1.481 0 CA-C-N 114.019 -1.091 . . . . 0.0 111.514 -175.571 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 2.4 t-20 -145.91 96.81 2.86 Favored 'General case' 0 N--CA 1.447 -0.576 0 N-CA-C 109.442 -0.577 . . . . 0.0 109.442 -177.451 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' TRP . . . . . 0.707 ' CE3' ' HA ' ' A' ' 79' ' ' ARG . 29.9 m95 -83.65 -4.1 58.31 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-N 115.561 -0.745 . . . . 0.0 110.385 -175.145 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -109.26 14.65 23.67 Favored 'General case' 0 C--N 1.315 -0.925 0 CA-C-N 114.805 -1.089 . . . . 0.0 110.282 178.017 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.951 HG21 ' HA2' ' A' ' 53' ' ' GLY . 8.9 tt -78.02 139.08 19.14 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.038 0 CA-C-O 121.509 0.671 . . . . 0.0 110.197 -179.148 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 13.1 t-20 -139.86 76.58 1.57 Allowed 'General case' 0 C--N 1.308 -1.2 0 N-CA-C 108.593 -0.892 . . . . 0.0 108.593 177.865 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 5.1 p -57.6 -29.2 64.3 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 114.366 -1.288 . . . . 0.0 110.997 -178.982 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 96.06 22.81 19.11 Favored Glycine 0 N--CA 1.437 -1.252 0 N-CA-C 110.922 -0.871 . . . . 0.0 110.922 178.552 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 39.0 p-10 -102.8 4.25 37.65 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 120.881 0.372 . . . . 0.0 111.015 -177.085 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . 0.431 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 94.82 -8.09 70.63 Favored Glycine 0 N--CA 1.448 -0.55 0 N-CA-C 111.535 -0.626 . . . . 0.0 111.535 178.639 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' TYR . . . . . 0.505 ' HA ' ' HA ' ' A' ' 58' ' ' ASP . 0.5 OUTLIER -112.64 132.94 54.93 Favored 'General case' 0 N--CA 1.446 -0.65 0 N-CA-C 106.71 -1.589 . . . . 0.0 106.71 -179.094 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' TYR . . . . . 0.533 ' O ' ' HA ' ' A' ' 56' ' ' GLN . 50.6 m-85 -104.64 171.36 7.37 Favored 'General case' 0 C--N 1.304 -1.375 0 N-CA-C 113.225 0.824 . . . . 0.0 113.225 -165.747 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.951 ' HA2' HG21 ' A' ' 45' ' ' ILE . . . -48.46 155.33 1.47 Allowed Glycine 0 N--CA 1.45 -0.373 0 CA-C-N 114.783 -1.099 . . . . 0.0 115.833 -170.204 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . 0.701 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 94.13 -106.41 3.41 Favored Glycine 0 N--CA 1.438 -1.172 0 CA-C-N 114.706 -0.747 . . . . 0.0 112.179 174.756 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -84.29 -1.52 6.44 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 CA-C-O 121.246 0.546 . . . . 0.0 111.534 -178.812 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' GLN . . . . . 0.533 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 5.4 mm-40 59.21 50.39 8.01 Favored 'General case' 0 N--CA 1.467 0.409 0 CA-C-N 114.502 -1.227 . . . . 0.0 113.965 167.059 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -116.23 160.07 20.94 Favored 'General case' 0 C--N 1.326 -0.431 0 C-N-CA 119.804 -0.758 . . . . 0.0 111.569 173.693 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.505 ' HA ' ' HA ' ' A' ' 51' ' ' TYR . 7.3 p-10 -71.11 160.78 32.27 Favored 'General case' 0 C--N 1.324 -0.506 0 N-CA-C 113.797 1.036 . . . . 0.0 113.797 -163.451 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.729 ' HA ' HE21 ' A' ' 59' ' ' GLN . 0.0 OUTLIER -55.36 -39.96 70.71 Favored 'General case' 0 N--CA 1.446 -0.65 0 CA-C-N 113.987 -1.46 . . . . 0.0 111.438 178.056 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -67.65 -48.66 54.98 Favored Glycine 0 C--O 1.225 -0.467 0 CA-C-N 115.417 -0.81 . . . . 0.0 112.042 -175.816 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 89.0 m -66.4 -40.63 89.74 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-O 121.067 0.46 . . . . 0.0 110.641 177.226 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' TRP . . . . . 0.488 ' HZ3' ' HG3' ' A' ' 82' ' ' GLN . 56.9 t-105 -56.48 -48.98 75.98 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-O 121.622 0.725 . . . . 0.0 109.5 175.407 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . 0.775 ' HG3' HD11 ' A' ' 68' ' ' LEU . 27.9 tt0 -66.85 -34.33 77.56 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 115.015 -0.993 . . . . 0.0 110.985 179.845 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -63.96 -41.86 97.44 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.968 -0.56 . . . . 0.0 111.454 -177.441 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 36.5 m-80 -81.52 -7.86 59.64 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.079 -0.51 . . . . 0.0 109.983 175.618 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . 0.452 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 83.29 48.34 5.39 Favored Glycine 0 N--CA 1.45 -0.413 0 CA-C-N 115.507 -0.769 . . . . 0.0 112.647 174.975 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . 0.64 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -79.68 -15.98 78.43 Favored Glycine 0 CA--C 1.504 -0.649 0 C-N-CA 120.87 -0.681 . . . . 0.0 111.904 -176.352 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 0.775 HD11 ' HG3' ' A' ' 63' ' ' GLU . 19.2 mt -61.72 -28.83 69.7 Favored 'General case' 0 C--N 1.314 -0.97 0 C-N-CA 123.346 0.659 . . . . 0.0 111.956 -172.953 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . 0.452 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 5.6 ptp180 -68.05 -28.45 67.39 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-O 121.557 0.694 . . . . 0.0 109.789 178.861 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' TYR . . . . . 0.728 ' HB3' ' HG2' ' A' ' 81' ' ' GLU . 89.0 m-85 -81.47 -34.66 31.26 Favored 'General case' 0 N--CA 1.439 -0.983 0 N-CA-C 107.872 -1.158 . . . . 0.0 107.872 176.848 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.571 ' HB2' ' HB3' ' A' ' 77' ' ' ALA . . . 165.33 125.22 0.02 OUTLIER Pre-proline 0 N--CA 1.445 -0.687 0 CA-C-N 112.336 -2.211 . . . . 0.0 107.115 -179.296 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' PRO . . . . . 0.552 ' HA ' ' HA ' ' A' ' 68' ' ' LEU . 26.8 Cg_exo -53.71 -5.97 0.36 Allowed 'Trans proline' 0 C--N 1.334 -0.232 0 C-N-CA 123.14 2.56 . . . . 0.0 114.169 -178.745 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 11.2 ptm180 -148.28 141.0 24.57 Favored 'General case' 0 C--N 1.314 -0.966 0 N-CA-C 109.231 -0.655 . . . . 0.0 109.231 175.387 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -60.72 -27.01 67.59 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.674 -0.694 . . . . 0.0 112.65 -176.39 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . 0.58 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 3.5 p30 -80.08 -5.95 56.81 Favored 'General case' 0 C--N 1.322 -0.618 0 C-N-CA 120.007 -0.677 . . . . 0.0 110.921 -177.785 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.53 ' HB3' ' HB1' ' A' ' 71' ' ' ALA . 59.2 tp -97.89 -32.72 11.54 Favored 'General case' 0 C--N 1.321 -0.66 0 N-CA-C 109.113 -0.699 . . . . 0.0 109.113 174.815 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . 0.686 ' HB1' ' CB ' ' A' ' 81' ' ' GLU . . . -79.68 164.29 23.87 Favored 'General case' 0 N--CA 1.447 -0.586 0 CA-C-N 115.243 -0.889 . . . . 0.0 109.911 174.485 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 42.8 p -101.13 -173.89 2.48 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 116.573 -0.285 . . . . 0.0 110.801 -177.879 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . 0.848 HH21 ' HB2' ' A' ' 32' ' ' ASP . 41.2 mtp180 -50.42 -52.58 36.38 Favored 'General case' 0 CA--C 1.515 -0.402 0 CA-C-O 121.218 0.532 . . . . 0.0 111.295 -178.137 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' GLU . . . . . 0.692 ' HA ' HD13 ' A' ' 83' ' ' ILE . 6.9 pt-20 -66.0 -27.77 68.38 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-N 115.139 -0.937 . . . . 0.0 112.061 -173.873 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' GLU . . . . . 0.728 ' HG2' ' HB3' ' A' ' 70' ' ' TYR . 3.2 mp0 -72.83 -46.26 54.03 Favored 'General case' 0 C--N 1.324 -0.507 0 C-N-CA 120.762 -0.375 . . . . 0.0 111.758 174.239 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' GLN . . . . . 0.613 ' HB2' ' HZ3' ' A' ' 43' ' ' TRP . 0.1 OUTLIER -58.96 -34.72 72.12 Favored 'General case' 0 CA--C 1.506 -0.735 0 N-CA-C 109.108 -0.701 . . . . 0.0 109.108 175.125 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . 0.692 HD13 ' HA ' ' A' ' 80' ' ' GLU . 60.3 mt -60.62 -48.75 87.28 Favored 'Isoleucine or valine' 0 C--O 1.211 -0.957 0 CA-C-N 114.731 -1.122 . . . . 0.0 110.022 173.636 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . 0.62 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -63.67 -45.26 90.91 Favored 'General case' 0 C--O 1.238 0.452 0 CA-C-O 121.439 0.637 . . . . 0.0 111.897 -174.98 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . 0.477 HG22 ' HA2' ' A' ' 67' ' ' GLY . 34.8 t -66.52 -48.1 81.58 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.775 0 CA-C-N 115.756 -0.656 . . . . 0.0 110.651 -179.206 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . 0.528 ' HB2' ' CH2' ' A' ' 31' ' ' TRP . . . -61.46 -28.08 69.03 Favored 'General case' 0 N--CA 1.45 -0.45 0 CA-C-N 115.468 -0.787 . . . . 0.0 110.415 174.976 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' GLU . . . . . 0.678 ' HG2' ' O ' ' A' ' 83' ' ' ILE . 36.0 mm-40 -59.09 -43.37 91.84 Favored 'General case' 0 CA--C 1.513 -0.457 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.63 179.78 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.512 ' O ' ' HG3' ' A' ' 92' ' ' ARG . 48.8 t -65.27 -42.8 94.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 C-N-CA 120.385 -0.526 . . . . 0.0 109.893 175.851 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' THR . . . . . 0.743 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 0.2 OUTLIER -66.82 -46.88 73.75 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 115.956 -0.565 . . . . 0.0 111.465 -175.271 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . 0.474 ' HG3' ' N ' ' A' ' 91' ' ' LEU . 4.9 ptt180 -66.09 -31.18 71.9 Favored 'General case' 0 C--O 1.218 -0.577 0 CA-C-O 122.042 0.925 . . . . 0.0 109.083 -179.018 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . 0.474 ' N ' ' HG3' ' A' ' 90' ' ' ARG . 56.3 tp -61.84 -30.5 70.89 Favored 'General case' 0 C--N 1.308 -1.211 0 CA-C-N 114.494 -1.23 . . . . 0.0 111.509 -175.633 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . 0.512 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 7.6 mtm180 -90.68 -45.73 8.69 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-N 115.559 -0.746 . . . . 0.0 110.205 -175.402 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' GLN . . . . . 0.475 ' NE2' HG22 ' A' ' 89' ' ' THR . 21.1 pt20 -104.03 -27.32 12.2 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 114.897 -1.047 . . . . 0.0 113.039 -169.923 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 106.75 -107.71 2.74 Favored Glycine 0 N--CA 1.44 -1.034 0 N-CA-C 109.134 -1.586 . . . . 0.0 109.134 -175.214 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' TRP . . . . . 0.546 ' CZ2' HD12 ' A' ' 30' ' ' ILE . 29.7 m95 -138.51 21.56 2.73 Favored 'General case' 0 C--N 1.308 -1.21 0 N-CA-C 106.348 -1.723 . . . . 0.0 106.348 172.995 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -56.26 -35.16 64.31 Favored Glycine 0 C--N 1.335 0.514 0 CA-C-N 114.706 -1.134 . . . . 0.0 112.901 179.752 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . 0.401 ' HB1' ' OE1' ' A' ' 93' ' ' GLN . . . -79.25 -15.38 58.1 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.78 0.324 . . . . 0.0 110.533 178.092 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 98' ' ' TRP . . . . . 0.743 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 24.7 m-90 -104.92 107.81 59.59 Favored Pre-proline 0 C--N 1.323 -0.572 0 CA-C-O 121.459 0.647 . . . . 0.0 110.019 178.722 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . 0.419 ' HD3' ' HA ' ' A' ' 98' ' ' TRP . 37.6 Cg_exo -64.73 -139.39 0.01 OUTLIER 'Trans proline' 0 CA--C 1.534 0.52 0 C-N-CA 123.764 2.976 . . . . 0.0 114.762 -174.102 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . 0.567 ' O ' ' HD2' ' A' ' 104' ' ' ARG . 23.8 t -55.89 -25.84 19.67 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.266 0 CA-C-N 115.441 -0.8 . . . . 0.0 110.746 -178.126 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 89.9 m -60.12 -38.73 83.91 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.321 176.907 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 102' ' ' ALA . . . . . 0.541 ' HB2' ' HB3' ' A' ' 98' ' ' TRP . . . -70.48 -41.2 73.02 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.686 0.279 . . . . 0.0 110.452 178.434 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -59.63 -44.81 93.33 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 121.189 0.519 . . . . 0.0 110.025 178.208 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 104' ' ' ARG . . . . . 0.567 ' HD2' ' O ' ' A' ' 100' ' ' VAL . 0.0 OUTLIER -62.52 -37.01 84.42 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.393 -0.821 . . . . 0.0 111.052 176.787 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 105' ' ' ALA . . . . . 0.599 ' HB1' ' HA ' ' A' ' 30' ' ' ILE . . . -78.77 -22.45 46.36 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 115.624 -0.716 . . . . 0.0 111.905 -176.165 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 114.56 62.13 0.39 Allowed Glycine 0 CA--C 1.519 0.325 0 C-N-CA 121.143 -0.551 . . . . 0.0 112.392 -178.185 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -61.47 140.61 58.04 Favored 'General case' 0 C--O 1.236 0.343 0 C-N-CA 122.789 0.435 . . . . 0.0 110.799 -179.331 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 8.7 ptm180 . . . . . 0 C--O 1.245 0.858 0 CA-C-O 118.556 -0.735 . . . . 0.0 110.555 -172.452 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 23.6 p-10 . . . . . 0 N--CA 1.477 0.904 0 CA-C-O 121.219 0.533 . . . . 0.0 110.352 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 12.4 p -78.64 -27.97 14.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.748 -175.885 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 14.6 p -72.73 134.54 29.59 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.797 0 CA-C-N 116.068 -0.514 . . . . 0.0 109.904 175.324 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 10.7 t -82.64 137.84 20.39 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.571 0 N-CA-C 109.352 -0.61 . . . . 0.0 109.352 179.008 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' THR . . . . . 0.421 ' HA ' ' HD3' ' A' ' 6' ' ' PRO . 8.4 p -96.7 110.29 52.55 Favored Pre-proline 0 C--N 1.314 -0.952 0 CA-C-N 115.602 -0.726 . . . . 0.0 111.342 -175.819 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.421 ' HD3' ' HA ' ' A' ' 5' ' ' THR . 3.1 Cg_exo -81.7 171.87 12.83 Favored 'Trans proline' 0 N--CA 1.452 -0.92 0 C-N-CA 123.379 2.72 . . . . 0.0 111.925 179.512 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . 0.441 ' C ' ' H ' ' A' ' 9' ' ' GLU . . . -124.46 -165.15 1.33 Allowed 'General case' 0 C--N 1.311 -1.102 0 CA-C-N 114.37 -1.286 . . . . 0.0 110.335 -179.011 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . 0.43 ' HB3' ' O ' ' A' ' 7' ' ' ALA . 51.2 t-80 75.92 -9.81 1.38 Allowed 'General case' 0 C--O 1.232 0.172 0 O-C-N 124.262 0.976 . . . . 0.0 109.704 -172.533 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . 0.441 ' H ' ' C ' ' A' ' 7' ' ' ALA . 7.9 pt-20 -91.1 138.22 31.77 Favored 'General case' 0 N--CA 1.452 -0.352 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.178 177.561 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -143.57 73.58 1.4 Allowed 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 115.858 -0.61 . . . . 0.0 109.938 178.993 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 96.1 t -65.57 -50.47 71.7 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.669 0 CA-C-N 115.209 -0.905 . . . . 0.0 110.169 179.732 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 79.7 t 27.97 84.58 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.447 -0.623 0 C-N-CA 125.011 1.324 . . . . 0.0 113.147 178.588 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . 0.484 ' HD3' ' H ' ' A' ' 13' ' ' ARG . 0.1 OUTLIER -107.35 115.59 30.44 Favored 'General case' 0 C--N 1.303 -1.432 0 CA-C-N 114.095 -1.411 . . . . 0.0 109.644 179.967 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.9 t -110.99 161.3 9.55 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.254 0 CA-C-N 114.514 -1.221 . . . . 0.0 109.25 -179.452 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 104.13 76.08 1.08 Allowed Glycine 0 N--CA 1.434 -1.484 0 CA-C-N 115.124 -0.944 . . . . 0.0 111.557 -178.895 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 41.7 m -73.46 -23.52 60.1 Favored 'General case' 0 N--CA 1.442 -0.838 0 CA-C-O 121.485 0.66 . . . . 0.0 110.039 179.066 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . 0.454 ' N ' ' HD3' ' A' ' 18' ' ' PRO . 73.1 mmtt 52.99 64.68 6.83 Favored Pre-proline 0 C--N 1.32 -0.679 0 CA-C-N 114.311 -1.313 . . . . 0.0 112.109 179.754 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . 0.454 ' HD3' ' N ' ' A' ' 17' ' ' LYS . 36.3 Cg_exo -69.29 115.92 4.26 Favored 'Trans proline' 0 CA--C 1.505 -0.946 0 C-N-CA 122.969 2.446 . . . . 0.0 111.669 174.283 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 170.35 39.38 0.03 OUTLIER Glycine 0 C--N 1.297 -1.633 0 CA-C-N 113.728 -1.578 . . . . 0.0 112.534 179.436 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 28.6 m -69.36 -39.27 78.17 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-O 121.439 0.638 . . . . 0.0 109.602 175.29 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . 0.45 ' O ' ' HD3' ' A' ' 23' ' ' PRO . 37.8 mt-10 -148.04 150.69 34.39 Favored 'General case' 0 N--CA 1.443 -0.805 0 N-CA-C 108.004 -1.11 . . . . 0.0 108.004 179.81 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 53.6 t -84.63 110.68 29.14 Favored Pre-proline 0 C--N 1.309 -1.181 0 N-CA-C 109.526 -0.546 . . . . 0.0 109.526 175.365 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . 0.45 ' HD3' ' O ' ' A' ' 21' ' ' GLU . 49.3 Cg_exo -55.56 141.78 82.59 Favored 'Trans proline' 0 C--N 1.345 0.38 0 C-N-CA 123.117 2.545 . . . . 0.0 111.827 179.99 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 10.8 Cg_endo -55.18 140.13 80.91 Favored 'Trans proline' 0 N--CA 1.455 -0.755 0 C-N-CA 123.02 2.48 . . . . 0.0 111.728 179.43 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 49.5 t -116.72 131.32 69.71 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.044 0 CA-C-N 114.968 -1.014 . . . . 0.0 110.601 -174.062 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . 0.401 HD11 ' N ' ' A' ' 26' ' ' ILE . 3.3 mp -72.8 -25.18 21.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 115.51 -0.768 . . . . 0.0 109.906 -176.595 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -91.65 -0.27 57.56 Favored 'General case' 0 CA--C 1.503 -0.846 0 CA-C-N 115.239 -0.892 . . . . 0.0 109.904 -175.876 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -61.21 -15.22 43.57 Favored Glycine 0 CA--C 1.505 -0.565 0 CA-C-N 114.904 -1.043 . . . . 0.0 110.543 177.646 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 23.2 m -77.28 -37.23 53.28 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 114.666 -0.767 . . . . 0.0 110.068 177.598 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.554 ' O ' HG13 ' A' ' 34' ' ' ILE . 1.1 mm -71.38 -39.08 71.36 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.751 0 N-CA-C 107.029 -1.471 . . . . 0.0 107.029 178.693 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' TRP . . . . . 0.621 ' HZ2' ' HD3' ' A' ' 90' ' ' ARG . 24.3 m95 -68.54 -36.91 79.48 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-N 114.054 -1.43 . . . . 0.0 110.793 -176.154 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 7.8 t70 -74.92 -36.2 62.17 Favored 'General case' 0 N--CA 1.444 -0.743 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.587 177.203 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . 0.489 ' HB1' ' HB3' ' A' ' 105' ' ' ALA . . . -70.92 -35.52 72.29 Favored 'General case' 0 N--CA 1.448 -0.533 0 C-N-CA 120.736 -0.386 . . . . 0.0 110.846 178.937 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . 0.554 HG13 ' O ' ' A' ' 30' ' ' ILE . 75.8 mt -66.96 -46.07 85.75 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.222 0 CA-C-O 120.987 0.423 . . . . 0.0 110.002 174.662 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -57.61 -38.22 74.57 Favored 'General case' 0 CA--C 1.515 -0.373 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.297 176.92 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . 0.54 ' HA2' ' CA ' ' A' ' 41' ' ' GLY . . . -77.96 -1.64 79.69 Favored Glycine 0 N--CA 1.449 -0.436 0 CA-C-N 115.421 -0.809 . . . . 0.0 112.028 179.341 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 38.5 t -106.61 -57.09 2.1 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 115.825 -0.187 . . . . 0.0 111.361 -177.319 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . 0.815 ' HG3' ' SG ' ' A' ' 101' ' ' CYS . 9.9 mt-10 -88.09 -30.83 19.58 Favored 'General case' 0 CA--C 1.514 -0.422 0 C-N-CA 120.949 -0.301 . . . . 0.0 111.101 -175.207 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -96.68 -7.44 34.07 Favored 'General case' 0 N--CA 1.449 -0.488 0 C-N-CA 120.765 -0.374 . . . . 0.0 111.527 -179.079 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 82.09 2.6 90.61 Favored Glycine 0 CA--C 1.505 -0.575 0 N-CA-C 110.0 -1.24 . . . . 0.0 110.0 -177.962 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . 0.54 ' CA ' ' HA2' ' A' ' 36' ' ' GLY . . . 89.76 54.62 2.17 Favored Glycine 0 N--CA 1.433 -1.511 0 CA-C-N 114.208 -0.996 . . . . 0.0 111.807 -178.043 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 53.0 t30 -147.82 124.57 11.18 Favored 'General case' 0 N--CA 1.443 -0.793 0 N-CA-C 109.147 -0.686 . . . . 0.0 109.147 -178.983 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' TRP . . . . . 0.775 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 20.5 m95 -99.44 1.61 44.32 Favored 'General case' 0 C--N 1.301 -1.527 0 CA-C-N 115.132 -0.94 . . . . 0.0 110.004 -174.467 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -111.59 5.48 19.42 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.088 -0.96 . . . . 0.0 111.102 177.188 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 13.0 tt -75.26 143.32 13.42 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.769 0 CA-C-O 120.946 0.403 . . . . 0.0 110.196 -178.927 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 40.7 t-20 -156.46 96.62 1.68 Allowed 'General case' 0 C--N 1.311 -1.089 0 CA-C-O 121.154 0.502 . . . . 0.0 109.826 179.399 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 20.5 p -76.72 -22.0 54.5 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 115.782 -0.645 . . . . 0.0 111.262 -177.154 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 98.33 21.73 16.62 Favored Glycine 0 N--CA 1.442 -0.902 0 CA-C-N 115.549 -0.751 . . . . 0.0 111.272 -179.016 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 66.3 t30 -91.16 11.89 21.8 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 121.59 0.71 . . . . 0.0 110.934 -177.358 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 84.58 -14.41 46.92 Favored Glycine 0 N--CA 1.453 -0.224 0 N-CA-C 111.234 -0.746 . . . . 0.0 111.234 -178.281 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' TYR . . . . . 0.612 ' CE1' ' HB2' ' A' ' 58' ' ' ASP . 0.5 OUTLIER -98.07 142.4 29.81 Favored 'General case' 0 N--CA 1.445 -0.693 0 N-CA-C 108.174 -1.047 . . . . 0.0 108.174 173.226 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' TYR . . . . . 0.8 ' CE1' ' HB2' ' A' ' 59' ' ' GLN . 4.7 m-85 -108.56 170.28 8.12 Favored 'General case' 0 C--N 1.311 -1.097 0 CA-C-N 116.019 -0.537 . . . . 0.0 111.456 -174.323 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -58.89 172.56 4.07 Favored Glycine 0 N--CA 1.452 -0.286 0 N-CA-C 115.123 0.809 . . . . 0.0 115.123 -170.202 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . 0.751 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 87.01 -111.73 3.7 Favored Glycine 0 N--CA 1.443 -0.865 0 C-N-CA 120.962 -0.637 . . . . 0.0 111.577 -179.607 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.436 HG11 ' CE3' ' A' ' 31' ' ' TRP . 6.2 t -84.28 6.43 2.02 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.74 0 CA-C-O 121.736 0.779 . . . . 0.0 109.778 179.959 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' GLN . . . . . 0.702 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 8.4 tp-100 53.54 51.91 14.31 Favored 'General case' 0 C--O 1.236 0.366 0 CA-C-N 114.427 -1.26 . . . . 0.0 112.872 164.816 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 6.9 p90 -120.15 167.94 11.72 Favored 'General case' 0 N--CA 1.443 -0.801 0 C-N-CA 119.555 -0.858 . . . . 0.0 111.897 174.245 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.612 ' HB2' ' CE1' ' A' ' 51' ' ' TYR . 0.6 OUTLIER -71.09 141.81 50.82 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 114.242 -1.345 . . . . 0.0 113.062 -165.636 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.8 ' HB2' ' CE1' ' A' ' 52' ' ' TYR . 0.0 OUTLIER -56.2 -38.12 70.56 Favored 'General case' 0 N--CA 1.446 -0.628 0 CA-C-N 113.389 -1.732 . . . . 0.0 111.522 178.074 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -63.89 -48.93 71.5 Favored Glycine 0 N--CA 1.441 -1.006 0 CA-C-N 115.938 -0.573 . . . . 0.0 112.019 178.102 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 68.8 m -61.47 -42.21 98.43 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 121.279 0.561 . . . . 0.0 110.4 175.076 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' TRP . . . . . 0.443 ' CZ3' ' HA ' ' A' ' 82' ' ' GLN . 43.4 t-105 -56.13 -49.83 72.81 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.055 -0.975 . . . . 0.0 109.981 175.635 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . 0.655 ' HG3' HD12 ' A' ' 68' ' ' LEU . 29.3 tt0 -66.8 -39.36 87.71 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 115.195 -0.912 . . . . 0.0 110.756 -178.663 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -62.25 -39.5 93.07 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.553 -0.749 . . . . 0.0 110.92 -176.922 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . 0.572 ' OD1' ' HB ' ' A' ' 89' ' ' THR . 10.7 m120 -75.59 -21.14 58.08 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.198 177.014 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 101.7 39.36 2.97 Favored Glycine 0 N--CA 1.449 -0.493 0 C-N-CA 120.957 -0.64 . . . . 0.0 112.28 178.317 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . 0.652 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -79.25 -16.66 77.99 Favored Glycine 0 N--CA 1.44 -1.048 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.073 -173.915 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 0.655 HD12 ' HG3' ' A' ' 63' ' ' GLU . 26.4 mt -63.55 -23.76 67.52 Favored 'General case' 0 N--CA 1.442 -0.828 0 CA-C-N 115.502 -0.349 . . . . 0.0 111.566 -172.932 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . 0.564 ' HG3' ' N ' ' A' ' 70' ' ' TYR . 0.0 OUTLIER -70.77 -32.68 69.89 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 121.186 0.517 . . . . 0.0 110.068 176.165 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' TYR . . . . . 0.68 ' HB3' ' CG ' ' A' ' 81' ' ' GLU . 86.9 m-85 -76.13 -33.17 59.43 Favored 'General case' 0 CA--C 1.503 -0.852 0 N-CA-C 107.574 -1.269 . . . . 0.0 107.574 -179.934 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.738 ' HB2' ' HB3' ' A' ' 77' ' ' ALA . . . 163.26 125.48 0.01 OUTLIER Pre-proline 0 C--N 1.321 -0.654 0 CA-C-N 111.903 -2.408 . . . . 0.0 106.688 179.293 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' PRO . . . . . 0.567 ' HA ' ' HA ' ' A' ' 68' ' ' LEU . 17.3 Cg_exo -55.16 -4.0 0.37 Allowed 'Trans proline' 0 C--N 1.331 -0.342 0 C-N-CA 122.85 2.366 . . . . 0.0 113.633 -179.799 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' ARG . . . . . 0.418 ' H ' ' C ' ' A' ' 71' ' ' ALA . 14.8 ptm180 -145.83 136.94 24.7 Favored 'General case' 0 C--N 1.317 -0.836 0 CA-C-O 121.269 0.557 . . . . 0.0 109.657 176.6 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -63.43 -25.49 68.3 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 115.455 -0.793 . . . . 0.0 111.914 -177.467 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . 0.485 ' OD1' ' HD2' ' A' ' 52' ' ' TYR . 26.9 p-10 -88.16 10.0 20.88 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-O 121.292 0.568 . . . . 0.0 110.847 -177.714 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 68.7 tp -113.0 -34.43 5.74 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.46 -0.791 . . . . 0.0 109.048 168.121 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . 0.738 ' HB3' ' HB2' ' A' ' 71' ' ' ALA . . . -78.31 153.43 31.75 Favored 'General case' 0 N--CA 1.443 -0.799 0 CA-C-N 115.357 -0.838 . . . . 0.0 109.851 177.687 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 33.5 p -96.54 -173.98 2.91 Favored 'General case' 0 C--N 1.317 -0.84 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.35 -176.951 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . 0.775 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 49.1 mtt85 -50.63 -52.56 38.43 Favored 'General case' 0 CA--C 1.513 -0.46 0 O-C-N 123.519 0.512 . . . . 0.0 111.549 -178.06 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 80' ' ' GLU . . . . . 0.543 ' HG3' ' OE2' ' A' ' 81' ' ' GLU . 9.3 pt-20 -59.28 -42.96 92.5 Favored 'General case' 0 C--N 1.318 -0.786 0 CA-C-N 116.026 -0.534 . . . . 0.0 111.962 -176.627 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 81' ' ' GLU . . . . . 0.68 ' CG ' ' HB3' ' A' ' 70' ' ' TYR . 4.9 mp0 -63.68 -51.99 62.64 Favored 'General case' 0 N--CA 1.454 -0.229 0 N-CA-C 112.094 0.405 . . . . 0.0 112.094 173.987 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 82' ' ' GLN . . . . . 0.455 ' NE2' ' HE3' ' A' ' 43' ' ' TRP . 51.4 mt-30 -59.16 -43.35 92.07 Favored 'General case' 0 CA--C 1.509 -0.611 0 CA-C-O 121.067 0.461 . . . . 0.0 110.459 -176.303 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . 0.662 ' O ' ' HG2' ' A' ' 87' ' ' GLU . 34.3 mt -59.53 -41.88 86.23 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.793 0 CA-C-N 115.157 -0.928 . . . . 0.0 110.006 -178.886 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . 0.607 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -64.52 -42.8 95.55 Favored 'General case' 0 C--O 1.236 0.394 0 CA-C-O 121.705 0.764 . . . . 0.0 111.043 -177.793 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . 0.414 HG21 ' HA2' ' A' ' 67' ' ' GLY . 48.3 t -65.53 -49.12 80.01 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 CA-C-N 115.539 -0.755 . . . . 0.0 110.906 178.188 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -58.48 -30.47 67.01 Favored 'General case' 0 N--CA 1.452 -0.362 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.534 173.965 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 87' ' ' GLU . . . . . 0.662 ' HG2' ' O ' ' A' ' 83' ' ' ILE . 26.4 mm-40 -58.99 -44.06 91.56 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.45 -178.749 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.567 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 98.1 t -64.18 -50.68 75.71 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 C-N-CA 120.555 -0.458 . . . . 0.0 110.622 -179.799 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 89' ' ' THR . . . . . 0.572 ' HB ' ' OD1' ' A' ' 65' ' ' ASN . 12.5 t -73.59 -35.63 65.44 Favored 'General case' 0 C--N 1.318 -0.793 0 C-N-CA 120.796 -0.362 . . . . 0.0 111.66 -174.612 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . 0.636 ' HG3' ' N ' ' A' ' 91' ' ' LEU . 10.9 ptt85 -60.77 -41.6 95.82 Favored 'General case' 0 N--CA 1.471 0.597 0 CA-C-N 117.919 0.327 . . . . 0.0 110.783 -179.194 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . 0.636 ' N ' ' HG3' ' A' ' 90' ' ' ARG . 4.5 pp -69.8 -23.83 63.39 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.845 -0.616 . . . . 0.0 111.419 -172.43 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . 0.528 ' NE ' ' HA ' ' A' ' 89' ' ' THR . 1.9 mtm180 -81.22 -47.96 12.71 Favored 'General case' 0 N--CA 1.447 -0.606 0 CA-C-O 121.576 0.703 . . . . 0.0 109.468 -178.948 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 93' ' ' GLN . . . . . 0.477 ' OE1' ' HB1' ' A' ' 97' ' ' ALA . 17.6 pt20 -95.94 -27.14 15.3 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 114.731 -1.122 . . . . 0.0 112.872 -167.633 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 91.76 39.86 5.43 Favored Glycine 0 CA--C 1.504 -0.615 0 C-N-CA 120.344 -0.931 . . . . 0.0 111.985 170.441 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 95' ' ' TRP . . . . . 0.45 ' HA ' ' HE3' ' A' ' 98' ' ' TRP . 6.9 m95 63.74 17.27 10.35 Favored 'General case' 0 C--O 1.22 -0.474 0 N-CA-C 109.255 -0.646 . . . . 0.0 109.255 -179.231 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -70.47 -30.29 69.12 Favored Glycine 0 N--CA 1.451 -0.344 0 CA-C-N 115.504 -0.771 . . . . 0.0 112.598 177.989 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . 0.477 ' HB1' ' OE1' ' A' ' 93' ' ' GLN . . . -69.99 -30.11 67.36 Favored 'General case' 0 CA--C 1.514 -0.439 0 CA-C-O 120.924 0.392 . . . . 0.0 110.21 177.488 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 98' ' ' TRP . . . . . 0.487 ' CZ3' ' HH2' ' A' ' 31' ' ' TRP . 25.6 m-90 -98.47 104.55 24.45 Favored Pre-proline 0 C--N 1.323 -0.571 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 177.353 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . 0.405 ' HD3' ' O ' ' A' ' 97' ' ' ALA . 20.2 Cg_exo -70.99 -94.2 0.01 OUTLIER 'Trans proline' 0 CA--C 1.534 0.505 0 C-N-CA 122.889 2.393 . . . . 0.0 114.734 -172.22 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 60.6 t -70.99 -31.95 46.84 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 CA-C-O 121.822 0.82 . . . . 0.0 110.19 -173.98 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 101' ' ' CYS . . . . . 0.815 ' SG ' ' HG3' ' A' ' 38' ' ' GLU . 75.6 m -78.26 -26.1 47.05 Favored 'General case' 0 C--N 1.315 -0.932 0 CA-C-N 114.772 -1.104 . . . . 0.0 112.27 -168.832 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 102' ' ' ALA . . . . . 0.478 ' HB3' ' HB2' ' A' ' 98' ' ' TRP . . . -69.93 -46.19 65.89 Favored 'General case' 0 C--N 1.326 -0.444 0 C-N-CA 120.549 -0.461 . . . . 0.0 110.23 176.249 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -65.33 -35.92 82.46 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.699 -179.358 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 104' ' ' ARG . . . . . 0.414 ' HG2' ' HA ' ' A' ' 101' ' ' CYS . 0.0 OUTLIER -73.41 -21.45 60.48 Favored 'General case' 0 N--CA 1.444 -0.725 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.425 179.785 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 105' ' ' ALA . . . . . 0.489 ' HB3' ' HB1' ' A' ' 33' ' ' ALA . . . -96.08 -22.82 17.1 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.821 -0.627 . . . . 0.0 111.581 -178.157 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 119.02 63.66 0.29 Allowed Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 121.236 -0.507 . . . . 0.0 112.236 -176.86 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -64.09 145.15 56.42 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.776 0.322 . . . . 0.0 110.782 179.36 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 51.8 mtp180 . . . . . 0 C--O 1.249 1.06 0 CA-C-O 118.395 -0.812 . . . . 0.0 110.332 -173.293 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 5.3 m-20 . . . . . 0 N--CA 1.482 1.143 0 CA-C-O 121.198 0.523 . . . . 0.0 110.607 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 61.9 t -75.99 -43.46 38.78 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 CA-C-N 115.616 -0.72 . . . . 0.0 109.472 177.558 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 48.6 t -77.77 95.65 1.63 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.798 0 CA-C-N 115.701 -0.681 . . . . 0.0 109.481 173.74 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 11.5 t -75.56 144.68 11.71 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.044 -177.894 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' THR . . . . . 0.403 ' HA ' ' HD3' ' A' ' 6' ' ' PRO . 11.3 p -103.92 107.75 57.78 Favored Pre-proline 0 C--N 1.314 -0.955 0 CA-C-N 115.874 -0.603 . . . . 0.0 111.045 -177.571 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.403 ' HD3' ' HA ' ' A' ' 5' ' ' THR . 1.5 Cg_endo -86.1 170.13 8.48 Favored 'Trans proline' 0 N--CA 1.448 -1.169 0 C-N-CA 123.502 2.801 . . . . 0.0 111.263 177.329 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -82.7 81.96 8.25 Favored 'General case' 0 C--N 1.307 -1.245 0 CA-C-N 114.892 -1.049 . . . . 0.0 110.985 -179.292 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 31.8 m170 -74.87 -18.45 60.43 Favored 'General case' 0 C--N 1.316 -0.883 0 N-CA-C 107.666 -1.235 . . . . 0.0 107.666 169.821 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 12.7 pt-20 -115.11 132.15 56.7 Favored 'General case' 0 N--CA 1.44 -0.934 0 CA-C-N 114.795 -1.093 . . . . 0.0 109.609 175.607 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -147.38 73.51 1.29 Allowed 'General case' 0 C--N 1.321 -0.65 0 CA-C-O 121.523 0.678 . . . . 0.0 110.412 -179.152 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 58.0 t -75.21 -56.39 8.91 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.711 0 CA-C-N 114.938 -1.028 . . . . 0.0 110.439 -179.297 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 72.1 t 21.52 84.33 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.451 -0.414 0 C-N-CA 125.598 1.559 . . . . 0.0 113.162 177.272 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . 0.409 ' HG3' ' O ' ' A' ' 13' ' ' ARG . 6.6 ptp180 -70.29 112.44 6.62 Favored 'General case' 0 C--N 1.306 -1.308 0 CA-C-N 114.098 -1.41 . . . . 0.0 110.106 -179.646 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . 0.429 HG21 ' N ' ' A' ' 15' ' ' GLY . 7.4 p -72.48 163.04 4.09 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.42 0 CA-C-N 114.021 -1.445 . . . . 0.0 110.392 178.49 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . 0.484 ' O ' ' HG3' ' A' ' 17' ' ' LYS . . . -90.52 -75.62 1.3 Allowed Glycine 0 C--N 1.299 -1.516 0 CA-C-N 113.654 -1.612 . . . . 0.0 111.03 -176.724 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' THR . . . . . 0.47 ' C ' ' HD3' ' A' ' 18' ' ' PRO . 93.6 m 63.98 -21.99 0.07 Allowed 'General case' 0 N--CA 1.437 -1.115 0 N-CA-C 114.653 1.353 . . . . 0.0 114.653 176.708 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . 0.779 ' HD2' ' O ' ' A' ' 17' ' ' LYS . 0.0 OUTLIER -114.05 74.94 2.84 Favored Pre-proline 0 C--N 1.319 -0.742 0 N-CA-C 112.814 0.672 . . . . 0.0 112.814 178.487 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . 0.47 ' HD3' ' C ' ' A' ' 16' ' ' THR . 31.5 Cg_exo -66.54 115.06 3.33 Favored 'Trans proline' 0 CA--C 1.509 -0.75 0 C-N-CA 123.217 2.612 . . . . 0.0 112.427 178.045 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -112.45 -53.19 0.5 Allowed Glycine 0 C--N 1.299 -1.523 0 CA-C-N 113.448 -1.705 . . . . 0.0 111.342 179.786 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 13.7 m -69.56 -42.8 74.05 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.494 -0.353 . . . . 0.0 110.9 178.368 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 34.8 mt-10 47.01 87.94 0.02 OUTLIER 'General case' 0 N--CA 1.453 -0.279 0 CA-C-O 121.769 0.795 . . . . 0.0 112.431 -176.088 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.685 HG23 ' HB ' ' A' ' 78' ' ' THR . 37.8 t -92.17 124.14 60.61 Favored Pre-proline 0 C--N 1.312 -1.054 0 CA-C-N 114.926 -1.034 . . . . 0.0 109.785 -178.866 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_exo -57.54 127.11 24.11 Favored 'Trans proline' 0 N--CA 1.461 -0.412 0 C-N-CA 122.867 2.378 . . . . 0.0 112.786 -177.923 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 23.0 Cg_exo -68.11 142.93 57.7 Favored 'Trans proline' 0 N--CA 1.435 -1.944 0 C-N-CA 123.447 2.764 . . . . 0.0 113.205 177.535 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 44.1 t -102.31 158.22 4.55 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.141 0 CA-C-N 114.478 -1.237 . . . . 0.0 108.18 173.331 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 46.2 mm -54.56 -38.93 43.71 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.695 0 CA-C-O 121.001 0.429 . . . . 0.0 111.683 -173.284 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 15.0 m-20 -103.87 3.99 34.39 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-O 121.865 0.84 . . . . 0.0 109.532 -179.172 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . 0.466 ' HA2' ' HB2' ' A' ' 31' ' ' TRP . . . -70.23 -6.32 56.98 Favored Glycine 0 N--CA 1.44 -1.057 0 CA-C-N 114.481 -1.236 . . . . 0.0 110.38 176.526 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 9.6 m -76.96 -39.4 50.71 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-O 121.659 0.742 . . . . 0.0 109.087 174.661 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.498 ' O ' HG13 ' A' ' 34' ' ' ILE . 1.0 OUTLIER -69.65 -38.1 75.64 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.576 0 N-CA-C 107.492 -1.299 . . . . 0.0 107.492 177.366 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' TRP . . . . . 0.503 ' CD1' HG22 ' A' ' 83' ' ' ILE . 43.2 m95 -71.41 -35.91 71.16 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 114.262 -1.336 . . . . 0.0 110.487 -177.857 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.505 ' HB2' HH21 ' A' ' 79' ' ' ARG . 15.5 t70 -74.28 -34.56 63.6 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.385 178.328 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -69.89 -34.47 73.59 Favored 'General case' 0 N--CA 1.446 -0.629 0 C-N-CA 120.756 -0.377 . . . . 0.0 110.12 177.705 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . 0.557 ' HA ' ' HB3' ' A' ' 101' ' ' CYS . 61.9 mt -67.33 -47.44 81.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.312 174.399 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . 0.442 ' HA ' ' O ' ' A' ' 54' ' ' GLY . . . -58.76 -39.14 80.12 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.501 177.554 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -76.13 -8.79 85.42 Favored Glycine 0 N--CA 1.451 -0.337 0 CA-C-N 115.559 -0.746 . . . . 0.0 112.081 179.603 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 1.7 t -97.16 -57.96 2.13 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-O 120.678 0.275 . . . . 0.0 111.417 -178.6 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . 0.542 ' HB2' ' SG ' ' A' ' 101' ' ' CYS . 8.0 tp10 -87.97 -33.02 18.57 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 121.207 0.527 . . . . 0.0 109.999 -171.315 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -95.71 -13.05 24.52 Favored 'General case' 0 N--CA 1.448 -0.538 0 CA-C-N 115.631 -0.713 . . . . 0.0 111.197 -178.749 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 82.52 1.34 90.47 Favored Glycine 0 N--CA 1.448 -0.505 0 N-CA-C 109.983 -1.247 . . . . 0.0 109.983 -177.04 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 93.65 55.63 1.52 Allowed Glycine 0 N--CA 1.436 -1.327 0 CA-C-N 114.372 -0.914 . . . . 0.0 111.61 -176.543 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . 0.559 ' HB3' ' HB ' ' A' ' 45' ' ' ILE . 0.3 OUTLIER -142.93 94.6 2.65 Favored 'General case' 0 N--CA 1.447 -0.606 0 N-CA-C 108.704 -0.85 . . . . 0.0 108.704 -177.689 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' TRP . . . . . 0.75 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 38.3 m95 -76.65 -10.71 59.58 Favored 'General case' 0 C--N 1.317 -0.844 0 CA-C-O 121.384 0.611 . . . . 0.0 110.423 -175.385 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -107.73 15.38 24.66 Favored 'General case' 0 C--N 1.318 -0.795 0 CA-C-N 114.981 -1.009 . . . . 0.0 111.731 -178.624 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.726 HG21 ' HA2' ' A' ' 53' ' ' GLY . 9.9 tt -83.21 142.42 13.56 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.619 0 CA-C-O 121.432 0.634 . . . . 0.0 111.344 -175.639 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 9.7 m120 -133.53 88.19 2.46 Favored 'General case' 0 C--N 1.316 -0.873 0 N-CA-C 108.539 -0.911 . . . . 0.0 108.539 176.663 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 1.2 p -69.31 -24.09 63.89 Favored 'General case' 0 C--N 1.315 -0.934 0 CA-C-N 115.769 -0.651 . . . . 0.0 110.603 179.708 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 94.57 19.0 33.51 Favored Glycine 0 N--CA 1.444 -0.795 0 N-CA-C 111.272 -0.731 . . . . 0.0 111.272 176.412 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 30.7 p-10 -94.7 11.62 30.64 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.141 0.496 . . . . 0.0 111.134 -175.301 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . 0.469 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 89.9 -11.59 70.07 Favored Glycine 0 N--CA 1.445 -0.724 0 N-CA-C 110.823 -0.911 . . . . 0.0 110.823 -178.243 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' TYR . . . . . 0.588 ' CE1' ' HB3' ' A' ' 58' ' ' ASP . 0.8 OUTLIER -109.94 151.64 26.85 Favored 'General case' 0 CA--C 1.512 -0.488 0 N-CA-C 107.827 -1.175 . . . . 0.0 107.827 178.722 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' TYR . . . . . 0.612 ' CE1' ' HB2' ' A' ' 59' ' ' GLN . 24.2 m-85 -115.36 170.4 8.43 Favored 'General case' 0 C--N 1.313 -0.995 0 C-N-CA 120.647 -0.421 . . . . 0.0 111.316 -170.294 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.726 ' HA2' HG21 ' A' ' 45' ' ' ILE . . . -56.92 166.72 4.72 Favored Glycine 0 N--CA 1.451 -0.354 0 N-CA-C 114.818 0.687 . . . . 0.0 114.818 -169.744 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . 0.671 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 88.19 -103.78 2.97 Favored Glycine 0 N--CA 1.444 -0.791 0 C-N-CA 121.253 -0.499 . . . . 0.0 112.237 177.305 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.48 ' HB ' ' CD1' ' A' ' 57' ' ' PHE . 2.5 t -83.27 -2.82 6.95 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 CA-C-O 121.445 0.64 . . . . 0.0 109.785 -177.873 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' GLN . . . . . 0.598 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 2.0 mm-40 55.91 42.33 28.94 Favored 'General case' 0 N--CA 1.462 0.139 0 CA-C-N 114.747 -1.115 . . . . 0.0 113.102 169.727 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . 0.48 ' CD1' ' HB ' ' A' ' 55' ' ' VAL . 1.5 p90 -114.88 165.63 12.64 Favored 'General case' 0 C--N 1.322 -0.616 0 C-N-CA 119.912 -0.715 . . . . 0.0 111.041 175.253 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.588 ' HB3' ' CE1' ' A' ' 51' ' ' TYR . 8.1 p-10 -76.02 155.56 34.82 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 122.075 0.941 . . . . 0.0 112.619 -164.238 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.612 ' HB2' ' CE1' ' A' ' 52' ' ' TYR . 3.6 tp-100 -61.42 -32.11 72.06 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 113.414 -1.721 . . . . 0.0 111.14 179.767 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -65.94 -49.5 58.26 Favored Glycine 0 C--N 1.316 -0.553 0 CA-C-N 115.48 -0.782 . . . . 0.0 111.786 -179.862 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 90.9 m -66.67 -40.75 88.75 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-O 120.787 0.327 . . . . 0.0 110.996 175.979 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' TRP . . . . . 0.484 ' CH2' ' HA ' ' A' ' 74' ' ' ALA . 46.2 t-105 -56.38 -49.53 74.18 Favored 'General case' 0 N--CA 1.45 -0.462 0 CA-C-O 121.656 0.741 . . . . 0.0 109.293 176.137 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . 0.427 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 33.6 tt0 -68.11 -32.28 72.47 Favored 'General case' 0 N--CA 1.444 -0.763 0 CA-C-N 115.022 -0.99 . . . . 0.0 110.855 179.857 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -64.26 -39.03 93.11 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.891 -179.588 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . 0.573 ' HB2' HG13 ' A' ' 85' ' ' VAL . 5.5 m120 -78.76 -14.05 59.48 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 121.597 0.713 . . . . 0.0 109.485 175.134 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . 0.565 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 82.68 49.15 5.25 Favored Glycine 0 N--CA 1.445 -0.702 0 CA-C-N 115.061 -0.972 . . . . 0.0 111.608 -179.924 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . 0.618 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -78.67 -15.39 80.86 Favored Glycine 0 N--CA 1.442 -0.96 0 C-N-CA 121.273 -0.489 . . . . 0.0 112.432 -174.765 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 0.866 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 6.8 mp -59.21 -27.27 65.57 Favored 'General case' 0 C--N 1.323 -0.575 0 N-CA-C 111.872 0.323 . . . . 0.0 111.872 -175.568 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . 0.565 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 9.1 ptp180 -65.33 -30.12 70.93 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 121.353 0.597 . . . . 0.0 110.046 177.182 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' TYR . . . . . 0.978 ' HB3' ' HB3' ' A' ' 81' ' ' GLU . 75.0 m-85 -81.49 -34.3 31.39 Favored 'General case' 0 N--CA 1.441 -0.905 0 N-CA-C 107.638 -1.245 . . . . 0.0 107.638 176.405 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.681 ' HB1' ' HB2' ' A' ' 77' ' ' ALA . . . 162.67 128.92 0.01 OUTLIER Pre-proline 0 CA--C 1.513 -0.465 0 CA-C-N 112.653 -2.067 . . . . 0.0 107.009 -179.568 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' PRO . . . . . 0.866 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 20.4 Cg_exo -57.35 -4.93 1.3 Allowed 'Trans proline' 0 C--N 1.333 -0.26 0 C-N-CA 122.77 2.313 . . . . 0.0 113.767 -177.17 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' ARG . . . . . 0.409 ' HE ' ' CG ' ' A' ' 75' ' ' ASP . 10.7 ptm180 -147.86 139.01 23.45 Favored 'General case' 0 C--N 1.317 -0.805 0 N-CA-C 109.367 -0.605 . . . . 0.0 109.367 176.526 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . 0.484 ' HA ' ' CH2' ' A' ' 62' ' ' TRP . . . -55.95 -29.84 60.77 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 114.941 -1.027 . . . . 0.0 112.52 -177.193 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . 0.531 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 4.6 p-10 -83.97 -4.68 58.9 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 120.967 0.413 . . . . 0.0 111.256 -176.037 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 68.1 tp -100.0 -29.74 12.37 Favored 'General case' 0 C--N 1.322 -0.59 0 N-CA-C 108.46 -0.941 . . . . 0.0 108.46 172.549 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . 0.782 ' HB3' ' HB2' ' A' ' 81' ' ' GLU . . . -79.28 159.16 27.36 Favored 'General case' 0 N--CA 1.44 -0.968 0 CA-C-N 114.78 -1.1 . . . . 0.0 109.795 175.113 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' THR . . . . . 0.685 ' HB ' HG23 ' A' ' 22' ' ' VAL . 61.9 p -100.35 -175.19 2.85 Favored 'General case' 0 C--N 1.309 -1.188 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.355 -176.974 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . 0.75 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 77.7 mtp180 -50.01 -52.93 30.11 Favored 'General case' 0 C--N 1.329 -0.293 0 O-C-N 123.416 0.447 . . . . 0.0 111.265 178.819 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 80' ' ' GLU . . . . . 0.436 ' HA ' HD11 ' A' ' 83' ' ' ILE . 17.0 pt-20 -60.8 -37.23 81.24 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.873 -0.603 . . . . 0.0 111.434 -174.43 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 81' ' ' GLU . . . . . 0.978 ' HB3' ' HB3' ' A' ' 70' ' ' TYR . 4.2 mm-40 -70.22 -50.32 41.05 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 121.031 0.443 . . . . 0.0 109.959 -179.465 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 82' ' ' GLN . . . . . 0.553 ' HB2' ' HZ3' ' A' ' 43' ' ' TRP . 41.7 mt-30 -60.03 -34.45 73.4 Favored 'General case' 0 CA--C 1.513 -0.465 0 CA-C-N 115.515 -0.766 . . . . 0.0 110.201 -179.319 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . 0.68 ' O ' ' HG2' ' A' ' 87' ' ' GLU . 40.3 mt -60.77 -49.1 85.91 Favored 'Isoleucine or valine' 0 C--O 1.212 -0.883 0 N-CA-C 109.084 -0.71 . . . . 0.0 109.084 175.855 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . 0.578 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -62.1 -44.09 97.4 Favored 'General case' 0 C--O 1.237 0.414 0 CA-C-O 121.277 0.56 . . . . 0.0 111.867 -176.353 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . 0.573 HG13 ' HB2' ' A' ' 65' ' ' ASN . 40.0 t -66.24 -49.32 76.86 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.609 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.862 179.432 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . 0.458 ' HB1' ' CH2' ' A' ' 31' ' ' TRP . . . -59.11 -29.54 67.45 Favored 'General case' 0 N--CA 1.447 -0.592 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.404 174.572 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 87' ' ' GLU . . . . . 0.849 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 15.7 mm-40 -59.46 -44.3 93.0 Favored 'General case' 0 C--O 1.222 -0.386 0 CA-C-N 115.846 -0.616 . . . . 0.0 110.492 -178.599 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.438 ' O ' ' HG3' ' A' ' 92' ' ' ARG . 70.6 t -60.52 -49.3 84.93 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.303 0 C-N-CA 120.288 -0.565 . . . . 0.0 110.091 179.747 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 89' ' ' THR . . . . . 0.565 HG22 ' NE2' ' A' ' 93' ' ' GLN . 24.0 m -66.24 -43.8 85.57 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-N 115.683 -0.69 . . . . 0.0 111.437 -177.155 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . 0.647 ' HA ' ' OE1' ' A' ' 93' ' ' GLN . 3.2 ppt_? -60.96 -34.34 74.59 Favored 'General case' 0 N--CA 1.467 0.4 0 N-CA-C 112.073 0.397 . . . . 0.0 112.073 -176.48 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . 0.849 ' HG ' ' O ' ' A' ' 87' ' ' GLU . 46.5 mt -62.87 -33.25 74.88 Favored 'General case' 0 N--CA 1.471 0.587 0 CA-C-O 121.47 0.652 . . . . 0.0 110.152 -177.998 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . 0.438 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 6.5 mtm180 -81.57 -50.57 9.21 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-N 114.818 -1.083 . . . . 0.0 110.103 -169.85 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 93' ' ' GLN . . . . . 0.647 ' OE1' ' HA ' ' A' ' 90' ' ' ARG . 0.0 OUTLIER -96.13 -23.55 16.7 Favored 'General case' 0 C--N 1.318 -0.785 0 C-N-CA 119.733 -0.787 . . . . 0.0 113.045 -171.682 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 88.48 40.41 6.42 Favored Glycine 0 CA--C 1.508 -0.345 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.156 172.466 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 95' ' ' TRP . . . . . 0.521 ' CZ2' ' HD3' ' A' ' 90' ' ' ARG . 22.1 m95 67.16 9.09 6.68 Favored 'General case' 0 C--O 1.221 -0.423 0 C-N-CA 123.6 0.76 . . . . 0.0 110.033 -179.124 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -71.97 -23.48 77.93 Favored Glycine 0 N--CA 1.451 -0.305 0 CA-C-N 115.891 -0.595 . . . . 0.0 112.444 178.155 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . 0.411 ' HB3' ' HG3' ' A' ' 93' ' ' GLN . . . -72.7 -28.1 62.47 Favored 'General case' 0 CA--C 1.516 -0.337 0 CA-C-O 121.046 0.451 . . . . 0.0 109.988 177.641 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 98' ' ' TRP . . . . . 0.517 ' HZ3' ' HA ' ' A' ' 90' ' ' ARG . 28.6 m-90 -101.02 104.16 30.31 Favored Pre-proline 0 N--CA 1.448 -0.567 0 CA-C-N 115.146 -0.934 . . . . 0.0 108.966 176.528 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . 0.409 ' HD3' ' HA ' ' A' ' 98' ' ' TRP . 15.7 Cg_exo -73.95 -88.38 0.0 OUTLIER 'Trans proline' 0 CA--C 1.53 0.32 0 C-N-CA 123.182 2.588 . . . . 0.0 114.993 -171.127 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . 0.416 ' HA ' HH21 ' A' ' 104' ' ' ARG . 80.5 t -69.45 -30.08 44.24 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-O 121.142 0.496 . . . . 0.0 110.693 -172.393 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 101' ' ' CYS . . . . . 0.557 ' HB3' ' HA ' ' A' ' 34' ' ' ILE . 87.1 m -79.79 -37.64 34.84 Favored 'General case' 0 C--N 1.317 -0.812 0 CA-C-N 115.7 -0.682 . . . . 0.0 112.403 -170.102 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 102' ' ' ALA . . . . . 0.435 ' HB2' ' HB3' ' A' ' 95' ' ' TRP . . . -69.62 -40.33 76.66 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.828 0.347 . . . . 0.0 110.912 -178.556 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -61.48 -38.55 87.71 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-O 121.318 0.58 . . . . 0.0 110.588 177.127 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 104' ' ' ARG . . . . . 0.416 HH21 ' HA ' ' A' ' 100' ' ' VAL . 1.4 mpp_? -74.58 -18.45 60.57 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.371 -0.831 . . . . 0.0 111.618 176.77 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -96.49 -22.8 16.89 Favored 'General case' 0 C--N 1.327 -0.399 0 N-CA-C 112.659 0.615 . . . . 0.0 112.659 -173.638 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 106.11 64.21 0.62 Allowed Glycine 0 CA--C 1.52 0.4 0 C-N-CA 120.793 -0.718 . . . . 0.0 112.252 -177.582 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -72.24 149.14 44.83 Favored 'General case' 0 C--N 1.326 -0.436 0 C-N-CA 122.906 0.483 . . . . 0.0 111.28 -174.867 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.245 0.819 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.619 -175.403 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 2.5 p-10 . . . . . 0 N--CA 1.472 0.66 0 N-CA-C 108.924 -0.769 . . . . 0.0 108.924 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 50.1 t -62.78 -35.32 70.31 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 114.981 -1.009 . . . . 0.0 112.644 -173.153 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 91.8 t -62.26 108.52 0.55 Allowed 'Isoleucine or valine' 0 C--O 1.236 0.382 0 CA-C-O 120.92 0.391 . . . . 0.0 111.457 -179.758 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 12.7 t -88.0 147.7 5.08 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 N-CA-C 109.596 -0.52 . . . . 0.0 109.596 177.193 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 23.2 p -92.88 117.52 67.58 Favored Pre-proline 0 C--N 1.315 -0.907 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.766 -179.647 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 5.0 Cg_exo -80.89 161.07 21.2 Favored 'Trans proline' 0 N--CA 1.448 -1.188 0 C-N-CA 122.902 2.401 . . . . 0.0 111.434 177.797 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -147.38 87.63 1.67 Allowed 'General case' 0 C--N 1.307 -1.276 0 CA-C-N 114.786 -1.097 . . . . 0.0 112.037 -175.596 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 63.5 t60 -104.29 -13.08 16.28 Favored 'General case' 0 C--N 1.312 -1.044 0 N-CA-C 107.132 -1.433 . . . . 0.0 107.132 165.198 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 9.3 pt-20 -84.97 158.01 20.63 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 113.899 -1.5 . . . . 0.0 111.396 -177.031 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -138.01 69.58 1.39 Allowed 'General case' 0 C--N 1.317 -0.838 0 CA-C-N 114.998 -1.001 . . . . 0.0 108.874 172.042 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 38.7 t -99.9 -73.26 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.442 -0.844 0 CA-C-N 114.752 -1.113 . . . . 0.0 110.571 -176.219 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.432 ' O ' HG11 ' A' ' 12' ' ' VAL . 77.9 t 21.34 75.32 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.447 -0.618 0 O-C-N 125.19 1.556 . . . . 0.0 111.993 -174.188 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . 0.403 HH11 ' HD3' ' A' ' 13' ' ' ARG . 0.0 OUTLIER -88.9 95.94 10.51 Favored 'General case' 0 C--N 1.303 -1.455 0 CA-C-N 113.938 -1.483 . . . . 0.0 111.227 -173.801 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 4.6 t -128.44 161.61 36.75 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.593 0 CA-C-N 113.298 -1.774 . . . . 0.0 108.748 -179.627 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 94.88 63.15 1.0 Allowed Glycine 0 C--N 1.309 -0.966 0 N-CA-C 111.113 -0.795 . . . . 0.0 111.113 -177.93 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 12.8 m -76.52 -22.94 53.76 Favored 'General case' 0 C--N 1.316 -0.886 0 CA-C-N 114.437 -0.881 . . . . 0.0 111.317 -175.069 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . 0.485 ' HD2' ' N ' ' A' ' 17' ' ' LYS . 0.0 OUTLIER -133.09 114.57 13.84 Favored Pre-proline 0 C--N 1.311 -1.066 0 CA-C-N 114.922 -1.036 . . . . 0.0 110.138 -178.841 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . 0.413 ' HD3' ' HA ' ' A' ' 17' ' ' LYS . 8.3 Cg_exo -73.84 173.58 13.75 Favored 'Trans proline' 0 N--CA 1.461 -0.431 0 C-N-CA 123.312 2.675 . . . . 0.0 112.938 179.97 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 135.77 -38.67 1.76 Allowed Glycine 0 N--CA 1.44 -1.053 0 CA-C-N 114.063 -1.426 . . . . 0.0 111.58 179.974 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 21.4 m -60.23 -34.58 73.87 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-N 114.69 -0.755 . . . . 0.0 112.43 -177.846 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 3.3 pm0 -58.59 120.47 8.93 Favored 'General case' 0 N--CA 1.451 -0.415 0 CA-C-O 122.391 1.091 . . . . 0.0 111.314 -176.981 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 45.6 t -87.88 129.3 50.91 Favored Pre-proline 0 C--N 1.301 -1.512 0 CA-C-N 113.615 -1.63 . . . . 0.0 110.301 178.911 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_exo -53.89 142.75 62.91 Favored 'Trans proline' 0 C--N 1.344 0.338 0 C-N-CA 122.964 2.443 . . . . 0.0 111.639 176.933 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 10.4 Cg_endo -54.69 138.89 76.75 Favored 'Trans proline' 0 N--CA 1.459 -0.525 0 C-N-CA 123.427 2.751 . . . . 0.0 112.777 -175.069 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.971 HG12 HD13 ' A' ' 83' ' ' ILE . 14.8 p -107.07 128.43 61.96 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.087 0 CA-C-N 114.603 -1.181 . . . . 0.0 111.239 -178.22 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 45.3 mm -82.53 -25.47 8.7 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-N 115.611 -0.722 . . . . 0.0 110.423 177.067 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.447 ' O ' HG12 ' A' ' 30' ' ' ILE . 18.4 m-20 -108.52 15.93 23.43 Favored 'General case' 0 CA--C 1.511 -0.53 0 CA-C-N 115.442 -0.799 . . . . 0.0 109.784 -172.653 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . 0.499 ' N ' HG22 ' A' ' 25' ' ' VAL . . . -69.91 -8.36 60.88 Favored Glycine 0 CA--C 1.5 -0.874 0 N-CA-C 110.343 -1.103 . . . . 0.0 110.343 177.921 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 16.4 m -76.55 -35.04 58.47 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 114.591 -0.805 . . . . 0.0 109.197 175.857 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.613 ' HA ' ' HB1' ' A' ' 105' ' ' ALA . 1.1 mm -71.46 -36.95 62.62 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.645 0 N-CA-C 107.245 -1.391 . . . . 0.0 107.245 177.105 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' TRP . . . . . 0.545 ' CH2' ' HB2' ' A' ' 86' ' ' ALA . 34.6 m95 -71.15 -36.3 72.0 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 114.089 -1.414 . . . . 0.0 111.012 -177.259 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.752 ' HB2' HH21 ' A' ' 79' ' ' ARG . 17.5 t70 -74.79 -36.7 62.51 Favored 'General case' 0 N--CA 1.445 -0.694 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.477 179.119 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . 0.464 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -70.47 -34.19 72.12 Favored 'General case' 0 N--CA 1.448 -0.537 0 C-N-CA 120.817 -0.353 . . . . 0.0 110.695 178.687 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . 0.548 HG13 ' O ' ' A' ' 30' ' ' ILE . 65.9 mt -64.73 -44.67 96.51 Favored 'Isoleucine or valine' 0 C--O 1.235 0.327 0 CA-C-O 121.286 0.565 . . . . 0.0 109.988 173.914 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . 0.436 ' HA ' ' O ' ' A' ' 54' ' ' GLY . . . -59.59 -35.03 73.51 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.511 -0.768 . . . . 0.0 110.261 176.245 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . 0.509 ' HA2' ' N ' ' A' ' 41' ' ' GLY . . . -78.94 4.37 61.82 Favored Glycine 0 N--CA 1.452 -0.293 0 CA-C-N 115.368 -0.833 . . . . 0.0 112.341 179.643 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 27.0 t -108.15 -53.84 2.58 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 120.576 0.227 . . . . 0.0 111.114 -179.499 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . 0.436 ' HG2' ' SG ' ' A' ' 101' ' ' CYS . 36.7 mm-40 -87.86 -33.1 18.67 Favored 'General case' 0 CA--C 1.515 -0.39 0 CA-C-O 121.093 0.473 . . . . 0.0 110.552 -176.547 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -105.1 -9.71 17.62 Favored 'General case' 0 N--CA 1.447 -0.587 0 CA-C-N 116.044 -0.525 . . . . 0.0 112.124 -175.201 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 75.11 17.51 80.23 Favored Glycine 0 CA--C 1.505 -0.577 0 N-CA-C 109.635 -1.386 . . . . 0.0 109.635 -177.199 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . 0.509 ' N ' ' HA2' ' A' ' 36' ' ' GLY . . . 75.24 61.51 2.99 Favored Glycine 0 N--CA 1.432 -1.598 0 CA-C-N 114.019 -1.091 . . . . 0.0 111.455 -174.953 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . 0.495 HD21 ' HB ' ' A' ' 45' ' ' ILE . 3.7 t30 -145.84 100.16 3.37 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 108.332 -0.988 . . . . 0.0 108.332 -177.251 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' TRP . . . . . 0.8 ' HA ' ' N ' ' A' ' 54' ' ' GLY . 30.2 m95 -84.47 -3.82 58.59 Favored 'General case' 0 C--N 1.317 -0.833 0 CA-C-O 121.605 0.717 . . . . 0.0 110.664 -170.785 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -111.64 15.69 20.93 Favored 'General case' 0 C--N 1.311 -1.091 0 CA-C-N 114.806 -1.088 . . . . 0.0 110.86 178.768 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.789 HG22 ' HA2' ' A' ' 53' ' ' GLY . 10.5 tt -79.38 137.63 21.4 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.733 0 CA-C-O 121.163 0.506 . . . . 0.0 110.508 -177.85 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 46.4 t30 -171.24 103.72 0.21 Allowed 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 115.956 -0.566 . . . . 0.0 110.379 178.948 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 25.3 p -82.63 -11.51 58.33 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 115.767 -0.651 . . . . 0.0 111.09 177.586 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 104.07 21.28 9.64 Favored Glycine 0 N--CA 1.449 -0.483 0 C-N-CA 120.808 -0.711 . . . . 0.0 111.386 -175.348 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 8.6 p30 -82.15 -4.86 57.84 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 115.623 -0.288 . . . . 0.0 111.161 -178.335 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . 0.546 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 96.3 -11.95 66.88 Favored Glycine 0 N--CA 1.448 -0.525 0 C-N-CA 121.305 -0.474 . . . . 0.0 112.039 177.755 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' TYR . . . . . 0.569 ' HA ' ' HA ' ' A' ' 58' ' ' ASP . 0.6 OUTLIER -112.37 151.61 29.59 Favored 'General case' 0 CA--C 1.514 -0.412 0 N-CA-C 107.834 -1.173 . . . . 0.0 107.834 176.349 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' TYR . . . . . 0.68 ' O ' ' HA ' ' A' ' 56' ' ' GLN . 42.9 m-85 -116.61 170.39 8.62 Favored 'General case' 0 C--N 1.313 -0.984 0 C-N-CA 120.4 -0.52 . . . . 0.0 112.203 -166.242 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.789 ' HA2' HG22 ' A' ' 45' ' ' ILE . . . -60.12 172.18 5.83 Favored Glycine 0 N--CA 1.446 -0.658 0 N-CA-C 115.548 0.979 . . . . 0.0 115.548 -167.653 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . 0.8 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 87.53 -109.35 3.46 Favored Glycine 0 N--CA 1.437 -1.234 0 CA-C-N 114.486 -0.857 . . . . 0.0 111.636 177.557 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.513 HG12 ' CE3' ' A' ' 31' ' ' TRP . 0.5 OUTLIER -84.16 2.21 3.93 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.594 0 CA-C-O 121.351 0.596 . . . . 0.0 110.868 178.793 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' GLN . . . . . 0.755 ' HA ' HE21 ' A' ' 56' ' ' GLN . 0.0 OUTLIER 59.5 51.36 6.6 Favored 'General case' 0 CA--C 1.532 0.271 0 CA-C-N 114.207 -1.361 . . . . 0.0 113.316 164.952 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -119.12 168.37 10.91 Favored 'General case' 0 C--N 1.326 -0.454 0 C-N-CA 119.465 -0.894 . . . . 0.0 111.865 174.215 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.569 ' HA ' ' HA ' ' A' ' 51' ' ' TYR . 7.4 p-10 -78.53 166.11 22.95 Favored 'General case' 0 C--N 1.327 -0.383 0 N-CA-C 113.724 1.009 . . . . 0.0 113.724 -163.459 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.452 ' HB2' ' HE1' ' A' ' 52' ' ' TYR . 5.6 tp-100 -61.08 -39.96 91.87 Favored 'General case' 0 N--CA 1.446 -0.667 0 CA-C-N 114.775 -1.102 . . . . 0.0 111.244 177.601 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -64.32 -49.55 65.16 Favored Glycine 0 C--N 1.317 -0.483 0 CA-C-N 115.665 -0.698 . . . . 0.0 111.572 -175.185 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 87.9 m -66.77 -41.58 87.5 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-N 115.612 -0.294 . . . . 0.0 111.167 176.591 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' TRP . . . . . 0.437 ' CE2' ' HA3' ' A' ' 67' ' ' GLY . 57.2 t-105 -56.48 -48.4 77.19 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 121.773 0.796 . . . . 0.0 109.437 177.0 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . 0.459 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 29.3 tt0 -67.44 -34.22 76.76 Favored 'General case' 0 C--N 1.317 -0.833 0 CA-C-N 114.8 -1.091 . . . . 0.0 111.131 -179.655 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -65.14 -41.36 94.87 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.899 -0.592 . . . . 0.0 111.129 -177.166 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . 0.563 ' HB2' HG11 ' A' ' 85' ' ' VAL . 31.4 m-80 -82.94 -9.2 59.41 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.715 0.293 . . . . 0.0 110.502 177.232 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . 0.504 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 91.46 49.79 2.91 Favored Glycine 0 C--N 1.334 0.433 0 C-N-CA 121.181 -0.533 . . . . 0.0 113.168 173.218 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . 0.483 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -80.61 -28.2 48.29 Favored Glycine 0 N--CA 1.439 -1.127 0 C-N-CA 121.041 -0.6 . . . . 0.0 113.107 -177.391 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 0.895 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 7.2 mp -57.4 -23.58 50.2 Favored 'General case' 0 N--CA 1.452 -0.355 0 N-CA-C 112.2 0.445 . . . . 0.0 112.2 -173.032 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . 0.504 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 1.5 ptm180 -67.56 -31.67 71.91 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-O 121.043 0.449 . . . . 0.0 109.971 178.529 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' TYR . . . . . 1.049 ' HB3' ' HG2' ' A' ' 81' ' ' GLU . 63.5 m-85 -83.99 -36.63 23.04 Favored 'General case' 0 N--CA 1.44 -0.946 0 N-CA-C 107.327 -1.36 . . . . 0.0 107.327 177.218 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.64 ' HB1' ' HB1' ' A' ' 77' ' ' ALA . . . 169.1 126.96 0.04 OUTLIER Pre-proline 0 N--CA 1.443 -0.784 0 CA-C-N 112.899 -1.955 . . . . 0.0 107.406 -175.89 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' PRO . . . . . 0.895 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 21.5 Cg_exo -56.85 -5.9 1.48 Allowed 'Trans proline' 0 C--N 1.33 -0.417 0 C-N-CA 122.982 2.454 . . . . 0.0 113.705 -177.542 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' ARG . . . . . 0.615 ' HB2' ' CD2' ' A' ' 52' ' ' TYR . 28.3 ptt-85 -149.74 140.32 22.53 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-O 121.188 0.518 . . . . 0.0 110.356 176.756 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -57.65 -22.83 48.04 Favored 'General case' 0 C--O 1.217 -0.645 0 CA-C-N 114.851 -1.068 . . . . 0.0 113.189 -178.98 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . 0.564 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 0.0 OUTLIER -76.76 -23.15 52.95 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 121.227 0.537 . . . . 0.0 110.921 -179.159 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.497 ' HB3' ' HB3' ' A' ' 71' ' ' ALA . 54.9 tp -87.68 -33.19 18.86 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 115.567 -0.742 . . . . 0.0 109.191 176.034 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . 0.73 ' HB2' ' CB ' ' A' ' 81' ' ' GLU . . . -79.15 158.47 27.71 Favored 'General case' 0 N--CA 1.445 -0.723 0 CA-C-N 115.344 -0.844 . . . . 0.0 110.97 176.1 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 47.5 p -101.5 -172.48 2.17 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.231 -178.444 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . 0.752 HH21 ' HB2' ' A' ' 32' ' ' ASP . 66.8 mtp180 -49.52 -52.55 28.85 Favored 'General case' 0 N--CA 1.466 0.325 0 CA-C-N 116.433 -0.349 . . . . 0.0 111.521 -177.955 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 10.2 pt-20 -62.69 -33.07 74.33 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 116.023 -0.535 . . . . 0.0 111.365 -174.977 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 81' ' ' GLU . . . . . 1.049 ' HG2' ' HB3' ' A' ' 70' ' ' TYR . 5.9 mt-10 -71.9 -47.53 52.03 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.532 -0.304 . . . . 0.0 111.235 178.43 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 82' ' ' GLN . . . . . 0.568 ' NE2' ' HE3' ' A' ' 43' ' ' TRP . 0.1 OUTLIER -59.5 -39.61 84.38 Favored 'General case' 0 CA--C 1.505 -0.752 0 N-CA-C 109.509 -0.552 . . . . 0.0 109.509 174.551 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . 0.971 HD13 HG12 ' A' ' 25' ' ' VAL . 27.2 mt -60.1 -49.75 82.87 Favored 'Isoleucine or valine' 0 C--O 1.209 -1.03 0 CA-C-N 114.848 -1.069 . . . . 0.0 110.591 177.471 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . 0.615 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -60.8 -46.02 92.14 Favored 'General case' 0 C--O 1.242 0.664 0 CA-C-O 121.409 0.623 . . . . 0.0 111.973 -177.176 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . 0.563 HG11 ' HB2' ' A' ' 65' ' ' ASN . 58.6 t -66.51 -48.27 81.07 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.737 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.448 -179.525 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . 0.545 ' HB2' ' CH2' ' A' ' 31' ' ' TRP . . . -59.95 -28.49 67.69 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.584 -0.735 . . . . 0.0 110.793 174.065 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 87' ' ' GLU . . . . . 0.676 ' HG2' ' O ' ' A' ' 83' ' ' ILE . 10.9 mm-40 -59.26 -45.0 92.38 Favored 'General case' 0 N--CA 1.468 0.434 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.166 -179.17 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.65 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 62.1 t -65.95 -42.49 91.93 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.295 0 C-N-CA 120.115 -0.634 . . . . 0.0 109.594 175.933 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 89' ' ' THR . . . . . 0.89 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 1.1 m -64.0 -45.28 89.69 Favored 'General case' 0 C--N 1.319 -0.758 0 CA-C-N 115.613 -0.721 . . . . 0.0 111.498 -176.136 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . 0.534 ' HA ' ' HZ3' ' A' ' 98' ' ' TRP . 5.0 ptt180 -69.29 -33.17 72.79 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.679 -175.559 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . 0.65 ' HG ' ' O ' ' A' ' 88' ' ' VAL . 4.6 pp -68.59 -24.46 64.6 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 121.368 0.604 . . . . 0.0 110.309 -173.4 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . 0.46 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 4.2 mtm180 -84.36 -43.87 14.32 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-O 122.14 0.972 . . . . 0.0 109.163 176.451 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 93' ' ' GLN . . . . . 0.697 ' NE2' HG23 ' A' ' 89' ' ' THR . 21.9 mt-30 -87.84 -28.23 21.75 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 113.746 -1.57 . . . . 0.0 114.329 -167.43 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 74.89 32.63 56.65 Favored Glycine 0 CA--C 1.51 -0.245 0 N-CA-C 111.858 -0.497 . . . . 0.0 111.858 179.894 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 95' ' ' TRP . . . . . 0.431 ' CH2' ' HB ' ' A' ' 30' ' ' ILE . 28.6 m95 67.05 5.02 3.86 Favored 'General case' 0 C--O 1.216 -0.678 0 C-N-CA 123.451 0.701 . . . . 0.0 110.082 -177.151 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -59.39 -43.8 97.12 Favored Glycine 0 CA--C 1.518 0.233 0 CA-C-N 116.125 -0.489 . . . . 0.0 113.327 -178.557 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -69.67 -21.15 63.54 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.826 0.346 . . . . 0.0 110.971 -179.371 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 98' ' ' TRP . . . . . 0.89 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 21.6 m-90 -90.31 108.93 29.97 Favored Pre-proline 0 N--CA 1.445 -0.681 0 N-CA-C 108.127 -1.064 . . . . 0.0 108.127 174.303 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . 0.451 ' HD3' ' HA ' ' A' ' 98' ' ' TRP . 46.9 Cg_exo -62.97 -138.89 0.0 OUTLIER 'Trans proline' 0 CA--C 1.533 0.44 0 C-N-CA 123.616 2.877 . . . . 0.0 114.45 -171.828 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 4.2 p -55.38 -25.92 18.1 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.195 0 CA-C-O 121.427 0.632 . . . . 0.0 110.759 -176.939 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 101' ' ' CYS . . . . . 0.436 ' SG ' ' HG2' ' A' ' 38' ' ' GLU . 39.9 m -55.98 -39.16 71.43 Favored 'General case' 0 C--N 1.317 -0.844 0 CA-C-N 114.896 -1.047 . . . . 0.0 111.427 177.703 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -70.86 -41.42 71.44 Favored 'General case' 0 CA--C 1.519 -0.219 0 CA-C-O 120.877 0.37 . . . . 0.0 110.722 179.609 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -64.34 -43.02 95.91 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 121.074 0.464 . . . . 0.0 110.274 178.171 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 60.1 mtp180 -62.92 -30.82 71.84 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 115.51 -0.768 . . . . 0.0 110.897 176.696 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 105' ' ' ALA . . . . . 0.613 ' HB1' ' HA ' ' A' ' 30' ' ' ILE . . . -85.23 -21.27 29.16 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.72 -0.673 . . . . 0.0 111.456 -177.966 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . 0.466 ' O ' ' HG2' ' A' ' 108' ' ' ARG . . . 102.55 67.71 0.78 Allowed Glycine 0 CA--C 1.52 0.393 0 CA-C-N 115.892 -0.595 . . . . 0.0 112.288 -178.636 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -57.54 147.63 26.32 Favored 'General case' 0 C--O 1.236 0.362 0 C-N-CA 122.895 0.478 . . . . 0.0 111.6 -177.609 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 108' ' ' ARG . . . . . 0.466 ' HG2' ' O ' ' A' ' 106' ' ' GLY . 3.6 ptp180 . . . . . 0 C--O 1.251 1.149 0 CA-C-O 118.496 -0.764 . . . . 0.0 110.582 -171.575 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 90.9 m-20 . . . . . 0 N--CA 1.48 1.062 0 CA-C-O 120.778 0.323 . . . . 0.0 110.88 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 43.1 t -95.24 -38.18 8.5 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 N-CA-C 109.128 -0.693 . . . . 0.0 109.128 175.498 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 7.3 p -65.14 123.73 18.6 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.624 0 CA-C-N 115.284 -0.871 . . . . 0.0 110.939 176.411 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 4.0 p -73.44 147.58 9.42 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.988 179.256 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 62.3 p -121.51 112.85 32.39 Favored Pre-proline 0 C--N 1.317 -0.817 0 CA-C-N 115.273 -0.876 . . . . 0.0 109.747 179.283 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 20.0 Cg_exo -39.18 111.42 0.12 Allowed 'Trans proline' 0 CA--C 1.509 -0.744 0 C-N-CA 124.248 3.299 . . . . 0.0 113.864 -178.851 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -108.5 23.37 14.62 Favored 'General case' 0 C--N 1.302 -1.472 0 CA-C-N 113.477 -1.692 . . . . 0.0 110.277 -177.899 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 32.8 t60 -78.1 -8.29 58.06 Favored 'General case' 0 C--N 1.313 -0.991 0 CA-C-N 114.727 -1.124 . . . . 0.0 108.258 170.822 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . 0.463 ' OE1' ' HB ' ' A' ' 11' ' ' VAL . 6.1 pt-20 -82.72 142.26 31.77 Favored 'General case' 0 C--O 1.235 0.297 0 CA-C-N 115.283 -0.871 . . . . 0.0 110.522 -178.599 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -109.66 54.19 0.67 Allowed 'General case' 0 C--N 1.322 -0.619 0 CA-C-O 122.177 0.989 . . . . 0.0 109.76 175.728 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.511 HG11 ' HG2' ' A' ' 13' ' ' ARG . 84.5 t -124.09 -67.04 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.163 0 CA-C-N 113.824 -1.535 . . . . 0.0 109.606 -178.596 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.413 ' O ' HG12 ' A' ' 12' ' ' VAL . 78.5 t 26.18 81.19 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.447 -0.615 0 C-N-CA 125.183 1.393 . . . . 0.0 113.067 -179.446 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . 0.511 ' HG2' HG11 ' A' ' 11' ' ' VAL . 8.8 ptm180 -119.81 130.24 54.82 Favored 'General case' 0 N--CA 1.424 -1.759 0 CA-C-N 113.724 -1.58 . . . . 0.0 109.43 178.325 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.5 t -96.15 160.42 2.83 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.393 0 CA-C-N 115.168 -0.924 . . . . 0.0 109.534 -178.442 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 174.6 -82.44 0.08 OUTLIER Glycine 0 N--CA 1.429 -1.824 0 N-CA-C 110.331 -1.108 . . . . 0.0 110.331 -179.408 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 18.0 m -93.45 -49.88 5.71 Favored 'General case' 0 N--CA 1.434 -1.243 0 N-CA-C 109.978 -0.378 . . . . 0.0 109.978 174.253 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . 0.449 ' HZ1' ' HB3' ' A' ' 17' ' ' LYS . 3.5 mmmp? 32.77 77.1 0.36 Allowed Pre-proline 0 N--CA 1.467 0.408 0 O-C-N 124.948 1.405 . . . . 0.0 112.495 -177.737 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 0.9 OUTLIER -34.1 118.14 0.11 Allowed 'Trans proline' 0 C--N 1.351 0.674 0 C-N-CA 124.822 3.681 . . . . 0.0 115.101 -176.678 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -164.01 -52.08 0.02 OUTLIER Glycine 0 N--CA 1.436 -1.336 0 CA-C-N 113.186 -1.825 . . . . 0.0 111.25 179.078 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 20.8 m -69.46 -32.98 72.24 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-O 121.322 0.582 . . . . 0.0 110.71 177.785 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 46.7 mt-10 -105.02 119.34 38.78 Favored 'General case' 0 N--CA 1.442 -0.845 0 CA-C-N 115.618 -0.719 . . . . 0.0 109.552 178.907 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 47.1 t -76.8 124.78 87.64 Favored Pre-proline 0 C--N 1.309 -1.178 0 CA-C-N 115.623 -0.717 . . . . 0.0 109.482 175.213 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_exo -54.16 128.3 29.33 Favored 'Trans proline' 0 C--N 1.347 0.448 0 C-N-CA 122.944 2.429 . . . . 0.0 112.811 -177.324 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 13.4 Cg_endo -57.32 160.72 12.85 Favored 'Trans proline' 0 N--CA 1.46 -0.481 0 C-N-CA 123.998 3.132 . . . . 0.0 112.784 176.611 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 79.4 t -80.78 124.83 39.03 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.008 0 CA-C-N 115.012 -0.994 . . . . 0.0 109.135 177.378 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 51.1 mm -55.88 -36.42 43.82 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.602 0 N-CA-C 114.463 1.282 . . . . 0.0 114.463 -161.732 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.538 ' O ' HG12 ' A' ' 30' ' ' ILE . 26.3 m-20 -102.65 4.98 38.83 Favored 'General case' 0 C--N 1.311 -1.083 0 CA-C-O 121.744 0.783 . . . . 0.0 109.688 -173.267 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . 0.533 ' HA3' HD13 ' A' ' 83' ' ' ILE . . . -72.36 -1.03 49.72 Favored Glycine 0 N--CA 1.434 -1.462 0 CA-C-N 114.596 -1.184 . . . . 0.0 111.091 178.403 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 14.9 m -73.8 -40.96 63.02 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-O 121.744 0.783 . . . . 0.0 109.293 175.089 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.538 HG12 ' O ' ' A' ' 27' ' ' ASP . 0.0 OUTLIER -70.99 -36.33 63.13 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.633 0 CA-C-N 114.548 -1.205 . . . . 0.0 107.78 177.218 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' TRP . . . . . 0.625 ' CD1' HG22 ' A' ' 83' ' ' ILE . 49.1 m95 -72.34 -35.96 68.7 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 114.781 -1.1 . . . . 0.0 111.075 -178.32 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.444 ' HB3' ' O ' ' A' ' 28' ' ' GLY . 0.0 OUTLIER -71.0 -35.88 72.24 Favored 'General case' 0 N--CA 1.45 -0.449 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.115 177.395 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . 0.444 ' HB2' ' CB ' ' A' ' 105' ' ' ALA . . . -70.38 -37.19 74.49 Favored 'General case' 0 N--CA 1.446 -0.65 0 C-N-CA 120.869 -0.332 . . . . 0.0 110.944 177.816 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . 0.517 HG13 ' O ' ' A' ' 30' ' ' ILE . 72.6 mt -67.04 -46.97 83.44 Favored 'Isoleucine or valine' 0 C--O 1.234 0.238 0 CA-C-O 121.036 0.446 . . . . 0.0 110.215 174.949 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -57.96 -38.31 75.77 Favored 'General case' 0 N--CA 1.451 -0.386 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.445 176.833 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -72.71 -13.31 78.29 Favored Glycine 0 N--CA 1.451 -0.352 0 CA-C-N 115.683 -0.689 . . . . 0.0 111.838 179.824 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 53.1 t -95.9 -59.09 1.93 Allowed 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.639 -0.28 . . . . 0.0 111.413 -177.092 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . 0.854 ' HG3' ' SG ' ' A' ' 101' ' ' CYS . 26.5 mt-10 -88.93 -22.95 22.84 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 120.651 0.263 . . . . 0.0 111.619 -173.536 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -106.26 -12.13 15.81 Favored 'General case' 0 N--CA 1.447 -0.58 0 C-N-CA 120.184 -0.607 . . . . 0.0 111.717 -179.208 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 77.99 15.98 80.45 Favored Glycine 0 CA--C 1.507 -0.459 0 N-CA-C 109.935 -1.266 . . . . 0.0 109.935 -176.861 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 73.07 57.03 5.43 Favored Glycine 0 N--CA 1.435 -1.416 0 CA-C-N 114.072 -1.064 . . . . 0.0 111.516 -175.334 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 2.6 t-20 -140.19 98.55 3.47 Favored 'General case' 0 N--CA 1.447 -0.609 0 N-CA-C 109.194 -0.669 . . . . 0.0 109.194 -177.713 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' TRP . . . . . 0.767 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 32.3 m95 -84.07 2.37 39.6 Favored 'General case' 0 C--N 1.319 -0.758 0 CA-C-N 115.485 -0.78 . . . . 0.0 109.973 -174.799 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -111.15 1.76 17.46 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-N 114.903 -1.044 . . . . 0.0 111.488 177.41 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.858 HG23 ' HA2' ' A' ' 53' ' ' GLY . 6.4 tt -66.91 143.91 15.13 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.677 0 CA-C-O 121.268 0.556 . . . . 0.0 110.358 -177.34 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . 0.441 ' ND2' ' HD1' ' A' ' 52' ' ' TYR . 9.4 t-20 -152.08 98.67 2.46 Favored 'General case' 0 C--N 1.309 -1.179 0 CA-C-O 121.234 0.54 . . . . 0.0 109.67 -178.49 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 21.1 p -75.38 -21.33 58.36 Favored 'General case' 0 C--N 1.317 -0.817 0 CA-C-N 115.362 -0.835 . . . . 0.0 110.292 179.259 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 91.04 18.53 46.46 Favored Glycine 0 N--CA 1.443 -0.848 0 CA-C-N 115.339 -0.846 . . . . 0.0 111.038 178.272 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 28.5 p-10 -95.44 4.47 53.26 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.891 0.377 . . . . 0.0 111.647 -174.407 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . 0.453 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 95.47 -8.22 68.96 Favored Glycine 0 N--CA 1.45 -0.424 0 C-N-CA 120.49 -0.862 . . . . 0.0 111.832 -178.055 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' TYR . . . . . 0.562 ' CE1' ' HB3' ' A' ' 58' ' ' ASP . 0.2 OUTLIER -112.89 144.65 42.08 Favored 'General case' 0 CA--C 1.511 -0.544 0 N-CA-C 106.826 -1.546 . . . . 0.0 106.826 176.131 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' TYR . . . . . 0.611 ' O ' ' HA ' ' A' ' 56' ' ' GLN . 53.6 m-85 -117.38 169.05 9.8 Favored 'General case' 0 C--N 1.306 -1.307 0 N-CA-C 113.488 0.922 . . . . 0.0 113.488 -165.388 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.858 ' HA2' HG23 ' A' ' 45' ' ' ILE . . . -62.89 159.05 36.36 Favored Glycine 0 CA--C 1.501 -0.797 0 CA-C-N 114.845 -1.071 . . . . 0.0 114.018 -171.991 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . 0.578 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 101.72 -103.73 2.56 Favored Glycine 0 N--CA 1.437 -1.249 0 N-CA-C 111.402 -0.679 . . . . 0.0 111.402 -177.212 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.55 HG23 ' HG2' ' A' ' 82' ' ' GLN . 2.8 t -92.05 0.78 9.23 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 CA-C-O 121.652 0.739 . . . . 0.0 109.898 -178.61 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' GLN . . . . . 0.611 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 8.3 mm-40 59.51 50.37 7.55 Favored 'General case' 0 N--CA 1.464 0.269 0 CA-C-N 114.644 -1.162 . . . . 0.0 113.901 167.92 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 17.8 p90 -120.91 171.45 8.62 Favored 'General case' 0 C--N 1.325 -0.478 0 C-N-CA 119.833 -0.747 . . . . 0.0 112.092 175.112 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.562 ' HB3' ' CE1' ' A' ' 51' ' ' TYR . 6.4 p-10 -82.37 158.6 23.29 Favored 'General case' 0 CA--C 1.516 -0.356 0 N-CA-C 113.686 0.995 . . . . 0.0 113.686 -163.417 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.431 ' HB2' ' CE2' ' A' ' 52' ' ' TYR . 20.6 tp60 -57.84 -39.79 78.53 Favored 'General case' 0 N--CA 1.442 -0.828 0 CA-C-N 113.279 -1.782 . . . . 0.0 111.714 179.229 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -67.47 -49.46 50.9 Favored Glycine 0 N--CA 1.45 -0.404 0 CA-C-N 115.603 -0.726 . . . . 0.0 112.034 -175.303 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 83.2 m -62.87 -41.05 99.25 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 121.252 0.548 . . . . 0.0 110.389 176.57 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' TRP . . . . . 0.438 ' CH2' ' HA ' ' A' ' 74' ' ' ALA . 54.1 t-105 -56.99 -50.1 73.74 Favored 'General case' 0 N--CA 1.444 -0.737 0 CA-C-N 115.265 -0.88 . . . . 0.0 109.687 176.734 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . 0.463 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 36.7 tt0 -67.1 -39.28 86.7 Favored 'General case' 0 N--CA 1.445 -0.683 0 CA-C-N 114.918 -1.037 . . . . 0.0 110.91 -178.183 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -62.11 -40.95 97.62 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.539 -0.755 . . . . 0.0 111.109 -176.682 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 9.3 m120 -82.3 -9.61 59.41 Favored 'General case' 0 N--CA 1.45 -0.461 0 CA-C-O 120.908 0.385 . . . . 0.0 110.768 178.521 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 93.23 47.57 3.03 Favored Glycine 0 C--N 1.333 0.373 0 CA-C-N 116.089 -0.505 . . . . 0.0 112.659 173.784 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . 0.587 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -80.2 -22.92 62.1 Favored Glycine 0 N--CA 1.44 -1.045 0 C-N-CA 120.966 -0.635 . . . . 0.0 112.868 -174.621 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 0.871 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 6.8 mp -61.51 -23.48 65.95 Favored 'General case' 0 N--CA 1.447 -0.595 0 N-CA-C 112.483 0.549 . . . . 0.0 112.483 -172.569 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . 0.435 ' HG3' ' N ' ' A' ' 70' ' ' TYR . 3.8 ptm180 -69.02 -30.96 69.44 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 121.19 0.519 . . . . 0.0 110.145 176.041 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' TYR . . . . . 0.791 ' HB3' ' HG3' ' A' ' 81' ' ' GLU . 79.5 m-85 -79.71 -34.8 39.78 Favored 'General case' 0 N--CA 1.446 -0.674 0 N-CA-C 107.679 -1.23 . . . . 0.0 107.679 177.144 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.688 ' HB1' ' HB2' ' A' ' 77' ' ' ALA . . . 161.57 128.73 0.01 OUTLIER Pre-proline 0 CA--C 1.509 -0.602 0 CA-C-N 112.609 -2.087 . . . . 0.0 106.689 -178.452 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' PRO . . . . . 0.871 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 32.3 Cg_exo -54.9 -6.68 0.7 Allowed 'Trans proline' 0 C--N 1.33 -0.416 0 C-N-CA 123.171 2.581 . . . . 0.0 114.246 -177.08 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' ARG . . . . . 0.421 ' HE ' ' CG ' ' A' ' 75' ' ' ASP . 12.4 ptm180 -149.59 142.77 25.06 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-O 121.095 0.474 . . . . 0.0 109.794 176.515 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . 0.438 ' HA ' ' CH2' ' A' ' 62' ' ' TRP . . . -61.06 -23.48 65.49 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.267 -0.879 . . . . 0.0 113.017 -175.159 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . 0.481 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 9.4 p-10 -88.21 -0.57 57.26 Favored 'General case' 0 C--N 1.33 -0.262 0 C-N-CA 120.544 -0.462 . . . . 0.0 110.905 -179.54 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 62.0 tp -103.75 -31.11 10.0 Favored 'General case' 0 C--N 1.323 -0.584 0 N-CA-C 109.026 -0.731 . . . . 0.0 109.026 172.641 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . 0.688 ' HB2' ' HB1' ' A' ' 71' ' ' ALA . . . -79.81 162.05 25.32 Favored 'General case' 0 N--CA 1.446 -0.631 0 CA-C-N 115.142 -0.935 . . . . 0.0 109.426 174.262 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 61.7 p -100.66 -175.0 2.78 Favored 'General case' 0 C--N 1.312 -1.046 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.874 -176.688 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . 0.767 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 11.9 mtp180 -50.92 -55.24 18.11 Favored 'General case' 0 C--O 1.222 -0.383 0 O-C-N 123.406 0.441 . . . . 0.0 110.594 179.518 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 11.3 pt-20 -61.76 -41.88 98.27 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 115.893 -0.594 . . . . 0.0 111.501 -174.326 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 81' ' ' GLU . . . . . 0.791 ' HG3' ' HB3' ' A' ' 70' ' ' TYR . 0.2 OUTLIER -64.2 -52.05 60.73 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 115.405 -0.816 . . . . 0.0 112.138 177.457 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 82' ' ' GLN . . . . . 0.55 ' HG2' HG23 ' A' ' 55' ' ' VAL . 5.7 tt0 -68.1 -31.34 70.89 Favored 'General case' 0 C--N 1.317 -0.805 0 CA-C-N 115.364 -0.835 . . . . 0.0 110.409 -176.759 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . 0.625 HG22 ' CD1' ' A' ' 31' ' ' TRP . 25.0 mt -59.83 -44.54 94.33 Favored 'Isoleucine or valine' 0 C--O 1.216 -0.691 0 CA-C-N 115.471 -0.786 . . . . 0.0 109.563 173.524 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . 0.585 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -63.22 -40.64 98.04 Favored 'General case' 0 C--O 1.236 0.371 0 CA-C-O 121.352 0.596 . . . . 0.0 111.16 -175.632 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 44.2 t -69.02 -48.04 72.09 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 CA-C-N 115.685 -0.688 . . . . 0.0 110.919 177.758 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -57.05 -30.43 64.25 Favored 'General case' 0 N--CA 1.449 -0.48 0 CA-C-O 120.895 0.378 . . . . 0.0 110.401 172.796 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 87' ' ' GLU . . . . . 0.809 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 8.1 mm-40 -60.48 -44.58 95.78 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.196 -179.178 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 83.4 t -62.23 -44.91 99.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 C-N-CA 120.407 -0.517 . . . . 0.0 109.857 178.864 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 89' ' ' THR . . . . . 0.684 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 1.2 m -61.92 -47.78 83.4 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 115.504 -0.771 . . . . 0.0 111.478 -178.896 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . 0.733 ' HA ' ' OE1' ' A' ' 93' ' ' GLN . 2.5 ptt180 -62.02 -32.66 73.17 Favored 'General case' 0 CA--C 1.52 -0.176 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.361 -174.992 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . 0.809 ' HG ' ' O ' ' A' ' 87' ' ' GLU . 45.6 mt -61.06 -33.9 74.04 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-O 121.358 0.599 . . . . 0.0 110.529 -176.965 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 1.3 mtm180 -86.75 -45.36 11.01 Favored 'General case' 0 N--CA 1.443 -0.788 0 CA-C-N 115.221 -0.9 . . . . 0.0 110.589 -169.707 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 93' ' ' GLN . . . . . 0.733 ' OE1' ' HA ' ' A' ' 90' ' ' ARG . 0.0 OUTLIER -99.55 -21.32 15.95 Favored 'General case' 0 C--N 1.323 -0.572 0 N-CA-C 113.13 0.789 . . . . 0.0 113.13 -172.376 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 82.93 38.86 10.82 Favored Glycine 0 C--N 1.333 0.39 0 C-N-CA 120.926 -0.654 . . . . 0.0 112.523 171.441 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 95' ' ' TRP . . . . . 0.593 ' CZ2' ' HD3' ' A' ' 90' ' ' ARG . 20.7 m95 66.6 11.06 7.89 Favored 'General case' 0 C--O 1.221 -0.4 0 C-N-CA 123.445 0.698 . . . . 0.0 110.247 -179.212 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -68.7 -35.22 79.89 Favored Glycine 0 N--CA 1.453 -0.226 0 C-N-CA 121.236 -0.507 . . . . 0.0 112.352 176.817 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . 0.442 ' O ' ' HD3' ' A' ' 99' ' ' PRO . . . -66.85 -29.63 69.59 Favored 'General case' 0 CA--C 1.517 -0.294 0 CA-C-O 121.051 0.453 . . . . 0.0 110.577 178.857 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 98' ' ' TRP . . . . . 0.684 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 24.3 m-90 -92.72 108.41 31.57 Favored Pre-proline 0 N--CA 1.445 -0.722 0 N-CA-C 108.438 -0.949 . . . . 0.0 108.438 177.52 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . 0.442 ' HD3' ' O ' ' A' ' 97' ' ' ALA . 45.7 Cg_exo -63.08 -131.3 0.0 OUTLIER 'Trans proline' 0 CA--C 1.541 0.854 0 C-N-CA 123.492 2.794 . . . . 0.0 114.5 -175.06 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 39.2 t -55.65 -29.41 24.97 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.146 0 O-C-N 122.081 -0.387 . . . . 0.0 111.612 -174.662 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 101' ' ' CYS . . . . . 0.854 ' SG ' ' HG3' ' A' ' 38' ' ' GLU . 71.1 m -68.4 -31.97 71.69 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 116.56 -0.291 . . . . 0.0 111.604 -174.87 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 102' ' ' ALA . . . . . 0.554 ' HB2' ' CB ' ' A' ' 98' ' ' TRP . . . -70.36 -43.66 69.72 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.033 0.444 . . . . 0.0 110.335 176.185 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -62.08 -40.21 95.06 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.267 178.583 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 104' ' ' ARG . . . . . 0.627 ' HA ' ' NE ' ' A' ' 104' ' ' ARG . 1.9 mmp_? -69.16 -25.72 64.51 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.408 -0.814 . . . . 0.0 111.45 177.68 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 105' ' ' ALA . . . . . 0.444 ' CB ' ' HB2' ' A' ' 33' ' ' ALA . . . -83.38 -21.6 33.0 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.911 -177.477 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 105.38 47.75 1.11 Allowed Glycine 0 CA--C 1.521 0.456 0 C-N-CA 120.88 -0.676 . . . . 0.0 111.98 -176.599 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -57.74 149.45 22.06 Favored 'General case' 0 C--N 1.327 -0.395 0 C-N-CA 123.636 0.774 . . . . 0.0 112.23 -178.858 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 108' ' ' ARG . . . . . 0.459 ' O ' ' HD3' ' A' ' 108' ' ' ARG . 0.0 OUTLIER . . . . . 0 C--O 1.246 0.899 0 CA-C-N 115.771 -0.649 . . . . 0.0 110.373 -177.095 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 91.5 m-20 . . . . . 0 N--CA 1.483 1.22 0 CA-C-O 120.855 0.36 . . . . 0.0 110.586 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 59.6 t -97.49 -39.39 8.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 115.99 -0.55 . . . . 0.0 109.901 177.518 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 7.1 p -56.89 138.52 17.56 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 CA-C-N 115.3 -0.864 . . . . 0.0 110.338 174.521 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 2.9 p -63.42 137.42 24.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-O 121.514 0.673 . . . . 0.0 110.887 -179.908 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' THR . . . . . 0.468 ' HA ' ' HD3' ' A' ' 6' ' ' PRO . 13.4 t -104.4 133.99 19.91 Favored Pre-proline 0 C--N 1.309 -1.191 0 CA-C-N 114.754 -1.112 . . . . 0.0 110.05 -174.045 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.468 ' HD3' ' HA ' ' A' ' 5' ' ' THR . 56.1 Cg_endo -89.66 176.71 2.84 Favored 'Trans proline' 0 N--CA 1.45 -1.055 0 C-N-CA 123.403 2.735 . . . . 0.0 112.619 -178.258 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . 0.424 ' C ' ' H ' ' A' ' 9' ' ' GLU . . . -113.87 167.12 10.91 Favored 'General case' 0 C--N 1.309 -1.175 0 CA-C-N 114.389 -1.278 . . . . 0.0 110.001 178.082 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 37.6 t60 69.58 -0.23 2.7 Favored 'General case' 0 C--N 1.333 -0.116 0 O-C-N 124.093 0.87 . . . . 0.0 109.698 -171.785 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . 0.424 ' H ' ' C ' ' A' ' 7' ' ' ALA . 10.3 pt-20 -62.17 138.85 58.47 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.571 -0.74 . . . . 0.0 110.539 178.79 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -125.59 63.83 1.19 Allowed 'General case' 0 C--N 1.316 -0.863 0 CA-C-O 121.87 0.843 . . . . 0.0 109.778 178.886 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 59.7 t -78.55 -50.54 18.86 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.909 0 CA-C-N 114.436 -1.256 . . . . 0.0 109.149 179.207 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 77.0 t 25.91 80.55 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.444 -0.747 0 O-C-N 125.141 1.526 . . . . 0.0 113.03 -179.614 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . 0.415 ' NE ' ' HA ' ' A' ' 13' ' ' ARG . 4.8 mmp_? -142.0 132.96 25.93 Favored 'General case' 0 C--N 1.305 -1.333 0 CA-C-N 113.859 -1.519 . . . . 0.0 110.512 178.944 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.6 t -115.28 158.62 15.54 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.364 0 CA-C-N 114.526 -1.215 . . . . 0.0 109.397 -178.84 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -159.49 64.19 0.29 Allowed Glycine 0 N--CA 1.428 -1.885 0 CA-C-N 114.937 -1.029 . . . . 0.0 111.252 178.052 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 2.0 m -68.3 -43.87 76.71 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-N 114.693 -0.753 . . . . 0.0 110.648 -176.596 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 71.7 mmtt 37.69 72.61 0.84 Allowed Pre-proline 0 C--N 1.324 -0.506 0 O-C-N 124.909 1.381 . . . . 0.0 111.738 -177.656 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 16.8 Cg_exo -68.53 168.49 19.63 Favored 'Trans proline' 0 CA--C 1.512 -0.587 0 C-N-CA 123.345 2.697 . . . . 0.0 112.91 -174.105 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -146.92 -44.31 0.03 OUTLIER Glycine 0 N--CA 1.44 -1.097 0 CA-C-N 113.696 -1.593 . . . . 0.0 111.054 -179.449 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 25.6 m -66.73 -34.12 77.14 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 114.938 -0.631 . . . . 0.0 110.394 177.506 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 9.8 pt-20 -116.27 140.25 49.51 Favored 'General case' 0 N--CA 1.431 -1.398 0 N-CA-C 108.393 -0.966 . . . . 0.0 108.393 177.315 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 43.3 t -80.01 128.49 73.56 Favored Pre-proline 0 C--N 1.306 -1.289 0 CA-C-N 115.191 -0.913 . . . . 0.0 111.831 -170.803 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_exo -54.39 130.36 39.51 Favored 'Trans proline' 0 C--N 1.348 0.509 0 C-N-CA 123.369 2.713 . . . . 0.0 112.304 177.039 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 11.9 Cg_endo -55.37 141.71 81.17 Favored 'Trans proline' 0 N--CA 1.457 -0.643 0 C-N-CA 123.925 3.083 . . . . 0.0 113.696 -174.909 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.475 ' HB ' HG23 ' A' ' 83' ' ' ILE . 46.2 t -95.69 148.22 5.37 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.977 0 CA-C-N 114.19 -1.368 . . . . 0.0 108.888 175.614 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . 0.555 HG21 HH12 ' A' ' 108' ' ' ARG . 3.2 mp -60.44 -25.43 34.26 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-N 115.421 -0.809 . . . . 0.0 112.21 -170.872 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.48 ' O ' HG12 ' A' ' 30' ' ' ILE . 27.5 m-20 -99.68 -1.65 37.42 Favored 'General case' 0 CA--C 1.507 -0.708 0 CA-C-O 121.41 0.624 . . . . 0.0 110.092 -178.431 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -63.4 -12.19 44.34 Favored Glycine 0 CA--C 1.504 -0.614 0 CA-C-N 114.977 -1.01 . . . . 0.0 111.206 -177.726 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 19.3 m -76.24 -43.35 42.4 Favored 'General case' 0 C--N 1.317 -0.809 0 CA-C-O 121.914 0.864 . . . . 0.0 109.477 177.95 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.523 HG22 ' HB1' ' A' ' 105' ' ' ALA . 0.1 OUTLIER -68.9 -38.85 79.15 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.802 0 CA-C-N 114.178 -1.373 . . . . 0.0 107.871 179.775 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' TRP . . . . . 0.455 ' CD1' HG21 ' A' ' 83' ' ' ILE . 17.1 m95 -67.48 -36.96 82.14 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 114.735 -1.121 . . . . 0.0 110.511 -177.627 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 9.7 t70 -75.2 -38.86 60.57 Favored 'General case' 0 N--CA 1.444 -0.759 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.692 179.017 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . 0.529 ' HB3' ' HB3' ' A' ' 105' ' ' ALA . . . -70.82 -35.79 72.64 Favored 'General case' 0 N--CA 1.448 -0.548 0 C-N-CA 120.78 -0.368 . . . . 0.0 110.903 178.737 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . 0.489 HG13 ' O ' ' A' ' 30' ' ' ILE . 64.8 mt -62.33 -45.6 98.38 Favored 'Isoleucine or valine' 0 C--O 1.234 0.247 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 173.646 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . 0.553 ' HA ' ' O ' ' A' ' 54' ' ' GLY . . . -57.62 -38.52 75.1 Favored 'General case' 0 N--CA 1.451 -0.404 0 CA-C-N 115.506 -0.77 . . . . 0.0 110.056 176.734 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . 0.444 ' HA2' ' N ' ' A' ' 41' ' ' GLY . . . -73.6 -22.06 78.81 Favored Glycine 0 N--CA 1.451 -0.338 0 CA-C-N 115.467 -0.788 . . . . 0.0 111.944 -179.814 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 6.3 t -84.53 -56.65 3.5 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-O 120.831 0.348 . . . . 0.0 111.608 -178.704 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . 0.405 ' HB2' ' SG ' ' A' ' 101' ' ' CYS . 11.4 tp10 -87.61 -30.53 20.41 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 121.063 0.459 . . . . 0.0 110.511 -170.453 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -107.59 -8.01 16.31 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.956 -0.566 . . . . 0.0 111.871 -176.565 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 80.23 4.06 89.79 Favored Glycine 0 CA--C 1.507 -0.408 0 N-CA-C 110.239 -1.144 . . . . 0.0 110.239 -177.535 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . 0.444 ' N ' ' HA2' ' A' ' 36' ' ' GLY . . . 89.95 56.41 1.85 Allowed Glycine 0 N--CA 1.432 -1.568 0 CA-C-N 114.006 -1.097 . . . . 0.0 111.302 -175.986 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 2.4 t-20 -141.71 99.48 3.56 Favored 'General case' 0 N--CA 1.447 -0.596 0 N-CA-C 108.732 -0.84 . . . . 0.0 108.732 -175.655 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' TRP . . . . . 0.757 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 23.4 m95 -83.81 -4.33 58.57 Favored 'General case' 0 C--N 1.313 -1.005 0 CA-C-N 115.723 -0.672 . . . . 0.0 110.158 -173.39 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . 0.423 ' HA ' ' HB2' ' A' ' 75' ' ' ASP . . . -109.3 10.74 25.57 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 115.183 -0.917 . . . . 0.0 111.06 179.351 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.72 HG21 ' HA2' ' A' ' 53' ' ' GLY . 9.0 tt -76.09 144.57 11.71 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.792 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.31 179.892 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 10.3 t-20 -142.46 97.96 3.21 Favored 'General case' 0 C--N 1.31 -1.111 0 N-CA-C 108.995 -0.743 . . . . 0.0 108.995 177.393 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 10.0 p -70.08 -22.28 63.06 Favored 'General case' 0 N--CA 1.445 -0.715 0 CA-C-N 114.819 -1.082 . . . . 0.0 111.345 -173.753 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 90.39 17.2 53.66 Favored Glycine 0 N--CA 1.44 -1.066 0 N-CA-C 110.094 -1.202 . . . . 0.0 110.094 -176.773 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 5.1 m-20 -91.34 -5.91 53.85 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.169 -0.516 . . . . 0.0 111.01 -175.183 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . 0.418 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 94.25 -5.1 71.16 Favored Glycine 0 N--CA 1.444 -0.77 0 N-CA-C 110.081 -1.208 . . . . 0.0 110.081 -172.676 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' TYR . . . . . 0.546 ' HA ' ' HA ' ' A' ' 58' ' ' ASP . 0.4 OUTLIER -111.61 149.15 31.91 Favored 'General case' 0 N--CA 1.446 -0.664 0 N-CA-C 106.976 -1.491 . . . . 0.0 106.976 177.916 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' TYR . . . . . 0.686 ' O ' ' HA ' ' A' ' 56' ' ' GLN . 71.0 m-85 -114.59 170.37 8.36 Favored 'General case' 0 C--N 1.307 -1.245 0 C-N-CA 120.432 -0.507 . . . . 0.0 111.908 -168.655 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.72 ' HA2' HG21 ' A' ' 45' ' ' ILE . . . -57.94 171.91 3.45 Favored Glycine 0 C--O 1.227 -0.321 0 N-CA-C 115.072 0.789 . . . . 0.0 115.072 -168.919 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . 0.669 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 80.4 -101.76 2.02 Favored Glycine 0 N--CA 1.442 -0.924 0 C-N-CA 120.955 -0.641 . . . . 0.0 112.148 177.367 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.485 ' HB ' ' CD1' ' A' ' 57' ' ' PHE . 2.4 t -83.3 -3.04 7.13 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-O 121.646 0.736 . . . . 0.0 110.296 -176.68 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' GLN . . . . . 0.686 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 7.7 tp-100 54.83 50.47 15.6 Favored 'General case' 0 CA--C 1.53 0.186 0 CA-C-N 114.034 -1.439 . . . . 0.0 112.852 169.203 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . 0.485 ' CD1' ' HB ' ' A' ' 55' ' ' VAL . 2.0 p90 -121.54 163.32 19.05 Favored 'General case' 0 C--N 1.325 -0.474 0 C-N-CA 120.213 -0.595 . . . . 0.0 111.532 176.995 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.546 ' HA ' ' HA ' ' A' ' 51' ' ' TYR . 7.8 p-10 -72.29 162.3 29.65 Favored 'General case' 0 CA--C 1.514 -0.419 0 N-CA-C 113.76 1.022 . . . . 0.0 113.76 -163.511 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.433 ' HB2' ' HE1' ' A' ' 52' ' ' TYR . 17.7 tp60 -55.15 -42.2 72.76 Favored 'General case' 0 N--CA 1.441 -0.878 0 CA-C-N 114.327 -1.306 . . . . 0.0 110.969 177.206 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -67.84 -50.44 41.63 Favored Glycine 0 C--O 1.224 -0.481 0 CA-C-N 115.183 -0.917 . . . . 0.0 112.584 -172.819 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 97.1 m -61.67 -41.46 97.57 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 121.177 0.513 . . . . 0.0 110.8 177.139 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' TRP . . . . . 0.451 ' CH2' ' HA ' ' A' ' 74' ' ' ALA . 52.4 t-105 -58.23 -49.11 78.23 Favored 'General case' 0 N--CA 1.446 -0.671 0 CA-C-N 115.467 -0.788 . . . . 0.0 109.691 175.786 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . 0.483 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 36.2 tt0 -67.13 -36.75 82.55 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.193 -0.912 . . . . 0.0 110.801 -178.205 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -63.53 -41.49 98.47 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.591 -0.731 . . . . 0.0 111.195 -176.882 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . 0.641 HD21 ' N ' ' A' ' 65' ' ' ASN . 0.7 OUTLIER -81.09 -8.74 59.83 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 121.1 0.476 . . . . 0.0 110.22 177.632 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . 0.455 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 89.35 48.6 3.71 Favored Glycine 0 C--N 1.334 0.433 0 CA-C-N 115.746 -0.661 . . . . 0.0 112.271 174.678 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . 0.482 ' HA2' ' HD1' ' A' ' 70' ' ' TYR . . . -79.36 -22.91 64.02 Favored Glycine 0 N--CA 1.439 -1.121 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.838 -175.051 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 0.82 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 6.9 mp -58.89 -25.95 63.84 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 112.893 0.701 . . . . 0.0 112.893 -172.945 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . 0.455 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 14.9 ptp180 -70.5 -29.24 65.7 Favored 'General case' 0 C--N 1.318 -0.772 0 CA-C-O 121.079 0.466 . . . . 0.0 110.553 176.643 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' TYR . . . . . 0.611 ' HB3' ' CG ' ' A' ' 81' ' ' GLU . 74.2 m-85 -79.32 -34.25 42.46 Favored 'General case' 0 N--CA 1.444 -0.749 0 N-CA-C 107.05 -1.463 . . . . 0.0 107.05 175.764 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.702 ' HB2' ' HB3' ' A' ' 77' ' ' ALA . . . 161.81 130.27 0.01 OUTLIER Pre-proline 0 CA--C 1.511 -0.524 0 CA-C-N 112.037 -2.347 . . . . 0.0 106.817 -179.117 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' PRO . . . . . 0.82 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 13.5 Cg_exo -58.33 -2.13 0.85 Allowed 'Trans proline' 0 C--N 1.33 -0.415 0 C-N-CA 122.837 2.358 . . . . 0.0 113.965 -177.083 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' ARG . . . . . 0.44 ' HB2' ' CD2' ' A' ' 52' ' ' TYR . 0.0 OUTLIER -153.3 142.56 21.52 Favored 'General case' 0 C--N 1.316 -0.85 0 N-CA-C 109.211 -0.663 . . . . 0.0 109.211 177.695 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . 0.451 ' HA ' ' CH2' ' A' ' 62' ' ' TRP . . . -60.2 -27.94 67.57 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.32 -0.855 . . . . 0.0 112.721 -175.464 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . 0.553 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 6.7 p-10 -86.87 3.2 46.44 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 121.246 0.546 . . . . 0.0 110.824 -176.6 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.526 ' HB3' ' HB1' ' A' ' 71' ' ' ALA . 50.7 tp -103.68 -34.12 8.72 Favored 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 171.155 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . 0.702 ' HB3' ' HB2' ' A' ' 71' ' ' ALA . . . -79.86 161.51 25.56 Favored 'General case' 0 N--CA 1.448 -0.568 0 CA-C-N 115.1 -0.955 . . . . 0.0 109.93 175.621 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 36.1 p -101.2 -173.19 2.31 Favored 'General case' 0 C--N 1.318 -0.796 0 C-N-CA 120.788 -0.365 . . . . 0.0 110.74 179.874 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . 0.757 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 9.0 mtp85 -52.59 -51.98 57.34 Favored 'General case' 0 CA--C 1.513 -0.46 0 O-C-N 123.592 0.558 . . . . 0.0 110.953 -174.789 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 1.3 pm0 -59.71 -41.67 91.34 Favored 'General case' 0 C--N 1.317 -0.836 0 CA-C-N 115.319 -0.855 . . . . 0.0 112.131 -176.504 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 81' ' ' GLU . . . . . 0.632 ' CB ' ' HB1' ' A' ' 77' ' ' ALA . 2.3 mp0 -62.26 -51.23 68.57 Favored 'General case' 0 C--O 1.234 0.254 0 O-C-N 122.352 -0.218 . . . . 0.0 111.322 174.377 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 82' ' ' GLN . . . . . 0.43 ' HB2' ' HZ3' ' A' ' 43' ' ' TRP . 50.3 mt-30 -60.9 -37.01 80.74 Favored 'General case' 0 CA--C 1.514 -0.413 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.66 -177.9 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . 0.495 ' O ' ' HB3' ' A' ' 87' ' ' GLU . 42.1 mt -59.28 -45.51 93.06 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.777 0 CA-C-N 115.139 -0.937 . . . . 0.0 109.801 176.742 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . 0.632 ' O ' ' HG3' ' A' ' 87' ' ' GLU . . . -66.35 -45.98 78.32 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.621 -177.908 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . 0.416 HG22 ' O ' ' A' ' 81' ' ' GLU . 44.0 t -66.06 -49.01 79.61 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-O 120.779 0.323 . . . . 0.0 111.631 -179.926 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -67.02 -31.3 71.75 Favored 'General case' 0 CA--C 1.516 -0.359 0 CA-C-O 121.147 0.498 . . . . 0.0 110.498 -179.719 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 87' ' ' GLU . . . . . 0.757 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 0.1 OUTLIER -69.69 -31.5 69.58 Favored 'General case' 0 C--N 1.322 -0.604 0 C-N-CA 120.149 -0.62 . . . . 0.0 110.325 -176.455 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.574 ' O ' ' HG3' ' A' ' 92' ' ' ARG . 69.1 t -61.43 -40.77 87.47 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.224 0 N-CA-C 108.839 -0.8 . . . . 0.0 108.839 172.89 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 89' ' ' THR . . . . . 0.892 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 4.3 m -64.8 -43.32 93.54 Favored 'General case' 0 N--CA 1.447 -0.597 0 CA-C-N 115.648 -0.706 . . . . 0.0 110.388 179.367 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . 0.522 ' HG3' ' O ' ' A' ' 87' ' ' GLU . 1.2 ppt_? -61.53 -31.24 71.24 Favored 'General case' 0 C--O 1.223 -0.336 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.561 179.907 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . 0.757 ' HG ' ' O ' ' A' ' 87' ' ' GLU . 28.8 mt -64.07 -33.56 76.03 Favored 'General case' 0 C--N 1.318 -0.801 0 CA-C-O 121.63 0.729 . . . . 0.0 109.88 -179.872 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . 0.574 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 7.6 mtm180 -91.62 -51.58 5.18 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 115.058 -0.974 . . . . 0.0 110.618 -169.925 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 93' ' ' GLN . . . . . 0.558 HE22 ' HZ3' ' A' ' 98' ' ' TRP . 0.0 OUTLIER -106.49 -14.51 15.05 Favored 'General case' 0 N--CA 1.443 -0.786 0 CA-C-N 115.446 -0.797 . . . . 0.0 112.016 -175.293 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.415 ' O ' ' HA ' ' A' ' 90' ' ' ARG . . . 86.74 -109.14 3.39 Favored Glycine 0 CA--C 1.496 -1.116 0 N-CA-C 110.797 -0.921 . . . . 0.0 110.797 178.813 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 95' ' ' TRP . . . . . 0.452 ' HA ' ' HE3' ' A' ' 98' ' ' TRP . 6.6 m95 -141.17 24.39 2.14 Favored 'General case' 0 C--N 1.311 -1.103 0 N-CA-C 107.207 -1.405 . . . . 0.0 107.207 -179.794 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -77.29 -20.76 74.57 Favored Glycine 0 N--CA 1.447 -0.594 0 CA-C-N 114.381 -1.281 . . . . 0.0 111.831 175.616 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . 0.436 ' O ' ' HD3' ' A' ' 99' ' ' PRO . . . -90.35 -24.04 20.95 Favored 'General case' 0 CA--C 1.516 -0.364 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 176.248 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 98' ' ' TRP . . . . . 0.892 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 24.3 m-90 -96.59 104.69 18.88 Favored Pre-proline 0 N--CA 1.451 -0.42 0 N-CA-C 108.811 -0.811 . . . . 0.0 108.811 173.643 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . 0.462 ' HD3' ' HA ' ' A' ' 98' ' ' TRP . 28.9 Cg_exo -67.34 -110.1 0.0 OUTLIER 'Trans proline' 0 CA--C 1.538 0.719 0 C-N-CA 123.49 2.793 . . . . 0.0 114.757 -171.826 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . 0.491 ' O ' ' HG2' ' A' ' 104' ' ' ARG . 40.8 t -67.41 -31.5 53.09 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-O 121.305 0.574 . . . . 0.0 110.432 -174.506 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 101' ' ' CYS . . . . . 0.405 ' SG ' ' HB2' ' A' ' 38' ' ' GLU . 98.5 m -68.71 -32.78 72.82 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 115.28 -0.873 . . . . 0.0 111.92 -171.82 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 102' ' ' ALA . . . . . 0.444 ' HB2' ' CB ' ' A' ' 98' ' ' TRP . . . -69.65 -44.63 70.16 Favored 'General case' 0 C--N 1.324 -0.513 0 C-N-CA 120.651 -0.419 . . . . 0.0 110.202 178.822 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -65.66 -34.28 77.85 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 121.172 0.511 . . . . 0.0 110.406 178.5 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 104' ' ' ARG . . . . . 0.491 ' HG2' ' O ' ' A' ' 100' ' ' VAL . 3.4 mmp_? -70.3 -28.5 65.23 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.129 176.544 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 105' ' ' ALA . . . . . 0.529 ' HB3' ' HB3' ' A' ' 33' ' ' ALA . . . -89.43 -20.82 23.46 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.808 -0.633 . . . . 0.0 112.114 -175.549 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 110.4 64.35 0.52 Allowed Glycine 0 N--CA 1.447 -0.61 0 C-N-CA 120.95 -0.643 . . . . 0.0 111.681 -177.155 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -63.53 149.25 46.67 Favored 'General case' 0 C--N 1.328 -0.337 0 C-N-CA 122.848 0.459 . . . . 0.0 110.824 -176.823 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 108' ' ' ARG . . . . . 0.555 HH12 HG21 ' A' ' 26' ' ' ILE . 91.2 mtt180 . . . . . 0 C--O 1.247 0.944 0 CA-C-O 118.368 -0.825 . . . . 0.0 109.756 -173.016 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 2.7 m-20 . . . . . 0 N--CA 1.476 0.828 0 N-CA-C 109.31 -0.626 . . . . 0.0 109.31 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 18.7 t -78.27 64.2 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.312 -1.044 0 CA-C-N 114.84 -1.073 . . . . 0.0 110.318 -176.348 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 56.4 t -66.68 108.23 1.03 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.864 0 CA-C-N 115.093 -0.958 . . . . 0.0 110.484 173.869 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 11.5 t -100.48 149.2 6.2 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.569 0 N-CA-C 109.407 -0.59 . . . . 0.0 109.407 179.934 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' THR . . . . . 0.434 ' HA ' ' HD3' ' A' ' 6' ' ' PRO . 70.0 p -111.2 122.11 38.65 Favored Pre-proline 0 C--N 1.314 -0.936 0 CA-C-O 121.187 0.518 . . . . 0.0 110.963 -179.63 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.493 ' C ' ' H ' ' A' ' 8' ' ' HIS . 6.3 Cg_exo -80.45 178.19 7.34 Favored 'Trans proline' 0 N--CA 1.453 -0.866 0 C-N-CA 123.275 2.65 . . . . 0.0 109.708 170.008 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -77.36 24.8 0.18 Allowed 'General case' 0 C--N 1.308 -1.203 0 CA-C-O 121.663 0.744 . . . . 0.0 111.074 -179.809 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . 0.493 ' H ' ' C ' ' A' ' 6' ' ' PRO . 37.3 t60 -78.41 -9.71 59.4 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 114.614 -1.176 . . . . 0.0 108.244 167.177 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 13.5 pt-20 -81.57 144.59 31.16 Favored 'General case' 0 N--CA 1.453 -0.315 0 N-CA-C 109.232 -0.655 . . . . 0.0 109.232 177.774 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -82.86 55.06 2.91 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-O 122.156 0.979 . . . . 0.0 110.534 -176.974 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 15.0 p -69.47 -19.42 23.24 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.039 0 CA-C-N 113.476 -1.693 . . . . 0.0 110.058 179.41 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 5.6 t 54.69 105.11 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.441 -0.901 0 CA-C-O 122.802 1.287 . . . . 0.0 112.783 178.968 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 38.4 ptt180 -74.02 159.58 32.49 Favored 'General case' 0 N--CA 1.432 -1.359 0 CA-C-N 113.665 -1.607 . . . . 0.0 108.999 175.78 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.5 t -76.99 158.27 5.3 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.682 0 CA-C-N 114.152 -1.385 . . . . 0.0 110.637 -173.915 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -116.03 64.32 0.33 Allowed Glycine 0 N--CA 1.428 -1.841 0 CA-C-N 114.271 -1.331 . . . . 0.0 110.554 177.675 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 2.2 m -62.71 -32.24 73.31 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-N 113.953 -1.124 . . . . 0.0 112.137 -176.612 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -80.74 117.52 68.28 Favored Pre-proline 0 C--N 1.311 -1.091 0 CA-C-N 114.619 -1.173 . . . . 0.0 111.309 -176.156 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 26.0 Cg_exo -64.24 172.98 5.61 Favored 'Trans proline' 0 N--CA 1.453 -0.862 0 C-N-CA 123.597 2.865 . . . . 0.0 111.159 171.151 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 121.53 51.25 0.24 Allowed Glycine 0 C--N 1.297 -1.616 0 N-CA-C 109.804 -1.319 . . . . 0.0 109.804 -172.051 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 22.8 m -66.43 -33.36 75.53 Favored 'General case' 0 C--N 1.316 -0.857 0 CA-C-N 114.445 -0.878 . . . . 0.0 110.835 -178.426 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 2.2 mp0 46.65 84.64 0.03 OUTLIER 'General case' 0 N--CA 1.447 -0.579 0 CA-C-O 121.886 0.85 . . . . 0.0 110.687 -168.396 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 48.2 t -74.55 119.75 78.15 Favored Pre-proline 0 C--N 1.31 -1.11 0 CA-C-N 114.151 -1.386 . . . . 0.0 109.871 -175.024 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_exo -54.75 128.63 31.17 Favored 'Trans proline' 0 N--CA 1.453 -0.874 0 C-N-CA 122.394 2.063 . . . . 0.0 110.912 177.268 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 9.6 Cg_endo -54.57 138.83 75.57 Favored 'Trans proline' 0 N--CA 1.451 -0.974 0 C-N-CA 122.752 2.301 . . . . 0.0 112.332 -175.166 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.478 ' HB ' HG21 ' A' ' 83' ' ' ILE . 38.1 t -85.4 144.86 8.77 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.156 0 CA-C-N 114.389 -1.278 . . . . 0.0 108.999 -178.563 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 41.2 mm -60.55 -24.43 31.59 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 CA-C-N 115.246 -0.888 . . . . 0.0 112.026 -173.222 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -95.77 2.81 54.07 Favored 'General case' 0 CA--C 1.507 -0.679 0 CA-C-O 121.742 0.782 . . . . 0.0 109.605 -179.03 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -65.84 -9.54 46.57 Favored Glycine 0 N--CA 1.441 -0.969 0 CA-C-N 114.868 -1.06 . . . . 0.0 110.721 177.381 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 21.8 m -76.93 -41.5 43.16 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-O 121.571 0.7 . . . . 0.0 109.387 175.181 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.543 ' HA ' ' HB1' ' A' ' 105' ' ' ALA . 0.8 OUTLIER -66.68 -38.81 82.34 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.64 0 N-CA-C 107.645 -1.243 . . . . 0.0 107.645 177.223 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' TRP . . . . . 0.473 ' CD1' HG22 ' A' ' 83' ' ' ILE . 36.8 m95 -70.91 -35.75 72.42 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 114.627 -1.169 . . . . 0.0 110.894 -177.922 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.41 ' HB2' HH21 ' A' ' 79' ' ' ARG . 1.9 t70 -72.53 -36.76 68.4 Favored 'General case' 0 N--CA 1.449 -0.509 0 CA-C-N 116.387 -0.37 . . . . 0.0 110.338 177.771 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . 0.493 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -70.19 -35.36 73.9 Favored 'General case' 0 N--CA 1.448 -0.552 0 C-N-CA 120.627 -0.429 . . . . 0.0 110.392 177.96 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . 0.443 HG13 ' O ' ' A' ' 30' ' ' ILE . 64.5 mt -67.13 -43.54 88.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.312 174.05 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . 0.513 ' HA ' ' O ' ' A' ' 54' ' ' GLY . . . -59.59 -35.02 73.47 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 121.313 0.578 . . . . 0.0 110.15 175.973 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . 0.418 ' HA2' ' N ' ' A' ' 41' ' ' GLY . . . -77.62 -14.97 81.88 Favored Glycine 0 N--CA 1.448 -0.564 0 CA-C-N 115.497 -0.774 . . . . 0.0 111.873 178.409 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 36.8 t -95.92 -48.01 5.89 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-O 120.737 0.303 . . . . 0.0 111.387 -177.032 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . 0.483 ' HG2' ' SG ' ' A' ' 101' ' ' CYS . 8.5 mm-40 -86.91 -34.2 19.46 Favored 'General case' 0 CA--C 1.511 -0.541 0 CA-C-O 121.077 0.465 . . . . 0.0 110.17 -175.538 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -107.94 -12.47 15.16 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.613 -0.721 . . . . 0.0 112.064 -174.089 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 76.31 16.65 80.55 Favored Glycine 0 N--CA 1.449 -0.461 0 N-CA-C 109.957 -1.257 . . . . 0.0 109.957 -176.767 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . 0.418 ' N ' ' HA2' ' A' ' 36' ' ' GLY . . . 82.98 59.91 2.12 Favored Glycine 0 N--CA 1.434 -1.475 0 CA-C-N 113.944 -1.128 . . . . 0.0 111.807 -176.904 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . 0.823 ' HB3' ' HB ' ' A' ' 45' ' ' ILE . 3.4 m120 -146.1 96.02 2.72 Favored 'General case' 0 C--N 1.324 -0.515 0 N-CA-C 109.223 -0.658 . . . . 0.0 109.223 -178.893 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' TRP . . . . . 0.685 ' CE2' ' HG2' ' A' ' 79' ' ' ARG . 52.5 m95 -78.88 -14.39 59.26 Favored 'General case' 0 C--N 1.314 -0.975 0 CA-C-N 115.711 -0.677 . . . . 0.0 109.803 -177.941 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -102.48 7.97 40.12 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 115.271 -0.877 . . . . 0.0 111.289 -179.692 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.823 ' HB ' ' HB3' ' A' ' 42' ' ' ASN . 8.2 tt -74.18 145.16 11.62 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.708 0 CA-C-O 121.401 0.619 . . . . 0.0 110.984 -177.182 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 17.4 t-20 -141.5 96.19 2.94 Favored 'General case' 0 C--N 1.309 -1.183 0 N-CA-C 109.099 -0.704 . . . . 0.0 109.099 178.953 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 19.7 p -68.61 -21.3 64.51 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 115.029 -0.987 . . . . 0.0 111.058 -177.486 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 88.06 18.22 56.27 Favored Glycine 0 N--CA 1.441 -1.001 0 N-CA-C 110.373 -1.091 . . . . 0.0 110.373 179.44 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 92.2 m-20 -97.37 10.23 40.2 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 121.092 0.472 . . . . 0.0 111.347 -174.621 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . 0.422 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 90.96 -11.6 71.59 Favored Glycine 0 N--CA 1.443 -0.842 0 N-CA-C 110.853 -0.899 . . . . 0.0 110.853 -178.003 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' TYR . . . . . 0.568 ' HA ' ' HA ' ' A' ' 58' ' ' ASP . 0.7 OUTLIER -109.58 152.36 25.61 Favored 'General case' 0 CA--C 1.509 -0.624 0 N-CA-C 108.092 -1.077 . . . . 0.0 108.092 178.026 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' TYR . . . . . 0.754 ' O ' ' HA ' ' A' ' 56' ' ' GLN . 18.4 m-85 -112.81 169.93 8.56 Favored 'General case' 0 C--N 1.31 -1.12 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.698 -169.763 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.435 ' CA ' HG22 ' A' ' 45' ' ' ILE . . . -66.08 -171.79 4.07 Favored Glycine 0 N--CA 1.451 -0.361 0 N-CA-C 115.025 0.77 . . . . 0.0 115.025 -168.353 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . 0.624 ' CA ' ' HA ' ' A' ' 43' ' ' TRP . . . 75.27 -101.97 1.42 Allowed Glycine 0 N--CA 1.443 -0.847 0 CA-C-N 114.738 -0.731 . . . . 0.0 112.177 178.475 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.496 ' HB ' ' CE1' ' A' ' 57' ' ' PHE . 2.3 t -84.3 -3.54 7.95 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 CA-C-O 121.606 0.717 . . . . 0.0 109.541 179.409 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' GLN . . . . . 0.754 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 0.0 OUTLIER 57.93 46.83 16.04 Favored 'General case' 0 N--CA 1.463 0.179 0 CA-C-N 114.432 -1.258 . . . . 0.0 113.556 170.256 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . 0.496 ' CE1' ' HB ' ' A' ' 55' ' ' VAL . 0.3 OUTLIER -117.15 166.61 12.03 Favored 'General case' 0 C--N 1.323 -0.581 0 C-N-CA 119.597 -0.841 . . . . 0.0 111.956 175.069 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.568 ' HA ' ' HA ' ' A' ' 51' ' ' TYR . 7.2 p-10 -74.8 162.89 28.25 Favored 'General case' 0 CA--C 1.514 -0.411 0 CA-C-N 115.444 -0.798 . . . . 0.0 113.071 -167.055 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.506 ' HB2' ' CE1' ' A' ' 52' ' ' TYR . 4.5 tp-100 -63.06 -35.36 79.99 Favored 'General case' 0 N--CA 1.448 -0.567 0 CA-C-N 114.318 -1.31 . . . . 0.0 111.069 179.623 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -65.15 -49.69 60.75 Favored Glycine 0 C--N 1.312 -0.756 0 CA-C-N 115.368 -0.833 . . . . 0.0 111.437 -178.067 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 91.5 m -65.9 -42.6 90.01 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-O 120.757 0.313 . . . . 0.0 110.986 176.375 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' TRP . . . . . 0.474 ' CH2' ' HA ' ' A' ' 74' ' ' ALA . 60.3 t-105 -56.26 -47.72 77.98 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 121.549 0.69 . . . . 0.0 109.656 177.353 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . 0.417 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 5.1 tp10 -66.13 -34.78 78.83 Favored 'General case' 0 C--N 1.318 -0.802 0 CA-C-N 114.818 -1.083 . . . . 0.0 110.505 179.002 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -63.58 -42.54 98.29 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.17 -177.439 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . 0.714 ' HB2' HG12 ' A' ' 85' ' ' VAL . 27.4 m-80 -81.09 -9.99 59.74 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.927 0.394 . . . . 0.0 110.313 176.872 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . 0.467 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 87.69 51.83 3.15 Favored Glycine 0 C--O 1.225 -0.447 0 CA-C-N 115.888 -0.596 . . . . 0.0 112.429 175.357 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . 0.572 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -80.14 -23.77 60.68 Favored Glycine 0 N--CA 1.442 -0.956 0 C-N-CA 120.946 -0.645 . . . . 0.0 112.666 -176.604 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 1.058 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 7.2 mp -61.25 -17.66 54.48 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 112.877 0.695 . . . . 0.0 112.877 -172.751 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . 0.467 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 17.5 ptp180 -70.59 -34.75 72.5 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-O 121.154 0.502 . . . . 0.0 109.775 174.724 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' TYR . . . . . 0.666 ' HB3' ' HB3' ' A' ' 81' ' ' GLU . 54.1 m-85 -80.94 -34.59 33.18 Favored 'General case' 0 N--CA 1.444 -0.77 0 N-CA-C 107.551 -1.278 . . . . 0.0 107.551 179.221 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.613 ' HB1' ' HB2' ' A' ' 77' ' ' ALA . . . 166.32 127.14 0.03 OUTLIER Pre-proline 0 N--CA 1.445 -0.722 0 CA-C-N 112.755 -2.02 . . . . 0.0 106.995 -178.096 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' PRO . . . . . 1.058 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 24.4 Cg_exo -55.91 -7.18 1.49 Allowed 'Trans proline' 0 C--N 1.334 -0.227 0 C-N-CA 122.958 2.439 . . . . 0.0 113.821 -177.68 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' ARG . . . . . 0.489 ' HB2' ' CD2' ' A' ' 52' ' ' TYR . 11.4 ptm180 -144.58 137.12 26.53 Favored 'General case' 0 C--N 1.314 -0.935 0 N-CA-C 108.987 -0.746 . . . . 0.0 108.987 178.059 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . 0.474 ' HA ' ' CH2' ' A' ' 62' ' ' TRP . . . -55.78 -31.45 62.63 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 114.935 -1.029 . . . . 0.0 112.614 -175.993 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . 0.617 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 6.4 p-10 -81.2 -10.02 59.69 Favored 'General case' 0 C--N 1.328 -0.34 0 C-N-CA 120.426 -0.51 . . . . 0.0 111.312 -174.443 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 67.9 tp -93.94 -27.7 16.22 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-O 121.798 0.808 . . . . 0.0 108.921 172.801 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . 0.751 ' HB3' ' HB2' ' A' ' 81' ' ' GLU . . . -79.16 159.38 27.44 Favored 'General case' 0 N--CA 1.441 -0.909 0 CA-C-N 114.723 -1.126 . . . . 0.0 109.863 174.779 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' THR . . . . . 0.414 ' HG1' ' CD ' ' A' ' 80' ' ' GLU . 70.6 p -100.91 -174.59 2.66 Favored 'General case' 0 C--N 1.313 -0.983 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.932 -176.818 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . 0.685 ' HG2' ' CE2' ' A' ' 43' ' ' TRP . 77.0 mtp180 -51.02 -53.53 32.65 Favored 'General case' 0 CA--C 1.514 -0.419 0 CA-C-O 120.893 0.378 . . . . 0.0 110.702 -178.675 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 80' ' ' GLU . . . . . 0.414 ' CD ' ' HG1' ' A' ' 78' ' ' THR . 1.7 pm0 -63.18 -36.11 82.53 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-N 115.463 -0.789 . . . . 0.0 111.804 -175.016 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 81' ' ' GLU . . . . . 0.751 ' HB2' ' HB3' ' A' ' 77' ' ' ALA . 3.5 mm-40 -66.75 -50.7 61.88 Favored 'General case' 0 CA--C 1.516 -0.356 0 CA-C-O 121.041 0.448 . . . . 0.0 110.104 178.827 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 82' ' ' GLN . . . . . 0.572 ' HB2' ' HZ3' ' A' ' 43' ' ' TRP . 48.0 mt-30 -64.68 -35.81 82.23 Favored 'General case' 0 CA--C 1.511 -0.541 0 CA-C-N 115.685 -0.688 . . . . 0.0 110.062 -178.452 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . 0.659 ' O ' ' HG2' ' A' ' 87' ' ' GLU . 53.1 mt -59.23 -48.87 85.44 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.812 0 CA-C-N 115.45 -0.796 . . . . 0.0 109.265 174.199 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . 0.526 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -61.51 -42.24 98.52 Favored 'General case' 0 C--O 1.239 0.517 0 CA-C-O 121.083 0.468 . . . . 0.0 111.615 -177.682 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . 0.714 HG12 ' HB2' ' A' ' 65' ' ' ASN . 69.5 t -67.85 -48.5 75.17 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.85 179.494 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . 0.406 ' HB1' ' CH2' ' A' ' 31' ' ' TRP . . . -60.74 -29.12 69.19 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.543 174.594 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 87' ' ' GLU . . . . . 0.659 ' HG2' ' O ' ' A' ' 83' ' ' ILE . 14.8 mm-40 -59.75 -44.31 93.87 Favored 'General case' 0 N--CA 1.469 0.477 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.494 -179.797 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.574 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 61.7 t -62.94 -40.49 89.12 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.44 0 N-CA-C 109.712 -0.477 . . . . 0.0 109.712 176.641 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 89' ' ' THR . . . . . 0.842 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 1.0 OUTLIER -70.03 -48.9 56.1 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.958 -0.565 . . . . 0.0 111.484 -175.89 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . 0.615 ' HA ' ' OE1' ' A' ' 93' ' ' GLN . 2.3 ptt180 -60.86 -33.63 73.38 Favored 'General case' 0 CA--C 1.519 -0.24 0 CA-C-N 116.025 -0.534 . . . . 0.0 111.638 -173.539 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . 0.574 ' HG ' ' O ' ' A' ' 88' ' ' VAL . 4.7 pp -71.42 -21.84 61.93 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.588 -175.188 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . 0.564 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 22.0 mtm180 -88.02 -52.39 5.28 Favored 'General case' 0 CA--C 1.509 -0.615 0 CA-C-O 121.247 0.546 . . . . 0.0 110.689 -175.8 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 93' ' ' GLN . . . . . 0.615 ' OE1' ' HA ' ' A' ' 90' ' ' ARG . 0.0 OUTLIER -95.3 -21.83 18.16 Favored 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 113.048 0.758 . . . . 0.0 113.048 -171.356 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 88.1 42.34 5.97 Favored Glycine 0 CA--C 1.506 -0.492 0 C-N-CA 120.488 -0.863 . . . . 0.0 111.97 172.251 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 95' ' ' TRP . . . . . 0.43 ' HA ' ' HE3' ' A' ' 98' ' ' TRP . 6.7 m95 62.7 12.15 5.4 Favored 'General case' 0 C--O 1.22 -0.489 0 C-N-CA 123.587 0.755 . . . . 0.0 109.801 -179.347 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -74.14 -20.0 79.73 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 121.172 -0.537 . . . . 0.0 112.458 179.46 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -78.58 -27.23 45.68 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 121.157 0.503 . . . . 0.0 109.872 176.628 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 98' ' ' TRP . . . . . 0.842 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 27.0 m-90 -101.04 103.65 26.9 Favored Pre-proline 0 C--N 1.324 -0.53 0 N-CA-C 108.86 -0.793 . . . . 0.0 108.86 176.399 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 14.7 Cg_exo -74.77 -88.54 0.0 OUTLIER 'Trans proline' 0 CA--C 1.53 0.28 0 C-N-CA 123.034 2.489 . . . . 0.0 114.872 -170.894 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 61.1 t -70.59 -29.91 40.29 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 CA-C-O 121.555 0.693 . . . . 0.0 110.565 -171.966 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 101' ' ' CYS . . . . . 0.483 ' SG ' ' HG2' ' A' ' 38' ' ' GLU . 85.0 m -83.29 -32.48 26.33 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-N 115.14 -0.936 . . . . 0.0 112.021 -169.012 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -68.11 -43.01 79.42 Favored 'General case' 0 C--N 1.327 -0.393 0 C-N-CA 120.47 -0.492 . . . . 0.0 110.098 177.493 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -60.58 -36.12 77.74 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 121.194 0.521 . . . . 0.0 110.739 177.515 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 35.5 mtp180 -73.03 -38.83 66.41 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.702 -0.681 . . . . 0.0 111.183 177.379 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 105' ' ' ALA . . . . . 0.543 ' HB1' ' HA ' ' A' ' 30' ' ' ILE . . . -80.79 -22.42 40.1 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 115.632 -0.713 . . . . 0.0 112.567 -173.69 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 116.57 62.44 0.33 Allowed Glycine 0 CA--C 1.521 0.415 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.31 -178.623 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -63.25 149.46 45.51 Favored 'General case' 0 C--N 1.328 -0.337 0 C-N-CA 122.927 0.491 . . . . 0.0 110.748 179.417 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 72.0 mtp180 . . . . . 0 C--O 1.247 0.937 0 CA-C-O 118.247 -0.882 . . . . 0.0 111.089 -170.546 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 89.1 m-20 . . . . . 0 N--CA 1.476 0.842 0 CA-C-O 121.619 0.723 . . . . 0.0 110.697 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 9.1 p -95.55 -3.88 10.4 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.073 0 CA-C-N 114.769 -1.105 . . . . 0.0 109.811 178.384 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 60.1 t -59.29 108.01 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 CA-C-N 115.19 -0.913 . . . . 0.0 110.698 176.936 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 6.7 p -84.07 147.79 5.45 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.557 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.64 179.246 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 9.7 t -98.7 123.96 47.86 Favored Pre-proline 0 C--N 1.311 -1.091 0 CA-C-N 115.437 -0.801 . . . . 0.0 110.083 179.313 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo -84.38 118.06 2.19 Favored 'Trans proline' 0 N--CA 1.448 -1.197 0 C-N-CA 123.278 2.652 . . . . 0.0 112.07 -176.443 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -79.21 81.11 5.51 Favored 'General case' 0 C--N 1.3 -1.543 0 CA-C-N 114.087 -1.415 . . . . 0.0 110.062 175.699 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 44.9 t-80 -79.09 -10.5 59.84 Favored 'General case' 0 C--N 1.313 -0.999 0 CA-C-N 114.387 -1.279 . . . . 0.0 108.028 174.726 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 8.4 mt-10 -87.13 123.05 31.76 Favored 'General case' 0 N--CA 1.448 -0.56 0 CA-C-N 114.67 -1.15 . . . . 0.0 110.226 176.748 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -122.19 56.08 1.11 Allowed 'General case' 0 C--N 1.319 -0.734 0 CA-C-O 122.09 0.948 . . . . 0.0 110.282 178.442 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 62.0 t -77.62 -51.44 18.19 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.091 0 CA-C-N 114.179 -1.373 . . . . 0.0 109.222 174.732 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 7.3 p 23.02 74.76 0.01 OUTLIER 'Isoleucine or valine' 0 C--O 1.234 0.261 0 C-N-CA 125.601 1.56 . . . . 0.0 114.125 176.778 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 56.1 mtm180 -146.66 109.96 4.78 Favored 'General case' 0 C--N 1.304 -1.392 0 CA-C-N 113.792 -1.549 . . . . 0.0 111.54 177.421 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 3.0 t -122.67 166.33 17.56 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.136 0 CA-C-N 114.537 -1.21 . . . . 0.0 108.336 177.734 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 78.02 61.88 2.45 Favored Glycine 0 C--N 1.304 -1.195 0 N-CA-C 110.352 -1.099 . . . . 0.0 110.352 177.474 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' THR . . . . . 0.55 ' O ' ' HD3' ' A' ' 18' ' ' PRO . 85.2 m -79.08 -23.56 44.08 Favored 'General case' 0 N--CA 1.438 -1.067 0 CA-C-N 114.299 -0.95 . . . . 0.0 111.391 -172.082 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . 0.748 ' HD2' ' O ' ' A' ' 17' ' ' LYS . 0.0 OUTLIER -86.92 110.34 31.94 Favored Pre-proline 0 C--N 1.318 -0.773 0 CA-C-O 121.853 0.835 . . . . 0.0 112.275 -179.478 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . 0.55 ' HD3' ' O ' ' A' ' 16' ' ' THR . 1.9 Cg_endo -84.71 172.11 9.21 Favored 'Trans proline' 0 N--CA 1.45 -1.042 0 C-N-CA 123.373 2.715 . . . . 0.0 111.648 173.744 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 92.16 33.17 7.85 Favored Glycine 0 C--N 1.309 -0.951 0 CA-C-N 114.708 -1.133 . . . . 0.0 111.823 179.656 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 90.6 m -71.29 -29.94 65.65 Favored 'General case' 0 C--N 1.311 -1.082 0 CA-C-N 114.568 -0.816 . . . . 0.0 109.858 176.048 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 42.7 mt-10 -138.44 140.01 39.11 Favored 'General case' 0 N--CA 1.439 -0.989 0 N-CA-C 107.524 -1.287 . . . . 0.0 107.524 179.228 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.444 ' HA ' ' HD3' ' A' ' 23' ' ' PRO . 41.4 t -71.84 117.59 59.2 Favored Pre-proline 0 C--N 1.317 -0.846 0 O-C-N 123.389 0.431 . . . . 0.0 110.189 -177.374 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . 0.444 ' HD3' ' HA ' ' A' ' 22' ' ' VAL . 47.7 Cg_exo -56.98 126.5 22.43 Favored 'Trans proline' 0 N--CA 1.458 -0.58 0 C-N-CA 123.235 2.623 . . . . 0.0 113.583 -173.12 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . 0.797 ' HB3' HH22 ' A' ' 79' ' ' ARG . 35.3 Cg_endo -65.34 161.25 38.69 Favored 'Trans proline' 0 N--CA 1.45 -1.079 0 C-N-CA 123.834 3.022 . . . . 0.0 113.079 172.951 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.593 ' HB ' HD13 ' A' ' 83' ' ' ILE . 38.2 t -80.25 153.54 4.48 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.05 0 N-CA-C 107.466 -1.309 . . . . 0.0 107.466 168.641 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 40.2 mm -55.6 -32.73 31.41 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.692 0 N-CA-C 113.634 0.975 . . . . 0.0 113.634 -162.25 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.57 ' O ' HG12 ' A' ' 30' ' ' ILE . 6.2 m-20 -105.1 -0.02 27.05 Favored 'General case' 0 C--N 1.312 -1.024 0 CA-C-O 121.909 0.861 . . . . 0.0 110.057 179.371 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . 0.577 ' HA2' ' HB2' ' A' ' 31' ' ' TRP . . . -72.52 0.94 39.28 Favored Glycine 0 N--CA 1.436 -1.319 0 CA-C-N 114.464 -1.244 . . . . 0.0 111.053 178.77 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 13.8 m -76.41 -39.13 54.45 Favored 'General case' 0 C--N 1.32 -0.716 0 N-CA-C 108.892 -0.781 . . . . 0.0 108.892 173.458 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.57 HG12 ' O ' ' A' ' 27' ' ' ASP . 0.2 OUTLIER -71.99 -39.1 66.01 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 CA-C-N 114.327 -1.306 . . . . 0.0 107.527 176.317 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' TRP . . . . . 0.577 ' HB2' ' HA2' ' A' ' 28' ' ' GLY . 22.9 m95 -70.69 -35.56 72.84 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-N 114.483 -1.235 . . . . 0.0 110.333 -176.443 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.695 ' HB2' HH21 ' A' ' 79' ' ' ARG . 7.0 t70 -76.87 -32.24 57.34 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.458 179.7 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -70.45 -37.73 74.36 Favored 'General case' 0 N--CA 1.447 -0.601 0 C-N-CA 120.729 -0.388 . . . . 0.0 110.27 175.051 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . 0.471 HG13 ' O ' ' A' ' 30' ' ' ILE . 62.0 mt -64.89 -44.4 96.22 Favored 'Isoleucine or valine' 0 C--O 1.235 0.293 0 CA-C-O 120.954 0.407 . . . . 0.0 110.324 174.535 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . 0.482 ' O ' ' HB3' ' A' ' 39' ' ' ALA . . . -57.84 -39.25 77.27 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.236 0.541 . . . . 0.0 110.032 175.127 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -74.07 -9.01 79.85 Favored Glycine 0 N--CA 1.452 -0.299 0 CA-C-N 115.568 -0.742 . . . . 0.0 111.761 179.736 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 44.8 t -97.22 -62.85 1.19 Allowed 'General case' 0 N--CA 1.446 -0.648 0 CA-C-N 115.554 -0.323 . . . . 0.0 111.077 -178.068 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . 0.871 ' HG3' ' SG ' ' A' ' 101' ' ' CYS . 27.3 mt-10 -89.36 -27.32 20.56 Favored 'General case' 0 C--N 1.328 -0.357 0 N-CA-C 111.778 0.288 . . . . 0.0 111.778 -174.181 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . 0.482 ' HB3' ' O ' ' A' ' 35' ' ' ALA . . . -95.14 -17.11 22.08 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 121.015 0.435 . . . . 0.0 112.021 -176.457 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 81.54 14.05 78.99 Favored Glycine 0 N--CA 1.447 -0.599 0 N-CA-C 109.709 -1.357 . . . . 0.0 109.709 -174.622 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 77.52 57.2 3.66 Favored Glycine 0 N--CA 1.438 -1.203 0 CA-C-N 114.236 -0.982 . . . . 0.0 112.656 179.874 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 55.9 t30 -150.73 127.5 10.96 Favored 'General case' 0 CA--C 1.503 -0.853 0 N-CA-C 109.201 -0.666 . . . . 0.0 109.201 178.19 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' TRP . . . . . 0.752 ' HA ' ' N ' ' A' ' 54' ' ' GLY . 26.2 m95 -100.28 -2.02 34.79 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-N 115.437 -0.801 . . . . 0.0 110.099 -174.167 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -112.19 8.77 19.98 Favored 'General case' 0 C--N 1.318 -0.772 0 CA-C-N 115.052 -0.977 . . . . 0.0 111.021 178.574 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.57 HG23 ' HA2' ' A' ' 53' ' ' GLY . 12.5 tt -74.3 143.89 13.01 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.76 0 CA-C-O 120.988 0.423 . . . . 0.0 110.176 -178.784 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 13.3 t-20 -149.63 85.21 1.43 Allowed 'General case' 0 C--N 1.314 -0.939 0 CA-C-O 121.299 0.571 . . . . 0.0 110.302 -177.793 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -69.89 -20.03 63.4 Favored 'General case' 0 N--CA 1.445 -0.7 0 CA-C-N 115.476 -0.784 . . . . 0.0 111.058 177.88 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 92.05 21.56 32.74 Favored Glycine 0 N--CA 1.444 -0.795 0 C-N-CA 120.909 -0.662 . . . . 0.0 111.698 174.578 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 4.2 p-10 -94.97 14.38 21.91 Favored 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 112.082 0.401 . . . . 0.0 112.082 -175.275 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . 0.52 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 92.39 -13.92 66.01 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 121.32 -0.467 . . . . 0.0 112.171 176.5 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' TYR . . . . . 0.612 ' CE1' ' HB2' ' A' ' 58' ' ' ASP . 0.3 OUTLIER -110.0 155.29 22.0 Favored 'General case' 0 C--N 1.323 -0.546 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 173.505 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' TYR . . . . . 0.719 ' O ' ' HA ' ' A' ' 56' ' ' GLN . 63.5 m-85 -119.38 171.05 8.6 Favored 'General case' 0 C--N 1.312 -1.06 0 N-CA-C 112.657 0.614 . . . . 0.0 112.657 -168.467 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.57 ' HA2' HG23 ' A' ' 45' ' ' ILE . . . -53.87 163.19 3.07 Favored Glycine 0 N--CA 1.449 -0.44 0 CA-C-N 115.356 -0.838 . . . . 0.0 114.09 -175.527 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . 0.752 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 90.27 -109.51 3.66 Favored Glycine 0 N--CA 1.442 -0.921 0 C-N-CA 121.05 -0.595 . . . . 0.0 112.397 178.738 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.436 ' HB ' ' CD1' ' A' ' 57' ' ' PHE . 2.5 t -83.63 0.7 4.58 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-O 121.968 0.89 . . . . 0.0 109.784 -177.065 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' GLN . . . . . 0.719 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 0.0 OUTLIER 53.97 50.18 17.32 Favored 'General case' 0 N--CA 1.449 -0.495 0 CA-C-N 113.826 -1.534 . . . . 0.0 112.729 170.679 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . 0.436 ' CD1' ' HB ' ' A' ' 55' ' ' VAL . 2.5 p90 -119.04 166.63 12.65 Favored 'General case' 0 C--N 1.323 -0.564 0 C-N-CA 119.304 -0.958 . . . . 0.0 111.914 174.837 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.612 ' HB2' ' CE1' ' A' ' 51' ' ' TYR . 0.0 OUTLIER -75.75 157.46 33.49 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 114.32 -1.309 . . . . 0.0 113.777 -162.071 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.47 ' HB2' ' HE1' ' A' ' 52' ' ' TYR . 22.1 tp60 -53.34 -44.25 68.33 Favored 'General case' 0 N--CA 1.441 -0.9 0 CA-C-N 114.171 -1.377 . . . . 0.0 111.463 179.243 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -68.49 -49.05 47.16 Favored Glycine 0 C--O 1.22 -0.735 0 CA-C-N 115.325 -0.852 . . . . 0.0 112.396 -176.106 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 46.3 m -60.77 -40.61 93.15 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-O 121.552 0.691 . . . . 0.0 110.519 179.098 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' TRP . . . . . 0.468 ' CZ3' ' HA ' ' A' ' 82' ' ' GLN . 50.6 t-105 -61.98 -48.86 78.45 Favored 'General case' 0 C--N 1.318 -0.794 0 CA-C-N 114.845 -1.071 . . . . 0.0 109.863 175.279 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . 0.596 ' HB2' HD12 ' A' ' 68' ' ' LEU . 0.0 OUTLIER -67.97 -36.39 79.97 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.733 -0.667 . . . . 0.0 110.353 -176.801 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . 0.482 ' N ' ' HG3' ' A' ' 63' ' ' GLU . . . -66.16 -41.05 90.89 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.433 -0.803 . . . . 0.0 111.28 -175.972 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . 0.455 ' HB3' ' HB ' ' A' ' 88' ' ' VAL . 84.5 m-20 -84.09 -3.61 58.2 Favored 'General case' 0 N--CA 1.446 -0.669 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.61 176.906 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . 0.482 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 85.74 46.92 5.27 Favored Glycine 0 N--CA 1.448 -0.532 0 CA-C-N 115.573 -0.74 . . . . 0.0 113.107 171.11 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . 0.618 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -80.28 -16.46 76.23 Favored Glycine 0 N--CA 1.443 -0.899 0 C-N-CA 120.672 -0.775 . . . . 0.0 111.828 179.918 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 0.616 ' HA ' ' HA ' ' A' ' 72' ' ' PRO . 14.6 mt -64.74 -22.74 67.05 Favored 'General case' 0 C--N 1.32 -0.707 0 C-N-CA 122.817 0.447 . . . . 0.0 111.363 -171.332 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . 0.482 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 14.9 ptm180 -70.85 -32.49 69.53 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.311 176.138 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' TYR . . . . . 0.675 ' HB3' ' HB3' ' A' ' 81' ' ' GLU . 58.9 m-85 -80.09 -33.33 38.88 Favored 'General case' 0 N--CA 1.445 -0.697 0 N-CA-C 107.217 -1.401 . . . . 0.0 107.217 178.19 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.653 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 165.94 127.12 0.03 OUTLIER Pre-proline 0 CA--C 1.511 -0.538 0 CA-C-N 112.447 -2.161 . . . . 0.0 107.122 178.693 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' PRO . . . . . 0.616 ' HA ' ' HA ' ' A' ' 68' ' ' LEU . 15.5 Cg_exo -56.2 -0.8 0.23 Allowed 'Trans proline' 0 CA--C 1.531 0.369 0 C-N-CA 122.961 2.441 . . . . 0.0 114.231 -177.849 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 13.0 ptm180 -150.82 142.46 23.62 Favored 'General case' 0 C--N 1.317 -0.839 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 172.776 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . 0.426 ' HA ' ' CH2' ' A' ' 62' ' ' TRP . . . -58.69 -30.34 67.33 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.332 -0.849 . . . . 0.0 112.89 -175.899 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . 0.438 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 15.7 p-10 -87.33 5.54 37.98 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 121.269 0.557 . . . . 0.0 111.129 -176.232 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.425 ' HB3' ' HB2' ' A' ' 71' ' ' ALA . 65.2 tp -105.67 -30.17 9.64 Favored 'General case' 0 C--N 1.319 -0.72 0 N-CA-C 108.359 -0.978 . . . . 0.0 108.359 168.967 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . 0.671 ' HB3' ' HB2' ' A' ' 81' ' ' GLU . . . -79.47 164.48 23.91 Favored 'General case' 0 N--CA 1.444 -0.739 0 CA-C-N 114.446 -1.252 . . . . 0.0 110.183 175.933 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' THR . . . . . 0.443 ' OG1' ' HG2' ' A' ' 81' ' ' GLU . 65.9 p -99.97 -178.89 3.99 Favored 'General case' 0 C--N 1.313 -0.994 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.414 -177.042 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . 0.797 HH22 ' HB3' ' A' ' 24' ' ' PRO . 47.2 mtp180 -52.71 -53.67 44.32 Favored 'General case' 0 CA--C 1.516 -0.342 0 CA-C-O 121.045 0.45 . . . . 0.0 110.374 -178.536 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 80' ' ' GLU . . . . . 0.591 ' HA ' HD11 ' A' ' 83' ' ' ILE . 2.7 pm0 -60.51 -32.64 71.65 Favored 'General case' 0 C--N 1.317 -0.816 0 CA-C-N 115.083 -0.962 . . . . 0.0 112.254 -176.818 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 81' ' ' GLU . . . . . 0.675 ' HB3' ' HB3' ' A' ' 70' ' ' TYR . 5.4 mm-40 -70.64 -50.41 37.13 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-O 120.877 0.37 . . . . 0.0 110.031 177.477 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 82' ' ' GLN . . . . . 0.468 ' HA ' ' CZ3' ' A' ' 62' ' ' TRP . 51.2 mt-30 -61.11 -35.61 77.49 Favored 'General case' 0 CA--C 1.507 -0.69 0 CA-C-N 115.582 -0.736 . . . . 0.0 109.631 179.833 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . 0.682 ' O ' ' HG2' ' A' ' 87' ' ' GLU . 39.2 mt -59.55 -49.16 84.69 Favored 'Isoleucine or valine' 0 C--O 1.211 -0.952 0 CA-C-N 114.714 -1.13 . . . . 0.0 109.763 174.829 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . 0.607 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -61.25 -41.58 97.15 Favored 'General case' 0 C--O 1.236 0.365 0 CA-C-O 121.403 0.62 . . . . 0.0 111.579 -177.606 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . 0.449 HG21 ' O ' ' A' ' 81' ' ' GLU . 34.7 t -69.2 -47.85 71.89 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.794 178.528 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -58.22 -29.44 65.72 Favored 'General case' 0 N--CA 1.45 -0.446 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.364 172.99 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 87' ' ' GLU . . . . . 0.682 ' HG2' ' O ' ' A' ' 83' ' ' ILE . 14.5 mm-40 -60.03 -44.62 94.5 Favored 'General case' 0 N--CA 1.469 0.497 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.111 179.277 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.636 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 60.8 t -63.56 -47.71 90.21 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.437 0 N-CA-C 109.473 -0.566 . . . . 0.0 109.473 174.243 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 89' ' ' THR . . . . . 0.904 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 0.7 OUTLIER -59.21 -49.86 76.22 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-N 115.696 -0.684 . . . . 0.0 111.387 -176.508 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . 0.498 ' HA ' ' HZ3' ' A' ' 98' ' ' TRP . 27.0 ptt85 -60.51 -34.97 74.87 Favored 'General case' 0 C--O 1.223 -0.314 0 CA-C-N 116.723 -0.217 . . . . 0.0 111.232 -172.477 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . 0.636 ' HG ' ' O ' ' A' ' 88' ' ' VAL . 4.5 pp -74.71 -22.82 58.63 Favored 'General case' 0 C--N 1.318 -0.798 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.52 -173.488 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . 0.591 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 15.6 mtm180 -80.82 -52.71 7.19 Favored 'General case' 0 CA--C 1.505 -0.773 0 CA-C-O 121.13 0.491 . . . . 0.0 109.877 -176.04 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 4.9 pm0 -103.75 -15.36 15.76 Favored 'General case' 0 N--CA 1.445 -0.681 0 C-N-CA 119.645 -0.822 . . . . 0.0 113.022 -173.411 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 87.33 45.12 5.39 Favored Glycine 0 CA--C 1.498 -1.03 0 C-N-CA 120.732 -0.747 . . . . 0.0 111.88 168.424 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 95' ' ' TRP . . . . . 0.476 ' HA ' ' HE3' ' A' ' 98' ' ' TRP . 15.7 m95 66.47 2.23 2.39 Favored 'General case' 0 C--O 1.216 -0.669 0 C-N-CA 123.236 0.614 . . . . 0.0 109.979 -178.276 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -70.35 -13.01 70.23 Favored Glycine 0 C--N 1.335 0.517 0 C-N-CA 121.447 -0.406 . . . . 0.0 112.792 -178.108 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -81.93 -23.66 36.06 Favored 'General case' 0 C--N 1.325 -0.471 0 N-CA-C 109.525 -0.546 . . . . 0.0 109.525 175.159 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 98' ' ' TRP . . . . . 0.904 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 29.0 m-90 -103.16 104.95 43.59 Favored Pre-proline 0 N--CA 1.45 -0.444 0 N-CA-C 108.745 -0.835 . . . . 0.0 108.745 175.146 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . 0.403 ' HD3' ' HA ' ' A' ' 98' ' ' TRP . 15.0 Cg_exo -74.43 -87.09 0.0 OUTLIER 'Trans proline' 0 CA--C 1.53 0.305 0 C-N-CA 122.902 2.401 . . . . 0.0 114.673 -172.666 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 48.4 t -71.25 -27.92 30.83 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-O 121.322 0.582 . . . . 0.0 111.086 -170.949 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 101' ' ' CYS . . . . . 0.871 ' SG ' ' HG3' ' A' ' 38' ' ' GLU . 64.2 m -90.99 -27.55 18.59 Favored 'General case' 0 C--N 1.314 -0.946 0 CA-C-N 115.915 -0.584 . . . . 0.0 112.545 -168.772 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 102' ' ' ALA . . . . . 0.573 ' HB2' ' HB2' ' A' ' 98' ' ' TRP . . . -67.54 -46.43 72.82 Favored 'General case' 0 C--N 1.33 -0.268 0 C-N-CA 120.515 -0.474 . . . . 0.0 110.928 -178.719 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -61.22 -39.09 88.95 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-O 121.097 0.475 . . . . 0.0 110.634 179.25 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -66.56 -39.77 88.68 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.469 -0.787 . . . . 0.0 111.548 176.655 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 105' ' ' ALA . . . . . 0.41 ' HB3' HG21 ' A' ' 30' ' ' ILE . . . -77.56 -22.51 50.89 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.929 -175.933 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 116.02 55.83 0.34 Allowed Glycine 0 N--CA 1.452 -0.236 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.528 -178.942 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -57.52 149.2 21.67 Favored 'General case' 0 CA--C 1.517 -0.305 0 C-N-CA 123.049 0.54 . . . . 0.0 110.572 179.149 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 69.9 mtp180 . . . . . 0 C--O 1.249 1.04 0 CA-C-O 118.202 -0.904 . . . . 0.0 110.465 -170.19 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 16.6 p-10 . . . . . 0 N--CA 1.475 0.801 0 CA-C-O 122.016 0.913 . . . . 0.0 110.537 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 73.5 t -65.03 -41.49 92.17 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.008 0 CA-C-N 114.681 -1.145 . . . . 0.0 110.286 176.138 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 14.8 p -73.29 137.71 22.8 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.646 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.343 175.605 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 14.0 t -75.41 140.33 17.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 N-CA-C 109.265 -0.643 . . . . 0.0 109.265 177.96 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' THR . . . . . 0.432 ' HA ' ' HD3' ' A' ' 6' ' ' PRO . 8.7 p -121.19 134.29 24.4 Favored Pre-proline 0 C--N 1.312 -1.043 0 CA-C-N 115.826 -0.625 . . . . 0.0 111.899 -170.587 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.432 ' HD3' ' HA ' ' A' ' 5' ' ' THR . 10.6 Cg_exo -73.13 -172.59 1.04 Allowed 'Trans proline' 0 CA--C 1.51 -0.687 0 C-N-CA 123.59 2.86 . . . . 0.0 110.797 170.021 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . 0.854 ' HB2' ' HG2' ' A' ' 9' ' ' GLU . . . 71.95 102.69 0.07 Allowed 'General case' 0 C--N 1.319 -0.734 0 O-C-N 124.633 1.208 . . . . 0.0 111.343 -178.802 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 18.6 m170 -69.34 -10.81 59.57 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 114.286 -1.325 . . . . 0.0 108.564 173.368 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . 0.854 ' HG2' ' HB2' ' A' ' 7' ' ' ALA . 18.4 pt-20 -72.38 143.14 48.68 Favored 'General case' 0 C--O 1.233 0.203 0 CA-C-N 115.029 -0.987 . . . . 0.0 110.336 -179.761 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -84.65 58.84 5.14 Favored 'General case' 0 CA--C 1.511 -0.537 0 CA-C-O 122.28 1.038 . . . . 0.0 110.943 -176.085 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 77.4 t -92.0 -47.21 14.17 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.245 0 CA-C-N 113.603 -1.635 . . . . 0.0 109.61 173.322 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 20.2 t -68.45 73.79 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.416 -2.133 0 CA-C-O 122.288 1.042 . . . . 0.0 109.69 170.455 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . 0.447 ' HG3' ' O ' ' A' ' 13' ' ' ARG . 16.0 ptt180 -64.54 112.39 3.13 Favored 'General case' 0 C--N 1.3 -1.559 0 CA-C-N 113.389 -1.732 . . . . 0.0 111.815 -176.228 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 5.2 t -122.39 162.12 22.54 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.641 0 CA-C-N 113.265 -1.789 . . . . 0.0 107.454 171.284 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 128.76 91.69 0.68 Allowed Glycine 0 C--N 1.304 -1.211 0 C-N-CA 121.152 -0.547 . . . . 0.0 112.109 -179.613 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' THR . . . . . 0.516 ' O ' ' HD3' ' A' ' 18' ' ' PRO . 27.3 m -95.0 -23.8 17.21 Favored 'General case' 0 N--CA 1.44 -0.927 0 CA-C-O 121.313 0.578 . . . . 0.0 111.117 -177.985 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 11.2 mptt -93.49 102.04 6.89 Favored Pre-proline 0 C--N 1.319 -0.759 0 CA-C-N 115.394 -0.821 . . . . 0.0 110.714 179.736 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . 0.516 ' HD3' ' O ' ' A' ' 16' ' ' THR . 66.5 Cg_endo -79.39 133.84 10.94 Favored 'Trans proline' 0 N--CA 1.448 -1.198 0 C-N-CA 123.282 2.655 . . . . 0.0 111.556 179.592 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 123.67 -50.11 0.87 Allowed Glycine 0 C--N 1.301 -1.412 0 CA-C-N 114.481 -1.236 . . . . 0.0 110.447 -178.706 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 83.4 m -63.07 -39.74 95.6 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-O 121.769 0.795 . . . . 0.0 109.641 172.228 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . 0.463 ' O ' ' HD3' ' A' ' 23' ' ' PRO . 8.5 pt-20 -135.69 157.59 46.48 Favored 'General case' 0 N--CA 1.428 -1.566 0 CA-C-N 114.953 -1.021 . . . . 0.0 108.339 178.068 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 35.5 t -88.67 109.87 32.92 Favored Pre-proline 0 C--N 1.311 -1.107 0 CA-C-N 115.324 -0.853 . . . . 0.0 111.442 -174.269 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . 0.463 ' HD3' ' O ' ' A' ' 21' ' ' GLU . 21.5 Cg_exo -67.59 143.48 62.66 Favored 'Trans proline' 0 N--CA 1.46 -0.48 0 C-N-CA 123.691 2.928 . . . . 0.0 113.681 -179.486 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 12.1 Cg_endo -56.8 165.16 5.12 Favored 'Trans proline' 0 C--N 1.345 0.356 0 C-N-CA 124.279 3.319 . . . . 0.0 112.125 167.476 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.777 HG23 HD13 ' A' ' 83' ' ' ILE . 4.6 p -75.01 123.98 31.86 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.868 0 CA-C-O 121.985 0.898 . . . . 0.0 109.997 -176.355 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 49.7 mm -65.94 -44.67 92.37 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.32 0 CA-C-N 114.538 -1.21 . . . . 0.0 113.096 -170.482 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.607 ' O ' HG12 ' A' ' 30' ' ' ILE . 13.0 m-20 -101.21 2.62 40.19 Favored 'General case' 0 CA--C 1.502 -0.899 0 CA-C-O 121.891 0.853 . . . . 0.0 109.208 -176.662 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . 0.721 ' HA2' ' HB2' ' A' ' 31' ' ' TRP . . . -77.75 2.7 62.91 Favored Glycine 0 N--CA 1.433 -1.534 0 CA-C-N 114.583 -1.19 . . . . 0.0 110.611 -177.76 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 17.0 m -76.23 -40.36 52.26 Favored 'General case' 0 C--N 1.318 -0.794 0 N-CA-C 108.77 -0.826 . . . . 0.0 108.77 173.626 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.666 ' HA ' ' HB2' ' A' ' 105' ' ' ALA . 0.0 OUTLIER -71.52 -38.03 66.32 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.679 0 N-CA-C 107.348 -1.353 . . . . 0.0 107.348 176.573 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' TRP . . . . . 0.721 ' HB2' ' HA2' ' A' ' 28' ' ' GLY . 14.6 m95 -71.85 -36.29 70.11 Favored 'General case' 0 N--CA 1.438 -1.054 0 CA-C-N 114.251 -1.34 . . . . 0.0 110.601 -176.188 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 31.7 t70 -77.23 -34.31 56.01 Favored 'General case' 0 N--CA 1.446 -0.66 0 CA-C-N 116.529 -0.305 . . . . 0.0 110.931 178.082 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . 0.495 ' HB2' ' CB ' ' A' ' 105' ' ' ALA . . . -70.16 -34.08 72.56 Favored 'General case' 0 N--CA 1.448 -0.532 0 C-N-CA 120.288 -0.565 . . . . 0.0 110.278 177.523 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . 0.507 HG13 ' O ' ' A' ' 30' ' ' ILE . 68.3 mt -67.88 -46.55 81.92 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-O 121.07 0.462 . . . . 0.0 110.176 172.298 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -58.72 -38.91 79.36 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.277 176.89 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . 0.507 ' HA2' ' N ' ' A' ' 41' ' ' GLY . . . -74.88 -12.97 82.84 Favored Glycine 0 C--O 1.228 -0.26 0 CA-C-N 115.618 -0.719 . . . . 0.0 111.535 178.699 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 40.8 t -89.5 -60.94 1.81 Allowed 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 115.356 -0.422 . . . . 0.0 110.93 -177.748 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . 0.821 ' HG3' ' SG ' ' A' ' 101' ' ' CYS . 34.3 mt-10 -89.55 -28.37 19.64 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 120.687 0.28 . . . . 0.0 111.534 -174.441 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -101.49 -12.01 18.87 Favored 'General case' 0 C--N 1.326 -0.452 0 C-N-CA 120.43 -0.508 . . . . 0.0 111.785 -178.14 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 81.03 6.52 89.4 Favored Glycine 0 N--CA 1.45 -0.371 0 N-CA-C 110.027 -1.229 . . . . 0.0 110.027 -177.846 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . 0.507 ' N ' ' HA2' ' A' ' 36' ' ' GLY . . . 85.35 53.88 2.98 Favored Glycine 0 N--CA 1.437 -1.274 0 CA-C-N 114.148 -1.026 . . . . 0.0 111.942 -177.71 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . 0.416 ' OD1' ' HB ' ' A' ' 45' ' ' ILE . 2.3 t-20 -138.71 99.32 3.77 Favored 'General case' 0 N--CA 1.447 -0.58 0 N-CA-C 108.829 -0.804 . . . . 0.0 108.829 -175.84 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' TRP . . . . . 0.663 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 37.1 m95 -81.48 -10.32 59.51 Favored 'General case' 0 C--N 1.312 -1.026 0 CA-C-N 115.389 -0.823 . . . . 0.0 110.805 -172.664 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -107.0 8.71 30.56 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 115.504 -0.771 . . . . 0.0 110.829 -179.492 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.416 ' HB ' ' OD1' ' A' ' 42' ' ' ASN . 9.3 tt -72.56 144.27 13.17 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.916 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 179.578 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 22.4 t-20 -154.22 98.47 2.14 Favored 'General case' 0 C--N 1.309 -1.183 0 CA-C-O 121.384 0.612 . . . . 0.0 109.372 -179.956 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 17.5 p -72.51 -24.05 61.1 Favored 'General case' 0 C--N 1.317 -0.819 0 CA-C-N 114.76 -1.109 . . . . 0.0 110.919 -177.376 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 93.48 20.64 31.56 Favored Glycine 0 N--CA 1.441 -0.981 0 N-CA-C 110.722 -0.951 . . . . 0.0 110.722 -178.698 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 82.8 m-20 -93.18 12.8 23.14 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.877 0.37 . . . . 0.0 111.415 -176.234 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . 0.527 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 85.29 -11.73 60.18 Favored Glycine 0 N--CA 1.449 -0.46 0 N-CA-C 111.209 -0.757 . . . . 0.0 111.209 -177.883 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' TYR . . . . . 0.559 ' HA ' ' HA ' ' A' ' 58' ' ' ASP . 0.3 OUTLIER -112.22 146.37 38.25 Favored 'General case' 0 CA--C 1.51 -0.562 0 N-CA-C 107.197 -1.408 . . . . 0.0 107.197 177.214 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' TYR . . . . . 0.818 ' O ' ' HA ' ' A' ' 56' ' ' GLN . 32.8 m-85 -110.73 170.5 8.05 Favored 'General case' 0 C--N 1.309 -1.154 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.697 -165.96 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -69.06 -174.37 9.98 Favored Glycine 0 C--O 1.228 -0.223 0 N-CA-C 114.907 0.723 . . . . 0.0 114.907 -169.761 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . 0.599 ' CA ' ' HA ' ' A' ' 43' ' ' TRP . . . 80.0 -107.53 2.62 Favored Glycine 0 N--CA 1.442 -0.942 0 C-N-CA 120.859 -0.686 . . . . 0.0 111.457 -178.349 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.419 HG12 ' HE1' ' A' ' 98' ' ' TRP . 3.4 t -88.21 4.22 4.84 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 CA-C-O 121.554 0.692 . . . . 0.0 109.618 179.016 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' GLN . . . . . 0.818 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 7.0 tt0 54.5 53.82 10.22 Favored 'General case' 0 CA--C 1.535 0.379 0 N-CA-C 114.854 1.427 . . . . 0.0 114.854 164.887 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -121.15 170.26 9.73 Favored 'General case' 0 C--N 1.326 -0.418 0 C-N-CA 119.447 -0.901 . . . . 0.0 112.018 171.652 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.559 ' HA ' ' HA ' ' A' ' 51' ' ' TYR . 6.9 p-10 -76.25 165.22 25.18 Favored 'General case' 0 C--N 1.331 -0.219 0 N-CA-C 113.311 0.856 . . . . 0.0 113.311 -166.809 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.478 ' HB2' ' HE1' ' A' ' 52' ' ' TYR . 5.9 tp-100 -63.15 -37.99 89.4 Favored 'General case' 0 N--CA 1.448 -0.568 0 CA-C-N 114.881 -1.054 . . . . 0.0 110.827 179.127 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -63.46 -49.78 67.28 Favored Glycine 0 C--N 1.314 -0.68 0 CA-C-N 115.551 -0.75 . . . . 0.0 111.777 -175.643 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 86.4 m -63.91 -44.19 93.7 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-O 120.954 0.407 . . . . 0.0 111.201 176.414 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' TRP . . . . . 0.451 ' CZ3' ' HA ' ' A' ' 82' ' ' GLN . 54.4 t-105 -56.86 -48.95 76.93 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 121.84 0.828 . . . . 0.0 109.967 177.546 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . 0.519 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 36.0 tt0 -67.39 -34.68 77.76 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-N 114.611 -1.177 . . . . 0.0 110.471 -178.426 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -64.85 -41.9 95.32 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.645 -0.707 . . . . 0.0 110.993 -178.711 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . 0.565 ' HB2' HG11 ' A' ' 85' ' ' VAL . 7.9 m120 -82.06 -2.85 53.19 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.459 177.144 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . 0.563 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 83.57 47.62 5.6 Favored Glycine 0 C--O 1.225 -0.467 0 CA-C-N 115.782 -0.645 . . . . 0.0 112.587 173.245 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . 0.602 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -80.03 -21.96 64.43 Favored Glycine 0 N--CA 1.438 -1.197 0 C-N-CA 120.956 -0.64 . . . . 0.0 112.934 -175.107 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 0.878 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 6.8 mp -61.61 -22.73 65.49 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 112.048 0.388 . . . . 0.0 112.048 -172.43 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . 0.563 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 9.6 ptm180 -67.74 -33.68 75.33 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 121.254 0.549 . . . . 0.0 109.963 176.522 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' TYR . . . . . 0.788 ' HB3' ' HG3' ' A' ' 81' ' ' GLU . 63.5 m-85 -79.91 -34.51 38.92 Favored 'General case' 0 N--CA 1.444 -0.772 0 N-CA-C 107.499 -1.297 . . . . 0.0 107.499 178.159 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.697 ' HB2' ' HB3' ' A' ' 77' ' ' ALA . . . 163.99 129.05 0.02 OUTLIER Pre-proline 0 CA--C 1.51 -0.568 0 CA-C-N 112.595 -2.093 . . . . 0.0 107.198 -179.888 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' PRO . . . . . 0.878 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 16.9 Cg_exo -58.46 -3.02 1.15 Allowed 'Trans proline' 0 C--N 1.332 -0.299 0 C-N-CA 122.622 2.215 . . . . 0.0 113.559 -177.911 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' ARG . . . . . 0.405 ' HB2' ' CD2' ' A' ' 52' ' ' TYR . 13.5 ptm180 -146.63 137.36 23.99 Favored 'General case' 0 C--N 1.319 -0.731 0 N-CA-C 109.289 -0.634 . . . . 0.0 109.289 177.342 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . 0.424 ' HA ' ' CH2' ' A' ' 62' ' ' TRP . . . -58.11 -29.52 65.56 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.312 -0.858 . . . . 0.0 112.611 -178.066 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 14.7 p-10 -87.84 9.19 22.72 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 121.364 0.602 . . . . 0.0 110.852 -176.092 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.416 ' HB3' ' HB1' ' A' ' 71' ' ' ALA . 58.6 tp -110.07 -33.63 6.63 Favored 'General case' 0 C--N 1.322 -0.627 0 N-CA-C 108.322 -0.992 . . . . 0.0 108.322 169.81 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . 0.712 ' HB1' ' HB3' ' A' ' 81' ' ' GLU . . . -78.39 163.36 25.72 Favored 'General case' 0 N--CA 1.445 -0.691 0 CA-C-N 114.771 -1.104 . . . . 0.0 110.393 177.084 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 71.5 p -99.36 -174.49 2.75 Favored 'General case' 0 C--N 1.315 -0.931 0 CA-C-N 115.656 -0.702 . . . . 0.0 110.337 -174.532 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . 0.663 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 23.7 mtt85 -53.93 -56.81 14.33 Favored 'General case' 0 CA--C 1.512 -0.509 0 CA-C-O 120.988 0.423 . . . . 0.0 110.772 178.848 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 1.8 pm0 -58.22 -41.18 83.51 Favored 'General case' 0 C--N 1.314 -0.937 0 CA-C-N 115.043 -0.981 . . . . 0.0 111.262 -176.391 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 81' ' ' GLU . . . . . 0.788 ' HG3' ' HB3' ' A' ' 70' ' ' TYR . 0.4 OUTLIER -63.18 -52.72 61.21 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 115.5 -0.773 . . . . 0.0 112.161 175.835 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 82' ' ' GLN . . . . . 0.451 ' HA ' ' CZ3' ' A' ' 62' ' ' TRP . 53.4 mt-30 -60.66 -43.09 98.04 Favored 'General case' 0 CA--C 1.509 -0.613 0 CA-C-O 121.762 0.791 . . . . 0.0 109.833 -178.972 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . 0.777 HD13 HG23 ' A' ' 25' ' ' VAL . 10.8 mt -59.5 -39.74 80.07 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.993 0 CA-C-N 114.276 -1.329 . . . . 0.0 110.303 -177.822 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . 0.426 ' O ' HG23 ' A' ' 88' ' ' VAL . . . -62.1 -42.46 99.24 Favored 'General case' 0 C--N 1.319 -0.752 0 CA-C-O 121.273 0.559 . . . . 0.0 110.476 -179.181 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . 0.565 HG11 ' HB2' ' A' ' 65' ' ' ASN . 43.0 t -70.05 -50.77 45.26 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 CA-C-N 115.764 -0.653 . . . . 0.0 111.741 -179.569 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -65.69 -31.49 72.52 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 121.489 0.662 . . . . 0.0 110.858 -179.6 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 87' ' ' GLU . . . . . 0.773 ' HA ' ' HG2' ' A' ' 90' ' ' ARG . 0.7 OUTLIER -71.16 -28.41 64.24 Favored 'General case' 0 C--N 1.316 -0.855 0 CA-C-N 115.716 -0.674 . . . . 0.0 110.436 -178.348 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.666 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 88.1 t -61.86 -46.47 96.43 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.26 0 N-CA-C 109.299 -0.63 . . . . 0.0 109.299 168.54 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 89' ' ' THR . . . . . 0.483 ' O ' ' HG2' ' A' ' 93' ' ' GLN . 0.1 OUTLIER -64.64 -45.71 85.63 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 115.697 -0.683 . . . . 0.0 111.866 -177.48 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . 0.773 ' HG2' ' HA ' ' A' ' 87' ' ' GLU . 22.5 ptt180 -58.91 -35.36 72.94 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.98 -0.555 . . . . 0.0 111.048 -175.799 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . 0.666 ' HG ' ' O ' ' A' ' 88' ' ' VAL . 4.6 pp -74.69 -24.39 58.76 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.022 -0.536 . . . . 0.0 110.827 -169.536 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . 0.452 ' NH2' HG22 ' A' ' 89' ' ' THR . 3.9 mtm180 -85.59 -45.56 11.63 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.783 -0.644 . . . . 0.0 109.686 -177.948 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 93' ' ' GLN . . . . . 0.483 ' HG2' ' O ' ' A' ' 89' ' ' THR . 24.0 pt20 -98.6 -29.12 13.24 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.192 -0.913 . . . . 0.0 113.188 -169.715 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 87.42 46.67 4.88 Favored Glycine 0 CA--C 1.505 -0.58 0 C-N-CA 120.426 -0.893 . . . . 0.0 111.06 176.463 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 95' ' ' TRP . . . . . 0.494 ' HA ' ' HE3' ' A' ' 98' ' ' TRP . 1.9 m95 58.59 27.0 15.12 Favored 'General case' 0 C--O 1.223 -0.34 0 CA-C-O 121.484 0.659 . . . . 0.0 109.687 177.457 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -70.83 -30.5 68.12 Favored Glycine 0 N--CA 1.449 -0.445 0 CA-C-N 115.349 -0.841 . . . . 0.0 112.245 176.618 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . 0.42 ' O ' ' HD3' ' A' ' 99' ' ' PRO . . . -79.46 -24.84 42.13 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 120.66 0.267 . . . . 0.0 110.57 177.114 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 98' ' ' TRP . . . . . 0.494 ' HE3' ' HA ' ' A' ' 95' ' ' TRP . 23.8 m-90 -101.96 103.25 28.17 Favored Pre-proline 0 C--N 1.327 -0.389 0 N-CA-C 109.406 -0.59 . . . . 0.0 109.406 175.897 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . 0.43 ' HB2' ' H ' ' A' ' 100' ' ' VAL . 22.0 Cg_exo -70.52 -101.7 0.01 OUTLIER 'Trans proline' 0 CA--C 1.539 0.746 0 C-N-CA 123.242 2.628 . . . . 0.0 114.991 -173.013 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . 0.476 ' O ' ' HD2' ' A' ' 104' ' ' ARG . 41.0 t -69.82 -27.94 35.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 121.596 0.712 . . . . 0.0 110.452 -171.598 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 101' ' ' CYS . . . . . 0.821 ' SG ' ' HG3' ' A' ' 38' ' ' GLU . 79.1 m -73.07 -32.38 64.97 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-N 115.228 -0.896 . . . . 0.0 111.511 -171.416 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -70.0 -46.18 65.69 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 120.757 0.313 . . . . 0.0 110.953 -179.892 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -62.25 -37.28 84.83 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 121.097 0.475 . . . . 0.0 110.773 179.514 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 104' ' ' ARG . . . . . 0.476 ' HD2' ' O ' ' A' ' 100' ' ' VAL . 0.0 OUTLIER -73.02 -30.47 63.78 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.627 -0.715 . . . . 0.0 111.583 178.566 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 105' ' ' ALA . . . . . 0.666 ' HB2' ' HA ' ' A' ' 30' ' ' ILE . . . -82.17 -21.38 36.57 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.692 -176.997 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 109.39 60.93 0.52 Allowed Glycine 0 CA--C 1.518 0.25 0 C-N-CA 121.011 -0.614 . . . . 0.0 112.158 -178.122 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -66.41 152.67 44.62 Favored 'General case' 0 N--CA 1.45 -0.442 0 C-N-CA 122.642 0.377 . . . . 0.0 111.013 -176.562 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 20.7 mmt180 . . . . . 0 C--O 1.244 0.814 0 CA-C-O 118.404 -0.808 . . . . 0.0 110.959 176.677 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 84.0 m-20 . . . . . 0 N--CA 1.477 0.917 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 9.1 t -82.85 54.02 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-O 121.886 0.85 . . . . 0.0 110.056 179.361 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 12.1 p -87.07 140.45 15.78 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.986 0 CA-C-N 115.265 -0.88 . . . . 0.0 111.044 177.599 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 6.8 t -95.37 140.76 16.31 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.538 0 N-CA-C 108.86 -0.793 . . . . 0.0 108.86 173.891 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 4.6 p -124.88 135.54 26.87 Favored Pre-proline 0 C--N 1.313 -1.001 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.564 -172.853 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 3.3 Cg_exo -76.64 166.26 27.48 Favored 'Trans proline' 0 N--CA 1.453 -0.856 0 C-N-CA 123.219 2.613 . . . . 0.0 110.267 171.592 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . 52.13 39.63 27.05 Favored 'General case' 0 C--N 1.314 -0.955 0 CA-C-N 114.985 -1.007 . . . . 0.0 110.49 -172.617 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 6.1 t60 -80.88 -2.29 46.88 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-N 114.194 -1.366 . . . . 0.0 108.228 174.383 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 9.5 pt-20 -64.61 147.61 52.59 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 114.584 -1.189 . . . . 0.0 110.253 174.368 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -109.5 66.6 0.63 Allowed 'General case' 0 C--N 1.317 -0.809 0 CA-C-O 121.87 0.843 . . . . 0.0 110.622 -172.914 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 58.3 t -67.99 -68.91 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.312 -1.045 0 CA-C-N 114.358 -1.292 . . . . 0.0 109.724 175.023 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 6.9 p 26.0 79.03 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.347 0.498 0 CA-C-O 122.952 1.358 . . . . 0.0 112.932 176.481 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 14.6 ptm180 -95.89 119.21 33.99 Favored 'General case' 0 N--CA 1.432 -1.368 0 CA-C-N 113.86 -1.518 . . . . 0.0 110.592 -174.349 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 9.5 t -124.19 166.11 19.96 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.372 0 CA-C-N 113.616 -1.629 . . . . 0.0 108.283 176.937 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -168.5 -83.54 0.05 OUTLIER Glycine 0 N--CA 1.426 -1.993 0 C-N-CA 120.698 -0.763 . . . . 0.0 111.827 179.172 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' THR . . . . . 0.493 ' O ' ' HD3' ' A' ' 18' ' ' PRO . 8.1 m -75.25 -35.8 61.36 Favored 'General case' 0 N--CA 1.437 -1.107 0 CA-C-O 121.127 0.489 . . . . 0.0 112.196 -174.751 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . 0.42 ' HD2' ' HB ' ' A' ' 16' ' ' THR . 0.0 OUTLIER -105.82 93.74 7.93 Favored Pre-proline 0 C--N 1.312 -1.042 0 CA-C-N 115.574 -0.739 . . . . 0.0 109.826 179.185 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . 0.493 ' HD3' ' O ' ' A' ' 16' ' ' THR . 21.3 Cg_exo -65.43 170.63 10.61 Favored 'Trans proline' 0 CA--C 1.51 -0.701 0 C-N-CA 123.157 2.571 . . . . 0.0 112.582 -174.375 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 117.93 42.32 0.61 Allowed Glycine 0 C--N 1.305 -1.185 0 CA-C-N 114.337 -1.301 . . . . 0.0 111.861 -176.761 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 2.8 m -69.73 -48.32 59.89 Favored 'General case' 0 C--N 1.32 -0.693 0 N-CA-C 108.739 -0.838 . . . . 0.0 108.739 175.257 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 49.0 mt-10 -129.94 110.55 11.77 Favored 'General case' 0 N--CA 1.443 -0.784 0 CA-C-N 114.254 -1.339 . . . . 0.0 108.606 174.61 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.692 ' O ' ' HD3' ' A' ' 79' ' ' ARG . 81.4 t -70.92 137.96 85.14 Favored Pre-proline 0 C--N 1.318 -0.781 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.045 -176.176 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . 0.409 ' HA ' ' HD2' ' A' ' 24' ' ' PRO . 62.9 Cg_exo -54.48 126.29 21.81 Favored 'Trans proline' 0 N--CA 1.457 -0.619 0 C-N-CA 122.523 2.148 . . . . 0.0 112.383 179.923 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . 0.409 ' HD2' ' HA ' ' A' ' 23' ' ' PRO . 29.7 Cg_endo -63.62 149.79 90.06 Favored 'Trans proline' 0 N--CA 1.452 -0.915 0 C-N-CA 123.839 3.026 . . . . 0.0 113.752 -178.273 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.82 ' HB ' HG23 ' A' ' 83' ' ' ILE . 43.4 t -87.03 160.09 3.02 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.134 0 N-CA-C 106.845 -1.539 . . . . 0.0 106.845 165.651 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 3.0 mp -54.35 -34.0 27.12 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.842 0 CA-C-O 120.854 0.359 . . . . 0.0 111.836 -167.319 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.515 ' O ' HG12 ' A' ' 30' ' ' ILE . 11.2 m-20 -104.59 -3.06 24.28 Favored 'General case' 0 CA--C 1.504 -0.805 0 CA-C-O 121.364 0.602 . . . . 0.0 110.931 -178.974 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . 0.697 ' HA3' ' CD1' ' A' ' 83' ' ' ILE . . . -76.05 1.65 58.75 Favored Glycine 0 CA--C 1.498 -0.998 0 N-CA-C 110.715 -0.954 . . . . 0.0 110.715 -179.336 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 19.1 m -76.99 -40.86 45.22 Favored 'General case' 0 C--N 1.322 -0.628 0 N-CA-C 108.497 -0.927 . . . . 0.0 108.497 171.381 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.515 HG12 ' O ' ' A' ' 27' ' ' ASP . 0.7 OUTLIER -67.29 -40.21 84.43 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.457 0 CA-C-N 114.399 -1.273 . . . . 0.0 107.724 175.946 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' TRP . . . . . 0.559 ' HB2' ' HA2' ' A' ' 28' ' ' GLY . 36.5 m95 -67.41 -36.68 81.76 Favored 'General case' 0 C--N 1.318 -0.776 0 CA-C-N 114.17 -1.377 . . . . 0.0 110.378 -177.826 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.415 ' CB ' HH21 ' A' ' 79' ' ' ARG . 4.6 t70 -77.19 -33.34 56.38 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 115.748 -0.66 . . . . 0.0 110.62 -179.5 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . 0.422 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -70.13 -34.07 72.61 Favored 'General case' 0 N--CA 1.447 -0.575 0 C-N-CA 120.506 -0.478 . . . . 0.0 109.977 176.159 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . 0.513 HG13 ' O ' ' A' ' 30' ' ' ILE . 74.2 mt -65.52 -43.45 94.32 Favored 'Isoleucine or valine' 0 C--O 1.234 0.268 0 CA-C-N 116.057 -0.519 . . . . 0.0 109.865 172.23 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . 0.448 ' HA ' ' O ' ' A' ' 54' ' ' GLY . . . -57.57 -37.4 73.09 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.059 175.211 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . 0.401 ' HA2' ' N ' ' A' ' 41' ' ' GLY . . . -70.89 -15.98 74.31 Favored Glycine 0 N--CA 1.449 -0.45 0 CA-C-N 115.27 -0.877 . . . . 0.0 112.181 179.299 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 44.1 t -85.19 -58.87 2.51 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 120.611 0.243 . . . . 0.0 111.186 -177.256 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 8.6 tp10 -89.09 -34.04 16.89 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-O 121.074 0.464 . . . . 0.0 110.877 -172.693 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -97.63 -14.66 20.83 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.029 -0.532 . . . . 0.0 111.511 -175.427 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 86.31 -4.51 85.99 Favored Glycine 0 N--CA 1.448 -0.523 0 N-CA-C 109.847 -1.301 . . . . 0.0 109.847 -174.408 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . 0.401 ' N ' ' HA2' ' A' ' 36' ' ' GLY . . . 102.04 56.06 0.85 Allowed Glycine 0 N--CA 1.435 -1.37 0 CA-C-N 114.213 -0.993 . . . . 0.0 112.058 -179.235 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 43.8 t-20 -144.33 127.25 16.38 Favored 'General case' 0 N--CA 1.44 -0.968 0 N-CA-C 108.263 -1.014 . . . . 0.0 108.263 -179.602 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' TRP . . . . . 0.677 ' HZ3' ' HB2' ' A' ' 82' ' ' GLN . 40.5 m95 -99.28 -13.27 19.74 Favored 'General case' 0 C--N 1.305 -1.351 0 CA-C-N 115.398 -0.819 . . . . 0.0 110.935 -173.385 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -100.53 -6.77 24.94 Favored 'General case' 0 C--N 1.316 -0.881 0 CA-C-N 115.199 -0.909 . . . . 0.0 110.479 -177.889 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 10.0 tt -62.33 141.58 17.67 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.996 0 CA-C-N 115.474 -0.784 . . . . 0.0 109.921 178.556 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 43.3 t-20 -158.73 103.52 1.73 Allowed 'General case' 0 C--N 1.312 -1.025 0 CA-C-O 121.03 0.443 . . . . 0.0 110.112 -177.655 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 11.2 p -82.75 -15.01 53.46 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 115.718 -0.674 . . . . 0.0 111.923 -177.56 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 90.47 25.23 26.4 Favored Glycine 0 N--CA 1.446 -0.662 0 N-CA-C 110.943 -0.863 . . . . 0.0 110.943 -177.743 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 65.0 t30 -83.63 -1.76 54.63 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 121.222 0.534 . . . . 0.0 111.222 -175.352 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . 0.482 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 95.19 -9.34 69.89 Favored Glycine 0 CA--C 1.505 -0.539 0 N-CA-C 110.093 -1.203 . . . . 0.0 110.093 -175.734 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' TYR . . . . . 0.555 ' HA ' ' HA ' ' A' ' 58' ' ' ASP . 0.5 OUTLIER -117.98 158.2 25.36 Favored 'General case' 0 N--CA 1.441 -0.923 0 N-CA-C 106.118 -1.808 . . . . 0.0 106.118 177.998 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' TYR . . . . . 0.703 ' O ' ' HA ' ' A' ' 56' ' ' GLN . 35.1 m-85 -118.41 169.59 9.63 Favored 'General case' 0 C--N 1.303 -1.447 0 C-N-CA 120.222 -0.591 . . . . 0.0 110.851 -172.241 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -65.14 -173.26 3.81 Favored Glycine 0 N--CA 1.448 -0.515 0 C-N-CA 121.173 -0.537 . . . . 0.0 114.362 -170.019 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . 0.582 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 77.39 -104.97 2.01 Favored Glycine 0 N--CA 1.439 -1.157 0 N-CA-C 111.346 -0.702 . . . . 0.0 111.346 -179.635 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.407 HG11 ' HE1' ' A' ' 98' ' ' TRP . 2.2 t -83.41 -1.83 6.25 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 CA-C-O 121.503 0.668 . . . . 0.0 109.676 -179.122 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' GLN . . . . . 0.803 ' HA ' HE21 ' A' ' 56' ' ' GLN . 0.0 OUTLIER 57.34 45.18 20.52 Favored 'General case' 0 N--CA 1.464 0.249 0 CA-C-N 114.541 -1.209 . . . . 0.0 113.444 169.584 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 1.1 p90 -117.89 168.53 10.41 Favored 'General case' 0 C--N 1.328 -0.357 0 C-N-CA 119.582 -0.847 . . . . 0.0 112.035 176.476 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.555 ' HA ' ' HA ' ' A' ' 51' ' ' TYR . 7.5 p-10 -79.33 164.15 24.31 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.141 -0.936 . . . . 0.0 113.419 -164.39 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.682 ' HA ' HE21 ' A' ' 59' ' ' GLN . 0.0 OUTLIER -63.25 -36.63 84.3 Favored 'General case' 0 N--CA 1.449 -0.487 0 CA-C-N 114.101 -1.409 . . . . 0.0 111.578 179.188 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -68.0 -50.33 41.4 Favored Glycine 0 C--N 1.32 -0.324 0 C-N-CA 121.2 -0.524 . . . . 0.0 112.303 -175.703 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 88.5 m -61.7 -42.16 98.56 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 121.157 0.503 . . . . 0.0 110.113 175.689 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' TRP . . . . . 0.595 ' HH2' ' CD ' ' A' ' 81' ' ' GLU . 59.3 t-105 -56.85 -49.68 74.73 Favored 'General case' 0 N--CA 1.447 -0.623 0 CA-C-N 114.985 -1.007 . . . . 0.0 110.209 177.264 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . 0.909 ' HG3' HD12 ' A' ' 68' ' ' LEU . 29.1 tt0 -67.15 -34.38 77.44 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 115.026 -0.988 . . . . 0.0 110.773 -177.18 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -67.91 -41.58 82.45 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.897 -0.592 . . . . 0.0 111.082 -178.44 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . 0.661 ' HB2' HG11 ' A' ' 85' ' ' VAL . 4.8 m120 -71.8 -15.79 62.16 Favored 'General case' 0 C--N 1.332 -0.154 0 CA-C-O 121.349 0.595 . . . . 0.0 109.773 174.99 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 88.32 44.74 5.21 Favored Glycine 0 N--CA 1.446 -0.7 0 CA-C-N 115.208 -0.906 . . . . 0.0 111.752 178.422 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . 0.587 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -78.5 -19.58 73.53 Favored Glycine 0 CA--C 1.5 -0.865 0 C-N-CA 120.612 -0.804 . . . . 0.0 111.123 -173.818 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 0.909 HD12 ' HG3' ' A' ' 63' ' ' GLU . 11.8 mt -61.32 -24.86 66.74 Favored 'General case' 0 C--N 1.317 -0.807 0 CA-C-N 114.664 -0.768 . . . . 0.0 110.806 -174.667 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 12.1 ptm180 -70.34 -28.61 65.27 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.461 -0.79 . . . . 0.0 109.856 179.664 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' TYR . . . . . 0.587 ' HD2' ' HA2' ' A' ' 67' ' ' GLY . 47.7 m-85 -85.49 -34.47 21.58 Favored 'General case' 0 N--CA 1.439 -1.007 0 N-CA-C 107.143 -1.428 . . . . 0.0 107.143 176.201 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.769 ' HB2' ' HB3' ' A' ' 76' ' ' LEU . . . 170.22 127.27 0.05 OUTLIER Pre-proline 0 C--O 1.217 -0.617 0 CA-C-N 112.729 -2.032 . . . . 0.0 107.712 -178.029 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' PRO . . . . . 0.556 ' HA ' ' HA ' ' A' ' 68' ' ' LEU . 17.2 Cg_exo -58.32 -0.96 0.54 Allowed 'Trans proline' 0 C--N 1.331 -0.39 0 C-N-CA 122.968 2.445 . . . . 0.0 113.8 -179.455 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' ARG . . . . . 0.41 ' HE ' ' CG ' ' A' ' 75' ' ' ASP . 13.4 ptm180 -152.85 143.04 22.43 Favored 'General case' 0 C--N 1.318 -0.799 0 N-CA-C 109.232 -0.655 . . . . 0.0 109.232 174.059 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . 0.469 ' HA ' ' CH2' ' A' ' 62' ' ' TRP . . . -61.7 -25.48 67.44 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.574 -0.739 . . . . 0.0 112.359 -174.381 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . 0.41 ' CG ' ' HE ' ' A' ' 73' ' ' ARG . 17.2 p-10 -89.36 10.91 20.7 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-O 121.049 0.452 . . . . 0.0 111.363 -178.041 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.769 ' HB3' ' HB2' ' A' ' 71' ' ' ALA . 42.0 tp -104.29 -42.71 5.42 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.345 177.207 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . 0.711 ' HB1' ' OE2' ' A' ' 81' ' ' GLU . . . -100.73 170.47 8.32 Favored 'General case' 0 N--CA 1.45 -0.473 0 CA-C-O 121.136 0.493 . . . . 0.0 109.932 177.826 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' THR . . . . . 0.6 ' HB ' HG22 ' A' ' 22' ' ' VAL . 41.3 p -85.06 168.71 14.63 Favored 'General case' 0 C--N 1.312 -1.063 0 N-CA-C 113.2 0.815 . . . . 0.0 113.2 -167.775 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . 0.692 ' HD3' ' O ' ' A' ' 22' ' ' VAL . 7.1 ptm180 -47.4 -36.09 9.29 Favored 'General case' 0 N--CA 1.466 0.352 0 C-N-CA 122.724 0.41 . . . . 0.0 112.087 -175.238 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 80' ' ' GLU . . . . . 0.903 ' HA ' HD11 ' A' ' 83' ' ' ILE . 16.1 pt-20 -62.36 -31.22 71.83 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.407 -178.556 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 81' ' ' GLU . . . . . 0.711 ' OE2' ' HB1' ' A' ' 77' ' ' ALA . 0.0 OUTLIER -72.53 -48.86 36.99 Favored 'General case' 0 N--CA 1.428 -1.545 0 N-CA-C 110.075 -0.343 . . . . 0.0 110.075 177.163 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 82' ' ' GLN . . . . . 0.677 ' HB2' ' HZ3' ' A' ' 43' ' ' TRP . 67.1 mt-30 -59.82 -31.8 70.06 Favored 'General case' 0 CA--C 1.511 -0.521 0 C-N-CA 120.874 -0.331 . . . . 0.0 110.225 178.245 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . 0.903 HD11 ' HA ' ' A' ' 80' ' ' GLU . 79.7 mt -59.32 -51.5 71.92 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.782 0 CA-C-N 115.892 -0.594 . . . . 0.0 109.626 173.328 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . 0.476 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -62.36 -44.42 96.51 Favored 'General case' 0 C--O 1.238 0.459 0 CA-C-O 121.635 0.731 . . . . 0.0 111.285 -175.081 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . 0.661 HG11 ' HB2' ' A' ' 65' ' ' ASN . 48.9 t -67.97 -49.17 71.0 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.635 0 CA-C-N 115.388 -0.823 . . . . 0.0 111.107 -177.876 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -60.61 -29.7 69.38 Favored 'General case' 0 N--CA 1.451 -0.416 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.175 175.581 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 87' ' ' GLU . . . . . 0.77 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 28.7 mt-10 -60.31 -42.86 96.46 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.59 179.885 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.418 ' O ' ' HG3' ' A' ' 92' ' ' ARG . 75.6 t -60.67 -50.0 82.22 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.284 0 C-N-CA 120.37 -0.532 . . . . 0.0 110.189 178.943 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 89' ' ' THR . . . . . 0.485 ' HA ' ' NE ' ' A' ' 92' ' ' ARG . 97.0 m -64.11 -38.82 92.45 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-N 115.524 -0.762 . . . . 0.0 111.252 -178.442 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . 0.654 HH11 ' HG2' ' A' ' 87' ' ' GLU . 1.4 ptt180 -60.52 -35.88 77.04 Favored 'General case' 0 N--CA 1.464 0.258 0 CA-C-N 116.613 -0.267 . . . . 0.0 111.387 -179.674 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . 0.77 ' HG ' ' O ' ' A' ' 87' ' ' GLU . 32.1 mt -64.18 -29.02 70.16 Favored 'General case' 0 N--CA 1.47 0.534 0 CA-C-O 121.708 0.766 . . . . 0.0 110.15 -174.821 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . 0.485 ' NE ' ' HA ' ' A' ' 89' ' ' THR . 9.8 mtm180 -87.65 -43.89 11.61 Favored 'General case' 0 C--N 1.314 -0.956 0 CA-C-N 114.541 -1.209 . . . . 0.0 110.516 -169.573 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 93' ' ' GLN . . . . . 0.529 ' OE1' ' HA ' ' A' ' 90' ' ' ARG . 0.0 OUTLIER -105.79 -17.74 14.28 Favored 'General case' 0 CA--C 1.545 0.769 0 N-CA-C 113.956 1.095 . . . . 0.0 113.956 -173.965 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 79.86 44.34 9.23 Favored Glycine 0 C--N 1.335 0.513 0 C-N-CA 121.312 -0.47 . . . . 0.0 112.983 171.929 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 95' ' ' TRP . . . . . 0.402 ' CZ2' ' HD2' ' A' ' 90' ' ' ARG . 13.4 m95 61.62 19.94 10.87 Favored 'General case' 0 C--O 1.223 -0.338 0 C-N-CA 123.483 0.713 . . . . 0.0 109.618 -179.059 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -77.42 -32.98 45.23 Favored Glycine 0 N--CA 1.453 -0.189 0 CA-C-N 115.381 -0.827 . . . . 0.0 112.385 176.348 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -72.66 -24.85 61.09 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 121.338 0.589 . . . . 0.0 109.781 178.953 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 98' ' ' TRP . . . . . 0.448 ' HZ3' ' HA ' ' A' ' 90' ' ' ARG . 25.0 m-90 -95.33 108.22 37.69 Favored Pre-proline 0 N--CA 1.441 -0.88 0 N-CA-C 108.358 -0.979 . . . . 0.0 108.358 175.001 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 45.4 Cg_exo -64.14 -141.76 0.01 OUTLIER 'Trans proline' 0 CA--C 1.532 0.394 0 C-N-CA 123.466 2.777 . . . . 0.0 113.906 -174.189 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 4.3 t -56.21 -21.79 12.67 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.425 0 CA-C-O 120.928 0.394 . . . . 0.0 111.176 -175.542 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 77.5 m -56.87 -39.18 73.86 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-N 116.573 -0.285 . . . . 0.0 111.04 175.09 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -71.27 -37.96 71.88 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-O 120.905 0.383 . . . . 0.0 110.351 177.572 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -61.19 -41.64 97.18 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.638 177.44 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -67.59 -30.29 69.86 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.833 -0.621 . . . . 0.0 111.131 175.531 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 105' ' ' ALA . . . . . 0.422 ' CB ' ' HB3' ' A' ' 33' ' ' ALA . . . -86.28 -22.8 26.6 Favored 'General case' 0 C--N 1.326 -0.428 0 N-CA-C 112.709 0.633 . . . . 0.0 112.709 -172.812 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 104.16 65.74 0.7 Allowed Glycine 0 CA--C 1.521 0.447 0 C-N-CA 120.795 -0.716 . . . . 0.0 112.5 -178.182 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -70.28 148.59 48.36 Favored 'General case' 0 C--N 1.324 -0.525 0 C-N-CA 122.905 0.482 . . . . 0.0 110.773 -176.699 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 108' ' ' ARG . . . . . 0.44 ' O ' ' HD3' ' A' ' 108' ' ' ARG . 0.0 OUTLIER . . . . . 0 C--O 1.247 0.96 0 CA-C-O 119.069 -0.491 . . . . 0.0 111.181 -174.505 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 6.9 p30 . . . . . 0 N--CA 1.474 0.727 0 CA-C-O 122.025 0.917 . . . . 0.0 110.713 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 12.9 p -67.13 -31.51 53.58 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.965 0 CA-C-N 114.733 -1.121 . . . . 0.0 110.577 178.385 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 94.8 t -82.32 94.01 2.79 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.752 0 CA-C-O 121.235 0.54 . . . . 0.0 110.345 177.185 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 7.6 t -81.59 146.74 6.89 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.657 0 CA-C-N 115.902 -0.59 . . . . 0.0 109.965 -179.821 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 1.6 p -124.71 103.1 31.62 Favored Pre-proline 0 C--N 1.315 -0.897 0 CA-C-N 115.868 -0.605 . . . . 0.0 110.08 178.153 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_exo -79.99 164.3 22.57 Favored 'Trans proline' 0 N--CA 1.451 -0.984 0 C-N-CA 123.217 2.611 . . . . 0.0 112.705 -175.294 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -102.51 91.01 4.04 Favored 'General case' 0 C--N 1.309 -1.153 0 CA-C-N 114.158 -1.383 . . . . 0.0 110.802 -179.554 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 49.5 m80 -86.08 -10.65 54.54 Favored 'General case' 0 C--N 1.314 -0.977 0 CA-C-N 114.333 -1.303 . . . . 0.0 107.949 173.07 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 11.9 mt-10 -81.22 178.1 8.6 Favored 'General case' 0 CA--C 1.505 -0.777 0 CA-C-N 114.434 -1.257 . . . . 0.0 112.513 -178.064 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . 65.78 51.03 1.47 Allowed 'General case' 0 C--N 1.314 -0.954 0 CA-C-N 112.81 -1.996 . . . . 0.0 109.539 -172.437 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 51.8 t -66.49 -27.79 41.4 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.805 0 CA-C-N 113.042 -1.89 . . . . 0.0 110.132 179.025 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 53.7 t 36.68 88.16 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.445 -0.701 0 C-N-CA 124.868 1.267 . . . . 0.0 113.28 177.757 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 39.5 mtm180 -96.76 112.89 24.45 Favored 'General case' 0 C--N 1.307 -1.266 0 CA-C-N 114.294 -1.321 . . . . 0.0 110.279 174.53 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 3.4 t -113.67 159.72 13.49 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.208 0 CA-C-N 114.68 -1.146 . . . . 0.0 108.893 178.625 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 90.05 83.74 1.36 Allowed Glycine 0 N--CA 1.438 -1.17 0 N-CA-C 110.898 -0.881 . . . . 0.0 110.898 -177.938 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 22.7 m -70.46 -30.54 67.39 Favored 'General case' 0 N--CA 1.441 -0.925 0 CA-C-O 121.418 0.627 . . . . 0.0 110.728 -175.899 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . 0.834 ' HD2' ' O ' ' A' ' 17' ' ' LYS . 0.0 OUTLIER -109.49 97.28 26.34 Favored Pre-proline 0 C--N 1.313 -0.981 0 CA-C-N 115.222 -0.899 . . . . 0.0 111.042 174.779 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 83.0 Cg_endo -75.32 113.75 3.84 Favored 'Trans proline' 0 N--CA 1.459 -0.533 0 C-N-CA 122.985 2.456 . . . . 0.0 112.509 -176.544 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -101.4 -14.53 30.02 Favored Glycine 0 C--N 1.301 -1.378 0 CA-C-N 113.882 -1.508 . . . . 0.0 112.107 -178.552 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 2.0 m -56.19 -46.03 79.56 Favored 'General case' 0 C--N 1.307 -1.251 0 CA-C-N 113.793 -1.203 . . . . 0.0 111.842 -177.758 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . 0.457 ' O ' ' HD3' ' A' ' 23' ' ' PRO . 38.4 mt-10 -138.2 142.07 40.0 Favored 'General case' 0 N--CA 1.443 -0.778 0 CA-C-N 115.967 -0.56 . . . . 0.0 109.559 -177.202 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 46.9 t -88.03 108.02 19.15 Favored Pre-proline 0 C--N 1.315 -0.894 0 N-CA-C 108.688 -0.856 . . . . 0.0 108.688 170.869 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . 0.465 ' HA ' ' HD2' ' A' ' 24' ' ' PRO . 27.7 Cg_exo -63.0 129.32 25.49 Favored 'Trans proline' 0 N--CA 1.457 -0.625 0 C-N-CA 122.735 2.29 . . . . 0.0 112.573 -177.265 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . 0.465 ' HD2' ' HA ' ' A' ' 23' ' ' PRO . 11.5 Cg_endo -56.57 140.16 89.23 Favored 'Trans proline' 0 N--CA 1.452 -0.919 0 C-N-CA 122.624 2.216 . . . . 0.0 110.621 171.934 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.514 HG11 HG23 ' A' ' 83' ' ' ILE . 38.7 t -81.52 125.99 39.74 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.207 0 CA-C-N 115.659 -0.701 . . . . 0.0 111.095 -172.044 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . 0.405 ' N ' HD13 ' A' ' 26' ' ' ILE . 3.4 mp -75.42 -32.78 26.04 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-N 114.752 -1.113 . . . . 0.0 112.775 -167.157 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.43 ' O ' HG12 ' A' ' 30' ' ' ILE . 6.3 m-20 -85.76 8.51 19.62 Favored 'General case' 0 CA--C 1.503 -0.83 0 CA-C-O 121.548 0.69 . . . . 0.0 109.833 -174.961 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . 0.577 ' HA3' HD12 ' A' ' 83' ' ' ILE . . . -63.51 -9.05 29.4 Favored Glycine 0 N--CA 1.436 -1.343 0 CA-C-N 114.909 -1.041 . . . . 0.0 110.905 174.506 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 8.4 m -71.34 -44.25 65.44 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-O 121.681 0.753 . . . . 0.0 109.293 175.195 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.505 ' O ' HG13 ' A' ' 34' ' ' ILE . 0.4 OUTLIER -69.15 -39.45 79.37 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.604 0 CA-C-N 114.576 -1.193 . . . . 0.0 107.881 178.533 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' TRP . . . . . 0.688 ' CD1' HG22 ' A' ' 83' ' ' ILE . 39.5 m95 -67.95 -35.93 79.24 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 114.493 -1.231 . . . . 0.0 110.528 -177.15 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.432 ' CG ' HH21 ' A' ' 79' ' ' ARG . 3.9 t70 -71.23 -42.25 69.12 Favored 'General case' 0 N--CA 1.447 -0.621 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.256 177.665 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . 0.437 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -67.33 -33.77 75.95 Favored 'General case' 0 N--CA 1.446 -0.662 0 CA-C-N 116.44 -0.345 . . . . 0.0 110.511 -179.665 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . 0.505 HG13 ' O ' ' A' ' 30' ' ' ILE . 65.7 mt -64.41 -46.14 93.82 Favored 'Isoleucine or valine' 0 C--O 1.234 0.255 0 CA-C-O 121.046 0.45 . . . . 0.0 109.865 172.457 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . 0.477 ' HA ' ' NE2' ' A' ' 56' ' ' GLN . . . -57.99 -38.85 76.86 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.133 176.065 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . 0.414 ' HA2' ' N ' ' A' ' 41' ' ' GLY . . . -65.44 -28.83 74.01 Favored Glycine 0 N--CA 1.451 -0.329 0 CA-C-N 115.588 -0.733 . . . . 0.0 111.97 179.248 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 6.7 t -76.25 -64.49 1.09 Allowed 'General case' 0 C--N 1.318 -0.764 0 N-CA-C 111.926 0.343 . . . . 0.0 111.926 -178.823 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . 0.501 ' HB3' ' CD ' ' A' ' 56' ' ' GLN . 11.2 tp10 -88.19 -31.79 18.93 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 121.062 0.458 . . . . 0.0 110.692 -168.939 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -96.89 -9.15 29.11 Favored 'General case' 0 N--CA 1.45 -0.436 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.764 -175.348 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 78.57 16.66 78.96 Favored Glycine 0 CA--C 1.503 -0.685 0 N-CA-C 109.848 -1.301 . . . . 0.0 109.848 -177.929 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . 0.414 ' N ' ' HA2' ' A' ' 36' ' ' GLY . . . 69.19 59.69 5.67 Favored Glycine 0 N--CA 1.432 -1.606 0 CA-C-N 113.992 -1.104 . . . . 0.0 111.928 -177.179 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 62.2 t30 -147.12 122.17 10.09 Favored 'General case' 0 CA--C 1.505 -0.77 0 N-CA-C 109.134 -0.691 . . . . 0.0 109.134 179.346 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' TRP . . . . . 0.71 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 33.9 m95 -97.5 -6.25 34.1 Favored 'General case' 0 C--N 1.306 -1.315 0 CA-C-N 114.956 -1.02 . . . . 0.0 109.935 -173.168 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -110.51 9.93 23.17 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-N 114.907 -1.042 . . . . 0.0 111.183 -179.073 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.74 HG23 ' HA2' ' A' ' 53' ' ' GLY . 3.2 tt -71.09 143.21 14.66 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.615 0 N-CA-C 109.477 -0.564 . . . . 0.0 109.477 179.099 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 45.0 t-20 -165.2 96.05 0.68 Allowed 'General case' 0 C--N 1.312 -1.041 0 CA-C-O 121.047 0.451 . . . . 0.0 110.132 -176.577 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 17.8 p -82.32 -12.06 58.22 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.392 179.832 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 89.29 22.15 38.8 Favored Glycine 0 N--CA 1.446 -0.697 0 N-CA-C 111.275 -0.73 . . . . 0.0 111.275 178.985 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 8.6 p30 -88.36 5.86 40.05 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 121.03 0.443 . . . . 0.0 110.99 -176.031 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . 0.496 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 95.77 -12.22 67.53 Favored Glycine 0 N--CA 1.448 -0.536 0 CA-C-N 115.913 -0.585 . . . . 0.0 112.117 -178.234 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' TYR . . . . . 0.544 ' HA ' ' HA ' ' A' ' 58' ' ' ASP . 0.1 OUTLIER -112.99 161.29 17.2 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 108.026 -1.102 . . . . 0.0 108.026 173.494 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' TYR . . . . . 0.406 ' HE1' ' HB2' ' A' ' 59' ' ' GLN . 42.7 m-85 -125.62 170.26 11.67 Favored 'General case' 0 C--N 1.313 -0.982 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.686 -170.752 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.74 ' HA2' HG23 ' A' ' 45' ' ' ILE . . . -70.36 -172.59 11.31 Favored Glycine 0 N--CA 1.446 -0.678 0 CA-C-N 116.177 -0.465 . . . . 0.0 114.23 -171.69 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . 0.626 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 81.91 -111.03 3.27 Favored Glycine 0 N--CA 1.443 -0.888 0 C-N-CA 121.011 -0.614 . . . . 0.0 111.76 -179.154 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.529 ' HB ' ' CE2' ' A' ' 57' ' ' PHE . 1.8 t -91.69 19.96 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-O 121.183 0.516 . . . . 0.0 110.53 -178.488 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' GLN . . . . . 0.501 ' CD ' ' HB3' ' A' ' 38' ' ' GLU . 7.0 mp0 59.51 50.31 7.6 Favored 'General case' 0 N--CA 1.47 0.547 0 CA-C-N 115.168 -0.924 . . . . 0.0 111.704 171.496 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . 0.529 ' CE2' ' HB ' ' A' ' 55' ' ' VAL . 57.3 m-85 -81.45 138.07 35.57 Favored 'General case' 0 CA--C 1.504 -0.804 0 CA-C-N 115.77 -0.65 . . . . 0.0 112.266 178.345 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.544 ' HA ' ' HA ' ' A' ' 51' ' ' TYR . 7.9 p-10 -79.45 155.96 28.08 Favored 'General case' 0 C--N 1.313 -1.003 0 N-CA-C 108.535 -0.913 . . . . 0.0 108.535 163.631 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.406 ' HB2' ' HE1' ' A' ' 52' ' ' TYR . 19.0 tp60 -54.63 -36.47 64.56 Favored 'General case' 0 N--CA 1.445 -0.701 0 CA-C-O 121.188 0.518 . . . . 0.0 110.352 -179.026 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -68.51 -50.5 37.13 Favored Glycine 0 C--O 1.225 -0.428 0 CA-C-N 114.795 -1.093 . . . . 0.0 113.041 -173.557 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 99.1 m -67.51 -40.32 85.12 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 121.082 0.468 . . . . 0.0 110.299 -179.197 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' TRP . . . . . 0.503 ' CZ3' ' HA ' ' A' ' 82' ' ' GLN . 53.5 t-105 -57.82 -48.72 78.93 Favored 'General case' 0 N--CA 1.443 -0.789 0 CA-C-N 115.468 -0.787 . . . . 0.0 109.367 176.586 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . 0.503 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 44.9 tt0 -67.93 -33.97 75.71 Favored 'General case' 0 N--CA 1.444 -0.738 0 CA-C-N 115.07 -0.968 . . . . 0.0 110.695 -179.431 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -63.09 -41.49 99.42 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.839 -178.75 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . 0.654 ' HB2' HG11 ' A' ' 85' ' ' VAL . 7.5 m120 -73.92 -19.55 60.66 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 121.438 0.637 . . . . 0.0 110.054 176.41 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . 0.594 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 90.13 45.72 4.36 Favored Glycine 0 N--CA 1.446 -0.674 0 CA-C-N 115.148 -0.933 . . . . 0.0 111.534 -178.55 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . 0.724 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -78.59 -15.7 80.42 Favored Glycine 0 N--CA 1.445 -0.744 0 C-N-CA 120.998 -0.62 . . . . 0.0 112.359 -172.806 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 0.866 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 7.1 mp -60.27 -27.54 67.34 Favored 'General case' 0 C--N 1.316 -0.865 0 N-CA-C 112.875 0.694 . . . . 0.0 112.875 -175.918 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . 0.594 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 17.1 ptm180 -65.25 -32.44 74.1 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 121.602 0.715 . . . . 0.0 109.748 175.545 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 70' ' ' TYR . . . . . 0.724 ' HD2' ' HA2' ' A' ' 67' ' ' GLY . 93.1 m-85 -77.78 -34.55 52.23 Favored 'General case' 0 N--CA 1.439 -0.988 0 N-CA-C 107.877 -1.157 . . . . 0.0 107.877 177.388 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.657 ' HB1' ' HB2' ' A' ' 77' ' ' ALA . . . 160.42 129.56 0.0 OUTLIER Pre-proline 0 CA--C 1.513 -0.48 0 CA-C-N 112.21 -2.268 . . . . 0.0 106.738 179.308 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 72' ' ' PRO . . . . . 0.866 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 17.4 Cg_exo -58.18 -4.12 1.49 Allowed 'Trans proline' 0 CA--C 1.53 0.278 0 C-N-CA 122.582 2.188 . . . . 0.0 113.506 -176.919 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 13.2 ptm180 -145.29 136.29 24.72 Favored 'General case' 0 C--N 1.321 -0.647 0 N-CA-C 108.99 -0.745 . . . . 0.0 108.99 175.801 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . 0.474 ' HA ' ' CH2' ' A' ' 62' ' ' TRP . . . -55.87 -30.7 61.92 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 114.873 -1.058 . . . . 0.0 112.772 -177.763 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . 0.424 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 20.8 p-10 -88.27 9.55 22.74 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 120.907 0.384 . . . . 0.0 111.362 -176.314 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 60.7 tp -109.98 -33.14 6.79 Favored 'General case' 0 C--N 1.323 -0.56 0 N-CA-C 108.783 -0.821 . . . . 0.0 108.783 170.246 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . 0.657 ' HB2' ' HB1' ' A' ' 71' ' ' ALA . . . -79.85 163.17 24.59 Favored 'General case' 0 N--CA 1.444 -0.759 0 CA-C-N 115.061 -0.972 . . . . 0.0 109.272 174.143 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 32.0 p -99.39 -173.91 2.6 Favored 'General case' 0 C--N 1.315 -0.927 0 C-N-CA 120.799 -0.36 . . . . 0.0 110.385 -178.497 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . 0.71 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 20.7 mtp180 -51.0 -54.34 25.39 Favored 'General case' 0 C--O 1.22 -0.452 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.99 -177.378 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 80' ' ' GLU . . . . . 0.452 ' HA ' HD13 ' A' ' 83' ' ' ILE . 9.0 pt-20 -61.41 -41.42 97.12 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.829 -172.683 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 81' ' ' GLU . . . . . 0.706 ' HB3' ' HB3' ' A' ' 70' ' ' TYR . 3.6 mp0 -59.24 -51.77 68.53 Favored 'General case' 0 C--N 1.323 -0.551 0 N-CA-C 112.016 0.376 . . . . 0.0 112.016 172.74 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 82' ' ' GLN . . . . . 0.503 ' HA ' ' CZ3' ' A' ' 62' ' ' TRP . 34.8 mt-30 -59.67 -39.07 83.25 Favored 'General case' 0 CA--C 1.51 -0.561 0 CA-C-O 121.719 0.771 . . . . 0.0 109.681 179.903 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . 0.688 HG22 ' CD1' ' A' ' 31' ' ' TRP . 34.8 mt -60.85 -44.42 97.66 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.903 0 CA-C-N 114.112 -1.404 . . . . 0.0 110.61 179.557 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . 0.603 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -66.34 -35.76 81.18 Favored 'General case' 0 C--O 1.236 0.37 0 CA-C-O 121.559 0.695 . . . . 0.0 110.939 -178.613 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . 0.654 HG11 ' HB2' ' A' ' 65' ' ' ASN . 57.4 t -66.15 -48.18 82.25 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.65 0 CA-C-N 115.595 -0.73 . . . . 0.0 110.082 174.672 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -58.76 -30.65 67.68 Favored 'General case' 0 CA--C 1.518 -0.284 0 CA-C-N 115.766 -0.652 . . . . 0.0 110.567 173.551 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 87' ' ' GLU . . . . . 0.664 ' HG2' ' O ' ' A' ' 83' ' ' ILE . 30.9 mm-40 -59.06 -43.32 91.7 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.735 -0.666 . . . . 0.0 110.368 179.754 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.504 ' O ' ' HG3' ' A' ' 92' ' ' ARG . 91.1 t -62.9 -49.49 83.42 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-O 120.851 0.357 . . . . 0.0 110.446 177.901 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 89' ' ' THR . . . . . 0.573 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 23.8 m -66.17 -42.16 89.31 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.936 -0.574 . . . . 0.0 111.312 -176.479 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . 0.649 ' HA ' ' OE1' ' A' ' 93' ' ' GLN . 8.1 ptt180 -69.17 -32.76 72.3 Favored 'General case' 0 CA--C 1.515 -0.392 0 CA-C-O 121.729 0.776 . . . . 0.0 109.435 -179.255 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . 0.447 ' HB2' ' O ' ' A' ' 87' ' ' GLU . 49.4 tp -57.14 -27.44 61.85 Favored 'General case' 0 C--N 1.315 -0.92 0 CA-C-N 114.762 -1.108 . . . . 0.0 111.09 -179.179 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . 0.504 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 6.7 mtm180 -92.14 -50.97 5.41 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 115.407 -0.815 . . . . 0.0 110.581 -175.846 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 93' ' ' GLN . . . . . 0.649 ' OE1' ' HA ' ' A' ' 90' ' ' ARG . 0.0 OUTLIER -104.93 -15.1 15.24 Favored 'General case' 0 CA--C 1.539 0.531 0 N-CA-C 113.44 0.904 . . . . 0.0 113.44 -170.151 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.475 ' O ' ' HB2' ' A' ' 90' ' ' ARG . . . 101.32 -97.55 1.67 Allowed Glycine 0 CA--C 1.498 -0.996 0 N-CA-C 110.096 -1.202 . . . . 0.0 110.096 -179.631 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 95' ' ' TRP . . . . . . . . . . . . . 25.3 m95 -145.89 19.45 1.45 Allowed 'General case' 0 C--N 1.315 -0.895 0 N-CA-C 106.246 -1.761 . . . . 0.0 106.246 171.867 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -66.03 -26.59 72.4 Favored Glycine 0 N--CA 1.451 -0.325 0 CA-C-N 114.581 -1.191 . . . . 0.0 112.833 -177.181 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -81.36 -15.19 56.04 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 121.272 0.558 . . . . 0.0 109.966 177.341 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 98' ' ' TRP . . . . . 0.573 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 28.3 m-90 -106.7 107.95 61.09 Favored Pre-proline 0 N--CA 1.445 -0.685 0 CA-C-N 115.472 -0.785 . . . . 0.0 109.42 177.657 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . 0.445 ' HD3' ' HA ' ' A' ' 98' ' ' TRP . 50.6 Cg_exo -61.99 -138.17 0.0 OUTLIER 'Trans proline' 0 CA--C 1.534 0.495 0 C-N-CA 123.876 3.051 . . . . 0.0 114.1 -174.628 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 15.0 m -54.97 -26.49 17.62 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.292 0 CA-C-O 121.166 0.507 . . . . 0.0 111.731 -176.468 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 101' ' ' CYS . . . . . 0.441 ' SG ' ' HB2' ' A' ' 38' ' ' GLU . 83.0 m -56.38 -35.3 67.56 Favored 'General case' 0 C--N 1.313 -0.985 0 CA-C-N 115.195 -0.911 . . . . 0.0 111.553 177.72 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -70.88 -45.83 63.68 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.768 0.318 . . . . 0.0 110.934 178.479 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -59.46 -42.69 92.57 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 121.086 0.469 . . . . 0.0 110.621 177.256 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 49.3 mtp180 -67.14 -19.46 65.61 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.348 -0.842 . . . . 0.0 111.14 178.199 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 105' ' ' ALA . . . . . 0.437 ' CB ' ' HB3' ' A' ' 33' ' ' ALA . . . -96.43 -20.39 18.47 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.938 -0.573 . . . . 0.0 112.109 -176.489 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 102.29 55.28 0.86 Allowed Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.887 -0.673 . . . . 0.0 111.802 -175.996 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -57.58 149.74 20.74 Favored 'General case' 0 C--N 1.329 -0.29 0 C-N-CA 123.224 0.61 . . . . 0.0 111.352 -179.639 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 28.0 mtp180 . . . . . 0 C--O 1.25 1.118 0 CA-C-O 118.317 -0.849 . . . . 0.0 109.49 -171.547 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 79.4 m-20 . . . . . 0 N--CA 1.478 0.936 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 72.5 t -110.83 -57.2 4.12 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.657 0 CA-C-O 120.958 0.408 . . . . 0.0 110.37 179.899 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 24.6 t -84.41 77.35 1.31 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.804 0 CA-C-O 121.644 0.735 . . . . 0.0 110.969 -176.925 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 17.1 t -125.33 142.18 42.95 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.838 0 CA-C-N 115.09 -0.959 . . . . 0.0 109.018 176.812 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 20.0 p -128.24 102.8 20.87 Favored Pre-proline 0 C--N 1.313 -1.01 0 CA-C-N 116.121 -0.491 . . . . 0.0 111.372 -176.787 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 5.1 Cg_exo -78.43 136.34 13.96 Favored 'Trans proline' 0 N--CA 1.448 -1.189 0 C-N-CA 123.304 2.67 . . . . 0.0 110.53 174.417 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . 53.9 42.03 31.84 Favored 'General case' 0 C--N 1.305 -1.352 0 CA-C-N 114.129 -1.396 . . . . 0.0 110.717 -173.376 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 85.6 t60 -69.33 -14.72 63.08 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-N 114.372 -1.286 . . . . 0.0 108.795 171.535 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 12.8 pt-20 -95.18 128.04 41.71 Favored 'General case' 0 N--CA 1.445 -0.722 0 CA-C-N 115.316 -0.856 . . . . 0.0 109.042 175.469 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -128.63 67.29 1.39 Allowed 'General case' 0 C--N 1.314 -0.966 0 CA-C-O 121.724 0.773 . . . . 0.0 110.232 -176.833 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 7.2 p -64.28 -38.39 82.4 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.899 0 CA-C-N 114.515 -1.221 . . . . 0.0 110.319 179.051 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.464 ' O ' ' HG3' ' A' ' 13' ' ' ARG . 61.1 t 5.38 72.39 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.348 0.539 0 C-N-CA 126.487 1.915 . . . . 0.0 114.03 -176.92 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . 0.464 ' HG3' ' O ' ' A' ' 12' ' ' VAL . 83.9 mtm180 -160.29 135.82 8.18 Favored 'General case' 0 C--N 1.304 -1.399 0 CA-C-N 113.074 -1.876 . . . . 0.0 108.107 -179.526 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.3 t -71.92 148.77 9.64 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.218 0 CA-C-O 121.564 0.697 . . . . 0.0 109.514 -176.677 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -114.35 57.74 0.45 Allowed Glycine 0 N--CA 1.428 -1.881 0 CA-C-N 114.804 -1.089 . . . . 0.0 111.945 -176.471 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 3.2 m -71.9 -35.3 69.69 Favored 'General case' 0 C--N 1.313 -1.019 0 CA-C-O 122.072 0.939 . . . . 0.0 109.599 177.628 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . 0.774 ' HB2' ' HG2' ' A' ' 21' ' ' GLU . 0.0 OUTLIER -65.8 119.78 63.54 Favored Pre-proline 0 C--N 1.315 -0.9 0 CA-C-N 113.692 -1.595 . . . . 0.0 111.332 -179.969 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 16.1 Cg_exo -70.11 -175.56 1.28 Allowed 'Trans proline' 0 CA--C 1.511 -0.644 0 C-N-CA 123.558 2.839 . . . . 0.0 111.178 171.293 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -61.87 -28.03 69.53 Favored Glycine 0 C--N 1.308 -1.024 0 N-CA-C 109.994 -1.242 . . . . 0.0 109.994 176.461 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 4.5 m -58.38 -40.84 83.41 Favored 'General case' 0 C--N 1.312 -1.062 0 CA-C-N 112.991 -1.604 . . . . 0.0 111.913 177.4 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . 0.774 ' HG2' ' HB2' ' A' ' 17' ' ' LYS . 23.0 mt-10 37.26 77.92 0.04 OUTLIER 'General case' 0 C--O 1.234 0.265 0 N-CA-C 113.684 0.994 . . . . 0.0 113.684 -173.675 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.594 ' CG2' ' HB3' ' A' ' 80' ' ' GLU . 3.7 p -91.15 125.1 59.68 Favored Pre-proline 0 C--N 1.302 -1.474 0 CA-C-N 114.14 -1.391 . . . . 0.0 110.264 172.557 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_exo -54.99 129.56 36.02 Favored 'Trans proline' 0 C--N 1.344 0.292 0 C-N-CA 122.332 2.021 . . . . 0.0 110.7 170.387 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 11.4 Cg_endo -55.15 140.56 80.86 Favored 'Trans proline' 0 N--CA 1.457 -0.634 0 C-N-CA 123.377 2.718 . . . . 0.0 113.286 -172.753 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 22.1 t -116.58 151.68 18.37 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.916 0 CA-C-N 114.557 -1.201 . . . . 0.0 108.734 177.316 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 3.1 mp -55.98 -42.69 72.54 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.557 0 CA-C-O 120.988 0.423 . . . . 0.0 111.513 -167.599 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.516 ' HB2' ' OE1' ' A' ' 87' ' ' GLU . 31.1 m-20 -122.95 10.58 9.51 Favored 'General case' 0 C--N 1.316 -0.876 0 CA-C-N 115.583 -0.735 . . . . 0.0 110.286 -173.687 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . 0.58 ' HA2' ' HD1' ' A' ' 31' ' ' TRP . . . -60.55 -14.07 33.67 Favored Glycine 0 N--CA 1.448 -0.516 0 CA-C-N 115.631 -0.713 . . . . 0.0 111.683 -177.816 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 3.6 m -76.65 -41.9 44.04 Favored 'General case' 0 C--N 1.318 -0.772 0 CA-C-O 121.901 0.857 . . . . 0.0 109.576 178.263 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.524 ' O ' HG13 ' A' ' 34' ' ' ILE . 0.5 OUTLIER -66.95 -38.21 80.93 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.696 0 CA-C-N 114.263 -1.335 . . . . 0.0 107.891 -179.66 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' TRP . . . . . 0.58 ' HD1' ' HA2' ' A' ' 28' ' ' GLY . 38.2 m95 -66.33 -35.99 81.77 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 114.852 -1.067 . . . . 0.0 110.519 -177.215 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 5.4 t0 -70.1 -42.88 72.12 Favored 'General case' 0 N--CA 1.442 -0.86 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.138 178.621 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . 0.441 ' HB1' ' HB3' ' A' ' 105' ' ' ALA . . . -69.35 -34.22 74.28 Favored 'General case' 0 N--CA 1.445 -0.704 0 C-N-CA 120.39 -0.524 . . . . 0.0 110.683 179.457 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . 0.524 HG13 ' O ' ' A' ' 30' ' ' ILE . 51.9 mt -62.61 -43.65 98.69 Favored 'Isoleucine or valine' 0 C--O 1.235 0.295 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.429 174.692 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . 0.535 ' HA ' ' O ' ' A' ' 54' ' ' GLY . . . -61.84 -34.94 76.88 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.285 176.349 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . 0.435 ' HA2' ' N ' ' A' ' 41' ' ' GLY . . . -72.46 -16.9 77.51 Favored Glycine 0 N--CA 1.451 -0.328 0 CA-C-N 115.503 -0.771 . . . . 0.0 111.902 179.332 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 7.1 t -81.62 -61.88 1.8 Allowed 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.575 -0.313 . . . . 0.0 111.78 -177.388 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 14.0 tp10 -88.76 -33.73 17.37 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-O 121.109 0.48 . . . . 0.0 110.714 -172.641 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -99.13 -10.53 22.4 Favored 'General case' 0 N--CA 1.446 -0.626 0 CA-C-N 115.986 -0.552 . . . . 0.0 111.797 -173.817 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 75.13 15.9 80.87 Favored Glycine 0 N--CA 1.448 -0.522 0 N-CA-C 109.666 -1.374 . . . . 0.0 109.666 -177.041 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . 0.435 ' N ' ' HA2' ' A' ' 36' ' ' GLY . . . 79.18 61.73 2.31 Favored Glycine 0 N--CA 1.434 -1.478 0 CA-C-N 114.045 -1.077 . . . . 0.0 111.465 -174.64 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 2.4 t-20 -142.91 95.63 2.8 Favored 'General case' 0 C--N 1.323 -0.581 0 N-CA-C 108.799 -0.815 . . . . 0.0 108.799 -179.46 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' TRP . . . . . 0.758 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 18.2 m95 -78.29 -3.23 41.87 Favored 'General case' 0 C--N 1.314 -0.944 0 CA-C-N 115.413 -0.812 . . . . 0.0 110.122 -174.269 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -112.58 14.21 20.11 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.273 -0.876 . . . . 0.0 111.7 -179.111 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.926 HG23 ' HA2' ' A' ' 53' ' ' GLY . 2.9 tt -75.61 145.08 11.2 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.45 0 CA-C-O 121.24 0.543 . . . . 0.0 110.214 179.435 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 14.1 t-20 -146.88 87.62 1.7 Allowed 'General case' 0 C--N 1.312 -1.028 0 N-CA-C 109.649 -0.5 . . . . 0.0 109.649 179.188 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 22.4 p -68.6 -28.16 66.68 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.657 -0.701 . . . . 0.0 110.268 179.72 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 100.01 18.09 23.34 Favored Glycine 0 N--CA 1.444 -0.785 0 CA-C-N 115.382 -0.827 . . . . 0.0 111.162 179.474 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 32.9 p-10 -92.85 10.63 30.24 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 120.878 0.37 . . . . 0.0 111.419 -175.147 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . 0.537 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 90.51 -11.66 70.78 Favored Glycine 0 N--CA 1.449 -0.433 0 N-CA-C 111.707 -0.557 . . . . 0.0 111.707 179.715 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' TYR . . . . . 0.561 ' CE1' ' HB3' ' A' ' 58' ' ' ASP . 0.6 OUTLIER -111.9 162.07 15.72 Favored 'General case' 0 N--CA 1.446 -0.644 0 N-CA-C 106.541 -1.652 . . . . 0.0 106.541 177.671 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' TYR . . . . . 0.444 ' O ' ' HA ' ' A' ' 56' ' ' GLN . 39.3 m-85 -125.85 169.68 12.38 Favored 'General case' 0 C--N 1.31 -1.114 0 C-N-CA 119.82 -0.752 . . . . 0.0 112.028 -168.313 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.926 ' HA2' HG23 ' A' ' 45' ' ' ILE . . . -60.52 160.04 24.59 Favored Glycine 0 CA--C 1.5 -0.893 0 CA-C-N 115.121 -0.945 . . . . 0.0 113.54 -175.045 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . 0.626 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 92.15 -109.55 3.77 Favored Glycine 0 N--CA 1.437 -1.267 0 C-N-CA 120.515 -0.85 . . . . 0.0 111.615 -177.751 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.554 HG12 ' NE1' ' A' ' 98' ' ' TRP . 3.9 t -87.15 13.18 1.03 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-O 121.378 0.609 . . . . 0.0 110.466 -174.266 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 56' ' ' GLN . . . . . 0.446 ' HG2' ' O ' ' A' ' 55' ' ' VAL . 0.0 OUTLIER 51.07 33.85 9.88 Favored 'General case' 0 N--CA 1.473 0.689 0 N-CA-C 114.454 1.279 . . . . 0.0 114.454 164.975 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 4.7 p90 -113.77 168.95 9.35 Favored 'General case' 0 C--N 1.325 -0.475 0 C-N-CA 119.348 -0.941 . . . . 0.0 112.169 178.593 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.561 ' HB3' ' CE1' ' A' ' 51' ' ' TYR . 5.5 p-10 -83.83 164.53 19.44 Favored 'General case' 0 CA--C 1.517 -0.311 0 N-CA-C 113.887 1.069 . . . . 0.0 113.887 -163.379 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.402 ' HB2' ' HE1' ' A' ' 52' ' ' TYR . 5.2 tp-100 -63.38 -39.58 94.92 Favored 'General case' 0 N--CA 1.449 -0.481 0 CA-C-N 113.553 -1.658 . . . . 0.0 111.969 179.695 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -65.52 -48.03 72.25 Favored Glycine 0 C--N 1.317 -0.504 0 C-N-CA 121.124 -0.56 . . . . 0.0 111.991 -176.217 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 98.4 m -64.85 -42.05 95.21 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-O 120.936 0.398 . . . . 0.0 110.85 176.052 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 62' ' ' TRP . . . . . 0.439 ' CH2' ' HA ' ' A' ' 82' ' ' GLN . 53.4 t-105 -56.91 -49.76 74.6 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 121.733 0.778 . . . . 0.0 109.871 176.764 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . 0.516 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 1.8 tm-20 -67.68 -33.48 75.0 Favored 'General case' 0 C--N 1.318 -0.802 0 CA-C-N 114.677 -1.147 . . . . 0.0 110.656 -178.246 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -66.86 -40.8 87.98 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.923 -179.581 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 8.2 m120 -82.93 -1.78 53.22 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 121.056 0.455 . . . . 0.0 110.328 177.163 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 80.17 48.93 6.18 Favored Glycine 0 C--N 1.334 0.446 0 CA-C-N 115.6 -0.727 . . . . 0.0 112.413 173.686 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . 0.54 ' HA2' ' HD1' ' A' ' 70' ' ' TYR . . . -80.25 -18.71 71.01 Favored Glycine 0 N--CA 1.442 -0.953 0 C-N-CA 120.828 -0.701 . . . . 0.0 112.959 -176.338 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 0.735 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 6.5 mp -60.84 -28.47 68.85 Favored 'General case' 0 C--N 1.322 -0.616 0 N-CA-C 112.379 0.511 . . . . 0.0 112.379 -172.364 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 16.3 ptm180 -67.85 -28.79 67.85 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 121.457 0.646 . . . . 0.0 110.188 176.206 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 70' ' ' TYR . . . . . 0.62 ' HB3' ' HG3' ' A' ' 81' ' ' GLU . 86.4 m-85 -79.4 -34.11 42.12 Favored 'General case' 0 N--CA 1.442 -0.838 0 N-CA-C 107.419 -1.326 . . . . 0.0 107.419 175.708 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.679 ' HB2' ' HB2' ' A' ' 77' ' ' ALA . . . 159.13 128.39 0.0 OUTLIER Pre-proline 0 CA--C 1.51 -0.589 0 CA-C-N 112.473 -2.149 . . . . 0.0 106.539 -179.474 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 72' ' ' PRO . . . . . 0.735 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 23.3 Cg_exo -55.64 -6.08 0.94 Allowed 'Trans proline' 0 CA--C 1.527 0.166 0 C-N-CA 122.829 2.353 . . . . 0.0 113.808 -176.824 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 12.8 ptm180 -146.84 138.49 24.38 Favored 'General case' 0 C--N 1.322 -0.597 0 N-CA-C 109.521 -0.548 . . . . 0.0 109.521 177.927 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . 0.419 ' HA ' ' CH2' ' A' ' 62' ' ' TRP . . . -61.7 -23.0 65.82 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 113.052 0.76 . . . . 0.0 113.052 -176.168 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . 0.66 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 5.5 p-10 -84.86 -7.68 59.08 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 121.191 0.52 . . . . 0.0 110.65 -179.051 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 54.6 tp -97.68 -31.47 12.25 Favored 'General case' 0 C--N 1.322 -0.623 0 N-CA-C 109.249 -0.648 . . . . 0.0 109.249 173.591 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . 0.712 ' HB3' ' HB3' ' A' ' 81' ' ' GLU . . . -78.55 155.22 29.82 Favored 'General case' 0 N--CA 1.444 -0.757 0 CA-C-N 115.267 -0.879 . . . . 0.0 109.562 176.277 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 48.0 p -97.86 -173.9 2.74 Favored 'General case' 0 C--N 1.311 -1.093 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.539 -176.766 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . 0.758 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 2.1 mtp180 -51.44 -53.62 35.19 Favored 'General case' 0 C--O 1.219 -0.518 0 O-C-N 123.184 0.302 . . . . 0.0 111.073 -178.044 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 80' ' ' GLU . . . . . 0.594 ' HB3' ' CG2' ' A' ' 22' ' ' VAL . 1.6 pm0 -62.47 -45.47 92.89 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-O 120.949 0.404 . . . . 0.0 111.6 -176.5 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 81' ' ' GLU . . . . . 0.712 ' HB3' ' HB3' ' A' ' 77' ' ' ALA . 0.4 OUTLIER -60.88 -52.3 65.66 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 121.204 0.526 . . . . 0.0 112.332 178.194 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 82' ' ' GLN . . . . . 0.501 ' HG2' HG21 ' A' ' 55' ' ' VAL . 6.0 tt0 -69.84 -33.94 72.97 Favored 'General case' 0 C--N 1.316 -0.876 0 CA-C-N 115.449 -0.796 . . . . 0.0 110.735 -175.305 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . 0.553 ' O ' ' HG2' ' A' ' 87' ' ' GLU . 24.3 mt -60.52 -43.18 93.82 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.638 0 CA-C-N 115.535 -0.757 . . . . 0.0 109.905 174.155 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . 0.568 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -64.51 -39.29 93.51 Favored 'General case' 0 C--O 1.237 0.411 0 CA-C-O 121.421 0.629 . . . . 0.0 111.076 -174.867 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 51.5 t -68.29 -49.28 68.2 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 CA-C-N 115.645 -0.707 . . . . 0.0 111.162 177.761 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -58.69 -29.82 66.93 Favored 'General case' 0 C--O 1.234 0.267 0 CA-C-O 120.955 0.407 . . . . 0.0 110.532 174.232 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 87' ' ' GLU . . . . . 0.718 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 8.8 mm-40 -59.36 -44.42 92.69 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.467 -0.788 . . . . 0.0 109.766 179.279 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.436 ' O ' ' HG3' ' A' ' 92' ' ' ARG . 70.4 t -62.03 -46.26 96.89 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.209 0 CA-C-O 120.933 0.397 . . . . 0.0 109.938 176.473 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 89' ' ' THR . . . . . 0.94 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 0.2 OUTLIER -60.03 -48.61 81.02 Favored 'General case' 0 N--CA 1.447 -0.59 0 CA-C-N 115.67 -0.695 . . . . 0.0 112.004 -175.141 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . 0.68 ' HA ' ' OE1' ' A' ' 93' ' ' GLN . 0.2 OUTLIER -60.46 -33.41 72.51 Favored 'General case' 0 CA--C 1.518 -0.28 0 CA-C-N 116.036 -0.529 . . . . 0.0 111.349 -173.433 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . 0.718 ' HG ' ' O ' ' A' ' 87' ' ' GLU . 24.4 mt -66.53 -26.26 67.07 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 121.364 0.602 . . . . 0.0 110.139 -175.039 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . 0.436 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 10.3 mtm180 -89.13 -49.94 6.45 Favored 'General case' 0 C--N 1.317 -0.84 0 CA-C-N 114.957 -1.02 . . . . 0.0 110.377 -172.18 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 93' ' ' GLN . . . . . 0.68 ' OE1' ' HA ' ' A' ' 90' ' ' ARG . 0.0 OUTLIER -99.05 -22.94 15.46 Favored 'General case' 0 CA--C 1.54 0.582 0 N-CA-C 113.457 0.91 . . . . 0.0 113.457 -171.599 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 81.7 47.19 6.42 Favored Glycine 0 C--N 1.335 0.522 0 C-N-CA 120.81 -0.709 . . . . 0.0 111.921 173.225 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 95' ' ' TRP . . . . . 0.434 ' HH2' ' HB3' ' A' ' 27' ' ' ASP . 4.9 m95 59.34 21.15 9.4 Favored 'General case' 0 C--O 1.221 -0.404 0 CA-C-O 121.567 0.698 . . . . 0.0 109.674 -179.02 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.441 ' H ' ' HG2' ' A' ' 93' ' ' GLN . . . -78.09 -18.62 76.3 Favored Glycine 0 N--CA 1.452 -0.262 0 CA-C-N 115.4 -0.818 . . . . 0.0 112.11 174.645 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -81.79 -31.84 31.65 Favored 'General case' 0 C--N 1.326 -0.421 0 N-CA-C 109.541 -0.54 . . . . 0.0 109.541 176.421 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 98' ' ' TRP . . . . . 0.94 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 17.2 m-90 -105.68 103.9 45.88 Favored Pre-proline 0 C--N 1.323 -0.577 0 CA-C-N 115.286 -0.87 . . . . 0.0 109.143 177.265 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . 0.417 ' HD3' ' HA ' ' A' ' 98' ' ' TRP . 11.3 Cg_exo -77.2 -90.85 0.0 OUTLIER 'Trans proline' 0 CA--C 1.536 0.589 0 C-N-CA 122.789 2.326 . . . . 0.0 114.543 -173.467 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . 0.474 ' O ' ' HD2' ' A' ' 104' ' ' ARG . 4.5 p -69.77 -29.37 40.6 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.349 0 CA-C-O 121.962 0.887 . . . . 0.0 110.196 -172.525 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 78.0 m -73.39 -38.8 65.52 Favored 'General case' 0 C--N 1.312 -1.061 0 CA-C-N 114.281 -1.327 . . . . 0.0 111.564 -174.05 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 102' ' ' ALA . . . . . 0.421 ' HB1' ' HB2' ' A' ' 98' ' ' TRP . . . -70.27 -42.37 72.22 Favored 'General case' 0 C--N 1.326 -0.441 0 C-N-CA 120.761 -0.376 . . . . 0.0 110.499 178.494 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -59.3 -45.47 91.19 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 121.2 0.524 . . . . 0.0 110.59 178.552 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 104' ' ' ARG . . . . . 0.474 ' HD2' ' O ' ' A' ' 100' ' ' VAL . 0.0 OUTLIER -71.82 -18.5 62.08 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 115.566 -0.743 . . . . 0.0 111.888 179.512 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 105' ' ' ALA . . . . . 0.455 ' HB1' HG22 ' A' ' 30' ' ' ILE . . . -92.16 -21.35 20.45 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 121.001 0.429 . . . . 0.0 111.45 179.508 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 110.5 63.06 0.51 Allowed Glycine 0 N--CA 1.451 -0.353 0 CA-C-N 116.005 -0.543 . . . . 0.0 112.018 -177.885 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -65.13 149.39 49.99 Favored 'General case' 0 C--N 1.33 -0.244 0 C-N-CA 122.806 0.442 . . . . 0.0 110.908 -178.25 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 71.7 mtp180 . . . . . 0 C--O 1.246 0.884 0 CA-C-O 118.638 -0.696 . . . . 0.0 110.195 -170.995 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 17.2 m120 . . . . . 0 N--CA 1.476 0.844 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 24.4 t 56.26 87.88 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.449 -0.522 0 CA-C-O 122.211 1.005 . . . . 0.0 110.445 -174.988 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 87.2 t -64.72 120.59 11.92 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.641 0 CA-C-N 114.51 -1.223 . . . . 0.0 112.466 -174.618 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 10.8 t -106.87 140.85 23.64 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 N-CA-C 107.873 -1.158 . . . . 0.0 107.873 167.262 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 3.3 t -90.11 117.65 68.23 Favored Pre-proline 0 C--N 1.313 -0.986 0 CA-C-O 121.361 0.6 . . . . 0.0 112.429 -171.992 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 1.7 Cg_endo -85.25 165.23 11.11 Favored 'Trans proline' 0 N--CA 1.445 -1.328 0 C-N-CA 123.317 2.678 . . . . 0.0 110.339 171.619 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . 54.96 21.73 3.89 Favored 'General case' 0 C--N 1.316 -0.882 0 CA-C-N 115.06 -0.973 . . . . 0.0 112.305 -176.739 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 33.4 t-80 -80.92 -5.78 57.87 Favored 'General case' 0 C--N 1.322 -0.619 0 N-CA-C 108.285 -1.005 . . . . 0.0 108.285 169.937 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 12.2 pt-20 -63.84 145.5 55.68 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 114.712 -1.131 . . . . 0.0 111.453 -175.68 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -104.29 64.15 0.76 Allowed 'General case' 0 C--N 1.319 -0.739 0 CA-C-O 121.934 0.873 . . . . 0.0 109.608 -178.835 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 7.2 p -57.83 -27.83 31.51 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.896 0 CA-C-N 113.781 -1.554 . . . . 0.0 111.245 178.687 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 38.4 t 41.65 90.49 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.445 -0.698 0 CA-C-O 122.558 1.17 . . . . 0.0 112.425 -179.527 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 12.6 ptp180 -88.81 114.41 25.4 Favored 'General case' 0 C--N 1.306 -1.312 0 CA-C-N 114.107 -1.406 . . . . 0.0 108.871 178.069 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 3.3 t -79.88 161.11 4.11 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.347 0 CA-C-N 114.656 -1.156 . . . . 0.0 110.559 -175.445 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 153.31 86.23 0.05 OUTLIER Glycine 0 N--CA 1.431 -1.673 0 CA-C-N 114.053 -1.431 . . . . 0.0 111.308 -178.704 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 8.6 m -65.53 -35.94 82.36 Favored 'General case' 0 N--CA 1.446 -0.655 0 CA-C-O 121.113 0.482 . . . . 0.0 110.147 -179.231 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 34.1 mmtp 37.63 78.76 0.34 Allowed Pre-proline 0 C--N 1.327 -0.384 0 CA-C-N 114.028 -1.442 . . . . 0.0 113.007 175.456 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 27.2 Cg_exo -64.29 163.45 26.35 Favored 'Trans proline' 0 N--CA 1.457 -0.675 0 C-N-CA 122.65 2.233 . . . . 0.0 112.162 177.843 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 133.69 -52.06 0.83 Allowed Glycine 0 C--N 1.304 -1.244 0 CA-C-N 114.295 -1.32 . . . . 0.0 110.417 -174.007 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 51.4 m -67.31 -30.02 69.76 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 121.957 0.884 . . . . 0.0 108.949 168.688 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 42.4 mt-10 -126.71 137.35 53.24 Favored 'General case' 0 N--CA 1.437 -1.085 0 CA-C-N 114.545 -1.207 . . . . 0.0 108.004 177.103 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 93.3 t -80.23 125.62 80.97 Favored Pre-proline 0 C--N 1.31 -1.142 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.987 -176.362 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_exo -53.74 140.1 67.25 Favored 'Trans proline' 0 C--N 1.347 0.478 0 C-N-CA 123.328 2.685 . . . . 0.0 112.03 178.737 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 10.9 Cg_endo -55.58 139.33 82.6 Favored 'Trans proline' 0 N--CA 1.455 -0.785 0 C-N-CA 123.332 2.688 . . . . 0.0 112.953 -177.936 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.97 HG13 HD13 ' A' ' 83' ' ' ILE . 9.1 p -95.36 130.21 44.43 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.038 0 CA-C-N 114.311 -1.313 . . . . 0.0 110.158 178.142 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 49.9 mm -82.14 -30.22 9.77 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 CA-C-O 121.142 0.496 . . . . 0.0 110.513 178.499 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.414 ' O ' HG13 ' A' ' 30' ' ' ILE . 15.0 m-20 -86.21 -3.67 59.02 Favored 'General case' 0 CA--C 1.498 -1.036 0 CA-C-O 121.88 0.848 . . . . 0.0 109.791 -178.438 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . 0.619 ' HA2' ' HB2' ' A' ' 31' ' ' TRP . . . -70.66 -7.44 61.36 Favored Glycine 0 N--CA 1.438 -1.228 0 CA-C-N 114.659 -1.155 . . . . 0.0 110.295 -179.12 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 41.7 m -77.05 -38.35 52.9 Favored 'General case' 0 C--N 1.32 -0.717 0 N-CA-C 109.029 -0.73 . . . . 0.0 109.029 173.997 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.568 ' HA ' ' HB3' ' A' ' 105' ' ' ALA . 0.2 OUTLIER -71.92 -37.1 60.07 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.692 0 N-CA-C 107.844 -1.169 . . . . 0.0 107.844 175.929 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' TRP . . . . . 0.619 ' HB2' ' HA2' ' A' ' 28' ' ' GLY . 38.9 m95 -71.38 -38.29 71.55 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 114.611 -1.177 . . . . 0.0 110.391 -178.377 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 28.3 t70 -78.31 -30.14 48.17 Favored 'General case' 0 N--CA 1.442 -0.846 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.041 178.599 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . 0.497 ' HB1' ' CB ' ' A' ' 105' ' ' ALA . . . -70.6 -33.78 71.43 Favored 'General case' 0 N--CA 1.452 -0.371 0 O-C-N 122.012 -0.43 . . . . 0.0 110.177 176.389 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . 0.521 HG13 ' O ' ' A' ' 30' ' ' ILE . 70.3 mt -64.73 -46.14 93.07 Favored 'Isoleucine or valine' 0 C--O 1.234 0.239 0 CA-C-O 121.241 0.544 . . . . 0.0 109.804 171.473 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . 0.488 ' HA ' ' O ' ' A' ' 54' ' ' GLY . . . -58.61 -39.45 80.48 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.547 -0.751 . . . . 0.0 110.453 176.177 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -76.51 -7.25 85.33 Favored Glycine 0 C--N 1.319 -0.363 0 CA-C-N 115.462 -0.79 . . . . 0.0 111.763 179.923 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 9.3 t -92.47 -64.78 1.06 Allowed 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 115.428 -0.386 . . . . 0.0 110.972 -178.981 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . 0.8 ' HG3' ' SG ' ' A' ' 101' ' ' CYS . 25.7 mt-10 -90.49 -33.64 15.87 Favored 'General case' 0 C--N 1.325 -0.473 0 C-N-CA 120.522 -0.471 . . . . 0.0 111.419 -175.684 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . 0.416 ' HB2' ' O ' ' A' ' 35' ' ' ALA . . . -89.62 -11.86 41.37 Favored 'General case' 0 C--N 1.325 -0.495 0 C-N-CA 120.697 -0.401 . . . . 0.0 111.641 -176.033 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 76.32 13.36 83.41 Favored Glycine 0 CA--C 1.505 -0.556 0 N-CA-C 110.225 -1.15 . . . . 0.0 110.225 -179.672 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 79.64 57.45 3.1 Favored Glycine 0 N--CA 1.433 -1.549 0 CA-C-N 113.915 -1.143 . . . . 0.0 111.759 -176.038 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . 0.414 ' OD1' ' HB ' ' A' ' 45' ' ' ILE . 2.4 t-20 -147.8 106.12 3.77 Favored 'General case' 0 N--CA 1.448 -0.548 0 N-CA-C 108.76 -0.83 . . . . 0.0 108.76 -177.752 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' TRP . . . . . 0.747 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 35.2 m95 -83.92 -12.38 55.49 Favored 'General case' 0 C--N 1.311 -1.07 0 CA-C-N 115.643 -0.708 . . . . 0.0 110.315 -174.031 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -106.67 13.98 27.46 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 115.346 -0.843 . . . . 0.0 110.895 -179.508 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.525 HG22 ' HA3' ' A' ' 53' ' ' GLY . 7.0 tt -77.51 144.38 11.56 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.01 0 N-CA-C 109.239 -0.652 . . . . 0.0 109.239 177.412 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 41.1 t-20 -156.59 100.67 1.96 Allowed 'General case' 0 C--N 1.313 -1.022 0 CA-C-O 121.213 0.53 . . . . 0.0 109.614 -177.625 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 14.6 p -72.59 -24.75 61.13 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.298 -0.864 . . . . 0.0 110.383 179.527 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 96.12 17.77 33.65 Favored Glycine 0 N--CA 1.441 -1.013 0 CA-C-N 115.413 -0.812 . . . . 0.0 111.181 178.537 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 1.6 p-10 -90.34 9.47 28.76 Favored 'General case' 0 C--N 1.329 -0.32 0 C-N-CA 120.56 -0.456 . . . . 0.0 111.356 -173.141 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . 0.465 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 95.42 -11.55 68.66 Favored Glycine 0 N--CA 1.454 -0.154 0 C-N-CA 120.88 -0.676 . . . . 0.0 111.774 -179.194 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' TYR . . . . . 0.559 ' HA ' ' HA ' ' A' ' 58' ' ' ASP . 0.1 OUTLIER -113.67 159.82 19.28 Favored 'General case' 0 N--CA 1.447 -0.62 0 N-CA-C 106.655 -1.609 . . . . 0.0 106.655 174.186 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' TYR . . . . . 0.807 ' O ' ' HA ' ' A' ' 56' ' ' GLN . 50.8 m-85 -123.67 170.67 10.24 Favored 'General case' 0 C--N 1.311 -1.104 0 C-N-CA 120.639 -0.425 . . . . 0.0 111.116 -169.336 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.525 ' HA3' HG22 ' A' ' 45' ' ' ILE . . . -69.88 -168.27 6.56 Favored Glycine 0 N--CA 1.445 -0.753 0 N-CA-C 114.373 0.509 . . . . 0.0 114.373 -172.851 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . 0.645 ' CA ' ' HA ' ' A' ' 43' ' ' TRP . . . 73.46 -107.84 2.34 Favored Glycine 0 N--CA 1.441 -0.977 0 N-CA-C 111.335 -0.706 . . . . 0.0 111.335 -179.466 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.554 HG21 ' HB3' ' A' ' 82' ' ' GLN . 1.7 m -83.73 -0.43 5.39 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-O 121.464 0.649 . . . . 0.0 110.702 179.413 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 56' ' ' GLN . . . . . 0.807 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 7.8 tp-100 57.97 52.98 7.22 Favored 'General case' 0 CA--C 1.535 0.393 0 CA-C-N 114.157 -1.383 . . . . 0.0 114.546 164.404 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -126.73 171.92 10.78 Favored 'General case' 0 C--O 1.233 0.233 0 C-N-CA 118.969 -1.092 . . . . 0.0 112.806 172.512 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.559 ' HA ' ' HA ' ' A' ' 51' ' ' TYR . 7.9 p-10 -77.72 162.34 27.05 Favored 'General case' 0 CA--C 1.515 -0.393 0 N-CA-C 113.945 1.091 . . . . 0.0 113.945 -163.756 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.757 ' HA ' HE21 ' A' ' 59' ' ' GLN . 0.0 OUTLIER -57.67 -41.98 82.62 Favored 'General case' 0 N--CA 1.445 -0.719 0 CA-C-N 114.367 -1.288 . . . . 0.0 111.137 177.194 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -67.61 -49.44 50.16 Favored Glycine 0 CA--C 1.507 -0.431 0 C-N-CA 120.993 -0.622 . . . . 0.0 112.22 -171.787 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 38.8 m -64.97 -42.03 94.92 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-O 120.904 0.383 . . . . 0.0 111.029 177.804 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 62' ' ' TRP . . . . . 0.473 ' CZ3' ' HA ' ' A' ' 82' ' ' GLN . 47.7 t-105 -56.63 -48.2 78.03 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 121.775 0.798 . . . . 0.0 109.514 175.29 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . 0.662 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 36.9 tt0 -65.74 -37.56 86.72 Favored 'General case' 0 N--CA 1.443 -0.791 0 CA-C-N 114.738 -1.119 . . . . 0.0 110.892 -179.151 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -66.02 -41.39 91.04 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.857 -177.941 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . 0.415 ' HB2' HG13 ' A' ' 85' ' ' VAL . 9.4 m120 -76.8 -13.04 60.05 Favored 'General case' 0 N--CA 1.45 -0.445 0 CA-C-O 120.883 0.373 . . . . 0.0 110.261 177.493 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . 0.525 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 92.11 45.43 3.85 Favored Glycine 0 C--N 1.333 0.393 0 CA-C-N 115.846 -0.616 . . . . 0.0 112.642 175.327 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . 0.571 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -79.91 -20.31 68.26 Favored Glycine 0 N--CA 1.443 -0.89 0 C-N-CA 120.807 -0.711 . . . . 0.0 112.848 -174.495 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 0.96 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 6.7 mp -64.37 -23.47 67.3 Favored 'General case' 0 C--N 1.319 -0.756 0 N-CA-C 112.424 0.527 . . . . 0.0 112.424 -172.933 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . 0.525 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 13.2 ptp180 -65.26 -31.16 72.17 Favored 'General case' 0 C--N 1.324 -0.509 0 N-CA-C 109.113 -0.699 . . . . 0.0 109.113 175.884 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 70' ' ' TYR . . . . . 0.601 ' HB3' ' HB3' ' A' ' 81' ' ' GLU . 92.4 m-85 -81.12 -36.05 30.82 Favored 'General case' 0 N--CA 1.439 -0.992 0 CA-C-N 114.683 -1.144 . . . . 0.0 107.94 177.394 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.499 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 164.72 127.55 0.02 OUTLIER Pre-proline 0 N--CA 1.448 -0.567 0 CA-C-N 112.626 -2.079 . . . . 0.0 107.342 -178.364 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 72' ' ' PRO . . . . . 0.96 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 17.4 Cg_exo -59.03 -3.44 1.6 Allowed 'Trans proline' 0 C--N 1.334 -0.217 0 C-N-CA 122.724 2.282 . . . . 0.0 113.586 -178.557 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 13.0 ptm180 -144.05 133.74 23.66 Favored 'General case' 0 C--N 1.315 -0.913 0 N-CA-C 108.127 -1.064 . . . . 0.0 108.127 175.986 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . 0.446 ' HA ' ' CH2' ' A' ' 62' ' ' TRP . . . -57.99 -28.8 64.74 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 115.578 -0.737 . . . . 0.0 112.372 -175.897 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 20.9 p-10 -84.24 -2.86 57.68 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 121.111 0.481 . . . . 0.0 111.499 -175.944 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.468 ' HB3' ' HB2' ' A' ' 71' ' ' ALA . 62.5 tp -96.38 -28.01 14.66 Favored 'General case' 0 C--N 1.322 -0.624 0 N-CA-C 108.413 -0.958 . . . . 0.0 108.413 170.342 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . 0.729 ' HB3' ' HB2' ' A' ' 81' ' ' GLU . . . -80.18 154.4 28.0 Favored 'General case' 0 N--CA 1.444 -0.77 0 CA-C-N 114.413 -1.267 . . . . 0.0 110.093 173.443 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 44.6 p -100.03 -172.5 2.24 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-N 116.392 -0.367 . . . . 0.0 110.136 179.291 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . 0.747 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 19.2 mtt180 -48.73 -53.28 19.59 Favored 'General case' 0 CA--C 1.509 -0.605 0 CA-C-O 121.205 0.526 . . . . 0.0 111.277 -177.924 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 80' ' ' GLU . . . . . 0.568 ' HG3' ' OE2' ' A' ' 81' ' ' GLU . 3.4 pt-20 -59.88 -41.04 90.68 Favored 'General case' 0 C--N 1.312 -1.04 0 CA-C-N 114.958 -1.019 . . . . 0.0 112.086 -175.553 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 81' ' ' GLU . . . . . 0.729 ' HB2' ' HB3' ' A' ' 77' ' ' ALA . 4.6 mp0 -67.46 -51.99 44.8 Favored 'General case' 0 C--O 1.232 0.181 0 N-CA-C 112.132 0.419 . . . . 0.0 112.132 174.444 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 82' ' ' GLN . . . . . 0.554 ' HB3' HG21 ' A' ' 55' ' ' VAL . 54.3 mt-30 -59.98 -43.44 95.12 Favored 'General case' 0 CA--C 1.512 -0.501 0 CA-C-O 121.116 0.484 . . . . 0.0 110.54 -175.73 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . 0.97 HD13 HG13 ' A' ' 25' ' ' VAL . 15.4 mt -60.69 -40.81 85.98 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.787 0 CA-C-N 114.947 -1.024 . . . . 0.0 110.568 178.851 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . 0.577 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -63.6 -42.13 98.26 Favored 'General case' 0 C--O 1.239 0.524 0 CA-C-O 121.428 0.632 . . . . 0.0 111.366 -177.917 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . 0.415 HG13 ' HB2' ' A' ' 65' ' ' ASN . 44.5 t -69.05 -48.01 72.05 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.675 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.243 178.99 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . 0.435 ' HB2' ' CH2' ' A' ' 31' ' ' TRP . . . -57.85 -29.69 65.19 Favored 'General case' 0 N--CA 1.452 -0.34 0 CA-C-N 115.603 -0.726 . . . . 0.0 110.594 174.062 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 87' ' ' GLU . . . . . 0.622 ' HG2' ' O ' ' A' ' 83' ' ' ILE . 15.9 mm-40 -60.81 -40.64 93.5 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.193 178.738 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.499 ' O ' ' HG3' ' A' ' 92' ' ' ARG . 59.0 t -63.08 -48.06 89.61 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-O 121.276 0.56 . . . . 0.0 109.716 173.546 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 89' ' ' THR . . . . . 0.738 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 0.3 OUTLIER -63.41 -47.47 81.85 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 115.559 -0.746 . . . . 0.0 112.224 -174.832 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . 0.536 ' HB3' ' CH2' ' A' ' 31' ' ' TRP . 4.8 ptt180 -62.54 -32.82 73.84 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 121.519 0.676 . . . . 0.0 109.216 -176.276 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . 0.535 ' N ' ' HG3' ' A' ' 90' ' ' ARG . 64.3 tp -66.09 -32.18 73.5 Favored 'General case' 0 C--N 1.313 -1.01 0 CA-C-N 114.029 -1.441 . . . . 0.0 111.622 -173.236 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . 0.499 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 3.5 mtm180 -84.98 -46.46 11.2 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-O 121.507 0.67 . . . . 0.0 110.077 -175.116 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 93' ' ' GLN . . . . . 0.406 ' OE1' ' HB2' ' A' ' 97' ' ' ALA . 4.5 pt20 -101.89 -27.31 13.06 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 115.218 -0.901 . . . . 0.0 113.155 -168.5 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 92.3 39.62 5.33 Favored Glycine 0 CA--C 1.505 -0.555 0 C-N-CA 120.416 -0.897 . . . . 0.0 111.926 174.547 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 95' ' ' TRP . . . . . 0.499 ' CH2' ' HB ' ' A' ' 30' ' ' ILE . 38.7 m95 71.37 6.91 5.92 Favored 'General case' 0 C--O 1.218 -0.589 0 C-N-CA 123.399 0.68 . . . . 0.0 109.6 -178.462 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -58.46 -37.56 88.58 Favored Glycine 0 CA--C 1.521 0.44 0 CA-C-N 115.595 -0.73 . . . . 0.0 113.741 -179.826 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . 0.406 ' HB2' ' OE1' ' A' ' 93' ' ' GLN . . . -68.92 -22.2 64.16 Favored 'General case' 0 CA--C 1.519 -0.241 0 CA-C-N 117.219 0.51 . . . . 0.0 110.657 179.139 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 98' ' ' TRP . . . . . 0.738 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 27.7 m-90 -100.9 104.09 29.45 Favored Pre-proline 0 N--CA 1.449 -0.483 0 N-CA-C 109.05 -0.722 . . . . 0.0 109.05 175.918 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 16.5 Cg_exo -72.85 -89.96 0.01 OUTLIER 'Trans proline' 0 CA--C 1.533 0.427 0 C-N-CA 122.872 2.382 . . . . 0.0 114.738 -171.509 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 49.0 t -71.68 -30.28 37.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-O 121.811 0.815 . . . . 0.0 110.103 -173.122 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 101' ' ' CYS . . . . . 0.8 ' SG ' ' HG3' ' A' ' 38' ' ' GLU . 70.4 m -76.77 -27.57 55.36 Favored 'General case' 0 C--N 1.317 -0.835 0 CA-C-N 115.099 -0.955 . . . . 0.0 111.869 -169.713 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -69.68 -46.0 67.05 Favored 'General case' 0 C--N 1.329 -0.317 0 C-N-CA 120.75 -0.38 . . . . 0.0 110.753 -179.628 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -67.62 -32.12 72.61 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 120.856 0.36 . . . . 0.0 110.647 -179.946 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -74.1 -21.94 59.69 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.85 177.261 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 105' ' ' ALA . . . . . 0.568 ' HB3' ' HA ' ' A' ' 30' ' ' ILE . . . -96.17 -22.07 17.51 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.815 -0.629 . . . . 0.0 112.057 -176.26 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 108.62 57.08 0.56 Allowed Glycine 0 CA--C 1.522 0.492 0 C-N-CA 120.871 -0.681 . . . . 0.0 112.186 -177.517 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -61.54 149.73 38.09 Favored 'General case' 0 C--N 1.329 -0.321 0 C-N-CA 123.253 0.621 . . . . 0.0 111.551 -175.674 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 72.9 mtp180 . . . . . 0 C--O 1.245 0.859 0 CA-C-O 118.686 -0.673 . . . . 0.0 110.419 -173.855 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 90.8 m-20 . . . . . 0 N--CA 1.478 0.946 0 CA-C-O 120.857 0.36 . . . . 0.0 110.141 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 10.0 p -91.36 34.85 0.1 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.513 0 CA-C-O 122.232 1.015 . . . . 0.0 109.887 -177.354 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 6.0 p -66.39 121.51 15.61 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.67 0 CA-C-N 114.845 -1.07 . . . . 0.0 112.35 -176.898 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 15.7 t -104.24 144.54 14.24 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.628 0 N-CA-C 108.715 -0.846 . . . . 0.0 108.715 171.155 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 35.6 p -89.72 123.13 67.22 Favored Pre-proline 0 C--N 1.313 -0.986 0 CA-C-N 116.45 -0.341 . . . . 0.0 110.378 -178.829 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -77.61 152.84 29.86 Favored 'Trans proline' 0 N--CA 1.449 -1.101 0 C-N-CA 122.777 2.318 . . . . 0.0 110.979 177.33 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -70.25 101.46 1.9 Allowed 'General case' 0 C--N 1.307 -1.24 0 CA-C-O 122.12 0.962 . . . . 0.0 110.314 -178.496 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 45.6 t-80 164.66 -11.03 0.0 OUTLIER 'General case' 0 C--N 1.309 -1.182 0 CA-C-N 112.651 -2.068 . . . . 0.0 105.678 -170.249 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 13.7 pt-20 -62.73 135.67 57.48 Favored 'General case' 0 C--O 1.234 0.241 0 CA-C-N 114.372 -1.286 . . . . 0.0 109.757 178.215 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -124.92 68.51 1.11 Allowed 'General case' 0 C--N 1.318 -0.789 0 CA-C-O 121.536 0.684 . . . . 0.0 110.748 -175.164 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 12.0 p -66.46 -31.09 52.01 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.743 0 CA-C-N 114.37 -1.286 . . . . 0.0 109.703 176.162 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 98.4 t 11.74 84.78 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.448 -0.574 0 C-N-CA 126.34 1.856 . . . . 0.0 114.235 175.111 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . 0.537 ' HG3' ' O ' ' A' ' 13' ' ' ARG . 4.2 ptp180 -99.58 112.03 24.3 Favored 'General case' 0 C--N 1.302 -1.465 0 CA-C-N 113.989 -1.459 . . . . 0.0 109.36 173.664 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 3.0 t -91.09 160.1 2.74 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.484 0 CA-C-N 114.487 -1.233 . . . . 0.0 109.035 179.235 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 88.79 72.34 1.27 Allowed Glycine 0 C--N 1.303 -1.288 0 N-CA-C 110.384 -1.087 . . . . 0.0 110.384 -175.842 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' THR . . . . . 0.475 ' O ' ' HD3' ' A' ' 18' ' ' PRO . 25.5 m -74.85 -34.49 62.3 Favored 'General case' 0 N--CA 1.438 -1.056 0 CA-C-O 121.577 0.703 . . . . 0.0 110.55 -175.681 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 11.4 mmmm -102.27 101.25 18.4 Favored Pre-proline 0 C--N 1.316 -0.866 0 CA-C-N 114.649 -1.16 . . . . 0.0 110.604 178.011 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . 0.475 ' HD3' ' O ' ' A' ' 16' ' ' THR . 5.2 Cg_exo -78.94 172.02 15.6 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 C-N-CA 123.067 2.511 . . . . 0.0 112.02 177.0 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 120.19 47.6 0.34 Allowed Glycine 0 C--N 1.308 -1.02 0 CA-C-N 114.522 -1.217 . . . . 0.0 111.864 -178.492 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 27.5 m -68.86 -31.02 69.68 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-O 121.571 0.7 . . . . 0.0 110.707 178.898 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 44.1 mt-10 -117.88 143.75 46.03 Favored 'General case' 0 N--CA 1.433 -1.284 0 CA-C-N 115.348 -0.842 . . . . 0.0 109.062 -176.854 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 38.8 t -85.36 114.17 54.78 Favored Pre-proline 0 C--N 1.305 -1.341 0 CA-C-N 115.374 -0.83 . . . . 0.0 110.392 -178.53 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_exo -59.74 130.88 37.04 Favored 'Trans proline' 0 N--CA 1.462 -0.342 0 C-N-CA 123.055 2.503 . . . . 0.0 112.394 -178.642 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 9.6 Cg_endo -55.0 140.96 79.93 Favored 'Trans proline' 0 N--CA 1.456 -0.724 0 C-N-CA 123.275 2.65 . . . . 0.0 112.069 177.195 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.584 ' HB ' HG22 ' A' ' 83' ' ' ILE . 26.8 t -113.77 140.62 33.24 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.143 0 CA-C-N 114.729 -1.123 . . . . 0.0 109.513 -177.683 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 2.7 mp -61.85 -25.37 36.93 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.353 0 CA-C-N 115.48 -0.782 . . . . 0.0 111.913 -173.876 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 8.7 m-20 -88.03 1.69 53.62 Favored 'General case' 0 CA--C 1.502 -0.889 0 CA-C-O 121.511 0.672 . . . . 0.0 109.774 -177.952 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . 0.484 ' HA2' ' HB2' ' A' ' 31' ' ' TRP . . . -64.62 -11.62 49.48 Favored Glycine 0 N--CA 1.44 -1.073 0 CA-C-N 114.893 -1.049 . . . . 0.0 110.64 176.536 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 11.9 m -76.92 -36.88 56.3 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-O 121.854 0.835 . . . . 0.0 109.592 176.511 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.548 ' HA ' ' HB1' ' A' ' 105' ' ' ALA . 1.2 mm -71.34 -40.79 73.71 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 N-CA-C 107.088 -1.449 . . . . 0.0 107.088 176.701 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' TRP . . . . . 0.554 ' HA ' ' CE3' ' A' ' 31' ' ' TRP . 14.3 m95 -67.93 -35.83 79.09 Favored 'General case' 0 C--N 1.315 -0.898 0 CA-C-N 113.711 -1.586 . . . . 0.0 110.536 -175.528 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.572 ' HB2' HH21 ' A' ' 79' ' ' ARG . 12.4 t70 -77.18 -36.6 54.91 Favored 'General case' 0 N--CA 1.44 -0.937 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.712 -179.532 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . 0.519 ' HB2' ' CB ' ' A' ' 105' ' ' ALA . . . -70.65 -34.02 71.59 Favored 'General case' 0 N--CA 1.448 -0.558 0 C-N-CA 120.692 -0.403 . . . . 0.0 110.789 177.124 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . 0.529 HG13 ' O ' ' A' ' 30' ' ' ILE . 60.5 mt -64.94 -46.83 90.48 Favored 'Isoleucine or valine' 0 C--O 1.234 0.25 0 CA-C-O 120.889 0.376 . . . . 0.0 110.559 175.359 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . 0.423 ' O ' ' HB3' ' A' ' 39' ' ' ALA . . . -61.75 -34.67 76.25 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 121.328 0.585 . . . . 0.0 110.285 176.761 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . 0.467 ' HA2' ' N ' ' A' ' 41' ' ' GLY . . . -75.58 -9.47 84.69 Favored Glycine 0 N--CA 1.449 -0.462 0 CA-C-N 115.525 -0.762 . . . . 0.0 111.47 178.117 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.451 ' HB3' ' O ' ' A' ' 34' ' ' ILE . 1.7 t -91.03 -63.13 1.31 Allowed 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 115.399 -0.401 . . . . 0.0 111.409 -177.508 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . 0.733 ' HG3' ' SG ' ' A' ' 101' ' ' CYS . 13.9 mt-10 -89.27 -33.9 16.8 Favored 'General case' 0 C--N 1.327 -0.381 0 C-N-CA 120.405 -0.518 . . . . 0.0 111.39 -175.262 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . 0.423 ' HB3' ' O ' ' A' ' 35' ' ' ALA . . . -88.93 -9.02 53.06 Favored 'General case' 0 C--N 1.323 -0.567 0 C-N-CA 120.706 -0.398 . . . . 0.0 111.367 -177.335 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 75.5 15.92 80.94 Favored Glycine 0 CA--C 1.504 -0.637 0 N-CA-C 110.033 -1.227 . . . . 0.0 110.033 -178.689 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . 0.467 ' N ' ' HA2' ' A' ' 36' ' ' GLY . . . 75.76 60.39 3.19 Favored Glycine 0 N--CA 1.434 -1.491 0 CA-C-N 114.047 -1.076 . . . . 0.0 111.25 -174.273 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 2.1 t-20 -142.71 95.42 2.78 Favored 'General case' 0 N--CA 1.448 -0.538 0 N-CA-C 109.242 -0.651 . . . . 0.0 109.242 -178.759 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' TRP . . . . . 0.687 ' HA ' ' N ' ' A' ' 54' ' ' GLY . 36.8 m95 -79.96 -4.03 50.78 Favored 'General case' 0 C--N 1.317 -0.824 0 CA-C-N 115.516 -0.765 . . . . 0.0 110.319 -176.465 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -111.78 15.07 21.07 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 114.893 -1.049 . . . . 0.0 111.416 179.548 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.814 HG23 ' HA2' ' A' ' 53' ' ' GLY . 10.8 tt -76.64 141.44 15.67 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.719 0 CA-C-O 121.297 0.57 . . . . 0.0 110.398 179.612 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 19.1 m120 -142.01 95.93 2.88 Favored 'General case' 0 C--N 1.312 -1.053 0 CA-C-O 121.34 0.59 . . . . 0.0 109.513 -177.927 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 34.3 p -66.47 -23.7 66.31 Favored 'General case' 0 C--N 1.318 -0.791 0 CA-C-N 114.959 -1.019 . . . . 0.0 110.52 -179.097 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 88.55 14.54 61.44 Favored Glycine 0 N--CA 1.441 -0.989 0 N-CA-C 110.135 -1.186 . . . . 0.0 110.135 -178.408 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 2.6 t30 -96.16 5.25 51.49 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.423 0.63 . . . . 0.0 110.67 -173.229 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 95.53 -1.34 64.0 Favored Glycine 0 N--CA 1.447 -0.618 0 C-N-CA 120.612 -0.804 . . . . 0.0 111.103 -176.223 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' TYR . . . . . 0.529 ' HA ' ' O ' ' A' ' 57' ' ' PHE . 0.7 OUTLIER -110.88 161.36 15.9 Favored 'General case' 0 N--CA 1.444 -0.77 0 N-CA-C 107.724 -1.213 . . . . 0.0 107.724 179.077 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' TYR . . . . . 0.413 ' CD1' ' HB2' ' A' ' 73' ' ' ARG . 43.8 m-85 -129.62 170.05 14.27 Favored 'General case' 0 C--N 1.313 -1.013 0 CA-C-O 120.877 0.37 . . . . 0.0 111.823 -170.092 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.814 ' HA2' HG23 ' A' ' 45' ' ' ILE . . . -60.61 164.8 15.32 Favored Glycine 0 N--CA 1.448 -0.562 0 N-CA-C 115.127 0.811 . . . . 0.0 115.127 -168.663 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . 0.687 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 90.22 -96.29 2.19 Favored Glycine 0 N--CA 1.439 -1.152 0 CA-C-N 114.659 -0.77 . . . . 0.0 112.258 177.652 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -102.21 12.46 7.09 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.672 0 CA-C-O 120.77 0.319 . . . . 0.0 111.49 -175.803 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 56' ' ' GLN . . . . . . . . . . . . . 21.4 mm-40 60.24 43.64 13.6 Favored 'General case' 0 N--CA 1.47 0.557 0 CA-C-N 115.427 -0.806 . . . . 0.0 112.417 173.903 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . 0.529 ' O ' ' HA ' ' A' ' 51' ' ' TYR . 24.3 m-85 -63.38 127.09 29.72 Favored 'General case' 0 CA--C 1.505 -0.757 0 CA-C-N 115.306 -0.861 . . . . 0.0 112.173 172.847 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.475 ' HA ' ' HA ' ' A' ' 51' ' ' TYR . 6.7 p-10 -72.62 156.77 38.63 Favored 'General case' 0 C--N 1.317 -0.84 0 N-CA-C 108.414 -0.958 . . . . 0.0 108.414 163.522 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.826 ' HA ' HE21 ' A' ' 59' ' ' GLN . 0.0 OUTLIER -58.44 -35.2 71.76 Favored 'General case' 0 C--N 1.316 -0.89 0 CA-C-O 120.733 0.301 . . . . 0.0 111.039 -177.221 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -68.13 -49.69 45.08 Favored Glycine 0 N--CA 1.451 -0.349 0 CA-C-N 116.045 -0.525 . . . . 0.0 112.494 -175.945 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 82.0 m -67.7 -40.97 84.28 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 120.933 0.397 . . . . 0.0 110.735 178.767 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 62' ' ' TRP . . . . . 0.506 ' CE2' ' HA3' ' A' ' 67' ' ' GLY . 65.6 t-105 -58.05 -47.56 82.77 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-O 121.547 0.689 . . . . 0.0 109.416 176.436 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . 0.41 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 33.8 tt0 -67.4 -32.51 73.45 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 115.182 -0.917 . . . . 0.0 110.924 -179.979 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -66.42 -42.37 87.85 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.71 -175.832 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . 0.782 ' HB2' HG12 ' A' ' 85' ' ' VAL . 26.1 m-80 -82.86 -5.9 59.2 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.874 0.368 . . . . 0.0 110.292 176.031 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . 0.584 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 90.61 48.15 3.53 Favored Glycine 0 C--N 1.332 0.327 0 CA-C-N 115.928 -0.578 . . . . 0.0 112.931 171.056 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . 0.576 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -79.8 -29.48 47.33 Favored Glycine 0 N--CA 1.438 -1.203 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.43 -176.053 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 1.008 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 8.2 mp -56.78 -22.0 32.71 Favored 'General case' 0 N--CA 1.447 -0.605 0 N-CA-C 112.997 0.74 . . . . 0.0 112.997 -175.189 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . 0.584 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 12.3 ptm180 -70.76 -30.26 66.71 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-O 121.431 0.634 . . . . 0.0 110.076 177.744 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 70' ' ' TYR . . . . . 1.016 ' HB3' ' HG2' ' A' ' 81' ' ' GLU . 46.7 m-85 -85.41 -36.0 20.95 Favored 'General case' 0 N--CA 1.443 -0.817 0 N-CA-C 107.447 -1.316 . . . . 0.0 107.447 177.037 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.639 ' HB1' ' HB1' ' A' ' 77' ' ' ALA . . . 170.74 126.23 0.05 OUTLIER Pre-proline 0 N--CA 1.445 -0.722 0 CA-C-N 112.863 -1.972 . . . . 0.0 107.522 -176.24 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 72' ' ' PRO . . . . . 1.008 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 26.4 Cg_exo -56.43 -6.15 1.37 Allowed 'Trans proline' 0 C--N 1.333 -0.28 0 C-N-CA 123.005 2.47 . . . . 0.0 113.785 -178.289 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 73' ' ' ARG . . . . . 0.413 ' HB2' ' CD1' ' A' ' 52' ' ' TYR . 13.5 ptm180 -147.53 138.67 23.64 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-O 121.28 0.562 . . . . 0.0 109.559 176.155 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -56.33 -30.22 62.31 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 114.861 -1.063 . . . . 0.0 113.307 -176.289 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 5.4 p-10 -80.47 -11.82 59.63 Favored 'General case' 0 C--N 1.327 -0.379 0 C-N-CA 120.428 -0.509 . . . . 0.0 110.899 -176.988 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.535 ' HB3' ' HB3' ' A' ' 71' ' ' ALA . 46.4 tp -90.16 -31.8 16.92 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-O 121.937 0.875 . . . . 0.0 108.76 173.621 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . 0.639 ' HB1' ' HB1' ' A' ' 71' ' ' ALA . . . -79.68 162.98 24.9 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 114.489 -1.232 . . . . 0.0 110.255 174.122 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 64.1 p -102.11 176.59 5.15 Favored 'General case' 0 C--N 1.318 -0.782 0 CA-C-N 116.399 -0.364 . . . . 0.0 110.721 179.155 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . 0.641 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 41.8 mtp180 -47.37 -50.84 21.35 Favored 'General case' 0 CA--C 1.511 -0.549 0 C-N-CA 123.103 0.561 . . . . 0.0 111.255 -174.75 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 80' ' ' GLU . . . . . 0.534 ' HA ' HD11 ' A' ' 83' ' ' ILE . 3.4 pm0 -60.01 -31.78 70.26 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-N 115.729 -0.669 . . . . 0.0 111.52 -176.815 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 81' ' ' GLU . . . . . 1.016 ' HG2' ' HB3' ' A' ' 70' ' ' TYR . 5.4 mt-10 -71.72 -47.4 54.16 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 116.619 -0.264 . . . . 0.0 111.524 176.302 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 82' ' ' GLN . . . . . 0.569 ' HB2' ' HZ3' ' A' ' 43' ' ' TRP . 5.9 mp0 -60.78 -36.52 79.18 Favored 'General case' 0 CA--C 1.514 -0.428 0 C-N-CA 120.213 -0.595 . . . . 0.0 109.447 175.466 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . 0.584 HG22 ' HB ' ' A' ' 25' ' ' VAL . 53.7 mt -60.7 -49.28 85.15 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.635 0 CA-C-N 115.104 -0.953 . . . . 0.0 110.47 178.111 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . 0.473 ' O ' ' HG3' ' A' ' 87' ' ' GLU . . . -60.35 -45.76 92.32 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-O 120.957 0.408 . . . . 0.0 111.517 -179.53 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . 0.782 HG12 ' HB2' ' A' ' 65' ' ' ASN . 63.6 t -69.1 -49.26 63.87 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.554 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.551 -178.588 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . 0.524 ' CA ' ' HZ ' ' A' ' 57' ' ' PHE . . . -64.56 -32.05 73.53 Favored 'General case' 0 CA--C 1.509 -0.619 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.897 179.645 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 87' ' ' GLU . . . . . 0.566 ' O ' ' HG3' ' A' ' 90' ' ' ARG . 1.3 pp20? -70.83 -29.65 65.85 Favored 'General case' 0 C--N 1.321 -0.665 0 C-N-CA 120.271 -0.572 . . . . 0.0 110.117 -177.624 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.716 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 61.2 t -64.74 -41.47 92.28 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.285 0 N-CA-C 109.136 -0.69 . . . . 0.0 109.136 168.093 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 89' ' ' THR . . . . . 0.943 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 1.8 m -65.02 -47.01 78.98 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 115.66 -0.7 . . . . 0.0 111.166 -177.906 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . 0.672 ' HA ' ' OE1' ' A' ' 93' ' ' GLN . 3.0 ppt_? -60.69 -34.1 73.85 Favored 'General case' 0 CA--C 1.516 -0.365 0 CA-C-N 115.801 -0.636 . . . . 0.0 111.598 -175.774 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . 0.716 ' HG ' ' O ' ' A' ' 88' ' ' VAL . 4.5 pp -72.51 -22.22 61.07 Favored 'General case' 0 C--N 1.319 -0.758 0 CA-C-O 121.222 0.534 . . . . 0.0 110.185 -175.035 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . 0.579 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 10.4 mtm180 -84.57 -51.59 6.76 Favored 'General case' 0 CA--C 1.51 -0.574 0 CA-C-N 115.699 -0.682 . . . . 0.0 110.069 -177.713 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 93' ' ' GLN . . . . . 0.672 ' OE1' ' HA ' ' A' ' 90' ' ' ARG . 0.0 OUTLIER -99.17 -22.91 15.43 Favored 'General case' 0 C--N 1.325 -0.474 0 N-CA-C 113.148 0.795 . . . . 0.0 113.148 -171.127 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 94.52 35.04 6.07 Favored Glycine 0 CA--C 1.508 -0.397 0 C-N-CA 120.849 -0.691 . . . . 0.0 112.439 171.254 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 95' ' ' TRP . . . . . 0.421 ' HA ' ' HE3' ' A' ' 98' ' ' TRP . 20.1 m95 66.27 7.87 5.2 Favored 'General case' 0 C--O 1.22 -0.472 0 C-N-CA 123.602 0.761 . . . . 0.0 109.542 -177.146 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -65.55 -32.55 83.66 Favored Glycine 0 C--N 1.332 0.337 0 C-N-CA 121.083 -0.58 . . . . 0.0 112.169 -179.996 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -67.44 -28.92 68.29 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.792 0.329 . . . . 0.0 110.639 178.998 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 98' ' ' TRP . . . . . 0.943 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 26.5 m-90 -100.1 104.44 29.25 Favored Pre-proline 0 N--CA 1.448 -0.55 0 N-CA-C 108.923 -0.769 . . . . 0.0 108.923 176.246 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . 0.424 ' HD3' ' HA ' ' A' ' 98' ' ' TRP . 17.0 Cg_exo -72.53 -91.29 0.01 OUTLIER 'Trans proline' 0 CA--C 1.533 0.434 0 C-N-CA 123.101 2.534 . . . . 0.0 114.682 -171.884 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . 0.41 ' H ' ' HB2' ' A' ' 99' ' ' PRO . 41.5 t -70.67 -28.05 32.98 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-O 121.764 0.792 . . . . 0.0 110.234 -172.938 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 101' ' ' CYS . . . . . 0.733 ' SG ' ' HG3' ' A' ' 38' ' ' GLU . 84.7 m -75.66 -38.4 58.81 Favored 'General case' 0 C--N 1.315 -0.906 0 CA-C-N 115.063 -0.971 . . . . 0.0 111.881 -171.588 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -68.05 -44.48 76.28 Favored 'General case' 0 C--N 1.327 -0.398 0 C-N-CA 120.591 -0.444 . . . . 0.0 110.309 -179.861 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -59.49 -37.44 78.25 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 121.081 0.467 . . . . 0.0 111.053 179.075 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 15.9 tpp180 -73.98 -34.33 64.17 Favored 'General case' 0 N--CA 1.431 -1.398 0 CA-C-N 115.578 -0.737 . . . . 0.0 111.429 179.323 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 105' ' ' ALA . . . . . 0.548 ' HB1' ' HA ' ' A' ' 30' ' ' ILE . . . -88.12 -22.65 23.98 Favored 'General case' 0 C--N 1.326 -0.416 0 N-CA-C 112.667 0.617 . . . . 0.0 112.667 -172.878 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 120.33 58.42 0.24 Allowed Glycine 0 CA--C 1.521 0.415 0 C-N-CA 120.661 -0.781 . . . . 0.0 112.527 -177.927 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -66.68 148.8 51.42 Favored 'General case' 0 C--N 1.325 -0.478 0 C-N-CA 122.771 0.428 . . . . 0.0 110.519 -179.355 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 72.3 mtp180 . . . . . 0 C--O 1.247 0.949 0 CA-C-O 117.946 -1.026 . . . . 0.0 110.777 -171.924 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 26.8 p-10 . . . . . 0 N--CA 1.476 0.827 0 CA-C-O 121.218 0.532 . . . . 0.0 110.721 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 9.5 p -102.59 15.94 5.29 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-O 121.973 0.892 . . . . 0.0 109.518 175.406 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 60.0 t -60.51 114.04 1.01 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.375 0 CA-C-N 114.692 -1.14 . . . . 0.0 112.206 -176.753 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 24.4 t -102.24 150.13 6.47 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 N-CA-C 108.577 -0.897 . . . . 0.0 108.577 173.54 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 21.4 p -81.26 113.61 42.77 Favored Pre-proline 0 C--N 1.316 -0.855 0 CA-C-N 116.406 -0.361 . . . . 0.0 111.089 -177.34 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_exo -61.2 106.42 0.39 Allowed 'Trans proline' 0 CA--C 1.505 -0.946 0 C-N-CA 123.212 2.608 . . . . 0.0 111.822 178.955 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -112.52 36.47 3.4 Favored 'General case' 0 C--N 1.293 -1.87 0 CA-C-N 113.283 -1.78 . . . . 0.0 111.115 -175.883 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 98.3 m-70 -72.52 -11.37 60.63 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-N 114.867 -1.06 . . . . 0.0 109.006 169.776 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -114.11 133.77 55.33 Favored 'General case' 0 N--CA 1.442 -0.864 0 CA-C-N 115.157 -0.928 . . . . 0.0 109.464 178.368 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -150.33 69.03 0.99 Allowed 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 121.839 0.828 . . . . 0.0 110.523 -178.518 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 11.8 p -85.57 -28.29 6.33 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.923 0 CA-C-N 114.703 -1.135 . . . . 0.0 110.404 179.923 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.438 ' O ' ' HG2' ' A' ' 13' ' ' ARG . 7.1 p 31.34 79.75 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.342 0.254 0 C-N-CA 124.699 1.2 . . . . 0.0 112.601 -176.851 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . 0.438 ' HG2' ' O ' ' A' ' 12' ' ' VAL . 14.7 ptp180 47.73 124.33 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.658 0 CA-C-N 113.102 -1.863 . . . . 0.0 113.528 -172.725 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 3.5 t -66.69 152.12 9.8 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.895 0 N-CA-C 108.395 -0.965 . . . . 0.0 108.395 174.855 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -127.45 66.71 0.56 Allowed Glycine 0 N--CA 1.426 -1.973 0 CA-C-N 115.313 -0.858 . . . . 0.0 112.927 -173.549 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 9.8 m -84.24 -32.4 24.48 Favored 'General case' 0 N--CA 1.439 -1.014 0 CA-C-O 121.714 0.768 . . . . 0.0 109.72 175.154 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . 0.428 ' HA ' ' HD3' ' A' ' 18' ' ' PRO . 70.4 mmtt -65.7 113.22 10.98 Favored Pre-proline 0 C--N 1.317 -0.819 0 CA-C-N 114.369 -1.287 . . . . 0.0 110.967 179.016 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . 0.428 ' HD3' ' HA ' ' A' ' 17' ' ' LYS . 22.3 Cg_exo -67.85 161.51 43.66 Favored 'Trans proline' 0 N--CA 1.455 -0.779 0 C-N-CA 123.387 2.724 . . . . 0.0 112.352 178.885 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 103.94 -26.5 22.97 Favored Glycine 0 C--N 1.303 -1.28 0 CA-C-N 114.248 -1.342 . . . . 0.0 110.261 -177.379 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 21.6 m -59.06 -35.64 73.69 Favored 'General case' 0 C--N 1.313 -1.01 0 CA-C-N 113.527 -1.337 . . . . 0.0 110.983 176.84 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . 0.509 ' O ' ' HD3' ' A' ' 23' ' ' PRO . 1.5 mp0 -64.46 107.9 1.5 Allowed 'General case' 0 CA--C 1.506 -0.72 0 CA-C-O 121.521 0.677 . . . . 0.0 109.835 178.892 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 37.8 t -81.73 114.29 49.01 Favored Pre-proline 0 C--N 1.305 -1.352 0 CA-C-N 114.428 -1.26 . . . . 0.0 110.77 -179.331 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . 0.509 ' HD3' ' O ' ' A' ' 21' ' ' GLU . 35.8 Cg_exo -60.68 154.82 52.19 Favored 'Trans proline' 0 N--CA 1.459 -0.551 0 C-N-CA 123.005 2.47 . . . . 0.0 110.979 170.605 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 7.7 Cg_endo -52.27 140.14 52.66 Favored 'Trans proline' 0 N--CA 1.451 -0.981 0 C-N-CA 122.193 1.929 . . . . 0.0 110.643 178.004 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.463 ' HB ' ' CG2' ' A' ' 83' ' ' ILE . 93.5 t -79.17 124.96 38.19 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.296 0 CA-C-N 114.683 -1.144 . . . . 0.0 112.301 -163.675 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 43.0 mm -67.65 -30.0 47.18 Favored 'Isoleucine or valine' 0 C--O 1.235 0.297 0 CA-C-N 114.114 -1.403 . . . . 0.0 112.689 -171.376 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.593 ' O ' HG12 ' A' ' 30' ' ' ILE . 16.1 m-20 -83.6 2.43 37.37 Favored 'General case' 0 CA--C 1.499 -1.006 0 CA-C-O 121.998 0.904 . . . . 0.0 108.919 -176.939 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . 0.737 ' HA3' HD12 ' A' ' 83' ' ' ILE . . . -67.55 -1.25 15.12 Favored Glycine 0 N--CA 1.433 -1.534 0 CA-C-N 114.143 -1.39 . . . . 0.0 110.844 172.693 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' SER . . . . . 0.401 ' H ' ' C ' ' A' ' 27' ' ' ASP . 19.0 m -73.71 -38.31 64.89 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-O 121.46 0.648 . . . . 0.0 109.405 173.203 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.593 HG12 ' O ' ' A' ' 27' ' ' ASP . 0.3 OUTLIER -71.69 -38.84 67.93 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.551 0 N-CA-C 107.179 -1.415 . . . . 0.0 107.179 175.595 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' TRP . . . . . 0.671 ' CD1' HG21 ' A' ' 83' ' ' ILE . 38.8 m95 -69.2 -36.69 77.56 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 114.359 -1.292 . . . . 0.0 110.667 -176.828 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 18.1 t70 -75.33 -33.93 61.17 Favored 'General case' 0 N--CA 1.444 -0.726 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.444 179.775 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . 0.48 ' HB1' ' CB ' ' A' ' 105' ' ' ALA . . . -70.42 -35.26 73.31 Favored 'General case' 0 N--CA 1.444 -0.739 0 C-N-CA 120.441 -0.503 . . . . 0.0 109.965 175.307 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . 0.553 HG13 ' O ' ' A' ' 30' ' ' ILE . 64.6 mt -64.59 -42.59 95.55 Favored 'Isoleucine or valine' 0 C--O 1.234 0.243 0 CA-C-O 120.996 0.427 . . . . 0.0 109.949 172.947 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . 0.428 ' HA ' ' O ' ' A' ' 54' ' ' GLY . . . -57.22 -38.02 73.11 Favored 'General case' 0 N--CA 1.451 -0.418 0 CA-C-N 115.78 -0.646 . . . . 0.0 109.997 174.608 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -73.49 -13.39 80.08 Favored Glycine 0 N--CA 1.45 -0.431 0 CA-C-N 115.375 -0.829 . . . . 0.0 112.051 179.456 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 37.3 t -94.19 -60.11 1.81 Allowed 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 120.702 0.286 . . . . 0.0 111.291 -178.999 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 9.0 tp10 -88.04 -34.32 18.03 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 121.099 0.476 . . . . 0.0 110.223 -170.972 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -92.76 -16.28 25.6 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.99 -0.55 . . . . 0.0 111.268 -177.528 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 83.52 5.33 88.57 Favored Glycine 0 CA--C 1.507 -0.461 0 N-CA-C 110.118 -1.193 . . . . 0.0 110.118 -176.124 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 90.28 59.23 1.48 Allowed Glycine 0 N--CA 1.434 -1.44 0 CA-C-N 114.095 -1.053 . . . . 0.0 112.034 -178.912 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . 0.477 HD21 ' HB ' ' A' ' 45' ' ' ILE . 66.0 t30 -152.44 126.32 9.01 Favored 'General case' 0 CA--C 1.507 -0.674 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 178.12 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' TRP . . . . . 0.751 ' HA ' ' N ' ' A' ' 54' ' ' GLY . 37.4 m95 -98.16 -12.89 21.25 Favored 'General case' 0 C--N 1.307 -1.263 0 CA-C-N 115.769 -0.65 . . . . 0.0 110.475 -174.171 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -102.95 5.23 38.24 Favored 'General case' 0 C--N 1.316 -0.875 0 CA-C-N 114.922 -1.036 . . . . 0.0 110.729 -179.113 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.477 ' HB ' HD21 ' A' ' 42' ' ' ASN . 9.8 tt -73.57 142.15 15.3 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.981 0 CA-C-N 115.921 -0.581 . . . . 0.0 109.876 -178.55 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 40.3 t-20 -154.63 99.15 2.14 Favored 'General case' 0 C--N 1.307 -1.281 0 N-CA-C 109.446 -0.576 . . . . 0.0 109.446 179.611 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 34.8 p -74.58 -15.79 60.83 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 115.626 -0.716 . . . . 0.0 110.937 -177.33 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 94.84 19.76 30.57 Favored Glycine 0 N--CA 1.448 -0.559 0 N-CA-C 111.431 -0.668 . . . . 0.0 111.431 178.932 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 32.5 p-10 -95.64 2.68 54.23 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-O 120.987 0.423 . . . . 0.0 111.421 -176.374 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 95.49 -11.33 68.72 Favored Glycine 0 N--CA 1.448 -0.553 0 N-CA-C 111.425 -0.67 . . . . 0.0 111.425 179.108 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' TYR . . . . . 0.608 ' CD1' ' HB2' ' A' ' 58' ' ' ASP . 0.5 OUTLIER -106.69 132.64 52.45 Favored 'General case' 0 CA--C 1.505 -0.752 0 N-CA-C 107.283 -1.377 . . . . 0.0 107.283 178.46 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' TYR . . . . . 0.659 ' O ' ' HA ' ' A' ' 56' ' ' GLN . 30.9 m-85 -103.07 169.44 8.56 Favored 'General case' 0 C--N 1.304 -1.371 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.972 -168.433 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -59.53 173.54 4.34 Favored Glycine 0 N--CA 1.448 -0.526 0 N-CA-C 115.086 0.794 . . . . 0.0 115.086 -169.151 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . 0.751 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 82.13 -99.58 2.04 Favored Glycine 0 N--CA 1.436 -1.329 0 CA-C-N 114.872 -0.664 . . . . 0.0 111.698 178.944 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.565 ' HB ' ' CD1' ' A' ' 57' ' ' PHE . 2.0 t -84.25 -3.41 7.83 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-O 121.774 0.797 . . . . 0.0 109.938 -177.511 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 56' ' ' GLN . . . . . 0.851 ' HA ' HE21 ' A' ' 56' ' ' GLN . 0.0 OUTLIER 55.81 50.36 14.27 Favored 'General case' 0 N--CA 1.46 0.04 0 CA-C-N 114.058 -1.428 . . . . 0.0 112.479 171.429 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . 0.565 ' CD1' ' HB ' ' A' ' 55' ' ' VAL . 3.8 p90 -124.62 165.36 18.01 Favored 'General case' 0 C--N 1.323 -0.546 0 C-N-CA 119.912 -0.715 . . . . 0.0 111.859 177.453 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.608 ' HB2' ' CD1' ' A' ' 51' ' ' TYR . 0.0 OUTLIER -77.12 152.04 35.11 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 114.382 -1.281 . . . . 0.0 113.758 -163.169 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.664 ' HA ' HE21 ' A' ' 59' ' ' GLN . 0.0 OUTLIER -50.82 -41.55 57.57 Favored 'General case' 0 N--CA 1.451 -0.393 0 CA-C-N 113.225 -1.807 . . . . 0.0 112.122 177.699 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -67.6 -49.1 52.67 Favored Glycine 0 C--N 1.315 -0.616 0 CA-C-N 115.507 -0.769 . . . . 0.0 112.013 -176.38 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 89.0 m -64.88 -41.16 95.87 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-O 120.919 0.39 . . . . 0.0 110.631 176.99 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 62' ' ' TRP . . . . . 0.509 ' CZ3' ' HA ' ' A' ' 82' ' ' GLN . 40.9 t-105 -57.0 -47.79 79.99 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 121.622 0.725 . . . . 0.0 109.617 174.725 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . 0.523 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 20.2 tt0 -65.28 -36.79 85.16 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-N 114.872 -1.058 . . . . 0.0 110.792 -179.932 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -67.57 -35.47 79.07 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 115.427 -0.806 . . . . 0.0 110.518 -177.672 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . 0.513 ' HB2' HG13 ' A' ' 85' ' ' VAL . 10.7 m120 -78.51 -12.9 60.04 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.249 175.823 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . 0.561 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 87.81 44.11 5.54 Favored Glycine 0 N--CA 1.447 -0.569 0 CA-C-N 115.411 -0.813 . . . . 0.0 112.035 177.345 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . 0.601 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -78.74 -22.04 67.48 Favored Glycine 0 N--CA 1.439 -1.117 0 C-N-CA 120.595 -0.812 . . . . 0.0 112.361 -173.52 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 0.932 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 7.1 mp -60.68 -21.25 62.64 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 112.592 0.59 . . . . 0.0 112.592 -174.334 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . 0.561 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 10.0 ptp180 -70.56 -32.9 70.49 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-O 121.253 0.549 . . . . 0.0 109.835 175.185 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 70' ' ' TYR . . . . . 0.65 ' HB3' ' CG ' ' A' ' 81' ' ' GLU . 73.2 m-85 -80.53 -34.59 35.42 Favored 'General case' 0 N--CA 1.443 -0.812 0 N-CA-C 107.47 -1.308 . . . . 0.0 107.47 178.502 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.698 ' HB1' ' HB1' ' A' ' 77' ' ' ALA . . . 164.12 129.12 0.02 OUTLIER Pre-proline 0 CA--C 1.511 -0.551 0 CA-C-N 112.616 -2.084 . . . . 0.0 106.759 -179.49 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 72' ' ' PRO . . . . . 0.932 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 20.4 Cg_exo -57.14 -4.75 1.12 Allowed 'Trans proline' 0 C--N 1.333 -0.244 0 C-N-CA 122.84 2.36 . . . . 0.0 113.932 -177.2 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 13.8 ptm180 -148.11 141.09 24.86 Favored 'General case' 0 C--N 1.317 -0.815 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 176.259 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . 0.507 ' HA ' ' CH2' ' A' ' 62' ' ' TRP . . . -59.12 -31.7 69.17 Favored 'General case' 0 C--O 1.219 -0.509 0 CA-C-N 115.615 -0.72 . . . . 0.0 112.298 -177.109 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 8.4 p-10 -85.17 9.68 14.35 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 121.282 0.563 . . . . 0.0 111.263 -174.673 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 50.2 tp -112.13 -33.01 6.37 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.519 -0.764 . . . . 0.0 109.182 173.667 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . 0.698 ' HB1' ' HB1' ' A' ' 71' ' ' ALA . . . -79.6 164.71 23.61 Favored 'General case' 0 N--CA 1.448 -0.548 0 CA-C-N 115.065 -0.97 . . . . 0.0 109.449 173.029 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 19.4 p -100.5 -176.99 3.36 Favored 'General case' 0 C--N 1.322 -0.626 0 C-N-CA 120.429 -0.509 . . . . 0.0 110.292 -179.997 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . 0.611 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 2.5 mtp180 -49.3 -52.63 26.47 Favored 'General case' 0 CA--C 1.512 -0.517 0 O-C-N 123.403 0.439 . . . . 0.0 111.178 -174.505 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 80' ' ' GLU . . . . . 0.55 ' HG3' ' OE2' ' A' ' 81' ' ' GLU . 11.7 pt-20 -58.39 -42.26 86.67 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.892 -174.806 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 81' ' ' GLU . . . . . 0.65 ' CG ' ' HB3' ' A' ' 70' ' ' TYR . 5.2 mp0 -63.5 -52.71 60.08 Favored 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 111.956 0.354 . . . . 0.0 111.956 174.186 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 82' ' ' GLN . . . . . 0.509 ' HA ' ' CZ3' ' A' ' 62' ' ' TRP . 40.7 mt-30 -59.7 -38.11 80.69 Favored 'General case' 0 CA--C 1.518 -0.268 0 CA-C-O 121.54 0.686 . . . . 0.0 110.097 -176.577 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . 0.737 HD12 ' HA3' ' A' ' 28' ' ' GLY . 31.7 mt -61.57 -49.51 84.09 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.843 0 CA-C-N 114.276 -1.329 . . . . 0.0 111.082 173.832 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . 0.637 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -62.67 -38.79 91.72 Favored 'General case' 0 N--CA 1.466 0.342 0 CA-C-O 121.195 0.522 . . . . 0.0 111.886 -176.08 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . 0.513 HG13 ' HB2' ' A' ' 65' ' ' ASN . 60.5 t -64.45 -47.73 88.13 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.495 175.853 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -59.44 -30.86 68.79 Favored 'General case' 0 N--CA 1.453 -0.282 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.051 174.497 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 87' ' ' GLU . . . . . 0.793 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 14.4 mm-40 -59.51 -44.31 93.17 Favored 'General case' 0 C--O 1.219 -0.51 0 CA-C-N 115.344 -0.844 . . . . 0.0 110.484 179.736 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.468 ' HB ' ' HB3' ' A' ' 65' ' ' ASN . 70.7 t -61.48 -49.92 82.46 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.404 0 CA-C-O 121.049 0.452 . . . . 0.0 110.574 -176.414 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 89' ' ' THR . . . . . 0.509 HG23 ' CH2' ' A' ' 98' ' ' TRP . 13.7 t -72.64 -33.76 66.82 Favored 'General case' 0 N--CA 1.438 -1.027 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.074 -176.482 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . 0.563 ' HG2' ' HA ' ' A' ' 87' ' ' GLU . 0.8 OUTLIER -60.33 -32.1 70.93 Favored 'General case' 0 N--CA 1.472 0.644 0 CA-C-O 121.176 0.512 . . . . 0.0 110.229 175.982 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . 0.793 ' HG ' ' O ' ' A' ' 87' ' ' GLU . 19.4 mt -62.51 -33.08 74.17 Favored 'General case' 0 C--N 1.317 -0.805 0 CA-C-O 121.428 0.632 . . . . 0.0 109.733 177.312 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . 0.46 ' NE ' ' HA ' ' A' ' 89' ' ' THR . 2.8 mtm180 -86.29 -52.63 5.51 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-N 115.068 -0.969 . . . . 0.0 110.911 -172.975 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -117.05 2.95 12.73 Favored 'General case' 0 N--CA 1.448 -0.533 0 C-N-CA 119.862 -0.735 . . . . 0.0 112.461 -174.076 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.434 ' HA2' ' O ' ' A' ' 90' ' ' ARG . . . 74.64 -119.98 6.27 Favored Glycine 0 CA--C 1.485 -1.786 0 N-CA-C 111.02 -0.832 . . . . 0.0 111.02 171.943 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 95' ' ' TRP . . . . . 0.445 ' HB3' ' CB ' ' A' ' 102' ' ' ALA . 3.4 m95 -127.57 31.65 5.13 Favored 'General case' 0 C--N 1.299 -1.62 0 N-CA-C 106.338 -1.727 . . . . 0.0 106.338 179.834 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -82.17 -25.92 50.15 Favored Glycine 0 N--CA 1.446 -0.666 0 CA-C-N 114.027 -1.442 . . . . 0.0 110.915 171.539 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -81.14 -23.3 38.41 Favored 'General case' 0 CA--C 1.515 -0.372 0 N-CA-C 109.663 -0.495 . . . . 0.0 109.663 174.352 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 98' ' ' TRP . . . . . 0.509 ' CH2' HG23 ' A' ' 89' ' ' THR . 23.7 m-90 -107.93 107.35 60.17 Favored Pre-proline 0 N--CA 1.448 -0.547 0 CA-C-N 115.776 -0.647 . . . . 0.0 109.909 177.071 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_exo -62.34 -137.01 0.0 OUTLIER 'Trans proline' 0 CA--C 1.535 0.526 0 C-N-CA 123.647 2.898 . . . . 0.0 114.119 -177.044 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 2.9 m -54.54 -28.24 18.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 115.88 -0.6 . . . . 0.0 112.152 -177.787 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 82.5 m -56.8 -39.23 73.75 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.263 178.933 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 102' ' ' ALA . . . . . 0.445 ' CB ' ' HB3' ' A' ' 95' ' ' TRP . . . -71.41 -43.94 65.84 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.845 0.355 . . . . 0.0 111.008 178.118 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -61.54 -44.57 96.8 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.851 -179.649 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -67.33 -19.41 65.45 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.728 -0.669 . . . . 0.0 111.159 177.279 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 105' ' ' ALA . . . . . 0.48 ' CB ' ' HB1' ' A' ' 33' ' ' ALA . . . -91.03 -21.15 21.4 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.913 -0.585 . . . . 0.0 111.606 -178.547 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 111.37 61.52 0.47 Allowed Glycine 0 CA--C 1.519 0.344 0 C-N-CA 121.087 -0.577 . . . . 0.0 111.967 -176.481 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -64.11 149.42 47.69 Favored 'General case' 0 C--N 1.328 -0.355 0 C-N-CA 122.878 0.471 . . . . 0.0 111.006 -176.716 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 74.0 mtp180 . . . . . 0 C--O 1.247 0.946 0 CA-C-O 118.503 -0.761 . . . . 0.0 109.912 -173.899 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 18.3 p-10 . . . . . 0 N--CA 1.48 1.063 0 CA-C-O 121.296 0.57 . . . . 0.0 110.562 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 46.3 t -86.85 -41.51 14.84 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 CA-C-N 115.784 -0.644 . . . . 0.0 109.487 179.027 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 11.6 p -72.21 138.51 21.4 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.856 0 CA-C-N 115.226 -0.897 . . . . 0.0 110.516 176.094 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . 0.519 ' O ' ' HD3' ' A' ' 6' ' ' PRO . 9.3 t -85.38 141.66 14.25 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.577 0 N-CA-C 108.911 -0.774 . . . . 0.0 108.911 176.255 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 16.4 p -104.22 101.94 29.64 Favored Pre-proline 0 C--N 1.318 -0.794 0 CA-C-O 121.057 0.456 . . . . 0.0 111.116 -177.465 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.519 ' HD3' ' O ' ' A' ' 4' ' ' VAL . 61.6 Cg_endo -103.2 169.15 0.22 Allowed 'Trans proline' 0 N--CA 1.444 -1.395 0 C-N-CA 124.09 3.193 . . . . 0.0 112.238 178.785 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -121.36 73.06 1.02 Allowed 'General case' 0 C--N 1.312 -1.027 0 CA-C-N 115.345 -0.843 . . . . 0.0 110.488 173.889 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 32.5 m170 -86.26 -14.79 42.74 Favored 'General case' 0 C--N 1.314 -0.949 0 CA-C-N 114.518 -1.219 . . . . 0.0 107.786 172.366 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 4.8 mt-10 -73.32 121.2 20.04 Favored 'General case' 0 CA--C 1.513 -0.477 0 CA-C-N 114.507 -1.224 . . . . 0.0 111.618 -177.337 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . 0.473 ' O ' HG11 ' A' ' 12' ' ' VAL . . . -153.05 65.24 0.78 Allowed 'General case' 0 C--N 1.316 -0.884 0 CA-C-N 115.272 -0.876 . . . . 0.0 109.152 173.466 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.415 HG12 ' N ' ' A' ' 12' ' ' VAL . 7.1 p -52.92 -49.67 47.43 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.692 0 CA-C-N 114.701 -1.136 . . . . 0.0 111.319 179.789 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.473 HG11 ' O ' ' A' ' 10' ' ' ALA . 7.6 p 29.68 85.26 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.344 0.35 0 C-N-CA 125.099 1.359 . . . . 0.0 113.74 177.676 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 9.5 ptm180 -85.37 112.22 20.64 Favored 'General case' 0 C--N 1.306 -1.286 0 CA-C-N 114.204 -1.362 . . . . 0.0 110.059 -179.403 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 3.0 t -115.97 161.9 14.38 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.5 0 CA-C-N 114.435 -1.257 . . . . 0.0 109.79 -178.261 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 109.3 53.79 0.59 Allowed Glycine 0 N--CA 1.441 -1.029 0 CA-C-N 114.867 -1.06 . . . . 0.0 111.581 178.975 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 8.8 m -91.27 -27.21 18.57 Favored 'General case' 0 C--N 1.31 -1.115 0 CA-C-N 114.075 -1.063 . . . . 0.0 110.254 179.895 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -74.77 116.31 52.49 Favored Pre-proline 0 C--N 1.314 -0.945 0 CA-C-N 113.972 -1.467 . . . . 0.0 110.987 -176.775 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -81.8 169.45 14.97 Favored 'Trans proline' 0 N--CA 1.453 -0.876 0 C-N-CA 123.502 2.801 . . . . 0.0 111.563 172.653 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -111.3 -33.5 2.31 Favored Glycine 0 C--N 1.306 -1.097 0 CA-C-N 114.337 -1.301 . . . . 0.0 111.028 178.953 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 23.1 m -64.43 -32.94 74.77 Favored 'General case' 0 C--N 1.315 -0.917 0 CA-C-N 114.281 -0.96 . . . . 0.0 111.174 178.669 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 45.2 mt-10 -131.87 138.82 48.59 Favored 'General case' 0 N--CA 1.441 -0.92 0 CA-C-N 115.885 -0.598 . . . . 0.0 109.921 -175.596 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 61.6 t -85.42 124.34 71.74 Favored Pre-proline 0 C--N 1.312 -1.062 0 CA-C-N 115.458 -0.792 . . . . 0.0 109.159 175.315 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -53.62 128.54 29.87 Favored 'Trans proline' 0 C--N 1.346 0.421 0 C-N-CA 122.887 2.391 . . . . 0.0 112.665 -176.198 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 10.6 Cg_endo -55.43 144.16 74.13 Favored 'Trans proline' 0 N--CA 1.459 -0.55 0 C-N-CA 123.725 2.95 . . . . 0.0 112.698 -179.285 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.815 HG21 HD13 ' A' ' 83' ' ' ILE . 14.8 p -85.0 125.69 40.34 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.981 0 CA-C-N 114.749 -1.114 . . . . 0.0 111.146 -177.253 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 42.9 mm -82.85 -31.42 9.15 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.638 0 CA-C-N 115.419 -0.809 . . . . 0.0 111.35 -179.11 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.582 ' O ' HG12 ' A' ' 30' ' ' ILE . 4.5 m-20 -106.9 6.27 29.13 Favored 'General case' 0 CA--C 1.507 -0.711 0 CA-C-O 121.62 0.724 . . . . 0.0 109.745 -172.947 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . 0.704 ' HA2' ' HB2' ' A' ' 31' ' ' TRP . . . -81.24 3.45 77.19 Favored Glycine 0 CA--C 1.494 -1.259 0 N-CA-C 110.863 -0.895 . . . . 0.0 110.863 -174.504 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 5.8 m -76.39 -48.2 20.65 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-O 121.727 0.775 . . . . 0.0 109.069 176.864 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.786 HG22 ' O ' ' A' ' 105' ' ' ALA . 4.0 pt -71.77 -34.78 52.92 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.182 0 CA-C-N 114.626 -1.17 . . . . 0.0 109.675 175.807 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' TRP . . . . . 0.704 ' HB2' ' HA2' ' A' ' 28' ' ' GLY . 6.5 m95 -66.26 -35.46 80.46 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.311 -0.858 . . . . 0.0 110.085 177.54 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.727 ' HB2' HH21 ' A' ' 79' ' ' ARG . 13.9 t70 -76.37 -34.42 58.92 Favored 'General case' 0 N--CA 1.449 -0.496 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.215 177.135 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . 0.413 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -65.67 -36.0 82.4 Favored 'General case' 0 N--CA 1.445 -0.683 0 C-N-CA 120.775 -0.37 . . . . 0.0 110.328 176.794 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . 0.492 ' HA ' ' HB3' ' A' ' 101' ' ' CYS . 10.0 mt -67.4 -44.09 87.24 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-O 120.895 0.379 . . . . 0.0 110.706 174.28 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . 0.479 ' HA ' ' O ' ' A' ' 54' ' ' GLY . . . -60.22 -34.13 73.23 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-O 121.464 0.65 . . . . 0.0 110.334 177.023 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -76.35 -18.97 78.81 Favored Glycine 0 N--CA 1.448 -0.551 0 CA-C-N 115.306 -0.861 . . . . 0.0 111.231 177.117 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 7.9 t -86.72 -57.1 3.11 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.238 -0.481 . . . . 0.0 111.536 -176.743 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . 0.868 ' HG2' ' SG ' ' A' ' 101' ' ' CYS . 15.6 mm-40 -87.77 -33.61 18.6 Favored 'General case' 0 CA--C 1.515 -0.39 0 CA-C-O 120.821 0.343 . . . . 0.0 111.078 -174.933 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . 0.476 ' HB1' ' O ' ' A' ' 35' ' ' ALA . . . -96.66 -11.31 25.37 Favored 'General case' 0 C--N 1.324 -0.511 0 C-N-CA 120.424 -0.511 . . . . 0.0 112.124 -173.891 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 80.3 8.28 87.73 Favored Glycine 0 CA--C 1.506 -0.53 0 N-CA-C 110.125 -1.19 . . . . 0.0 110.125 -177.291 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 87.62 56.24 2.16 Favored Glycine 0 N--CA 1.434 -1.455 0 CA-C-N 114.129 -1.036 . . . . 0.0 112.595 179.706 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 50.7 t30 -154.44 122.77 6.06 Favored 'General case' 0 CA--C 1.507 -0.71 0 N-CA-C 109.413 -0.588 . . . . 0.0 109.413 176.993 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' TRP . . . . . 0.713 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 26.3 m95 -96.25 -12.64 24.25 Favored 'General case' 0 C--N 1.308 -1.231 0 CA-C-N 115.055 -0.975 . . . . 0.0 110.415 -173.298 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -101.95 8.97 40.91 Favored 'General case' 0 C--N 1.318 -0.782 0 CA-C-N 115.367 -0.833 . . . . 0.0 110.786 -178.36 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.726 HG21 ' CA ' ' A' ' 53' ' ' GLY . 2.0 tt -72.87 144.22 13.12 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.769 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.006 179.249 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 47.6 t-20 -160.42 101.37 1.36 Allowed 'General case' 0 C--N 1.314 -0.972 0 N-CA-C 109.432 -0.581 . . . . 0.0 109.432 -179.525 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 23.4 p -82.89 -17.13 44.85 Favored 'General case' 0 N--CA 1.445 -0.724 0 CA-C-N 115.559 -0.746 . . . . 0.0 111.222 -178.974 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 91.33 22.19 32.77 Favored Glycine 0 N--CA 1.445 -0.745 0 N-CA-C 111.141 -0.784 . . . . 0.0 111.141 178.398 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 28.7 p-10 -93.67 11.38 29.18 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 121.2 0.524 . . . . 0.0 111.385 -175.904 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . 0.464 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 94.36 -11.38 70.41 Favored Glycine 0 N--CA 1.447 -0.576 0 C-N-CA 120.874 -0.679 . . . . 0.0 111.524 -178.486 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 51' ' ' TYR . . . . . 0.544 ' HA ' ' HA ' ' A' ' 58' ' ' ASP . 0.2 OUTLIER -114.64 162.62 16.54 Favored 'General case' 0 N--CA 1.447 -0.591 0 N-CA-C 107.787 -1.19 . . . . 0.0 107.787 176.94 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 52' ' ' TYR . . . . . 0.517 ' HB2' ' HB3' ' A' ' 74' ' ' ALA . 26.9 m-85 -127.9 169.68 13.67 Favored 'General case' 0 C--N 1.309 -1.191 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.046 -172.717 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.726 ' CA ' HG21 ' A' ' 45' ' ' ILE . . . -68.85 -170.68 6.56 Favored Glycine 0 N--CA 1.445 -0.719 0 N-CA-C 114.342 0.497 . . . . 0.0 114.342 -170.944 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . 0.675 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 75.49 -107.3 2.28 Favored Glycine 0 N--CA 1.44 -1.057 0 C-N-CA 120.984 -0.627 . . . . 0.0 111.856 179.248 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 2.1 t -88.56 9.61 2.29 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.655 0 CA-C-O 121.203 0.525 . . . . 0.0 110.357 -177.403 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 56' ' ' GLN . . . . . 0.63 ' HG3' ' HB3' ' A' ' 38' ' ' GLU . 7.7 mm-40 60.02 50.42 6.66 Favored 'General case' 0 N--CA 1.468 0.426 0 CA-C-N 115.197 -0.911 . . . . 0.0 112.66 174.513 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . 0.501 ' HZ ' ' CA ' ' A' ' 86' ' ' ALA . 49.9 m-85 -76.2 132.24 39.82 Favored 'General case' 0 CA--C 1.503 -0.861 0 CA-C-N 115.126 -0.943 . . . . 0.0 112.301 176.345 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.544 ' HA ' ' HA ' ' A' ' 51' ' ' TYR . 5.6 p-10 -72.54 153.76 41.15 Favored 'General case' 0 C--N 1.315 -0.897 0 C-N-CA 119.542 -0.863 . . . . 0.0 108.707 159.644 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.702 ' HA ' HE21 ' A' ' 59' ' ' GLN . 0.0 OUTLIER -54.92 -36.33 65.13 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-O 120.67 0.271 . . . . 0.0 111.482 -178.187 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -67.63 -49.67 48.33 Favored Glycine 0 C--O 1.226 -0.372 0 CA-C-N 116.046 -0.525 . . . . 0.0 112.445 -174.289 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 88.4 m -65.68 -41.4 92.46 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 121.366 0.603 . . . . 0.0 110.894 179.084 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 62' ' ' TRP . . . . . 0.455 ' CE2' ' HA3' ' A' ' 67' ' ' GLY . 56.5 t-105 -59.07 -48.91 79.87 Favored 'General case' 0 N--CA 1.444 -0.762 0 CA-C-N 115.104 -0.953 . . . . 0.0 109.467 177.144 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . 0.444 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 34.8 tt0 -68.18 -34.64 76.68 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 115.051 -0.977 . . . . 0.0 111.05 -178.604 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -64.43 -41.34 96.64 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.942 -0.572 . . . . 0.0 111.394 -175.914 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . 0.63 HD21 ' N ' ' A' ' 65' ' ' ASN . 0.7 OUTLIER -84.99 -8.63 58.65 Favored 'General case' 0 N--CA 1.451 -0.384 0 CA-C-O 121.109 0.48 . . . . 0.0 110.21 177.394 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 91.76 52.85 2.2 Favored Glycine 0 N--CA 1.451 -0.36 0 CA-C-N 115.762 -0.653 . . . . 0.0 113.15 172.627 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . 0.537 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -80.02 -26.46 55.57 Favored Glycine 0 N--CA 1.439 -1.121 0 C-N-CA 120.669 -0.777 . . . . 0.0 112.338 -178.599 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 0.992 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 7.6 mp -57.56 -23.0 48.14 Favored 'General case' 0 N--CA 1.45 -0.463 0 N-CA-C 113.272 0.841 . . . . 0.0 113.272 -173.256 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . 0.439 ' HG3' ' N ' ' A' ' 70' ' ' TYR . 1.1 ptp180 -70.39 -31.89 69.31 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-O 121.005 0.431 . . . . 0.0 110.044 176.829 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 70' ' ' TYR . . . . . 1.013 ' HB3' ' HG3' ' A' ' 81' ' ' GLU . 67.5 m-85 -81.39 -34.53 31.58 Favored 'General case' 0 CA--C 1.505 -0.766 0 N-CA-C 107.457 -1.312 . . . . 0.0 107.457 177.274 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.581 ' HB1' ' HB1' ' A' ' 77' ' ' ALA . . . 165.77 129.6 0.03 OUTLIER Pre-proline 0 C--O 1.218 -0.572 0 CA-C-N 112.272 -2.24 . . . . 0.0 107.259 -178.225 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 72' ' ' PRO . . . . . 0.992 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 7.0 Cg_exo -61.02 0.22 0.96 Allowed 'Trans proline' 0 C--N 1.331 -0.367 0 C-N-CA 122.786 2.324 . . . . 0.0 113.536 -177.318 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 73' ' ' ARG . . . . . 0.461 ' HB2' ' CD2' ' A' ' 52' ' ' TYR . 3.4 ptt180 -151.79 136.65 17.19 Favored 'General case' 0 N--CA 1.441 -0.923 0 N-CA-C 108.968 -0.753 . . . . 0.0 108.968 178.817 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . 0.517 ' HB3' ' HB2' ' A' ' 52' ' ' TYR . . . -56.05 -29.55 60.65 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 115.064 -0.971 . . . . 0.0 113.136 -177.081 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . 0.531 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 11.6 p-10 -83.54 -2.26 55.59 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 121.014 0.435 . . . . 0.0 111.205 -175.729 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.477 ' HB3' ' HB3' ' A' ' 71' ' ' ALA . 61.6 tp -101.51 -31.48 10.86 Favored 'General case' 0 C--N 1.322 -0.604 0 N-CA-C 108.536 -0.913 . . . . 0.0 108.536 172.103 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . 0.669 ' HB2' ' HB3' ' A' ' 81' ' ' GLU . . . -78.82 163.26 25.48 Favored 'General case' 0 N--CA 1.443 -0.825 0 CA-C-N 114.739 -1.118 . . . . 0.0 109.86 174.963 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 61.2 p -101.33 -174.59 2.64 Favored 'General case' 0 C--N 1.31 -1.149 0 CA-C-N 115.934 -0.575 . . . . 0.0 111.072 -176.956 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . 0.727 HH21 ' HB2' ' A' ' 32' ' ' ASP . 46.2 mtp180 -54.07 -54.44 39.29 Favored 'General case' 0 CA--C 1.515 -0.374 0 CA-C-O 120.759 0.314 . . . . 0.0 110.437 179.256 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 1.9 pm0 -60.19 -40.37 89.81 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.275 -0.875 . . . . 0.0 111.289 -176.52 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 81' ' ' GLU . . . . . 1.013 ' HG3' ' HB3' ' A' ' 70' ' ' TYR . 0.3 OUTLIER -62.62 -51.19 68.28 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.921 -0.582 . . . . 0.0 112.272 175.94 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 82' ' ' GLN . . . . . 0.607 ' HB2' ' HZ3' ' A' ' 43' ' ' TRP . 53.4 mt-30 -64.07 -35.83 82.01 Favored 'General case' 0 CA--C 1.515 -0.4 0 CA-C-O 121.103 0.478 . . . . 0.0 109.715 179.973 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . 0.815 HD13 HG21 ' A' ' 25' ' ' VAL . 14.7 mt -59.8 -45.43 94.79 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 CA-C-N 115.239 -0.891 . . . . 0.0 110.526 176.636 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . 0.473 ' O ' HG21 ' A' ' 88' ' ' VAL . . . -60.15 -44.29 95.08 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-O 121.209 0.528 . . . . 0.0 110.511 -178.449 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 67.5 t -69.1 -48.58 68.53 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.604 0 CA-C-N 115.428 -0.806 . . . . 0.0 111.493 179.341 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . 0.501 ' CA ' ' HZ ' ' A' ' 57' ' ' PHE . . . -62.6 -34.63 77.4 Favored 'General case' 0 CA--C 1.51 -0.584 0 CA-C-O 121.378 0.608 . . . . 0.0 110.536 179.891 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 87' ' ' GLU . . . . . 0.638 ' HA ' ' HG2' ' A' ' 90' ' ' ARG . 0.7 OUTLIER -71.49 -28.99 64.3 Favored 'General case' 0 C--N 1.315 -0.892 0 CA-C-N 115.525 -0.761 . . . . 0.0 109.965 -176.46 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.642 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 59.9 t -62.47 -42.56 96.19 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.191 0 N-CA-C 109.212 -0.662 . . . . 0.0 109.212 168.969 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 89' ' ' THR . . . . . 0.7 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 0.2 OUTLIER -71.96 -41.23 68.0 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 115.869 -0.605 . . . . 0.0 111.54 -174.445 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . 0.638 ' HG2' ' HA ' ' A' ' 87' ' ' GLU . 30.3 ptt180 -59.27 -36.87 76.3 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.657 -175.775 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . 0.642 ' HG ' ' O ' ' A' ' 88' ' ' VAL . 4.6 pp -74.88 -25.25 58.82 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.616 -0.72 . . . . 0.0 111.388 -170.087 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . 0.45 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 1.7 mtm180 -85.01 -46.24 11.38 Favored 'General case' 0 CA--C 1.511 -0.533 0 CA-C-O 121.513 0.673 . . . . 0.0 109.796 -176.113 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 16.6 pt20 -98.71 -29.45 13.01 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.15 -0.932 . . . . 0.0 113.01 -168.592 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 91.86 35.85 6.64 Favored Glycine 0 N--CA 1.446 -0.637 0 C-N-CA 120.167 -1.016 . . . . 0.0 111.355 175.459 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 95' ' ' TRP . . . . . 0.492 ' HA ' ' HE3' ' A' ' 98' ' ' TRP . 31.2 m95 68.3 22.66 7.97 Favored 'General case' 0 C--O 1.222 -0.378 0 CA-C-O 121.486 0.66 . . . . 0.0 110.027 177.186 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -70.11 -27.15 73.32 Favored Glycine 0 N--CA 1.449 -0.454 0 CA-C-N 115.135 -0.938 . . . . 0.0 112.35 175.519 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -75.45 -30.49 59.98 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.782 0.325 . . . . 0.0 110.58 177.242 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 98' ' ' TRP . . . . . 0.7 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 16.5 m-90 -103.8 104.76 44.55 Favored Pre-proline 0 C--N 1.324 -0.527 0 N-CA-C 109.706 -0.479 . . . . 0.0 109.706 179.972 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 17.5 Cg_exo -71.09 -93.12 0.01 OUTLIER 'Trans proline' 0 CA--C 1.537 0.645 0 C-N-CA 123.192 2.594 . . . . 0.0 114.523 -173.341 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . 0.468 ' O ' ' HD2' ' A' ' 104' ' ' ARG . 1.3 p -71.68 -27.57 28.54 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.391 0 CA-C-O 121.89 0.852 . . . . 0.0 109.781 -172.686 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 101' ' ' CYS . . . . . 0.868 ' SG ' ' HG2' ' A' ' 38' ' ' GLU . 33.2 m -65.74 -34.76 78.92 Favored 'General case' 0 C--N 1.318 -0.772 0 CA-C-N 114.313 -1.312 . . . . 0.0 111.056 -175.712 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 102' ' ' ALA . . . . . 0.589 ' HB2' ' HB3' ' A' ' 107' ' ' ALA . . . -65.53 -46.55 79.16 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-O 120.945 0.403 . . . . 0.0 110.146 -179.782 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -63.7 -40.59 97.16 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.282 0.563 . . . . 0.0 110.545 179.352 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 104' ' ' ARG . . . . . 0.468 ' HD2' ' O ' ' A' ' 100' ' ' VAL . 0.0 OUTLIER -71.9 -37.89 70.02 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.661 -0.7 . . . . 0.0 111.918 -179.346 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 105' ' ' ALA . . . . . 0.786 ' O ' HG22 ' A' ' 30' ' ' ILE . . . -82.37 -27.84 31.88 Favored 'General case' 0 C--N 1.329 -0.313 0 N-CA-C 112.009 0.374 . . . . 0.0 112.009 -176.166 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 109.4 67.02 0.58 Allowed Glycine 0 CA--C 1.522 0.486 0 C-N-CA 120.64 -0.791 . . . . 0.0 112.277 -173.741 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 107' ' ' ALA . . . . . 0.589 ' HB3' ' HB2' ' A' ' 102' ' ' ALA . . . -58.4 149.81 23.92 Favored 'General case' 0 C--N 1.324 -0.516 0 C-N-CA 123.586 0.754 . . . . 0.0 111.664 178.808 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 8.9 ptm180 . . . . . 0 C--O 1.247 0.945 0 CA-C-N 115.476 -0.783 . . . . 0.0 110.165 -173.168 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 16.0 m120 . . . . . 0 N--CA 1.474 0.752 0 CA-C-O 121.142 0.496 . . . . 0.0 109.847 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 10.5 p -81.94 -15.63 12.12 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.05 0 CA-C-N 115.505 -0.771 . . . . 0.0 109.851 178.696 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 5.4 p -66.07 96.96 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.788 0 CA-C-N 115.221 -0.899 . . . . 0.0 111.811 178.351 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 12.0 t -99.04 139.7 20.23 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.659 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 171.895 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' THR . . . . . 0.411 ' HA ' ' HD3' ' A' ' 6' ' ' PRO . 8.7 p -113.92 132.19 22.77 Favored Pre-proline 0 C--N 1.309 -1.177 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.599 -173.805 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.411 ' HD3' ' HA ' ' A' ' 5' ' ' THR . 9.4 Cg_exo -74.63 166.31 29.65 Favored 'Trans proline' 0 N--CA 1.45 -1.084 0 C-N-CA 123.24 2.627 . . . . 0.0 110.099 170.182 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . 57.79 -166.01 0.15 Allowed 'General case' 0 C--N 1.312 -1.023 0 CA-C-N 115.069 -0.969 . . . . 0.0 110.412 -172.742 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 18.9 t-80 64.11 10.42 5.43 Favored 'General case' 0 N--CA 1.465 0.293 0 CA-C-O 122.309 1.052 . . . . 0.0 108.764 -172.911 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 10.9 pt-20 -64.35 158.56 23.24 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-N 113.913 -1.494 . . . . 0.0 112.258 -178.918 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -150.17 81.06 1.37 Allowed 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 114.713 -1.13 . . . . 0.0 109.438 178.477 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 14.6 p -58.86 -31.82 45.81 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 CA-C-N 115.182 -0.917 . . . . 0.0 111.871 -178.333 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 6.0 p 34.27 84.11 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.343 0.309 0 CA-C-O 122.823 1.296 . . . . 0.0 113.119 -179.631 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 44.2 mtm180 -89.04 112.98 24.05 Favored 'General case' 0 N--CA 1.432 -1.352 0 CA-C-N 114.01 -1.45 . . . . 0.0 110.833 -177.475 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.8 t -97.55 162.09 2.73 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.204 0 CA-C-N 114.683 -1.144 . . . . 0.0 109.251 178.069 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 129.21 93.99 0.74 Allowed Glycine 0 C--N 1.305 -1.151 0 CA-C-N 115.158 -0.928 . . . . 0.0 111.672 179.66 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' THR . . . . . 0.483 ' HB ' ' HD3' ' A' ' 17' ' ' LYS . 36.9 m -81.54 -33.5 31.71 Favored 'General case' 0 N--CA 1.442 -0.833 0 CA-C-O 121.388 0.613 . . . . 0.0 111.675 -176.926 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . 0.483 ' HD3' ' HB ' ' A' ' 16' ' ' THR . 2.5 mppt? -112.59 97.52 40.9 Favored Pre-proline 0 C--N 1.315 -0.924 0 CA-C-N 115.541 -0.754 . . . . 0.0 110.599 -177.772 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . 0.442 ' HD3' ' O ' ' A' ' 16' ' ' THR . 2.2 Cg_endo -86.86 174.4 5.57 Favored 'Trans proline' 0 N--CA 1.449 -1.14 0 C-N-CA 123.204 2.603 . . . . 0.0 111.862 176.06 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 87.8 32.55 12.71 Favored Glycine 0 C--N 1.309 -0.924 0 CA-C-N 114.699 -1.137 . . . . 0.0 111.5 177.729 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 29.8 m -70.07 -30.29 67.5 Favored 'General case' 0 C--N 1.312 -1.054 0 CA-C-N 114.267 -0.966 . . . . 0.0 109.539 175.718 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 31.2 mt-10 -138.91 141.48 38.52 Favored 'General case' 0 N--CA 1.438 -1.043 0 N-CA-C 107.591 -1.263 . . . . 0.0 107.591 -179.678 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.744 HG13 ' HG3' ' A' ' 80' ' ' GLU . 30.3 t -73.32 125.01 91.08 Favored Pre-proline 0 C--N 1.312 -1.063 0 N-CA-C 109.464 -0.569 . . . . 0.0 109.464 178.366 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 51.0 Cg_exo -53.26 129.86 35.58 Favored 'Trans proline' 0 C--N 1.346 0.423 0 C-N-CA 123.223 2.615 . . . . 0.0 112.822 -173.729 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 10.7 Cg_endo -55.05 141.2 79.84 Favored 'Trans proline' 0 N--CA 1.457 -0.643 0 C-N-CA 123.576 2.851 . . . . 0.0 112.539 -178.853 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.779 HG22 HG23 ' A' ' 83' ' ' ILE . 13.3 p -89.09 127.83 41.56 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.082 0 CA-C-N 114.613 -1.176 . . . . 0.0 111.004 -177.89 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 37.2 mm -83.64 -26.13 7.61 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-N 115.788 -0.642 . . . . 0.0 111.643 -179.879 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.638 ' O ' HG12 ' A' ' 30' ' ' ILE . 2.5 m-20 -110.27 6.39 22.48 Favored 'General case' 0 CA--C 1.506 -0.737 0 CA-C-O 121.86 0.838 . . . . 0.0 109.297 -172.553 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . 0.557 ' HA2' ' HB2' ' A' ' 31' ' ' TRP . . . -79.81 3.81 68.12 Favored Glycine 0 N--CA 1.434 -1.45 0 CA-C-N 114.841 -1.072 . . . . 0.0 110.496 -174.829 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 19.9 t -77.06 -38.86 51.77 Favored 'General case' 0 C--N 1.318 -0.798 0 N-CA-C 108.701 -0.851 . . . . 0.0 108.701 173.456 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.813 ' HA ' ' HB2' ' A' ' 105' ' ' ALA . 0.0 OUTLIER -71.48 -36.66 61.39 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.669 0 N-CA-C 107.166 -1.42 . . . . 0.0 107.166 177.167 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' TRP . . . . . 0.557 ' HB2' ' HA2' ' A' ' 28' ' ' GLY . 14.6 m95 -75.05 -37.91 61.55 Favored 'General case' 0 N--CA 1.442 -0.826 0 CA-C-N 114.447 -1.252 . . . . 0.0 110.726 -176.863 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 23.2 t70 -78.44 -33.28 48.62 Favored 'General case' 0 N--CA 1.442 -0.846 0 CA-C-N 116.445 -0.343 . . . . 0.0 110.933 178.365 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . 0.454 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -68.52 -36.74 79.28 Favored 'General case' 0 N--CA 1.454 -0.26 0 C-N-CA 120.18 -0.608 . . . . 0.0 110.561 176.37 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . 0.491 HG23 ' CD1' ' A' ' 98' ' ' TRP . 79.7 mt -66.63 -46.22 86.54 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-O 120.761 0.315 . . . . 0.0 110.169 174.494 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . 0.413 ' O ' ' HB2' ' A' ' 39' ' ' ALA . . . -58.05 -34.62 70.29 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 121.292 0.568 . . . . 0.0 110.448 176.13 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . 0.518 ' HA2' ' N ' ' A' ' 41' ' ' GLY . . . -80.47 -11.23 84.38 Favored Glycine 0 N--CA 1.45 -0.429 0 CA-C-N 115.616 -0.72 . . . . 0.0 111.975 179.27 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 44.3 t -97.96 -50.75 4.29 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 120.643 0.259 . . . . 0.0 111.309 -176.991 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . 0.577 ' HG2' ' SG ' ' A' ' 101' ' ' CYS . 13.7 mt-10 -88.02 -31.85 19.1 Favored 'General case' 0 CA--C 1.513 -0.474 0 CA-C-O 120.906 0.384 . . . . 0.0 110.346 -175.403 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . 0.413 ' HB2' ' O ' ' A' ' 35' ' ' ALA . . . -103.17 -9.18 19.85 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.828 -177.904 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 77.97 9.92 86.59 Favored Glycine 0 CA--C 1.507 -0.432 0 N-CA-C 110.011 -1.236 . . . . 0.0 110.011 -177.586 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . 0.518 ' N ' ' HA2' ' A' ' 36' ' ' GLY . . . 85.9 59.25 1.9 Allowed Glycine 0 N--CA 1.435 -1.384 0 CA-C-N 114.049 -1.076 . . . . 0.0 111.337 -176.398 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . 0.594 ' HB3' ' HB ' ' A' ' 45' ' ' ILE . 1.8 t30 -140.46 89.3 2.27 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 109.215 -0.661 . . . . 0.0 109.215 -176.105 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' TRP . . . . . 0.62 ' HA ' ' N ' ' A' ' 54' ' ' GLY . 50.0 m95 -75.19 -7.83 54.92 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-O 121.563 0.697 . . . . 0.0 110.135 -176.506 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -104.73 9.51 35.01 Favored 'General case' 0 C--N 1.316 -0.867 0 CA-C-N 114.851 -1.068 . . . . 0.0 111.473 -179.637 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.899 HG23 ' HA2' ' A' ' 53' ' ' GLY . 9.7 tt -74.41 143.21 13.74 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.794 0 CA-C-O 121.194 0.521 . . . . 0.0 110.699 -176.862 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 15.3 t-20 -148.37 88.07 1.62 Allowed 'General case' 0 C--N 1.314 -0.958 0 CA-C-O 121.145 0.497 . . . . 0.0 109.681 179.177 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 5.1 p -72.45 -23.95 61.13 Favored 'General case' 0 C--N 1.319 -0.752 0 CA-C-N 115.297 -0.865 . . . . 0.0 111.129 -179.342 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 96.8 16.71 35.26 Favored Glycine 0 N--CA 1.448 -0.513 0 C-N-CA 120.951 -0.642 . . . . 0.0 111.552 178.79 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 12.0 m120 -79.93 2.72 22.36 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.807 0.337 . . . . 0.0 111.006 -175.397 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . 0.459 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 85.7 -3.87 86.55 Favored Glycine 0 N--CA 1.446 -0.678 0 N-CA-C 109.905 -1.278 . . . . 0.0 109.905 -168.396 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 51' ' ' TYR . . . . . 0.488 ' CE1' ' HB3' ' A' ' 58' ' ' ASP . 0.4 OUTLIER -109.09 155.72 20.64 Favored 'General case' 0 N--CA 1.45 -0.453 0 N-CA-C 107.036 -1.468 . . . . 0.0 107.036 177.94 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 52' ' ' TYR . . . . . 0.821 ' O ' ' HA ' ' A' ' 56' ' ' GLN . 47.3 m-85 -129.55 171.32 12.71 Favored 'General case' 0 C--N 1.317 -0.823 0 C-N-CA 120.266 -0.574 . . . . 0.0 112.536 -170.303 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.899 ' HA2' HG23 ' A' ' 45' ' ' ILE . . . -47.97 154.69 1.4 Allowed Glycine 0 N--CA 1.453 -0.172 0 N-CA-C 115.583 0.993 . . . . 0.0 115.583 -171.459 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . 0.62 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 97.79 -109.8 3.89 Favored Glycine 0 N--CA 1.442 -0.923 0 CA-C-N 114.653 -0.774 . . . . 0.0 111.708 176.631 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 1.9 m -84.58 -3.22 7.82 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 CA-C-O 121.681 0.753 . . . . 0.0 110.924 178.403 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 56' ' ' GLN . . . . . 0.821 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 6.1 tt0 55.29 51.4 13.14 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 113.855 -1.521 . . . . 0.0 113.803 168.12 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 1.6 p90 -109.85 172.53 6.8 Favored 'General case' 0 C--O 1.236 0.349 0 C-N-CA 119.731 -0.787 . . . . 0.0 111.533 173.928 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.488 ' HB3' ' CE1' ' A' ' 51' ' ' TYR . 6.8 p-10 -79.0 156.48 28.42 Favored 'General case' 0 C--N 1.329 -0.308 0 N-CA-C 113.733 1.012 . . . . 0.0 113.733 -161.499 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.668 ' HA ' HE21 ' A' ' 59' ' ' GLN . 0.0 OUTLIER -57.03 -38.58 73.38 Favored 'General case' 0 N--CA 1.449 -0.48 0 CA-C-N 113.492 -1.685 . . . . 0.0 111.579 178.805 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -67.38 -49.67 50.02 Favored Glycine 0 N--CA 1.44 -1.089 0 CA-C-N 115.881 -0.6 . . . . 0.0 112.182 -174.256 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 61' ' ' THR . . . . . 0.439 HG23 HG22 ' A' ' 89' ' ' THR . 91.6 m -65.8 -41.64 91.67 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 121.37 0.605 . . . . 0.0 110.425 176.405 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 62' ' ' TRP . . . . . 0.6 ' CH2' ' HA ' ' A' ' 74' ' ' ALA . 44.8 t-105 -56.27 -49.49 74.07 Favored 'General case' 0 N--CA 1.447 -0.615 0 CA-C-N 115.129 -0.941 . . . . 0.0 109.958 177.485 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . 0.64 ' HG3' HD11 ' A' ' 68' ' ' LEU . 18.3 tt0 -67.45 -36.47 81.25 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-N 114.907 -1.042 . . . . 0.0 110.77 -179.226 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -64.95 -41.52 95.41 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.657 -0.701 . . . . 0.0 111.059 -177.578 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . 0.617 ' HB2' HG12 ' A' ' 85' ' ' VAL . 8.4 m120 -81.68 -16.44 51.28 Favored 'General case' 0 C--N 1.325 -0.473 0 N-CA-C 109.557 -0.534 . . . . 0.0 109.557 177.991 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 97.01 45.48 2.61 Favored Glycine 0 N--CA 1.449 -0.442 0 CA-C-N 115.784 -0.643 . . . . 0.0 113.538 170.648 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -79.42 -24.47 60.85 Favored Glycine 0 N--CA 1.44 -1.037 0 N-CA-C 110.762 -0.935 . . . . 0.0 110.762 -179.543 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 0.642 ' HA ' ' HA ' ' A' ' 72' ' ' PRO . 19.1 mt -54.63 -25.77 28.75 Favored 'General case' 0 N--CA 1.449 -0.503 0 CA-C-O 121.365 0.602 . . . . 0.0 110.728 -176.3 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 8.4 ptm180 -71.98 -27.79 63.0 Favored 'General case' 0 N--CA 1.439 -0.996 0 CA-C-N 115.132 -0.94 . . . . 0.0 109.922 -175.835 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 70' ' ' TYR . . . . . 0.768 ' HB2' ' OE2' ' A' ' 81' ' ' GLU . 10.4 m-85 -94.13 -33.25 13.41 Favored 'General case' 0 N--CA 1.433 -1.308 0 N-CA-C 106.625 -1.62 . . . . 0.0 106.625 177.566 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.915 ' HB1' ' HB3' ' A' ' 76' ' ' LEU . . . 179.16 122.38 0.21 Allowed Pre-proline 0 N--CA 1.447 -0.621 0 CA-C-N 113.422 -1.717 . . . . 0.0 108.754 -178.589 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 72' ' ' PRO . . . . . 0.642 ' HA ' ' HA ' ' A' ' 68' ' ' LEU . 11.9 Cg_exo -61.2 1.58 0.62 Allowed 'Trans proline' 0 CA--C 1.528 0.216 0 C-N-CA 122.683 2.255 . . . . 0.0 113.293 179.417 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 73' ' ' ARG . . . . . 0.506 ' HB2' ' CD2' ' A' ' 52' ' ' TYR . 15.1 ptm180 -151.28 138.2 19.02 Favored 'General case' 0 C--N 1.316 -0.889 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 175.236 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . 0.6 ' HA ' ' CH2' ' A' ' 62' ' ' TRP . . . -58.36 -28.53 65.22 Favored 'General case' 0 C--O 1.218 -0.561 0 CA-C-N 115.543 -0.753 . . . . 0.0 112.584 -174.082 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 11.3 p-10 -87.95 10.15 19.81 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-O 121.062 0.458 . . . . 0.0 111.009 -176.393 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.915 ' HB3' ' HB1' ' A' ' 71' ' ' ALA . 41.6 tp -101.03 -40.16 7.36 Favored 'General case' 0 N--CA 1.45 -0.447 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.121 176.352 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . 0.856 ' HB2' ' HG2' ' A' ' 81' ' ' GLU . . . -103.84 168.81 8.89 Favored 'General case' 0 N--CA 1.447 -0.596 0 CA-C-O 121.108 0.48 . . . . 0.0 110.467 176.757 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 78' ' ' THR . . . . . 0.541 ' HG1' ' CD ' ' A' ' 80' ' ' GLU . 43.6 p -90.17 -177.96 5.28 Favored 'General case' 0 C--N 1.315 -0.918 0 CA-C-N 115.676 -0.693 . . . . 0.0 112.785 -167.303 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . 0.589 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 5.0 mtp180 -49.27 -48.83 45.68 Favored 'General case' 0 CA--C 1.513 -0.457 0 C-N-CA 123.94 0.896 . . . . 0.0 111.782 -171.899 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 80' ' ' GLU . . . . . 0.744 ' HG3' HG13 ' A' ' 22' ' ' VAL . 2.3 pm0 -60.53 -30.31 69.67 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.567 -0.742 . . . . 0.0 111.74 -175.957 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 81' ' ' GLU . . . . . 0.856 ' HG2' ' HB2' ' A' ' 77' ' ' ALA . 0.0 OUTLIER -71.71 -50.38 30.8 Favored 'General case' 0 N--CA 1.449 -0.485 0 C-N-CA 120.934 -0.306 . . . . 0.0 110.311 176.011 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 82' ' ' GLN . . . . . 0.739 ' N ' ' HG3' ' A' ' 81' ' ' GLU . 4.6 mt-30 -59.64 -35.47 74.47 Favored 'General case' 0 CA--C 1.508 -0.661 0 N-CA-C 109.336 -0.616 . . . . 0.0 109.336 -179.851 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . 0.779 HG23 HG22 ' A' ' 25' ' ' VAL . 21.8 mt -61.37 -47.2 94.53 Favored 'Isoleucine or valine' 0 C--O 1.212 -0.92 0 CA-C-N 114.824 -1.08 . . . . 0.0 110.527 175.755 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . 0.635 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -61.03 -43.92 98.17 Favored 'General case' 0 C--O 1.239 0.527 0 CA-C-O 121.378 0.608 . . . . 0.0 111.462 -176.555 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . 0.617 HG12 ' HB2' ' A' ' 65' ' ' ASN . 22.1 t -69.1 -48.47 69.06 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-N 115.927 -0.578 . . . . 0.0 110.549 179.551 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -57.66 -28.68 63.96 Favored 'General case' 0 C--O 1.223 -0.311 0 CA-C-N 115.868 -0.606 . . . . 0.0 110.618 173.925 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 87' ' ' GLU . . . . . 0.669 ' HG2' ' O ' ' A' ' 83' ' ' ILE . 6.6 mm-40 -59.76 -44.87 93.65 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.955 -0.566 . . . . 0.0 109.65 178.166 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.707 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 46.4 t -69.59 -42.34 80.57 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 C-N-CA 120.573 -0.451 . . . . 0.0 110.02 175.58 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 89' ' ' THR . . . . . 0.834 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 2.6 m -59.81 -48.09 83.07 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 116.43 -0.35 . . . . 0.0 111.443 -178.898 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . 0.648 ' HA ' ' OE1' ' A' ' 93' ' ' GLN . 7.9 ptt180 -65.67 -34.19 77.64 Favored 'General case' 0 CA--C 1.517 -0.31 0 CA-C-O 120.941 0.4 . . . . 0.0 111.421 -174.874 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . 0.707 ' HG ' ' O ' ' A' ' 88' ' ' VAL . 4.6 pp -70.52 -22.26 62.65 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.892 -174.143 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . 0.555 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 9.8 mtm180 -84.98 -52.28 6.09 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -178.698 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 93' ' ' GLN . . . . . 0.648 ' OE1' ' HA ' ' A' ' 90' ' ' ARG . 0.0 OUTLIER -96.78 -24.75 15.77 Favored 'General case' 0 CA--C 1.539 0.53 0 N-CA-C 113.602 0.964 . . . . 0.0 113.602 -169.275 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 80.51 50.83 5.17 Favored Glycine 0 CA--C 1.507 -0.414 0 C-N-CA 120.728 -0.749 . . . . 0.0 111.783 176.762 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 95' ' ' TRP . . . . . 0.452 ' HA ' ' HE3' ' A' ' 98' ' ' TRP . 1.4 m95 56.61 29.2 15.21 Favored 'General case' 0 C--O 1.223 -0.3 0 CA-C-O 121.582 0.706 . . . . 0.0 109.754 177.355 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.638 ' H ' ' HG2' ' A' ' 93' ' ' GLN . . . -83.93 -24.78 47.74 Favored Glycine 0 N--CA 1.449 -0.439 0 CA-C-N 115.314 -0.857 . . . . 0.0 111.87 174.912 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -80.9 -23.88 38.65 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 121.238 0.542 . . . . 0.0 109.685 176.423 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 98' ' ' TRP . . . . . 0.834 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 23.4 m-90 -101.01 108.01 52.52 Favored Pre-proline 0 N--CA 1.445 -0.708 0 N-CA-C 108.59 -0.893 . . . . 0.0 108.59 175.63 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . 0.433 ' HD3' ' HA ' ' A' ' 98' ' ' TRP . 45.0 Cg_exo -63.7 -133.68 0.0 OUTLIER 'Trans proline' 0 CA--C 1.541 0.828 0 C-N-CA 123.654 2.903 . . . . 0.0 113.991 -175.928 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 41.8 t -55.22 -25.56 16.99 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.287 0 CA-C-O 120.886 0.374 . . . . 0.0 111.637 -175.116 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 101' ' ' CYS . . . . . 0.577 ' SG ' ' HG2' ' A' ' 38' ' ' GLU . 85.1 m -63.99 -25.66 68.23 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 116.315 -0.402 . . . . 0.0 111.686 -178.25 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -69.36 -44.63 71.17 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.922 0.392 . . . . 0.0 110.368 177.704 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -67.42 -36.63 81.63 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 121.19 0.519 . . . . 0.0 110.142 178.554 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 9.8 mmm180 -64.73 -32.56 74.29 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.352 -0.84 . . . . 0.0 110.937 176.844 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 105' ' ' ALA . . . . . 0.813 ' HB2' ' HA ' ' A' ' 30' ' ' ILE . . . -89.01 -22.46 22.97 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 116.136 -0.484 . . . . 0.0 112.085 -176.076 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 103.18 68.04 0.77 Allowed Glycine 0 CA--C 1.521 0.445 0 C-N-CA 120.97 -0.633 . . . . 0.0 112.313 -177.794 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -64.45 152.71 40.88 Favored 'General case' 0 N--CA 1.45 -0.452 0 C-N-CA 122.856 0.462 . . . . 0.0 111.256 -176.063 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 25.5 mmt180 . . . . . 0 C--O 1.248 0.987 0 CA-C-O 118.289 -0.862 . . . . 0.0 111.56 177.64 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 26.2 p-10 . . . . . 0 N--CA 1.473 0.683 0 CA-C-O 121.909 0.862 . . . . 0.0 110.849 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 48.9 t -73.59 -49.37 36.36 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.981 0 N-CA-C 108.434 -0.95 . . . . 0.0 108.434 173.301 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 62.1 t -97.19 132.74 41.05 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.033 0 CA-C-N 115.001 -1.0 . . . . 0.0 109.14 172.671 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 8.0 t -85.39 142.61 12.98 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 CA-C-O 120.766 0.317 . . . . 0.0 110.165 -178.669 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' THR . . . . . 0.43 ' HA ' ' HD3' ' A' ' 6' ' ' PRO . 11.8 p -105.76 109.12 62.87 Favored Pre-proline 0 C--N 1.318 -0.804 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.926 -179.613 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.43 ' HD3' ' HA ' ' A' ' 5' ' ' THR . 17.9 Cg_endo -92.4 160.04 3.03 Favored 'Trans proline' 0 N--CA 1.441 -1.561 0 C-N-CA 123.223 2.615 . . . . 0.0 111.746 178.644 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . 0.553 ' C ' ' H ' ' A' ' 9' ' ' GLU . . . 53.33 -157.42 0.17 Allowed 'General case' 0 C--N 1.317 -0.811 0 CA-C-N 114.739 -1.119 . . . . 0.0 111.579 -178.297 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . 0.428 ' HB3' ' O ' ' A' ' 7' ' ' ALA . 80.2 t60 71.52 -21.16 0.22 Allowed 'General case' 0 C--O 1.235 0.293 0 O-C-N 123.703 0.627 . . . . 0.0 110.092 -171.772 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . 0.553 ' H ' ' C ' ' A' ' 7' ' ' ALA . 12.7 pt-20 -104.47 147.26 27.77 Favored 'General case' 0 N--CA 1.442 -0.873 0 CA-C-O 121.084 0.468 . . . . 0.0 110.819 -179.276 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -126.0 74.35 1.42 Allowed 'General case' 0 C--N 1.32 -0.679 0 CA-C-O 121.664 0.745 . . . . 0.0 109.808 -177.191 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.648 HG11 ' HG3' ' A' ' 13' ' ' ARG . 53.9 t -59.93 -57.36 12.06 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.97 0 CA-C-N 114.243 -1.344 . . . . 0.0 111.026 179.306 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 4.9 p 34.33 86.7 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.237 0.443 0 CA-C-O 122.73 1.252 . . . . 0.0 113.445 -179.211 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . 0.648 ' HG3' HG11 ' A' ' 11' ' ' VAL . 23.0 mtm180 -112.12 112.03 23.35 Favored 'General case' 0 C--N 1.312 -1.041 0 CA-C-N 114.105 -1.407 . . . . 0.0 110.824 -179.209 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 3.4 t -112.38 165.0 7.65 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.924 0 CA-C-N 114.856 -1.065 . . . . 0.0 108.744 178.576 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 143.43 94.71 0.2 Allowed Glycine 0 N--CA 1.439 -1.104 0 CA-C-N 115.674 -0.694 . . . . 0.0 112.406 178.97 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -64.52 -67.31 0.44 Allowed 'General case' 0 N--CA 1.446 -0.644 0 CA-C-O 121.025 0.441 . . . . 0.0 110.495 179.16 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 40.5 mmtm 33.83 79.06 0.29 Allowed Pre-proline 0 C--N 1.326 -0.455 0 CA-C-N 113.829 -1.532 . . . . 0.0 113.386 177.754 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 5.7 Cg_exo -75.32 164.56 32.53 Favored 'Trans proline' 0 N--CA 1.455 -0.746 0 C-N-CA 122.654 2.236 . . . . 0.0 111.666 177.765 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 67.59 43.69 84.96 Favored Glycine 0 C--N 1.307 -1.033 0 CA-C-N 114.499 -1.228 . . . . 0.0 111.256 -177.233 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -62.3 -50.63 70.91 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 114.7 -0.75 . . . . 0.0 110.814 -177.11 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 44.6 mt-10 -140.67 135.7 31.91 Favored 'General case' 0 N--CA 1.445 -0.702 0 N-CA-C 108.688 -0.856 . . . . 0.0 108.688 177.025 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 60.7 t -94.5 118.52 66.94 Favored Pre-proline 0 C--N 1.316 -0.852 0 CA-C-N 115.924 -0.58 . . . . 0.0 111.255 -175.284 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_exo -55.22 142.95 77.35 Favored 'Trans proline' 0 C--N 1.345 0.363 0 C-N-CA 123.341 2.694 . . . . 0.0 112.174 176.064 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 9.6 Cg_endo -54.84 148.28 47.11 Favored 'Trans proline' 0 C--N 1.346 0.401 0 C-N-CA 123.815 3.01 . . . . 0.0 113.916 -178.958 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.534 ' HB ' ' HA3' ' A' ' 28' ' ' GLY . 78.3 t -111.22 158.6 11.66 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.82 0 CA-C-N 113.722 -1.581 . . . . 0.0 109.207 -178.395 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 48.1 mm -54.98 -36.7 39.37 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-O 120.739 0.304 . . . . 0.0 111.812 -175.939 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.441 ' O ' HG13 ' A' ' 30' ' ' ILE . 48.6 m-20 -104.14 -12.25 16.83 Favored 'General case' 0 CA--C 1.503 -0.838 0 CA-C-O 122.316 1.055 . . . . 0.0 108.817 175.386 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . 0.625 ' HA2' ' HB2' ' A' ' 31' ' ' TRP . . . -72.15 -2.7 54.29 Favored Glycine 0 N--CA 1.442 -0.923 0 CA-C-N 113.677 -1.602 . . . . 0.0 111.555 -176.637 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 6.3 p -78.02 -48.09 16.96 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-O 122.049 0.928 . . . . 0.0 109.568 174.677 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.736 ' HA ' ' HB2' ' A' ' 105' ' ' ALA . 0.1 OUTLIER -62.89 -35.64 72.11 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.971 0 CA-C-N 113.392 -1.731 . . . . 0.0 107.713 175.691 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' TRP . . . . . 0.625 ' HB2' ' HA2' ' A' ' 28' ' ' GLY . 18.5 m95 -73.58 -36.91 65.61 Favored 'General case' 0 C--N 1.317 -0.817 0 CA-C-N 114.301 -1.318 . . . . 0.0 110.821 -178.092 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 1.6 t70 -77.92 -34.39 51.37 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.596 179.671 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . 0.45 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -70.07 -34.28 72.98 Favored 'General case' 0 N--CA 1.45 -0.474 0 C-N-CA 120.877 -0.329 . . . . 0.0 110.339 176.584 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . 0.51 HG13 ' O ' ' A' ' 30' ' ' ILE . 54.0 mt -65.12 -45.1 95.19 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.225 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 172.311 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . 0.544 ' HA ' ' O ' ' A' ' 54' ' ' GLY . . . -57.59 -36.41 71.68 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.228 176.613 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -73.92 -21.12 79.57 Favored Glycine 0 N--CA 1.451 -0.328 0 CA-C-N 115.574 -0.739 . . . . 0.0 112.237 178.886 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 18.5 t -93.75 -52.9 4.24 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-O 121.038 0.447 . . . . 0.0 111.811 -176.593 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 9.3 tp10 -87.58 -32.3 19.41 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 121.399 0.619 . . . . 0.0 110.107 -171.667 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . 0.417 ' HB3' ' O ' ' A' ' 35' ' ' ALA . . . -101.51 -13.57 17.85 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 115.644 -0.707 . . . . 0.0 111.616 -177.805 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 80.1 13.08 82.54 Favored Glycine 0 CA--C 1.505 -0.555 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 -176.808 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 81.03 58.83 2.55 Favored Glycine 0 N--CA 1.436 -1.319 0 CA-C-N 114.143 -1.028 . . . . 0.0 111.965 -177.569 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . 0.798 ' HB3' ' HB ' ' A' ' 45' ' ' ILE . 2.0 t30 -151.44 97.34 2.39 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 108.73 -0.841 . . . . 0.0 108.73 -178.229 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' TRP . . . . . 0.716 ' HZ3' ' HB2' ' A' ' 82' ' ' GLN . 49.8 m95 -75.51 -17.03 60.22 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-O 121.49 0.662 . . . . 0.0 110.495 -176.348 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -101.2 14.31 32.36 Favored 'General case' 0 C--N 1.313 -0.995 0 CA-C-N 115.007 -0.997 . . . . 0.0 110.693 -179.451 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.798 ' HB ' ' HB3' ' A' ' 42' ' ' ASN . 6.2 tt -77.44 143.26 13.1 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.951 0 CA-C-O 121.083 0.468 . . . . 0.0 109.759 -178.487 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . 0.576 ' ND2' HH21 ' A' ' 73' ' ' ARG . 29.3 t-20 -145.54 89.1 1.89 Allowed 'General case' 0 C--N 1.304 -1.399 0 CA-C-O 121.814 0.816 . . . . 0.0 108.994 179.369 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 2.6 p -67.98 -22.03 65.03 Favored 'General case' 0 N--CA 1.443 -0.81 0 CA-C-N 114.091 -1.413 . . . . 0.0 111.142 -178.418 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 90.03 23.45 32.45 Favored Glycine 0 N--CA 1.441 -0.984 0 N-CA-C 111.112 -0.795 . . . . 0.0 111.112 178.109 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . 0.482 HD21 ' H ' ' A' ' 51' ' ' TYR . 0.3 OUTLIER -101.58 15.42 28.95 Favored 'General case' 0 C--N 1.326 -0.426 0 N-CA-C 112.384 0.513 . . . . 0.0 112.384 -177.214 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . 0.411 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 93.48 -10.91 72.39 Favored Glycine 0 CA--C 1.509 -0.309 0 N-CA-C 111.401 -0.68 . . . . 0.0 111.401 177.608 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 51' ' ' TYR . . . . . 0.543 ' CD1' ' HB2' ' A' ' 58' ' ' ASP . 0.1 OUTLIER -118.79 149.28 41.76 Favored 'General case' 0 N--CA 1.445 -0.713 0 N-CA-C 106.434 -1.691 . . . . 0.0 106.434 -177.566 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 52' ' ' TYR . . . . . 0.649 ' O ' ' HA ' ' A' ' 56' ' ' GLN . 22.4 m-85 -119.56 170.9 8.76 Favored 'General case' 0 C--N 1.309 -1.18 0 C-N-CA 119.921 -0.711 . . . . 0.0 112.183 -169.298 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.757 ' HA2' HG22 ' A' ' 45' ' ' ILE . . . -57.56 167.64 5.07 Favored Glycine 0 N--CA 1.449 -0.493 0 N-CA-C 115.939 1.136 . . . . 0.0 115.939 -166.115 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . 0.64 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 86.62 -102.08 2.7 Favored Glycine 0 N--CA 1.437 -1.296 0 CA-C-N 114.202 -0.999 . . . . 0.0 111.541 178.247 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.684 HG22 ' HB3' ' A' ' 82' ' ' GLN . 3.1 m -85.4 -2.85 7.91 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.737 0 CA-C-O 120.434 0.159 . . . . 0.0 111.329 -179.586 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 56' ' ' GLN . . . . . 0.649 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 8.9 tp-100 52.78 52.94 12.96 Favored 'General case' 0 CA--C 1.534 0.339 0 N-CA-C 113.481 0.919 . . . . 0.0 113.481 166.17 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -120.57 163.33 18.16 Favored 'General case' 0 C--N 1.327 -0.379 0 C-N-CA 119.862 -0.735 . . . . 0.0 111.366 170.996 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.543 ' HB2' ' CD1' ' A' ' 51' ' ' TYR . 0.0 OUTLIER -73.6 155.1 39.44 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 114.799 -1.092 . . . . 0.0 113.365 -164.565 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.737 ' HA ' HE21 ' A' ' 59' ' ' GLN . 0.0 OUTLIER -53.3 -39.98 64.4 Favored 'General case' 0 N--CA 1.451 -0.402 0 CA-C-N 114.078 -1.419 . . . . 0.0 112.303 -179.905 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -68.39 -49.45 45.04 Favored Glycine 0 C--O 1.225 -0.441 0 CA-C-N 115.921 -0.582 . . . . 0.0 112.03 -177.264 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 32.8 m -65.64 -38.18 88.63 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-O 121.461 0.648 . . . . 0.0 110.26 176.105 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 62' ' ' TRP . . . . . 0.571 ' CH2' ' HA ' ' A' ' 74' ' ' ALA . 39.1 t-105 -56.67 -48.89 76.61 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 115.32 -0.854 . . . . 0.0 109.643 173.9 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . 0.563 ' CB ' HD11 ' A' ' 68' ' ' LEU . 60.6 tt0 -67.07 -33.97 76.66 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-N 114.876 -1.056 . . . . 0.0 110.943 179.359 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -63.04 -42.03 99.65 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.796 -0.638 . . . . 0.0 111.366 -177.81 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 33.0 m-80 -86.64 -11.76 50.44 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.977 0.418 . . . . 0.0 110.303 177.809 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . 0.413 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 92.93 52.38 2.1 Favored Glycine 0 C--O 1.22 -0.743 0 CA-C-N 115.858 -0.61 . . . . 0.0 114.043 170.533 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . 0.47 ' HA3' ' CE2' ' A' ' 62' ' ' TRP . . . -80.28 -27.95 50.43 Favored Glycine 0 N--CA 1.441 -0.967 0 C-N-CA 120.666 -0.778 . . . . 0.0 112.629 179.694 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 0.637 ' HA ' ' HA ' ' A' ' 72' ' ' PRO . 2.4 mp -59.3 -20.51 55.04 Favored 'General case' 0 CA--C 1.519 -0.241 0 CA-C-O 120.864 0.364 . . . . 0.0 111.923 -170.084 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . 0.413 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 9.1 ptp180 -72.55 -28.1 62.63 Favored 'General case' 0 N--CA 1.44 -0.944 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.225 -179.155 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 70' ' ' TYR . . . . . 0.699 ' HB2' ' CD ' ' A' ' 81' ' ' GLU . 10.5 m-85 -92.26 -33.29 14.71 Favored 'General case' 0 N--CA 1.433 -1.316 0 N-CA-C 106.683 -1.599 . . . . 0.0 106.683 176.894 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.651 ' HB2' ' HB3' ' A' ' 76' ' ' LEU . . . 175.34 126.86 0.13 Allowed Pre-proline 0 N--CA 1.45 -0.443 0 CA-C-N 113.005 -1.907 . . . . 0.0 108.494 179.107 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 72' ' ' PRO . . . . . 0.637 ' HA ' ' HA ' ' A' ' 68' ' ' LEU . 6.1 Cg_exo -62.46 3.86 0.42 Allowed 'Trans proline' 0 C--N 1.333 -0.272 0 C-N-CA 122.717 2.278 . . . . 0.0 113.709 -178.987 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 73' ' ' ARG . . . . . 0.576 HH21 ' ND2' ' A' ' 46' ' ' ASN . 11.0 ptm180 -154.53 142.51 20.17 Favored 'General case' 0 C--N 1.316 -0.877 0 N-CA-C 108.988 -0.745 . . . . 0.0 108.988 177.302 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . 0.571 ' HA ' ' CH2' ' A' ' 62' ' ' TRP . . . -61.69 -29.45 70.1 Favored 'General case' 0 C--O 1.219 -0.508 0 CA-C-N 115.935 -0.575 . . . . 0.0 112.284 -176.675 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 18.6 p-10 -86.44 12.01 11.2 Favored 'General case' 0 C--N 1.317 -0.836 0 CA-C-O 121.168 0.508 . . . . 0.0 111.032 -175.091 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.651 ' HB3' ' HB2' ' A' ' 71' ' ' ALA . 39.6 tp -108.38 -43.58 4.3 Favored 'General case' 0 N--CA 1.449 -0.5 0 CA-C-N 115.586 -0.734 . . . . 0.0 110.429 175.39 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . 0.67 ' HB1' ' HG2' ' A' ' 81' ' ' GLU . . . -99.06 167.85 10.45 Favored 'General case' 0 N--CA 1.449 -0.475 0 CA-C-O 121.58 0.705 . . . . 0.0 111.079 178.767 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 78' ' ' THR . . . . . 0.417 ' OG1' ' HG2' ' A' ' 80' ' ' GLU . 27.6 p -91.78 178.73 5.82 Favored 'General case' 0 C--N 1.316 -0.877 0 CA-C-N 115.002 -0.999 . . . . 0.0 112.69 -167.564 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . 0.659 ' HG2' ' CE2' ' A' ' 43' ' ' TRP . 64.5 mtp180 -45.89 -42.9 13.2 Favored 'General case' 0 N--CA 1.469 0.501 0 C-N-CA 123.523 0.729 . . . . 0.0 111.88 -174.779 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 80' ' ' GLU . . . . . 0.421 ' HG3' ' N ' ' A' ' 81' ' ' GLU . 7.4 pt-20 -57.19 -37.57 72.37 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 115.738 -0.665 . . . . 0.0 111.002 -177.423 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 81' ' ' GLU . . . . . 0.699 ' CD ' ' HB2' ' A' ' 70' ' ' TYR . 0.0 OUTLIER -72.03 -49.48 36.49 Favored 'General case' 0 N--CA 1.444 -0.731 0 CA-C-N 116.665 -0.243 . . . . 0.0 110.65 -179.238 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 82' ' ' GLN . . . . . 0.716 ' HB2' ' HZ3' ' A' ' 43' ' ' TRP . 9.4 mp0 -61.97 -32.38 72.82 Favored 'General case' 0 CA--C 1.509 -0.61 0 C-N-CA 120.343 -0.543 . . . . 0.0 110.198 -179.276 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . 0.681 ' O ' ' HB3' ' A' ' 87' ' ' GLU . 40.7 mt -64.37 -46.05 94.17 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.753 0 CA-C-N 115.459 -0.791 . . . . 0.0 109.788 176.598 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . 0.466 ' O ' ' HG3' ' A' ' 87' ' ' GLU . . . -66.12 -48.22 71.57 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 121.038 0.447 . . . . 0.0 111.649 -176.7 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 47.2 t -69.58 -48.35 66.42 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.577 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.874 -175.414 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . 0.448 ' HB1' ' CZ2' ' A' ' 98' ' ' TRP . . . -66.56 -30.15 70.38 Favored 'General case' 0 N--CA 1.444 -0.728 0 CA-C-O 121.026 0.441 . . . . 0.0 110.234 179.682 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 87' ' ' GLU . . . . . 0.681 ' HB3' ' O ' ' A' ' 83' ' ' ILE . 0.4 OUTLIER -70.44 -30.19 66.97 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.774 -177.138 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.665 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 59.1 t -61.29 -42.38 93.34 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.284 0 N-CA-C 108.812 -0.81 . . . . 0.0 108.812 170.732 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 89' ' ' THR . . . . . 0.849 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 0.2 OUTLIER -67.25 -43.83 80.91 Favored 'General case' 0 C--N 1.316 -0.872 0 CA-C-N 115.517 -0.765 . . . . 0.0 110.631 -179.45 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . 0.582 ' HG3' ' O ' ' A' ' 87' ' ' GLU . 3.0 ppt_? -63.25 -34.37 77.52 Favored 'General case' 0 CA--C 1.517 -0.295 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.764 -177.512 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . 0.665 ' HG ' ' O ' ' A' ' 88' ' ' VAL . 4.4 pp -73.5 -23.7 60.08 Favored 'General case' 0 C--N 1.322 -0.588 0 O-C-N 123.312 0.383 . . . . 0.0 110.949 -171.387 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . 0.533 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 4.6 mtm180 -84.3 -48.5 9.66 Favored 'General case' 0 CA--C 1.512 -0.511 0 CA-C-O 121.516 0.674 . . . . 0.0 109.628 -178.386 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 93' ' ' GLN . . . . . 0.538 ' NE2' HG21 ' A' ' 89' ' ' THR . 21.7 pt20 -98.47 -28.47 13.59 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 114.967 -1.015 . . . . 0.0 113.285 -169.1 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 92.54 40.1 5.13 Favored Glycine 0 CA--C 1.509 -0.323 0 C-N-CA 120.504 -0.855 . . . . 0.0 111.759 176.013 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 95' ' ' TRP . . . . . 0.566 ' CZ2' HD12 ' A' ' 30' ' ' ILE . 34.4 m95 68.7 11.53 8.38 Favored 'General case' 0 C--O 1.216 -0.671 0 C-N-CA 123.316 0.646 . . . . 0.0 110.165 178.536 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -58.85 -29.51 64.82 Favored Glycine 0 CA--C 1.522 0.49 0 CA-C-N 115.523 -0.762 . . . . 0.0 113.463 178.795 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -80.83 -17.64 50.12 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.938 0.399 . . . . 0.0 110.884 178.031 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 98' ' ' TRP . . . . . 0.849 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 30.0 m-90 -104.93 108.02 60.13 Favored Pre-proline 0 C--N 1.324 -0.51 0 CA-C-N 116.052 -0.522 . . . . 0.0 109.736 178.517 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 39.5 Cg_exo -64.43 -134.63 0.0 OUTLIER 'Trans proline' 0 CA--C 1.537 0.631 0 C-N-CA 123.95 3.1 . . . . 0.0 114.148 -175.845 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 3.8 m -54.14 -27.48 16.55 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.229 0 N-CA-C 112.442 0.534 . . . . 0.0 112.442 -176.813 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 77.1 m -60.81 -40.36 92.41 Favored 'General case' 0 C--N 1.317 -0.847 0 CA-C-N 115.887 -0.597 . . . . 0.0 111.37 179.183 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 102' ' ' ALA . . . . . 0.432 ' HB3' ' CB ' ' A' ' 98' ' ' TRP . . . -72.03 -41.6 67.31 Favored 'General case' 0 CA--C 1.517 -0.295 0 CA-C-O 121.092 0.473 . . . . 0.0 110.26 177.302 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -59.27 -46.21 89.15 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.577 -0.738 . . . . 0.0 110.917 179.128 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 3.0 mpp_? -73.71 -22.08 60.03 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.816 -0.629 . . . . 0.0 111.423 179.854 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 105' ' ' ALA . . . . . 0.736 ' HB2' ' HA ' ' A' ' 30' ' ' ILE . . . -83.06 -20.89 34.09 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.397 179.433 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 104.52 60.72 0.66 Allowed Glycine 0 CA--C 1.519 0.305 0 C-N-CA 121.111 -0.566 . . . . 0.0 112.142 -179.178 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -64.11 141.53 58.74 Favored 'General case' 0 C--O 1.235 0.295 0 C-N-CA 122.659 0.384 . . . . 0.0 111.939 -176.574 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 108' ' ' ARG . . . . . 0.654 ' OXT' ' HD3' ' A' ' 108' ' ' ARG . 0.0 OUTLIER . . . . . 0 C--O 1.246 0.903 0 CA-C-O 118.567 -0.73 . . . . 0.0 110.726 -177.491 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 70.5 m-20 . . . . . 0 N--CA 1.474 0.773 0 CA-C-O 121.338 0.59 . . . . 0.0 110.496 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 46.2 t -116.3 80.71 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.799 0 N-CA-C 108.441 -0.948 . . . . 0.0 108.441 178.018 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 7.5 p -30.68 122.93 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.47 0.529 0 CA-C-N 114.537 -1.211 . . . . 0.0 112.813 179.499 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 6.4 t -89.69 146.05 6.66 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.575 0 CA-C-N 115.367 -0.833 . . . . 0.0 110.174 -175.951 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 14.1 p -89.97 125.68 59.83 Favored Pre-proline 0 C--N 1.317 -0.822 0 CA-C-N 115.624 -0.716 . . . . 0.0 111.17 -178.044 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 37.6 Cg_endo -88.72 156.01 6.2 Favored 'Trans proline' 0 N--CA 1.439 -1.695 0 C-N-CA 123.164 2.576 . . . . 0.0 110.595 176.65 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . 50.42 46.47 25.21 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-O 122.155 0.979 . . . . 0.0 110.442 -174.067 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 54.7 t-80 -77.6 -8.14 57.41 Favored 'General case' 0 C--N 1.314 -0.953 0 CA-C-N 113.766 -1.561 . . . . 0.0 108.855 176.075 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 3.8 mm-40 -56.03 138.5 49.1 Favored 'General case' 0 CA--C 1.515 -0.391 0 CA-C-N 115.453 -0.794 . . . . 0.0 112.532 -177.138 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -121.66 59.71 0.97 Allowed 'General case' 0 C--N 1.316 -0.875 0 CA-C-N 114.584 -1.189 . . . . 0.0 108.794 173.929 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 85.7 t -61.61 -46.35 96.74 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.734 0 CA-C-N 113.92 -1.491 . . . . 0.0 110.79 -179.992 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 6.0 p 34.9 82.14 0.01 OUTLIER 'Isoleucine or valine' 0 C--O 1.234 0.278 0 O-C-N 124.728 1.267 . . . . 0.0 112.731 -176.758 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . 0.453 ' HD2' ' HA ' ' A' ' 13' ' ' ARG . 0.2 OUTLIER 64.17 133.29 0.02 OUTLIER 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 113.404 -1.725 . . . . 0.0 113.221 -176.911 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.7 t -88.76 158.45 3.0 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.089 0 N-CA-C 108.651 -0.87 . . . . 0.0 108.651 175.767 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -163.81 84.87 0.11 Allowed Glycine 0 N--CA 1.428 -1.839 0 CA-C-N 115.309 -0.86 . . . . 0.0 112.483 -177.871 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' THR . . . . . 0.645 ' HB ' ' HD3' ' A' ' 17' ' ' LYS . 3.5 m -63.1 -38.04 89.59 Favored 'General case' 0 N--CA 1.447 -0.601 0 CA-C-O 121.852 0.834 . . . . 0.0 110.176 176.726 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . 0.645 ' HD3' ' HB ' ' A' ' 16' ' ' THR . 0.0 OUTLIER -123.71 85.06 53.48 Favored Pre-proline 0 C--N 1.316 -0.879 0 CA-C-N 114.439 -1.255 . . . . 0.0 109.592 176.668 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_exo -61.62 117.12 3.91 Favored 'Trans proline' 0 CA--C 1.506 -0.877 0 C-N-CA 122.784 2.323 . . . . 0.0 112.167 177.195 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 144.44 53.09 0.03 OUTLIER Glycine 0 C--N 1.299 -1.514 0 CA-C-N 113.667 -1.606 . . . . 0.0 113.471 178.184 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 35.5 m -69.94 -33.76 72.56 Favored 'General case' 0 C--N 1.32 -0.698 0 N-CA-C 108.879 -0.786 . . . . 0.0 108.879 170.092 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 48.1 mt-10 -123.71 125.84 45.48 Favored 'General case' 0 N--CA 1.439 -0.996 0 CA-C-N 115.089 -0.959 . . . . 0.0 108.853 176.754 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.4 ' HA ' ' HD3' ' A' ' 23' ' ' PRO . 31.6 t -71.24 131.04 87.15 Favored Pre-proline 0 C--N 1.313 -0.987 0 CA-C-N 115.522 -0.763 . . . . 0.0 110.295 -177.24 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . 0.426 ' HA ' ' HD2' ' A' ' 24' ' ' PRO . 50.0 Cg_exo -53.71 129.37 33.64 Favored 'Trans proline' 0 C--N 1.348 0.538 0 C-N-CA 123.135 2.557 . . . . 0.0 112.588 -179.002 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . 0.426 ' HD2' ' HA ' ' A' ' 23' ' ' PRO . 11.0 Cg_endo -55.46 141.46 82.38 Favored 'Trans proline' 0 N--CA 1.458 -0.583 0 C-N-CA 123.844 3.03 . . . . 0.0 113.093 -179.36 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.448 ' CG2' ' HA3' ' A' ' 28' ' ' GLY . 1.5 p -80.21 119.24 29.32 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.984 0 CA-C-N 114.623 -1.171 . . . . 0.0 111.238 179.895 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 42.1 mm -88.82 -54.44 7.79 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-N 115.356 -0.838 . . . . 0.0 111.692 177.414 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.71 ' O ' HG12 ' A' ' 30' ' ' ILE . 33.5 m-20 -128.2 34.88 4.5 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 114.735 -1.12 . . . . 0.0 108.553 -170.688 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . 0.482 ' HA2' ' CD1' ' A' ' 31' ' ' TRP . . . -72.22 -2.6 54.33 Favored Glycine 0 CA--C 1.5 -0.856 0 N-CA-C 110.605 -0.998 . . . . 0.0 110.605 177.482 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 16.4 m -69.63 -37.41 76.8 Favored 'General case' 0 C--N 1.317 -0.828 0 CA-C-O 121.499 0.666 . . . . 0.0 109.352 173.564 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.71 HG12 ' O ' ' A' ' 27' ' ' ASP . 0.3 OUTLIER -69.55 -35.97 68.9 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.672 0 N-CA-C 107.159 -1.422 . . . . 0.0 107.159 176.364 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' TRP . . . . . 0.541 ' CZ2' ' HD3' ' A' ' 90' ' ' ARG . 21.7 m95 -71.45 -36.45 71.23 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 114.255 -1.339 . . . . 0.0 110.776 -177.394 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 27.1 t70 -76.82 -33.39 57.96 Favored 'General case' 0 N--CA 1.445 -0.713 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.167 177.904 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . 0.488 ' HB1' ' CB ' ' A' ' 105' ' ' ALA . . . -70.69 -34.07 71.58 Favored 'General case' 0 N--CA 1.447 -0.592 0 C-N-CA 120.432 -0.507 . . . . 0.0 110.138 176.529 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . 0.515 ' HA ' ' HB3' ' A' ' 101' ' ' CYS . 56.9 mt -67.38 -41.7 86.58 Favored 'Isoleucine or valine' 0 C--O 1.234 0.28 0 CA-C-N 115.851 -0.613 . . . . 0.0 109.99 172.647 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . 0.497 ' HA ' ' O ' ' A' ' 54' ' ' GLY . . . -58.75 -38.68 78.97 Favored 'General case' 0 CA--C 1.515 -0.379 0 CA-C-O 121.448 0.642 . . . . 0.0 110.112 174.045 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -75.29 -10.1 84.34 Favored Glycine 0 N--CA 1.449 -0.443 0 CA-C-N 115.192 -0.913 . . . . 0.0 111.343 179.22 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.416 ' HB3' ' O ' ' A' ' 34' ' ' ILE . 14.4 t -90.87 -66.72 0.9 Allowed 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.174 -0.513 . . . . 0.0 111.327 -178.607 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . 0.857 ' HG3' ' SG ' ' A' ' 101' ' ' CYS . 53.7 mt-10 -89.7 -34.48 16.22 Favored 'General case' 0 CA--C 1.513 -0.45 0 C-N-CA 120.399 -0.521 . . . . 0.0 110.918 -174.023 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . 0.47 ' HB1' ' O ' ' A' ' 35' ' ' ALA . . . -84.15 -18.32 37.12 Favored 'General case' 0 N--CA 1.445 -0.685 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.227 -176.363 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 80.35 12.57 82.96 Favored Glycine 0 CA--C 1.503 -0.701 0 N-CA-C 109.991 -1.243 . . . . 0.0 109.991 -177.351 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 82.81 61.47 1.94 Allowed Glycine 0 N--CA 1.434 -1.44 0 CA-C-N 114.066 -1.067 . . . . 0.0 111.866 -176.689 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . 0.48 ' HB3' ' HB ' ' A' ' 45' ' ' ILE . 52.8 t-20 -155.1 124.37 6.32 Favored 'General case' 0 N--CA 1.442 -0.835 0 N-CA-C 108.624 -0.88 . . . . 0.0 108.624 -179.215 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 43' ' ' TRP . . . . . 0.76 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 44.9 m95 -97.27 -10.41 25.78 Favored 'General case' 0 C--N 1.308 -1.217 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.9 -174.207 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -110.16 9.34 23.95 Favored 'General case' 0 C--N 1.315 -0.91 0 CA-C-N 115.115 -0.948 . . . . 0.0 110.982 179.938 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.48 ' HB ' ' HB3' ' A' ' 42' ' ' ASN . 11.5 tt -73.78 143.27 13.84 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.875 0 CA-C-O 121.462 0.649 . . . . 0.0 110.959 -178.438 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -135.11 94.71 3.18 Favored 'General case' 0 C--N 1.311 -1.097 0 N-CA-C 109.028 -0.73 . . . . 0.0 109.028 179.46 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 1.7 p -73.79 -12.19 60.62 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-N 115.628 -0.714 . . . . 0.0 110.933 -178.269 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 85.29 21.84 53.42 Favored Glycine 0 N--CA 1.443 -0.878 0 N-CA-C 111.179 -0.769 . . . . 0.0 111.179 174.1 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 33.4 p-10 -103.44 10.17 37.4 Favored 'General case' 0 C--N 1.322 -0.612 0 C-N-CA 120.894 -0.322 . . . . 0.0 111.562 -174.944 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . 0.532 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 87.32 -2.66 86.68 Favored Glycine 0 N--CA 1.454 -0.149 0 C-N-CA 120.87 -0.681 . . . . 0.0 111.658 -178.252 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 51' ' ' TYR . . . . . 0.549 ' HA ' ' HA ' ' A' ' 58' ' ' ASP . 0.3 OUTLIER -116.51 147.7 41.52 Favored 'General case' 0 CA--C 1.508 -0.643 0 N-CA-C 106.5 -1.667 . . . . 0.0 106.5 178.649 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 52' ' ' TYR . . . . . 0.713 ' O ' ' HA ' ' A' ' 56' ' ' GLN . 47.9 m-85 -114.7 163.79 14.97 Favored 'General case' 0 C--N 1.304 -1.376 0 C-N-CA 119.821 -0.751 . . . . 0.0 111.688 -170.247 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.418 ' CA ' HG23 ' A' ' 45' ' ' ILE . . . -60.56 177.95 3.41 Favored Glycine 0 N--CA 1.448 -0.54 0 O-C-N 124.047 0.842 . . . . 0.0 114.849 -167.801 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . 0.662 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 85.87 -108.7 3.27 Favored Glycine 0 N--CA 1.436 -1.359 0 N-CA-C 111.121 -0.792 . . . . 0.0 111.121 -178.417 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.478 HG22 ' HB3' ' A' ' 82' ' ' GLN . 0.2 OUTLIER -83.2 -1.03 5.54 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.69 0 CA-C-O 121.437 0.637 . . . . 0.0 110.067 178.713 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 56' ' ' GLN . . . . . 0.713 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 20.0 tp60 56.12 50.43 13.61 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 114.265 -1.334 . . . . 0.0 113.28 164.678 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -118.72 169.5 9.78 Favored 'General case' 0 C--N 1.329 -0.317 0 C-N-CA 119.44 -0.904 . . . . 0.0 111.478 172.209 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.549 ' HA ' ' HA ' ' A' ' 51' ' ' TYR . 8.3 p-10 -74.38 162.13 29.17 Favored 'General case' 0 C--N 1.327 -0.382 0 N-CA-C 113.995 1.109 . . . . 0.0 113.995 -163.992 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.428 ' HB2' ' CE2' ' A' ' 52' ' ' TYR . 20.6 tp60 -56.06 -42.61 76.89 Favored 'General case' 0 N--CA 1.443 -0.813 0 CA-C-N 114.085 -1.416 . . . . 0.0 111.084 177.256 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -67.77 -49.68 47.44 Favored Glycine 0 N--CA 1.451 -0.365 0 CA-C-N 115.056 -0.974 . . . . 0.0 112.667 -173.896 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 92.3 m -64.63 -40.24 95.12 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-O 120.644 0.259 . . . . 0.0 110.958 177.91 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 62' ' ' TRP . . . . . 0.459 ' CZ3' ' HA ' ' A' ' 82' ' ' GLN . 54.4 t-105 -56.64 -49.3 75.41 Favored 'General case' 0 N--CA 1.45 -0.454 0 CA-C-O 121.809 0.814 . . . . 0.0 109.102 175.008 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . 0.545 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 29.5 tt0 -64.83 -35.67 81.85 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 114.653 -1.158 . . . . 0.0 111.319 -179.979 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -64.93 -42.4 94.72 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.976 -0.556 . . . . 0.0 111.335 -174.606 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 33.8 m-80 -81.49 -9.24 59.75 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.981 0.42 . . . . 0.0 110.369 176.815 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . 0.557 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 92.29 50.38 2.61 Favored Glycine 0 C--N 1.332 0.309 0 CA-C-N 115.865 -0.607 . . . . 0.0 112.658 173.288 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . 0.559 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -80.03 -23.59 61.24 Favored Glycine 0 N--CA 1.438 -1.205 0 C-N-CA 120.887 -0.673 . . . . 0.0 112.781 -176.48 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 0.891 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 6.9 mp -60.87 -22.9 64.73 Favored 'General case' 0 N--CA 1.448 -0.552 0 N-CA-C 112.139 0.422 . . . . 0.0 112.139 -172.893 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . 0.557 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 3.7 ptp180 -68.37 -32.81 73.16 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-O 121.12 0.486 . . . . 0.0 109.928 177.002 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 70' ' ' TYR . . . . . 0.608 ' HB3' ' CG ' ' A' ' 81' ' ' GLU . 65.6 m-85 -82.26 -34.23 28.85 Favored 'General case' 0 N--CA 1.44 -0.948 0 N-CA-C 107.564 -1.273 . . . . 0.0 107.564 178.915 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.651 ' HB2' ' HB3' ' A' ' 77' ' ' ALA . . . 168.35 124.35 0.04 OUTLIER Pre-proline 0 N--CA 1.448 -0.528 0 CA-C-N 112.868 -1.969 . . . . 0.0 107.319 -178.835 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 72' ' ' PRO . . . . . 0.891 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 24.8 Cg_exo -54.98 -7.38 0.95 Allowed 'Trans proline' 0 C--N 1.335 -0.174 0 C-N-CA 123.003 2.468 . . . . 0.0 114.11 -177.534 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 12.8 ptm180 -146.42 137.16 24.13 Favored 'General case' 0 C--N 1.319 -0.754 0 N-CA-C 108.853 -0.795 . . . . 0.0 108.853 176.472 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . 0.432 ' HA ' ' CH2' ' A' ' 62' ' ' TRP . . . -56.26 -32.0 64.11 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.151 -0.931 . . . . 0.0 112.574 -176.992 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . 0.591 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 4.9 p-10 -78.81 -8.14 58.51 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 121.108 0.48 . . . . 0.0 110.93 -175.312 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 64.5 tp -93.61 -32.04 14.26 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 108.781 -0.822 . . . . 0.0 108.781 173.605 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . 0.765 ' HB1' ' HB2' ' A' ' 81' ' ' GLU . . . -79.68 157.96 27.1 Favored 'General case' 0 N--CA 1.445 -0.713 0 CA-C-N 114.964 -1.016 . . . . 0.0 110.487 176.092 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 40.6 p -100.62 -172.48 2.2 Favored 'General case' 0 C--N 1.315 -0.906 0 CA-C-N 115.937 -0.574 . . . . 0.0 109.918 179.698 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . 0.76 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 10.9 mtt180 -51.14 -52.71 41.33 Favored 'General case' 0 CA--C 1.51 -0.579 0 O-C-N 123.432 0.457 . . . . 0.0 111.029 -175.433 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 1.3 pm0 -57.71 -48.31 79.93 Favored 'General case' 0 C--N 1.314 -0.943 0 CA-C-N 115.135 -0.938 . . . . 0.0 112.142 -176.374 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 81' ' ' GLU . . . . . 0.765 ' HB2' ' HB1' ' A' ' 77' ' ' ALA . 6.5 mp0 -61.31 -50.48 72.79 Favored 'General case' 0 C--O 1.233 0.221 0 N-CA-C 111.9 0.333 . . . . 0.0 111.9 176.491 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 82' ' ' GLN . . . . . 0.478 ' HB3' HG22 ' A' ' 55' ' ' VAL . 51.4 mt-30 -59.93 -39.94 87.22 Favored 'General case' 0 CA--C 1.516 -0.355 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.229 -177.819 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . 0.676 ' O ' ' HG2' ' A' ' 87' ' ' GLU . 28.3 mt -61.78 -45.54 98.46 Favored 'Isoleucine or valine' 0 C--O 1.212 -0.886 0 CA-C-N 115.36 -0.836 . . . . 0.0 110.151 178.601 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . 0.537 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -59.48 -43.4 93.28 Favored 'General case' 0 C--O 1.239 0.509 0 CA-C-O 121.154 0.502 . . . . 0.0 111.336 -178.347 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 60.5 t -68.66 -48.11 73.28 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.649 179.517 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -59.8 -30.08 68.66 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.63 -0.714 . . . . 0.0 110.518 176.08 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 87' ' ' GLU . . . . . 0.676 ' HG2' ' O ' ' A' ' 83' ' ' ILE . 40.1 mm-40 -60.22 -45.81 91.92 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.371 -0.831 . . . . 0.0 110.396 -179.998 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.569 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 24.6 t -64.58 -41.74 93.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 121.392 0.615 . . . . 0.0 109.645 177.823 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 89' ' ' THR . . . . . 0.78 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 0.5 OUTLIER -67.56 -46.7 71.95 Favored 'General case' 0 C--N 1.318 -0.791 0 CA-C-N 115.635 -0.711 . . . . 0.0 111.581 -175.662 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . 0.541 ' HD3' ' CZ2' ' A' ' 31' ' ' TRP . 13.8 ptt180 -64.55 -34.16 77.59 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.494 -0.321 . . . . 0.0 111.192 -175.247 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . 0.569 ' HG ' ' O ' ' A' ' 88' ' ' VAL . 4.4 pp -72.63 -23.74 60.96 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.289 -171.92 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . 0.523 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 6.6 mtm180 -83.93 -48.53 9.89 Favored 'General case' 0 CA--C 1.511 -0.53 0 CA-C-O 121.437 0.636 . . . . 0.0 109.734 -178.638 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 93' ' ' GLN . . . . . 0.621 ' NE2' HG23 ' A' ' 89' ' ' THR . 28.9 pt20 -98.44 -28.98 13.38 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 114.773 -1.103 . . . . 0.0 113.741 -168.135 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 82.99 48.5 5.41 Favored Glycine 0 N--CA 1.448 -0.502 0 C-N-CA 120.11 -1.043 . . . . 0.0 111.357 178.784 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 95' ' ' TRP . . . . . 0.498 ' HA ' ' HE3' ' A' ' 98' ' ' TRP . 2.4 m95 62.59 24.12 14.35 Favored 'General case' 0 C--O 1.224 -0.274 0 C-N-CA 123.176 0.591 . . . . 0.0 110.288 176.103 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -69.19 -24.51 75.93 Favored Glycine 0 CA--C 1.52 0.359 0 CA-C-N 115.706 -0.679 . . . . 0.0 112.433 175.977 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . 0.429 ' O ' ' HD3' ' A' ' 99' ' ' PRO . . . -82.05 -34.14 29.61 Favored 'General case' 0 CA--C 1.516 -0.355 0 CA-C-O 120.888 0.375 . . . . 0.0 110.474 176.289 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 98' ' ' TRP . . . . . 0.78 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 22.4 m-90 -96.37 103.55 14.41 Favored Pre-proline 0 N--CA 1.451 -0.414 0 CA-C-N 115.713 -0.676 . . . . 0.0 109.202 -179.62 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . 0.429 ' HD3' ' O ' ' A' ' 97' ' ' ALA . 16.4 Cg_exo -73.44 -98.72 0.01 OUTLIER 'Trans proline' 0 CA--C 1.537 0.656 0 C-N-CA 123.27 2.646 . . . . 0.0 114.869 -170.682 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 32.8 t -70.22 -27.27 31.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-O 121.702 0.763 . . . . 0.0 110.01 -172.853 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 101' ' ' CYS . . . . . 0.857 ' SG ' ' HG3' ' A' ' 38' ' ' GLU . 38.7 m -67.08 -33.98 76.66 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-N 114.755 -1.111 . . . . 0.0 111.13 -174.77 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 102' ' ' ALA . . . . . 0.437 ' HB1' ' HB3' ' A' ' 107' ' ' ALA . . . -65.38 -45.44 84.03 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.817 0.342 . . . . 0.0 110.69 179.839 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -64.76 -36.28 83.79 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 121.102 0.477 . . . . 0.0 110.545 178.824 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 21.1 mmm180 -74.03 -23.35 59.39 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.553 -0.749 . . . . 0.0 111.693 179.057 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 105' ' ' ALA . . . . . 0.615 ' HB1' ' HA ' ' A' ' 30' ' ' ILE . . . -96.91 -21.53 17.41 Favored 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 112.496 0.554 . . . . 0.0 112.496 -174.472 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 103.94 65.15 0.69 Allowed Glycine 0 CA--C 1.518 0.253 0 C-N-CA 120.827 -0.702 . . . . 0.0 111.919 -177.753 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 107' ' ' ALA . . . . . 0.437 ' HB3' ' HB1' ' A' ' 102' ' ' ALA . . . -71.93 152.75 42.3 Favored 'General case' 0 C--N 1.326 -0.433 0 C-N-CA 122.877 0.471 . . . . 0.0 111.674 -174.912 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 10.7 mmm180 . . . . . 0 C--O 1.25 1.081 0 CA-C-O 117.926 -1.035 . . . . 0.0 111.408 175.043 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 6.0 p30 . . . . . 0 N--CA 1.473 0.676 0 CA-C-O 121.928 0.871 . . . . 0.0 109.722 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 11.2 p -77.8 -18.63 13.93 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.979 0 CA-C-N 114.851 -1.068 . . . . 0.0 110.347 179.881 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 7.9 p -62.53 128.52 24.45 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.618 0 CA-C-N 115.657 -0.701 . . . . 0.0 110.922 177.956 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 25.1 t -96.78 155.06 3.55 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.735 0 CA-C-N 115.555 -0.748 . . . . 0.0 109.01 178.178 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' THR . . . . . 0.427 ' HA ' ' HD3' ' A' ' 6' ' ' PRO . 14.6 p -77.38 112.84 26.42 Favored Pre-proline 0 C--N 1.317 -0.837 0 CA-C-N 115.929 -0.578 . . . . 0.0 111.528 -176.807 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.427 ' HD3' ' HA ' ' A' ' 5' ' ' THR . 11.2 Cg_endo -92.66 170.96 2.39 Favored 'Trans proline' 0 N--CA 1.446 -1.31 0 C-N-CA 123.502 2.801 . . . . 0.0 111.518 178.091 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -91.53 63.26 4.74 Favored 'General case' 0 C--N 1.31 -1.121 0 CA-C-O 122.056 0.932 . . . . 0.0 110.569 178.785 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 65.1 m170 -95.9 -1.31 49.59 Favored 'General case' 0 C--N 1.31 -1.129 0 CA-C-N 114.079 -1.419 . . . . 0.0 108.796 173.451 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 6.0 pt-20 -56.71 143.46 36.35 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 114.693 -1.139 . . . . 0.0 111.662 -177.296 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -145.45 71.07 1.27 Allowed 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 115.206 -0.906 . . . . 0.0 109.0 176.541 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 8.9 p -73.14 -22.91 19.71 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.554 0 CA-C-N 114.981 -1.009 . . . . 0.0 111.305 -173.328 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 7.1 p 29.61 77.92 0.01 OUTLIER 'Isoleucine or valine' 0 C--O 1.238 0.471 0 CA-C-O 122.988 1.375 . . . . 0.0 112.745 -177.749 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 31.5 ptt180 -103.28 106.96 17.6 Favored 'General case' 0 C--N 1.306 -1.313 0 CA-C-N 113.66 -1.609 . . . . 0.0 110.617 -176.203 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . 0.401 HG12 ' N ' ' A' ' 15' ' ' GLY . 4.1 t -136.06 163.93 33.12 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.387 0 CA-C-N 114.016 -1.447 . . . . 0.0 109.151 -179.446 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . 0.401 ' N ' HG12 ' A' ' 14' ' ' VAL . . . -171.12 64.47 0.16 Allowed Glycine 0 N--CA 1.432 -1.58 0 CA-C-N 115.499 -0.773 . . . . 0.0 111.694 176.755 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 4.5 m -75.59 -31.11 59.83 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-N 114.788 -0.706 . . . . 0.0 111.592 -175.278 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . 0.425 ' HA ' ' HD3' ' A' ' 18' ' ' PRO . 63.8 mmtt -58.18 110.16 2.35 Favored Pre-proline 0 C--N 1.318 -0.793 0 CA-C-N 114.731 -1.122 . . . . 0.0 111.379 -175.823 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . 0.425 ' HD3' ' HA ' ' A' ' 17' ' ' LYS . 1.9 Cg_endo -86.36 168.73 8.67 Favored 'Trans proline' 0 N--CA 1.45 -1.086 0 C-N-CA 123.76 2.973 . . . . 0.0 112.066 177.747 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -106.38 27.98 15.09 Favored Glycine 0 C--N 1.309 -0.966 0 CA-C-N 114.637 -1.165 . . . . 0.0 111.175 178.972 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 18.1 m -69.54 -39.5 77.43 Favored 'General case' 0 C--N 1.314 -0.958 0 CA-C-N 114.182 -1.009 . . . . 0.0 110.44 179.397 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 46.8 mt-10 -115.42 121.78 43.79 Favored 'General case' 0 N--CA 1.438 -1.062 0 N-CA-C 108.714 -0.847 . . . . 0.0 108.714 177.877 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 45.9 t -71.65 118.81 69.83 Favored Pre-proline 0 C--N 1.314 -0.964 0 CA-C-N 115.557 -0.747 . . . . 0.0 111.057 -175.963 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -55.85 139.74 84.43 Favored 'Trans proline' 0 N--CA 1.459 -0.534 0 C-N-CA 123.31 2.673 . . . . 0.0 112.021 177.085 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 10.3 Cg_endo -54.65 140.12 76.36 Favored 'Trans proline' 0 N--CA 1.455 -0.739 0 C-N-CA 123.373 2.715 . . . . 0.0 112.874 -176.675 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.451 ' HB ' HG21 ' A' ' 83' ' ' ILE . 46.4 t -89.22 137.82 20.49 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.095 0 CA-C-N 114.17 -1.377 . . . . 0.0 109.49 -178.348 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 46.1 mm -63.03 -25.46 38.61 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.615 0 CA-C-N 115.289 -0.868 . . . . 0.0 111.804 -172.374 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.523 ' O ' HG12 ' A' ' 30' ' ' ILE . 7.3 m-20 -104.22 -0.02 28.89 Favored 'General case' 0 CA--C 1.504 -0.794 0 CA-C-O 121.669 0.747 . . . . 0.0 109.498 -179.605 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . 0.555 ' HA2' ' HD1' ' A' ' 31' ' ' TRP . . . -67.49 -8.02 49.46 Favored Glycine 0 N--CA 1.445 -0.748 0 CA-C-N 114.786 -1.097 . . . . 0.0 110.715 179.484 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 6.1 m -76.72 -39.05 53.13 Favored 'General case' 0 C--N 1.318 -0.779 0 CA-C-O 121.652 0.739 . . . . 0.0 109.239 176.388 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.591 ' HA ' ' HB3' ' A' ' 105' ' ' ALA . 0.7 OUTLIER -68.58 -38.49 79.15 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.592 0 N-CA-C 107.35 -1.352 . . . . 0.0 107.35 177.429 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' TRP . . . . . 0.555 ' HD1' ' HA2' ' A' ' 28' ' ' GLY . 34.8 m95 -68.52 -36.68 79.2 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 114.535 -1.212 . . . . 0.0 110.378 -177.296 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.688 ' HB2' HH21 ' A' ' 79' ' ' ARG . 33.5 t70 -73.77 -41.23 62.74 Favored 'General case' 0 N--CA 1.445 -0.703 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.1 179.043 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . 0.486 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -70.1 -33.11 71.45 Favored 'General case' 0 N--CA 1.448 -0.55 0 CA-C-N 116.405 -0.361 . . . . 0.0 110.912 -179.966 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . 0.609 ' HA ' ' HB3' ' A' ' 101' ' ' CYS . 50.9 mt -64.23 -49.28 81.88 Favored 'Isoleucine or valine' 0 C--O 1.234 0.256 0 CA-C-O 120.777 0.322 . . . . 0.0 110.56 174.893 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . 0.509 ' O ' ' HB3' ' A' ' 39' ' ' ALA . . . -66.02 -33.7 76.4 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 121.296 0.57 . . . . 0.0 110.218 178.528 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . 0.426 ' HA2' ' N ' ' A' ' 41' ' ' GLY . . . -71.61 -21.98 78.72 Favored Glycine 0 N--CA 1.448 -0.526 0 N-CA-C 111.101 -0.799 . . . . 0.0 111.101 176.892 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -76.19 -69.33 0.51 Allowed 'General case' 0 N--CA 1.448 -0.551 0 CA-C-N 115.291 -0.455 . . . . 0.0 111.536 -178.574 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . 0.667 ' HB2' ' SG ' ' A' ' 101' ' ' CYS . 15.3 tt0 -90.9 -32.99 15.79 Favored 'General case' 0 C--N 1.323 -0.572 0 C-N-CA 119.743 -0.783 . . . . 0.0 110.871 -171.455 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . 0.509 ' HB3' ' O ' ' A' ' 35' ' ' ALA . . . -84.46 -13.85 50.87 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.996 -178.855 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 74.89 20.5 79.44 Favored Glycine 0 CA--C 1.501 -0.839 0 N-CA-C 109.853 -1.299 . . . . 0.0 109.853 -179.472 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . 0.426 ' N ' ' HA2' ' A' ' 36' ' ' GLY . . . 72.2 64.03 2.77 Favored Glycine 0 N--CA 1.433 -1.564 0 CA-C-N 114.108 -1.046 . . . . 0.0 111.093 -172.837 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . 0.702 ' HB3' ' HB ' ' A' ' 45' ' ' ILE . 0.2 OUTLIER -140.99 84.21 1.92 Allowed 'General case' 0 C--N 1.322 -0.595 0 N-CA-C 108.815 -0.809 . . . . 0.0 108.815 -177.193 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 43' ' ' TRP . . . . . 0.756 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 37.0 m95 -73.65 -11.59 60.46 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 115.741 -0.663 . . . . 0.0 109.973 -177.922 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -106.6 14.38 27.08 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 115.37 -0.832 . . . . 0.0 111.406 179.583 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.721 HG22 ' HA2' ' A' ' 53' ' ' GLY . 9.0 tt -75.86 144.62 11.7 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.812 0 N-CA-C 109.695 -0.483 . . . . 0.0 109.695 179.83 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 21.7 t-20 -153.99 94.65 1.77 Allowed 'General case' 0 C--N 1.308 -1.208 0 CA-C-O 121.302 0.572 . . . . 0.0 110.38 -178.867 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 16.3 p -76.57 -19.56 57.76 Favored 'General case' 0 N--CA 1.445 -0.709 0 CA-C-N 115.225 -0.898 . . . . 0.0 110.718 178.925 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 87.85 24.02 36.78 Favored Glycine 0 N--CA 1.445 -0.759 0 N-CA-C 110.954 -0.859 . . . . 0.0 110.954 179.256 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 3.8 m-20 -97.54 14.4 26.66 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 121.065 0.459 . . . . 0.0 111.52 -174.259 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . 0.463 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 87.46 -16.03 51.4 Favored Glycine 0 N--CA 1.452 -0.28 0 CA-C-N 115.717 -0.674 . . . . 0.0 111.772 179.631 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 51' ' ' TYR . . . . . 0.741 ' CE1' ' HB2' ' A' ' 58' ' ' ASP . 0.3 OUTLIER -102.72 131.89 49.23 Favored 'General case' 0 N--CA 1.446 -0.66 0 N-CA-C 107.805 -1.183 . . . . 0.0 107.805 169.623 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 52' ' ' TYR . . . . . 0.71 ' CE1' ' HB2' ' A' ' 59' ' ' GLN . 15.0 m-85 -104.26 169.64 8.37 Favored 'General case' 0 C--N 1.311 -1.096 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.85 -173.184 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.721 ' HA2' HG22 ' A' ' 45' ' ' ILE . . . -51.91 158.09 3.1 Favored Glycine 0 CA--C 1.509 -0.326 0 N-CA-C 115.613 1.005 . . . . 0.0 115.613 -169.361 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . 0.57 ' CA ' ' HA ' ' A' ' 43' ' ' TRP . . . 98.49 -113.05 4.62 Favored Glycine 0 N--CA 1.438 -1.168 0 CA-C-N 114.486 -0.857 . . . . 0.0 111.369 175.444 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 1.3 m -86.91 -6.09 10.45 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.73 0 CA-C-O 120.442 0.163 . . . . 0.0 110.82 178.38 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 56' ' ' GLN . . . . . 0.597 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 10.5 pt20 45.52 51.71 9.64 Favored 'General case' 0 N--CA 1.479 1.003 0 N-CA-C 114.502 1.297 . . . . 0.0 114.502 167.483 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . 0.569 ' O ' ' HB ' ' A' ' 61' ' ' THR . 19.7 p90 -103.67 21.62 15.84 Favored 'General case' 0 C--N 1.328 -0.344 0 N-CA-C 113.25 0.833 . . . . 0.0 113.25 -176.071 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.741 ' HB2' ' CE1' ' A' ' 51' ' ' TYR . 0.4 OUTLIER 89.06 135.82 0.04 OUTLIER 'General case' 0 C--N 1.317 -0.838 0 C-N-CA 124.615 1.166 . . . . 0.0 111.953 168.399 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.71 ' HB2' ' CE1' ' A' ' 52' ' ' TYR . 0.0 OUTLIER -58.81 -34.23 71.27 Favored 'General case' 0 CA--C 1.512 -0.493 0 CA-C-N 114.195 -1.366 . . . . 0.0 110.932 -179.332 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -67.06 -44.05 89.05 Favored Glycine 0 N--CA 1.449 -0.463 0 C-N-CA 120.717 -0.754 . . . . 0.0 111.619 177.667 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 61' ' ' THR . . . . . 0.569 ' HB ' ' O ' ' A' ' 57' ' ' PHE . 89.5 m -71.02 -41.2 71.16 Favored 'General case' 0 N--CA 1.445 -0.685 0 CA-C-O 121.048 0.452 . . . . 0.0 110.324 178.023 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 62' ' ' TRP . . . . . 0.455 ' CH2' ' HA ' ' A' ' 74' ' ' ALA . 41.1 t-105 -55.57 -49.98 71.27 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.455 -0.793 . . . . 0.0 110.215 172.71 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . 0.487 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 3.7 tp10 -63.54 -40.34 96.75 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 115.437 -0.801 . . . . 0.0 110.555 179.512 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -61.39 -41.37 97.02 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.753 -0.658 . . . . 0.0 110.804 -177.486 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . 0.435 ' HB3' ' HB ' ' A' ' 88' ' ' VAL . 9.3 m120 -80.55 -9.6 59.77 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.439 178.358 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . 0.485 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 85.32 46.8 5.43 Favored Glycine 0 N--CA 1.449 -0.445 0 CA-C-N 115.736 -0.665 . . . . 0.0 112.689 175.716 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . 0.607 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -78.95 -18.53 74.78 Favored Glycine 0 N--CA 1.442 -0.961 0 C-N-CA 120.868 -0.682 . . . . 0.0 112.429 -174.668 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 0.972 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 7.0 mp -60.12 -24.11 64.41 Favored 'General case' 0 N--CA 1.445 -0.688 0 N-CA-C 112.545 0.572 . . . . 0.0 112.545 -175.0 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . 0.485 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 9.1 ptp180 -67.2 -31.85 72.52 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 121.405 0.622 . . . . 0.0 109.771 175.933 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 70' ' ' TYR . . . . . 0.83 ' HB3' ' HB3' ' A' ' 81' ' ' GLU . 74.5 m-85 -81.47 -33.91 31.72 Favored 'General case' 0 N--CA 1.443 -0.814 0 N-CA-C 107.728 -1.212 . . . . 0.0 107.728 178.199 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.548 ' HB1' ' HB3' ' A' ' 77' ' ' ALA . . . 165.9 126.01 0.03 OUTLIER Pre-proline 0 CA--C 1.512 -0.517 0 CA-C-N 112.897 -1.956 . . . . 0.0 107.325 -179.011 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 72' ' ' PRO . . . . . 0.972 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 21.2 Cg_exo -56.91 -6.66 1.87 Allowed 'Trans proline' 0 C--N 1.333 -0.242 0 C-N-CA 122.495 2.13 . . . . 0.0 113.587 -179.412 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 13.9 ptm180 -143.85 137.49 27.97 Favored 'General case' 0 C--N 1.321 -0.671 0 N-CA-C 109.228 -0.656 . . . . 0.0 109.228 177.752 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . 0.455 ' HA ' ' CH2' ' A' ' 62' ' ' TRP . . . -60.14 -28.06 67.58 Favored 'General case' 0 C--O 1.218 -0.569 0 CA-C-N 114.999 -1.0 . . . . 0.0 111.916 -176.96 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . 0.519 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 20.7 p-10 -88.13 3.56 48.69 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 121.186 0.517 . . . . 0.0 111.761 -176.449 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 66.9 tp -100.57 -30.67 11.65 Favored 'General case' 0 C--N 1.321 -0.64 0 N-CA-C 108.29 -1.004 . . . . 0.0 108.29 168.637 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . 0.907 ' HB1' ' HB2' ' A' ' 81' ' ' GLU . . . -78.89 143.87 35.48 Favored 'General case' 0 N--CA 1.441 -0.914 0 CA-C-N 114.617 -1.174 . . . . 0.0 110.704 176.486 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 27.7 p -93.88 -170.55 2.35 Favored 'General case' 0 C--N 1.314 -0.969 0 CA-C-N 115.417 -0.811 . . . . 0.0 109.117 178.93 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . 0.756 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 57.0 mtp180 -48.53 -51.38 27.79 Favored 'General case' 0 C--N 1.33 -0.262 0 O-C-N 123.196 0.31 . . . . 0.0 111.001 -178.512 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 10.2 pt-20 -57.64 -48.28 79.9 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.856 -0.611 . . . . 0.0 112.264 -173.776 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 81' ' ' GLU . . . . . 0.907 ' HB2' ' HB1' ' A' ' 77' ' ' ALA . 16.9 mp0 -65.25 -51.09 63.04 Favored 'General case' 0 N--CA 1.452 -0.358 0 N-CA-C 112.056 0.391 . . . . 0.0 112.056 177.339 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 82' ' ' GLN . . . . . 0.645 ' HB2' ' HZ3' ' A' ' 43' ' ' TRP . 46.0 mt-30 -61.6 -38.64 88.34 Favored 'General case' 0 CA--C 1.51 -0.561 0 CA-C-O 120.754 0.312 . . . . 0.0 110.833 -175.426 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . 0.636 ' O ' ' HG2' ' A' ' 87' ' ' GLU . 50.2 mt -59.34 -44.46 92.43 Favored 'Isoleucine or valine' 0 C--O 1.215 -0.715 0 CA-C-N 115.512 -0.767 . . . . 0.0 109.865 176.889 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . 0.674 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -66.01 -41.92 90.4 Favored 'General case' 0 C--O 1.237 0.441 0 CA-C-O 121.29 0.567 . . . . 0.0 111.571 -176.841 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . 0.526 HG22 ' O ' ' A' ' 81' ' ' GLU . 14.8 t -69.12 -47.94 71.89 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.696 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.454 178.969 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -58.23 -28.67 65.09 Favored 'General case' 0 C--O 1.232 0.143 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.431 173.389 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 87' ' ' GLU . . . . . 0.766 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 20.2 mm-40 -59.15 -43.87 92.07 Favored 'General case' 0 CA--C 1.51 -0.589 0 CA-C-N 115.32 -0.855 . . . . 0.0 109.619 178.926 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.575 ' O ' ' HG3' ' A' ' 92' ' ' ARG . 40.6 t -63.1 -43.55 99.0 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 CA-C-O 121.293 0.568 . . . . 0.0 109.933 175.572 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 89' ' ' THR . . . . . 1.007 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 0.2 OUTLIER -62.61 -47.12 85.16 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.746 -0.661 . . . . 0.0 111.982 -176.016 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . 0.482 ' HB3' ' CZ2' ' A' ' 31' ' ' TRP . 30.4 ptt85 -60.16 -29.39 68.63 Favored 'General case' 0 N--CA 1.467 0.381 0 CA-C-O 121.313 0.578 . . . . 0.0 110.448 -178.996 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . 0.766 ' HG ' ' O ' ' A' ' 87' ' ' GLU . 33.4 mt -66.97 -35.01 79.01 Favored 'General case' 0 C--N 1.314 -0.948 0 CA-C-O 121.406 0.622 . . . . 0.0 109.885 -179.918 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . 0.575 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 4.7 mtm180 -89.11 -51.54 5.54 Favored 'General case' 0 N--CA 1.443 -0.78 0 CA-C-N 115.348 -0.842 . . . . 0.0 110.13 -171.807 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 93' ' ' GLN . . . . . 0.488 HE22 ' HZ3' ' A' ' 98' ' ' TRP . 0.0 OUTLIER -108.72 -15.85 14.31 Favored 'General case' 0 N--CA 1.44 -0.946 0 CA-C-N 115.087 -0.96 . . . . 0.0 111.942 -173.151 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.478 ' HA2' ' O ' ' A' ' 90' ' ' ARG . . . 83.6 -107.41 2.93 Favored Glycine 0 CA--C 1.494 -1.232 0 N-CA-C 111.082 -0.807 . . . . 0.0 111.082 177.911 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 95' ' ' TRP . . . . . . . . . . . . . 3.5 m95 -142.81 27.32 1.66 Allowed 'General case' 0 C--N 1.313 -0.994 0 N-CA-C 106.901 -1.518 . . . . 0.0 106.901 179.813 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -79.19 -22.46 65.38 Favored Glycine 0 N--CA 1.448 -0.546 0 CA-C-N 114.457 -1.247 . . . . 0.0 111.079 173.195 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . 0.433 ' O ' ' HD3' ' A' ' 99' ' ' PRO . . . -85.12 -32.16 22.92 Favored 'General case' 0 C--N 1.327 -0.373 0 N-CA-C 109.378 -0.601 . . . . 0.0 109.378 174.419 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 98' ' ' TRP . . . . . 1.007 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 16.9 m-90 -101.14 100.72 13.94 Favored Pre-proline 0 C--O 1.221 -0.441 0 N-CA-C 109.009 -0.737 . . . . 0.0 109.009 174.027 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . 0.433 ' HD3' ' O ' ' A' ' 97' ' ' ALA . 10.3 Cg_exo -79.33 -88.49 0.0 OUTLIER 'Trans proline' 0 CA--C 1.532 0.411 0 C-N-CA 122.848 2.365 . . . . 0.0 115.085 -171.828 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . 0.401 ' H ' ' HB2' ' A' ' 99' ' ' PRO . 63.3 t -69.96 -28.32 36.06 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.349 0 CA-C-O 121.679 0.752 . . . . 0.0 110.047 -172.461 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 101' ' ' CYS . . . . . 0.667 ' SG ' ' HB2' ' A' ' 38' ' ' GLU . 87.4 m -72.21 -27.25 62.42 Favored 'General case' 0 C--N 1.317 -0.84 0 CA-C-N 115.25 -0.887 . . . . 0.0 111.084 -176.759 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 102' ' ' ALA . . . . . 0.58 ' HB1' ' HB1' ' A' ' 107' ' ' ALA . . . -69.93 -40.41 75.55 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.808 0.337 . . . . 0.0 110.333 175.658 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -63.08 -37.81 88.68 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 121.432 0.634 . . . . 0.0 110.336 177.591 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -72.88 -30.62 64.1 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.243 -0.89 . . . . 0.0 111.686 177.363 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 105' ' ' ALA . . . . . 0.591 ' HB3' ' HA ' ' A' ' 30' ' ' ILE . . . -96.32 -22.58 17.11 Favored 'General case' 0 C--N 1.325 -0.457 0 N-CA-C 113.001 0.741 . . . . 0.0 113.001 -172.271 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 104.13 69.85 0.8 Allowed Glycine 0 CA--C 1.52 0.376 0 C-N-CA 120.832 -0.699 . . . . 0.0 112.134 -177.302 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 107' ' ' ALA . . . . . 0.58 ' HB1' ' HB1' ' A' ' 102' ' ' ALA . . . -60.02 146.7 41.78 Favored 'General case' 0 CA--C 1.517 -0.325 0 C-N-CA 122.709 0.403 . . . . 0.0 110.912 -179.899 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 97.3 mtt180 . . . . . 0 C--O 1.248 1.013 0 CA-C-O 118.323 -0.846 . . . . 0.0 111.021 -170.482 . . . . . . . . 0 0 . 1 . 021 nuclear orig full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 93.5 m-20 . . . . . 0 N--CA 1.476 0.865 0 CA-C-O 121.562 0.696 . . . . 0.0 110.536 . . . . . . . . . 0 0 . 1 . 021 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 6.5 p -112.64 0.65 8.97 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.149 0 CA-C-N 114.976 -1.011 . . . . 0.0 109.599 176.441 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 9.0 p -58.07 139.14 18.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 115.116 -0.947 . . . . 0.0 111.144 176.937 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 2.8 p -61.11 142.53 15.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 121.362 0.601 . . . . 0.0 111.172 178.624 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 5' ' ' THR . . . . . 0.44 ' HA ' ' HD3' ' A' ' 6' ' ' PRO . 8.9 t -95.02 132.73 27.54 Favored Pre-proline 0 C--N 1.313 -1.001 0 CA-C-N 115.211 -0.904 . . . . 0.0 111.119 -174.107 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.44 ' HD3' ' HA ' ' A' ' 5' ' ' THR . 0.9 OUTLIER -83.6 179.48 4.88 Favored 'Trans proline' 0 N--CA 1.456 -0.682 0 C-N-CA 123.768 2.979 . . . . 0.0 111.945 175.614 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . 58.26 55.15 5.24 Favored 'General case' 0 C--N 1.318 -0.778 0 CA-C-N 114.632 -1.167 . . . . 0.0 111.664 -179.812 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 79.3 t60 -83.98 -9.59 58.56 Favored 'General case' 0 C--N 1.31 -1.113 0 CA-C-N 114.034 -1.439 . . . . 0.0 108.724 172.484 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 17.2 pt-20 -64.71 135.92 56.38 Favored 'General case' 0 N--CA 1.453 -0.304 0 CA-C-N 115.289 -0.869 . . . . 0.0 110.056 -179.601 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -104.13 66.88 0.84 Allowed 'General case' 0 C--N 1.319 -0.72 0 CA-C-O 122.035 0.921 . . . . 0.0 110.737 -173.388 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 47.9 t -82.83 -61.32 1.79 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.179 0 CA-C-N 114.215 -1.357 . . . . 0.0 109.449 173.431 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 5.9 p 32.74 84.09 0.01 OUTLIER 'Isoleucine or valine' 0 C--O 1.237 0.419 0 C-N-CA 124.953 1.301 . . . . 0.0 113.677 178.87 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 7.1 ttm180 63.68 140.77 0.02 OUTLIER 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 113.597 -1.638 . . . . 0.0 113.298 177.689 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . 0.57 HG21 HG23 ' A' ' 20' ' ' THR . 3.0 t -103.72 160.38 4.67 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.981 0 N-CA-C 108.174 -1.047 . . . . 0.0 108.174 173.447 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -121.49 -54.71 0.22 Allowed Glycine 0 N--CA 1.433 -1.565 0 CA-C-N 115.423 -0.808 . . . . 0.0 111.638 -176.032 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 16' ' ' THR . . . . . 0.433 ' O ' ' HD3' ' A' ' 18' ' ' PRO . 20.8 m -65.51 -39.17 91.55 Favored 'General case' 0 C--N 1.312 -1.036 0 CA-C-N 114.555 -0.823 . . . . 0.0 110.755 178.722 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . 0.416 ' O ' ' HB ' ' A' ' 14' ' ' VAL . 27.1 mmtm -104.09 99.4 16.72 Favored Pre-proline 0 C--N 1.314 -0.969 0 CA-C-N 115.034 -0.985 . . . . 0.0 109.689 175.476 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . 0.433 ' HD3' ' O ' ' A' ' 16' ' ' THR . 14.8 Cg_exo -71.46 155.48 59.69 Favored 'Trans proline' 0 N--CA 1.452 -0.954 0 C-N-CA 122.352 2.035 . . . . 0.0 110.964 176.051 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 84.61 51.2 3.94 Favored Glycine 0 C--N 1.299 -1.503 0 CA-C-N 114.86 -1.064 . . . . 0.0 110.895 -178.001 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 20' ' ' THR . . . . . 0.57 HG23 HG21 ' A' ' 14' ' ' VAL . 26.5 m -58.42 -41.35 84.79 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 121.697 0.76 . . . . 0.0 110.034 179.514 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 48.5 mt-10 -144.75 140.06 28.27 Favored 'General case' 0 N--CA 1.439 -0.98 0 N-CA-C 106.59 -1.633 . . . . 0.0 106.59 175.053 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.451 ' HA ' ' HD3' ' A' ' 23' ' ' PRO . 41.0 t -71.2 113.89 22.97 Favored Pre-proline 0 C--N 1.314 -0.961 0 N-CA-C 107.99 -1.115 . . . . 0.0 107.99 176.731 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . 0.457 ' HA ' ' HD2' ' A' ' 24' ' ' PRO . 51.7 Cg_exo -53.74 125.89 20.09 Favored 'Trans proline' 0 C--N 1.345 0.362 0 C-N-CA 122.871 2.381 . . . . 0.0 113.672 -163.522 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . 0.457 ' HD2' ' HA ' ' A' ' 23' ' ' PRO . 10.3 Cg_endo -57.12 140.13 91.89 Favored 'Trans proline' 0 N--CA 1.447 -1.22 0 C-N-CA 123.186 2.591 . . . . 0.0 111.538 172.93 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.615 ' HB ' ' CG2' ' A' ' 83' ' ' ILE . 60.4 t -115.2 137.0 50.12 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.359 0 CA-C-N 114.722 -1.126 . . . . 0.0 109.119 179.567 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 34.9 mm -61.08 -23.81 31.12 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-N 115.409 -0.814 . . . . 0.0 112.171 -170.65 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.435 ' O ' HG12 ' A' ' 30' ' ' ILE . 19.4 m-20 -99.05 2.94 46.64 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-O 121.441 0.639 . . . . 0.0 109.791 -177.196 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -64.3 -11.54 47.05 Favored Glycine 0 CA--C 1.503 -0.656 0 CA-C-N 114.961 -1.018 . . . . 0.0 111.051 179.635 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 4.4 m -75.73 -41.27 53.85 Favored 'General case' 0 C--N 1.318 -0.794 0 CA-C-O 121.956 0.884 . . . . 0.0 109.116 177.225 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.554 ' HA ' ' HB1' ' A' ' 105' ' ' ALA . 0.9 OUTLIER -67.91 -38.99 80.94 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.726 0 CA-C-N 113.898 -1.501 . . . . 0.0 107.735 178.423 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 31' ' ' TRP . . . . . 0.494 ' HB2' HG12 ' A' ' 83' ' ' ILE . 32.6 m95 -67.98 -35.96 79.23 Favored 'General case' 0 C--N 1.317 -0.845 0 CA-C-N 114.472 -1.24 . . . . 0.0 110.619 -177.684 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.817 ' HB2' HH21 ' A' ' 79' ' ' ARG . 23.3 t70 -73.07 -37.59 66.74 Favored 'General case' 0 N--CA 1.446 -0.654 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.44 -179.349 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . 0.542 ' HB1' ' CB ' ' A' ' 105' ' ' ALA . . . -70.99 -34.15 71.1 Favored 'General case' 0 N--CA 1.446 -0.632 0 C-N-CA 120.707 -0.397 . . . . 0.0 110.787 176.494 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . 0.531 HG13 ' O ' ' A' ' 30' ' ' ILE . 61.1 mt -67.34 -46.89 82.76 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.283 0 CA-C-O 121.108 0.48 . . . . 0.0 110.701 175.201 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . 0.455 ' O ' ' HB3' ' A' ' 39' ' ' ALA . . . -63.19 -34.39 77.54 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.408 178.108 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -72.63 -15.01 77.67 Favored Glycine 0 N--CA 1.449 -0.491 0 N-CA-C 111.181 -0.768 . . . . 0.0 111.181 176.729 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.436 ' HB3' ' O ' ' A' ' 34' ' ' ILE . 41.3 t -87.18 -64.5 1.14 Allowed 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.296 -0.452 . . . . 0.0 111.292 -176.702 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . 0.784 ' HG3' ' SG ' ' A' ' 101' ' ' CYS . 40.8 mt-10 -88.94 -29.62 19.42 Favored 'General case' 0 CA--C 1.516 -0.357 0 CA-C-O 120.813 0.34 . . . . 0.0 111.784 -173.277 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . 0.455 ' HB3' ' O ' ' A' ' 35' ' ' ALA . . . -92.72 -11.33 34.26 Favored 'General case' 0 C--N 1.322 -0.619 0 C-N-CA 120.455 -0.498 . . . . 0.0 111.316 -176.956 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 76.24 15.52 81.39 Favored Glycine 0 N--CA 1.446 -0.664 0 N-CA-C 109.782 -1.327 . . . . 0.0 109.782 -176.229 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 75.11 51.68 7.4 Favored Glycine 0 N--CA 1.436 -1.339 0 CA-C-N 114.268 -0.966 . . . . 0.0 111.939 -176.449 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 2.2 t-20 -140.67 100.1 3.78 Favored 'General case' 0 N--CA 1.448 -0.542 0 N-CA-C 108.855 -0.795 . . . . 0.0 108.855 179.947 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 43' ' ' TRP . . . . . 0.715 ' CE3' ' HA ' ' A' ' 79' ' ' ARG . 30.9 m95 -82.78 -12.69 57.31 Favored 'General case' 0 C--N 1.313 -1.009 0 CA-C-N 115.241 -0.891 . . . . 0.0 110.529 -172.846 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -104.61 10.99 34.7 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 115.455 -0.793 . . . . 0.0 111.272 -178.145 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.682 HG23 ' CA ' ' A' ' 53' ' ' GLY . 4.0 tt -74.04 143.72 13.28 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.655 0 CA-C-O 121.0 0.429 . . . . 0.0 109.915 179.507 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 17.6 t-20 -142.75 87.22 1.98 Allowed 'General case' 0 C--N 1.313 -0.989 0 CA-C-O 121.286 0.565 . . . . 0.0 109.567 -179.171 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 22.7 p -74.12 -24.57 59.47 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.648 179.983 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 92.43 19.57 37.94 Favored Glycine 0 N--CA 1.445 -0.709 0 N-CA-C 110.824 -0.91 . . . . 0.0 110.824 -177.913 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 64.8 t30 -74.94 -7.31 53.19 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 121.384 0.611 . . . . 0.0 111.12 -174.635 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . 0.515 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 95.73 -12.94 67.03 Favored Glycine 0 CA--C 1.504 -0.643 0 N-CA-C 109.47 -1.452 . . . . 0.0 109.47 -173.252 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 51' ' ' TYR . . . . . 0.534 ' HA ' ' HA ' ' A' ' 58' ' ' ASP . 0.5 OUTLIER -114.74 160.9 18.86 Favored 'General case' 0 N--CA 1.439 -0.984 0 N-CA-C 106.132 -1.803 . . . . 0.0 106.132 173.187 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 52' ' ' TYR . . . . . 0.563 ' O ' ' HA ' ' A' ' 56' ' ' GLN . 55.5 m-85 -123.51 169.4 11.44 Favored 'General case' 0 C--N 1.308 -1.207 0 C-N-CA 120.085 -0.646 . . . . 0.0 111.403 -169.702 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.682 ' CA ' HG23 ' A' ' 45' ' ' ILE . . . -59.31 171.34 5.25 Favored Glycine 0 N--CA 1.445 -0.724 0 O-C-N 123.778 0.674 . . . . 0.0 113.821 -173.212 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . 0.695 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 87.79 -107.78 3.33 Favored Glycine 0 N--CA 1.44 -1.09 0 C-N-CA 120.708 -0.758 . . . . 0.0 111.77 -179.391 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.513 ' HB ' ' CD1' ' A' ' 57' ' ' PHE . 2.0 t -84.6 0.58 5.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.542 0 CA-C-O 121.276 0.56 . . . . 0.0 110.277 -177.555 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 56' ' ' GLN . . . . . 0.563 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 79.3 mm-40 58.05 44.59 19.16 Favored 'General case' 0 N--CA 1.462 0.164 0 CA-C-N 114.971 -1.013 . . . . 0.0 113.169 170.886 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . 0.513 ' CD1' ' HB ' ' A' ' 55' ' ' VAL . 1.6 p90 -118.98 164.26 15.72 Favored 'General case' 0 C--N 1.325 -0.472 0 C-N-CA 119.435 -0.906 . . . . 0.0 111.914 177.301 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.534 ' HA ' ' HA ' ' A' ' 51' ' ' TYR . 7.9 p-10 -74.81 165.57 25.03 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 114.985 -1.007 . . . . 0.0 113.685 -163.512 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.424 ' HB2' ' HE1' ' A' ' 52' ' ' TYR . 19.5 tp60 -59.26 -41.95 90.04 Favored 'General case' 0 N--CA 1.438 -1.044 0 CA-C-N 114.538 -1.21 . . . . 0.0 110.945 178.184 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -68.1 -49.45 46.89 Favored Glycine 0 C--O 1.225 -0.45 0 CA-C-N 115.617 -0.719 . . . . 0.0 112.614 -172.35 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 86.7 m -62.25 -42.37 99.26 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-O 121.098 0.475 . . . . 0.0 110.761 178.624 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 62' ' ' TRP . . . . . 0.503 ' CH2' ' HA ' ' A' ' 74' ' ' ALA . 53.4 t-105 -56.62 -51.25 69.41 Favored 'General case' 0 N--CA 1.448 -0.565 0 CA-C-N 115.133 -0.94 . . . . 0.0 109.39 175.323 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . 1.021 ' HG3' HD13 ' A' ' 68' ' ' LEU . 24.0 tt0 -64.43 -38.36 90.75 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-N 114.544 -1.207 . . . . 0.0 111.275 -177.606 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -67.71 -42.39 82.03 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.935 -0.575 . . . . 0.0 111.424 -175.027 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . 0.62 HD21 ' N ' ' A' ' 65' ' ' ASN . 0.7 OUTLIER -77.96 -8.85 58.69 Favored 'General case' 0 N--CA 1.451 -0.405 0 CA-C-O 121.316 0.579 . . . . 0.0 109.672 176.812 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . 0.509 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 90.17 47.71 3.76 Favored Glycine 0 N--CA 1.449 -0.498 0 CA-C-N 115.438 -0.801 . . . . 0.0 112.417 173.386 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . 0.549 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -80.47 -16.39 76.01 Favored Glycine 0 N--CA 1.444 -0.813 0 C-N-CA 120.876 -0.678 . . . . 0.0 112.065 -177.14 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 1.021 HD13 ' HG3' ' A' ' 63' ' ' GLU . 20.8 mt -65.53 -28.58 69.27 Favored 'General case' 0 C--N 1.314 -0.937 0 CA-C-O 120.999 0.428 . . . . 0.0 111.351 -171.06 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . 0.509 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 11.7 ptm180 -65.04 -31.69 73.04 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.217 175.379 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 70' ' ' TYR . . . . . 0.803 ' HB3' ' HB3' ' A' ' 81' ' ' GLU . 89.9 m-85 -77.4 -34.61 54.79 Favored 'General case' 0 CA--C 1.505 -0.755 0 N-CA-C 107.723 -1.214 . . . . 0.0 107.723 178.328 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.559 ' HB2' ' HB3' ' A' ' 77' ' ' ALA . . . 164.65 123.57 0.02 OUTLIER Pre-proline 0 C--N 1.319 -0.724 0 CA-C-N 112.125 -2.307 . . . . 0.0 106.859 -178.232 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 72' ' ' PRO . . . . . 0.53 ' HA ' ' HA ' ' A' ' 68' ' ' LEU . 38.6 Cg_exo -51.76 -6.48 0.17 Allowed 'Trans proline' 0 CA--C 1.53 0.282 0 C-N-CA 123.16 2.573 . . . . 0.0 114.393 -178.513 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 9.2 ptm180 -146.85 142.67 27.91 Favored 'General case' 0 C--N 1.315 -0.91 0 N-CA-C 108.825 -0.805 . . . . 0.0 108.825 174.905 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . 0.503 ' HA ' ' CH2' ' A' ' 62' ' ' TRP . . . -58.35 -33.08 69.15 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.679 -0.691 . . . . 0.0 112.753 -177.129 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . 0.557 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 4.3 p-10 -80.28 -10.22 59.75 Favored 'General case' 0 C--N 1.331 -0.231 0 C-N-CA 120.668 -0.413 . . . . 0.0 111.247 -173.931 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.466 ' HB3' ' HB1' ' A' ' 71' ' ' ALA . 62.5 tp -87.23 -32.49 19.74 Favored 'General case' 0 C--N 1.323 -0.552 0 N-CA-C 108.869 -0.789 . . . . 0.0 108.869 173.66 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . 0.815 ' HB1' ' HB2' ' A' ' 81' ' ' GLU . . . -82.22 161.08 22.84 Favored 'General case' 0 N--CA 1.442 -0.853 0 CA-C-N 114.98 -1.009 . . . . 0.0 110.371 176.171 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 20.0 p -100.59 -170.59 1.88 Allowed 'General case' 0 C--N 1.316 -0.876 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.088 179.127 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . 0.817 HH21 ' HB2' ' A' ' 32' ' ' ASP . 39.1 mtp180 -48.98 -53.48 19.66 Favored 'General case' 0 CA--C 1.515 -0.391 0 O-C-N 123.498 0.499 . . . . 0.0 111.005 -177.044 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 2.5 pt-20 -60.91 -42.47 98.16 Favored 'General case' 0 C--N 1.315 -0.928 0 CA-C-N 114.972 -1.013 . . . . 0.0 112.895 -171.486 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 81' ' ' GLU . . . . . 0.815 ' HB2' ' HB1' ' A' ' 77' ' ' ALA . 9.1 mp0 -63.38 -50.67 68.99 Favored 'General case' 0 N--CA 1.455 -0.196 0 CA-C-N 118.194 0.452 . . . . 0.0 111.491 175.163 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 82' ' ' GLN . . . . . 0.58 ' HB2' ' HZ3' ' A' ' 43' ' ' TRP . 48.0 mt-30 -61.87 -36.79 82.3 Favored 'General case' 0 CA--C 1.515 -0.369 0 CA-C-O 121.122 0.487 . . . . 0.0 110.309 -177.673 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . 0.615 ' CG2' ' HB ' ' A' ' 25' ' ' VAL . 33.8 mt -59.4 -44.0 91.61 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.686 0 CA-C-N 114.982 -1.008 . . . . 0.0 109.973 177.119 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . 0.604 ' O ' ' HG3' ' A' ' 87' ' ' GLU . . . -66.57 -45.38 79.49 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 116.038 -0.528 . . . . 0.0 111.47 -179.503 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . 0.509 HG21 ' O ' ' A' ' 81' ' ' GLU . 40.1 t -67.73 -50.21 62.56 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-N 116.305 -0.407 . . . . 0.0 112.018 -179.343 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -63.67 -30.96 71.99 Favored 'General case' 0 N--CA 1.449 -0.502 0 CA-C-O 121.002 0.43 . . . . 0.0 110.542 178.962 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 87' ' ' GLU . . . . . 0.604 ' HG3' ' O ' ' A' ' 84' ' ' ALA . 0.1 OUTLIER -70.36 -29.97 66.78 Favored 'General case' 0 C--N 1.325 -0.489 0 C-N-CA 120.418 -0.513 . . . . 0.0 110.438 -177.788 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 53.8 t -62.31 -43.31 97.92 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.258 0 N-CA-C 108.831 -0.803 . . . . 0.0 108.831 170.479 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 89' ' ' THR . . . . . 0.706 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 0.6 OUTLIER -65.67 -43.22 89.98 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 115.232 -0.895 . . . . 0.0 110.689 -177.971 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . 0.586 ' HG3' ' O ' ' A' ' 87' ' ' GLU . 4.2 ppt_? -66.37 -33.52 75.89 Favored 'General case' 0 CA--C 1.513 -0.47 0 N-CA-C 109.213 -0.662 . . . . 0.0 109.213 -178.929 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . 0.456 ' O ' HD11 ' A' ' 91' ' ' LEU . 2.2 tm? -57.21 -34.8 68.91 Favored 'General case' 0 C--N 1.318 -0.786 0 CA-C-N 114.386 -1.279 . . . . 0.0 110.095 -174.931 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 3.4 mtm180 -92.49 -39.9 11.13 Favored 'General case' 0 C--N 1.315 -0.934 0 CA-C-N 115.18 -0.918 . . . . 0.0 109.91 -172.227 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 93' ' ' GLN . . . . . 0.479 ' NE2' ' CZ3' ' A' ' 98' ' ' TRP . 7.5 pt20 -94.63 -30.73 14.18 Favored 'General case' 0 C--N 1.316 -0.871 0 CA-C-N 114.27 -1.332 . . . . 0.0 113.777 -169.335 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 86.17 32.46 17.03 Favored Glycine 0 CA--C 1.52 0.345 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.619 178.207 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 95' ' ' TRP . . . . . 0.453 ' CE2' ' HD3' ' A' ' 90' ' ' ARG . 13.5 m95 66.82 16.27 10.33 Favored 'General case' 0 N--CA 1.466 0.355 0 C-N-CA 123.395 0.678 . . . . 0.0 110.085 178.095 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -63.94 -41.69 98.59 Favored Glycine 0 CA--C 1.519 0.326 0 CA-C-N 115.461 -0.79 . . . . 0.0 113.65 -179.852 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . 0.492 ' O ' ' HD3' ' A' ' 99' ' ' PRO . . . -78.59 -21.62 48.3 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 117.072 0.436 . . . . 0.0 111.259 -178.456 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 98' ' ' TRP . . . . . 0.706 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 16.3 m-90 -85.54 104.53 5.2 Favored Pre-proline 0 C--O 1.225 -0.226 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 170.118 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . 0.492 ' HD3' ' O ' ' A' ' 97' ' ' ALA . 11.7 Cg_exo -76.28 -95.59 0.01 OUTLIER 'Trans proline' 0 N--CA 1.457 -0.648 0 C-N-CA 122.435 2.09 . . . . 0.0 115.087 -171.275 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 38.3 t -71.32 -30.09 38.49 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.445 0 CA-C-O 121.72 0.771 . . . . 0.0 110.411 -169.07 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 101' ' ' CYS . . . . . 0.784 ' SG ' ' HG3' ' A' ' 38' ' ' GLU . 60.8 m -81.8 -25.66 35.04 Favored 'General case' 0 C--N 1.316 -0.855 0 CA-C-N 115.193 -0.912 . . . . 0.0 111.363 -169.722 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -69.82 -45.21 68.39 Favored 'General case' 0 C--N 1.33 -0.276 0 N-CA-C 110.04 -0.355 . . . . 0.0 110.04 176.502 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -61.96 -39.34 91.78 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 121.307 0.575 . . . . 0.0 110.63 177.512 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 12.5 mtp180 -66.09 -39.02 89.66 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.438 -0.801 . . . . 0.0 111.476 177.405 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 105' ' ' ALA . . . . . 0.554 ' HB1' ' HA ' ' A' ' 30' ' ' ILE . . . -83.56 -22.07 32.47 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 112.583 0.586 . . . . 0.0 112.583 -174.026 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 107.71 61.05 0.56 Allowed Glycine 0 CA--C 1.521 0.459 0 C-N-CA 121.035 -0.602 . . . . 0.0 112.506 -179.56 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -62.45 149.22 43.28 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 121.037 0.446 . . . . 0.0 111.528 -176.342 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 92.6 mtt180 . . . . . 0 C--O 1.249 1.067 0 CA-C-N 115.628 -0.715 . . . . 0.0 110.57 -172.596 . . . . . . . . 0 0 . 1 . 022 nuclear orig full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 13.4 m120 . . . . . 0 N--CA 1.479 1.019 0 N-CA-C 110.045 -0.354 . . . . 0.0 110.045 . . . . . . . . . 0 0 . 1 . 022 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 54.2 t -82.33 -54.73 8.98 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.508 178.804 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . 0.489 ' O ' HG13 ' A' ' 4' ' ' VAL . 56.7 t -92.91 107.03 18.58 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.797 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.324 -179.254 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . 0.489 HG13 ' O ' ' A' ' 3' ' ' VAL . 2.4 p 50.97 165.97 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.535 0.366 0 N-CA-C 115.08 1.511 . . . . 0.0 115.08 176.081 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 5' ' ' THR . . . . . 0.42 ' HA ' ' HD3' ' A' ' 6' ' ' PRO . 2.5 p -104.71 126.73 30.5 Favored Pre-proline 0 C--N 1.314 -0.943 0 CA-C-N 113.552 -1.658 . . . . 0.0 109.91 175.965 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.42 ' HD3' ' HA ' ' A' ' 5' ' ' THR . 16.9 Cg_exo -68.21 173.94 8.78 Favored 'Trans proline' 0 CA--C 1.513 -0.526 0 C-N-CA 123.231 2.621 . . . . 0.0 112.436 -178.34 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . 61.3 76.84 0.35 Allowed 'General case' 0 C--N 1.315 -0.924 0 CA-C-N 114.031 -1.44 . . . . 0.0 111.73 -177.297 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 9.9 t-160 -105.89 8.1 32.49 Favored 'General case' 0 C--N 1.314 -0.97 0 CA-C-N 114.12 -1.4 . . . . 0.0 107.796 171.981 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 10.5 pt-20 -47.88 147.28 2.06 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 113.871 -1.513 . . . . 0.0 112.419 178.913 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -109.08 67.97 0.67 Allowed 'General case' 0 C--N 1.318 -0.767 0 CA-C-O 122.049 0.928 . . . . 0.0 110.183 -176.18 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 12.0 p -65.11 -27.11 41.46 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.017 0 CA-C-N 113.953 -1.476 . . . . 0.0 109.929 174.844 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 6.1 p 35.21 91.7 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.239 0.514 0 C-N-CA 125.43 1.492 . . . . 0.0 114.675 173.986 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 47.8 mtm180 -71.72 113.19 8.5 Favored 'General case' 0 N--CA 1.429 -1.525 0 CA-C-N 113.748 -1.569 . . . . 0.0 108.1 170.791 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.5 p -37.81 119.0 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.813 0 CA-C-N 114.039 -1.437 . . . . 0.0 113.87 -172.27 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -145.68 60.34 0.49 Allowed Glycine 0 N--CA 1.43 -1.703 0 CA-C-N 113.531 -1.668 . . . . 0.0 111.008 177.406 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 90.1 m -98.48 -22.14 16.17 Favored 'General case' 0 C--N 1.312 -1.046 0 CA-C-N 114.458 -0.871 . . . . 0.0 110.404 -175.902 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . 0.55 ' HG2' ' O ' ' A' ' 76' ' ' LEU . 0.0 OUTLIER 50.81 87.47 0.13 Allowed Pre-proline 0 C--N 1.321 -0.674 0 CA-C-N 115.001 -1.0 . . . . 0.0 112.008 -178.763 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 26.2 Cg_exo -42.45 111.43 0.2 Allowed 'Trans proline' 0 CA--C 1.508 -0.788 0 C-N-CA 123.595 2.864 . . . . 0.0 112.741 176.084 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 154.18 55.76 0.01 OUTLIER Glycine 0 C--N 1.299 -1.478 0 CA-C-N 113.058 -1.883 . . . . 0.0 110.178 -174.028 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 3.9 m -57.2 -40.3 77.16 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 114.525 -0.837 . . . . 0.0 111.912 -173.734 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 42.1 mt-10 -117.33 82.28 1.79 Allowed 'General case' 0 CA--C 1.512 -0.499 0 CA-C-O 121.708 0.766 . . . . 0.0 111.634 177.863 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 3.3 p -75.65 123.97 88.62 Favored Pre-proline 0 C--N 1.307 -1.272 0 CA-C-N 114.282 -1.326 . . . . 0.0 110.017 174.471 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_exo -55.19 126.82 23.83 Favored 'Trans proline' 0 C--O 1.235 0.348 0 C-N-CA 122.6 2.2 . . . . 0.0 112.699 -178.554 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_exo -57.26 141.28 94.58 Favored 'Trans proline' 0 N--CA 1.443 -1.497 0 C-N-CA 123.263 2.642 . . . . 0.0 112.851 175.487 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 33.6 t -100.75 157.59 4.12 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.171 0 CA-C-N 114.665 -1.152 . . . . 0.0 108.68 176.782 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 49.6 mm -55.32 -39.27 51.45 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-O 121.013 0.435 . . . . 0.0 111.586 -170.874 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.464 ' O ' HG12 ' A' ' 30' ' ' ILE . 7.6 m-20 -111.25 9.08 21.72 Favored 'General case' 0 C--N 1.318 -0.785 0 CA-C-O 121.749 0.785 . . . . 0.0 109.397 -178.908 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -69.92 -5.31 51.9 Favored Glycine 0 N--CA 1.441 -1.004 0 CA-C-N 114.702 -1.136 . . . . 0.0 110.802 178.701 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 12.5 m -76.86 -42.95 38.0 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-O 121.813 0.816 . . . . 0.0 109.11 174.512 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.713 ' HA ' ' HB3' ' A' ' 105' ' ' ALA . 0.4 OUTLIER -66.58 -38.75 82.3 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-N 114.274 -1.33 . . . . 0.0 107.728 178.426 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 31' ' ' TRP . . . . . 0.459 ' CZ2' ' HD3' ' A' ' 90' ' ' ARG . 26.3 m95 -70.05 -35.0 73.94 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 114.572 -1.195 . . . . 0.0 110.516 -178.395 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 32.5 t70 -76.14 -37.63 57.77 Favored 'General case' 0 N--CA 1.449 -0.518 0 CA-C-N 116.024 -0.534 . . . . 0.0 110.349 -179.095 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . 0.524 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -70.59 -34.06 71.75 Favored 'General case' 0 N--CA 1.45 -0.441 0 C-N-CA 120.792 -0.363 . . . . 0.0 110.647 177.417 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . 0.498 HG13 ' O ' ' A' ' 30' ' ' ILE . 74.6 mt -65.55 -45.11 93.48 Favored 'Isoleucine or valine' 0 C--O 1.234 0.252 0 CA-C-O 121.168 0.509 . . . . 0.0 109.841 173.113 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -58.45 -38.3 77.22 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.611 -0.722 . . . . 0.0 110.014 175.074 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . 0.406 ' HA2' ' N ' ' A' ' 41' ' ' GLY . . . -72.2 -12.31 76.0 Favored Glycine 0 N--CA 1.449 -0.456 0 CA-C-N 115.399 -0.819 . . . . 0.0 111.835 179.139 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 46.8 t -88.78 -62.77 1.41 Allowed 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 115.614 -0.293 . . . . 0.0 111.118 -178.249 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 34.2 mt-10 -90.0 -33.37 16.39 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 120.969 0.414 . . . . 0.0 111.185 -174.107 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -93.78 -8.57 40.24 Favored 'General case' 0 N--CA 1.45 -0.471 0 C-N-CA 120.547 -0.461 . . . . 0.0 111.763 -174.755 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 79.71 7.16 88.71 Favored Glycine 0 CA--C 1.505 -0.579 0 N-CA-C 110.26 -1.136 . . . . 0.0 110.26 -178.106 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . 0.406 ' N ' ' HA2' ' A' ' 36' ' ' GLY . . . 81.76 50.78 4.81 Favored Glycine 0 N--CA 1.435 -1.374 0 CA-C-N 114.324 -0.938 . . . . 0.0 112.656 -178.537 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 44.7 t-20 -144.26 128.56 17.82 Favored 'General case' 0 N--CA 1.441 -0.9 0 N-CA-C 107.871 -1.159 . . . . 0.0 107.871 178.256 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 43' ' ' TRP . . . . . 0.785 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 17.6 m95 -103.38 0.41 31.25 Favored 'General case' 0 C--N 1.306 -1.304 0 CA-C-N 115.589 -0.732 . . . . 0.0 110.313 -173.549 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -112.55 -2.47 14.61 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-N 115.4 -0.818 . . . . 0.0 111.011 178.396 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 10.0 tt -66.6 143.4 15.63 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.79 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.078 177.991 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 17.7 t-20 -143.59 91.68 2.27 Favored 'General case' 0 C--N 1.317 -0.83 0 CA-C-O 121.471 0.653 . . . . 0.0 109.334 -179.077 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -73.69 -19.17 60.9 Favored 'General case' 0 N--CA 1.437 -1.085 0 CA-C-N 115.065 -0.971 . . . . 0.0 110.555 177.51 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 82.88 23.01 56.82 Favored Glycine 0 N--CA 1.445 -0.732 0 CA-C-N 115.51 -0.768 . . . . 0.0 111.247 174.315 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 4.6 p-10 -93.5 15.38 16.11 Favored 'General case' 0 C--N 1.325 -0.5 0 N-CA-C 112.247 0.462 . . . . 0.0 112.247 -172.073 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . 0.517 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 95.06 -13.51 66.91 Favored Glycine 0 CA--C 1.508 -0.358 0 N-CA-C 110.789 -0.925 . . . . 0.0 110.789 178.859 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 51' ' ' TYR . . . . . 0.517 ' HD1' ' C ' ' A' ' 50' ' ' GLY . 0.1 OUTLIER -121.52 161.58 22.06 Favored 'General case' 0 N--CA 1.441 -0.881 0 N-CA-C 105.286 -2.116 . . . . 0.0 105.286 174.483 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 52' ' ' TYR . . . . . 0.729 ' O ' ' HA ' ' A' ' 56' ' ' GLN . 20.8 m-85 -126.97 167.85 15.33 Favored 'General case' 0 C--N 1.302 -1.487 0 C-N-CA 119.621 -0.832 . . . . 0.0 111.231 -169.827 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -55.31 164.18 4.1 Favored Glycine 0 N--CA 1.446 -0.689 0 O-C-N 123.881 0.738 . . . . 0.0 114.105 -175.852 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . 0.604 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 97.1 -112.99 4.59 Favored Glycine 0 N--CA 1.439 -1.155 0 N-CA-C 111.421 -0.672 . . . . 0.0 111.421 -176.423 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.48 HG22 ' HB3' ' A' ' 82' ' ' GLN . 2.2 t -84.81 -3.5 8.13 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 CA-C-O 121.826 0.822 . . . . 0.0 109.783 -178.418 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 56' ' ' GLN . . . . . 0.729 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 6.4 tt0 50.36 50.57 18.47 Favored 'General case' 0 N--CA 1.463 0.213 0 CA-C-N 113.774 -1.557 . . . . 0.0 113.498 173.314 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . 0.45 ' CD1' ' HB ' ' A' ' 55' ' ' VAL . 2.8 p90 -113.41 159.35 19.55 Favored 'General case' 0 C--N 1.321 -0.64 0 C-N-CA 119.925 -0.71 . . . . 0.0 110.684 171.668 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.415 ' HB3' ' CD1' ' A' ' 51' ' ' TYR . 5.9 p-10 -71.29 157.75 37.57 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-O 121.75 0.786 . . . . 0.0 112.869 -163.922 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.669 ' HA ' HE21 ' A' ' 59' ' ' GLN . 0.0 OUTLIER -55.8 -35.75 66.65 Favored 'General case' 0 N--CA 1.447 -0.603 0 CA-C-N 114.193 -1.367 . . . . 0.0 111.371 178.944 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -68.12 -49.75 44.7 Favored Glycine 0 N--CA 1.45 -0.407 0 CA-C-N 115.572 -0.74 . . . . 0.0 112.155 -175.896 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 51.3 m -65.19 -41.23 94.76 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-O 121.113 0.482 . . . . 0.0 110.595 176.447 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 62' ' ' TRP . . . . . 0.595 ' CZ3' ' HG2' ' A' ' 82' ' ' GLN . 54.5 t-105 -56.5 -48.89 76.23 Favored 'General case' 0 N--CA 1.448 -0.531 0 CA-C-N 115.493 -0.776 . . . . 0.0 109.389 175.833 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . 0.468 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 34.9 tt0 -68.25 -32.49 72.71 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 115.105 -0.952 . . . . 0.0 111.217 -179.505 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -65.53 -41.21 93.34 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.991 -0.549 . . . . 0.0 110.711 -178.552 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . 0.502 ' HB2' HG13 ' A' ' 85' ' ' VAL . 5.9 m120 -81.13 -8.07 59.69 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.45 0.643 . . . . 0.0 109.862 175.239 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . 0.416 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 80.74 50.26 5.34 Favored Glycine 0 N--CA 1.449 -0.454 0 CA-C-N 115.031 -0.986 . . . . 0.0 112.828 174.903 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . 0.595 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -78.58 -18.55 75.46 Favored Glycine 0 N--CA 1.442 -0.966 0 C-N-CA 120.957 -0.64 . . . . 0.0 112.086 -176.499 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 0.893 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 7.0 mp -60.34 -20.2 58.4 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 111.994 0.368 . . . . 0.0 111.994 -176.09 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . 0.416 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 9.9 ptm180 -70.57 -31.86 69.05 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-O 121.253 0.549 . . . . 0.0 109.823 177.238 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 70' ' ' TYR . . . . . 0.595 ' HD2' ' HA2' ' A' ' 67' ' ' GLY . 43.8 m-85 -85.3 -34.0 21.99 Favored 'General case' 0 N--CA 1.438 -1.04 0 N-CA-C 107.71 -1.218 . . . . 0.0 107.71 178.239 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.495 ' HB3' ' HB3' ' A' ' 76' ' ' LEU . . . 170.69 122.06 0.05 OUTLIER Pre-proline 0 N--CA 1.45 -0.454 0 CA-C-N 113.247 -1.797 . . . . 0.0 107.83 -177.301 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 72' ' ' PRO . . . . . 0.893 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 25.1 Cg_exo -55.34 -7.94 1.48 Allowed 'Trans proline' 0 C--N 1.334 -0.192 0 C-N-CA 123.01 2.473 . . . . 0.0 113.789 -178.737 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 13.4 ptm180 -142.99 136.86 28.88 Favored 'General case' 0 C--N 1.317 -0.825 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 177.461 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . 0.471 ' HA ' ' CH2' ' A' ' 62' ' ' TRP . . . -60.22 -28.11 67.74 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.199 -0.91 . . . . 0.0 112.238 -175.351 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . 0.565 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 19.5 p-10 -84.79 -8.99 58.6 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 121.072 0.463 . . . . 0.0 111.344 -176.712 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.55 ' O ' ' HG2' ' A' ' 17' ' ' LYS . 57.2 tp -84.96 -32.36 23.07 Favored 'General case' 0 C--N 1.32 -0.682 0 N-CA-C 108.107 -1.071 . . . . 0.0 108.107 169.361 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . 0.938 ' HB3' ' HB2' ' A' ' 81' ' ' GLU . . . -77.93 154.23 31.82 Favored 'General case' 0 N--CA 1.44 -0.935 0 CA-C-N 114.953 -1.021 . . . . 0.0 110.851 177.071 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 78' ' ' THR . . . . . 0.529 ' H ' ' CD ' ' A' ' 81' ' ' GLU . 19.5 p -99.91 -169.89 1.81 Allowed 'General case' 0 C--N 1.315 -0.895 0 CA-C-N 115.656 -0.702 . . . . 0.0 109.552 176.786 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . 0.785 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 79.8 mtp180 -49.66 -51.41 38.22 Favored 'General case' 0 C--N 1.329 -0.31 0 O-C-N 123.418 0.449 . . . . 0.0 111.305 -176.974 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 80' ' ' GLU . . . . . 0.439 ' HG3' ' N ' ' A' ' 81' ' ' GLU . 10.0 pt-20 -60.87 -47.56 85.82 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 112.457 0.54 . . . . 0.0 112.457 -173.361 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 81' ' ' GLU . . . . . 0.938 ' HB2' ' HB3' ' A' ' 77' ' ' ALA . 4.4 mp0 -60.96 -50.64 72.59 Favored 'General case' 0 CA--C 1.518 -0.26 0 CA-C-O 121.064 0.459 . . . . 0.0 111.03 178.382 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 82' ' ' GLN . . . . . 0.595 ' HG2' ' CZ3' ' A' ' 62' ' ' TRP . 34.2 mt-30 -63.65 -37.05 85.88 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.789 -0.641 . . . . 0.0 111.421 -176.682 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . 0.68 ' O ' ' HG2' ' A' ' 87' ' ' GLU . 40.0 mt -60.14 -44.47 95.27 Favored 'Isoleucine or valine' 0 C--O 1.213 -0.841 0 N-CA-C 109.461 -0.57 . . . . 0.0 109.461 174.211 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . 0.602 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -62.7 -43.6 98.39 Favored 'General case' 0 C--O 1.236 0.346 0 CA-C-O 121.208 0.528 . . . . 0.0 111.792 -177.023 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . 0.502 HG13 ' HB2' ' A' ' 65' ' ' ASN . 32.4 t -67.5 -47.86 79.07 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.332 178.845 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -59.07 -29.75 67.56 Favored 'General case' 0 N--CA 1.455 -0.225 0 CA-C-N 115.531 -0.759 . . . . 0.0 110.468 174.859 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 87' ' ' GLU . . . . . 0.68 ' HG2' ' O ' ' A' ' 83' ' ' ILE . 25.9 mm-40 -59.51 -43.42 93.38 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.605 -0.725 . . . . 0.0 110.115 178.649 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.681 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 96.9 t -62.64 -48.47 88.04 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.322 0 CA-C-O 121.127 0.489 . . . . 0.0 110.124 176.454 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 89' ' ' THR . . . . . 0.76 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 0.2 OUTLIER -64.56 -47.62 78.07 Favored 'General case' 0 C--N 1.317 -0.84 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.989 -175.433 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . 0.459 ' HD3' ' CZ2' ' A' ' 31' ' ' TRP . 7.9 ptt180 -62.52 -33.06 74.14 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.858 -175.84 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . 0.681 ' HG ' ' O ' ' A' ' 88' ' ' VAL . 4.4 pp -73.57 -23.45 59.95 Favored 'General case' 0 C--N 1.321 -0.637 0 C-N-CA 120.623 -0.431 . . . . 0.0 111.069 -172.013 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . 0.547 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 6.1 mtm180 -84.2 -45.86 12.48 Favored 'General case' 0 N--CA 1.45 -0.468 0 CA-C-O 121.369 0.605 . . . . 0.0 109.654 -178.487 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 9.1 pt20 -102.89 -27.98 12.32 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 113.924 1.083 . . . . 0.0 113.924 -169.603 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 83.68 50.95 4.23 Favored Glycine 0 CA--C 1.507 -0.448 0 C-N-CA 120.699 -0.762 . . . . 0.0 111.834 178.735 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 95' ' ' TRP . . . . . 0.485 ' HA ' ' HE3' ' A' ' 98' ' ' TRP . 2.5 m95 60.47 22.77 12.41 Favored 'General case' 0 C--O 1.224 -0.251 0 CA-C-O 121.282 0.563 . . . . 0.0 109.674 177.098 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -75.53 -20.77 78.23 Favored Glycine 0 N--CA 1.447 -0.586 0 CA-C-N 115.368 -0.833 . . . . 0.0 112.569 178.454 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -89.77 -17.49 28.12 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 121.096 0.475 . . . . 0.0 110.173 176.253 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 98' ' ' TRP . . . . . 0.76 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 23.3 m-90 -100.09 113.14 65.14 Favored Pre-proline 0 N--CA 1.444 -0.738 0 CA-C-N 115.73 -0.668 . . . . 0.0 109.433 178.748 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . 0.431 ' HD3' ' HA ' ' A' ' 98' ' ' TRP . 52.8 Cg_exo -61.93 -145.33 0.01 OUTLIER 'Trans proline' 0 CA--C 1.535 0.542 0 C-N-CA 123.954 3.103 . . . . 0.0 114.315 -173.738 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . 0.406 HG13 ' HG3' ' A' ' 104' ' ' ARG . 58.5 t -55.84 -24.4 16.88 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.307 0 CA-C-N 115.919 -0.582 . . . . 0.0 111.032 -179.791 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 56.6 m -56.44 -36.36 68.91 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.003 177.436 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -69.77 -42.88 73.23 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.834 0.349 . . . . 0.0 110.639 178.891 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -64.37 -42.78 96.0 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.51 178.837 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 104' ' ' ARG . . . . . 0.406 ' HG3' HG13 ' A' ' 100' ' ' VAL . 68.4 mtp180 -60.14 -39.49 86.5 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.389 -0.823 . . . . 0.0 110.916 176.262 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 105' ' ' ALA . . . . . 0.713 ' HB3' ' HA ' ' A' ' 30' ' ' ILE . . . -78.07 -22.05 49.63 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.628 -0.714 . . . . 0.0 112.114 -175.997 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 102.51 64.41 0.73 Allowed Glycine 0 CA--C 1.519 0.318 0 C-N-CA 120.935 -0.65 . . . . 0.0 112.188 -178.23 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -71.1 152.34 43.57 Favored 'General case' 0 C--N 1.324 -0.527 0 C-N-CA 122.649 0.379 . . . . 0.0 111.491 -175.29 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 27.6 mtt180 . . . . . 0 C--O 1.247 0.971 0 CA-C-O 117.702 -1.142 . . . . 0.0 112.464 174.618 . . . . . . . . 0 0 . 1 . 023 nuclear orig full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 17.0 p-10 . . . . . 0 N--CA 1.478 0.965 0 CA-C-O 121.192 0.52 . . . . 0.0 110.693 . . . . . . . . . 0 0 . 1 . 023 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 11.0 p -97.37 -19.99 5.82 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 115.744 -0.662 . . . . 0.0 110.417 177.367 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 57.9 t -73.89 126.15 34.17 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.698 0 CA-C-N 115.642 -0.708 . . . . 0.0 111.394 -177.263 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 9.4 t -81.03 135.9 24.22 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 N-CA-C 109.025 -0.732 . . . . 0.0 109.025 174.131 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 5' ' ' THR . . . . . 0.447 ' HA ' ' HD3' ' A' ' 6' ' ' PRO . 4.3 p -128.52 120.19 20.74 Favored Pre-proline 0 C--N 1.31 -1.143 0 CA-C-N 115.834 -0.621 . . . . 0.0 111.38 -172.354 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.447 ' HD3' ' HA ' ' A' ' 5' ' ' THR . 4.9 Cg_exo -78.58 164.61 25.83 Favored 'Trans proline' 0 N--CA 1.451 -1.012 0 C-N-CA 122.961 2.44 . . . . 0.0 111.094 175.96 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . 0.562 ' C ' ' H ' ' A' ' 9' ' ' GLU . . . 57.5 -177.48 0.06 Allowed 'General case' 0 C--N 1.316 -0.876 0 CA-C-N 114.504 -1.225 . . . . 0.0 111.267 -175.881 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . 0.446 ' HB3' ' O ' ' A' ' 7' ' ' ALA . 53.7 t-80 69.49 -9.72 0.63 Allowed 'General case' 0 CA--C 1.531 0.239 0 CA-C-O 121.533 0.682 . . . . 0.0 109.7 -173.225 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . 0.562 ' H ' ' C ' ' A' ' 7' ' ' ALA . 10.1 pt-20 -78.87 141.85 37.32 Favored 'General case' 0 N--CA 1.45 -0.471 0 CA-C-N 115.384 -0.825 . . . . 0.0 110.185 -179.092 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -117.7 67.62 0.75 Allowed 'General case' 0 C--N 1.319 -0.731 0 CA-C-O 121.683 0.754 . . . . 0.0 109.497 -177.84 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 60.7 t -57.59 -59.06 3.76 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.792 0 CA-C-N 114.076 -1.42 . . . . 0.0 111.002 -179.835 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 6.0 p 31.2 81.96 0.01 OUTLIER 'Isoleucine or valine' 0 C--O 1.236 0.353 0 CA-C-O 122.733 1.254 . . . . 0.0 113.041 -178.593 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 37.1 ptt180 -130.68 137.03 49.36 Favored 'General case' 0 N--CA 1.433 -1.303 0 CA-C-N 113.917 -1.492 . . . . 0.0 109.709 -178.533 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 3.5 t -92.65 156.49 3.03 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.179 0 N-CA-C 108.078 -1.082 . . . . 0.0 108.078 170.341 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 175.15 75.66 0.05 OUTLIER Glycine 0 N--CA 1.429 -1.786 0 CA-C-N 115.479 -0.782 . . . . 0.0 112.831 -177.543 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 60.9 m -94.5 -22.56 18.16 Favored 'General case' 0 N--CA 1.436 -1.142 0 CA-C-O 121.828 0.823 . . . . 0.0 108.846 173.834 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 27.1 mmmt -61.94 110.2 2.99 Favored Pre-proline 0 C--N 1.322 -0.598 0 CA-C-N 114.122 -1.399 . . . . 0.0 111.395 175.597 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . 0.42 ' C ' ' H ' ' A' ' 20' ' ' THR . 1.2 Cg_endo -85.21 173.39 7.85 Favored 'Trans proline' 0 N--CA 1.455 -0.768 0 C-N-CA 123.638 2.892 . . . . 0.0 111.778 176.159 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -86.81 34.25 3.58 Favored Glycine 0 C--N 1.313 -0.702 0 CA-C-N 114.753 -1.112 . . . . 0.0 111.244 -179.163 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 20' ' ' THR . . . . . 0.42 ' H ' ' C ' ' A' ' 18' ' ' PRO . 2.4 m -61.34 -42.91 99.47 Favored 'General case' 0 C--N 1.316 -0.862 0 CA-C-N 113.985 -1.108 . . . . 0.0 110.725 -179.002 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 7.7 pt-20 -84.65 72.95 10.64 Favored 'General case' 0 N--CA 1.448 -0.562 0 CA-C-O 122.779 1.276 . . . . 0.0 110.196 177.052 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 5.4 p -72.13 137.3 81.77 Favored Pre-proline 0 C--N 1.298 -1.636 0 CA-C-N 113.028 -1.896 . . . . 0.0 110.504 -178.094 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 52.2 Cg_exo -54.04 133.95 57.56 Favored 'Trans proline' 0 C--N 1.347 0.454 0 C-N-CA 122.797 2.331 . . . . 0.0 111.575 175.744 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 10.6 Cg_endo -54.65 141.38 75.21 Favored 'Trans proline' 0 N--CA 1.458 -0.564 0 C-N-CA 123.508 2.805 . . . . 0.0 112.915 -176.663 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.571 ' HB ' HD11 ' A' ' 83' ' ' ILE . 68.5 t -80.75 128.69 38.49 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.006 0 CA-C-N 114.772 -1.104 . . . . 0.0 109.656 -178.154 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 41.1 mm -56.83 -39.89 67.6 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.432 0 CA-C-N 114.719 -1.128 . . . . 0.0 113.572 -167.133 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.642 ' O ' HG12 ' A' ' 30' ' ' ILE . 26.0 t0 -80.55 -16.77 53.36 Favored 'General case' 0 CA--C 1.498 -1.037 0 CA-C-O 122.725 1.25 . . . . 0.0 108.8 -174.512 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . 0.801 ' HA2' ' HB2' ' A' ' 31' ' ' TRP . . . -75.02 6.58 26.64 Favored Glycine 0 N--CA 1.435 -1.418 0 CA-C-N 113.081 -1.872 . . . . 0.0 111.638 -178.162 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 59.6 m -76.69 -42.3 42.09 Favored 'General case' 0 C--N 1.315 -0.904 0 CA-C-O 121.508 0.67 . . . . 0.0 109.346 172.941 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.642 HG12 ' O ' ' A' ' 27' ' ' ASP . 0.0 OUTLIER -71.23 -38.85 71.87 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 N-CA-C 107.517 -1.29 . . . . 0.0 107.517 174.939 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 31' ' ' TRP . . . . . 0.801 ' HB2' ' HA2' ' A' ' 28' ' ' GLY . 20.8 m95 -67.91 -35.15 77.96 Favored 'General case' 0 N--CA 1.445 -0.714 0 CA-C-N 114.543 -1.208 . . . . 0.0 110.686 -177.231 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 6.3 t70 -73.62 -43.12 60.42 Favored 'General case' 0 N--CA 1.446 -0.627 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.951 177.531 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . 0.545 ' HB2' ' CB ' ' A' ' 105' ' ' ALA . . . -68.82 -33.56 74.04 Favored 'General case' 0 N--CA 1.446 -0.639 0 C-N-CA 120.331 -0.548 . . . . 0.0 110.394 -179.497 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . 0.447 HG13 ' O ' ' A' ' 30' ' ' ILE . 65.1 mt -66.89 -43.89 89.19 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.172 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.128 173.066 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -58.04 -35.76 71.78 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 121.299 0.571 . . . . 0.0 110.288 176.375 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . 0.432 ' HA2' ' N ' ' A' ' 41' ' ' GLY . . . -74.02 -22.21 78.19 Favored Glycine 0 N--CA 1.45 -0.383 0 CA-C-N 115.52 -0.764 . . . . 0.0 111.725 178.617 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 11.9 t -87.41 -52.82 5.16 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 115.377 -0.411 . . . . 0.0 111.87 -176.939 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 10.2 tp10 -87.77 -34.01 18.46 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-O 121.071 0.462 . . . . 0.0 110.161 -172.955 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -103.76 -7.81 20.32 Favored 'General case' 0 C--N 1.323 -0.544 0 C-N-CA 120.437 -0.505 . . . . 0.0 112.186 -175.099 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 77.75 13.26 83.64 Favored Glycine 0 CA--C 1.505 -0.58 0 N-CA-C 109.985 -1.246 . . . . 0.0 109.985 -177.666 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . 0.432 ' N ' ' HA2' ' A' ' 36' ' ' GLY . . . 76.74 58.28 3.55 Favored Glycine 0 N--CA 1.434 -1.488 0 CA-C-N 114.236 -0.982 . . . . 0.0 111.975 -177.236 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . 0.57 ' HB3' ' HB ' ' A' ' 45' ' ' ILE . 2.9 t30 -145.88 103.37 3.75 Favored 'General case' 0 N--CA 1.447 -0.593 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 179.901 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 43' ' ' TRP . . . . . 0.758 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 35.6 m95 -82.63 -6.58 59.44 Favored 'General case' 0 C--N 1.314 -0.972 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.649 -172.887 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -111.86 14.7 20.99 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 115.259 -0.882 . . . . 0.0 111.33 179.417 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.57 ' HB ' ' HB3' ' A' ' 42' ' ' ASN . 10.2 tt -79.93 140.54 16.59 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.773 0 N-CA-C 109.138 -0.69 . . . . 0.0 109.138 -179.599 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 10.0 t-20 -149.14 107.22 3.72 Favored 'General case' 0 C--N 1.307 -1.281 0 CA-C-O 121.289 0.566 . . . . 0.0 109.716 -174.861 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 24.5 p -82.45 -22.96 35.02 Favored 'General case' 0 N--CA 1.437 -1.109 0 CA-C-N 115.185 -0.916 . . . . 0.0 109.997 178.946 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 90.63 20.57 40.12 Favored Glycine 0 N--CA 1.443 -0.88 0 N-CA-C 110.902 -0.879 . . . . 0.0 110.902 178.702 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 27.5 p-10 -93.64 11.39 29.06 Favored 'General case' 0 C--N 1.327 -0.379 0 C-N-CA 120.656 -0.418 . . . . 0.0 111.684 -173.359 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 93.97 -12.31 69.44 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.699 -0.763 . . . . 0.0 111.431 -177.95 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 51' ' ' TYR . . . . . 0.755 ' CE1' ' HB2' ' A' ' 58' ' ' ASP . 0.2 OUTLIER -108.02 160.66 15.62 Favored 'General case' 0 N--CA 1.446 -0.673 0 N-CA-C 106.982 -1.488 . . . . 0.0 106.982 172.811 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 52' ' ' TYR . . . . . 0.864 ' O ' ' HA ' ' A' ' 56' ' ' GLN . 31.6 m-85 -130.35 170.57 13.98 Favored 'General case' 0 C--N 1.318 -0.783 0 C-N-CA 120.668 -0.413 . . . . 0.0 111.045 -171.298 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.484 ' HA2' HG23 ' A' ' 45' ' ' ILE . . . -61.63 177.91 4.61 Favored Glycine 0 N--CA 1.452 -0.28 0 N-CA-C 114.833 0.693 . . . . 0.0 114.833 -171.717 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . 0.675 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 82.61 -104.96 2.57 Favored Glycine 0 N--CA 1.445 -0.702 0 C-N-CA 121.039 -0.6 . . . . 0.0 111.718 -179.877 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.424 ' HB ' ' CD1' ' A' ' 57' ' ' PHE . 2.1 t -83.84 -2.66 7.08 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.657 0 CA-C-O 121.902 0.858 . . . . 0.0 109.616 -179.385 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 56' ' ' GLN . . . . . 0.864 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 5.7 tt0 53.3 52.54 13.35 Favored 'General case' 0 N--CA 1.462 0.149 0 CA-C-N 113.681 -1.599 . . . . 0.0 113.3 171.981 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . 0.501 ' CZ ' ' HE3' ' A' ' 62' ' ' TRP . 16.5 p90 -121.13 173.34 7.35 Favored 'General case' 0 C--N 1.324 -0.519 0 C-N-CA 119.849 -0.74 . . . . 0.0 112.657 176.09 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.755 ' HB2' ' CE1' ' A' ' 51' ' ' TYR . 0.0 OUTLIER -83.97 153.63 23.79 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 114.534 -1.212 . . . . 0.0 114.091 -161.854 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.435 ' HB2' ' HE1' ' A' ' 52' ' ' TYR . 6.3 tp-100 -56.38 -41.91 76.99 Favored 'General case' 0 N--CA 1.447 -0.597 0 CA-C-N 113.656 -1.611 . . . . 0.0 111.985 178.973 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -64.97 -48.42 71.39 Favored Glycine 0 N--CA 1.445 -0.747 0 C-N-CA 120.944 -0.645 . . . . 0.0 111.574 -176.747 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 67.6 m -65.89 -43.83 87.09 Favored 'General case' 0 C--N 1.318 -0.779 0 C-N-CA 122.696 0.398 . . . . 0.0 111.069 176.443 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 62' ' ' TRP . . . . . 0.501 ' HE3' ' CZ ' ' A' ' 57' ' ' PHE . 45.5 t-105 -56.98 -48.21 78.93 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 121.397 0.618 . . . . 0.0 109.729 177.008 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . 0.425 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 3.6 tm-20 -68.05 -32.82 73.44 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 115.143 -0.935 . . . . 0.0 110.39 -178.401 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -66.62 -41.81 87.77 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.717 -0.674 . . . . 0.0 111.493 -178.009 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . 0.638 ' HB2' HG12 ' A' ' 85' ' ' VAL . 50.6 m-20 -76.43 -15.41 59.93 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.002 0.429 . . . . 0.0 110.511 175.839 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . 0.518 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 94.36 48.09 2.66 Favored Glycine 0 C--N 1.333 0.379 0 CA-C-N 115.735 -0.666 . . . . 0.0 112.199 176.966 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . 0.597 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -79.98 -26.24 56.13 Favored Glycine 0 N--CA 1.44 -1.081 0 C-N-CA 121.12 -0.562 . . . . 0.0 112.907 -174.699 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 0.988 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 7.5 mp -60.5 -25.44 66.08 Favored 'General case' 0 N--CA 1.445 -0.705 0 N-CA-C 112.814 0.672 . . . . 0.0 112.814 -173.761 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . 0.527 ' HG3' ' N ' ' A' ' 70' ' ' TYR . 1.3 ptm180 -65.07 -33.64 76.52 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 121.35 0.595 . . . . 0.0 109.615 175.242 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 70' ' ' TYR . . . . . 0.602 ' HB3' ' CG ' ' A' ' 81' ' ' GLU . 84.3 m-85 -78.08 -35.43 49.4 Favored 'General case' 0 N--CA 1.438 -1.059 0 N-CA-C 107.483 -1.303 . . . . 0.0 107.483 178.159 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.596 ' HB1' ' HB2' ' A' ' 77' ' ' ALA . . . 162.03 130.15 0.01 OUTLIER Pre-proline 0 N--CA 1.447 -0.588 0 CA-C-N 112.676 -2.057 . . . . 0.0 106.756 -179.106 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 72' ' ' PRO . . . . . 0.988 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 26.5 Cg_exo -56.41 -6.54 1.52 Allowed 'Trans proline' 0 C--N 1.334 -0.226 0 C-N-CA 122.955 2.436 . . . . 0.0 113.862 -176.894 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 73' ' ' ARG . . . . . 0.474 ' HB2' ' CD2' ' A' ' 52' ' ' TYR . 0.2 OUTLIER -147.0 143.08 28.15 Favored 'General case' 0 C--N 1.317 -0.811 0 N-CA-C 109.533 -0.543 . . . . 0.0 109.533 176.523 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . 0.446 ' HA ' ' CH2' ' A' ' 62' ' ' TRP . . . -58.94 -26.5 64.44 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.413 -0.812 . . . . 0.0 112.722 -177.05 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . 0.465 ' HB2' ' NH2' ' A' ' 73' ' ' ARG . 0.0 OUTLIER -74.27 -25.43 59.61 Favored 'General case' 0 CA--C 1.518 -0.265 0 CA-C-O 121.096 0.474 . . . . 0.0 110.704 -177.258 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.524 ' HB3' ' HB3' ' A' ' 71' ' ' ALA . 55.3 tp -86.76 -30.22 21.76 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-O 121.342 0.591 . . . . 0.0 109.972 -178.635 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . 0.654 ' HB3' ' CB ' ' A' ' 81' ' ' GLU . . . -82.97 161.05 21.9 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 115.383 -0.826 . . . . 0.0 109.66 172.992 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 18.7 p -101.32 -171.78 2.05 Favored 'General case' 0 C--N 1.32 -0.714 0 C-N-CA 120.611 -0.435 . . . . 0.0 110.054 -179.359 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . 0.758 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 2.8 mtt85 -49.36 -53.12 23.99 Favored 'General case' 0 C--N 1.326 -0.436 0 O-C-N 123.487 0.492 . . . . 0.0 111.916 -177.69 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 80' ' ' GLU . . . . . 0.779 ' HA ' HD12 ' A' ' 83' ' ' ILE . 0.0 OUTLIER -61.4 -40.35 94.05 Favored 'General case' 0 C--N 1.324 -0.534 0 O-C-N 123.206 0.316 . . . . 0.0 111.578 -172.275 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 81' ' ' GLU . . . . . 0.654 ' CB ' ' HB3' ' A' ' 77' ' ' ALA . 47.0 mp0 -61.9 -51.48 67.97 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.724 0.297 . . . . 0.0 111.343 175.505 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 82' ' ' GLN . . . . . 0.416 ' HB2' ' HZ3' ' A' ' 43' ' ' TRP . 46.7 mt-30 -59.71 -35.51 74.66 Favored 'General case' 0 CA--C 1.513 -0.473 0 CA-C-O 121.141 0.496 . . . . 0.0 110.198 -178.83 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . 0.779 HD12 ' HA ' ' A' ' 80' ' ' GLU . 35.4 mt -59.47 -49.53 83.27 Favored 'Isoleucine or valine' 0 C--O 1.212 -0.896 0 CA-C-N 114.95 -1.023 . . . . 0.0 109.955 176.905 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . 0.56 ' O ' ' HG3' ' A' ' 87' ' ' GLU . . . -61.27 -44.26 97.52 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-O 121.199 0.523 . . . . 0.0 111.162 -176.188 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . 0.638 HG12 ' HB2' ' A' ' 65' ' ' ASN . 21.8 t -69.33 -49.02 64.34 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.823 179.776 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -66.2 -32.15 73.42 Favored 'General case' 0 CA--C 1.515 -0.379 0 CA-C-O 121.137 0.494 . . . . 0.0 110.888 -179.912 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 87' ' ' GLU . . . . . 0.748 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 0.0 OUTLIER -70.5 -31.52 68.66 Favored 'General case' 0 C--N 1.317 -0.817 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.255 -176.054 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.452 ' O ' ' HG3' ' A' ' 92' ' ' ARG . 71.8 t -60.63 -42.51 92.02 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.373 0 N-CA-C 108.892 -0.781 . . . . 0.0 108.892 172.399 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 89' ' ' THR . . . . . 0.82 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 1.1 m -67.42 -43.7 80.57 Favored 'General case' 0 N--CA 1.441 -0.879 0 CA-C-N 114.766 -1.106 . . . . 0.0 111.023 -176.139 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . 0.644 ' HA ' ' OE1' ' A' ' 93' ' ' GLN . 36.2 ptt85 -60.51 -32.46 71.47 Favored 'General case' 0 N--CA 1.461 0.102 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.472 -174.677 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . 0.748 ' HG ' ' O ' ' A' ' 87' ' ' GLU . 18.4 mt -67.7 -25.42 65.66 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-O 121.559 0.695 . . . . 0.0 110.197 -176.804 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . 0.452 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 11.4 mtm180 -90.15 -51.48 5.43 Favored 'General case' 0 C--N 1.317 -0.838 0 CA-C-N 114.992 -1.004 . . . . 0.0 110.44 -171.253 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 93' ' ' GLN . . . . . 0.644 ' OE1' ' HA ' ' A' ' 90' ' ' ARG . 0.0 OUTLIER -96.52 -23.59 16.47 Favored 'General case' 0 C--N 1.32 -0.689 0 N-CA-C 113.047 0.758 . . . . 0.0 113.047 -172.088 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 78.38 51.29 5.72 Favored Glycine 0 CA--C 1.506 -0.53 0 C-N-CA 120.507 -0.854 . . . . 0.0 111.565 176.695 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 95' ' ' TRP . . . . . 0.553 ' CZ2' ' HD2' ' A' ' 90' ' ' ARG . 2.6 m95 59.79 23.5 12.44 Favored 'General case' 0 C--N 1.329 -0.317 0 C-N-CA 123.361 0.665 . . . . 0.0 110.685 175.217 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.537 ' H ' ' HG2' ' A' ' 93' ' ' GLN . . . -77.75 -17.73 78.33 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.935 -0.65 . . . . 0.0 111.682 173.64 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -87.52 -23.09 24.5 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 121.301 0.572 . . . . 0.0 110.137 176.618 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 98' ' ' TRP . . . . . 0.82 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 20.8 m-90 -110.44 108.68 58.43 Favored Pre-proline 0 N--CA 1.448 -0.55 0 CA-C-N 115.417 -0.811 . . . . 0.0 109.797 179.315 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . 0.414 ' HD3' ' HA ' ' A' ' 98' ' ' TRP . 52.6 Cg_exo -61.48 -135.43 0.0 OUTLIER 'Trans proline' 0 CA--C 1.538 0.711 0 C-N-CA 124.083 3.189 . . . . 0.0 114.16 -175.151 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 21.2 t -56.42 -23.21 16.23 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.249 0 CA-C-N 116.397 -0.365 . . . . 0.0 110.95 -178.409 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 68.5 m -54.79 -38.12 66.9 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.013 -0.54 . . . . 0.0 111.024 178.011 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -69.44 -45.89 68.06 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.827 0.346 . . . . 0.0 110.757 -179.163 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -63.56 -35.82 81.77 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.514 179.365 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 4.7 mmp_? -70.79 -31.56 68.37 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.561 -0.745 . . . . 0.0 111.356 177.821 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 105' ' ' ALA . . . . . 0.641 ' HB1' ' HA ' ' A' ' 30' ' ' ILE . . . -89.0 -22.51 22.96 Favored 'General case' 0 C--N 1.326 -0.438 0 N-CA-C 112.664 0.616 . . . . 0.0 112.664 -173.079 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 113.23 58.52 0.41 Allowed Glycine 0 CA--C 1.521 0.437 0 C-N-CA 120.569 -0.824 . . . . 0.0 112.473 -178.333 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -66.69 154.36 40.83 Favored 'General case' 0 C--N 1.325 -0.472 0 C-N-CA 123.402 0.681 . . . . 0.0 111.775 -175.763 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 23.5 mmt180 . . . . . 0 C--O 1.247 0.95 0 CA-C-O 118.09 -0.957 . . . . 0.0 111.346 177.353 . . . . . . . . 0 0 . 1 . 024 nuclear orig full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 71.5 m-20 . . . . . 0 N--CA 1.484 1.246 0 CA-C-O 121.245 0.545 . . . . 0.0 111.275 . . . . . . . . . 0 0 . 1 . 024 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.2 p -93.72 -12.73 8.69 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.643 0 CA-C-O 121.65 0.738 . . . . 0.0 109.235 175.401 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 7.2 p -66.79 141.48 17.9 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.581 0 CA-C-N 115.094 -0.957 . . . . 0.0 110.902 176.887 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 21.7 t -113.32 146.55 17.8 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 N-CA-C 109.478 -0.564 . . . . 0.0 109.478 176.124 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 15.6 p -121.66 102.72 41.55 Favored Pre-proline 0 C--N 1.314 -0.974 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.323 -178.165 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 98.6 Cg_endo -75.79 96.67 1.06 Allowed 'Trans proline' 0 N--CA 1.459 -0.537 0 C-N-CA 122.613 2.208 . . . . 0.0 112.114 -179.206 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . 0.495 ' C ' ' H ' ' A' ' 9' ' ' GLU . . . -163.51 -168.4 1.66 Allowed 'General case' 0 C--N 1.29 -1.984 0 CA-C-N 113.323 -1.762 . . . . 0.0 109.64 -177.57 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 31.3 t60 70.56 -9.23 0.81 Allowed 'General case' 0 CA--C 1.532 0.282 0 O-C-N 123.878 0.736 . . . . 0.0 109.891 -174.83 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . 0.495 ' H ' ' C ' ' A' ' 7' ' ' ALA . 13.9 pt-20 -71.18 137.92 49.14 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.574 -179.547 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -143.21 79.76 1.65 Allowed 'General case' 0 N--CA 1.447 -0.595 0 CA-C-N 115.7 -0.682 . . . . 0.0 110.245 -176.885 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 61.7 t -67.07 -56.92 11.81 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.838 0 CA-C-N 115.089 -0.96 . . . . 0.0 109.915 176.443 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 75.8 t 25.18 80.31 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.448 -0.532 0 C-N-CA 125.52 1.528 . . . . 0.0 113.371 177.258 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 40.5 ptt180 -144.43 128.33 17.41 Favored 'General case' 0 C--N 1.304 -1.404 0 CA-C-N 114.031 -1.441 . . . . 0.0 110.246 178.541 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 3.7 t -128.21 161.39 36.69 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.894 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 176.116 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 138.83 101.66 0.53 Allowed Glycine 0 N--CA 1.434 -1.435 0 CA-C-N 115.609 -0.723 . . . . 0.0 112.985 177.928 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 17.6 m -80.94 -43.8 19.2 Favored 'General case' 0 N--CA 1.445 -0.687 0 CA-C-O 121.191 0.519 . . . . 0.0 110.274 175.313 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER 41.12 65.98 3.99 Favored Pre-proline 0 C--N 1.322 -0.589 0 CA-C-N 114.353 -1.294 . . . . 0.0 114.032 178.244 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 2.2 Cg_endo -83.08 163.97 15.36 Favored 'Trans proline' 0 N--CA 1.447 -1.258 0 C-N-CA 122.445 2.097 . . . . 0.0 110.534 170.721 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 94.45 -39.89 2.82 Favored Glycine 0 C--N 1.304 -1.237 0 N-CA-C 109.243 -1.543 . . . . 0.0 109.243 -176.918 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 38.4 m -68.19 -44.34 76.08 Favored 'General case' 0 N--CA 1.44 -0.963 0 CA-C-N 113.772 -1.214 . . . . 0.0 109.138 169.3 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 42.9 mt-10 -116.01 114.27 24.36 Favored 'General case' 0 N--CA 1.443 -0.787 0 CA-C-N 114.942 -1.026 . . . . 0.0 109.575 175.805 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 55.3 t -72.74 119.88 77.71 Favored Pre-proline 0 C--N 1.317 -0.817 0 N-CA-C 108.441 -0.948 . . . . 0.0 108.441 174.022 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . 0.431 ' HA ' ' HD2' ' A' ' 24' ' ' PRO . 50.7 Cg_exo -54.5 125.88 20.44 Favored 'Trans proline' 0 N--CA 1.461 -0.387 0 C-N-CA 122.497 2.132 . . . . 0.0 112.991 -173.205 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . 0.431 ' HD2' ' HA ' ' A' ' 23' ' ' PRO . 15.1 Cg_endo -58.03 163.36 9.8 Favored 'Trans proline' 0 N--CA 1.456 -0.734 0 C-N-CA 124.189 3.259 . . . . 0.0 112.042 172.264 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 89.9 t -76.9 158.19 5.33 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.948 0 N-CA-C 107.837 -1.172 . . . . 0.0 107.837 178.597 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 42.8 mm -53.54 -25.52 11.26 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.875 0 N-CA-C 114.38 1.252 . . . . 0.0 114.38 -157.267 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.502 ' O ' HG12 ' A' ' 30' ' ' ILE . 46.5 m-20 -127.07 15.93 7.3 Favored 'General case' 0 C--N 1.313 -0.978 0 CA-C-O 121.542 0.687 . . . . 0.0 109.741 -177.803 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . 0.65 ' HA2' HG12 ' A' ' 83' ' ' ILE . . . -68.24 -6.51 47.49 Favored Glycine 0 N--CA 1.438 -1.203 0 CA-C-N 115.029 -0.987 . . . . 0.0 111.896 -178.878 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 4.9 m -74.47 -46.27 40.78 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-O 122.064 0.935 . . . . 0.0 109.105 176.623 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.595 ' HA ' ' HB3' ' A' ' 105' ' ' ALA . 0.0 OUTLIER -69.77 -38.47 76.11 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.777 0 CA-C-N 114.129 -1.396 . . . . 0.0 108.263 179.242 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 31' ' ' TRP . . . . . 0.545 ' HA ' ' CE3' ' A' ' 31' ' ' TRP . 9.0 m95 -70.55 -36.29 73.57 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 114.86 -1.063 . . . . 0.0 110.861 -177.589 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 4.4 t70 -72.79 -39.37 66.78 Favored 'General case' 0 N--CA 1.446 -0.663 0 CA-C-N 116.481 -0.327 . . . . 0.0 110.521 178.174 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . 0.454 ' HB2' ' CB ' ' A' ' 105' ' ' ALA . . . -69.54 -37.43 77.08 Favored 'General case' 0 N--CA 1.445 -0.69 0 C-N-CA 120.637 -0.425 . . . . 0.0 110.782 179.294 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . 0.482 HG13 ' O ' ' A' ' 30' ' ' ILE . 75.5 mt -67.46 -44.42 86.79 Favored 'Isoleucine or valine' 0 C--O 1.232 0.177 0 CA-C-O 120.809 0.338 . . . . 0.0 110.454 175.524 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -60.86 -31.83 71.28 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 121.252 0.549 . . . . 0.0 110.229 176.907 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -77.42 -22.78 69.52 Favored Glycine 0 N--CA 1.45 -0.395 0 CA-C-N 115.596 -0.729 . . . . 0.0 111.516 177.54 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 40.9 t -76.83 -58.36 3.32 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 115.367 -0.417 . . . . 0.0 111.041 -179.055 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 17.5 mt-10 -89.1 -32.9 17.31 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 116.353 -0.385 . . . . 0.0 111.3 -171.365 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -102.05 -17.61 15.98 Favored 'General case' 0 C--N 1.323 -0.576 0 C-N-CA 120.507 -0.477 . . . . 0.0 112.183 -177.562 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 81.36 9.99 85.2 Favored Glycine 0 N--CA 1.448 -0.535 0 N-CA-C 109.805 -1.318 . . . . 0.0 109.805 -175.709 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 88.39 62.71 1.39 Allowed Glycine 0 N--CA 1.438 -1.199 0 CA-C-N 114.156 -1.022 . . . . 0.0 111.713 -176.931 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . 0.697 HD21 ' HB ' ' A' ' 45' ' ' ILE . 3.3 t30 -139.31 87.98 2.23 Favored 'General case' 0 C--N 1.326 -0.418 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 -177.142 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 43' ' ' TRP . . . . . 0.771 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 37.9 m95 -76.41 -11.47 59.9 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-O 121.171 0.51 . . . . 0.0 111.259 -172.669 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -102.66 15.56 28.95 Favored 'General case' 0 C--N 1.314 -0.955 0 CA-C-N 115.793 -0.64 . . . . 0.0 110.447 -179.94 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.697 ' HB ' HD21 ' A' ' 42' ' ' ASN . 10.1 tt -77.53 139.94 17.86 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.003 0 CA-C-N 115.861 -0.609 . . . . 0.0 110.799 -177.771 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 34.1 t-20 -150.59 92.35 1.84 Allowed 'General case' 0 C--N 1.314 -0.957 0 CA-C-N 115.522 -0.763 . . . . 0.0 109.363 179.578 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 8.9 p -76.19 -15.67 60.0 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 115.581 -0.736 . . . . 0.0 111.668 -176.279 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 93.43 21.95 28.07 Favored Glycine 0 N--CA 1.448 -0.561 0 N-CA-C 111.149 -0.78 . . . . 0.0 111.149 -179.904 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 4.9 m-20 -90.7 -0.57 57.74 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 120.857 0.361 . . . . 0.0 111.434 -177.005 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . 0.506 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 86.53 -8.42 75.01 Favored Glycine 0 N--CA 1.449 -0.478 0 N-CA-C 110.888 -0.885 . . . . 0.0 110.888 -172.775 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 51' ' ' TYR . . . . . 0.566 ' N ' ' HD1' ' A' ' 51' ' ' TYR . 0.1 OUTLIER -114.27 140.47 48.57 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 107.459 -1.312 . . . . 0.0 107.459 175.434 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 52' ' ' TYR . . . . . 0.477 ' O ' ' HA ' ' A' ' 56' ' ' GLN . 0.1 OUTLIER -140.33 163.82 31.75 Favored 'General case' 0 C--N 1.319 -0.748 0 N-CA-C 112.7 0.63 . . . . 0.0 112.7 -170.991 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 65.45 105.66 0.01 OUTLIER Glycine 0 C--O 1.221 -0.684 0 N-CA-C 116.287 1.275 . . . . 0.0 116.287 164.198 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . 0.466 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 57.99 -83.45 0.01 OUTLIER Glycine 0 C--N 1.339 0.696 0 N-CA-C 114.579 0.591 . . . . 0.0 114.579 165.226 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 3.7 m -83.16 -6.29 9.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-O 120.932 0.396 . . . . 0.0 110.282 178.337 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 56' ' ' GLN . . . . . 0.477 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 9.8 mt-30 50.19 51.84 15.93 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 114.934 -1.03 . . . . 0.0 113.203 166.788 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 5.5 p90 -102.13 166.68 10.47 Favored 'General case' 0 C--N 1.323 -0.572 0 C-N-CA 119.382 -0.927 . . . . 0.0 110.705 174.926 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.55 ' HB3' ' CE1' ' A' ' 51' ' ' TYR . 4.9 p-10 -74.48 155.99 37.41 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 122.223 1.011 . . . . 0.0 113.548 -163.276 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.414 ' HB2' ' CE1' ' A' ' 52' ' ' TYR . 23.3 tp60 -57.06 -39.58 75.17 Favored 'General case' 0 N--CA 1.441 -0.877 0 CA-C-N 113.175 -1.829 . . . . 0.0 111.633 179.813 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -67.74 -49.29 50.41 Favored Glycine 0 N--CA 1.451 -0.352 0 CA-C-N 115.422 -0.808 . . . . 0.0 112.248 -176.332 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 97.8 m -64.15 -40.83 96.98 Favored 'General case' 0 C--N 1.322 -0.602 0 C-N-CA 122.829 0.451 . . . . 0.0 110.827 176.761 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 62' ' ' TRP . . . . . 0.545 ' CH2' ' HA ' ' A' ' 74' ' ' ALA . 45.6 t-105 -55.92 -48.58 75.42 Favored 'General case' 0 N--CA 1.45 -0.471 0 CA-C-O 121.71 0.767 . . . . 0.0 109.221 174.859 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . 0.521 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 33.2 tt0 -64.64 -36.57 84.67 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-N 114.821 -1.081 . . . . 0.0 110.989 179.187 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -65.47 -41.16 93.64 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.75 -0.659 . . . . 0.0 110.948 -177.282 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . 0.443 ' HB3' ' HB ' ' A' ' 88' ' ' VAL . 8.2 m120 -80.79 -7.76 59.49 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 121.043 0.449 . . . . 0.0 110.339 177.968 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . 0.586 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 87.64 46.8 4.77 Favored Glycine 0 N--CA 1.447 -0.582 0 CA-C-N 115.622 -0.717 . . . . 0.0 112.511 174.207 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . 0.582 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -78.68 -25.05 61.28 Favored Glycine 0 N--CA 1.44 -1.095 0 C-N-CA 120.579 -0.819 . . . . 0.0 112.007 -175.435 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 0.906 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 7.3 mp -57.78 -23.27 51.46 Favored 'General case' 0 N--CA 1.446 -0.628 0 N-CA-C 112.671 0.619 . . . . 0.0 112.671 -175.38 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . 0.586 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 5.6 ptp180 -70.74 -29.39 65.63 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-O 121.327 0.584 . . . . 0.0 109.761 178.281 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 70' ' ' TYR . . . . . 0.739 ' HB3' ' CG ' ' A' ' 81' ' ' GLU . 43.5 m-85 -87.24 -34.62 18.89 Favored 'General case' 0 N--CA 1.439 -1.005 0 N-CA-C 107.373 -1.343 . . . . 0.0 107.373 177.724 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.531 ' HB1' ' HB2' ' A' ' 77' ' ' ALA . . . 170.12 125.31 0.05 OUTLIER Pre-proline 0 N--CA 1.449 -0.51 0 CA-C-N 113.198 -1.819 . . . . 0.0 107.89 -177.39 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 72' ' ' PRO . . . . . 0.906 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 15.9 Cg_exo -59.79 -2.8 1.73 Allowed 'Trans proline' 0 C--N 1.333 -0.27 0 C-N-CA 122.803 2.335 . . . . 0.0 113.562 -179.044 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 15.5 ptm180 -143.48 138.19 29.07 Favored 'General case' 0 C--N 1.316 -0.851 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 176.614 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . 0.568 ' HB1' ' OE1' ' A' ' 82' ' ' GLN . . . -59.09 -31.24 68.73 Favored 'General case' 0 C--N 1.316 -0.863 0 CA-C-N 114.952 -1.022 . . . . 0.0 112.393 -176.206 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 20.7 p-10 -88.93 9.0 26.51 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 120.961 0.41 . . . . 0.0 112.014 -175.956 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.493 ' HB3' ' HB3' ' A' ' 71' ' ' ALA . 68.3 tp -103.79 -28.93 11.34 Favored 'General case' 0 C--N 1.321 -0.634 0 N-CA-C 108.614 -0.884 . . . . 0.0 108.614 169.974 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . 0.716 ' HB3' ' CB ' ' A' ' 81' ' ' GLU . . . -79.91 153.68 28.82 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-N 114.545 -1.207 . . . . 0.0 110.39 176.553 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 21.9 p -99.79 -171.81 2.12 Favored 'General case' 0 C--N 1.32 -0.712 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.854 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . 0.771 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 4.0 mtp180 -50.65 -52.91 35.29 Favored 'General case' 0 C--O 1.222 -0.367 0 O-C-N 123.356 0.41 . . . . 0.0 110.779 -175.999 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 80' ' ' GLU . . . . . 0.428 ' HG3' ' OE2' ' A' ' 81' ' ' GLU . 10.5 pt-20 -58.92 -40.03 83.32 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.726 -0.67 . . . . 0.0 111.688 -174.154 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 81' ' ' GLU . . . . . 0.739 ' CG ' ' HB3' ' A' ' 70' ' ' TYR . 8.8 mp0 -67.8 -52.36 37.95 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 120.815 0.34 . . . . 0.0 111.812 176.397 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 82' ' ' GLN . . . . . 0.568 ' OE1' ' HB1' ' A' ' 74' ' ' ALA . 31.3 mt-30 -64.37 -31.28 72.43 Favored 'General case' 0 CA--C 1.514 -0.434 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.724 -175.7 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . 0.65 HG12 ' HA2' ' A' ' 28' ' ' GLY . 27.9 mt -59.58 -48.16 88.37 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 CA-C-N 115.413 -0.812 . . . . 0.0 109.771 172.66 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . 0.506 ' HA ' ' HG2' ' A' ' 87' ' ' GLU . . . -62.57 -43.27 99.24 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.989 -0.55 . . . . 0.0 112.056 -177.465 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . 0.411 HG23 ' O ' ' A' ' 81' ' ' GLU . 21.3 t -69.85 -49.76 54.57 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.69 0 O-C-N 122.112 -0.368 . . . . 0.0 111.346 -178.939 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -66.77 -31.17 71.63 Favored 'General case' 0 N--CA 1.446 -0.632 0 CA-C-N 115.947 -0.569 . . . . 0.0 110.403 -179.463 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 87' ' ' GLU . . . . . 0.808 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 6.5 pt-20 -67.62 -32.2 72.74 Favored 'General case' 0 C--O 1.219 -0.551 0 C-N-CA 120.272 -0.571 . . . . 0.0 109.72 -177.637 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.446 ' O ' ' HG3' ' A' ' 92' ' ' ARG . 87.3 t -61.77 -46.95 95.42 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.273 0 CA-C-O 121.421 0.629 . . . . 0.0 109.394 172.625 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 89' ' ' THR . . . . . 0.697 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 0.2 OUTLIER -60.8 -45.43 94.44 Favored 'General case' 0 N--CA 1.443 -0.794 0 CA-C-N 115.289 -0.869 . . . . 0.0 111.377 -178.184 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . 0.666 ' HG3' ' O ' ' A' ' 87' ' ' GLU . 5.6 ppt_? -60.35 -32.63 71.44 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.478 -177.095 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . 0.808 ' HG ' ' O ' ' A' ' 87' ' ' GLU . 38.6 mt -61.88 -43.01 99.72 Favored 'General case' 0 N--CA 1.473 0.676 0 CA-C-O 122.165 0.983 . . . . 0.0 110.047 -176.706 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . 0.446 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 4.4 mtm180 -78.24 -45.17 23.62 Favored 'General case' 0 C--N 1.316 -0.864 0 CA-C-N 113.828 -1.533 . . . . 0.0 110.083 -167.327 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 13.9 pt20 -100.99 -26.74 13.62 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-N 114.605 -1.179 . . . . 0.0 112.857 -170.094 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 87.56 40.19 6.91 Favored Glycine 0 CA--C 1.508 -0.378 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.176 174.775 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 95' ' ' TRP . . . . . 0.499 ' CZ2' ' HD3' ' A' ' 90' ' ' ARG . 18.5 m95 64.54 18.66 11.49 Favored 'General case' 0 C--O 1.219 -0.527 0 CA-C-O 121.455 0.645 . . . . 0.0 109.815 179.912 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -66.41 -29.8 75.46 Favored Glycine 0 CA--C 1.519 0.299 0 CA-C-N 115.163 -0.926 . . . . 0.0 112.862 175.462 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -81.83 -21.21 37.75 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.879 0.371 . . . . 0.0 110.625 178.692 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 98' ' ' TRP . . . . . 0.697 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 24.6 m-90 -99.3 109.06 53.31 Favored Pre-proline 0 N--CA 1.446 -0.625 0 N-CA-C 109.245 -0.65 . . . . 0.0 109.245 177.637 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . 0.425 ' HD3' ' HA ' ' A' ' 98' ' ' TRP . 44.8 Cg_exo -63.24 -139.48 0.0 OUTLIER 'Trans proline' 0 CA--C 1.535 0.541 0 C-N-CA 123.578 2.852 . . . . 0.0 114.331 -174.909 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . 0.416 ' O ' ' HD2' ' A' ' 104' ' ' ARG . 45.0 t -54.98 -23.98 13.64 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.315 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.682 -174.185 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 60.7 m -63.42 -31.66 72.88 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.549 -179.847 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -69.72 -46.03 66.88 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.617 0.246 . . . . 0.0 111.124 -177.364 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -66.09 -36.56 83.52 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 121.019 0.438 . . . . 0.0 110.652 179.896 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 104' ' ' ARG . . . . . 0.416 ' HD2' ' O ' ' A' ' 100' ' ' VAL . 0.0 OUTLIER -70.78 -24.13 62.52 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.78 -0.646 . . . . 0.0 111.23 177.194 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 105' ' ' ALA . . . . . 0.595 ' HB3' ' HA ' ' A' ' 30' ' ' ILE . . . -88.83 -21.46 23.71 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.583 -178.386 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . 0.46 ' O ' ' HG2' ' A' ' 108' ' ' ARG . . . 112.29 63.09 0.46 Allowed Glycine 0 CA--C 1.52 0.354 0 C-N-CA 120.996 -0.621 . . . . 0.0 112.129 -178.0 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -57.91 142.06 47.35 Favored 'General case' 0 C--N 1.329 -0.321 0 C-N-CA 122.679 0.392 . . . . 0.0 111.084 -179.321 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 108' ' ' ARG . . . . . 0.46 ' HG2' ' O ' ' A' ' 106' ' ' GLY . 4.6 ptp180 . . . . . 0 C--O 1.247 0.961 0 CA-C-O 118.484 -0.769 . . . . 0.0 111.093 -170.195 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 1' ' ' ASN . . . . . 0.508 ' HB3' HG11 ' A' ' 3' ' ' VAL . 77.8 m-20 . . . . . 0 N--CA 1.479 0.985 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 . . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 8.8 p -89.21 -6.92 10.86 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-O 121.019 0.438 . . . . 0.0 110.589 -177.424 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . 0.508 HG11 ' HB3' ' A' ' 1' ' ' ASN . 7.7 p -58.26 123.61 10.51 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.481 0 CA-C-O 121.413 0.625 . . . . 0.0 111.681 -179.952 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . 0.491 ' O ' ' HD3' ' A' ' 6' ' ' PRO . 17.2 t -100.11 154.24 4.41 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 CA-C-N 115.621 -0.718 . . . . 0.0 109.357 179.511 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 2.0 p -90.18 107.78 21.88 Favored Pre-proline 0 C--N 1.319 -0.728 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.129 179.192 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.491 ' HD3' ' O ' ' A' ' 4' ' ' VAL . 24.6 Cg_exo -68.8 97.54 0.56 Allowed 'Trans proline' 0 CA--C 1.505 -0.974 0 C-N-CA 123.062 2.508 . . . . 0.0 111.922 177.565 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -124.55 47.7 2.07 Favored 'General case' 0 C--N 1.291 -1.97 0 CA-C-N 113.012 -1.903 . . . . 0.0 111.058 -175.706 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 41.8 t60 -85.65 -7.84 58.58 Favored 'General case' 0 C--N 1.308 -1.198 0 CA-C-N 114.497 -1.229 . . . . 0.0 108.481 172.133 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 13.7 pt-20 -118.41 159.78 22.85 Favored 'General case' 0 N--CA 1.446 -0.657 0 CA-C-N 114.634 -1.166 . . . . 0.0 110.222 -179.183 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -139.64 64.5 1.46 Allowed 'General case' 0 C--N 1.318 -0.774 0 CA-C-O 121.948 0.88 . . . . 0.0 110.998 176.884 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 60.4 t -105.39 -72.56 0.64 Allowed 'Isoleucine or valine' 0 C--N 1.314 -0.952 0 CA-C-N 114.687 -1.142 . . . . 0.0 109.597 177.219 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 6.8 p 27.7 78.66 0.01 OUTLIER 'Isoleucine or valine' 0 C--O 1.236 0.383 0 O-C-N 124.91 1.382 . . . . 0.0 113.284 176.598 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 26.7 ptt180 -93.58 94.94 8.91 Favored 'General case' 0 C--N 1.306 -1.284 0 CA-C-O 122.903 1.335 . . . . 0.0 110.73 -178.232 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 7.4 t -124.23 163.28 24.35 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.655 0 CA-C-N 113.134 -1.848 . . . . 0.0 108.039 -179.501 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 88.8 78.71 1.3 Allowed Glycine 0 C--N 1.305 -1.189 0 N-CA-C 110.567 -1.013 . . . . 0.0 110.567 -175.792 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 16' ' ' THR . . . . . 0.48 ' HB ' ' HD2' ' A' ' 17' ' ' LYS . 4.0 m -62.8 -36.99 84.96 Favored 'General case' 0 N--CA 1.444 -0.756 0 CA-C-O 121.709 0.766 . . . . 0.0 111.158 -174.902 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . 0.48 ' HD2' ' HB ' ' A' ' 16' ' ' THR . 0.0 OUTLIER -122.12 99.51 43.52 Favored Pre-proline 0 C--N 1.313 -0.985 0 CA-C-N 114.856 -1.066 . . . . 0.0 110.045 177.523 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 10.8 Cg_exo -72.95 165.86 31.63 Favored 'Trans proline' 0 CA--C 1.511 -0.648 0 C-N-CA 123.197 2.598 . . . . 0.0 112.639 -179.316 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -100.24 35.78 4.57 Favored Glycine 0 C--N 1.308 -0.982 0 CA-C-N 114.036 -1.438 . . . . 0.0 110.65 -178.346 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 6.2 m -62.52 -49.13 76.56 Favored 'General case' 0 C--N 1.316 -0.891 0 CA-C-N 114.26 -0.97 . . . . 0.0 111.339 -177.949 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 49.5 mt-10 -131.91 114.66 14.92 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.823 -179.491 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 57.0 t -87.01 112.72 49.48 Favored Pre-proline 0 C--N 1.322 -0.617 0 N-CA-C 109.328 -0.619 . . . . 0.0 109.328 174.378 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 51.9 Cg_exo -54.7 131.84 48.21 Favored 'Trans proline' 0 N--CA 1.46 -0.474 0 C-N-CA 122.845 2.363 . . . . 0.0 111.877 179.413 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 10.3 Cg_endo -54.52 139.25 75.37 Favored 'Trans proline' 0 N--CA 1.456 -0.707 0 C-N-CA 123.23 2.62 . . . . 0.0 112.274 -176.478 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 1.005 HG13 HD13 ' A' ' 83' ' ' ILE . 7.5 p -90.16 127.9 42.42 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.243 0 CA-C-N 114.501 -1.227 . . . . 0.0 111.459 -175.859 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 47.5 mm -76.86 -25.31 15.7 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.714 0 CA-C-N 115.254 -0.884 . . . . 0.0 111.074 -178.658 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.435 ' O ' HG12 ' A' ' 30' ' ' ILE . 50.0 m-20 -111.07 17.96 19.89 Favored 'General case' 0 CA--C 1.506 -0.713 0 CA-C-O 121.392 0.615 . . . . 0.0 109.693 -177.508 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . 0.515 ' N ' HG22 ' A' ' 25' ' ' VAL . . . -70.34 -7.84 61.19 Favored Glycine 0 N--CA 1.44 -1.066 0 N-CA-C 110.024 -1.231 . . . . 0.0 110.024 176.577 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 8.7 m -74.39 -39.42 62.7 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 114.644 -0.778 . . . . 0.0 109.122 174.621 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.634 ' HA ' ' HB1' ' A' ' 105' ' ' ALA . 1.0 OUTLIER -68.18 -39.58 81.45 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 N-CA-C 107.402 -1.333 . . . . 0.0 107.402 177.771 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 31' ' ' TRP . . . . . 0.589 ' CZ2' ' HD3' ' A' ' 90' ' ' ARG . 27.2 m95 -70.61 -37.35 73.85 Favored 'General case' 0 N--CA 1.443 -0.795 0 CA-C-N 114.301 -1.318 . . . . 0.0 110.345 -177.051 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.626 ' HB2' HH21 ' A' ' 79' ' ' ARG . 21.8 t70 -79.34 -33.85 42.69 Favored 'General case' 0 N--CA 1.448 -0.549 0 CA-C-N 115.965 -0.561 . . . . 0.0 111.258 -179.55 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . 0.47 ' HB2' ' CB ' ' A' ' 105' ' ' ALA . . . -68.63 -32.97 73.21 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 176.713 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . 0.544 HG13 ' O ' ' A' ' 30' ' ' ILE . 66.3 mt -61.07 -45.39 98.66 Favored 'Isoleucine or valine' 0 C--O 1.234 0.289 0 CA-C-N 116.172 -0.467 . . . . 0.0 109.85 171.315 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . 0.754 ' HA ' ' NE2' ' A' ' 56' ' ' GLN . . . -61.34 -36.03 79.05 Favored 'General case' 0 CA--C 1.513 -0.475 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.684 177.6 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -73.56 -18.13 79.32 Favored Glycine 0 N--CA 1.448 -0.509 0 N-CA-C 111.025 -0.83 . . . . 0.0 111.025 179.44 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . 0.496 ' HB3' ' O ' ' A' ' 34' ' ' ILE . 8.3 t -77.14 -70.64 0.45 Allowed 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 115.102 -0.549 . . . . 0.0 111.587 -178.065 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . 0.707 ' HG2' ' SG ' ' A' ' 101' ' ' CYS . 4.5 mm-40 -90.44 -33.54 15.96 Favored 'General case' 0 CA--C 1.511 -0.554 0 C-N-CA 120.435 -0.506 . . . . 0.0 111.133 -172.65 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . 0.477 ' HB1' ' O ' ' A' ' 35' ' ' ALA . . . -84.57 -15.69 44.79 Favored 'General case' 0 N--CA 1.443 -0.8 0 CA-C-N 115.997 -0.547 . . . . 0.0 111.125 -177.182 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 75.84 13.29 83.23 Favored Glycine 0 CA--C 1.504 -0.607 0 N-CA-C 109.687 -1.365 . . . . 0.0 109.687 -177.456 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 88.62 63.33 1.35 Allowed Glycine 0 N--CA 1.432 -1.583 0 CA-C-N 113.957 -1.121 . . . . 0.0 111.436 -175.424 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . 0.79 ' HB3' ' HB ' ' A' ' 45' ' ' ILE . 6.6 m120 -146.59 103.32 3.65 Favored 'General case' 0 CA--C 1.513 -0.456 0 CA-C-O 121.125 0.488 . . . . 0.0 110.003 -177.962 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 43' ' ' TRP . . . . . 0.688 ' HA ' ' N ' ' A' ' 54' ' ' GLY . 44.5 m95 -84.97 -6.87 59.33 Favored 'General case' 0 C--N 1.311 -1.066 0 CA-C-O 121.642 0.734 . . . . 0.0 110.128 178.155 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -109.72 13.96 23.51 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-N 114.924 -1.034 . . . . 0.0 111.546 178.449 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.79 ' HB ' ' HB3' ' A' ' 42' ' ' ASN . 11.2 tt -87.23 143.67 10.85 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.712 0 CA-C-O 120.85 0.357 . . . . 0.0 110.595 -177.833 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 4.8 p30 -161.71 113.55 1.75 Allowed 'General case' 0 C--N 1.315 -0.916 0 CA-C-O 121.375 0.607 . . . . 0.0 110.482 175.974 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 30.5 p -82.32 -20.17 37.91 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 115.739 -0.664 . . . . 0.0 111.684 -175.22 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 102.66 25.01 7.87 Favored Glycine 0 N--CA 1.445 -0.757 0 N-CA-C 110.703 -0.959 . . . . 0.0 110.703 -175.204 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 3.4 t30 -95.01 -2.91 49.36 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 121.533 0.682 . . . . 0.0 110.346 -178.64 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 96.3 -13.81 65.23 Favored Glycine 0 C--O 1.227 -0.314 0 CA-C-N 115.548 -0.751 . . . . 0.0 111.526 179.202 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 51' ' ' TYR . . . . . 0.57 ' N ' ' CD1' ' A' ' 51' ' ' TYR . 0.3 OUTLIER -99.55 137.94 37.33 Favored 'General case' 0 CA--C 1.511 -0.541 0 N-CA-C 108.234 -1.024 . . . . 0.0 108.234 174.543 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 52' ' ' TYR . . . . . 0.646 ' CE1' ' HB2' ' A' ' 59' ' ' GLN . 15.9 m-85 -107.62 169.5 8.55 Favored 'General case' 0 C--N 1.312 -1.065 0 C-N-CA 120.685 -0.406 . . . . 0.0 111.698 -172.199 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -63.01 169.59 16.49 Favored Glycine 0 N--CA 1.449 -0.484 0 N-CA-C 115.256 0.862 . . . . 0.0 115.256 -166.613 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . 0.688 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 85.11 -93.17 1.81 Allowed Glycine 0 N--CA 1.44 -1.086 0 CA-C-N 114.508 -0.846 . . . . 0.0 112.01 177.983 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.59 HG21 ' HB3' ' A' ' 82' ' ' GLN . 0.4 OUTLIER -90.95 -2.15 10.14 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.764 0 CA-C-O 121.017 0.437 . . . . 0.0 111.403 -177.447 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 56' ' ' GLN . . . . . 0.754 ' NE2' ' HA ' ' A' ' 35' ' ' ALA . 9.2 mt-30 58.02 46.94 15.58 Favored 'General case' 0 N--CA 1.472 0.625 0 N-CA-C 113.849 1.055 . . . . 0.0 113.849 164.645 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -125.3 157.77 35.83 Favored 'General case' 0 C--N 1.318 -0.765 0 C-N-CA 119.221 -0.992 . . . . 0.0 111.296 174.87 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.569 ' HA ' ' HA ' ' A' ' 51' ' ' TYR . 24.1 t70 -65.21 144.12 57.39 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 114.33 -1.304 . . . . 0.0 112.052 -167.709 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.646 ' HB2' ' CE1' ' A' ' 52' ' ' TYR . 0.0 OUTLIER -51.87 -36.15 47.5 Favored 'General case' 0 N--CA 1.448 -0.562 0 CA-C-N 114.131 -1.395 . . . . 0.0 111.807 179.017 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -67.43 -41.98 90.04 Favored Glycine 0 N--CA 1.449 -0.438 0 N-CA-C 111.453 -0.659 . . . . 0.0 111.453 179.386 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 64.1 m -71.47 -38.69 71.23 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 120.759 0.314 . . . . 0.0 110.434 176.368 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 62' ' ' TRP . . . . . 0.568 ' CH2' ' HA ' ' A' ' 74' ' ' ALA . 43.3 t-105 -55.59 -47.57 76.26 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 121.64 0.733 . . . . 0.0 109.089 172.571 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . 0.507 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 27.6 tt0 -64.67 -33.53 76.16 Favored 'General case' 0 N--CA 1.443 -0.775 0 CA-C-N 114.784 -1.098 . . . . 0.0 110.711 178.127 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -64.36 -42.84 96.0 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 115.928 -0.578 . . . . 0.0 111.624 -176.598 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . 0.412 ' HB2' HG13 ' A' ' 85' ' ' VAL . 10.2 m-80 -74.16 -19.31 60.6 Favored 'General case' 0 N--CA 1.462 0.173 0 CA-C-O 121.254 0.549 . . . . 0.0 109.892 174.01 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . 0.4 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 94.02 48.12 2.73 Favored Glycine 0 N--CA 1.448 -0.514 0 CA-C-N 115.536 -0.756 . . . . 0.0 111.814 179.309 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . 0.524 ' HA2' ' HD1' ' A' ' 70' ' ' TYR . . . -79.59 -17.37 75.76 Favored Glycine 0 N--CA 1.44 -1.068 0 C-N-CA 120.992 -0.623 . . . . 0.0 113.044 -173.377 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 0.783 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 6.5 mp -61.68 -23.3 66.0 Favored 'General case' 0 N--CA 1.45 -0.441 0 N-CA-C 112.179 0.437 . . . . 0.0 112.179 -173.372 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . 0.4 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 4.8 ptt180 -70.52 -29.49 66.0 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 121.04 0.448 . . . . 0.0 110.604 175.552 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 70' ' ' TYR . . . . . 0.572 ' HB3' ' HB3' ' A' ' 81' ' ' GLU . 74.7 m-85 -79.27 -33.65 43.25 Favored 'General case' 0 N--CA 1.446 -0.642 0 N-CA-C 107.185 -1.413 . . . . 0.0 107.185 175.891 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.615 ' HB2' ' HB1' ' A' ' 77' ' ' ALA . . . 163.02 127.69 0.01 OUTLIER Pre-proline 0 C--O 1.22 -0.452 0 CA-C-N 112.662 -2.063 . . . . 0.0 107.044 -179.709 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 72' ' ' PRO . . . . . 0.783 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 16.6 Cg_exo -56.92 -4.77 1.02 Allowed 'Trans proline' 0 C--N 1.334 -0.194 0 C-N-CA 122.605 2.203 . . . . 0.0 113.774 -177.97 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 14.4 ptm180 -145.38 140.19 27.5 Favored 'General case' 0 C--N 1.318 -0.798 0 N-CA-C 108.501 -0.925 . . . . 0.0 108.501 175.888 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . 0.568 ' HA ' ' CH2' ' A' ' 62' ' ' TRP . . . -57.68 -36.03 71.38 Favored 'General case' 0 C--O 1.219 -0.535 0 CA-C-N 115.448 -0.796 . . . . 0.0 111.691 -176.77 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . 0.458 ' OD1' ' HD2' ' A' ' 52' ' ' TYR . 11.6 p-10 -84.03 2.58 38.43 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 120.935 0.398 . . . . 0.0 111.455 -173.08 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.461 ' HB3' ' HB1' ' A' ' 71' ' ' ALA . 49.2 tp -98.13 -33.96 10.94 Favored 'General case' 0 C--N 1.323 -0.568 0 N-CA-C 108.419 -0.956 . . . . 0.0 108.419 170.893 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . 0.765 ' HB2' ' HB2' ' A' ' 81' ' ' GLU . . . -79.32 163.27 25.02 Favored 'General case' 0 N--CA 1.444 -0.768 0 CA-C-N 114.785 -1.098 . . . . 0.0 109.959 175.242 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 38.3 p -101.0 178.23 4.73 Favored 'General case' 0 C--N 1.316 -0.887 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.121 179.491 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . 0.64 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 60.4 mtp180 -46.1 -48.37 17.18 Favored 'General case' 0 N--CA 1.467 0.399 0 O-C-N 123.693 0.621 . . . . 0.0 111.32 -176.06 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 6.0 pt-20 -61.7 -42.03 98.4 Favored 'General case' 0 C--N 1.315 -0.915 0 CA-C-N 115.756 -0.656 . . . . 0.0 112.659 -177.375 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 81' ' ' GLU . . . . . 0.765 ' HB2' ' HB2' ' A' ' 77' ' ' ALA . 5.7 mp0 -65.68 -50.48 64.74 Favored 'General case' 0 C--O 1.231 0.121 0 CA-C-N 118.369 0.531 . . . . 0.0 111.824 172.936 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 82' ' ' GLN . . . . . 0.59 ' HB3' HG21 ' A' ' 55' ' ' VAL . 4.0 mt-30 -57.76 -40.78 80.55 Favored 'General case' 0 CA--C 1.515 -0.379 0 CA-C-O 121.217 0.532 . . . . 0.0 110.26 -177.707 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . 1.005 HD13 HG13 ' A' ' 25' ' ' VAL . 11.6 mt -61.82 -45.49 98.59 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.696 0 CA-C-N 114.898 -1.047 . . . . 0.0 110.593 178.045 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . 0.554 ' O ' ' HG3' ' A' ' 87' ' ' GLU . . . -62.33 -44.49 96.37 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.911 0.386 . . . . 0.0 111.513 -177.575 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . 0.475 HG21 ' O ' ' A' ' 81' ' ' GLU . 21.7 t -67.27 -48.84 76.88 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 CA-C-N 116.535 -0.302 . . . . 0.0 111.457 179.291 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -65.04 -30.97 71.98 Favored 'General case' 0 N--CA 1.451 -0.423 0 CA-C-O 121.148 0.499 . . . . 0.0 110.558 179.145 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 87' ' ' GLU . . . . . 0.636 ' O ' ' HG2' ' A' ' 90' ' ' ARG . 0.7 OUTLIER -71.86 -27.71 63.05 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.876 -177.526 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.719 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 88.8 t -62.21 -40.1 86.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 N-CA-C 108.805 -0.813 . . . . 0.0 108.805 166.805 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 89' ' ' THR . . . . . 0.781 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 2.7 m -67.86 -43.05 80.33 Favored 'General case' 0 C--N 1.318 -0.772 0 CA-C-N 115.524 -0.762 . . . . 0.0 111.005 -178.89 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . 0.636 ' HG2' ' O ' ' A' ' 87' ' ' GLU . 26.3 ptt180 -60.08 -34.34 73.31 Favored 'General case' 0 N--CA 1.47 0.54 0 C-N-CA 122.761 0.424 . . . . 0.0 111.447 -175.906 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . 0.719 ' HG ' ' O ' ' A' ' 88' ' ' VAL . 4.3 pp -73.15 -21.83 60.63 Favored 'General case' 0 C--N 1.318 -0.774 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.588 -174.361 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . 0.466 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 6.7 mtm180 -86.61 -51.1 6.35 Favored 'General case' 0 CA--C 1.511 -0.538 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.135 -176.607 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 93' ' ' GLN . . . . . 0.612 ' OE1' ' HA ' ' A' ' 90' ' ' ARG . 0.0 OUTLIER -98.03 -25.43 14.96 Favored 'General case' 0 CA--C 1.538 0.487 0 N-CA-C 113.311 0.856 . . . . 0.0 113.311 -170.779 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 90.47 40.1 5.79 Favored Glycine 0 CA--C 1.507 -0.447 0 C-N-CA 120.672 -0.775 . . . . 0.0 111.99 173.462 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 95' ' ' TRP . . . . . 0.456 ' HB3' ' HB2' ' A' ' 102' ' ' ALA . 10.2 m95 64.35 11.71 6.66 Favored 'General case' 0 C--O 1.223 -0.328 0 C-N-CA 123.678 0.791 . . . . 0.0 110.142 -179.131 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -71.66 -28.33 69.43 Favored Glycine 0 C--N 1.33 0.2 0 C-N-CA 121.114 -0.565 . . . . 0.0 112.433 177.982 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -70.0 -29.2 66.23 Favored 'General case' 0 CA--C 1.516 -0.334 0 CA-C-O 121.183 0.516 . . . . 0.0 110.2 178.667 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 98' ' ' TRP . . . . . 0.781 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 26.2 m-90 -98.74 103.84 21.35 Favored Pre-proline 0 N--CA 1.446 -0.638 0 N-CA-C 108.299 -1.0 . . . . 0.0 108.299 174.948 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 22.9 Cg_exo -69.25 -94.23 0.01 OUTLIER 'Trans proline' 0 CA--C 1.532 0.424 0 C-N-CA 123.176 2.584 . . . . 0.0 114.727 -170.438 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 47.9 t -70.92 -29.74 38.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-O 121.702 0.763 . . . . 0.0 110.013 -174.385 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 101' ' ' CYS . . . . . 0.707 ' SG ' ' HG2' ' A' ' 38' ' ' GLU . 64.0 m -71.13 -38.41 72.27 Favored 'General case' 0 C--N 1.317 -0.807 0 CA-C-N 114.789 -1.096 . . . . 0.0 111.794 -170.895 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 102' ' ' ALA . . . . . 0.456 ' HB2' ' HB3' ' A' ' 95' ' ' TRP . . . -69.99 -43.14 72.06 Favored 'General case' 0 C--N 1.327 -0.401 0 C-N-CA 120.698 -0.401 . . . . 0.0 110.704 179.86 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -61.67 -37.19 83.18 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 121.355 0.598 . . . . 0.0 110.464 178.42 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 104' ' ' ARG . . . . . 0.58 ' HA ' ' NE ' ' A' ' 104' ' ' ARG . 4.8 mmp_? -71.33 -34.84 70.91 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.495 -0.775 . . . . 0.0 111.563 176.323 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 105' ' ' ALA . . . . . 0.634 ' HB1' ' HA ' ' A' ' 30' ' ' ILE . . . -83.4 -22.33 32.77 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.158 -0.474 . . . . 0.0 112.208 -174.775 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 114.81 59.23 0.36 Allowed Glycine 0 CA--C 1.521 0.425 0 C-N-CA 120.818 -0.706 . . . . 0.0 112.37 -178.611 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -61.65 148.03 43.9 Favored 'General case' 0 CA--C 1.515 -0.367 0 C-N-CA 122.91 0.484 . . . . 0.0 110.635 179.478 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.245 0.845 0 CA-C-O 118.29 -0.862 . . . . 0.0 110.059 -173.013 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 5.6 m-20 . . . . . 0 N--CA 1.48 1.051 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 . . . . . . . . . 0 0 . 1 . 026 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 14.7 p 35.1 57.87 0.15 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.514 0 O-C-N 124.424 1.077 . . . . 0.0 111.851 -174.134 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 6.3 p -64.18 100.06 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.522 0 CA-C-N 114.798 -1.092 . . . . 0.0 112.436 -176.537 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 14.3 p -117.75 148.84 20.28 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.764 0 CA-C-N 115.699 -0.682 . . . . 0.0 110.583 173.472 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 4.6 p -129.37 113.2 18.17 Favored Pre-proline 0 C--N 1.308 -1.207 0 CA-C-N 115.169 -0.923 . . . . 0.0 110.473 178.331 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 62.4 Cg_exo -45.99 107.56 0.12 Allowed 'Trans proline' 0 CA--C 1.505 -0.943 0 C-N-CA 123.809 3.006 . . . . 0.0 113.507 -178.547 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -111.27 171.45 7.47 Favored 'General case' 0 C--N 1.297 -1.704 0 CA-C-N 113.357 -1.747 . . . . 0.0 110.656 -178.706 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 31.0 t-80 68.55 6.04 5.19 Favored 'General case' 0 N--CA 1.456 -0.153 0 O-C-N 124.23 0.956 . . . . 0.0 109.345 -174.149 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 11.4 pt-20 -52.66 135.0 35.68 Favored 'General case' 0 C--O 1.235 0.309 0 CA-C-N 115.099 -0.955 . . . . 0.0 110.778 177.175 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -120.92 65.7 0.86 Allowed 'General case' 0 C--N 1.32 -0.681 0 CA-C-O 121.873 0.844 . . . . 0.0 110.668 -176.787 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 58.2 t -78.63 -40.96 24.48 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.021 0 CA-C-N 114.404 -1.271 . . . . 0.0 109.57 176.408 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 6.2 p 31.7 80.83 0.01 OUTLIER 'Isoleucine or valine' 0 C--O 1.235 0.341 0 O-C-N 124.729 1.268 . . . . 0.0 113.163 178.26 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . 0.462 ' HG3' ' O ' ' A' ' 13' ' ' ARG . 10.3 ptp180 -102.85 114.03 27.96 Favored 'General case' 0 C--N 1.307 -1.271 0 CA-C-N 114.016 -1.447 . . . . 0.0 109.323 179.79 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.9 t -110.01 161.32 8.47 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.421 0 CA-C-N 115.09 -0.959 . . . . 0.0 109.456 -179.98 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 137.61 71.63 0.05 OUTLIER Glycine 0 N--CA 1.436 -1.366 0 CA-C-N 115.075 -0.966 . . . . 0.0 111.978 179.542 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 41.9 m -82.85 -21.99 34.22 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-O 121.591 0.71 . . . . 0.0 110.392 179.993 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 26.1 mmtp -56.29 108.93 1.36 Allowed Pre-proline 0 C--N 1.322 -0.615 0 CA-C-N 114.393 -1.276 . . . . 0.0 111.703 178.003 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -79.42 162.96 24.86 Favored 'Trans proline' 0 N--CA 1.451 -0.987 0 C-N-CA 123.476 2.784 . . . . 0.0 112.231 178.014 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -123.82 35.79 3.17 Favored Glycine 0 C--N 1.306 -1.09 0 CA-C-N 114.088 -1.415 . . . . 0.0 111.359 179.224 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 7.1 m -61.12 -41.93 97.6 Favored 'General case' 0 C--N 1.317 -0.807 0 CA-C-N 114.49 -0.855 . . . . 0.0 110.509 177.768 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 43.2 mt-10 -135.14 103.85 5.7 Favored 'General case' 0 N--CA 1.442 -0.873 0 N-CA-C 108.279 -1.008 . . . . 0.0 108.279 -179.318 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 4.6 p -71.84 115.53 38.92 Favored Pre-proline 0 C--N 1.315 -0.895 0 CA-C-N 115.019 -0.991 . . . . 0.0 112.491 -169.472 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_exo -68.2 151.59 76.73 Favored 'Trans proline' 0 N--CA 1.456 -0.702 0 C-N-CA 123.078 2.518 . . . . 0.0 111.57 172.686 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 9.9 Cg_endo -55.4 140.76 82.63 Favored 'Trans proline' 0 N--CA 1.454 -0.836 0 C-N-CA 122.546 2.164 . . . . 0.0 111.185 173.714 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.51 HG11 HG23 ' A' ' 83' ' ' ILE . 14.0 t -107.15 133.05 52.94 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.074 0 CA-C-N 115.232 -0.895 . . . . 0.0 111.024 -173.399 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 44.6 mm -73.08 -23.87 20.45 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 CA-C-N 115.224 -0.898 . . . . 0.0 111.736 -173.524 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 7.9 m-20 -81.28 -5.33 57.68 Favored 'General case' 0 CA--C 1.503 -0.856 0 CA-C-O 121.656 0.741 . . . . 0.0 109.395 -177.374 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . 0.527 ' HA2' ' HB2' ' A' ' 31' ' ' TRP . . . -66.83 -5.78 33.59 Favored Glycine 0 N--CA 1.439 -1.131 0 CA-C-N 114.229 -1.35 . . . . 0.0 110.902 179.94 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 12.7 m -76.38 -44.66 35.27 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-O 121.419 0.628 . . . . 0.0 109.813 175.792 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.582 ' HB ' ' CH2' ' A' ' 95' ' ' TRP . 0.1 OUTLIER -71.01 -35.94 61.39 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.594 0 N-CA-C 108.113 -1.069 . . . . 0.0 108.113 178.078 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 31' ' ' TRP . . . . . 0.688 ' CD1' HG13 ' A' ' 83' ' ' ILE . 48.9 m95 -71.75 -35.64 70.18 Favored 'General case' 0 N--CA 1.442 -0.865 0 CA-C-N 114.658 -1.156 . . . . 0.0 110.19 -178.975 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 20.4 t70 -77.0 -29.31 55.41 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.342 178.908 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -68.55 -35.06 76.9 Favored 'General case' 0 N--CA 1.444 -0.732 0 N-CA-C 109.671 -0.492 . . . . 0.0 109.671 175.215 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . 0.572 ' HA ' ' HB3' ' A' ' 101' ' ' CYS . 58.0 mt -67.64 -49.34 71.15 Favored 'Isoleucine or valine' 0 C--O 1.233 0.199 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.402 173.908 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . 0.443 ' O ' ' HB2' ' A' ' 39' ' ' ALA . . . -59.08 -41.26 87.6 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.778 -0.646 . . . . 0.0 110.454 178.951 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . 0.402 ' HA2' ' N ' ' A' ' 41' ' ' GLY . . . -72.09 -18.95 78.2 Favored Glycine 0 N--CA 1.449 -0.484 0 CA-C-N 115.453 -0.794 . . . . 0.0 111.649 179.069 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 3.6 t -84.24 -62.93 1.44 Allowed 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.433 -0.383 . . . . 0.0 111.463 -178.088 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . 0.575 ' HB2' ' SG ' ' A' ' 101' ' ' CYS . 15.9 tt0 -89.06 -33.2 17.21 Favored 'General case' 0 C--N 1.324 -0.517 0 C-N-CA 120.532 -0.467 . . . . 0.0 110.602 -170.908 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . 0.443 ' HB2' ' O ' ' A' ' 35' ' ' ALA . . . -91.18 -12.36 35.62 Favored 'General case' 0 N--CA 1.453 -0.286 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.301 -178.857 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 82.0 4.93 90.11 Favored Glycine 0 CA--C 1.505 -0.552 0 N-CA-C 109.923 -1.271 . . . . 0.0 109.923 -178.857 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . 0.402 ' N ' ' HA2' ' A' ' 36' ' ' GLY . . . 87.3 61.56 1.55 Allowed Glycine 0 N--CA 1.434 -1.482 0 CA-C-N 113.946 -1.127 . . . . 0.0 111.369 -175.291 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . 0.634 ' HB3' ' HB ' ' A' ' 45' ' ' ILE . 0.3 OUTLIER -144.96 96.57 2.88 Favored 'General case' 0 N--CA 1.448 -0.559 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 -177.217 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 43' ' ' TRP . . . . . 0.744 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 46.3 m95 -79.04 -14.1 59.37 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.968 -175.223 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -107.49 14.24 26.03 Favored 'General case' 0 C--N 1.316 -0.861 0 CA-C-N 115.525 -0.761 . . . . 0.0 111.399 179.962 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.634 ' HB ' ' HB3' ' A' ' 42' ' ' ASN . 8.6 tt -78.13 144.56 11.11 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.738 0 CA-C-O 120.994 0.426 . . . . 0.0 110.181 -178.612 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 29.0 t-20 -150.26 86.74 1.43 Allowed 'General case' 0 C--N 1.31 -1.141 0 CA-C-O 121.437 0.637 . . . . 0.0 109.664 178.952 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 6.1 p -68.7 -25.79 64.96 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.122 -0.945 . . . . 0.0 111.464 -178.342 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 100.98 21.01 12.44 Favored Glycine 0 N--CA 1.445 -0.712 0 C-N-CA 120.985 -0.626 . . . . 0.0 111.545 -179.652 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 4.3 m-20 -81.42 -4.05 54.67 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 121.229 0.538 . . . . 0.0 111.029 -179.243 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 95.91 -13.6 65.9 Favored Glycine 0 N--CA 1.446 -0.635 0 N-CA-C 110.038 -1.225 . . . . 0.0 110.038 -176.592 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 51' ' ' TYR . . . . . 0.669 ' CD1' ' HB2' ' A' ' 58' ' ' ASP . 0.1 OUTLIER -102.81 144.99 30.43 Favored 'General case' 0 N--CA 1.446 -0.643 0 N-CA-C 107.631 -1.248 . . . . 0.0 107.631 174.048 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 52' ' ' TYR . . . . . 0.825 ' O ' ' HA ' ' A' ' 56' ' ' GLN . 10.3 m-85 -108.61 164.81 12.03 Favored 'General case' 0 C--N 1.308 -1.205 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.717 -172.147 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.451 ' HA2' HG22 ' A' ' 45' ' ' ILE . . . -58.13 172.73 3.27 Favored Glycine 0 C--O 1.229 -0.182 0 N-CA-C 115.702 1.041 . . . . 0.0 115.702 -166.107 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . 0.631 ' CA ' ' HA ' ' A' ' 43' ' ' TRP . . . 91.55 -111.02 3.93 Favored Glycine 0 N--CA 1.446 -0.671 0 CA-C-N 114.86 -0.67 . . . . 0.0 111.509 -178.799 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 1.9 m -83.23 -2.64 6.79 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 CA-C-O 122.077 0.942 . . . . 0.0 110.454 176.22 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 56' ' ' GLN . . . . . 0.825 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 5.9 tt0 50.49 52.1 15.51 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 113.436 -1.711 . . . . 0.0 114.18 168.921 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . 0.415 ' HZ ' HG13 ' A' ' 85' ' ' VAL . 7.2 p90 -105.74 158.49 16.69 Favored 'General case' 0 C--N 1.321 -0.652 0 C-N-CA 119.123 -1.031 . . . . 0.0 110.368 170.788 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.669 ' HB2' ' CD1' ' A' ' 51' ' ' TYR . 0.5 OUTLIER -64.54 144.19 57.38 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 114.888 -1.051 . . . . 0.0 112.016 -168.793 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.694 ' HB2' ' CE1' ' A' ' 52' ' ' TYR . 4.6 tp-100 -63.1 -30.29 71.48 Favored 'General case' 0 C--O 1.218 -0.555 0 CA-C-N 114.841 -1.072 . . . . 0.0 111.54 -178.562 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -64.83 -44.17 95.08 Favored Glycine 0 C--N 1.316 -0.529 0 N-CA-C 110.84 -0.904 . . . . 0.0 110.84 174.949 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 88.6 m -71.36 -40.18 70.82 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-O 121.093 0.473 . . . . 0.0 111.207 175.299 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 62' ' ' TRP . . . . . 0.757 ' CZ3' HG12 ' A' ' 85' ' ' VAL . 29.5 t-105 -55.12 -46.59 75.62 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-O 121.492 0.663 . . . . 0.0 109.694 173.229 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . 0.562 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 32.0 tt0 -67.24 -35.2 79.05 Favored 'General case' 0 C--N 1.316 -0.876 0 CA-C-N 114.957 -1.019 . . . . 0.0 111.01 179.305 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -64.89 -40.85 95.74 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.936 -0.574 . . . . 0.0 110.958 -178.509 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . 0.432 ' HB3' ' HB ' ' A' ' 88' ' ' VAL . 34.8 m-80 -81.68 -7.29 59.58 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.045 -0.525 . . . . 0.0 111.085 177.039 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 87.14 45.1 5.45 Favored Glycine 0 C--N 1.331 0.269 0 C-N-CA 121.022 -0.609 . . . . 0.0 112.812 173.639 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . 0.574 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -79.67 -22.34 64.49 Favored Glycine 0 N--CA 1.441 -0.973 0 C-N-CA 121.184 -0.532 . . . . 0.0 112.783 -175.861 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 0.821 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 6.7 mp -60.66 -23.67 64.98 Favored 'General case' 0 C--N 1.328 -0.341 0 N-CA-C 112.345 0.498 . . . . 0.0 112.345 -172.338 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 35.7 ptt180 -71.56 -27.02 62.87 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-O 120.933 0.397 . . . . 0.0 110.374 178.882 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 70' ' ' TYR . . . . . 0.98 ' HB3' ' HG2' ' A' ' 81' ' ' GLU . 51.8 m-85 -82.98 -34.41 26.38 Favored 'General case' 0 N--CA 1.444 -0.746 0 N-CA-C 107.09 -1.448 . . . . 0.0 107.09 174.056 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.522 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 167.25 130.12 0.04 OUTLIER Pre-proline 0 C--N 1.327 -0.397 0 CA-C-N 112.456 -2.157 . . . . 0.0 108.866 -178.783 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 72' ' ' PRO . . . . . 0.821 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 36.6 Cg_endo -67.97 29.58 0.14 Allowed 'Trans proline' 0 N--CA 1.476 0.487 0 C-N-CA 122.862 2.374 . . . . 0.0 113.877 179.311 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 73' ' ' ARG . . . . . 0.496 ' H ' ' C ' ' A' ' 71' ' ' ALA . 14.7 ptm180 -176.27 140.15 0.38 Allowed 'General case' 0 C--N 1.321 -0.66 0 N-CA-C 108.665 -0.865 . . . . 0.0 108.665 178.136 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . 0.543 ' HA ' ' CH2' ' A' ' 62' ' ' TRP . . . -66.47 -27.15 67.57 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.788 -0.642 . . . . 0.0 111.795 -174.949 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . 0.442 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 21.1 p-10 -86.57 -4.92 59.24 Favored 'General case' 0 C--N 1.324 -0.532 0 C-N-CA 120.832 -0.347 . . . . 0.0 111.61 -174.825 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 65.2 tp -97.85 -28.61 13.77 Favored 'General case' 0 C--N 1.322 -0.604 0 N-CA-C 108.97 -0.752 . . . . 0.0 108.97 171.31 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . 0.66 ' HB3' ' HB3' ' A' ' 81' ' ' GLU . . . -78.05 148.54 34.24 Favored 'General case' 0 N--CA 1.441 -0.919 0 CA-C-N 115.12 -0.946 . . . . 0.0 109.934 175.309 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 47.0 p -91.79 -175.61 4.2 Favored 'General case' 0 C--N 1.31 -1.135 0 CA-C-N 115.608 -0.724 . . . . 0.0 109.982 -178.617 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . 0.744 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 43.1 mtp-105 -53.7 -54.84 32.2 Favored 'General case' 0 CA--C 1.515 -0.382 0 CA-C-O 120.979 0.419 . . . . 0.0 110.167 -178.31 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 2.6 pm0 -56.85 -39.02 73.52 Favored 'General case' 0 C--N 1.318 -0.787 0 CA-C-N 115.454 -0.794 . . . . 0.0 111.486 -176.362 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 81' ' ' GLU . . . . . 0.98 ' HG2' ' HB3' ' A' ' 70' ' ' TYR . 1.0 OUTLIER -66.93 -50.8 61.23 Favored 'General case' 0 C--N 1.323 -0.582 0 N-CA-C 112.419 0.526 . . . . 0.0 112.419 175.188 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 82' ' ' GLN . . . . . 0.604 ' HB2' ' HZ3' ' A' ' 43' ' ' TRP . 56.1 mt-30 -61.45 -34.89 76.18 Favored 'General case' 0 CA--C 1.514 -0.417 0 C-N-CA 121.023 -0.271 . . . . 0.0 110.318 -178.402 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . 0.688 HG13 ' CD1' ' A' ' 31' ' ' TRP . 1.4 mp -60.12 -46.19 94.78 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.089 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.76 173.518 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . 0.609 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -62.6 -44.75 95.53 Favored 'General case' 0 C--O 1.238 0.498 0 CA-C-O 121.533 0.683 . . . . 0.0 111.663 -172.813 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . 0.757 HG12 ' CZ3' ' A' ' 62' ' ' TRP . 2.7 p -70.68 -43.66 77.24 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.721 0 CA-C-N 115.949 -0.569 . . . . 0.0 111.027 -179.91 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . 0.44 ' HB3' ' CH2' ' A' ' 31' ' ' TRP . . . -61.04 -28.4 69.03 Favored 'General case' 0 N--CA 1.451 -0.415 0 CA-C-N 115.764 -0.653 . . . . 0.0 109.69 174.396 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 87' ' ' GLU . . . . . 0.685 ' HG3' ' O ' ' A' ' 83' ' ' ILE . 30.6 mt-10 -61.18 -43.84 98.25 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.398 -0.819 . . . . 0.0 109.888 179.203 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.669 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 41.2 t -61.81 -46.08 97.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-O 121.178 0.513 . . . . 0.0 109.799 176.244 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 89' ' ' THR . . . . . 0.805 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 0.2 OUTLIER -67.42 -45.95 74.6 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 115.961 -0.563 . . . . 0.0 111.499 -175.25 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . 0.629 ' HD3' ' HZ2' ' A' ' 31' ' ' TRP . 23.2 ptt180 -62.87 -34.23 76.94 Favored 'General case' 0 C--O 1.221 -0.418 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.742 -177.259 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . 0.669 ' HG ' ' O ' ' A' ' 88' ' ' VAL . 4.2 pp -73.55 -23.78 60.02 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-O 120.951 0.405 . . . . 0.0 110.904 -171.82 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . 0.566 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 4.7 mtm180 -82.06 -46.91 13.26 Favored 'General case' 0 CA--C 1.51 -0.588 0 CA-C-O 121.426 0.632 . . . . 0.0 109.608 -179.11 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 93' ' ' GLN . . . . . 0.475 ' NE2' HG21 ' A' ' 89' ' ' THR . 13.2 pt20 -103.42 -27.95 12.1 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 114.759 -1.109 . . . . 0.0 113.965 -168.344 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 92.02 39.98 5.32 Favored Glycine 0 C--N 1.332 0.338 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.436 175.983 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 95' ' ' TRP . . . . . 0.606 ' HZ2' HH11 ' A' ' 90' ' ' ARG . 33.2 m95 70.06 9.62 7.13 Favored 'General case' 0 C--O 1.219 -0.55 0 C-N-CA 123.338 0.655 . . . . 0.0 109.609 -179.933 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -59.44 -41.78 97.23 Favored Glycine 0 N--CA 1.453 -0.223 0 CA-C-N 115.28 -0.873 . . . . 0.0 113.476 -178.68 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . 0.413 ' O ' ' HD3' ' A' ' 99' ' ' PRO . . . -70.03 -17.87 63.28 Favored 'General case' 0 N--CA 1.464 0.275 0 CA-C-N 117.117 0.459 . . . . 0.0 110.793 179.772 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 98' ' ' TRP . . . . . 0.805 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 24.6 m-90 -95.65 107.84 36.12 Favored Pre-proline 0 N--CA 1.448 -0.564 0 N-CA-C 108.794 -0.817 . . . . 0.0 108.794 176.171 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . 0.427 ' HD3' ' HA ' ' A' ' 98' ' ' TRP . 41.7 Cg_exo -63.77 -132.46 0.0 OUTLIER 'Trans proline' 0 CA--C 1.539 0.746 0 C-N-CA 123.857 3.038 . . . . 0.0 114.408 -173.804 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 18.3 t -55.48 -26.24 19.0 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.252 0 CA-C-O 120.82 0.343 . . . . 0.0 111.497 -174.623 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 101' ' ' CYS . . . . . 0.575 ' SG ' ' HB2' ' A' ' 38' ' ' GLU . 75.0 m -64.75 -34.41 78.27 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 116.339 -0.392 . . . . 0.0 111.528 -178.553 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -70.03 -40.78 74.97 Favored 'General case' 0 CA--C 1.519 -0.232 0 CA-C-O 120.971 0.415 . . . . 0.0 110.226 177.642 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -63.09 -39.38 94.52 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.353 176.904 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 104' ' ' ARG . . . . . 0.444 ' HA ' ' NE ' ' A' ' 104' ' ' ARG . 14.9 mmp_? -71.69 -31.49 66.82 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.605 -0.725 . . . . 0.0 111.003 178.844 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 105' ' ' ALA . . . . . 0.473 ' CB ' HG22 ' A' ' 30' ' ' ILE . . . -80.71 -23.95 39.14 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 120.989 0.423 . . . . 0.0 111.735 -177.356 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 97.98 59.3 0.95 Allowed Glycine 0 CA--C 1.522 0.471 0 C-N-CA 120.983 -0.627 . . . . 0.0 112.096 -176.707 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -57.62 146.72 29.56 Favored 'General case' 0 C--N 1.329 -0.311 0 C-N-CA 123.274 0.629 . . . . 0.0 112.356 -177.612 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 108' ' ' ARG . . . . . 0.693 ' O ' ' HD3' ' A' ' 108' ' ' ARG . 0.0 OUTLIER . . . . . 0 C--O 1.25 1.09 0 CA-C-O 118.545 -0.74 . . . . 0.0 110.594 -175.899 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 33.4 m-80 . . . . . 0 N--CA 1.476 0.866 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 . . . . . . . . . 0 0 . 1 . 027 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 12.1 p -75.79 -16.81 15.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-O 121.243 0.544 . . . . 0.0 110.192 -179.628 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 79.5 t -70.93 120.21 18.5 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.557 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.923 176.671 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 15.8 t -90.31 147.0 5.51 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 N-CA-C 109.626 -0.509 . . . . 0.0 109.626 178.069 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 8.8 p -103.14 108.3 58.31 Favored Pre-proline 0 C--N 1.317 -0.811 0 CA-C-N 115.94 -0.573 . . . . 0.0 111.292 -178.722 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 43.1 Cg_endo -98.7 165.71 0.64 Allowed 'Trans proline' 0 N--CA 1.442 -1.529 0 C-N-CA 123.585 2.857 . . . . 0.0 111.856 175.812 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -84.02 48.22 1.43 Allowed 'General case' 0 C--N 1.315 -0.929 0 CA-C-O 122.104 0.954 . . . . 0.0 110.045 176.338 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 9.7 t60 -77.29 -3.75 41.46 Favored 'General case' 0 C--N 1.314 -0.963 0 CA-C-N 113.745 -1.57 . . . . 0.0 108.86 176.23 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 11.8 pt-20 -53.46 133.53 40.68 Favored 'General case' 0 C--O 1.234 0.242 0 CA-C-N 115.249 -0.887 . . . . 0.0 111.028 -178.999 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -149.74 73.94 1.2 Allowed 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 115.529 -0.759 . . . . 0.0 109.796 179.46 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 59.0 t -71.61 -50.01 42.39 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.729 0 CA-C-N 114.876 -1.056 . . . . 0.0 111.041 -176.905 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 5.2 p 32.93 82.88 0.01 OUTLIER 'Isoleucine or valine' 0 C--O 1.235 0.334 0 CA-C-O 122.765 1.269 . . . . 0.0 112.761 -176.913 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . 0.459 ' HG3' ' O ' ' A' ' 13' ' ' ARG . 2.5 ptp180 -82.6 118.33 23.22 Favored 'General case' 0 C--N 1.309 -1.165 0 CA-C-N 113.993 -1.458 . . . . 0.0 110.24 -177.329 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 3.3 t -107.45 164.45 4.89 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.36 0 CA-C-N 114.442 -1.254 . . . . 0.0 109.12 175.66 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 139.99 71.1 0.04 OUTLIER Glycine 0 N--CA 1.437 -1.296 0 CA-C-N 115.26 -0.882 . . . . 0.0 111.471 178.914 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 86.3 m -115.12 -26.25 7.76 Favored 'General case' 0 N--CA 1.44 -0.96 0 CA-C-N 115.001 -0.599 . . . . 0.0 111.261 -175.945 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 28.1 mmtp -66.14 108.33 2.19 Favored Pre-proline 0 C--N 1.322 -0.59 0 CA-C-N 115.594 -0.73 . . . . 0.0 111.186 -175.661 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 5.3 Cg_endo -88.67 173.76 4.27 Favored 'Trans proline' 0 N--CA 1.45 -1.04 0 C-N-CA 123.889 3.059 . . . . 0.0 112.104 178.483 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -122.38 19.68 8.06 Favored Glycine 0 CA--C 1.5 -0.874 0 CA-C-N 114.915 -1.038 . . . . 0.0 112.015 177.499 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 16.2 m -70.34 -38.32 74.82 Favored 'General case' 0 C--N 1.308 -1.216 0 CA-C-N 114.161 -1.02 . . . . 0.0 109.742 177.126 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 7.9 pt-20 -133.63 157.59 45.37 Favored 'General case' 0 N--CA 1.431 -1.395 0 CA-C-N 114.802 -1.09 . . . . 0.0 108.225 176.464 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 64.0 t -107.87 107.5 60.35 Favored Pre-proline 0 C--N 1.3 -1.56 0 CA-C-N 115.741 -0.663 . . . . 0.0 109.501 174.897 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_exo -55.13 129.59 36.09 Favored 'Trans proline' 0 N--CA 1.46 -0.461 0 C-N-CA 122.677 2.251 . . . . 0.0 111.063 175.234 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 10.1 Cg_endo -54.34 139.5 73.59 Favored 'Trans proline' 0 N--CA 1.453 -0.864 0 C-N-CA 123.06 2.507 . . . . 0.0 112.004 -176.823 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.494 ' HB ' HG21 ' A' ' 83' ' ' ILE . 41.7 t -112.99 125.39 70.24 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.227 0 CA-C-N 114.665 -1.152 . . . . 0.0 110.611 -173.527 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 43.6 mm -66.76 -23.28 30.88 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-N 115.401 -0.818 . . . . 0.0 110.278 -177.885 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.46 ' O ' HG12 ' A' ' 30' ' ' ILE . 5.8 m-20 -79.2 -1.63 37.22 Favored 'General case' 0 CA--C 1.504 -0.804 0 CA-C-N 115.237 -0.892 . . . . 0.0 109.523 -178.84 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . 0.579 ' HA2' ' HB2' ' A' ' 31' ' ' TRP . . . -69.1 -9.31 60.01 Favored Glycine 0 N--CA 1.437 -1.266 0 N-CA-C 110.302 -1.119 . . . . 0.0 110.302 176.222 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 17.6 m -76.97 -47.83 19.72 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 121.405 0.622 . . . . 0.0 110.073 177.12 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.766 HG21 ' O ' ' A' ' 105' ' ' ALA . 4.2 pt -71.67 -34.64 52.9 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.923 0 CA-C-N 115.087 -0.96 . . . . 0.0 109.641 176.844 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 31' ' ' TRP . . . . . 0.667 ' CZ2' ' HD3' ' A' ' 90' ' ' ARG . 12.1 m95 -63.75 -37.18 86.41 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 115.334 -0.848 . . . . 0.0 109.528 175.652 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 36.2 t70 -77.63 -31.32 52.7 Favored 'General case' 0 N--CA 1.448 -0.54 0 CA-C-N 115.837 -0.62 . . . . 0.0 111.133 179.793 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . 0.514 ' HB1' ' HB3' ' A' ' 105' ' ' ALA . . . -69.0 -33.75 74.17 Favored 'General case' 0 N--CA 1.446 -0.642 0 C-N-CA 120.409 -0.516 . . . . 0.0 109.727 176.706 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . 0.469 HG13 ' O ' ' A' ' 30' ' ' ILE . 74.1 mt -67.43 -42.81 87.66 Favored 'Isoleucine or valine' 0 C--O 1.233 0.215 0 CA-C-O 121.132 0.491 . . . . 0.0 109.722 171.72 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . 0.597 ' HA ' ' O ' ' A' ' 54' ' ' GLY . . . -57.76 -35.25 70.48 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.574 -0.739 . . . . 0.0 110.452 175.917 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . 0.493 ' HA2' ' N ' ' A' ' 41' ' ' GLY . . . -78.67 -5.44 88.29 Favored Glycine 0 N--CA 1.449 -0.46 0 CA-C-N 115.267 -0.879 . . . . 0.0 112.138 179.412 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 42.6 t -103.07 -54.17 2.67 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 120.742 0.306 . . . . 0.0 110.892 -178.483 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . 0.454 ' HG2' ' SG ' ' A' ' 101' ' ' CYS . 30.1 mm-40 -87.06 -31.05 20.72 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 121.162 0.506 . . . . 0.0 110.758 -174.717 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -103.22 -10.51 18.71 Favored 'General case' 0 N--CA 1.447 -0.6 0 CA-C-N 116.029 -0.532 . . . . 0.0 111.262 -179.043 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 76.22 14.23 82.52 Favored Glycine 0 CA--C 1.503 -0.7 0 N-CA-C 109.864 -1.294 . . . . 0.0 109.864 -178.455 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . 0.493 ' N ' ' HA2' ' A' ' 36' ' ' GLY . . . 81.66 62.53 1.93 Allowed Glycine 0 N--CA 1.432 -1.596 0 CA-C-N 113.94 -1.13 . . . . 0.0 111.82 -176.568 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . 0.559 ' HB3' ' HB ' ' A' ' 45' ' ' ILE . 3.4 t30 -155.87 96.97 1.78 Allowed 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 109.136 -0.69 . . . . 0.0 109.136 -178.557 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 43' ' ' TRP . . . . . 0.719 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 33.0 m95 -73.35 -11.04 60.35 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-O 121.285 0.564 . . . . 0.0 111.007 -175.319 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -106.25 14.91 26.91 Favored 'General case' 0 C--N 1.314 -0.952 0 CA-C-N 115.575 -0.739 . . . . 0.0 111.432 -179.059 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.823 HG21 ' HA2' ' A' ' 53' ' ' GLY . 7.0 tt -78.86 142.92 13.39 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.793 0 CA-C-O 121.138 0.494 . . . . 0.0 110.121 -178.106 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . 0.545 ' ND2' HH21 ' A' ' 73' ' ' ARG . 9.3 t-20 -148.29 90.05 1.77 Allowed 'General case' 0 C--N 1.312 -1.027 0 CA-C-O 121.114 0.483 . . . . 0.0 109.958 178.923 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 13.9 p -76.48 -16.65 59.6 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 115.87 -0.605 . . . . 0.0 111.724 -176.92 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 94.93 21.99 24.31 Favored Glycine 0 N--CA 1.447 -0.625 0 N-CA-C 110.942 -0.863 . . . . 0.0 110.942 -177.931 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 10.4 t-20 -86.1 -12.27 50.48 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 121.302 0.573 . . . . 0.0 110.964 -175.098 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . 0.415 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 95.21 -9.47 69.83 Favored Glycine 0 N--CA 1.448 -0.517 0 N-CA-C 110.184 -1.166 . . . . 0.0 110.184 -175.386 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 51' ' ' TYR . . . . . 0.482 ' N ' ' CD1' ' A' ' 51' ' ' TYR . 0.5 OUTLIER -110.73 146.68 35.87 Favored 'General case' 0 CA--C 1.505 -0.777 0 N-CA-C 105.914 -1.884 . . . . 0.0 105.914 175.373 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 52' ' ' TYR . . . . . 0.574 ' O ' ' HA ' ' A' ' 56' ' ' GLN . 45.0 m-85 -112.9 167.58 10.39 Favored 'General case' 0 C--N 1.304 -1.412 0 C-N-CA 119.623 -0.831 . . . . 0.0 112.905 -167.835 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.823 ' HA2' HG21 ' A' ' 45' ' ' ILE . . . -54.86 157.15 7.19 Favored Glycine 0 N--CA 1.446 -0.682 0 CA-C-N 114.787 -1.097 . . . . 0.0 114.105 -171.698 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . 0.676 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 97.03 -109.86 3.93 Favored Glycine 0 N--CA 1.437 -1.244 0 C-N-CA 120.803 -0.713 . . . . 0.0 111.72 -178.411 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.524 HG21 ' HG2' ' A' ' 82' ' ' GLN . 3.1 t -84.83 -0.46 5.94 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 CA-C-O 121.771 0.796 . . . . 0.0 110.354 -176.344 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 56' ' ' GLN . . . . . 0.574 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 8.1 tp-100 56.66 50.49 12.61 Favored 'General case' 0 C--N 1.339 0.141 0 CA-C-N 114.195 -1.366 . . . . 0.0 112.685 168.289 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . 0.445 ' CE1' ' HB2' ' A' ' 86' ' ' ALA . 7.8 p90 -116.98 162.76 17.26 Favored 'General case' 0 C--N 1.321 -0.659 0 C-N-CA 120.105 -0.638 . . . . 0.0 111.083 175.287 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.481 ' HB3' ' CE1' ' A' ' 51' ' ' TYR . 6.4 p-10 -76.28 160.17 29.9 Favored 'General case' 0 C--N 1.324 -0.511 0 N-CA-C 113.594 0.961 . . . . 0.0 113.594 -162.957 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.403 ' HB2' ' CE2' ' A' ' 52' ' ' TYR . 13.1 tp60 -57.24 -39.45 75.59 Favored 'General case' 0 N--CA 1.443 -0.808 0 CA-C-N 114.036 -1.438 . . . . 0.0 111.563 178.888 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -66.74 -49.89 51.99 Favored Glycine 0 C--O 1.225 -0.436 0 CA-C-N 115.653 -0.703 . . . . 0.0 112.468 -175.746 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 93.6 m -60.68 -44.06 96.96 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 121.15 0.5 . . . . 0.0 110.681 176.051 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 62' ' ' TRP . . . . . 0.438 ' HE3' ' CZ ' ' A' ' 57' ' ' PHE . 52.3 t-105 -57.05 -48.61 78.11 Favored 'General case' 0 N--CA 1.445 -0.68 0 CA-C-N 115.331 -0.849 . . . . 0.0 109.895 176.667 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . 0.505 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 31.4 tt0 -67.48 -35.09 78.48 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-N 115.141 -0.936 . . . . 0.0 110.875 -177.593 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -67.03 -41.67 86.16 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.76 -0.655 . . . . 0.0 111.04 -176.639 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . 0.401 ' HB2' HG12 ' A' ' 85' ' ' VAL . 8.1 m120 -77.69 -9.06 58.78 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 121.112 0.482 . . . . 0.0 110.156 176.137 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 88.35 45.2 5.07 Favored Glycine 0 C--N 1.332 0.341 0 CA-C-N 115.734 -0.666 . . . . 0.0 112.395 174.05 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . 0.514 ' HA2' ' CD1' ' A' ' 70' ' ' TYR . . . -79.02 -20.28 70.62 Favored Glycine 0 N--CA 1.442 -0.964 0 C-N-CA 120.883 -0.675 . . . . 0.0 112.879 -172.937 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 0.828 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 6.7 mp -61.27 -24.05 66.12 Favored 'General case' 0 N--CA 1.45 -0.434 0 N-CA-C 112.281 0.475 . . . . 0.0 112.281 -173.72 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . 0.5 ' HG3' ' N ' ' A' ' 70' ' ' TYR . 0.7 OUTLIER -70.62 -29.42 65.8 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 121.206 0.527 . . . . 0.0 110.135 176.143 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 70' ' ' TYR . . . . . 0.839 ' HB3' ' HB3' ' A' ' 81' ' ' GLU . 71.7 m-85 -79.7 -34.35 40.23 Favored 'General case' 0 N--CA 1.446 -0.655 0 N-CA-C 107.329 -1.36 . . . . 0.0 107.329 176.449 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.695 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 162.51 127.57 0.01 OUTLIER Pre-proline 0 C--O 1.218 -0.558 0 CA-C-N 112.401 -2.182 . . . . 0.0 107.098 -178.286 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 72' ' ' PRO . . . . . 0.828 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 17.9 Cg_exo -57.13 -1.97 0.47 Allowed 'Trans proline' 0 C--N 1.332 -0.34 0 C-N-CA 122.991 2.46 . . . . 0.0 114.058 -177.453 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 73' ' ' ARG . . . . . 0.545 HH21 ' ND2' ' A' ' 46' ' ' ASN . 12.5 ptm180 -152.56 141.89 21.55 Favored 'General case' 0 C--N 1.319 -0.726 0 N-CA-C 109.64 -0.504 . . . . 0.0 109.64 176.998 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . 0.556 ' HB3' ' HB2' ' A' ' 52' ' ' TYR . . . -63.44 -22.07 66.67 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.509 -0.769 . . . . 0.0 113.028 -176.798 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . 0.496 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 5.2 p-10 -88.29 2.92 51.38 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 121.328 0.585 . . . . 0.0 110.847 -179.781 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.443 ' HB3' ' HB2' ' A' ' 71' ' ' ALA . 53.5 tp -106.27 -34.86 7.35 Favored 'General case' 0 C--N 1.321 -0.654 0 N-CA-C 108.858 -0.793 . . . . 0.0 108.858 174.246 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . 0.783 ' HB3' ' HB2' ' A' ' 81' ' ' GLU . . . -79.83 158.12 26.85 Favored 'General case' 0 N--CA 1.446 -0.627 0 CA-C-N 114.99 -1.005 . . . . 0.0 110.057 174.512 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 25.4 p -100.77 -171.64 2.04 Favored 'General case' 0 C--N 1.314 -0.965 0 CA-C-N 116.2 -0.455 . . . . 0.0 109.8 -179.435 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . 0.719 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 35.9 mtt85 -49.21 -51.95 29.91 Favored 'General case' 0 C--O 1.218 -0.559 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.79 -179.959 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -57.45 -47.61 81.35 Favored 'General case' 0 C--N 1.321 -0.666 0 N-CA-C 112.148 0.425 . . . . 0.0 112.148 -174.854 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 81' ' ' GLU . . . . . 0.839 ' HB3' ' HB3' ' A' ' 70' ' ' TYR . 60.6 mp0 -65.6 -51.23 61.28 Favored 'General case' 0 CA--C 1.517 -0.318 0 CA-C-O 120.983 0.421 . . . . 0.0 111.403 177.228 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 82' ' ' GLN . . . . . 0.524 ' HG2' HG21 ' A' ' 55' ' ' VAL . 4.2 tt0 -65.0 -34.35 78.24 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.606 -0.724 . . . . 0.0 111.361 -173.657 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . 0.583 ' O ' ' HB3' ' A' ' 87' ' ' GLU . 8.1 mt -61.63 -46.13 97.2 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 N-CA-C 109.471 -0.566 . . . . 0.0 109.471 174.193 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . . . . . . . . . . . -61.37 -47.48 85.68 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.205 -176.825 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . 0.401 HG12 ' HB2' ' A' ' 65' ' ' ASN . 46.5 t -65.97 -50.28 70.85 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-N 116.137 -0.483 . . . . 0.0 112.207 -179.997 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . 0.445 ' HB2' ' CE1' ' A' ' 57' ' ' PHE . . . -63.87 -32.05 73.44 Favored 'General case' 0 CA--C 1.515 -0.394 0 CA-C-O 121.397 0.618 . . . . 0.0 110.437 179.702 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 87' ' ' GLU . . . . . 0.653 ' HA ' ' HG2' ' A' ' 90' ' ' ARG . 0.4 OUTLIER -71.32 -27.28 63.28 Favored 'General case' 0 C--N 1.317 -0.844 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.871 -178.136 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.678 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 94.6 t -61.22 -44.17 97.85 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.254 0 N-CA-C 108.701 -0.852 . . . . 0.0 108.701 169.295 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 89' ' ' THR . . . . . 0.665 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 0.3 OUTLIER -66.81 -43.81 82.87 Favored 'General case' 0 C--N 1.316 -0.852 0 CA-C-N 115.582 -0.735 . . . . 0.0 111.375 -179.778 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . 0.667 ' HD3' ' CZ2' ' A' ' 31' ' ' TRP . 20.7 ptt180 -59.88 -35.11 74.13 Favored 'General case' 0 C--O 1.222 -0.392 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.707 -176.197 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . 0.678 ' HG ' ' O ' ' A' ' 88' ' ' VAL . 4.6 pp -74.44 -24.77 59.12 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 121.042 0.448 . . . . 0.0 111.102 -171.678 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . 0.492 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 2.5 mtm180 -81.79 -45.24 15.87 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-O 121.568 0.699 . . . . 0.0 109.514 -178.044 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 6.6 pt20 -104.27 -28.06 11.63 Favored 'General case' 0 C--N 1.322 -0.618 0 N-CA-C 113.59 0.959 . . . . 0.0 113.59 -169.696 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 88.35 44.23 5.35 Favored Glycine 0 CA--C 1.507 -0.419 0 C-N-CA 120.625 -0.797 . . . . 0.0 112.136 176.195 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 95' ' ' TRP . . . . . 0.522 ' HZ2' HH11 ' A' ' 90' ' ' ARG . 23.6 m95 66.87 13.63 9.5 Favored 'General case' 0 C--O 1.218 -0.6 0 CA-C-O 121.173 0.511 . . . . 0.0 109.812 178.396 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -65.53 -31.62 80.74 Favored Glycine 0 N--CA 1.451 -0.304 0 CA-C-N 115.588 -0.733 . . . . 0.0 113.132 177.289 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -76.49 -21.52 55.72 Favored 'General case' 0 CA--C 1.515 -0.385 0 CA-C-O 121.152 0.501 . . . . 0.0 110.411 178.508 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 98' ' ' TRP . . . . . 0.665 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 25.1 m-90 -100.26 108.62 53.41 Favored Pre-proline 0 N--CA 1.443 -0.803 0 CA-C-N 115.521 -0.763 . . . . 0.0 109.202 178.42 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . 0.446 ' HD3' ' HA ' ' A' ' 98' ' ' TRP . 52.5 Cg_exo -62.25 -138.46 0.0 OUTLIER 'Trans proline' 0 CA--C 1.535 0.56 0 C-N-CA 123.831 3.021 . . . . 0.0 114.265 -174.026 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 3.4 m -54.11 -26.3 14.6 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.915 -177.882 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 101' ' ' CYS . . . . . 0.454 ' SG ' ' HG2' ' A' ' 38' ' ' GLU . 62.0 m -56.69 -39.64 74.16 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-N 115.75 -0.659 . . . . 0.0 111.525 178.035 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -70.8 -44.24 67.0 Favored 'General case' 0 CA--C 1.519 -0.23 0 CA-C-O 121.008 0.432 . . . . 0.0 110.716 179.871 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -60.68 -44.15 96.85 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.634 179.724 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -66.87 -34.03 76.91 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.712 -0.676 . . . . 0.0 111.049 176.957 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 105' ' ' ALA . . . . . 0.766 ' O ' HG21 ' A' ' 30' ' ' ILE . . . -76.51 -26.77 55.6 Favored 'General case' 0 C--N 1.331 -0.238 0 N-CA-C 111.895 0.332 . . . . 0.0 111.895 -175.285 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 111.62 60.28 0.46 Allowed Glycine 0 CA--C 1.521 0.415 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.234 -175.31 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -70.11 148.61 48.52 Favored 'General case' 0 C--N 1.327 -0.375 0 C-N-CA 122.579 0.351 . . . . 0.0 110.891 -178.94 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 108' ' ' ARG . . . . . 0.439 ' O ' ' HD3' ' A' ' 108' ' ' ARG . 0.0 OUTLIER . . . . . 0 C--O 1.245 0.825 0 CA-C-O 118.559 -0.734 . . . . 0.0 110.318 -177.082 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 91.0 m-20 . . . . . 0 N--CA 1.48 1.061 0 CA-C-O 120.965 0.412 . . . . 0.0 110.437 . . . . . . . . . 0 0 . 1 . 028 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 8.0 p -75.3 -42.87 43.71 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.13 178.635 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 7.4 p -76.44 115.09 17.56 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.893 0 CA-C-O 121.418 0.628 . . . . 0.0 110.69 175.754 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 11.1 t -97.26 148.75 5.37 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.14 -179.396 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 5' ' ' THR . . . . . 0.437 ' HA ' ' HD3' ' A' ' 6' ' ' PRO . 1.2 p -82.09 113.75 45.73 Favored Pre-proline 0 C--N 1.319 -0.729 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.641 178.948 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.437 ' HD3' ' HA ' ' A' ' 5' ' ' THR . 3.4 Cg_exo -75.78 170.23 20.6 Favored 'Trans proline' 0 N--CA 1.456 -0.735 0 C-N-CA 122.97 2.447 . . . . 0.0 112.004 -177.519 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -96.54 35.72 1.46 Allowed 'General case' 0 C--N 1.31 -1.147 0 CA-C-N 114.623 -1.171 . . . . 0.0 110.997 -177.672 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 31.3 t-80 -76.27 -7.42 54.87 Favored 'General case' 0 C--N 1.315 -0.91 0 CA-C-N 114.854 -1.066 . . . . 0.0 108.345 169.733 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 12.8 pt-20 -67.85 157.4 34.94 Favored 'General case' 0 N--CA 1.45 -0.433 0 CA-C-N 114.745 -1.116 . . . . 0.0 110.409 177.52 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -144.36 78.55 1.58 Allowed 'General case' 0 C--N 1.315 -0.906 0 CA-C-N 115.472 -0.785 . . . . 0.0 110.061 -178.862 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 57.8 t -68.84 -75.12 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 CA-C-N 114.98 -1.009 . . . . 0.0 109.48 177.125 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 5.1 p 25.15 82.49 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.343 0.325 0 C-N-CA 125.078 1.351 . . . . 0.0 113.554 172.489 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 54.9 mtm180 -87.84 100.72 13.08 Favored 'General case' 0 C--N 1.305 -1.355 0 CA-C-N 114.202 -1.363 . . . . 0.0 111.377 -177.817 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 7.0 t -133.32 166.41 29.34 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.144 0 CA-C-N 113.915 -1.493 . . . . 0.0 108.636 178.82 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 141.7 68.41 0.03 OUTLIER Glycine 0 N--CA 1.439 -1.111 0 CA-C-N 115.598 -0.728 . . . . 0.0 111.94 177.381 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 19.9 m -95.85 -25.47 16.0 Favored 'General case' 0 N--CA 1.442 -0.837 0 CA-C-N 114.992 -0.604 . . . . 0.0 110.945 -177.192 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 29.6 mmmt -46.37 114.68 2.74 Favored Pre-proline 0 C--N 1.322 -0.626 0 CA-C-N 114.215 -1.357 . . . . 0.0 112.633 -176.003 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 17.1 Cg_exo -70.41 162.78 41.14 Favored 'Trans proline' 0 CA--C 1.509 -0.726 0 C-N-CA 123.668 2.912 . . . . 0.0 112.066 175.039 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -131.4 33.06 2.84 Favored Glycine 0 C--N 1.305 -1.153 0 CA-C-N 114.318 -1.31 . . . . 0.0 111.825 -177.405 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 10.5 m -64.82 -53.24 49.95 Favored 'General case' 0 C--N 1.314 -0.953 0 CA-C-N 114.57 -0.815 . . . . 0.0 109.744 177.591 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . 0.534 ' O ' ' HD3' ' A' ' 23' ' ' PRO . 33.5 mt-10 -144.65 107.43 4.46 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 108.57 -0.9 . . . . 0.0 108.57 173.387 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.403 ' O ' HG12 ' A' ' 22' ' ' VAL . 7.4 p -92.24 110.58 45.42 Favored Pre-proline 0 C--N 1.317 -0.823 0 CA-C-O 121.569 0.7 . . . . 0.0 111.465 -175.717 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . 0.534 ' HD3' ' O ' ' A' ' 21' ' ' GLU . 27.3 Cg_exo -62.95 155.01 63.06 Favored 'Trans proline' 0 N--CA 1.46 -0.458 0 C-N-CA 123.52 2.813 . . . . 0.0 111.789 175.824 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 8.0 Cg_endo -52.78 140.91 56.29 Favored 'Trans proline' 0 N--CA 1.451 -1.012 0 C-N-CA 122.302 2.001 . . . . 0.0 109.865 172.091 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.96 HG12 HG23 ' A' ' 83' ' ' ILE . 97.2 t -79.83 124.57 38.11 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.243 0 CA-C-O 122.143 0.973 . . . . 0.0 113.254 -161.896 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 48.4 mm -81.24 -25.84 10.43 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 CA-C-N 113.89 -1.505 . . . . 0.0 110.873 -179.372 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.498 ' O ' HG12 ' A' ' 30' ' ' ILE . 7.0 m-20 -84.8 1.3 47.43 Favored 'General case' 0 CA--C 1.504 -0.803 0 CA-C-O 121.791 0.805 . . . . 0.0 108.849 -177.235 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . 0.597 ' HA2' ' HB2' ' A' ' 31' ' ' TRP . . . -66.25 -5.05 25.93 Favored Glycine 0 N--CA 1.44 -1.092 0 CA-C-N 114.488 -1.233 . . . . 0.0 110.581 176.721 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 22.3 m -77.2 -40.44 45.15 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 120.989 0.423 . . . . 0.0 109.98 174.053 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.507 ' O ' HG13 ' A' ' 34' ' ' ILE . 0.6 OUTLIER -65.25 -38.92 83.82 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.513 0 N-CA-C 107.038 -1.467 . . . . 0.0 107.038 174.108 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 31' ' ' TRP . . . . . 0.672 ' CD1' HG13 ' A' ' 83' ' ' ILE . 31.7 m95 -72.1 -36.49 69.48 Favored 'General case' 0 N--CA 1.438 -1.075 0 CA-C-N 113.598 -1.637 . . . . 0.0 111.031 -175.998 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 6.6 t70 -72.63 -34.65 67.46 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.016 178.203 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -67.3 -37.01 82.67 Favored 'General case' 0 N--CA 1.445 -0.685 0 C-N-CA 120.64 -0.424 . . . . 0.0 109.923 177.119 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . 0.507 HG13 ' O ' ' A' ' 30' ' ' ILE . 74.2 mt -67.66 -46.43 82.79 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.171 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.523 174.491 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -58.91 -34.22 71.45 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 121.215 0.531 . . . . 0.0 110.516 177.563 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . 0.528 ' HA2' ' N ' ' A' ' 41' ' ' GLY . . . -78.83 -7.03 88.51 Favored Glycine 0 N--CA 1.45 -0.418 0 CA-C-N 115.617 -0.72 . . . . 0.0 111.719 178.616 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 46.0 t -94.81 -58.1 2.27 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-O 120.775 0.321 . . . . 0.0 110.607 -179.221 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . 0.416 ' HG3' ' SG ' ' A' ' 101' ' ' CYS . 40.2 mt-10 -89.29 -25.61 21.58 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.379 -0.373 . . . . 0.0 111.345 -173.52 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -107.53 -12.95 15.18 Favored 'General case' 0 C--N 1.324 -0.527 0 C-N-CA 120.444 -0.502 . . . . 0.0 111.869 -179.011 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 78.72 13.57 83.01 Favored Glycine 0 CA--C 1.503 -0.665 0 N-CA-C 109.789 -1.324 . . . . 0.0 109.789 -177.371 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . 0.528 ' N ' ' HA2' ' A' ' 36' ' ' GLY . . . 78.87 61.52 2.39 Favored Glycine 0 N--CA 1.435 -1.391 0 CA-C-N 114.069 -1.066 . . . . 0.0 111.855 -177.053 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . 0.583 HD21 ' HB ' ' A' ' 45' ' ' ILE . 4.1 t30 -145.66 96.98 2.9 Favored 'General case' 0 N--CA 1.45 -0.449 0 N-CA-C 109.044 -0.724 . . . . 0.0 109.044 -177.968 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 43' ' ' TRP . . . . . 0.852 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 16.1 m95 -82.72 -1.42 51.34 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-O 121.554 0.692 . . . . 0.0 111.156 -170.412 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -113.62 9.55 17.89 Favored 'General case' 0 C--N 1.314 -0.967 0 CA-C-N 115.039 -0.982 . . . . 0.0 111.095 178.713 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.94 HG23 ' HA2' ' A' ' 53' ' ' GLY . 9.5 tt -72.65 143.22 14.2 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.68 0 CA-C-O 121.177 0.513 . . . . 0.0 110.654 -175.603 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 15.3 t-20 -150.8 97.05 2.43 Favored 'General case' 0 C--N 1.311 -1.1 0 N-CA-C 109.399 -0.593 . . . . 0.0 109.399 177.732 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 11.1 p -74.89 -16.67 60.66 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 115.798 -0.637 . . . . 0.0 111.006 -177.7 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 101.4 13.03 34.09 Favored Glycine 0 N--CA 1.445 -0.705 0 CA-C-N 115.818 -0.628 . . . . 0.0 111.612 178.059 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 31.7 p-10 -91.65 3.01 56.07 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.801 0.334 . . . . 0.0 111.4 -176.381 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . 0.403 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 94.9 -2.54 66.55 Favored Glycine 0 N--CA 1.449 -0.494 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.265 179.909 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 51' ' ' TYR . . . . . 0.526 ' HA ' ' HA ' ' A' ' 58' ' ' ASP . 0.4 OUTLIER -108.59 162.6 13.99 Favored 'General case' 0 CA--C 1.515 -0.374 0 N-CA-C 108.464 -0.939 . . . . 0.0 108.464 176.874 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 52' ' ' TYR . . . . . 0.616 ' O ' ' HA ' ' A' ' 56' ' ' GLN . 61.6 m-85 -123.32 169.73 11.03 Favored 'General case' 0 C--N 1.315 -0.927 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.617 -170.874 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.94 ' HA2' HG23 ' A' ' 45' ' ' ILE . . . -64.58 157.89 44.24 Favored Glycine 0 N--CA 1.445 -0.765 0 CA-C-N 115.585 -0.734 . . . . 0.0 114.105 -169.913 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . 0.657 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 107.1 -111.73 3.57 Favored Glycine 0 N--CA 1.442 -0.964 0 N-CA-C 111.653 -0.579 . . . . 0.0 111.653 179.3 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 3.1 m -93.42 12.9 2.75 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 CA-C-O 121.906 0.86 . . . . 0.0 110.385 176.69 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 56' ' ' GLN . . . . . 0.616 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 4.1 tt0 60.8 49.85 5.83 Favored 'General case' 0 C--N 1.317 -0.845 0 CA-C-N 113.673 -1.603 . . . . 0.0 112.178 172.652 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . 0.415 ' HZ ' ' CA ' ' A' ' 86' ' ' ALA . 27.3 m-85 -60.97 133.93 56.59 Favored 'General case' 0 CA--C 1.506 -0.717 0 CA-C-N 115.35 -0.841 . . . . 0.0 111.547 169.626 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.526 ' HA ' ' HA ' ' A' ' 51' ' ' TYR . 6.2 p-10 -74.01 156.13 37.85 Favored 'General case' 0 C--N 1.315 -0.932 0 C-N-CA 119.509 -0.877 . . . . 0.0 108.831 163.928 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 21.0 tp60 -52.52 -39.06 60.93 Favored 'General case' 0 N--CA 1.443 -0.778 0 CA-C-O 121.098 0.475 . . . . 0.0 111.039 -179.082 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -69.7 -50.95 27.62 Favored Glycine 0 C--O 1.222 -0.599 0 CA-C-N 115.127 -0.942 . . . . 0.0 113.237 -174.005 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 95.6 m -64.8 -35.24 80.46 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 121.201 0.524 . . . . 0.0 110.771 179.369 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 62' ' ' TRP . . . . . 0.674 ' CZ3' ' HA ' ' A' ' 82' ' ' GLN . 59.8 t-105 -60.99 -49.04 79.07 Favored 'General case' 0 N--CA 1.443 -0.779 0 CA-C-O 121.579 0.704 . . . . 0.0 109.258 174.768 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . 0.479 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 40.8 tt0 -67.24 -33.96 76.44 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-N 114.858 -1.064 . . . . 0.0 110.858 -179.017 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -63.36 -42.65 98.89 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.815 -0.63 . . . . 0.0 112.057 -175.341 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . 0.636 ' HB2' HG13 ' A' ' 85' ' ' VAL . 37.1 m-80 -83.43 -10.41 58.41 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.826 0.346 . . . . 0.0 110.409 176.209 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . 0.447 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 94.09 51.44 2.08 Favored Glycine 0 C--N 1.332 0.35 0 C-N-CA 121.007 -0.616 . . . . 0.0 112.839 173.831 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . 0.591 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -79.73 -23.96 61.19 Favored Glycine 0 N--CA 1.439 -1.116 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.821 -176.49 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 0.842 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 6.9 mp -59.47 -26.8 65.54 Favored 'General case' 0 C--N 1.323 -0.545 0 N-CA-C 112.553 0.575 . . . . 0.0 112.553 -172.748 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . 0.447 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 3.4 ptm180 -65.5 -33.15 75.27 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 121.36 0.6 . . . . 0.0 109.877 177.335 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 70' ' ' TYR . . . . . 1.07 ' HB3' ' HG2' ' A' ' 81' ' ' GLU . 74.1 m-85 -81.26 -34.79 31.83 Favored 'General case' 0 N--CA 1.439 -0.98 0 N-CA-C 107.956 -1.127 . . . . 0.0 107.956 179.389 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.676 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 164.63 126.12 0.02 OUTLIER Pre-proline 0 N--CA 1.448 -0.552 0 CA-C-N 112.63 -2.077 . . . . 0.0 106.989 -178.766 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 72' ' ' PRO . . . . . 0.842 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 26.5 Cg_exo -55.17 -5.88 0.66 Allowed 'Trans proline' 0 C--N 1.332 -0.3 0 C-N-CA 123.216 2.61 . . . . 0.0 114.076 -177.808 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 73' ' ' ARG . . . . . 0.414 HH11 ' HD2' ' A' ' 73' ' ' ARG . 9.9 ptm180 -146.97 138.37 24.14 Favored 'General case' 0 C--N 1.318 -0.795 0 CA-C-O 121.459 0.647 . . . . 0.0 110.402 175.776 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -60.12 -20.68 59.46 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 114.839 -1.073 . . . . 0.0 112.6 -178.889 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . 0.598 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 0.0 OUTLIER -76.83 -22.17 53.97 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 121.262 0.553 . . . . 0.0 110.602 -178.536 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 57.9 tp -92.66 -33.36 14.4 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.643 -0.708 . . . . 0.0 110.022 177.766 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . 0.692 ' HB3' ' HB3' ' A' ' 81' ' ' GLU . . . -77.8 154.84 31.51 Favored 'General case' 0 N--CA 1.447 -0.581 0 CA-C-N 115.48 -0.782 . . . . 0.0 110.66 178.657 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 72.9 p -96.41 -174.39 3.04 Favored 'General case' 0 C--N 1.314 -0.955 0 CA-C-N 115.214 -0.903 . . . . 0.0 110.84 -176.65 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . 0.852 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 0.1 OUTLIER -50.9 -54.75 21.35 Favored 'General case' 0 C--O 1.216 -0.668 0 CA-C-O 120.699 0.285 . . . . 0.0 110.376 -179.093 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -60.35 -38.22 83.14 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-O 121.261 0.553 . . . . 0.0 111.289 -174.086 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 81' ' ' GLU . . . . . 1.07 ' HG2' ' HB3' ' A' ' 70' ' ' TYR . 2.9 mt-10 -72.32 -52.99 13.7 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 115.505 -0.771 . . . . 0.0 112.297 -179.98 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 82' ' ' GLN . . . . . 0.674 ' HA ' ' CZ3' ' A' ' 62' ' ' TRP . 3.7 tt0 -63.78 -34.47 77.97 Favored 'General case' 0 C--N 1.317 -0.841 0 CA-C-N 115.28 -0.873 . . . . 0.0 109.621 -178.441 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . 0.96 HG23 HG12 ' A' ' 25' ' ' VAL . 0.5 OUTLIER -70.02 -39.56 77.47 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.235 0 CA-C-N 114.632 -1.167 . . . . 0.0 110.965 177.907 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . 0.421 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -58.98 -36.19 74.46 Favored 'General case' 0 C--O 1.237 0.418 0 CA-C-O 121.587 0.708 . . . . 0.0 110.321 -178.272 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . 0.636 HG13 ' HB2' ' A' ' 65' ' ' ASN . 44.6 t -67.21 -46.89 83.14 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-N 115.173 -0.921 . . . . 0.0 110.187 176.57 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . 0.415 ' CA ' ' HZ ' ' A' ' 57' ' ' PHE . . . -61.67 -31.92 72.07 Favored 'General case' 0 N--CA 1.451 -0.378 0 CA-C-N 115.465 -0.789 . . . . 0.0 110.641 175.813 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 87' ' ' GLU . . . . . 0.622 ' HA ' ' HG2' ' A' ' 90' ' ' ARG . 21.4 mm-40 -60.53 -44.29 96.22 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.616 -177.809 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.575 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 96.8 t -62.52 -51.78 68.03 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.425 0 C-N-CA 120.431 -0.508 . . . . 0.0 110.553 -179.13 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 89' ' ' THR . . . . . 0.541 ' HA ' ' NE ' ' A' ' 92' ' ' ARG . 14.8 t -74.09 -35.08 64.17 Favored 'General case' 0 N--CA 1.439 -0.99 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.505 -175.278 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . 0.622 ' HG2' ' HA ' ' A' ' 87' ' ' GLU . 3.3 ptt180 -62.26 -36.84 83.3 Favored 'General case' 0 N--CA 1.471 0.595 0 O-C-N 122.252 -0.28 . . . . 0.0 111.165 -178.337 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . 0.596 ' N ' ' HG3' ' A' ' 90' ' ' ARG . 4.5 pp -73.03 -23.75 60.63 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.311 -172.964 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . 0.541 ' NE ' ' HA ' ' A' ' 89' ' ' THR . 4.4 mtm180 -82.08 -43.09 18.31 Favored 'General case' 0 CA--C 1.51 -0.581 0 CA-C-O 121.797 0.808 . . . . 0.0 109.652 -178.274 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 93' ' ' GLN . . . . . 0.474 ' OE1' ' HB2' ' A' ' 97' ' ' ALA . 19.0 pt20 -99.98 -27.35 13.62 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 114.764 -1.107 . . . . 0.0 113.111 -170.485 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 84.14 47.75 5.39 Favored Glycine 0 CA--C 1.502 -0.772 0 C-N-CA 120.698 -0.763 . . . . 0.0 111.616 174.795 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 95' ' ' TRP . . . . . 0.503 ' HA ' ' HE3' ' A' ' 98' ' ' TRP . 2.9 m95 63.27 17.4 10.21 Favored 'General case' 0 C--O 1.219 -0.512 0 C-N-CA 123.148 0.579 . . . . 0.0 109.647 177.71 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -66.79 -36.64 91.47 Favored Glycine 0 C--N 1.333 0.372 0 CA-C-N 115.896 -0.593 . . . . 0.0 112.253 179.586 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . 0.474 ' HB2' ' OE1' ' A' ' 93' ' ' GLN . . . -69.94 -23.45 63.2 Favored 'General case' 0 CA--C 1.517 -0.296 0 CA-C-O 120.709 0.29 . . . . 0.0 110.577 177.768 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 98' ' ' TRP . . . . . 0.503 ' HE3' ' HA ' ' A' ' 95' ' ' TRP . 25.1 m-90 -98.94 108.11 47.4 Favored Pre-proline 0 N--CA 1.447 -0.6 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 179.095 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 43.6 Cg_exo -63.36 -136.13 0.0 OUTLIER 'Trans proline' 0 CA--C 1.537 0.665 0 C-N-CA 123.671 2.914 . . . . 0.0 114.083 -174.275 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 44.3 t -55.19 -24.77 15.61 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.259 0 CA-C-O 121.241 0.543 . . . . 0.0 111.49 -176.106 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 101' ' ' CYS . . . . . 0.416 ' SG ' ' HG3' ' A' ' 38' ' ' GLU . 61.0 m -62.84 -34.81 78.12 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 116.064 -0.516 . . . . 0.0 111.502 -179.217 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -70.34 -41.05 73.71 Favored 'General case' 0 C--N 1.333 -0.136 0 CA-C-O 121.014 0.435 . . . . 0.0 110.775 177.975 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -64.72 -34.74 79.02 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.002 -0.544 . . . . 0.0 110.272 178.235 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 55.7 mtp180 -73.87 -19.08 60.83 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.505 -0.77 . . . . 0.0 111.864 176.468 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -95.76 -21.69 17.99 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 116.094 -0.503 . . . . 0.0 112.096 -172.951 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 99.93 67.13 0.84 Allowed Glycine 0 N--CA 1.454 -0.161 0 C-N-CA 120.777 -0.725 . . . . 0.0 111.88 -177.03 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -64.67 152.02 43.42 Favored 'General case' 0 N--CA 1.45 -0.468 0 C-N-CA 122.67 0.388 . . . . 0.0 111.022 -174.147 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 18.0 mmt180 . . . . . 0 C--O 1.241 0.656 0 O-C-N 124.019 0.824 . . . . 0.0 111.416 177.948 . . . . . . . . 0 0 . 1 . 029 nuclear orig full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 89.8 m-20 . . . . . 0 N--CA 1.479 0.989 0 CA-C-O 120.73 0.3 . . . . 0.0 110.301 . . . . . . . . . 0 0 . 1 . 029 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 47.8 t -98.8 -34.92 4.66 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 CA-C-O 121.283 0.563 . . . . 0.0 110.318 179.475 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 39.3 t -83.54 134.12 27.64 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.757 0 CA-C-N 115.563 -0.744 . . . . 0.0 110.976 -179.099 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 9.3 t -87.3 138.59 18.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 N-CA-C 109.382 -0.599 . . . . 0.0 109.382 175.838 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 22.1 p -129.73 105.98 17.02 Favored Pre-proline 0 C--N 1.314 -0.957 0 CA-C-N 115.971 -0.559 . . . . 0.0 111.4 -174.58 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 3.4 Cg_exo -80.98 168.41 17.29 Favored 'Trans proline' 0 N--CA 1.452 -0.945 0 C-N-CA 122.805 2.337 . . . . 0.0 111.644 178.279 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -141.09 -171.98 3.39 Favored 'General case' 0 C--N 1.307 -1.26 0 CA-C-N 114.769 -1.105 . . . . 0.0 110.457 -178.714 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 26.4 t-80 69.33 6.3 5.61 Favored 'General case' 0 C--O 1.232 0.167 0 O-C-N 124.068 0.855 . . . . 0.0 109.481 -173.23 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -50.45 135.03 22.99 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.016 -0.993 . . . . 0.0 109.974 174.819 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -123.7 70.88 1.07 Allowed 'General case' 0 C--N 1.318 -0.778 0 CA-C-O 121.674 0.749 . . . . 0.0 110.911 -171.63 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.477 ' O ' ' HG3' ' A' ' 13' ' ' ARG . 99.5 t -65.18 -48.33 84.03 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.015 0 CA-C-N 114.314 -1.312 . . . . 0.0 109.809 174.955 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 3.6 p -31.34 95.34 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.436 -1.144 0 C-N-CA 125.358 1.463 . . . . 0.0 113.376 170.98 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . 0.477 ' HG3' ' O ' ' A' ' 11' ' ' VAL . 22.7 mtm180 -127.33 114.45 17.6 Favored 'General case' 0 C--N 1.302 -1.471 0 CA-C-N 113.543 -1.662 . . . . 0.0 110.304 176.487 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.7 t -98.28 160.37 3.14 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.872 0 CA-C-N 115.492 -0.776 . . . . 0.0 109.634 179.341 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 145.02 97.01 0.21 Allowed Glycine 0 N--CA 1.439 -1.122 0 CA-C-N 115.124 -0.943 . . . . 0.0 111.924 -179.561 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 24.1 m -86.23 -33.72 20.65 Favored 'General case' 0 N--CA 1.446 -0.672 0 CA-C-O 120.655 0.264 . . . . 0.0 111.496 -176.924 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . 0.479 ' HB2' ' HE3' ' A' ' 17' ' ' LYS . 0.0 OUTLIER 42.66 75.64 0.61 Allowed Pre-proline 0 C--N 1.321 -0.673 0 CA-C-N 115.406 -0.815 . . . . 0.0 111.491 -175.304 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 7.0 Cg_exo -74.62 165.88 30.62 Favored 'Trans proline' 0 N--CA 1.458 -0.606 0 C-N-CA 122.75 2.3 . . . . 0.0 112.034 -179.543 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -99.3 23.43 36.33 Favored Glycine 0 C--N 1.309 -0.937 0 CA-C-N 114.598 -1.183 . . . . 0.0 112.439 -176.753 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 2.6 m -70.05 -44.25 69.57 Favored 'General case' 0 C--N 1.307 -1.246 0 CA-C-O 122.164 0.983 . . . . 0.0 109.264 177.122 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . 0.406 ' O ' ' HD3' ' A' ' 23' ' ' PRO . 11.9 pt-20 -130.56 150.84 51.57 Favored 'General case' 0 N--CA 1.42 -1.938 0 N-CA-C 106.789 -1.56 . . . . 0.0 106.789 178.511 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 30.1 t -72.86 114.99 35.62 Favored Pre-proline 0 C--N 1.3 -1.56 0 CA-C-N 115.947 -0.57 . . . . 0.0 110.506 -177.414 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . 0.406 ' HD3' ' O ' ' A' ' 21' ' ' GLU . 47.9 Cg_exo -55.99 152.45 36.68 Favored 'Trans proline' 0 C--N 1.346 0.417 0 C-N-CA 122.919 2.412 . . . . 0.0 111.264 175.921 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 9.9 Cg_endo -54.07 138.49 70.82 Favored 'Trans proline' 0 N--CA 1.452 -0.946 0 C-N-CA 122.64 2.226 . . . . 0.0 111.439 -178.914 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 20.9 t -103.4 131.37 52.03 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.243 0 CA-C-N 114.723 -1.126 . . . . 0.0 109.603 -174.106 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 45.1 mm -65.34 -26.01 38.47 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 CA-C-N 115.601 -0.727 . . . . 0.0 110.918 -174.506 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.408 ' O ' HG12 ' A' ' 30' ' ' ILE . 14.2 m-20 -89.97 -12.84 37.56 Favored 'General case' 0 CA--C 1.498 -1.049 0 CA-C-O 121.729 0.776 . . . . 0.0 109.598 179.27 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -63.09 -16.52 57.75 Favored Glycine 0 C--N 1.309 -0.963 0 CA-C-N 114.321 -1.309 . . . . 0.0 111.247 -177.047 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 15.5 m -77.66 -39.84 43.67 Favored 'General case' 0 C--N 1.315 -0.909 0 CA-C-O 121.811 0.815 . . . . 0.0 109.359 178.397 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.572 ' O ' HG13 ' A' ' 34' ' ' ILE . 0.5 OUTLIER -69.76 -39.73 78.29 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.706 0 CA-C-N 114.111 -1.404 . . . . 0.0 107.497 179.194 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 31' ' ' TRP . . . . . 0.476 ' CZ2' ' HB3' ' A' ' 90' ' ' ARG . 18.1 m95 -68.35 -37.42 80.48 Favored 'General case' 0 C--N 1.317 -0.828 0 CA-C-N 114.195 -1.366 . . . . 0.0 110.809 -177.017 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 7.7 t70 -76.38 -32.32 58.52 Favored 'General case' 0 N--CA 1.447 -0.621 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.74 179.335 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . 0.498 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -71.05 -37.19 72.52 Favored 'General case' 0 N--CA 1.448 -0.527 0 C-N-CA 120.684 -0.406 . . . . 0.0 110.691 176.48 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . 0.572 HG13 ' O ' ' A' ' 30' ' ' ILE . 82.3 mt -67.16 -41.81 87.37 Favored 'Isoleucine or valine' 0 C--O 1.234 0.262 0 CA-C-O 121.212 0.53 . . . . 0.0 109.892 175.032 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . 0.642 ' HA ' ' O ' ' A' ' 54' ' ' GLY . . . -57.44 -37.91 73.58 Favored 'General case' 0 CA--C 1.515 -0.382 0 CA-C-N 115.511 -0.768 . . . . 0.0 110.317 175.997 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -78.38 -3.91 86.47 Favored Glycine 0 N--CA 1.45 -0.374 0 CA-C-N 115.246 -0.888 . . . . 0.0 111.638 179.883 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 41.0 t -97.51 -60.14 1.63 Allowed 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 115.689 -0.256 . . . . 0.0 111.055 -178.415 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . 0.616 ' HG3' ' SG ' ' A' ' 101' ' ' CYS . 39.2 mt-10 -89.28 -33.78 16.83 Favored 'General case' 0 CA--C 1.516 -0.356 0 CA-C-O 120.715 0.293 . . . . 0.0 111.388 -173.418 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -95.42 -14.06 24.11 Favored 'General case' 0 C--N 1.324 -0.534 0 C-N-CA 120.676 -0.409 . . . . 0.0 111.693 -176.819 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 77.97 20.22 73.63 Favored Glycine 0 N--CA 1.445 -0.745 0 N-CA-C 109.754 -1.338 . . . . 0.0 109.754 -175.799 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 71.07 56.47 7.0 Favored Glycine 0 N--CA 1.437 -1.28 0 CA-C-N 114.185 -1.008 . . . . 0.0 112.036 -176.412 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . 0.599 HD21 ' HB ' ' A' ' 45' ' ' ILE . 3.7 t30 -141.23 88.03 2.13 Favored 'General case' 0 N--CA 1.447 -0.597 0 N-CA-C 108.89 -0.782 . . . . 0.0 108.89 -177.592 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 43' ' ' TRP . . . . . 0.737 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 22.1 m95 -70.37 -13.03 61.97 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.515 -0.766 . . . . 0.0 111.176 -173.31 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -102.94 14.05 32.87 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 115.959 -0.564 . . . . 0.0 111.543 -177.624 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.789 HG23 ' HA2' ' A' ' 53' ' ' GLY . 3.6 tt -82.82 144.29 10.44 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.598 0 CA-C-O 120.915 0.388 . . . . 0.0 110.171 -177.955 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 44.5 t-20 -158.24 90.51 1.04 Allowed 'General case' 0 C--N 1.314 -0.95 0 N-CA-C 109.67 -0.493 . . . . 0.0 109.67 178.708 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 35.2 p -76.8 -24.05 52.81 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.622 -0.717 . . . . 0.0 110.92 -179.849 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 99.36 23.94 10.72 Favored Glycine 0 N--CA 1.442 -0.921 0 CA-C-N 115.458 -0.792 . . . . 0.0 111.377 -179.346 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 35.2 p30 -85.4 5.41 31.04 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.986 0.422 . . . . 0.0 111.559 179.656 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . 0.45 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 96.28 -10.63 67.42 Favored Glycine 0 N--CA 1.446 -0.653 0 N-CA-C 111.625 -0.59 . . . . 0.0 111.625 179.153 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 51' ' ' TYR . . . . . 0.521 ' HA ' ' HA ' ' A' ' 58' ' ' ASP . 0.2 OUTLIER -117.84 156.2 28.8 Favored 'General case' 0 CA--C 1.505 -0.75 0 N-CA-C 106.593 -1.632 . . . . 0.0 106.593 179.393 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 52' ' ' TYR . . . . . 0.562 ' O ' ' HA ' ' A' ' 56' ' ' GLN . 46.2 m-85 -120.35 165.44 14.88 Favored 'General case' 0 C--N 1.307 -1.258 0 C-N-CA 119.69 -0.804 . . . . 0.0 112.466 -170.415 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.789 ' HA2' HG23 ' A' ' 45' ' ' ILE . . . -57.93 157.81 16.14 Favored Glycine 0 CA--C 1.502 -0.752 0 CA-C-N 114.854 -1.067 . . . . 0.0 114.41 -169.901 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . 0.653 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 99.52 -109.23 3.7 Favored Glycine 0 N--CA 1.436 -1.314 0 N-CA-C 111.246 -0.741 . . . . 0.0 111.246 -178.693 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.448 HG13 ' CE3' ' A' ' 31' ' ' TRP . 3.2 t -84.31 -2.11 6.88 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.67 0 CA-C-O 121.791 0.805 . . . . 0.0 110.025 -177.151 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 56' ' ' GLN . . . . . 0.797 ' HA ' HE21 ' A' ' 56' ' ' GLN . 0.0 OUTLIER 57.97 50.51 10.17 Favored 'General case' 0 N--CA 1.461 0.088 0 CA-C-N 114.141 -1.391 . . . . 0.0 112.833 166.598 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 10.3 p90 -117.34 162.38 18.01 Favored 'General case' 0 C--N 1.324 -0.511 0 C-N-CA 120.443 -0.503 . . . . 0.0 111.071 175.166 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.521 ' HA ' ' HA ' ' A' ' 51' ' ' TYR . 5.0 p-10 -77.01 163.19 26.92 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 113.667 0.988 . . . . 0.0 113.667 -163.733 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.769 ' HA ' HE21 ' A' ' 59' ' ' GLN . 0.0 OUTLIER -60.57 -40.45 91.71 Favored 'General case' 0 N--CA 1.446 -0.653 0 CA-C-N 113.714 -1.585 . . . . 0.0 111.883 -179.934 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -65.41 -45.2 91.45 Favored Glycine 0 C--N 1.321 -0.286 0 C-N-CA 121.077 -0.582 . . . . 0.0 111.953 -176.952 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 61' ' ' THR . . . . . 0.503 ' CG2' HG23 ' A' ' 89' ' ' THR . 95.0 m -66.61 -43.98 83.31 Favored 'General case' 0 C--N 1.32 -0.701 0 C-N-CA 122.558 0.343 . . . . 0.0 111.077 176.524 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 62' ' ' TRP . . . . . . . . . . . . . 50.3 t-105 -57.63 -47.3 82.6 Favored 'General case' 0 N--CA 1.45 -0.426 0 CA-C-O 121.62 0.724 . . . . 0.0 109.876 176.539 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . 0.449 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 29.2 tt0 -67.31 -33.35 75.09 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 115.09 -0.959 . . . . 0.0 110.614 -178.336 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -66.54 -42.87 86.51 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.76 -0.655 . . . . 0.0 110.745 -176.806 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . 0.495 ' HB2' HG13 ' A' ' 85' ' ' VAL . 7.2 m120 -75.22 -13.97 60.49 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 121.041 0.448 . . . . 0.0 110.387 176.655 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 91.98 46.64 3.57 Favored Glycine 0 N--CA 1.448 -0.533 0 CA-C-N 115.675 -0.693 . . . . 0.0 111.855 176.114 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . 0.521 ' O ' ' HB2' ' A' ' 70' ' ' TYR . . . -79.52 -21.81 65.97 Favored Glycine 0 N--CA 1.439 -1.142 0 C-N-CA 120.882 -0.675 . . . . 0.0 112.835 -172.648 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 0.872 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 7.4 mp -58.98 -29.93 67.57 Favored 'General case' 0 C--N 1.319 -0.73 0 N-CA-C 112.764 0.653 . . . . 0.0 112.764 -173.191 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 12.3 ptm180 -66.02 -29.36 69.72 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-O 121.491 0.662 . . . . 0.0 110.105 176.324 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 70' ' ' TYR . . . . . 0.815 ' HB3' ' HG2' ' A' ' 81' ' ' GLU . 86.8 m-85 -78.14 -36.2 48.02 Favored 'General case' 0 N--CA 1.445 -0.717 0 N-CA-C 107.366 -1.346 . . . . 0.0 107.366 175.493 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.65 ' HB2' ' HB1' ' A' ' 77' ' ' ALA . . . 158.26 130.67 0.0 OUTLIER Pre-proline 0 CA--C 1.508 -0.659 0 CA-C-N 112.096 -2.32 . . . . 0.0 106.262 -177.949 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 72' ' ' PRO . . . . . 0.872 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 18.4 Cg_exo -56.89 -4.45 0.92 Allowed 'Trans proline' 0 C--N 1.331 -0.343 0 C-N-CA 122.988 2.459 . . . . 0.0 114.103 -174.655 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 3.4 ptt180 -154.48 143.78 21.29 Favored 'General case' 0 C--N 1.318 -0.766 0 CA-C-O 121.308 0.575 . . . . 0.0 110.759 176.894 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . 0.535 ' HB2' ' HB2' ' A' ' 52' ' ' TYR . . . -57.95 -21.97 46.68 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.635 -175.514 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . 0.641 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 5.0 p-10 -87.57 -9.88 53.14 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 121.357 0.598 . . . . 0.0 110.672 -178.642 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.517 HD21 ' HD2' ' A' ' 72' ' ' PRO . 57.6 tp -99.86 -30.5 12.0 Favored 'General case' 0 C--N 1.319 -0.73 0 N-CA-C 108.846 -0.798 . . . . 0.0 108.846 175.301 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . 0.65 ' HB1' ' HB2' ' A' ' 71' ' ' ALA . . . -79.63 160.71 26.27 Favored 'General case' 0 N--CA 1.442 -0.846 0 CA-C-N 115.041 -0.982 . . . . 0.0 109.789 173.118 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 36.0 p -100.48 -178.92 3.95 Favored 'General case' 0 C--N 1.309 -1.188 0 CA-C-N 115.564 -0.744 . . . . 0.0 110.914 -178.023 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . 0.737 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 5.5 mtt180 -51.17 -53.75 31.8 Favored 'General case' 0 CA--C 1.511 -0.525 0 CA-C-O 120.871 0.367 . . . . 0.0 111.031 -179.516 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 1.9 pm0 -58.36 -39.65 80.1 Favored 'General case' 0 C--N 1.314 -0.938 0 CA-C-N 115.393 -0.821 . . . . 0.0 111.602 -177.888 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 81' ' ' GLU . . . . . 0.815 ' HG2' ' HB3' ' A' ' 70' ' ' TYR . 4.1 mt-10 -70.01 -51.54 31.48 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 121.13 0.49 . . . . 0.0 111.923 178.014 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 82' ' ' GLN . . . . . 0.451 ' CD ' ' HB1' ' A' ' 74' ' ' ALA . 5.3 tt0 -65.69 -33.9 76.94 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-N 115.377 -0.829 . . . . 0.0 110.591 -176.904 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . 0.431 HG21 ' CD1' ' A' ' 31' ' ' TRP . 24.4 mt -61.56 -45.06 99.44 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.678 0 CA-C-N 115.708 -0.678 . . . . 0.0 109.849 174.073 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . 0.643 ' O ' ' HG3' ' A' ' 87' ' ' GLU . . . -64.54 -41.1 96.56 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.945 0.403 . . . . 0.0 111.59 -176.804 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . 0.495 HG13 ' HB2' ' A' ' 65' ' ' ASN . 50.2 t -69.05 -48.99 66.58 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-O 120.968 0.413 . . . . 0.0 111.127 179.255 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -65.7 -31.79 72.99 Favored 'General case' 0 N--CA 1.449 -0.484 0 CA-C-N 115.914 -0.584 . . . . 0.0 110.76 -179.893 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 87' ' ' GLU . . . . . 0.643 ' HG3' ' O ' ' A' ' 84' ' ' ALA . 0.1 OUTLIER -70.1 -28.93 65.8 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.228 -177.373 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.552 ' O ' ' HG3' ' A' ' 92' ' ' ARG . 85.9 t -61.11 -48.64 88.11 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.177 0 N-CA-C 109.241 -0.651 . . . . 0.0 109.241 169.703 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 89' ' ' THR . . . . . 0.547 ' HB ' ' CH2' ' A' ' 98' ' ' TRP . 0.1 OUTLIER -64.9 -44.18 90.43 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 115.647 -0.706 . . . . 0.0 112.143 -176.257 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . 0.476 ' HB3' ' CZ2' ' A' ' 31' ' ' TRP . 0.0 OUTLIER -61.2 -32.23 71.99 Favored 'General case' 0 CA--C 1.511 -0.535 0 CA-C-O 121.727 0.775 . . . . 0.0 108.974 -177.068 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . 0.411 HD11 HH12 ' A' ' 90' ' ' ARG . 48.4 tp -69.48 -27.42 65.2 Favored 'General case' 0 C--N 1.313 -0.984 0 CA-C-N 113.966 -1.47 . . . . 0.0 111.276 -174.418 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . 0.552 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 4.1 mtm180 -90.59 -48.29 7.17 Favored 'General case' 0 C--N 1.317 -0.805 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.293 -175.832 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 93' ' ' GLN . . . . . 0.411 HE21 ' HZ3' ' A' ' 98' ' ' TRP . 15.3 pt20 -99.07 -27.78 13.68 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-N 114.965 -1.016 . . . . 0.0 113.006 -168.995 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 89.17 41.15 5.92 Favored Glycine 0 CA--C 1.501 -0.842 0 C-N-CA 119.971 -1.109 . . . . 0.0 110.796 178.926 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 95' ' ' TRP . . . . . 0.517 ' HA ' ' HE3' ' A' ' 98' ' ' TRP . 6.1 m95 67.16 19.8 10.33 Favored 'General case' 0 C--O 1.216 -0.674 0 CA-C-N 114.893 -0.654 . . . . 0.0 109.288 176.455 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.406 ' H ' ' HG3' ' A' ' 93' ' ' GLN . . . -64.1 -30.44 77.77 Favored Glycine 0 N--CA 1.452 -0.286 0 CA-C-N 115.465 -0.789 . . . . 0.0 112.886 178.462 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -75.14 -20.68 59.28 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 121.006 0.431 . . . . 0.0 110.142 176.584 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 98' ' ' TRP . . . . . 0.547 ' CH2' ' HB ' ' A' ' 89' ' ' THR . 22.3 m-90 -104.31 111.67 65.24 Favored Pre-proline 0 N--CA 1.446 -0.631 0 CA-C-N 115.72 -0.673 . . . . 0.0 110.335 -177.905 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . 0.41 ' HD3' ' HA ' ' A' ' 98' ' ' TRP . 52.5 Cg_exo -61.48 -140.2 0.0 OUTLIER 'Trans proline' 0 CA--C 1.534 0.487 0 C-N-CA 123.644 2.896 . . . . 0.0 114.444 -175.31 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . 0.482 ' O ' ' HD2' ' A' ' 104' ' ' ARG . 12.6 m -54.7 -29.52 21.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.654 -0.703 . . . . 0.0 111.26 -178.363 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 101' ' ' CYS . . . . . 0.616 ' SG ' ' HG3' ' A' ' 38' ' ' GLU . 59.3 m -56.34 -35.56 67.76 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-N 115.205 -0.907 . . . . 0.0 111.706 -179.591 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -69.62 -42.56 74.19 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 121.072 0.463 . . . . 0.0 110.51 179.117 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -66.76 -37.72 85.18 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.656 179.42 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 104' ' ' ARG . . . . . 0.482 ' HD2' ' O ' ' A' ' 100' ' ' VAL . 0.0 OUTLIER -72.6 -20.54 61.28 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.804 -0.635 . . . . 0.0 111.009 178.373 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 105' ' ' ALA . . . . . 0.552 ' HB3' ' HA ' ' A' ' 30' ' ' ILE . . . -91.38 -20.91 21.31 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 115.821 -0.627 . . . . 0.0 111.694 -177.392 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 103.82 54.46 0.81 Allowed Glycine 0 CA--C 1.518 0.244 0 C-N-CA 121.005 -0.617 . . . . 0.0 112.188 179.987 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -67.74 151.25 47.54 Favored 'General case' 0 N--CA 1.449 -0.522 0 C-N-CA 122.385 0.274 . . . . 0.0 111.691 -175.44 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 14.5 mtt180 . . . . . 0 C--O 1.252 1.2 0 O-C-N 124.211 0.944 . . . . 0.0 111.673 174.85 . . . . . . . . 0 0 . 1 . 030 nuclear orig full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 13.3 m120 . . . . . 0 N--CA 1.479 0.988 0 CA-C-O 121.266 0.555 . . . . 0.0 110.311 . . . . . . . . . 0 0 . 1 . 030 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 9.9 p -99.92 -16.19 7.21 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.815 0 CA-C-N 115.503 -0.771 . . . . 0.0 110.651 -176.275 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 59.2 t -61.06 116.18 1.87 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.376 0 CA-C-N 115.804 -0.635 . . . . 0.0 110.796 178.826 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 11.5 t -70.27 141.15 17.4 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.535 0 N-CA-C 109.354 -0.609 . . . . 0.0 109.354 177.292 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 38.7 p -83.01 124.57 76.48 Favored Pre-proline 0 C--N 1.313 -0.986 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.605 -176.707 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 40.1 Cg_endo -63.41 131.0 30.16 Favored 'Trans proline' 0 N--CA 1.452 -0.924 0 C-N-CA 123.219 2.613 . . . . 0.0 111.722 179.869 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . 0.47 ' C ' ' H ' ' A' ' 9' ' ' GLU . . . -141.14 -170.62 3.1 Favored 'General case' 0 C--N 1.295 -1.772 0 CA-C-N 113.754 -1.567 . . . . 0.0 110.407 -179.554 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 45.2 t-80 71.75 -10.45 0.84 Allowed 'General case' 0 C--O 1.231 0.106 0 O-C-N 124.053 0.845 . . . . 0.0 110.125 -172.925 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . 0.47 ' H ' ' C ' ' A' ' 7' ' ' ALA . 12.5 pt-20 -90.76 133.55 35.09 Favored 'General case' 0 N--CA 1.448 -0.554 0 CA-C-N 116.164 -0.471 . . . . 0.0 109.914 -179.703 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -151.06 68.46 0.94 Allowed 'General case' 0 C--N 1.317 -0.836 0 CA-C-O 121.534 0.683 . . . . 0.0 109.43 176.22 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 65.6 t -65.87 -60.03 3.21 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.846 0 CA-C-N 114.758 -1.11 . . . . 0.0 110.395 -178.395 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 7.1 p 26.24 76.12 0.01 OUTLIER 'Isoleucine or valine' 0 C--O 1.238 0.48 0 CA-C-O 123.067 1.413 . . . . 0.0 112.95 179.868 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 28.3 mtp180 -89.19 97.57 11.28 Favored 'General case' 0 C--N 1.304 -1.377 0 CA-C-N 113.691 -1.595 . . . . 0.0 111.282 -176.796 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 3.4 t -117.14 157.3 18.22 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.607 0 CA-C-N 114.861 -1.063 . . . . 0.0 108.311 177.13 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 179.28 81.17 0.06 OUTLIER Glycine 0 N--CA 1.424 -2.149 0 CA-C-N 115.405 -0.816 . . . . 0.0 112.583 -178.228 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 6.7 m -79.9 -44.08 21.05 Favored 'General case' 0 N--CA 1.437 -1.076 0 N-CA-C 109.612 -0.514 . . . . 0.0 109.612 176.181 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER 34.73 64.9 1.71 Allowed Pre-proline 0 N--CA 1.471 0.583 0 CA-C-N 114.2 -1.364 . . . . 0.0 112.104 179.661 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 5.8 Cg_exo -78.88 161.48 27.07 Favored 'Trans proline' 0 N--CA 1.451 -1.002 0 C-N-CA 122.91 2.407 . . . . 0.0 113.193 -173.022 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -125.44 37.38 2.54 Favored Glycine 0 C--N 1.304 -1.196 0 CA-C-N 113.597 -1.638 . . . . 0.0 110.472 176.183 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 3.7 m -58.64 -43.57 89.81 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 114.206 -0.997 . . . . 0.0 110.67 -178.888 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 50.5 mt-10 -138.28 124.1 19.93 Favored 'General case' 0 N--CA 1.448 -0.553 0 N-CA-C 108.947 -0.76 . . . . 0.0 108.947 175.718 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 79.2 t -72.57 130.57 85.53 Favored Pre-proline 0 C--N 1.32 -0.699 0 N-CA-C 109.045 -0.724 . . . . 0.0 109.045 176.385 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . 0.404 ' HA ' ' HD2' ' A' ' 24' ' ' PRO . 59.6 Cg_exo -52.39 127.99 26.01 Favored 'Trans proline' 0 C--N 1.347 0.488 0 C-N-CA 122.506 2.138 . . . . 0.0 111.446 -177.905 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . 0.404 ' HD2' ' HA ' ' A' ' 23' ' ' PRO . 11.2 Cg_endo -55.42 141.29 82.41 Favored 'Trans proline' 0 N--CA 1.452 -0.912 0 C-N-CA 123.755 2.97 . . . . 0.0 113.593 -172.553 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.42 ' HB ' HG22 ' A' ' 83' ' ' ILE . 60.2 t -80.0 138.95 18.97 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.206 0 CA-C-N 113.765 -1.561 . . . . 0.0 107.618 174.687 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 43.8 mm -63.29 -25.57 38.76 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-N 115.749 -0.659 . . . . 0.0 111.771 -169.816 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.52 ' O ' HG12 ' A' ' 30' ' ' ILE . 71.8 m-20 -94.21 -1.01 54.78 Favored 'General case' 0 CA--C 1.505 -0.767 0 CA-C-O 122.075 0.941 . . . . 0.0 108.869 -179.674 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . 0.58 ' HA2' ' HB2' ' A' ' 31' ' ' TRP . . . -71.58 -3.0 52.89 Favored Glycine 0 N--CA 1.439 -1.123 0 CA-C-N 113.899 -1.5 . . . . 0.0 110.219 174.958 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 5.6 m -76.34 -37.57 57.15 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 108.655 -0.868 . . . . 0.0 108.655 174.086 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.52 HG12 ' O ' ' A' ' 27' ' ' ASP . 0.9 OUTLIER -70.15 -37.99 73.47 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 N-CA-C 106.943 -1.503 . . . . 0.0 106.943 175.683 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' A' A ' 31' ' ' TRP . . . . . 0.58 ' HB2' ' HA2' ' A' ' 28' ' ' GLY . 22.8 m95 -70.27 -36.41 74.41 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 114.122 -1.399 . . . . 0.0 110.754 -177.079 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.709 ' HB2' HH21 ' A' ' 79' ' ' ARG . 26.5 t70 -76.8 -36.17 57.13 Favored 'General case' 0 N--CA 1.444 -0.73 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.385 179.643 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . 0.435 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -70.77 -36.66 73.17 Favored 'General case' 0 N--CA 1.448 -0.526 0 CA-C-O 120.768 0.318 . . . . 0.0 110.809 176.944 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . 0.496 HG13 ' O ' ' A' ' 30' ' ' ILE . 59.3 mt -63.97 -43.91 97.78 Favored 'Isoleucine or valine' 0 C--O 1.234 0.267 0 CA-C-O 121.041 0.448 . . . . 0.0 110.006 173.789 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . 0.457 ' HA ' ' O ' ' A' ' 54' ' ' GLY . . . -57.1 -39.39 74.96 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.551 -0.75 . . . . 0.0 110.151 176.584 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -73.0 -17.68 78.73 Favored Glycine 0 N--CA 1.452 -0.283 0 CA-C-N 115.299 -0.864 . . . . 0.0 111.813 -179.528 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 11.1 t -88.24 -60.9 1.84 Allowed 'General case' 0 C--N 1.322 -0.63 0 CA-C-O 120.778 0.323 . . . . 0.0 111.404 -178.783 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 38' ' ' GLU . . . . . 0.777 ' HG3' ' HG2' ' A' ' 56' ' ' GLN . 8.8 tp10 -88.06 -33.49 18.3 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-O 121.009 0.433 . . . . 0.0 110.509 -169.513 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -96.85 -7.46 33.45 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.086 -0.506 . . . . 0.0 111.605 -176.468 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 76.2 17.2 80.16 Favored Glycine 0 N--CA 1.448 -0.523 0 N-CA-C 109.987 -1.245 . . . . 0.0 109.987 -177.322 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 72.81 55.29 6.6 Favored Glycine 0 N--CA 1.436 -1.306 0 CA-C-N 114.084 -1.058 . . . . 0.0 112.034 -177.334 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 42' ' ' ASN . . . . . 0.726 ' HB3' ' HB ' ' A' ' 45' ' ' ILE . 2.2 t30 -148.17 105.83 3.68 Favored 'General case' 0 CA--C 1.511 -0.521 0 N-CA-C 108.396 -0.964 . . . . 0.0 108.396 -176.444 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 43' ' ' TRP . . . . . 0.869 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 30.4 m95 -83.26 -6.87 59.62 Favored 'General case' 0 C--N 1.309 -1.161 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.551 -173.125 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -111.08 15.03 21.84 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.594 -0.73 . . . . 0.0 111.698 177.792 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.726 ' HB ' ' HB3' ' A' ' 42' ' ' ASN . 11.0 tt -86.73 144.78 8.66 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.624 0 CA-C-O 120.835 0.35 . . . . 0.0 110.868 -176.545 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 45.6 t30 -153.62 111.29 3.52 Favored 'General case' 0 C--N 1.316 -0.89 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 174.178 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 6.9 p -82.4 -15.81 51.33 Favored 'General case' 0 C--N 1.315 -0.896 0 CA-C-N 115.809 -0.632 . . . . 0.0 111.342 -179.679 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 95.92 20.53 25.89 Favored Glycine 0 N--CA 1.446 -0.673 0 N-CA-C 111.174 -0.77 . . . . 0.0 111.174 -177.555 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 8.8 p30 -85.73 -5.29 59.28 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 121.136 0.493 . . . . 0.0 111.221 -176.16 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . 0.47 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 96.87 -12.99 65.61 Favored Glycine 0 N--CA 1.448 -0.5 0 CA-C-N 115.945 -0.57 . . . . 0.0 111.832 178.411 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 51' ' ' TYR . . . . . 0.535 ' HA ' ' HA ' ' A' ' 58' ' ' ASP . 0.9 OUTLIER -108.82 137.19 47.14 Favored 'General case' 0 CA--C 1.511 -0.529 0 N-CA-C 107.376 -1.342 . . . . 0.0 107.376 172.609 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' A' A ' 52' ' ' TYR . . . . . 0.674 ' CE1' ' HB2' ' A' ' 59' ' ' GLN . 26.6 m-85 -99.83 156.54 17.06 Favored 'General case' 0 C--N 1.307 -1.243 0 C-N-CA 120.607 -0.437 . . . . 0.0 111.255 -167.892 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -61.16 -176.07 1.74 Allowed Glycine 0 C--N 1.329 0.19 0 N-CA-C 115.387 0.915 . . . . 0.0 115.387 -167.632 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . 0.72 ' CA ' ' HA ' ' A' ' 43' ' ' TRP . . . 86.84 -105.12 3.0 Favored Glycine 0 N--CA 1.446 -0.646 0 N-CA-C 111.318 -0.713 . . . . 0.0 111.318 -174.768 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.509 ' HB ' ' CD1' ' A' ' 57' ' ' PHE . 3.1 t -83.58 -4.47 8.44 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.751 0 N-CA-C 108.53 -0.915 . . . . 0.0 108.53 176.857 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 56' ' ' GLN . . . . . 0.777 ' HG2' ' HG3' ' A' ' 38' ' ' GLU . 14.8 tp60 58.38 43.56 19.64 Favored 'General case' 0 C--O 1.231 0.115 0 CA-C-N 114.021 -1.445 . . . . 0.0 112.377 169.651 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 57' ' ' PHE . . . . . 0.509 ' CD1' ' HB ' ' A' ' 55' ' ' VAL . 3.7 p90 -111.44 168.92 9.16 Favored 'General case' 0 C--N 1.323 -0.546 0 C-N-CA 120.181 -0.608 . . . . 0.0 110.888 174.829 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.535 ' HA ' ' HA ' ' A' ' 51' ' ' TYR . 7.7 p-10 -78.07 153.77 31.96 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 122.014 0.912 . . . . 0.0 112.38 -165.514 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.674 ' HB2' ' CE1' ' A' ' 52' ' ' TYR . 4.9 tp-100 -63.77 -30.69 71.75 Favored 'General case' 0 N--CA 1.444 -0.737 0 CA-C-N 113.827 -1.533 . . . . 0.0 111.098 -179.804 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -62.96 -50.29 64.88 Favored Glycine 0 C--N 1.314 -0.689 0 C-N-CA 120.743 -0.741 . . . . 0.0 111.676 178.195 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 99.4 m -65.85 -41.86 91.17 Favored 'General case' 0 C--N 1.321 -0.674 0 C-N-CA 122.707 0.403 . . . . 0.0 111.065 175.697 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 62' ' ' TRP . . . . . 0.529 ' CH2' ' HA ' ' A' ' 74' ' ' ALA . 50.0 t-105 -56.33 -48.74 76.14 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-O 121.617 0.722 . . . . 0.0 109.546 177.487 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . 0.54 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 55.7 tt0 -67.76 -34.78 77.49 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 114.901 -1.045 . . . . 0.0 110.712 -179.76 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -62.66 -41.09 98.88 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.773 -179.398 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . 0.644 ' OD1' ' HB ' ' A' ' 89' ' ' THR . 7.9 m120 -79.96 -11.16 59.81 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.536 177.9 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . 0.551 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 84.03 49.0 4.93 Favored Glycine 0 N--CA 1.448 -0.528 0 CA-C-N 115.47 -0.786 . . . . 0.0 112.105 178.485 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . 0.594 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -80.17 -18.93 70.7 Favored Glycine 0 N--CA 1.439 -1.124 0 C-N-CA 121.104 -0.57 . . . . 0.0 112.725 -176.214 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 0.667 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 6.4 mp -62.31 -23.1 66.55 Favored 'General case' 0 N--CA 1.45 -0.425 0 N-CA-C 112.035 0.383 . . . . 0.0 112.035 -172.578 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . 0.551 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 13.9 ptp180 -68.69 -32.19 71.83 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-O 121.259 0.552 . . . . 0.0 110.118 176.84 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 70' ' ' TYR . . . . . 0.67 ' HB3' ' HB3' ' A' ' 81' ' ' GLU . 67.7 m-85 -82.18 -33.99 29.22 Favored 'General case' 0 N--CA 1.442 -0.834 0 N-CA-C 107.436 -1.32 . . . . 0.0 107.436 178.443 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 71' ' ' ALA . . . . . 0.544 ' HB2' ' HB1' ' A' ' 77' ' ' ALA . . . 169.14 122.86 0.04 OUTLIER Pre-proline 0 N--CA 1.447 -0.61 0 CA-C-N 112.654 -2.066 . . . . 0.0 107.445 -178.423 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 72' ' ' PRO . . . . . 0.667 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 20.9 Cg_exo -55.28 -7.02 0.98 Allowed 'Trans proline' 0 CA--C 1.527 0.138 0 C-N-CA 122.807 2.338 . . . . 0.0 113.76 -178.81 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 73' ' ' ARG . . . . . 0.411 ' HE ' ' CG ' ' A' ' 75' ' ' ASP . 12.1 ptm180 -145.39 137.98 25.96 Favored 'General case' 0 C--N 1.318 -0.772 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 177.491 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . 0.529 ' HA ' ' CH2' ' A' ' 62' ' ' TRP . . . -55.76 -35.43 66.19 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 114.802 -1.09 . . . . 0.0 112.248 -176.005 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . 0.651 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 14.9 p-10 -80.95 -7.35 59.49 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 121.092 0.472 . . . . 0.0 111.531 -173.782 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.505 ' HB3' ' HB1' ' A' ' 71' ' ' ALA . 60.2 tp -87.7 -33.06 18.87 Favored 'General case' 0 C--N 1.318 -0.773 0 N-CA-C 108.688 -0.856 . . . . 0.0 108.688 171.776 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . 0.931 ' HB2' ' HB2' ' A' ' 81' ' ' GLU . . . -79.29 153.37 29.92 Favored 'General case' 0 N--CA 1.446 -0.659 0 CA-C-N 115.01 -0.995 . . . . 0.0 111.012 176.444 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 22.8 p -101.16 -170.3 1.82 Allowed 'General case' 0 C--N 1.315 -0.929 0 CA-C-N 115.77 -0.65 . . . . 0.0 109.517 179.131 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . 0.869 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 53.1 mtp180 -50.67 -48.66 58.35 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.903 0.382 . . . . 0.0 111.341 -176.808 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 7.3 pt-20 -57.88 -49.29 77.21 Favored 'General case' 0 C--N 1.319 -0.75 0 CA-C-N 115.391 -0.822 . . . . 0.0 112.432 -175.517 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 81' ' ' GLU . . . . . 0.931 ' HB2' ' HB2' ' A' ' 77' ' ' ALA . 26.1 mp0 -66.29 -50.46 63.58 Favored 'General case' 0 CA--C 1.52 -0.208 0 O-C-N 122.06 -0.4 . . . . 0.0 111.559 178.0 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 82' ' ' GLN . . . . . 0.666 ' HB2' ' HZ3' ' A' ' 43' ' ' TRP . 52.0 mt-30 -62.44 -33.67 75.27 Favored 'General case' 0 CA--C 1.513 -0.448 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.003 -174.576 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . 0.641 ' O ' ' HG2' ' A' ' 87' ' ' GLU . 27.2 mt -60.53 -49.11 85.67 Favored 'Isoleucine or valine' 0 C--O 1.216 -0.663 0 N-CA-C 109.188 -0.671 . . . . 0.0 109.188 174.986 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . 0.59 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -57.12 -47.68 80.51 Favored 'General case' 0 C--O 1.239 0.53 0 CA-C-O 121.522 0.677 . . . . 0.0 111.821 -178.281 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . 0.42 HG11 ' HB2' ' A' ' 65' ' ' ASN . 45.7 t -65.97 -48.82 80.48 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.587 0 CA-C-N 115.827 -0.624 . . . . 0.0 111.284 -179.458 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -59.21 -30.31 68.14 Favored 'General case' 0 N--CA 1.45 -0.468 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.439 175.572 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 87' ' ' GLU . . . . . 0.641 ' HG2' ' O ' ' A' ' 83' ' ' ILE . 21.1 mm-40 -59.58 -43.97 93.48 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.957 -179.111 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.631 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 94.2 t -64.9 -50.98 72.52 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 C-N-CA 120.56 -0.456 . . . . 0.0 110.915 179.289 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 89' ' ' THR . . . . . 0.644 ' HB ' ' OD1' ' A' ' 65' ' ' ASN . 14.7 t -72.8 -34.89 67.2 Favored 'General case' 0 C--N 1.317 -0.843 0 C-N-CA 120.495 -0.482 . . . . 0.0 111.499 -173.599 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . 0.621 ' HG3' ' N ' ' A' ' 91' ' ' LEU . 4.3 ptt180 -60.45 -39.31 87.08 Favored 'General case' 0 N--CA 1.466 0.338 0 O-C-N 122.291 -0.256 . . . . 0.0 110.978 -178.267 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . 0.631 ' HG ' ' O ' ' A' ' 88' ' ' VAL . 4.5 pp -72.72 -23.91 60.91 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 115.956 -0.566 . . . . 0.0 111.479 -173.28 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . 0.549 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 10.8 mtm180 -79.28 -48.17 14.61 Favored 'General case' 0 CA--C 1.509 -0.61 0 CA-C-O 121.803 0.811 . . . . 0.0 109.456 -176.882 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 93' ' ' GLN . . . . . 0.51 ' OE1' ' HB3' ' A' ' 97' ' ' ALA . 14.8 pt20 -97.37 -28.38 14.05 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 114.413 -1.267 . . . . 0.0 113.149 -169.773 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 96.89 39.92 3.96 Favored Glycine 0 CA--C 1.503 -0.682 0 C-N-CA 120.215 -0.993 . . . . 0.0 111.119 172.892 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 95' ' ' TRP . . . . . 0.52 ' HA ' ' HE3' ' A' ' 98' ' ' TRP . 12.3 m95 68.11 9.3 7.1 Favored 'General case' 0 C--O 1.218 -0.592 0 N-CA-C 108.953 -0.758 . . . . 0.0 108.953 -178.151 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -62.39 -32.13 81.86 Favored Glycine 0 C--N 1.334 0.451 0 CA-C-N 115.592 -0.731 . . . . 0.0 113.14 -177.814 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . 0.51 ' HB3' ' OE1' ' A' ' 93' ' ' GLN . . . -64.45 -24.26 67.56 Favored 'General case' 0 CA--C 1.514 -0.406 0 CA-C-O 120.902 0.382 . . . . 0.0 110.073 176.312 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 98' ' ' TRP . . . . . 0.554 ' HB2' ' HB3' ' A' ' 102' ' ' ALA . 19.6 m-90 -108.63 105.07 56.25 Favored Pre-proline 0 C--N 1.324 -0.522 0 CA-C-N 115.829 -0.623 . . . . 0.0 109.976 178.893 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 19.1 Cg_exo -72.14 -94.08 0.01 OUTLIER 'Trans proline' 0 CA--C 1.536 0.604 0 C-N-CA 122.888 2.392 . . . . 0.0 113.851 -175.59 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 46.5 t -71.44 -26.78 27.1 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.176 0 CA-C-O 121.637 0.732 . . . . 0.0 110.324 -174.799 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 101' ' ' CYS . . . . . 0.44 ' SG ' ' HB2' ' A' ' 38' ' ' GLU . 80.2 m -73.02 -37.48 66.91 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 115.217 -0.901 . . . . 0.0 111.742 -172.987 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 102' ' ' ALA . . . . . 0.554 ' HB3' ' HB2' ' A' ' 98' ' ' TRP . . . -69.7 -44.14 71.01 Favored 'General case' 0 C--N 1.327 -0.382 0 C-N-CA 120.811 -0.356 . . . . 0.0 110.267 179.258 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -61.27 -37.41 83.03 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 121.193 0.521 . . . . 0.0 110.92 179.715 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -72.11 -23.84 61.38 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.731 -0.668 . . . . 0.0 111.818 177.526 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 105' ' ' ALA . . . . . 0.486 ' HB1' ' HA ' ' A' ' 30' ' ' ILE . . . -95.63 -22.78 17.37 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 116.1 -0.5 . . . . 0.0 112.154 -174.619 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 121.55 58.47 0.22 Allowed Glycine 0 CA--C 1.521 0.437 0 C-N-CA 121.05 -0.595 . . . . 0.0 112.189 -176.765 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -72.21 150.4 43.73 Favored 'General case' 0 C--N 1.327 -0.386 0 C-N-CA 122.871 0.469 . . . . 0.0 111.079 -176.494 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 108' ' ' ARG . . . . . 0.454 ' HB2' ' HE1' ' A' ' 95' ' ' TRP . 93.1 mtt180 . . . . . 0 C--O 1.25 1.09 0 CA-C-O 118.303 -0.855 . . . . 0.0 110.636 -174.644 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 27' ' ' ASP . . . . . 0.493 ' O ' HG13 ' A' ' 30' ' ' ILE . 14.0 m-20 . . . . . 0 N--CA 1.445 -0.687 0 CA-C-O 121.73 0.776 . . . . 0.0 109.009 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -64.27 -10.51 41.96 Favored Glycine 0 N--CA 1.441 -1.008 0 CA-C-N 114.572 -1.194 . . . . 0.0 110.55 174.198 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 47.0 m -76.32 -37.44 57.38 Favored 'General case' 0 N--CA 1.45 -0.464 0 CA-C-O 121.268 0.556 . . . . 0.0 109.867 175.363 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.601 ' HA ' ' HB1' ' A' ' 105' ' ' ALA . 0.2 OUTLIER -69.23 -36.27 71.93 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 N-CA-C 107.718 -1.216 . . . . 0.0 107.718 175.468 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 31' ' ' TRP . . . . . 0.572 ' CH2' ' HB1' ' A' ' 86' ' ' ALA . 42.1 m95 -70.55 -36.31 73.6 Favored 'General case' 0 C--N 1.318 -0.786 0 CA-C-N 114.401 -1.272 . . . . 0.0 110.487 -179.226 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.883 ' HB2' HH21 ' A' ' 79' ' ' ARG . 23.6 t70 -76.43 -37.66 56.67 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.583 179.271 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 33' ' ' ALA . . . . . 0.476 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -69.58 -33.98 73.5 Favored 'General case' 0 N--CA 1.447 -0.599 0 C-N-CA 120.852 -0.339 . . . . 0.0 110.62 178.331 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 34' ' ' ILE . . . . . 0.537 HG13 ' O ' ' A' ' 30' ' ' ILE . 78.0 mt -64.29 -47.48 89.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-O 121.009 0.433 . . . . 0.0 110.001 172.443 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 35' ' ' ALA . . . . . 0.417 ' HA ' ' O ' ' A' ' 54' ' ' GLY . . . -57.87 -39.79 78.64 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.681 -0.69 . . . . 0.0 110.169 177.446 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 36' ' ' GLY . . . . . 0.518 ' HA2' ' N ' ' A' ' 41' ' ' GLY . . . -70.26 -18.14 74.76 Favored Glycine 0 N--CA 1.453 -0.202 0 CA-C-N 115.501 -0.772 . . . . 0.0 112.135 179.496 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 26.4 t -90.94 -53.04 4.56 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-O 120.931 0.396 . . . . 0.0 111.419 -178.402 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 6.9 tp10 -87.23 -33.2 19.39 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.289 -170.747 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -105.5 -10.63 16.79 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.809 -0.632 . . . . 0.0 111.606 -177.528 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 78.95 14.68 81.72 Favored Glycine 0 CA--C 1.504 -0.598 0 N-CA-C 109.75 -1.34 . . . . 0.0 109.75 -175.206 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 41' ' ' GLY . . . . . 0.518 ' N ' ' HA2' ' A' ' 36' ' ' GLY . . . 78.49 63.25 2.15 Favored Glycine 0 N--CA 1.434 -1.481 0 CA-C-N 114.019 -1.091 . . . . 0.0 111.514 -175.571 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 2.4 t-20 -145.91 96.81 2.86 Favored 'General case' 0 N--CA 1.447 -0.576 0 N-CA-C 109.442 -0.577 . . . . 0.0 109.442 -177.451 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 43' ' ' TRP . . . . . 0.721 ' CE3' ' HA ' ' A' ' 79' ' ' ARG . 29.9 m95 -83.65 -4.1 58.31 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-N 115.561 -0.745 . . . . 0.0 110.385 -175.145 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -109.26 14.65 23.67 Favored 'General case' 0 C--N 1.315 -0.925 0 CA-C-N 114.805 -1.089 . . . . 0.0 110.282 178.017 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.97 HG22 ' HA2' ' A' ' 53' ' ' GLY . 8.9 tt -78.02 139.08 19.14 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.038 0 CA-C-O 121.509 0.671 . . . . 0.0 110.197 -179.148 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 4.4 t30 -139.86 76.58 1.57 Allowed 'General case' 0 C--N 1.308 -1.2 0 N-CA-C 108.593 -0.892 . . . . 0.0 108.593 177.865 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 5.1 p -57.6 -29.2 64.3 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 114.366 -1.288 . . . . 0.0 110.997 -178.982 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 96.06 22.81 19.11 Favored Glycine 0 N--CA 1.437 -1.252 0 N-CA-C 110.922 -0.871 . . . . 0.0 110.922 178.552 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 39.0 p-10 -102.8 4.25 37.65 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 120.881 0.372 . . . . 0.0 111.015 -177.085 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 50' ' ' GLY . . . . . 0.418 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 94.82 -8.09 70.63 Favored Glycine 0 N--CA 1.448 -0.55 0 N-CA-C 111.535 -0.626 . . . . 0.0 111.535 178.639 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 51' ' ' TYR . . . . . 0.577 ' HA ' ' HA ' ' A' ' 58' ' ' ASP . 0.5 OUTLIER -112.64 132.94 54.93 Favored 'General case' 0 N--CA 1.446 -0.65 0 N-CA-C 106.71 -1.589 . . . . 0.0 106.71 -179.094 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 52' ' ' TYR . . . . . 0.696 ' HB2' ' HB3' ' A' ' 74' ' ' ALA . 50.6 m-85 -104.64 171.36 7.37 Favored 'General case' 0 C--N 1.304 -1.375 0 N-CA-C 113.225 0.824 . . . . 0.0 113.225 -165.747 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.97 ' HA2' HG22 ' A' ' 45' ' ' ILE . . . -48.46 155.33 1.47 Allowed Glycine 0 N--CA 1.45 -0.373 0 CA-C-N 114.783 -1.099 . . . . 0.0 115.833 -170.204 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 54' ' ' GLY . . . . . 0.709 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 94.13 -106.41 3.41 Favored Glycine 0 N--CA 1.438 -1.172 0 CA-C-N 114.706 -0.747 . . . . 0.0 112.179 174.756 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -84.29 -1.52 6.44 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 CA-C-O 121.246 0.546 . . . . 0.0 111.534 -178.812 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 56' ' ' GLN . . . . . 0.556 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 5.4 mm-40 59.21 50.39 8.01 Favored 'General case' 0 N--CA 1.467 0.409 0 CA-C-N 114.502 -1.227 . . . . 0.0 113.965 167.059 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -116.23 160.07 20.94 Favored 'General case' 0 C--N 1.326 -0.431 0 C-N-CA 119.804 -0.758 . . . . 0.0 111.569 173.693 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.577 ' HA ' ' HA ' ' A' ' 51' ' ' TYR . 7.3 p-10 -71.11 160.78 32.27 Favored 'General case' 0 C--N 1.324 -0.506 0 N-CA-C 113.797 1.036 . . . . 0.0 113.797 -163.451 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 59' ' ' GLN . . . . . 0.491 ' HB2' ' CE2' ' A' ' 52' ' ' TYR . 6.1 tp60 -55.36 -39.96 70.71 Favored 'General case' 0 N--CA 1.446 -0.65 0 CA-C-N 113.987 -1.46 . . . . 0.0 111.438 178.056 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -67.65 -48.66 54.98 Favored Glycine 0 C--O 1.225 -0.467 0 CA-C-N 115.417 -0.81 . . . . 0.0 112.042 -175.816 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 89.0 m -66.4 -40.63 89.74 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-O 121.067 0.46 . . . . 0.0 110.641 177.226 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 62' ' ' TRP . . . . . 0.488 ' HZ3' ' HG3' ' A' ' 82' ' ' GLN . 56.9 t-105 -56.48 -48.98 75.98 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-O 121.622 0.725 . . . . 0.0 109.5 175.407 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 63' ' ' GLU . . . . . 0.785 ' HG3' HD11 ' A' ' 68' ' ' LEU . 27.9 tt0 -66.85 -34.33 77.56 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 115.015 -0.993 . . . . 0.0 110.985 179.845 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -63.96 -41.86 97.44 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.968 -0.56 . . . . 0.0 111.454 -177.441 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 36.5 m-80 -81.52 -7.86 59.64 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.079 -0.51 . . . . 0.0 109.983 175.618 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 66' ' ' GLY . . . . . 0.456 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 83.29 48.34 5.39 Favored Glycine 0 N--CA 1.45 -0.413 0 CA-C-N 115.507 -0.769 . . . . 0.0 112.647 174.975 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 67' ' ' GLY . . . . . 0.645 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -79.68 -15.98 78.43 Favored Glycine 0 CA--C 1.504 -0.649 0 C-N-CA 120.87 -0.681 . . . . 0.0 111.904 -176.352 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.785 HD11 ' HG3' ' A' ' 63' ' ' GLU . 19.2 mt -61.72 -28.83 69.7 Favored 'General case' 0 C--N 1.314 -0.97 0 C-N-CA 123.346 0.659 . . . . 0.0 111.956 -172.953 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 69' ' ' ARG . . . . . 0.456 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 5.6 ptp180 -68.05 -28.45 67.39 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-O 121.557 0.694 . . . . 0.0 109.789 178.861 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 70' ' ' TYR . . . . . 0.758 ' HB3' ' HG2' ' A' ' 81' ' ' GLU . 89.0 m-85 -81.47 -34.66 31.26 Favored 'General case' 0 N--CA 1.439 -0.983 0 N-CA-C 107.872 -1.158 . . . . 0.0 107.872 176.848 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.586 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 165.33 125.22 0.02 OUTLIER Pre-proline 0 N--CA 1.445 -0.687 0 CA-C-N 112.336 -2.211 . . . . 0.0 107.115 -179.296 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 72' ' ' PRO . . . . . 0.566 ' HA ' ' HA ' ' A' ' 68' ' ' LEU . 26.8 Cg_exo -53.71 -5.97 0.36 Allowed 'Trans proline' 0 C--N 1.334 -0.232 0 C-N-CA 123.14 2.56 . . . . 0.0 114.169 -178.745 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 11.2 ptm180 -148.28 141.0 24.57 Favored 'General case' 0 C--N 1.314 -0.966 0 N-CA-C 109.231 -0.655 . . . . 0.0 109.231 175.387 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 74' ' ' ALA . . . . . 0.696 ' HB3' ' HB2' ' A' ' 52' ' ' TYR . . . -60.72 -27.01 67.59 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.674 -0.694 . . . . 0.0 112.65 -176.39 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 75' ' ' ASP . . . . . 0.601 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 3.5 p30 -80.08 -5.95 56.81 Favored 'General case' 0 C--N 1.322 -0.618 0 C-N-CA 120.007 -0.677 . . . . 0.0 110.921 -177.785 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.542 ' HB3' ' HB1' ' A' ' 71' ' ' ALA . 59.2 tp -97.89 -32.72 11.54 Favored 'General case' 0 C--N 1.321 -0.66 0 N-CA-C 109.113 -0.699 . . . . 0.0 109.113 174.815 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 77' ' ' ALA . . . . . 0.697 ' HB1' ' CB ' ' A' ' 81' ' ' GLU . . . -79.68 164.29 23.87 Favored 'General case' 0 N--CA 1.447 -0.586 0 CA-C-N 115.243 -0.889 . . . . 0.0 109.911 174.485 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 42.8 p -101.13 -173.89 2.48 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 116.573 -0.285 . . . . 0.0 110.801 -177.879 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 79' ' ' ARG . . . . . 0.883 HH21 ' HB2' ' A' ' 32' ' ' ASP . 41.2 mtp180 -50.42 -52.58 36.38 Favored 'General case' 0 CA--C 1.515 -0.402 0 CA-C-O 121.218 0.532 . . . . 0.0 111.295 -178.137 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 80' ' ' GLU . . . . . 0.687 ' HA ' HD12 ' A' ' 83' ' ' ILE . 6.9 pt-20 -66.0 -27.77 68.38 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-N 115.139 -0.937 . . . . 0.0 112.061 -173.873 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 81' ' ' GLU . . . . . 0.758 ' HG2' ' HB3' ' A' ' 70' ' ' TYR . 3.2 mp0 -72.83 -46.26 54.03 Favored 'General case' 0 C--N 1.324 -0.507 0 C-N-CA 120.762 -0.375 . . . . 0.0 111.758 174.239 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 82' ' ' GLN . . . . . 0.632 ' HB2' ' HZ3' ' A' ' 43' ' ' TRP . 0.1 OUTLIER -58.96 -34.72 72.12 Favored 'General case' 0 CA--C 1.506 -0.735 0 N-CA-C 109.108 -0.701 . . . . 0.0 109.108 175.125 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.687 HD12 ' HA ' ' A' ' 80' ' ' GLU . 60.3 mt -60.62 -48.75 87.28 Favored 'Isoleucine or valine' 0 C--O 1.211 -0.957 0 CA-C-N 114.731 -1.122 . . . . 0.0 110.022 173.636 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 84' ' ' ALA . . . . . 0.632 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -63.67 -45.26 90.91 Favored 'General case' 0 C--O 1.238 0.452 0 CA-C-O 121.439 0.637 . . . . 0.0 111.897 -174.98 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.502 HG22 ' HA2' ' A' ' 67' ' ' GLY . 34.8 t -66.52 -48.1 81.58 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.775 0 CA-C-N 115.756 -0.656 . . . . 0.0 110.651 -179.206 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 86' ' ' ALA . . . . . 0.572 ' HB1' ' CH2' ' A' ' 31' ' ' TRP . . . -61.46 -28.08 69.03 Favored 'General case' 0 N--CA 1.45 -0.45 0 CA-C-N 115.468 -0.787 . . . . 0.0 110.415 174.976 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 87' ' ' GLU . . . . . 0.679 ' HG2' ' O ' ' A' ' 83' ' ' ILE . 36.0 mm-40 -59.09 -43.37 91.84 Favored 'General case' 0 CA--C 1.513 -0.457 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.63 179.78 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.522 ' O ' ' HG3' ' A' ' 92' ' ' ARG . 48.8 t -65.27 -42.8 94.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 C-N-CA 120.385 -0.526 . . . . 0.0 109.893 175.851 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 89' ' ' THR . . . . . 0.745 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 0.2 OUTLIER -66.82 -46.88 73.75 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 115.956 -0.565 . . . . 0.0 111.465 -175.271 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 90' ' ' ARG . . . . . 0.483 ' HG3' ' N ' ' A' ' 91' ' ' LEU . 4.9 ptt180 -66.09 -31.18 71.9 Favored 'General case' 0 C--O 1.218 -0.577 0 CA-C-O 122.042 0.925 . . . . 0.0 109.083 -179.018 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 91' ' ' LEU . . . . . 0.483 ' N ' ' HG3' ' A' ' 90' ' ' ARG . 56.3 tp -61.84 -30.5 70.89 Favored 'General case' 0 C--N 1.308 -1.211 0 CA-C-N 114.494 -1.23 . . . . 0.0 111.509 -175.633 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 92' ' ' ARG . . . . . 0.522 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 7.6 mtm180 -90.68 -45.73 8.69 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-N 115.559 -0.746 . . . . 0.0 110.205 -175.402 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 93' ' ' GLN . . . . . 0.532 ' NE2' HG22 ' A' ' 89' ' ' THR . 21.1 pt20 -104.03 -27.32 12.2 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 114.897 -1.047 . . . . 0.0 113.039 -169.923 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 94' ' ' GLY . . . . . 0.412 ' O ' ' HB2' ' A' ' 90' ' ' ARG . . . 106.75 -107.71 2.74 Favored Glycine 0 N--CA 1.44 -1.034 0 N-CA-C 109.134 -1.586 . . . . 0.0 109.134 -175.214 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 95' ' ' TRP . . . . . 0.556 ' CZ2' HD12 ' A' ' 30' ' ' ILE . 29.7 m95 -138.51 21.56 2.73 Favored 'General case' 0 C--N 1.308 -1.21 0 N-CA-C 106.348 -1.723 . . . . 0.0 106.348 172.995 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -56.26 -35.16 64.31 Favored Glycine 0 C--N 1.335 0.514 0 CA-C-N 114.706 -1.134 . . . . 0.0 112.901 179.752 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -79.25 -15.38 58.1 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.78 0.324 . . . . 0.0 110.533 178.092 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 98' ' ' TRP . . . . . 0.745 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 24.7 m-90 -104.92 107.81 59.59 Favored Pre-proline 0 C--N 1.323 -0.572 0 CA-C-O 121.459 0.647 . . . . 0.0 110.019 178.722 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 99' ' ' PRO . . . . . 0.427 ' HD3' ' HA ' ' A' ' 98' ' ' TRP . 37.6 Cg_exo -64.73 -139.39 0.01 OUTLIER 'Trans proline' 0 CA--C 1.534 0.52 0 C-N-CA 123.764 2.976 . . . . 0.0 114.762 -174.102 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 100' ' ' VAL . . . . . 0.563 ' O ' ' HD2' ' A' ' 104' ' ' ARG . 23.8 t -55.89 -25.84 19.67 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.266 0 CA-C-N 115.441 -0.8 . . . . 0.0 110.746 -178.126 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 89.9 m -60.12 -38.73 83.91 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.321 176.907 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 102' ' ' ALA . . . . . 0.567 ' HB2' ' HB3' ' A' ' 98' ' ' TRP . . . -70.48 -41.2 73.02 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.686 0.279 . . . . 0.0 110.452 178.434 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -59.63 -44.81 93.33 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 121.189 0.519 . . . . 0.0 110.025 178.208 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 104' ' ' ARG . . . . . 0.563 ' HD2' ' O ' ' A' ' 100' ' ' VAL . 0.0 OUTLIER -62.52 -37.01 84.42 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.393 -0.821 . . . . 0.0 111.052 176.787 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 105' ' ' ALA . . . . . 0.601 ' HB1' ' HA ' ' A' ' 30' ' ' ILE . . . -78.77 -22.45 46.36 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 115.624 -0.716 . . . . 0.0 111.905 -176.165 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 114.56 62.13 0.39 Allowed Glycine 0 CA--C 1.519 0.325 0 C-N-CA 121.143 -0.551 . . . . 0.0 112.392 -178.185 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -61.47 140.61 58.04 Favored 'General case' 0 C--O 1.236 0.343 0 C-N-CA 122.789 0.435 . . . . 0.0 110.799 -179.331 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 8.7 ptm180 . . . . . 0 C--O 1.245 0.858 0 CA-C-O 118.556 -0.735 . . . . 0.0 110.555 -172.452 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 . . . . . 0 CA--C 1.503 -0.846 0 CA-C-O 121.449 0.642 . . . . 0.0 109.904 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -61.21 -15.22 43.57 Favored Glycine 0 CA--C 1.505 -0.565 0 CA-C-N 114.904 -1.043 . . . . 0.0 110.543 177.646 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 23.2 m -77.28 -37.23 53.28 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 114.666 -0.767 . . . . 0.0 110.068 177.598 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.556 ' O ' HG13 ' A' ' 34' ' ' ILE . 1.1 mm -71.38 -39.08 71.36 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.751 0 N-CA-C 107.029 -1.471 . . . . 0.0 107.029 178.693 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 31' ' ' TRP . . . . . 0.621 ' HZ2' ' HD3' ' A' ' 90' ' ' ARG . 24.3 m95 -68.54 -36.91 79.48 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-N 114.054 -1.43 . . . . 0.0 110.793 -176.154 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 7.8 t70 -74.92 -36.2 62.17 Favored 'General case' 0 N--CA 1.444 -0.743 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.587 177.203 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 33' ' ' ALA . . . . . 0.455 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -70.92 -35.52 72.29 Favored 'General case' 0 N--CA 1.448 -0.533 0 C-N-CA 120.736 -0.386 . . . . 0.0 110.846 178.937 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 34' ' ' ILE . . . . . 0.556 HG13 ' O ' ' A' ' 30' ' ' ILE . 75.8 mt -66.96 -46.07 85.75 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.222 0 CA-C-O 120.987 0.423 . . . . 0.0 110.002 174.662 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -57.61 -38.22 74.57 Favored 'General case' 0 CA--C 1.515 -0.373 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.297 176.92 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 36' ' ' GLY . . . . . 0.549 ' HA2' ' CA ' ' A' ' 41' ' ' GLY . . . -77.96 -1.64 79.69 Favored Glycine 0 N--CA 1.449 -0.436 0 CA-C-N 115.421 -0.809 . . . . 0.0 112.028 179.341 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 38.5 t -106.61 -57.09 2.1 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 115.825 -0.187 . . . . 0.0 111.361 -177.319 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 38' ' ' GLU . . . . . 0.824 ' HG3' ' SG ' ' A' ' 101' ' ' CYS . 9.9 mt-10 -88.09 -30.83 19.58 Favored 'General case' 0 CA--C 1.514 -0.422 0 C-N-CA 120.949 -0.301 . . . . 0.0 111.101 -175.207 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -96.68 -7.44 34.07 Favored 'General case' 0 N--CA 1.449 -0.488 0 C-N-CA 120.765 -0.374 . . . . 0.0 111.527 -179.079 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 82.09 2.6 90.61 Favored Glycine 0 CA--C 1.505 -0.575 0 N-CA-C 110.0 -1.24 . . . . 0.0 110.0 -177.962 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 41' ' ' GLY . . . . . 0.549 ' CA ' ' HA2' ' A' ' 36' ' ' GLY . . . 89.76 54.62 2.17 Favored Glycine 0 N--CA 1.433 -1.511 0 CA-C-N 114.208 -0.996 . . . . 0.0 111.807 -178.043 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 53.0 t30 -147.82 124.57 11.18 Favored 'General case' 0 N--CA 1.443 -0.793 0 N-CA-C 109.147 -0.686 . . . . 0.0 109.147 -178.983 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 43' ' ' TRP . . . . . 0.78 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 20.5 m95 -99.44 1.61 44.32 Favored 'General case' 0 C--N 1.301 -1.527 0 CA-C-N 115.132 -0.94 . . . . 0.0 110.004 -174.467 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -111.59 5.48 19.42 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.088 -0.96 . . . . 0.0 111.102 177.188 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 13.0 tt -75.26 143.32 13.42 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.769 0 CA-C-O 120.946 0.403 . . . . 0.0 110.196 -178.927 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 40.7 t-20 -156.46 96.62 1.68 Allowed 'General case' 0 C--N 1.311 -1.089 0 CA-C-O 121.154 0.502 . . . . 0.0 109.826 179.399 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 20.5 p -76.72 -22.0 54.5 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 115.782 -0.645 . . . . 0.0 111.262 -177.154 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 98.33 21.73 16.62 Favored Glycine 0 N--CA 1.442 -0.902 0 CA-C-N 115.549 -0.751 . . . . 0.0 111.272 -179.016 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 66.3 t30 -91.16 11.89 21.8 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 121.59 0.71 . . . . 0.0 110.934 -177.358 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 84.58 -14.41 46.92 Favored Glycine 0 N--CA 1.453 -0.224 0 N-CA-C 111.234 -0.746 . . . . 0.0 111.234 -178.281 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 51' ' ' TYR . . . . . 0.628 ' CE1' ' HB2' ' A' ' 58' ' ' ASP . 0.5 OUTLIER -98.07 142.4 29.81 Favored 'General case' 0 N--CA 1.445 -0.693 0 N-CA-C 108.174 -1.047 . . . . 0.0 108.174 173.226 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 52' ' ' TYR . . . . . 0.821 ' CE1' ' HB2' ' A' ' 59' ' ' GLN . 4.7 m-85 -108.56 170.28 8.12 Favored 'General case' 0 C--N 1.311 -1.097 0 CA-C-N 116.019 -0.537 . . . . 0.0 111.456 -174.323 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -58.89 172.56 4.07 Favored Glycine 0 N--CA 1.452 -0.286 0 N-CA-C 115.123 0.809 . . . . 0.0 115.123 -170.202 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 54' ' ' GLY . . . . . 0.764 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 87.01 -111.73 3.7 Favored Glycine 0 N--CA 1.443 -0.865 0 C-N-CA 120.962 -0.637 . . . . 0.0 111.577 -179.607 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.508 HG11 ' CE3' ' A' ' 31' ' ' TRP . 6.2 t -84.28 6.43 2.02 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.74 0 CA-C-O 121.736 0.779 . . . . 0.0 109.778 179.959 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 56' ' ' GLN . . . . . 0.715 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 52.3 tp60 53.54 51.91 14.31 Favored 'General case' 0 C--O 1.236 0.366 0 CA-C-N 114.427 -1.26 . . . . 0.0 112.872 164.816 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 6.9 p90 -120.15 167.94 11.72 Favored 'General case' 0 N--CA 1.443 -0.801 0 C-N-CA 119.555 -0.858 . . . . 0.0 111.897 174.245 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.628 ' HB2' ' CE1' ' A' ' 51' ' ' TYR . 0.6 OUTLIER -71.09 141.81 50.82 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 114.242 -1.345 . . . . 0.0 113.062 -165.636 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 59' ' ' GLN . . . . . 0.821 ' HB2' ' CE1' ' A' ' 52' ' ' TYR . 5.3 tp60 -56.2 -38.12 70.56 Favored 'General case' 0 N--CA 1.446 -0.628 0 CA-C-N 113.389 -1.732 . . . . 0.0 111.522 178.074 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -63.89 -48.93 71.5 Favored Glycine 0 N--CA 1.441 -1.006 0 CA-C-N 115.938 -0.573 . . . . 0.0 112.019 178.102 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 68.8 m -61.47 -42.21 98.43 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 121.279 0.561 . . . . 0.0 110.4 175.076 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 62' ' ' TRP . . . . . 0.455 ' CZ3' ' HA ' ' A' ' 82' ' ' GLN . 43.4 t-105 -56.13 -49.83 72.81 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.055 -0.975 . . . . 0.0 109.981 175.635 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 63' ' ' GLU . . . . . 0.631 ' HG3' HD11 ' A' ' 68' ' ' LEU . 29.3 tt0 -66.8 -39.36 87.71 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 115.195 -0.912 . . . . 0.0 110.756 -178.663 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -62.25 -39.5 93.07 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.553 -0.749 . . . . 0.0 110.92 -176.922 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 65' ' ' ASN . . . . . 0.586 ' OD1' ' HB ' ' A' ' 89' ' ' THR . 10.7 m120 -75.59 -21.14 58.08 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.198 177.014 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 101.7 39.36 2.97 Favored Glycine 0 N--CA 1.449 -0.493 0 C-N-CA 120.957 -0.64 . . . . 0.0 112.28 178.317 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 67' ' ' GLY . . . . . 0.655 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -79.25 -16.66 77.99 Favored Glycine 0 N--CA 1.44 -1.048 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.073 -173.915 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.631 HD11 ' HG3' ' A' ' 63' ' ' GLU . 26.4 mt -63.55 -23.76 67.52 Favored 'General case' 0 N--CA 1.442 -0.828 0 CA-C-N 115.502 -0.349 . . . . 0.0 111.566 -172.932 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 69' ' ' ARG . . . . . 0.57 ' HG3' ' N ' ' A' ' 70' ' ' TYR . 0.0 OUTLIER -70.77 -32.68 69.89 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 121.186 0.517 . . . . 0.0 110.068 176.165 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 70' ' ' TYR . . . . . 0.692 ' HB3' ' CG ' ' A' ' 81' ' ' GLU . 86.9 m-85 -76.13 -33.17 59.43 Favored 'General case' 0 CA--C 1.503 -0.852 0 N-CA-C 107.574 -1.269 . . . . 0.0 107.574 -179.934 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.754 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 163.26 125.48 0.01 OUTLIER Pre-proline 0 C--N 1.321 -0.654 0 CA-C-N 111.903 -2.408 . . . . 0.0 106.688 179.293 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 72' ' ' PRO . . . . . 0.606 ' HA ' ' HA ' ' A' ' 68' ' ' LEU . 17.3 Cg_exo -55.16 -4.0 0.37 Allowed 'Trans proline' 0 C--N 1.331 -0.342 0 C-N-CA 122.85 2.366 . . . . 0.0 113.633 -179.799 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 73' ' ' ARG . . . . . 0.401 ' HB2' ' CD2' ' A' ' 52' ' ' TYR . 14.8 ptm180 -145.83 136.94 24.7 Favored 'General case' 0 C--N 1.317 -0.836 0 CA-C-O 121.269 0.557 . . . . 0.0 109.657 176.6 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 74' ' ' ALA . . . . . 0.499 ' HB3' ' HB2' ' A' ' 52' ' ' TYR . . . -63.43 -25.49 68.3 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 115.455 -0.793 . . . . 0.0 111.914 -177.467 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 75' ' ' ASP . . . . . 0.484 ' OD1' ' HD2' ' A' ' 52' ' ' TYR . 26.9 p-10 -88.16 10.0 20.88 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-O 121.292 0.568 . . . . 0.0 110.847 -177.714 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 68.7 tp -113.0 -34.43 5.74 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.46 -0.791 . . . . 0.0 109.048 168.121 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 77' ' ' ALA . . . . . 0.754 ' HB2' ' HB3' ' A' ' 71' ' ' ALA . . . -78.31 153.43 31.75 Favored 'General case' 0 N--CA 1.443 -0.799 0 CA-C-N 115.357 -0.838 . . . . 0.0 109.851 177.687 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 33.5 p -96.54 -173.98 2.91 Favored 'General case' 0 C--N 1.317 -0.84 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.35 -176.951 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 79' ' ' ARG . . . . . 0.78 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 49.1 mtt85 -50.63 -52.56 38.43 Favored 'General case' 0 CA--C 1.513 -0.46 0 O-C-N 123.519 0.512 . . . . 0.0 111.549 -178.06 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 80' ' ' GLU . . . . . 0.563 ' HG3' ' OE2' ' A' ' 81' ' ' GLU . 9.3 pt-20 -59.28 -42.96 92.5 Favored 'General case' 0 C--N 1.318 -0.786 0 CA-C-N 116.026 -0.534 . . . . 0.0 111.962 -176.627 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 81' ' ' GLU . . . . . 0.692 ' CG ' ' HB3' ' A' ' 70' ' ' TYR . 4.9 mp0 -63.68 -51.99 62.64 Favored 'General case' 0 N--CA 1.454 -0.229 0 N-CA-C 112.094 0.405 . . . . 0.0 112.094 173.987 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 82' ' ' GLN . . . . . 0.46 ' NE2' ' HE3' ' A' ' 43' ' ' TRP . 51.4 mt-30 -59.16 -43.35 92.07 Favored 'General case' 0 CA--C 1.509 -0.611 0 CA-C-O 121.067 0.461 . . . . 0.0 110.459 -176.303 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.668 ' O ' ' HG2' ' A' ' 87' ' ' GLU . 34.3 mt -59.53 -41.88 86.23 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.793 0 CA-C-N 115.157 -0.928 . . . . 0.0 110.006 -178.886 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 84' ' ' ALA . . . . . 0.615 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -64.52 -42.8 95.55 Favored 'General case' 0 C--O 1.236 0.394 0 CA-C-O 121.705 0.764 . . . . 0.0 111.043 -177.793 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.431 HG22 ' HA2' ' A' ' 67' ' ' GLY . 48.3 t -65.53 -49.12 80.01 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 CA-C-N 115.539 -0.755 . . . . 0.0 110.906 178.188 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 86' ' ' ALA . . . . . 0.405 ' HB1' ' CH2' ' A' ' 31' ' ' TRP . . . -58.48 -30.47 67.01 Favored 'General case' 0 N--CA 1.452 -0.362 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.534 173.965 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 87' ' ' GLU . . . . . 0.668 ' HG2' ' O ' ' A' ' 83' ' ' ILE . 26.4 mm-40 -58.99 -44.06 91.56 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.45 -178.749 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.569 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 98.1 t -64.18 -50.68 75.71 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 C-N-CA 120.555 -0.458 . . . . 0.0 110.622 -179.799 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 89' ' ' THR . . . . . 0.586 ' HB ' ' OD1' ' A' ' 65' ' ' ASN . 12.5 t -73.59 -35.63 65.44 Favored 'General case' 0 C--N 1.318 -0.793 0 C-N-CA 120.796 -0.362 . . . . 0.0 111.66 -174.612 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 90' ' ' ARG . . . . . 0.641 ' HG3' ' N ' ' A' ' 91' ' ' LEU . 10.9 ptt85 -60.77 -41.6 95.82 Favored 'General case' 0 N--CA 1.471 0.597 0 CA-C-N 117.919 0.327 . . . . 0.0 110.783 -179.194 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 91' ' ' LEU . . . . . 0.641 ' N ' ' HG3' ' A' ' 90' ' ' ARG . 4.5 pp -69.8 -23.83 63.39 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.845 -0.616 . . . . 0.0 111.419 -172.43 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 92' ' ' ARG . . . . . 0.546 ' NE ' ' HA ' ' A' ' 89' ' ' THR . 1.9 mtm180 -81.22 -47.96 12.71 Favored 'General case' 0 N--CA 1.447 -0.606 0 CA-C-O 121.576 0.703 . . . . 0.0 109.468 -178.948 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 93' ' ' GLN . . . . . 0.615 ' NE2' ' HB2' ' A' ' 97' ' ' ALA . 3.5 pt20 -95.94 -27.14 15.3 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 114.731 -1.122 . . . . 0.0 112.872 -167.633 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 91.76 39.86 5.43 Favored Glycine 0 CA--C 1.504 -0.615 0 C-N-CA 120.344 -0.931 . . . . 0.0 111.985 170.441 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 95' ' ' TRP . . . . . 0.447 ' HB3' ' HB1' ' A' ' 102' ' ' ALA . 6.9 m95 63.74 17.27 10.35 Favored 'General case' 0 C--O 1.22 -0.474 0 N-CA-C 109.255 -0.646 . . . . 0.0 109.255 -179.231 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -70.47 -30.29 69.12 Favored Glycine 0 N--CA 1.451 -0.344 0 CA-C-N 115.504 -0.771 . . . . 0.0 112.598 177.989 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 97' ' ' ALA . . . . . 0.615 ' HB2' ' NE2' ' A' ' 93' ' ' GLN . . . -69.99 -30.11 67.36 Favored 'General case' 0 CA--C 1.514 -0.439 0 CA-C-O 120.924 0.392 . . . . 0.0 110.21 177.488 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 98' ' ' TRP . . . . . 0.509 ' HB2' ' HB2' ' A' ' 102' ' ' ALA . 25.6 m-90 -98.47 104.55 24.45 Favored Pre-proline 0 C--N 1.323 -0.571 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 177.353 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_exo -70.99 -94.2 0.01 OUTLIER 'Trans proline' 0 CA--C 1.534 0.505 0 C-N-CA 122.889 2.393 . . . . 0.0 114.734 -172.22 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 60.6 t -70.99 -31.95 46.84 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 CA-C-O 121.822 0.82 . . . . 0.0 110.19 -173.98 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 101' ' ' CYS . . . . . 0.824 ' SG ' ' HG3' ' A' ' 38' ' ' GLU . 75.6 m -78.26 -26.1 47.05 Favored 'General case' 0 C--N 1.315 -0.932 0 CA-C-N 114.772 -1.104 . . . . 0.0 112.27 -168.832 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 102' ' ' ALA . . . . . 0.509 ' HB2' ' HB2' ' A' ' 98' ' ' TRP . . . -69.93 -46.19 65.89 Favored 'General case' 0 C--N 1.326 -0.444 0 C-N-CA 120.549 -0.461 . . . . 0.0 110.23 176.249 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -65.33 -35.92 82.46 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.699 -179.358 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 104' ' ' ARG . . . . . 0.471 ' HG2' ' HA ' ' A' ' 101' ' ' CYS . 0.0 OUTLIER -73.41 -21.45 60.48 Favored 'General case' 0 N--CA 1.444 -0.725 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.425 179.785 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 105' ' ' ALA . . . . . 0.466 ' HB1' ' HA ' ' A' ' 30' ' ' ILE . . . -96.08 -22.82 17.1 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.821 -0.627 . . . . 0.0 111.581 -178.157 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 119.02 63.66 0.29 Allowed Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 121.236 -0.507 . . . . 0.0 112.236 -176.86 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -64.09 145.15 56.42 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.776 0.322 . . . . 0.0 110.782 179.36 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 51.8 mtp180 . . . . . 0 C--O 1.249 1.06 0 CA-C-O 118.395 -0.812 . . . . 0.0 110.332 -173.293 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 15.0 m-20 . . . . . 0 CA--C 1.507 -0.706 0 CA-C-O 121.865 0.84 . . . . 0.0 109.532 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 28' ' ' GLY . . . . . 0.463 ' HA2' ' HB2' ' A' ' 31' ' ' TRP . . . -70.23 -6.32 56.98 Favored Glycine 0 N--CA 1.44 -1.057 0 CA-C-N 114.481 -1.236 . . . . 0.0 110.38 176.526 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 9.6 m -76.96 -39.4 50.71 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-O 121.659 0.742 . . . . 0.0 109.087 174.661 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.496 ' O ' HG13 ' A' ' 34' ' ' ILE . 1.0 OUTLIER -69.65 -38.1 75.64 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.576 0 N-CA-C 107.492 -1.299 . . . . 0.0 107.492 177.366 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 31' ' ' TRP . . . . . 0.513 ' CD1' HG23 ' A' ' 83' ' ' ILE . 43.2 m95 -71.41 -35.91 71.16 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 114.262 -1.336 . . . . 0.0 110.487 -177.857 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.533 ' HB2' HH21 ' A' ' 79' ' ' ARG . 15.5 t70 -74.28 -34.56 63.6 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.385 178.328 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -69.89 -34.47 73.59 Favored 'General case' 0 N--CA 1.446 -0.629 0 C-N-CA 120.756 -0.377 . . . . 0.0 110.12 177.705 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 34' ' ' ILE . . . . . 0.566 ' HA ' ' HB3' ' A' ' 101' ' ' CYS . 61.9 mt -67.33 -47.44 81.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.312 174.399 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 35' ' ' ALA . . . . . 0.445 ' HA ' ' O ' ' A' ' 54' ' ' GLY . . . -58.76 -39.14 80.12 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.501 177.554 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -76.13 -8.79 85.42 Favored Glycine 0 N--CA 1.451 -0.337 0 CA-C-N 115.559 -0.746 . . . . 0.0 112.081 179.603 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 1.7 t -97.16 -57.96 2.13 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-O 120.678 0.275 . . . . 0.0 111.417 -178.6 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 38' ' ' GLU . . . . . 0.545 ' HB2' ' SG ' ' A' ' 101' ' ' CYS . 8.0 tp10 -87.97 -33.02 18.57 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 121.207 0.527 . . . . 0.0 109.999 -171.315 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 39' ' ' ALA . . . . . 0.412 ' HB3' ' O ' ' A' ' 35' ' ' ALA . . . -95.71 -13.05 24.52 Favored 'General case' 0 N--CA 1.448 -0.538 0 CA-C-N 115.631 -0.713 . . . . 0.0 111.197 -178.749 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 82.52 1.34 90.47 Favored Glycine 0 N--CA 1.448 -0.505 0 N-CA-C 109.983 -1.247 . . . . 0.0 109.983 -177.04 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 93.65 55.63 1.52 Allowed Glycine 0 N--CA 1.436 -1.327 0 CA-C-N 114.372 -0.914 . . . . 0.0 111.61 -176.543 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 42' ' ' ASN . . . . . 0.556 ' HB3' ' HB ' ' A' ' 45' ' ' ILE . 17.5 t-20 -142.93 94.6 2.65 Favored 'General case' 0 N--CA 1.447 -0.606 0 N-CA-C 108.704 -0.85 . . . . 0.0 108.704 -177.689 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 43' ' ' TRP . . . . . 0.754 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 38.3 m95 -76.65 -10.71 59.58 Favored 'General case' 0 C--N 1.317 -0.844 0 CA-C-O 121.384 0.611 . . . . 0.0 110.423 -175.385 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 44' ' ' ALA . . . . . 0.426 ' HA ' ' HB2' ' A' ' 75' ' ' ASP . . . -107.73 15.38 24.66 Favored 'General case' 0 C--N 1.318 -0.795 0 CA-C-N 114.981 -1.009 . . . . 0.0 111.731 -178.624 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.746 HG22 ' HA2' ' A' ' 53' ' ' GLY . 9.9 tt -83.21 142.42 13.56 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.619 0 CA-C-O 121.432 0.634 . . . . 0.0 111.344 -175.639 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 46' ' ' ASN . . . . . 0.41 HD22 ' HA ' ' A' ' 46' ' ' ASN . 9.7 m120 -133.53 88.19 2.46 Favored 'General case' 0 C--N 1.316 -0.873 0 N-CA-C 108.539 -0.911 . . . . 0.0 108.539 176.663 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 1.2 p -69.31 -24.09 63.89 Favored 'General case' 0 C--N 1.315 -0.934 0 CA-C-N 115.769 -0.651 . . . . 0.0 110.603 179.708 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 94.57 19.0 33.51 Favored Glycine 0 N--CA 1.444 -0.795 0 N-CA-C 111.272 -0.731 . . . . 0.0 111.272 176.412 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 30.7 p-10 -94.7 11.62 30.64 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.141 0.496 . . . . 0.0 111.134 -175.301 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 50' ' ' GLY . . . . . 0.452 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 89.9 -11.59 70.07 Favored Glycine 0 N--CA 1.445 -0.724 0 N-CA-C 110.823 -0.911 . . . . 0.0 110.823 -178.243 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 51' ' ' TYR . . . . . 0.604 ' CE1' ' HB3' ' A' ' 58' ' ' ASP . 0.8 OUTLIER -109.94 151.64 26.85 Favored 'General case' 0 CA--C 1.512 -0.488 0 N-CA-C 107.827 -1.175 . . . . 0.0 107.827 178.722 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 52' ' ' TYR . . . . . 0.633 ' CE1' ' HB2' ' A' ' 59' ' ' GLN . 24.2 m-85 -115.36 170.4 8.43 Favored 'General case' 0 C--N 1.313 -0.995 0 C-N-CA 120.647 -0.421 . . . . 0.0 111.316 -170.294 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.746 ' HA2' HG22 ' A' ' 45' ' ' ILE . . . -56.92 166.72 4.72 Favored Glycine 0 N--CA 1.451 -0.354 0 N-CA-C 114.818 0.687 . . . . 0.0 114.818 -169.744 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 54' ' ' GLY . . . . . 0.678 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 88.19 -103.78 2.97 Favored Glycine 0 N--CA 1.444 -0.791 0 C-N-CA 121.253 -0.499 . . . . 0.0 112.237 177.305 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.516 HG12 ' HE1' ' A' ' 98' ' ' TRP . 2.5 t -83.27 -2.82 6.95 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 CA-C-O 121.445 0.64 . . . . 0.0 109.785 -177.873 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 56' ' ' GLN . . . . . 0.613 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 2.0 mm-40 55.91 42.33 28.94 Favored 'General case' 0 N--CA 1.462 0.139 0 CA-C-N 114.747 -1.115 . . . . 0.0 113.102 169.727 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 57' ' ' PHE . . . . . 0.487 ' CD1' ' HB ' ' A' ' 55' ' ' VAL . 1.5 p90 -114.88 165.63 12.64 Favored 'General case' 0 C--N 1.322 -0.616 0 C-N-CA 119.912 -0.715 . . . . 0.0 111.041 175.253 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.604 ' HB3' ' CE1' ' A' ' 51' ' ' TYR . 8.1 p-10 -76.02 155.56 34.82 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 122.075 0.941 . . . . 0.0 112.619 -164.238 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 59' ' ' GLN . . . . . 0.633 ' HB2' ' CE1' ' A' ' 52' ' ' TYR . 3.6 tp-100 -61.42 -32.11 72.06 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 113.414 -1.721 . . . . 0.0 111.14 179.767 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -65.94 -49.5 58.26 Favored Glycine 0 C--N 1.316 -0.553 0 CA-C-N 115.48 -0.782 . . . . 0.0 111.786 -179.862 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 90.9 m -66.67 -40.75 88.75 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-O 120.787 0.327 . . . . 0.0 110.996 175.979 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 62' ' ' TRP . . . . . 0.473 ' CH2' ' HA ' ' A' ' 74' ' ' ALA . 46.2 t-105 -56.38 -49.53 74.18 Favored 'General case' 0 N--CA 1.45 -0.462 0 CA-C-O 121.656 0.741 . . . . 0.0 109.293 176.137 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 63' ' ' GLU . . . . . 0.431 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 33.6 tt0 -68.11 -32.28 72.47 Favored 'General case' 0 N--CA 1.444 -0.763 0 CA-C-N 115.022 -0.99 . . . . 0.0 110.855 179.857 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -64.26 -39.03 93.11 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.891 -179.588 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 65' ' ' ASN . . . . . 0.578 ' HB2' HG13 ' A' ' 85' ' ' VAL . 5.5 m120 -78.76 -14.05 59.48 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 121.597 0.713 . . . . 0.0 109.485 175.134 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 66' ' ' GLY . . . . . 0.582 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 82.68 49.15 5.25 Favored Glycine 0 N--CA 1.445 -0.702 0 CA-C-N 115.061 -0.972 . . . . 0.0 111.608 -179.924 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 67' ' ' GLY . . . . . 0.629 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -78.67 -15.39 80.86 Favored Glycine 0 N--CA 1.442 -0.96 0 C-N-CA 121.273 -0.489 . . . . 0.0 112.432 -174.765 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.837 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 6.8 mp -59.21 -27.27 65.57 Favored 'General case' 0 C--N 1.323 -0.575 0 N-CA-C 111.872 0.323 . . . . 0.0 111.872 -175.568 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 69' ' ' ARG . . . . . 0.582 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 9.1 ptp180 -65.33 -30.12 70.93 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 121.353 0.597 . . . . 0.0 110.046 177.182 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 70' ' ' TYR . . . . . 0.999 ' HB3' ' HB3' ' A' ' 81' ' ' GLU . 75.0 m-85 -81.49 -34.3 31.39 Favored 'General case' 0 N--CA 1.441 -0.905 0 N-CA-C 107.638 -1.245 . . . . 0.0 107.638 176.405 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.696 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 162.67 128.92 0.01 OUTLIER Pre-proline 0 CA--C 1.513 -0.465 0 CA-C-N 112.653 -2.067 . . . . 0.0 107.009 -179.568 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 72' ' ' PRO . . . . . 0.837 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 20.4 Cg_exo -57.35 -4.93 1.3 Allowed 'Trans proline' 0 C--N 1.333 -0.26 0 C-N-CA 122.77 2.313 . . . . 0.0 113.767 -177.17 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 73' ' ' ARG . . . . . 0.428 ' HE ' ' CG ' ' A' ' 75' ' ' ASP . 10.7 ptm180 -147.86 139.01 23.45 Favored 'General case' 0 C--N 1.317 -0.805 0 N-CA-C 109.367 -0.605 . . . . 0.0 109.367 176.526 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 74' ' ' ALA . . . . . 0.473 ' HA ' ' CH2' ' A' ' 62' ' ' TRP . . . -55.95 -29.84 60.77 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 114.941 -1.027 . . . . 0.0 112.52 -177.193 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 75' ' ' ASP . . . . . 0.546 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 4.6 p-10 -83.97 -4.68 58.9 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 120.967 0.413 . . . . 0.0 111.256 -176.037 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 68.1 tp -100.0 -29.74 12.37 Favored 'General case' 0 C--N 1.322 -0.59 0 N-CA-C 108.46 -0.941 . . . . 0.0 108.46 172.549 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 77' ' ' ALA . . . . . 0.805 ' HB1' ' HB2' ' A' ' 81' ' ' GLU . . . -79.28 159.16 27.36 Favored 'General case' 0 N--CA 1.44 -0.968 0 CA-C-N 114.78 -1.1 . . . . 0.0 109.795 175.113 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 61.9 p -100.35 -175.19 2.85 Favored 'General case' 0 C--N 1.309 -1.188 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.355 -176.974 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 79' ' ' ARG . . . . . 0.754 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 77.7 mtp180 -50.01 -52.93 30.11 Favored 'General case' 0 C--N 1.329 -0.293 0 O-C-N 123.416 0.447 . . . . 0.0 111.265 178.819 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 80' ' ' GLU . . . . . 0.46 ' HA ' HD12 ' A' ' 83' ' ' ILE . 17.0 pt-20 -60.8 -37.23 81.24 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.873 -0.603 . . . . 0.0 111.434 -174.43 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 81' ' ' GLU . . . . . 0.999 ' HB3' ' HB3' ' A' ' 70' ' ' TYR . 4.2 mm-40 -70.22 -50.32 41.05 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 121.031 0.443 . . . . 0.0 109.959 -179.465 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 82' ' ' GLN . . . . . 0.57 ' HB2' ' HZ3' ' A' ' 43' ' ' TRP . 41.7 mt-30 -60.03 -34.45 73.4 Favored 'General case' 0 CA--C 1.513 -0.465 0 CA-C-N 115.515 -0.766 . . . . 0.0 110.201 -179.319 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.69 ' O ' ' HG2' ' A' ' 87' ' ' GLU . 40.3 mt -60.77 -49.1 85.91 Favored 'Isoleucine or valine' 0 C--O 1.212 -0.883 0 N-CA-C 109.084 -0.71 . . . . 0.0 109.084 175.855 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 84' ' ' ALA . . . . . 0.587 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -62.1 -44.09 97.4 Favored 'General case' 0 C--O 1.237 0.414 0 CA-C-O 121.277 0.56 . . . . 0.0 111.867 -176.353 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.578 HG13 ' HB2' ' A' ' 65' ' ' ASN . 40.0 t -66.24 -49.32 76.86 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.609 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.862 179.432 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 86' ' ' ALA . . . . . 0.474 ' HB1' ' CH2' ' A' ' 31' ' ' TRP . . . -59.11 -29.54 67.45 Favored 'General case' 0 N--CA 1.447 -0.592 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.404 174.572 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 87' ' ' GLU . . . . . 0.86 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 15.7 mm-40 -59.46 -44.3 93.0 Favored 'General case' 0 C--O 1.222 -0.386 0 CA-C-N 115.846 -0.616 . . . . 0.0 110.492 -178.599 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.448 ' O ' ' HG3' ' A' ' 92' ' ' ARG . 70.6 t -60.52 -49.3 84.93 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.303 0 C-N-CA 120.288 -0.565 . . . . 0.0 110.091 179.747 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 89' ' ' THR . . . . . 0.675 HG22 ' NE2' ' A' ' 93' ' ' GLN . 24.0 m -66.24 -43.8 85.57 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-N 115.683 -0.69 . . . . 0.0 111.437 -177.155 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 90' ' ' ARG . . . . . 0.657 ' HA ' ' OE1' ' A' ' 93' ' ' GLN . 3.2 ppt_? -60.96 -34.34 74.59 Favored 'General case' 0 N--CA 1.467 0.4 0 N-CA-C 112.073 0.397 . . . . 0.0 112.073 -176.48 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 91' ' ' LEU . . . . . 0.86 ' HG ' ' O ' ' A' ' 87' ' ' GLU . 46.5 mt -62.87 -33.25 74.88 Favored 'General case' 0 N--CA 1.471 0.587 0 CA-C-O 121.47 0.652 . . . . 0.0 110.152 -177.998 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 92' ' ' ARG . . . . . 0.483 ' NH2' HG23 ' A' ' 89' ' ' THR . 6.5 mtm180 -81.57 -50.57 9.21 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-N 114.818 -1.083 . . . . 0.0 110.103 -169.85 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 93' ' ' GLN . . . . . 0.675 ' NE2' HG22 ' A' ' 89' ' ' THR . 0.0 OUTLIER -96.13 -23.55 16.7 Favored 'General case' 0 C--N 1.318 -0.785 0 C-N-CA 119.733 -0.787 . . . . 0.0 113.045 -171.682 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 88.48 40.41 6.42 Favored Glycine 0 CA--C 1.508 -0.345 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.156 172.466 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 95' ' ' TRP . . . . . 0.531 ' CZ2' ' HD3' ' A' ' 90' ' ' ARG . 22.1 m95 67.16 9.09 6.68 Favored 'General case' 0 C--O 1.221 -0.423 0 C-N-CA 123.6 0.76 . . . . 0.0 110.033 -179.124 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -71.97 -23.48 77.93 Favored Glycine 0 N--CA 1.451 -0.305 0 CA-C-N 115.891 -0.595 . . . . 0.0 112.444 178.155 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -72.7 -28.1 62.47 Favored 'General case' 0 CA--C 1.516 -0.337 0 CA-C-O 121.046 0.451 . . . . 0.0 109.988 177.641 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 98' ' ' TRP . . . . . 0.516 ' HE1' HG12 ' A' ' 55' ' ' VAL . 28.6 m-90 -101.02 104.16 30.31 Favored Pre-proline 0 N--CA 1.448 -0.567 0 CA-C-N 115.146 -0.934 . . . . 0.0 108.966 176.528 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 99' ' ' PRO . . . . . 0.404 ' HD3' ' HA ' ' A' ' 98' ' ' TRP . 15.7 Cg_exo -73.95 -88.38 0.0 OUTLIER 'Trans proline' 0 CA--C 1.53 0.32 0 C-N-CA 123.182 2.588 . . . . 0.0 114.993 -171.127 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 100' ' ' VAL . . . . . 0.427 ' HA ' HH21 ' A' ' 104' ' ' ARG . 80.5 t -69.45 -30.08 44.24 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-O 121.142 0.496 . . . . 0.0 110.693 -172.393 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 101' ' ' CYS . . . . . 0.566 ' HB3' ' HA ' ' A' ' 34' ' ' ILE . 87.1 m -79.79 -37.64 34.84 Favored 'General case' 0 C--N 1.317 -0.812 0 CA-C-N 115.7 -0.682 . . . . 0.0 112.403 -170.102 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 102' ' ' ALA . . . . . 0.442 ' HB1' ' HB3' ' A' ' 95' ' ' TRP . . . -69.62 -40.33 76.66 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.828 0.347 . . . . 0.0 110.912 -178.556 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -61.48 -38.55 87.71 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-O 121.318 0.58 . . . . 0.0 110.588 177.127 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 104' ' ' ARG . . . . . 0.427 HH21 ' HA ' ' A' ' 100' ' ' VAL . 1.4 mpp_? -74.58 -18.45 60.57 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.371 -0.831 . . . . 0.0 111.618 176.77 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -96.49 -22.8 16.89 Favored 'General case' 0 C--N 1.327 -0.399 0 N-CA-C 112.659 0.615 . . . . 0.0 112.659 -173.638 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 106.11 64.21 0.62 Allowed Glycine 0 CA--C 1.52 0.4 0 C-N-CA 120.793 -0.718 . . . . 0.0 112.252 -177.582 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -72.24 149.14 44.83 Favored 'General case' 0 C--N 1.326 -0.436 0 C-N-CA 122.906 0.483 . . . . 0.0 111.28 -174.867 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.245 0.819 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.619 -175.403 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 27' ' ' ASP . . . . . 0.463 ' O ' HG12 ' A' ' 30' ' ' ILE . 18.4 m-20 . . . . . 0 CA--C 1.511 -0.53 0 CA-C-O 121.42 0.628 . . . . 0.0 109.784 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -69.91 -8.36 60.88 Favored Glycine 0 CA--C 1.5 -0.874 0 N-CA-C 110.343 -1.103 . . . . 0.0 110.343 177.921 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 16.4 m -76.55 -35.04 58.47 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 114.591 -0.805 . . . . 0.0 109.197 175.857 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.622 ' HA ' ' HB1' ' A' ' 105' ' ' ALA . 1.1 mm -71.46 -36.95 62.62 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.645 0 N-CA-C 107.245 -1.391 . . . . 0.0 107.245 177.105 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 31' ' ' TRP . . . . . 0.572 ' CH2' ' HB1' ' A' ' 86' ' ' ALA . 34.6 m95 -71.15 -36.3 72.0 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 114.089 -1.414 . . . . 0.0 111.012 -177.259 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.784 ' HB2' HH21 ' A' ' 79' ' ' ARG . 17.5 t70 -74.79 -36.7 62.51 Favored 'General case' 0 N--CA 1.445 -0.694 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.477 179.119 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 33' ' ' ALA . . . . . 0.442 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -70.47 -34.19 72.12 Favored 'General case' 0 N--CA 1.448 -0.537 0 C-N-CA 120.817 -0.353 . . . . 0.0 110.695 178.687 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 34' ' ' ILE . . . . . 0.547 HG13 ' O ' ' A' ' 30' ' ' ILE . 65.9 mt -64.73 -44.67 96.51 Favored 'Isoleucine or valine' 0 C--O 1.235 0.327 0 CA-C-O 121.286 0.565 . . . . 0.0 109.988 173.914 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 35' ' ' ALA . . . . . 0.441 ' HA ' ' O ' ' A' ' 54' ' ' GLY . . . -59.59 -35.03 73.51 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.511 -0.768 . . . . 0.0 110.261 176.245 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 36' ' ' GLY . . . . . 0.51 ' HA2' ' N ' ' A' ' 41' ' ' GLY . . . -78.94 4.37 61.82 Favored Glycine 0 N--CA 1.452 -0.293 0 CA-C-N 115.368 -0.833 . . . . 0.0 112.341 179.643 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 27.0 t -108.15 -53.84 2.58 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 120.576 0.227 . . . . 0.0 111.114 -179.499 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 38' ' ' GLU . . . . . 0.444 ' HG2' ' SG ' ' A' ' 101' ' ' CYS . 36.7 mm-40 -87.86 -33.1 18.67 Favored 'General case' 0 CA--C 1.515 -0.39 0 CA-C-O 121.093 0.473 . . . . 0.0 110.552 -176.547 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -105.1 -9.71 17.62 Favored 'General case' 0 N--CA 1.447 -0.587 0 CA-C-N 116.044 -0.525 . . . . 0.0 112.124 -175.201 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 75.11 17.51 80.23 Favored Glycine 0 CA--C 1.505 -0.577 0 N-CA-C 109.635 -1.386 . . . . 0.0 109.635 -177.199 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 41' ' ' GLY . . . . . 0.51 ' N ' ' HA2' ' A' ' 36' ' ' GLY . . . 75.24 61.51 2.99 Favored Glycine 0 N--CA 1.432 -1.598 0 CA-C-N 114.019 -1.091 . . . . 0.0 111.455 -174.953 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 42' ' ' ASN . . . . . 0.436 ' HB3' ' HB ' ' A' ' 45' ' ' ILE . 4.6 t-20 -145.84 100.16 3.37 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 108.332 -0.988 . . . . 0.0 108.332 -177.251 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 43' ' ' TRP . . . . . 0.81 ' HA ' ' N ' ' A' ' 54' ' ' GLY . 30.2 m95 -84.47 -3.82 58.59 Favored 'General case' 0 C--N 1.317 -0.833 0 CA-C-O 121.605 0.717 . . . . 0.0 110.664 -170.785 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -111.64 15.69 20.93 Favored 'General case' 0 C--N 1.311 -1.091 0 CA-C-N 114.806 -1.088 . . . . 0.0 110.86 178.768 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.818 HG22 ' HA2' ' A' ' 53' ' ' GLY . 10.5 tt -79.38 137.63 21.4 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.733 0 CA-C-O 121.163 0.506 . . . . 0.0 110.508 -177.85 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 46.4 t30 -171.24 103.72 0.21 Allowed 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 115.956 -0.566 . . . . 0.0 110.379 178.948 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 25.3 p -82.63 -11.51 58.33 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 115.767 -0.651 . . . . 0.0 111.09 177.586 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 104.07 21.28 9.64 Favored Glycine 0 N--CA 1.449 -0.483 0 C-N-CA 120.808 -0.711 . . . . 0.0 111.386 -175.348 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 8.6 p30 -82.15 -4.86 57.84 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 115.623 -0.288 . . . . 0.0 111.161 -178.335 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 50' ' ' GLY . . . . . 0.538 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 96.3 -11.95 66.88 Favored Glycine 0 N--CA 1.448 -0.525 0 C-N-CA 121.305 -0.474 . . . . 0.0 112.039 177.755 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 51' ' ' TYR . . . . . 0.647 ' HA ' ' HA ' ' A' ' 58' ' ' ASP . 0.6 OUTLIER -112.37 151.61 29.59 Favored 'General case' 0 CA--C 1.514 -0.412 0 N-CA-C 107.834 -1.173 . . . . 0.0 107.834 176.349 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 52' ' ' TYR . . . . . 0.696 ' O ' ' HA ' ' A' ' 56' ' ' GLN . 42.9 m-85 -116.61 170.39 8.62 Favored 'General case' 0 C--N 1.313 -0.984 0 C-N-CA 120.4 -0.52 . . . . 0.0 112.203 -166.242 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.818 ' HA2' HG22 ' A' ' 45' ' ' ILE . . . -60.12 172.18 5.83 Favored Glycine 0 N--CA 1.446 -0.658 0 N-CA-C 115.548 0.979 . . . . 0.0 115.548 -167.653 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 54' ' ' GLY . . . . . 0.81 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 87.53 -109.35 3.46 Favored Glycine 0 N--CA 1.437 -1.234 0 CA-C-N 114.486 -0.857 . . . . 0.0 111.636 177.557 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.518 HG11 ' CE3' ' A' ' 31' ' ' TRP . 0.5 OUTLIER -84.16 2.21 3.93 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.594 0 CA-C-O 121.351 0.596 . . . . 0.0 110.868 178.793 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 56' ' ' GLN . . . . . 0.696 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 6.6 tp60 59.5 51.36 6.6 Favored 'General case' 0 CA--C 1.532 0.271 0 CA-C-N 114.207 -1.361 . . . . 0.0 113.316 164.952 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 57' ' ' PHE . . . . . 0.477 ' CE1' HG23 ' A' ' 55' ' ' VAL . 0.3 OUTLIER -119.12 168.37 10.91 Favored 'General case' 0 C--N 1.326 -0.454 0 C-N-CA 119.465 -0.894 . . . . 0.0 111.865 174.215 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.647 ' HA ' ' HA ' ' A' ' 51' ' ' TYR . 7.4 p-10 -78.53 166.11 22.95 Favored 'General case' 0 C--N 1.327 -0.383 0 N-CA-C 113.724 1.009 . . . . 0.0 113.724 -163.459 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 59' ' ' GLN . . . . . 0.48 ' HB2' ' HE1' ' A' ' 52' ' ' TYR . 5.6 tp-100 -61.08 -39.96 91.87 Favored 'General case' 0 N--CA 1.446 -0.667 0 CA-C-N 114.775 -1.102 . . . . 0.0 111.244 177.601 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -64.32 -49.55 65.16 Favored Glycine 0 C--N 1.317 -0.483 0 CA-C-N 115.665 -0.698 . . . . 0.0 111.572 -175.185 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 87.9 m -66.77 -41.58 87.5 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-N 115.612 -0.294 . . . . 0.0 111.167 176.591 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 62' ' ' TRP . . . . . 0.447 ' HZ3' ' HA ' ' A' ' 82' ' ' GLN . 57.2 t-105 -56.48 -48.4 77.19 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 121.773 0.796 . . . . 0.0 109.437 177.0 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 63' ' ' GLU . . . . . 0.444 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 29.3 tt0 -67.44 -34.22 76.76 Favored 'General case' 0 C--N 1.317 -0.833 0 CA-C-N 114.8 -1.091 . . . . 0.0 111.131 -179.655 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -65.14 -41.36 94.87 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.899 -0.592 . . . . 0.0 111.129 -177.166 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 65' ' ' ASN . . . . . 0.566 ' HB2' HG13 ' A' ' 85' ' ' VAL . 31.4 m-80 -82.94 -9.2 59.41 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.715 0.293 . . . . 0.0 110.502 177.232 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 66' ' ' GLY . . . . . 0.515 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 91.46 49.79 2.91 Favored Glycine 0 C--N 1.334 0.433 0 C-N-CA 121.181 -0.533 . . . . 0.0 113.168 173.218 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 67' ' ' GLY . . . . . 0.483 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -80.61 -28.2 48.29 Favored Glycine 0 N--CA 1.439 -1.127 0 C-N-CA 121.041 -0.6 . . . . 0.0 113.107 -177.391 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.898 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 7.2 mp -57.4 -23.58 50.2 Favored 'General case' 0 N--CA 1.452 -0.355 0 N-CA-C 112.2 0.445 . . . . 0.0 112.2 -173.032 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 69' ' ' ARG . . . . . 0.515 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 1.5 ptm180 -67.56 -31.67 71.91 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-O 121.043 0.449 . . . . 0.0 109.971 178.529 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 70' ' ' TYR . . . . . 1.021 ' HB3' ' HG2' ' A' ' 81' ' ' GLU . 63.5 m-85 -83.99 -36.63 23.04 Favored 'General case' 0 N--CA 1.44 -0.946 0 N-CA-C 107.327 -1.36 . . . . 0.0 107.327 177.218 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.636 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 169.1 126.96 0.04 OUTLIER Pre-proline 0 N--CA 1.443 -0.784 0 CA-C-N 112.899 -1.955 . . . . 0.0 107.406 -175.89 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 72' ' ' PRO . . . . . 0.898 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 21.5 Cg_exo -56.85 -5.9 1.48 Allowed 'Trans proline' 0 C--N 1.33 -0.417 0 C-N-CA 122.982 2.454 . . . . 0.0 113.705 -177.542 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 73' ' ' ARG . . . . . 0.63 ' HB2' ' CD2' ' A' ' 52' ' ' TYR . 28.3 ptt-85 -149.74 140.32 22.53 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-O 121.188 0.518 . . . . 0.0 110.356 176.756 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 74' ' ' ALA . . . . . 0.491 ' HB3' ' HB2' ' A' ' 52' ' ' TYR . . . -57.65 -22.83 48.04 Favored 'General case' 0 C--O 1.217 -0.645 0 CA-C-N 114.851 -1.068 . . . . 0.0 113.189 -178.98 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 75' ' ' ASP . . . . . 0.57 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 0.0 OUTLIER -76.76 -23.15 52.95 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 121.227 0.537 . . . . 0.0 110.921 -179.159 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.504 ' HB3' ' HB1' ' A' ' 71' ' ' ALA . 54.9 tp -87.68 -33.19 18.86 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 115.567 -0.742 . . . . 0.0 109.191 176.034 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 77' ' ' ALA . . . . . 0.742 ' HB1' ' CB ' ' A' ' 81' ' ' GLU . . . -79.15 158.47 27.71 Favored 'General case' 0 N--CA 1.445 -0.723 0 CA-C-N 115.344 -0.844 . . . . 0.0 110.97 176.1 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 47.5 p -101.5 -172.48 2.17 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.231 -178.444 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 79' ' ' ARG . . . . . 0.784 HH21 ' HB2' ' A' ' 32' ' ' ASP . 66.8 mtp180 -49.52 -52.55 28.85 Favored 'General case' 0 N--CA 1.466 0.325 0 CA-C-N 116.433 -0.349 . . . . 0.0 111.521 -177.955 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 10.2 pt-20 -62.69 -33.07 74.33 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 116.023 -0.535 . . . . 0.0 111.365 -174.977 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 81' ' ' GLU . . . . . 1.021 ' HG2' ' HB3' ' A' ' 70' ' ' TYR . 5.9 mt-10 -71.9 -47.53 52.03 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.532 -0.304 . . . . 0.0 111.235 178.43 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 82' ' ' GLN . . . . . 0.57 ' NE2' ' HE3' ' A' ' 43' ' ' TRP . 0.1 OUTLIER -59.5 -39.61 84.38 Favored 'General case' 0 CA--C 1.505 -0.752 0 N-CA-C 109.509 -0.552 . . . . 0.0 109.509 174.551 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.68 ' O ' ' HG2' ' A' ' 87' ' ' GLU . 27.2 mt -60.1 -49.75 82.87 Favored 'Isoleucine or valine' 0 C--O 1.209 -1.03 0 CA-C-N 114.848 -1.069 . . . . 0.0 110.591 177.471 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 84' ' ' ALA . . . . . 0.622 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -60.8 -46.02 92.14 Favored 'General case' 0 C--O 1.242 0.664 0 CA-C-O 121.409 0.623 . . . . 0.0 111.973 -177.176 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.566 HG13 ' HB2' ' A' ' 65' ' ' ASN . 58.6 t -66.51 -48.27 81.07 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.737 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.448 -179.525 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 86' ' ' ALA . . . . . 0.572 ' HB1' ' CH2' ' A' ' 31' ' ' TRP . . . -59.95 -28.49 67.69 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.584 -0.735 . . . . 0.0 110.793 174.065 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 87' ' ' GLU . . . . . 0.68 ' HG2' ' O ' ' A' ' 83' ' ' ILE . 10.9 mm-40 -59.26 -45.0 92.38 Favored 'General case' 0 N--CA 1.468 0.434 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.166 -179.17 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.653 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 62.1 t -65.95 -42.49 91.93 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.295 0 C-N-CA 120.115 -0.634 . . . . 0.0 109.594 175.933 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 89' ' ' THR . . . . . 0.895 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 1.1 m -64.0 -45.28 89.69 Favored 'General case' 0 C--N 1.319 -0.758 0 CA-C-N 115.613 -0.721 . . . . 0.0 111.498 -176.136 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 90' ' ' ARG . . . . . 0.547 ' HA ' ' HZ3' ' A' ' 98' ' ' TRP . 5.0 ptt180 -69.29 -33.17 72.79 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.679 -175.559 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 91' ' ' LEU . . . . . 0.653 ' HG ' ' O ' ' A' ' 88' ' ' VAL . 4.6 pp -68.59 -24.46 64.6 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 121.368 0.604 . . . . 0.0 110.309 -173.4 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 92' ' ' ARG . . . . . 0.464 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 4.2 mtm180 -84.36 -43.87 14.32 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-O 122.14 0.972 . . . . 0.0 109.163 176.451 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 93' ' ' GLN . . . . . 0.595 ' OE1' HG22 ' A' ' 89' ' ' THR . 93.0 mt-30 -87.84 -28.23 21.75 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 113.746 -1.57 . . . . 0.0 114.329 -167.43 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 74.89 32.63 56.65 Favored Glycine 0 CA--C 1.51 -0.245 0 N-CA-C 111.858 -0.497 . . . . 0.0 111.858 179.894 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 95' ' ' TRP . . . . . 0.42 ' CH2' ' HB ' ' A' ' 30' ' ' ILE . 28.6 m95 67.05 5.02 3.86 Favored 'General case' 0 C--O 1.216 -0.678 0 C-N-CA 123.451 0.701 . . . . 0.0 110.082 -177.151 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -59.39 -43.8 97.12 Favored Glycine 0 CA--C 1.518 0.233 0 CA-C-N 116.125 -0.489 . . . . 0.0 113.327 -178.557 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -69.67 -21.15 63.54 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.826 0.346 . . . . 0.0 110.971 -179.371 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 98' ' ' TRP . . . . . 0.895 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 21.6 m-90 -90.31 108.93 29.97 Favored Pre-proline 0 N--CA 1.445 -0.681 0 N-CA-C 108.127 -1.064 . . . . 0.0 108.127 174.303 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 99' ' ' PRO . . . . . 0.436 ' HD3' ' HA ' ' A' ' 98' ' ' TRP . 46.9 Cg_exo -62.97 -138.89 0.0 OUTLIER 'Trans proline' 0 CA--C 1.533 0.44 0 C-N-CA 123.616 2.877 . . . . 0.0 114.45 -171.828 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 4.2 p -55.38 -25.92 18.1 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.195 0 CA-C-O 121.427 0.632 . . . . 0.0 110.759 -176.939 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 101' ' ' CYS . . . . . 0.444 ' SG ' ' HG2' ' A' ' 38' ' ' GLU . 39.9 m -55.98 -39.16 71.43 Favored 'General case' 0 C--N 1.317 -0.844 0 CA-C-N 114.896 -1.047 . . . . 0.0 111.427 177.703 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -70.86 -41.42 71.44 Favored 'General case' 0 CA--C 1.519 -0.219 0 CA-C-O 120.877 0.37 . . . . 0.0 110.722 179.609 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -64.34 -43.02 95.91 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 121.074 0.464 . . . . 0.0 110.274 178.171 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 60.1 mtp180 -62.92 -30.82 71.84 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 115.51 -0.768 . . . . 0.0 110.897 176.696 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 105' ' ' ALA . . . . . 0.622 ' HB1' ' HA ' ' A' ' 30' ' ' ILE . . . -85.23 -21.27 29.16 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.72 -0.673 . . . . 0.0 111.456 -177.966 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 106' ' ' GLY . . . . . 0.466 ' O ' ' HG2' ' A' ' 108' ' ' ARG . . . 102.55 67.71 0.78 Allowed Glycine 0 CA--C 1.52 0.393 0 CA-C-N 115.892 -0.595 . . . . 0.0 112.288 -178.636 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -57.54 147.63 26.32 Favored 'General case' 0 C--O 1.236 0.362 0 C-N-CA 122.895 0.478 . . . . 0.0 111.6 -177.609 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 108' ' ' ARG . . . . . 0.466 ' HG2' ' O ' ' A' ' 106' ' ' GLY . 3.6 ptp180 . . . . . 0 C--O 1.251 1.149 0 CA-C-O 118.496 -0.764 . . . . 0.0 110.582 -171.575 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 27' ' ' ASP . . . . . 0.555 ' O ' HG12 ' A' ' 30' ' ' ILE . 26.3 m-20 . . . . . 0 CA--C 1.5 -0.946 0 CA-C-O 121.744 0.783 . . . . 0.0 109.688 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 28' ' ' GLY . . . . . 0.585 ' HA3' HD13 ' A' ' 83' ' ' ILE . . . -72.36 -1.03 49.72 Favored Glycine 0 N--CA 1.434 -1.462 0 CA-C-N 114.596 -1.184 . . . . 0.0 111.091 178.403 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 14.9 m -73.8 -40.96 63.02 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-O 121.744 0.783 . . . . 0.0 109.293 175.089 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.555 HG12 ' O ' ' A' ' 27' ' ' ASP . 0.0 OUTLIER -70.99 -36.33 63.13 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.633 0 CA-C-N 114.548 -1.205 . . . . 0.0 107.78 177.218 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 31' ' ' TRP . . . . . 0.656 ' CD1' HG23 ' A' ' 83' ' ' ILE . 49.1 m95 -72.34 -35.96 68.7 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 114.781 -1.1 . . . . 0.0 111.075 -178.32 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.457 ' HB3' ' O ' ' A' ' 28' ' ' GLY . 0.0 OUTLIER -71.0 -35.88 72.24 Favored 'General case' 0 N--CA 1.45 -0.449 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.115 177.395 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 33' ' ' ALA . . . . . 0.416 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -70.38 -37.19 74.49 Favored 'General case' 0 N--CA 1.446 -0.65 0 C-N-CA 120.869 -0.332 . . . . 0.0 110.944 177.816 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 34' ' ' ILE . . . . . 0.515 HG13 ' O ' ' A' ' 30' ' ' ILE . 72.6 mt -67.04 -46.97 83.44 Favored 'Isoleucine or valine' 0 C--O 1.234 0.238 0 CA-C-O 121.036 0.446 . . . . 0.0 110.215 174.949 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -57.96 -38.31 75.77 Favored 'General case' 0 N--CA 1.451 -0.386 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.445 176.833 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -72.71 -13.31 78.29 Favored Glycine 0 N--CA 1.451 -0.352 0 CA-C-N 115.683 -0.689 . . . . 0.0 111.838 179.824 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 53.1 t -95.9 -59.09 1.93 Allowed 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.639 -0.28 . . . . 0.0 111.413 -177.092 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 38' ' ' GLU . . . . . 0.869 ' HG3' ' SG ' ' A' ' 101' ' ' CYS . 26.5 mt-10 -88.93 -22.95 22.84 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 120.651 0.263 . . . . 0.0 111.619 -173.536 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -106.26 -12.13 15.81 Favored 'General case' 0 N--CA 1.447 -0.58 0 C-N-CA 120.184 -0.607 . . . . 0.0 111.717 -179.208 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 77.99 15.98 80.45 Favored Glycine 0 CA--C 1.507 -0.459 0 N-CA-C 109.935 -1.266 . . . . 0.0 109.935 -176.861 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 73.07 57.03 5.43 Favored Glycine 0 N--CA 1.435 -1.416 0 CA-C-N 114.072 -1.064 . . . . 0.0 111.516 -175.334 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 2.6 t-20 -140.19 98.55 3.47 Favored 'General case' 0 N--CA 1.447 -0.609 0 N-CA-C 109.194 -0.669 . . . . 0.0 109.194 -177.713 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 43' ' ' TRP . . . . . 0.773 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 32.3 m95 -84.07 2.37 39.6 Favored 'General case' 0 C--N 1.319 -0.758 0 CA-C-N 115.485 -0.78 . . . . 0.0 109.973 -174.799 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -111.15 1.76 17.46 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-N 114.903 -1.044 . . . . 0.0 111.488 177.41 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.899 HG22 ' HA2' ' A' ' 53' ' ' GLY . 6.4 tt -66.91 143.91 15.13 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.677 0 CA-C-O 121.268 0.556 . . . . 0.0 110.358 -177.34 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 2.1 t30 -152.08 98.67 2.46 Favored 'General case' 0 C--N 1.309 -1.179 0 CA-C-O 121.234 0.54 . . . . 0.0 109.67 -178.49 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 21.1 p -75.38 -21.33 58.36 Favored 'General case' 0 C--N 1.317 -0.817 0 CA-C-N 115.362 -0.835 . . . . 0.0 110.292 179.259 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 91.04 18.53 46.46 Favored Glycine 0 N--CA 1.443 -0.848 0 CA-C-N 115.339 -0.846 . . . . 0.0 111.038 178.272 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 28.5 p-10 -95.44 4.47 53.26 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.891 0.377 . . . . 0.0 111.647 -174.407 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 50' ' ' GLY . . . . . 0.438 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 95.47 -8.22 68.96 Favored Glycine 0 N--CA 1.45 -0.424 0 C-N-CA 120.49 -0.862 . . . . 0.0 111.832 -178.055 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 51' ' ' TYR . . . . . 0.579 ' CE1' ' HB3' ' A' ' 58' ' ' ASP . 0.2 OUTLIER -112.89 144.65 42.08 Favored 'General case' 0 CA--C 1.511 -0.544 0 N-CA-C 106.826 -1.546 . . . . 0.0 106.826 176.131 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 52' ' ' TYR . . . . . 0.736 ' HB2' ' HB3' ' A' ' 74' ' ' ALA . 53.6 m-85 -117.38 169.05 9.8 Favored 'General case' 0 C--N 1.306 -1.307 0 N-CA-C 113.488 0.922 . . . . 0.0 113.488 -165.388 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.899 ' HA2' HG22 ' A' ' 45' ' ' ILE . . . -62.89 159.05 36.36 Favored Glycine 0 CA--C 1.501 -0.797 0 CA-C-N 114.845 -1.071 . . . . 0.0 114.018 -171.991 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 54' ' ' GLY . . . . . 0.583 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 101.72 -103.73 2.56 Favored Glycine 0 N--CA 1.437 -1.249 0 N-CA-C 111.402 -0.679 . . . . 0.0 111.402 -177.212 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.571 HG12 ' HE1' ' A' ' 98' ' ' TRP . 2.8 t -92.05 0.78 9.23 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 CA-C-O 121.652 0.739 . . . . 0.0 109.898 -178.61 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 56' ' ' GLN . . . . . 0.635 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 8.3 mm-40 59.51 50.37 7.55 Favored 'General case' 0 N--CA 1.464 0.269 0 CA-C-N 114.644 -1.162 . . . . 0.0 113.901 167.92 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 17.8 p90 -120.91 171.45 8.62 Favored 'General case' 0 C--N 1.325 -0.478 0 C-N-CA 119.833 -0.747 . . . . 0.0 112.092 175.112 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.579 ' HB3' ' CE1' ' A' ' 51' ' ' TYR . 6.4 p-10 -82.37 158.6 23.29 Favored 'General case' 0 CA--C 1.516 -0.356 0 N-CA-C 113.686 0.995 . . . . 0.0 113.686 -163.417 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 59' ' ' GLN . . . . . 0.429 ' HB2' ' CE2' ' A' ' 52' ' ' TYR . 20.6 tp60 -57.84 -39.79 78.53 Favored 'General case' 0 N--CA 1.442 -0.828 0 CA-C-N 113.279 -1.782 . . . . 0.0 111.714 179.229 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -67.47 -49.46 50.9 Favored Glycine 0 N--CA 1.45 -0.404 0 CA-C-N 115.603 -0.726 . . . . 0.0 112.034 -175.303 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 83.2 m -62.87 -41.05 99.25 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 121.252 0.548 . . . . 0.0 110.389 176.57 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 62' ' ' TRP . . . . . 0.424 ' CH2' ' HA ' ' A' ' 74' ' ' ALA . 54.1 t-105 -56.99 -50.1 73.74 Favored 'General case' 0 N--CA 1.444 -0.737 0 CA-C-N 115.265 -0.88 . . . . 0.0 109.687 176.734 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 63' ' ' GLU . . . . . 0.46 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 36.7 tt0 -67.1 -39.28 86.7 Favored 'General case' 0 N--CA 1.445 -0.683 0 CA-C-N 114.918 -1.037 . . . . 0.0 110.91 -178.183 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -62.11 -40.95 97.62 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.539 -0.755 . . . . 0.0 111.109 -176.682 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 9.3 m120 -82.3 -9.61 59.41 Favored 'General case' 0 N--CA 1.45 -0.461 0 CA-C-O 120.908 0.385 . . . . 0.0 110.768 178.521 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 93.23 47.57 3.03 Favored Glycine 0 C--N 1.333 0.373 0 CA-C-N 116.089 -0.505 . . . . 0.0 112.659 173.784 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 67' ' ' GLY . . . . . 0.592 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -80.2 -22.92 62.1 Favored Glycine 0 N--CA 1.44 -1.045 0 C-N-CA 120.966 -0.635 . . . . 0.0 112.868 -174.621 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.848 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 6.8 mp -61.51 -23.48 65.95 Favored 'General case' 0 N--CA 1.447 -0.595 0 N-CA-C 112.483 0.549 . . . . 0.0 112.483 -172.569 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 69' ' ' ARG . . . . . 0.428 ' HG3' ' N ' ' A' ' 70' ' ' TYR . 3.8 ptm180 -69.02 -30.96 69.44 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 121.19 0.519 . . . . 0.0 110.145 176.041 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 70' ' ' TYR . . . . . 0.792 ' HB3' ' HG3' ' A' ' 81' ' ' GLU . 79.5 m-85 -79.71 -34.8 39.78 Favored 'General case' 0 N--CA 1.446 -0.674 0 N-CA-C 107.679 -1.23 . . . . 0.0 107.679 177.144 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.696 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 161.57 128.73 0.01 OUTLIER Pre-proline 0 CA--C 1.509 -0.602 0 CA-C-N 112.609 -2.087 . . . . 0.0 106.689 -178.452 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 72' ' ' PRO . . . . . 0.848 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 32.3 Cg_exo -54.9 -6.68 0.7 Allowed 'Trans proline' 0 C--N 1.33 -0.416 0 C-N-CA 123.171 2.581 . . . . 0.0 114.246 -177.08 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 73' ' ' ARG . . . . . 0.402 ' HE ' ' CG ' ' A' ' 75' ' ' ASP . 12.4 ptm180 -149.59 142.77 25.06 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-O 121.095 0.474 . . . . 0.0 109.794 176.515 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 74' ' ' ALA . . . . . 0.736 ' HB3' ' HB2' ' A' ' 52' ' ' TYR . . . -61.06 -23.48 65.49 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.267 -0.879 . . . . 0.0 113.017 -175.159 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 75' ' ' ASP . . . . . 0.503 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 9.4 p-10 -88.21 -0.57 57.26 Favored 'General case' 0 C--N 1.33 -0.262 0 C-N-CA 120.544 -0.462 . . . . 0.0 110.905 -179.54 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.405 HD23 ' HD2' ' A' ' 72' ' ' PRO . 62.0 tp -103.75 -31.11 10.0 Favored 'General case' 0 C--N 1.323 -0.584 0 N-CA-C 109.026 -0.731 . . . . 0.0 109.026 172.641 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 77' ' ' ALA . . . . . 0.709 ' HB1' ' HB3' ' A' ' 81' ' ' GLU . . . -79.81 162.05 25.32 Favored 'General case' 0 N--CA 1.446 -0.631 0 CA-C-N 115.142 -0.935 . . . . 0.0 109.426 174.262 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 61.7 p -100.66 -175.0 2.78 Favored 'General case' 0 C--N 1.312 -1.046 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.874 -176.688 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 79' ' ' ARG . . . . . 0.773 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 11.9 mtp180 -50.92 -55.24 18.11 Favored 'General case' 0 C--O 1.222 -0.383 0 O-C-N 123.406 0.441 . . . . 0.0 110.594 179.518 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 11.3 pt-20 -61.76 -41.88 98.27 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 115.893 -0.594 . . . . 0.0 111.501 -174.326 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 81' ' ' GLU . . . . . 0.792 ' HG3' ' HB3' ' A' ' 70' ' ' TYR . 0.2 OUTLIER -64.2 -52.05 60.73 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 115.405 -0.816 . . . . 0.0 112.138 177.457 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 82' ' ' GLN . . . . . 0.571 ' HG2' HG23 ' A' ' 55' ' ' VAL . 5.7 tt0 -68.1 -31.34 70.89 Favored 'General case' 0 C--N 1.317 -0.805 0 CA-C-N 115.364 -0.835 . . . . 0.0 110.409 -176.759 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.656 HG23 ' CD1' ' A' ' 31' ' ' TRP . 25.0 mt -59.83 -44.54 94.33 Favored 'Isoleucine or valine' 0 C--O 1.216 -0.691 0 CA-C-N 115.471 -0.786 . . . . 0.0 109.563 173.524 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 84' ' ' ALA . . . . . 0.592 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -63.22 -40.64 98.04 Favored 'General case' 0 C--O 1.236 0.371 0 CA-C-O 121.352 0.596 . . . . 0.0 111.16 -175.632 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 44.2 t -69.02 -48.04 72.09 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 CA-C-N 115.685 -0.688 . . . . 0.0 110.919 177.758 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -57.05 -30.43 64.25 Favored 'General case' 0 N--CA 1.449 -0.48 0 CA-C-O 120.895 0.378 . . . . 0.0 110.401 172.796 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 87' ' ' GLU . . . . . 0.824 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 8.1 mm-40 -60.48 -44.58 95.78 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.196 -179.178 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 83.4 t -62.23 -44.91 99.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 C-N-CA 120.407 -0.517 . . . . 0.0 109.857 178.864 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 89' ' ' THR . . . . . 0.694 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 1.2 m -61.92 -47.78 83.4 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 115.504 -0.771 . . . . 0.0 111.478 -178.896 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 90' ' ' ARG . . . . . 0.738 ' HA ' ' OE1' ' A' ' 93' ' ' GLN . 2.5 ptt180 -62.02 -32.66 73.17 Favored 'General case' 0 CA--C 1.52 -0.176 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.361 -174.992 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 91' ' ' LEU . . . . . 0.824 ' HG ' ' O ' ' A' ' 87' ' ' GLU . 45.6 mt -61.06 -33.9 74.04 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-O 121.358 0.599 . . . . 0.0 110.529 -176.965 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 1.3 mtm180 -86.75 -45.36 11.01 Favored 'General case' 0 N--CA 1.443 -0.788 0 CA-C-N 115.221 -0.9 . . . . 0.0 110.589 -169.707 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 93' ' ' GLN . . . . . 0.738 ' OE1' ' HA ' ' A' ' 90' ' ' ARG . 0.0 OUTLIER -99.55 -21.32 15.95 Favored 'General case' 0 C--N 1.323 -0.572 0 N-CA-C 113.13 0.789 . . . . 0.0 113.13 -172.376 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 82.93 38.86 10.82 Favored Glycine 0 C--N 1.333 0.39 0 C-N-CA 120.926 -0.654 . . . . 0.0 112.523 171.441 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 95' ' ' TRP . . . . . 0.605 ' CZ2' ' HD3' ' A' ' 90' ' ' ARG . 20.7 m95 66.6 11.06 7.89 Favored 'General case' 0 C--O 1.221 -0.4 0 C-N-CA 123.445 0.698 . . . . 0.0 110.247 -179.212 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -68.7 -35.22 79.89 Favored Glycine 0 N--CA 1.453 -0.226 0 C-N-CA 121.236 -0.507 . . . . 0.0 112.352 176.817 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 97' ' ' ALA . . . . . 0.437 ' H ' ' CG ' ' A' ' 93' ' ' GLN . . . -66.85 -29.63 69.59 Favored 'General case' 0 CA--C 1.517 -0.294 0 CA-C-O 121.051 0.453 . . . . 0.0 110.577 178.857 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 98' ' ' TRP . . . . . 0.694 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 24.3 m-90 -92.72 108.41 31.57 Favored Pre-proline 0 N--CA 1.445 -0.722 0 N-CA-C 108.438 -0.949 . . . . 0.0 108.438 177.52 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 99' ' ' PRO . . . . . 0.429 ' HD3' ' O ' ' A' ' 97' ' ' ALA . 45.7 Cg_exo -63.08 -131.3 0.0 OUTLIER 'Trans proline' 0 CA--C 1.541 0.854 0 C-N-CA 123.492 2.794 . . . . 0.0 114.5 -175.06 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 39.2 t -55.65 -29.41 24.97 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.146 0 O-C-N 122.081 -0.387 . . . . 0.0 111.612 -174.662 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 101' ' ' CYS . . . . . 0.869 ' SG ' ' HG3' ' A' ' 38' ' ' GLU . 71.1 m -68.4 -31.97 71.69 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 116.56 -0.291 . . . . 0.0 111.604 -174.87 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 102' ' ' ALA . . . . . 0.556 ' HB2' ' CB ' ' A' ' 98' ' ' TRP . . . -70.36 -43.66 69.72 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.033 0.444 . . . . 0.0 110.335 176.185 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -62.08 -40.21 95.06 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.267 178.583 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 104' ' ' ARG . . . . . 0.625 ' NE ' ' HA ' ' A' ' 104' ' ' ARG . 1.9 mmp_? -69.16 -25.72 64.51 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.408 -0.814 . . . . 0.0 111.45 177.68 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 105' ' ' ALA . . . . . 0.416 ' CB ' ' HB3' ' A' ' 33' ' ' ALA . . . -83.38 -21.6 33.0 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.911 -177.477 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 105.38 47.75 1.11 Allowed Glycine 0 CA--C 1.521 0.456 0 C-N-CA 120.88 -0.676 . . . . 0.0 111.98 -176.599 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -57.74 149.45 22.06 Favored 'General case' 0 C--N 1.327 -0.395 0 C-N-CA 123.636 0.774 . . . . 0.0 112.23 -178.858 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 108' ' ' ARG . . . . . 0.447 ' HD3' ' O ' ' A' ' 108' ' ' ARG . 0.0 OUTLIER . . . . . 0 C--O 1.246 0.899 0 CA-C-N 115.771 -0.649 . . . . 0.0 110.373 -177.095 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 27' ' ' ASP . . . . . 0.487 ' O ' HG12 ' A' ' 30' ' ' ILE . 27.5 m-20 . . . . . 0 CA--C 1.507 -0.708 0 CA-C-O 121.41 0.624 . . . . 0.0 110.092 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -63.4 -12.19 44.34 Favored Glycine 0 CA--C 1.504 -0.614 0 CA-C-N 114.977 -1.01 . . . . 0.0 111.206 -177.726 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 19.3 m -76.24 -43.35 42.4 Favored 'General case' 0 C--N 1.317 -0.809 0 CA-C-O 121.914 0.864 . . . . 0.0 109.477 177.95 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.504 ' HA ' ' HB1' ' A' ' 105' ' ' ALA . 0.1 OUTLIER -68.9 -38.85 79.15 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.802 0 CA-C-N 114.178 -1.373 . . . . 0.0 107.871 179.775 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 31' ' ' TRP . . . . . 0.49 ' CD1' HG23 ' A' ' 83' ' ' ILE . 17.1 m95 -67.48 -36.96 82.14 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 114.735 -1.121 . . . . 0.0 110.511 -177.627 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 9.7 t70 -75.2 -38.86 60.57 Favored 'General case' 0 N--CA 1.444 -0.759 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.692 179.017 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 33' ' ' ALA . . . . . 0.451 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -70.82 -35.79 72.64 Favored 'General case' 0 N--CA 1.448 -0.548 0 C-N-CA 120.78 -0.368 . . . . 0.0 110.903 178.737 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 34' ' ' ILE . . . . . 0.486 HG13 ' O ' ' A' ' 30' ' ' ILE . 64.8 mt -62.33 -45.6 98.38 Favored 'Isoleucine or valine' 0 C--O 1.234 0.247 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 173.646 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 35' ' ' ALA . . . . . 0.56 ' HA ' ' O ' ' A' ' 54' ' ' GLY . . . -57.62 -38.52 75.1 Favored 'General case' 0 N--CA 1.451 -0.404 0 CA-C-N 115.506 -0.77 . . . . 0.0 110.056 176.734 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 36' ' ' GLY . . . . . 0.445 ' HA2' ' N ' ' A' ' 41' ' ' GLY . . . -73.6 -22.06 78.81 Favored Glycine 0 N--CA 1.451 -0.338 0 CA-C-N 115.467 -0.788 . . . . 0.0 111.944 -179.814 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 6.3 t -84.53 -56.65 3.5 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-O 120.831 0.348 . . . . 0.0 111.608 -178.704 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 38' ' ' GLU . . . . . 0.406 ' HB2' ' SG ' ' A' ' 101' ' ' CYS . 11.4 tp10 -87.61 -30.53 20.41 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 121.063 0.459 . . . . 0.0 110.511 -170.453 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -107.59 -8.01 16.31 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.956 -0.566 . . . . 0.0 111.871 -176.565 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 80.23 4.06 89.79 Favored Glycine 0 CA--C 1.507 -0.408 0 N-CA-C 110.239 -1.144 . . . . 0.0 110.239 -177.535 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 41' ' ' GLY . . . . . 0.445 ' N ' ' HA2' ' A' ' 36' ' ' GLY . . . 89.95 56.41 1.85 Allowed Glycine 0 N--CA 1.432 -1.568 0 CA-C-N 114.006 -1.097 . . . . 0.0 111.302 -175.986 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 2.4 t-20 -141.71 99.48 3.56 Favored 'General case' 0 N--CA 1.447 -0.596 0 N-CA-C 108.732 -0.84 . . . . 0.0 108.732 -175.655 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 43' ' ' TRP . . . . . 0.76 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 23.4 m95 -83.81 -4.33 58.57 Favored 'General case' 0 C--N 1.313 -1.005 0 CA-C-N 115.723 -0.672 . . . . 0.0 110.158 -173.39 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 44' ' ' ALA . . . . . 0.454 ' HA ' ' HB2' ' A' ' 75' ' ' ASP . . . -109.3 10.74 25.57 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 115.183 -0.917 . . . . 0.0 111.06 179.351 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.726 HG22 ' HA2' ' A' ' 53' ' ' GLY . 9.0 tt -76.09 144.57 11.71 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.792 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.31 179.892 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 10.3 t-20 -142.46 97.96 3.21 Favored 'General case' 0 C--N 1.31 -1.111 0 N-CA-C 108.995 -0.743 . . . . 0.0 108.995 177.393 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 10.0 p -70.08 -22.28 63.06 Favored 'General case' 0 N--CA 1.445 -0.715 0 CA-C-N 114.819 -1.082 . . . . 0.0 111.345 -173.753 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 90.39 17.2 53.66 Favored Glycine 0 N--CA 1.44 -1.066 0 N-CA-C 110.094 -1.202 . . . . 0.0 110.094 -176.773 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 5.1 m-20 -91.34 -5.91 53.85 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.169 -0.516 . . . . 0.0 111.01 -175.183 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 50' ' ' GLY . . . . . 0.407 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 94.25 -5.1 71.16 Favored Glycine 0 N--CA 1.444 -0.77 0 N-CA-C 110.081 -1.208 . . . . 0.0 110.081 -172.676 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 51' ' ' TYR . . . . . 0.623 ' HA ' ' HA ' ' A' ' 58' ' ' ASP . 0.4 OUTLIER -111.61 149.15 31.91 Favored 'General case' 0 N--CA 1.446 -0.664 0 N-CA-C 106.976 -1.491 . . . . 0.0 106.976 177.916 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 52' ' ' TYR . . . . . 0.699 ' O ' ' HA ' ' A' ' 56' ' ' GLN . 71.0 m-85 -114.59 170.37 8.36 Favored 'General case' 0 C--N 1.307 -1.245 0 C-N-CA 120.432 -0.507 . . . . 0.0 111.908 -168.655 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.726 ' HA2' HG22 ' A' ' 45' ' ' ILE . . . -57.94 171.91 3.45 Favored Glycine 0 C--O 1.227 -0.321 0 N-CA-C 115.072 0.789 . . . . 0.0 115.072 -168.919 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 54' ' ' GLY . . . . . 0.675 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 80.4 -101.76 2.02 Favored Glycine 0 N--CA 1.442 -0.924 0 C-N-CA 120.955 -0.641 . . . . 0.0 112.148 177.367 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.512 HG12 ' HE1' ' A' ' 98' ' ' TRP . 2.4 t -83.3 -3.04 7.13 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-O 121.646 0.736 . . . . 0.0 110.296 -176.68 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 56' ' ' GLN . . . . . 0.699 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 7.7 tp-100 54.83 50.47 15.6 Favored 'General case' 0 CA--C 1.53 0.186 0 CA-C-N 114.034 -1.439 . . . . 0.0 112.852 169.203 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 57' ' ' PHE . . . . . 0.496 ' CE1' ' HB ' ' A' ' 55' ' ' VAL . 2.0 p90 -121.54 163.32 19.05 Favored 'General case' 0 C--N 1.325 -0.474 0 C-N-CA 120.213 -0.595 . . . . 0.0 111.532 176.995 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.623 ' HA ' ' HA ' ' A' ' 51' ' ' TYR . 7.8 p-10 -72.29 162.3 29.65 Favored 'General case' 0 CA--C 1.514 -0.419 0 N-CA-C 113.76 1.022 . . . . 0.0 113.76 -163.511 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 59' ' ' GLN . . . . . 0.44 ' HB2' ' HE1' ' A' ' 52' ' ' TYR . 17.7 tp60 -55.15 -42.2 72.76 Favored 'General case' 0 N--CA 1.441 -0.878 0 CA-C-N 114.327 -1.306 . . . . 0.0 110.969 177.206 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -67.84 -50.44 41.63 Favored Glycine 0 C--O 1.224 -0.481 0 CA-C-N 115.183 -0.917 . . . . 0.0 112.584 -172.819 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 97.1 m -61.67 -41.46 97.57 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 121.177 0.513 . . . . 0.0 110.8 177.139 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 62' ' ' TRP . . . . . 0.439 ' CH2' ' HA ' ' A' ' 74' ' ' ALA . 52.4 t-105 -58.23 -49.11 78.23 Favored 'General case' 0 N--CA 1.446 -0.671 0 CA-C-N 115.467 -0.788 . . . . 0.0 109.691 175.786 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 63' ' ' GLU . . . . . 0.479 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 36.2 tt0 -67.13 -36.75 82.55 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.193 -0.912 . . . . 0.0 110.801 -178.205 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -63.53 -41.49 98.47 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.591 -0.731 . . . . 0.0 111.195 -176.882 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 65' ' ' ASN . . . . . 0.646 HD22 ' N ' ' A' ' 65' ' ' ASN . 0.7 OUTLIER -81.09 -8.74 59.83 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 121.1 0.476 . . . . 0.0 110.22 177.632 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 66' ' ' GLY . . . . . 0.47 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 89.35 48.6 3.71 Favored Glycine 0 C--N 1.334 0.433 0 CA-C-N 115.746 -0.661 . . . . 0.0 112.271 174.678 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 67' ' ' GLY . . . . . 0.484 ' HA2' ' HD1' ' A' ' 70' ' ' TYR . . . -79.36 -22.91 64.02 Favored Glycine 0 N--CA 1.439 -1.121 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.838 -175.051 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.79 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 6.9 mp -58.89 -25.95 63.84 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 112.893 0.701 . . . . 0.0 112.893 -172.945 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 69' ' ' ARG . . . . . 0.47 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 14.9 ptp180 -70.5 -29.24 65.7 Favored 'General case' 0 C--N 1.318 -0.772 0 CA-C-O 121.079 0.466 . . . . 0.0 110.553 176.643 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 70' ' ' TYR . . . . . 0.622 ' HB3' ' CG ' ' A' ' 81' ' ' GLU . 74.2 m-85 -79.32 -34.25 42.46 Favored 'General case' 0 N--CA 1.444 -0.749 0 N-CA-C 107.05 -1.463 . . . . 0.0 107.05 175.764 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.679 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 161.81 130.27 0.01 OUTLIER Pre-proline 0 CA--C 1.511 -0.524 0 CA-C-N 112.037 -2.347 . . . . 0.0 106.817 -179.117 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 72' ' ' PRO . . . . . 0.79 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 13.5 Cg_exo -58.33 -2.13 0.85 Allowed 'Trans proline' 0 C--N 1.33 -0.415 0 C-N-CA 122.837 2.358 . . . . 0.0 113.965 -177.083 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 73' ' ' ARG . . . . . 0.455 ' HB2' ' CD2' ' A' ' 52' ' ' TYR . 0.0 OUTLIER -153.3 142.56 21.52 Favored 'General case' 0 C--N 1.316 -0.85 0 N-CA-C 109.211 -0.663 . . . . 0.0 109.211 177.695 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 74' ' ' ALA . . . . . 0.509 ' HB3' ' HB2' ' A' ' 52' ' ' TYR . . . -60.2 -27.94 67.57 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.32 -0.855 . . . . 0.0 112.721 -175.464 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 75' ' ' ASP . . . . . 0.575 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 6.7 p-10 -86.87 3.2 46.44 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 121.246 0.546 . . . . 0.0 110.824 -176.6 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.525 ' HB3' ' HB1' ' A' ' 71' ' ' ALA . 50.7 tp -103.68 -34.12 8.72 Favored 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 171.155 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 77' ' ' ALA . . . . . 0.679 ' HB2' ' HB3' ' A' ' 71' ' ' ALA . . . -79.86 161.51 25.56 Favored 'General case' 0 N--CA 1.448 -0.568 0 CA-C-N 115.1 -0.955 . . . . 0.0 109.93 175.621 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 36.1 p -101.2 -173.19 2.31 Favored 'General case' 0 C--N 1.318 -0.796 0 C-N-CA 120.788 -0.365 . . . . 0.0 110.74 179.874 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 79' ' ' ARG . . . . . 0.76 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 9.0 mtp85 -52.59 -51.98 57.34 Favored 'General case' 0 CA--C 1.513 -0.46 0 O-C-N 123.592 0.558 . . . . 0.0 110.953 -174.789 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 1.3 pm0 -59.71 -41.67 91.34 Favored 'General case' 0 C--N 1.317 -0.836 0 CA-C-N 115.319 -0.855 . . . . 0.0 112.131 -176.504 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 81' ' ' GLU . . . . . 0.648 ' CB ' ' HB1' ' A' ' 77' ' ' ALA . 2.3 mp0 -62.26 -51.23 68.57 Favored 'General case' 0 C--O 1.234 0.254 0 O-C-N 122.352 -0.218 . . . . 0.0 111.322 174.377 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 82' ' ' GLN . . . . . 0.437 ' HB2' ' HZ3' ' A' ' 43' ' ' TRP . 50.3 mt-30 -60.9 -37.01 80.74 Favored 'General case' 0 CA--C 1.514 -0.413 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.66 -177.9 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.49 HG23 ' CD1' ' A' ' 31' ' ' TRP . 42.1 mt -59.28 -45.51 93.06 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.777 0 CA-C-N 115.139 -0.937 . . . . 0.0 109.801 176.742 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 84' ' ' ALA . . . . . 0.649 ' O ' ' HG3' ' A' ' 87' ' ' GLU . . . -66.35 -45.98 78.32 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.621 -177.908 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.424 HG23 ' O ' ' A' ' 81' ' ' GLU . 44.0 t -66.06 -49.01 79.61 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-O 120.779 0.323 . . . . 0.0 111.631 -179.926 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -67.02 -31.3 71.75 Favored 'General case' 0 CA--C 1.516 -0.359 0 CA-C-O 121.147 0.498 . . . . 0.0 110.498 -179.719 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 87' ' ' GLU . . . . . 0.768 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 0.1 OUTLIER -69.69 -31.5 69.58 Favored 'General case' 0 C--N 1.322 -0.604 0 C-N-CA 120.149 -0.62 . . . . 0.0 110.325 -176.455 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.584 ' O ' ' HG3' ' A' ' 92' ' ' ARG . 69.1 t -61.43 -40.77 87.47 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.224 0 N-CA-C 108.839 -0.8 . . . . 0.0 108.839 172.89 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 89' ' ' THR . . . . . 0.91 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 4.3 m -64.8 -43.32 93.54 Favored 'General case' 0 N--CA 1.447 -0.597 0 CA-C-N 115.648 -0.706 . . . . 0.0 110.388 179.367 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 90' ' ' ARG . . . . . 0.54 ' HG3' ' O ' ' A' ' 87' ' ' GLU . 1.2 ppt_? -61.53 -31.24 71.24 Favored 'General case' 0 C--O 1.223 -0.336 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.561 179.907 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 91' ' ' LEU . . . . . 0.768 ' HG ' ' O ' ' A' ' 87' ' ' GLU . 28.8 mt -64.07 -33.56 76.03 Favored 'General case' 0 C--N 1.318 -0.801 0 CA-C-O 121.63 0.729 . . . . 0.0 109.88 -179.872 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 92' ' ' ARG . . . . . 0.584 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 7.6 mtm180 -91.62 -51.58 5.18 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 115.058 -0.974 . . . . 0.0 110.618 -169.925 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 93' ' ' GLN . . . . . 0.574 HE22 ' HZ3' ' A' ' 98' ' ' TRP . 0.0 OUTLIER -106.49 -14.51 15.05 Favored 'General case' 0 N--CA 1.443 -0.786 0 CA-C-N 115.446 -0.797 . . . . 0.0 112.016 -175.293 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 94' ' ' GLY . . . . . 0.441 ' O ' ' HA ' ' A' ' 90' ' ' ARG . . . 86.74 -109.14 3.39 Favored Glycine 0 CA--C 1.496 -1.116 0 N-CA-C 110.797 -0.921 . . . . 0.0 110.797 178.813 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 95' ' ' TRP . . . . . 0.46 ' HB3' ' HB1' ' A' ' 102' ' ' ALA . 6.6 m95 -141.17 24.39 2.14 Favored 'General case' 0 C--N 1.311 -1.103 0 N-CA-C 107.207 -1.405 . . . . 0.0 107.207 -179.794 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -77.29 -20.76 74.57 Favored Glycine 0 N--CA 1.447 -0.594 0 CA-C-N 114.381 -1.281 . . . . 0.0 111.831 175.616 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 97' ' ' ALA . . . . . 0.426 ' O ' ' HD3' ' A' ' 99' ' ' PRO . . . -90.35 -24.04 20.95 Favored 'General case' 0 CA--C 1.516 -0.364 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 176.248 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 98' ' ' TRP . . . . . 0.91 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 24.3 m-90 -96.59 104.69 18.88 Favored Pre-proline 0 N--CA 1.451 -0.42 0 N-CA-C 108.811 -0.811 . . . . 0.0 108.811 173.643 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 99' ' ' PRO . . . . . 0.503 ' HB2' ' H ' ' A' ' 100' ' ' VAL . 28.9 Cg_exo -67.34 -110.1 0.0 OUTLIER 'Trans proline' 0 CA--C 1.538 0.719 0 C-N-CA 123.49 2.793 . . . . 0.0 114.757 -171.826 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 100' ' ' VAL . . . . . 0.503 ' H ' ' HB2' ' A' ' 99' ' ' PRO . 40.8 t -67.41 -31.5 53.09 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-O 121.305 0.574 . . . . 0.0 110.432 -174.506 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 101' ' ' CYS . . . . . 0.406 ' SG ' ' HB2' ' A' ' 38' ' ' GLU . 98.5 m -68.71 -32.78 72.82 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 115.28 -0.873 . . . . 0.0 111.92 -171.82 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 102' ' ' ALA . . . . . 0.46 ' HB1' ' HB3' ' A' ' 95' ' ' TRP . . . -69.65 -44.63 70.16 Favored 'General case' 0 C--N 1.324 -0.513 0 C-N-CA 120.651 -0.419 . . . . 0.0 110.202 178.822 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -65.66 -34.28 77.85 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 121.172 0.511 . . . . 0.0 110.406 178.5 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 104' ' ' ARG . . . . . 0.494 ' HG2' ' O ' ' A' ' 100' ' ' VAL . 3.4 mmp_? -70.3 -28.5 65.23 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.129 176.544 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 105' ' ' ALA . . . . . 0.504 ' HB1' ' HA ' ' A' ' 30' ' ' ILE . . . -89.43 -20.82 23.46 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.808 -0.633 . . . . 0.0 112.114 -175.549 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 110.4 64.35 0.52 Allowed Glycine 0 N--CA 1.447 -0.61 0 C-N-CA 120.95 -0.643 . . . . 0.0 111.681 -177.155 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -63.53 149.25 46.67 Favored 'General case' 0 C--N 1.328 -0.337 0 C-N-CA 122.848 0.459 . . . . 0.0 110.824 -176.823 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 108' ' ' ARG . . . . . 0.416 ' CZ ' HD11 ' A' ' 30' ' ' ILE . 91.2 mtt180 . . . . . 0 C--O 1.247 0.944 0 CA-C-O 118.368 -0.825 . . . . 0.0 109.756 -173.016 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 27' ' ' ASP . . . . . 0.4 ' O ' HG12 ' A' ' 30' ' ' ILE . 4.3 m-20 . . . . . 0 CA--C 1.507 -0.679 0 CA-C-O 121.742 0.782 . . . . 0.0 109.605 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -65.84 -9.54 46.57 Favored Glycine 0 N--CA 1.441 -0.969 0 CA-C-N 114.868 -1.06 . . . . 0.0 110.721 177.381 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 21.8 m -76.93 -41.5 43.16 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-O 121.571 0.7 . . . . 0.0 109.387 175.181 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.553 ' HA ' ' HB1' ' A' ' 105' ' ' ALA . 0.8 OUTLIER -66.68 -38.81 82.34 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.64 0 N-CA-C 107.645 -1.243 . . . . 0.0 107.645 177.223 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 31' ' ' TRP . . . . . 0.485 ' CD1' HG23 ' A' ' 83' ' ' ILE . 36.8 m95 -70.91 -35.75 72.42 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 114.627 -1.169 . . . . 0.0 110.894 -177.922 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.442 ' HB2' HH21 ' A' ' 79' ' ' ARG . 1.9 t70 -72.53 -36.76 68.4 Favored 'General case' 0 N--CA 1.449 -0.509 0 CA-C-N 116.387 -0.37 . . . . 0.0 110.338 177.771 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 33' ' ' ALA . . . . . 0.489 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -70.19 -35.36 73.9 Favored 'General case' 0 N--CA 1.448 -0.552 0 C-N-CA 120.627 -0.429 . . . . 0.0 110.392 177.96 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 34' ' ' ILE . . . . . 0.44 HG13 ' O ' ' A' ' 30' ' ' ILE . 64.5 mt -67.13 -43.54 88.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.312 174.05 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 35' ' ' ALA . . . . . 0.521 ' HA ' ' O ' ' A' ' 54' ' ' GLY . . . -59.59 -35.02 73.47 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 121.313 0.578 . . . . 0.0 110.15 175.973 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 36' ' ' GLY . . . . . 0.422 ' HA2' ' N ' ' A' ' 41' ' ' GLY . . . -77.62 -14.97 81.88 Favored Glycine 0 N--CA 1.448 -0.564 0 CA-C-N 115.497 -0.774 . . . . 0.0 111.873 178.409 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 36.8 t -95.92 -48.01 5.89 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-O 120.737 0.303 . . . . 0.0 111.387 -177.032 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 38' ' ' GLU . . . . . 0.481 ' HG2' ' SG ' ' A' ' 101' ' ' CYS . 8.5 mm-40 -86.91 -34.2 19.46 Favored 'General case' 0 CA--C 1.511 -0.541 0 CA-C-O 121.077 0.465 . . . . 0.0 110.17 -175.538 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -107.94 -12.47 15.16 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.613 -0.721 . . . . 0.0 112.064 -174.089 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 76.31 16.65 80.55 Favored Glycine 0 N--CA 1.449 -0.461 0 N-CA-C 109.957 -1.257 . . . . 0.0 109.957 -176.767 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 41' ' ' GLY . . . . . 0.422 ' N ' ' HA2' ' A' ' 36' ' ' GLY . . . 82.98 59.91 2.12 Favored Glycine 0 N--CA 1.434 -1.475 0 CA-C-N 113.944 -1.128 . . . . 0.0 111.807 -176.904 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 42' ' ' ASN . . . . . 0.849 ' HB3' ' HB ' ' A' ' 45' ' ' ILE . 3.4 m120 -146.1 96.02 2.72 Favored 'General case' 0 C--N 1.324 -0.515 0 N-CA-C 109.223 -0.658 . . . . 0.0 109.223 -178.893 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 43' ' ' TRP . . . . . 0.695 ' CE2' ' HG2' ' A' ' 79' ' ' ARG . 52.5 m95 -78.88 -14.39 59.26 Favored 'General case' 0 C--N 1.314 -0.975 0 CA-C-N 115.711 -0.677 . . . . 0.0 109.803 -177.941 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 44' ' ' ALA . . . . . 0.414 ' HA ' ' HB2' ' A' ' 75' ' ' ASP . . . -102.48 7.97 40.12 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 115.271 -0.877 . . . . 0.0 111.289 -179.692 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.849 ' HB ' ' HB3' ' A' ' 42' ' ' ASN . 8.2 tt -74.18 145.16 11.62 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.708 0 CA-C-O 121.401 0.619 . . . . 0.0 110.984 -177.182 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 17.4 t-20 -141.5 96.19 2.94 Favored 'General case' 0 C--N 1.309 -1.183 0 N-CA-C 109.099 -0.704 . . . . 0.0 109.099 178.953 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 19.7 p -68.61 -21.3 64.51 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 115.029 -0.987 . . . . 0.0 111.058 -177.486 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 88.06 18.22 56.27 Favored Glycine 0 N--CA 1.441 -1.001 0 N-CA-C 110.373 -1.091 . . . . 0.0 110.373 179.44 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 92.2 m-20 -97.37 10.23 40.2 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 121.092 0.472 . . . . 0.0 111.347 -174.621 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 50' ' ' GLY . . . . . 0.406 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 90.96 -11.6 71.59 Favored Glycine 0 N--CA 1.443 -0.842 0 N-CA-C 110.853 -0.899 . . . . 0.0 110.853 -178.003 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 51' ' ' TYR . . . . . 0.634 ' HA ' ' HA ' ' A' ' 58' ' ' ASP . 0.7 OUTLIER -109.58 152.36 25.61 Favored 'General case' 0 CA--C 1.509 -0.624 0 N-CA-C 108.092 -1.077 . . . . 0.0 108.092 178.026 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 52' ' ' TYR . . . . . 0.78 ' O ' ' HA ' ' A' ' 56' ' ' GLN . 18.4 m-85 -112.81 169.93 8.56 Favored 'General case' 0 C--N 1.31 -1.12 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.698 -169.763 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.441 ' CA ' HG22 ' A' ' 45' ' ' ILE . . . -66.08 -171.79 4.07 Favored Glycine 0 N--CA 1.451 -0.361 0 N-CA-C 115.025 0.77 . . . . 0.0 115.025 -168.353 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 54' ' ' GLY . . . . . 0.639 ' CA ' ' HA ' ' A' ' 43' ' ' TRP . . . 75.27 -101.97 1.42 Allowed Glycine 0 N--CA 1.443 -0.847 0 CA-C-N 114.738 -0.731 . . . . 0.0 112.177 178.475 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.551 HG12 ' HE1' ' A' ' 98' ' ' TRP . 2.3 t -84.3 -3.54 7.95 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 CA-C-O 121.606 0.717 . . . . 0.0 109.541 179.409 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 56' ' ' GLN . . . . . 0.78 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 15.9 mm-40 57.93 46.83 16.04 Favored 'General case' 0 N--CA 1.463 0.179 0 CA-C-N 114.432 -1.258 . . . . 0.0 113.556 170.256 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 57' ' ' PHE . . . . . 0.507 ' CE1' ' HB ' ' A' ' 55' ' ' VAL . 0.3 OUTLIER -117.15 166.61 12.03 Favored 'General case' 0 C--N 1.323 -0.581 0 C-N-CA 119.597 -0.841 . . . . 0.0 111.956 175.069 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.634 ' HA ' ' HA ' ' A' ' 51' ' ' TYR . 7.2 p-10 -74.8 162.89 28.25 Favored 'General case' 0 CA--C 1.514 -0.411 0 CA-C-N 115.444 -0.798 . . . . 0.0 113.071 -167.055 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 59' ' ' GLN . . . . . 0.531 ' HB2' ' CE1' ' A' ' 52' ' ' TYR . 4.5 tp-100 -63.06 -35.36 79.99 Favored 'General case' 0 N--CA 1.448 -0.567 0 CA-C-N 114.318 -1.31 . . . . 0.0 111.069 179.623 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -65.15 -49.69 60.75 Favored Glycine 0 C--N 1.312 -0.756 0 CA-C-N 115.368 -0.833 . . . . 0.0 111.437 -178.067 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 91.5 m -65.9 -42.6 90.01 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-O 120.757 0.313 . . . . 0.0 110.986 176.375 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 62' ' ' TRP . . . . . 0.464 ' CH2' ' HA ' ' A' ' 74' ' ' ALA . 60.3 t-105 -56.26 -47.72 77.98 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 121.549 0.69 . . . . 0.0 109.656 177.353 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 5.1 tp10 -66.13 -34.78 78.83 Favored 'General case' 0 C--N 1.318 -0.802 0 CA-C-N 114.818 -1.083 . . . . 0.0 110.505 179.002 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -63.58 -42.54 98.29 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.17 -177.439 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 65' ' ' ASN . . . . . 0.73 ' HB2' HG13 ' A' ' 85' ' ' VAL . 27.4 m-80 -81.09 -9.99 59.74 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.927 0.394 . . . . 0.0 110.313 176.872 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 66' ' ' GLY . . . . . 0.472 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 87.69 51.83 3.15 Favored Glycine 0 C--O 1.225 -0.447 0 CA-C-N 115.888 -0.596 . . . . 0.0 112.429 175.357 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 67' ' ' GLY . . . . . 0.581 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -80.14 -23.77 60.68 Favored Glycine 0 N--CA 1.442 -0.956 0 C-N-CA 120.946 -0.645 . . . . 0.0 112.666 -176.604 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 1.033 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 7.2 mp -61.25 -17.66 54.48 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 112.877 0.695 . . . . 0.0 112.877 -172.751 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 69' ' ' ARG . . . . . 0.472 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 17.5 ptp180 -70.59 -34.75 72.5 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-O 121.154 0.502 . . . . 0.0 109.775 174.724 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 70' ' ' TYR . . . . . 0.661 ' HB3' ' HB3' ' A' ' 81' ' ' GLU . 54.1 m-85 -80.94 -34.59 33.18 Favored 'General case' 0 N--CA 1.444 -0.77 0 N-CA-C 107.551 -1.278 . . . . 0.0 107.551 179.221 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.609 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 166.32 127.14 0.03 OUTLIER Pre-proline 0 N--CA 1.445 -0.722 0 CA-C-N 112.755 -2.02 . . . . 0.0 106.995 -178.096 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 72' ' ' PRO . . . . . 1.033 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 24.4 Cg_exo -55.91 -7.18 1.49 Allowed 'Trans proline' 0 C--N 1.334 -0.227 0 C-N-CA 122.958 2.439 . . . . 0.0 113.821 -177.68 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 73' ' ' ARG . . . . . 0.504 ' HB2' ' CD2' ' A' ' 52' ' ' TYR . 11.4 ptm180 -144.58 137.12 26.53 Favored 'General case' 0 C--N 1.314 -0.935 0 N-CA-C 108.987 -0.746 . . . . 0.0 108.987 178.059 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 74' ' ' ALA . . . . . 0.517 ' HB3' ' HB2' ' A' ' 52' ' ' TYR . . . -55.78 -31.45 62.63 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 114.935 -1.029 . . . . 0.0 112.614 -175.993 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 75' ' ' ASP . . . . . 0.639 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 6.4 p-10 -81.2 -10.02 59.69 Favored 'General case' 0 C--N 1.328 -0.34 0 C-N-CA 120.426 -0.51 . . . . 0.0 111.312 -174.443 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 67.9 tp -93.94 -27.7 16.22 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-O 121.798 0.808 . . . . 0.0 108.921 172.801 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 77' ' ' ALA . . . . . 0.779 ' HB1' ' HB2' ' A' ' 81' ' ' GLU . . . -79.16 159.38 27.44 Favored 'General case' 0 N--CA 1.441 -0.909 0 CA-C-N 114.723 -1.126 . . . . 0.0 109.863 174.779 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 70.6 p -100.91 -174.59 2.66 Favored 'General case' 0 C--N 1.313 -0.983 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.932 -176.818 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 79' ' ' ARG . . . . . 0.695 ' HG2' ' CE2' ' A' ' 43' ' ' TRP . 77.0 mtp180 -51.02 -53.53 32.65 Favored 'General case' 0 CA--C 1.514 -0.419 0 CA-C-O 120.893 0.378 . . . . 0.0 110.702 -178.675 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 1.7 pm0 -63.18 -36.11 82.53 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-N 115.463 -0.789 . . . . 0.0 111.804 -175.016 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 81' ' ' GLU . . . . . 0.779 ' HB2' ' HB1' ' A' ' 77' ' ' ALA . 3.5 mm-40 -66.75 -50.7 61.88 Favored 'General case' 0 CA--C 1.516 -0.356 0 CA-C-O 121.041 0.448 . . . . 0.0 110.104 178.827 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 82' ' ' GLN . . . . . 0.586 ' HB2' ' HZ3' ' A' ' 43' ' ' TRP . 48.0 mt-30 -64.68 -35.81 82.23 Favored 'General case' 0 CA--C 1.511 -0.541 0 CA-C-N 115.685 -0.688 . . . . 0.0 110.062 -178.452 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.667 ' O ' ' HG2' ' A' ' 87' ' ' GLU . 53.1 mt -59.23 -48.87 85.44 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.812 0 CA-C-N 115.45 -0.796 . . . . 0.0 109.265 174.199 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 84' ' ' ALA . . . . . 0.538 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -61.51 -42.24 98.52 Favored 'General case' 0 C--O 1.239 0.517 0 CA-C-O 121.083 0.468 . . . . 0.0 111.615 -177.682 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.73 HG13 ' HB2' ' A' ' 65' ' ' ASN . 69.5 t -67.85 -48.5 75.17 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.85 179.494 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 86' ' ' ALA . . . . . 0.435 ' HB1' ' CH2' ' A' ' 31' ' ' TRP . . . -60.74 -29.12 69.19 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.543 174.594 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 87' ' ' GLU . . . . . 0.667 ' HG2' ' O ' ' A' ' 83' ' ' ILE . 14.8 mm-40 -59.75 -44.31 93.87 Favored 'General case' 0 N--CA 1.469 0.477 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.494 -179.797 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.573 ' O ' ' HG3' ' A' ' 92' ' ' ARG . 61.7 t -62.94 -40.49 89.12 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.44 0 N-CA-C 109.712 -0.477 . . . . 0.0 109.712 176.641 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 89' ' ' THR . . . . . 0.859 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 1.0 OUTLIER -70.03 -48.9 56.1 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.958 -0.565 . . . . 0.0 111.484 -175.89 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 90' ' ' ARG . . . . . 0.625 ' HA ' ' OE1' ' A' ' 93' ' ' GLN . 2.3 ptt180 -60.86 -33.63 73.38 Favored 'General case' 0 CA--C 1.519 -0.24 0 CA-C-N 116.025 -0.534 . . . . 0.0 111.638 -173.539 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 91' ' ' LEU . . . . . 0.571 ' HG ' ' O ' ' A' ' 88' ' ' VAL . 4.7 pp -71.42 -21.84 61.93 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.588 -175.188 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 92' ' ' ARG . . . . . 0.573 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 22.0 mtm180 -88.02 -52.39 5.28 Favored 'General case' 0 CA--C 1.509 -0.615 0 CA-C-O 121.247 0.546 . . . . 0.0 110.689 -175.8 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 93' ' ' GLN . . . . . 0.625 ' OE1' ' HA ' ' A' ' 90' ' ' ARG . 0.0 OUTLIER -95.3 -21.83 18.16 Favored 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 113.048 0.758 . . . . 0.0 113.048 -171.356 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 88.1 42.34 5.97 Favored Glycine 0 CA--C 1.506 -0.492 0 C-N-CA 120.488 -0.863 . . . . 0.0 111.97 172.251 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 95' ' ' TRP . . . . . 0.417 ' HA ' ' HE3' ' A' ' 98' ' ' TRP . 6.7 m95 62.7 12.15 5.4 Favored 'General case' 0 C--O 1.22 -0.489 0 C-N-CA 123.587 0.755 . . . . 0.0 109.801 -179.347 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -74.14 -20.0 79.73 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 121.172 -0.537 . . . . 0.0 112.458 179.46 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -78.58 -27.23 45.68 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 121.157 0.503 . . . . 0.0 109.872 176.628 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 98' ' ' TRP . . . . . 0.859 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 27.0 m-90 -101.04 103.65 26.9 Favored Pre-proline 0 C--N 1.324 -0.53 0 N-CA-C 108.86 -0.793 . . . . 0.0 108.86 176.399 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 99' ' ' PRO . . . . . 0.404 ' HB2' ' H ' ' A' ' 100' ' ' VAL . 14.7 Cg_exo -74.77 -88.54 0.0 OUTLIER 'Trans proline' 0 CA--C 1.53 0.28 0 C-N-CA 123.034 2.489 . . . . 0.0 114.872 -170.894 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 100' ' ' VAL . . . . . 0.404 ' H ' ' HB2' ' A' ' 99' ' ' PRO . 61.1 t -70.59 -29.91 40.29 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 CA-C-O 121.555 0.693 . . . . 0.0 110.565 -171.966 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 101' ' ' CYS . . . . . 0.481 ' SG ' ' HG2' ' A' ' 38' ' ' GLU . 85.0 m -83.29 -32.48 26.33 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-N 115.14 -0.936 . . . . 0.0 112.021 -169.012 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -68.11 -43.01 79.42 Favored 'General case' 0 C--N 1.327 -0.393 0 C-N-CA 120.47 -0.492 . . . . 0.0 110.098 177.493 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -60.58 -36.12 77.74 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 121.194 0.521 . . . . 0.0 110.739 177.515 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 35.5 mtp180 -73.03 -38.83 66.41 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.702 -0.681 . . . . 0.0 111.183 177.379 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 105' ' ' ALA . . . . . 0.553 ' HB1' ' HA ' ' A' ' 30' ' ' ILE . . . -80.79 -22.42 40.1 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 115.632 -0.713 . . . . 0.0 112.567 -173.69 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 116.57 62.44 0.33 Allowed Glycine 0 CA--C 1.521 0.415 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.31 -178.623 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -63.25 149.46 45.51 Favored 'General case' 0 C--N 1.328 -0.337 0 C-N-CA 122.927 0.491 . . . . 0.0 110.748 179.417 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 72.0 mtp180 . . . . . 0 C--O 1.247 0.937 0 CA-C-O 118.247 -0.882 . . . . 0.0 111.089 -170.546 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 27' ' ' ASP . . . . . 0.586 ' O ' HG12 ' A' ' 30' ' ' ILE . 6.2 m-20 . . . . . 0 CA--C 1.499 -1.006 0 CA-C-O 121.909 0.861 . . . . 0.0 110.057 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 28' ' ' GLY . . . . . 0.576 ' HA2' ' HB2' ' A' ' 31' ' ' TRP . . . -72.52 0.94 39.28 Favored Glycine 0 N--CA 1.436 -1.319 0 CA-C-N 114.464 -1.244 . . . . 0.0 111.053 178.77 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 13.8 m -76.41 -39.13 54.45 Favored 'General case' 0 C--N 1.32 -0.716 0 N-CA-C 108.892 -0.781 . . . . 0.0 108.892 173.458 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.586 HG12 ' O ' ' A' ' 27' ' ' ASP . 0.2 OUTLIER -71.99 -39.1 66.01 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 CA-C-N 114.327 -1.306 . . . . 0.0 107.527 176.317 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 31' ' ' TRP . . . . . 0.576 ' HB2' ' HA2' ' A' ' 28' ' ' GLY . 22.9 m95 -70.69 -35.56 72.84 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-N 114.483 -1.235 . . . . 0.0 110.333 -176.443 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.73 ' HB2' HH21 ' A' ' 79' ' ' ARG . 7.0 t70 -76.87 -32.24 57.34 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.458 179.7 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -70.45 -37.73 74.36 Favored 'General case' 0 N--CA 1.447 -0.601 0 C-N-CA 120.729 -0.388 . . . . 0.0 110.27 175.051 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 34' ' ' ILE . . . . . 0.47 HG13 ' O ' ' A' ' 30' ' ' ILE . 62.0 mt -64.89 -44.4 96.22 Favored 'Isoleucine or valine' 0 C--O 1.235 0.293 0 CA-C-O 120.954 0.407 . . . . 0.0 110.324 174.535 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 35' ' ' ALA . . . . . 0.498 ' O ' ' HB3' ' A' ' 39' ' ' ALA . . . -57.84 -39.25 77.27 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.236 0.541 . . . . 0.0 110.032 175.127 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -74.07 -9.01 79.85 Favored Glycine 0 N--CA 1.452 -0.299 0 CA-C-N 115.568 -0.742 . . . . 0.0 111.761 179.736 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 44.8 t -97.22 -62.85 1.19 Allowed 'General case' 0 N--CA 1.446 -0.648 0 CA-C-N 115.554 -0.323 . . . . 0.0 111.077 -178.068 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 38' ' ' GLU . . . . . 0.879 ' HG3' ' SG ' ' A' ' 101' ' ' CYS . 27.3 mt-10 -89.36 -27.32 20.56 Favored 'General case' 0 C--N 1.328 -0.357 0 N-CA-C 111.778 0.288 . . . . 0.0 111.778 -174.181 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 39' ' ' ALA . . . . . 0.498 ' HB3' ' O ' ' A' ' 35' ' ' ALA . . . -95.14 -17.11 22.08 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 121.015 0.435 . . . . 0.0 112.021 -176.457 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 81.54 14.05 78.99 Favored Glycine 0 N--CA 1.447 -0.599 0 N-CA-C 109.709 -1.357 . . . . 0.0 109.709 -174.622 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 77.52 57.2 3.66 Favored Glycine 0 N--CA 1.438 -1.203 0 CA-C-N 114.236 -0.982 . . . . 0.0 112.656 179.874 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 55.9 t30 -150.73 127.5 10.96 Favored 'General case' 0 CA--C 1.503 -0.853 0 N-CA-C 109.201 -0.666 . . . . 0.0 109.201 178.19 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 43' ' ' TRP . . . . . 0.763 ' HA ' ' N ' ' A' ' 54' ' ' GLY . 26.2 m95 -100.28 -2.02 34.79 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-N 115.437 -0.801 . . . . 0.0 110.099 -174.167 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -112.19 8.77 19.98 Favored 'General case' 0 C--N 1.318 -0.772 0 CA-C-N 115.052 -0.977 . . . . 0.0 111.021 178.574 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.611 HG22 ' HA2' ' A' ' 53' ' ' GLY . 12.5 tt -74.3 143.89 13.01 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.76 0 CA-C-O 120.988 0.423 . . . . 0.0 110.176 -178.784 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 13.3 t-20 -149.63 85.21 1.43 Allowed 'General case' 0 C--N 1.314 -0.939 0 CA-C-O 121.299 0.571 . . . . 0.0 110.302 -177.793 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -69.89 -20.03 63.4 Favored 'General case' 0 N--CA 1.445 -0.7 0 CA-C-N 115.476 -0.784 . . . . 0.0 111.058 177.88 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 92.05 21.56 32.74 Favored Glycine 0 N--CA 1.444 -0.795 0 C-N-CA 120.909 -0.662 . . . . 0.0 111.698 174.578 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 4.2 p-10 -94.97 14.38 21.91 Favored 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 112.082 0.401 . . . . 0.0 112.082 -175.275 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 50' ' ' GLY . . . . . 0.507 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 92.39 -13.92 66.01 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 121.32 -0.467 . . . . 0.0 112.171 176.5 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 51' ' ' TYR . . . . . 0.628 ' CE1' ' HB2' ' A' ' 58' ' ' ASP . 0.3 OUTLIER -110.0 155.29 22.0 Favored 'General case' 0 C--N 1.323 -0.546 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 173.505 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 52' ' ' TYR . . . . . 0.726 ' O ' ' HA ' ' A' ' 56' ' ' GLN . 63.5 m-85 -119.38 171.05 8.6 Favored 'General case' 0 C--N 1.312 -1.06 0 N-CA-C 112.657 0.614 . . . . 0.0 112.657 -168.467 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.611 ' HA2' HG22 ' A' ' 45' ' ' ILE . . . -53.87 163.19 3.07 Favored Glycine 0 N--CA 1.449 -0.44 0 CA-C-N 115.356 -0.838 . . . . 0.0 114.09 -175.527 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 54' ' ' GLY . . . . . 0.763 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 90.27 -109.51 3.66 Favored Glycine 0 N--CA 1.442 -0.921 0 C-N-CA 121.05 -0.595 . . . . 0.0 112.397 178.738 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.506 HG12 ' HE1' ' A' ' 98' ' ' TRP . 2.5 t -83.63 0.7 4.58 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-O 121.968 0.89 . . . . 0.0 109.784 -177.065 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 56' ' ' GLN . . . . . 0.726 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 2.3 tt0 53.97 50.18 17.32 Favored 'General case' 0 N--CA 1.449 -0.495 0 CA-C-N 113.826 -1.534 . . . . 0.0 112.729 170.679 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 57' ' ' PHE . . . . . 0.445 ' CD1' ' HB ' ' A' ' 55' ' ' VAL . 2.5 p90 -119.04 166.63 12.65 Favored 'General case' 0 C--N 1.323 -0.564 0 C-N-CA 119.304 -0.958 . . . . 0.0 111.914 174.837 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.628 ' HB2' ' CE1' ' A' ' 51' ' ' TYR . 0.0 OUTLIER -75.75 157.46 33.49 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 114.32 -1.309 . . . . 0.0 113.777 -162.071 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 59' ' ' GLN . . . . . 0.492 ' HB2' ' HE1' ' A' ' 52' ' ' TYR . 22.1 tp60 -53.34 -44.25 68.33 Favored 'General case' 0 N--CA 1.441 -0.9 0 CA-C-N 114.171 -1.377 . . . . 0.0 111.463 179.243 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -68.49 -49.05 47.16 Favored Glycine 0 C--O 1.22 -0.735 0 CA-C-N 115.325 -0.852 . . . . 0.0 112.396 -176.106 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 46.3 m -60.77 -40.61 93.15 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-O 121.552 0.691 . . . . 0.0 110.519 179.098 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 62' ' ' TRP . . . . . 0.484 ' CZ3' ' HA ' ' A' ' 82' ' ' GLN . 50.6 t-105 -61.98 -48.86 78.45 Favored 'General case' 0 C--N 1.318 -0.794 0 CA-C-N 114.845 -1.071 . . . . 0.0 109.863 175.279 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 63' ' ' GLU . . . . . 0.599 ' HB2' HD11 ' A' ' 68' ' ' LEU . 0.0 OUTLIER -67.97 -36.39 79.97 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.733 -0.667 . . . . 0.0 110.353 -176.801 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 64' ' ' ALA . . . . . 0.48 ' N ' ' HG3' ' A' ' 63' ' ' GLU . . . -66.16 -41.05 90.89 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.433 -0.803 . . . . 0.0 111.28 -175.972 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 65' ' ' ASN . . . . . 0.459 ' HB3' ' HB ' ' A' ' 88' ' ' VAL . 17.3 m120 -84.09 -3.61 58.2 Favored 'General case' 0 N--CA 1.446 -0.669 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.61 176.906 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 66' ' ' GLY . . . . . 0.497 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 85.74 46.92 5.27 Favored Glycine 0 N--CA 1.448 -0.532 0 CA-C-N 115.573 -0.74 . . . . 0.0 113.107 171.11 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 67' ' ' GLY . . . . . 0.627 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -80.28 -16.46 76.23 Favored Glycine 0 N--CA 1.443 -0.899 0 C-N-CA 120.672 -0.775 . . . . 0.0 111.828 179.918 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.662 ' HA ' ' HA ' ' A' ' 72' ' ' PRO . 14.6 mt -64.74 -22.74 67.05 Favored 'General case' 0 C--N 1.32 -0.707 0 C-N-CA 122.817 0.447 . . . . 0.0 111.363 -171.332 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 69' ' ' ARG . . . . . 0.497 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 14.9 ptm180 -70.85 -32.49 69.53 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.311 176.138 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 70' ' ' TYR . . . . . 0.675 ' HB3' ' HB3' ' A' ' 81' ' ' GLU . 58.9 m-85 -80.09 -33.33 38.88 Favored 'General case' 0 N--CA 1.445 -0.697 0 N-CA-C 107.217 -1.401 . . . . 0.0 107.217 178.19 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.673 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 165.94 127.12 0.03 OUTLIER Pre-proline 0 CA--C 1.511 -0.538 0 CA-C-N 112.447 -2.161 . . . . 0.0 107.122 178.693 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 72' ' ' PRO . . . . . 0.662 ' HA ' ' HA ' ' A' ' 68' ' ' LEU . 15.5 Cg_exo -56.2 -0.8 0.23 Allowed 'Trans proline' 0 CA--C 1.531 0.369 0 C-N-CA 122.961 2.441 . . . . 0.0 114.231 -177.849 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 13.0 ptm180 -150.82 142.46 23.62 Favored 'General case' 0 C--N 1.317 -0.839 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 172.776 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 74' ' ' ALA . . . . . 0.561 ' HB3' ' HB2' ' A' ' 52' ' ' TYR . . . -58.69 -30.34 67.33 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.332 -0.849 . . . . 0.0 112.89 -175.899 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 75' ' ' ASP . . . . . 0.459 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 15.7 p-10 -87.33 5.54 37.98 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 121.269 0.557 . . . . 0.0 111.129 -176.232 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.436 ' HB3' ' HB1' ' A' ' 71' ' ' ALA . 65.2 tp -105.67 -30.17 9.64 Favored 'General case' 0 C--N 1.319 -0.72 0 N-CA-C 108.359 -0.978 . . . . 0.0 108.359 168.967 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 77' ' ' ALA . . . . . 0.706 ' HB1' ' HB2' ' A' ' 81' ' ' GLU . . . -79.47 164.48 23.91 Favored 'General case' 0 N--CA 1.444 -0.739 0 CA-C-N 114.446 -1.252 . . . . 0.0 110.183 175.933 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 78' ' ' THR . . . . . 0.461 ' OG1' ' HG2' ' A' ' 81' ' ' GLU . 65.9 p -99.97 -178.89 3.99 Favored 'General case' 0 C--N 1.313 -0.994 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.414 -177.042 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 79' ' ' ARG . . . . . 0.73 HH21 ' HB2' ' A' ' 32' ' ' ASP . 47.2 mtp180 -52.71 -53.67 44.32 Favored 'General case' 0 CA--C 1.516 -0.342 0 CA-C-O 121.045 0.45 . . . . 0.0 110.374 -178.536 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 80' ' ' GLU . . . . . 0.61 ' HA ' HD12 ' A' ' 83' ' ' ILE . 2.7 pm0 -60.51 -32.64 71.65 Favored 'General case' 0 C--N 1.317 -0.816 0 CA-C-N 115.083 -0.962 . . . . 0.0 112.254 -176.818 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 81' ' ' GLU . . . . . 0.706 ' HB2' ' HB1' ' A' ' 77' ' ' ALA . 5.4 mm-40 -70.64 -50.41 37.13 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-O 120.877 0.37 . . . . 0.0 110.031 177.477 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 82' ' ' GLN . . . . . 0.484 ' HA ' ' CZ3' ' A' ' 62' ' ' TRP . 51.2 mt-30 -61.11 -35.61 77.49 Favored 'General case' 0 CA--C 1.507 -0.69 0 CA-C-N 115.582 -0.736 . . . . 0.0 109.631 179.833 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.687 ' O ' ' HG2' ' A' ' 87' ' ' GLU . 39.2 mt -59.55 -49.16 84.69 Favored 'Isoleucine or valine' 0 C--O 1.211 -0.952 0 CA-C-N 114.714 -1.13 . . . . 0.0 109.763 174.829 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 84' ' ' ALA . . . . . 0.616 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -61.25 -41.58 97.15 Favored 'General case' 0 C--O 1.236 0.365 0 CA-C-O 121.403 0.62 . . . . 0.0 111.579 -177.606 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.465 HG23 ' O ' ' A' ' 81' ' ' GLU . 34.7 t -69.2 -47.85 71.89 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.794 178.528 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -58.22 -29.44 65.72 Favored 'General case' 0 N--CA 1.45 -0.446 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.364 172.99 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 87' ' ' GLU . . . . . 0.687 ' HG2' ' O ' ' A' ' 83' ' ' ILE . 14.5 mm-40 -60.03 -44.62 94.5 Favored 'General case' 0 N--CA 1.469 0.497 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.111 179.277 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.638 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 60.8 t -63.56 -47.71 90.21 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.437 0 N-CA-C 109.473 -0.566 . . . . 0.0 109.473 174.243 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 89' ' ' THR . . . . . 0.898 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 0.7 OUTLIER -59.21 -49.86 76.22 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-N 115.696 -0.684 . . . . 0.0 111.387 -176.508 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 90' ' ' ARG . . . . . 0.509 ' HA ' ' HZ3' ' A' ' 98' ' ' TRP . 27.0 ptt85 -60.51 -34.97 74.87 Favored 'General case' 0 C--O 1.223 -0.314 0 CA-C-N 116.723 -0.217 . . . . 0.0 111.232 -172.477 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 91' ' ' LEU . . . . . 0.638 ' HG ' ' O ' ' A' ' 88' ' ' VAL . 4.5 pp -74.71 -22.82 58.63 Favored 'General case' 0 C--N 1.318 -0.798 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.52 -173.488 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 92' ' ' ARG . . . . . 0.605 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 15.6 mtm180 -80.82 -52.71 7.19 Favored 'General case' 0 CA--C 1.505 -0.773 0 CA-C-O 121.13 0.491 . . . . 0.0 109.877 -176.04 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 4.9 pm0 -103.75 -15.36 15.76 Favored 'General case' 0 N--CA 1.445 -0.681 0 C-N-CA 119.645 -0.822 . . . . 0.0 113.022 -173.411 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 87.33 45.12 5.39 Favored Glycine 0 CA--C 1.498 -1.03 0 C-N-CA 120.732 -0.747 . . . . 0.0 111.88 168.424 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 95' ' ' TRP . . . . . 0.472 ' HA ' ' HE3' ' A' ' 98' ' ' TRP . 15.7 m95 66.47 2.23 2.39 Favored 'General case' 0 C--O 1.216 -0.669 0 C-N-CA 123.236 0.614 . . . . 0.0 109.979 -178.276 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -70.35 -13.01 70.23 Favored Glycine 0 C--N 1.335 0.517 0 C-N-CA 121.447 -0.406 . . . . 0.0 112.792 -178.108 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -81.93 -23.66 36.06 Favored 'General case' 0 C--N 1.325 -0.471 0 N-CA-C 109.525 -0.546 . . . . 0.0 109.525 175.159 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 98' ' ' TRP . . . . . 0.898 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 29.0 m-90 -103.16 104.95 43.59 Favored Pre-proline 0 N--CA 1.45 -0.444 0 N-CA-C 108.745 -0.835 . . . . 0.0 108.745 175.146 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 99' ' ' PRO . . . . . 0.419 ' HD3' ' HA ' ' A' ' 98' ' ' TRP . 15.0 Cg_exo -74.43 -87.09 0.0 OUTLIER 'Trans proline' 0 CA--C 1.53 0.305 0 C-N-CA 122.902 2.401 . . . . 0.0 114.673 -172.666 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 48.4 t -71.25 -27.92 30.83 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-O 121.322 0.582 . . . . 0.0 111.086 -170.949 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 101' ' ' CYS . . . . . 0.879 ' SG ' ' HG3' ' A' ' 38' ' ' GLU . 64.2 m -90.99 -27.55 18.59 Favored 'General case' 0 C--N 1.314 -0.946 0 CA-C-N 115.915 -0.584 . . . . 0.0 112.545 -168.772 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 102' ' ' ALA . . . . . 0.596 ' HB2' ' HB2' ' A' ' 98' ' ' TRP . . . -67.54 -46.43 72.82 Favored 'General case' 0 C--N 1.33 -0.268 0 C-N-CA 120.515 -0.474 . . . . 0.0 110.928 -178.719 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -61.22 -39.09 88.95 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-O 121.097 0.475 . . . . 0.0 110.634 179.25 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -66.56 -39.77 88.68 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.469 -0.787 . . . . 0.0 111.548 176.655 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -77.56 -22.51 50.89 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.929 -175.933 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 116.02 55.83 0.34 Allowed Glycine 0 N--CA 1.452 -0.236 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.528 -178.942 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -57.52 149.2 21.67 Favored 'General case' 0 CA--C 1.517 -0.305 0 C-N-CA 123.049 0.54 . . . . 0.0 110.572 179.149 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 69.9 mtp180 . . . . . 0 C--O 1.249 1.04 0 CA-C-O 118.202 -0.904 . . . . 0.0 110.465 -170.19 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 27' ' ' ASP . . . . . 0.623 ' O ' HG12 ' A' ' 30' ' ' ILE . 13.0 m-20 . . . . . 0 CA--C 1.502 -0.899 0 CA-C-O 121.891 0.853 . . . . 0.0 109.208 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 28' ' ' GLY . . . . . 0.711 ' HA2' ' HB2' ' A' ' 31' ' ' TRP . . . -77.75 2.7 62.91 Favored Glycine 0 N--CA 1.433 -1.534 0 CA-C-N 114.583 -1.19 . . . . 0.0 110.611 -177.76 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 17.0 m -76.23 -40.36 52.26 Favored 'General case' 0 C--N 1.318 -0.794 0 N-CA-C 108.77 -0.826 . . . . 0.0 108.77 173.626 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.632 ' HA ' ' HB1' ' A' ' 105' ' ' ALA . 0.0 OUTLIER -71.52 -38.03 66.32 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.679 0 N-CA-C 107.348 -1.353 . . . . 0.0 107.348 176.573 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 31' ' ' TRP . . . . . 0.711 ' HB2' ' HA2' ' A' ' 28' ' ' GLY . 14.6 m95 -71.85 -36.29 70.11 Favored 'General case' 0 N--CA 1.438 -1.054 0 CA-C-N 114.251 -1.34 . . . . 0.0 110.601 -176.188 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 31.7 t70 -77.23 -34.31 56.01 Favored 'General case' 0 N--CA 1.446 -0.66 0 CA-C-N 116.529 -0.305 . . . . 0.0 110.931 178.082 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 33' ' ' ALA . . . . . 0.487 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -70.16 -34.08 72.56 Favored 'General case' 0 N--CA 1.448 -0.532 0 C-N-CA 120.288 -0.565 . . . . 0.0 110.278 177.523 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 34' ' ' ILE . . . . . 0.501 HG13 ' O ' ' A' ' 30' ' ' ILE . 68.3 mt -67.88 -46.55 81.92 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-O 121.07 0.462 . . . . 0.0 110.176 172.298 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 35' ' ' ALA . . . . . 0.413 ' O ' ' HB3' ' A' ' 39' ' ' ALA . . . -58.72 -38.91 79.36 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.277 176.89 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 36' ' ' GLY . . . . . 0.509 ' HA2' ' N ' ' A' ' 41' ' ' GLY . . . -74.88 -12.97 82.84 Favored Glycine 0 C--O 1.228 -0.26 0 CA-C-N 115.618 -0.719 . . . . 0.0 111.535 178.699 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 40.8 t -89.5 -60.94 1.81 Allowed 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 115.356 -0.422 . . . . 0.0 110.93 -177.748 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 38' ' ' GLU . . . . . 0.832 ' HG3' ' SG ' ' A' ' 101' ' ' CYS . 34.3 mt-10 -89.55 -28.37 19.64 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 120.687 0.28 . . . . 0.0 111.534 -174.441 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 39' ' ' ALA . . . . . 0.413 ' HB3' ' O ' ' A' ' 35' ' ' ALA . . . -101.49 -12.01 18.87 Favored 'General case' 0 C--N 1.326 -0.452 0 C-N-CA 120.43 -0.508 . . . . 0.0 111.785 -178.14 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 81.03 6.52 89.4 Favored Glycine 0 N--CA 1.45 -0.371 0 N-CA-C 110.027 -1.229 . . . . 0.0 110.027 -177.846 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 41' ' ' GLY . . . . . 0.509 ' N ' ' HA2' ' A' ' 36' ' ' GLY . . . 85.35 53.88 2.98 Favored Glycine 0 N--CA 1.437 -1.274 0 CA-C-N 114.148 -1.026 . . . . 0.0 111.942 -177.71 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 42' ' ' ASN . . . . . 0.412 ' OD1' ' HB ' ' A' ' 45' ' ' ILE . 2.3 t-20 -138.71 99.32 3.77 Favored 'General case' 0 N--CA 1.447 -0.58 0 N-CA-C 108.829 -0.804 . . . . 0.0 108.829 -175.84 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 43' ' ' TRP . . . . . 0.667 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 37.1 m95 -81.48 -10.32 59.51 Favored 'General case' 0 C--N 1.312 -1.026 0 CA-C-N 115.389 -0.823 . . . . 0.0 110.805 -172.664 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -107.0 8.71 30.56 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 115.504 -0.771 . . . . 0.0 110.829 -179.492 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.427 HG22 ' CA ' ' A' ' 53' ' ' GLY . 9.3 tt -72.56 144.27 13.17 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.916 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 179.578 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 22.4 t-20 -154.22 98.47 2.14 Favored 'General case' 0 C--N 1.309 -1.183 0 CA-C-O 121.384 0.612 . . . . 0.0 109.372 -179.956 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 17.5 p -72.51 -24.05 61.1 Favored 'General case' 0 C--N 1.317 -0.819 0 CA-C-N 114.76 -1.109 . . . . 0.0 110.919 -177.376 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 93.48 20.64 31.56 Favored Glycine 0 N--CA 1.441 -0.981 0 N-CA-C 110.722 -0.951 . . . . 0.0 110.722 -178.698 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 82.8 m-20 -93.18 12.8 23.14 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.877 0.37 . . . . 0.0 111.415 -176.234 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 50' ' ' GLY . . . . . 0.516 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 85.29 -11.73 60.18 Favored Glycine 0 N--CA 1.449 -0.46 0 N-CA-C 111.209 -0.757 . . . . 0.0 111.209 -177.883 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 51' ' ' TYR . . . . . 0.649 ' HA ' ' HA ' ' A' ' 58' ' ' ASP . 0.3 OUTLIER -112.22 146.37 38.25 Favored 'General case' 0 CA--C 1.51 -0.562 0 N-CA-C 107.197 -1.408 . . . . 0.0 107.197 177.214 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 52' ' ' TYR . . . . . 0.831 ' O ' ' HA ' ' A' ' 56' ' ' GLN . 32.8 m-85 -110.73 170.5 8.05 Favored 'General case' 0 C--N 1.309 -1.154 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.697 -165.96 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.427 ' CA ' HG22 ' A' ' 45' ' ' ILE . . . -69.06 -174.37 9.98 Favored Glycine 0 C--O 1.228 -0.223 0 N-CA-C 114.907 0.723 . . . . 0.0 114.907 -169.761 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 54' ' ' GLY . . . . . 0.608 ' CA ' ' HA ' ' A' ' 43' ' ' TRP . . . 80.0 -107.53 2.62 Favored Glycine 0 N--CA 1.442 -0.942 0 C-N-CA 120.859 -0.686 . . . . 0.0 111.457 -178.349 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.547 HG12 ' HE1' ' A' ' 98' ' ' TRP . 3.4 t -88.21 4.22 4.84 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 CA-C-O 121.554 0.692 . . . . 0.0 109.618 179.016 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 56' ' ' GLN . . . . . 0.831 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 40.3 tt0 54.5 53.82 10.22 Favored 'General case' 0 CA--C 1.535 0.379 0 N-CA-C 114.854 1.427 . . . . 0.0 114.854 164.887 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -121.15 170.26 9.73 Favored 'General case' 0 C--N 1.326 -0.418 0 C-N-CA 119.447 -0.901 . . . . 0.0 112.018 171.652 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.649 ' HA ' ' HA ' ' A' ' 51' ' ' TYR . 6.9 p-10 -76.25 165.22 25.18 Favored 'General case' 0 C--N 1.331 -0.219 0 N-CA-C 113.311 0.856 . . . . 0.0 113.311 -166.809 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 59' ' ' GLN . . . . . 0.507 ' HB2' ' HE1' ' A' ' 52' ' ' TYR . 5.9 tp-100 -63.15 -37.99 89.4 Favored 'General case' 0 N--CA 1.448 -0.568 0 CA-C-N 114.881 -1.054 . . . . 0.0 110.827 179.127 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -63.46 -49.78 67.28 Favored Glycine 0 C--N 1.314 -0.68 0 CA-C-N 115.551 -0.75 . . . . 0.0 111.777 -175.643 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 86.4 m -63.91 -44.19 93.7 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-O 120.954 0.407 . . . . 0.0 111.201 176.414 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 62' ' ' TRP . . . . . 0.459 ' CZ3' ' HA ' ' A' ' 82' ' ' GLN . 54.4 t-105 -56.86 -48.95 76.93 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 121.84 0.828 . . . . 0.0 109.967 177.546 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 63' ' ' GLU . . . . . 0.516 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 36.0 tt0 -67.39 -34.68 77.76 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-N 114.611 -1.177 . . . . 0.0 110.471 -178.426 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -64.85 -41.9 95.32 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.645 -0.707 . . . . 0.0 110.993 -178.711 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 65' ' ' ASN . . . . . 0.579 ' HB2' HG13 ' A' ' 85' ' ' VAL . 7.9 m120 -82.06 -2.85 53.19 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.459 177.144 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 66' ' ' GLY . . . . . 0.58 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 83.57 47.62 5.6 Favored Glycine 0 C--O 1.225 -0.467 0 CA-C-N 115.782 -0.645 . . . . 0.0 112.587 173.245 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 67' ' ' GLY . . . . . 0.607 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -80.03 -21.96 64.43 Favored Glycine 0 N--CA 1.438 -1.197 0 C-N-CA 120.956 -0.64 . . . . 0.0 112.934 -175.107 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.837 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 6.8 mp -61.61 -22.73 65.49 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 112.048 0.388 . . . . 0.0 112.048 -172.43 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 69' ' ' ARG . . . . . 0.58 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 9.6 ptm180 -67.74 -33.68 75.33 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 121.254 0.549 . . . . 0.0 109.963 176.522 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 70' ' ' TYR . . . . . 0.786 ' HB3' ' HG3' ' A' ' 81' ' ' GLU . 63.5 m-85 -79.91 -34.51 38.92 Favored 'General case' 0 N--CA 1.444 -0.772 0 N-CA-C 107.499 -1.297 . . . . 0.0 107.499 178.159 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.707 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 163.99 129.05 0.02 OUTLIER Pre-proline 0 CA--C 1.51 -0.568 0 CA-C-N 112.595 -2.093 . . . . 0.0 107.198 -179.888 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 72' ' ' PRO . . . . . 0.837 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 16.9 Cg_exo -58.46 -3.02 1.15 Allowed 'Trans proline' 0 C--N 1.332 -0.299 0 C-N-CA 122.622 2.215 . . . . 0.0 113.559 -177.911 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 73' ' ' ARG . . . . . 0.421 ' HB2' ' CD2' ' A' ' 52' ' ' TYR . 13.5 ptm180 -146.63 137.36 23.99 Favored 'General case' 0 C--N 1.319 -0.731 0 N-CA-C 109.289 -0.634 . . . . 0.0 109.289 177.342 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 74' ' ' ALA . . . . . 0.499 ' HB3' ' HB2' ' A' ' 52' ' ' TYR . . . -58.11 -29.52 65.56 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.312 -0.858 . . . . 0.0 112.611 -178.066 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 75' ' ' ASP . . . . . 0.404 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 14.7 p-10 -87.84 9.19 22.72 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 121.364 0.602 . . . . 0.0 110.852 -176.092 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.432 ' HB3' ' HB1' ' A' ' 71' ' ' ALA . 58.6 tp -110.07 -33.63 6.63 Favored 'General case' 0 C--N 1.322 -0.627 0 N-CA-C 108.322 -0.992 . . . . 0.0 108.322 169.81 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 77' ' ' ALA . . . . . 0.739 ' HB1' ' HB3' ' A' ' 81' ' ' GLU . . . -78.39 163.36 25.72 Favored 'General case' 0 N--CA 1.445 -0.691 0 CA-C-N 114.771 -1.104 . . . . 0.0 110.393 177.084 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 71.5 p -99.36 -174.49 2.75 Favored 'General case' 0 C--N 1.315 -0.931 0 CA-C-N 115.656 -0.702 . . . . 0.0 110.337 -174.532 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 79' ' ' ARG . . . . . 0.667 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 23.7 mtt85 -53.93 -56.81 14.33 Favored 'General case' 0 CA--C 1.512 -0.509 0 CA-C-O 120.988 0.423 . . . . 0.0 110.772 178.848 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 1.8 pm0 -58.22 -41.18 83.51 Favored 'General case' 0 C--N 1.314 -0.937 0 CA-C-N 115.043 -0.981 . . . . 0.0 111.262 -176.391 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 81' ' ' GLU . . . . . 0.786 ' HG3' ' HB3' ' A' ' 70' ' ' TYR . 0.4 OUTLIER -63.18 -52.72 61.21 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 115.5 -0.773 . . . . 0.0 112.161 175.835 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 82' ' ' GLN . . . . . 0.459 ' HA ' ' CZ3' ' A' ' 62' ' ' TRP . 53.4 mt-30 -60.66 -43.09 98.04 Favored 'General case' 0 CA--C 1.509 -0.613 0 CA-C-O 121.762 0.791 . . . . 0.0 109.833 -178.972 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.672 HG23 ' CD1' ' A' ' 31' ' ' TRP . 10.8 mt -59.5 -39.74 80.07 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.993 0 CA-C-N 114.276 -1.329 . . . . 0.0 110.303 -177.822 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 84' ' ' ALA . . . . . 0.436 ' O ' HG23 ' A' ' 88' ' ' VAL . . . -62.1 -42.46 99.24 Favored 'General case' 0 C--N 1.319 -0.752 0 CA-C-O 121.273 0.559 . . . . 0.0 110.476 -179.181 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.579 HG13 ' HB2' ' A' ' 65' ' ' ASN . 43.0 t -70.05 -50.77 45.26 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 CA-C-N 115.764 -0.653 . . . . 0.0 111.741 -179.569 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -65.69 -31.49 72.52 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 121.489 0.662 . . . . 0.0 110.858 -179.6 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 87' ' ' GLU . . . . . 0.759 ' HA ' ' HG2' ' A' ' 90' ' ' ARG . 0.7 OUTLIER -71.16 -28.41 64.24 Favored 'General case' 0 C--N 1.316 -0.855 0 CA-C-N 115.716 -0.674 . . . . 0.0 110.436 -178.348 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.674 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 88.1 t -61.86 -46.47 96.43 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.26 0 N-CA-C 109.299 -0.63 . . . . 0.0 109.299 168.54 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 89' ' ' THR . . . . . 0.48 ' O ' ' HG2' ' A' ' 93' ' ' GLN . 0.1 OUTLIER -64.64 -45.71 85.63 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 115.697 -0.683 . . . . 0.0 111.866 -177.48 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 90' ' ' ARG . . . . . 0.759 ' HG2' ' HA ' ' A' ' 87' ' ' GLU . 22.5 ptt180 -58.91 -35.36 72.94 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.98 -0.555 . . . . 0.0 111.048 -175.799 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 91' ' ' LEU . . . . . 0.674 ' HG ' ' O ' ' A' ' 88' ' ' VAL . 4.6 pp -74.69 -24.39 58.76 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.022 -0.536 . . . . 0.0 110.827 -169.536 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 92' ' ' ARG . . . . . 0.455 ' HE ' ' HB2' ' A' ' 92' ' ' ARG . 3.9 mtm180 -85.59 -45.56 11.63 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.783 -0.644 . . . . 0.0 109.686 -177.948 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 93' ' ' GLN . . . . . 0.48 ' HG2' ' O ' ' A' ' 89' ' ' THR . 24.0 pt20 -98.6 -29.12 13.24 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.192 -0.913 . . . . 0.0 113.188 -169.715 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 87.42 46.67 4.88 Favored Glycine 0 CA--C 1.505 -0.58 0 C-N-CA 120.426 -0.893 . . . . 0.0 111.06 176.463 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 95' ' ' TRP . . . . . 0.506 ' HA ' ' HE3' ' A' ' 98' ' ' TRP . 1.9 m95 58.59 27.0 15.12 Favored 'General case' 0 C--O 1.223 -0.34 0 CA-C-O 121.484 0.659 . . . . 0.0 109.687 177.457 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -70.83 -30.5 68.12 Favored Glycine 0 N--CA 1.449 -0.445 0 CA-C-N 115.349 -0.841 . . . . 0.0 112.245 176.618 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 97' ' ' ALA . . . . . 0.41 ' O ' ' HD3' ' A' ' 99' ' ' PRO . . . -79.46 -24.84 42.13 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 120.66 0.267 . . . . 0.0 110.57 177.114 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 98' ' ' TRP . . . . . 0.547 ' HE1' HG12 ' A' ' 55' ' ' VAL . 23.8 m-90 -101.96 103.25 28.17 Favored Pre-proline 0 C--N 1.327 -0.389 0 N-CA-C 109.406 -0.59 . . . . 0.0 109.406 175.897 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 99' ' ' PRO . . . . . 0.424 ' HB2' ' H ' ' A' ' 100' ' ' VAL . 22.0 Cg_exo -70.52 -101.7 0.01 OUTLIER 'Trans proline' 0 CA--C 1.539 0.746 0 C-N-CA 123.242 2.628 . . . . 0.0 114.991 -173.013 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 100' ' ' VAL . . . . . 0.48 ' O ' ' HD2' ' A' ' 104' ' ' ARG . 41.0 t -69.82 -27.94 35.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 121.596 0.712 . . . . 0.0 110.452 -171.598 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 101' ' ' CYS . . . . . 0.832 ' SG ' ' HG3' ' A' ' 38' ' ' GLU . 79.1 m -73.07 -32.38 64.97 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-N 115.228 -0.896 . . . . 0.0 111.511 -171.416 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -70.0 -46.18 65.69 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 120.757 0.313 . . . . 0.0 110.953 -179.892 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -62.25 -37.28 84.83 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 121.097 0.475 . . . . 0.0 110.773 179.514 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 104' ' ' ARG . . . . . 0.48 ' HD2' ' O ' ' A' ' 100' ' ' VAL . 0.0 OUTLIER -73.02 -30.47 63.78 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.627 -0.715 . . . . 0.0 111.583 178.566 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 105' ' ' ALA . . . . . 0.632 ' HB1' ' HA ' ' A' ' 30' ' ' ILE . . . -82.17 -21.38 36.57 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.692 -176.997 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 109.39 60.93 0.52 Allowed Glycine 0 CA--C 1.518 0.25 0 C-N-CA 121.011 -0.614 . . . . 0.0 112.158 -178.122 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -66.41 152.67 44.62 Favored 'General case' 0 N--CA 1.45 -0.442 0 C-N-CA 122.642 0.377 . . . . 0.0 111.013 -176.562 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 20.7 mmt180 . . . . . 0 C--O 1.244 0.814 0 CA-C-O 118.404 -0.808 . . . . 0.0 110.959 176.677 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 27' ' ' ASP . . . . . 0.531 ' O ' HG12 ' A' ' 30' ' ' ILE . 11.2 m-20 . . . . . 0 CA--C 1.504 -0.805 0 CA-C-O 121.364 0.602 . . . . 0.0 110.931 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 28' ' ' GLY . . . . . 0.703 ' HA3' ' CD1' ' A' ' 83' ' ' ILE . . . -76.05 1.65 58.75 Favored Glycine 0 CA--C 1.498 -0.998 0 N-CA-C 110.715 -0.954 . . . . 0.0 110.715 -179.336 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 19.1 m -76.99 -40.86 45.22 Favored 'General case' 0 C--N 1.322 -0.628 0 N-CA-C 108.497 -0.927 . . . . 0.0 108.497 171.381 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.531 HG12 ' O ' ' A' ' 27' ' ' ASP . 0.7 OUTLIER -67.29 -40.21 84.43 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.457 0 CA-C-N 114.399 -1.273 . . . . 0.0 107.724 175.946 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 31' ' ' TRP . . . . . 0.56 ' HB2' ' HA2' ' A' ' 28' ' ' GLY . 36.5 m95 -67.41 -36.68 81.76 Favored 'General case' 0 C--N 1.318 -0.776 0 CA-C-N 114.17 -1.377 . . . . 0.0 110.378 -177.826 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.427 ' CB ' HH21 ' A' ' 79' ' ' ARG . 4.6 t70 -77.19 -33.34 56.38 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 115.748 -0.66 . . . . 0.0 110.62 -179.5 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 33' ' ' ALA . . . . . 0.417 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -70.13 -34.07 72.61 Favored 'General case' 0 N--CA 1.447 -0.575 0 C-N-CA 120.506 -0.478 . . . . 0.0 109.977 176.159 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 34' ' ' ILE . . . . . 0.515 HG13 ' O ' ' A' ' 30' ' ' ILE . 74.2 mt -65.52 -43.45 94.32 Favored 'Isoleucine or valine' 0 C--O 1.234 0.268 0 CA-C-N 116.057 -0.519 . . . . 0.0 109.865 172.23 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 35' ' ' ALA . . . . . 0.451 ' HA ' ' O ' ' A' ' 54' ' ' GLY . . . -57.57 -37.4 73.09 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.059 175.211 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 36' ' ' GLY . . . . . 0.4 ' HA2' ' N ' ' A' ' 41' ' ' GLY . . . -70.89 -15.98 74.31 Favored Glycine 0 N--CA 1.449 -0.45 0 CA-C-N 115.27 -0.877 . . . . 0.0 112.181 179.299 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 44.1 t -85.19 -58.87 2.51 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 120.611 0.243 . . . . 0.0 111.186 -177.256 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 8.6 tp10 -89.09 -34.04 16.89 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-O 121.074 0.464 . . . . 0.0 110.877 -172.693 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -97.63 -14.66 20.83 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.029 -0.532 . . . . 0.0 111.511 -175.427 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 86.31 -4.51 85.99 Favored Glycine 0 N--CA 1.448 -0.523 0 N-CA-C 109.847 -1.301 . . . . 0.0 109.847 -174.408 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 41' ' ' GLY . . . . . 0.4 ' N ' ' HA2' ' A' ' 36' ' ' GLY . . . 102.04 56.06 0.85 Allowed Glycine 0 N--CA 1.435 -1.37 0 CA-C-N 114.213 -0.993 . . . . 0.0 112.058 -179.235 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 43.8 t-20 -144.33 127.25 16.38 Favored 'General case' 0 N--CA 1.44 -0.968 0 N-CA-C 108.263 -1.014 . . . . 0.0 108.263 -179.602 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 43' ' ' TRP . . . . . 0.691 ' HZ3' ' HB2' ' A' ' 82' ' ' GLN . 40.5 m95 -99.28 -13.27 19.74 Favored 'General case' 0 C--N 1.305 -1.351 0 CA-C-N 115.398 -0.819 . . . . 0.0 110.935 -173.385 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -100.53 -6.77 24.94 Favored 'General case' 0 C--N 1.316 -0.881 0 CA-C-N 115.199 -0.909 . . . . 0.0 110.479 -177.889 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 10.0 tt -62.33 141.58 17.67 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.996 0 CA-C-N 115.474 -0.784 . . . . 0.0 109.921 178.556 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 43.3 t-20 -158.73 103.52 1.73 Allowed 'General case' 0 C--N 1.312 -1.025 0 CA-C-O 121.03 0.443 . . . . 0.0 110.112 -177.655 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 11.2 p -82.75 -15.01 53.46 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 115.718 -0.674 . . . . 0.0 111.923 -177.56 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 90.47 25.23 26.4 Favored Glycine 0 N--CA 1.446 -0.662 0 N-CA-C 110.943 -0.863 . . . . 0.0 110.943 -177.743 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 65.0 t30 -83.63 -1.76 54.63 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 121.222 0.534 . . . . 0.0 111.222 -175.352 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 50' ' ' GLY . . . . . 0.469 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 95.19 -9.34 69.89 Favored Glycine 0 CA--C 1.505 -0.539 0 N-CA-C 110.093 -1.203 . . . . 0.0 110.093 -175.734 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 51' ' ' TYR . . . . . 0.66 ' HA ' ' HA ' ' A' ' 58' ' ' ASP . 0.5 OUTLIER -117.98 158.2 25.36 Favored 'General case' 0 N--CA 1.441 -0.923 0 N-CA-C 106.118 -1.808 . . . . 0.0 106.118 177.998 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 52' ' ' TYR . . . . . 0.73 ' O ' ' HA ' ' A' ' 56' ' ' GLN . 35.1 m-85 -118.41 169.59 9.63 Favored 'General case' 0 C--N 1.303 -1.447 0 C-N-CA 120.222 -0.591 . . . . 0.0 110.851 -172.241 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -65.14 -173.26 3.81 Favored Glycine 0 N--CA 1.448 -0.515 0 C-N-CA 121.173 -0.537 . . . . 0.0 114.362 -170.019 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 54' ' ' GLY . . . . . 0.599 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 77.39 -104.97 2.01 Favored Glycine 0 N--CA 1.439 -1.157 0 N-CA-C 111.346 -0.702 . . . . 0.0 111.346 -179.635 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.556 HG12 ' HE1' ' A' ' 98' ' ' TRP . 2.2 t -83.41 -1.83 6.25 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 CA-C-O 121.503 0.668 . . . . 0.0 109.676 -179.122 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 56' ' ' GLN . . . . . 0.73 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 20.1 mm-40 57.34 45.18 20.52 Favored 'General case' 0 N--CA 1.464 0.249 0 CA-C-N 114.541 -1.209 . . . . 0.0 113.444 169.584 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 1.1 p90 -117.89 168.53 10.41 Favored 'General case' 0 C--N 1.328 -0.357 0 C-N-CA 119.582 -0.847 . . . . 0.0 112.035 176.476 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.66 ' HA ' ' HA ' ' A' ' 51' ' ' TYR . 7.5 p-10 -79.33 164.15 24.31 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.141 -0.936 . . . . 0.0 113.419 -164.39 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 59' ' ' GLN . . . . . 0.489 ' HB2' ' CE2' ' A' ' 52' ' ' TYR . 6.1 tp60 -63.25 -36.63 84.3 Favored 'General case' 0 N--CA 1.449 -0.487 0 CA-C-N 114.101 -1.409 . . . . 0.0 111.578 179.188 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -68.0 -50.33 41.4 Favored Glycine 0 C--N 1.32 -0.324 0 C-N-CA 121.2 -0.524 . . . . 0.0 112.303 -175.703 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 88.5 m -61.7 -42.16 98.56 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 121.157 0.503 . . . . 0.0 110.113 175.689 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 62' ' ' TRP . . . . . 0.591 ' HH2' ' CD ' ' A' ' 81' ' ' GLU . 59.3 t-105 -56.85 -49.68 74.73 Favored 'General case' 0 N--CA 1.447 -0.623 0 CA-C-N 114.985 -1.007 . . . . 0.0 110.209 177.264 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 63' ' ' GLU . . . . . 0.914 ' HG3' HD11 ' A' ' 68' ' ' LEU . 29.1 tt0 -67.15 -34.38 77.44 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 115.026 -0.988 . . . . 0.0 110.773 -177.18 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -67.91 -41.58 82.45 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.897 -0.592 . . . . 0.0 111.082 -178.44 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 65' ' ' ASN . . . . . 0.68 ' HB2' HG13 ' A' ' 85' ' ' VAL . 4.8 m120 -71.8 -15.79 62.16 Favored 'General case' 0 C--N 1.332 -0.154 0 CA-C-O 121.349 0.595 . . . . 0.0 109.773 174.99 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 88.32 44.74 5.21 Favored Glycine 0 N--CA 1.446 -0.7 0 CA-C-N 115.208 -0.906 . . . . 0.0 111.752 178.422 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 67' ' ' GLY . . . . . 0.589 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -78.5 -19.58 73.53 Favored Glycine 0 CA--C 1.5 -0.865 0 C-N-CA 120.612 -0.804 . . . . 0.0 111.123 -173.818 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.914 HD11 ' HG3' ' A' ' 63' ' ' GLU . 11.8 mt -61.32 -24.86 66.74 Favored 'General case' 0 C--N 1.317 -0.807 0 CA-C-N 114.664 -0.768 . . . . 0.0 110.806 -174.667 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 12.1 ptm180 -70.34 -28.61 65.27 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.461 -0.79 . . . . 0.0 109.856 179.664 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 70' ' ' TYR . . . . . 0.589 ' HD2' ' HA2' ' A' ' 67' ' ' GLY . 47.7 m-85 -85.49 -34.47 21.58 Favored 'General case' 0 N--CA 1.439 -1.007 0 N-CA-C 107.143 -1.428 . . . . 0.0 107.143 176.201 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.785 ' HB1' ' HB3' ' A' ' 76' ' ' LEU . . . 170.22 127.27 0.05 OUTLIER Pre-proline 0 C--O 1.217 -0.617 0 CA-C-N 112.729 -2.032 . . . . 0.0 107.712 -178.029 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 72' ' ' PRO . . . . . 0.604 ' HA ' ' HA ' ' A' ' 68' ' ' LEU . 17.2 Cg_exo -58.32 -0.96 0.54 Allowed 'Trans proline' 0 C--N 1.331 -0.39 0 C-N-CA 122.968 2.445 . . . . 0.0 113.8 -179.455 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 73' ' ' ARG . . . . . 0.428 ' HE ' ' CG ' ' A' ' 75' ' ' ASP . 13.4 ptm180 -152.85 143.04 22.43 Favored 'General case' 0 C--N 1.318 -0.799 0 N-CA-C 109.232 -0.655 . . . . 0.0 109.232 174.059 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 74' ' ' ALA . . . . . 0.593 ' HB3' ' HB2' ' A' ' 52' ' ' TYR . . . -61.7 -25.48 67.44 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.574 -0.739 . . . . 0.0 112.359 -174.381 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 75' ' ' ASP . . . . . 0.428 ' CG ' ' HE ' ' A' ' 73' ' ' ARG . 17.2 p-10 -89.36 10.91 20.7 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-O 121.049 0.452 . . . . 0.0 111.363 -178.041 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.785 ' HB3' ' HB1' ' A' ' 71' ' ' ALA . 42.0 tp -104.29 -42.71 5.42 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.345 177.207 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 77' ' ' ALA . . . . . 0.718 ' HB3' ' OE2' ' A' ' 81' ' ' GLU . . . -100.73 170.47 8.32 Favored 'General case' 0 N--CA 1.45 -0.473 0 CA-C-O 121.136 0.493 . . . . 0.0 109.932 177.826 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 78' ' ' THR . . . . . 0.552 ' OG1' ' HG2' ' A' ' 80' ' ' GLU . 41.3 p -85.06 168.71 14.63 Favored 'General case' 0 C--N 1.312 -1.063 0 N-CA-C 113.2 0.815 . . . . 0.0 113.2 -167.775 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 79' ' ' ARG . . . . . 0.614 ' HA ' ' CE3' ' A' ' 43' ' ' TRP . 7.1 ptm180 -47.4 -36.09 9.29 Favored 'General case' 0 N--CA 1.466 0.352 0 C-N-CA 122.724 0.41 . . . . 0.0 112.087 -175.238 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 80' ' ' GLU . . . . . 0.917 ' HA ' HD12 ' A' ' 83' ' ' ILE . 16.1 pt-20 -62.36 -31.22 71.83 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.407 -178.556 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 81' ' ' GLU . . . . . 0.718 ' OE2' ' HB3' ' A' ' 77' ' ' ALA . 0.0 OUTLIER -72.53 -48.86 36.99 Favored 'General case' 0 N--CA 1.428 -1.545 0 N-CA-C 110.075 -0.343 . . . . 0.0 110.075 177.163 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 82' ' ' GLN . . . . . 0.691 ' HB2' ' HZ3' ' A' ' 43' ' ' TRP . 67.1 mt-30 -59.82 -31.8 70.06 Favored 'General case' 0 CA--C 1.511 -0.521 0 C-N-CA 120.874 -0.331 . . . . 0.0 110.225 178.245 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.917 HD12 ' HA ' ' A' ' 80' ' ' GLU . 79.7 mt -59.32 -51.5 71.92 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.782 0 CA-C-N 115.892 -0.594 . . . . 0.0 109.626 173.328 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 84' ' ' ALA . . . . . 0.48 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -62.36 -44.42 96.51 Favored 'General case' 0 C--O 1.238 0.459 0 CA-C-O 121.635 0.731 . . . . 0.0 111.285 -175.081 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.68 HG13 ' HB2' ' A' ' 65' ' ' ASN . 48.9 t -67.97 -49.17 71.0 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.635 0 CA-C-N 115.388 -0.823 . . . . 0.0 111.107 -177.876 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -60.61 -29.7 69.38 Favored 'General case' 0 N--CA 1.451 -0.416 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.175 175.581 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 87' ' ' GLU . . . . . 0.774 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 28.7 mt-10 -60.31 -42.86 96.46 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.59 179.885 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.427 ' O ' ' HG3' ' A' ' 92' ' ' ARG . 75.6 t -60.67 -50.0 82.22 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.284 0 C-N-CA 120.37 -0.532 . . . . 0.0 110.189 178.943 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 89' ' ' THR . . . . . 0.705 HG22 ' NE2' ' A' ' 93' ' ' GLN . 97.0 m -64.11 -38.82 92.45 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-N 115.524 -0.762 . . . . 0.0 111.252 -178.442 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 90' ' ' ARG . . . . . 0.664 HH11 ' HG2' ' A' ' 87' ' ' GLU . 1.4 ptt180 -60.52 -35.88 77.04 Favored 'General case' 0 N--CA 1.464 0.258 0 CA-C-N 116.613 -0.267 . . . . 0.0 111.387 -179.674 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 91' ' ' LEU . . . . . 0.774 ' HG ' ' O ' ' A' ' 87' ' ' GLU . 32.1 mt -64.18 -29.02 70.16 Favored 'General case' 0 N--CA 1.47 0.534 0 CA-C-O 121.708 0.766 . . . . 0.0 110.15 -174.821 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 92' ' ' ARG . . . . . 0.625 ' NH2' HG23 ' A' ' 89' ' ' THR . 9.8 mtm180 -87.65 -43.89 11.61 Favored 'General case' 0 C--N 1.314 -0.956 0 CA-C-N 114.541 -1.209 . . . . 0.0 110.516 -169.573 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 93' ' ' GLN . . . . . 0.705 ' NE2' HG22 ' A' ' 89' ' ' THR . 0.0 OUTLIER -105.79 -17.74 14.28 Favored 'General case' 0 CA--C 1.545 0.769 0 N-CA-C 113.956 1.095 . . . . 0.0 113.956 -173.965 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 79.86 44.34 9.23 Favored Glycine 0 C--N 1.335 0.513 0 C-N-CA 121.312 -0.47 . . . . 0.0 112.983 171.929 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 95' ' ' TRP . . . . . 0.4 ' CZ2' ' HD2' ' A' ' 90' ' ' ARG . 13.4 m95 61.62 19.94 10.87 Favored 'General case' 0 C--O 1.223 -0.338 0 C-N-CA 123.483 0.713 . . . . 0.0 109.618 -179.059 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.421 ' H ' ' HG2' ' A' ' 93' ' ' GLN . . . -77.42 -32.98 45.23 Favored Glycine 0 N--CA 1.453 -0.189 0 CA-C-N 115.381 -0.827 . . . . 0.0 112.385 176.348 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 97' ' ' ALA . . . . . 0.428 ' H ' ' CG ' ' A' ' 93' ' ' GLN . . . -72.66 -24.85 61.09 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 121.338 0.589 . . . . 0.0 109.781 178.953 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 98' ' ' TRP . . . . . 0.556 ' HE1' HG12 ' A' ' 55' ' ' VAL . 25.0 m-90 -95.33 108.22 37.69 Favored Pre-proline 0 N--CA 1.441 -0.88 0 N-CA-C 108.358 -0.979 . . . . 0.0 108.358 175.001 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 45.4 Cg_exo -64.14 -141.76 0.01 OUTLIER 'Trans proline' 0 CA--C 1.532 0.394 0 C-N-CA 123.466 2.777 . . . . 0.0 113.906 -174.189 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 4.3 t -56.21 -21.79 12.67 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.425 0 CA-C-O 120.928 0.394 . . . . 0.0 111.176 -175.542 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 77.5 m -56.87 -39.18 73.86 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-N 116.573 -0.285 . . . . 0.0 111.04 175.09 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -71.27 -37.96 71.88 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-O 120.905 0.383 . . . . 0.0 110.351 177.572 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -61.19 -41.64 97.18 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.638 177.44 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -67.59 -30.29 69.86 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.833 -0.621 . . . . 0.0 111.131 175.531 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 105' ' ' ALA . . . . . 0.417 ' CB ' ' HB3' ' A' ' 33' ' ' ALA . . . -86.28 -22.8 26.6 Favored 'General case' 0 C--N 1.326 -0.428 0 N-CA-C 112.709 0.633 . . . . 0.0 112.709 -172.812 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 104.16 65.74 0.7 Allowed Glycine 0 CA--C 1.521 0.447 0 C-N-CA 120.795 -0.716 . . . . 0.0 112.5 -178.182 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -70.28 148.59 48.36 Favored 'General case' 0 C--N 1.324 -0.525 0 C-N-CA 122.905 0.482 . . . . 0.0 110.773 -176.699 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 108' ' ' ARG . . . . . 0.431 ' HD3' ' O ' ' A' ' 108' ' ' ARG . 0.0 OUTLIER . . . . . 0 C--O 1.247 0.96 0 CA-C-O 119.069 -0.491 . . . . 0.0 111.181 -174.505 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 27' ' ' ASP . . . . . 0.445 ' O ' HG12 ' A' ' 30' ' ' ILE . 6.3 m-20 . . . . . 0 CA--C 1.503 -0.83 0 CA-C-O 121.548 0.69 . . . . 0.0 109.833 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 28' ' ' GLY . . . . . 0.622 ' HA3' HD13 ' A' ' 83' ' ' ILE . . . -63.51 -9.05 29.4 Favored Glycine 0 N--CA 1.436 -1.343 0 CA-C-N 114.909 -1.041 . . . . 0.0 110.905 174.506 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 8.4 m -71.34 -44.25 65.44 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-O 121.681 0.753 . . . . 0.0 109.293 175.195 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.505 ' O ' HG13 ' A' ' 34' ' ' ILE . 0.4 OUTLIER -69.15 -39.45 79.37 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.604 0 CA-C-N 114.576 -1.193 . . . . 0.0 107.881 178.533 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 31' ' ' TRP . . . . . 0.774 ' CD1' HG23 ' A' ' 83' ' ' ILE . 39.5 m95 -67.95 -35.93 79.24 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 114.493 -1.231 . . . . 0.0 110.528 -177.15 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.432 ' CG ' HH21 ' A' ' 79' ' ' ARG . 3.9 t70 -71.23 -42.25 69.12 Favored 'General case' 0 N--CA 1.447 -0.621 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.256 177.665 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 33' ' ' ALA . . . . . 0.424 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -67.33 -33.77 75.95 Favored 'General case' 0 N--CA 1.446 -0.662 0 CA-C-N 116.44 -0.345 . . . . 0.0 110.511 -179.665 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 34' ' ' ILE . . . . . 0.505 HG13 ' O ' ' A' ' 30' ' ' ILE . 65.7 mt -64.41 -46.14 93.82 Favored 'Isoleucine or valine' 0 C--O 1.234 0.255 0 CA-C-O 121.046 0.45 . . . . 0.0 109.865 172.457 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -57.99 -38.85 76.86 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.133 176.065 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 36' ' ' GLY . . . . . 0.412 ' HA2' ' N ' ' A' ' 41' ' ' GLY . . . -65.44 -28.83 74.01 Favored Glycine 0 N--CA 1.451 -0.329 0 CA-C-N 115.588 -0.733 . . . . 0.0 111.97 179.248 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 6.7 t -76.25 -64.49 1.09 Allowed 'General case' 0 C--N 1.318 -0.764 0 N-CA-C 111.926 0.343 . . . . 0.0 111.926 -178.823 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 38' ' ' GLU . . . . . 0.51 ' HB3' ' CD ' ' A' ' 56' ' ' GLN . 11.2 tp10 -88.19 -31.79 18.93 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 121.062 0.458 . . . . 0.0 110.692 -168.939 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -96.89 -9.15 29.11 Favored 'General case' 0 N--CA 1.45 -0.436 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.764 -175.348 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 78.57 16.66 78.96 Favored Glycine 0 CA--C 1.503 -0.685 0 N-CA-C 109.848 -1.301 . . . . 0.0 109.848 -177.929 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 41' ' ' GLY . . . . . 0.412 ' N ' ' HA2' ' A' ' 36' ' ' GLY . . . 69.19 59.69 5.67 Favored Glycine 0 N--CA 1.432 -1.606 0 CA-C-N 113.992 -1.104 . . . . 0.0 111.928 -177.179 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 62.2 t30 -147.12 122.17 10.09 Favored 'General case' 0 CA--C 1.505 -0.77 0 N-CA-C 109.134 -0.691 . . . . 0.0 109.134 179.346 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 43' ' ' TRP . . . . . 0.705 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 33.9 m95 -97.5 -6.25 34.1 Favored 'General case' 0 C--N 1.306 -1.315 0 CA-C-N 114.956 -1.02 . . . . 0.0 109.935 -173.168 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -110.51 9.93 23.17 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-N 114.907 -1.042 . . . . 0.0 111.183 -179.073 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.767 HG22 ' HA2' ' A' ' 53' ' ' GLY . 3.2 tt -71.09 143.21 14.66 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.615 0 N-CA-C 109.477 -0.564 . . . . 0.0 109.477 179.099 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 45.0 t-20 -165.2 96.05 0.68 Allowed 'General case' 0 C--N 1.312 -1.041 0 CA-C-O 121.047 0.451 . . . . 0.0 110.132 -176.577 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 17.8 p -82.32 -12.06 58.22 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.392 179.832 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 89.29 22.15 38.8 Favored Glycine 0 N--CA 1.446 -0.697 0 N-CA-C 111.275 -0.73 . . . . 0.0 111.275 178.985 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 8.6 p30 -88.36 5.86 40.05 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 121.03 0.443 . . . . 0.0 110.99 -176.031 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 50' ' ' GLY . . . . . 0.49 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 95.77 -12.22 67.53 Favored Glycine 0 N--CA 1.448 -0.536 0 CA-C-N 115.913 -0.585 . . . . 0.0 112.117 -178.234 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 51' ' ' TYR . . . . . 0.597 ' HA ' ' HA ' ' A' ' 58' ' ' ASP . 0.1 OUTLIER -112.99 161.29 17.2 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 108.026 -1.102 . . . . 0.0 108.026 173.494 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 52' ' ' TYR . . . . . 0.479 ' HB2' ' HB3' ' A' ' 74' ' ' ALA . 42.7 m-85 -125.62 170.26 11.67 Favored 'General case' 0 C--N 1.313 -0.982 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.686 -170.752 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.767 ' HA2' HG22 ' A' ' 45' ' ' ILE . . . -70.36 -172.59 11.31 Favored Glycine 0 N--CA 1.446 -0.678 0 CA-C-N 116.177 -0.465 . . . . 0.0 114.23 -171.69 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 54' ' ' GLY . . . . . 0.638 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 81.91 -111.03 3.27 Favored Glycine 0 N--CA 1.443 -0.888 0 C-N-CA 121.011 -0.614 . . . . 0.0 111.76 -179.154 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.54 ' HB ' ' CE2' ' A' ' 57' ' ' PHE . 1.8 t -91.69 19.96 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-O 121.183 0.516 . . . . 0.0 110.53 -178.488 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 56' ' ' GLN . . . . . 0.51 ' CD ' ' HB3' ' A' ' 38' ' ' GLU . 0.0 OUTLIER 59.51 50.31 7.6 Favored 'General case' 0 N--CA 1.47 0.547 0 CA-C-N 115.168 -0.924 . . . . 0.0 111.704 171.496 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 57' ' ' PHE . . . . . 0.54 ' CE2' ' HB ' ' A' ' 55' ' ' VAL . 57.3 m-85 -81.45 138.07 35.57 Favored 'General case' 0 CA--C 1.504 -0.804 0 CA-C-N 115.77 -0.65 . . . . 0.0 112.266 178.345 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.597 ' HA ' ' HA ' ' A' ' 51' ' ' TYR . 7.9 p-10 -79.45 155.96 28.08 Favored 'General case' 0 C--N 1.313 -1.003 0 N-CA-C 108.535 -0.913 . . . . 0.0 108.535 163.631 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 59' ' ' GLN . . . . . 0.406 ' HB2' ' HE1' ' A' ' 52' ' ' TYR . 19.0 tp60 -54.63 -36.47 64.56 Favored 'General case' 0 N--CA 1.445 -0.701 0 CA-C-O 121.188 0.518 . . . . 0.0 110.352 -179.026 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -68.51 -50.5 37.13 Favored Glycine 0 C--O 1.225 -0.428 0 CA-C-N 114.795 -1.093 . . . . 0.0 113.041 -173.557 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 99.1 m -67.51 -40.32 85.12 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 121.082 0.468 . . . . 0.0 110.299 -179.197 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 62' ' ' TRP . . . . . 0.518 ' CZ3' ' HA ' ' A' ' 82' ' ' GLN . 53.5 t-105 -57.82 -48.72 78.93 Favored 'General case' 0 N--CA 1.443 -0.789 0 CA-C-N 115.468 -0.787 . . . . 0.0 109.367 176.586 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 63' ' ' GLU . . . . . 0.504 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 44.9 tt0 -67.93 -33.97 75.71 Favored 'General case' 0 N--CA 1.444 -0.738 0 CA-C-N 115.07 -0.968 . . . . 0.0 110.695 -179.431 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -63.09 -41.49 99.42 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.839 -178.75 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 65' ' ' ASN . . . . . 0.667 ' HB2' HG13 ' A' ' 85' ' ' VAL . 7.5 m120 -73.92 -19.55 60.66 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 121.438 0.637 . . . . 0.0 110.054 176.41 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 66' ' ' GLY . . . . . 0.609 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 90.13 45.72 4.36 Favored Glycine 0 N--CA 1.446 -0.674 0 CA-C-N 115.148 -0.933 . . . . 0.0 111.534 -178.55 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 67' ' ' GLY . . . . . 0.73 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -78.59 -15.7 80.42 Favored Glycine 0 N--CA 1.445 -0.744 0 C-N-CA 120.998 -0.62 . . . . 0.0 112.359 -172.806 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.841 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 7.1 mp -60.27 -27.54 67.34 Favored 'General case' 0 C--N 1.316 -0.865 0 N-CA-C 112.875 0.694 . . . . 0.0 112.875 -175.918 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 69' ' ' ARG . . . . . 0.609 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 17.1 ptm180 -65.25 -32.44 74.1 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 121.602 0.715 . . . . 0.0 109.748 175.545 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 70' ' ' TYR . . . . . 0.73 ' HD2' ' HA2' ' A' ' 67' ' ' GLY . 93.1 m-85 -77.78 -34.55 52.23 Favored 'General case' 0 N--CA 1.439 -0.988 0 N-CA-C 107.877 -1.157 . . . . 0.0 107.877 177.388 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.683 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 160.42 129.56 0.0 OUTLIER Pre-proline 0 CA--C 1.513 -0.48 0 CA-C-N 112.21 -2.268 . . . . 0.0 106.738 179.308 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 72' ' ' PRO . . . . . 0.841 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 17.4 Cg_exo -58.18 -4.12 1.49 Allowed 'Trans proline' 0 CA--C 1.53 0.278 0 C-N-CA 122.582 2.188 . . . . 0.0 113.506 -176.919 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 13.2 ptm180 -145.29 136.29 24.72 Favored 'General case' 0 C--N 1.321 -0.647 0 N-CA-C 108.99 -0.745 . . . . 0.0 108.99 175.801 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 74' ' ' ALA . . . . . 0.479 ' HB3' ' HB2' ' A' ' 52' ' ' TYR . . . -55.87 -30.7 61.92 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 114.873 -1.058 . . . . 0.0 112.772 -177.763 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 75' ' ' ASP . . . . . 0.442 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 20.8 p-10 -88.27 9.55 22.74 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 120.907 0.384 . . . . 0.0 111.362 -176.314 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 60.7 tp -109.98 -33.14 6.79 Favored 'General case' 0 C--N 1.323 -0.56 0 N-CA-C 108.783 -0.821 . . . . 0.0 108.783 170.246 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 77' ' ' ALA . . . . . 0.683 ' HB2' ' HB3' ' A' ' 71' ' ' ALA . . . -79.85 163.17 24.59 Favored 'General case' 0 N--CA 1.444 -0.759 0 CA-C-N 115.061 -0.972 . . . . 0.0 109.272 174.143 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 32.0 p -99.39 -173.91 2.6 Favored 'General case' 0 C--N 1.315 -0.927 0 C-N-CA 120.799 -0.36 . . . . 0.0 110.385 -178.497 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 79' ' ' ARG . . . . . 0.705 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 20.7 mtp180 -51.0 -54.34 25.39 Favored 'General case' 0 C--O 1.22 -0.452 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.99 -177.378 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 80' ' ' GLU . . . . . 0.456 ' HG3' ' OE2' ' A' ' 81' ' ' GLU . 9.0 pt-20 -61.41 -41.42 97.12 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.829 -172.683 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 81' ' ' GLU . . . . . 0.7 ' HB3' ' HB3' ' A' ' 70' ' ' TYR . 3.6 mp0 -59.24 -51.77 68.53 Favored 'General case' 0 C--N 1.323 -0.551 0 N-CA-C 112.016 0.376 . . . . 0.0 112.016 172.74 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 82' ' ' GLN . . . . . 0.518 ' HA ' ' CZ3' ' A' ' 62' ' ' TRP . 34.8 mt-30 -59.67 -39.07 83.25 Favored 'General case' 0 CA--C 1.51 -0.561 0 CA-C-O 121.719 0.771 . . . . 0.0 109.681 179.903 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.774 HG23 ' CD1' ' A' ' 31' ' ' TRP . 34.8 mt -60.85 -44.42 97.66 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.903 0 CA-C-N 114.112 -1.404 . . . . 0.0 110.61 179.557 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 84' ' ' ALA . . . . . 0.606 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -66.34 -35.76 81.18 Favored 'General case' 0 C--O 1.236 0.37 0 CA-C-O 121.559 0.695 . . . . 0.0 110.939 -178.613 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.667 HG13 ' HB2' ' A' ' 65' ' ' ASN . 57.4 t -66.15 -48.18 82.25 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.65 0 CA-C-N 115.595 -0.73 . . . . 0.0 110.082 174.672 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -58.76 -30.65 67.68 Favored 'General case' 0 CA--C 1.518 -0.284 0 CA-C-N 115.766 -0.652 . . . . 0.0 110.567 173.551 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 87' ' ' GLU . . . . . 0.673 ' HG2' ' O ' ' A' ' 83' ' ' ILE . 30.9 mm-40 -59.06 -43.32 91.7 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.735 -0.666 . . . . 0.0 110.368 179.754 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.515 ' O ' ' HG3' ' A' ' 92' ' ' ARG . 91.1 t -62.9 -49.49 83.42 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-O 120.851 0.357 . . . . 0.0 110.446 177.901 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 89' ' ' THR . . . . . 0.609 HG22 ' NE2' ' A' ' 93' ' ' GLN . 23.8 m -66.17 -42.16 89.31 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.936 -0.574 . . . . 0.0 111.312 -176.479 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 90' ' ' ARG . . . . . 0.646 ' HA ' ' OE1' ' A' ' 93' ' ' GLN . 8.1 ptt180 -69.17 -32.76 72.3 Favored 'General case' 0 CA--C 1.515 -0.392 0 CA-C-O 121.729 0.776 . . . . 0.0 109.435 -179.255 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 91' ' ' LEU . . . . . 0.46 ' HB2' ' O ' ' A' ' 87' ' ' GLU . 49.4 tp -57.14 -27.44 61.85 Favored 'General case' 0 C--N 1.315 -0.92 0 CA-C-N 114.762 -1.108 . . . . 0.0 111.09 -179.179 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 92' ' ' ARG . . . . . 0.535 ' NH2' HG23 ' A' ' 89' ' ' THR . 6.7 mtm180 -92.14 -50.97 5.41 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 115.407 -0.815 . . . . 0.0 110.581 -175.846 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 93' ' ' GLN . . . . . 0.646 ' OE1' ' HA ' ' A' ' 90' ' ' ARG . 0.0 OUTLIER -104.93 -15.1 15.24 Favored 'General case' 0 CA--C 1.539 0.531 0 N-CA-C 113.44 0.904 . . . . 0.0 113.44 -170.151 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 94' ' ' GLY . . . . . 0.484 ' O ' ' HB2' ' A' ' 90' ' ' ARG . . . 101.32 -97.55 1.67 Allowed Glycine 0 CA--C 1.498 -0.996 0 N-CA-C 110.096 -1.202 . . . . 0.0 110.096 -179.631 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 95' ' ' TRP . . . . . . . . . . . . . 25.3 m95 -145.89 19.45 1.45 Allowed 'General case' 0 C--N 1.315 -0.895 0 N-CA-C 106.246 -1.761 . . . . 0.0 106.246 171.867 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -66.03 -26.59 72.4 Favored Glycine 0 N--CA 1.451 -0.325 0 CA-C-N 114.581 -1.191 . . . . 0.0 112.833 -177.181 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -81.36 -15.19 56.04 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 121.272 0.558 . . . . 0.0 109.966 177.341 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 98' ' ' TRP . . . . . 0.594 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 28.3 m-90 -106.7 107.95 61.09 Favored Pre-proline 0 N--CA 1.445 -0.685 0 CA-C-N 115.472 -0.785 . . . . 0.0 109.42 177.657 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 99' ' ' PRO . . . . . 0.452 ' HD3' ' HA ' ' A' ' 98' ' ' TRP . 50.6 Cg_exo -61.99 -138.17 0.0 OUTLIER 'Trans proline' 0 CA--C 1.534 0.495 0 C-N-CA 123.876 3.051 . . . . 0.0 114.1 -174.628 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 15.0 m -54.97 -26.49 17.62 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.292 0 CA-C-O 121.166 0.507 . . . . 0.0 111.731 -176.468 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 101' ' ' CYS . . . . . 0.446 ' SG ' ' HB2' ' A' ' 38' ' ' GLU . 83.0 m -56.38 -35.3 67.56 Favored 'General case' 0 C--N 1.313 -0.985 0 CA-C-N 115.195 -0.911 . . . . 0.0 111.553 177.72 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -70.88 -45.83 63.68 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.768 0.318 . . . . 0.0 110.934 178.479 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -59.46 -42.69 92.57 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 121.086 0.469 . . . . 0.0 110.621 177.256 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 49.3 mtp180 -67.14 -19.46 65.61 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.348 -0.842 . . . . 0.0 111.14 178.199 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 105' ' ' ALA . . . . . 0.424 ' CB ' ' HB3' ' A' ' 33' ' ' ALA . . . -96.43 -20.39 18.47 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.938 -0.573 . . . . 0.0 112.109 -176.489 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 102.29 55.28 0.86 Allowed Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.887 -0.673 . . . . 0.0 111.802 -175.996 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -57.58 149.74 20.74 Favored 'General case' 0 C--N 1.329 -0.29 0 C-N-CA 123.224 0.61 . . . . 0.0 111.352 -179.639 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 28.0 mtp180 . . . . . 0 C--O 1.25 1.118 0 CA-C-O 118.317 -0.849 . . . . 0.0 109.49 -171.547 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 27' ' ' ASP . . . . . 0.525 ' HB2' ' OE1' ' A' ' 87' ' ' GLU . 31.1 m-20 . . . . . 0 CA--C 1.511 -0.556 0 CA-C-O 121.059 0.457 . . . . 0.0 110.286 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 28' ' ' GLY . . . . . 0.583 ' HA2' ' HD1' ' A' ' 31' ' ' TRP . . . -60.55 -14.07 33.67 Favored Glycine 0 N--CA 1.448 -0.516 0 CA-C-N 115.631 -0.713 . . . . 0.0 111.683 -177.816 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 3.6 m -76.65 -41.9 44.04 Favored 'General case' 0 C--N 1.318 -0.772 0 CA-C-O 121.901 0.857 . . . . 0.0 109.576 178.263 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.525 ' O ' HG13 ' A' ' 34' ' ' ILE . 0.5 OUTLIER -66.95 -38.21 80.93 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.696 0 CA-C-N 114.263 -1.335 . . . . 0.0 107.891 -179.66 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 31' ' ' TRP . . . . . 0.583 ' HD1' ' HA2' ' A' ' 28' ' ' GLY . 38.2 m95 -66.33 -35.99 81.77 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 114.852 -1.067 . . . . 0.0 110.519 -177.215 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 5.4 t0 -70.1 -42.88 72.12 Favored 'General case' 0 N--CA 1.442 -0.86 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.138 178.621 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 33' ' ' ALA . . . . . 0.426 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -69.35 -34.22 74.28 Favored 'General case' 0 N--CA 1.445 -0.704 0 C-N-CA 120.39 -0.524 . . . . 0.0 110.683 179.457 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 34' ' ' ILE . . . . . 0.525 HG13 ' O ' ' A' ' 30' ' ' ILE . 51.9 mt -62.61 -43.65 98.69 Favored 'Isoleucine or valine' 0 C--O 1.235 0.295 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.429 174.692 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 35' ' ' ALA . . . . . 0.541 ' HA ' ' O ' ' A' ' 54' ' ' GLY . . . -61.84 -34.94 76.88 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.285 176.349 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 36' ' ' GLY . . . . . 0.433 ' HA2' ' N ' ' A' ' 41' ' ' GLY . . . -72.46 -16.9 77.51 Favored Glycine 0 N--CA 1.451 -0.328 0 CA-C-N 115.503 -0.771 . . . . 0.0 111.902 179.332 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 7.1 t -81.62 -61.88 1.8 Allowed 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.575 -0.313 . . . . 0.0 111.78 -177.388 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 14.0 tp10 -88.76 -33.73 17.37 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-O 121.109 0.48 . . . . 0.0 110.714 -172.641 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -99.13 -10.53 22.4 Favored 'General case' 0 N--CA 1.446 -0.626 0 CA-C-N 115.986 -0.552 . . . . 0.0 111.797 -173.817 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 75.13 15.9 80.87 Favored Glycine 0 N--CA 1.448 -0.522 0 N-CA-C 109.666 -1.374 . . . . 0.0 109.666 -177.041 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 41' ' ' GLY . . . . . 0.433 ' N ' ' HA2' ' A' ' 36' ' ' GLY . . . 79.18 61.73 2.31 Favored Glycine 0 N--CA 1.434 -1.478 0 CA-C-N 114.045 -1.077 . . . . 0.0 111.465 -174.64 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 2.4 t-20 -142.91 95.63 2.8 Favored 'General case' 0 C--N 1.323 -0.581 0 N-CA-C 108.799 -0.815 . . . . 0.0 108.799 -179.46 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 43' ' ' TRP . . . . . 0.764 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 18.2 m95 -78.29 -3.23 41.87 Favored 'General case' 0 C--N 1.314 -0.944 0 CA-C-N 115.413 -0.812 . . . . 0.0 110.122 -174.269 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -112.58 14.21 20.11 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.273 -0.876 . . . . 0.0 111.7 -179.111 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.949 HG22 ' HA2' ' A' ' 53' ' ' GLY . 2.9 tt -75.61 145.08 11.2 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.45 0 CA-C-O 121.24 0.543 . . . . 0.0 110.214 179.435 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 14.1 t-20 -146.88 87.62 1.7 Allowed 'General case' 0 C--N 1.312 -1.028 0 N-CA-C 109.649 -0.5 . . . . 0.0 109.649 179.188 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 22.4 p -68.6 -28.16 66.68 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.657 -0.701 . . . . 0.0 110.268 179.72 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 100.01 18.09 23.34 Favored Glycine 0 N--CA 1.444 -0.785 0 CA-C-N 115.382 -0.827 . . . . 0.0 111.162 179.474 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 32.9 p-10 -92.85 10.63 30.24 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 120.878 0.37 . . . . 0.0 111.419 -175.147 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 50' ' ' GLY . . . . . 0.525 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 90.51 -11.66 70.78 Favored Glycine 0 N--CA 1.449 -0.433 0 N-CA-C 111.707 -0.557 . . . . 0.0 111.707 179.715 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 51' ' ' TYR . . . . . 0.581 ' CE1' ' HB3' ' A' ' 58' ' ' ASP . 0.6 OUTLIER -111.9 162.07 15.72 Favored 'General case' 0 N--CA 1.446 -0.644 0 N-CA-C 106.541 -1.652 . . . . 0.0 106.541 177.671 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 52' ' ' TYR . . . . . 0.749 ' HB2' ' HB3' ' A' ' 74' ' ' ALA . 39.3 m-85 -125.85 169.68 12.38 Favored 'General case' 0 C--N 1.31 -1.114 0 C-N-CA 119.82 -0.752 . . . . 0.0 112.028 -168.313 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.949 ' HA2' HG22 ' A' ' 45' ' ' ILE . . . -60.52 160.04 24.59 Favored Glycine 0 CA--C 1.5 -0.893 0 CA-C-N 115.121 -0.945 . . . . 0.0 113.54 -175.045 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 54' ' ' GLY . . . . . 0.629 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 92.15 -109.55 3.77 Favored Glycine 0 N--CA 1.437 -1.267 0 C-N-CA 120.515 -0.85 . . . . 0.0 111.615 -177.751 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.581 HG12 ' NE1' ' A' ' 98' ' ' TRP . 3.9 t -87.15 13.18 1.03 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-O 121.378 0.609 . . . . 0.0 110.466 -174.266 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 56' ' ' GLN . . . . . 0.478 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 5.9 pm0 51.07 33.85 9.88 Favored 'General case' 0 N--CA 1.473 0.689 0 N-CA-C 114.454 1.279 . . . . 0.0 114.454 164.975 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 4.7 p90 -113.77 168.95 9.35 Favored 'General case' 0 C--N 1.325 -0.475 0 C-N-CA 119.348 -0.941 . . . . 0.0 112.169 178.593 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.581 ' HB3' ' CE1' ' A' ' 51' ' ' TYR . 5.5 p-10 -83.83 164.53 19.44 Favored 'General case' 0 CA--C 1.517 -0.311 0 N-CA-C 113.887 1.069 . . . . 0.0 113.887 -163.379 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 59' ' ' GLN . . . . . 0.421 ' HB2' ' HE1' ' A' ' 52' ' ' TYR . 5.2 tp-100 -63.38 -39.58 94.92 Favored 'General case' 0 N--CA 1.449 -0.481 0 CA-C-N 113.553 -1.658 . . . . 0.0 111.969 179.695 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -65.52 -48.03 72.25 Favored Glycine 0 C--N 1.317 -0.504 0 C-N-CA 121.124 -0.56 . . . . 0.0 111.991 -176.217 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 98.4 m -64.85 -42.05 95.21 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-O 120.936 0.398 . . . . 0.0 110.85 176.052 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 62' ' ' TRP . . . . . 0.437 ' CH2' ' HA ' ' A' ' 82' ' ' GLN . 53.4 t-105 -56.91 -49.76 74.6 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 121.733 0.778 . . . . 0.0 109.871 176.764 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 63' ' ' GLU . . . . . 0.522 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 1.8 tm-20 -67.68 -33.48 75.0 Favored 'General case' 0 C--N 1.318 -0.802 0 CA-C-N 114.677 -1.147 . . . . 0.0 110.656 -178.246 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -66.86 -40.8 87.98 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.923 -179.581 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 65' ' ' ASN . . . . . 0.405 HD21 ' NH1' ' A' ' 92' ' ' ARG . 8.2 m120 -82.93 -1.78 53.22 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 121.056 0.455 . . . . 0.0 110.328 177.163 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 80.17 48.93 6.18 Favored Glycine 0 C--N 1.334 0.446 0 CA-C-N 115.6 -0.727 . . . . 0.0 112.413 173.686 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 67' ' ' GLY . . . . . 0.545 ' HA2' ' HD1' ' A' ' 70' ' ' TYR . . . -80.25 -18.71 71.01 Favored Glycine 0 N--CA 1.442 -0.953 0 C-N-CA 120.828 -0.701 . . . . 0.0 112.959 -176.338 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.729 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 6.5 mp -60.84 -28.47 68.85 Favored 'General case' 0 C--N 1.322 -0.616 0 N-CA-C 112.379 0.511 . . . . 0.0 112.379 -172.364 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 16.3 ptm180 -67.85 -28.79 67.85 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 121.457 0.646 . . . . 0.0 110.188 176.206 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 70' ' ' TYR . . . . . 0.627 ' HB3' ' HG3' ' A' ' 81' ' ' GLU . 86.4 m-85 -79.4 -34.11 42.12 Favored 'General case' 0 N--CA 1.442 -0.838 0 N-CA-C 107.419 -1.326 . . . . 0.0 107.419 175.708 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.68 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 159.13 128.39 0.0 OUTLIER Pre-proline 0 CA--C 1.51 -0.589 0 CA-C-N 112.473 -2.149 . . . . 0.0 106.539 -179.474 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 72' ' ' PRO . . . . . 0.729 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 23.3 Cg_exo -55.64 -6.08 0.94 Allowed 'Trans proline' 0 CA--C 1.527 0.166 0 C-N-CA 122.829 2.353 . . . . 0.0 113.808 -176.824 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 12.8 ptm180 -146.84 138.49 24.38 Favored 'General case' 0 C--N 1.322 -0.597 0 N-CA-C 109.521 -0.548 . . . . 0.0 109.521 177.927 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 74' ' ' ALA . . . . . 0.749 ' HB3' ' HB2' ' A' ' 52' ' ' TYR . . . -61.7 -23.0 65.82 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 113.052 0.76 . . . . 0.0 113.052 -176.168 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 75' ' ' ASP . . . . . 0.677 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 5.5 p-10 -84.86 -7.68 59.08 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 121.191 0.52 . . . . 0.0 110.65 -179.051 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 54.6 tp -97.68 -31.47 12.25 Favored 'General case' 0 C--N 1.322 -0.623 0 N-CA-C 109.249 -0.648 . . . . 0.0 109.249 173.591 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 77' ' ' ALA . . . . . 0.727 ' HB1' ' HB3' ' A' ' 81' ' ' GLU . . . -78.55 155.22 29.82 Favored 'General case' 0 N--CA 1.444 -0.757 0 CA-C-N 115.267 -0.879 . . . . 0.0 109.562 176.277 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 48.0 p -97.86 -173.9 2.74 Favored 'General case' 0 C--N 1.311 -1.093 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.539 -176.766 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 79' ' ' ARG . . . . . 0.764 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 2.1 mtp180 -51.44 -53.62 35.19 Favored 'General case' 0 C--O 1.219 -0.518 0 O-C-N 123.184 0.302 . . . . 0.0 111.073 -178.044 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 80' ' ' GLU . . . . . 0.411 ' HG2' ' H ' ' A' ' 81' ' ' GLU . 1.6 pm0 -62.47 -45.47 92.89 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-O 120.949 0.404 . . . . 0.0 111.6 -176.5 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 81' ' ' GLU . . . . . 0.727 ' HB3' ' HB1' ' A' ' 77' ' ' ALA . 0.4 OUTLIER -60.88 -52.3 65.66 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 121.204 0.526 . . . . 0.0 112.332 178.194 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 82' ' ' GLN . . . . . 0.513 ' HG2' HG23 ' A' ' 55' ' ' VAL . 6.0 tt0 -69.84 -33.94 72.97 Favored 'General case' 0 C--N 1.316 -0.876 0 CA-C-N 115.449 -0.796 . . . . 0.0 110.735 -175.305 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.568 ' O ' ' HG2' ' A' ' 87' ' ' GLU . 24.3 mt -60.52 -43.18 93.82 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.638 0 CA-C-N 115.535 -0.757 . . . . 0.0 109.905 174.155 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 84' ' ' ALA . . . . . 0.579 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -64.51 -39.29 93.51 Favored 'General case' 0 C--O 1.237 0.411 0 CA-C-O 121.421 0.629 . . . . 0.0 111.076 -174.867 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 51.5 t -68.29 -49.28 68.2 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 CA-C-N 115.645 -0.707 . . . . 0.0 111.162 177.761 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -58.69 -29.82 66.93 Favored 'General case' 0 C--O 1.234 0.267 0 CA-C-O 120.955 0.407 . . . . 0.0 110.532 174.232 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 87' ' ' GLU . . . . . 0.724 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 8.8 mm-40 -59.36 -44.42 92.69 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.467 -0.788 . . . . 0.0 109.766 179.279 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.442 ' O ' ' HG3' ' A' ' 92' ' ' ARG . 70.4 t -62.03 -46.26 96.89 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.209 0 CA-C-O 120.933 0.397 . . . . 0.0 109.938 176.473 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 89' ' ' THR . . . . . 0.938 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 0.2 OUTLIER -60.03 -48.61 81.02 Favored 'General case' 0 N--CA 1.447 -0.59 0 CA-C-N 115.67 -0.695 . . . . 0.0 112.004 -175.141 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 90' ' ' ARG . . . . . 0.69 ' HA ' ' OE1' ' A' ' 93' ' ' GLN . 0.2 OUTLIER -60.46 -33.41 72.51 Favored 'General case' 0 CA--C 1.518 -0.28 0 CA-C-N 116.036 -0.529 . . . . 0.0 111.349 -173.433 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 91' ' ' LEU . . . . . 0.724 ' HG ' ' O ' ' A' ' 87' ' ' GLU . 24.4 mt -66.53 -26.26 67.07 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 121.364 0.602 . . . . 0.0 110.139 -175.039 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 92' ' ' ARG . . . . . 0.442 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 10.3 mtm180 -89.13 -49.94 6.45 Favored 'General case' 0 C--N 1.317 -0.84 0 CA-C-N 114.957 -1.02 . . . . 0.0 110.377 -172.18 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 93' ' ' GLN . . . . . 0.69 ' OE1' ' HA ' ' A' ' 90' ' ' ARG . 0.0 OUTLIER -99.05 -22.94 15.46 Favored 'General case' 0 CA--C 1.54 0.582 0 N-CA-C 113.457 0.91 . . . . 0.0 113.457 -171.599 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 81.7 47.19 6.42 Favored Glycine 0 C--N 1.335 0.522 0 C-N-CA 120.81 -0.709 . . . . 0.0 111.921 173.225 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 95' ' ' TRP . . . . . 0.443 ' HH2' ' HB3' ' A' ' 27' ' ' ASP . 4.9 m95 59.34 21.15 9.4 Favored 'General case' 0 C--O 1.221 -0.404 0 CA-C-O 121.567 0.698 . . . . 0.0 109.674 -179.02 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.538 ' H ' ' HG2' ' A' ' 93' ' ' GLN . . . -78.09 -18.62 76.3 Favored Glycine 0 N--CA 1.452 -0.262 0 CA-C-N 115.4 -0.818 . . . . 0.0 112.11 174.645 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -81.79 -31.84 31.65 Favored 'General case' 0 C--N 1.326 -0.421 0 N-CA-C 109.541 -0.54 . . . . 0.0 109.541 176.421 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 98' ' ' TRP . . . . . 0.938 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 17.2 m-90 -105.68 103.9 45.88 Favored Pre-proline 0 C--N 1.323 -0.577 0 CA-C-N 115.286 -0.87 . . . . 0.0 109.143 177.265 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 99' ' ' PRO . . . . . 0.414 ' HD3' ' HA ' ' A' ' 98' ' ' TRP . 11.3 Cg_exo -77.2 -90.85 0.0 OUTLIER 'Trans proline' 0 CA--C 1.536 0.589 0 C-N-CA 122.789 2.326 . . . . 0.0 114.543 -173.467 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 100' ' ' VAL . . . . . 0.473 ' O ' ' HD2' ' A' ' 104' ' ' ARG . 4.5 p -69.77 -29.37 40.6 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.349 0 CA-C-O 121.962 0.887 . . . . 0.0 110.196 -172.525 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 78.0 m -73.39 -38.8 65.52 Favored 'General case' 0 C--N 1.312 -1.061 0 CA-C-N 114.281 -1.327 . . . . 0.0 111.564 -174.05 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 102' ' ' ALA . . . . . 0.447 ' HB2' ' HB2' ' A' ' 98' ' ' TRP . . . -70.27 -42.37 72.22 Favored 'General case' 0 C--N 1.326 -0.441 0 C-N-CA 120.761 -0.376 . . . . 0.0 110.499 178.494 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -59.3 -45.47 91.19 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 121.2 0.524 . . . . 0.0 110.59 178.552 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 104' ' ' ARG . . . . . 0.473 ' HD2' ' O ' ' A' ' 100' ' ' VAL . 0.0 OUTLIER -71.82 -18.5 62.08 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 115.566 -0.743 . . . . 0.0 111.888 179.512 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 105' ' ' ALA . . . . . 0.431 ' HB3' HG22 ' A' ' 30' ' ' ILE . . . -92.16 -21.35 20.45 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 121.001 0.429 . . . . 0.0 111.45 179.508 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 110.5 63.06 0.51 Allowed Glycine 0 N--CA 1.451 -0.353 0 CA-C-N 116.005 -0.543 . . . . 0.0 112.018 -177.885 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -65.13 149.39 49.99 Favored 'General case' 0 C--N 1.33 -0.244 0 C-N-CA 122.806 0.442 . . . . 0.0 110.908 -178.25 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 71.7 mtp180 . . . . . 0 C--O 1.246 0.884 0 CA-C-O 118.638 -0.696 . . . . 0.0 110.195 -170.995 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 27' ' ' ASP . . . . . 0.424 ' O ' HG13 ' A' ' 30' ' ' ILE . 15.0 m-20 . . . . . 0 CA--C 1.498 -1.036 0 CA-C-O 121.88 0.848 . . . . 0.0 109.791 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 28' ' ' GLY . . . . . 0.607 ' HA2' ' HB2' ' A' ' 31' ' ' TRP . . . -70.66 -7.44 61.36 Favored Glycine 0 N--CA 1.438 -1.228 0 CA-C-N 114.659 -1.155 . . . . 0.0 110.295 -179.12 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 41.7 m -77.05 -38.35 52.9 Favored 'General case' 0 C--N 1.32 -0.717 0 N-CA-C 109.029 -0.73 . . . . 0.0 109.029 173.997 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.576 ' HA ' ' HB1' ' A' ' 105' ' ' ALA . 0.2 OUTLIER -71.92 -37.1 60.07 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.692 0 N-CA-C 107.844 -1.169 . . . . 0.0 107.844 175.929 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 31' ' ' TRP . . . . . 0.607 ' HB2' ' HA2' ' A' ' 28' ' ' GLY . 38.9 m95 -71.38 -38.29 71.55 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 114.611 -1.177 . . . . 0.0 110.391 -178.377 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 28.3 t70 -78.31 -30.14 48.17 Favored 'General case' 0 N--CA 1.442 -0.846 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.041 178.599 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 33' ' ' ALA . . . . . 0.481 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -70.6 -33.78 71.43 Favored 'General case' 0 N--CA 1.452 -0.371 0 O-C-N 122.012 -0.43 . . . . 0.0 110.177 176.389 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 34' ' ' ILE . . . . . 0.534 ' HA ' ' HB3' ' A' ' 101' ' ' CYS . 70.3 mt -64.73 -46.14 93.07 Favored 'Isoleucine or valine' 0 C--O 1.234 0.239 0 CA-C-O 121.241 0.544 . . . . 0.0 109.804 171.473 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 35' ' ' ALA . . . . . 0.486 ' HA ' ' O ' ' A' ' 54' ' ' GLY . . . -58.61 -39.45 80.48 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.547 -0.751 . . . . 0.0 110.453 176.177 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -76.51 -7.25 85.33 Favored Glycine 0 C--N 1.319 -0.363 0 CA-C-N 115.462 -0.79 . . . . 0.0 111.763 179.923 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 9.3 t -92.47 -64.78 1.06 Allowed 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 115.428 -0.386 . . . . 0.0 110.972 -178.981 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 38' ' ' GLU . . . . . 0.806 ' HG3' ' SG ' ' A' ' 101' ' ' CYS . 25.7 mt-10 -90.49 -33.64 15.87 Favored 'General case' 0 C--N 1.325 -0.473 0 C-N-CA 120.522 -0.471 . . . . 0.0 111.419 -175.684 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 39' ' ' ALA . . . . . 0.438 ' HB3' ' O ' ' A' ' 35' ' ' ALA . . . -89.62 -11.86 41.37 Favored 'General case' 0 C--N 1.325 -0.495 0 C-N-CA 120.697 -0.401 . . . . 0.0 111.641 -176.033 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 76.32 13.36 83.41 Favored Glycine 0 CA--C 1.505 -0.556 0 N-CA-C 110.225 -1.15 . . . . 0.0 110.225 -179.672 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 79.64 57.45 3.1 Favored Glycine 0 N--CA 1.433 -1.549 0 CA-C-N 113.915 -1.143 . . . . 0.0 111.759 -176.038 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 42' ' ' ASN . . . . . 0.413 ' OD1' ' HB ' ' A' ' 45' ' ' ILE . 2.4 t-20 -147.8 106.12 3.77 Favored 'General case' 0 N--CA 1.448 -0.548 0 N-CA-C 108.76 -0.83 . . . . 0.0 108.76 -177.752 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 43' ' ' TRP . . . . . 0.753 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 35.2 m95 -83.92 -12.38 55.49 Favored 'General case' 0 C--N 1.311 -1.07 0 CA-C-N 115.643 -0.708 . . . . 0.0 110.315 -174.031 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -106.67 13.98 27.46 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 115.346 -0.843 . . . . 0.0 110.895 -179.508 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.566 HG22 ' HA3' ' A' ' 53' ' ' GLY . 7.0 tt -77.51 144.38 11.56 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.01 0 N-CA-C 109.239 -0.652 . . . . 0.0 109.239 177.412 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 41.1 t-20 -156.59 100.67 1.96 Allowed 'General case' 0 C--N 1.313 -1.022 0 CA-C-O 121.213 0.53 . . . . 0.0 109.614 -177.625 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 14.6 p -72.59 -24.75 61.13 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.298 -0.864 . . . . 0.0 110.383 179.527 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 96.12 17.77 33.65 Favored Glycine 0 N--CA 1.441 -1.013 0 CA-C-N 115.413 -0.812 . . . . 0.0 111.181 178.537 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 1.6 p-10 -90.34 9.47 28.76 Favored 'General case' 0 C--N 1.329 -0.32 0 C-N-CA 120.56 -0.456 . . . . 0.0 111.356 -173.141 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 50' ' ' GLY . . . . . 0.452 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 95.42 -11.55 68.66 Favored Glycine 0 N--CA 1.454 -0.154 0 C-N-CA 120.88 -0.676 . . . . 0.0 111.774 -179.194 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 51' ' ' TYR . . . . . 0.658 ' HA ' ' HA ' ' A' ' 58' ' ' ASP . 0.1 OUTLIER -113.67 159.82 19.28 Favored 'General case' 0 N--CA 1.447 -0.62 0 N-CA-C 106.655 -1.609 . . . . 0.0 106.655 174.186 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 52' ' ' TYR . . . . . 0.835 ' O ' ' HA ' ' A' ' 56' ' ' GLN . 50.8 m-85 -123.67 170.67 10.24 Favored 'General case' 0 C--N 1.311 -1.104 0 C-N-CA 120.639 -0.425 . . . . 0.0 111.116 -169.336 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.566 ' HA3' HG22 ' A' ' 45' ' ' ILE . . . -69.88 -168.27 6.56 Favored Glycine 0 N--CA 1.445 -0.753 0 N-CA-C 114.373 0.509 . . . . 0.0 114.373 -172.851 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 54' ' ' GLY . . . . . 0.653 ' CA ' ' HA ' ' A' ' 43' ' ' TRP . . . 73.46 -107.84 2.34 Favored Glycine 0 N--CA 1.441 -0.977 0 N-CA-C 111.335 -0.706 . . . . 0.0 111.335 -179.466 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.533 HG22 ' HB3' ' A' ' 82' ' ' GLN . 1.7 m -83.73 -0.43 5.39 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-O 121.464 0.649 . . . . 0.0 110.702 179.413 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 56' ' ' GLN . . . . . 0.835 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 49.8 tp60 57.97 52.98 7.22 Favored 'General case' 0 CA--C 1.535 0.393 0 CA-C-N 114.157 -1.383 . . . . 0.0 114.546 164.404 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -126.73 171.92 10.78 Favored 'General case' 0 C--O 1.233 0.233 0 C-N-CA 118.969 -1.092 . . . . 0.0 112.806 172.512 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.658 ' HA ' ' HA ' ' A' ' 51' ' ' TYR . 7.9 p-10 -77.72 162.34 27.05 Favored 'General case' 0 CA--C 1.515 -0.393 0 N-CA-C 113.945 1.091 . . . . 0.0 113.945 -163.756 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 59' ' ' GLN . . . . . 0.479 ' HB2' ' HE1' ' A' ' 52' ' ' TYR . 7.1 tp60 -57.67 -41.98 82.62 Favored 'General case' 0 N--CA 1.445 -0.719 0 CA-C-N 114.367 -1.288 . . . . 0.0 111.137 177.194 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -67.61 -49.44 50.16 Favored Glycine 0 CA--C 1.507 -0.431 0 C-N-CA 120.993 -0.622 . . . . 0.0 112.22 -171.787 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 38.8 m -64.97 -42.03 94.92 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-O 120.904 0.383 . . . . 0.0 111.029 177.804 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 62' ' ' TRP . . . . . 0.484 ' CZ3' ' HA ' ' A' ' 82' ' ' GLN . 47.7 t-105 -56.63 -48.2 78.03 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 121.775 0.798 . . . . 0.0 109.514 175.29 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 63' ' ' GLU . . . . . 0.659 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 36.9 tt0 -65.74 -37.56 86.72 Favored 'General case' 0 N--CA 1.443 -0.791 0 CA-C-N 114.738 -1.119 . . . . 0.0 110.892 -179.151 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -66.02 -41.39 91.04 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.857 -177.941 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 65' ' ' ASN . . . . . 0.447 ' HB2' HG13 ' A' ' 85' ' ' VAL . 9.4 m120 -76.8 -13.04 60.05 Favored 'General case' 0 N--CA 1.45 -0.445 0 CA-C-O 120.883 0.373 . . . . 0.0 110.261 177.493 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 66' ' ' GLY . . . . . 0.532 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 92.11 45.43 3.85 Favored Glycine 0 C--N 1.333 0.393 0 CA-C-N 115.846 -0.616 . . . . 0.0 112.642 175.327 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 67' ' ' GLY . . . . . 0.573 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -79.91 -20.31 68.26 Favored Glycine 0 N--CA 1.443 -0.89 0 C-N-CA 120.807 -0.711 . . . . 0.0 112.848 -174.495 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 1.0 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 6.7 mp -64.37 -23.47 67.3 Favored 'General case' 0 C--N 1.319 -0.756 0 N-CA-C 112.424 0.527 . . . . 0.0 112.424 -172.933 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 69' ' ' ARG . . . . . 0.532 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 13.2 ptp180 -65.26 -31.16 72.17 Favored 'General case' 0 C--N 1.324 -0.509 0 N-CA-C 109.113 -0.699 . . . . 0.0 109.113 175.884 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 70' ' ' TYR . . . . . 0.588 ' HB3' ' HB3' ' A' ' 81' ' ' GLU . 92.4 m-85 -81.12 -36.05 30.82 Favored 'General case' 0 N--CA 1.439 -0.992 0 CA-C-N 114.683 -1.144 . . . . 0.0 107.94 177.394 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.52 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 164.72 127.55 0.02 OUTLIER Pre-proline 0 N--CA 1.448 -0.567 0 CA-C-N 112.626 -2.079 . . . . 0.0 107.342 -178.364 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 72' ' ' PRO . . . . . 1.0 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 17.4 Cg_exo -59.03 -3.44 1.6 Allowed 'Trans proline' 0 C--N 1.334 -0.217 0 C-N-CA 122.724 2.282 . . . . 0.0 113.586 -178.557 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 13.0 ptm180 -144.05 133.74 23.66 Favored 'General case' 0 C--N 1.315 -0.913 0 N-CA-C 108.127 -1.064 . . . . 0.0 108.127 175.986 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 74' ' ' ALA . . . . . 0.658 ' HB3' ' HB2' ' A' ' 52' ' ' TYR . . . -57.99 -28.8 64.74 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 115.578 -0.737 . . . . 0.0 112.372 -175.897 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 20.9 p-10 -84.24 -2.86 57.68 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 121.111 0.481 . . . . 0.0 111.499 -175.944 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.477 ' HB3' ' HB1' ' A' ' 71' ' ' ALA . 62.5 tp -96.38 -28.01 14.66 Favored 'General case' 0 C--N 1.322 -0.624 0 N-CA-C 108.413 -0.958 . . . . 0.0 108.413 170.342 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 77' ' ' ALA . . . . . 0.754 ' HB1' ' HB2' ' A' ' 81' ' ' GLU . . . -80.18 154.4 28.0 Favored 'General case' 0 N--CA 1.444 -0.77 0 CA-C-N 114.413 -1.267 . . . . 0.0 110.093 173.443 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 44.6 p -100.03 -172.5 2.24 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-N 116.392 -0.367 . . . . 0.0 110.136 179.291 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 79' ' ' ARG . . . . . 0.753 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 19.2 mtt180 -48.73 -53.28 19.59 Favored 'General case' 0 CA--C 1.509 -0.605 0 CA-C-O 121.205 0.526 . . . . 0.0 111.277 -177.924 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 80' ' ' GLU . . . . . 0.586 ' HG3' ' OE2' ' A' ' 81' ' ' GLU . 3.4 pt-20 -59.88 -41.04 90.68 Favored 'General case' 0 C--N 1.312 -1.04 0 CA-C-N 114.958 -1.019 . . . . 0.0 112.086 -175.553 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 81' ' ' GLU . . . . . 0.754 ' HB2' ' HB1' ' A' ' 77' ' ' ALA . 4.6 mp0 -67.46 -51.99 44.8 Favored 'General case' 0 C--O 1.232 0.181 0 N-CA-C 112.132 0.419 . . . . 0.0 112.132 174.444 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 82' ' ' GLN . . . . . 0.533 ' HB3' HG22 ' A' ' 55' ' ' VAL . 54.3 mt-30 -59.98 -43.44 95.12 Favored 'General case' 0 CA--C 1.512 -0.501 0 CA-C-O 121.116 0.484 . . . . 0.0 110.54 -175.73 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.631 ' O ' ' HG2' ' A' ' 87' ' ' GLU . 15.4 mt -60.69 -40.81 85.98 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.787 0 CA-C-N 114.947 -1.024 . . . . 0.0 110.568 178.851 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 84' ' ' ALA . . . . . 0.585 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -63.6 -42.13 98.26 Favored 'General case' 0 C--O 1.239 0.524 0 CA-C-O 121.428 0.632 . . . . 0.0 111.366 -177.917 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.447 HG13 ' HB2' ' A' ' 65' ' ' ASN . 44.5 t -69.05 -48.01 72.05 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.675 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.243 178.99 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 86' ' ' ALA . . . . . 0.476 ' HB1' ' CH2' ' A' ' 31' ' ' TRP . . . -57.85 -29.69 65.19 Favored 'General case' 0 N--CA 1.452 -0.34 0 CA-C-N 115.603 -0.726 . . . . 0.0 110.594 174.062 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 87' ' ' GLU . . . . . 0.631 ' HG2' ' O ' ' A' ' 83' ' ' ILE . 15.9 mm-40 -60.81 -40.64 93.5 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.193 178.738 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.504 ' O ' ' HG3' ' A' ' 92' ' ' ARG . 59.0 t -63.08 -48.06 89.61 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-O 121.276 0.56 . . . . 0.0 109.716 173.546 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 89' ' ' THR . . . . . 0.741 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 0.3 OUTLIER -63.41 -47.47 81.85 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 115.559 -0.746 . . . . 0.0 112.224 -174.832 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 90' ' ' ARG . . . . . 0.547 ' HB3' ' CH2' ' A' ' 31' ' ' TRP . 4.8 ptt180 -62.54 -32.82 73.84 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 121.519 0.676 . . . . 0.0 109.216 -176.276 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 91' ' ' LEU . . . . . 0.537 ' N ' ' HG3' ' A' ' 90' ' ' ARG . 64.3 tp -66.09 -32.18 73.5 Favored 'General case' 0 C--N 1.313 -1.01 0 CA-C-N 114.029 -1.441 . . . . 0.0 111.622 -173.236 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 92' ' ' ARG . . . . . 0.504 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 3.5 mtm180 -84.98 -46.46 11.2 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-O 121.507 0.67 . . . . 0.0 110.077 -175.116 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 93' ' ' GLN . . . . . 0.499 HE22 HG22 ' A' ' 89' ' ' THR . 4.5 pt20 -101.89 -27.31 13.06 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 115.218 -0.901 . . . . 0.0 113.155 -168.5 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 92.3 39.62 5.33 Favored Glycine 0 CA--C 1.505 -0.555 0 C-N-CA 120.416 -0.897 . . . . 0.0 111.926 174.547 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 95' ' ' TRP . . . . . 0.499 ' CH2' ' HB ' ' A' ' 30' ' ' ILE . 38.7 m95 71.37 6.91 5.92 Favored 'General case' 0 C--O 1.218 -0.589 0 C-N-CA 123.399 0.68 . . . . 0.0 109.6 -178.462 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -58.46 -37.56 88.58 Favored Glycine 0 CA--C 1.521 0.44 0 CA-C-N 115.595 -0.73 . . . . 0.0 113.741 -179.826 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -68.92 -22.2 64.16 Favored 'General case' 0 CA--C 1.519 -0.241 0 CA-C-N 117.219 0.51 . . . . 0.0 110.657 179.139 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 98' ' ' TRP . . . . . 0.741 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 27.7 m-90 -100.9 104.09 29.45 Favored Pre-proline 0 N--CA 1.449 -0.483 0 N-CA-C 109.05 -0.722 . . . . 0.0 109.05 175.918 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 99' ' ' PRO . . . . . 0.408 ' HD3' ' HA ' ' A' ' 98' ' ' TRP . 16.5 Cg_exo -72.85 -89.96 0.01 OUTLIER 'Trans proline' 0 CA--C 1.533 0.427 0 C-N-CA 122.872 2.382 . . . . 0.0 114.738 -171.509 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 49.0 t -71.68 -30.28 37.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-O 121.811 0.815 . . . . 0.0 110.103 -173.122 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 101' ' ' CYS . . . . . 0.806 ' SG ' ' HG3' ' A' ' 38' ' ' GLU . 70.4 m -76.77 -27.57 55.36 Favored 'General case' 0 C--N 1.317 -0.835 0 CA-C-N 115.099 -0.955 . . . . 0.0 111.869 -169.713 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -69.68 -46.0 67.05 Favored 'General case' 0 C--N 1.329 -0.317 0 C-N-CA 120.75 -0.38 . . . . 0.0 110.753 -179.628 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -67.62 -32.12 72.61 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 120.856 0.36 . . . . 0.0 110.647 -179.946 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -74.1 -21.94 59.69 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.85 177.261 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 105' ' ' ALA . . . . . 0.576 ' HB1' ' HA ' ' A' ' 30' ' ' ILE . . . -96.17 -22.07 17.51 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.815 -0.629 . . . . 0.0 112.057 -176.26 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 108.62 57.08 0.56 Allowed Glycine 0 CA--C 1.522 0.492 0 C-N-CA 120.871 -0.681 . . . . 0.0 112.186 -177.517 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -61.54 149.73 38.09 Favored 'General case' 0 C--N 1.329 -0.321 0 C-N-CA 123.253 0.621 . . . . 0.0 111.551 -175.674 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 72.9 mtp180 . . . . . 0 C--O 1.245 0.859 0 CA-C-O 118.686 -0.673 . . . . 0.0 110.419 -173.855 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 8.7 m-20 . . . . . 0 CA--C 1.502 -0.889 0 CA-C-O 121.511 0.672 . . . . 0.0 109.774 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 28' ' ' GLY . . . . . 0.483 ' HA2' ' HB2' ' A' ' 31' ' ' TRP . . . -64.62 -11.62 49.48 Favored Glycine 0 N--CA 1.44 -1.073 0 CA-C-N 114.893 -1.049 . . . . 0.0 110.64 176.536 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 11.9 m -76.92 -36.88 56.3 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-O 121.854 0.835 . . . . 0.0 109.592 176.511 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.536 ' HA ' ' HB1' ' A' ' 105' ' ' ALA . 1.2 mm -71.34 -40.79 73.71 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 N-CA-C 107.088 -1.449 . . . . 0.0 107.088 176.701 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 31' ' ' TRP . . . . . 0.557 ' HA ' ' CE3' ' A' ' 31' ' ' TRP . 14.3 m95 -67.93 -35.83 79.09 Favored 'General case' 0 C--N 1.315 -0.898 0 CA-C-N 113.711 -1.586 . . . . 0.0 110.536 -175.528 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.607 ' HB2' HH21 ' A' ' 79' ' ' ARG . 12.4 t70 -77.18 -36.6 54.91 Favored 'General case' 0 N--CA 1.44 -0.937 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.712 -179.532 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 33' ' ' ALA . . . . . 0.476 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -70.65 -34.02 71.59 Favored 'General case' 0 N--CA 1.448 -0.558 0 C-N-CA 120.692 -0.403 . . . . 0.0 110.789 177.124 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 34' ' ' ILE . . . . . 0.527 HG13 ' O ' ' A' ' 30' ' ' ILE . 60.5 mt -64.94 -46.83 90.48 Favored 'Isoleucine or valine' 0 C--O 1.234 0.25 0 CA-C-O 120.889 0.376 . . . . 0.0 110.559 175.359 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 35' ' ' ALA . . . . . 0.44 ' O ' ' HB3' ' A' ' 39' ' ' ALA . . . -61.75 -34.67 76.25 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 121.328 0.585 . . . . 0.0 110.285 176.761 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 36' ' ' GLY . . . . . 0.469 ' HA2' ' N ' ' A' ' 41' ' ' GLY . . . -75.58 -9.47 84.69 Favored Glycine 0 N--CA 1.449 -0.462 0 CA-C-N 115.525 -0.762 . . . . 0.0 111.47 178.117 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.459 ' HB3' ' O ' ' A' ' 34' ' ' ILE . 1.7 t -91.03 -63.13 1.31 Allowed 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 115.399 -0.401 . . . . 0.0 111.409 -177.508 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 38' ' ' GLU . . . . . 0.731 ' HG3' ' SG ' ' A' ' 101' ' ' CYS . 13.9 mt-10 -89.27 -33.9 16.8 Favored 'General case' 0 C--N 1.327 -0.381 0 C-N-CA 120.405 -0.518 . . . . 0.0 111.39 -175.262 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 39' ' ' ALA . . . . . 0.44 ' HB3' ' O ' ' A' ' 35' ' ' ALA . . . -88.93 -9.02 53.06 Favored 'General case' 0 C--N 1.323 -0.567 0 C-N-CA 120.706 -0.398 . . . . 0.0 111.367 -177.335 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 75.5 15.92 80.94 Favored Glycine 0 CA--C 1.504 -0.637 0 N-CA-C 110.033 -1.227 . . . . 0.0 110.033 -178.689 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 41' ' ' GLY . . . . . 0.469 ' N ' ' HA2' ' A' ' 36' ' ' GLY . . . 75.76 60.39 3.19 Favored Glycine 0 N--CA 1.434 -1.491 0 CA-C-N 114.047 -1.076 . . . . 0.0 111.25 -174.273 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 2.1 t-20 -142.71 95.42 2.78 Favored 'General case' 0 N--CA 1.448 -0.538 0 N-CA-C 109.242 -0.651 . . . . 0.0 109.242 -178.759 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 43' ' ' TRP . . . . . 0.699 ' HA ' ' N ' ' A' ' 54' ' ' GLY . 36.8 m95 -79.96 -4.03 50.78 Favored 'General case' 0 C--N 1.317 -0.824 0 CA-C-N 115.516 -0.765 . . . . 0.0 110.319 -176.465 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -111.78 15.07 21.07 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 114.893 -1.049 . . . . 0.0 111.416 179.548 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.841 HG22 ' HA2' ' A' ' 53' ' ' GLY . 10.8 tt -76.64 141.44 15.67 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.719 0 CA-C-O 121.297 0.57 . . . . 0.0 110.398 179.612 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 19.1 m120 -142.01 95.93 2.88 Favored 'General case' 0 C--N 1.312 -1.053 0 CA-C-O 121.34 0.59 . . . . 0.0 109.513 -177.927 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 34.3 p -66.47 -23.7 66.31 Favored 'General case' 0 C--N 1.318 -0.791 0 CA-C-N 114.959 -1.019 . . . . 0.0 110.52 -179.097 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 88.55 14.54 61.44 Favored Glycine 0 N--CA 1.441 -0.989 0 N-CA-C 110.135 -1.186 . . . . 0.0 110.135 -178.408 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 2.6 t30 -96.16 5.25 51.49 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.423 0.63 . . . . 0.0 110.67 -173.229 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 95.53 -1.34 64.0 Favored Glycine 0 N--CA 1.447 -0.618 0 C-N-CA 120.612 -0.804 . . . . 0.0 111.103 -176.223 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 51' ' ' TYR . . . . . 0.528 ' HA ' ' O ' ' A' ' 57' ' ' PHE . 0.7 OUTLIER -110.88 161.36 15.9 Favored 'General case' 0 N--CA 1.444 -0.77 0 N-CA-C 107.724 -1.213 . . . . 0.0 107.724 179.077 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 52' ' ' TYR . . . . . 0.543 ' HB2' ' HB3' ' A' ' 74' ' ' ALA . 43.8 m-85 -129.62 170.05 14.27 Favored 'General case' 0 C--N 1.313 -1.013 0 CA-C-O 120.877 0.37 . . . . 0.0 111.823 -170.092 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.841 ' HA2' HG22 ' A' ' 45' ' ' ILE . . . -60.61 164.8 15.32 Favored Glycine 0 N--CA 1.448 -0.562 0 N-CA-C 115.127 0.811 . . . . 0.0 115.127 -168.663 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 54' ' ' GLY . . . . . 0.699 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 90.22 -96.29 2.19 Favored Glycine 0 N--CA 1.439 -1.152 0 CA-C-N 114.659 -0.77 . . . . 0.0 112.258 177.652 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -102.21 12.46 7.09 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.672 0 CA-C-O 120.77 0.319 . . . . 0.0 111.49 -175.803 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 56' ' ' GLN . . . . . . . . . . . . . 21.4 mm-40 60.24 43.64 13.6 Favored 'General case' 0 N--CA 1.47 0.557 0 CA-C-N 115.427 -0.806 . . . . 0.0 112.417 173.903 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 57' ' ' PHE . . . . . 0.528 ' O ' ' HA ' ' A' ' 51' ' ' TYR . 24.3 m-85 -63.38 127.09 29.72 Favored 'General case' 0 CA--C 1.505 -0.757 0 CA-C-N 115.306 -0.861 . . . . 0.0 112.173 172.847 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.512 ' HA ' ' HA ' ' A' ' 51' ' ' TYR . 6.7 p-10 -72.62 156.77 38.63 Favored 'General case' 0 C--N 1.317 -0.84 0 N-CA-C 108.414 -0.958 . . . . 0.0 108.414 163.522 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 7.5 tp60 -58.44 -35.2 71.76 Favored 'General case' 0 C--N 1.316 -0.89 0 CA-C-O 120.733 0.301 . . . . 0.0 111.039 -177.221 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -68.13 -49.69 45.08 Favored Glycine 0 N--CA 1.451 -0.349 0 CA-C-N 116.045 -0.525 . . . . 0.0 112.494 -175.945 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 82.0 m -67.7 -40.97 84.28 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 120.933 0.397 . . . . 0.0 110.735 178.767 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 62' ' ' TRP . . . . . 0.518 ' HB2' ' HB3' ' A' ' 57' ' ' PHE . 65.6 t-105 -58.05 -47.56 82.77 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-O 121.547 0.689 . . . . 0.0 109.416 176.436 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 63' ' ' GLU . . . . . 0.4 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 33.8 tt0 -67.4 -32.51 73.45 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 115.182 -0.917 . . . . 0.0 110.924 -179.979 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -66.42 -42.37 87.85 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.71 -175.832 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 65' ' ' ASN . . . . . 0.78 ' HB2' HG13 ' A' ' 85' ' ' VAL . 26.1 m-80 -82.86 -5.9 59.2 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.874 0.368 . . . . 0.0 110.292 176.031 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 66' ' ' GLY . . . . . 0.593 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 90.61 48.15 3.53 Favored Glycine 0 C--N 1.332 0.327 0 CA-C-N 115.928 -0.578 . . . . 0.0 112.931 171.056 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 67' ' ' GLY . . . . . 0.58 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -79.8 -29.48 47.33 Favored Glycine 0 N--CA 1.438 -1.203 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.43 -176.053 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 1.046 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 8.2 mp -56.78 -22.0 32.71 Favored 'General case' 0 N--CA 1.447 -0.605 0 N-CA-C 112.997 0.74 . . . . 0.0 112.997 -175.189 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 69' ' ' ARG . . . . . 0.593 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 12.3 ptm180 -70.76 -30.26 66.71 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-O 121.431 0.634 . . . . 0.0 110.076 177.744 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 70' ' ' TYR . . . . . 0.984 ' HB3' ' HG2' ' A' ' 81' ' ' GLU . 46.7 m-85 -85.41 -36.0 20.95 Favored 'General case' 0 N--CA 1.443 -0.817 0 N-CA-C 107.447 -1.316 . . . . 0.0 107.447 177.037 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.644 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 170.74 126.23 0.05 OUTLIER Pre-proline 0 N--CA 1.445 -0.722 0 CA-C-N 112.863 -1.972 . . . . 0.0 107.522 -176.24 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 72' ' ' PRO . . . . . 1.046 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 26.4 Cg_exo -56.43 -6.15 1.37 Allowed 'Trans proline' 0 C--N 1.333 -0.28 0 C-N-CA 123.005 2.47 . . . . 0.0 113.785 -178.289 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 73' ' ' ARG . . . . . 0.432 ' HB2' ' CD1' ' A' ' 52' ' ' TYR . 13.5 ptm180 -147.53 138.67 23.64 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-O 121.28 0.562 . . . . 0.0 109.559 176.155 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 74' ' ' ALA . . . . . 0.543 ' HB3' ' HB2' ' A' ' 52' ' ' TYR . . . -56.33 -30.22 62.31 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 114.861 -1.063 . . . . 0.0 113.307 -176.289 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 5.4 p-10 -80.47 -11.82 59.63 Favored 'General case' 0 C--N 1.327 -0.379 0 C-N-CA 120.428 -0.509 . . . . 0.0 110.899 -176.988 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.542 ' HB3' ' HB1' ' A' ' 71' ' ' ALA . 46.4 tp -90.16 -31.8 16.92 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-O 121.937 0.875 . . . . 0.0 108.76 173.621 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 77' ' ' ALA . . . . . 0.644 ' HB2' ' HB3' ' A' ' 71' ' ' ALA . . . -79.68 162.98 24.9 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 114.489 -1.232 . . . . 0.0 110.255 174.122 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 64.1 p -102.11 176.59 5.15 Favored 'General case' 0 C--N 1.318 -0.782 0 CA-C-N 116.399 -0.364 . . . . 0.0 110.721 179.155 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 79' ' ' ARG . . . . . 0.632 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 41.8 mtp180 -47.37 -50.84 21.35 Favored 'General case' 0 CA--C 1.511 -0.549 0 C-N-CA 123.103 0.561 . . . . 0.0 111.255 -174.75 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 80' ' ' GLU . . . . . 0.537 ' HA ' HD12 ' A' ' 83' ' ' ILE . 3.4 pm0 -60.01 -31.78 70.26 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-N 115.729 -0.669 . . . . 0.0 111.52 -176.815 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 81' ' ' GLU . . . . . 0.984 ' HG2' ' HB3' ' A' ' 70' ' ' TYR . 5.4 mt-10 -71.72 -47.4 54.16 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 116.619 -0.264 . . . . 0.0 111.524 176.302 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 82' ' ' GLN . . . . . 0.582 ' HB2' ' HZ3' ' A' ' 43' ' ' TRP . 5.9 mp0 -60.78 -36.52 79.18 Favored 'General case' 0 CA--C 1.514 -0.428 0 C-N-CA 120.213 -0.595 . . . . 0.0 109.447 175.466 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.537 HD12 ' HA ' ' A' ' 80' ' ' GLU . 53.7 mt -60.7 -49.28 85.15 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.635 0 CA-C-N 115.104 -0.953 . . . . 0.0 110.47 178.111 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 84' ' ' ALA . . . . . 0.484 ' O ' ' HG3' ' A' ' 87' ' ' GLU . . . -60.35 -45.76 92.32 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-O 120.957 0.408 . . . . 0.0 111.517 -179.53 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.78 HG13 ' HB2' ' A' ' 65' ' ' ASN . 63.6 t -69.1 -49.26 63.87 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.554 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.551 -178.588 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 86' ' ' ALA . . . . . 0.526 ' CA ' ' HZ ' ' A' ' 57' ' ' PHE . . . -64.56 -32.05 73.53 Favored 'General case' 0 CA--C 1.509 -0.619 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.897 179.645 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 87' ' ' GLU . . . . . 0.575 ' O ' ' HG3' ' A' ' 90' ' ' ARG . 1.3 pp20? -70.83 -29.65 65.85 Favored 'General case' 0 C--N 1.321 -0.665 0 C-N-CA 120.271 -0.572 . . . . 0.0 110.117 -177.624 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.722 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 61.2 t -64.74 -41.47 92.28 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.285 0 N-CA-C 109.136 -0.69 . . . . 0.0 109.136 168.093 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 89' ' ' THR . . . . . 0.942 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 1.8 m -65.02 -47.01 78.98 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 115.66 -0.7 . . . . 0.0 111.166 -177.906 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 90' ' ' ARG . . . . . 0.684 ' HA ' ' OE1' ' A' ' 93' ' ' GLN . 3.0 ppt_? -60.69 -34.1 73.85 Favored 'General case' 0 CA--C 1.516 -0.365 0 CA-C-N 115.801 -0.636 . . . . 0.0 111.598 -175.774 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 91' ' ' LEU . . . . . 0.722 ' HG ' ' O ' ' A' ' 88' ' ' VAL . 4.5 pp -72.51 -22.22 61.07 Favored 'General case' 0 C--N 1.319 -0.758 0 CA-C-O 121.222 0.534 . . . . 0.0 110.185 -175.035 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 92' ' ' ARG . . . . . 0.591 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 10.4 mtm180 -84.57 -51.59 6.76 Favored 'General case' 0 CA--C 1.51 -0.574 0 CA-C-N 115.699 -0.682 . . . . 0.0 110.069 -177.713 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 93' ' ' GLN . . . . . 0.684 ' OE1' ' HA ' ' A' ' 90' ' ' ARG . 0.0 OUTLIER -99.17 -22.91 15.43 Favored 'General case' 0 C--N 1.325 -0.474 0 N-CA-C 113.148 0.795 . . . . 0.0 113.148 -171.127 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 94.52 35.04 6.07 Favored Glycine 0 CA--C 1.508 -0.397 0 C-N-CA 120.849 -0.691 . . . . 0.0 112.439 171.254 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 95' ' ' TRP . . . . . 0.425 ' HE1' ' HB2' ' A' ' 108' ' ' ARG . 20.1 m95 66.27 7.87 5.2 Favored 'General case' 0 C--O 1.22 -0.472 0 C-N-CA 123.602 0.761 . . . . 0.0 109.542 -177.146 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -65.55 -32.55 83.66 Favored Glycine 0 C--N 1.332 0.337 0 C-N-CA 121.083 -0.58 . . . . 0.0 112.169 -179.996 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -67.44 -28.92 68.29 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.792 0.329 . . . . 0.0 110.639 178.998 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 98' ' ' TRP . . . . . 0.942 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 26.5 m-90 -100.1 104.44 29.25 Favored Pre-proline 0 N--CA 1.448 -0.55 0 N-CA-C 108.923 -0.769 . . . . 0.0 108.923 176.246 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 99' ' ' PRO . . . . . 0.427 ' HB2' ' H ' ' A' ' 100' ' ' VAL . 17.0 Cg_exo -72.53 -91.29 0.01 OUTLIER 'Trans proline' 0 CA--C 1.533 0.434 0 C-N-CA 123.101 2.534 . . . . 0.0 114.682 -171.884 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 100' ' ' VAL . . . . . 0.427 ' H ' ' HB2' ' A' ' 99' ' ' PRO . 41.5 t -70.67 -28.05 32.98 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-O 121.764 0.792 . . . . 0.0 110.234 -172.938 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 101' ' ' CYS . . . . . 0.731 ' SG ' ' HG3' ' A' ' 38' ' ' GLU . 84.7 m -75.66 -38.4 58.81 Favored 'General case' 0 C--N 1.315 -0.906 0 CA-C-N 115.063 -0.971 . . . . 0.0 111.881 -171.588 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -68.05 -44.48 76.28 Favored 'General case' 0 C--N 1.327 -0.398 0 C-N-CA 120.591 -0.444 . . . . 0.0 110.309 -179.861 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -59.49 -37.44 78.25 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 121.081 0.467 . . . . 0.0 111.053 179.075 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 15.9 tpp180 -73.98 -34.33 64.17 Favored 'General case' 0 N--CA 1.431 -1.398 0 CA-C-N 115.578 -0.737 . . . . 0.0 111.429 179.323 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 105' ' ' ALA . . . . . 0.536 ' HB1' ' HA ' ' A' ' 30' ' ' ILE . . . -88.12 -22.65 23.98 Favored 'General case' 0 C--N 1.326 -0.416 0 N-CA-C 112.667 0.617 . . . . 0.0 112.667 -172.878 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 120.33 58.42 0.24 Allowed Glycine 0 CA--C 1.521 0.415 0 C-N-CA 120.661 -0.781 . . . . 0.0 112.527 -177.927 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -66.68 148.8 51.42 Favored 'General case' 0 C--N 1.325 -0.478 0 C-N-CA 122.771 0.428 . . . . 0.0 110.519 -179.355 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 108' ' ' ARG . . . . . 0.425 ' HB2' ' HE1' ' A' ' 95' ' ' TRP . 72.3 mtp180 . . . . . 0 C--O 1.247 0.949 0 CA-C-O 117.946 -1.026 . . . . 0.0 110.777 -171.924 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 27' ' ' ASP . . . . . 0.609 ' O ' HG12 ' A' ' 30' ' ' ILE . 16.1 m-20 . . . . . 0 CA--C 1.499 -1.006 0 CA-C-O 121.998 0.904 . . . . 0.0 108.919 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 28' ' ' GLY . . . . . 0.775 ' HA3' HD13 ' A' ' 83' ' ' ILE . . . -67.55 -1.25 15.12 Favored Glycine 0 N--CA 1.433 -1.534 0 CA-C-N 114.143 -1.39 . . . . 0.0 110.844 172.693 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 19.0 m -73.71 -38.31 64.89 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-O 121.46 0.648 . . . . 0.0 109.405 173.203 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.609 HG12 ' O ' ' A' ' 27' ' ' ASP . 0.3 OUTLIER -71.69 -38.84 67.93 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.551 0 N-CA-C 107.179 -1.415 . . . . 0.0 107.179 175.595 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 31' ' ' TRP . . . . . 0.764 ' CD1' HG23 ' A' ' 83' ' ' ILE . 38.8 m95 -69.2 -36.69 77.56 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 114.359 -1.292 . . . . 0.0 110.667 -176.828 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 18.1 t70 -75.33 -33.93 61.17 Favored 'General case' 0 N--CA 1.444 -0.726 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.444 179.775 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 33' ' ' ALA . . . . . 0.468 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -70.42 -35.26 73.31 Favored 'General case' 0 N--CA 1.444 -0.739 0 C-N-CA 120.441 -0.503 . . . . 0.0 109.965 175.307 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 34' ' ' ILE . . . . . 0.554 HG13 ' O ' ' A' ' 30' ' ' ILE . 64.6 mt -64.59 -42.59 95.55 Favored 'Isoleucine or valine' 0 C--O 1.234 0.243 0 CA-C-O 120.996 0.427 . . . . 0.0 109.949 172.947 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 35' ' ' ALA . . . . . 0.432 ' HA ' ' O ' ' A' ' 54' ' ' GLY . . . -57.22 -38.02 73.11 Favored 'General case' 0 N--CA 1.451 -0.418 0 CA-C-N 115.78 -0.646 . . . . 0.0 109.997 174.608 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -73.49 -13.39 80.08 Favored Glycine 0 N--CA 1.45 -0.431 0 CA-C-N 115.375 -0.829 . . . . 0.0 112.051 179.456 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 37.3 t -94.19 -60.11 1.81 Allowed 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 120.702 0.286 . . . . 0.0 111.291 -178.999 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 9.0 tp10 -88.04 -34.32 18.03 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 121.099 0.476 . . . . 0.0 110.223 -170.972 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 39' ' ' ALA . . . . . 0.419 ' HB3' ' O ' ' A' ' 35' ' ' ALA . . . -92.76 -16.28 25.6 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.99 -0.55 . . . . 0.0 111.268 -177.528 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 83.52 5.33 88.57 Favored Glycine 0 CA--C 1.507 -0.461 0 N-CA-C 110.118 -1.193 . . . . 0.0 110.118 -176.124 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 90.28 59.23 1.48 Allowed Glycine 0 N--CA 1.434 -1.44 0 CA-C-N 114.095 -1.053 . . . . 0.0 112.034 -178.912 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 42' ' ' ASN . . . . . 0.441 ' HB3' ' HB ' ' A' ' 45' ' ' ILE . 2.0 t-20 -152.44 126.32 9.01 Favored 'General case' 0 CA--C 1.507 -0.674 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 178.12 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 43' ' ' TRP . . . . . 0.768 ' HA ' ' N ' ' A' ' 54' ' ' GLY . 37.4 m95 -98.16 -12.89 21.25 Favored 'General case' 0 C--N 1.307 -1.263 0 CA-C-N 115.769 -0.65 . . . . 0.0 110.475 -174.171 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -102.95 5.23 38.24 Favored 'General case' 0 C--N 1.316 -0.875 0 CA-C-N 114.922 -1.036 . . . . 0.0 110.729 -179.113 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.441 ' HB ' ' HB3' ' A' ' 42' ' ' ASN . 9.8 tt -73.57 142.15 15.3 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.981 0 CA-C-N 115.921 -0.581 . . . . 0.0 109.876 -178.55 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 40.3 t-20 -154.63 99.15 2.14 Favored 'General case' 0 C--N 1.307 -1.281 0 N-CA-C 109.446 -0.576 . . . . 0.0 109.446 179.611 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 34.8 p -74.58 -15.79 60.83 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 115.626 -0.716 . . . . 0.0 110.937 -177.33 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 94.84 19.76 30.57 Favored Glycine 0 N--CA 1.448 -0.559 0 N-CA-C 111.431 -0.668 . . . . 0.0 111.431 178.932 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 32.5 p-10 -95.64 2.68 54.23 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-O 120.987 0.423 . . . . 0.0 111.421 -176.374 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 95.49 -11.33 68.72 Favored Glycine 0 N--CA 1.448 -0.553 0 N-CA-C 111.425 -0.67 . . . . 0.0 111.425 179.108 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 51' ' ' TYR . . . . . 0.625 ' CD1' ' HB2' ' A' ' 58' ' ' ASP . 0.5 OUTLIER -106.69 132.64 52.45 Favored 'General case' 0 CA--C 1.505 -0.752 0 N-CA-C 107.283 -1.377 . . . . 0.0 107.283 178.46 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 52' ' ' TYR . . . . . 0.716 ' HB2' ' HB3' ' A' ' 74' ' ' ALA . 30.9 m-85 -103.07 169.44 8.56 Favored 'General case' 0 C--N 1.304 -1.371 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.972 -168.433 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.427 ' HA2' HG22 ' A' ' 45' ' ' ILE . . . -59.53 173.54 4.34 Favored Glycine 0 N--CA 1.448 -0.526 0 N-CA-C 115.086 0.794 . . . . 0.0 115.086 -169.151 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 54' ' ' GLY . . . . . 0.768 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 82.13 -99.58 2.04 Favored Glycine 0 N--CA 1.436 -1.329 0 CA-C-N 114.872 -0.664 . . . . 0.0 111.698 178.944 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.571 ' HB ' ' CD1' ' A' ' 57' ' ' PHE . 2.0 t -84.25 -3.41 7.83 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-O 121.774 0.797 . . . . 0.0 109.938 -177.511 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 56' ' ' GLN . . . . . 0.672 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 6.9 tp60 55.81 50.36 14.27 Favored 'General case' 0 N--CA 1.46 0.04 0 CA-C-N 114.058 -1.428 . . . . 0.0 112.479 171.429 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 57' ' ' PHE . . . . . 0.571 ' CD1' ' HB ' ' A' ' 55' ' ' VAL . 3.8 p90 -124.62 165.36 18.01 Favored 'General case' 0 C--N 1.323 -0.546 0 C-N-CA 119.912 -0.715 . . . . 0.0 111.859 177.453 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.625 ' HB2' ' CD1' ' A' ' 51' ' ' TYR . 0.0 OUTLIER -77.12 152.04 35.11 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 114.382 -1.281 . . . . 0.0 113.758 -163.169 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 59' ' ' GLN . . . . . 0.592 ' HB2' ' CE2' ' A' ' 52' ' ' TYR . 5.7 tp60 -50.82 -41.55 57.57 Favored 'General case' 0 N--CA 1.451 -0.393 0 CA-C-N 113.225 -1.807 . . . . 0.0 112.122 177.699 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -67.6 -49.1 52.67 Favored Glycine 0 C--N 1.315 -0.616 0 CA-C-N 115.507 -0.769 . . . . 0.0 112.013 -176.38 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 89.0 m -64.88 -41.16 95.87 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-O 120.919 0.39 . . . . 0.0 110.631 176.99 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 62' ' ' TRP . . . . . 0.524 ' CZ3' ' HA ' ' A' ' 82' ' ' GLN . 40.9 t-105 -57.0 -47.79 79.99 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 121.622 0.725 . . . . 0.0 109.617 174.725 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 63' ' ' GLU . . . . . 0.521 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 20.2 tt0 -65.28 -36.79 85.16 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-N 114.872 -1.058 . . . . 0.0 110.792 -179.932 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -67.57 -35.47 79.07 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 115.427 -0.806 . . . . 0.0 110.518 -177.672 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 65' ' ' ASN . . . . . 0.542 ' HB2' HG13 ' A' ' 85' ' ' VAL . 10.7 m120 -78.51 -12.9 60.04 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.249 175.823 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 66' ' ' GLY . . . . . 0.579 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 87.81 44.11 5.54 Favored Glycine 0 N--CA 1.447 -0.569 0 CA-C-N 115.411 -0.813 . . . . 0.0 112.035 177.345 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 67' ' ' GLY . . . . . 0.603 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -78.74 -22.04 67.48 Favored Glycine 0 N--CA 1.439 -1.117 0 C-N-CA 120.595 -0.812 . . . . 0.0 112.361 -173.52 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.929 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 7.1 mp -60.68 -21.25 62.64 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 112.592 0.59 . . . . 0.0 112.592 -174.334 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 69' ' ' ARG . . . . . 0.579 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 10.0 ptp180 -70.56 -32.9 70.49 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-O 121.253 0.549 . . . . 0.0 109.835 175.185 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 70' ' ' TYR . . . . . 0.662 ' HB3' ' CG ' ' A' ' 81' ' ' GLU . 73.2 m-85 -80.53 -34.59 35.42 Favored 'General case' 0 N--CA 1.443 -0.812 0 N-CA-C 107.47 -1.308 . . . . 0.0 107.47 178.502 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.683 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 164.12 129.12 0.02 OUTLIER Pre-proline 0 CA--C 1.511 -0.551 0 CA-C-N 112.616 -2.084 . . . . 0.0 106.759 -179.49 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 72' ' ' PRO . . . . . 0.929 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 20.4 Cg_exo -57.14 -4.75 1.12 Allowed 'Trans proline' 0 C--N 1.333 -0.244 0 C-N-CA 122.84 2.36 . . . . 0.0 113.932 -177.2 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 13.8 ptm180 -148.11 141.09 24.86 Favored 'General case' 0 C--N 1.317 -0.815 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 176.259 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 74' ' ' ALA . . . . . 0.716 ' HB3' ' HB2' ' A' ' 52' ' ' TYR . . . -59.12 -31.7 69.17 Favored 'General case' 0 C--O 1.219 -0.509 0 CA-C-N 115.615 -0.72 . . . . 0.0 112.298 -177.109 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 8.4 p-10 -85.17 9.68 14.35 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 121.282 0.563 . . . . 0.0 111.263 -174.673 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 50.2 tp -112.13 -33.01 6.37 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.519 -0.764 . . . . 0.0 109.182 173.667 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 77' ' ' ALA . . . . . 0.683 ' HB2' ' HB3' ' A' ' 71' ' ' ALA . . . -79.6 164.71 23.61 Favored 'General case' 0 N--CA 1.448 -0.548 0 CA-C-N 115.065 -0.97 . . . . 0.0 109.449 173.029 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 19.4 p -100.5 -176.99 3.36 Favored 'General case' 0 C--N 1.322 -0.626 0 C-N-CA 120.429 -0.509 . . . . 0.0 110.292 -179.997 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 79' ' ' ARG . . . . . 0.606 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 2.5 mtp180 -49.3 -52.63 26.47 Favored 'General case' 0 CA--C 1.512 -0.517 0 O-C-N 123.403 0.439 . . . . 0.0 111.178 -174.505 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 80' ' ' GLU . . . . . 0.562 ' HG3' ' OE2' ' A' ' 81' ' ' GLU . 11.7 pt-20 -58.39 -42.26 86.67 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.892 -174.806 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 81' ' ' GLU . . . . . 0.662 ' CG ' ' HB3' ' A' ' 70' ' ' TYR . 5.2 mp0 -63.5 -52.71 60.08 Favored 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 111.956 0.354 . . . . 0.0 111.956 174.186 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 82' ' ' GLN . . . . . 0.524 ' HA ' ' CZ3' ' A' ' 62' ' ' TRP . 40.7 mt-30 -59.7 -38.11 80.69 Favored 'General case' 0 CA--C 1.518 -0.268 0 CA-C-O 121.54 0.686 . . . . 0.0 110.097 -176.577 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.775 HD13 ' HA3' ' A' ' 28' ' ' GLY . 31.7 mt -61.57 -49.51 84.09 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.843 0 CA-C-N 114.276 -1.329 . . . . 0.0 111.082 173.832 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 84' ' ' ALA . . . . . 0.647 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -62.67 -38.79 91.72 Favored 'General case' 0 N--CA 1.466 0.342 0 CA-C-O 121.195 0.522 . . . . 0.0 111.886 -176.08 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.542 HG13 ' HB2' ' A' ' 65' ' ' ASN . 60.5 t -64.45 -47.73 88.13 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.495 175.853 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -59.44 -30.86 68.79 Favored 'General case' 0 N--CA 1.453 -0.282 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.051 174.497 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 87' ' ' GLU . . . . . 0.804 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 14.4 mm-40 -59.51 -44.31 93.17 Favored 'General case' 0 C--O 1.219 -0.51 0 CA-C-N 115.344 -0.844 . . . . 0.0 110.484 179.736 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.473 ' HB ' ' HB3' ' A' ' 65' ' ' ASN . 70.7 t -61.48 -49.92 82.46 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.404 0 CA-C-O 121.049 0.452 . . . . 0.0 110.574 -176.414 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 89' ' ' THR . . . . . 0.624 HG23 ' CH2' ' A' ' 98' ' ' TRP . 13.7 t -72.64 -33.76 66.82 Favored 'General case' 0 N--CA 1.438 -1.027 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.074 -176.482 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 90' ' ' ARG . . . . . 0.567 ' HG2' ' HA ' ' A' ' 87' ' ' GLU . 0.8 OUTLIER -60.33 -32.1 70.93 Favored 'General case' 0 N--CA 1.472 0.644 0 CA-C-O 121.176 0.512 . . . . 0.0 110.229 175.982 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 91' ' ' LEU . . . . . 0.804 ' HG ' ' O ' ' A' ' 87' ' ' GLU . 19.4 mt -62.51 -33.08 74.17 Favored 'General case' 0 C--N 1.317 -0.805 0 CA-C-O 121.428 0.632 . . . . 0.0 109.733 177.312 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 92' ' ' ARG . . . . . 0.487 ' NE ' ' HA ' ' A' ' 89' ' ' THR . 2.8 mtm180 -86.29 -52.63 5.51 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-N 115.068 -0.969 . . . . 0.0 110.911 -172.975 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -117.05 2.95 12.73 Favored 'General case' 0 N--CA 1.448 -0.533 0 C-N-CA 119.862 -0.735 . . . . 0.0 112.461 -174.076 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 94' ' ' GLY . . . . . 0.429 ' HA2' ' O ' ' A' ' 90' ' ' ARG . . . 74.64 -119.98 6.27 Favored Glycine 0 CA--C 1.485 -1.786 0 N-CA-C 111.02 -0.832 . . . . 0.0 111.02 171.943 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 95' ' ' TRP . . . . . 0.457 ' HB3' ' CB ' ' A' ' 102' ' ' ALA . 3.4 m95 -127.57 31.65 5.13 Favored 'General case' 0 C--N 1.299 -1.62 0 N-CA-C 106.338 -1.727 . . . . 0.0 106.338 179.834 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -82.17 -25.92 50.15 Favored Glycine 0 N--CA 1.446 -0.666 0 CA-C-N 114.027 -1.442 . . . . 0.0 110.915 171.539 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -81.14 -23.3 38.41 Favored 'General case' 0 CA--C 1.515 -0.372 0 N-CA-C 109.663 -0.495 . . . . 0.0 109.663 174.352 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 98' ' ' TRP . . . . . 0.624 ' CH2' HG23 ' A' ' 89' ' ' THR . 23.7 m-90 -107.93 107.35 60.17 Favored Pre-proline 0 N--CA 1.448 -0.547 0 CA-C-N 115.776 -0.647 . . . . 0.0 109.909 177.071 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_exo -62.34 -137.01 0.0 OUTLIER 'Trans proline' 0 CA--C 1.535 0.526 0 C-N-CA 123.647 2.898 . . . . 0.0 114.119 -177.044 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 2.9 m -54.54 -28.24 18.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 115.88 -0.6 . . . . 0.0 112.152 -177.787 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 82.5 m -56.8 -39.23 73.75 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.263 178.933 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 102' ' ' ALA . . . . . 0.457 ' CB ' ' HB3' ' A' ' 95' ' ' TRP . . . -71.41 -43.94 65.84 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.845 0.355 . . . . 0.0 111.008 178.118 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -61.54 -44.57 96.8 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.851 -179.649 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -67.33 -19.41 65.45 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.728 -0.669 . . . . 0.0 111.159 177.279 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 105' ' ' ALA . . . . . 0.468 ' CB ' ' HB3' ' A' ' 33' ' ' ALA . . . -91.03 -21.15 21.4 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.913 -0.585 . . . . 0.0 111.606 -178.547 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 111.37 61.52 0.47 Allowed Glycine 0 CA--C 1.519 0.344 0 C-N-CA 121.087 -0.577 . . . . 0.0 111.967 -176.481 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -64.11 149.42 47.69 Favored 'General case' 0 C--N 1.328 -0.355 0 C-N-CA 122.878 0.471 . . . . 0.0 111.006 -176.716 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 74.0 mtp180 . . . . . 0 C--O 1.247 0.946 0 CA-C-O 118.503 -0.761 . . . . 0.0 109.912 -173.899 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 27' ' ' ASP . . . . . 0.603 ' O ' HG12 ' A' ' 30' ' ' ILE . 4.5 m-20 . . . . . 0 CA--C 1.507 -0.711 0 CA-C-O 121.62 0.724 . . . . 0.0 109.745 . . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 28' ' ' GLY . . . . . 0.712 ' HA2' ' HB2' ' A' ' 31' ' ' TRP . . . -81.24 3.45 77.19 Favored Glycine 0 CA--C 1.494 -1.259 0 N-CA-C 110.863 -0.895 . . . . 0.0 110.863 -174.504 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 5.8 m -76.39 -48.2 20.65 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-O 121.727 0.775 . . . . 0.0 109.069 176.864 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.797 HG22 ' O ' ' A' ' 105' ' ' ALA . 4.0 pt -71.77 -34.78 52.92 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.182 0 CA-C-N 114.626 -1.17 . . . . 0.0 109.675 175.807 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 31' ' ' TRP . . . . . 0.712 ' HB2' ' HA2' ' A' ' 28' ' ' GLY . 6.5 m95 -66.26 -35.46 80.46 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.311 -0.858 . . . . 0.0 110.085 177.54 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.763 ' HB2' HH21 ' A' ' 79' ' ' ARG . 13.9 t70 -76.37 -34.42 58.92 Favored 'General case' 0 N--CA 1.449 -0.496 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.215 177.135 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.67 -36.0 82.4 Favored 'General case' 0 N--CA 1.445 -0.683 0 C-N-CA 120.775 -0.37 . . . . 0.0 110.328 176.794 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 34' ' ' ILE . . . . . 0.497 HD12 ' CZ3' ' A' ' 31' ' ' TRP . 10.0 mt -67.4 -44.09 87.24 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-O 120.895 0.379 . . . . 0.0 110.706 174.28 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 35' ' ' ALA . . . . . 0.501 ' O ' ' HB3' ' A' ' 39' ' ' ALA . . . -60.22 -34.13 73.23 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-O 121.464 0.65 . . . . 0.0 110.334 177.023 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -76.35 -18.97 78.81 Favored Glycine 0 N--CA 1.448 -0.551 0 CA-C-N 115.306 -0.861 . . . . 0.0 111.231 177.117 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 7.9 t -86.72 -57.1 3.11 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.238 -0.481 . . . . 0.0 111.536 -176.743 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 38' ' ' GLU . . . . . 0.878 ' HG2' ' SG ' ' A' ' 101' ' ' CYS . 15.6 mm-40 -87.77 -33.61 18.6 Favored 'General case' 0 CA--C 1.515 -0.39 0 CA-C-O 120.821 0.343 . . . . 0.0 111.078 -174.933 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 39' ' ' ALA . . . . . 0.501 ' HB3' ' O ' ' A' ' 35' ' ' ALA . . . -96.66 -11.31 25.37 Favored 'General case' 0 C--N 1.324 -0.511 0 C-N-CA 120.424 -0.511 . . . . 0.0 112.124 -173.891 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 80.3 8.28 87.73 Favored Glycine 0 CA--C 1.506 -0.53 0 N-CA-C 110.125 -1.19 . . . . 0.0 110.125 -177.291 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 87.62 56.24 2.16 Favored Glycine 0 N--CA 1.434 -1.455 0 CA-C-N 114.129 -1.036 . . . . 0.0 112.595 179.706 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 50.7 t30 -154.44 122.77 6.06 Favored 'General case' 0 CA--C 1.507 -0.71 0 N-CA-C 109.413 -0.588 . . . . 0.0 109.413 176.993 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 43' ' ' TRP . . . . . 0.712 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 26.3 m95 -96.25 -12.64 24.25 Favored 'General case' 0 C--N 1.308 -1.231 0 CA-C-N 115.055 -0.975 . . . . 0.0 110.415 -173.298 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -101.95 8.97 40.91 Favored 'General case' 0 C--N 1.318 -0.782 0 CA-C-N 115.367 -0.833 . . . . 0.0 110.786 -178.36 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.738 HG22 ' CA ' ' A' ' 53' ' ' GLY . 2.0 tt -72.87 144.22 13.12 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.769 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.006 179.249 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 47.6 t-20 -160.42 101.37 1.36 Allowed 'General case' 0 C--N 1.314 -0.972 0 N-CA-C 109.432 -0.581 . . . . 0.0 109.432 -179.525 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 23.4 p -82.89 -17.13 44.85 Favored 'General case' 0 N--CA 1.445 -0.724 0 CA-C-N 115.559 -0.746 . . . . 0.0 111.222 -178.974 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 91.33 22.19 32.77 Favored Glycine 0 N--CA 1.445 -0.745 0 N-CA-C 111.141 -0.784 . . . . 0.0 111.141 178.398 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 28.7 p-10 -93.67 11.38 29.18 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 121.2 0.524 . . . . 0.0 111.385 -175.904 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 50' ' ' GLY . . . . . 0.461 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 94.36 -11.38 70.41 Favored Glycine 0 N--CA 1.447 -0.576 0 C-N-CA 120.874 -0.679 . . . . 0.0 111.524 -178.486 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 51' ' ' TYR . . . . . 0.601 ' HA ' ' HA ' ' A' ' 58' ' ' ASP . 0.2 OUTLIER -114.64 162.62 16.54 Favored 'General case' 0 N--CA 1.447 -0.591 0 N-CA-C 107.787 -1.19 . . . . 0.0 107.787 176.94 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 52' ' ' TYR . . . . . 0.635 ' HB2' ' HB3' ' A' ' 74' ' ' ALA . 26.9 m-85 -127.9 169.68 13.67 Favored 'General case' 0 C--N 1.309 -1.191 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.046 -172.717 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.738 ' CA ' HG22 ' A' ' 45' ' ' ILE . . . -68.85 -170.68 6.56 Favored Glycine 0 N--CA 1.445 -0.719 0 N-CA-C 114.342 0.497 . . . . 0.0 114.342 -170.944 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 54' ' ' GLY . . . . . 0.689 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 75.49 -107.3 2.28 Favored Glycine 0 N--CA 1.44 -1.057 0 C-N-CA 120.984 -0.627 . . . . 0.0 111.856 179.248 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.492 HG12 ' HE1' ' A' ' 98' ' ' TRP . 2.1 t -88.56 9.61 2.29 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.655 0 CA-C-O 121.203 0.525 . . . . 0.0 110.357 -177.403 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 56' ' ' GLN . . . . . 0.659 ' HG3' ' HB3' ' A' ' 38' ' ' GLU . 7.1 mm100 60.02 50.42 6.66 Favored 'General case' 0 N--CA 1.468 0.426 0 CA-C-N 115.197 -0.911 . . . . 0.0 112.66 174.513 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 57' ' ' PHE . . . . . 0.502 ' HZ ' ' CA ' ' A' ' 86' ' ' ALA . 49.9 m-85 -76.2 132.24 39.82 Favored 'General case' 0 CA--C 1.503 -0.861 0 CA-C-N 115.126 -0.943 . . . . 0.0 112.301 176.345 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.601 ' HA ' ' HA ' ' A' ' 51' ' ' TYR . 5.6 p-10 -72.54 153.76 41.15 Favored 'General case' 0 C--N 1.315 -0.897 0 C-N-CA 119.542 -0.863 . . . . 0.0 108.707 159.644 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 59' ' ' GLN . . . . . 0.409 ' HB2' ' HE1' ' A' ' 52' ' ' TYR . 7.0 tp60 -54.92 -36.33 65.13 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-O 120.67 0.271 . . . . 0.0 111.482 -178.187 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -67.63 -49.67 48.33 Favored Glycine 0 C--O 1.226 -0.372 0 CA-C-N 116.046 -0.525 . . . . 0.0 112.445 -174.289 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 88.4 m -65.68 -41.4 92.46 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 121.366 0.603 . . . . 0.0 110.894 179.084 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 62' ' ' TRP . . . . . 0.466 ' CE2' ' HA3' ' A' ' 67' ' ' GLY . 56.5 t-105 -59.07 -48.91 79.87 Favored 'General case' 0 N--CA 1.444 -0.762 0 CA-C-N 115.104 -0.953 . . . . 0.0 109.467 177.144 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 63' ' ' GLU . . . . . 0.439 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 34.8 tt0 -68.18 -34.64 76.68 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 115.051 -0.977 . . . . 0.0 111.05 -178.604 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -64.43 -41.34 96.64 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.942 -0.572 . . . . 0.0 111.394 -175.914 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 65' ' ' ASN . . . . . 0.649 HD22 ' N ' ' A' ' 65' ' ' ASN . 0.7 OUTLIER -84.99 -8.63 58.65 Favored 'General case' 0 N--CA 1.451 -0.384 0 CA-C-O 121.109 0.48 . . . . 0.0 110.21 177.394 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 91.76 52.85 2.2 Favored Glycine 0 N--CA 1.451 -0.36 0 CA-C-N 115.762 -0.653 . . . . 0.0 113.15 172.627 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 67' ' ' GLY . . . . . 0.538 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -80.02 -26.46 55.57 Favored Glycine 0 N--CA 1.439 -1.121 0 C-N-CA 120.669 -0.777 . . . . 0.0 112.338 -178.599 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.962 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 7.6 mp -57.56 -23.0 48.14 Favored 'General case' 0 N--CA 1.45 -0.463 0 N-CA-C 113.272 0.841 . . . . 0.0 113.272 -173.256 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 69' ' ' ARG . . . . . 0.435 ' HG3' ' N ' ' A' ' 70' ' ' TYR . 1.1 ptp180 -70.39 -31.89 69.31 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-O 121.005 0.431 . . . . 0.0 110.044 176.829 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 70' ' ' TYR . . . . . 1.022 ' HB3' ' HG3' ' A' ' 81' ' ' GLU . 67.5 m-85 -81.39 -34.53 31.58 Favored 'General case' 0 CA--C 1.505 -0.766 0 N-CA-C 107.457 -1.312 . . . . 0.0 107.457 177.274 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.592 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 165.77 129.6 0.03 OUTLIER Pre-proline 0 C--O 1.218 -0.572 0 CA-C-N 112.272 -2.24 . . . . 0.0 107.259 -178.225 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 72' ' ' PRO . . . . . 0.962 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 7.0 Cg_exo -61.02 0.22 0.96 Allowed 'Trans proline' 0 C--N 1.331 -0.367 0 C-N-CA 122.786 2.324 . . . . 0.0 113.536 -177.318 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 73' ' ' ARG . . . . . 0.476 ' HB2' ' CD2' ' A' ' 52' ' ' TYR . 3.4 ptt180 -151.79 136.65 17.19 Favored 'General case' 0 N--CA 1.441 -0.923 0 N-CA-C 108.968 -0.753 . . . . 0.0 108.968 178.817 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 74' ' ' ALA . . . . . 0.635 ' HB3' ' HB2' ' A' ' 52' ' ' TYR . . . -56.05 -29.55 60.65 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 115.064 -0.971 . . . . 0.0 113.136 -177.081 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 75' ' ' ASP . . . . . 0.544 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 11.6 p-10 -83.54 -2.26 55.59 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 121.014 0.435 . . . . 0.0 111.205 -175.729 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.487 ' HB3' ' HB1' ' A' ' 71' ' ' ALA . 61.6 tp -101.51 -31.48 10.86 Favored 'General case' 0 C--N 1.322 -0.604 0 N-CA-C 108.536 -0.913 . . . . 0.0 108.536 172.103 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 77' ' ' ALA . . . . . 0.695 ' HB1' ' HB3' ' A' ' 81' ' ' GLU . . . -78.82 163.26 25.48 Favored 'General case' 0 N--CA 1.443 -0.825 0 CA-C-N 114.739 -1.118 . . . . 0.0 109.86 174.963 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 61.2 p -101.33 -174.59 2.64 Favored 'General case' 0 C--N 1.31 -1.149 0 CA-C-N 115.934 -0.575 . . . . 0.0 111.072 -176.956 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 79' ' ' ARG . . . . . 0.763 HH21 ' HB2' ' A' ' 32' ' ' ASP . 46.2 mtp180 -54.07 -54.44 39.29 Favored 'General case' 0 CA--C 1.515 -0.374 0 CA-C-O 120.759 0.314 . . . . 0.0 110.437 179.256 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 1.9 pm0 -60.19 -40.37 89.81 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.275 -0.875 . . . . 0.0 111.289 -176.52 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 81' ' ' GLU . . . . . 1.022 ' HG3' ' HB3' ' A' ' 70' ' ' TYR . 0.3 OUTLIER -62.62 -51.19 68.28 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.921 -0.582 . . . . 0.0 112.272 175.94 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 82' ' ' GLN . . . . . 0.62 ' HB2' ' HZ3' ' A' ' 43' ' ' TRP . 53.4 mt-30 -64.07 -35.83 82.01 Favored 'General case' 0 CA--C 1.515 -0.4 0 CA-C-O 121.103 0.478 . . . . 0.0 109.715 179.973 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.608 HG23 ' CD1' ' A' ' 31' ' ' TRP . 14.7 mt -59.8 -45.43 94.79 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 CA-C-N 115.239 -0.891 . . . . 0.0 110.526 176.636 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 84' ' ' ALA . . . . . 0.485 ' O ' HG23 ' A' ' 88' ' ' VAL . . . -60.15 -44.29 95.08 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-O 121.209 0.528 . . . . 0.0 110.511 -178.449 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 67.5 t -69.1 -48.58 68.53 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.604 0 CA-C-N 115.428 -0.806 . . . . 0.0 111.493 179.341 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 86' ' ' ALA . . . . . 0.502 ' CA ' ' HZ ' ' A' ' 57' ' ' PHE . . . -62.6 -34.63 77.4 Favored 'General case' 0 CA--C 1.51 -0.584 0 CA-C-O 121.378 0.608 . . . . 0.0 110.536 179.891 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 87' ' ' GLU . . . . . 0.634 ' HA ' ' HG2' ' A' ' 90' ' ' ARG . 0.7 OUTLIER -71.49 -28.99 64.3 Favored 'General case' 0 C--N 1.315 -0.892 0 CA-C-N 115.525 -0.761 . . . . 0.0 109.965 -176.46 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.636 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 59.9 t -62.47 -42.56 96.19 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.191 0 N-CA-C 109.212 -0.662 . . . . 0.0 109.212 168.969 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 89' ' ' THR . . . . . 0.71 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 0.2 OUTLIER -71.96 -41.23 68.0 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 115.869 -0.605 . . . . 0.0 111.54 -174.445 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 90' ' ' ARG . . . . . 0.634 ' HG2' ' HA ' ' A' ' 87' ' ' GLU . 30.3 ptt180 -59.27 -36.87 76.3 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.657 -175.775 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 91' ' ' LEU . . . . . 0.636 ' HG ' ' O ' ' A' ' 88' ' ' VAL . 4.6 pp -74.88 -25.25 58.82 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.616 -0.72 . . . . 0.0 111.388 -170.087 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 92' ' ' ARG . . . . . 0.457 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 1.7 mtm180 -85.01 -46.24 11.38 Favored 'General case' 0 CA--C 1.511 -0.533 0 CA-C-O 121.513 0.673 . . . . 0.0 109.796 -176.113 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 93' ' ' GLN . . . . . 0.439 ' NE2' HG22 ' A' ' 89' ' ' THR . 16.6 pt20 -98.71 -29.45 13.01 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.15 -0.932 . . . . 0.0 113.01 -168.592 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 91.86 35.85 6.64 Favored Glycine 0 N--CA 1.446 -0.637 0 C-N-CA 120.167 -1.016 . . . . 0.0 111.355 175.459 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 95' ' ' TRP . . . . . 0.504 ' HA ' ' HE3' ' A' ' 98' ' ' TRP . 31.2 m95 68.3 22.66 7.97 Favored 'General case' 0 C--O 1.222 -0.378 0 CA-C-O 121.486 0.66 . . . . 0.0 110.027 177.186 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -70.11 -27.15 73.32 Favored Glycine 0 N--CA 1.449 -0.454 0 CA-C-N 115.135 -0.938 . . . . 0.0 112.35 175.519 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -75.45 -30.49 59.98 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.782 0.325 . . . . 0.0 110.58 177.242 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 98' ' ' TRP . . . . . 0.71 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 16.5 m-90 -103.8 104.76 44.55 Favored Pre-proline 0 C--N 1.324 -0.527 0 N-CA-C 109.706 -0.479 . . . . 0.0 109.706 179.972 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 99' ' ' PRO . . . . . 0.405 ' HD3' ' HA ' ' A' ' 98' ' ' TRP . 17.5 Cg_exo -71.09 -93.12 0.01 OUTLIER 'Trans proline' 0 CA--C 1.537 0.645 0 C-N-CA 123.192 2.594 . . . . 0.0 114.523 -173.341 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 100' ' ' VAL . . . . . 0.472 ' O ' ' HD2' ' A' ' 104' ' ' ARG . 1.3 p -71.68 -27.57 28.54 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.391 0 CA-C-O 121.89 0.852 . . . . 0.0 109.781 -172.686 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 101' ' ' CYS . . . . . 0.878 ' SG ' ' HG2' ' A' ' 38' ' ' GLU . 33.2 m -65.74 -34.76 78.92 Favored 'General case' 0 C--N 1.318 -0.772 0 CA-C-N 114.313 -1.312 . . . . 0.0 111.056 -175.712 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 102' ' ' ALA . . . . . 0.668 ' HB1' ' HB2' ' A' ' 107' ' ' ALA . . . -65.53 -46.55 79.16 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-O 120.945 0.403 . . . . 0.0 110.146 -179.782 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -63.7 -40.59 97.16 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.282 0.563 . . . . 0.0 110.545 179.352 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 104' ' ' ARG . . . . . 0.472 ' HD2' ' O ' ' A' ' 100' ' ' VAL . 0.0 OUTLIER -71.9 -37.89 70.02 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.661 -0.7 . . . . 0.0 111.918 -179.346 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 105' ' ' ALA . . . . . 0.797 ' O ' HG22 ' A' ' 30' ' ' ILE . . . -82.37 -27.84 31.88 Favored 'General case' 0 C--N 1.329 -0.313 0 N-CA-C 112.009 0.374 . . . . 0.0 112.009 -176.166 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 109.4 67.02 0.58 Allowed Glycine 0 CA--C 1.522 0.486 0 C-N-CA 120.64 -0.791 . . . . 0.0 112.277 -173.741 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 107' ' ' ALA . . . . . 0.668 ' HB2' ' HB1' ' A' ' 102' ' ' ALA . . . -58.4 149.81 23.92 Favored 'General case' 0 C--N 1.324 -0.516 0 C-N-CA 123.586 0.754 . . . . 0.0 111.664 178.808 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 8.9 ptm180 . . . . . 0 C--O 1.247 0.945 0 CA-C-N 115.476 -0.783 . . . . 0.0 110.165 -173.168 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 27' ' ' ASP . . . . . 0.654 ' O ' HG12 ' A' ' 30' ' ' ILE . 2.5 m-20 . . . . . 0 CA--C 1.506 -0.737 0 CA-C-O 121.86 0.838 . . . . 0.0 109.297 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 28' ' ' GLY . . . . . 0.556 ' HA2' ' HB2' ' A' ' 31' ' ' TRP . . . -79.81 3.81 68.12 Favored Glycine 0 N--CA 1.434 -1.45 0 CA-C-N 114.841 -1.072 . . . . 0.0 110.496 -174.829 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 19.9 t -77.06 -38.86 51.77 Favored 'General case' 0 C--N 1.318 -0.798 0 N-CA-C 108.701 -0.851 . . . . 0.0 108.701 173.456 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.806 ' HA ' ' HB1' ' A' ' 105' ' ' ALA . 0.0 OUTLIER -71.48 -36.66 61.39 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.669 0 N-CA-C 107.166 -1.42 . . . . 0.0 107.166 177.167 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 31' ' ' TRP . . . . . 0.556 ' HB2' ' HA2' ' A' ' 28' ' ' GLY . 14.6 m95 -75.05 -37.91 61.55 Favored 'General case' 0 N--CA 1.442 -0.826 0 CA-C-N 114.447 -1.252 . . . . 0.0 110.726 -176.863 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 23.2 t70 -78.44 -33.28 48.62 Favored 'General case' 0 N--CA 1.442 -0.846 0 CA-C-N 116.445 -0.343 . . . . 0.0 110.933 178.365 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 33' ' ' ALA . . . . . 0.443 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -68.52 -36.74 79.28 Favored 'General case' 0 N--CA 1.454 -0.26 0 C-N-CA 120.18 -0.608 . . . . 0.0 110.561 176.37 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 34' ' ' ILE . . . . . 0.504 HG21 ' CD1' ' A' ' 98' ' ' TRP . 79.7 mt -66.63 -46.22 86.54 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-O 120.761 0.315 . . . . 0.0 110.169 174.494 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 35' ' ' ALA . . . . . 0.439 ' O ' ' HB3' ' A' ' 39' ' ' ALA . . . -58.05 -34.62 70.29 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 121.292 0.568 . . . . 0.0 110.448 176.13 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 36' ' ' GLY . . . . . 0.519 ' HA2' ' N ' ' A' ' 41' ' ' GLY . . . -80.47 -11.23 84.38 Favored Glycine 0 N--CA 1.45 -0.429 0 CA-C-N 115.616 -0.72 . . . . 0.0 111.975 179.27 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 44.3 t -97.96 -50.75 4.29 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 120.643 0.259 . . . . 0.0 111.309 -176.991 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 38' ' ' GLU . . . . . 0.601 ' HG2' ' SG ' ' A' ' 101' ' ' CYS . 13.7 mt-10 -88.02 -31.85 19.1 Favored 'General case' 0 CA--C 1.513 -0.474 0 CA-C-O 120.906 0.384 . . . . 0.0 110.346 -175.403 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 39' ' ' ALA . . . . . 0.439 ' HB3' ' O ' ' A' ' 35' ' ' ALA . . . -103.17 -9.18 19.85 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.828 -177.904 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 77.97 9.92 86.59 Favored Glycine 0 CA--C 1.507 -0.432 0 N-CA-C 110.011 -1.236 . . . . 0.0 110.011 -177.586 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 41' ' ' GLY . . . . . 0.519 ' N ' ' HA2' ' A' ' 36' ' ' GLY . . . 85.9 59.25 1.9 Allowed Glycine 0 N--CA 1.435 -1.384 0 CA-C-N 114.049 -1.076 . . . . 0.0 111.337 -176.398 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 42' ' ' ASN . . . . . 0.604 ' HB3' ' HB ' ' A' ' 45' ' ' ILE . 1.6 t-20 -140.46 89.3 2.27 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 109.215 -0.661 . . . . 0.0 109.215 -176.105 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 43' ' ' TRP . . . . . 0.631 ' HA ' ' N ' ' A' ' 54' ' ' GLY . 50.0 m95 -75.19 -7.83 54.92 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-O 121.563 0.697 . . . . 0.0 110.135 -176.506 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -104.73 9.51 35.01 Favored 'General case' 0 C--N 1.316 -0.867 0 CA-C-N 114.851 -1.068 . . . . 0.0 111.473 -179.637 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.916 HG22 ' HA2' ' A' ' 53' ' ' GLY . 9.7 tt -74.41 143.21 13.74 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.794 0 CA-C-O 121.194 0.521 . . . . 0.0 110.699 -176.862 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 15.3 t-20 -148.37 88.07 1.62 Allowed 'General case' 0 C--N 1.314 -0.958 0 CA-C-O 121.145 0.497 . . . . 0.0 109.681 179.177 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 5.1 p -72.45 -23.95 61.13 Favored 'General case' 0 C--N 1.319 -0.752 0 CA-C-N 115.297 -0.865 . . . . 0.0 111.129 -179.342 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 96.8 16.71 35.26 Favored Glycine 0 N--CA 1.448 -0.513 0 C-N-CA 120.951 -0.642 . . . . 0.0 111.552 178.79 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 12.0 m120 -79.93 2.72 22.36 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.807 0.337 . . . . 0.0 111.006 -175.397 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 50' ' ' GLY . . . . . 0.45 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 85.7 -3.87 86.55 Favored Glycine 0 N--CA 1.446 -0.678 0 N-CA-C 109.905 -1.278 . . . . 0.0 109.905 -168.396 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 51' ' ' TYR . . . . . 0.506 ' CE1' ' HB3' ' A' ' 58' ' ' ASP . 0.4 OUTLIER -109.09 155.72 20.64 Favored 'General case' 0 N--CA 1.45 -0.453 0 N-CA-C 107.036 -1.468 . . . . 0.0 107.036 177.94 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 52' ' ' TYR . . . . . 0.828 ' O ' ' HA ' ' A' ' 56' ' ' GLN . 47.3 m-85 -129.55 171.32 12.71 Favored 'General case' 0 C--N 1.317 -0.823 0 C-N-CA 120.266 -0.574 . . . . 0.0 112.536 -170.303 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.916 ' HA2' HG22 ' A' ' 45' ' ' ILE . . . -47.97 154.69 1.4 Allowed Glycine 0 N--CA 1.453 -0.172 0 N-CA-C 115.583 0.993 . . . . 0.0 115.583 -171.459 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 54' ' ' GLY . . . . . 0.631 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 97.79 -109.8 3.89 Favored Glycine 0 N--CA 1.442 -0.923 0 CA-C-N 114.653 -0.774 . . . . 0.0 111.708 176.631 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.432 HG23 ' CD1' ' A' ' 57' ' ' PHE . 1.9 m -84.58 -3.22 7.82 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 CA-C-O 121.681 0.753 . . . . 0.0 110.924 178.403 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 56' ' ' GLN . . . . . 0.828 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 34.8 tt0 55.29 51.4 13.14 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 113.855 -1.521 . . . . 0.0 113.803 168.12 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 57' ' ' PHE . . . . . 0.432 ' CD1' HG23 ' A' ' 55' ' ' VAL . 1.6 p90 -109.85 172.53 6.8 Favored 'General case' 0 C--O 1.236 0.349 0 C-N-CA 119.731 -0.787 . . . . 0.0 111.533 173.928 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.506 ' HB3' ' CE1' ' A' ' 51' ' ' TYR . 6.8 p-10 -79.0 156.48 28.42 Favored 'General case' 0 C--N 1.329 -0.308 0 N-CA-C 113.733 1.012 . . . . 0.0 113.733 -161.499 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 59' ' ' GLN . . . . . 0.471 ' HB2' ' HE1' ' A' ' 52' ' ' TYR . 7.0 tp60 -57.03 -38.58 73.38 Favored 'General case' 0 N--CA 1.449 -0.48 0 CA-C-N 113.492 -1.685 . . . . 0.0 111.579 178.805 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -67.38 -49.67 50.02 Favored Glycine 0 N--CA 1.44 -1.089 0 CA-C-N 115.881 -0.6 . . . . 0.0 112.182 -174.256 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 91.6 m -65.8 -41.64 91.67 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 121.37 0.605 . . . . 0.0 110.425 176.405 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 62' ' ' TRP . . . . . 0.594 ' CH2' ' HA ' ' A' ' 74' ' ' ALA . 44.8 t-105 -56.27 -49.49 74.07 Favored 'General case' 0 N--CA 1.447 -0.615 0 CA-C-N 115.129 -0.941 . . . . 0.0 109.958 177.485 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 63' ' ' GLU . . . . . 0.671 ' HG3' HD11 ' A' ' 68' ' ' LEU . 18.3 tt0 -67.45 -36.47 81.25 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-N 114.907 -1.042 . . . . 0.0 110.77 -179.226 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -64.95 -41.52 95.41 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.657 -0.701 . . . . 0.0 111.059 -177.578 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 65' ' ' ASN . . . . . 0.633 ' HB2' HG13 ' A' ' 85' ' ' VAL . 8.4 m120 -81.68 -16.44 51.28 Favored 'General case' 0 C--N 1.325 -0.473 0 N-CA-C 109.557 -0.534 . . . . 0.0 109.557 177.991 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 97.01 45.48 2.61 Favored Glycine 0 N--CA 1.449 -0.442 0 CA-C-N 115.784 -0.643 . . . . 0.0 113.538 170.648 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 67' ' ' GLY . . . . . 0.402 ' HA2' ' CD2' ' A' ' 70' ' ' TYR . . . -79.42 -24.47 60.85 Favored Glycine 0 N--CA 1.44 -1.037 0 N-CA-C 110.762 -0.935 . . . . 0.0 110.762 -179.543 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.683 ' HA ' ' HA ' ' A' ' 72' ' ' PRO . 19.1 mt -54.63 -25.77 28.75 Favored 'General case' 0 N--CA 1.449 -0.503 0 CA-C-O 121.365 0.602 . . . . 0.0 110.728 -176.3 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 8.4 ptm180 -71.98 -27.79 63.0 Favored 'General case' 0 N--CA 1.439 -0.996 0 CA-C-N 115.132 -0.94 . . . . 0.0 109.922 -175.835 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 70' ' ' TYR . . . . . 0.801 ' HB2' ' OE2' ' A' ' 81' ' ' GLU . 10.4 m-85 -94.13 -33.25 13.41 Favored 'General case' 0 N--CA 1.433 -1.308 0 N-CA-C 106.625 -1.62 . . . . 0.0 106.625 177.566 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.933 ' HB1' ' HB3' ' A' ' 76' ' ' LEU . . . 179.16 122.38 0.21 Allowed Pre-proline 0 N--CA 1.447 -0.621 0 CA-C-N 113.422 -1.717 . . . . 0.0 108.754 -178.589 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 72' ' ' PRO . . . . . 0.683 ' HA ' ' HA ' ' A' ' 68' ' ' LEU . 11.9 Cg_exo -61.2 1.58 0.62 Allowed 'Trans proline' 0 CA--C 1.528 0.216 0 C-N-CA 122.683 2.255 . . . . 0.0 113.293 179.417 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 73' ' ' ARG . . . . . 0.522 ' HB2' ' CD2' ' A' ' 52' ' ' TYR . 15.1 ptm180 -151.28 138.2 19.02 Favored 'General case' 0 C--N 1.316 -0.889 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 175.236 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 74' ' ' ALA . . . . . 0.672 ' HB3' ' HB2' ' A' ' 52' ' ' TYR . . . -58.36 -28.53 65.22 Favored 'General case' 0 C--O 1.218 -0.561 0 CA-C-N 115.543 -0.753 . . . . 0.0 112.584 -174.082 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 11.3 p-10 -87.95 10.15 19.81 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-O 121.062 0.458 . . . . 0.0 111.009 -176.393 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.933 ' HB3' ' HB1' ' A' ' 71' ' ' ALA . 41.6 tp -101.03 -40.16 7.36 Favored 'General case' 0 N--CA 1.45 -0.447 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.121 176.352 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 77' ' ' ALA . . . . . 0.847 ' HB3' ' HG2' ' A' ' 81' ' ' GLU . . . -103.84 168.81 8.89 Favored 'General case' 0 N--CA 1.447 -0.596 0 CA-C-O 121.108 0.48 . . . . 0.0 110.467 176.757 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 43.6 p -90.17 -177.96 5.28 Favored 'General case' 0 C--N 1.315 -0.918 0 CA-C-N 115.676 -0.693 . . . . 0.0 112.785 -167.303 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 79' ' ' ARG . . . . . 0.576 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 5.0 mtp180 -49.27 -48.83 45.68 Favored 'General case' 0 CA--C 1.513 -0.457 0 C-N-CA 123.94 0.896 . . . . 0.0 111.782 -171.899 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 2.3 pm0 -60.53 -30.31 69.67 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.567 -0.742 . . . . 0.0 111.74 -175.957 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 81' ' ' GLU . . . . . 0.847 ' HG2' ' HB3' ' A' ' 77' ' ' ALA . 0.0 OUTLIER -71.71 -50.38 30.8 Favored 'General case' 0 N--CA 1.449 -0.485 0 C-N-CA 120.934 -0.306 . . . . 0.0 110.311 176.011 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 82' ' ' GLN . . . . . 0.747 ' N ' ' HG3' ' A' ' 81' ' ' GLU . 4.6 mt-30 -59.64 -35.47 74.47 Favored 'General case' 0 CA--C 1.508 -0.661 0 N-CA-C 109.336 -0.616 . . . . 0.0 109.336 -179.851 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.675 ' O ' ' HG2' ' A' ' 87' ' ' GLU . 21.8 mt -61.37 -47.2 94.53 Favored 'Isoleucine or valine' 0 C--O 1.212 -0.92 0 CA-C-N 114.824 -1.08 . . . . 0.0 110.527 175.755 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 84' ' ' ALA . . . . . 0.643 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -61.03 -43.92 98.17 Favored 'General case' 0 C--O 1.239 0.527 0 CA-C-O 121.378 0.608 . . . . 0.0 111.462 -176.555 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.633 HG13 ' HB2' ' A' ' 65' ' ' ASN . 22.1 t -69.1 -48.47 69.06 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-N 115.927 -0.578 . . . . 0.0 110.549 179.551 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -57.66 -28.68 63.96 Favored 'General case' 0 C--O 1.223 -0.311 0 CA-C-N 115.868 -0.606 . . . . 0.0 110.618 173.925 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 87' ' ' GLU . . . . . 0.675 ' HG2' ' O ' ' A' ' 83' ' ' ILE . 6.6 mm-40 -59.76 -44.87 93.65 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.955 -0.566 . . . . 0.0 109.65 178.166 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.712 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 46.4 t -69.59 -42.34 80.57 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 C-N-CA 120.573 -0.451 . . . . 0.0 110.02 175.58 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 89' ' ' THR . . . . . 0.845 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 2.6 m -59.81 -48.09 83.07 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 116.43 -0.35 . . . . 0.0 111.443 -178.898 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 90' ' ' ARG . . . . . 0.654 ' HA ' ' OE1' ' A' ' 93' ' ' GLN . 7.9 ptt180 -65.67 -34.19 77.64 Favored 'General case' 0 CA--C 1.517 -0.31 0 CA-C-O 120.941 0.4 . . . . 0.0 111.421 -174.874 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 91' ' ' LEU . . . . . 0.712 ' HG ' ' O ' ' A' ' 88' ' ' VAL . 4.6 pp -70.52 -22.26 62.65 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.892 -174.143 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 92' ' ' ARG . . . . . 0.562 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 9.8 mtm180 -84.98 -52.28 6.09 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -178.698 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 93' ' ' GLN . . . . . 0.732 ' HG2' ' H ' ' A' ' 96' ' ' GLY . 0.0 OUTLIER -96.78 -24.75 15.77 Favored 'General case' 0 CA--C 1.539 0.53 0 N-CA-C 113.602 0.964 . . . . 0.0 113.602 -169.275 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 80.51 50.83 5.17 Favored Glycine 0 CA--C 1.507 -0.414 0 C-N-CA 120.728 -0.749 . . . . 0.0 111.783 176.762 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 95' ' ' TRP . . . . . 0.461 ' HA ' ' HE3' ' A' ' 98' ' ' TRP . 1.4 m95 56.61 29.2 15.21 Favored 'General case' 0 C--O 1.223 -0.3 0 CA-C-O 121.582 0.706 . . . . 0.0 109.754 177.355 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.732 ' H ' ' HG2' ' A' ' 93' ' ' GLN . . . -83.93 -24.78 47.74 Favored Glycine 0 N--CA 1.449 -0.439 0 CA-C-N 115.314 -0.857 . . . . 0.0 111.87 174.912 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -80.9 -23.88 38.65 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 121.238 0.542 . . . . 0.0 109.685 176.423 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 98' ' ' TRP . . . . . 0.845 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 23.4 m-90 -101.01 108.01 52.52 Favored Pre-proline 0 N--CA 1.445 -0.708 0 N-CA-C 108.59 -0.893 . . . . 0.0 108.59 175.63 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 99' ' ' PRO . . . . . 0.43 ' HD3' ' HA ' ' A' ' 98' ' ' TRP . 45.0 Cg_exo -63.7 -133.68 0.0 OUTLIER 'Trans proline' 0 CA--C 1.541 0.828 0 C-N-CA 123.654 2.903 . . . . 0.0 113.991 -175.928 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 41.8 t -55.22 -25.56 16.99 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.287 0 CA-C-O 120.886 0.374 . . . . 0.0 111.637 -175.116 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 101' ' ' CYS . . . . . 0.601 ' SG ' ' HG2' ' A' ' 38' ' ' GLU . 85.1 m -63.99 -25.66 68.23 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 116.315 -0.402 . . . . 0.0 111.686 -178.25 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -69.36 -44.63 71.17 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.922 0.392 . . . . 0.0 110.368 177.704 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -67.42 -36.63 81.63 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 121.19 0.519 . . . . 0.0 110.142 178.554 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 104' ' ' ARG . . . . . 0.416 HH11 ' HD3' ' A' ' 104' ' ' ARG . 9.8 mmm180 -64.73 -32.56 74.29 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.352 -0.84 . . . . 0.0 110.937 176.844 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 105' ' ' ALA . . . . . 0.806 ' HB1' ' HA ' ' A' ' 30' ' ' ILE . . . -89.01 -22.46 22.97 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 116.136 -0.484 . . . . 0.0 112.085 -176.076 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 103.18 68.04 0.77 Allowed Glycine 0 CA--C 1.521 0.445 0 C-N-CA 120.97 -0.633 . . . . 0.0 112.313 -177.794 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -64.45 152.71 40.88 Favored 'General case' 0 N--CA 1.45 -0.452 0 C-N-CA 122.856 0.462 . . . . 0.0 111.256 -176.063 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 25.5 mmt180 . . . . . 0 C--O 1.248 0.987 0 CA-C-O 118.289 -0.862 . . . . 0.0 111.56 177.64 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 27' ' ' ASP . . . . . 0.449 ' O ' HG13 ' A' ' 30' ' ' ILE . 48.6 m-20 . . . . . 0 CA--C 1.503 -0.838 0 CA-C-O 122.316 1.055 . . . . 0.0 108.817 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 28' ' ' GLY . . . . . 0.625 ' HA2' ' HB2' ' A' ' 31' ' ' TRP . . . -72.15 -2.7 54.29 Favored Glycine 0 N--CA 1.442 -0.923 0 CA-C-N 113.677 -1.602 . . . . 0.0 111.555 -176.637 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 6.3 p -78.02 -48.09 16.96 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-O 122.049 0.928 . . . . 0.0 109.568 174.677 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.741 ' HA ' ' HB1' ' A' ' 105' ' ' ALA . 0.1 OUTLIER -62.89 -35.64 72.11 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.971 0 CA-C-N 113.392 -1.731 . . . . 0.0 107.713 175.691 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 31' ' ' TRP . . . . . 0.625 ' HB2' ' HA2' ' A' ' 28' ' ' GLY . 18.5 m95 -73.58 -36.91 65.61 Favored 'General case' 0 C--N 1.317 -0.817 0 CA-C-N 114.301 -1.318 . . . . 0.0 110.821 -178.092 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 1.6 t70 -77.92 -34.39 51.37 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.596 179.671 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 33' ' ' ALA . . . . . 0.448 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -70.07 -34.28 72.98 Favored 'General case' 0 N--CA 1.45 -0.474 0 C-N-CA 120.877 -0.329 . . . . 0.0 110.339 176.584 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 34' ' ' ILE . . . . . 0.504 HG13 ' O ' ' A' ' 30' ' ' ILE . 54.0 mt -65.12 -45.1 95.19 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.225 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 172.311 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 35' ' ' ALA . . . . . 0.552 ' HA ' ' O ' ' A' ' 54' ' ' GLY . . . -57.59 -36.41 71.68 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.228 176.613 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -73.92 -21.12 79.57 Favored Glycine 0 N--CA 1.451 -0.328 0 CA-C-N 115.574 -0.739 . . . . 0.0 112.237 178.886 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 18.5 t -93.75 -52.9 4.24 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-O 121.038 0.447 . . . . 0.0 111.811 -176.593 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 9.3 tp10 -87.58 -32.3 19.41 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 121.399 0.619 . . . . 0.0 110.107 -171.667 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 39' ' ' ALA . . . . . 0.448 ' HB3' ' O ' ' A' ' 35' ' ' ALA . . . -101.51 -13.57 17.85 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 115.644 -0.707 . . . . 0.0 111.616 -177.805 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 80.1 13.08 82.54 Favored Glycine 0 CA--C 1.505 -0.555 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 -176.808 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 81.03 58.83 2.55 Favored Glycine 0 N--CA 1.436 -1.319 0 CA-C-N 114.143 -1.028 . . . . 0.0 111.965 -177.569 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 42' ' ' ASN . . . . . 0.81 ' HB3' ' HB ' ' A' ' 45' ' ' ILE . 2.1 t-20 -151.44 97.34 2.39 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 108.73 -0.841 . . . . 0.0 108.73 -178.229 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 43' ' ' TRP . . . . . 0.731 ' HZ3' ' HB2' ' A' ' 82' ' ' GLN . 49.8 m95 -75.51 -17.03 60.22 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-O 121.49 0.662 . . . . 0.0 110.495 -176.348 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -101.2 14.31 32.36 Favored 'General case' 0 C--N 1.313 -0.995 0 CA-C-N 115.007 -0.997 . . . . 0.0 110.693 -179.451 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.81 ' HB ' ' HB3' ' A' ' 42' ' ' ASN . 6.2 tt -77.44 143.26 13.1 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.951 0 CA-C-O 121.083 0.468 . . . . 0.0 109.759 -178.487 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 46' ' ' ASN . . . . . 0.598 ' ND2' HH21 ' A' ' 73' ' ' ARG . 29.3 t-20 -145.54 89.1 1.89 Allowed 'General case' 0 C--N 1.304 -1.399 0 CA-C-O 121.814 0.816 . . . . 0.0 108.994 179.369 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 2.6 p -67.98 -22.03 65.03 Favored 'General case' 0 N--CA 1.443 -0.81 0 CA-C-N 114.091 -1.413 . . . . 0.0 111.142 -178.418 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 90.03 23.45 32.45 Favored Glycine 0 N--CA 1.441 -0.984 0 N-CA-C 111.112 -0.795 . . . . 0.0 111.112 178.109 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 17.3 p30 -101.58 15.42 28.95 Favored 'General case' 0 C--N 1.326 -0.426 0 N-CA-C 112.384 0.513 . . . . 0.0 112.384 -177.214 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 93.48 -10.91 72.39 Favored Glycine 0 CA--C 1.509 -0.309 0 N-CA-C 111.401 -0.68 . . . . 0.0 111.401 177.608 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 51' ' ' TYR . . . . . 0.562 ' CD1' ' HB2' ' A' ' 58' ' ' ASP . 0.1 OUTLIER -118.79 149.28 41.76 Favored 'General case' 0 N--CA 1.445 -0.713 0 N-CA-C 106.434 -1.691 . . . . 0.0 106.434 -177.566 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 52' ' ' TYR . . . . . 0.711 ' HB2' ' HB3' ' A' ' 74' ' ' ALA . 22.4 m-85 -119.56 170.9 8.76 Favored 'General case' 0 C--N 1.309 -1.18 0 C-N-CA 119.921 -0.711 . . . . 0.0 112.183 -169.298 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.794 ' HA2' HG22 ' A' ' 45' ' ' ILE . . . -57.56 167.64 5.07 Favored Glycine 0 N--CA 1.449 -0.493 0 N-CA-C 115.939 1.136 . . . . 0.0 115.939 -166.115 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 54' ' ' GLY . . . . . 0.652 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 86.62 -102.08 2.7 Favored Glycine 0 N--CA 1.437 -1.296 0 CA-C-N 114.202 -0.999 . . . . 0.0 111.541 178.247 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.584 HG22 ' HB3' ' A' ' 82' ' ' GLN . 3.1 m -85.4 -2.85 7.91 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.737 0 CA-C-O 120.434 0.159 . . . . 0.0 111.329 -179.586 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 56' ' ' GLN . . . . . 0.666 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 8.9 tp-100 52.78 52.94 12.96 Favored 'General case' 0 CA--C 1.534 0.339 0 N-CA-C 113.481 0.919 . . . . 0.0 113.481 166.17 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 57' ' ' PHE . . . . . 0.407 ' CD1' HG23 ' A' ' 55' ' ' VAL . 1.0 OUTLIER -120.57 163.33 18.16 Favored 'General case' 0 C--N 1.327 -0.379 0 C-N-CA 119.862 -0.735 . . . . 0.0 111.366 170.996 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.562 ' HB2' ' CD1' ' A' ' 51' ' ' TYR . 0.0 OUTLIER -73.6 155.1 39.44 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 114.799 -1.092 . . . . 0.0 113.365 -164.565 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 59' ' ' GLN . . . . . 0.458 ' HB2' ' CE2' ' A' ' 52' ' ' TYR . 6.6 tp60 -53.3 -39.98 64.4 Favored 'General case' 0 N--CA 1.451 -0.402 0 CA-C-N 114.078 -1.419 . . . . 0.0 112.303 -179.905 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -68.39 -49.45 45.04 Favored Glycine 0 C--O 1.225 -0.441 0 CA-C-N 115.921 -0.582 . . . . 0.0 112.03 -177.264 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 32.8 m -65.64 -38.18 88.63 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-O 121.461 0.648 . . . . 0.0 110.26 176.105 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 62' ' ' TRP . . . . . 0.559 ' CH2' ' HA ' ' A' ' 74' ' ' ALA . 39.1 t-105 -56.67 -48.89 76.61 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 115.32 -0.854 . . . . 0.0 109.643 173.9 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 63' ' ' GLU . . . . . 0.575 ' CB ' HD11 ' A' ' 68' ' ' LEU . 60.6 tt0 -67.07 -33.97 76.66 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-N 114.876 -1.056 . . . . 0.0 110.943 179.359 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -63.04 -42.03 99.65 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.796 -0.638 . . . . 0.0 111.366 -177.81 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 33.0 m-80 -86.64 -11.76 50.44 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.977 0.418 . . . . 0.0 110.303 177.809 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 66' ' ' GLY . . . . . 0.418 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 92.93 52.38 2.1 Favored Glycine 0 C--O 1.22 -0.743 0 CA-C-N 115.858 -0.61 . . . . 0.0 114.043 170.533 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 67' ' ' GLY . . . . . 0.475 ' HA3' ' CE2' ' A' ' 62' ' ' TRP . . . -80.28 -27.95 50.43 Favored Glycine 0 N--CA 1.441 -0.967 0 C-N-CA 120.666 -0.778 . . . . 0.0 112.629 179.694 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.652 ' HA ' ' HA ' ' A' ' 72' ' ' PRO . 2.4 mp -59.3 -20.51 55.04 Favored 'General case' 0 CA--C 1.519 -0.241 0 CA-C-O 120.864 0.364 . . . . 0.0 111.923 -170.084 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 69' ' ' ARG . . . . . 0.418 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 9.1 ptp180 -72.55 -28.1 62.63 Favored 'General case' 0 N--CA 1.44 -0.944 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.225 -179.155 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 70' ' ' TYR . . . . . 0.717 ' HB2' ' CD ' ' A' ' 81' ' ' GLU . 10.5 m-85 -92.26 -33.29 14.71 Favored 'General case' 0 N--CA 1.433 -1.316 0 N-CA-C 106.683 -1.599 . . . . 0.0 106.683 176.894 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.667 ' HB1' ' HB3' ' A' ' 76' ' ' LEU . . . 175.34 126.86 0.13 Allowed Pre-proline 0 N--CA 1.45 -0.443 0 CA-C-N 113.005 -1.907 . . . . 0.0 108.494 179.107 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 72' ' ' PRO . . . . . 0.652 ' HA ' ' HA ' ' A' ' 68' ' ' LEU . 6.1 Cg_exo -62.46 3.86 0.42 Allowed 'Trans proline' 0 C--N 1.333 -0.272 0 C-N-CA 122.717 2.278 . . . . 0.0 113.709 -178.987 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 73' ' ' ARG . . . . . 0.598 HH21 ' ND2' ' A' ' 46' ' ' ASN . 11.0 ptm180 -154.53 142.51 20.17 Favored 'General case' 0 C--N 1.316 -0.877 0 N-CA-C 108.988 -0.745 . . . . 0.0 108.988 177.302 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 74' ' ' ALA . . . . . 0.711 ' HB3' ' HB2' ' A' ' 52' ' ' TYR . . . -61.69 -29.45 70.1 Favored 'General case' 0 C--O 1.219 -0.508 0 CA-C-N 115.935 -0.575 . . . . 0.0 112.284 -176.675 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 18.6 p-10 -86.44 12.01 11.2 Favored 'General case' 0 C--N 1.317 -0.836 0 CA-C-O 121.168 0.508 . . . . 0.0 111.032 -175.091 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.667 ' HB3' ' HB1' ' A' ' 71' ' ' ALA . 39.6 tp -108.38 -43.58 4.3 Favored 'General case' 0 N--CA 1.449 -0.5 0 CA-C-N 115.586 -0.734 . . . . 0.0 110.429 175.39 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 77' ' ' ALA . . . . . 0.654 ' HB3' ' HG2' ' A' ' 81' ' ' GLU . . . -99.06 167.85 10.45 Favored 'General case' 0 N--CA 1.449 -0.475 0 CA-C-O 121.58 0.705 . . . . 0.0 111.079 178.767 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 78' ' ' THR . . . . . 0.435 ' OG1' ' HG2' ' A' ' 80' ' ' GLU . 27.6 p -91.78 178.73 5.82 Favored 'General case' 0 C--N 1.316 -0.877 0 CA-C-N 115.002 -0.999 . . . . 0.0 112.69 -167.564 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 79' ' ' ARG . . . . . 0.667 ' HG2' ' CE2' ' A' ' 43' ' ' TRP . 64.5 mtp180 -45.89 -42.9 13.2 Favored 'General case' 0 N--CA 1.469 0.501 0 C-N-CA 123.523 0.729 . . . . 0.0 111.88 -174.779 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 80' ' ' GLU . . . . . 0.435 ' HG2' ' OG1' ' A' ' 78' ' ' THR . 7.4 pt-20 -57.19 -37.57 72.37 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 115.738 -0.665 . . . . 0.0 111.002 -177.423 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 81' ' ' GLU . . . . . 0.717 ' CD ' ' HB2' ' A' ' 70' ' ' TYR . 0.0 OUTLIER -72.03 -49.48 36.49 Favored 'General case' 0 N--CA 1.444 -0.731 0 CA-C-N 116.665 -0.243 . . . . 0.0 110.65 -179.238 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 82' ' ' GLN . . . . . 0.731 ' HB2' ' HZ3' ' A' ' 43' ' ' TRP . 9.4 mp0 -61.97 -32.38 72.82 Favored 'General case' 0 CA--C 1.509 -0.61 0 C-N-CA 120.343 -0.543 . . . . 0.0 110.198 -179.276 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.67 ' O ' ' HB3' ' A' ' 87' ' ' GLU . 40.7 mt -64.37 -46.05 94.17 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.753 0 CA-C-N 115.459 -0.791 . . . . 0.0 109.788 176.598 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 84' ' ' ALA . . . . . 0.484 ' O ' ' HG3' ' A' ' 87' ' ' GLU . . . -66.12 -48.22 71.57 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 121.038 0.447 . . . . 0.0 111.649 -176.7 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 47.2 t -69.58 -48.35 66.42 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.577 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.874 -175.414 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 86' ' ' ALA . . . . . 0.431 ' HB1' ' CZ2' ' A' ' 98' ' ' TRP . . . -66.56 -30.15 70.38 Favored 'General case' 0 N--CA 1.444 -0.728 0 CA-C-O 121.026 0.441 . . . . 0.0 110.234 179.682 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 87' ' ' GLU . . . . . 0.67 ' HB3' ' O ' ' A' ' 83' ' ' ILE . 0.4 OUTLIER -70.44 -30.19 66.97 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.774 -177.138 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.671 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 59.1 t -61.29 -42.38 93.34 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.284 0 N-CA-C 108.812 -0.81 . . . . 0.0 108.812 170.732 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 89' ' ' THR . . . . . 0.855 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 0.2 OUTLIER -67.25 -43.83 80.91 Favored 'General case' 0 C--N 1.316 -0.872 0 CA-C-N 115.517 -0.765 . . . . 0.0 110.631 -179.45 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 90' ' ' ARG . . . . . 0.599 ' HG3' ' O ' ' A' ' 87' ' ' GLU . 3.0 ppt_? -63.25 -34.37 77.52 Favored 'General case' 0 CA--C 1.517 -0.295 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.764 -177.512 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 91' ' ' LEU . . . . . 0.671 ' HG ' ' O ' ' A' ' 88' ' ' VAL . 4.4 pp -73.5 -23.7 60.08 Favored 'General case' 0 C--N 1.322 -0.588 0 O-C-N 123.312 0.383 . . . . 0.0 110.949 -171.387 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 92' ' ' ARG . . . . . 0.543 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 4.6 mtm180 -84.3 -48.5 9.66 Favored 'General case' 0 CA--C 1.512 -0.511 0 CA-C-O 121.516 0.674 . . . . 0.0 109.628 -178.386 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 93' ' ' GLN . . . . . 0.539 HE22 ' HB2' ' A' ' 97' ' ' ALA . 4.6 pt20 -98.47 -28.47 13.59 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 114.967 -1.015 . . . . 0.0 113.285 -169.1 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 92.54 40.1 5.13 Favored Glycine 0 CA--C 1.509 -0.323 0 C-N-CA 120.504 -0.855 . . . . 0.0 111.759 176.013 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 95' ' ' TRP . . . . . 0.587 ' CZ2' HD12 ' A' ' 30' ' ' ILE . 34.4 m95 68.7 11.53 8.38 Favored 'General case' 0 C--O 1.216 -0.671 0 C-N-CA 123.316 0.646 . . . . 0.0 110.165 178.536 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -58.85 -29.51 64.82 Favored Glycine 0 CA--C 1.522 0.49 0 CA-C-N 115.523 -0.762 . . . . 0.0 113.463 178.795 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 97' ' ' ALA . . . . . 0.539 ' HB2' HE22 ' A' ' 93' ' ' GLN . . . -80.83 -17.64 50.12 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.938 0.399 . . . . 0.0 110.884 178.031 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 98' ' ' TRP . . . . . 0.855 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 30.0 m-90 -104.93 108.02 60.13 Favored Pre-proline 0 C--N 1.324 -0.51 0 CA-C-N 116.052 -0.522 . . . . 0.0 109.736 178.517 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 39.5 Cg_exo -64.43 -134.63 0.0 OUTLIER 'Trans proline' 0 CA--C 1.537 0.631 0 C-N-CA 123.95 3.1 . . . . 0.0 114.148 -175.845 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 3.8 m -54.14 -27.48 16.55 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.229 0 N-CA-C 112.442 0.534 . . . . 0.0 112.442 -176.813 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 77.1 m -60.81 -40.36 92.41 Favored 'General case' 0 C--N 1.317 -0.847 0 CA-C-N 115.887 -0.597 . . . . 0.0 111.37 179.183 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 102' ' ' ALA . . . . . 0.422 ' HB2' ' CB ' ' A' ' 98' ' ' TRP . . . -72.03 -41.6 67.31 Favored 'General case' 0 CA--C 1.517 -0.295 0 CA-C-O 121.092 0.473 . . . . 0.0 110.26 177.302 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -59.27 -46.21 89.15 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.577 -0.738 . . . . 0.0 110.917 179.128 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 3.0 mpp_? -73.71 -22.08 60.03 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.816 -0.629 . . . . 0.0 111.423 179.854 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 105' ' ' ALA . . . . . 0.741 ' HB1' ' HA ' ' A' ' 30' ' ' ILE . . . -83.06 -20.89 34.09 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.397 179.433 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 104.52 60.72 0.66 Allowed Glycine 0 CA--C 1.519 0.305 0 C-N-CA 121.111 -0.566 . . . . 0.0 112.142 -179.178 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -64.11 141.53 58.74 Favored 'General case' 0 C--O 1.235 0.295 0 C-N-CA 122.659 0.384 . . . . 0.0 111.939 -176.574 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 108' ' ' ARG . . . . . 0.658 ' HD3' ' OXT' ' A' ' 108' ' ' ARG . 0.0 OUTLIER . . . . . 0 C--O 1.246 0.903 0 CA-C-O 118.567 -0.73 . . . . 0.0 110.726 -177.491 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 27' ' ' ASP . . . . . 0.726 ' O ' HG12 ' A' ' 30' ' ' ILE . 33.5 m-20 . . . . . 0 N--CA 1.448 -0.557 0 N-CA-C 108.553 -0.906 . . . . 0.0 108.553 . . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 28' ' ' GLY . . . . . 0.487 ' HA2' ' CD1' ' A' ' 31' ' ' TRP . . . -72.22 -2.6 54.33 Favored Glycine 0 CA--C 1.5 -0.856 0 N-CA-C 110.605 -0.998 . . . . 0.0 110.605 177.482 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 16.4 m -69.63 -37.41 76.8 Favored 'General case' 0 C--N 1.317 -0.828 0 CA-C-O 121.499 0.666 . . . . 0.0 109.352 173.564 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.726 HG12 ' O ' ' A' ' 27' ' ' ASP . 0.3 OUTLIER -69.55 -35.97 68.9 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.672 0 N-CA-C 107.159 -1.422 . . . . 0.0 107.159 176.364 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 31' ' ' TRP . . . . . 0.537 ' CZ2' ' HD3' ' A' ' 90' ' ' ARG . 21.7 m95 -71.45 -36.45 71.23 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 114.255 -1.339 . . . . 0.0 110.776 -177.394 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 27.1 t70 -76.82 -33.39 57.96 Favored 'General case' 0 N--CA 1.445 -0.713 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.167 177.904 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 33' ' ' ALA . . . . . 0.468 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -70.69 -34.07 71.58 Favored 'General case' 0 N--CA 1.447 -0.592 0 C-N-CA 120.432 -0.507 . . . . 0.0 110.138 176.529 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 34' ' ' ILE . . . . . 0.527 ' HA ' ' HB3' ' A' ' 101' ' ' CYS . 56.9 mt -67.38 -41.7 86.58 Favored 'Isoleucine or valine' 0 C--O 1.234 0.28 0 CA-C-N 115.851 -0.613 . . . . 0.0 109.99 172.647 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 35' ' ' ALA . . . . . 0.5 ' HA ' ' O ' ' A' ' 54' ' ' GLY . . . -58.75 -38.68 78.97 Favored 'General case' 0 CA--C 1.515 -0.379 0 CA-C-O 121.448 0.642 . . . . 0.0 110.112 174.045 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -75.29 -10.1 84.34 Favored Glycine 0 N--CA 1.449 -0.443 0 CA-C-N 115.192 -0.913 . . . . 0.0 111.343 179.22 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.427 ' HB3' ' O ' ' A' ' 34' ' ' ILE . 14.4 t -90.87 -66.72 0.9 Allowed 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.174 -0.513 . . . . 0.0 111.327 -178.607 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 38' ' ' GLU . . . . . 0.872 ' HG3' ' SG ' ' A' ' 101' ' ' CYS . 53.7 mt-10 -89.7 -34.48 16.22 Favored 'General case' 0 CA--C 1.513 -0.45 0 C-N-CA 120.399 -0.521 . . . . 0.0 110.918 -174.023 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 39' ' ' ALA . . . . . 0.493 ' HB3' ' O ' ' A' ' 35' ' ' ALA . . . -84.15 -18.32 37.12 Favored 'General case' 0 N--CA 1.445 -0.685 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.227 -176.363 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 80.35 12.57 82.96 Favored Glycine 0 CA--C 1.503 -0.701 0 N-CA-C 109.991 -1.243 . . . . 0.0 109.991 -177.351 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 82.81 61.47 1.94 Allowed Glycine 0 N--CA 1.434 -1.44 0 CA-C-N 114.066 -1.067 . . . . 0.0 111.866 -176.689 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 42' ' ' ASN . . . . . 0.473 ' HB3' ' HB ' ' A' ' 45' ' ' ILE . 52.8 t-20 -155.1 124.37 6.32 Favored 'General case' 0 N--CA 1.442 -0.835 0 N-CA-C 108.624 -0.88 . . . . 0.0 108.624 -179.215 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 43' ' ' TRP . . . . . 0.764 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 44.9 m95 -97.27 -10.41 25.78 Favored 'General case' 0 C--N 1.308 -1.217 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.9 -174.207 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 44' ' ' ALA . . . . . 0.424 ' HA ' ' HB2' ' A' ' 75' ' ' ASP . . . -110.16 9.34 23.95 Favored 'General case' 0 C--N 1.315 -0.91 0 CA-C-N 115.115 -0.948 . . . . 0.0 110.982 179.938 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.473 ' HB ' ' HB3' ' A' ' 42' ' ' ASN . 11.5 tt -73.78 143.27 13.84 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.875 0 CA-C-O 121.462 0.649 . . . . 0.0 110.959 -178.438 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -135.11 94.71 3.18 Favored 'General case' 0 C--N 1.311 -1.097 0 N-CA-C 109.028 -0.73 . . . . 0.0 109.028 179.46 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 1.7 p -73.79 -12.19 60.62 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-N 115.628 -0.714 . . . . 0.0 110.933 -178.269 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 85.29 21.84 53.42 Favored Glycine 0 N--CA 1.443 -0.878 0 N-CA-C 111.179 -0.769 . . . . 0.0 111.179 174.1 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 33.4 p-10 -103.44 10.17 37.4 Favored 'General case' 0 C--N 1.322 -0.612 0 C-N-CA 120.894 -0.322 . . . . 0.0 111.562 -174.944 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 50' ' ' GLY . . . . . 0.524 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 87.32 -2.66 86.68 Favored Glycine 0 N--CA 1.454 -0.149 0 C-N-CA 120.87 -0.681 . . . . 0.0 111.658 -178.252 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 51' ' ' TYR . . . . . 0.666 ' HA ' ' HA ' ' A' ' 58' ' ' ASP . 0.3 OUTLIER -116.51 147.7 41.52 Favored 'General case' 0 CA--C 1.508 -0.643 0 N-CA-C 106.5 -1.667 . . . . 0.0 106.5 178.649 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 52' ' ' TYR . . . . . 0.729 ' O ' ' HA ' ' A' ' 56' ' ' GLN . 47.9 m-85 -114.7 163.79 14.97 Favored 'General case' 0 C--N 1.304 -1.376 0 C-N-CA 119.821 -0.751 . . . . 0.0 111.688 -170.247 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.427 ' CA ' HG22 ' A' ' 45' ' ' ILE . . . -60.56 177.95 3.41 Favored Glycine 0 N--CA 1.448 -0.54 0 O-C-N 124.047 0.842 . . . . 0.0 114.849 -167.801 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 54' ' ' GLY . . . . . 0.674 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 85.87 -108.7 3.27 Favored Glycine 0 N--CA 1.436 -1.359 0 N-CA-C 111.121 -0.792 . . . . 0.0 111.121 -178.417 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.433 HG22 ' HB3' ' A' ' 82' ' ' GLN . 0.2 OUTLIER -83.2 -1.03 5.54 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.69 0 CA-C-O 121.437 0.637 . . . . 0.0 110.067 178.713 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 56' ' ' GLN . . . . . 0.729 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 20.0 tp60 56.12 50.43 13.61 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 114.265 -1.334 . . . . 0.0 113.28 164.678 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -118.72 169.5 9.78 Favored 'General case' 0 C--N 1.329 -0.317 0 C-N-CA 119.44 -0.904 . . . . 0.0 111.478 172.209 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.666 ' HA ' ' HA ' ' A' ' 51' ' ' TYR . 8.3 p-10 -74.38 162.13 29.17 Favored 'General case' 0 C--N 1.327 -0.382 0 N-CA-C 113.995 1.109 . . . . 0.0 113.995 -163.992 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 59' ' ' GLN . . . . . 0.427 ' HB2' ' CE2' ' A' ' 52' ' ' TYR . 20.6 tp60 -56.06 -42.61 76.89 Favored 'General case' 0 N--CA 1.443 -0.813 0 CA-C-N 114.085 -1.416 . . . . 0.0 111.084 177.256 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -67.77 -49.68 47.44 Favored Glycine 0 N--CA 1.451 -0.365 0 CA-C-N 115.056 -0.974 . . . . 0.0 112.667 -173.896 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 92.3 m -64.63 -40.24 95.12 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-O 120.644 0.259 . . . . 0.0 110.958 177.91 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 62' ' ' TRP . . . . . 0.472 ' CZ3' ' HA ' ' A' ' 82' ' ' GLN . 54.4 t-105 -56.64 -49.3 75.41 Favored 'General case' 0 N--CA 1.45 -0.454 0 CA-C-O 121.809 0.814 . . . . 0.0 109.102 175.008 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 63' ' ' GLU . . . . . 0.532 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 29.5 tt0 -64.83 -35.67 81.85 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 114.653 -1.158 . . . . 0.0 111.319 -179.979 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -64.93 -42.4 94.72 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.976 -0.556 . . . . 0.0 111.335 -174.606 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 33.8 m-80 -81.49 -9.24 59.75 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.981 0.42 . . . . 0.0 110.369 176.815 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 66' ' ' GLY . . . . . 0.569 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 92.29 50.38 2.61 Favored Glycine 0 C--N 1.332 0.309 0 CA-C-N 115.865 -0.607 . . . . 0.0 112.658 173.288 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 67' ' ' GLY . . . . . 0.564 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -80.03 -23.59 61.24 Favored Glycine 0 N--CA 1.438 -1.205 0 C-N-CA 120.887 -0.673 . . . . 0.0 112.781 -176.48 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.908 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 6.9 mp -60.87 -22.9 64.73 Favored 'General case' 0 N--CA 1.448 -0.552 0 N-CA-C 112.139 0.422 . . . . 0.0 112.139 -172.893 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 69' ' ' ARG . . . . . 0.569 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 3.7 ptp180 -68.37 -32.81 73.16 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-O 121.12 0.486 . . . . 0.0 109.928 177.002 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 70' ' ' TYR . . . . . 0.622 ' HB3' ' CG ' ' A' ' 81' ' ' GLU . 65.6 m-85 -82.26 -34.23 28.85 Favored 'General case' 0 N--CA 1.44 -0.948 0 N-CA-C 107.564 -1.273 . . . . 0.0 107.564 178.915 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.659 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 168.35 124.35 0.04 OUTLIER Pre-proline 0 N--CA 1.448 -0.528 0 CA-C-N 112.868 -1.969 . . . . 0.0 107.319 -178.835 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 72' ' ' PRO . . . . . 0.908 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 24.8 Cg_exo -54.98 -7.38 0.95 Allowed 'Trans proline' 0 C--N 1.335 -0.174 0 C-N-CA 123.003 2.468 . . . . 0.0 114.11 -177.534 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 12.8 ptm180 -146.42 137.16 24.13 Favored 'General case' 0 C--N 1.319 -0.754 0 N-CA-C 108.853 -0.795 . . . . 0.0 108.853 176.472 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 74' ' ' ALA . . . . . 0.608 ' HB3' ' HB2' ' A' ' 52' ' ' TYR . . . -56.26 -32.0 64.11 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.151 -0.931 . . . . 0.0 112.574 -176.992 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 75' ' ' ASP . . . . . 0.611 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 4.9 p-10 -78.81 -8.14 58.51 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 121.108 0.48 . . . . 0.0 110.93 -175.312 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 64.5 tp -93.61 -32.04 14.26 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 108.781 -0.822 . . . . 0.0 108.781 173.605 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 77' ' ' ALA . . . . . 0.79 ' HB1' ' HB2' ' A' ' 81' ' ' GLU . . . -79.68 157.96 27.1 Favored 'General case' 0 N--CA 1.445 -0.713 0 CA-C-N 114.964 -1.016 . . . . 0.0 110.487 176.092 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 40.6 p -100.62 -172.48 2.2 Favored 'General case' 0 C--N 1.315 -0.906 0 CA-C-N 115.937 -0.574 . . . . 0.0 109.918 179.698 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 79' ' ' ARG . . . . . 0.764 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 10.9 mtt180 -51.14 -52.71 41.33 Favored 'General case' 0 CA--C 1.51 -0.579 0 O-C-N 123.432 0.457 . . . . 0.0 111.029 -175.433 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 1.3 pm0 -57.71 -48.31 79.93 Favored 'General case' 0 C--N 1.314 -0.943 0 CA-C-N 115.135 -0.938 . . . . 0.0 112.142 -176.374 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 81' ' ' GLU . . . . . 0.79 ' HB2' ' HB1' ' A' ' 77' ' ' ALA . 6.5 mp0 -61.31 -50.48 72.79 Favored 'General case' 0 C--O 1.233 0.221 0 N-CA-C 111.9 0.333 . . . . 0.0 111.9 176.491 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 82' ' ' GLN . . . . . 0.472 ' HA ' ' CZ3' ' A' ' 62' ' ' TRP . 51.4 mt-30 -59.93 -39.94 87.22 Favored 'General case' 0 CA--C 1.516 -0.355 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.229 -177.819 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.682 ' O ' ' HG2' ' A' ' 87' ' ' GLU . 28.3 mt -61.78 -45.54 98.46 Favored 'Isoleucine or valine' 0 C--O 1.212 -0.886 0 CA-C-N 115.36 -0.836 . . . . 0.0 110.151 178.601 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 84' ' ' ALA . . . . . 0.541 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -59.48 -43.4 93.28 Favored 'General case' 0 C--O 1.239 0.509 0 CA-C-O 121.154 0.502 . . . . 0.0 111.336 -178.347 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 60.5 t -68.66 -48.11 73.28 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.649 179.517 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -59.8 -30.08 68.66 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.63 -0.714 . . . . 0.0 110.518 176.08 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 87' ' ' GLU . . . . . 0.682 ' HG2' ' O ' ' A' ' 83' ' ' ILE . 40.1 mm-40 -60.22 -45.81 91.92 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.371 -0.831 . . . . 0.0 110.396 -179.998 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.571 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 24.6 t -64.58 -41.74 93.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 121.392 0.615 . . . . 0.0 109.645 177.823 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 89' ' ' THR . . . . . 0.777 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 0.5 OUTLIER -67.56 -46.7 71.95 Favored 'General case' 0 C--N 1.318 -0.791 0 CA-C-N 115.635 -0.711 . . . . 0.0 111.581 -175.662 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 90' ' ' ARG . . . . . 0.537 ' HD3' ' CZ2' ' A' ' 31' ' ' TRP . 13.8 ptt180 -64.55 -34.16 77.59 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.494 -0.321 . . . . 0.0 111.192 -175.247 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 91' ' ' LEU . . . . . 0.571 ' HG ' ' O ' ' A' ' 88' ' ' VAL . 4.4 pp -72.63 -23.74 60.96 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.289 -171.92 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 92' ' ' ARG . . . . . 0.525 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 6.6 mtm180 -83.93 -48.53 9.89 Favored 'General case' 0 CA--C 1.511 -0.53 0 CA-C-O 121.437 0.636 . . . . 0.0 109.734 -178.638 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 93' ' ' GLN . . . . . 0.669 ' NE2' HG22 ' A' ' 89' ' ' THR . 28.9 pt20 -98.44 -28.98 13.38 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 114.773 -1.103 . . . . 0.0 113.741 -168.135 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 82.99 48.5 5.41 Favored Glycine 0 N--CA 1.448 -0.502 0 C-N-CA 120.11 -1.043 . . . . 0.0 111.357 178.784 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 95' ' ' TRP . . . . . 0.511 ' HA ' ' HE3' ' A' ' 98' ' ' TRP . 2.4 m95 62.59 24.12 14.35 Favored 'General case' 0 C--O 1.224 -0.274 0 C-N-CA 123.176 0.591 . . . . 0.0 110.288 176.103 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -69.19 -24.51 75.93 Favored Glycine 0 CA--C 1.52 0.359 0 CA-C-N 115.706 -0.679 . . . . 0.0 112.433 175.977 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 97' ' ' ALA . . . . . 0.407 ' O ' ' HD3' ' A' ' 99' ' ' PRO . . . -82.05 -34.14 29.61 Favored 'General case' 0 CA--C 1.516 -0.355 0 CA-C-O 120.888 0.375 . . . . 0.0 110.474 176.289 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 98' ' ' TRP . . . . . 0.777 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 22.4 m-90 -96.37 103.55 14.41 Favored Pre-proline 0 N--CA 1.451 -0.414 0 CA-C-N 115.713 -0.676 . . . . 0.0 109.202 -179.62 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 99' ' ' PRO . . . . . 0.487 ' HB2' ' H ' ' A' ' 100' ' ' VAL . 16.4 Cg_exo -73.44 -98.72 0.01 OUTLIER 'Trans proline' 0 CA--C 1.537 0.656 0 C-N-CA 123.27 2.646 . . . . 0.0 114.869 -170.682 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 100' ' ' VAL . . . . . 0.487 ' H ' ' HB2' ' A' ' 99' ' ' PRO . 32.8 t -70.22 -27.27 31.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-O 121.702 0.763 . . . . 0.0 110.01 -172.853 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 101' ' ' CYS . . . . . 0.872 ' SG ' ' HG3' ' A' ' 38' ' ' GLU . 38.7 m -67.08 -33.98 76.66 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-N 114.755 -1.111 . . . . 0.0 111.13 -174.77 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 102' ' ' ALA . . . . . 0.503 ' HB1' ' HB2' ' A' ' 107' ' ' ALA . . . -65.38 -45.44 84.03 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.817 0.342 . . . . 0.0 110.69 179.839 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -64.76 -36.28 83.79 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 121.102 0.477 . . . . 0.0 110.545 178.824 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 21.1 mmm180 -74.03 -23.35 59.39 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.553 -0.749 . . . . 0.0 111.693 179.057 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 105' ' ' ALA . . . . . 0.626 ' HB1' ' HA ' ' A' ' 30' ' ' ILE . . . -96.91 -21.53 17.41 Favored 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 112.496 0.554 . . . . 0.0 112.496 -174.472 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 103.94 65.15 0.69 Allowed Glycine 0 CA--C 1.518 0.253 0 C-N-CA 120.827 -0.702 . . . . 0.0 111.919 -177.753 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 107' ' ' ALA . . . . . 0.503 ' HB2' ' HB1' ' A' ' 102' ' ' ALA . . . -71.93 152.75 42.3 Favored 'General case' 0 C--N 1.326 -0.433 0 C-N-CA 122.877 0.471 . . . . 0.0 111.674 -174.912 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 10.7 mmm180 . . . . . 0 C--O 1.25 1.081 0 CA-C-O 117.926 -1.035 . . . . 0.0 111.408 175.043 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 27' ' ' ASP . . . . . 0.535 ' O ' HG12 ' A' ' 30' ' ' ILE . 7.3 m-20 . . . . . 0 CA--C 1.504 -0.794 0 CA-C-O 121.669 0.747 . . . . 0.0 109.498 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 28' ' ' GLY . . . . . 0.551 ' HA2' ' HD1' ' A' ' 31' ' ' TRP . . . -67.49 -8.02 49.46 Favored Glycine 0 N--CA 1.445 -0.748 0 CA-C-N 114.786 -1.097 . . . . 0.0 110.715 179.484 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 6.1 m -76.72 -39.05 53.13 Favored 'General case' 0 C--N 1.318 -0.779 0 CA-C-O 121.652 0.739 . . . . 0.0 109.239 176.388 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.605 ' HA ' ' HB1' ' A' ' 105' ' ' ALA . 0.7 OUTLIER -68.58 -38.49 79.15 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.592 0 N-CA-C 107.35 -1.352 . . . . 0.0 107.35 177.429 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 31' ' ' TRP . . . . . 0.58 ' CD1' HG23 ' A' ' 83' ' ' ILE . 34.8 m95 -68.52 -36.68 79.2 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 114.535 -1.212 . . . . 0.0 110.378 -177.296 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.723 ' HB2' HH21 ' A' ' 79' ' ' ARG . 33.5 t70 -73.77 -41.23 62.74 Favored 'General case' 0 N--CA 1.445 -0.703 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.1 179.043 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 33' ' ' ALA . . . . . 0.457 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -70.1 -33.11 71.45 Favored 'General case' 0 N--CA 1.448 -0.55 0 CA-C-N 116.405 -0.361 . . . . 0.0 110.912 -179.966 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 34' ' ' ILE . . . . . 0.608 ' HA ' ' HB3' ' A' ' 101' ' ' CYS . 50.9 mt -64.23 -49.28 81.88 Favored 'Isoleucine or valine' 0 C--O 1.234 0.256 0 CA-C-O 120.777 0.322 . . . . 0.0 110.56 174.893 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 35' ' ' ALA . . . . . 0.514 ' O ' ' HB3' ' A' ' 39' ' ' ALA . . . -66.02 -33.7 76.4 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 121.296 0.57 . . . . 0.0 110.218 178.528 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 36' ' ' GLY . . . . . 0.425 ' HA2' ' N ' ' A' ' 41' ' ' GLY . . . -71.61 -21.98 78.72 Favored Glycine 0 N--CA 1.448 -0.526 0 N-CA-C 111.101 -0.799 . . . . 0.0 111.101 176.892 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -76.19 -69.33 0.51 Allowed 'General case' 0 N--CA 1.448 -0.551 0 CA-C-N 115.291 -0.455 . . . . 0.0 111.536 -178.574 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 38' ' ' GLU . . . . . 0.678 ' HB2' ' SG ' ' A' ' 101' ' ' CYS . 15.3 tt0 -90.9 -32.99 15.79 Favored 'General case' 0 C--N 1.323 -0.572 0 C-N-CA 119.743 -0.783 . . . . 0.0 110.871 -171.455 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 39' ' ' ALA . . . . . 0.514 ' HB3' ' O ' ' A' ' 35' ' ' ALA . . . -84.46 -13.85 50.87 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.996 -178.855 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 74.89 20.5 79.44 Favored Glycine 0 CA--C 1.501 -0.839 0 N-CA-C 109.853 -1.299 . . . . 0.0 109.853 -179.472 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 41' ' ' GLY . . . . . 0.425 ' N ' ' HA2' ' A' ' 36' ' ' GLY . . . 72.2 64.03 2.77 Favored Glycine 0 N--CA 1.433 -1.564 0 CA-C-N 114.108 -1.046 . . . . 0.0 111.093 -172.837 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 42' ' ' ASN . . . . . 0.702 ' HB3' ' HB ' ' A' ' 45' ' ' ILE . 7.2 t-20 -140.99 84.21 1.92 Allowed 'General case' 0 C--N 1.322 -0.595 0 N-CA-C 108.815 -0.809 . . . . 0.0 108.815 -177.193 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 43' ' ' TRP . . . . . 0.762 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 37.0 m95 -73.65 -11.59 60.46 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 115.741 -0.663 . . . . 0.0 109.973 -177.922 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -106.6 14.38 27.08 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 115.37 -0.832 . . . . 0.0 111.406 179.583 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.732 HG22 ' HA2' ' A' ' 53' ' ' GLY . 9.0 tt -75.86 144.62 11.7 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.812 0 N-CA-C 109.695 -0.483 . . . . 0.0 109.695 179.83 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 21.7 t-20 -153.99 94.65 1.77 Allowed 'General case' 0 C--N 1.308 -1.208 0 CA-C-O 121.302 0.572 . . . . 0.0 110.38 -178.867 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 16.3 p -76.57 -19.56 57.76 Favored 'General case' 0 N--CA 1.445 -0.709 0 CA-C-N 115.225 -0.898 . . . . 0.0 110.718 178.925 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 87.85 24.02 36.78 Favored Glycine 0 N--CA 1.445 -0.759 0 N-CA-C 110.954 -0.859 . . . . 0.0 110.954 179.256 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 3.8 m-20 -97.54 14.4 26.66 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 121.065 0.459 . . . . 0.0 111.52 -174.259 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 50' ' ' GLY . . . . . 0.446 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 87.46 -16.03 51.4 Favored Glycine 0 N--CA 1.452 -0.28 0 CA-C-N 115.717 -0.674 . . . . 0.0 111.772 179.631 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 51' ' ' TYR . . . . . 0.748 ' CE1' ' HB2' ' A' ' 58' ' ' ASP . 0.3 OUTLIER -102.72 131.89 49.23 Favored 'General case' 0 N--CA 1.446 -0.66 0 N-CA-C 107.805 -1.183 . . . . 0.0 107.805 169.623 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 52' ' ' TYR . . . . . 0.735 ' CE1' ' HB2' ' A' ' 59' ' ' GLN . 15.0 m-85 -104.26 169.64 8.37 Favored 'General case' 0 C--N 1.311 -1.096 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.85 -173.184 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.732 ' HA2' HG22 ' A' ' 45' ' ' ILE . . . -51.91 158.09 3.1 Favored Glycine 0 CA--C 1.509 -0.326 0 N-CA-C 115.613 1.005 . . . . 0.0 115.613 -169.361 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 54' ' ' GLY . . . . . 0.582 ' CA ' ' HA ' ' A' ' 43' ' ' TRP . . . 98.49 -113.05 4.62 Favored Glycine 0 N--CA 1.438 -1.168 0 CA-C-N 114.486 -0.857 . . . . 0.0 111.369 175.444 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.427 HG23 ' CD1' ' A' ' 57' ' ' PHE . 1.3 m -86.91 -6.09 10.45 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.73 0 CA-C-O 120.442 0.163 . . . . 0.0 110.82 178.38 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 56' ' ' GLN . . . . . 0.578 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 10.5 pt20 45.52 51.71 9.64 Favored 'General case' 0 N--CA 1.479 1.003 0 N-CA-C 114.502 1.297 . . . . 0.0 114.502 167.483 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 57' ' ' PHE . . . . . 0.578 ' O ' ' HB3' ' A' ' 58' ' ' ASP . 19.7 p90 -103.67 21.62 15.84 Favored 'General case' 0 C--N 1.328 -0.344 0 N-CA-C 113.25 0.833 . . . . 0.0 113.25 -176.071 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.748 ' HB2' ' CE1' ' A' ' 51' ' ' TYR . 0.4 OUTLIER 89.06 135.82 0.04 OUTLIER 'General case' 0 C--N 1.317 -0.838 0 C-N-CA 124.615 1.166 . . . . 0.0 111.953 168.399 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 59' ' ' GLN . . . . . 0.735 ' HB2' ' CE1' ' A' ' 52' ' ' TYR . 5.4 tp60 -58.81 -34.23 71.27 Favored 'General case' 0 CA--C 1.512 -0.493 0 CA-C-N 114.195 -1.366 . . . . 0.0 110.932 -179.332 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -67.06 -44.05 89.05 Favored Glycine 0 N--CA 1.449 -0.463 0 C-N-CA 120.717 -0.754 . . . . 0.0 111.619 177.667 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 61' ' ' THR . . . . . 0.577 ' HB ' ' O ' ' A' ' 57' ' ' PHE . 89.5 m -71.02 -41.2 71.16 Favored 'General case' 0 N--CA 1.445 -0.685 0 CA-C-O 121.048 0.452 . . . . 0.0 110.324 178.023 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 62' ' ' TRP . . . . . 0.453 ' CH2' ' HA ' ' A' ' 74' ' ' ALA . 41.1 t-105 -55.57 -49.98 71.27 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.455 -0.793 . . . . 0.0 110.215 172.71 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 63' ' ' GLU . . . . . 0.485 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 3.7 tp10 -63.54 -40.34 96.75 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 115.437 -0.801 . . . . 0.0 110.555 179.512 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -61.39 -41.37 97.02 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.753 -0.658 . . . . 0.0 110.804 -177.486 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 65' ' ' ASN . . . . . 0.441 ' HB3' ' HB ' ' A' ' 88' ' ' VAL . 9.3 m120 -80.55 -9.6 59.77 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.439 178.358 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 66' ' ' GLY . . . . . 0.498 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 85.32 46.8 5.43 Favored Glycine 0 N--CA 1.449 -0.445 0 CA-C-N 115.736 -0.665 . . . . 0.0 112.689 175.716 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 67' ' ' GLY . . . . . 0.613 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -78.95 -18.53 74.78 Favored Glycine 0 N--CA 1.442 -0.961 0 C-N-CA 120.868 -0.682 . . . . 0.0 112.429 -174.668 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.988 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 7.0 mp -60.12 -24.11 64.41 Favored 'General case' 0 N--CA 1.445 -0.688 0 N-CA-C 112.545 0.572 . . . . 0.0 112.545 -175.0 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 69' ' ' ARG . . . . . 0.498 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 9.1 ptp180 -67.2 -31.85 72.52 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 121.405 0.622 . . . . 0.0 109.771 175.933 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 70' ' ' TYR . . . . . 0.815 ' HB3' ' HB3' ' A' ' 81' ' ' GLU . 74.5 m-85 -81.47 -33.91 31.72 Favored 'General case' 0 N--CA 1.443 -0.814 0 N-CA-C 107.728 -1.212 . . . . 0.0 107.728 178.199 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.573 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 165.9 126.01 0.03 OUTLIER Pre-proline 0 CA--C 1.512 -0.517 0 CA-C-N 112.897 -1.956 . . . . 0.0 107.325 -179.011 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 72' ' ' PRO . . . . . 0.988 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 21.2 Cg_exo -56.91 -6.66 1.87 Allowed 'Trans proline' 0 C--N 1.333 -0.242 0 C-N-CA 122.495 2.13 . . . . 0.0 113.587 -179.412 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 13.9 ptm180 -143.85 137.49 27.97 Favored 'General case' 0 C--N 1.321 -0.671 0 N-CA-C 109.228 -0.656 . . . . 0.0 109.228 177.752 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 74' ' ' ALA . . . . . 0.473 ' HB3' ' HB2' ' A' ' 52' ' ' TYR . . . -60.14 -28.06 67.58 Favored 'General case' 0 C--O 1.218 -0.569 0 CA-C-N 114.999 -1.0 . . . . 0.0 111.916 -176.96 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 75' ' ' ASP . . . . . 0.538 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 20.7 p-10 -88.13 3.56 48.69 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 121.186 0.517 . . . . 0.0 111.761 -176.449 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 66.9 tp -100.57 -30.67 11.65 Favored 'General case' 0 C--N 1.321 -0.64 0 N-CA-C 108.29 -1.004 . . . . 0.0 108.29 168.637 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 77' ' ' ALA . . . . . 0.921 ' HB1' ' HB2' ' A' ' 81' ' ' GLU . . . -78.89 143.87 35.48 Favored 'General case' 0 N--CA 1.441 -0.914 0 CA-C-N 114.617 -1.174 . . . . 0.0 110.704 176.486 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 27.7 p -93.88 -170.55 2.35 Favored 'General case' 0 C--N 1.314 -0.969 0 CA-C-N 115.417 -0.811 . . . . 0.0 109.117 178.93 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 79' ' ' ARG . . . . . 0.762 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 57.0 mtp180 -48.53 -51.38 27.79 Favored 'General case' 0 C--N 1.33 -0.262 0 O-C-N 123.196 0.31 . . . . 0.0 111.001 -178.512 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 10.2 pt-20 -57.64 -48.28 79.9 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.856 -0.611 . . . . 0.0 112.264 -173.776 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 81' ' ' GLU . . . . . 0.921 ' HB2' ' HB1' ' A' ' 77' ' ' ALA . 16.9 mp0 -65.25 -51.09 63.04 Favored 'General case' 0 N--CA 1.452 -0.358 0 N-CA-C 112.056 0.391 . . . . 0.0 112.056 177.339 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 82' ' ' GLN . . . . . 0.661 ' HB2' ' HZ3' ' A' ' 43' ' ' TRP . 46.0 mt-30 -61.6 -38.64 88.34 Favored 'General case' 0 CA--C 1.51 -0.561 0 CA-C-O 120.754 0.312 . . . . 0.0 110.833 -175.426 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.641 ' O ' ' HG2' ' A' ' 87' ' ' GLU . 50.2 mt -59.34 -44.46 92.43 Favored 'Isoleucine or valine' 0 C--O 1.215 -0.715 0 CA-C-N 115.512 -0.767 . . . . 0.0 109.865 176.889 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 84' ' ' ALA . . . . . 0.684 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -66.01 -41.92 90.4 Favored 'General case' 0 C--O 1.237 0.441 0 CA-C-O 121.29 0.567 . . . . 0.0 111.571 -176.841 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.539 HG23 ' O ' ' A' ' 81' ' ' GLU . 14.8 t -69.12 -47.94 71.89 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.696 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.454 178.969 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -58.23 -28.67 65.09 Favored 'General case' 0 C--O 1.232 0.143 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.431 173.389 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 87' ' ' GLU . . . . . 0.773 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 20.2 mm-40 -59.15 -43.87 92.07 Favored 'General case' 0 CA--C 1.51 -0.589 0 CA-C-N 115.32 -0.855 . . . . 0.0 109.619 178.926 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.584 ' O ' ' HG3' ' A' ' 92' ' ' ARG . 40.6 t -63.1 -43.55 99.0 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 CA-C-O 121.293 0.568 . . . . 0.0 109.933 175.572 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 89' ' ' THR . . . . . 1.005 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 0.2 OUTLIER -62.61 -47.12 85.16 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.746 -0.661 . . . . 0.0 111.982 -176.016 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 90' ' ' ARG . . . . . 0.491 ' HB3' ' CH2' ' A' ' 31' ' ' TRP . 30.4 ptt85 -60.16 -29.39 68.63 Favored 'General case' 0 N--CA 1.467 0.381 0 CA-C-O 121.313 0.578 . . . . 0.0 110.448 -178.996 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 91' ' ' LEU . . . . . 0.773 ' HG ' ' O ' ' A' ' 87' ' ' GLU . 33.4 mt -66.97 -35.01 79.01 Favored 'General case' 0 C--N 1.314 -0.948 0 CA-C-O 121.406 0.622 . . . . 0.0 109.885 -179.918 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 92' ' ' ARG . . . . . 0.584 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 4.7 mtm180 -89.11 -51.54 5.54 Favored 'General case' 0 N--CA 1.443 -0.78 0 CA-C-N 115.348 -0.842 . . . . 0.0 110.13 -171.807 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 93' ' ' GLN . . . . . 0.51 HE22 ' HZ3' ' A' ' 98' ' ' TRP . 0.0 OUTLIER -108.72 -15.85 14.31 Favored 'General case' 0 N--CA 1.44 -0.946 0 CA-C-N 115.087 -0.96 . . . . 0.0 111.942 -173.151 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 94' ' ' GLY . . . . . 0.478 ' HA2' ' O ' ' A' ' 90' ' ' ARG . . . 83.6 -107.41 2.93 Favored Glycine 0 CA--C 1.494 -1.232 0 N-CA-C 111.082 -0.807 . . . . 0.0 111.082 177.911 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 95' ' ' TRP . . . . . . . . . . . . . 3.5 m95 -142.81 27.32 1.66 Allowed 'General case' 0 C--N 1.313 -0.994 0 N-CA-C 106.901 -1.518 . . . . 0.0 106.901 179.813 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -79.19 -22.46 65.38 Favored Glycine 0 N--CA 1.448 -0.546 0 CA-C-N 114.457 -1.247 . . . . 0.0 111.079 173.195 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 97' ' ' ALA . . . . . 0.418 ' O ' ' HD3' ' A' ' 99' ' ' PRO . . . -85.12 -32.16 22.92 Favored 'General case' 0 C--N 1.327 -0.373 0 N-CA-C 109.378 -0.601 . . . . 0.0 109.378 174.419 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 98' ' ' TRP . . . . . 1.005 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 16.9 m-90 -101.14 100.72 13.94 Favored Pre-proline 0 C--O 1.221 -0.441 0 N-CA-C 109.009 -0.737 . . . . 0.0 109.009 174.027 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 99' ' ' PRO . . . . . 0.418 ' HD3' ' O ' ' A' ' 97' ' ' ALA . 10.3 Cg_exo -79.33 -88.49 0.0 OUTLIER 'Trans proline' 0 CA--C 1.532 0.411 0 C-N-CA 122.848 2.365 . . . . 0.0 115.085 -171.828 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 63.3 t -69.96 -28.32 36.06 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.349 0 CA-C-O 121.679 0.752 . . . . 0.0 110.047 -172.461 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 101' ' ' CYS . . . . . 0.678 ' SG ' ' HB2' ' A' ' 38' ' ' GLU . 87.4 m -72.21 -27.25 62.42 Favored 'General case' 0 C--N 1.317 -0.84 0 CA-C-N 115.25 -0.887 . . . . 0.0 111.084 -176.759 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 102' ' ' ALA . . . . . 0.679 ' HB1' ' HB2' ' A' ' 107' ' ' ALA . . . -69.93 -40.41 75.55 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.808 0.337 . . . . 0.0 110.333 175.658 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -63.08 -37.81 88.68 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 121.432 0.634 . . . . 0.0 110.336 177.591 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -72.88 -30.62 64.1 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.243 -0.89 . . . . 0.0 111.686 177.363 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 105' ' ' ALA . . . . . 0.605 ' HB1' ' HA ' ' A' ' 30' ' ' ILE . . . -96.32 -22.58 17.11 Favored 'General case' 0 C--N 1.325 -0.457 0 N-CA-C 113.001 0.741 . . . . 0.0 113.001 -172.271 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 104.13 69.85 0.8 Allowed Glycine 0 CA--C 1.52 0.376 0 C-N-CA 120.832 -0.699 . . . . 0.0 112.134 -177.302 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 107' ' ' ALA . . . . . 0.679 ' HB2' ' HB1' ' A' ' 102' ' ' ALA . . . -60.02 146.7 41.78 Favored 'General case' 0 CA--C 1.517 -0.325 0 C-N-CA 122.709 0.403 . . . . 0.0 110.912 -179.899 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 97.3 mtt180 . . . . . 0 C--O 1.248 1.013 0 CA-C-O 118.323 -0.846 . . . . 0.0 111.021 -170.482 . . . . . . . . 0 0 . 1 . 021 nuclear build core ' A' A ' 27' ' ' ASP . . . . . 0.446 ' O ' HG12 ' A' ' 30' ' ' ILE . 19.4 m-20 . . . . . 0 CA--C 1.508 -0.643 0 CA-C-O 121.441 0.639 . . . . 0.0 109.791 . . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 28' ' ' GLY . . . . . 0.412 ' HA3' HD13 ' A' ' 83' ' ' ILE . . . -64.3 -11.54 47.05 Favored Glycine 0 CA--C 1.503 -0.656 0 CA-C-N 114.961 -1.018 . . . . 0.0 111.051 179.635 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 4.4 m -75.73 -41.27 53.85 Favored 'General case' 0 C--N 1.318 -0.794 0 CA-C-O 121.956 0.884 . . . . 0.0 109.116 177.225 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.547 ' HA ' ' HB1' ' A' ' 105' ' ' ALA . 0.9 OUTLIER -67.91 -38.99 80.94 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.726 0 CA-C-N 113.898 -1.501 . . . . 0.0 107.735 178.423 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 31' ' ' TRP . . . . . 0.522 ' HB2' HG12 ' A' ' 83' ' ' ILE . 32.6 m95 -67.98 -35.96 79.23 Favored 'General case' 0 C--N 1.317 -0.845 0 CA-C-N 114.472 -1.24 . . . . 0.0 110.619 -177.684 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.84 ' HB2' HH21 ' A' ' 79' ' ' ARG . 23.3 t70 -73.07 -37.59 66.74 Favored 'General case' 0 N--CA 1.446 -0.654 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.44 -179.349 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 33' ' ' ALA . . . . . 0.513 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -70.99 -34.15 71.1 Favored 'General case' 0 N--CA 1.446 -0.632 0 C-N-CA 120.707 -0.397 . . . . 0.0 110.787 176.494 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 34' ' ' ILE . . . . . 0.53 HG13 ' O ' ' A' ' 30' ' ' ILE . 61.1 mt -67.34 -46.89 82.76 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.283 0 CA-C-O 121.108 0.48 . . . . 0.0 110.701 175.201 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 35' ' ' ALA . . . . . 0.468 ' O ' ' HB3' ' A' ' 39' ' ' ALA . . . -63.19 -34.39 77.54 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.408 178.108 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -72.63 -15.01 77.67 Favored Glycine 0 N--CA 1.449 -0.491 0 N-CA-C 111.181 -0.768 . . . . 0.0 111.181 176.729 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.448 ' HB3' ' O ' ' A' ' 34' ' ' ILE . 41.3 t -87.18 -64.5 1.14 Allowed 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.296 -0.452 . . . . 0.0 111.292 -176.702 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 38' ' ' GLU . . . . . 0.803 ' HG3' ' SG ' ' A' ' 101' ' ' CYS . 40.8 mt-10 -88.94 -29.62 19.42 Favored 'General case' 0 CA--C 1.516 -0.357 0 CA-C-O 120.813 0.34 . . . . 0.0 111.784 -173.277 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 39' ' ' ALA . . . . . 0.468 ' HB3' ' O ' ' A' ' 35' ' ' ALA . . . -92.72 -11.33 34.26 Favored 'General case' 0 C--N 1.322 -0.619 0 C-N-CA 120.455 -0.498 . . . . 0.0 111.316 -176.956 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 76.24 15.52 81.39 Favored Glycine 0 N--CA 1.446 -0.664 0 N-CA-C 109.782 -1.327 . . . . 0.0 109.782 -176.229 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 75.11 51.68 7.4 Favored Glycine 0 N--CA 1.436 -1.339 0 CA-C-N 114.268 -0.966 . . . . 0.0 111.939 -176.449 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 2.2 t-20 -140.67 100.1 3.78 Favored 'General case' 0 N--CA 1.448 -0.542 0 N-CA-C 108.855 -0.795 . . . . 0.0 108.855 179.947 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 43' ' ' TRP . . . . . 0.729 ' CE3' ' HA ' ' A' ' 79' ' ' ARG . 30.9 m95 -82.78 -12.69 57.31 Favored 'General case' 0 C--N 1.313 -1.009 0 CA-C-N 115.241 -0.891 . . . . 0.0 110.529 -172.846 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -104.61 10.99 34.7 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 115.455 -0.793 . . . . 0.0 111.272 -178.145 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.699 HG22 ' HA2' ' A' ' 53' ' ' GLY . 4.0 tt -74.04 143.72 13.28 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.655 0 CA-C-O 121.0 0.429 . . . . 0.0 109.915 179.507 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 3.8 t30 -142.75 87.22 1.98 Allowed 'General case' 0 C--N 1.313 -0.989 0 CA-C-O 121.286 0.565 . . . . 0.0 109.567 -179.171 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 22.7 p -74.12 -24.57 59.47 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.648 179.983 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 92.43 19.57 37.94 Favored Glycine 0 N--CA 1.445 -0.709 0 N-CA-C 110.824 -0.91 . . . . 0.0 110.824 -177.913 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 64.8 t30 -74.94 -7.31 53.19 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 121.384 0.611 . . . . 0.0 111.12 -174.635 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 50' ' ' GLY . . . . . 0.498 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 95.73 -12.94 67.03 Favored Glycine 0 CA--C 1.504 -0.643 0 N-CA-C 109.47 -1.452 . . . . 0.0 109.47 -173.252 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 51' ' ' TYR . . . . . 0.629 ' HA ' ' HA ' ' A' ' 58' ' ' ASP . 0.5 OUTLIER -114.74 160.9 18.86 Favored 'General case' 0 N--CA 1.439 -0.984 0 N-CA-C 106.132 -1.803 . . . . 0.0 106.132 173.187 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 52' ' ' TYR . . . . . 0.687 ' HB2' ' HB3' ' A' ' 74' ' ' ALA . 55.5 m-85 -123.51 169.4 11.44 Favored 'General case' 0 C--N 1.308 -1.207 0 C-N-CA 120.085 -0.646 . . . . 0.0 111.403 -169.702 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.699 ' HA2' HG22 ' A' ' 45' ' ' ILE . . . -59.31 171.34 5.25 Favored Glycine 0 N--CA 1.445 -0.724 0 O-C-N 123.778 0.674 . . . . 0.0 113.821 -173.212 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 54' ' ' GLY . . . . . 0.707 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 87.79 -107.78 3.33 Favored Glycine 0 N--CA 1.44 -1.09 0 C-N-CA 120.708 -0.758 . . . . 0.0 111.77 -179.391 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.524 ' HB ' ' CD1' ' A' ' 57' ' ' PHE . 2.0 t -84.6 0.58 5.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.542 0 CA-C-O 121.276 0.56 . . . . 0.0 110.277 -177.555 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 56' ' ' GLN . . . . . 0.585 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 12.4 mm100 58.05 44.59 19.16 Favored 'General case' 0 N--CA 1.462 0.164 0 CA-C-N 114.971 -1.013 . . . . 0.0 113.169 170.886 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 57' ' ' PHE . . . . . 0.524 ' CD1' ' HB ' ' A' ' 55' ' ' VAL . 1.6 p90 -118.98 164.26 15.72 Favored 'General case' 0 C--N 1.325 -0.472 0 C-N-CA 119.435 -0.906 . . . . 0.0 111.914 177.301 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.629 ' HA ' ' HA ' ' A' ' 51' ' ' TYR . 7.9 p-10 -74.81 165.57 25.03 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 114.985 -1.007 . . . . 0.0 113.685 -163.512 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 59' ' ' GLN . . . . . 0.439 ' HB2' ' HE1' ' A' ' 52' ' ' TYR . 19.5 tp60 -59.26 -41.95 90.04 Favored 'General case' 0 N--CA 1.438 -1.044 0 CA-C-N 114.538 -1.21 . . . . 0.0 110.945 178.184 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -68.1 -49.45 46.89 Favored Glycine 0 C--O 1.225 -0.45 0 CA-C-N 115.617 -0.719 . . . . 0.0 112.614 -172.35 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 86.7 m -62.25 -42.37 99.26 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-O 121.098 0.475 . . . . 0.0 110.761 178.624 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 62' ' ' TRP . . . . . 0.501 ' CH2' ' HA ' ' A' ' 74' ' ' ALA . 53.4 t-105 -56.62 -51.25 69.41 Favored 'General case' 0 N--CA 1.448 -0.565 0 CA-C-N 115.133 -0.94 . . . . 0.0 109.39 175.323 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 63' ' ' GLU . . . . . 1.033 ' HG3' HD11 ' A' ' 68' ' ' LEU . 24.0 tt0 -64.43 -38.36 90.75 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-N 114.544 -1.207 . . . . 0.0 111.275 -177.606 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -67.71 -42.39 82.03 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.935 -0.575 . . . . 0.0 111.424 -175.027 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 65' ' ' ASN . . . . . 0.624 HD22 ' N ' ' A' ' 65' ' ' ASN . 0.7 OUTLIER -77.96 -8.85 58.69 Favored 'General case' 0 N--CA 1.451 -0.405 0 CA-C-O 121.316 0.579 . . . . 0.0 109.672 176.812 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 66' ' ' GLY . . . . . 0.524 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 90.17 47.71 3.76 Favored Glycine 0 N--CA 1.449 -0.498 0 CA-C-N 115.438 -0.801 . . . . 0.0 112.417 173.386 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 67' ' ' GLY . . . . . 0.545 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -80.47 -16.39 76.01 Favored Glycine 0 N--CA 1.444 -0.813 0 C-N-CA 120.876 -0.678 . . . . 0.0 112.065 -177.14 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 1.033 HD11 ' HG3' ' A' ' 63' ' ' GLU . 20.8 mt -65.53 -28.58 69.27 Favored 'General case' 0 C--N 1.314 -0.937 0 CA-C-O 120.999 0.428 . . . . 0.0 111.351 -171.06 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 69' ' ' ARG . . . . . 0.524 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 11.7 ptm180 -65.04 -31.69 73.04 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.217 175.379 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 70' ' ' TYR . . . . . 0.796 ' HB3' ' HB3' ' A' ' 81' ' ' GLU . 89.9 m-85 -77.4 -34.61 54.79 Favored 'General case' 0 CA--C 1.505 -0.755 0 N-CA-C 107.723 -1.214 . . . . 0.0 107.723 178.328 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.582 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 164.65 123.57 0.02 OUTLIER Pre-proline 0 C--N 1.319 -0.724 0 CA-C-N 112.125 -2.307 . . . . 0.0 106.859 -178.232 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 72' ' ' PRO . . . . . 0.59 ' HA ' ' HA ' ' A' ' 68' ' ' LEU . 38.6 Cg_exo -51.76 -6.48 0.17 Allowed 'Trans proline' 0 CA--C 1.53 0.282 0 C-N-CA 123.16 2.573 . . . . 0.0 114.393 -178.513 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 9.2 ptm180 -146.85 142.67 27.91 Favored 'General case' 0 C--N 1.315 -0.91 0 N-CA-C 108.825 -0.805 . . . . 0.0 108.825 174.905 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 74' ' ' ALA . . . . . 0.687 ' HB3' ' HB2' ' A' ' 52' ' ' TYR . . . -58.35 -33.08 69.15 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.679 -0.691 . . . . 0.0 112.753 -177.129 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 75' ' ' ASP . . . . . 0.572 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 4.3 p-10 -80.28 -10.22 59.75 Favored 'General case' 0 C--N 1.331 -0.231 0 C-N-CA 120.668 -0.413 . . . . 0.0 111.247 -173.931 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.477 ' HB3' ' HB1' ' A' ' 71' ' ' ALA . 62.5 tp -87.23 -32.49 19.74 Favored 'General case' 0 C--N 1.323 -0.552 0 N-CA-C 108.869 -0.789 . . . . 0.0 108.869 173.66 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 77' ' ' ALA . . . . . 0.837 ' HB1' ' HB2' ' A' ' 81' ' ' GLU . . . -82.22 161.08 22.84 Favored 'General case' 0 N--CA 1.442 -0.853 0 CA-C-N 114.98 -1.009 . . . . 0.0 110.371 176.171 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 20.0 p -100.59 -170.59 1.88 Allowed 'General case' 0 C--N 1.316 -0.876 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.088 179.127 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 79' ' ' ARG . . . . . 0.84 HH21 ' HB2' ' A' ' 32' ' ' ASP . 39.1 mtp180 -48.98 -53.48 19.66 Favored 'General case' 0 CA--C 1.515 -0.391 0 O-C-N 123.498 0.499 . . . . 0.0 111.005 -177.044 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 2.5 pt-20 -60.91 -42.47 98.16 Favored 'General case' 0 C--N 1.315 -0.928 0 CA-C-N 114.972 -1.013 . . . . 0.0 112.895 -171.486 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 81' ' ' GLU . . . . . 0.837 ' HB2' ' HB1' ' A' ' 77' ' ' ALA . 9.1 mp0 -63.38 -50.67 68.99 Favored 'General case' 0 N--CA 1.455 -0.196 0 CA-C-N 118.194 0.452 . . . . 0.0 111.491 175.163 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 82' ' ' GLN . . . . . 0.6 ' HB2' ' HZ3' ' A' ' 43' ' ' TRP . 48.0 mt-30 -61.87 -36.79 82.3 Favored 'General case' 0 CA--C 1.515 -0.369 0 CA-C-O 121.122 0.487 . . . . 0.0 110.309 -177.673 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.557 ' O ' ' HB3' ' A' ' 87' ' ' GLU . 33.8 mt -59.4 -44.0 91.61 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.686 0 CA-C-N 114.982 -1.008 . . . . 0.0 109.973 177.119 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 84' ' ' ALA . . . . . 0.616 ' O ' ' HG3' ' A' ' 87' ' ' GLU . . . -66.57 -45.38 79.49 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 116.038 -0.528 . . . . 0.0 111.47 -179.503 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.518 HG23 ' O ' ' A' ' 81' ' ' GLU . 40.1 t -67.73 -50.21 62.56 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-N 116.305 -0.407 . . . . 0.0 112.018 -179.343 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -63.67 -30.96 71.99 Favored 'General case' 0 N--CA 1.449 -0.502 0 CA-C-O 121.002 0.43 . . . . 0.0 110.542 178.962 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 87' ' ' GLU . . . . . 0.616 ' HG3' ' O ' ' A' ' 84' ' ' ALA . 0.1 OUTLIER -70.36 -29.97 66.78 Favored 'General case' 0 C--N 1.325 -0.489 0 C-N-CA 120.418 -0.513 . . . . 0.0 110.438 -177.788 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 53.8 t -62.31 -43.31 97.92 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.258 0 N-CA-C 108.831 -0.803 . . . . 0.0 108.831 170.479 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 89' ' ' THR . . . . . 0.704 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 0.6 OUTLIER -65.67 -43.22 89.98 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 115.232 -0.895 . . . . 0.0 110.689 -177.971 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 90' ' ' ARG . . . . . 0.601 ' HG3' ' O ' ' A' ' 87' ' ' GLU . 4.2 ppt_? -66.37 -33.52 75.89 Favored 'General case' 0 CA--C 1.513 -0.47 0 N-CA-C 109.213 -0.662 . . . . 0.0 109.213 -178.929 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 91' ' ' LEU . . . . . 0.464 ' HB2' ' O ' ' A' ' 87' ' ' GLU . 2.2 tm? -57.21 -34.8 68.91 Favored 'General case' 0 C--N 1.318 -0.786 0 CA-C-N 114.386 -1.279 . . . . 0.0 110.095 -174.931 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 92' ' ' ARG . . . . . 0.497 ' HE ' ' HB2' ' A' ' 92' ' ' ARG . 3.4 mtm180 -92.49 -39.9 11.13 Favored 'General case' 0 C--N 1.315 -0.934 0 CA-C-N 115.18 -0.918 . . . . 0.0 109.91 -172.227 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 93' ' ' GLN . . . . . 0.49 ' NE2' HG22 ' A' ' 89' ' ' THR . 7.5 pt20 -94.63 -30.73 14.18 Favored 'General case' 0 C--N 1.316 -0.871 0 CA-C-N 114.27 -1.332 . . . . 0.0 113.777 -169.335 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 86.17 32.46 17.03 Favored Glycine 0 CA--C 1.52 0.345 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.619 178.207 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 95' ' ' TRP . . . . . 0.453 ' CE2' ' HD3' ' A' ' 90' ' ' ARG . 13.5 m95 66.82 16.27 10.33 Favored 'General case' 0 N--CA 1.466 0.355 0 C-N-CA 123.395 0.678 . . . . 0.0 110.085 178.095 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -63.94 -41.69 98.59 Favored Glycine 0 CA--C 1.519 0.326 0 CA-C-N 115.461 -0.79 . . . . 0.0 113.65 -179.852 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 97' ' ' ALA . . . . . 0.47 ' O ' ' HD3' ' A' ' 99' ' ' PRO . . . -78.59 -21.62 48.3 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 117.072 0.436 . . . . 0.0 111.259 -178.456 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 98' ' ' TRP . . . . . 0.704 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 16.3 m-90 -85.54 104.53 5.2 Favored Pre-proline 0 C--O 1.225 -0.226 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 170.118 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 99' ' ' PRO . . . . . 0.47 ' HD3' ' O ' ' A' ' 97' ' ' ALA . 11.7 Cg_exo -76.28 -95.59 0.01 OUTLIER 'Trans proline' 0 N--CA 1.457 -0.648 0 C-N-CA 122.435 2.09 . . . . 0.0 115.087 -171.275 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 100' ' ' VAL . . . . . 0.424 ' H ' ' HB2' ' A' ' 99' ' ' PRO . 38.3 t -71.32 -30.09 38.49 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.445 0 CA-C-O 121.72 0.771 . . . . 0.0 110.411 -169.07 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 101' ' ' CYS . . . . . 0.803 ' SG ' ' HG3' ' A' ' 38' ' ' GLU . 60.8 m -81.8 -25.66 35.04 Favored 'General case' 0 C--N 1.316 -0.855 0 CA-C-N 115.193 -0.912 . . . . 0.0 111.363 -169.722 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 102' ' ' ALA . . . . . 0.453 ' HB1' ' HB2' ' A' ' 107' ' ' ALA . . . -69.82 -45.21 68.39 Favored 'General case' 0 C--N 1.33 -0.276 0 N-CA-C 110.04 -0.355 . . . . 0.0 110.04 176.502 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -61.96 -39.34 91.78 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 121.307 0.575 . . . . 0.0 110.63 177.512 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 12.5 mtp180 -66.09 -39.02 89.66 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.438 -0.801 . . . . 0.0 111.476 177.405 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 105' ' ' ALA . . . . . 0.547 ' HB1' ' HA ' ' A' ' 30' ' ' ILE . . . -83.56 -22.07 32.47 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 112.583 0.586 . . . . 0.0 112.583 -174.026 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 107.71 61.05 0.56 Allowed Glycine 0 CA--C 1.521 0.459 0 C-N-CA 121.035 -0.602 . . . . 0.0 112.506 -179.56 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 107' ' ' ALA . . . . . 0.453 ' HB2' ' HB1' ' A' ' 102' ' ' ALA . . . -62.45 149.22 43.28 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 121.037 0.446 . . . . 0.0 111.528 -176.342 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 108' ' ' ARG . . . . . 0.405 ' CZ ' HD11 ' A' ' 30' ' ' ILE . 92.6 mtt180 . . . . . 0 C--O 1.249 1.067 0 CA-C-N 115.628 -0.715 . . . . 0.0 110.57 -172.596 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 27' ' ' ASP . . . . . 0.479 ' O ' HG12 ' A' ' 30' ' ' ILE . 7.6 m-20 . . . . . 0 CA--C 1.507 -0.677 0 CA-C-O 121.749 0.785 . . . . 0.0 109.397 . . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -69.92 -5.31 51.9 Favored Glycine 0 N--CA 1.441 -1.004 0 CA-C-N 114.702 -1.136 . . . . 0.0 110.802 178.701 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 12.5 m -76.86 -42.95 38.0 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-O 121.813 0.816 . . . . 0.0 109.11 174.512 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.695 ' HA ' ' HB1' ' A' ' 105' ' ' ALA . 0.4 OUTLIER -66.58 -38.75 82.3 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-N 114.274 -1.33 . . . . 0.0 107.728 178.426 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 31' ' ' TRP . . . . . 0.455 ' CZ2' ' HD3' ' A' ' 90' ' ' ARG . 26.3 m95 -70.05 -35.0 73.94 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 114.572 -1.195 . . . . 0.0 110.516 -178.395 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.401 ' HB2' HH21 ' A' ' 79' ' ' ARG . 32.5 t70 -76.14 -37.63 57.77 Favored 'General case' 0 N--CA 1.449 -0.518 0 CA-C-N 116.024 -0.534 . . . . 0.0 110.349 -179.095 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 33' ' ' ALA . . . . . 0.511 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -70.59 -34.06 71.75 Favored 'General case' 0 N--CA 1.45 -0.441 0 C-N-CA 120.792 -0.363 . . . . 0.0 110.647 177.417 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 34' ' ' ILE . . . . . 0.494 HG13 ' O ' ' A' ' 30' ' ' ILE . 74.6 mt -65.55 -45.11 93.48 Favored 'Isoleucine or valine' 0 C--O 1.234 0.252 0 CA-C-O 121.168 0.509 . . . . 0.0 109.841 173.113 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -58.45 -38.3 77.22 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.611 -0.722 . . . . 0.0 110.014 175.074 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 36' ' ' GLY . . . . . 0.408 ' HA2' ' N ' ' A' ' 41' ' ' GLY . . . -72.2 -12.31 76.0 Favored Glycine 0 N--CA 1.449 -0.456 0 CA-C-N 115.399 -0.819 . . . . 0.0 111.835 179.139 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 46.8 t -88.78 -62.77 1.41 Allowed 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 115.614 -0.293 . . . . 0.0 111.118 -178.249 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 38' ' ' GLU . . . . . 0.416 ' HG3' ' SG ' ' A' ' 101' ' ' CYS . 34.2 mt-10 -90.0 -33.37 16.39 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 120.969 0.414 . . . . 0.0 111.185 -174.107 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -93.78 -8.57 40.24 Favored 'General case' 0 N--CA 1.45 -0.471 0 C-N-CA 120.547 -0.461 . . . . 0.0 111.763 -174.755 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 79.71 7.16 88.71 Favored Glycine 0 CA--C 1.505 -0.579 0 N-CA-C 110.26 -1.136 . . . . 0.0 110.26 -178.106 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 41' ' ' GLY . . . . . 0.408 ' N ' ' HA2' ' A' ' 36' ' ' GLY . . . 81.76 50.78 4.81 Favored Glycine 0 N--CA 1.435 -1.374 0 CA-C-N 114.324 -0.938 . . . . 0.0 112.656 -178.537 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 44.7 t-20 -144.26 128.56 17.82 Favored 'General case' 0 N--CA 1.441 -0.9 0 N-CA-C 107.871 -1.159 . . . . 0.0 107.871 178.256 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 43' ' ' TRP . . . . . 0.791 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 17.6 m95 -103.38 0.41 31.25 Favored 'General case' 0 C--N 1.306 -1.304 0 CA-C-N 115.589 -0.732 . . . . 0.0 110.313 -173.549 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -112.55 -2.47 14.61 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-N 115.4 -0.818 . . . . 0.0 111.011 178.396 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 10.0 tt -66.6 143.4 15.63 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.79 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.078 177.991 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 2.4 t30 -143.59 91.68 2.27 Favored 'General case' 0 C--N 1.317 -0.83 0 CA-C-O 121.471 0.653 . . . . 0.0 109.334 -179.077 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -73.69 -19.17 60.9 Favored 'General case' 0 N--CA 1.437 -1.085 0 CA-C-N 115.065 -0.971 . . . . 0.0 110.555 177.51 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 82.88 23.01 56.82 Favored Glycine 0 N--CA 1.445 -0.732 0 CA-C-N 115.51 -0.768 . . . . 0.0 111.247 174.315 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 4.6 p-10 -93.5 15.38 16.11 Favored 'General case' 0 C--N 1.325 -0.5 0 N-CA-C 112.247 0.462 . . . . 0.0 112.247 -172.073 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 50' ' ' GLY . . . . . 0.498 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 95.06 -13.51 66.91 Favored Glycine 0 CA--C 1.508 -0.358 0 N-CA-C 110.789 -0.925 . . . . 0.0 110.789 178.859 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 51' ' ' TYR . . . . . 0.498 ' HD1' ' C ' ' A' ' 50' ' ' GLY . 0.1 OUTLIER -121.52 161.58 22.06 Favored 'General case' 0 N--CA 1.441 -0.881 0 N-CA-C 105.286 -2.116 . . . . 0.0 105.286 174.483 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 52' ' ' TYR . . . . . 0.736 ' O ' ' HA ' ' A' ' 56' ' ' GLN . 20.8 m-85 -126.97 167.85 15.33 Favored 'General case' 0 C--N 1.302 -1.487 0 C-N-CA 119.621 -0.832 . . . . 0.0 111.231 -169.827 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -55.31 164.18 4.1 Favored Glycine 0 N--CA 1.446 -0.689 0 O-C-N 123.881 0.738 . . . . 0.0 114.105 -175.852 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 54' ' ' GLY . . . . . 0.616 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 97.1 -112.99 4.59 Favored Glycine 0 N--CA 1.439 -1.155 0 N-CA-C 111.421 -0.672 . . . . 0.0 111.421 -176.423 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.59 HG12 ' HE1' ' A' ' 98' ' ' TRP . 2.2 t -84.81 -3.5 8.13 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 CA-C-O 121.826 0.822 . . . . 0.0 109.783 -178.418 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 56' ' ' GLN . . . . . 0.736 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 37.8 tt0 50.36 50.57 18.47 Favored 'General case' 0 N--CA 1.463 0.213 0 CA-C-N 113.774 -1.557 . . . . 0.0 113.498 173.314 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 57' ' ' PHE . . . . . 0.458 ' CD1' ' HB ' ' A' ' 55' ' ' VAL . 2.8 p90 -113.41 159.35 19.55 Favored 'General case' 0 C--N 1.321 -0.64 0 C-N-CA 119.925 -0.71 . . . . 0.0 110.684 171.668 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.433 ' HA ' ' HA ' ' A' ' 51' ' ' TYR . 5.9 p-10 -71.29 157.75 37.57 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-O 121.75 0.786 . . . . 0.0 112.869 -163.922 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 59' ' ' GLN . . . . . 0.481 ' HB2' ' CE2' ' A' ' 52' ' ' TYR . 6.7 tp60 -55.8 -35.75 66.65 Favored 'General case' 0 N--CA 1.447 -0.603 0 CA-C-N 114.193 -1.367 . . . . 0.0 111.371 178.944 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -68.12 -49.75 44.7 Favored Glycine 0 N--CA 1.45 -0.407 0 CA-C-N 115.572 -0.74 . . . . 0.0 112.155 -175.896 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 51.3 m -65.19 -41.23 94.76 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-O 121.113 0.482 . . . . 0.0 110.595 176.447 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 62' ' ' TRP . . . . . 0.611 ' CZ3' ' HG2' ' A' ' 82' ' ' GLN . 54.5 t-105 -56.5 -48.89 76.23 Favored 'General case' 0 N--CA 1.448 -0.531 0 CA-C-N 115.493 -0.776 . . . . 0.0 109.389 175.833 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 63' ' ' GLU . . . . . 0.457 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 34.9 tt0 -68.25 -32.49 72.71 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 115.105 -0.952 . . . . 0.0 111.217 -179.505 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -65.53 -41.21 93.34 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.991 -0.549 . . . . 0.0 110.711 -178.552 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 65' ' ' ASN . . . . . 0.52 ' HB2' HG13 ' A' ' 85' ' ' VAL . 5.9 m120 -81.13 -8.07 59.69 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.45 0.643 . . . . 0.0 109.862 175.239 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 66' ' ' GLY . . . . . 0.412 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 80.74 50.26 5.34 Favored Glycine 0 N--CA 1.449 -0.454 0 CA-C-N 115.031 -0.986 . . . . 0.0 112.828 174.903 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 67' ' ' GLY . . . . . 0.602 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -78.58 -18.55 75.46 Favored Glycine 0 N--CA 1.442 -0.966 0 C-N-CA 120.957 -0.64 . . . . 0.0 112.086 -176.499 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.933 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 7.0 mp -60.34 -20.2 58.4 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 111.994 0.368 . . . . 0.0 111.994 -176.09 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 69' ' ' ARG . . . . . 0.412 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 9.9 ptm180 -70.57 -31.86 69.05 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-O 121.253 0.549 . . . . 0.0 109.823 177.238 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 70' ' ' TYR . . . . . 0.602 ' HD2' ' HA2' ' A' ' 67' ' ' GLY . 43.8 m-85 -85.3 -34.0 21.99 Favored 'General case' 0 N--CA 1.438 -1.04 0 N-CA-C 107.71 -1.218 . . . . 0.0 107.71 178.239 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.511 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 170.69 122.06 0.05 OUTLIER Pre-proline 0 N--CA 1.45 -0.454 0 CA-C-N 113.247 -1.797 . . . . 0.0 107.83 -177.301 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 72' ' ' PRO . . . . . 0.933 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 25.1 Cg_exo -55.34 -7.94 1.48 Allowed 'Trans proline' 0 C--N 1.334 -0.192 0 C-N-CA 123.01 2.473 . . . . 0.0 113.789 -178.737 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 13.4 ptm180 -142.99 136.86 28.88 Favored 'General case' 0 C--N 1.317 -0.825 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 177.461 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 74' ' ' ALA . . . . . 0.618 ' HB3' ' HB2' ' A' ' 52' ' ' TYR . . . -60.22 -28.11 67.74 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.199 -0.91 . . . . 0.0 112.238 -175.351 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 75' ' ' ASP . . . . . 0.587 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 19.5 p-10 -84.79 -8.99 58.6 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 121.072 0.463 . . . . 0.0 111.344 -176.712 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.504 ' HB3' ' HB1' ' A' ' 71' ' ' ALA . 57.2 tp -84.96 -32.36 23.07 Favored 'General case' 0 C--N 1.32 -0.682 0 N-CA-C 108.107 -1.071 . . . . 0.0 108.107 169.361 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 77' ' ' ALA . . . . . 0.953 ' HB1' ' HB2' ' A' ' 81' ' ' GLU . . . -77.93 154.23 31.82 Favored 'General case' 0 N--CA 1.44 -0.935 0 CA-C-N 114.953 -1.021 . . . . 0.0 110.851 177.071 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 78' ' ' THR . . . . . 0.562 ' H ' ' CD ' ' A' ' 81' ' ' GLU . 19.5 p -99.91 -169.89 1.81 Allowed 'General case' 0 C--N 1.315 -0.895 0 CA-C-N 115.656 -0.702 . . . . 0.0 109.552 176.786 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 79' ' ' ARG . . . . . 0.791 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 79.8 mtp180 -49.66 -51.41 38.22 Favored 'General case' 0 C--N 1.329 -0.31 0 O-C-N 123.418 0.449 . . . . 0.0 111.305 -176.974 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 80' ' ' GLU . . . . . 0.448 ' HG3' ' N ' ' A' ' 81' ' ' GLU . 10.0 pt-20 -60.87 -47.56 85.82 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 112.457 0.54 . . . . 0.0 112.457 -173.361 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 81' ' ' GLU . . . . . 0.953 ' HB2' ' HB1' ' A' ' 77' ' ' ALA . 4.4 mp0 -60.96 -50.64 72.59 Favored 'General case' 0 CA--C 1.518 -0.26 0 CA-C-O 121.064 0.459 . . . . 0.0 111.03 178.382 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 82' ' ' GLN . . . . . 0.611 ' HG2' ' CZ3' ' A' ' 62' ' ' TRP . 34.2 mt-30 -63.65 -37.05 85.88 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.789 -0.641 . . . . 0.0 111.421 -176.682 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.685 ' O ' ' HG2' ' A' ' 87' ' ' GLU . 40.0 mt -60.14 -44.47 95.27 Favored 'Isoleucine or valine' 0 C--O 1.213 -0.841 0 N-CA-C 109.461 -0.57 . . . . 0.0 109.461 174.211 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 84' ' ' ALA . . . . . 0.612 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -62.7 -43.6 98.39 Favored 'General case' 0 C--O 1.236 0.346 0 CA-C-O 121.208 0.528 . . . . 0.0 111.792 -177.023 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.52 HG13 ' HB2' ' A' ' 65' ' ' ASN . 32.4 t -67.5 -47.86 79.07 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.332 178.845 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 86' ' ' ALA . . . . . 0.416 ' HB1' ' CH2' ' A' ' 31' ' ' TRP . . . -59.07 -29.75 67.56 Favored 'General case' 0 N--CA 1.455 -0.225 0 CA-C-N 115.531 -0.759 . . . . 0.0 110.468 174.859 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 87' ' ' GLU . . . . . 0.685 ' HG2' ' O ' ' A' ' 83' ' ' ILE . 25.9 mm-40 -59.51 -43.42 93.38 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.605 -0.725 . . . . 0.0 110.115 178.649 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.691 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 96.9 t -62.64 -48.47 88.04 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.322 0 CA-C-O 121.127 0.489 . . . . 0.0 110.124 176.454 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 89' ' ' THR . . . . . 0.766 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 0.2 OUTLIER -64.56 -47.62 78.07 Favored 'General case' 0 C--N 1.317 -0.84 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.989 -175.433 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 90' ' ' ARG . . . . . 0.455 ' HD3' ' CZ2' ' A' ' 31' ' ' TRP . 7.9 ptt180 -62.52 -33.06 74.14 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.858 -175.84 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 91' ' ' LEU . . . . . 0.691 ' HG ' ' O ' ' A' ' 88' ' ' VAL . 4.4 pp -73.57 -23.45 59.95 Favored 'General case' 0 C--N 1.321 -0.637 0 C-N-CA 120.623 -0.431 . . . . 0.0 111.069 -172.013 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 92' ' ' ARG . . . . . 0.553 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 6.1 mtm180 -84.2 -45.86 12.48 Favored 'General case' 0 N--CA 1.45 -0.468 0 CA-C-O 121.369 0.605 . . . . 0.0 109.654 -178.487 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 93' ' ' GLN . . . . . 0.423 HE21 ' HZ3' ' A' ' 98' ' ' TRP . 9.1 pt20 -102.89 -27.98 12.32 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 113.924 1.083 . . . . 0.0 113.924 -169.603 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 83.68 50.95 4.23 Favored Glycine 0 CA--C 1.507 -0.448 0 C-N-CA 120.699 -0.762 . . . . 0.0 111.834 178.735 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 95' ' ' TRP . . . . . 0.492 ' HA ' ' HE3' ' A' ' 98' ' ' TRP . 2.5 m95 60.47 22.77 12.41 Favored 'General case' 0 C--O 1.224 -0.251 0 CA-C-O 121.282 0.563 . . . . 0.0 109.674 177.098 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -75.53 -20.77 78.23 Favored Glycine 0 N--CA 1.447 -0.586 0 CA-C-N 115.368 -0.833 . . . . 0.0 112.569 178.454 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -89.77 -17.49 28.12 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 121.096 0.475 . . . . 0.0 110.173 176.253 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 98' ' ' TRP . . . . . 0.766 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 23.3 m-90 -100.09 113.14 65.14 Favored Pre-proline 0 N--CA 1.444 -0.738 0 CA-C-N 115.73 -0.668 . . . . 0.0 109.433 178.748 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 99' ' ' PRO . . . . . 0.43 ' HD3' ' HA ' ' A' ' 98' ' ' TRP . 52.8 Cg_exo -61.93 -145.33 0.01 OUTLIER 'Trans proline' 0 CA--C 1.535 0.542 0 C-N-CA 123.954 3.103 . . . . 0.0 114.315 -173.738 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 100' ' ' VAL . . . . . 0.421 HG12 ' HG3' ' A' ' 104' ' ' ARG . 58.5 t -55.84 -24.4 16.88 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.307 0 CA-C-N 115.919 -0.582 . . . . 0.0 111.032 -179.791 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 101' ' ' CYS . . . . . 0.416 ' SG ' ' HG3' ' A' ' 38' ' ' GLU . 56.6 m -56.44 -36.36 68.91 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.003 177.436 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -69.77 -42.88 73.23 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.834 0.349 . . . . 0.0 110.639 178.891 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -64.37 -42.78 96.0 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.51 178.837 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 104' ' ' ARG . . . . . 0.421 ' HG3' HG12 ' A' ' 100' ' ' VAL . 68.4 mtp180 -60.14 -39.49 86.5 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.389 -0.823 . . . . 0.0 110.916 176.262 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 105' ' ' ALA . . . . . 0.695 ' HB1' ' HA ' ' A' ' 30' ' ' ILE . . . -78.07 -22.05 49.63 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.628 -0.714 . . . . 0.0 112.114 -175.997 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 102.51 64.41 0.73 Allowed Glycine 0 CA--C 1.519 0.318 0 C-N-CA 120.935 -0.65 . . . . 0.0 112.188 -178.23 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -71.1 152.34 43.57 Favored 'General case' 0 C--N 1.324 -0.527 0 C-N-CA 122.649 0.379 . . . . 0.0 111.491 -175.29 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 27.6 mtt180 . . . . . 0 C--O 1.247 0.971 0 CA-C-O 117.702 -1.142 . . . . 0.0 112.464 174.618 . . . . . . . . 0 0 . 1 . 023 nuclear build core ' A' A ' 27' ' ' ASP . . . . . 0.655 ' O ' HG12 ' A' ' 30' ' ' ILE . 26.0 t0 . . . . . 0 CA--C 1.498 -1.037 0 CA-C-O 122.725 1.25 . . . . 0.0 108.8 . . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 28' ' ' GLY . . . . . 0.803 ' HA2' ' HB2' ' A' ' 31' ' ' TRP . . . -75.02 6.58 26.64 Favored Glycine 0 N--CA 1.435 -1.418 0 CA-C-N 113.081 -1.872 . . . . 0.0 111.638 -178.162 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 59.6 m -76.69 -42.3 42.09 Favored 'General case' 0 C--N 1.315 -0.904 0 CA-C-O 121.508 0.67 . . . . 0.0 109.346 172.941 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.655 HG12 ' O ' ' A' ' 27' ' ' ASP . 0.0 OUTLIER -71.23 -38.85 71.87 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 N-CA-C 107.517 -1.29 . . . . 0.0 107.517 174.939 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 31' ' ' TRP . . . . . 0.803 ' HB2' ' HA2' ' A' ' 28' ' ' GLY . 20.8 m95 -67.91 -35.15 77.96 Favored 'General case' 0 N--CA 1.445 -0.714 0 CA-C-N 114.543 -1.208 . . . . 0.0 110.686 -177.231 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 6.3 t70 -73.62 -43.12 60.42 Favored 'General case' 0 N--CA 1.446 -0.627 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.951 177.531 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 33' ' ' ALA . . . . . 0.504 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -68.82 -33.56 74.04 Favored 'General case' 0 N--CA 1.446 -0.639 0 C-N-CA 120.331 -0.548 . . . . 0.0 110.394 -179.497 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 34' ' ' ILE . . . . . 0.445 HG13 ' O ' ' A' ' 30' ' ' ILE . 65.1 mt -66.89 -43.89 89.19 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.172 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.128 173.066 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -58.04 -35.76 71.78 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 121.299 0.571 . . . . 0.0 110.288 176.375 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 36' ' ' GLY . . . . . 0.429 ' HA2' ' N ' ' A' ' 41' ' ' GLY . . . -74.02 -22.21 78.19 Favored Glycine 0 N--CA 1.45 -0.383 0 CA-C-N 115.52 -0.764 . . . . 0.0 111.725 178.617 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 11.9 t -87.41 -52.82 5.16 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 115.377 -0.411 . . . . 0.0 111.87 -176.939 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 10.2 tp10 -87.77 -34.01 18.46 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-O 121.071 0.462 . . . . 0.0 110.161 -172.955 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -103.76 -7.81 20.32 Favored 'General case' 0 C--N 1.323 -0.544 0 C-N-CA 120.437 -0.505 . . . . 0.0 112.186 -175.099 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 77.75 13.26 83.64 Favored Glycine 0 CA--C 1.505 -0.58 0 N-CA-C 109.985 -1.246 . . . . 0.0 109.985 -177.666 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 41' ' ' GLY . . . . . 0.429 ' N ' ' HA2' ' A' ' 36' ' ' GLY . . . 76.74 58.28 3.55 Favored Glycine 0 N--CA 1.434 -1.488 0 CA-C-N 114.236 -0.982 . . . . 0.0 111.975 -177.236 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 42' ' ' ASN . . . . . 0.57 ' HB3' ' HB ' ' A' ' 45' ' ' ILE . 2.7 t-20 -145.88 103.37 3.75 Favored 'General case' 0 N--CA 1.447 -0.593 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 179.901 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 43' ' ' TRP . . . . . 0.76 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 35.6 m95 -82.63 -6.58 59.44 Favored 'General case' 0 C--N 1.314 -0.972 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.649 -172.887 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -111.86 14.7 20.99 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 115.259 -0.882 . . . . 0.0 111.33 179.417 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.57 ' HB ' ' HB3' ' A' ' 42' ' ' ASN . 10.2 tt -79.93 140.54 16.59 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.773 0 N-CA-C 109.138 -0.69 . . . . 0.0 109.138 -179.599 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 10.0 t-20 -149.14 107.22 3.72 Favored 'General case' 0 C--N 1.307 -1.281 0 CA-C-O 121.289 0.566 . . . . 0.0 109.716 -174.861 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 24.5 p -82.45 -22.96 35.02 Favored 'General case' 0 N--CA 1.437 -1.109 0 CA-C-N 115.185 -0.916 . . . . 0.0 109.997 178.946 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 90.63 20.57 40.12 Favored Glycine 0 N--CA 1.443 -0.88 0 N-CA-C 110.902 -0.879 . . . . 0.0 110.902 178.702 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 27.5 p-10 -93.64 11.39 29.06 Favored 'General case' 0 C--N 1.327 -0.379 0 C-N-CA 120.656 -0.418 . . . . 0.0 111.684 -173.359 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 93.97 -12.31 69.44 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.699 -0.763 . . . . 0.0 111.431 -177.95 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 51' ' ' TYR . . . . . 0.771 ' CE1' ' HB2' ' A' ' 58' ' ' ASP . 0.2 OUTLIER -108.02 160.66 15.62 Favored 'General case' 0 N--CA 1.446 -0.673 0 N-CA-C 106.982 -1.488 . . . . 0.0 106.982 172.811 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 52' ' ' TYR . . . . . 0.873 ' O ' ' HA ' ' A' ' 56' ' ' GLN . 31.6 m-85 -130.35 170.57 13.98 Favored 'General case' 0 C--N 1.318 -0.783 0 C-N-CA 120.668 -0.413 . . . . 0.0 111.045 -171.298 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.495 ' HA2' HG22 ' A' ' 45' ' ' ILE . . . -61.63 177.91 4.61 Favored Glycine 0 N--CA 1.452 -0.28 0 N-CA-C 114.833 0.693 . . . . 0.0 114.833 -171.717 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 54' ' ' GLY . . . . . 0.685 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 82.61 -104.96 2.57 Favored Glycine 0 N--CA 1.445 -0.702 0 C-N-CA 121.039 -0.6 . . . . 0.0 111.718 -179.877 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.569 HG12 ' HE1' ' A' ' 98' ' ' TRP . 2.1 t -83.84 -2.66 7.08 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.657 0 CA-C-O 121.902 0.858 . . . . 0.0 109.616 -179.385 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 56' ' ' GLN . . . . . 0.873 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 35.0 tt0 53.3 52.54 13.35 Favored 'General case' 0 N--CA 1.462 0.149 0 CA-C-N 113.681 -1.599 . . . . 0.0 113.3 171.981 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 57' ' ' PHE . . . . . 0.497 ' CZ ' ' HE3' ' A' ' 62' ' ' TRP . 16.5 p90 -121.13 173.34 7.35 Favored 'General case' 0 C--N 1.324 -0.519 0 C-N-CA 119.849 -0.74 . . . . 0.0 112.657 176.09 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.771 ' HB2' ' CE1' ' A' ' 51' ' ' TYR . 0.0 OUTLIER -83.97 153.63 23.79 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 114.534 -1.212 . . . . 0.0 114.091 -161.854 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 59' ' ' GLN . . . . . 0.461 ' HB2' ' HE1' ' A' ' 52' ' ' TYR . 6.3 tp-100 -56.38 -41.91 76.99 Favored 'General case' 0 N--CA 1.447 -0.597 0 CA-C-N 113.656 -1.611 . . . . 0.0 111.985 178.973 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -64.97 -48.42 71.39 Favored Glycine 0 N--CA 1.445 -0.747 0 C-N-CA 120.944 -0.645 . . . . 0.0 111.574 -176.747 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 67.6 m -65.89 -43.83 87.09 Favored 'General case' 0 C--N 1.318 -0.779 0 C-N-CA 122.696 0.398 . . . . 0.0 111.069 176.443 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 62' ' ' TRP . . . . . 0.497 ' HE3' ' CZ ' ' A' ' 57' ' ' PHE . 45.5 t-105 -56.98 -48.21 78.93 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 121.397 0.618 . . . . 0.0 109.729 177.008 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 63' ' ' GLU . . . . . 0.429 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 3.6 tm-20 -68.05 -32.82 73.44 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 115.143 -0.935 . . . . 0.0 110.39 -178.401 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -66.62 -41.81 87.77 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.717 -0.674 . . . . 0.0 111.493 -178.009 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 65' ' ' ASN . . . . . 0.66 ' HB2' HG13 ' A' ' 85' ' ' VAL . 12.8 m120 -76.43 -15.41 59.93 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.002 0.429 . . . . 0.0 110.511 175.839 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 66' ' ' GLY . . . . . 0.537 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 94.36 48.09 2.66 Favored Glycine 0 C--N 1.333 0.379 0 CA-C-N 115.735 -0.666 . . . . 0.0 112.199 176.966 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 67' ' ' GLY . . . . . 0.599 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -79.98 -26.24 56.13 Favored Glycine 0 N--CA 1.44 -1.081 0 C-N-CA 121.12 -0.562 . . . . 0.0 112.907 -174.699 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 1.035 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 7.5 mp -60.5 -25.44 66.08 Favored 'General case' 0 N--CA 1.445 -0.705 0 N-CA-C 112.814 0.672 . . . . 0.0 112.814 -173.761 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 69' ' ' ARG . . . . . 0.537 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 1.3 ptm180 -65.07 -33.64 76.52 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 121.35 0.595 . . . . 0.0 109.615 175.242 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 70' ' ' TYR . . . . . 0.618 ' HB3' ' CG ' ' A' ' 81' ' ' GLU . 84.3 m-85 -78.08 -35.43 49.4 Favored 'General case' 0 N--CA 1.438 -1.059 0 N-CA-C 107.483 -1.303 . . . . 0.0 107.483 178.159 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.592 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 162.03 130.15 0.01 OUTLIER Pre-proline 0 N--CA 1.447 -0.588 0 CA-C-N 112.676 -2.057 . . . . 0.0 106.756 -179.106 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 72' ' ' PRO . . . . . 1.035 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 26.5 Cg_exo -56.41 -6.54 1.52 Allowed 'Trans proline' 0 C--N 1.334 -0.226 0 C-N-CA 122.955 2.436 . . . . 0.0 113.862 -176.894 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 73' ' ' ARG . . . . . 0.493 ' HB2' ' CD2' ' A' ' 52' ' ' TYR . 0.2 OUTLIER -147.0 143.08 28.15 Favored 'General case' 0 C--N 1.317 -0.811 0 N-CA-C 109.533 -0.543 . . . . 0.0 109.533 176.523 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 74' ' ' ALA . . . . . 0.589 ' HB3' ' HB2' ' A' ' 52' ' ' TYR . . . -58.94 -26.5 64.44 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.413 -0.812 . . . . 0.0 112.722 -177.05 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 75' ' ' ASP . . . . . 0.479 ' HB2' ' NH2' ' A' ' 73' ' ' ARG . 0.0 OUTLIER -74.27 -25.43 59.61 Favored 'General case' 0 CA--C 1.518 -0.265 0 CA-C-O 121.096 0.474 . . . . 0.0 110.704 -177.258 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.528 ' HB3' ' HB1' ' A' ' 71' ' ' ALA . 55.3 tp -86.76 -30.22 21.76 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-O 121.342 0.591 . . . . 0.0 109.972 -178.635 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 77' ' ' ALA . . . . . 0.664 ' HB1' ' CB ' ' A' ' 81' ' ' GLU . . . -82.97 161.05 21.9 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 115.383 -0.826 . . . . 0.0 109.66 172.992 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 18.7 p -101.32 -171.78 2.05 Favored 'General case' 0 C--N 1.32 -0.714 0 C-N-CA 120.611 -0.435 . . . . 0.0 110.054 -179.359 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 79' ' ' ARG . . . . . 0.76 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 2.8 mtt85 -49.36 -53.12 23.99 Favored 'General case' 0 C--N 1.326 -0.436 0 O-C-N 123.487 0.492 . . . . 0.0 111.916 -177.69 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 80' ' ' GLU . . . . . 0.766 ' HA ' HD12 ' A' ' 83' ' ' ILE . 0.0 OUTLIER -61.4 -40.35 94.05 Favored 'General case' 0 C--N 1.324 -0.534 0 O-C-N 123.206 0.316 . . . . 0.0 111.578 -172.275 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 81' ' ' GLU . . . . . 0.664 ' CB ' ' HB1' ' A' ' 77' ' ' ALA . 47.0 mp0 -61.9 -51.48 67.97 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.724 0.297 . . . . 0.0 111.343 175.505 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 82' ' ' GLN . . . . . 0.424 ' HB2' ' HZ3' ' A' ' 43' ' ' TRP . 46.7 mt-30 -59.71 -35.51 74.66 Favored 'General case' 0 CA--C 1.513 -0.473 0 CA-C-O 121.141 0.496 . . . . 0.0 110.198 -178.83 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.766 HD12 ' HA ' ' A' ' 80' ' ' GLU . 35.4 mt -59.47 -49.53 83.27 Favored 'Isoleucine or valine' 0 C--O 1.212 -0.896 0 CA-C-N 114.95 -1.023 . . . . 0.0 109.955 176.905 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 84' ' ' ALA . . . . . 0.571 ' O ' ' HG3' ' A' ' 87' ' ' GLU . . . -61.27 -44.26 97.52 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-O 121.199 0.523 . . . . 0.0 111.162 -176.188 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.66 HG13 ' HB2' ' A' ' 65' ' ' ASN . 21.8 t -69.33 -49.02 64.34 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.823 179.776 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -66.2 -32.15 73.42 Favored 'General case' 0 CA--C 1.515 -0.379 0 CA-C-O 121.137 0.494 . . . . 0.0 110.888 -179.912 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 87' ' ' GLU . . . . . 0.752 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 0.0 OUTLIER -70.5 -31.52 68.66 Favored 'General case' 0 C--N 1.317 -0.817 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.255 -176.054 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.463 ' O ' ' HG3' ' A' ' 92' ' ' ARG . 71.8 t -60.63 -42.51 92.02 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.373 0 N-CA-C 108.892 -0.781 . . . . 0.0 108.892 172.399 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 89' ' ' THR . . . . . 0.816 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 1.1 m -67.42 -43.7 80.57 Favored 'General case' 0 N--CA 1.441 -0.879 0 CA-C-N 114.766 -1.106 . . . . 0.0 111.023 -176.139 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 90' ' ' ARG . . . . . 0.647 ' HA ' ' OE1' ' A' ' 93' ' ' GLN . 36.2 ptt85 -60.51 -32.46 71.47 Favored 'General case' 0 N--CA 1.461 0.102 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.472 -174.677 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 91' ' ' LEU . . . . . 0.752 ' HG ' ' O ' ' A' ' 87' ' ' GLU . 18.4 mt -67.7 -25.42 65.66 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-O 121.559 0.695 . . . . 0.0 110.197 -176.804 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 92' ' ' ARG . . . . . 0.463 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 11.4 mtm180 -90.15 -51.48 5.43 Favored 'General case' 0 C--N 1.317 -0.838 0 CA-C-N 114.992 -1.004 . . . . 0.0 110.44 -171.253 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 93' ' ' GLN . . . . . 0.647 ' OE1' ' HA ' ' A' ' 90' ' ' ARG . 0.0 OUTLIER -96.52 -23.59 16.47 Favored 'General case' 0 C--N 1.32 -0.689 0 N-CA-C 113.047 0.758 . . . . 0.0 113.047 -172.088 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 78.38 51.29 5.72 Favored Glycine 0 CA--C 1.506 -0.53 0 C-N-CA 120.507 -0.854 . . . . 0.0 111.565 176.695 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 95' ' ' TRP . . . . . 0.572 ' CZ2' ' HD2' ' A' ' 90' ' ' ARG . 2.6 m95 59.79 23.5 12.44 Favored 'General case' 0 C--N 1.329 -0.317 0 C-N-CA 123.361 0.665 . . . . 0.0 110.685 175.217 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.643 ' H ' ' HG2' ' A' ' 93' ' ' GLN . . . -77.75 -17.73 78.33 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.935 -0.65 . . . . 0.0 111.682 173.64 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -87.52 -23.09 24.5 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 121.301 0.572 . . . . 0.0 110.137 176.618 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 98' ' ' TRP . . . . . 0.816 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 20.8 m-90 -110.44 108.68 58.43 Favored Pre-proline 0 N--CA 1.448 -0.55 0 CA-C-N 115.417 -0.811 . . . . 0.0 109.797 179.315 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 99' ' ' PRO . . . . . 0.423 ' HD3' ' HA ' ' A' ' 98' ' ' TRP . 52.6 Cg_exo -61.48 -135.43 0.0 OUTLIER 'Trans proline' 0 CA--C 1.538 0.711 0 C-N-CA 124.083 3.189 . . . . 0.0 114.16 -175.151 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 21.2 t -56.42 -23.21 16.23 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.249 0 CA-C-N 116.397 -0.365 . . . . 0.0 110.95 -178.409 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 68.5 m -54.79 -38.12 66.9 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.013 -0.54 . . . . 0.0 111.024 178.011 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -69.44 -45.89 68.06 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.827 0.346 . . . . 0.0 110.757 -179.163 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -63.56 -35.82 81.77 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.514 179.365 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 4.7 mmp_? -70.79 -31.56 68.37 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.561 -0.745 . . . . 0.0 111.356 177.821 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 105' ' ' ALA . . . . . 0.644 ' HB1' ' HA ' ' A' ' 30' ' ' ILE . . . -89.0 -22.51 22.96 Favored 'General case' 0 C--N 1.326 -0.438 0 N-CA-C 112.664 0.616 . . . . 0.0 112.664 -173.079 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 113.23 58.52 0.41 Allowed Glycine 0 CA--C 1.521 0.437 0 C-N-CA 120.569 -0.824 . . . . 0.0 112.473 -178.333 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -66.69 154.36 40.83 Favored 'General case' 0 C--N 1.325 -0.472 0 C-N-CA 123.402 0.681 . . . . 0.0 111.775 -175.763 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 23.5 mmt180 . . . . . 0 C--O 1.247 0.95 0 CA-C-O 118.09 -0.957 . . . . 0.0 111.346 177.353 . . . . . . . . 0 0 . 1 . 024 nuclear build core ' A' A ' 27' ' ' ASP . . . . . 0.515 ' O ' HG12 ' A' ' 30' ' ' ILE . 46.5 m-20 . . . . . 0 CA--C 1.507 -0.673 0 CA-C-O 121.542 0.687 . . . . 0.0 109.741 . . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 28' ' ' GLY . . . . . 0.669 ' HA2' HG12 ' A' ' 83' ' ' ILE . . . -68.24 -6.51 47.49 Favored Glycine 0 N--CA 1.438 -1.203 0 CA-C-N 115.029 -0.987 . . . . 0.0 111.896 -178.878 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 4.9 m -74.47 -46.27 40.78 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-O 122.064 0.935 . . . . 0.0 109.105 176.623 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.606 ' HA ' ' HB1' ' A' ' 105' ' ' ALA . 0.0 OUTLIER -69.77 -38.47 76.11 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.777 0 CA-C-N 114.129 -1.396 . . . . 0.0 108.263 179.242 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 31' ' ' TRP . . . . . 0.573 ' HD1' HG23 ' A' ' 83' ' ' ILE . 9.0 m95 -70.55 -36.29 73.57 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 114.86 -1.063 . . . . 0.0 110.861 -177.589 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 4.4 t70 -72.79 -39.37 66.78 Favored 'General case' 0 N--CA 1.446 -0.663 0 CA-C-N 116.481 -0.327 . . . . 0.0 110.521 178.174 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 33' ' ' ALA . . . . . 0.437 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -69.54 -37.43 77.08 Favored 'General case' 0 N--CA 1.445 -0.69 0 C-N-CA 120.637 -0.425 . . . . 0.0 110.782 179.294 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 34' ' ' ILE . . . . . 0.477 HG13 ' O ' ' A' ' 30' ' ' ILE . 75.5 mt -67.46 -44.42 86.79 Favored 'Isoleucine or valine' 0 C--O 1.232 0.177 0 CA-C-O 120.809 0.338 . . . . 0.0 110.454 175.524 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -60.86 -31.83 71.28 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 121.252 0.549 . . . . 0.0 110.229 176.907 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -77.42 -22.78 69.52 Favored Glycine 0 N--CA 1.45 -0.395 0 CA-C-N 115.596 -0.729 . . . . 0.0 111.516 177.54 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 40.9 t -76.83 -58.36 3.32 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 115.367 -0.417 . . . . 0.0 111.041 -179.055 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 17.5 mt-10 -89.1 -32.9 17.31 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 116.353 -0.385 . . . . 0.0 111.3 -171.365 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -102.05 -17.61 15.98 Favored 'General case' 0 C--N 1.323 -0.576 0 C-N-CA 120.507 -0.477 . . . . 0.0 112.183 -177.562 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 81.36 9.99 85.2 Favored Glycine 0 N--CA 1.448 -0.535 0 N-CA-C 109.805 -1.318 . . . . 0.0 109.805 -175.709 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 88.39 62.71 1.39 Allowed Glycine 0 N--CA 1.438 -1.199 0 CA-C-N 114.156 -1.022 . . . . 0.0 111.713 -176.931 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 4.1 t-20 -139.31 87.98 2.23 Favored 'General case' 0 C--N 1.326 -0.418 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 -177.142 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 43' ' ' TRP . . . . . 0.778 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 37.9 m95 -76.41 -11.47 59.9 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-O 121.171 0.51 . . . . 0.0 111.259 -172.669 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -102.66 15.56 28.95 Favored 'General case' 0 C--N 1.314 -0.955 0 CA-C-N 115.793 -0.64 . . . . 0.0 110.447 -179.94 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 10.1 tt -77.53 139.94 17.86 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.003 0 CA-C-N 115.861 -0.609 . . . . 0.0 110.799 -177.771 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 34.1 t-20 -150.59 92.35 1.84 Allowed 'General case' 0 C--N 1.314 -0.957 0 CA-C-N 115.522 -0.763 . . . . 0.0 109.363 179.578 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 8.9 p -76.19 -15.67 60.0 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 115.581 -0.736 . . . . 0.0 111.668 -176.279 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 93.43 21.95 28.07 Favored Glycine 0 N--CA 1.448 -0.561 0 N-CA-C 111.149 -0.78 . . . . 0.0 111.149 -179.904 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 4.9 m-20 -90.7 -0.57 57.74 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 120.857 0.361 . . . . 0.0 111.434 -177.005 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 50' ' ' GLY . . . . . 0.492 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 86.53 -8.42 75.01 Favored Glycine 0 N--CA 1.449 -0.478 0 N-CA-C 110.888 -0.885 . . . . 0.0 110.888 -172.775 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 51' ' ' TYR . . . . . 0.566 ' CE1' ' HB3' ' A' ' 58' ' ' ASP . 0.1 OUTLIER -114.27 140.47 48.57 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 107.459 -1.312 . . . . 0.0 107.459 175.434 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 52' ' ' TYR . . . . . 0.505 ' O ' ' HA ' ' A' ' 56' ' ' GLN . 0.1 OUTLIER -140.33 163.82 31.75 Favored 'General case' 0 C--N 1.319 -0.748 0 N-CA-C 112.7 0.63 . . . . 0.0 112.7 -170.991 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.413 ' HA2' ' O ' ' A' ' 43' ' ' TRP . . . 65.45 105.66 0.01 OUTLIER Glycine 0 C--O 1.221 -0.684 0 N-CA-C 116.287 1.275 . . . . 0.0 116.287 164.198 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 54' ' ' GLY . . . . . 0.479 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 57.99 -83.45 0.01 OUTLIER Glycine 0 C--N 1.339 0.696 0 N-CA-C 114.579 0.591 . . . . 0.0 114.579 165.226 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.478 HG23 ' HD1' ' A' ' 57' ' ' PHE . 3.7 m -83.16 -6.29 9.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-O 120.932 0.396 . . . . 0.0 110.282 178.337 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 56' ' ' GLN . . . . . 0.505 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 9.8 mt-30 50.19 51.84 15.93 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 114.934 -1.03 . . . . 0.0 113.203 166.788 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 57' ' ' PHE . . . . . 0.478 ' HD1' HG23 ' A' ' 55' ' ' VAL . 5.5 p90 -102.13 166.68 10.47 Favored 'General case' 0 C--N 1.323 -0.572 0 C-N-CA 119.382 -0.927 . . . . 0.0 110.705 174.926 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.566 ' HB3' ' CE1' ' A' ' 51' ' ' TYR . 4.9 p-10 -74.48 155.99 37.41 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 122.223 1.011 . . . . 0.0 113.548 -163.276 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 59' ' ' GLN . . . . . 0.413 ' HB2' ' CE1' ' A' ' 52' ' ' TYR . 23.3 tp60 -57.06 -39.58 75.17 Favored 'General case' 0 N--CA 1.441 -0.877 0 CA-C-N 113.175 -1.829 . . . . 0.0 111.633 179.813 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -67.74 -49.29 50.41 Favored Glycine 0 N--CA 1.451 -0.352 0 CA-C-N 115.422 -0.808 . . . . 0.0 112.248 -176.332 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 97.8 m -64.15 -40.83 96.98 Favored 'General case' 0 C--N 1.322 -0.602 0 C-N-CA 122.829 0.451 . . . . 0.0 110.827 176.761 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 62' ' ' TRP . . . . . 0.545 ' CH2' ' HA ' ' A' ' 74' ' ' ALA . 45.6 t-105 -55.92 -48.58 75.42 Favored 'General case' 0 N--CA 1.45 -0.471 0 CA-C-O 121.71 0.767 . . . . 0.0 109.221 174.859 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 63' ' ' GLU . . . . . 0.515 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 33.2 tt0 -64.64 -36.57 84.67 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-N 114.821 -1.081 . . . . 0.0 110.989 179.187 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -65.47 -41.16 93.64 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.75 -0.659 . . . . 0.0 110.948 -177.282 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 65' ' ' ASN . . . . . 0.443 ' HB3' ' HB ' ' A' ' 88' ' ' VAL . 8.2 m120 -80.79 -7.76 59.49 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 121.043 0.449 . . . . 0.0 110.339 177.968 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 66' ' ' GLY . . . . . 0.595 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 87.64 46.8 4.77 Favored Glycine 0 N--CA 1.447 -0.582 0 CA-C-N 115.622 -0.717 . . . . 0.0 112.511 174.207 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 67' ' ' GLY . . . . . 0.588 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -78.68 -25.05 61.28 Favored Glycine 0 N--CA 1.44 -1.095 0 C-N-CA 120.579 -0.819 . . . . 0.0 112.007 -175.435 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.922 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 7.3 mp -57.78 -23.27 51.46 Favored 'General case' 0 N--CA 1.446 -0.628 0 N-CA-C 112.671 0.619 . . . . 0.0 112.671 -175.38 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 69' ' ' ARG . . . . . 0.595 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 5.6 ptp180 -70.74 -29.39 65.63 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-O 121.327 0.584 . . . . 0.0 109.761 178.281 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 70' ' ' TYR . . . . . 0.749 ' HB3' ' CG ' ' A' ' 81' ' ' GLU . 43.5 m-85 -87.24 -34.62 18.89 Favored 'General case' 0 N--CA 1.439 -1.005 0 N-CA-C 107.373 -1.343 . . . . 0.0 107.373 177.724 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.526 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 170.12 125.31 0.05 OUTLIER Pre-proline 0 N--CA 1.449 -0.51 0 CA-C-N 113.198 -1.819 . . . . 0.0 107.89 -177.39 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 72' ' ' PRO . . . . . 0.922 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 15.9 Cg_exo -59.79 -2.8 1.73 Allowed 'Trans proline' 0 C--N 1.333 -0.27 0 C-N-CA 122.803 2.335 . . . . 0.0 113.562 -179.044 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 15.5 ptm180 -143.48 138.19 29.07 Favored 'General case' 0 C--N 1.316 -0.851 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 176.614 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 74' ' ' ALA . . . . . 0.594 ' HB1' ' OE1' ' A' ' 82' ' ' GLN . . . -59.09 -31.24 68.73 Favored 'General case' 0 C--N 1.316 -0.863 0 CA-C-N 114.952 -1.022 . . . . 0.0 112.393 -176.206 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 20.7 p-10 -88.93 9.0 26.51 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 120.961 0.41 . . . . 0.0 112.014 -175.956 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.505 ' HB3' ' HB1' ' A' ' 71' ' ' ALA . 68.3 tp -103.79 -28.93 11.34 Favored 'General case' 0 C--N 1.321 -0.634 0 N-CA-C 108.614 -0.884 . . . . 0.0 108.614 169.974 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 77' ' ' ALA . . . . . 0.72 ' HB1' ' CB ' ' A' ' 81' ' ' GLU . . . -79.91 153.68 28.82 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-N 114.545 -1.207 . . . . 0.0 110.39 176.553 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 21.9 p -99.79 -171.81 2.12 Favored 'General case' 0 C--N 1.32 -0.712 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.854 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 79' ' ' ARG . . . . . 0.778 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 4.0 mtp180 -50.65 -52.91 35.29 Favored 'General case' 0 C--O 1.222 -0.367 0 O-C-N 123.356 0.41 . . . . 0.0 110.779 -175.999 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 80' ' ' GLU . . . . . 0.438 ' HG3' ' OE2' ' A' ' 81' ' ' GLU . 10.5 pt-20 -58.92 -40.03 83.32 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.726 -0.67 . . . . 0.0 111.688 -174.154 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 81' ' ' GLU . . . . . 0.749 ' CG ' ' HB3' ' A' ' 70' ' ' TYR . 8.8 mp0 -67.8 -52.36 37.95 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 120.815 0.34 . . . . 0.0 111.812 176.397 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 82' ' ' GLN . . . . . 0.594 ' OE1' ' HB1' ' A' ' 74' ' ' ALA . 31.3 mt-30 -64.37 -31.28 72.43 Favored 'General case' 0 CA--C 1.514 -0.434 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.724 -175.7 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.669 HG12 ' HA2' ' A' ' 28' ' ' GLY . 27.9 mt -59.58 -48.16 88.37 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 CA-C-N 115.413 -0.812 . . . . 0.0 109.771 172.66 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 84' ' ' ALA . . . . . 0.542 ' HA ' ' HG2' ' A' ' 87' ' ' GLU . . . -62.57 -43.27 99.24 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.989 -0.55 . . . . 0.0 112.056 -177.465 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.417 HG23 ' O ' ' A' ' 81' ' ' GLU . 21.3 t -69.85 -49.76 54.57 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.69 0 O-C-N 122.112 -0.368 . . . . 0.0 111.346 -178.939 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -66.77 -31.17 71.63 Favored 'General case' 0 N--CA 1.446 -0.632 0 CA-C-N 115.947 -0.569 . . . . 0.0 110.403 -179.463 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 87' ' ' GLU . . . . . 0.816 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 6.5 pt-20 -67.62 -32.2 72.74 Favored 'General case' 0 C--O 1.219 -0.551 0 C-N-CA 120.272 -0.571 . . . . 0.0 109.72 -177.637 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.452 ' O ' ' HG3' ' A' ' 92' ' ' ARG . 87.3 t -61.77 -46.95 95.42 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.273 0 CA-C-O 121.421 0.629 . . . . 0.0 109.394 172.625 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 89' ' ' THR . . . . . 0.699 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 0.2 OUTLIER -60.8 -45.43 94.44 Favored 'General case' 0 N--CA 1.443 -0.794 0 CA-C-N 115.289 -0.869 . . . . 0.0 111.377 -178.184 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 90' ' ' ARG . . . . . 0.688 ' HG3' ' O ' ' A' ' 87' ' ' GLU . 5.6 ppt_? -60.35 -32.63 71.44 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.478 -177.095 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 91' ' ' LEU . . . . . 0.816 ' HG ' ' O ' ' A' ' 87' ' ' GLU . 38.6 mt -61.88 -43.01 99.72 Favored 'General case' 0 N--CA 1.473 0.676 0 CA-C-O 122.165 0.983 . . . . 0.0 110.047 -176.706 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 92' ' ' ARG . . . . . 0.462 ' HE ' ' HB2' ' A' ' 92' ' ' ARG . 4.4 mtm180 -78.24 -45.17 23.62 Favored 'General case' 0 C--N 1.316 -0.864 0 CA-C-N 113.828 -1.533 . . . . 0.0 110.083 -167.327 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 93' ' ' GLN . . . . . 0.496 ' NE2' ' HB2' ' A' ' 97' ' ' ALA . 3.2 pt20 -100.99 -26.74 13.62 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-N 114.605 -1.179 . . . . 0.0 112.857 -170.094 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 87.56 40.19 6.91 Favored Glycine 0 CA--C 1.508 -0.378 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.176 174.775 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 95' ' ' TRP . . . . . 0.494 ' CZ2' ' HD3' ' A' ' 90' ' ' ARG . 18.5 m95 64.54 18.66 11.49 Favored 'General case' 0 C--O 1.219 -0.527 0 CA-C-O 121.455 0.645 . . . . 0.0 109.815 179.912 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -66.41 -29.8 75.46 Favored Glycine 0 CA--C 1.519 0.299 0 CA-C-N 115.163 -0.926 . . . . 0.0 112.862 175.462 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 97' ' ' ALA . . . . . 0.496 ' HB2' ' NE2' ' A' ' 93' ' ' GLN . . . -81.83 -21.21 37.75 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.879 0.371 . . . . 0.0 110.625 178.692 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 98' ' ' TRP . . . . . 0.699 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 24.6 m-90 -99.3 109.06 53.31 Favored Pre-proline 0 N--CA 1.446 -0.625 0 N-CA-C 109.245 -0.65 . . . . 0.0 109.245 177.637 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 99' ' ' PRO . . . . . 0.42 ' HD3' ' HA ' ' A' ' 98' ' ' TRP . 44.8 Cg_exo -63.24 -139.48 0.0 OUTLIER 'Trans proline' 0 CA--C 1.535 0.541 0 C-N-CA 123.578 2.852 . . . . 0.0 114.331 -174.909 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 100' ' ' VAL . . . . . 0.422 ' O ' ' HD2' ' A' ' 104' ' ' ARG . 45.0 t -54.98 -23.98 13.64 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.315 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.682 -174.185 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 60.7 m -63.42 -31.66 72.88 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.549 -179.847 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -69.72 -46.03 66.88 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.617 0.246 . . . . 0.0 111.124 -177.364 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -66.09 -36.56 83.52 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 121.019 0.438 . . . . 0.0 110.652 179.896 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 104' ' ' ARG . . . . . 0.422 ' HD2' ' O ' ' A' ' 100' ' ' VAL . 0.0 OUTLIER -70.78 -24.13 62.52 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.78 -0.646 . . . . 0.0 111.23 177.194 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 105' ' ' ALA . . . . . 0.606 ' HB1' ' HA ' ' A' ' 30' ' ' ILE . . . -88.83 -21.46 23.71 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.583 -178.386 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 106' ' ' GLY . . . . . 0.457 ' O ' ' HG2' ' A' ' 108' ' ' ARG . . . 112.29 63.09 0.46 Allowed Glycine 0 CA--C 1.52 0.354 0 C-N-CA 120.996 -0.621 . . . . 0.0 112.129 -178.0 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -57.91 142.06 47.35 Favored 'General case' 0 C--N 1.329 -0.321 0 C-N-CA 122.679 0.392 . . . . 0.0 111.084 -179.321 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 108' ' ' ARG . . . . . 0.457 ' HG2' ' O ' ' A' ' 106' ' ' GLY . 4.6 ptp180 . . . . . 0 C--O 1.247 0.961 0 CA-C-O 118.484 -0.769 . . . . 0.0 111.093 -170.195 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 27' ' ' ASP . . . . . 0.445 ' O ' HG12 ' A' ' 30' ' ' ILE . 50.0 m-20 . . . . . 0 CA--C 1.506 -0.713 0 CA-C-O 121.392 0.615 . . . . 0.0 109.693 . . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -70.34 -7.84 61.19 Favored Glycine 0 N--CA 1.44 -1.066 0 N-CA-C 110.024 -1.231 . . . . 0.0 110.024 176.577 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 8.7 m -74.39 -39.42 62.7 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 114.644 -0.778 . . . . 0.0 109.122 174.621 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.622 ' HA ' ' HB1' ' A' ' 105' ' ' ALA . 1.0 OUTLIER -68.18 -39.58 81.45 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 N-CA-C 107.402 -1.333 . . . . 0.0 107.402 177.771 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 31' ' ' TRP . . . . . 0.588 ' CZ2' ' HD3' ' A' ' 90' ' ' ARG . 27.2 m95 -70.61 -37.35 73.85 Favored 'General case' 0 N--CA 1.443 -0.795 0 CA-C-N 114.301 -1.318 . . . . 0.0 110.345 -177.051 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.671 ' HB2' HH21 ' A' ' 79' ' ' ARG . 21.8 t70 -79.34 -33.85 42.69 Favored 'General case' 0 N--CA 1.448 -0.549 0 CA-C-N 115.965 -0.561 . . . . 0.0 111.258 -179.55 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 33' ' ' ALA . . . . . 0.466 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -68.63 -32.97 73.21 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 176.713 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 34' ' ' ILE . . . . . 0.541 HG13 ' O ' ' A' ' 30' ' ' ILE . 66.3 mt -61.07 -45.39 98.66 Favored 'Isoleucine or valine' 0 C--O 1.234 0.289 0 CA-C-N 116.172 -0.467 . . . . 0.0 109.85 171.315 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 35' ' ' ALA . . . . . 0.767 ' HA ' ' NE2' ' A' ' 56' ' ' GLN . . . -61.34 -36.03 79.05 Favored 'General case' 0 CA--C 1.513 -0.475 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.684 177.6 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -73.56 -18.13 79.32 Favored Glycine 0 N--CA 1.448 -0.509 0 N-CA-C 111.025 -0.83 . . . . 0.0 111.025 179.44 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 37' ' ' CYS . . . . . 0.509 ' HB3' ' O ' ' A' ' 34' ' ' ILE . 8.3 t -77.14 -70.64 0.45 Allowed 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 115.102 -0.549 . . . . 0.0 111.587 -178.065 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 38' ' ' GLU . . . . . 0.728 ' HG2' ' SG ' ' A' ' 101' ' ' CYS . 4.5 mm-40 -90.44 -33.54 15.96 Favored 'General case' 0 CA--C 1.511 -0.554 0 C-N-CA 120.435 -0.506 . . . . 0.0 111.133 -172.65 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 39' ' ' ALA . . . . . 0.501 ' HB3' ' O ' ' A' ' 35' ' ' ALA . . . -84.57 -15.69 44.79 Favored 'General case' 0 N--CA 1.443 -0.8 0 CA-C-N 115.997 -0.547 . . . . 0.0 111.125 -177.182 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 75.84 13.29 83.23 Favored Glycine 0 CA--C 1.504 -0.607 0 N-CA-C 109.687 -1.365 . . . . 0.0 109.687 -177.456 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 88.62 63.33 1.35 Allowed Glycine 0 N--CA 1.432 -1.583 0 CA-C-N 113.957 -1.121 . . . . 0.0 111.436 -175.424 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 42' ' ' ASN . . . . . 0.823 ' HB3' ' HB ' ' A' ' 45' ' ' ILE . 6.6 m120 -146.59 103.32 3.65 Favored 'General case' 0 CA--C 1.513 -0.456 0 CA-C-O 121.125 0.488 . . . . 0.0 110.003 -177.962 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 43' ' ' TRP . . . . . 0.704 ' HA ' ' N ' ' A' ' 54' ' ' GLY . 44.5 m95 -84.97 -6.87 59.33 Favored 'General case' 0 C--N 1.311 -1.066 0 CA-C-O 121.642 0.734 . . . . 0.0 110.128 178.155 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -109.72 13.96 23.51 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-N 114.924 -1.034 . . . . 0.0 111.546 178.449 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.823 ' HB ' ' HB3' ' A' ' 42' ' ' ASN . 11.2 tt -87.23 143.67 10.85 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.712 0 CA-C-O 120.85 0.357 . . . . 0.0 110.595 -177.833 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -161.71 113.55 1.75 Allowed 'General case' 0 C--N 1.315 -0.916 0 CA-C-O 121.375 0.607 . . . . 0.0 110.482 175.974 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 30.5 p -82.32 -20.17 37.91 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 115.739 -0.664 . . . . 0.0 111.684 -175.22 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 102.66 25.01 7.87 Favored Glycine 0 N--CA 1.445 -0.757 0 N-CA-C 110.703 -0.959 . . . . 0.0 110.703 -175.204 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 3.4 t30 -95.01 -2.91 49.36 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 121.533 0.682 . . . . 0.0 110.346 -178.64 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 96.3 -13.81 65.23 Favored Glycine 0 C--O 1.227 -0.314 0 CA-C-N 115.548 -0.751 . . . . 0.0 111.526 179.202 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 51' ' ' TYR . . . . . 0.6 ' HA ' ' HA ' ' A' ' 58' ' ' ASP . 0.3 OUTLIER -99.55 137.94 37.33 Favored 'General case' 0 CA--C 1.511 -0.541 0 N-CA-C 108.234 -1.024 . . . . 0.0 108.234 174.543 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 52' ' ' TYR . . . . . 0.673 ' CE1' ' HB2' ' A' ' 59' ' ' GLN . 15.9 m-85 -107.62 169.5 8.55 Favored 'General case' 0 C--N 1.312 -1.065 0 C-N-CA 120.685 -0.406 . . . . 0.0 111.698 -172.199 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -63.01 169.59 16.49 Favored Glycine 0 N--CA 1.449 -0.484 0 N-CA-C 115.256 0.862 . . . . 0.0 115.256 -166.613 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 54' ' ' GLY . . . . . 0.704 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 85.11 -93.17 1.81 Allowed Glycine 0 N--CA 1.44 -1.086 0 CA-C-N 114.508 -0.846 . . . . 0.0 112.01 177.983 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.528 HG22 ' HB3' ' A' ' 82' ' ' GLN . 0.4 OUTLIER -90.95 -2.15 10.14 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.764 0 CA-C-O 121.017 0.437 . . . . 0.0 111.403 -177.447 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 56' ' ' GLN . . . . . 0.767 ' NE2' ' HA ' ' A' ' 35' ' ' ALA . 9.2 mt-30 58.02 46.94 15.58 Favored 'General case' 0 N--CA 1.472 0.625 0 N-CA-C 113.849 1.055 . . . . 0.0 113.849 164.645 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -125.3 157.77 35.83 Favored 'General case' 0 C--N 1.318 -0.765 0 C-N-CA 119.221 -0.992 . . . . 0.0 111.296 174.87 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.6 ' HA ' ' HA ' ' A' ' 51' ' ' TYR . 24.1 t70 -65.21 144.12 57.39 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 114.33 -1.304 . . . . 0.0 112.052 -167.709 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 59' ' ' GLN . . . . . 0.673 ' HB2' ' CE1' ' A' ' 52' ' ' TYR . 4.0 tp60 -51.87 -36.15 47.5 Favored 'General case' 0 N--CA 1.448 -0.562 0 CA-C-N 114.131 -1.395 . . . . 0.0 111.807 179.017 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -67.43 -41.98 90.04 Favored Glycine 0 N--CA 1.449 -0.438 0 N-CA-C 111.453 -0.659 . . . . 0.0 111.453 179.386 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 64.1 m -71.47 -38.69 71.23 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 120.759 0.314 . . . . 0.0 110.434 176.368 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 62' ' ' TRP . . . . . 0.563 ' CH2' ' HA ' ' A' ' 74' ' ' ALA . 43.3 t-105 -55.59 -47.57 76.26 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 121.64 0.733 . . . . 0.0 109.089 172.571 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 63' ' ' GLU . . . . . 0.503 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 27.6 tt0 -64.67 -33.53 76.16 Favored 'General case' 0 N--CA 1.443 -0.775 0 CA-C-N 114.784 -1.098 . . . . 0.0 110.711 178.127 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -64.36 -42.84 96.0 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 115.928 -0.578 . . . . 0.0 111.624 -176.598 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 65' ' ' ASN . . . . . 0.455 ' HB2' HG13 ' A' ' 85' ' ' VAL . 10.2 m-80 -74.16 -19.31 60.6 Favored 'General case' 0 N--CA 1.462 0.173 0 CA-C-O 121.254 0.549 . . . . 0.0 109.892 174.01 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 66' ' ' GLY . . . . . 0.422 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 94.02 48.12 2.73 Favored Glycine 0 N--CA 1.448 -0.514 0 CA-C-N 115.536 -0.756 . . . . 0.0 111.814 179.309 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 67' ' ' GLY . . . . . 0.524 ' HA2' ' HD1' ' A' ' 70' ' ' TYR . . . -79.59 -17.37 75.76 Favored Glycine 0 N--CA 1.44 -1.068 0 C-N-CA 120.992 -0.623 . . . . 0.0 113.044 -173.377 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.817 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 6.5 mp -61.68 -23.3 66.0 Favored 'General case' 0 N--CA 1.45 -0.441 0 N-CA-C 112.179 0.437 . . . . 0.0 112.179 -173.372 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 69' ' ' ARG . . . . . 0.422 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 4.8 ptt180 -70.52 -29.49 66.0 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 121.04 0.448 . . . . 0.0 110.604 175.552 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 70' ' ' TYR . . . . . 0.567 ' HB3' ' HB3' ' A' ' 81' ' ' GLU . 74.7 m-85 -79.27 -33.65 43.25 Favored 'General case' 0 N--CA 1.446 -0.642 0 N-CA-C 107.185 -1.413 . . . . 0.0 107.185 175.891 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.616 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 163.02 127.69 0.01 OUTLIER Pre-proline 0 C--O 1.22 -0.452 0 CA-C-N 112.662 -2.063 . . . . 0.0 107.044 -179.709 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 72' ' ' PRO . . . . . 0.817 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 16.6 Cg_exo -56.92 -4.77 1.02 Allowed 'Trans proline' 0 C--N 1.334 -0.194 0 C-N-CA 122.605 2.203 . . . . 0.0 113.774 -177.97 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 14.4 ptm180 -145.38 140.19 27.5 Favored 'General case' 0 C--N 1.318 -0.798 0 N-CA-C 108.501 -0.925 . . . . 0.0 108.501 175.888 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 74' ' ' ALA . . . . . 0.563 ' HA ' ' CH2' ' A' ' 62' ' ' TRP . . . -57.68 -36.03 71.38 Favored 'General case' 0 C--O 1.219 -0.535 0 CA-C-N 115.448 -0.796 . . . . 0.0 111.691 -176.77 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 75' ' ' ASP . . . . . 0.457 ' OD1' ' HD2' ' A' ' 52' ' ' TYR . 11.6 p-10 -84.03 2.58 38.43 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 120.935 0.398 . . . . 0.0 111.455 -173.08 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.468 ' HB3' ' HB1' ' A' ' 71' ' ' ALA . 49.2 tp -98.13 -33.96 10.94 Favored 'General case' 0 C--N 1.323 -0.568 0 N-CA-C 108.419 -0.956 . . . . 0.0 108.419 170.893 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 77' ' ' ALA . . . . . 0.793 ' HB1' ' HB2' ' A' ' 81' ' ' GLU . . . -79.32 163.27 25.02 Favored 'General case' 0 N--CA 1.444 -0.768 0 CA-C-N 114.785 -1.098 . . . . 0.0 109.959 175.242 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 38.3 p -101.0 178.23 4.73 Favored 'General case' 0 C--N 1.316 -0.887 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.121 179.491 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 79' ' ' ARG . . . . . 0.671 HH21 ' HB2' ' A' ' 32' ' ' ASP . 60.4 mtp180 -46.1 -48.37 17.18 Favored 'General case' 0 N--CA 1.467 0.399 0 O-C-N 123.693 0.621 . . . . 0.0 111.32 -176.06 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 80' ' ' GLU . . . . . 0.403 ' HG3' ' OE2' ' A' ' 81' ' ' GLU . 6.0 pt-20 -61.7 -42.03 98.4 Favored 'General case' 0 C--N 1.315 -0.915 0 CA-C-N 115.756 -0.656 . . . . 0.0 112.659 -177.375 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 81' ' ' GLU . . . . . 0.793 ' HB2' ' HB1' ' A' ' 77' ' ' ALA . 5.7 mp0 -65.68 -50.48 64.74 Favored 'General case' 0 C--O 1.231 0.121 0 CA-C-N 118.369 0.531 . . . . 0.0 111.824 172.936 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 82' ' ' GLN . . . . . 0.528 ' HB3' HG22 ' A' ' 55' ' ' VAL . 4.0 mt-30 -57.76 -40.78 80.55 Favored 'General case' 0 CA--C 1.515 -0.379 0 CA-C-O 121.217 0.532 . . . . 0.0 110.26 -177.707 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.508 HG12 ' CB ' ' A' ' 31' ' ' TRP . 11.6 mt -61.82 -45.49 98.59 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.696 0 CA-C-N 114.898 -1.047 . . . . 0.0 110.593 178.045 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 84' ' ' ALA . . . . . 0.565 ' O ' ' HG3' ' A' ' 87' ' ' GLU . . . -62.33 -44.49 96.37 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.911 0.386 . . . . 0.0 111.513 -177.575 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.486 HG23 ' O ' ' A' ' 81' ' ' GLU . 21.7 t -67.27 -48.84 76.88 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 CA-C-N 116.535 -0.302 . . . . 0.0 111.457 179.291 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -65.04 -30.97 71.98 Favored 'General case' 0 N--CA 1.451 -0.423 0 CA-C-O 121.148 0.499 . . . . 0.0 110.558 179.145 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 87' ' ' GLU . . . . . 0.657 ' O ' ' HG2' ' A' ' 90' ' ' ARG . 0.7 OUTLIER -71.86 -27.71 63.05 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.876 -177.526 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.718 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 88.8 t -62.21 -40.1 86.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 N-CA-C 108.805 -0.813 . . . . 0.0 108.805 166.805 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 89' ' ' THR . . . . . 0.786 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 2.7 m -67.86 -43.05 80.33 Favored 'General case' 0 C--N 1.318 -0.772 0 CA-C-N 115.524 -0.762 . . . . 0.0 111.005 -178.89 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 90' ' ' ARG . . . . . 0.657 ' HG2' ' O ' ' A' ' 87' ' ' GLU . 26.3 ptt180 -60.08 -34.34 73.31 Favored 'General case' 0 N--CA 1.47 0.54 0 C-N-CA 122.761 0.424 . . . . 0.0 111.447 -175.906 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 91' ' ' LEU . . . . . 0.718 ' HG ' ' O ' ' A' ' 88' ' ' VAL . 4.3 pp -73.15 -21.83 60.63 Favored 'General case' 0 C--N 1.318 -0.774 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.588 -174.361 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 92' ' ' ARG . . . . . 0.475 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 6.7 mtm180 -86.61 -51.1 6.35 Favored 'General case' 0 CA--C 1.511 -0.538 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.135 -176.607 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 93' ' ' GLN . . . . . 0.627 ' OE1' ' HA ' ' A' ' 90' ' ' ARG . 0.0 OUTLIER -98.03 -25.43 14.96 Favored 'General case' 0 CA--C 1.538 0.487 0 N-CA-C 113.311 0.856 . . . . 0.0 113.311 -170.779 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 90.47 40.1 5.79 Favored Glycine 0 CA--C 1.507 -0.447 0 C-N-CA 120.672 -0.775 . . . . 0.0 111.99 173.462 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 95' ' ' TRP . . . . . 0.48 ' HB3' ' HB1' ' A' ' 102' ' ' ALA . 10.2 m95 64.35 11.71 6.66 Favored 'General case' 0 C--O 1.223 -0.328 0 C-N-CA 123.678 0.791 . . . . 0.0 110.142 -179.131 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -71.66 -28.33 69.43 Favored Glycine 0 C--N 1.33 0.2 0 C-N-CA 121.114 -0.565 . . . . 0.0 112.433 177.982 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -70.0 -29.2 66.23 Favored 'General case' 0 CA--C 1.516 -0.334 0 CA-C-O 121.183 0.516 . . . . 0.0 110.2 178.667 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 98' ' ' TRP . . . . . 0.786 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 26.2 m-90 -98.74 103.84 21.35 Favored Pre-proline 0 N--CA 1.446 -0.638 0 N-CA-C 108.299 -1.0 . . . . 0.0 108.299 174.948 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 99' ' ' PRO . . . . . 0.465 ' HB2' ' H ' ' A' ' 100' ' ' VAL . 22.9 Cg_exo -69.25 -94.23 0.01 OUTLIER 'Trans proline' 0 CA--C 1.532 0.424 0 C-N-CA 123.176 2.584 . . . . 0.0 114.727 -170.438 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 100' ' ' VAL . . . . . 0.465 ' H ' ' HB2' ' A' ' 99' ' ' PRO . 47.9 t -70.92 -29.74 38.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-O 121.702 0.763 . . . . 0.0 110.013 -174.385 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 101' ' ' CYS . . . . . 0.728 ' SG ' ' HG2' ' A' ' 38' ' ' GLU . 64.0 m -71.13 -38.41 72.27 Favored 'General case' 0 C--N 1.317 -0.807 0 CA-C-N 114.789 -1.096 . . . . 0.0 111.794 -170.895 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 102' ' ' ALA . . . . . 0.48 ' HB1' ' HB3' ' A' ' 95' ' ' TRP . . . -69.99 -43.14 72.06 Favored 'General case' 0 C--N 1.327 -0.401 0 C-N-CA 120.698 -0.401 . . . . 0.0 110.704 179.86 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -61.67 -37.19 83.18 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 121.355 0.598 . . . . 0.0 110.464 178.42 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 104' ' ' ARG . . . . . 0.57 ' NE ' ' HA ' ' A' ' 104' ' ' ARG . 4.8 mmp_? -71.33 -34.84 70.91 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.495 -0.775 . . . . 0.0 111.563 176.323 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 105' ' ' ALA . . . . . 0.622 ' HB1' ' HA ' ' A' ' 30' ' ' ILE . . . -83.4 -22.33 32.77 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.158 -0.474 . . . . 0.0 112.208 -174.775 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 114.81 59.23 0.36 Allowed Glycine 0 CA--C 1.521 0.425 0 C-N-CA 120.818 -0.706 . . . . 0.0 112.37 -178.611 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -61.65 148.03 43.9 Favored 'General case' 0 CA--C 1.515 -0.367 0 C-N-CA 122.91 0.484 . . . . 0.0 110.635 179.478 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.245 0.845 0 CA-C-O 118.29 -0.862 . . . . 0.0 110.059 -173.013 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 7.9 m-20 . . . . . 0 CA--C 1.503 -0.856 0 CA-C-O 121.656 0.741 . . . . 0.0 109.395 . . . . . . . . . 0 0 . 1 . 026 nuclear build core ' A' A ' 28' ' ' GLY . . . . . 0.53 ' HA2' ' HB2' ' A' ' 31' ' ' TRP . . . -66.83 -5.78 33.59 Favored Glycine 0 N--CA 1.439 -1.131 0 CA-C-N 114.229 -1.35 . . . . 0.0 110.902 179.94 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 12.7 m -76.38 -44.66 35.27 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-O 121.419 0.628 . . . . 0.0 109.813 175.792 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.581 ' HB ' ' CH2' ' A' ' 95' ' ' TRP . 0.1 OUTLIER -71.01 -35.94 61.39 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.594 0 N-CA-C 108.113 -1.069 . . . . 0.0 108.113 178.078 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 31' ' ' TRP . . . . . 0.72 ' CD1' HG13 ' A' ' 83' ' ' ILE . 48.9 m95 -71.75 -35.64 70.18 Favored 'General case' 0 N--CA 1.442 -0.865 0 CA-C-N 114.658 -1.156 . . . . 0.0 110.19 -178.975 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 20.4 t70 -77.0 -29.31 55.41 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.342 178.908 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -68.55 -35.06 76.9 Favored 'General case' 0 N--CA 1.444 -0.732 0 N-CA-C 109.671 -0.492 . . . . 0.0 109.671 175.215 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 34' ' ' ILE . . . . . 0.581 ' HA ' ' HB3' ' A' ' 101' ' ' CYS . 58.0 mt -67.64 -49.34 71.15 Favored 'Isoleucine or valine' 0 C--O 1.233 0.199 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.402 173.908 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 35' ' ' ALA . . . . . 0.455 ' O ' ' HB3' ' A' ' 39' ' ' ALA . . . -59.08 -41.26 87.6 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.778 -0.646 . . . . 0.0 110.454 178.951 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 36' ' ' GLY . . . . . 0.4 ' HA2' ' N ' ' A' ' 41' ' ' GLY . . . -72.09 -18.95 78.2 Favored Glycine 0 N--CA 1.449 -0.484 0 CA-C-N 115.453 -0.794 . . . . 0.0 111.649 179.069 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 3.6 t -84.24 -62.93 1.44 Allowed 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.433 -0.383 . . . . 0.0 111.463 -178.088 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 38' ' ' GLU . . . . . 0.575 ' HB2' ' SG ' ' A' ' 101' ' ' CYS . 15.9 tt0 -89.06 -33.2 17.21 Favored 'General case' 0 C--N 1.324 -0.517 0 C-N-CA 120.532 -0.467 . . . . 0.0 110.602 -170.908 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 39' ' ' ALA . . . . . 0.455 ' HB3' ' O ' ' A' ' 35' ' ' ALA . . . -91.18 -12.36 35.62 Favored 'General case' 0 N--CA 1.453 -0.286 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.301 -178.857 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 82.0 4.93 90.11 Favored Glycine 0 CA--C 1.505 -0.552 0 N-CA-C 109.923 -1.271 . . . . 0.0 109.923 -178.857 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 41' ' ' GLY . . . . . 0.4 ' N ' ' HA2' ' A' ' 36' ' ' GLY . . . 87.3 61.56 1.55 Allowed Glycine 0 N--CA 1.434 -1.482 0 CA-C-N 113.946 -1.127 . . . . 0.0 111.369 -175.291 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 42' ' ' ASN . . . . . 0.64 ' HB3' ' HB ' ' A' ' 45' ' ' ILE . 15.5 t-20 -144.96 96.57 2.88 Favored 'General case' 0 N--CA 1.448 -0.559 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 -177.217 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 43' ' ' TRP . . . . . 0.749 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 46.3 m95 -79.04 -14.1 59.37 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.968 -175.223 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -107.49 14.24 26.03 Favored 'General case' 0 C--N 1.316 -0.861 0 CA-C-N 115.525 -0.761 . . . . 0.0 111.399 179.962 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.64 ' HB ' ' HB3' ' A' ' 42' ' ' ASN . 8.6 tt -78.13 144.56 11.11 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.738 0 CA-C-O 120.994 0.426 . . . . 0.0 110.181 -178.612 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 29.0 t-20 -150.26 86.74 1.43 Allowed 'General case' 0 C--N 1.31 -1.141 0 CA-C-O 121.437 0.637 . . . . 0.0 109.664 178.952 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 6.1 p -68.7 -25.79 64.96 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.122 -0.945 . . . . 0.0 111.464 -178.342 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 100.98 21.01 12.44 Favored Glycine 0 N--CA 1.445 -0.712 0 C-N-CA 120.985 -0.626 . . . . 0.0 111.545 -179.652 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 4.3 m-20 -81.42 -4.05 54.67 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 121.229 0.538 . . . . 0.0 111.029 -179.243 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 95.91 -13.6 65.9 Favored Glycine 0 N--CA 1.446 -0.635 0 N-CA-C 110.038 -1.225 . . . . 0.0 110.038 -176.592 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 51' ' ' TYR . . . . . 0.671 ' CD1' ' HB2' ' A' ' 58' ' ' ASP . 0.1 OUTLIER -102.81 144.99 30.43 Favored 'General case' 0 N--CA 1.446 -0.643 0 N-CA-C 107.631 -1.248 . . . . 0.0 107.631 174.048 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 52' ' ' TYR . . . . . 0.842 ' O ' ' HA ' ' A' ' 56' ' ' GLN . 10.3 m-85 -108.61 164.81 12.03 Favored 'General case' 0 C--N 1.308 -1.205 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.717 -172.147 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.463 ' HA2' HG22 ' A' ' 45' ' ' ILE . . . -58.13 172.73 3.27 Favored Glycine 0 C--O 1.229 -0.182 0 N-CA-C 115.702 1.041 . . . . 0.0 115.702 -166.107 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 54' ' ' GLY . . . . . 0.64 ' CA ' ' HA ' ' A' ' 43' ' ' TRP . . . 91.55 -111.02 3.93 Favored Glycine 0 N--CA 1.446 -0.671 0 CA-C-N 114.86 -0.67 . . . . 0.0 111.509 -178.799 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.4 HG23 ' CD1' ' A' ' 57' ' ' PHE . 1.9 m -83.23 -2.64 6.79 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 CA-C-O 122.077 0.942 . . . . 0.0 110.454 176.22 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 56' ' ' GLN . . . . . 0.842 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 33.5 tt0 50.49 52.1 15.51 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 113.436 -1.711 . . . . 0.0 114.18 168.921 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 57' ' ' PHE . . . . . 0.453 ' HZ ' HG13 ' A' ' 85' ' ' VAL . 7.2 p90 -105.74 158.49 16.69 Favored 'General case' 0 C--N 1.321 -0.652 0 C-N-CA 119.123 -1.031 . . . . 0.0 110.368 170.788 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.671 ' HB2' ' CD1' ' A' ' 51' ' ' TYR . 0.5 OUTLIER -64.54 144.19 57.38 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 114.888 -1.051 . . . . 0.0 112.016 -168.793 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 59' ' ' GLN . . . . . 0.713 ' HB2' ' CE1' ' A' ' 52' ' ' TYR . 38.2 tp60 -63.1 -30.29 71.48 Favored 'General case' 0 C--O 1.218 -0.555 0 CA-C-N 114.841 -1.072 . . . . 0.0 111.54 -178.562 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -64.83 -44.17 95.08 Favored Glycine 0 C--N 1.316 -0.529 0 N-CA-C 110.84 -0.904 . . . . 0.0 110.84 174.949 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 88.6 m -71.36 -40.18 70.82 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-O 121.093 0.473 . . . . 0.0 111.207 175.299 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 62' ' ' TRP . . . . . 0.761 ' CZ3' HG11 ' A' ' 85' ' ' VAL . 29.5 t-105 -55.12 -46.59 75.62 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-O 121.492 0.663 . . . . 0.0 109.694 173.229 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 63' ' ' GLU . . . . . 0.562 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 32.0 tt0 -67.24 -35.2 79.05 Favored 'General case' 0 C--N 1.316 -0.876 0 CA-C-N 114.957 -1.019 . . . . 0.0 111.01 179.305 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -64.89 -40.85 95.74 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.936 -0.574 . . . . 0.0 110.958 -178.509 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 65' ' ' ASN . . . . . 0.44 ' HB3' ' HB ' ' A' ' 88' ' ' VAL . 34.8 m-80 -81.68 -7.29 59.58 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.045 -0.525 . . . . 0.0 111.085 177.039 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 87.14 45.1 5.45 Favored Glycine 0 C--N 1.331 0.269 0 C-N-CA 121.022 -0.609 . . . . 0.0 112.812 173.639 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 67' ' ' GLY . . . . . 0.581 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -79.67 -22.34 64.49 Favored Glycine 0 N--CA 1.441 -0.973 0 C-N-CA 121.184 -0.532 . . . . 0.0 112.783 -175.861 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.798 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 6.7 mp -60.66 -23.67 64.98 Favored 'General case' 0 C--N 1.328 -0.341 0 N-CA-C 112.345 0.498 . . . . 0.0 112.345 -172.338 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 35.7 ptt180 -71.56 -27.02 62.87 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-O 120.933 0.397 . . . . 0.0 110.374 178.882 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 70' ' ' TYR . . . . . 1.012 ' HB3' ' HG2' ' A' ' 81' ' ' GLU . 51.8 m-85 -82.98 -34.41 26.38 Favored 'General case' 0 N--CA 1.444 -0.746 0 N-CA-C 107.09 -1.448 . . . . 0.0 107.09 174.056 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.554 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 167.25 130.12 0.04 OUTLIER Pre-proline 0 C--N 1.327 -0.397 0 CA-C-N 112.456 -2.157 . . . . 0.0 108.866 -178.783 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 72' ' ' PRO . . . . . 0.798 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 36.6 Cg_endo -67.97 29.58 0.14 Allowed 'Trans proline' 0 N--CA 1.476 0.487 0 C-N-CA 122.862 2.374 . . . . 0.0 113.877 179.311 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 73' ' ' ARG . . . . . 0.465 ' H ' ' C ' ' A' ' 71' ' ' ALA . 14.7 ptm180 -176.27 140.15 0.38 Allowed 'General case' 0 C--N 1.321 -0.66 0 N-CA-C 108.665 -0.865 . . . . 0.0 108.665 178.136 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 74' ' ' ALA . . . . . 0.544 ' HA ' ' CH2' ' A' ' 62' ' ' TRP . . . -66.47 -27.15 67.57 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.788 -0.642 . . . . 0.0 111.795 -174.949 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 75' ' ' ASP . . . . . 0.462 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 21.1 p-10 -86.57 -4.92 59.24 Favored 'General case' 0 C--N 1.324 -0.532 0 C-N-CA 120.832 -0.347 . . . . 0.0 111.61 -174.825 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 65.2 tp -97.85 -28.61 13.77 Favored 'General case' 0 C--N 1.322 -0.604 0 N-CA-C 108.97 -0.752 . . . . 0.0 108.97 171.31 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 77' ' ' ALA . . . . . 0.685 ' HB1' ' HB3' ' A' ' 81' ' ' GLU . . . -78.05 148.54 34.24 Favored 'General case' 0 N--CA 1.441 -0.919 0 CA-C-N 115.12 -0.946 . . . . 0.0 109.934 175.309 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 47.0 p -91.79 -175.61 4.2 Favored 'General case' 0 C--N 1.31 -1.135 0 CA-C-N 115.608 -0.724 . . . . 0.0 109.982 -178.617 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 79' ' ' ARG . . . . . 0.749 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 43.1 mtp-105 -53.7 -54.84 32.2 Favored 'General case' 0 CA--C 1.515 -0.382 0 CA-C-O 120.979 0.419 . . . . 0.0 110.167 -178.31 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 2.6 pm0 -56.85 -39.02 73.52 Favored 'General case' 0 C--N 1.318 -0.787 0 CA-C-N 115.454 -0.794 . . . . 0.0 111.486 -176.362 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 81' ' ' GLU . . . . . 1.012 ' HG2' ' HB3' ' A' ' 70' ' ' TYR . 1.0 OUTLIER -66.93 -50.8 61.23 Favored 'General case' 0 C--N 1.323 -0.582 0 N-CA-C 112.419 0.526 . . . . 0.0 112.419 175.188 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 82' ' ' GLN . . . . . 0.614 ' HB2' ' HZ3' ' A' ' 43' ' ' TRP . 56.1 mt-30 -61.45 -34.89 76.18 Favored 'General case' 0 CA--C 1.514 -0.417 0 C-N-CA 121.023 -0.271 . . . . 0.0 110.318 -178.402 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.72 HG13 ' CD1' ' A' ' 31' ' ' TRP . 1.4 mp -60.12 -46.19 94.78 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.089 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.76 173.518 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 84' ' ' ALA . . . . . 0.616 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -62.6 -44.75 95.53 Favored 'General case' 0 C--O 1.238 0.498 0 CA-C-O 121.533 0.683 . . . . 0.0 111.663 -172.813 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.761 HG11 ' CZ3' ' A' ' 62' ' ' TRP . 2.7 p -70.68 -43.66 77.24 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.721 0 CA-C-N 115.949 -0.569 . . . . 0.0 111.027 -179.91 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 86' ' ' ALA . . . . . 0.463 ' HB1' ' CH2' ' A' ' 31' ' ' TRP . . . -61.04 -28.4 69.03 Favored 'General case' 0 N--CA 1.451 -0.415 0 CA-C-N 115.764 -0.653 . . . . 0.0 109.69 174.396 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 87' ' ' GLU . . . . . 0.687 ' HG3' ' O ' ' A' ' 83' ' ' ILE . 30.6 mt-10 -61.18 -43.84 98.25 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.398 -0.819 . . . . 0.0 109.888 179.203 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.675 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 41.2 t -61.81 -46.08 97.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-O 121.178 0.513 . . . . 0.0 109.799 176.244 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 89' ' ' THR . . . . . 0.798 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 0.2 OUTLIER -67.42 -45.95 74.6 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 115.961 -0.563 . . . . 0.0 111.499 -175.25 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 90' ' ' ARG . . . . . 0.636 ' HD3' ' HZ2' ' A' ' 31' ' ' TRP . 23.2 ptt180 -62.87 -34.23 76.94 Favored 'General case' 0 C--O 1.221 -0.418 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.742 -177.259 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 91' ' ' LEU . . . . . 0.675 ' HG ' ' O ' ' A' ' 88' ' ' VAL . 4.2 pp -73.55 -23.78 60.02 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-O 120.951 0.405 . . . . 0.0 110.904 -171.82 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 92' ' ' ARG . . . . . 0.573 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 4.7 mtm180 -82.06 -46.91 13.26 Favored 'General case' 0 CA--C 1.51 -0.588 0 CA-C-O 121.426 0.632 . . . . 0.0 109.608 -179.11 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 93' ' ' GLN . . . . . 0.511 ' NE2' ' HB2' ' A' ' 97' ' ' ALA . 2.5 pt20 -103.42 -27.95 12.1 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 114.759 -1.109 . . . . 0.0 113.965 -168.344 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 92.02 39.98 5.32 Favored Glycine 0 C--N 1.332 0.338 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.436 175.983 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 95' ' ' TRP . . . . . 0.603 ' HZ2' HH11 ' A' ' 90' ' ' ARG . 33.2 m95 70.06 9.62 7.13 Favored 'General case' 0 C--O 1.219 -0.55 0 C-N-CA 123.338 0.655 . . . . 0.0 109.609 -179.933 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -59.44 -41.78 97.23 Favored Glycine 0 N--CA 1.453 -0.223 0 CA-C-N 115.28 -0.873 . . . . 0.0 113.476 -178.68 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 97' ' ' ALA . . . . . 0.511 ' HB2' ' NE2' ' A' ' 93' ' ' GLN . . . -70.03 -17.87 63.28 Favored 'General case' 0 N--CA 1.464 0.275 0 CA-C-N 117.117 0.459 . . . . 0.0 110.793 179.772 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 98' ' ' TRP . . . . . 0.798 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 24.6 m-90 -95.65 107.84 36.12 Favored Pre-proline 0 N--CA 1.448 -0.564 0 N-CA-C 108.794 -0.817 . . . . 0.0 108.794 176.171 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 99' ' ' PRO . . . . . 0.424 ' HD3' ' HA ' ' A' ' 98' ' ' TRP . 41.7 Cg_exo -63.77 -132.46 0.0 OUTLIER 'Trans proline' 0 CA--C 1.539 0.746 0 C-N-CA 123.857 3.038 . . . . 0.0 114.408 -173.804 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 18.3 t -55.48 -26.24 19.0 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.252 0 CA-C-O 120.82 0.343 . . . . 0.0 111.497 -174.623 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 101' ' ' CYS . . . . . 0.581 ' HB3' ' HA ' ' A' ' 34' ' ' ILE . 75.0 m -64.75 -34.41 78.27 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 116.339 -0.392 . . . . 0.0 111.528 -178.553 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -70.03 -40.78 74.97 Favored 'General case' 0 CA--C 1.519 -0.232 0 CA-C-O 120.971 0.415 . . . . 0.0 110.226 177.642 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -63.09 -39.38 94.52 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.353 176.904 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 104' ' ' ARG . . . . . 0.452 ' NE ' ' HA ' ' A' ' 104' ' ' ARG . 14.9 mmp_? -71.69 -31.49 66.82 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.605 -0.725 . . . . 0.0 111.003 178.844 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 105' ' ' ALA . . . . . 0.486 ' CB ' HG22 ' A' ' 30' ' ' ILE . . . -80.71 -23.95 39.14 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 120.989 0.423 . . . . 0.0 111.735 -177.356 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 97.98 59.3 0.95 Allowed Glycine 0 CA--C 1.522 0.471 0 C-N-CA 120.983 -0.627 . . . . 0.0 112.096 -176.707 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -57.62 146.72 29.56 Favored 'General case' 0 C--N 1.329 -0.311 0 C-N-CA 123.274 0.629 . . . . 0.0 112.356 -177.612 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 108' ' ' ARG . . . . . 0.694 ' HD3' ' O ' ' A' ' 108' ' ' ARG . 0.0 OUTLIER . . . . . 0 C--O 1.25 1.09 0 CA-C-O 118.545 -0.74 . . . . 0.0 110.594 -175.899 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 27' ' ' ASP . . . . . 0.482 ' O ' HG12 ' A' ' 30' ' ' ILE . 5.8 m-20 . . . . . 0 CA--C 1.504 -0.804 0 CA-C-O 121.874 0.845 . . . . 0.0 109.523 . . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 28' ' ' GLY . . . . . 0.572 ' HA2' ' HB2' ' A' ' 31' ' ' TRP . . . -69.1 -9.31 60.01 Favored Glycine 0 N--CA 1.437 -1.266 0 N-CA-C 110.302 -1.119 . . . . 0.0 110.302 176.222 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 17.6 m -76.97 -47.83 19.72 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 121.405 0.622 . . . . 0.0 110.073 177.12 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.773 HG22 ' O ' ' A' ' 105' ' ' ALA . 4.2 pt -71.67 -34.64 52.9 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.923 0 CA-C-N 115.087 -0.96 . . . . 0.0 109.641 176.844 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 31' ' ' TRP . . . . . 0.673 ' CZ2' ' HD3' ' A' ' 90' ' ' ARG . 12.1 m95 -63.75 -37.18 86.41 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 115.334 -0.848 . . . . 0.0 109.528 175.652 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 36.2 t70 -77.63 -31.32 52.7 Favored 'General case' 0 N--CA 1.448 -0.54 0 CA-C-N 115.837 -0.62 . . . . 0.0 111.133 179.793 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 33' ' ' ALA . . . . . 0.468 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -69.0 -33.75 74.17 Favored 'General case' 0 N--CA 1.446 -0.642 0 C-N-CA 120.409 -0.516 . . . . 0.0 109.727 176.706 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 34' ' ' ILE . . . . . 0.471 HG13 ' O ' ' A' ' 30' ' ' ILE . 74.1 mt -67.43 -42.81 87.66 Favored 'Isoleucine or valine' 0 C--O 1.233 0.215 0 CA-C-O 121.132 0.491 . . . . 0.0 109.722 171.72 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 35' ' ' ALA . . . . . 0.604 ' HA ' ' O ' ' A' ' 54' ' ' GLY . . . -57.76 -35.25 70.48 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.574 -0.739 . . . . 0.0 110.452 175.917 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 36' ' ' GLY . . . . . 0.491 ' HA2' ' N ' ' A' ' 41' ' ' GLY . . . -78.67 -5.44 88.29 Favored Glycine 0 N--CA 1.449 -0.46 0 CA-C-N 115.267 -0.879 . . . . 0.0 112.138 179.412 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 42.6 t -103.07 -54.17 2.67 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 120.742 0.306 . . . . 0.0 110.892 -178.483 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 38' ' ' GLU . . . . . 0.461 ' HG2' ' SG ' ' A' ' 101' ' ' CYS . 30.1 mm-40 -87.06 -31.05 20.72 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 121.162 0.506 . . . . 0.0 110.758 -174.717 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -103.22 -10.51 18.71 Favored 'General case' 0 N--CA 1.447 -0.6 0 CA-C-N 116.029 -0.532 . . . . 0.0 111.262 -179.043 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 76.22 14.23 82.52 Favored Glycine 0 CA--C 1.503 -0.7 0 N-CA-C 109.864 -1.294 . . . . 0.0 109.864 -178.455 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 41' ' ' GLY . . . . . 0.491 ' N ' ' HA2' ' A' ' 36' ' ' GLY . . . 81.66 62.53 1.93 Allowed Glycine 0 N--CA 1.432 -1.596 0 CA-C-N 113.94 -1.13 . . . . 0.0 111.82 -176.568 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 42' ' ' ASN . . . . . 0.565 ' HB3' ' HB ' ' A' ' 45' ' ' ILE . 2.9 t-20 -155.87 96.97 1.78 Allowed 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 109.136 -0.69 . . . . 0.0 109.136 -178.557 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 43' ' ' TRP . . . . . 0.725 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 33.0 m95 -73.35 -11.04 60.35 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-O 121.285 0.564 . . . . 0.0 111.007 -175.319 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -106.25 14.91 26.91 Favored 'General case' 0 C--N 1.314 -0.952 0 CA-C-N 115.575 -0.739 . . . . 0.0 111.432 -179.059 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.851 HG22 ' HA2' ' A' ' 53' ' ' GLY . 7.0 tt -78.86 142.92 13.39 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.793 0 CA-C-O 121.138 0.494 . . . . 0.0 110.121 -178.106 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 3.2 t30 -148.29 90.05 1.77 Allowed 'General case' 0 C--N 1.312 -1.027 0 CA-C-O 121.114 0.483 . . . . 0.0 109.958 178.923 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 13.9 p -76.48 -16.65 59.6 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 115.87 -0.605 . . . . 0.0 111.724 -176.92 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 94.93 21.99 24.31 Favored Glycine 0 N--CA 1.447 -0.625 0 N-CA-C 110.942 -0.863 . . . . 0.0 110.942 -177.931 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 10.4 t-20 -86.1 -12.27 50.48 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 121.302 0.573 . . . . 0.0 110.964 -175.098 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 50' ' ' GLY . . . . . 0.402 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 95.21 -9.47 69.83 Favored Glycine 0 N--CA 1.448 -0.517 0 N-CA-C 110.184 -1.166 . . . . 0.0 110.184 -175.386 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 51' ' ' TYR . . . . . 0.545 ' HA ' ' HA ' ' A' ' 58' ' ' ASP . 0.5 OUTLIER -110.73 146.68 35.87 Favored 'General case' 0 CA--C 1.505 -0.777 0 N-CA-C 105.914 -1.884 . . . . 0.0 105.914 175.373 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 52' ' ' TYR . . . . . 0.788 ' HB2' ' HB3' ' A' ' 74' ' ' ALA . 45.0 m-85 -112.9 167.58 10.39 Favored 'General case' 0 C--N 1.304 -1.412 0 C-N-CA 119.623 -0.831 . . . . 0.0 112.905 -167.835 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.851 ' HA2' HG22 ' A' ' 45' ' ' ILE . . . -54.86 157.15 7.19 Favored Glycine 0 N--CA 1.446 -0.682 0 CA-C-N 114.787 -1.097 . . . . 0.0 114.105 -171.698 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 54' ' ' GLY . . . . . 0.689 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 97.03 -109.86 3.93 Favored Glycine 0 N--CA 1.437 -1.244 0 C-N-CA 120.803 -0.713 . . . . 0.0 111.72 -178.411 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.546 HG23 ' HG2' ' A' ' 82' ' ' GLN . 3.1 t -84.83 -0.46 5.94 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 CA-C-O 121.771 0.796 . . . . 0.0 110.354 -176.344 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 56' ' ' GLN . . . . . 0.587 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 8.1 tp-100 56.66 50.49 12.61 Favored 'General case' 0 C--N 1.339 0.141 0 CA-C-N 114.195 -1.366 . . . . 0.0 112.685 168.289 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 57' ' ' PHE . . . . . 0.47 ' CE1' ' HB2' ' A' ' 86' ' ' ALA . 7.8 p90 -116.98 162.76 17.26 Favored 'General case' 0 C--N 1.321 -0.659 0 C-N-CA 120.105 -0.638 . . . . 0.0 111.083 175.287 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.545 ' HA ' ' HA ' ' A' ' 51' ' ' TYR . 6.4 p-10 -76.28 160.17 29.9 Favored 'General case' 0 C--N 1.324 -0.511 0 N-CA-C 113.594 0.961 . . . . 0.0 113.594 -162.957 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 13.1 tp60 -57.24 -39.45 75.59 Favored 'General case' 0 N--CA 1.443 -0.808 0 CA-C-N 114.036 -1.438 . . . . 0.0 111.563 178.888 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -66.74 -49.89 51.99 Favored Glycine 0 C--O 1.225 -0.436 0 CA-C-N 115.653 -0.703 . . . . 0.0 112.468 -175.746 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 93.6 m -60.68 -44.06 96.96 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 121.15 0.5 . . . . 0.0 110.681 176.051 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 62' ' ' TRP . . . . . 0.433 ' HE3' ' CZ ' ' A' ' 57' ' ' PHE . 52.3 t-105 -57.05 -48.61 78.11 Favored 'General case' 0 N--CA 1.445 -0.68 0 CA-C-N 115.331 -0.849 . . . . 0.0 109.895 176.667 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 63' ' ' GLU . . . . . 0.503 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 31.4 tt0 -67.48 -35.09 78.48 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-N 115.141 -0.936 . . . . 0.0 110.875 -177.593 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -67.03 -41.67 86.16 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.76 -0.655 . . . . 0.0 111.04 -176.639 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 65' ' ' ASN . . . . . 0.441 ' HB2' HG13 ' A' ' 85' ' ' VAL . 8.1 m120 -77.69 -9.06 58.78 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 121.112 0.482 . . . . 0.0 110.156 176.137 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 88.35 45.2 5.07 Favored Glycine 0 C--N 1.332 0.341 0 CA-C-N 115.734 -0.666 . . . . 0.0 112.395 174.05 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 67' ' ' GLY . . . . . 0.518 ' HA2' ' CD1' ' A' ' 70' ' ' TYR . . . -79.02 -20.28 70.62 Favored Glycine 0 N--CA 1.442 -0.964 0 C-N-CA 120.883 -0.675 . . . . 0.0 112.879 -172.937 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.818 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 6.7 mp -61.27 -24.05 66.12 Favored 'General case' 0 N--CA 1.45 -0.434 0 N-CA-C 112.281 0.475 . . . . 0.0 112.281 -173.72 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 69' ' ' ARG . . . . . 0.497 ' HG3' ' N ' ' A' ' 70' ' ' TYR . 0.7 OUTLIER -70.62 -29.42 65.8 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 121.206 0.527 . . . . 0.0 110.135 176.143 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 70' ' ' TYR . . . . . 0.842 ' HB3' ' HB3' ' A' ' 81' ' ' GLU . 71.7 m-85 -79.7 -34.35 40.23 Favored 'General case' 0 N--CA 1.446 -0.655 0 N-CA-C 107.329 -1.36 . . . . 0.0 107.329 176.449 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.675 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 162.51 127.57 0.01 OUTLIER Pre-proline 0 C--O 1.218 -0.558 0 CA-C-N 112.401 -2.182 . . . . 0.0 107.098 -178.286 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 72' ' ' PRO . . . . . 0.818 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 17.9 Cg_exo -57.13 -1.97 0.47 Allowed 'Trans proline' 0 C--N 1.332 -0.34 0 C-N-CA 122.991 2.46 . . . . 0.0 114.058 -177.453 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 12.5 ptm180 -152.56 141.89 21.55 Favored 'General case' 0 C--N 1.319 -0.726 0 N-CA-C 109.64 -0.504 . . . . 0.0 109.64 176.998 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 74' ' ' ALA . . . . . 0.788 ' HB3' ' HB2' ' A' ' 52' ' ' TYR . . . -63.44 -22.07 66.67 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.509 -0.769 . . . . 0.0 113.028 -176.798 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 75' ' ' ASP . . . . . 0.517 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 5.2 p-10 -88.29 2.92 51.38 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 121.328 0.585 . . . . 0.0 110.847 -179.781 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.435 ' HB3' ' HB1' ' A' ' 71' ' ' ALA . 53.5 tp -106.27 -34.86 7.35 Favored 'General case' 0 C--N 1.321 -0.654 0 N-CA-C 108.858 -0.793 . . . . 0.0 108.858 174.246 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 77' ' ' ALA . . . . . 0.815 ' HB1' ' HB2' ' A' ' 81' ' ' GLU . . . -79.83 158.12 26.85 Favored 'General case' 0 N--CA 1.446 -0.627 0 CA-C-N 114.99 -1.005 . . . . 0.0 110.057 174.512 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 25.4 p -100.77 -171.64 2.04 Favored 'General case' 0 C--N 1.314 -0.965 0 CA-C-N 116.2 -0.455 . . . . 0.0 109.8 -179.435 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 79' ' ' ARG . . . . . 0.725 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 35.9 mtt85 -49.21 -51.95 29.91 Favored 'General case' 0 C--O 1.218 -0.559 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.79 -179.959 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -57.45 -47.61 81.35 Favored 'General case' 0 C--N 1.321 -0.666 0 N-CA-C 112.148 0.425 . . . . 0.0 112.148 -174.854 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 81' ' ' GLU . . . . . 0.842 ' HB3' ' HB3' ' A' ' 70' ' ' TYR . 60.6 mp0 -65.6 -51.23 61.28 Favored 'General case' 0 CA--C 1.517 -0.318 0 CA-C-O 120.983 0.421 . . . . 0.0 111.403 177.228 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 82' ' ' GLN . . . . . 0.546 ' HG2' HG23 ' A' ' 55' ' ' VAL . 4.2 tt0 -65.0 -34.35 78.24 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.606 -0.724 . . . . 0.0 111.361 -173.657 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.582 ' O ' ' HB3' ' A' ' 87' ' ' GLU . 8.1 mt -61.63 -46.13 97.2 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 N-CA-C 109.471 -0.566 . . . . 0.0 109.471 174.193 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 84' ' ' ALA . . . . . . . . . . . . . . . -61.37 -47.48 85.68 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.205 -176.825 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.441 HG13 ' HB2' ' A' ' 65' ' ' ASN . 46.5 t -65.97 -50.28 70.85 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-N 116.137 -0.483 . . . . 0.0 112.207 -179.997 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 86' ' ' ALA . . . . . 0.47 ' HB2' ' CE1' ' A' ' 57' ' ' PHE . . . -63.87 -32.05 73.44 Favored 'General case' 0 CA--C 1.515 -0.394 0 CA-C-O 121.397 0.618 . . . . 0.0 110.437 179.702 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 87' ' ' GLU . . . . . 0.675 ' HA ' ' HG2' ' A' ' 90' ' ' ARG . 0.4 OUTLIER -71.32 -27.28 63.28 Favored 'General case' 0 C--N 1.317 -0.844 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.871 -178.136 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.672 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 94.6 t -61.22 -44.17 97.85 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.254 0 N-CA-C 108.701 -0.852 . . . . 0.0 108.701 169.295 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 89' ' ' THR . . . . . 0.677 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 0.3 OUTLIER -66.81 -43.81 82.87 Favored 'General case' 0 C--N 1.316 -0.852 0 CA-C-N 115.582 -0.735 . . . . 0.0 111.375 -179.778 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 90' ' ' ARG . . . . . 0.675 ' HG2' ' HA ' ' A' ' 87' ' ' GLU . 20.7 ptt180 -59.88 -35.11 74.13 Favored 'General case' 0 C--O 1.222 -0.392 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.707 -176.197 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 91' ' ' LEU . . . . . 0.672 ' HG ' ' O ' ' A' ' 88' ' ' VAL . 4.6 pp -74.44 -24.77 59.12 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 121.042 0.448 . . . . 0.0 111.102 -171.678 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 92' ' ' ARG . . . . . 0.501 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 2.5 mtm180 -81.79 -45.24 15.87 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-O 121.568 0.699 . . . . 0.0 109.514 -178.044 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 93' ' ' GLN . . . . . 0.42 HE21 ' HZ3' ' A' ' 98' ' ' TRP . 6.6 pt20 -104.27 -28.06 11.63 Favored 'General case' 0 C--N 1.322 -0.618 0 N-CA-C 113.59 0.959 . . . . 0.0 113.59 -169.696 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 88.35 44.23 5.35 Favored Glycine 0 CA--C 1.507 -0.419 0 C-N-CA 120.625 -0.797 . . . . 0.0 112.136 176.195 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 95' ' ' TRP . . . . . 0.531 ' HZ2' HH11 ' A' ' 90' ' ' ARG . 23.6 m95 66.87 13.63 9.5 Favored 'General case' 0 C--O 1.218 -0.6 0 CA-C-O 121.173 0.511 . . . . 0.0 109.812 178.396 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -65.53 -31.62 80.74 Favored Glycine 0 N--CA 1.451 -0.304 0 CA-C-N 115.588 -0.733 . . . . 0.0 113.132 177.289 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -76.49 -21.52 55.72 Favored 'General case' 0 CA--C 1.515 -0.385 0 CA-C-O 121.152 0.501 . . . . 0.0 110.411 178.508 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 98' ' ' TRP . . . . . 0.677 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 25.1 m-90 -100.26 108.62 53.41 Favored Pre-proline 0 N--CA 1.443 -0.803 0 CA-C-N 115.521 -0.763 . . . . 0.0 109.202 178.42 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 99' ' ' PRO . . . . . 0.45 ' HD3' ' HA ' ' A' ' 98' ' ' TRP . 52.5 Cg_exo -62.25 -138.46 0.0 OUTLIER 'Trans proline' 0 CA--C 1.535 0.56 0 C-N-CA 123.831 3.021 . . . . 0.0 114.265 -174.026 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 3.4 m -54.11 -26.3 14.6 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.915 -177.882 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 101' ' ' CYS . . . . . 0.461 ' SG ' ' HG2' ' A' ' 38' ' ' GLU . 62.0 m -56.69 -39.64 74.16 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-N 115.75 -0.659 . . . . 0.0 111.525 178.035 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -70.8 -44.24 67.0 Favored 'General case' 0 CA--C 1.519 -0.23 0 CA-C-O 121.008 0.432 . . . . 0.0 110.716 179.871 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -60.68 -44.15 96.85 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.634 179.724 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -66.87 -34.03 76.91 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.712 -0.676 . . . . 0.0 111.049 176.957 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 105' ' ' ALA . . . . . 0.773 ' O ' HG22 ' A' ' 30' ' ' ILE . . . -76.51 -26.77 55.6 Favored 'General case' 0 C--N 1.331 -0.238 0 N-CA-C 111.895 0.332 . . . . 0.0 111.895 -175.285 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 111.62 60.28 0.46 Allowed Glycine 0 CA--C 1.521 0.415 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.234 -175.31 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -70.11 148.61 48.52 Favored 'General case' 0 C--N 1.327 -0.375 0 C-N-CA 122.579 0.351 . . . . 0.0 110.891 -178.94 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 108' ' ' ARG . . . . . 0.434 ' HD3' ' O ' ' A' ' 108' ' ' ARG . 0.0 OUTLIER . . . . . 0 C--O 1.245 0.825 0 CA-C-O 118.559 -0.734 . . . . 0.0 110.318 -177.082 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 27' ' ' ASP . . . . . 0.514 ' O ' HG12 ' A' ' 30' ' ' ILE . 7.0 m-20 . . . . . 0 CA--C 1.504 -0.803 0 CA-C-O 121.791 0.805 . . . . 0.0 108.849 . . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 28' ' ' GLY . . . . . 0.599 ' HA2' ' HB2' ' A' ' 31' ' ' TRP . . . -66.25 -5.05 25.93 Favored Glycine 0 N--CA 1.44 -1.092 0 CA-C-N 114.488 -1.233 . . . . 0.0 110.581 176.721 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 22.3 m -77.2 -40.44 45.15 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 120.989 0.423 . . . . 0.0 109.98 174.053 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.514 HG12 ' O ' ' A' ' 27' ' ' ASP . 0.6 OUTLIER -65.25 -38.92 83.82 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.513 0 N-CA-C 107.038 -1.467 . . . . 0.0 107.038 174.108 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 31' ' ' TRP . . . . . 0.684 ' CD1' HG13 ' A' ' 83' ' ' ILE . 31.7 m95 -72.1 -36.49 69.48 Favored 'General case' 0 N--CA 1.438 -1.075 0 CA-C-N 113.598 -1.637 . . . . 0.0 111.031 -175.998 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 6.6 t70 -72.63 -34.65 67.46 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.016 178.203 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -67.3 -37.01 82.67 Favored 'General case' 0 N--CA 1.445 -0.685 0 C-N-CA 120.64 -0.424 . . . . 0.0 109.923 177.119 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 34' ' ' ILE . . . . . 0.509 HG13 ' O ' ' A' ' 30' ' ' ILE . 74.2 mt -67.66 -46.43 82.79 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.171 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.523 174.491 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -58.91 -34.22 71.45 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 121.215 0.531 . . . . 0.0 110.516 177.563 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 36' ' ' GLY . . . . . 0.528 ' HA2' ' N ' ' A' ' 41' ' ' GLY . . . -78.83 -7.03 88.51 Favored Glycine 0 N--CA 1.45 -0.418 0 CA-C-N 115.617 -0.72 . . . . 0.0 111.719 178.616 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 46.0 t -94.81 -58.1 2.27 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-O 120.775 0.321 . . . . 0.0 110.607 -179.221 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 38' ' ' GLU . . . . . 0.436 ' HG3' ' SG ' ' A' ' 101' ' ' CYS . 40.2 mt-10 -89.29 -25.61 21.58 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.379 -0.373 . . . . 0.0 111.345 -173.52 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -107.53 -12.95 15.18 Favored 'General case' 0 C--N 1.324 -0.527 0 C-N-CA 120.444 -0.502 . . . . 0.0 111.869 -179.011 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 78.72 13.57 83.01 Favored Glycine 0 CA--C 1.503 -0.665 0 N-CA-C 109.789 -1.324 . . . . 0.0 109.789 -177.371 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 41' ' ' GLY . . . . . 0.528 ' N ' ' HA2' ' A' ' 36' ' ' GLY . . . 78.87 61.52 2.39 Favored Glycine 0 N--CA 1.435 -1.391 0 CA-C-N 114.069 -1.066 . . . . 0.0 111.855 -177.053 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 42' ' ' ASN . . . . . 0.438 ' HB3' ' HB ' ' A' ' 45' ' ' ILE . 4.1 t-20 -145.66 96.98 2.9 Favored 'General case' 0 N--CA 1.45 -0.449 0 N-CA-C 109.044 -0.724 . . . . 0.0 109.044 -177.968 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 43' ' ' TRP . . . . . 0.867 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 16.1 m95 -82.72 -1.42 51.34 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-O 121.554 0.692 . . . . 0.0 111.156 -170.412 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -113.62 9.55 17.89 Favored 'General case' 0 C--N 1.314 -0.967 0 CA-C-N 115.039 -0.982 . . . . 0.0 111.095 178.713 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.952 HG22 ' HA2' ' A' ' 53' ' ' GLY . 9.5 tt -72.65 143.22 14.2 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.68 0 CA-C-O 121.177 0.513 . . . . 0.0 110.654 -175.603 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 15.3 t-20 -150.8 97.05 2.43 Favored 'General case' 0 C--N 1.311 -1.1 0 N-CA-C 109.399 -0.593 . . . . 0.0 109.399 177.732 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 11.1 p -74.89 -16.67 60.66 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 115.798 -0.637 . . . . 0.0 111.006 -177.7 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 101.4 13.03 34.09 Favored Glycine 0 N--CA 1.445 -0.705 0 CA-C-N 115.818 -0.628 . . . . 0.0 111.612 178.059 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 31.7 p-10 -91.65 3.01 56.07 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.801 0.334 . . . . 0.0 111.4 -176.381 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 94.9 -2.54 66.55 Favored Glycine 0 N--CA 1.449 -0.494 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.265 179.909 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 51' ' ' TYR . . . . . 0.571 ' HA ' ' HA ' ' A' ' 58' ' ' ASP . 0.4 OUTLIER -108.59 162.6 13.99 Favored 'General case' 0 CA--C 1.515 -0.374 0 N-CA-C 108.464 -0.939 . . . . 0.0 108.464 176.874 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 52' ' ' TYR . . . . . 0.627 ' O ' ' HA ' ' A' ' 56' ' ' GLN . 61.6 m-85 -123.32 169.73 11.03 Favored 'General case' 0 C--N 1.315 -0.927 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.617 -170.874 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.952 ' HA2' HG22 ' A' ' 45' ' ' ILE . . . -64.58 157.89 44.24 Favored Glycine 0 N--CA 1.445 -0.765 0 CA-C-N 115.585 -0.734 . . . . 0.0 114.105 -169.913 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 54' ' ' GLY . . . . . 0.669 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 107.1 -111.73 3.57 Favored Glycine 0 N--CA 1.442 -0.964 0 N-CA-C 111.653 -0.579 . . . . 0.0 111.653 179.3 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 3.1 m -93.42 12.9 2.75 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 CA-C-O 121.906 0.86 . . . . 0.0 110.385 176.69 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 56' ' ' GLN . . . . . 0.627 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 22.2 tt0 60.8 49.85 5.83 Favored 'General case' 0 C--N 1.317 -0.845 0 CA-C-N 113.673 -1.603 . . . . 0.0 112.178 172.652 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 57' ' ' PHE . . . . . 0.416 ' HZ ' ' CA ' ' A' ' 86' ' ' ALA . 27.3 m-85 -60.97 133.93 56.59 Favored 'General case' 0 CA--C 1.506 -0.717 0 CA-C-N 115.35 -0.841 . . . . 0.0 111.547 169.626 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.571 ' HA ' ' HA ' ' A' ' 51' ' ' TYR . 6.2 p-10 -74.01 156.13 37.85 Favored 'General case' 0 C--N 1.315 -0.932 0 C-N-CA 119.509 -0.877 . . . . 0.0 108.831 163.928 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 21.0 tp60 -52.52 -39.06 60.93 Favored 'General case' 0 N--CA 1.443 -0.778 0 CA-C-O 121.098 0.475 . . . . 0.0 111.039 -179.082 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -69.7 -50.95 27.62 Favored Glycine 0 C--O 1.222 -0.599 0 CA-C-N 115.127 -0.942 . . . . 0.0 113.237 -174.005 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 95.6 m -64.8 -35.24 80.46 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 121.201 0.524 . . . . 0.0 110.771 179.369 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 62' ' ' TRP . . . . . 0.698 ' CZ3' ' HA ' ' A' ' 82' ' ' GLN . 59.8 t-105 -60.99 -49.04 79.07 Favored 'General case' 0 N--CA 1.443 -0.779 0 CA-C-O 121.579 0.704 . . . . 0.0 109.258 174.768 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 63' ' ' GLU . . . . . 0.469 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 40.8 tt0 -67.24 -33.96 76.44 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-N 114.858 -1.064 . . . . 0.0 110.858 -179.017 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -63.36 -42.65 98.89 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.815 -0.63 . . . . 0.0 112.057 -175.341 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 65' ' ' ASN . . . . . 0.634 ' HB2' HG13 ' A' ' 85' ' ' VAL . 37.1 m-80 -83.43 -10.41 58.41 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.826 0.346 . . . . 0.0 110.409 176.209 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 66' ' ' GLY . . . . . 0.459 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 94.09 51.44 2.08 Favored Glycine 0 C--N 1.332 0.35 0 C-N-CA 121.007 -0.616 . . . . 0.0 112.839 173.831 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 67' ' ' GLY . . . . . 0.596 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -79.73 -23.96 61.19 Favored Glycine 0 N--CA 1.439 -1.116 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.821 -176.49 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.824 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 6.9 mp -59.47 -26.8 65.54 Favored 'General case' 0 C--N 1.323 -0.545 0 N-CA-C 112.553 0.575 . . . . 0.0 112.553 -172.748 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 69' ' ' ARG . . . . . 0.459 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 3.4 ptm180 -65.5 -33.15 75.27 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 121.36 0.6 . . . . 0.0 109.877 177.335 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 70' ' ' TYR . . . . . 1.067 ' HB3' ' HG2' ' A' ' 81' ' ' GLU . 74.1 m-85 -81.26 -34.79 31.83 Favored 'General case' 0 N--CA 1.439 -0.98 0 N-CA-C 107.956 -1.127 . . . . 0.0 107.956 179.389 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.681 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 164.63 126.12 0.02 OUTLIER Pre-proline 0 N--CA 1.448 -0.552 0 CA-C-N 112.63 -2.077 . . . . 0.0 106.989 -178.766 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 72' ' ' PRO . . . . . 0.824 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 26.5 Cg_exo -55.17 -5.88 0.66 Allowed 'Trans proline' 0 C--N 1.332 -0.3 0 C-N-CA 123.216 2.61 . . . . 0.0 114.076 -177.808 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 73' ' ' ARG . . . . . 0.423 HH11 ' HD2' ' A' ' 73' ' ' ARG . 9.9 ptm180 -146.97 138.37 24.14 Favored 'General case' 0 C--N 1.318 -0.795 0 CA-C-O 121.459 0.647 . . . . 0.0 110.402 175.776 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 74' ' ' ALA . . . . . 0.407 ' HB2' ' CE3' ' A' ' 62' ' ' TRP . . . -60.12 -20.68 59.46 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 114.839 -1.073 . . . . 0.0 112.6 -178.889 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 75' ' ' ASP . . . . . 0.615 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 0.0 OUTLIER -76.83 -22.17 53.97 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 121.262 0.553 . . . . 0.0 110.602 -178.536 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 57.9 tp -92.66 -33.36 14.4 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.643 -0.708 . . . . 0.0 110.022 177.766 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 77' ' ' ALA . . . . . 0.715 ' HB1' ' HB3' ' A' ' 81' ' ' GLU . . . -77.8 154.84 31.51 Favored 'General case' 0 N--CA 1.447 -0.581 0 CA-C-N 115.48 -0.782 . . . . 0.0 110.66 178.657 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 72.9 p -96.41 -174.39 3.04 Favored 'General case' 0 C--N 1.314 -0.955 0 CA-C-N 115.214 -0.903 . . . . 0.0 110.84 -176.65 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 79' ' ' ARG . . . . . 0.867 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 0.1 OUTLIER -50.9 -54.75 21.35 Favored 'General case' 0 C--O 1.216 -0.668 0 CA-C-O 120.699 0.285 . . . . 0.0 110.376 -179.093 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -60.35 -38.22 83.14 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-O 121.261 0.553 . . . . 0.0 111.289 -174.086 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 81' ' ' GLU . . . . . 1.067 ' HG2' ' HB3' ' A' ' 70' ' ' TYR . 2.9 mt-10 -72.32 -52.99 13.7 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 115.505 -0.771 . . . . 0.0 112.297 -179.98 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 82' ' ' GLN . . . . . 0.698 ' HA ' ' CZ3' ' A' ' 62' ' ' TRP . 3.7 tt0 -63.78 -34.47 77.97 Favored 'General case' 0 C--N 1.317 -0.841 0 CA-C-N 115.28 -0.873 . . . . 0.0 109.621 -178.441 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.684 HG13 ' CD1' ' A' ' 31' ' ' TRP . 0.5 OUTLIER -70.02 -39.56 77.47 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.235 0 CA-C-N 114.632 -1.167 . . . . 0.0 110.965 177.907 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 84' ' ' ALA . . . . . 0.427 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -58.98 -36.19 74.46 Favored 'General case' 0 C--O 1.237 0.418 0 CA-C-O 121.587 0.708 . . . . 0.0 110.321 -178.272 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.634 HG13 ' HB2' ' A' ' 65' ' ' ASN . 44.6 t -67.21 -46.89 83.14 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-N 115.173 -0.921 . . . . 0.0 110.187 176.57 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 86' ' ' ALA . . . . . 0.416 ' CA ' ' HZ ' ' A' ' 57' ' ' PHE . . . -61.67 -31.92 72.07 Favored 'General case' 0 N--CA 1.451 -0.378 0 CA-C-N 115.465 -0.789 . . . . 0.0 110.641 175.813 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 87' ' ' GLU . . . . . 0.631 ' HA ' ' HG2' ' A' ' 90' ' ' ARG . 21.4 mm-40 -60.53 -44.29 96.22 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.616 -177.809 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.568 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 96.8 t -62.52 -51.78 68.03 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.425 0 C-N-CA 120.431 -0.508 . . . . 0.0 110.553 -179.13 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 89' ' ' THR . . . . . 0.56 ' HA ' ' NE ' ' A' ' 92' ' ' ARG . 14.8 t -74.09 -35.08 64.17 Favored 'General case' 0 N--CA 1.439 -0.99 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.505 -175.278 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 90' ' ' ARG . . . . . 0.631 ' HG2' ' HA ' ' A' ' 87' ' ' GLU . 3.3 ptt180 -62.26 -36.84 83.3 Favored 'General case' 0 N--CA 1.471 0.595 0 O-C-N 122.252 -0.28 . . . . 0.0 111.165 -178.337 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 91' ' ' LEU . . . . . 0.6 ' N ' ' HG3' ' A' ' 90' ' ' ARG . 4.5 pp -73.03 -23.75 60.63 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.311 -172.964 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 92' ' ' ARG . . . . . 0.56 ' NE ' ' HA ' ' A' ' 89' ' ' THR . 4.4 mtm180 -82.08 -43.09 18.31 Favored 'General case' 0 CA--C 1.51 -0.581 0 CA-C-O 121.797 0.808 . . . . 0.0 109.652 -178.274 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 93' ' ' GLN . . . . . 0.574 ' NE2' ' HB2' ' A' ' 97' ' ' ALA . 4.1 pt20 -99.98 -27.35 13.62 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 114.764 -1.107 . . . . 0.0 113.111 -170.485 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 84.14 47.75 5.39 Favored Glycine 0 CA--C 1.502 -0.772 0 C-N-CA 120.698 -0.763 . . . . 0.0 111.616 174.795 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 95' ' ' TRP . . . . . 0.514 ' HA ' ' HE3' ' A' ' 98' ' ' TRP . 2.9 m95 63.27 17.4 10.21 Favored 'General case' 0 C--O 1.219 -0.512 0 C-N-CA 123.148 0.579 . . . . 0.0 109.647 177.71 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -66.79 -36.64 91.47 Favored Glycine 0 C--N 1.333 0.372 0 CA-C-N 115.896 -0.593 . . . . 0.0 112.253 179.586 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 97' ' ' ALA . . . . . 0.574 ' HB2' ' NE2' ' A' ' 93' ' ' GLN . . . -69.94 -23.45 63.2 Favored 'General case' 0 CA--C 1.517 -0.296 0 CA-C-O 120.709 0.29 . . . . 0.0 110.577 177.768 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 98' ' ' TRP . . . . . 0.514 ' HE3' ' HA ' ' A' ' 95' ' ' TRP . 25.1 m-90 -98.94 108.11 47.4 Favored Pre-proline 0 N--CA 1.447 -0.6 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 179.095 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 99' ' ' PRO . . . . . 0.469 ' HD3' ' HA ' ' A' ' 98' ' ' TRP . 43.6 Cg_exo -63.36 -136.13 0.0 OUTLIER 'Trans proline' 0 CA--C 1.537 0.665 0 C-N-CA 123.671 2.914 . . . . 0.0 114.083 -174.275 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 44.3 t -55.19 -24.77 15.61 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.259 0 CA-C-O 121.241 0.543 . . . . 0.0 111.49 -176.106 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 101' ' ' CYS . . . . . 0.436 ' SG ' ' HG3' ' A' ' 38' ' ' GLU . 61.0 m -62.84 -34.81 78.12 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 116.064 -0.516 . . . . 0.0 111.502 -179.217 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -70.34 -41.05 73.71 Favored 'General case' 0 C--N 1.333 -0.136 0 CA-C-O 121.014 0.435 . . . . 0.0 110.775 177.975 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -64.72 -34.74 79.02 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.002 -0.544 . . . . 0.0 110.272 178.235 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 55.7 mtp180 -73.87 -19.08 60.83 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.505 -0.77 . . . . 0.0 111.864 176.468 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -95.76 -21.69 17.99 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 116.094 -0.503 . . . . 0.0 112.096 -172.951 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 99.93 67.13 0.84 Allowed Glycine 0 N--CA 1.454 -0.161 0 C-N-CA 120.777 -0.725 . . . . 0.0 111.88 -177.03 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -64.67 152.02 43.42 Favored 'General case' 0 N--CA 1.45 -0.468 0 C-N-CA 122.67 0.388 . . . . 0.0 111.022 -174.147 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 18.0 mmt180 . . . . . 0 C--O 1.241 0.656 0 O-C-N 124.019 0.824 . . . . 0.0 111.416 177.948 . . . . . . . . 0 0 . 1 . 029 nuclear build core ' A' A ' 27' ' ' ASP . . . . . 0.42 ' O ' HG12 ' A' ' 30' ' ' ILE . 14.2 m-20 . . . . . 0 CA--C 1.498 -1.049 0 CA-C-O 121.729 0.776 . . . . 0.0 109.598 . . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -63.09 -16.52 57.75 Favored Glycine 0 C--N 1.309 -0.963 0 CA-C-N 114.321 -1.309 . . . . 0.0 111.247 -177.047 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 15.5 m -77.66 -39.84 43.67 Favored 'General case' 0 C--N 1.315 -0.909 0 CA-C-O 121.811 0.815 . . . . 0.0 109.359 178.397 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.571 ' O ' HG13 ' A' ' 34' ' ' ILE . 0.5 OUTLIER -69.76 -39.73 78.29 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.706 0 CA-C-N 114.111 -1.404 . . . . 0.0 107.497 179.194 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 31' ' ' TRP . . . . . 0.519 ' CE3' HG11 ' A' ' 55' ' ' VAL . 18.1 m95 -68.35 -37.42 80.48 Favored 'General case' 0 C--N 1.317 -0.828 0 CA-C-N 114.195 -1.366 . . . . 0.0 110.809 -177.017 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 7.7 t70 -76.38 -32.32 58.52 Favored 'General case' 0 N--CA 1.447 -0.621 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.74 179.335 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 33' ' ' ALA . . . . . 0.484 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -71.05 -37.19 72.52 Favored 'General case' 0 N--CA 1.448 -0.527 0 C-N-CA 120.684 -0.406 . . . . 0.0 110.691 176.48 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 34' ' ' ILE . . . . . 0.571 HG13 ' O ' ' A' ' 30' ' ' ILE . 82.3 mt -67.16 -41.81 87.37 Favored 'Isoleucine or valine' 0 C--O 1.234 0.262 0 CA-C-O 121.212 0.53 . . . . 0.0 109.892 175.032 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 35' ' ' ALA . . . . . 0.651 ' HA ' ' O ' ' A' ' 54' ' ' GLY . . . -57.44 -37.91 73.58 Favored 'General case' 0 CA--C 1.515 -0.382 0 CA-C-N 115.511 -0.768 . . . . 0.0 110.317 175.997 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -78.38 -3.91 86.47 Favored Glycine 0 N--CA 1.45 -0.374 0 CA-C-N 115.246 -0.888 . . . . 0.0 111.638 179.883 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 41.0 t -97.51 -60.14 1.63 Allowed 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 115.689 -0.256 . . . . 0.0 111.055 -178.415 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 38' ' ' GLU . . . . . 0.637 ' HG3' ' SG ' ' A' ' 101' ' ' CYS . 39.2 mt-10 -89.28 -33.78 16.83 Favored 'General case' 0 CA--C 1.516 -0.356 0 CA-C-O 120.715 0.293 . . . . 0.0 111.388 -173.418 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -95.42 -14.06 24.11 Favored 'General case' 0 C--N 1.324 -0.534 0 C-N-CA 120.676 -0.409 . . . . 0.0 111.693 -176.819 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 77.97 20.22 73.63 Favored Glycine 0 N--CA 1.445 -0.745 0 N-CA-C 109.754 -1.338 . . . . 0.0 109.754 -175.799 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 71.07 56.47 7.0 Favored Glycine 0 N--CA 1.437 -1.28 0 CA-C-N 114.185 -1.008 . . . . 0.0 112.036 -176.412 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 5.7 t-20 -141.23 88.03 2.13 Favored 'General case' 0 N--CA 1.447 -0.597 0 N-CA-C 108.89 -0.782 . . . . 0.0 108.89 -177.592 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 43' ' ' TRP . . . . . 0.735 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 22.1 m95 -70.37 -13.03 61.97 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.515 -0.766 . . . . 0.0 111.176 -173.31 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -102.94 14.05 32.87 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 115.959 -0.564 . . . . 0.0 111.543 -177.624 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.819 HG22 ' HA2' ' A' ' 53' ' ' GLY . 3.6 tt -82.82 144.29 10.44 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.598 0 CA-C-O 120.915 0.388 . . . . 0.0 110.171 -177.955 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 44.5 t-20 -158.24 90.51 1.04 Allowed 'General case' 0 C--N 1.314 -0.95 0 N-CA-C 109.67 -0.493 . . . . 0.0 109.67 178.708 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 35.2 p -76.8 -24.05 52.81 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.622 -0.717 . . . . 0.0 110.92 -179.849 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 99.36 23.94 10.72 Favored Glycine 0 N--CA 1.442 -0.921 0 CA-C-N 115.458 -0.792 . . . . 0.0 111.377 -179.346 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 35.2 p30 -85.4 5.41 31.04 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.986 0.422 . . . . 0.0 111.559 179.656 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 50' ' ' GLY . . . . . 0.432 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 96.28 -10.63 67.42 Favored Glycine 0 N--CA 1.446 -0.653 0 N-CA-C 111.625 -0.59 . . . . 0.0 111.625 179.153 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 51' ' ' TYR . . . . . 0.6 ' HA ' ' HA ' ' A' ' 58' ' ' ASP . 0.2 OUTLIER -117.84 156.2 28.8 Favored 'General case' 0 CA--C 1.505 -0.75 0 N-CA-C 106.593 -1.632 . . . . 0.0 106.593 179.393 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 52' ' ' TYR . . . . . 0.651 ' HB2' ' HB3' ' A' ' 74' ' ' ALA . 46.2 m-85 -120.35 165.44 14.88 Favored 'General case' 0 C--N 1.307 -1.258 0 C-N-CA 119.69 -0.804 . . . . 0.0 112.466 -170.415 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.819 ' HA2' HG22 ' A' ' 45' ' ' ILE . . . -57.93 157.81 16.14 Favored Glycine 0 CA--C 1.502 -0.752 0 CA-C-N 114.854 -1.067 . . . . 0.0 114.41 -169.901 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 54' ' ' GLY . . . . . 0.667 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 99.52 -109.23 3.7 Favored Glycine 0 N--CA 1.436 -1.314 0 N-CA-C 111.246 -0.741 . . . . 0.0 111.246 -178.693 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.53 HG12 ' NE1' ' A' ' 98' ' ' TRP . 3.2 t -84.31 -2.11 6.88 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.67 0 CA-C-O 121.791 0.805 . . . . 0.0 110.025 -177.151 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 56' ' ' GLN . . . . . 0.571 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 6.9 tp60 57.97 50.51 10.17 Favored 'General case' 0 N--CA 1.461 0.088 0 CA-C-N 114.141 -1.391 . . . . 0.0 112.833 166.598 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 57' ' ' PHE . . . . . 0.416 ' CE1' ' HB2' ' A' ' 86' ' ' ALA . 10.3 p90 -117.34 162.38 18.01 Favored 'General case' 0 C--N 1.324 -0.511 0 C-N-CA 120.443 -0.503 . . . . 0.0 111.071 175.166 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.6 ' HA ' ' HA ' ' A' ' 51' ' ' TYR . 5.0 p-10 -77.01 163.19 26.92 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 113.667 0.988 . . . . 0.0 113.667 -163.733 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 59' ' ' GLN . . . . . 0.466 ' HB2' ' CE2' ' A' ' 52' ' ' TYR . 6.2 tp60 -60.57 -40.45 91.71 Favored 'General case' 0 N--CA 1.446 -0.653 0 CA-C-N 113.714 -1.585 . . . . 0.0 111.883 -179.934 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -65.41 -45.2 91.45 Favored Glycine 0 C--N 1.321 -0.286 0 C-N-CA 121.077 -0.582 . . . . 0.0 111.953 -176.952 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 61' ' ' THR . . . . . 0.555 ' CG2' HG21 ' A' ' 89' ' ' THR . 95.0 m -66.61 -43.98 83.31 Favored 'General case' 0 C--N 1.32 -0.701 0 C-N-CA 122.558 0.343 . . . . 0.0 111.077 176.524 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 62' ' ' TRP . . . . . . . . . . . . . 50.3 t-105 -57.63 -47.3 82.6 Favored 'General case' 0 N--CA 1.45 -0.426 0 CA-C-O 121.62 0.724 . . . . 0.0 109.876 176.539 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 63' ' ' GLU . . . . . 0.447 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 29.2 tt0 -67.31 -33.35 75.09 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 115.09 -0.959 . . . . 0.0 110.614 -178.336 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -66.54 -42.87 86.51 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.76 -0.655 . . . . 0.0 110.745 -176.806 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 65' ' ' ASN . . . . . 0.486 ' HB2' HG13 ' A' ' 85' ' ' VAL . 7.2 m120 -75.22 -13.97 60.49 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 121.041 0.448 . . . . 0.0 110.387 176.655 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 91.98 46.64 3.57 Favored Glycine 0 N--CA 1.448 -0.533 0 CA-C-N 115.675 -0.693 . . . . 0.0 111.855 176.114 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 67' ' ' GLY . . . . . 0.478 ' O ' ' HB2' ' A' ' 70' ' ' TYR . . . -79.52 -21.81 65.97 Favored Glycine 0 N--CA 1.439 -1.142 0 C-N-CA 120.882 -0.675 . . . . 0.0 112.835 -172.648 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.858 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 7.4 mp -58.98 -29.93 67.57 Favored 'General case' 0 C--N 1.319 -0.73 0 N-CA-C 112.764 0.653 . . . . 0.0 112.764 -173.191 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 12.3 ptm180 -66.02 -29.36 69.72 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-O 121.491 0.662 . . . . 0.0 110.105 176.324 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 70' ' ' TYR . . . . . 0.81 ' HB3' ' HG2' ' A' ' 81' ' ' GLU . 86.8 m-85 -78.14 -36.2 48.02 Favored 'General case' 0 N--CA 1.445 -0.717 0 N-CA-C 107.366 -1.346 . . . . 0.0 107.366 175.493 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.656 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 158.26 130.67 0.0 OUTLIER Pre-proline 0 CA--C 1.508 -0.659 0 CA-C-N 112.096 -2.32 . . . . 0.0 106.262 -177.949 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 72' ' ' PRO . . . . . 0.858 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 18.4 Cg_exo -56.89 -4.45 0.92 Allowed 'Trans proline' 0 C--N 1.331 -0.343 0 C-N-CA 122.988 2.459 . . . . 0.0 114.103 -174.655 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 3.4 ptt180 -154.48 143.78 21.29 Favored 'General case' 0 C--N 1.318 -0.766 0 CA-C-O 121.308 0.575 . . . . 0.0 110.759 176.894 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 74' ' ' ALA . . . . . 0.651 ' HB3' ' HB2' ' A' ' 52' ' ' TYR . . . -57.95 -21.97 46.68 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.635 -175.514 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 75' ' ' ASP . . . . . 0.66 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 5.0 p-10 -87.57 -9.88 53.14 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 121.357 0.598 . . . . 0.0 110.672 -178.642 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.542 HD23 ' HD2' ' A' ' 72' ' ' PRO . 57.6 tp -99.86 -30.5 12.0 Favored 'General case' 0 C--N 1.319 -0.73 0 N-CA-C 108.846 -0.798 . . . . 0.0 108.846 175.301 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 77' ' ' ALA . . . . . 0.656 ' HB2' ' HB3' ' A' ' 71' ' ' ALA . . . -79.63 160.71 26.27 Favored 'General case' 0 N--CA 1.442 -0.846 0 CA-C-N 115.041 -0.982 . . . . 0.0 109.789 173.118 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 36.0 p -100.48 -178.92 3.95 Favored 'General case' 0 C--N 1.309 -1.188 0 CA-C-N 115.564 -0.744 . . . . 0.0 110.914 -178.023 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 79' ' ' ARG . . . . . 0.735 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 5.5 mtt180 -51.17 -53.75 31.8 Favored 'General case' 0 CA--C 1.511 -0.525 0 CA-C-O 120.871 0.367 . . . . 0.0 111.031 -179.516 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 1.9 pm0 -58.36 -39.65 80.1 Favored 'General case' 0 C--N 1.314 -0.938 0 CA-C-N 115.393 -0.821 . . . . 0.0 111.602 -177.888 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 81' ' ' GLU . . . . . 0.81 ' HG2' ' HB3' ' A' ' 70' ' ' TYR . 4.1 mt-10 -70.01 -51.54 31.48 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 121.13 0.49 . . . . 0.0 111.923 178.014 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 82' ' ' GLN . . . . . 0.467 HE21 ' HE3' ' A' ' 43' ' ' TRP . 5.3 tt0 -65.69 -33.9 76.94 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-N 115.377 -0.829 . . . . 0.0 110.591 -176.904 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.445 HG23 ' CD1' ' A' ' 31' ' ' TRP . 24.4 mt -61.56 -45.06 99.44 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.678 0 CA-C-N 115.708 -0.678 . . . . 0.0 109.849 174.073 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 84' ' ' ALA . . . . . 0.654 ' O ' ' HG3' ' A' ' 87' ' ' GLU . . . -64.54 -41.1 96.56 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.945 0.403 . . . . 0.0 111.59 -176.804 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.486 HG13 ' HB2' ' A' ' 65' ' ' ASN . 50.2 t -69.05 -48.99 66.58 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-O 120.968 0.413 . . . . 0.0 111.127 179.255 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 86' ' ' ALA . . . . . 0.416 ' HB2' ' CE1' ' A' ' 57' ' ' PHE . . . -65.7 -31.79 72.99 Favored 'General case' 0 N--CA 1.449 -0.484 0 CA-C-N 115.914 -0.584 . . . . 0.0 110.76 -179.893 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 87' ' ' GLU . . . . . 0.654 ' HG3' ' O ' ' A' ' 84' ' ' ALA . 0.1 OUTLIER -70.1 -28.93 65.8 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.228 -177.373 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.56 ' O ' ' HG3' ' A' ' 92' ' ' ARG . 85.9 t -61.11 -48.64 88.11 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.177 0 N-CA-C 109.241 -0.651 . . . . 0.0 109.241 169.703 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 89' ' ' THR . . . . . 0.562 ' HB ' ' CH2' ' A' ' 98' ' ' TRP . 0.1 OUTLIER -64.9 -44.18 90.43 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 115.647 -0.706 . . . . 0.0 112.143 -176.257 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 90' ' ' ARG . . . . . 0.478 ' HB3' ' CZ2' ' A' ' 31' ' ' TRP . 0.0 OUTLIER -61.2 -32.23 71.99 Favored 'General case' 0 CA--C 1.511 -0.535 0 CA-C-O 121.727 0.775 . . . . 0.0 108.974 -177.068 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 91' ' ' LEU . . . . . 0.42 HD13 HH12 ' A' ' 90' ' ' ARG . 48.4 tp -69.48 -27.42 65.2 Favored 'General case' 0 C--N 1.313 -0.984 0 CA-C-N 113.966 -1.47 . . . . 0.0 111.276 -174.418 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 92' ' ' ARG . . . . . 0.56 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 4.1 mtm180 -90.59 -48.29 7.17 Favored 'General case' 0 C--N 1.317 -0.805 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.293 -175.832 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 93' ' ' GLN . . . . . 0.474 ' HG3' ' H ' ' A' ' 96' ' ' GLY . 3.4 pt20 -99.07 -27.78 13.68 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-N 114.965 -1.016 . . . . 0.0 113.006 -168.995 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 89.17 41.15 5.92 Favored Glycine 0 CA--C 1.501 -0.842 0 C-N-CA 119.971 -1.109 . . . . 0.0 110.796 178.926 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 95' ' ' TRP . . . . . 0.525 ' HA ' ' HE3' ' A' ' 98' ' ' TRP . 6.1 m95 67.16 19.8 10.33 Favored 'General case' 0 C--O 1.216 -0.674 0 CA-C-N 114.893 -0.654 . . . . 0.0 109.288 176.455 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 96' ' ' GLY . . . . . 0.474 ' H ' ' HG3' ' A' ' 93' ' ' GLN . . . -64.1 -30.44 77.77 Favored Glycine 0 N--CA 1.452 -0.286 0 CA-C-N 115.465 -0.789 . . . . 0.0 112.886 178.462 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 97' ' ' ALA . . . . . 0.454 ' HB2' HE22 ' A' ' 93' ' ' GLN . . . -75.14 -20.68 59.28 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 121.006 0.431 . . . . 0.0 110.142 176.584 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 98' ' ' TRP . . . . . 0.562 ' CH2' ' HB ' ' A' ' 89' ' ' THR . 22.3 m-90 -104.31 111.67 65.24 Favored Pre-proline 0 N--CA 1.446 -0.631 0 CA-C-N 115.72 -0.673 . . . . 0.0 110.335 -177.905 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 99' ' ' PRO . . . . . 0.412 ' HD3' ' HA ' ' A' ' 98' ' ' TRP . 52.5 Cg_exo -61.48 -140.2 0.0 OUTLIER 'Trans proline' 0 CA--C 1.534 0.487 0 C-N-CA 123.644 2.896 . . . . 0.0 114.444 -175.31 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 100' ' ' VAL . . . . . 0.477 ' O ' ' HD2' ' A' ' 104' ' ' ARG . 12.6 m -54.7 -29.52 21.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.654 -0.703 . . . . 0.0 111.26 -178.363 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 101' ' ' CYS . . . . . 0.637 ' SG ' ' HG3' ' A' ' 38' ' ' GLU . 59.3 m -56.34 -35.56 67.76 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-N 115.205 -0.907 . . . . 0.0 111.706 -179.591 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -69.62 -42.56 74.19 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 121.072 0.463 . . . . 0.0 110.51 179.117 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -66.76 -37.72 85.18 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.656 179.42 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 104' ' ' ARG . . . . . 0.477 ' HD2' ' O ' ' A' ' 100' ' ' VAL . 0.0 OUTLIER -72.6 -20.54 61.28 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.804 -0.635 . . . . 0.0 111.009 178.373 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 105' ' ' ALA . . . . . 0.562 ' HB1' ' HA ' ' A' ' 30' ' ' ILE . . . -91.38 -20.91 21.31 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 115.821 -0.627 . . . . 0.0 111.694 -177.392 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 103.82 54.46 0.81 Allowed Glycine 0 CA--C 1.518 0.244 0 C-N-CA 121.005 -0.617 . . . . 0.0 112.188 179.987 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -67.74 151.25 47.54 Favored 'General case' 0 N--CA 1.449 -0.522 0 C-N-CA 122.385 0.274 . . . . 0.0 111.691 -175.44 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 14.5 mtt180 . . . . . 0 C--O 1.252 1.2 0 O-C-N 124.211 0.944 . . . . 0.0 111.673 174.85 . . . . . . . . 0 0 . 1 . 030 nuclear build core ' A' A ' 27' ' ' ASP . . . . . 0.535 ' O ' HG12 ' A' ' 30' ' ' ILE . 71.8 m-20 . . . . . 0 CA--C 1.505 -0.767 0 CA-C-O 122.075 0.941 . . . . 0.0 108.869 . . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 28' ' ' GLY . . . . . 0.576 ' HA2' ' HB2' ' A' ' 31' ' ' TRP . . . -71.58 -3.0 52.89 Favored Glycine 0 N--CA 1.439 -1.123 0 CA-C-N 113.899 -1.5 . . . . 0.0 110.219 174.958 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 5.6 m -76.34 -37.57 57.15 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 108.655 -0.868 . . . . 0.0 108.655 174.086 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.535 HG12 ' O ' ' A' ' 27' ' ' ASP . 0.9 OUTLIER -70.15 -37.99 73.47 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 N-CA-C 106.943 -1.503 . . . . 0.0 106.943 175.683 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' A' A ' 31' ' ' TRP . . . . . 0.576 ' HB2' ' HA2' ' A' ' 28' ' ' GLY . 22.8 m95 -70.27 -36.41 74.41 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 114.122 -1.399 . . . . 0.0 110.754 -177.079 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.735 ' HB2' HH21 ' A' ' 79' ' ' ARG . 26.5 t70 -76.8 -36.17 57.13 Favored 'General case' 0 N--CA 1.444 -0.73 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.385 179.643 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 33' ' ' ALA . . . . . 0.415 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -70.77 -36.66 73.17 Favored 'General case' 0 N--CA 1.448 -0.526 0 CA-C-O 120.768 0.318 . . . . 0.0 110.809 176.944 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 34' ' ' ILE . . . . . 0.496 HG13 ' O ' ' A' ' 30' ' ' ILE . 59.3 mt -63.97 -43.91 97.78 Favored 'Isoleucine or valine' 0 C--O 1.234 0.267 0 CA-C-O 121.041 0.448 . . . . 0.0 110.006 173.789 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 35' ' ' ALA . . . . . 0.46 ' HA ' ' O ' ' A' ' 54' ' ' GLY . . . -57.1 -39.39 74.96 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.551 -0.75 . . . . 0.0 110.151 176.584 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -73.0 -17.68 78.73 Favored Glycine 0 N--CA 1.452 -0.283 0 CA-C-N 115.299 -0.864 . . . . 0.0 111.813 -179.528 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 11.1 t -88.24 -60.9 1.84 Allowed 'General case' 0 C--N 1.322 -0.63 0 CA-C-O 120.778 0.323 . . . . 0.0 111.404 -178.783 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 38' ' ' GLU . . . . . 0.806 ' HG3' ' HG2' ' A' ' 56' ' ' GLN . 8.8 tp10 -88.06 -33.49 18.3 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-O 121.009 0.433 . . . . 0.0 110.509 -169.513 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -96.85 -7.46 33.45 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.086 -0.506 . . . . 0.0 111.605 -176.468 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 76.2 17.2 80.16 Favored Glycine 0 N--CA 1.448 -0.523 0 N-CA-C 109.987 -1.245 . . . . 0.0 109.987 -177.322 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 72.81 55.29 6.6 Favored Glycine 0 N--CA 1.436 -1.306 0 CA-C-N 114.084 -1.058 . . . . 0.0 112.034 -177.334 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 42' ' ' ASN . . . . . 0.74 ' HB3' ' HB ' ' A' ' 45' ' ' ILE . 2.5 t-20 -148.17 105.83 3.68 Favored 'General case' 0 CA--C 1.511 -0.521 0 N-CA-C 108.396 -0.964 . . . . 0.0 108.396 -176.444 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 43' ' ' TRP . . . . . 0.876 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 30.4 m95 -83.26 -6.87 59.62 Favored 'General case' 0 C--N 1.309 -1.161 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.551 -173.125 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -111.08 15.03 21.84 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.594 -0.73 . . . . 0.0 111.698 177.792 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.74 ' HB ' ' HB3' ' A' ' 42' ' ' ASN . 11.0 tt -86.73 144.78 8.66 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.624 0 CA-C-O 120.835 0.35 . . . . 0.0 110.868 -176.545 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 45.6 t30 -153.62 111.29 3.52 Favored 'General case' 0 C--N 1.316 -0.89 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 174.178 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 6.9 p -82.4 -15.81 51.33 Favored 'General case' 0 C--N 1.315 -0.896 0 CA-C-N 115.809 -0.632 . . . . 0.0 111.342 -179.679 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 95.92 20.53 25.89 Favored Glycine 0 N--CA 1.446 -0.673 0 N-CA-C 111.174 -0.77 . . . . 0.0 111.174 -177.555 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 8.8 p30 -85.73 -5.29 59.28 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 121.136 0.493 . . . . 0.0 111.221 -176.16 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 50' ' ' GLY . . . . . 0.454 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 96.87 -12.99 65.61 Favored Glycine 0 N--CA 1.448 -0.5 0 CA-C-N 115.945 -0.57 . . . . 0.0 111.832 178.411 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 51' ' ' TYR . . . . . 0.608 ' HA ' ' HA ' ' A' ' 58' ' ' ASP . 0.9 OUTLIER -108.82 137.19 47.14 Favored 'General case' 0 CA--C 1.511 -0.529 0 N-CA-C 107.376 -1.342 . . . . 0.0 107.376 172.609 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' A' A ' 52' ' ' TYR . . . . . 0.697 ' CE1' ' HB2' ' A' ' 59' ' ' GLN . 26.6 m-85 -99.83 156.54 17.06 Favored 'General case' 0 C--N 1.307 -1.243 0 C-N-CA 120.607 -0.437 . . . . 0.0 111.255 -167.892 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -61.16 -176.07 1.74 Allowed Glycine 0 C--N 1.329 0.19 0 N-CA-C 115.387 0.915 . . . . 0.0 115.387 -167.632 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 54' ' ' GLY . . . . . 0.732 ' CA ' ' HA ' ' A' ' 43' ' ' TRP . . . 86.84 -105.12 3.0 Favored Glycine 0 N--CA 1.446 -0.646 0 N-CA-C 111.318 -0.713 . . . . 0.0 111.318 -174.768 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.516 ' HB ' ' CD1' ' A' ' 57' ' ' PHE . 3.1 t -83.58 -4.47 8.44 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.751 0 N-CA-C 108.53 -0.915 . . . . 0.0 108.53 176.857 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 56' ' ' GLN . . . . . 0.806 ' HG2' ' HG3' ' A' ' 38' ' ' GLU . 14.8 tp60 58.38 43.56 19.64 Favored 'General case' 0 C--O 1.231 0.115 0 CA-C-N 114.021 -1.445 . . . . 0.0 112.377 169.651 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 57' ' ' PHE . . . . . 0.516 ' CD1' ' HB ' ' A' ' 55' ' ' VAL . 3.7 p90 -111.44 168.92 9.16 Favored 'General case' 0 C--N 1.323 -0.546 0 C-N-CA 120.181 -0.608 . . . . 0.0 110.888 174.829 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.608 ' HA ' ' HA ' ' A' ' 51' ' ' TYR . 7.7 p-10 -78.07 153.77 31.96 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 122.014 0.912 . . . . 0.0 112.38 -165.514 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 59' ' ' GLN . . . . . 0.697 ' HB2' ' CE1' ' A' ' 52' ' ' TYR . 40.6 tp60 -63.77 -30.69 71.75 Favored 'General case' 0 N--CA 1.444 -0.737 0 CA-C-N 113.827 -1.533 . . . . 0.0 111.098 -179.804 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -62.96 -50.29 64.88 Favored Glycine 0 C--N 1.314 -0.689 0 C-N-CA 120.743 -0.741 . . . . 0.0 111.676 178.195 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 99.4 m -65.85 -41.86 91.17 Favored 'General case' 0 C--N 1.321 -0.674 0 C-N-CA 122.707 0.403 . . . . 0.0 111.065 175.697 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 62' ' ' TRP . . . . . 0.522 ' CH2' ' HA ' ' A' ' 74' ' ' ALA . 50.0 t-105 -56.33 -48.74 76.14 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-O 121.617 0.722 . . . . 0.0 109.546 177.487 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 63' ' ' GLU . . . . . 0.538 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 55.7 tt0 -67.76 -34.78 77.49 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 114.901 -1.045 . . . . 0.0 110.712 -179.76 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -62.66 -41.09 98.88 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.773 -179.398 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 65' ' ' ASN . . . . . 0.655 ' OD1' ' HB ' ' A' ' 89' ' ' THR . 7.9 m120 -79.96 -11.16 59.81 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.536 177.9 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 66' ' ' GLY . . . . . 0.562 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 84.03 49.0 4.93 Favored Glycine 0 N--CA 1.448 -0.528 0 CA-C-N 115.47 -0.786 . . . . 0.0 112.105 178.485 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 67' ' ' GLY . . . . . 0.604 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -80.17 -18.93 70.7 Favored Glycine 0 N--CA 1.439 -1.124 0 C-N-CA 121.104 -0.57 . . . . 0.0 112.725 -176.214 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.696 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 6.4 mp -62.31 -23.1 66.55 Favored 'General case' 0 N--CA 1.45 -0.425 0 N-CA-C 112.035 0.383 . . . . 0.0 112.035 -172.578 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 69' ' ' ARG . . . . . 0.562 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 13.9 ptp180 -68.69 -32.19 71.83 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-O 121.259 0.552 . . . . 0.0 110.118 176.84 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 70' ' ' TYR . . . . . 0.653 ' HB3' ' HB3' ' A' ' 81' ' ' GLU . 67.7 m-85 -82.18 -33.99 29.22 Favored 'General case' 0 N--CA 1.442 -0.834 0 N-CA-C 107.436 -1.32 . . . . 0.0 107.436 178.443 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 71' ' ' ALA . . . . . 0.546 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 169.14 122.86 0.04 OUTLIER Pre-proline 0 N--CA 1.447 -0.61 0 CA-C-N 112.654 -2.066 . . . . 0.0 107.445 -178.423 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 72' ' ' PRO . . . . . 0.696 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 20.9 Cg_exo -55.28 -7.02 0.98 Allowed 'Trans proline' 0 CA--C 1.527 0.138 0 C-N-CA 122.807 2.338 . . . . 0.0 113.76 -178.81 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 73' ' ' ARG . . . . . 0.437 ' HE ' ' CG ' ' A' ' 75' ' ' ASP . 12.1 ptm180 -145.39 137.98 25.96 Favored 'General case' 0 C--N 1.318 -0.772 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 177.491 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 74' ' ' ALA . . . . . 0.522 ' HA ' ' CH2' ' A' ' 62' ' ' TRP . . . -55.76 -35.43 66.19 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 114.802 -1.09 . . . . 0.0 112.248 -176.005 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 75' ' ' ASP . . . . . 0.673 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 14.9 p-10 -80.95 -7.35 59.49 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 121.092 0.472 . . . . 0.0 111.531 -173.782 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.517 ' HB3' ' HB1' ' A' ' 71' ' ' ALA . 60.2 tp -87.7 -33.06 18.87 Favored 'General case' 0 C--N 1.318 -0.773 0 N-CA-C 108.688 -0.856 . . . . 0.0 108.688 171.776 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 77' ' ' ALA . . . . . 0.943 ' HB1' ' HB2' ' A' ' 81' ' ' GLU . . . -79.29 153.37 29.92 Favored 'General case' 0 N--CA 1.446 -0.659 0 CA-C-N 115.01 -0.995 . . . . 0.0 111.012 176.444 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 22.8 p -101.16 -170.3 1.82 Allowed 'General case' 0 C--N 1.315 -0.929 0 CA-C-N 115.77 -0.65 . . . . 0.0 109.517 179.131 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 79' ' ' ARG . . . . . 0.876 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 53.1 mtp180 -50.67 -48.66 58.35 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.903 0.382 . . . . 0.0 111.341 -176.808 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 7.3 pt-20 -57.88 -49.29 77.21 Favored 'General case' 0 C--N 1.319 -0.75 0 CA-C-N 115.391 -0.822 . . . . 0.0 112.432 -175.517 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 81' ' ' GLU . . . . . 0.943 ' HB2' ' HB1' ' A' ' 77' ' ' ALA . 26.1 mp0 -66.29 -50.46 63.58 Favored 'General case' 0 CA--C 1.52 -0.208 0 O-C-N 122.06 -0.4 . . . . 0.0 111.559 178.0 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 82' ' ' GLN . . . . . 0.68 ' HB2' ' HZ3' ' A' ' 43' ' ' TRP . 52.0 mt-30 -62.44 -33.67 75.27 Favored 'General case' 0 CA--C 1.513 -0.448 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.003 -174.576 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.643 ' O ' ' HG2' ' A' ' 87' ' ' GLU . 27.2 mt -60.53 -49.11 85.67 Favored 'Isoleucine or valine' 0 C--O 1.216 -0.663 0 N-CA-C 109.188 -0.671 . . . . 0.0 109.188 174.986 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 84' ' ' ALA . . . . . 0.598 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -57.12 -47.68 80.51 Favored 'General case' 0 C--O 1.239 0.53 0 CA-C-O 121.522 0.677 . . . . 0.0 111.821 -178.281 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.431 HG13 ' HB2' ' A' ' 65' ' ' ASN . 45.7 t -65.97 -48.82 80.48 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.587 0 CA-C-N 115.827 -0.624 . . . . 0.0 111.284 -179.458 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 86' ' ' ALA . . . . . 0.42 ' HB1' ' CH2' ' A' ' 31' ' ' TRP . . . -59.21 -30.31 68.14 Favored 'General case' 0 N--CA 1.45 -0.468 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.439 175.572 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 87' ' ' GLU . . . . . 0.643 ' HG2' ' O ' ' A' ' 83' ' ' ILE . 21.1 mm-40 -59.58 -43.97 93.48 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.957 -179.111 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.632 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 94.2 t -64.9 -50.98 72.52 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 C-N-CA 120.56 -0.456 . . . . 0.0 110.915 179.289 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 89' ' ' THR . . . . . 0.655 ' HB ' ' OD1' ' A' ' 65' ' ' ASN . 14.7 t -72.8 -34.89 67.2 Favored 'General case' 0 C--N 1.317 -0.843 0 C-N-CA 120.495 -0.482 . . . . 0.0 111.499 -173.599 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 90' ' ' ARG . . . . . 0.623 ' HG3' ' N ' ' A' ' 91' ' ' LEU . 4.3 ptt180 -60.45 -39.31 87.08 Favored 'General case' 0 N--CA 1.466 0.338 0 O-C-N 122.291 -0.256 . . . . 0.0 110.978 -178.267 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 91' ' ' LEU . . . . . 0.632 ' HG ' ' O ' ' A' ' 88' ' ' VAL . 4.5 pp -72.72 -23.91 60.91 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 115.956 -0.566 . . . . 0.0 111.479 -173.28 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 92' ' ' ARG . . . . . 0.559 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 10.8 mtm180 -79.28 -48.17 14.61 Favored 'General case' 0 CA--C 1.509 -0.61 0 CA-C-O 121.803 0.811 . . . . 0.0 109.456 -176.882 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 93' ' ' GLN . . . . . 0.651 ' NE2' ' HB2' ' A' ' 97' ' ' ALA . 3.6 pt20 -97.37 -28.38 14.05 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 114.413 -1.267 . . . . 0.0 113.149 -169.773 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 96.89 39.92 3.96 Favored Glycine 0 CA--C 1.503 -0.682 0 C-N-CA 120.215 -0.993 . . . . 0.0 111.119 172.892 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 95' ' ' TRP . . . . . 0.517 ' HA ' ' HE3' ' A' ' 98' ' ' TRP . 12.3 m95 68.11 9.3 7.1 Favored 'General case' 0 C--O 1.218 -0.592 0 N-CA-C 108.953 -0.758 . . . . 0.0 108.953 -178.151 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -62.39 -32.13 81.86 Favored Glycine 0 C--N 1.334 0.451 0 CA-C-N 115.592 -0.731 . . . . 0.0 113.14 -177.814 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 97' ' ' ALA . . . . . 0.651 ' HB2' ' NE2' ' A' ' 93' ' ' GLN . . . -64.45 -24.26 67.56 Favored 'General case' 0 CA--C 1.514 -0.406 0 CA-C-O 120.902 0.382 . . . . 0.0 110.073 176.312 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 98' ' ' TRP . . . . . 0.581 ' HB2' ' HB2' ' A' ' 102' ' ' ALA . 19.6 m-90 -108.63 105.07 56.25 Favored Pre-proline 0 C--N 1.324 -0.522 0 CA-C-N 115.829 -0.623 . . . . 0.0 109.976 178.893 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 99' ' ' PRO . . . . . 0.439 ' HB2' ' H ' ' A' ' 100' ' ' VAL . 19.1 Cg_exo -72.14 -94.08 0.01 OUTLIER 'Trans proline' 0 CA--C 1.536 0.604 0 C-N-CA 122.888 2.392 . . . . 0.0 113.851 -175.59 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 100' ' ' VAL . . . . . 0.439 ' H ' ' HB2' ' A' ' 99' ' ' PRO . 46.5 t -71.44 -26.78 27.1 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.176 0 CA-C-O 121.637 0.732 . . . . 0.0 110.324 -174.799 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 101' ' ' CYS . . . . . 0.446 ' SG ' ' HB2' ' A' ' 38' ' ' GLU . 80.2 m -73.02 -37.48 66.91 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 115.217 -0.901 . . . . 0.0 111.742 -172.987 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 102' ' ' ALA . . . . . 0.581 ' HB2' ' HB2' ' A' ' 98' ' ' TRP . . . -69.7 -44.14 71.01 Favored 'General case' 0 C--N 1.327 -0.382 0 C-N-CA 120.811 -0.356 . . . . 0.0 110.267 179.258 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -61.27 -37.41 83.03 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 121.193 0.521 . . . . 0.0 110.92 179.715 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -72.11 -23.84 61.38 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.731 -0.668 . . . . 0.0 111.818 177.526 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 105' ' ' ALA . . . . . 0.48 ' HB1' ' HA ' ' A' ' 30' ' ' ILE . . . -95.63 -22.78 17.37 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 116.1 -0.5 . . . . 0.0 112.154 -174.619 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 121.55 58.47 0.22 Allowed Glycine 0 CA--C 1.521 0.437 0 C-N-CA 121.05 -0.595 . . . . 0.0 112.189 -176.765 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -72.21 150.4 43.73 Favored 'General case' 0 C--N 1.327 -0.386 0 C-N-CA 122.871 0.469 . . . . 0.0 111.079 -176.494 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 108' ' ' ARG . . . . . 0.476 ' HB2' ' HE1' ' A' ' 95' ' ' TRP . 93.1 mtt180 . . . . . 0 C--O 1.25 1.09 0 CA-C-O 118.303 -0.855 . . . . 0.0 110.636 -174.644 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 94.8 m-20 . . . . . 0 N--CA 1.477 0.921 0 CA-C-O 120.835 0.35 . . . . 0.0 110.318 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 13.0 p -69.29 -16.18 20.39 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.331 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.589 178.426 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 60.9 t -61.26 107.61 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.472 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.397 176.102 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 4.7 p -73.86 141.04 16.71 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 CA-C-O 121.814 0.816 . . . . 0.0 111.446 -177.654 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 1.5 p -110.5 114.56 54.95 Favored Pre-proline 0 C--N 1.311 -1.07 0 CA-C-N 114.456 -1.247 . . . . 0.0 110.915 -176.932 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 7.8 Cg_endo -88.58 168.82 5.9 Favored 'Trans proline' 0 N--CA 1.449 -1.102 0 C-N-CA 123.327 2.685 . . . . 0.0 111.686 177.991 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -76.87 88.59 3.46 Favored 'General case' 0 C--N 1.311 -1.071 0 CA-C-N 114.607 -1.179 . . . . 0.0 110.621 179.03 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 29.6 m170 -82.85 -11.48 58.19 Favored 'General case' 0 C--N 1.312 -1.036 0 CA-C-N 114.344 -1.298 . . . . 0.0 108.332 172.368 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 11.7 pt-20 -78.85 139.15 38.39 Favored 'General case' 0 N--CA 1.452 -0.371 0 CA-C-N 115.568 -0.742 . . . . 0.0 110.645 -178.566 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -147.95 77.03 1.4 Allowed 'General case' 0 C--N 1.319 -0.756 0 CA-C-N 115.448 -0.796 . . . . 0.0 109.609 179.226 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 62.7 t -66.92 -71.72 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.63 0 CA-C-N 115.004 -0.998 . . . . 0.0 110.496 -178.999 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 5.9 p 25.73 77.79 0.01 OUTLIER 'Isoleucine or valine' 0 C--O 1.237 0.434 0 CA-C-O 122.842 1.306 . . . . 0.0 112.641 179.64 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 64.3 mtm180 -78.56 109.11 12.46 Favored 'General case' 0 N--CA 1.434 -1.267 0 CA-C-N 113.939 -1.482 . . . . 0.0 111.655 -173.328 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.8 t -96.36 154.44 3.57 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.426 0 CA-C-N 113.996 -1.456 . . . . 0.0 107.702 172.074 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -102.66 -63.91 0.72 Allowed Glycine 0 C--N 1.301 -1.373 0 CA-C-N 115.366 -0.834 . . . . 0.0 111.411 -173.642 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 24.2 m -147.87 -46.48 0.16 Allowed 'General case' 0 N--CA 1.429 -1.492 0 CA-C-N 114.583 -0.809 . . . . 0.0 110.371 178.803 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 66.8 mmtt -66.0 108.66 2.39 Favored Pre-proline 0 C--N 1.317 -0.841 0 CA-C-N 114.89 -1.05 . . . . 0.0 109.461 179.653 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 97.7 Cg_endo -71.81 106.44 1.99 Allowed 'Trans proline' 0 N--CA 1.452 -0.922 0 C-N-CA 122.853 2.368 . . . . 0.0 111.113 -178.998 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 82.99 56.97 2.61 Favored Glycine 0 C--N 1.294 -1.789 0 CA-C-N 113.259 -1.791 . . . . 0.0 110.428 -173.096 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 1.4 m -56.44 -53.06 61.88 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.364 -0.418 . . . . 0.0 110.136 179.216 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -145.96 110.34 5.05 Favored 'General case' 0 N--CA 1.451 -0.411 0 CA-C-N 115.848 -0.614 . . . . 0.0 110.446 174.617 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 64.7 t -109.31 112.92 59.07 Favored Pre-proline 0 C--N 1.316 -0.853 0 N-CA-C 109.117 -0.697 . . . . 0.0 109.117 175.044 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.495 ' HA ' ' HD2' ' A' ' 24' ' ' PRO . 48.1 Cg_exo -55.71 128.65 31.23 Favored 'Trans proline' 0 N--CA 1.462 -0.358 0 C-N-CA 122.616 2.211 . . . . 0.0 112.145 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 24' ' ' PRO . . . . . 0.495 ' HD2' ' HA ' ' A' ' 23' ' ' PRO . 11.0 Cg_endo -56.28 140.68 88.39 Favored 'Trans proline' 0 N--CA 1.453 -0.901 0 C-N-CA 123.132 2.554 . . . . 0.0 111.862 176.384 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.551 ' HB ' HG21 ' A' ' 83' ' ' ILE . 85.9 t -116.76 126.38 74.17 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.162 0 CA-C-N 114.96 -1.018 . . . . 0.0 110.01 -178.46 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 43.4 mm -68.92 -23.21 27.1 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-N 115.531 -0.759 . . . . 0.0 111.152 -174.204 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.493 ' O ' HG13 ' A' ' 30' ' ' ILE . 14.0 m-20 -91.68 6.44 45.85 Favored 'General case' 0 N--CA 1.445 -0.687 0 CA-C-O 121.73 0.776 . . . . 0.0 109.009 -177.663 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -64.27 -10.51 41.96 Favored Glycine 0 N--CA 1.441 -1.008 0 CA-C-N 114.572 -1.194 . . . . 0.0 110.55 174.198 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 47.0 m -76.32 -37.44 57.38 Favored 'General case' 0 N--CA 1.45 -0.464 0 CA-C-O 121.268 0.556 . . . . 0.0 109.867 175.363 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.601 ' HA ' ' HB1' ' A' ' 105' ' ' ALA . 0.2 OUTLIER -69.23 -36.27 71.93 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 N-CA-C 107.718 -1.216 . . . . 0.0 107.718 175.468 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 31' ' ' TRP . . . . . 0.572 ' CH2' ' HB1' ' A' ' 86' ' ' ALA . 42.1 m95 -70.55 -36.31 73.6 Favored 'General case' 0 C--N 1.318 -0.786 0 CA-C-N 114.401 -1.272 . . . . 0.0 110.487 -179.226 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.883 ' HB2' HH21 ' A' ' 79' ' ' ARG . 23.6 t70 -76.43 -37.66 56.67 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.583 179.271 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 33' ' ' ALA . . . . . 0.476 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -69.58 -33.98 73.5 Favored 'General case' 0 N--CA 1.447 -0.599 0 C-N-CA 120.852 -0.339 . . . . 0.0 110.62 178.331 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 34' ' ' ILE . . . . . 0.537 HG13 ' O ' ' A' ' 30' ' ' ILE . 78.0 mt -64.29 -47.48 89.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-O 121.009 0.433 . . . . 0.0 110.001 172.443 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 35' ' ' ALA . . . . . 0.417 ' HA ' ' O ' ' A' ' 54' ' ' GLY . . . -57.87 -39.79 78.64 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.681 -0.69 . . . . 0.0 110.169 177.446 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 36' ' ' GLY . . . . . 0.518 ' HA2' ' N ' ' A' ' 41' ' ' GLY . . . -70.26 -18.14 74.76 Favored Glycine 0 N--CA 1.453 -0.202 0 CA-C-N 115.501 -0.772 . . . . 0.0 112.135 179.496 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 26.4 t -90.94 -53.04 4.56 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-O 120.931 0.396 . . . . 0.0 111.419 -178.402 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 6.9 tp10 -87.23 -33.2 19.39 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.289 -170.747 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -105.5 -10.63 16.79 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.809 -0.632 . . . . 0.0 111.606 -177.528 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 78.95 14.68 81.72 Favored Glycine 0 CA--C 1.504 -0.598 0 N-CA-C 109.75 -1.34 . . . . 0.0 109.75 -175.206 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 41' ' ' GLY . . . . . 0.518 ' N ' ' HA2' ' A' ' 36' ' ' GLY . . . 78.49 63.25 2.15 Favored Glycine 0 N--CA 1.434 -1.481 0 CA-C-N 114.019 -1.091 . . . . 0.0 111.514 -175.571 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 2.4 t-20 -145.91 96.81 2.86 Favored 'General case' 0 N--CA 1.447 -0.576 0 N-CA-C 109.442 -0.577 . . . . 0.0 109.442 -177.451 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 43' ' ' TRP . . . . . 0.721 ' CE3' ' HA ' ' A' ' 79' ' ' ARG . 29.9 m95 -83.65 -4.1 58.31 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-N 115.561 -0.745 . . . . 0.0 110.385 -175.145 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -109.26 14.65 23.67 Favored 'General case' 0 C--N 1.315 -0.925 0 CA-C-N 114.805 -1.089 . . . . 0.0 110.282 178.017 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.97 HG22 ' HA2' ' A' ' 53' ' ' GLY . 8.9 tt -78.02 139.08 19.14 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.038 0 CA-C-O 121.509 0.671 . . . . 0.0 110.197 -179.148 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 4.4 t30 -139.86 76.58 1.57 Allowed 'General case' 0 C--N 1.308 -1.2 0 N-CA-C 108.593 -0.892 . . . . 0.0 108.593 177.865 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 5.1 p -57.6 -29.2 64.3 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 114.366 -1.288 . . . . 0.0 110.997 -178.982 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 96.06 22.81 19.11 Favored Glycine 0 N--CA 1.437 -1.252 0 N-CA-C 110.922 -0.871 . . . . 0.0 110.922 178.552 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 39.0 p-10 -102.8 4.25 37.65 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 120.881 0.372 . . . . 0.0 111.015 -177.085 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 50' ' ' GLY . . . . . 0.418 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 94.82 -8.09 70.63 Favored Glycine 0 N--CA 1.448 -0.55 0 N-CA-C 111.535 -0.626 . . . . 0.0 111.535 178.639 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 51' ' ' TYR . . . . . 0.577 ' HA ' ' HA ' ' A' ' 58' ' ' ASP . 0.5 OUTLIER -112.64 132.94 54.93 Favored 'General case' 0 N--CA 1.446 -0.65 0 N-CA-C 106.71 -1.589 . . . . 0.0 106.71 -179.094 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 52' ' ' TYR . . . . . 0.696 ' HB2' ' HB3' ' A' ' 74' ' ' ALA . 50.6 m-85 -104.64 171.36 7.37 Favored 'General case' 0 C--N 1.304 -1.375 0 N-CA-C 113.225 0.824 . . . . 0.0 113.225 -165.747 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.97 ' HA2' HG22 ' A' ' 45' ' ' ILE . . . -48.46 155.33 1.47 Allowed Glycine 0 N--CA 1.45 -0.373 0 CA-C-N 114.783 -1.099 . . . . 0.0 115.833 -170.204 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.709 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 94.13 -106.41 3.41 Favored Glycine 0 N--CA 1.438 -1.172 0 CA-C-N 114.706 -0.747 . . . . 0.0 112.179 174.756 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -84.29 -1.52 6.44 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 CA-C-O 121.246 0.546 . . . . 0.0 111.534 -178.812 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 56' ' ' GLN . . . . . 0.556 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 5.4 mm-40 59.21 50.39 8.01 Favored 'General case' 0 N--CA 1.467 0.409 0 CA-C-N 114.502 -1.227 . . . . 0.0 113.965 167.059 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -116.23 160.07 20.94 Favored 'General case' 0 C--N 1.326 -0.431 0 C-N-CA 119.804 -0.758 . . . . 0.0 111.569 173.693 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.577 ' HA ' ' HA ' ' A' ' 51' ' ' TYR . 7.3 p-10 -71.11 160.78 32.27 Favored 'General case' 0 C--N 1.324 -0.506 0 N-CA-C 113.797 1.036 . . . . 0.0 113.797 -163.451 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.491 ' HB2' ' CE2' ' A' ' 52' ' ' TYR . 6.1 tp60 -55.36 -39.96 70.71 Favored 'General case' 0 N--CA 1.446 -0.65 0 CA-C-N 113.987 -1.46 . . . . 0.0 111.438 178.056 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -67.65 -48.66 54.98 Favored Glycine 0 C--O 1.225 -0.467 0 CA-C-N 115.417 -0.81 . . . . 0.0 112.042 -175.816 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 89.0 m -66.4 -40.63 89.74 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-O 121.067 0.46 . . . . 0.0 110.641 177.226 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 62' ' ' TRP . . . . . 0.488 ' HZ3' ' HG3' ' A' ' 82' ' ' GLN . 56.9 t-105 -56.48 -48.98 75.98 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-O 121.622 0.725 . . . . 0.0 109.5 175.407 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 63' ' ' GLU . . . . . 0.785 ' HG3' HD11 ' A' ' 68' ' ' LEU . 27.9 tt0 -66.85 -34.33 77.56 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 115.015 -0.993 . . . . 0.0 110.985 179.845 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -63.96 -41.86 97.44 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.968 -0.56 . . . . 0.0 111.454 -177.441 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 36.5 m-80 -81.52 -7.86 59.64 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.079 -0.51 . . . . 0.0 109.983 175.618 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 66' ' ' GLY . . . . . 0.456 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 83.29 48.34 5.39 Favored Glycine 0 N--CA 1.45 -0.413 0 CA-C-N 115.507 -0.769 . . . . 0.0 112.647 174.975 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.645 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -79.68 -15.98 78.43 Favored Glycine 0 CA--C 1.504 -0.649 0 C-N-CA 120.87 -0.681 . . . . 0.0 111.904 -176.352 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.785 HD11 ' HG3' ' A' ' 63' ' ' GLU . 19.2 mt -61.72 -28.83 69.7 Favored 'General case' 0 C--N 1.314 -0.97 0 C-N-CA 123.346 0.659 . . . . 0.0 111.956 -172.953 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 69' ' ' ARG . . . . . 0.456 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 5.6 ptp180 -68.05 -28.45 67.39 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-O 121.557 0.694 . . . . 0.0 109.789 178.861 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 70' ' ' TYR . . . . . 0.758 ' HB3' ' HG2' ' A' ' 81' ' ' GLU . 89.0 m-85 -81.47 -34.66 31.26 Favored 'General case' 0 N--CA 1.439 -0.983 0 N-CA-C 107.872 -1.158 . . . . 0.0 107.872 176.848 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.586 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 165.33 125.22 0.02 OUTLIER Pre-proline 0 N--CA 1.445 -0.687 0 CA-C-N 112.336 -2.211 . . . . 0.0 107.115 -179.296 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 72' ' ' PRO . . . . . 0.566 ' HA ' ' HA ' ' A' ' 68' ' ' LEU . 26.8 Cg_exo -53.71 -5.97 0.36 Allowed 'Trans proline' 0 C--N 1.334 -0.232 0 C-N-CA 123.14 2.56 . . . . 0.0 114.169 -178.745 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 11.2 ptm180 -148.28 141.0 24.57 Favored 'General case' 0 C--N 1.314 -0.966 0 N-CA-C 109.231 -0.655 . . . . 0.0 109.231 175.387 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 74' ' ' ALA . . . . . 0.696 ' HB3' ' HB2' ' A' ' 52' ' ' TYR . . . -60.72 -27.01 67.59 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.674 -0.694 . . . . 0.0 112.65 -176.39 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 75' ' ' ASP . . . . . 0.601 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 3.5 p30 -80.08 -5.95 56.81 Favored 'General case' 0 C--N 1.322 -0.618 0 C-N-CA 120.007 -0.677 . . . . 0.0 110.921 -177.785 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.542 ' HB3' ' HB1' ' A' ' 71' ' ' ALA . 59.2 tp -97.89 -32.72 11.54 Favored 'General case' 0 C--N 1.321 -0.66 0 N-CA-C 109.113 -0.699 . . . . 0.0 109.113 174.815 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 77' ' ' ALA . . . . . 0.697 ' HB1' ' CB ' ' A' ' 81' ' ' GLU . . . -79.68 164.29 23.87 Favored 'General case' 0 N--CA 1.447 -0.586 0 CA-C-N 115.243 -0.889 . . . . 0.0 109.911 174.485 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 42.8 p -101.13 -173.89 2.48 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 116.573 -0.285 . . . . 0.0 110.801 -177.879 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 79' ' ' ARG . . . . . 0.883 HH21 ' HB2' ' A' ' 32' ' ' ASP . 41.2 mtp180 -50.42 -52.58 36.38 Favored 'General case' 0 CA--C 1.515 -0.402 0 CA-C-O 121.218 0.532 . . . . 0.0 111.295 -178.137 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 80' ' ' GLU . . . . . 0.687 ' HA ' HD12 ' A' ' 83' ' ' ILE . 6.9 pt-20 -66.0 -27.77 68.38 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-N 115.139 -0.937 . . . . 0.0 112.061 -173.873 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 81' ' ' GLU . . . . . 0.758 ' HG2' ' HB3' ' A' ' 70' ' ' TYR . 3.2 mp0 -72.83 -46.26 54.03 Favored 'General case' 0 C--N 1.324 -0.507 0 C-N-CA 120.762 -0.375 . . . . 0.0 111.758 174.239 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 82' ' ' GLN . . . . . 0.632 ' HB2' ' HZ3' ' A' ' 43' ' ' TRP . 0.1 OUTLIER -58.96 -34.72 72.12 Favored 'General case' 0 CA--C 1.506 -0.735 0 N-CA-C 109.108 -0.701 . . . . 0.0 109.108 175.125 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.687 HD12 ' HA ' ' A' ' 80' ' ' GLU . 60.3 mt -60.62 -48.75 87.28 Favored 'Isoleucine or valine' 0 C--O 1.211 -0.957 0 CA-C-N 114.731 -1.122 . . . . 0.0 110.022 173.636 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 84' ' ' ALA . . . . . 0.632 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -63.67 -45.26 90.91 Favored 'General case' 0 C--O 1.238 0.452 0 CA-C-O 121.439 0.637 . . . . 0.0 111.897 -174.98 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.502 HG22 ' HA2' ' A' ' 67' ' ' GLY . 34.8 t -66.52 -48.1 81.58 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.775 0 CA-C-N 115.756 -0.656 . . . . 0.0 110.651 -179.206 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 86' ' ' ALA . . . . . 0.572 ' HB1' ' CH2' ' A' ' 31' ' ' TRP . . . -61.46 -28.08 69.03 Favored 'General case' 0 N--CA 1.45 -0.45 0 CA-C-N 115.468 -0.787 . . . . 0.0 110.415 174.976 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 87' ' ' GLU . . . . . 0.679 ' HG2' ' O ' ' A' ' 83' ' ' ILE . 36.0 mm-40 -59.09 -43.37 91.84 Favored 'General case' 0 CA--C 1.513 -0.457 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.63 179.78 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.522 ' O ' ' HG3' ' A' ' 92' ' ' ARG . 48.8 t -65.27 -42.8 94.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 C-N-CA 120.385 -0.526 . . . . 0.0 109.893 175.851 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 89' ' ' THR . . . . . 0.745 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 0.2 OUTLIER -66.82 -46.88 73.75 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 115.956 -0.565 . . . . 0.0 111.465 -175.271 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 90' ' ' ARG . . . . . 0.483 ' HG3' ' N ' ' A' ' 91' ' ' LEU . 4.9 ptt180 -66.09 -31.18 71.9 Favored 'General case' 0 C--O 1.218 -0.577 0 CA-C-O 122.042 0.925 . . . . 0.0 109.083 -179.018 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 91' ' ' LEU . . . . . 0.483 ' N ' ' HG3' ' A' ' 90' ' ' ARG . 56.3 tp -61.84 -30.5 70.89 Favored 'General case' 0 C--N 1.308 -1.211 0 CA-C-N 114.494 -1.23 . . . . 0.0 111.509 -175.633 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 92' ' ' ARG . . . . . 0.522 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 7.6 mtm180 -90.68 -45.73 8.69 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-N 115.559 -0.746 . . . . 0.0 110.205 -175.402 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 93' ' ' GLN . . . . . 0.532 ' NE2' HG22 ' A' ' 89' ' ' THR . 21.1 pt20 -104.03 -27.32 12.2 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 114.897 -1.047 . . . . 0.0 113.039 -169.923 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.412 ' O ' ' HB2' ' A' ' 90' ' ' ARG . . . 106.75 -107.71 2.74 Favored Glycine 0 N--CA 1.44 -1.034 0 N-CA-C 109.134 -1.586 . . . . 0.0 109.134 -175.214 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 95' ' ' TRP . . . . . 0.556 ' CZ2' HD12 ' A' ' 30' ' ' ILE . 29.7 m95 -138.51 21.56 2.73 Favored 'General case' 0 C--N 1.308 -1.21 0 N-CA-C 106.348 -1.723 . . . . 0.0 106.348 172.995 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -56.26 -35.16 64.31 Favored Glycine 0 C--N 1.335 0.514 0 CA-C-N 114.706 -1.134 . . . . 0.0 112.901 179.752 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -79.25 -15.38 58.1 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.78 0.324 . . . . 0.0 110.533 178.092 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 98' ' ' TRP . . . . . 0.745 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 24.7 m-90 -104.92 107.81 59.59 Favored Pre-proline 0 C--N 1.323 -0.572 0 CA-C-O 121.459 0.647 . . . . 0.0 110.019 178.722 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 99' ' ' PRO . . . . . 0.427 ' HD3' ' HA ' ' A' ' 98' ' ' TRP . 37.6 Cg_exo -64.73 -139.39 0.01 OUTLIER 'Trans proline' 0 CA--C 1.534 0.52 0 C-N-CA 123.764 2.976 . . . . 0.0 114.762 -174.102 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 100' ' ' VAL . . . . . 0.563 ' O ' ' HD2' ' A' ' 104' ' ' ARG . 23.8 t -55.89 -25.84 19.67 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.266 0 CA-C-N 115.441 -0.8 . . . . 0.0 110.746 -178.126 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 89.9 m -60.12 -38.73 83.91 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.321 176.907 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 102' ' ' ALA . . . . . 0.567 ' HB2' ' HB3' ' A' ' 98' ' ' TRP . . . -70.48 -41.2 73.02 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.686 0.279 . . . . 0.0 110.452 178.434 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -59.63 -44.81 93.33 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 121.189 0.519 . . . . 0.0 110.025 178.208 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 104' ' ' ARG . . . . . 0.563 ' HD2' ' O ' ' A' ' 100' ' ' VAL . 0.0 OUTLIER -62.52 -37.01 84.42 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.393 -0.821 . . . . 0.0 111.052 176.787 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 105' ' ' ALA . . . . . 0.601 ' HB1' ' HA ' ' A' ' 30' ' ' ILE . . . -78.77 -22.45 46.36 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 115.624 -0.716 . . . . 0.0 111.905 -176.165 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 114.56 62.13 0.39 Allowed Glycine 0 CA--C 1.519 0.325 0 C-N-CA 121.143 -0.551 . . . . 0.0 112.392 -178.185 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -61.47 140.61 58.04 Favored 'General case' 0 C--O 1.236 0.343 0 C-N-CA 122.789 0.435 . . . . 0.0 110.799 -179.331 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 8.7 ptm180 . . . . . 0 C--O 1.245 0.858 0 CA-C-O 118.556 -0.735 . . . . 0.0 110.555 -172.452 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 23.6 p-10 . . . . . 0 N--CA 1.477 0.904 0 CA-C-O 121.219 0.533 . . . . 0.0 110.352 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 12.4 p -78.64 -27.97 14.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.748 -175.885 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 14.6 p -72.73 134.54 29.59 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.797 0 CA-C-N 116.068 -0.514 . . . . 0.0 109.904 175.324 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 10.7 t -82.64 137.84 20.39 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.571 0 N-CA-C 109.352 -0.61 . . . . 0.0 109.352 179.008 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' THR . . . . . 0.437 ' HA ' ' HD3' ' A' ' 6' ' ' PRO . 8.4 p -96.7 110.29 52.55 Favored Pre-proline 0 C--N 1.314 -0.952 0 CA-C-N 115.602 -0.726 . . . . 0.0 111.342 -175.819 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.437 ' HD3' ' HA ' ' A' ' 5' ' ' THR . 3.1 Cg_exo -81.7 171.87 12.83 Favored 'Trans proline' 0 N--CA 1.452 -0.92 0 C-N-CA 123.379 2.72 . . . . 0.0 111.925 179.512 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 7' ' ' ALA . . . . . 0.442 ' O ' ' HB3' ' A' ' 8' ' ' HIS . . . -124.46 -165.15 1.33 Allowed 'General case' 0 C--N 1.311 -1.102 0 CA-C-N 114.37 -1.286 . . . . 0.0 110.335 -179.011 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 8' ' ' HIS . . . . . 0.442 ' HB3' ' O ' ' A' ' 7' ' ' ALA . 51.2 t-80 75.92 -9.81 1.38 Allowed 'General case' 0 C--O 1.232 0.172 0 O-C-N 124.262 0.976 . . . . 0.0 109.704 -172.533 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 7.9 pt-20 -91.1 138.22 31.77 Favored 'General case' 0 N--CA 1.452 -0.352 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.178 177.561 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -143.57 73.58 1.4 Allowed 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 115.858 -0.61 . . . . 0.0 109.938 178.993 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 96.1 t -65.57 -50.47 71.7 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.669 0 CA-C-N 115.209 -0.905 . . . . 0.0 110.169 179.732 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 79.7 t 27.97 84.58 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.447 -0.623 0 C-N-CA 125.011 1.324 . . . . 0.0 113.147 178.588 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' ARG . . . . . 0.601 ' HD3' ' H ' ' A' ' 13' ' ' ARG . 0.1 OUTLIER -107.35 115.59 30.44 Favored 'General case' 0 C--N 1.303 -1.432 0 CA-C-N 114.095 -1.411 . . . . 0.0 109.644 179.967 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.9 t -110.99 161.3 9.55 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.254 0 CA-C-N 114.514 -1.221 . . . . 0.0 109.25 -179.452 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 104.13 76.08 1.08 Allowed Glycine 0 N--CA 1.434 -1.484 0 CA-C-N 115.124 -0.944 . . . . 0.0 111.557 -178.895 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 41.7 m -73.46 -23.52 60.1 Favored 'General case' 0 N--CA 1.442 -0.838 0 CA-C-O 121.485 0.66 . . . . 0.0 110.039 179.066 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' LYS . . . . . 0.451 ' N ' ' HD3' ' A' ' 18' ' ' PRO . 73.1 mmtt 52.99 64.68 6.83 Favored Pre-proline 0 C--N 1.32 -0.679 0 CA-C-N 114.311 -1.313 . . . . 0.0 112.109 179.754 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 18' ' ' PRO . . . . . 0.451 ' HD3' ' N ' ' A' ' 17' ' ' LYS . 36.3 Cg_exo -69.29 115.92 4.26 Favored 'Trans proline' 0 CA--C 1.505 -0.946 0 C-N-CA 122.969 2.446 . . . . 0.0 111.669 174.283 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 170.35 39.38 0.03 OUTLIER Glycine 0 C--N 1.297 -1.633 0 CA-C-N 113.728 -1.578 . . . . 0.0 112.534 179.436 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 28.6 m -69.36 -39.27 78.17 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-O 121.439 0.638 . . . . 0.0 109.602 175.29 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 21' ' ' GLU . . . . . 0.449 ' O ' ' HD3' ' A' ' 23' ' ' PRO . 37.8 mt-10 -148.04 150.69 34.39 Favored 'General case' 0 N--CA 1.443 -0.805 0 N-CA-C 108.004 -1.11 . . . . 0.0 108.004 179.81 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 53.6 t -84.63 110.68 29.14 Favored Pre-proline 0 C--N 1.309 -1.181 0 N-CA-C 109.526 -0.546 . . . . 0.0 109.526 175.365 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.449 ' HD3' ' O ' ' A' ' 21' ' ' GLU . 49.3 Cg_exo -55.56 141.78 82.59 Favored 'Trans proline' 0 C--N 1.345 0.38 0 C-N-CA 123.117 2.545 . . . . 0.0 111.827 179.99 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 10.8 Cg_endo -55.18 140.13 80.91 Favored 'Trans proline' 0 N--CA 1.455 -0.755 0 C-N-CA 123.02 2.48 . . . . 0.0 111.728 179.43 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.591 HG12 ' H ' ' A' ' 27' ' ' ASP . 49.5 t -116.72 131.32 69.71 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.044 0 CA-C-N 114.968 -1.014 . . . . 0.0 110.601 -174.062 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.441 ' N ' HD12 ' A' ' 26' ' ' ILE . 3.3 mp -72.8 -25.18 21.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 115.51 -0.768 . . . . 0.0 109.906 -176.595 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.591 ' H ' HG12 ' A' ' 25' ' ' VAL . 4.3 m-20 -91.65 -0.27 57.56 Favored 'General case' 0 CA--C 1.503 -0.846 0 CA-C-N 115.239 -0.892 . . . . 0.0 109.904 -175.876 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -61.21 -15.22 43.57 Favored Glycine 0 CA--C 1.505 -0.565 0 CA-C-N 114.904 -1.043 . . . . 0.0 110.543 177.646 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 23.2 m -77.28 -37.23 53.28 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 114.666 -0.767 . . . . 0.0 110.068 177.598 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.556 ' O ' HG13 ' A' ' 34' ' ' ILE . 1.1 mm -71.38 -39.08 71.36 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.751 0 N-CA-C 107.029 -1.471 . . . . 0.0 107.029 178.693 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 31' ' ' TRP . . . . . 0.621 ' HZ2' ' HD3' ' A' ' 90' ' ' ARG . 24.3 m95 -68.54 -36.91 79.48 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-N 114.054 -1.43 . . . . 0.0 110.793 -176.154 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 7.8 t70 -74.92 -36.2 62.17 Favored 'General case' 0 N--CA 1.444 -0.743 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.587 177.203 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 33' ' ' ALA . . . . . 0.455 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -70.92 -35.52 72.29 Favored 'General case' 0 N--CA 1.448 -0.533 0 C-N-CA 120.736 -0.386 . . . . 0.0 110.846 178.937 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 34' ' ' ILE . . . . . 0.556 HG13 ' O ' ' A' ' 30' ' ' ILE . 75.8 mt -66.96 -46.07 85.75 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.222 0 CA-C-O 120.987 0.423 . . . . 0.0 110.002 174.662 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -57.61 -38.22 74.57 Favored 'General case' 0 CA--C 1.515 -0.373 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.297 176.92 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 36' ' ' GLY . . . . . 0.549 ' HA2' ' CA ' ' A' ' 41' ' ' GLY . . . -77.96 -1.64 79.69 Favored Glycine 0 N--CA 1.449 -0.436 0 CA-C-N 115.421 -0.809 . . . . 0.0 112.028 179.341 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 38.5 t -106.61 -57.09 2.1 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 115.825 -0.187 . . . . 0.0 111.361 -177.319 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 38' ' ' GLU . . . . . 0.824 ' HG3' ' SG ' ' A' ' 101' ' ' CYS . 9.9 mt-10 -88.09 -30.83 19.58 Favored 'General case' 0 CA--C 1.514 -0.422 0 C-N-CA 120.949 -0.301 . . . . 0.0 111.101 -175.207 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -96.68 -7.44 34.07 Favored 'General case' 0 N--CA 1.449 -0.488 0 C-N-CA 120.765 -0.374 . . . . 0.0 111.527 -179.079 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 82.09 2.6 90.61 Favored Glycine 0 CA--C 1.505 -0.575 0 N-CA-C 110.0 -1.24 . . . . 0.0 110.0 -177.962 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 41' ' ' GLY . . . . . 0.549 ' CA ' ' HA2' ' A' ' 36' ' ' GLY . . . 89.76 54.62 2.17 Favored Glycine 0 N--CA 1.433 -1.511 0 CA-C-N 114.208 -0.996 . . . . 0.0 111.807 -178.043 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 53.0 t30 -147.82 124.57 11.18 Favored 'General case' 0 N--CA 1.443 -0.793 0 N-CA-C 109.147 -0.686 . . . . 0.0 109.147 -178.983 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 43' ' ' TRP . . . . . 0.78 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 20.5 m95 -99.44 1.61 44.32 Favored 'General case' 0 C--N 1.301 -1.527 0 CA-C-N 115.132 -0.94 . . . . 0.0 110.004 -174.467 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -111.59 5.48 19.42 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.088 -0.96 . . . . 0.0 111.102 177.188 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 13.0 tt -75.26 143.32 13.42 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.769 0 CA-C-O 120.946 0.403 . . . . 0.0 110.196 -178.927 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 40.7 t-20 -156.46 96.62 1.68 Allowed 'General case' 0 C--N 1.311 -1.089 0 CA-C-O 121.154 0.502 . . . . 0.0 109.826 179.399 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 20.5 p -76.72 -22.0 54.5 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 115.782 -0.645 . . . . 0.0 111.262 -177.154 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 98.33 21.73 16.62 Favored Glycine 0 N--CA 1.442 -0.902 0 CA-C-N 115.549 -0.751 . . . . 0.0 111.272 -179.016 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 66.3 t30 -91.16 11.89 21.8 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 121.59 0.71 . . . . 0.0 110.934 -177.358 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 84.58 -14.41 46.92 Favored Glycine 0 N--CA 1.453 -0.224 0 N-CA-C 111.234 -0.746 . . . . 0.0 111.234 -178.281 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 51' ' ' TYR . . . . . 0.628 ' CE1' ' HB2' ' A' ' 58' ' ' ASP . 0.5 OUTLIER -98.07 142.4 29.81 Favored 'General case' 0 N--CA 1.445 -0.693 0 N-CA-C 108.174 -1.047 . . . . 0.0 108.174 173.226 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 52' ' ' TYR . . . . . 0.821 ' CE1' ' HB2' ' A' ' 59' ' ' GLN . 4.7 m-85 -108.56 170.28 8.12 Favored 'General case' 0 C--N 1.311 -1.097 0 CA-C-N 116.019 -0.537 . . . . 0.0 111.456 -174.323 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -58.89 172.56 4.07 Favored Glycine 0 N--CA 1.452 -0.286 0 N-CA-C 115.123 0.809 . . . . 0.0 115.123 -170.202 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.764 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 87.01 -111.73 3.7 Favored Glycine 0 N--CA 1.443 -0.865 0 C-N-CA 120.962 -0.637 . . . . 0.0 111.577 -179.607 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.508 HG11 ' CE3' ' A' ' 31' ' ' TRP . 6.2 t -84.28 6.43 2.02 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.74 0 CA-C-O 121.736 0.779 . . . . 0.0 109.778 179.959 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 56' ' ' GLN . . . . . 0.715 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 52.3 tp60 53.54 51.91 14.31 Favored 'General case' 0 C--O 1.236 0.366 0 CA-C-N 114.427 -1.26 . . . . 0.0 112.872 164.816 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 6.9 p90 -120.15 167.94 11.72 Favored 'General case' 0 N--CA 1.443 -0.801 0 C-N-CA 119.555 -0.858 . . . . 0.0 111.897 174.245 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.628 ' HB2' ' CE1' ' A' ' 51' ' ' TYR . 0.6 OUTLIER -71.09 141.81 50.82 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 114.242 -1.345 . . . . 0.0 113.062 -165.636 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.821 ' HB2' ' CE1' ' A' ' 52' ' ' TYR . 5.3 tp60 -56.2 -38.12 70.56 Favored 'General case' 0 N--CA 1.446 -0.628 0 CA-C-N 113.389 -1.732 . . . . 0.0 111.522 178.074 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -63.89 -48.93 71.5 Favored Glycine 0 N--CA 1.441 -1.006 0 CA-C-N 115.938 -0.573 . . . . 0.0 112.019 178.102 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 68.8 m -61.47 -42.21 98.43 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 121.279 0.561 . . . . 0.0 110.4 175.076 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 62' ' ' TRP . . . . . 0.455 ' CZ3' ' HA ' ' A' ' 82' ' ' GLN . 43.4 t-105 -56.13 -49.83 72.81 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.055 -0.975 . . . . 0.0 109.981 175.635 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 63' ' ' GLU . . . . . 0.631 ' HG3' HD11 ' A' ' 68' ' ' LEU . 29.3 tt0 -66.8 -39.36 87.71 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 115.195 -0.912 . . . . 0.0 110.756 -178.663 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -62.25 -39.5 93.07 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.553 -0.749 . . . . 0.0 110.92 -176.922 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 65' ' ' ASN . . . . . 0.586 ' OD1' ' HB ' ' A' ' 89' ' ' THR . 10.7 m120 -75.59 -21.14 58.08 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.198 177.014 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 101.7 39.36 2.97 Favored Glycine 0 N--CA 1.449 -0.493 0 C-N-CA 120.957 -0.64 . . . . 0.0 112.28 178.317 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.655 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -79.25 -16.66 77.99 Favored Glycine 0 N--CA 1.44 -1.048 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.073 -173.915 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.631 HD11 ' HG3' ' A' ' 63' ' ' GLU . 26.4 mt -63.55 -23.76 67.52 Favored 'General case' 0 N--CA 1.442 -0.828 0 CA-C-N 115.502 -0.349 . . . . 0.0 111.566 -172.932 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 69' ' ' ARG . . . . . 0.57 ' HG3' ' N ' ' A' ' 70' ' ' TYR . 0.0 OUTLIER -70.77 -32.68 69.89 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 121.186 0.517 . . . . 0.0 110.068 176.165 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 70' ' ' TYR . . . . . 0.692 ' HB3' ' CG ' ' A' ' 81' ' ' GLU . 86.9 m-85 -76.13 -33.17 59.43 Favored 'General case' 0 CA--C 1.503 -0.852 0 N-CA-C 107.574 -1.269 . . . . 0.0 107.574 -179.934 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.754 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 163.26 125.48 0.01 OUTLIER Pre-proline 0 C--N 1.321 -0.654 0 CA-C-N 111.903 -2.408 . . . . 0.0 106.688 179.293 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 72' ' ' PRO . . . . . 0.606 ' HA ' ' HA ' ' A' ' 68' ' ' LEU . 17.3 Cg_exo -55.16 -4.0 0.37 Allowed 'Trans proline' 0 C--N 1.331 -0.342 0 C-N-CA 122.85 2.366 . . . . 0.0 113.633 -179.799 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 73' ' ' ARG . . . . . 0.401 ' HB2' ' CD2' ' A' ' 52' ' ' TYR . 14.8 ptm180 -145.83 136.94 24.7 Favored 'General case' 0 C--N 1.317 -0.836 0 CA-C-O 121.269 0.557 . . . . 0.0 109.657 176.6 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 74' ' ' ALA . . . . . 0.499 ' HB3' ' HB2' ' A' ' 52' ' ' TYR . . . -63.43 -25.49 68.3 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 115.455 -0.793 . . . . 0.0 111.914 -177.467 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 75' ' ' ASP . . . . . 0.484 ' OD1' ' HD2' ' A' ' 52' ' ' TYR . 26.9 p-10 -88.16 10.0 20.88 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-O 121.292 0.568 . . . . 0.0 110.847 -177.714 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 68.7 tp -113.0 -34.43 5.74 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.46 -0.791 . . . . 0.0 109.048 168.121 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 77' ' ' ALA . . . . . 0.754 ' HB2' ' HB3' ' A' ' 71' ' ' ALA . . . -78.31 153.43 31.75 Favored 'General case' 0 N--CA 1.443 -0.799 0 CA-C-N 115.357 -0.838 . . . . 0.0 109.851 177.687 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 33.5 p -96.54 -173.98 2.91 Favored 'General case' 0 C--N 1.317 -0.84 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.35 -176.951 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 79' ' ' ARG . . . . . 0.78 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 49.1 mtt85 -50.63 -52.56 38.43 Favored 'General case' 0 CA--C 1.513 -0.46 0 O-C-N 123.519 0.512 . . . . 0.0 111.549 -178.06 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 80' ' ' GLU . . . . . 0.563 ' HG3' ' OE2' ' A' ' 81' ' ' GLU . 9.3 pt-20 -59.28 -42.96 92.5 Favored 'General case' 0 C--N 1.318 -0.786 0 CA-C-N 116.026 -0.534 . . . . 0.0 111.962 -176.627 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 81' ' ' GLU . . . . . 0.692 ' CG ' ' HB3' ' A' ' 70' ' ' TYR . 4.9 mp0 -63.68 -51.99 62.64 Favored 'General case' 0 N--CA 1.454 -0.229 0 N-CA-C 112.094 0.405 . . . . 0.0 112.094 173.987 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 82' ' ' GLN . . . . . 0.46 ' NE2' ' HE3' ' A' ' 43' ' ' TRP . 51.4 mt-30 -59.16 -43.35 92.07 Favored 'General case' 0 CA--C 1.509 -0.611 0 CA-C-O 121.067 0.461 . . . . 0.0 110.459 -176.303 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.668 ' O ' ' HG2' ' A' ' 87' ' ' GLU . 34.3 mt -59.53 -41.88 86.23 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.793 0 CA-C-N 115.157 -0.928 . . . . 0.0 110.006 -178.886 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 84' ' ' ALA . . . . . 0.615 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -64.52 -42.8 95.55 Favored 'General case' 0 C--O 1.236 0.394 0 CA-C-O 121.705 0.764 . . . . 0.0 111.043 -177.793 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.431 HG22 ' HA2' ' A' ' 67' ' ' GLY . 48.3 t -65.53 -49.12 80.01 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 CA-C-N 115.539 -0.755 . . . . 0.0 110.906 178.188 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 86' ' ' ALA . . . . . 0.405 ' HB1' ' CH2' ' A' ' 31' ' ' TRP . . . -58.48 -30.47 67.01 Favored 'General case' 0 N--CA 1.452 -0.362 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.534 173.965 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 87' ' ' GLU . . . . . 0.668 ' HG2' ' O ' ' A' ' 83' ' ' ILE . 26.4 mm-40 -58.99 -44.06 91.56 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.45 -178.749 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.569 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 98.1 t -64.18 -50.68 75.71 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 C-N-CA 120.555 -0.458 . . . . 0.0 110.622 -179.799 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 89' ' ' THR . . . . . 0.586 ' HB ' ' OD1' ' A' ' 65' ' ' ASN . 12.5 t -73.59 -35.63 65.44 Favored 'General case' 0 C--N 1.318 -0.793 0 C-N-CA 120.796 -0.362 . . . . 0.0 111.66 -174.612 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 90' ' ' ARG . . . . . 0.641 ' HG3' ' N ' ' A' ' 91' ' ' LEU . 10.9 ptt85 -60.77 -41.6 95.82 Favored 'General case' 0 N--CA 1.471 0.597 0 CA-C-N 117.919 0.327 . . . . 0.0 110.783 -179.194 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 91' ' ' LEU . . . . . 0.641 ' N ' ' HG3' ' A' ' 90' ' ' ARG . 4.5 pp -69.8 -23.83 63.39 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.845 -0.616 . . . . 0.0 111.419 -172.43 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 92' ' ' ARG . . . . . 0.546 ' NE ' ' HA ' ' A' ' 89' ' ' THR . 1.9 mtm180 -81.22 -47.96 12.71 Favored 'General case' 0 N--CA 1.447 -0.606 0 CA-C-O 121.576 0.703 . . . . 0.0 109.468 -178.948 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 93' ' ' GLN . . . . . 0.615 ' NE2' ' HB2' ' A' ' 97' ' ' ALA . 3.5 pt20 -95.94 -27.14 15.3 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 114.731 -1.122 . . . . 0.0 112.872 -167.633 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 91.76 39.86 5.43 Favored Glycine 0 CA--C 1.504 -0.615 0 C-N-CA 120.344 -0.931 . . . . 0.0 111.985 170.441 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 95' ' ' TRP . . . . . 0.447 ' HB3' ' HB1' ' A' ' 102' ' ' ALA . 6.9 m95 63.74 17.27 10.35 Favored 'General case' 0 C--O 1.22 -0.474 0 N-CA-C 109.255 -0.646 . . . . 0.0 109.255 -179.231 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -70.47 -30.29 69.12 Favored Glycine 0 N--CA 1.451 -0.344 0 CA-C-N 115.504 -0.771 . . . . 0.0 112.598 177.989 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 97' ' ' ALA . . . . . 0.615 ' HB2' ' NE2' ' A' ' 93' ' ' GLN . . . -69.99 -30.11 67.36 Favored 'General case' 0 CA--C 1.514 -0.439 0 CA-C-O 120.924 0.392 . . . . 0.0 110.21 177.488 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 98' ' ' TRP . . . . . 0.509 ' HB2' ' HB2' ' A' ' 102' ' ' ALA . 25.6 m-90 -98.47 104.55 24.45 Favored Pre-proline 0 C--N 1.323 -0.571 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 177.353 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_exo -70.99 -94.2 0.01 OUTLIER 'Trans proline' 0 CA--C 1.534 0.505 0 C-N-CA 122.889 2.393 . . . . 0.0 114.734 -172.22 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 60.6 t -70.99 -31.95 46.84 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 CA-C-O 121.822 0.82 . . . . 0.0 110.19 -173.98 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 101' ' ' CYS . . . . . 0.824 ' SG ' ' HG3' ' A' ' 38' ' ' GLU . 75.6 m -78.26 -26.1 47.05 Favored 'General case' 0 C--N 1.315 -0.932 0 CA-C-N 114.772 -1.104 . . . . 0.0 112.27 -168.832 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 102' ' ' ALA . . . . . 0.509 ' HB2' ' HB2' ' A' ' 98' ' ' TRP . . . -69.93 -46.19 65.89 Favored 'General case' 0 C--N 1.326 -0.444 0 C-N-CA 120.549 -0.461 . . . . 0.0 110.23 176.249 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -65.33 -35.92 82.46 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.699 -179.358 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 104' ' ' ARG . . . . . 0.471 ' HG2' ' HA ' ' A' ' 101' ' ' CYS . 0.0 OUTLIER -73.41 -21.45 60.48 Favored 'General case' 0 N--CA 1.444 -0.725 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.425 179.785 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 105' ' ' ALA . . . . . 0.466 ' HB1' ' HA ' ' A' ' 30' ' ' ILE . . . -96.08 -22.82 17.1 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.821 -0.627 . . . . 0.0 111.581 -178.157 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 119.02 63.66 0.29 Allowed Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 121.236 -0.507 . . . . 0.0 112.236 -176.86 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -64.09 145.15 56.42 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.776 0.322 . . . . 0.0 110.782 179.36 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 51.8 mtp180 . . . . . 0 C--O 1.249 1.06 0 CA-C-O 118.395 -0.812 . . . . 0.0 110.332 -173.293 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 5.3 m-20 . . . . . 0 N--CA 1.482 1.143 0 CA-C-O 121.198 0.523 . . . . 0.0 110.607 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 61.9 t -75.99 -43.46 38.78 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 CA-C-N 115.616 -0.72 . . . . 0.0 109.472 177.558 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 48.6 t -77.77 95.65 1.63 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.798 0 CA-C-N 115.701 -0.681 . . . . 0.0 109.481 173.74 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 11.5 t -75.56 144.68 11.71 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.044 -177.894 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' THR . . . . . 0.414 ' HA ' ' HD3' ' A' ' 6' ' ' PRO . 11.3 p -103.92 107.75 57.78 Favored Pre-proline 0 C--N 1.314 -0.955 0 CA-C-N 115.874 -0.603 . . . . 0.0 111.045 -177.571 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.414 ' HD3' ' HA ' ' A' ' 5' ' ' THR . 1.5 Cg_endo -86.1 170.13 8.48 Favored 'Trans proline' 0 N--CA 1.448 -1.169 0 C-N-CA 123.502 2.801 . . . . 0.0 111.263 177.329 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -82.7 81.96 8.25 Favored 'General case' 0 C--N 1.307 -1.245 0 CA-C-N 114.892 -1.049 . . . . 0.0 110.985 -179.292 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 31.8 m170 -74.87 -18.45 60.43 Favored 'General case' 0 C--N 1.316 -0.883 0 N-CA-C 107.666 -1.235 . . . . 0.0 107.666 169.821 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 12.7 pt-20 -115.11 132.15 56.7 Favored 'General case' 0 N--CA 1.44 -0.934 0 CA-C-N 114.795 -1.093 . . . . 0.0 109.609 175.607 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -147.38 73.51 1.29 Allowed 'General case' 0 C--N 1.321 -0.65 0 CA-C-O 121.523 0.678 . . . . 0.0 110.412 -179.152 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 58.0 t -75.21 -56.39 8.91 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.711 0 CA-C-N 114.938 -1.028 . . . . 0.0 110.439 -179.297 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 72.1 t 21.52 84.33 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.451 -0.414 0 C-N-CA 125.598 1.559 . . . . 0.0 113.162 177.272 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' ARG . . . . . 0.42 ' O ' ' HG3' ' A' ' 13' ' ' ARG . 6.6 ptp180 -70.29 112.44 6.62 Favored 'General case' 0 C--N 1.306 -1.308 0 CA-C-N 114.098 -1.41 . . . . 0.0 110.106 -179.646 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.481 HG22 ' N ' ' A' ' 15' ' ' GLY . 7.4 p -72.48 163.04 4.09 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.42 0 CA-C-N 114.021 -1.445 . . . . 0.0 110.392 178.49 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 15' ' ' GLY . . . . . 0.485 ' O ' ' HG3' ' A' ' 17' ' ' LYS . . . -90.52 -75.62 1.3 Allowed Glycine 0 C--N 1.299 -1.516 0 CA-C-N 113.654 -1.612 . . . . 0.0 111.03 -176.724 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.479 ' C ' ' HD3' ' A' ' 18' ' ' PRO . 93.6 m 63.98 -21.99 0.07 Allowed 'General case' 0 N--CA 1.437 -1.115 0 N-CA-C 114.653 1.353 . . . . 0.0 114.653 176.708 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 17' ' ' LYS . . . . . 0.782 ' HD2' ' O ' ' A' ' 17' ' ' LYS . 0.0 OUTLIER -114.05 74.94 2.84 Favored Pre-proline 0 C--N 1.319 -0.742 0 N-CA-C 112.814 0.672 . . . . 0.0 112.814 178.487 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 18' ' ' PRO . . . . . 0.479 ' HD3' ' C ' ' A' ' 16' ' ' THR . 31.5 Cg_exo -66.54 115.06 3.33 Favored 'Trans proline' 0 CA--C 1.509 -0.75 0 C-N-CA 123.217 2.612 . . . . 0.0 112.427 178.045 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -112.45 -53.19 0.5 Allowed Glycine 0 C--N 1.299 -1.523 0 CA-C-N 113.448 -1.705 . . . . 0.0 111.342 179.786 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 13.7 m -69.56 -42.8 74.05 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.494 -0.353 . . . . 0.0 110.9 178.368 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 34.8 mt-10 47.01 87.94 0.02 OUTLIER 'General case' 0 N--CA 1.453 -0.279 0 CA-C-O 121.769 0.795 . . . . 0.0 112.431 -176.088 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.716 HG21 ' HB ' ' A' ' 78' ' ' THR . 37.8 t -92.17 124.14 60.61 Favored Pre-proline 0 C--N 1.312 -1.054 0 CA-C-N 114.926 -1.034 . . . . 0.0 109.785 -178.866 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.457 ' HA ' ' HD3' ' A' ' 24' ' ' PRO . 45.1 Cg_exo -57.54 127.11 24.11 Favored 'Trans proline' 0 N--CA 1.461 -0.412 0 C-N-CA 122.867 2.378 . . . . 0.0 112.786 -177.923 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 24' ' ' PRO . . . . . 0.457 ' HD3' ' HA ' ' A' ' 23' ' ' PRO . 23.0 Cg_exo -68.11 142.93 57.7 Favored 'Trans proline' 0 N--CA 1.435 -1.944 0 C-N-CA 123.447 2.764 . . . . 0.0 113.205 177.535 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 44.1 t -102.31 158.22 4.55 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.141 0 CA-C-N 114.478 -1.237 . . . . 0.0 108.18 173.331 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 46.2 mm -54.56 -38.93 43.71 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.695 0 CA-C-O 121.001 0.429 . . . . 0.0 111.683 -173.284 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 15.0 m-20 -103.87 3.99 34.39 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-O 121.865 0.84 . . . . 0.0 109.532 -179.172 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 28' ' ' GLY . . . . . 0.463 ' HA2' ' HB2' ' A' ' 31' ' ' TRP . . . -70.23 -6.32 56.98 Favored Glycine 0 N--CA 1.44 -1.057 0 CA-C-N 114.481 -1.236 . . . . 0.0 110.38 176.526 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 9.6 m -76.96 -39.4 50.71 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-O 121.659 0.742 . . . . 0.0 109.087 174.661 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.496 ' O ' HG13 ' A' ' 34' ' ' ILE . 1.0 OUTLIER -69.65 -38.1 75.64 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.576 0 N-CA-C 107.492 -1.299 . . . . 0.0 107.492 177.366 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 31' ' ' TRP . . . . . 0.513 ' CD1' HG23 ' A' ' 83' ' ' ILE . 43.2 m95 -71.41 -35.91 71.16 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 114.262 -1.336 . . . . 0.0 110.487 -177.857 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.533 ' HB2' HH21 ' A' ' 79' ' ' ARG . 15.5 t70 -74.28 -34.56 63.6 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.385 178.328 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -69.89 -34.47 73.59 Favored 'General case' 0 N--CA 1.446 -0.629 0 C-N-CA 120.756 -0.377 . . . . 0.0 110.12 177.705 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 34' ' ' ILE . . . . . 0.566 ' HA ' ' HB3' ' A' ' 101' ' ' CYS . 61.9 mt -67.33 -47.44 81.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.312 174.399 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 35' ' ' ALA . . . . . 0.445 ' HA ' ' O ' ' A' ' 54' ' ' GLY . . . -58.76 -39.14 80.12 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.501 177.554 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -76.13 -8.79 85.42 Favored Glycine 0 N--CA 1.451 -0.337 0 CA-C-N 115.559 -0.746 . . . . 0.0 112.081 179.603 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 1.7 t -97.16 -57.96 2.13 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-O 120.678 0.275 . . . . 0.0 111.417 -178.6 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 38' ' ' GLU . . . . . 0.545 ' HB2' ' SG ' ' A' ' 101' ' ' CYS . 8.0 tp10 -87.97 -33.02 18.57 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 121.207 0.527 . . . . 0.0 109.999 -171.315 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 39' ' ' ALA . . . . . 0.412 ' HB3' ' O ' ' A' ' 35' ' ' ALA . . . -95.71 -13.05 24.52 Favored 'General case' 0 N--CA 1.448 -0.538 0 CA-C-N 115.631 -0.713 . . . . 0.0 111.197 -178.749 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 82.52 1.34 90.47 Favored Glycine 0 N--CA 1.448 -0.505 0 N-CA-C 109.983 -1.247 . . . . 0.0 109.983 -177.04 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 93.65 55.63 1.52 Allowed Glycine 0 N--CA 1.436 -1.327 0 CA-C-N 114.372 -0.914 . . . . 0.0 111.61 -176.543 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 42' ' ' ASN . . . . . 0.556 ' HB3' ' HB ' ' A' ' 45' ' ' ILE . 17.5 t-20 -142.93 94.6 2.65 Favored 'General case' 0 N--CA 1.447 -0.606 0 N-CA-C 108.704 -0.85 . . . . 0.0 108.704 -177.689 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 43' ' ' TRP . . . . . 0.754 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 38.3 m95 -76.65 -10.71 59.58 Favored 'General case' 0 C--N 1.317 -0.844 0 CA-C-O 121.384 0.611 . . . . 0.0 110.423 -175.385 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 44' ' ' ALA . . . . . 0.426 ' HA ' ' HB2' ' A' ' 75' ' ' ASP . . . -107.73 15.38 24.66 Favored 'General case' 0 C--N 1.318 -0.795 0 CA-C-N 114.981 -1.009 . . . . 0.0 111.731 -178.624 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.746 HG22 ' HA2' ' A' ' 53' ' ' GLY . 9.9 tt -83.21 142.42 13.56 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.619 0 CA-C-O 121.432 0.634 . . . . 0.0 111.344 -175.639 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 46' ' ' ASN . . . . . 0.41 HD22 ' HA ' ' A' ' 46' ' ' ASN . 9.7 m120 -133.53 88.19 2.46 Favored 'General case' 0 C--N 1.316 -0.873 0 N-CA-C 108.539 -0.911 . . . . 0.0 108.539 176.663 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 1.2 p -69.31 -24.09 63.89 Favored 'General case' 0 C--N 1.315 -0.934 0 CA-C-N 115.769 -0.651 . . . . 0.0 110.603 179.708 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 94.57 19.0 33.51 Favored Glycine 0 N--CA 1.444 -0.795 0 N-CA-C 111.272 -0.731 . . . . 0.0 111.272 176.412 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 30.7 p-10 -94.7 11.62 30.64 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.141 0.496 . . . . 0.0 111.134 -175.301 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 50' ' ' GLY . . . . . 0.452 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 89.9 -11.59 70.07 Favored Glycine 0 N--CA 1.445 -0.724 0 N-CA-C 110.823 -0.911 . . . . 0.0 110.823 -178.243 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 51' ' ' TYR . . . . . 0.604 ' CE1' ' HB3' ' A' ' 58' ' ' ASP . 0.8 OUTLIER -109.94 151.64 26.85 Favored 'General case' 0 CA--C 1.512 -0.488 0 N-CA-C 107.827 -1.175 . . . . 0.0 107.827 178.722 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 52' ' ' TYR . . . . . 0.633 ' CE1' ' HB2' ' A' ' 59' ' ' GLN . 24.2 m-85 -115.36 170.4 8.43 Favored 'General case' 0 C--N 1.313 -0.995 0 C-N-CA 120.647 -0.421 . . . . 0.0 111.316 -170.294 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.746 ' HA2' HG22 ' A' ' 45' ' ' ILE . . . -56.92 166.72 4.72 Favored Glycine 0 N--CA 1.451 -0.354 0 N-CA-C 114.818 0.687 . . . . 0.0 114.818 -169.744 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.678 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 88.19 -103.78 2.97 Favored Glycine 0 N--CA 1.444 -0.791 0 C-N-CA 121.253 -0.499 . . . . 0.0 112.237 177.305 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.516 HG12 ' HE1' ' A' ' 98' ' ' TRP . 2.5 t -83.27 -2.82 6.95 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 CA-C-O 121.445 0.64 . . . . 0.0 109.785 -177.873 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 56' ' ' GLN . . . . . 0.613 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 2.0 mm-40 55.91 42.33 28.94 Favored 'General case' 0 N--CA 1.462 0.139 0 CA-C-N 114.747 -1.115 . . . . 0.0 113.102 169.727 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 57' ' ' PHE . . . . . 0.487 ' CD1' ' HB ' ' A' ' 55' ' ' VAL . 1.5 p90 -114.88 165.63 12.64 Favored 'General case' 0 C--N 1.322 -0.616 0 C-N-CA 119.912 -0.715 . . . . 0.0 111.041 175.253 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.604 ' HB3' ' CE1' ' A' ' 51' ' ' TYR . 8.1 p-10 -76.02 155.56 34.82 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 122.075 0.941 . . . . 0.0 112.619 -164.238 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.633 ' HB2' ' CE1' ' A' ' 52' ' ' TYR . 3.6 tp-100 -61.42 -32.11 72.06 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 113.414 -1.721 . . . . 0.0 111.14 179.767 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -65.94 -49.5 58.26 Favored Glycine 0 C--N 1.316 -0.553 0 CA-C-N 115.48 -0.782 . . . . 0.0 111.786 -179.862 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 90.9 m -66.67 -40.75 88.75 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-O 120.787 0.327 . . . . 0.0 110.996 175.979 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 62' ' ' TRP . . . . . 0.473 ' CH2' ' HA ' ' A' ' 74' ' ' ALA . 46.2 t-105 -56.38 -49.53 74.18 Favored 'General case' 0 N--CA 1.45 -0.462 0 CA-C-O 121.656 0.741 . . . . 0.0 109.293 176.137 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 63' ' ' GLU . . . . . 0.431 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 33.6 tt0 -68.11 -32.28 72.47 Favored 'General case' 0 N--CA 1.444 -0.763 0 CA-C-N 115.022 -0.99 . . . . 0.0 110.855 179.857 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -64.26 -39.03 93.11 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.891 -179.588 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 65' ' ' ASN . . . . . 0.578 ' HB2' HG13 ' A' ' 85' ' ' VAL . 5.5 m120 -78.76 -14.05 59.48 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 121.597 0.713 . . . . 0.0 109.485 175.134 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 66' ' ' GLY . . . . . 0.582 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 82.68 49.15 5.25 Favored Glycine 0 N--CA 1.445 -0.702 0 CA-C-N 115.061 -0.972 . . . . 0.0 111.608 -179.924 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.629 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -78.67 -15.39 80.86 Favored Glycine 0 N--CA 1.442 -0.96 0 C-N-CA 121.273 -0.489 . . . . 0.0 112.432 -174.765 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.837 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 6.8 mp -59.21 -27.27 65.57 Favored 'General case' 0 C--N 1.323 -0.575 0 N-CA-C 111.872 0.323 . . . . 0.0 111.872 -175.568 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 69' ' ' ARG . . . . . 0.582 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 9.1 ptp180 -65.33 -30.12 70.93 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 121.353 0.597 . . . . 0.0 110.046 177.182 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 70' ' ' TYR . . . . . 0.999 ' HB3' ' HB3' ' A' ' 81' ' ' GLU . 75.0 m-85 -81.49 -34.3 31.39 Favored 'General case' 0 N--CA 1.441 -0.905 0 N-CA-C 107.638 -1.245 . . . . 0.0 107.638 176.405 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.696 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 162.67 128.92 0.01 OUTLIER Pre-proline 0 CA--C 1.513 -0.465 0 CA-C-N 112.653 -2.067 . . . . 0.0 107.009 -179.568 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 72' ' ' PRO . . . . . 0.837 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 20.4 Cg_exo -57.35 -4.93 1.3 Allowed 'Trans proline' 0 C--N 1.333 -0.26 0 C-N-CA 122.77 2.313 . . . . 0.0 113.767 -177.17 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 73' ' ' ARG . . . . . 0.428 ' HE ' ' CG ' ' A' ' 75' ' ' ASP . 10.7 ptm180 -147.86 139.01 23.45 Favored 'General case' 0 C--N 1.317 -0.805 0 N-CA-C 109.367 -0.605 . . . . 0.0 109.367 176.526 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 74' ' ' ALA . . . . . 0.473 ' HA ' ' CH2' ' A' ' 62' ' ' TRP . . . -55.95 -29.84 60.77 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 114.941 -1.027 . . . . 0.0 112.52 -177.193 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 75' ' ' ASP . . . . . 0.546 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 4.6 p-10 -83.97 -4.68 58.9 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 120.967 0.413 . . . . 0.0 111.256 -176.037 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 68.1 tp -100.0 -29.74 12.37 Favored 'General case' 0 C--N 1.322 -0.59 0 N-CA-C 108.46 -0.941 . . . . 0.0 108.46 172.549 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 77' ' ' ALA . . . . . 0.805 ' HB1' ' HB2' ' A' ' 81' ' ' GLU . . . -79.28 159.16 27.36 Favored 'General case' 0 N--CA 1.44 -0.968 0 CA-C-N 114.78 -1.1 . . . . 0.0 109.795 175.113 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 78' ' ' THR . . . . . 0.716 ' HB ' HG21 ' A' ' 22' ' ' VAL . 61.9 p -100.35 -175.19 2.85 Favored 'General case' 0 C--N 1.309 -1.188 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.355 -176.974 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 79' ' ' ARG . . . . . 0.754 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 77.7 mtp180 -50.01 -52.93 30.11 Favored 'General case' 0 C--N 1.329 -0.293 0 O-C-N 123.416 0.447 . . . . 0.0 111.265 178.819 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 80' ' ' GLU . . . . . 0.46 ' HA ' HD12 ' A' ' 83' ' ' ILE . 17.0 pt-20 -60.8 -37.23 81.24 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.873 -0.603 . . . . 0.0 111.434 -174.43 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 81' ' ' GLU . . . . . 0.999 ' HB3' ' HB3' ' A' ' 70' ' ' TYR . 4.2 mm-40 -70.22 -50.32 41.05 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 121.031 0.443 . . . . 0.0 109.959 -179.465 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 82' ' ' GLN . . . . . 0.57 ' HB2' ' HZ3' ' A' ' 43' ' ' TRP . 41.7 mt-30 -60.03 -34.45 73.4 Favored 'General case' 0 CA--C 1.513 -0.465 0 CA-C-N 115.515 -0.766 . . . . 0.0 110.201 -179.319 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.69 ' O ' ' HG2' ' A' ' 87' ' ' GLU . 40.3 mt -60.77 -49.1 85.91 Favored 'Isoleucine or valine' 0 C--O 1.212 -0.883 0 N-CA-C 109.084 -0.71 . . . . 0.0 109.084 175.855 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 84' ' ' ALA . . . . . 0.587 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -62.1 -44.09 97.4 Favored 'General case' 0 C--O 1.237 0.414 0 CA-C-O 121.277 0.56 . . . . 0.0 111.867 -176.353 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.578 HG13 ' HB2' ' A' ' 65' ' ' ASN . 40.0 t -66.24 -49.32 76.86 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.609 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.862 179.432 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 86' ' ' ALA . . . . . 0.474 ' HB1' ' CH2' ' A' ' 31' ' ' TRP . . . -59.11 -29.54 67.45 Favored 'General case' 0 N--CA 1.447 -0.592 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.404 174.572 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 87' ' ' GLU . . . . . 0.86 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 15.7 mm-40 -59.46 -44.3 93.0 Favored 'General case' 0 C--O 1.222 -0.386 0 CA-C-N 115.846 -0.616 . . . . 0.0 110.492 -178.599 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.448 ' O ' ' HG3' ' A' ' 92' ' ' ARG . 70.6 t -60.52 -49.3 84.93 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.303 0 C-N-CA 120.288 -0.565 . . . . 0.0 110.091 179.747 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 89' ' ' THR . . . . . 0.675 HG22 ' NE2' ' A' ' 93' ' ' GLN . 24.0 m -66.24 -43.8 85.57 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-N 115.683 -0.69 . . . . 0.0 111.437 -177.155 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 90' ' ' ARG . . . . . 0.657 ' HA ' ' OE1' ' A' ' 93' ' ' GLN . 3.2 ppt_? -60.96 -34.34 74.59 Favored 'General case' 0 N--CA 1.467 0.4 0 N-CA-C 112.073 0.397 . . . . 0.0 112.073 -176.48 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 91' ' ' LEU . . . . . 0.86 ' HG ' ' O ' ' A' ' 87' ' ' GLU . 46.5 mt -62.87 -33.25 74.88 Favored 'General case' 0 N--CA 1.471 0.587 0 CA-C-O 121.47 0.652 . . . . 0.0 110.152 -177.998 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 92' ' ' ARG . . . . . 0.483 ' NH2' HG23 ' A' ' 89' ' ' THR . 6.5 mtm180 -81.57 -50.57 9.21 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-N 114.818 -1.083 . . . . 0.0 110.103 -169.85 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 93' ' ' GLN . . . . . 0.675 ' NE2' HG22 ' A' ' 89' ' ' THR . 0.0 OUTLIER -96.13 -23.55 16.7 Favored 'General case' 0 C--N 1.318 -0.785 0 C-N-CA 119.733 -0.787 . . . . 0.0 113.045 -171.682 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 88.48 40.41 6.42 Favored Glycine 0 CA--C 1.508 -0.345 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.156 172.466 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 95' ' ' TRP . . . . . 0.531 ' CZ2' ' HD3' ' A' ' 90' ' ' ARG . 22.1 m95 67.16 9.09 6.68 Favored 'General case' 0 C--O 1.221 -0.423 0 C-N-CA 123.6 0.76 . . . . 0.0 110.033 -179.124 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -71.97 -23.48 77.93 Favored Glycine 0 N--CA 1.451 -0.305 0 CA-C-N 115.891 -0.595 . . . . 0.0 112.444 178.155 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -72.7 -28.1 62.47 Favored 'General case' 0 CA--C 1.516 -0.337 0 CA-C-O 121.046 0.451 . . . . 0.0 109.988 177.641 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 98' ' ' TRP . . . . . 0.516 ' HE1' HG12 ' A' ' 55' ' ' VAL . 28.6 m-90 -101.02 104.16 30.31 Favored Pre-proline 0 N--CA 1.448 -0.567 0 CA-C-N 115.146 -0.934 . . . . 0.0 108.966 176.528 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 99' ' ' PRO . . . . . 0.404 ' HD3' ' HA ' ' A' ' 98' ' ' TRP . 15.7 Cg_exo -73.95 -88.38 0.0 OUTLIER 'Trans proline' 0 CA--C 1.53 0.32 0 C-N-CA 123.182 2.588 . . . . 0.0 114.993 -171.127 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 100' ' ' VAL . . . . . 0.427 ' HA ' HH21 ' A' ' 104' ' ' ARG . 80.5 t -69.45 -30.08 44.24 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-O 121.142 0.496 . . . . 0.0 110.693 -172.393 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 101' ' ' CYS . . . . . 0.566 ' HB3' ' HA ' ' A' ' 34' ' ' ILE . 87.1 m -79.79 -37.64 34.84 Favored 'General case' 0 C--N 1.317 -0.812 0 CA-C-N 115.7 -0.682 . . . . 0.0 112.403 -170.102 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 102' ' ' ALA . . . . . 0.442 ' HB1' ' HB3' ' A' ' 95' ' ' TRP . . . -69.62 -40.33 76.66 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.828 0.347 . . . . 0.0 110.912 -178.556 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -61.48 -38.55 87.71 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-O 121.318 0.58 . . . . 0.0 110.588 177.127 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 104' ' ' ARG . . . . . 0.427 HH21 ' HA ' ' A' ' 100' ' ' VAL . 1.4 mpp_? -74.58 -18.45 60.57 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.371 -0.831 . . . . 0.0 111.618 176.77 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -96.49 -22.8 16.89 Favored 'General case' 0 C--N 1.327 -0.399 0 N-CA-C 112.659 0.615 . . . . 0.0 112.659 -173.638 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 106.11 64.21 0.62 Allowed Glycine 0 CA--C 1.52 0.4 0 C-N-CA 120.793 -0.718 . . . . 0.0 112.252 -177.582 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -72.24 149.14 44.83 Favored 'General case' 0 C--N 1.326 -0.436 0 C-N-CA 122.906 0.483 . . . . 0.0 111.28 -174.867 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.245 0.819 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.619 -175.403 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 2.5 p-10 . . . . . 0 N--CA 1.472 0.66 0 N-CA-C 108.924 -0.769 . . . . 0.0 108.924 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 50.1 t -62.78 -35.32 70.31 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 114.981 -1.009 . . . . 0.0 112.644 -173.153 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 91.8 t -62.26 108.52 0.55 Allowed 'Isoleucine or valine' 0 C--O 1.236 0.382 0 CA-C-O 120.92 0.391 . . . . 0.0 111.457 -179.758 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 12.7 t -88.0 147.7 5.08 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 N-CA-C 109.596 -0.52 . . . . 0.0 109.596 177.193 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' THR . . . . . 0.404 ' HA ' ' HD3' ' A' ' 6' ' ' PRO . 23.2 p -92.88 117.52 67.58 Favored Pre-proline 0 C--N 1.315 -0.907 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.766 -179.647 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.404 ' HD3' ' HA ' ' A' ' 5' ' ' THR . 5.0 Cg_exo -80.89 161.07 21.2 Favored 'Trans proline' 0 N--CA 1.448 -1.188 0 C-N-CA 122.902 2.401 . . . . 0.0 111.434 177.797 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -147.38 87.63 1.67 Allowed 'General case' 0 C--N 1.307 -1.276 0 CA-C-N 114.786 -1.097 . . . . 0.0 112.037 -175.596 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 63.5 t60 -104.29 -13.08 16.28 Favored 'General case' 0 C--N 1.312 -1.044 0 N-CA-C 107.132 -1.433 . . . . 0.0 107.132 165.198 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' GLU . . . . . 0.403 ' HB2' HG23 ' A' ' 11' ' ' VAL . 9.3 pt-20 -84.97 158.01 20.63 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 113.899 -1.5 . . . . 0.0 111.396 -177.031 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -138.01 69.58 1.39 Allowed 'General case' 0 C--N 1.317 -0.838 0 CA-C-N 114.998 -1.001 . . . . 0.0 108.874 172.042 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.403 HG23 ' HB2' ' A' ' 9' ' ' GLU . 38.7 t -99.9 -73.26 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.442 -0.844 0 CA-C-N 114.752 -1.113 . . . . 0.0 110.571 -176.219 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.43 ' O ' HG12 ' A' ' 12' ' ' VAL . 77.9 t 21.34 75.32 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.447 -0.618 0 O-C-N 125.19 1.556 . . . . 0.0 111.993 -174.188 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 13' ' ' ARG . . . . . 0.405 HH11 ' HD3' ' A' ' 13' ' ' ARG . 0.0 OUTLIER -88.9 95.94 10.51 Favored 'General case' 0 C--N 1.303 -1.455 0 CA-C-N 113.938 -1.483 . . . . 0.0 111.227 -173.801 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 4.6 t -128.44 161.61 36.75 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.593 0 CA-C-N 113.298 -1.774 . . . . 0.0 108.748 -179.627 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 94.88 63.15 1.0 Allowed Glycine 0 C--N 1.309 -0.966 0 N-CA-C 111.113 -0.795 . . . . 0.0 111.113 -177.93 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 12.8 m -76.52 -22.94 53.76 Favored 'General case' 0 C--N 1.316 -0.886 0 CA-C-N 114.437 -0.881 . . . . 0.0 111.317 -175.069 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' LYS . . . . . 0.464 ' N ' ' HD2' ' A' ' 17' ' ' LYS . 0.0 OUTLIER -133.09 114.57 13.84 Favored Pre-proline 0 C--N 1.311 -1.066 0 CA-C-N 114.922 -1.036 . . . . 0.0 110.138 -178.841 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 18' ' ' PRO . . . . . 0.426 ' HD3' ' HA ' ' A' ' 17' ' ' LYS . 8.3 Cg_exo -73.84 173.58 13.75 Favored 'Trans proline' 0 N--CA 1.461 -0.431 0 C-N-CA 123.312 2.675 . . . . 0.0 112.938 179.97 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 135.77 -38.67 1.76 Allowed Glycine 0 N--CA 1.44 -1.053 0 CA-C-N 114.063 -1.426 . . . . 0.0 111.58 179.974 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 21.4 m -60.23 -34.58 73.87 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-N 114.69 -0.755 . . . . 0.0 112.43 -177.846 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 3.3 pm0 -58.59 120.47 8.93 Favored 'General case' 0 N--CA 1.451 -0.415 0 CA-C-O 122.391 1.091 . . . . 0.0 111.314 -176.981 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 45.6 t -87.88 129.3 50.91 Favored Pre-proline 0 C--N 1.301 -1.512 0 CA-C-N 113.615 -1.63 . . . . 0.0 110.301 178.911 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_exo -53.89 142.75 62.91 Favored 'Trans proline' 0 C--N 1.344 0.338 0 C-N-CA 122.964 2.443 . . . . 0.0 111.639 176.933 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 10.4 Cg_endo -54.69 138.89 76.75 Favored 'Trans proline' 0 N--CA 1.459 -0.525 0 C-N-CA 123.427 2.751 . . . . 0.0 112.777 -175.069 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.989 HG11 HD13 ' A' ' 83' ' ' ILE . 14.8 p -107.07 128.43 61.96 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.087 0 CA-C-N 114.603 -1.181 . . . . 0.0 111.239 -178.22 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 45.3 mm -82.53 -25.47 8.7 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-N 115.611 -0.722 . . . . 0.0 110.423 177.067 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.463 ' O ' HG12 ' A' ' 30' ' ' ILE . 18.4 m-20 -108.52 15.93 23.43 Favored 'General case' 0 CA--C 1.511 -0.53 0 CA-C-N 115.442 -0.799 . . . . 0.0 109.784 -172.653 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -69.91 -8.36 60.88 Favored Glycine 0 CA--C 1.5 -0.874 0 N-CA-C 110.343 -1.103 . . . . 0.0 110.343 177.921 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 16.4 m -76.55 -35.04 58.47 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 114.591 -0.805 . . . . 0.0 109.197 175.857 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.622 ' HA ' ' HB1' ' A' ' 105' ' ' ALA . 1.1 mm -71.46 -36.95 62.62 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.645 0 N-CA-C 107.245 -1.391 . . . . 0.0 107.245 177.105 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 31' ' ' TRP . . . . . 0.572 ' CH2' ' HB1' ' A' ' 86' ' ' ALA . 34.6 m95 -71.15 -36.3 72.0 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 114.089 -1.414 . . . . 0.0 111.012 -177.259 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.784 ' HB2' HH21 ' A' ' 79' ' ' ARG . 17.5 t70 -74.79 -36.7 62.51 Favored 'General case' 0 N--CA 1.445 -0.694 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.477 179.119 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 33' ' ' ALA . . . . . 0.442 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -70.47 -34.19 72.12 Favored 'General case' 0 N--CA 1.448 -0.537 0 C-N-CA 120.817 -0.353 . . . . 0.0 110.695 178.687 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 34' ' ' ILE . . . . . 0.547 HG13 ' O ' ' A' ' 30' ' ' ILE . 65.9 mt -64.73 -44.67 96.51 Favored 'Isoleucine or valine' 0 C--O 1.235 0.327 0 CA-C-O 121.286 0.565 . . . . 0.0 109.988 173.914 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 35' ' ' ALA . . . . . 0.441 ' HA ' ' O ' ' A' ' 54' ' ' GLY . . . -59.59 -35.03 73.51 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.511 -0.768 . . . . 0.0 110.261 176.245 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 36' ' ' GLY . . . . . 0.51 ' HA2' ' N ' ' A' ' 41' ' ' GLY . . . -78.94 4.37 61.82 Favored Glycine 0 N--CA 1.452 -0.293 0 CA-C-N 115.368 -0.833 . . . . 0.0 112.341 179.643 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 27.0 t -108.15 -53.84 2.58 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 120.576 0.227 . . . . 0.0 111.114 -179.499 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 38' ' ' GLU . . . . . 0.444 ' HG2' ' SG ' ' A' ' 101' ' ' CYS . 36.7 mm-40 -87.86 -33.1 18.67 Favored 'General case' 0 CA--C 1.515 -0.39 0 CA-C-O 121.093 0.473 . . . . 0.0 110.552 -176.547 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -105.1 -9.71 17.62 Favored 'General case' 0 N--CA 1.447 -0.587 0 CA-C-N 116.044 -0.525 . . . . 0.0 112.124 -175.201 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 75.11 17.51 80.23 Favored Glycine 0 CA--C 1.505 -0.577 0 N-CA-C 109.635 -1.386 . . . . 0.0 109.635 -177.199 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 41' ' ' GLY . . . . . 0.51 ' N ' ' HA2' ' A' ' 36' ' ' GLY . . . 75.24 61.51 2.99 Favored Glycine 0 N--CA 1.432 -1.598 0 CA-C-N 114.019 -1.091 . . . . 0.0 111.455 -174.953 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 42' ' ' ASN . . . . . 0.436 ' HB3' ' HB ' ' A' ' 45' ' ' ILE . 4.6 t-20 -145.84 100.16 3.37 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 108.332 -0.988 . . . . 0.0 108.332 -177.251 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 43' ' ' TRP . . . . . 0.81 ' HA ' ' N ' ' A' ' 54' ' ' GLY . 30.2 m95 -84.47 -3.82 58.59 Favored 'General case' 0 C--N 1.317 -0.833 0 CA-C-O 121.605 0.717 . . . . 0.0 110.664 -170.785 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -111.64 15.69 20.93 Favored 'General case' 0 C--N 1.311 -1.091 0 CA-C-N 114.806 -1.088 . . . . 0.0 110.86 178.768 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.818 HG22 ' HA2' ' A' ' 53' ' ' GLY . 10.5 tt -79.38 137.63 21.4 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.733 0 CA-C-O 121.163 0.506 . . . . 0.0 110.508 -177.85 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 46.4 t30 -171.24 103.72 0.21 Allowed 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 115.956 -0.566 . . . . 0.0 110.379 178.948 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 25.3 p -82.63 -11.51 58.33 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 115.767 -0.651 . . . . 0.0 111.09 177.586 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 104.07 21.28 9.64 Favored Glycine 0 N--CA 1.449 -0.483 0 C-N-CA 120.808 -0.711 . . . . 0.0 111.386 -175.348 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 8.6 p30 -82.15 -4.86 57.84 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 115.623 -0.288 . . . . 0.0 111.161 -178.335 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 50' ' ' GLY . . . . . 0.538 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 96.3 -11.95 66.88 Favored Glycine 0 N--CA 1.448 -0.525 0 C-N-CA 121.305 -0.474 . . . . 0.0 112.039 177.755 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 51' ' ' TYR . . . . . 0.647 ' HA ' ' HA ' ' A' ' 58' ' ' ASP . 0.6 OUTLIER -112.37 151.61 29.59 Favored 'General case' 0 CA--C 1.514 -0.412 0 N-CA-C 107.834 -1.173 . . . . 0.0 107.834 176.349 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 52' ' ' TYR . . . . . 0.696 ' O ' ' HA ' ' A' ' 56' ' ' GLN . 42.9 m-85 -116.61 170.39 8.62 Favored 'General case' 0 C--N 1.313 -0.984 0 C-N-CA 120.4 -0.52 . . . . 0.0 112.203 -166.242 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.818 ' HA2' HG22 ' A' ' 45' ' ' ILE . . . -60.12 172.18 5.83 Favored Glycine 0 N--CA 1.446 -0.658 0 N-CA-C 115.548 0.979 . . . . 0.0 115.548 -167.653 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.81 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 87.53 -109.35 3.46 Favored Glycine 0 N--CA 1.437 -1.234 0 CA-C-N 114.486 -0.857 . . . . 0.0 111.636 177.557 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.518 HG11 ' CE3' ' A' ' 31' ' ' TRP . 0.5 OUTLIER -84.16 2.21 3.93 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.594 0 CA-C-O 121.351 0.596 . . . . 0.0 110.868 178.793 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 56' ' ' GLN . . . . . 0.696 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 6.6 tp60 59.5 51.36 6.6 Favored 'General case' 0 CA--C 1.532 0.271 0 CA-C-N 114.207 -1.361 . . . . 0.0 113.316 164.952 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 57' ' ' PHE . . . . . 0.477 ' CE1' HG23 ' A' ' 55' ' ' VAL . 0.3 OUTLIER -119.12 168.37 10.91 Favored 'General case' 0 C--N 1.326 -0.454 0 C-N-CA 119.465 -0.894 . . . . 0.0 111.865 174.215 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.647 ' HA ' ' HA ' ' A' ' 51' ' ' TYR . 7.4 p-10 -78.53 166.11 22.95 Favored 'General case' 0 C--N 1.327 -0.383 0 N-CA-C 113.724 1.009 . . . . 0.0 113.724 -163.459 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.48 ' HB2' ' HE1' ' A' ' 52' ' ' TYR . 5.6 tp-100 -61.08 -39.96 91.87 Favored 'General case' 0 N--CA 1.446 -0.667 0 CA-C-N 114.775 -1.102 . . . . 0.0 111.244 177.601 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -64.32 -49.55 65.16 Favored Glycine 0 C--N 1.317 -0.483 0 CA-C-N 115.665 -0.698 . . . . 0.0 111.572 -175.185 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 87.9 m -66.77 -41.58 87.5 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-N 115.612 -0.294 . . . . 0.0 111.167 176.591 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 62' ' ' TRP . . . . . 0.447 ' HZ3' ' HA ' ' A' ' 82' ' ' GLN . 57.2 t-105 -56.48 -48.4 77.19 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 121.773 0.796 . . . . 0.0 109.437 177.0 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 63' ' ' GLU . . . . . 0.444 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 29.3 tt0 -67.44 -34.22 76.76 Favored 'General case' 0 C--N 1.317 -0.833 0 CA-C-N 114.8 -1.091 . . . . 0.0 111.131 -179.655 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -65.14 -41.36 94.87 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.899 -0.592 . . . . 0.0 111.129 -177.166 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 65' ' ' ASN . . . . . 0.566 ' HB2' HG13 ' A' ' 85' ' ' VAL . 31.4 m-80 -82.94 -9.2 59.41 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.715 0.293 . . . . 0.0 110.502 177.232 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 66' ' ' GLY . . . . . 0.515 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 91.46 49.79 2.91 Favored Glycine 0 C--N 1.334 0.433 0 C-N-CA 121.181 -0.533 . . . . 0.0 113.168 173.218 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.483 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -80.61 -28.2 48.29 Favored Glycine 0 N--CA 1.439 -1.127 0 C-N-CA 121.041 -0.6 . . . . 0.0 113.107 -177.391 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.898 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 7.2 mp -57.4 -23.58 50.2 Favored 'General case' 0 N--CA 1.452 -0.355 0 N-CA-C 112.2 0.445 . . . . 0.0 112.2 -173.032 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 69' ' ' ARG . . . . . 0.515 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 1.5 ptm180 -67.56 -31.67 71.91 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-O 121.043 0.449 . . . . 0.0 109.971 178.529 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 70' ' ' TYR . . . . . 1.021 ' HB3' ' HG2' ' A' ' 81' ' ' GLU . 63.5 m-85 -83.99 -36.63 23.04 Favored 'General case' 0 N--CA 1.44 -0.946 0 N-CA-C 107.327 -1.36 . . . . 0.0 107.327 177.218 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.636 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 169.1 126.96 0.04 OUTLIER Pre-proline 0 N--CA 1.443 -0.784 0 CA-C-N 112.899 -1.955 . . . . 0.0 107.406 -175.89 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 72' ' ' PRO . . . . . 0.898 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 21.5 Cg_exo -56.85 -5.9 1.48 Allowed 'Trans proline' 0 C--N 1.33 -0.417 0 C-N-CA 122.982 2.454 . . . . 0.0 113.705 -177.542 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 73' ' ' ARG . . . . . 0.63 ' HB2' ' CD2' ' A' ' 52' ' ' TYR . 28.3 ptt-85 -149.74 140.32 22.53 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-O 121.188 0.518 . . . . 0.0 110.356 176.756 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 74' ' ' ALA . . . . . 0.491 ' HB3' ' HB2' ' A' ' 52' ' ' TYR . . . -57.65 -22.83 48.04 Favored 'General case' 0 C--O 1.217 -0.645 0 CA-C-N 114.851 -1.068 . . . . 0.0 113.189 -178.98 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 75' ' ' ASP . . . . . 0.57 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 0.0 OUTLIER -76.76 -23.15 52.95 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 121.227 0.537 . . . . 0.0 110.921 -179.159 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.504 ' HB3' ' HB1' ' A' ' 71' ' ' ALA . 54.9 tp -87.68 -33.19 18.86 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 115.567 -0.742 . . . . 0.0 109.191 176.034 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 77' ' ' ALA . . . . . 0.742 ' HB1' ' CB ' ' A' ' 81' ' ' GLU . . . -79.15 158.47 27.71 Favored 'General case' 0 N--CA 1.445 -0.723 0 CA-C-N 115.344 -0.844 . . . . 0.0 110.97 176.1 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 47.5 p -101.5 -172.48 2.17 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.231 -178.444 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 79' ' ' ARG . . . . . 0.784 HH21 ' HB2' ' A' ' 32' ' ' ASP . 66.8 mtp180 -49.52 -52.55 28.85 Favored 'General case' 0 N--CA 1.466 0.325 0 CA-C-N 116.433 -0.349 . . . . 0.0 111.521 -177.955 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 10.2 pt-20 -62.69 -33.07 74.33 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 116.023 -0.535 . . . . 0.0 111.365 -174.977 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 81' ' ' GLU . . . . . 1.021 ' HG2' ' HB3' ' A' ' 70' ' ' TYR . 5.9 mt-10 -71.9 -47.53 52.03 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.532 -0.304 . . . . 0.0 111.235 178.43 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 82' ' ' GLN . . . . . 0.57 ' NE2' ' HE3' ' A' ' 43' ' ' TRP . 0.1 OUTLIER -59.5 -39.61 84.38 Favored 'General case' 0 CA--C 1.505 -0.752 0 N-CA-C 109.509 -0.552 . . . . 0.0 109.509 174.551 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.989 HD13 HG11 ' A' ' 25' ' ' VAL . 27.2 mt -60.1 -49.75 82.87 Favored 'Isoleucine or valine' 0 C--O 1.209 -1.03 0 CA-C-N 114.848 -1.069 . . . . 0.0 110.591 177.471 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 84' ' ' ALA . . . . . 0.622 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -60.8 -46.02 92.14 Favored 'General case' 0 C--O 1.242 0.664 0 CA-C-O 121.409 0.623 . . . . 0.0 111.973 -177.176 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.566 HG13 ' HB2' ' A' ' 65' ' ' ASN . 58.6 t -66.51 -48.27 81.07 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.737 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.448 -179.525 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 86' ' ' ALA . . . . . 0.572 ' HB1' ' CH2' ' A' ' 31' ' ' TRP . . . -59.95 -28.49 67.69 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.584 -0.735 . . . . 0.0 110.793 174.065 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 87' ' ' GLU . . . . . 0.68 ' HG2' ' O ' ' A' ' 83' ' ' ILE . 10.9 mm-40 -59.26 -45.0 92.38 Favored 'General case' 0 N--CA 1.468 0.434 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.166 -179.17 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.653 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 62.1 t -65.95 -42.49 91.93 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.295 0 C-N-CA 120.115 -0.634 . . . . 0.0 109.594 175.933 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 89' ' ' THR . . . . . 0.895 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 1.1 m -64.0 -45.28 89.69 Favored 'General case' 0 C--N 1.319 -0.758 0 CA-C-N 115.613 -0.721 . . . . 0.0 111.498 -176.136 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 90' ' ' ARG . . . . . 0.547 ' HA ' ' HZ3' ' A' ' 98' ' ' TRP . 5.0 ptt180 -69.29 -33.17 72.79 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.679 -175.559 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 91' ' ' LEU . . . . . 0.653 ' HG ' ' O ' ' A' ' 88' ' ' VAL . 4.6 pp -68.59 -24.46 64.6 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 121.368 0.604 . . . . 0.0 110.309 -173.4 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 92' ' ' ARG . . . . . 0.464 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 4.2 mtm180 -84.36 -43.87 14.32 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-O 122.14 0.972 . . . . 0.0 109.163 176.451 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 93' ' ' GLN . . . . . 0.595 ' OE1' HG22 ' A' ' 89' ' ' THR . 93.0 mt-30 -87.84 -28.23 21.75 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 113.746 -1.57 . . . . 0.0 114.329 -167.43 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 74.89 32.63 56.65 Favored Glycine 0 CA--C 1.51 -0.245 0 N-CA-C 111.858 -0.497 . . . . 0.0 111.858 179.894 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 95' ' ' TRP . . . . . 0.42 ' CH2' ' HB ' ' A' ' 30' ' ' ILE . 28.6 m95 67.05 5.02 3.86 Favored 'General case' 0 C--O 1.216 -0.678 0 C-N-CA 123.451 0.701 . . . . 0.0 110.082 -177.151 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -59.39 -43.8 97.12 Favored Glycine 0 CA--C 1.518 0.233 0 CA-C-N 116.125 -0.489 . . . . 0.0 113.327 -178.557 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -69.67 -21.15 63.54 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.826 0.346 . . . . 0.0 110.971 -179.371 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 98' ' ' TRP . . . . . 0.895 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 21.6 m-90 -90.31 108.93 29.97 Favored Pre-proline 0 N--CA 1.445 -0.681 0 N-CA-C 108.127 -1.064 . . . . 0.0 108.127 174.303 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 99' ' ' PRO . . . . . 0.436 ' HD3' ' HA ' ' A' ' 98' ' ' TRP . 46.9 Cg_exo -62.97 -138.89 0.0 OUTLIER 'Trans proline' 0 CA--C 1.533 0.44 0 C-N-CA 123.616 2.877 . . . . 0.0 114.45 -171.828 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 4.2 p -55.38 -25.92 18.1 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.195 0 CA-C-O 121.427 0.632 . . . . 0.0 110.759 -176.939 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 101' ' ' CYS . . . . . 0.444 ' SG ' ' HG2' ' A' ' 38' ' ' GLU . 39.9 m -55.98 -39.16 71.43 Favored 'General case' 0 C--N 1.317 -0.844 0 CA-C-N 114.896 -1.047 . . . . 0.0 111.427 177.703 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -70.86 -41.42 71.44 Favored 'General case' 0 CA--C 1.519 -0.219 0 CA-C-O 120.877 0.37 . . . . 0.0 110.722 179.609 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -64.34 -43.02 95.91 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 121.074 0.464 . . . . 0.0 110.274 178.171 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 60.1 mtp180 -62.92 -30.82 71.84 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 115.51 -0.768 . . . . 0.0 110.897 176.696 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 105' ' ' ALA . . . . . 0.622 ' HB1' ' HA ' ' A' ' 30' ' ' ILE . . . -85.23 -21.27 29.16 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.72 -0.673 . . . . 0.0 111.456 -177.966 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 106' ' ' GLY . . . . . 0.466 ' O ' ' HG2' ' A' ' 108' ' ' ARG . . . 102.55 67.71 0.78 Allowed Glycine 0 CA--C 1.52 0.393 0 CA-C-N 115.892 -0.595 . . . . 0.0 112.288 -178.636 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -57.54 147.63 26.32 Favored 'General case' 0 C--O 1.236 0.362 0 C-N-CA 122.895 0.478 . . . . 0.0 111.6 -177.609 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 108' ' ' ARG . . . . . 0.466 ' HG2' ' O ' ' A' ' 106' ' ' GLY . 3.6 ptp180 . . . . . 0 C--O 1.251 1.149 0 CA-C-O 118.496 -0.764 . . . . 0.0 110.582 -171.575 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 90.9 m-20 . . . . . 0 N--CA 1.48 1.062 0 CA-C-O 120.778 0.323 . . . . 0.0 110.88 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 43.1 t -95.24 -38.18 8.5 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 N-CA-C 109.128 -0.693 . . . . 0.0 109.128 175.498 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 7.3 p -65.14 123.73 18.6 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.624 0 CA-C-N 115.284 -0.871 . . . . 0.0 110.939 176.411 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 4.0 p -73.44 147.58 9.42 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.988 179.256 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 62.3 p -121.51 112.85 32.39 Favored Pre-proline 0 C--N 1.317 -0.817 0 CA-C-N 115.273 -0.876 . . . . 0.0 109.747 179.283 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 20.0 Cg_exo -39.18 111.42 0.12 Allowed 'Trans proline' 0 CA--C 1.509 -0.744 0 C-N-CA 124.248 3.299 . . . . 0.0 113.864 -178.851 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -108.5 23.37 14.62 Favored 'General case' 0 C--N 1.302 -1.472 0 CA-C-N 113.477 -1.692 . . . . 0.0 110.277 -177.899 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 32.8 t60 -78.1 -8.29 58.06 Favored 'General case' 0 C--N 1.313 -0.991 0 CA-C-N 114.727 -1.124 . . . . 0.0 108.258 170.822 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' GLU . . . . . 0.48 ' OE1' ' HB ' ' A' ' 11' ' ' VAL . 6.1 pt-20 -82.72 142.26 31.77 Favored 'General case' 0 C--O 1.235 0.297 0 CA-C-N 115.283 -0.871 . . . . 0.0 110.522 -178.599 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -109.66 54.19 0.67 Allowed 'General case' 0 C--N 1.322 -0.619 0 CA-C-O 122.177 0.989 . . . . 0.0 109.76 175.728 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.524 HG12 ' HG2' ' A' ' 13' ' ' ARG . 84.5 t -124.09 -67.04 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.163 0 CA-C-N 113.824 -1.535 . . . . 0.0 109.606 -178.596 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.411 ' O ' HG12 ' A' ' 12' ' ' VAL . 78.5 t 26.18 81.19 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.447 -0.615 0 C-N-CA 125.183 1.393 . . . . 0.0 113.067 -179.446 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 13' ' ' ARG . . . . . 0.524 ' HG2' HG12 ' A' ' 11' ' ' VAL . 8.8 ptm180 -119.81 130.24 54.82 Favored 'General case' 0 N--CA 1.424 -1.759 0 CA-C-N 113.724 -1.58 . . . . 0.0 109.43 178.325 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.5 t -96.15 160.42 2.83 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.393 0 CA-C-N 115.168 -0.924 . . . . 0.0 109.534 -178.442 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 174.6 -82.44 0.08 OUTLIER Glycine 0 N--CA 1.429 -1.824 0 N-CA-C 110.331 -1.108 . . . . 0.0 110.331 -179.408 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 18.0 m -93.45 -49.88 5.71 Favored 'General case' 0 N--CA 1.434 -1.243 0 N-CA-C 109.978 -0.378 . . . . 0.0 109.978 174.253 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 3.5 mmmp? 32.77 77.1 0.36 Allowed Pre-proline 0 N--CA 1.467 0.408 0 O-C-N 124.948 1.405 . . . . 0.0 112.495 -177.737 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 0.9 OUTLIER -34.1 118.14 0.11 Allowed 'Trans proline' 0 C--N 1.351 0.674 0 C-N-CA 124.822 3.681 . . . . 0.0 115.101 -176.678 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -164.01 -52.08 0.02 OUTLIER Glycine 0 N--CA 1.436 -1.336 0 CA-C-N 113.186 -1.825 . . . . 0.0 111.25 179.078 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 20.8 m -69.46 -32.98 72.24 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-O 121.322 0.582 . . . . 0.0 110.71 177.785 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 46.7 mt-10 -105.02 119.34 38.78 Favored 'General case' 0 N--CA 1.442 -0.845 0 CA-C-N 115.618 -0.719 . . . . 0.0 109.552 178.907 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 47.1 t -76.8 124.78 87.64 Favored Pre-proline 0 C--N 1.309 -1.178 0 CA-C-N 115.623 -0.717 . . . . 0.0 109.482 175.213 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_exo -54.16 128.3 29.33 Favored 'Trans proline' 0 C--N 1.347 0.448 0 C-N-CA 122.944 2.429 . . . . 0.0 112.811 -177.324 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 13.4 Cg_endo -57.32 160.72 12.85 Favored 'Trans proline' 0 N--CA 1.46 -0.481 0 C-N-CA 123.998 3.132 . . . . 0.0 112.784 176.611 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 79.4 t -80.78 124.83 39.03 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.008 0 CA-C-N 115.012 -0.994 . . . . 0.0 109.135 177.378 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 51.1 mm -55.88 -36.42 43.82 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.602 0 N-CA-C 114.463 1.282 . . . . 0.0 114.463 -161.732 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.555 ' O ' HG12 ' A' ' 30' ' ' ILE . 26.3 m-20 -102.65 4.98 38.83 Favored 'General case' 0 C--N 1.311 -1.083 0 CA-C-O 121.744 0.783 . . . . 0.0 109.688 -173.267 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 28' ' ' GLY . . . . . 0.585 ' HA3' HD13 ' A' ' 83' ' ' ILE . . . -72.36 -1.03 49.72 Favored Glycine 0 N--CA 1.434 -1.462 0 CA-C-N 114.596 -1.184 . . . . 0.0 111.091 178.403 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 14.9 m -73.8 -40.96 63.02 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-O 121.744 0.783 . . . . 0.0 109.293 175.089 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.555 HG12 ' O ' ' A' ' 27' ' ' ASP . 0.0 OUTLIER -70.99 -36.33 63.13 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.633 0 CA-C-N 114.548 -1.205 . . . . 0.0 107.78 177.218 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 31' ' ' TRP . . . . . 0.656 ' CD1' HG23 ' A' ' 83' ' ' ILE . 49.1 m95 -72.34 -35.96 68.7 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 114.781 -1.1 . . . . 0.0 111.075 -178.32 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.457 ' HB3' ' O ' ' A' ' 28' ' ' GLY . 0.0 OUTLIER -71.0 -35.88 72.24 Favored 'General case' 0 N--CA 1.45 -0.449 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.115 177.395 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 33' ' ' ALA . . . . . 0.416 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -70.38 -37.19 74.49 Favored 'General case' 0 N--CA 1.446 -0.65 0 C-N-CA 120.869 -0.332 . . . . 0.0 110.944 177.816 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 34' ' ' ILE . . . . . 0.515 HG13 ' O ' ' A' ' 30' ' ' ILE . 72.6 mt -67.04 -46.97 83.44 Favored 'Isoleucine or valine' 0 C--O 1.234 0.238 0 CA-C-O 121.036 0.446 . . . . 0.0 110.215 174.949 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -57.96 -38.31 75.77 Favored 'General case' 0 N--CA 1.451 -0.386 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.445 176.833 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -72.71 -13.31 78.29 Favored Glycine 0 N--CA 1.451 -0.352 0 CA-C-N 115.683 -0.689 . . . . 0.0 111.838 179.824 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 53.1 t -95.9 -59.09 1.93 Allowed 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.639 -0.28 . . . . 0.0 111.413 -177.092 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 38' ' ' GLU . . . . . 0.869 ' HG3' ' SG ' ' A' ' 101' ' ' CYS . 26.5 mt-10 -88.93 -22.95 22.84 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 120.651 0.263 . . . . 0.0 111.619 -173.536 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -106.26 -12.13 15.81 Favored 'General case' 0 N--CA 1.447 -0.58 0 C-N-CA 120.184 -0.607 . . . . 0.0 111.717 -179.208 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 77.99 15.98 80.45 Favored Glycine 0 CA--C 1.507 -0.459 0 N-CA-C 109.935 -1.266 . . . . 0.0 109.935 -176.861 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 73.07 57.03 5.43 Favored Glycine 0 N--CA 1.435 -1.416 0 CA-C-N 114.072 -1.064 . . . . 0.0 111.516 -175.334 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 2.6 t-20 -140.19 98.55 3.47 Favored 'General case' 0 N--CA 1.447 -0.609 0 N-CA-C 109.194 -0.669 . . . . 0.0 109.194 -177.713 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 43' ' ' TRP . . . . . 0.773 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 32.3 m95 -84.07 2.37 39.6 Favored 'General case' 0 C--N 1.319 -0.758 0 CA-C-N 115.485 -0.78 . . . . 0.0 109.973 -174.799 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -111.15 1.76 17.46 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-N 114.903 -1.044 . . . . 0.0 111.488 177.41 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.899 HG22 ' HA2' ' A' ' 53' ' ' GLY . 6.4 tt -66.91 143.91 15.13 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.677 0 CA-C-O 121.268 0.556 . . . . 0.0 110.358 -177.34 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 2.1 t30 -152.08 98.67 2.46 Favored 'General case' 0 C--N 1.309 -1.179 0 CA-C-O 121.234 0.54 . . . . 0.0 109.67 -178.49 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 21.1 p -75.38 -21.33 58.36 Favored 'General case' 0 C--N 1.317 -0.817 0 CA-C-N 115.362 -0.835 . . . . 0.0 110.292 179.259 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 91.04 18.53 46.46 Favored Glycine 0 N--CA 1.443 -0.848 0 CA-C-N 115.339 -0.846 . . . . 0.0 111.038 178.272 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 28.5 p-10 -95.44 4.47 53.26 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.891 0.377 . . . . 0.0 111.647 -174.407 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 50' ' ' GLY . . . . . 0.438 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 95.47 -8.22 68.96 Favored Glycine 0 N--CA 1.45 -0.424 0 C-N-CA 120.49 -0.862 . . . . 0.0 111.832 -178.055 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 51' ' ' TYR . . . . . 0.579 ' CE1' ' HB3' ' A' ' 58' ' ' ASP . 0.2 OUTLIER -112.89 144.65 42.08 Favored 'General case' 0 CA--C 1.511 -0.544 0 N-CA-C 106.826 -1.546 . . . . 0.0 106.826 176.131 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 52' ' ' TYR . . . . . 0.736 ' HB2' ' HB3' ' A' ' 74' ' ' ALA . 53.6 m-85 -117.38 169.05 9.8 Favored 'General case' 0 C--N 1.306 -1.307 0 N-CA-C 113.488 0.922 . . . . 0.0 113.488 -165.388 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.899 ' HA2' HG22 ' A' ' 45' ' ' ILE . . . -62.89 159.05 36.36 Favored Glycine 0 CA--C 1.501 -0.797 0 CA-C-N 114.845 -1.071 . . . . 0.0 114.018 -171.991 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.583 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 101.72 -103.73 2.56 Favored Glycine 0 N--CA 1.437 -1.249 0 N-CA-C 111.402 -0.679 . . . . 0.0 111.402 -177.212 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.571 HG12 ' HE1' ' A' ' 98' ' ' TRP . 2.8 t -92.05 0.78 9.23 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 CA-C-O 121.652 0.739 . . . . 0.0 109.898 -178.61 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 56' ' ' GLN . . . . . 0.635 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 8.3 mm-40 59.51 50.37 7.55 Favored 'General case' 0 N--CA 1.464 0.269 0 CA-C-N 114.644 -1.162 . . . . 0.0 113.901 167.92 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 17.8 p90 -120.91 171.45 8.62 Favored 'General case' 0 C--N 1.325 -0.478 0 C-N-CA 119.833 -0.747 . . . . 0.0 112.092 175.112 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.579 ' HB3' ' CE1' ' A' ' 51' ' ' TYR . 6.4 p-10 -82.37 158.6 23.29 Favored 'General case' 0 CA--C 1.516 -0.356 0 N-CA-C 113.686 0.995 . . . . 0.0 113.686 -163.417 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.429 ' HB2' ' CE2' ' A' ' 52' ' ' TYR . 20.6 tp60 -57.84 -39.79 78.53 Favored 'General case' 0 N--CA 1.442 -0.828 0 CA-C-N 113.279 -1.782 . . . . 0.0 111.714 179.229 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -67.47 -49.46 50.9 Favored Glycine 0 N--CA 1.45 -0.404 0 CA-C-N 115.603 -0.726 . . . . 0.0 112.034 -175.303 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 83.2 m -62.87 -41.05 99.25 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 121.252 0.548 . . . . 0.0 110.389 176.57 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 62' ' ' TRP . . . . . 0.424 ' CH2' ' HA ' ' A' ' 74' ' ' ALA . 54.1 t-105 -56.99 -50.1 73.74 Favored 'General case' 0 N--CA 1.444 -0.737 0 CA-C-N 115.265 -0.88 . . . . 0.0 109.687 176.734 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 63' ' ' GLU . . . . . 0.46 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 36.7 tt0 -67.1 -39.28 86.7 Favored 'General case' 0 N--CA 1.445 -0.683 0 CA-C-N 114.918 -1.037 . . . . 0.0 110.91 -178.183 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -62.11 -40.95 97.62 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.539 -0.755 . . . . 0.0 111.109 -176.682 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 9.3 m120 -82.3 -9.61 59.41 Favored 'General case' 0 N--CA 1.45 -0.461 0 CA-C-O 120.908 0.385 . . . . 0.0 110.768 178.521 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 93.23 47.57 3.03 Favored Glycine 0 C--N 1.333 0.373 0 CA-C-N 116.089 -0.505 . . . . 0.0 112.659 173.784 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.592 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -80.2 -22.92 62.1 Favored Glycine 0 N--CA 1.44 -1.045 0 C-N-CA 120.966 -0.635 . . . . 0.0 112.868 -174.621 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.848 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 6.8 mp -61.51 -23.48 65.95 Favored 'General case' 0 N--CA 1.447 -0.595 0 N-CA-C 112.483 0.549 . . . . 0.0 112.483 -172.569 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 69' ' ' ARG . . . . . 0.428 ' HG3' ' N ' ' A' ' 70' ' ' TYR . 3.8 ptm180 -69.02 -30.96 69.44 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 121.19 0.519 . . . . 0.0 110.145 176.041 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 70' ' ' TYR . . . . . 0.792 ' HB3' ' HG3' ' A' ' 81' ' ' GLU . 79.5 m-85 -79.71 -34.8 39.78 Favored 'General case' 0 N--CA 1.446 -0.674 0 N-CA-C 107.679 -1.23 . . . . 0.0 107.679 177.144 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.696 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 161.57 128.73 0.01 OUTLIER Pre-proline 0 CA--C 1.509 -0.602 0 CA-C-N 112.609 -2.087 . . . . 0.0 106.689 -178.452 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 72' ' ' PRO . . . . . 0.848 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 32.3 Cg_exo -54.9 -6.68 0.7 Allowed 'Trans proline' 0 C--N 1.33 -0.416 0 C-N-CA 123.171 2.581 . . . . 0.0 114.246 -177.08 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 73' ' ' ARG . . . . . 0.402 ' HE ' ' CG ' ' A' ' 75' ' ' ASP . 12.4 ptm180 -149.59 142.77 25.06 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-O 121.095 0.474 . . . . 0.0 109.794 176.515 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 74' ' ' ALA . . . . . 0.736 ' HB3' ' HB2' ' A' ' 52' ' ' TYR . . . -61.06 -23.48 65.49 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.267 -0.879 . . . . 0.0 113.017 -175.159 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 75' ' ' ASP . . . . . 0.503 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 9.4 p-10 -88.21 -0.57 57.26 Favored 'General case' 0 C--N 1.33 -0.262 0 C-N-CA 120.544 -0.462 . . . . 0.0 110.905 -179.54 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.405 HD23 ' HD2' ' A' ' 72' ' ' PRO . 62.0 tp -103.75 -31.11 10.0 Favored 'General case' 0 C--N 1.323 -0.584 0 N-CA-C 109.026 -0.731 . . . . 0.0 109.026 172.641 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 77' ' ' ALA . . . . . 0.709 ' HB1' ' HB3' ' A' ' 81' ' ' GLU . . . -79.81 162.05 25.32 Favored 'General case' 0 N--CA 1.446 -0.631 0 CA-C-N 115.142 -0.935 . . . . 0.0 109.426 174.262 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 61.7 p -100.66 -175.0 2.78 Favored 'General case' 0 C--N 1.312 -1.046 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.874 -176.688 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 79' ' ' ARG . . . . . 0.773 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 11.9 mtp180 -50.92 -55.24 18.11 Favored 'General case' 0 C--O 1.222 -0.383 0 O-C-N 123.406 0.441 . . . . 0.0 110.594 179.518 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 11.3 pt-20 -61.76 -41.88 98.27 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 115.893 -0.594 . . . . 0.0 111.501 -174.326 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 81' ' ' GLU . . . . . 0.792 ' HG3' ' HB3' ' A' ' 70' ' ' TYR . 0.2 OUTLIER -64.2 -52.05 60.73 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 115.405 -0.816 . . . . 0.0 112.138 177.457 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 82' ' ' GLN . . . . . 0.571 ' HG2' HG23 ' A' ' 55' ' ' VAL . 5.7 tt0 -68.1 -31.34 70.89 Favored 'General case' 0 C--N 1.317 -0.805 0 CA-C-N 115.364 -0.835 . . . . 0.0 110.409 -176.759 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.656 HG23 ' CD1' ' A' ' 31' ' ' TRP . 25.0 mt -59.83 -44.54 94.33 Favored 'Isoleucine or valine' 0 C--O 1.216 -0.691 0 CA-C-N 115.471 -0.786 . . . . 0.0 109.563 173.524 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 84' ' ' ALA . . . . . 0.592 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -63.22 -40.64 98.04 Favored 'General case' 0 C--O 1.236 0.371 0 CA-C-O 121.352 0.596 . . . . 0.0 111.16 -175.632 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 44.2 t -69.02 -48.04 72.09 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 CA-C-N 115.685 -0.688 . . . . 0.0 110.919 177.758 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -57.05 -30.43 64.25 Favored 'General case' 0 N--CA 1.449 -0.48 0 CA-C-O 120.895 0.378 . . . . 0.0 110.401 172.796 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 87' ' ' GLU . . . . . 0.824 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 8.1 mm-40 -60.48 -44.58 95.78 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.196 -179.178 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 83.4 t -62.23 -44.91 99.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 C-N-CA 120.407 -0.517 . . . . 0.0 109.857 178.864 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 89' ' ' THR . . . . . 0.694 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 1.2 m -61.92 -47.78 83.4 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 115.504 -0.771 . . . . 0.0 111.478 -178.896 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 90' ' ' ARG . . . . . 0.738 ' HA ' ' OE1' ' A' ' 93' ' ' GLN . 2.5 ptt180 -62.02 -32.66 73.17 Favored 'General case' 0 CA--C 1.52 -0.176 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.361 -174.992 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 91' ' ' LEU . . . . . 0.824 ' HG ' ' O ' ' A' ' 87' ' ' GLU . 45.6 mt -61.06 -33.9 74.04 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-O 121.358 0.599 . . . . 0.0 110.529 -176.965 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 1.3 mtm180 -86.75 -45.36 11.01 Favored 'General case' 0 N--CA 1.443 -0.788 0 CA-C-N 115.221 -0.9 . . . . 0.0 110.589 -169.707 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 93' ' ' GLN . . . . . 0.738 ' OE1' ' HA ' ' A' ' 90' ' ' ARG . 0.0 OUTLIER -99.55 -21.32 15.95 Favored 'General case' 0 C--N 1.323 -0.572 0 N-CA-C 113.13 0.789 . . . . 0.0 113.13 -172.376 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 82.93 38.86 10.82 Favored Glycine 0 C--N 1.333 0.39 0 C-N-CA 120.926 -0.654 . . . . 0.0 112.523 171.441 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 95' ' ' TRP . . . . . 0.605 ' CZ2' ' HD3' ' A' ' 90' ' ' ARG . 20.7 m95 66.6 11.06 7.89 Favored 'General case' 0 C--O 1.221 -0.4 0 C-N-CA 123.445 0.698 . . . . 0.0 110.247 -179.212 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -68.7 -35.22 79.89 Favored Glycine 0 N--CA 1.453 -0.226 0 C-N-CA 121.236 -0.507 . . . . 0.0 112.352 176.817 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 97' ' ' ALA . . . . . 0.437 ' H ' ' CG ' ' A' ' 93' ' ' GLN . . . -66.85 -29.63 69.59 Favored 'General case' 0 CA--C 1.517 -0.294 0 CA-C-O 121.051 0.453 . . . . 0.0 110.577 178.857 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 98' ' ' TRP . . . . . 0.694 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 24.3 m-90 -92.72 108.41 31.57 Favored Pre-proline 0 N--CA 1.445 -0.722 0 N-CA-C 108.438 -0.949 . . . . 0.0 108.438 177.52 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 99' ' ' PRO . . . . . 0.429 ' HD3' ' O ' ' A' ' 97' ' ' ALA . 45.7 Cg_exo -63.08 -131.3 0.0 OUTLIER 'Trans proline' 0 CA--C 1.541 0.854 0 C-N-CA 123.492 2.794 . . . . 0.0 114.5 -175.06 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 39.2 t -55.65 -29.41 24.97 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.146 0 O-C-N 122.081 -0.387 . . . . 0.0 111.612 -174.662 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 101' ' ' CYS . . . . . 0.869 ' SG ' ' HG3' ' A' ' 38' ' ' GLU . 71.1 m -68.4 -31.97 71.69 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 116.56 -0.291 . . . . 0.0 111.604 -174.87 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 102' ' ' ALA . . . . . 0.556 ' HB2' ' CB ' ' A' ' 98' ' ' TRP . . . -70.36 -43.66 69.72 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.033 0.444 . . . . 0.0 110.335 176.185 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -62.08 -40.21 95.06 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.267 178.583 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 104' ' ' ARG . . . . . 0.625 ' NE ' ' HA ' ' A' ' 104' ' ' ARG . 1.9 mmp_? -69.16 -25.72 64.51 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.408 -0.814 . . . . 0.0 111.45 177.68 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 105' ' ' ALA . . . . . 0.416 ' CB ' ' HB3' ' A' ' 33' ' ' ALA . . . -83.38 -21.6 33.0 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.911 -177.477 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 105.38 47.75 1.11 Allowed Glycine 0 CA--C 1.521 0.456 0 C-N-CA 120.88 -0.676 . . . . 0.0 111.98 -176.599 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -57.74 149.45 22.06 Favored 'General case' 0 C--N 1.327 -0.395 0 C-N-CA 123.636 0.774 . . . . 0.0 112.23 -178.858 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 108' ' ' ARG . . . . . 0.447 ' HD3' ' O ' ' A' ' 108' ' ' ARG . 0.0 OUTLIER . . . . . 0 C--O 1.246 0.899 0 CA-C-N 115.771 -0.649 . . . . 0.0 110.373 -177.095 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 91.5 m-20 . . . . . 0 N--CA 1.483 1.22 0 CA-C-O 120.855 0.36 . . . . 0.0 110.586 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 59.6 t -97.49 -39.39 8.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 115.99 -0.55 . . . . 0.0 109.901 177.518 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 7.1 p -56.89 138.52 17.56 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 CA-C-N 115.3 -0.864 . . . . 0.0 110.338 174.521 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 2.9 p -63.42 137.42 24.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-O 121.514 0.673 . . . . 0.0 110.887 -179.908 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' THR . . . . . 0.486 ' HA ' ' HD3' ' A' ' 6' ' ' PRO . 13.4 t -104.4 133.99 19.91 Favored Pre-proline 0 C--N 1.309 -1.191 0 CA-C-N 114.754 -1.112 . . . . 0.0 110.05 -174.045 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.486 ' HD3' ' HA ' ' A' ' 5' ' ' THR . 56.1 Cg_endo -89.66 176.71 2.84 Favored 'Trans proline' 0 N--CA 1.45 -1.055 0 C-N-CA 123.403 2.735 . . . . 0.0 112.619 -178.258 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -113.87 167.12 10.91 Favored 'General case' 0 C--N 1.309 -1.175 0 CA-C-N 114.389 -1.278 . . . . 0.0 110.001 178.082 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 37.6 t60 69.58 -0.23 2.7 Favored 'General case' 0 C--N 1.333 -0.116 0 O-C-N 124.093 0.87 . . . . 0.0 109.698 -171.785 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' GLU . . . . . 0.411 ' OE1' ' HD2' ' A' ' 6' ' ' PRO . 10.3 pt-20 -62.17 138.85 58.47 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.571 -0.74 . . . . 0.0 110.539 178.79 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -125.59 63.83 1.19 Allowed 'General case' 0 C--N 1.316 -0.863 0 CA-C-O 121.87 0.843 . . . . 0.0 109.778 178.886 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 59.7 t -78.55 -50.54 18.86 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.909 0 CA-C-N 114.436 -1.256 . . . . 0.0 109.149 179.207 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 77.0 t 25.91 80.55 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.444 -0.747 0 O-C-N 125.141 1.526 . . . . 0.0 113.03 -179.614 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' ARG . . . . . 0.437 ' NE ' ' HA ' ' A' ' 13' ' ' ARG . 4.8 mmp_? -142.0 132.96 25.93 Favored 'General case' 0 C--N 1.305 -1.333 0 CA-C-N 113.859 -1.519 . . . . 0.0 110.512 178.944 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.6 t -115.28 158.62 15.54 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.364 0 CA-C-N 114.526 -1.215 . . . . 0.0 109.397 -178.84 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -159.49 64.19 0.29 Allowed Glycine 0 N--CA 1.428 -1.885 0 CA-C-N 114.937 -1.029 . . . . 0.0 111.252 178.052 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 2.0 m -68.3 -43.87 76.71 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-N 114.693 -0.753 . . . . 0.0 110.648 -176.596 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 71.7 mmtt 37.69 72.61 0.84 Allowed Pre-proline 0 C--N 1.324 -0.506 0 O-C-N 124.909 1.381 . . . . 0.0 111.738 -177.656 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 16.8 Cg_exo -68.53 168.49 19.63 Favored 'Trans proline' 0 CA--C 1.512 -0.587 0 C-N-CA 123.345 2.697 . . . . 0.0 112.91 -174.105 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -146.92 -44.31 0.03 OUTLIER Glycine 0 N--CA 1.44 -1.097 0 CA-C-N 113.696 -1.593 . . . . 0.0 111.054 -179.449 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 25.6 m -66.73 -34.12 77.14 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 114.938 -0.631 . . . . 0.0 110.394 177.506 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 9.8 pt-20 -116.27 140.25 49.51 Favored 'General case' 0 N--CA 1.431 -1.398 0 N-CA-C 108.393 -0.966 . . . . 0.0 108.393 177.315 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.4 ' HA ' ' HD3' ' A' ' 23' ' ' PRO . 43.3 t -80.01 128.49 73.56 Favored Pre-proline 0 C--N 1.306 -1.289 0 CA-C-N 115.191 -0.913 . . . . 0.0 111.831 -170.803 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.413 ' HA ' ' HD2' ' A' ' 24' ' ' PRO . 53.9 Cg_exo -54.39 130.36 39.51 Favored 'Trans proline' 0 C--N 1.348 0.509 0 C-N-CA 123.369 2.713 . . . . 0.0 112.304 177.039 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 24' ' ' PRO . . . . . 0.413 ' HD2' ' HA ' ' A' ' 23' ' ' PRO . 11.9 Cg_endo -55.37 141.71 81.17 Favored 'Trans proline' 0 N--CA 1.457 -0.643 0 C-N-CA 123.925 3.083 . . . . 0.0 113.696 -174.909 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.484 ' HB ' HG21 ' A' ' 83' ' ' ILE . 46.2 t -95.69 148.22 5.37 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.977 0 CA-C-N 114.19 -1.368 . . . . 0.0 108.888 175.614 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.574 HG22 HH12 ' A' ' 108' ' ' ARG . 3.2 mp -60.44 -25.43 34.26 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-N 115.421 -0.809 . . . . 0.0 112.21 -170.872 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.487 ' O ' HG12 ' A' ' 30' ' ' ILE . 27.5 m-20 -99.68 -1.65 37.42 Favored 'General case' 0 CA--C 1.507 -0.708 0 CA-C-O 121.41 0.624 . . . . 0.0 110.092 -178.431 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -63.4 -12.19 44.34 Favored Glycine 0 CA--C 1.504 -0.614 0 CA-C-N 114.977 -1.01 . . . . 0.0 111.206 -177.726 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 19.3 m -76.24 -43.35 42.4 Favored 'General case' 0 C--N 1.317 -0.809 0 CA-C-O 121.914 0.864 . . . . 0.0 109.477 177.95 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.504 ' HA ' ' HB1' ' A' ' 105' ' ' ALA . 0.1 OUTLIER -68.9 -38.85 79.15 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.802 0 CA-C-N 114.178 -1.373 . . . . 0.0 107.871 179.775 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 31' ' ' TRP . . . . . 0.49 ' CD1' HG23 ' A' ' 83' ' ' ILE . 17.1 m95 -67.48 -36.96 82.14 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 114.735 -1.121 . . . . 0.0 110.511 -177.627 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 9.7 t70 -75.2 -38.86 60.57 Favored 'General case' 0 N--CA 1.444 -0.759 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.692 179.017 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 33' ' ' ALA . . . . . 0.451 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -70.82 -35.79 72.64 Favored 'General case' 0 N--CA 1.448 -0.548 0 C-N-CA 120.78 -0.368 . . . . 0.0 110.903 178.737 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 34' ' ' ILE . . . . . 0.486 HG13 ' O ' ' A' ' 30' ' ' ILE . 64.8 mt -62.33 -45.6 98.38 Favored 'Isoleucine or valine' 0 C--O 1.234 0.247 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 173.646 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 35' ' ' ALA . . . . . 0.56 ' HA ' ' O ' ' A' ' 54' ' ' GLY . . . -57.62 -38.52 75.1 Favored 'General case' 0 N--CA 1.451 -0.404 0 CA-C-N 115.506 -0.77 . . . . 0.0 110.056 176.734 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 36' ' ' GLY . . . . . 0.445 ' HA2' ' N ' ' A' ' 41' ' ' GLY . . . -73.6 -22.06 78.81 Favored Glycine 0 N--CA 1.451 -0.338 0 CA-C-N 115.467 -0.788 . . . . 0.0 111.944 -179.814 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 6.3 t -84.53 -56.65 3.5 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-O 120.831 0.348 . . . . 0.0 111.608 -178.704 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 38' ' ' GLU . . . . . 0.406 ' HB2' ' SG ' ' A' ' 101' ' ' CYS . 11.4 tp10 -87.61 -30.53 20.41 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 121.063 0.459 . . . . 0.0 110.511 -170.453 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -107.59 -8.01 16.31 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.956 -0.566 . . . . 0.0 111.871 -176.565 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 80.23 4.06 89.79 Favored Glycine 0 CA--C 1.507 -0.408 0 N-CA-C 110.239 -1.144 . . . . 0.0 110.239 -177.535 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 41' ' ' GLY . . . . . 0.445 ' N ' ' HA2' ' A' ' 36' ' ' GLY . . . 89.95 56.41 1.85 Allowed Glycine 0 N--CA 1.432 -1.568 0 CA-C-N 114.006 -1.097 . . . . 0.0 111.302 -175.986 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 2.4 t-20 -141.71 99.48 3.56 Favored 'General case' 0 N--CA 1.447 -0.596 0 N-CA-C 108.732 -0.84 . . . . 0.0 108.732 -175.655 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 43' ' ' TRP . . . . . 0.76 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 23.4 m95 -83.81 -4.33 58.57 Favored 'General case' 0 C--N 1.313 -1.005 0 CA-C-N 115.723 -0.672 . . . . 0.0 110.158 -173.39 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 44' ' ' ALA . . . . . 0.454 ' HA ' ' HB2' ' A' ' 75' ' ' ASP . . . -109.3 10.74 25.57 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 115.183 -0.917 . . . . 0.0 111.06 179.351 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.726 HG22 ' HA2' ' A' ' 53' ' ' GLY . 9.0 tt -76.09 144.57 11.71 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.792 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.31 179.892 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 10.3 t-20 -142.46 97.96 3.21 Favored 'General case' 0 C--N 1.31 -1.111 0 N-CA-C 108.995 -0.743 . . . . 0.0 108.995 177.393 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 10.0 p -70.08 -22.28 63.06 Favored 'General case' 0 N--CA 1.445 -0.715 0 CA-C-N 114.819 -1.082 . . . . 0.0 111.345 -173.753 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 90.39 17.2 53.66 Favored Glycine 0 N--CA 1.44 -1.066 0 N-CA-C 110.094 -1.202 . . . . 0.0 110.094 -176.773 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 5.1 m-20 -91.34 -5.91 53.85 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.169 -0.516 . . . . 0.0 111.01 -175.183 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 50' ' ' GLY . . . . . 0.407 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 94.25 -5.1 71.16 Favored Glycine 0 N--CA 1.444 -0.77 0 N-CA-C 110.081 -1.208 . . . . 0.0 110.081 -172.676 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 51' ' ' TYR . . . . . 0.623 ' HA ' ' HA ' ' A' ' 58' ' ' ASP . 0.4 OUTLIER -111.61 149.15 31.91 Favored 'General case' 0 N--CA 1.446 -0.664 0 N-CA-C 106.976 -1.491 . . . . 0.0 106.976 177.916 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 52' ' ' TYR . . . . . 0.699 ' O ' ' HA ' ' A' ' 56' ' ' GLN . 71.0 m-85 -114.59 170.37 8.36 Favored 'General case' 0 C--N 1.307 -1.245 0 C-N-CA 120.432 -0.507 . . . . 0.0 111.908 -168.655 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.726 ' HA2' HG22 ' A' ' 45' ' ' ILE . . . -57.94 171.91 3.45 Favored Glycine 0 C--O 1.227 -0.321 0 N-CA-C 115.072 0.789 . . . . 0.0 115.072 -168.919 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.675 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 80.4 -101.76 2.02 Favored Glycine 0 N--CA 1.442 -0.924 0 C-N-CA 120.955 -0.641 . . . . 0.0 112.148 177.367 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.512 HG12 ' HE1' ' A' ' 98' ' ' TRP . 2.4 t -83.3 -3.04 7.13 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-O 121.646 0.736 . . . . 0.0 110.296 -176.68 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 56' ' ' GLN . . . . . 0.699 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 7.7 tp-100 54.83 50.47 15.6 Favored 'General case' 0 CA--C 1.53 0.186 0 CA-C-N 114.034 -1.439 . . . . 0.0 112.852 169.203 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 57' ' ' PHE . . . . . 0.496 ' CE1' ' HB ' ' A' ' 55' ' ' VAL . 2.0 p90 -121.54 163.32 19.05 Favored 'General case' 0 C--N 1.325 -0.474 0 C-N-CA 120.213 -0.595 . . . . 0.0 111.532 176.995 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.623 ' HA ' ' HA ' ' A' ' 51' ' ' TYR . 7.8 p-10 -72.29 162.3 29.65 Favored 'General case' 0 CA--C 1.514 -0.419 0 N-CA-C 113.76 1.022 . . . . 0.0 113.76 -163.511 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.44 ' HB2' ' HE1' ' A' ' 52' ' ' TYR . 17.7 tp60 -55.15 -42.2 72.76 Favored 'General case' 0 N--CA 1.441 -0.878 0 CA-C-N 114.327 -1.306 . . . . 0.0 110.969 177.206 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -67.84 -50.44 41.63 Favored Glycine 0 C--O 1.224 -0.481 0 CA-C-N 115.183 -0.917 . . . . 0.0 112.584 -172.819 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 97.1 m -61.67 -41.46 97.57 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 121.177 0.513 . . . . 0.0 110.8 177.139 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 62' ' ' TRP . . . . . 0.439 ' CH2' ' HA ' ' A' ' 74' ' ' ALA . 52.4 t-105 -58.23 -49.11 78.23 Favored 'General case' 0 N--CA 1.446 -0.671 0 CA-C-N 115.467 -0.788 . . . . 0.0 109.691 175.786 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 63' ' ' GLU . . . . . 0.479 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 36.2 tt0 -67.13 -36.75 82.55 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.193 -0.912 . . . . 0.0 110.801 -178.205 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -63.53 -41.49 98.47 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.591 -0.731 . . . . 0.0 111.195 -176.882 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 65' ' ' ASN . . . . . 0.646 HD22 ' N ' ' A' ' 65' ' ' ASN . 0.7 OUTLIER -81.09 -8.74 59.83 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 121.1 0.476 . . . . 0.0 110.22 177.632 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 66' ' ' GLY . . . . . 0.47 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 89.35 48.6 3.71 Favored Glycine 0 C--N 1.334 0.433 0 CA-C-N 115.746 -0.661 . . . . 0.0 112.271 174.678 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.484 ' HA2' ' HD1' ' A' ' 70' ' ' TYR . . . -79.36 -22.91 64.02 Favored Glycine 0 N--CA 1.439 -1.121 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.838 -175.051 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.79 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 6.9 mp -58.89 -25.95 63.84 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 112.893 0.701 . . . . 0.0 112.893 -172.945 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 69' ' ' ARG . . . . . 0.47 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 14.9 ptp180 -70.5 -29.24 65.7 Favored 'General case' 0 C--N 1.318 -0.772 0 CA-C-O 121.079 0.466 . . . . 0.0 110.553 176.643 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 70' ' ' TYR . . . . . 0.622 ' HB3' ' CG ' ' A' ' 81' ' ' GLU . 74.2 m-85 -79.32 -34.25 42.46 Favored 'General case' 0 N--CA 1.444 -0.749 0 N-CA-C 107.05 -1.463 . . . . 0.0 107.05 175.764 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.679 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 161.81 130.27 0.01 OUTLIER Pre-proline 0 CA--C 1.511 -0.524 0 CA-C-N 112.037 -2.347 . . . . 0.0 106.817 -179.117 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 72' ' ' PRO . . . . . 0.79 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 13.5 Cg_exo -58.33 -2.13 0.85 Allowed 'Trans proline' 0 C--N 1.33 -0.415 0 C-N-CA 122.837 2.358 . . . . 0.0 113.965 -177.083 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 73' ' ' ARG . . . . . 0.455 ' HB2' ' CD2' ' A' ' 52' ' ' TYR . 0.0 OUTLIER -153.3 142.56 21.52 Favored 'General case' 0 C--N 1.316 -0.85 0 N-CA-C 109.211 -0.663 . . . . 0.0 109.211 177.695 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 74' ' ' ALA . . . . . 0.509 ' HB3' ' HB2' ' A' ' 52' ' ' TYR . . . -60.2 -27.94 67.57 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.32 -0.855 . . . . 0.0 112.721 -175.464 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 75' ' ' ASP . . . . . 0.575 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 6.7 p-10 -86.87 3.2 46.44 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 121.246 0.546 . . . . 0.0 110.824 -176.6 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.525 ' HB3' ' HB1' ' A' ' 71' ' ' ALA . 50.7 tp -103.68 -34.12 8.72 Favored 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 171.155 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 77' ' ' ALA . . . . . 0.679 ' HB2' ' HB3' ' A' ' 71' ' ' ALA . . . -79.86 161.51 25.56 Favored 'General case' 0 N--CA 1.448 -0.568 0 CA-C-N 115.1 -0.955 . . . . 0.0 109.93 175.621 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 36.1 p -101.2 -173.19 2.31 Favored 'General case' 0 C--N 1.318 -0.796 0 C-N-CA 120.788 -0.365 . . . . 0.0 110.74 179.874 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 79' ' ' ARG . . . . . 0.76 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 9.0 mtp85 -52.59 -51.98 57.34 Favored 'General case' 0 CA--C 1.513 -0.46 0 O-C-N 123.592 0.558 . . . . 0.0 110.953 -174.789 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 1.3 pm0 -59.71 -41.67 91.34 Favored 'General case' 0 C--N 1.317 -0.836 0 CA-C-N 115.319 -0.855 . . . . 0.0 112.131 -176.504 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 81' ' ' GLU . . . . . 0.648 ' CB ' ' HB1' ' A' ' 77' ' ' ALA . 2.3 mp0 -62.26 -51.23 68.57 Favored 'General case' 0 C--O 1.234 0.254 0 O-C-N 122.352 -0.218 . . . . 0.0 111.322 174.377 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 82' ' ' GLN . . . . . 0.437 ' HB2' ' HZ3' ' A' ' 43' ' ' TRP . 50.3 mt-30 -60.9 -37.01 80.74 Favored 'General case' 0 CA--C 1.514 -0.413 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.66 -177.9 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.49 HG23 ' CD1' ' A' ' 31' ' ' TRP . 42.1 mt -59.28 -45.51 93.06 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.777 0 CA-C-N 115.139 -0.937 . . . . 0.0 109.801 176.742 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 84' ' ' ALA . . . . . 0.649 ' O ' ' HG3' ' A' ' 87' ' ' GLU . . . -66.35 -45.98 78.32 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.621 -177.908 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.424 HG23 ' O ' ' A' ' 81' ' ' GLU . 44.0 t -66.06 -49.01 79.61 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-O 120.779 0.323 . . . . 0.0 111.631 -179.926 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -67.02 -31.3 71.75 Favored 'General case' 0 CA--C 1.516 -0.359 0 CA-C-O 121.147 0.498 . . . . 0.0 110.498 -179.719 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 87' ' ' GLU . . . . . 0.768 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 0.1 OUTLIER -69.69 -31.5 69.58 Favored 'General case' 0 C--N 1.322 -0.604 0 C-N-CA 120.149 -0.62 . . . . 0.0 110.325 -176.455 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.584 ' O ' ' HG3' ' A' ' 92' ' ' ARG . 69.1 t -61.43 -40.77 87.47 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.224 0 N-CA-C 108.839 -0.8 . . . . 0.0 108.839 172.89 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 89' ' ' THR . . . . . 0.91 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 4.3 m -64.8 -43.32 93.54 Favored 'General case' 0 N--CA 1.447 -0.597 0 CA-C-N 115.648 -0.706 . . . . 0.0 110.388 179.367 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 90' ' ' ARG . . . . . 0.54 ' HG3' ' O ' ' A' ' 87' ' ' GLU . 1.2 ppt_? -61.53 -31.24 71.24 Favored 'General case' 0 C--O 1.223 -0.336 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.561 179.907 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 91' ' ' LEU . . . . . 0.768 ' HG ' ' O ' ' A' ' 87' ' ' GLU . 28.8 mt -64.07 -33.56 76.03 Favored 'General case' 0 C--N 1.318 -0.801 0 CA-C-O 121.63 0.729 . . . . 0.0 109.88 -179.872 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 92' ' ' ARG . . . . . 0.584 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 7.6 mtm180 -91.62 -51.58 5.18 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 115.058 -0.974 . . . . 0.0 110.618 -169.925 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 93' ' ' GLN . . . . . 0.574 HE22 ' HZ3' ' A' ' 98' ' ' TRP . 0.0 OUTLIER -106.49 -14.51 15.05 Favored 'General case' 0 N--CA 1.443 -0.786 0 CA-C-N 115.446 -0.797 . . . . 0.0 112.016 -175.293 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.441 ' O ' ' HA ' ' A' ' 90' ' ' ARG . . . 86.74 -109.14 3.39 Favored Glycine 0 CA--C 1.496 -1.116 0 N-CA-C 110.797 -0.921 . . . . 0.0 110.797 178.813 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 95' ' ' TRP . . . . . 0.46 ' HB3' ' HB1' ' A' ' 102' ' ' ALA . 6.6 m95 -141.17 24.39 2.14 Favored 'General case' 0 C--N 1.311 -1.103 0 N-CA-C 107.207 -1.405 . . . . 0.0 107.207 -179.794 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -77.29 -20.76 74.57 Favored Glycine 0 N--CA 1.447 -0.594 0 CA-C-N 114.381 -1.281 . . . . 0.0 111.831 175.616 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 97' ' ' ALA . . . . . 0.426 ' O ' ' HD3' ' A' ' 99' ' ' PRO . . . -90.35 -24.04 20.95 Favored 'General case' 0 CA--C 1.516 -0.364 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 176.248 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 98' ' ' TRP . . . . . 0.91 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 24.3 m-90 -96.59 104.69 18.88 Favored Pre-proline 0 N--CA 1.451 -0.42 0 N-CA-C 108.811 -0.811 . . . . 0.0 108.811 173.643 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 99' ' ' PRO . . . . . 0.503 ' HB2' ' H ' ' A' ' 100' ' ' VAL . 28.9 Cg_exo -67.34 -110.1 0.0 OUTLIER 'Trans proline' 0 CA--C 1.538 0.719 0 C-N-CA 123.49 2.793 . . . . 0.0 114.757 -171.826 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 100' ' ' VAL . . . . . 0.503 ' H ' ' HB2' ' A' ' 99' ' ' PRO . 40.8 t -67.41 -31.5 53.09 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-O 121.305 0.574 . . . . 0.0 110.432 -174.506 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 101' ' ' CYS . . . . . 0.406 ' SG ' ' HB2' ' A' ' 38' ' ' GLU . 98.5 m -68.71 -32.78 72.82 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 115.28 -0.873 . . . . 0.0 111.92 -171.82 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 102' ' ' ALA . . . . . 0.46 ' HB1' ' HB3' ' A' ' 95' ' ' TRP . . . -69.65 -44.63 70.16 Favored 'General case' 0 C--N 1.324 -0.513 0 C-N-CA 120.651 -0.419 . . . . 0.0 110.202 178.822 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -65.66 -34.28 77.85 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 121.172 0.511 . . . . 0.0 110.406 178.5 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 104' ' ' ARG . . . . . 0.494 ' HG2' ' O ' ' A' ' 100' ' ' VAL . 3.4 mmp_? -70.3 -28.5 65.23 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.129 176.544 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 105' ' ' ALA . . . . . 0.504 ' HB1' ' HA ' ' A' ' 30' ' ' ILE . . . -89.43 -20.82 23.46 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.808 -0.633 . . . . 0.0 112.114 -175.549 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 110.4 64.35 0.52 Allowed Glycine 0 N--CA 1.447 -0.61 0 C-N-CA 120.95 -0.643 . . . . 0.0 111.681 -177.155 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -63.53 149.25 46.67 Favored 'General case' 0 C--N 1.328 -0.337 0 C-N-CA 122.848 0.459 . . . . 0.0 110.824 -176.823 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 108' ' ' ARG . . . . . 0.574 HH12 HG22 ' A' ' 26' ' ' ILE . 91.2 mtt180 . . . . . 0 C--O 1.247 0.944 0 CA-C-O 118.368 -0.825 . . . . 0.0 109.756 -173.016 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 2.7 m-20 . . . . . 0 N--CA 1.476 0.828 0 N-CA-C 109.31 -0.626 . . . . 0.0 109.31 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 18.7 t -78.27 64.2 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.312 -1.044 0 CA-C-N 114.84 -1.073 . . . . 0.0 110.318 -176.348 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 56.4 t -66.68 108.23 1.03 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.864 0 CA-C-N 115.093 -0.958 . . . . 0.0 110.484 173.869 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 11.5 t -100.48 149.2 6.2 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.569 0 N-CA-C 109.407 -0.59 . . . . 0.0 109.407 179.934 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' THR . . . . . 0.443 ' HA ' ' HD3' ' A' ' 6' ' ' PRO . 70.0 p -111.2 122.11 38.65 Favored Pre-proline 0 C--N 1.314 -0.936 0 CA-C-O 121.187 0.518 . . . . 0.0 110.963 -179.63 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.453 ' C ' ' H ' ' A' ' 8' ' ' HIS . 6.3 Cg_exo -80.45 178.19 7.34 Favored 'Trans proline' 0 N--CA 1.453 -0.866 0 C-N-CA 123.275 2.65 . . . . 0.0 109.708 170.008 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -77.36 24.8 0.18 Allowed 'General case' 0 C--N 1.308 -1.203 0 CA-C-O 121.663 0.744 . . . . 0.0 111.074 -179.809 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' HIS . . . . . 0.453 ' H ' ' C ' ' A' ' 6' ' ' PRO . 37.3 t60 -78.41 -9.71 59.4 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 114.614 -1.176 . . . . 0.0 108.244 167.177 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 13.5 pt-20 -81.57 144.59 31.16 Favored 'General case' 0 N--CA 1.453 -0.315 0 N-CA-C 109.232 -0.655 . . . . 0.0 109.232 177.774 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -82.86 55.06 2.91 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-O 122.156 0.979 . . . . 0.0 110.534 -176.974 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 15.0 p -69.47 -19.42 23.24 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.039 0 CA-C-N 113.476 -1.693 . . . . 0.0 110.058 179.41 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 5.6 t 54.69 105.11 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.441 -0.901 0 CA-C-O 122.802 1.287 . . . . 0.0 112.783 178.968 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 38.4 ptt180 -74.02 159.58 32.49 Favored 'General case' 0 N--CA 1.432 -1.359 0 CA-C-N 113.665 -1.607 . . . . 0.0 108.999 175.78 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.5 t -76.99 158.27 5.3 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.682 0 CA-C-N 114.152 -1.385 . . . . 0.0 110.637 -173.915 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -116.03 64.32 0.33 Allowed Glycine 0 N--CA 1.428 -1.841 0 CA-C-N 114.271 -1.331 . . . . 0.0 110.554 177.675 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 2.2 m -62.71 -32.24 73.31 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-N 113.953 -1.124 . . . . 0.0 112.137 -176.612 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -80.74 117.52 68.28 Favored Pre-proline 0 C--N 1.311 -1.091 0 CA-C-N 114.619 -1.173 . . . . 0.0 111.309 -176.156 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 26.0 Cg_exo -64.24 172.98 5.61 Favored 'Trans proline' 0 N--CA 1.453 -0.862 0 C-N-CA 123.597 2.865 . . . . 0.0 111.159 171.151 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 121.53 51.25 0.24 Allowed Glycine 0 C--N 1.297 -1.616 0 N-CA-C 109.804 -1.319 . . . . 0.0 109.804 -172.051 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 22.8 m -66.43 -33.36 75.53 Favored 'General case' 0 C--N 1.316 -0.857 0 CA-C-N 114.445 -0.878 . . . . 0.0 110.835 -178.426 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 2.2 mp0 46.65 84.64 0.03 OUTLIER 'General case' 0 N--CA 1.447 -0.579 0 CA-C-O 121.886 0.85 . . . . 0.0 110.687 -168.396 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 48.2 t -74.55 119.75 78.15 Favored Pre-proline 0 C--N 1.31 -1.11 0 CA-C-N 114.151 -1.386 . . . . 0.0 109.871 -175.024 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_exo -54.75 128.63 31.17 Favored 'Trans proline' 0 N--CA 1.453 -0.874 0 C-N-CA 122.394 2.063 . . . . 0.0 110.912 177.268 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 9.6 Cg_endo -54.57 138.83 75.57 Favored 'Trans proline' 0 N--CA 1.451 -0.974 0 C-N-CA 122.752 2.301 . . . . 0.0 112.332 -175.166 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.488 ' HB ' HG21 ' A' ' 83' ' ' ILE . 38.1 t -85.4 144.86 8.77 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.156 0 CA-C-N 114.389 -1.278 . . . . 0.0 108.999 -178.563 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 41.2 mm -60.55 -24.43 31.59 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 CA-C-N 115.246 -0.888 . . . . 0.0 112.026 -173.222 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.4 ' O ' HG12 ' A' ' 30' ' ' ILE . 4.3 m-20 -95.77 2.81 54.07 Favored 'General case' 0 CA--C 1.507 -0.679 0 CA-C-O 121.742 0.782 . . . . 0.0 109.605 -179.03 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -65.84 -9.54 46.57 Favored Glycine 0 N--CA 1.441 -0.969 0 CA-C-N 114.868 -1.06 . . . . 0.0 110.721 177.381 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 21.8 m -76.93 -41.5 43.16 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-O 121.571 0.7 . . . . 0.0 109.387 175.181 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.553 ' HA ' ' HB1' ' A' ' 105' ' ' ALA . 0.8 OUTLIER -66.68 -38.81 82.34 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.64 0 N-CA-C 107.645 -1.243 . . . . 0.0 107.645 177.223 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 31' ' ' TRP . . . . . 0.485 ' CD1' HG23 ' A' ' 83' ' ' ILE . 36.8 m95 -70.91 -35.75 72.42 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 114.627 -1.169 . . . . 0.0 110.894 -177.922 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.442 ' HB2' HH21 ' A' ' 79' ' ' ARG . 1.9 t70 -72.53 -36.76 68.4 Favored 'General case' 0 N--CA 1.449 -0.509 0 CA-C-N 116.387 -0.37 . . . . 0.0 110.338 177.771 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 33' ' ' ALA . . . . . 0.489 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -70.19 -35.36 73.9 Favored 'General case' 0 N--CA 1.448 -0.552 0 C-N-CA 120.627 -0.429 . . . . 0.0 110.392 177.96 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 34' ' ' ILE . . . . . 0.44 HG13 ' O ' ' A' ' 30' ' ' ILE . 64.5 mt -67.13 -43.54 88.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.312 174.05 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 35' ' ' ALA . . . . . 0.521 ' HA ' ' O ' ' A' ' 54' ' ' GLY . . . -59.59 -35.02 73.47 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 121.313 0.578 . . . . 0.0 110.15 175.973 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 36' ' ' GLY . . . . . 0.422 ' HA2' ' N ' ' A' ' 41' ' ' GLY . . . -77.62 -14.97 81.88 Favored Glycine 0 N--CA 1.448 -0.564 0 CA-C-N 115.497 -0.774 . . . . 0.0 111.873 178.409 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 36.8 t -95.92 -48.01 5.89 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-O 120.737 0.303 . . . . 0.0 111.387 -177.032 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 38' ' ' GLU . . . . . 0.481 ' HG2' ' SG ' ' A' ' 101' ' ' CYS . 8.5 mm-40 -86.91 -34.2 19.46 Favored 'General case' 0 CA--C 1.511 -0.541 0 CA-C-O 121.077 0.465 . . . . 0.0 110.17 -175.538 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -107.94 -12.47 15.16 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.613 -0.721 . . . . 0.0 112.064 -174.089 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 76.31 16.65 80.55 Favored Glycine 0 N--CA 1.449 -0.461 0 N-CA-C 109.957 -1.257 . . . . 0.0 109.957 -176.767 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 41' ' ' GLY . . . . . 0.422 ' N ' ' HA2' ' A' ' 36' ' ' GLY . . . 82.98 59.91 2.12 Favored Glycine 0 N--CA 1.434 -1.475 0 CA-C-N 113.944 -1.128 . . . . 0.0 111.807 -176.904 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 42' ' ' ASN . . . . . 0.849 ' HB3' ' HB ' ' A' ' 45' ' ' ILE . 3.4 m120 -146.1 96.02 2.72 Favored 'General case' 0 C--N 1.324 -0.515 0 N-CA-C 109.223 -0.658 . . . . 0.0 109.223 -178.893 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 43' ' ' TRP . . . . . 0.695 ' CE2' ' HG2' ' A' ' 79' ' ' ARG . 52.5 m95 -78.88 -14.39 59.26 Favored 'General case' 0 C--N 1.314 -0.975 0 CA-C-N 115.711 -0.677 . . . . 0.0 109.803 -177.941 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 44' ' ' ALA . . . . . 0.414 ' HA ' ' HB2' ' A' ' 75' ' ' ASP . . . -102.48 7.97 40.12 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 115.271 -0.877 . . . . 0.0 111.289 -179.692 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.849 ' HB ' ' HB3' ' A' ' 42' ' ' ASN . 8.2 tt -74.18 145.16 11.62 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.708 0 CA-C-O 121.401 0.619 . . . . 0.0 110.984 -177.182 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 17.4 t-20 -141.5 96.19 2.94 Favored 'General case' 0 C--N 1.309 -1.183 0 N-CA-C 109.099 -0.704 . . . . 0.0 109.099 178.953 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 19.7 p -68.61 -21.3 64.51 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 115.029 -0.987 . . . . 0.0 111.058 -177.486 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 88.06 18.22 56.27 Favored Glycine 0 N--CA 1.441 -1.001 0 N-CA-C 110.373 -1.091 . . . . 0.0 110.373 179.44 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 92.2 m-20 -97.37 10.23 40.2 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 121.092 0.472 . . . . 0.0 111.347 -174.621 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 50' ' ' GLY . . . . . 0.406 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 90.96 -11.6 71.59 Favored Glycine 0 N--CA 1.443 -0.842 0 N-CA-C 110.853 -0.899 . . . . 0.0 110.853 -178.003 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 51' ' ' TYR . . . . . 0.634 ' HA ' ' HA ' ' A' ' 58' ' ' ASP . 0.7 OUTLIER -109.58 152.36 25.61 Favored 'General case' 0 CA--C 1.509 -0.624 0 N-CA-C 108.092 -1.077 . . . . 0.0 108.092 178.026 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 52' ' ' TYR . . . . . 0.78 ' O ' ' HA ' ' A' ' 56' ' ' GLN . 18.4 m-85 -112.81 169.93 8.56 Favored 'General case' 0 C--N 1.31 -1.12 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.698 -169.763 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.441 ' CA ' HG22 ' A' ' 45' ' ' ILE . . . -66.08 -171.79 4.07 Favored Glycine 0 N--CA 1.451 -0.361 0 N-CA-C 115.025 0.77 . . . . 0.0 115.025 -168.353 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.639 ' CA ' ' HA ' ' A' ' 43' ' ' TRP . . . 75.27 -101.97 1.42 Allowed Glycine 0 N--CA 1.443 -0.847 0 CA-C-N 114.738 -0.731 . . . . 0.0 112.177 178.475 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.551 HG12 ' HE1' ' A' ' 98' ' ' TRP . 2.3 t -84.3 -3.54 7.95 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 CA-C-O 121.606 0.717 . . . . 0.0 109.541 179.409 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 56' ' ' GLN . . . . . 0.78 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 15.9 mm-40 57.93 46.83 16.04 Favored 'General case' 0 N--CA 1.463 0.179 0 CA-C-N 114.432 -1.258 . . . . 0.0 113.556 170.256 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 57' ' ' PHE . . . . . 0.507 ' CE1' ' HB ' ' A' ' 55' ' ' VAL . 0.3 OUTLIER -117.15 166.61 12.03 Favored 'General case' 0 C--N 1.323 -0.581 0 C-N-CA 119.597 -0.841 . . . . 0.0 111.956 175.069 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.634 ' HA ' ' HA ' ' A' ' 51' ' ' TYR . 7.2 p-10 -74.8 162.89 28.25 Favored 'General case' 0 CA--C 1.514 -0.411 0 CA-C-N 115.444 -0.798 . . . . 0.0 113.071 -167.055 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.531 ' HB2' ' CE1' ' A' ' 52' ' ' TYR . 4.5 tp-100 -63.06 -35.36 79.99 Favored 'General case' 0 N--CA 1.448 -0.567 0 CA-C-N 114.318 -1.31 . . . . 0.0 111.069 179.623 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -65.15 -49.69 60.75 Favored Glycine 0 C--N 1.312 -0.756 0 CA-C-N 115.368 -0.833 . . . . 0.0 111.437 -178.067 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 91.5 m -65.9 -42.6 90.01 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-O 120.757 0.313 . . . . 0.0 110.986 176.375 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 62' ' ' TRP . . . . . 0.464 ' CH2' ' HA ' ' A' ' 74' ' ' ALA . 60.3 t-105 -56.26 -47.72 77.98 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 121.549 0.69 . . . . 0.0 109.656 177.353 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 5.1 tp10 -66.13 -34.78 78.83 Favored 'General case' 0 C--N 1.318 -0.802 0 CA-C-N 114.818 -1.083 . . . . 0.0 110.505 179.002 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -63.58 -42.54 98.29 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.17 -177.439 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 65' ' ' ASN . . . . . 0.73 ' HB2' HG13 ' A' ' 85' ' ' VAL . 27.4 m-80 -81.09 -9.99 59.74 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.927 0.394 . . . . 0.0 110.313 176.872 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 66' ' ' GLY . . . . . 0.472 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 87.69 51.83 3.15 Favored Glycine 0 C--O 1.225 -0.447 0 CA-C-N 115.888 -0.596 . . . . 0.0 112.429 175.357 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.581 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -80.14 -23.77 60.68 Favored Glycine 0 N--CA 1.442 -0.956 0 C-N-CA 120.946 -0.645 . . . . 0.0 112.666 -176.604 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 1.033 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 7.2 mp -61.25 -17.66 54.48 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 112.877 0.695 . . . . 0.0 112.877 -172.751 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 69' ' ' ARG . . . . . 0.472 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 17.5 ptp180 -70.59 -34.75 72.5 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-O 121.154 0.502 . . . . 0.0 109.775 174.724 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 70' ' ' TYR . . . . . 0.661 ' HB3' ' HB3' ' A' ' 81' ' ' GLU . 54.1 m-85 -80.94 -34.59 33.18 Favored 'General case' 0 N--CA 1.444 -0.77 0 N-CA-C 107.551 -1.278 . . . . 0.0 107.551 179.221 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.609 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 166.32 127.14 0.03 OUTLIER Pre-proline 0 N--CA 1.445 -0.722 0 CA-C-N 112.755 -2.02 . . . . 0.0 106.995 -178.096 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 72' ' ' PRO . . . . . 1.033 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 24.4 Cg_exo -55.91 -7.18 1.49 Allowed 'Trans proline' 0 C--N 1.334 -0.227 0 C-N-CA 122.958 2.439 . . . . 0.0 113.821 -177.68 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 73' ' ' ARG . . . . . 0.504 ' HB2' ' CD2' ' A' ' 52' ' ' TYR . 11.4 ptm180 -144.58 137.12 26.53 Favored 'General case' 0 C--N 1.314 -0.935 0 N-CA-C 108.987 -0.746 . . . . 0.0 108.987 178.059 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 74' ' ' ALA . . . . . 0.517 ' HB3' ' HB2' ' A' ' 52' ' ' TYR . . . -55.78 -31.45 62.63 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 114.935 -1.029 . . . . 0.0 112.614 -175.993 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 75' ' ' ASP . . . . . 0.639 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 6.4 p-10 -81.2 -10.02 59.69 Favored 'General case' 0 C--N 1.328 -0.34 0 C-N-CA 120.426 -0.51 . . . . 0.0 111.312 -174.443 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 67.9 tp -93.94 -27.7 16.22 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-O 121.798 0.808 . . . . 0.0 108.921 172.801 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 77' ' ' ALA . . . . . 0.779 ' HB1' ' HB2' ' A' ' 81' ' ' GLU . . . -79.16 159.38 27.44 Favored 'General case' 0 N--CA 1.441 -0.909 0 CA-C-N 114.723 -1.126 . . . . 0.0 109.863 174.779 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 70.6 p -100.91 -174.59 2.66 Favored 'General case' 0 C--N 1.313 -0.983 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.932 -176.818 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 79' ' ' ARG . . . . . 0.695 ' HG2' ' CE2' ' A' ' 43' ' ' TRP . 77.0 mtp180 -51.02 -53.53 32.65 Favored 'General case' 0 CA--C 1.514 -0.419 0 CA-C-O 120.893 0.378 . . . . 0.0 110.702 -178.675 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 1.7 pm0 -63.18 -36.11 82.53 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-N 115.463 -0.789 . . . . 0.0 111.804 -175.016 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 81' ' ' GLU . . . . . 0.779 ' HB2' ' HB1' ' A' ' 77' ' ' ALA . 3.5 mm-40 -66.75 -50.7 61.88 Favored 'General case' 0 CA--C 1.516 -0.356 0 CA-C-O 121.041 0.448 . . . . 0.0 110.104 178.827 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 82' ' ' GLN . . . . . 0.586 ' HB2' ' HZ3' ' A' ' 43' ' ' TRP . 48.0 mt-30 -64.68 -35.81 82.23 Favored 'General case' 0 CA--C 1.511 -0.541 0 CA-C-N 115.685 -0.688 . . . . 0.0 110.062 -178.452 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.667 ' O ' ' HG2' ' A' ' 87' ' ' GLU . 53.1 mt -59.23 -48.87 85.44 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.812 0 CA-C-N 115.45 -0.796 . . . . 0.0 109.265 174.199 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 84' ' ' ALA . . . . . 0.538 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -61.51 -42.24 98.52 Favored 'General case' 0 C--O 1.239 0.517 0 CA-C-O 121.083 0.468 . . . . 0.0 111.615 -177.682 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.73 HG13 ' HB2' ' A' ' 65' ' ' ASN . 69.5 t -67.85 -48.5 75.17 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.85 179.494 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 86' ' ' ALA . . . . . 0.435 ' HB1' ' CH2' ' A' ' 31' ' ' TRP . . . -60.74 -29.12 69.19 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.543 174.594 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 87' ' ' GLU . . . . . 0.667 ' HG2' ' O ' ' A' ' 83' ' ' ILE . 14.8 mm-40 -59.75 -44.31 93.87 Favored 'General case' 0 N--CA 1.469 0.477 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.494 -179.797 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.573 ' O ' ' HG3' ' A' ' 92' ' ' ARG . 61.7 t -62.94 -40.49 89.12 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.44 0 N-CA-C 109.712 -0.477 . . . . 0.0 109.712 176.641 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 89' ' ' THR . . . . . 0.859 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 1.0 OUTLIER -70.03 -48.9 56.1 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.958 -0.565 . . . . 0.0 111.484 -175.89 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 90' ' ' ARG . . . . . 0.625 ' HA ' ' OE1' ' A' ' 93' ' ' GLN . 2.3 ptt180 -60.86 -33.63 73.38 Favored 'General case' 0 CA--C 1.519 -0.24 0 CA-C-N 116.025 -0.534 . . . . 0.0 111.638 -173.539 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 91' ' ' LEU . . . . . 0.571 ' HG ' ' O ' ' A' ' 88' ' ' VAL . 4.7 pp -71.42 -21.84 61.93 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.588 -175.188 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 92' ' ' ARG . . . . . 0.573 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 22.0 mtm180 -88.02 -52.39 5.28 Favored 'General case' 0 CA--C 1.509 -0.615 0 CA-C-O 121.247 0.546 . . . . 0.0 110.689 -175.8 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 93' ' ' GLN . . . . . 0.625 ' OE1' ' HA ' ' A' ' 90' ' ' ARG . 0.0 OUTLIER -95.3 -21.83 18.16 Favored 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 113.048 0.758 . . . . 0.0 113.048 -171.356 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 88.1 42.34 5.97 Favored Glycine 0 CA--C 1.506 -0.492 0 C-N-CA 120.488 -0.863 . . . . 0.0 111.97 172.251 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 95' ' ' TRP . . . . . 0.417 ' HA ' ' HE3' ' A' ' 98' ' ' TRP . 6.7 m95 62.7 12.15 5.4 Favored 'General case' 0 C--O 1.22 -0.489 0 C-N-CA 123.587 0.755 . . . . 0.0 109.801 -179.347 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -74.14 -20.0 79.73 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 121.172 -0.537 . . . . 0.0 112.458 179.46 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -78.58 -27.23 45.68 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 121.157 0.503 . . . . 0.0 109.872 176.628 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 98' ' ' TRP . . . . . 0.859 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 27.0 m-90 -101.04 103.65 26.9 Favored Pre-proline 0 C--N 1.324 -0.53 0 N-CA-C 108.86 -0.793 . . . . 0.0 108.86 176.399 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 99' ' ' PRO . . . . . 0.404 ' HB2' ' H ' ' A' ' 100' ' ' VAL . 14.7 Cg_exo -74.77 -88.54 0.0 OUTLIER 'Trans proline' 0 CA--C 1.53 0.28 0 C-N-CA 123.034 2.489 . . . . 0.0 114.872 -170.894 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 100' ' ' VAL . . . . . 0.404 ' H ' ' HB2' ' A' ' 99' ' ' PRO . 61.1 t -70.59 -29.91 40.29 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 CA-C-O 121.555 0.693 . . . . 0.0 110.565 -171.966 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 101' ' ' CYS . . . . . 0.481 ' SG ' ' HG2' ' A' ' 38' ' ' GLU . 85.0 m -83.29 -32.48 26.33 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-N 115.14 -0.936 . . . . 0.0 112.021 -169.012 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -68.11 -43.01 79.42 Favored 'General case' 0 C--N 1.327 -0.393 0 C-N-CA 120.47 -0.492 . . . . 0.0 110.098 177.493 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -60.58 -36.12 77.74 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 121.194 0.521 . . . . 0.0 110.739 177.515 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 35.5 mtp180 -73.03 -38.83 66.41 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.702 -0.681 . . . . 0.0 111.183 177.379 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 105' ' ' ALA . . . . . 0.553 ' HB1' ' HA ' ' A' ' 30' ' ' ILE . . . -80.79 -22.42 40.1 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 115.632 -0.713 . . . . 0.0 112.567 -173.69 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 116.57 62.44 0.33 Allowed Glycine 0 CA--C 1.521 0.415 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.31 -178.623 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -63.25 149.46 45.51 Favored 'General case' 0 C--N 1.328 -0.337 0 C-N-CA 122.927 0.491 . . . . 0.0 110.748 179.417 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 72.0 mtp180 . . . . . 0 C--O 1.247 0.937 0 CA-C-O 118.247 -0.882 . . . . 0.0 111.089 -170.546 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 89.1 m-20 . . . . . 0 N--CA 1.476 0.842 0 CA-C-O 121.619 0.723 . . . . 0.0 110.697 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 9.1 p -95.55 -3.88 10.4 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.073 0 CA-C-N 114.769 -1.105 . . . . 0.0 109.811 178.384 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 60.1 t -59.29 108.01 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 CA-C-N 115.19 -0.913 . . . . 0.0 110.698 176.936 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 6.7 p -84.07 147.79 5.45 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.557 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.64 179.246 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 9.7 t -98.7 123.96 47.86 Favored Pre-proline 0 C--N 1.311 -1.091 0 CA-C-N 115.437 -0.801 . . . . 0.0 110.083 179.313 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo -84.38 118.06 2.19 Favored 'Trans proline' 0 N--CA 1.448 -1.197 0 C-N-CA 123.278 2.652 . . . . 0.0 112.07 -176.443 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -79.21 81.11 5.51 Favored 'General case' 0 C--N 1.3 -1.543 0 CA-C-N 114.087 -1.415 . . . . 0.0 110.062 175.699 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 44.9 t-80 -79.09 -10.5 59.84 Favored 'General case' 0 C--N 1.313 -0.999 0 CA-C-N 114.387 -1.279 . . . . 0.0 108.028 174.726 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 8.4 mt-10 -87.13 123.05 31.76 Favored 'General case' 0 N--CA 1.448 -0.56 0 CA-C-N 114.67 -1.15 . . . . 0.0 110.226 176.748 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -122.19 56.08 1.11 Allowed 'General case' 0 C--N 1.319 -0.734 0 CA-C-O 122.09 0.948 . . . . 0.0 110.282 178.442 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 62.0 t -77.62 -51.44 18.19 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.091 0 CA-C-N 114.179 -1.373 . . . . 0.0 109.222 174.732 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 7.3 p 23.02 74.76 0.01 OUTLIER 'Isoleucine or valine' 0 C--O 1.234 0.261 0 C-N-CA 125.601 1.56 . . . . 0.0 114.125 176.778 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 56.1 mtm180 -146.66 109.96 4.78 Favored 'General case' 0 C--N 1.304 -1.392 0 CA-C-N 113.792 -1.549 . . . . 0.0 111.54 177.421 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 3.0 t -122.67 166.33 17.56 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.136 0 CA-C-N 114.537 -1.21 . . . . 0.0 108.336 177.734 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 78.02 61.88 2.45 Favored Glycine 0 C--N 1.304 -1.195 0 N-CA-C 110.352 -1.099 . . . . 0.0 110.352 177.474 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.542 ' O ' ' HD3' ' A' ' 18' ' ' PRO . 85.2 m -79.08 -23.56 44.08 Favored 'General case' 0 N--CA 1.438 -1.067 0 CA-C-N 114.299 -0.95 . . . . 0.0 111.391 -172.082 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 17' ' ' LYS . . . . . 0.764 ' HD2' ' O ' ' A' ' 17' ' ' LYS . 0.0 OUTLIER -86.92 110.34 31.94 Favored Pre-proline 0 C--N 1.318 -0.773 0 CA-C-O 121.853 0.835 . . . . 0.0 112.275 -179.478 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 18' ' ' PRO . . . . . 0.542 ' HD3' ' O ' ' A' ' 16' ' ' THR . 1.9 Cg_endo -84.71 172.11 9.21 Favored 'Trans proline' 0 N--CA 1.45 -1.042 0 C-N-CA 123.373 2.715 . . . . 0.0 111.648 173.744 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 92.16 33.17 7.85 Favored Glycine 0 C--N 1.309 -0.951 0 CA-C-N 114.708 -1.133 . . . . 0.0 111.823 179.656 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 90.6 m -71.29 -29.94 65.65 Favored 'General case' 0 C--N 1.311 -1.082 0 CA-C-N 114.568 -0.816 . . . . 0.0 109.858 176.048 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 42.7 mt-10 -138.44 140.01 39.11 Favored 'General case' 0 N--CA 1.439 -0.989 0 N-CA-C 107.524 -1.287 . . . . 0.0 107.524 179.228 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.46 ' HA ' ' HD3' ' A' ' 23' ' ' PRO . 41.4 t -71.84 117.59 59.2 Favored Pre-proline 0 C--N 1.317 -0.846 0 O-C-N 123.389 0.431 . . . . 0.0 110.189 -177.374 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.46 ' HD3' ' HA ' ' A' ' 22' ' ' VAL . 47.7 Cg_exo -56.98 126.5 22.43 Favored 'Trans proline' 0 N--CA 1.458 -0.58 0 C-N-CA 123.235 2.623 . . . . 0.0 113.583 -173.12 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 24' ' ' PRO . . . . . 0.845 ' HB3' HH22 ' A' ' 79' ' ' ARG . 35.3 Cg_endo -65.34 161.25 38.69 Favored 'Trans proline' 0 N--CA 1.45 -1.079 0 C-N-CA 123.834 3.022 . . . . 0.0 113.079 172.951 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.599 ' HB ' HD13 ' A' ' 83' ' ' ILE . 38.2 t -80.25 153.54 4.48 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.05 0 N-CA-C 107.466 -1.309 . . . . 0.0 107.466 168.641 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 40.2 mm -55.6 -32.73 31.41 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.692 0 N-CA-C 113.634 0.975 . . . . 0.0 113.634 -162.25 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.586 ' O ' HG12 ' A' ' 30' ' ' ILE . 6.2 m-20 -105.1 -0.02 27.05 Favored 'General case' 0 C--N 1.312 -1.024 0 CA-C-O 121.909 0.861 . . . . 0.0 110.057 179.371 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 28' ' ' GLY . . . . . 0.576 ' HA2' ' HB2' ' A' ' 31' ' ' TRP . . . -72.52 0.94 39.28 Favored Glycine 0 N--CA 1.436 -1.319 0 CA-C-N 114.464 -1.244 . . . . 0.0 111.053 178.77 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 13.8 m -76.41 -39.13 54.45 Favored 'General case' 0 C--N 1.32 -0.716 0 N-CA-C 108.892 -0.781 . . . . 0.0 108.892 173.458 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.586 HG12 ' O ' ' A' ' 27' ' ' ASP . 0.2 OUTLIER -71.99 -39.1 66.01 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 CA-C-N 114.327 -1.306 . . . . 0.0 107.527 176.317 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 31' ' ' TRP . . . . . 0.576 ' HB2' ' HA2' ' A' ' 28' ' ' GLY . 22.9 m95 -70.69 -35.56 72.84 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-N 114.483 -1.235 . . . . 0.0 110.333 -176.443 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.73 ' HB2' HH21 ' A' ' 79' ' ' ARG . 7.0 t70 -76.87 -32.24 57.34 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.458 179.7 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -70.45 -37.73 74.36 Favored 'General case' 0 N--CA 1.447 -0.601 0 C-N-CA 120.729 -0.388 . . . . 0.0 110.27 175.051 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 34' ' ' ILE . . . . . 0.47 HG13 ' O ' ' A' ' 30' ' ' ILE . 62.0 mt -64.89 -44.4 96.22 Favored 'Isoleucine or valine' 0 C--O 1.235 0.293 0 CA-C-O 120.954 0.407 . . . . 0.0 110.324 174.535 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 35' ' ' ALA . . . . . 0.498 ' O ' ' HB3' ' A' ' 39' ' ' ALA . . . -57.84 -39.25 77.27 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.236 0.541 . . . . 0.0 110.032 175.127 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -74.07 -9.01 79.85 Favored Glycine 0 N--CA 1.452 -0.299 0 CA-C-N 115.568 -0.742 . . . . 0.0 111.761 179.736 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 44.8 t -97.22 -62.85 1.19 Allowed 'General case' 0 N--CA 1.446 -0.648 0 CA-C-N 115.554 -0.323 . . . . 0.0 111.077 -178.068 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 38' ' ' GLU . . . . . 0.879 ' HG3' ' SG ' ' A' ' 101' ' ' CYS . 27.3 mt-10 -89.36 -27.32 20.56 Favored 'General case' 0 C--N 1.328 -0.357 0 N-CA-C 111.778 0.288 . . . . 0.0 111.778 -174.181 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 39' ' ' ALA . . . . . 0.498 ' HB3' ' O ' ' A' ' 35' ' ' ALA . . . -95.14 -17.11 22.08 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 121.015 0.435 . . . . 0.0 112.021 -176.457 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 81.54 14.05 78.99 Favored Glycine 0 N--CA 1.447 -0.599 0 N-CA-C 109.709 -1.357 . . . . 0.0 109.709 -174.622 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 77.52 57.2 3.66 Favored Glycine 0 N--CA 1.438 -1.203 0 CA-C-N 114.236 -0.982 . . . . 0.0 112.656 179.874 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 55.9 t30 -150.73 127.5 10.96 Favored 'General case' 0 CA--C 1.503 -0.853 0 N-CA-C 109.201 -0.666 . . . . 0.0 109.201 178.19 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 43' ' ' TRP . . . . . 0.763 ' HA ' ' N ' ' A' ' 54' ' ' GLY . 26.2 m95 -100.28 -2.02 34.79 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-N 115.437 -0.801 . . . . 0.0 110.099 -174.167 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -112.19 8.77 19.98 Favored 'General case' 0 C--N 1.318 -0.772 0 CA-C-N 115.052 -0.977 . . . . 0.0 111.021 178.574 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.611 HG22 ' HA2' ' A' ' 53' ' ' GLY . 12.5 tt -74.3 143.89 13.01 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.76 0 CA-C-O 120.988 0.423 . . . . 0.0 110.176 -178.784 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 13.3 t-20 -149.63 85.21 1.43 Allowed 'General case' 0 C--N 1.314 -0.939 0 CA-C-O 121.299 0.571 . . . . 0.0 110.302 -177.793 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -69.89 -20.03 63.4 Favored 'General case' 0 N--CA 1.445 -0.7 0 CA-C-N 115.476 -0.784 . . . . 0.0 111.058 177.88 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 92.05 21.56 32.74 Favored Glycine 0 N--CA 1.444 -0.795 0 C-N-CA 120.909 -0.662 . . . . 0.0 111.698 174.578 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 4.2 p-10 -94.97 14.38 21.91 Favored 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 112.082 0.401 . . . . 0.0 112.082 -175.275 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 50' ' ' GLY . . . . . 0.507 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 92.39 -13.92 66.01 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 121.32 -0.467 . . . . 0.0 112.171 176.5 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 51' ' ' TYR . . . . . 0.628 ' CE1' ' HB2' ' A' ' 58' ' ' ASP . 0.3 OUTLIER -110.0 155.29 22.0 Favored 'General case' 0 C--N 1.323 -0.546 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 173.505 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 52' ' ' TYR . . . . . 0.726 ' O ' ' HA ' ' A' ' 56' ' ' GLN . 63.5 m-85 -119.38 171.05 8.6 Favored 'General case' 0 C--N 1.312 -1.06 0 N-CA-C 112.657 0.614 . . . . 0.0 112.657 -168.467 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.611 ' HA2' HG22 ' A' ' 45' ' ' ILE . . . -53.87 163.19 3.07 Favored Glycine 0 N--CA 1.449 -0.44 0 CA-C-N 115.356 -0.838 . . . . 0.0 114.09 -175.527 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.763 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 90.27 -109.51 3.66 Favored Glycine 0 N--CA 1.442 -0.921 0 C-N-CA 121.05 -0.595 . . . . 0.0 112.397 178.738 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.506 HG12 ' HE1' ' A' ' 98' ' ' TRP . 2.5 t -83.63 0.7 4.58 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-O 121.968 0.89 . . . . 0.0 109.784 -177.065 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 56' ' ' GLN . . . . . 0.726 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 2.3 tt0 53.97 50.18 17.32 Favored 'General case' 0 N--CA 1.449 -0.495 0 CA-C-N 113.826 -1.534 . . . . 0.0 112.729 170.679 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 57' ' ' PHE . . . . . 0.445 ' CD1' ' HB ' ' A' ' 55' ' ' VAL . 2.5 p90 -119.04 166.63 12.65 Favored 'General case' 0 C--N 1.323 -0.564 0 C-N-CA 119.304 -0.958 . . . . 0.0 111.914 174.837 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.628 ' HB2' ' CE1' ' A' ' 51' ' ' TYR . 0.0 OUTLIER -75.75 157.46 33.49 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 114.32 -1.309 . . . . 0.0 113.777 -162.071 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.492 ' HB2' ' HE1' ' A' ' 52' ' ' TYR . 22.1 tp60 -53.34 -44.25 68.33 Favored 'General case' 0 N--CA 1.441 -0.9 0 CA-C-N 114.171 -1.377 . . . . 0.0 111.463 179.243 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -68.49 -49.05 47.16 Favored Glycine 0 C--O 1.22 -0.735 0 CA-C-N 115.325 -0.852 . . . . 0.0 112.396 -176.106 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 46.3 m -60.77 -40.61 93.15 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-O 121.552 0.691 . . . . 0.0 110.519 179.098 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 62' ' ' TRP . . . . . 0.484 ' CZ3' ' HA ' ' A' ' 82' ' ' GLN . 50.6 t-105 -61.98 -48.86 78.45 Favored 'General case' 0 C--N 1.318 -0.794 0 CA-C-N 114.845 -1.071 . . . . 0.0 109.863 175.279 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 63' ' ' GLU . . . . . 0.599 ' HB2' HD11 ' A' ' 68' ' ' LEU . 0.0 OUTLIER -67.97 -36.39 79.97 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.733 -0.667 . . . . 0.0 110.353 -176.801 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 64' ' ' ALA . . . . . 0.48 ' N ' ' HG3' ' A' ' 63' ' ' GLU . . . -66.16 -41.05 90.89 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.433 -0.803 . . . . 0.0 111.28 -175.972 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 65' ' ' ASN . . . . . 0.459 ' HB3' ' HB ' ' A' ' 88' ' ' VAL . 17.3 m120 -84.09 -3.61 58.2 Favored 'General case' 0 N--CA 1.446 -0.669 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.61 176.906 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 66' ' ' GLY . . . . . 0.497 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 85.74 46.92 5.27 Favored Glycine 0 N--CA 1.448 -0.532 0 CA-C-N 115.573 -0.74 . . . . 0.0 113.107 171.11 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.627 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -80.28 -16.46 76.23 Favored Glycine 0 N--CA 1.443 -0.899 0 C-N-CA 120.672 -0.775 . . . . 0.0 111.828 179.918 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.662 ' HA ' ' HA ' ' A' ' 72' ' ' PRO . 14.6 mt -64.74 -22.74 67.05 Favored 'General case' 0 C--N 1.32 -0.707 0 C-N-CA 122.817 0.447 . . . . 0.0 111.363 -171.332 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 69' ' ' ARG . . . . . 0.497 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 14.9 ptm180 -70.85 -32.49 69.53 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.311 176.138 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 70' ' ' TYR . . . . . 0.675 ' HB3' ' HB3' ' A' ' 81' ' ' GLU . 58.9 m-85 -80.09 -33.33 38.88 Favored 'General case' 0 N--CA 1.445 -0.697 0 N-CA-C 107.217 -1.401 . . . . 0.0 107.217 178.19 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.673 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 165.94 127.12 0.03 OUTLIER Pre-proline 0 CA--C 1.511 -0.538 0 CA-C-N 112.447 -2.161 . . . . 0.0 107.122 178.693 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 72' ' ' PRO . . . . . 0.662 ' HA ' ' HA ' ' A' ' 68' ' ' LEU . 15.5 Cg_exo -56.2 -0.8 0.23 Allowed 'Trans proline' 0 CA--C 1.531 0.369 0 C-N-CA 122.961 2.441 . . . . 0.0 114.231 -177.849 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 13.0 ptm180 -150.82 142.46 23.62 Favored 'General case' 0 C--N 1.317 -0.839 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 172.776 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 74' ' ' ALA . . . . . 0.561 ' HB3' ' HB2' ' A' ' 52' ' ' TYR . . . -58.69 -30.34 67.33 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.332 -0.849 . . . . 0.0 112.89 -175.899 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 75' ' ' ASP . . . . . 0.459 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 15.7 p-10 -87.33 5.54 37.98 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 121.269 0.557 . . . . 0.0 111.129 -176.232 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.436 ' HB3' ' HB1' ' A' ' 71' ' ' ALA . 65.2 tp -105.67 -30.17 9.64 Favored 'General case' 0 C--N 1.319 -0.72 0 N-CA-C 108.359 -0.978 . . . . 0.0 108.359 168.967 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 77' ' ' ALA . . . . . 0.706 ' HB1' ' HB2' ' A' ' 81' ' ' GLU . . . -79.47 164.48 23.91 Favored 'General case' 0 N--CA 1.444 -0.739 0 CA-C-N 114.446 -1.252 . . . . 0.0 110.183 175.933 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 78' ' ' THR . . . . . 0.461 ' OG1' ' HG2' ' A' ' 81' ' ' GLU . 65.9 p -99.97 -178.89 3.99 Favored 'General case' 0 C--N 1.313 -0.994 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.414 -177.042 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 79' ' ' ARG . . . . . 0.845 HH22 ' HB3' ' A' ' 24' ' ' PRO . 47.2 mtp180 -52.71 -53.67 44.32 Favored 'General case' 0 CA--C 1.516 -0.342 0 CA-C-O 121.045 0.45 . . . . 0.0 110.374 -178.536 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 80' ' ' GLU . . . . . 0.61 ' HA ' HD12 ' A' ' 83' ' ' ILE . 2.7 pm0 -60.51 -32.64 71.65 Favored 'General case' 0 C--N 1.317 -0.816 0 CA-C-N 115.083 -0.962 . . . . 0.0 112.254 -176.818 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 81' ' ' GLU . . . . . 0.706 ' HB2' ' HB1' ' A' ' 77' ' ' ALA . 5.4 mm-40 -70.64 -50.41 37.13 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-O 120.877 0.37 . . . . 0.0 110.031 177.477 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 82' ' ' GLN . . . . . 0.484 ' HA ' ' CZ3' ' A' ' 62' ' ' TRP . 51.2 mt-30 -61.11 -35.61 77.49 Favored 'General case' 0 CA--C 1.507 -0.69 0 CA-C-N 115.582 -0.736 . . . . 0.0 109.631 179.833 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.687 ' O ' ' HG2' ' A' ' 87' ' ' GLU . 39.2 mt -59.55 -49.16 84.69 Favored 'Isoleucine or valine' 0 C--O 1.211 -0.952 0 CA-C-N 114.714 -1.13 . . . . 0.0 109.763 174.829 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 84' ' ' ALA . . . . . 0.616 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -61.25 -41.58 97.15 Favored 'General case' 0 C--O 1.236 0.365 0 CA-C-O 121.403 0.62 . . . . 0.0 111.579 -177.606 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.465 HG23 ' O ' ' A' ' 81' ' ' GLU . 34.7 t -69.2 -47.85 71.89 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.794 178.528 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -58.22 -29.44 65.72 Favored 'General case' 0 N--CA 1.45 -0.446 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.364 172.99 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 87' ' ' GLU . . . . . 0.687 ' HG2' ' O ' ' A' ' 83' ' ' ILE . 14.5 mm-40 -60.03 -44.62 94.5 Favored 'General case' 0 N--CA 1.469 0.497 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.111 179.277 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.638 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 60.8 t -63.56 -47.71 90.21 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.437 0 N-CA-C 109.473 -0.566 . . . . 0.0 109.473 174.243 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 89' ' ' THR . . . . . 0.898 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 0.7 OUTLIER -59.21 -49.86 76.22 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-N 115.696 -0.684 . . . . 0.0 111.387 -176.508 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 90' ' ' ARG . . . . . 0.509 ' HA ' ' HZ3' ' A' ' 98' ' ' TRP . 27.0 ptt85 -60.51 -34.97 74.87 Favored 'General case' 0 C--O 1.223 -0.314 0 CA-C-N 116.723 -0.217 . . . . 0.0 111.232 -172.477 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 91' ' ' LEU . . . . . 0.638 ' HG ' ' O ' ' A' ' 88' ' ' VAL . 4.5 pp -74.71 -22.82 58.63 Favored 'General case' 0 C--N 1.318 -0.798 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.52 -173.488 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 92' ' ' ARG . . . . . 0.605 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 15.6 mtm180 -80.82 -52.71 7.19 Favored 'General case' 0 CA--C 1.505 -0.773 0 CA-C-O 121.13 0.491 . . . . 0.0 109.877 -176.04 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 4.9 pm0 -103.75 -15.36 15.76 Favored 'General case' 0 N--CA 1.445 -0.681 0 C-N-CA 119.645 -0.822 . . . . 0.0 113.022 -173.411 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 87.33 45.12 5.39 Favored Glycine 0 CA--C 1.498 -1.03 0 C-N-CA 120.732 -0.747 . . . . 0.0 111.88 168.424 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 95' ' ' TRP . . . . . 0.472 ' HA ' ' HE3' ' A' ' 98' ' ' TRP . 15.7 m95 66.47 2.23 2.39 Favored 'General case' 0 C--O 1.216 -0.669 0 C-N-CA 123.236 0.614 . . . . 0.0 109.979 -178.276 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -70.35 -13.01 70.23 Favored Glycine 0 C--N 1.335 0.517 0 C-N-CA 121.447 -0.406 . . . . 0.0 112.792 -178.108 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -81.93 -23.66 36.06 Favored 'General case' 0 C--N 1.325 -0.471 0 N-CA-C 109.525 -0.546 . . . . 0.0 109.525 175.159 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 98' ' ' TRP . . . . . 0.898 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 29.0 m-90 -103.16 104.95 43.59 Favored Pre-proline 0 N--CA 1.45 -0.444 0 N-CA-C 108.745 -0.835 . . . . 0.0 108.745 175.146 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 99' ' ' PRO . . . . . 0.419 ' HD3' ' HA ' ' A' ' 98' ' ' TRP . 15.0 Cg_exo -74.43 -87.09 0.0 OUTLIER 'Trans proline' 0 CA--C 1.53 0.305 0 C-N-CA 122.902 2.401 . . . . 0.0 114.673 -172.666 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 48.4 t -71.25 -27.92 30.83 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-O 121.322 0.582 . . . . 0.0 111.086 -170.949 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 101' ' ' CYS . . . . . 0.879 ' SG ' ' HG3' ' A' ' 38' ' ' GLU . 64.2 m -90.99 -27.55 18.59 Favored 'General case' 0 C--N 1.314 -0.946 0 CA-C-N 115.915 -0.584 . . . . 0.0 112.545 -168.772 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 102' ' ' ALA . . . . . 0.596 ' HB2' ' HB2' ' A' ' 98' ' ' TRP . . . -67.54 -46.43 72.82 Favored 'General case' 0 C--N 1.33 -0.268 0 C-N-CA 120.515 -0.474 . . . . 0.0 110.928 -178.719 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -61.22 -39.09 88.95 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-O 121.097 0.475 . . . . 0.0 110.634 179.25 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -66.56 -39.77 88.68 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.469 -0.787 . . . . 0.0 111.548 176.655 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -77.56 -22.51 50.89 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.929 -175.933 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 116.02 55.83 0.34 Allowed Glycine 0 N--CA 1.452 -0.236 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.528 -178.942 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -57.52 149.2 21.67 Favored 'General case' 0 CA--C 1.517 -0.305 0 C-N-CA 123.049 0.54 . . . . 0.0 110.572 179.149 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 69.9 mtp180 . . . . . 0 C--O 1.249 1.04 0 CA-C-O 118.202 -0.904 . . . . 0.0 110.465 -170.19 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 16.6 p-10 . . . . . 0 N--CA 1.475 0.801 0 CA-C-O 122.016 0.913 . . . . 0.0 110.537 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 73.5 t -65.03 -41.49 92.17 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.008 0 CA-C-N 114.681 -1.145 . . . . 0.0 110.286 176.138 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 14.8 p -73.29 137.71 22.8 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.646 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.343 175.605 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 14.0 t -75.41 140.33 17.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 N-CA-C 109.265 -0.643 . . . . 0.0 109.265 177.96 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' THR . . . . . 0.461 ' HA ' ' HD3' ' A' ' 6' ' ' PRO . 8.7 p -121.19 134.29 24.4 Favored Pre-proline 0 C--N 1.312 -1.043 0 CA-C-N 115.826 -0.625 . . . . 0.0 111.899 -170.587 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.461 ' HD3' ' HA ' ' A' ' 5' ' ' THR . 10.6 Cg_exo -73.13 -172.59 1.04 Allowed 'Trans proline' 0 CA--C 1.51 -0.687 0 C-N-CA 123.59 2.86 . . . . 0.0 110.797 170.021 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 7' ' ' ALA . . . . . 0.882 ' HB1' ' HG2' ' A' ' 9' ' ' GLU . . . 71.95 102.69 0.07 Allowed 'General case' 0 C--N 1.319 -0.734 0 O-C-N 124.633 1.208 . . . . 0.0 111.343 -178.802 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 18.6 m170 -69.34 -10.81 59.57 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 114.286 -1.325 . . . . 0.0 108.564 173.368 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' GLU . . . . . 0.882 ' HG2' ' HB1' ' A' ' 7' ' ' ALA . 18.4 pt-20 -72.38 143.14 48.68 Favored 'General case' 0 C--O 1.233 0.203 0 CA-C-N 115.029 -0.987 . . . . 0.0 110.336 -179.761 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -84.65 58.84 5.14 Favored 'General case' 0 CA--C 1.511 -0.537 0 CA-C-O 122.28 1.038 . . . . 0.0 110.943 -176.085 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 77.4 t -92.0 -47.21 14.17 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.245 0 CA-C-N 113.603 -1.635 . . . . 0.0 109.61 173.322 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 20.2 t -68.45 73.79 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.416 -2.133 0 CA-C-O 122.288 1.042 . . . . 0.0 109.69 170.455 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' ARG . . . . . 0.445 ' O ' ' HG3' ' A' ' 13' ' ' ARG . 16.0 ptt180 -64.54 112.39 3.13 Favored 'General case' 0 C--N 1.3 -1.559 0 CA-C-N 113.389 -1.732 . . . . 0.0 111.815 -176.228 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 5.2 t -122.39 162.12 22.54 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.641 0 CA-C-N 113.265 -1.789 . . . . 0.0 107.454 171.284 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 128.76 91.69 0.68 Allowed Glycine 0 C--N 1.304 -1.211 0 C-N-CA 121.152 -0.547 . . . . 0.0 112.109 -179.613 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.535 ' O ' ' HD3' ' A' ' 18' ' ' PRO . 27.3 m -95.0 -23.8 17.21 Favored 'General case' 0 N--CA 1.44 -0.927 0 CA-C-O 121.313 0.578 . . . . 0.0 111.117 -177.985 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 11.2 mptt -93.49 102.04 6.89 Favored Pre-proline 0 C--N 1.319 -0.759 0 CA-C-N 115.394 -0.821 . . . . 0.0 110.714 179.736 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' PRO . . . . . 0.535 ' HD3' ' O ' ' A' ' 16' ' ' THR . 66.5 Cg_endo -79.39 133.84 10.94 Favored 'Trans proline' 0 N--CA 1.448 -1.198 0 C-N-CA 123.282 2.655 . . . . 0.0 111.556 179.592 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 123.67 -50.11 0.87 Allowed Glycine 0 C--N 1.301 -1.412 0 CA-C-N 114.481 -1.236 . . . . 0.0 110.447 -178.706 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 83.4 m -63.07 -39.74 95.6 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-O 121.769 0.795 . . . . 0.0 109.641 172.228 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 21' ' ' GLU . . . . . 0.456 ' O ' ' HD3' ' A' ' 23' ' ' PRO . 8.5 pt-20 -135.69 157.59 46.48 Favored 'General case' 0 N--CA 1.428 -1.566 0 CA-C-N 114.953 -1.021 . . . . 0.0 108.339 178.068 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 35.5 t -88.67 109.87 32.92 Favored Pre-proline 0 C--N 1.311 -1.107 0 CA-C-N 115.324 -0.853 . . . . 0.0 111.442 -174.269 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.456 ' HD3' ' O ' ' A' ' 21' ' ' GLU . 21.5 Cg_exo -67.59 143.48 62.66 Favored 'Trans proline' 0 N--CA 1.46 -0.48 0 C-N-CA 123.691 2.928 . . . . 0.0 113.681 -179.486 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 24' ' ' PRO . . . . . 0.406 ' HD2' ' HA ' ' A' ' 23' ' ' PRO . 12.1 Cg_endo -56.8 165.16 5.12 Favored 'Trans proline' 0 C--N 1.345 0.356 0 C-N-CA 124.279 3.319 . . . . 0.0 112.125 167.476 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.783 HG21 HD13 ' A' ' 83' ' ' ILE . 4.6 p -75.01 123.98 31.86 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.868 0 CA-C-O 121.985 0.898 . . . . 0.0 109.997 -176.355 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 49.7 mm -65.94 -44.67 92.37 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.32 0 CA-C-N 114.538 -1.21 . . . . 0.0 113.096 -170.482 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.623 ' O ' HG12 ' A' ' 30' ' ' ILE . 13.0 m-20 -101.21 2.62 40.19 Favored 'General case' 0 CA--C 1.502 -0.899 0 CA-C-O 121.891 0.853 . . . . 0.0 109.208 -176.662 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 28' ' ' GLY . . . . . 0.711 ' HA2' ' HB2' ' A' ' 31' ' ' TRP . . . -77.75 2.7 62.91 Favored Glycine 0 N--CA 1.433 -1.534 0 CA-C-N 114.583 -1.19 . . . . 0.0 110.611 -177.76 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 17.0 m -76.23 -40.36 52.26 Favored 'General case' 0 C--N 1.318 -0.794 0 N-CA-C 108.77 -0.826 . . . . 0.0 108.77 173.626 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.632 ' HA ' ' HB1' ' A' ' 105' ' ' ALA . 0.0 OUTLIER -71.52 -38.03 66.32 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.679 0 N-CA-C 107.348 -1.353 . . . . 0.0 107.348 176.573 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 31' ' ' TRP . . . . . 0.711 ' HB2' ' HA2' ' A' ' 28' ' ' GLY . 14.6 m95 -71.85 -36.29 70.11 Favored 'General case' 0 N--CA 1.438 -1.054 0 CA-C-N 114.251 -1.34 . . . . 0.0 110.601 -176.188 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 31.7 t70 -77.23 -34.31 56.01 Favored 'General case' 0 N--CA 1.446 -0.66 0 CA-C-N 116.529 -0.305 . . . . 0.0 110.931 178.082 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 33' ' ' ALA . . . . . 0.487 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -70.16 -34.08 72.56 Favored 'General case' 0 N--CA 1.448 -0.532 0 C-N-CA 120.288 -0.565 . . . . 0.0 110.278 177.523 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 34' ' ' ILE . . . . . 0.501 HG13 ' O ' ' A' ' 30' ' ' ILE . 68.3 mt -67.88 -46.55 81.92 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-O 121.07 0.462 . . . . 0.0 110.176 172.298 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 35' ' ' ALA . . . . . 0.413 ' O ' ' HB3' ' A' ' 39' ' ' ALA . . . -58.72 -38.91 79.36 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.277 176.89 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 36' ' ' GLY . . . . . 0.509 ' HA2' ' N ' ' A' ' 41' ' ' GLY . . . -74.88 -12.97 82.84 Favored Glycine 0 C--O 1.228 -0.26 0 CA-C-N 115.618 -0.719 . . . . 0.0 111.535 178.699 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 40.8 t -89.5 -60.94 1.81 Allowed 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 115.356 -0.422 . . . . 0.0 110.93 -177.748 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 38' ' ' GLU . . . . . 0.832 ' HG3' ' SG ' ' A' ' 101' ' ' CYS . 34.3 mt-10 -89.55 -28.37 19.64 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 120.687 0.28 . . . . 0.0 111.534 -174.441 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 39' ' ' ALA . . . . . 0.413 ' HB3' ' O ' ' A' ' 35' ' ' ALA . . . -101.49 -12.01 18.87 Favored 'General case' 0 C--N 1.326 -0.452 0 C-N-CA 120.43 -0.508 . . . . 0.0 111.785 -178.14 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 81.03 6.52 89.4 Favored Glycine 0 N--CA 1.45 -0.371 0 N-CA-C 110.027 -1.229 . . . . 0.0 110.027 -177.846 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 41' ' ' GLY . . . . . 0.509 ' N ' ' HA2' ' A' ' 36' ' ' GLY . . . 85.35 53.88 2.98 Favored Glycine 0 N--CA 1.437 -1.274 0 CA-C-N 114.148 -1.026 . . . . 0.0 111.942 -177.71 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 42' ' ' ASN . . . . . 0.412 ' OD1' ' HB ' ' A' ' 45' ' ' ILE . 2.3 t-20 -138.71 99.32 3.77 Favored 'General case' 0 N--CA 1.447 -0.58 0 N-CA-C 108.829 -0.804 . . . . 0.0 108.829 -175.84 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 43' ' ' TRP . . . . . 0.667 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 37.1 m95 -81.48 -10.32 59.51 Favored 'General case' 0 C--N 1.312 -1.026 0 CA-C-N 115.389 -0.823 . . . . 0.0 110.805 -172.664 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -107.0 8.71 30.56 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 115.504 -0.771 . . . . 0.0 110.829 -179.492 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.427 HG22 ' CA ' ' A' ' 53' ' ' GLY . 9.3 tt -72.56 144.27 13.17 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.916 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 179.578 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 22.4 t-20 -154.22 98.47 2.14 Favored 'General case' 0 C--N 1.309 -1.183 0 CA-C-O 121.384 0.612 . . . . 0.0 109.372 -179.956 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 17.5 p -72.51 -24.05 61.1 Favored 'General case' 0 C--N 1.317 -0.819 0 CA-C-N 114.76 -1.109 . . . . 0.0 110.919 -177.376 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 93.48 20.64 31.56 Favored Glycine 0 N--CA 1.441 -0.981 0 N-CA-C 110.722 -0.951 . . . . 0.0 110.722 -178.698 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 82.8 m-20 -93.18 12.8 23.14 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.877 0.37 . . . . 0.0 111.415 -176.234 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 50' ' ' GLY . . . . . 0.516 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 85.29 -11.73 60.18 Favored Glycine 0 N--CA 1.449 -0.46 0 N-CA-C 111.209 -0.757 . . . . 0.0 111.209 -177.883 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 51' ' ' TYR . . . . . 0.649 ' HA ' ' HA ' ' A' ' 58' ' ' ASP . 0.3 OUTLIER -112.22 146.37 38.25 Favored 'General case' 0 CA--C 1.51 -0.562 0 N-CA-C 107.197 -1.408 . . . . 0.0 107.197 177.214 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 52' ' ' TYR . . . . . 0.831 ' O ' ' HA ' ' A' ' 56' ' ' GLN . 32.8 m-85 -110.73 170.5 8.05 Favored 'General case' 0 C--N 1.309 -1.154 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.697 -165.96 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.427 ' CA ' HG22 ' A' ' 45' ' ' ILE . . . -69.06 -174.37 9.98 Favored Glycine 0 C--O 1.228 -0.223 0 N-CA-C 114.907 0.723 . . . . 0.0 114.907 -169.761 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.608 ' CA ' ' HA ' ' A' ' 43' ' ' TRP . . . 80.0 -107.53 2.62 Favored Glycine 0 N--CA 1.442 -0.942 0 C-N-CA 120.859 -0.686 . . . . 0.0 111.457 -178.349 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.547 HG12 ' HE1' ' A' ' 98' ' ' TRP . 3.4 t -88.21 4.22 4.84 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 CA-C-O 121.554 0.692 . . . . 0.0 109.618 179.016 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 56' ' ' GLN . . . . . 0.831 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 40.3 tt0 54.5 53.82 10.22 Favored 'General case' 0 CA--C 1.535 0.379 0 N-CA-C 114.854 1.427 . . . . 0.0 114.854 164.887 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -121.15 170.26 9.73 Favored 'General case' 0 C--N 1.326 -0.418 0 C-N-CA 119.447 -0.901 . . . . 0.0 112.018 171.652 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.649 ' HA ' ' HA ' ' A' ' 51' ' ' TYR . 6.9 p-10 -76.25 165.22 25.18 Favored 'General case' 0 C--N 1.331 -0.219 0 N-CA-C 113.311 0.856 . . . . 0.0 113.311 -166.809 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.507 ' HB2' ' HE1' ' A' ' 52' ' ' TYR . 5.9 tp-100 -63.15 -37.99 89.4 Favored 'General case' 0 N--CA 1.448 -0.568 0 CA-C-N 114.881 -1.054 . . . . 0.0 110.827 179.127 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -63.46 -49.78 67.28 Favored Glycine 0 C--N 1.314 -0.68 0 CA-C-N 115.551 -0.75 . . . . 0.0 111.777 -175.643 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 86.4 m -63.91 -44.19 93.7 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-O 120.954 0.407 . . . . 0.0 111.201 176.414 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 62' ' ' TRP . . . . . 0.459 ' CZ3' ' HA ' ' A' ' 82' ' ' GLN . 54.4 t-105 -56.86 -48.95 76.93 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 121.84 0.828 . . . . 0.0 109.967 177.546 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 63' ' ' GLU . . . . . 0.516 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 36.0 tt0 -67.39 -34.68 77.76 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-N 114.611 -1.177 . . . . 0.0 110.471 -178.426 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -64.85 -41.9 95.32 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.645 -0.707 . . . . 0.0 110.993 -178.711 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 65' ' ' ASN . . . . . 0.579 ' HB2' HG13 ' A' ' 85' ' ' VAL . 7.9 m120 -82.06 -2.85 53.19 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.459 177.144 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 66' ' ' GLY . . . . . 0.58 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 83.57 47.62 5.6 Favored Glycine 0 C--O 1.225 -0.467 0 CA-C-N 115.782 -0.645 . . . . 0.0 112.587 173.245 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.607 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -80.03 -21.96 64.43 Favored Glycine 0 N--CA 1.438 -1.197 0 C-N-CA 120.956 -0.64 . . . . 0.0 112.934 -175.107 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.837 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 6.8 mp -61.61 -22.73 65.49 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 112.048 0.388 . . . . 0.0 112.048 -172.43 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 69' ' ' ARG . . . . . 0.58 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 9.6 ptm180 -67.74 -33.68 75.33 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 121.254 0.549 . . . . 0.0 109.963 176.522 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 70' ' ' TYR . . . . . 0.786 ' HB3' ' HG3' ' A' ' 81' ' ' GLU . 63.5 m-85 -79.91 -34.51 38.92 Favored 'General case' 0 N--CA 1.444 -0.772 0 N-CA-C 107.499 -1.297 . . . . 0.0 107.499 178.159 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.707 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 163.99 129.05 0.02 OUTLIER Pre-proline 0 CA--C 1.51 -0.568 0 CA-C-N 112.595 -2.093 . . . . 0.0 107.198 -179.888 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 72' ' ' PRO . . . . . 0.837 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 16.9 Cg_exo -58.46 -3.02 1.15 Allowed 'Trans proline' 0 C--N 1.332 -0.299 0 C-N-CA 122.622 2.215 . . . . 0.0 113.559 -177.911 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 73' ' ' ARG . . . . . 0.421 ' HB2' ' CD2' ' A' ' 52' ' ' TYR . 13.5 ptm180 -146.63 137.36 23.99 Favored 'General case' 0 C--N 1.319 -0.731 0 N-CA-C 109.289 -0.634 . . . . 0.0 109.289 177.342 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 74' ' ' ALA . . . . . 0.499 ' HB3' ' HB2' ' A' ' 52' ' ' TYR . . . -58.11 -29.52 65.56 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.312 -0.858 . . . . 0.0 112.611 -178.066 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 75' ' ' ASP . . . . . 0.404 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 14.7 p-10 -87.84 9.19 22.72 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 121.364 0.602 . . . . 0.0 110.852 -176.092 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.432 ' HB3' ' HB1' ' A' ' 71' ' ' ALA . 58.6 tp -110.07 -33.63 6.63 Favored 'General case' 0 C--N 1.322 -0.627 0 N-CA-C 108.322 -0.992 . . . . 0.0 108.322 169.81 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 77' ' ' ALA . . . . . 0.739 ' HB1' ' HB3' ' A' ' 81' ' ' GLU . . . -78.39 163.36 25.72 Favored 'General case' 0 N--CA 1.445 -0.691 0 CA-C-N 114.771 -1.104 . . . . 0.0 110.393 177.084 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 71.5 p -99.36 -174.49 2.75 Favored 'General case' 0 C--N 1.315 -0.931 0 CA-C-N 115.656 -0.702 . . . . 0.0 110.337 -174.532 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 79' ' ' ARG . . . . . 0.667 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 23.7 mtt85 -53.93 -56.81 14.33 Favored 'General case' 0 CA--C 1.512 -0.509 0 CA-C-O 120.988 0.423 . . . . 0.0 110.772 178.848 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 1.8 pm0 -58.22 -41.18 83.51 Favored 'General case' 0 C--N 1.314 -0.937 0 CA-C-N 115.043 -0.981 . . . . 0.0 111.262 -176.391 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 81' ' ' GLU . . . . . 0.786 ' HG3' ' HB3' ' A' ' 70' ' ' TYR . 0.4 OUTLIER -63.18 -52.72 61.21 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 115.5 -0.773 . . . . 0.0 112.161 175.835 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 82' ' ' GLN . . . . . 0.459 ' HA ' ' CZ3' ' A' ' 62' ' ' TRP . 53.4 mt-30 -60.66 -43.09 98.04 Favored 'General case' 0 CA--C 1.509 -0.613 0 CA-C-O 121.762 0.791 . . . . 0.0 109.833 -178.972 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.783 HD13 HG21 ' A' ' 25' ' ' VAL . 10.8 mt -59.5 -39.74 80.07 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.993 0 CA-C-N 114.276 -1.329 . . . . 0.0 110.303 -177.822 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 84' ' ' ALA . . . . . 0.436 ' O ' HG23 ' A' ' 88' ' ' VAL . . . -62.1 -42.46 99.24 Favored 'General case' 0 C--N 1.319 -0.752 0 CA-C-O 121.273 0.559 . . . . 0.0 110.476 -179.181 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.579 HG13 ' HB2' ' A' ' 65' ' ' ASN . 43.0 t -70.05 -50.77 45.26 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 CA-C-N 115.764 -0.653 . . . . 0.0 111.741 -179.569 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -65.69 -31.49 72.52 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 121.489 0.662 . . . . 0.0 110.858 -179.6 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 87' ' ' GLU . . . . . 0.759 ' HA ' ' HG2' ' A' ' 90' ' ' ARG . 0.7 OUTLIER -71.16 -28.41 64.24 Favored 'General case' 0 C--N 1.316 -0.855 0 CA-C-N 115.716 -0.674 . . . . 0.0 110.436 -178.348 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.674 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 88.1 t -61.86 -46.47 96.43 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.26 0 N-CA-C 109.299 -0.63 . . . . 0.0 109.299 168.54 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 89' ' ' THR . . . . . 0.48 ' O ' ' HG2' ' A' ' 93' ' ' GLN . 0.1 OUTLIER -64.64 -45.71 85.63 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 115.697 -0.683 . . . . 0.0 111.866 -177.48 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 90' ' ' ARG . . . . . 0.759 ' HG2' ' HA ' ' A' ' 87' ' ' GLU . 22.5 ptt180 -58.91 -35.36 72.94 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.98 -0.555 . . . . 0.0 111.048 -175.799 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 91' ' ' LEU . . . . . 0.674 ' HG ' ' O ' ' A' ' 88' ' ' VAL . 4.6 pp -74.69 -24.39 58.76 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.022 -0.536 . . . . 0.0 110.827 -169.536 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 92' ' ' ARG . . . . . 0.455 ' HE ' ' HB2' ' A' ' 92' ' ' ARG . 3.9 mtm180 -85.59 -45.56 11.63 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.783 -0.644 . . . . 0.0 109.686 -177.948 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 93' ' ' GLN . . . . . 0.48 ' HG2' ' O ' ' A' ' 89' ' ' THR . 24.0 pt20 -98.6 -29.12 13.24 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.192 -0.913 . . . . 0.0 113.188 -169.715 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 87.42 46.67 4.88 Favored Glycine 0 CA--C 1.505 -0.58 0 C-N-CA 120.426 -0.893 . . . . 0.0 111.06 176.463 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 95' ' ' TRP . . . . . 0.506 ' HA ' ' HE3' ' A' ' 98' ' ' TRP . 1.9 m95 58.59 27.0 15.12 Favored 'General case' 0 C--O 1.223 -0.34 0 CA-C-O 121.484 0.659 . . . . 0.0 109.687 177.457 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -70.83 -30.5 68.12 Favored Glycine 0 N--CA 1.449 -0.445 0 CA-C-N 115.349 -0.841 . . . . 0.0 112.245 176.618 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 97' ' ' ALA . . . . . 0.41 ' O ' ' HD3' ' A' ' 99' ' ' PRO . . . -79.46 -24.84 42.13 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 120.66 0.267 . . . . 0.0 110.57 177.114 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 98' ' ' TRP . . . . . 0.547 ' HE1' HG12 ' A' ' 55' ' ' VAL . 23.8 m-90 -101.96 103.25 28.17 Favored Pre-proline 0 C--N 1.327 -0.389 0 N-CA-C 109.406 -0.59 . . . . 0.0 109.406 175.897 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 99' ' ' PRO . . . . . 0.424 ' HB2' ' H ' ' A' ' 100' ' ' VAL . 22.0 Cg_exo -70.52 -101.7 0.01 OUTLIER 'Trans proline' 0 CA--C 1.539 0.746 0 C-N-CA 123.242 2.628 . . . . 0.0 114.991 -173.013 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 100' ' ' VAL . . . . . 0.48 ' O ' ' HD2' ' A' ' 104' ' ' ARG . 41.0 t -69.82 -27.94 35.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 121.596 0.712 . . . . 0.0 110.452 -171.598 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 101' ' ' CYS . . . . . 0.832 ' SG ' ' HG3' ' A' ' 38' ' ' GLU . 79.1 m -73.07 -32.38 64.97 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-N 115.228 -0.896 . . . . 0.0 111.511 -171.416 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -70.0 -46.18 65.69 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 120.757 0.313 . . . . 0.0 110.953 -179.892 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -62.25 -37.28 84.83 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 121.097 0.475 . . . . 0.0 110.773 179.514 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 104' ' ' ARG . . . . . 0.48 ' HD2' ' O ' ' A' ' 100' ' ' VAL . 0.0 OUTLIER -73.02 -30.47 63.78 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.627 -0.715 . . . . 0.0 111.583 178.566 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 105' ' ' ALA . . . . . 0.632 ' HB1' ' HA ' ' A' ' 30' ' ' ILE . . . -82.17 -21.38 36.57 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.692 -176.997 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 109.39 60.93 0.52 Allowed Glycine 0 CA--C 1.518 0.25 0 C-N-CA 121.011 -0.614 . . . . 0.0 112.158 -178.122 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -66.41 152.67 44.62 Favored 'General case' 0 N--CA 1.45 -0.442 0 C-N-CA 122.642 0.377 . . . . 0.0 111.013 -176.562 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 20.7 mmt180 . . . . . 0 C--O 1.244 0.814 0 CA-C-O 118.404 -0.808 . . . . 0.0 110.959 176.677 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 84.0 m-20 . . . . . 0 N--CA 1.477 0.917 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 9.1 t -82.85 54.02 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-O 121.886 0.85 . . . . 0.0 110.056 179.361 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 12.1 p -87.07 140.45 15.78 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.986 0 CA-C-N 115.265 -0.88 . . . . 0.0 111.044 177.599 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 6.8 t -95.37 140.76 16.31 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.538 0 N-CA-C 108.86 -0.793 . . . . 0.0 108.86 173.891 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' THR . . . . . 0.45 ' HA ' ' HD3' ' A' ' 6' ' ' PRO . 4.6 p -124.88 135.54 26.87 Favored Pre-proline 0 C--N 1.313 -1.001 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.564 -172.853 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.45 ' HD3' ' HA ' ' A' ' 5' ' ' THR . 3.3 Cg_exo -76.64 166.26 27.48 Favored 'Trans proline' 0 N--CA 1.453 -0.856 0 C-N-CA 123.219 2.613 . . . . 0.0 110.267 171.592 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . 52.13 39.63 27.05 Favored 'General case' 0 C--N 1.314 -0.955 0 CA-C-N 114.985 -1.007 . . . . 0.0 110.49 -172.617 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 6.1 t60 -80.88 -2.29 46.88 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-N 114.194 -1.366 . . . . 0.0 108.228 174.383 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 9.5 pt-20 -64.61 147.61 52.59 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 114.584 -1.189 . . . . 0.0 110.253 174.368 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -109.5 66.6 0.63 Allowed 'General case' 0 C--N 1.317 -0.809 0 CA-C-O 121.87 0.843 . . . . 0.0 110.622 -172.914 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 58.3 t -67.99 -68.91 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.312 -1.045 0 CA-C-N 114.358 -1.292 . . . . 0.0 109.724 175.023 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 6.9 p 26.0 79.03 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.347 0.498 0 CA-C-O 122.952 1.358 . . . . 0.0 112.932 176.481 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 14.6 ptm180 -95.89 119.21 33.99 Favored 'General case' 0 N--CA 1.432 -1.368 0 CA-C-N 113.86 -1.518 . . . . 0.0 110.592 -174.349 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.417 HG12 ' N ' ' A' ' 15' ' ' GLY . 9.5 t -124.19 166.11 19.96 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.372 0 CA-C-N 113.616 -1.629 . . . . 0.0 108.283 176.937 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 15' ' ' GLY . . . . . 0.417 ' N ' HG12 ' A' ' 14' ' ' VAL . . . -168.5 -83.54 0.05 OUTLIER Glycine 0 N--CA 1.426 -1.993 0 C-N-CA 120.698 -0.763 . . . . 0.0 111.827 179.172 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.504 ' O ' ' HD3' ' A' ' 18' ' ' PRO . 8.1 m -75.25 -35.8 61.36 Favored 'General case' 0 N--CA 1.437 -1.107 0 CA-C-O 121.127 0.489 . . . . 0.0 112.196 -174.751 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 17' ' ' LYS . . . . . 0.433 ' HD2' ' HB ' ' A' ' 16' ' ' THR . 0.0 OUTLIER -105.82 93.74 7.93 Favored Pre-proline 0 C--N 1.312 -1.042 0 CA-C-N 115.574 -0.739 . . . . 0.0 109.826 179.185 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 18' ' ' PRO . . . . . 0.504 ' HD3' ' O ' ' A' ' 16' ' ' THR . 21.3 Cg_exo -65.43 170.63 10.61 Favored 'Trans proline' 0 CA--C 1.51 -0.701 0 C-N-CA 123.157 2.571 . . . . 0.0 112.582 -174.375 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 117.93 42.32 0.61 Allowed Glycine 0 C--N 1.305 -1.185 0 CA-C-N 114.337 -1.301 . . . . 0.0 111.861 -176.761 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 2.8 m -69.73 -48.32 59.89 Favored 'General case' 0 C--N 1.32 -0.693 0 N-CA-C 108.739 -0.838 . . . . 0.0 108.739 175.257 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 49.0 mt-10 -129.94 110.55 11.77 Favored 'General case' 0 N--CA 1.443 -0.784 0 CA-C-N 114.254 -1.339 . . . . 0.0 108.606 174.61 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.704 ' O ' ' HD3' ' A' ' 79' ' ' ARG . 81.4 t -70.92 137.96 85.14 Favored Pre-proline 0 C--N 1.318 -0.781 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.045 -176.176 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.461 ' HA ' ' HD2' ' A' ' 24' ' ' PRO . 62.9 Cg_exo -54.48 126.29 21.81 Favored 'Trans proline' 0 N--CA 1.457 -0.619 0 C-N-CA 122.523 2.148 . . . . 0.0 112.383 179.923 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 24' ' ' PRO . . . . . 0.461 ' HD2' ' HA ' ' A' ' 23' ' ' PRO . 29.7 Cg_endo -63.62 149.79 90.06 Favored 'Trans proline' 0 N--CA 1.452 -0.915 0 C-N-CA 123.839 3.026 . . . . 0.0 113.752 -178.273 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.836 ' HB ' HG21 ' A' ' 83' ' ' ILE . 43.4 t -87.03 160.09 3.02 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.134 0 N-CA-C 106.845 -1.539 . . . . 0.0 106.845 165.651 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.468 ' H ' HD12 ' A' ' 26' ' ' ILE . 3.0 mp -54.35 -34.0 27.12 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.842 0 CA-C-O 120.854 0.359 . . . . 0.0 111.836 -167.319 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.531 ' O ' HG12 ' A' ' 30' ' ' ILE . 11.2 m-20 -104.59 -3.06 24.28 Favored 'General case' 0 CA--C 1.504 -0.805 0 CA-C-O 121.364 0.602 . . . . 0.0 110.931 -178.974 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 28' ' ' GLY . . . . . 0.703 ' HA3' ' CD1' ' A' ' 83' ' ' ILE . . . -76.05 1.65 58.75 Favored Glycine 0 CA--C 1.498 -0.998 0 N-CA-C 110.715 -0.954 . . . . 0.0 110.715 -179.336 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 19.1 m -76.99 -40.86 45.22 Favored 'General case' 0 C--N 1.322 -0.628 0 N-CA-C 108.497 -0.927 . . . . 0.0 108.497 171.381 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.531 HG12 ' O ' ' A' ' 27' ' ' ASP . 0.7 OUTLIER -67.29 -40.21 84.43 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.457 0 CA-C-N 114.399 -1.273 . . . . 0.0 107.724 175.946 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 31' ' ' TRP . . . . . 0.56 ' HB2' ' HA2' ' A' ' 28' ' ' GLY . 36.5 m95 -67.41 -36.68 81.76 Favored 'General case' 0 C--N 1.318 -0.776 0 CA-C-N 114.17 -1.377 . . . . 0.0 110.378 -177.826 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.427 ' CB ' HH21 ' A' ' 79' ' ' ARG . 4.6 t70 -77.19 -33.34 56.38 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 115.748 -0.66 . . . . 0.0 110.62 -179.5 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 33' ' ' ALA . . . . . 0.417 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -70.13 -34.07 72.61 Favored 'General case' 0 N--CA 1.447 -0.575 0 C-N-CA 120.506 -0.478 . . . . 0.0 109.977 176.159 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 34' ' ' ILE . . . . . 0.515 HG13 ' O ' ' A' ' 30' ' ' ILE . 74.2 mt -65.52 -43.45 94.32 Favored 'Isoleucine or valine' 0 C--O 1.234 0.268 0 CA-C-N 116.057 -0.519 . . . . 0.0 109.865 172.23 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 35' ' ' ALA . . . . . 0.451 ' HA ' ' O ' ' A' ' 54' ' ' GLY . . . -57.57 -37.4 73.09 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.059 175.211 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 36' ' ' GLY . . . . . 0.4 ' HA2' ' N ' ' A' ' 41' ' ' GLY . . . -70.89 -15.98 74.31 Favored Glycine 0 N--CA 1.449 -0.45 0 CA-C-N 115.27 -0.877 . . . . 0.0 112.181 179.299 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 44.1 t -85.19 -58.87 2.51 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 120.611 0.243 . . . . 0.0 111.186 -177.256 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 8.6 tp10 -89.09 -34.04 16.89 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-O 121.074 0.464 . . . . 0.0 110.877 -172.693 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -97.63 -14.66 20.83 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.029 -0.532 . . . . 0.0 111.511 -175.427 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 86.31 -4.51 85.99 Favored Glycine 0 N--CA 1.448 -0.523 0 N-CA-C 109.847 -1.301 . . . . 0.0 109.847 -174.408 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 41' ' ' GLY . . . . . 0.4 ' N ' ' HA2' ' A' ' 36' ' ' GLY . . . 102.04 56.06 0.85 Allowed Glycine 0 N--CA 1.435 -1.37 0 CA-C-N 114.213 -0.993 . . . . 0.0 112.058 -179.235 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 43.8 t-20 -144.33 127.25 16.38 Favored 'General case' 0 N--CA 1.44 -0.968 0 N-CA-C 108.263 -1.014 . . . . 0.0 108.263 -179.602 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 43' ' ' TRP . . . . . 0.691 ' HZ3' ' HB2' ' A' ' 82' ' ' GLN . 40.5 m95 -99.28 -13.27 19.74 Favored 'General case' 0 C--N 1.305 -1.351 0 CA-C-N 115.398 -0.819 . . . . 0.0 110.935 -173.385 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -100.53 -6.77 24.94 Favored 'General case' 0 C--N 1.316 -0.881 0 CA-C-N 115.199 -0.909 . . . . 0.0 110.479 -177.889 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 10.0 tt -62.33 141.58 17.67 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.996 0 CA-C-N 115.474 -0.784 . . . . 0.0 109.921 178.556 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 43.3 t-20 -158.73 103.52 1.73 Allowed 'General case' 0 C--N 1.312 -1.025 0 CA-C-O 121.03 0.443 . . . . 0.0 110.112 -177.655 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 11.2 p -82.75 -15.01 53.46 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 115.718 -0.674 . . . . 0.0 111.923 -177.56 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 90.47 25.23 26.4 Favored Glycine 0 N--CA 1.446 -0.662 0 N-CA-C 110.943 -0.863 . . . . 0.0 110.943 -177.743 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 65.0 t30 -83.63 -1.76 54.63 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 121.222 0.534 . . . . 0.0 111.222 -175.352 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 50' ' ' GLY . . . . . 0.469 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 95.19 -9.34 69.89 Favored Glycine 0 CA--C 1.505 -0.539 0 N-CA-C 110.093 -1.203 . . . . 0.0 110.093 -175.734 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 51' ' ' TYR . . . . . 0.66 ' HA ' ' HA ' ' A' ' 58' ' ' ASP . 0.5 OUTLIER -117.98 158.2 25.36 Favored 'General case' 0 N--CA 1.441 -0.923 0 N-CA-C 106.118 -1.808 . . . . 0.0 106.118 177.998 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 52' ' ' TYR . . . . . 0.73 ' O ' ' HA ' ' A' ' 56' ' ' GLN . 35.1 m-85 -118.41 169.59 9.63 Favored 'General case' 0 C--N 1.303 -1.447 0 C-N-CA 120.222 -0.591 . . . . 0.0 110.851 -172.241 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -65.14 -173.26 3.81 Favored Glycine 0 N--CA 1.448 -0.515 0 C-N-CA 121.173 -0.537 . . . . 0.0 114.362 -170.019 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.599 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 77.39 -104.97 2.01 Favored Glycine 0 N--CA 1.439 -1.157 0 N-CA-C 111.346 -0.702 . . . . 0.0 111.346 -179.635 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.556 HG12 ' HE1' ' A' ' 98' ' ' TRP . 2.2 t -83.41 -1.83 6.25 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 CA-C-O 121.503 0.668 . . . . 0.0 109.676 -179.122 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 56' ' ' GLN . . . . . 0.73 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 20.1 mm-40 57.34 45.18 20.52 Favored 'General case' 0 N--CA 1.464 0.249 0 CA-C-N 114.541 -1.209 . . . . 0.0 113.444 169.584 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 1.1 p90 -117.89 168.53 10.41 Favored 'General case' 0 C--N 1.328 -0.357 0 C-N-CA 119.582 -0.847 . . . . 0.0 112.035 176.476 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.66 ' HA ' ' HA ' ' A' ' 51' ' ' TYR . 7.5 p-10 -79.33 164.15 24.31 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.141 -0.936 . . . . 0.0 113.419 -164.39 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.489 ' HB2' ' CE2' ' A' ' 52' ' ' TYR . 6.1 tp60 -63.25 -36.63 84.3 Favored 'General case' 0 N--CA 1.449 -0.487 0 CA-C-N 114.101 -1.409 . . . . 0.0 111.578 179.188 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -68.0 -50.33 41.4 Favored Glycine 0 C--N 1.32 -0.324 0 C-N-CA 121.2 -0.524 . . . . 0.0 112.303 -175.703 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 88.5 m -61.7 -42.16 98.56 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 121.157 0.503 . . . . 0.0 110.113 175.689 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 62' ' ' TRP . . . . . 0.591 ' HH2' ' CD ' ' A' ' 81' ' ' GLU . 59.3 t-105 -56.85 -49.68 74.73 Favored 'General case' 0 N--CA 1.447 -0.623 0 CA-C-N 114.985 -1.007 . . . . 0.0 110.209 177.264 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 63' ' ' GLU . . . . . 0.914 ' HG3' HD11 ' A' ' 68' ' ' LEU . 29.1 tt0 -67.15 -34.38 77.44 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 115.026 -0.988 . . . . 0.0 110.773 -177.18 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -67.91 -41.58 82.45 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.897 -0.592 . . . . 0.0 111.082 -178.44 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 65' ' ' ASN . . . . . 0.68 ' HB2' HG13 ' A' ' 85' ' ' VAL . 4.8 m120 -71.8 -15.79 62.16 Favored 'General case' 0 C--N 1.332 -0.154 0 CA-C-O 121.349 0.595 . . . . 0.0 109.773 174.99 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 88.32 44.74 5.21 Favored Glycine 0 N--CA 1.446 -0.7 0 CA-C-N 115.208 -0.906 . . . . 0.0 111.752 178.422 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.589 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -78.5 -19.58 73.53 Favored Glycine 0 CA--C 1.5 -0.865 0 C-N-CA 120.612 -0.804 . . . . 0.0 111.123 -173.818 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.914 HD11 ' HG3' ' A' ' 63' ' ' GLU . 11.8 mt -61.32 -24.86 66.74 Favored 'General case' 0 C--N 1.317 -0.807 0 CA-C-N 114.664 -0.768 . . . . 0.0 110.806 -174.667 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 12.1 ptm180 -70.34 -28.61 65.27 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.461 -0.79 . . . . 0.0 109.856 179.664 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 70' ' ' TYR . . . . . 0.589 ' HD2' ' HA2' ' A' ' 67' ' ' GLY . 47.7 m-85 -85.49 -34.47 21.58 Favored 'General case' 0 N--CA 1.439 -1.007 0 N-CA-C 107.143 -1.428 . . . . 0.0 107.143 176.201 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.785 ' HB1' ' HB3' ' A' ' 76' ' ' LEU . . . 170.22 127.27 0.05 OUTLIER Pre-proline 0 C--O 1.217 -0.617 0 CA-C-N 112.729 -2.032 . . . . 0.0 107.712 -178.029 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 72' ' ' PRO . . . . . 0.604 ' HA ' ' HA ' ' A' ' 68' ' ' LEU . 17.2 Cg_exo -58.32 -0.96 0.54 Allowed 'Trans proline' 0 C--N 1.331 -0.39 0 C-N-CA 122.968 2.445 . . . . 0.0 113.8 -179.455 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 73' ' ' ARG . . . . . 0.428 ' HE ' ' CG ' ' A' ' 75' ' ' ASP . 13.4 ptm180 -152.85 143.04 22.43 Favored 'General case' 0 C--N 1.318 -0.799 0 N-CA-C 109.232 -0.655 . . . . 0.0 109.232 174.059 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 74' ' ' ALA . . . . . 0.593 ' HB3' ' HB2' ' A' ' 52' ' ' TYR . . . -61.7 -25.48 67.44 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.574 -0.739 . . . . 0.0 112.359 -174.381 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 75' ' ' ASP . . . . . 0.428 ' CG ' ' HE ' ' A' ' 73' ' ' ARG . 17.2 p-10 -89.36 10.91 20.7 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-O 121.049 0.452 . . . . 0.0 111.363 -178.041 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.785 ' HB3' ' HB1' ' A' ' 71' ' ' ALA . 42.0 tp -104.29 -42.71 5.42 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.345 177.207 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 77' ' ' ALA . . . . . 0.718 ' HB3' ' OE2' ' A' ' 81' ' ' GLU . . . -100.73 170.47 8.32 Favored 'General case' 0 N--CA 1.45 -0.473 0 CA-C-O 121.136 0.493 . . . . 0.0 109.932 177.826 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 78' ' ' THR . . . . . 0.622 ' HB ' HG21 ' A' ' 22' ' ' VAL . 41.3 p -85.06 168.71 14.63 Favored 'General case' 0 C--N 1.312 -1.063 0 N-CA-C 113.2 0.815 . . . . 0.0 113.2 -167.775 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 79' ' ' ARG . . . . . 0.704 ' HD3' ' O ' ' A' ' 22' ' ' VAL . 7.1 ptm180 -47.4 -36.09 9.29 Favored 'General case' 0 N--CA 1.466 0.352 0 C-N-CA 122.724 0.41 . . . . 0.0 112.087 -175.238 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 80' ' ' GLU . . . . . 0.917 ' HA ' HD12 ' A' ' 83' ' ' ILE . 16.1 pt-20 -62.36 -31.22 71.83 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.407 -178.556 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 81' ' ' GLU . . . . . 0.718 ' OE2' ' HB3' ' A' ' 77' ' ' ALA . 0.0 OUTLIER -72.53 -48.86 36.99 Favored 'General case' 0 N--CA 1.428 -1.545 0 N-CA-C 110.075 -0.343 . . . . 0.0 110.075 177.163 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 82' ' ' GLN . . . . . 0.691 ' HB2' ' HZ3' ' A' ' 43' ' ' TRP . 67.1 mt-30 -59.82 -31.8 70.06 Favored 'General case' 0 CA--C 1.511 -0.521 0 C-N-CA 120.874 -0.331 . . . . 0.0 110.225 178.245 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.917 HD12 ' HA ' ' A' ' 80' ' ' GLU . 79.7 mt -59.32 -51.5 71.92 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.782 0 CA-C-N 115.892 -0.594 . . . . 0.0 109.626 173.328 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 84' ' ' ALA . . . . . 0.48 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -62.36 -44.42 96.51 Favored 'General case' 0 C--O 1.238 0.459 0 CA-C-O 121.635 0.731 . . . . 0.0 111.285 -175.081 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.68 HG13 ' HB2' ' A' ' 65' ' ' ASN . 48.9 t -67.97 -49.17 71.0 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.635 0 CA-C-N 115.388 -0.823 . . . . 0.0 111.107 -177.876 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -60.61 -29.7 69.38 Favored 'General case' 0 N--CA 1.451 -0.416 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.175 175.581 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 87' ' ' GLU . . . . . 0.774 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 28.7 mt-10 -60.31 -42.86 96.46 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.59 179.885 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.427 ' O ' ' HG3' ' A' ' 92' ' ' ARG . 75.6 t -60.67 -50.0 82.22 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.284 0 C-N-CA 120.37 -0.532 . . . . 0.0 110.189 178.943 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 89' ' ' THR . . . . . 0.705 HG22 ' NE2' ' A' ' 93' ' ' GLN . 97.0 m -64.11 -38.82 92.45 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-N 115.524 -0.762 . . . . 0.0 111.252 -178.442 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 90' ' ' ARG . . . . . 0.664 HH11 ' HG2' ' A' ' 87' ' ' GLU . 1.4 ptt180 -60.52 -35.88 77.04 Favored 'General case' 0 N--CA 1.464 0.258 0 CA-C-N 116.613 -0.267 . . . . 0.0 111.387 -179.674 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 91' ' ' LEU . . . . . 0.774 ' HG ' ' O ' ' A' ' 87' ' ' GLU . 32.1 mt -64.18 -29.02 70.16 Favored 'General case' 0 N--CA 1.47 0.534 0 CA-C-O 121.708 0.766 . . . . 0.0 110.15 -174.821 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 92' ' ' ARG . . . . . 0.625 ' NH2' HG23 ' A' ' 89' ' ' THR . 9.8 mtm180 -87.65 -43.89 11.61 Favored 'General case' 0 C--N 1.314 -0.956 0 CA-C-N 114.541 -1.209 . . . . 0.0 110.516 -169.573 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 93' ' ' GLN . . . . . 0.705 ' NE2' HG22 ' A' ' 89' ' ' THR . 0.0 OUTLIER -105.79 -17.74 14.28 Favored 'General case' 0 CA--C 1.545 0.769 0 N-CA-C 113.956 1.095 . . . . 0.0 113.956 -173.965 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 79.86 44.34 9.23 Favored Glycine 0 C--N 1.335 0.513 0 C-N-CA 121.312 -0.47 . . . . 0.0 112.983 171.929 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 95' ' ' TRP . . . . . 0.4 ' CZ2' ' HD2' ' A' ' 90' ' ' ARG . 13.4 m95 61.62 19.94 10.87 Favored 'General case' 0 C--O 1.223 -0.338 0 C-N-CA 123.483 0.713 . . . . 0.0 109.618 -179.059 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.421 ' H ' ' HG2' ' A' ' 93' ' ' GLN . . . -77.42 -32.98 45.23 Favored Glycine 0 N--CA 1.453 -0.189 0 CA-C-N 115.381 -0.827 . . . . 0.0 112.385 176.348 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 97' ' ' ALA . . . . . 0.428 ' H ' ' CG ' ' A' ' 93' ' ' GLN . . . -72.66 -24.85 61.09 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 121.338 0.589 . . . . 0.0 109.781 178.953 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 98' ' ' TRP . . . . . 0.556 ' HE1' HG12 ' A' ' 55' ' ' VAL . 25.0 m-90 -95.33 108.22 37.69 Favored Pre-proline 0 N--CA 1.441 -0.88 0 N-CA-C 108.358 -0.979 . . . . 0.0 108.358 175.001 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 45.4 Cg_exo -64.14 -141.76 0.01 OUTLIER 'Trans proline' 0 CA--C 1.532 0.394 0 C-N-CA 123.466 2.777 . . . . 0.0 113.906 -174.189 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 4.3 t -56.21 -21.79 12.67 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.425 0 CA-C-O 120.928 0.394 . . . . 0.0 111.176 -175.542 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 77.5 m -56.87 -39.18 73.86 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-N 116.573 -0.285 . . . . 0.0 111.04 175.09 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -71.27 -37.96 71.88 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-O 120.905 0.383 . . . . 0.0 110.351 177.572 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -61.19 -41.64 97.18 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.638 177.44 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -67.59 -30.29 69.86 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.833 -0.621 . . . . 0.0 111.131 175.531 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 105' ' ' ALA . . . . . 0.417 ' CB ' ' HB3' ' A' ' 33' ' ' ALA . . . -86.28 -22.8 26.6 Favored 'General case' 0 C--N 1.326 -0.428 0 N-CA-C 112.709 0.633 . . . . 0.0 112.709 -172.812 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 104.16 65.74 0.7 Allowed Glycine 0 CA--C 1.521 0.447 0 C-N-CA 120.795 -0.716 . . . . 0.0 112.5 -178.182 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -70.28 148.59 48.36 Favored 'General case' 0 C--N 1.324 -0.525 0 C-N-CA 122.905 0.482 . . . . 0.0 110.773 -176.699 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 108' ' ' ARG . . . . . 0.431 ' HD3' ' O ' ' A' ' 108' ' ' ARG . 0.0 OUTLIER . . . . . 0 C--O 1.247 0.96 0 CA-C-O 119.069 -0.491 . . . . 0.0 111.181 -174.505 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 6.9 p30 . . . . . 0 N--CA 1.474 0.727 0 CA-C-O 122.025 0.917 . . . . 0.0 110.713 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 12.9 p -67.13 -31.51 53.58 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.965 0 CA-C-N 114.733 -1.121 . . . . 0.0 110.577 178.385 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 94.8 t -82.32 94.01 2.79 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.752 0 CA-C-O 121.235 0.54 . . . . 0.0 110.345 177.185 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 7.6 t -81.59 146.74 6.89 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.657 0 CA-C-N 115.902 -0.59 . . . . 0.0 109.965 -179.821 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 5' ' ' THR . . . . . 0.472 ' HA ' ' HD3' ' A' ' 6' ' ' PRO . 1.6 p -124.71 103.1 31.62 Favored Pre-proline 0 C--N 1.315 -0.897 0 CA-C-N 115.868 -0.605 . . . . 0.0 110.08 178.153 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.472 ' HD3' ' HA ' ' A' ' 5' ' ' THR . 6.2 Cg_exo -79.99 164.3 22.57 Favored 'Trans proline' 0 N--CA 1.451 -0.984 0 C-N-CA 123.217 2.611 . . . . 0.0 112.705 -175.294 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -102.51 91.01 4.04 Favored 'General case' 0 C--N 1.309 -1.153 0 CA-C-N 114.158 -1.383 . . . . 0.0 110.802 -179.554 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 49.5 m80 -86.08 -10.65 54.54 Favored 'General case' 0 C--N 1.314 -0.977 0 CA-C-N 114.333 -1.303 . . . . 0.0 107.949 173.07 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 11.9 mt-10 -81.22 178.1 8.6 Favored 'General case' 0 CA--C 1.505 -0.777 0 CA-C-N 114.434 -1.257 . . . . 0.0 112.513 -178.064 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . 65.78 51.03 1.47 Allowed 'General case' 0 C--N 1.314 -0.954 0 CA-C-N 112.81 -1.996 . . . . 0.0 109.539 -172.437 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 51.8 t -66.49 -27.79 41.4 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.805 0 CA-C-N 113.042 -1.89 . . . . 0.0 110.132 179.025 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 53.7 t 36.68 88.16 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.445 -0.701 0 C-N-CA 124.868 1.267 . . . . 0.0 113.28 177.757 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 39.5 mtm180 -96.76 112.89 24.45 Favored 'General case' 0 C--N 1.307 -1.266 0 CA-C-N 114.294 -1.321 . . . . 0.0 110.279 174.53 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 3.4 t -113.67 159.72 13.49 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.208 0 CA-C-N 114.68 -1.146 . . . . 0.0 108.893 178.625 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 90.05 83.74 1.36 Allowed Glycine 0 N--CA 1.438 -1.17 0 N-CA-C 110.898 -0.881 . . . . 0.0 110.898 -177.938 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 22.7 m -70.46 -30.54 67.39 Favored 'General case' 0 N--CA 1.441 -0.925 0 CA-C-O 121.418 0.627 . . . . 0.0 110.728 -175.899 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 17' ' ' LYS . . . . . 0.83 ' HD2' ' O ' ' A' ' 17' ' ' LYS . 0.0 OUTLIER -109.49 97.28 26.34 Favored Pre-proline 0 C--N 1.313 -0.981 0 CA-C-N 115.222 -0.899 . . . . 0.0 111.042 174.779 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 83.0 Cg_endo -75.32 113.75 3.84 Favored 'Trans proline' 0 N--CA 1.459 -0.533 0 C-N-CA 122.985 2.456 . . . . 0.0 112.509 -176.544 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -101.4 -14.53 30.02 Favored Glycine 0 C--N 1.301 -1.378 0 CA-C-N 113.882 -1.508 . . . . 0.0 112.107 -178.552 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 2.0 m -56.19 -46.03 79.56 Favored 'General case' 0 C--N 1.307 -1.251 0 CA-C-N 113.793 -1.203 . . . . 0.0 111.842 -177.758 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 21' ' ' GLU . . . . . 0.463 ' O ' ' HD3' ' A' ' 23' ' ' PRO . 38.4 mt-10 -138.2 142.07 40.0 Favored 'General case' 0 N--CA 1.443 -0.778 0 CA-C-N 115.967 -0.56 . . . . 0.0 109.559 -177.202 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 46.9 t -88.03 108.02 19.15 Favored Pre-proline 0 C--N 1.315 -0.894 0 N-CA-C 108.688 -0.856 . . . . 0.0 108.688 170.869 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.515 ' HA ' ' HD2' ' A' ' 24' ' ' PRO . 27.7 Cg_exo -63.0 129.32 25.49 Favored 'Trans proline' 0 N--CA 1.457 -0.625 0 C-N-CA 122.735 2.29 . . . . 0.0 112.573 -177.265 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 24' ' ' PRO . . . . . 0.515 ' HD2' ' HA ' ' A' ' 23' ' ' PRO . 11.5 Cg_endo -56.57 140.16 89.23 Favored 'Trans proline' 0 N--CA 1.452 -0.919 0 C-N-CA 122.624 2.216 . . . . 0.0 110.621 171.934 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.51 HG11 HG22 ' A' ' 83' ' ' ILE . 38.7 t -81.52 125.99 39.74 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.207 0 CA-C-N 115.659 -0.701 . . . . 0.0 111.095 -172.044 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.426 ' N ' HD12 ' A' ' 26' ' ' ILE . 3.4 mp -75.42 -32.78 26.04 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-N 114.752 -1.113 . . . . 0.0 112.775 -167.157 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.445 ' O ' HG12 ' A' ' 30' ' ' ILE . 6.3 m-20 -85.76 8.51 19.62 Favored 'General case' 0 CA--C 1.503 -0.83 0 CA-C-O 121.548 0.69 . . . . 0.0 109.833 -174.961 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 28' ' ' GLY . . . . . 0.622 ' HA3' HD13 ' A' ' 83' ' ' ILE . . . -63.51 -9.05 29.4 Favored Glycine 0 N--CA 1.436 -1.343 0 CA-C-N 114.909 -1.041 . . . . 0.0 110.905 174.506 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 8.4 m -71.34 -44.25 65.44 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-O 121.681 0.753 . . . . 0.0 109.293 175.195 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.505 ' O ' HG13 ' A' ' 34' ' ' ILE . 0.4 OUTLIER -69.15 -39.45 79.37 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.604 0 CA-C-N 114.576 -1.193 . . . . 0.0 107.881 178.533 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 31' ' ' TRP . . . . . 0.774 ' CD1' HG23 ' A' ' 83' ' ' ILE . 39.5 m95 -67.95 -35.93 79.24 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 114.493 -1.231 . . . . 0.0 110.528 -177.15 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.432 ' CG ' HH21 ' A' ' 79' ' ' ARG . 3.9 t70 -71.23 -42.25 69.12 Favored 'General case' 0 N--CA 1.447 -0.621 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.256 177.665 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 33' ' ' ALA . . . . . 0.424 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -67.33 -33.77 75.95 Favored 'General case' 0 N--CA 1.446 -0.662 0 CA-C-N 116.44 -0.345 . . . . 0.0 110.511 -179.665 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 34' ' ' ILE . . . . . 0.505 HG13 ' O ' ' A' ' 30' ' ' ILE . 65.7 mt -64.41 -46.14 93.82 Favored 'Isoleucine or valine' 0 C--O 1.234 0.255 0 CA-C-O 121.046 0.45 . . . . 0.0 109.865 172.457 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -57.99 -38.85 76.86 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.133 176.065 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 36' ' ' GLY . . . . . 0.412 ' HA2' ' N ' ' A' ' 41' ' ' GLY . . . -65.44 -28.83 74.01 Favored Glycine 0 N--CA 1.451 -0.329 0 CA-C-N 115.588 -0.733 . . . . 0.0 111.97 179.248 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 6.7 t -76.25 -64.49 1.09 Allowed 'General case' 0 C--N 1.318 -0.764 0 N-CA-C 111.926 0.343 . . . . 0.0 111.926 -178.823 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 38' ' ' GLU . . . . . 0.51 ' HB3' ' CD ' ' A' ' 56' ' ' GLN . 11.2 tp10 -88.19 -31.79 18.93 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 121.062 0.458 . . . . 0.0 110.692 -168.939 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -96.89 -9.15 29.11 Favored 'General case' 0 N--CA 1.45 -0.436 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.764 -175.348 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 78.57 16.66 78.96 Favored Glycine 0 CA--C 1.503 -0.685 0 N-CA-C 109.848 -1.301 . . . . 0.0 109.848 -177.929 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 41' ' ' GLY . . . . . 0.412 ' N ' ' HA2' ' A' ' 36' ' ' GLY . . . 69.19 59.69 5.67 Favored Glycine 0 N--CA 1.432 -1.606 0 CA-C-N 113.992 -1.104 . . . . 0.0 111.928 -177.179 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 62.2 t30 -147.12 122.17 10.09 Favored 'General case' 0 CA--C 1.505 -0.77 0 N-CA-C 109.134 -0.691 . . . . 0.0 109.134 179.346 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 43' ' ' TRP . . . . . 0.705 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 33.9 m95 -97.5 -6.25 34.1 Favored 'General case' 0 C--N 1.306 -1.315 0 CA-C-N 114.956 -1.02 . . . . 0.0 109.935 -173.168 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -110.51 9.93 23.17 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-N 114.907 -1.042 . . . . 0.0 111.183 -179.073 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.767 HG22 ' HA2' ' A' ' 53' ' ' GLY . 3.2 tt -71.09 143.21 14.66 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.615 0 N-CA-C 109.477 -0.564 . . . . 0.0 109.477 179.099 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 45.0 t-20 -165.2 96.05 0.68 Allowed 'General case' 0 C--N 1.312 -1.041 0 CA-C-O 121.047 0.451 . . . . 0.0 110.132 -176.577 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 17.8 p -82.32 -12.06 58.22 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.392 179.832 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 89.29 22.15 38.8 Favored Glycine 0 N--CA 1.446 -0.697 0 N-CA-C 111.275 -0.73 . . . . 0.0 111.275 178.985 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 8.6 p30 -88.36 5.86 40.05 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 121.03 0.443 . . . . 0.0 110.99 -176.031 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 50' ' ' GLY . . . . . 0.49 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 95.77 -12.22 67.53 Favored Glycine 0 N--CA 1.448 -0.536 0 CA-C-N 115.913 -0.585 . . . . 0.0 112.117 -178.234 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 51' ' ' TYR . . . . . 0.597 ' HA ' ' HA ' ' A' ' 58' ' ' ASP . 0.1 OUTLIER -112.99 161.29 17.2 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 108.026 -1.102 . . . . 0.0 108.026 173.494 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 52' ' ' TYR . . . . . 0.479 ' HB2' ' HB3' ' A' ' 74' ' ' ALA . 42.7 m-85 -125.62 170.26 11.67 Favored 'General case' 0 C--N 1.313 -0.982 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.686 -170.752 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.767 ' HA2' HG22 ' A' ' 45' ' ' ILE . . . -70.36 -172.59 11.31 Favored Glycine 0 N--CA 1.446 -0.678 0 CA-C-N 116.177 -0.465 . . . . 0.0 114.23 -171.69 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.638 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 81.91 -111.03 3.27 Favored Glycine 0 N--CA 1.443 -0.888 0 C-N-CA 121.011 -0.614 . . . . 0.0 111.76 -179.154 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.54 ' HB ' ' CE2' ' A' ' 57' ' ' PHE . 1.8 t -91.69 19.96 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-O 121.183 0.516 . . . . 0.0 110.53 -178.488 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 56' ' ' GLN . . . . . 0.51 ' CD ' ' HB3' ' A' ' 38' ' ' GLU . 0.0 OUTLIER 59.51 50.31 7.6 Favored 'General case' 0 N--CA 1.47 0.547 0 CA-C-N 115.168 -0.924 . . . . 0.0 111.704 171.496 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 57' ' ' PHE . . . . . 0.54 ' CE2' ' HB ' ' A' ' 55' ' ' VAL . 57.3 m-85 -81.45 138.07 35.57 Favored 'General case' 0 CA--C 1.504 -0.804 0 CA-C-N 115.77 -0.65 . . . . 0.0 112.266 178.345 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.597 ' HA ' ' HA ' ' A' ' 51' ' ' TYR . 7.9 p-10 -79.45 155.96 28.08 Favored 'General case' 0 C--N 1.313 -1.003 0 N-CA-C 108.535 -0.913 . . . . 0.0 108.535 163.631 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.406 ' HB2' ' HE1' ' A' ' 52' ' ' TYR . 19.0 tp60 -54.63 -36.47 64.56 Favored 'General case' 0 N--CA 1.445 -0.701 0 CA-C-O 121.188 0.518 . . . . 0.0 110.352 -179.026 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -68.51 -50.5 37.13 Favored Glycine 0 C--O 1.225 -0.428 0 CA-C-N 114.795 -1.093 . . . . 0.0 113.041 -173.557 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 99.1 m -67.51 -40.32 85.12 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 121.082 0.468 . . . . 0.0 110.299 -179.197 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 62' ' ' TRP . . . . . 0.518 ' CZ3' ' HA ' ' A' ' 82' ' ' GLN . 53.5 t-105 -57.82 -48.72 78.93 Favored 'General case' 0 N--CA 1.443 -0.789 0 CA-C-N 115.468 -0.787 . . . . 0.0 109.367 176.586 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 63' ' ' GLU . . . . . 0.504 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 44.9 tt0 -67.93 -33.97 75.71 Favored 'General case' 0 N--CA 1.444 -0.738 0 CA-C-N 115.07 -0.968 . . . . 0.0 110.695 -179.431 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -63.09 -41.49 99.42 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.839 -178.75 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 65' ' ' ASN . . . . . 0.667 ' HB2' HG13 ' A' ' 85' ' ' VAL . 7.5 m120 -73.92 -19.55 60.66 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 121.438 0.637 . . . . 0.0 110.054 176.41 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 66' ' ' GLY . . . . . 0.609 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 90.13 45.72 4.36 Favored Glycine 0 N--CA 1.446 -0.674 0 CA-C-N 115.148 -0.933 . . . . 0.0 111.534 -178.55 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.73 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -78.59 -15.7 80.42 Favored Glycine 0 N--CA 1.445 -0.744 0 C-N-CA 120.998 -0.62 . . . . 0.0 112.359 -172.806 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.841 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 7.1 mp -60.27 -27.54 67.34 Favored 'General case' 0 C--N 1.316 -0.865 0 N-CA-C 112.875 0.694 . . . . 0.0 112.875 -175.918 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 69' ' ' ARG . . . . . 0.609 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 17.1 ptm180 -65.25 -32.44 74.1 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 121.602 0.715 . . . . 0.0 109.748 175.545 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 70' ' ' TYR . . . . . 0.73 ' HD2' ' HA2' ' A' ' 67' ' ' GLY . 93.1 m-85 -77.78 -34.55 52.23 Favored 'General case' 0 N--CA 1.439 -0.988 0 N-CA-C 107.877 -1.157 . . . . 0.0 107.877 177.388 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.683 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 160.42 129.56 0.0 OUTLIER Pre-proline 0 CA--C 1.513 -0.48 0 CA-C-N 112.21 -2.268 . . . . 0.0 106.738 179.308 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 72' ' ' PRO . . . . . 0.841 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 17.4 Cg_exo -58.18 -4.12 1.49 Allowed 'Trans proline' 0 CA--C 1.53 0.278 0 C-N-CA 122.582 2.188 . . . . 0.0 113.506 -176.919 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 13.2 ptm180 -145.29 136.29 24.72 Favored 'General case' 0 C--N 1.321 -0.647 0 N-CA-C 108.99 -0.745 . . . . 0.0 108.99 175.801 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 74' ' ' ALA . . . . . 0.479 ' HB3' ' HB2' ' A' ' 52' ' ' TYR . . . -55.87 -30.7 61.92 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 114.873 -1.058 . . . . 0.0 112.772 -177.763 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 75' ' ' ASP . . . . . 0.442 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 20.8 p-10 -88.27 9.55 22.74 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 120.907 0.384 . . . . 0.0 111.362 -176.314 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 60.7 tp -109.98 -33.14 6.79 Favored 'General case' 0 C--N 1.323 -0.56 0 N-CA-C 108.783 -0.821 . . . . 0.0 108.783 170.246 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 77' ' ' ALA . . . . . 0.683 ' HB2' ' HB3' ' A' ' 71' ' ' ALA . . . -79.85 163.17 24.59 Favored 'General case' 0 N--CA 1.444 -0.759 0 CA-C-N 115.061 -0.972 . . . . 0.0 109.272 174.143 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 32.0 p -99.39 -173.91 2.6 Favored 'General case' 0 C--N 1.315 -0.927 0 C-N-CA 120.799 -0.36 . . . . 0.0 110.385 -178.497 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 79' ' ' ARG . . . . . 0.705 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 20.7 mtp180 -51.0 -54.34 25.39 Favored 'General case' 0 C--O 1.22 -0.452 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.99 -177.378 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 80' ' ' GLU . . . . . 0.456 ' HG3' ' OE2' ' A' ' 81' ' ' GLU . 9.0 pt-20 -61.41 -41.42 97.12 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.829 -172.683 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 81' ' ' GLU . . . . . 0.7 ' HB3' ' HB3' ' A' ' 70' ' ' TYR . 3.6 mp0 -59.24 -51.77 68.53 Favored 'General case' 0 C--N 1.323 -0.551 0 N-CA-C 112.016 0.376 . . . . 0.0 112.016 172.74 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 82' ' ' GLN . . . . . 0.518 ' HA ' ' CZ3' ' A' ' 62' ' ' TRP . 34.8 mt-30 -59.67 -39.07 83.25 Favored 'General case' 0 CA--C 1.51 -0.561 0 CA-C-O 121.719 0.771 . . . . 0.0 109.681 179.903 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.774 HG23 ' CD1' ' A' ' 31' ' ' TRP . 34.8 mt -60.85 -44.42 97.66 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.903 0 CA-C-N 114.112 -1.404 . . . . 0.0 110.61 179.557 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 84' ' ' ALA . . . . . 0.606 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -66.34 -35.76 81.18 Favored 'General case' 0 C--O 1.236 0.37 0 CA-C-O 121.559 0.695 . . . . 0.0 110.939 -178.613 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.667 HG13 ' HB2' ' A' ' 65' ' ' ASN . 57.4 t -66.15 -48.18 82.25 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.65 0 CA-C-N 115.595 -0.73 . . . . 0.0 110.082 174.672 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -58.76 -30.65 67.68 Favored 'General case' 0 CA--C 1.518 -0.284 0 CA-C-N 115.766 -0.652 . . . . 0.0 110.567 173.551 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 87' ' ' GLU . . . . . 0.673 ' HG2' ' O ' ' A' ' 83' ' ' ILE . 30.9 mm-40 -59.06 -43.32 91.7 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.735 -0.666 . . . . 0.0 110.368 179.754 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.515 ' O ' ' HG3' ' A' ' 92' ' ' ARG . 91.1 t -62.9 -49.49 83.42 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-O 120.851 0.357 . . . . 0.0 110.446 177.901 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 89' ' ' THR . . . . . 0.609 HG22 ' NE2' ' A' ' 93' ' ' GLN . 23.8 m -66.17 -42.16 89.31 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.936 -0.574 . . . . 0.0 111.312 -176.479 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 90' ' ' ARG . . . . . 0.646 ' HA ' ' OE1' ' A' ' 93' ' ' GLN . 8.1 ptt180 -69.17 -32.76 72.3 Favored 'General case' 0 CA--C 1.515 -0.392 0 CA-C-O 121.729 0.776 . . . . 0.0 109.435 -179.255 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 91' ' ' LEU . . . . . 0.46 ' HB2' ' O ' ' A' ' 87' ' ' GLU . 49.4 tp -57.14 -27.44 61.85 Favored 'General case' 0 C--N 1.315 -0.92 0 CA-C-N 114.762 -1.108 . . . . 0.0 111.09 -179.179 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 92' ' ' ARG . . . . . 0.535 ' NH2' HG23 ' A' ' 89' ' ' THR . 6.7 mtm180 -92.14 -50.97 5.41 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 115.407 -0.815 . . . . 0.0 110.581 -175.846 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 93' ' ' GLN . . . . . 0.646 ' OE1' ' HA ' ' A' ' 90' ' ' ARG . 0.0 OUTLIER -104.93 -15.1 15.24 Favored 'General case' 0 CA--C 1.539 0.531 0 N-CA-C 113.44 0.904 . . . . 0.0 113.44 -170.151 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.484 ' O ' ' HB2' ' A' ' 90' ' ' ARG . . . 101.32 -97.55 1.67 Allowed Glycine 0 CA--C 1.498 -0.996 0 N-CA-C 110.096 -1.202 . . . . 0.0 110.096 -179.631 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 95' ' ' TRP . . . . . . . . . . . . . 25.3 m95 -145.89 19.45 1.45 Allowed 'General case' 0 C--N 1.315 -0.895 0 N-CA-C 106.246 -1.761 . . . . 0.0 106.246 171.867 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -66.03 -26.59 72.4 Favored Glycine 0 N--CA 1.451 -0.325 0 CA-C-N 114.581 -1.191 . . . . 0.0 112.833 -177.181 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -81.36 -15.19 56.04 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 121.272 0.558 . . . . 0.0 109.966 177.341 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 98' ' ' TRP . . . . . 0.594 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 28.3 m-90 -106.7 107.95 61.09 Favored Pre-proline 0 N--CA 1.445 -0.685 0 CA-C-N 115.472 -0.785 . . . . 0.0 109.42 177.657 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 99' ' ' PRO . . . . . 0.452 ' HD3' ' HA ' ' A' ' 98' ' ' TRP . 50.6 Cg_exo -61.99 -138.17 0.0 OUTLIER 'Trans proline' 0 CA--C 1.534 0.495 0 C-N-CA 123.876 3.051 . . . . 0.0 114.1 -174.628 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 15.0 m -54.97 -26.49 17.62 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.292 0 CA-C-O 121.166 0.507 . . . . 0.0 111.731 -176.468 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 101' ' ' CYS . . . . . 0.446 ' SG ' ' HB2' ' A' ' 38' ' ' GLU . 83.0 m -56.38 -35.3 67.56 Favored 'General case' 0 C--N 1.313 -0.985 0 CA-C-N 115.195 -0.911 . . . . 0.0 111.553 177.72 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -70.88 -45.83 63.68 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.768 0.318 . . . . 0.0 110.934 178.479 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -59.46 -42.69 92.57 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 121.086 0.469 . . . . 0.0 110.621 177.256 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 49.3 mtp180 -67.14 -19.46 65.61 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.348 -0.842 . . . . 0.0 111.14 178.199 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 105' ' ' ALA . . . . . 0.424 ' CB ' ' HB3' ' A' ' 33' ' ' ALA . . . -96.43 -20.39 18.47 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.938 -0.573 . . . . 0.0 112.109 -176.489 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 102.29 55.28 0.86 Allowed Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.887 -0.673 . . . . 0.0 111.802 -175.996 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -57.58 149.74 20.74 Favored 'General case' 0 C--N 1.329 -0.29 0 C-N-CA 123.224 0.61 . . . . 0.0 111.352 -179.639 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 28.0 mtp180 . . . . . 0 C--O 1.25 1.118 0 CA-C-O 118.317 -0.849 . . . . 0.0 109.49 -171.547 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 79.4 m-20 . . . . . 0 N--CA 1.478 0.936 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 72.5 t -110.83 -57.2 4.12 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.657 0 CA-C-O 120.958 0.408 . . . . 0.0 110.37 179.899 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 24.6 t -84.41 77.35 1.31 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.804 0 CA-C-O 121.644 0.735 . . . . 0.0 110.969 -176.925 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 17.1 t -125.33 142.18 42.95 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.838 0 CA-C-N 115.09 -0.959 . . . . 0.0 109.018 176.812 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 20.0 p -128.24 102.8 20.87 Favored Pre-proline 0 C--N 1.313 -1.01 0 CA-C-N 116.121 -0.491 . . . . 0.0 111.372 -176.787 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 5.1 Cg_exo -78.43 136.34 13.96 Favored 'Trans proline' 0 N--CA 1.448 -1.189 0 C-N-CA 123.304 2.67 . . . . 0.0 110.53 174.417 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . 53.9 42.03 31.84 Favored 'General case' 0 C--N 1.305 -1.352 0 CA-C-N 114.129 -1.396 . . . . 0.0 110.717 -173.376 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 85.6 t60 -69.33 -14.72 63.08 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-N 114.372 -1.286 . . . . 0.0 108.795 171.535 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 12.8 pt-20 -95.18 128.04 41.71 Favored 'General case' 0 N--CA 1.445 -0.722 0 CA-C-N 115.316 -0.856 . . . . 0.0 109.042 175.469 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -128.63 67.29 1.39 Allowed 'General case' 0 C--N 1.314 -0.966 0 CA-C-O 121.724 0.773 . . . . 0.0 110.232 -176.833 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 7.2 p -64.28 -38.39 82.4 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.899 0 CA-C-N 114.515 -1.221 . . . . 0.0 110.319 179.051 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.478 ' O ' ' HG3' ' A' ' 13' ' ' ARG . 61.1 t 5.38 72.39 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.348 0.539 0 C-N-CA 126.487 1.915 . . . . 0.0 114.03 -176.92 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 13' ' ' ARG . . . . . 0.478 ' HG3' ' O ' ' A' ' 12' ' ' VAL . 83.9 mtm180 -160.29 135.82 8.18 Favored 'General case' 0 C--N 1.304 -1.399 0 CA-C-N 113.074 -1.876 . . . . 0.0 108.107 -179.526 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.3 t -71.92 148.77 9.64 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.218 0 CA-C-O 121.564 0.697 . . . . 0.0 109.514 -176.677 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -114.35 57.74 0.45 Allowed Glycine 0 N--CA 1.428 -1.881 0 CA-C-N 114.804 -1.089 . . . . 0.0 111.945 -176.471 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 3.2 m -71.9 -35.3 69.69 Favored 'General case' 0 C--N 1.313 -1.019 0 CA-C-O 122.072 0.939 . . . . 0.0 109.599 177.628 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 17' ' ' LYS . . . . . 0.794 ' HB2' ' HG2' ' A' ' 21' ' ' GLU . 0.0 OUTLIER -65.8 119.78 63.54 Favored Pre-proline 0 C--N 1.315 -0.9 0 CA-C-N 113.692 -1.595 . . . . 0.0 111.332 -179.969 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 18' ' ' PRO . . . . . 0.442 ' HD3' ' HA ' ' A' ' 17' ' ' LYS . 16.1 Cg_exo -70.11 -175.56 1.28 Allowed 'Trans proline' 0 CA--C 1.511 -0.644 0 C-N-CA 123.558 2.839 . . . . 0.0 111.178 171.293 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -61.87 -28.03 69.53 Favored Glycine 0 C--N 1.308 -1.024 0 N-CA-C 109.994 -1.242 . . . . 0.0 109.994 176.461 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 4.5 m -58.38 -40.84 83.41 Favored 'General case' 0 C--N 1.312 -1.062 0 CA-C-N 112.991 -1.604 . . . . 0.0 111.913 177.4 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 21' ' ' GLU . . . . . 0.794 ' HG2' ' HB2' ' A' ' 17' ' ' LYS . 23.0 mt-10 37.26 77.92 0.04 OUTLIER 'General case' 0 C--O 1.234 0.265 0 N-CA-C 113.684 0.994 . . . . 0.0 113.684 -173.675 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.615 ' CG2' ' HB3' ' A' ' 80' ' ' GLU . 3.7 p -91.15 125.1 59.68 Favored Pre-proline 0 C--N 1.302 -1.474 0 CA-C-N 114.14 -1.391 . . . . 0.0 110.264 172.557 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_exo -54.99 129.56 36.02 Favored 'Trans proline' 0 C--N 1.344 0.292 0 C-N-CA 122.332 2.021 . . . . 0.0 110.7 170.387 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 11.4 Cg_endo -55.15 140.56 80.86 Favored 'Trans proline' 0 N--CA 1.457 -0.634 0 C-N-CA 123.377 2.718 . . . . 0.0 113.286 -172.753 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 22.1 t -116.58 151.68 18.37 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.916 0 CA-C-N 114.557 -1.201 . . . . 0.0 108.734 177.316 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.49 ' H ' HD12 ' A' ' 26' ' ' ILE . 3.1 mp -55.98 -42.69 72.54 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.557 0 CA-C-O 120.988 0.423 . . . . 0.0 111.513 -167.599 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.525 ' HB2' ' OE1' ' A' ' 87' ' ' GLU . 31.1 m-20 -122.95 10.58 9.51 Favored 'General case' 0 C--N 1.316 -0.876 0 CA-C-N 115.583 -0.735 . . . . 0.0 110.286 -173.687 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 28' ' ' GLY . . . . . 0.583 ' HA2' ' HD1' ' A' ' 31' ' ' TRP . . . -60.55 -14.07 33.67 Favored Glycine 0 N--CA 1.448 -0.516 0 CA-C-N 115.631 -0.713 . . . . 0.0 111.683 -177.816 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 3.6 m -76.65 -41.9 44.04 Favored 'General case' 0 C--N 1.318 -0.772 0 CA-C-O 121.901 0.857 . . . . 0.0 109.576 178.263 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.525 ' O ' HG13 ' A' ' 34' ' ' ILE . 0.5 OUTLIER -66.95 -38.21 80.93 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.696 0 CA-C-N 114.263 -1.335 . . . . 0.0 107.891 -179.66 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 31' ' ' TRP . . . . . 0.583 ' HD1' ' HA2' ' A' ' 28' ' ' GLY . 38.2 m95 -66.33 -35.99 81.77 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 114.852 -1.067 . . . . 0.0 110.519 -177.215 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 5.4 t0 -70.1 -42.88 72.12 Favored 'General case' 0 N--CA 1.442 -0.86 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.138 178.621 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 33' ' ' ALA . . . . . 0.426 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -69.35 -34.22 74.28 Favored 'General case' 0 N--CA 1.445 -0.704 0 C-N-CA 120.39 -0.524 . . . . 0.0 110.683 179.457 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 34' ' ' ILE . . . . . 0.525 HG13 ' O ' ' A' ' 30' ' ' ILE . 51.9 mt -62.61 -43.65 98.69 Favored 'Isoleucine or valine' 0 C--O 1.235 0.295 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.429 174.692 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 35' ' ' ALA . . . . . 0.541 ' HA ' ' O ' ' A' ' 54' ' ' GLY . . . -61.84 -34.94 76.88 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.285 176.349 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 36' ' ' GLY . . . . . 0.433 ' HA2' ' N ' ' A' ' 41' ' ' GLY . . . -72.46 -16.9 77.51 Favored Glycine 0 N--CA 1.451 -0.328 0 CA-C-N 115.503 -0.771 . . . . 0.0 111.902 179.332 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 7.1 t -81.62 -61.88 1.8 Allowed 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.575 -0.313 . . . . 0.0 111.78 -177.388 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 14.0 tp10 -88.76 -33.73 17.37 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-O 121.109 0.48 . . . . 0.0 110.714 -172.641 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -99.13 -10.53 22.4 Favored 'General case' 0 N--CA 1.446 -0.626 0 CA-C-N 115.986 -0.552 . . . . 0.0 111.797 -173.817 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 75.13 15.9 80.87 Favored Glycine 0 N--CA 1.448 -0.522 0 N-CA-C 109.666 -1.374 . . . . 0.0 109.666 -177.041 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 41' ' ' GLY . . . . . 0.433 ' N ' ' HA2' ' A' ' 36' ' ' GLY . . . 79.18 61.73 2.31 Favored Glycine 0 N--CA 1.434 -1.478 0 CA-C-N 114.045 -1.077 . . . . 0.0 111.465 -174.64 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 2.4 t-20 -142.91 95.63 2.8 Favored 'General case' 0 C--N 1.323 -0.581 0 N-CA-C 108.799 -0.815 . . . . 0.0 108.799 -179.46 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 43' ' ' TRP . . . . . 0.764 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 18.2 m95 -78.29 -3.23 41.87 Favored 'General case' 0 C--N 1.314 -0.944 0 CA-C-N 115.413 -0.812 . . . . 0.0 110.122 -174.269 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -112.58 14.21 20.11 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.273 -0.876 . . . . 0.0 111.7 -179.111 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.949 HG22 ' HA2' ' A' ' 53' ' ' GLY . 2.9 tt -75.61 145.08 11.2 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.45 0 CA-C-O 121.24 0.543 . . . . 0.0 110.214 179.435 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 14.1 t-20 -146.88 87.62 1.7 Allowed 'General case' 0 C--N 1.312 -1.028 0 N-CA-C 109.649 -0.5 . . . . 0.0 109.649 179.188 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 22.4 p -68.6 -28.16 66.68 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.657 -0.701 . . . . 0.0 110.268 179.72 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 100.01 18.09 23.34 Favored Glycine 0 N--CA 1.444 -0.785 0 CA-C-N 115.382 -0.827 . . . . 0.0 111.162 179.474 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 32.9 p-10 -92.85 10.63 30.24 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 120.878 0.37 . . . . 0.0 111.419 -175.147 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 50' ' ' GLY . . . . . 0.525 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 90.51 -11.66 70.78 Favored Glycine 0 N--CA 1.449 -0.433 0 N-CA-C 111.707 -0.557 . . . . 0.0 111.707 179.715 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 51' ' ' TYR . . . . . 0.581 ' CE1' ' HB3' ' A' ' 58' ' ' ASP . 0.6 OUTLIER -111.9 162.07 15.72 Favored 'General case' 0 N--CA 1.446 -0.644 0 N-CA-C 106.541 -1.652 . . . . 0.0 106.541 177.671 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 52' ' ' TYR . . . . . 0.749 ' HB2' ' HB3' ' A' ' 74' ' ' ALA . 39.3 m-85 -125.85 169.68 12.38 Favored 'General case' 0 C--N 1.31 -1.114 0 C-N-CA 119.82 -0.752 . . . . 0.0 112.028 -168.313 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.949 ' HA2' HG22 ' A' ' 45' ' ' ILE . . . -60.52 160.04 24.59 Favored Glycine 0 CA--C 1.5 -0.893 0 CA-C-N 115.121 -0.945 . . . . 0.0 113.54 -175.045 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.629 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 92.15 -109.55 3.77 Favored Glycine 0 N--CA 1.437 -1.267 0 C-N-CA 120.515 -0.85 . . . . 0.0 111.615 -177.751 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.581 HG12 ' NE1' ' A' ' 98' ' ' TRP . 3.9 t -87.15 13.18 1.03 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-O 121.378 0.609 . . . . 0.0 110.466 -174.266 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 56' ' ' GLN . . . . . 0.478 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 5.9 pm0 51.07 33.85 9.88 Favored 'General case' 0 N--CA 1.473 0.689 0 N-CA-C 114.454 1.279 . . . . 0.0 114.454 164.975 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 4.7 p90 -113.77 168.95 9.35 Favored 'General case' 0 C--N 1.325 -0.475 0 C-N-CA 119.348 -0.941 . . . . 0.0 112.169 178.593 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.581 ' HB3' ' CE1' ' A' ' 51' ' ' TYR . 5.5 p-10 -83.83 164.53 19.44 Favored 'General case' 0 CA--C 1.517 -0.311 0 N-CA-C 113.887 1.069 . . . . 0.0 113.887 -163.379 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.421 ' HB2' ' HE1' ' A' ' 52' ' ' TYR . 5.2 tp-100 -63.38 -39.58 94.92 Favored 'General case' 0 N--CA 1.449 -0.481 0 CA-C-N 113.553 -1.658 . . . . 0.0 111.969 179.695 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -65.52 -48.03 72.25 Favored Glycine 0 C--N 1.317 -0.504 0 C-N-CA 121.124 -0.56 . . . . 0.0 111.991 -176.217 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 98.4 m -64.85 -42.05 95.21 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-O 120.936 0.398 . . . . 0.0 110.85 176.052 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 62' ' ' TRP . . . . . 0.437 ' CH2' ' HA ' ' A' ' 82' ' ' GLN . 53.4 t-105 -56.91 -49.76 74.6 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 121.733 0.778 . . . . 0.0 109.871 176.764 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 63' ' ' GLU . . . . . 0.522 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 1.8 tm-20 -67.68 -33.48 75.0 Favored 'General case' 0 C--N 1.318 -0.802 0 CA-C-N 114.677 -1.147 . . . . 0.0 110.656 -178.246 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -66.86 -40.8 87.98 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.923 -179.581 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 65' ' ' ASN . . . . . 0.405 HD21 ' NH1' ' A' ' 92' ' ' ARG . 8.2 m120 -82.93 -1.78 53.22 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 121.056 0.455 . . . . 0.0 110.328 177.163 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 80.17 48.93 6.18 Favored Glycine 0 C--N 1.334 0.446 0 CA-C-N 115.6 -0.727 . . . . 0.0 112.413 173.686 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.545 ' HA2' ' HD1' ' A' ' 70' ' ' TYR . . . -80.25 -18.71 71.01 Favored Glycine 0 N--CA 1.442 -0.953 0 C-N-CA 120.828 -0.701 . . . . 0.0 112.959 -176.338 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.729 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 6.5 mp -60.84 -28.47 68.85 Favored 'General case' 0 C--N 1.322 -0.616 0 N-CA-C 112.379 0.511 . . . . 0.0 112.379 -172.364 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 16.3 ptm180 -67.85 -28.79 67.85 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 121.457 0.646 . . . . 0.0 110.188 176.206 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 70' ' ' TYR . . . . . 0.627 ' HB3' ' HG3' ' A' ' 81' ' ' GLU . 86.4 m-85 -79.4 -34.11 42.12 Favored 'General case' 0 N--CA 1.442 -0.838 0 N-CA-C 107.419 -1.326 . . . . 0.0 107.419 175.708 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.68 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 159.13 128.39 0.0 OUTLIER Pre-proline 0 CA--C 1.51 -0.589 0 CA-C-N 112.473 -2.149 . . . . 0.0 106.539 -179.474 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 72' ' ' PRO . . . . . 0.729 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 23.3 Cg_exo -55.64 -6.08 0.94 Allowed 'Trans proline' 0 CA--C 1.527 0.166 0 C-N-CA 122.829 2.353 . . . . 0.0 113.808 -176.824 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 12.8 ptm180 -146.84 138.49 24.38 Favored 'General case' 0 C--N 1.322 -0.597 0 N-CA-C 109.521 -0.548 . . . . 0.0 109.521 177.927 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 74' ' ' ALA . . . . . 0.749 ' HB3' ' HB2' ' A' ' 52' ' ' TYR . . . -61.7 -23.0 65.82 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 113.052 0.76 . . . . 0.0 113.052 -176.168 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 75' ' ' ASP . . . . . 0.677 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 5.5 p-10 -84.86 -7.68 59.08 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 121.191 0.52 . . . . 0.0 110.65 -179.051 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 54.6 tp -97.68 -31.47 12.25 Favored 'General case' 0 C--N 1.322 -0.623 0 N-CA-C 109.249 -0.648 . . . . 0.0 109.249 173.591 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 77' ' ' ALA . . . . . 0.727 ' HB1' ' HB3' ' A' ' 81' ' ' GLU . . . -78.55 155.22 29.82 Favored 'General case' 0 N--CA 1.444 -0.757 0 CA-C-N 115.267 -0.879 . . . . 0.0 109.562 176.277 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 48.0 p -97.86 -173.9 2.74 Favored 'General case' 0 C--N 1.311 -1.093 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.539 -176.766 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 79' ' ' ARG . . . . . 0.764 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 2.1 mtp180 -51.44 -53.62 35.19 Favored 'General case' 0 C--O 1.219 -0.518 0 O-C-N 123.184 0.302 . . . . 0.0 111.073 -178.044 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 80' ' ' GLU . . . . . 0.615 ' HB3' ' CG2' ' A' ' 22' ' ' VAL . 1.6 pm0 -62.47 -45.47 92.89 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-O 120.949 0.404 . . . . 0.0 111.6 -176.5 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 81' ' ' GLU . . . . . 0.727 ' HB3' ' HB1' ' A' ' 77' ' ' ALA . 0.4 OUTLIER -60.88 -52.3 65.66 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 121.204 0.526 . . . . 0.0 112.332 178.194 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 82' ' ' GLN . . . . . 0.513 ' HG2' HG23 ' A' ' 55' ' ' VAL . 6.0 tt0 -69.84 -33.94 72.97 Favored 'General case' 0 C--N 1.316 -0.876 0 CA-C-N 115.449 -0.796 . . . . 0.0 110.735 -175.305 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.568 ' O ' ' HG2' ' A' ' 87' ' ' GLU . 24.3 mt -60.52 -43.18 93.82 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.638 0 CA-C-N 115.535 -0.757 . . . . 0.0 109.905 174.155 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 84' ' ' ALA . . . . . 0.579 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -64.51 -39.29 93.51 Favored 'General case' 0 C--O 1.237 0.411 0 CA-C-O 121.421 0.629 . . . . 0.0 111.076 -174.867 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 51.5 t -68.29 -49.28 68.2 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 CA-C-N 115.645 -0.707 . . . . 0.0 111.162 177.761 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -58.69 -29.82 66.93 Favored 'General case' 0 C--O 1.234 0.267 0 CA-C-O 120.955 0.407 . . . . 0.0 110.532 174.232 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 87' ' ' GLU . . . . . 0.724 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 8.8 mm-40 -59.36 -44.42 92.69 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.467 -0.788 . . . . 0.0 109.766 179.279 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.442 ' O ' ' HG3' ' A' ' 92' ' ' ARG . 70.4 t -62.03 -46.26 96.89 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.209 0 CA-C-O 120.933 0.397 . . . . 0.0 109.938 176.473 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 89' ' ' THR . . . . . 0.938 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 0.2 OUTLIER -60.03 -48.61 81.02 Favored 'General case' 0 N--CA 1.447 -0.59 0 CA-C-N 115.67 -0.695 . . . . 0.0 112.004 -175.141 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 90' ' ' ARG . . . . . 0.69 ' HA ' ' OE1' ' A' ' 93' ' ' GLN . 0.2 OUTLIER -60.46 -33.41 72.51 Favored 'General case' 0 CA--C 1.518 -0.28 0 CA-C-N 116.036 -0.529 . . . . 0.0 111.349 -173.433 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 91' ' ' LEU . . . . . 0.724 ' HG ' ' O ' ' A' ' 87' ' ' GLU . 24.4 mt -66.53 -26.26 67.07 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 121.364 0.602 . . . . 0.0 110.139 -175.039 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 92' ' ' ARG . . . . . 0.442 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 10.3 mtm180 -89.13 -49.94 6.45 Favored 'General case' 0 C--N 1.317 -0.84 0 CA-C-N 114.957 -1.02 . . . . 0.0 110.377 -172.18 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 93' ' ' GLN . . . . . 0.69 ' OE1' ' HA ' ' A' ' 90' ' ' ARG . 0.0 OUTLIER -99.05 -22.94 15.46 Favored 'General case' 0 CA--C 1.54 0.582 0 N-CA-C 113.457 0.91 . . . . 0.0 113.457 -171.599 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 81.7 47.19 6.42 Favored Glycine 0 C--N 1.335 0.522 0 C-N-CA 120.81 -0.709 . . . . 0.0 111.921 173.225 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 95' ' ' TRP . . . . . 0.443 ' HH2' ' HB3' ' A' ' 27' ' ' ASP . 4.9 m95 59.34 21.15 9.4 Favored 'General case' 0 C--O 1.221 -0.404 0 CA-C-O 121.567 0.698 . . . . 0.0 109.674 -179.02 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.538 ' H ' ' HG2' ' A' ' 93' ' ' GLN . . . -78.09 -18.62 76.3 Favored Glycine 0 N--CA 1.452 -0.262 0 CA-C-N 115.4 -0.818 . . . . 0.0 112.11 174.645 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -81.79 -31.84 31.65 Favored 'General case' 0 C--N 1.326 -0.421 0 N-CA-C 109.541 -0.54 . . . . 0.0 109.541 176.421 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 98' ' ' TRP . . . . . 0.938 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 17.2 m-90 -105.68 103.9 45.88 Favored Pre-proline 0 C--N 1.323 -0.577 0 CA-C-N 115.286 -0.87 . . . . 0.0 109.143 177.265 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 99' ' ' PRO . . . . . 0.414 ' HD3' ' HA ' ' A' ' 98' ' ' TRP . 11.3 Cg_exo -77.2 -90.85 0.0 OUTLIER 'Trans proline' 0 CA--C 1.536 0.589 0 C-N-CA 122.789 2.326 . . . . 0.0 114.543 -173.467 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 100' ' ' VAL . . . . . 0.473 ' O ' ' HD2' ' A' ' 104' ' ' ARG . 4.5 p -69.77 -29.37 40.6 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.349 0 CA-C-O 121.962 0.887 . . . . 0.0 110.196 -172.525 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 78.0 m -73.39 -38.8 65.52 Favored 'General case' 0 C--N 1.312 -1.061 0 CA-C-N 114.281 -1.327 . . . . 0.0 111.564 -174.05 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 102' ' ' ALA . . . . . 0.447 ' HB2' ' HB2' ' A' ' 98' ' ' TRP . . . -70.27 -42.37 72.22 Favored 'General case' 0 C--N 1.326 -0.441 0 C-N-CA 120.761 -0.376 . . . . 0.0 110.499 178.494 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -59.3 -45.47 91.19 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 121.2 0.524 . . . . 0.0 110.59 178.552 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 104' ' ' ARG . . . . . 0.473 ' HD2' ' O ' ' A' ' 100' ' ' VAL . 0.0 OUTLIER -71.82 -18.5 62.08 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 115.566 -0.743 . . . . 0.0 111.888 179.512 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 105' ' ' ALA . . . . . 0.431 ' HB3' HG22 ' A' ' 30' ' ' ILE . . . -92.16 -21.35 20.45 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 121.001 0.429 . . . . 0.0 111.45 179.508 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 110.5 63.06 0.51 Allowed Glycine 0 N--CA 1.451 -0.353 0 CA-C-N 116.005 -0.543 . . . . 0.0 112.018 -177.885 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -65.13 149.39 49.99 Favored 'General case' 0 C--N 1.33 -0.244 0 C-N-CA 122.806 0.442 . . . . 0.0 110.908 -178.25 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 71.7 mtp180 . . . . . 0 C--O 1.246 0.884 0 CA-C-O 118.638 -0.696 . . . . 0.0 110.195 -170.995 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 17.2 m120 . . . . . 0 N--CA 1.476 0.844 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 24.4 t 56.26 87.88 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.449 -0.522 0 CA-C-O 122.211 1.005 . . . . 0.0 110.445 -174.988 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 87.2 t -64.72 120.59 11.92 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.641 0 CA-C-N 114.51 -1.223 . . . . 0.0 112.466 -174.618 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 10.8 t -106.87 140.85 23.64 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 N-CA-C 107.873 -1.158 . . . . 0.0 107.873 167.262 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 3.3 t -90.11 117.65 68.23 Favored Pre-proline 0 C--N 1.313 -0.986 0 CA-C-O 121.361 0.6 . . . . 0.0 112.429 -171.992 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 1.7 Cg_endo -85.25 165.23 11.11 Favored 'Trans proline' 0 N--CA 1.445 -1.328 0 C-N-CA 123.317 2.678 . . . . 0.0 110.339 171.619 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . 54.96 21.73 3.89 Favored 'General case' 0 C--N 1.316 -0.882 0 CA-C-N 115.06 -0.973 . . . . 0.0 112.305 -176.739 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 33.4 t-80 -80.92 -5.78 57.87 Favored 'General case' 0 C--N 1.322 -0.619 0 N-CA-C 108.285 -1.005 . . . . 0.0 108.285 169.937 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 12.2 pt-20 -63.84 145.5 55.68 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 114.712 -1.131 . . . . 0.0 111.453 -175.68 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -104.29 64.15 0.76 Allowed 'General case' 0 C--N 1.319 -0.739 0 CA-C-O 121.934 0.873 . . . . 0.0 109.608 -178.835 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 7.2 p -57.83 -27.83 31.51 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.896 0 CA-C-N 113.781 -1.554 . . . . 0.0 111.245 178.687 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 38.4 t 41.65 90.49 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.445 -0.698 0 CA-C-O 122.558 1.17 . . . . 0.0 112.425 -179.527 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' ARG . . . . . 0.409 HH11 ' HD3' ' A' ' 13' ' ' ARG . 12.6 ptp180 -88.81 114.41 25.4 Favored 'General case' 0 C--N 1.306 -1.312 0 CA-C-N 114.107 -1.406 . . . . 0.0 108.871 178.069 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.4 HG12 ' N ' ' A' ' 15' ' ' GLY . 3.3 t -79.88 161.11 4.11 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.347 0 CA-C-N 114.656 -1.156 . . . . 0.0 110.559 -175.445 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 15' ' ' GLY . . . . . 0.4 ' N ' HG12 ' A' ' 14' ' ' VAL . . . 153.31 86.23 0.05 OUTLIER Glycine 0 N--CA 1.431 -1.673 0 CA-C-N 114.053 -1.431 . . . . 0.0 111.308 -178.704 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 8.6 m -65.53 -35.94 82.36 Favored 'General case' 0 N--CA 1.446 -0.655 0 CA-C-O 121.113 0.482 . . . . 0.0 110.147 -179.231 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 34.1 mmtp 37.63 78.76 0.34 Allowed Pre-proline 0 C--N 1.327 -0.384 0 CA-C-N 114.028 -1.442 . . . . 0.0 113.007 175.456 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 27.2 Cg_exo -64.29 163.45 26.35 Favored 'Trans proline' 0 N--CA 1.457 -0.675 0 C-N-CA 122.65 2.233 . . . . 0.0 112.162 177.843 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 133.69 -52.06 0.83 Allowed Glycine 0 C--N 1.304 -1.244 0 CA-C-N 114.295 -1.32 . . . . 0.0 110.417 -174.007 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 51.4 m -67.31 -30.02 69.76 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 121.957 0.884 . . . . 0.0 108.949 168.688 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 42.4 mt-10 -126.71 137.35 53.24 Favored 'General case' 0 N--CA 1.437 -1.085 0 CA-C-N 114.545 -1.207 . . . . 0.0 108.004 177.103 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 93.3 t -80.23 125.62 80.97 Favored Pre-proline 0 C--N 1.31 -1.142 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.987 -176.362 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_exo -53.74 140.1 67.25 Favored 'Trans proline' 0 C--N 1.347 0.478 0 C-N-CA 123.328 2.685 . . . . 0.0 112.03 178.737 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 10.9 Cg_endo -55.58 139.33 82.6 Favored 'Trans proline' 0 N--CA 1.455 -0.785 0 C-N-CA 123.332 2.688 . . . . 0.0 112.953 -177.936 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.955 HG11 HD13 ' A' ' 83' ' ' ILE . 9.1 p -95.36 130.21 44.43 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.038 0 CA-C-N 114.311 -1.313 . . . . 0.0 110.158 178.142 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 49.9 mm -82.14 -30.22 9.77 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 CA-C-O 121.142 0.496 . . . . 0.0 110.513 178.499 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.424 ' O ' HG13 ' A' ' 30' ' ' ILE . 15.0 m-20 -86.21 -3.67 59.02 Favored 'General case' 0 CA--C 1.498 -1.036 0 CA-C-O 121.88 0.848 . . . . 0.0 109.791 -178.438 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 28' ' ' GLY . . . . . 0.607 ' HA2' ' HB2' ' A' ' 31' ' ' TRP . . . -70.66 -7.44 61.36 Favored Glycine 0 N--CA 1.438 -1.228 0 CA-C-N 114.659 -1.155 . . . . 0.0 110.295 -179.12 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 41.7 m -77.05 -38.35 52.9 Favored 'General case' 0 C--N 1.32 -0.717 0 N-CA-C 109.029 -0.73 . . . . 0.0 109.029 173.997 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.576 ' HA ' ' HB1' ' A' ' 105' ' ' ALA . 0.2 OUTLIER -71.92 -37.1 60.07 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.692 0 N-CA-C 107.844 -1.169 . . . . 0.0 107.844 175.929 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 31' ' ' TRP . . . . . 0.607 ' HB2' ' HA2' ' A' ' 28' ' ' GLY . 38.9 m95 -71.38 -38.29 71.55 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 114.611 -1.177 . . . . 0.0 110.391 -178.377 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 28.3 t70 -78.31 -30.14 48.17 Favored 'General case' 0 N--CA 1.442 -0.846 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.041 178.599 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 33' ' ' ALA . . . . . 0.481 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -70.6 -33.78 71.43 Favored 'General case' 0 N--CA 1.452 -0.371 0 O-C-N 122.012 -0.43 . . . . 0.0 110.177 176.389 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 34' ' ' ILE . . . . . 0.534 ' HA ' ' HB3' ' A' ' 101' ' ' CYS . 70.3 mt -64.73 -46.14 93.07 Favored 'Isoleucine or valine' 0 C--O 1.234 0.239 0 CA-C-O 121.241 0.544 . . . . 0.0 109.804 171.473 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 35' ' ' ALA . . . . . 0.486 ' HA ' ' O ' ' A' ' 54' ' ' GLY . . . -58.61 -39.45 80.48 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.547 -0.751 . . . . 0.0 110.453 176.177 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -76.51 -7.25 85.33 Favored Glycine 0 C--N 1.319 -0.363 0 CA-C-N 115.462 -0.79 . . . . 0.0 111.763 179.923 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 9.3 t -92.47 -64.78 1.06 Allowed 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 115.428 -0.386 . . . . 0.0 110.972 -178.981 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 38' ' ' GLU . . . . . 0.806 ' HG3' ' SG ' ' A' ' 101' ' ' CYS . 25.7 mt-10 -90.49 -33.64 15.87 Favored 'General case' 0 C--N 1.325 -0.473 0 C-N-CA 120.522 -0.471 . . . . 0.0 111.419 -175.684 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 39' ' ' ALA . . . . . 0.438 ' HB3' ' O ' ' A' ' 35' ' ' ALA . . . -89.62 -11.86 41.37 Favored 'General case' 0 C--N 1.325 -0.495 0 C-N-CA 120.697 -0.401 . . . . 0.0 111.641 -176.033 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 76.32 13.36 83.41 Favored Glycine 0 CA--C 1.505 -0.556 0 N-CA-C 110.225 -1.15 . . . . 0.0 110.225 -179.672 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 79.64 57.45 3.1 Favored Glycine 0 N--CA 1.433 -1.549 0 CA-C-N 113.915 -1.143 . . . . 0.0 111.759 -176.038 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 42' ' ' ASN . . . . . 0.413 ' OD1' ' HB ' ' A' ' 45' ' ' ILE . 2.4 t-20 -147.8 106.12 3.77 Favored 'General case' 0 N--CA 1.448 -0.548 0 N-CA-C 108.76 -0.83 . . . . 0.0 108.76 -177.752 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 43' ' ' TRP . . . . . 0.753 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 35.2 m95 -83.92 -12.38 55.49 Favored 'General case' 0 C--N 1.311 -1.07 0 CA-C-N 115.643 -0.708 . . . . 0.0 110.315 -174.031 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -106.67 13.98 27.46 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 115.346 -0.843 . . . . 0.0 110.895 -179.508 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.566 HG22 ' HA3' ' A' ' 53' ' ' GLY . 7.0 tt -77.51 144.38 11.56 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.01 0 N-CA-C 109.239 -0.652 . . . . 0.0 109.239 177.412 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 41.1 t-20 -156.59 100.67 1.96 Allowed 'General case' 0 C--N 1.313 -1.022 0 CA-C-O 121.213 0.53 . . . . 0.0 109.614 -177.625 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 14.6 p -72.59 -24.75 61.13 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.298 -0.864 . . . . 0.0 110.383 179.527 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 96.12 17.77 33.65 Favored Glycine 0 N--CA 1.441 -1.013 0 CA-C-N 115.413 -0.812 . . . . 0.0 111.181 178.537 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 1.6 p-10 -90.34 9.47 28.76 Favored 'General case' 0 C--N 1.329 -0.32 0 C-N-CA 120.56 -0.456 . . . . 0.0 111.356 -173.141 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 50' ' ' GLY . . . . . 0.452 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 95.42 -11.55 68.66 Favored Glycine 0 N--CA 1.454 -0.154 0 C-N-CA 120.88 -0.676 . . . . 0.0 111.774 -179.194 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 51' ' ' TYR . . . . . 0.658 ' HA ' ' HA ' ' A' ' 58' ' ' ASP . 0.1 OUTLIER -113.67 159.82 19.28 Favored 'General case' 0 N--CA 1.447 -0.62 0 N-CA-C 106.655 -1.609 . . . . 0.0 106.655 174.186 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 52' ' ' TYR . . . . . 0.835 ' O ' ' HA ' ' A' ' 56' ' ' GLN . 50.8 m-85 -123.67 170.67 10.24 Favored 'General case' 0 C--N 1.311 -1.104 0 C-N-CA 120.639 -0.425 . . . . 0.0 111.116 -169.336 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.566 ' HA3' HG22 ' A' ' 45' ' ' ILE . . . -69.88 -168.27 6.56 Favored Glycine 0 N--CA 1.445 -0.753 0 N-CA-C 114.373 0.509 . . . . 0.0 114.373 -172.851 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.653 ' CA ' ' HA ' ' A' ' 43' ' ' TRP . . . 73.46 -107.84 2.34 Favored Glycine 0 N--CA 1.441 -0.977 0 N-CA-C 111.335 -0.706 . . . . 0.0 111.335 -179.466 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.533 HG22 ' HB3' ' A' ' 82' ' ' GLN . 1.7 m -83.73 -0.43 5.39 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-O 121.464 0.649 . . . . 0.0 110.702 179.413 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 56' ' ' GLN . . . . . 0.835 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 49.8 tp60 57.97 52.98 7.22 Favored 'General case' 0 CA--C 1.535 0.393 0 CA-C-N 114.157 -1.383 . . . . 0.0 114.546 164.404 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -126.73 171.92 10.78 Favored 'General case' 0 C--O 1.233 0.233 0 C-N-CA 118.969 -1.092 . . . . 0.0 112.806 172.512 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.658 ' HA ' ' HA ' ' A' ' 51' ' ' TYR . 7.9 p-10 -77.72 162.34 27.05 Favored 'General case' 0 CA--C 1.515 -0.393 0 N-CA-C 113.945 1.091 . . . . 0.0 113.945 -163.756 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.479 ' HB2' ' HE1' ' A' ' 52' ' ' TYR . 7.1 tp60 -57.67 -41.98 82.62 Favored 'General case' 0 N--CA 1.445 -0.719 0 CA-C-N 114.367 -1.288 . . . . 0.0 111.137 177.194 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -67.61 -49.44 50.16 Favored Glycine 0 CA--C 1.507 -0.431 0 C-N-CA 120.993 -0.622 . . . . 0.0 112.22 -171.787 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 38.8 m -64.97 -42.03 94.92 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-O 120.904 0.383 . . . . 0.0 111.029 177.804 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 62' ' ' TRP . . . . . 0.484 ' CZ3' ' HA ' ' A' ' 82' ' ' GLN . 47.7 t-105 -56.63 -48.2 78.03 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 121.775 0.798 . . . . 0.0 109.514 175.29 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 63' ' ' GLU . . . . . 0.659 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 36.9 tt0 -65.74 -37.56 86.72 Favored 'General case' 0 N--CA 1.443 -0.791 0 CA-C-N 114.738 -1.119 . . . . 0.0 110.892 -179.151 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -66.02 -41.39 91.04 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.857 -177.941 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 65' ' ' ASN . . . . . 0.447 ' HB2' HG13 ' A' ' 85' ' ' VAL . 9.4 m120 -76.8 -13.04 60.05 Favored 'General case' 0 N--CA 1.45 -0.445 0 CA-C-O 120.883 0.373 . . . . 0.0 110.261 177.493 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 66' ' ' GLY . . . . . 0.532 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 92.11 45.43 3.85 Favored Glycine 0 C--N 1.333 0.393 0 CA-C-N 115.846 -0.616 . . . . 0.0 112.642 175.327 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.573 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -79.91 -20.31 68.26 Favored Glycine 0 N--CA 1.443 -0.89 0 C-N-CA 120.807 -0.711 . . . . 0.0 112.848 -174.495 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 1.0 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 6.7 mp -64.37 -23.47 67.3 Favored 'General case' 0 C--N 1.319 -0.756 0 N-CA-C 112.424 0.527 . . . . 0.0 112.424 -172.933 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 69' ' ' ARG . . . . . 0.532 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 13.2 ptp180 -65.26 -31.16 72.17 Favored 'General case' 0 C--N 1.324 -0.509 0 N-CA-C 109.113 -0.699 . . . . 0.0 109.113 175.884 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 70' ' ' TYR . . . . . 0.588 ' HB3' ' HB3' ' A' ' 81' ' ' GLU . 92.4 m-85 -81.12 -36.05 30.82 Favored 'General case' 0 N--CA 1.439 -0.992 0 CA-C-N 114.683 -1.144 . . . . 0.0 107.94 177.394 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.52 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 164.72 127.55 0.02 OUTLIER Pre-proline 0 N--CA 1.448 -0.567 0 CA-C-N 112.626 -2.079 . . . . 0.0 107.342 -178.364 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 72' ' ' PRO . . . . . 1.0 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 17.4 Cg_exo -59.03 -3.44 1.6 Allowed 'Trans proline' 0 C--N 1.334 -0.217 0 C-N-CA 122.724 2.282 . . . . 0.0 113.586 -178.557 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 13.0 ptm180 -144.05 133.74 23.66 Favored 'General case' 0 C--N 1.315 -0.913 0 N-CA-C 108.127 -1.064 . . . . 0.0 108.127 175.986 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 74' ' ' ALA . . . . . 0.658 ' HB3' ' HB2' ' A' ' 52' ' ' TYR . . . -57.99 -28.8 64.74 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 115.578 -0.737 . . . . 0.0 112.372 -175.897 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 20.9 p-10 -84.24 -2.86 57.68 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 121.111 0.481 . . . . 0.0 111.499 -175.944 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.477 ' HB3' ' HB1' ' A' ' 71' ' ' ALA . 62.5 tp -96.38 -28.01 14.66 Favored 'General case' 0 C--N 1.322 -0.624 0 N-CA-C 108.413 -0.958 . . . . 0.0 108.413 170.342 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 77' ' ' ALA . . . . . 0.754 ' HB1' ' HB2' ' A' ' 81' ' ' GLU . . . -80.18 154.4 28.0 Favored 'General case' 0 N--CA 1.444 -0.77 0 CA-C-N 114.413 -1.267 . . . . 0.0 110.093 173.443 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 44.6 p -100.03 -172.5 2.24 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-N 116.392 -0.367 . . . . 0.0 110.136 179.291 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 79' ' ' ARG . . . . . 0.753 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 19.2 mtt180 -48.73 -53.28 19.59 Favored 'General case' 0 CA--C 1.509 -0.605 0 CA-C-O 121.205 0.526 . . . . 0.0 111.277 -177.924 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 80' ' ' GLU . . . . . 0.586 ' HG3' ' OE2' ' A' ' 81' ' ' GLU . 3.4 pt-20 -59.88 -41.04 90.68 Favored 'General case' 0 C--N 1.312 -1.04 0 CA-C-N 114.958 -1.019 . . . . 0.0 112.086 -175.553 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 81' ' ' GLU . . . . . 0.754 ' HB2' ' HB1' ' A' ' 77' ' ' ALA . 4.6 mp0 -67.46 -51.99 44.8 Favored 'General case' 0 C--O 1.232 0.181 0 N-CA-C 112.132 0.419 . . . . 0.0 112.132 174.444 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 82' ' ' GLN . . . . . 0.533 ' HB3' HG22 ' A' ' 55' ' ' VAL . 54.3 mt-30 -59.98 -43.44 95.12 Favored 'General case' 0 CA--C 1.512 -0.501 0 CA-C-O 121.116 0.484 . . . . 0.0 110.54 -175.73 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.955 HD13 HG11 ' A' ' 25' ' ' VAL . 15.4 mt -60.69 -40.81 85.98 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.787 0 CA-C-N 114.947 -1.024 . . . . 0.0 110.568 178.851 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 84' ' ' ALA . . . . . 0.585 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -63.6 -42.13 98.26 Favored 'General case' 0 C--O 1.239 0.524 0 CA-C-O 121.428 0.632 . . . . 0.0 111.366 -177.917 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.447 HG13 ' HB2' ' A' ' 65' ' ' ASN . 44.5 t -69.05 -48.01 72.05 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.675 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.243 178.99 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 86' ' ' ALA . . . . . 0.476 ' HB1' ' CH2' ' A' ' 31' ' ' TRP . . . -57.85 -29.69 65.19 Favored 'General case' 0 N--CA 1.452 -0.34 0 CA-C-N 115.603 -0.726 . . . . 0.0 110.594 174.062 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 87' ' ' GLU . . . . . 0.631 ' HG2' ' O ' ' A' ' 83' ' ' ILE . 15.9 mm-40 -60.81 -40.64 93.5 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.193 178.738 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.504 ' O ' ' HG3' ' A' ' 92' ' ' ARG . 59.0 t -63.08 -48.06 89.61 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-O 121.276 0.56 . . . . 0.0 109.716 173.546 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 89' ' ' THR . . . . . 0.741 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 0.3 OUTLIER -63.41 -47.47 81.85 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 115.559 -0.746 . . . . 0.0 112.224 -174.832 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 90' ' ' ARG . . . . . 0.547 ' HB3' ' CH2' ' A' ' 31' ' ' TRP . 4.8 ptt180 -62.54 -32.82 73.84 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 121.519 0.676 . . . . 0.0 109.216 -176.276 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 91' ' ' LEU . . . . . 0.537 ' N ' ' HG3' ' A' ' 90' ' ' ARG . 64.3 tp -66.09 -32.18 73.5 Favored 'General case' 0 C--N 1.313 -1.01 0 CA-C-N 114.029 -1.441 . . . . 0.0 111.622 -173.236 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 92' ' ' ARG . . . . . 0.504 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 3.5 mtm180 -84.98 -46.46 11.2 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-O 121.507 0.67 . . . . 0.0 110.077 -175.116 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 93' ' ' GLN . . . . . 0.499 HE22 HG22 ' A' ' 89' ' ' THR . 4.5 pt20 -101.89 -27.31 13.06 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 115.218 -0.901 . . . . 0.0 113.155 -168.5 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 92.3 39.62 5.33 Favored Glycine 0 CA--C 1.505 -0.555 0 C-N-CA 120.416 -0.897 . . . . 0.0 111.926 174.547 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 95' ' ' TRP . . . . . 0.499 ' CH2' ' HB ' ' A' ' 30' ' ' ILE . 38.7 m95 71.37 6.91 5.92 Favored 'General case' 0 C--O 1.218 -0.589 0 C-N-CA 123.399 0.68 . . . . 0.0 109.6 -178.462 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -58.46 -37.56 88.58 Favored Glycine 0 CA--C 1.521 0.44 0 CA-C-N 115.595 -0.73 . . . . 0.0 113.741 -179.826 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -68.92 -22.2 64.16 Favored 'General case' 0 CA--C 1.519 -0.241 0 CA-C-N 117.219 0.51 . . . . 0.0 110.657 179.139 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 98' ' ' TRP . . . . . 0.741 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 27.7 m-90 -100.9 104.09 29.45 Favored Pre-proline 0 N--CA 1.449 -0.483 0 N-CA-C 109.05 -0.722 . . . . 0.0 109.05 175.918 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 99' ' ' PRO . . . . . 0.408 ' HD3' ' HA ' ' A' ' 98' ' ' TRP . 16.5 Cg_exo -72.85 -89.96 0.01 OUTLIER 'Trans proline' 0 CA--C 1.533 0.427 0 C-N-CA 122.872 2.382 . . . . 0.0 114.738 -171.509 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 49.0 t -71.68 -30.28 37.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-O 121.811 0.815 . . . . 0.0 110.103 -173.122 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 101' ' ' CYS . . . . . 0.806 ' SG ' ' HG3' ' A' ' 38' ' ' GLU . 70.4 m -76.77 -27.57 55.36 Favored 'General case' 0 C--N 1.317 -0.835 0 CA-C-N 115.099 -0.955 . . . . 0.0 111.869 -169.713 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -69.68 -46.0 67.05 Favored 'General case' 0 C--N 1.329 -0.317 0 C-N-CA 120.75 -0.38 . . . . 0.0 110.753 -179.628 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -67.62 -32.12 72.61 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 120.856 0.36 . . . . 0.0 110.647 -179.946 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -74.1 -21.94 59.69 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.85 177.261 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 105' ' ' ALA . . . . . 0.576 ' HB1' ' HA ' ' A' ' 30' ' ' ILE . . . -96.17 -22.07 17.51 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.815 -0.629 . . . . 0.0 112.057 -176.26 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 108.62 57.08 0.56 Allowed Glycine 0 CA--C 1.522 0.492 0 C-N-CA 120.871 -0.681 . . . . 0.0 112.186 -177.517 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -61.54 149.73 38.09 Favored 'General case' 0 C--N 1.329 -0.321 0 C-N-CA 123.253 0.621 . . . . 0.0 111.551 -175.674 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 72.9 mtp180 . . . . . 0 C--O 1.245 0.859 0 CA-C-O 118.686 -0.673 . . . . 0.0 110.419 -173.855 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 90.8 m-20 . . . . . 0 N--CA 1.478 0.946 0 CA-C-O 120.857 0.36 . . . . 0.0 110.141 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 10.0 p -91.36 34.85 0.1 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.513 0 CA-C-O 122.232 1.015 . . . . 0.0 109.887 -177.354 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 6.0 p -66.39 121.51 15.61 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.67 0 CA-C-N 114.845 -1.07 . . . . 0.0 112.35 -176.898 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 15.7 t -104.24 144.54 14.24 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.628 0 N-CA-C 108.715 -0.846 . . . . 0.0 108.715 171.155 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 35.6 p -89.72 123.13 67.22 Favored Pre-proline 0 C--N 1.313 -0.986 0 CA-C-N 116.45 -0.341 . . . . 0.0 110.378 -178.829 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -77.61 152.84 29.86 Favored 'Trans proline' 0 N--CA 1.449 -1.101 0 C-N-CA 122.777 2.318 . . . . 0.0 110.979 177.33 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -70.25 101.46 1.9 Allowed 'General case' 0 C--N 1.307 -1.24 0 CA-C-O 122.12 0.962 . . . . 0.0 110.314 -178.496 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' HIS . . . . . 0.441 ' H ' ' H ' ' A' ' 9' ' ' GLU . 45.6 t-80 164.66 -11.03 0.0 OUTLIER 'General case' 0 C--N 1.309 -1.182 0 CA-C-N 112.651 -2.068 . . . . 0.0 105.678 -170.249 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 9' ' ' GLU . . . . . 0.441 ' H ' ' H ' ' A' ' 8' ' ' HIS . 13.7 pt-20 -62.73 135.67 57.48 Favored 'General case' 0 C--O 1.234 0.241 0 CA-C-N 114.372 -1.286 . . . . 0.0 109.757 178.215 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -124.92 68.51 1.11 Allowed 'General case' 0 C--N 1.318 -0.789 0 CA-C-O 121.536 0.684 . . . . 0.0 110.748 -175.164 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 12.0 p -66.46 -31.09 52.01 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.743 0 CA-C-N 114.37 -1.286 . . . . 0.0 109.703 176.162 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 98.4 t 11.74 84.78 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.448 -0.574 0 C-N-CA 126.34 1.856 . . . . 0.0 114.235 175.111 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' ARG . . . . . 0.522 ' O ' ' HG3' ' A' ' 13' ' ' ARG . 4.2 ptp180 -99.58 112.03 24.3 Favored 'General case' 0 C--N 1.302 -1.465 0 CA-C-N 113.989 -1.459 . . . . 0.0 109.36 173.664 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 3.0 t -91.09 160.1 2.74 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.484 0 CA-C-N 114.487 -1.233 . . . . 0.0 109.035 179.235 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 88.79 72.34 1.27 Allowed Glycine 0 C--N 1.303 -1.288 0 N-CA-C 110.384 -1.087 . . . . 0.0 110.384 -175.842 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.48 ' O ' ' HD3' ' A' ' 18' ' ' PRO . 25.5 m -74.85 -34.49 62.3 Favored 'General case' 0 N--CA 1.438 -1.056 0 CA-C-O 121.577 0.703 . . . . 0.0 110.55 -175.681 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 11.4 mmmm -102.27 101.25 18.4 Favored Pre-proline 0 C--N 1.316 -0.866 0 CA-C-N 114.649 -1.16 . . . . 0.0 110.604 178.011 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 18' ' ' PRO . . . . . 0.48 ' HD3' ' O ' ' A' ' 16' ' ' THR . 5.2 Cg_exo -78.94 172.02 15.6 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 C-N-CA 123.067 2.511 . . . . 0.0 112.02 177.0 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 120.19 47.6 0.34 Allowed Glycine 0 C--N 1.308 -1.02 0 CA-C-N 114.522 -1.217 . . . . 0.0 111.864 -178.492 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 27.5 m -68.86 -31.02 69.68 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-O 121.571 0.7 . . . . 0.0 110.707 178.898 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 44.1 mt-10 -117.88 143.75 46.03 Favored 'General case' 0 N--CA 1.433 -1.284 0 CA-C-N 115.348 -0.842 . . . . 0.0 109.062 -176.854 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 38.8 t -85.36 114.17 54.78 Favored Pre-proline 0 C--N 1.305 -1.341 0 CA-C-N 115.374 -0.83 . . . . 0.0 110.392 -178.53 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.432 ' HA ' ' HD2' ' A' ' 24' ' ' PRO . 36.4 Cg_exo -59.74 130.88 37.04 Favored 'Trans proline' 0 N--CA 1.462 -0.342 0 C-N-CA 123.055 2.503 . . . . 0.0 112.394 -178.642 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 24' ' ' PRO . . . . . 0.432 ' HD2' ' HA ' ' A' ' 23' ' ' PRO . 9.6 Cg_endo -55.0 140.96 79.93 Favored 'Trans proline' 0 N--CA 1.456 -0.724 0 C-N-CA 123.275 2.65 . . . . 0.0 112.069 177.195 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.617 ' HB ' HG21 ' A' ' 83' ' ' ILE . 26.8 t -113.77 140.62 33.24 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.143 0 CA-C-N 114.729 -1.123 . . . . 0.0 109.513 -177.683 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.403 ' N ' HD12 ' A' ' 26' ' ' ILE . 2.7 mp -61.85 -25.37 36.93 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.353 0 CA-C-N 115.48 -0.782 . . . . 0.0 111.913 -173.876 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 8.7 m-20 -88.03 1.69 53.62 Favored 'General case' 0 CA--C 1.502 -0.889 0 CA-C-O 121.511 0.672 . . . . 0.0 109.774 -177.952 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 28' ' ' GLY . . . . . 0.483 ' HA2' ' HB2' ' A' ' 31' ' ' TRP . . . -64.62 -11.62 49.48 Favored Glycine 0 N--CA 1.44 -1.073 0 CA-C-N 114.893 -1.049 . . . . 0.0 110.64 176.536 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 11.9 m -76.92 -36.88 56.3 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-O 121.854 0.835 . . . . 0.0 109.592 176.511 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.536 ' HA ' ' HB1' ' A' ' 105' ' ' ALA . 1.2 mm -71.34 -40.79 73.71 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 N-CA-C 107.088 -1.449 . . . . 0.0 107.088 176.701 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 31' ' ' TRP . . . . . 0.557 ' HA ' ' CE3' ' A' ' 31' ' ' TRP . 14.3 m95 -67.93 -35.83 79.09 Favored 'General case' 0 C--N 1.315 -0.898 0 CA-C-N 113.711 -1.586 . . . . 0.0 110.536 -175.528 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.607 ' HB2' HH21 ' A' ' 79' ' ' ARG . 12.4 t70 -77.18 -36.6 54.91 Favored 'General case' 0 N--CA 1.44 -0.937 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.712 -179.532 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 33' ' ' ALA . . . . . 0.476 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -70.65 -34.02 71.59 Favored 'General case' 0 N--CA 1.448 -0.558 0 C-N-CA 120.692 -0.403 . . . . 0.0 110.789 177.124 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 34' ' ' ILE . . . . . 0.527 HG13 ' O ' ' A' ' 30' ' ' ILE . 60.5 mt -64.94 -46.83 90.48 Favored 'Isoleucine or valine' 0 C--O 1.234 0.25 0 CA-C-O 120.889 0.376 . . . . 0.0 110.559 175.359 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 35' ' ' ALA . . . . . 0.44 ' O ' ' HB3' ' A' ' 39' ' ' ALA . . . -61.75 -34.67 76.25 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 121.328 0.585 . . . . 0.0 110.285 176.761 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 36' ' ' GLY . . . . . 0.469 ' HA2' ' N ' ' A' ' 41' ' ' GLY . . . -75.58 -9.47 84.69 Favored Glycine 0 N--CA 1.449 -0.462 0 CA-C-N 115.525 -0.762 . . . . 0.0 111.47 178.117 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.459 ' HB3' ' O ' ' A' ' 34' ' ' ILE . 1.7 t -91.03 -63.13 1.31 Allowed 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 115.399 -0.401 . . . . 0.0 111.409 -177.508 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 38' ' ' GLU . . . . . 0.731 ' HG3' ' SG ' ' A' ' 101' ' ' CYS . 13.9 mt-10 -89.27 -33.9 16.8 Favored 'General case' 0 C--N 1.327 -0.381 0 C-N-CA 120.405 -0.518 . . . . 0.0 111.39 -175.262 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 39' ' ' ALA . . . . . 0.44 ' HB3' ' O ' ' A' ' 35' ' ' ALA . . . -88.93 -9.02 53.06 Favored 'General case' 0 C--N 1.323 -0.567 0 C-N-CA 120.706 -0.398 . . . . 0.0 111.367 -177.335 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 75.5 15.92 80.94 Favored Glycine 0 CA--C 1.504 -0.637 0 N-CA-C 110.033 -1.227 . . . . 0.0 110.033 -178.689 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 41' ' ' GLY . . . . . 0.469 ' N ' ' HA2' ' A' ' 36' ' ' GLY . . . 75.76 60.39 3.19 Favored Glycine 0 N--CA 1.434 -1.491 0 CA-C-N 114.047 -1.076 . . . . 0.0 111.25 -174.273 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 2.1 t-20 -142.71 95.42 2.78 Favored 'General case' 0 N--CA 1.448 -0.538 0 N-CA-C 109.242 -0.651 . . . . 0.0 109.242 -178.759 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 43' ' ' TRP . . . . . 0.699 ' HA ' ' N ' ' A' ' 54' ' ' GLY . 36.8 m95 -79.96 -4.03 50.78 Favored 'General case' 0 C--N 1.317 -0.824 0 CA-C-N 115.516 -0.765 . . . . 0.0 110.319 -176.465 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -111.78 15.07 21.07 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 114.893 -1.049 . . . . 0.0 111.416 179.548 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.841 HG22 ' HA2' ' A' ' 53' ' ' GLY . 10.8 tt -76.64 141.44 15.67 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.719 0 CA-C-O 121.297 0.57 . . . . 0.0 110.398 179.612 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 19.1 m120 -142.01 95.93 2.88 Favored 'General case' 0 C--N 1.312 -1.053 0 CA-C-O 121.34 0.59 . . . . 0.0 109.513 -177.927 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 34.3 p -66.47 -23.7 66.31 Favored 'General case' 0 C--N 1.318 -0.791 0 CA-C-N 114.959 -1.019 . . . . 0.0 110.52 -179.097 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 88.55 14.54 61.44 Favored Glycine 0 N--CA 1.441 -0.989 0 N-CA-C 110.135 -1.186 . . . . 0.0 110.135 -178.408 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 2.6 t30 -96.16 5.25 51.49 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.423 0.63 . . . . 0.0 110.67 -173.229 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 95.53 -1.34 64.0 Favored Glycine 0 N--CA 1.447 -0.618 0 C-N-CA 120.612 -0.804 . . . . 0.0 111.103 -176.223 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 51' ' ' TYR . . . . . 0.528 ' HA ' ' O ' ' A' ' 57' ' ' PHE . 0.7 OUTLIER -110.88 161.36 15.9 Favored 'General case' 0 N--CA 1.444 -0.77 0 N-CA-C 107.724 -1.213 . . . . 0.0 107.724 179.077 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 52' ' ' TYR . . . . . 0.543 ' HB2' ' HB3' ' A' ' 74' ' ' ALA . 43.8 m-85 -129.62 170.05 14.27 Favored 'General case' 0 C--N 1.313 -1.013 0 CA-C-O 120.877 0.37 . . . . 0.0 111.823 -170.092 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.841 ' HA2' HG22 ' A' ' 45' ' ' ILE . . . -60.61 164.8 15.32 Favored Glycine 0 N--CA 1.448 -0.562 0 N-CA-C 115.127 0.811 . . . . 0.0 115.127 -168.663 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.699 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 90.22 -96.29 2.19 Favored Glycine 0 N--CA 1.439 -1.152 0 CA-C-N 114.659 -0.77 . . . . 0.0 112.258 177.652 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -102.21 12.46 7.09 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.672 0 CA-C-O 120.77 0.319 . . . . 0.0 111.49 -175.803 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 56' ' ' GLN . . . . . . . . . . . . . 21.4 mm-40 60.24 43.64 13.6 Favored 'General case' 0 N--CA 1.47 0.557 0 CA-C-N 115.427 -0.806 . . . . 0.0 112.417 173.903 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 57' ' ' PHE . . . . . 0.528 ' O ' ' HA ' ' A' ' 51' ' ' TYR . 24.3 m-85 -63.38 127.09 29.72 Favored 'General case' 0 CA--C 1.505 -0.757 0 CA-C-N 115.306 -0.861 . . . . 0.0 112.173 172.847 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.512 ' HA ' ' HA ' ' A' ' 51' ' ' TYR . 6.7 p-10 -72.62 156.77 38.63 Favored 'General case' 0 C--N 1.317 -0.84 0 N-CA-C 108.414 -0.958 . . . . 0.0 108.414 163.522 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 7.5 tp60 -58.44 -35.2 71.76 Favored 'General case' 0 C--N 1.316 -0.89 0 CA-C-O 120.733 0.301 . . . . 0.0 111.039 -177.221 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -68.13 -49.69 45.08 Favored Glycine 0 N--CA 1.451 -0.349 0 CA-C-N 116.045 -0.525 . . . . 0.0 112.494 -175.945 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 82.0 m -67.7 -40.97 84.28 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 120.933 0.397 . . . . 0.0 110.735 178.767 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 62' ' ' TRP . . . . . 0.518 ' HB2' ' HB3' ' A' ' 57' ' ' PHE . 65.6 t-105 -58.05 -47.56 82.77 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-O 121.547 0.689 . . . . 0.0 109.416 176.436 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 63' ' ' GLU . . . . . 0.4 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 33.8 tt0 -67.4 -32.51 73.45 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 115.182 -0.917 . . . . 0.0 110.924 -179.979 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -66.42 -42.37 87.85 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.71 -175.832 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 65' ' ' ASN . . . . . 0.78 ' HB2' HG13 ' A' ' 85' ' ' VAL . 26.1 m-80 -82.86 -5.9 59.2 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.874 0.368 . . . . 0.0 110.292 176.031 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 66' ' ' GLY . . . . . 0.593 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 90.61 48.15 3.53 Favored Glycine 0 C--N 1.332 0.327 0 CA-C-N 115.928 -0.578 . . . . 0.0 112.931 171.056 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.58 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -79.8 -29.48 47.33 Favored Glycine 0 N--CA 1.438 -1.203 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.43 -176.053 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 1.046 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 8.2 mp -56.78 -22.0 32.71 Favored 'General case' 0 N--CA 1.447 -0.605 0 N-CA-C 112.997 0.74 . . . . 0.0 112.997 -175.189 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 69' ' ' ARG . . . . . 0.593 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 12.3 ptm180 -70.76 -30.26 66.71 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-O 121.431 0.634 . . . . 0.0 110.076 177.744 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 70' ' ' TYR . . . . . 0.984 ' HB3' ' HG2' ' A' ' 81' ' ' GLU . 46.7 m-85 -85.41 -36.0 20.95 Favored 'General case' 0 N--CA 1.443 -0.817 0 N-CA-C 107.447 -1.316 . . . . 0.0 107.447 177.037 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.644 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 170.74 126.23 0.05 OUTLIER Pre-proline 0 N--CA 1.445 -0.722 0 CA-C-N 112.863 -1.972 . . . . 0.0 107.522 -176.24 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 72' ' ' PRO . . . . . 1.046 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 26.4 Cg_exo -56.43 -6.15 1.37 Allowed 'Trans proline' 0 C--N 1.333 -0.28 0 C-N-CA 123.005 2.47 . . . . 0.0 113.785 -178.289 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 73' ' ' ARG . . . . . 0.432 ' HB2' ' CD1' ' A' ' 52' ' ' TYR . 13.5 ptm180 -147.53 138.67 23.64 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-O 121.28 0.562 . . . . 0.0 109.559 176.155 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 74' ' ' ALA . . . . . 0.543 ' HB3' ' HB2' ' A' ' 52' ' ' TYR . . . -56.33 -30.22 62.31 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 114.861 -1.063 . . . . 0.0 113.307 -176.289 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 5.4 p-10 -80.47 -11.82 59.63 Favored 'General case' 0 C--N 1.327 -0.379 0 C-N-CA 120.428 -0.509 . . . . 0.0 110.899 -176.988 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.542 ' HB3' ' HB1' ' A' ' 71' ' ' ALA . 46.4 tp -90.16 -31.8 16.92 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-O 121.937 0.875 . . . . 0.0 108.76 173.621 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 77' ' ' ALA . . . . . 0.644 ' HB2' ' HB3' ' A' ' 71' ' ' ALA . . . -79.68 162.98 24.9 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 114.489 -1.232 . . . . 0.0 110.255 174.122 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 64.1 p -102.11 176.59 5.15 Favored 'General case' 0 C--N 1.318 -0.782 0 CA-C-N 116.399 -0.364 . . . . 0.0 110.721 179.155 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 79' ' ' ARG . . . . . 0.632 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 41.8 mtp180 -47.37 -50.84 21.35 Favored 'General case' 0 CA--C 1.511 -0.549 0 C-N-CA 123.103 0.561 . . . . 0.0 111.255 -174.75 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 80' ' ' GLU . . . . . 0.537 ' HA ' HD12 ' A' ' 83' ' ' ILE . 3.4 pm0 -60.01 -31.78 70.26 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-N 115.729 -0.669 . . . . 0.0 111.52 -176.815 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 81' ' ' GLU . . . . . 0.984 ' HG2' ' HB3' ' A' ' 70' ' ' TYR . 5.4 mt-10 -71.72 -47.4 54.16 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 116.619 -0.264 . . . . 0.0 111.524 176.302 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 82' ' ' GLN . . . . . 0.582 ' HB2' ' HZ3' ' A' ' 43' ' ' TRP . 5.9 mp0 -60.78 -36.52 79.18 Favored 'General case' 0 CA--C 1.514 -0.428 0 C-N-CA 120.213 -0.595 . . . . 0.0 109.447 175.466 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.617 HG21 ' HB ' ' A' ' 25' ' ' VAL . 53.7 mt -60.7 -49.28 85.15 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.635 0 CA-C-N 115.104 -0.953 . . . . 0.0 110.47 178.111 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 84' ' ' ALA . . . . . 0.484 ' O ' ' HG3' ' A' ' 87' ' ' GLU . . . -60.35 -45.76 92.32 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-O 120.957 0.408 . . . . 0.0 111.517 -179.53 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.78 HG13 ' HB2' ' A' ' 65' ' ' ASN . 63.6 t -69.1 -49.26 63.87 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.554 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.551 -178.588 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 86' ' ' ALA . . . . . 0.526 ' CA ' ' HZ ' ' A' ' 57' ' ' PHE . . . -64.56 -32.05 73.53 Favored 'General case' 0 CA--C 1.509 -0.619 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.897 179.645 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 87' ' ' GLU . . . . . 0.575 ' O ' ' HG3' ' A' ' 90' ' ' ARG . 1.3 pp20? -70.83 -29.65 65.85 Favored 'General case' 0 C--N 1.321 -0.665 0 C-N-CA 120.271 -0.572 . . . . 0.0 110.117 -177.624 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.722 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 61.2 t -64.74 -41.47 92.28 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.285 0 N-CA-C 109.136 -0.69 . . . . 0.0 109.136 168.093 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 89' ' ' THR . . . . . 0.942 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 1.8 m -65.02 -47.01 78.98 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 115.66 -0.7 . . . . 0.0 111.166 -177.906 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 90' ' ' ARG . . . . . 0.684 ' HA ' ' OE1' ' A' ' 93' ' ' GLN . 3.0 ppt_? -60.69 -34.1 73.85 Favored 'General case' 0 CA--C 1.516 -0.365 0 CA-C-N 115.801 -0.636 . . . . 0.0 111.598 -175.774 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 91' ' ' LEU . . . . . 0.722 ' HG ' ' O ' ' A' ' 88' ' ' VAL . 4.5 pp -72.51 -22.22 61.07 Favored 'General case' 0 C--N 1.319 -0.758 0 CA-C-O 121.222 0.534 . . . . 0.0 110.185 -175.035 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 92' ' ' ARG . . . . . 0.591 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 10.4 mtm180 -84.57 -51.59 6.76 Favored 'General case' 0 CA--C 1.51 -0.574 0 CA-C-N 115.699 -0.682 . . . . 0.0 110.069 -177.713 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 93' ' ' GLN . . . . . 0.684 ' OE1' ' HA ' ' A' ' 90' ' ' ARG . 0.0 OUTLIER -99.17 -22.91 15.43 Favored 'General case' 0 C--N 1.325 -0.474 0 N-CA-C 113.148 0.795 . . . . 0.0 113.148 -171.127 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 94.52 35.04 6.07 Favored Glycine 0 CA--C 1.508 -0.397 0 C-N-CA 120.849 -0.691 . . . . 0.0 112.439 171.254 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 95' ' ' TRP . . . . . 0.425 ' HE1' ' HB2' ' A' ' 108' ' ' ARG . 20.1 m95 66.27 7.87 5.2 Favored 'General case' 0 C--O 1.22 -0.472 0 C-N-CA 123.602 0.761 . . . . 0.0 109.542 -177.146 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -65.55 -32.55 83.66 Favored Glycine 0 C--N 1.332 0.337 0 C-N-CA 121.083 -0.58 . . . . 0.0 112.169 -179.996 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -67.44 -28.92 68.29 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.792 0.329 . . . . 0.0 110.639 178.998 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 98' ' ' TRP . . . . . 0.942 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 26.5 m-90 -100.1 104.44 29.25 Favored Pre-proline 0 N--CA 1.448 -0.55 0 N-CA-C 108.923 -0.769 . . . . 0.0 108.923 176.246 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 99' ' ' PRO . . . . . 0.427 ' HB2' ' H ' ' A' ' 100' ' ' VAL . 17.0 Cg_exo -72.53 -91.29 0.01 OUTLIER 'Trans proline' 0 CA--C 1.533 0.434 0 C-N-CA 123.101 2.534 . . . . 0.0 114.682 -171.884 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 100' ' ' VAL . . . . . 0.427 ' H ' ' HB2' ' A' ' 99' ' ' PRO . 41.5 t -70.67 -28.05 32.98 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-O 121.764 0.792 . . . . 0.0 110.234 -172.938 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 101' ' ' CYS . . . . . 0.731 ' SG ' ' HG3' ' A' ' 38' ' ' GLU . 84.7 m -75.66 -38.4 58.81 Favored 'General case' 0 C--N 1.315 -0.906 0 CA-C-N 115.063 -0.971 . . . . 0.0 111.881 -171.588 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -68.05 -44.48 76.28 Favored 'General case' 0 C--N 1.327 -0.398 0 C-N-CA 120.591 -0.444 . . . . 0.0 110.309 -179.861 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -59.49 -37.44 78.25 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 121.081 0.467 . . . . 0.0 111.053 179.075 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 15.9 tpp180 -73.98 -34.33 64.17 Favored 'General case' 0 N--CA 1.431 -1.398 0 CA-C-N 115.578 -0.737 . . . . 0.0 111.429 179.323 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 105' ' ' ALA . . . . . 0.536 ' HB1' ' HA ' ' A' ' 30' ' ' ILE . . . -88.12 -22.65 23.98 Favored 'General case' 0 C--N 1.326 -0.416 0 N-CA-C 112.667 0.617 . . . . 0.0 112.667 -172.878 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 120.33 58.42 0.24 Allowed Glycine 0 CA--C 1.521 0.415 0 C-N-CA 120.661 -0.781 . . . . 0.0 112.527 -177.927 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -66.68 148.8 51.42 Favored 'General case' 0 C--N 1.325 -0.478 0 C-N-CA 122.771 0.428 . . . . 0.0 110.519 -179.355 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 108' ' ' ARG . . . . . 0.425 ' HB2' ' HE1' ' A' ' 95' ' ' TRP . 72.3 mtp180 . . . . . 0 C--O 1.247 0.949 0 CA-C-O 117.946 -1.026 . . . . 0.0 110.777 -171.924 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 26.8 p-10 . . . . . 0 N--CA 1.476 0.827 0 CA-C-O 121.218 0.532 . . . . 0.0 110.721 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 9.5 p -102.59 15.94 5.29 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-O 121.973 0.892 . . . . 0.0 109.518 175.406 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 60.0 t -60.51 114.04 1.01 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.375 0 CA-C-N 114.692 -1.14 . . . . 0.0 112.206 -176.753 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 24.4 t -102.24 150.13 6.47 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 N-CA-C 108.577 -0.897 . . . . 0.0 108.577 173.54 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 21.4 p -81.26 113.61 42.77 Favored Pre-proline 0 C--N 1.316 -0.855 0 CA-C-N 116.406 -0.361 . . . . 0.0 111.089 -177.34 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_exo -61.2 106.42 0.39 Allowed 'Trans proline' 0 CA--C 1.505 -0.946 0 C-N-CA 123.212 2.608 . . . . 0.0 111.822 178.955 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -112.52 36.47 3.4 Favored 'General case' 0 C--N 1.293 -1.87 0 CA-C-N 113.283 -1.78 . . . . 0.0 111.115 -175.883 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 98.3 m-70 -72.52 -11.37 60.63 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-N 114.867 -1.06 . . . . 0.0 109.006 169.776 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -114.11 133.77 55.33 Favored 'General case' 0 N--CA 1.442 -0.864 0 CA-C-N 115.157 -0.928 . . . . 0.0 109.464 178.368 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -150.33 69.03 0.99 Allowed 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 121.839 0.828 . . . . 0.0 110.523 -178.518 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 11.8 p -85.57 -28.29 6.33 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.923 0 CA-C-N 114.703 -1.135 . . . . 0.0 110.404 179.923 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.456 ' O ' ' HG2' ' A' ' 13' ' ' ARG . 7.1 p 31.34 79.75 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.342 0.254 0 C-N-CA 124.699 1.2 . . . . 0.0 112.601 -176.851 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 13' ' ' ARG . . . . . 0.456 ' HG2' ' O ' ' A' ' 12' ' ' VAL . 14.7 ptp180 47.73 124.33 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.658 0 CA-C-N 113.102 -1.863 . . . . 0.0 113.528 -172.725 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 3.5 t -66.69 152.12 9.8 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.895 0 N-CA-C 108.395 -0.965 . . . . 0.0 108.395 174.855 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -127.45 66.71 0.56 Allowed Glycine 0 N--CA 1.426 -1.973 0 CA-C-N 115.313 -0.858 . . . . 0.0 112.927 -173.549 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 9.8 m -84.24 -32.4 24.48 Favored 'General case' 0 N--CA 1.439 -1.014 0 CA-C-O 121.714 0.768 . . . . 0.0 109.72 175.154 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 17' ' ' LYS . . . . . 0.434 ' HA ' ' HD3' ' A' ' 18' ' ' PRO . 70.4 mmtt -65.7 113.22 10.98 Favored Pre-proline 0 C--N 1.317 -0.819 0 CA-C-N 114.369 -1.287 . . . . 0.0 110.967 179.016 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 18' ' ' PRO . . . . . 0.434 ' HD3' ' HA ' ' A' ' 17' ' ' LYS . 22.3 Cg_exo -67.85 161.51 43.66 Favored 'Trans proline' 0 N--CA 1.455 -0.779 0 C-N-CA 123.387 2.724 . . . . 0.0 112.352 178.885 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 103.94 -26.5 22.97 Favored Glycine 0 C--N 1.303 -1.28 0 CA-C-N 114.248 -1.342 . . . . 0.0 110.261 -177.379 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 21.6 m -59.06 -35.64 73.69 Favored 'General case' 0 C--N 1.313 -1.01 0 CA-C-N 113.527 -1.337 . . . . 0.0 110.983 176.84 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 21' ' ' GLU . . . . . 0.513 ' O ' ' HD3' ' A' ' 23' ' ' PRO . 1.5 mp0 -64.46 107.9 1.5 Allowed 'General case' 0 CA--C 1.506 -0.72 0 CA-C-O 121.521 0.677 . . . . 0.0 109.835 178.892 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 37.8 t -81.73 114.29 49.01 Favored Pre-proline 0 C--N 1.305 -1.352 0 CA-C-N 114.428 -1.26 . . . . 0.0 110.77 -179.331 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.513 ' HD3' ' O ' ' A' ' 21' ' ' GLU . 35.8 Cg_exo -60.68 154.82 52.19 Favored 'Trans proline' 0 N--CA 1.459 -0.551 0 C-N-CA 123.005 2.47 . . . . 0.0 110.979 170.605 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 7.7 Cg_endo -52.27 140.14 52.66 Favored 'Trans proline' 0 N--CA 1.451 -0.981 0 C-N-CA 122.193 1.929 . . . . 0.0 110.643 178.004 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.557 ' HB ' HG21 ' A' ' 83' ' ' ILE . 93.5 t -79.17 124.96 38.19 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.296 0 CA-C-N 114.683 -1.144 . . . . 0.0 112.301 -163.675 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 43.0 mm -67.65 -30.0 47.18 Favored 'Isoleucine or valine' 0 C--O 1.235 0.297 0 CA-C-N 114.114 -1.403 . . . . 0.0 112.689 -171.376 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.609 ' O ' HG12 ' A' ' 30' ' ' ILE . 16.1 m-20 -83.6 2.43 37.37 Favored 'General case' 0 CA--C 1.499 -1.006 0 CA-C-O 121.998 0.904 . . . . 0.0 108.919 -176.939 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 28' ' ' GLY . . . . . 0.775 ' HA3' HD13 ' A' ' 83' ' ' ILE . . . -67.55 -1.25 15.12 Favored Glycine 0 N--CA 1.433 -1.534 0 CA-C-N 114.143 -1.39 . . . . 0.0 110.844 172.693 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 19.0 m -73.71 -38.31 64.89 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-O 121.46 0.648 . . . . 0.0 109.405 173.203 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.609 HG12 ' O ' ' A' ' 27' ' ' ASP . 0.3 OUTLIER -71.69 -38.84 67.93 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.551 0 N-CA-C 107.179 -1.415 . . . . 0.0 107.179 175.595 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 31' ' ' TRP . . . . . 0.764 ' CD1' HG23 ' A' ' 83' ' ' ILE . 38.8 m95 -69.2 -36.69 77.56 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 114.359 -1.292 . . . . 0.0 110.667 -176.828 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 18.1 t70 -75.33 -33.93 61.17 Favored 'General case' 0 N--CA 1.444 -0.726 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.444 179.775 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 33' ' ' ALA . . . . . 0.468 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -70.42 -35.26 73.31 Favored 'General case' 0 N--CA 1.444 -0.739 0 C-N-CA 120.441 -0.503 . . . . 0.0 109.965 175.307 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 34' ' ' ILE . . . . . 0.554 HG13 ' O ' ' A' ' 30' ' ' ILE . 64.6 mt -64.59 -42.59 95.55 Favored 'Isoleucine or valine' 0 C--O 1.234 0.243 0 CA-C-O 120.996 0.427 . . . . 0.0 109.949 172.947 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 35' ' ' ALA . . . . . 0.432 ' HA ' ' O ' ' A' ' 54' ' ' GLY . . . -57.22 -38.02 73.11 Favored 'General case' 0 N--CA 1.451 -0.418 0 CA-C-N 115.78 -0.646 . . . . 0.0 109.997 174.608 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -73.49 -13.39 80.08 Favored Glycine 0 N--CA 1.45 -0.431 0 CA-C-N 115.375 -0.829 . . . . 0.0 112.051 179.456 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 37.3 t -94.19 -60.11 1.81 Allowed 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 120.702 0.286 . . . . 0.0 111.291 -178.999 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 9.0 tp10 -88.04 -34.32 18.03 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 121.099 0.476 . . . . 0.0 110.223 -170.972 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 39' ' ' ALA . . . . . 0.419 ' HB3' ' O ' ' A' ' 35' ' ' ALA . . . -92.76 -16.28 25.6 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.99 -0.55 . . . . 0.0 111.268 -177.528 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 83.52 5.33 88.57 Favored Glycine 0 CA--C 1.507 -0.461 0 N-CA-C 110.118 -1.193 . . . . 0.0 110.118 -176.124 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 90.28 59.23 1.48 Allowed Glycine 0 N--CA 1.434 -1.44 0 CA-C-N 114.095 -1.053 . . . . 0.0 112.034 -178.912 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 42' ' ' ASN . . . . . 0.441 ' HB3' ' HB ' ' A' ' 45' ' ' ILE . 2.0 t-20 -152.44 126.32 9.01 Favored 'General case' 0 CA--C 1.507 -0.674 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 178.12 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 43' ' ' TRP . . . . . 0.768 ' HA ' ' N ' ' A' ' 54' ' ' GLY . 37.4 m95 -98.16 -12.89 21.25 Favored 'General case' 0 C--N 1.307 -1.263 0 CA-C-N 115.769 -0.65 . . . . 0.0 110.475 -174.171 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -102.95 5.23 38.24 Favored 'General case' 0 C--N 1.316 -0.875 0 CA-C-N 114.922 -1.036 . . . . 0.0 110.729 -179.113 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.441 ' HB ' ' HB3' ' A' ' 42' ' ' ASN . 9.8 tt -73.57 142.15 15.3 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.981 0 CA-C-N 115.921 -0.581 . . . . 0.0 109.876 -178.55 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 40.3 t-20 -154.63 99.15 2.14 Favored 'General case' 0 C--N 1.307 -1.281 0 N-CA-C 109.446 -0.576 . . . . 0.0 109.446 179.611 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 34.8 p -74.58 -15.79 60.83 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 115.626 -0.716 . . . . 0.0 110.937 -177.33 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 94.84 19.76 30.57 Favored Glycine 0 N--CA 1.448 -0.559 0 N-CA-C 111.431 -0.668 . . . . 0.0 111.431 178.932 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 32.5 p-10 -95.64 2.68 54.23 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-O 120.987 0.423 . . . . 0.0 111.421 -176.374 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 95.49 -11.33 68.72 Favored Glycine 0 N--CA 1.448 -0.553 0 N-CA-C 111.425 -0.67 . . . . 0.0 111.425 179.108 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 51' ' ' TYR . . . . . 0.625 ' CD1' ' HB2' ' A' ' 58' ' ' ASP . 0.5 OUTLIER -106.69 132.64 52.45 Favored 'General case' 0 CA--C 1.505 -0.752 0 N-CA-C 107.283 -1.377 . . . . 0.0 107.283 178.46 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 52' ' ' TYR . . . . . 0.716 ' HB2' ' HB3' ' A' ' 74' ' ' ALA . 30.9 m-85 -103.07 169.44 8.56 Favored 'General case' 0 C--N 1.304 -1.371 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.972 -168.433 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.427 ' HA2' HG22 ' A' ' 45' ' ' ILE . . . -59.53 173.54 4.34 Favored Glycine 0 N--CA 1.448 -0.526 0 N-CA-C 115.086 0.794 . . . . 0.0 115.086 -169.151 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.768 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 82.13 -99.58 2.04 Favored Glycine 0 N--CA 1.436 -1.329 0 CA-C-N 114.872 -0.664 . . . . 0.0 111.698 178.944 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.571 ' HB ' ' CD1' ' A' ' 57' ' ' PHE . 2.0 t -84.25 -3.41 7.83 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-O 121.774 0.797 . . . . 0.0 109.938 -177.511 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 56' ' ' GLN . . . . . 0.672 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 6.9 tp60 55.81 50.36 14.27 Favored 'General case' 0 N--CA 1.46 0.04 0 CA-C-N 114.058 -1.428 . . . . 0.0 112.479 171.429 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 57' ' ' PHE . . . . . 0.571 ' CD1' ' HB ' ' A' ' 55' ' ' VAL . 3.8 p90 -124.62 165.36 18.01 Favored 'General case' 0 C--N 1.323 -0.546 0 C-N-CA 119.912 -0.715 . . . . 0.0 111.859 177.453 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.625 ' HB2' ' CD1' ' A' ' 51' ' ' TYR . 0.0 OUTLIER -77.12 152.04 35.11 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 114.382 -1.281 . . . . 0.0 113.758 -163.169 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.592 ' HB2' ' CE2' ' A' ' 52' ' ' TYR . 5.7 tp60 -50.82 -41.55 57.57 Favored 'General case' 0 N--CA 1.451 -0.393 0 CA-C-N 113.225 -1.807 . . . . 0.0 112.122 177.699 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -67.6 -49.1 52.67 Favored Glycine 0 C--N 1.315 -0.616 0 CA-C-N 115.507 -0.769 . . . . 0.0 112.013 -176.38 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 89.0 m -64.88 -41.16 95.87 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-O 120.919 0.39 . . . . 0.0 110.631 176.99 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 62' ' ' TRP . . . . . 0.524 ' CZ3' ' HA ' ' A' ' 82' ' ' GLN . 40.9 t-105 -57.0 -47.79 79.99 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 121.622 0.725 . . . . 0.0 109.617 174.725 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 63' ' ' GLU . . . . . 0.521 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 20.2 tt0 -65.28 -36.79 85.16 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-N 114.872 -1.058 . . . . 0.0 110.792 -179.932 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -67.57 -35.47 79.07 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 115.427 -0.806 . . . . 0.0 110.518 -177.672 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 65' ' ' ASN . . . . . 0.542 ' HB2' HG13 ' A' ' 85' ' ' VAL . 10.7 m120 -78.51 -12.9 60.04 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.249 175.823 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 66' ' ' GLY . . . . . 0.579 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 87.81 44.11 5.54 Favored Glycine 0 N--CA 1.447 -0.569 0 CA-C-N 115.411 -0.813 . . . . 0.0 112.035 177.345 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.603 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -78.74 -22.04 67.48 Favored Glycine 0 N--CA 1.439 -1.117 0 C-N-CA 120.595 -0.812 . . . . 0.0 112.361 -173.52 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.929 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 7.1 mp -60.68 -21.25 62.64 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 112.592 0.59 . . . . 0.0 112.592 -174.334 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 69' ' ' ARG . . . . . 0.579 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 10.0 ptp180 -70.56 -32.9 70.49 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-O 121.253 0.549 . . . . 0.0 109.835 175.185 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 70' ' ' TYR . . . . . 0.662 ' HB3' ' CG ' ' A' ' 81' ' ' GLU . 73.2 m-85 -80.53 -34.59 35.42 Favored 'General case' 0 N--CA 1.443 -0.812 0 N-CA-C 107.47 -1.308 . . . . 0.0 107.47 178.502 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.683 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 164.12 129.12 0.02 OUTLIER Pre-proline 0 CA--C 1.511 -0.551 0 CA-C-N 112.616 -2.084 . . . . 0.0 106.759 -179.49 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 72' ' ' PRO . . . . . 0.929 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 20.4 Cg_exo -57.14 -4.75 1.12 Allowed 'Trans proline' 0 C--N 1.333 -0.244 0 C-N-CA 122.84 2.36 . . . . 0.0 113.932 -177.2 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 13.8 ptm180 -148.11 141.09 24.86 Favored 'General case' 0 C--N 1.317 -0.815 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 176.259 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 74' ' ' ALA . . . . . 0.716 ' HB3' ' HB2' ' A' ' 52' ' ' TYR . . . -59.12 -31.7 69.17 Favored 'General case' 0 C--O 1.219 -0.509 0 CA-C-N 115.615 -0.72 . . . . 0.0 112.298 -177.109 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 8.4 p-10 -85.17 9.68 14.35 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 121.282 0.563 . . . . 0.0 111.263 -174.673 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 50.2 tp -112.13 -33.01 6.37 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.519 -0.764 . . . . 0.0 109.182 173.667 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 77' ' ' ALA . . . . . 0.683 ' HB2' ' HB3' ' A' ' 71' ' ' ALA . . . -79.6 164.71 23.61 Favored 'General case' 0 N--CA 1.448 -0.548 0 CA-C-N 115.065 -0.97 . . . . 0.0 109.449 173.029 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 19.4 p -100.5 -176.99 3.36 Favored 'General case' 0 C--N 1.322 -0.626 0 C-N-CA 120.429 -0.509 . . . . 0.0 110.292 -179.997 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 79' ' ' ARG . . . . . 0.606 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 2.5 mtp180 -49.3 -52.63 26.47 Favored 'General case' 0 CA--C 1.512 -0.517 0 O-C-N 123.403 0.439 . . . . 0.0 111.178 -174.505 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 80' ' ' GLU . . . . . 0.562 ' HG3' ' OE2' ' A' ' 81' ' ' GLU . 11.7 pt-20 -58.39 -42.26 86.67 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.892 -174.806 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 81' ' ' GLU . . . . . 0.662 ' CG ' ' HB3' ' A' ' 70' ' ' TYR . 5.2 mp0 -63.5 -52.71 60.08 Favored 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 111.956 0.354 . . . . 0.0 111.956 174.186 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 82' ' ' GLN . . . . . 0.524 ' HA ' ' CZ3' ' A' ' 62' ' ' TRP . 40.7 mt-30 -59.7 -38.11 80.69 Favored 'General case' 0 CA--C 1.518 -0.268 0 CA-C-O 121.54 0.686 . . . . 0.0 110.097 -176.577 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.775 HD13 ' HA3' ' A' ' 28' ' ' GLY . 31.7 mt -61.57 -49.51 84.09 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.843 0 CA-C-N 114.276 -1.329 . . . . 0.0 111.082 173.832 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 84' ' ' ALA . . . . . 0.647 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -62.67 -38.79 91.72 Favored 'General case' 0 N--CA 1.466 0.342 0 CA-C-O 121.195 0.522 . . . . 0.0 111.886 -176.08 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.542 HG13 ' HB2' ' A' ' 65' ' ' ASN . 60.5 t -64.45 -47.73 88.13 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.495 175.853 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -59.44 -30.86 68.79 Favored 'General case' 0 N--CA 1.453 -0.282 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.051 174.497 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 87' ' ' GLU . . . . . 0.804 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 14.4 mm-40 -59.51 -44.31 93.17 Favored 'General case' 0 C--O 1.219 -0.51 0 CA-C-N 115.344 -0.844 . . . . 0.0 110.484 179.736 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.473 ' HB ' ' HB3' ' A' ' 65' ' ' ASN . 70.7 t -61.48 -49.92 82.46 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.404 0 CA-C-O 121.049 0.452 . . . . 0.0 110.574 -176.414 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 89' ' ' THR . . . . . 0.624 HG23 ' CH2' ' A' ' 98' ' ' TRP . 13.7 t -72.64 -33.76 66.82 Favored 'General case' 0 N--CA 1.438 -1.027 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.074 -176.482 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 90' ' ' ARG . . . . . 0.567 ' HG2' ' HA ' ' A' ' 87' ' ' GLU . 0.8 OUTLIER -60.33 -32.1 70.93 Favored 'General case' 0 N--CA 1.472 0.644 0 CA-C-O 121.176 0.512 . . . . 0.0 110.229 175.982 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 91' ' ' LEU . . . . . 0.804 ' HG ' ' O ' ' A' ' 87' ' ' GLU . 19.4 mt -62.51 -33.08 74.17 Favored 'General case' 0 C--N 1.317 -0.805 0 CA-C-O 121.428 0.632 . . . . 0.0 109.733 177.312 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 92' ' ' ARG . . . . . 0.487 ' NE ' ' HA ' ' A' ' 89' ' ' THR . 2.8 mtm180 -86.29 -52.63 5.51 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-N 115.068 -0.969 . . . . 0.0 110.911 -172.975 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -117.05 2.95 12.73 Favored 'General case' 0 N--CA 1.448 -0.533 0 C-N-CA 119.862 -0.735 . . . . 0.0 112.461 -174.076 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.429 ' HA2' ' O ' ' A' ' 90' ' ' ARG . . . 74.64 -119.98 6.27 Favored Glycine 0 CA--C 1.485 -1.786 0 N-CA-C 111.02 -0.832 . . . . 0.0 111.02 171.943 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 95' ' ' TRP . . . . . 0.457 ' HB3' ' CB ' ' A' ' 102' ' ' ALA . 3.4 m95 -127.57 31.65 5.13 Favored 'General case' 0 C--N 1.299 -1.62 0 N-CA-C 106.338 -1.727 . . . . 0.0 106.338 179.834 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -82.17 -25.92 50.15 Favored Glycine 0 N--CA 1.446 -0.666 0 CA-C-N 114.027 -1.442 . . . . 0.0 110.915 171.539 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -81.14 -23.3 38.41 Favored 'General case' 0 CA--C 1.515 -0.372 0 N-CA-C 109.663 -0.495 . . . . 0.0 109.663 174.352 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 98' ' ' TRP . . . . . 0.624 ' CH2' HG23 ' A' ' 89' ' ' THR . 23.7 m-90 -107.93 107.35 60.17 Favored Pre-proline 0 N--CA 1.448 -0.547 0 CA-C-N 115.776 -0.647 . . . . 0.0 109.909 177.071 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_exo -62.34 -137.01 0.0 OUTLIER 'Trans proline' 0 CA--C 1.535 0.526 0 C-N-CA 123.647 2.898 . . . . 0.0 114.119 -177.044 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 2.9 m -54.54 -28.24 18.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 115.88 -0.6 . . . . 0.0 112.152 -177.787 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 82.5 m -56.8 -39.23 73.75 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.263 178.933 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 102' ' ' ALA . . . . . 0.457 ' CB ' ' HB3' ' A' ' 95' ' ' TRP . . . -71.41 -43.94 65.84 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.845 0.355 . . . . 0.0 111.008 178.118 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -61.54 -44.57 96.8 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.851 -179.649 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -67.33 -19.41 65.45 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.728 -0.669 . . . . 0.0 111.159 177.279 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 105' ' ' ALA . . . . . 0.468 ' CB ' ' HB3' ' A' ' 33' ' ' ALA . . . -91.03 -21.15 21.4 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.913 -0.585 . . . . 0.0 111.606 -178.547 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 111.37 61.52 0.47 Allowed Glycine 0 CA--C 1.519 0.344 0 C-N-CA 121.087 -0.577 . . . . 0.0 111.967 -176.481 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -64.11 149.42 47.69 Favored 'General case' 0 C--N 1.328 -0.355 0 C-N-CA 122.878 0.471 . . . . 0.0 111.006 -176.716 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 74.0 mtp180 . . . . . 0 C--O 1.247 0.946 0 CA-C-O 118.503 -0.761 . . . . 0.0 109.912 -173.899 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 18.3 p-10 . . . . . 0 N--CA 1.48 1.063 0 CA-C-O 121.296 0.57 . . . . 0.0 110.562 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 46.3 t -86.85 -41.51 14.84 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 CA-C-N 115.784 -0.644 . . . . 0.0 109.487 179.027 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 11.6 p -72.21 138.51 21.4 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.856 0 CA-C-N 115.226 -0.897 . . . . 0.0 110.516 176.094 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.526 ' O ' ' HD3' ' A' ' 6' ' ' PRO . 9.3 t -85.38 141.66 14.25 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.577 0 N-CA-C 108.911 -0.774 . . . . 0.0 108.911 176.255 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 16.4 p -104.22 101.94 29.64 Favored Pre-proline 0 C--N 1.318 -0.794 0 CA-C-O 121.057 0.456 . . . . 0.0 111.116 -177.465 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.526 ' HD3' ' O ' ' A' ' 4' ' ' VAL . 61.6 Cg_endo -103.2 169.15 0.22 Allowed 'Trans proline' 0 N--CA 1.444 -1.395 0 C-N-CA 124.09 3.193 . . . . 0.0 112.238 178.785 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -121.36 73.06 1.02 Allowed 'General case' 0 C--N 1.312 -1.027 0 CA-C-N 115.345 -0.843 . . . . 0.0 110.488 173.889 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 32.5 m170 -86.26 -14.79 42.74 Favored 'General case' 0 C--N 1.314 -0.949 0 CA-C-N 114.518 -1.219 . . . . 0.0 107.786 172.366 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 4.8 mt-10 -73.32 121.2 20.04 Favored 'General case' 0 CA--C 1.513 -0.477 0 CA-C-N 114.507 -1.224 . . . . 0.0 111.618 -177.337 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 10' ' ' ALA . . . . . 0.481 ' O ' HG12 ' A' ' 12' ' ' VAL . . . -153.05 65.24 0.78 Allowed 'General case' 0 C--N 1.316 -0.884 0 CA-C-N 115.272 -0.876 . . . . 0.0 109.152 173.466 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.41 HG13 ' N ' ' A' ' 12' ' ' VAL . 7.1 p -52.92 -49.67 47.43 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.692 0 CA-C-N 114.701 -1.136 . . . . 0.0 111.319 179.789 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.481 HG12 ' O ' ' A' ' 10' ' ' ALA . 7.6 p 29.68 85.26 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.344 0.35 0 C-N-CA 125.099 1.359 . . . . 0.0 113.74 177.676 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 9.5 ptm180 -85.37 112.22 20.64 Favored 'General case' 0 C--N 1.306 -1.286 0 CA-C-N 114.204 -1.362 . . . . 0.0 110.059 -179.403 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 3.0 t -115.97 161.9 14.38 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.5 0 CA-C-N 114.435 -1.257 . . . . 0.0 109.79 -178.261 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 109.3 53.79 0.59 Allowed Glycine 0 N--CA 1.441 -1.029 0 CA-C-N 114.867 -1.06 . . . . 0.0 111.581 178.975 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 8.8 m -91.27 -27.21 18.57 Favored 'General case' 0 C--N 1.31 -1.115 0 CA-C-N 114.075 -1.063 . . . . 0.0 110.254 179.895 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 17' ' ' LYS . . . . . 0.409 ' HA ' ' HD3' ' A' ' 18' ' ' PRO . 0.1 OUTLIER -74.77 116.31 52.49 Favored Pre-proline 0 C--N 1.314 -0.945 0 CA-C-N 113.972 -1.467 . . . . 0.0 110.987 -176.775 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 18' ' ' PRO . . . . . 0.409 ' HD3' ' HA ' ' A' ' 17' ' ' LYS . 5.2 Cg_exo -81.8 169.45 14.97 Favored 'Trans proline' 0 N--CA 1.453 -0.876 0 C-N-CA 123.502 2.801 . . . . 0.0 111.563 172.653 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -111.3 -33.5 2.31 Favored Glycine 0 C--N 1.306 -1.097 0 CA-C-N 114.337 -1.301 . . . . 0.0 111.028 178.953 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 23.1 m -64.43 -32.94 74.77 Favored 'General case' 0 C--N 1.315 -0.917 0 CA-C-N 114.281 -0.96 . . . . 0.0 111.174 178.669 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 45.2 mt-10 -131.87 138.82 48.59 Favored 'General case' 0 N--CA 1.441 -0.92 0 CA-C-N 115.885 -0.598 . . . . 0.0 109.921 -175.596 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 61.6 t -85.42 124.34 71.74 Favored Pre-proline 0 C--N 1.312 -1.062 0 CA-C-N 115.458 -0.792 . . . . 0.0 109.159 175.315 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -53.62 128.54 29.87 Favored 'Trans proline' 0 C--N 1.346 0.421 0 C-N-CA 122.887 2.391 . . . . 0.0 112.665 -176.198 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 10.6 Cg_endo -55.43 144.16 74.13 Favored 'Trans proline' 0 N--CA 1.459 -0.55 0 C-N-CA 123.725 2.95 . . . . 0.0 112.698 -179.285 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.861 HG21 HG21 ' A' ' 83' ' ' ILE . 14.8 p -85.0 125.69 40.34 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.981 0 CA-C-N 114.749 -1.114 . . . . 0.0 111.146 -177.253 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 42.9 mm -82.85 -31.42 9.15 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.638 0 CA-C-N 115.419 -0.809 . . . . 0.0 111.35 -179.11 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.603 ' O ' HG12 ' A' ' 30' ' ' ILE . 4.5 m-20 -106.9 6.27 29.13 Favored 'General case' 0 CA--C 1.507 -0.711 0 CA-C-O 121.62 0.724 . . . . 0.0 109.745 -172.947 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 28' ' ' GLY . . . . . 0.712 ' HA2' ' HB2' ' A' ' 31' ' ' TRP . . . -81.24 3.45 77.19 Favored Glycine 0 CA--C 1.494 -1.259 0 N-CA-C 110.863 -0.895 . . . . 0.0 110.863 -174.504 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 5.8 m -76.39 -48.2 20.65 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-O 121.727 0.775 . . . . 0.0 109.069 176.864 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.797 HG22 ' O ' ' A' ' 105' ' ' ALA . 4.0 pt -71.77 -34.78 52.92 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.182 0 CA-C-N 114.626 -1.17 . . . . 0.0 109.675 175.807 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 31' ' ' TRP . . . . . 0.712 ' HB2' ' HA2' ' A' ' 28' ' ' GLY . 6.5 m95 -66.26 -35.46 80.46 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.311 -0.858 . . . . 0.0 110.085 177.54 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.763 ' HB2' HH21 ' A' ' 79' ' ' ARG . 13.9 t70 -76.37 -34.42 58.92 Favored 'General case' 0 N--CA 1.449 -0.496 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.215 177.135 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.67 -36.0 82.4 Favored 'General case' 0 N--CA 1.445 -0.683 0 C-N-CA 120.775 -0.37 . . . . 0.0 110.328 176.794 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 34' ' ' ILE . . . . . 0.497 HD12 ' CZ3' ' A' ' 31' ' ' TRP . 10.0 mt -67.4 -44.09 87.24 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-O 120.895 0.379 . . . . 0.0 110.706 174.28 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 35' ' ' ALA . . . . . 0.501 ' O ' ' HB3' ' A' ' 39' ' ' ALA . . . -60.22 -34.13 73.23 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-O 121.464 0.65 . . . . 0.0 110.334 177.023 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -76.35 -18.97 78.81 Favored Glycine 0 N--CA 1.448 -0.551 0 CA-C-N 115.306 -0.861 . . . . 0.0 111.231 177.117 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 7.9 t -86.72 -57.1 3.11 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.238 -0.481 . . . . 0.0 111.536 -176.743 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 38' ' ' GLU . . . . . 0.878 ' HG2' ' SG ' ' A' ' 101' ' ' CYS . 15.6 mm-40 -87.77 -33.61 18.6 Favored 'General case' 0 CA--C 1.515 -0.39 0 CA-C-O 120.821 0.343 . . . . 0.0 111.078 -174.933 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 39' ' ' ALA . . . . . 0.501 ' HB3' ' O ' ' A' ' 35' ' ' ALA . . . -96.66 -11.31 25.37 Favored 'General case' 0 C--N 1.324 -0.511 0 C-N-CA 120.424 -0.511 . . . . 0.0 112.124 -173.891 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 80.3 8.28 87.73 Favored Glycine 0 CA--C 1.506 -0.53 0 N-CA-C 110.125 -1.19 . . . . 0.0 110.125 -177.291 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 87.62 56.24 2.16 Favored Glycine 0 N--CA 1.434 -1.455 0 CA-C-N 114.129 -1.036 . . . . 0.0 112.595 179.706 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 50.7 t30 -154.44 122.77 6.06 Favored 'General case' 0 CA--C 1.507 -0.71 0 N-CA-C 109.413 -0.588 . . . . 0.0 109.413 176.993 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 43' ' ' TRP . . . . . 0.712 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 26.3 m95 -96.25 -12.64 24.25 Favored 'General case' 0 C--N 1.308 -1.231 0 CA-C-N 115.055 -0.975 . . . . 0.0 110.415 -173.298 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -101.95 8.97 40.91 Favored 'General case' 0 C--N 1.318 -0.782 0 CA-C-N 115.367 -0.833 . . . . 0.0 110.786 -178.36 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.738 HG22 ' CA ' ' A' ' 53' ' ' GLY . 2.0 tt -72.87 144.22 13.12 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.769 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.006 179.249 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 47.6 t-20 -160.42 101.37 1.36 Allowed 'General case' 0 C--N 1.314 -0.972 0 N-CA-C 109.432 -0.581 . . . . 0.0 109.432 -179.525 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 23.4 p -82.89 -17.13 44.85 Favored 'General case' 0 N--CA 1.445 -0.724 0 CA-C-N 115.559 -0.746 . . . . 0.0 111.222 -178.974 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 91.33 22.19 32.77 Favored Glycine 0 N--CA 1.445 -0.745 0 N-CA-C 111.141 -0.784 . . . . 0.0 111.141 178.398 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 28.7 p-10 -93.67 11.38 29.18 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 121.2 0.524 . . . . 0.0 111.385 -175.904 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 50' ' ' GLY . . . . . 0.461 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 94.36 -11.38 70.41 Favored Glycine 0 N--CA 1.447 -0.576 0 C-N-CA 120.874 -0.679 . . . . 0.0 111.524 -178.486 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 51' ' ' TYR . . . . . 0.601 ' HA ' ' HA ' ' A' ' 58' ' ' ASP . 0.2 OUTLIER -114.64 162.62 16.54 Favored 'General case' 0 N--CA 1.447 -0.591 0 N-CA-C 107.787 -1.19 . . . . 0.0 107.787 176.94 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 52' ' ' TYR . . . . . 0.635 ' HB2' ' HB3' ' A' ' 74' ' ' ALA . 26.9 m-85 -127.9 169.68 13.67 Favored 'General case' 0 C--N 1.309 -1.191 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.046 -172.717 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.738 ' CA ' HG22 ' A' ' 45' ' ' ILE . . . -68.85 -170.68 6.56 Favored Glycine 0 N--CA 1.445 -0.719 0 N-CA-C 114.342 0.497 . . . . 0.0 114.342 -170.944 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.689 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 75.49 -107.3 2.28 Favored Glycine 0 N--CA 1.44 -1.057 0 C-N-CA 120.984 -0.627 . . . . 0.0 111.856 179.248 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.492 HG12 ' HE1' ' A' ' 98' ' ' TRP . 2.1 t -88.56 9.61 2.29 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.655 0 CA-C-O 121.203 0.525 . . . . 0.0 110.357 -177.403 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 56' ' ' GLN . . . . . 0.659 ' HG3' ' HB3' ' A' ' 38' ' ' GLU . 7.1 mm100 60.02 50.42 6.66 Favored 'General case' 0 N--CA 1.468 0.426 0 CA-C-N 115.197 -0.911 . . . . 0.0 112.66 174.513 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 57' ' ' PHE . . . . . 0.502 ' HZ ' ' CA ' ' A' ' 86' ' ' ALA . 49.9 m-85 -76.2 132.24 39.82 Favored 'General case' 0 CA--C 1.503 -0.861 0 CA-C-N 115.126 -0.943 . . . . 0.0 112.301 176.345 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.601 ' HA ' ' HA ' ' A' ' 51' ' ' TYR . 5.6 p-10 -72.54 153.76 41.15 Favored 'General case' 0 C--N 1.315 -0.897 0 C-N-CA 119.542 -0.863 . . . . 0.0 108.707 159.644 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.409 ' HB2' ' HE1' ' A' ' 52' ' ' TYR . 7.0 tp60 -54.92 -36.33 65.13 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-O 120.67 0.271 . . . . 0.0 111.482 -178.187 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -67.63 -49.67 48.33 Favored Glycine 0 C--O 1.226 -0.372 0 CA-C-N 116.046 -0.525 . . . . 0.0 112.445 -174.289 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 88.4 m -65.68 -41.4 92.46 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 121.366 0.603 . . . . 0.0 110.894 179.084 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 62' ' ' TRP . . . . . 0.466 ' CE2' ' HA3' ' A' ' 67' ' ' GLY . 56.5 t-105 -59.07 -48.91 79.87 Favored 'General case' 0 N--CA 1.444 -0.762 0 CA-C-N 115.104 -0.953 . . . . 0.0 109.467 177.144 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 63' ' ' GLU . . . . . 0.439 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 34.8 tt0 -68.18 -34.64 76.68 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 115.051 -0.977 . . . . 0.0 111.05 -178.604 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -64.43 -41.34 96.64 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.942 -0.572 . . . . 0.0 111.394 -175.914 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 65' ' ' ASN . . . . . 0.649 HD22 ' N ' ' A' ' 65' ' ' ASN . 0.7 OUTLIER -84.99 -8.63 58.65 Favored 'General case' 0 N--CA 1.451 -0.384 0 CA-C-O 121.109 0.48 . . . . 0.0 110.21 177.394 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 91.76 52.85 2.2 Favored Glycine 0 N--CA 1.451 -0.36 0 CA-C-N 115.762 -0.653 . . . . 0.0 113.15 172.627 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.538 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -80.02 -26.46 55.57 Favored Glycine 0 N--CA 1.439 -1.121 0 C-N-CA 120.669 -0.777 . . . . 0.0 112.338 -178.599 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.962 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 7.6 mp -57.56 -23.0 48.14 Favored 'General case' 0 N--CA 1.45 -0.463 0 N-CA-C 113.272 0.841 . . . . 0.0 113.272 -173.256 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 69' ' ' ARG . . . . . 0.435 ' HG3' ' N ' ' A' ' 70' ' ' TYR . 1.1 ptp180 -70.39 -31.89 69.31 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-O 121.005 0.431 . . . . 0.0 110.044 176.829 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 70' ' ' TYR . . . . . 1.022 ' HB3' ' HG3' ' A' ' 81' ' ' GLU . 67.5 m-85 -81.39 -34.53 31.58 Favored 'General case' 0 CA--C 1.505 -0.766 0 N-CA-C 107.457 -1.312 . . . . 0.0 107.457 177.274 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.592 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 165.77 129.6 0.03 OUTLIER Pre-proline 0 C--O 1.218 -0.572 0 CA-C-N 112.272 -2.24 . . . . 0.0 107.259 -178.225 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 72' ' ' PRO . . . . . 0.962 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 7.0 Cg_exo -61.02 0.22 0.96 Allowed 'Trans proline' 0 C--N 1.331 -0.367 0 C-N-CA 122.786 2.324 . . . . 0.0 113.536 -177.318 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 73' ' ' ARG . . . . . 0.476 ' HB2' ' CD2' ' A' ' 52' ' ' TYR . 3.4 ptt180 -151.79 136.65 17.19 Favored 'General case' 0 N--CA 1.441 -0.923 0 N-CA-C 108.968 -0.753 . . . . 0.0 108.968 178.817 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 74' ' ' ALA . . . . . 0.635 ' HB3' ' HB2' ' A' ' 52' ' ' TYR . . . -56.05 -29.55 60.65 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 115.064 -0.971 . . . . 0.0 113.136 -177.081 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 75' ' ' ASP . . . . . 0.544 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 11.6 p-10 -83.54 -2.26 55.59 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 121.014 0.435 . . . . 0.0 111.205 -175.729 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.487 ' HB3' ' HB1' ' A' ' 71' ' ' ALA . 61.6 tp -101.51 -31.48 10.86 Favored 'General case' 0 C--N 1.322 -0.604 0 N-CA-C 108.536 -0.913 . . . . 0.0 108.536 172.103 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 77' ' ' ALA . . . . . 0.695 ' HB1' ' HB3' ' A' ' 81' ' ' GLU . . . -78.82 163.26 25.48 Favored 'General case' 0 N--CA 1.443 -0.825 0 CA-C-N 114.739 -1.118 . . . . 0.0 109.86 174.963 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 61.2 p -101.33 -174.59 2.64 Favored 'General case' 0 C--N 1.31 -1.149 0 CA-C-N 115.934 -0.575 . . . . 0.0 111.072 -176.956 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 79' ' ' ARG . . . . . 0.763 HH21 ' HB2' ' A' ' 32' ' ' ASP . 46.2 mtp180 -54.07 -54.44 39.29 Favored 'General case' 0 CA--C 1.515 -0.374 0 CA-C-O 120.759 0.314 . . . . 0.0 110.437 179.256 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 1.9 pm0 -60.19 -40.37 89.81 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.275 -0.875 . . . . 0.0 111.289 -176.52 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 81' ' ' GLU . . . . . 1.022 ' HG3' ' HB3' ' A' ' 70' ' ' TYR . 0.3 OUTLIER -62.62 -51.19 68.28 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.921 -0.582 . . . . 0.0 112.272 175.94 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 82' ' ' GLN . . . . . 0.62 ' HB2' ' HZ3' ' A' ' 43' ' ' TRP . 53.4 mt-30 -64.07 -35.83 82.01 Favored 'General case' 0 CA--C 1.515 -0.4 0 CA-C-O 121.103 0.478 . . . . 0.0 109.715 179.973 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.861 HG21 HG21 ' A' ' 25' ' ' VAL . 14.7 mt -59.8 -45.43 94.79 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 CA-C-N 115.239 -0.891 . . . . 0.0 110.526 176.636 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 84' ' ' ALA . . . . . 0.485 ' O ' HG23 ' A' ' 88' ' ' VAL . . . -60.15 -44.29 95.08 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-O 121.209 0.528 . . . . 0.0 110.511 -178.449 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 67.5 t -69.1 -48.58 68.53 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.604 0 CA-C-N 115.428 -0.806 . . . . 0.0 111.493 179.341 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 86' ' ' ALA . . . . . 0.502 ' CA ' ' HZ ' ' A' ' 57' ' ' PHE . . . -62.6 -34.63 77.4 Favored 'General case' 0 CA--C 1.51 -0.584 0 CA-C-O 121.378 0.608 . . . . 0.0 110.536 179.891 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 87' ' ' GLU . . . . . 0.634 ' HA ' ' HG2' ' A' ' 90' ' ' ARG . 0.7 OUTLIER -71.49 -28.99 64.3 Favored 'General case' 0 C--N 1.315 -0.892 0 CA-C-N 115.525 -0.761 . . . . 0.0 109.965 -176.46 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.636 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 59.9 t -62.47 -42.56 96.19 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.191 0 N-CA-C 109.212 -0.662 . . . . 0.0 109.212 168.969 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 89' ' ' THR . . . . . 0.71 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 0.2 OUTLIER -71.96 -41.23 68.0 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 115.869 -0.605 . . . . 0.0 111.54 -174.445 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 90' ' ' ARG . . . . . 0.634 ' HG2' ' HA ' ' A' ' 87' ' ' GLU . 30.3 ptt180 -59.27 -36.87 76.3 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.657 -175.775 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 91' ' ' LEU . . . . . 0.636 ' HG ' ' O ' ' A' ' 88' ' ' VAL . 4.6 pp -74.88 -25.25 58.82 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.616 -0.72 . . . . 0.0 111.388 -170.087 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 92' ' ' ARG . . . . . 0.457 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 1.7 mtm180 -85.01 -46.24 11.38 Favored 'General case' 0 CA--C 1.511 -0.533 0 CA-C-O 121.513 0.673 . . . . 0.0 109.796 -176.113 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 93' ' ' GLN . . . . . 0.439 ' NE2' HG22 ' A' ' 89' ' ' THR . 16.6 pt20 -98.71 -29.45 13.01 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.15 -0.932 . . . . 0.0 113.01 -168.592 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 91.86 35.85 6.64 Favored Glycine 0 N--CA 1.446 -0.637 0 C-N-CA 120.167 -1.016 . . . . 0.0 111.355 175.459 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 95' ' ' TRP . . . . . 0.504 ' HA ' ' HE3' ' A' ' 98' ' ' TRP . 31.2 m95 68.3 22.66 7.97 Favored 'General case' 0 C--O 1.222 -0.378 0 CA-C-O 121.486 0.66 . . . . 0.0 110.027 177.186 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -70.11 -27.15 73.32 Favored Glycine 0 N--CA 1.449 -0.454 0 CA-C-N 115.135 -0.938 . . . . 0.0 112.35 175.519 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -75.45 -30.49 59.98 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.782 0.325 . . . . 0.0 110.58 177.242 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 98' ' ' TRP . . . . . 0.71 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 16.5 m-90 -103.8 104.76 44.55 Favored Pre-proline 0 C--N 1.324 -0.527 0 N-CA-C 109.706 -0.479 . . . . 0.0 109.706 179.972 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 99' ' ' PRO . . . . . 0.405 ' HD3' ' HA ' ' A' ' 98' ' ' TRP . 17.5 Cg_exo -71.09 -93.12 0.01 OUTLIER 'Trans proline' 0 CA--C 1.537 0.645 0 C-N-CA 123.192 2.594 . . . . 0.0 114.523 -173.341 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 100' ' ' VAL . . . . . 0.472 ' O ' ' HD2' ' A' ' 104' ' ' ARG . 1.3 p -71.68 -27.57 28.54 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.391 0 CA-C-O 121.89 0.852 . . . . 0.0 109.781 -172.686 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 101' ' ' CYS . . . . . 0.878 ' SG ' ' HG2' ' A' ' 38' ' ' GLU . 33.2 m -65.74 -34.76 78.92 Favored 'General case' 0 C--N 1.318 -0.772 0 CA-C-N 114.313 -1.312 . . . . 0.0 111.056 -175.712 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 102' ' ' ALA . . . . . 0.668 ' HB1' ' HB2' ' A' ' 107' ' ' ALA . . . -65.53 -46.55 79.16 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-O 120.945 0.403 . . . . 0.0 110.146 -179.782 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -63.7 -40.59 97.16 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.282 0.563 . . . . 0.0 110.545 179.352 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 104' ' ' ARG . . . . . 0.472 ' HD2' ' O ' ' A' ' 100' ' ' VAL . 0.0 OUTLIER -71.9 -37.89 70.02 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.661 -0.7 . . . . 0.0 111.918 -179.346 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 105' ' ' ALA . . . . . 0.797 ' O ' HG22 ' A' ' 30' ' ' ILE . . . -82.37 -27.84 31.88 Favored 'General case' 0 C--N 1.329 -0.313 0 N-CA-C 112.009 0.374 . . . . 0.0 112.009 -176.166 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 109.4 67.02 0.58 Allowed Glycine 0 CA--C 1.522 0.486 0 C-N-CA 120.64 -0.791 . . . . 0.0 112.277 -173.741 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 107' ' ' ALA . . . . . 0.668 ' HB2' ' HB1' ' A' ' 102' ' ' ALA . . . -58.4 149.81 23.92 Favored 'General case' 0 C--N 1.324 -0.516 0 C-N-CA 123.586 0.754 . . . . 0.0 111.664 178.808 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 8.9 ptm180 . . . . . 0 C--O 1.247 0.945 0 CA-C-N 115.476 -0.783 . . . . 0.0 110.165 -173.168 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 89.0 m-20 . . . . . 0 N--CA 1.474 0.752 0 CA-C-O 121.142 0.496 . . . . 0.0 109.847 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 10.5 p -81.94 -15.63 12.12 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.05 0 CA-C-N 115.505 -0.771 . . . . 0.0 109.851 178.696 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 3' ' ' VAL . . . . . 0.407 ' O ' HG13 ' A' ' 3' ' ' VAL . 5.4 p -66.07 96.96 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.788 0 CA-C-N 115.221 -0.899 . . . . 0.0 111.811 178.351 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 12.0 t -99.04 139.7 20.23 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.659 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 171.895 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 5' ' ' THR . . . . . 0.429 ' HA ' ' HD3' ' A' ' 6' ' ' PRO . 8.7 p -113.92 132.19 22.77 Favored Pre-proline 0 C--N 1.309 -1.177 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.599 -173.805 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.429 ' HD3' ' HA ' ' A' ' 5' ' ' THR . 9.4 Cg_exo -74.63 166.31 29.65 Favored 'Trans proline' 0 N--CA 1.45 -1.084 0 C-N-CA 123.24 2.627 . . . . 0.0 110.099 170.182 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . 57.79 -166.01 0.15 Allowed 'General case' 0 C--N 1.312 -1.023 0 CA-C-N 115.069 -0.969 . . . . 0.0 110.412 -172.742 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 18.9 t-80 64.11 10.42 5.43 Favored 'General case' 0 N--CA 1.465 0.293 0 CA-C-O 122.309 1.052 . . . . 0.0 108.764 -172.911 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 10.9 pt-20 -64.35 158.56 23.24 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-N 113.913 -1.494 . . . . 0.0 112.258 -178.918 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -150.17 81.06 1.37 Allowed 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 114.713 -1.13 . . . . 0.0 109.438 178.477 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 14.6 p -58.86 -31.82 45.81 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 CA-C-N 115.182 -0.917 . . . . 0.0 111.871 -178.333 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 6.0 p 34.27 84.11 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.343 0.309 0 CA-C-O 122.823 1.296 . . . . 0.0 113.119 -179.631 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 44.2 mtm180 -89.04 112.98 24.05 Favored 'General case' 0 N--CA 1.432 -1.352 0 CA-C-N 114.01 -1.45 . . . . 0.0 110.833 -177.475 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.8 t -97.55 162.09 2.73 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.204 0 CA-C-N 114.683 -1.144 . . . . 0.0 109.251 178.069 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 129.21 93.99 0.74 Allowed Glycine 0 C--N 1.305 -1.151 0 CA-C-N 115.158 -0.928 . . . . 0.0 111.672 179.66 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.521 ' HB ' ' HD3' ' A' ' 17' ' ' LYS . 36.9 m -81.54 -33.5 31.71 Favored 'General case' 0 N--CA 1.442 -0.833 0 CA-C-O 121.388 0.613 . . . . 0.0 111.675 -176.926 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 17' ' ' LYS . . . . . 0.521 ' HD3' ' HB ' ' A' ' 16' ' ' THR . 2.5 mppt? -112.59 97.52 40.9 Favored Pre-proline 0 C--N 1.315 -0.924 0 CA-C-N 115.541 -0.754 . . . . 0.0 110.599 -177.772 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 18' ' ' PRO . . . . . 0.45 ' HD3' ' O ' ' A' ' 16' ' ' THR . 2.2 Cg_endo -86.86 174.4 5.57 Favored 'Trans proline' 0 N--CA 1.449 -1.14 0 C-N-CA 123.204 2.603 . . . . 0.0 111.862 176.06 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 87.8 32.55 12.71 Favored Glycine 0 C--N 1.309 -0.924 0 CA-C-N 114.699 -1.137 . . . . 0.0 111.5 177.729 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 29.8 m -70.07 -30.29 67.5 Favored 'General case' 0 C--N 1.312 -1.054 0 CA-C-N 114.267 -0.966 . . . . 0.0 109.539 175.718 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 31.2 mt-10 -138.91 141.48 38.52 Favored 'General case' 0 N--CA 1.438 -1.043 0 N-CA-C 107.591 -1.263 . . . . 0.0 107.591 -179.678 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.75 HG11 ' HG3' ' A' ' 80' ' ' GLU . 30.3 t -73.32 125.01 91.08 Favored Pre-proline 0 C--N 1.312 -1.063 0 N-CA-C 109.464 -0.569 . . . . 0.0 109.464 178.366 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.437 ' HA ' ' HD2' ' A' ' 24' ' ' PRO . 51.0 Cg_exo -53.26 129.86 35.58 Favored 'Trans proline' 0 C--N 1.346 0.423 0 C-N-CA 123.223 2.615 . . . . 0.0 112.822 -173.729 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 24' ' ' PRO . . . . . 0.437 ' HD2' ' HA ' ' A' ' 23' ' ' PRO . 10.7 Cg_endo -55.05 141.2 79.84 Favored 'Trans proline' 0 N--CA 1.457 -0.643 0 C-N-CA 123.576 2.851 . . . . 0.0 112.539 -178.853 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.796 HG21 HG21 ' A' ' 83' ' ' ILE . 13.3 p -89.09 127.83 41.56 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.082 0 CA-C-N 114.613 -1.176 . . . . 0.0 111.004 -177.89 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 37.2 mm -83.64 -26.13 7.61 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-N 115.788 -0.642 . . . . 0.0 111.643 -179.879 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.654 ' O ' HG12 ' A' ' 30' ' ' ILE . 2.5 m-20 -110.27 6.39 22.48 Favored 'General case' 0 CA--C 1.506 -0.737 0 CA-C-O 121.86 0.838 . . . . 0.0 109.297 -172.553 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 28' ' ' GLY . . . . . 0.556 ' HA2' ' HB2' ' A' ' 31' ' ' TRP . . . -79.81 3.81 68.12 Favored Glycine 0 N--CA 1.434 -1.45 0 CA-C-N 114.841 -1.072 . . . . 0.0 110.496 -174.829 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 19.9 t -77.06 -38.86 51.77 Favored 'General case' 0 C--N 1.318 -0.798 0 N-CA-C 108.701 -0.851 . . . . 0.0 108.701 173.456 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.806 ' HA ' ' HB1' ' A' ' 105' ' ' ALA . 0.0 OUTLIER -71.48 -36.66 61.39 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.669 0 N-CA-C 107.166 -1.42 . . . . 0.0 107.166 177.167 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 31' ' ' TRP . . . . . 0.556 ' HB2' ' HA2' ' A' ' 28' ' ' GLY . 14.6 m95 -75.05 -37.91 61.55 Favored 'General case' 0 N--CA 1.442 -0.826 0 CA-C-N 114.447 -1.252 . . . . 0.0 110.726 -176.863 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 23.2 t70 -78.44 -33.28 48.62 Favored 'General case' 0 N--CA 1.442 -0.846 0 CA-C-N 116.445 -0.343 . . . . 0.0 110.933 178.365 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 33' ' ' ALA . . . . . 0.443 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -68.52 -36.74 79.28 Favored 'General case' 0 N--CA 1.454 -0.26 0 C-N-CA 120.18 -0.608 . . . . 0.0 110.561 176.37 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 34' ' ' ILE . . . . . 0.504 HG21 ' CD1' ' A' ' 98' ' ' TRP . 79.7 mt -66.63 -46.22 86.54 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-O 120.761 0.315 . . . . 0.0 110.169 174.494 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 35' ' ' ALA . . . . . 0.439 ' O ' ' HB3' ' A' ' 39' ' ' ALA . . . -58.05 -34.62 70.29 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 121.292 0.568 . . . . 0.0 110.448 176.13 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 36' ' ' GLY . . . . . 0.519 ' HA2' ' N ' ' A' ' 41' ' ' GLY . . . -80.47 -11.23 84.38 Favored Glycine 0 N--CA 1.45 -0.429 0 CA-C-N 115.616 -0.72 . . . . 0.0 111.975 179.27 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 44.3 t -97.96 -50.75 4.29 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 120.643 0.259 . . . . 0.0 111.309 -176.991 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 38' ' ' GLU . . . . . 0.601 ' HG2' ' SG ' ' A' ' 101' ' ' CYS . 13.7 mt-10 -88.02 -31.85 19.1 Favored 'General case' 0 CA--C 1.513 -0.474 0 CA-C-O 120.906 0.384 . . . . 0.0 110.346 -175.403 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 39' ' ' ALA . . . . . 0.439 ' HB3' ' O ' ' A' ' 35' ' ' ALA . . . -103.17 -9.18 19.85 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.828 -177.904 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 77.97 9.92 86.59 Favored Glycine 0 CA--C 1.507 -0.432 0 N-CA-C 110.011 -1.236 . . . . 0.0 110.011 -177.586 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 41' ' ' GLY . . . . . 0.519 ' N ' ' HA2' ' A' ' 36' ' ' GLY . . . 85.9 59.25 1.9 Allowed Glycine 0 N--CA 1.435 -1.384 0 CA-C-N 114.049 -1.076 . . . . 0.0 111.337 -176.398 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 42' ' ' ASN . . . . . 0.604 ' HB3' ' HB ' ' A' ' 45' ' ' ILE . 1.6 t-20 -140.46 89.3 2.27 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 109.215 -0.661 . . . . 0.0 109.215 -176.105 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 43' ' ' TRP . . . . . 0.631 ' HA ' ' N ' ' A' ' 54' ' ' GLY . 50.0 m95 -75.19 -7.83 54.92 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-O 121.563 0.697 . . . . 0.0 110.135 -176.506 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -104.73 9.51 35.01 Favored 'General case' 0 C--N 1.316 -0.867 0 CA-C-N 114.851 -1.068 . . . . 0.0 111.473 -179.637 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.916 HG22 ' HA2' ' A' ' 53' ' ' GLY . 9.7 tt -74.41 143.21 13.74 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.794 0 CA-C-O 121.194 0.521 . . . . 0.0 110.699 -176.862 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 15.3 t-20 -148.37 88.07 1.62 Allowed 'General case' 0 C--N 1.314 -0.958 0 CA-C-O 121.145 0.497 . . . . 0.0 109.681 179.177 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 5.1 p -72.45 -23.95 61.13 Favored 'General case' 0 C--N 1.319 -0.752 0 CA-C-N 115.297 -0.865 . . . . 0.0 111.129 -179.342 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 96.8 16.71 35.26 Favored Glycine 0 N--CA 1.448 -0.513 0 C-N-CA 120.951 -0.642 . . . . 0.0 111.552 178.79 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 12.0 m120 -79.93 2.72 22.36 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.807 0.337 . . . . 0.0 111.006 -175.397 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 50' ' ' GLY . . . . . 0.45 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 85.7 -3.87 86.55 Favored Glycine 0 N--CA 1.446 -0.678 0 N-CA-C 109.905 -1.278 . . . . 0.0 109.905 -168.396 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 51' ' ' TYR . . . . . 0.506 ' CE1' ' HB3' ' A' ' 58' ' ' ASP . 0.4 OUTLIER -109.09 155.72 20.64 Favored 'General case' 0 N--CA 1.45 -0.453 0 N-CA-C 107.036 -1.468 . . . . 0.0 107.036 177.94 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 52' ' ' TYR . . . . . 0.828 ' O ' ' HA ' ' A' ' 56' ' ' GLN . 47.3 m-85 -129.55 171.32 12.71 Favored 'General case' 0 C--N 1.317 -0.823 0 C-N-CA 120.266 -0.574 . . . . 0.0 112.536 -170.303 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.916 ' HA2' HG22 ' A' ' 45' ' ' ILE . . . -47.97 154.69 1.4 Allowed Glycine 0 N--CA 1.453 -0.172 0 N-CA-C 115.583 0.993 . . . . 0.0 115.583 -171.459 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.631 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 97.79 -109.8 3.89 Favored Glycine 0 N--CA 1.442 -0.923 0 CA-C-N 114.653 -0.774 . . . . 0.0 111.708 176.631 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.432 HG23 ' CD1' ' A' ' 57' ' ' PHE . 1.9 m -84.58 -3.22 7.82 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 CA-C-O 121.681 0.753 . . . . 0.0 110.924 178.403 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 56' ' ' GLN . . . . . 0.828 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 34.8 tt0 55.29 51.4 13.14 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 113.855 -1.521 . . . . 0.0 113.803 168.12 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 57' ' ' PHE . . . . . 0.432 ' CD1' HG23 ' A' ' 55' ' ' VAL . 1.6 p90 -109.85 172.53 6.8 Favored 'General case' 0 C--O 1.236 0.349 0 C-N-CA 119.731 -0.787 . . . . 0.0 111.533 173.928 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.506 ' HB3' ' CE1' ' A' ' 51' ' ' TYR . 6.8 p-10 -79.0 156.48 28.42 Favored 'General case' 0 C--N 1.329 -0.308 0 N-CA-C 113.733 1.012 . . . . 0.0 113.733 -161.499 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.471 ' HB2' ' HE1' ' A' ' 52' ' ' TYR . 7.0 tp60 -57.03 -38.58 73.38 Favored 'General case' 0 N--CA 1.449 -0.48 0 CA-C-N 113.492 -1.685 . . . . 0.0 111.579 178.805 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -67.38 -49.67 50.02 Favored Glycine 0 N--CA 1.44 -1.089 0 CA-C-N 115.881 -0.6 . . . . 0.0 112.182 -174.256 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 91.6 m -65.8 -41.64 91.67 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 121.37 0.605 . . . . 0.0 110.425 176.405 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 62' ' ' TRP . . . . . 0.594 ' CH2' ' HA ' ' A' ' 74' ' ' ALA . 44.8 t-105 -56.27 -49.49 74.07 Favored 'General case' 0 N--CA 1.447 -0.615 0 CA-C-N 115.129 -0.941 . . . . 0.0 109.958 177.485 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 63' ' ' GLU . . . . . 0.671 ' HG3' HD11 ' A' ' 68' ' ' LEU . 18.3 tt0 -67.45 -36.47 81.25 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-N 114.907 -1.042 . . . . 0.0 110.77 -179.226 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -64.95 -41.52 95.41 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.657 -0.701 . . . . 0.0 111.059 -177.578 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 65' ' ' ASN . . . . . 0.633 ' HB2' HG13 ' A' ' 85' ' ' VAL . 8.4 m120 -81.68 -16.44 51.28 Favored 'General case' 0 C--N 1.325 -0.473 0 N-CA-C 109.557 -0.534 . . . . 0.0 109.557 177.991 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 97.01 45.48 2.61 Favored Glycine 0 N--CA 1.449 -0.442 0 CA-C-N 115.784 -0.643 . . . . 0.0 113.538 170.648 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.402 ' HA2' ' CD2' ' A' ' 70' ' ' TYR . . . -79.42 -24.47 60.85 Favored Glycine 0 N--CA 1.44 -1.037 0 N-CA-C 110.762 -0.935 . . . . 0.0 110.762 -179.543 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.683 ' HA ' ' HA ' ' A' ' 72' ' ' PRO . 19.1 mt -54.63 -25.77 28.75 Favored 'General case' 0 N--CA 1.449 -0.503 0 CA-C-O 121.365 0.602 . . . . 0.0 110.728 -176.3 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 8.4 ptm180 -71.98 -27.79 63.0 Favored 'General case' 0 N--CA 1.439 -0.996 0 CA-C-N 115.132 -0.94 . . . . 0.0 109.922 -175.835 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 70' ' ' TYR . . . . . 0.801 ' HB2' ' OE2' ' A' ' 81' ' ' GLU . 10.4 m-85 -94.13 -33.25 13.41 Favored 'General case' 0 N--CA 1.433 -1.308 0 N-CA-C 106.625 -1.62 . . . . 0.0 106.625 177.566 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.933 ' HB1' ' HB3' ' A' ' 76' ' ' LEU . . . 179.16 122.38 0.21 Allowed Pre-proline 0 N--CA 1.447 -0.621 0 CA-C-N 113.422 -1.717 . . . . 0.0 108.754 -178.589 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 72' ' ' PRO . . . . . 0.683 ' HA ' ' HA ' ' A' ' 68' ' ' LEU . 11.9 Cg_exo -61.2 1.58 0.62 Allowed 'Trans proline' 0 CA--C 1.528 0.216 0 C-N-CA 122.683 2.255 . . . . 0.0 113.293 179.417 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 73' ' ' ARG . . . . . 0.522 ' HB2' ' CD2' ' A' ' 52' ' ' TYR . 15.1 ptm180 -151.28 138.2 19.02 Favored 'General case' 0 C--N 1.316 -0.889 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 175.236 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 74' ' ' ALA . . . . . 0.672 ' HB3' ' HB2' ' A' ' 52' ' ' TYR . . . -58.36 -28.53 65.22 Favored 'General case' 0 C--O 1.218 -0.561 0 CA-C-N 115.543 -0.753 . . . . 0.0 112.584 -174.082 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 11.3 p-10 -87.95 10.15 19.81 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-O 121.062 0.458 . . . . 0.0 111.009 -176.393 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.933 ' HB3' ' HB1' ' A' ' 71' ' ' ALA . 41.6 tp -101.03 -40.16 7.36 Favored 'General case' 0 N--CA 1.45 -0.447 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.121 176.352 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 77' ' ' ALA . . . . . 0.847 ' HB3' ' HG2' ' A' ' 81' ' ' GLU . . . -103.84 168.81 8.89 Favored 'General case' 0 N--CA 1.447 -0.596 0 CA-C-O 121.108 0.48 . . . . 0.0 110.467 176.757 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 43.6 p -90.17 -177.96 5.28 Favored 'General case' 0 C--N 1.315 -0.918 0 CA-C-N 115.676 -0.693 . . . . 0.0 112.785 -167.303 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 79' ' ' ARG . . . . . 0.576 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 5.0 mtp180 -49.27 -48.83 45.68 Favored 'General case' 0 CA--C 1.513 -0.457 0 C-N-CA 123.94 0.896 . . . . 0.0 111.782 -171.899 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 80' ' ' GLU . . . . . 0.75 ' HG3' HG11 ' A' ' 22' ' ' VAL . 2.3 pm0 -60.53 -30.31 69.67 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.567 -0.742 . . . . 0.0 111.74 -175.957 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 81' ' ' GLU . . . . . 0.847 ' HG2' ' HB3' ' A' ' 77' ' ' ALA . 0.0 OUTLIER -71.71 -50.38 30.8 Favored 'General case' 0 N--CA 1.449 -0.485 0 C-N-CA 120.934 -0.306 . . . . 0.0 110.311 176.011 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 82' ' ' GLN . . . . . 0.747 ' N ' ' HG3' ' A' ' 81' ' ' GLU . 4.6 mt-30 -59.64 -35.47 74.47 Favored 'General case' 0 CA--C 1.508 -0.661 0 N-CA-C 109.336 -0.616 . . . . 0.0 109.336 -179.851 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.796 HG21 HG21 ' A' ' 25' ' ' VAL . 21.8 mt -61.37 -47.2 94.53 Favored 'Isoleucine or valine' 0 C--O 1.212 -0.92 0 CA-C-N 114.824 -1.08 . . . . 0.0 110.527 175.755 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 84' ' ' ALA . . . . . 0.643 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -61.03 -43.92 98.17 Favored 'General case' 0 C--O 1.239 0.527 0 CA-C-O 121.378 0.608 . . . . 0.0 111.462 -176.555 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.633 HG13 ' HB2' ' A' ' 65' ' ' ASN . 22.1 t -69.1 -48.47 69.06 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-N 115.927 -0.578 . . . . 0.0 110.549 179.551 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -57.66 -28.68 63.96 Favored 'General case' 0 C--O 1.223 -0.311 0 CA-C-N 115.868 -0.606 . . . . 0.0 110.618 173.925 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 87' ' ' GLU . . . . . 0.675 ' HG2' ' O ' ' A' ' 83' ' ' ILE . 6.6 mm-40 -59.76 -44.87 93.65 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.955 -0.566 . . . . 0.0 109.65 178.166 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.712 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 46.4 t -69.59 -42.34 80.57 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 C-N-CA 120.573 -0.451 . . . . 0.0 110.02 175.58 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 89' ' ' THR . . . . . 0.845 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 2.6 m -59.81 -48.09 83.07 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 116.43 -0.35 . . . . 0.0 111.443 -178.898 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 90' ' ' ARG . . . . . 0.654 ' HA ' ' OE1' ' A' ' 93' ' ' GLN . 7.9 ptt180 -65.67 -34.19 77.64 Favored 'General case' 0 CA--C 1.517 -0.31 0 CA-C-O 120.941 0.4 . . . . 0.0 111.421 -174.874 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 91' ' ' LEU . . . . . 0.712 ' HG ' ' O ' ' A' ' 88' ' ' VAL . 4.6 pp -70.52 -22.26 62.65 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.892 -174.143 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 92' ' ' ARG . . . . . 0.562 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 9.8 mtm180 -84.98 -52.28 6.09 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -178.698 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 93' ' ' GLN . . . . . 0.732 ' HG2' ' H ' ' A' ' 96' ' ' GLY . 0.0 OUTLIER -96.78 -24.75 15.77 Favored 'General case' 0 CA--C 1.539 0.53 0 N-CA-C 113.602 0.964 . . . . 0.0 113.602 -169.275 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 80.51 50.83 5.17 Favored Glycine 0 CA--C 1.507 -0.414 0 C-N-CA 120.728 -0.749 . . . . 0.0 111.783 176.762 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 95' ' ' TRP . . . . . 0.461 ' HA ' ' HE3' ' A' ' 98' ' ' TRP . 1.4 m95 56.61 29.2 15.21 Favored 'General case' 0 C--O 1.223 -0.3 0 CA-C-O 121.582 0.706 . . . . 0.0 109.754 177.355 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.732 ' H ' ' HG2' ' A' ' 93' ' ' GLN . . . -83.93 -24.78 47.74 Favored Glycine 0 N--CA 1.449 -0.439 0 CA-C-N 115.314 -0.857 . . . . 0.0 111.87 174.912 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -80.9 -23.88 38.65 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 121.238 0.542 . . . . 0.0 109.685 176.423 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 98' ' ' TRP . . . . . 0.845 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 23.4 m-90 -101.01 108.01 52.52 Favored Pre-proline 0 N--CA 1.445 -0.708 0 N-CA-C 108.59 -0.893 . . . . 0.0 108.59 175.63 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 99' ' ' PRO . . . . . 0.43 ' HD3' ' HA ' ' A' ' 98' ' ' TRP . 45.0 Cg_exo -63.7 -133.68 0.0 OUTLIER 'Trans proline' 0 CA--C 1.541 0.828 0 C-N-CA 123.654 2.903 . . . . 0.0 113.991 -175.928 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 41.8 t -55.22 -25.56 16.99 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.287 0 CA-C-O 120.886 0.374 . . . . 0.0 111.637 -175.116 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 101' ' ' CYS . . . . . 0.601 ' SG ' ' HG2' ' A' ' 38' ' ' GLU . 85.1 m -63.99 -25.66 68.23 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 116.315 -0.402 . . . . 0.0 111.686 -178.25 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -69.36 -44.63 71.17 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.922 0.392 . . . . 0.0 110.368 177.704 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -67.42 -36.63 81.63 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 121.19 0.519 . . . . 0.0 110.142 178.554 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 104' ' ' ARG . . . . . 0.416 HH11 ' HD3' ' A' ' 104' ' ' ARG . 9.8 mmm180 -64.73 -32.56 74.29 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.352 -0.84 . . . . 0.0 110.937 176.844 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 105' ' ' ALA . . . . . 0.806 ' HB1' ' HA ' ' A' ' 30' ' ' ILE . . . -89.01 -22.46 22.97 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 116.136 -0.484 . . . . 0.0 112.085 -176.076 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 103.18 68.04 0.77 Allowed Glycine 0 CA--C 1.521 0.445 0 C-N-CA 120.97 -0.633 . . . . 0.0 112.313 -177.794 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -64.45 152.71 40.88 Favored 'General case' 0 N--CA 1.45 -0.452 0 C-N-CA 122.856 0.462 . . . . 0.0 111.256 -176.063 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 25.5 mmt180 . . . . . 0 C--O 1.248 0.987 0 CA-C-O 118.289 -0.862 . . . . 0.0 111.56 177.64 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 26.2 p-10 . . . . . 0 N--CA 1.473 0.683 0 CA-C-O 121.909 0.862 . . . . 0.0 110.849 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 48.9 t -73.59 -49.37 36.36 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.981 0 N-CA-C 108.434 -0.95 . . . . 0.0 108.434 173.301 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 62.1 t -97.19 132.74 41.05 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.033 0 CA-C-N 115.001 -1.0 . . . . 0.0 109.14 172.671 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 8.0 t -85.39 142.61 12.98 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 CA-C-O 120.766 0.317 . . . . 0.0 110.165 -178.669 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 5' ' ' THR . . . . . 0.445 ' HA ' ' HD3' ' A' ' 6' ' ' PRO . 11.8 p -105.76 109.12 62.87 Favored Pre-proline 0 C--N 1.318 -0.804 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.926 -179.613 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.445 ' HD3' ' HA ' ' A' ' 5' ' ' THR . 17.9 Cg_endo -92.4 160.04 3.03 Favored 'Trans proline' 0 N--CA 1.441 -1.561 0 C-N-CA 123.223 2.615 . . . . 0.0 111.746 178.644 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 7' ' ' ALA . . . . . 0.512 ' C ' ' H ' ' A' ' 9' ' ' GLU . . . 53.33 -157.42 0.17 Allowed 'General case' 0 C--N 1.317 -0.811 0 CA-C-N 114.739 -1.119 . . . . 0.0 111.579 -178.297 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 8' ' ' HIS . . . . . 0.441 ' HB3' ' O ' ' A' ' 7' ' ' ALA . 80.2 t60 71.52 -21.16 0.22 Allowed 'General case' 0 C--O 1.235 0.293 0 O-C-N 123.703 0.627 . . . . 0.0 110.092 -171.772 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 9' ' ' GLU . . . . . 0.512 ' H ' ' C ' ' A' ' 7' ' ' ALA . 12.7 pt-20 -104.47 147.26 27.77 Favored 'General case' 0 N--CA 1.442 -0.873 0 CA-C-O 121.084 0.468 . . . . 0.0 110.819 -179.276 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -126.0 74.35 1.42 Allowed 'General case' 0 C--N 1.32 -0.679 0 CA-C-O 121.664 0.745 . . . . 0.0 109.808 -177.191 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.666 HG12 ' HG3' ' A' ' 13' ' ' ARG . 53.9 t -59.93 -57.36 12.06 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.97 0 CA-C-N 114.243 -1.344 . . . . 0.0 111.026 179.306 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 4.9 p 34.33 86.7 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.237 0.443 0 CA-C-O 122.73 1.252 . . . . 0.0 113.445 -179.211 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 13' ' ' ARG . . . . . 0.666 ' HG3' HG12 ' A' ' 11' ' ' VAL . 23.0 mtm180 -112.12 112.03 23.35 Favored 'General case' 0 C--N 1.312 -1.041 0 CA-C-N 114.105 -1.407 . . . . 0.0 110.824 -179.209 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 3.4 t -112.38 165.0 7.65 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.924 0 CA-C-N 114.856 -1.065 . . . . 0.0 108.744 178.576 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 143.43 94.71 0.2 Allowed Glycine 0 N--CA 1.439 -1.104 0 CA-C-N 115.674 -0.694 . . . . 0.0 112.406 178.97 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -64.52 -67.31 0.44 Allowed 'General case' 0 N--CA 1.446 -0.644 0 CA-C-O 121.025 0.441 . . . . 0.0 110.495 179.16 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 40.5 mmtm 33.83 79.06 0.29 Allowed Pre-proline 0 C--N 1.326 -0.455 0 CA-C-N 113.829 -1.532 . . . . 0.0 113.386 177.754 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 5.7 Cg_exo -75.32 164.56 32.53 Favored 'Trans proline' 0 N--CA 1.455 -0.746 0 C-N-CA 122.654 2.236 . . . . 0.0 111.666 177.765 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 67.59 43.69 84.96 Favored Glycine 0 C--N 1.307 -1.033 0 CA-C-N 114.499 -1.228 . . . . 0.0 111.256 -177.233 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -62.3 -50.63 70.91 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 114.7 -0.75 . . . . 0.0 110.814 -177.11 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 44.6 mt-10 -140.67 135.7 31.91 Favored 'General case' 0 N--CA 1.445 -0.702 0 N-CA-C 108.688 -0.856 . . . . 0.0 108.688 177.025 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 60.7 t -94.5 118.52 66.94 Favored Pre-proline 0 C--N 1.316 -0.852 0 CA-C-N 115.924 -0.58 . . . . 0.0 111.255 -175.284 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_exo -55.22 142.95 77.35 Favored 'Trans proline' 0 C--N 1.345 0.363 0 C-N-CA 123.341 2.694 . . . . 0.0 112.174 176.064 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 9.6 Cg_endo -54.84 148.28 47.11 Favored 'Trans proline' 0 C--N 1.346 0.401 0 C-N-CA 123.815 3.01 . . . . 0.0 113.916 -178.958 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.553 ' HB ' ' HA3' ' A' ' 28' ' ' GLY . 78.3 t -111.22 158.6 11.66 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.82 0 CA-C-N 113.722 -1.581 . . . . 0.0 109.207 -178.395 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 48.1 mm -54.98 -36.7 39.37 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-O 120.739 0.304 . . . . 0.0 111.812 -175.939 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.449 ' O ' HG13 ' A' ' 30' ' ' ILE . 48.6 m-20 -104.14 -12.25 16.83 Favored 'General case' 0 CA--C 1.503 -0.838 0 CA-C-O 122.316 1.055 . . . . 0.0 108.817 175.386 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 28' ' ' GLY . . . . . 0.625 ' HA2' ' HB2' ' A' ' 31' ' ' TRP . . . -72.15 -2.7 54.29 Favored Glycine 0 N--CA 1.442 -0.923 0 CA-C-N 113.677 -1.602 . . . . 0.0 111.555 -176.637 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 6.3 p -78.02 -48.09 16.96 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-O 122.049 0.928 . . . . 0.0 109.568 174.677 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.741 ' HA ' ' HB1' ' A' ' 105' ' ' ALA . 0.1 OUTLIER -62.89 -35.64 72.11 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.971 0 CA-C-N 113.392 -1.731 . . . . 0.0 107.713 175.691 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 31' ' ' TRP . . . . . 0.625 ' HB2' ' HA2' ' A' ' 28' ' ' GLY . 18.5 m95 -73.58 -36.91 65.61 Favored 'General case' 0 C--N 1.317 -0.817 0 CA-C-N 114.301 -1.318 . . . . 0.0 110.821 -178.092 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 1.6 t70 -77.92 -34.39 51.37 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.596 179.671 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 33' ' ' ALA . . . . . 0.448 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -70.07 -34.28 72.98 Favored 'General case' 0 N--CA 1.45 -0.474 0 C-N-CA 120.877 -0.329 . . . . 0.0 110.339 176.584 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 34' ' ' ILE . . . . . 0.504 HG13 ' O ' ' A' ' 30' ' ' ILE . 54.0 mt -65.12 -45.1 95.19 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.225 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 172.311 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 35' ' ' ALA . . . . . 0.552 ' HA ' ' O ' ' A' ' 54' ' ' GLY . . . -57.59 -36.41 71.68 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.228 176.613 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -73.92 -21.12 79.57 Favored Glycine 0 N--CA 1.451 -0.328 0 CA-C-N 115.574 -0.739 . . . . 0.0 112.237 178.886 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 18.5 t -93.75 -52.9 4.24 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-O 121.038 0.447 . . . . 0.0 111.811 -176.593 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 9.3 tp10 -87.58 -32.3 19.41 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 121.399 0.619 . . . . 0.0 110.107 -171.667 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 39' ' ' ALA . . . . . 0.448 ' HB3' ' O ' ' A' ' 35' ' ' ALA . . . -101.51 -13.57 17.85 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 115.644 -0.707 . . . . 0.0 111.616 -177.805 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 80.1 13.08 82.54 Favored Glycine 0 CA--C 1.505 -0.555 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 -176.808 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 81.03 58.83 2.55 Favored Glycine 0 N--CA 1.436 -1.319 0 CA-C-N 114.143 -1.028 . . . . 0.0 111.965 -177.569 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 42' ' ' ASN . . . . . 0.81 ' HB3' ' HB ' ' A' ' 45' ' ' ILE . 2.1 t-20 -151.44 97.34 2.39 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 108.73 -0.841 . . . . 0.0 108.73 -178.229 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 43' ' ' TRP . . . . . 0.731 ' HZ3' ' HB2' ' A' ' 82' ' ' GLN . 49.8 m95 -75.51 -17.03 60.22 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-O 121.49 0.662 . . . . 0.0 110.495 -176.348 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -101.2 14.31 32.36 Favored 'General case' 0 C--N 1.313 -0.995 0 CA-C-N 115.007 -0.997 . . . . 0.0 110.693 -179.451 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.81 ' HB ' ' HB3' ' A' ' 42' ' ' ASN . 6.2 tt -77.44 143.26 13.1 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.951 0 CA-C-O 121.083 0.468 . . . . 0.0 109.759 -178.487 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 46' ' ' ASN . . . . . 0.598 ' ND2' HH21 ' A' ' 73' ' ' ARG . 29.3 t-20 -145.54 89.1 1.89 Allowed 'General case' 0 C--N 1.304 -1.399 0 CA-C-O 121.814 0.816 . . . . 0.0 108.994 179.369 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 2.6 p -67.98 -22.03 65.03 Favored 'General case' 0 N--CA 1.443 -0.81 0 CA-C-N 114.091 -1.413 . . . . 0.0 111.142 -178.418 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 90.03 23.45 32.45 Favored Glycine 0 N--CA 1.441 -0.984 0 N-CA-C 111.112 -0.795 . . . . 0.0 111.112 178.109 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 17.3 p30 -101.58 15.42 28.95 Favored 'General case' 0 C--N 1.326 -0.426 0 N-CA-C 112.384 0.513 . . . . 0.0 112.384 -177.214 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 93.48 -10.91 72.39 Favored Glycine 0 CA--C 1.509 -0.309 0 N-CA-C 111.401 -0.68 . . . . 0.0 111.401 177.608 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 51' ' ' TYR . . . . . 0.562 ' CD1' ' HB2' ' A' ' 58' ' ' ASP . 0.1 OUTLIER -118.79 149.28 41.76 Favored 'General case' 0 N--CA 1.445 -0.713 0 N-CA-C 106.434 -1.691 . . . . 0.0 106.434 -177.566 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 52' ' ' TYR . . . . . 0.711 ' HB2' ' HB3' ' A' ' 74' ' ' ALA . 22.4 m-85 -119.56 170.9 8.76 Favored 'General case' 0 C--N 1.309 -1.18 0 C-N-CA 119.921 -0.711 . . . . 0.0 112.183 -169.298 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.794 ' HA2' HG22 ' A' ' 45' ' ' ILE . . . -57.56 167.64 5.07 Favored Glycine 0 N--CA 1.449 -0.493 0 N-CA-C 115.939 1.136 . . . . 0.0 115.939 -166.115 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.652 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 86.62 -102.08 2.7 Favored Glycine 0 N--CA 1.437 -1.296 0 CA-C-N 114.202 -0.999 . . . . 0.0 111.541 178.247 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.584 HG22 ' HB3' ' A' ' 82' ' ' GLN . 3.1 m -85.4 -2.85 7.91 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.737 0 CA-C-O 120.434 0.159 . . . . 0.0 111.329 -179.586 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 56' ' ' GLN . . . . . 0.666 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 8.9 tp-100 52.78 52.94 12.96 Favored 'General case' 0 CA--C 1.534 0.339 0 N-CA-C 113.481 0.919 . . . . 0.0 113.481 166.17 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 57' ' ' PHE . . . . . 0.407 ' CD1' HG23 ' A' ' 55' ' ' VAL . 1.0 OUTLIER -120.57 163.33 18.16 Favored 'General case' 0 C--N 1.327 -0.379 0 C-N-CA 119.862 -0.735 . . . . 0.0 111.366 170.996 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.562 ' HB2' ' CD1' ' A' ' 51' ' ' TYR . 0.0 OUTLIER -73.6 155.1 39.44 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 114.799 -1.092 . . . . 0.0 113.365 -164.565 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.458 ' HB2' ' CE2' ' A' ' 52' ' ' TYR . 6.6 tp60 -53.3 -39.98 64.4 Favored 'General case' 0 N--CA 1.451 -0.402 0 CA-C-N 114.078 -1.419 . . . . 0.0 112.303 -179.905 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -68.39 -49.45 45.04 Favored Glycine 0 C--O 1.225 -0.441 0 CA-C-N 115.921 -0.582 . . . . 0.0 112.03 -177.264 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 32.8 m -65.64 -38.18 88.63 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-O 121.461 0.648 . . . . 0.0 110.26 176.105 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 62' ' ' TRP . . . . . 0.559 ' CH2' ' HA ' ' A' ' 74' ' ' ALA . 39.1 t-105 -56.67 -48.89 76.61 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 115.32 -0.854 . . . . 0.0 109.643 173.9 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 63' ' ' GLU . . . . . 0.575 ' CB ' HD11 ' A' ' 68' ' ' LEU . 60.6 tt0 -67.07 -33.97 76.66 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-N 114.876 -1.056 . . . . 0.0 110.943 179.359 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -63.04 -42.03 99.65 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.796 -0.638 . . . . 0.0 111.366 -177.81 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 33.0 m-80 -86.64 -11.76 50.44 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.977 0.418 . . . . 0.0 110.303 177.809 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 66' ' ' GLY . . . . . 0.418 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 92.93 52.38 2.1 Favored Glycine 0 C--O 1.22 -0.743 0 CA-C-N 115.858 -0.61 . . . . 0.0 114.043 170.533 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.475 ' HA3' ' CE2' ' A' ' 62' ' ' TRP . . . -80.28 -27.95 50.43 Favored Glycine 0 N--CA 1.441 -0.967 0 C-N-CA 120.666 -0.778 . . . . 0.0 112.629 179.694 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.652 ' HA ' ' HA ' ' A' ' 72' ' ' PRO . 2.4 mp -59.3 -20.51 55.04 Favored 'General case' 0 CA--C 1.519 -0.241 0 CA-C-O 120.864 0.364 . . . . 0.0 111.923 -170.084 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 69' ' ' ARG . . . . . 0.418 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 9.1 ptp180 -72.55 -28.1 62.63 Favored 'General case' 0 N--CA 1.44 -0.944 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.225 -179.155 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 70' ' ' TYR . . . . . 0.717 ' HB2' ' CD ' ' A' ' 81' ' ' GLU . 10.5 m-85 -92.26 -33.29 14.71 Favored 'General case' 0 N--CA 1.433 -1.316 0 N-CA-C 106.683 -1.599 . . . . 0.0 106.683 176.894 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.667 ' HB1' ' HB3' ' A' ' 76' ' ' LEU . . . 175.34 126.86 0.13 Allowed Pre-proline 0 N--CA 1.45 -0.443 0 CA-C-N 113.005 -1.907 . . . . 0.0 108.494 179.107 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 72' ' ' PRO . . . . . 0.652 ' HA ' ' HA ' ' A' ' 68' ' ' LEU . 6.1 Cg_exo -62.46 3.86 0.42 Allowed 'Trans proline' 0 C--N 1.333 -0.272 0 C-N-CA 122.717 2.278 . . . . 0.0 113.709 -178.987 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 73' ' ' ARG . . . . . 0.598 HH21 ' ND2' ' A' ' 46' ' ' ASN . 11.0 ptm180 -154.53 142.51 20.17 Favored 'General case' 0 C--N 1.316 -0.877 0 N-CA-C 108.988 -0.745 . . . . 0.0 108.988 177.302 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 74' ' ' ALA . . . . . 0.711 ' HB3' ' HB2' ' A' ' 52' ' ' TYR . . . -61.69 -29.45 70.1 Favored 'General case' 0 C--O 1.219 -0.508 0 CA-C-N 115.935 -0.575 . . . . 0.0 112.284 -176.675 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 18.6 p-10 -86.44 12.01 11.2 Favored 'General case' 0 C--N 1.317 -0.836 0 CA-C-O 121.168 0.508 . . . . 0.0 111.032 -175.091 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.667 ' HB3' ' HB1' ' A' ' 71' ' ' ALA . 39.6 tp -108.38 -43.58 4.3 Favored 'General case' 0 N--CA 1.449 -0.5 0 CA-C-N 115.586 -0.734 . . . . 0.0 110.429 175.39 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 77' ' ' ALA . . . . . 0.654 ' HB3' ' HG2' ' A' ' 81' ' ' GLU . . . -99.06 167.85 10.45 Favored 'General case' 0 N--CA 1.449 -0.475 0 CA-C-O 121.58 0.705 . . . . 0.0 111.079 178.767 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 78' ' ' THR . . . . . 0.435 ' OG1' ' HG2' ' A' ' 80' ' ' GLU . 27.6 p -91.78 178.73 5.82 Favored 'General case' 0 C--N 1.316 -0.877 0 CA-C-N 115.002 -0.999 . . . . 0.0 112.69 -167.564 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 79' ' ' ARG . . . . . 0.667 ' HG2' ' CE2' ' A' ' 43' ' ' TRP . 64.5 mtp180 -45.89 -42.9 13.2 Favored 'General case' 0 N--CA 1.469 0.501 0 C-N-CA 123.523 0.729 . . . . 0.0 111.88 -174.779 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 80' ' ' GLU . . . . . 0.435 ' HG2' ' OG1' ' A' ' 78' ' ' THR . 7.4 pt-20 -57.19 -37.57 72.37 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 115.738 -0.665 . . . . 0.0 111.002 -177.423 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 81' ' ' GLU . . . . . 0.717 ' CD ' ' HB2' ' A' ' 70' ' ' TYR . 0.0 OUTLIER -72.03 -49.48 36.49 Favored 'General case' 0 N--CA 1.444 -0.731 0 CA-C-N 116.665 -0.243 . . . . 0.0 110.65 -179.238 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 82' ' ' GLN . . . . . 0.731 ' HB2' ' HZ3' ' A' ' 43' ' ' TRP . 9.4 mp0 -61.97 -32.38 72.82 Favored 'General case' 0 CA--C 1.509 -0.61 0 C-N-CA 120.343 -0.543 . . . . 0.0 110.198 -179.276 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.67 ' O ' ' HB3' ' A' ' 87' ' ' GLU . 40.7 mt -64.37 -46.05 94.17 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.753 0 CA-C-N 115.459 -0.791 . . . . 0.0 109.788 176.598 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 84' ' ' ALA . . . . . 0.484 ' O ' ' HG3' ' A' ' 87' ' ' GLU . . . -66.12 -48.22 71.57 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 121.038 0.447 . . . . 0.0 111.649 -176.7 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 47.2 t -69.58 -48.35 66.42 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.577 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.874 -175.414 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 86' ' ' ALA . . . . . 0.431 ' HB1' ' CZ2' ' A' ' 98' ' ' TRP . . . -66.56 -30.15 70.38 Favored 'General case' 0 N--CA 1.444 -0.728 0 CA-C-O 121.026 0.441 . . . . 0.0 110.234 179.682 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 87' ' ' GLU . . . . . 0.67 ' HB3' ' O ' ' A' ' 83' ' ' ILE . 0.4 OUTLIER -70.44 -30.19 66.97 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.774 -177.138 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.671 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 59.1 t -61.29 -42.38 93.34 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.284 0 N-CA-C 108.812 -0.81 . . . . 0.0 108.812 170.732 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 89' ' ' THR . . . . . 0.855 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 0.2 OUTLIER -67.25 -43.83 80.91 Favored 'General case' 0 C--N 1.316 -0.872 0 CA-C-N 115.517 -0.765 . . . . 0.0 110.631 -179.45 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 90' ' ' ARG . . . . . 0.599 ' HG3' ' O ' ' A' ' 87' ' ' GLU . 3.0 ppt_? -63.25 -34.37 77.52 Favored 'General case' 0 CA--C 1.517 -0.295 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.764 -177.512 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 91' ' ' LEU . . . . . 0.671 ' HG ' ' O ' ' A' ' 88' ' ' VAL . 4.4 pp -73.5 -23.7 60.08 Favored 'General case' 0 C--N 1.322 -0.588 0 O-C-N 123.312 0.383 . . . . 0.0 110.949 -171.387 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 92' ' ' ARG . . . . . 0.543 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 4.6 mtm180 -84.3 -48.5 9.66 Favored 'General case' 0 CA--C 1.512 -0.511 0 CA-C-O 121.516 0.674 . . . . 0.0 109.628 -178.386 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 93' ' ' GLN . . . . . 0.539 HE22 ' HB2' ' A' ' 97' ' ' ALA . 4.6 pt20 -98.47 -28.47 13.59 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 114.967 -1.015 . . . . 0.0 113.285 -169.1 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 92.54 40.1 5.13 Favored Glycine 0 CA--C 1.509 -0.323 0 C-N-CA 120.504 -0.855 . . . . 0.0 111.759 176.013 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 95' ' ' TRP . . . . . 0.587 ' CZ2' HD12 ' A' ' 30' ' ' ILE . 34.4 m95 68.7 11.53 8.38 Favored 'General case' 0 C--O 1.216 -0.671 0 C-N-CA 123.316 0.646 . . . . 0.0 110.165 178.536 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -58.85 -29.51 64.82 Favored Glycine 0 CA--C 1.522 0.49 0 CA-C-N 115.523 -0.762 . . . . 0.0 113.463 178.795 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 97' ' ' ALA . . . . . 0.539 ' HB2' HE22 ' A' ' 93' ' ' GLN . . . -80.83 -17.64 50.12 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.938 0.399 . . . . 0.0 110.884 178.031 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 98' ' ' TRP . . . . . 0.855 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 30.0 m-90 -104.93 108.02 60.13 Favored Pre-proline 0 C--N 1.324 -0.51 0 CA-C-N 116.052 -0.522 . . . . 0.0 109.736 178.517 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 39.5 Cg_exo -64.43 -134.63 0.0 OUTLIER 'Trans proline' 0 CA--C 1.537 0.631 0 C-N-CA 123.95 3.1 . . . . 0.0 114.148 -175.845 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 3.8 m -54.14 -27.48 16.55 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.229 0 N-CA-C 112.442 0.534 . . . . 0.0 112.442 -176.813 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 77.1 m -60.81 -40.36 92.41 Favored 'General case' 0 C--N 1.317 -0.847 0 CA-C-N 115.887 -0.597 . . . . 0.0 111.37 179.183 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 102' ' ' ALA . . . . . 0.422 ' HB2' ' CB ' ' A' ' 98' ' ' TRP . . . -72.03 -41.6 67.31 Favored 'General case' 0 CA--C 1.517 -0.295 0 CA-C-O 121.092 0.473 . . . . 0.0 110.26 177.302 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -59.27 -46.21 89.15 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.577 -0.738 . . . . 0.0 110.917 179.128 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 3.0 mpp_? -73.71 -22.08 60.03 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.816 -0.629 . . . . 0.0 111.423 179.854 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 105' ' ' ALA . . . . . 0.741 ' HB1' ' HA ' ' A' ' 30' ' ' ILE . . . -83.06 -20.89 34.09 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.397 179.433 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 104.52 60.72 0.66 Allowed Glycine 0 CA--C 1.519 0.305 0 C-N-CA 121.111 -0.566 . . . . 0.0 112.142 -179.178 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -64.11 141.53 58.74 Favored 'General case' 0 C--O 1.235 0.295 0 C-N-CA 122.659 0.384 . . . . 0.0 111.939 -176.574 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 108' ' ' ARG . . . . . 0.658 ' HD3' ' OXT' ' A' ' 108' ' ' ARG . 0.0 OUTLIER . . . . . 0 C--O 1.246 0.903 0 CA-C-O 118.567 -0.73 . . . . 0.0 110.726 -177.491 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 70.5 m-20 . . . . . 0 N--CA 1.474 0.773 0 CA-C-O 121.338 0.59 . . . . 0.0 110.496 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 46.2 t -116.3 80.71 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.799 0 N-CA-C 108.441 -0.948 . . . . 0.0 108.441 178.018 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 7.5 p -30.68 122.93 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.47 0.529 0 CA-C-N 114.537 -1.211 . . . . 0.0 112.813 179.499 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 6.4 t -89.69 146.05 6.66 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.575 0 CA-C-N 115.367 -0.833 . . . . 0.0 110.174 -175.951 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 5' ' ' THR . . . . . 0.472 ' HA ' ' HD3' ' A' ' 6' ' ' PRO . 14.1 p -89.97 125.68 59.83 Favored Pre-proline 0 C--N 1.317 -0.822 0 CA-C-N 115.624 -0.716 . . . . 0.0 111.17 -178.044 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.472 ' HD3' ' HA ' ' A' ' 5' ' ' THR . 37.6 Cg_endo -88.72 156.01 6.2 Favored 'Trans proline' 0 N--CA 1.439 -1.695 0 C-N-CA 123.164 2.576 . . . . 0.0 110.595 176.65 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . 50.42 46.47 25.21 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-O 122.155 0.979 . . . . 0.0 110.442 -174.067 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 54.7 t-80 -77.6 -8.14 57.41 Favored 'General case' 0 C--N 1.314 -0.953 0 CA-C-N 113.766 -1.561 . . . . 0.0 108.855 176.075 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 3.8 mm-40 -56.03 138.5 49.1 Favored 'General case' 0 CA--C 1.515 -0.391 0 CA-C-N 115.453 -0.794 . . . . 0.0 112.532 -177.138 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -121.66 59.71 0.97 Allowed 'General case' 0 C--N 1.316 -0.875 0 CA-C-N 114.584 -1.189 . . . . 0.0 108.794 173.929 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 85.7 t -61.61 -46.35 96.74 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.734 0 CA-C-N 113.92 -1.491 . . . . 0.0 110.79 -179.992 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 6.0 p 34.9 82.14 0.01 OUTLIER 'Isoleucine or valine' 0 C--O 1.234 0.278 0 O-C-N 124.728 1.267 . . . . 0.0 112.731 -176.758 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 13' ' ' ARG . . . . . 0.453 ' HD2' ' HA ' ' A' ' 13' ' ' ARG . 0.2 OUTLIER 64.17 133.29 0.02 OUTLIER 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 113.404 -1.725 . . . . 0.0 113.221 -176.911 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.7 t -88.76 158.45 3.0 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.089 0 N-CA-C 108.651 -0.87 . . . . 0.0 108.651 175.767 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -163.81 84.87 0.11 Allowed Glycine 0 N--CA 1.428 -1.839 0 CA-C-N 115.309 -0.86 . . . . 0.0 112.483 -177.871 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.683 ' HB ' ' HD3' ' A' ' 17' ' ' LYS . 3.5 m -63.1 -38.04 89.59 Favored 'General case' 0 N--CA 1.447 -0.601 0 CA-C-O 121.852 0.834 . . . . 0.0 110.176 176.726 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 17' ' ' LYS . . . . . 0.683 ' HD3' ' HB ' ' A' ' 16' ' ' THR . 0.0 OUTLIER -123.71 85.06 53.48 Favored Pre-proline 0 C--N 1.316 -0.879 0 CA-C-N 114.439 -1.255 . . . . 0.0 109.592 176.668 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_exo -61.62 117.12 3.91 Favored 'Trans proline' 0 CA--C 1.506 -0.877 0 C-N-CA 122.784 2.323 . . . . 0.0 112.167 177.195 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 144.44 53.09 0.03 OUTLIER Glycine 0 C--N 1.299 -1.514 0 CA-C-N 113.667 -1.606 . . . . 0.0 113.471 178.184 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 35.5 m -69.94 -33.76 72.56 Favored 'General case' 0 C--N 1.32 -0.698 0 N-CA-C 108.879 -0.786 . . . . 0.0 108.879 170.092 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 48.1 mt-10 -123.71 125.84 45.48 Favored 'General case' 0 N--CA 1.439 -0.996 0 CA-C-N 115.089 -0.959 . . . . 0.0 108.853 176.754 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 31.6 t -71.24 131.04 87.15 Favored Pre-proline 0 C--N 1.313 -0.987 0 CA-C-N 115.522 -0.763 . . . . 0.0 110.295 -177.24 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.438 ' HA ' ' HD2' ' A' ' 24' ' ' PRO . 50.0 Cg_exo -53.71 129.37 33.64 Favored 'Trans proline' 0 C--N 1.348 0.538 0 C-N-CA 123.135 2.557 . . . . 0.0 112.588 -179.002 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 24' ' ' PRO . . . . . 0.438 ' HD2' ' HA ' ' A' ' 23' ' ' PRO . 11.0 Cg_endo -55.46 141.46 82.38 Favored 'Trans proline' 0 N--CA 1.458 -0.583 0 C-N-CA 123.844 3.03 . . . . 0.0 113.093 -179.36 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.451 ' CG2' HD13 ' A' ' 83' ' ' ILE . 1.5 p -80.21 119.24 29.32 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.984 0 CA-C-N 114.623 -1.171 . . . . 0.0 111.238 179.895 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 42.1 mm -88.82 -54.44 7.79 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-N 115.356 -0.838 . . . . 0.0 111.692 177.414 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.726 ' O ' HG12 ' A' ' 30' ' ' ILE . 33.5 m-20 -128.2 34.88 4.5 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 114.735 -1.12 . . . . 0.0 108.553 -170.688 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 28' ' ' GLY . . . . . 0.487 ' HA2' ' CD1' ' A' ' 31' ' ' TRP . . . -72.22 -2.6 54.33 Favored Glycine 0 CA--C 1.5 -0.856 0 N-CA-C 110.605 -0.998 . . . . 0.0 110.605 177.482 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 16.4 m -69.63 -37.41 76.8 Favored 'General case' 0 C--N 1.317 -0.828 0 CA-C-O 121.499 0.666 . . . . 0.0 109.352 173.564 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.726 HG12 ' O ' ' A' ' 27' ' ' ASP . 0.3 OUTLIER -69.55 -35.97 68.9 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.672 0 N-CA-C 107.159 -1.422 . . . . 0.0 107.159 176.364 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 31' ' ' TRP . . . . . 0.537 ' CZ2' ' HD3' ' A' ' 90' ' ' ARG . 21.7 m95 -71.45 -36.45 71.23 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 114.255 -1.339 . . . . 0.0 110.776 -177.394 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 27.1 t70 -76.82 -33.39 57.96 Favored 'General case' 0 N--CA 1.445 -0.713 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.167 177.904 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 33' ' ' ALA . . . . . 0.468 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -70.69 -34.07 71.58 Favored 'General case' 0 N--CA 1.447 -0.592 0 C-N-CA 120.432 -0.507 . . . . 0.0 110.138 176.529 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 34' ' ' ILE . . . . . 0.527 ' HA ' ' HB3' ' A' ' 101' ' ' CYS . 56.9 mt -67.38 -41.7 86.58 Favored 'Isoleucine or valine' 0 C--O 1.234 0.28 0 CA-C-N 115.851 -0.613 . . . . 0.0 109.99 172.647 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 35' ' ' ALA . . . . . 0.5 ' HA ' ' O ' ' A' ' 54' ' ' GLY . . . -58.75 -38.68 78.97 Favored 'General case' 0 CA--C 1.515 -0.379 0 CA-C-O 121.448 0.642 . . . . 0.0 110.112 174.045 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -75.29 -10.1 84.34 Favored Glycine 0 N--CA 1.449 -0.443 0 CA-C-N 115.192 -0.913 . . . . 0.0 111.343 179.22 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.427 ' HB3' ' O ' ' A' ' 34' ' ' ILE . 14.4 t -90.87 -66.72 0.9 Allowed 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.174 -0.513 . . . . 0.0 111.327 -178.607 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 38' ' ' GLU . . . . . 0.872 ' HG3' ' SG ' ' A' ' 101' ' ' CYS . 53.7 mt-10 -89.7 -34.48 16.22 Favored 'General case' 0 CA--C 1.513 -0.45 0 C-N-CA 120.399 -0.521 . . . . 0.0 110.918 -174.023 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 39' ' ' ALA . . . . . 0.493 ' HB3' ' O ' ' A' ' 35' ' ' ALA . . . -84.15 -18.32 37.12 Favored 'General case' 0 N--CA 1.445 -0.685 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.227 -176.363 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 80.35 12.57 82.96 Favored Glycine 0 CA--C 1.503 -0.701 0 N-CA-C 109.991 -1.243 . . . . 0.0 109.991 -177.351 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 82.81 61.47 1.94 Allowed Glycine 0 N--CA 1.434 -1.44 0 CA-C-N 114.066 -1.067 . . . . 0.0 111.866 -176.689 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 42' ' ' ASN . . . . . 0.473 ' HB3' ' HB ' ' A' ' 45' ' ' ILE . 52.8 t-20 -155.1 124.37 6.32 Favored 'General case' 0 N--CA 1.442 -0.835 0 N-CA-C 108.624 -0.88 . . . . 0.0 108.624 -179.215 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 43' ' ' TRP . . . . . 0.764 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 44.9 m95 -97.27 -10.41 25.78 Favored 'General case' 0 C--N 1.308 -1.217 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.9 -174.207 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 44' ' ' ALA . . . . . 0.424 ' HA ' ' HB2' ' A' ' 75' ' ' ASP . . . -110.16 9.34 23.95 Favored 'General case' 0 C--N 1.315 -0.91 0 CA-C-N 115.115 -0.948 . . . . 0.0 110.982 179.938 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.473 ' HB ' ' HB3' ' A' ' 42' ' ' ASN . 11.5 tt -73.78 143.27 13.84 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.875 0 CA-C-O 121.462 0.649 . . . . 0.0 110.959 -178.438 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -135.11 94.71 3.18 Favored 'General case' 0 C--N 1.311 -1.097 0 N-CA-C 109.028 -0.73 . . . . 0.0 109.028 179.46 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 1.7 p -73.79 -12.19 60.62 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-N 115.628 -0.714 . . . . 0.0 110.933 -178.269 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 85.29 21.84 53.42 Favored Glycine 0 N--CA 1.443 -0.878 0 N-CA-C 111.179 -0.769 . . . . 0.0 111.179 174.1 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 33.4 p-10 -103.44 10.17 37.4 Favored 'General case' 0 C--N 1.322 -0.612 0 C-N-CA 120.894 -0.322 . . . . 0.0 111.562 -174.944 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 50' ' ' GLY . . . . . 0.524 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 87.32 -2.66 86.68 Favored Glycine 0 N--CA 1.454 -0.149 0 C-N-CA 120.87 -0.681 . . . . 0.0 111.658 -178.252 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 51' ' ' TYR . . . . . 0.666 ' HA ' ' HA ' ' A' ' 58' ' ' ASP . 0.3 OUTLIER -116.51 147.7 41.52 Favored 'General case' 0 CA--C 1.508 -0.643 0 N-CA-C 106.5 -1.667 . . . . 0.0 106.5 178.649 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 52' ' ' TYR . . . . . 0.729 ' O ' ' HA ' ' A' ' 56' ' ' GLN . 47.9 m-85 -114.7 163.79 14.97 Favored 'General case' 0 C--N 1.304 -1.376 0 C-N-CA 119.821 -0.751 . . . . 0.0 111.688 -170.247 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.427 ' CA ' HG22 ' A' ' 45' ' ' ILE . . . -60.56 177.95 3.41 Favored Glycine 0 N--CA 1.448 -0.54 0 O-C-N 124.047 0.842 . . . . 0.0 114.849 -167.801 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.674 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 85.87 -108.7 3.27 Favored Glycine 0 N--CA 1.436 -1.359 0 N-CA-C 111.121 -0.792 . . . . 0.0 111.121 -178.417 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.433 HG22 ' HB3' ' A' ' 82' ' ' GLN . 0.2 OUTLIER -83.2 -1.03 5.54 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.69 0 CA-C-O 121.437 0.637 . . . . 0.0 110.067 178.713 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 56' ' ' GLN . . . . . 0.729 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 20.0 tp60 56.12 50.43 13.61 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 114.265 -1.334 . . . . 0.0 113.28 164.678 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -118.72 169.5 9.78 Favored 'General case' 0 C--N 1.329 -0.317 0 C-N-CA 119.44 -0.904 . . . . 0.0 111.478 172.209 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.666 ' HA ' ' HA ' ' A' ' 51' ' ' TYR . 8.3 p-10 -74.38 162.13 29.17 Favored 'General case' 0 C--N 1.327 -0.382 0 N-CA-C 113.995 1.109 . . . . 0.0 113.995 -163.992 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.427 ' HB2' ' CE2' ' A' ' 52' ' ' TYR . 20.6 tp60 -56.06 -42.61 76.89 Favored 'General case' 0 N--CA 1.443 -0.813 0 CA-C-N 114.085 -1.416 . . . . 0.0 111.084 177.256 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -67.77 -49.68 47.44 Favored Glycine 0 N--CA 1.451 -0.365 0 CA-C-N 115.056 -0.974 . . . . 0.0 112.667 -173.896 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 92.3 m -64.63 -40.24 95.12 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-O 120.644 0.259 . . . . 0.0 110.958 177.91 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 62' ' ' TRP . . . . . 0.472 ' CZ3' ' HA ' ' A' ' 82' ' ' GLN . 54.4 t-105 -56.64 -49.3 75.41 Favored 'General case' 0 N--CA 1.45 -0.454 0 CA-C-O 121.809 0.814 . . . . 0.0 109.102 175.008 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 63' ' ' GLU . . . . . 0.532 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 29.5 tt0 -64.83 -35.67 81.85 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 114.653 -1.158 . . . . 0.0 111.319 -179.979 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -64.93 -42.4 94.72 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.976 -0.556 . . . . 0.0 111.335 -174.606 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 33.8 m-80 -81.49 -9.24 59.75 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.981 0.42 . . . . 0.0 110.369 176.815 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 66' ' ' GLY . . . . . 0.569 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 92.29 50.38 2.61 Favored Glycine 0 C--N 1.332 0.309 0 CA-C-N 115.865 -0.607 . . . . 0.0 112.658 173.288 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.564 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -80.03 -23.59 61.24 Favored Glycine 0 N--CA 1.438 -1.205 0 C-N-CA 120.887 -0.673 . . . . 0.0 112.781 -176.48 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.908 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 6.9 mp -60.87 -22.9 64.73 Favored 'General case' 0 N--CA 1.448 -0.552 0 N-CA-C 112.139 0.422 . . . . 0.0 112.139 -172.893 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 69' ' ' ARG . . . . . 0.569 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 3.7 ptp180 -68.37 -32.81 73.16 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-O 121.12 0.486 . . . . 0.0 109.928 177.002 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 70' ' ' TYR . . . . . 0.622 ' HB3' ' CG ' ' A' ' 81' ' ' GLU . 65.6 m-85 -82.26 -34.23 28.85 Favored 'General case' 0 N--CA 1.44 -0.948 0 N-CA-C 107.564 -1.273 . . . . 0.0 107.564 178.915 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.659 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 168.35 124.35 0.04 OUTLIER Pre-proline 0 N--CA 1.448 -0.528 0 CA-C-N 112.868 -1.969 . . . . 0.0 107.319 -178.835 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 72' ' ' PRO . . . . . 0.908 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 24.8 Cg_exo -54.98 -7.38 0.95 Allowed 'Trans proline' 0 C--N 1.335 -0.174 0 C-N-CA 123.003 2.468 . . . . 0.0 114.11 -177.534 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 12.8 ptm180 -146.42 137.16 24.13 Favored 'General case' 0 C--N 1.319 -0.754 0 N-CA-C 108.853 -0.795 . . . . 0.0 108.853 176.472 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 74' ' ' ALA . . . . . 0.608 ' HB3' ' HB2' ' A' ' 52' ' ' TYR . . . -56.26 -32.0 64.11 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.151 -0.931 . . . . 0.0 112.574 -176.992 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 75' ' ' ASP . . . . . 0.611 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 4.9 p-10 -78.81 -8.14 58.51 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 121.108 0.48 . . . . 0.0 110.93 -175.312 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 64.5 tp -93.61 -32.04 14.26 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 108.781 -0.822 . . . . 0.0 108.781 173.605 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 77' ' ' ALA . . . . . 0.79 ' HB1' ' HB2' ' A' ' 81' ' ' GLU . . . -79.68 157.96 27.1 Favored 'General case' 0 N--CA 1.445 -0.713 0 CA-C-N 114.964 -1.016 . . . . 0.0 110.487 176.092 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 40.6 p -100.62 -172.48 2.2 Favored 'General case' 0 C--N 1.315 -0.906 0 CA-C-N 115.937 -0.574 . . . . 0.0 109.918 179.698 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 79' ' ' ARG . . . . . 0.764 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 10.9 mtt180 -51.14 -52.71 41.33 Favored 'General case' 0 CA--C 1.51 -0.579 0 O-C-N 123.432 0.457 . . . . 0.0 111.029 -175.433 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 1.3 pm0 -57.71 -48.31 79.93 Favored 'General case' 0 C--N 1.314 -0.943 0 CA-C-N 115.135 -0.938 . . . . 0.0 112.142 -176.374 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 81' ' ' GLU . . . . . 0.79 ' HB2' ' HB1' ' A' ' 77' ' ' ALA . 6.5 mp0 -61.31 -50.48 72.79 Favored 'General case' 0 C--O 1.233 0.221 0 N-CA-C 111.9 0.333 . . . . 0.0 111.9 176.491 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 82' ' ' GLN . . . . . 0.472 ' HA ' ' CZ3' ' A' ' 62' ' ' TRP . 51.4 mt-30 -59.93 -39.94 87.22 Favored 'General case' 0 CA--C 1.516 -0.355 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.229 -177.819 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.682 ' O ' ' HG2' ' A' ' 87' ' ' GLU . 28.3 mt -61.78 -45.54 98.46 Favored 'Isoleucine or valine' 0 C--O 1.212 -0.886 0 CA-C-N 115.36 -0.836 . . . . 0.0 110.151 178.601 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 84' ' ' ALA . . . . . 0.541 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -59.48 -43.4 93.28 Favored 'General case' 0 C--O 1.239 0.509 0 CA-C-O 121.154 0.502 . . . . 0.0 111.336 -178.347 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 60.5 t -68.66 -48.11 73.28 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.649 179.517 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -59.8 -30.08 68.66 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.63 -0.714 . . . . 0.0 110.518 176.08 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 87' ' ' GLU . . . . . 0.682 ' HG2' ' O ' ' A' ' 83' ' ' ILE . 40.1 mm-40 -60.22 -45.81 91.92 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.371 -0.831 . . . . 0.0 110.396 -179.998 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.571 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 24.6 t -64.58 -41.74 93.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 121.392 0.615 . . . . 0.0 109.645 177.823 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 89' ' ' THR . . . . . 0.777 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 0.5 OUTLIER -67.56 -46.7 71.95 Favored 'General case' 0 C--N 1.318 -0.791 0 CA-C-N 115.635 -0.711 . . . . 0.0 111.581 -175.662 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 90' ' ' ARG . . . . . 0.537 ' HD3' ' CZ2' ' A' ' 31' ' ' TRP . 13.8 ptt180 -64.55 -34.16 77.59 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.494 -0.321 . . . . 0.0 111.192 -175.247 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 91' ' ' LEU . . . . . 0.571 ' HG ' ' O ' ' A' ' 88' ' ' VAL . 4.4 pp -72.63 -23.74 60.96 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.289 -171.92 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 92' ' ' ARG . . . . . 0.525 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 6.6 mtm180 -83.93 -48.53 9.89 Favored 'General case' 0 CA--C 1.511 -0.53 0 CA-C-O 121.437 0.636 . . . . 0.0 109.734 -178.638 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 93' ' ' GLN . . . . . 0.669 ' NE2' HG22 ' A' ' 89' ' ' THR . 28.9 pt20 -98.44 -28.98 13.38 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 114.773 -1.103 . . . . 0.0 113.741 -168.135 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 82.99 48.5 5.41 Favored Glycine 0 N--CA 1.448 -0.502 0 C-N-CA 120.11 -1.043 . . . . 0.0 111.357 178.784 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 95' ' ' TRP . . . . . 0.511 ' HA ' ' HE3' ' A' ' 98' ' ' TRP . 2.4 m95 62.59 24.12 14.35 Favored 'General case' 0 C--O 1.224 -0.274 0 C-N-CA 123.176 0.591 . . . . 0.0 110.288 176.103 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -69.19 -24.51 75.93 Favored Glycine 0 CA--C 1.52 0.359 0 CA-C-N 115.706 -0.679 . . . . 0.0 112.433 175.977 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 97' ' ' ALA . . . . . 0.407 ' O ' ' HD3' ' A' ' 99' ' ' PRO . . . -82.05 -34.14 29.61 Favored 'General case' 0 CA--C 1.516 -0.355 0 CA-C-O 120.888 0.375 . . . . 0.0 110.474 176.289 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 98' ' ' TRP . . . . . 0.777 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 22.4 m-90 -96.37 103.55 14.41 Favored Pre-proline 0 N--CA 1.451 -0.414 0 CA-C-N 115.713 -0.676 . . . . 0.0 109.202 -179.62 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 99' ' ' PRO . . . . . 0.487 ' HB2' ' H ' ' A' ' 100' ' ' VAL . 16.4 Cg_exo -73.44 -98.72 0.01 OUTLIER 'Trans proline' 0 CA--C 1.537 0.656 0 C-N-CA 123.27 2.646 . . . . 0.0 114.869 -170.682 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 100' ' ' VAL . . . . . 0.487 ' H ' ' HB2' ' A' ' 99' ' ' PRO . 32.8 t -70.22 -27.27 31.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-O 121.702 0.763 . . . . 0.0 110.01 -172.853 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 101' ' ' CYS . . . . . 0.872 ' SG ' ' HG3' ' A' ' 38' ' ' GLU . 38.7 m -67.08 -33.98 76.66 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-N 114.755 -1.111 . . . . 0.0 111.13 -174.77 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 102' ' ' ALA . . . . . 0.503 ' HB1' ' HB2' ' A' ' 107' ' ' ALA . . . -65.38 -45.44 84.03 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.817 0.342 . . . . 0.0 110.69 179.839 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -64.76 -36.28 83.79 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 121.102 0.477 . . . . 0.0 110.545 178.824 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 21.1 mmm180 -74.03 -23.35 59.39 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.553 -0.749 . . . . 0.0 111.693 179.057 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 105' ' ' ALA . . . . . 0.626 ' HB1' ' HA ' ' A' ' 30' ' ' ILE . . . -96.91 -21.53 17.41 Favored 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 112.496 0.554 . . . . 0.0 112.496 -174.472 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 103.94 65.15 0.69 Allowed Glycine 0 CA--C 1.518 0.253 0 C-N-CA 120.827 -0.702 . . . . 0.0 111.919 -177.753 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 107' ' ' ALA . . . . . 0.503 ' HB2' ' HB1' ' A' ' 102' ' ' ALA . . . -71.93 152.75 42.3 Favored 'General case' 0 C--N 1.326 -0.433 0 C-N-CA 122.877 0.471 . . . . 0.0 111.674 -174.912 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 10.7 mmm180 . . . . . 0 C--O 1.25 1.081 0 CA-C-O 117.926 -1.035 . . . . 0.0 111.408 175.043 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 6.0 p30 . . . . . 0 N--CA 1.473 0.676 0 CA-C-O 121.928 0.871 . . . . 0.0 109.722 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 11.2 p -77.8 -18.63 13.93 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.979 0 CA-C-N 114.851 -1.068 . . . . 0.0 110.347 179.881 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 7.9 p -62.53 128.52 24.45 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.618 0 CA-C-N 115.657 -0.701 . . . . 0.0 110.922 177.956 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 25.1 t -96.78 155.06 3.55 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.735 0 CA-C-N 115.555 -0.748 . . . . 0.0 109.01 178.178 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 5' ' ' THR . . . . . 0.464 ' HA ' ' HD3' ' A' ' 6' ' ' PRO . 14.6 p -77.38 112.84 26.42 Favored Pre-proline 0 C--N 1.317 -0.837 0 CA-C-N 115.929 -0.578 . . . . 0.0 111.528 -176.807 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.464 ' HD3' ' HA ' ' A' ' 5' ' ' THR . 11.2 Cg_endo -92.66 170.96 2.39 Favored 'Trans proline' 0 N--CA 1.446 -1.31 0 C-N-CA 123.502 2.801 . . . . 0.0 111.518 178.091 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -91.53 63.26 4.74 Favored 'General case' 0 C--N 1.31 -1.121 0 CA-C-O 122.056 0.932 . . . . 0.0 110.569 178.785 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 65.1 m170 -95.9 -1.31 49.59 Favored 'General case' 0 C--N 1.31 -1.129 0 CA-C-N 114.079 -1.419 . . . . 0.0 108.796 173.451 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 6.0 pt-20 -56.71 143.46 36.35 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 114.693 -1.139 . . . . 0.0 111.662 -177.296 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -145.45 71.07 1.27 Allowed 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 115.206 -0.906 . . . . 0.0 109.0 176.541 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 8.9 p -73.14 -22.91 19.71 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.554 0 CA-C-N 114.981 -1.009 . . . . 0.0 111.305 -173.328 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 7.1 p 29.61 77.92 0.01 OUTLIER 'Isoleucine or valine' 0 C--O 1.238 0.471 0 CA-C-O 122.988 1.375 . . . . 0.0 112.745 -177.749 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 31.5 ptt180 -103.28 106.96 17.6 Favored 'General case' 0 C--N 1.306 -1.313 0 CA-C-N 113.66 -1.609 . . . . 0.0 110.617 -176.203 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.406 HG12 ' N ' ' A' ' 15' ' ' GLY . 4.1 t -136.06 163.93 33.12 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.387 0 CA-C-N 114.016 -1.447 . . . . 0.0 109.151 -179.446 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 15' ' ' GLY . . . . . 0.406 ' N ' HG12 ' A' ' 14' ' ' VAL . . . -171.12 64.47 0.16 Allowed Glycine 0 N--CA 1.432 -1.58 0 CA-C-N 115.499 -0.773 . . . . 0.0 111.694 176.755 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 4.5 m -75.59 -31.11 59.83 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-N 114.788 -0.706 . . . . 0.0 111.592 -175.278 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 17' ' ' LYS . . . . . 0.475 ' HA ' ' HD3' ' A' ' 18' ' ' PRO . 63.8 mmtt -58.18 110.16 2.35 Favored Pre-proline 0 C--N 1.318 -0.793 0 CA-C-N 114.731 -1.122 . . . . 0.0 111.379 -175.823 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 18' ' ' PRO . . . . . 0.475 ' HD3' ' HA ' ' A' ' 17' ' ' LYS . 1.9 Cg_endo -86.36 168.73 8.67 Favored 'Trans proline' 0 N--CA 1.45 -1.086 0 C-N-CA 123.76 2.973 . . . . 0.0 112.066 177.747 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -106.38 27.98 15.09 Favored Glycine 0 C--N 1.309 -0.966 0 CA-C-N 114.637 -1.165 . . . . 0.0 111.175 178.972 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 18.1 m -69.54 -39.5 77.43 Favored 'General case' 0 C--N 1.314 -0.958 0 CA-C-N 114.182 -1.009 . . . . 0.0 110.44 179.397 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 46.8 mt-10 -115.42 121.78 43.79 Favored 'General case' 0 N--CA 1.438 -1.062 0 N-CA-C 108.714 -0.847 . . . . 0.0 108.714 177.877 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 45.9 t -71.65 118.81 69.83 Favored Pre-proline 0 C--N 1.314 -0.964 0 CA-C-N 115.557 -0.747 . . . . 0.0 111.057 -175.963 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -55.85 139.74 84.43 Favored 'Trans proline' 0 N--CA 1.459 -0.534 0 C-N-CA 123.31 2.673 . . . . 0.0 112.021 177.085 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 10.3 Cg_endo -54.65 140.12 76.36 Favored 'Trans proline' 0 N--CA 1.455 -0.739 0 C-N-CA 123.373 2.715 . . . . 0.0 112.874 -176.675 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.469 ' HB ' HG21 ' A' ' 83' ' ' ILE . 46.4 t -89.22 137.82 20.49 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.095 0 CA-C-N 114.17 -1.377 . . . . 0.0 109.49 -178.348 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 46.1 mm -63.03 -25.46 38.61 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.615 0 CA-C-N 115.289 -0.868 . . . . 0.0 111.804 -172.374 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.535 ' O ' HG12 ' A' ' 30' ' ' ILE . 7.3 m-20 -104.22 -0.02 28.89 Favored 'General case' 0 CA--C 1.504 -0.794 0 CA-C-O 121.669 0.747 . . . . 0.0 109.498 -179.605 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 28' ' ' GLY . . . . . 0.551 ' HA2' ' HD1' ' A' ' 31' ' ' TRP . . . -67.49 -8.02 49.46 Favored Glycine 0 N--CA 1.445 -0.748 0 CA-C-N 114.786 -1.097 . . . . 0.0 110.715 179.484 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 6.1 m -76.72 -39.05 53.13 Favored 'General case' 0 C--N 1.318 -0.779 0 CA-C-O 121.652 0.739 . . . . 0.0 109.239 176.388 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.605 ' HA ' ' HB1' ' A' ' 105' ' ' ALA . 0.7 OUTLIER -68.58 -38.49 79.15 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.592 0 N-CA-C 107.35 -1.352 . . . . 0.0 107.35 177.429 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 31' ' ' TRP . . . . . 0.58 ' CD1' HG23 ' A' ' 83' ' ' ILE . 34.8 m95 -68.52 -36.68 79.2 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 114.535 -1.212 . . . . 0.0 110.378 -177.296 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.723 ' HB2' HH21 ' A' ' 79' ' ' ARG . 33.5 t70 -73.77 -41.23 62.74 Favored 'General case' 0 N--CA 1.445 -0.703 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.1 179.043 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 33' ' ' ALA . . . . . 0.457 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -70.1 -33.11 71.45 Favored 'General case' 0 N--CA 1.448 -0.55 0 CA-C-N 116.405 -0.361 . . . . 0.0 110.912 -179.966 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 34' ' ' ILE . . . . . 0.608 ' HA ' ' HB3' ' A' ' 101' ' ' CYS . 50.9 mt -64.23 -49.28 81.88 Favored 'Isoleucine or valine' 0 C--O 1.234 0.256 0 CA-C-O 120.777 0.322 . . . . 0.0 110.56 174.893 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 35' ' ' ALA . . . . . 0.514 ' O ' ' HB3' ' A' ' 39' ' ' ALA . . . -66.02 -33.7 76.4 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 121.296 0.57 . . . . 0.0 110.218 178.528 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 36' ' ' GLY . . . . . 0.425 ' HA2' ' N ' ' A' ' 41' ' ' GLY . . . -71.61 -21.98 78.72 Favored Glycine 0 N--CA 1.448 -0.526 0 N-CA-C 111.101 -0.799 . . . . 0.0 111.101 176.892 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -76.19 -69.33 0.51 Allowed 'General case' 0 N--CA 1.448 -0.551 0 CA-C-N 115.291 -0.455 . . . . 0.0 111.536 -178.574 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 38' ' ' GLU . . . . . 0.678 ' HB2' ' SG ' ' A' ' 101' ' ' CYS . 15.3 tt0 -90.9 -32.99 15.79 Favored 'General case' 0 C--N 1.323 -0.572 0 C-N-CA 119.743 -0.783 . . . . 0.0 110.871 -171.455 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 39' ' ' ALA . . . . . 0.514 ' HB3' ' O ' ' A' ' 35' ' ' ALA . . . -84.46 -13.85 50.87 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.996 -178.855 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 74.89 20.5 79.44 Favored Glycine 0 CA--C 1.501 -0.839 0 N-CA-C 109.853 -1.299 . . . . 0.0 109.853 -179.472 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 41' ' ' GLY . . . . . 0.425 ' N ' ' HA2' ' A' ' 36' ' ' GLY . . . 72.2 64.03 2.77 Favored Glycine 0 N--CA 1.433 -1.564 0 CA-C-N 114.108 -1.046 . . . . 0.0 111.093 -172.837 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 42' ' ' ASN . . . . . 0.702 ' HB3' ' HB ' ' A' ' 45' ' ' ILE . 7.2 t-20 -140.99 84.21 1.92 Allowed 'General case' 0 C--N 1.322 -0.595 0 N-CA-C 108.815 -0.809 . . . . 0.0 108.815 -177.193 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 43' ' ' TRP . . . . . 0.762 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 37.0 m95 -73.65 -11.59 60.46 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 115.741 -0.663 . . . . 0.0 109.973 -177.922 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -106.6 14.38 27.08 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 115.37 -0.832 . . . . 0.0 111.406 179.583 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.732 HG22 ' HA2' ' A' ' 53' ' ' GLY . 9.0 tt -75.86 144.62 11.7 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.812 0 N-CA-C 109.695 -0.483 . . . . 0.0 109.695 179.83 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 21.7 t-20 -153.99 94.65 1.77 Allowed 'General case' 0 C--N 1.308 -1.208 0 CA-C-O 121.302 0.572 . . . . 0.0 110.38 -178.867 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 16.3 p -76.57 -19.56 57.76 Favored 'General case' 0 N--CA 1.445 -0.709 0 CA-C-N 115.225 -0.898 . . . . 0.0 110.718 178.925 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 87.85 24.02 36.78 Favored Glycine 0 N--CA 1.445 -0.759 0 N-CA-C 110.954 -0.859 . . . . 0.0 110.954 179.256 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 3.8 m-20 -97.54 14.4 26.66 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 121.065 0.459 . . . . 0.0 111.52 -174.259 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 50' ' ' GLY . . . . . 0.446 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 87.46 -16.03 51.4 Favored Glycine 0 N--CA 1.452 -0.28 0 CA-C-N 115.717 -0.674 . . . . 0.0 111.772 179.631 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 51' ' ' TYR . . . . . 0.748 ' CE1' ' HB2' ' A' ' 58' ' ' ASP . 0.3 OUTLIER -102.72 131.89 49.23 Favored 'General case' 0 N--CA 1.446 -0.66 0 N-CA-C 107.805 -1.183 . . . . 0.0 107.805 169.623 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 52' ' ' TYR . . . . . 0.735 ' CE1' ' HB2' ' A' ' 59' ' ' GLN . 15.0 m-85 -104.26 169.64 8.37 Favored 'General case' 0 C--N 1.311 -1.096 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.85 -173.184 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.732 ' HA2' HG22 ' A' ' 45' ' ' ILE . . . -51.91 158.09 3.1 Favored Glycine 0 CA--C 1.509 -0.326 0 N-CA-C 115.613 1.005 . . . . 0.0 115.613 -169.361 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.582 ' CA ' ' HA ' ' A' ' 43' ' ' TRP . . . 98.49 -113.05 4.62 Favored Glycine 0 N--CA 1.438 -1.168 0 CA-C-N 114.486 -0.857 . . . . 0.0 111.369 175.444 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.427 HG23 ' CD1' ' A' ' 57' ' ' PHE . 1.3 m -86.91 -6.09 10.45 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.73 0 CA-C-O 120.442 0.163 . . . . 0.0 110.82 178.38 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 56' ' ' GLN . . . . . 0.578 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 10.5 pt20 45.52 51.71 9.64 Favored 'General case' 0 N--CA 1.479 1.003 0 N-CA-C 114.502 1.297 . . . . 0.0 114.502 167.483 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 57' ' ' PHE . . . . . 0.578 ' O ' ' HB3' ' A' ' 58' ' ' ASP . 19.7 p90 -103.67 21.62 15.84 Favored 'General case' 0 C--N 1.328 -0.344 0 N-CA-C 113.25 0.833 . . . . 0.0 113.25 -176.071 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.748 ' HB2' ' CE1' ' A' ' 51' ' ' TYR . 0.4 OUTLIER 89.06 135.82 0.04 OUTLIER 'General case' 0 C--N 1.317 -0.838 0 C-N-CA 124.615 1.166 . . . . 0.0 111.953 168.399 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.735 ' HB2' ' CE1' ' A' ' 52' ' ' TYR . 5.4 tp60 -58.81 -34.23 71.27 Favored 'General case' 0 CA--C 1.512 -0.493 0 CA-C-N 114.195 -1.366 . . . . 0.0 110.932 -179.332 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -67.06 -44.05 89.05 Favored Glycine 0 N--CA 1.449 -0.463 0 C-N-CA 120.717 -0.754 . . . . 0.0 111.619 177.667 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 61' ' ' THR . . . . . 0.577 ' HB ' ' O ' ' A' ' 57' ' ' PHE . 89.5 m -71.02 -41.2 71.16 Favored 'General case' 0 N--CA 1.445 -0.685 0 CA-C-O 121.048 0.452 . . . . 0.0 110.324 178.023 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 62' ' ' TRP . . . . . 0.453 ' CH2' ' HA ' ' A' ' 74' ' ' ALA . 41.1 t-105 -55.57 -49.98 71.27 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.455 -0.793 . . . . 0.0 110.215 172.71 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 63' ' ' GLU . . . . . 0.485 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 3.7 tp10 -63.54 -40.34 96.75 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 115.437 -0.801 . . . . 0.0 110.555 179.512 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -61.39 -41.37 97.02 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.753 -0.658 . . . . 0.0 110.804 -177.486 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 65' ' ' ASN . . . . . 0.441 ' HB3' ' HB ' ' A' ' 88' ' ' VAL . 9.3 m120 -80.55 -9.6 59.77 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.439 178.358 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 66' ' ' GLY . . . . . 0.498 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 85.32 46.8 5.43 Favored Glycine 0 N--CA 1.449 -0.445 0 CA-C-N 115.736 -0.665 . . . . 0.0 112.689 175.716 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.613 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -78.95 -18.53 74.78 Favored Glycine 0 N--CA 1.442 -0.961 0 C-N-CA 120.868 -0.682 . . . . 0.0 112.429 -174.668 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.988 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 7.0 mp -60.12 -24.11 64.41 Favored 'General case' 0 N--CA 1.445 -0.688 0 N-CA-C 112.545 0.572 . . . . 0.0 112.545 -175.0 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 69' ' ' ARG . . . . . 0.498 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 9.1 ptp180 -67.2 -31.85 72.52 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 121.405 0.622 . . . . 0.0 109.771 175.933 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 70' ' ' TYR . . . . . 0.815 ' HB3' ' HB3' ' A' ' 81' ' ' GLU . 74.5 m-85 -81.47 -33.91 31.72 Favored 'General case' 0 N--CA 1.443 -0.814 0 N-CA-C 107.728 -1.212 . . . . 0.0 107.728 178.199 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.573 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 165.9 126.01 0.03 OUTLIER Pre-proline 0 CA--C 1.512 -0.517 0 CA-C-N 112.897 -1.956 . . . . 0.0 107.325 -179.011 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 72' ' ' PRO . . . . . 0.988 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 21.2 Cg_exo -56.91 -6.66 1.87 Allowed 'Trans proline' 0 C--N 1.333 -0.242 0 C-N-CA 122.495 2.13 . . . . 0.0 113.587 -179.412 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 13.9 ptm180 -143.85 137.49 27.97 Favored 'General case' 0 C--N 1.321 -0.671 0 N-CA-C 109.228 -0.656 . . . . 0.0 109.228 177.752 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 74' ' ' ALA . . . . . 0.473 ' HB3' ' HB2' ' A' ' 52' ' ' TYR . . . -60.14 -28.06 67.58 Favored 'General case' 0 C--O 1.218 -0.569 0 CA-C-N 114.999 -1.0 . . . . 0.0 111.916 -176.96 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 75' ' ' ASP . . . . . 0.538 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 20.7 p-10 -88.13 3.56 48.69 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 121.186 0.517 . . . . 0.0 111.761 -176.449 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 66.9 tp -100.57 -30.67 11.65 Favored 'General case' 0 C--N 1.321 -0.64 0 N-CA-C 108.29 -1.004 . . . . 0.0 108.29 168.637 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 77' ' ' ALA . . . . . 0.921 ' HB1' ' HB2' ' A' ' 81' ' ' GLU . . . -78.89 143.87 35.48 Favored 'General case' 0 N--CA 1.441 -0.914 0 CA-C-N 114.617 -1.174 . . . . 0.0 110.704 176.486 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 27.7 p -93.88 -170.55 2.35 Favored 'General case' 0 C--N 1.314 -0.969 0 CA-C-N 115.417 -0.811 . . . . 0.0 109.117 178.93 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 79' ' ' ARG . . . . . 0.762 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 57.0 mtp180 -48.53 -51.38 27.79 Favored 'General case' 0 C--N 1.33 -0.262 0 O-C-N 123.196 0.31 . . . . 0.0 111.001 -178.512 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 10.2 pt-20 -57.64 -48.28 79.9 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.856 -0.611 . . . . 0.0 112.264 -173.776 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 81' ' ' GLU . . . . . 0.921 ' HB2' ' HB1' ' A' ' 77' ' ' ALA . 16.9 mp0 -65.25 -51.09 63.04 Favored 'General case' 0 N--CA 1.452 -0.358 0 N-CA-C 112.056 0.391 . . . . 0.0 112.056 177.339 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 82' ' ' GLN . . . . . 0.661 ' HB2' ' HZ3' ' A' ' 43' ' ' TRP . 46.0 mt-30 -61.6 -38.64 88.34 Favored 'General case' 0 CA--C 1.51 -0.561 0 CA-C-O 120.754 0.312 . . . . 0.0 110.833 -175.426 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.641 ' O ' ' HG2' ' A' ' 87' ' ' GLU . 50.2 mt -59.34 -44.46 92.43 Favored 'Isoleucine or valine' 0 C--O 1.215 -0.715 0 CA-C-N 115.512 -0.767 . . . . 0.0 109.865 176.889 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 84' ' ' ALA . . . . . 0.684 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -66.01 -41.92 90.4 Favored 'General case' 0 C--O 1.237 0.441 0 CA-C-O 121.29 0.567 . . . . 0.0 111.571 -176.841 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.539 HG23 ' O ' ' A' ' 81' ' ' GLU . 14.8 t -69.12 -47.94 71.89 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.696 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.454 178.969 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -58.23 -28.67 65.09 Favored 'General case' 0 C--O 1.232 0.143 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.431 173.389 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 87' ' ' GLU . . . . . 0.773 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 20.2 mm-40 -59.15 -43.87 92.07 Favored 'General case' 0 CA--C 1.51 -0.589 0 CA-C-N 115.32 -0.855 . . . . 0.0 109.619 178.926 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.584 ' O ' ' HG3' ' A' ' 92' ' ' ARG . 40.6 t -63.1 -43.55 99.0 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 CA-C-O 121.293 0.568 . . . . 0.0 109.933 175.572 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 89' ' ' THR . . . . . 1.005 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 0.2 OUTLIER -62.61 -47.12 85.16 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.746 -0.661 . . . . 0.0 111.982 -176.016 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 90' ' ' ARG . . . . . 0.491 ' HB3' ' CH2' ' A' ' 31' ' ' TRP . 30.4 ptt85 -60.16 -29.39 68.63 Favored 'General case' 0 N--CA 1.467 0.381 0 CA-C-O 121.313 0.578 . . . . 0.0 110.448 -178.996 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 91' ' ' LEU . . . . . 0.773 ' HG ' ' O ' ' A' ' 87' ' ' GLU . 33.4 mt -66.97 -35.01 79.01 Favored 'General case' 0 C--N 1.314 -0.948 0 CA-C-O 121.406 0.622 . . . . 0.0 109.885 -179.918 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 92' ' ' ARG . . . . . 0.584 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 4.7 mtm180 -89.11 -51.54 5.54 Favored 'General case' 0 N--CA 1.443 -0.78 0 CA-C-N 115.348 -0.842 . . . . 0.0 110.13 -171.807 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 93' ' ' GLN . . . . . 0.51 HE22 ' HZ3' ' A' ' 98' ' ' TRP . 0.0 OUTLIER -108.72 -15.85 14.31 Favored 'General case' 0 N--CA 1.44 -0.946 0 CA-C-N 115.087 -0.96 . . . . 0.0 111.942 -173.151 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.478 ' HA2' ' O ' ' A' ' 90' ' ' ARG . . . 83.6 -107.41 2.93 Favored Glycine 0 CA--C 1.494 -1.232 0 N-CA-C 111.082 -0.807 . . . . 0.0 111.082 177.911 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 95' ' ' TRP . . . . . . . . . . . . . 3.5 m95 -142.81 27.32 1.66 Allowed 'General case' 0 C--N 1.313 -0.994 0 N-CA-C 106.901 -1.518 . . . . 0.0 106.901 179.813 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -79.19 -22.46 65.38 Favored Glycine 0 N--CA 1.448 -0.546 0 CA-C-N 114.457 -1.247 . . . . 0.0 111.079 173.195 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 97' ' ' ALA . . . . . 0.418 ' O ' ' HD3' ' A' ' 99' ' ' PRO . . . -85.12 -32.16 22.92 Favored 'General case' 0 C--N 1.327 -0.373 0 N-CA-C 109.378 -0.601 . . . . 0.0 109.378 174.419 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 98' ' ' TRP . . . . . 1.005 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 16.9 m-90 -101.14 100.72 13.94 Favored Pre-proline 0 C--O 1.221 -0.441 0 N-CA-C 109.009 -0.737 . . . . 0.0 109.009 174.027 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 99' ' ' PRO . . . . . 0.418 ' HD3' ' O ' ' A' ' 97' ' ' ALA . 10.3 Cg_exo -79.33 -88.49 0.0 OUTLIER 'Trans proline' 0 CA--C 1.532 0.411 0 C-N-CA 122.848 2.365 . . . . 0.0 115.085 -171.828 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 63.3 t -69.96 -28.32 36.06 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.349 0 CA-C-O 121.679 0.752 . . . . 0.0 110.047 -172.461 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 101' ' ' CYS . . . . . 0.678 ' SG ' ' HB2' ' A' ' 38' ' ' GLU . 87.4 m -72.21 -27.25 62.42 Favored 'General case' 0 C--N 1.317 -0.84 0 CA-C-N 115.25 -0.887 . . . . 0.0 111.084 -176.759 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 102' ' ' ALA . . . . . 0.679 ' HB1' ' HB2' ' A' ' 107' ' ' ALA . . . -69.93 -40.41 75.55 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.808 0.337 . . . . 0.0 110.333 175.658 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -63.08 -37.81 88.68 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 121.432 0.634 . . . . 0.0 110.336 177.591 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -72.88 -30.62 64.1 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.243 -0.89 . . . . 0.0 111.686 177.363 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 105' ' ' ALA . . . . . 0.605 ' HB1' ' HA ' ' A' ' 30' ' ' ILE . . . -96.32 -22.58 17.11 Favored 'General case' 0 C--N 1.325 -0.457 0 N-CA-C 113.001 0.741 . . . . 0.0 113.001 -172.271 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 104.13 69.85 0.8 Allowed Glycine 0 CA--C 1.52 0.376 0 C-N-CA 120.832 -0.699 . . . . 0.0 112.134 -177.302 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 107' ' ' ALA . . . . . 0.679 ' HB2' ' HB1' ' A' ' 102' ' ' ALA . . . -60.02 146.7 41.78 Favored 'General case' 0 CA--C 1.517 -0.325 0 C-N-CA 122.709 0.403 . . . . 0.0 110.912 -179.899 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 97.3 mtt180 . . . . . 0 C--O 1.248 1.013 0 CA-C-O 118.323 -0.846 . . . . 0.0 111.021 -170.482 . . . . . . . . 0 0 . 1 . 021 nuclear build full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 93.5 m-20 . . . . . 0 N--CA 1.476 0.865 0 CA-C-O 121.562 0.696 . . . . 0.0 110.536 . . . . . . . . . 0 0 . 1 . 021 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 6.5 p -112.64 0.65 8.97 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.149 0 CA-C-N 114.976 -1.011 . . . . 0.0 109.599 176.441 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 9.0 p -58.07 139.14 18.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 115.116 -0.947 . . . . 0.0 111.144 176.937 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 2.8 p -61.11 142.53 15.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 121.362 0.601 . . . . 0.0 111.172 178.624 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 5' ' ' THR . . . . . 0.462 ' HA ' ' HD3' ' A' ' 6' ' ' PRO . 8.9 t -95.02 132.73 27.54 Favored Pre-proline 0 C--N 1.313 -1.001 0 CA-C-N 115.211 -0.904 . . . . 0.0 111.119 -174.107 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.462 ' HD3' ' HA ' ' A' ' 5' ' ' THR . 0.9 OUTLIER -83.6 179.48 4.88 Favored 'Trans proline' 0 N--CA 1.456 -0.682 0 C-N-CA 123.768 2.979 . . . . 0.0 111.945 175.614 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . 58.26 55.15 5.24 Favored 'General case' 0 C--N 1.318 -0.778 0 CA-C-N 114.632 -1.167 . . . . 0.0 111.664 -179.812 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 79.3 t60 -83.98 -9.59 58.56 Favored 'General case' 0 C--N 1.31 -1.113 0 CA-C-N 114.034 -1.439 . . . . 0.0 108.724 172.484 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 17.2 pt-20 -64.71 135.92 56.38 Favored 'General case' 0 N--CA 1.453 -0.304 0 CA-C-N 115.289 -0.869 . . . . 0.0 110.056 -179.601 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -104.13 66.88 0.84 Allowed 'General case' 0 C--N 1.319 -0.72 0 CA-C-O 122.035 0.921 . . . . 0.0 110.737 -173.388 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 47.9 t -82.83 -61.32 1.79 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.179 0 CA-C-N 114.215 -1.357 . . . . 0.0 109.449 173.431 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 5.9 p 32.74 84.09 0.01 OUTLIER 'Isoleucine or valine' 0 C--O 1.237 0.419 0 C-N-CA 124.953 1.301 . . . . 0.0 113.677 178.87 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 7.1 ttm180 63.68 140.77 0.02 OUTLIER 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 113.597 -1.638 . . . . 0.0 113.298 177.689 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.56 HG23 HG23 ' A' ' 20' ' ' THR . 3.0 t -103.72 160.38 4.67 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.981 0 N-CA-C 108.174 -1.047 . . . . 0.0 108.174 173.447 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -121.49 -54.71 0.22 Allowed Glycine 0 N--CA 1.433 -1.565 0 CA-C-N 115.423 -0.808 . . . . 0.0 111.638 -176.032 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.443 ' O ' ' HD3' ' A' ' 18' ' ' PRO . 20.8 m -65.51 -39.17 91.55 Favored 'General case' 0 C--N 1.312 -1.036 0 CA-C-N 114.555 -0.823 . . . . 0.0 110.755 178.722 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 17' ' ' LYS . . . . . 0.424 ' O ' ' HB ' ' A' ' 14' ' ' VAL . 27.1 mmtm -104.09 99.4 16.72 Favored Pre-proline 0 C--N 1.314 -0.969 0 CA-C-N 115.034 -0.985 . . . . 0.0 109.689 175.476 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 18' ' ' PRO . . . . . 0.443 ' HD3' ' O ' ' A' ' 16' ' ' THR . 14.8 Cg_exo -71.46 155.48 59.69 Favored 'Trans proline' 0 N--CA 1.452 -0.954 0 C-N-CA 122.352 2.035 . . . . 0.0 110.964 176.051 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 84.61 51.2 3.94 Favored Glycine 0 C--N 1.299 -1.503 0 CA-C-N 114.86 -1.064 . . . . 0.0 110.895 -178.001 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 20' ' ' THR . . . . . 0.56 HG23 HG23 ' A' ' 14' ' ' VAL . 26.5 m -58.42 -41.35 84.79 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 121.697 0.76 . . . . 0.0 110.034 179.514 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 48.5 mt-10 -144.75 140.06 28.27 Favored 'General case' 0 N--CA 1.439 -0.98 0 N-CA-C 106.59 -1.633 . . . . 0.0 106.59 175.053 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.442 ' HA ' ' HD3' ' A' ' 23' ' ' PRO . 41.0 t -71.2 113.89 22.97 Favored Pre-proline 0 C--N 1.314 -0.961 0 N-CA-C 107.99 -1.115 . . . . 0.0 107.99 176.731 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.469 ' HA ' ' HD2' ' A' ' 24' ' ' PRO . 51.7 Cg_exo -53.74 125.89 20.09 Favored 'Trans proline' 0 C--N 1.345 0.362 0 C-N-CA 122.871 2.381 . . . . 0.0 113.672 -163.522 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 24' ' ' PRO . . . . . 0.469 ' HD2' ' HA ' ' A' ' 23' ' ' PRO . 10.3 Cg_endo -57.12 140.13 91.89 Favored 'Trans proline' 0 N--CA 1.447 -1.22 0 C-N-CA 123.186 2.591 . . . . 0.0 111.538 172.93 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.616 ' HB ' ' CG2' ' A' ' 83' ' ' ILE . 60.4 t -115.2 137.0 50.12 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.359 0 CA-C-N 114.722 -1.126 . . . . 0.0 109.119 179.567 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 34.9 mm -61.08 -23.81 31.12 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-N 115.409 -0.814 . . . . 0.0 112.171 -170.65 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.446 ' O ' HG12 ' A' ' 30' ' ' ILE . 19.4 m-20 -99.05 2.94 46.64 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-O 121.441 0.639 . . . . 0.0 109.791 -177.196 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 28' ' ' GLY . . . . . 0.412 ' HA3' HD13 ' A' ' 83' ' ' ILE . . . -64.3 -11.54 47.05 Favored Glycine 0 CA--C 1.503 -0.656 0 CA-C-N 114.961 -1.018 . . . . 0.0 111.051 179.635 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 4.4 m -75.73 -41.27 53.85 Favored 'General case' 0 C--N 1.318 -0.794 0 CA-C-O 121.956 0.884 . . . . 0.0 109.116 177.225 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.547 ' HA ' ' HB1' ' A' ' 105' ' ' ALA . 0.9 OUTLIER -67.91 -38.99 80.94 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.726 0 CA-C-N 113.898 -1.501 . . . . 0.0 107.735 178.423 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 31' ' ' TRP . . . . . 0.522 ' HB2' HG12 ' A' ' 83' ' ' ILE . 32.6 m95 -67.98 -35.96 79.23 Favored 'General case' 0 C--N 1.317 -0.845 0 CA-C-N 114.472 -1.24 . . . . 0.0 110.619 -177.684 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.84 ' HB2' HH21 ' A' ' 79' ' ' ARG . 23.3 t70 -73.07 -37.59 66.74 Favored 'General case' 0 N--CA 1.446 -0.654 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.44 -179.349 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 33' ' ' ALA . . . . . 0.513 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -70.99 -34.15 71.1 Favored 'General case' 0 N--CA 1.446 -0.632 0 C-N-CA 120.707 -0.397 . . . . 0.0 110.787 176.494 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 34' ' ' ILE . . . . . 0.53 HG13 ' O ' ' A' ' 30' ' ' ILE . 61.1 mt -67.34 -46.89 82.76 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.283 0 CA-C-O 121.108 0.48 . . . . 0.0 110.701 175.201 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 35' ' ' ALA . . . . . 0.468 ' O ' ' HB3' ' A' ' 39' ' ' ALA . . . -63.19 -34.39 77.54 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.408 178.108 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -72.63 -15.01 77.67 Favored Glycine 0 N--CA 1.449 -0.491 0 N-CA-C 111.181 -0.768 . . . . 0.0 111.181 176.729 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.448 ' HB3' ' O ' ' A' ' 34' ' ' ILE . 41.3 t -87.18 -64.5 1.14 Allowed 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.296 -0.452 . . . . 0.0 111.292 -176.702 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 38' ' ' GLU . . . . . 0.803 ' HG3' ' SG ' ' A' ' 101' ' ' CYS . 40.8 mt-10 -88.94 -29.62 19.42 Favored 'General case' 0 CA--C 1.516 -0.357 0 CA-C-O 120.813 0.34 . . . . 0.0 111.784 -173.277 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 39' ' ' ALA . . . . . 0.468 ' HB3' ' O ' ' A' ' 35' ' ' ALA . . . -92.72 -11.33 34.26 Favored 'General case' 0 C--N 1.322 -0.619 0 C-N-CA 120.455 -0.498 . . . . 0.0 111.316 -176.956 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 76.24 15.52 81.39 Favored Glycine 0 N--CA 1.446 -0.664 0 N-CA-C 109.782 -1.327 . . . . 0.0 109.782 -176.229 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 75.11 51.68 7.4 Favored Glycine 0 N--CA 1.436 -1.339 0 CA-C-N 114.268 -0.966 . . . . 0.0 111.939 -176.449 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 2.2 t-20 -140.67 100.1 3.78 Favored 'General case' 0 N--CA 1.448 -0.542 0 N-CA-C 108.855 -0.795 . . . . 0.0 108.855 179.947 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 43' ' ' TRP . . . . . 0.729 ' CE3' ' HA ' ' A' ' 79' ' ' ARG . 30.9 m95 -82.78 -12.69 57.31 Favored 'General case' 0 C--N 1.313 -1.009 0 CA-C-N 115.241 -0.891 . . . . 0.0 110.529 -172.846 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -104.61 10.99 34.7 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 115.455 -0.793 . . . . 0.0 111.272 -178.145 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.699 HG22 ' HA2' ' A' ' 53' ' ' GLY . 4.0 tt -74.04 143.72 13.28 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.655 0 CA-C-O 121.0 0.429 . . . . 0.0 109.915 179.507 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 3.8 t30 -142.75 87.22 1.98 Allowed 'General case' 0 C--N 1.313 -0.989 0 CA-C-O 121.286 0.565 . . . . 0.0 109.567 -179.171 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 22.7 p -74.12 -24.57 59.47 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.648 179.983 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 92.43 19.57 37.94 Favored Glycine 0 N--CA 1.445 -0.709 0 N-CA-C 110.824 -0.91 . . . . 0.0 110.824 -177.913 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 64.8 t30 -74.94 -7.31 53.19 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 121.384 0.611 . . . . 0.0 111.12 -174.635 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 50' ' ' GLY . . . . . 0.498 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 95.73 -12.94 67.03 Favored Glycine 0 CA--C 1.504 -0.643 0 N-CA-C 109.47 -1.452 . . . . 0.0 109.47 -173.252 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 51' ' ' TYR . . . . . 0.629 ' HA ' ' HA ' ' A' ' 58' ' ' ASP . 0.5 OUTLIER -114.74 160.9 18.86 Favored 'General case' 0 N--CA 1.439 -0.984 0 N-CA-C 106.132 -1.803 . . . . 0.0 106.132 173.187 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 52' ' ' TYR . . . . . 0.687 ' HB2' ' HB3' ' A' ' 74' ' ' ALA . 55.5 m-85 -123.51 169.4 11.44 Favored 'General case' 0 C--N 1.308 -1.207 0 C-N-CA 120.085 -0.646 . . . . 0.0 111.403 -169.702 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.699 ' HA2' HG22 ' A' ' 45' ' ' ILE . . . -59.31 171.34 5.25 Favored Glycine 0 N--CA 1.445 -0.724 0 O-C-N 123.778 0.674 . . . . 0.0 113.821 -173.212 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.707 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 87.79 -107.78 3.33 Favored Glycine 0 N--CA 1.44 -1.09 0 C-N-CA 120.708 -0.758 . . . . 0.0 111.77 -179.391 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.524 ' HB ' ' CD1' ' A' ' 57' ' ' PHE . 2.0 t -84.6 0.58 5.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.542 0 CA-C-O 121.276 0.56 . . . . 0.0 110.277 -177.555 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 56' ' ' GLN . . . . . 0.585 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 12.4 mm100 58.05 44.59 19.16 Favored 'General case' 0 N--CA 1.462 0.164 0 CA-C-N 114.971 -1.013 . . . . 0.0 113.169 170.886 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 57' ' ' PHE . . . . . 0.524 ' CD1' ' HB ' ' A' ' 55' ' ' VAL . 1.6 p90 -118.98 164.26 15.72 Favored 'General case' 0 C--N 1.325 -0.472 0 C-N-CA 119.435 -0.906 . . . . 0.0 111.914 177.301 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.629 ' HA ' ' HA ' ' A' ' 51' ' ' TYR . 7.9 p-10 -74.81 165.57 25.03 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 114.985 -1.007 . . . . 0.0 113.685 -163.512 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.439 ' HB2' ' HE1' ' A' ' 52' ' ' TYR . 19.5 tp60 -59.26 -41.95 90.04 Favored 'General case' 0 N--CA 1.438 -1.044 0 CA-C-N 114.538 -1.21 . . . . 0.0 110.945 178.184 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -68.1 -49.45 46.89 Favored Glycine 0 C--O 1.225 -0.45 0 CA-C-N 115.617 -0.719 . . . . 0.0 112.614 -172.35 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 86.7 m -62.25 -42.37 99.26 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-O 121.098 0.475 . . . . 0.0 110.761 178.624 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 62' ' ' TRP . . . . . 0.501 ' CH2' ' HA ' ' A' ' 74' ' ' ALA . 53.4 t-105 -56.62 -51.25 69.41 Favored 'General case' 0 N--CA 1.448 -0.565 0 CA-C-N 115.133 -0.94 . . . . 0.0 109.39 175.323 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 63' ' ' GLU . . . . . 1.033 ' HG3' HD11 ' A' ' 68' ' ' LEU . 24.0 tt0 -64.43 -38.36 90.75 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-N 114.544 -1.207 . . . . 0.0 111.275 -177.606 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -67.71 -42.39 82.03 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.935 -0.575 . . . . 0.0 111.424 -175.027 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 65' ' ' ASN . . . . . 0.624 HD22 ' N ' ' A' ' 65' ' ' ASN . 0.7 OUTLIER -77.96 -8.85 58.69 Favored 'General case' 0 N--CA 1.451 -0.405 0 CA-C-O 121.316 0.579 . . . . 0.0 109.672 176.812 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 66' ' ' GLY . . . . . 0.524 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 90.17 47.71 3.76 Favored Glycine 0 N--CA 1.449 -0.498 0 CA-C-N 115.438 -0.801 . . . . 0.0 112.417 173.386 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.545 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -80.47 -16.39 76.01 Favored Glycine 0 N--CA 1.444 -0.813 0 C-N-CA 120.876 -0.678 . . . . 0.0 112.065 -177.14 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 1.033 HD11 ' HG3' ' A' ' 63' ' ' GLU . 20.8 mt -65.53 -28.58 69.27 Favored 'General case' 0 C--N 1.314 -0.937 0 CA-C-O 120.999 0.428 . . . . 0.0 111.351 -171.06 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 69' ' ' ARG . . . . . 0.524 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 11.7 ptm180 -65.04 -31.69 73.04 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.217 175.379 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 70' ' ' TYR . . . . . 0.796 ' HB3' ' HB3' ' A' ' 81' ' ' GLU . 89.9 m-85 -77.4 -34.61 54.79 Favored 'General case' 0 CA--C 1.505 -0.755 0 N-CA-C 107.723 -1.214 . . . . 0.0 107.723 178.328 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.582 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 164.65 123.57 0.02 OUTLIER Pre-proline 0 C--N 1.319 -0.724 0 CA-C-N 112.125 -2.307 . . . . 0.0 106.859 -178.232 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 72' ' ' PRO . . . . . 0.59 ' HA ' ' HA ' ' A' ' 68' ' ' LEU . 38.6 Cg_exo -51.76 -6.48 0.17 Allowed 'Trans proline' 0 CA--C 1.53 0.282 0 C-N-CA 123.16 2.573 . . . . 0.0 114.393 -178.513 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 9.2 ptm180 -146.85 142.67 27.91 Favored 'General case' 0 C--N 1.315 -0.91 0 N-CA-C 108.825 -0.805 . . . . 0.0 108.825 174.905 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 74' ' ' ALA . . . . . 0.687 ' HB3' ' HB2' ' A' ' 52' ' ' TYR . . . -58.35 -33.08 69.15 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.679 -0.691 . . . . 0.0 112.753 -177.129 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 75' ' ' ASP . . . . . 0.572 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 4.3 p-10 -80.28 -10.22 59.75 Favored 'General case' 0 C--N 1.331 -0.231 0 C-N-CA 120.668 -0.413 . . . . 0.0 111.247 -173.931 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.477 ' HB3' ' HB1' ' A' ' 71' ' ' ALA . 62.5 tp -87.23 -32.49 19.74 Favored 'General case' 0 C--N 1.323 -0.552 0 N-CA-C 108.869 -0.789 . . . . 0.0 108.869 173.66 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 77' ' ' ALA . . . . . 0.837 ' HB1' ' HB2' ' A' ' 81' ' ' GLU . . . -82.22 161.08 22.84 Favored 'General case' 0 N--CA 1.442 -0.853 0 CA-C-N 114.98 -1.009 . . . . 0.0 110.371 176.171 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 20.0 p -100.59 -170.59 1.88 Allowed 'General case' 0 C--N 1.316 -0.876 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.088 179.127 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 79' ' ' ARG . . . . . 0.84 HH21 ' HB2' ' A' ' 32' ' ' ASP . 39.1 mtp180 -48.98 -53.48 19.66 Favored 'General case' 0 CA--C 1.515 -0.391 0 O-C-N 123.498 0.499 . . . . 0.0 111.005 -177.044 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 2.5 pt-20 -60.91 -42.47 98.16 Favored 'General case' 0 C--N 1.315 -0.928 0 CA-C-N 114.972 -1.013 . . . . 0.0 112.895 -171.486 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 81' ' ' GLU . . . . . 0.837 ' HB2' ' HB1' ' A' ' 77' ' ' ALA . 9.1 mp0 -63.38 -50.67 68.99 Favored 'General case' 0 N--CA 1.455 -0.196 0 CA-C-N 118.194 0.452 . . . . 0.0 111.491 175.163 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 82' ' ' GLN . . . . . 0.6 ' HB2' ' HZ3' ' A' ' 43' ' ' TRP . 48.0 mt-30 -61.87 -36.79 82.3 Favored 'General case' 0 CA--C 1.515 -0.369 0 CA-C-O 121.122 0.487 . . . . 0.0 110.309 -177.673 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.616 ' CG2' ' HB ' ' A' ' 25' ' ' VAL . 33.8 mt -59.4 -44.0 91.61 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.686 0 CA-C-N 114.982 -1.008 . . . . 0.0 109.973 177.119 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 84' ' ' ALA . . . . . 0.616 ' O ' ' HG3' ' A' ' 87' ' ' GLU . . . -66.57 -45.38 79.49 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 116.038 -0.528 . . . . 0.0 111.47 -179.503 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.518 HG23 ' O ' ' A' ' 81' ' ' GLU . 40.1 t -67.73 -50.21 62.56 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-N 116.305 -0.407 . . . . 0.0 112.018 -179.343 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -63.67 -30.96 71.99 Favored 'General case' 0 N--CA 1.449 -0.502 0 CA-C-O 121.002 0.43 . . . . 0.0 110.542 178.962 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 87' ' ' GLU . . . . . 0.616 ' HG3' ' O ' ' A' ' 84' ' ' ALA . 0.1 OUTLIER -70.36 -29.97 66.78 Favored 'General case' 0 C--N 1.325 -0.489 0 C-N-CA 120.418 -0.513 . . . . 0.0 110.438 -177.788 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 53.8 t -62.31 -43.31 97.92 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.258 0 N-CA-C 108.831 -0.803 . . . . 0.0 108.831 170.479 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 89' ' ' THR . . . . . 0.704 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 0.6 OUTLIER -65.67 -43.22 89.98 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 115.232 -0.895 . . . . 0.0 110.689 -177.971 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 90' ' ' ARG . . . . . 0.601 ' HG3' ' O ' ' A' ' 87' ' ' GLU . 4.2 ppt_? -66.37 -33.52 75.89 Favored 'General case' 0 CA--C 1.513 -0.47 0 N-CA-C 109.213 -0.662 . . . . 0.0 109.213 -178.929 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 91' ' ' LEU . . . . . 0.464 ' HB2' ' O ' ' A' ' 87' ' ' GLU . 2.2 tm? -57.21 -34.8 68.91 Favored 'General case' 0 C--N 1.318 -0.786 0 CA-C-N 114.386 -1.279 . . . . 0.0 110.095 -174.931 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 92' ' ' ARG . . . . . 0.497 ' HE ' ' HB2' ' A' ' 92' ' ' ARG . 3.4 mtm180 -92.49 -39.9 11.13 Favored 'General case' 0 C--N 1.315 -0.934 0 CA-C-N 115.18 -0.918 . . . . 0.0 109.91 -172.227 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 93' ' ' GLN . . . . . 0.49 ' NE2' HG22 ' A' ' 89' ' ' THR . 7.5 pt20 -94.63 -30.73 14.18 Favored 'General case' 0 C--N 1.316 -0.871 0 CA-C-N 114.27 -1.332 . . . . 0.0 113.777 -169.335 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 86.17 32.46 17.03 Favored Glycine 0 CA--C 1.52 0.345 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.619 178.207 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 95' ' ' TRP . . . . . 0.453 ' CE2' ' HD3' ' A' ' 90' ' ' ARG . 13.5 m95 66.82 16.27 10.33 Favored 'General case' 0 N--CA 1.466 0.355 0 C-N-CA 123.395 0.678 . . . . 0.0 110.085 178.095 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -63.94 -41.69 98.59 Favored Glycine 0 CA--C 1.519 0.326 0 CA-C-N 115.461 -0.79 . . . . 0.0 113.65 -179.852 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 97' ' ' ALA . . . . . 0.47 ' O ' ' HD3' ' A' ' 99' ' ' PRO . . . -78.59 -21.62 48.3 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 117.072 0.436 . . . . 0.0 111.259 -178.456 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 98' ' ' TRP . . . . . 0.704 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 16.3 m-90 -85.54 104.53 5.2 Favored Pre-proline 0 C--O 1.225 -0.226 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 170.118 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 99' ' ' PRO . . . . . 0.47 ' HD3' ' O ' ' A' ' 97' ' ' ALA . 11.7 Cg_exo -76.28 -95.59 0.01 OUTLIER 'Trans proline' 0 N--CA 1.457 -0.648 0 C-N-CA 122.435 2.09 . . . . 0.0 115.087 -171.275 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 100' ' ' VAL . . . . . 0.424 ' H ' ' HB2' ' A' ' 99' ' ' PRO . 38.3 t -71.32 -30.09 38.49 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.445 0 CA-C-O 121.72 0.771 . . . . 0.0 110.411 -169.07 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 101' ' ' CYS . . . . . 0.803 ' SG ' ' HG3' ' A' ' 38' ' ' GLU . 60.8 m -81.8 -25.66 35.04 Favored 'General case' 0 C--N 1.316 -0.855 0 CA-C-N 115.193 -0.912 . . . . 0.0 111.363 -169.722 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 102' ' ' ALA . . . . . 0.453 ' HB1' ' HB2' ' A' ' 107' ' ' ALA . . . -69.82 -45.21 68.39 Favored 'General case' 0 C--N 1.33 -0.276 0 N-CA-C 110.04 -0.355 . . . . 0.0 110.04 176.502 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -61.96 -39.34 91.78 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 121.307 0.575 . . . . 0.0 110.63 177.512 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 12.5 mtp180 -66.09 -39.02 89.66 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.438 -0.801 . . . . 0.0 111.476 177.405 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 105' ' ' ALA . . . . . 0.547 ' HB1' ' HA ' ' A' ' 30' ' ' ILE . . . -83.56 -22.07 32.47 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 112.583 0.586 . . . . 0.0 112.583 -174.026 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 107.71 61.05 0.56 Allowed Glycine 0 CA--C 1.521 0.459 0 C-N-CA 121.035 -0.602 . . . . 0.0 112.506 -179.56 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 107' ' ' ALA . . . . . 0.453 ' HB2' ' HB1' ' A' ' 102' ' ' ALA . . . -62.45 149.22 43.28 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 121.037 0.446 . . . . 0.0 111.528 -176.342 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 108' ' ' ARG . . . . . 0.405 ' CZ ' HD11 ' A' ' 30' ' ' ILE . 92.6 mtt180 . . . . . 0 C--O 1.249 1.067 0 CA-C-N 115.628 -0.715 . . . . 0.0 110.57 -172.596 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 91.7 m-20 . . . . . 0 N--CA 1.479 1.019 0 N-CA-C 110.045 -0.354 . . . . 0.0 110.045 . . . . . . . . . 0 0 . 1 . 022 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 54.2 t -82.33 -54.73 8.98 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.508 178.804 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 3' ' ' VAL . . . . . 0.465 ' O ' HG12 ' A' ' 4' ' ' VAL . 56.7 t -92.91 107.03 18.58 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.797 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.324 -179.254 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.476 HG22 ' H ' ' A' ' 5' ' ' THR . 2.4 p 50.97 165.97 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.535 0.366 0 N-CA-C 115.08 1.511 . . . . 0.0 115.08 176.081 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 5' ' ' THR . . . . . 0.509 ' HA ' ' HD3' ' A' ' 6' ' ' PRO . 2.5 p -104.71 126.73 30.5 Favored Pre-proline 0 C--N 1.314 -0.943 0 CA-C-N 113.552 -1.658 . . . . 0.0 109.91 175.965 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.509 ' HD3' ' HA ' ' A' ' 5' ' ' THR . 16.9 Cg_exo -68.21 173.94 8.78 Favored 'Trans proline' 0 CA--C 1.513 -0.526 0 C-N-CA 123.231 2.621 . . . . 0.0 112.436 -178.34 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . 61.3 76.84 0.35 Allowed 'General case' 0 C--N 1.315 -0.924 0 CA-C-N 114.031 -1.44 . . . . 0.0 111.73 -177.297 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 9.9 t-160 -105.89 8.1 32.49 Favored 'General case' 0 C--N 1.314 -0.97 0 CA-C-N 114.12 -1.4 . . . . 0.0 107.796 171.981 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 10.5 pt-20 -47.88 147.28 2.06 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 113.871 -1.513 . . . . 0.0 112.419 178.913 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -109.08 67.97 0.67 Allowed 'General case' 0 C--N 1.318 -0.767 0 CA-C-O 122.049 0.928 . . . . 0.0 110.183 -176.18 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 12.0 p -65.11 -27.11 41.46 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.017 0 CA-C-N 113.953 -1.476 . . . . 0.0 109.929 174.844 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 6.1 p 35.21 91.7 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.239 0.514 0 C-N-CA 125.43 1.492 . . . . 0.0 114.675 173.986 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 13' ' ' ARG . . . . . 0.407 HH11 ' HD2' ' A' ' 13' ' ' ARG . 47.8 mtm180 -71.72 113.19 8.5 Favored 'General case' 0 N--CA 1.429 -1.525 0 CA-C-N 113.748 -1.569 . . . . 0.0 108.1 170.791 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.5 p -37.81 119.0 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.813 0 CA-C-N 114.039 -1.437 . . . . 0.0 113.87 -172.27 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -145.68 60.34 0.49 Allowed Glycine 0 N--CA 1.43 -1.703 0 CA-C-N 113.531 -1.668 . . . . 0.0 111.008 177.406 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 90.1 m -98.48 -22.14 16.17 Favored 'General case' 0 C--N 1.312 -1.046 0 CA-C-N 114.458 -0.871 . . . . 0.0 110.404 -175.902 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 17' ' ' LYS . . . . . 0.565 ' HG2' ' O ' ' A' ' 76' ' ' LEU . 0.0 OUTLIER 50.81 87.47 0.13 Allowed Pre-proline 0 C--N 1.321 -0.674 0 CA-C-N 115.001 -1.0 . . . . 0.0 112.008 -178.763 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 26.2 Cg_exo -42.45 111.43 0.2 Allowed 'Trans proline' 0 CA--C 1.508 -0.788 0 C-N-CA 123.595 2.864 . . . . 0.0 112.741 176.084 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 154.18 55.76 0.01 OUTLIER Glycine 0 C--N 1.299 -1.478 0 CA-C-N 113.058 -1.883 . . . . 0.0 110.178 -174.028 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 3.9 m -57.2 -40.3 77.16 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 114.525 -0.837 . . . . 0.0 111.912 -173.734 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 42.1 mt-10 -117.33 82.28 1.79 Allowed 'General case' 0 CA--C 1.512 -0.499 0 CA-C-O 121.708 0.766 . . . . 0.0 111.634 177.863 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 3.3 p -75.65 123.97 88.62 Favored Pre-proline 0 C--N 1.307 -1.272 0 CA-C-N 114.282 -1.326 . . . . 0.0 110.017 174.471 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_exo -55.19 126.82 23.83 Favored 'Trans proline' 0 C--O 1.235 0.348 0 C-N-CA 122.6 2.2 . . . . 0.0 112.699 -178.554 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_exo -57.26 141.28 94.58 Favored 'Trans proline' 0 N--CA 1.443 -1.497 0 C-N-CA 123.263 2.642 . . . . 0.0 112.851 175.487 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 33.6 t -100.75 157.59 4.12 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.171 0 CA-C-N 114.665 -1.152 . . . . 0.0 108.68 176.782 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 49.6 mm -55.32 -39.27 51.45 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-O 121.013 0.435 . . . . 0.0 111.586 -170.874 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.479 ' O ' HG12 ' A' ' 30' ' ' ILE . 7.6 m-20 -111.25 9.08 21.72 Favored 'General case' 0 C--N 1.318 -0.785 0 CA-C-O 121.749 0.785 . . . . 0.0 109.397 -178.908 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -69.92 -5.31 51.9 Favored Glycine 0 N--CA 1.441 -1.004 0 CA-C-N 114.702 -1.136 . . . . 0.0 110.802 178.701 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 12.5 m -76.86 -42.95 38.0 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-O 121.813 0.816 . . . . 0.0 109.11 174.512 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.695 ' HA ' ' HB1' ' A' ' 105' ' ' ALA . 0.4 OUTLIER -66.58 -38.75 82.3 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-N 114.274 -1.33 . . . . 0.0 107.728 178.426 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 31' ' ' TRP . . . . . 0.455 ' CZ2' ' HD3' ' A' ' 90' ' ' ARG . 26.3 m95 -70.05 -35.0 73.94 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 114.572 -1.195 . . . . 0.0 110.516 -178.395 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.401 ' HB2' HH21 ' A' ' 79' ' ' ARG . 32.5 t70 -76.14 -37.63 57.77 Favored 'General case' 0 N--CA 1.449 -0.518 0 CA-C-N 116.024 -0.534 . . . . 0.0 110.349 -179.095 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 33' ' ' ALA . . . . . 0.511 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -70.59 -34.06 71.75 Favored 'General case' 0 N--CA 1.45 -0.441 0 C-N-CA 120.792 -0.363 . . . . 0.0 110.647 177.417 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 34' ' ' ILE . . . . . 0.494 HG13 ' O ' ' A' ' 30' ' ' ILE . 74.6 mt -65.55 -45.11 93.48 Favored 'Isoleucine or valine' 0 C--O 1.234 0.252 0 CA-C-O 121.168 0.509 . . . . 0.0 109.841 173.113 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -58.45 -38.3 77.22 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.611 -0.722 . . . . 0.0 110.014 175.074 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 36' ' ' GLY . . . . . 0.408 ' HA2' ' N ' ' A' ' 41' ' ' GLY . . . -72.2 -12.31 76.0 Favored Glycine 0 N--CA 1.449 -0.456 0 CA-C-N 115.399 -0.819 . . . . 0.0 111.835 179.139 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 46.8 t -88.78 -62.77 1.41 Allowed 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 115.614 -0.293 . . . . 0.0 111.118 -178.249 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 38' ' ' GLU . . . . . 0.416 ' HG3' ' SG ' ' A' ' 101' ' ' CYS . 34.2 mt-10 -90.0 -33.37 16.39 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 120.969 0.414 . . . . 0.0 111.185 -174.107 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -93.78 -8.57 40.24 Favored 'General case' 0 N--CA 1.45 -0.471 0 C-N-CA 120.547 -0.461 . . . . 0.0 111.763 -174.755 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 79.71 7.16 88.71 Favored Glycine 0 CA--C 1.505 -0.579 0 N-CA-C 110.26 -1.136 . . . . 0.0 110.26 -178.106 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 41' ' ' GLY . . . . . 0.408 ' N ' ' HA2' ' A' ' 36' ' ' GLY . . . 81.76 50.78 4.81 Favored Glycine 0 N--CA 1.435 -1.374 0 CA-C-N 114.324 -0.938 . . . . 0.0 112.656 -178.537 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 44.7 t-20 -144.26 128.56 17.82 Favored 'General case' 0 N--CA 1.441 -0.9 0 N-CA-C 107.871 -1.159 . . . . 0.0 107.871 178.256 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 43' ' ' TRP . . . . . 0.791 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 17.6 m95 -103.38 0.41 31.25 Favored 'General case' 0 C--N 1.306 -1.304 0 CA-C-N 115.589 -0.732 . . . . 0.0 110.313 -173.549 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -112.55 -2.47 14.61 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-N 115.4 -0.818 . . . . 0.0 111.011 178.396 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 10.0 tt -66.6 143.4 15.63 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.79 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.078 177.991 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 2.4 t30 -143.59 91.68 2.27 Favored 'General case' 0 C--N 1.317 -0.83 0 CA-C-O 121.471 0.653 . . . . 0.0 109.334 -179.077 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -73.69 -19.17 60.9 Favored 'General case' 0 N--CA 1.437 -1.085 0 CA-C-N 115.065 -0.971 . . . . 0.0 110.555 177.51 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 82.88 23.01 56.82 Favored Glycine 0 N--CA 1.445 -0.732 0 CA-C-N 115.51 -0.768 . . . . 0.0 111.247 174.315 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 4.6 p-10 -93.5 15.38 16.11 Favored 'General case' 0 C--N 1.325 -0.5 0 N-CA-C 112.247 0.462 . . . . 0.0 112.247 -172.073 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 50' ' ' GLY . . . . . 0.498 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 95.06 -13.51 66.91 Favored Glycine 0 CA--C 1.508 -0.358 0 N-CA-C 110.789 -0.925 . . . . 0.0 110.789 178.859 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 51' ' ' TYR . . . . . 0.498 ' HD1' ' C ' ' A' ' 50' ' ' GLY . 0.1 OUTLIER -121.52 161.58 22.06 Favored 'General case' 0 N--CA 1.441 -0.881 0 N-CA-C 105.286 -2.116 . . . . 0.0 105.286 174.483 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 52' ' ' TYR . . . . . 0.736 ' O ' ' HA ' ' A' ' 56' ' ' GLN . 20.8 m-85 -126.97 167.85 15.33 Favored 'General case' 0 C--N 1.302 -1.487 0 C-N-CA 119.621 -0.832 . . . . 0.0 111.231 -169.827 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -55.31 164.18 4.1 Favored Glycine 0 N--CA 1.446 -0.689 0 O-C-N 123.881 0.738 . . . . 0.0 114.105 -175.852 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.616 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 97.1 -112.99 4.59 Favored Glycine 0 N--CA 1.439 -1.155 0 N-CA-C 111.421 -0.672 . . . . 0.0 111.421 -176.423 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.59 HG12 ' HE1' ' A' ' 98' ' ' TRP . 2.2 t -84.81 -3.5 8.13 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 CA-C-O 121.826 0.822 . . . . 0.0 109.783 -178.418 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 56' ' ' GLN . . . . . 0.736 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 37.8 tt0 50.36 50.57 18.47 Favored 'General case' 0 N--CA 1.463 0.213 0 CA-C-N 113.774 -1.557 . . . . 0.0 113.498 173.314 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 57' ' ' PHE . . . . . 0.458 ' CD1' ' HB ' ' A' ' 55' ' ' VAL . 2.8 p90 -113.41 159.35 19.55 Favored 'General case' 0 C--N 1.321 -0.64 0 C-N-CA 119.925 -0.71 . . . . 0.0 110.684 171.668 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.433 ' HA ' ' HA ' ' A' ' 51' ' ' TYR . 5.9 p-10 -71.29 157.75 37.57 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-O 121.75 0.786 . . . . 0.0 112.869 -163.922 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.481 ' HB2' ' CE2' ' A' ' 52' ' ' TYR . 6.7 tp60 -55.8 -35.75 66.65 Favored 'General case' 0 N--CA 1.447 -0.603 0 CA-C-N 114.193 -1.367 . . . . 0.0 111.371 178.944 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -68.12 -49.75 44.7 Favored Glycine 0 N--CA 1.45 -0.407 0 CA-C-N 115.572 -0.74 . . . . 0.0 112.155 -175.896 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 51.3 m -65.19 -41.23 94.76 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-O 121.113 0.482 . . . . 0.0 110.595 176.447 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 62' ' ' TRP . . . . . 0.611 ' CZ3' ' HG2' ' A' ' 82' ' ' GLN . 54.5 t-105 -56.5 -48.89 76.23 Favored 'General case' 0 N--CA 1.448 -0.531 0 CA-C-N 115.493 -0.776 . . . . 0.0 109.389 175.833 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 63' ' ' GLU . . . . . 0.457 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 34.9 tt0 -68.25 -32.49 72.71 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 115.105 -0.952 . . . . 0.0 111.217 -179.505 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -65.53 -41.21 93.34 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.991 -0.549 . . . . 0.0 110.711 -178.552 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 65' ' ' ASN . . . . . 0.52 ' HB2' HG13 ' A' ' 85' ' ' VAL . 5.9 m120 -81.13 -8.07 59.69 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.45 0.643 . . . . 0.0 109.862 175.239 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 66' ' ' GLY . . . . . 0.412 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 80.74 50.26 5.34 Favored Glycine 0 N--CA 1.449 -0.454 0 CA-C-N 115.031 -0.986 . . . . 0.0 112.828 174.903 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.602 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -78.58 -18.55 75.46 Favored Glycine 0 N--CA 1.442 -0.966 0 C-N-CA 120.957 -0.64 . . . . 0.0 112.086 -176.499 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.933 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 7.0 mp -60.34 -20.2 58.4 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 111.994 0.368 . . . . 0.0 111.994 -176.09 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 69' ' ' ARG . . . . . 0.412 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 9.9 ptm180 -70.57 -31.86 69.05 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-O 121.253 0.549 . . . . 0.0 109.823 177.238 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 70' ' ' TYR . . . . . 0.602 ' HD2' ' HA2' ' A' ' 67' ' ' GLY . 43.8 m-85 -85.3 -34.0 21.99 Favored 'General case' 0 N--CA 1.438 -1.04 0 N-CA-C 107.71 -1.218 . . . . 0.0 107.71 178.239 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.511 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 170.69 122.06 0.05 OUTLIER Pre-proline 0 N--CA 1.45 -0.454 0 CA-C-N 113.247 -1.797 . . . . 0.0 107.83 -177.301 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 72' ' ' PRO . . . . . 0.933 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 25.1 Cg_exo -55.34 -7.94 1.48 Allowed 'Trans proline' 0 C--N 1.334 -0.192 0 C-N-CA 123.01 2.473 . . . . 0.0 113.789 -178.737 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 13.4 ptm180 -142.99 136.86 28.88 Favored 'General case' 0 C--N 1.317 -0.825 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 177.461 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 74' ' ' ALA . . . . . 0.618 ' HB3' ' HB2' ' A' ' 52' ' ' TYR . . . -60.22 -28.11 67.74 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.199 -0.91 . . . . 0.0 112.238 -175.351 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 75' ' ' ASP . . . . . 0.587 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 19.5 p-10 -84.79 -8.99 58.6 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 121.072 0.463 . . . . 0.0 111.344 -176.712 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.565 ' O ' ' HG2' ' A' ' 17' ' ' LYS . 57.2 tp -84.96 -32.36 23.07 Favored 'General case' 0 C--N 1.32 -0.682 0 N-CA-C 108.107 -1.071 . . . . 0.0 108.107 169.361 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 77' ' ' ALA . . . . . 0.953 ' HB1' ' HB2' ' A' ' 81' ' ' GLU . . . -77.93 154.23 31.82 Favored 'General case' 0 N--CA 1.44 -0.935 0 CA-C-N 114.953 -1.021 . . . . 0.0 110.851 177.071 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 78' ' ' THR . . . . . 0.562 ' H ' ' CD ' ' A' ' 81' ' ' GLU . 19.5 p -99.91 -169.89 1.81 Allowed 'General case' 0 C--N 1.315 -0.895 0 CA-C-N 115.656 -0.702 . . . . 0.0 109.552 176.786 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 79' ' ' ARG . . . . . 0.791 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 79.8 mtp180 -49.66 -51.41 38.22 Favored 'General case' 0 C--N 1.329 -0.31 0 O-C-N 123.418 0.449 . . . . 0.0 111.305 -176.974 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 80' ' ' GLU . . . . . 0.448 ' HG3' ' N ' ' A' ' 81' ' ' GLU . 10.0 pt-20 -60.87 -47.56 85.82 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 112.457 0.54 . . . . 0.0 112.457 -173.361 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 81' ' ' GLU . . . . . 0.953 ' HB2' ' HB1' ' A' ' 77' ' ' ALA . 4.4 mp0 -60.96 -50.64 72.59 Favored 'General case' 0 CA--C 1.518 -0.26 0 CA-C-O 121.064 0.459 . . . . 0.0 111.03 178.382 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 82' ' ' GLN . . . . . 0.611 ' HG2' ' CZ3' ' A' ' 62' ' ' TRP . 34.2 mt-30 -63.65 -37.05 85.88 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.789 -0.641 . . . . 0.0 111.421 -176.682 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.685 ' O ' ' HG2' ' A' ' 87' ' ' GLU . 40.0 mt -60.14 -44.47 95.27 Favored 'Isoleucine or valine' 0 C--O 1.213 -0.841 0 N-CA-C 109.461 -0.57 . . . . 0.0 109.461 174.211 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 84' ' ' ALA . . . . . 0.612 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -62.7 -43.6 98.39 Favored 'General case' 0 C--O 1.236 0.346 0 CA-C-O 121.208 0.528 . . . . 0.0 111.792 -177.023 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.52 HG13 ' HB2' ' A' ' 65' ' ' ASN . 32.4 t -67.5 -47.86 79.07 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.332 178.845 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 86' ' ' ALA . . . . . 0.416 ' HB1' ' CH2' ' A' ' 31' ' ' TRP . . . -59.07 -29.75 67.56 Favored 'General case' 0 N--CA 1.455 -0.225 0 CA-C-N 115.531 -0.759 . . . . 0.0 110.468 174.859 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 87' ' ' GLU . . . . . 0.685 ' HG2' ' O ' ' A' ' 83' ' ' ILE . 25.9 mm-40 -59.51 -43.42 93.38 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.605 -0.725 . . . . 0.0 110.115 178.649 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.691 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 96.9 t -62.64 -48.47 88.04 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.322 0 CA-C-O 121.127 0.489 . . . . 0.0 110.124 176.454 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 89' ' ' THR . . . . . 0.766 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 0.2 OUTLIER -64.56 -47.62 78.07 Favored 'General case' 0 C--N 1.317 -0.84 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.989 -175.433 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 90' ' ' ARG . . . . . 0.455 ' HD3' ' CZ2' ' A' ' 31' ' ' TRP . 7.9 ptt180 -62.52 -33.06 74.14 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.858 -175.84 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 91' ' ' LEU . . . . . 0.691 ' HG ' ' O ' ' A' ' 88' ' ' VAL . 4.4 pp -73.57 -23.45 59.95 Favored 'General case' 0 C--N 1.321 -0.637 0 C-N-CA 120.623 -0.431 . . . . 0.0 111.069 -172.013 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 92' ' ' ARG . . . . . 0.553 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 6.1 mtm180 -84.2 -45.86 12.48 Favored 'General case' 0 N--CA 1.45 -0.468 0 CA-C-O 121.369 0.605 . . . . 0.0 109.654 -178.487 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 93' ' ' GLN . . . . . 0.423 HE21 ' HZ3' ' A' ' 98' ' ' TRP . 9.1 pt20 -102.89 -27.98 12.32 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 113.924 1.083 . . . . 0.0 113.924 -169.603 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 83.68 50.95 4.23 Favored Glycine 0 CA--C 1.507 -0.448 0 C-N-CA 120.699 -0.762 . . . . 0.0 111.834 178.735 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 95' ' ' TRP . . . . . 0.492 ' HA ' ' HE3' ' A' ' 98' ' ' TRP . 2.5 m95 60.47 22.77 12.41 Favored 'General case' 0 C--O 1.224 -0.251 0 CA-C-O 121.282 0.563 . . . . 0.0 109.674 177.098 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -75.53 -20.77 78.23 Favored Glycine 0 N--CA 1.447 -0.586 0 CA-C-N 115.368 -0.833 . . . . 0.0 112.569 178.454 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -89.77 -17.49 28.12 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 121.096 0.475 . . . . 0.0 110.173 176.253 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 98' ' ' TRP . . . . . 0.766 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 23.3 m-90 -100.09 113.14 65.14 Favored Pre-proline 0 N--CA 1.444 -0.738 0 CA-C-N 115.73 -0.668 . . . . 0.0 109.433 178.748 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 99' ' ' PRO . . . . . 0.43 ' HD3' ' HA ' ' A' ' 98' ' ' TRP . 52.8 Cg_exo -61.93 -145.33 0.01 OUTLIER 'Trans proline' 0 CA--C 1.535 0.542 0 C-N-CA 123.954 3.103 . . . . 0.0 114.315 -173.738 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 100' ' ' VAL . . . . . 0.421 HG12 ' HG3' ' A' ' 104' ' ' ARG . 58.5 t -55.84 -24.4 16.88 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.307 0 CA-C-N 115.919 -0.582 . . . . 0.0 111.032 -179.791 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 101' ' ' CYS . . . . . 0.416 ' SG ' ' HG3' ' A' ' 38' ' ' GLU . 56.6 m -56.44 -36.36 68.91 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.003 177.436 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -69.77 -42.88 73.23 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.834 0.349 . . . . 0.0 110.639 178.891 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -64.37 -42.78 96.0 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.51 178.837 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 104' ' ' ARG . . . . . 0.421 ' HG3' HG12 ' A' ' 100' ' ' VAL . 68.4 mtp180 -60.14 -39.49 86.5 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.389 -0.823 . . . . 0.0 110.916 176.262 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 105' ' ' ALA . . . . . 0.695 ' HB1' ' HA ' ' A' ' 30' ' ' ILE . . . -78.07 -22.05 49.63 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.628 -0.714 . . . . 0.0 112.114 -175.997 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 102.51 64.41 0.73 Allowed Glycine 0 CA--C 1.519 0.318 0 C-N-CA 120.935 -0.65 . . . . 0.0 112.188 -178.23 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -71.1 152.34 43.57 Favored 'General case' 0 C--N 1.324 -0.527 0 C-N-CA 122.649 0.379 . . . . 0.0 111.491 -175.29 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 27.6 mtt180 . . . . . 0 C--O 1.247 0.971 0 CA-C-O 117.702 -1.142 . . . . 0.0 112.464 174.618 . . . . . . . . 0 0 . 1 . 023 nuclear build full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 17.0 p-10 . . . . . 0 N--CA 1.478 0.965 0 CA-C-O 121.192 0.52 . . . . 0.0 110.693 . . . . . . . . . 0 0 . 1 . 023 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 11.0 p -97.37 -19.99 5.82 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 115.744 -0.662 . . . . 0.0 110.417 177.367 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 57.9 t -73.89 126.15 34.17 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.698 0 CA-C-N 115.642 -0.708 . . . . 0.0 111.394 -177.263 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 9.4 t -81.03 135.9 24.22 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 N-CA-C 109.025 -0.732 . . . . 0.0 109.025 174.131 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 5' ' ' THR . . . . . 0.465 ' HA ' ' HD3' ' A' ' 6' ' ' PRO . 4.3 p -128.52 120.19 20.74 Favored Pre-proline 0 C--N 1.31 -1.143 0 CA-C-N 115.834 -0.621 . . . . 0.0 111.38 -172.354 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.465 ' HD3' ' HA ' ' A' ' 5' ' ' THR . 4.9 Cg_exo -78.58 164.61 25.83 Favored 'Trans proline' 0 N--CA 1.451 -1.012 0 C-N-CA 122.961 2.44 . . . . 0.0 111.094 175.96 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 7' ' ' ALA . . . . . 0.507 ' C ' ' H ' ' A' ' 9' ' ' GLU . . . 57.5 -177.48 0.06 Allowed 'General case' 0 C--N 1.316 -0.876 0 CA-C-N 114.504 -1.225 . . . . 0.0 111.267 -175.881 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 8' ' ' HIS . . . . . 0.456 ' HB3' ' O ' ' A' ' 7' ' ' ALA . 53.7 t-80 69.49 -9.72 0.63 Allowed 'General case' 0 CA--C 1.531 0.239 0 CA-C-O 121.533 0.682 . . . . 0.0 109.7 -173.225 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 9' ' ' GLU . . . . . 0.507 ' H ' ' C ' ' A' ' 7' ' ' ALA . 10.1 pt-20 -78.87 141.85 37.32 Favored 'General case' 0 N--CA 1.45 -0.471 0 CA-C-N 115.384 -0.825 . . . . 0.0 110.185 -179.092 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -117.7 67.62 0.75 Allowed 'General case' 0 C--N 1.319 -0.731 0 CA-C-O 121.683 0.754 . . . . 0.0 109.497 -177.84 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 60.7 t -57.59 -59.06 3.76 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.792 0 CA-C-N 114.076 -1.42 . . . . 0.0 111.002 -179.835 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 6.0 p 31.2 81.96 0.01 OUTLIER 'Isoleucine or valine' 0 C--O 1.236 0.353 0 CA-C-O 122.733 1.254 . . . . 0.0 113.041 -178.593 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 37.1 ptt180 -130.68 137.03 49.36 Favored 'General case' 0 N--CA 1.433 -1.303 0 CA-C-N 113.917 -1.492 . . . . 0.0 109.709 -178.533 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 3.5 t -92.65 156.49 3.03 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.179 0 N-CA-C 108.078 -1.082 . . . . 0.0 108.078 170.341 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 175.15 75.66 0.05 OUTLIER Glycine 0 N--CA 1.429 -1.786 0 CA-C-N 115.479 -0.782 . . . . 0.0 112.831 -177.543 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 60.9 m -94.5 -22.56 18.16 Favored 'General case' 0 N--CA 1.436 -1.142 0 CA-C-O 121.828 0.823 . . . . 0.0 108.846 173.834 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 27.1 mmmt -61.94 110.2 2.99 Favored Pre-proline 0 C--N 1.322 -0.598 0 CA-C-N 114.122 -1.399 . . . . 0.0 111.395 175.597 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 1.2 Cg_endo -85.21 173.39 7.85 Favored 'Trans proline' 0 N--CA 1.455 -0.768 0 C-N-CA 123.638 2.892 . . . . 0.0 111.778 176.159 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -86.81 34.25 3.58 Favored Glycine 0 C--N 1.313 -0.702 0 CA-C-N 114.753 -1.112 . . . . 0.0 111.244 -179.163 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 2.4 m -61.34 -42.91 99.47 Favored 'General case' 0 C--N 1.316 -0.862 0 CA-C-N 113.985 -1.108 . . . . 0.0 110.725 -179.002 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 7.7 pt-20 -84.65 72.95 10.64 Favored 'General case' 0 N--CA 1.448 -0.562 0 CA-C-O 122.779 1.276 . . . . 0.0 110.196 177.052 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 5.4 p -72.13 137.3 81.77 Favored Pre-proline 0 C--N 1.298 -1.636 0 CA-C-N 113.028 -1.896 . . . . 0.0 110.504 -178.094 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 52.2 Cg_exo -54.04 133.95 57.56 Favored 'Trans proline' 0 C--N 1.347 0.454 0 C-N-CA 122.797 2.331 . . . . 0.0 111.575 175.744 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 10.6 Cg_endo -54.65 141.38 75.21 Favored 'Trans proline' 0 N--CA 1.458 -0.564 0 C-N-CA 123.508 2.805 . . . . 0.0 112.915 -176.663 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.602 ' HB ' HD13 ' A' ' 83' ' ' ILE . 68.5 t -80.75 128.69 38.49 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.006 0 CA-C-N 114.772 -1.104 . . . . 0.0 109.656 -178.154 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 41.1 mm -56.83 -39.89 67.6 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.432 0 CA-C-N 114.719 -1.128 . . . . 0.0 113.572 -167.133 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.655 ' O ' HG12 ' A' ' 30' ' ' ILE . 26.0 t0 -80.55 -16.77 53.36 Favored 'General case' 0 CA--C 1.498 -1.037 0 CA-C-O 122.725 1.25 . . . . 0.0 108.8 -174.512 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 28' ' ' GLY . . . . . 0.803 ' HA2' ' HB2' ' A' ' 31' ' ' TRP . . . -75.02 6.58 26.64 Favored Glycine 0 N--CA 1.435 -1.418 0 CA-C-N 113.081 -1.872 . . . . 0.0 111.638 -178.162 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 59.6 m -76.69 -42.3 42.09 Favored 'General case' 0 C--N 1.315 -0.904 0 CA-C-O 121.508 0.67 . . . . 0.0 109.346 172.941 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.655 HG12 ' O ' ' A' ' 27' ' ' ASP . 0.0 OUTLIER -71.23 -38.85 71.87 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 N-CA-C 107.517 -1.29 . . . . 0.0 107.517 174.939 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 31' ' ' TRP . . . . . 0.803 ' HB2' ' HA2' ' A' ' 28' ' ' GLY . 20.8 m95 -67.91 -35.15 77.96 Favored 'General case' 0 N--CA 1.445 -0.714 0 CA-C-N 114.543 -1.208 . . . . 0.0 110.686 -177.231 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 6.3 t70 -73.62 -43.12 60.42 Favored 'General case' 0 N--CA 1.446 -0.627 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.951 177.531 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 33' ' ' ALA . . . . . 0.504 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -68.82 -33.56 74.04 Favored 'General case' 0 N--CA 1.446 -0.639 0 C-N-CA 120.331 -0.548 . . . . 0.0 110.394 -179.497 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 34' ' ' ILE . . . . . 0.445 HG13 ' O ' ' A' ' 30' ' ' ILE . 65.1 mt -66.89 -43.89 89.19 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.172 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.128 173.066 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -58.04 -35.76 71.78 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 121.299 0.571 . . . . 0.0 110.288 176.375 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 36' ' ' GLY . . . . . 0.429 ' HA2' ' N ' ' A' ' 41' ' ' GLY . . . -74.02 -22.21 78.19 Favored Glycine 0 N--CA 1.45 -0.383 0 CA-C-N 115.52 -0.764 . . . . 0.0 111.725 178.617 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 11.9 t -87.41 -52.82 5.16 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 115.377 -0.411 . . . . 0.0 111.87 -176.939 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 10.2 tp10 -87.77 -34.01 18.46 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-O 121.071 0.462 . . . . 0.0 110.161 -172.955 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -103.76 -7.81 20.32 Favored 'General case' 0 C--N 1.323 -0.544 0 C-N-CA 120.437 -0.505 . . . . 0.0 112.186 -175.099 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 77.75 13.26 83.64 Favored Glycine 0 CA--C 1.505 -0.58 0 N-CA-C 109.985 -1.246 . . . . 0.0 109.985 -177.666 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 41' ' ' GLY . . . . . 0.429 ' N ' ' HA2' ' A' ' 36' ' ' GLY . . . 76.74 58.28 3.55 Favored Glycine 0 N--CA 1.434 -1.488 0 CA-C-N 114.236 -0.982 . . . . 0.0 111.975 -177.236 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 42' ' ' ASN . . . . . 0.57 ' HB3' ' HB ' ' A' ' 45' ' ' ILE . 2.7 t-20 -145.88 103.37 3.75 Favored 'General case' 0 N--CA 1.447 -0.593 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 179.901 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 43' ' ' TRP . . . . . 0.76 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 35.6 m95 -82.63 -6.58 59.44 Favored 'General case' 0 C--N 1.314 -0.972 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.649 -172.887 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -111.86 14.7 20.99 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 115.259 -0.882 . . . . 0.0 111.33 179.417 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.57 ' HB ' ' HB3' ' A' ' 42' ' ' ASN . 10.2 tt -79.93 140.54 16.59 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.773 0 N-CA-C 109.138 -0.69 . . . . 0.0 109.138 -179.599 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 10.0 t-20 -149.14 107.22 3.72 Favored 'General case' 0 C--N 1.307 -1.281 0 CA-C-O 121.289 0.566 . . . . 0.0 109.716 -174.861 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 24.5 p -82.45 -22.96 35.02 Favored 'General case' 0 N--CA 1.437 -1.109 0 CA-C-N 115.185 -0.916 . . . . 0.0 109.997 178.946 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 90.63 20.57 40.12 Favored Glycine 0 N--CA 1.443 -0.88 0 N-CA-C 110.902 -0.879 . . . . 0.0 110.902 178.702 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 27.5 p-10 -93.64 11.39 29.06 Favored 'General case' 0 C--N 1.327 -0.379 0 C-N-CA 120.656 -0.418 . . . . 0.0 111.684 -173.359 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 93.97 -12.31 69.44 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.699 -0.763 . . . . 0.0 111.431 -177.95 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 51' ' ' TYR . . . . . 0.771 ' CE1' ' HB2' ' A' ' 58' ' ' ASP . 0.2 OUTLIER -108.02 160.66 15.62 Favored 'General case' 0 N--CA 1.446 -0.673 0 N-CA-C 106.982 -1.488 . . . . 0.0 106.982 172.811 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 52' ' ' TYR . . . . . 0.873 ' O ' ' HA ' ' A' ' 56' ' ' GLN . 31.6 m-85 -130.35 170.57 13.98 Favored 'General case' 0 C--N 1.318 -0.783 0 C-N-CA 120.668 -0.413 . . . . 0.0 111.045 -171.298 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.495 ' HA2' HG22 ' A' ' 45' ' ' ILE . . . -61.63 177.91 4.61 Favored Glycine 0 N--CA 1.452 -0.28 0 N-CA-C 114.833 0.693 . . . . 0.0 114.833 -171.717 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.685 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 82.61 -104.96 2.57 Favored Glycine 0 N--CA 1.445 -0.702 0 C-N-CA 121.039 -0.6 . . . . 0.0 111.718 -179.877 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.569 HG12 ' HE1' ' A' ' 98' ' ' TRP . 2.1 t -83.84 -2.66 7.08 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.657 0 CA-C-O 121.902 0.858 . . . . 0.0 109.616 -179.385 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 56' ' ' GLN . . . . . 0.873 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 35.0 tt0 53.3 52.54 13.35 Favored 'General case' 0 N--CA 1.462 0.149 0 CA-C-N 113.681 -1.599 . . . . 0.0 113.3 171.981 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 57' ' ' PHE . . . . . 0.497 ' CZ ' ' HE3' ' A' ' 62' ' ' TRP . 16.5 p90 -121.13 173.34 7.35 Favored 'General case' 0 C--N 1.324 -0.519 0 C-N-CA 119.849 -0.74 . . . . 0.0 112.657 176.09 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.771 ' HB2' ' CE1' ' A' ' 51' ' ' TYR . 0.0 OUTLIER -83.97 153.63 23.79 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 114.534 -1.212 . . . . 0.0 114.091 -161.854 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.461 ' HB2' ' HE1' ' A' ' 52' ' ' TYR . 6.3 tp-100 -56.38 -41.91 76.99 Favored 'General case' 0 N--CA 1.447 -0.597 0 CA-C-N 113.656 -1.611 . . . . 0.0 111.985 178.973 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -64.97 -48.42 71.39 Favored Glycine 0 N--CA 1.445 -0.747 0 C-N-CA 120.944 -0.645 . . . . 0.0 111.574 -176.747 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 67.6 m -65.89 -43.83 87.09 Favored 'General case' 0 C--N 1.318 -0.779 0 C-N-CA 122.696 0.398 . . . . 0.0 111.069 176.443 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 62' ' ' TRP . . . . . 0.497 ' HE3' ' CZ ' ' A' ' 57' ' ' PHE . 45.5 t-105 -56.98 -48.21 78.93 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 121.397 0.618 . . . . 0.0 109.729 177.008 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 63' ' ' GLU . . . . . 0.429 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 3.6 tm-20 -68.05 -32.82 73.44 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 115.143 -0.935 . . . . 0.0 110.39 -178.401 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -66.62 -41.81 87.77 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.717 -0.674 . . . . 0.0 111.493 -178.009 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 65' ' ' ASN . . . . . 0.66 ' HB2' HG13 ' A' ' 85' ' ' VAL . 12.8 m120 -76.43 -15.41 59.93 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.002 0.429 . . . . 0.0 110.511 175.839 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 66' ' ' GLY . . . . . 0.537 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 94.36 48.09 2.66 Favored Glycine 0 C--N 1.333 0.379 0 CA-C-N 115.735 -0.666 . . . . 0.0 112.199 176.966 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.599 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -79.98 -26.24 56.13 Favored Glycine 0 N--CA 1.44 -1.081 0 C-N-CA 121.12 -0.562 . . . . 0.0 112.907 -174.699 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 1.035 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 7.5 mp -60.5 -25.44 66.08 Favored 'General case' 0 N--CA 1.445 -0.705 0 N-CA-C 112.814 0.672 . . . . 0.0 112.814 -173.761 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 69' ' ' ARG . . . . . 0.537 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 1.3 ptm180 -65.07 -33.64 76.52 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 121.35 0.595 . . . . 0.0 109.615 175.242 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 70' ' ' TYR . . . . . 0.618 ' HB3' ' CG ' ' A' ' 81' ' ' GLU . 84.3 m-85 -78.08 -35.43 49.4 Favored 'General case' 0 N--CA 1.438 -1.059 0 N-CA-C 107.483 -1.303 . . . . 0.0 107.483 178.159 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.592 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 162.03 130.15 0.01 OUTLIER Pre-proline 0 N--CA 1.447 -0.588 0 CA-C-N 112.676 -2.057 . . . . 0.0 106.756 -179.106 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 72' ' ' PRO . . . . . 1.035 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 26.5 Cg_exo -56.41 -6.54 1.52 Allowed 'Trans proline' 0 C--N 1.334 -0.226 0 C-N-CA 122.955 2.436 . . . . 0.0 113.862 -176.894 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 73' ' ' ARG . . . . . 0.493 ' HB2' ' CD2' ' A' ' 52' ' ' TYR . 0.2 OUTLIER -147.0 143.08 28.15 Favored 'General case' 0 C--N 1.317 -0.811 0 N-CA-C 109.533 -0.543 . . . . 0.0 109.533 176.523 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 74' ' ' ALA . . . . . 0.589 ' HB3' ' HB2' ' A' ' 52' ' ' TYR . . . -58.94 -26.5 64.44 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.413 -0.812 . . . . 0.0 112.722 -177.05 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 75' ' ' ASP . . . . . 0.479 ' HB2' ' NH2' ' A' ' 73' ' ' ARG . 0.0 OUTLIER -74.27 -25.43 59.61 Favored 'General case' 0 CA--C 1.518 -0.265 0 CA-C-O 121.096 0.474 . . . . 0.0 110.704 -177.258 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.528 ' HB3' ' HB1' ' A' ' 71' ' ' ALA . 55.3 tp -86.76 -30.22 21.76 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-O 121.342 0.591 . . . . 0.0 109.972 -178.635 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 77' ' ' ALA . . . . . 0.664 ' HB1' ' CB ' ' A' ' 81' ' ' GLU . . . -82.97 161.05 21.9 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 115.383 -0.826 . . . . 0.0 109.66 172.992 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 18.7 p -101.32 -171.78 2.05 Favored 'General case' 0 C--N 1.32 -0.714 0 C-N-CA 120.611 -0.435 . . . . 0.0 110.054 -179.359 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 79' ' ' ARG . . . . . 0.76 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 2.8 mtt85 -49.36 -53.12 23.99 Favored 'General case' 0 C--N 1.326 -0.436 0 O-C-N 123.487 0.492 . . . . 0.0 111.916 -177.69 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 80' ' ' GLU . . . . . 0.766 ' HA ' HD12 ' A' ' 83' ' ' ILE . 0.0 OUTLIER -61.4 -40.35 94.05 Favored 'General case' 0 C--N 1.324 -0.534 0 O-C-N 123.206 0.316 . . . . 0.0 111.578 -172.275 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 81' ' ' GLU . . . . . 0.664 ' CB ' ' HB1' ' A' ' 77' ' ' ALA . 47.0 mp0 -61.9 -51.48 67.97 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.724 0.297 . . . . 0.0 111.343 175.505 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 82' ' ' GLN . . . . . 0.424 ' HB2' ' HZ3' ' A' ' 43' ' ' TRP . 46.7 mt-30 -59.71 -35.51 74.66 Favored 'General case' 0 CA--C 1.513 -0.473 0 CA-C-O 121.141 0.496 . . . . 0.0 110.198 -178.83 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.766 HD12 ' HA ' ' A' ' 80' ' ' GLU . 35.4 mt -59.47 -49.53 83.27 Favored 'Isoleucine or valine' 0 C--O 1.212 -0.896 0 CA-C-N 114.95 -1.023 . . . . 0.0 109.955 176.905 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 84' ' ' ALA . . . . . 0.571 ' O ' ' HG3' ' A' ' 87' ' ' GLU . . . -61.27 -44.26 97.52 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-O 121.199 0.523 . . . . 0.0 111.162 -176.188 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.66 HG13 ' HB2' ' A' ' 65' ' ' ASN . 21.8 t -69.33 -49.02 64.34 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.823 179.776 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -66.2 -32.15 73.42 Favored 'General case' 0 CA--C 1.515 -0.379 0 CA-C-O 121.137 0.494 . . . . 0.0 110.888 -179.912 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 87' ' ' GLU . . . . . 0.752 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 0.0 OUTLIER -70.5 -31.52 68.66 Favored 'General case' 0 C--N 1.317 -0.817 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.255 -176.054 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.463 ' O ' ' HG3' ' A' ' 92' ' ' ARG . 71.8 t -60.63 -42.51 92.02 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.373 0 N-CA-C 108.892 -0.781 . . . . 0.0 108.892 172.399 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 89' ' ' THR . . . . . 0.816 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 1.1 m -67.42 -43.7 80.57 Favored 'General case' 0 N--CA 1.441 -0.879 0 CA-C-N 114.766 -1.106 . . . . 0.0 111.023 -176.139 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 90' ' ' ARG . . . . . 0.647 ' HA ' ' OE1' ' A' ' 93' ' ' GLN . 36.2 ptt85 -60.51 -32.46 71.47 Favored 'General case' 0 N--CA 1.461 0.102 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.472 -174.677 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 91' ' ' LEU . . . . . 0.752 ' HG ' ' O ' ' A' ' 87' ' ' GLU . 18.4 mt -67.7 -25.42 65.66 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-O 121.559 0.695 . . . . 0.0 110.197 -176.804 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 92' ' ' ARG . . . . . 0.463 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 11.4 mtm180 -90.15 -51.48 5.43 Favored 'General case' 0 C--N 1.317 -0.838 0 CA-C-N 114.992 -1.004 . . . . 0.0 110.44 -171.253 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 93' ' ' GLN . . . . . 0.647 ' OE1' ' HA ' ' A' ' 90' ' ' ARG . 0.0 OUTLIER -96.52 -23.59 16.47 Favored 'General case' 0 C--N 1.32 -0.689 0 N-CA-C 113.047 0.758 . . . . 0.0 113.047 -172.088 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 78.38 51.29 5.72 Favored Glycine 0 CA--C 1.506 -0.53 0 C-N-CA 120.507 -0.854 . . . . 0.0 111.565 176.695 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 95' ' ' TRP . . . . . 0.572 ' CZ2' ' HD2' ' A' ' 90' ' ' ARG . 2.6 m95 59.79 23.5 12.44 Favored 'General case' 0 C--N 1.329 -0.317 0 C-N-CA 123.361 0.665 . . . . 0.0 110.685 175.217 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.643 ' H ' ' HG2' ' A' ' 93' ' ' GLN . . . -77.75 -17.73 78.33 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.935 -0.65 . . . . 0.0 111.682 173.64 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -87.52 -23.09 24.5 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 121.301 0.572 . . . . 0.0 110.137 176.618 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 98' ' ' TRP . . . . . 0.816 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 20.8 m-90 -110.44 108.68 58.43 Favored Pre-proline 0 N--CA 1.448 -0.55 0 CA-C-N 115.417 -0.811 . . . . 0.0 109.797 179.315 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 99' ' ' PRO . . . . . 0.423 ' HD3' ' HA ' ' A' ' 98' ' ' TRP . 52.6 Cg_exo -61.48 -135.43 0.0 OUTLIER 'Trans proline' 0 CA--C 1.538 0.711 0 C-N-CA 124.083 3.189 . . . . 0.0 114.16 -175.151 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 21.2 t -56.42 -23.21 16.23 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.249 0 CA-C-N 116.397 -0.365 . . . . 0.0 110.95 -178.409 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 68.5 m -54.79 -38.12 66.9 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.013 -0.54 . . . . 0.0 111.024 178.011 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -69.44 -45.89 68.06 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.827 0.346 . . . . 0.0 110.757 -179.163 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -63.56 -35.82 81.77 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.514 179.365 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 4.7 mmp_? -70.79 -31.56 68.37 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.561 -0.745 . . . . 0.0 111.356 177.821 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 105' ' ' ALA . . . . . 0.644 ' HB1' ' HA ' ' A' ' 30' ' ' ILE . . . -89.0 -22.51 22.96 Favored 'General case' 0 C--N 1.326 -0.438 0 N-CA-C 112.664 0.616 . . . . 0.0 112.664 -173.079 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 113.23 58.52 0.41 Allowed Glycine 0 CA--C 1.521 0.437 0 C-N-CA 120.569 -0.824 . . . . 0.0 112.473 -178.333 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -66.69 154.36 40.83 Favored 'General case' 0 C--N 1.325 -0.472 0 C-N-CA 123.402 0.681 . . . . 0.0 111.775 -175.763 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 23.5 mmt180 . . . . . 0 C--O 1.247 0.95 0 CA-C-O 118.09 -0.957 . . . . 0.0 111.346 177.353 . . . . . . . . 0 0 . 1 . 024 nuclear build full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 71.5 m-20 . . . . . 0 N--CA 1.484 1.246 0 CA-C-O 121.245 0.545 . . . . 0.0 111.275 . . . . . . . . . 0 0 . 1 . 024 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.2 p -93.72 -12.73 8.69 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.643 0 CA-C-O 121.65 0.738 . . . . 0.0 109.235 175.401 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 7.2 p -66.79 141.48 17.9 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.581 0 CA-C-N 115.094 -0.957 . . . . 0.0 110.902 176.887 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 21.7 t -113.32 146.55 17.8 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 N-CA-C 109.478 -0.564 . . . . 0.0 109.478 176.124 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 15.6 p -121.66 102.72 41.55 Favored Pre-proline 0 C--N 1.314 -0.974 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.323 -178.165 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 98.6 Cg_endo -75.79 96.67 1.06 Allowed 'Trans proline' 0 N--CA 1.459 -0.537 0 C-N-CA 122.613 2.208 . . . . 0.0 112.114 -179.206 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 7' ' ' ALA . . . . . 0.459 ' C ' ' H ' ' A' ' 9' ' ' GLU . . . -163.51 -168.4 1.66 Allowed 'General case' 0 C--N 1.29 -1.984 0 CA-C-N 113.323 -1.762 . . . . 0.0 109.64 -177.57 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 31.3 t60 70.56 -9.23 0.81 Allowed 'General case' 0 CA--C 1.532 0.282 0 O-C-N 123.878 0.736 . . . . 0.0 109.891 -174.83 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 9' ' ' GLU . . . . . 0.459 ' H ' ' C ' ' A' ' 7' ' ' ALA . 13.9 pt-20 -71.18 137.92 49.14 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.574 -179.547 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -143.21 79.76 1.65 Allowed 'General case' 0 N--CA 1.447 -0.595 0 CA-C-N 115.7 -0.682 . . . . 0.0 110.245 -176.885 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.404 HG12 ' HG2' ' A' ' 13' ' ' ARG . 61.7 t -67.07 -56.92 11.81 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.838 0 CA-C-N 115.089 -0.96 . . . . 0.0 109.915 176.443 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 75.8 t 25.18 80.31 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.448 -0.532 0 C-N-CA 125.52 1.528 . . . . 0.0 113.371 177.258 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 13' ' ' ARG . . . . . 0.404 ' HG2' HG12 ' A' ' 11' ' ' VAL . 40.5 ptt180 -144.43 128.33 17.41 Favored 'General case' 0 C--N 1.304 -1.404 0 CA-C-N 114.031 -1.441 . . . . 0.0 110.246 178.541 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 3.7 t -128.21 161.39 36.69 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.894 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 176.116 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 138.83 101.66 0.53 Allowed Glycine 0 N--CA 1.434 -1.435 0 CA-C-N 115.609 -0.723 . . . . 0.0 112.985 177.928 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 17.6 m -80.94 -43.8 19.2 Favored 'General case' 0 N--CA 1.445 -0.687 0 CA-C-O 121.191 0.519 . . . . 0.0 110.274 175.313 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER 41.12 65.98 3.99 Favored Pre-proline 0 C--N 1.322 -0.589 0 CA-C-N 114.353 -1.294 . . . . 0.0 114.032 178.244 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 2.2 Cg_endo -83.08 163.97 15.36 Favored 'Trans proline' 0 N--CA 1.447 -1.258 0 C-N-CA 122.445 2.097 . . . . 0.0 110.534 170.721 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 94.45 -39.89 2.82 Favored Glycine 0 C--N 1.304 -1.237 0 N-CA-C 109.243 -1.543 . . . . 0.0 109.243 -176.918 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 38.4 m -68.19 -44.34 76.08 Favored 'General case' 0 N--CA 1.44 -0.963 0 CA-C-N 113.772 -1.214 . . . . 0.0 109.138 169.3 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 42.9 mt-10 -116.01 114.27 24.36 Favored 'General case' 0 N--CA 1.443 -0.787 0 CA-C-N 114.942 -1.026 . . . . 0.0 109.575 175.805 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 55.3 t -72.74 119.88 77.71 Favored Pre-proline 0 C--N 1.317 -0.817 0 N-CA-C 108.441 -0.948 . . . . 0.0 108.441 174.022 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.48 ' HA ' ' HD2' ' A' ' 24' ' ' PRO . 50.7 Cg_exo -54.5 125.88 20.44 Favored 'Trans proline' 0 N--CA 1.461 -0.387 0 C-N-CA 122.497 2.132 . . . . 0.0 112.991 -173.205 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 24' ' ' PRO . . . . . 0.48 ' HD2' ' HA ' ' A' ' 23' ' ' PRO . 15.1 Cg_endo -58.03 163.36 9.8 Favored 'Trans proline' 0 N--CA 1.456 -0.734 0 C-N-CA 124.189 3.259 . . . . 0.0 112.042 172.264 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.538 ' HB ' HG21 ' A' ' 83' ' ' ILE . 89.9 t -76.9 158.19 5.33 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.948 0 N-CA-C 107.837 -1.172 . . . . 0.0 107.837 178.597 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 42.8 mm -53.54 -25.52 11.26 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.875 0 N-CA-C 114.38 1.252 . . . . 0.0 114.38 -157.267 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.515 ' O ' HG12 ' A' ' 30' ' ' ILE . 46.5 m-20 -127.07 15.93 7.3 Favored 'General case' 0 C--N 1.313 -0.978 0 CA-C-O 121.542 0.687 . . . . 0.0 109.741 -177.803 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 28' ' ' GLY . . . . . 0.669 ' HA2' HG12 ' A' ' 83' ' ' ILE . . . -68.24 -6.51 47.49 Favored Glycine 0 N--CA 1.438 -1.203 0 CA-C-N 115.029 -0.987 . . . . 0.0 111.896 -178.878 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 4.9 m -74.47 -46.27 40.78 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-O 122.064 0.935 . . . . 0.0 109.105 176.623 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.606 ' HA ' ' HB1' ' A' ' 105' ' ' ALA . 0.0 OUTLIER -69.77 -38.47 76.11 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.777 0 CA-C-N 114.129 -1.396 . . . . 0.0 108.263 179.242 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 31' ' ' TRP . . . . . 0.573 ' HD1' HG23 ' A' ' 83' ' ' ILE . 9.0 m95 -70.55 -36.29 73.57 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 114.86 -1.063 . . . . 0.0 110.861 -177.589 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 4.4 t70 -72.79 -39.37 66.78 Favored 'General case' 0 N--CA 1.446 -0.663 0 CA-C-N 116.481 -0.327 . . . . 0.0 110.521 178.174 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 33' ' ' ALA . . . . . 0.437 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -69.54 -37.43 77.08 Favored 'General case' 0 N--CA 1.445 -0.69 0 C-N-CA 120.637 -0.425 . . . . 0.0 110.782 179.294 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 34' ' ' ILE . . . . . 0.477 HG13 ' O ' ' A' ' 30' ' ' ILE . 75.5 mt -67.46 -44.42 86.79 Favored 'Isoleucine or valine' 0 C--O 1.232 0.177 0 CA-C-O 120.809 0.338 . . . . 0.0 110.454 175.524 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -60.86 -31.83 71.28 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 121.252 0.549 . . . . 0.0 110.229 176.907 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -77.42 -22.78 69.52 Favored Glycine 0 N--CA 1.45 -0.395 0 CA-C-N 115.596 -0.729 . . . . 0.0 111.516 177.54 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 40.9 t -76.83 -58.36 3.32 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 115.367 -0.417 . . . . 0.0 111.041 -179.055 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 17.5 mt-10 -89.1 -32.9 17.31 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 116.353 -0.385 . . . . 0.0 111.3 -171.365 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -102.05 -17.61 15.98 Favored 'General case' 0 C--N 1.323 -0.576 0 C-N-CA 120.507 -0.477 . . . . 0.0 112.183 -177.562 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 81.36 9.99 85.2 Favored Glycine 0 N--CA 1.448 -0.535 0 N-CA-C 109.805 -1.318 . . . . 0.0 109.805 -175.709 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 88.39 62.71 1.39 Allowed Glycine 0 N--CA 1.438 -1.199 0 CA-C-N 114.156 -1.022 . . . . 0.0 111.713 -176.931 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 4.1 t-20 -139.31 87.98 2.23 Favored 'General case' 0 C--N 1.326 -0.418 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 -177.142 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 43' ' ' TRP . . . . . 0.778 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 37.9 m95 -76.41 -11.47 59.9 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-O 121.171 0.51 . . . . 0.0 111.259 -172.669 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -102.66 15.56 28.95 Favored 'General case' 0 C--N 1.314 -0.955 0 CA-C-N 115.793 -0.64 . . . . 0.0 110.447 -179.94 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 10.1 tt -77.53 139.94 17.86 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.003 0 CA-C-N 115.861 -0.609 . . . . 0.0 110.799 -177.771 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 34.1 t-20 -150.59 92.35 1.84 Allowed 'General case' 0 C--N 1.314 -0.957 0 CA-C-N 115.522 -0.763 . . . . 0.0 109.363 179.578 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 8.9 p -76.19 -15.67 60.0 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 115.581 -0.736 . . . . 0.0 111.668 -176.279 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 93.43 21.95 28.07 Favored Glycine 0 N--CA 1.448 -0.561 0 N-CA-C 111.149 -0.78 . . . . 0.0 111.149 -179.904 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 4.9 m-20 -90.7 -0.57 57.74 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 120.857 0.361 . . . . 0.0 111.434 -177.005 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 50' ' ' GLY . . . . . 0.492 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 86.53 -8.42 75.01 Favored Glycine 0 N--CA 1.449 -0.478 0 N-CA-C 110.888 -0.885 . . . . 0.0 110.888 -172.775 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 51' ' ' TYR . . . . . 0.566 ' CE1' ' HB3' ' A' ' 58' ' ' ASP . 0.1 OUTLIER -114.27 140.47 48.57 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 107.459 -1.312 . . . . 0.0 107.459 175.434 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 52' ' ' TYR . . . . . 0.505 ' O ' ' HA ' ' A' ' 56' ' ' GLN . 0.1 OUTLIER -140.33 163.82 31.75 Favored 'General case' 0 C--N 1.319 -0.748 0 N-CA-C 112.7 0.63 . . . . 0.0 112.7 -170.991 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.413 ' HA2' ' O ' ' A' ' 43' ' ' TRP . . . 65.45 105.66 0.01 OUTLIER Glycine 0 C--O 1.221 -0.684 0 N-CA-C 116.287 1.275 . . . . 0.0 116.287 164.198 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.479 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 57.99 -83.45 0.01 OUTLIER Glycine 0 C--N 1.339 0.696 0 N-CA-C 114.579 0.591 . . . . 0.0 114.579 165.226 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.478 HG23 ' HD1' ' A' ' 57' ' ' PHE . 3.7 m -83.16 -6.29 9.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-O 120.932 0.396 . . . . 0.0 110.282 178.337 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 56' ' ' GLN . . . . . 0.505 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 9.8 mt-30 50.19 51.84 15.93 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 114.934 -1.03 . . . . 0.0 113.203 166.788 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 57' ' ' PHE . . . . . 0.478 ' HD1' HG23 ' A' ' 55' ' ' VAL . 5.5 p90 -102.13 166.68 10.47 Favored 'General case' 0 C--N 1.323 -0.572 0 C-N-CA 119.382 -0.927 . . . . 0.0 110.705 174.926 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.566 ' HB3' ' CE1' ' A' ' 51' ' ' TYR . 4.9 p-10 -74.48 155.99 37.41 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 122.223 1.011 . . . . 0.0 113.548 -163.276 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.413 ' HB2' ' CE1' ' A' ' 52' ' ' TYR . 23.3 tp60 -57.06 -39.58 75.17 Favored 'General case' 0 N--CA 1.441 -0.877 0 CA-C-N 113.175 -1.829 . . . . 0.0 111.633 179.813 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -67.74 -49.29 50.41 Favored Glycine 0 N--CA 1.451 -0.352 0 CA-C-N 115.422 -0.808 . . . . 0.0 112.248 -176.332 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 97.8 m -64.15 -40.83 96.98 Favored 'General case' 0 C--N 1.322 -0.602 0 C-N-CA 122.829 0.451 . . . . 0.0 110.827 176.761 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 62' ' ' TRP . . . . . 0.545 ' CH2' ' HA ' ' A' ' 74' ' ' ALA . 45.6 t-105 -55.92 -48.58 75.42 Favored 'General case' 0 N--CA 1.45 -0.471 0 CA-C-O 121.71 0.767 . . . . 0.0 109.221 174.859 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 63' ' ' GLU . . . . . 0.515 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 33.2 tt0 -64.64 -36.57 84.67 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-N 114.821 -1.081 . . . . 0.0 110.989 179.187 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -65.47 -41.16 93.64 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.75 -0.659 . . . . 0.0 110.948 -177.282 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 65' ' ' ASN . . . . . 0.443 ' HB3' ' HB ' ' A' ' 88' ' ' VAL . 8.2 m120 -80.79 -7.76 59.49 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 121.043 0.449 . . . . 0.0 110.339 177.968 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 66' ' ' GLY . . . . . 0.595 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 87.64 46.8 4.77 Favored Glycine 0 N--CA 1.447 -0.582 0 CA-C-N 115.622 -0.717 . . . . 0.0 112.511 174.207 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.588 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -78.68 -25.05 61.28 Favored Glycine 0 N--CA 1.44 -1.095 0 C-N-CA 120.579 -0.819 . . . . 0.0 112.007 -175.435 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.922 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 7.3 mp -57.78 -23.27 51.46 Favored 'General case' 0 N--CA 1.446 -0.628 0 N-CA-C 112.671 0.619 . . . . 0.0 112.671 -175.38 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 69' ' ' ARG . . . . . 0.595 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 5.6 ptp180 -70.74 -29.39 65.63 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-O 121.327 0.584 . . . . 0.0 109.761 178.281 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 70' ' ' TYR . . . . . 0.749 ' HB3' ' CG ' ' A' ' 81' ' ' GLU . 43.5 m-85 -87.24 -34.62 18.89 Favored 'General case' 0 N--CA 1.439 -1.005 0 N-CA-C 107.373 -1.343 . . . . 0.0 107.373 177.724 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.526 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 170.12 125.31 0.05 OUTLIER Pre-proline 0 N--CA 1.449 -0.51 0 CA-C-N 113.198 -1.819 . . . . 0.0 107.89 -177.39 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 72' ' ' PRO . . . . . 0.922 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 15.9 Cg_exo -59.79 -2.8 1.73 Allowed 'Trans proline' 0 C--N 1.333 -0.27 0 C-N-CA 122.803 2.335 . . . . 0.0 113.562 -179.044 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 15.5 ptm180 -143.48 138.19 29.07 Favored 'General case' 0 C--N 1.316 -0.851 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 176.614 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 74' ' ' ALA . . . . . 0.594 ' HB1' ' OE1' ' A' ' 82' ' ' GLN . . . -59.09 -31.24 68.73 Favored 'General case' 0 C--N 1.316 -0.863 0 CA-C-N 114.952 -1.022 . . . . 0.0 112.393 -176.206 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 20.7 p-10 -88.93 9.0 26.51 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 120.961 0.41 . . . . 0.0 112.014 -175.956 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.505 ' HB3' ' HB1' ' A' ' 71' ' ' ALA . 68.3 tp -103.79 -28.93 11.34 Favored 'General case' 0 C--N 1.321 -0.634 0 N-CA-C 108.614 -0.884 . . . . 0.0 108.614 169.974 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 77' ' ' ALA . . . . . 0.72 ' HB1' ' CB ' ' A' ' 81' ' ' GLU . . . -79.91 153.68 28.82 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-N 114.545 -1.207 . . . . 0.0 110.39 176.553 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 21.9 p -99.79 -171.81 2.12 Favored 'General case' 0 C--N 1.32 -0.712 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.854 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 79' ' ' ARG . . . . . 0.778 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 4.0 mtp180 -50.65 -52.91 35.29 Favored 'General case' 0 C--O 1.222 -0.367 0 O-C-N 123.356 0.41 . . . . 0.0 110.779 -175.999 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 80' ' ' GLU . . . . . 0.438 ' HG3' ' OE2' ' A' ' 81' ' ' GLU . 10.5 pt-20 -58.92 -40.03 83.32 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.726 -0.67 . . . . 0.0 111.688 -174.154 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 81' ' ' GLU . . . . . 0.749 ' CG ' ' HB3' ' A' ' 70' ' ' TYR . 8.8 mp0 -67.8 -52.36 37.95 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 120.815 0.34 . . . . 0.0 111.812 176.397 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 82' ' ' GLN . . . . . 0.594 ' OE1' ' HB1' ' A' ' 74' ' ' ALA . 31.3 mt-30 -64.37 -31.28 72.43 Favored 'General case' 0 CA--C 1.514 -0.434 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.724 -175.7 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.669 HG12 ' HA2' ' A' ' 28' ' ' GLY . 27.9 mt -59.58 -48.16 88.37 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 CA-C-N 115.413 -0.812 . . . . 0.0 109.771 172.66 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 84' ' ' ALA . . . . . 0.542 ' HA ' ' HG2' ' A' ' 87' ' ' GLU . . . -62.57 -43.27 99.24 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.989 -0.55 . . . . 0.0 112.056 -177.465 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.417 HG23 ' O ' ' A' ' 81' ' ' GLU . 21.3 t -69.85 -49.76 54.57 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.69 0 O-C-N 122.112 -0.368 . . . . 0.0 111.346 -178.939 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -66.77 -31.17 71.63 Favored 'General case' 0 N--CA 1.446 -0.632 0 CA-C-N 115.947 -0.569 . . . . 0.0 110.403 -179.463 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 87' ' ' GLU . . . . . 0.816 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 6.5 pt-20 -67.62 -32.2 72.74 Favored 'General case' 0 C--O 1.219 -0.551 0 C-N-CA 120.272 -0.571 . . . . 0.0 109.72 -177.637 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.452 ' O ' ' HG3' ' A' ' 92' ' ' ARG . 87.3 t -61.77 -46.95 95.42 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.273 0 CA-C-O 121.421 0.629 . . . . 0.0 109.394 172.625 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 89' ' ' THR . . . . . 0.699 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 0.2 OUTLIER -60.8 -45.43 94.44 Favored 'General case' 0 N--CA 1.443 -0.794 0 CA-C-N 115.289 -0.869 . . . . 0.0 111.377 -178.184 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 90' ' ' ARG . . . . . 0.688 ' HG3' ' O ' ' A' ' 87' ' ' GLU . 5.6 ppt_? -60.35 -32.63 71.44 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.478 -177.095 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 91' ' ' LEU . . . . . 0.816 ' HG ' ' O ' ' A' ' 87' ' ' GLU . 38.6 mt -61.88 -43.01 99.72 Favored 'General case' 0 N--CA 1.473 0.676 0 CA-C-O 122.165 0.983 . . . . 0.0 110.047 -176.706 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 92' ' ' ARG . . . . . 0.462 ' HE ' ' HB2' ' A' ' 92' ' ' ARG . 4.4 mtm180 -78.24 -45.17 23.62 Favored 'General case' 0 C--N 1.316 -0.864 0 CA-C-N 113.828 -1.533 . . . . 0.0 110.083 -167.327 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 93' ' ' GLN . . . . . 0.496 ' NE2' ' HB2' ' A' ' 97' ' ' ALA . 3.2 pt20 -100.99 -26.74 13.62 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-N 114.605 -1.179 . . . . 0.0 112.857 -170.094 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 87.56 40.19 6.91 Favored Glycine 0 CA--C 1.508 -0.378 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.176 174.775 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 95' ' ' TRP . . . . . 0.494 ' CZ2' ' HD3' ' A' ' 90' ' ' ARG . 18.5 m95 64.54 18.66 11.49 Favored 'General case' 0 C--O 1.219 -0.527 0 CA-C-O 121.455 0.645 . . . . 0.0 109.815 179.912 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -66.41 -29.8 75.46 Favored Glycine 0 CA--C 1.519 0.299 0 CA-C-N 115.163 -0.926 . . . . 0.0 112.862 175.462 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 97' ' ' ALA . . . . . 0.496 ' HB2' ' NE2' ' A' ' 93' ' ' GLN . . . -81.83 -21.21 37.75 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.879 0.371 . . . . 0.0 110.625 178.692 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 98' ' ' TRP . . . . . 0.699 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 24.6 m-90 -99.3 109.06 53.31 Favored Pre-proline 0 N--CA 1.446 -0.625 0 N-CA-C 109.245 -0.65 . . . . 0.0 109.245 177.637 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 99' ' ' PRO . . . . . 0.42 ' HD3' ' HA ' ' A' ' 98' ' ' TRP . 44.8 Cg_exo -63.24 -139.48 0.0 OUTLIER 'Trans proline' 0 CA--C 1.535 0.541 0 C-N-CA 123.578 2.852 . . . . 0.0 114.331 -174.909 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 100' ' ' VAL . . . . . 0.422 ' O ' ' HD2' ' A' ' 104' ' ' ARG . 45.0 t -54.98 -23.98 13.64 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.315 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.682 -174.185 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 60.7 m -63.42 -31.66 72.88 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.549 -179.847 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -69.72 -46.03 66.88 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.617 0.246 . . . . 0.0 111.124 -177.364 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -66.09 -36.56 83.52 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 121.019 0.438 . . . . 0.0 110.652 179.896 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 104' ' ' ARG . . . . . 0.422 ' HD2' ' O ' ' A' ' 100' ' ' VAL . 0.0 OUTLIER -70.78 -24.13 62.52 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.78 -0.646 . . . . 0.0 111.23 177.194 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 105' ' ' ALA . . . . . 0.606 ' HB1' ' HA ' ' A' ' 30' ' ' ILE . . . -88.83 -21.46 23.71 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.583 -178.386 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 106' ' ' GLY . . . . . 0.457 ' O ' ' HG2' ' A' ' 108' ' ' ARG . . . 112.29 63.09 0.46 Allowed Glycine 0 CA--C 1.52 0.354 0 C-N-CA 120.996 -0.621 . . . . 0.0 112.129 -178.0 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -57.91 142.06 47.35 Favored 'General case' 0 C--N 1.329 -0.321 0 C-N-CA 122.679 0.392 . . . . 0.0 111.084 -179.321 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 108' ' ' ARG . . . . . 0.457 ' HG2' ' O ' ' A' ' 106' ' ' GLY . 4.6 ptp180 . . . . . 0 C--O 1.247 0.961 0 CA-C-O 118.484 -0.769 . . . . 0.0 111.093 -170.195 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 1' ' ' ASN . . . . . 0.527 ' HB3' HG12 ' A' ' 3' ' ' VAL . 77.8 m-20 . . . . . 0 N--CA 1.479 0.985 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 . . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 8.8 p -89.21 -6.92 10.86 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-O 121.019 0.438 . . . . 0.0 110.589 -177.424 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 3' ' ' VAL . . . . . 0.527 HG12 ' HB3' ' A' ' 1' ' ' ASN . 7.7 p -58.26 123.61 10.51 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.481 0 CA-C-O 121.413 0.625 . . . . 0.0 111.681 -179.952 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.486 ' O ' ' HD3' ' A' ' 6' ' ' PRO . 17.2 t -100.11 154.24 4.41 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 CA-C-N 115.621 -0.718 . . . . 0.0 109.357 179.511 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 2.0 p -90.18 107.78 21.88 Favored Pre-proline 0 C--N 1.319 -0.728 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.129 179.192 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.486 ' HD3' ' O ' ' A' ' 4' ' ' VAL . 24.6 Cg_exo -68.8 97.54 0.56 Allowed 'Trans proline' 0 CA--C 1.505 -0.974 0 C-N-CA 123.062 2.508 . . . . 0.0 111.922 177.565 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -124.55 47.7 2.07 Favored 'General case' 0 C--N 1.291 -1.97 0 CA-C-N 113.012 -1.903 . . . . 0.0 111.058 -175.706 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 41.8 t60 -85.65 -7.84 58.58 Favored 'General case' 0 C--N 1.308 -1.198 0 CA-C-N 114.497 -1.229 . . . . 0.0 108.481 172.133 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 13.7 pt-20 -118.41 159.78 22.85 Favored 'General case' 0 N--CA 1.446 -0.657 0 CA-C-N 114.634 -1.166 . . . . 0.0 110.222 -179.183 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -139.64 64.5 1.46 Allowed 'General case' 0 C--N 1.318 -0.774 0 CA-C-O 121.948 0.88 . . . . 0.0 110.998 176.884 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 60.4 t -105.39 -72.56 0.64 Allowed 'Isoleucine or valine' 0 C--N 1.314 -0.952 0 CA-C-N 114.687 -1.142 . . . . 0.0 109.597 177.219 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 6.8 p 27.7 78.66 0.01 OUTLIER 'Isoleucine or valine' 0 C--O 1.236 0.383 0 O-C-N 124.91 1.382 . . . . 0.0 113.284 176.598 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 26.7 ptt180 -93.58 94.94 8.91 Favored 'General case' 0 C--N 1.306 -1.284 0 CA-C-O 122.903 1.335 . . . . 0.0 110.73 -178.232 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 7.4 t -124.23 163.28 24.35 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.655 0 CA-C-N 113.134 -1.848 . . . . 0.0 108.039 -179.501 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 88.8 78.71 1.3 Allowed Glycine 0 C--N 1.305 -1.189 0 N-CA-C 110.567 -1.013 . . . . 0.0 110.567 -175.792 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.494 ' HB ' ' HD2' ' A' ' 17' ' ' LYS . 4.0 m -62.8 -36.99 84.96 Favored 'General case' 0 N--CA 1.444 -0.756 0 CA-C-O 121.709 0.766 . . . . 0.0 111.158 -174.902 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 17' ' ' LYS . . . . . 0.494 ' HD2' ' HB ' ' A' ' 16' ' ' THR . 0.0 OUTLIER -122.12 99.51 43.52 Favored Pre-proline 0 C--N 1.313 -0.985 0 CA-C-N 114.856 -1.066 . . . . 0.0 110.045 177.523 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 10.8 Cg_exo -72.95 165.86 31.63 Favored 'Trans proline' 0 CA--C 1.511 -0.648 0 C-N-CA 123.197 2.598 . . . . 0.0 112.639 -179.316 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -100.24 35.78 4.57 Favored Glycine 0 C--N 1.308 -0.982 0 CA-C-N 114.036 -1.438 . . . . 0.0 110.65 -178.346 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 6.2 m -62.52 -49.13 76.56 Favored 'General case' 0 C--N 1.316 -0.891 0 CA-C-N 114.26 -0.97 . . . . 0.0 111.339 -177.949 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 49.5 mt-10 -131.91 114.66 14.92 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.823 -179.491 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 57.0 t -87.01 112.72 49.48 Favored Pre-proline 0 C--N 1.322 -0.617 0 N-CA-C 109.328 -0.619 . . . . 0.0 109.328 174.378 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 51.9 Cg_exo -54.7 131.84 48.21 Favored 'Trans proline' 0 N--CA 1.46 -0.474 0 C-N-CA 122.845 2.363 . . . . 0.0 111.877 179.413 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 10.3 Cg_endo -54.52 139.25 75.37 Favored 'Trans proline' 0 N--CA 1.456 -0.707 0 C-N-CA 123.23 2.62 . . . . 0.0 112.274 -176.478 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 1.039 HG11 HD13 ' A' ' 83' ' ' ILE . 7.5 p -90.16 127.9 42.42 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.243 0 CA-C-N 114.501 -1.227 . . . . 0.0 111.459 -175.859 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 47.5 mm -76.86 -25.31 15.7 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.714 0 CA-C-N 115.254 -0.884 . . . . 0.0 111.074 -178.658 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.445 ' O ' HG12 ' A' ' 30' ' ' ILE . 50.0 m-20 -111.07 17.96 19.89 Favored 'General case' 0 CA--C 1.506 -0.713 0 CA-C-O 121.392 0.615 . . . . 0.0 109.693 -177.508 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 28' ' ' GLY . . . . . 0.501 ' HA3' HG13 ' A' ' 25' ' ' VAL . . . -70.34 -7.84 61.19 Favored Glycine 0 N--CA 1.44 -1.066 0 N-CA-C 110.024 -1.231 . . . . 0.0 110.024 176.577 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 8.7 m -74.39 -39.42 62.7 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 114.644 -0.778 . . . . 0.0 109.122 174.621 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.622 ' HA ' ' HB1' ' A' ' 105' ' ' ALA . 1.0 OUTLIER -68.18 -39.58 81.45 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 N-CA-C 107.402 -1.333 . . . . 0.0 107.402 177.771 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 31' ' ' TRP . . . . . 0.588 ' CZ2' ' HD3' ' A' ' 90' ' ' ARG . 27.2 m95 -70.61 -37.35 73.85 Favored 'General case' 0 N--CA 1.443 -0.795 0 CA-C-N 114.301 -1.318 . . . . 0.0 110.345 -177.051 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.671 ' HB2' HH21 ' A' ' 79' ' ' ARG . 21.8 t70 -79.34 -33.85 42.69 Favored 'General case' 0 N--CA 1.448 -0.549 0 CA-C-N 115.965 -0.561 . . . . 0.0 111.258 -179.55 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 33' ' ' ALA . . . . . 0.466 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -68.63 -32.97 73.21 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 176.713 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 34' ' ' ILE . . . . . 0.541 HG13 ' O ' ' A' ' 30' ' ' ILE . 66.3 mt -61.07 -45.39 98.66 Favored 'Isoleucine or valine' 0 C--O 1.234 0.289 0 CA-C-N 116.172 -0.467 . . . . 0.0 109.85 171.315 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 35' ' ' ALA . . . . . 0.767 ' HA ' ' NE2' ' A' ' 56' ' ' GLN . . . -61.34 -36.03 79.05 Favored 'General case' 0 CA--C 1.513 -0.475 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.684 177.6 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -73.56 -18.13 79.32 Favored Glycine 0 N--CA 1.448 -0.509 0 N-CA-C 111.025 -0.83 . . . . 0.0 111.025 179.44 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 37' ' ' CYS . . . . . 0.509 ' HB3' ' O ' ' A' ' 34' ' ' ILE . 8.3 t -77.14 -70.64 0.45 Allowed 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 115.102 -0.549 . . . . 0.0 111.587 -178.065 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 38' ' ' GLU . . . . . 0.728 ' HG2' ' SG ' ' A' ' 101' ' ' CYS . 4.5 mm-40 -90.44 -33.54 15.96 Favored 'General case' 0 CA--C 1.511 -0.554 0 C-N-CA 120.435 -0.506 . . . . 0.0 111.133 -172.65 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 39' ' ' ALA . . . . . 0.501 ' HB3' ' O ' ' A' ' 35' ' ' ALA . . . -84.57 -15.69 44.79 Favored 'General case' 0 N--CA 1.443 -0.8 0 CA-C-N 115.997 -0.547 . . . . 0.0 111.125 -177.182 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 75.84 13.29 83.23 Favored Glycine 0 CA--C 1.504 -0.607 0 N-CA-C 109.687 -1.365 . . . . 0.0 109.687 -177.456 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 88.62 63.33 1.35 Allowed Glycine 0 N--CA 1.432 -1.583 0 CA-C-N 113.957 -1.121 . . . . 0.0 111.436 -175.424 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 42' ' ' ASN . . . . . 0.823 ' HB3' ' HB ' ' A' ' 45' ' ' ILE . 6.6 m120 -146.59 103.32 3.65 Favored 'General case' 0 CA--C 1.513 -0.456 0 CA-C-O 121.125 0.488 . . . . 0.0 110.003 -177.962 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 43' ' ' TRP . . . . . 0.704 ' HA ' ' N ' ' A' ' 54' ' ' GLY . 44.5 m95 -84.97 -6.87 59.33 Favored 'General case' 0 C--N 1.311 -1.066 0 CA-C-O 121.642 0.734 . . . . 0.0 110.128 178.155 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -109.72 13.96 23.51 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-N 114.924 -1.034 . . . . 0.0 111.546 178.449 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.823 ' HB ' ' HB3' ' A' ' 42' ' ' ASN . 11.2 tt -87.23 143.67 10.85 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.712 0 CA-C-O 120.85 0.357 . . . . 0.0 110.595 -177.833 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -161.71 113.55 1.75 Allowed 'General case' 0 C--N 1.315 -0.916 0 CA-C-O 121.375 0.607 . . . . 0.0 110.482 175.974 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 30.5 p -82.32 -20.17 37.91 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 115.739 -0.664 . . . . 0.0 111.684 -175.22 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 102.66 25.01 7.87 Favored Glycine 0 N--CA 1.445 -0.757 0 N-CA-C 110.703 -0.959 . . . . 0.0 110.703 -175.204 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 3.4 t30 -95.01 -2.91 49.36 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 121.533 0.682 . . . . 0.0 110.346 -178.64 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 96.3 -13.81 65.23 Favored Glycine 0 C--O 1.227 -0.314 0 CA-C-N 115.548 -0.751 . . . . 0.0 111.526 179.202 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 51' ' ' TYR . . . . . 0.6 ' HA ' ' HA ' ' A' ' 58' ' ' ASP . 0.3 OUTLIER -99.55 137.94 37.33 Favored 'General case' 0 CA--C 1.511 -0.541 0 N-CA-C 108.234 -1.024 . . . . 0.0 108.234 174.543 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 52' ' ' TYR . . . . . 0.673 ' CE1' ' HB2' ' A' ' 59' ' ' GLN . 15.9 m-85 -107.62 169.5 8.55 Favored 'General case' 0 C--N 1.312 -1.065 0 C-N-CA 120.685 -0.406 . . . . 0.0 111.698 -172.199 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -63.01 169.59 16.49 Favored Glycine 0 N--CA 1.449 -0.484 0 N-CA-C 115.256 0.862 . . . . 0.0 115.256 -166.613 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.704 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 85.11 -93.17 1.81 Allowed Glycine 0 N--CA 1.44 -1.086 0 CA-C-N 114.508 -0.846 . . . . 0.0 112.01 177.983 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.528 HG22 ' HB3' ' A' ' 82' ' ' GLN . 0.4 OUTLIER -90.95 -2.15 10.14 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.764 0 CA-C-O 121.017 0.437 . . . . 0.0 111.403 -177.447 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 56' ' ' GLN . . . . . 0.767 ' NE2' ' HA ' ' A' ' 35' ' ' ALA . 9.2 mt-30 58.02 46.94 15.58 Favored 'General case' 0 N--CA 1.472 0.625 0 N-CA-C 113.849 1.055 . . . . 0.0 113.849 164.645 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -125.3 157.77 35.83 Favored 'General case' 0 C--N 1.318 -0.765 0 C-N-CA 119.221 -0.992 . . . . 0.0 111.296 174.87 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.6 ' HA ' ' HA ' ' A' ' 51' ' ' TYR . 24.1 t70 -65.21 144.12 57.39 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 114.33 -1.304 . . . . 0.0 112.052 -167.709 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.673 ' HB2' ' CE1' ' A' ' 52' ' ' TYR . 4.0 tp60 -51.87 -36.15 47.5 Favored 'General case' 0 N--CA 1.448 -0.562 0 CA-C-N 114.131 -1.395 . . . . 0.0 111.807 179.017 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -67.43 -41.98 90.04 Favored Glycine 0 N--CA 1.449 -0.438 0 N-CA-C 111.453 -0.659 . . . . 0.0 111.453 179.386 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 64.1 m -71.47 -38.69 71.23 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 120.759 0.314 . . . . 0.0 110.434 176.368 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 62' ' ' TRP . . . . . 0.563 ' CH2' ' HA ' ' A' ' 74' ' ' ALA . 43.3 t-105 -55.59 -47.57 76.26 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 121.64 0.733 . . . . 0.0 109.089 172.571 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 63' ' ' GLU . . . . . 0.503 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 27.6 tt0 -64.67 -33.53 76.16 Favored 'General case' 0 N--CA 1.443 -0.775 0 CA-C-N 114.784 -1.098 . . . . 0.0 110.711 178.127 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -64.36 -42.84 96.0 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 115.928 -0.578 . . . . 0.0 111.624 -176.598 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 65' ' ' ASN . . . . . 0.455 ' HB2' HG13 ' A' ' 85' ' ' VAL . 10.2 m-80 -74.16 -19.31 60.6 Favored 'General case' 0 N--CA 1.462 0.173 0 CA-C-O 121.254 0.549 . . . . 0.0 109.892 174.01 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 66' ' ' GLY . . . . . 0.422 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 94.02 48.12 2.73 Favored Glycine 0 N--CA 1.448 -0.514 0 CA-C-N 115.536 -0.756 . . . . 0.0 111.814 179.309 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.524 ' HA2' ' HD1' ' A' ' 70' ' ' TYR . . . -79.59 -17.37 75.76 Favored Glycine 0 N--CA 1.44 -1.068 0 C-N-CA 120.992 -0.623 . . . . 0.0 113.044 -173.377 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.817 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 6.5 mp -61.68 -23.3 66.0 Favored 'General case' 0 N--CA 1.45 -0.441 0 N-CA-C 112.179 0.437 . . . . 0.0 112.179 -173.372 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 69' ' ' ARG . . . . . 0.422 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 4.8 ptt180 -70.52 -29.49 66.0 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 121.04 0.448 . . . . 0.0 110.604 175.552 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 70' ' ' TYR . . . . . 0.567 ' HB3' ' HB3' ' A' ' 81' ' ' GLU . 74.7 m-85 -79.27 -33.65 43.25 Favored 'General case' 0 N--CA 1.446 -0.642 0 N-CA-C 107.185 -1.413 . . . . 0.0 107.185 175.891 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.616 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 163.02 127.69 0.01 OUTLIER Pre-proline 0 C--O 1.22 -0.452 0 CA-C-N 112.662 -2.063 . . . . 0.0 107.044 -179.709 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 72' ' ' PRO . . . . . 0.817 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 16.6 Cg_exo -56.92 -4.77 1.02 Allowed 'Trans proline' 0 C--N 1.334 -0.194 0 C-N-CA 122.605 2.203 . . . . 0.0 113.774 -177.97 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 14.4 ptm180 -145.38 140.19 27.5 Favored 'General case' 0 C--N 1.318 -0.798 0 N-CA-C 108.501 -0.925 . . . . 0.0 108.501 175.888 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 74' ' ' ALA . . . . . 0.563 ' HA ' ' CH2' ' A' ' 62' ' ' TRP . . . -57.68 -36.03 71.38 Favored 'General case' 0 C--O 1.219 -0.535 0 CA-C-N 115.448 -0.796 . . . . 0.0 111.691 -176.77 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 75' ' ' ASP . . . . . 0.457 ' OD1' ' HD2' ' A' ' 52' ' ' TYR . 11.6 p-10 -84.03 2.58 38.43 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 120.935 0.398 . . . . 0.0 111.455 -173.08 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.468 ' HB3' ' HB1' ' A' ' 71' ' ' ALA . 49.2 tp -98.13 -33.96 10.94 Favored 'General case' 0 C--N 1.323 -0.568 0 N-CA-C 108.419 -0.956 . . . . 0.0 108.419 170.893 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 77' ' ' ALA . . . . . 0.793 ' HB1' ' HB2' ' A' ' 81' ' ' GLU . . . -79.32 163.27 25.02 Favored 'General case' 0 N--CA 1.444 -0.768 0 CA-C-N 114.785 -1.098 . . . . 0.0 109.959 175.242 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 38.3 p -101.0 178.23 4.73 Favored 'General case' 0 C--N 1.316 -0.887 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.121 179.491 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 79' ' ' ARG . . . . . 0.671 HH21 ' HB2' ' A' ' 32' ' ' ASP . 60.4 mtp180 -46.1 -48.37 17.18 Favored 'General case' 0 N--CA 1.467 0.399 0 O-C-N 123.693 0.621 . . . . 0.0 111.32 -176.06 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 80' ' ' GLU . . . . . 0.403 ' HG3' ' OE2' ' A' ' 81' ' ' GLU . 6.0 pt-20 -61.7 -42.03 98.4 Favored 'General case' 0 C--N 1.315 -0.915 0 CA-C-N 115.756 -0.656 . . . . 0.0 112.659 -177.375 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 81' ' ' GLU . . . . . 0.793 ' HB2' ' HB1' ' A' ' 77' ' ' ALA . 5.7 mp0 -65.68 -50.48 64.74 Favored 'General case' 0 C--O 1.231 0.121 0 CA-C-N 118.369 0.531 . . . . 0.0 111.824 172.936 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 82' ' ' GLN . . . . . 0.528 ' HB3' HG22 ' A' ' 55' ' ' VAL . 4.0 mt-30 -57.76 -40.78 80.55 Favored 'General case' 0 CA--C 1.515 -0.379 0 CA-C-O 121.217 0.532 . . . . 0.0 110.26 -177.707 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 1.039 HD13 HG11 ' A' ' 25' ' ' VAL . 11.6 mt -61.82 -45.49 98.59 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.696 0 CA-C-N 114.898 -1.047 . . . . 0.0 110.593 178.045 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 84' ' ' ALA . . . . . 0.565 ' O ' ' HG3' ' A' ' 87' ' ' GLU . . . -62.33 -44.49 96.37 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.911 0.386 . . . . 0.0 111.513 -177.575 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.486 HG23 ' O ' ' A' ' 81' ' ' GLU . 21.7 t -67.27 -48.84 76.88 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 CA-C-N 116.535 -0.302 . . . . 0.0 111.457 179.291 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -65.04 -30.97 71.98 Favored 'General case' 0 N--CA 1.451 -0.423 0 CA-C-O 121.148 0.499 . . . . 0.0 110.558 179.145 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 87' ' ' GLU . . . . . 0.657 ' O ' ' HG2' ' A' ' 90' ' ' ARG . 0.7 OUTLIER -71.86 -27.71 63.05 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.876 -177.526 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.718 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 88.8 t -62.21 -40.1 86.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 N-CA-C 108.805 -0.813 . . . . 0.0 108.805 166.805 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 89' ' ' THR . . . . . 0.786 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 2.7 m -67.86 -43.05 80.33 Favored 'General case' 0 C--N 1.318 -0.772 0 CA-C-N 115.524 -0.762 . . . . 0.0 111.005 -178.89 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 90' ' ' ARG . . . . . 0.657 ' HG2' ' O ' ' A' ' 87' ' ' GLU . 26.3 ptt180 -60.08 -34.34 73.31 Favored 'General case' 0 N--CA 1.47 0.54 0 C-N-CA 122.761 0.424 . . . . 0.0 111.447 -175.906 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 91' ' ' LEU . . . . . 0.718 ' HG ' ' O ' ' A' ' 88' ' ' VAL . 4.3 pp -73.15 -21.83 60.63 Favored 'General case' 0 C--N 1.318 -0.774 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.588 -174.361 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 92' ' ' ARG . . . . . 0.475 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 6.7 mtm180 -86.61 -51.1 6.35 Favored 'General case' 0 CA--C 1.511 -0.538 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.135 -176.607 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 93' ' ' GLN . . . . . 0.627 ' OE1' ' HA ' ' A' ' 90' ' ' ARG . 0.0 OUTLIER -98.03 -25.43 14.96 Favored 'General case' 0 CA--C 1.538 0.487 0 N-CA-C 113.311 0.856 . . . . 0.0 113.311 -170.779 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 90.47 40.1 5.79 Favored Glycine 0 CA--C 1.507 -0.447 0 C-N-CA 120.672 -0.775 . . . . 0.0 111.99 173.462 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 95' ' ' TRP . . . . . 0.48 ' HB3' ' HB1' ' A' ' 102' ' ' ALA . 10.2 m95 64.35 11.71 6.66 Favored 'General case' 0 C--O 1.223 -0.328 0 C-N-CA 123.678 0.791 . . . . 0.0 110.142 -179.131 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -71.66 -28.33 69.43 Favored Glycine 0 C--N 1.33 0.2 0 C-N-CA 121.114 -0.565 . . . . 0.0 112.433 177.982 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -70.0 -29.2 66.23 Favored 'General case' 0 CA--C 1.516 -0.334 0 CA-C-O 121.183 0.516 . . . . 0.0 110.2 178.667 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 98' ' ' TRP . . . . . 0.786 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 26.2 m-90 -98.74 103.84 21.35 Favored Pre-proline 0 N--CA 1.446 -0.638 0 N-CA-C 108.299 -1.0 . . . . 0.0 108.299 174.948 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 99' ' ' PRO . . . . . 0.465 ' HB2' ' H ' ' A' ' 100' ' ' VAL . 22.9 Cg_exo -69.25 -94.23 0.01 OUTLIER 'Trans proline' 0 CA--C 1.532 0.424 0 C-N-CA 123.176 2.584 . . . . 0.0 114.727 -170.438 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 100' ' ' VAL . . . . . 0.465 ' H ' ' HB2' ' A' ' 99' ' ' PRO . 47.9 t -70.92 -29.74 38.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-O 121.702 0.763 . . . . 0.0 110.013 -174.385 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 101' ' ' CYS . . . . . 0.728 ' SG ' ' HG2' ' A' ' 38' ' ' GLU . 64.0 m -71.13 -38.41 72.27 Favored 'General case' 0 C--N 1.317 -0.807 0 CA-C-N 114.789 -1.096 . . . . 0.0 111.794 -170.895 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 102' ' ' ALA . . . . . 0.48 ' HB1' ' HB3' ' A' ' 95' ' ' TRP . . . -69.99 -43.14 72.06 Favored 'General case' 0 C--N 1.327 -0.401 0 C-N-CA 120.698 -0.401 . . . . 0.0 110.704 179.86 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -61.67 -37.19 83.18 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 121.355 0.598 . . . . 0.0 110.464 178.42 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 104' ' ' ARG . . . . . 0.57 ' NE ' ' HA ' ' A' ' 104' ' ' ARG . 4.8 mmp_? -71.33 -34.84 70.91 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.495 -0.775 . . . . 0.0 111.563 176.323 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 105' ' ' ALA . . . . . 0.622 ' HB1' ' HA ' ' A' ' 30' ' ' ILE . . . -83.4 -22.33 32.77 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.158 -0.474 . . . . 0.0 112.208 -174.775 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 114.81 59.23 0.36 Allowed Glycine 0 CA--C 1.521 0.425 0 C-N-CA 120.818 -0.706 . . . . 0.0 112.37 -178.611 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -61.65 148.03 43.9 Favored 'General case' 0 CA--C 1.515 -0.367 0 C-N-CA 122.91 0.484 . . . . 0.0 110.635 179.478 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.245 0.845 0 CA-C-O 118.29 -0.862 . . . . 0.0 110.059 -173.013 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 5.6 m-20 . . . . . 0 N--CA 1.48 1.051 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 . . . . . . . . . 0 0 . 1 . 026 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 14.7 p 35.1 57.87 0.15 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.514 0 O-C-N 124.424 1.077 . . . . 0.0 111.851 -174.134 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 6.3 p -64.18 100.06 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.522 0 CA-C-N 114.798 -1.092 . . . . 0.0 112.436 -176.537 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 14.3 p -117.75 148.84 20.28 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.764 0 CA-C-N 115.699 -0.682 . . . . 0.0 110.583 173.472 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 4.6 p -129.37 113.2 18.17 Favored Pre-proline 0 C--N 1.308 -1.207 0 CA-C-N 115.169 -0.923 . . . . 0.0 110.473 178.331 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 62.4 Cg_exo -45.99 107.56 0.12 Allowed 'Trans proline' 0 CA--C 1.505 -0.943 0 C-N-CA 123.809 3.006 . . . . 0.0 113.507 -178.547 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -111.27 171.45 7.47 Favored 'General case' 0 C--N 1.297 -1.704 0 CA-C-N 113.357 -1.747 . . . . 0.0 110.656 -178.706 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 31.0 t-80 68.55 6.04 5.19 Favored 'General case' 0 N--CA 1.456 -0.153 0 O-C-N 124.23 0.956 . . . . 0.0 109.345 -174.149 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 11.4 pt-20 -52.66 135.0 35.68 Favored 'General case' 0 C--O 1.235 0.309 0 CA-C-N 115.099 -0.955 . . . . 0.0 110.778 177.175 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -120.92 65.7 0.86 Allowed 'General case' 0 C--N 1.32 -0.681 0 CA-C-O 121.873 0.844 . . . . 0.0 110.668 -176.787 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 58.2 t -78.63 -40.96 24.48 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.021 0 CA-C-N 114.404 -1.271 . . . . 0.0 109.57 176.408 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 6.2 p 31.7 80.83 0.01 OUTLIER 'Isoleucine or valine' 0 C--O 1.235 0.341 0 O-C-N 124.729 1.268 . . . . 0.0 113.163 178.26 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 13' ' ' ARG . . . . . 0.465 ' O ' ' HG3' ' A' ' 13' ' ' ARG . 10.3 ptp180 -102.85 114.03 27.96 Favored 'General case' 0 C--N 1.307 -1.271 0 CA-C-N 114.016 -1.447 . . . . 0.0 109.323 179.79 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.9 t -110.01 161.32 8.47 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.421 0 CA-C-N 115.09 -0.959 . . . . 0.0 109.456 -179.98 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 137.61 71.63 0.05 OUTLIER Glycine 0 N--CA 1.436 -1.366 0 CA-C-N 115.075 -0.966 . . . . 0.0 111.978 179.542 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 41.9 m -82.85 -21.99 34.22 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-O 121.591 0.71 . . . . 0.0 110.392 179.993 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 26.1 mmtp -56.29 108.93 1.36 Allowed Pre-proline 0 C--N 1.322 -0.615 0 CA-C-N 114.393 -1.276 . . . . 0.0 111.703 178.003 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -79.42 162.96 24.86 Favored 'Trans proline' 0 N--CA 1.451 -0.987 0 C-N-CA 123.476 2.784 . . . . 0.0 112.231 178.014 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -123.82 35.79 3.17 Favored Glycine 0 C--N 1.306 -1.09 0 CA-C-N 114.088 -1.415 . . . . 0.0 111.359 179.224 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 7.1 m -61.12 -41.93 97.6 Favored 'General case' 0 C--N 1.317 -0.807 0 CA-C-N 114.49 -0.855 . . . . 0.0 110.509 177.768 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 43.2 mt-10 -135.14 103.85 5.7 Favored 'General case' 0 N--CA 1.442 -0.873 0 N-CA-C 108.279 -1.008 . . . . 0.0 108.279 -179.318 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 4.6 p -71.84 115.53 38.92 Favored Pre-proline 0 C--N 1.315 -0.895 0 CA-C-N 115.019 -0.991 . . . . 0.0 112.491 -169.472 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_exo -68.2 151.59 76.73 Favored 'Trans proline' 0 N--CA 1.456 -0.702 0 C-N-CA 123.078 2.518 . . . . 0.0 111.57 172.686 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 9.9 Cg_endo -55.4 140.76 82.63 Favored 'Trans proline' 0 N--CA 1.454 -0.836 0 C-N-CA 122.546 2.164 . . . . 0.0 111.185 173.714 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.575 HG11 HG21 ' A' ' 83' ' ' ILE . 14.0 t -107.15 133.05 52.94 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.074 0 CA-C-N 115.232 -0.895 . . . . 0.0 111.024 -173.399 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 44.6 mm -73.08 -23.87 20.45 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 CA-C-N 115.224 -0.898 . . . . 0.0 111.736 -173.524 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 7.9 m-20 -81.28 -5.33 57.68 Favored 'General case' 0 CA--C 1.503 -0.856 0 CA-C-O 121.656 0.741 . . . . 0.0 109.395 -177.374 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 28' ' ' GLY . . . . . 0.53 ' HA2' ' HB2' ' A' ' 31' ' ' TRP . . . -66.83 -5.78 33.59 Favored Glycine 0 N--CA 1.439 -1.131 0 CA-C-N 114.229 -1.35 . . . . 0.0 110.902 179.94 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 12.7 m -76.38 -44.66 35.27 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-O 121.419 0.628 . . . . 0.0 109.813 175.792 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.581 ' HB ' ' CH2' ' A' ' 95' ' ' TRP . 0.1 OUTLIER -71.01 -35.94 61.39 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.594 0 N-CA-C 108.113 -1.069 . . . . 0.0 108.113 178.078 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 31' ' ' TRP . . . . . 0.72 ' CD1' HG13 ' A' ' 83' ' ' ILE . 48.9 m95 -71.75 -35.64 70.18 Favored 'General case' 0 N--CA 1.442 -0.865 0 CA-C-N 114.658 -1.156 . . . . 0.0 110.19 -178.975 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 20.4 t70 -77.0 -29.31 55.41 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.342 178.908 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -68.55 -35.06 76.9 Favored 'General case' 0 N--CA 1.444 -0.732 0 N-CA-C 109.671 -0.492 . . . . 0.0 109.671 175.215 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 34' ' ' ILE . . . . . 0.581 ' HA ' ' HB3' ' A' ' 101' ' ' CYS . 58.0 mt -67.64 -49.34 71.15 Favored 'Isoleucine or valine' 0 C--O 1.233 0.199 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.402 173.908 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 35' ' ' ALA . . . . . 0.455 ' O ' ' HB3' ' A' ' 39' ' ' ALA . . . -59.08 -41.26 87.6 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.778 -0.646 . . . . 0.0 110.454 178.951 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 36' ' ' GLY . . . . . 0.4 ' HA2' ' N ' ' A' ' 41' ' ' GLY . . . -72.09 -18.95 78.2 Favored Glycine 0 N--CA 1.449 -0.484 0 CA-C-N 115.453 -0.794 . . . . 0.0 111.649 179.069 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 3.6 t -84.24 -62.93 1.44 Allowed 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.433 -0.383 . . . . 0.0 111.463 -178.088 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 38' ' ' GLU . . . . . 0.575 ' HB2' ' SG ' ' A' ' 101' ' ' CYS . 15.9 tt0 -89.06 -33.2 17.21 Favored 'General case' 0 C--N 1.324 -0.517 0 C-N-CA 120.532 -0.467 . . . . 0.0 110.602 -170.908 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 39' ' ' ALA . . . . . 0.455 ' HB3' ' O ' ' A' ' 35' ' ' ALA . . . -91.18 -12.36 35.62 Favored 'General case' 0 N--CA 1.453 -0.286 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.301 -178.857 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 82.0 4.93 90.11 Favored Glycine 0 CA--C 1.505 -0.552 0 N-CA-C 109.923 -1.271 . . . . 0.0 109.923 -178.857 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 41' ' ' GLY . . . . . 0.4 ' N ' ' HA2' ' A' ' 36' ' ' GLY . . . 87.3 61.56 1.55 Allowed Glycine 0 N--CA 1.434 -1.482 0 CA-C-N 113.946 -1.127 . . . . 0.0 111.369 -175.291 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 42' ' ' ASN . . . . . 0.64 ' HB3' ' HB ' ' A' ' 45' ' ' ILE . 15.5 t-20 -144.96 96.57 2.88 Favored 'General case' 0 N--CA 1.448 -0.559 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 -177.217 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 43' ' ' TRP . . . . . 0.749 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 46.3 m95 -79.04 -14.1 59.37 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.968 -175.223 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -107.49 14.24 26.03 Favored 'General case' 0 C--N 1.316 -0.861 0 CA-C-N 115.525 -0.761 . . . . 0.0 111.399 179.962 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.64 ' HB ' ' HB3' ' A' ' 42' ' ' ASN . 8.6 tt -78.13 144.56 11.11 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.738 0 CA-C-O 120.994 0.426 . . . . 0.0 110.181 -178.612 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 29.0 t-20 -150.26 86.74 1.43 Allowed 'General case' 0 C--N 1.31 -1.141 0 CA-C-O 121.437 0.637 . . . . 0.0 109.664 178.952 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 6.1 p -68.7 -25.79 64.96 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.122 -0.945 . . . . 0.0 111.464 -178.342 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 100.98 21.01 12.44 Favored Glycine 0 N--CA 1.445 -0.712 0 C-N-CA 120.985 -0.626 . . . . 0.0 111.545 -179.652 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 4.3 m-20 -81.42 -4.05 54.67 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 121.229 0.538 . . . . 0.0 111.029 -179.243 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 95.91 -13.6 65.9 Favored Glycine 0 N--CA 1.446 -0.635 0 N-CA-C 110.038 -1.225 . . . . 0.0 110.038 -176.592 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 51' ' ' TYR . . . . . 0.671 ' CD1' ' HB2' ' A' ' 58' ' ' ASP . 0.1 OUTLIER -102.81 144.99 30.43 Favored 'General case' 0 N--CA 1.446 -0.643 0 N-CA-C 107.631 -1.248 . . . . 0.0 107.631 174.048 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 52' ' ' TYR . . . . . 0.842 ' O ' ' HA ' ' A' ' 56' ' ' GLN . 10.3 m-85 -108.61 164.81 12.03 Favored 'General case' 0 C--N 1.308 -1.205 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.717 -172.147 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.463 ' HA2' HG22 ' A' ' 45' ' ' ILE . . . -58.13 172.73 3.27 Favored Glycine 0 C--O 1.229 -0.182 0 N-CA-C 115.702 1.041 . . . . 0.0 115.702 -166.107 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.64 ' CA ' ' HA ' ' A' ' 43' ' ' TRP . . . 91.55 -111.02 3.93 Favored Glycine 0 N--CA 1.446 -0.671 0 CA-C-N 114.86 -0.67 . . . . 0.0 111.509 -178.799 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.4 HG23 ' CD1' ' A' ' 57' ' ' PHE . 1.9 m -83.23 -2.64 6.79 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 CA-C-O 122.077 0.942 . . . . 0.0 110.454 176.22 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 56' ' ' GLN . . . . . 0.842 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 33.5 tt0 50.49 52.1 15.51 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 113.436 -1.711 . . . . 0.0 114.18 168.921 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 57' ' ' PHE . . . . . 0.453 ' HZ ' HG13 ' A' ' 85' ' ' VAL . 7.2 p90 -105.74 158.49 16.69 Favored 'General case' 0 C--N 1.321 -0.652 0 C-N-CA 119.123 -1.031 . . . . 0.0 110.368 170.788 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.671 ' HB2' ' CD1' ' A' ' 51' ' ' TYR . 0.5 OUTLIER -64.54 144.19 57.38 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 114.888 -1.051 . . . . 0.0 112.016 -168.793 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.713 ' HB2' ' CE1' ' A' ' 52' ' ' TYR . 38.2 tp60 -63.1 -30.29 71.48 Favored 'General case' 0 C--O 1.218 -0.555 0 CA-C-N 114.841 -1.072 . . . . 0.0 111.54 -178.562 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -64.83 -44.17 95.08 Favored Glycine 0 C--N 1.316 -0.529 0 N-CA-C 110.84 -0.904 . . . . 0.0 110.84 174.949 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 88.6 m -71.36 -40.18 70.82 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-O 121.093 0.473 . . . . 0.0 111.207 175.299 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 62' ' ' TRP . . . . . 0.761 ' CZ3' HG11 ' A' ' 85' ' ' VAL . 29.5 t-105 -55.12 -46.59 75.62 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-O 121.492 0.663 . . . . 0.0 109.694 173.229 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 63' ' ' GLU . . . . . 0.562 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 32.0 tt0 -67.24 -35.2 79.05 Favored 'General case' 0 C--N 1.316 -0.876 0 CA-C-N 114.957 -1.019 . . . . 0.0 111.01 179.305 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -64.89 -40.85 95.74 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.936 -0.574 . . . . 0.0 110.958 -178.509 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 65' ' ' ASN . . . . . 0.44 ' HB3' ' HB ' ' A' ' 88' ' ' VAL . 34.8 m-80 -81.68 -7.29 59.58 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.045 -0.525 . . . . 0.0 111.085 177.039 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 87.14 45.1 5.45 Favored Glycine 0 C--N 1.331 0.269 0 C-N-CA 121.022 -0.609 . . . . 0.0 112.812 173.639 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.581 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -79.67 -22.34 64.49 Favored Glycine 0 N--CA 1.441 -0.973 0 C-N-CA 121.184 -0.532 . . . . 0.0 112.783 -175.861 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.798 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 6.7 mp -60.66 -23.67 64.98 Favored 'General case' 0 C--N 1.328 -0.341 0 N-CA-C 112.345 0.498 . . . . 0.0 112.345 -172.338 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 35.7 ptt180 -71.56 -27.02 62.87 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-O 120.933 0.397 . . . . 0.0 110.374 178.882 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 70' ' ' TYR . . . . . 1.012 ' HB3' ' HG2' ' A' ' 81' ' ' GLU . 51.8 m-85 -82.98 -34.41 26.38 Favored 'General case' 0 N--CA 1.444 -0.746 0 N-CA-C 107.09 -1.448 . . . . 0.0 107.09 174.056 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.554 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 167.25 130.12 0.04 OUTLIER Pre-proline 0 C--N 1.327 -0.397 0 CA-C-N 112.456 -2.157 . . . . 0.0 108.866 -178.783 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 72' ' ' PRO . . . . . 0.798 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 36.6 Cg_endo -67.97 29.58 0.14 Allowed 'Trans proline' 0 N--CA 1.476 0.487 0 C-N-CA 122.862 2.374 . . . . 0.0 113.877 179.311 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 73' ' ' ARG . . . . . 0.465 ' H ' ' C ' ' A' ' 71' ' ' ALA . 14.7 ptm180 -176.27 140.15 0.38 Allowed 'General case' 0 C--N 1.321 -0.66 0 N-CA-C 108.665 -0.865 . . . . 0.0 108.665 178.136 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 74' ' ' ALA . . . . . 0.544 ' HA ' ' CH2' ' A' ' 62' ' ' TRP . . . -66.47 -27.15 67.57 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.788 -0.642 . . . . 0.0 111.795 -174.949 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 75' ' ' ASP . . . . . 0.462 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 21.1 p-10 -86.57 -4.92 59.24 Favored 'General case' 0 C--N 1.324 -0.532 0 C-N-CA 120.832 -0.347 . . . . 0.0 111.61 -174.825 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 65.2 tp -97.85 -28.61 13.77 Favored 'General case' 0 C--N 1.322 -0.604 0 N-CA-C 108.97 -0.752 . . . . 0.0 108.97 171.31 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 77' ' ' ALA . . . . . 0.685 ' HB1' ' HB3' ' A' ' 81' ' ' GLU . . . -78.05 148.54 34.24 Favored 'General case' 0 N--CA 1.441 -0.919 0 CA-C-N 115.12 -0.946 . . . . 0.0 109.934 175.309 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 47.0 p -91.79 -175.61 4.2 Favored 'General case' 0 C--N 1.31 -1.135 0 CA-C-N 115.608 -0.724 . . . . 0.0 109.982 -178.617 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 79' ' ' ARG . . . . . 0.749 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 43.1 mtp-105 -53.7 -54.84 32.2 Favored 'General case' 0 CA--C 1.515 -0.382 0 CA-C-O 120.979 0.419 . . . . 0.0 110.167 -178.31 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 2.6 pm0 -56.85 -39.02 73.52 Favored 'General case' 0 C--N 1.318 -0.787 0 CA-C-N 115.454 -0.794 . . . . 0.0 111.486 -176.362 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 81' ' ' GLU . . . . . 1.012 ' HG2' ' HB3' ' A' ' 70' ' ' TYR . 1.0 OUTLIER -66.93 -50.8 61.23 Favored 'General case' 0 C--N 1.323 -0.582 0 N-CA-C 112.419 0.526 . . . . 0.0 112.419 175.188 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 82' ' ' GLN . . . . . 0.614 ' HB2' ' HZ3' ' A' ' 43' ' ' TRP . 56.1 mt-30 -61.45 -34.89 76.18 Favored 'General case' 0 CA--C 1.514 -0.417 0 C-N-CA 121.023 -0.271 . . . . 0.0 110.318 -178.402 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.72 HG13 ' CD1' ' A' ' 31' ' ' TRP . 1.4 mp -60.12 -46.19 94.78 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.089 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.76 173.518 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 84' ' ' ALA . . . . . 0.616 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -62.6 -44.75 95.53 Favored 'General case' 0 C--O 1.238 0.498 0 CA-C-O 121.533 0.683 . . . . 0.0 111.663 -172.813 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.761 HG11 ' CZ3' ' A' ' 62' ' ' TRP . 2.7 p -70.68 -43.66 77.24 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.721 0 CA-C-N 115.949 -0.569 . . . . 0.0 111.027 -179.91 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 86' ' ' ALA . . . . . 0.463 ' HB1' ' CH2' ' A' ' 31' ' ' TRP . . . -61.04 -28.4 69.03 Favored 'General case' 0 N--CA 1.451 -0.415 0 CA-C-N 115.764 -0.653 . . . . 0.0 109.69 174.396 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 87' ' ' GLU . . . . . 0.687 ' HG3' ' O ' ' A' ' 83' ' ' ILE . 30.6 mt-10 -61.18 -43.84 98.25 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.398 -0.819 . . . . 0.0 109.888 179.203 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.675 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 41.2 t -61.81 -46.08 97.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-O 121.178 0.513 . . . . 0.0 109.799 176.244 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 89' ' ' THR . . . . . 0.798 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 0.2 OUTLIER -67.42 -45.95 74.6 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 115.961 -0.563 . . . . 0.0 111.499 -175.25 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 90' ' ' ARG . . . . . 0.636 ' HD3' ' HZ2' ' A' ' 31' ' ' TRP . 23.2 ptt180 -62.87 -34.23 76.94 Favored 'General case' 0 C--O 1.221 -0.418 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.742 -177.259 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 91' ' ' LEU . . . . . 0.675 ' HG ' ' O ' ' A' ' 88' ' ' VAL . 4.2 pp -73.55 -23.78 60.02 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-O 120.951 0.405 . . . . 0.0 110.904 -171.82 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 92' ' ' ARG . . . . . 0.573 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 4.7 mtm180 -82.06 -46.91 13.26 Favored 'General case' 0 CA--C 1.51 -0.588 0 CA-C-O 121.426 0.632 . . . . 0.0 109.608 -179.11 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 93' ' ' GLN . . . . . 0.511 ' NE2' ' HB2' ' A' ' 97' ' ' ALA . 2.5 pt20 -103.42 -27.95 12.1 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 114.759 -1.109 . . . . 0.0 113.965 -168.344 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 92.02 39.98 5.32 Favored Glycine 0 C--N 1.332 0.338 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.436 175.983 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 95' ' ' TRP . . . . . 0.603 ' HZ2' HH11 ' A' ' 90' ' ' ARG . 33.2 m95 70.06 9.62 7.13 Favored 'General case' 0 C--O 1.219 -0.55 0 C-N-CA 123.338 0.655 . . . . 0.0 109.609 -179.933 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -59.44 -41.78 97.23 Favored Glycine 0 N--CA 1.453 -0.223 0 CA-C-N 115.28 -0.873 . . . . 0.0 113.476 -178.68 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 97' ' ' ALA . . . . . 0.511 ' HB2' ' NE2' ' A' ' 93' ' ' GLN . . . -70.03 -17.87 63.28 Favored 'General case' 0 N--CA 1.464 0.275 0 CA-C-N 117.117 0.459 . . . . 0.0 110.793 179.772 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 98' ' ' TRP . . . . . 0.798 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 24.6 m-90 -95.65 107.84 36.12 Favored Pre-proline 0 N--CA 1.448 -0.564 0 N-CA-C 108.794 -0.817 . . . . 0.0 108.794 176.171 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 99' ' ' PRO . . . . . 0.424 ' HD3' ' HA ' ' A' ' 98' ' ' TRP . 41.7 Cg_exo -63.77 -132.46 0.0 OUTLIER 'Trans proline' 0 CA--C 1.539 0.746 0 C-N-CA 123.857 3.038 . . . . 0.0 114.408 -173.804 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 18.3 t -55.48 -26.24 19.0 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.252 0 CA-C-O 120.82 0.343 . . . . 0.0 111.497 -174.623 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 101' ' ' CYS . . . . . 0.581 ' HB3' ' HA ' ' A' ' 34' ' ' ILE . 75.0 m -64.75 -34.41 78.27 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 116.339 -0.392 . . . . 0.0 111.528 -178.553 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -70.03 -40.78 74.97 Favored 'General case' 0 CA--C 1.519 -0.232 0 CA-C-O 120.971 0.415 . . . . 0.0 110.226 177.642 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -63.09 -39.38 94.52 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.353 176.904 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 104' ' ' ARG . . . . . 0.452 ' NE ' ' HA ' ' A' ' 104' ' ' ARG . 14.9 mmp_? -71.69 -31.49 66.82 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.605 -0.725 . . . . 0.0 111.003 178.844 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 105' ' ' ALA . . . . . 0.486 ' CB ' HG22 ' A' ' 30' ' ' ILE . . . -80.71 -23.95 39.14 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 120.989 0.423 . . . . 0.0 111.735 -177.356 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 97.98 59.3 0.95 Allowed Glycine 0 CA--C 1.522 0.471 0 C-N-CA 120.983 -0.627 . . . . 0.0 112.096 -176.707 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -57.62 146.72 29.56 Favored 'General case' 0 C--N 1.329 -0.311 0 C-N-CA 123.274 0.629 . . . . 0.0 112.356 -177.612 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 108' ' ' ARG . . . . . 0.694 ' HD3' ' O ' ' A' ' 108' ' ' ARG . 0.0 OUTLIER . . . . . 0 C--O 1.25 1.09 0 CA-C-O 118.545 -0.74 . . . . 0.0 110.594 -175.899 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 33.4 m-80 . . . . . 0 N--CA 1.476 0.866 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 . . . . . . . . . 0 0 . 1 . 027 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 12.1 p -75.79 -16.81 15.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-O 121.243 0.544 . . . . 0.0 110.192 -179.628 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 79.5 t -70.93 120.21 18.5 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.557 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.923 176.671 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 15.8 t -90.31 147.0 5.51 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 N-CA-C 109.626 -0.509 . . . . 0.0 109.626 178.069 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 8.8 p -103.14 108.3 58.31 Favored Pre-proline 0 C--N 1.317 -0.811 0 CA-C-N 115.94 -0.573 . . . . 0.0 111.292 -178.722 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 43.1 Cg_endo -98.7 165.71 0.64 Allowed 'Trans proline' 0 N--CA 1.442 -1.529 0 C-N-CA 123.585 2.857 . . . . 0.0 111.856 175.812 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -84.02 48.22 1.43 Allowed 'General case' 0 C--N 1.315 -0.929 0 CA-C-O 122.104 0.954 . . . . 0.0 110.045 176.338 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 9.7 t60 -77.29 -3.75 41.46 Favored 'General case' 0 C--N 1.314 -0.963 0 CA-C-N 113.745 -1.57 . . . . 0.0 108.86 176.23 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 11.8 pt-20 -53.46 133.53 40.68 Favored 'General case' 0 C--O 1.234 0.242 0 CA-C-N 115.249 -0.887 . . . . 0.0 111.028 -178.999 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -149.74 73.94 1.2 Allowed 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 115.529 -0.759 . . . . 0.0 109.796 179.46 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 59.0 t -71.61 -50.01 42.39 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.729 0 CA-C-N 114.876 -1.056 . . . . 0.0 111.041 -176.905 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 5.2 p 32.93 82.88 0.01 OUTLIER 'Isoleucine or valine' 0 C--O 1.235 0.334 0 CA-C-O 122.765 1.269 . . . . 0.0 112.761 -176.913 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 13' ' ' ARG . . . . . 0.466 ' O ' ' HG3' ' A' ' 13' ' ' ARG . 2.5 ptp180 -82.6 118.33 23.22 Favored 'General case' 0 C--N 1.309 -1.165 0 CA-C-N 113.993 -1.458 . . . . 0.0 110.24 -177.329 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 3.3 t -107.45 164.45 4.89 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.36 0 CA-C-N 114.442 -1.254 . . . . 0.0 109.12 175.66 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 139.99 71.1 0.04 OUTLIER Glycine 0 N--CA 1.437 -1.296 0 CA-C-N 115.26 -0.882 . . . . 0.0 111.471 178.914 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 86.3 m -115.12 -26.25 7.76 Favored 'General case' 0 N--CA 1.44 -0.96 0 CA-C-N 115.001 -0.599 . . . . 0.0 111.261 -175.945 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 17' ' ' LYS . . . . . 0.472 ' HA ' ' HD3' ' A' ' 18' ' ' PRO . 28.1 mmtp -66.14 108.33 2.19 Favored Pre-proline 0 C--N 1.322 -0.59 0 CA-C-N 115.594 -0.73 . . . . 0.0 111.186 -175.661 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 18' ' ' PRO . . . . . 0.472 ' HD3' ' HA ' ' A' ' 17' ' ' LYS . 5.3 Cg_endo -88.67 173.76 4.27 Favored 'Trans proline' 0 N--CA 1.45 -1.04 0 C-N-CA 123.889 3.059 . . . . 0.0 112.104 178.483 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -122.38 19.68 8.06 Favored Glycine 0 CA--C 1.5 -0.874 0 CA-C-N 114.915 -1.038 . . . . 0.0 112.015 177.499 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 16.2 m -70.34 -38.32 74.82 Favored 'General case' 0 C--N 1.308 -1.216 0 CA-C-N 114.161 -1.02 . . . . 0.0 109.742 177.126 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 7.9 pt-20 -133.63 157.59 45.37 Favored 'General case' 0 N--CA 1.431 -1.395 0 CA-C-N 114.802 -1.09 . . . . 0.0 108.225 176.464 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 64.0 t -107.87 107.5 60.35 Favored Pre-proline 0 C--N 1.3 -1.56 0 CA-C-N 115.741 -0.663 . . . . 0.0 109.501 174.897 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.428 ' HA ' ' HD2' ' A' ' 24' ' ' PRO . 53.2 Cg_exo -55.13 129.59 36.09 Favored 'Trans proline' 0 N--CA 1.46 -0.461 0 C-N-CA 122.677 2.251 . . . . 0.0 111.063 175.234 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 24' ' ' PRO . . . . . 0.428 ' HD2' ' HA ' ' A' ' 23' ' ' PRO . 10.1 Cg_endo -54.34 139.5 73.59 Favored 'Trans proline' 0 N--CA 1.453 -0.864 0 C-N-CA 123.06 2.507 . . . . 0.0 112.004 -176.823 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.546 HG12 ' H ' ' A' ' 27' ' ' ASP . 41.7 t -112.99 125.39 70.24 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.227 0 CA-C-N 114.665 -1.152 . . . . 0.0 110.611 -173.527 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 43.6 mm -66.76 -23.28 30.88 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-N 115.401 -0.818 . . . . 0.0 110.278 -177.885 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.546 ' H ' HG12 ' A' ' 25' ' ' VAL . 5.8 m-20 -79.2 -1.63 37.22 Favored 'General case' 0 CA--C 1.504 -0.804 0 CA-C-N 115.237 -0.892 . . . . 0.0 109.523 -178.84 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 28' ' ' GLY . . . . . 0.572 ' HA2' ' HB2' ' A' ' 31' ' ' TRP . . . -69.1 -9.31 60.01 Favored Glycine 0 N--CA 1.437 -1.266 0 N-CA-C 110.302 -1.119 . . . . 0.0 110.302 176.222 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 17.6 m -76.97 -47.83 19.72 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 121.405 0.622 . . . . 0.0 110.073 177.12 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.773 HG22 ' O ' ' A' ' 105' ' ' ALA . 4.2 pt -71.67 -34.64 52.9 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.923 0 CA-C-N 115.087 -0.96 . . . . 0.0 109.641 176.844 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 31' ' ' TRP . . . . . 0.673 ' CZ2' ' HD3' ' A' ' 90' ' ' ARG . 12.1 m95 -63.75 -37.18 86.41 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 115.334 -0.848 . . . . 0.0 109.528 175.652 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 36.2 t70 -77.63 -31.32 52.7 Favored 'General case' 0 N--CA 1.448 -0.54 0 CA-C-N 115.837 -0.62 . . . . 0.0 111.133 179.793 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 33' ' ' ALA . . . . . 0.468 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -69.0 -33.75 74.17 Favored 'General case' 0 N--CA 1.446 -0.642 0 C-N-CA 120.409 -0.516 . . . . 0.0 109.727 176.706 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 34' ' ' ILE . . . . . 0.471 HG13 ' O ' ' A' ' 30' ' ' ILE . 74.1 mt -67.43 -42.81 87.66 Favored 'Isoleucine or valine' 0 C--O 1.233 0.215 0 CA-C-O 121.132 0.491 . . . . 0.0 109.722 171.72 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 35' ' ' ALA . . . . . 0.604 ' HA ' ' O ' ' A' ' 54' ' ' GLY . . . -57.76 -35.25 70.48 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.574 -0.739 . . . . 0.0 110.452 175.917 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 36' ' ' GLY . . . . . 0.491 ' HA2' ' N ' ' A' ' 41' ' ' GLY . . . -78.67 -5.44 88.29 Favored Glycine 0 N--CA 1.449 -0.46 0 CA-C-N 115.267 -0.879 . . . . 0.0 112.138 179.412 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 42.6 t -103.07 -54.17 2.67 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 120.742 0.306 . . . . 0.0 110.892 -178.483 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 38' ' ' GLU . . . . . 0.461 ' HG2' ' SG ' ' A' ' 101' ' ' CYS . 30.1 mm-40 -87.06 -31.05 20.72 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 121.162 0.506 . . . . 0.0 110.758 -174.717 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -103.22 -10.51 18.71 Favored 'General case' 0 N--CA 1.447 -0.6 0 CA-C-N 116.029 -0.532 . . . . 0.0 111.262 -179.043 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 76.22 14.23 82.52 Favored Glycine 0 CA--C 1.503 -0.7 0 N-CA-C 109.864 -1.294 . . . . 0.0 109.864 -178.455 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 41' ' ' GLY . . . . . 0.491 ' N ' ' HA2' ' A' ' 36' ' ' GLY . . . 81.66 62.53 1.93 Allowed Glycine 0 N--CA 1.432 -1.596 0 CA-C-N 113.94 -1.13 . . . . 0.0 111.82 -176.568 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 42' ' ' ASN . . . . . 0.565 ' HB3' ' HB ' ' A' ' 45' ' ' ILE . 2.9 t-20 -155.87 96.97 1.78 Allowed 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 109.136 -0.69 . . . . 0.0 109.136 -178.557 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 43' ' ' TRP . . . . . 0.725 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 33.0 m95 -73.35 -11.04 60.35 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-O 121.285 0.564 . . . . 0.0 111.007 -175.319 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -106.25 14.91 26.91 Favored 'General case' 0 C--N 1.314 -0.952 0 CA-C-N 115.575 -0.739 . . . . 0.0 111.432 -179.059 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.851 HG22 ' HA2' ' A' ' 53' ' ' GLY . 7.0 tt -78.86 142.92 13.39 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.793 0 CA-C-O 121.138 0.494 . . . . 0.0 110.121 -178.106 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 3.2 t30 -148.29 90.05 1.77 Allowed 'General case' 0 C--N 1.312 -1.027 0 CA-C-O 121.114 0.483 . . . . 0.0 109.958 178.923 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 13.9 p -76.48 -16.65 59.6 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 115.87 -0.605 . . . . 0.0 111.724 -176.92 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 94.93 21.99 24.31 Favored Glycine 0 N--CA 1.447 -0.625 0 N-CA-C 110.942 -0.863 . . . . 0.0 110.942 -177.931 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 10.4 t-20 -86.1 -12.27 50.48 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 121.302 0.573 . . . . 0.0 110.964 -175.098 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 50' ' ' GLY . . . . . 0.402 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 95.21 -9.47 69.83 Favored Glycine 0 N--CA 1.448 -0.517 0 N-CA-C 110.184 -1.166 . . . . 0.0 110.184 -175.386 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 51' ' ' TYR . . . . . 0.545 ' HA ' ' HA ' ' A' ' 58' ' ' ASP . 0.5 OUTLIER -110.73 146.68 35.87 Favored 'General case' 0 CA--C 1.505 -0.777 0 N-CA-C 105.914 -1.884 . . . . 0.0 105.914 175.373 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 52' ' ' TYR . . . . . 0.788 ' HB2' ' HB3' ' A' ' 74' ' ' ALA . 45.0 m-85 -112.9 167.58 10.39 Favored 'General case' 0 C--N 1.304 -1.412 0 C-N-CA 119.623 -0.831 . . . . 0.0 112.905 -167.835 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.851 ' HA2' HG22 ' A' ' 45' ' ' ILE . . . -54.86 157.15 7.19 Favored Glycine 0 N--CA 1.446 -0.682 0 CA-C-N 114.787 -1.097 . . . . 0.0 114.105 -171.698 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.689 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 97.03 -109.86 3.93 Favored Glycine 0 N--CA 1.437 -1.244 0 C-N-CA 120.803 -0.713 . . . . 0.0 111.72 -178.411 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.546 HG23 ' HG2' ' A' ' 82' ' ' GLN . 3.1 t -84.83 -0.46 5.94 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 CA-C-O 121.771 0.796 . . . . 0.0 110.354 -176.344 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 56' ' ' GLN . . . . . 0.587 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 8.1 tp-100 56.66 50.49 12.61 Favored 'General case' 0 C--N 1.339 0.141 0 CA-C-N 114.195 -1.366 . . . . 0.0 112.685 168.289 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 57' ' ' PHE . . . . . 0.47 ' CE1' ' HB2' ' A' ' 86' ' ' ALA . 7.8 p90 -116.98 162.76 17.26 Favored 'General case' 0 C--N 1.321 -0.659 0 C-N-CA 120.105 -0.638 . . . . 0.0 111.083 175.287 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.545 ' HA ' ' HA ' ' A' ' 51' ' ' TYR . 6.4 p-10 -76.28 160.17 29.9 Favored 'General case' 0 C--N 1.324 -0.511 0 N-CA-C 113.594 0.961 . . . . 0.0 113.594 -162.957 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 13.1 tp60 -57.24 -39.45 75.59 Favored 'General case' 0 N--CA 1.443 -0.808 0 CA-C-N 114.036 -1.438 . . . . 0.0 111.563 178.888 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -66.74 -49.89 51.99 Favored Glycine 0 C--O 1.225 -0.436 0 CA-C-N 115.653 -0.703 . . . . 0.0 112.468 -175.746 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 93.6 m -60.68 -44.06 96.96 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 121.15 0.5 . . . . 0.0 110.681 176.051 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 62' ' ' TRP . . . . . 0.433 ' HE3' ' CZ ' ' A' ' 57' ' ' PHE . 52.3 t-105 -57.05 -48.61 78.11 Favored 'General case' 0 N--CA 1.445 -0.68 0 CA-C-N 115.331 -0.849 . . . . 0.0 109.895 176.667 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 63' ' ' GLU . . . . . 0.503 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 31.4 tt0 -67.48 -35.09 78.48 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-N 115.141 -0.936 . . . . 0.0 110.875 -177.593 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -67.03 -41.67 86.16 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.76 -0.655 . . . . 0.0 111.04 -176.639 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 65' ' ' ASN . . . . . 0.441 ' HB2' HG13 ' A' ' 85' ' ' VAL . 8.1 m120 -77.69 -9.06 58.78 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 121.112 0.482 . . . . 0.0 110.156 176.137 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 88.35 45.2 5.07 Favored Glycine 0 C--N 1.332 0.341 0 CA-C-N 115.734 -0.666 . . . . 0.0 112.395 174.05 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.518 ' HA2' ' CD1' ' A' ' 70' ' ' TYR . . . -79.02 -20.28 70.62 Favored Glycine 0 N--CA 1.442 -0.964 0 C-N-CA 120.883 -0.675 . . . . 0.0 112.879 -172.937 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.818 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 6.7 mp -61.27 -24.05 66.12 Favored 'General case' 0 N--CA 1.45 -0.434 0 N-CA-C 112.281 0.475 . . . . 0.0 112.281 -173.72 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 69' ' ' ARG . . . . . 0.497 ' HG3' ' N ' ' A' ' 70' ' ' TYR . 0.7 OUTLIER -70.62 -29.42 65.8 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 121.206 0.527 . . . . 0.0 110.135 176.143 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 70' ' ' TYR . . . . . 0.842 ' HB3' ' HB3' ' A' ' 81' ' ' GLU . 71.7 m-85 -79.7 -34.35 40.23 Favored 'General case' 0 N--CA 1.446 -0.655 0 N-CA-C 107.329 -1.36 . . . . 0.0 107.329 176.449 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.675 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 162.51 127.57 0.01 OUTLIER Pre-proline 0 C--O 1.218 -0.558 0 CA-C-N 112.401 -2.182 . . . . 0.0 107.098 -178.286 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 72' ' ' PRO . . . . . 0.818 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 17.9 Cg_exo -57.13 -1.97 0.47 Allowed 'Trans proline' 0 C--N 1.332 -0.34 0 C-N-CA 122.991 2.46 . . . . 0.0 114.058 -177.453 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 12.5 ptm180 -152.56 141.89 21.55 Favored 'General case' 0 C--N 1.319 -0.726 0 N-CA-C 109.64 -0.504 . . . . 0.0 109.64 176.998 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 74' ' ' ALA . . . . . 0.788 ' HB3' ' HB2' ' A' ' 52' ' ' TYR . . . -63.44 -22.07 66.67 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.509 -0.769 . . . . 0.0 113.028 -176.798 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 75' ' ' ASP . . . . . 0.517 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 5.2 p-10 -88.29 2.92 51.38 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 121.328 0.585 . . . . 0.0 110.847 -179.781 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.435 ' HB3' ' HB1' ' A' ' 71' ' ' ALA . 53.5 tp -106.27 -34.86 7.35 Favored 'General case' 0 C--N 1.321 -0.654 0 N-CA-C 108.858 -0.793 . . . . 0.0 108.858 174.246 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 77' ' ' ALA . . . . . 0.815 ' HB1' ' HB2' ' A' ' 81' ' ' GLU . . . -79.83 158.12 26.85 Favored 'General case' 0 N--CA 1.446 -0.627 0 CA-C-N 114.99 -1.005 . . . . 0.0 110.057 174.512 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 25.4 p -100.77 -171.64 2.04 Favored 'General case' 0 C--N 1.314 -0.965 0 CA-C-N 116.2 -0.455 . . . . 0.0 109.8 -179.435 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 79' ' ' ARG . . . . . 0.725 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 35.9 mtt85 -49.21 -51.95 29.91 Favored 'General case' 0 C--O 1.218 -0.559 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.79 -179.959 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -57.45 -47.61 81.35 Favored 'General case' 0 C--N 1.321 -0.666 0 N-CA-C 112.148 0.425 . . . . 0.0 112.148 -174.854 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 81' ' ' GLU . . . . . 0.842 ' HB3' ' HB3' ' A' ' 70' ' ' TYR . 60.6 mp0 -65.6 -51.23 61.28 Favored 'General case' 0 CA--C 1.517 -0.318 0 CA-C-O 120.983 0.421 . . . . 0.0 111.403 177.228 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 82' ' ' GLN . . . . . 0.546 ' HG2' HG23 ' A' ' 55' ' ' VAL . 4.2 tt0 -65.0 -34.35 78.24 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.606 -0.724 . . . . 0.0 111.361 -173.657 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.582 ' O ' ' HB3' ' A' ' 87' ' ' GLU . 8.1 mt -61.63 -46.13 97.2 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 N-CA-C 109.471 -0.566 . . . . 0.0 109.471 174.193 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 84' ' ' ALA . . . . . . . . . . . . . . . -61.37 -47.48 85.68 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.205 -176.825 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.441 HG13 ' HB2' ' A' ' 65' ' ' ASN . 46.5 t -65.97 -50.28 70.85 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-N 116.137 -0.483 . . . . 0.0 112.207 -179.997 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 86' ' ' ALA . . . . . 0.47 ' HB2' ' CE1' ' A' ' 57' ' ' PHE . . . -63.87 -32.05 73.44 Favored 'General case' 0 CA--C 1.515 -0.394 0 CA-C-O 121.397 0.618 . . . . 0.0 110.437 179.702 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 87' ' ' GLU . . . . . 0.675 ' HA ' ' HG2' ' A' ' 90' ' ' ARG . 0.4 OUTLIER -71.32 -27.28 63.28 Favored 'General case' 0 C--N 1.317 -0.844 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.871 -178.136 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.672 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 94.6 t -61.22 -44.17 97.85 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.254 0 N-CA-C 108.701 -0.852 . . . . 0.0 108.701 169.295 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 89' ' ' THR . . . . . 0.677 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 0.3 OUTLIER -66.81 -43.81 82.87 Favored 'General case' 0 C--N 1.316 -0.852 0 CA-C-N 115.582 -0.735 . . . . 0.0 111.375 -179.778 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 90' ' ' ARG . . . . . 0.675 ' HG2' ' HA ' ' A' ' 87' ' ' GLU . 20.7 ptt180 -59.88 -35.11 74.13 Favored 'General case' 0 C--O 1.222 -0.392 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.707 -176.197 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 91' ' ' LEU . . . . . 0.672 ' HG ' ' O ' ' A' ' 88' ' ' VAL . 4.6 pp -74.44 -24.77 59.12 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 121.042 0.448 . . . . 0.0 111.102 -171.678 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 92' ' ' ARG . . . . . 0.501 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 2.5 mtm180 -81.79 -45.24 15.87 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-O 121.568 0.699 . . . . 0.0 109.514 -178.044 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 93' ' ' GLN . . . . . 0.42 HE21 ' HZ3' ' A' ' 98' ' ' TRP . 6.6 pt20 -104.27 -28.06 11.63 Favored 'General case' 0 C--N 1.322 -0.618 0 N-CA-C 113.59 0.959 . . . . 0.0 113.59 -169.696 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 88.35 44.23 5.35 Favored Glycine 0 CA--C 1.507 -0.419 0 C-N-CA 120.625 -0.797 . . . . 0.0 112.136 176.195 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 95' ' ' TRP . . . . . 0.531 ' HZ2' HH11 ' A' ' 90' ' ' ARG . 23.6 m95 66.87 13.63 9.5 Favored 'General case' 0 C--O 1.218 -0.6 0 CA-C-O 121.173 0.511 . . . . 0.0 109.812 178.396 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -65.53 -31.62 80.74 Favored Glycine 0 N--CA 1.451 -0.304 0 CA-C-N 115.588 -0.733 . . . . 0.0 113.132 177.289 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -76.49 -21.52 55.72 Favored 'General case' 0 CA--C 1.515 -0.385 0 CA-C-O 121.152 0.501 . . . . 0.0 110.411 178.508 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 98' ' ' TRP . . . . . 0.677 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 25.1 m-90 -100.26 108.62 53.41 Favored Pre-proline 0 N--CA 1.443 -0.803 0 CA-C-N 115.521 -0.763 . . . . 0.0 109.202 178.42 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 99' ' ' PRO . . . . . 0.45 ' HD3' ' HA ' ' A' ' 98' ' ' TRP . 52.5 Cg_exo -62.25 -138.46 0.0 OUTLIER 'Trans proline' 0 CA--C 1.535 0.56 0 C-N-CA 123.831 3.021 . . . . 0.0 114.265 -174.026 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 3.4 m -54.11 -26.3 14.6 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.915 -177.882 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 101' ' ' CYS . . . . . 0.461 ' SG ' ' HG2' ' A' ' 38' ' ' GLU . 62.0 m -56.69 -39.64 74.16 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-N 115.75 -0.659 . . . . 0.0 111.525 178.035 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -70.8 -44.24 67.0 Favored 'General case' 0 CA--C 1.519 -0.23 0 CA-C-O 121.008 0.432 . . . . 0.0 110.716 179.871 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -60.68 -44.15 96.85 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.634 179.724 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -66.87 -34.03 76.91 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.712 -0.676 . . . . 0.0 111.049 176.957 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 105' ' ' ALA . . . . . 0.773 ' O ' HG22 ' A' ' 30' ' ' ILE . . . -76.51 -26.77 55.6 Favored 'General case' 0 C--N 1.331 -0.238 0 N-CA-C 111.895 0.332 . . . . 0.0 111.895 -175.285 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 111.62 60.28 0.46 Allowed Glycine 0 CA--C 1.521 0.415 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.234 -175.31 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -70.11 148.61 48.52 Favored 'General case' 0 C--N 1.327 -0.375 0 C-N-CA 122.579 0.351 . . . . 0.0 110.891 -178.94 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 108' ' ' ARG . . . . . 0.434 ' HD3' ' O ' ' A' ' 108' ' ' ARG . 0.0 OUTLIER . . . . . 0 C--O 1.245 0.825 0 CA-C-O 118.559 -0.734 . . . . 0.0 110.318 -177.082 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 91.0 m-20 . . . . . 0 N--CA 1.48 1.061 0 CA-C-O 120.965 0.412 . . . . 0.0 110.437 . . . . . . . . . 0 0 . 1 . 028 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 8.0 p -75.3 -42.87 43.71 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.13 178.635 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 7.4 p -76.44 115.09 17.56 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.893 0 CA-C-O 121.418 0.628 . . . . 0.0 110.69 175.754 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 11.1 t -97.26 148.75 5.37 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.14 -179.396 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 5' ' ' THR . . . . . 0.457 ' HA ' ' HD3' ' A' ' 6' ' ' PRO . 1.2 p -82.09 113.75 45.73 Favored Pre-proline 0 C--N 1.319 -0.729 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.641 178.948 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.457 ' HD3' ' HA ' ' A' ' 5' ' ' THR . 3.4 Cg_exo -75.78 170.23 20.6 Favored 'Trans proline' 0 N--CA 1.456 -0.735 0 C-N-CA 122.97 2.447 . . . . 0.0 112.004 -177.519 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -96.54 35.72 1.46 Allowed 'General case' 0 C--N 1.31 -1.147 0 CA-C-N 114.623 -1.171 . . . . 0.0 110.997 -177.672 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 31.3 t-80 -76.27 -7.42 54.87 Favored 'General case' 0 C--N 1.315 -0.91 0 CA-C-N 114.854 -1.066 . . . . 0.0 108.345 169.733 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 12.8 pt-20 -67.85 157.4 34.94 Favored 'General case' 0 N--CA 1.45 -0.433 0 CA-C-N 114.745 -1.116 . . . . 0.0 110.409 177.52 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -144.36 78.55 1.58 Allowed 'General case' 0 C--N 1.315 -0.906 0 CA-C-N 115.472 -0.785 . . . . 0.0 110.061 -178.862 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 57.8 t -68.84 -75.12 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 CA-C-N 114.98 -1.009 . . . . 0.0 109.48 177.125 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 5.1 p 25.15 82.49 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.343 0.325 0 C-N-CA 125.078 1.351 . . . . 0.0 113.554 172.489 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 54.9 mtm180 -87.84 100.72 13.08 Favored 'General case' 0 C--N 1.305 -1.355 0 CA-C-N 114.202 -1.363 . . . . 0.0 111.377 -177.817 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.433 HG12 ' N ' ' A' ' 15' ' ' GLY . 7.0 t -133.32 166.41 29.34 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.144 0 CA-C-N 113.915 -1.493 . . . . 0.0 108.636 178.82 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 15' ' ' GLY . . . . . 0.433 ' N ' HG12 ' A' ' 14' ' ' VAL . . . 141.7 68.41 0.03 OUTLIER Glycine 0 N--CA 1.439 -1.111 0 CA-C-N 115.598 -0.728 . . . . 0.0 111.94 177.381 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 19.9 m -95.85 -25.47 16.0 Favored 'General case' 0 N--CA 1.442 -0.837 0 CA-C-N 114.992 -0.604 . . . . 0.0 110.945 -177.192 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 17' ' ' LYS . . . . . 0.42 ' HA ' ' HD3' ' A' ' 18' ' ' PRO . 29.6 mmmt -46.37 114.68 2.74 Favored Pre-proline 0 C--N 1.322 -0.626 0 CA-C-N 114.215 -1.357 . . . . 0.0 112.633 -176.003 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 18' ' ' PRO . . . . . 0.42 ' HD3' ' HA ' ' A' ' 17' ' ' LYS . 17.1 Cg_exo -70.41 162.78 41.14 Favored 'Trans proline' 0 CA--C 1.509 -0.726 0 C-N-CA 123.668 2.912 . . . . 0.0 112.066 175.039 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -131.4 33.06 2.84 Favored Glycine 0 C--N 1.305 -1.153 0 CA-C-N 114.318 -1.31 . . . . 0.0 111.825 -177.405 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 10.5 m -64.82 -53.24 49.95 Favored 'General case' 0 C--N 1.314 -0.953 0 CA-C-N 114.57 -0.815 . . . . 0.0 109.744 177.591 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 21' ' ' GLU . . . . . 0.54 ' O ' ' HD3' ' A' ' 23' ' ' PRO . 33.5 mt-10 -144.65 107.43 4.46 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 108.57 -0.9 . . . . 0.0 108.57 173.387 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 7.4 p -92.24 110.58 45.42 Favored Pre-proline 0 C--N 1.317 -0.823 0 CA-C-O 121.569 0.7 . . . . 0.0 111.465 -175.717 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.54 ' HD3' ' O ' ' A' ' 21' ' ' GLU . 27.3 Cg_exo -62.95 155.01 63.06 Favored 'Trans proline' 0 N--CA 1.46 -0.458 0 C-N-CA 123.52 2.813 . . . . 0.0 111.789 175.824 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 8.0 Cg_endo -52.78 140.91 56.29 Favored 'Trans proline' 0 N--CA 1.451 -1.012 0 C-N-CA 122.302 2.001 . . . . 0.0 109.865 172.091 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.97 HG11 HG21 ' A' ' 83' ' ' ILE . 97.2 t -79.83 124.57 38.11 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.243 0 CA-C-O 122.143 0.973 . . . . 0.0 113.254 -161.896 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 48.4 mm -81.24 -25.84 10.43 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 CA-C-N 113.89 -1.505 . . . . 0.0 110.873 -179.372 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.514 ' O ' HG12 ' A' ' 30' ' ' ILE . 7.0 m-20 -84.8 1.3 47.43 Favored 'General case' 0 CA--C 1.504 -0.803 0 CA-C-O 121.791 0.805 . . . . 0.0 108.849 -177.235 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 28' ' ' GLY . . . . . 0.599 ' HA2' ' HB2' ' A' ' 31' ' ' TRP . . . -66.25 -5.05 25.93 Favored Glycine 0 N--CA 1.44 -1.092 0 CA-C-N 114.488 -1.233 . . . . 0.0 110.581 176.721 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 22.3 m -77.2 -40.44 45.15 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 120.989 0.423 . . . . 0.0 109.98 174.053 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.514 HG12 ' O ' ' A' ' 27' ' ' ASP . 0.6 OUTLIER -65.25 -38.92 83.82 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.513 0 N-CA-C 107.038 -1.467 . . . . 0.0 107.038 174.108 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 31' ' ' TRP . . . . . 0.684 ' CD1' HG13 ' A' ' 83' ' ' ILE . 31.7 m95 -72.1 -36.49 69.48 Favored 'General case' 0 N--CA 1.438 -1.075 0 CA-C-N 113.598 -1.637 . . . . 0.0 111.031 -175.998 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 6.6 t70 -72.63 -34.65 67.46 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.016 178.203 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -67.3 -37.01 82.67 Favored 'General case' 0 N--CA 1.445 -0.685 0 C-N-CA 120.64 -0.424 . . . . 0.0 109.923 177.119 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 34' ' ' ILE . . . . . 0.509 HG13 ' O ' ' A' ' 30' ' ' ILE . 74.2 mt -67.66 -46.43 82.79 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.171 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.523 174.491 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -58.91 -34.22 71.45 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 121.215 0.531 . . . . 0.0 110.516 177.563 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 36' ' ' GLY . . . . . 0.528 ' HA2' ' N ' ' A' ' 41' ' ' GLY . . . -78.83 -7.03 88.51 Favored Glycine 0 N--CA 1.45 -0.418 0 CA-C-N 115.617 -0.72 . . . . 0.0 111.719 178.616 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 46.0 t -94.81 -58.1 2.27 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-O 120.775 0.321 . . . . 0.0 110.607 -179.221 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 38' ' ' GLU . . . . . 0.436 ' HG3' ' SG ' ' A' ' 101' ' ' CYS . 40.2 mt-10 -89.29 -25.61 21.58 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.379 -0.373 . . . . 0.0 111.345 -173.52 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -107.53 -12.95 15.18 Favored 'General case' 0 C--N 1.324 -0.527 0 C-N-CA 120.444 -0.502 . . . . 0.0 111.869 -179.011 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 78.72 13.57 83.01 Favored Glycine 0 CA--C 1.503 -0.665 0 N-CA-C 109.789 -1.324 . . . . 0.0 109.789 -177.371 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 41' ' ' GLY . . . . . 0.528 ' N ' ' HA2' ' A' ' 36' ' ' GLY . . . 78.87 61.52 2.39 Favored Glycine 0 N--CA 1.435 -1.391 0 CA-C-N 114.069 -1.066 . . . . 0.0 111.855 -177.053 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 42' ' ' ASN . . . . . 0.438 ' HB3' ' HB ' ' A' ' 45' ' ' ILE . 4.1 t-20 -145.66 96.98 2.9 Favored 'General case' 0 N--CA 1.45 -0.449 0 N-CA-C 109.044 -0.724 . . . . 0.0 109.044 -177.968 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 43' ' ' TRP . . . . . 0.867 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 16.1 m95 -82.72 -1.42 51.34 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-O 121.554 0.692 . . . . 0.0 111.156 -170.412 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -113.62 9.55 17.89 Favored 'General case' 0 C--N 1.314 -0.967 0 CA-C-N 115.039 -0.982 . . . . 0.0 111.095 178.713 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.952 HG22 ' HA2' ' A' ' 53' ' ' GLY . 9.5 tt -72.65 143.22 14.2 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.68 0 CA-C-O 121.177 0.513 . . . . 0.0 110.654 -175.603 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 15.3 t-20 -150.8 97.05 2.43 Favored 'General case' 0 C--N 1.311 -1.1 0 N-CA-C 109.399 -0.593 . . . . 0.0 109.399 177.732 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 11.1 p -74.89 -16.67 60.66 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 115.798 -0.637 . . . . 0.0 111.006 -177.7 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 101.4 13.03 34.09 Favored Glycine 0 N--CA 1.445 -0.705 0 CA-C-N 115.818 -0.628 . . . . 0.0 111.612 178.059 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 31.7 p-10 -91.65 3.01 56.07 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.801 0.334 . . . . 0.0 111.4 -176.381 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 94.9 -2.54 66.55 Favored Glycine 0 N--CA 1.449 -0.494 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.265 179.909 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 51' ' ' TYR . . . . . 0.571 ' HA ' ' HA ' ' A' ' 58' ' ' ASP . 0.4 OUTLIER -108.59 162.6 13.99 Favored 'General case' 0 CA--C 1.515 -0.374 0 N-CA-C 108.464 -0.939 . . . . 0.0 108.464 176.874 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 52' ' ' TYR . . . . . 0.627 ' O ' ' HA ' ' A' ' 56' ' ' GLN . 61.6 m-85 -123.32 169.73 11.03 Favored 'General case' 0 C--N 1.315 -0.927 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.617 -170.874 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.952 ' HA2' HG22 ' A' ' 45' ' ' ILE . . . -64.58 157.89 44.24 Favored Glycine 0 N--CA 1.445 -0.765 0 CA-C-N 115.585 -0.734 . . . . 0.0 114.105 -169.913 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.669 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 107.1 -111.73 3.57 Favored Glycine 0 N--CA 1.442 -0.964 0 N-CA-C 111.653 -0.579 . . . . 0.0 111.653 179.3 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 3.1 m -93.42 12.9 2.75 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 CA-C-O 121.906 0.86 . . . . 0.0 110.385 176.69 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 56' ' ' GLN . . . . . 0.627 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 22.2 tt0 60.8 49.85 5.83 Favored 'General case' 0 C--N 1.317 -0.845 0 CA-C-N 113.673 -1.603 . . . . 0.0 112.178 172.652 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 57' ' ' PHE . . . . . 0.416 ' HZ ' ' CA ' ' A' ' 86' ' ' ALA . 27.3 m-85 -60.97 133.93 56.59 Favored 'General case' 0 CA--C 1.506 -0.717 0 CA-C-N 115.35 -0.841 . . . . 0.0 111.547 169.626 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.571 ' HA ' ' HA ' ' A' ' 51' ' ' TYR . 6.2 p-10 -74.01 156.13 37.85 Favored 'General case' 0 C--N 1.315 -0.932 0 C-N-CA 119.509 -0.877 . . . . 0.0 108.831 163.928 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 21.0 tp60 -52.52 -39.06 60.93 Favored 'General case' 0 N--CA 1.443 -0.778 0 CA-C-O 121.098 0.475 . . . . 0.0 111.039 -179.082 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -69.7 -50.95 27.62 Favored Glycine 0 C--O 1.222 -0.599 0 CA-C-N 115.127 -0.942 . . . . 0.0 113.237 -174.005 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 95.6 m -64.8 -35.24 80.46 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 121.201 0.524 . . . . 0.0 110.771 179.369 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 62' ' ' TRP . . . . . 0.698 ' CZ3' ' HA ' ' A' ' 82' ' ' GLN . 59.8 t-105 -60.99 -49.04 79.07 Favored 'General case' 0 N--CA 1.443 -0.779 0 CA-C-O 121.579 0.704 . . . . 0.0 109.258 174.768 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 63' ' ' GLU . . . . . 0.469 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 40.8 tt0 -67.24 -33.96 76.44 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-N 114.858 -1.064 . . . . 0.0 110.858 -179.017 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -63.36 -42.65 98.89 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.815 -0.63 . . . . 0.0 112.057 -175.341 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 65' ' ' ASN . . . . . 0.634 ' HB2' HG13 ' A' ' 85' ' ' VAL . 37.1 m-80 -83.43 -10.41 58.41 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.826 0.346 . . . . 0.0 110.409 176.209 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 66' ' ' GLY . . . . . 0.459 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 94.09 51.44 2.08 Favored Glycine 0 C--N 1.332 0.35 0 C-N-CA 121.007 -0.616 . . . . 0.0 112.839 173.831 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.596 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -79.73 -23.96 61.19 Favored Glycine 0 N--CA 1.439 -1.116 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.821 -176.49 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.824 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 6.9 mp -59.47 -26.8 65.54 Favored 'General case' 0 C--N 1.323 -0.545 0 N-CA-C 112.553 0.575 . . . . 0.0 112.553 -172.748 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 69' ' ' ARG . . . . . 0.459 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 3.4 ptm180 -65.5 -33.15 75.27 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 121.36 0.6 . . . . 0.0 109.877 177.335 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 70' ' ' TYR . . . . . 1.067 ' HB3' ' HG2' ' A' ' 81' ' ' GLU . 74.1 m-85 -81.26 -34.79 31.83 Favored 'General case' 0 N--CA 1.439 -0.98 0 N-CA-C 107.956 -1.127 . . . . 0.0 107.956 179.389 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.681 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 164.63 126.12 0.02 OUTLIER Pre-proline 0 N--CA 1.448 -0.552 0 CA-C-N 112.63 -2.077 . . . . 0.0 106.989 -178.766 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 72' ' ' PRO . . . . . 0.824 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 26.5 Cg_exo -55.17 -5.88 0.66 Allowed 'Trans proline' 0 C--N 1.332 -0.3 0 C-N-CA 123.216 2.61 . . . . 0.0 114.076 -177.808 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 73' ' ' ARG . . . . . 0.423 HH11 ' HD2' ' A' ' 73' ' ' ARG . 9.9 ptm180 -146.97 138.37 24.14 Favored 'General case' 0 C--N 1.318 -0.795 0 CA-C-O 121.459 0.647 . . . . 0.0 110.402 175.776 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 74' ' ' ALA . . . . . 0.407 ' HB2' ' CE3' ' A' ' 62' ' ' TRP . . . -60.12 -20.68 59.46 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 114.839 -1.073 . . . . 0.0 112.6 -178.889 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 75' ' ' ASP . . . . . 0.615 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 0.0 OUTLIER -76.83 -22.17 53.97 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 121.262 0.553 . . . . 0.0 110.602 -178.536 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 57.9 tp -92.66 -33.36 14.4 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.643 -0.708 . . . . 0.0 110.022 177.766 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 77' ' ' ALA . . . . . 0.715 ' HB1' ' HB3' ' A' ' 81' ' ' GLU . . . -77.8 154.84 31.51 Favored 'General case' 0 N--CA 1.447 -0.581 0 CA-C-N 115.48 -0.782 . . . . 0.0 110.66 178.657 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 72.9 p -96.41 -174.39 3.04 Favored 'General case' 0 C--N 1.314 -0.955 0 CA-C-N 115.214 -0.903 . . . . 0.0 110.84 -176.65 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 79' ' ' ARG . . . . . 0.867 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 0.1 OUTLIER -50.9 -54.75 21.35 Favored 'General case' 0 C--O 1.216 -0.668 0 CA-C-O 120.699 0.285 . . . . 0.0 110.376 -179.093 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -60.35 -38.22 83.14 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-O 121.261 0.553 . . . . 0.0 111.289 -174.086 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 81' ' ' GLU . . . . . 1.067 ' HG2' ' HB3' ' A' ' 70' ' ' TYR . 2.9 mt-10 -72.32 -52.99 13.7 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 115.505 -0.771 . . . . 0.0 112.297 -179.98 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 82' ' ' GLN . . . . . 0.698 ' HA ' ' CZ3' ' A' ' 62' ' ' TRP . 3.7 tt0 -63.78 -34.47 77.97 Favored 'General case' 0 C--N 1.317 -0.841 0 CA-C-N 115.28 -0.873 . . . . 0.0 109.621 -178.441 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.97 HG21 HG11 ' A' ' 25' ' ' VAL . 0.5 OUTLIER -70.02 -39.56 77.47 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.235 0 CA-C-N 114.632 -1.167 . . . . 0.0 110.965 177.907 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 84' ' ' ALA . . . . . 0.427 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -58.98 -36.19 74.46 Favored 'General case' 0 C--O 1.237 0.418 0 CA-C-O 121.587 0.708 . . . . 0.0 110.321 -178.272 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.634 HG13 ' HB2' ' A' ' 65' ' ' ASN . 44.6 t -67.21 -46.89 83.14 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-N 115.173 -0.921 . . . . 0.0 110.187 176.57 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 86' ' ' ALA . . . . . 0.416 ' CA ' ' HZ ' ' A' ' 57' ' ' PHE . . . -61.67 -31.92 72.07 Favored 'General case' 0 N--CA 1.451 -0.378 0 CA-C-N 115.465 -0.789 . . . . 0.0 110.641 175.813 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 87' ' ' GLU . . . . . 0.631 ' HA ' ' HG2' ' A' ' 90' ' ' ARG . 21.4 mm-40 -60.53 -44.29 96.22 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.616 -177.809 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.568 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 96.8 t -62.52 -51.78 68.03 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.425 0 C-N-CA 120.431 -0.508 . . . . 0.0 110.553 -179.13 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 89' ' ' THR . . . . . 0.56 ' HA ' ' NE ' ' A' ' 92' ' ' ARG . 14.8 t -74.09 -35.08 64.17 Favored 'General case' 0 N--CA 1.439 -0.99 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.505 -175.278 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 90' ' ' ARG . . . . . 0.631 ' HG2' ' HA ' ' A' ' 87' ' ' GLU . 3.3 ptt180 -62.26 -36.84 83.3 Favored 'General case' 0 N--CA 1.471 0.595 0 O-C-N 122.252 -0.28 . . . . 0.0 111.165 -178.337 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 91' ' ' LEU . . . . . 0.6 ' N ' ' HG3' ' A' ' 90' ' ' ARG . 4.5 pp -73.03 -23.75 60.63 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.311 -172.964 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 92' ' ' ARG . . . . . 0.56 ' NE ' ' HA ' ' A' ' 89' ' ' THR . 4.4 mtm180 -82.08 -43.09 18.31 Favored 'General case' 0 CA--C 1.51 -0.581 0 CA-C-O 121.797 0.808 . . . . 0.0 109.652 -178.274 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 93' ' ' GLN . . . . . 0.574 ' NE2' ' HB2' ' A' ' 97' ' ' ALA . 4.1 pt20 -99.98 -27.35 13.62 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 114.764 -1.107 . . . . 0.0 113.111 -170.485 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 84.14 47.75 5.39 Favored Glycine 0 CA--C 1.502 -0.772 0 C-N-CA 120.698 -0.763 . . . . 0.0 111.616 174.795 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 95' ' ' TRP . . . . . 0.514 ' HA ' ' HE3' ' A' ' 98' ' ' TRP . 2.9 m95 63.27 17.4 10.21 Favored 'General case' 0 C--O 1.219 -0.512 0 C-N-CA 123.148 0.579 . . . . 0.0 109.647 177.71 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -66.79 -36.64 91.47 Favored Glycine 0 C--N 1.333 0.372 0 CA-C-N 115.896 -0.593 . . . . 0.0 112.253 179.586 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 97' ' ' ALA . . . . . 0.574 ' HB2' ' NE2' ' A' ' 93' ' ' GLN . . . -69.94 -23.45 63.2 Favored 'General case' 0 CA--C 1.517 -0.296 0 CA-C-O 120.709 0.29 . . . . 0.0 110.577 177.768 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 98' ' ' TRP . . . . . 0.514 ' HE3' ' HA ' ' A' ' 95' ' ' TRP . 25.1 m-90 -98.94 108.11 47.4 Favored Pre-proline 0 N--CA 1.447 -0.6 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 179.095 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 99' ' ' PRO . . . . . 0.469 ' HD3' ' HA ' ' A' ' 98' ' ' TRP . 43.6 Cg_exo -63.36 -136.13 0.0 OUTLIER 'Trans proline' 0 CA--C 1.537 0.665 0 C-N-CA 123.671 2.914 . . . . 0.0 114.083 -174.275 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 44.3 t -55.19 -24.77 15.61 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.259 0 CA-C-O 121.241 0.543 . . . . 0.0 111.49 -176.106 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 101' ' ' CYS . . . . . 0.436 ' SG ' ' HG3' ' A' ' 38' ' ' GLU . 61.0 m -62.84 -34.81 78.12 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 116.064 -0.516 . . . . 0.0 111.502 -179.217 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -70.34 -41.05 73.71 Favored 'General case' 0 C--N 1.333 -0.136 0 CA-C-O 121.014 0.435 . . . . 0.0 110.775 177.975 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -64.72 -34.74 79.02 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.002 -0.544 . . . . 0.0 110.272 178.235 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 55.7 mtp180 -73.87 -19.08 60.83 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.505 -0.77 . . . . 0.0 111.864 176.468 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -95.76 -21.69 17.99 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 116.094 -0.503 . . . . 0.0 112.096 -172.951 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 99.93 67.13 0.84 Allowed Glycine 0 N--CA 1.454 -0.161 0 C-N-CA 120.777 -0.725 . . . . 0.0 111.88 -177.03 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -64.67 152.02 43.42 Favored 'General case' 0 N--CA 1.45 -0.468 0 C-N-CA 122.67 0.388 . . . . 0.0 111.022 -174.147 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 18.0 mmt180 . . . . . 0 C--O 1.241 0.656 0 O-C-N 124.019 0.824 . . . . 0.0 111.416 177.948 . . . . . . . . 0 0 . 1 . 029 nuclear build full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 89.8 m-20 . . . . . 0 N--CA 1.479 0.989 0 CA-C-O 120.73 0.3 . . . . 0.0 110.301 . . . . . . . . . 0 0 . 1 . 029 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 47.8 t -98.8 -34.92 4.66 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 CA-C-O 121.283 0.563 . . . . 0.0 110.318 179.475 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 39.3 t -83.54 134.12 27.64 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.757 0 CA-C-N 115.563 -0.744 . . . . 0.0 110.976 -179.099 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 9.3 t -87.3 138.59 18.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 N-CA-C 109.382 -0.599 . . . . 0.0 109.382 175.838 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 22.1 p -129.73 105.98 17.02 Favored Pre-proline 0 C--N 1.314 -0.957 0 CA-C-N 115.971 -0.559 . . . . 0.0 111.4 -174.58 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 3.4 Cg_exo -80.98 168.41 17.29 Favored 'Trans proline' 0 N--CA 1.452 -0.945 0 C-N-CA 122.805 2.337 . . . . 0.0 111.644 178.279 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -141.09 -171.98 3.39 Favored 'General case' 0 C--N 1.307 -1.26 0 CA-C-N 114.769 -1.105 . . . . 0.0 110.457 -178.714 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 26.4 t-80 69.33 6.3 5.61 Favored 'General case' 0 C--O 1.232 0.167 0 O-C-N 124.068 0.855 . . . . 0.0 109.481 -173.23 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -50.45 135.03 22.99 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.016 -0.993 . . . . 0.0 109.974 174.819 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -123.7 70.88 1.07 Allowed 'General case' 0 C--N 1.318 -0.778 0 CA-C-O 121.674 0.749 . . . . 0.0 110.911 -171.63 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.476 ' O ' ' HG3' ' A' ' 13' ' ' ARG . 99.5 t -65.18 -48.33 84.03 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.015 0 CA-C-N 114.314 -1.312 . . . . 0.0 109.809 174.955 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 3.6 p -31.34 95.34 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.436 -1.144 0 C-N-CA 125.358 1.463 . . . . 0.0 113.376 170.98 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 13' ' ' ARG . . . . . 0.476 ' HG3' ' O ' ' A' ' 11' ' ' VAL . 22.7 mtm180 -127.33 114.45 17.6 Favored 'General case' 0 C--N 1.302 -1.471 0 CA-C-N 113.543 -1.662 . . . . 0.0 110.304 176.487 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.7 t -98.28 160.37 3.14 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.872 0 CA-C-N 115.492 -0.776 . . . . 0.0 109.634 179.341 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 145.02 97.01 0.21 Allowed Glycine 0 N--CA 1.439 -1.122 0 CA-C-N 115.124 -0.943 . . . . 0.0 111.924 -179.561 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 24.1 m -86.23 -33.72 20.65 Favored 'General case' 0 N--CA 1.446 -0.672 0 CA-C-O 120.655 0.264 . . . . 0.0 111.496 -176.924 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 17' ' ' LYS . . . . . 0.46 ' HE3' ' HB2' ' A' ' 17' ' ' LYS . 0.0 OUTLIER 42.66 75.64 0.61 Allowed Pre-proline 0 C--N 1.321 -0.673 0 CA-C-N 115.406 -0.815 . . . . 0.0 111.491 -175.304 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 7.0 Cg_exo -74.62 165.88 30.62 Favored 'Trans proline' 0 N--CA 1.458 -0.606 0 C-N-CA 122.75 2.3 . . . . 0.0 112.034 -179.543 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -99.3 23.43 36.33 Favored Glycine 0 C--N 1.309 -0.937 0 CA-C-N 114.598 -1.183 . . . . 0.0 112.439 -176.753 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 2.6 m -70.05 -44.25 69.57 Favored 'General case' 0 C--N 1.307 -1.246 0 CA-C-O 122.164 0.983 . . . . 0.0 109.264 177.122 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 21' ' ' GLU . . . . . 0.404 ' O ' ' HD3' ' A' ' 23' ' ' PRO . 11.9 pt-20 -130.56 150.84 51.57 Favored 'General case' 0 N--CA 1.42 -1.938 0 N-CA-C 106.789 -1.56 . . . . 0.0 106.789 178.511 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 30.1 t -72.86 114.99 35.62 Favored Pre-proline 0 C--N 1.3 -1.56 0 CA-C-N 115.947 -0.57 . . . . 0.0 110.506 -177.414 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.404 ' HD3' ' O ' ' A' ' 21' ' ' GLU . 47.9 Cg_exo -55.99 152.45 36.68 Favored 'Trans proline' 0 C--N 1.346 0.417 0 C-N-CA 122.919 2.412 . . . . 0.0 111.264 175.921 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 9.9 Cg_endo -54.07 138.49 70.82 Favored 'Trans proline' 0 N--CA 1.452 -0.946 0 C-N-CA 122.64 2.226 . . . . 0.0 111.439 -178.914 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.417 HG12 ' H ' ' A' ' 27' ' ' ASP . 20.9 t -103.4 131.37 52.03 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.243 0 CA-C-N 114.723 -1.126 . . . . 0.0 109.603 -174.106 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 45.1 mm -65.34 -26.01 38.47 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 CA-C-N 115.601 -0.727 . . . . 0.0 110.918 -174.506 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.42 ' O ' HG12 ' A' ' 30' ' ' ILE . 14.2 m-20 -89.97 -12.84 37.56 Favored 'General case' 0 CA--C 1.498 -1.049 0 CA-C-O 121.729 0.776 . . . . 0.0 109.598 179.27 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -63.09 -16.52 57.75 Favored Glycine 0 C--N 1.309 -0.963 0 CA-C-N 114.321 -1.309 . . . . 0.0 111.247 -177.047 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 15.5 m -77.66 -39.84 43.67 Favored 'General case' 0 C--N 1.315 -0.909 0 CA-C-O 121.811 0.815 . . . . 0.0 109.359 178.397 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.571 ' O ' HG13 ' A' ' 34' ' ' ILE . 0.5 OUTLIER -69.76 -39.73 78.29 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.706 0 CA-C-N 114.111 -1.404 . . . . 0.0 107.497 179.194 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 31' ' ' TRP . . . . . 0.519 ' CE3' HG11 ' A' ' 55' ' ' VAL . 18.1 m95 -68.35 -37.42 80.48 Favored 'General case' 0 C--N 1.317 -0.828 0 CA-C-N 114.195 -1.366 . . . . 0.0 110.809 -177.017 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 7.7 t70 -76.38 -32.32 58.52 Favored 'General case' 0 N--CA 1.447 -0.621 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.74 179.335 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 33' ' ' ALA . . . . . 0.484 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -71.05 -37.19 72.52 Favored 'General case' 0 N--CA 1.448 -0.527 0 C-N-CA 120.684 -0.406 . . . . 0.0 110.691 176.48 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 34' ' ' ILE . . . . . 0.571 HG13 ' O ' ' A' ' 30' ' ' ILE . 82.3 mt -67.16 -41.81 87.37 Favored 'Isoleucine or valine' 0 C--O 1.234 0.262 0 CA-C-O 121.212 0.53 . . . . 0.0 109.892 175.032 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 35' ' ' ALA . . . . . 0.651 ' HA ' ' O ' ' A' ' 54' ' ' GLY . . . -57.44 -37.91 73.58 Favored 'General case' 0 CA--C 1.515 -0.382 0 CA-C-N 115.511 -0.768 . . . . 0.0 110.317 175.997 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -78.38 -3.91 86.47 Favored Glycine 0 N--CA 1.45 -0.374 0 CA-C-N 115.246 -0.888 . . . . 0.0 111.638 179.883 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 41.0 t -97.51 -60.14 1.63 Allowed 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 115.689 -0.256 . . . . 0.0 111.055 -178.415 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 38' ' ' GLU . . . . . 0.637 ' HG3' ' SG ' ' A' ' 101' ' ' CYS . 39.2 mt-10 -89.28 -33.78 16.83 Favored 'General case' 0 CA--C 1.516 -0.356 0 CA-C-O 120.715 0.293 . . . . 0.0 111.388 -173.418 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -95.42 -14.06 24.11 Favored 'General case' 0 C--N 1.324 -0.534 0 C-N-CA 120.676 -0.409 . . . . 0.0 111.693 -176.819 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 77.97 20.22 73.63 Favored Glycine 0 N--CA 1.445 -0.745 0 N-CA-C 109.754 -1.338 . . . . 0.0 109.754 -175.799 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 71.07 56.47 7.0 Favored Glycine 0 N--CA 1.437 -1.28 0 CA-C-N 114.185 -1.008 . . . . 0.0 112.036 -176.412 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 5.7 t-20 -141.23 88.03 2.13 Favored 'General case' 0 N--CA 1.447 -0.597 0 N-CA-C 108.89 -0.782 . . . . 0.0 108.89 -177.592 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 43' ' ' TRP . . . . . 0.735 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 22.1 m95 -70.37 -13.03 61.97 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.515 -0.766 . . . . 0.0 111.176 -173.31 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -102.94 14.05 32.87 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 115.959 -0.564 . . . . 0.0 111.543 -177.624 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.819 HG22 ' HA2' ' A' ' 53' ' ' GLY . 3.6 tt -82.82 144.29 10.44 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.598 0 CA-C-O 120.915 0.388 . . . . 0.0 110.171 -177.955 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 44.5 t-20 -158.24 90.51 1.04 Allowed 'General case' 0 C--N 1.314 -0.95 0 N-CA-C 109.67 -0.493 . . . . 0.0 109.67 178.708 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 35.2 p -76.8 -24.05 52.81 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.622 -0.717 . . . . 0.0 110.92 -179.849 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 99.36 23.94 10.72 Favored Glycine 0 N--CA 1.442 -0.921 0 CA-C-N 115.458 -0.792 . . . . 0.0 111.377 -179.346 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 35.2 p30 -85.4 5.41 31.04 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.986 0.422 . . . . 0.0 111.559 179.656 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 50' ' ' GLY . . . . . 0.432 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 96.28 -10.63 67.42 Favored Glycine 0 N--CA 1.446 -0.653 0 N-CA-C 111.625 -0.59 . . . . 0.0 111.625 179.153 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 51' ' ' TYR . . . . . 0.6 ' HA ' ' HA ' ' A' ' 58' ' ' ASP . 0.2 OUTLIER -117.84 156.2 28.8 Favored 'General case' 0 CA--C 1.505 -0.75 0 N-CA-C 106.593 -1.632 . . . . 0.0 106.593 179.393 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 52' ' ' TYR . . . . . 0.651 ' HB2' ' HB3' ' A' ' 74' ' ' ALA . 46.2 m-85 -120.35 165.44 14.88 Favored 'General case' 0 C--N 1.307 -1.258 0 C-N-CA 119.69 -0.804 . . . . 0.0 112.466 -170.415 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.819 ' HA2' HG22 ' A' ' 45' ' ' ILE . . . -57.93 157.81 16.14 Favored Glycine 0 CA--C 1.502 -0.752 0 CA-C-N 114.854 -1.067 . . . . 0.0 114.41 -169.901 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.667 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 99.52 -109.23 3.7 Favored Glycine 0 N--CA 1.436 -1.314 0 N-CA-C 111.246 -0.741 . . . . 0.0 111.246 -178.693 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.53 HG12 ' NE1' ' A' ' 98' ' ' TRP . 3.2 t -84.31 -2.11 6.88 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.67 0 CA-C-O 121.791 0.805 . . . . 0.0 110.025 -177.151 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 56' ' ' GLN . . . . . 0.571 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 6.9 tp60 57.97 50.51 10.17 Favored 'General case' 0 N--CA 1.461 0.088 0 CA-C-N 114.141 -1.391 . . . . 0.0 112.833 166.598 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 57' ' ' PHE . . . . . 0.416 ' CE1' ' HB2' ' A' ' 86' ' ' ALA . 10.3 p90 -117.34 162.38 18.01 Favored 'General case' 0 C--N 1.324 -0.511 0 C-N-CA 120.443 -0.503 . . . . 0.0 111.071 175.166 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.6 ' HA ' ' HA ' ' A' ' 51' ' ' TYR . 5.0 p-10 -77.01 163.19 26.92 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 113.667 0.988 . . . . 0.0 113.667 -163.733 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.466 ' HB2' ' CE2' ' A' ' 52' ' ' TYR . 6.2 tp60 -60.57 -40.45 91.71 Favored 'General case' 0 N--CA 1.446 -0.653 0 CA-C-N 113.714 -1.585 . . . . 0.0 111.883 -179.934 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -65.41 -45.2 91.45 Favored Glycine 0 C--N 1.321 -0.286 0 C-N-CA 121.077 -0.582 . . . . 0.0 111.953 -176.952 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 61' ' ' THR . . . . . 0.555 ' CG2' HG21 ' A' ' 89' ' ' THR . 95.0 m -66.61 -43.98 83.31 Favored 'General case' 0 C--N 1.32 -0.701 0 C-N-CA 122.558 0.343 . . . . 0.0 111.077 176.524 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 62' ' ' TRP . . . . . . . . . . . . . 50.3 t-105 -57.63 -47.3 82.6 Favored 'General case' 0 N--CA 1.45 -0.426 0 CA-C-O 121.62 0.724 . . . . 0.0 109.876 176.539 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 63' ' ' GLU . . . . . 0.447 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 29.2 tt0 -67.31 -33.35 75.09 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 115.09 -0.959 . . . . 0.0 110.614 -178.336 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -66.54 -42.87 86.51 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.76 -0.655 . . . . 0.0 110.745 -176.806 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 65' ' ' ASN . . . . . 0.486 ' HB2' HG13 ' A' ' 85' ' ' VAL . 7.2 m120 -75.22 -13.97 60.49 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 121.041 0.448 . . . . 0.0 110.387 176.655 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 91.98 46.64 3.57 Favored Glycine 0 N--CA 1.448 -0.533 0 CA-C-N 115.675 -0.693 . . . . 0.0 111.855 176.114 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.478 ' O ' ' HB2' ' A' ' 70' ' ' TYR . . . -79.52 -21.81 65.97 Favored Glycine 0 N--CA 1.439 -1.142 0 C-N-CA 120.882 -0.675 . . . . 0.0 112.835 -172.648 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.858 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 7.4 mp -58.98 -29.93 67.57 Favored 'General case' 0 C--N 1.319 -0.73 0 N-CA-C 112.764 0.653 . . . . 0.0 112.764 -173.191 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 12.3 ptm180 -66.02 -29.36 69.72 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-O 121.491 0.662 . . . . 0.0 110.105 176.324 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 70' ' ' TYR . . . . . 0.81 ' HB3' ' HG2' ' A' ' 81' ' ' GLU . 86.8 m-85 -78.14 -36.2 48.02 Favored 'General case' 0 N--CA 1.445 -0.717 0 N-CA-C 107.366 -1.346 . . . . 0.0 107.366 175.493 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.656 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 158.26 130.67 0.0 OUTLIER Pre-proline 0 CA--C 1.508 -0.659 0 CA-C-N 112.096 -2.32 . . . . 0.0 106.262 -177.949 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 72' ' ' PRO . . . . . 0.858 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 18.4 Cg_exo -56.89 -4.45 0.92 Allowed 'Trans proline' 0 C--N 1.331 -0.343 0 C-N-CA 122.988 2.459 . . . . 0.0 114.103 -174.655 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 3.4 ptt180 -154.48 143.78 21.29 Favored 'General case' 0 C--N 1.318 -0.766 0 CA-C-O 121.308 0.575 . . . . 0.0 110.759 176.894 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 74' ' ' ALA . . . . . 0.651 ' HB3' ' HB2' ' A' ' 52' ' ' TYR . . . -57.95 -21.97 46.68 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.635 -175.514 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 75' ' ' ASP . . . . . 0.66 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 5.0 p-10 -87.57 -9.88 53.14 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 121.357 0.598 . . . . 0.0 110.672 -178.642 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.542 HD23 ' HD2' ' A' ' 72' ' ' PRO . 57.6 tp -99.86 -30.5 12.0 Favored 'General case' 0 C--N 1.319 -0.73 0 N-CA-C 108.846 -0.798 . . . . 0.0 108.846 175.301 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 77' ' ' ALA . . . . . 0.656 ' HB2' ' HB3' ' A' ' 71' ' ' ALA . . . -79.63 160.71 26.27 Favored 'General case' 0 N--CA 1.442 -0.846 0 CA-C-N 115.041 -0.982 . . . . 0.0 109.789 173.118 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 36.0 p -100.48 -178.92 3.95 Favored 'General case' 0 C--N 1.309 -1.188 0 CA-C-N 115.564 -0.744 . . . . 0.0 110.914 -178.023 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 79' ' ' ARG . . . . . 0.735 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 5.5 mtt180 -51.17 -53.75 31.8 Favored 'General case' 0 CA--C 1.511 -0.525 0 CA-C-O 120.871 0.367 . . . . 0.0 111.031 -179.516 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 1.9 pm0 -58.36 -39.65 80.1 Favored 'General case' 0 C--N 1.314 -0.938 0 CA-C-N 115.393 -0.821 . . . . 0.0 111.602 -177.888 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 81' ' ' GLU . . . . . 0.81 ' HG2' ' HB3' ' A' ' 70' ' ' TYR . 4.1 mt-10 -70.01 -51.54 31.48 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 121.13 0.49 . . . . 0.0 111.923 178.014 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 82' ' ' GLN . . . . . 0.467 HE21 ' HE3' ' A' ' 43' ' ' TRP . 5.3 tt0 -65.69 -33.9 76.94 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-N 115.377 -0.829 . . . . 0.0 110.591 -176.904 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.445 HG23 ' CD1' ' A' ' 31' ' ' TRP . 24.4 mt -61.56 -45.06 99.44 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.678 0 CA-C-N 115.708 -0.678 . . . . 0.0 109.849 174.073 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 84' ' ' ALA . . . . . 0.654 ' O ' ' HG3' ' A' ' 87' ' ' GLU . . . -64.54 -41.1 96.56 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.945 0.403 . . . . 0.0 111.59 -176.804 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.486 HG13 ' HB2' ' A' ' 65' ' ' ASN . 50.2 t -69.05 -48.99 66.58 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-O 120.968 0.413 . . . . 0.0 111.127 179.255 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 86' ' ' ALA . . . . . 0.416 ' HB2' ' CE1' ' A' ' 57' ' ' PHE . . . -65.7 -31.79 72.99 Favored 'General case' 0 N--CA 1.449 -0.484 0 CA-C-N 115.914 -0.584 . . . . 0.0 110.76 -179.893 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 87' ' ' GLU . . . . . 0.654 ' HG3' ' O ' ' A' ' 84' ' ' ALA . 0.1 OUTLIER -70.1 -28.93 65.8 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.228 -177.373 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.56 ' O ' ' HG3' ' A' ' 92' ' ' ARG . 85.9 t -61.11 -48.64 88.11 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.177 0 N-CA-C 109.241 -0.651 . . . . 0.0 109.241 169.703 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 89' ' ' THR . . . . . 0.562 ' HB ' ' CH2' ' A' ' 98' ' ' TRP . 0.1 OUTLIER -64.9 -44.18 90.43 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 115.647 -0.706 . . . . 0.0 112.143 -176.257 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 90' ' ' ARG . . . . . 0.478 ' HB3' ' CZ2' ' A' ' 31' ' ' TRP . 0.0 OUTLIER -61.2 -32.23 71.99 Favored 'General case' 0 CA--C 1.511 -0.535 0 CA-C-O 121.727 0.775 . . . . 0.0 108.974 -177.068 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 91' ' ' LEU . . . . . 0.42 HD13 HH12 ' A' ' 90' ' ' ARG . 48.4 tp -69.48 -27.42 65.2 Favored 'General case' 0 C--N 1.313 -0.984 0 CA-C-N 113.966 -1.47 . . . . 0.0 111.276 -174.418 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 92' ' ' ARG . . . . . 0.56 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 4.1 mtm180 -90.59 -48.29 7.17 Favored 'General case' 0 C--N 1.317 -0.805 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.293 -175.832 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 93' ' ' GLN . . . . . 0.474 ' HG3' ' H ' ' A' ' 96' ' ' GLY . 3.4 pt20 -99.07 -27.78 13.68 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-N 114.965 -1.016 . . . . 0.0 113.006 -168.995 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 89.17 41.15 5.92 Favored Glycine 0 CA--C 1.501 -0.842 0 C-N-CA 119.971 -1.109 . . . . 0.0 110.796 178.926 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 95' ' ' TRP . . . . . 0.525 ' HA ' ' HE3' ' A' ' 98' ' ' TRP . 6.1 m95 67.16 19.8 10.33 Favored 'General case' 0 C--O 1.216 -0.674 0 CA-C-N 114.893 -0.654 . . . . 0.0 109.288 176.455 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.474 ' H ' ' HG3' ' A' ' 93' ' ' GLN . . . -64.1 -30.44 77.77 Favored Glycine 0 N--CA 1.452 -0.286 0 CA-C-N 115.465 -0.789 . . . . 0.0 112.886 178.462 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 97' ' ' ALA . . . . . 0.454 ' HB2' HE22 ' A' ' 93' ' ' GLN . . . -75.14 -20.68 59.28 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 121.006 0.431 . . . . 0.0 110.142 176.584 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 98' ' ' TRP . . . . . 0.562 ' CH2' ' HB ' ' A' ' 89' ' ' THR . 22.3 m-90 -104.31 111.67 65.24 Favored Pre-proline 0 N--CA 1.446 -0.631 0 CA-C-N 115.72 -0.673 . . . . 0.0 110.335 -177.905 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 99' ' ' PRO . . . . . 0.412 ' HD3' ' HA ' ' A' ' 98' ' ' TRP . 52.5 Cg_exo -61.48 -140.2 0.0 OUTLIER 'Trans proline' 0 CA--C 1.534 0.487 0 C-N-CA 123.644 2.896 . . . . 0.0 114.444 -175.31 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 100' ' ' VAL . . . . . 0.477 ' O ' ' HD2' ' A' ' 104' ' ' ARG . 12.6 m -54.7 -29.52 21.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.654 -0.703 . . . . 0.0 111.26 -178.363 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 101' ' ' CYS . . . . . 0.637 ' SG ' ' HG3' ' A' ' 38' ' ' GLU . 59.3 m -56.34 -35.56 67.76 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-N 115.205 -0.907 . . . . 0.0 111.706 -179.591 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -69.62 -42.56 74.19 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 121.072 0.463 . . . . 0.0 110.51 179.117 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -66.76 -37.72 85.18 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.656 179.42 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 104' ' ' ARG . . . . . 0.477 ' HD2' ' O ' ' A' ' 100' ' ' VAL . 0.0 OUTLIER -72.6 -20.54 61.28 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.804 -0.635 . . . . 0.0 111.009 178.373 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 105' ' ' ALA . . . . . 0.562 ' HB1' ' HA ' ' A' ' 30' ' ' ILE . . . -91.38 -20.91 21.31 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 115.821 -0.627 . . . . 0.0 111.694 -177.392 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 103.82 54.46 0.81 Allowed Glycine 0 CA--C 1.518 0.244 0 C-N-CA 121.005 -0.617 . . . . 0.0 112.188 179.987 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -67.74 151.25 47.54 Favored 'General case' 0 N--CA 1.449 -0.522 0 C-N-CA 122.385 0.274 . . . . 0.0 111.691 -175.44 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 14.5 mtt180 . . . . . 0 C--O 1.252 1.2 0 O-C-N 124.211 0.944 . . . . 0.0 111.673 174.85 . . . . . . . . 0 0 . 1 . 030 nuclear build full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 13.3 m120 . . . . . 0 N--CA 1.479 0.988 0 CA-C-O 121.266 0.555 . . . . 0.0 110.311 . . . . . . . . . 0 0 . 1 . 030 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 9.9 p -99.92 -16.19 7.21 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.815 0 CA-C-N 115.503 -0.771 . . . . 0.0 110.651 -176.275 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 59.2 t -61.06 116.18 1.87 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.376 0 CA-C-N 115.804 -0.635 . . . . 0.0 110.796 178.826 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 11.5 t -70.27 141.15 17.4 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.535 0 N-CA-C 109.354 -0.609 . . . . 0.0 109.354 177.292 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 38.7 p -83.01 124.57 76.48 Favored Pre-proline 0 C--N 1.313 -0.986 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.605 -176.707 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 40.1 Cg_endo -63.41 131.0 30.16 Favored 'Trans proline' 0 N--CA 1.452 -0.924 0 C-N-CA 123.219 2.613 . . . . 0.0 111.722 179.869 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 7' ' ' ALA . . . . . 0.431 ' C ' ' H ' ' A' ' 9' ' ' GLU . . . -141.14 -170.62 3.1 Favored 'General case' 0 C--N 1.295 -1.772 0 CA-C-N 113.754 -1.567 . . . . 0.0 110.407 -179.554 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 45.2 t-80 71.75 -10.45 0.84 Allowed 'General case' 0 C--O 1.231 0.106 0 O-C-N 124.053 0.845 . . . . 0.0 110.125 -172.925 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 9' ' ' GLU . . . . . 0.431 ' H ' ' C ' ' A' ' 7' ' ' ALA . 12.5 pt-20 -90.76 133.55 35.09 Favored 'General case' 0 N--CA 1.448 -0.554 0 CA-C-N 116.164 -0.471 . . . . 0.0 109.914 -179.703 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -151.06 68.46 0.94 Allowed 'General case' 0 C--N 1.317 -0.836 0 CA-C-O 121.534 0.683 . . . . 0.0 109.43 176.22 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 65.6 t -65.87 -60.03 3.21 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.846 0 CA-C-N 114.758 -1.11 . . . . 0.0 110.395 -178.395 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 7.1 p 26.24 76.12 0.01 OUTLIER 'Isoleucine or valine' 0 C--O 1.238 0.48 0 CA-C-O 123.067 1.413 . . . . 0.0 112.95 179.868 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 28.3 mtp180 -89.19 97.57 11.28 Favored 'General case' 0 C--N 1.304 -1.377 0 CA-C-N 113.691 -1.595 . . . . 0.0 111.282 -176.796 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 3.4 t -117.14 157.3 18.22 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.607 0 CA-C-N 114.861 -1.063 . . . . 0.0 108.311 177.13 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 179.28 81.17 0.06 OUTLIER Glycine 0 N--CA 1.424 -2.149 0 CA-C-N 115.405 -0.816 . . . . 0.0 112.583 -178.228 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 6.7 m -79.9 -44.08 21.05 Favored 'General case' 0 N--CA 1.437 -1.076 0 N-CA-C 109.612 -0.514 . . . . 0.0 109.612 176.181 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER 34.73 64.9 1.71 Allowed Pre-proline 0 N--CA 1.471 0.583 0 CA-C-N 114.2 -1.364 . . . . 0.0 112.104 179.661 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 5.8 Cg_exo -78.88 161.48 27.07 Favored 'Trans proline' 0 N--CA 1.451 -1.002 0 C-N-CA 122.91 2.407 . . . . 0.0 113.193 -173.022 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -125.44 37.38 2.54 Favored Glycine 0 C--N 1.304 -1.196 0 CA-C-N 113.597 -1.638 . . . . 0.0 110.472 176.183 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 3.7 m -58.64 -43.57 89.81 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 114.206 -0.997 . . . . 0.0 110.67 -178.888 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 50.5 mt-10 -138.28 124.1 19.93 Favored 'General case' 0 N--CA 1.448 -0.553 0 N-CA-C 108.947 -0.76 . . . . 0.0 108.947 175.718 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 79.2 t -72.57 130.57 85.53 Favored Pre-proline 0 C--N 1.32 -0.699 0 N-CA-C 109.045 -0.724 . . . . 0.0 109.045 176.385 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.437 ' HA ' ' HD2' ' A' ' 24' ' ' PRO . 59.6 Cg_exo -52.39 127.99 26.01 Favored 'Trans proline' 0 C--N 1.347 0.488 0 C-N-CA 122.506 2.138 . . . . 0.0 111.446 -177.905 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 24' ' ' PRO . . . . . 0.437 ' HD2' ' HA ' ' A' ' 23' ' ' PRO . 11.2 Cg_endo -55.42 141.29 82.41 Favored 'Trans proline' 0 N--CA 1.452 -0.912 0 C-N-CA 123.755 2.97 . . . . 0.0 113.593 -172.553 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.427 ' HB ' HG21 ' A' ' 83' ' ' ILE . 60.2 t -80.0 138.95 18.97 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.206 0 CA-C-N 113.765 -1.561 . . . . 0.0 107.618 174.687 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 43.8 mm -63.29 -25.57 38.76 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-N 115.749 -0.659 . . . . 0.0 111.771 -169.816 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.535 ' O ' HG12 ' A' ' 30' ' ' ILE . 71.8 m-20 -94.21 -1.01 54.78 Favored 'General case' 0 CA--C 1.505 -0.767 0 CA-C-O 122.075 0.941 . . . . 0.0 108.869 -179.674 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 28' ' ' GLY . . . . . 0.576 ' HA2' ' HB2' ' A' ' 31' ' ' TRP . . . -71.58 -3.0 52.89 Favored Glycine 0 N--CA 1.439 -1.123 0 CA-C-N 113.899 -1.5 . . . . 0.0 110.219 174.958 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 5.6 m -76.34 -37.57 57.15 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 108.655 -0.868 . . . . 0.0 108.655 174.086 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.535 HG12 ' O ' ' A' ' 27' ' ' ASP . 0.9 OUTLIER -70.15 -37.99 73.47 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 N-CA-C 106.943 -1.503 . . . . 0.0 106.943 175.683 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 31' ' ' TRP . . . . . 0.576 ' HB2' ' HA2' ' A' ' 28' ' ' GLY . 22.8 m95 -70.27 -36.41 74.41 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 114.122 -1.399 . . . . 0.0 110.754 -177.079 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.735 ' HB2' HH21 ' A' ' 79' ' ' ARG . 26.5 t70 -76.8 -36.17 57.13 Favored 'General case' 0 N--CA 1.444 -0.73 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.385 179.643 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 33' ' ' ALA . . . . . 0.415 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -70.77 -36.66 73.17 Favored 'General case' 0 N--CA 1.448 -0.526 0 CA-C-O 120.768 0.318 . . . . 0.0 110.809 176.944 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 34' ' ' ILE . . . . . 0.496 HG13 ' O ' ' A' ' 30' ' ' ILE . 59.3 mt -63.97 -43.91 97.78 Favored 'Isoleucine or valine' 0 C--O 1.234 0.267 0 CA-C-O 121.041 0.448 . . . . 0.0 110.006 173.789 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 35' ' ' ALA . . . . . 0.46 ' HA ' ' O ' ' A' ' 54' ' ' GLY . . . -57.1 -39.39 74.96 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.551 -0.75 . . . . 0.0 110.151 176.584 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -73.0 -17.68 78.73 Favored Glycine 0 N--CA 1.452 -0.283 0 CA-C-N 115.299 -0.864 . . . . 0.0 111.813 -179.528 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 11.1 t -88.24 -60.9 1.84 Allowed 'General case' 0 C--N 1.322 -0.63 0 CA-C-O 120.778 0.323 . . . . 0.0 111.404 -178.783 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 38' ' ' GLU . . . . . 0.806 ' HG3' ' HG2' ' A' ' 56' ' ' GLN . 8.8 tp10 -88.06 -33.49 18.3 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-O 121.009 0.433 . . . . 0.0 110.509 -169.513 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -96.85 -7.46 33.45 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.086 -0.506 . . . . 0.0 111.605 -176.468 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 76.2 17.2 80.16 Favored Glycine 0 N--CA 1.448 -0.523 0 N-CA-C 109.987 -1.245 . . . . 0.0 109.987 -177.322 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 72.81 55.29 6.6 Favored Glycine 0 N--CA 1.436 -1.306 0 CA-C-N 114.084 -1.058 . . . . 0.0 112.034 -177.334 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 42' ' ' ASN . . . . . 0.74 ' HB3' ' HB ' ' A' ' 45' ' ' ILE . 2.5 t-20 -148.17 105.83 3.68 Favored 'General case' 0 CA--C 1.511 -0.521 0 N-CA-C 108.396 -0.964 . . . . 0.0 108.396 -176.444 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 43' ' ' TRP . . . . . 0.876 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 30.4 m95 -83.26 -6.87 59.62 Favored 'General case' 0 C--N 1.309 -1.161 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.551 -173.125 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -111.08 15.03 21.84 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.594 -0.73 . . . . 0.0 111.698 177.792 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.74 ' HB ' ' HB3' ' A' ' 42' ' ' ASN . 11.0 tt -86.73 144.78 8.66 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.624 0 CA-C-O 120.835 0.35 . . . . 0.0 110.868 -176.545 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 45.6 t30 -153.62 111.29 3.52 Favored 'General case' 0 C--N 1.316 -0.89 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 174.178 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 6.9 p -82.4 -15.81 51.33 Favored 'General case' 0 C--N 1.315 -0.896 0 CA-C-N 115.809 -0.632 . . . . 0.0 111.342 -179.679 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 95.92 20.53 25.89 Favored Glycine 0 N--CA 1.446 -0.673 0 N-CA-C 111.174 -0.77 . . . . 0.0 111.174 -177.555 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 8.8 p30 -85.73 -5.29 59.28 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 121.136 0.493 . . . . 0.0 111.221 -176.16 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 50' ' ' GLY . . . . . 0.454 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 96.87 -12.99 65.61 Favored Glycine 0 N--CA 1.448 -0.5 0 CA-C-N 115.945 -0.57 . . . . 0.0 111.832 178.411 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 51' ' ' TYR . . . . . 0.608 ' HA ' ' HA ' ' A' ' 58' ' ' ASP . 0.9 OUTLIER -108.82 137.19 47.14 Favored 'General case' 0 CA--C 1.511 -0.529 0 N-CA-C 107.376 -1.342 . . . . 0.0 107.376 172.609 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 52' ' ' TYR . . . . . 0.697 ' CE1' ' HB2' ' A' ' 59' ' ' GLN . 26.6 m-85 -99.83 156.54 17.06 Favored 'General case' 0 C--N 1.307 -1.243 0 C-N-CA 120.607 -0.437 . . . . 0.0 111.255 -167.892 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -61.16 -176.07 1.74 Allowed Glycine 0 C--N 1.329 0.19 0 N-CA-C 115.387 0.915 . . . . 0.0 115.387 -167.632 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.732 ' CA ' ' HA ' ' A' ' 43' ' ' TRP . . . 86.84 -105.12 3.0 Favored Glycine 0 N--CA 1.446 -0.646 0 N-CA-C 111.318 -0.713 . . . . 0.0 111.318 -174.768 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.516 ' HB ' ' CD1' ' A' ' 57' ' ' PHE . 3.1 t -83.58 -4.47 8.44 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.751 0 N-CA-C 108.53 -0.915 . . . . 0.0 108.53 176.857 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 56' ' ' GLN . . . . . 0.806 ' HG2' ' HG3' ' A' ' 38' ' ' GLU . 14.8 tp60 58.38 43.56 19.64 Favored 'General case' 0 C--O 1.231 0.115 0 CA-C-N 114.021 -1.445 . . . . 0.0 112.377 169.651 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 57' ' ' PHE . . . . . 0.516 ' CD1' ' HB ' ' A' ' 55' ' ' VAL . 3.7 p90 -111.44 168.92 9.16 Favored 'General case' 0 C--N 1.323 -0.546 0 C-N-CA 120.181 -0.608 . . . . 0.0 110.888 174.829 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.608 ' HA ' ' HA ' ' A' ' 51' ' ' TYR . 7.7 p-10 -78.07 153.77 31.96 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 122.014 0.912 . . . . 0.0 112.38 -165.514 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.697 ' HB2' ' CE1' ' A' ' 52' ' ' TYR . 40.6 tp60 -63.77 -30.69 71.75 Favored 'General case' 0 N--CA 1.444 -0.737 0 CA-C-N 113.827 -1.533 . . . . 0.0 111.098 -179.804 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -62.96 -50.29 64.88 Favored Glycine 0 C--N 1.314 -0.689 0 C-N-CA 120.743 -0.741 . . . . 0.0 111.676 178.195 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 99.4 m -65.85 -41.86 91.17 Favored 'General case' 0 C--N 1.321 -0.674 0 C-N-CA 122.707 0.403 . . . . 0.0 111.065 175.697 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 62' ' ' TRP . . . . . 0.522 ' CH2' ' HA ' ' A' ' 74' ' ' ALA . 50.0 t-105 -56.33 -48.74 76.14 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-O 121.617 0.722 . . . . 0.0 109.546 177.487 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 63' ' ' GLU . . . . . 0.538 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 55.7 tt0 -67.76 -34.78 77.49 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 114.901 -1.045 . . . . 0.0 110.712 -179.76 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -62.66 -41.09 98.88 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.773 -179.398 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 65' ' ' ASN . . . . . 0.655 ' OD1' ' HB ' ' A' ' 89' ' ' THR . 7.9 m120 -79.96 -11.16 59.81 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.536 177.9 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 66' ' ' GLY . . . . . 0.562 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 84.03 49.0 4.93 Favored Glycine 0 N--CA 1.448 -0.528 0 CA-C-N 115.47 -0.786 . . . . 0.0 112.105 178.485 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.604 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -80.17 -18.93 70.7 Favored Glycine 0 N--CA 1.439 -1.124 0 C-N-CA 121.104 -0.57 . . . . 0.0 112.725 -176.214 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.696 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 6.4 mp -62.31 -23.1 66.55 Favored 'General case' 0 N--CA 1.45 -0.425 0 N-CA-C 112.035 0.383 . . . . 0.0 112.035 -172.578 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 69' ' ' ARG . . . . . 0.562 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 13.9 ptp180 -68.69 -32.19 71.83 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-O 121.259 0.552 . . . . 0.0 110.118 176.84 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 70' ' ' TYR . . . . . 0.653 ' HB3' ' HB3' ' A' ' 81' ' ' GLU . 67.7 m-85 -82.18 -33.99 29.22 Favored 'General case' 0 N--CA 1.442 -0.834 0 N-CA-C 107.436 -1.32 . . . . 0.0 107.436 178.443 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 71' ' ' ALA . . . . . 0.546 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 169.14 122.86 0.04 OUTLIER Pre-proline 0 N--CA 1.447 -0.61 0 CA-C-N 112.654 -2.066 . . . . 0.0 107.445 -178.423 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 72' ' ' PRO . . . . . 0.696 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 20.9 Cg_exo -55.28 -7.02 0.98 Allowed 'Trans proline' 0 CA--C 1.527 0.138 0 C-N-CA 122.807 2.338 . . . . 0.0 113.76 -178.81 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 73' ' ' ARG . . . . . 0.437 ' HE ' ' CG ' ' A' ' 75' ' ' ASP . 12.1 ptm180 -145.39 137.98 25.96 Favored 'General case' 0 C--N 1.318 -0.772 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 177.491 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 74' ' ' ALA . . . . . 0.522 ' HA ' ' CH2' ' A' ' 62' ' ' TRP . . . -55.76 -35.43 66.19 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 114.802 -1.09 . . . . 0.0 112.248 -176.005 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 75' ' ' ASP . . . . . 0.673 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 14.9 p-10 -80.95 -7.35 59.49 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 121.092 0.472 . . . . 0.0 111.531 -173.782 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.517 ' HB3' ' HB1' ' A' ' 71' ' ' ALA . 60.2 tp -87.7 -33.06 18.87 Favored 'General case' 0 C--N 1.318 -0.773 0 N-CA-C 108.688 -0.856 . . . . 0.0 108.688 171.776 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 77' ' ' ALA . . . . . 0.943 ' HB1' ' HB2' ' A' ' 81' ' ' GLU . . . -79.29 153.37 29.92 Favored 'General case' 0 N--CA 1.446 -0.659 0 CA-C-N 115.01 -0.995 . . . . 0.0 111.012 176.444 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 22.8 p -101.16 -170.3 1.82 Allowed 'General case' 0 C--N 1.315 -0.929 0 CA-C-N 115.77 -0.65 . . . . 0.0 109.517 179.131 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 79' ' ' ARG . . . . . 0.876 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 53.1 mtp180 -50.67 -48.66 58.35 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.903 0.382 . . . . 0.0 111.341 -176.808 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 7.3 pt-20 -57.88 -49.29 77.21 Favored 'General case' 0 C--N 1.319 -0.75 0 CA-C-N 115.391 -0.822 . . . . 0.0 112.432 -175.517 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 81' ' ' GLU . . . . . 0.943 ' HB2' ' HB1' ' A' ' 77' ' ' ALA . 26.1 mp0 -66.29 -50.46 63.58 Favored 'General case' 0 CA--C 1.52 -0.208 0 O-C-N 122.06 -0.4 . . . . 0.0 111.559 178.0 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 82' ' ' GLN . . . . . 0.68 ' HB2' ' HZ3' ' A' ' 43' ' ' TRP . 52.0 mt-30 -62.44 -33.67 75.27 Favored 'General case' 0 CA--C 1.513 -0.448 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.003 -174.576 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.643 ' O ' ' HG2' ' A' ' 87' ' ' GLU . 27.2 mt -60.53 -49.11 85.67 Favored 'Isoleucine or valine' 0 C--O 1.216 -0.663 0 N-CA-C 109.188 -0.671 . . . . 0.0 109.188 174.986 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 84' ' ' ALA . . . . . 0.598 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -57.12 -47.68 80.51 Favored 'General case' 0 C--O 1.239 0.53 0 CA-C-O 121.522 0.677 . . . . 0.0 111.821 -178.281 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.431 HG13 ' HB2' ' A' ' 65' ' ' ASN . 45.7 t -65.97 -48.82 80.48 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.587 0 CA-C-N 115.827 -0.624 . . . . 0.0 111.284 -179.458 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 86' ' ' ALA . . . . . 0.42 ' HB1' ' CH2' ' A' ' 31' ' ' TRP . . . -59.21 -30.31 68.14 Favored 'General case' 0 N--CA 1.45 -0.468 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.439 175.572 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 87' ' ' GLU . . . . . 0.643 ' HG2' ' O ' ' A' ' 83' ' ' ILE . 21.1 mm-40 -59.58 -43.97 93.48 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.957 -179.111 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.632 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 94.2 t -64.9 -50.98 72.52 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 C-N-CA 120.56 -0.456 . . . . 0.0 110.915 179.289 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 89' ' ' THR . . . . . 0.655 ' HB ' ' OD1' ' A' ' 65' ' ' ASN . 14.7 t -72.8 -34.89 67.2 Favored 'General case' 0 C--N 1.317 -0.843 0 C-N-CA 120.495 -0.482 . . . . 0.0 111.499 -173.599 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 90' ' ' ARG . . . . . 0.623 ' HG3' ' N ' ' A' ' 91' ' ' LEU . 4.3 ptt180 -60.45 -39.31 87.08 Favored 'General case' 0 N--CA 1.466 0.338 0 O-C-N 122.291 -0.256 . . . . 0.0 110.978 -178.267 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 91' ' ' LEU . . . . . 0.632 ' HG ' ' O ' ' A' ' 88' ' ' VAL . 4.5 pp -72.72 -23.91 60.91 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 115.956 -0.566 . . . . 0.0 111.479 -173.28 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 92' ' ' ARG . . . . . 0.559 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 10.8 mtm180 -79.28 -48.17 14.61 Favored 'General case' 0 CA--C 1.509 -0.61 0 CA-C-O 121.803 0.811 . . . . 0.0 109.456 -176.882 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 93' ' ' GLN . . . . . 0.651 ' NE2' ' HB2' ' A' ' 97' ' ' ALA . 3.6 pt20 -97.37 -28.38 14.05 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 114.413 -1.267 . . . . 0.0 113.149 -169.773 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 96.89 39.92 3.96 Favored Glycine 0 CA--C 1.503 -0.682 0 C-N-CA 120.215 -0.993 . . . . 0.0 111.119 172.892 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 95' ' ' TRP . . . . . 0.517 ' HA ' ' HE3' ' A' ' 98' ' ' TRP . 12.3 m95 68.11 9.3 7.1 Favored 'General case' 0 C--O 1.218 -0.592 0 N-CA-C 108.953 -0.758 . . . . 0.0 108.953 -178.151 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -62.39 -32.13 81.86 Favored Glycine 0 C--N 1.334 0.451 0 CA-C-N 115.592 -0.731 . . . . 0.0 113.14 -177.814 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 97' ' ' ALA . . . . . 0.651 ' HB2' ' NE2' ' A' ' 93' ' ' GLN . . . -64.45 -24.26 67.56 Favored 'General case' 0 CA--C 1.514 -0.406 0 CA-C-O 120.902 0.382 . . . . 0.0 110.073 176.312 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 98' ' ' TRP . . . . . 0.581 ' HB2' ' HB2' ' A' ' 102' ' ' ALA . 19.6 m-90 -108.63 105.07 56.25 Favored Pre-proline 0 C--N 1.324 -0.522 0 CA-C-N 115.829 -0.623 . . . . 0.0 109.976 178.893 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 99' ' ' PRO . . . . . 0.439 ' HB2' ' H ' ' A' ' 100' ' ' VAL . 19.1 Cg_exo -72.14 -94.08 0.01 OUTLIER 'Trans proline' 0 CA--C 1.536 0.604 0 C-N-CA 122.888 2.392 . . . . 0.0 113.851 -175.59 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 100' ' ' VAL . . . . . 0.439 ' H ' ' HB2' ' A' ' 99' ' ' PRO . 46.5 t -71.44 -26.78 27.1 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.176 0 CA-C-O 121.637 0.732 . . . . 0.0 110.324 -174.799 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 101' ' ' CYS . . . . . 0.446 ' SG ' ' HB2' ' A' ' 38' ' ' GLU . 80.2 m -73.02 -37.48 66.91 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 115.217 -0.901 . . . . 0.0 111.742 -172.987 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 102' ' ' ALA . . . . . 0.581 ' HB2' ' HB2' ' A' ' 98' ' ' TRP . . . -69.7 -44.14 71.01 Favored 'General case' 0 C--N 1.327 -0.382 0 C-N-CA 120.811 -0.356 . . . . 0.0 110.267 179.258 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -61.27 -37.41 83.03 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 121.193 0.521 . . . . 0.0 110.92 179.715 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -72.11 -23.84 61.38 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.731 -0.668 . . . . 0.0 111.818 177.526 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 105' ' ' ALA . . . . . 0.48 ' HB1' ' HA ' ' A' ' 30' ' ' ILE . . . -95.63 -22.78 17.37 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 116.1 -0.5 . . . . 0.0 112.154 -174.619 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 121.55 58.47 0.22 Allowed Glycine 0 CA--C 1.521 0.437 0 C-N-CA 121.05 -0.595 . . . . 0.0 112.189 -176.765 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -72.21 150.4 43.73 Favored 'General case' 0 C--N 1.327 -0.386 0 C-N-CA 122.871 0.469 . . . . 0.0 111.079 -176.494 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 108' ' ' ARG . . . . . 0.476 ' HB2' ' HE1' ' A' ' 95' ' ' TRP . 93.1 mtt180 . . . . . 0 C--O 1.25 1.09 0 CA-C-O 118.303 -0.855 . . . . 0.0 110.636 -174.644 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . 0.493 ' O ' HG13 ' A' ' 30' ' ' ILE . 14.0 m-20 . . . . . 0 N--CA 1.445 -0.687 0 CA-C-O 121.73 0.776 . . . . 0.0 109.009 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -64.27 -10.51 41.96 Favored Glycine 0 N--CA 1.441 -1.008 0 CA-C-N 114.572 -1.194 . . . . 0.0 110.55 174.198 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 47.0 m -76.32 -37.44 57.38 Favored 'General case' 0 N--CA 1.45 -0.464 0 CA-C-O 121.268 0.556 . . . . 0.0 109.867 175.363 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.601 ' HA ' ' HB1' ' A' ' 105' ' ' ALA . 0.2 OUTLIER -69.23 -36.27 71.93 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 N-CA-C 107.718 -1.216 . . . . 0.0 107.718 175.468 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' TRP . . . . . 0.572 ' CH2' ' HB1' ' A' ' 86' ' ' ALA . 42.1 m95 -70.55 -36.31 73.6 Favored 'General case' 0 C--N 1.318 -0.786 0 CA-C-N 114.401 -1.272 . . . . 0.0 110.487 -179.226 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.883 ' HB2' HH21 ' A' ' 79' ' ' ARG . 23.6 t70 -76.43 -37.66 56.67 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.583 179.271 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . 0.476 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -69.58 -33.98 73.5 Favored 'General case' 0 N--CA 1.447 -0.599 0 C-N-CA 120.852 -0.339 . . . . 0.0 110.62 178.331 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . 0.537 HG13 ' O ' ' A' ' 30' ' ' ILE . 78.0 mt -64.29 -47.48 89.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-O 121.009 0.433 . . . . 0.0 110.001 172.443 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . 0.417 ' HA ' ' O ' ' A' ' 54' ' ' GLY . . . -57.87 -39.79 78.64 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.681 -0.69 . . . . 0.0 110.169 177.446 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . 0.518 ' HA2' ' N ' ' A' ' 41' ' ' GLY . . . -70.26 -18.14 74.76 Favored Glycine 0 N--CA 1.453 -0.202 0 CA-C-N 115.501 -0.772 . . . . 0.0 112.135 179.496 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 26.4 t -90.94 -53.04 4.56 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-O 120.931 0.396 . . . . 0.0 111.419 -178.402 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 6.9 tp10 -87.23 -33.2 19.39 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.289 -170.747 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -105.5 -10.63 16.79 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.809 -0.632 . . . . 0.0 111.606 -177.528 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 78.95 14.68 81.72 Favored Glycine 0 CA--C 1.504 -0.598 0 N-CA-C 109.75 -1.34 . . . . 0.0 109.75 -175.206 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . 0.518 ' N ' ' HA2' ' A' ' 36' ' ' GLY . . . 78.49 63.25 2.15 Favored Glycine 0 N--CA 1.434 -1.481 0 CA-C-N 114.019 -1.091 . . . . 0.0 111.514 -175.571 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 2.4 t-20 -145.91 96.81 2.86 Favored 'General case' 0 N--CA 1.447 -0.576 0 N-CA-C 109.442 -0.577 . . . . 0.0 109.442 -177.451 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' TRP . . . . . 0.721 ' CE3' ' HA ' ' A' ' 79' ' ' ARG . 29.9 m95 -83.65 -4.1 58.31 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-N 115.561 -0.745 . . . . 0.0 110.385 -175.145 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -109.26 14.65 23.67 Favored 'General case' 0 C--N 1.315 -0.925 0 CA-C-N 114.805 -1.089 . . . . 0.0 110.282 178.017 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.97 HG22 ' HA2' ' A' ' 53' ' ' GLY . 8.9 tt -78.02 139.08 19.14 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.038 0 CA-C-O 121.509 0.671 . . . . 0.0 110.197 -179.148 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 13.1 t-20 -139.86 76.58 1.57 Allowed 'General case' 0 C--N 1.308 -1.2 0 N-CA-C 108.593 -0.892 . . . . 0.0 108.593 177.865 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 5.1 p -57.6 -29.2 64.3 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 114.366 -1.288 . . . . 0.0 110.997 -178.982 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 96.06 22.81 19.11 Favored Glycine 0 N--CA 1.437 -1.252 0 N-CA-C 110.922 -0.871 . . . . 0.0 110.922 178.552 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 39.0 p-10 -102.8 4.25 37.65 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 120.881 0.372 . . . . 0.0 111.015 -177.085 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . 0.418 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 94.82 -8.09 70.63 Favored Glycine 0 N--CA 1.448 -0.55 0 N-CA-C 111.535 -0.626 . . . . 0.0 111.535 178.639 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' TYR . . . . . 0.577 ' HA ' ' HA ' ' A' ' 58' ' ' ASP . 0.5 OUTLIER -112.64 132.94 54.93 Favored 'General case' 0 N--CA 1.446 -0.65 0 N-CA-C 106.71 -1.589 . . . . 0.0 106.71 -179.094 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' TYR . . . . . 0.696 ' HB2' ' HB3' ' A' ' 74' ' ' ALA . 50.6 m-85 -104.64 171.36 7.37 Favored 'General case' 0 C--N 1.304 -1.375 0 N-CA-C 113.225 0.824 . . . . 0.0 113.225 -165.747 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.97 ' HA2' HG22 ' A' ' 45' ' ' ILE . . . -48.46 155.33 1.47 Allowed Glycine 0 N--CA 1.45 -0.373 0 CA-C-N 114.783 -1.099 . . . . 0.0 115.833 -170.204 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . 0.709 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 94.13 -106.41 3.41 Favored Glycine 0 N--CA 1.438 -1.172 0 CA-C-N 114.706 -0.747 . . . . 0.0 112.179 174.756 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -84.29 -1.52 6.44 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 CA-C-O 121.246 0.546 . . . . 0.0 111.534 -178.812 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' GLN . . . . . 0.556 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 5.4 mm-40 59.21 50.39 8.01 Favored 'General case' 0 N--CA 1.467 0.409 0 CA-C-N 114.502 -1.227 . . . . 0.0 113.965 167.059 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -116.23 160.07 20.94 Favored 'General case' 0 C--N 1.326 -0.431 0 C-N-CA 119.804 -0.758 . . . . 0.0 111.569 173.693 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.577 ' HA ' ' HA ' ' A' ' 51' ' ' TYR . 7.3 p-10 -71.11 160.78 32.27 Favored 'General case' 0 C--N 1.324 -0.506 0 N-CA-C 113.797 1.036 . . . . 0.0 113.797 -163.451 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . 0.786 ' HA ' HE21 ' A' ' 59' ' ' GLN . 0.0 OUTLIER -55.36 -39.96 70.71 Favored 'General case' 0 N--CA 1.446 -0.65 0 CA-C-N 113.987 -1.46 . . . . 0.0 111.438 178.056 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -67.65 -48.66 54.98 Favored Glycine 0 C--O 1.225 -0.467 0 CA-C-N 115.417 -0.81 . . . . 0.0 112.042 -175.816 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 89.0 m -66.4 -40.63 89.74 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-O 121.067 0.46 . . . . 0.0 110.641 177.226 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' TRP . . . . . 0.488 ' HZ3' ' HG3' ' A' ' 82' ' ' GLN . 56.9 t-105 -56.48 -48.98 75.98 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-O 121.622 0.725 . . . . 0.0 109.5 175.407 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . 0.785 ' HG3' HD11 ' A' ' 68' ' ' LEU . 27.9 tt0 -66.85 -34.33 77.56 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 115.015 -0.993 . . . . 0.0 110.985 179.845 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -63.96 -41.86 97.44 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.968 -0.56 . . . . 0.0 111.454 -177.441 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 36.5 m-80 -81.52 -7.86 59.64 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.079 -0.51 . . . . 0.0 109.983 175.618 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . 0.456 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 83.29 48.34 5.39 Favored Glycine 0 N--CA 1.45 -0.413 0 CA-C-N 115.507 -0.769 . . . . 0.0 112.647 174.975 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . 0.645 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -79.68 -15.98 78.43 Favored Glycine 0 CA--C 1.504 -0.649 0 C-N-CA 120.87 -0.681 . . . . 0.0 111.904 -176.352 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.785 HD11 ' HG3' ' A' ' 63' ' ' GLU . 19.2 mt -61.72 -28.83 69.7 Favored 'General case' 0 C--N 1.314 -0.97 0 C-N-CA 123.346 0.659 . . . . 0.0 111.956 -172.953 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . 0.456 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 5.6 ptp180 -68.05 -28.45 67.39 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-O 121.557 0.694 . . . . 0.0 109.789 178.861 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 70' ' ' TYR . . . . . 0.758 ' HB3' ' HG2' ' A' ' 81' ' ' GLU . 89.0 m-85 -81.47 -34.66 31.26 Favored 'General case' 0 N--CA 1.439 -0.983 0 N-CA-C 107.872 -1.158 . . . . 0.0 107.872 176.848 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.586 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 165.33 125.22 0.02 OUTLIER Pre-proline 0 N--CA 1.445 -0.687 0 CA-C-N 112.336 -2.211 . . . . 0.0 107.115 -179.296 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 72' ' ' PRO . . . . . 0.566 ' HA ' ' HA ' ' A' ' 68' ' ' LEU . 26.8 Cg_exo -53.71 -5.97 0.36 Allowed 'Trans proline' 0 C--N 1.334 -0.232 0 C-N-CA 123.14 2.56 . . . . 0.0 114.169 -178.745 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 11.2 ptm180 -148.28 141.0 24.57 Favored 'General case' 0 C--N 1.314 -0.966 0 N-CA-C 109.231 -0.655 . . . . 0.0 109.231 175.387 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . 0.696 ' HB3' ' HB2' ' A' ' 52' ' ' TYR . . . -60.72 -27.01 67.59 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.674 -0.694 . . . . 0.0 112.65 -176.39 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . 0.601 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 3.5 p30 -80.08 -5.95 56.81 Favored 'General case' 0 C--N 1.322 -0.618 0 C-N-CA 120.007 -0.677 . . . . 0.0 110.921 -177.785 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.542 ' HB3' ' HB1' ' A' ' 71' ' ' ALA . 59.2 tp -97.89 -32.72 11.54 Favored 'General case' 0 C--N 1.321 -0.66 0 N-CA-C 109.113 -0.699 . . . . 0.0 109.113 174.815 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . 0.697 ' HB1' ' CB ' ' A' ' 81' ' ' GLU . . . -79.68 164.29 23.87 Favored 'General case' 0 N--CA 1.447 -0.586 0 CA-C-N 115.243 -0.889 . . . . 0.0 109.911 174.485 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 42.8 p -101.13 -173.89 2.48 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 116.573 -0.285 . . . . 0.0 110.801 -177.879 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . 0.883 HH21 ' HB2' ' A' ' 32' ' ' ASP . 41.2 mtp180 -50.42 -52.58 36.38 Favored 'General case' 0 CA--C 1.515 -0.402 0 CA-C-O 121.218 0.532 . . . . 0.0 111.295 -178.137 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 80' ' ' GLU . . . . . 0.687 ' HA ' HD12 ' A' ' 83' ' ' ILE . 6.9 pt-20 -66.0 -27.77 68.38 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-N 115.139 -0.937 . . . . 0.0 112.061 -173.873 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 81' ' ' GLU . . . . . 0.758 ' HG2' ' HB3' ' A' ' 70' ' ' TYR . 3.2 mp0 -72.83 -46.26 54.03 Favored 'General case' 0 C--N 1.324 -0.507 0 C-N-CA 120.762 -0.375 . . . . 0.0 111.758 174.239 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 82' ' ' GLN . . . . . 0.632 ' HB2' ' HZ3' ' A' ' 43' ' ' TRP . 0.1 OUTLIER -58.96 -34.72 72.12 Favored 'General case' 0 CA--C 1.506 -0.735 0 N-CA-C 109.108 -0.701 . . . . 0.0 109.108 175.125 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.687 HD12 ' HA ' ' A' ' 80' ' ' GLU . 60.3 mt -60.62 -48.75 87.28 Favored 'Isoleucine or valine' 0 C--O 1.211 -0.957 0 CA-C-N 114.731 -1.122 . . . . 0.0 110.022 173.636 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 84' ' ' ALA . . . . . 0.632 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -63.67 -45.26 90.91 Favored 'General case' 0 C--O 1.238 0.452 0 CA-C-O 121.439 0.637 . . . . 0.0 111.897 -174.98 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.502 HG22 ' HA2' ' A' ' 67' ' ' GLY . 34.8 t -66.52 -48.1 81.58 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.775 0 CA-C-N 115.756 -0.656 . . . . 0.0 110.651 -179.206 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 86' ' ' ALA . . . . . 0.572 ' HB1' ' CH2' ' A' ' 31' ' ' TRP . . . -61.46 -28.08 69.03 Favored 'General case' 0 N--CA 1.45 -0.45 0 CA-C-N 115.468 -0.787 . . . . 0.0 110.415 174.976 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 87' ' ' GLU . . . . . 0.679 ' HG2' ' O ' ' A' ' 83' ' ' ILE . 36.0 mm-40 -59.09 -43.37 91.84 Favored 'General case' 0 CA--C 1.513 -0.457 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.63 179.78 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.522 ' O ' ' HG3' ' A' ' 92' ' ' ARG . 48.8 t -65.27 -42.8 94.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 C-N-CA 120.385 -0.526 . . . . 0.0 109.893 175.851 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . 0.745 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 0.2 OUTLIER -66.82 -46.88 73.75 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 115.956 -0.565 . . . . 0.0 111.465 -175.271 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 90' ' ' ARG . . . . . 0.483 ' HG3' ' N ' ' A' ' 91' ' ' LEU . 4.9 ptt180 -66.09 -31.18 71.9 Favored 'General case' 0 C--O 1.218 -0.577 0 CA-C-O 122.042 0.925 . . . . 0.0 109.083 -179.018 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 91' ' ' LEU . . . . . 0.483 ' N ' ' HG3' ' A' ' 90' ' ' ARG . 56.3 tp -61.84 -30.5 70.89 Favored 'General case' 0 C--N 1.308 -1.211 0 CA-C-N 114.494 -1.23 . . . . 0.0 111.509 -175.633 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . 0.522 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 7.6 mtm180 -90.68 -45.73 8.69 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-N 115.559 -0.746 . . . . 0.0 110.205 -175.402 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 93' ' ' GLN . . . . . 0.532 ' NE2' HG22 ' A' ' 89' ' ' THR . 21.1 pt20 -104.03 -27.32 12.2 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 114.897 -1.047 . . . . 0.0 113.039 -169.923 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . 0.412 ' O ' ' HB2' ' A' ' 90' ' ' ARG . . . 106.75 -107.71 2.74 Favored Glycine 0 N--CA 1.44 -1.034 0 N-CA-C 109.134 -1.586 . . . . 0.0 109.134 -175.214 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 95' ' ' TRP . . . . . 0.556 ' CZ2' HD12 ' A' ' 30' ' ' ILE . 29.7 m95 -138.51 21.56 2.73 Favored 'General case' 0 C--N 1.308 -1.21 0 N-CA-C 106.348 -1.723 . . . . 0.0 106.348 172.995 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -56.26 -35.16 64.31 Favored Glycine 0 C--N 1.335 0.514 0 CA-C-N 114.706 -1.134 . . . . 0.0 112.901 179.752 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -79.25 -15.38 58.1 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.78 0.324 . . . . 0.0 110.533 178.092 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 98' ' ' TRP . . . . . 0.745 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 24.7 m-90 -104.92 107.81 59.59 Favored Pre-proline 0 C--N 1.323 -0.572 0 CA-C-O 121.459 0.647 . . . . 0.0 110.019 178.722 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 99' ' ' PRO . . . . . 0.427 ' HD3' ' HA ' ' A' ' 98' ' ' TRP . 37.6 Cg_exo -64.73 -139.39 0.01 OUTLIER 'Trans proline' 0 CA--C 1.534 0.52 0 C-N-CA 123.764 2.976 . . . . 0.0 114.762 -174.102 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . 0.563 ' O ' ' HD2' ' A' ' 104' ' ' ARG . 23.8 t -55.89 -25.84 19.67 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.266 0 CA-C-N 115.441 -0.8 . . . . 0.0 110.746 -178.126 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 89.9 m -60.12 -38.73 83.91 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.321 176.907 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 102' ' ' ALA . . . . . 0.567 ' HB2' ' HB3' ' A' ' 98' ' ' TRP . . . -70.48 -41.2 73.02 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.686 0.279 . . . . 0.0 110.452 178.434 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -59.63 -44.81 93.33 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 121.189 0.519 . . . . 0.0 110.025 178.208 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 104' ' ' ARG . . . . . 0.563 ' HD2' ' O ' ' A' ' 100' ' ' VAL . 0.0 OUTLIER -62.52 -37.01 84.42 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.393 -0.821 . . . . 0.0 111.052 176.787 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 105' ' ' ALA . . . . . 0.601 ' HB1' ' HA ' ' A' ' 30' ' ' ILE . . . -78.77 -22.45 46.36 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 115.624 -0.716 . . . . 0.0 111.905 -176.165 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 114.56 62.13 0.39 Allowed Glycine 0 CA--C 1.519 0.325 0 C-N-CA 121.143 -0.551 . . . . 0.0 112.392 -178.185 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -61.47 140.61 58.04 Favored 'General case' 0 C--O 1.236 0.343 0 C-N-CA 122.789 0.435 . . . . 0.0 110.799 -179.331 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 8.7 ptm180 . . . . . 0 C--O 1.245 0.858 0 CA-C-O 118.556 -0.735 . . . . 0.0 110.555 -172.452 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 . . . . . 0 CA--C 1.503 -0.846 0 CA-C-O 121.449 0.642 . . . . 0.0 109.904 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -61.21 -15.22 43.57 Favored Glycine 0 CA--C 1.505 -0.565 0 CA-C-N 114.904 -1.043 . . . . 0.0 110.543 177.646 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 23.2 m -77.28 -37.23 53.28 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 114.666 -0.767 . . . . 0.0 110.068 177.598 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.556 ' O ' HG13 ' A' ' 34' ' ' ILE . 1.1 mm -71.38 -39.08 71.36 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.751 0 N-CA-C 107.029 -1.471 . . . . 0.0 107.029 178.693 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' TRP . . . . . 0.621 ' HZ2' ' HD3' ' A' ' 90' ' ' ARG . 24.3 m95 -68.54 -36.91 79.48 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-N 114.054 -1.43 . . . . 0.0 110.793 -176.154 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 7.8 t70 -74.92 -36.2 62.17 Favored 'General case' 0 N--CA 1.444 -0.743 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.587 177.203 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . 0.455 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -70.92 -35.52 72.29 Favored 'General case' 0 N--CA 1.448 -0.533 0 C-N-CA 120.736 -0.386 . . . . 0.0 110.846 178.937 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . 0.556 HG13 ' O ' ' A' ' 30' ' ' ILE . 75.8 mt -66.96 -46.07 85.75 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.222 0 CA-C-O 120.987 0.423 . . . . 0.0 110.002 174.662 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -57.61 -38.22 74.57 Favored 'General case' 0 CA--C 1.515 -0.373 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.297 176.92 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . 0.549 ' HA2' ' CA ' ' A' ' 41' ' ' GLY . . . -77.96 -1.64 79.69 Favored Glycine 0 N--CA 1.449 -0.436 0 CA-C-N 115.421 -0.809 . . . . 0.0 112.028 179.341 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 38.5 t -106.61 -57.09 2.1 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 115.825 -0.187 . . . . 0.0 111.361 -177.319 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . 0.824 ' HG3' ' SG ' ' A' ' 101' ' ' CYS . 9.9 mt-10 -88.09 -30.83 19.58 Favored 'General case' 0 CA--C 1.514 -0.422 0 C-N-CA 120.949 -0.301 . . . . 0.0 111.101 -175.207 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -96.68 -7.44 34.07 Favored 'General case' 0 N--CA 1.449 -0.488 0 C-N-CA 120.765 -0.374 . . . . 0.0 111.527 -179.079 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 82.09 2.6 90.61 Favored Glycine 0 CA--C 1.505 -0.575 0 N-CA-C 110.0 -1.24 . . . . 0.0 110.0 -177.962 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . 0.549 ' CA ' ' HA2' ' A' ' 36' ' ' GLY . . . 89.76 54.62 2.17 Favored Glycine 0 N--CA 1.433 -1.511 0 CA-C-N 114.208 -0.996 . . . . 0.0 111.807 -178.043 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 53.0 t30 -147.82 124.57 11.18 Favored 'General case' 0 N--CA 1.443 -0.793 0 N-CA-C 109.147 -0.686 . . . . 0.0 109.147 -178.983 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' TRP . . . . . 0.78 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 20.5 m95 -99.44 1.61 44.32 Favored 'General case' 0 C--N 1.301 -1.527 0 CA-C-N 115.132 -0.94 . . . . 0.0 110.004 -174.467 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -111.59 5.48 19.42 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.088 -0.96 . . . . 0.0 111.102 177.188 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 13.0 tt -75.26 143.32 13.42 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.769 0 CA-C-O 120.946 0.403 . . . . 0.0 110.196 -178.927 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 40.7 t-20 -156.46 96.62 1.68 Allowed 'General case' 0 C--N 1.311 -1.089 0 CA-C-O 121.154 0.502 . . . . 0.0 109.826 179.399 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 20.5 p -76.72 -22.0 54.5 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 115.782 -0.645 . . . . 0.0 111.262 -177.154 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 98.33 21.73 16.62 Favored Glycine 0 N--CA 1.442 -0.902 0 CA-C-N 115.549 -0.751 . . . . 0.0 111.272 -179.016 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 66.3 t30 -91.16 11.89 21.8 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 121.59 0.71 . . . . 0.0 110.934 -177.358 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 84.58 -14.41 46.92 Favored Glycine 0 N--CA 1.453 -0.224 0 N-CA-C 111.234 -0.746 . . . . 0.0 111.234 -178.281 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' TYR . . . . . 0.628 ' CE1' ' HB2' ' A' ' 58' ' ' ASP . 0.5 OUTLIER -98.07 142.4 29.81 Favored 'General case' 0 N--CA 1.445 -0.693 0 N-CA-C 108.174 -1.047 . . . . 0.0 108.174 173.226 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' TYR . . . . . 0.821 ' CE1' ' HB2' ' A' ' 59' ' ' GLN . 4.7 m-85 -108.56 170.28 8.12 Favored 'General case' 0 C--N 1.311 -1.097 0 CA-C-N 116.019 -0.537 . . . . 0.0 111.456 -174.323 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -58.89 172.56 4.07 Favored Glycine 0 N--CA 1.452 -0.286 0 N-CA-C 115.123 0.809 . . . . 0.0 115.123 -170.202 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . 0.764 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 87.01 -111.73 3.7 Favored Glycine 0 N--CA 1.443 -0.865 0 C-N-CA 120.962 -0.637 . . . . 0.0 111.577 -179.607 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.508 HG11 ' CE3' ' A' ' 31' ' ' TRP . 6.2 t -84.28 6.43 2.02 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.74 0 CA-C-O 121.736 0.779 . . . . 0.0 109.778 179.959 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' GLN . . . . . 0.715 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 8.4 tp-100 53.54 51.91 14.31 Favored 'General case' 0 C--O 1.236 0.366 0 CA-C-N 114.427 -1.26 . . . . 0.0 112.872 164.816 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 6.9 p90 -120.15 167.94 11.72 Favored 'General case' 0 N--CA 1.443 -0.801 0 C-N-CA 119.555 -0.858 . . . . 0.0 111.897 174.245 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.628 ' HB2' ' CE1' ' A' ' 51' ' ' TYR . 0.6 OUTLIER -71.09 141.81 50.82 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 114.242 -1.345 . . . . 0.0 113.062 -165.636 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . 0.821 ' HB2' ' CE1' ' A' ' 52' ' ' TYR . 0.0 OUTLIER -56.2 -38.12 70.56 Favored 'General case' 0 N--CA 1.446 -0.628 0 CA-C-N 113.389 -1.732 . . . . 0.0 111.522 178.074 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -63.89 -48.93 71.5 Favored Glycine 0 N--CA 1.441 -1.006 0 CA-C-N 115.938 -0.573 . . . . 0.0 112.019 178.102 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 68.8 m -61.47 -42.21 98.43 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 121.279 0.561 . . . . 0.0 110.4 175.076 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' TRP . . . . . 0.455 ' CZ3' ' HA ' ' A' ' 82' ' ' GLN . 43.4 t-105 -56.13 -49.83 72.81 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.055 -0.975 . . . . 0.0 109.981 175.635 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . 0.631 ' HG3' HD11 ' A' ' 68' ' ' LEU . 29.3 tt0 -66.8 -39.36 87.71 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 115.195 -0.912 . . . . 0.0 110.756 -178.663 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -62.25 -39.5 93.07 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.553 -0.749 . . . . 0.0 110.92 -176.922 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . 0.586 ' OD1' ' HB ' ' A' ' 89' ' ' THR . 10.7 m120 -75.59 -21.14 58.08 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.198 177.014 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 101.7 39.36 2.97 Favored Glycine 0 N--CA 1.449 -0.493 0 C-N-CA 120.957 -0.64 . . . . 0.0 112.28 178.317 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . 0.655 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -79.25 -16.66 77.99 Favored Glycine 0 N--CA 1.44 -1.048 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.073 -173.915 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.631 HD11 ' HG3' ' A' ' 63' ' ' GLU . 26.4 mt -63.55 -23.76 67.52 Favored 'General case' 0 N--CA 1.442 -0.828 0 CA-C-N 115.502 -0.349 . . . . 0.0 111.566 -172.932 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . 0.57 ' HG3' ' N ' ' A' ' 70' ' ' TYR . 0.0 OUTLIER -70.77 -32.68 69.89 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 121.186 0.517 . . . . 0.0 110.068 176.165 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 70' ' ' TYR . . . . . 0.692 ' HB3' ' CG ' ' A' ' 81' ' ' GLU . 86.9 m-85 -76.13 -33.17 59.43 Favored 'General case' 0 CA--C 1.503 -0.852 0 N-CA-C 107.574 -1.269 . . . . 0.0 107.574 -179.934 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.754 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 163.26 125.48 0.01 OUTLIER Pre-proline 0 C--N 1.321 -0.654 0 CA-C-N 111.903 -2.408 . . . . 0.0 106.688 179.293 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 72' ' ' PRO . . . . . 0.606 ' HA ' ' HA ' ' A' ' 68' ' ' LEU . 17.3 Cg_exo -55.16 -4.0 0.37 Allowed 'Trans proline' 0 C--N 1.331 -0.342 0 C-N-CA 122.85 2.366 . . . . 0.0 113.633 -179.799 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 73' ' ' ARG . . . . . 0.401 ' HB2' ' CD2' ' A' ' 52' ' ' TYR . 14.8 ptm180 -145.83 136.94 24.7 Favored 'General case' 0 C--N 1.317 -0.836 0 CA-C-O 121.269 0.557 . . . . 0.0 109.657 176.6 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . 0.499 ' HB3' ' HB2' ' A' ' 52' ' ' TYR . . . -63.43 -25.49 68.3 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 115.455 -0.793 . . . . 0.0 111.914 -177.467 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . 0.484 ' OD1' ' HD2' ' A' ' 52' ' ' TYR . 26.9 p-10 -88.16 10.0 20.88 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-O 121.292 0.568 . . . . 0.0 110.847 -177.714 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 68.7 tp -113.0 -34.43 5.74 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.46 -0.791 . . . . 0.0 109.048 168.121 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . 0.754 ' HB2' ' HB3' ' A' ' 71' ' ' ALA . . . -78.31 153.43 31.75 Favored 'General case' 0 N--CA 1.443 -0.799 0 CA-C-N 115.357 -0.838 . . . . 0.0 109.851 177.687 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 33.5 p -96.54 -173.98 2.91 Favored 'General case' 0 C--N 1.317 -0.84 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.35 -176.951 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . 0.78 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 49.1 mtt85 -50.63 -52.56 38.43 Favored 'General case' 0 CA--C 1.513 -0.46 0 O-C-N 123.519 0.512 . . . . 0.0 111.549 -178.06 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 80' ' ' GLU . . . . . 0.563 ' HG3' ' OE2' ' A' ' 81' ' ' GLU . 9.3 pt-20 -59.28 -42.96 92.5 Favored 'General case' 0 C--N 1.318 -0.786 0 CA-C-N 116.026 -0.534 . . . . 0.0 111.962 -176.627 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 81' ' ' GLU . . . . . 0.692 ' CG ' ' HB3' ' A' ' 70' ' ' TYR . 4.9 mp0 -63.68 -51.99 62.64 Favored 'General case' 0 N--CA 1.454 -0.229 0 N-CA-C 112.094 0.405 . . . . 0.0 112.094 173.987 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 82' ' ' GLN . . . . . 0.46 ' NE2' ' HE3' ' A' ' 43' ' ' TRP . 51.4 mt-30 -59.16 -43.35 92.07 Favored 'General case' 0 CA--C 1.509 -0.611 0 CA-C-O 121.067 0.461 . . . . 0.0 110.459 -176.303 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.668 ' O ' ' HG2' ' A' ' 87' ' ' GLU . 34.3 mt -59.53 -41.88 86.23 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.793 0 CA-C-N 115.157 -0.928 . . . . 0.0 110.006 -178.886 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 84' ' ' ALA . . . . . 0.615 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -64.52 -42.8 95.55 Favored 'General case' 0 C--O 1.236 0.394 0 CA-C-O 121.705 0.764 . . . . 0.0 111.043 -177.793 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.431 HG22 ' HA2' ' A' ' 67' ' ' GLY . 48.3 t -65.53 -49.12 80.01 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 CA-C-N 115.539 -0.755 . . . . 0.0 110.906 178.188 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 86' ' ' ALA . . . . . 0.405 ' HB1' ' CH2' ' A' ' 31' ' ' TRP . . . -58.48 -30.47 67.01 Favored 'General case' 0 N--CA 1.452 -0.362 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.534 173.965 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 87' ' ' GLU . . . . . 0.668 ' HG2' ' O ' ' A' ' 83' ' ' ILE . 26.4 mm-40 -58.99 -44.06 91.56 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.45 -178.749 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.569 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 98.1 t -64.18 -50.68 75.71 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 C-N-CA 120.555 -0.458 . . . . 0.0 110.622 -179.799 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . 0.586 ' HB ' ' OD1' ' A' ' 65' ' ' ASN . 12.5 t -73.59 -35.63 65.44 Favored 'General case' 0 C--N 1.318 -0.793 0 C-N-CA 120.796 -0.362 . . . . 0.0 111.66 -174.612 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 90' ' ' ARG . . . . . 0.641 ' HG3' ' N ' ' A' ' 91' ' ' LEU . 10.9 ptt85 -60.77 -41.6 95.82 Favored 'General case' 0 N--CA 1.471 0.597 0 CA-C-N 117.919 0.327 . . . . 0.0 110.783 -179.194 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 91' ' ' LEU . . . . . 0.641 ' N ' ' HG3' ' A' ' 90' ' ' ARG . 4.5 pp -69.8 -23.83 63.39 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.845 -0.616 . . . . 0.0 111.419 -172.43 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . 0.546 ' NE ' ' HA ' ' A' ' 89' ' ' THR . 1.9 mtm180 -81.22 -47.96 12.71 Favored 'General case' 0 N--CA 1.447 -0.606 0 CA-C-O 121.576 0.703 . . . . 0.0 109.468 -178.948 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 93' ' ' GLN . . . . . 0.465 ' OE1' ' HB2' ' A' ' 97' ' ' ALA . 17.6 pt20 -95.94 -27.14 15.3 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 114.731 -1.122 . . . . 0.0 112.872 -167.633 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 91.76 39.86 5.43 Favored Glycine 0 CA--C 1.504 -0.615 0 C-N-CA 120.344 -0.931 . . . . 0.0 111.985 170.441 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 95' ' ' TRP . . . . . 0.447 ' HB3' ' HB1' ' A' ' 102' ' ' ALA . 6.9 m95 63.74 17.27 10.35 Favored 'General case' 0 C--O 1.22 -0.474 0 N-CA-C 109.255 -0.646 . . . . 0.0 109.255 -179.231 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -70.47 -30.29 69.12 Favored Glycine 0 N--CA 1.451 -0.344 0 CA-C-N 115.504 -0.771 . . . . 0.0 112.598 177.989 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . 0.465 ' HB2' ' OE1' ' A' ' 93' ' ' GLN . . . -69.99 -30.11 67.36 Favored 'General case' 0 CA--C 1.514 -0.439 0 CA-C-O 120.924 0.392 . . . . 0.0 110.21 177.488 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 98' ' ' TRP . . . . . 0.509 ' HB2' ' HB2' ' A' ' 102' ' ' ALA . 25.6 m-90 -98.47 104.55 24.45 Favored Pre-proline 0 C--N 1.323 -0.571 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 177.353 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_exo -70.99 -94.2 0.01 OUTLIER 'Trans proline' 0 CA--C 1.534 0.505 0 C-N-CA 122.889 2.393 . . . . 0.0 114.734 -172.22 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 60.6 t -70.99 -31.95 46.84 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 CA-C-O 121.822 0.82 . . . . 0.0 110.19 -173.98 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 101' ' ' CYS . . . . . 0.824 ' SG ' ' HG3' ' A' ' 38' ' ' GLU . 75.6 m -78.26 -26.1 47.05 Favored 'General case' 0 C--N 1.315 -0.932 0 CA-C-N 114.772 -1.104 . . . . 0.0 112.27 -168.832 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 102' ' ' ALA . . . . . 0.509 ' HB2' ' HB2' ' A' ' 98' ' ' TRP . . . -69.93 -46.19 65.89 Favored 'General case' 0 C--N 1.326 -0.444 0 C-N-CA 120.549 -0.461 . . . . 0.0 110.23 176.249 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -65.33 -35.92 82.46 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.699 -179.358 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 104' ' ' ARG . . . . . 0.471 ' HG2' ' HA ' ' A' ' 101' ' ' CYS . 0.0 OUTLIER -73.41 -21.45 60.48 Favored 'General case' 0 N--CA 1.444 -0.725 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.425 179.785 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 105' ' ' ALA . . . . . 0.466 ' HB1' ' HA ' ' A' ' 30' ' ' ILE . . . -96.08 -22.82 17.1 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.821 -0.627 . . . . 0.0 111.581 -178.157 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 119.02 63.66 0.29 Allowed Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 121.236 -0.507 . . . . 0.0 112.236 -176.86 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -64.09 145.15 56.42 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.776 0.322 . . . . 0.0 110.782 179.36 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 51.8 mtp180 . . . . . 0 C--O 1.249 1.06 0 CA-C-O 118.395 -0.812 . . . . 0.0 110.332 -173.293 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 15.0 m-20 . . . . . 0 CA--C 1.507 -0.706 0 CA-C-O 121.865 0.84 . . . . 0.0 109.532 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . 0.463 ' HA2' ' HB2' ' A' ' 31' ' ' TRP . . . -70.23 -6.32 56.98 Favored Glycine 0 N--CA 1.44 -1.057 0 CA-C-N 114.481 -1.236 . . . . 0.0 110.38 176.526 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 9.6 m -76.96 -39.4 50.71 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-O 121.659 0.742 . . . . 0.0 109.087 174.661 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.496 ' O ' HG13 ' A' ' 34' ' ' ILE . 1.0 OUTLIER -69.65 -38.1 75.64 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.576 0 N-CA-C 107.492 -1.299 . . . . 0.0 107.492 177.366 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' TRP . . . . . 0.513 ' CD1' HG23 ' A' ' 83' ' ' ILE . 43.2 m95 -71.41 -35.91 71.16 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 114.262 -1.336 . . . . 0.0 110.487 -177.857 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.533 ' HB2' HH21 ' A' ' 79' ' ' ARG . 15.5 t70 -74.28 -34.56 63.6 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.385 178.328 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -69.89 -34.47 73.59 Favored 'General case' 0 N--CA 1.446 -0.629 0 C-N-CA 120.756 -0.377 . . . . 0.0 110.12 177.705 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . 0.566 ' HA ' ' HB3' ' A' ' 101' ' ' CYS . 61.9 mt -67.33 -47.44 81.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.312 174.399 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . 0.445 ' HA ' ' O ' ' A' ' 54' ' ' GLY . . . -58.76 -39.14 80.12 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.501 177.554 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -76.13 -8.79 85.42 Favored Glycine 0 N--CA 1.451 -0.337 0 CA-C-N 115.559 -0.746 . . . . 0.0 112.081 179.603 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 1.7 t -97.16 -57.96 2.13 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-O 120.678 0.275 . . . . 0.0 111.417 -178.6 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . 0.545 ' HB2' ' SG ' ' A' ' 101' ' ' CYS . 8.0 tp10 -87.97 -33.02 18.57 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 121.207 0.527 . . . . 0.0 109.999 -171.315 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . 0.412 ' HB3' ' O ' ' A' ' 35' ' ' ALA . . . -95.71 -13.05 24.52 Favored 'General case' 0 N--CA 1.448 -0.538 0 CA-C-N 115.631 -0.713 . . . . 0.0 111.197 -178.749 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 82.52 1.34 90.47 Favored Glycine 0 N--CA 1.448 -0.505 0 N-CA-C 109.983 -1.247 . . . . 0.0 109.983 -177.04 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 93.65 55.63 1.52 Allowed Glycine 0 N--CA 1.436 -1.327 0 CA-C-N 114.372 -0.914 . . . . 0.0 111.61 -176.543 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' ASN . . . . . 0.556 ' HB3' ' HB ' ' A' ' 45' ' ' ILE . 0.3 OUTLIER -142.93 94.6 2.65 Favored 'General case' 0 N--CA 1.447 -0.606 0 N-CA-C 108.704 -0.85 . . . . 0.0 108.704 -177.689 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' TRP . . . . . 0.754 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 38.3 m95 -76.65 -10.71 59.58 Favored 'General case' 0 C--N 1.317 -0.844 0 CA-C-O 121.384 0.611 . . . . 0.0 110.423 -175.385 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . 0.426 ' HA ' ' HB2' ' A' ' 75' ' ' ASP . . . -107.73 15.38 24.66 Favored 'General case' 0 C--N 1.318 -0.795 0 CA-C-N 114.981 -1.009 . . . . 0.0 111.731 -178.624 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.746 HG22 ' HA2' ' A' ' 53' ' ' GLY . 9.9 tt -83.21 142.42 13.56 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.619 0 CA-C-O 121.432 0.634 . . . . 0.0 111.344 -175.639 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . 0.41 HD22 ' HA ' ' A' ' 46' ' ' ASN . 9.7 m120 -133.53 88.19 2.46 Favored 'General case' 0 C--N 1.316 -0.873 0 N-CA-C 108.539 -0.911 . . . . 0.0 108.539 176.663 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 1.2 p -69.31 -24.09 63.89 Favored 'General case' 0 C--N 1.315 -0.934 0 CA-C-N 115.769 -0.651 . . . . 0.0 110.603 179.708 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 94.57 19.0 33.51 Favored Glycine 0 N--CA 1.444 -0.795 0 N-CA-C 111.272 -0.731 . . . . 0.0 111.272 176.412 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 30.7 p-10 -94.7 11.62 30.64 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.141 0.496 . . . . 0.0 111.134 -175.301 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . 0.452 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 89.9 -11.59 70.07 Favored Glycine 0 N--CA 1.445 -0.724 0 N-CA-C 110.823 -0.911 . . . . 0.0 110.823 -178.243 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' TYR . . . . . 0.604 ' CE1' ' HB3' ' A' ' 58' ' ' ASP . 0.8 OUTLIER -109.94 151.64 26.85 Favored 'General case' 0 CA--C 1.512 -0.488 0 N-CA-C 107.827 -1.175 . . . . 0.0 107.827 178.722 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' TYR . . . . . 0.633 ' CE1' ' HB2' ' A' ' 59' ' ' GLN . 24.2 m-85 -115.36 170.4 8.43 Favored 'General case' 0 C--N 1.313 -0.995 0 C-N-CA 120.647 -0.421 . . . . 0.0 111.316 -170.294 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.746 ' HA2' HG22 ' A' ' 45' ' ' ILE . . . -56.92 166.72 4.72 Favored Glycine 0 N--CA 1.451 -0.354 0 N-CA-C 114.818 0.687 . . . . 0.0 114.818 -169.744 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . 0.678 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 88.19 -103.78 2.97 Favored Glycine 0 N--CA 1.444 -0.791 0 C-N-CA 121.253 -0.499 . . . . 0.0 112.237 177.305 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.516 HG12 ' HE1' ' A' ' 98' ' ' TRP . 2.5 t -83.27 -2.82 6.95 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 CA-C-O 121.445 0.64 . . . . 0.0 109.785 -177.873 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' GLN . . . . . 0.613 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 2.0 mm-40 55.91 42.33 28.94 Favored 'General case' 0 N--CA 1.462 0.139 0 CA-C-N 114.747 -1.115 . . . . 0.0 113.102 169.727 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . 0.487 ' CD1' ' HB ' ' A' ' 55' ' ' VAL . 1.5 p90 -114.88 165.63 12.64 Favored 'General case' 0 C--N 1.322 -0.616 0 C-N-CA 119.912 -0.715 . . . . 0.0 111.041 175.253 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.604 ' HB3' ' CE1' ' A' ' 51' ' ' TYR . 8.1 p-10 -76.02 155.56 34.82 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 122.075 0.941 . . . . 0.0 112.619 -164.238 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . 0.633 ' HB2' ' CE1' ' A' ' 52' ' ' TYR . 3.6 tp-100 -61.42 -32.11 72.06 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 113.414 -1.721 . . . . 0.0 111.14 179.767 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -65.94 -49.5 58.26 Favored Glycine 0 C--N 1.316 -0.553 0 CA-C-N 115.48 -0.782 . . . . 0.0 111.786 -179.862 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 90.9 m -66.67 -40.75 88.75 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-O 120.787 0.327 . . . . 0.0 110.996 175.979 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' TRP . . . . . 0.473 ' CH2' ' HA ' ' A' ' 74' ' ' ALA . 46.2 t-105 -56.38 -49.53 74.18 Favored 'General case' 0 N--CA 1.45 -0.462 0 CA-C-O 121.656 0.741 . . . . 0.0 109.293 176.137 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . 0.431 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 33.6 tt0 -68.11 -32.28 72.47 Favored 'General case' 0 N--CA 1.444 -0.763 0 CA-C-N 115.022 -0.99 . . . . 0.0 110.855 179.857 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -64.26 -39.03 93.11 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.891 -179.588 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . 0.578 ' HB2' HG13 ' A' ' 85' ' ' VAL . 5.5 m120 -78.76 -14.05 59.48 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 121.597 0.713 . . . . 0.0 109.485 175.134 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . 0.582 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 82.68 49.15 5.25 Favored Glycine 0 N--CA 1.445 -0.702 0 CA-C-N 115.061 -0.972 . . . . 0.0 111.608 -179.924 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . 0.629 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -78.67 -15.39 80.86 Favored Glycine 0 N--CA 1.442 -0.96 0 C-N-CA 121.273 -0.489 . . . . 0.0 112.432 -174.765 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.837 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 6.8 mp -59.21 -27.27 65.57 Favored 'General case' 0 C--N 1.323 -0.575 0 N-CA-C 111.872 0.323 . . . . 0.0 111.872 -175.568 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . 0.582 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 9.1 ptp180 -65.33 -30.12 70.93 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 121.353 0.597 . . . . 0.0 110.046 177.182 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 70' ' ' TYR . . . . . 0.999 ' HB3' ' HB3' ' A' ' 81' ' ' GLU . 75.0 m-85 -81.49 -34.3 31.39 Favored 'General case' 0 N--CA 1.441 -0.905 0 N-CA-C 107.638 -1.245 . . . . 0.0 107.638 176.405 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.696 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 162.67 128.92 0.01 OUTLIER Pre-proline 0 CA--C 1.513 -0.465 0 CA-C-N 112.653 -2.067 . . . . 0.0 107.009 -179.568 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 72' ' ' PRO . . . . . 0.837 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 20.4 Cg_exo -57.35 -4.93 1.3 Allowed 'Trans proline' 0 C--N 1.333 -0.26 0 C-N-CA 122.77 2.313 . . . . 0.0 113.767 -177.17 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 73' ' ' ARG . . . . . 0.428 ' HE ' ' CG ' ' A' ' 75' ' ' ASP . 10.7 ptm180 -147.86 139.01 23.45 Favored 'General case' 0 C--N 1.317 -0.805 0 N-CA-C 109.367 -0.605 . . . . 0.0 109.367 176.526 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . 0.473 ' HA ' ' CH2' ' A' ' 62' ' ' TRP . . . -55.95 -29.84 60.77 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 114.941 -1.027 . . . . 0.0 112.52 -177.193 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . 0.546 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 4.6 p-10 -83.97 -4.68 58.9 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 120.967 0.413 . . . . 0.0 111.256 -176.037 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 68.1 tp -100.0 -29.74 12.37 Favored 'General case' 0 C--N 1.322 -0.59 0 N-CA-C 108.46 -0.941 . . . . 0.0 108.46 172.549 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . 0.805 ' HB1' ' HB2' ' A' ' 81' ' ' GLU . . . -79.28 159.16 27.36 Favored 'General case' 0 N--CA 1.44 -0.968 0 CA-C-N 114.78 -1.1 . . . . 0.0 109.795 175.113 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 61.9 p -100.35 -175.19 2.85 Favored 'General case' 0 C--N 1.309 -1.188 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.355 -176.974 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . 0.754 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 77.7 mtp180 -50.01 -52.93 30.11 Favored 'General case' 0 C--N 1.329 -0.293 0 O-C-N 123.416 0.447 . . . . 0.0 111.265 178.819 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 80' ' ' GLU . . . . . 0.46 ' HA ' HD12 ' A' ' 83' ' ' ILE . 17.0 pt-20 -60.8 -37.23 81.24 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.873 -0.603 . . . . 0.0 111.434 -174.43 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 81' ' ' GLU . . . . . 0.999 ' HB3' ' HB3' ' A' ' 70' ' ' TYR . 4.2 mm-40 -70.22 -50.32 41.05 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 121.031 0.443 . . . . 0.0 109.959 -179.465 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 82' ' ' GLN . . . . . 0.57 ' HB2' ' HZ3' ' A' ' 43' ' ' TRP . 41.7 mt-30 -60.03 -34.45 73.4 Favored 'General case' 0 CA--C 1.513 -0.465 0 CA-C-N 115.515 -0.766 . . . . 0.0 110.201 -179.319 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.69 ' O ' ' HG2' ' A' ' 87' ' ' GLU . 40.3 mt -60.77 -49.1 85.91 Favored 'Isoleucine or valine' 0 C--O 1.212 -0.883 0 N-CA-C 109.084 -0.71 . . . . 0.0 109.084 175.855 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 84' ' ' ALA . . . . . 0.587 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -62.1 -44.09 97.4 Favored 'General case' 0 C--O 1.237 0.414 0 CA-C-O 121.277 0.56 . . . . 0.0 111.867 -176.353 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.578 HG13 ' HB2' ' A' ' 65' ' ' ASN . 40.0 t -66.24 -49.32 76.86 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.609 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.862 179.432 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 86' ' ' ALA . . . . . 0.474 ' HB1' ' CH2' ' A' ' 31' ' ' TRP . . . -59.11 -29.54 67.45 Favored 'General case' 0 N--CA 1.447 -0.592 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.404 174.572 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 87' ' ' GLU . . . . . 0.86 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 15.7 mm-40 -59.46 -44.3 93.0 Favored 'General case' 0 C--O 1.222 -0.386 0 CA-C-N 115.846 -0.616 . . . . 0.0 110.492 -178.599 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.448 ' O ' ' HG3' ' A' ' 92' ' ' ARG . 70.6 t -60.52 -49.3 84.93 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.303 0 C-N-CA 120.288 -0.565 . . . . 0.0 110.091 179.747 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . 0.675 HG22 ' NE2' ' A' ' 93' ' ' GLN . 24.0 m -66.24 -43.8 85.57 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-N 115.683 -0.69 . . . . 0.0 111.437 -177.155 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 90' ' ' ARG . . . . . 0.657 ' HA ' ' OE1' ' A' ' 93' ' ' GLN . 3.2 ppt_? -60.96 -34.34 74.59 Favored 'General case' 0 N--CA 1.467 0.4 0 N-CA-C 112.073 0.397 . . . . 0.0 112.073 -176.48 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 91' ' ' LEU . . . . . 0.86 ' HG ' ' O ' ' A' ' 87' ' ' GLU . 46.5 mt -62.87 -33.25 74.88 Favored 'General case' 0 N--CA 1.471 0.587 0 CA-C-O 121.47 0.652 . . . . 0.0 110.152 -177.998 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . 0.483 ' NH2' HG23 ' A' ' 89' ' ' THR . 6.5 mtm180 -81.57 -50.57 9.21 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-N 114.818 -1.083 . . . . 0.0 110.103 -169.85 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 93' ' ' GLN . . . . . 0.675 ' NE2' HG22 ' A' ' 89' ' ' THR . 0.0 OUTLIER -96.13 -23.55 16.7 Favored 'General case' 0 C--N 1.318 -0.785 0 C-N-CA 119.733 -0.787 . . . . 0.0 113.045 -171.682 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 88.48 40.41 6.42 Favored Glycine 0 CA--C 1.508 -0.345 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.156 172.466 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 95' ' ' TRP . . . . . 0.531 ' CZ2' ' HD3' ' A' ' 90' ' ' ARG . 22.1 m95 67.16 9.09 6.68 Favored 'General case' 0 C--O 1.221 -0.423 0 C-N-CA 123.6 0.76 . . . . 0.0 110.033 -179.124 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -71.97 -23.48 77.93 Favored Glycine 0 N--CA 1.451 -0.305 0 CA-C-N 115.891 -0.595 . . . . 0.0 112.444 178.155 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -72.7 -28.1 62.47 Favored 'General case' 0 CA--C 1.516 -0.337 0 CA-C-O 121.046 0.451 . . . . 0.0 109.988 177.641 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 98' ' ' TRP . . . . . 0.516 ' HE1' HG12 ' A' ' 55' ' ' VAL . 28.6 m-90 -101.02 104.16 30.31 Favored Pre-proline 0 N--CA 1.448 -0.567 0 CA-C-N 115.146 -0.934 . . . . 0.0 108.966 176.528 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 99' ' ' PRO . . . . . 0.404 ' HD3' ' HA ' ' A' ' 98' ' ' TRP . 15.7 Cg_exo -73.95 -88.38 0.0 OUTLIER 'Trans proline' 0 CA--C 1.53 0.32 0 C-N-CA 123.182 2.588 . . . . 0.0 114.993 -171.127 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . 0.427 ' HA ' HH21 ' A' ' 104' ' ' ARG . 80.5 t -69.45 -30.08 44.24 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-O 121.142 0.496 . . . . 0.0 110.693 -172.393 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 101' ' ' CYS . . . . . 0.566 ' HB3' ' HA ' ' A' ' 34' ' ' ILE . 87.1 m -79.79 -37.64 34.84 Favored 'General case' 0 C--N 1.317 -0.812 0 CA-C-N 115.7 -0.682 . . . . 0.0 112.403 -170.102 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 102' ' ' ALA . . . . . 0.442 ' HB1' ' HB3' ' A' ' 95' ' ' TRP . . . -69.62 -40.33 76.66 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.828 0.347 . . . . 0.0 110.912 -178.556 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -61.48 -38.55 87.71 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-O 121.318 0.58 . . . . 0.0 110.588 177.127 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 104' ' ' ARG . . . . . 0.427 HH21 ' HA ' ' A' ' 100' ' ' VAL . 1.4 mpp_? -74.58 -18.45 60.57 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.371 -0.831 . . . . 0.0 111.618 176.77 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -96.49 -22.8 16.89 Favored 'General case' 0 C--N 1.327 -0.399 0 N-CA-C 112.659 0.615 . . . . 0.0 112.659 -173.638 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 106.11 64.21 0.62 Allowed Glycine 0 CA--C 1.52 0.4 0 C-N-CA 120.793 -0.718 . . . . 0.0 112.252 -177.582 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -72.24 149.14 44.83 Favored 'General case' 0 C--N 1.326 -0.436 0 C-N-CA 122.906 0.483 . . . . 0.0 111.28 -174.867 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.245 0.819 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.619 -175.403 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . 0.463 ' O ' HG12 ' A' ' 30' ' ' ILE . 18.4 m-20 . . . . . 0 CA--C 1.511 -0.53 0 CA-C-O 121.42 0.628 . . . . 0.0 109.784 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -69.91 -8.36 60.88 Favored Glycine 0 CA--C 1.5 -0.874 0 N-CA-C 110.343 -1.103 . . . . 0.0 110.343 177.921 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 16.4 m -76.55 -35.04 58.47 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 114.591 -0.805 . . . . 0.0 109.197 175.857 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.622 ' HA ' ' HB1' ' A' ' 105' ' ' ALA . 1.1 mm -71.46 -36.95 62.62 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.645 0 N-CA-C 107.245 -1.391 . . . . 0.0 107.245 177.105 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' TRP . . . . . 0.572 ' CH2' ' HB1' ' A' ' 86' ' ' ALA . 34.6 m95 -71.15 -36.3 72.0 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 114.089 -1.414 . . . . 0.0 111.012 -177.259 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.784 ' HB2' HH21 ' A' ' 79' ' ' ARG . 17.5 t70 -74.79 -36.7 62.51 Favored 'General case' 0 N--CA 1.445 -0.694 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.477 179.119 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . 0.442 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -70.47 -34.19 72.12 Favored 'General case' 0 N--CA 1.448 -0.537 0 C-N-CA 120.817 -0.353 . . . . 0.0 110.695 178.687 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . 0.547 HG13 ' O ' ' A' ' 30' ' ' ILE . 65.9 mt -64.73 -44.67 96.51 Favored 'Isoleucine or valine' 0 C--O 1.235 0.327 0 CA-C-O 121.286 0.565 . . . . 0.0 109.988 173.914 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . 0.441 ' HA ' ' O ' ' A' ' 54' ' ' GLY . . . -59.59 -35.03 73.51 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.511 -0.768 . . . . 0.0 110.261 176.245 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . 0.51 ' HA2' ' N ' ' A' ' 41' ' ' GLY . . . -78.94 4.37 61.82 Favored Glycine 0 N--CA 1.452 -0.293 0 CA-C-N 115.368 -0.833 . . . . 0.0 112.341 179.643 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 27.0 t -108.15 -53.84 2.58 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 120.576 0.227 . . . . 0.0 111.114 -179.499 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . 0.444 ' HG2' ' SG ' ' A' ' 101' ' ' CYS . 36.7 mm-40 -87.86 -33.1 18.67 Favored 'General case' 0 CA--C 1.515 -0.39 0 CA-C-O 121.093 0.473 . . . . 0.0 110.552 -176.547 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -105.1 -9.71 17.62 Favored 'General case' 0 N--CA 1.447 -0.587 0 CA-C-N 116.044 -0.525 . . . . 0.0 112.124 -175.201 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 75.11 17.51 80.23 Favored Glycine 0 CA--C 1.505 -0.577 0 N-CA-C 109.635 -1.386 . . . . 0.0 109.635 -177.199 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . 0.51 ' N ' ' HA2' ' A' ' 36' ' ' GLY . . . 75.24 61.51 2.99 Favored Glycine 0 N--CA 1.432 -1.598 0 CA-C-N 114.019 -1.091 . . . . 0.0 111.455 -174.953 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' ASN . . . . . 0.508 HD22 ' HB ' ' A' ' 45' ' ' ILE . 3.7 t30 -145.84 100.16 3.37 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 108.332 -0.988 . . . . 0.0 108.332 -177.251 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' TRP . . . . . 0.81 ' HA ' ' N ' ' A' ' 54' ' ' GLY . 30.2 m95 -84.47 -3.82 58.59 Favored 'General case' 0 C--N 1.317 -0.833 0 CA-C-O 121.605 0.717 . . . . 0.0 110.664 -170.785 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -111.64 15.69 20.93 Favored 'General case' 0 C--N 1.311 -1.091 0 CA-C-N 114.806 -1.088 . . . . 0.0 110.86 178.768 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.818 HG22 ' HA2' ' A' ' 53' ' ' GLY . 10.5 tt -79.38 137.63 21.4 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.733 0 CA-C-O 121.163 0.506 . . . . 0.0 110.508 -177.85 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 46.4 t30 -171.24 103.72 0.21 Allowed 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 115.956 -0.566 . . . . 0.0 110.379 178.948 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 25.3 p -82.63 -11.51 58.33 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 115.767 -0.651 . . . . 0.0 111.09 177.586 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 104.07 21.28 9.64 Favored Glycine 0 N--CA 1.449 -0.483 0 C-N-CA 120.808 -0.711 . . . . 0.0 111.386 -175.348 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 8.6 p30 -82.15 -4.86 57.84 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 115.623 -0.288 . . . . 0.0 111.161 -178.335 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . 0.538 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 96.3 -11.95 66.88 Favored Glycine 0 N--CA 1.448 -0.525 0 C-N-CA 121.305 -0.474 . . . . 0.0 112.039 177.755 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' TYR . . . . . 0.647 ' HA ' ' HA ' ' A' ' 58' ' ' ASP . 0.6 OUTLIER -112.37 151.61 29.59 Favored 'General case' 0 CA--C 1.514 -0.412 0 N-CA-C 107.834 -1.173 . . . . 0.0 107.834 176.349 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' TYR . . . . . 0.696 ' O ' ' HA ' ' A' ' 56' ' ' GLN . 42.9 m-85 -116.61 170.39 8.62 Favored 'General case' 0 C--N 1.313 -0.984 0 C-N-CA 120.4 -0.52 . . . . 0.0 112.203 -166.242 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.818 ' HA2' HG22 ' A' ' 45' ' ' ILE . . . -60.12 172.18 5.83 Favored Glycine 0 N--CA 1.446 -0.658 0 N-CA-C 115.548 0.979 . . . . 0.0 115.548 -167.653 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . 0.81 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 87.53 -109.35 3.46 Favored Glycine 0 N--CA 1.437 -1.234 0 CA-C-N 114.486 -0.857 . . . . 0.0 111.636 177.557 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.518 HG11 ' CE3' ' A' ' 31' ' ' TRP . 0.5 OUTLIER -84.16 2.21 3.93 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.594 0 CA-C-O 121.351 0.596 . . . . 0.0 110.868 178.793 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' GLN . . . . . 0.772 ' HA ' HE21 ' A' ' 56' ' ' GLN . 0.0 OUTLIER 59.5 51.36 6.6 Favored 'General case' 0 CA--C 1.532 0.271 0 CA-C-N 114.207 -1.361 . . . . 0.0 113.316 164.952 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . 0.477 ' CE1' HG23 ' A' ' 55' ' ' VAL . 0.3 OUTLIER -119.12 168.37 10.91 Favored 'General case' 0 C--N 1.326 -0.454 0 C-N-CA 119.465 -0.894 . . . . 0.0 111.865 174.215 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.647 ' HA ' ' HA ' ' A' ' 51' ' ' TYR . 7.4 p-10 -78.53 166.11 22.95 Favored 'General case' 0 C--N 1.327 -0.383 0 N-CA-C 113.724 1.009 . . . . 0.0 113.724 -163.459 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . 0.48 ' HB2' ' HE1' ' A' ' 52' ' ' TYR . 5.6 tp-100 -61.08 -39.96 91.87 Favored 'General case' 0 N--CA 1.446 -0.667 0 CA-C-N 114.775 -1.102 . . . . 0.0 111.244 177.601 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -64.32 -49.55 65.16 Favored Glycine 0 C--N 1.317 -0.483 0 CA-C-N 115.665 -0.698 . . . . 0.0 111.572 -175.185 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 87.9 m -66.77 -41.58 87.5 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-N 115.612 -0.294 . . . . 0.0 111.167 176.591 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' TRP . . . . . 0.447 ' HZ3' ' HA ' ' A' ' 82' ' ' GLN . 57.2 t-105 -56.48 -48.4 77.19 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 121.773 0.796 . . . . 0.0 109.437 177.0 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . 0.444 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 29.3 tt0 -67.44 -34.22 76.76 Favored 'General case' 0 C--N 1.317 -0.833 0 CA-C-N 114.8 -1.091 . . . . 0.0 111.131 -179.655 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -65.14 -41.36 94.87 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.899 -0.592 . . . . 0.0 111.129 -177.166 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . 0.566 ' HB2' HG13 ' A' ' 85' ' ' VAL . 31.4 m-80 -82.94 -9.2 59.41 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.715 0.293 . . . . 0.0 110.502 177.232 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . 0.515 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 91.46 49.79 2.91 Favored Glycine 0 C--N 1.334 0.433 0 C-N-CA 121.181 -0.533 . . . . 0.0 113.168 173.218 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . 0.483 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -80.61 -28.2 48.29 Favored Glycine 0 N--CA 1.439 -1.127 0 C-N-CA 121.041 -0.6 . . . . 0.0 113.107 -177.391 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.898 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 7.2 mp -57.4 -23.58 50.2 Favored 'General case' 0 N--CA 1.452 -0.355 0 N-CA-C 112.2 0.445 . . . . 0.0 112.2 -173.032 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . 0.515 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 1.5 ptm180 -67.56 -31.67 71.91 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-O 121.043 0.449 . . . . 0.0 109.971 178.529 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 70' ' ' TYR . . . . . 1.021 ' HB3' ' HG2' ' A' ' 81' ' ' GLU . 63.5 m-85 -83.99 -36.63 23.04 Favored 'General case' 0 N--CA 1.44 -0.946 0 N-CA-C 107.327 -1.36 . . . . 0.0 107.327 177.218 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.636 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 169.1 126.96 0.04 OUTLIER Pre-proline 0 N--CA 1.443 -0.784 0 CA-C-N 112.899 -1.955 . . . . 0.0 107.406 -175.89 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 72' ' ' PRO . . . . . 0.898 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 21.5 Cg_exo -56.85 -5.9 1.48 Allowed 'Trans proline' 0 C--N 1.33 -0.417 0 C-N-CA 122.982 2.454 . . . . 0.0 113.705 -177.542 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 73' ' ' ARG . . . . . 0.63 ' HB2' ' CD2' ' A' ' 52' ' ' TYR . 28.3 ptt-85 -149.74 140.32 22.53 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-O 121.188 0.518 . . . . 0.0 110.356 176.756 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . 0.491 ' HB3' ' HB2' ' A' ' 52' ' ' TYR . . . -57.65 -22.83 48.04 Favored 'General case' 0 C--O 1.217 -0.645 0 CA-C-N 114.851 -1.068 . . . . 0.0 113.189 -178.98 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . 0.57 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 0.0 OUTLIER -76.76 -23.15 52.95 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 121.227 0.537 . . . . 0.0 110.921 -179.159 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.504 ' HB3' ' HB1' ' A' ' 71' ' ' ALA . 54.9 tp -87.68 -33.19 18.86 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 115.567 -0.742 . . . . 0.0 109.191 176.034 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . 0.742 ' HB1' ' CB ' ' A' ' 81' ' ' GLU . . . -79.15 158.47 27.71 Favored 'General case' 0 N--CA 1.445 -0.723 0 CA-C-N 115.344 -0.844 . . . . 0.0 110.97 176.1 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 47.5 p -101.5 -172.48 2.17 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.231 -178.444 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . 0.784 HH21 ' HB2' ' A' ' 32' ' ' ASP . 66.8 mtp180 -49.52 -52.55 28.85 Favored 'General case' 0 N--CA 1.466 0.325 0 CA-C-N 116.433 -0.349 . . . . 0.0 111.521 -177.955 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 10.2 pt-20 -62.69 -33.07 74.33 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 116.023 -0.535 . . . . 0.0 111.365 -174.977 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 81' ' ' GLU . . . . . 1.021 ' HG2' ' HB3' ' A' ' 70' ' ' TYR . 5.9 mt-10 -71.9 -47.53 52.03 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.532 -0.304 . . . . 0.0 111.235 178.43 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 82' ' ' GLN . . . . . 0.57 ' NE2' ' HE3' ' A' ' 43' ' ' TRP . 0.1 OUTLIER -59.5 -39.61 84.38 Favored 'General case' 0 CA--C 1.505 -0.752 0 N-CA-C 109.509 -0.552 . . . . 0.0 109.509 174.551 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.68 ' O ' ' HG2' ' A' ' 87' ' ' GLU . 27.2 mt -60.1 -49.75 82.87 Favored 'Isoleucine or valine' 0 C--O 1.209 -1.03 0 CA-C-N 114.848 -1.069 . . . . 0.0 110.591 177.471 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 84' ' ' ALA . . . . . 0.622 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -60.8 -46.02 92.14 Favored 'General case' 0 C--O 1.242 0.664 0 CA-C-O 121.409 0.623 . . . . 0.0 111.973 -177.176 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.566 HG13 ' HB2' ' A' ' 65' ' ' ASN . 58.6 t -66.51 -48.27 81.07 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.737 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.448 -179.525 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 86' ' ' ALA . . . . . 0.572 ' HB1' ' CH2' ' A' ' 31' ' ' TRP . . . -59.95 -28.49 67.69 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.584 -0.735 . . . . 0.0 110.793 174.065 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 87' ' ' GLU . . . . . 0.68 ' HG2' ' O ' ' A' ' 83' ' ' ILE . 10.9 mm-40 -59.26 -45.0 92.38 Favored 'General case' 0 N--CA 1.468 0.434 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.166 -179.17 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.653 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 62.1 t -65.95 -42.49 91.93 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.295 0 C-N-CA 120.115 -0.634 . . . . 0.0 109.594 175.933 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . 0.895 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 1.1 m -64.0 -45.28 89.69 Favored 'General case' 0 C--N 1.319 -0.758 0 CA-C-N 115.613 -0.721 . . . . 0.0 111.498 -176.136 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 90' ' ' ARG . . . . . 0.547 ' HA ' ' HZ3' ' A' ' 98' ' ' TRP . 5.0 ptt180 -69.29 -33.17 72.79 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.679 -175.559 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 91' ' ' LEU . . . . . 0.653 ' HG ' ' O ' ' A' ' 88' ' ' VAL . 4.6 pp -68.59 -24.46 64.6 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 121.368 0.604 . . . . 0.0 110.309 -173.4 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . 0.464 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 4.2 mtm180 -84.36 -43.87 14.32 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-O 122.14 0.972 . . . . 0.0 109.163 176.451 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 93' ' ' GLN . . . . . 0.745 ' NE2' HG22 ' A' ' 89' ' ' THR . 21.9 mt-30 -87.84 -28.23 21.75 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 113.746 -1.57 . . . . 0.0 114.329 -167.43 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 74.89 32.63 56.65 Favored Glycine 0 CA--C 1.51 -0.245 0 N-CA-C 111.858 -0.497 . . . . 0.0 111.858 179.894 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 95' ' ' TRP . . . . . 0.42 ' CH2' ' HB ' ' A' ' 30' ' ' ILE . 28.6 m95 67.05 5.02 3.86 Favored 'General case' 0 C--O 1.216 -0.678 0 C-N-CA 123.451 0.701 . . . . 0.0 110.082 -177.151 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -59.39 -43.8 97.12 Favored Glycine 0 CA--C 1.518 0.233 0 CA-C-N 116.125 -0.489 . . . . 0.0 113.327 -178.557 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -69.67 -21.15 63.54 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.826 0.346 . . . . 0.0 110.971 -179.371 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 98' ' ' TRP . . . . . 0.895 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 21.6 m-90 -90.31 108.93 29.97 Favored Pre-proline 0 N--CA 1.445 -0.681 0 N-CA-C 108.127 -1.064 . . . . 0.0 108.127 174.303 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 99' ' ' PRO . . . . . 0.436 ' HD3' ' HA ' ' A' ' 98' ' ' TRP . 46.9 Cg_exo -62.97 -138.89 0.0 OUTLIER 'Trans proline' 0 CA--C 1.533 0.44 0 C-N-CA 123.616 2.877 . . . . 0.0 114.45 -171.828 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 4.2 p -55.38 -25.92 18.1 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.195 0 CA-C-O 121.427 0.632 . . . . 0.0 110.759 -176.939 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 101' ' ' CYS . . . . . 0.444 ' SG ' ' HG2' ' A' ' 38' ' ' GLU . 39.9 m -55.98 -39.16 71.43 Favored 'General case' 0 C--N 1.317 -0.844 0 CA-C-N 114.896 -1.047 . . . . 0.0 111.427 177.703 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -70.86 -41.42 71.44 Favored 'General case' 0 CA--C 1.519 -0.219 0 CA-C-O 120.877 0.37 . . . . 0.0 110.722 179.609 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -64.34 -43.02 95.91 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 121.074 0.464 . . . . 0.0 110.274 178.171 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 60.1 mtp180 -62.92 -30.82 71.84 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 115.51 -0.768 . . . . 0.0 110.897 176.696 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 105' ' ' ALA . . . . . 0.622 ' HB1' ' HA ' ' A' ' 30' ' ' ILE . . . -85.23 -21.27 29.16 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.72 -0.673 . . . . 0.0 111.456 -177.966 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . 0.466 ' O ' ' HG2' ' A' ' 108' ' ' ARG . . . 102.55 67.71 0.78 Allowed Glycine 0 CA--C 1.52 0.393 0 CA-C-N 115.892 -0.595 . . . . 0.0 112.288 -178.636 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -57.54 147.63 26.32 Favored 'General case' 0 C--O 1.236 0.362 0 C-N-CA 122.895 0.478 . . . . 0.0 111.6 -177.609 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 108' ' ' ARG . . . . . 0.466 ' HG2' ' O ' ' A' ' 106' ' ' GLY . 3.6 ptp180 . . . . . 0 C--O 1.251 1.149 0 CA-C-O 118.496 -0.764 . . . . 0.0 110.582 -171.575 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . 0.555 ' O ' HG12 ' A' ' 30' ' ' ILE . 26.3 m-20 . . . . . 0 CA--C 1.5 -0.946 0 CA-C-O 121.744 0.783 . . . . 0.0 109.688 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . 0.585 ' HA3' HD13 ' A' ' 83' ' ' ILE . . . -72.36 -1.03 49.72 Favored Glycine 0 N--CA 1.434 -1.462 0 CA-C-N 114.596 -1.184 . . . . 0.0 111.091 178.403 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 14.9 m -73.8 -40.96 63.02 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-O 121.744 0.783 . . . . 0.0 109.293 175.089 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.555 HG12 ' O ' ' A' ' 27' ' ' ASP . 0.0 OUTLIER -70.99 -36.33 63.13 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.633 0 CA-C-N 114.548 -1.205 . . . . 0.0 107.78 177.218 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' TRP . . . . . 0.656 ' CD1' HG23 ' A' ' 83' ' ' ILE . 49.1 m95 -72.34 -35.96 68.7 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 114.781 -1.1 . . . . 0.0 111.075 -178.32 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.457 ' HB3' ' O ' ' A' ' 28' ' ' GLY . 0.0 OUTLIER -71.0 -35.88 72.24 Favored 'General case' 0 N--CA 1.45 -0.449 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.115 177.395 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . 0.416 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -70.38 -37.19 74.49 Favored 'General case' 0 N--CA 1.446 -0.65 0 C-N-CA 120.869 -0.332 . . . . 0.0 110.944 177.816 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . 0.515 HG13 ' O ' ' A' ' 30' ' ' ILE . 72.6 mt -67.04 -46.97 83.44 Favored 'Isoleucine or valine' 0 C--O 1.234 0.238 0 CA-C-O 121.036 0.446 . . . . 0.0 110.215 174.949 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -57.96 -38.31 75.77 Favored 'General case' 0 N--CA 1.451 -0.386 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.445 176.833 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -72.71 -13.31 78.29 Favored Glycine 0 N--CA 1.451 -0.352 0 CA-C-N 115.683 -0.689 . . . . 0.0 111.838 179.824 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 53.1 t -95.9 -59.09 1.93 Allowed 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.639 -0.28 . . . . 0.0 111.413 -177.092 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . 0.869 ' HG3' ' SG ' ' A' ' 101' ' ' CYS . 26.5 mt-10 -88.93 -22.95 22.84 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 120.651 0.263 . . . . 0.0 111.619 -173.536 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -106.26 -12.13 15.81 Favored 'General case' 0 N--CA 1.447 -0.58 0 C-N-CA 120.184 -0.607 . . . . 0.0 111.717 -179.208 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 77.99 15.98 80.45 Favored Glycine 0 CA--C 1.507 -0.459 0 N-CA-C 109.935 -1.266 . . . . 0.0 109.935 -176.861 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 73.07 57.03 5.43 Favored Glycine 0 N--CA 1.435 -1.416 0 CA-C-N 114.072 -1.064 . . . . 0.0 111.516 -175.334 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 2.6 t-20 -140.19 98.55 3.47 Favored 'General case' 0 N--CA 1.447 -0.609 0 N-CA-C 109.194 -0.669 . . . . 0.0 109.194 -177.713 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' TRP . . . . . 0.773 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 32.3 m95 -84.07 2.37 39.6 Favored 'General case' 0 C--N 1.319 -0.758 0 CA-C-N 115.485 -0.78 . . . . 0.0 109.973 -174.799 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -111.15 1.76 17.46 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-N 114.903 -1.044 . . . . 0.0 111.488 177.41 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.899 HG22 ' HA2' ' A' ' 53' ' ' GLY . 6.4 tt -66.91 143.91 15.13 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.677 0 CA-C-O 121.268 0.556 . . . . 0.0 110.358 -177.34 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . 0.447 ' ND2' ' HD1' ' A' ' 52' ' ' TYR . 9.4 t-20 -152.08 98.67 2.46 Favored 'General case' 0 C--N 1.309 -1.179 0 CA-C-O 121.234 0.54 . . . . 0.0 109.67 -178.49 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 21.1 p -75.38 -21.33 58.36 Favored 'General case' 0 C--N 1.317 -0.817 0 CA-C-N 115.362 -0.835 . . . . 0.0 110.292 179.259 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 91.04 18.53 46.46 Favored Glycine 0 N--CA 1.443 -0.848 0 CA-C-N 115.339 -0.846 . . . . 0.0 111.038 178.272 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 28.5 p-10 -95.44 4.47 53.26 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.891 0.377 . . . . 0.0 111.647 -174.407 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . 0.438 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 95.47 -8.22 68.96 Favored Glycine 0 N--CA 1.45 -0.424 0 C-N-CA 120.49 -0.862 . . . . 0.0 111.832 -178.055 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' TYR . . . . . 0.579 ' CE1' ' HB3' ' A' ' 58' ' ' ASP . 0.2 OUTLIER -112.89 144.65 42.08 Favored 'General case' 0 CA--C 1.511 -0.544 0 N-CA-C 106.826 -1.546 . . . . 0.0 106.826 176.131 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' TYR . . . . . 0.736 ' HB2' ' HB3' ' A' ' 74' ' ' ALA . 53.6 m-85 -117.38 169.05 9.8 Favored 'General case' 0 C--N 1.306 -1.307 0 N-CA-C 113.488 0.922 . . . . 0.0 113.488 -165.388 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.899 ' HA2' HG22 ' A' ' 45' ' ' ILE . . . -62.89 159.05 36.36 Favored Glycine 0 CA--C 1.501 -0.797 0 CA-C-N 114.845 -1.071 . . . . 0.0 114.018 -171.991 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . 0.583 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 101.72 -103.73 2.56 Favored Glycine 0 N--CA 1.437 -1.249 0 N-CA-C 111.402 -0.679 . . . . 0.0 111.402 -177.212 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.571 HG23 ' HG2' ' A' ' 82' ' ' GLN . 2.8 t -92.05 0.78 9.23 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 CA-C-O 121.652 0.739 . . . . 0.0 109.898 -178.61 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' GLN . . . . . 0.635 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 8.3 mm-40 59.51 50.37 7.55 Favored 'General case' 0 N--CA 1.464 0.269 0 CA-C-N 114.644 -1.162 . . . . 0.0 113.901 167.92 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 17.8 p90 -120.91 171.45 8.62 Favored 'General case' 0 C--N 1.325 -0.478 0 C-N-CA 119.833 -0.747 . . . . 0.0 112.092 175.112 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.579 ' HB3' ' CE1' ' A' ' 51' ' ' TYR . 6.4 p-10 -82.37 158.6 23.29 Favored 'General case' 0 CA--C 1.516 -0.356 0 N-CA-C 113.686 0.995 . . . . 0.0 113.686 -163.417 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . 0.429 ' HB2' ' CE2' ' A' ' 52' ' ' TYR . 20.6 tp60 -57.84 -39.79 78.53 Favored 'General case' 0 N--CA 1.442 -0.828 0 CA-C-N 113.279 -1.782 . . . . 0.0 111.714 179.229 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -67.47 -49.46 50.9 Favored Glycine 0 N--CA 1.45 -0.404 0 CA-C-N 115.603 -0.726 . . . . 0.0 112.034 -175.303 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 83.2 m -62.87 -41.05 99.25 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 121.252 0.548 . . . . 0.0 110.389 176.57 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' TRP . . . . . 0.424 ' CH2' ' HA ' ' A' ' 74' ' ' ALA . 54.1 t-105 -56.99 -50.1 73.74 Favored 'General case' 0 N--CA 1.444 -0.737 0 CA-C-N 115.265 -0.88 . . . . 0.0 109.687 176.734 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . 0.46 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 36.7 tt0 -67.1 -39.28 86.7 Favored 'General case' 0 N--CA 1.445 -0.683 0 CA-C-N 114.918 -1.037 . . . . 0.0 110.91 -178.183 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -62.11 -40.95 97.62 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.539 -0.755 . . . . 0.0 111.109 -176.682 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 9.3 m120 -82.3 -9.61 59.41 Favored 'General case' 0 N--CA 1.45 -0.461 0 CA-C-O 120.908 0.385 . . . . 0.0 110.768 178.521 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 93.23 47.57 3.03 Favored Glycine 0 C--N 1.333 0.373 0 CA-C-N 116.089 -0.505 . . . . 0.0 112.659 173.784 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . 0.592 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -80.2 -22.92 62.1 Favored Glycine 0 N--CA 1.44 -1.045 0 C-N-CA 120.966 -0.635 . . . . 0.0 112.868 -174.621 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.848 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 6.8 mp -61.51 -23.48 65.95 Favored 'General case' 0 N--CA 1.447 -0.595 0 N-CA-C 112.483 0.549 . . . . 0.0 112.483 -172.569 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . 0.428 ' HG3' ' N ' ' A' ' 70' ' ' TYR . 3.8 ptm180 -69.02 -30.96 69.44 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 121.19 0.519 . . . . 0.0 110.145 176.041 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 70' ' ' TYR . . . . . 0.792 ' HB3' ' HG3' ' A' ' 81' ' ' GLU . 79.5 m-85 -79.71 -34.8 39.78 Favored 'General case' 0 N--CA 1.446 -0.674 0 N-CA-C 107.679 -1.23 . . . . 0.0 107.679 177.144 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.696 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 161.57 128.73 0.01 OUTLIER Pre-proline 0 CA--C 1.509 -0.602 0 CA-C-N 112.609 -2.087 . . . . 0.0 106.689 -178.452 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 72' ' ' PRO . . . . . 0.848 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 32.3 Cg_exo -54.9 -6.68 0.7 Allowed 'Trans proline' 0 C--N 1.33 -0.416 0 C-N-CA 123.171 2.581 . . . . 0.0 114.246 -177.08 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 73' ' ' ARG . . . . . 0.402 ' HE ' ' CG ' ' A' ' 75' ' ' ASP . 12.4 ptm180 -149.59 142.77 25.06 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-O 121.095 0.474 . . . . 0.0 109.794 176.515 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . 0.736 ' HB3' ' HB2' ' A' ' 52' ' ' TYR . . . -61.06 -23.48 65.49 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.267 -0.879 . . . . 0.0 113.017 -175.159 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . 0.503 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 9.4 p-10 -88.21 -0.57 57.26 Favored 'General case' 0 C--N 1.33 -0.262 0 C-N-CA 120.544 -0.462 . . . . 0.0 110.905 -179.54 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.405 HD23 ' HD2' ' A' ' 72' ' ' PRO . 62.0 tp -103.75 -31.11 10.0 Favored 'General case' 0 C--N 1.323 -0.584 0 N-CA-C 109.026 -0.731 . . . . 0.0 109.026 172.641 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . 0.709 ' HB1' ' HB3' ' A' ' 81' ' ' GLU . . . -79.81 162.05 25.32 Favored 'General case' 0 N--CA 1.446 -0.631 0 CA-C-N 115.142 -0.935 . . . . 0.0 109.426 174.262 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 61.7 p -100.66 -175.0 2.78 Favored 'General case' 0 C--N 1.312 -1.046 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.874 -176.688 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . 0.773 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 11.9 mtp180 -50.92 -55.24 18.11 Favored 'General case' 0 C--O 1.222 -0.383 0 O-C-N 123.406 0.441 . . . . 0.0 110.594 179.518 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 11.3 pt-20 -61.76 -41.88 98.27 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 115.893 -0.594 . . . . 0.0 111.501 -174.326 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 81' ' ' GLU . . . . . 0.792 ' HG3' ' HB3' ' A' ' 70' ' ' TYR . 0.2 OUTLIER -64.2 -52.05 60.73 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 115.405 -0.816 . . . . 0.0 112.138 177.457 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 82' ' ' GLN . . . . . 0.571 ' HG2' HG23 ' A' ' 55' ' ' VAL . 5.7 tt0 -68.1 -31.34 70.89 Favored 'General case' 0 C--N 1.317 -0.805 0 CA-C-N 115.364 -0.835 . . . . 0.0 110.409 -176.759 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.656 HG23 ' CD1' ' A' ' 31' ' ' TRP . 25.0 mt -59.83 -44.54 94.33 Favored 'Isoleucine or valine' 0 C--O 1.216 -0.691 0 CA-C-N 115.471 -0.786 . . . . 0.0 109.563 173.524 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 84' ' ' ALA . . . . . 0.592 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -63.22 -40.64 98.04 Favored 'General case' 0 C--O 1.236 0.371 0 CA-C-O 121.352 0.596 . . . . 0.0 111.16 -175.632 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 44.2 t -69.02 -48.04 72.09 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 CA-C-N 115.685 -0.688 . . . . 0.0 110.919 177.758 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -57.05 -30.43 64.25 Favored 'General case' 0 N--CA 1.449 -0.48 0 CA-C-O 120.895 0.378 . . . . 0.0 110.401 172.796 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 87' ' ' GLU . . . . . 0.824 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 8.1 mm-40 -60.48 -44.58 95.78 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.196 -179.178 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 83.4 t -62.23 -44.91 99.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 C-N-CA 120.407 -0.517 . . . . 0.0 109.857 178.864 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . 0.694 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 1.2 m -61.92 -47.78 83.4 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 115.504 -0.771 . . . . 0.0 111.478 -178.896 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 90' ' ' ARG . . . . . 0.738 ' HA ' ' OE1' ' A' ' 93' ' ' GLN . 2.5 ptt180 -62.02 -32.66 73.17 Favored 'General case' 0 CA--C 1.52 -0.176 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.361 -174.992 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 91' ' ' LEU . . . . . 0.824 ' HG ' ' O ' ' A' ' 87' ' ' GLU . 45.6 mt -61.06 -33.9 74.04 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-O 121.358 0.599 . . . . 0.0 110.529 -176.965 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 1.3 mtm180 -86.75 -45.36 11.01 Favored 'General case' 0 N--CA 1.443 -0.788 0 CA-C-N 115.221 -0.9 . . . . 0.0 110.589 -169.707 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 93' ' ' GLN . . . . . 0.738 ' OE1' ' HA ' ' A' ' 90' ' ' ARG . 0.0 OUTLIER -99.55 -21.32 15.95 Favored 'General case' 0 C--N 1.323 -0.572 0 N-CA-C 113.13 0.789 . . . . 0.0 113.13 -172.376 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 82.93 38.86 10.82 Favored Glycine 0 C--N 1.333 0.39 0 C-N-CA 120.926 -0.654 . . . . 0.0 112.523 171.441 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 95' ' ' TRP . . . . . 0.605 ' CZ2' ' HD3' ' A' ' 90' ' ' ARG . 20.7 m95 66.6 11.06 7.89 Favored 'General case' 0 C--O 1.221 -0.4 0 C-N-CA 123.445 0.698 . . . . 0.0 110.247 -179.212 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -68.7 -35.22 79.89 Favored Glycine 0 N--CA 1.453 -0.226 0 C-N-CA 121.236 -0.507 . . . . 0.0 112.352 176.817 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . 0.437 ' H ' ' CG ' ' A' ' 93' ' ' GLN . . . -66.85 -29.63 69.59 Favored 'General case' 0 CA--C 1.517 -0.294 0 CA-C-O 121.051 0.453 . . . . 0.0 110.577 178.857 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 98' ' ' TRP . . . . . 0.694 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 24.3 m-90 -92.72 108.41 31.57 Favored Pre-proline 0 N--CA 1.445 -0.722 0 N-CA-C 108.438 -0.949 . . . . 0.0 108.438 177.52 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 99' ' ' PRO . . . . . 0.429 ' HD3' ' O ' ' A' ' 97' ' ' ALA . 45.7 Cg_exo -63.08 -131.3 0.0 OUTLIER 'Trans proline' 0 CA--C 1.541 0.854 0 C-N-CA 123.492 2.794 . . . . 0.0 114.5 -175.06 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 39.2 t -55.65 -29.41 24.97 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.146 0 O-C-N 122.081 -0.387 . . . . 0.0 111.612 -174.662 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 101' ' ' CYS . . . . . 0.869 ' SG ' ' HG3' ' A' ' 38' ' ' GLU . 71.1 m -68.4 -31.97 71.69 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 116.56 -0.291 . . . . 0.0 111.604 -174.87 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 102' ' ' ALA . . . . . 0.556 ' HB2' ' CB ' ' A' ' 98' ' ' TRP . . . -70.36 -43.66 69.72 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.033 0.444 . . . . 0.0 110.335 176.185 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -62.08 -40.21 95.06 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.267 178.583 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 104' ' ' ARG . . . . . 0.625 ' HA ' ' NE ' ' A' ' 104' ' ' ARG . 1.9 mmp_? -69.16 -25.72 64.51 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.408 -0.814 . . . . 0.0 111.45 177.68 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 105' ' ' ALA . . . . . 0.416 ' CB ' ' HB3' ' A' ' 33' ' ' ALA . . . -83.38 -21.6 33.0 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.911 -177.477 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 105.38 47.75 1.11 Allowed Glycine 0 CA--C 1.521 0.456 0 C-N-CA 120.88 -0.676 . . . . 0.0 111.98 -176.599 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -57.74 149.45 22.06 Favored 'General case' 0 C--N 1.327 -0.395 0 C-N-CA 123.636 0.774 . . . . 0.0 112.23 -178.858 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 108' ' ' ARG . . . . . 0.447 ' O ' ' HD3' ' A' ' 108' ' ' ARG . 0.0 OUTLIER . . . . . 0 C--O 1.246 0.899 0 CA-C-N 115.771 -0.649 . . . . 0.0 110.373 -177.095 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . 0.487 ' O ' HG12 ' A' ' 30' ' ' ILE . 27.5 m-20 . . . . . 0 CA--C 1.507 -0.708 0 CA-C-O 121.41 0.624 . . . . 0.0 110.092 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -63.4 -12.19 44.34 Favored Glycine 0 CA--C 1.504 -0.614 0 CA-C-N 114.977 -1.01 . . . . 0.0 111.206 -177.726 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 19.3 m -76.24 -43.35 42.4 Favored 'General case' 0 C--N 1.317 -0.809 0 CA-C-O 121.914 0.864 . . . . 0.0 109.477 177.95 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.504 ' HA ' ' HB1' ' A' ' 105' ' ' ALA . 0.1 OUTLIER -68.9 -38.85 79.15 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.802 0 CA-C-N 114.178 -1.373 . . . . 0.0 107.871 179.775 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' TRP . . . . . 0.49 ' CD1' HG23 ' A' ' 83' ' ' ILE . 17.1 m95 -67.48 -36.96 82.14 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 114.735 -1.121 . . . . 0.0 110.511 -177.627 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 9.7 t70 -75.2 -38.86 60.57 Favored 'General case' 0 N--CA 1.444 -0.759 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.692 179.017 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . 0.451 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -70.82 -35.79 72.64 Favored 'General case' 0 N--CA 1.448 -0.548 0 C-N-CA 120.78 -0.368 . . . . 0.0 110.903 178.737 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . 0.486 HG13 ' O ' ' A' ' 30' ' ' ILE . 64.8 mt -62.33 -45.6 98.38 Favored 'Isoleucine or valine' 0 C--O 1.234 0.247 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 173.646 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . 0.56 ' HA ' ' O ' ' A' ' 54' ' ' GLY . . . -57.62 -38.52 75.1 Favored 'General case' 0 N--CA 1.451 -0.404 0 CA-C-N 115.506 -0.77 . . . . 0.0 110.056 176.734 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . 0.445 ' HA2' ' N ' ' A' ' 41' ' ' GLY . . . -73.6 -22.06 78.81 Favored Glycine 0 N--CA 1.451 -0.338 0 CA-C-N 115.467 -0.788 . . . . 0.0 111.944 -179.814 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 6.3 t -84.53 -56.65 3.5 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-O 120.831 0.348 . . . . 0.0 111.608 -178.704 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . 0.406 ' HB2' ' SG ' ' A' ' 101' ' ' CYS . 11.4 tp10 -87.61 -30.53 20.41 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 121.063 0.459 . . . . 0.0 110.511 -170.453 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -107.59 -8.01 16.31 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.956 -0.566 . . . . 0.0 111.871 -176.565 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 80.23 4.06 89.79 Favored Glycine 0 CA--C 1.507 -0.408 0 N-CA-C 110.239 -1.144 . . . . 0.0 110.239 -177.535 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . 0.445 ' N ' ' HA2' ' A' ' 36' ' ' GLY . . . 89.95 56.41 1.85 Allowed Glycine 0 N--CA 1.432 -1.568 0 CA-C-N 114.006 -1.097 . . . . 0.0 111.302 -175.986 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 2.4 t-20 -141.71 99.48 3.56 Favored 'General case' 0 N--CA 1.447 -0.596 0 N-CA-C 108.732 -0.84 . . . . 0.0 108.732 -175.655 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' TRP . . . . . 0.76 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 23.4 m95 -83.81 -4.33 58.57 Favored 'General case' 0 C--N 1.313 -1.005 0 CA-C-N 115.723 -0.672 . . . . 0.0 110.158 -173.39 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . 0.454 ' HA ' ' HB2' ' A' ' 75' ' ' ASP . . . -109.3 10.74 25.57 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 115.183 -0.917 . . . . 0.0 111.06 179.351 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.726 HG22 ' HA2' ' A' ' 53' ' ' GLY . 9.0 tt -76.09 144.57 11.71 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.792 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.31 179.892 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 10.3 t-20 -142.46 97.96 3.21 Favored 'General case' 0 C--N 1.31 -1.111 0 N-CA-C 108.995 -0.743 . . . . 0.0 108.995 177.393 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 10.0 p -70.08 -22.28 63.06 Favored 'General case' 0 N--CA 1.445 -0.715 0 CA-C-N 114.819 -1.082 . . . . 0.0 111.345 -173.753 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 90.39 17.2 53.66 Favored Glycine 0 N--CA 1.44 -1.066 0 N-CA-C 110.094 -1.202 . . . . 0.0 110.094 -176.773 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 5.1 m-20 -91.34 -5.91 53.85 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.169 -0.516 . . . . 0.0 111.01 -175.183 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . 0.407 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 94.25 -5.1 71.16 Favored Glycine 0 N--CA 1.444 -0.77 0 N-CA-C 110.081 -1.208 . . . . 0.0 110.081 -172.676 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' TYR . . . . . 0.623 ' HA ' ' HA ' ' A' ' 58' ' ' ASP . 0.4 OUTLIER -111.61 149.15 31.91 Favored 'General case' 0 N--CA 1.446 -0.664 0 N-CA-C 106.976 -1.491 . . . . 0.0 106.976 177.916 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' TYR . . . . . 0.699 ' O ' ' HA ' ' A' ' 56' ' ' GLN . 71.0 m-85 -114.59 170.37 8.36 Favored 'General case' 0 C--N 1.307 -1.245 0 C-N-CA 120.432 -0.507 . . . . 0.0 111.908 -168.655 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.726 ' HA2' HG22 ' A' ' 45' ' ' ILE . . . -57.94 171.91 3.45 Favored Glycine 0 C--O 1.227 -0.321 0 N-CA-C 115.072 0.789 . . . . 0.0 115.072 -168.919 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . 0.675 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 80.4 -101.76 2.02 Favored Glycine 0 N--CA 1.442 -0.924 0 C-N-CA 120.955 -0.641 . . . . 0.0 112.148 177.367 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.512 HG12 ' HE1' ' A' ' 98' ' ' TRP . 2.4 t -83.3 -3.04 7.13 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-O 121.646 0.736 . . . . 0.0 110.296 -176.68 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' GLN . . . . . 0.699 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 7.7 tp-100 54.83 50.47 15.6 Favored 'General case' 0 CA--C 1.53 0.186 0 CA-C-N 114.034 -1.439 . . . . 0.0 112.852 169.203 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . 0.496 ' CE1' ' HB ' ' A' ' 55' ' ' VAL . 2.0 p90 -121.54 163.32 19.05 Favored 'General case' 0 C--N 1.325 -0.474 0 C-N-CA 120.213 -0.595 . . . . 0.0 111.532 176.995 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.623 ' HA ' ' HA ' ' A' ' 51' ' ' TYR . 7.8 p-10 -72.29 162.3 29.65 Favored 'General case' 0 CA--C 1.514 -0.419 0 N-CA-C 113.76 1.022 . . . . 0.0 113.76 -163.511 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . 0.44 ' HB2' ' HE1' ' A' ' 52' ' ' TYR . 17.7 tp60 -55.15 -42.2 72.76 Favored 'General case' 0 N--CA 1.441 -0.878 0 CA-C-N 114.327 -1.306 . . . . 0.0 110.969 177.206 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -67.84 -50.44 41.63 Favored Glycine 0 C--O 1.224 -0.481 0 CA-C-N 115.183 -0.917 . . . . 0.0 112.584 -172.819 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 97.1 m -61.67 -41.46 97.57 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 121.177 0.513 . . . . 0.0 110.8 177.139 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' TRP . . . . . 0.439 ' CH2' ' HA ' ' A' ' 74' ' ' ALA . 52.4 t-105 -58.23 -49.11 78.23 Favored 'General case' 0 N--CA 1.446 -0.671 0 CA-C-N 115.467 -0.788 . . . . 0.0 109.691 175.786 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . 0.479 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 36.2 tt0 -67.13 -36.75 82.55 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.193 -0.912 . . . . 0.0 110.801 -178.205 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -63.53 -41.49 98.47 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.591 -0.731 . . . . 0.0 111.195 -176.882 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . 0.646 HD22 ' N ' ' A' ' 65' ' ' ASN . 0.7 OUTLIER -81.09 -8.74 59.83 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 121.1 0.476 . . . . 0.0 110.22 177.632 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . 0.47 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 89.35 48.6 3.71 Favored Glycine 0 C--N 1.334 0.433 0 CA-C-N 115.746 -0.661 . . . . 0.0 112.271 174.678 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . 0.484 ' HA2' ' HD1' ' A' ' 70' ' ' TYR . . . -79.36 -22.91 64.02 Favored Glycine 0 N--CA 1.439 -1.121 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.838 -175.051 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.79 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 6.9 mp -58.89 -25.95 63.84 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 112.893 0.701 . . . . 0.0 112.893 -172.945 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . 0.47 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 14.9 ptp180 -70.5 -29.24 65.7 Favored 'General case' 0 C--N 1.318 -0.772 0 CA-C-O 121.079 0.466 . . . . 0.0 110.553 176.643 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 70' ' ' TYR . . . . . 0.622 ' HB3' ' CG ' ' A' ' 81' ' ' GLU . 74.2 m-85 -79.32 -34.25 42.46 Favored 'General case' 0 N--CA 1.444 -0.749 0 N-CA-C 107.05 -1.463 . . . . 0.0 107.05 175.764 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.679 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 161.81 130.27 0.01 OUTLIER Pre-proline 0 CA--C 1.511 -0.524 0 CA-C-N 112.037 -2.347 . . . . 0.0 106.817 -179.117 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 72' ' ' PRO . . . . . 0.79 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 13.5 Cg_exo -58.33 -2.13 0.85 Allowed 'Trans proline' 0 C--N 1.33 -0.415 0 C-N-CA 122.837 2.358 . . . . 0.0 113.965 -177.083 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 73' ' ' ARG . . . . . 0.455 ' HB2' ' CD2' ' A' ' 52' ' ' TYR . 0.0 OUTLIER -153.3 142.56 21.52 Favored 'General case' 0 C--N 1.316 -0.85 0 N-CA-C 109.211 -0.663 . . . . 0.0 109.211 177.695 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . 0.509 ' HB3' ' HB2' ' A' ' 52' ' ' TYR . . . -60.2 -27.94 67.57 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.32 -0.855 . . . . 0.0 112.721 -175.464 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . 0.575 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 6.7 p-10 -86.87 3.2 46.44 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 121.246 0.546 . . . . 0.0 110.824 -176.6 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.525 ' HB3' ' HB1' ' A' ' 71' ' ' ALA . 50.7 tp -103.68 -34.12 8.72 Favored 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 171.155 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . 0.679 ' HB2' ' HB3' ' A' ' 71' ' ' ALA . . . -79.86 161.51 25.56 Favored 'General case' 0 N--CA 1.448 -0.568 0 CA-C-N 115.1 -0.955 . . . . 0.0 109.93 175.621 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 36.1 p -101.2 -173.19 2.31 Favored 'General case' 0 C--N 1.318 -0.796 0 C-N-CA 120.788 -0.365 . . . . 0.0 110.74 179.874 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . 0.76 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 9.0 mtp85 -52.59 -51.98 57.34 Favored 'General case' 0 CA--C 1.513 -0.46 0 O-C-N 123.592 0.558 . . . . 0.0 110.953 -174.789 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 1.3 pm0 -59.71 -41.67 91.34 Favored 'General case' 0 C--N 1.317 -0.836 0 CA-C-N 115.319 -0.855 . . . . 0.0 112.131 -176.504 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 81' ' ' GLU . . . . . 0.648 ' CB ' ' HB1' ' A' ' 77' ' ' ALA . 2.3 mp0 -62.26 -51.23 68.57 Favored 'General case' 0 C--O 1.234 0.254 0 O-C-N 122.352 -0.218 . . . . 0.0 111.322 174.377 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 82' ' ' GLN . . . . . 0.437 ' HB2' ' HZ3' ' A' ' 43' ' ' TRP . 50.3 mt-30 -60.9 -37.01 80.74 Favored 'General case' 0 CA--C 1.514 -0.413 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.66 -177.9 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.49 HG23 ' CD1' ' A' ' 31' ' ' TRP . 42.1 mt -59.28 -45.51 93.06 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.777 0 CA-C-N 115.139 -0.937 . . . . 0.0 109.801 176.742 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 84' ' ' ALA . . . . . 0.649 ' O ' ' HG3' ' A' ' 87' ' ' GLU . . . -66.35 -45.98 78.32 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.621 -177.908 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.424 HG23 ' O ' ' A' ' 81' ' ' GLU . 44.0 t -66.06 -49.01 79.61 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-O 120.779 0.323 . . . . 0.0 111.631 -179.926 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -67.02 -31.3 71.75 Favored 'General case' 0 CA--C 1.516 -0.359 0 CA-C-O 121.147 0.498 . . . . 0.0 110.498 -179.719 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 87' ' ' GLU . . . . . 0.768 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 0.1 OUTLIER -69.69 -31.5 69.58 Favored 'General case' 0 C--N 1.322 -0.604 0 C-N-CA 120.149 -0.62 . . . . 0.0 110.325 -176.455 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.584 ' O ' ' HG3' ' A' ' 92' ' ' ARG . 69.1 t -61.43 -40.77 87.47 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.224 0 N-CA-C 108.839 -0.8 . . . . 0.0 108.839 172.89 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . 0.91 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 4.3 m -64.8 -43.32 93.54 Favored 'General case' 0 N--CA 1.447 -0.597 0 CA-C-N 115.648 -0.706 . . . . 0.0 110.388 179.367 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 90' ' ' ARG . . . . . 0.54 ' HG3' ' O ' ' A' ' 87' ' ' GLU . 1.2 ppt_? -61.53 -31.24 71.24 Favored 'General case' 0 C--O 1.223 -0.336 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.561 179.907 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 91' ' ' LEU . . . . . 0.768 ' HG ' ' O ' ' A' ' 87' ' ' GLU . 28.8 mt -64.07 -33.56 76.03 Favored 'General case' 0 C--N 1.318 -0.801 0 CA-C-O 121.63 0.729 . . . . 0.0 109.88 -179.872 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . 0.584 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 7.6 mtm180 -91.62 -51.58 5.18 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 115.058 -0.974 . . . . 0.0 110.618 -169.925 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 93' ' ' GLN . . . . . 0.574 HE22 ' HZ3' ' A' ' 98' ' ' TRP . 0.0 OUTLIER -106.49 -14.51 15.05 Favored 'General case' 0 N--CA 1.443 -0.786 0 CA-C-N 115.446 -0.797 . . . . 0.0 112.016 -175.293 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . 0.441 ' O ' ' HA ' ' A' ' 90' ' ' ARG . . . 86.74 -109.14 3.39 Favored Glycine 0 CA--C 1.496 -1.116 0 N-CA-C 110.797 -0.921 . . . . 0.0 110.797 178.813 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 95' ' ' TRP . . . . . 0.46 ' HB3' ' HB1' ' A' ' 102' ' ' ALA . 6.6 m95 -141.17 24.39 2.14 Favored 'General case' 0 C--N 1.311 -1.103 0 N-CA-C 107.207 -1.405 . . . . 0.0 107.207 -179.794 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -77.29 -20.76 74.57 Favored Glycine 0 N--CA 1.447 -0.594 0 CA-C-N 114.381 -1.281 . . . . 0.0 111.831 175.616 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . 0.426 ' O ' ' HD3' ' A' ' 99' ' ' PRO . . . -90.35 -24.04 20.95 Favored 'General case' 0 CA--C 1.516 -0.364 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 176.248 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 98' ' ' TRP . . . . . 0.91 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 24.3 m-90 -96.59 104.69 18.88 Favored Pre-proline 0 N--CA 1.451 -0.42 0 N-CA-C 108.811 -0.811 . . . . 0.0 108.811 173.643 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 99' ' ' PRO . . . . . 0.503 ' HB2' ' H ' ' A' ' 100' ' ' VAL . 28.9 Cg_exo -67.34 -110.1 0.0 OUTLIER 'Trans proline' 0 CA--C 1.538 0.719 0 C-N-CA 123.49 2.793 . . . . 0.0 114.757 -171.826 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . 0.503 ' H ' ' HB2' ' A' ' 99' ' ' PRO . 40.8 t -67.41 -31.5 53.09 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-O 121.305 0.574 . . . . 0.0 110.432 -174.506 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 101' ' ' CYS . . . . . 0.406 ' SG ' ' HB2' ' A' ' 38' ' ' GLU . 98.5 m -68.71 -32.78 72.82 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 115.28 -0.873 . . . . 0.0 111.92 -171.82 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 102' ' ' ALA . . . . . 0.46 ' HB1' ' HB3' ' A' ' 95' ' ' TRP . . . -69.65 -44.63 70.16 Favored 'General case' 0 C--N 1.324 -0.513 0 C-N-CA 120.651 -0.419 . . . . 0.0 110.202 178.822 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -65.66 -34.28 77.85 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 121.172 0.511 . . . . 0.0 110.406 178.5 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 104' ' ' ARG . . . . . 0.494 ' HG2' ' O ' ' A' ' 100' ' ' VAL . 3.4 mmp_? -70.3 -28.5 65.23 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.129 176.544 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 105' ' ' ALA . . . . . 0.504 ' HB1' ' HA ' ' A' ' 30' ' ' ILE . . . -89.43 -20.82 23.46 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.808 -0.633 . . . . 0.0 112.114 -175.549 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 110.4 64.35 0.52 Allowed Glycine 0 N--CA 1.447 -0.61 0 C-N-CA 120.95 -0.643 . . . . 0.0 111.681 -177.155 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -63.53 149.25 46.67 Favored 'General case' 0 C--N 1.328 -0.337 0 C-N-CA 122.848 0.459 . . . . 0.0 110.824 -176.823 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 108' ' ' ARG . . . . . 0.416 ' CZ ' HD11 ' A' ' 30' ' ' ILE . 91.2 mtt180 . . . . . 0 C--O 1.247 0.944 0 CA-C-O 118.368 -0.825 . . . . 0.0 109.756 -173.016 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . 0.4 ' O ' HG12 ' A' ' 30' ' ' ILE . 4.3 m-20 . . . . . 0 CA--C 1.507 -0.679 0 CA-C-O 121.742 0.782 . . . . 0.0 109.605 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -65.84 -9.54 46.57 Favored Glycine 0 N--CA 1.441 -0.969 0 CA-C-N 114.868 -1.06 . . . . 0.0 110.721 177.381 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 21.8 m -76.93 -41.5 43.16 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-O 121.571 0.7 . . . . 0.0 109.387 175.181 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.553 ' HA ' ' HB1' ' A' ' 105' ' ' ALA . 0.8 OUTLIER -66.68 -38.81 82.34 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.64 0 N-CA-C 107.645 -1.243 . . . . 0.0 107.645 177.223 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' TRP . . . . . 0.485 ' CD1' HG23 ' A' ' 83' ' ' ILE . 36.8 m95 -70.91 -35.75 72.42 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 114.627 -1.169 . . . . 0.0 110.894 -177.922 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.442 ' HB2' HH21 ' A' ' 79' ' ' ARG . 1.9 t70 -72.53 -36.76 68.4 Favored 'General case' 0 N--CA 1.449 -0.509 0 CA-C-N 116.387 -0.37 . . . . 0.0 110.338 177.771 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . 0.489 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -70.19 -35.36 73.9 Favored 'General case' 0 N--CA 1.448 -0.552 0 C-N-CA 120.627 -0.429 . . . . 0.0 110.392 177.96 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . 0.44 HG13 ' O ' ' A' ' 30' ' ' ILE . 64.5 mt -67.13 -43.54 88.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.312 174.05 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . 0.521 ' HA ' ' O ' ' A' ' 54' ' ' GLY . . . -59.59 -35.02 73.47 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 121.313 0.578 . . . . 0.0 110.15 175.973 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . 0.422 ' HA2' ' N ' ' A' ' 41' ' ' GLY . . . -77.62 -14.97 81.88 Favored Glycine 0 N--CA 1.448 -0.564 0 CA-C-N 115.497 -0.774 . . . . 0.0 111.873 178.409 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 36.8 t -95.92 -48.01 5.89 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-O 120.737 0.303 . . . . 0.0 111.387 -177.032 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . 0.481 ' HG2' ' SG ' ' A' ' 101' ' ' CYS . 8.5 mm-40 -86.91 -34.2 19.46 Favored 'General case' 0 CA--C 1.511 -0.541 0 CA-C-O 121.077 0.465 . . . . 0.0 110.17 -175.538 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -107.94 -12.47 15.16 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.613 -0.721 . . . . 0.0 112.064 -174.089 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 76.31 16.65 80.55 Favored Glycine 0 N--CA 1.449 -0.461 0 N-CA-C 109.957 -1.257 . . . . 0.0 109.957 -176.767 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . 0.422 ' N ' ' HA2' ' A' ' 36' ' ' GLY . . . 82.98 59.91 2.12 Favored Glycine 0 N--CA 1.434 -1.475 0 CA-C-N 113.944 -1.128 . . . . 0.0 111.807 -176.904 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' ASN . . . . . 0.849 ' HB3' ' HB ' ' A' ' 45' ' ' ILE . 3.4 m120 -146.1 96.02 2.72 Favored 'General case' 0 C--N 1.324 -0.515 0 N-CA-C 109.223 -0.658 . . . . 0.0 109.223 -178.893 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' TRP . . . . . 0.695 ' CE2' ' HG2' ' A' ' 79' ' ' ARG . 52.5 m95 -78.88 -14.39 59.26 Favored 'General case' 0 C--N 1.314 -0.975 0 CA-C-N 115.711 -0.677 . . . . 0.0 109.803 -177.941 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . 0.414 ' HA ' ' HB2' ' A' ' 75' ' ' ASP . . . -102.48 7.97 40.12 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 115.271 -0.877 . . . . 0.0 111.289 -179.692 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.849 ' HB ' ' HB3' ' A' ' 42' ' ' ASN . 8.2 tt -74.18 145.16 11.62 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.708 0 CA-C-O 121.401 0.619 . . . . 0.0 110.984 -177.182 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 17.4 t-20 -141.5 96.19 2.94 Favored 'General case' 0 C--N 1.309 -1.183 0 N-CA-C 109.099 -0.704 . . . . 0.0 109.099 178.953 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 19.7 p -68.61 -21.3 64.51 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 115.029 -0.987 . . . . 0.0 111.058 -177.486 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 88.06 18.22 56.27 Favored Glycine 0 N--CA 1.441 -1.001 0 N-CA-C 110.373 -1.091 . . . . 0.0 110.373 179.44 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 92.2 m-20 -97.37 10.23 40.2 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 121.092 0.472 . . . . 0.0 111.347 -174.621 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . 0.406 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 90.96 -11.6 71.59 Favored Glycine 0 N--CA 1.443 -0.842 0 N-CA-C 110.853 -0.899 . . . . 0.0 110.853 -178.003 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 51' ' ' TYR . . . . . 0.634 ' HA ' ' HA ' ' A' ' 58' ' ' ASP . 0.7 OUTLIER -109.58 152.36 25.61 Favored 'General case' 0 CA--C 1.509 -0.624 0 N-CA-C 108.092 -1.077 . . . . 0.0 108.092 178.026 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 52' ' ' TYR . . . . . 0.78 ' O ' ' HA ' ' A' ' 56' ' ' GLN . 18.4 m-85 -112.81 169.93 8.56 Favored 'General case' 0 C--N 1.31 -1.12 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.698 -169.763 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.441 ' CA ' HG22 ' A' ' 45' ' ' ILE . . . -66.08 -171.79 4.07 Favored Glycine 0 N--CA 1.451 -0.361 0 N-CA-C 115.025 0.77 . . . . 0.0 115.025 -168.353 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . 0.639 ' CA ' ' HA ' ' A' ' 43' ' ' TRP . . . 75.27 -101.97 1.42 Allowed Glycine 0 N--CA 1.443 -0.847 0 CA-C-N 114.738 -0.731 . . . . 0.0 112.177 178.475 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.551 HG12 ' HE1' ' A' ' 98' ' ' TRP . 2.3 t -84.3 -3.54 7.95 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 CA-C-O 121.606 0.717 . . . . 0.0 109.541 179.409 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' GLN . . . . . 0.78 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 0.0 OUTLIER 57.93 46.83 16.04 Favored 'General case' 0 N--CA 1.463 0.179 0 CA-C-N 114.432 -1.258 . . . . 0.0 113.556 170.256 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . 0.507 ' CE1' ' HB ' ' A' ' 55' ' ' VAL . 0.3 OUTLIER -117.15 166.61 12.03 Favored 'General case' 0 C--N 1.323 -0.581 0 C-N-CA 119.597 -0.841 . . . . 0.0 111.956 175.069 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.634 ' HA ' ' HA ' ' A' ' 51' ' ' TYR . 7.2 p-10 -74.8 162.89 28.25 Favored 'General case' 0 CA--C 1.514 -0.411 0 CA-C-N 115.444 -0.798 . . . . 0.0 113.071 -167.055 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . 0.531 ' HB2' ' CE1' ' A' ' 52' ' ' TYR . 4.5 tp-100 -63.06 -35.36 79.99 Favored 'General case' 0 N--CA 1.448 -0.567 0 CA-C-N 114.318 -1.31 . . . . 0.0 111.069 179.623 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -65.15 -49.69 60.75 Favored Glycine 0 C--N 1.312 -0.756 0 CA-C-N 115.368 -0.833 . . . . 0.0 111.437 -178.067 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 91.5 m -65.9 -42.6 90.01 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-O 120.757 0.313 . . . . 0.0 110.986 176.375 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 62' ' ' TRP . . . . . 0.464 ' CH2' ' HA ' ' A' ' 74' ' ' ALA . 60.3 t-105 -56.26 -47.72 77.98 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 121.549 0.69 . . . . 0.0 109.656 177.353 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 5.1 tp10 -66.13 -34.78 78.83 Favored 'General case' 0 C--N 1.318 -0.802 0 CA-C-N 114.818 -1.083 . . . . 0.0 110.505 179.002 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -63.58 -42.54 98.29 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.17 -177.439 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . 0.73 ' HB2' HG13 ' A' ' 85' ' ' VAL . 27.4 m-80 -81.09 -9.99 59.74 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.927 0.394 . . . . 0.0 110.313 176.872 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . 0.472 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 87.69 51.83 3.15 Favored Glycine 0 C--O 1.225 -0.447 0 CA-C-N 115.888 -0.596 . . . . 0.0 112.429 175.357 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . 0.581 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -80.14 -23.77 60.68 Favored Glycine 0 N--CA 1.442 -0.956 0 C-N-CA 120.946 -0.645 . . . . 0.0 112.666 -176.604 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 1.033 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 7.2 mp -61.25 -17.66 54.48 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 112.877 0.695 . . . . 0.0 112.877 -172.751 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . 0.472 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 17.5 ptp180 -70.59 -34.75 72.5 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-O 121.154 0.502 . . . . 0.0 109.775 174.724 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 70' ' ' TYR . . . . . 0.661 ' HB3' ' HB3' ' A' ' 81' ' ' GLU . 54.1 m-85 -80.94 -34.59 33.18 Favored 'General case' 0 N--CA 1.444 -0.77 0 N-CA-C 107.551 -1.278 . . . . 0.0 107.551 179.221 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.609 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 166.32 127.14 0.03 OUTLIER Pre-proline 0 N--CA 1.445 -0.722 0 CA-C-N 112.755 -2.02 . . . . 0.0 106.995 -178.096 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 72' ' ' PRO . . . . . 1.033 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 24.4 Cg_exo -55.91 -7.18 1.49 Allowed 'Trans proline' 0 C--N 1.334 -0.227 0 C-N-CA 122.958 2.439 . . . . 0.0 113.821 -177.68 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 73' ' ' ARG . . . . . 0.504 ' HB2' ' CD2' ' A' ' 52' ' ' TYR . 11.4 ptm180 -144.58 137.12 26.53 Favored 'General case' 0 C--N 1.314 -0.935 0 N-CA-C 108.987 -0.746 . . . . 0.0 108.987 178.059 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . 0.517 ' HB3' ' HB2' ' A' ' 52' ' ' TYR . . . -55.78 -31.45 62.63 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 114.935 -1.029 . . . . 0.0 112.614 -175.993 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . 0.639 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 6.4 p-10 -81.2 -10.02 59.69 Favored 'General case' 0 C--N 1.328 -0.34 0 C-N-CA 120.426 -0.51 . . . . 0.0 111.312 -174.443 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 67.9 tp -93.94 -27.7 16.22 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-O 121.798 0.808 . . . . 0.0 108.921 172.801 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . 0.779 ' HB1' ' HB2' ' A' ' 81' ' ' GLU . . . -79.16 159.38 27.44 Favored 'General case' 0 N--CA 1.441 -0.909 0 CA-C-N 114.723 -1.126 . . . . 0.0 109.863 174.779 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 70.6 p -100.91 -174.59 2.66 Favored 'General case' 0 C--N 1.313 -0.983 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.932 -176.818 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . 0.695 ' HG2' ' CE2' ' A' ' 43' ' ' TRP . 77.0 mtp180 -51.02 -53.53 32.65 Favored 'General case' 0 CA--C 1.514 -0.419 0 CA-C-O 120.893 0.378 . . . . 0.0 110.702 -178.675 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 1.7 pm0 -63.18 -36.11 82.53 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-N 115.463 -0.789 . . . . 0.0 111.804 -175.016 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 81' ' ' GLU . . . . . 0.779 ' HB2' ' HB1' ' A' ' 77' ' ' ALA . 3.5 mm-40 -66.75 -50.7 61.88 Favored 'General case' 0 CA--C 1.516 -0.356 0 CA-C-O 121.041 0.448 . . . . 0.0 110.104 178.827 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 82' ' ' GLN . . . . . 0.586 ' HB2' ' HZ3' ' A' ' 43' ' ' TRP . 48.0 mt-30 -64.68 -35.81 82.23 Favored 'General case' 0 CA--C 1.511 -0.541 0 CA-C-N 115.685 -0.688 . . . . 0.0 110.062 -178.452 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.667 ' O ' ' HG2' ' A' ' 87' ' ' GLU . 53.1 mt -59.23 -48.87 85.44 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.812 0 CA-C-N 115.45 -0.796 . . . . 0.0 109.265 174.199 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 84' ' ' ALA . . . . . 0.538 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -61.51 -42.24 98.52 Favored 'General case' 0 C--O 1.239 0.517 0 CA-C-O 121.083 0.468 . . . . 0.0 111.615 -177.682 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.73 HG13 ' HB2' ' A' ' 65' ' ' ASN . 69.5 t -67.85 -48.5 75.17 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.85 179.494 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 86' ' ' ALA . . . . . 0.435 ' HB1' ' CH2' ' A' ' 31' ' ' TRP . . . -60.74 -29.12 69.19 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.543 174.594 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 87' ' ' GLU . . . . . 0.667 ' HG2' ' O ' ' A' ' 83' ' ' ILE . 14.8 mm-40 -59.75 -44.31 93.87 Favored 'General case' 0 N--CA 1.469 0.477 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.494 -179.797 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.573 ' O ' ' HG3' ' A' ' 92' ' ' ARG . 61.7 t -62.94 -40.49 89.12 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.44 0 N-CA-C 109.712 -0.477 . . . . 0.0 109.712 176.641 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . 0.859 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 1.0 OUTLIER -70.03 -48.9 56.1 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.958 -0.565 . . . . 0.0 111.484 -175.89 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 90' ' ' ARG . . . . . 0.625 ' HA ' ' OE1' ' A' ' 93' ' ' GLN . 2.3 ptt180 -60.86 -33.63 73.38 Favored 'General case' 0 CA--C 1.519 -0.24 0 CA-C-N 116.025 -0.534 . . . . 0.0 111.638 -173.539 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 91' ' ' LEU . . . . . 0.571 ' HG ' ' O ' ' A' ' 88' ' ' VAL . 4.7 pp -71.42 -21.84 61.93 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.588 -175.188 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . 0.573 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 22.0 mtm180 -88.02 -52.39 5.28 Favored 'General case' 0 CA--C 1.509 -0.615 0 CA-C-O 121.247 0.546 . . . . 0.0 110.689 -175.8 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 93' ' ' GLN . . . . . 0.625 ' OE1' ' HA ' ' A' ' 90' ' ' ARG . 0.0 OUTLIER -95.3 -21.83 18.16 Favored 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 113.048 0.758 . . . . 0.0 113.048 -171.356 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 88.1 42.34 5.97 Favored Glycine 0 CA--C 1.506 -0.492 0 C-N-CA 120.488 -0.863 . . . . 0.0 111.97 172.251 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 95' ' ' TRP . . . . . 0.417 ' HA ' ' HE3' ' A' ' 98' ' ' TRP . 6.7 m95 62.7 12.15 5.4 Favored 'General case' 0 C--O 1.22 -0.489 0 C-N-CA 123.587 0.755 . . . . 0.0 109.801 -179.347 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -74.14 -20.0 79.73 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 121.172 -0.537 . . . . 0.0 112.458 179.46 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -78.58 -27.23 45.68 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 121.157 0.503 . . . . 0.0 109.872 176.628 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 98' ' ' TRP . . . . . 0.859 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 27.0 m-90 -101.04 103.65 26.9 Favored Pre-proline 0 C--N 1.324 -0.53 0 N-CA-C 108.86 -0.793 . . . . 0.0 108.86 176.399 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 99' ' ' PRO . . . . . 0.404 ' HB2' ' H ' ' A' ' 100' ' ' VAL . 14.7 Cg_exo -74.77 -88.54 0.0 OUTLIER 'Trans proline' 0 CA--C 1.53 0.28 0 C-N-CA 123.034 2.489 . . . . 0.0 114.872 -170.894 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . 0.404 ' H ' ' HB2' ' A' ' 99' ' ' PRO . 61.1 t -70.59 -29.91 40.29 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 CA-C-O 121.555 0.693 . . . . 0.0 110.565 -171.966 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 101' ' ' CYS . . . . . 0.481 ' SG ' ' HG2' ' A' ' 38' ' ' GLU . 85.0 m -83.29 -32.48 26.33 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-N 115.14 -0.936 . . . . 0.0 112.021 -169.012 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -68.11 -43.01 79.42 Favored 'General case' 0 C--N 1.327 -0.393 0 C-N-CA 120.47 -0.492 . . . . 0.0 110.098 177.493 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -60.58 -36.12 77.74 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 121.194 0.521 . . . . 0.0 110.739 177.515 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 35.5 mtp180 -73.03 -38.83 66.41 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.702 -0.681 . . . . 0.0 111.183 177.379 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 105' ' ' ALA . . . . . 0.553 ' HB1' ' HA ' ' A' ' 30' ' ' ILE . . . -80.79 -22.42 40.1 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 115.632 -0.713 . . . . 0.0 112.567 -173.69 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 116.57 62.44 0.33 Allowed Glycine 0 CA--C 1.521 0.415 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.31 -178.623 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -63.25 149.46 45.51 Favored 'General case' 0 C--N 1.328 -0.337 0 C-N-CA 122.927 0.491 . . . . 0.0 110.748 179.417 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 72.0 mtp180 . . . . . 0 C--O 1.247 0.937 0 CA-C-O 118.247 -0.882 . . . . 0.0 111.089 -170.546 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . 0.586 ' O ' HG12 ' A' ' 30' ' ' ILE . 6.2 m-20 . . . . . 0 CA--C 1.499 -1.006 0 CA-C-O 121.909 0.861 . . . . 0.0 110.057 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . 0.576 ' HA2' ' HB2' ' A' ' 31' ' ' TRP . . . -72.52 0.94 39.28 Favored Glycine 0 N--CA 1.436 -1.319 0 CA-C-N 114.464 -1.244 . . . . 0.0 111.053 178.77 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 13.8 m -76.41 -39.13 54.45 Favored 'General case' 0 C--N 1.32 -0.716 0 N-CA-C 108.892 -0.781 . . . . 0.0 108.892 173.458 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.586 HG12 ' O ' ' A' ' 27' ' ' ASP . 0.2 OUTLIER -71.99 -39.1 66.01 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 CA-C-N 114.327 -1.306 . . . . 0.0 107.527 176.317 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' TRP . . . . . 0.576 ' HB2' ' HA2' ' A' ' 28' ' ' GLY . 22.9 m95 -70.69 -35.56 72.84 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-N 114.483 -1.235 . . . . 0.0 110.333 -176.443 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.73 ' HB2' HH21 ' A' ' 79' ' ' ARG . 7.0 t70 -76.87 -32.24 57.34 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.458 179.7 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -70.45 -37.73 74.36 Favored 'General case' 0 N--CA 1.447 -0.601 0 C-N-CA 120.729 -0.388 . . . . 0.0 110.27 175.051 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . 0.47 HG13 ' O ' ' A' ' 30' ' ' ILE . 62.0 mt -64.89 -44.4 96.22 Favored 'Isoleucine or valine' 0 C--O 1.235 0.293 0 CA-C-O 120.954 0.407 . . . . 0.0 110.324 174.535 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . 0.498 ' O ' ' HB3' ' A' ' 39' ' ' ALA . . . -57.84 -39.25 77.27 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.236 0.541 . . . . 0.0 110.032 175.127 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -74.07 -9.01 79.85 Favored Glycine 0 N--CA 1.452 -0.299 0 CA-C-N 115.568 -0.742 . . . . 0.0 111.761 179.736 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 44.8 t -97.22 -62.85 1.19 Allowed 'General case' 0 N--CA 1.446 -0.648 0 CA-C-N 115.554 -0.323 . . . . 0.0 111.077 -178.068 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . 0.879 ' HG3' ' SG ' ' A' ' 101' ' ' CYS . 27.3 mt-10 -89.36 -27.32 20.56 Favored 'General case' 0 C--N 1.328 -0.357 0 N-CA-C 111.778 0.288 . . . . 0.0 111.778 -174.181 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . 0.498 ' HB3' ' O ' ' A' ' 35' ' ' ALA . . . -95.14 -17.11 22.08 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 121.015 0.435 . . . . 0.0 112.021 -176.457 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 81.54 14.05 78.99 Favored Glycine 0 N--CA 1.447 -0.599 0 N-CA-C 109.709 -1.357 . . . . 0.0 109.709 -174.622 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 77.52 57.2 3.66 Favored Glycine 0 N--CA 1.438 -1.203 0 CA-C-N 114.236 -0.982 . . . . 0.0 112.656 179.874 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 55.9 t30 -150.73 127.5 10.96 Favored 'General case' 0 CA--C 1.503 -0.853 0 N-CA-C 109.201 -0.666 . . . . 0.0 109.201 178.19 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' TRP . . . . . 0.763 ' HA ' ' N ' ' A' ' 54' ' ' GLY . 26.2 m95 -100.28 -2.02 34.79 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-N 115.437 -0.801 . . . . 0.0 110.099 -174.167 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -112.19 8.77 19.98 Favored 'General case' 0 C--N 1.318 -0.772 0 CA-C-N 115.052 -0.977 . . . . 0.0 111.021 178.574 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.611 HG22 ' HA2' ' A' ' 53' ' ' GLY . 12.5 tt -74.3 143.89 13.01 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.76 0 CA-C-O 120.988 0.423 . . . . 0.0 110.176 -178.784 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 13.3 t-20 -149.63 85.21 1.43 Allowed 'General case' 0 C--N 1.314 -0.939 0 CA-C-O 121.299 0.571 . . . . 0.0 110.302 -177.793 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -69.89 -20.03 63.4 Favored 'General case' 0 N--CA 1.445 -0.7 0 CA-C-N 115.476 -0.784 . . . . 0.0 111.058 177.88 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 92.05 21.56 32.74 Favored Glycine 0 N--CA 1.444 -0.795 0 C-N-CA 120.909 -0.662 . . . . 0.0 111.698 174.578 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 4.2 p-10 -94.97 14.38 21.91 Favored 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 112.082 0.401 . . . . 0.0 112.082 -175.275 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . 0.507 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 92.39 -13.92 66.01 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 121.32 -0.467 . . . . 0.0 112.171 176.5 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 51' ' ' TYR . . . . . 0.628 ' CE1' ' HB2' ' A' ' 58' ' ' ASP . 0.3 OUTLIER -110.0 155.29 22.0 Favored 'General case' 0 C--N 1.323 -0.546 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 173.505 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 52' ' ' TYR . . . . . 0.726 ' O ' ' HA ' ' A' ' 56' ' ' GLN . 63.5 m-85 -119.38 171.05 8.6 Favored 'General case' 0 C--N 1.312 -1.06 0 N-CA-C 112.657 0.614 . . . . 0.0 112.657 -168.467 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.611 ' HA2' HG22 ' A' ' 45' ' ' ILE . . . -53.87 163.19 3.07 Favored Glycine 0 N--CA 1.449 -0.44 0 CA-C-N 115.356 -0.838 . . . . 0.0 114.09 -175.527 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . 0.763 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 90.27 -109.51 3.66 Favored Glycine 0 N--CA 1.442 -0.921 0 C-N-CA 121.05 -0.595 . . . . 0.0 112.397 178.738 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.506 HG12 ' HE1' ' A' ' 98' ' ' TRP . 2.5 t -83.63 0.7 4.58 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-O 121.968 0.89 . . . . 0.0 109.784 -177.065 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' GLN . . . . . 0.726 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 0.0 OUTLIER 53.97 50.18 17.32 Favored 'General case' 0 N--CA 1.449 -0.495 0 CA-C-N 113.826 -1.534 . . . . 0.0 112.729 170.679 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . 0.445 ' CD1' ' HB ' ' A' ' 55' ' ' VAL . 2.5 p90 -119.04 166.63 12.65 Favored 'General case' 0 C--N 1.323 -0.564 0 C-N-CA 119.304 -0.958 . . . . 0.0 111.914 174.837 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.628 ' HB2' ' CE1' ' A' ' 51' ' ' TYR . 0.0 OUTLIER -75.75 157.46 33.49 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 114.32 -1.309 . . . . 0.0 113.777 -162.071 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . 0.492 ' HB2' ' HE1' ' A' ' 52' ' ' TYR . 22.1 tp60 -53.34 -44.25 68.33 Favored 'General case' 0 N--CA 1.441 -0.9 0 CA-C-N 114.171 -1.377 . . . . 0.0 111.463 179.243 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -68.49 -49.05 47.16 Favored Glycine 0 C--O 1.22 -0.735 0 CA-C-N 115.325 -0.852 . . . . 0.0 112.396 -176.106 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 46.3 m -60.77 -40.61 93.15 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-O 121.552 0.691 . . . . 0.0 110.519 179.098 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 62' ' ' TRP . . . . . 0.484 ' CZ3' ' HA ' ' A' ' 82' ' ' GLN . 50.6 t-105 -61.98 -48.86 78.45 Favored 'General case' 0 C--N 1.318 -0.794 0 CA-C-N 114.845 -1.071 . . . . 0.0 109.863 175.279 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . 0.599 ' HB2' HD11 ' A' ' 68' ' ' LEU . 0.0 OUTLIER -67.97 -36.39 79.97 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.733 -0.667 . . . . 0.0 110.353 -176.801 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . 0.48 ' N ' ' HG3' ' A' ' 63' ' ' GLU . . . -66.16 -41.05 90.89 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.433 -0.803 . . . . 0.0 111.28 -175.972 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . 0.459 ' HB3' ' HB ' ' A' ' 88' ' ' VAL . 84.5 m-20 -84.09 -3.61 58.2 Favored 'General case' 0 N--CA 1.446 -0.669 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.61 176.906 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . 0.497 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 85.74 46.92 5.27 Favored Glycine 0 N--CA 1.448 -0.532 0 CA-C-N 115.573 -0.74 . . . . 0.0 113.107 171.11 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . 0.627 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -80.28 -16.46 76.23 Favored Glycine 0 N--CA 1.443 -0.899 0 C-N-CA 120.672 -0.775 . . . . 0.0 111.828 179.918 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.662 ' HA ' ' HA ' ' A' ' 72' ' ' PRO . 14.6 mt -64.74 -22.74 67.05 Favored 'General case' 0 C--N 1.32 -0.707 0 C-N-CA 122.817 0.447 . . . . 0.0 111.363 -171.332 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . 0.497 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 14.9 ptm180 -70.85 -32.49 69.53 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.311 176.138 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 70' ' ' TYR . . . . . 0.675 ' HB3' ' HB3' ' A' ' 81' ' ' GLU . 58.9 m-85 -80.09 -33.33 38.88 Favored 'General case' 0 N--CA 1.445 -0.697 0 N-CA-C 107.217 -1.401 . . . . 0.0 107.217 178.19 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.673 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 165.94 127.12 0.03 OUTLIER Pre-proline 0 CA--C 1.511 -0.538 0 CA-C-N 112.447 -2.161 . . . . 0.0 107.122 178.693 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 72' ' ' PRO . . . . . 0.662 ' HA ' ' HA ' ' A' ' 68' ' ' LEU . 15.5 Cg_exo -56.2 -0.8 0.23 Allowed 'Trans proline' 0 CA--C 1.531 0.369 0 C-N-CA 122.961 2.441 . . . . 0.0 114.231 -177.849 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 13.0 ptm180 -150.82 142.46 23.62 Favored 'General case' 0 C--N 1.317 -0.839 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 172.776 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . 0.561 ' HB3' ' HB2' ' A' ' 52' ' ' TYR . . . -58.69 -30.34 67.33 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.332 -0.849 . . . . 0.0 112.89 -175.899 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . 0.459 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 15.7 p-10 -87.33 5.54 37.98 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 121.269 0.557 . . . . 0.0 111.129 -176.232 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.436 ' HB3' ' HB1' ' A' ' 71' ' ' ALA . 65.2 tp -105.67 -30.17 9.64 Favored 'General case' 0 C--N 1.319 -0.72 0 N-CA-C 108.359 -0.978 . . . . 0.0 108.359 168.967 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . 0.706 ' HB1' ' HB2' ' A' ' 81' ' ' GLU . . . -79.47 164.48 23.91 Favored 'General case' 0 N--CA 1.444 -0.739 0 CA-C-N 114.446 -1.252 . . . . 0.0 110.183 175.933 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . 0.461 ' OG1' ' HG2' ' A' ' 81' ' ' GLU . 65.9 p -99.97 -178.89 3.99 Favored 'General case' 0 C--N 1.313 -0.994 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.414 -177.042 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . 0.73 HH21 ' HB2' ' A' ' 32' ' ' ASP . 47.2 mtp180 -52.71 -53.67 44.32 Favored 'General case' 0 CA--C 1.516 -0.342 0 CA-C-O 121.045 0.45 . . . . 0.0 110.374 -178.536 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 80' ' ' GLU . . . . . 0.61 ' HA ' HD12 ' A' ' 83' ' ' ILE . 2.7 pm0 -60.51 -32.64 71.65 Favored 'General case' 0 C--N 1.317 -0.816 0 CA-C-N 115.083 -0.962 . . . . 0.0 112.254 -176.818 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 81' ' ' GLU . . . . . 0.706 ' HB2' ' HB1' ' A' ' 77' ' ' ALA . 5.4 mm-40 -70.64 -50.41 37.13 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-O 120.877 0.37 . . . . 0.0 110.031 177.477 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 82' ' ' GLN . . . . . 0.484 ' HA ' ' CZ3' ' A' ' 62' ' ' TRP . 51.2 mt-30 -61.11 -35.61 77.49 Favored 'General case' 0 CA--C 1.507 -0.69 0 CA-C-N 115.582 -0.736 . . . . 0.0 109.631 179.833 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.687 ' O ' ' HG2' ' A' ' 87' ' ' GLU . 39.2 mt -59.55 -49.16 84.69 Favored 'Isoleucine or valine' 0 C--O 1.211 -0.952 0 CA-C-N 114.714 -1.13 . . . . 0.0 109.763 174.829 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 84' ' ' ALA . . . . . 0.616 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -61.25 -41.58 97.15 Favored 'General case' 0 C--O 1.236 0.365 0 CA-C-O 121.403 0.62 . . . . 0.0 111.579 -177.606 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.465 HG23 ' O ' ' A' ' 81' ' ' GLU . 34.7 t -69.2 -47.85 71.89 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.794 178.528 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -58.22 -29.44 65.72 Favored 'General case' 0 N--CA 1.45 -0.446 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.364 172.99 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 87' ' ' GLU . . . . . 0.687 ' HG2' ' O ' ' A' ' 83' ' ' ILE . 14.5 mm-40 -60.03 -44.62 94.5 Favored 'General case' 0 N--CA 1.469 0.497 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.111 179.277 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.638 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 60.8 t -63.56 -47.71 90.21 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.437 0 N-CA-C 109.473 -0.566 . . . . 0.0 109.473 174.243 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . 0.898 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 0.7 OUTLIER -59.21 -49.86 76.22 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-N 115.696 -0.684 . . . . 0.0 111.387 -176.508 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 90' ' ' ARG . . . . . 0.509 ' HA ' ' HZ3' ' A' ' 98' ' ' TRP . 27.0 ptt85 -60.51 -34.97 74.87 Favored 'General case' 0 C--O 1.223 -0.314 0 CA-C-N 116.723 -0.217 . . . . 0.0 111.232 -172.477 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 91' ' ' LEU . . . . . 0.638 ' HG ' ' O ' ' A' ' 88' ' ' VAL . 4.5 pp -74.71 -22.82 58.63 Favored 'General case' 0 C--N 1.318 -0.798 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.52 -173.488 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . 0.605 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 15.6 mtm180 -80.82 -52.71 7.19 Favored 'General case' 0 CA--C 1.505 -0.773 0 CA-C-O 121.13 0.491 . . . . 0.0 109.877 -176.04 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 4.9 pm0 -103.75 -15.36 15.76 Favored 'General case' 0 N--CA 1.445 -0.681 0 C-N-CA 119.645 -0.822 . . . . 0.0 113.022 -173.411 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 87.33 45.12 5.39 Favored Glycine 0 CA--C 1.498 -1.03 0 C-N-CA 120.732 -0.747 . . . . 0.0 111.88 168.424 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 95' ' ' TRP . . . . . 0.472 ' HA ' ' HE3' ' A' ' 98' ' ' TRP . 15.7 m95 66.47 2.23 2.39 Favored 'General case' 0 C--O 1.216 -0.669 0 C-N-CA 123.236 0.614 . . . . 0.0 109.979 -178.276 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -70.35 -13.01 70.23 Favored Glycine 0 C--N 1.335 0.517 0 C-N-CA 121.447 -0.406 . . . . 0.0 112.792 -178.108 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -81.93 -23.66 36.06 Favored 'General case' 0 C--N 1.325 -0.471 0 N-CA-C 109.525 -0.546 . . . . 0.0 109.525 175.159 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 98' ' ' TRP . . . . . 0.898 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 29.0 m-90 -103.16 104.95 43.59 Favored Pre-proline 0 N--CA 1.45 -0.444 0 N-CA-C 108.745 -0.835 . . . . 0.0 108.745 175.146 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 99' ' ' PRO . . . . . 0.419 ' HD3' ' HA ' ' A' ' 98' ' ' TRP . 15.0 Cg_exo -74.43 -87.09 0.0 OUTLIER 'Trans proline' 0 CA--C 1.53 0.305 0 C-N-CA 122.902 2.401 . . . . 0.0 114.673 -172.666 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 48.4 t -71.25 -27.92 30.83 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-O 121.322 0.582 . . . . 0.0 111.086 -170.949 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 101' ' ' CYS . . . . . 0.879 ' SG ' ' HG3' ' A' ' 38' ' ' GLU . 64.2 m -90.99 -27.55 18.59 Favored 'General case' 0 C--N 1.314 -0.946 0 CA-C-N 115.915 -0.584 . . . . 0.0 112.545 -168.772 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 102' ' ' ALA . . . . . 0.596 ' HB2' ' HB2' ' A' ' 98' ' ' TRP . . . -67.54 -46.43 72.82 Favored 'General case' 0 C--N 1.33 -0.268 0 C-N-CA 120.515 -0.474 . . . . 0.0 110.928 -178.719 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -61.22 -39.09 88.95 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-O 121.097 0.475 . . . . 0.0 110.634 179.25 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -66.56 -39.77 88.68 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.469 -0.787 . . . . 0.0 111.548 176.655 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -77.56 -22.51 50.89 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.929 -175.933 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 116.02 55.83 0.34 Allowed Glycine 0 N--CA 1.452 -0.236 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.528 -178.942 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -57.52 149.2 21.67 Favored 'General case' 0 CA--C 1.517 -0.305 0 C-N-CA 123.049 0.54 . . . . 0.0 110.572 179.149 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 69.9 mtp180 . . . . . 0 C--O 1.249 1.04 0 CA-C-O 118.202 -0.904 . . . . 0.0 110.465 -170.19 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . 0.623 ' O ' HG12 ' A' ' 30' ' ' ILE . 13.0 m-20 . . . . . 0 CA--C 1.502 -0.899 0 CA-C-O 121.891 0.853 . . . . 0.0 109.208 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . 0.711 ' HA2' ' HB2' ' A' ' 31' ' ' TRP . . . -77.75 2.7 62.91 Favored Glycine 0 N--CA 1.433 -1.534 0 CA-C-N 114.583 -1.19 . . . . 0.0 110.611 -177.76 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 17.0 m -76.23 -40.36 52.26 Favored 'General case' 0 C--N 1.318 -0.794 0 N-CA-C 108.77 -0.826 . . . . 0.0 108.77 173.626 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.632 ' HA ' ' HB1' ' A' ' 105' ' ' ALA . 0.0 OUTLIER -71.52 -38.03 66.32 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.679 0 N-CA-C 107.348 -1.353 . . . . 0.0 107.348 176.573 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' TRP . . . . . 0.711 ' HB2' ' HA2' ' A' ' 28' ' ' GLY . 14.6 m95 -71.85 -36.29 70.11 Favored 'General case' 0 N--CA 1.438 -1.054 0 CA-C-N 114.251 -1.34 . . . . 0.0 110.601 -176.188 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 31.7 t70 -77.23 -34.31 56.01 Favored 'General case' 0 N--CA 1.446 -0.66 0 CA-C-N 116.529 -0.305 . . . . 0.0 110.931 178.082 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . 0.487 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -70.16 -34.08 72.56 Favored 'General case' 0 N--CA 1.448 -0.532 0 C-N-CA 120.288 -0.565 . . . . 0.0 110.278 177.523 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . 0.501 HG13 ' O ' ' A' ' 30' ' ' ILE . 68.3 mt -67.88 -46.55 81.92 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-O 121.07 0.462 . . . . 0.0 110.176 172.298 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . 0.413 ' O ' ' HB3' ' A' ' 39' ' ' ALA . . . -58.72 -38.91 79.36 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.277 176.89 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . 0.509 ' HA2' ' N ' ' A' ' 41' ' ' GLY . . . -74.88 -12.97 82.84 Favored Glycine 0 C--O 1.228 -0.26 0 CA-C-N 115.618 -0.719 . . . . 0.0 111.535 178.699 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 40.8 t -89.5 -60.94 1.81 Allowed 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 115.356 -0.422 . . . . 0.0 110.93 -177.748 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . 0.832 ' HG3' ' SG ' ' A' ' 101' ' ' CYS . 34.3 mt-10 -89.55 -28.37 19.64 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 120.687 0.28 . . . . 0.0 111.534 -174.441 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . 0.413 ' HB3' ' O ' ' A' ' 35' ' ' ALA . . . -101.49 -12.01 18.87 Favored 'General case' 0 C--N 1.326 -0.452 0 C-N-CA 120.43 -0.508 . . . . 0.0 111.785 -178.14 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 81.03 6.52 89.4 Favored Glycine 0 N--CA 1.45 -0.371 0 N-CA-C 110.027 -1.229 . . . . 0.0 110.027 -177.846 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . 0.509 ' N ' ' HA2' ' A' ' 36' ' ' GLY . . . 85.35 53.88 2.98 Favored Glycine 0 N--CA 1.437 -1.274 0 CA-C-N 114.148 -1.026 . . . . 0.0 111.942 -177.71 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' ASN . . . . . 0.412 ' OD1' ' HB ' ' A' ' 45' ' ' ILE . 2.3 t-20 -138.71 99.32 3.77 Favored 'General case' 0 N--CA 1.447 -0.58 0 N-CA-C 108.829 -0.804 . . . . 0.0 108.829 -175.84 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' TRP . . . . . 0.667 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 37.1 m95 -81.48 -10.32 59.51 Favored 'General case' 0 C--N 1.312 -1.026 0 CA-C-N 115.389 -0.823 . . . . 0.0 110.805 -172.664 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -107.0 8.71 30.56 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 115.504 -0.771 . . . . 0.0 110.829 -179.492 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.427 HG22 ' CA ' ' A' ' 53' ' ' GLY . 9.3 tt -72.56 144.27 13.17 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.916 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 179.578 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 22.4 t-20 -154.22 98.47 2.14 Favored 'General case' 0 C--N 1.309 -1.183 0 CA-C-O 121.384 0.612 . . . . 0.0 109.372 -179.956 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 17.5 p -72.51 -24.05 61.1 Favored 'General case' 0 C--N 1.317 -0.819 0 CA-C-N 114.76 -1.109 . . . . 0.0 110.919 -177.376 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 93.48 20.64 31.56 Favored Glycine 0 N--CA 1.441 -0.981 0 N-CA-C 110.722 -0.951 . . . . 0.0 110.722 -178.698 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 82.8 m-20 -93.18 12.8 23.14 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.877 0.37 . . . . 0.0 111.415 -176.234 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . 0.516 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 85.29 -11.73 60.18 Favored Glycine 0 N--CA 1.449 -0.46 0 N-CA-C 111.209 -0.757 . . . . 0.0 111.209 -177.883 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 51' ' ' TYR . . . . . 0.649 ' HA ' ' HA ' ' A' ' 58' ' ' ASP . 0.3 OUTLIER -112.22 146.37 38.25 Favored 'General case' 0 CA--C 1.51 -0.562 0 N-CA-C 107.197 -1.408 . . . . 0.0 107.197 177.214 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 52' ' ' TYR . . . . . 0.831 ' O ' ' HA ' ' A' ' 56' ' ' GLN . 32.8 m-85 -110.73 170.5 8.05 Favored 'General case' 0 C--N 1.309 -1.154 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.697 -165.96 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.427 ' CA ' HG22 ' A' ' 45' ' ' ILE . . . -69.06 -174.37 9.98 Favored Glycine 0 C--O 1.228 -0.223 0 N-CA-C 114.907 0.723 . . . . 0.0 114.907 -169.761 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . 0.608 ' CA ' ' HA ' ' A' ' 43' ' ' TRP . . . 80.0 -107.53 2.62 Favored Glycine 0 N--CA 1.442 -0.942 0 C-N-CA 120.859 -0.686 . . . . 0.0 111.457 -178.349 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.547 HG12 ' HE1' ' A' ' 98' ' ' TRP . 3.4 t -88.21 4.22 4.84 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 CA-C-O 121.554 0.692 . . . . 0.0 109.618 179.016 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' GLN . . . . . 0.831 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 7.0 tt0 54.5 53.82 10.22 Favored 'General case' 0 CA--C 1.535 0.379 0 N-CA-C 114.854 1.427 . . . . 0.0 114.854 164.887 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -121.15 170.26 9.73 Favored 'General case' 0 C--N 1.326 -0.418 0 C-N-CA 119.447 -0.901 . . . . 0.0 112.018 171.652 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.649 ' HA ' ' HA ' ' A' ' 51' ' ' TYR . 6.9 p-10 -76.25 165.22 25.18 Favored 'General case' 0 C--N 1.331 -0.219 0 N-CA-C 113.311 0.856 . . . . 0.0 113.311 -166.809 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . 0.507 ' HB2' ' HE1' ' A' ' 52' ' ' TYR . 5.9 tp-100 -63.15 -37.99 89.4 Favored 'General case' 0 N--CA 1.448 -0.568 0 CA-C-N 114.881 -1.054 . . . . 0.0 110.827 179.127 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -63.46 -49.78 67.28 Favored Glycine 0 C--N 1.314 -0.68 0 CA-C-N 115.551 -0.75 . . . . 0.0 111.777 -175.643 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 86.4 m -63.91 -44.19 93.7 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-O 120.954 0.407 . . . . 0.0 111.201 176.414 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 62' ' ' TRP . . . . . 0.459 ' CZ3' ' HA ' ' A' ' 82' ' ' GLN . 54.4 t-105 -56.86 -48.95 76.93 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 121.84 0.828 . . . . 0.0 109.967 177.546 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . 0.516 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 36.0 tt0 -67.39 -34.68 77.76 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-N 114.611 -1.177 . . . . 0.0 110.471 -178.426 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -64.85 -41.9 95.32 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.645 -0.707 . . . . 0.0 110.993 -178.711 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . 0.579 ' HB2' HG13 ' A' ' 85' ' ' VAL . 7.9 m120 -82.06 -2.85 53.19 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.459 177.144 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . 0.58 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 83.57 47.62 5.6 Favored Glycine 0 C--O 1.225 -0.467 0 CA-C-N 115.782 -0.645 . . . . 0.0 112.587 173.245 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . 0.607 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -80.03 -21.96 64.43 Favored Glycine 0 N--CA 1.438 -1.197 0 C-N-CA 120.956 -0.64 . . . . 0.0 112.934 -175.107 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.837 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 6.8 mp -61.61 -22.73 65.49 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 112.048 0.388 . . . . 0.0 112.048 -172.43 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . 0.58 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 9.6 ptm180 -67.74 -33.68 75.33 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 121.254 0.549 . . . . 0.0 109.963 176.522 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 70' ' ' TYR . . . . . 0.786 ' HB3' ' HG3' ' A' ' 81' ' ' GLU . 63.5 m-85 -79.91 -34.51 38.92 Favored 'General case' 0 N--CA 1.444 -0.772 0 N-CA-C 107.499 -1.297 . . . . 0.0 107.499 178.159 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.707 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 163.99 129.05 0.02 OUTLIER Pre-proline 0 CA--C 1.51 -0.568 0 CA-C-N 112.595 -2.093 . . . . 0.0 107.198 -179.888 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 72' ' ' PRO . . . . . 0.837 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 16.9 Cg_exo -58.46 -3.02 1.15 Allowed 'Trans proline' 0 C--N 1.332 -0.299 0 C-N-CA 122.622 2.215 . . . . 0.0 113.559 -177.911 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 73' ' ' ARG . . . . . 0.421 ' HB2' ' CD2' ' A' ' 52' ' ' TYR . 13.5 ptm180 -146.63 137.36 23.99 Favored 'General case' 0 C--N 1.319 -0.731 0 N-CA-C 109.289 -0.634 . . . . 0.0 109.289 177.342 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . 0.499 ' HB3' ' HB2' ' A' ' 52' ' ' TYR . . . -58.11 -29.52 65.56 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.312 -0.858 . . . . 0.0 112.611 -178.066 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . 0.404 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 14.7 p-10 -87.84 9.19 22.72 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 121.364 0.602 . . . . 0.0 110.852 -176.092 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.432 ' HB3' ' HB1' ' A' ' 71' ' ' ALA . 58.6 tp -110.07 -33.63 6.63 Favored 'General case' 0 C--N 1.322 -0.627 0 N-CA-C 108.322 -0.992 . . . . 0.0 108.322 169.81 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . 0.739 ' HB1' ' HB3' ' A' ' 81' ' ' GLU . . . -78.39 163.36 25.72 Favored 'General case' 0 N--CA 1.445 -0.691 0 CA-C-N 114.771 -1.104 . . . . 0.0 110.393 177.084 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 71.5 p -99.36 -174.49 2.75 Favored 'General case' 0 C--N 1.315 -0.931 0 CA-C-N 115.656 -0.702 . . . . 0.0 110.337 -174.532 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . 0.667 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 23.7 mtt85 -53.93 -56.81 14.33 Favored 'General case' 0 CA--C 1.512 -0.509 0 CA-C-O 120.988 0.423 . . . . 0.0 110.772 178.848 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 1.8 pm0 -58.22 -41.18 83.51 Favored 'General case' 0 C--N 1.314 -0.937 0 CA-C-N 115.043 -0.981 . . . . 0.0 111.262 -176.391 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 81' ' ' GLU . . . . . 0.786 ' HG3' ' HB3' ' A' ' 70' ' ' TYR . 0.4 OUTLIER -63.18 -52.72 61.21 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 115.5 -0.773 . . . . 0.0 112.161 175.835 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 82' ' ' GLN . . . . . 0.459 ' HA ' ' CZ3' ' A' ' 62' ' ' TRP . 53.4 mt-30 -60.66 -43.09 98.04 Favored 'General case' 0 CA--C 1.509 -0.613 0 CA-C-O 121.762 0.791 . . . . 0.0 109.833 -178.972 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.672 HG23 ' CD1' ' A' ' 31' ' ' TRP . 10.8 mt -59.5 -39.74 80.07 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.993 0 CA-C-N 114.276 -1.329 . . . . 0.0 110.303 -177.822 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 84' ' ' ALA . . . . . 0.436 ' O ' HG23 ' A' ' 88' ' ' VAL . . . -62.1 -42.46 99.24 Favored 'General case' 0 C--N 1.319 -0.752 0 CA-C-O 121.273 0.559 . . . . 0.0 110.476 -179.181 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.579 HG13 ' HB2' ' A' ' 65' ' ' ASN . 43.0 t -70.05 -50.77 45.26 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 CA-C-N 115.764 -0.653 . . . . 0.0 111.741 -179.569 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -65.69 -31.49 72.52 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 121.489 0.662 . . . . 0.0 110.858 -179.6 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 87' ' ' GLU . . . . . 0.759 ' HA ' ' HG2' ' A' ' 90' ' ' ARG . 0.7 OUTLIER -71.16 -28.41 64.24 Favored 'General case' 0 C--N 1.316 -0.855 0 CA-C-N 115.716 -0.674 . . . . 0.0 110.436 -178.348 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.674 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 88.1 t -61.86 -46.47 96.43 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.26 0 N-CA-C 109.299 -0.63 . . . . 0.0 109.299 168.54 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . 0.48 ' O ' ' HG2' ' A' ' 93' ' ' GLN . 0.1 OUTLIER -64.64 -45.71 85.63 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 115.697 -0.683 . . . . 0.0 111.866 -177.48 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 90' ' ' ARG . . . . . 0.759 ' HG2' ' HA ' ' A' ' 87' ' ' GLU . 22.5 ptt180 -58.91 -35.36 72.94 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.98 -0.555 . . . . 0.0 111.048 -175.799 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 91' ' ' LEU . . . . . 0.674 ' HG ' ' O ' ' A' ' 88' ' ' VAL . 4.6 pp -74.69 -24.39 58.76 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.022 -0.536 . . . . 0.0 110.827 -169.536 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . 0.455 ' HE ' ' HB2' ' A' ' 92' ' ' ARG . 3.9 mtm180 -85.59 -45.56 11.63 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.783 -0.644 . . . . 0.0 109.686 -177.948 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 93' ' ' GLN . . . . . 0.48 ' HG2' ' O ' ' A' ' 89' ' ' THR . 24.0 pt20 -98.6 -29.12 13.24 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.192 -0.913 . . . . 0.0 113.188 -169.715 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 87.42 46.67 4.88 Favored Glycine 0 CA--C 1.505 -0.58 0 C-N-CA 120.426 -0.893 . . . . 0.0 111.06 176.463 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 95' ' ' TRP . . . . . 0.506 ' HA ' ' HE3' ' A' ' 98' ' ' TRP . 1.9 m95 58.59 27.0 15.12 Favored 'General case' 0 C--O 1.223 -0.34 0 CA-C-O 121.484 0.659 . . . . 0.0 109.687 177.457 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -70.83 -30.5 68.12 Favored Glycine 0 N--CA 1.449 -0.445 0 CA-C-N 115.349 -0.841 . . . . 0.0 112.245 176.618 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . 0.41 ' O ' ' HD3' ' A' ' 99' ' ' PRO . . . -79.46 -24.84 42.13 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 120.66 0.267 . . . . 0.0 110.57 177.114 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 98' ' ' TRP . . . . . 0.547 ' HE1' HG12 ' A' ' 55' ' ' VAL . 23.8 m-90 -101.96 103.25 28.17 Favored Pre-proline 0 C--N 1.327 -0.389 0 N-CA-C 109.406 -0.59 . . . . 0.0 109.406 175.897 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 99' ' ' PRO . . . . . 0.424 ' HB2' ' H ' ' A' ' 100' ' ' VAL . 22.0 Cg_exo -70.52 -101.7 0.01 OUTLIER 'Trans proline' 0 CA--C 1.539 0.746 0 C-N-CA 123.242 2.628 . . . . 0.0 114.991 -173.013 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . 0.48 ' O ' ' HD2' ' A' ' 104' ' ' ARG . 41.0 t -69.82 -27.94 35.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 121.596 0.712 . . . . 0.0 110.452 -171.598 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 101' ' ' CYS . . . . . 0.832 ' SG ' ' HG3' ' A' ' 38' ' ' GLU . 79.1 m -73.07 -32.38 64.97 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-N 115.228 -0.896 . . . . 0.0 111.511 -171.416 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -70.0 -46.18 65.69 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 120.757 0.313 . . . . 0.0 110.953 -179.892 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -62.25 -37.28 84.83 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 121.097 0.475 . . . . 0.0 110.773 179.514 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 104' ' ' ARG . . . . . 0.48 ' HD2' ' O ' ' A' ' 100' ' ' VAL . 0.0 OUTLIER -73.02 -30.47 63.78 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.627 -0.715 . . . . 0.0 111.583 178.566 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 105' ' ' ALA . . . . . 0.632 ' HB1' ' HA ' ' A' ' 30' ' ' ILE . . . -82.17 -21.38 36.57 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.692 -176.997 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 109.39 60.93 0.52 Allowed Glycine 0 CA--C 1.518 0.25 0 C-N-CA 121.011 -0.614 . . . . 0.0 112.158 -178.122 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -66.41 152.67 44.62 Favored 'General case' 0 N--CA 1.45 -0.442 0 C-N-CA 122.642 0.377 . . . . 0.0 111.013 -176.562 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 20.7 mmt180 . . . . . 0 C--O 1.244 0.814 0 CA-C-O 118.404 -0.808 . . . . 0.0 110.959 176.677 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . 0.531 ' O ' HG12 ' A' ' 30' ' ' ILE . 11.2 m-20 . . . . . 0 CA--C 1.504 -0.805 0 CA-C-O 121.364 0.602 . . . . 0.0 110.931 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . 0.703 ' HA3' ' CD1' ' A' ' 83' ' ' ILE . . . -76.05 1.65 58.75 Favored Glycine 0 CA--C 1.498 -0.998 0 N-CA-C 110.715 -0.954 . . . . 0.0 110.715 -179.336 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 19.1 m -76.99 -40.86 45.22 Favored 'General case' 0 C--N 1.322 -0.628 0 N-CA-C 108.497 -0.927 . . . . 0.0 108.497 171.381 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.531 HG12 ' O ' ' A' ' 27' ' ' ASP . 0.7 OUTLIER -67.29 -40.21 84.43 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.457 0 CA-C-N 114.399 -1.273 . . . . 0.0 107.724 175.946 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' TRP . . . . . 0.56 ' HB2' ' HA2' ' A' ' 28' ' ' GLY . 36.5 m95 -67.41 -36.68 81.76 Favored 'General case' 0 C--N 1.318 -0.776 0 CA-C-N 114.17 -1.377 . . . . 0.0 110.378 -177.826 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.427 ' CB ' HH21 ' A' ' 79' ' ' ARG . 4.6 t70 -77.19 -33.34 56.38 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 115.748 -0.66 . . . . 0.0 110.62 -179.5 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . 0.417 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -70.13 -34.07 72.61 Favored 'General case' 0 N--CA 1.447 -0.575 0 C-N-CA 120.506 -0.478 . . . . 0.0 109.977 176.159 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . 0.515 HG13 ' O ' ' A' ' 30' ' ' ILE . 74.2 mt -65.52 -43.45 94.32 Favored 'Isoleucine or valine' 0 C--O 1.234 0.268 0 CA-C-N 116.057 -0.519 . . . . 0.0 109.865 172.23 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . 0.451 ' HA ' ' O ' ' A' ' 54' ' ' GLY . . . -57.57 -37.4 73.09 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.059 175.211 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . 0.4 ' HA2' ' N ' ' A' ' 41' ' ' GLY . . . -70.89 -15.98 74.31 Favored Glycine 0 N--CA 1.449 -0.45 0 CA-C-N 115.27 -0.877 . . . . 0.0 112.181 179.299 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 44.1 t -85.19 -58.87 2.51 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 120.611 0.243 . . . . 0.0 111.186 -177.256 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 8.6 tp10 -89.09 -34.04 16.89 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-O 121.074 0.464 . . . . 0.0 110.877 -172.693 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -97.63 -14.66 20.83 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.029 -0.532 . . . . 0.0 111.511 -175.427 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 86.31 -4.51 85.99 Favored Glycine 0 N--CA 1.448 -0.523 0 N-CA-C 109.847 -1.301 . . . . 0.0 109.847 -174.408 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . 0.4 ' N ' ' HA2' ' A' ' 36' ' ' GLY . . . 102.04 56.06 0.85 Allowed Glycine 0 N--CA 1.435 -1.37 0 CA-C-N 114.213 -0.993 . . . . 0.0 112.058 -179.235 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 43.8 t-20 -144.33 127.25 16.38 Favored 'General case' 0 N--CA 1.44 -0.968 0 N-CA-C 108.263 -1.014 . . . . 0.0 108.263 -179.602 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' TRP . . . . . 0.691 ' HZ3' ' HB2' ' A' ' 82' ' ' GLN . 40.5 m95 -99.28 -13.27 19.74 Favored 'General case' 0 C--N 1.305 -1.351 0 CA-C-N 115.398 -0.819 . . . . 0.0 110.935 -173.385 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -100.53 -6.77 24.94 Favored 'General case' 0 C--N 1.316 -0.881 0 CA-C-N 115.199 -0.909 . . . . 0.0 110.479 -177.889 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 10.0 tt -62.33 141.58 17.67 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.996 0 CA-C-N 115.474 -0.784 . . . . 0.0 109.921 178.556 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 43.3 t-20 -158.73 103.52 1.73 Allowed 'General case' 0 C--N 1.312 -1.025 0 CA-C-O 121.03 0.443 . . . . 0.0 110.112 -177.655 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 11.2 p -82.75 -15.01 53.46 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 115.718 -0.674 . . . . 0.0 111.923 -177.56 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 90.47 25.23 26.4 Favored Glycine 0 N--CA 1.446 -0.662 0 N-CA-C 110.943 -0.863 . . . . 0.0 110.943 -177.743 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 65.0 t30 -83.63 -1.76 54.63 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 121.222 0.534 . . . . 0.0 111.222 -175.352 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . 0.469 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 95.19 -9.34 69.89 Favored Glycine 0 CA--C 1.505 -0.539 0 N-CA-C 110.093 -1.203 . . . . 0.0 110.093 -175.734 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 51' ' ' TYR . . . . . 0.66 ' HA ' ' HA ' ' A' ' 58' ' ' ASP . 0.5 OUTLIER -117.98 158.2 25.36 Favored 'General case' 0 N--CA 1.441 -0.923 0 N-CA-C 106.118 -1.808 . . . . 0.0 106.118 177.998 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 52' ' ' TYR . . . . . 0.73 ' O ' ' HA ' ' A' ' 56' ' ' GLN . 35.1 m-85 -118.41 169.59 9.63 Favored 'General case' 0 C--N 1.303 -1.447 0 C-N-CA 120.222 -0.591 . . . . 0.0 110.851 -172.241 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -65.14 -173.26 3.81 Favored Glycine 0 N--CA 1.448 -0.515 0 C-N-CA 121.173 -0.537 . . . . 0.0 114.362 -170.019 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . 0.599 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 77.39 -104.97 2.01 Favored Glycine 0 N--CA 1.439 -1.157 0 N-CA-C 111.346 -0.702 . . . . 0.0 111.346 -179.635 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.556 HG12 ' HE1' ' A' ' 98' ' ' TRP . 2.2 t -83.41 -1.83 6.25 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 CA-C-O 121.503 0.668 . . . . 0.0 109.676 -179.122 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' GLN . . . . . 0.79 ' HA ' HE21 ' A' ' 56' ' ' GLN . 0.0 OUTLIER 57.34 45.18 20.52 Favored 'General case' 0 N--CA 1.464 0.249 0 CA-C-N 114.541 -1.209 . . . . 0.0 113.444 169.584 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 1.1 p90 -117.89 168.53 10.41 Favored 'General case' 0 C--N 1.328 -0.357 0 C-N-CA 119.582 -0.847 . . . . 0.0 112.035 176.476 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.66 ' HA ' ' HA ' ' A' ' 51' ' ' TYR . 7.5 p-10 -79.33 164.15 24.31 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.141 -0.936 . . . . 0.0 113.419 -164.39 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . 0.703 ' HA ' HE21 ' A' ' 59' ' ' GLN . 0.0 OUTLIER -63.25 -36.63 84.3 Favored 'General case' 0 N--CA 1.449 -0.487 0 CA-C-N 114.101 -1.409 . . . . 0.0 111.578 179.188 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -68.0 -50.33 41.4 Favored Glycine 0 C--N 1.32 -0.324 0 C-N-CA 121.2 -0.524 . . . . 0.0 112.303 -175.703 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 88.5 m -61.7 -42.16 98.56 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 121.157 0.503 . . . . 0.0 110.113 175.689 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 62' ' ' TRP . . . . . 0.591 ' HH2' ' CD ' ' A' ' 81' ' ' GLU . 59.3 t-105 -56.85 -49.68 74.73 Favored 'General case' 0 N--CA 1.447 -0.623 0 CA-C-N 114.985 -1.007 . . . . 0.0 110.209 177.264 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . 0.914 ' HG3' HD11 ' A' ' 68' ' ' LEU . 29.1 tt0 -67.15 -34.38 77.44 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 115.026 -0.988 . . . . 0.0 110.773 -177.18 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -67.91 -41.58 82.45 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.897 -0.592 . . . . 0.0 111.082 -178.44 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . 0.68 ' HB2' HG13 ' A' ' 85' ' ' VAL . 4.8 m120 -71.8 -15.79 62.16 Favored 'General case' 0 C--N 1.332 -0.154 0 CA-C-O 121.349 0.595 . . . . 0.0 109.773 174.99 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 88.32 44.74 5.21 Favored Glycine 0 N--CA 1.446 -0.7 0 CA-C-N 115.208 -0.906 . . . . 0.0 111.752 178.422 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . 0.589 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -78.5 -19.58 73.53 Favored Glycine 0 CA--C 1.5 -0.865 0 C-N-CA 120.612 -0.804 . . . . 0.0 111.123 -173.818 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.914 HD11 ' HG3' ' A' ' 63' ' ' GLU . 11.8 mt -61.32 -24.86 66.74 Favored 'General case' 0 C--N 1.317 -0.807 0 CA-C-N 114.664 -0.768 . . . . 0.0 110.806 -174.667 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 12.1 ptm180 -70.34 -28.61 65.27 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.461 -0.79 . . . . 0.0 109.856 179.664 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 70' ' ' TYR . . . . . 0.589 ' HD2' ' HA2' ' A' ' 67' ' ' GLY . 47.7 m-85 -85.49 -34.47 21.58 Favored 'General case' 0 N--CA 1.439 -1.007 0 N-CA-C 107.143 -1.428 . . . . 0.0 107.143 176.201 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.785 ' HB1' ' HB3' ' A' ' 76' ' ' LEU . . . 170.22 127.27 0.05 OUTLIER Pre-proline 0 C--O 1.217 -0.617 0 CA-C-N 112.729 -2.032 . . . . 0.0 107.712 -178.029 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 72' ' ' PRO . . . . . 0.604 ' HA ' ' HA ' ' A' ' 68' ' ' LEU . 17.2 Cg_exo -58.32 -0.96 0.54 Allowed 'Trans proline' 0 C--N 1.331 -0.39 0 C-N-CA 122.968 2.445 . . . . 0.0 113.8 -179.455 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 73' ' ' ARG . . . . . 0.428 ' HE ' ' CG ' ' A' ' 75' ' ' ASP . 13.4 ptm180 -152.85 143.04 22.43 Favored 'General case' 0 C--N 1.318 -0.799 0 N-CA-C 109.232 -0.655 . . . . 0.0 109.232 174.059 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . 0.593 ' HB3' ' HB2' ' A' ' 52' ' ' TYR . . . -61.7 -25.48 67.44 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.574 -0.739 . . . . 0.0 112.359 -174.381 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . 0.428 ' CG ' ' HE ' ' A' ' 73' ' ' ARG . 17.2 p-10 -89.36 10.91 20.7 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-O 121.049 0.452 . . . . 0.0 111.363 -178.041 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.785 ' HB3' ' HB1' ' A' ' 71' ' ' ALA . 42.0 tp -104.29 -42.71 5.42 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.345 177.207 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . 0.718 ' HB3' ' OE2' ' A' ' 81' ' ' GLU . . . -100.73 170.47 8.32 Favored 'General case' 0 N--CA 1.45 -0.473 0 CA-C-O 121.136 0.493 . . . . 0.0 109.932 177.826 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . 0.552 ' OG1' ' HG2' ' A' ' 80' ' ' GLU . 41.3 p -85.06 168.71 14.63 Favored 'General case' 0 C--N 1.312 -1.063 0 N-CA-C 113.2 0.815 . . . . 0.0 113.2 -167.775 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . 0.614 ' HA ' ' CE3' ' A' ' 43' ' ' TRP . 7.1 ptm180 -47.4 -36.09 9.29 Favored 'General case' 0 N--CA 1.466 0.352 0 C-N-CA 122.724 0.41 . . . . 0.0 112.087 -175.238 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 80' ' ' GLU . . . . . 0.917 ' HA ' HD12 ' A' ' 83' ' ' ILE . 16.1 pt-20 -62.36 -31.22 71.83 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.407 -178.556 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 81' ' ' GLU . . . . . 0.718 ' OE2' ' HB3' ' A' ' 77' ' ' ALA . 0.0 OUTLIER -72.53 -48.86 36.99 Favored 'General case' 0 N--CA 1.428 -1.545 0 N-CA-C 110.075 -0.343 . . . . 0.0 110.075 177.163 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 82' ' ' GLN . . . . . 0.691 ' HB2' ' HZ3' ' A' ' 43' ' ' TRP . 67.1 mt-30 -59.82 -31.8 70.06 Favored 'General case' 0 CA--C 1.511 -0.521 0 C-N-CA 120.874 -0.331 . . . . 0.0 110.225 178.245 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.917 HD12 ' HA ' ' A' ' 80' ' ' GLU . 79.7 mt -59.32 -51.5 71.92 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.782 0 CA-C-N 115.892 -0.594 . . . . 0.0 109.626 173.328 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 84' ' ' ALA . . . . . 0.48 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -62.36 -44.42 96.51 Favored 'General case' 0 C--O 1.238 0.459 0 CA-C-O 121.635 0.731 . . . . 0.0 111.285 -175.081 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.68 HG13 ' HB2' ' A' ' 65' ' ' ASN . 48.9 t -67.97 -49.17 71.0 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.635 0 CA-C-N 115.388 -0.823 . . . . 0.0 111.107 -177.876 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -60.61 -29.7 69.38 Favored 'General case' 0 N--CA 1.451 -0.416 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.175 175.581 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 87' ' ' GLU . . . . . 0.774 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 28.7 mt-10 -60.31 -42.86 96.46 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.59 179.885 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.427 ' O ' ' HG3' ' A' ' 92' ' ' ARG . 75.6 t -60.67 -50.0 82.22 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.284 0 C-N-CA 120.37 -0.532 . . . . 0.0 110.189 178.943 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . 0.705 HG22 ' NE2' ' A' ' 93' ' ' GLN . 97.0 m -64.11 -38.82 92.45 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-N 115.524 -0.762 . . . . 0.0 111.252 -178.442 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 90' ' ' ARG . . . . . 0.664 HH11 ' HG2' ' A' ' 87' ' ' GLU . 1.4 ptt180 -60.52 -35.88 77.04 Favored 'General case' 0 N--CA 1.464 0.258 0 CA-C-N 116.613 -0.267 . . . . 0.0 111.387 -179.674 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 91' ' ' LEU . . . . . 0.774 ' HG ' ' O ' ' A' ' 87' ' ' GLU . 32.1 mt -64.18 -29.02 70.16 Favored 'General case' 0 N--CA 1.47 0.534 0 CA-C-O 121.708 0.766 . . . . 0.0 110.15 -174.821 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . 0.625 ' NH2' HG23 ' A' ' 89' ' ' THR . 9.8 mtm180 -87.65 -43.89 11.61 Favored 'General case' 0 C--N 1.314 -0.956 0 CA-C-N 114.541 -1.209 . . . . 0.0 110.516 -169.573 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 93' ' ' GLN . . . . . 0.705 ' NE2' HG22 ' A' ' 89' ' ' THR . 0.0 OUTLIER -105.79 -17.74 14.28 Favored 'General case' 0 CA--C 1.545 0.769 0 N-CA-C 113.956 1.095 . . . . 0.0 113.956 -173.965 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 79.86 44.34 9.23 Favored Glycine 0 C--N 1.335 0.513 0 C-N-CA 121.312 -0.47 . . . . 0.0 112.983 171.929 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 95' ' ' TRP . . . . . 0.4 ' CZ2' ' HD2' ' A' ' 90' ' ' ARG . 13.4 m95 61.62 19.94 10.87 Favored 'General case' 0 C--O 1.223 -0.338 0 C-N-CA 123.483 0.713 . . . . 0.0 109.618 -179.059 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.421 ' H ' ' HG2' ' A' ' 93' ' ' GLN . . . -77.42 -32.98 45.23 Favored Glycine 0 N--CA 1.453 -0.189 0 CA-C-N 115.381 -0.827 . . . . 0.0 112.385 176.348 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . 0.428 ' H ' ' CG ' ' A' ' 93' ' ' GLN . . . -72.66 -24.85 61.09 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 121.338 0.589 . . . . 0.0 109.781 178.953 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 98' ' ' TRP . . . . . 0.556 ' HE1' HG12 ' A' ' 55' ' ' VAL . 25.0 m-90 -95.33 108.22 37.69 Favored Pre-proline 0 N--CA 1.441 -0.88 0 N-CA-C 108.358 -0.979 . . . . 0.0 108.358 175.001 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 45.4 Cg_exo -64.14 -141.76 0.01 OUTLIER 'Trans proline' 0 CA--C 1.532 0.394 0 C-N-CA 123.466 2.777 . . . . 0.0 113.906 -174.189 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 4.3 t -56.21 -21.79 12.67 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.425 0 CA-C-O 120.928 0.394 . . . . 0.0 111.176 -175.542 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 77.5 m -56.87 -39.18 73.86 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-N 116.573 -0.285 . . . . 0.0 111.04 175.09 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -71.27 -37.96 71.88 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-O 120.905 0.383 . . . . 0.0 110.351 177.572 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -61.19 -41.64 97.18 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.638 177.44 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -67.59 -30.29 69.86 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.833 -0.621 . . . . 0.0 111.131 175.531 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 105' ' ' ALA . . . . . 0.417 ' CB ' ' HB3' ' A' ' 33' ' ' ALA . . . -86.28 -22.8 26.6 Favored 'General case' 0 C--N 1.326 -0.428 0 N-CA-C 112.709 0.633 . . . . 0.0 112.709 -172.812 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 104.16 65.74 0.7 Allowed Glycine 0 CA--C 1.521 0.447 0 C-N-CA 120.795 -0.716 . . . . 0.0 112.5 -178.182 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -70.28 148.59 48.36 Favored 'General case' 0 C--N 1.324 -0.525 0 C-N-CA 122.905 0.482 . . . . 0.0 110.773 -176.699 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 108' ' ' ARG . . . . . 0.431 ' O ' ' HD3' ' A' ' 108' ' ' ARG . 0.0 OUTLIER . . . . . 0 C--O 1.247 0.96 0 CA-C-O 119.069 -0.491 . . . . 0.0 111.181 -174.505 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . 0.445 ' O ' HG12 ' A' ' 30' ' ' ILE . 6.3 m-20 . . . . . 0 CA--C 1.503 -0.83 0 CA-C-O 121.548 0.69 . . . . 0.0 109.833 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . 0.622 ' HA3' HD13 ' A' ' 83' ' ' ILE . . . -63.51 -9.05 29.4 Favored Glycine 0 N--CA 1.436 -1.343 0 CA-C-N 114.909 -1.041 . . . . 0.0 110.905 174.506 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 8.4 m -71.34 -44.25 65.44 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-O 121.681 0.753 . . . . 0.0 109.293 175.195 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.505 ' O ' HG13 ' A' ' 34' ' ' ILE . 0.4 OUTLIER -69.15 -39.45 79.37 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.604 0 CA-C-N 114.576 -1.193 . . . . 0.0 107.881 178.533 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' TRP . . . . . 0.774 ' CD1' HG23 ' A' ' 83' ' ' ILE . 39.5 m95 -67.95 -35.93 79.24 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 114.493 -1.231 . . . . 0.0 110.528 -177.15 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.432 ' CG ' HH21 ' A' ' 79' ' ' ARG . 3.9 t70 -71.23 -42.25 69.12 Favored 'General case' 0 N--CA 1.447 -0.621 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.256 177.665 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . 0.424 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -67.33 -33.77 75.95 Favored 'General case' 0 N--CA 1.446 -0.662 0 CA-C-N 116.44 -0.345 . . . . 0.0 110.511 -179.665 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . 0.505 HG13 ' O ' ' A' ' 30' ' ' ILE . 65.7 mt -64.41 -46.14 93.82 Favored 'Isoleucine or valine' 0 C--O 1.234 0.255 0 CA-C-O 121.046 0.45 . . . . 0.0 109.865 172.457 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . 0.486 ' HA ' ' NE2' ' A' ' 56' ' ' GLN . . . -57.99 -38.85 76.86 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.133 176.065 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . 0.412 ' HA2' ' N ' ' A' ' 41' ' ' GLY . . . -65.44 -28.83 74.01 Favored Glycine 0 N--CA 1.451 -0.329 0 CA-C-N 115.588 -0.733 . . . . 0.0 111.97 179.248 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 6.7 t -76.25 -64.49 1.09 Allowed 'General case' 0 C--N 1.318 -0.764 0 N-CA-C 111.926 0.343 . . . . 0.0 111.926 -178.823 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . 0.51 ' HB3' ' CD ' ' A' ' 56' ' ' GLN . 11.2 tp10 -88.19 -31.79 18.93 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 121.062 0.458 . . . . 0.0 110.692 -168.939 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -96.89 -9.15 29.11 Favored 'General case' 0 N--CA 1.45 -0.436 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.764 -175.348 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 78.57 16.66 78.96 Favored Glycine 0 CA--C 1.503 -0.685 0 N-CA-C 109.848 -1.301 . . . . 0.0 109.848 -177.929 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . 0.412 ' N ' ' HA2' ' A' ' 36' ' ' GLY . . . 69.19 59.69 5.67 Favored Glycine 0 N--CA 1.432 -1.606 0 CA-C-N 113.992 -1.104 . . . . 0.0 111.928 -177.179 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 62.2 t30 -147.12 122.17 10.09 Favored 'General case' 0 CA--C 1.505 -0.77 0 N-CA-C 109.134 -0.691 . . . . 0.0 109.134 179.346 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 43' ' ' TRP . . . . . 0.705 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 33.9 m95 -97.5 -6.25 34.1 Favored 'General case' 0 C--N 1.306 -1.315 0 CA-C-N 114.956 -1.02 . . . . 0.0 109.935 -173.168 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -110.51 9.93 23.17 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-N 114.907 -1.042 . . . . 0.0 111.183 -179.073 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.767 HG22 ' HA2' ' A' ' 53' ' ' GLY . 3.2 tt -71.09 143.21 14.66 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.615 0 N-CA-C 109.477 -0.564 . . . . 0.0 109.477 179.099 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 45.0 t-20 -165.2 96.05 0.68 Allowed 'General case' 0 C--N 1.312 -1.041 0 CA-C-O 121.047 0.451 . . . . 0.0 110.132 -176.577 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 17.8 p -82.32 -12.06 58.22 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.392 179.832 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 89.29 22.15 38.8 Favored Glycine 0 N--CA 1.446 -0.697 0 N-CA-C 111.275 -0.73 . . . . 0.0 111.275 178.985 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 8.6 p30 -88.36 5.86 40.05 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 121.03 0.443 . . . . 0.0 110.99 -176.031 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . 0.49 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 95.77 -12.22 67.53 Favored Glycine 0 N--CA 1.448 -0.536 0 CA-C-N 115.913 -0.585 . . . . 0.0 112.117 -178.234 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 51' ' ' TYR . . . . . 0.597 ' HA ' ' HA ' ' A' ' 58' ' ' ASP . 0.1 OUTLIER -112.99 161.29 17.2 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 108.026 -1.102 . . . . 0.0 108.026 173.494 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 52' ' ' TYR . . . . . 0.479 ' HB2' ' HB3' ' A' ' 74' ' ' ALA . 42.7 m-85 -125.62 170.26 11.67 Favored 'General case' 0 C--N 1.313 -0.982 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.686 -170.752 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.767 ' HA2' HG22 ' A' ' 45' ' ' ILE . . . -70.36 -172.59 11.31 Favored Glycine 0 N--CA 1.446 -0.678 0 CA-C-N 116.177 -0.465 . . . . 0.0 114.23 -171.69 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . 0.638 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 81.91 -111.03 3.27 Favored Glycine 0 N--CA 1.443 -0.888 0 C-N-CA 121.011 -0.614 . . . . 0.0 111.76 -179.154 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.54 ' HB ' ' CE2' ' A' ' 57' ' ' PHE . 1.8 t -91.69 19.96 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-O 121.183 0.516 . . . . 0.0 110.53 -178.488 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 56' ' ' GLN . . . . . 0.51 ' CD ' ' HB3' ' A' ' 38' ' ' GLU . 7.0 mp0 59.51 50.31 7.6 Favored 'General case' 0 N--CA 1.47 0.547 0 CA-C-N 115.168 -0.924 . . . . 0.0 111.704 171.496 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . 0.54 ' CE2' ' HB ' ' A' ' 55' ' ' VAL . 57.3 m-85 -81.45 138.07 35.57 Favored 'General case' 0 CA--C 1.504 -0.804 0 CA-C-N 115.77 -0.65 . . . . 0.0 112.266 178.345 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.597 ' HA ' ' HA ' ' A' ' 51' ' ' TYR . 7.9 p-10 -79.45 155.96 28.08 Favored 'General case' 0 C--N 1.313 -1.003 0 N-CA-C 108.535 -0.913 . . . . 0.0 108.535 163.631 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . 0.406 ' HB2' ' HE1' ' A' ' 52' ' ' TYR . 19.0 tp60 -54.63 -36.47 64.56 Favored 'General case' 0 N--CA 1.445 -0.701 0 CA-C-O 121.188 0.518 . . . . 0.0 110.352 -179.026 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -68.51 -50.5 37.13 Favored Glycine 0 C--O 1.225 -0.428 0 CA-C-N 114.795 -1.093 . . . . 0.0 113.041 -173.557 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 99.1 m -67.51 -40.32 85.12 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 121.082 0.468 . . . . 0.0 110.299 -179.197 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 62' ' ' TRP . . . . . 0.518 ' CZ3' ' HA ' ' A' ' 82' ' ' GLN . 53.5 t-105 -57.82 -48.72 78.93 Favored 'General case' 0 N--CA 1.443 -0.789 0 CA-C-N 115.468 -0.787 . . . . 0.0 109.367 176.586 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . 0.504 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 44.9 tt0 -67.93 -33.97 75.71 Favored 'General case' 0 N--CA 1.444 -0.738 0 CA-C-N 115.07 -0.968 . . . . 0.0 110.695 -179.431 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -63.09 -41.49 99.42 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.839 -178.75 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . 0.667 ' HB2' HG13 ' A' ' 85' ' ' VAL . 7.5 m120 -73.92 -19.55 60.66 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 121.438 0.637 . . . . 0.0 110.054 176.41 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . 0.609 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 90.13 45.72 4.36 Favored Glycine 0 N--CA 1.446 -0.674 0 CA-C-N 115.148 -0.933 . . . . 0.0 111.534 -178.55 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . 0.73 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -78.59 -15.7 80.42 Favored Glycine 0 N--CA 1.445 -0.744 0 C-N-CA 120.998 -0.62 . . . . 0.0 112.359 -172.806 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.841 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 7.1 mp -60.27 -27.54 67.34 Favored 'General case' 0 C--N 1.316 -0.865 0 N-CA-C 112.875 0.694 . . . . 0.0 112.875 -175.918 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . 0.609 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 17.1 ptm180 -65.25 -32.44 74.1 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 121.602 0.715 . . . . 0.0 109.748 175.545 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 70' ' ' TYR . . . . . 0.73 ' HD2' ' HA2' ' A' ' 67' ' ' GLY . 93.1 m-85 -77.78 -34.55 52.23 Favored 'General case' 0 N--CA 1.439 -0.988 0 N-CA-C 107.877 -1.157 . . . . 0.0 107.877 177.388 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.683 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 160.42 129.56 0.0 OUTLIER Pre-proline 0 CA--C 1.513 -0.48 0 CA-C-N 112.21 -2.268 . . . . 0.0 106.738 179.308 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 72' ' ' PRO . . . . . 0.841 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 17.4 Cg_exo -58.18 -4.12 1.49 Allowed 'Trans proline' 0 CA--C 1.53 0.278 0 C-N-CA 122.582 2.188 . . . . 0.0 113.506 -176.919 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 13.2 ptm180 -145.29 136.29 24.72 Favored 'General case' 0 C--N 1.321 -0.647 0 N-CA-C 108.99 -0.745 . . . . 0.0 108.99 175.801 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . 0.479 ' HB3' ' HB2' ' A' ' 52' ' ' TYR . . . -55.87 -30.7 61.92 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 114.873 -1.058 . . . . 0.0 112.772 -177.763 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . 0.442 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 20.8 p-10 -88.27 9.55 22.74 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 120.907 0.384 . . . . 0.0 111.362 -176.314 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 60.7 tp -109.98 -33.14 6.79 Favored 'General case' 0 C--N 1.323 -0.56 0 N-CA-C 108.783 -0.821 . . . . 0.0 108.783 170.246 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . 0.683 ' HB2' ' HB3' ' A' ' 71' ' ' ALA . . . -79.85 163.17 24.59 Favored 'General case' 0 N--CA 1.444 -0.759 0 CA-C-N 115.061 -0.972 . . . . 0.0 109.272 174.143 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 32.0 p -99.39 -173.91 2.6 Favored 'General case' 0 C--N 1.315 -0.927 0 C-N-CA 120.799 -0.36 . . . . 0.0 110.385 -178.497 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . 0.705 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 20.7 mtp180 -51.0 -54.34 25.39 Favored 'General case' 0 C--O 1.22 -0.452 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.99 -177.378 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 80' ' ' GLU . . . . . 0.456 ' HG3' ' OE2' ' A' ' 81' ' ' GLU . 9.0 pt-20 -61.41 -41.42 97.12 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.829 -172.683 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 81' ' ' GLU . . . . . 0.7 ' HB3' ' HB3' ' A' ' 70' ' ' TYR . 3.6 mp0 -59.24 -51.77 68.53 Favored 'General case' 0 C--N 1.323 -0.551 0 N-CA-C 112.016 0.376 . . . . 0.0 112.016 172.74 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 82' ' ' GLN . . . . . 0.518 ' HA ' ' CZ3' ' A' ' 62' ' ' TRP . 34.8 mt-30 -59.67 -39.07 83.25 Favored 'General case' 0 CA--C 1.51 -0.561 0 CA-C-O 121.719 0.771 . . . . 0.0 109.681 179.903 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.774 HG23 ' CD1' ' A' ' 31' ' ' TRP . 34.8 mt -60.85 -44.42 97.66 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.903 0 CA-C-N 114.112 -1.404 . . . . 0.0 110.61 179.557 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 84' ' ' ALA . . . . . 0.606 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -66.34 -35.76 81.18 Favored 'General case' 0 C--O 1.236 0.37 0 CA-C-O 121.559 0.695 . . . . 0.0 110.939 -178.613 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.667 HG13 ' HB2' ' A' ' 65' ' ' ASN . 57.4 t -66.15 -48.18 82.25 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.65 0 CA-C-N 115.595 -0.73 . . . . 0.0 110.082 174.672 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -58.76 -30.65 67.68 Favored 'General case' 0 CA--C 1.518 -0.284 0 CA-C-N 115.766 -0.652 . . . . 0.0 110.567 173.551 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 87' ' ' GLU . . . . . 0.673 ' HG2' ' O ' ' A' ' 83' ' ' ILE . 30.9 mm-40 -59.06 -43.32 91.7 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.735 -0.666 . . . . 0.0 110.368 179.754 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.515 ' O ' ' HG3' ' A' ' 92' ' ' ARG . 91.1 t -62.9 -49.49 83.42 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-O 120.851 0.357 . . . . 0.0 110.446 177.901 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . 0.609 HG22 ' NE2' ' A' ' 93' ' ' GLN . 23.8 m -66.17 -42.16 89.31 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.936 -0.574 . . . . 0.0 111.312 -176.479 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 90' ' ' ARG . . . . . 0.646 ' HA ' ' OE1' ' A' ' 93' ' ' GLN . 8.1 ptt180 -69.17 -32.76 72.3 Favored 'General case' 0 CA--C 1.515 -0.392 0 CA-C-O 121.729 0.776 . . . . 0.0 109.435 -179.255 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 91' ' ' LEU . . . . . 0.46 ' HB2' ' O ' ' A' ' 87' ' ' GLU . 49.4 tp -57.14 -27.44 61.85 Favored 'General case' 0 C--N 1.315 -0.92 0 CA-C-N 114.762 -1.108 . . . . 0.0 111.09 -179.179 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . 0.535 ' NH2' HG23 ' A' ' 89' ' ' THR . 6.7 mtm180 -92.14 -50.97 5.41 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 115.407 -0.815 . . . . 0.0 110.581 -175.846 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 93' ' ' GLN . . . . . 0.646 ' OE1' ' HA ' ' A' ' 90' ' ' ARG . 0.0 OUTLIER -104.93 -15.1 15.24 Favored 'General case' 0 CA--C 1.539 0.531 0 N-CA-C 113.44 0.904 . . . . 0.0 113.44 -170.151 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . 0.484 ' O ' ' HB2' ' A' ' 90' ' ' ARG . . . 101.32 -97.55 1.67 Allowed Glycine 0 CA--C 1.498 -0.996 0 N-CA-C 110.096 -1.202 . . . . 0.0 110.096 -179.631 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 95' ' ' TRP . . . . . . . . . . . . . 25.3 m95 -145.89 19.45 1.45 Allowed 'General case' 0 C--N 1.315 -0.895 0 N-CA-C 106.246 -1.761 . . . . 0.0 106.246 171.867 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -66.03 -26.59 72.4 Favored Glycine 0 N--CA 1.451 -0.325 0 CA-C-N 114.581 -1.191 . . . . 0.0 112.833 -177.181 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -81.36 -15.19 56.04 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 121.272 0.558 . . . . 0.0 109.966 177.341 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 98' ' ' TRP . . . . . 0.594 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 28.3 m-90 -106.7 107.95 61.09 Favored Pre-proline 0 N--CA 1.445 -0.685 0 CA-C-N 115.472 -0.785 . . . . 0.0 109.42 177.657 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 99' ' ' PRO . . . . . 0.452 ' HD3' ' HA ' ' A' ' 98' ' ' TRP . 50.6 Cg_exo -61.99 -138.17 0.0 OUTLIER 'Trans proline' 0 CA--C 1.534 0.495 0 C-N-CA 123.876 3.051 . . . . 0.0 114.1 -174.628 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 15.0 m -54.97 -26.49 17.62 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.292 0 CA-C-O 121.166 0.507 . . . . 0.0 111.731 -176.468 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 101' ' ' CYS . . . . . 0.446 ' SG ' ' HB2' ' A' ' 38' ' ' GLU . 83.0 m -56.38 -35.3 67.56 Favored 'General case' 0 C--N 1.313 -0.985 0 CA-C-N 115.195 -0.911 . . . . 0.0 111.553 177.72 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -70.88 -45.83 63.68 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.768 0.318 . . . . 0.0 110.934 178.479 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -59.46 -42.69 92.57 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 121.086 0.469 . . . . 0.0 110.621 177.256 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 49.3 mtp180 -67.14 -19.46 65.61 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.348 -0.842 . . . . 0.0 111.14 178.199 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 105' ' ' ALA . . . . . 0.424 ' CB ' ' HB3' ' A' ' 33' ' ' ALA . . . -96.43 -20.39 18.47 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.938 -0.573 . . . . 0.0 112.109 -176.489 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 102.29 55.28 0.86 Allowed Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.887 -0.673 . . . . 0.0 111.802 -175.996 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -57.58 149.74 20.74 Favored 'General case' 0 C--N 1.329 -0.29 0 C-N-CA 123.224 0.61 . . . . 0.0 111.352 -179.639 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 28.0 mtp180 . . . . . 0 C--O 1.25 1.118 0 CA-C-O 118.317 -0.849 . . . . 0.0 109.49 -171.547 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . 0.525 ' HB2' ' OE1' ' A' ' 87' ' ' GLU . 31.1 m-20 . . . . . 0 CA--C 1.511 -0.556 0 CA-C-O 121.059 0.457 . . . . 0.0 110.286 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . 0.583 ' HA2' ' HD1' ' A' ' 31' ' ' TRP . . . -60.55 -14.07 33.67 Favored Glycine 0 N--CA 1.448 -0.516 0 CA-C-N 115.631 -0.713 . . . . 0.0 111.683 -177.816 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 3.6 m -76.65 -41.9 44.04 Favored 'General case' 0 C--N 1.318 -0.772 0 CA-C-O 121.901 0.857 . . . . 0.0 109.576 178.263 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.525 ' O ' HG13 ' A' ' 34' ' ' ILE . 0.5 OUTLIER -66.95 -38.21 80.93 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.696 0 CA-C-N 114.263 -1.335 . . . . 0.0 107.891 -179.66 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' TRP . . . . . 0.583 ' HD1' ' HA2' ' A' ' 28' ' ' GLY . 38.2 m95 -66.33 -35.99 81.77 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 114.852 -1.067 . . . . 0.0 110.519 -177.215 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 5.4 t0 -70.1 -42.88 72.12 Favored 'General case' 0 N--CA 1.442 -0.86 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.138 178.621 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . 0.426 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -69.35 -34.22 74.28 Favored 'General case' 0 N--CA 1.445 -0.704 0 C-N-CA 120.39 -0.524 . . . . 0.0 110.683 179.457 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . 0.525 HG13 ' O ' ' A' ' 30' ' ' ILE . 51.9 mt -62.61 -43.65 98.69 Favored 'Isoleucine or valine' 0 C--O 1.235 0.295 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.429 174.692 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . 0.541 ' HA ' ' O ' ' A' ' 54' ' ' GLY . . . -61.84 -34.94 76.88 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.285 176.349 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . 0.433 ' HA2' ' N ' ' A' ' 41' ' ' GLY . . . -72.46 -16.9 77.51 Favored Glycine 0 N--CA 1.451 -0.328 0 CA-C-N 115.503 -0.771 . . . . 0.0 111.902 179.332 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 7.1 t -81.62 -61.88 1.8 Allowed 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.575 -0.313 . . . . 0.0 111.78 -177.388 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 14.0 tp10 -88.76 -33.73 17.37 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-O 121.109 0.48 . . . . 0.0 110.714 -172.641 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -99.13 -10.53 22.4 Favored 'General case' 0 N--CA 1.446 -0.626 0 CA-C-N 115.986 -0.552 . . . . 0.0 111.797 -173.817 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 75.13 15.9 80.87 Favored Glycine 0 N--CA 1.448 -0.522 0 N-CA-C 109.666 -1.374 . . . . 0.0 109.666 -177.041 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . 0.433 ' N ' ' HA2' ' A' ' 36' ' ' GLY . . . 79.18 61.73 2.31 Favored Glycine 0 N--CA 1.434 -1.478 0 CA-C-N 114.045 -1.077 . . . . 0.0 111.465 -174.64 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 2.4 t-20 -142.91 95.63 2.8 Favored 'General case' 0 C--N 1.323 -0.581 0 N-CA-C 108.799 -0.815 . . . . 0.0 108.799 -179.46 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 43' ' ' TRP . . . . . 0.764 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 18.2 m95 -78.29 -3.23 41.87 Favored 'General case' 0 C--N 1.314 -0.944 0 CA-C-N 115.413 -0.812 . . . . 0.0 110.122 -174.269 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -112.58 14.21 20.11 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.273 -0.876 . . . . 0.0 111.7 -179.111 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.949 HG22 ' HA2' ' A' ' 53' ' ' GLY . 2.9 tt -75.61 145.08 11.2 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.45 0 CA-C-O 121.24 0.543 . . . . 0.0 110.214 179.435 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 14.1 t-20 -146.88 87.62 1.7 Allowed 'General case' 0 C--N 1.312 -1.028 0 N-CA-C 109.649 -0.5 . . . . 0.0 109.649 179.188 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 22.4 p -68.6 -28.16 66.68 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.657 -0.701 . . . . 0.0 110.268 179.72 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 100.01 18.09 23.34 Favored Glycine 0 N--CA 1.444 -0.785 0 CA-C-N 115.382 -0.827 . . . . 0.0 111.162 179.474 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 32.9 p-10 -92.85 10.63 30.24 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 120.878 0.37 . . . . 0.0 111.419 -175.147 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . 0.525 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 90.51 -11.66 70.78 Favored Glycine 0 N--CA 1.449 -0.433 0 N-CA-C 111.707 -0.557 . . . . 0.0 111.707 179.715 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 51' ' ' TYR . . . . . 0.581 ' CE1' ' HB3' ' A' ' 58' ' ' ASP . 0.6 OUTLIER -111.9 162.07 15.72 Favored 'General case' 0 N--CA 1.446 -0.644 0 N-CA-C 106.541 -1.652 . . . . 0.0 106.541 177.671 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 52' ' ' TYR . . . . . 0.749 ' HB2' ' HB3' ' A' ' 74' ' ' ALA . 39.3 m-85 -125.85 169.68 12.38 Favored 'General case' 0 C--N 1.31 -1.114 0 C-N-CA 119.82 -0.752 . . . . 0.0 112.028 -168.313 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.949 ' HA2' HG22 ' A' ' 45' ' ' ILE . . . -60.52 160.04 24.59 Favored Glycine 0 CA--C 1.5 -0.893 0 CA-C-N 115.121 -0.945 . . . . 0.0 113.54 -175.045 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . 0.629 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 92.15 -109.55 3.77 Favored Glycine 0 N--CA 1.437 -1.267 0 C-N-CA 120.515 -0.85 . . . . 0.0 111.615 -177.751 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.581 HG12 ' NE1' ' A' ' 98' ' ' TRP . 3.9 t -87.15 13.18 1.03 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-O 121.378 0.609 . . . . 0.0 110.466 -174.266 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 56' ' ' GLN . . . . . 0.478 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 0.0 OUTLIER 51.07 33.85 9.88 Favored 'General case' 0 N--CA 1.473 0.689 0 N-CA-C 114.454 1.279 . . . . 0.0 114.454 164.975 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 4.7 p90 -113.77 168.95 9.35 Favored 'General case' 0 C--N 1.325 -0.475 0 C-N-CA 119.348 -0.941 . . . . 0.0 112.169 178.593 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.581 ' HB3' ' CE1' ' A' ' 51' ' ' TYR . 5.5 p-10 -83.83 164.53 19.44 Favored 'General case' 0 CA--C 1.517 -0.311 0 N-CA-C 113.887 1.069 . . . . 0.0 113.887 -163.379 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . 0.421 ' HB2' ' HE1' ' A' ' 52' ' ' TYR . 5.2 tp-100 -63.38 -39.58 94.92 Favored 'General case' 0 N--CA 1.449 -0.481 0 CA-C-N 113.553 -1.658 . . . . 0.0 111.969 179.695 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -65.52 -48.03 72.25 Favored Glycine 0 C--N 1.317 -0.504 0 C-N-CA 121.124 -0.56 . . . . 0.0 111.991 -176.217 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 98.4 m -64.85 -42.05 95.21 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-O 120.936 0.398 . . . . 0.0 110.85 176.052 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 62' ' ' TRP . . . . . 0.437 ' CH2' ' HA ' ' A' ' 82' ' ' GLN . 53.4 t-105 -56.91 -49.76 74.6 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 121.733 0.778 . . . . 0.0 109.871 176.764 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . 0.522 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 1.8 tm-20 -67.68 -33.48 75.0 Favored 'General case' 0 C--N 1.318 -0.802 0 CA-C-N 114.677 -1.147 . . . . 0.0 110.656 -178.246 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -66.86 -40.8 87.98 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.923 -179.581 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . 0.405 HD21 ' NH1' ' A' ' 92' ' ' ARG . 8.2 m120 -82.93 -1.78 53.22 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 121.056 0.455 . . . . 0.0 110.328 177.163 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 80.17 48.93 6.18 Favored Glycine 0 C--N 1.334 0.446 0 CA-C-N 115.6 -0.727 . . . . 0.0 112.413 173.686 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . 0.545 ' HA2' ' HD1' ' A' ' 70' ' ' TYR . . . -80.25 -18.71 71.01 Favored Glycine 0 N--CA 1.442 -0.953 0 C-N-CA 120.828 -0.701 . . . . 0.0 112.959 -176.338 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.729 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 6.5 mp -60.84 -28.47 68.85 Favored 'General case' 0 C--N 1.322 -0.616 0 N-CA-C 112.379 0.511 . . . . 0.0 112.379 -172.364 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 16.3 ptm180 -67.85 -28.79 67.85 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 121.457 0.646 . . . . 0.0 110.188 176.206 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 70' ' ' TYR . . . . . 0.627 ' HB3' ' HG3' ' A' ' 81' ' ' GLU . 86.4 m-85 -79.4 -34.11 42.12 Favored 'General case' 0 N--CA 1.442 -0.838 0 N-CA-C 107.419 -1.326 . . . . 0.0 107.419 175.708 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.68 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 159.13 128.39 0.0 OUTLIER Pre-proline 0 CA--C 1.51 -0.589 0 CA-C-N 112.473 -2.149 . . . . 0.0 106.539 -179.474 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 72' ' ' PRO . . . . . 0.729 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 23.3 Cg_exo -55.64 -6.08 0.94 Allowed 'Trans proline' 0 CA--C 1.527 0.166 0 C-N-CA 122.829 2.353 . . . . 0.0 113.808 -176.824 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 12.8 ptm180 -146.84 138.49 24.38 Favored 'General case' 0 C--N 1.322 -0.597 0 N-CA-C 109.521 -0.548 . . . . 0.0 109.521 177.927 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . 0.749 ' HB3' ' HB2' ' A' ' 52' ' ' TYR . . . -61.7 -23.0 65.82 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 113.052 0.76 . . . . 0.0 113.052 -176.168 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . 0.677 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 5.5 p-10 -84.86 -7.68 59.08 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 121.191 0.52 . . . . 0.0 110.65 -179.051 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 54.6 tp -97.68 -31.47 12.25 Favored 'General case' 0 C--N 1.322 -0.623 0 N-CA-C 109.249 -0.648 . . . . 0.0 109.249 173.591 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . 0.727 ' HB1' ' HB3' ' A' ' 81' ' ' GLU . . . -78.55 155.22 29.82 Favored 'General case' 0 N--CA 1.444 -0.757 0 CA-C-N 115.267 -0.879 . . . . 0.0 109.562 176.277 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 48.0 p -97.86 -173.9 2.74 Favored 'General case' 0 C--N 1.311 -1.093 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.539 -176.766 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . 0.764 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 2.1 mtp180 -51.44 -53.62 35.19 Favored 'General case' 0 C--O 1.219 -0.518 0 O-C-N 123.184 0.302 . . . . 0.0 111.073 -178.044 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 80' ' ' GLU . . . . . 0.411 ' HG2' ' H ' ' A' ' 81' ' ' GLU . 1.6 pm0 -62.47 -45.47 92.89 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-O 120.949 0.404 . . . . 0.0 111.6 -176.5 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 81' ' ' GLU . . . . . 0.727 ' HB3' ' HB1' ' A' ' 77' ' ' ALA . 0.4 OUTLIER -60.88 -52.3 65.66 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 121.204 0.526 . . . . 0.0 112.332 178.194 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 82' ' ' GLN . . . . . 0.513 ' HG2' HG23 ' A' ' 55' ' ' VAL . 6.0 tt0 -69.84 -33.94 72.97 Favored 'General case' 0 C--N 1.316 -0.876 0 CA-C-N 115.449 -0.796 . . . . 0.0 110.735 -175.305 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.568 ' O ' ' HG2' ' A' ' 87' ' ' GLU . 24.3 mt -60.52 -43.18 93.82 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.638 0 CA-C-N 115.535 -0.757 . . . . 0.0 109.905 174.155 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 84' ' ' ALA . . . . . 0.579 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -64.51 -39.29 93.51 Favored 'General case' 0 C--O 1.237 0.411 0 CA-C-O 121.421 0.629 . . . . 0.0 111.076 -174.867 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 51.5 t -68.29 -49.28 68.2 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 CA-C-N 115.645 -0.707 . . . . 0.0 111.162 177.761 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -58.69 -29.82 66.93 Favored 'General case' 0 C--O 1.234 0.267 0 CA-C-O 120.955 0.407 . . . . 0.0 110.532 174.232 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 87' ' ' GLU . . . . . 0.724 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 8.8 mm-40 -59.36 -44.42 92.69 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.467 -0.788 . . . . 0.0 109.766 179.279 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.442 ' O ' ' HG3' ' A' ' 92' ' ' ARG . 70.4 t -62.03 -46.26 96.89 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.209 0 CA-C-O 120.933 0.397 . . . . 0.0 109.938 176.473 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . 0.938 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 0.2 OUTLIER -60.03 -48.61 81.02 Favored 'General case' 0 N--CA 1.447 -0.59 0 CA-C-N 115.67 -0.695 . . . . 0.0 112.004 -175.141 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 90' ' ' ARG . . . . . 0.69 ' HA ' ' OE1' ' A' ' 93' ' ' GLN . 0.2 OUTLIER -60.46 -33.41 72.51 Favored 'General case' 0 CA--C 1.518 -0.28 0 CA-C-N 116.036 -0.529 . . . . 0.0 111.349 -173.433 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 91' ' ' LEU . . . . . 0.724 ' HG ' ' O ' ' A' ' 87' ' ' GLU . 24.4 mt -66.53 -26.26 67.07 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 121.364 0.602 . . . . 0.0 110.139 -175.039 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . 0.442 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 10.3 mtm180 -89.13 -49.94 6.45 Favored 'General case' 0 C--N 1.317 -0.84 0 CA-C-N 114.957 -1.02 . . . . 0.0 110.377 -172.18 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 93' ' ' GLN . . . . . 0.69 ' OE1' ' HA ' ' A' ' 90' ' ' ARG . 0.0 OUTLIER -99.05 -22.94 15.46 Favored 'General case' 0 CA--C 1.54 0.582 0 N-CA-C 113.457 0.91 . . . . 0.0 113.457 -171.599 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 81.7 47.19 6.42 Favored Glycine 0 C--N 1.335 0.522 0 C-N-CA 120.81 -0.709 . . . . 0.0 111.921 173.225 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 95' ' ' TRP . . . . . 0.443 ' HH2' ' HB3' ' A' ' 27' ' ' ASP . 4.9 m95 59.34 21.15 9.4 Favored 'General case' 0 C--O 1.221 -0.404 0 CA-C-O 121.567 0.698 . . . . 0.0 109.674 -179.02 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.538 ' H ' ' HG2' ' A' ' 93' ' ' GLN . . . -78.09 -18.62 76.3 Favored Glycine 0 N--CA 1.452 -0.262 0 CA-C-N 115.4 -0.818 . . . . 0.0 112.11 174.645 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -81.79 -31.84 31.65 Favored 'General case' 0 C--N 1.326 -0.421 0 N-CA-C 109.541 -0.54 . . . . 0.0 109.541 176.421 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 98' ' ' TRP . . . . . 0.938 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 17.2 m-90 -105.68 103.9 45.88 Favored Pre-proline 0 C--N 1.323 -0.577 0 CA-C-N 115.286 -0.87 . . . . 0.0 109.143 177.265 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 99' ' ' PRO . . . . . 0.414 ' HD3' ' HA ' ' A' ' 98' ' ' TRP . 11.3 Cg_exo -77.2 -90.85 0.0 OUTLIER 'Trans proline' 0 CA--C 1.536 0.589 0 C-N-CA 122.789 2.326 . . . . 0.0 114.543 -173.467 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . 0.473 ' O ' ' HD2' ' A' ' 104' ' ' ARG . 4.5 p -69.77 -29.37 40.6 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.349 0 CA-C-O 121.962 0.887 . . . . 0.0 110.196 -172.525 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 78.0 m -73.39 -38.8 65.52 Favored 'General case' 0 C--N 1.312 -1.061 0 CA-C-N 114.281 -1.327 . . . . 0.0 111.564 -174.05 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 102' ' ' ALA . . . . . 0.447 ' HB2' ' HB2' ' A' ' 98' ' ' TRP . . . -70.27 -42.37 72.22 Favored 'General case' 0 C--N 1.326 -0.441 0 C-N-CA 120.761 -0.376 . . . . 0.0 110.499 178.494 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -59.3 -45.47 91.19 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 121.2 0.524 . . . . 0.0 110.59 178.552 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 104' ' ' ARG . . . . . 0.473 ' HD2' ' O ' ' A' ' 100' ' ' VAL . 0.0 OUTLIER -71.82 -18.5 62.08 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 115.566 -0.743 . . . . 0.0 111.888 179.512 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 105' ' ' ALA . . . . . 0.431 ' HB3' HG22 ' A' ' 30' ' ' ILE . . . -92.16 -21.35 20.45 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 121.001 0.429 . . . . 0.0 111.45 179.508 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 110.5 63.06 0.51 Allowed Glycine 0 N--CA 1.451 -0.353 0 CA-C-N 116.005 -0.543 . . . . 0.0 112.018 -177.885 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -65.13 149.39 49.99 Favored 'General case' 0 C--N 1.33 -0.244 0 C-N-CA 122.806 0.442 . . . . 0.0 110.908 -178.25 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 71.7 mtp180 . . . . . 0 C--O 1.246 0.884 0 CA-C-O 118.638 -0.696 . . . . 0.0 110.195 -170.995 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . 0.424 ' O ' HG13 ' A' ' 30' ' ' ILE . 15.0 m-20 . . . . . 0 CA--C 1.498 -1.036 0 CA-C-O 121.88 0.848 . . . . 0.0 109.791 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . 0.607 ' HA2' ' HB2' ' A' ' 31' ' ' TRP . . . -70.66 -7.44 61.36 Favored Glycine 0 N--CA 1.438 -1.228 0 CA-C-N 114.659 -1.155 . . . . 0.0 110.295 -179.12 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 41.7 m -77.05 -38.35 52.9 Favored 'General case' 0 C--N 1.32 -0.717 0 N-CA-C 109.029 -0.73 . . . . 0.0 109.029 173.997 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.576 ' HA ' ' HB1' ' A' ' 105' ' ' ALA . 0.2 OUTLIER -71.92 -37.1 60.07 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.692 0 N-CA-C 107.844 -1.169 . . . . 0.0 107.844 175.929 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' TRP . . . . . 0.607 ' HB2' ' HA2' ' A' ' 28' ' ' GLY . 38.9 m95 -71.38 -38.29 71.55 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 114.611 -1.177 . . . . 0.0 110.391 -178.377 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 28.3 t70 -78.31 -30.14 48.17 Favored 'General case' 0 N--CA 1.442 -0.846 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.041 178.599 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . 0.481 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -70.6 -33.78 71.43 Favored 'General case' 0 N--CA 1.452 -0.371 0 O-C-N 122.012 -0.43 . . . . 0.0 110.177 176.389 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . 0.534 ' HA ' ' HB3' ' A' ' 101' ' ' CYS . 70.3 mt -64.73 -46.14 93.07 Favored 'Isoleucine or valine' 0 C--O 1.234 0.239 0 CA-C-O 121.241 0.544 . . . . 0.0 109.804 171.473 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . 0.486 ' HA ' ' O ' ' A' ' 54' ' ' GLY . . . -58.61 -39.45 80.48 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.547 -0.751 . . . . 0.0 110.453 176.177 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -76.51 -7.25 85.33 Favored Glycine 0 C--N 1.319 -0.363 0 CA-C-N 115.462 -0.79 . . . . 0.0 111.763 179.923 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 9.3 t -92.47 -64.78 1.06 Allowed 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 115.428 -0.386 . . . . 0.0 110.972 -178.981 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . 0.806 ' HG3' ' SG ' ' A' ' 101' ' ' CYS . 25.7 mt-10 -90.49 -33.64 15.87 Favored 'General case' 0 C--N 1.325 -0.473 0 C-N-CA 120.522 -0.471 . . . . 0.0 111.419 -175.684 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . 0.438 ' HB3' ' O ' ' A' ' 35' ' ' ALA . . . -89.62 -11.86 41.37 Favored 'General case' 0 C--N 1.325 -0.495 0 C-N-CA 120.697 -0.401 . . . . 0.0 111.641 -176.033 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 76.32 13.36 83.41 Favored Glycine 0 CA--C 1.505 -0.556 0 N-CA-C 110.225 -1.15 . . . . 0.0 110.225 -179.672 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 79.64 57.45 3.1 Favored Glycine 0 N--CA 1.433 -1.549 0 CA-C-N 113.915 -1.143 . . . . 0.0 111.759 -176.038 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 42' ' ' ASN . . . . . 0.413 ' OD1' ' HB ' ' A' ' 45' ' ' ILE . 2.4 t-20 -147.8 106.12 3.77 Favored 'General case' 0 N--CA 1.448 -0.548 0 N-CA-C 108.76 -0.83 . . . . 0.0 108.76 -177.752 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 43' ' ' TRP . . . . . 0.753 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 35.2 m95 -83.92 -12.38 55.49 Favored 'General case' 0 C--N 1.311 -1.07 0 CA-C-N 115.643 -0.708 . . . . 0.0 110.315 -174.031 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -106.67 13.98 27.46 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 115.346 -0.843 . . . . 0.0 110.895 -179.508 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.566 HG22 ' HA3' ' A' ' 53' ' ' GLY . 7.0 tt -77.51 144.38 11.56 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.01 0 N-CA-C 109.239 -0.652 . . . . 0.0 109.239 177.412 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 41.1 t-20 -156.59 100.67 1.96 Allowed 'General case' 0 C--N 1.313 -1.022 0 CA-C-O 121.213 0.53 . . . . 0.0 109.614 -177.625 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 14.6 p -72.59 -24.75 61.13 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.298 -0.864 . . . . 0.0 110.383 179.527 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 96.12 17.77 33.65 Favored Glycine 0 N--CA 1.441 -1.013 0 CA-C-N 115.413 -0.812 . . . . 0.0 111.181 178.537 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 1.6 p-10 -90.34 9.47 28.76 Favored 'General case' 0 C--N 1.329 -0.32 0 C-N-CA 120.56 -0.456 . . . . 0.0 111.356 -173.141 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . 0.452 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 95.42 -11.55 68.66 Favored Glycine 0 N--CA 1.454 -0.154 0 C-N-CA 120.88 -0.676 . . . . 0.0 111.774 -179.194 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 51' ' ' TYR . . . . . 0.658 ' HA ' ' HA ' ' A' ' 58' ' ' ASP . 0.1 OUTLIER -113.67 159.82 19.28 Favored 'General case' 0 N--CA 1.447 -0.62 0 N-CA-C 106.655 -1.609 . . . . 0.0 106.655 174.186 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 52' ' ' TYR . . . . . 0.835 ' O ' ' HA ' ' A' ' 56' ' ' GLN . 50.8 m-85 -123.67 170.67 10.24 Favored 'General case' 0 C--N 1.311 -1.104 0 C-N-CA 120.639 -0.425 . . . . 0.0 111.116 -169.336 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.566 ' HA3' HG22 ' A' ' 45' ' ' ILE . . . -69.88 -168.27 6.56 Favored Glycine 0 N--CA 1.445 -0.753 0 N-CA-C 114.373 0.509 . . . . 0.0 114.373 -172.851 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . 0.653 ' CA ' ' HA ' ' A' ' 43' ' ' TRP . . . 73.46 -107.84 2.34 Favored Glycine 0 N--CA 1.441 -0.977 0 N-CA-C 111.335 -0.706 . . . . 0.0 111.335 -179.466 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.533 HG22 ' HB3' ' A' ' 82' ' ' GLN . 1.7 m -83.73 -0.43 5.39 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-O 121.464 0.649 . . . . 0.0 110.702 179.413 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 56' ' ' GLN . . . . . 0.835 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 7.8 tp-100 57.97 52.98 7.22 Favored 'General case' 0 CA--C 1.535 0.393 0 CA-C-N 114.157 -1.383 . . . . 0.0 114.546 164.404 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -126.73 171.92 10.78 Favored 'General case' 0 C--O 1.233 0.233 0 C-N-CA 118.969 -1.092 . . . . 0.0 112.806 172.512 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.658 ' HA ' ' HA ' ' A' ' 51' ' ' TYR . 7.9 p-10 -77.72 162.34 27.05 Favored 'General case' 0 CA--C 1.515 -0.393 0 N-CA-C 113.945 1.091 . . . . 0.0 113.945 -163.756 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . 0.785 ' HA ' HE21 ' A' ' 59' ' ' GLN . 0.0 OUTLIER -57.67 -41.98 82.62 Favored 'General case' 0 N--CA 1.445 -0.719 0 CA-C-N 114.367 -1.288 . . . . 0.0 111.137 177.194 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -67.61 -49.44 50.16 Favored Glycine 0 CA--C 1.507 -0.431 0 C-N-CA 120.993 -0.622 . . . . 0.0 112.22 -171.787 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 38.8 m -64.97 -42.03 94.92 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-O 120.904 0.383 . . . . 0.0 111.029 177.804 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 62' ' ' TRP . . . . . 0.484 ' CZ3' ' HA ' ' A' ' 82' ' ' GLN . 47.7 t-105 -56.63 -48.2 78.03 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 121.775 0.798 . . . . 0.0 109.514 175.29 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . 0.659 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 36.9 tt0 -65.74 -37.56 86.72 Favored 'General case' 0 N--CA 1.443 -0.791 0 CA-C-N 114.738 -1.119 . . . . 0.0 110.892 -179.151 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -66.02 -41.39 91.04 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.857 -177.941 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . 0.447 ' HB2' HG13 ' A' ' 85' ' ' VAL . 9.4 m120 -76.8 -13.04 60.05 Favored 'General case' 0 N--CA 1.45 -0.445 0 CA-C-O 120.883 0.373 . . . . 0.0 110.261 177.493 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . 0.532 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 92.11 45.43 3.85 Favored Glycine 0 C--N 1.333 0.393 0 CA-C-N 115.846 -0.616 . . . . 0.0 112.642 175.327 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . 0.573 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -79.91 -20.31 68.26 Favored Glycine 0 N--CA 1.443 -0.89 0 C-N-CA 120.807 -0.711 . . . . 0.0 112.848 -174.495 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 1.0 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 6.7 mp -64.37 -23.47 67.3 Favored 'General case' 0 C--N 1.319 -0.756 0 N-CA-C 112.424 0.527 . . . . 0.0 112.424 -172.933 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . 0.532 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 13.2 ptp180 -65.26 -31.16 72.17 Favored 'General case' 0 C--N 1.324 -0.509 0 N-CA-C 109.113 -0.699 . . . . 0.0 109.113 175.884 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 70' ' ' TYR . . . . . 0.588 ' HB3' ' HB3' ' A' ' 81' ' ' GLU . 92.4 m-85 -81.12 -36.05 30.82 Favored 'General case' 0 N--CA 1.439 -0.992 0 CA-C-N 114.683 -1.144 . . . . 0.0 107.94 177.394 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.52 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 164.72 127.55 0.02 OUTLIER Pre-proline 0 N--CA 1.448 -0.567 0 CA-C-N 112.626 -2.079 . . . . 0.0 107.342 -178.364 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 72' ' ' PRO . . . . . 1.0 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 17.4 Cg_exo -59.03 -3.44 1.6 Allowed 'Trans proline' 0 C--N 1.334 -0.217 0 C-N-CA 122.724 2.282 . . . . 0.0 113.586 -178.557 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 13.0 ptm180 -144.05 133.74 23.66 Favored 'General case' 0 C--N 1.315 -0.913 0 N-CA-C 108.127 -1.064 . . . . 0.0 108.127 175.986 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . 0.658 ' HB3' ' HB2' ' A' ' 52' ' ' TYR . . . -57.99 -28.8 64.74 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 115.578 -0.737 . . . . 0.0 112.372 -175.897 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 20.9 p-10 -84.24 -2.86 57.68 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 121.111 0.481 . . . . 0.0 111.499 -175.944 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.477 ' HB3' ' HB1' ' A' ' 71' ' ' ALA . 62.5 tp -96.38 -28.01 14.66 Favored 'General case' 0 C--N 1.322 -0.624 0 N-CA-C 108.413 -0.958 . . . . 0.0 108.413 170.342 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . 0.754 ' HB1' ' HB2' ' A' ' 81' ' ' GLU . . . -80.18 154.4 28.0 Favored 'General case' 0 N--CA 1.444 -0.77 0 CA-C-N 114.413 -1.267 . . . . 0.0 110.093 173.443 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 44.6 p -100.03 -172.5 2.24 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-N 116.392 -0.367 . . . . 0.0 110.136 179.291 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . 0.753 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 19.2 mtt180 -48.73 -53.28 19.59 Favored 'General case' 0 CA--C 1.509 -0.605 0 CA-C-O 121.205 0.526 . . . . 0.0 111.277 -177.924 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 80' ' ' GLU . . . . . 0.586 ' HG3' ' OE2' ' A' ' 81' ' ' GLU . 3.4 pt-20 -59.88 -41.04 90.68 Favored 'General case' 0 C--N 1.312 -1.04 0 CA-C-N 114.958 -1.019 . . . . 0.0 112.086 -175.553 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 81' ' ' GLU . . . . . 0.754 ' HB2' ' HB1' ' A' ' 77' ' ' ALA . 4.6 mp0 -67.46 -51.99 44.8 Favored 'General case' 0 C--O 1.232 0.181 0 N-CA-C 112.132 0.419 . . . . 0.0 112.132 174.444 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 82' ' ' GLN . . . . . 0.533 ' HB3' HG22 ' A' ' 55' ' ' VAL . 54.3 mt-30 -59.98 -43.44 95.12 Favored 'General case' 0 CA--C 1.512 -0.501 0 CA-C-O 121.116 0.484 . . . . 0.0 110.54 -175.73 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.631 ' O ' ' HG2' ' A' ' 87' ' ' GLU . 15.4 mt -60.69 -40.81 85.98 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.787 0 CA-C-N 114.947 -1.024 . . . . 0.0 110.568 178.851 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 84' ' ' ALA . . . . . 0.585 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -63.6 -42.13 98.26 Favored 'General case' 0 C--O 1.239 0.524 0 CA-C-O 121.428 0.632 . . . . 0.0 111.366 -177.917 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.447 HG13 ' HB2' ' A' ' 65' ' ' ASN . 44.5 t -69.05 -48.01 72.05 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.675 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.243 178.99 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 86' ' ' ALA . . . . . 0.476 ' HB1' ' CH2' ' A' ' 31' ' ' TRP . . . -57.85 -29.69 65.19 Favored 'General case' 0 N--CA 1.452 -0.34 0 CA-C-N 115.603 -0.726 . . . . 0.0 110.594 174.062 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 87' ' ' GLU . . . . . 0.631 ' HG2' ' O ' ' A' ' 83' ' ' ILE . 15.9 mm-40 -60.81 -40.64 93.5 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.193 178.738 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.504 ' O ' ' HG3' ' A' ' 92' ' ' ARG . 59.0 t -63.08 -48.06 89.61 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-O 121.276 0.56 . . . . 0.0 109.716 173.546 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . 0.741 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 0.3 OUTLIER -63.41 -47.47 81.85 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 115.559 -0.746 . . . . 0.0 112.224 -174.832 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 90' ' ' ARG . . . . . 0.547 ' HB3' ' CH2' ' A' ' 31' ' ' TRP . 4.8 ptt180 -62.54 -32.82 73.84 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 121.519 0.676 . . . . 0.0 109.216 -176.276 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 91' ' ' LEU . . . . . 0.537 ' N ' ' HG3' ' A' ' 90' ' ' ARG . 64.3 tp -66.09 -32.18 73.5 Favored 'General case' 0 C--N 1.313 -1.01 0 CA-C-N 114.029 -1.441 . . . . 0.0 111.622 -173.236 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . 0.504 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 3.5 mtm180 -84.98 -46.46 11.2 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-O 121.507 0.67 . . . . 0.0 110.077 -175.116 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 93' ' ' GLN . . . . . 0.499 HE22 HG22 ' A' ' 89' ' ' THR . 4.5 pt20 -101.89 -27.31 13.06 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 115.218 -0.901 . . . . 0.0 113.155 -168.5 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 92.3 39.62 5.33 Favored Glycine 0 CA--C 1.505 -0.555 0 C-N-CA 120.416 -0.897 . . . . 0.0 111.926 174.547 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 95' ' ' TRP . . . . . 0.499 ' CH2' ' HB ' ' A' ' 30' ' ' ILE . 38.7 m95 71.37 6.91 5.92 Favored 'General case' 0 C--O 1.218 -0.589 0 C-N-CA 123.399 0.68 . . . . 0.0 109.6 -178.462 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -58.46 -37.56 88.58 Favored Glycine 0 CA--C 1.521 0.44 0 CA-C-N 115.595 -0.73 . . . . 0.0 113.741 -179.826 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -68.92 -22.2 64.16 Favored 'General case' 0 CA--C 1.519 -0.241 0 CA-C-N 117.219 0.51 . . . . 0.0 110.657 179.139 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 98' ' ' TRP . . . . . 0.741 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 27.7 m-90 -100.9 104.09 29.45 Favored Pre-proline 0 N--CA 1.449 -0.483 0 N-CA-C 109.05 -0.722 . . . . 0.0 109.05 175.918 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 99' ' ' PRO . . . . . 0.408 ' HD3' ' HA ' ' A' ' 98' ' ' TRP . 16.5 Cg_exo -72.85 -89.96 0.01 OUTLIER 'Trans proline' 0 CA--C 1.533 0.427 0 C-N-CA 122.872 2.382 . . . . 0.0 114.738 -171.509 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 49.0 t -71.68 -30.28 37.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-O 121.811 0.815 . . . . 0.0 110.103 -173.122 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 101' ' ' CYS . . . . . 0.806 ' SG ' ' HG3' ' A' ' 38' ' ' GLU . 70.4 m -76.77 -27.57 55.36 Favored 'General case' 0 C--N 1.317 -0.835 0 CA-C-N 115.099 -0.955 . . . . 0.0 111.869 -169.713 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -69.68 -46.0 67.05 Favored 'General case' 0 C--N 1.329 -0.317 0 C-N-CA 120.75 -0.38 . . . . 0.0 110.753 -179.628 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -67.62 -32.12 72.61 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 120.856 0.36 . . . . 0.0 110.647 -179.946 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -74.1 -21.94 59.69 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.85 177.261 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 105' ' ' ALA . . . . . 0.576 ' HB1' ' HA ' ' A' ' 30' ' ' ILE . . . -96.17 -22.07 17.51 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.815 -0.629 . . . . 0.0 112.057 -176.26 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 108.62 57.08 0.56 Allowed Glycine 0 CA--C 1.522 0.492 0 C-N-CA 120.871 -0.681 . . . . 0.0 112.186 -177.517 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -61.54 149.73 38.09 Favored 'General case' 0 C--N 1.329 -0.321 0 C-N-CA 123.253 0.621 . . . . 0.0 111.551 -175.674 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 72.9 mtp180 . . . . . 0 C--O 1.245 0.859 0 CA-C-O 118.686 -0.673 . . . . 0.0 110.419 -173.855 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 8.7 m-20 . . . . . 0 CA--C 1.502 -0.889 0 CA-C-O 121.511 0.672 . . . . 0.0 109.774 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . 0.483 ' HA2' ' HB2' ' A' ' 31' ' ' TRP . . . -64.62 -11.62 49.48 Favored Glycine 0 N--CA 1.44 -1.073 0 CA-C-N 114.893 -1.049 . . . . 0.0 110.64 176.536 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 11.9 m -76.92 -36.88 56.3 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-O 121.854 0.835 . . . . 0.0 109.592 176.511 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.536 ' HA ' ' HB1' ' A' ' 105' ' ' ALA . 1.2 mm -71.34 -40.79 73.71 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 N-CA-C 107.088 -1.449 . . . . 0.0 107.088 176.701 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' TRP . . . . . 0.557 ' HA ' ' CE3' ' A' ' 31' ' ' TRP . 14.3 m95 -67.93 -35.83 79.09 Favored 'General case' 0 C--N 1.315 -0.898 0 CA-C-N 113.711 -1.586 . . . . 0.0 110.536 -175.528 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.607 ' HB2' HH21 ' A' ' 79' ' ' ARG . 12.4 t70 -77.18 -36.6 54.91 Favored 'General case' 0 N--CA 1.44 -0.937 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.712 -179.532 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . 0.476 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -70.65 -34.02 71.59 Favored 'General case' 0 N--CA 1.448 -0.558 0 C-N-CA 120.692 -0.403 . . . . 0.0 110.789 177.124 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . 0.527 HG13 ' O ' ' A' ' 30' ' ' ILE . 60.5 mt -64.94 -46.83 90.48 Favored 'Isoleucine or valine' 0 C--O 1.234 0.25 0 CA-C-O 120.889 0.376 . . . . 0.0 110.559 175.359 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . 0.44 ' O ' ' HB3' ' A' ' 39' ' ' ALA . . . -61.75 -34.67 76.25 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 121.328 0.585 . . . . 0.0 110.285 176.761 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . 0.469 ' HA2' ' N ' ' A' ' 41' ' ' GLY . . . -75.58 -9.47 84.69 Favored Glycine 0 N--CA 1.449 -0.462 0 CA-C-N 115.525 -0.762 . . . . 0.0 111.47 178.117 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.459 ' HB3' ' O ' ' A' ' 34' ' ' ILE . 1.7 t -91.03 -63.13 1.31 Allowed 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 115.399 -0.401 . . . . 0.0 111.409 -177.508 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . 0.731 ' HG3' ' SG ' ' A' ' 101' ' ' CYS . 13.9 mt-10 -89.27 -33.9 16.8 Favored 'General case' 0 C--N 1.327 -0.381 0 C-N-CA 120.405 -0.518 . . . . 0.0 111.39 -175.262 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . 0.44 ' HB3' ' O ' ' A' ' 35' ' ' ALA . . . -88.93 -9.02 53.06 Favored 'General case' 0 C--N 1.323 -0.567 0 C-N-CA 120.706 -0.398 . . . . 0.0 111.367 -177.335 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 75.5 15.92 80.94 Favored Glycine 0 CA--C 1.504 -0.637 0 N-CA-C 110.033 -1.227 . . . . 0.0 110.033 -178.689 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . 0.469 ' N ' ' HA2' ' A' ' 36' ' ' GLY . . . 75.76 60.39 3.19 Favored Glycine 0 N--CA 1.434 -1.491 0 CA-C-N 114.047 -1.076 . . . . 0.0 111.25 -174.273 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 2.1 t-20 -142.71 95.42 2.78 Favored 'General case' 0 N--CA 1.448 -0.538 0 N-CA-C 109.242 -0.651 . . . . 0.0 109.242 -178.759 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 43' ' ' TRP . . . . . 0.699 ' HA ' ' N ' ' A' ' 54' ' ' GLY . 36.8 m95 -79.96 -4.03 50.78 Favored 'General case' 0 C--N 1.317 -0.824 0 CA-C-N 115.516 -0.765 . . . . 0.0 110.319 -176.465 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -111.78 15.07 21.07 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 114.893 -1.049 . . . . 0.0 111.416 179.548 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.841 HG22 ' HA2' ' A' ' 53' ' ' GLY . 10.8 tt -76.64 141.44 15.67 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.719 0 CA-C-O 121.297 0.57 . . . . 0.0 110.398 179.612 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 19.1 m120 -142.01 95.93 2.88 Favored 'General case' 0 C--N 1.312 -1.053 0 CA-C-O 121.34 0.59 . . . . 0.0 109.513 -177.927 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 34.3 p -66.47 -23.7 66.31 Favored 'General case' 0 C--N 1.318 -0.791 0 CA-C-N 114.959 -1.019 . . . . 0.0 110.52 -179.097 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 88.55 14.54 61.44 Favored Glycine 0 N--CA 1.441 -0.989 0 N-CA-C 110.135 -1.186 . . . . 0.0 110.135 -178.408 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 2.6 t30 -96.16 5.25 51.49 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.423 0.63 . . . . 0.0 110.67 -173.229 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 95.53 -1.34 64.0 Favored Glycine 0 N--CA 1.447 -0.618 0 C-N-CA 120.612 -0.804 . . . . 0.0 111.103 -176.223 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 51' ' ' TYR . . . . . 0.528 ' HA ' ' O ' ' A' ' 57' ' ' PHE . 0.7 OUTLIER -110.88 161.36 15.9 Favored 'General case' 0 N--CA 1.444 -0.77 0 N-CA-C 107.724 -1.213 . . . . 0.0 107.724 179.077 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 52' ' ' TYR . . . . . 0.543 ' HB2' ' HB3' ' A' ' 74' ' ' ALA . 43.8 m-85 -129.62 170.05 14.27 Favored 'General case' 0 C--N 1.313 -1.013 0 CA-C-O 120.877 0.37 . . . . 0.0 111.823 -170.092 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.841 ' HA2' HG22 ' A' ' 45' ' ' ILE . . . -60.61 164.8 15.32 Favored Glycine 0 N--CA 1.448 -0.562 0 N-CA-C 115.127 0.811 . . . . 0.0 115.127 -168.663 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . 0.699 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 90.22 -96.29 2.19 Favored Glycine 0 N--CA 1.439 -1.152 0 CA-C-N 114.659 -0.77 . . . . 0.0 112.258 177.652 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -102.21 12.46 7.09 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.672 0 CA-C-O 120.77 0.319 . . . . 0.0 111.49 -175.803 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 56' ' ' GLN . . . . . . . . . . . . . 21.4 mm-40 60.24 43.64 13.6 Favored 'General case' 0 N--CA 1.47 0.557 0 CA-C-N 115.427 -0.806 . . . . 0.0 112.417 173.903 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . 0.528 ' O ' ' HA ' ' A' ' 51' ' ' TYR . 24.3 m-85 -63.38 127.09 29.72 Favored 'General case' 0 CA--C 1.505 -0.757 0 CA-C-N 115.306 -0.861 . . . . 0.0 112.173 172.847 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.512 ' HA ' ' HA ' ' A' ' 51' ' ' TYR . 6.7 p-10 -72.62 156.77 38.63 Favored 'General case' 0 C--N 1.317 -0.84 0 N-CA-C 108.414 -0.958 . . . . 0.0 108.414 163.522 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . 0.854 ' HA ' HE21 ' A' ' 59' ' ' GLN . 0.0 OUTLIER -58.44 -35.2 71.76 Favored 'General case' 0 C--N 1.316 -0.89 0 CA-C-O 120.733 0.301 . . . . 0.0 111.039 -177.221 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -68.13 -49.69 45.08 Favored Glycine 0 N--CA 1.451 -0.349 0 CA-C-N 116.045 -0.525 . . . . 0.0 112.494 -175.945 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 82.0 m -67.7 -40.97 84.28 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 120.933 0.397 . . . . 0.0 110.735 178.767 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 62' ' ' TRP . . . . . 0.518 ' HB2' ' HB3' ' A' ' 57' ' ' PHE . 65.6 t-105 -58.05 -47.56 82.77 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-O 121.547 0.689 . . . . 0.0 109.416 176.436 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . 0.4 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 33.8 tt0 -67.4 -32.51 73.45 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 115.182 -0.917 . . . . 0.0 110.924 -179.979 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -66.42 -42.37 87.85 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.71 -175.832 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . 0.78 ' HB2' HG13 ' A' ' 85' ' ' VAL . 26.1 m-80 -82.86 -5.9 59.2 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.874 0.368 . . . . 0.0 110.292 176.031 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . 0.593 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 90.61 48.15 3.53 Favored Glycine 0 C--N 1.332 0.327 0 CA-C-N 115.928 -0.578 . . . . 0.0 112.931 171.056 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . 0.58 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -79.8 -29.48 47.33 Favored Glycine 0 N--CA 1.438 -1.203 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.43 -176.053 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 1.046 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 8.2 mp -56.78 -22.0 32.71 Favored 'General case' 0 N--CA 1.447 -0.605 0 N-CA-C 112.997 0.74 . . . . 0.0 112.997 -175.189 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . 0.593 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 12.3 ptm180 -70.76 -30.26 66.71 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-O 121.431 0.634 . . . . 0.0 110.076 177.744 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 70' ' ' TYR . . . . . 0.984 ' HB3' ' HG2' ' A' ' 81' ' ' GLU . 46.7 m-85 -85.41 -36.0 20.95 Favored 'General case' 0 N--CA 1.443 -0.817 0 N-CA-C 107.447 -1.316 . . . . 0.0 107.447 177.037 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.644 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 170.74 126.23 0.05 OUTLIER Pre-proline 0 N--CA 1.445 -0.722 0 CA-C-N 112.863 -1.972 . . . . 0.0 107.522 -176.24 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 72' ' ' PRO . . . . . 1.046 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 26.4 Cg_exo -56.43 -6.15 1.37 Allowed 'Trans proline' 0 C--N 1.333 -0.28 0 C-N-CA 123.005 2.47 . . . . 0.0 113.785 -178.289 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 73' ' ' ARG . . . . . 0.432 ' HB2' ' CD1' ' A' ' 52' ' ' TYR . 13.5 ptm180 -147.53 138.67 23.64 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-O 121.28 0.562 . . . . 0.0 109.559 176.155 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . 0.543 ' HB3' ' HB2' ' A' ' 52' ' ' TYR . . . -56.33 -30.22 62.31 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 114.861 -1.063 . . . . 0.0 113.307 -176.289 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 5.4 p-10 -80.47 -11.82 59.63 Favored 'General case' 0 C--N 1.327 -0.379 0 C-N-CA 120.428 -0.509 . . . . 0.0 110.899 -176.988 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.542 ' HB3' ' HB1' ' A' ' 71' ' ' ALA . 46.4 tp -90.16 -31.8 16.92 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-O 121.937 0.875 . . . . 0.0 108.76 173.621 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . 0.644 ' HB2' ' HB3' ' A' ' 71' ' ' ALA . . . -79.68 162.98 24.9 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 114.489 -1.232 . . . . 0.0 110.255 174.122 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 64.1 p -102.11 176.59 5.15 Favored 'General case' 0 C--N 1.318 -0.782 0 CA-C-N 116.399 -0.364 . . . . 0.0 110.721 179.155 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . 0.632 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 41.8 mtp180 -47.37 -50.84 21.35 Favored 'General case' 0 CA--C 1.511 -0.549 0 C-N-CA 123.103 0.561 . . . . 0.0 111.255 -174.75 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 80' ' ' GLU . . . . . 0.537 ' HA ' HD12 ' A' ' 83' ' ' ILE . 3.4 pm0 -60.01 -31.78 70.26 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-N 115.729 -0.669 . . . . 0.0 111.52 -176.815 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 81' ' ' GLU . . . . . 0.984 ' HG2' ' HB3' ' A' ' 70' ' ' TYR . 5.4 mt-10 -71.72 -47.4 54.16 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 116.619 -0.264 . . . . 0.0 111.524 176.302 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 82' ' ' GLN . . . . . 0.582 ' HB2' ' HZ3' ' A' ' 43' ' ' TRP . 5.9 mp0 -60.78 -36.52 79.18 Favored 'General case' 0 CA--C 1.514 -0.428 0 C-N-CA 120.213 -0.595 . . . . 0.0 109.447 175.466 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.537 HD12 ' HA ' ' A' ' 80' ' ' GLU . 53.7 mt -60.7 -49.28 85.15 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.635 0 CA-C-N 115.104 -0.953 . . . . 0.0 110.47 178.111 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 84' ' ' ALA . . . . . 0.484 ' O ' ' HG3' ' A' ' 87' ' ' GLU . . . -60.35 -45.76 92.32 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-O 120.957 0.408 . . . . 0.0 111.517 -179.53 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.78 HG13 ' HB2' ' A' ' 65' ' ' ASN . 63.6 t -69.1 -49.26 63.87 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.554 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.551 -178.588 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 86' ' ' ALA . . . . . 0.526 ' CA ' ' HZ ' ' A' ' 57' ' ' PHE . . . -64.56 -32.05 73.53 Favored 'General case' 0 CA--C 1.509 -0.619 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.897 179.645 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 87' ' ' GLU . . . . . 0.575 ' O ' ' HG3' ' A' ' 90' ' ' ARG . 1.3 pp20? -70.83 -29.65 65.85 Favored 'General case' 0 C--N 1.321 -0.665 0 C-N-CA 120.271 -0.572 . . . . 0.0 110.117 -177.624 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.722 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 61.2 t -64.74 -41.47 92.28 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.285 0 N-CA-C 109.136 -0.69 . . . . 0.0 109.136 168.093 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . 0.942 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 1.8 m -65.02 -47.01 78.98 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 115.66 -0.7 . . . . 0.0 111.166 -177.906 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 90' ' ' ARG . . . . . 0.684 ' HA ' ' OE1' ' A' ' 93' ' ' GLN . 3.0 ppt_? -60.69 -34.1 73.85 Favored 'General case' 0 CA--C 1.516 -0.365 0 CA-C-N 115.801 -0.636 . . . . 0.0 111.598 -175.774 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 91' ' ' LEU . . . . . 0.722 ' HG ' ' O ' ' A' ' 88' ' ' VAL . 4.5 pp -72.51 -22.22 61.07 Favored 'General case' 0 C--N 1.319 -0.758 0 CA-C-O 121.222 0.534 . . . . 0.0 110.185 -175.035 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . 0.591 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 10.4 mtm180 -84.57 -51.59 6.76 Favored 'General case' 0 CA--C 1.51 -0.574 0 CA-C-N 115.699 -0.682 . . . . 0.0 110.069 -177.713 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 93' ' ' GLN . . . . . 0.684 ' OE1' ' HA ' ' A' ' 90' ' ' ARG . 0.0 OUTLIER -99.17 -22.91 15.43 Favored 'General case' 0 C--N 1.325 -0.474 0 N-CA-C 113.148 0.795 . . . . 0.0 113.148 -171.127 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 94.52 35.04 6.07 Favored Glycine 0 CA--C 1.508 -0.397 0 C-N-CA 120.849 -0.691 . . . . 0.0 112.439 171.254 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 95' ' ' TRP . . . . . 0.425 ' HE1' ' HB2' ' A' ' 108' ' ' ARG . 20.1 m95 66.27 7.87 5.2 Favored 'General case' 0 C--O 1.22 -0.472 0 C-N-CA 123.602 0.761 . . . . 0.0 109.542 -177.146 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -65.55 -32.55 83.66 Favored Glycine 0 C--N 1.332 0.337 0 C-N-CA 121.083 -0.58 . . . . 0.0 112.169 -179.996 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -67.44 -28.92 68.29 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.792 0.329 . . . . 0.0 110.639 178.998 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 98' ' ' TRP . . . . . 0.942 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 26.5 m-90 -100.1 104.44 29.25 Favored Pre-proline 0 N--CA 1.448 -0.55 0 N-CA-C 108.923 -0.769 . . . . 0.0 108.923 176.246 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 99' ' ' PRO . . . . . 0.427 ' HB2' ' H ' ' A' ' 100' ' ' VAL . 17.0 Cg_exo -72.53 -91.29 0.01 OUTLIER 'Trans proline' 0 CA--C 1.533 0.434 0 C-N-CA 123.101 2.534 . . . . 0.0 114.682 -171.884 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . 0.427 ' H ' ' HB2' ' A' ' 99' ' ' PRO . 41.5 t -70.67 -28.05 32.98 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-O 121.764 0.792 . . . . 0.0 110.234 -172.938 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 101' ' ' CYS . . . . . 0.731 ' SG ' ' HG3' ' A' ' 38' ' ' GLU . 84.7 m -75.66 -38.4 58.81 Favored 'General case' 0 C--N 1.315 -0.906 0 CA-C-N 115.063 -0.971 . . . . 0.0 111.881 -171.588 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -68.05 -44.48 76.28 Favored 'General case' 0 C--N 1.327 -0.398 0 C-N-CA 120.591 -0.444 . . . . 0.0 110.309 -179.861 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -59.49 -37.44 78.25 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 121.081 0.467 . . . . 0.0 111.053 179.075 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 15.9 tpp180 -73.98 -34.33 64.17 Favored 'General case' 0 N--CA 1.431 -1.398 0 CA-C-N 115.578 -0.737 . . . . 0.0 111.429 179.323 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 105' ' ' ALA . . . . . 0.536 ' HB1' ' HA ' ' A' ' 30' ' ' ILE . . . -88.12 -22.65 23.98 Favored 'General case' 0 C--N 1.326 -0.416 0 N-CA-C 112.667 0.617 . . . . 0.0 112.667 -172.878 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 120.33 58.42 0.24 Allowed Glycine 0 CA--C 1.521 0.415 0 C-N-CA 120.661 -0.781 . . . . 0.0 112.527 -177.927 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -66.68 148.8 51.42 Favored 'General case' 0 C--N 1.325 -0.478 0 C-N-CA 122.771 0.428 . . . . 0.0 110.519 -179.355 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 108' ' ' ARG . . . . . 0.425 ' HB2' ' HE1' ' A' ' 95' ' ' TRP . 72.3 mtp180 . . . . . 0 C--O 1.247 0.949 0 CA-C-O 117.946 -1.026 . . . . 0.0 110.777 -171.924 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . 0.609 ' O ' HG12 ' A' ' 30' ' ' ILE . 16.1 m-20 . . . . . 0 CA--C 1.499 -1.006 0 CA-C-O 121.998 0.904 . . . . 0.0 108.919 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . 0.775 ' HA3' HD13 ' A' ' 83' ' ' ILE . . . -67.55 -1.25 15.12 Favored Glycine 0 N--CA 1.433 -1.534 0 CA-C-N 114.143 -1.39 . . . . 0.0 110.844 172.693 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 19.0 m -73.71 -38.31 64.89 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-O 121.46 0.648 . . . . 0.0 109.405 173.203 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.609 HG12 ' O ' ' A' ' 27' ' ' ASP . 0.3 OUTLIER -71.69 -38.84 67.93 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.551 0 N-CA-C 107.179 -1.415 . . . . 0.0 107.179 175.595 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' TRP . . . . . 0.764 ' CD1' HG23 ' A' ' 83' ' ' ILE . 38.8 m95 -69.2 -36.69 77.56 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 114.359 -1.292 . . . . 0.0 110.667 -176.828 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 18.1 t70 -75.33 -33.93 61.17 Favored 'General case' 0 N--CA 1.444 -0.726 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.444 179.775 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . 0.468 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -70.42 -35.26 73.31 Favored 'General case' 0 N--CA 1.444 -0.739 0 C-N-CA 120.441 -0.503 . . . . 0.0 109.965 175.307 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . 0.554 HG13 ' O ' ' A' ' 30' ' ' ILE . 64.6 mt -64.59 -42.59 95.55 Favored 'Isoleucine or valine' 0 C--O 1.234 0.243 0 CA-C-O 120.996 0.427 . . . . 0.0 109.949 172.947 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . 0.432 ' HA ' ' O ' ' A' ' 54' ' ' GLY . . . -57.22 -38.02 73.11 Favored 'General case' 0 N--CA 1.451 -0.418 0 CA-C-N 115.78 -0.646 . . . . 0.0 109.997 174.608 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -73.49 -13.39 80.08 Favored Glycine 0 N--CA 1.45 -0.431 0 CA-C-N 115.375 -0.829 . . . . 0.0 112.051 179.456 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 37.3 t -94.19 -60.11 1.81 Allowed 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 120.702 0.286 . . . . 0.0 111.291 -178.999 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 9.0 tp10 -88.04 -34.32 18.03 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 121.099 0.476 . . . . 0.0 110.223 -170.972 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . 0.419 ' HB3' ' O ' ' A' ' 35' ' ' ALA . . . -92.76 -16.28 25.6 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.99 -0.55 . . . . 0.0 111.268 -177.528 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 83.52 5.33 88.57 Favored Glycine 0 CA--C 1.507 -0.461 0 N-CA-C 110.118 -1.193 . . . . 0.0 110.118 -176.124 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 90.28 59.23 1.48 Allowed Glycine 0 N--CA 1.434 -1.44 0 CA-C-N 114.095 -1.053 . . . . 0.0 112.034 -178.912 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 42' ' ' ASN . . . . . 0.486 HD22 ' HB ' ' A' ' 45' ' ' ILE . 66.0 t30 -152.44 126.32 9.01 Favored 'General case' 0 CA--C 1.507 -0.674 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 178.12 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 43' ' ' TRP . . . . . 0.768 ' HA ' ' N ' ' A' ' 54' ' ' GLY . 37.4 m95 -98.16 -12.89 21.25 Favored 'General case' 0 C--N 1.307 -1.263 0 CA-C-N 115.769 -0.65 . . . . 0.0 110.475 -174.171 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -102.95 5.23 38.24 Favored 'General case' 0 C--N 1.316 -0.875 0 CA-C-N 114.922 -1.036 . . . . 0.0 110.729 -179.113 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.486 ' HB ' HD22 ' A' ' 42' ' ' ASN . 9.8 tt -73.57 142.15 15.3 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.981 0 CA-C-N 115.921 -0.581 . . . . 0.0 109.876 -178.55 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 40.3 t-20 -154.63 99.15 2.14 Favored 'General case' 0 C--N 1.307 -1.281 0 N-CA-C 109.446 -0.576 . . . . 0.0 109.446 179.611 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 34.8 p -74.58 -15.79 60.83 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 115.626 -0.716 . . . . 0.0 110.937 -177.33 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 94.84 19.76 30.57 Favored Glycine 0 N--CA 1.448 -0.559 0 N-CA-C 111.431 -0.668 . . . . 0.0 111.431 178.932 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 32.5 p-10 -95.64 2.68 54.23 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-O 120.987 0.423 . . . . 0.0 111.421 -176.374 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 95.49 -11.33 68.72 Favored Glycine 0 N--CA 1.448 -0.553 0 N-CA-C 111.425 -0.67 . . . . 0.0 111.425 179.108 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 51' ' ' TYR . . . . . 0.625 ' CD1' ' HB2' ' A' ' 58' ' ' ASP . 0.5 OUTLIER -106.69 132.64 52.45 Favored 'General case' 0 CA--C 1.505 -0.752 0 N-CA-C 107.283 -1.377 . . . . 0.0 107.283 178.46 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 52' ' ' TYR . . . . . 0.716 ' HB2' ' HB3' ' A' ' 74' ' ' ALA . 30.9 m-85 -103.07 169.44 8.56 Favored 'General case' 0 C--N 1.304 -1.371 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.972 -168.433 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.427 ' HA2' HG22 ' A' ' 45' ' ' ILE . . . -59.53 173.54 4.34 Favored Glycine 0 N--CA 1.448 -0.526 0 N-CA-C 115.086 0.794 . . . . 0.0 115.086 -169.151 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . 0.768 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 82.13 -99.58 2.04 Favored Glycine 0 N--CA 1.436 -1.329 0 CA-C-N 114.872 -0.664 . . . . 0.0 111.698 178.944 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.571 ' HB ' ' CD1' ' A' ' 57' ' ' PHE . 2.0 t -84.25 -3.41 7.83 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-O 121.774 0.797 . . . . 0.0 109.938 -177.511 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 56' ' ' GLN . . . . . 0.891 ' HA ' HE21 ' A' ' 56' ' ' GLN . 0.0 OUTLIER 55.81 50.36 14.27 Favored 'General case' 0 N--CA 1.46 0.04 0 CA-C-N 114.058 -1.428 . . . . 0.0 112.479 171.429 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . 0.571 ' CD1' ' HB ' ' A' ' 55' ' ' VAL . 3.8 p90 -124.62 165.36 18.01 Favored 'General case' 0 C--N 1.323 -0.546 0 C-N-CA 119.912 -0.715 . . . . 0.0 111.859 177.453 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.625 ' HB2' ' CD1' ' A' ' 51' ' ' TYR . 0.0 OUTLIER -77.12 152.04 35.11 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 114.382 -1.281 . . . . 0.0 113.758 -163.169 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . 0.713 ' HA ' HE21 ' A' ' 59' ' ' GLN . 0.0 OUTLIER -50.82 -41.55 57.57 Favored 'General case' 0 N--CA 1.451 -0.393 0 CA-C-N 113.225 -1.807 . . . . 0.0 112.122 177.699 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -67.6 -49.1 52.67 Favored Glycine 0 C--N 1.315 -0.616 0 CA-C-N 115.507 -0.769 . . . . 0.0 112.013 -176.38 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 89.0 m -64.88 -41.16 95.87 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-O 120.919 0.39 . . . . 0.0 110.631 176.99 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 62' ' ' TRP . . . . . 0.524 ' CZ3' ' HA ' ' A' ' 82' ' ' GLN . 40.9 t-105 -57.0 -47.79 79.99 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 121.622 0.725 . . . . 0.0 109.617 174.725 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . 0.521 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 20.2 tt0 -65.28 -36.79 85.16 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-N 114.872 -1.058 . . . . 0.0 110.792 -179.932 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -67.57 -35.47 79.07 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 115.427 -0.806 . . . . 0.0 110.518 -177.672 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . 0.542 ' HB2' HG13 ' A' ' 85' ' ' VAL . 10.7 m120 -78.51 -12.9 60.04 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.249 175.823 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . 0.579 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 87.81 44.11 5.54 Favored Glycine 0 N--CA 1.447 -0.569 0 CA-C-N 115.411 -0.813 . . . . 0.0 112.035 177.345 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . 0.603 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -78.74 -22.04 67.48 Favored Glycine 0 N--CA 1.439 -1.117 0 C-N-CA 120.595 -0.812 . . . . 0.0 112.361 -173.52 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.929 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 7.1 mp -60.68 -21.25 62.64 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 112.592 0.59 . . . . 0.0 112.592 -174.334 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . 0.579 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 10.0 ptp180 -70.56 -32.9 70.49 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-O 121.253 0.549 . . . . 0.0 109.835 175.185 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 70' ' ' TYR . . . . . 0.662 ' HB3' ' CG ' ' A' ' 81' ' ' GLU . 73.2 m-85 -80.53 -34.59 35.42 Favored 'General case' 0 N--CA 1.443 -0.812 0 N-CA-C 107.47 -1.308 . . . . 0.0 107.47 178.502 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.683 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 164.12 129.12 0.02 OUTLIER Pre-proline 0 CA--C 1.511 -0.551 0 CA-C-N 112.616 -2.084 . . . . 0.0 106.759 -179.49 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 72' ' ' PRO . . . . . 0.929 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 20.4 Cg_exo -57.14 -4.75 1.12 Allowed 'Trans proline' 0 C--N 1.333 -0.244 0 C-N-CA 122.84 2.36 . . . . 0.0 113.932 -177.2 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 13.8 ptm180 -148.11 141.09 24.86 Favored 'General case' 0 C--N 1.317 -0.815 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 176.259 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . 0.716 ' HB3' ' HB2' ' A' ' 52' ' ' TYR . . . -59.12 -31.7 69.17 Favored 'General case' 0 C--O 1.219 -0.509 0 CA-C-N 115.615 -0.72 . . . . 0.0 112.298 -177.109 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 8.4 p-10 -85.17 9.68 14.35 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 121.282 0.563 . . . . 0.0 111.263 -174.673 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 50.2 tp -112.13 -33.01 6.37 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.519 -0.764 . . . . 0.0 109.182 173.667 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . 0.683 ' HB2' ' HB3' ' A' ' 71' ' ' ALA . . . -79.6 164.71 23.61 Favored 'General case' 0 N--CA 1.448 -0.548 0 CA-C-N 115.065 -0.97 . . . . 0.0 109.449 173.029 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 19.4 p -100.5 -176.99 3.36 Favored 'General case' 0 C--N 1.322 -0.626 0 C-N-CA 120.429 -0.509 . . . . 0.0 110.292 -179.997 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . 0.606 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 2.5 mtp180 -49.3 -52.63 26.47 Favored 'General case' 0 CA--C 1.512 -0.517 0 O-C-N 123.403 0.439 . . . . 0.0 111.178 -174.505 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 80' ' ' GLU . . . . . 0.562 ' HG3' ' OE2' ' A' ' 81' ' ' GLU . 11.7 pt-20 -58.39 -42.26 86.67 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.892 -174.806 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 81' ' ' GLU . . . . . 0.662 ' CG ' ' HB3' ' A' ' 70' ' ' TYR . 5.2 mp0 -63.5 -52.71 60.08 Favored 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 111.956 0.354 . . . . 0.0 111.956 174.186 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 82' ' ' GLN . . . . . 0.524 ' HA ' ' CZ3' ' A' ' 62' ' ' TRP . 40.7 mt-30 -59.7 -38.11 80.69 Favored 'General case' 0 CA--C 1.518 -0.268 0 CA-C-O 121.54 0.686 . . . . 0.0 110.097 -176.577 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.775 HD13 ' HA3' ' A' ' 28' ' ' GLY . 31.7 mt -61.57 -49.51 84.09 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.843 0 CA-C-N 114.276 -1.329 . . . . 0.0 111.082 173.832 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 84' ' ' ALA . . . . . 0.647 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -62.67 -38.79 91.72 Favored 'General case' 0 N--CA 1.466 0.342 0 CA-C-O 121.195 0.522 . . . . 0.0 111.886 -176.08 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.542 HG13 ' HB2' ' A' ' 65' ' ' ASN . 60.5 t -64.45 -47.73 88.13 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.495 175.853 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -59.44 -30.86 68.79 Favored 'General case' 0 N--CA 1.453 -0.282 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.051 174.497 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 87' ' ' GLU . . . . . 0.804 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 14.4 mm-40 -59.51 -44.31 93.17 Favored 'General case' 0 C--O 1.219 -0.51 0 CA-C-N 115.344 -0.844 . . . . 0.0 110.484 179.736 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.473 ' HB ' ' HB3' ' A' ' 65' ' ' ASN . 70.7 t -61.48 -49.92 82.46 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.404 0 CA-C-O 121.049 0.452 . . . . 0.0 110.574 -176.414 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . 0.624 HG23 ' CH2' ' A' ' 98' ' ' TRP . 13.7 t -72.64 -33.76 66.82 Favored 'General case' 0 N--CA 1.438 -1.027 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.074 -176.482 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 90' ' ' ARG . . . . . 0.567 ' HG2' ' HA ' ' A' ' 87' ' ' GLU . 0.8 OUTLIER -60.33 -32.1 70.93 Favored 'General case' 0 N--CA 1.472 0.644 0 CA-C-O 121.176 0.512 . . . . 0.0 110.229 175.982 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 91' ' ' LEU . . . . . 0.804 ' HG ' ' O ' ' A' ' 87' ' ' GLU . 19.4 mt -62.51 -33.08 74.17 Favored 'General case' 0 C--N 1.317 -0.805 0 CA-C-O 121.428 0.632 . . . . 0.0 109.733 177.312 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . 0.487 ' NE ' ' HA ' ' A' ' 89' ' ' THR . 2.8 mtm180 -86.29 -52.63 5.51 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-N 115.068 -0.969 . . . . 0.0 110.911 -172.975 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -117.05 2.95 12.73 Favored 'General case' 0 N--CA 1.448 -0.533 0 C-N-CA 119.862 -0.735 . . . . 0.0 112.461 -174.076 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . 0.429 ' HA2' ' O ' ' A' ' 90' ' ' ARG . . . 74.64 -119.98 6.27 Favored Glycine 0 CA--C 1.485 -1.786 0 N-CA-C 111.02 -0.832 . . . . 0.0 111.02 171.943 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 95' ' ' TRP . . . . . 0.457 ' HB3' ' CB ' ' A' ' 102' ' ' ALA . 3.4 m95 -127.57 31.65 5.13 Favored 'General case' 0 C--N 1.299 -1.62 0 N-CA-C 106.338 -1.727 . . . . 0.0 106.338 179.834 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -82.17 -25.92 50.15 Favored Glycine 0 N--CA 1.446 -0.666 0 CA-C-N 114.027 -1.442 . . . . 0.0 110.915 171.539 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -81.14 -23.3 38.41 Favored 'General case' 0 CA--C 1.515 -0.372 0 N-CA-C 109.663 -0.495 . . . . 0.0 109.663 174.352 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 98' ' ' TRP . . . . . 0.624 ' CH2' HG23 ' A' ' 89' ' ' THR . 23.7 m-90 -107.93 107.35 60.17 Favored Pre-proline 0 N--CA 1.448 -0.547 0 CA-C-N 115.776 -0.647 . . . . 0.0 109.909 177.071 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_exo -62.34 -137.01 0.0 OUTLIER 'Trans proline' 0 CA--C 1.535 0.526 0 C-N-CA 123.647 2.898 . . . . 0.0 114.119 -177.044 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 2.9 m -54.54 -28.24 18.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 115.88 -0.6 . . . . 0.0 112.152 -177.787 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 82.5 m -56.8 -39.23 73.75 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.263 178.933 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 102' ' ' ALA . . . . . 0.457 ' CB ' ' HB3' ' A' ' 95' ' ' TRP . . . -71.41 -43.94 65.84 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.845 0.355 . . . . 0.0 111.008 178.118 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -61.54 -44.57 96.8 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.851 -179.649 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -67.33 -19.41 65.45 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.728 -0.669 . . . . 0.0 111.159 177.279 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 105' ' ' ALA . . . . . 0.468 ' CB ' ' HB3' ' A' ' 33' ' ' ALA . . . -91.03 -21.15 21.4 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.913 -0.585 . . . . 0.0 111.606 -178.547 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 111.37 61.52 0.47 Allowed Glycine 0 CA--C 1.519 0.344 0 C-N-CA 121.087 -0.577 . . . . 0.0 111.967 -176.481 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -64.11 149.42 47.69 Favored 'General case' 0 C--N 1.328 -0.355 0 C-N-CA 122.878 0.471 . . . . 0.0 111.006 -176.716 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 74.0 mtp180 . . . . . 0 C--O 1.247 0.946 0 CA-C-O 118.503 -0.761 . . . . 0.0 109.912 -173.899 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . 0.603 ' O ' HG12 ' A' ' 30' ' ' ILE . 4.5 m-20 . . . . . 0 CA--C 1.507 -0.711 0 CA-C-O 121.62 0.724 . . . . 0.0 109.745 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . 0.712 ' HA2' ' HB2' ' A' ' 31' ' ' TRP . . . -81.24 3.45 77.19 Favored Glycine 0 CA--C 1.494 -1.259 0 N-CA-C 110.863 -0.895 . . . . 0.0 110.863 -174.504 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 5.8 m -76.39 -48.2 20.65 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-O 121.727 0.775 . . . . 0.0 109.069 176.864 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.797 HG22 ' O ' ' A' ' 105' ' ' ALA . 4.0 pt -71.77 -34.78 52.92 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.182 0 CA-C-N 114.626 -1.17 . . . . 0.0 109.675 175.807 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' TRP . . . . . 0.712 ' HB2' ' HA2' ' A' ' 28' ' ' GLY . 6.5 m95 -66.26 -35.46 80.46 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.311 -0.858 . . . . 0.0 110.085 177.54 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.763 ' HB2' HH21 ' A' ' 79' ' ' ARG . 13.9 t70 -76.37 -34.42 58.92 Favored 'General case' 0 N--CA 1.449 -0.496 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.215 177.135 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.67 -36.0 82.4 Favored 'General case' 0 N--CA 1.445 -0.683 0 C-N-CA 120.775 -0.37 . . . . 0.0 110.328 176.794 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . 0.497 HD12 ' CZ3' ' A' ' 31' ' ' TRP . 10.0 mt -67.4 -44.09 87.24 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-O 120.895 0.379 . . . . 0.0 110.706 174.28 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . 0.501 ' O ' ' HB3' ' A' ' 39' ' ' ALA . . . -60.22 -34.13 73.23 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-O 121.464 0.65 . . . . 0.0 110.334 177.023 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -76.35 -18.97 78.81 Favored Glycine 0 N--CA 1.448 -0.551 0 CA-C-N 115.306 -0.861 . . . . 0.0 111.231 177.117 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 7.9 t -86.72 -57.1 3.11 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.238 -0.481 . . . . 0.0 111.536 -176.743 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . 0.878 ' HG2' ' SG ' ' A' ' 101' ' ' CYS . 15.6 mm-40 -87.77 -33.61 18.6 Favored 'General case' 0 CA--C 1.515 -0.39 0 CA-C-O 120.821 0.343 . . . . 0.0 111.078 -174.933 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . 0.501 ' HB3' ' O ' ' A' ' 35' ' ' ALA . . . -96.66 -11.31 25.37 Favored 'General case' 0 C--N 1.324 -0.511 0 C-N-CA 120.424 -0.511 . . . . 0.0 112.124 -173.891 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 80.3 8.28 87.73 Favored Glycine 0 CA--C 1.506 -0.53 0 N-CA-C 110.125 -1.19 . . . . 0.0 110.125 -177.291 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 87.62 56.24 2.16 Favored Glycine 0 N--CA 1.434 -1.455 0 CA-C-N 114.129 -1.036 . . . . 0.0 112.595 179.706 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 50.7 t30 -154.44 122.77 6.06 Favored 'General case' 0 CA--C 1.507 -0.71 0 N-CA-C 109.413 -0.588 . . . . 0.0 109.413 176.993 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 43' ' ' TRP . . . . . 0.712 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 26.3 m95 -96.25 -12.64 24.25 Favored 'General case' 0 C--N 1.308 -1.231 0 CA-C-N 115.055 -0.975 . . . . 0.0 110.415 -173.298 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -101.95 8.97 40.91 Favored 'General case' 0 C--N 1.318 -0.782 0 CA-C-N 115.367 -0.833 . . . . 0.0 110.786 -178.36 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.738 HG22 ' CA ' ' A' ' 53' ' ' GLY . 2.0 tt -72.87 144.22 13.12 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.769 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.006 179.249 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 47.6 t-20 -160.42 101.37 1.36 Allowed 'General case' 0 C--N 1.314 -0.972 0 N-CA-C 109.432 -0.581 . . . . 0.0 109.432 -179.525 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 23.4 p -82.89 -17.13 44.85 Favored 'General case' 0 N--CA 1.445 -0.724 0 CA-C-N 115.559 -0.746 . . . . 0.0 111.222 -178.974 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 91.33 22.19 32.77 Favored Glycine 0 N--CA 1.445 -0.745 0 N-CA-C 111.141 -0.784 . . . . 0.0 111.141 178.398 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 28.7 p-10 -93.67 11.38 29.18 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 121.2 0.524 . . . . 0.0 111.385 -175.904 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . 0.461 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 94.36 -11.38 70.41 Favored Glycine 0 N--CA 1.447 -0.576 0 C-N-CA 120.874 -0.679 . . . . 0.0 111.524 -178.486 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 51' ' ' TYR . . . . . 0.601 ' HA ' ' HA ' ' A' ' 58' ' ' ASP . 0.2 OUTLIER -114.64 162.62 16.54 Favored 'General case' 0 N--CA 1.447 -0.591 0 N-CA-C 107.787 -1.19 . . . . 0.0 107.787 176.94 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 52' ' ' TYR . . . . . 0.635 ' HB2' ' HB3' ' A' ' 74' ' ' ALA . 26.9 m-85 -127.9 169.68 13.67 Favored 'General case' 0 C--N 1.309 -1.191 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.046 -172.717 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.738 ' CA ' HG22 ' A' ' 45' ' ' ILE . . . -68.85 -170.68 6.56 Favored Glycine 0 N--CA 1.445 -0.719 0 N-CA-C 114.342 0.497 . . . . 0.0 114.342 -170.944 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . 0.689 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 75.49 -107.3 2.28 Favored Glycine 0 N--CA 1.44 -1.057 0 C-N-CA 120.984 -0.627 . . . . 0.0 111.856 179.248 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.492 HG12 ' HE1' ' A' ' 98' ' ' TRP . 2.1 t -88.56 9.61 2.29 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.655 0 CA-C-O 121.203 0.525 . . . . 0.0 110.357 -177.403 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 56' ' ' GLN . . . . . 0.659 ' HG3' ' HB3' ' A' ' 38' ' ' GLU . 7.7 mm-40 60.02 50.42 6.66 Favored 'General case' 0 N--CA 1.468 0.426 0 CA-C-N 115.197 -0.911 . . . . 0.0 112.66 174.513 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . 0.502 ' HZ ' ' CA ' ' A' ' 86' ' ' ALA . 49.9 m-85 -76.2 132.24 39.82 Favored 'General case' 0 CA--C 1.503 -0.861 0 CA-C-N 115.126 -0.943 . . . . 0.0 112.301 176.345 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.601 ' HA ' ' HA ' ' A' ' 51' ' ' TYR . 5.6 p-10 -72.54 153.76 41.15 Favored 'General case' 0 C--N 1.315 -0.897 0 C-N-CA 119.542 -0.863 . . . . 0.0 108.707 159.644 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . 0.748 ' HA ' HE21 ' A' ' 59' ' ' GLN . 0.0 OUTLIER -54.92 -36.33 65.13 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-O 120.67 0.271 . . . . 0.0 111.482 -178.187 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -67.63 -49.67 48.33 Favored Glycine 0 C--O 1.226 -0.372 0 CA-C-N 116.046 -0.525 . . . . 0.0 112.445 -174.289 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 88.4 m -65.68 -41.4 92.46 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 121.366 0.603 . . . . 0.0 110.894 179.084 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 62' ' ' TRP . . . . . 0.466 ' CE2' ' HA3' ' A' ' 67' ' ' GLY . 56.5 t-105 -59.07 -48.91 79.87 Favored 'General case' 0 N--CA 1.444 -0.762 0 CA-C-N 115.104 -0.953 . . . . 0.0 109.467 177.144 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . 0.439 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 34.8 tt0 -68.18 -34.64 76.68 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 115.051 -0.977 . . . . 0.0 111.05 -178.604 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -64.43 -41.34 96.64 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.942 -0.572 . . . . 0.0 111.394 -175.914 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . 0.649 HD22 ' N ' ' A' ' 65' ' ' ASN . 0.7 OUTLIER -84.99 -8.63 58.65 Favored 'General case' 0 N--CA 1.451 -0.384 0 CA-C-O 121.109 0.48 . . . . 0.0 110.21 177.394 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 91.76 52.85 2.2 Favored Glycine 0 N--CA 1.451 -0.36 0 CA-C-N 115.762 -0.653 . . . . 0.0 113.15 172.627 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . 0.538 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -80.02 -26.46 55.57 Favored Glycine 0 N--CA 1.439 -1.121 0 C-N-CA 120.669 -0.777 . . . . 0.0 112.338 -178.599 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.962 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 7.6 mp -57.56 -23.0 48.14 Favored 'General case' 0 N--CA 1.45 -0.463 0 N-CA-C 113.272 0.841 . . . . 0.0 113.272 -173.256 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . 0.435 ' HG3' ' N ' ' A' ' 70' ' ' TYR . 1.1 ptp180 -70.39 -31.89 69.31 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-O 121.005 0.431 . . . . 0.0 110.044 176.829 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 70' ' ' TYR . . . . . 1.022 ' HB3' ' HG3' ' A' ' 81' ' ' GLU . 67.5 m-85 -81.39 -34.53 31.58 Favored 'General case' 0 CA--C 1.505 -0.766 0 N-CA-C 107.457 -1.312 . . . . 0.0 107.457 177.274 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.592 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 165.77 129.6 0.03 OUTLIER Pre-proline 0 C--O 1.218 -0.572 0 CA-C-N 112.272 -2.24 . . . . 0.0 107.259 -178.225 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 72' ' ' PRO . . . . . 0.962 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 7.0 Cg_exo -61.02 0.22 0.96 Allowed 'Trans proline' 0 C--N 1.331 -0.367 0 C-N-CA 122.786 2.324 . . . . 0.0 113.536 -177.318 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 73' ' ' ARG . . . . . 0.476 ' HB2' ' CD2' ' A' ' 52' ' ' TYR . 3.4 ptt180 -151.79 136.65 17.19 Favored 'General case' 0 N--CA 1.441 -0.923 0 N-CA-C 108.968 -0.753 . . . . 0.0 108.968 178.817 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . 0.635 ' HB3' ' HB2' ' A' ' 52' ' ' TYR . . . -56.05 -29.55 60.65 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 115.064 -0.971 . . . . 0.0 113.136 -177.081 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . 0.544 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 11.6 p-10 -83.54 -2.26 55.59 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 121.014 0.435 . . . . 0.0 111.205 -175.729 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.487 ' HB3' ' HB1' ' A' ' 71' ' ' ALA . 61.6 tp -101.51 -31.48 10.86 Favored 'General case' 0 C--N 1.322 -0.604 0 N-CA-C 108.536 -0.913 . . . . 0.0 108.536 172.103 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . 0.695 ' HB1' ' HB3' ' A' ' 81' ' ' GLU . . . -78.82 163.26 25.48 Favored 'General case' 0 N--CA 1.443 -0.825 0 CA-C-N 114.739 -1.118 . . . . 0.0 109.86 174.963 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 61.2 p -101.33 -174.59 2.64 Favored 'General case' 0 C--N 1.31 -1.149 0 CA-C-N 115.934 -0.575 . . . . 0.0 111.072 -176.956 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . 0.763 HH21 ' HB2' ' A' ' 32' ' ' ASP . 46.2 mtp180 -54.07 -54.44 39.29 Favored 'General case' 0 CA--C 1.515 -0.374 0 CA-C-O 120.759 0.314 . . . . 0.0 110.437 179.256 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 1.9 pm0 -60.19 -40.37 89.81 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.275 -0.875 . . . . 0.0 111.289 -176.52 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 81' ' ' GLU . . . . . 1.022 ' HG3' ' HB3' ' A' ' 70' ' ' TYR . 0.3 OUTLIER -62.62 -51.19 68.28 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.921 -0.582 . . . . 0.0 112.272 175.94 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 82' ' ' GLN . . . . . 0.62 ' HB2' ' HZ3' ' A' ' 43' ' ' TRP . 53.4 mt-30 -64.07 -35.83 82.01 Favored 'General case' 0 CA--C 1.515 -0.4 0 CA-C-O 121.103 0.478 . . . . 0.0 109.715 179.973 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.608 HG23 ' CD1' ' A' ' 31' ' ' TRP . 14.7 mt -59.8 -45.43 94.79 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 CA-C-N 115.239 -0.891 . . . . 0.0 110.526 176.636 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 84' ' ' ALA . . . . . 0.485 ' O ' HG23 ' A' ' 88' ' ' VAL . . . -60.15 -44.29 95.08 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-O 121.209 0.528 . . . . 0.0 110.511 -178.449 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 67.5 t -69.1 -48.58 68.53 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.604 0 CA-C-N 115.428 -0.806 . . . . 0.0 111.493 179.341 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 86' ' ' ALA . . . . . 0.502 ' CA ' ' HZ ' ' A' ' 57' ' ' PHE . . . -62.6 -34.63 77.4 Favored 'General case' 0 CA--C 1.51 -0.584 0 CA-C-O 121.378 0.608 . . . . 0.0 110.536 179.891 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 87' ' ' GLU . . . . . 0.634 ' HA ' ' HG2' ' A' ' 90' ' ' ARG . 0.7 OUTLIER -71.49 -28.99 64.3 Favored 'General case' 0 C--N 1.315 -0.892 0 CA-C-N 115.525 -0.761 . . . . 0.0 109.965 -176.46 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.636 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 59.9 t -62.47 -42.56 96.19 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.191 0 N-CA-C 109.212 -0.662 . . . . 0.0 109.212 168.969 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . 0.71 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 0.2 OUTLIER -71.96 -41.23 68.0 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 115.869 -0.605 . . . . 0.0 111.54 -174.445 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 90' ' ' ARG . . . . . 0.634 ' HG2' ' HA ' ' A' ' 87' ' ' GLU . 30.3 ptt180 -59.27 -36.87 76.3 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.657 -175.775 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 91' ' ' LEU . . . . . 0.636 ' HG ' ' O ' ' A' ' 88' ' ' VAL . 4.6 pp -74.88 -25.25 58.82 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.616 -0.72 . . . . 0.0 111.388 -170.087 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . 0.457 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 1.7 mtm180 -85.01 -46.24 11.38 Favored 'General case' 0 CA--C 1.511 -0.533 0 CA-C-O 121.513 0.673 . . . . 0.0 109.796 -176.113 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 93' ' ' GLN . . . . . 0.439 ' NE2' HG22 ' A' ' 89' ' ' THR . 16.6 pt20 -98.71 -29.45 13.01 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.15 -0.932 . . . . 0.0 113.01 -168.592 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 91.86 35.85 6.64 Favored Glycine 0 N--CA 1.446 -0.637 0 C-N-CA 120.167 -1.016 . . . . 0.0 111.355 175.459 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 95' ' ' TRP . . . . . 0.504 ' HA ' ' HE3' ' A' ' 98' ' ' TRP . 31.2 m95 68.3 22.66 7.97 Favored 'General case' 0 C--O 1.222 -0.378 0 CA-C-O 121.486 0.66 . . . . 0.0 110.027 177.186 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -70.11 -27.15 73.32 Favored Glycine 0 N--CA 1.449 -0.454 0 CA-C-N 115.135 -0.938 . . . . 0.0 112.35 175.519 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -75.45 -30.49 59.98 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.782 0.325 . . . . 0.0 110.58 177.242 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 98' ' ' TRP . . . . . 0.71 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 16.5 m-90 -103.8 104.76 44.55 Favored Pre-proline 0 C--N 1.324 -0.527 0 N-CA-C 109.706 -0.479 . . . . 0.0 109.706 179.972 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 99' ' ' PRO . . . . . 0.405 ' HD3' ' HA ' ' A' ' 98' ' ' TRP . 17.5 Cg_exo -71.09 -93.12 0.01 OUTLIER 'Trans proline' 0 CA--C 1.537 0.645 0 C-N-CA 123.192 2.594 . . . . 0.0 114.523 -173.341 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . 0.472 ' O ' ' HD2' ' A' ' 104' ' ' ARG . 1.3 p -71.68 -27.57 28.54 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.391 0 CA-C-O 121.89 0.852 . . . . 0.0 109.781 -172.686 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 101' ' ' CYS . . . . . 0.878 ' SG ' ' HG2' ' A' ' 38' ' ' GLU . 33.2 m -65.74 -34.76 78.92 Favored 'General case' 0 C--N 1.318 -0.772 0 CA-C-N 114.313 -1.312 . . . . 0.0 111.056 -175.712 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 102' ' ' ALA . . . . . 0.668 ' HB1' ' HB2' ' A' ' 107' ' ' ALA . . . -65.53 -46.55 79.16 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-O 120.945 0.403 . . . . 0.0 110.146 -179.782 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -63.7 -40.59 97.16 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.282 0.563 . . . . 0.0 110.545 179.352 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 104' ' ' ARG . . . . . 0.472 ' HD2' ' O ' ' A' ' 100' ' ' VAL . 0.0 OUTLIER -71.9 -37.89 70.02 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.661 -0.7 . . . . 0.0 111.918 -179.346 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 105' ' ' ALA . . . . . 0.797 ' O ' HG22 ' A' ' 30' ' ' ILE . . . -82.37 -27.84 31.88 Favored 'General case' 0 C--N 1.329 -0.313 0 N-CA-C 112.009 0.374 . . . . 0.0 112.009 -176.166 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 109.4 67.02 0.58 Allowed Glycine 0 CA--C 1.522 0.486 0 C-N-CA 120.64 -0.791 . . . . 0.0 112.277 -173.741 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 107' ' ' ALA . . . . . 0.668 ' HB2' ' HB1' ' A' ' 102' ' ' ALA . . . -58.4 149.81 23.92 Favored 'General case' 0 C--N 1.324 -0.516 0 C-N-CA 123.586 0.754 . . . . 0.0 111.664 178.808 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 8.9 ptm180 . . . . . 0 C--O 1.247 0.945 0 CA-C-N 115.476 -0.783 . . . . 0.0 110.165 -173.168 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . 0.654 ' O ' HG12 ' A' ' 30' ' ' ILE . 2.5 m-20 . . . . . 0 CA--C 1.506 -0.737 0 CA-C-O 121.86 0.838 . . . . 0.0 109.297 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . 0.556 ' HA2' ' HB2' ' A' ' 31' ' ' TRP . . . -79.81 3.81 68.12 Favored Glycine 0 N--CA 1.434 -1.45 0 CA-C-N 114.841 -1.072 . . . . 0.0 110.496 -174.829 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 19.9 t -77.06 -38.86 51.77 Favored 'General case' 0 C--N 1.318 -0.798 0 N-CA-C 108.701 -0.851 . . . . 0.0 108.701 173.456 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.806 ' HA ' ' HB1' ' A' ' 105' ' ' ALA . 0.0 OUTLIER -71.48 -36.66 61.39 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.669 0 N-CA-C 107.166 -1.42 . . . . 0.0 107.166 177.167 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' TRP . . . . . 0.556 ' HB2' ' HA2' ' A' ' 28' ' ' GLY . 14.6 m95 -75.05 -37.91 61.55 Favored 'General case' 0 N--CA 1.442 -0.826 0 CA-C-N 114.447 -1.252 . . . . 0.0 110.726 -176.863 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 23.2 t70 -78.44 -33.28 48.62 Favored 'General case' 0 N--CA 1.442 -0.846 0 CA-C-N 116.445 -0.343 . . . . 0.0 110.933 178.365 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . 0.443 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -68.52 -36.74 79.28 Favored 'General case' 0 N--CA 1.454 -0.26 0 C-N-CA 120.18 -0.608 . . . . 0.0 110.561 176.37 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . 0.504 HG21 ' CD1' ' A' ' 98' ' ' TRP . 79.7 mt -66.63 -46.22 86.54 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-O 120.761 0.315 . . . . 0.0 110.169 174.494 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . 0.439 ' O ' ' HB3' ' A' ' 39' ' ' ALA . . . -58.05 -34.62 70.29 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 121.292 0.568 . . . . 0.0 110.448 176.13 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . 0.519 ' HA2' ' N ' ' A' ' 41' ' ' GLY . . . -80.47 -11.23 84.38 Favored Glycine 0 N--CA 1.45 -0.429 0 CA-C-N 115.616 -0.72 . . . . 0.0 111.975 179.27 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 44.3 t -97.96 -50.75 4.29 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 120.643 0.259 . . . . 0.0 111.309 -176.991 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . 0.601 ' HG2' ' SG ' ' A' ' 101' ' ' CYS . 13.7 mt-10 -88.02 -31.85 19.1 Favored 'General case' 0 CA--C 1.513 -0.474 0 CA-C-O 120.906 0.384 . . . . 0.0 110.346 -175.403 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . 0.439 ' HB3' ' O ' ' A' ' 35' ' ' ALA . . . -103.17 -9.18 19.85 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.828 -177.904 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 77.97 9.92 86.59 Favored Glycine 0 CA--C 1.507 -0.432 0 N-CA-C 110.011 -1.236 . . . . 0.0 110.011 -177.586 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . 0.519 ' N ' ' HA2' ' A' ' 36' ' ' GLY . . . 85.9 59.25 1.9 Allowed Glycine 0 N--CA 1.435 -1.384 0 CA-C-N 114.049 -1.076 . . . . 0.0 111.337 -176.398 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 42' ' ' ASN . . . . . 0.604 ' HB3' ' HB ' ' A' ' 45' ' ' ILE . 1.8 t30 -140.46 89.3 2.27 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 109.215 -0.661 . . . . 0.0 109.215 -176.105 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 43' ' ' TRP . . . . . 0.631 ' HA ' ' N ' ' A' ' 54' ' ' GLY . 50.0 m95 -75.19 -7.83 54.92 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-O 121.563 0.697 . . . . 0.0 110.135 -176.506 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -104.73 9.51 35.01 Favored 'General case' 0 C--N 1.316 -0.867 0 CA-C-N 114.851 -1.068 . . . . 0.0 111.473 -179.637 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.916 HG22 ' HA2' ' A' ' 53' ' ' GLY . 9.7 tt -74.41 143.21 13.74 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.794 0 CA-C-O 121.194 0.521 . . . . 0.0 110.699 -176.862 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 15.3 t-20 -148.37 88.07 1.62 Allowed 'General case' 0 C--N 1.314 -0.958 0 CA-C-O 121.145 0.497 . . . . 0.0 109.681 179.177 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 5.1 p -72.45 -23.95 61.13 Favored 'General case' 0 C--N 1.319 -0.752 0 CA-C-N 115.297 -0.865 . . . . 0.0 111.129 -179.342 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 96.8 16.71 35.26 Favored Glycine 0 N--CA 1.448 -0.513 0 C-N-CA 120.951 -0.642 . . . . 0.0 111.552 178.79 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 12.0 m120 -79.93 2.72 22.36 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.807 0.337 . . . . 0.0 111.006 -175.397 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . 0.45 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 85.7 -3.87 86.55 Favored Glycine 0 N--CA 1.446 -0.678 0 N-CA-C 109.905 -1.278 . . . . 0.0 109.905 -168.396 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 51' ' ' TYR . . . . . 0.506 ' CE1' ' HB3' ' A' ' 58' ' ' ASP . 0.4 OUTLIER -109.09 155.72 20.64 Favored 'General case' 0 N--CA 1.45 -0.453 0 N-CA-C 107.036 -1.468 . . . . 0.0 107.036 177.94 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 52' ' ' TYR . . . . . 0.828 ' O ' ' HA ' ' A' ' 56' ' ' GLN . 47.3 m-85 -129.55 171.32 12.71 Favored 'General case' 0 C--N 1.317 -0.823 0 C-N-CA 120.266 -0.574 . . . . 0.0 112.536 -170.303 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.916 ' HA2' HG22 ' A' ' 45' ' ' ILE . . . -47.97 154.69 1.4 Allowed Glycine 0 N--CA 1.453 -0.172 0 N-CA-C 115.583 0.993 . . . . 0.0 115.583 -171.459 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . 0.631 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 97.79 -109.8 3.89 Favored Glycine 0 N--CA 1.442 -0.923 0 CA-C-N 114.653 -0.774 . . . . 0.0 111.708 176.631 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.432 HG23 ' CD1' ' A' ' 57' ' ' PHE . 1.9 m -84.58 -3.22 7.82 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 CA-C-O 121.681 0.753 . . . . 0.0 110.924 178.403 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 56' ' ' GLN . . . . . 0.828 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 6.1 tt0 55.29 51.4 13.14 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 113.855 -1.521 . . . . 0.0 113.803 168.12 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . 0.432 ' CD1' HG23 ' A' ' 55' ' ' VAL . 1.6 p90 -109.85 172.53 6.8 Favored 'General case' 0 C--O 1.236 0.349 0 C-N-CA 119.731 -0.787 . . . . 0.0 111.533 173.928 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.506 ' HB3' ' CE1' ' A' ' 51' ' ' TYR . 6.8 p-10 -79.0 156.48 28.42 Favored 'General case' 0 C--N 1.329 -0.308 0 N-CA-C 113.733 1.012 . . . . 0.0 113.733 -161.499 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . 0.667 ' HA ' HE21 ' A' ' 59' ' ' GLN . 0.0 OUTLIER -57.03 -38.58 73.38 Favored 'General case' 0 N--CA 1.449 -0.48 0 CA-C-N 113.492 -1.685 . . . . 0.0 111.579 178.805 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -67.38 -49.67 50.02 Favored Glycine 0 N--CA 1.44 -1.089 0 CA-C-N 115.881 -0.6 . . . . 0.0 112.182 -174.256 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 91.6 m -65.8 -41.64 91.67 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 121.37 0.605 . . . . 0.0 110.425 176.405 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 62' ' ' TRP . . . . . 0.594 ' CH2' ' HA ' ' A' ' 74' ' ' ALA . 44.8 t-105 -56.27 -49.49 74.07 Favored 'General case' 0 N--CA 1.447 -0.615 0 CA-C-N 115.129 -0.941 . . . . 0.0 109.958 177.485 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . 0.671 ' HG3' HD11 ' A' ' 68' ' ' LEU . 18.3 tt0 -67.45 -36.47 81.25 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-N 114.907 -1.042 . . . . 0.0 110.77 -179.226 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -64.95 -41.52 95.41 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.657 -0.701 . . . . 0.0 111.059 -177.578 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . 0.633 ' HB2' HG13 ' A' ' 85' ' ' VAL . 8.4 m120 -81.68 -16.44 51.28 Favored 'General case' 0 C--N 1.325 -0.473 0 N-CA-C 109.557 -0.534 . . . . 0.0 109.557 177.991 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 97.01 45.48 2.61 Favored Glycine 0 N--CA 1.449 -0.442 0 CA-C-N 115.784 -0.643 . . . . 0.0 113.538 170.648 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . 0.402 ' HA2' ' CD2' ' A' ' 70' ' ' TYR . . . -79.42 -24.47 60.85 Favored Glycine 0 N--CA 1.44 -1.037 0 N-CA-C 110.762 -0.935 . . . . 0.0 110.762 -179.543 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.683 ' HA ' ' HA ' ' A' ' 72' ' ' PRO . 19.1 mt -54.63 -25.77 28.75 Favored 'General case' 0 N--CA 1.449 -0.503 0 CA-C-O 121.365 0.602 . . . . 0.0 110.728 -176.3 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 8.4 ptm180 -71.98 -27.79 63.0 Favored 'General case' 0 N--CA 1.439 -0.996 0 CA-C-N 115.132 -0.94 . . . . 0.0 109.922 -175.835 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 70' ' ' TYR . . . . . 0.801 ' HB2' ' OE2' ' A' ' 81' ' ' GLU . 10.4 m-85 -94.13 -33.25 13.41 Favored 'General case' 0 N--CA 1.433 -1.308 0 N-CA-C 106.625 -1.62 . . . . 0.0 106.625 177.566 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.933 ' HB1' ' HB3' ' A' ' 76' ' ' LEU . . . 179.16 122.38 0.21 Allowed Pre-proline 0 N--CA 1.447 -0.621 0 CA-C-N 113.422 -1.717 . . . . 0.0 108.754 -178.589 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 72' ' ' PRO . . . . . 0.683 ' HA ' ' HA ' ' A' ' 68' ' ' LEU . 11.9 Cg_exo -61.2 1.58 0.62 Allowed 'Trans proline' 0 CA--C 1.528 0.216 0 C-N-CA 122.683 2.255 . . . . 0.0 113.293 179.417 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 73' ' ' ARG . . . . . 0.522 ' HB2' ' CD2' ' A' ' 52' ' ' TYR . 15.1 ptm180 -151.28 138.2 19.02 Favored 'General case' 0 C--N 1.316 -0.889 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 175.236 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . 0.672 ' HB3' ' HB2' ' A' ' 52' ' ' TYR . . . -58.36 -28.53 65.22 Favored 'General case' 0 C--O 1.218 -0.561 0 CA-C-N 115.543 -0.753 . . . . 0.0 112.584 -174.082 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 11.3 p-10 -87.95 10.15 19.81 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-O 121.062 0.458 . . . . 0.0 111.009 -176.393 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.933 ' HB3' ' HB1' ' A' ' 71' ' ' ALA . 41.6 tp -101.03 -40.16 7.36 Favored 'General case' 0 N--CA 1.45 -0.447 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.121 176.352 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . 0.847 ' HB3' ' HG2' ' A' ' 81' ' ' GLU . . . -103.84 168.81 8.89 Favored 'General case' 0 N--CA 1.447 -0.596 0 CA-C-O 121.108 0.48 . . . . 0.0 110.467 176.757 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 43.6 p -90.17 -177.96 5.28 Favored 'General case' 0 C--N 1.315 -0.918 0 CA-C-N 115.676 -0.693 . . . . 0.0 112.785 -167.303 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . 0.576 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 5.0 mtp180 -49.27 -48.83 45.68 Favored 'General case' 0 CA--C 1.513 -0.457 0 C-N-CA 123.94 0.896 . . . . 0.0 111.782 -171.899 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 2.3 pm0 -60.53 -30.31 69.67 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.567 -0.742 . . . . 0.0 111.74 -175.957 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 81' ' ' GLU . . . . . 0.847 ' HG2' ' HB3' ' A' ' 77' ' ' ALA . 0.0 OUTLIER -71.71 -50.38 30.8 Favored 'General case' 0 N--CA 1.449 -0.485 0 C-N-CA 120.934 -0.306 . . . . 0.0 110.311 176.011 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 82' ' ' GLN . . . . . 0.747 ' N ' ' HG3' ' A' ' 81' ' ' GLU . 4.6 mt-30 -59.64 -35.47 74.47 Favored 'General case' 0 CA--C 1.508 -0.661 0 N-CA-C 109.336 -0.616 . . . . 0.0 109.336 -179.851 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.675 ' O ' ' HG2' ' A' ' 87' ' ' GLU . 21.8 mt -61.37 -47.2 94.53 Favored 'Isoleucine or valine' 0 C--O 1.212 -0.92 0 CA-C-N 114.824 -1.08 . . . . 0.0 110.527 175.755 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 84' ' ' ALA . . . . . 0.643 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -61.03 -43.92 98.17 Favored 'General case' 0 C--O 1.239 0.527 0 CA-C-O 121.378 0.608 . . . . 0.0 111.462 -176.555 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.633 HG13 ' HB2' ' A' ' 65' ' ' ASN . 22.1 t -69.1 -48.47 69.06 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-N 115.927 -0.578 . . . . 0.0 110.549 179.551 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -57.66 -28.68 63.96 Favored 'General case' 0 C--O 1.223 -0.311 0 CA-C-N 115.868 -0.606 . . . . 0.0 110.618 173.925 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 87' ' ' GLU . . . . . 0.675 ' HG2' ' O ' ' A' ' 83' ' ' ILE . 6.6 mm-40 -59.76 -44.87 93.65 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.955 -0.566 . . . . 0.0 109.65 178.166 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.712 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 46.4 t -69.59 -42.34 80.57 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 C-N-CA 120.573 -0.451 . . . . 0.0 110.02 175.58 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . 0.845 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 2.6 m -59.81 -48.09 83.07 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 116.43 -0.35 . . . . 0.0 111.443 -178.898 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 90' ' ' ARG . . . . . 0.654 ' HA ' ' OE1' ' A' ' 93' ' ' GLN . 7.9 ptt180 -65.67 -34.19 77.64 Favored 'General case' 0 CA--C 1.517 -0.31 0 CA-C-O 120.941 0.4 . . . . 0.0 111.421 -174.874 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 91' ' ' LEU . . . . . 0.712 ' HG ' ' O ' ' A' ' 88' ' ' VAL . 4.6 pp -70.52 -22.26 62.65 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.892 -174.143 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . 0.562 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 9.8 mtm180 -84.98 -52.28 6.09 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -178.698 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 93' ' ' GLN . . . . . 0.732 ' HG2' ' H ' ' A' ' 96' ' ' GLY . 0.0 OUTLIER -96.78 -24.75 15.77 Favored 'General case' 0 CA--C 1.539 0.53 0 N-CA-C 113.602 0.964 . . . . 0.0 113.602 -169.275 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 80.51 50.83 5.17 Favored Glycine 0 CA--C 1.507 -0.414 0 C-N-CA 120.728 -0.749 . . . . 0.0 111.783 176.762 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 95' ' ' TRP . . . . . 0.461 ' HA ' ' HE3' ' A' ' 98' ' ' TRP . 1.4 m95 56.61 29.2 15.21 Favored 'General case' 0 C--O 1.223 -0.3 0 CA-C-O 121.582 0.706 . . . . 0.0 109.754 177.355 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.732 ' H ' ' HG2' ' A' ' 93' ' ' GLN . . . -83.93 -24.78 47.74 Favored Glycine 0 N--CA 1.449 -0.439 0 CA-C-N 115.314 -0.857 . . . . 0.0 111.87 174.912 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -80.9 -23.88 38.65 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 121.238 0.542 . . . . 0.0 109.685 176.423 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 98' ' ' TRP . . . . . 0.845 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 23.4 m-90 -101.01 108.01 52.52 Favored Pre-proline 0 N--CA 1.445 -0.708 0 N-CA-C 108.59 -0.893 . . . . 0.0 108.59 175.63 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 99' ' ' PRO . . . . . 0.43 ' HD3' ' HA ' ' A' ' 98' ' ' TRP . 45.0 Cg_exo -63.7 -133.68 0.0 OUTLIER 'Trans proline' 0 CA--C 1.541 0.828 0 C-N-CA 123.654 2.903 . . . . 0.0 113.991 -175.928 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 41.8 t -55.22 -25.56 16.99 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.287 0 CA-C-O 120.886 0.374 . . . . 0.0 111.637 -175.116 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 101' ' ' CYS . . . . . 0.601 ' SG ' ' HG2' ' A' ' 38' ' ' GLU . 85.1 m -63.99 -25.66 68.23 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 116.315 -0.402 . . . . 0.0 111.686 -178.25 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -69.36 -44.63 71.17 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.922 0.392 . . . . 0.0 110.368 177.704 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -67.42 -36.63 81.63 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 121.19 0.519 . . . . 0.0 110.142 178.554 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 104' ' ' ARG . . . . . 0.416 HH11 ' HD3' ' A' ' 104' ' ' ARG . 9.8 mmm180 -64.73 -32.56 74.29 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.352 -0.84 . . . . 0.0 110.937 176.844 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 105' ' ' ALA . . . . . 0.806 ' HB1' ' HA ' ' A' ' 30' ' ' ILE . . . -89.01 -22.46 22.97 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 116.136 -0.484 . . . . 0.0 112.085 -176.076 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 103.18 68.04 0.77 Allowed Glycine 0 CA--C 1.521 0.445 0 C-N-CA 120.97 -0.633 . . . . 0.0 112.313 -177.794 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -64.45 152.71 40.88 Favored 'General case' 0 N--CA 1.45 -0.452 0 C-N-CA 122.856 0.462 . . . . 0.0 111.256 -176.063 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 25.5 mmt180 . . . . . 0 C--O 1.248 0.987 0 CA-C-O 118.289 -0.862 . . . . 0.0 111.56 177.64 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . 0.449 ' O ' HG13 ' A' ' 30' ' ' ILE . 48.6 m-20 . . . . . 0 CA--C 1.503 -0.838 0 CA-C-O 122.316 1.055 . . . . 0.0 108.817 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . 0.625 ' HA2' ' HB2' ' A' ' 31' ' ' TRP . . . -72.15 -2.7 54.29 Favored Glycine 0 N--CA 1.442 -0.923 0 CA-C-N 113.677 -1.602 . . . . 0.0 111.555 -176.637 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 6.3 p -78.02 -48.09 16.96 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-O 122.049 0.928 . . . . 0.0 109.568 174.677 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.741 ' HA ' ' HB1' ' A' ' 105' ' ' ALA . 0.1 OUTLIER -62.89 -35.64 72.11 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.971 0 CA-C-N 113.392 -1.731 . . . . 0.0 107.713 175.691 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' TRP . . . . . 0.625 ' HB2' ' HA2' ' A' ' 28' ' ' GLY . 18.5 m95 -73.58 -36.91 65.61 Favored 'General case' 0 C--N 1.317 -0.817 0 CA-C-N 114.301 -1.318 . . . . 0.0 110.821 -178.092 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 1.6 t70 -77.92 -34.39 51.37 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.596 179.671 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . 0.448 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -70.07 -34.28 72.98 Favored 'General case' 0 N--CA 1.45 -0.474 0 C-N-CA 120.877 -0.329 . . . . 0.0 110.339 176.584 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . 0.504 HG13 ' O ' ' A' ' 30' ' ' ILE . 54.0 mt -65.12 -45.1 95.19 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.225 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 172.311 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . 0.552 ' HA ' ' O ' ' A' ' 54' ' ' GLY . . . -57.59 -36.41 71.68 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.228 176.613 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -73.92 -21.12 79.57 Favored Glycine 0 N--CA 1.451 -0.328 0 CA-C-N 115.574 -0.739 . . . . 0.0 112.237 178.886 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 18.5 t -93.75 -52.9 4.24 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-O 121.038 0.447 . . . . 0.0 111.811 -176.593 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 9.3 tp10 -87.58 -32.3 19.41 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 121.399 0.619 . . . . 0.0 110.107 -171.667 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . 0.448 ' HB3' ' O ' ' A' ' 35' ' ' ALA . . . -101.51 -13.57 17.85 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 115.644 -0.707 . . . . 0.0 111.616 -177.805 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 80.1 13.08 82.54 Favored Glycine 0 CA--C 1.505 -0.555 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 -176.808 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 81.03 58.83 2.55 Favored Glycine 0 N--CA 1.436 -1.319 0 CA-C-N 114.143 -1.028 . . . . 0.0 111.965 -177.569 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 42' ' ' ASN . . . . . 0.81 ' HB3' ' HB ' ' A' ' 45' ' ' ILE . 2.0 t30 -151.44 97.34 2.39 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 108.73 -0.841 . . . . 0.0 108.73 -178.229 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 43' ' ' TRP . . . . . 0.731 ' HZ3' ' HB2' ' A' ' 82' ' ' GLN . 49.8 m95 -75.51 -17.03 60.22 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-O 121.49 0.662 . . . . 0.0 110.495 -176.348 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -101.2 14.31 32.36 Favored 'General case' 0 C--N 1.313 -0.995 0 CA-C-N 115.007 -0.997 . . . . 0.0 110.693 -179.451 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.81 ' HB ' ' HB3' ' A' ' 42' ' ' ASN . 6.2 tt -77.44 143.26 13.1 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.951 0 CA-C-O 121.083 0.468 . . . . 0.0 109.759 -178.487 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . 0.598 ' ND2' HH21 ' A' ' 73' ' ' ARG . 29.3 t-20 -145.54 89.1 1.89 Allowed 'General case' 0 C--N 1.304 -1.399 0 CA-C-O 121.814 0.816 . . . . 0.0 108.994 179.369 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 2.6 p -67.98 -22.03 65.03 Favored 'General case' 0 N--CA 1.443 -0.81 0 CA-C-N 114.091 -1.413 . . . . 0.0 111.142 -178.418 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 90.03 23.45 32.45 Favored Glycine 0 N--CA 1.441 -0.984 0 N-CA-C 111.112 -0.795 . . . . 0.0 111.112 178.109 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 49' ' ' ASN . . . . . 0.615 HD22 ' H ' ' A' ' 51' ' ' TYR . 0.3 OUTLIER -101.58 15.42 28.95 Favored 'General case' 0 C--N 1.326 -0.426 0 N-CA-C 112.384 0.513 . . . . 0.0 112.384 -177.214 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 93.48 -10.91 72.39 Favored Glycine 0 CA--C 1.509 -0.309 0 N-CA-C 111.401 -0.68 . . . . 0.0 111.401 177.608 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 51' ' ' TYR . . . . . 0.615 ' H ' HD22 ' A' ' 49' ' ' ASN . 0.1 OUTLIER -118.79 149.28 41.76 Favored 'General case' 0 N--CA 1.445 -0.713 0 N-CA-C 106.434 -1.691 . . . . 0.0 106.434 -177.566 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 52' ' ' TYR . . . . . 0.711 ' HB2' ' HB3' ' A' ' 74' ' ' ALA . 22.4 m-85 -119.56 170.9 8.76 Favored 'General case' 0 C--N 1.309 -1.18 0 C-N-CA 119.921 -0.711 . . . . 0.0 112.183 -169.298 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.794 ' HA2' HG22 ' A' ' 45' ' ' ILE . . . -57.56 167.64 5.07 Favored Glycine 0 N--CA 1.449 -0.493 0 N-CA-C 115.939 1.136 . . . . 0.0 115.939 -166.115 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . 0.652 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 86.62 -102.08 2.7 Favored Glycine 0 N--CA 1.437 -1.296 0 CA-C-N 114.202 -0.999 . . . . 0.0 111.541 178.247 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.584 HG22 ' HB3' ' A' ' 82' ' ' GLN . 3.1 m -85.4 -2.85 7.91 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.737 0 CA-C-O 120.434 0.159 . . . . 0.0 111.329 -179.586 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 56' ' ' GLN . . . . . 0.666 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 8.9 tp-100 52.78 52.94 12.96 Favored 'General case' 0 CA--C 1.534 0.339 0 N-CA-C 113.481 0.919 . . . . 0.0 113.481 166.17 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . 0.407 ' CD1' HG23 ' A' ' 55' ' ' VAL . 1.0 OUTLIER -120.57 163.33 18.16 Favored 'General case' 0 C--N 1.327 -0.379 0 C-N-CA 119.862 -0.735 . . . . 0.0 111.366 170.996 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.562 ' HB2' ' CD1' ' A' ' 51' ' ' TYR . 0.0 OUTLIER -73.6 155.1 39.44 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 114.799 -1.092 . . . . 0.0 113.365 -164.565 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . 0.764 ' HA ' HE21 ' A' ' 59' ' ' GLN . 0.0 OUTLIER -53.3 -39.98 64.4 Favored 'General case' 0 N--CA 1.451 -0.402 0 CA-C-N 114.078 -1.419 . . . . 0.0 112.303 -179.905 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -68.39 -49.45 45.04 Favored Glycine 0 C--O 1.225 -0.441 0 CA-C-N 115.921 -0.582 . . . . 0.0 112.03 -177.264 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 32.8 m -65.64 -38.18 88.63 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-O 121.461 0.648 . . . . 0.0 110.26 176.105 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 62' ' ' TRP . . . . . 0.559 ' CH2' ' HA ' ' A' ' 74' ' ' ALA . 39.1 t-105 -56.67 -48.89 76.61 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 115.32 -0.854 . . . . 0.0 109.643 173.9 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . 0.575 ' CB ' HD11 ' A' ' 68' ' ' LEU . 60.6 tt0 -67.07 -33.97 76.66 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-N 114.876 -1.056 . . . . 0.0 110.943 179.359 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -63.04 -42.03 99.65 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.796 -0.638 . . . . 0.0 111.366 -177.81 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 33.0 m-80 -86.64 -11.76 50.44 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.977 0.418 . . . . 0.0 110.303 177.809 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . 0.418 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 92.93 52.38 2.1 Favored Glycine 0 C--O 1.22 -0.743 0 CA-C-N 115.858 -0.61 . . . . 0.0 114.043 170.533 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . 0.475 ' HA3' ' CE2' ' A' ' 62' ' ' TRP . . . -80.28 -27.95 50.43 Favored Glycine 0 N--CA 1.441 -0.967 0 C-N-CA 120.666 -0.778 . . . . 0.0 112.629 179.694 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.652 ' HA ' ' HA ' ' A' ' 72' ' ' PRO . 2.4 mp -59.3 -20.51 55.04 Favored 'General case' 0 CA--C 1.519 -0.241 0 CA-C-O 120.864 0.364 . . . . 0.0 111.923 -170.084 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . 0.418 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 9.1 ptp180 -72.55 -28.1 62.63 Favored 'General case' 0 N--CA 1.44 -0.944 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.225 -179.155 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 70' ' ' TYR . . . . . 0.717 ' HB2' ' CD ' ' A' ' 81' ' ' GLU . 10.5 m-85 -92.26 -33.29 14.71 Favored 'General case' 0 N--CA 1.433 -1.316 0 N-CA-C 106.683 -1.599 . . . . 0.0 106.683 176.894 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.667 ' HB1' ' HB3' ' A' ' 76' ' ' LEU . . . 175.34 126.86 0.13 Allowed Pre-proline 0 N--CA 1.45 -0.443 0 CA-C-N 113.005 -1.907 . . . . 0.0 108.494 179.107 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 72' ' ' PRO . . . . . 0.652 ' HA ' ' HA ' ' A' ' 68' ' ' LEU . 6.1 Cg_exo -62.46 3.86 0.42 Allowed 'Trans proline' 0 C--N 1.333 -0.272 0 C-N-CA 122.717 2.278 . . . . 0.0 113.709 -178.987 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 73' ' ' ARG . . . . . 0.598 HH21 ' ND2' ' A' ' 46' ' ' ASN . 11.0 ptm180 -154.53 142.51 20.17 Favored 'General case' 0 C--N 1.316 -0.877 0 N-CA-C 108.988 -0.745 . . . . 0.0 108.988 177.302 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . 0.711 ' HB3' ' HB2' ' A' ' 52' ' ' TYR . . . -61.69 -29.45 70.1 Favored 'General case' 0 C--O 1.219 -0.508 0 CA-C-N 115.935 -0.575 . . . . 0.0 112.284 -176.675 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 18.6 p-10 -86.44 12.01 11.2 Favored 'General case' 0 C--N 1.317 -0.836 0 CA-C-O 121.168 0.508 . . . . 0.0 111.032 -175.091 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.667 ' HB3' ' HB1' ' A' ' 71' ' ' ALA . 39.6 tp -108.38 -43.58 4.3 Favored 'General case' 0 N--CA 1.449 -0.5 0 CA-C-N 115.586 -0.734 . . . . 0.0 110.429 175.39 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . 0.654 ' HB3' ' HG2' ' A' ' 81' ' ' GLU . . . -99.06 167.85 10.45 Favored 'General case' 0 N--CA 1.449 -0.475 0 CA-C-O 121.58 0.705 . . . . 0.0 111.079 178.767 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . 0.435 ' OG1' ' HG2' ' A' ' 80' ' ' GLU . 27.6 p -91.78 178.73 5.82 Favored 'General case' 0 C--N 1.316 -0.877 0 CA-C-N 115.002 -0.999 . . . . 0.0 112.69 -167.564 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . 0.667 ' HG2' ' CE2' ' A' ' 43' ' ' TRP . 64.5 mtp180 -45.89 -42.9 13.2 Favored 'General case' 0 N--CA 1.469 0.501 0 C-N-CA 123.523 0.729 . . . . 0.0 111.88 -174.779 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 80' ' ' GLU . . . . . 0.435 ' HG2' ' OG1' ' A' ' 78' ' ' THR . 7.4 pt-20 -57.19 -37.57 72.37 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 115.738 -0.665 . . . . 0.0 111.002 -177.423 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 81' ' ' GLU . . . . . 0.717 ' CD ' ' HB2' ' A' ' 70' ' ' TYR . 0.0 OUTLIER -72.03 -49.48 36.49 Favored 'General case' 0 N--CA 1.444 -0.731 0 CA-C-N 116.665 -0.243 . . . . 0.0 110.65 -179.238 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 82' ' ' GLN . . . . . 0.731 ' HB2' ' HZ3' ' A' ' 43' ' ' TRP . 9.4 mp0 -61.97 -32.38 72.82 Favored 'General case' 0 CA--C 1.509 -0.61 0 C-N-CA 120.343 -0.543 . . . . 0.0 110.198 -179.276 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.67 ' O ' ' HB3' ' A' ' 87' ' ' GLU . 40.7 mt -64.37 -46.05 94.17 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.753 0 CA-C-N 115.459 -0.791 . . . . 0.0 109.788 176.598 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 84' ' ' ALA . . . . . 0.484 ' O ' ' HG3' ' A' ' 87' ' ' GLU . . . -66.12 -48.22 71.57 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 121.038 0.447 . . . . 0.0 111.649 -176.7 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 47.2 t -69.58 -48.35 66.42 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.577 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.874 -175.414 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 86' ' ' ALA . . . . . 0.431 ' HB1' ' CZ2' ' A' ' 98' ' ' TRP . . . -66.56 -30.15 70.38 Favored 'General case' 0 N--CA 1.444 -0.728 0 CA-C-O 121.026 0.441 . . . . 0.0 110.234 179.682 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 87' ' ' GLU . . . . . 0.67 ' HB3' ' O ' ' A' ' 83' ' ' ILE . 0.4 OUTLIER -70.44 -30.19 66.97 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.774 -177.138 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.671 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 59.1 t -61.29 -42.38 93.34 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.284 0 N-CA-C 108.812 -0.81 . . . . 0.0 108.812 170.732 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . 0.855 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 0.2 OUTLIER -67.25 -43.83 80.91 Favored 'General case' 0 C--N 1.316 -0.872 0 CA-C-N 115.517 -0.765 . . . . 0.0 110.631 -179.45 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 90' ' ' ARG . . . . . 0.599 ' HG3' ' O ' ' A' ' 87' ' ' GLU . 3.0 ppt_? -63.25 -34.37 77.52 Favored 'General case' 0 CA--C 1.517 -0.295 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.764 -177.512 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 91' ' ' LEU . . . . . 0.671 ' HG ' ' O ' ' A' ' 88' ' ' VAL . 4.4 pp -73.5 -23.7 60.08 Favored 'General case' 0 C--N 1.322 -0.588 0 O-C-N 123.312 0.383 . . . . 0.0 110.949 -171.387 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . 0.543 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 4.6 mtm180 -84.3 -48.5 9.66 Favored 'General case' 0 CA--C 1.512 -0.511 0 CA-C-O 121.516 0.674 . . . . 0.0 109.628 -178.386 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 93' ' ' GLN . . . . . 0.581 ' NE2' HG22 ' A' ' 89' ' ' THR . 21.7 pt20 -98.47 -28.47 13.59 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 114.967 -1.015 . . . . 0.0 113.285 -169.1 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 92.54 40.1 5.13 Favored Glycine 0 CA--C 1.509 -0.323 0 C-N-CA 120.504 -0.855 . . . . 0.0 111.759 176.013 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 95' ' ' TRP . . . . . 0.587 ' CZ2' HD12 ' A' ' 30' ' ' ILE . 34.4 m95 68.7 11.53 8.38 Favored 'General case' 0 C--O 1.216 -0.671 0 C-N-CA 123.316 0.646 . . . . 0.0 110.165 178.536 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -58.85 -29.51 64.82 Favored Glycine 0 CA--C 1.522 0.49 0 CA-C-N 115.523 -0.762 . . . . 0.0 113.463 178.795 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -80.83 -17.64 50.12 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.938 0.399 . . . . 0.0 110.884 178.031 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 98' ' ' TRP . . . . . 0.855 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 30.0 m-90 -104.93 108.02 60.13 Favored Pre-proline 0 C--N 1.324 -0.51 0 CA-C-N 116.052 -0.522 . . . . 0.0 109.736 178.517 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 39.5 Cg_exo -64.43 -134.63 0.0 OUTLIER 'Trans proline' 0 CA--C 1.537 0.631 0 C-N-CA 123.95 3.1 . . . . 0.0 114.148 -175.845 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 3.8 m -54.14 -27.48 16.55 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.229 0 N-CA-C 112.442 0.534 . . . . 0.0 112.442 -176.813 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 77.1 m -60.81 -40.36 92.41 Favored 'General case' 0 C--N 1.317 -0.847 0 CA-C-N 115.887 -0.597 . . . . 0.0 111.37 179.183 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 102' ' ' ALA . . . . . 0.422 ' HB2' ' CB ' ' A' ' 98' ' ' TRP . . . -72.03 -41.6 67.31 Favored 'General case' 0 CA--C 1.517 -0.295 0 CA-C-O 121.092 0.473 . . . . 0.0 110.26 177.302 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -59.27 -46.21 89.15 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.577 -0.738 . . . . 0.0 110.917 179.128 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 3.0 mpp_? -73.71 -22.08 60.03 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.816 -0.629 . . . . 0.0 111.423 179.854 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 105' ' ' ALA . . . . . 0.741 ' HB1' ' HA ' ' A' ' 30' ' ' ILE . . . -83.06 -20.89 34.09 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.397 179.433 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 104.52 60.72 0.66 Allowed Glycine 0 CA--C 1.519 0.305 0 C-N-CA 121.111 -0.566 . . . . 0.0 112.142 -179.178 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -64.11 141.53 58.74 Favored 'General case' 0 C--O 1.235 0.295 0 C-N-CA 122.659 0.384 . . . . 0.0 111.939 -176.574 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 108' ' ' ARG . . . . . 0.658 ' OXT' ' HD3' ' A' ' 108' ' ' ARG . 0.0 OUTLIER . . . . . 0 C--O 1.246 0.903 0 CA-C-O 118.567 -0.73 . . . . 0.0 110.726 -177.491 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . 0.726 ' O ' HG12 ' A' ' 30' ' ' ILE . 33.5 m-20 . . . . . 0 N--CA 1.448 -0.557 0 N-CA-C 108.553 -0.906 . . . . 0.0 108.553 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . 0.487 ' HA2' ' CD1' ' A' ' 31' ' ' TRP . . . -72.22 -2.6 54.33 Favored Glycine 0 CA--C 1.5 -0.856 0 N-CA-C 110.605 -0.998 . . . . 0.0 110.605 177.482 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 16.4 m -69.63 -37.41 76.8 Favored 'General case' 0 C--N 1.317 -0.828 0 CA-C-O 121.499 0.666 . . . . 0.0 109.352 173.564 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.726 HG12 ' O ' ' A' ' 27' ' ' ASP . 0.3 OUTLIER -69.55 -35.97 68.9 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.672 0 N-CA-C 107.159 -1.422 . . . . 0.0 107.159 176.364 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 31' ' ' TRP . . . . . 0.537 ' CZ2' ' HD3' ' A' ' 90' ' ' ARG . 21.7 m95 -71.45 -36.45 71.23 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 114.255 -1.339 . . . . 0.0 110.776 -177.394 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 27.1 t70 -76.82 -33.39 57.96 Favored 'General case' 0 N--CA 1.445 -0.713 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.167 177.904 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . 0.468 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -70.69 -34.07 71.58 Favored 'General case' 0 N--CA 1.447 -0.592 0 C-N-CA 120.432 -0.507 . . . . 0.0 110.138 176.529 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . 0.527 ' HA ' ' HB3' ' A' ' 101' ' ' CYS . 56.9 mt -67.38 -41.7 86.58 Favored 'Isoleucine or valine' 0 C--O 1.234 0.28 0 CA-C-N 115.851 -0.613 . . . . 0.0 109.99 172.647 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . 0.5 ' HA ' ' O ' ' A' ' 54' ' ' GLY . . . -58.75 -38.68 78.97 Favored 'General case' 0 CA--C 1.515 -0.379 0 CA-C-O 121.448 0.642 . . . . 0.0 110.112 174.045 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -75.29 -10.1 84.34 Favored Glycine 0 N--CA 1.449 -0.443 0 CA-C-N 115.192 -0.913 . . . . 0.0 111.343 179.22 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.427 ' HB3' ' O ' ' A' ' 34' ' ' ILE . 14.4 t -90.87 -66.72 0.9 Allowed 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.174 -0.513 . . . . 0.0 111.327 -178.607 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . 0.872 ' HG3' ' SG ' ' A' ' 101' ' ' CYS . 53.7 mt-10 -89.7 -34.48 16.22 Favored 'General case' 0 CA--C 1.513 -0.45 0 C-N-CA 120.399 -0.521 . . . . 0.0 110.918 -174.023 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . 0.493 ' HB3' ' O ' ' A' ' 35' ' ' ALA . . . -84.15 -18.32 37.12 Favored 'General case' 0 N--CA 1.445 -0.685 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.227 -176.363 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 80.35 12.57 82.96 Favored Glycine 0 CA--C 1.503 -0.701 0 N-CA-C 109.991 -1.243 . . . . 0.0 109.991 -177.351 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 82.81 61.47 1.94 Allowed Glycine 0 N--CA 1.434 -1.44 0 CA-C-N 114.066 -1.067 . . . . 0.0 111.866 -176.689 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 42' ' ' ASN . . . . . 0.473 ' HB3' ' HB ' ' A' ' 45' ' ' ILE . 52.8 t-20 -155.1 124.37 6.32 Favored 'General case' 0 N--CA 1.442 -0.835 0 N-CA-C 108.624 -0.88 . . . . 0.0 108.624 -179.215 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 43' ' ' TRP . . . . . 0.764 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 44.9 m95 -97.27 -10.41 25.78 Favored 'General case' 0 C--N 1.308 -1.217 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.9 -174.207 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . 0.424 ' HA ' ' HB2' ' A' ' 75' ' ' ASP . . . -110.16 9.34 23.95 Favored 'General case' 0 C--N 1.315 -0.91 0 CA-C-N 115.115 -0.948 . . . . 0.0 110.982 179.938 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.473 ' HB ' ' HB3' ' A' ' 42' ' ' ASN . 11.5 tt -73.78 143.27 13.84 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.875 0 CA-C-O 121.462 0.649 . . . . 0.0 110.959 -178.438 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -135.11 94.71 3.18 Favored 'General case' 0 C--N 1.311 -1.097 0 N-CA-C 109.028 -0.73 . . . . 0.0 109.028 179.46 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 1.7 p -73.79 -12.19 60.62 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-N 115.628 -0.714 . . . . 0.0 110.933 -178.269 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 85.29 21.84 53.42 Favored Glycine 0 N--CA 1.443 -0.878 0 N-CA-C 111.179 -0.769 . . . . 0.0 111.179 174.1 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 33.4 p-10 -103.44 10.17 37.4 Favored 'General case' 0 C--N 1.322 -0.612 0 C-N-CA 120.894 -0.322 . . . . 0.0 111.562 -174.944 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . 0.524 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 87.32 -2.66 86.68 Favored Glycine 0 N--CA 1.454 -0.149 0 C-N-CA 120.87 -0.681 . . . . 0.0 111.658 -178.252 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 51' ' ' TYR . . . . . 0.666 ' HA ' ' HA ' ' A' ' 58' ' ' ASP . 0.3 OUTLIER -116.51 147.7 41.52 Favored 'General case' 0 CA--C 1.508 -0.643 0 N-CA-C 106.5 -1.667 . . . . 0.0 106.5 178.649 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 52' ' ' TYR . . . . . 0.729 ' O ' ' HA ' ' A' ' 56' ' ' GLN . 47.9 m-85 -114.7 163.79 14.97 Favored 'General case' 0 C--N 1.304 -1.376 0 C-N-CA 119.821 -0.751 . . . . 0.0 111.688 -170.247 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.427 ' CA ' HG22 ' A' ' 45' ' ' ILE . . . -60.56 177.95 3.41 Favored Glycine 0 N--CA 1.448 -0.54 0 O-C-N 124.047 0.842 . . . . 0.0 114.849 -167.801 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . 0.674 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 85.87 -108.7 3.27 Favored Glycine 0 N--CA 1.436 -1.359 0 N-CA-C 111.121 -0.792 . . . . 0.0 111.121 -178.417 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.433 HG22 ' HB3' ' A' ' 82' ' ' GLN . 0.2 OUTLIER -83.2 -1.03 5.54 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.69 0 CA-C-O 121.437 0.637 . . . . 0.0 110.067 178.713 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 56' ' ' GLN . . . . . 0.729 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 20.0 tp60 56.12 50.43 13.61 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 114.265 -1.334 . . . . 0.0 113.28 164.678 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -118.72 169.5 9.78 Favored 'General case' 0 C--N 1.329 -0.317 0 C-N-CA 119.44 -0.904 . . . . 0.0 111.478 172.209 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.666 ' HA ' ' HA ' ' A' ' 51' ' ' TYR . 8.3 p-10 -74.38 162.13 29.17 Favored 'General case' 0 C--N 1.327 -0.382 0 N-CA-C 113.995 1.109 . . . . 0.0 113.995 -163.992 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . 0.427 ' HB2' ' CE2' ' A' ' 52' ' ' TYR . 20.6 tp60 -56.06 -42.61 76.89 Favored 'General case' 0 N--CA 1.443 -0.813 0 CA-C-N 114.085 -1.416 . . . . 0.0 111.084 177.256 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -67.77 -49.68 47.44 Favored Glycine 0 N--CA 1.451 -0.365 0 CA-C-N 115.056 -0.974 . . . . 0.0 112.667 -173.896 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 92.3 m -64.63 -40.24 95.12 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-O 120.644 0.259 . . . . 0.0 110.958 177.91 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 62' ' ' TRP . . . . . 0.472 ' CZ3' ' HA ' ' A' ' 82' ' ' GLN . 54.4 t-105 -56.64 -49.3 75.41 Favored 'General case' 0 N--CA 1.45 -0.454 0 CA-C-O 121.809 0.814 . . . . 0.0 109.102 175.008 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . 0.532 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 29.5 tt0 -64.83 -35.67 81.85 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 114.653 -1.158 . . . . 0.0 111.319 -179.979 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -64.93 -42.4 94.72 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.976 -0.556 . . . . 0.0 111.335 -174.606 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 33.8 m-80 -81.49 -9.24 59.75 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.981 0.42 . . . . 0.0 110.369 176.815 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . 0.569 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 92.29 50.38 2.61 Favored Glycine 0 C--N 1.332 0.309 0 CA-C-N 115.865 -0.607 . . . . 0.0 112.658 173.288 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . 0.564 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -80.03 -23.59 61.24 Favored Glycine 0 N--CA 1.438 -1.205 0 C-N-CA 120.887 -0.673 . . . . 0.0 112.781 -176.48 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.908 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 6.9 mp -60.87 -22.9 64.73 Favored 'General case' 0 N--CA 1.448 -0.552 0 N-CA-C 112.139 0.422 . . . . 0.0 112.139 -172.893 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . 0.569 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 3.7 ptp180 -68.37 -32.81 73.16 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-O 121.12 0.486 . . . . 0.0 109.928 177.002 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 70' ' ' TYR . . . . . 0.622 ' HB3' ' CG ' ' A' ' 81' ' ' GLU . 65.6 m-85 -82.26 -34.23 28.85 Favored 'General case' 0 N--CA 1.44 -0.948 0 N-CA-C 107.564 -1.273 . . . . 0.0 107.564 178.915 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.659 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 168.35 124.35 0.04 OUTLIER Pre-proline 0 N--CA 1.448 -0.528 0 CA-C-N 112.868 -1.969 . . . . 0.0 107.319 -178.835 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 72' ' ' PRO . . . . . 0.908 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 24.8 Cg_exo -54.98 -7.38 0.95 Allowed 'Trans proline' 0 C--N 1.335 -0.174 0 C-N-CA 123.003 2.468 . . . . 0.0 114.11 -177.534 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 12.8 ptm180 -146.42 137.16 24.13 Favored 'General case' 0 C--N 1.319 -0.754 0 N-CA-C 108.853 -0.795 . . . . 0.0 108.853 176.472 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . 0.608 ' HB3' ' HB2' ' A' ' 52' ' ' TYR . . . -56.26 -32.0 64.11 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.151 -0.931 . . . . 0.0 112.574 -176.992 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . 0.611 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 4.9 p-10 -78.81 -8.14 58.51 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 121.108 0.48 . . . . 0.0 110.93 -175.312 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 64.5 tp -93.61 -32.04 14.26 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 108.781 -0.822 . . . . 0.0 108.781 173.605 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . 0.79 ' HB1' ' HB2' ' A' ' 81' ' ' GLU . . . -79.68 157.96 27.1 Favored 'General case' 0 N--CA 1.445 -0.713 0 CA-C-N 114.964 -1.016 . . . . 0.0 110.487 176.092 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 40.6 p -100.62 -172.48 2.2 Favored 'General case' 0 C--N 1.315 -0.906 0 CA-C-N 115.937 -0.574 . . . . 0.0 109.918 179.698 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . 0.764 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 10.9 mtt180 -51.14 -52.71 41.33 Favored 'General case' 0 CA--C 1.51 -0.579 0 O-C-N 123.432 0.457 . . . . 0.0 111.029 -175.433 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 1.3 pm0 -57.71 -48.31 79.93 Favored 'General case' 0 C--N 1.314 -0.943 0 CA-C-N 115.135 -0.938 . . . . 0.0 112.142 -176.374 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 81' ' ' GLU . . . . . 0.79 ' HB2' ' HB1' ' A' ' 77' ' ' ALA . 6.5 mp0 -61.31 -50.48 72.79 Favored 'General case' 0 C--O 1.233 0.221 0 N-CA-C 111.9 0.333 . . . . 0.0 111.9 176.491 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 82' ' ' GLN . . . . . 0.472 ' HA ' ' CZ3' ' A' ' 62' ' ' TRP . 51.4 mt-30 -59.93 -39.94 87.22 Favored 'General case' 0 CA--C 1.516 -0.355 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.229 -177.819 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.682 ' O ' ' HG2' ' A' ' 87' ' ' GLU . 28.3 mt -61.78 -45.54 98.46 Favored 'Isoleucine or valine' 0 C--O 1.212 -0.886 0 CA-C-N 115.36 -0.836 . . . . 0.0 110.151 178.601 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 84' ' ' ALA . . . . . 0.541 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -59.48 -43.4 93.28 Favored 'General case' 0 C--O 1.239 0.509 0 CA-C-O 121.154 0.502 . . . . 0.0 111.336 -178.347 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 60.5 t -68.66 -48.11 73.28 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.649 179.517 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -59.8 -30.08 68.66 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.63 -0.714 . . . . 0.0 110.518 176.08 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 87' ' ' GLU . . . . . 0.682 ' HG2' ' O ' ' A' ' 83' ' ' ILE . 40.1 mm-40 -60.22 -45.81 91.92 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.371 -0.831 . . . . 0.0 110.396 -179.998 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.571 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 24.6 t -64.58 -41.74 93.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 121.392 0.615 . . . . 0.0 109.645 177.823 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . 0.777 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 0.5 OUTLIER -67.56 -46.7 71.95 Favored 'General case' 0 C--N 1.318 -0.791 0 CA-C-N 115.635 -0.711 . . . . 0.0 111.581 -175.662 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 90' ' ' ARG . . . . . 0.537 ' HD3' ' CZ2' ' A' ' 31' ' ' TRP . 13.8 ptt180 -64.55 -34.16 77.59 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.494 -0.321 . . . . 0.0 111.192 -175.247 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 91' ' ' LEU . . . . . 0.571 ' HG ' ' O ' ' A' ' 88' ' ' VAL . 4.4 pp -72.63 -23.74 60.96 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.289 -171.92 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . 0.525 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 6.6 mtm180 -83.93 -48.53 9.89 Favored 'General case' 0 CA--C 1.511 -0.53 0 CA-C-O 121.437 0.636 . . . . 0.0 109.734 -178.638 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 93' ' ' GLN . . . . . 0.669 ' NE2' HG22 ' A' ' 89' ' ' THR . 28.9 pt20 -98.44 -28.98 13.38 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 114.773 -1.103 . . . . 0.0 113.741 -168.135 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 82.99 48.5 5.41 Favored Glycine 0 N--CA 1.448 -0.502 0 C-N-CA 120.11 -1.043 . . . . 0.0 111.357 178.784 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 95' ' ' TRP . . . . . 0.511 ' HA ' ' HE3' ' A' ' 98' ' ' TRP . 2.4 m95 62.59 24.12 14.35 Favored 'General case' 0 C--O 1.224 -0.274 0 C-N-CA 123.176 0.591 . . . . 0.0 110.288 176.103 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -69.19 -24.51 75.93 Favored Glycine 0 CA--C 1.52 0.359 0 CA-C-N 115.706 -0.679 . . . . 0.0 112.433 175.977 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . 0.407 ' O ' ' HD3' ' A' ' 99' ' ' PRO . . . -82.05 -34.14 29.61 Favored 'General case' 0 CA--C 1.516 -0.355 0 CA-C-O 120.888 0.375 . . . . 0.0 110.474 176.289 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 98' ' ' TRP . . . . . 0.777 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 22.4 m-90 -96.37 103.55 14.41 Favored Pre-proline 0 N--CA 1.451 -0.414 0 CA-C-N 115.713 -0.676 . . . . 0.0 109.202 -179.62 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 99' ' ' PRO . . . . . 0.487 ' HB2' ' H ' ' A' ' 100' ' ' VAL . 16.4 Cg_exo -73.44 -98.72 0.01 OUTLIER 'Trans proline' 0 CA--C 1.537 0.656 0 C-N-CA 123.27 2.646 . . . . 0.0 114.869 -170.682 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . 0.487 ' H ' ' HB2' ' A' ' 99' ' ' PRO . 32.8 t -70.22 -27.27 31.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-O 121.702 0.763 . . . . 0.0 110.01 -172.853 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 101' ' ' CYS . . . . . 0.872 ' SG ' ' HG3' ' A' ' 38' ' ' GLU . 38.7 m -67.08 -33.98 76.66 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-N 114.755 -1.111 . . . . 0.0 111.13 -174.77 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 102' ' ' ALA . . . . . 0.503 ' HB1' ' HB2' ' A' ' 107' ' ' ALA . . . -65.38 -45.44 84.03 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.817 0.342 . . . . 0.0 110.69 179.839 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -64.76 -36.28 83.79 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 121.102 0.477 . . . . 0.0 110.545 178.824 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 21.1 mmm180 -74.03 -23.35 59.39 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.553 -0.749 . . . . 0.0 111.693 179.057 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 105' ' ' ALA . . . . . 0.626 ' HB1' ' HA ' ' A' ' 30' ' ' ILE . . . -96.91 -21.53 17.41 Favored 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 112.496 0.554 . . . . 0.0 112.496 -174.472 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 103.94 65.15 0.69 Allowed Glycine 0 CA--C 1.518 0.253 0 C-N-CA 120.827 -0.702 . . . . 0.0 111.919 -177.753 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 107' ' ' ALA . . . . . 0.503 ' HB2' ' HB1' ' A' ' 102' ' ' ALA . . . -71.93 152.75 42.3 Favored 'General case' 0 C--N 1.326 -0.433 0 C-N-CA 122.877 0.471 . . . . 0.0 111.674 -174.912 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 10.7 mmm180 . . . . . 0 C--O 1.25 1.081 0 CA-C-O 117.926 -1.035 . . . . 0.0 111.408 175.043 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . 0.535 ' O ' HG12 ' A' ' 30' ' ' ILE . 7.3 m-20 . . . . . 0 CA--C 1.504 -0.794 0 CA-C-O 121.669 0.747 . . . . 0.0 109.498 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . 0.551 ' HA2' ' HD1' ' A' ' 31' ' ' TRP . . . -67.49 -8.02 49.46 Favored Glycine 0 N--CA 1.445 -0.748 0 CA-C-N 114.786 -1.097 . . . . 0.0 110.715 179.484 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 6.1 m -76.72 -39.05 53.13 Favored 'General case' 0 C--N 1.318 -0.779 0 CA-C-O 121.652 0.739 . . . . 0.0 109.239 176.388 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.605 ' HA ' ' HB1' ' A' ' 105' ' ' ALA . 0.7 OUTLIER -68.58 -38.49 79.15 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.592 0 N-CA-C 107.35 -1.352 . . . . 0.0 107.35 177.429 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 31' ' ' TRP . . . . . 0.58 ' CD1' HG23 ' A' ' 83' ' ' ILE . 34.8 m95 -68.52 -36.68 79.2 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 114.535 -1.212 . . . . 0.0 110.378 -177.296 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.723 ' HB2' HH21 ' A' ' 79' ' ' ARG . 33.5 t70 -73.77 -41.23 62.74 Favored 'General case' 0 N--CA 1.445 -0.703 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.1 179.043 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . 0.457 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -70.1 -33.11 71.45 Favored 'General case' 0 N--CA 1.448 -0.55 0 CA-C-N 116.405 -0.361 . . . . 0.0 110.912 -179.966 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . 0.608 ' HA ' ' HB3' ' A' ' 101' ' ' CYS . 50.9 mt -64.23 -49.28 81.88 Favored 'Isoleucine or valine' 0 C--O 1.234 0.256 0 CA-C-O 120.777 0.322 . . . . 0.0 110.56 174.893 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . 0.514 ' O ' ' HB3' ' A' ' 39' ' ' ALA . . . -66.02 -33.7 76.4 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 121.296 0.57 . . . . 0.0 110.218 178.528 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . 0.425 ' HA2' ' N ' ' A' ' 41' ' ' GLY . . . -71.61 -21.98 78.72 Favored Glycine 0 N--CA 1.448 -0.526 0 N-CA-C 111.101 -0.799 . . . . 0.0 111.101 176.892 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -76.19 -69.33 0.51 Allowed 'General case' 0 N--CA 1.448 -0.551 0 CA-C-N 115.291 -0.455 . . . . 0.0 111.536 -178.574 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . 0.678 ' HB2' ' SG ' ' A' ' 101' ' ' CYS . 15.3 tt0 -90.9 -32.99 15.79 Favored 'General case' 0 C--N 1.323 -0.572 0 C-N-CA 119.743 -0.783 . . . . 0.0 110.871 -171.455 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . 0.514 ' HB3' ' O ' ' A' ' 35' ' ' ALA . . . -84.46 -13.85 50.87 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.996 -178.855 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 74.89 20.5 79.44 Favored Glycine 0 CA--C 1.501 -0.839 0 N-CA-C 109.853 -1.299 . . . . 0.0 109.853 -179.472 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . 0.425 ' N ' ' HA2' ' A' ' 36' ' ' GLY . . . 72.2 64.03 2.77 Favored Glycine 0 N--CA 1.433 -1.564 0 CA-C-N 114.108 -1.046 . . . . 0.0 111.093 -172.837 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 42' ' ' ASN . . . . . 0.702 ' HB3' ' HB ' ' A' ' 45' ' ' ILE . 0.2 OUTLIER -140.99 84.21 1.92 Allowed 'General case' 0 C--N 1.322 -0.595 0 N-CA-C 108.815 -0.809 . . . . 0.0 108.815 -177.193 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 43' ' ' TRP . . . . . 0.762 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 37.0 m95 -73.65 -11.59 60.46 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 115.741 -0.663 . . . . 0.0 109.973 -177.922 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -106.6 14.38 27.08 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 115.37 -0.832 . . . . 0.0 111.406 179.583 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.732 HG22 ' HA2' ' A' ' 53' ' ' GLY . 9.0 tt -75.86 144.62 11.7 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.812 0 N-CA-C 109.695 -0.483 . . . . 0.0 109.695 179.83 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 21.7 t-20 -153.99 94.65 1.77 Allowed 'General case' 0 C--N 1.308 -1.208 0 CA-C-O 121.302 0.572 . . . . 0.0 110.38 -178.867 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 16.3 p -76.57 -19.56 57.76 Favored 'General case' 0 N--CA 1.445 -0.709 0 CA-C-N 115.225 -0.898 . . . . 0.0 110.718 178.925 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 87.85 24.02 36.78 Favored Glycine 0 N--CA 1.445 -0.759 0 N-CA-C 110.954 -0.859 . . . . 0.0 110.954 179.256 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 3.8 m-20 -97.54 14.4 26.66 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 121.065 0.459 . . . . 0.0 111.52 -174.259 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . 0.446 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 87.46 -16.03 51.4 Favored Glycine 0 N--CA 1.452 -0.28 0 CA-C-N 115.717 -0.674 . . . . 0.0 111.772 179.631 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 51' ' ' TYR . . . . . 0.748 ' CE1' ' HB2' ' A' ' 58' ' ' ASP . 0.3 OUTLIER -102.72 131.89 49.23 Favored 'General case' 0 N--CA 1.446 -0.66 0 N-CA-C 107.805 -1.183 . . . . 0.0 107.805 169.623 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 52' ' ' TYR . . . . . 0.735 ' CE1' ' HB2' ' A' ' 59' ' ' GLN . 15.0 m-85 -104.26 169.64 8.37 Favored 'General case' 0 C--N 1.311 -1.096 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.85 -173.184 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.732 ' HA2' HG22 ' A' ' 45' ' ' ILE . . . -51.91 158.09 3.1 Favored Glycine 0 CA--C 1.509 -0.326 0 N-CA-C 115.613 1.005 . . . . 0.0 115.613 -169.361 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . 0.582 ' CA ' ' HA ' ' A' ' 43' ' ' TRP . . . 98.49 -113.05 4.62 Favored Glycine 0 N--CA 1.438 -1.168 0 CA-C-N 114.486 -0.857 . . . . 0.0 111.369 175.444 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.427 HG23 ' CD1' ' A' ' 57' ' ' PHE . 1.3 m -86.91 -6.09 10.45 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.73 0 CA-C-O 120.442 0.163 . . . . 0.0 110.82 178.38 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 56' ' ' GLN . . . . . 0.578 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 10.5 pt20 45.52 51.71 9.64 Favored 'General case' 0 N--CA 1.479 1.003 0 N-CA-C 114.502 1.297 . . . . 0.0 114.502 167.483 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . 0.578 ' O ' ' HB3' ' A' ' 58' ' ' ASP . 19.7 p90 -103.67 21.62 15.84 Favored 'General case' 0 C--N 1.328 -0.344 0 N-CA-C 113.25 0.833 . . . . 0.0 113.25 -176.071 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.748 ' HB2' ' CE1' ' A' ' 51' ' ' TYR . 0.4 OUTLIER 89.06 135.82 0.04 OUTLIER 'General case' 0 C--N 1.317 -0.838 0 C-N-CA 124.615 1.166 . . . . 0.0 111.953 168.399 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . 0.735 ' HB2' ' CE1' ' A' ' 52' ' ' TYR . 0.0 OUTLIER -58.81 -34.23 71.27 Favored 'General case' 0 CA--C 1.512 -0.493 0 CA-C-N 114.195 -1.366 . . . . 0.0 110.932 -179.332 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -67.06 -44.05 89.05 Favored Glycine 0 N--CA 1.449 -0.463 0 C-N-CA 120.717 -0.754 . . . . 0.0 111.619 177.667 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . 0.577 ' HB ' ' O ' ' A' ' 57' ' ' PHE . 89.5 m -71.02 -41.2 71.16 Favored 'General case' 0 N--CA 1.445 -0.685 0 CA-C-O 121.048 0.452 . . . . 0.0 110.324 178.023 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 62' ' ' TRP . . . . . 0.453 ' CH2' ' HA ' ' A' ' 74' ' ' ALA . 41.1 t-105 -55.57 -49.98 71.27 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.455 -0.793 . . . . 0.0 110.215 172.71 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . 0.485 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 3.7 tp10 -63.54 -40.34 96.75 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 115.437 -0.801 . . . . 0.0 110.555 179.512 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -61.39 -41.37 97.02 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.753 -0.658 . . . . 0.0 110.804 -177.486 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . 0.441 ' HB3' ' HB ' ' A' ' 88' ' ' VAL . 9.3 m120 -80.55 -9.6 59.77 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.439 178.358 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . 0.498 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 85.32 46.8 5.43 Favored Glycine 0 N--CA 1.449 -0.445 0 CA-C-N 115.736 -0.665 . . . . 0.0 112.689 175.716 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . 0.613 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -78.95 -18.53 74.78 Favored Glycine 0 N--CA 1.442 -0.961 0 C-N-CA 120.868 -0.682 . . . . 0.0 112.429 -174.668 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.988 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 7.0 mp -60.12 -24.11 64.41 Favored 'General case' 0 N--CA 1.445 -0.688 0 N-CA-C 112.545 0.572 . . . . 0.0 112.545 -175.0 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . 0.498 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 9.1 ptp180 -67.2 -31.85 72.52 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 121.405 0.622 . . . . 0.0 109.771 175.933 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 70' ' ' TYR . . . . . 0.815 ' HB3' ' HB3' ' A' ' 81' ' ' GLU . 74.5 m-85 -81.47 -33.91 31.72 Favored 'General case' 0 N--CA 1.443 -0.814 0 N-CA-C 107.728 -1.212 . . . . 0.0 107.728 178.199 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.573 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 165.9 126.01 0.03 OUTLIER Pre-proline 0 CA--C 1.512 -0.517 0 CA-C-N 112.897 -1.956 . . . . 0.0 107.325 -179.011 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 72' ' ' PRO . . . . . 0.988 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 21.2 Cg_exo -56.91 -6.66 1.87 Allowed 'Trans proline' 0 C--N 1.333 -0.242 0 C-N-CA 122.495 2.13 . . . . 0.0 113.587 -179.412 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 13.9 ptm180 -143.85 137.49 27.97 Favored 'General case' 0 C--N 1.321 -0.671 0 N-CA-C 109.228 -0.656 . . . . 0.0 109.228 177.752 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . 0.473 ' HB3' ' HB2' ' A' ' 52' ' ' TYR . . . -60.14 -28.06 67.58 Favored 'General case' 0 C--O 1.218 -0.569 0 CA-C-N 114.999 -1.0 . . . . 0.0 111.916 -176.96 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . 0.538 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 20.7 p-10 -88.13 3.56 48.69 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 121.186 0.517 . . . . 0.0 111.761 -176.449 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 66.9 tp -100.57 -30.67 11.65 Favored 'General case' 0 C--N 1.321 -0.64 0 N-CA-C 108.29 -1.004 . . . . 0.0 108.29 168.637 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . 0.921 ' HB1' ' HB2' ' A' ' 81' ' ' GLU . . . -78.89 143.87 35.48 Favored 'General case' 0 N--CA 1.441 -0.914 0 CA-C-N 114.617 -1.174 . . . . 0.0 110.704 176.486 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 27.7 p -93.88 -170.55 2.35 Favored 'General case' 0 C--N 1.314 -0.969 0 CA-C-N 115.417 -0.811 . . . . 0.0 109.117 178.93 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . 0.762 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 57.0 mtp180 -48.53 -51.38 27.79 Favored 'General case' 0 C--N 1.33 -0.262 0 O-C-N 123.196 0.31 . . . . 0.0 111.001 -178.512 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 10.2 pt-20 -57.64 -48.28 79.9 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.856 -0.611 . . . . 0.0 112.264 -173.776 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 81' ' ' GLU . . . . . 0.921 ' HB2' ' HB1' ' A' ' 77' ' ' ALA . 16.9 mp0 -65.25 -51.09 63.04 Favored 'General case' 0 N--CA 1.452 -0.358 0 N-CA-C 112.056 0.391 . . . . 0.0 112.056 177.339 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 82' ' ' GLN . . . . . 0.661 ' HB2' ' HZ3' ' A' ' 43' ' ' TRP . 46.0 mt-30 -61.6 -38.64 88.34 Favored 'General case' 0 CA--C 1.51 -0.561 0 CA-C-O 120.754 0.312 . . . . 0.0 110.833 -175.426 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.641 ' O ' ' HG2' ' A' ' 87' ' ' GLU . 50.2 mt -59.34 -44.46 92.43 Favored 'Isoleucine or valine' 0 C--O 1.215 -0.715 0 CA-C-N 115.512 -0.767 . . . . 0.0 109.865 176.889 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 84' ' ' ALA . . . . . 0.684 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -66.01 -41.92 90.4 Favored 'General case' 0 C--O 1.237 0.441 0 CA-C-O 121.29 0.567 . . . . 0.0 111.571 -176.841 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.539 HG23 ' O ' ' A' ' 81' ' ' GLU . 14.8 t -69.12 -47.94 71.89 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.696 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.454 178.969 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -58.23 -28.67 65.09 Favored 'General case' 0 C--O 1.232 0.143 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.431 173.389 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 87' ' ' GLU . . . . . 0.773 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 20.2 mm-40 -59.15 -43.87 92.07 Favored 'General case' 0 CA--C 1.51 -0.589 0 CA-C-N 115.32 -0.855 . . . . 0.0 109.619 178.926 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.584 ' O ' ' HG3' ' A' ' 92' ' ' ARG . 40.6 t -63.1 -43.55 99.0 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 CA-C-O 121.293 0.568 . . . . 0.0 109.933 175.572 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . 1.005 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 0.2 OUTLIER -62.61 -47.12 85.16 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.746 -0.661 . . . . 0.0 111.982 -176.016 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 90' ' ' ARG . . . . . 0.491 ' HB3' ' CH2' ' A' ' 31' ' ' TRP . 30.4 ptt85 -60.16 -29.39 68.63 Favored 'General case' 0 N--CA 1.467 0.381 0 CA-C-O 121.313 0.578 . . . . 0.0 110.448 -178.996 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 91' ' ' LEU . . . . . 0.773 ' HG ' ' O ' ' A' ' 87' ' ' GLU . 33.4 mt -66.97 -35.01 79.01 Favored 'General case' 0 C--N 1.314 -0.948 0 CA-C-O 121.406 0.622 . . . . 0.0 109.885 -179.918 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . 0.584 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 4.7 mtm180 -89.11 -51.54 5.54 Favored 'General case' 0 N--CA 1.443 -0.78 0 CA-C-N 115.348 -0.842 . . . . 0.0 110.13 -171.807 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 93' ' ' GLN . . . . . 0.51 HE22 ' HZ3' ' A' ' 98' ' ' TRP . 0.0 OUTLIER -108.72 -15.85 14.31 Favored 'General case' 0 N--CA 1.44 -0.946 0 CA-C-N 115.087 -0.96 . . . . 0.0 111.942 -173.151 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . 0.478 ' HA2' ' O ' ' A' ' 90' ' ' ARG . . . 83.6 -107.41 2.93 Favored Glycine 0 CA--C 1.494 -1.232 0 N-CA-C 111.082 -0.807 . . . . 0.0 111.082 177.911 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 95' ' ' TRP . . . . . . . . . . . . . 3.5 m95 -142.81 27.32 1.66 Allowed 'General case' 0 C--N 1.313 -0.994 0 N-CA-C 106.901 -1.518 . . . . 0.0 106.901 179.813 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -79.19 -22.46 65.38 Favored Glycine 0 N--CA 1.448 -0.546 0 CA-C-N 114.457 -1.247 . . . . 0.0 111.079 173.195 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . 0.418 ' O ' ' HD3' ' A' ' 99' ' ' PRO . . . -85.12 -32.16 22.92 Favored 'General case' 0 C--N 1.327 -0.373 0 N-CA-C 109.378 -0.601 . . . . 0.0 109.378 174.419 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 98' ' ' TRP . . . . . 1.005 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 16.9 m-90 -101.14 100.72 13.94 Favored Pre-proline 0 C--O 1.221 -0.441 0 N-CA-C 109.009 -0.737 . . . . 0.0 109.009 174.027 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 99' ' ' PRO . . . . . 0.418 ' HD3' ' O ' ' A' ' 97' ' ' ALA . 10.3 Cg_exo -79.33 -88.49 0.0 OUTLIER 'Trans proline' 0 CA--C 1.532 0.411 0 C-N-CA 122.848 2.365 . . . . 0.0 115.085 -171.828 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 63.3 t -69.96 -28.32 36.06 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.349 0 CA-C-O 121.679 0.752 . . . . 0.0 110.047 -172.461 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 101' ' ' CYS . . . . . 0.678 ' SG ' ' HB2' ' A' ' 38' ' ' GLU . 87.4 m -72.21 -27.25 62.42 Favored 'General case' 0 C--N 1.317 -0.84 0 CA-C-N 115.25 -0.887 . . . . 0.0 111.084 -176.759 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 102' ' ' ALA . . . . . 0.679 ' HB1' ' HB2' ' A' ' 107' ' ' ALA . . . -69.93 -40.41 75.55 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.808 0.337 . . . . 0.0 110.333 175.658 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -63.08 -37.81 88.68 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 121.432 0.634 . . . . 0.0 110.336 177.591 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -72.88 -30.62 64.1 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.243 -0.89 . . . . 0.0 111.686 177.363 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 105' ' ' ALA . . . . . 0.605 ' HB1' ' HA ' ' A' ' 30' ' ' ILE . . . -96.32 -22.58 17.11 Favored 'General case' 0 C--N 1.325 -0.457 0 N-CA-C 113.001 0.741 . . . . 0.0 113.001 -172.271 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 104.13 69.85 0.8 Allowed Glycine 0 CA--C 1.52 0.376 0 C-N-CA 120.832 -0.699 . . . . 0.0 112.134 -177.302 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 107' ' ' ALA . . . . . 0.679 ' HB2' ' HB1' ' A' ' 102' ' ' ALA . . . -60.02 146.7 41.78 Favored 'General case' 0 CA--C 1.517 -0.325 0 C-N-CA 122.709 0.403 . . . . 0.0 110.912 -179.899 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 97.3 mtt180 . . . . . 0 C--O 1.248 1.013 0 CA-C-O 118.323 -0.846 . . . . 0.0 111.021 -170.482 . . . . . . . . 0 0 . 1 . 021 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . 0.446 ' O ' HG12 ' A' ' 30' ' ' ILE . 19.4 m-20 . . . . . 0 CA--C 1.508 -0.643 0 CA-C-O 121.441 0.639 . . . . 0.0 109.791 . . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . 0.412 ' HA3' HD13 ' A' ' 83' ' ' ILE . . . -64.3 -11.54 47.05 Favored Glycine 0 CA--C 1.503 -0.656 0 CA-C-N 114.961 -1.018 . . . . 0.0 111.051 179.635 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 4.4 m -75.73 -41.27 53.85 Favored 'General case' 0 C--N 1.318 -0.794 0 CA-C-O 121.956 0.884 . . . . 0.0 109.116 177.225 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.547 ' HA ' ' HB1' ' A' ' 105' ' ' ALA . 0.9 OUTLIER -67.91 -38.99 80.94 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.726 0 CA-C-N 113.898 -1.501 . . . . 0.0 107.735 178.423 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 31' ' ' TRP . . . . . 0.522 ' HB2' HG12 ' A' ' 83' ' ' ILE . 32.6 m95 -67.98 -35.96 79.23 Favored 'General case' 0 C--N 1.317 -0.845 0 CA-C-N 114.472 -1.24 . . . . 0.0 110.619 -177.684 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.84 ' HB2' HH21 ' A' ' 79' ' ' ARG . 23.3 t70 -73.07 -37.59 66.74 Favored 'General case' 0 N--CA 1.446 -0.654 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.44 -179.349 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . 0.513 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -70.99 -34.15 71.1 Favored 'General case' 0 N--CA 1.446 -0.632 0 C-N-CA 120.707 -0.397 . . . . 0.0 110.787 176.494 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . 0.53 HG13 ' O ' ' A' ' 30' ' ' ILE . 61.1 mt -67.34 -46.89 82.76 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.283 0 CA-C-O 121.108 0.48 . . . . 0.0 110.701 175.201 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . 0.468 ' O ' ' HB3' ' A' ' 39' ' ' ALA . . . -63.19 -34.39 77.54 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.408 178.108 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -72.63 -15.01 77.67 Favored Glycine 0 N--CA 1.449 -0.491 0 N-CA-C 111.181 -0.768 . . . . 0.0 111.181 176.729 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.448 ' HB3' ' O ' ' A' ' 34' ' ' ILE . 41.3 t -87.18 -64.5 1.14 Allowed 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.296 -0.452 . . . . 0.0 111.292 -176.702 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . 0.803 ' HG3' ' SG ' ' A' ' 101' ' ' CYS . 40.8 mt-10 -88.94 -29.62 19.42 Favored 'General case' 0 CA--C 1.516 -0.357 0 CA-C-O 120.813 0.34 . . . . 0.0 111.784 -173.277 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . 0.468 ' HB3' ' O ' ' A' ' 35' ' ' ALA . . . -92.72 -11.33 34.26 Favored 'General case' 0 C--N 1.322 -0.619 0 C-N-CA 120.455 -0.498 . . . . 0.0 111.316 -176.956 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 76.24 15.52 81.39 Favored Glycine 0 N--CA 1.446 -0.664 0 N-CA-C 109.782 -1.327 . . . . 0.0 109.782 -176.229 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 75.11 51.68 7.4 Favored Glycine 0 N--CA 1.436 -1.339 0 CA-C-N 114.268 -0.966 . . . . 0.0 111.939 -176.449 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 2.2 t-20 -140.67 100.1 3.78 Favored 'General case' 0 N--CA 1.448 -0.542 0 N-CA-C 108.855 -0.795 . . . . 0.0 108.855 179.947 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 43' ' ' TRP . . . . . 0.729 ' CE3' ' HA ' ' A' ' 79' ' ' ARG . 30.9 m95 -82.78 -12.69 57.31 Favored 'General case' 0 C--N 1.313 -1.009 0 CA-C-N 115.241 -0.891 . . . . 0.0 110.529 -172.846 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -104.61 10.99 34.7 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 115.455 -0.793 . . . . 0.0 111.272 -178.145 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.699 HG22 ' HA2' ' A' ' 53' ' ' GLY . 4.0 tt -74.04 143.72 13.28 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.655 0 CA-C-O 121.0 0.429 . . . . 0.0 109.915 179.507 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 17.6 t-20 -142.75 87.22 1.98 Allowed 'General case' 0 C--N 1.313 -0.989 0 CA-C-O 121.286 0.565 . . . . 0.0 109.567 -179.171 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 22.7 p -74.12 -24.57 59.47 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.648 179.983 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 92.43 19.57 37.94 Favored Glycine 0 N--CA 1.445 -0.709 0 N-CA-C 110.824 -0.91 . . . . 0.0 110.824 -177.913 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 64.8 t30 -74.94 -7.31 53.19 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 121.384 0.611 . . . . 0.0 111.12 -174.635 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . 0.498 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 95.73 -12.94 67.03 Favored Glycine 0 CA--C 1.504 -0.643 0 N-CA-C 109.47 -1.452 . . . . 0.0 109.47 -173.252 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 51' ' ' TYR . . . . . 0.629 ' HA ' ' HA ' ' A' ' 58' ' ' ASP . 0.5 OUTLIER -114.74 160.9 18.86 Favored 'General case' 0 N--CA 1.439 -0.984 0 N-CA-C 106.132 -1.803 . . . . 0.0 106.132 173.187 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 52' ' ' TYR . . . . . 0.687 ' HB2' ' HB3' ' A' ' 74' ' ' ALA . 55.5 m-85 -123.51 169.4 11.44 Favored 'General case' 0 C--N 1.308 -1.207 0 C-N-CA 120.085 -0.646 . . . . 0.0 111.403 -169.702 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.699 ' HA2' HG22 ' A' ' 45' ' ' ILE . . . -59.31 171.34 5.25 Favored Glycine 0 N--CA 1.445 -0.724 0 O-C-N 123.778 0.674 . . . . 0.0 113.821 -173.212 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . 0.707 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 87.79 -107.78 3.33 Favored Glycine 0 N--CA 1.44 -1.09 0 C-N-CA 120.708 -0.758 . . . . 0.0 111.77 -179.391 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.524 ' HB ' ' CD1' ' A' ' 57' ' ' PHE . 2.0 t -84.6 0.58 5.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.542 0 CA-C-O 121.276 0.56 . . . . 0.0 110.277 -177.555 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 56' ' ' GLN . . . . . 0.585 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 79.3 mm-40 58.05 44.59 19.16 Favored 'General case' 0 N--CA 1.462 0.164 0 CA-C-N 114.971 -1.013 . . . . 0.0 113.169 170.886 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . 0.524 ' CD1' ' HB ' ' A' ' 55' ' ' VAL . 1.6 p90 -118.98 164.26 15.72 Favored 'General case' 0 C--N 1.325 -0.472 0 C-N-CA 119.435 -0.906 . . . . 0.0 111.914 177.301 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.629 ' HA ' ' HA ' ' A' ' 51' ' ' TYR . 7.9 p-10 -74.81 165.57 25.03 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 114.985 -1.007 . . . . 0.0 113.685 -163.512 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . 0.439 ' HB2' ' HE1' ' A' ' 52' ' ' TYR . 19.5 tp60 -59.26 -41.95 90.04 Favored 'General case' 0 N--CA 1.438 -1.044 0 CA-C-N 114.538 -1.21 . . . . 0.0 110.945 178.184 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -68.1 -49.45 46.89 Favored Glycine 0 C--O 1.225 -0.45 0 CA-C-N 115.617 -0.719 . . . . 0.0 112.614 -172.35 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 86.7 m -62.25 -42.37 99.26 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-O 121.098 0.475 . . . . 0.0 110.761 178.624 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 62' ' ' TRP . . . . . 0.501 ' CH2' ' HA ' ' A' ' 74' ' ' ALA . 53.4 t-105 -56.62 -51.25 69.41 Favored 'General case' 0 N--CA 1.448 -0.565 0 CA-C-N 115.133 -0.94 . . . . 0.0 109.39 175.323 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . 1.033 ' HG3' HD11 ' A' ' 68' ' ' LEU . 24.0 tt0 -64.43 -38.36 90.75 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-N 114.544 -1.207 . . . . 0.0 111.275 -177.606 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -67.71 -42.39 82.03 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.935 -0.575 . . . . 0.0 111.424 -175.027 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . 0.624 HD22 ' N ' ' A' ' 65' ' ' ASN . 0.7 OUTLIER -77.96 -8.85 58.69 Favored 'General case' 0 N--CA 1.451 -0.405 0 CA-C-O 121.316 0.579 . . . . 0.0 109.672 176.812 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . 0.524 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 90.17 47.71 3.76 Favored Glycine 0 N--CA 1.449 -0.498 0 CA-C-N 115.438 -0.801 . . . . 0.0 112.417 173.386 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . 0.545 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -80.47 -16.39 76.01 Favored Glycine 0 N--CA 1.444 -0.813 0 C-N-CA 120.876 -0.678 . . . . 0.0 112.065 -177.14 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 1.033 HD11 ' HG3' ' A' ' 63' ' ' GLU . 20.8 mt -65.53 -28.58 69.27 Favored 'General case' 0 C--N 1.314 -0.937 0 CA-C-O 120.999 0.428 . . . . 0.0 111.351 -171.06 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . 0.524 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 11.7 ptm180 -65.04 -31.69 73.04 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.217 175.379 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 70' ' ' TYR . . . . . 0.796 ' HB3' ' HB3' ' A' ' 81' ' ' GLU . 89.9 m-85 -77.4 -34.61 54.79 Favored 'General case' 0 CA--C 1.505 -0.755 0 N-CA-C 107.723 -1.214 . . . . 0.0 107.723 178.328 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.582 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 164.65 123.57 0.02 OUTLIER Pre-proline 0 C--N 1.319 -0.724 0 CA-C-N 112.125 -2.307 . . . . 0.0 106.859 -178.232 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 72' ' ' PRO . . . . . 0.59 ' HA ' ' HA ' ' A' ' 68' ' ' LEU . 38.6 Cg_exo -51.76 -6.48 0.17 Allowed 'Trans proline' 0 CA--C 1.53 0.282 0 C-N-CA 123.16 2.573 . . . . 0.0 114.393 -178.513 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 9.2 ptm180 -146.85 142.67 27.91 Favored 'General case' 0 C--N 1.315 -0.91 0 N-CA-C 108.825 -0.805 . . . . 0.0 108.825 174.905 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . 0.687 ' HB3' ' HB2' ' A' ' 52' ' ' TYR . . . -58.35 -33.08 69.15 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.679 -0.691 . . . . 0.0 112.753 -177.129 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . 0.572 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 4.3 p-10 -80.28 -10.22 59.75 Favored 'General case' 0 C--N 1.331 -0.231 0 C-N-CA 120.668 -0.413 . . . . 0.0 111.247 -173.931 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.477 ' HB3' ' HB1' ' A' ' 71' ' ' ALA . 62.5 tp -87.23 -32.49 19.74 Favored 'General case' 0 C--N 1.323 -0.552 0 N-CA-C 108.869 -0.789 . . . . 0.0 108.869 173.66 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . 0.837 ' HB1' ' HB2' ' A' ' 81' ' ' GLU . . . -82.22 161.08 22.84 Favored 'General case' 0 N--CA 1.442 -0.853 0 CA-C-N 114.98 -1.009 . . . . 0.0 110.371 176.171 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 20.0 p -100.59 -170.59 1.88 Allowed 'General case' 0 C--N 1.316 -0.876 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.088 179.127 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . 0.84 HH21 ' HB2' ' A' ' 32' ' ' ASP . 39.1 mtp180 -48.98 -53.48 19.66 Favored 'General case' 0 CA--C 1.515 -0.391 0 O-C-N 123.498 0.499 . . . . 0.0 111.005 -177.044 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 2.5 pt-20 -60.91 -42.47 98.16 Favored 'General case' 0 C--N 1.315 -0.928 0 CA-C-N 114.972 -1.013 . . . . 0.0 112.895 -171.486 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 81' ' ' GLU . . . . . 0.837 ' HB2' ' HB1' ' A' ' 77' ' ' ALA . 9.1 mp0 -63.38 -50.67 68.99 Favored 'General case' 0 N--CA 1.455 -0.196 0 CA-C-N 118.194 0.452 . . . . 0.0 111.491 175.163 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 82' ' ' GLN . . . . . 0.6 ' HB2' ' HZ3' ' A' ' 43' ' ' TRP . 48.0 mt-30 -61.87 -36.79 82.3 Favored 'General case' 0 CA--C 1.515 -0.369 0 CA-C-O 121.122 0.487 . . . . 0.0 110.309 -177.673 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.557 ' O ' ' HB3' ' A' ' 87' ' ' GLU . 33.8 mt -59.4 -44.0 91.61 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.686 0 CA-C-N 114.982 -1.008 . . . . 0.0 109.973 177.119 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 84' ' ' ALA . . . . . 0.616 ' O ' ' HG3' ' A' ' 87' ' ' GLU . . . -66.57 -45.38 79.49 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 116.038 -0.528 . . . . 0.0 111.47 -179.503 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.518 HG23 ' O ' ' A' ' 81' ' ' GLU . 40.1 t -67.73 -50.21 62.56 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-N 116.305 -0.407 . . . . 0.0 112.018 -179.343 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -63.67 -30.96 71.99 Favored 'General case' 0 N--CA 1.449 -0.502 0 CA-C-O 121.002 0.43 . . . . 0.0 110.542 178.962 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 87' ' ' GLU . . . . . 0.616 ' HG3' ' O ' ' A' ' 84' ' ' ALA . 0.1 OUTLIER -70.36 -29.97 66.78 Favored 'General case' 0 C--N 1.325 -0.489 0 C-N-CA 120.418 -0.513 . . . . 0.0 110.438 -177.788 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 53.8 t -62.31 -43.31 97.92 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.258 0 N-CA-C 108.831 -0.803 . . . . 0.0 108.831 170.479 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . 0.704 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 0.6 OUTLIER -65.67 -43.22 89.98 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 115.232 -0.895 . . . . 0.0 110.689 -177.971 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 90' ' ' ARG . . . . . 0.601 ' HG3' ' O ' ' A' ' 87' ' ' GLU . 4.2 ppt_? -66.37 -33.52 75.89 Favored 'General case' 0 CA--C 1.513 -0.47 0 N-CA-C 109.213 -0.662 . . . . 0.0 109.213 -178.929 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 91' ' ' LEU . . . . . 0.464 ' HB2' ' O ' ' A' ' 87' ' ' GLU . 2.2 tm? -57.21 -34.8 68.91 Favored 'General case' 0 C--N 1.318 -0.786 0 CA-C-N 114.386 -1.279 . . . . 0.0 110.095 -174.931 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . 0.497 ' HE ' ' HB2' ' A' ' 92' ' ' ARG . 3.4 mtm180 -92.49 -39.9 11.13 Favored 'General case' 0 C--N 1.315 -0.934 0 CA-C-N 115.18 -0.918 . . . . 0.0 109.91 -172.227 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 93' ' ' GLN . . . . . 0.49 ' NE2' HG22 ' A' ' 89' ' ' THR . 7.5 pt20 -94.63 -30.73 14.18 Favored 'General case' 0 C--N 1.316 -0.871 0 CA-C-N 114.27 -1.332 . . . . 0.0 113.777 -169.335 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 86.17 32.46 17.03 Favored Glycine 0 CA--C 1.52 0.345 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.619 178.207 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 95' ' ' TRP . . . . . 0.453 ' CE2' ' HD3' ' A' ' 90' ' ' ARG . 13.5 m95 66.82 16.27 10.33 Favored 'General case' 0 N--CA 1.466 0.355 0 C-N-CA 123.395 0.678 . . . . 0.0 110.085 178.095 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -63.94 -41.69 98.59 Favored Glycine 0 CA--C 1.519 0.326 0 CA-C-N 115.461 -0.79 . . . . 0.0 113.65 -179.852 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . 0.47 ' O ' ' HD3' ' A' ' 99' ' ' PRO . . . -78.59 -21.62 48.3 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 117.072 0.436 . . . . 0.0 111.259 -178.456 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 98' ' ' TRP . . . . . 0.704 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 16.3 m-90 -85.54 104.53 5.2 Favored Pre-proline 0 C--O 1.225 -0.226 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 170.118 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 99' ' ' PRO . . . . . 0.47 ' HD3' ' O ' ' A' ' 97' ' ' ALA . 11.7 Cg_exo -76.28 -95.59 0.01 OUTLIER 'Trans proline' 0 N--CA 1.457 -0.648 0 C-N-CA 122.435 2.09 . . . . 0.0 115.087 -171.275 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . 0.424 ' H ' ' HB2' ' A' ' 99' ' ' PRO . 38.3 t -71.32 -30.09 38.49 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.445 0 CA-C-O 121.72 0.771 . . . . 0.0 110.411 -169.07 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 101' ' ' CYS . . . . . 0.803 ' SG ' ' HG3' ' A' ' 38' ' ' GLU . 60.8 m -81.8 -25.66 35.04 Favored 'General case' 0 C--N 1.316 -0.855 0 CA-C-N 115.193 -0.912 . . . . 0.0 111.363 -169.722 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 102' ' ' ALA . . . . . 0.453 ' HB1' ' HB2' ' A' ' 107' ' ' ALA . . . -69.82 -45.21 68.39 Favored 'General case' 0 C--N 1.33 -0.276 0 N-CA-C 110.04 -0.355 . . . . 0.0 110.04 176.502 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -61.96 -39.34 91.78 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 121.307 0.575 . . . . 0.0 110.63 177.512 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 12.5 mtp180 -66.09 -39.02 89.66 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.438 -0.801 . . . . 0.0 111.476 177.405 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 105' ' ' ALA . . . . . 0.547 ' HB1' ' HA ' ' A' ' 30' ' ' ILE . . . -83.56 -22.07 32.47 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 112.583 0.586 . . . . 0.0 112.583 -174.026 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 107.71 61.05 0.56 Allowed Glycine 0 CA--C 1.521 0.459 0 C-N-CA 121.035 -0.602 . . . . 0.0 112.506 -179.56 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 107' ' ' ALA . . . . . 0.453 ' HB2' ' HB1' ' A' ' 102' ' ' ALA . . . -62.45 149.22 43.28 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 121.037 0.446 . . . . 0.0 111.528 -176.342 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 108' ' ' ARG . . . . . 0.405 ' CZ ' HD11 ' A' ' 30' ' ' ILE . 92.6 mtt180 . . . . . 0 C--O 1.249 1.067 0 CA-C-N 115.628 -0.715 . . . . 0.0 110.57 -172.596 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . 0.479 ' O ' HG12 ' A' ' 30' ' ' ILE . 7.6 m-20 . . . . . 0 CA--C 1.507 -0.677 0 CA-C-O 121.749 0.785 . . . . 0.0 109.397 . . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -69.92 -5.31 51.9 Favored Glycine 0 N--CA 1.441 -1.004 0 CA-C-N 114.702 -1.136 . . . . 0.0 110.802 178.701 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 12.5 m -76.86 -42.95 38.0 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-O 121.813 0.816 . . . . 0.0 109.11 174.512 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.695 ' HA ' ' HB1' ' A' ' 105' ' ' ALA . 0.4 OUTLIER -66.58 -38.75 82.3 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-N 114.274 -1.33 . . . . 0.0 107.728 178.426 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 31' ' ' TRP . . . . . 0.455 ' CZ2' ' HD3' ' A' ' 90' ' ' ARG . 26.3 m95 -70.05 -35.0 73.94 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 114.572 -1.195 . . . . 0.0 110.516 -178.395 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.401 ' HB2' HH21 ' A' ' 79' ' ' ARG . 32.5 t70 -76.14 -37.63 57.77 Favored 'General case' 0 N--CA 1.449 -0.518 0 CA-C-N 116.024 -0.534 . . . . 0.0 110.349 -179.095 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . 0.511 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -70.59 -34.06 71.75 Favored 'General case' 0 N--CA 1.45 -0.441 0 C-N-CA 120.792 -0.363 . . . . 0.0 110.647 177.417 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . 0.494 HG13 ' O ' ' A' ' 30' ' ' ILE . 74.6 mt -65.55 -45.11 93.48 Favored 'Isoleucine or valine' 0 C--O 1.234 0.252 0 CA-C-O 121.168 0.509 . . . . 0.0 109.841 173.113 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -58.45 -38.3 77.22 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.611 -0.722 . . . . 0.0 110.014 175.074 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . 0.408 ' HA2' ' N ' ' A' ' 41' ' ' GLY . . . -72.2 -12.31 76.0 Favored Glycine 0 N--CA 1.449 -0.456 0 CA-C-N 115.399 -0.819 . . . . 0.0 111.835 179.139 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 46.8 t -88.78 -62.77 1.41 Allowed 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 115.614 -0.293 . . . . 0.0 111.118 -178.249 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . 0.416 ' HG3' ' SG ' ' A' ' 101' ' ' CYS . 34.2 mt-10 -90.0 -33.37 16.39 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 120.969 0.414 . . . . 0.0 111.185 -174.107 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -93.78 -8.57 40.24 Favored 'General case' 0 N--CA 1.45 -0.471 0 C-N-CA 120.547 -0.461 . . . . 0.0 111.763 -174.755 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 79.71 7.16 88.71 Favored Glycine 0 CA--C 1.505 -0.579 0 N-CA-C 110.26 -1.136 . . . . 0.0 110.26 -178.106 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . 0.408 ' N ' ' HA2' ' A' ' 36' ' ' GLY . . . 81.76 50.78 4.81 Favored Glycine 0 N--CA 1.435 -1.374 0 CA-C-N 114.324 -0.938 . . . . 0.0 112.656 -178.537 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 44.7 t-20 -144.26 128.56 17.82 Favored 'General case' 0 N--CA 1.441 -0.9 0 N-CA-C 107.871 -1.159 . . . . 0.0 107.871 178.256 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 43' ' ' TRP . . . . . 0.791 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 17.6 m95 -103.38 0.41 31.25 Favored 'General case' 0 C--N 1.306 -1.304 0 CA-C-N 115.589 -0.732 . . . . 0.0 110.313 -173.549 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -112.55 -2.47 14.61 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-N 115.4 -0.818 . . . . 0.0 111.011 178.396 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 10.0 tt -66.6 143.4 15.63 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.79 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.078 177.991 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 17.7 t-20 -143.59 91.68 2.27 Favored 'General case' 0 C--N 1.317 -0.83 0 CA-C-O 121.471 0.653 . . . . 0.0 109.334 -179.077 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -73.69 -19.17 60.9 Favored 'General case' 0 N--CA 1.437 -1.085 0 CA-C-N 115.065 -0.971 . . . . 0.0 110.555 177.51 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 82.88 23.01 56.82 Favored Glycine 0 N--CA 1.445 -0.732 0 CA-C-N 115.51 -0.768 . . . . 0.0 111.247 174.315 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 4.6 p-10 -93.5 15.38 16.11 Favored 'General case' 0 C--N 1.325 -0.5 0 N-CA-C 112.247 0.462 . . . . 0.0 112.247 -172.073 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . 0.498 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 95.06 -13.51 66.91 Favored Glycine 0 CA--C 1.508 -0.358 0 N-CA-C 110.789 -0.925 . . . . 0.0 110.789 178.859 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 51' ' ' TYR . . . . . 0.498 ' HD1' ' C ' ' A' ' 50' ' ' GLY . 0.1 OUTLIER -121.52 161.58 22.06 Favored 'General case' 0 N--CA 1.441 -0.881 0 N-CA-C 105.286 -2.116 . . . . 0.0 105.286 174.483 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 52' ' ' TYR . . . . . 0.736 ' O ' ' HA ' ' A' ' 56' ' ' GLN . 20.8 m-85 -126.97 167.85 15.33 Favored 'General case' 0 C--N 1.302 -1.487 0 C-N-CA 119.621 -0.832 . . . . 0.0 111.231 -169.827 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -55.31 164.18 4.1 Favored Glycine 0 N--CA 1.446 -0.689 0 O-C-N 123.881 0.738 . . . . 0.0 114.105 -175.852 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . 0.616 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 97.1 -112.99 4.59 Favored Glycine 0 N--CA 1.439 -1.155 0 N-CA-C 111.421 -0.672 . . . . 0.0 111.421 -176.423 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.59 HG12 ' HE1' ' A' ' 98' ' ' TRP . 2.2 t -84.81 -3.5 8.13 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 CA-C-O 121.826 0.822 . . . . 0.0 109.783 -178.418 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 56' ' ' GLN . . . . . 0.736 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 6.4 tt0 50.36 50.57 18.47 Favored 'General case' 0 N--CA 1.463 0.213 0 CA-C-N 113.774 -1.557 . . . . 0.0 113.498 173.314 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . 0.458 ' CD1' ' HB ' ' A' ' 55' ' ' VAL . 2.8 p90 -113.41 159.35 19.55 Favored 'General case' 0 C--N 1.321 -0.64 0 C-N-CA 119.925 -0.71 . . . . 0.0 110.684 171.668 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.433 ' HA ' ' HA ' ' A' ' 51' ' ' TYR . 5.9 p-10 -71.29 157.75 37.57 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-O 121.75 0.786 . . . . 0.0 112.869 -163.922 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . 0.71 ' HA ' HE21 ' A' ' 59' ' ' GLN . 0.0 OUTLIER -55.8 -35.75 66.65 Favored 'General case' 0 N--CA 1.447 -0.603 0 CA-C-N 114.193 -1.367 . . . . 0.0 111.371 178.944 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -68.12 -49.75 44.7 Favored Glycine 0 N--CA 1.45 -0.407 0 CA-C-N 115.572 -0.74 . . . . 0.0 112.155 -175.896 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 51.3 m -65.19 -41.23 94.76 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-O 121.113 0.482 . . . . 0.0 110.595 176.447 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 62' ' ' TRP . . . . . 0.611 ' CZ3' ' HG2' ' A' ' 82' ' ' GLN . 54.5 t-105 -56.5 -48.89 76.23 Favored 'General case' 0 N--CA 1.448 -0.531 0 CA-C-N 115.493 -0.776 . . . . 0.0 109.389 175.833 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . 0.457 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 34.9 tt0 -68.25 -32.49 72.71 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 115.105 -0.952 . . . . 0.0 111.217 -179.505 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -65.53 -41.21 93.34 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.991 -0.549 . . . . 0.0 110.711 -178.552 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . 0.52 ' HB2' HG13 ' A' ' 85' ' ' VAL . 5.9 m120 -81.13 -8.07 59.69 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.45 0.643 . . . . 0.0 109.862 175.239 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . 0.412 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 80.74 50.26 5.34 Favored Glycine 0 N--CA 1.449 -0.454 0 CA-C-N 115.031 -0.986 . . . . 0.0 112.828 174.903 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . 0.602 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -78.58 -18.55 75.46 Favored Glycine 0 N--CA 1.442 -0.966 0 C-N-CA 120.957 -0.64 . . . . 0.0 112.086 -176.499 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.933 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 7.0 mp -60.34 -20.2 58.4 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 111.994 0.368 . . . . 0.0 111.994 -176.09 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . 0.412 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 9.9 ptm180 -70.57 -31.86 69.05 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-O 121.253 0.549 . . . . 0.0 109.823 177.238 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 70' ' ' TYR . . . . . 0.602 ' HD2' ' HA2' ' A' ' 67' ' ' GLY . 43.8 m-85 -85.3 -34.0 21.99 Favored 'General case' 0 N--CA 1.438 -1.04 0 N-CA-C 107.71 -1.218 . . . . 0.0 107.71 178.239 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.511 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 170.69 122.06 0.05 OUTLIER Pre-proline 0 N--CA 1.45 -0.454 0 CA-C-N 113.247 -1.797 . . . . 0.0 107.83 -177.301 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 72' ' ' PRO . . . . . 0.933 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 25.1 Cg_exo -55.34 -7.94 1.48 Allowed 'Trans proline' 0 C--N 1.334 -0.192 0 C-N-CA 123.01 2.473 . . . . 0.0 113.789 -178.737 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 13.4 ptm180 -142.99 136.86 28.88 Favored 'General case' 0 C--N 1.317 -0.825 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 177.461 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . 0.618 ' HB3' ' HB2' ' A' ' 52' ' ' TYR . . . -60.22 -28.11 67.74 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.199 -0.91 . . . . 0.0 112.238 -175.351 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . 0.587 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 19.5 p-10 -84.79 -8.99 58.6 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 121.072 0.463 . . . . 0.0 111.344 -176.712 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.504 ' HB3' ' HB1' ' A' ' 71' ' ' ALA . 57.2 tp -84.96 -32.36 23.07 Favored 'General case' 0 C--N 1.32 -0.682 0 N-CA-C 108.107 -1.071 . . . . 0.0 108.107 169.361 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . 0.953 ' HB1' ' HB2' ' A' ' 81' ' ' GLU . . . -77.93 154.23 31.82 Favored 'General case' 0 N--CA 1.44 -0.935 0 CA-C-N 114.953 -1.021 . . . . 0.0 110.851 177.071 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . 0.562 ' H ' ' CD ' ' A' ' 81' ' ' GLU . 19.5 p -99.91 -169.89 1.81 Allowed 'General case' 0 C--N 1.315 -0.895 0 CA-C-N 115.656 -0.702 . . . . 0.0 109.552 176.786 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . 0.791 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 79.8 mtp180 -49.66 -51.41 38.22 Favored 'General case' 0 C--N 1.329 -0.31 0 O-C-N 123.418 0.449 . . . . 0.0 111.305 -176.974 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 80' ' ' GLU . . . . . 0.448 ' HG3' ' N ' ' A' ' 81' ' ' GLU . 10.0 pt-20 -60.87 -47.56 85.82 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 112.457 0.54 . . . . 0.0 112.457 -173.361 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 81' ' ' GLU . . . . . 0.953 ' HB2' ' HB1' ' A' ' 77' ' ' ALA . 4.4 mp0 -60.96 -50.64 72.59 Favored 'General case' 0 CA--C 1.518 -0.26 0 CA-C-O 121.064 0.459 . . . . 0.0 111.03 178.382 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 82' ' ' GLN . . . . . 0.611 ' HG2' ' CZ3' ' A' ' 62' ' ' TRP . 34.2 mt-30 -63.65 -37.05 85.88 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.789 -0.641 . . . . 0.0 111.421 -176.682 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.685 ' O ' ' HG2' ' A' ' 87' ' ' GLU . 40.0 mt -60.14 -44.47 95.27 Favored 'Isoleucine or valine' 0 C--O 1.213 -0.841 0 N-CA-C 109.461 -0.57 . . . . 0.0 109.461 174.211 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 84' ' ' ALA . . . . . 0.612 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -62.7 -43.6 98.39 Favored 'General case' 0 C--O 1.236 0.346 0 CA-C-O 121.208 0.528 . . . . 0.0 111.792 -177.023 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.52 HG13 ' HB2' ' A' ' 65' ' ' ASN . 32.4 t -67.5 -47.86 79.07 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.332 178.845 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 86' ' ' ALA . . . . . 0.416 ' HB1' ' CH2' ' A' ' 31' ' ' TRP . . . -59.07 -29.75 67.56 Favored 'General case' 0 N--CA 1.455 -0.225 0 CA-C-N 115.531 -0.759 . . . . 0.0 110.468 174.859 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 87' ' ' GLU . . . . . 0.685 ' HG2' ' O ' ' A' ' 83' ' ' ILE . 25.9 mm-40 -59.51 -43.42 93.38 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.605 -0.725 . . . . 0.0 110.115 178.649 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.691 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 96.9 t -62.64 -48.47 88.04 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.322 0 CA-C-O 121.127 0.489 . . . . 0.0 110.124 176.454 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . 0.766 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 0.2 OUTLIER -64.56 -47.62 78.07 Favored 'General case' 0 C--N 1.317 -0.84 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.989 -175.433 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 90' ' ' ARG . . . . . 0.455 ' HD3' ' CZ2' ' A' ' 31' ' ' TRP . 7.9 ptt180 -62.52 -33.06 74.14 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.858 -175.84 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 91' ' ' LEU . . . . . 0.691 ' HG ' ' O ' ' A' ' 88' ' ' VAL . 4.4 pp -73.57 -23.45 59.95 Favored 'General case' 0 C--N 1.321 -0.637 0 C-N-CA 120.623 -0.431 . . . . 0.0 111.069 -172.013 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . 0.553 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 6.1 mtm180 -84.2 -45.86 12.48 Favored 'General case' 0 N--CA 1.45 -0.468 0 CA-C-O 121.369 0.605 . . . . 0.0 109.654 -178.487 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 93' ' ' GLN . . . . . 0.423 HE21 ' HZ3' ' A' ' 98' ' ' TRP . 9.1 pt20 -102.89 -27.98 12.32 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 113.924 1.083 . . . . 0.0 113.924 -169.603 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 83.68 50.95 4.23 Favored Glycine 0 CA--C 1.507 -0.448 0 C-N-CA 120.699 -0.762 . . . . 0.0 111.834 178.735 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 95' ' ' TRP . . . . . 0.492 ' HA ' ' HE3' ' A' ' 98' ' ' TRP . 2.5 m95 60.47 22.77 12.41 Favored 'General case' 0 C--O 1.224 -0.251 0 CA-C-O 121.282 0.563 . . . . 0.0 109.674 177.098 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -75.53 -20.77 78.23 Favored Glycine 0 N--CA 1.447 -0.586 0 CA-C-N 115.368 -0.833 . . . . 0.0 112.569 178.454 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -89.77 -17.49 28.12 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 121.096 0.475 . . . . 0.0 110.173 176.253 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 98' ' ' TRP . . . . . 0.766 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 23.3 m-90 -100.09 113.14 65.14 Favored Pre-proline 0 N--CA 1.444 -0.738 0 CA-C-N 115.73 -0.668 . . . . 0.0 109.433 178.748 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 99' ' ' PRO . . . . . 0.43 ' HD3' ' HA ' ' A' ' 98' ' ' TRP . 52.8 Cg_exo -61.93 -145.33 0.01 OUTLIER 'Trans proline' 0 CA--C 1.535 0.542 0 C-N-CA 123.954 3.103 . . . . 0.0 114.315 -173.738 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . 0.421 HG12 ' HG3' ' A' ' 104' ' ' ARG . 58.5 t -55.84 -24.4 16.88 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.307 0 CA-C-N 115.919 -0.582 . . . . 0.0 111.032 -179.791 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 101' ' ' CYS . . . . . 0.416 ' SG ' ' HG3' ' A' ' 38' ' ' GLU . 56.6 m -56.44 -36.36 68.91 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.003 177.436 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -69.77 -42.88 73.23 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.834 0.349 . . . . 0.0 110.639 178.891 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -64.37 -42.78 96.0 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.51 178.837 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 104' ' ' ARG . . . . . 0.421 ' HG3' HG12 ' A' ' 100' ' ' VAL . 68.4 mtp180 -60.14 -39.49 86.5 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.389 -0.823 . . . . 0.0 110.916 176.262 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 105' ' ' ALA . . . . . 0.695 ' HB1' ' HA ' ' A' ' 30' ' ' ILE . . . -78.07 -22.05 49.63 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.628 -0.714 . . . . 0.0 112.114 -175.997 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 102.51 64.41 0.73 Allowed Glycine 0 CA--C 1.519 0.318 0 C-N-CA 120.935 -0.65 . . . . 0.0 112.188 -178.23 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -71.1 152.34 43.57 Favored 'General case' 0 C--N 1.324 -0.527 0 C-N-CA 122.649 0.379 . . . . 0.0 111.491 -175.29 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 27.6 mtt180 . . . . . 0 C--O 1.247 0.971 0 CA-C-O 117.702 -1.142 . . . . 0.0 112.464 174.618 . . . . . . . . 0 0 . 1 . 023 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . 0.655 ' O ' HG12 ' A' ' 30' ' ' ILE . 26.0 t0 . . . . . 0 CA--C 1.498 -1.037 0 CA-C-O 122.725 1.25 . . . . 0.0 108.8 . . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . 0.803 ' HA2' ' HB2' ' A' ' 31' ' ' TRP . . . -75.02 6.58 26.64 Favored Glycine 0 N--CA 1.435 -1.418 0 CA-C-N 113.081 -1.872 . . . . 0.0 111.638 -178.162 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 59.6 m -76.69 -42.3 42.09 Favored 'General case' 0 C--N 1.315 -0.904 0 CA-C-O 121.508 0.67 . . . . 0.0 109.346 172.941 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.655 HG12 ' O ' ' A' ' 27' ' ' ASP . 0.0 OUTLIER -71.23 -38.85 71.87 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 N-CA-C 107.517 -1.29 . . . . 0.0 107.517 174.939 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 31' ' ' TRP . . . . . 0.803 ' HB2' ' HA2' ' A' ' 28' ' ' GLY . 20.8 m95 -67.91 -35.15 77.96 Favored 'General case' 0 N--CA 1.445 -0.714 0 CA-C-N 114.543 -1.208 . . . . 0.0 110.686 -177.231 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 6.3 t70 -73.62 -43.12 60.42 Favored 'General case' 0 N--CA 1.446 -0.627 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.951 177.531 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . 0.504 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -68.82 -33.56 74.04 Favored 'General case' 0 N--CA 1.446 -0.639 0 C-N-CA 120.331 -0.548 . . . . 0.0 110.394 -179.497 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . 0.445 HG13 ' O ' ' A' ' 30' ' ' ILE . 65.1 mt -66.89 -43.89 89.19 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.172 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.128 173.066 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -58.04 -35.76 71.78 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 121.299 0.571 . . . . 0.0 110.288 176.375 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . 0.429 ' HA2' ' N ' ' A' ' 41' ' ' GLY . . . -74.02 -22.21 78.19 Favored Glycine 0 N--CA 1.45 -0.383 0 CA-C-N 115.52 -0.764 . . . . 0.0 111.725 178.617 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 11.9 t -87.41 -52.82 5.16 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 115.377 -0.411 . . . . 0.0 111.87 -176.939 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 10.2 tp10 -87.77 -34.01 18.46 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-O 121.071 0.462 . . . . 0.0 110.161 -172.955 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -103.76 -7.81 20.32 Favored 'General case' 0 C--N 1.323 -0.544 0 C-N-CA 120.437 -0.505 . . . . 0.0 112.186 -175.099 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 77.75 13.26 83.64 Favored Glycine 0 CA--C 1.505 -0.58 0 N-CA-C 109.985 -1.246 . . . . 0.0 109.985 -177.666 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . 0.429 ' N ' ' HA2' ' A' ' 36' ' ' GLY . . . 76.74 58.28 3.55 Favored Glycine 0 N--CA 1.434 -1.488 0 CA-C-N 114.236 -0.982 . . . . 0.0 111.975 -177.236 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 42' ' ' ASN . . . . . 0.57 ' HB3' ' HB ' ' A' ' 45' ' ' ILE . 2.9 t30 -145.88 103.37 3.75 Favored 'General case' 0 N--CA 1.447 -0.593 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 179.901 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 43' ' ' TRP . . . . . 0.76 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 35.6 m95 -82.63 -6.58 59.44 Favored 'General case' 0 C--N 1.314 -0.972 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.649 -172.887 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -111.86 14.7 20.99 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 115.259 -0.882 . . . . 0.0 111.33 179.417 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.57 ' HB ' ' HB3' ' A' ' 42' ' ' ASN . 10.2 tt -79.93 140.54 16.59 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.773 0 N-CA-C 109.138 -0.69 . . . . 0.0 109.138 -179.599 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 10.0 t-20 -149.14 107.22 3.72 Favored 'General case' 0 C--N 1.307 -1.281 0 CA-C-O 121.289 0.566 . . . . 0.0 109.716 -174.861 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 24.5 p -82.45 -22.96 35.02 Favored 'General case' 0 N--CA 1.437 -1.109 0 CA-C-N 115.185 -0.916 . . . . 0.0 109.997 178.946 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 90.63 20.57 40.12 Favored Glycine 0 N--CA 1.443 -0.88 0 N-CA-C 110.902 -0.879 . . . . 0.0 110.902 178.702 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 27.5 p-10 -93.64 11.39 29.06 Favored 'General case' 0 C--N 1.327 -0.379 0 C-N-CA 120.656 -0.418 . . . . 0.0 111.684 -173.359 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 93.97 -12.31 69.44 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.699 -0.763 . . . . 0.0 111.431 -177.95 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 51' ' ' TYR . . . . . 0.771 ' CE1' ' HB2' ' A' ' 58' ' ' ASP . 0.2 OUTLIER -108.02 160.66 15.62 Favored 'General case' 0 N--CA 1.446 -0.673 0 N-CA-C 106.982 -1.488 . . . . 0.0 106.982 172.811 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 52' ' ' TYR . . . . . 0.873 ' O ' ' HA ' ' A' ' 56' ' ' GLN . 31.6 m-85 -130.35 170.57 13.98 Favored 'General case' 0 C--N 1.318 -0.783 0 C-N-CA 120.668 -0.413 . . . . 0.0 111.045 -171.298 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.495 ' HA2' HG22 ' A' ' 45' ' ' ILE . . . -61.63 177.91 4.61 Favored Glycine 0 N--CA 1.452 -0.28 0 N-CA-C 114.833 0.693 . . . . 0.0 114.833 -171.717 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . 0.685 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 82.61 -104.96 2.57 Favored Glycine 0 N--CA 1.445 -0.702 0 C-N-CA 121.039 -0.6 . . . . 0.0 111.718 -179.877 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.569 HG12 ' HE1' ' A' ' 98' ' ' TRP . 2.1 t -83.84 -2.66 7.08 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.657 0 CA-C-O 121.902 0.858 . . . . 0.0 109.616 -179.385 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 56' ' ' GLN . . . . . 0.873 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 5.7 tt0 53.3 52.54 13.35 Favored 'General case' 0 N--CA 1.462 0.149 0 CA-C-N 113.681 -1.599 . . . . 0.0 113.3 171.981 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . 0.497 ' CZ ' ' HE3' ' A' ' 62' ' ' TRP . 16.5 p90 -121.13 173.34 7.35 Favored 'General case' 0 C--N 1.324 -0.519 0 C-N-CA 119.849 -0.74 . . . . 0.0 112.657 176.09 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.771 ' HB2' ' CE1' ' A' ' 51' ' ' TYR . 0.0 OUTLIER -83.97 153.63 23.79 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 114.534 -1.212 . . . . 0.0 114.091 -161.854 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . 0.461 ' HB2' ' HE1' ' A' ' 52' ' ' TYR . 6.3 tp-100 -56.38 -41.91 76.99 Favored 'General case' 0 N--CA 1.447 -0.597 0 CA-C-N 113.656 -1.611 . . . . 0.0 111.985 178.973 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -64.97 -48.42 71.39 Favored Glycine 0 N--CA 1.445 -0.747 0 C-N-CA 120.944 -0.645 . . . . 0.0 111.574 -176.747 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 67.6 m -65.89 -43.83 87.09 Favored 'General case' 0 C--N 1.318 -0.779 0 C-N-CA 122.696 0.398 . . . . 0.0 111.069 176.443 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 62' ' ' TRP . . . . . 0.497 ' HE3' ' CZ ' ' A' ' 57' ' ' PHE . 45.5 t-105 -56.98 -48.21 78.93 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 121.397 0.618 . . . . 0.0 109.729 177.008 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . 0.429 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 3.6 tm-20 -68.05 -32.82 73.44 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 115.143 -0.935 . . . . 0.0 110.39 -178.401 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -66.62 -41.81 87.77 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.717 -0.674 . . . . 0.0 111.493 -178.009 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . 0.66 ' HB2' HG13 ' A' ' 85' ' ' VAL . 50.6 m-20 -76.43 -15.41 59.93 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.002 0.429 . . . . 0.0 110.511 175.839 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . 0.537 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 94.36 48.09 2.66 Favored Glycine 0 C--N 1.333 0.379 0 CA-C-N 115.735 -0.666 . . . . 0.0 112.199 176.966 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . 0.599 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -79.98 -26.24 56.13 Favored Glycine 0 N--CA 1.44 -1.081 0 C-N-CA 121.12 -0.562 . . . . 0.0 112.907 -174.699 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 1.035 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 7.5 mp -60.5 -25.44 66.08 Favored 'General case' 0 N--CA 1.445 -0.705 0 N-CA-C 112.814 0.672 . . . . 0.0 112.814 -173.761 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . 0.537 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 1.3 ptm180 -65.07 -33.64 76.52 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 121.35 0.595 . . . . 0.0 109.615 175.242 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 70' ' ' TYR . . . . . 0.618 ' HB3' ' CG ' ' A' ' 81' ' ' GLU . 84.3 m-85 -78.08 -35.43 49.4 Favored 'General case' 0 N--CA 1.438 -1.059 0 N-CA-C 107.483 -1.303 . . . . 0.0 107.483 178.159 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.592 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 162.03 130.15 0.01 OUTLIER Pre-proline 0 N--CA 1.447 -0.588 0 CA-C-N 112.676 -2.057 . . . . 0.0 106.756 -179.106 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 72' ' ' PRO . . . . . 1.035 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 26.5 Cg_exo -56.41 -6.54 1.52 Allowed 'Trans proline' 0 C--N 1.334 -0.226 0 C-N-CA 122.955 2.436 . . . . 0.0 113.862 -176.894 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 73' ' ' ARG . . . . . 0.493 ' HB2' ' CD2' ' A' ' 52' ' ' TYR . 0.2 OUTLIER -147.0 143.08 28.15 Favored 'General case' 0 C--N 1.317 -0.811 0 N-CA-C 109.533 -0.543 . . . . 0.0 109.533 176.523 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . 0.589 ' HB3' ' HB2' ' A' ' 52' ' ' TYR . . . -58.94 -26.5 64.44 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.413 -0.812 . . . . 0.0 112.722 -177.05 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . 0.479 ' HB2' ' NH2' ' A' ' 73' ' ' ARG . 0.0 OUTLIER -74.27 -25.43 59.61 Favored 'General case' 0 CA--C 1.518 -0.265 0 CA-C-O 121.096 0.474 . . . . 0.0 110.704 -177.258 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.528 ' HB3' ' HB1' ' A' ' 71' ' ' ALA . 55.3 tp -86.76 -30.22 21.76 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-O 121.342 0.591 . . . . 0.0 109.972 -178.635 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . 0.664 ' HB1' ' CB ' ' A' ' 81' ' ' GLU . . . -82.97 161.05 21.9 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 115.383 -0.826 . . . . 0.0 109.66 172.992 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 18.7 p -101.32 -171.78 2.05 Favored 'General case' 0 C--N 1.32 -0.714 0 C-N-CA 120.611 -0.435 . . . . 0.0 110.054 -179.359 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . 0.76 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 2.8 mtt85 -49.36 -53.12 23.99 Favored 'General case' 0 C--N 1.326 -0.436 0 O-C-N 123.487 0.492 . . . . 0.0 111.916 -177.69 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 80' ' ' GLU . . . . . 0.766 ' HA ' HD12 ' A' ' 83' ' ' ILE . 0.0 OUTLIER -61.4 -40.35 94.05 Favored 'General case' 0 C--N 1.324 -0.534 0 O-C-N 123.206 0.316 . . . . 0.0 111.578 -172.275 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 81' ' ' GLU . . . . . 0.664 ' CB ' ' HB1' ' A' ' 77' ' ' ALA . 47.0 mp0 -61.9 -51.48 67.97 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.724 0.297 . . . . 0.0 111.343 175.505 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 82' ' ' GLN . . . . . 0.424 ' HB2' ' HZ3' ' A' ' 43' ' ' TRP . 46.7 mt-30 -59.71 -35.51 74.66 Favored 'General case' 0 CA--C 1.513 -0.473 0 CA-C-O 121.141 0.496 . . . . 0.0 110.198 -178.83 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.766 HD12 ' HA ' ' A' ' 80' ' ' GLU . 35.4 mt -59.47 -49.53 83.27 Favored 'Isoleucine or valine' 0 C--O 1.212 -0.896 0 CA-C-N 114.95 -1.023 . . . . 0.0 109.955 176.905 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 84' ' ' ALA . . . . . 0.571 ' O ' ' HG3' ' A' ' 87' ' ' GLU . . . -61.27 -44.26 97.52 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-O 121.199 0.523 . . . . 0.0 111.162 -176.188 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.66 HG13 ' HB2' ' A' ' 65' ' ' ASN . 21.8 t -69.33 -49.02 64.34 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.823 179.776 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -66.2 -32.15 73.42 Favored 'General case' 0 CA--C 1.515 -0.379 0 CA-C-O 121.137 0.494 . . . . 0.0 110.888 -179.912 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 87' ' ' GLU . . . . . 0.752 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 0.0 OUTLIER -70.5 -31.52 68.66 Favored 'General case' 0 C--N 1.317 -0.817 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.255 -176.054 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.463 ' O ' ' HG3' ' A' ' 92' ' ' ARG . 71.8 t -60.63 -42.51 92.02 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.373 0 N-CA-C 108.892 -0.781 . . . . 0.0 108.892 172.399 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . 0.816 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 1.1 m -67.42 -43.7 80.57 Favored 'General case' 0 N--CA 1.441 -0.879 0 CA-C-N 114.766 -1.106 . . . . 0.0 111.023 -176.139 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 90' ' ' ARG . . . . . 0.647 ' HA ' ' OE1' ' A' ' 93' ' ' GLN . 36.2 ptt85 -60.51 -32.46 71.47 Favored 'General case' 0 N--CA 1.461 0.102 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.472 -174.677 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 91' ' ' LEU . . . . . 0.752 ' HG ' ' O ' ' A' ' 87' ' ' GLU . 18.4 mt -67.7 -25.42 65.66 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-O 121.559 0.695 . . . . 0.0 110.197 -176.804 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . 0.463 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 11.4 mtm180 -90.15 -51.48 5.43 Favored 'General case' 0 C--N 1.317 -0.838 0 CA-C-N 114.992 -1.004 . . . . 0.0 110.44 -171.253 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 93' ' ' GLN . . . . . 0.647 ' OE1' ' HA ' ' A' ' 90' ' ' ARG . 0.0 OUTLIER -96.52 -23.59 16.47 Favored 'General case' 0 C--N 1.32 -0.689 0 N-CA-C 113.047 0.758 . . . . 0.0 113.047 -172.088 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 78.38 51.29 5.72 Favored Glycine 0 CA--C 1.506 -0.53 0 C-N-CA 120.507 -0.854 . . . . 0.0 111.565 176.695 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 95' ' ' TRP . . . . . 0.572 ' CZ2' ' HD2' ' A' ' 90' ' ' ARG . 2.6 m95 59.79 23.5 12.44 Favored 'General case' 0 C--N 1.329 -0.317 0 C-N-CA 123.361 0.665 . . . . 0.0 110.685 175.217 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.643 ' H ' ' HG2' ' A' ' 93' ' ' GLN . . . -77.75 -17.73 78.33 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.935 -0.65 . . . . 0.0 111.682 173.64 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -87.52 -23.09 24.5 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 121.301 0.572 . . . . 0.0 110.137 176.618 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 98' ' ' TRP . . . . . 0.816 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 20.8 m-90 -110.44 108.68 58.43 Favored Pre-proline 0 N--CA 1.448 -0.55 0 CA-C-N 115.417 -0.811 . . . . 0.0 109.797 179.315 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 99' ' ' PRO . . . . . 0.423 ' HD3' ' HA ' ' A' ' 98' ' ' TRP . 52.6 Cg_exo -61.48 -135.43 0.0 OUTLIER 'Trans proline' 0 CA--C 1.538 0.711 0 C-N-CA 124.083 3.189 . . . . 0.0 114.16 -175.151 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 21.2 t -56.42 -23.21 16.23 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.249 0 CA-C-N 116.397 -0.365 . . . . 0.0 110.95 -178.409 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 68.5 m -54.79 -38.12 66.9 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.013 -0.54 . . . . 0.0 111.024 178.011 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -69.44 -45.89 68.06 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.827 0.346 . . . . 0.0 110.757 -179.163 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -63.56 -35.82 81.77 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.514 179.365 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 4.7 mmp_? -70.79 -31.56 68.37 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.561 -0.745 . . . . 0.0 111.356 177.821 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 105' ' ' ALA . . . . . 0.644 ' HB1' ' HA ' ' A' ' 30' ' ' ILE . . . -89.0 -22.51 22.96 Favored 'General case' 0 C--N 1.326 -0.438 0 N-CA-C 112.664 0.616 . . . . 0.0 112.664 -173.079 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 113.23 58.52 0.41 Allowed Glycine 0 CA--C 1.521 0.437 0 C-N-CA 120.569 -0.824 . . . . 0.0 112.473 -178.333 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -66.69 154.36 40.83 Favored 'General case' 0 C--N 1.325 -0.472 0 C-N-CA 123.402 0.681 . . . . 0.0 111.775 -175.763 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 23.5 mmt180 . . . . . 0 C--O 1.247 0.95 0 CA-C-O 118.09 -0.957 . . . . 0.0 111.346 177.353 . . . . . . . . 0 0 . 1 . 024 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . 0.515 ' O ' HG12 ' A' ' 30' ' ' ILE . 46.5 m-20 . . . . . 0 CA--C 1.507 -0.673 0 CA-C-O 121.542 0.687 . . . . 0.0 109.741 . . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . 0.669 ' HA2' HG12 ' A' ' 83' ' ' ILE . . . -68.24 -6.51 47.49 Favored Glycine 0 N--CA 1.438 -1.203 0 CA-C-N 115.029 -0.987 . . . . 0.0 111.896 -178.878 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 4.9 m -74.47 -46.27 40.78 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-O 122.064 0.935 . . . . 0.0 109.105 176.623 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.606 ' HA ' ' HB1' ' A' ' 105' ' ' ALA . 0.0 OUTLIER -69.77 -38.47 76.11 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.777 0 CA-C-N 114.129 -1.396 . . . . 0.0 108.263 179.242 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 31' ' ' TRP . . . . . 0.573 ' HD1' HG23 ' A' ' 83' ' ' ILE . 9.0 m95 -70.55 -36.29 73.57 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 114.86 -1.063 . . . . 0.0 110.861 -177.589 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 4.4 t70 -72.79 -39.37 66.78 Favored 'General case' 0 N--CA 1.446 -0.663 0 CA-C-N 116.481 -0.327 . . . . 0.0 110.521 178.174 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . 0.437 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -69.54 -37.43 77.08 Favored 'General case' 0 N--CA 1.445 -0.69 0 C-N-CA 120.637 -0.425 . . . . 0.0 110.782 179.294 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . 0.477 HG13 ' O ' ' A' ' 30' ' ' ILE . 75.5 mt -67.46 -44.42 86.79 Favored 'Isoleucine or valine' 0 C--O 1.232 0.177 0 CA-C-O 120.809 0.338 . . . . 0.0 110.454 175.524 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -60.86 -31.83 71.28 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 121.252 0.549 . . . . 0.0 110.229 176.907 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -77.42 -22.78 69.52 Favored Glycine 0 N--CA 1.45 -0.395 0 CA-C-N 115.596 -0.729 . . . . 0.0 111.516 177.54 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 40.9 t -76.83 -58.36 3.32 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 115.367 -0.417 . . . . 0.0 111.041 -179.055 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 17.5 mt-10 -89.1 -32.9 17.31 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 116.353 -0.385 . . . . 0.0 111.3 -171.365 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -102.05 -17.61 15.98 Favored 'General case' 0 C--N 1.323 -0.576 0 C-N-CA 120.507 -0.477 . . . . 0.0 112.183 -177.562 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 81.36 9.99 85.2 Favored Glycine 0 N--CA 1.448 -0.535 0 N-CA-C 109.805 -1.318 . . . . 0.0 109.805 -175.709 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 88.39 62.71 1.39 Allowed Glycine 0 N--CA 1.438 -1.199 0 CA-C-N 114.156 -1.022 . . . . 0.0 111.713 -176.931 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 42' ' ' ASN . . . . . 0.727 HD22 ' HB ' ' A' ' 45' ' ' ILE . 3.3 t30 -139.31 87.98 2.23 Favored 'General case' 0 C--N 1.326 -0.418 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 -177.142 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 43' ' ' TRP . . . . . 0.778 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 37.9 m95 -76.41 -11.47 59.9 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-O 121.171 0.51 . . . . 0.0 111.259 -172.669 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -102.66 15.56 28.95 Favored 'General case' 0 C--N 1.314 -0.955 0 CA-C-N 115.793 -0.64 . . . . 0.0 110.447 -179.94 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.727 ' HB ' HD22 ' A' ' 42' ' ' ASN . 10.1 tt -77.53 139.94 17.86 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.003 0 CA-C-N 115.861 -0.609 . . . . 0.0 110.799 -177.771 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 34.1 t-20 -150.59 92.35 1.84 Allowed 'General case' 0 C--N 1.314 -0.957 0 CA-C-N 115.522 -0.763 . . . . 0.0 109.363 179.578 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 8.9 p -76.19 -15.67 60.0 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 115.581 -0.736 . . . . 0.0 111.668 -176.279 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 93.43 21.95 28.07 Favored Glycine 0 N--CA 1.448 -0.561 0 N-CA-C 111.149 -0.78 . . . . 0.0 111.149 -179.904 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 4.9 m-20 -90.7 -0.57 57.74 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 120.857 0.361 . . . . 0.0 111.434 -177.005 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . 0.492 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 86.53 -8.42 75.01 Favored Glycine 0 N--CA 1.449 -0.478 0 N-CA-C 110.888 -0.885 . . . . 0.0 110.888 -172.775 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 51' ' ' TYR . . . . . 0.566 ' CE1' ' HB3' ' A' ' 58' ' ' ASP . 0.1 OUTLIER -114.27 140.47 48.57 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 107.459 -1.312 . . . . 0.0 107.459 175.434 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 52' ' ' TYR . . . . . 0.505 ' O ' ' HA ' ' A' ' 56' ' ' GLN . 0.1 OUTLIER -140.33 163.82 31.75 Favored 'General case' 0 C--N 1.319 -0.748 0 N-CA-C 112.7 0.63 . . . . 0.0 112.7 -170.991 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.413 ' HA2' ' O ' ' A' ' 43' ' ' TRP . . . 65.45 105.66 0.01 OUTLIER Glycine 0 C--O 1.221 -0.684 0 N-CA-C 116.287 1.275 . . . . 0.0 116.287 164.198 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . 0.479 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 57.99 -83.45 0.01 OUTLIER Glycine 0 C--N 1.339 0.696 0 N-CA-C 114.579 0.591 . . . . 0.0 114.579 165.226 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.478 HG23 ' HD1' ' A' ' 57' ' ' PHE . 3.7 m -83.16 -6.29 9.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-O 120.932 0.396 . . . . 0.0 110.282 178.337 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 56' ' ' GLN . . . . . 0.505 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 9.8 mt-30 50.19 51.84 15.93 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 114.934 -1.03 . . . . 0.0 113.203 166.788 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . 0.478 ' HD1' HG23 ' A' ' 55' ' ' VAL . 5.5 p90 -102.13 166.68 10.47 Favored 'General case' 0 C--N 1.323 -0.572 0 C-N-CA 119.382 -0.927 . . . . 0.0 110.705 174.926 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.566 ' HB3' ' CE1' ' A' ' 51' ' ' TYR . 4.9 p-10 -74.48 155.99 37.41 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 122.223 1.011 . . . . 0.0 113.548 -163.276 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . 0.413 ' HB2' ' CE1' ' A' ' 52' ' ' TYR . 23.3 tp60 -57.06 -39.58 75.17 Favored 'General case' 0 N--CA 1.441 -0.877 0 CA-C-N 113.175 -1.829 . . . . 0.0 111.633 179.813 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -67.74 -49.29 50.41 Favored Glycine 0 N--CA 1.451 -0.352 0 CA-C-N 115.422 -0.808 . . . . 0.0 112.248 -176.332 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 97.8 m -64.15 -40.83 96.98 Favored 'General case' 0 C--N 1.322 -0.602 0 C-N-CA 122.829 0.451 . . . . 0.0 110.827 176.761 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 62' ' ' TRP . . . . . 0.545 ' CH2' ' HA ' ' A' ' 74' ' ' ALA . 45.6 t-105 -55.92 -48.58 75.42 Favored 'General case' 0 N--CA 1.45 -0.471 0 CA-C-O 121.71 0.767 . . . . 0.0 109.221 174.859 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . 0.515 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 33.2 tt0 -64.64 -36.57 84.67 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-N 114.821 -1.081 . . . . 0.0 110.989 179.187 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -65.47 -41.16 93.64 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.75 -0.659 . . . . 0.0 110.948 -177.282 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . 0.443 ' HB3' ' HB ' ' A' ' 88' ' ' VAL . 8.2 m120 -80.79 -7.76 59.49 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 121.043 0.449 . . . . 0.0 110.339 177.968 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . 0.595 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 87.64 46.8 4.77 Favored Glycine 0 N--CA 1.447 -0.582 0 CA-C-N 115.622 -0.717 . . . . 0.0 112.511 174.207 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . 0.588 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -78.68 -25.05 61.28 Favored Glycine 0 N--CA 1.44 -1.095 0 C-N-CA 120.579 -0.819 . . . . 0.0 112.007 -175.435 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.922 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 7.3 mp -57.78 -23.27 51.46 Favored 'General case' 0 N--CA 1.446 -0.628 0 N-CA-C 112.671 0.619 . . . . 0.0 112.671 -175.38 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . 0.595 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 5.6 ptp180 -70.74 -29.39 65.63 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-O 121.327 0.584 . . . . 0.0 109.761 178.281 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 70' ' ' TYR . . . . . 0.749 ' HB3' ' CG ' ' A' ' 81' ' ' GLU . 43.5 m-85 -87.24 -34.62 18.89 Favored 'General case' 0 N--CA 1.439 -1.005 0 N-CA-C 107.373 -1.343 . . . . 0.0 107.373 177.724 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.526 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 170.12 125.31 0.05 OUTLIER Pre-proline 0 N--CA 1.449 -0.51 0 CA-C-N 113.198 -1.819 . . . . 0.0 107.89 -177.39 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 72' ' ' PRO . . . . . 0.922 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 15.9 Cg_exo -59.79 -2.8 1.73 Allowed 'Trans proline' 0 C--N 1.333 -0.27 0 C-N-CA 122.803 2.335 . . . . 0.0 113.562 -179.044 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 15.5 ptm180 -143.48 138.19 29.07 Favored 'General case' 0 C--N 1.316 -0.851 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 176.614 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . 0.594 ' HB1' ' OE1' ' A' ' 82' ' ' GLN . . . -59.09 -31.24 68.73 Favored 'General case' 0 C--N 1.316 -0.863 0 CA-C-N 114.952 -1.022 . . . . 0.0 112.393 -176.206 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 20.7 p-10 -88.93 9.0 26.51 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 120.961 0.41 . . . . 0.0 112.014 -175.956 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.505 ' HB3' ' HB1' ' A' ' 71' ' ' ALA . 68.3 tp -103.79 -28.93 11.34 Favored 'General case' 0 C--N 1.321 -0.634 0 N-CA-C 108.614 -0.884 . . . . 0.0 108.614 169.974 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . 0.72 ' HB1' ' CB ' ' A' ' 81' ' ' GLU . . . -79.91 153.68 28.82 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-N 114.545 -1.207 . . . . 0.0 110.39 176.553 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 21.9 p -99.79 -171.81 2.12 Favored 'General case' 0 C--N 1.32 -0.712 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.854 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . 0.778 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 4.0 mtp180 -50.65 -52.91 35.29 Favored 'General case' 0 C--O 1.222 -0.367 0 O-C-N 123.356 0.41 . . . . 0.0 110.779 -175.999 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 80' ' ' GLU . . . . . 0.438 ' HG3' ' OE2' ' A' ' 81' ' ' GLU . 10.5 pt-20 -58.92 -40.03 83.32 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.726 -0.67 . . . . 0.0 111.688 -174.154 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 81' ' ' GLU . . . . . 0.749 ' CG ' ' HB3' ' A' ' 70' ' ' TYR . 8.8 mp0 -67.8 -52.36 37.95 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 120.815 0.34 . . . . 0.0 111.812 176.397 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 82' ' ' GLN . . . . . 0.594 ' OE1' ' HB1' ' A' ' 74' ' ' ALA . 31.3 mt-30 -64.37 -31.28 72.43 Favored 'General case' 0 CA--C 1.514 -0.434 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.724 -175.7 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.669 HG12 ' HA2' ' A' ' 28' ' ' GLY . 27.9 mt -59.58 -48.16 88.37 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 CA-C-N 115.413 -0.812 . . . . 0.0 109.771 172.66 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 84' ' ' ALA . . . . . 0.542 ' HA ' ' HG2' ' A' ' 87' ' ' GLU . . . -62.57 -43.27 99.24 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.989 -0.55 . . . . 0.0 112.056 -177.465 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.417 HG23 ' O ' ' A' ' 81' ' ' GLU . 21.3 t -69.85 -49.76 54.57 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.69 0 O-C-N 122.112 -0.368 . . . . 0.0 111.346 -178.939 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -66.77 -31.17 71.63 Favored 'General case' 0 N--CA 1.446 -0.632 0 CA-C-N 115.947 -0.569 . . . . 0.0 110.403 -179.463 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 87' ' ' GLU . . . . . 0.816 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 6.5 pt-20 -67.62 -32.2 72.74 Favored 'General case' 0 C--O 1.219 -0.551 0 C-N-CA 120.272 -0.571 . . . . 0.0 109.72 -177.637 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.452 ' O ' ' HG3' ' A' ' 92' ' ' ARG . 87.3 t -61.77 -46.95 95.42 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.273 0 CA-C-O 121.421 0.629 . . . . 0.0 109.394 172.625 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . 0.699 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 0.2 OUTLIER -60.8 -45.43 94.44 Favored 'General case' 0 N--CA 1.443 -0.794 0 CA-C-N 115.289 -0.869 . . . . 0.0 111.377 -178.184 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 90' ' ' ARG . . . . . 0.688 ' HG3' ' O ' ' A' ' 87' ' ' GLU . 5.6 ppt_? -60.35 -32.63 71.44 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.478 -177.095 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 91' ' ' LEU . . . . . 0.816 ' HG ' ' O ' ' A' ' 87' ' ' GLU . 38.6 mt -61.88 -43.01 99.72 Favored 'General case' 0 N--CA 1.473 0.676 0 CA-C-O 122.165 0.983 . . . . 0.0 110.047 -176.706 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . 0.462 ' HE ' ' HB2' ' A' ' 92' ' ' ARG . 4.4 mtm180 -78.24 -45.17 23.62 Favored 'General case' 0 C--N 1.316 -0.864 0 CA-C-N 113.828 -1.533 . . . . 0.0 110.083 -167.327 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 93' ' ' GLN . . . . . 0.423 HE21 ' HZ3' ' A' ' 98' ' ' TRP . 13.9 pt20 -100.99 -26.74 13.62 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-N 114.605 -1.179 . . . . 0.0 112.857 -170.094 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 87.56 40.19 6.91 Favored Glycine 0 CA--C 1.508 -0.378 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.176 174.775 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 95' ' ' TRP . . . . . 0.494 ' CZ2' ' HD3' ' A' ' 90' ' ' ARG . 18.5 m95 64.54 18.66 11.49 Favored 'General case' 0 C--O 1.219 -0.527 0 CA-C-O 121.455 0.645 . . . . 0.0 109.815 179.912 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -66.41 -29.8 75.46 Favored Glycine 0 CA--C 1.519 0.299 0 CA-C-N 115.163 -0.926 . . . . 0.0 112.862 175.462 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -81.83 -21.21 37.75 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.879 0.371 . . . . 0.0 110.625 178.692 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 98' ' ' TRP . . . . . 0.699 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 24.6 m-90 -99.3 109.06 53.31 Favored Pre-proline 0 N--CA 1.446 -0.625 0 N-CA-C 109.245 -0.65 . . . . 0.0 109.245 177.637 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 99' ' ' PRO . . . . . 0.42 ' HD3' ' HA ' ' A' ' 98' ' ' TRP . 44.8 Cg_exo -63.24 -139.48 0.0 OUTLIER 'Trans proline' 0 CA--C 1.535 0.541 0 C-N-CA 123.578 2.852 . . . . 0.0 114.331 -174.909 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . 0.422 ' O ' ' HD2' ' A' ' 104' ' ' ARG . 45.0 t -54.98 -23.98 13.64 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.315 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.682 -174.185 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 60.7 m -63.42 -31.66 72.88 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.549 -179.847 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -69.72 -46.03 66.88 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.617 0.246 . . . . 0.0 111.124 -177.364 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -66.09 -36.56 83.52 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 121.019 0.438 . . . . 0.0 110.652 179.896 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 104' ' ' ARG . . . . . 0.422 ' HD2' ' O ' ' A' ' 100' ' ' VAL . 0.0 OUTLIER -70.78 -24.13 62.52 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.78 -0.646 . . . . 0.0 111.23 177.194 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 105' ' ' ALA . . . . . 0.606 ' HB1' ' HA ' ' A' ' 30' ' ' ILE . . . -88.83 -21.46 23.71 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.583 -178.386 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . 0.457 ' O ' ' HG2' ' A' ' 108' ' ' ARG . . . 112.29 63.09 0.46 Allowed Glycine 0 CA--C 1.52 0.354 0 C-N-CA 120.996 -0.621 . . . . 0.0 112.129 -178.0 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -57.91 142.06 47.35 Favored 'General case' 0 C--N 1.329 -0.321 0 C-N-CA 122.679 0.392 . . . . 0.0 111.084 -179.321 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 108' ' ' ARG . . . . . 0.457 ' HG2' ' O ' ' A' ' 106' ' ' GLY . 4.6 ptp180 . . . . . 0 C--O 1.247 0.961 0 CA-C-O 118.484 -0.769 . . . . 0.0 111.093 -170.195 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . 0.445 ' O ' HG12 ' A' ' 30' ' ' ILE . 50.0 m-20 . . . . . 0 CA--C 1.506 -0.713 0 CA-C-O 121.392 0.615 . . . . 0.0 109.693 . . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -70.34 -7.84 61.19 Favored Glycine 0 N--CA 1.44 -1.066 0 N-CA-C 110.024 -1.231 . . . . 0.0 110.024 176.577 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 8.7 m -74.39 -39.42 62.7 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 114.644 -0.778 . . . . 0.0 109.122 174.621 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.622 ' HA ' ' HB1' ' A' ' 105' ' ' ALA . 1.0 OUTLIER -68.18 -39.58 81.45 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 N-CA-C 107.402 -1.333 . . . . 0.0 107.402 177.771 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 31' ' ' TRP . . . . . 0.588 ' CZ2' ' HD3' ' A' ' 90' ' ' ARG . 27.2 m95 -70.61 -37.35 73.85 Favored 'General case' 0 N--CA 1.443 -0.795 0 CA-C-N 114.301 -1.318 . . . . 0.0 110.345 -177.051 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.671 ' HB2' HH21 ' A' ' 79' ' ' ARG . 21.8 t70 -79.34 -33.85 42.69 Favored 'General case' 0 N--CA 1.448 -0.549 0 CA-C-N 115.965 -0.561 . . . . 0.0 111.258 -179.55 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . 0.466 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -68.63 -32.97 73.21 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 176.713 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . 0.541 HG13 ' O ' ' A' ' 30' ' ' ILE . 66.3 mt -61.07 -45.39 98.66 Favored 'Isoleucine or valine' 0 C--O 1.234 0.289 0 CA-C-N 116.172 -0.467 . . . . 0.0 109.85 171.315 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . 0.767 ' HA ' ' NE2' ' A' ' 56' ' ' GLN . . . -61.34 -36.03 79.05 Favored 'General case' 0 CA--C 1.513 -0.475 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.684 177.6 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -73.56 -18.13 79.32 Favored Glycine 0 N--CA 1.448 -0.509 0 N-CA-C 111.025 -0.83 . . . . 0.0 111.025 179.44 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . 0.509 ' HB3' ' O ' ' A' ' 34' ' ' ILE . 8.3 t -77.14 -70.64 0.45 Allowed 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 115.102 -0.549 . . . . 0.0 111.587 -178.065 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . 0.728 ' HG2' ' SG ' ' A' ' 101' ' ' CYS . 4.5 mm-40 -90.44 -33.54 15.96 Favored 'General case' 0 CA--C 1.511 -0.554 0 C-N-CA 120.435 -0.506 . . . . 0.0 111.133 -172.65 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . 0.501 ' HB3' ' O ' ' A' ' 35' ' ' ALA . . . -84.57 -15.69 44.79 Favored 'General case' 0 N--CA 1.443 -0.8 0 CA-C-N 115.997 -0.547 . . . . 0.0 111.125 -177.182 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 75.84 13.29 83.23 Favored Glycine 0 CA--C 1.504 -0.607 0 N-CA-C 109.687 -1.365 . . . . 0.0 109.687 -177.456 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 88.62 63.33 1.35 Allowed Glycine 0 N--CA 1.432 -1.583 0 CA-C-N 113.957 -1.121 . . . . 0.0 111.436 -175.424 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 42' ' ' ASN . . . . . 0.823 ' HB3' ' HB ' ' A' ' 45' ' ' ILE . 6.6 m120 -146.59 103.32 3.65 Favored 'General case' 0 CA--C 1.513 -0.456 0 CA-C-O 121.125 0.488 . . . . 0.0 110.003 -177.962 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 43' ' ' TRP . . . . . 0.704 ' HA ' ' N ' ' A' ' 54' ' ' GLY . 44.5 m95 -84.97 -6.87 59.33 Favored 'General case' 0 C--N 1.311 -1.066 0 CA-C-O 121.642 0.734 . . . . 0.0 110.128 178.155 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -109.72 13.96 23.51 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-N 114.924 -1.034 . . . . 0.0 111.546 178.449 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.823 ' HB ' ' HB3' ' A' ' 42' ' ' ASN . 11.2 tt -87.23 143.67 10.85 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.712 0 CA-C-O 120.85 0.357 . . . . 0.0 110.595 -177.833 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 4.8 p30 -161.71 113.55 1.75 Allowed 'General case' 0 C--N 1.315 -0.916 0 CA-C-O 121.375 0.607 . . . . 0.0 110.482 175.974 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 30.5 p -82.32 -20.17 37.91 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 115.739 -0.664 . . . . 0.0 111.684 -175.22 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 102.66 25.01 7.87 Favored Glycine 0 N--CA 1.445 -0.757 0 N-CA-C 110.703 -0.959 . . . . 0.0 110.703 -175.204 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 3.4 t30 -95.01 -2.91 49.36 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 121.533 0.682 . . . . 0.0 110.346 -178.64 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 96.3 -13.81 65.23 Favored Glycine 0 C--O 1.227 -0.314 0 CA-C-N 115.548 -0.751 . . . . 0.0 111.526 179.202 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 51' ' ' TYR . . . . . 0.6 ' HA ' ' HA ' ' A' ' 58' ' ' ASP . 0.3 OUTLIER -99.55 137.94 37.33 Favored 'General case' 0 CA--C 1.511 -0.541 0 N-CA-C 108.234 -1.024 . . . . 0.0 108.234 174.543 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 52' ' ' TYR . . . . . 0.673 ' CE1' ' HB2' ' A' ' 59' ' ' GLN . 15.9 m-85 -107.62 169.5 8.55 Favored 'General case' 0 C--N 1.312 -1.065 0 C-N-CA 120.685 -0.406 . . . . 0.0 111.698 -172.199 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -63.01 169.59 16.49 Favored Glycine 0 N--CA 1.449 -0.484 0 N-CA-C 115.256 0.862 . . . . 0.0 115.256 -166.613 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . 0.704 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 85.11 -93.17 1.81 Allowed Glycine 0 N--CA 1.44 -1.086 0 CA-C-N 114.508 -0.846 . . . . 0.0 112.01 177.983 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.528 HG22 ' HB3' ' A' ' 82' ' ' GLN . 0.4 OUTLIER -90.95 -2.15 10.14 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.764 0 CA-C-O 121.017 0.437 . . . . 0.0 111.403 -177.447 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 56' ' ' GLN . . . . . 0.767 ' NE2' ' HA ' ' A' ' 35' ' ' ALA . 9.2 mt-30 58.02 46.94 15.58 Favored 'General case' 0 N--CA 1.472 0.625 0 N-CA-C 113.849 1.055 . . . . 0.0 113.849 164.645 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -125.3 157.77 35.83 Favored 'General case' 0 C--N 1.318 -0.765 0 C-N-CA 119.221 -0.992 . . . . 0.0 111.296 174.87 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.6 ' HA ' ' HA ' ' A' ' 51' ' ' TYR . 24.1 t70 -65.21 144.12 57.39 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 114.33 -1.304 . . . . 0.0 112.052 -167.709 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . 0.673 ' HB2' ' CE1' ' A' ' 52' ' ' TYR . 0.0 OUTLIER -51.87 -36.15 47.5 Favored 'General case' 0 N--CA 1.448 -0.562 0 CA-C-N 114.131 -1.395 . . . . 0.0 111.807 179.017 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -67.43 -41.98 90.04 Favored Glycine 0 N--CA 1.449 -0.438 0 N-CA-C 111.453 -0.659 . . . . 0.0 111.453 179.386 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 64.1 m -71.47 -38.69 71.23 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 120.759 0.314 . . . . 0.0 110.434 176.368 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 62' ' ' TRP . . . . . 0.563 ' CH2' ' HA ' ' A' ' 74' ' ' ALA . 43.3 t-105 -55.59 -47.57 76.26 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 121.64 0.733 . . . . 0.0 109.089 172.571 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . 0.503 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 27.6 tt0 -64.67 -33.53 76.16 Favored 'General case' 0 N--CA 1.443 -0.775 0 CA-C-N 114.784 -1.098 . . . . 0.0 110.711 178.127 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -64.36 -42.84 96.0 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 115.928 -0.578 . . . . 0.0 111.624 -176.598 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . 0.455 ' HB2' HG13 ' A' ' 85' ' ' VAL . 10.2 m-80 -74.16 -19.31 60.6 Favored 'General case' 0 N--CA 1.462 0.173 0 CA-C-O 121.254 0.549 . . . . 0.0 109.892 174.01 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . 0.422 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 94.02 48.12 2.73 Favored Glycine 0 N--CA 1.448 -0.514 0 CA-C-N 115.536 -0.756 . . . . 0.0 111.814 179.309 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . 0.524 ' HA2' ' HD1' ' A' ' 70' ' ' TYR . . . -79.59 -17.37 75.76 Favored Glycine 0 N--CA 1.44 -1.068 0 C-N-CA 120.992 -0.623 . . . . 0.0 113.044 -173.377 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.817 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 6.5 mp -61.68 -23.3 66.0 Favored 'General case' 0 N--CA 1.45 -0.441 0 N-CA-C 112.179 0.437 . . . . 0.0 112.179 -173.372 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . 0.422 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 4.8 ptt180 -70.52 -29.49 66.0 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 121.04 0.448 . . . . 0.0 110.604 175.552 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 70' ' ' TYR . . . . . 0.567 ' HB3' ' HB3' ' A' ' 81' ' ' GLU . 74.7 m-85 -79.27 -33.65 43.25 Favored 'General case' 0 N--CA 1.446 -0.642 0 N-CA-C 107.185 -1.413 . . . . 0.0 107.185 175.891 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.616 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 163.02 127.69 0.01 OUTLIER Pre-proline 0 C--O 1.22 -0.452 0 CA-C-N 112.662 -2.063 . . . . 0.0 107.044 -179.709 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 72' ' ' PRO . . . . . 0.817 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 16.6 Cg_exo -56.92 -4.77 1.02 Allowed 'Trans proline' 0 C--N 1.334 -0.194 0 C-N-CA 122.605 2.203 . . . . 0.0 113.774 -177.97 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 14.4 ptm180 -145.38 140.19 27.5 Favored 'General case' 0 C--N 1.318 -0.798 0 N-CA-C 108.501 -0.925 . . . . 0.0 108.501 175.888 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . 0.563 ' HA ' ' CH2' ' A' ' 62' ' ' TRP . . . -57.68 -36.03 71.38 Favored 'General case' 0 C--O 1.219 -0.535 0 CA-C-N 115.448 -0.796 . . . . 0.0 111.691 -176.77 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . 0.457 ' OD1' ' HD2' ' A' ' 52' ' ' TYR . 11.6 p-10 -84.03 2.58 38.43 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 120.935 0.398 . . . . 0.0 111.455 -173.08 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.468 ' HB3' ' HB1' ' A' ' 71' ' ' ALA . 49.2 tp -98.13 -33.96 10.94 Favored 'General case' 0 C--N 1.323 -0.568 0 N-CA-C 108.419 -0.956 . . . . 0.0 108.419 170.893 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . 0.793 ' HB1' ' HB2' ' A' ' 81' ' ' GLU . . . -79.32 163.27 25.02 Favored 'General case' 0 N--CA 1.444 -0.768 0 CA-C-N 114.785 -1.098 . . . . 0.0 109.959 175.242 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 38.3 p -101.0 178.23 4.73 Favored 'General case' 0 C--N 1.316 -0.887 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.121 179.491 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . 0.671 HH21 ' HB2' ' A' ' 32' ' ' ASP . 60.4 mtp180 -46.1 -48.37 17.18 Favored 'General case' 0 N--CA 1.467 0.399 0 O-C-N 123.693 0.621 . . . . 0.0 111.32 -176.06 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 80' ' ' GLU . . . . . 0.403 ' HG3' ' OE2' ' A' ' 81' ' ' GLU . 6.0 pt-20 -61.7 -42.03 98.4 Favored 'General case' 0 C--N 1.315 -0.915 0 CA-C-N 115.756 -0.656 . . . . 0.0 112.659 -177.375 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 81' ' ' GLU . . . . . 0.793 ' HB2' ' HB1' ' A' ' 77' ' ' ALA . 5.7 mp0 -65.68 -50.48 64.74 Favored 'General case' 0 C--O 1.231 0.121 0 CA-C-N 118.369 0.531 . . . . 0.0 111.824 172.936 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 82' ' ' GLN . . . . . 0.528 ' HB3' HG22 ' A' ' 55' ' ' VAL . 4.0 mt-30 -57.76 -40.78 80.55 Favored 'General case' 0 CA--C 1.515 -0.379 0 CA-C-O 121.217 0.532 . . . . 0.0 110.26 -177.707 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.508 HG12 ' CB ' ' A' ' 31' ' ' TRP . 11.6 mt -61.82 -45.49 98.59 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.696 0 CA-C-N 114.898 -1.047 . . . . 0.0 110.593 178.045 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 84' ' ' ALA . . . . . 0.565 ' O ' ' HG3' ' A' ' 87' ' ' GLU . . . -62.33 -44.49 96.37 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.911 0.386 . . . . 0.0 111.513 -177.575 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.486 HG23 ' O ' ' A' ' 81' ' ' GLU . 21.7 t -67.27 -48.84 76.88 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 CA-C-N 116.535 -0.302 . . . . 0.0 111.457 179.291 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -65.04 -30.97 71.98 Favored 'General case' 0 N--CA 1.451 -0.423 0 CA-C-O 121.148 0.499 . . . . 0.0 110.558 179.145 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 87' ' ' GLU . . . . . 0.657 ' O ' ' HG2' ' A' ' 90' ' ' ARG . 0.7 OUTLIER -71.86 -27.71 63.05 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.876 -177.526 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.718 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 88.8 t -62.21 -40.1 86.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 N-CA-C 108.805 -0.813 . . . . 0.0 108.805 166.805 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . 0.786 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 2.7 m -67.86 -43.05 80.33 Favored 'General case' 0 C--N 1.318 -0.772 0 CA-C-N 115.524 -0.762 . . . . 0.0 111.005 -178.89 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 90' ' ' ARG . . . . . 0.657 ' HG2' ' O ' ' A' ' 87' ' ' GLU . 26.3 ptt180 -60.08 -34.34 73.31 Favored 'General case' 0 N--CA 1.47 0.54 0 C-N-CA 122.761 0.424 . . . . 0.0 111.447 -175.906 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 91' ' ' LEU . . . . . 0.718 ' HG ' ' O ' ' A' ' 88' ' ' VAL . 4.3 pp -73.15 -21.83 60.63 Favored 'General case' 0 C--N 1.318 -0.774 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.588 -174.361 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . 0.475 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 6.7 mtm180 -86.61 -51.1 6.35 Favored 'General case' 0 CA--C 1.511 -0.538 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.135 -176.607 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 93' ' ' GLN . . . . . 0.627 ' OE1' ' HA ' ' A' ' 90' ' ' ARG . 0.0 OUTLIER -98.03 -25.43 14.96 Favored 'General case' 0 CA--C 1.538 0.487 0 N-CA-C 113.311 0.856 . . . . 0.0 113.311 -170.779 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 90.47 40.1 5.79 Favored Glycine 0 CA--C 1.507 -0.447 0 C-N-CA 120.672 -0.775 . . . . 0.0 111.99 173.462 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 95' ' ' TRP . . . . . 0.48 ' HB3' ' HB1' ' A' ' 102' ' ' ALA . 10.2 m95 64.35 11.71 6.66 Favored 'General case' 0 C--O 1.223 -0.328 0 C-N-CA 123.678 0.791 . . . . 0.0 110.142 -179.131 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -71.66 -28.33 69.43 Favored Glycine 0 C--N 1.33 0.2 0 C-N-CA 121.114 -0.565 . . . . 0.0 112.433 177.982 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -70.0 -29.2 66.23 Favored 'General case' 0 CA--C 1.516 -0.334 0 CA-C-O 121.183 0.516 . . . . 0.0 110.2 178.667 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 98' ' ' TRP . . . . . 0.786 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 26.2 m-90 -98.74 103.84 21.35 Favored Pre-proline 0 N--CA 1.446 -0.638 0 N-CA-C 108.299 -1.0 . . . . 0.0 108.299 174.948 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 99' ' ' PRO . . . . . 0.465 ' HB2' ' H ' ' A' ' 100' ' ' VAL . 22.9 Cg_exo -69.25 -94.23 0.01 OUTLIER 'Trans proline' 0 CA--C 1.532 0.424 0 C-N-CA 123.176 2.584 . . . . 0.0 114.727 -170.438 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . 0.465 ' H ' ' HB2' ' A' ' 99' ' ' PRO . 47.9 t -70.92 -29.74 38.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-O 121.702 0.763 . . . . 0.0 110.013 -174.385 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 101' ' ' CYS . . . . . 0.728 ' SG ' ' HG2' ' A' ' 38' ' ' GLU . 64.0 m -71.13 -38.41 72.27 Favored 'General case' 0 C--N 1.317 -0.807 0 CA-C-N 114.789 -1.096 . . . . 0.0 111.794 -170.895 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 102' ' ' ALA . . . . . 0.48 ' HB1' ' HB3' ' A' ' 95' ' ' TRP . . . -69.99 -43.14 72.06 Favored 'General case' 0 C--N 1.327 -0.401 0 C-N-CA 120.698 -0.401 . . . . 0.0 110.704 179.86 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -61.67 -37.19 83.18 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 121.355 0.598 . . . . 0.0 110.464 178.42 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 104' ' ' ARG . . . . . 0.57 ' HA ' ' NE ' ' A' ' 104' ' ' ARG . 4.8 mmp_? -71.33 -34.84 70.91 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.495 -0.775 . . . . 0.0 111.563 176.323 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 105' ' ' ALA . . . . . 0.622 ' HB1' ' HA ' ' A' ' 30' ' ' ILE . . . -83.4 -22.33 32.77 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.158 -0.474 . . . . 0.0 112.208 -174.775 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 114.81 59.23 0.36 Allowed Glycine 0 CA--C 1.521 0.425 0 C-N-CA 120.818 -0.706 . . . . 0.0 112.37 -178.611 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -61.65 148.03 43.9 Favored 'General case' 0 CA--C 1.515 -0.367 0 C-N-CA 122.91 0.484 . . . . 0.0 110.635 179.478 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.245 0.845 0 CA-C-O 118.29 -0.862 . . . . 0.0 110.059 -173.013 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 7.9 m-20 . . . . . 0 CA--C 1.503 -0.856 0 CA-C-O 121.656 0.741 . . . . 0.0 109.395 . . . . . . . . . 0 0 . 1 . 026 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . 0.53 ' HA2' ' HB2' ' A' ' 31' ' ' TRP . . . -66.83 -5.78 33.59 Favored Glycine 0 N--CA 1.439 -1.131 0 CA-C-N 114.229 -1.35 . . . . 0.0 110.902 179.94 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 12.7 m -76.38 -44.66 35.27 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-O 121.419 0.628 . . . . 0.0 109.813 175.792 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.581 ' HB ' ' CH2' ' A' ' 95' ' ' TRP . 0.1 OUTLIER -71.01 -35.94 61.39 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.594 0 N-CA-C 108.113 -1.069 . . . . 0.0 108.113 178.078 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 31' ' ' TRP . . . . . 0.72 ' CD1' HG13 ' A' ' 83' ' ' ILE . 48.9 m95 -71.75 -35.64 70.18 Favored 'General case' 0 N--CA 1.442 -0.865 0 CA-C-N 114.658 -1.156 . . . . 0.0 110.19 -178.975 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 20.4 t70 -77.0 -29.31 55.41 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.342 178.908 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -68.55 -35.06 76.9 Favored 'General case' 0 N--CA 1.444 -0.732 0 N-CA-C 109.671 -0.492 . . . . 0.0 109.671 175.215 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . 0.581 ' HA ' ' HB3' ' A' ' 101' ' ' CYS . 58.0 mt -67.64 -49.34 71.15 Favored 'Isoleucine or valine' 0 C--O 1.233 0.199 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.402 173.908 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . 0.455 ' O ' ' HB3' ' A' ' 39' ' ' ALA . . . -59.08 -41.26 87.6 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.778 -0.646 . . . . 0.0 110.454 178.951 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . 0.4 ' HA2' ' N ' ' A' ' 41' ' ' GLY . . . -72.09 -18.95 78.2 Favored Glycine 0 N--CA 1.449 -0.484 0 CA-C-N 115.453 -0.794 . . . . 0.0 111.649 179.069 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 3.6 t -84.24 -62.93 1.44 Allowed 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.433 -0.383 . . . . 0.0 111.463 -178.088 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . 0.575 ' HB2' ' SG ' ' A' ' 101' ' ' CYS . 15.9 tt0 -89.06 -33.2 17.21 Favored 'General case' 0 C--N 1.324 -0.517 0 C-N-CA 120.532 -0.467 . . . . 0.0 110.602 -170.908 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . 0.455 ' HB3' ' O ' ' A' ' 35' ' ' ALA . . . -91.18 -12.36 35.62 Favored 'General case' 0 N--CA 1.453 -0.286 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.301 -178.857 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 82.0 4.93 90.11 Favored Glycine 0 CA--C 1.505 -0.552 0 N-CA-C 109.923 -1.271 . . . . 0.0 109.923 -178.857 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . 0.4 ' N ' ' HA2' ' A' ' 36' ' ' GLY . . . 87.3 61.56 1.55 Allowed Glycine 0 N--CA 1.434 -1.482 0 CA-C-N 113.946 -1.127 . . . . 0.0 111.369 -175.291 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 42' ' ' ASN . . . . . 0.64 ' HB3' ' HB ' ' A' ' 45' ' ' ILE . 0.3 OUTLIER -144.96 96.57 2.88 Favored 'General case' 0 N--CA 1.448 -0.559 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 -177.217 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 43' ' ' TRP . . . . . 0.749 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 46.3 m95 -79.04 -14.1 59.37 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.968 -175.223 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -107.49 14.24 26.03 Favored 'General case' 0 C--N 1.316 -0.861 0 CA-C-N 115.525 -0.761 . . . . 0.0 111.399 179.962 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.64 ' HB ' ' HB3' ' A' ' 42' ' ' ASN . 8.6 tt -78.13 144.56 11.11 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.738 0 CA-C-O 120.994 0.426 . . . . 0.0 110.181 -178.612 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 29.0 t-20 -150.26 86.74 1.43 Allowed 'General case' 0 C--N 1.31 -1.141 0 CA-C-O 121.437 0.637 . . . . 0.0 109.664 178.952 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 6.1 p -68.7 -25.79 64.96 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.122 -0.945 . . . . 0.0 111.464 -178.342 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 100.98 21.01 12.44 Favored Glycine 0 N--CA 1.445 -0.712 0 C-N-CA 120.985 -0.626 . . . . 0.0 111.545 -179.652 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 4.3 m-20 -81.42 -4.05 54.67 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 121.229 0.538 . . . . 0.0 111.029 -179.243 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 95.91 -13.6 65.9 Favored Glycine 0 N--CA 1.446 -0.635 0 N-CA-C 110.038 -1.225 . . . . 0.0 110.038 -176.592 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 51' ' ' TYR . . . . . 0.671 ' CD1' ' HB2' ' A' ' 58' ' ' ASP . 0.1 OUTLIER -102.81 144.99 30.43 Favored 'General case' 0 N--CA 1.446 -0.643 0 N-CA-C 107.631 -1.248 . . . . 0.0 107.631 174.048 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 52' ' ' TYR . . . . . 0.842 ' O ' ' HA ' ' A' ' 56' ' ' GLN . 10.3 m-85 -108.61 164.81 12.03 Favored 'General case' 0 C--N 1.308 -1.205 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.717 -172.147 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.463 ' HA2' HG22 ' A' ' 45' ' ' ILE . . . -58.13 172.73 3.27 Favored Glycine 0 C--O 1.229 -0.182 0 N-CA-C 115.702 1.041 . . . . 0.0 115.702 -166.107 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . 0.64 ' CA ' ' HA ' ' A' ' 43' ' ' TRP . . . 91.55 -111.02 3.93 Favored Glycine 0 N--CA 1.446 -0.671 0 CA-C-N 114.86 -0.67 . . . . 0.0 111.509 -178.799 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.4 HG23 ' CD1' ' A' ' 57' ' ' PHE . 1.9 m -83.23 -2.64 6.79 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 CA-C-O 122.077 0.942 . . . . 0.0 110.454 176.22 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 56' ' ' GLN . . . . . 0.842 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 5.9 tt0 50.49 52.1 15.51 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 113.436 -1.711 . . . . 0.0 114.18 168.921 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . 0.453 ' HZ ' HG13 ' A' ' 85' ' ' VAL . 7.2 p90 -105.74 158.49 16.69 Favored 'General case' 0 C--N 1.321 -0.652 0 C-N-CA 119.123 -1.031 . . . . 0.0 110.368 170.788 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.671 ' HB2' ' CD1' ' A' ' 51' ' ' TYR . 0.5 OUTLIER -64.54 144.19 57.38 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 114.888 -1.051 . . . . 0.0 112.016 -168.793 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . 0.713 ' HB2' ' CE1' ' A' ' 52' ' ' TYR . 4.6 tp-100 -63.1 -30.29 71.48 Favored 'General case' 0 C--O 1.218 -0.555 0 CA-C-N 114.841 -1.072 . . . . 0.0 111.54 -178.562 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -64.83 -44.17 95.08 Favored Glycine 0 C--N 1.316 -0.529 0 N-CA-C 110.84 -0.904 . . . . 0.0 110.84 174.949 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 88.6 m -71.36 -40.18 70.82 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-O 121.093 0.473 . . . . 0.0 111.207 175.299 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 62' ' ' TRP . . . . . 0.761 ' CZ3' HG11 ' A' ' 85' ' ' VAL . 29.5 t-105 -55.12 -46.59 75.62 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-O 121.492 0.663 . . . . 0.0 109.694 173.229 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . 0.562 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 32.0 tt0 -67.24 -35.2 79.05 Favored 'General case' 0 C--N 1.316 -0.876 0 CA-C-N 114.957 -1.019 . . . . 0.0 111.01 179.305 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -64.89 -40.85 95.74 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.936 -0.574 . . . . 0.0 110.958 -178.509 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . 0.44 ' HB3' ' HB ' ' A' ' 88' ' ' VAL . 34.8 m-80 -81.68 -7.29 59.58 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.045 -0.525 . . . . 0.0 111.085 177.039 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 87.14 45.1 5.45 Favored Glycine 0 C--N 1.331 0.269 0 C-N-CA 121.022 -0.609 . . . . 0.0 112.812 173.639 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . 0.581 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -79.67 -22.34 64.49 Favored Glycine 0 N--CA 1.441 -0.973 0 C-N-CA 121.184 -0.532 . . . . 0.0 112.783 -175.861 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.798 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 6.7 mp -60.66 -23.67 64.98 Favored 'General case' 0 C--N 1.328 -0.341 0 N-CA-C 112.345 0.498 . . . . 0.0 112.345 -172.338 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 35.7 ptt180 -71.56 -27.02 62.87 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-O 120.933 0.397 . . . . 0.0 110.374 178.882 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 70' ' ' TYR . . . . . 1.012 ' HB3' ' HG2' ' A' ' 81' ' ' GLU . 51.8 m-85 -82.98 -34.41 26.38 Favored 'General case' 0 N--CA 1.444 -0.746 0 N-CA-C 107.09 -1.448 . . . . 0.0 107.09 174.056 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.554 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 167.25 130.12 0.04 OUTLIER Pre-proline 0 C--N 1.327 -0.397 0 CA-C-N 112.456 -2.157 . . . . 0.0 108.866 -178.783 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 72' ' ' PRO . . . . . 0.798 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 36.6 Cg_endo -67.97 29.58 0.14 Allowed 'Trans proline' 0 N--CA 1.476 0.487 0 C-N-CA 122.862 2.374 . . . . 0.0 113.877 179.311 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 73' ' ' ARG . . . . . 0.465 ' H ' ' C ' ' A' ' 71' ' ' ALA . 14.7 ptm180 -176.27 140.15 0.38 Allowed 'General case' 0 C--N 1.321 -0.66 0 N-CA-C 108.665 -0.865 . . . . 0.0 108.665 178.136 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . 0.544 ' HA ' ' CH2' ' A' ' 62' ' ' TRP . . . -66.47 -27.15 67.57 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.788 -0.642 . . . . 0.0 111.795 -174.949 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . 0.462 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 21.1 p-10 -86.57 -4.92 59.24 Favored 'General case' 0 C--N 1.324 -0.532 0 C-N-CA 120.832 -0.347 . . . . 0.0 111.61 -174.825 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 65.2 tp -97.85 -28.61 13.77 Favored 'General case' 0 C--N 1.322 -0.604 0 N-CA-C 108.97 -0.752 . . . . 0.0 108.97 171.31 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . 0.685 ' HB1' ' HB3' ' A' ' 81' ' ' GLU . . . -78.05 148.54 34.24 Favored 'General case' 0 N--CA 1.441 -0.919 0 CA-C-N 115.12 -0.946 . . . . 0.0 109.934 175.309 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 47.0 p -91.79 -175.61 4.2 Favored 'General case' 0 C--N 1.31 -1.135 0 CA-C-N 115.608 -0.724 . . . . 0.0 109.982 -178.617 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . 0.749 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 43.1 mtp-105 -53.7 -54.84 32.2 Favored 'General case' 0 CA--C 1.515 -0.382 0 CA-C-O 120.979 0.419 . . . . 0.0 110.167 -178.31 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 2.6 pm0 -56.85 -39.02 73.52 Favored 'General case' 0 C--N 1.318 -0.787 0 CA-C-N 115.454 -0.794 . . . . 0.0 111.486 -176.362 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 81' ' ' GLU . . . . . 1.012 ' HG2' ' HB3' ' A' ' 70' ' ' TYR . 1.0 OUTLIER -66.93 -50.8 61.23 Favored 'General case' 0 C--N 1.323 -0.582 0 N-CA-C 112.419 0.526 . . . . 0.0 112.419 175.188 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 82' ' ' GLN . . . . . 0.614 ' HB2' ' HZ3' ' A' ' 43' ' ' TRP . 56.1 mt-30 -61.45 -34.89 76.18 Favored 'General case' 0 CA--C 1.514 -0.417 0 C-N-CA 121.023 -0.271 . . . . 0.0 110.318 -178.402 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.72 HG13 ' CD1' ' A' ' 31' ' ' TRP . 1.4 mp -60.12 -46.19 94.78 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.089 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.76 173.518 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 84' ' ' ALA . . . . . 0.616 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -62.6 -44.75 95.53 Favored 'General case' 0 C--O 1.238 0.498 0 CA-C-O 121.533 0.683 . . . . 0.0 111.663 -172.813 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.761 HG11 ' CZ3' ' A' ' 62' ' ' TRP . 2.7 p -70.68 -43.66 77.24 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.721 0 CA-C-N 115.949 -0.569 . . . . 0.0 111.027 -179.91 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 86' ' ' ALA . . . . . 0.463 ' HB1' ' CH2' ' A' ' 31' ' ' TRP . . . -61.04 -28.4 69.03 Favored 'General case' 0 N--CA 1.451 -0.415 0 CA-C-N 115.764 -0.653 . . . . 0.0 109.69 174.396 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 87' ' ' GLU . . . . . 0.687 ' HG3' ' O ' ' A' ' 83' ' ' ILE . 30.6 mt-10 -61.18 -43.84 98.25 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.398 -0.819 . . . . 0.0 109.888 179.203 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.675 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 41.2 t -61.81 -46.08 97.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-O 121.178 0.513 . . . . 0.0 109.799 176.244 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . 0.798 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 0.2 OUTLIER -67.42 -45.95 74.6 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 115.961 -0.563 . . . . 0.0 111.499 -175.25 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 90' ' ' ARG . . . . . 0.636 ' HD3' ' HZ2' ' A' ' 31' ' ' TRP . 23.2 ptt180 -62.87 -34.23 76.94 Favored 'General case' 0 C--O 1.221 -0.418 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.742 -177.259 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 91' ' ' LEU . . . . . 0.675 ' HG ' ' O ' ' A' ' 88' ' ' VAL . 4.2 pp -73.55 -23.78 60.02 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-O 120.951 0.405 . . . . 0.0 110.904 -171.82 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . 0.573 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 4.7 mtm180 -82.06 -46.91 13.26 Favored 'General case' 0 CA--C 1.51 -0.588 0 CA-C-O 121.426 0.632 . . . . 0.0 109.608 -179.11 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 93' ' ' GLN . . . . . 0.573 ' NE2' HG22 ' A' ' 89' ' ' THR . 13.2 pt20 -103.42 -27.95 12.1 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 114.759 -1.109 . . . . 0.0 113.965 -168.344 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 92.02 39.98 5.32 Favored Glycine 0 C--N 1.332 0.338 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.436 175.983 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 95' ' ' TRP . . . . . 0.603 ' HZ2' HH11 ' A' ' 90' ' ' ARG . 33.2 m95 70.06 9.62 7.13 Favored 'General case' 0 C--O 1.219 -0.55 0 C-N-CA 123.338 0.655 . . . . 0.0 109.609 -179.933 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -59.44 -41.78 97.23 Favored Glycine 0 N--CA 1.453 -0.223 0 CA-C-N 115.28 -0.873 . . . . 0.0 113.476 -178.68 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . 0.403 ' O ' ' HD3' ' A' ' 99' ' ' PRO . . . -70.03 -17.87 63.28 Favored 'General case' 0 N--CA 1.464 0.275 0 CA-C-N 117.117 0.459 . . . . 0.0 110.793 179.772 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 98' ' ' TRP . . . . . 0.798 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 24.6 m-90 -95.65 107.84 36.12 Favored Pre-proline 0 N--CA 1.448 -0.564 0 N-CA-C 108.794 -0.817 . . . . 0.0 108.794 176.171 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 99' ' ' PRO . . . . . 0.424 ' HD3' ' HA ' ' A' ' 98' ' ' TRP . 41.7 Cg_exo -63.77 -132.46 0.0 OUTLIER 'Trans proline' 0 CA--C 1.539 0.746 0 C-N-CA 123.857 3.038 . . . . 0.0 114.408 -173.804 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 18.3 t -55.48 -26.24 19.0 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.252 0 CA-C-O 120.82 0.343 . . . . 0.0 111.497 -174.623 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 101' ' ' CYS . . . . . 0.581 ' HB3' ' HA ' ' A' ' 34' ' ' ILE . 75.0 m -64.75 -34.41 78.27 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 116.339 -0.392 . . . . 0.0 111.528 -178.553 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -70.03 -40.78 74.97 Favored 'General case' 0 CA--C 1.519 -0.232 0 CA-C-O 120.971 0.415 . . . . 0.0 110.226 177.642 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -63.09 -39.38 94.52 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.353 176.904 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 104' ' ' ARG . . . . . 0.452 ' HA ' ' NE ' ' A' ' 104' ' ' ARG . 14.9 mmp_? -71.69 -31.49 66.82 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.605 -0.725 . . . . 0.0 111.003 178.844 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 105' ' ' ALA . . . . . 0.486 ' CB ' HG22 ' A' ' 30' ' ' ILE . . . -80.71 -23.95 39.14 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 120.989 0.423 . . . . 0.0 111.735 -177.356 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 97.98 59.3 0.95 Allowed Glycine 0 CA--C 1.522 0.471 0 C-N-CA 120.983 -0.627 . . . . 0.0 112.096 -176.707 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -57.62 146.72 29.56 Favored 'General case' 0 C--N 1.329 -0.311 0 C-N-CA 123.274 0.629 . . . . 0.0 112.356 -177.612 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 108' ' ' ARG . . . . . 0.694 ' O ' ' HD3' ' A' ' 108' ' ' ARG . 0.0 OUTLIER . . . . . 0 C--O 1.25 1.09 0 CA-C-O 118.545 -0.74 . . . . 0.0 110.594 -175.899 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . 0.482 ' O ' HG12 ' A' ' 30' ' ' ILE . 5.8 m-20 . . . . . 0 CA--C 1.504 -0.804 0 CA-C-O 121.874 0.845 . . . . 0.0 109.523 . . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . 0.572 ' HA2' ' HB2' ' A' ' 31' ' ' TRP . . . -69.1 -9.31 60.01 Favored Glycine 0 N--CA 1.437 -1.266 0 N-CA-C 110.302 -1.119 . . . . 0.0 110.302 176.222 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 17.6 m -76.97 -47.83 19.72 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 121.405 0.622 . . . . 0.0 110.073 177.12 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.773 HG22 ' O ' ' A' ' 105' ' ' ALA . 4.2 pt -71.67 -34.64 52.9 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.923 0 CA-C-N 115.087 -0.96 . . . . 0.0 109.641 176.844 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 31' ' ' TRP . . . . . 0.673 ' CZ2' ' HD3' ' A' ' 90' ' ' ARG . 12.1 m95 -63.75 -37.18 86.41 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 115.334 -0.848 . . . . 0.0 109.528 175.652 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 36.2 t70 -77.63 -31.32 52.7 Favored 'General case' 0 N--CA 1.448 -0.54 0 CA-C-N 115.837 -0.62 . . . . 0.0 111.133 179.793 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . 0.468 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -69.0 -33.75 74.17 Favored 'General case' 0 N--CA 1.446 -0.642 0 C-N-CA 120.409 -0.516 . . . . 0.0 109.727 176.706 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . 0.471 HG13 ' O ' ' A' ' 30' ' ' ILE . 74.1 mt -67.43 -42.81 87.66 Favored 'Isoleucine or valine' 0 C--O 1.233 0.215 0 CA-C-O 121.132 0.491 . . . . 0.0 109.722 171.72 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . 0.604 ' HA ' ' O ' ' A' ' 54' ' ' GLY . . . -57.76 -35.25 70.48 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.574 -0.739 . . . . 0.0 110.452 175.917 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . 0.491 ' HA2' ' N ' ' A' ' 41' ' ' GLY . . . -78.67 -5.44 88.29 Favored Glycine 0 N--CA 1.449 -0.46 0 CA-C-N 115.267 -0.879 . . . . 0.0 112.138 179.412 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 42.6 t -103.07 -54.17 2.67 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 120.742 0.306 . . . . 0.0 110.892 -178.483 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . 0.461 ' HG2' ' SG ' ' A' ' 101' ' ' CYS . 30.1 mm-40 -87.06 -31.05 20.72 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 121.162 0.506 . . . . 0.0 110.758 -174.717 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -103.22 -10.51 18.71 Favored 'General case' 0 N--CA 1.447 -0.6 0 CA-C-N 116.029 -0.532 . . . . 0.0 111.262 -179.043 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 76.22 14.23 82.52 Favored Glycine 0 CA--C 1.503 -0.7 0 N-CA-C 109.864 -1.294 . . . . 0.0 109.864 -178.455 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . 0.491 ' N ' ' HA2' ' A' ' 36' ' ' GLY . . . 81.66 62.53 1.93 Allowed Glycine 0 N--CA 1.432 -1.596 0 CA-C-N 113.94 -1.13 . . . . 0.0 111.82 -176.568 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 42' ' ' ASN . . . . . 0.565 ' HB3' ' HB ' ' A' ' 45' ' ' ILE . 3.4 t30 -155.87 96.97 1.78 Allowed 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 109.136 -0.69 . . . . 0.0 109.136 -178.557 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 43' ' ' TRP . . . . . 0.725 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 33.0 m95 -73.35 -11.04 60.35 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-O 121.285 0.564 . . . . 0.0 111.007 -175.319 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -106.25 14.91 26.91 Favored 'General case' 0 C--N 1.314 -0.952 0 CA-C-N 115.575 -0.739 . . . . 0.0 111.432 -179.059 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.851 HG22 ' HA2' ' A' ' 53' ' ' GLY . 7.0 tt -78.86 142.92 13.39 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.793 0 CA-C-O 121.138 0.494 . . . . 0.0 110.121 -178.106 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . 0.562 ' ND2' HH21 ' A' ' 73' ' ' ARG . 9.3 t-20 -148.29 90.05 1.77 Allowed 'General case' 0 C--N 1.312 -1.027 0 CA-C-O 121.114 0.483 . . . . 0.0 109.958 178.923 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 13.9 p -76.48 -16.65 59.6 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 115.87 -0.605 . . . . 0.0 111.724 -176.92 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 94.93 21.99 24.31 Favored Glycine 0 N--CA 1.447 -0.625 0 N-CA-C 110.942 -0.863 . . . . 0.0 110.942 -177.931 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 10.4 t-20 -86.1 -12.27 50.48 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 121.302 0.573 . . . . 0.0 110.964 -175.098 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . 0.402 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 95.21 -9.47 69.83 Favored Glycine 0 N--CA 1.448 -0.517 0 N-CA-C 110.184 -1.166 . . . . 0.0 110.184 -175.386 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 51' ' ' TYR . . . . . 0.545 ' HA ' ' HA ' ' A' ' 58' ' ' ASP . 0.5 OUTLIER -110.73 146.68 35.87 Favored 'General case' 0 CA--C 1.505 -0.777 0 N-CA-C 105.914 -1.884 . . . . 0.0 105.914 175.373 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 52' ' ' TYR . . . . . 0.788 ' HB2' ' HB3' ' A' ' 74' ' ' ALA . 45.0 m-85 -112.9 167.58 10.39 Favored 'General case' 0 C--N 1.304 -1.412 0 C-N-CA 119.623 -0.831 . . . . 0.0 112.905 -167.835 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.851 ' HA2' HG22 ' A' ' 45' ' ' ILE . . . -54.86 157.15 7.19 Favored Glycine 0 N--CA 1.446 -0.682 0 CA-C-N 114.787 -1.097 . . . . 0.0 114.105 -171.698 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . 0.689 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 97.03 -109.86 3.93 Favored Glycine 0 N--CA 1.437 -1.244 0 C-N-CA 120.803 -0.713 . . . . 0.0 111.72 -178.411 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.546 HG23 ' HG2' ' A' ' 82' ' ' GLN . 3.1 t -84.83 -0.46 5.94 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 CA-C-O 121.771 0.796 . . . . 0.0 110.354 -176.344 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 56' ' ' GLN . . . . . 0.587 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 8.1 tp-100 56.66 50.49 12.61 Favored 'General case' 0 C--N 1.339 0.141 0 CA-C-N 114.195 -1.366 . . . . 0.0 112.685 168.289 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . 0.47 ' CE1' ' HB2' ' A' ' 86' ' ' ALA . 7.8 p90 -116.98 162.76 17.26 Favored 'General case' 0 C--N 1.321 -0.659 0 C-N-CA 120.105 -0.638 . . . . 0.0 111.083 175.287 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.545 ' HA ' ' HA ' ' A' ' 51' ' ' TYR . 6.4 p-10 -76.28 160.17 29.9 Favored 'General case' 0 C--N 1.324 -0.511 0 N-CA-C 113.594 0.961 . . . . 0.0 113.594 -162.957 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 13.1 tp60 -57.24 -39.45 75.59 Favored 'General case' 0 N--CA 1.443 -0.808 0 CA-C-N 114.036 -1.438 . . . . 0.0 111.563 178.888 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -66.74 -49.89 51.99 Favored Glycine 0 C--O 1.225 -0.436 0 CA-C-N 115.653 -0.703 . . . . 0.0 112.468 -175.746 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 93.6 m -60.68 -44.06 96.96 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 121.15 0.5 . . . . 0.0 110.681 176.051 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 62' ' ' TRP . . . . . 0.433 ' HE3' ' CZ ' ' A' ' 57' ' ' PHE . 52.3 t-105 -57.05 -48.61 78.11 Favored 'General case' 0 N--CA 1.445 -0.68 0 CA-C-N 115.331 -0.849 . . . . 0.0 109.895 176.667 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . 0.503 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 31.4 tt0 -67.48 -35.09 78.48 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-N 115.141 -0.936 . . . . 0.0 110.875 -177.593 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -67.03 -41.67 86.16 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.76 -0.655 . . . . 0.0 111.04 -176.639 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . 0.441 ' HB2' HG13 ' A' ' 85' ' ' VAL . 8.1 m120 -77.69 -9.06 58.78 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 121.112 0.482 . . . . 0.0 110.156 176.137 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 88.35 45.2 5.07 Favored Glycine 0 C--N 1.332 0.341 0 CA-C-N 115.734 -0.666 . . . . 0.0 112.395 174.05 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . 0.518 ' HA2' ' CD1' ' A' ' 70' ' ' TYR . . . -79.02 -20.28 70.62 Favored Glycine 0 N--CA 1.442 -0.964 0 C-N-CA 120.883 -0.675 . . . . 0.0 112.879 -172.937 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.818 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 6.7 mp -61.27 -24.05 66.12 Favored 'General case' 0 N--CA 1.45 -0.434 0 N-CA-C 112.281 0.475 . . . . 0.0 112.281 -173.72 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . 0.497 ' HG3' ' N ' ' A' ' 70' ' ' TYR . 0.7 OUTLIER -70.62 -29.42 65.8 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 121.206 0.527 . . . . 0.0 110.135 176.143 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 70' ' ' TYR . . . . . 0.842 ' HB3' ' HB3' ' A' ' 81' ' ' GLU . 71.7 m-85 -79.7 -34.35 40.23 Favored 'General case' 0 N--CA 1.446 -0.655 0 N-CA-C 107.329 -1.36 . . . . 0.0 107.329 176.449 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.675 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 162.51 127.57 0.01 OUTLIER Pre-proline 0 C--O 1.218 -0.558 0 CA-C-N 112.401 -2.182 . . . . 0.0 107.098 -178.286 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 72' ' ' PRO . . . . . 0.818 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 17.9 Cg_exo -57.13 -1.97 0.47 Allowed 'Trans proline' 0 C--N 1.332 -0.34 0 C-N-CA 122.991 2.46 . . . . 0.0 114.058 -177.453 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 73' ' ' ARG . . . . . 0.562 HH21 ' ND2' ' A' ' 46' ' ' ASN . 12.5 ptm180 -152.56 141.89 21.55 Favored 'General case' 0 C--N 1.319 -0.726 0 N-CA-C 109.64 -0.504 . . . . 0.0 109.64 176.998 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . 0.788 ' HB3' ' HB2' ' A' ' 52' ' ' TYR . . . -63.44 -22.07 66.67 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.509 -0.769 . . . . 0.0 113.028 -176.798 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . 0.517 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 5.2 p-10 -88.29 2.92 51.38 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 121.328 0.585 . . . . 0.0 110.847 -179.781 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.435 ' HB3' ' HB1' ' A' ' 71' ' ' ALA . 53.5 tp -106.27 -34.86 7.35 Favored 'General case' 0 C--N 1.321 -0.654 0 N-CA-C 108.858 -0.793 . . . . 0.0 108.858 174.246 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . 0.815 ' HB1' ' HB2' ' A' ' 81' ' ' GLU . . . -79.83 158.12 26.85 Favored 'General case' 0 N--CA 1.446 -0.627 0 CA-C-N 114.99 -1.005 . . . . 0.0 110.057 174.512 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 25.4 p -100.77 -171.64 2.04 Favored 'General case' 0 C--N 1.314 -0.965 0 CA-C-N 116.2 -0.455 . . . . 0.0 109.8 -179.435 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . 0.725 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 35.9 mtt85 -49.21 -51.95 29.91 Favored 'General case' 0 C--O 1.218 -0.559 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.79 -179.959 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -57.45 -47.61 81.35 Favored 'General case' 0 C--N 1.321 -0.666 0 N-CA-C 112.148 0.425 . . . . 0.0 112.148 -174.854 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 81' ' ' GLU . . . . . 0.842 ' HB3' ' HB3' ' A' ' 70' ' ' TYR . 60.6 mp0 -65.6 -51.23 61.28 Favored 'General case' 0 CA--C 1.517 -0.318 0 CA-C-O 120.983 0.421 . . . . 0.0 111.403 177.228 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 82' ' ' GLN . . . . . 0.546 ' HG2' HG23 ' A' ' 55' ' ' VAL . 4.2 tt0 -65.0 -34.35 78.24 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.606 -0.724 . . . . 0.0 111.361 -173.657 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.582 ' O ' ' HB3' ' A' ' 87' ' ' GLU . 8.1 mt -61.63 -46.13 97.2 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 N-CA-C 109.471 -0.566 . . . . 0.0 109.471 174.193 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 84' ' ' ALA . . . . . . . . . . . . . . . -61.37 -47.48 85.68 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.205 -176.825 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.441 HG13 ' HB2' ' A' ' 65' ' ' ASN . 46.5 t -65.97 -50.28 70.85 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-N 116.137 -0.483 . . . . 0.0 112.207 -179.997 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 86' ' ' ALA . . . . . 0.47 ' HB2' ' CE1' ' A' ' 57' ' ' PHE . . . -63.87 -32.05 73.44 Favored 'General case' 0 CA--C 1.515 -0.394 0 CA-C-O 121.397 0.618 . . . . 0.0 110.437 179.702 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 87' ' ' GLU . . . . . 0.675 ' HA ' ' HG2' ' A' ' 90' ' ' ARG . 0.4 OUTLIER -71.32 -27.28 63.28 Favored 'General case' 0 C--N 1.317 -0.844 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.871 -178.136 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.672 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 94.6 t -61.22 -44.17 97.85 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.254 0 N-CA-C 108.701 -0.852 . . . . 0.0 108.701 169.295 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . 0.677 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 0.3 OUTLIER -66.81 -43.81 82.87 Favored 'General case' 0 C--N 1.316 -0.852 0 CA-C-N 115.582 -0.735 . . . . 0.0 111.375 -179.778 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 90' ' ' ARG . . . . . 0.675 ' HG2' ' HA ' ' A' ' 87' ' ' GLU . 20.7 ptt180 -59.88 -35.11 74.13 Favored 'General case' 0 C--O 1.222 -0.392 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.707 -176.197 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 91' ' ' LEU . . . . . 0.672 ' HG ' ' O ' ' A' ' 88' ' ' VAL . 4.6 pp -74.44 -24.77 59.12 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 121.042 0.448 . . . . 0.0 111.102 -171.678 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . 0.501 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 2.5 mtm180 -81.79 -45.24 15.87 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-O 121.568 0.699 . . . . 0.0 109.514 -178.044 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 93' ' ' GLN . . . . . 0.42 HE21 ' HZ3' ' A' ' 98' ' ' TRP . 6.6 pt20 -104.27 -28.06 11.63 Favored 'General case' 0 C--N 1.322 -0.618 0 N-CA-C 113.59 0.959 . . . . 0.0 113.59 -169.696 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 88.35 44.23 5.35 Favored Glycine 0 CA--C 1.507 -0.419 0 C-N-CA 120.625 -0.797 . . . . 0.0 112.136 176.195 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 95' ' ' TRP . . . . . 0.531 ' HZ2' HH11 ' A' ' 90' ' ' ARG . 23.6 m95 66.87 13.63 9.5 Favored 'General case' 0 C--O 1.218 -0.6 0 CA-C-O 121.173 0.511 . . . . 0.0 109.812 178.396 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -65.53 -31.62 80.74 Favored Glycine 0 N--CA 1.451 -0.304 0 CA-C-N 115.588 -0.733 . . . . 0.0 113.132 177.289 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -76.49 -21.52 55.72 Favored 'General case' 0 CA--C 1.515 -0.385 0 CA-C-O 121.152 0.501 . . . . 0.0 110.411 178.508 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 98' ' ' TRP . . . . . 0.677 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 25.1 m-90 -100.26 108.62 53.41 Favored Pre-proline 0 N--CA 1.443 -0.803 0 CA-C-N 115.521 -0.763 . . . . 0.0 109.202 178.42 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 99' ' ' PRO . . . . . 0.45 ' HD3' ' HA ' ' A' ' 98' ' ' TRP . 52.5 Cg_exo -62.25 -138.46 0.0 OUTLIER 'Trans proline' 0 CA--C 1.535 0.56 0 C-N-CA 123.831 3.021 . . . . 0.0 114.265 -174.026 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 3.4 m -54.11 -26.3 14.6 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.915 -177.882 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 101' ' ' CYS . . . . . 0.461 ' SG ' ' HG2' ' A' ' 38' ' ' GLU . 62.0 m -56.69 -39.64 74.16 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-N 115.75 -0.659 . . . . 0.0 111.525 178.035 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -70.8 -44.24 67.0 Favored 'General case' 0 CA--C 1.519 -0.23 0 CA-C-O 121.008 0.432 . . . . 0.0 110.716 179.871 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -60.68 -44.15 96.85 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.634 179.724 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -66.87 -34.03 76.91 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.712 -0.676 . . . . 0.0 111.049 176.957 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 105' ' ' ALA . . . . . 0.773 ' O ' HG22 ' A' ' 30' ' ' ILE . . . -76.51 -26.77 55.6 Favored 'General case' 0 C--N 1.331 -0.238 0 N-CA-C 111.895 0.332 . . . . 0.0 111.895 -175.285 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 111.62 60.28 0.46 Allowed Glycine 0 CA--C 1.521 0.415 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.234 -175.31 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -70.11 148.61 48.52 Favored 'General case' 0 C--N 1.327 -0.375 0 C-N-CA 122.579 0.351 . . . . 0.0 110.891 -178.94 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 108' ' ' ARG . . . . . 0.434 ' O ' ' HD3' ' A' ' 108' ' ' ARG . 0.0 OUTLIER . . . . . 0 C--O 1.245 0.825 0 CA-C-O 118.559 -0.734 . . . . 0.0 110.318 -177.082 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . 0.514 ' O ' HG12 ' A' ' 30' ' ' ILE . 7.0 m-20 . . . . . 0 CA--C 1.504 -0.803 0 CA-C-O 121.791 0.805 . . . . 0.0 108.849 . . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . 0.599 ' HA2' ' HB2' ' A' ' 31' ' ' TRP . . . -66.25 -5.05 25.93 Favored Glycine 0 N--CA 1.44 -1.092 0 CA-C-N 114.488 -1.233 . . . . 0.0 110.581 176.721 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 22.3 m -77.2 -40.44 45.15 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 120.989 0.423 . . . . 0.0 109.98 174.053 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.514 HG12 ' O ' ' A' ' 27' ' ' ASP . 0.6 OUTLIER -65.25 -38.92 83.82 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.513 0 N-CA-C 107.038 -1.467 . . . . 0.0 107.038 174.108 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 31' ' ' TRP . . . . . 0.684 ' CD1' HG13 ' A' ' 83' ' ' ILE . 31.7 m95 -72.1 -36.49 69.48 Favored 'General case' 0 N--CA 1.438 -1.075 0 CA-C-N 113.598 -1.637 . . . . 0.0 111.031 -175.998 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 6.6 t70 -72.63 -34.65 67.46 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.016 178.203 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -67.3 -37.01 82.67 Favored 'General case' 0 N--CA 1.445 -0.685 0 C-N-CA 120.64 -0.424 . . . . 0.0 109.923 177.119 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . 0.509 HG13 ' O ' ' A' ' 30' ' ' ILE . 74.2 mt -67.66 -46.43 82.79 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.171 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.523 174.491 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -58.91 -34.22 71.45 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 121.215 0.531 . . . . 0.0 110.516 177.563 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . 0.528 ' HA2' ' N ' ' A' ' 41' ' ' GLY . . . -78.83 -7.03 88.51 Favored Glycine 0 N--CA 1.45 -0.418 0 CA-C-N 115.617 -0.72 . . . . 0.0 111.719 178.616 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 46.0 t -94.81 -58.1 2.27 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-O 120.775 0.321 . . . . 0.0 110.607 -179.221 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . 0.436 ' HG3' ' SG ' ' A' ' 101' ' ' CYS . 40.2 mt-10 -89.29 -25.61 21.58 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.379 -0.373 . . . . 0.0 111.345 -173.52 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -107.53 -12.95 15.18 Favored 'General case' 0 C--N 1.324 -0.527 0 C-N-CA 120.444 -0.502 . . . . 0.0 111.869 -179.011 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 78.72 13.57 83.01 Favored Glycine 0 CA--C 1.503 -0.665 0 N-CA-C 109.789 -1.324 . . . . 0.0 109.789 -177.371 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . 0.528 ' N ' ' HA2' ' A' ' 36' ' ' GLY . . . 78.87 61.52 2.39 Favored Glycine 0 N--CA 1.435 -1.391 0 CA-C-N 114.069 -1.066 . . . . 0.0 111.855 -177.053 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 42' ' ' ASN . . . . . 0.599 HD22 ' HB ' ' A' ' 45' ' ' ILE . 4.1 t30 -145.66 96.98 2.9 Favored 'General case' 0 N--CA 1.45 -0.449 0 N-CA-C 109.044 -0.724 . . . . 0.0 109.044 -177.968 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 43' ' ' TRP . . . . . 0.867 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 16.1 m95 -82.72 -1.42 51.34 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-O 121.554 0.692 . . . . 0.0 111.156 -170.412 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -113.62 9.55 17.89 Favored 'General case' 0 C--N 1.314 -0.967 0 CA-C-N 115.039 -0.982 . . . . 0.0 111.095 178.713 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.952 HG22 ' HA2' ' A' ' 53' ' ' GLY . 9.5 tt -72.65 143.22 14.2 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.68 0 CA-C-O 121.177 0.513 . . . . 0.0 110.654 -175.603 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 15.3 t-20 -150.8 97.05 2.43 Favored 'General case' 0 C--N 1.311 -1.1 0 N-CA-C 109.399 -0.593 . . . . 0.0 109.399 177.732 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 11.1 p -74.89 -16.67 60.66 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 115.798 -0.637 . . . . 0.0 111.006 -177.7 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 101.4 13.03 34.09 Favored Glycine 0 N--CA 1.445 -0.705 0 CA-C-N 115.818 -0.628 . . . . 0.0 111.612 178.059 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 31.7 p-10 -91.65 3.01 56.07 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.801 0.334 . . . . 0.0 111.4 -176.381 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 94.9 -2.54 66.55 Favored Glycine 0 N--CA 1.449 -0.494 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.265 179.909 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 51' ' ' TYR . . . . . 0.571 ' HA ' ' HA ' ' A' ' 58' ' ' ASP . 0.4 OUTLIER -108.59 162.6 13.99 Favored 'General case' 0 CA--C 1.515 -0.374 0 N-CA-C 108.464 -0.939 . . . . 0.0 108.464 176.874 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 52' ' ' TYR . . . . . 0.627 ' O ' ' HA ' ' A' ' 56' ' ' GLN . 61.6 m-85 -123.32 169.73 11.03 Favored 'General case' 0 C--N 1.315 -0.927 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.617 -170.874 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.952 ' HA2' HG22 ' A' ' 45' ' ' ILE . . . -64.58 157.89 44.24 Favored Glycine 0 N--CA 1.445 -0.765 0 CA-C-N 115.585 -0.734 . . . . 0.0 114.105 -169.913 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . 0.669 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 107.1 -111.73 3.57 Favored Glycine 0 N--CA 1.442 -0.964 0 N-CA-C 111.653 -0.579 . . . . 0.0 111.653 179.3 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 3.1 m -93.42 12.9 2.75 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 CA-C-O 121.906 0.86 . . . . 0.0 110.385 176.69 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 56' ' ' GLN . . . . . 0.627 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 4.1 tt0 60.8 49.85 5.83 Favored 'General case' 0 C--N 1.317 -0.845 0 CA-C-N 113.673 -1.603 . . . . 0.0 112.178 172.652 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . 0.416 ' HZ ' ' CA ' ' A' ' 86' ' ' ALA . 27.3 m-85 -60.97 133.93 56.59 Favored 'General case' 0 CA--C 1.506 -0.717 0 CA-C-N 115.35 -0.841 . . . . 0.0 111.547 169.626 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.571 ' HA ' ' HA ' ' A' ' 51' ' ' TYR . 6.2 p-10 -74.01 156.13 37.85 Favored 'General case' 0 C--N 1.315 -0.932 0 C-N-CA 119.509 -0.877 . . . . 0.0 108.831 163.928 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 21.0 tp60 -52.52 -39.06 60.93 Favored 'General case' 0 N--CA 1.443 -0.778 0 CA-C-O 121.098 0.475 . . . . 0.0 111.039 -179.082 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -69.7 -50.95 27.62 Favored Glycine 0 C--O 1.222 -0.599 0 CA-C-N 115.127 -0.942 . . . . 0.0 113.237 -174.005 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 95.6 m -64.8 -35.24 80.46 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 121.201 0.524 . . . . 0.0 110.771 179.369 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 62' ' ' TRP . . . . . 0.698 ' CZ3' ' HA ' ' A' ' 82' ' ' GLN . 59.8 t-105 -60.99 -49.04 79.07 Favored 'General case' 0 N--CA 1.443 -0.779 0 CA-C-O 121.579 0.704 . . . . 0.0 109.258 174.768 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . 0.469 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 40.8 tt0 -67.24 -33.96 76.44 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-N 114.858 -1.064 . . . . 0.0 110.858 -179.017 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -63.36 -42.65 98.89 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.815 -0.63 . . . . 0.0 112.057 -175.341 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . 0.634 ' HB2' HG13 ' A' ' 85' ' ' VAL . 37.1 m-80 -83.43 -10.41 58.41 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.826 0.346 . . . . 0.0 110.409 176.209 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . 0.459 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 94.09 51.44 2.08 Favored Glycine 0 C--N 1.332 0.35 0 C-N-CA 121.007 -0.616 . . . . 0.0 112.839 173.831 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . 0.596 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -79.73 -23.96 61.19 Favored Glycine 0 N--CA 1.439 -1.116 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.821 -176.49 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.824 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 6.9 mp -59.47 -26.8 65.54 Favored 'General case' 0 C--N 1.323 -0.545 0 N-CA-C 112.553 0.575 . . . . 0.0 112.553 -172.748 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . 0.459 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 3.4 ptm180 -65.5 -33.15 75.27 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 121.36 0.6 . . . . 0.0 109.877 177.335 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 70' ' ' TYR . . . . . 1.067 ' HB3' ' HG2' ' A' ' 81' ' ' GLU . 74.1 m-85 -81.26 -34.79 31.83 Favored 'General case' 0 N--CA 1.439 -0.98 0 N-CA-C 107.956 -1.127 . . . . 0.0 107.956 179.389 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.681 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 164.63 126.12 0.02 OUTLIER Pre-proline 0 N--CA 1.448 -0.552 0 CA-C-N 112.63 -2.077 . . . . 0.0 106.989 -178.766 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 72' ' ' PRO . . . . . 0.824 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 26.5 Cg_exo -55.17 -5.88 0.66 Allowed 'Trans proline' 0 C--N 1.332 -0.3 0 C-N-CA 123.216 2.61 . . . . 0.0 114.076 -177.808 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 73' ' ' ARG . . . . . 0.423 HH11 ' HD2' ' A' ' 73' ' ' ARG . 9.9 ptm180 -146.97 138.37 24.14 Favored 'General case' 0 C--N 1.318 -0.795 0 CA-C-O 121.459 0.647 . . . . 0.0 110.402 175.776 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . 0.407 ' HB2' ' CE3' ' A' ' 62' ' ' TRP . . . -60.12 -20.68 59.46 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 114.839 -1.073 . . . . 0.0 112.6 -178.889 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . 0.615 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 0.0 OUTLIER -76.83 -22.17 53.97 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 121.262 0.553 . . . . 0.0 110.602 -178.536 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 57.9 tp -92.66 -33.36 14.4 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.643 -0.708 . . . . 0.0 110.022 177.766 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . 0.715 ' HB1' ' HB3' ' A' ' 81' ' ' GLU . . . -77.8 154.84 31.51 Favored 'General case' 0 N--CA 1.447 -0.581 0 CA-C-N 115.48 -0.782 . . . . 0.0 110.66 178.657 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 72.9 p -96.41 -174.39 3.04 Favored 'General case' 0 C--N 1.314 -0.955 0 CA-C-N 115.214 -0.903 . . . . 0.0 110.84 -176.65 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . 0.867 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 0.1 OUTLIER -50.9 -54.75 21.35 Favored 'General case' 0 C--O 1.216 -0.668 0 CA-C-O 120.699 0.285 . . . . 0.0 110.376 -179.093 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -60.35 -38.22 83.14 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-O 121.261 0.553 . . . . 0.0 111.289 -174.086 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 81' ' ' GLU . . . . . 1.067 ' HG2' ' HB3' ' A' ' 70' ' ' TYR . 2.9 mt-10 -72.32 -52.99 13.7 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 115.505 -0.771 . . . . 0.0 112.297 -179.98 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 82' ' ' GLN . . . . . 0.698 ' HA ' ' CZ3' ' A' ' 62' ' ' TRP . 3.7 tt0 -63.78 -34.47 77.97 Favored 'General case' 0 C--N 1.317 -0.841 0 CA-C-N 115.28 -0.873 . . . . 0.0 109.621 -178.441 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.684 HG13 ' CD1' ' A' ' 31' ' ' TRP . 0.5 OUTLIER -70.02 -39.56 77.47 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.235 0 CA-C-N 114.632 -1.167 . . . . 0.0 110.965 177.907 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 84' ' ' ALA . . . . . 0.427 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -58.98 -36.19 74.46 Favored 'General case' 0 C--O 1.237 0.418 0 CA-C-O 121.587 0.708 . . . . 0.0 110.321 -178.272 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.634 HG13 ' HB2' ' A' ' 65' ' ' ASN . 44.6 t -67.21 -46.89 83.14 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-N 115.173 -0.921 . . . . 0.0 110.187 176.57 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 86' ' ' ALA . . . . . 0.416 ' CA ' ' HZ ' ' A' ' 57' ' ' PHE . . . -61.67 -31.92 72.07 Favored 'General case' 0 N--CA 1.451 -0.378 0 CA-C-N 115.465 -0.789 . . . . 0.0 110.641 175.813 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 87' ' ' GLU . . . . . 0.631 ' HA ' ' HG2' ' A' ' 90' ' ' ARG . 21.4 mm-40 -60.53 -44.29 96.22 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.616 -177.809 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.568 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 96.8 t -62.52 -51.78 68.03 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.425 0 C-N-CA 120.431 -0.508 . . . . 0.0 110.553 -179.13 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . 0.56 ' HA ' ' NE ' ' A' ' 92' ' ' ARG . 14.8 t -74.09 -35.08 64.17 Favored 'General case' 0 N--CA 1.439 -0.99 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.505 -175.278 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 90' ' ' ARG . . . . . 0.631 ' HG2' ' HA ' ' A' ' 87' ' ' GLU . 3.3 ptt180 -62.26 -36.84 83.3 Favored 'General case' 0 N--CA 1.471 0.595 0 O-C-N 122.252 -0.28 . . . . 0.0 111.165 -178.337 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 91' ' ' LEU . . . . . 0.6 ' N ' ' HG3' ' A' ' 90' ' ' ARG . 4.5 pp -73.03 -23.75 60.63 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.311 -172.964 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . 0.56 ' NE ' ' HA ' ' A' ' 89' ' ' THR . 4.4 mtm180 -82.08 -43.09 18.31 Favored 'General case' 0 CA--C 1.51 -0.581 0 CA-C-O 121.797 0.808 . . . . 0.0 109.652 -178.274 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 93' ' ' GLN . . . . . 0.424 ' OE1' ' HB2' ' A' ' 97' ' ' ALA . 19.0 pt20 -99.98 -27.35 13.62 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 114.764 -1.107 . . . . 0.0 113.111 -170.485 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 84.14 47.75 5.39 Favored Glycine 0 CA--C 1.502 -0.772 0 C-N-CA 120.698 -0.763 . . . . 0.0 111.616 174.795 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 95' ' ' TRP . . . . . 0.514 ' HA ' ' HE3' ' A' ' 98' ' ' TRP . 2.9 m95 63.27 17.4 10.21 Favored 'General case' 0 C--O 1.219 -0.512 0 C-N-CA 123.148 0.579 . . . . 0.0 109.647 177.71 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -66.79 -36.64 91.47 Favored Glycine 0 C--N 1.333 0.372 0 CA-C-N 115.896 -0.593 . . . . 0.0 112.253 179.586 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . 0.424 ' HB2' ' OE1' ' A' ' 93' ' ' GLN . . . -69.94 -23.45 63.2 Favored 'General case' 0 CA--C 1.517 -0.296 0 CA-C-O 120.709 0.29 . . . . 0.0 110.577 177.768 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 98' ' ' TRP . . . . . 0.514 ' HE3' ' HA ' ' A' ' 95' ' ' TRP . 25.1 m-90 -98.94 108.11 47.4 Favored Pre-proline 0 N--CA 1.447 -0.6 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 179.095 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 99' ' ' PRO . . . . . 0.469 ' HD3' ' HA ' ' A' ' 98' ' ' TRP . 43.6 Cg_exo -63.36 -136.13 0.0 OUTLIER 'Trans proline' 0 CA--C 1.537 0.665 0 C-N-CA 123.671 2.914 . . . . 0.0 114.083 -174.275 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 44.3 t -55.19 -24.77 15.61 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.259 0 CA-C-O 121.241 0.543 . . . . 0.0 111.49 -176.106 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 101' ' ' CYS . . . . . 0.436 ' SG ' ' HG3' ' A' ' 38' ' ' GLU . 61.0 m -62.84 -34.81 78.12 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 116.064 -0.516 . . . . 0.0 111.502 -179.217 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -70.34 -41.05 73.71 Favored 'General case' 0 C--N 1.333 -0.136 0 CA-C-O 121.014 0.435 . . . . 0.0 110.775 177.975 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -64.72 -34.74 79.02 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.002 -0.544 . . . . 0.0 110.272 178.235 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 55.7 mtp180 -73.87 -19.08 60.83 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.505 -0.77 . . . . 0.0 111.864 176.468 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -95.76 -21.69 17.99 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 116.094 -0.503 . . . . 0.0 112.096 -172.951 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 99.93 67.13 0.84 Allowed Glycine 0 N--CA 1.454 -0.161 0 C-N-CA 120.777 -0.725 . . . . 0.0 111.88 -177.03 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -64.67 152.02 43.42 Favored 'General case' 0 N--CA 1.45 -0.468 0 C-N-CA 122.67 0.388 . . . . 0.0 111.022 -174.147 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 18.0 mmt180 . . . . . 0 C--O 1.241 0.656 0 O-C-N 124.019 0.824 . . . . 0.0 111.416 177.948 . . . . . . . . 0 0 . 1 . 029 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . 0.42 ' O ' HG12 ' A' ' 30' ' ' ILE . 14.2 m-20 . . . . . 0 CA--C 1.498 -1.049 0 CA-C-O 121.729 0.776 . . . . 0.0 109.598 . . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -63.09 -16.52 57.75 Favored Glycine 0 C--N 1.309 -0.963 0 CA-C-N 114.321 -1.309 . . . . 0.0 111.247 -177.047 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 15.5 m -77.66 -39.84 43.67 Favored 'General case' 0 C--N 1.315 -0.909 0 CA-C-O 121.811 0.815 . . . . 0.0 109.359 178.397 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.571 ' O ' HG13 ' A' ' 34' ' ' ILE . 0.5 OUTLIER -69.76 -39.73 78.29 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.706 0 CA-C-N 114.111 -1.404 . . . . 0.0 107.497 179.194 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 31' ' ' TRP . . . . . 0.519 ' CE3' HG11 ' A' ' 55' ' ' VAL . 18.1 m95 -68.35 -37.42 80.48 Favored 'General case' 0 C--N 1.317 -0.828 0 CA-C-N 114.195 -1.366 . . . . 0.0 110.809 -177.017 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 7.7 t70 -76.38 -32.32 58.52 Favored 'General case' 0 N--CA 1.447 -0.621 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.74 179.335 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . 0.484 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -71.05 -37.19 72.52 Favored 'General case' 0 N--CA 1.448 -0.527 0 C-N-CA 120.684 -0.406 . . . . 0.0 110.691 176.48 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . 0.571 HG13 ' O ' ' A' ' 30' ' ' ILE . 82.3 mt -67.16 -41.81 87.37 Favored 'Isoleucine or valine' 0 C--O 1.234 0.262 0 CA-C-O 121.212 0.53 . . . . 0.0 109.892 175.032 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . 0.651 ' HA ' ' O ' ' A' ' 54' ' ' GLY . . . -57.44 -37.91 73.58 Favored 'General case' 0 CA--C 1.515 -0.382 0 CA-C-N 115.511 -0.768 . . . . 0.0 110.317 175.997 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -78.38 -3.91 86.47 Favored Glycine 0 N--CA 1.45 -0.374 0 CA-C-N 115.246 -0.888 . . . . 0.0 111.638 179.883 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 41.0 t -97.51 -60.14 1.63 Allowed 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 115.689 -0.256 . . . . 0.0 111.055 -178.415 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . 0.637 ' HG3' ' SG ' ' A' ' 101' ' ' CYS . 39.2 mt-10 -89.28 -33.78 16.83 Favored 'General case' 0 CA--C 1.516 -0.356 0 CA-C-O 120.715 0.293 . . . . 0.0 111.388 -173.418 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -95.42 -14.06 24.11 Favored 'General case' 0 C--N 1.324 -0.534 0 C-N-CA 120.676 -0.409 . . . . 0.0 111.693 -176.819 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 77.97 20.22 73.63 Favored Glycine 0 N--CA 1.445 -0.745 0 N-CA-C 109.754 -1.338 . . . . 0.0 109.754 -175.799 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 71.07 56.47 7.0 Favored Glycine 0 N--CA 1.437 -1.28 0 CA-C-N 114.185 -1.008 . . . . 0.0 112.036 -176.412 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 42' ' ' ASN . . . . . 0.607 HD22 ' HB ' ' A' ' 45' ' ' ILE . 3.7 t30 -141.23 88.03 2.13 Favored 'General case' 0 N--CA 1.447 -0.597 0 N-CA-C 108.89 -0.782 . . . . 0.0 108.89 -177.592 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 43' ' ' TRP . . . . . 0.735 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 22.1 m95 -70.37 -13.03 61.97 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.515 -0.766 . . . . 0.0 111.176 -173.31 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -102.94 14.05 32.87 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 115.959 -0.564 . . . . 0.0 111.543 -177.624 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.819 HG22 ' HA2' ' A' ' 53' ' ' GLY . 3.6 tt -82.82 144.29 10.44 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.598 0 CA-C-O 120.915 0.388 . . . . 0.0 110.171 -177.955 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 44.5 t-20 -158.24 90.51 1.04 Allowed 'General case' 0 C--N 1.314 -0.95 0 N-CA-C 109.67 -0.493 . . . . 0.0 109.67 178.708 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 35.2 p -76.8 -24.05 52.81 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.622 -0.717 . . . . 0.0 110.92 -179.849 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 99.36 23.94 10.72 Favored Glycine 0 N--CA 1.442 -0.921 0 CA-C-N 115.458 -0.792 . . . . 0.0 111.377 -179.346 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 35.2 p30 -85.4 5.41 31.04 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.986 0.422 . . . . 0.0 111.559 179.656 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . 0.432 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 96.28 -10.63 67.42 Favored Glycine 0 N--CA 1.446 -0.653 0 N-CA-C 111.625 -0.59 . . . . 0.0 111.625 179.153 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 51' ' ' TYR . . . . . 0.6 ' HA ' ' HA ' ' A' ' 58' ' ' ASP . 0.2 OUTLIER -117.84 156.2 28.8 Favored 'General case' 0 CA--C 1.505 -0.75 0 N-CA-C 106.593 -1.632 . . . . 0.0 106.593 179.393 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 52' ' ' TYR . . . . . 0.651 ' HB2' ' HB3' ' A' ' 74' ' ' ALA . 46.2 m-85 -120.35 165.44 14.88 Favored 'General case' 0 C--N 1.307 -1.258 0 C-N-CA 119.69 -0.804 . . . . 0.0 112.466 -170.415 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.819 ' HA2' HG22 ' A' ' 45' ' ' ILE . . . -57.93 157.81 16.14 Favored Glycine 0 CA--C 1.502 -0.752 0 CA-C-N 114.854 -1.067 . . . . 0.0 114.41 -169.901 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . 0.667 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 99.52 -109.23 3.7 Favored Glycine 0 N--CA 1.436 -1.314 0 N-CA-C 111.246 -0.741 . . . . 0.0 111.246 -178.693 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.53 HG12 ' NE1' ' A' ' 98' ' ' TRP . 3.2 t -84.31 -2.11 6.88 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.67 0 CA-C-O 121.791 0.805 . . . . 0.0 110.025 -177.151 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 56' ' ' GLN . . . . . 0.802 ' HA ' HE21 ' A' ' 56' ' ' GLN . 0.0 OUTLIER 57.97 50.51 10.17 Favored 'General case' 0 N--CA 1.461 0.088 0 CA-C-N 114.141 -1.391 . . . . 0.0 112.833 166.598 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . 0.416 ' CE1' ' HB2' ' A' ' 86' ' ' ALA . 10.3 p90 -117.34 162.38 18.01 Favored 'General case' 0 C--N 1.324 -0.511 0 C-N-CA 120.443 -0.503 . . . . 0.0 111.071 175.166 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.6 ' HA ' ' HA ' ' A' ' 51' ' ' TYR . 5.0 p-10 -77.01 163.19 26.92 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 113.667 0.988 . . . . 0.0 113.667 -163.733 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . 0.824 ' HA ' HE21 ' A' ' 59' ' ' GLN . 0.0 OUTLIER -60.57 -40.45 91.71 Favored 'General case' 0 N--CA 1.446 -0.653 0 CA-C-N 113.714 -1.585 . . . . 0.0 111.883 -179.934 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -65.41 -45.2 91.45 Favored Glycine 0 C--N 1.321 -0.286 0 C-N-CA 121.077 -0.582 . . . . 0.0 111.953 -176.952 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . 0.555 ' CG2' HG21 ' A' ' 89' ' ' THR . 95.0 m -66.61 -43.98 83.31 Favored 'General case' 0 C--N 1.32 -0.701 0 C-N-CA 122.558 0.343 . . . . 0.0 111.077 176.524 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 62' ' ' TRP . . . . . . . . . . . . . 50.3 t-105 -57.63 -47.3 82.6 Favored 'General case' 0 N--CA 1.45 -0.426 0 CA-C-O 121.62 0.724 . . . . 0.0 109.876 176.539 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . 0.447 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 29.2 tt0 -67.31 -33.35 75.09 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 115.09 -0.959 . . . . 0.0 110.614 -178.336 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -66.54 -42.87 86.51 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.76 -0.655 . . . . 0.0 110.745 -176.806 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . 0.486 ' HB2' HG13 ' A' ' 85' ' ' VAL . 7.2 m120 -75.22 -13.97 60.49 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 121.041 0.448 . . . . 0.0 110.387 176.655 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 91.98 46.64 3.57 Favored Glycine 0 N--CA 1.448 -0.533 0 CA-C-N 115.675 -0.693 . . . . 0.0 111.855 176.114 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . 0.478 ' O ' ' HB2' ' A' ' 70' ' ' TYR . . . -79.52 -21.81 65.97 Favored Glycine 0 N--CA 1.439 -1.142 0 C-N-CA 120.882 -0.675 . . . . 0.0 112.835 -172.648 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.858 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 7.4 mp -58.98 -29.93 67.57 Favored 'General case' 0 C--N 1.319 -0.73 0 N-CA-C 112.764 0.653 . . . . 0.0 112.764 -173.191 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 12.3 ptm180 -66.02 -29.36 69.72 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-O 121.491 0.662 . . . . 0.0 110.105 176.324 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 70' ' ' TYR . . . . . 0.81 ' HB3' ' HG2' ' A' ' 81' ' ' GLU . 86.8 m-85 -78.14 -36.2 48.02 Favored 'General case' 0 N--CA 1.445 -0.717 0 N-CA-C 107.366 -1.346 . . . . 0.0 107.366 175.493 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.656 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 158.26 130.67 0.0 OUTLIER Pre-proline 0 CA--C 1.508 -0.659 0 CA-C-N 112.096 -2.32 . . . . 0.0 106.262 -177.949 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 72' ' ' PRO . . . . . 0.858 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 18.4 Cg_exo -56.89 -4.45 0.92 Allowed 'Trans proline' 0 C--N 1.331 -0.343 0 C-N-CA 122.988 2.459 . . . . 0.0 114.103 -174.655 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 3.4 ptt180 -154.48 143.78 21.29 Favored 'General case' 0 C--N 1.318 -0.766 0 CA-C-O 121.308 0.575 . . . . 0.0 110.759 176.894 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . 0.651 ' HB3' ' HB2' ' A' ' 52' ' ' TYR . . . -57.95 -21.97 46.68 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.635 -175.514 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . 0.66 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 5.0 p-10 -87.57 -9.88 53.14 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 121.357 0.598 . . . . 0.0 110.672 -178.642 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.542 HD23 ' HD2' ' A' ' 72' ' ' PRO . 57.6 tp -99.86 -30.5 12.0 Favored 'General case' 0 C--N 1.319 -0.73 0 N-CA-C 108.846 -0.798 . . . . 0.0 108.846 175.301 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . 0.656 ' HB2' ' HB3' ' A' ' 71' ' ' ALA . . . -79.63 160.71 26.27 Favored 'General case' 0 N--CA 1.442 -0.846 0 CA-C-N 115.041 -0.982 . . . . 0.0 109.789 173.118 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 36.0 p -100.48 -178.92 3.95 Favored 'General case' 0 C--N 1.309 -1.188 0 CA-C-N 115.564 -0.744 . . . . 0.0 110.914 -178.023 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . 0.735 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 5.5 mtt180 -51.17 -53.75 31.8 Favored 'General case' 0 CA--C 1.511 -0.525 0 CA-C-O 120.871 0.367 . . . . 0.0 111.031 -179.516 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 1.9 pm0 -58.36 -39.65 80.1 Favored 'General case' 0 C--N 1.314 -0.938 0 CA-C-N 115.393 -0.821 . . . . 0.0 111.602 -177.888 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 81' ' ' GLU . . . . . 0.81 ' HG2' ' HB3' ' A' ' 70' ' ' TYR . 4.1 mt-10 -70.01 -51.54 31.48 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 121.13 0.49 . . . . 0.0 111.923 178.014 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 82' ' ' GLN . . . . . 0.467 HE21 ' HE3' ' A' ' 43' ' ' TRP . 5.3 tt0 -65.69 -33.9 76.94 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-N 115.377 -0.829 . . . . 0.0 110.591 -176.904 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.445 HG23 ' CD1' ' A' ' 31' ' ' TRP . 24.4 mt -61.56 -45.06 99.44 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.678 0 CA-C-N 115.708 -0.678 . . . . 0.0 109.849 174.073 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 84' ' ' ALA . . . . . 0.654 ' O ' ' HG3' ' A' ' 87' ' ' GLU . . . -64.54 -41.1 96.56 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.945 0.403 . . . . 0.0 111.59 -176.804 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.486 HG13 ' HB2' ' A' ' 65' ' ' ASN . 50.2 t -69.05 -48.99 66.58 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-O 120.968 0.413 . . . . 0.0 111.127 179.255 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 86' ' ' ALA . . . . . 0.416 ' HB2' ' CE1' ' A' ' 57' ' ' PHE . . . -65.7 -31.79 72.99 Favored 'General case' 0 N--CA 1.449 -0.484 0 CA-C-N 115.914 -0.584 . . . . 0.0 110.76 -179.893 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 87' ' ' GLU . . . . . 0.654 ' HG3' ' O ' ' A' ' 84' ' ' ALA . 0.1 OUTLIER -70.1 -28.93 65.8 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.228 -177.373 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.56 ' O ' ' HG3' ' A' ' 92' ' ' ARG . 85.9 t -61.11 -48.64 88.11 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.177 0 N-CA-C 109.241 -0.651 . . . . 0.0 109.241 169.703 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . 0.562 ' HB ' ' CH2' ' A' ' 98' ' ' TRP . 0.1 OUTLIER -64.9 -44.18 90.43 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 115.647 -0.706 . . . . 0.0 112.143 -176.257 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 90' ' ' ARG . . . . . 0.478 ' HB3' ' CZ2' ' A' ' 31' ' ' TRP . 0.0 OUTLIER -61.2 -32.23 71.99 Favored 'General case' 0 CA--C 1.511 -0.535 0 CA-C-O 121.727 0.775 . . . . 0.0 108.974 -177.068 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 91' ' ' LEU . . . . . 0.42 HD13 HH12 ' A' ' 90' ' ' ARG . 48.4 tp -69.48 -27.42 65.2 Favored 'General case' 0 C--N 1.313 -0.984 0 CA-C-N 113.966 -1.47 . . . . 0.0 111.276 -174.418 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . 0.56 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 4.1 mtm180 -90.59 -48.29 7.17 Favored 'General case' 0 C--N 1.317 -0.805 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.293 -175.832 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 93' ' ' GLN . . . . . 0.474 ' HG3' ' H ' ' A' ' 96' ' ' GLY . 15.3 pt20 -99.07 -27.78 13.68 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-N 114.965 -1.016 . . . . 0.0 113.006 -168.995 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 89.17 41.15 5.92 Favored Glycine 0 CA--C 1.501 -0.842 0 C-N-CA 119.971 -1.109 . . . . 0.0 110.796 178.926 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 95' ' ' TRP . . . . . 0.525 ' HA ' ' HE3' ' A' ' 98' ' ' TRP . 6.1 m95 67.16 19.8 10.33 Favored 'General case' 0 C--O 1.216 -0.674 0 CA-C-N 114.893 -0.654 . . . . 0.0 109.288 176.455 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . 0.474 ' H ' ' HG3' ' A' ' 93' ' ' GLN . . . -64.1 -30.44 77.77 Favored Glycine 0 N--CA 1.452 -0.286 0 CA-C-N 115.465 -0.789 . . . . 0.0 112.886 178.462 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -75.14 -20.68 59.28 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 121.006 0.431 . . . . 0.0 110.142 176.584 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 98' ' ' TRP . . . . . 0.562 ' CH2' ' HB ' ' A' ' 89' ' ' THR . 22.3 m-90 -104.31 111.67 65.24 Favored Pre-proline 0 N--CA 1.446 -0.631 0 CA-C-N 115.72 -0.673 . . . . 0.0 110.335 -177.905 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 99' ' ' PRO . . . . . 0.412 ' HD3' ' HA ' ' A' ' 98' ' ' TRP . 52.5 Cg_exo -61.48 -140.2 0.0 OUTLIER 'Trans proline' 0 CA--C 1.534 0.487 0 C-N-CA 123.644 2.896 . . . . 0.0 114.444 -175.31 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . 0.477 ' O ' ' HD2' ' A' ' 104' ' ' ARG . 12.6 m -54.7 -29.52 21.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.654 -0.703 . . . . 0.0 111.26 -178.363 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 101' ' ' CYS . . . . . 0.637 ' SG ' ' HG3' ' A' ' 38' ' ' GLU . 59.3 m -56.34 -35.56 67.76 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-N 115.205 -0.907 . . . . 0.0 111.706 -179.591 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -69.62 -42.56 74.19 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 121.072 0.463 . . . . 0.0 110.51 179.117 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -66.76 -37.72 85.18 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.656 179.42 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 104' ' ' ARG . . . . . 0.477 ' HD2' ' O ' ' A' ' 100' ' ' VAL . 0.0 OUTLIER -72.6 -20.54 61.28 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.804 -0.635 . . . . 0.0 111.009 178.373 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 105' ' ' ALA . . . . . 0.562 ' HB1' ' HA ' ' A' ' 30' ' ' ILE . . . -91.38 -20.91 21.31 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 115.821 -0.627 . . . . 0.0 111.694 -177.392 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 103.82 54.46 0.81 Allowed Glycine 0 CA--C 1.518 0.244 0 C-N-CA 121.005 -0.617 . . . . 0.0 112.188 179.987 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -67.74 151.25 47.54 Favored 'General case' 0 N--CA 1.449 -0.522 0 C-N-CA 122.385 0.274 . . . . 0.0 111.691 -175.44 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 14.5 mtt180 . . . . . 0 C--O 1.252 1.2 0 O-C-N 124.211 0.944 . . . . 0.0 111.673 174.85 . . . . . . . . 0 0 . 1 . 030 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . 0.535 ' O ' HG12 ' A' ' 30' ' ' ILE . 71.8 m-20 . . . . . 0 CA--C 1.505 -0.767 0 CA-C-O 122.075 0.941 . . . . 0.0 108.869 . . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . 0.576 ' HA2' ' HB2' ' A' ' 31' ' ' TRP . . . -71.58 -3.0 52.89 Favored Glycine 0 N--CA 1.439 -1.123 0 CA-C-N 113.899 -1.5 . . . . 0.0 110.219 174.958 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 5.6 m -76.34 -37.57 57.15 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 108.655 -0.868 . . . . 0.0 108.655 174.086 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.535 HG12 ' O ' ' A' ' 27' ' ' ASP . 0.9 OUTLIER -70.15 -37.99 73.47 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 N-CA-C 106.943 -1.503 . . . . 0.0 106.943 175.683 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 31' ' ' TRP . . . . . 0.576 ' HB2' ' HA2' ' A' ' 28' ' ' GLY . 22.8 m95 -70.27 -36.41 74.41 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 114.122 -1.399 . . . . 0.0 110.754 -177.079 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.735 ' HB2' HH21 ' A' ' 79' ' ' ARG . 26.5 t70 -76.8 -36.17 57.13 Favored 'General case' 0 N--CA 1.444 -0.73 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.385 179.643 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . 0.415 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -70.77 -36.66 73.17 Favored 'General case' 0 N--CA 1.448 -0.526 0 CA-C-O 120.768 0.318 . . . . 0.0 110.809 176.944 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 34' ' ' ILE . . . . . 0.496 HG13 ' O ' ' A' ' 30' ' ' ILE . 59.3 mt -63.97 -43.91 97.78 Favored 'Isoleucine or valine' 0 C--O 1.234 0.267 0 CA-C-O 121.041 0.448 . . . . 0.0 110.006 173.789 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . 0.46 ' HA ' ' O ' ' A' ' 54' ' ' GLY . . . -57.1 -39.39 74.96 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.551 -0.75 . . . . 0.0 110.151 176.584 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -73.0 -17.68 78.73 Favored Glycine 0 N--CA 1.452 -0.283 0 CA-C-N 115.299 -0.864 . . . . 0.0 111.813 -179.528 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 11.1 t -88.24 -60.9 1.84 Allowed 'General case' 0 C--N 1.322 -0.63 0 CA-C-O 120.778 0.323 . . . . 0.0 111.404 -178.783 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 38' ' ' GLU . . . . . 0.806 ' HG3' ' HG2' ' A' ' 56' ' ' GLN . 8.8 tp10 -88.06 -33.49 18.3 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-O 121.009 0.433 . . . . 0.0 110.509 -169.513 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -96.85 -7.46 33.45 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.086 -0.506 . . . . 0.0 111.605 -176.468 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 76.2 17.2 80.16 Favored Glycine 0 N--CA 1.448 -0.523 0 N-CA-C 109.987 -1.245 . . . . 0.0 109.987 -177.322 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 72.81 55.29 6.6 Favored Glycine 0 N--CA 1.436 -1.306 0 CA-C-N 114.084 -1.058 . . . . 0.0 112.034 -177.334 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 42' ' ' ASN . . . . . 0.74 ' HB3' ' HB ' ' A' ' 45' ' ' ILE . 2.2 t30 -148.17 105.83 3.68 Favored 'General case' 0 CA--C 1.511 -0.521 0 N-CA-C 108.396 -0.964 . . . . 0.0 108.396 -176.444 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 43' ' ' TRP . . . . . 0.876 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 30.4 m95 -83.26 -6.87 59.62 Favored 'General case' 0 C--N 1.309 -1.161 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.551 -173.125 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -111.08 15.03 21.84 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.594 -0.73 . . . . 0.0 111.698 177.792 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.74 ' HB ' ' HB3' ' A' ' 42' ' ' ASN . 11.0 tt -86.73 144.78 8.66 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.624 0 CA-C-O 120.835 0.35 . . . . 0.0 110.868 -176.545 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 45.6 t30 -153.62 111.29 3.52 Favored 'General case' 0 C--N 1.316 -0.89 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 174.178 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 6.9 p -82.4 -15.81 51.33 Favored 'General case' 0 C--N 1.315 -0.896 0 CA-C-N 115.809 -0.632 . . . . 0.0 111.342 -179.679 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 95.92 20.53 25.89 Favored Glycine 0 N--CA 1.446 -0.673 0 N-CA-C 111.174 -0.77 . . . . 0.0 111.174 -177.555 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 8.8 p30 -85.73 -5.29 59.28 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 121.136 0.493 . . . . 0.0 111.221 -176.16 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . 0.454 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 96.87 -12.99 65.61 Favored Glycine 0 N--CA 1.448 -0.5 0 CA-C-N 115.945 -0.57 . . . . 0.0 111.832 178.411 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 51' ' ' TYR . . . . . 0.608 ' HA ' ' HA ' ' A' ' 58' ' ' ASP . 0.9 OUTLIER -108.82 137.19 47.14 Favored 'General case' 0 CA--C 1.511 -0.529 0 N-CA-C 107.376 -1.342 . . . . 0.0 107.376 172.609 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 52' ' ' TYR . . . . . 0.697 ' CE1' ' HB2' ' A' ' 59' ' ' GLN . 26.6 m-85 -99.83 156.54 17.06 Favored 'General case' 0 C--N 1.307 -1.243 0 C-N-CA 120.607 -0.437 . . . . 0.0 111.255 -167.892 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -61.16 -176.07 1.74 Allowed Glycine 0 C--N 1.329 0.19 0 N-CA-C 115.387 0.915 . . . . 0.0 115.387 -167.632 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . 0.732 ' CA ' ' HA ' ' A' ' 43' ' ' TRP . . . 86.84 -105.12 3.0 Favored Glycine 0 N--CA 1.446 -0.646 0 N-CA-C 111.318 -0.713 . . . . 0.0 111.318 -174.768 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.516 ' HB ' ' CD1' ' A' ' 57' ' ' PHE . 3.1 t -83.58 -4.47 8.44 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.751 0 N-CA-C 108.53 -0.915 . . . . 0.0 108.53 176.857 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 56' ' ' GLN . . . . . 0.806 ' HG2' ' HG3' ' A' ' 38' ' ' GLU . 14.8 tp60 58.38 43.56 19.64 Favored 'General case' 0 C--O 1.231 0.115 0 CA-C-N 114.021 -1.445 . . . . 0.0 112.377 169.651 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 57' ' ' PHE . . . . . 0.516 ' CD1' ' HB ' ' A' ' 55' ' ' VAL . 3.7 p90 -111.44 168.92 9.16 Favored 'General case' 0 C--N 1.323 -0.546 0 C-N-CA 120.181 -0.608 . . . . 0.0 110.888 174.829 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.608 ' HA ' ' HA ' ' A' ' 51' ' ' TYR . 7.7 p-10 -78.07 153.77 31.96 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 122.014 0.912 . . . . 0.0 112.38 -165.514 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . 0.697 ' HB2' ' CE1' ' A' ' 52' ' ' TYR . 4.9 tp-100 -63.77 -30.69 71.75 Favored 'General case' 0 N--CA 1.444 -0.737 0 CA-C-N 113.827 -1.533 . . . . 0.0 111.098 -179.804 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -62.96 -50.29 64.88 Favored Glycine 0 C--N 1.314 -0.689 0 C-N-CA 120.743 -0.741 . . . . 0.0 111.676 178.195 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 99.4 m -65.85 -41.86 91.17 Favored 'General case' 0 C--N 1.321 -0.674 0 C-N-CA 122.707 0.403 . . . . 0.0 111.065 175.697 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 62' ' ' TRP . . . . . 0.522 ' CH2' ' HA ' ' A' ' 74' ' ' ALA . 50.0 t-105 -56.33 -48.74 76.14 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-O 121.617 0.722 . . . . 0.0 109.546 177.487 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . 0.538 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 55.7 tt0 -67.76 -34.78 77.49 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 114.901 -1.045 . . . . 0.0 110.712 -179.76 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -62.66 -41.09 98.88 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.773 -179.398 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . 0.655 ' OD1' ' HB ' ' A' ' 89' ' ' THR . 7.9 m120 -79.96 -11.16 59.81 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.536 177.9 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . 0.562 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 84.03 49.0 4.93 Favored Glycine 0 N--CA 1.448 -0.528 0 CA-C-N 115.47 -0.786 . . . . 0.0 112.105 178.485 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 67' ' ' GLY . . . . . 0.604 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -80.17 -18.93 70.7 Favored Glycine 0 N--CA 1.439 -1.124 0 C-N-CA 121.104 -0.57 . . . . 0.0 112.725 -176.214 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.696 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 6.4 mp -62.31 -23.1 66.55 Favored 'General case' 0 N--CA 1.45 -0.425 0 N-CA-C 112.035 0.383 . . . . 0.0 112.035 -172.578 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . 0.562 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 13.9 ptp180 -68.69 -32.19 71.83 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-O 121.259 0.552 . . . . 0.0 110.118 176.84 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 70' ' ' TYR . . . . . 0.653 ' HB3' ' HB3' ' A' ' 81' ' ' GLU . 67.7 m-85 -82.18 -33.99 29.22 Favored 'General case' 0 N--CA 1.442 -0.834 0 N-CA-C 107.436 -1.32 . . . . 0.0 107.436 178.443 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 71' ' ' ALA . . . . . 0.546 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 169.14 122.86 0.04 OUTLIER Pre-proline 0 N--CA 1.447 -0.61 0 CA-C-N 112.654 -2.066 . . . . 0.0 107.445 -178.423 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 72' ' ' PRO . . . . . 0.696 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 20.9 Cg_exo -55.28 -7.02 0.98 Allowed 'Trans proline' 0 CA--C 1.527 0.138 0 C-N-CA 122.807 2.338 . . . . 0.0 113.76 -178.81 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 73' ' ' ARG . . . . . 0.437 ' HE ' ' CG ' ' A' ' 75' ' ' ASP . 12.1 ptm180 -145.39 137.98 25.96 Favored 'General case' 0 C--N 1.318 -0.772 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 177.491 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . 0.522 ' HA ' ' CH2' ' A' ' 62' ' ' TRP . . . -55.76 -35.43 66.19 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 114.802 -1.09 . . . . 0.0 112.248 -176.005 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . 0.673 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 14.9 p-10 -80.95 -7.35 59.49 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 121.092 0.472 . . . . 0.0 111.531 -173.782 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.517 ' HB3' ' HB1' ' A' ' 71' ' ' ALA . 60.2 tp -87.7 -33.06 18.87 Favored 'General case' 0 C--N 1.318 -0.773 0 N-CA-C 108.688 -0.856 . . . . 0.0 108.688 171.776 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 77' ' ' ALA . . . . . 0.943 ' HB1' ' HB2' ' A' ' 81' ' ' GLU . . . -79.29 153.37 29.92 Favored 'General case' 0 N--CA 1.446 -0.659 0 CA-C-N 115.01 -0.995 . . . . 0.0 111.012 176.444 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 22.8 p -101.16 -170.3 1.82 Allowed 'General case' 0 C--N 1.315 -0.929 0 CA-C-N 115.77 -0.65 . . . . 0.0 109.517 179.131 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . 0.876 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 53.1 mtp180 -50.67 -48.66 58.35 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.903 0.382 . . . . 0.0 111.341 -176.808 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 7.3 pt-20 -57.88 -49.29 77.21 Favored 'General case' 0 C--N 1.319 -0.75 0 CA-C-N 115.391 -0.822 . . . . 0.0 112.432 -175.517 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 81' ' ' GLU . . . . . 0.943 ' HB2' ' HB1' ' A' ' 77' ' ' ALA . 26.1 mp0 -66.29 -50.46 63.58 Favored 'General case' 0 CA--C 1.52 -0.208 0 O-C-N 122.06 -0.4 . . . . 0.0 111.559 178.0 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 82' ' ' GLN . . . . . 0.68 ' HB2' ' HZ3' ' A' ' 43' ' ' TRP . 52.0 mt-30 -62.44 -33.67 75.27 Favored 'General case' 0 CA--C 1.513 -0.448 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.003 -174.576 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.643 ' O ' ' HG2' ' A' ' 87' ' ' GLU . 27.2 mt -60.53 -49.11 85.67 Favored 'Isoleucine or valine' 0 C--O 1.216 -0.663 0 N-CA-C 109.188 -0.671 . . . . 0.0 109.188 174.986 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 84' ' ' ALA . . . . . 0.598 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -57.12 -47.68 80.51 Favored 'General case' 0 C--O 1.239 0.53 0 CA-C-O 121.522 0.677 . . . . 0.0 111.821 -178.281 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.431 HG13 ' HB2' ' A' ' 65' ' ' ASN . 45.7 t -65.97 -48.82 80.48 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.587 0 CA-C-N 115.827 -0.624 . . . . 0.0 111.284 -179.458 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 86' ' ' ALA . . . . . 0.42 ' HB1' ' CH2' ' A' ' 31' ' ' TRP . . . -59.21 -30.31 68.14 Favored 'General case' 0 N--CA 1.45 -0.468 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.439 175.572 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 87' ' ' GLU . . . . . 0.643 ' HG2' ' O ' ' A' ' 83' ' ' ILE . 21.1 mm-40 -59.58 -43.97 93.48 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.957 -179.111 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.632 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 94.2 t -64.9 -50.98 72.52 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 C-N-CA 120.56 -0.456 . . . . 0.0 110.915 179.289 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 89' ' ' THR . . . . . 0.655 ' HB ' ' OD1' ' A' ' 65' ' ' ASN . 14.7 t -72.8 -34.89 67.2 Favored 'General case' 0 C--N 1.317 -0.843 0 C-N-CA 120.495 -0.482 . . . . 0.0 111.499 -173.599 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 90' ' ' ARG . . . . . 0.623 ' HG3' ' N ' ' A' ' 91' ' ' LEU . 4.3 ptt180 -60.45 -39.31 87.08 Favored 'General case' 0 N--CA 1.466 0.338 0 O-C-N 122.291 -0.256 . . . . 0.0 110.978 -178.267 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 91' ' ' LEU . . . . . 0.632 ' HG ' ' O ' ' A' ' 88' ' ' VAL . 4.5 pp -72.72 -23.91 60.91 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 115.956 -0.566 . . . . 0.0 111.479 -173.28 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . 0.559 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 10.8 mtm180 -79.28 -48.17 14.61 Favored 'General case' 0 CA--C 1.509 -0.61 0 CA-C-O 121.803 0.811 . . . . 0.0 109.456 -176.882 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 93' ' ' GLN . . . . . 0.501 ' OE1' ' HB2' ' A' ' 97' ' ' ALA . 14.8 pt20 -97.37 -28.38 14.05 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 114.413 -1.267 . . . . 0.0 113.149 -169.773 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 96.89 39.92 3.96 Favored Glycine 0 CA--C 1.503 -0.682 0 C-N-CA 120.215 -0.993 . . . . 0.0 111.119 172.892 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 95' ' ' TRP . . . . . 0.517 ' HA ' ' HE3' ' A' ' 98' ' ' TRP . 12.3 m95 68.11 9.3 7.1 Favored 'General case' 0 C--O 1.218 -0.592 0 N-CA-C 108.953 -0.758 . . . . 0.0 108.953 -178.151 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -62.39 -32.13 81.86 Favored Glycine 0 C--N 1.334 0.451 0 CA-C-N 115.592 -0.731 . . . . 0.0 113.14 -177.814 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . 0.501 ' HB2' ' OE1' ' A' ' 93' ' ' GLN . . . -64.45 -24.26 67.56 Favored 'General case' 0 CA--C 1.514 -0.406 0 CA-C-O 120.902 0.382 . . . . 0.0 110.073 176.312 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 98' ' ' TRP . . . . . 0.581 ' HB2' ' HB2' ' A' ' 102' ' ' ALA . 19.6 m-90 -108.63 105.07 56.25 Favored Pre-proline 0 C--N 1.324 -0.522 0 CA-C-N 115.829 -0.623 . . . . 0.0 109.976 178.893 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 99' ' ' PRO . . . . . 0.439 ' HB2' ' H ' ' A' ' 100' ' ' VAL . 19.1 Cg_exo -72.14 -94.08 0.01 OUTLIER 'Trans proline' 0 CA--C 1.536 0.604 0 C-N-CA 122.888 2.392 . . . . 0.0 113.851 -175.59 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . 0.439 ' H ' ' HB2' ' A' ' 99' ' ' PRO . 46.5 t -71.44 -26.78 27.1 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.176 0 CA-C-O 121.637 0.732 . . . . 0.0 110.324 -174.799 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 101' ' ' CYS . . . . . 0.446 ' SG ' ' HB2' ' A' ' 38' ' ' GLU . 80.2 m -73.02 -37.48 66.91 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 115.217 -0.901 . . . . 0.0 111.742 -172.987 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 102' ' ' ALA . . . . . 0.581 ' HB2' ' HB2' ' A' ' 98' ' ' TRP . . . -69.7 -44.14 71.01 Favored 'General case' 0 C--N 1.327 -0.382 0 C-N-CA 120.811 -0.356 . . . . 0.0 110.267 179.258 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -61.27 -37.41 83.03 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 121.193 0.521 . . . . 0.0 110.92 179.715 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -72.11 -23.84 61.38 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.731 -0.668 . . . . 0.0 111.818 177.526 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 105' ' ' ALA . . . . . 0.48 ' HB1' ' HA ' ' A' ' 30' ' ' ILE . . . -95.63 -22.78 17.37 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 116.1 -0.5 . . . . 0.0 112.154 -174.619 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 121.55 58.47 0.22 Allowed Glycine 0 CA--C 1.521 0.437 0 C-N-CA 121.05 -0.595 . . . . 0.0 112.189 -176.765 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -72.21 150.4 43.73 Favored 'General case' 0 C--N 1.327 -0.386 0 C-N-CA 122.871 0.469 . . . . 0.0 111.079 -176.494 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 108' ' ' ARG . . . . . 0.476 ' HB2' ' HE1' ' A' ' 95' ' ' TRP . 93.1 mtt180 . . . . . 0 C--O 1.25 1.09 0 CA-C-O 118.303 -0.855 . . . . 0.0 110.636 -174.644 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 94.8 m-20 . . . . . 0 N--CA 1.477 0.921 0 CA-C-O 120.835 0.35 . . . . 0.0 110.318 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 13.0 p -69.29 -16.18 20.39 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.331 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.589 178.426 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 60.9 t -61.26 107.61 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.472 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.397 176.102 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 4.7 p -73.86 141.04 16.71 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 CA-C-O 121.814 0.816 . . . . 0.0 111.446 -177.654 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 1.5 p -110.5 114.56 54.95 Favored Pre-proline 0 C--N 1.311 -1.07 0 CA-C-N 114.456 -1.247 . . . . 0.0 110.915 -176.932 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 7.8 Cg_endo -88.58 168.82 5.9 Favored 'Trans proline' 0 N--CA 1.449 -1.102 0 C-N-CA 123.327 2.685 . . . . 0.0 111.686 177.991 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -76.87 88.59 3.46 Favored 'General case' 0 C--N 1.311 -1.071 0 CA-C-N 114.607 -1.179 . . . . 0.0 110.621 179.03 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 29.6 m170 -82.85 -11.48 58.19 Favored 'General case' 0 C--N 1.312 -1.036 0 CA-C-N 114.344 -1.298 . . . . 0.0 108.332 172.368 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 11.7 pt-20 -78.85 139.15 38.39 Favored 'General case' 0 N--CA 1.452 -0.371 0 CA-C-N 115.568 -0.742 . . . . 0.0 110.645 -178.566 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -147.95 77.03 1.4 Allowed 'General case' 0 C--N 1.319 -0.756 0 CA-C-N 115.448 -0.796 . . . . 0.0 109.609 179.226 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 62.7 t -66.92 -71.72 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.63 0 CA-C-N 115.004 -0.998 . . . . 0.0 110.496 -178.999 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 5.9 p 25.73 77.79 0.01 OUTLIER 'Isoleucine or valine' 0 C--O 1.237 0.434 0 CA-C-O 122.842 1.306 . . . . 0.0 112.641 179.64 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 64.3 mtm180 -78.56 109.11 12.46 Favored 'General case' 0 N--CA 1.434 -1.267 0 CA-C-N 113.939 -1.482 . . . . 0.0 111.655 -173.328 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.8 t -96.36 154.44 3.57 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.426 0 CA-C-N 113.996 -1.456 . . . . 0.0 107.702 172.074 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -102.66 -63.91 0.72 Allowed Glycine 0 C--N 1.301 -1.373 0 CA-C-N 115.366 -0.834 . . . . 0.0 111.411 -173.642 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 24.2 m -147.87 -46.48 0.16 Allowed 'General case' 0 N--CA 1.429 -1.492 0 CA-C-N 114.583 -0.809 . . . . 0.0 110.371 178.803 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 66.8 mmtt -66.0 108.66 2.39 Favored Pre-proline 0 C--N 1.317 -0.841 0 CA-C-N 114.89 -1.05 . . . . 0.0 109.461 179.653 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 97.7 Cg_endo -71.81 106.44 1.99 Allowed 'Trans proline' 0 N--CA 1.452 -0.922 0 C-N-CA 122.853 2.368 . . . . 0.0 111.113 -178.998 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 82.99 56.97 2.61 Favored Glycine 0 C--N 1.294 -1.789 0 CA-C-N 113.259 -1.791 . . . . 0.0 110.428 -173.096 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 1.4 m -56.44 -53.06 61.88 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.364 -0.418 . . . . 0.0 110.136 179.216 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -145.96 110.34 5.05 Favored 'General case' 0 N--CA 1.451 -0.411 0 CA-C-N 115.848 -0.614 . . . . 0.0 110.446 174.617 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 64.7 t -109.31 112.92 59.07 Favored Pre-proline 0 C--N 1.316 -0.853 0 N-CA-C 109.117 -0.697 . . . . 0.0 109.117 175.044 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.495 ' HA ' ' HD2' ' A' ' 24' ' ' PRO . 48.1 Cg_exo -55.71 128.65 31.23 Favored 'Trans proline' 0 N--CA 1.462 -0.358 0 C-N-CA 122.616 2.211 . . . . 0.0 112.145 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . 0.495 ' HD2' ' HA ' ' A' ' 23' ' ' PRO . 11.0 Cg_endo -56.28 140.68 88.39 Favored 'Trans proline' 0 N--CA 1.453 -0.901 0 C-N-CA 123.132 2.554 . . . . 0.0 111.862 176.384 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.551 ' HB ' HG21 ' A' ' 83' ' ' ILE . 85.9 t -116.76 126.38 74.17 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.162 0 CA-C-N 114.96 -1.018 . . . . 0.0 110.01 -178.46 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 43.4 mm -68.92 -23.21 27.1 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-N 115.531 -0.759 . . . . 0.0 111.152 -174.204 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.493 ' O ' HG13 ' A' ' 30' ' ' ILE . 14.0 m-20 -91.68 6.44 45.85 Favored 'General case' 0 N--CA 1.445 -0.687 0 CA-C-O 121.73 0.776 . . . . 0.0 109.009 -177.663 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -64.27 -10.51 41.96 Favored Glycine 0 N--CA 1.441 -1.008 0 CA-C-N 114.572 -1.194 . . . . 0.0 110.55 174.198 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 47.0 m -76.32 -37.44 57.38 Favored 'General case' 0 N--CA 1.45 -0.464 0 CA-C-O 121.268 0.556 . . . . 0.0 109.867 175.363 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.601 ' HA ' ' HB1' ' A' ' 105' ' ' ALA . 0.2 OUTLIER -69.23 -36.27 71.93 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 N-CA-C 107.718 -1.216 . . . . 0.0 107.718 175.468 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' TRP . . . . . 0.572 ' CH2' ' HB1' ' A' ' 86' ' ' ALA . 42.1 m95 -70.55 -36.31 73.6 Favored 'General case' 0 C--N 1.318 -0.786 0 CA-C-N 114.401 -1.272 . . . . 0.0 110.487 -179.226 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.883 ' HB2' HH21 ' A' ' 79' ' ' ARG . 23.6 t70 -76.43 -37.66 56.67 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.583 179.271 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . 0.476 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -69.58 -33.98 73.5 Favored 'General case' 0 N--CA 1.447 -0.599 0 C-N-CA 120.852 -0.339 . . . . 0.0 110.62 178.331 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . 0.537 HG13 ' O ' ' A' ' 30' ' ' ILE . 78.0 mt -64.29 -47.48 89.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-O 121.009 0.433 . . . . 0.0 110.001 172.443 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . 0.417 ' HA ' ' O ' ' A' ' 54' ' ' GLY . . . -57.87 -39.79 78.64 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.681 -0.69 . . . . 0.0 110.169 177.446 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . 0.518 ' HA2' ' N ' ' A' ' 41' ' ' GLY . . . -70.26 -18.14 74.76 Favored Glycine 0 N--CA 1.453 -0.202 0 CA-C-N 115.501 -0.772 . . . . 0.0 112.135 179.496 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 26.4 t -90.94 -53.04 4.56 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-O 120.931 0.396 . . . . 0.0 111.419 -178.402 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 6.9 tp10 -87.23 -33.2 19.39 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.289 -170.747 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -105.5 -10.63 16.79 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.809 -0.632 . . . . 0.0 111.606 -177.528 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 78.95 14.68 81.72 Favored Glycine 0 CA--C 1.504 -0.598 0 N-CA-C 109.75 -1.34 . . . . 0.0 109.75 -175.206 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . 0.518 ' N ' ' HA2' ' A' ' 36' ' ' GLY . . . 78.49 63.25 2.15 Favored Glycine 0 N--CA 1.434 -1.481 0 CA-C-N 114.019 -1.091 . . . . 0.0 111.514 -175.571 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 2.4 t-20 -145.91 96.81 2.86 Favored 'General case' 0 N--CA 1.447 -0.576 0 N-CA-C 109.442 -0.577 . . . . 0.0 109.442 -177.451 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' TRP . . . . . 0.721 ' CE3' ' HA ' ' A' ' 79' ' ' ARG . 29.9 m95 -83.65 -4.1 58.31 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-N 115.561 -0.745 . . . . 0.0 110.385 -175.145 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -109.26 14.65 23.67 Favored 'General case' 0 C--N 1.315 -0.925 0 CA-C-N 114.805 -1.089 . . . . 0.0 110.282 178.017 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.97 HG22 ' HA2' ' A' ' 53' ' ' GLY . 8.9 tt -78.02 139.08 19.14 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.038 0 CA-C-O 121.509 0.671 . . . . 0.0 110.197 -179.148 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 13.1 t-20 -139.86 76.58 1.57 Allowed 'General case' 0 C--N 1.308 -1.2 0 N-CA-C 108.593 -0.892 . . . . 0.0 108.593 177.865 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 5.1 p -57.6 -29.2 64.3 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 114.366 -1.288 . . . . 0.0 110.997 -178.982 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 96.06 22.81 19.11 Favored Glycine 0 N--CA 1.437 -1.252 0 N-CA-C 110.922 -0.871 . . . . 0.0 110.922 178.552 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 39.0 p-10 -102.8 4.25 37.65 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 120.881 0.372 . . . . 0.0 111.015 -177.085 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . 0.418 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 94.82 -8.09 70.63 Favored Glycine 0 N--CA 1.448 -0.55 0 N-CA-C 111.535 -0.626 . . . . 0.0 111.535 178.639 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' TYR . . . . . 0.577 ' HA ' ' HA ' ' A' ' 58' ' ' ASP . 0.5 OUTLIER -112.64 132.94 54.93 Favored 'General case' 0 N--CA 1.446 -0.65 0 N-CA-C 106.71 -1.589 . . . . 0.0 106.71 -179.094 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' TYR . . . . . 0.696 ' HB2' ' HB3' ' A' ' 74' ' ' ALA . 50.6 m-85 -104.64 171.36 7.37 Favored 'General case' 0 C--N 1.304 -1.375 0 N-CA-C 113.225 0.824 . . . . 0.0 113.225 -165.747 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.97 ' HA2' HG22 ' A' ' 45' ' ' ILE . . . -48.46 155.33 1.47 Allowed Glycine 0 N--CA 1.45 -0.373 0 CA-C-N 114.783 -1.099 . . . . 0.0 115.833 -170.204 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.709 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 94.13 -106.41 3.41 Favored Glycine 0 N--CA 1.438 -1.172 0 CA-C-N 114.706 -0.747 . . . . 0.0 112.179 174.756 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -84.29 -1.52 6.44 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 CA-C-O 121.246 0.546 . . . . 0.0 111.534 -178.812 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' GLN . . . . . 0.556 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 5.4 mm-40 59.21 50.39 8.01 Favored 'General case' 0 N--CA 1.467 0.409 0 CA-C-N 114.502 -1.227 . . . . 0.0 113.965 167.059 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -116.23 160.07 20.94 Favored 'General case' 0 C--N 1.326 -0.431 0 C-N-CA 119.804 -0.758 . . . . 0.0 111.569 173.693 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.577 ' HA ' ' HA ' ' A' ' 51' ' ' TYR . 7.3 p-10 -71.11 160.78 32.27 Favored 'General case' 0 C--N 1.324 -0.506 0 N-CA-C 113.797 1.036 . . . . 0.0 113.797 -163.451 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.786 ' HA ' HE21 ' A' ' 59' ' ' GLN . 0.0 OUTLIER -55.36 -39.96 70.71 Favored 'General case' 0 N--CA 1.446 -0.65 0 CA-C-N 113.987 -1.46 . . . . 0.0 111.438 178.056 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -67.65 -48.66 54.98 Favored Glycine 0 C--O 1.225 -0.467 0 CA-C-N 115.417 -0.81 . . . . 0.0 112.042 -175.816 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 89.0 m -66.4 -40.63 89.74 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-O 121.067 0.46 . . . . 0.0 110.641 177.226 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' TRP . . . . . 0.488 ' HZ3' ' HG3' ' A' ' 82' ' ' GLN . 56.9 t-105 -56.48 -48.98 75.98 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-O 121.622 0.725 . . . . 0.0 109.5 175.407 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . 0.785 ' HG3' HD11 ' A' ' 68' ' ' LEU . 27.9 tt0 -66.85 -34.33 77.56 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 115.015 -0.993 . . . . 0.0 110.985 179.845 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -63.96 -41.86 97.44 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.968 -0.56 . . . . 0.0 111.454 -177.441 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 36.5 m-80 -81.52 -7.86 59.64 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.079 -0.51 . . . . 0.0 109.983 175.618 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . 0.456 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 83.29 48.34 5.39 Favored Glycine 0 N--CA 1.45 -0.413 0 CA-C-N 115.507 -0.769 . . . . 0.0 112.647 174.975 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.645 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -79.68 -15.98 78.43 Favored Glycine 0 CA--C 1.504 -0.649 0 C-N-CA 120.87 -0.681 . . . . 0.0 111.904 -176.352 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.785 HD11 ' HG3' ' A' ' 63' ' ' GLU . 19.2 mt -61.72 -28.83 69.7 Favored 'General case' 0 C--N 1.314 -0.97 0 C-N-CA 123.346 0.659 . . . . 0.0 111.956 -172.953 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . 0.456 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 5.6 ptp180 -68.05 -28.45 67.39 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-O 121.557 0.694 . . . . 0.0 109.789 178.861 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' TYR . . . . . 0.758 ' HB3' ' HG2' ' A' ' 81' ' ' GLU . 89.0 m-85 -81.47 -34.66 31.26 Favored 'General case' 0 N--CA 1.439 -0.983 0 N-CA-C 107.872 -1.158 . . . . 0.0 107.872 176.848 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.586 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 165.33 125.22 0.02 OUTLIER Pre-proline 0 N--CA 1.445 -0.687 0 CA-C-N 112.336 -2.211 . . . . 0.0 107.115 -179.296 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' PRO . . . . . 0.566 ' HA ' ' HA ' ' A' ' 68' ' ' LEU . 26.8 Cg_exo -53.71 -5.97 0.36 Allowed 'Trans proline' 0 C--N 1.334 -0.232 0 C-N-CA 123.14 2.56 . . . . 0.0 114.169 -178.745 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 11.2 ptm180 -148.28 141.0 24.57 Favored 'General case' 0 C--N 1.314 -0.966 0 N-CA-C 109.231 -0.655 . . . . 0.0 109.231 175.387 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . 0.696 ' HB3' ' HB2' ' A' ' 52' ' ' TYR . . . -60.72 -27.01 67.59 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.674 -0.694 . . . . 0.0 112.65 -176.39 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . 0.601 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 3.5 p30 -80.08 -5.95 56.81 Favored 'General case' 0 C--N 1.322 -0.618 0 C-N-CA 120.007 -0.677 . . . . 0.0 110.921 -177.785 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.542 ' HB3' ' HB1' ' A' ' 71' ' ' ALA . 59.2 tp -97.89 -32.72 11.54 Favored 'General case' 0 C--N 1.321 -0.66 0 N-CA-C 109.113 -0.699 . . . . 0.0 109.113 174.815 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . 0.697 ' HB1' ' CB ' ' A' ' 81' ' ' GLU . . . -79.68 164.29 23.87 Favored 'General case' 0 N--CA 1.447 -0.586 0 CA-C-N 115.243 -0.889 . . . . 0.0 109.911 174.485 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 42.8 p -101.13 -173.89 2.48 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 116.573 -0.285 . . . . 0.0 110.801 -177.879 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . 0.883 HH21 ' HB2' ' A' ' 32' ' ' ASP . 41.2 mtp180 -50.42 -52.58 36.38 Favored 'General case' 0 CA--C 1.515 -0.402 0 CA-C-O 121.218 0.532 . . . . 0.0 111.295 -178.137 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' GLU . . . . . 0.687 ' HA ' HD12 ' A' ' 83' ' ' ILE . 6.9 pt-20 -66.0 -27.77 68.38 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-N 115.139 -0.937 . . . . 0.0 112.061 -173.873 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' GLU . . . . . 0.758 ' HG2' ' HB3' ' A' ' 70' ' ' TYR . 3.2 mp0 -72.83 -46.26 54.03 Favored 'General case' 0 C--N 1.324 -0.507 0 C-N-CA 120.762 -0.375 . . . . 0.0 111.758 174.239 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' GLN . . . . . 0.632 ' HB2' ' HZ3' ' A' ' 43' ' ' TRP . 0.1 OUTLIER -58.96 -34.72 72.12 Favored 'General case' 0 CA--C 1.506 -0.735 0 N-CA-C 109.108 -0.701 . . . . 0.0 109.108 175.125 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.687 HD12 ' HA ' ' A' ' 80' ' ' GLU . 60.3 mt -60.62 -48.75 87.28 Favored 'Isoleucine or valine' 0 C--O 1.211 -0.957 0 CA-C-N 114.731 -1.122 . . . . 0.0 110.022 173.636 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . 0.632 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -63.67 -45.26 90.91 Favored 'General case' 0 C--O 1.238 0.452 0 CA-C-O 121.439 0.637 . . . . 0.0 111.897 -174.98 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.502 HG22 ' HA2' ' A' ' 67' ' ' GLY . 34.8 t -66.52 -48.1 81.58 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.775 0 CA-C-N 115.756 -0.656 . . . . 0.0 110.651 -179.206 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . 0.572 ' HB1' ' CH2' ' A' ' 31' ' ' TRP . . . -61.46 -28.08 69.03 Favored 'General case' 0 N--CA 1.45 -0.45 0 CA-C-N 115.468 -0.787 . . . . 0.0 110.415 174.976 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' GLU . . . . . 0.679 ' HG2' ' O ' ' A' ' 83' ' ' ILE . 36.0 mm-40 -59.09 -43.37 91.84 Favored 'General case' 0 CA--C 1.513 -0.457 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.63 179.78 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.522 ' O ' ' HG3' ' A' ' 92' ' ' ARG . 48.8 t -65.27 -42.8 94.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 C-N-CA 120.385 -0.526 . . . . 0.0 109.893 175.851 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . 0.745 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 0.2 OUTLIER -66.82 -46.88 73.75 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 115.956 -0.565 . . . . 0.0 111.465 -175.271 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . 0.483 ' HG3' ' N ' ' A' ' 91' ' ' LEU . 4.9 ptt180 -66.09 -31.18 71.9 Favored 'General case' 0 C--O 1.218 -0.577 0 CA-C-O 122.042 0.925 . . . . 0.0 109.083 -179.018 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . 0.483 ' N ' ' HG3' ' A' ' 90' ' ' ARG . 56.3 tp -61.84 -30.5 70.89 Favored 'General case' 0 C--N 1.308 -1.211 0 CA-C-N 114.494 -1.23 . . . . 0.0 111.509 -175.633 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . 0.522 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 7.6 mtm180 -90.68 -45.73 8.69 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-N 115.559 -0.746 . . . . 0.0 110.205 -175.402 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' GLN . . . . . 0.532 ' NE2' HG22 ' A' ' 89' ' ' THR . 21.1 pt20 -104.03 -27.32 12.2 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 114.897 -1.047 . . . . 0.0 113.039 -169.923 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.412 ' O ' ' HB2' ' A' ' 90' ' ' ARG . . . 106.75 -107.71 2.74 Favored Glycine 0 N--CA 1.44 -1.034 0 N-CA-C 109.134 -1.586 . . . . 0.0 109.134 -175.214 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' TRP . . . . . 0.556 ' CZ2' HD12 ' A' ' 30' ' ' ILE . 29.7 m95 -138.51 21.56 2.73 Favored 'General case' 0 C--N 1.308 -1.21 0 N-CA-C 106.348 -1.723 . . . . 0.0 106.348 172.995 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -56.26 -35.16 64.31 Favored Glycine 0 C--N 1.335 0.514 0 CA-C-N 114.706 -1.134 . . . . 0.0 112.901 179.752 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -79.25 -15.38 58.1 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.78 0.324 . . . . 0.0 110.533 178.092 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 98' ' ' TRP . . . . . 0.745 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 24.7 m-90 -104.92 107.81 59.59 Favored Pre-proline 0 C--N 1.323 -0.572 0 CA-C-O 121.459 0.647 . . . . 0.0 110.019 178.722 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . 0.427 ' HD3' ' HA ' ' A' ' 98' ' ' TRP . 37.6 Cg_exo -64.73 -139.39 0.01 OUTLIER 'Trans proline' 0 CA--C 1.534 0.52 0 C-N-CA 123.764 2.976 . . . . 0.0 114.762 -174.102 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . 0.563 ' O ' ' HD2' ' A' ' 104' ' ' ARG . 23.8 t -55.89 -25.84 19.67 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.266 0 CA-C-N 115.441 -0.8 . . . . 0.0 110.746 -178.126 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 89.9 m -60.12 -38.73 83.91 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.321 176.907 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 102' ' ' ALA . . . . . 0.567 ' HB2' ' HB3' ' A' ' 98' ' ' TRP . . . -70.48 -41.2 73.02 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.686 0.279 . . . . 0.0 110.452 178.434 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -59.63 -44.81 93.33 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 121.189 0.519 . . . . 0.0 110.025 178.208 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 104' ' ' ARG . . . . . 0.563 ' HD2' ' O ' ' A' ' 100' ' ' VAL . 0.0 OUTLIER -62.52 -37.01 84.42 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.393 -0.821 . . . . 0.0 111.052 176.787 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 105' ' ' ALA . . . . . 0.601 ' HB1' ' HA ' ' A' ' 30' ' ' ILE . . . -78.77 -22.45 46.36 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 115.624 -0.716 . . . . 0.0 111.905 -176.165 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 114.56 62.13 0.39 Allowed Glycine 0 CA--C 1.519 0.325 0 C-N-CA 121.143 -0.551 . . . . 0.0 112.392 -178.185 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -61.47 140.61 58.04 Favored 'General case' 0 C--O 1.236 0.343 0 C-N-CA 122.789 0.435 . . . . 0.0 110.799 -179.331 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 8.7 ptm180 . . . . . 0 C--O 1.245 0.858 0 CA-C-O 118.556 -0.735 . . . . 0.0 110.555 -172.452 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 23.6 p-10 . . . . . 0 N--CA 1.477 0.904 0 CA-C-O 121.219 0.533 . . . . 0.0 110.352 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 12.4 p -78.64 -27.97 14.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.748 -175.885 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 14.6 p -72.73 134.54 29.59 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.797 0 CA-C-N 116.068 -0.514 . . . . 0.0 109.904 175.324 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 10.7 t -82.64 137.84 20.39 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.571 0 N-CA-C 109.352 -0.61 . . . . 0.0 109.352 179.008 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . 0.437 ' HA ' ' HD3' ' A' ' 6' ' ' PRO . 8.4 p -96.7 110.29 52.55 Favored Pre-proline 0 C--N 1.314 -0.952 0 CA-C-N 115.602 -0.726 . . . . 0.0 111.342 -175.819 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.437 ' HD3' ' HA ' ' A' ' 5' ' ' THR . 3.1 Cg_exo -81.7 171.87 12.83 Favored 'Trans proline' 0 N--CA 1.452 -0.92 0 C-N-CA 123.379 2.72 . . . . 0.0 111.925 179.512 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . 0.442 ' O ' ' HB3' ' A' ' 8' ' ' HIS . . . -124.46 -165.15 1.33 Allowed 'General case' 0 C--N 1.311 -1.102 0 CA-C-N 114.37 -1.286 . . . . 0.0 110.335 -179.011 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . 0.442 ' HB3' ' O ' ' A' ' 7' ' ' ALA . 51.2 t-80 75.92 -9.81 1.38 Allowed 'General case' 0 C--O 1.232 0.172 0 O-C-N 124.262 0.976 . . . . 0.0 109.704 -172.533 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 7.9 pt-20 -91.1 138.22 31.77 Favored 'General case' 0 N--CA 1.452 -0.352 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.178 177.561 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -143.57 73.58 1.4 Allowed 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 115.858 -0.61 . . . . 0.0 109.938 178.993 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 96.1 t -65.57 -50.47 71.7 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.669 0 CA-C-N 115.209 -0.905 . . . . 0.0 110.169 179.732 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 79.7 t 27.97 84.58 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.447 -0.623 0 C-N-CA 125.011 1.324 . . . . 0.0 113.147 178.588 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . 0.601 ' HD3' ' H ' ' A' ' 13' ' ' ARG . 0.1 OUTLIER -107.35 115.59 30.44 Favored 'General case' 0 C--N 1.303 -1.432 0 CA-C-N 114.095 -1.411 . . . . 0.0 109.644 179.967 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.9 t -110.99 161.3 9.55 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.254 0 CA-C-N 114.514 -1.221 . . . . 0.0 109.25 -179.452 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 104.13 76.08 1.08 Allowed Glycine 0 N--CA 1.434 -1.484 0 CA-C-N 115.124 -0.944 . . . . 0.0 111.557 -178.895 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 41.7 m -73.46 -23.52 60.1 Favored 'General case' 0 N--CA 1.442 -0.838 0 CA-C-O 121.485 0.66 . . . . 0.0 110.039 179.066 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . 0.451 ' N ' ' HD3' ' A' ' 18' ' ' PRO . 73.1 mmtt 52.99 64.68 6.83 Favored Pre-proline 0 C--N 1.32 -0.679 0 CA-C-N 114.311 -1.313 . . . . 0.0 112.109 179.754 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . 0.451 ' HD3' ' N ' ' A' ' 17' ' ' LYS . 36.3 Cg_exo -69.29 115.92 4.26 Favored 'Trans proline' 0 CA--C 1.505 -0.946 0 C-N-CA 122.969 2.446 . . . . 0.0 111.669 174.283 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 170.35 39.38 0.03 OUTLIER Glycine 0 C--N 1.297 -1.633 0 CA-C-N 113.728 -1.578 . . . . 0.0 112.534 179.436 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 28.6 m -69.36 -39.27 78.17 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-O 121.439 0.638 . . . . 0.0 109.602 175.29 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . 0.449 ' O ' ' HD3' ' A' ' 23' ' ' PRO . 37.8 mt-10 -148.04 150.69 34.39 Favored 'General case' 0 N--CA 1.443 -0.805 0 N-CA-C 108.004 -1.11 . . . . 0.0 108.004 179.81 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 53.6 t -84.63 110.68 29.14 Favored Pre-proline 0 C--N 1.309 -1.181 0 N-CA-C 109.526 -0.546 . . . . 0.0 109.526 175.365 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.449 ' HD3' ' O ' ' A' ' 21' ' ' GLU . 49.3 Cg_exo -55.56 141.78 82.59 Favored 'Trans proline' 0 C--N 1.345 0.38 0 C-N-CA 123.117 2.545 . . . . 0.0 111.827 179.99 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 10.8 Cg_endo -55.18 140.13 80.91 Favored 'Trans proline' 0 N--CA 1.455 -0.755 0 C-N-CA 123.02 2.48 . . . . 0.0 111.728 179.43 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.591 HG12 ' H ' ' A' ' 27' ' ' ASP . 49.5 t -116.72 131.32 69.71 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.044 0 CA-C-N 114.968 -1.014 . . . . 0.0 110.601 -174.062 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.441 HD12 ' N ' ' A' ' 26' ' ' ILE . 3.3 mp -72.8 -25.18 21.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 115.51 -0.768 . . . . 0.0 109.906 -176.595 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.591 ' H ' HG12 ' A' ' 25' ' ' VAL . 4.3 m-20 -91.65 -0.27 57.56 Favored 'General case' 0 CA--C 1.503 -0.846 0 CA-C-N 115.239 -0.892 . . . . 0.0 109.904 -175.876 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -61.21 -15.22 43.57 Favored Glycine 0 CA--C 1.505 -0.565 0 CA-C-N 114.904 -1.043 . . . . 0.0 110.543 177.646 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 23.2 m -77.28 -37.23 53.28 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 114.666 -0.767 . . . . 0.0 110.068 177.598 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.556 ' O ' HG13 ' A' ' 34' ' ' ILE . 1.1 mm -71.38 -39.08 71.36 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.751 0 N-CA-C 107.029 -1.471 . . . . 0.0 107.029 178.693 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' TRP . . . . . 0.621 ' HZ2' ' HD3' ' A' ' 90' ' ' ARG . 24.3 m95 -68.54 -36.91 79.48 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-N 114.054 -1.43 . . . . 0.0 110.793 -176.154 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 7.8 t70 -74.92 -36.2 62.17 Favored 'General case' 0 N--CA 1.444 -0.743 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.587 177.203 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . 0.455 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -70.92 -35.52 72.29 Favored 'General case' 0 N--CA 1.448 -0.533 0 C-N-CA 120.736 -0.386 . . . . 0.0 110.846 178.937 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . 0.556 HG13 ' O ' ' A' ' 30' ' ' ILE . 75.8 mt -66.96 -46.07 85.75 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.222 0 CA-C-O 120.987 0.423 . . . . 0.0 110.002 174.662 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -57.61 -38.22 74.57 Favored 'General case' 0 CA--C 1.515 -0.373 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.297 176.92 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . 0.549 ' HA2' ' CA ' ' A' ' 41' ' ' GLY . . . -77.96 -1.64 79.69 Favored Glycine 0 N--CA 1.449 -0.436 0 CA-C-N 115.421 -0.809 . . . . 0.0 112.028 179.341 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 38.5 t -106.61 -57.09 2.1 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 115.825 -0.187 . . . . 0.0 111.361 -177.319 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . 0.824 ' HG3' ' SG ' ' A' ' 101' ' ' CYS . 9.9 mt-10 -88.09 -30.83 19.58 Favored 'General case' 0 CA--C 1.514 -0.422 0 C-N-CA 120.949 -0.301 . . . . 0.0 111.101 -175.207 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -96.68 -7.44 34.07 Favored 'General case' 0 N--CA 1.449 -0.488 0 C-N-CA 120.765 -0.374 . . . . 0.0 111.527 -179.079 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 82.09 2.6 90.61 Favored Glycine 0 CA--C 1.505 -0.575 0 N-CA-C 110.0 -1.24 . . . . 0.0 110.0 -177.962 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . 0.549 ' CA ' ' HA2' ' A' ' 36' ' ' GLY . . . 89.76 54.62 2.17 Favored Glycine 0 N--CA 1.433 -1.511 0 CA-C-N 114.208 -0.996 . . . . 0.0 111.807 -178.043 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 53.0 t30 -147.82 124.57 11.18 Favored 'General case' 0 N--CA 1.443 -0.793 0 N-CA-C 109.147 -0.686 . . . . 0.0 109.147 -178.983 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' TRP . . . . . 0.78 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 20.5 m95 -99.44 1.61 44.32 Favored 'General case' 0 C--N 1.301 -1.527 0 CA-C-N 115.132 -0.94 . . . . 0.0 110.004 -174.467 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -111.59 5.48 19.42 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.088 -0.96 . . . . 0.0 111.102 177.188 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 13.0 tt -75.26 143.32 13.42 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.769 0 CA-C-O 120.946 0.403 . . . . 0.0 110.196 -178.927 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 40.7 t-20 -156.46 96.62 1.68 Allowed 'General case' 0 C--N 1.311 -1.089 0 CA-C-O 121.154 0.502 . . . . 0.0 109.826 179.399 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 20.5 p -76.72 -22.0 54.5 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 115.782 -0.645 . . . . 0.0 111.262 -177.154 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 98.33 21.73 16.62 Favored Glycine 0 N--CA 1.442 -0.902 0 CA-C-N 115.549 -0.751 . . . . 0.0 111.272 -179.016 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 66.3 t30 -91.16 11.89 21.8 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 121.59 0.71 . . . . 0.0 110.934 -177.358 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 84.58 -14.41 46.92 Favored Glycine 0 N--CA 1.453 -0.224 0 N-CA-C 111.234 -0.746 . . . . 0.0 111.234 -178.281 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' TYR . . . . . 0.628 ' CE1' ' HB2' ' A' ' 58' ' ' ASP . 0.5 OUTLIER -98.07 142.4 29.81 Favored 'General case' 0 N--CA 1.445 -0.693 0 N-CA-C 108.174 -1.047 . . . . 0.0 108.174 173.226 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' TYR . . . . . 0.821 ' CE1' ' HB2' ' A' ' 59' ' ' GLN . 4.7 m-85 -108.56 170.28 8.12 Favored 'General case' 0 C--N 1.311 -1.097 0 CA-C-N 116.019 -0.537 . . . . 0.0 111.456 -174.323 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -58.89 172.56 4.07 Favored Glycine 0 N--CA 1.452 -0.286 0 N-CA-C 115.123 0.809 . . . . 0.0 115.123 -170.202 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.764 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 87.01 -111.73 3.7 Favored Glycine 0 N--CA 1.443 -0.865 0 C-N-CA 120.962 -0.637 . . . . 0.0 111.577 -179.607 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.508 HG11 ' CE3' ' A' ' 31' ' ' TRP . 6.2 t -84.28 6.43 2.02 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.74 0 CA-C-O 121.736 0.779 . . . . 0.0 109.778 179.959 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' GLN . . . . . 0.715 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 8.4 tp-100 53.54 51.91 14.31 Favored 'General case' 0 C--O 1.236 0.366 0 CA-C-N 114.427 -1.26 . . . . 0.0 112.872 164.816 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 6.9 p90 -120.15 167.94 11.72 Favored 'General case' 0 N--CA 1.443 -0.801 0 C-N-CA 119.555 -0.858 . . . . 0.0 111.897 174.245 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.628 ' HB2' ' CE1' ' A' ' 51' ' ' TYR . 0.6 OUTLIER -71.09 141.81 50.82 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 114.242 -1.345 . . . . 0.0 113.062 -165.636 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.821 ' HB2' ' CE1' ' A' ' 52' ' ' TYR . 0.0 OUTLIER -56.2 -38.12 70.56 Favored 'General case' 0 N--CA 1.446 -0.628 0 CA-C-N 113.389 -1.732 . . . . 0.0 111.522 178.074 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -63.89 -48.93 71.5 Favored Glycine 0 N--CA 1.441 -1.006 0 CA-C-N 115.938 -0.573 . . . . 0.0 112.019 178.102 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 68.8 m -61.47 -42.21 98.43 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 121.279 0.561 . . . . 0.0 110.4 175.076 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' TRP . . . . . 0.455 ' CZ3' ' HA ' ' A' ' 82' ' ' GLN . 43.4 t-105 -56.13 -49.83 72.81 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.055 -0.975 . . . . 0.0 109.981 175.635 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . 0.631 ' HG3' HD11 ' A' ' 68' ' ' LEU . 29.3 tt0 -66.8 -39.36 87.71 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 115.195 -0.912 . . . . 0.0 110.756 -178.663 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -62.25 -39.5 93.07 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.553 -0.749 . . . . 0.0 110.92 -176.922 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . 0.586 ' OD1' ' HB ' ' A' ' 89' ' ' THR . 10.7 m120 -75.59 -21.14 58.08 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.198 177.014 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 101.7 39.36 2.97 Favored Glycine 0 N--CA 1.449 -0.493 0 C-N-CA 120.957 -0.64 . . . . 0.0 112.28 178.317 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.655 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -79.25 -16.66 77.99 Favored Glycine 0 N--CA 1.44 -1.048 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.073 -173.915 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.631 HD11 ' HG3' ' A' ' 63' ' ' GLU . 26.4 mt -63.55 -23.76 67.52 Favored 'General case' 0 N--CA 1.442 -0.828 0 CA-C-N 115.502 -0.349 . . . . 0.0 111.566 -172.932 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . 0.57 ' HG3' ' N ' ' A' ' 70' ' ' TYR . 0.0 OUTLIER -70.77 -32.68 69.89 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 121.186 0.517 . . . . 0.0 110.068 176.165 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' TYR . . . . . 0.692 ' HB3' ' CG ' ' A' ' 81' ' ' GLU . 86.9 m-85 -76.13 -33.17 59.43 Favored 'General case' 0 CA--C 1.503 -0.852 0 N-CA-C 107.574 -1.269 . . . . 0.0 107.574 -179.934 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.754 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 163.26 125.48 0.01 OUTLIER Pre-proline 0 C--N 1.321 -0.654 0 CA-C-N 111.903 -2.408 . . . . 0.0 106.688 179.293 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' PRO . . . . . 0.606 ' HA ' ' HA ' ' A' ' 68' ' ' LEU . 17.3 Cg_exo -55.16 -4.0 0.37 Allowed 'Trans proline' 0 C--N 1.331 -0.342 0 C-N-CA 122.85 2.366 . . . . 0.0 113.633 -179.799 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' ARG . . . . . 0.401 ' HB2' ' CD2' ' A' ' 52' ' ' TYR . 14.8 ptm180 -145.83 136.94 24.7 Favored 'General case' 0 C--N 1.317 -0.836 0 CA-C-O 121.269 0.557 . . . . 0.0 109.657 176.6 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . 0.499 ' HB3' ' HB2' ' A' ' 52' ' ' TYR . . . -63.43 -25.49 68.3 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 115.455 -0.793 . . . . 0.0 111.914 -177.467 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . 0.484 ' OD1' ' HD2' ' A' ' 52' ' ' TYR . 26.9 p-10 -88.16 10.0 20.88 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-O 121.292 0.568 . . . . 0.0 110.847 -177.714 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 68.7 tp -113.0 -34.43 5.74 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.46 -0.791 . . . . 0.0 109.048 168.121 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . 0.754 ' HB2' ' HB3' ' A' ' 71' ' ' ALA . . . -78.31 153.43 31.75 Favored 'General case' 0 N--CA 1.443 -0.799 0 CA-C-N 115.357 -0.838 . . . . 0.0 109.851 177.687 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 33.5 p -96.54 -173.98 2.91 Favored 'General case' 0 C--N 1.317 -0.84 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.35 -176.951 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . 0.78 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 49.1 mtt85 -50.63 -52.56 38.43 Favored 'General case' 0 CA--C 1.513 -0.46 0 O-C-N 123.519 0.512 . . . . 0.0 111.549 -178.06 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 80' ' ' GLU . . . . . 0.563 ' HG3' ' OE2' ' A' ' 81' ' ' GLU . 9.3 pt-20 -59.28 -42.96 92.5 Favored 'General case' 0 C--N 1.318 -0.786 0 CA-C-N 116.026 -0.534 . . . . 0.0 111.962 -176.627 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 81' ' ' GLU . . . . . 0.692 ' CG ' ' HB3' ' A' ' 70' ' ' TYR . 4.9 mp0 -63.68 -51.99 62.64 Favored 'General case' 0 N--CA 1.454 -0.229 0 N-CA-C 112.094 0.405 . . . . 0.0 112.094 173.987 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 82' ' ' GLN . . . . . 0.46 ' NE2' ' HE3' ' A' ' 43' ' ' TRP . 51.4 mt-30 -59.16 -43.35 92.07 Favored 'General case' 0 CA--C 1.509 -0.611 0 CA-C-O 121.067 0.461 . . . . 0.0 110.459 -176.303 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.668 ' O ' ' HG2' ' A' ' 87' ' ' GLU . 34.3 mt -59.53 -41.88 86.23 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.793 0 CA-C-N 115.157 -0.928 . . . . 0.0 110.006 -178.886 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . 0.615 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -64.52 -42.8 95.55 Favored 'General case' 0 C--O 1.236 0.394 0 CA-C-O 121.705 0.764 . . . . 0.0 111.043 -177.793 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.431 HG22 ' HA2' ' A' ' 67' ' ' GLY . 48.3 t -65.53 -49.12 80.01 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 CA-C-N 115.539 -0.755 . . . . 0.0 110.906 178.188 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . 0.405 ' HB1' ' CH2' ' A' ' 31' ' ' TRP . . . -58.48 -30.47 67.01 Favored 'General case' 0 N--CA 1.452 -0.362 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.534 173.965 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 87' ' ' GLU . . . . . 0.668 ' HG2' ' O ' ' A' ' 83' ' ' ILE . 26.4 mm-40 -58.99 -44.06 91.56 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.45 -178.749 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.569 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 98.1 t -64.18 -50.68 75.71 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 C-N-CA 120.555 -0.458 . . . . 0.0 110.622 -179.799 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . 0.586 ' HB ' ' OD1' ' A' ' 65' ' ' ASN . 12.5 t -73.59 -35.63 65.44 Favored 'General case' 0 C--N 1.318 -0.793 0 C-N-CA 120.796 -0.362 . . . . 0.0 111.66 -174.612 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . 0.641 ' HG3' ' N ' ' A' ' 91' ' ' LEU . 10.9 ptt85 -60.77 -41.6 95.82 Favored 'General case' 0 N--CA 1.471 0.597 0 CA-C-N 117.919 0.327 . . . . 0.0 110.783 -179.194 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . 0.641 ' N ' ' HG3' ' A' ' 90' ' ' ARG . 4.5 pp -69.8 -23.83 63.39 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.845 -0.616 . . . . 0.0 111.419 -172.43 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . 0.546 ' NE ' ' HA ' ' A' ' 89' ' ' THR . 1.9 mtm180 -81.22 -47.96 12.71 Favored 'General case' 0 N--CA 1.447 -0.606 0 CA-C-O 121.576 0.703 . . . . 0.0 109.468 -178.948 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 93' ' ' GLN . . . . . 0.465 ' OE1' ' HB2' ' A' ' 97' ' ' ALA . 17.6 pt20 -95.94 -27.14 15.3 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 114.731 -1.122 . . . . 0.0 112.872 -167.633 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 91.76 39.86 5.43 Favored Glycine 0 CA--C 1.504 -0.615 0 C-N-CA 120.344 -0.931 . . . . 0.0 111.985 170.441 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 95' ' ' TRP . . . . . 0.447 ' HB3' ' HB1' ' A' ' 102' ' ' ALA . 6.9 m95 63.74 17.27 10.35 Favored 'General case' 0 C--O 1.22 -0.474 0 N-CA-C 109.255 -0.646 . . . . 0.0 109.255 -179.231 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -70.47 -30.29 69.12 Favored Glycine 0 N--CA 1.451 -0.344 0 CA-C-N 115.504 -0.771 . . . . 0.0 112.598 177.989 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . 0.465 ' HB2' ' OE1' ' A' ' 93' ' ' GLN . . . -69.99 -30.11 67.36 Favored 'General case' 0 CA--C 1.514 -0.439 0 CA-C-O 120.924 0.392 . . . . 0.0 110.21 177.488 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 98' ' ' TRP . . . . . 0.509 ' HB2' ' HB2' ' A' ' 102' ' ' ALA . 25.6 m-90 -98.47 104.55 24.45 Favored Pre-proline 0 C--N 1.323 -0.571 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 177.353 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_exo -70.99 -94.2 0.01 OUTLIER 'Trans proline' 0 CA--C 1.534 0.505 0 C-N-CA 122.889 2.393 . . . . 0.0 114.734 -172.22 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 60.6 t -70.99 -31.95 46.84 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 CA-C-O 121.822 0.82 . . . . 0.0 110.19 -173.98 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 101' ' ' CYS . . . . . 0.824 ' SG ' ' HG3' ' A' ' 38' ' ' GLU . 75.6 m -78.26 -26.1 47.05 Favored 'General case' 0 C--N 1.315 -0.932 0 CA-C-N 114.772 -1.104 . . . . 0.0 112.27 -168.832 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 102' ' ' ALA . . . . . 0.509 ' HB2' ' HB2' ' A' ' 98' ' ' TRP . . . -69.93 -46.19 65.89 Favored 'General case' 0 C--N 1.326 -0.444 0 C-N-CA 120.549 -0.461 . . . . 0.0 110.23 176.249 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -65.33 -35.92 82.46 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.699 -179.358 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 104' ' ' ARG . . . . . 0.471 ' HG2' ' HA ' ' A' ' 101' ' ' CYS . 0.0 OUTLIER -73.41 -21.45 60.48 Favored 'General case' 0 N--CA 1.444 -0.725 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.425 179.785 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 105' ' ' ALA . . . . . 0.466 ' HB1' ' HA ' ' A' ' 30' ' ' ILE . . . -96.08 -22.82 17.1 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.821 -0.627 . . . . 0.0 111.581 -178.157 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 119.02 63.66 0.29 Allowed Glycine 0 N--CA 1.45 -0.384 0 C-N-CA 121.236 -0.507 . . . . 0.0 112.236 -176.86 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -64.09 145.15 56.42 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.776 0.322 . . . . 0.0 110.782 179.36 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 51.8 mtp180 . . . . . 0 C--O 1.249 1.06 0 CA-C-O 118.395 -0.812 . . . . 0.0 110.332 -173.293 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 5.3 m-20 . . . . . 0 N--CA 1.482 1.143 0 CA-C-O 121.198 0.523 . . . . 0.0 110.607 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 61.9 t -75.99 -43.46 38.78 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 CA-C-N 115.616 -0.72 . . . . 0.0 109.472 177.558 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 48.6 t -77.77 95.65 1.63 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.798 0 CA-C-N 115.701 -0.681 . . . . 0.0 109.481 173.74 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 11.5 t -75.56 144.68 11.71 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.044 -177.894 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . 0.414 ' HA ' ' HD3' ' A' ' 6' ' ' PRO . 11.3 p -103.92 107.75 57.78 Favored Pre-proline 0 C--N 1.314 -0.955 0 CA-C-N 115.874 -0.603 . . . . 0.0 111.045 -177.571 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.414 ' HD3' ' HA ' ' A' ' 5' ' ' THR . 1.5 Cg_endo -86.1 170.13 8.48 Favored 'Trans proline' 0 N--CA 1.448 -1.169 0 C-N-CA 123.502 2.801 . . . . 0.0 111.263 177.329 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -82.7 81.96 8.25 Favored 'General case' 0 C--N 1.307 -1.245 0 CA-C-N 114.892 -1.049 . . . . 0.0 110.985 -179.292 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 31.8 m170 -74.87 -18.45 60.43 Favored 'General case' 0 C--N 1.316 -0.883 0 N-CA-C 107.666 -1.235 . . . . 0.0 107.666 169.821 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 12.7 pt-20 -115.11 132.15 56.7 Favored 'General case' 0 N--CA 1.44 -0.934 0 CA-C-N 114.795 -1.093 . . . . 0.0 109.609 175.607 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -147.38 73.51 1.29 Allowed 'General case' 0 C--N 1.321 -0.65 0 CA-C-O 121.523 0.678 . . . . 0.0 110.412 -179.152 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 58.0 t -75.21 -56.39 8.91 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.711 0 CA-C-N 114.938 -1.028 . . . . 0.0 110.439 -179.297 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 72.1 t 21.52 84.33 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.451 -0.414 0 C-N-CA 125.598 1.559 . . . . 0.0 113.162 177.272 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . 0.42 ' HG3' ' O ' ' A' ' 13' ' ' ARG . 6.6 ptp180 -70.29 112.44 6.62 Favored 'General case' 0 C--N 1.306 -1.308 0 CA-C-N 114.098 -1.41 . . . . 0.0 110.106 -179.646 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.481 HG22 ' N ' ' A' ' 15' ' ' GLY . 7.4 p -72.48 163.04 4.09 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.42 0 CA-C-N 114.021 -1.445 . . . . 0.0 110.392 178.49 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . 0.485 ' O ' ' HG3' ' A' ' 17' ' ' LYS . . . -90.52 -75.62 1.3 Allowed Glycine 0 C--N 1.299 -1.516 0 CA-C-N 113.654 -1.612 . . . . 0.0 111.03 -176.724 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.479 ' C ' ' HD3' ' A' ' 18' ' ' PRO . 93.6 m 63.98 -21.99 0.07 Allowed 'General case' 0 N--CA 1.437 -1.115 0 N-CA-C 114.653 1.353 . . . . 0.0 114.653 176.708 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . 0.782 ' HD2' ' O ' ' A' ' 17' ' ' LYS . 0.0 OUTLIER -114.05 74.94 2.84 Favored Pre-proline 0 C--N 1.319 -0.742 0 N-CA-C 112.814 0.672 . . . . 0.0 112.814 178.487 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . 0.479 ' HD3' ' C ' ' A' ' 16' ' ' THR . 31.5 Cg_exo -66.54 115.06 3.33 Favored 'Trans proline' 0 CA--C 1.509 -0.75 0 C-N-CA 123.217 2.612 . . . . 0.0 112.427 178.045 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -112.45 -53.19 0.5 Allowed Glycine 0 C--N 1.299 -1.523 0 CA-C-N 113.448 -1.705 . . . . 0.0 111.342 179.786 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 13.7 m -69.56 -42.8 74.05 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.494 -0.353 . . . . 0.0 110.9 178.368 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 34.8 mt-10 47.01 87.94 0.02 OUTLIER 'General case' 0 N--CA 1.453 -0.279 0 CA-C-O 121.769 0.795 . . . . 0.0 112.431 -176.088 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.716 HG21 ' HB ' ' A' ' 78' ' ' THR . 37.8 t -92.17 124.14 60.61 Favored Pre-proline 0 C--N 1.312 -1.054 0 CA-C-N 114.926 -1.034 . . . . 0.0 109.785 -178.866 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.457 ' HA ' ' HD3' ' A' ' 24' ' ' PRO . 45.1 Cg_exo -57.54 127.11 24.11 Favored 'Trans proline' 0 N--CA 1.461 -0.412 0 C-N-CA 122.867 2.378 . . . . 0.0 112.786 -177.923 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . 0.457 ' HD3' ' HA ' ' A' ' 23' ' ' PRO . 23.0 Cg_exo -68.11 142.93 57.7 Favored 'Trans proline' 0 N--CA 1.435 -1.944 0 C-N-CA 123.447 2.764 . . . . 0.0 113.205 177.535 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 44.1 t -102.31 158.22 4.55 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.141 0 CA-C-N 114.478 -1.237 . . . . 0.0 108.18 173.331 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 46.2 mm -54.56 -38.93 43.71 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.695 0 CA-C-O 121.001 0.429 . . . . 0.0 111.683 -173.284 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 15.0 m-20 -103.87 3.99 34.39 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-O 121.865 0.84 . . . . 0.0 109.532 -179.172 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . 0.463 ' HA2' ' HB2' ' A' ' 31' ' ' TRP . . . -70.23 -6.32 56.98 Favored Glycine 0 N--CA 1.44 -1.057 0 CA-C-N 114.481 -1.236 . . . . 0.0 110.38 176.526 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 9.6 m -76.96 -39.4 50.71 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-O 121.659 0.742 . . . . 0.0 109.087 174.661 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.496 ' O ' HG13 ' A' ' 34' ' ' ILE . 1.0 OUTLIER -69.65 -38.1 75.64 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.576 0 N-CA-C 107.492 -1.299 . . . . 0.0 107.492 177.366 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' TRP . . . . . 0.513 ' CD1' HG23 ' A' ' 83' ' ' ILE . 43.2 m95 -71.41 -35.91 71.16 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 114.262 -1.336 . . . . 0.0 110.487 -177.857 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.533 ' HB2' HH21 ' A' ' 79' ' ' ARG . 15.5 t70 -74.28 -34.56 63.6 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.385 178.328 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -69.89 -34.47 73.59 Favored 'General case' 0 N--CA 1.446 -0.629 0 C-N-CA 120.756 -0.377 . . . . 0.0 110.12 177.705 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . 0.566 ' HA ' ' HB3' ' A' ' 101' ' ' CYS . 61.9 mt -67.33 -47.44 81.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.312 174.399 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . 0.445 ' HA ' ' O ' ' A' ' 54' ' ' GLY . . . -58.76 -39.14 80.12 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.501 177.554 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -76.13 -8.79 85.42 Favored Glycine 0 N--CA 1.451 -0.337 0 CA-C-N 115.559 -0.746 . . . . 0.0 112.081 179.603 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 1.7 t -97.16 -57.96 2.13 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-O 120.678 0.275 . . . . 0.0 111.417 -178.6 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . 0.545 ' HB2' ' SG ' ' A' ' 101' ' ' CYS . 8.0 tp10 -87.97 -33.02 18.57 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-O 121.207 0.527 . . . . 0.0 109.999 -171.315 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . 0.412 ' HB3' ' O ' ' A' ' 35' ' ' ALA . . . -95.71 -13.05 24.52 Favored 'General case' 0 N--CA 1.448 -0.538 0 CA-C-N 115.631 -0.713 . . . . 0.0 111.197 -178.749 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 82.52 1.34 90.47 Favored Glycine 0 N--CA 1.448 -0.505 0 N-CA-C 109.983 -1.247 . . . . 0.0 109.983 -177.04 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 93.65 55.63 1.52 Allowed Glycine 0 N--CA 1.436 -1.327 0 CA-C-N 114.372 -0.914 . . . . 0.0 111.61 -176.543 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . 0.556 ' HB3' ' HB ' ' A' ' 45' ' ' ILE . 0.3 OUTLIER -142.93 94.6 2.65 Favored 'General case' 0 N--CA 1.447 -0.606 0 N-CA-C 108.704 -0.85 . . . . 0.0 108.704 -177.689 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' TRP . . . . . 0.754 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 38.3 m95 -76.65 -10.71 59.58 Favored 'General case' 0 C--N 1.317 -0.844 0 CA-C-O 121.384 0.611 . . . . 0.0 110.423 -175.385 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . 0.426 ' HA ' ' HB2' ' A' ' 75' ' ' ASP . . . -107.73 15.38 24.66 Favored 'General case' 0 C--N 1.318 -0.795 0 CA-C-N 114.981 -1.009 . . . . 0.0 111.731 -178.624 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.746 HG22 ' HA2' ' A' ' 53' ' ' GLY . 9.9 tt -83.21 142.42 13.56 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.619 0 CA-C-O 121.432 0.634 . . . . 0.0 111.344 -175.639 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . 0.41 HD22 ' HA ' ' A' ' 46' ' ' ASN . 9.7 m120 -133.53 88.19 2.46 Favored 'General case' 0 C--N 1.316 -0.873 0 N-CA-C 108.539 -0.911 . . . . 0.0 108.539 176.663 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 1.2 p -69.31 -24.09 63.89 Favored 'General case' 0 C--N 1.315 -0.934 0 CA-C-N 115.769 -0.651 . . . . 0.0 110.603 179.708 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 94.57 19.0 33.51 Favored Glycine 0 N--CA 1.444 -0.795 0 N-CA-C 111.272 -0.731 . . . . 0.0 111.272 176.412 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 30.7 p-10 -94.7 11.62 30.64 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.141 0.496 . . . . 0.0 111.134 -175.301 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . 0.452 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 89.9 -11.59 70.07 Favored Glycine 0 N--CA 1.445 -0.724 0 N-CA-C 110.823 -0.911 . . . . 0.0 110.823 -178.243 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' TYR . . . . . 0.604 ' CE1' ' HB3' ' A' ' 58' ' ' ASP . 0.8 OUTLIER -109.94 151.64 26.85 Favored 'General case' 0 CA--C 1.512 -0.488 0 N-CA-C 107.827 -1.175 . . . . 0.0 107.827 178.722 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' TYR . . . . . 0.633 ' CE1' ' HB2' ' A' ' 59' ' ' GLN . 24.2 m-85 -115.36 170.4 8.43 Favored 'General case' 0 C--N 1.313 -0.995 0 C-N-CA 120.647 -0.421 . . . . 0.0 111.316 -170.294 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.746 ' HA2' HG22 ' A' ' 45' ' ' ILE . . . -56.92 166.72 4.72 Favored Glycine 0 N--CA 1.451 -0.354 0 N-CA-C 114.818 0.687 . . . . 0.0 114.818 -169.744 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.678 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 88.19 -103.78 2.97 Favored Glycine 0 N--CA 1.444 -0.791 0 C-N-CA 121.253 -0.499 . . . . 0.0 112.237 177.305 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.516 HG12 ' HE1' ' A' ' 98' ' ' TRP . 2.5 t -83.27 -2.82 6.95 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 CA-C-O 121.445 0.64 . . . . 0.0 109.785 -177.873 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' GLN . . . . . 0.613 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 2.0 mm-40 55.91 42.33 28.94 Favored 'General case' 0 N--CA 1.462 0.139 0 CA-C-N 114.747 -1.115 . . . . 0.0 113.102 169.727 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . 0.487 ' CD1' ' HB ' ' A' ' 55' ' ' VAL . 1.5 p90 -114.88 165.63 12.64 Favored 'General case' 0 C--N 1.322 -0.616 0 C-N-CA 119.912 -0.715 . . . . 0.0 111.041 175.253 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.604 ' HB3' ' CE1' ' A' ' 51' ' ' TYR . 8.1 p-10 -76.02 155.56 34.82 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 122.075 0.941 . . . . 0.0 112.619 -164.238 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.633 ' HB2' ' CE1' ' A' ' 52' ' ' TYR . 3.6 tp-100 -61.42 -32.11 72.06 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 113.414 -1.721 . . . . 0.0 111.14 179.767 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -65.94 -49.5 58.26 Favored Glycine 0 C--N 1.316 -0.553 0 CA-C-N 115.48 -0.782 . . . . 0.0 111.786 -179.862 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 90.9 m -66.67 -40.75 88.75 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-O 120.787 0.327 . . . . 0.0 110.996 175.979 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' TRP . . . . . 0.473 ' CH2' ' HA ' ' A' ' 74' ' ' ALA . 46.2 t-105 -56.38 -49.53 74.18 Favored 'General case' 0 N--CA 1.45 -0.462 0 CA-C-O 121.656 0.741 . . . . 0.0 109.293 176.137 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . 0.431 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 33.6 tt0 -68.11 -32.28 72.47 Favored 'General case' 0 N--CA 1.444 -0.763 0 CA-C-N 115.022 -0.99 . . . . 0.0 110.855 179.857 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -64.26 -39.03 93.11 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.891 -179.588 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . 0.578 ' HB2' HG13 ' A' ' 85' ' ' VAL . 5.5 m120 -78.76 -14.05 59.48 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 121.597 0.713 . . . . 0.0 109.485 175.134 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . 0.582 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 82.68 49.15 5.25 Favored Glycine 0 N--CA 1.445 -0.702 0 CA-C-N 115.061 -0.972 . . . . 0.0 111.608 -179.924 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.629 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -78.67 -15.39 80.86 Favored Glycine 0 N--CA 1.442 -0.96 0 C-N-CA 121.273 -0.489 . . . . 0.0 112.432 -174.765 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.837 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 6.8 mp -59.21 -27.27 65.57 Favored 'General case' 0 C--N 1.323 -0.575 0 N-CA-C 111.872 0.323 . . . . 0.0 111.872 -175.568 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . 0.582 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 9.1 ptp180 -65.33 -30.12 70.93 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 121.353 0.597 . . . . 0.0 110.046 177.182 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' TYR . . . . . 0.999 ' HB3' ' HB3' ' A' ' 81' ' ' GLU . 75.0 m-85 -81.49 -34.3 31.39 Favored 'General case' 0 N--CA 1.441 -0.905 0 N-CA-C 107.638 -1.245 . . . . 0.0 107.638 176.405 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.696 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 162.67 128.92 0.01 OUTLIER Pre-proline 0 CA--C 1.513 -0.465 0 CA-C-N 112.653 -2.067 . . . . 0.0 107.009 -179.568 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' PRO . . . . . 0.837 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 20.4 Cg_exo -57.35 -4.93 1.3 Allowed 'Trans proline' 0 C--N 1.333 -0.26 0 C-N-CA 122.77 2.313 . . . . 0.0 113.767 -177.17 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' ARG . . . . . 0.428 ' HE ' ' CG ' ' A' ' 75' ' ' ASP . 10.7 ptm180 -147.86 139.01 23.45 Favored 'General case' 0 C--N 1.317 -0.805 0 N-CA-C 109.367 -0.605 . . . . 0.0 109.367 176.526 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . 0.473 ' HA ' ' CH2' ' A' ' 62' ' ' TRP . . . -55.95 -29.84 60.77 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 114.941 -1.027 . . . . 0.0 112.52 -177.193 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . 0.546 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 4.6 p-10 -83.97 -4.68 58.9 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 120.967 0.413 . . . . 0.0 111.256 -176.037 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 68.1 tp -100.0 -29.74 12.37 Favored 'General case' 0 C--N 1.322 -0.59 0 N-CA-C 108.46 -0.941 . . . . 0.0 108.46 172.549 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . 0.805 ' HB1' ' HB2' ' A' ' 81' ' ' GLU . . . -79.28 159.16 27.36 Favored 'General case' 0 N--CA 1.44 -0.968 0 CA-C-N 114.78 -1.1 . . . . 0.0 109.795 175.113 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . 0.716 ' HB ' HG21 ' A' ' 22' ' ' VAL . 61.9 p -100.35 -175.19 2.85 Favored 'General case' 0 C--N 1.309 -1.188 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.355 -176.974 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . 0.754 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 77.7 mtp180 -50.01 -52.93 30.11 Favored 'General case' 0 C--N 1.329 -0.293 0 O-C-N 123.416 0.447 . . . . 0.0 111.265 178.819 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 80' ' ' GLU . . . . . 0.46 ' HA ' HD12 ' A' ' 83' ' ' ILE . 17.0 pt-20 -60.8 -37.23 81.24 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.873 -0.603 . . . . 0.0 111.434 -174.43 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 81' ' ' GLU . . . . . 0.999 ' HB3' ' HB3' ' A' ' 70' ' ' TYR . 4.2 mm-40 -70.22 -50.32 41.05 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 121.031 0.443 . . . . 0.0 109.959 -179.465 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 82' ' ' GLN . . . . . 0.57 ' HB2' ' HZ3' ' A' ' 43' ' ' TRP . 41.7 mt-30 -60.03 -34.45 73.4 Favored 'General case' 0 CA--C 1.513 -0.465 0 CA-C-N 115.515 -0.766 . . . . 0.0 110.201 -179.319 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.69 ' O ' ' HG2' ' A' ' 87' ' ' GLU . 40.3 mt -60.77 -49.1 85.91 Favored 'Isoleucine or valine' 0 C--O 1.212 -0.883 0 N-CA-C 109.084 -0.71 . . . . 0.0 109.084 175.855 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . 0.587 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -62.1 -44.09 97.4 Favored 'General case' 0 C--O 1.237 0.414 0 CA-C-O 121.277 0.56 . . . . 0.0 111.867 -176.353 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.578 HG13 ' HB2' ' A' ' 65' ' ' ASN . 40.0 t -66.24 -49.32 76.86 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.609 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.862 179.432 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . 0.474 ' HB1' ' CH2' ' A' ' 31' ' ' TRP . . . -59.11 -29.54 67.45 Favored 'General case' 0 N--CA 1.447 -0.592 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.404 174.572 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 87' ' ' GLU . . . . . 0.86 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 15.7 mm-40 -59.46 -44.3 93.0 Favored 'General case' 0 C--O 1.222 -0.386 0 CA-C-N 115.846 -0.616 . . . . 0.0 110.492 -178.599 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.448 ' O ' ' HG3' ' A' ' 92' ' ' ARG . 70.6 t -60.52 -49.3 84.93 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.303 0 C-N-CA 120.288 -0.565 . . . . 0.0 110.091 179.747 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . 0.675 HG22 ' NE2' ' A' ' 93' ' ' GLN . 24.0 m -66.24 -43.8 85.57 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-N 115.683 -0.69 . . . . 0.0 111.437 -177.155 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . 0.657 ' HA ' ' OE1' ' A' ' 93' ' ' GLN . 3.2 ppt_? -60.96 -34.34 74.59 Favored 'General case' 0 N--CA 1.467 0.4 0 N-CA-C 112.073 0.397 . . . . 0.0 112.073 -176.48 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . 0.86 ' HG ' ' O ' ' A' ' 87' ' ' GLU . 46.5 mt -62.87 -33.25 74.88 Favored 'General case' 0 N--CA 1.471 0.587 0 CA-C-O 121.47 0.652 . . . . 0.0 110.152 -177.998 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . 0.483 ' NH2' HG23 ' A' ' 89' ' ' THR . 6.5 mtm180 -81.57 -50.57 9.21 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-N 114.818 -1.083 . . . . 0.0 110.103 -169.85 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 93' ' ' GLN . . . . . 0.675 ' NE2' HG22 ' A' ' 89' ' ' THR . 0.0 OUTLIER -96.13 -23.55 16.7 Favored 'General case' 0 C--N 1.318 -0.785 0 C-N-CA 119.733 -0.787 . . . . 0.0 113.045 -171.682 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 88.48 40.41 6.42 Favored Glycine 0 CA--C 1.508 -0.345 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.156 172.466 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 95' ' ' TRP . . . . . 0.531 ' CZ2' ' HD3' ' A' ' 90' ' ' ARG . 22.1 m95 67.16 9.09 6.68 Favored 'General case' 0 C--O 1.221 -0.423 0 C-N-CA 123.6 0.76 . . . . 0.0 110.033 -179.124 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -71.97 -23.48 77.93 Favored Glycine 0 N--CA 1.451 -0.305 0 CA-C-N 115.891 -0.595 . . . . 0.0 112.444 178.155 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -72.7 -28.1 62.47 Favored 'General case' 0 CA--C 1.516 -0.337 0 CA-C-O 121.046 0.451 . . . . 0.0 109.988 177.641 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 98' ' ' TRP . . . . . 0.516 ' HE1' HG12 ' A' ' 55' ' ' VAL . 28.6 m-90 -101.02 104.16 30.31 Favored Pre-proline 0 N--CA 1.448 -0.567 0 CA-C-N 115.146 -0.934 . . . . 0.0 108.966 176.528 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . 0.404 ' HD3' ' HA ' ' A' ' 98' ' ' TRP . 15.7 Cg_exo -73.95 -88.38 0.0 OUTLIER 'Trans proline' 0 CA--C 1.53 0.32 0 C-N-CA 123.182 2.588 . . . . 0.0 114.993 -171.127 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . 0.427 ' HA ' HH21 ' A' ' 104' ' ' ARG . 80.5 t -69.45 -30.08 44.24 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-O 121.142 0.496 . . . . 0.0 110.693 -172.393 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 101' ' ' CYS . . . . . 0.566 ' HB3' ' HA ' ' A' ' 34' ' ' ILE . 87.1 m -79.79 -37.64 34.84 Favored 'General case' 0 C--N 1.317 -0.812 0 CA-C-N 115.7 -0.682 . . . . 0.0 112.403 -170.102 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 102' ' ' ALA . . . . . 0.442 ' HB1' ' HB3' ' A' ' 95' ' ' TRP . . . -69.62 -40.33 76.66 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.828 0.347 . . . . 0.0 110.912 -178.556 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -61.48 -38.55 87.71 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-O 121.318 0.58 . . . . 0.0 110.588 177.127 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 104' ' ' ARG . . . . . 0.427 HH21 ' HA ' ' A' ' 100' ' ' VAL . 1.4 mpp_? -74.58 -18.45 60.57 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.371 -0.831 . . . . 0.0 111.618 176.77 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -96.49 -22.8 16.89 Favored 'General case' 0 C--N 1.327 -0.399 0 N-CA-C 112.659 0.615 . . . . 0.0 112.659 -173.638 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 106.11 64.21 0.62 Allowed Glycine 0 CA--C 1.52 0.4 0 C-N-CA 120.793 -0.718 . . . . 0.0 112.252 -177.582 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -72.24 149.14 44.83 Favored 'General case' 0 C--N 1.326 -0.436 0 C-N-CA 122.906 0.483 . . . . 0.0 111.28 -174.867 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.245 0.819 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.619 -175.403 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 2.5 p-10 . . . . . 0 N--CA 1.472 0.66 0 N-CA-C 108.924 -0.769 . . . . 0.0 108.924 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 50.1 t -62.78 -35.32 70.31 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 114.981 -1.009 . . . . 0.0 112.644 -173.153 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 91.8 t -62.26 108.52 0.55 Allowed 'Isoleucine or valine' 0 C--O 1.236 0.382 0 CA-C-O 120.92 0.391 . . . . 0.0 111.457 -179.758 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 12.7 t -88.0 147.7 5.08 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 N-CA-C 109.596 -0.52 . . . . 0.0 109.596 177.193 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . 0.404 ' HA ' ' HD3' ' A' ' 6' ' ' PRO . 23.2 p -92.88 117.52 67.58 Favored Pre-proline 0 C--N 1.315 -0.907 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.766 -179.647 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.404 ' HD3' ' HA ' ' A' ' 5' ' ' THR . 5.0 Cg_exo -80.89 161.07 21.2 Favored 'Trans proline' 0 N--CA 1.448 -1.188 0 C-N-CA 122.902 2.401 . . . . 0.0 111.434 177.797 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -147.38 87.63 1.67 Allowed 'General case' 0 C--N 1.307 -1.276 0 CA-C-N 114.786 -1.097 . . . . 0.0 112.037 -175.596 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 63.5 t60 -104.29 -13.08 16.28 Favored 'General case' 0 C--N 1.312 -1.044 0 N-CA-C 107.132 -1.433 . . . . 0.0 107.132 165.198 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . 0.403 ' HB2' HG23 ' A' ' 11' ' ' VAL . 9.3 pt-20 -84.97 158.01 20.63 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 113.899 -1.5 . . . . 0.0 111.396 -177.031 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -138.01 69.58 1.39 Allowed 'General case' 0 C--N 1.317 -0.838 0 CA-C-N 114.998 -1.001 . . . . 0.0 108.874 172.042 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.403 HG23 ' HB2' ' A' ' 9' ' ' GLU . 38.7 t -99.9 -73.26 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.442 -0.844 0 CA-C-N 114.752 -1.113 . . . . 0.0 110.571 -176.219 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.43 HG12 ' O ' ' A' ' 12' ' ' VAL . 77.9 t 21.34 75.32 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.447 -0.618 0 O-C-N 125.19 1.556 . . . . 0.0 111.993 -174.188 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . 0.405 HH11 ' HD3' ' A' ' 13' ' ' ARG . 0.0 OUTLIER -88.9 95.94 10.51 Favored 'General case' 0 C--N 1.303 -1.455 0 CA-C-N 113.938 -1.483 . . . . 0.0 111.227 -173.801 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 4.6 t -128.44 161.61 36.75 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.593 0 CA-C-N 113.298 -1.774 . . . . 0.0 108.748 -179.627 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 94.88 63.15 1.0 Allowed Glycine 0 C--N 1.309 -0.966 0 N-CA-C 111.113 -0.795 . . . . 0.0 111.113 -177.93 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 12.8 m -76.52 -22.94 53.76 Favored 'General case' 0 C--N 1.316 -0.886 0 CA-C-N 114.437 -0.881 . . . . 0.0 111.317 -175.069 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . 0.464 ' HD2' ' N ' ' A' ' 17' ' ' LYS . 0.0 OUTLIER -133.09 114.57 13.84 Favored Pre-proline 0 C--N 1.311 -1.066 0 CA-C-N 114.922 -1.036 . . . . 0.0 110.138 -178.841 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . 0.426 ' HD3' ' HA ' ' A' ' 17' ' ' LYS . 8.3 Cg_exo -73.84 173.58 13.75 Favored 'Trans proline' 0 N--CA 1.461 -0.431 0 C-N-CA 123.312 2.675 . . . . 0.0 112.938 179.97 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 135.77 -38.67 1.76 Allowed Glycine 0 N--CA 1.44 -1.053 0 CA-C-N 114.063 -1.426 . . . . 0.0 111.58 179.974 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 21.4 m -60.23 -34.58 73.87 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-N 114.69 -0.755 . . . . 0.0 112.43 -177.846 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 3.3 pm0 -58.59 120.47 8.93 Favored 'General case' 0 N--CA 1.451 -0.415 0 CA-C-O 122.391 1.091 . . . . 0.0 111.314 -176.981 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 45.6 t -87.88 129.3 50.91 Favored Pre-proline 0 C--N 1.301 -1.512 0 CA-C-N 113.615 -1.63 . . . . 0.0 110.301 178.911 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_exo -53.89 142.75 62.91 Favored 'Trans proline' 0 C--N 1.344 0.338 0 C-N-CA 122.964 2.443 . . . . 0.0 111.639 176.933 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 10.4 Cg_endo -54.69 138.89 76.75 Favored 'Trans proline' 0 N--CA 1.459 -0.525 0 C-N-CA 123.427 2.751 . . . . 0.0 112.777 -175.069 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.989 HG11 HD13 ' A' ' 83' ' ' ILE . 14.8 p -107.07 128.43 61.96 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.087 0 CA-C-N 114.603 -1.181 . . . . 0.0 111.239 -178.22 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 45.3 mm -82.53 -25.47 8.7 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-N 115.611 -0.722 . . . . 0.0 110.423 177.067 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.463 ' O ' HG12 ' A' ' 30' ' ' ILE . 18.4 m-20 -108.52 15.93 23.43 Favored 'General case' 0 CA--C 1.511 -0.53 0 CA-C-N 115.442 -0.799 . . . . 0.0 109.784 -172.653 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -69.91 -8.36 60.88 Favored Glycine 0 CA--C 1.5 -0.874 0 N-CA-C 110.343 -1.103 . . . . 0.0 110.343 177.921 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 16.4 m -76.55 -35.04 58.47 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 114.591 -0.805 . . . . 0.0 109.197 175.857 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.622 ' HA ' ' HB1' ' A' ' 105' ' ' ALA . 1.1 mm -71.46 -36.95 62.62 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.645 0 N-CA-C 107.245 -1.391 . . . . 0.0 107.245 177.105 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' TRP . . . . . 0.572 ' CH2' ' HB1' ' A' ' 86' ' ' ALA . 34.6 m95 -71.15 -36.3 72.0 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 114.089 -1.414 . . . . 0.0 111.012 -177.259 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.784 ' HB2' HH21 ' A' ' 79' ' ' ARG . 17.5 t70 -74.79 -36.7 62.51 Favored 'General case' 0 N--CA 1.445 -0.694 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.477 179.119 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . 0.442 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -70.47 -34.19 72.12 Favored 'General case' 0 N--CA 1.448 -0.537 0 C-N-CA 120.817 -0.353 . . . . 0.0 110.695 178.687 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . 0.547 HG13 ' O ' ' A' ' 30' ' ' ILE . 65.9 mt -64.73 -44.67 96.51 Favored 'Isoleucine or valine' 0 C--O 1.235 0.327 0 CA-C-O 121.286 0.565 . . . . 0.0 109.988 173.914 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . 0.441 ' HA ' ' O ' ' A' ' 54' ' ' GLY . . . -59.59 -35.03 73.51 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.511 -0.768 . . . . 0.0 110.261 176.245 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . 0.51 ' HA2' ' N ' ' A' ' 41' ' ' GLY . . . -78.94 4.37 61.82 Favored Glycine 0 N--CA 1.452 -0.293 0 CA-C-N 115.368 -0.833 . . . . 0.0 112.341 179.643 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 27.0 t -108.15 -53.84 2.58 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 120.576 0.227 . . . . 0.0 111.114 -179.499 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . 0.444 ' HG2' ' SG ' ' A' ' 101' ' ' CYS . 36.7 mm-40 -87.86 -33.1 18.67 Favored 'General case' 0 CA--C 1.515 -0.39 0 CA-C-O 121.093 0.473 . . . . 0.0 110.552 -176.547 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -105.1 -9.71 17.62 Favored 'General case' 0 N--CA 1.447 -0.587 0 CA-C-N 116.044 -0.525 . . . . 0.0 112.124 -175.201 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 75.11 17.51 80.23 Favored Glycine 0 CA--C 1.505 -0.577 0 N-CA-C 109.635 -1.386 . . . . 0.0 109.635 -177.199 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . 0.51 ' N ' ' HA2' ' A' ' 36' ' ' GLY . . . 75.24 61.51 2.99 Favored Glycine 0 N--CA 1.432 -1.598 0 CA-C-N 114.019 -1.091 . . . . 0.0 111.455 -174.953 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . 0.508 HD22 ' HB ' ' A' ' 45' ' ' ILE . 3.7 t30 -145.84 100.16 3.37 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 108.332 -0.988 . . . . 0.0 108.332 -177.251 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' TRP . . . . . 0.81 ' HA ' ' N ' ' A' ' 54' ' ' GLY . 30.2 m95 -84.47 -3.82 58.59 Favored 'General case' 0 C--N 1.317 -0.833 0 CA-C-O 121.605 0.717 . . . . 0.0 110.664 -170.785 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -111.64 15.69 20.93 Favored 'General case' 0 C--N 1.311 -1.091 0 CA-C-N 114.806 -1.088 . . . . 0.0 110.86 178.768 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.818 HG22 ' HA2' ' A' ' 53' ' ' GLY . 10.5 tt -79.38 137.63 21.4 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.733 0 CA-C-O 121.163 0.506 . . . . 0.0 110.508 -177.85 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 46.4 t30 -171.24 103.72 0.21 Allowed 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 115.956 -0.566 . . . . 0.0 110.379 178.948 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 25.3 p -82.63 -11.51 58.33 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 115.767 -0.651 . . . . 0.0 111.09 177.586 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 104.07 21.28 9.64 Favored Glycine 0 N--CA 1.449 -0.483 0 C-N-CA 120.808 -0.711 . . . . 0.0 111.386 -175.348 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 8.6 p30 -82.15 -4.86 57.84 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 115.623 -0.288 . . . . 0.0 111.161 -178.335 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . 0.538 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 96.3 -11.95 66.88 Favored Glycine 0 N--CA 1.448 -0.525 0 C-N-CA 121.305 -0.474 . . . . 0.0 112.039 177.755 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' TYR . . . . . 0.647 ' HA ' ' HA ' ' A' ' 58' ' ' ASP . 0.6 OUTLIER -112.37 151.61 29.59 Favored 'General case' 0 CA--C 1.514 -0.412 0 N-CA-C 107.834 -1.173 . . . . 0.0 107.834 176.349 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' TYR . . . . . 0.696 ' O ' ' HA ' ' A' ' 56' ' ' GLN . 42.9 m-85 -116.61 170.39 8.62 Favored 'General case' 0 C--N 1.313 -0.984 0 C-N-CA 120.4 -0.52 . . . . 0.0 112.203 -166.242 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.818 ' HA2' HG22 ' A' ' 45' ' ' ILE . . . -60.12 172.18 5.83 Favored Glycine 0 N--CA 1.446 -0.658 0 N-CA-C 115.548 0.979 . . . . 0.0 115.548 -167.653 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.81 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 87.53 -109.35 3.46 Favored Glycine 0 N--CA 1.437 -1.234 0 CA-C-N 114.486 -0.857 . . . . 0.0 111.636 177.557 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.518 HG11 ' CE3' ' A' ' 31' ' ' TRP . 0.5 OUTLIER -84.16 2.21 3.93 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.594 0 CA-C-O 121.351 0.596 . . . . 0.0 110.868 178.793 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' GLN . . . . . 0.772 ' HA ' HE21 ' A' ' 56' ' ' GLN . 0.0 OUTLIER 59.5 51.36 6.6 Favored 'General case' 0 CA--C 1.532 0.271 0 CA-C-N 114.207 -1.361 . . . . 0.0 113.316 164.952 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . 0.477 ' CE1' HG23 ' A' ' 55' ' ' VAL . 0.3 OUTLIER -119.12 168.37 10.91 Favored 'General case' 0 C--N 1.326 -0.454 0 C-N-CA 119.465 -0.894 . . . . 0.0 111.865 174.215 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.647 ' HA ' ' HA ' ' A' ' 51' ' ' TYR . 7.4 p-10 -78.53 166.11 22.95 Favored 'General case' 0 C--N 1.327 -0.383 0 N-CA-C 113.724 1.009 . . . . 0.0 113.724 -163.459 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.48 ' HB2' ' HE1' ' A' ' 52' ' ' TYR . 5.6 tp-100 -61.08 -39.96 91.87 Favored 'General case' 0 N--CA 1.446 -0.667 0 CA-C-N 114.775 -1.102 . . . . 0.0 111.244 177.601 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -64.32 -49.55 65.16 Favored Glycine 0 C--N 1.317 -0.483 0 CA-C-N 115.665 -0.698 . . . . 0.0 111.572 -175.185 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 87.9 m -66.77 -41.58 87.5 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-N 115.612 -0.294 . . . . 0.0 111.167 176.591 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' TRP . . . . . 0.447 ' HZ3' ' HA ' ' A' ' 82' ' ' GLN . 57.2 t-105 -56.48 -48.4 77.19 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 121.773 0.796 . . . . 0.0 109.437 177.0 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . 0.444 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 29.3 tt0 -67.44 -34.22 76.76 Favored 'General case' 0 C--N 1.317 -0.833 0 CA-C-N 114.8 -1.091 . . . . 0.0 111.131 -179.655 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -65.14 -41.36 94.87 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.899 -0.592 . . . . 0.0 111.129 -177.166 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . 0.566 ' HB2' HG13 ' A' ' 85' ' ' VAL . 31.4 m-80 -82.94 -9.2 59.41 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.715 0.293 . . . . 0.0 110.502 177.232 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . 0.515 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 91.46 49.79 2.91 Favored Glycine 0 C--N 1.334 0.433 0 C-N-CA 121.181 -0.533 . . . . 0.0 113.168 173.218 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.483 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -80.61 -28.2 48.29 Favored Glycine 0 N--CA 1.439 -1.127 0 C-N-CA 121.041 -0.6 . . . . 0.0 113.107 -177.391 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.898 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 7.2 mp -57.4 -23.58 50.2 Favored 'General case' 0 N--CA 1.452 -0.355 0 N-CA-C 112.2 0.445 . . . . 0.0 112.2 -173.032 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . 0.515 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 1.5 ptm180 -67.56 -31.67 71.91 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-O 121.043 0.449 . . . . 0.0 109.971 178.529 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' TYR . . . . . 1.021 ' HB3' ' HG2' ' A' ' 81' ' ' GLU . 63.5 m-85 -83.99 -36.63 23.04 Favored 'General case' 0 N--CA 1.44 -0.946 0 N-CA-C 107.327 -1.36 . . . . 0.0 107.327 177.218 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.636 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 169.1 126.96 0.04 OUTLIER Pre-proline 0 N--CA 1.443 -0.784 0 CA-C-N 112.899 -1.955 . . . . 0.0 107.406 -175.89 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' PRO . . . . . 0.898 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 21.5 Cg_exo -56.85 -5.9 1.48 Allowed 'Trans proline' 0 C--N 1.33 -0.417 0 C-N-CA 122.982 2.454 . . . . 0.0 113.705 -177.542 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' ARG . . . . . 0.63 ' HB2' ' CD2' ' A' ' 52' ' ' TYR . 28.3 ptt-85 -149.74 140.32 22.53 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-O 121.188 0.518 . . . . 0.0 110.356 176.756 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . 0.491 ' HB3' ' HB2' ' A' ' 52' ' ' TYR . . . -57.65 -22.83 48.04 Favored 'General case' 0 C--O 1.217 -0.645 0 CA-C-N 114.851 -1.068 . . . . 0.0 113.189 -178.98 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . 0.57 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 0.0 OUTLIER -76.76 -23.15 52.95 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 121.227 0.537 . . . . 0.0 110.921 -179.159 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.504 ' HB3' ' HB1' ' A' ' 71' ' ' ALA . 54.9 tp -87.68 -33.19 18.86 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 115.567 -0.742 . . . . 0.0 109.191 176.034 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . 0.742 ' HB1' ' CB ' ' A' ' 81' ' ' GLU . . . -79.15 158.47 27.71 Favored 'General case' 0 N--CA 1.445 -0.723 0 CA-C-N 115.344 -0.844 . . . . 0.0 110.97 176.1 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 47.5 p -101.5 -172.48 2.17 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.231 -178.444 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . 0.784 HH21 ' HB2' ' A' ' 32' ' ' ASP . 66.8 mtp180 -49.52 -52.55 28.85 Favored 'General case' 0 N--CA 1.466 0.325 0 CA-C-N 116.433 -0.349 . . . . 0.0 111.521 -177.955 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 10.2 pt-20 -62.69 -33.07 74.33 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 116.023 -0.535 . . . . 0.0 111.365 -174.977 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 81' ' ' GLU . . . . . 1.021 ' HG2' ' HB3' ' A' ' 70' ' ' TYR . 5.9 mt-10 -71.9 -47.53 52.03 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.532 -0.304 . . . . 0.0 111.235 178.43 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 82' ' ' GLN . . . . . 0.57 ' NE2' ' HE3' ' A' ' 43' ' ' TRP . 0.1 OUTLIER -59.5 -39.61 84.38 Favored 'General case' 0 CA--C 1.505 -0.752 0 N-CA-C 109.509 -0.552 . . . . 0.0 109.509 174.551 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.989 HD13 HG11 ' A' ' 25' ' ' VAL . 27.2 mt -60.1 -49.75 82.87 Favored 'Isoleucine or valine' 0 C--O 1.209 -1.03 0 CA-C-N 114.848 -1.069 . . . . 0.0 110.591 177.471 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . 0.622 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -60.8 -46.02 92.14 Favored 'General case' 0 C--O 1.242 0.664 0 CA-C-O 121.409 0.623 . . . . 0.0 111.973 -177.176 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.566 HG13 ' HB2' ' A' ' 65' ' ' ASN . 58.6 t -66.51 -48.27 81.07 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.737 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.448 -179.525 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . 0.572 ' HB1' ' CH2' ' A' ' 31' ' ' TRP . . . -59.95 -28.49 67.69 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.584 -0.735 . . . . 0.0 110.793 174.065 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 87' ' ' GLU . . . . . 0.68 ' HG2' ' O ' ' A' ' 83' ' ' ILE . 10.9 mm-40 -59.26 -45.0 92.38 Favored 'General case' 0 N--CA 1.468 0.434 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.166 -179.17 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.653 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 62.1 t -65.95 -42.49 91.93 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.295 0 C-N-CA 120.115 -0.634 . . . . 0.0 109.594 175.933 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . 0.895 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 1.1 m -64.0 -45.28 89.69 Favored 'General case' 0 C--N 1.319 -0.758 0 CA-C-N 115.613 -0.721 . . . . 0.0 111.498 -176.136 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . 0.547 ' HA ' ' HZ3' ' A' ' 98' ' ' TRP . 5.0 ptt180 -69.29 -33.17 72.79 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.679 -175.559 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . 0.653 ' HG ' ' O ' ' A' ' 88' ' ' VAL . 4.6 pp -68.59 -24.46 64.6 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 121.368 0.604 . . . . 0.0 110.309 -173.4 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . 0.464 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 4.2 mtm180 -84.36 -43.87 14.32 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-O 122.14 0.972 . . . . 0.0 109.163 176.451 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 93' ' ' GLN . . . . . 0.745 ' NE2' HG22 ' A' ' 89' ' ' THR . 21.9 mt-30 -87.84 -28.23 21.75 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 113.746 -1.57 . . . . 0.0 114.329 -167.43 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 74.89 32.63 56.65 Favored Glycine 0 CA--C 1.51 -0.245 0 N-CA-C 111.858 -0.497 . . . . 0.0 111.858 179.894 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 95' ' ' TRP . . . . . 0.42 ' CH2' ' HB ' ' A' ' 30' ' ' ILE . 28.6 m95 67.05 5.02 3.86 Favored 'General case' 0 C--O 1.216 -0.678 0 C-N-CA 123.451 0.701 . . . . 0.0 110.082 -177.151 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -59.39 -43.8 97.12 Favored Glycine 0 CA--C 1.518 0.233 0 CA-C-N 116.125 -0.489 . . . . 0.0 113.327 -178.557 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -69.67 -21.15 63.54 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.826 0.346 . . . . 0.0 110.971 -179.371 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 98' ' ' TRP . . . . . 0.895 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 21.6 m-90 -90.31 108.93 29.97 Favored Pre-proline 0 N--CA 1.445 -0.681 0 N-CA-C 108.127 -1.064 . . . . 0.0 108.127 174.303 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . 0.436 ' HD3' ' HA ' ' A' ' 98' ' ' TRP . 46.9 Cg_exo -62.97 -138.89 0.0 OUTLIER 'Trans proline' 0 CA--C 1.533 0.44 0 C-N-CA 123.616 2.877 . . . . 0.0 114.45 -171.828 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 4.2 p -55.38 -25.92 18.1 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.195 0 CA-C-O 121.427 0.632 . . . . 0.0 110.759 -176.939 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 101' ' ' CYS . . . . . 0.444 ' SG ' ' HG2' ' A' ' 38' ' ' GLU . 39.9 m -55.98 -39.16 71.43 Favored 'General case' 0 C--N 1.317 -0.844 0 CA-C-N 114.896 -1.047 . . . . 0.0 111.427 177.703 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -70.86 -41.42 71.44 Favored 'General case' 0 CA--C 1.519 -0.219 0 CA-C-O 120.877 0.37 . . . . 0.0 110.722 179.609 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -64.34 -43.02 95.91 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 121.074 0.464 . . . . 0.0 110.274 178.171 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 60.1 mtp180 -62.92 -30.82 71.84 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 115.51 -0.768 . . . . 0.0 110.897 176.696 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 105' ' ' ALA . . . . . 0.622 ' HB1' ' HA ' ' A' ' 30' ' ' ILE . . . -85.23 -21.27 29.16 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.72 -0.673 . . . . 0.0 111.456 -177.966 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . 0.466 ' O ' ' HG2' ' A' ' 108' ' ' ARG . . . 102.55 67.71 0.78 Allowed Glycine 0 CA--C 1.52 0.393 0 CA-C-N 115.892 -0.595 . . . . 0.0 112.288 -178.636 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -57.54 147.63 26.32 Favored 'General case' 0 C--O 1.236 0.362 0 C-N-CA 122.895 0.478 . . . . 0.0 111.6 -177.609 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 108' ' ' ARG . . . . . 0.466 ' HG2' ' O ' ' A' ' 106' ' ' GLY . 3.6 ptp180 . . . . . 0 C--O 1.251 1.149 0 CA-C-O 118.496 -0.764 . . . . 0.0 110.582 -171.575 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 90.9 m-20 . . . . . 0 N--CA 1.48 1.062 0 CA-C-O 120.778 0.323 . . . . 0.0 110.88 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 43.1 t -95.24 -38.18 8.5 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 N-CA-C 109.128 -0.693 . . . . 0.0 109.128 175.498 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 7.3 p -65.14 123.73 18.6 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.624 0 CA-C-N 115.284 -0.871 . . . . 0.0 110.939 176.411 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 4.0 p -73.44 147.58 9.42 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.988 179.256 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 62.3 p -121.51 112.85 32.39 Favored Pre-proline 0 C--N 1.317 -0.817 0 CA-C-N 115.273 -0.876 . . . . 0.0 109.747 179.283 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 20.0 Cg_exo -39.18 111.42 0.12 Allowed 'Trans proline' 0 CA--C 1.509 -0.744 0 C-N-CA 124.248 3.299 . . . . 0.0 113.864 -178.851 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -108.5 23.37 14.62 Favored 'General case' 0 C--N 1.302 -1.472 0 CA-C-N 113.477 -1.692 . . . . 0.0 110.277 -177.899 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 32.8 t60 -78.1 -8.29 58.06 Favored 'General case' 0 C--N 1.313 -0.991 0 CA-C-N 114.727 -1.124 . . . . 0.0 108.258 170.822 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . 0.48 ' OE1' ' HB ' ' A' ' 11' ' ' VAL . 6.1 pt-20 -82.72 142.26 31.77 Favored 'General case' 0 C--O 1.235 0.297 0 CA-C-N 115.283 -0.871 . . . . 0.0 110.522 -178.599 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -109.66 54.19 0.67 Allowed 'General case' 0 C--N 1.322 -0.619 0 CA-C-O 122.177 0.989 . . . . 0.0 109.76 175.728 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.524 HG12 ' HG2' ' A' ' 13' ' ' ARG . 84.5 t -124.09 -67.04 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.163 0 CA-C-N 113.824 -1.535 . . . . 0.0 109.606 -178.596 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.411 ' O ' HG12 ' A' ' 12' ' ' VAL . 78.5 t 26.18 81.19 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.447 -0.615 0 C-N-CA 125.183 1.393 . . . . 0.0 113.067 -179.446 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . 0.524 ' HG2' HG12 ' A' ' 11' ' ' VAL . 8.8 ptm180 -119.81 130.24 54.82 Favored 'General case' 0 N--CA 1.424 -1.759 0 CA-C-N 113.724 -1.58 . . . . 0.0 109.43 178.325 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.5 t -96.15 160.42 2.83 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.393 0 CA-C-N 115.168 -0.924 . . . . 0.0 109.534 -178.442 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 174.6 -82.44 0.08 OUTLIER Glycine 0 N--CA 1.429 -1.824 0 N-CA-C 110.331 -1.108 . . . . 0.0 110.331 -179.408 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 18.0 m -93.45 -49.88 5.71 Favored 'General case' 0 N--CA 1.434 -1.243 0 N-CA-C 109.978 -0.378 . . . . 0.0 109.978 174.253 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 3.5 mmmp? 32.77 77.1 0.36 Allowed Pre-proline 0 N--CA 1.467 0.408 0 O-C-N 124.948 1.405 . . . . 0.0 112.495 -177.737 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 0.9 OUTLIER -34.1 118.14 0.11 Allowed 'Trans proline' 0 C--N 1.351 0.674 0 C-N-CA 124.822 3.681 . . . . 0.0 115.101 -176.678 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -164.01 -52.08 0.02 OUTLIER Glycine 0 N--CA 1.436 -1.336 0 CA-C-N 113.186 -1.825 . . . . 0.0 111.25 179.078 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 20.8 m -69.46 -32.98 72.24 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-O 121.322 0.582 . . . . 0.0 110.71 177.785 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 46.7 mt-10 -105.02 119.34 38.78 Favored 'General case' 0 N--CA 1.442 -0.845 0 CA-C-N 115.618 -0.719 . . . . 0.0 109.552 178.907 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 47.1 t -76.8 124.78 87.64 Favored Pre-proline 0 C--N 1.309 -1.178 0 CA-C-N 115.623 -0.717 . . . . 0.0 109.482 175.213 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_exo -54.16 128.3 29.33 Favored 'Trans proline' 0 C--N 1.347 0.448 0 C-N-CA 122.944 2.429 . . . . 0.0 112.811 -177.324 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 13.4 Cg_endo -57.32 160.72 12.85 Favored 'Trans proline' 0 N--CA 1.46 -0.481 0 C-N-CA 123.998 3.132 . . . . 0.0 112.784 176.611 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 79.4 t -80.78 124.83 39.03 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.008 0 CA-C-N 115.012 -0.994 . . . . 0.0 109.135 177.378 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 51.1 mm -55.88 -36.42 43.82 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.602 0 N-CA-C 114.463 1.282 . . . . 0.0 114.463 -161.732 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.555 ' O ' HG12 ' A' ' 30' ' ' ILE . 26.3 m-20 -102.65 4.98 38.83 Favored 'General case' 0 C--N 1.311 -1.083 0 CA-C-O 121.744 0.783 . . . . 0.0 109.688 -173.267 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . 0.585 ' HA3' HD13 ' A' ' 83' ' ' ILE . . . -72.36 -1.03 49.72 Favored Glycine 0 N--CA 1.434 -1.462 0 CA-C-N 114.596 -1.184 . . . . 0.0 111.091 178.403 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 14.9 m -73.8 -40.96 63.02 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-O 121.744 0.783 . . . . 0.0 109.293 175.089 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.555 HG12 ' O ' ' A' ' 27' ' ' ASP . 0.0 OUTLIER -70.99 -36.33 63.13 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.633 0 CA-C-N 114.548 -1.205 . . . . 0.0 107.78 177.218 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' TRP . . . . . 0.656 ' CD1' HG23 ' A' ' 83' ' ' ILE . 49.1 m95 -72.34 -35.96 68.7 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 114.781 -1.1 . . . . 0.0 111.075 -178.32 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.457 ' HB3' ' O ' ' A' ' 28' ' ' GLY . 0.0 OUTLIER -71.0 -35.88 72.24 Favored 'General case' 0 N--CA 1.45 -0.449 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.115 177.395 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . 0.416 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -70.38 -37.19 74.49 Favored 'General case' 0 N--CA 1.446 -0.65 0 C-N-CA 120.869 -0.332 . . . . 0.0 110.944 177.816 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . 0.515 HG13 ' O ' ' A' ' 30' ' ' ILE . 72.6 mt -67.04 -46.97 83.44 Favored 'Isoleucine or valine' 0 C--O 1.234 0.238 0 CA-C-O 121.036 0.446 . . . . 0.0 110.215 174.949 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -57.96 -38.31 75.77 Favored 'General case' 0 N--CA 1.451 -0.386 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.445 176.833 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -72.71 -13.31 78.29 Favored Glycine 0 N--CA 1.451 -0.352 0 CA-C-N 115.683 -0.689 . . . . 0.0 111.838 179.824 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 53.1 t -95.9 -59.09 1.93 Allowed 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.639 -0.28 . . . . 0.0 111.413 -177.092 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . 0.869 ' HG3' ' SG ' ' A' ' 101' ' ' CYS . 26.5 mt-10 -88.93 -22.95 22.84 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 120.651 0.263 . . . . 0.0 111.619 -173.536 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -106.26 -12.13 15.81 Favored 'General case' 0 N--CA 1.447 -0.58 0 C-N-CA 120.184 -0.607 . . . . 0.0 111.717 -179.208 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 77.99 15.98 80.45 Favored Glycine 0 CA--C 1.507 -0.459 0 N-CA-C 109.935 -1.266 . . . . 0.0 109.935 -176.861 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 73.07 57.03 5.43 Favored Glycine 0 N--CA 1.435 -1.416 0 CA-C-N 114.072 -1.064 . . . . 0.0 111.516 -175.334 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 2.6 t-20 -140.19 98.55 3.47 Favored 'General case' 0 N--CA 1.447 -0.609 0 N-CA-C 109.194 -0.669 . . . . 0.0 109.194 -177.713 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' TRP . . . . . 0.773 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 32.3 m95 -84.07 2.37 39.6 Favored 'General case' 0 C--N 1.319 -0.758 0 CA-C-N 115.485 -0.78 . . . . 0.0 109.973 -174.799 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -111.15 1.76 17.46 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-N 114.903 -1.044 . . . . 0.0 111.488 177.41 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.899 HG22 ' HA2' ' A' ' 53' ' ' GLY . 6.4 tt -66.91 143.91 15.13 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.677 0 CA-C-O 121.268 0.556 . . . . 0.0 110.358 -177.34 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . 0.447 ' ND2' ' HD1' ' A' ' 52' ' ' TYR . 9.4 t-20 -152.08 98.67 2.46 Favored 'General case' 0 C--N 1.309 -1.179 0 CA-C-O 121.234 0.54 . . . . 0.0 109.67 -178.49 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 21.1 p -75.38 -21.33 58.36 Favored 'General case' 0 C--N 1.317 -0.817 0 CA-C-N 115.362 -0.835 . . . . 0.0 110.292 179.259 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 91.04 18.53 46.46 Favored Glycine 0 N--CA 1.443 -0.848 0 CA-C-N 115.339 -0.846 . . . . 0.0 111.038 178.272 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 28.5 p-10 -95.44 4.47 53.26 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.891 0.377 . . . . 0.0 111.647 -174.407 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . 0.438 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 95.47 -8.22 68.96 Favored Glycine 0 N--CA 1.45 -0.424 0 C-N-CA 120.49 -0.862 . . . . 0.0 111.832 -178.055 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' TYR . . . . . 0.579 ' CE1' ' HB3' ' A' ' 58' ' ' ASP . 0.2 OUTLIER -112.89 144.65 42.08 Favored 'General case' 0 CA--C 1.511 -0.544 0 N-CA-C 106.826 -1.546 . . . . 0.0 106.826 176.131 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' TYR . . . . . 0.736 ' HB2' ' HB3' ' A' ' 74' ' ' ALA . 53.6 m-85 -117.38 169.05 9.8 Favored 'General case' 0 C--N 1.306 -1.307 0 N-CA-C 113.488 0.922 . . . . 0.0 113.488 -165.388 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.899 ' HA2' HG22 ' A' ' 45' ' ' ILE . . . -62.89 159.05 36.36 Favored Glycine 0 CA--C 1.501 -0.797 0 CA-C-N 114.845 -1.071 . . . . 0.0 114.018 -171.991 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.583 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 101.72 -103.73 2.56 Favored Glycine 0 N--CA 1.437 -1.249 0 N-CA-C 111.402 -0.679 . . . . 0.0 111.402 -177.212 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.571 HG23 ' HG2' ' A' ' 82' ' ' GLN . 2.8 t -92.05 0.78 9.23 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 CA-C-O 121.652 0.739 . . . . 0.0 109.898 -178.61 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' GLN . . . . . 0.635 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 8.3 mm-40 59.51 50.37 7.55 Favored 'General case' 0 N--CA 1.464 0.269 0 CA-C-N 114.644 -1.162 . . . . 0.0 113.901 167.92 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 17.8 p90 -120.91 171.45 8.62 Favored 'General case' 0 C--N 1.325 -0.478 0 C-N-CA 119.833 -0.747 . . . . 0.0 112.092 175.112 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.579 ' HB3' ' CE1' ' A' ' 51' ' ' TYR . 6.4 p-10 -82.37 158.6 23.29 Favored 'General case' 0 CA--C 1.516 -0.356 0 N-CA-C 113.686 0.995 . . . . 0.0 113.686 -163.417 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.429 ' HB2' ' CE2' ' A' ' 52' ' ' TYR . 20.6 tp60 -57.84 -39.79 78.53 Favored 'General case' 0 N--CA 1.442 -0.828 0 CA-C-N 113.279 -1.782 . . . . 0.0 111.714 179.229 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -67.47 -49.46 50.9 Favored Glycine 0 N--CA 1.45 -0.404 0 CA-C-N 115.603 -0.726 . . . . 0.0 112.034 -175.303 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 83.2 m -62.87 -41.05 99.25 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 121.252 0.548 . . . . 0.0 110.389 176.57 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' TRP . . . . . 0.424 ' CH2' ' HA ' ' A' ' 74' ' ' ALA . 54.1 t-105 -56.99 -50.1 73.74 Favored 'General case' 0 N--CA 1.444 -0.737 0 CA-C-N 115.265 -0.88 . . . . 0.0 109.687 176.734 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . 0.46 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 36.7 tt0 -67.1 -39.28 86.7 Favored 'General case' 0 N--CA 1.445 -0.683 0 CA-C-N 114.918 -1.037 . . . . 0.0 110.91 -178.183 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -62.11 -40.95 97.62 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.539 -0.755 . . . . 0.0 111.109 -176.682 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 9.3 m120 -82.3 -9.61 59.41 Favored 'General case' 0 N--CA 1.45 -0.461 0 CA-C-O 120.908 0.385 . . . . 0.0 110.768 178.521 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 93.23 47.57 3.03 Favored Glycine 0 C--N 1.333 0.373 0 CA-C-N 116.089 -0.505 . . . . 0.0 112.659 173.784 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.592 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -80.2 -22.92 62.1 Favored Glycine 0 N--CA 1.44 -1.045 0 C-N-CA 120.966 -0.635 . . . . 0.0 112.868 -174.621 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.848 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 6.8 mp -61.51 -23.48 65.95 Favored 'General case' 0 N--CA 1.447 -0.595 0 N-CA-C 112.483 0.549 . . . . 0.0 112.483 -172.569 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . 0.428 ' HG3' ' N ' ' A' ' 70' ' ' TYR . 3.8 ptm180 -69.02 -30.96 69.44 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 121.19 0.519 . . . . 0.0 110.145 176.041 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' TYR . . . . . 0.792 ' HB3' ' HG3' ' A' ' 81' ' ' GLU . 79.5 m-85 -79.71 -34.8 39.78 Favored 'General case' 0 N--CA 1.446 -0.674 0 N-CA-C 107.679 -1.23 . . . . 0.0 107.679 177.144 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.696 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 161.57 128.73 0.01 OUTLIER Pre-proline 0 CA--C 1.509 -0.602 0 CA-C-N 112.609 -2.087 . . . . 0.0 106.689 -178.452 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' PRO . . . . . 0.848 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 32.3 Cg_exo -54.9 -6.68 0.7 Allowed 'Trans proline' 0 C--N 1.33 -0.416 0 C-N-CA 123.171 2.581 . . . . 0.0 114.246 -177.08 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' ARG . . . . . 0.402 ' HE ' ' CG ' ' A' ' 75' ' ' ASP . 12.4 ptm180 -149.59 142.77 25.06 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-O 121.095 0.474 . . . . 0.0 109.794 176.515 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . 0.736 ' HB3' ' HB2' ' A' ' 52' ' ' TYR . . . -61.06 -23.48 65.49 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.267 -0.879 . . . . 0.0 113.017 -175.159 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . 0.503 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 9.4 p-10 -88.21 -0.57 57.26 Favored 'General case' 0 C--N 1.33 -0.262 0 C-N-CA 120.544 -0.462 . . . . 0.0 110.905 -179.54 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.405 HD23 ' HD2' ' A' ' 72' ' ' PRO . 62.0 tp -103.75 -31.11 10.0 Favored 'General case' 0 C--N 1.323 -0.584 0 N-CA-C 109.026 -0.731 . . . . 0.0 109.026 172.641 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . 0.709 ' HB1' ' HB3' ' A' ' 81' ' ' GLU . . . -79.81 162.05 25.32 Favored 'General case' 0 N--CA 1.446 -0.631 0 CA-C-N 115.142 -0.935 . . . . 0.0 109.426 174.262 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 61.7 p -100.66 -175.0 2.78 Favored 'General case' 0 C--N 1.312 -1.046 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.874 -176.688 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . 0.773 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 11.9 mtp180 -50.92 -55.24 18.11 Favored 'General case' 0 C--O 1.222 -0.383 0 O-C-N 123.406 0.441 . . . . 0.0 110.594 179.518 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 11.3 pt-20 -61.76 -41.88 98.27 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 115.893 -0.594 . . . . 0.0 111.501 -174.326 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 81' ' ' GLU . . . . . 0.792 ' HG3' ' HB3' ' A' ' 70' ' ' TYR . 0.2 OUTLIER -64.2 -52.05 60.73 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 115.405 -0.816 . . . . 0.0 112.138 177.457 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 82' ' ' GLN . . . . . 0.571 ' HG2' HG23 ' A' ' 55' ' ' VAL . 5.7 tt0 -68.1 -31.34 70.89 Favored 'General case' 0 C--N 1.317 -0.805 0 CA-C-N 115.364 -0.835 . . . . 0.0 110.409 -176.759 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.656 HG23 ' CD1' ' A' ' 31' ' ' TRP . 25.0 mt -59.83 -44.54 94.33 Favored 'Isoleucine or valine' 0 C--O 1.216 -0.691 0 CA-C-N 115.471 -0.786 . . . . 0.0 109.563 173.524 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . 0.592 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -63.22 -40.64 98.04 Favored 'General case' 0 C--O 1.236 0.371 0 CA-C-O 121.352 0.596 . . . . 0.0 111.16 -175.632 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 44.2 t -69.02 -48.04 72.09 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 CA-C-N 115.685 -0.688 . . . . 0.0 110.919 177.758 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -57.05 -30.43 64.25 Favored 'General case' 0 N--CA 1.449 -0.48 0 CA-C-O 120.895 0.378 . . . . 0.0 110.401 172.796 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 87' ' ' GLU . . . . . 0.824 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 8.1 mm-40 -60.48 -44.58 95.78 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.196 -179.178 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 83.4 t -62.23 -44.91 99.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 C-N-CA 120.407 -0.517 . . . . 0.0 109.857 178.864 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . 0.694 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 1.2 m -61.92 -47.78 83.4 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 115.504 -0.771 . . . . 0.0 111.478 -178.896 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . 0.738 ' HA ' ' OE1' ' A' ' 93' ' ' GLN . 2.5 ptt180 -62.02 -32.66 73.17 Favored 'General case' 0 CA--C 1.52 -0.176 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.361 -174.992 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . 0.824 ' HG ' ' O ' ' A' ' 87' ' ' GLU . 45.6 mt -61.06 -33.9 74.04 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-O 121.358 0.599 . . . . 0.0 110.529 -176.965 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 1.3 mtm180 -86.75 -45.36 11.01 Favored 'General case' 0 N--CA 1.443 -0.788 0 CA-C-N 115.221 -0.9 . . . . 0.0 110.589 -169.707 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 93' ' ' GLN . . . . . 0.738 ' OE1' ' HA ' ' A' ' 90' ' ' ARG . 0.0 OUTLIER -99.55 -21.32 15.95 Favored 'General case' 0 C--N 1.323 -0.572 0 N-CA-C 113.13 0.789 . . . . 0.0 113.13 -172.376 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 82.93 38.86 10.82 Favored Glycine 0 C--N 1.333 0.39 0 C-N-CA 120.926 -0.654 . . . . 0.0 112.523 171.441 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 95' ' ' TRP . . . . . 0.605 ' CZ2' ' HD3' ' A' ' 90' ' ' ARG . 20.7 m95 66.6 11.06 7.89 Favored 'General case' 0 C--O 1.221 -0.4 0 C-N-CA 123.445 0.698 . . . . 0.0 110.247 -179.212 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -68.7 -35.22 79.89 Favored Glycine 0 N--CA 1.453 -0.226 0 C-N-CA 121.236 -0.507 . . . . 0.0 112.352 176.817 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . 0.437 ' H ' ' CG ' ' A' ' 93' ' ' GLN . . . -66.85 -29.63 69.59 Favored 'General case' 0 CA--C 1.517 -0.294 0 CA-C-O 121.051 0.453 . . . . 0.0 110.577 178.857 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 98' ' ' TRP . . . . . 0.694 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 24.3 m-90 -92.72 108.41 31.57 Favored Pre-proline 0 N--CA 1.445 -0.722 0 N-CA-C 108.438 -0.949 . . . . 0.0 108.438 177.52 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . 0.429 ' HD3' ' O ' ' A' ' 97' ' ' ALA . 45.7 Cg_exo -63.08 -131.3 0.0 OUTLIER 'Trans proline' 0 CA--C 1.541 0.854 0 C-N-CA 123.492 2.794 . . . . 0.0 114.5 -175.06 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 39.2 t -55.65 -29.41 24.97 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.146 0 O-C-N 122.081 -0.387 . . . . 0.0 111.612 -174.662 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 101' ' ' CYS . . . . . 0.869 ' SG ' ' HG3' ' A' ' 38' ' ' GLU . 71.1 m -68.4 -31.97 71.69 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 116.56 -0.291 . . . . 0.0 111.604 -174.87 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 102' ' ' ALA . . . . . 0.556 ' HB2' ' CB ' ' A' ' 98' ' ' TRP . . . -70.36 -43.66 69.72 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.033 0.444 . . . . 0.0 110.335 176.185 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -62.08 -40.21 95.06 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.267 178.583 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 104' ' ' ARG . . . . . 0.625 ' HA ' ' NE ' ' A' ' 104' ' ' ARG . 1.9 mmp_? -69.16 -25.72 64.51 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.408 -0.814 . . . . 0.0 111.45 177.68 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 105' ' ' ALA . . . . . 0.416 ' CB ' ' HB3' ' A' ' 33' ' ' ALA . . . -83.38 -21.6 33.0 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 116.125 -0.489 . . . . 0.0 111.911 -177.477 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 105.38 47.75 1.11 Allowed Glycine 0 CA--C 1.521 0.456 0 C-N-CA 120.88 -0.676 . . . . 0.0 111.98 -176.599 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -57.74 149.45 22.06 Favored 'General case' 0 C--N 1.327 -0.395 0 C-N-CA 123.636 0.774 . . . . 0.0 112.23 -178.858 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 108' ' ' ARG . . . . . 0.447 ' O ' ' HD3' ' A' ' 108' ' ' ARG . 0.0 OUTLIER . . . . . 0 C--O 1.246 0.899 0 CA-C-N 115.771 -0.649 . . . . 0.0 110.373 -177.095 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 91.5 m-20 . . . . . 0 N--CA 1.483 1.22 0 CA-C-O 120.855 0.36 . . . . 0.0 110.586 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 59.6 t -97.49 -39.39 8.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 115.99 -0.55 . . . . 0.0 109.901 177.518 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 7.1 p -56.89 138.52 17.56 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 CA-C-N 115.3 -0.864 . . . . 0.0 110.338 174.521 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 2.9 p -63.42 137.42 24.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-O 121.514 0.673 . . . . 0.0 110.887 -179.908 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . 0.486 ' HA ' ' HD3' ' A' ' 6' ' ' PRO . 13.4 t -104.4 133.99 19.91 Favored Pre-proline 0 C--N 1.309 -1.191 0 CA-C-N 114.754 -1.112 . . . . 0.0 110.05 -174.045 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.486 ' HD3' ' HA ' ' A' ' 5' ' ' THR . 56.1 Cg_endo -89.66 176.71 2.84 Favored 'Trans proline' 0 N--CA 1.45 -1.055 0 C-N-CA 123.403 2.735 . . . . 0.0 112.619 -178.258 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -113.87 167.12 10.91 Favored 'General case' 0 C--N 1.309 -1.175 0 CA-C-N 114.389 -1.278 . . . . 0.0 110.001 178.082 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 37.6 t60 69.58 -0.23 2.7 Favored 'General case' 0 C--N 1.333 -0.116 0 O-C-N 124.093 0.87 . . . . 0.0 109.698 -171.785 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . 0.411 ' OE1' ' HD2' ' A' ' 6' ' ' PRO . 10.3 pt-20 -62.17 138.85 58.47 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.571 -0.74 . . . . 0.0 110.539 178.79 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -125.59 63.83 1.19 Allowed 'General case' 0 C--N 1.316 -0.863 0 CA-C-O 121.87 0.843 . . . . 0.0 109.778 178.886 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 59.7 t -78.55 -50.54 18.86 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.909 0 CA-C-N 114.436 -1.256 . . . . 0.0 109.149 179.207 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 77.0 t 25.91 80.55 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.444 -0.747 0 O-C-N 125.141 1.526 . . . . 0.0 113.03 -179.614 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . 0.437 ' NE ' ' HA ' ' A' ' 13' ' ' ARG . 4.8 mmp_? -142.0 132.96 25.93 Favored 'General case' 0 C--N 1.305 -1.333 0 CA-C-N 113.859 -1.519 . . . . 0.0 110.512 178.944 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.6 t -115.28 158.62 15.54 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.364 0 CA-C-N 114.526 -1.215 . . . . 0.0 109.397 -178.84 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -159.49 64.19 0.29 Allowed Glycine 0 N--CA 1.428 -1.885 0 CA-C-N 114.937 -1.029 . . . . 0.0 111.252 178.052 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 2.0 m -68.3 -43.87 76.71 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-N 114.693 -0.753 . . . . 0.0 110.648 -176.596 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 71.7 mmtt 37.69 72.61 0.84 Allowed Pre-proline 0 C--N 1.324 -0.506 0 O-C-N 124.909 1.381 . . . . 0.0 111.738 -177.656 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 16.8 Cg_exo -68.53 168.49 19.63 Favored 'Trans proline' 0 CA--C 1.512 -0.587 0 C-N-CA 123.345 2.697 . . . . 0.0 112.91 -174.105 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -146.92 -44.31 0.03 OUTLIER Glycine 0 N--CA 1.44 -1.097 0 CA-C-N 113.696 -1.593 . . . . 0.0 111.054 -179.449 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 25.6 m -66.73 -34.12 77.14 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 114.938 -0.631 . . . . 0.0 110.394 177.506 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 9.8 pt-20 -116.27 140.25 49.51 Favored 'General case' 0 N--CA 1.431 -1.398 0 N-CA-C 108.393 -0.966 . . . . 0.0 108.393 177.315 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.4 ' HA ' ' HD3' ' A' ' 23' ' ' PRO . 43.3 t -80.01 128.49 73.56 Favored Pre-proline 0 C--N 1.306 -1.289 0 CA-C-N 115.191 -0.913 . . . . 0.0 111.831 -170.803 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.413 ' HA ' ' HD2' ' A' ' 24' ' ' PRO . 53.9 Cg_exo -54.39 130.36 39.51 Favored 'Trans proline' 0 C--N 1.348 0.509 0 C-N-CA 123.369 2.713 . . . . 0.0 112.304 177.039 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . 0.413 ' HD2' ' HA ' ' A' ' 23' ' ' PRO . 11.9 Cg_endo -55.37 141.71 81.17 Favored 'Trans proline' 0 N--CA 1.457 -0.643 0 C-N-CA 123.925 3.083 . . . . 0.0 113.696 -174.909 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.484 ' HB ' HG21 ' A' ' 83' ' ' ILE . 46.2 t -95.69 148.22 5.37 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.977 0 CA-C-N 114.19 -1.368 . . . . 0.0 108.888 175.614 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.574 HG22 HH12 ' A' ' 108' ' ' ARG . 3.2 mp -60.44 -25.43 34.26 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.434 0 CA-C-N 115.421 -0.809 . . . . 0.0 112.21 -170.872 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.487 ' O ' HG12 ' A' ' 30' ' ' ILE . 27.5 m-20 -99.68 -1.65 37.42 Favored 'General case' 0 CA--C 1.507 -0.708 0 CA-C-O 121.41 0.624 . . . . 0.0 110.092 -178.431 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -63.4 -12.19 44.34 Favored Glycine 0 CA--C 1.504 -0.614 0 CA-C-N 114.977 -1.01 . . . . 0.0 111.206 -177.726 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 19.3 m -76.24 -43.35 42.4 Favored 'General case' 0 C--N 1.317 -0.809 0 CA-C-O 121.914 0.864 . . . . 0.0 109.477 177.95 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.504 ' HA ' ' HB1' ' A' ' 105' ' ' ALA . 0.1 OUTLIER -68.9 -38.85 79.15 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.802 0 CA-C-N 114.178 -1.373 . . . . 0.0 107.871 179.775 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' TRP . . . . . 0.49 ' CD1' HG23 ' A' ' 83' ' ' ILE . 17.1 m95 -67.48 -36.96 82.14 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 114.735 -1.121 . . . . 0.0 110.511 -177.627 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 9.7 t70 -75.2 -38.86 60.57 Favored 'General case' 0 N--CA 1.444 -0.759 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.692 179.017 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . 0.451 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -70.82 -35.79 72.64 Favored 'General case' 0 N--CA 1.448 -0.548 0 C-N-CA 120.78 -0.368 . . . . 0.0 110.903 178.737 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . 0.486 HG13 ' O ' ' A' ' 30' ' ' ILE . 64.8 mt -62.33 -45.6 98.38 Favored 'Isoleucine or valine' 0 C--O 1.234 0.247 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 173.646 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . 0.56 ' HA ' ' O ' ' A' ' 54' ' ' GLY . . . -57.62 -38.52 75.1 Favored 'General case' 0 N--CA 1.451 -0.404 0 CA-C-N 115.506 -0.77 . . . . 0.0 110.056 176.734 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . 0.445 ' HA2' ' N ' ' A' ' 41' ' ' GLY . . . -73.6 -22.06 78.81 Favored Glycine 0 N--CA 1.451 -0.338 0 CA-C-N 115.467 -0.788 . . . . 0.0 111.944 -179.814 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 6.3 t -84.53 -56.65 3.5 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-O 120.831 0.348 . . . . 0.0 111.608 -178.704 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . 0.406 ' HB2' ' SG ' ' A' ' 101' ' ' CYS . 11.4 tp10 -87.61 -30.53 20.41 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 121.063 0.459 . . . . 0.0 110.511 -170.453 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -107.59 -8.01 16.31 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.956 -0.566 . . . . 0.0 111.871 -176.565 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 80.23 4.06 89.79 Favored Glycine 0 CA--C 1.507 -0.408 0 N-CA-C 110.239 -1.144 . . . . 0.0 110.239 -177.535 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . 0.445 ' N ' ' HA2' ' A' ' 36' ' ' GLY . . . 89.95 56.41 1.85 Allowed Glycine 0 N--CA 1.432 -1.568 0 CA-C-N 114.006 -1.097 . . . . 0.0 111.302 -175.986 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 2.4 t-20 -141.71 99.48 3.56 Favored 'General case' 0 N--CA 1.447 -0.596 0 N-CA-C 108.732 -0.84 . . . . 0.0 108.732 -175.655 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' TRP . . . . . 0.76 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 23.4 m95 -83.81 -4.33 58.57 Favored 'General case' 0 C--N 1.313 -1.005 0 CA-C-N 115.723 -0.672 . . . . 0.0 110.158 -173.39 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . 0.454 ' HA ' ' HB2' ' A' ' 75' ' ' ASP . . . -109.3 10.74 25.57 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 115.183 -0.917 . . . . 0.0 111.06 179.351 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.726 HG22 ' HA2' ' A' ' 53' ' ' GLY . 9.0 tt -76.09 144.57 11.71 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.792 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.31 179.892 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 10.3 t-20 -142.46 97.96 3.21 Favored 'General case' 0 C--N 1.31 -1.111 0 N-CA-C 108.995 -0.743 . . . . 0.0 108.995 177.393 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 10.0 p -70.08 -22.28 63.06 Favored 'General case' 0 N--CA 1.445 -0.715 0 CA-C-N 114.819 -1.082 . . . . 0.0 111.345 -173.753 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 90.39 17.2 53.66 Favored Glycine 0 N--CA 1.44 -1.066 0 N-CA-C 110.094 -1.202 . . . . 0.0 110.094 -176.773 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 5.1 m-20 -91.34 -5.91 53.85 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.169 -0.516 . . . . 0.0 111.01 -175.183 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . 0.407 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 94.25 -5.1 71.16 Favored Glycine 0 N--CA 1.444 -0.77 0 N-CA-C 110.081 -1.208 . . . . 0.0 110.081 -172.676 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' TYR . . . . . 0.623 ' HA ' ' HA ' ' A' ' 58' ' ' ASP . 0.4 OUTLIER -111.61 149.15 31.91 Favored 'General case' 0 N--CA 1.446 -0.664 0 N-CA-C 106.976 -1.491 . . . . 0.0 106.976 177.916 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' TYR . . . . . 0.699 ' O ' ' HA ' ' A' ' 56' ' ' GLN . 71.0 m-85 -114.59 170.37 8.36 Favored 'General case' 0 C--N 1.307 -1.245 0 C-N-CA 120.432 -0.507 . . . . 0.0 111.908 -168.655 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.726 ' HA2' HG22 ' A' ' 45' ' ' ILE . . . -57.94 171.91 3.45 Favored Glycine 0 C--O 1.227 -0.321 0 N-CA-C 115.072 0.789 . . . . 0.0 115.072 -168.919 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.675 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 80.4 -101.76 2.02 Favored Glycine 0 N--CA 1.442 -0.924 0 C-N-CA 120.955 -0.641 . . . . 0.0 112.148 177.367 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.512 HG12 ' HE1' ' A' ' 98' ' ' TRP . 2.4 t -83.3 -3.04 7.13 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-O 121.646 0.736 . . . . 0.0 110.296 -176.68 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' GLN . . . . . 0.699 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 7.7 tp-100 54.83 50.47 15.6 Favored 'General case' 0 CA--C 1.53 0.186 0 CA-C-N 114.034 -1.439 . . . . 0.0 112.852 169.203 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . 0.496 ' CE1' ' HB ' ' A' ' 55' ' ' VAL . 2.0 p90 -121.54 163.32 19.05 Favored 'General case' 0 C--N 1.325 -0.474 0 C-N-CA 120.213 -0.595 . . . . 0.0 111.532 176.995 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.623 ' HA ' ' HA ' ' A' ' 51' ' ' TYR . 7.8 p-10 -72.29 162.3 29.65 Favored 'General case' 0 CA--C 1.514 -0.419 0 N-CA-C 113.76 1.022 . . . . 0.0 113.76 -163.511 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.44 ' HB2' ' HE1' ' A' ' 52' ' ' TYR . 17.7 tp60 -55.15 -42.2 72.76 Favored 'General case' 0 N--CA 1.441 -0.878 0 CA-C-N 114.327 -1.306 . . . . 0.0 110.969 177.206 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -67.84 -50.44 41.63 Favored Glycine 0 C--O 1.224 -0.481 0 CA-C-N 115.183 -0.917 . . . . 0.0 112.584 -172.819 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 97.1 m -61.67 -41.46 97.57 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-O 121.177 0.513 . . . . 0.0 110.8 177.139 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' TRP . . . . . 0.439 ' CH2' ' HA ' ' A' ' 74' ' ' ALA . 52.4 t-105 -58.23 -49.11 78.23 Favored 'General case' 0 N--CA 1.446 -0.671 0 CA-C-N 115.467 -0.788 . . . . 0.0 109.691 175.786 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . 0.479 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 36.2 tt0 -67.13 -36.75 82.55 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.193 -0.912 . . . . 0.0 110.801 -178.205 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -63.53 -41.49 98.47 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.591 -0.731 . . . . 0.0 111.195 -176.882 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . 0.646 HD22 ' N ' ' A' ' 65' ' ' ASN . 0.7 OUTLIER -81.09 -8.74 59.83 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-O 121.1 0.476 . . . . 0.0 110.22 177.632 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . 0.47 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 89.35 48.6 3.71 Favored Glycine 0 C--N 1.334 0.433 0 CA-C-N 115.746 -0.661 . . . . 0.0 112.271 174.678 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.484 ' HA2' ' HD1' ' A' ' 70' ' ' TYR . . . -79.36 -22.91 64.02 Favored Glycine 0 N--CA 1.439 -1.121 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.838 -175.051 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.79 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 6.9 mp -58.89 -25.95 63.84 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 112.893 0.701 . . . . 0.0 112.893 -172.945 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . 0.47 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 14.9 ptp180 -70.5 -29.24 65.7 Favored 'General case' 0 C--N 1.318 -0.772 0 CA-C-O 121.079 0.466 . . . . 0.0 110.553 176.643 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' TYR . . . . . 0.622 ' HB3' ' CG ' ' A' ' 81' ' ' GLU . 74.2 m-85 -79.32 -34.25 42.46 Favored 'General case' 0 N--CA 1.444 -0.749 0 N-CA-C 107.05 -1.463 . . . . 0.0 107.05 175.764 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.679 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 161.81 130.27 0.01 OUTLIER Pre-proline 0 CA--C 1.511 -0.524 0 CA-C-N 112.037 -2.347 . . . . 0.0 106.817 -179.117 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' PRO . . . . . 0.79 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 13.5 Cg_exo -58.33 -2.13 0.85 Allowed 'Trans proline' 0 C--N 1.33 -0.415 0 C-N-CA 122.837 2.358 . . . . 0.0 113.965 -177.083 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' ARG . . . . . 0.455 ' HB2' ' CD2' ' A' ' 52' ' ' TYR . 0.0 OUTLIER -153.3 142.56 21.52 Favored 'General case' 0 C--N 1.316 -0.85 0 N-CA-C 109.211 -0.663 . . . . 0.0 109.211 177.695 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . 0.509 ' HB3' ' HB2' ' A' ' 52' ' ' TYR . . . -60.2 -27.94 67.57 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.32 -0.855 . . . . 0.0 112.721 -175.464 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . 0.575 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 6.7 p-10 -86.87 3.2 46.44 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 121.246 0.546 . . . . 0.0 110.824 -176.6 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.525 ' HB3' ' HB1' ' A' ' 71' ' ' ALA . 50.7 tp -103.68 -34.12 8.72 Favored 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 171.155 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . 0.679 ' HB2' ' HB3' ' A' ' 71' ' ' ALA . . . -79.86 161.51 25.56 Favored 'General case' 0 N--CA 1.448 -0.568 0 CA-C-N 115.1 -0.955 . . . . 0.0 109.93 175.621 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 36.1 p -101.2 -173.19 2.31 Favored 'General case' 0 C--N 1.318 -0.796 0 C-N-CA 120.788 -0.365 . . . . 0.0 110.74 179.874 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . 0.76 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 9.0 mtp85 -52.59 -51.98 57.34 Favored 'General case' 0 CA--C 1.513 -0.46 0 O-C-N 123.592 0.558 . . . . 0.0 110.953 -174.789 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 1.3 pm0 -59.71 -41.67 91.34 Favored 'General case' 0 C--N 1.317 -0.836 0 CA-C-N 115.319 -0.855 . . . . 0.0 112.131 -176.504 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 81' ' ' GLU . . . . . 0.648 ' CB ' ' HB1' ' A' ' 77' ' ' ALA . 2.3 mp0 -62.26 -51.23 68.57 Favored 'General case' 0 C--O 1.234 0.254 0 O-C-N 122.352 -0.218 . . . . 0.0 111.322 174.377 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 82' ' ' GLN . . . . . 0.437 ' HB2' ' HZ3' ' A' ' 43' ' ' TRP . 50.3 mt-30 -60.9 -37.01 80.74 Favored 'General case' 0 CA--C 1.514 -0.413 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.66 -177.9 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.49 HG23 ' CD1' ' A' ' 31' ' ' TRP . 42.1 mt -59.28 -45.51 93.06 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.777 0 CA-C-N 115.139 -0.937 . . . . 0.0 109.801 176.742 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . 0.649 ' O ' ' HG3' ' A' ' 87' ' ' GLU . . . -66.35 -45.98 78.32 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.621 -177.908 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.424 HG23 ' O ' ' A' ' 81' ' ' GLU . 44.0 t -66.06 -49.01 79.61 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-O 120.779 0.323 . . . . 0.0 111.631 -179.926 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -67.02 -31.3 71.75 Favored 'General case' 0 CA--C 1.516 -0.359 0 CA-C-O 121.147 0.498 . . . . 0.0 110.498 -179.719 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 87' ' ' GLU . . . . . 0.768 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 0.1 OUTLIER -69.69 -31.5 69.58 Favored 'General case' 0 C--N 1.322 -0.604 0 C-N-CA 120.149 -0.62 . . . . 0.0 110.325 -176.455 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.584 ' O ' ' HG3' ' A' ' 92' ' ' ARG . 69.1 t -61.43 -40.77 87.47 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.224 0 N-CA-C 108.839 -0.8 . . . . 0.0 108.839 172.89 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . 0.91 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 4.3 m -64.8 -43.32 93.54 Favored 'General case' 0 N--CA 1.447 -0.597 0 CA-C-N 115.648 -0.706 . . . . 0.0 110.388 179.367 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . 0.54 ' HG3' ' O ' ' A' ' 87' ' ' GLU . 1.2 ppt_? -61.53 -31.24 71.24 Favored 'General case' 0 C--O 1.223 -0.336 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.561 179.907 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . 0.768 ' HG ' ' O ' ' A' ' 87' ' ' GLU . 28.8 mt -64.07 -33.56 76.03 Favored 'General case' 0 C--N 1.318 -0.801 0 CA-C-O 121.63 0.729 . . . . 0.0 109.88 -179.872 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . 0.584 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 7.6 mtm180 -91.62 -51.58 5.18 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 115.058 -0.974 . . . . 0.0 110.618 -169.925 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 93' ' ' GLN . . . . . 0.574 HE22 ' HZ3' ' A' ' 98' ' ' TRP . 0.0 OUTLIER -106.49 -14.51 15.05 Favored 'General case' 0 N--CA 1.443 -0.786 0 CA-C-N 115.446 -0.797 . . . . 0.0 112.016 -175.293 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.441 ' O ' ' HA ' ' A' ' 90' ' ' ARG . . . 86.74 -109.14 3.39 Favored Glycine 0 CA--C 1.496 -1.116 0 N-CA-C 110.797 -0.921 . . . . 0.0 110.797 178.813 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 95' ' ' TRP . . . . . 0.46 ' HB3' ' HB1' ' A' ' 102' ' ' ALA . 6.6 m95 -141.17 24.39 2.14 Favored 'General case' 0 C--N 1.311 -1.103 0 N-CA-C 107.207 -1.405 . . . . 0.0 107.207 -179.794 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -77.29 -20.76 74.57 Favored Glycine 0 N--CA 1.447 -0.594 0 CA-C-N 114.381 -1.281 . . . . 0.0 111.831 175.616 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . 0.426 ' O ' ' HD3' ' A' ' 99' ' ' PRO . . . -90.35 -24.04 20.95 Favored 'General case' 0 CA--C 1.516 -0.364 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 176.248 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 98' ' ' TRP . . . . . 0.91 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 24.3 m-90 -96.59 104.69 18.88 Favored Pre-proline 0 N--CA 1.451 -0.42 0 N-CA-C 108.811 -0.811 . . . . 0.0 108.811 173.643 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . 0.503 ' HB2' ' H ' ' A' ' 100' ' ' VAL . 28.9 Cg_exo -67.34 -110.1 0.0 OUTLIER 'Trans proline' 0 CA--C 1.538 0.719 0 C-N-CA 123.49 2.793 . . . . 0.0 114.757 -171.826 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . 0.503 ' H ' ' HB2' ' A' ' 99' ' ' PRO . 40.8 t -67.41 -31.5 53.09 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-O 121.305 0.574 . . . . 0.0 110.432 -174.506 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 101' ' ' CYS . . . . . 0.406 ' SG ' ' HB2' ' A' ' 38' ' ' GLU . 98.5 m -68.71 -32.78 72.82 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 115.28 -0.873 . . . . 0.0 111.92 -171.82 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 102' ' ' ALA . . . . . 0.46 ' HB1' ' HB3' ' A' ' 95' ' ' TRP . . . -69.65 -44.63 70.16 Favored 'General case' 0 C--N 1.324 -0.513 0 C-N-CA 120.651 -0.419 . . . . 0.0 110.202 178.822 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -65.66 -34.28 77.85 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 121.172 0.511 . . . . 0.0 110.406 178.5 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 104' ' ' ARG . . . . . 0.494 ' HG2' ' O ' ' A' ' 100' ' ' VAL . 3.4 mmp_? -70.3 -28.5 65.23 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.129 176.544 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 105' ' ' ALA . . . . . 0.504 ' HB1' ' HA ' ' A' ' 30' ' ' ILE . . . -89.43 -20.82 23.46 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.808 -0.633 . . . . 0.0 112.114 -175.549 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 110.4 64.35 0.52 Allowed Glycine 0 N--CA 1.447 -0.61 0 C-N-CA 120.95 -0.643 . . . . 0.0 111.681 -177.155 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -63.53 149.25 46.67 Favored 'General case' 0 C--N 1.328 -0.337 0 C-N-CA 122.848 0.459 . . . . 0.0 110.824 -176.823 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 108' ' ' ARG . . . . . 0.574 HH12 HG22 ' A' ' 26' ' ' ILE . 91.2 mtt180 . . . . . 0 C--O 1.247 0.944 0 CA-C-O 118.368 -0.825 . . . . 0.0 109.756 -173.016 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 2.7 m-20 . . . . . 0 N--CA 1.476 0.828 0 N-CA-C 109.31 -0.626 . . . . 0.0 109.31 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 18.7 t -78.27 64.2 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.312 -1.044 0 CA-C-N 114.84 -1.073 . . . . 0.0 110.318 -176.348 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 56.4 t -66.68 108.23 1.03 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.864 0 CA-C-N 115.093 -0.958 . . . . 0.0 110.484 173.869 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 11.5 t -100.48 149.2 6.2 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.569 0 N-CA-C 109.407 -0.59 . . . . 0.0 109.407 179.934 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . 0.443 ' HA ' ' HD3' ' A' ' 6' ' ' PRO . 70.0 p -111.2 122.11 38.65 Favored Pre-proline 0 C--N 1.314 -0.936 0 CA-C-O 121.187 0.518 . . . . 0.0 110.963 -179.63 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.453 ' C ' ' H ' ' A' ' 8' ' ' HIS . 6.3 Cg_exo -80.45 178.19 7.34 Favored 'Trans proline' 0 N--CA 1.453 -0.866 0 C-N-CA 123.275 2.65 . . . . 0.0 109.708 170.008 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -77.36 24.8 0.18 Allowed 'General case' 0 C--N 1.308 -1.203 0 CA-C-O 121.663 0.744 . . . . 0.0 111.074 -179.809 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . 0.453 ' H ' ' C ' ' A' ' 6' ' ' PRO . 37.3 t60 -78.41 -9.71 59.4 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 114.614 -1.176 . . . . 0.0 108.244 167.177 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 13.5 pt-20 -81.57 144.59 31.16 Favored 'General case' 0 N--CA 1.453 -0.315 0 N-CA-C 109.232 -0.655 . . . . 0.0 109.232 177.774 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -82.86 55.06 2.91 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-O 122.156 0.979 . . . . 0.0 110.534 -176.974 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 15.0 p -69.47 -19.42 23.24 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.039 0 CA-C-N 113.476 -1.693 . . . . 0.0 110.058 179.41 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 5.6 t 54.69 105.11 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.441 -0.901 0 CA-C-O 122.802 1.287 . . . . 0.0 112.783 178.968 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 38.4 ptt180 -74.02 159.58 32.49 Favored 'General case' 0 N--CA 1.432 -1.359 0 CA-C-N 113.665 -1.607 . . . . 0.0 108.999 175.78 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.5 t -76.99 158.27 5.3 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.682 0 CA-C-N 114.152 -1.385 . . . . 0.0 110.637 -173.915 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -116.03 64.32 0.33 Allowed Glycine 0 N--CA 1.428 -1.841 0 CA-C-N 114.271 -1.331 . . . . 0.0 110.554 177.675 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 2.2 m -62.71 -32.24 73.31 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-N 113.953 -1.124 . . . . 0.0 112.137 -176.612 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -80.74 117.52 68.28 Favored Pre-proline 0 C--N 1.311 -1.091 0 CA-C-N 114.619 -1.173 . . . . 0.0 111.309 -176.156 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 26.0 Cg_exo -64.24 172.98 5.61 Favored 'Trans proline' 0 N--CA 1.453 -0.862 0 C-N-CA 123.597 2.865 . . . . 0.0 111.159 171.151 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 121.53 51.25 0.24 Allowed Glycine 0 C--N 1.297 -1.616 0 N-CA-C 109.804 -1.319 . . . . 0.0 109.804 -172.051 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 22.8 m -66.43 -33.36 75.53 Favored 'General case' 0 C--N 1.316 -0.857 0 CA-C-N 114.445 -0.878 . . . . 0.0 110.835 -178.426 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 2.2 mp0 46.65 84.64 0.03 OUTLIER 'General case' 0 N--CA 1.447 -0.579 0 CA-C-O 121.886 0.85 . . . . 0.0 110.687 -168.396 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 48.2 t -74.55 119.75 78.15 Favored Pre-proline 0 C--N 1.31 -1.11 0 CA-C-N 114.151 -1.386 . . . . 0.0 109.871 -175.024 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_exo -54.75 128.63 31.17 Favored 'Trans proline' 0 N--CA 1.453 -0.874 0 C-N-CA 122.394 2.063 . . . . 0.0 110.912 177.268 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 9.6 Cg_endo -54.57 138.83 75.57 Favored 'Trans proline' 0 N--CA 1.451 -0.974 0 C-N-CA 122.752 2.301 . . . . 0.0 112.332 -175.166 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.488 ' HB ' HG21 ' A' ' 83' ' ' ILE . 38.1 t -85.4 144.86 8.77 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.156 0 CA-C-N 114.389 -1.278 . . . . 0.0 108.999 -178.563 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 41.2 mm -60.55 -24.43 31.59 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 CA-C-N 115.246 -0.888 . . . . 0.0 112.026 -173.222 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.4 ' O ' HG12 ' A' ' 30' ' ' ILE . 4.3 m-20 -95.77 2.81 54.07 Favored 'General case' 0 CA--C 1.507 -0.679 0 CA-C-O 121.742 0.782 . . . . 0.0 109.605 -179.03 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -65.84 -9.54 46.57 Favored Glycine 0 N--CA 1.441 -0.969 0 CA-C-N 114.868 -1.06 . . . . 0.0 110.721 177.381 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 21.8 m -76.93 -41.5 43.16 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-O 121.571 0.7 . . . . 0.0 109.387 175.181 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.553 ' HA ' ' HB1' ' A' ' 105' ' ' ALA . 0.8 OUTLIER -66.68 -38.81 82.34 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.64 0 N-CA-C 107.645 -1.243 . . . . 0.0 107.645 177.223 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' TRP . . . . . 0.485 ' CD1' HG23 ' A' ' 83' ' ' ILE . 36.8 m95 -70.91 -35.75 72.42 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 114.627 -1.169 . . . . 0.0 110.894 -177.922 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.442 ' HB2' HH21 ' A' ' 79' ' ' ARG . 1.9 t70 -72.53 -36.76 68.4 Favored 'General case' 0 N--CA 1.449 -0.509 0 CA-C-N 116.387 -0.37 . . . . 0.0 110.338 177.771 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . 0.489 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -70.19 -35.36 73.9 Favored 'General case' 0 N--CA 1.448 -0.552 0 C-N-CA 120.627 -0.429 . . . . 0.0 110.392 177.96 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . 0.44 HG13 ' O ' ' A' ' 30' ' ' ILE . 64.5 mt -67.13 -43.54 88.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.312 174.05 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . 0.521 ' HA ' ' O ' ' A' ' 54' ' ' GLY . . . -59.59 -35.02 73.47 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 121.313 0.578 . . . . 0.0 110.15 175.973 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . 0.422 ' HA2' ' N ' ' A' ' 41' ' ' GLY . . . -77.62 -14.97 81.88 Favored Glycine 0 N--CA 1.448 -0.564 0 CA-C-N 115.497 -0.774 . . . . 0.0 111.873 178.409 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 36.8 t -95.92 -48.01 5.89 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-O 120.737 0.303 . . . . 0.0 111.387 -177.032 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . 0.481 ' HG2' ' SG ' ' A' ' 101' ' ' CYS . 8.5 mm-40 -86.91 -34.2 19.46 Favored 'General case' 0 CA--C 1.511 -0.541 0 CA-C-O 121.077 0.465 . . . . 0.0 110.17 -175.538 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -107.94 -12.47 15.16 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.613 -0.721 . . . . 0.0 112.064 -174.089 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 76.31 16.65 80.55 Favored Glycine 0 N--CA 1.449 -0.461 0 N-CA-C 109.957 -1.257 . . . . 0.0 109.957 -176.767 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . 0.422 ' N ' ' HA2' ' A' ' 36' ' ' GLY . . . 82.98 59.91 2.12 Favored Glycine 0 N--CA 1.434 -1.475 0 CA-C-N 113.944 -1.128 . . . . 0.0 111.807 -176.904 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . 0.849 ' HB3' ' HB ' ' A' ' 45' ' ' ILE . 3.4 m120 -146.1 96.02 2.72 Favored 'General case' 0 C--N 1.324 -0.515 0 N-CA-C 109.223 -0.658 . . . . 0.0 109.223 -178.893 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' TRP . . . . . 0.695 ' CE2' ' HG2' ' A' ' 79' ' ' ARG . 52.5 m95 -78.88 -14.39 59.26 Favored 'General case' 0 C--N 1.314 -0.975 0 CA-C-N 115.711 -0.677 . . . . 0.0 109.803 -177.941 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . 0.414 ' HA ' ' HB2' ' A' ' 75' ' ' ASP . . . -102.48 7.97 40.12 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 115.271 -0.877 . . . . 0.0 111.289 -179.692 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.849 ' HB ' ' HB3' ' A' ' 42' ' ' ASN . 8.2 tt -74.18 145.16 11.62 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.708 0 CA-C-O 121.401 0.619 . . . . 0.0 110.984 -177.182 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 17.4 t-20 -141.5 96.19 2.94 Favored 'General case' 0 C--N 1.309 -1.183 0 N-CA-C 109.099 -0.704 . . . . 0.0 109.099 178.953 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 19.7 p -68.61 -21.3 64.51 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 115.029 -0.987 . . . . 0.0 111.058 -177.486 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 88.06 18.22 56.27 Favored Glycine 0 N--CA 1.441 -1.001 0 N-CA-C 110.373 -1.091 . . . . 0.0 110.373 179.44 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 92.2 m-20 -97.37 10.23 40.2 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 121.092 0.472 . . . . 0.0 111.347 -174.621 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . 0.406 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 90.96 -11.6 71.59 Favored Glycine 0 N--CA 1.443 -0.842 0 N-CA-C 110.853 -0.899 . . . . 0.0 110.853 -178.003 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' TYR . . . . . 0.634 ' HA ' ' HA ' ' A' ' 58' ' ' ASP . 0.7 OUTLIER -109.58 152.36 25.61 Favored 'General case' 0 CA--C 1.509 -0.624 0 N-CA-C 108.092 -1.077 . . . . 0.0 108.092 178.026 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' TYR . . . . . 0.78 ' O ' ' HA ' ' A' ' 56' ' ' GLN . 18.4 m-85 -112.81 169.93 8.56 Favored 'General case' 0 C--N 1.31 -1.12 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.698 -169.763 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.441 ' CA ' HG22 ' A' ' 45' ' ' ILE . . . -66.08 -171.79 4.07 Favored Glycine 0 N--CA 1.451 -0.361 0 N-CA-C 115.025 0.77 . . . . 0.0 115.025 -168.353 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.639 ' CA ' ' HA ' ' A' ' 43' ' ' TRP . . . 75.27 -101.97 1.42 Allowed Glycine 0 N--CA 1.443 -0.847 0 CA-C-N 114.738 -0.731 . . . . 0.0 112.177 178.475 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.551 HG12 ' HE1' ' A' ' 98' ' ' TRP . 2.3 t -84.3 -3.54 7.95 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 CA-C-O 121.606 0.717 . . . . 0.0 109.541 179.409 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' GLN . . . . . 0.78 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 0.0 OUTLIER 57.93 46.83 16.04 Favored 'General case' 0 N--CA 1.463 0.179 0 CA-C-N 114.432 -1.258 . . . . 0.0 113.556 170.256 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . 0.507 ' CE1' ' HB ' ' A' ' 55' ' ' VAL . 0.3 OUTLIER -117.15 166.61 12.03 Favored 'General case' 0 C--N 1.323 -0.581 0 C-N-CA 119.597 -0.841 . . . . 0.0 111.956 175.069 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.634 ' HA ' ' HA ' ' A' ' 51' ' ' TYR . 7.2 p-10 -74.8 162.89 28.25 Favored 'General case' 0 CA--C 1.514 -0.411 0 CA-C-N 115.444 -0.798 . . . . 0.0 113.071 -167.055 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.531 ' HB2' ' CE1' ' A' ' 52' ' ' TYR . 4.5 tp-100 -63.06 -35.36 79.99 Favored 'General case' 0 N--CA 1.448 -0.567 0 CA-C-N 114.318 -1.31 . . . . 0.0 111.069 179.623 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -65.15 -49.69 60.75 Favored Glycine 0 C--N 1.312 -0.756 0 CA-C-N 115.368 -0.833 . . . . 0.0 111.437 -178.067 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 91.5 m -65.9 -42.6 90.01 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-O 120.757 0.313 . . . . 0.0 110.986 176.375 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' TRP . . . . . 0.464 ' CH2' ' HA ' ' A' ' 74' ' ' ALA . 60.3 t-105 -56.26 -47.72 77.98 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 121.549 0.69 . . . . 0.0 109.656 177.353 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 5.1 tp10 -66.13 -34.78 78.83 Favored 'General case' 0 C--N 1.318 -0.802 0 CA-C-N 114.818 -1.083 . . . . 0.0 110.505 179.002 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -63.58 -42.54 98.29 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.17 -177.439 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . 0.73 ' HB2' HG13 ' A' ' 85' ' ' VAL . 27.4 m-80 -81.09 -9.99 59.74 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.927 0.394 . . . . 0.0 110.313 176.872 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . 0.472 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 87.69 51.83 3.15 Favored Glycine 0 C--O 1.225 -0.447 0 CA-C-N 115.888 -0.596 . . . . 0.0 112.429 175.357 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.581 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -80.14 -23.77 60.68 Favored Glycine 0 N--CA 1.442 -0.956 0 C-N-CA 120.946 -0.645 . . . . 0.0 112.666 -176.604 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 1.033 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 7.2 mp -61.25 -17.66 54.48 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 112.877 0.695 . . . . 0.0 112.877 -172.751 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . 0.472 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 17.5 ptp180 -70.59 -34.75 72.5 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-O 121.154 0.502 . . . . 0.0 109.775 174.724 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' TYR . . . . . 0.661 ' HB3' ' HB3' ' A' ' 81' ' ' GLU . 54.1 m-85 -80.94 -34.59 33.18 Favored 'General case' 0 N--CA 1.444 -0.77 0 N-CA-C 107.551 -1.278 . . . . 0.0 107.551 179.221 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.609 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 166.32 127.14 0.03 OUTLIER Pre-proline 0 N--CA 1.445 -0.722 0 CA-C-N 112.755 -2.02 . . . . 0.0 106.995 -178.096 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' PRO . . . . . 1.033 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 24.4 Cg_exo -55.91 -7.18 1.49 Allowed 'Trans proline' 0 C--N 1.334 -0.227 0 C-N-CA 122.958 2.439 . . . . 0.0 113.821 -177.68 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' ARG . . . . . 0.504 ' HB2' ' CD2' ' A' ' 52' ' ' TYR . 11.4 ptm180 -144.58 137.12 26.53 Favored 'General case' 0 C--N 1.314 -0.935 0 N-CA-C 108.987 -0.746 . . . . 0.0 108.987 178.059 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . 0.517 ' HB3' ' HB2' ' A' ' 52' ' ' TYR . . . -55.78 -31.45 62.63 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 114.935 -1.029 . . . . 0.0 112.614 -175.993 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . 0.639 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 6.4 p-10 -81.2 -10.02 59.69 Favored 'General case' 0 C--N 1.328 -0.34 0 C-N-CA 120.426 -0.51 . . . . 0.0 111.312 -174.443 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 67.9 tp -93.94 -27.7 16.22 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-O 121.798 0.808 . . . . 0.0 108.921 172.801 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . 0.779 ' HB1' ' HB2' ' A' ' 81' ' ' GLU . . . -79.16 159.38 27.44 Favored 'General case' 0 N--CA 1.441 -0.909 0 CA-C-N 114.723 -1.126 . . . . 0.0 109.863 174.779 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 70.6 p -100.91 -174.59 2.66 Favored 'General case' 0 C--N 1.313 -0.983 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.932 -176.818 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . 0.695 ' HG2' ' CE2' ' A' ' 43' ' ' TRP . 77.0 mtp180 -51.02 -53.53 32.65 Favored 'General case' 0 CA--C 1.514 -0.419 0 CA-C-O 120.893 0.378 . . . . 0.0 110.702 -178.675 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 1.7 pm0 -63.18 -36.11 82.53 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-N 115.463 -0.789 . . . . 0.0 111.804 -175.016 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 81' ' ' GLU . . . . . 0.779 ' HB2' ' HB1' ' A' ' 77' ' ' ALA . 3.5 mm-40 -66.75 -50.7 61.88 Favored 'General case' 0 CA--C 1.516 -0.356 0 CA-C-O 121.041 0.448 . . . . 0.0 110.104 178.827 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 82' ' ' GLN . . . . . 0.586 ' HB2' ' HZ3' ' A' ' 43' ' ' TRP . 48.0 mt-30 -64.68 -35.81 82.23 Favored 'General case' 0 CA--C 1.511 -0.541 0 CA-C-N 115.685 -0.688 . . . . 0.0 110.062 -178.452 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.667 ' O ' ' HG2' ' A' ' 87' ' ' GLU . 53.1 mt -59.23 -48.87 85.44 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.812 0 CA-C-N 115.45 -0.796 . . . . 0.0 109.265 174.199 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . 0.538 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -61.51 -42.24 98.52 Favored 'General case' 0 C--O 1.239 0.517 0 CA-C-O 121.083 0.468 . . . . 0.0 111.615 -177.682 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.73 HG13 ' HB2' ' A' ' 65' ' ' ASN . 69.5 t -67.85 -48.5 75.17 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.85 179.494 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . 0.435 ' HB1' ' CH2' ' A' ' 31' ' ' TRP . . . -60.74 -29.12 69.19 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.543 174.594 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 87' ' ' GLU . . . . . 0.667 ' HG2' ' O ' ' A' ' 83' ' ' ILE . 14.8 mm-40 -59.75 -44.31 93.87 Favored 'General case' 0 N--CA 1.469 0.477 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.494 -179.797 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.573 ' O ' ' HG3' ' A' ' 92' ' ' ARG . 61.7 t -62.94 -40.49 89.12 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.44 0 N-CA-C 109.712 -0.477 . . . . 0.0 109.712 176.641 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . 0.859 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 1.0 OUTLIER -70.03 -48.9 56.1 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.958 -0.565 . . . . 0.0 111.484 -175.89 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . 0.625 ' HA ' ' OE1' ' A' ' 93' ' ' GLN . 2.3 ptt180 -60.86 -33.63 73.38 Favored 'General case' 0 CA--C 1.519 -0.24 0 CA-C-N 116.025 -0.534 . . . . 0.0 111.638 -173.539 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . 0.571 ' HG ' ' O ' ' A' ' 88' ' ' VAL . 4.7 pp -71.42 -21.84 61.93 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.588 -175.188 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . 0.573 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 22.0 mtm180 -88.02 -52.39 5.28 Favored 'General case' 0 CA--C 1.509 -0.615 0 CA-C-O 121.247 0.546 . . . . 0.0 110.689 -175.8 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 93' ' ' GLN . . . . . 0.625 ' OE1' ' HA ' ' A' ' 90' ' ' ARG . 0.0 OUTLIER -95.3 -21.83 18.16 Favored 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 113.048 0.758 . . . . 0.0 113.048 -171.356 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 88.1 42.34 5.97 Favored Glycine 0 CA--C 1.506 -0.492 0 C-N-CA 120.488 -0.863 . . . . 0.0 111.97 172.251 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 95' ' ' TRP . . . . . 0.417 ' HA ' ' HE3' ' A' ' 98' ' ' TRP . 6.7 m95 62.7 12.15 5.4 Favored 'General case' 0 C--O 1.22 -0.489 0 C-N-CA 123.587 0.755 . . . . 0.0 109.801 -179.347 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -74.14 -20.0 79.73 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 121.172 -0.537 . . . . 0.0 112.458 179.46 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -78.58 -27.23 45.68 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 121.157 0.503 . . . . 0.0 109.872 176.628 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 98' ' ' TRP . . . . . 0.859 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 27.0 m-90 -101.04 103.65 26.9 Favored Pre-proline 0 C--N 1.324 -0.53 0 N-CA-C 108.86 -0.793 . . . . 0.0 108.86 176.399 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . 0.404 ' HB2' ' H ' ' A' ' 100' ' ' VAL . 14.7 Cg_exo -74.77 -88.54 0.0 OUTLIER 'Trans proline' 0 CA--C 1.53 0.28 0 C-N-CA 123.034 2.489 . . . . 0.0 114.872 -170.894 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . 0.404 ' H ' ' HB2' ' A' ' 99' ' ' PRO . 61.1 t -70.59 -29.91 40.29 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 CA-C-O 121.555 0.693 . . . . 0.0 110.565 -171.966 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 101' ' ' CYS . . . . . 0.481 ' SG ' ' HG2' ' A' ' 38' ' ' GLU . 85.0 m -83.29 -32.48 26.33 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-N 115.14 -0.936 . . . . 0.0 112.021 -169.012 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -68.11 -43.01 79.42 Favored 'General case' 0 C--N 1.327 -0.393 0 C-N-CA 120.47 -0.492 . . . . 0.0 110.098 177.493 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -60.58 -36.12 77.74 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 121.194 0.521 . . . . 0.0 110.739 177.515 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 35.5 mtp180 -73.03 -38.83 66.41 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.702 -0.681 . . . . 0.0 111.183 177.379 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 105' ' ' ALA . . . . . 0.553 ' HB1' ' HA ' ' A' ' 30' ' ' ILE . . . -80.79 -22.42 40.1 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 115.632 -0.713 . . . . 0.0 112.567 -173.69 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 116.57 62.44 0.33 Allowed Glycine 0 CA--C 1.521 0.415 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.31 -178.623 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -63.25 149.46 45.51 Favored 'General case' 0 C--N 1.328 -0.337 0 C-N-CA 122.927 0.491 . . . . 0.0 110.748 179.417 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 72.0 mtp180 . . . . . 0 C--O 1.247 0.937 0 CA-C-O 118.247 -0.882 . . . . 0.0 111.089 -170.546 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 89.1 m-20 . . . . . 0 N--CA 1.476 0.842 0 CA-C-O 121.619 0.723 . . . . 0.0 110.697 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 9.1 p -95.55 -3.88 10.4 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.073 0 CA-C-N 114.769 -1.105 . . . . 0.0 109.811 178.384 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 60.1 t -59.29 108.01 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 CA-C-N 115.19 -0.913 . . . . 0.0 110.698 176.936 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 6.7 p -84.07 147.79 5.45 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.557 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.64 179.246 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 9.7 t -98.7 123.96 47.86 Favored Pre-proline 0 C--N 1.311 -1.091 0 CA-C-N 115.437 -0.801 . . . . 0.0 110.083 179.313 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo -84.38 118.06 2.19 Favored 'Trans proline' 0 N--CA 1.448 -1.197 0 C-N-CA 123.278 2.652 . . . . 0.0 112.07 -176.443 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -79.21 81.11 5.51 Favored 'General case' 0 C--N 1.3 -1.543 0 CA-C-N 114.087 -1.415 . . . . 0.0 110.062 175.699 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 44.9 t-80 -79.09 -10.5 59.84 Favored 'General case' 0 C--N 1.313 -0.999 0 CA-C-N 114.387 -1.279 . . . . 0.0 108.028 174.726 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 8.4 mt-10 -87.13 123.05 31.76 Favored 'General case' 0 N--CA 1.448 -0.56 0 CA-C-N 114.67 -1.15 . . . . 0.0 110.226 176.748 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -122.19 56.08 1.11 Allowed 'General case' 0 C--N 1.319 -0.734 0 CA-C-O 122.09 0.948 . . . . 0.0 110.282 178.442 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 62.0 t -77.62 -51.44 18.19 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.091 0 CA-C-N 114.179 -1.373 . . . . 0.0 109.222 174.732 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 7.3 p 23.02 74.76 0.01 OUTLIER 'Isoleucine or valine' 0 C--O 1.234 0.261 0 C-N-CA 125.601 1.56 . . . . 0.0 114.125 176.778 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 56.1 mtm180 -146.66 109.96 4.78 Favored 'General case' 0 C--N 1.304 -1.392 0 CA-C-N 113.792 -1.549 . . . . 0.0 111.54 177.421 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 3.0 t -122.67 166.33 17.56 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.136 0 CA-C-N 114.537 -1.21 . . . . 0.0 108.336 177.734 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 78.02 61.88 2.45 Favored Glycine 0 C--N 1.304 -1.195 0 N-CA-C 110.352 -1.099 . . . . 0.0 110.352 177.474 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.542 ' O ' ' HD3' ' A' ' 18' ' ' PRO . 85.2 m -79.08 -23.56 44.08 Favored 'General case' 0 N--CA 1.438 -1.067 0 CA-C-N 114.299 -0.95 . . . . 0.0 111.391 -172.082 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . 0.764 ' HD2' ' O ' ' A' ' 17' ' ' LYS . 0.0 OUTLIER -86.92 110.34 31.94 Favored Pre-proline 0 C--N 1.318 -0.773 0 CA-C-O 121.853 0.835 . . . . 0.0 112.275 -179.478 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . 0.542 ' HD3' ' O ' ' A' ' 16' ' ' THR . 1.9 Cg_endo -84.71 172.11 9.21 Favored 'Trans proline' 0 N--CA 1.45 -1.042 0 C-N-CA 123.373 2.715 . . . . 0.0 111.648 173.744 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 92.16 33.17 7.85 Favored Glycine 0 C--N 1.309 -0.951 0 CA-C-N 114.708 -1.133 . . . . 0.0 111.823 179.656 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 90.6 m -71.29 -29.94 65.65 Favored 'General case' 0 C--N 1.311 -1.082 0 CA-C-N 114.568 -0.816 . . . . 0.0 109.858 176.048 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 42.7 mt-10 -138.44 140.01 39.11 Favored 'General case' 0 N--CA 1.439 -0.989 0 N-CA-C 107.524 -1.287 . . . . 0.0 107.524 179.228 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.46 ' HA ' ' HD3' ' A' ' 23' ' ' PRO . 41.4 t -71.84 117.59 59.2 Favored Pre-proline 0 C--N 1.317 -0.846 0 O-C-N 123.389 0.431 . . . . 0.0 110.189 -177.374 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.46 ' HD3' ' HA ' ' A' ' 22' ' ' VAL . 47.7 Cg_exo -56.98 126.5 22.43 Favored 'Trans proline' 0 N--CA 1.458 -0.58 0 C-N-CA 123.235 2.623 . . . . 0.0 113.583 -173.12 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . 0.845 ' HB3' HH22 ' A' ' 79' ' ' ARG . 35.3 Cg_endo -65.34 161.25 38.69 Favored 'Trans proline' 0 N--CA 1.45 -1.079 0 C-N-CA 123.834 3.022 . . . . 0.0 113.079 172.951 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.599 ' HB ' HD13 ' A' ' 83' ' ' ILE . 38.2 t -80.25 153.54 4.48 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.05 0 N-CA-C 107.466 -1.309 . . . . 0.0 107.466 168.641 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 40.2 mm -55.6 -32.73 31.41 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.692 0 N-CA-C 113.634 0.975 . . . . 0.0 113.634 -162.25 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.586 ' O ' HG12 ' A' ' 30' ' ' ILE . 6.2 m-20 -105.1 -0.02 27.05 Favored 'General case' 0 C--N 1.312 -1.024 0 CA-C-O 121.909 0.861 . . . . 0.0 110.057 179.371 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . 0.576 ' HA2' ' HB2' ' A' ' 31' ' ' TRP . . . -72.52 0.94 39.28 Favored Glycine 0 N--CA 1.436 -1.319 0 CA-C-N 114.464 -1.244 . . . . 0.0 111.053 178.77 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 13.8 m -76.41 -39.13 54.45 Favored 'General case' 0 C--N 1.32 -0.716 0 N-CA-C 108.892 -0.781 . . . . 0.0 108.892 173.458 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.586 HG12 ' O ' ' A' ' 27' ' ' ASP . 0.2 OUTLIER -71.99 -39.1 66.01 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 CA-C-N 114.327 -1.306 . . . . 0.0 107.527 176.317 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' TRP . . . . . 0.576 ' HB2' ' HA2' ' A' ' 28' ' ' GLY . 22.9 m95 -70.69 -35.56 72.84 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-N 114.483 -1.235 . . . . 0.0 110.333 -176.443 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.73 ' HB2' HH21 ' A' ' 79' ' ' ARG . 7.0 t70 -76.87 -32.24 57.34 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.458 179.7 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -70.45 -37.73 74.36 Favored 'General case' 0 N--CA 1.447 -0.601 0 C-N-CA 120.729 -0.388 . . . . 0.0 110.27 175.051 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . 0.47 HG13 ' O ' ' A' ' 30' ' ' ILE . 62.0 mt -64.89 -44.4 96.22 Favored 'Isoleucine or valine' 0 C--O 1.235 0.293 0 CA-C-O 120.954 0.407 . . . . 0.0 110.324 174.535 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . 0.498 ' O ' ' HB3' ' A' ' 39' ' ' ALA . . . -57.84 -39.25 77.27 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.236 0.541 . . . . 0.0 110.032 175.127 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -74.07 -9.01 79.85 Favored Glycine 0 N--CA 1.452 -0.299 0 CA-C-N 115.568 -0.742 . . . . 0.0 111.761 179.736 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 44.8 t -97.22 -62.85 1.19 Allowed 'General case' 0 N--CA 1.446 -0.648 0 CA-C-N 115.554 -0.323 . . . . 0.0 111.077 -178.068 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . 0.879 ' HG3' ' SG ' ' A' ' 101' ' ' CYS . 27.3 mt-10 -89.36 -27.32 20.56 Favored 'General case' 0 C--N 1.328 -0.357 0 N-CA-C 111.778 0.288 . . . . 0.0 111.778 -174.181 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . 0.498 ' HB3' ' O ' ' A' ' 35' ' ' ALA . . . -95.14 -17.11 22.08 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 121.015 0.435 . . . . 0.0 112.021 -176.457 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 81.54 14.05 78.99 Favored Glycine 0 N--CA 1.447 -0.599 0 N-CA-C 109.709 -1.357 . . . . 0.0 109.709 -174.622 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 77.52 57.2 3.66 Favored Glycine 0 N--CA 1.438 -1.203 0 CA-C-N 114.236 -0.982 . . . . 0.0 112.656 179.874 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 55.9 t30 -150.73 127.5 10.96 Favored 'General case' 0 CA--C 1.503 -0.853 0 N-CA-C 109.201 -0.666 . . . . 0.0 109.201 178.19 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' TRP . . . . . 0.763 ' HA ' ' N ' ' A' ' 54' ' ' GLY . 26.2 m95 -100.28 -2.02 34.79 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-N 115.437 -0.801 . . . . 0.0 110.099 -174.167 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -112.19 8.77 19.98 Favored 'General case' 0 C--N 1.318 -0.772 0 CA-C-N 115.052 -0.977 . . . . 0.0 111.021 178.574 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.611 HG22 ' HA2' ' A' ' 53' ' ' GLY . 12.5 tt -74.3 143.89 13.01 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.76 0 CA-C-O 120.988 0.423 . . . . 0.0 110.176 -178.784 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 13.3 t-20 -149.63 85.21 1.43 Allowed 'General case' 0 C--N 1.314 -0.939 0 CA-C-O 121.299 0.571 . . . . 0.0 110.302 -177.793 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -69.89 -20.03 63.4 Favored 'General case' 0 N--CA 1.445 -0.7 0 CA-C-N 115.476 -0.784 . . . . 0.0 111.058 177.88 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 92.05 21.56 32.74 Favored Glycine 0 N--CA 1.444 -0.795 0 C-N-CA 120.909 -0.662 . . . . 0.0 111.698 174.578 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 4.2 p-10 -94.97 14.38 21.91 Favored 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 112.082 0.401 . . . . 0.0 112.082 -175.275 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . 0.507 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 92.39 -13.92 66.01 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 121.32 -0.467 . . . . 0.0 112.171 176.5 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' TYR . . . . . 0.628 ' CE1' ' HB2' ' A' ' 58' ' ' ASP . 0.3 OUTLIER -110.0 155.29 22.0 Favored 'General case' 0 C--N 1.323 -0.546 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 173.505 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' TYR . . . . . 0.726 ' O ' ' HA ' ' A' ' 56' ' ' GLN . 63.5 m-85 -119.38 171.05 8.6 Favored 'General case' 0 C--N 1.312 -1.06 0 N-CA-C 112.657 0.614 . . . . 0.0 112.657 -168.467 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.611 ' HA2' HG22 ' A' ' 45' ' ' ILE . . . -53.87 163.19 3.07 Favored Glycine 0 N--CA 1.449 -0.44 0 CA-C-N 115.356 -0.838 . . . . 0.0 114.09 -175.527 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.763 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 90.27 -109.51 3.66 Favored Glycine 0 N--CA 1.442 -0.921 0 C-N-CA 121.05 -0.595 . . . . 0.0 112.397 178.738 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.506 HG12 ' HE1' ' A' ' 98' ' ' TRP . 2.5 t -83.63 0.7 4.58 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-O 121.968 0.89 . . . . 0.0 109.784 -177.065 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' GLN . . . . . 0.726 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 0.0 OUTLIER 53.97 50.18 17.32 Favored 'General case' 0 N--CA 1.449 -0.495 0 CA-C-N 113.826 -1.534 . . . . 0.0 112.729 170.679 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . 0.445 ' CD1' ' HB ' ' A' ' 55' ' ' VAL . 2.5 p90 -119.04 166.63 12.65 Favored 'General case' 0 C--N 1.323 -0.564 0 C-N-CA 119.304 -0.958 . . . . 0.0 111.914 174.837 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.628 ' HB2' ' CE1' ' A' ' 51' ' ' TYR . 0.0 OUTLIER -75.75 157.46 33.49 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 114.32 -1.309 . . . . 0.0 113.777 -162.071 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.492 ' HB2' ' HE1' ' A' ' 52' ' ' TYR . 22.1 tp60 -53.34 -44.25 68.33 Favored 'General case' 0 N--CA 1.441 -0.9 0 CA-C-N 114.171 -1.377 . . . . 0.0 111.463 179.243 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -68.49 -49.05 47.16 Favored Glycine 0 C--O 1.22 -0.735 0 CA-C-N 115.325 -0.852 . . . . 0.0 112.396 -176.106 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 46.3 m -60.77 -40.61 93.15 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-O 121.552 0.691 . . . . 0.0 110.519 179.098 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' TRP . . . . . 0.484 ' CZ3' ' HA ' ' A' ' 82' ' ' GLN . 50.6 t-105 -61.98 -48.86 78.45 Favored 'General case' 0 C--N 1.318 -0.794 0 CA-C-N 114.845 -1.071 . . . . 0.0 109.863 175.279 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . 0.599 ' HB2' HD11 ' A' ' 68' ' ' LEU . 0.0 OUTLIER -67.97 -36.39 79.97 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.733 -0.667 . . . . 0.0 110.353 -176.801 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . 0.48 ' N ' ' HG3' ' A' ' 63' ' ' GLU . . . -66.16 -41.05 90.89 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.433 -0.803 . . . . 0.0 111.28 -175.972 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . 0.459 ' HB3' ' HB ' ' A' ' 88' ' ' VAL . 84.5 m-20 -84.09 -3.61 58.2 Favored 'General case' 0 N--CA 1.446 -0.669 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.61 176.906 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . 0.497 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 85.74 46.92 5.27 Favored Glycine 0 N--CA 1.448 -0.532 0 CA-C-N 115.573 -0.74 . . . . 0.0 113.107 171.11 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.627 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -80.28 -16.46 76.23 Favored Glycine 0 N--CA 1.443 -0.899 0 C-N-CA 120.672 -0.775 . . . . 0.0 111.828 179.918 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.662 ' HA ' ' HA ' ' A' ' 72' ' ' PRO . 14.6 mt -64.74 -22.74 67.05 Favored 'General case' 0 C--N 1.32 -0.707 0 C-N-CA 122.817 0.447 . . . . 0.0 111.363 -171.332 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . 0.497 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 14.9 ptm180 -70.85 -32.49 69.53 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.311 176.138 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' TYR . . . . . 0.675 ' HB3' ' HB3' ' A' ' 81' ' ' GLU . 58.9 m-85 -80.09 -33.33 38.88 Favored 'General case' 0 N--CA 1.445 -0.697 0 N-CA-C 107.217 -1.401 . . . . 0.0 107.217 178.19 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.673 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 165.94 127.12 0.03 OUTLIER Pre-proline 0 CA--C 1.511 -0.538 0 CA-C-N 112.447 -2.161 . . . . 0.0 107.122 178.693 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' PRO . . . . . 0.662 ' HA ' ' HA ' ' A' ' 68' ' ' LEU . 15.5 Cg_exo -56.2 -0.8 0.23 Allowed 'Trans proline' 0 CA--C 1.531 0.369 0 C-N-CA 122.961 2.441 . . . . 0.0 114.231 -177.849 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 13.0 ptm180 -150.82 142.46 23.62 Favored 'General case' 0 C--N 1.317 -0.839 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 172.776 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . 0.561 ' HB3' ' HB2' ' A' ' 52' ' ' TYR . . . -58.69 -30.34 67.33 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.332 -0.849 . . . . 0.0 112.89 -175.899 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . 0.459 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 15.7 p-10 -87.33 5.54 37.98 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 121.269 0.557 . . . . 0.0 111.129 -176.232 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.436 ' HB3' ' HB1' ' A' ' 71' ' ' ALA . 65.2 tp -105.67 -30.17 9.64 Favored 'General case' 0 C--N 1.319 -0.72 0 N-CA-C 108.359 -0.978 . . . . 0.0 108.359 168.967 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . 0.706 ' HB1' ' HB2' ' A' ' 81' ' ' GLU . . . -79.47 164.48 23.91 Favored 'General case' 0 N--CA 1.444 -0.739 0 CA-C-N 114.446 -1.252 . . . . 0.0 110.183 175.933 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . 0.461 ' OG1' ' HG2' ' A' ' 81' ' ' GLU . 65.9 p -99.97 -178.89 3.99 Favored 'General case' 0 C--N 1.313 -0.994 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.414 -177.042 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . 0.845 HH22 ' HB3' ' A' ' 24' ' ' PRO . 47.2 mtp180 -52.71 -53.67 44.32 Favored 'General case' 0 CA--C 1.516 -0.342 0 CA-C-O 121.045 0.45 . . . . 0.0 110.374 -178.536 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 80' ' ' GLU . . . . . 0.61 ' HA ' HD12 ' A' ' 83' ' ' ILE . 2.7 pm0 -60.51 -32.64 71.65 Favored 'General case' 0 C--N 1.317 -0.816 0 CA-C-N 115.083 -0.962 . . . . 0.0 112.254 -176.818 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 81' ' ' GLU . . . . . 0.706 ' HB2' ' HB1' ' A' ' 77' ' ' ALA . 5.4 mm-40 -70.64 -50.41 37.13 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-O 120.877 0.37 . . . . 0.0 110.031 177.477 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 82' ' ' GLN . . . . . 0.484 ' HA ' ' CZ3' ' A' ' 62' ' ' TRP . 51.2 mt-30 -61.11 -35.61 77.49 Favored 'General case' 0 CA--C 1.507 -0.69 0 CA-C-N 115.582 -0.736 . . . . 0.0 109.631 179.833 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.687 ' O ' ' HG2' ' A' ' 87' ' ' GLU . 39.2 mt -59.55 -49.16 84.69 Favored 'Isoleucine or valine' 0 C--O 1.211 -0.952 0 CA-C-N 114.714 -1.13 . . . . 0.0 109.763 174.829 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . 0.616 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -61.25 -41.58 97.15 Favored 'General case' 0 C--O 1.236 0.365 0 CA-C-O 121.403 0.62 . . . . 0.0 111.579 -177.606 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.465 HG23 ' O ' ' A' ' 81' ' ' GLU . 34.7 t -69.2 -47.85 71.89 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.794 178.528 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -58.22 -29.44 65.72 Favored 'General case' 0 N--CA 1.45 -0.446 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.364 172.99 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 87' ' ' GLU . . . . . 0.687 ' HG2' ' O ' ' A' ' 83' ' ' ILE . 14.5 mm-40 -60.03 -44.62 94.5 Favored 'General case' 0 N--CA 1.469 0.497 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.111 179.277 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.638 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 60.8 t -63.56 -47.71 90.21 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.437 0 N-CA-C 109.473 -0.566 . . . . 0.0 109.473 174.243 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . 0.898 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 0.7 OUTLIER -59.21 -49.86 76.22 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-N 115.696 -0.684 . . . . 0.0 111.387 -176.508 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . 0.509 ' HA ' ' HZ3' ' A' ' 98' ' ' TRP . 27.0 ptt85 -60.51 -34.97 74.87 Favored 'General case' 0 C--O 1.223 -0.314 0 CA-C-N 116.723 -0.217 . . . . 0.0 111.232 -172.477 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . 0.638 ' HG ' ' O ' ' A' ' 88' ' ' VAL . 4.5 pp -74.71 -22.82 58.63 Favored 'General case' 0 C--N 1.318 -0.798 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.52 -173.488 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . 0.605 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 15.6 mtm180 -80.82 -52.71 7.19 Favored 'General case' 0 CA--C 1.505 -0.773 0 CA-C-O 121.13 0.491 . . . . 0.0 109.877 -176.04 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 4.9 pm0 -103.75 -15.36 15.76 Favored 'General case' 0 N--CA 1.445 -0.681 0 C-N-CA 119.645 -0.822 . . . . 0.0 113.022 -173.411 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 87.33 45.12 5.39 Favored Glycine 0 CA--C 1.498 -1.03 0 C-N-CA 120.732 -0.747 . . . . 0.0 111.88 168.424 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 95' ' ' TRP . . . . . 0.472 ' HA ' ' HE3' ' A' ' 98' ' ' TRP . 15.7 m95 66.47 2.23 2.39 Favored 'General case' 0 C--O 1.216 -0.669 0 C-N-CA 123.236 0.614 . . . . 0.0 109.979 -178.276 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -70.35 -13.01 70.23 Favored Glycine 0 C--N 1.335 0.517 0 C-N-CA 121.447 -0.406 . . . . 0.0 112.792 -178.108 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -81.93 -23.66 36.06 Favored 'General case' 0 C--N 1.325 -0.471 0 N-CA-C 109.525 -0.546 . . . . 0.0 109.525 175.159 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 98' ' ' TRP . . . . . 0.898 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 29.0 m-90 -103.16 104.95 43.59 Favored Pre-proline 0 N--CA 1.45 -0.444 0 N-CA-C 108.745 -0.835 . . . . 0.0 108.745 175.146 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . 0.419 ' HD3' ' HA ' ' A' ' 98' ' ' TRP . 15.0 Cg_exo -74.43 -87.09 0.0 OUTLIER 'Trans proline' 0 CA--C 1.53 0.305 0 C-N-CA 122.902 2.401 . . . . 0.0 114.673 -172.666 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 48.4 t -71.25 -27.92 30.83 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-O 121.322 0.582 . . . . 0.0 111.086 -170.949 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 101' ' ' CYS . . . . . 0.879 ' SG ' ' HG3' ' A' ' 38' ' ' GLU . 64.2 m -90.99 -27.55 18.59 Favored 'General case' 0 C--N 1.314 -0.946 0 CA-C-N 115.915 -0.584 . . . . 0.0 112.545 -168.772 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 102' ' ' ALA . . . . . 0.596 ' HB2' ' HB2' ' A' ' 98' ' ' TRP . . . -67.54 -46.43 72.82 Favored 'General case' 0 C--N 1.33 -0.268 0 C-N-CA 120.515 -0.474 . . . . 0.0 110.928 -178.719 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -61.22 -39.09 88.95 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-O 121.097 0.475 . . . . 0.0 110.634 179.25 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -66.56 -39.77 88.68 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.469 -0.787 . . . . 0.0 111.548 176.655 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -77.56 -22.51 50.89 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.929 -175.933 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 116.02 55.83 0.34 Allowed Glycine 0 N--CA 1.452 -0.236 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.528 -178.942 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -57.52 149.2 21.67 Favored 'General case' 0 CA--C 1.517 -0.305 0 C-N-CA 123.049 0.54 . . . . 0.0 110.572 179.149 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 69.9 mtp180 . . . . . 0 C--O 1.249 1.04 0 CA-C-O 118.202 -0.904 . . . . 0.0 110.465 -170.19 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 16.6 p-10 . . . . . 0 N--CA 1.475 0.801 0 CA-C-O 122.016 0.913 . . . . 0.0 110.537 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 73.5 t -65.03 -41.49 92.17 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.008 0 CA-C-N 114.681 -1.145 . . . . 0.0 110.286 176.138 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 14.8 p -73.29 137.71 22.8 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.646 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.343 175.605 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 14.0 t -75.41 140.33 17.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 N-CA-C 109.265 -0.643 . . . . 0.0 109.265 177.96 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . 0.461 ' HA ' ' HD3' ' A' ' 6' ' ' PRO . 8.7 p -121.19 134.29 24.4 Favored Pre-proline 0 C--N 1.312 -1.043 0 CA-C-N 115.826 -0.625 . . . . 0.0 111.899 -170.587 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.461 ' HD3' ' HA ' ' A' ' 5' ' ' THR . 10.6 Cg_exo -73.13 -172.59 1.04 Allowed 'Trans proline' 0 CA--C 1.51 -0.687 0 C-N-CA 123.59 2.86 . . . . 0.0 110.797 170.021 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . 0.882 ' HB1' ' HG2' ' A' ' 9' ' ' GLU . . . 71.95 102.69 0.07 Allowed 'General case' 0 C--N 1.319 -0.734 0 O-C-N 124.633 1.208 . . . . 0.0 111.343 -178.802 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 18.6 m170 -69.34 -10.81 59.57 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 114.286 -1.325 . . . . 0.0 108.564 173.368 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . 0.882 ' HG2' ' HB1' ' A' ' 7' ' ' ALA . 18.4 pt-20 -72.38 143.14 48.68 Favored 'General case' 0 C--O 1.233 0.203 0 CA-C-N 115.029 -0.987 . . . . 0.0 110.336 -179.761 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -84.65 58.84 5.14 Favored 'General case' 0 CA--C 1.511 -0.537 0 CA-C-O 122.28 1.038 . . . . 0.0 110.943 -176.085 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 77.4 t -92.0 -47.21 14.17 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.245 0 CA-C-N 113.603 -1.635 . . . . 0.0 109.61 173.322 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 20.2 t -68.45 73.79 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.416 -2.133 0 CA-C-O 122.288 1.042 . . . . 0.0 109.69 170.455 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . 0.445 ' HG3' ' O ' ' A' ' 13' ' ' ARG . 16.0 ptt180 -64.54 112.39 3.13 Favored 'General case' 0 C--N 1.3 -1.559 0 CA-C-N 113.389 -1.732 . . . . 0.0 111.815 -176.228 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 5.2 t -122.39 162.12 22.54 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.641 0 CA-C-N 113.265 -1.789 . . . . 0.0 107.454 171.284 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 128.76 91.69 0.68 Allowed Glycine 0 C--N 1.304 -1.211 0 C-N-CA 121.152 -0.547 . . . . 0.0 112.109 -179.613 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.535 ' O ' ' HD3' ' A' ' 18' ' ' PRO . 27.3 m -95.0 -23.8 17.21 Favored 'General case' 0 N--CA 1.44 -0.927 0 CA-C-O 121.313 0.578 . . . . 0.0 111.117 -177.985 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 11.2 mptt -93.49 102.04 6.89 Favored Pre-proline 0 C--N 1.319 -0.759 0 CA-C-N 115.394 -0.821 . . . . 0.0 110.714 179.736 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . 0.535 ' HD3' ' O ' ' A' ' 16' ' ' THR . 66.5 Cg_endo -79.39 133.84 10.94 Favored 'Trans proline' 0 N--CA 1.448 -1.198 0 C-N-CA 123.282 2.655 . . . . 0.0 111.556 179.592 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 123.67 -50.11 0.87 Allowed Glycine 0 C--N 1.301 -1.412 0 CA-C-N 114.481 -1.236 . . . . 0.0 110.447 -178.706 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 83.4 m -63.07 -39.74 95.6 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-O 121.769 0.795 . . . . 0.0 109.641 172.228 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . 0.456 ' O ' ' HD3' ' A' ' 23' ' ' PRO . 8.5 pt-20 -135.69 157.59 46.48 Favored 'General case' 0 N--CA 1.428 -1.566 0 CA-C-N 114.953 -1.021 . . . . 0.0 108.339 178.068 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 35.5 t -88.67 109.87 32.92 Favored Pre-proline 0 C--N 1.311 -1.107 0 CA-C-N 115.324 -0.853 . . . . 0.0 111.442 -174.269 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.456 ' HD3' ' O ' ' A' ' 21' ' ' GLU . 21.5 Cg_exo -67.59 143.48 62.66 Favored 'Trans proline' 0 N--CA 1.46 -0.48 0 C-N-CA 123.691 2.928 . . . . 0.0 113.681 -179.486 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . 0.406 ' HD2' ' HA ' ' A' ' 23' ' ' PRO . 12.1 Cg_endo -56.8 165.16 5.12 Favored 'Trans proline' 0 C--N 1.345 0.356 0 C-N-CA 124.279 3.319 . . . . 0.0 112.125 167.476 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.783 HG21 HD13 ' A' ' 83' ' ' ILE . 4.6 p -75.01 123.98 31.86 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.868 0 CA-C-O 121.985 0.898 . . . . 0.0 109.997 -176.355 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 49.7 mm -65.94 -44.67 92.37 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.32 0 CA-C-N 114.538 -1.21 . . . . 0.0 113.096 -170.482 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.623 ' O ' HG12 ' A' ' 30' ' ' ILE . 13.0 m-20 -101.21 2.62 40.19 Favored 'General case' 0 CA--C 1.502 -0.899 0 CA-C-O 121.891 0.853 . . . . 0.0 109.208 -176.662 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . 0.711 ' HA2' ' HB2' ' A' ' 31' ' ' TRP . . . -77.75 2.7 62.91 Favored Glycine 0 N--CA 1.433 -1.534 0 CA-C-N 114.583 -1.19 . . . . 0.0 110.611 -177.76 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 17.0 m -76.23 -40.36 52.26 Favored 'General case' 0 C--N 1.318 -0.794 0 N-CA-C 108.77 -0.826 . . . . 0.0 108.77 173.626 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.632 ' HA ' ' HB1' ' A' ' 105' ' ' ALA . 0.0 OUTLIER -71.52 -38.03 66.32 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.679 0 N-CA-C 107.348 -1.353 . . . . 0.0 107.348 176.573 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' TRP . . . . . 0.711 ' HB2' ' HA2' ' A' ' 28' ' ' GLY . 14.6 m95 -71.85 -36.29 70.11 Favored 'General case' 0 N--CA 1.438 -1.054 0 CA-C-N 114.251 -1.34 . . . . 0.0 110.601 -176.188 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 31.7 t70 -77.23 -34.31 56.01 Favored 'General case' 0 N--CA 1.446 -0.66 0 CA-C-N 116.529 -0.305 . . . . 0.0 110.931 178.082 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . 0.487 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -70.16 -34.08 72.56 Favored 'General case' 0 N--CA 1.448 -0.532 0 C-N-CA 120.288 -0.565 . . . . 0.0 110.278 177.523 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . 0.501 HG13 ' O ' ' A' ' 30' ' ' ILE . 68.3 mt -67.88 -46.55 81.92 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-O 121.07 0.462 . . . . 0.0 110.176 172.298 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . 0.413 ' O ' ' HB3' ' A' ' 39' ' ' ALA . . . -58.72 -38.91 79.36 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.277 176.89 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . 0.509 ' HA2' ' N ' ' A' ' 41' ' ' GLY . . . -74.88 -12.97 82.84 Favored Glycine 0 C--O 1.228 -0.26 0 CA-C-N 115.618 -0.719 . . . . 0.0 111.535 178.699 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 40.8 t -89.5 -60.94 1.81 Allowed 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 115.356 -0.422 . . . . 0.0 110.93 -177.748 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . 0.832 ' HG3' ' SG ' ' A' ' 101' ' ' CYS . 34.3 mt-10 -89.55 -28.37 19.64 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 120.687 0.28 . . . . 0.0 111.534 -174.441 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . 0.413 ' HB3' ' O ' ' A' ' 35' ' ' ALA . . . -101.49 -12.01 18.87 Favored 'General case' 0 C--N 1.326 -0.452 0 C-N-CA 120.43 -0.508 . . . . 0.0 111.785 -178.14 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 81.03 6.52 89.4 Favored Glycine 0 N--CA 1.45 -0.371 0 N-CA-C 110.027 -1.229 . . . . 0.0 110.027 -177.846 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . 0.509 ' N ' ' HA2' ' A' ' 36' ' ' GLY . . . 85.35 53.88 2.98 Favored Glycine 0 N--CA 1.437 -1.274 0 CA-C-N 114.148 -1.026 . . . . 0.0 111.942 -177.71 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . 0.412 ' OD1' ' HB ' ' A' ' 45' ' ' ILE . 2.3 t-20 -138.71 99.32 3.77 Favored 'General case' 0 N--CA 1.447 -0.58 0 N-CA-C 108.829 -0.804 . . . . 0.0 108.829 -175.84 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' TRP . . . . . 0.667 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 37.1 m95 -81.48 -10.32 59.51 Favored 'General case' 0 C--N 1.312 -1.026 0 CA-C-N 115.389 -0.823 . . . . 0.0 110.805 -172.664 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -107.0 8.71 30.56 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 115.504 -0.771 . . . . 0.0 110.829 -179.492 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.427 HG22 ' CA ' ' A' ' 53' ' ' GLY . 9.3 tt -72.56 144.27 13.17 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.916 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 179.578 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 22.4 t-20 -154.22 98.47 2.14 Favored 'General case' 0 C--N 1.309 -1.183 0 CA-C-O 121.384 0.612 . . . . 0.0 109.372 -179.956 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 17.5 p -72.51 -24.05 61.1 Favored 'General case' 0 C--N 1.317 -0.819 0 CA-C-N 114.76 -1.109 . . . . 0.0 110.919 -177.376 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 93.48 20.64 31.56 Favored Glycine 0 N--CA 1.441 -0.981 0 N-CA-C 110.722 -0.951 . . . . 0.0 110.722 -178.698 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 82.8 m-20 -93.18 12.8 23.14 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.877 0.37 . . . . 0.0 111.415 -176.234 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . 0.516 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 85.29 -11.73 60.18 Favored Glycine 0 N--CA 1.449 -0.46 0 N-CA-C 111.209 -0.757 . . . . 0.0 111.209 -177.883 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' TYR . . . . . 0.649 ' HA ' ' HA ' ' A' ' 58' ' ' ASP . 0.3 OUTLIER -112.22 146.37 38.25 Favored 'General case' 0 CA--C 1.51 -0.562 0 N-CA-C 107.197 -1.408 . . . . 0.0 107.197 177.214 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' TYR . . . . . 0.831 ' O ' ' HA ' ' A' ' 56' ' ' GLN . 32.8 m-85 -110.73 170.5 8.05 Favored 'General case' 0 C--N 1.309 -1.154 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.697 -165.96 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.427 ' CA ' HG22 ' A' ' 45' ' ' ILE . . . -69.06 -174.37 9.98 Favored Glycine 0 C--O 1.228 -0.223 0 N-CA-C 114.907 0.723 . . . . 0.0 114.907 -169.761 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.608 ' CA ' ' HA ' ' A' ' 43' ' ' TRP . . . 80.0 -107.53 2.62 Favored Glycine 0 N--CA 1.442 -0.942 0 C-N-CA 120.859 -0.686 . . . . 0.0 111.457 -178.349 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.547 HG12 ' HE1' ' A' ' 98' ' ' TRP . 3.4 t -88.21 4.22 4.84 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 CA-C-O 121.554 0.692 . . . . 0.0 109.618 179.016 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' GLN . . . . . 0.831 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 7.0 tt0 54.5 53.82 10.22 Favored 'General case' 0 CA--C 1.535 0.379 0 N-CA-C 114.854 1.427 . . . . 0.0 114.854 164.887 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -121.15 170.26 9.73 Favored 'General case' 0 C--N 1.326 -0.418 0 C-N-CA 119.447 -0.901 . . . . 0.0 112.018 171.652 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.649 ' HA ' ' HA ' ' A' ' 51' ' ' TYR . 6.9 p-10 -76.25 165.22 25.18 Favored 'General case' 0 C--N 1.331 -0.219 0 N-CA-C 113.311 0.856 . . . . 0.0 113.311 -166.809 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.507 ' HB2' ' HE1' ' A' ' 52' ' ' TYR . 5.9 tp-100 -63.15 -37.99 89.4 Favored 'General case' 0 N--CA 1.448 -0.568 0 CA-C-N 114.881 -1.054 . . . . 0.0 110.827 179.127 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -63.46 -49.78 67.28 Favored Glycine 0 C--N 1.314 -0.68 0 CA-C-N 115.551 -0.75 . . . . 0.0 111.777 -175.643 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 86.4 m -63.91 -44.19 93.7 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-O 120.954 0.407 . . . . 0.0 111.201 176.414 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' TRP . . . . . 0.459 ' CZ3' ' HA ' ' A' ' 82' ' ' GLN . 54.4 t-105 -56.86 -48.95 76.93 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 121.84 0.828 . . . . 0.0 109.967 177.546 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . 0.516 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 36.0 tt0 -67.39 -34.68 77.76 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-N 114.611 -1.177 . . . . 0.0 110.471 -178.426 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -64.85 -41.9 95.32 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.645 -0.707 . . . . 0.0 110.993 -178.711 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . 0.579 ' HB2' HG13 ' A' ' 85' ' ' VAL . 7.9 m120 -82.06 -2.85 53.19 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.459 177.144 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . 0.58 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 83.57 47.62 5.6 Favored Glycine 0 C--O 1.225 -0.467 0 CA-C-N 115.782 -0.645 . . . . 0.0 112.587 173.245 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.607 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -80.03 -21.96 64.43 Favored Glycine 0 N--CA 1.438 -1.197 0 C-N-CA 120.956 -0.64 . . . . 0.0 112.934 -175.107 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.837 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 6.8 mp -61.61 -22.73 65.49 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 112.048 0.388 . . . . 0.0 112.048 -172.43 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . 0.58 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 9.6 ptm180 -67.74 -33.68 75.33 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 121.254 0.549 . . . . 0.0 109.963 176.522 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' TYR . . . . . 0.786 ' HB3' ' HG3' ' A' ' 81' ' ' GLU . 63.5 m-85 -79.91 -34.51 38.92 Favored 'General case' 0 N--CA 1.444 -0.772 0 N-CA-C 107.499 -1.297 . . . . 0.0 107.499 178.159 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.707 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 163.99 129.05 0.02 OUTLIER Pre-proline 0 CA--C 1.51 -0.568 0 CA-C-N 112.595 -2.093 . . . . 0.0 107.198 -179.888 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' PRO . . . . . 0.837 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 16.9 Cg_exo -58.46 -3.02 1.15 Allowed 'Trans proline' 0 C--N 1.332 -0.299 0 C-N-CA 122.622 2.215 . . . . 0.0 113.559 -177.911 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' ARG . . . . . 0.421 ' HB2' ' CD2' ' A' ' 52' ' ' TYR . 13.5 ptm180 -146.63 137.36 23.99 Favored 'General case' 0 C--N 1.319 -0.731 0 N-CA-C 109.289 -0.634 . . . . 0.0 109.289 177.342 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . 0.499 ' HB3' ' HB2' ' A' ' 52' ' ' TYR . . . -58.11 -29.52 65.56 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.312 -0.858 . . . . 0.0 112.611 -178.066 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . 0.404 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 14.7 p-10 -87.84 9.19 22.72 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 121.364 0.602 . . . . 0.0 110.852 -176.092 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.432 ' HB3' ' HB1' ' A' ' 71' ' ' ALA . 58.6 tp -110.07 -33.63 6.63 Favored 'General case' 0 C--N 1.322 -0.627 0 N-CA-C 108.322 -0.992 . . . . 0.0 108.322 169.81 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . 0.739 ' HB1' ' HB3' ' A' ' 81' ' ' GLU . . . -78.39 163.36 25.72 Favored 'General case' 0 N--CA 1.445 -0.691 0 CA-C-N 114.771 -1.104 . . . . 0.0 110.393 177.084 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 71.5 p -99.36 -174.49 2.75 Favored 'General case' 0 C--N 1.315 -0.931 0 CA-C-N 115.656 -0.702 . . . . 0.0 110.337 -174.532 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . 0.667 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 23.7 mtt85 -53.93 -56.81 14.33 Favored 'General case' 0 CA--C 1.512 -0.509 0 CA-C-O 120.988 0.423 . . . . 0.0 110.772 178.848 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 1.8 pm0 -58.22 -41.18 83.51 Favored 'General case' 0 C--N 1.314 -0.937 0 CA-C-N 115.043 -0.981 . . . . 0.0 111.262 -176.391 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 81' ' ' GLU . . . . . 0.786 ' HG3' ' HB3' ' A' ' 70' ' ' TYR . 0.4 OUTLIER -63.18 -52.72 61.21 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 115.5 -0.773 . . . . 0.0 112.161 175.835 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 82' ' ' GLN . . . . . 0.459 ' HA ' ' CZ3' ' A' ' 62' ' ' TRP . 53.4 mt-30 -60.66 -43.09 98.04 Favored 'General case' 0 CA--C 1.509 -0.613 0 CA-C-O 121.762 0.791 . . . . 0.0 109.833 -178.972 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.783 HD13 HG21 ' A' ' 25' ' ' VAL . 10.8 mt -59.5 -39.74 80.07 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.993 0 CA-C-N 114.276 -1.329 . . . . 0.0 110.303 -177.822 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . 0.436 ' O ' HG23 ' A' ' 88' ' ' VAL . . . -62.1 -42.46 99.24 Favored 'General case' 0 C--N 1.319 -0.752 0 CA-C-O 121.273 0.559 . . . . 0.0 110.476 -179.181 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.579 HG13 ' HB2' ' A' ' 65' ' ' ASN . 43.0 t -70.05 -50.77 45.26 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 CA-C-N 115.764 -0.653 . . . . 0.0 111.741 -179.569 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -65.69 -31.49 72.52 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 121.489 0.662 . . . . 0.0 110.858 -179.6 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 87' ' ' GLU . . . . . 0.759 ' HA ' ' HG2' ' A' ' 90' ' ' ARG . 0.7 OUTLIER -71.16 -28.41 64.24 Favored 'General case' 0 C--N 1.316 -0.855 0 CA-C-N 115.716 -0.674 . . . . 0.0 110.436 -178.348 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.674 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 88.1 t -61.86 -46.47 96.43 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.26 0 N-CA-C 109.299 -0.63 . . . . 0.0 109.299 168.54 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . 0.48 ' O ' ' HG2' ' A' ' 93' ' ' GLN . 0.1 OUTLIER -64.64 -45.71 85.63 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 115.697 -0.683 . . . . 0.0 111.866 -177.48 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . 0.759 ' HG2' ' HA ' ' A' ' 87' ' ' GLU . 22.5 ptt180 -58.91 -35.36 72.94 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.98 -0.555 . . . . 0.0 111.048 -175.799 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . 0.674 ' HG ' ' O ' ' A' ' 88' ' ' VAL . 4.6 pp -74.69 -24.39 58.76 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.022 -0.536 . . . . 0.0 110.827 -169.536 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . 0.455 ' HE ' ' HB2' ' A' ' 92' ' ' ARG . 3.9 mtm180 -85.59 -45.56 11.63 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.783 -0.644 . . . . 0.0 109.686 -177.948 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 93' ' ' GLN . . . . . 0.48 ' HG2' ' O ' ' A' ' 89' ' ' THR . 24.0 pt20 -98.6 -29.12 13.24 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.192 -0.913 . . . . 0.0 113.188 -169.715 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 87.42 46.67 4.88 Favored Glycine 0 CA--C 1.505 -0.58 0 C-N-CA 120.426 -0.893 . . . . 0.0 111.06 176.463 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 95' ' ' TRP . . . . . 0.506 ' HA ' ' HE3' ' A' ' 98' ' ' TRP . 1.9 m95 58.59 27.0 15.12 Favored 'General case' 0 C--O 1.223 -0.34 0 CA-C-O 121.484 0.659 . . . . 0.0 109.687 177.457 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -70.83 -30.5 68.12 Favored Glycine 0 N--CA 1.449 -0.445 0 CA-C-N 115.349 -0.841 . . . . 0.0 112.245 176.618 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . 0.41 ' O ' ' HD3' ' A' ' 99' ' ' PRO . . . -79.46 -24.84 42.13 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 120.66 0.267 . . . . 0.0 110.57 177.114 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 98' ' ' TRP . . . . . 0.547 ' HE1' HG12 ' A' ' 55' ' ' VAL . 23.8 m-90 -101.96 103.25 28.17 Favored Pre-proline 0 C--N 1.327 -0.389 0 N-CA-C 109.406 -0.59 . . . . 0.0 109.406 175.897 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . 0.424 ' HB2' ' H ' ' A' ' 100' ' ' VAL . 22.0 Cg_exo -70.52 -101.7 0.01 OUTLIER 'Trans proline' 0 CA--C 1.539 0.746 0 C-N-CA 123.242 2.628 . . . . 0.0 114.991 -173.013 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . 0.48 ' O ' ' HD2' ' A' ' 104' ' ' ARG . 41.0 t -69.82 -27.94 35.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 121.596 0.712 . . . . 0.0 110.452 -171.598 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 101' ' ' CYS . . . . . 0.832 ' SG ' ' HG3' ' A' ' 38' ' ' GLU . 79.1 m -73.07 -32.38 64.97 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-N 115.228 -0.896 . . . . 0.0 111.511 -171.416 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -70.0 -46.18 65.69 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 120.757 0.313 . . . . 0.0 110.953 -179.892 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -62.25 -37.28 84.83 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 121.097 0.475 . . . . 0.0 110.773 179.514 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 104' ' ' ARG . . . . . 0.48 ' HD2' ' O ' ' A' ' 100' ' ' VAL . 0.0 OUTLIER -73.02 -30.47 63.78 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.627 -0.715 . . . . 0.0 111.583 178.566 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 105' ' ' ALA . . . . . 0.632 ' HB1' ' HA ' ' A' ' 30' ' ' ILE . . . -82.17 -21.38 36.57 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.692 -176.997 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 109.39 60.93 0.52 Allowed Glycine 0 CA--C 1.518 0.25 0 C-N-CA 121.011 -0.614 . . . . 0.0 112.158 -178.122 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -66.41 152.67 44.62 Favored 'General case' 0 N--CA 1.45 -0.442 0 C-N-CA 122.642 0.377 . . . . 0.0 111.013 -176.562 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 20.7 mmt180 . . . . . 0 C--O 1.244 0.814 0 CA-C-O 118.404 -0.808 . . . . 0.0 110.959 176.677 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 84.0 m-20 . . . . . 0 N--CA 1.477 0.917 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 9.1 t -82.85 54.02 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-O 121.886 0.85 . . . . 0.0 110.056 179.361 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 12.1 p -87.07 140.45 15.78 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.986 0 CA-C-N 115.265 -0.88 . . . . 0.0 111.044 177.599 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 6.8 t -95.37 140.76 16.31 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.538 0 N-CA-C 108.86 -0.793 . . . . 0.0 108.86 173.891 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . 0.45 ' HA ' ' HD3' ' A' ' 6' ' ' PRO . 4.6 p -124.88 135.54 26.87 Favored Pre-proline 0 C--N 1.313 -1.001 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.564 -172.853 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.45 ' HD3' ' HA ' ' A' ' 5' ' ' THR . 3.3 Cg_exo -76.64 166.26 27.48 Favored 'Trans proline' 0 N--CA 1.453 -0.856 0 C-N-CA 123.219 2.613 . . . . 0.0 110.267 171.592 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . 52.13 39.63 27.05 Favored 'General case' 0 C--N 1.314 -0.955 0 CA-C-N 114.985 -1.007 . . . . 0.0 110.49 -172.617 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 6.1 t60 -80.88 -2.29 46.88 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-N 114.194 -1.366 . . . . 0.0 108.228 174.383 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 9.5 pt-20 -64.61 147.61 52.59 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 114.584 -1.189 . . . . 0.0 110.253 174.368 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -109.5 66.6 0.63 Allowed 'General case' 0 C--N 1.317 -0.809 0 CA-C-O 121.87 0.843 . . . . 0.0 110.622 -172.914 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 58.3 t -67.99 -68.91 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.312 -1.045 0 CA-C-N 114.358 -1.292 . . . . 0.0 109.724 175.023 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 6.9 p 26.0 79.03 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.347 0.498 0 CA-C-O 122.952 1.358 . . . . 0.0 112.932 176.481 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 14.6 ptm180 -95.89 119.21 33.99 Favored 'General case' 0 N--CA 1.432 -1.368 0 CA-C-N 113.86 -1.518 . . . . 0.0 110.592 -174.349 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.417 HG12 ' N ' ' A' ' 15' ' ' GLY . 9.5 t -124.19 166.11 19.96 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.372 0 CA-C-N 113.616 -1.629 . . . . 0.0 108.283 176.937 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . 0.417 ' N ' HG12 ' A' ' 14' ' ' VAL . . . -168.5 -83.54 0.05 OUTLIER Glycine 0 N--CA 1.426 -1.993 0 C-N-CA 120.698 -0.763 . . . . 0.0 111.827 179.172 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.504 ' O ' ' HD3' ' A' ' 18' ' ' PRO . 8.1 m -75.25 -35.8 61.36 Favored 'General case' 0 N--CA 1.437 -1.107 0 CA-C-O 121.127 0.489 . . . . 0.0 112.196 -174.751 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . 0.433 ' HD2' ' HB ' ' A' ' 16' ' ' THR . 0.0 OUTLIER -105.82 93.74 7.93 Favored Pre-proline 0 C--N 1.312 -1.042 0 CA-C-N 115.574 -0.739 . . . . 0.0 109.826 179.185 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . 0.504 ' HD3' ' O ' ' A' ' 16' ' ' THR . 21.3 Cg_exo -65.43 170.63 10.61 Favored 'Trans proline' 0 CA--C 1.51 -0.701 0 C-N-CA 123.157 2.571 . . . . 0.0 112.582 -174.375 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 117.93 42.32 0.61 Allowed Glycine 0 C--N 1.305 -1.185 0 CA-C-N 114.337 -1.301 . . . . 0.0 111.861 -176.761 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 2.8 m -69.73 -48.32 59.89 Favored 'General case' 0 C--N 1.32 -0.693 0 N-CA-C 108.739 -0.838 . . . . 0.0 108.739 175.257 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 49.0 mt-10 -129.94 110.55 11.77 Favored 'General case' 0 N--CA 1.443 -0.784 0 CA-C-N 114.254 -1.339 . . . . 0.0 108.606 174.61 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.704 ' O ' ' HD3' ' A' ' 79' ' ' ARG . 81.4 t -70.92 137.96 85.14 Favored Pre-proline 0 C--N 1.318 -0.781 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.045 -176.176 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.461 ' HA ' ' HD2' ' A' ' 24' ' ' PRO . 62.9 Cg_exo -54.48 126.29 21.81 Favored 'Trans proline' 0 N--CA 1.457 -0.619 0 C-N-CA 122.523 2.148 . . . . 0.0 112.383 179.923 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . 0.461 ' HD2' ' HA ' ' A' ' 23' ' ' PRO . 29.7 Cg_endo -63.62 149.79 90.06 Favored 'Trans proline' 0 N--CA 1.452 -0.915 0 C-N-CA 123.839 3.026 . . . . 0.0 113.752 -178.273 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.836 ' HB ' HG21 ' A' ' 83' ' ' ILE . 43.4 t -87.03 160.09 3.02 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.134 0 N-CA-C 106.845 -1.539 . . . . 0.0 106.845 165.651 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.468 ' H ' HD12 ' A' ' 26' ' ' ILE . 3.0 mp -54.35 -34.0 27.12 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.842 0 CA-C-O 120.854 0.359 . . . . 0.0 111.836 -167.319 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.531 ' O ' HG12 ' A' ' 30' ' ' ILE . 11.2 m-20 -104.59 -3.06 24.28 Favored 'General case' 0 CA--C 1.504 -0.805 0 CA-C-O 121.364 0.602 . . . . 0.0 110.931 -178.974 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . 0.703 ' HA3' ' CD1' ' A' ' 83' ' ' ILE . . . -76.05 1.65 58.75 Favored Glycine 0 CA--C 1.498 -0.998 0 N-CA-C 110.715 -0.954 . . . . 0.0 110.715 -179.336 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 19.1 m -76.99 -40.86 45.22 Favored 'General case' 0 C--N 1.322 -0.628 0 N-CA-C 108.497 -0.927 . . . . 0.0 108.497 171.381 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.531 HG12 ' O ' ' A' ' 27' ' ' ASP . 0.7 OUTLIER -67.29 -40.21 84.43 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.457 0 CA-C-N 114.399 -1.273 . . . . 0.0 107.724 175.946 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' TRP . . . . . 0.56 ' HB2' ' HA2' ' A' ' 28' ' ' GLY . 36.5 m95 -67.41 -36.68 81.76 Favored 'General case' 0 C--N 1.318 -0.776 0 CA-C-N 114.17 -1.377 . . . . 0.0 110.378 -177.826 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.427 ' CB ' HH21 ' A' ' 79' ' ' ARG . 4.6 t70 -77.19 -33.34 56.38 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 115.748 -0.66 . . . . 0.0 110.62 -179.5 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . 0.417 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -70.13 -34.07 72.61 Favored 'General case' 0 N--CA 1.447 -0.575 0 C-N-CA 120.506 -0.478 . . . . 0.0 109.977 176.159 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . 0.515 HG13 ' O ' ' A' ' 30' ' ' ILE . 74.2 mt -65.52 -43.45 94.32 Favored 'Isoleucine or valine' 0 C--O 1.234 0.268 0 CA-C-N 116.057 -0.519 . . . . 0.0 109.865 172.23 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . 0.451 ' HA ' ' O ' ' A' ' 54' ' ' GLY . . . -57.57 -37.4 73.09 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.059 175.211 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . 0.4 ' HA2' ' N ' ' A' ' 41' ' ' GLY . . . -70.89 -15.98 74.31 Favored Glycine 0 N--CA 1.449 -0.45 0 CA-C-N 115.27 -0.877 . . . . 0.0 112.181 179.299 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 44.1 t -85.19 -58.87 2.51 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 120.611 0.243 . . . . 0.0 111.186 -177.256 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 8.6 tp10 -89.09 -34.04 16.89 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-O 121.074 0.464 . . . . 0.0 110.877 -172.693 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -97.63 -14.66 20.83 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.029 -0.532 . . . . 0.0 111.511 -175.427 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 86.31 -4.51 85.99 Favored Glycine 0 N--CA 1.448 -0.523 0 N-CA-C 109.847 -1.301 . . . . 0.0 109.847 -174.408 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . 0.4 ' N ' ' HA2' ' A' ' 36' ' ' GLY . . . 102.04 56.06 0.85 Allowed Glycine 0 N--CA 1.435 -1.37 0 CA-C-N 114.213 -0.993 . . . . 0.0 112.058 -179.235 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 43.8 t-20 -144.33 127.25 16.38 Favored 'General case' 0 N--CA 1.44 -0.968 0 N-CA-C 108.263 -1.014 . . . . 0.0 108.263 -179.602 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' TRP . . . . . 0.691 ' HZ3' ' HB2' ' A' ' 82' ' ' GLN . 40.5 m95 -99.28 -13.27 19.74 Favored 'General case' 0 C--N 1.305 -1.351 0 CA-C-N 115.398 -0.819 . . . . 0.0 110.935 -173.385 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -100.53 -6.77 24.94 Favored 'General case' 0 C--N 1.316 -0.881 0 CA-C-N 115.199 -0.909 . . . . 0.0 110.479 -177.889 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 10.0 tt -62.33 141.58 17.67 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.996 0 CA-C-N 115.474 -0.784 . . . . 0.0 109.921 178.556 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 43.3 t-20 -158.73 103.52 1.73 Allowed 'General case' 0 C--N 1.312 -1.025 0 CA-C-O 121.03 0.443 . . . . 0.0 110.112 -177.655 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 11.2 p -82.75 -15.01 53.46 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 115.718 -0.674 . . . . 0.0 111.923 -177.56 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 90.47 25.23 26.4 Favored Glycine 0 N--CA 1.446 -0.662 0 N-CA-C 110.943 -0.863 . . . . 0.0 110.943 -177.743 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 65.0 t30 -83.63 -1.76 54.63 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 121.222 0.534 . . . . 0.0 111.222 -175.352 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . 0.469 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 95.19 -9.34 69.89 Favored Glycine 0 CA--C 1.505 -0.539 0 N-CA-C 110.093 -1.203 . . . . 0.0 110.093 -175.734 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' TYR . . . . . 0.66 ' HA ' ' HA ' ' A' ' 58' ' ' ASP . 0.5 OUTLIER -117.98 158.2 25.36 Favored 'General case' 0 N--CA 1.441 -0.923 0 N-CA-C 106.118 -1.808 . . . . 0.0 106.118 177.998 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' TYR . . . . . 0.73 ' O ' ' HA ' ' A' ' 56' ' ' GLN . 35.1 m-85 -118.41 169.59 9.63 Favored 'General case' 0 C--N 1.303 -1.447 0 C-N-CA 120.222 -0.591 . . . . 0.0 110.851 -172.241 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -65.14 -173.26 3.81 Favored Glycine 0 N--CA 1.448 -0.515 0 C-N-CA 121.173 -0.537 . . . . 0.0 114.362 -170.019 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.599 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 77.39 -104.97 2.01 Favored Glycine 0 N--CA 1.439 -1.157 0 N-CA-C 111.346 -0.702 . . . . 0.0 111.346 -179.635 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.556 HG12 ' HE1' ' A' ' 98' ' ' TRP . 2.2 t -83.41 -1.83 6.25 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 CA-C-O 121.503 0.668 . . . . 0.0 109.676 -179.122 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' GLN . . . . . 0.79 ' HA ' HE21 ' A' ' 56' ' ' GLN . 0.0 OUTLIER 57.34 45.18 20.52 Favored 'General case' 0 N--CA 1.464 0.249 0 CA-C-N 114.541 -1.209 . . . . 0.0 113.444 169.584 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 1.1 p90 -117.89 168.53 10.41 Favored 'General case' 0 C--N 1.328 -0.357 0 C-N-CA 119.582 -0.847 . . . . 0.0 112.035 176.476 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.66 ' HA ' ' HA ' ' A' ' 51' ' ' TYR . 7.5 p-10 -79.33 164.15 24.31 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.141 -0.936 . . . . 0.0 113.419 -164.39 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.703 ' HA ' HE21 ' A' ' 59' ' ' GLN . 0.0 OUTLIER -63.25 -36.63 84.3 Favored 'General case' 0 N--CA 1.449 -0.487 0 CA-C-N 114.101 -1.409 . . . . 0.0 111.578 179.188 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -68.0 -50.33 41.4 Favored Glycine 0 C--N 1.32 -0.324 0 C-N-CA 121.2 -0.524 . . . . 0.0 112.303 -175.703 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 88.5 m -61.7 -42.16 98.56 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 121.157 0.503 . . . . 0.0 110.113 175.689 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' TRP . . . . . 0.591 ' HH2' ' CD ' ' A' ' 81' ' ' GLU . 59.3 t-105 -56.85 -49.68 74.73 Favored 'General case' 0 N--CA 1.447 -0.623 0 CA-C-N 114.985 -1.007 . . . . 0.0 110.209 177.264 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . 0.914 ' HG3' HD11 ' A' ' 68' ' ' LEU . 29.1 tt0 -67.15 -34.38 77.44 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 115.026 -0.988 . . . . 0.0 110.773 -177.18 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -67.91 -41.58 82.45 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.897 -0.592 . . . . 0.0 111.082 -178.44 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . 0.68 ' HB2' HG13 ' A' ' 85' ' ' VAL . 4.8 m120 -71.8 -15.79 62.16 Favored 'General case' 0 C--N 1.332 -0.154 0 CA-C-O 121.349 0.595 . . . . 0.0 109.773 174.99 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 88.32 44.74 5.21 Favored Glycine 0 N--CA 1.446 -0.7 0 CA-C-N 115.208 -0.906 . . . . 0.0 111.752 178.422 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.589 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -78.5 -19.58 73.53 Favored Glycine 0 CA--C 1.5 -0.865 0 C-N-CA 120.612 -0.804 . . . . 0.0 111.123 -173.818 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.914 HD11 ' HG3' ' A' ' 63' ' ' GLU . 11.8 mt -61.32 -24.86 66.74 Favored 'General case' 0 C--N 1.317 -0.807 0 CA-C-N 114.664 -0.768 . . . . 0.0 110.806 -174.667 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 12.1 ptm180 -70.34 -28.61 65.27 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.461 -0.79 . . . . 0.0 109.856 179.664 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' TYR . . . . . 0.589 ' HD2' ' HA2' ' A' ' 67' ' ' GLY . 47.7 m-85 -85.49 -34.47 21.58 Favored 'General case' 0 N--CA 1.439 -1.007 0 N-CA-C 107.143 -1.428 . . . . 0.0 107.143 176.201 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.785 ' HB1' ' HB3' ' A' ' 76' ' ' LEU . . . 170.22 127.27 0.05 OUTLIER Pre-proline 0 C--O 1.217 -0.617 0 CA-C-N 112.729 -2.032 . . . . 0.0 107.712 -178.029 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' PRO . . . . . 0.604 ' HA ' ' HA ' ' A' ' 68' ' ' LEU . 17.2 Cg_exo -58.32 -0.96 0.54 Allowed 'Trans proline' 0 C--N 1.331 -0.39 0 C-N-CA 122.968 2.445 . . . . 0.0 113.8 -179.455 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' ARG . . . . . 0.428 ' HE ' ' CG ' ' A' ' 75' ' ' ASP . 13.4 ptm180 -152.85 143.04 22.43 Favored 'General case' 0 C--N 1.318 -0.799 0 N-CA-C 109.232 -0.655 . . . . 0.0 109.232 174.059 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . 0.593 ' HB3' ' HB2' ' A' ' 52' ' ' TYR . . . -61.7 -25.48 67.44 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.574 -0.739 . . . . 0.0 112.359 -174.381 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . 0.428 ' CG ' ' HE ' ' A' ' 73' ' ' ARG . 17.2 p-10 -89.36 10.91 20.7 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-O 121.049 0.452 . . . . 0.0 111.363 -178.041 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.785 ' HB3' ' HB1' ' A' ' 71' ' ' ALA . 42.0 tp -104.29 -42.71 5.42 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.345 177.207 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . 0.718 ' HB3' ' OE2' ' A' ' 81' ' ' GLU . . . -100.73 170.47 8.32 Favored 'General case' 0 N--CA 1.45 -0.473 0 CA-C-O 121.136 0.493 . . . . 0.0 109.932 177.826 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . 0.622 ' HB ' HG21 ' A' ' 22' ' ' VAL . 41.3 p -85.06 168.71 14.63 Favored 'General case' 0 C--N 1.312 -1.063 0 N-CA-C 113.2 0.815 . . . . 0.0 113.2 -167.775 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . 0.704 ' HD3' ' O ' ' A' ' 22' ' ' VAL . 7.1 ptm180 -47.4 -36.09 9.29 Favored 'General case' 0 N--CA 1.466 0.352 0 C-N-CA 122.724 0.41 . . . . 0.0 112.087 -175.238 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 80' ' ' GLU . . . . . 0.917 ' HA ' HD12 ' A' ' 83' ' ' ILE . 16.1 pt-20 -62.36 -31.22 71.83 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.407 -178.556 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 81' ' ' GLU . . . . . 0.718 ' OE2' ' HB3' ' A' ' 77' ' ' ALA . 0.0 OUTLIER -72.53 -48.86 36.99 Favored 'General case' 0 N--CA 1.428 -1.545 0 N-CA-C 110.075 -0.343 . . . . 0.0 110.075 177.163 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 82' ' ' GLN . . . . . 0.691 ' HB2' ' HZ3' ' A' ' 43' ' ' TRP . 67.1 mt-30 -59.82 -31.8 70.06 Favored 'General case' 0 CA--C 1.511 -0.521 0 C-N-CA 120.874 -0.331 . . . . 0.0 110.225 178.245 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.917 HD12 ' HA ' ' A' ' 80' ' ' GLU . 79.7 mt -59.32 -51.5 71.92 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.782 0 CA-C-N 115.892 -0.594 . . . . 0.0 109.626 173.328 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . 0.48 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -62.36 -44.42 96.51 Favored 'General case' 0 C--O 1.238 0.459 0 CA-C-O 121.635 0.731 . . . . 0.0 111.285 -175.081 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.68 HG13 ' HB2' ' A' ' 65' ' ' ASN . 48.9 t -67.97 -49.17 71.0 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.635 0 CA-C-N 115.388 -0.823 . . . . 0.0 111.107 -177.876 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -60.61 -29.7 69.38 Favored 'General case' 0 N--CA 1.451 -0.416 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.175 175.581 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 87' ' ' GLU . . . . . 0.774 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 28.7 mt-10 -60.31 -42.86 96.46 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.59 179.885 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.427 ' O ' ' HG3' ' A' ' 92' ' ' ARG . 75.6 t -60.67 -50.0 82.22 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.284 0 C-N-CA 120.37 -0.532 . . . . 0.0 110.189 178.943 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . 0.705 HG22 ' NE2' ' A' ' 93' ' ' GLN . 97.0 m -64.11 -38.82 92.45 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-N 115.524 -0.762 . . . . 0.0 111.252 -178.442 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . 0.664 HH11 ' HG2' ' A' ' 87' ' ' GLU . 1.4 ptt180 -60.52 -35.88 77.04 Favored 'General case' 0 N--CA 1.464 0.258 0 CA-C-N 116.613 -0.267 . . . . 0.0 111.387 -179.674 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . 0.774 ' HG ' ' O ' ' A' ' 87' ' ' GLU . 32.1 mt -64.18 -29.02 70.16 Favored 'General case' 0 N--CA 1.47 0.534 0 CA-C-O 121.708 0.766 . . . . 0.0 110.15 -174.821 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . 0.625 ' NH2' HG23 ' A' ' 89' ' ' THR . 9.8 mtm180 -87.65 -43.89 11.61 Favored 'General case' 0 C--N 1.314 -0.956 0 CA-C-N 114.541 -1.209 . . . . 0.0 110.516 -169.573 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 93' ' ' GLN . . . . . 0.705 ' NE2' HG22 ' A' ' 89' ' ' THR . 0.0 OUTLIER -105.79 -17.74 14.28 Favored 'General case' 0 CA--C 1.545 0.769 0 N-CA-C 113.956 1.095 . . . . 0.0 113.956 -173.965 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 79.86 44.34 9.23 Favored Glycine 0 C--N 1.335 0.513 0 C-N-CA 121.312 -0.47 . . . . 0.0 112.983 171.929 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 95' ' ' TRP . . . . . 0.4 ' CZ2' ' HD2' ' A' ' 90' ' ' ARG . 13.4 m95 61.62 19.94 10.87 Favored 'General case' 0 C--O 1.223 -0.338 0 C-N-CA 123.483 0.713 . . . . 0.0 109.618 -179.059 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.421 ' H ' ' HG2' ' A' ' 93' ' ' GLN . . . -77.42 -32.98 45.23 Favored Glycine 0 N--CA 1.453 -0.189 0 CA-C-N 115.381 -0.827 . . . . 0.0 112.385 176.348 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . 0.428 ' H ' ' CG ' ' A' ' 93' ' ' GLN . . . -72.66 -24.85 61.09 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 121.338 0.589 . . . . 0.0 109.781 178.953 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 98' ' ' TRP . . . . . 0.556 ' HE1' HG12 ' A' ' 55' ' ' VAL . 25.0 m-90 -95.33 108.22 37.69 Favored Pre-proline 0 N--CA 1.441 -0.88 0 N-CA-C 108.358 -0.979 . . . . 0.0 108.358 175.001 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 45.4 Cg_exo -64.14 -141.76 0.01 OUTLIER 'Trans proline' 0 CA--C 1.532 0.394 0 C-N-CA 123.466 2.777 . . . . 0.0 113.906 -174.189 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 4.3 t -56.21 -21.79 12.67 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.425 0 CA-C-O 120.928 0.394 . . . . 0.0 111.176 -175.542 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 77.5 m -56.87 -39.18 73.86 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-N 116.573 -0.285 . . . . 0.0 111.04 175.09 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -71.27 -37.96 71.88 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-O 120.905 0.383 . . . . 0.0 110.351 177.572 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -61.19 -41.64 97.18 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.638 177.44 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -67.59 -30.29 69.86 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.833 -0.621 . . . . 0.0 111.131 175.531 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 105' ' ' ALA . . . . . 0.417 ' CB ' ' HB3' ' A' ' 33' ' ' ALA . . . -86.28 -22.8 26.6 Favored 'General case' 0 C--N 1.326 -0.428 0 N-CA-C 112.709 0.633 . . . . 0.0 112.709 -172.812 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 104.16 65.74 0.7 Allowed Glycine 0 CA--C 1.521 0.447 0 C-N-CA 120.795 -0.716 . . . . 0.0 112.5 -178.182 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -70.28 148.59 48.36 Favored 'General case' 0 C--N 1.324 -0.525 0 C-N-CA 122.905 0.482 . . . . 0.0 110.773 -176.699 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 108' ' ' ARG . . . . . 0.431 ' O ' ' HD3' ' A' ' 108' ' ' ARG . 0.0 OUTLIER . . . . . 0 C--O 1.247 0.96 0 CA-C-O 119.069 -0.491 . . . . 0.0 111.181 -174.505 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 6.9 p30 . . . . . 0 N--CA 1.474 0.727 0 CA-C-O 122.025 0.917 . . . . 0.0 110.713 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 12.9 p -67.13 -31.51 53.58 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.965 0 CA-C-N 114.733 -1.121 . . . . 0.0 110.577 178.385 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 94.8 t -82.32 94.01 2.79 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.752 0 CA-C-O 121.235 0.54 . . . . 0.0 110.345 177.185 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 7.6 t -81.59 146.74 6.89 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.657 0 CA-C-N 115.902 -0.59 . . . . 0.0 109.965 -179.821 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . 0.472 ' HA ' ' HD3' ' A' ' 6' ' ' PRO . 1.6 p -124.71 103.1 31.62 Favored Pre-proline 0 C--N 1.315 -0.897 0 CA-C-N 115.868 -0.605 . . . . 0.0 110.08 178.153 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.472 ' HD3' ' HA ' ' A' ' 5' ' ' THR . 6.2 Cg_exo -79.99 164.3 22.57 Favored 'Trans proline' 0 N--CA 1.451 -0.984 0 C-N-CA 123.217 2.611 . . . . 0.0 112.705 -175.294 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -102.51 91.01 4.04 Favored 'General case' 0 C--N 1.309 -1.153 0 CA-C-N 114.158 -1.383 . . . . 0.0 110.802 -179.554 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 49.5 m80 -86.08 -10.65 54.54 Favored 'General case' 0 C--N 1.314 -0.977 0 CA-C-N 114.333 -1.303 . . . . 0.0 107.949 173.07 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 11.9 mt-10 -81.22 178.1 8.6 Favored 'General case' 0 CA--C 1.505 -0.777 0 CA-C-N 114.434 -1.257 . . . . 0.0 112.513 -178.064 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . 65.78 51.03 1.47 Allowed 'General case' 0 C--N 1.314 -0.954 0 CA-C-N 112.81 -1.996 . . . . 0.0 109.539 -172.437 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 51.8 t -66.49 -27.79 41.4 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.805 0 CA-C-N 113.042 -1.89 . . . . 0.0 110.132 179.025 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 53.7 t 36.68 88.16 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.445 -0.701 0 C-N-CA 124.868 1.267 . . . . 0.0 113.28 177.757 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 39.5 mtm180 -96.76 112.89 24.45 Favored 'General case' 0 C--N 1.307 -1.266 0 CA-C-N 114.294 -1.321 . . . . 0.0 110.279 174.53 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 3.4 t -113.67 159.72 13.49 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.208 0 CA-C-N 114.68 -1.146 . . . . 0.0 108.893 178.625 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 90.05 83.74 1.36 Allowed Glycine 0 N--CA 1.438 -1.17 0 N-CA-C 110.898 -0.881 . . . . 0.0 110.898 -177.938 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 22.7 m -70.46 -30.54 67.39 Favored 'General case' 0 N--CA 1.441 -0.925 0 CA-C-O 121.418 0.627 . . . . 0.0 110.728 -175.899 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . 0.83 ' HD2' ' O ' ' A' ' 17' ' ' LYS . 0.0 OUTLIER -109.49 97.28 26.34 Favored Pre-proline 0 C--N 1.313 -0.981 0 CA-C-N 115.222 -0.899 . . . . 0.0 111.042 174.779 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 83.0 Cg_endo -75.32 113.75 3.84 Favored 'Trans proline' 0 N--CA 1.459 -0.533 0 C-N-CA 122.985 2.456 . . . . 0.0 112.509 -176.544 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -101.4 -14.53 30.02 Favored Glycine 0 C--N 1.301 -1.378 0 CA-C-N 113.882 -1.508 . . . . 0.0 112.107 -178.552 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 2.0 m -56.19 -46.03 79.56 Favored 'General case' 0 C--N 1.307 -1.251 0 CA-C-N 113.793 -1.203 . . . . 0.0 111.842 -177.758 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . 0.463 ' O ' ' HD3' ' A' ' 23' ' ' PRO . 38.4 mt-10 -138.2 142.07 40.0 Favored 'General case' 0 N--CA 1.443 -0.778 0 CA-C-N 115.967 -0.56 . . . . 0.0 109.559 -177.202 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 46.9 t -88.03 108.02 19.15 Favored Pre-proline 0 C--N 1.315 -0.894 0 N-CA-C 108.688 -0.856 . . . . 0.0 108.688 170.869 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.515 ' HA ' ' HD2' ' A' ' 24' ' ' PRO . 27.7 Cg_exo -63.0 129.32 25.49 Favored 'Trans proline' 0 N--CA 1.457 -0.625 0 C-N-CA 122.735 2.29 . . . . 0.0 112.573 -177.265 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . 0.515 ' HD2' ' HA ' ' A' ' 23' ' ' PRO . 11.5 Cg_endo -56.57 140.16 89.23 Favored 'Trans proline' 0 N--CA 1.452 -0.919 0 C-N-CA 122.624 2.216 . . . . 0.0 110.621 171.934 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.51 HG11 HG22 ' A' ' 83' ' ' ILE . 38.7 t -81.52 125.99 39.74 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.207 0 CA-C-N 115.659 -0.701 . . . . 0.0 111.095 -172.044 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.426 HD12 ' N ' ' A' ' 26' ' ' ILE . 3.4 mp -75.42 -32.78 26.04 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-N 114.752 -1.113 . . . . 0.0 112.775 -167.157 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.445 ' O ' HG12 ' A' ' 30' ' ' ILE . 6.3 m-20 -85.76 8.51 19.62 Favored 'General case' 0 CA--C 1.503 -0.83 0 CA-C-O 121.548 0.69 . . . . 0.0 109.833 -174.961 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . 0.622 ' HA3' HD13 ' A' ' 83' ' ' ILE . . . -63.51 -9.05 29.4 Favored Glycine 0 N--CA 1.436 -1.343 0 CA-C-N 114.909 -1.041 . . . . 0.0 110.905 174.506 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 8.4 m -71.34 -44.25 65.44 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-O 121.681 0.753 . . . . 0.0 109.293 175.195 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.505 ' O ' HG13 ' A' ' 34' ' ' ILE . 0.4 OUTLIER -69.15 -39.45 79.37 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.604 0 CA-C-N 114.576 -1.193 . . . . 0.0 107.881 178.533 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' TRP . . . . . 0.774 ' CD1' HG23 ' A' ' 83' ' ' ILE . 39.5 m95 -67.95 -35.93 79.24 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 114.493 -1.231 . . . . 0.0 110.528 -177.15 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.432 ' CG ' HH21 ' A' ' 79' ' ' ARG . 3.9 t70 -71.23 -42.25 69.12 Favored 'General case' 0 N--CA 1.447 -0.621 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.256 177.665 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . 0.424 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -67.33 -33.77 75.95 Favored 'General case' 0 N--CA 1.446 -0.662 0 CA-C-N 116.44 -0.345 . . . . 0.0 110.511 -179.665 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . 0.505 HG13 ' O ' ' A' ' 30' ' ' ILE . 65.7 mt -64.41 -46.14 93.82 Favored 'Isoleucine or valine' 0 C--O 1.234 0.255 0 CA-C-O 121.046 0.45 . . . . 0.0 109.865 172.457 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . 0.486 ' HA ' ' NE2' ' A' ' 56' ' ' GLN . . . -57.99 -38.85 76.86 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.133 176.065 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . 0.412 ' HA2' ' N ' ' A' ' 41' ' ' GLY . . . -65.44 -28.83 74.01 Favored Glycine 0 N--CA 1.451 -0.329 0 CA-C-N 115.588 -0.733 . . . . 0.0 111.97 179.248 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 6.7 t -76.25 -64.49 1.09 Allowed 'General case' 0 C--N 1.318 -0.764 0 N-CA-C 111.926 0.343 . . . . 0.0 111.926 -178.823 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . 0.51 ' HB3' ' CD ' ' A' ' 56' ' ' GLN . 11.2 tp10 -88.19 -31.79 18.93 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 121.062 0.458 . . . . 0.0 110.692 -168.939 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -96.89 -9.15 29.11 Favored 'General case' 0 N--CA 1.45 -0.436 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.764 -175.348 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 78.57 16.66 78.96 Favored Glycine 0 CA--C 1.503 -0.685 0 N-CA-C 109.848 -1.301 . . . . 0.0 109.848 -177.929 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . 0.412 ' N ' ' HA2' ' A' ' 36' ' ' GLY . . . 69.19 59.69 5.67 Favored Glycine 0 N--CA 1.432 -1.606 0 CA-C-N 113.992 -1.104 . . . . 0.0 111.928 -177.179 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 62.2 t30 -147.12 122.17 10.09 Favored 'General case' 0 CA--C 1.505 -0.77 0 N-CA-C 109.134 -0.691 . . . . 0.0 109.134 179.346 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' TRP . . . . . 0.705 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 33.9 m95 -97.5 -6.25 34.1 Favored 'General case' 0 C--N 1.306 -1.315 0 CA-C-N 114.956 -1.02 . . . . 0.0 109.935 -173.168 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -110.51 9.93 23.17 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-N 114.907 -1.042 . . . . 0.0 111.183 -179.073 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.767 HG22 ' HA2' ' A' ' 53' ' ' GLY . 3.2 tt -71.09 143.21 14.66 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.615 0 N-CA-C 109.477 -0.564 . . . . 0.0 109.477 179.099 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 45.0 t-20 -165.2 96.05 0.68 Allowed 'General case' 0 C--N 1.312 -1.041 0 CA-C-O 121.047 0.451 . . . . 0.0 110.132 -176.577 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 17.8 p -82.32 -12.06 58.22 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.392 179.832 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 89.29 22.15 38.8 Favored Glycine 0 N--CA 1.446 -0.697 0 N-CA-C 111.275 -0.73 . . . . 0.0 111.275 178.985 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 8.6 p30 -88.36 5.86 40.05 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 121.03 0.443 . . . . 0.0 110.99 -176.031 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . 0.49 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 95.77 -12.22 67.53 Favored Glycine 0 N--CA 1.448 -0.536 0 CA-C-N 115.913 -0.585 . . . . 0.0 112.117 -178.234 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' TYR . . . . . 0.597 ' HA ' ' HA ' ' A' ' 58' ' ' ASP . 0.1 OUTLIER -112.99 161.29 17.2 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 108.026 -1.102 . . . . 0.0 108.026 173.494 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' TYR . . . . . 0.479 ' HB2' ' HB3' ' A' ' 74' ' ' ALA . 42.7 m-85 -125.62 170.26 11.67 Favored 'General case' 0 C--N 1.313 -0.982 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.686 -170.752 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.767 ' HA2' HG22 ' A' ' 45' ' ' ILE . . . -70.36 -172.59 11.31 Favored Glycine 0 N--CA 1.446 -0.678 0 CA-C-N 116.177 -0.465 . . . . 0.0 114.23 -171.69 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.638 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 81.91 -111.03 3.27 Favored Glycine 0 N--CA 1.443 -0.888 0 C-N-CA 121.011 -0.614 . . . . 0.0 111.76 -179.154 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.54 ' HB ' ' CE2' ' A' ' 57' ' ' PHE . 1.8 t -91.69 19.96 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-O 121.183 0.516 . . . . 0.0 110.53 -178.488 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' GLN . . . . . 0.51 ' CD ' ' HB3' ' A' ' 38' ' ' GLU . 7.0 mp0 59.51 50.31 7.6 Favored 'General case' 0 N--CA 1.47 0.547 0 CA-C-N 115.168 -0.924 . . . . 0.0 111.704 171.496 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . 0.54 ' CE2' ' HB ' ' A' ' 55' ' ' VAL . 57.3 m-85 -81.45 138.07 35.57 Favored 'General case' 0 CA--C 1.504 -0.804 0 CA-C-N 115.77 -0.65 . . . . 0.0 112.266 178.345 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.597 ' HA ' ' HA ' ' A' ' 51' ' ' TYR . 7.9 p-10 -79.45 155.96 28.08 Favored 'General case' 0 C--N 1.313 -1.003 0 N-CA-C 108.535 -0.913 . . . . 0.0 108.535 163.631 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.406 ' HB2' ' HE1' ' A' ' 52' ' ' TYR . 19.0 tp60 -54.63 -36.47 64.56 Favored 'General case' 0 N--CA 1.445 -0.701 0 CA-C-O 121.188 0.518 . . . . 0.0 110.352 -179.026 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -68.51 -50.5 37.13 Favored Glycine 0 C--O 1.225 -0.428 0 CA-C-N 114.795 -1.093 . . . . 0.0 113.041 -173.557 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 99.1 m -67.51 -40.32 85.12 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 121.082 0.468 . . . . 0.0 110.299 -179.197 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' TRP . . . . . 0.518 ' CZ3' ' HA ' ' A' ' 82' ' ' GLN . 53.5 t-105 -57.82 -48.72 78.93 Favored 'General case' 0 N--CA 1.443 -0.789 0 CA-C-N 115.468 -0.787 . . . . 0.0 109.367 176.586 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . 0.504 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 44.9 tt0 -67.93 -33.97 75.71 Favored 'General case' 0 N--CA 1.444 -0.738 0 CA-C-N 115.07 -0.968 . . . . 0.0 110.695 -179.431 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -63.09 -41.49 99.42 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.839 -178.75 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . 0.667 ' HB2' HG13 ' A' ' 85' ' ' VAL . 7.5 m120 -73.92 -19.55 60.66 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 121.438 0.637 . . . . 0.0 110.054 176.41 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . 0.609 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 90.13 45.72 4.36 Favored Glycine 0 N--CA 1.446 -0.674 0 CA-C-N 115.148 -0.933 . . . . 0.0 111.534 -178.55 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.73 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -78.59 -15.7 80.42 Favored Glycine 0 N--CA 1.445 -0.744 0 C-N-CA 120.998 -0.62 . . . . 0.0 112.359 -172.806 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.841 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 7.1 mp -60.27 -27.54 67.34 Favored 'General case' 0 C--N 1.316 -0.865 0 N-CA-C 112.875 0.694 . . . . 0.0 112.875 -175.918 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . 0.609 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 17.1 ptm180 -65.25 -32.44 74.1 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-O 121.602 0.715 . . . . 0.0 109.748 175.545 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 70' ' ' TYR . . . . . 0.73 ' HD2' ' HA2' ' A' ' 67' ' ' GLY . 93.1 m-85 -77.78 -34.55 52.23 Favored 'General case' 0 N--CA 1.439 -0.988 0 N-CA-C 107.877 -1.157 . . . . 0.0 107.877 177.388 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.683 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 160.42 129.56 0.0 OUTLIER Pre-proline 0 CA--C 1.513 -0.48 0 CA-C-N 112.21 -2.268 . . . . 0.0 106.738 179.308 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 72' ' ' PRO . . . . . 0.841 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 17.4 Cg_exo -58.18 -4.12 1.49 Allowed 'Trans proline' 0 CA--C 1.53 0.278 0 C-N-CA 122.582 2.188 . . . . 0.0 113.506 -176.919 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 13.2 ptm180 -145.29 136.29 24.72 Favored 'General case' 0 C--N 1.321 -0.647 0 N-CA-C 108.99 -0.745 . . . . 0.0 108.99 175.801 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . 0.479 ' HB3' ' HB2' ' A' ' 52' ' ' TYR . . . -55.87 -30.7 61.92 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 114.873 -1.058 . . . . 0.0 112.772 -177.763 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . 0.442 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 20.8 p-10 -88.27 9.55 22.74 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 120.907 0.384 . . . . 0.0 111.362 -176.314 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 60.7 tp -109.98 -33.14 6.79 Favored 'General case' 0 C--N 1.323 -0.56 0 N-CA-C 108.783 -0.821 . . . . 0.0 108.783 170.246 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . 0.683 ' HB2' ' HB3' ' A' ' 71' ' ' ALA . . . -79.85 163.17 24.59 Favored 'General case' 0 N--CA 1.444 -0.759 0 CA-C-N 115.061 -0.972 . . . . 0.0 109.272 174.143 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 32.0 p -99.39 -173.91 2.6 Favored 'General case' 0 C--N 1.315 -0.927 0 C-N-CA 120.799 -0.36 . . . . 0.0 110.385 -178.497 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . 0.705 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 20.7 mtp180 -51.0 -54.34 25.39 Favored 'General case' 0 C--O 1.22 -0.452 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.99 -177.378 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 80' ' ' GLU . . . . . 0.456 ' HG3' ' OE2' ' A' ' 81' ' ' GLU . 9.0 pt-20 -61.41 -41.42 97.12 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.829 -172.683 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 81' ' ' GLU . . . . . 0.7 ' HB3' ' HB3' ' A' ' 70' ' ' TYR . 3.6 mp0 -59.24 -51.77 68.53 Favored 'General case' 0 C--N 1.323 -0.551 0 N-CA-C 112.016 0.376 . . . . 0.0 112.016 172.74 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 82' ' ' GLN . . . . . 0.518 ' HA ' ' CZ3' ' A' ' 62' ' ' TRP . 34.8 mt-30 -59.67 -39.07 83.25 Favored 'General case' 0 CA--C 1.51 -0.561 0 CA-C-O 121.719 0.771 . . . . 0.0 109.681 179.903 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.774 HG23 ' CD1' ' A' ' 31' ' ' TRP . 34.8 mt -60.85 -44.42 97.66 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.903 0 CA-C-N 114.112 -1.404 . . . . 0.0 110.61 179.557 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . 0.606 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -66.34 -35.76 81.18 Favored 'General case' 0 C--O 1.236 0.37 0 CA-C-O 121.559 0.695 . . . . 0.0 110.939 -178.613 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.667 HG13 ' HB2' ' A' ' 65' ' ' ASN . 57.4 t -66.15 -48.18 82.25 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.65 0 CA-C-N 115.595 -0.73 . . . . 0.0 110.082 174.672 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -58.76 -30.65 67.68 Favored 'General case' 0 CA--C 1.518 -0.284 0 CA-C-N 115.766 -0.652 . . . . 0.0 110.567 173.551 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 87' ' ' GLU . . . . . 0.673 ' HG2' ' O ' ' A' ' 83' ' ' ILE . 30.9 mm-40 -59.06 -43.32 91.7 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.735 -0.666 . . . . 0.0 110.368 179.754 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.515 ' O ' ' HG3' ' A' ' 92' ' ' ARG . 91.1 t -62.9 -49.49 83.42 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-O 120.851 0.357 . . . . 0.0 110.446 177.901 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . 0.609 HG22 ' NE2' ' A' ' 93' ' ' GLN . 23.8 m -66.17 -42.16 89.31 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.936 -0.574 . . . . 0.0 111.312 -176.479 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . 0.646 ' HA ' ' OE1' ' A' ' 93' ' ' GLN . 8.1 ptt180 -69.17 -32.76 72.3 Favored 'General case' 0 CA--C 1.515 -0.392 0 CA-C-O 121.729 0.776 . . . . 0.0 109.435 -179.255 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . 0.46 ' HB2' ' O ' ' A' ' 87' ' ' GLU . 49.4 tp -57.14 -27.44 61.85 Favored 'General case' 0 C--N 1.315 -0.92 0 CA-C-N 114.762 -1.108 . . . . 0.0 111.09 -179.179 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . 0.535 ' NH2' HG23 ' A' ' 89' ' ' THR . 6.7 mtm180 -92.14 -50.97 5.41 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 115.407 -0.815 . . . . 0.0 110.581 -175.846 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 93' ' ' GLN . . . . . 0.646 ' OE1' ' HA ' ' A' ' 90' ' ' ARG . 0.0 OUTLIER -104.93 -15.1 15.24 Favored 'General case' 0 CA--C 1.539 0.531 0 N-CA-C 113.44 0.904 . . . . 0.0 113.44 -170.151 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.484 ' O ' ' HB2' ' A' ' 90' ' ' ARG . . . 101.32 -97.55 1.67 Allowed Glycine 0 CA--C 1.498 -0.996 0 N-CA-C 110.096 -1.202 . . . . 0.0 110.096 -179.631 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 95' ' ' TRP . . . . . . . . . . . . . 25.3 m95 -145.89 19.45 1.45 Allowed 'General case' 0 C--N 1.315 -0.895 0 N-CA-C 106.246 -1.761 . . . . 0.0 106.246 171.867 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -66.03 -26.59 72.4 Favored Glycine 0 N--CA 1.451 -0.325 0 CA-C-N 114.581 -1.191 . . . . 0.0 112.833 -177.181 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -81.36 -15.19 56.04 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 121.272 0.558 . . . . 0.0 109.966 177.341 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 98' ' ' TRP . . . . . 0.594 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 28.3 m-90 -106.7 107.95 61.09 Favored Pre-proline 0 N--CA 1.445 -0.685 0 CA-C-N 115.472 -0.785 . . . . 0.0 109.42 177.657 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . 0.452 ' HD3' ' HA ' ' A' ' 98' ' ' TRP . 50.6 Cg_exo -61.99 -138.17 0.0 OUTLIER 'Trans proline' 0 CA--C 1.534 0.495 0 C-N-CA 123.876 3.051 . . . . 0.0 114.1 -174.628 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 15.0 m -54.97 -26.49 17.62 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.292 0 CA-C-O 121.166 0.507 . . . . 0.0 111.731 -176.468 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 101' ' ' CYS . . . . . 0.446 ' SG ' ' HB2' ' A' ' 38' ' ' GLU . 83.0 m -56.38 -35.3 67.56 Favored 'General case' 0 C--N 1.313 -0.985 0 CA-C-N 115.195 -0.911 . . . . 0.0 111.553 177.72 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -70.88 -45.83 63.68 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.768 0.318 . . . . 0.0 110.934 178.479 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -59.46 -42.69 92.57 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 121.086 0.469 . . . . 0.0 110.621 177.256 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 49.3 mtp180 -67.14 -19.46 65.61 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.348 -0.842 . . . . 0.0 111.14 178.199 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 105' ' ' ALA . . . . . 0.424 ' CB ' ' HB3' ' A' ' 33' ' ' ALA . . . -96.43 -20.39 18.47 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.938 -0.573 . . . . 0.0 112.109 -176.489 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 102.29 55.28 0.86 Allowed Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.887 -0.673 . . . . 0.0 111.802 -175.996 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -57.58 149.74 20.74 Favored 'General case' 0 C--N 1.329 -0.29 0 C-N-CA 123.224 0.61 . . . . 0.0 111.352 -179.639 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 28.0 mtp180 . . . . . 0 C--O 1.25 1.118 0 CA-C-O 118.317 -0.849 . . . . 0.0 109.49 -171.547 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 79.4 m-20 . . . . . 0 N--CA 1.478 0.936 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 72.5 t -110.83 -57.2 4.12 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.657 0 CA-C-O 120.958 0.408 . . . . 0.0 110.37 179.899 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 24.6 t -84.41 77.35 1.31 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.804 0 CA-C-O 121.644 0.735 . . . . 0.0 110.969 -176.925 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 17.1 t -125.33 142.18 42.95 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.838 0 CA-C-N 115.09 -0.959 . . . . 0.0 109.018 176.812 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 20.0 p -128.24 102.8 20.87 Favored Pre-proline 0 C--N 1.313 -1.01 0 CA-C-N 116.121 -0.491 . . . . 0.0 111.372 -176.787 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 5.1 Cg_exo -78.43 136.34 13.96 Favored 'Trans proline' 0 N--CA 1.448 -1.189 0 C-N-CA 123.304 2.67 . . . . 0.0 110.53 174.417 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . 53.9 42.03 31.84 Favored 'General case' 0 C--N 1.305 -1.352 0 CA-C-N 114.129 -1.396 . . . . 0.0 110.717 -173.376 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 85.6 t60 -69.33 -14.72 63.08 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-N 114.372 -1.286 . . . . 0.0 108.795 171.535 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 12.8 pt-20 -95.18 128.04 41.71 Favored 'General case' 0 N--CA 1.445 -0.722 0 CA-C-N 115.316 -0.856 . . . . 0.0 109.042 175.469 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -128.63 67.29 1.39 Allowed 'General case' 0 C--N 1.314 -0.966 0 CA-C-O 121.724 0.773 . . . . 0.0 110.232 -176.833 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 7.2 p -64.28 -38.39 82.4 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.899 0 CA-C-N 114.515 -1.221 . . . . 0.0 110.319 179.051 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.478 ' O ' ' HG3' ' A' ' 13' ' ' ARG . 61.1 t 5.38 72.39 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.348 0.539 0 C-N-CA 126.487 1.915 . . . . 0.0 114.03 -176.92 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . 0.478 ' HG3' ' O ' ' A' ' 12' ' ' VAL . 83.9 mtm180 -160.29 135.82 8.18 Favored 'General case' 0 C--N 1.304 -1.399 0 CA-C-N 113.074 -1.876 . . . . 0.0 108.107 -179.526 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.3 t -71.92 148.77 9.64 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.218 0 CA-C-O 121.564 0.697 . . . . 0.0 109.514 -176.677 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -114.35 57.74 0.45 Allowed Glycine 0 N--CA 1.428 -1.881 0 CA-C-N 114.804 -1.089 . . . . 0.0 111.945 -176.471 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 3.2 m -71.9 -35.3 69.69 Favored 'General case' 0 C--N 1.313 -1.019 0 CA-C-O 122.072 0.939 . . . . 0.0 109.599 177.628 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . 0.794 ' HB2' ' HG2' ' A' ' 21' ' ' GLU . 0.0 OUTLIER -65.8 119.78 63.54 Favored Pre-proline 0 C--N 1.315 -0.9 0 CA-C-N 113.692 -1.595 . . . . 0.0 111.332 -179.969 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . 0.442 ' HD3' ' HA ' ' A' ' 17' ' ' LYS . 16.1 Cg_exo -70.11 -175.56 1.28 Allowed 'Trans proline' 0 CA--C 1.511 -0.644 0 C-N-CA 123.558 2.839 . . . . 0.0 111.178 171.293 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -61.87 -28.03 69.53 Favored Glycine 0 C--N 1.308 -1.024 0 N-CA-C 109.994 -1.242 . . . . 0.0 109.994 176.461 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 4.5 m -58.38 -40.84 83.41 Favored 'General case' 0 C--N 1.312 -1.062 0 CA-C-N 112.991 -1.604 . . . . 0.0 111.913 177.4 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . 0.794 ' HG2' ' HB2' ' A' ' 17' ' ' LYS . 23.0 mt-10 37.26 77.92 0.04 OUTLIER 'General case' 0 C--O 1.234 0.265 0 N-CA-C 113.684 0.994 . . . . 0.0 113.684 -173.675 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.615 ' CG2' ' HB3' ' A' ' 80' ' ' GLU . 3.7 p -91.15 125.1 59.68 Favored Pre-proline 0 C--N 1.302 -1.474 0 CA-C-N 114.14 -1.391 . . . . 0.0 110.264 172.557 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_exo -54.99 129.56 36.02 Favored 'Trans proline' 0 C--N 1.344 0.292 0 C-N-CA 122.332 2.021 . . . . 0.0 110.7 170.387 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 11.4 Cg_endo -55.15 140.56 80.86 Favored 'Trans proline' 0 N--CA 1.457 -0.634 0 C-N-CA 123.377 2.718 . . . . 0.0 113.286 -172.753 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 22.1 t -116.58 151.68 18.37 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.916 0 CA-C-N 114.557 -1.201 . . . . 0.0 108.734 177.316 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.49 ' H ' HD12 ' A' ' 26' ' ' ILE . 3.1 mp -55.98 -42.69 72.54 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.557 0 CA-C-O 120.988 0.423 . . . . 0.0 111.513 -167.599 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.525 ' HB2' ' OE1' ' A' ' 87' ' ' GLU . 31.1 m-20 -122.95 10.58 9.51 Favored 'General case' 0 C--N 1.316 -0.876 0 CA-C-N 115.583 -0.735 . . . . 0.0 110.286 -173.687 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . 0.583 ' HA2' ' HD1' ' A' ' 31' ' ' TRP . . . -60.55 -14.07 33.67 Favored Glycine 0 N--CA 1.448 -0.516 0 CA-C-N 115.631 -0.713 . . . . 0.0 111.683 -177.816 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 3.6 m -76.65 -41.9 44.04 Favored 'General case' 0 C--N 1.318 -0.772 0 CA-C-O 121.901 0.857 . . . . 0.0 109.576 178.263 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.525 ' O ' HG13 ' A' ' 34' ' ' ILE . 0.5 OUTLIER -66.95 -38.21 80.93 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.696 0 CA-C-N 114.263 -1.335 . . . . 0.0 107.891 -179.66 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' TRP . . . . . 0.583 ' HD1' ' HA2' ' A' ' 28' ' ' GLY . 38.2 m95 -66.33 -35.99 81.77 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 114.852 -1.067 . . . . 0.0 110.519 -177.215 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 5.4 t0 -70.1 -42.88 72.12 Favored 'General case' 0 N--CA 1.442 -0.86 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.138 178.621 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . 0.426 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -69.35 -34.22 74.28 Favored 'General case' 0 N--CA 1.445 -0.704 0 C-N-CA 120.39 -0.524 . . . . 0.0 110.683 179.457 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . 0.525 HG13 ' O ' ' A' ' 30' ' ' ILE . 51.9 mt -62.61 -43.65 98.69 Favored 'Isoleucine or valine' 0 C--O 1.235 0.295 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.429 174.692 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . 0.541 ' HA ' ' O ' ' A' ' 54' ' ' GLY . . . -61.84 -34.94 76.88 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.285 176.349 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . 0.433 ' HA2' ' N ' ' A' ' 41' ' ' GLY . . . -72.46 -16.9 77.51 Favored Glycine 0 N--CA 1.451 -0.328 0 CA-C-N 115.503 -0.771 . . . . 0.0 111.902 179.332 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 7.1 t -81.62 -61.88 1.8 Allowed 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.575 -0.313 . . . . 0.0 111.78 -177.388 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 14.0 tp10 -88.76 -33.73 17.37 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-O 121.109 0.48 . . . . 0.0 110.714 -172.641 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -99.13 -10.53 22.4 Favored 'General case' 0 N--CA 1.446 -0.626 0 CA-C-N 115.986 -0.552 . . . . 0.0 111.797 -173.817 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 75.13 15.9 80.87 Favored Glycine 0 N--CA 1.448 -0.522 0 N-CA-C 109.666 -1.374 . . . . 0.0 109.666 -177.041 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . 0.433 ' N ' ' HA2' ' A' ' 36' ' ' GLY . . . 79.18 61.73 2.31 Favored Glycine 0 N--CA 1.434 -1.478 0 CA-C-N 114.045 -1.077 . . . . 0.0 111.465 -174.64 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 2.4 t-20 -142.91 95.63 2.8 Favored 'General case' 0 C--N 1.323 -0.581 0 N-CA-C 108.799 -0.815 . . . . 0.0 108.799 -179.46 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' TRP . . . . . 0.764 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 18.2 m95 -78.29 -3.23 41.87 Favored 'General case' 0 C--N 1.314 -0.944 0 CA-C-N 115.413 -0.812 . . . . 0.0 110.122 -174.269 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -112.58 14.21 20.11 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.273 -0.876 . . . . 0.0 111.7 -179.111 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.949 HG22 ' HA2' ' A' ' 53' ' ' GLY . 2.9 tt -75.61 145.08 11.2 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.45 0 CA-C-O 121.24 0.543 . . . . 0.0 110.214 179.435 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 14.1 t-20 -146.88 87.62 1.7 Allowed 'General case' 0 C--N 1.312 -1.028 0 N-CA-C 109.649 -0.5 . . . . 0.0 109.649 179.188 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 22.4 p -68.6 -28.16 66.68 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.657 -0.701 . . . . 0.0 110.268 179.72 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 100.01 18.09 23.34 Favored Glycine 0 N--CA 1.444 -0.785 0 CA-C-N 115.382 -0.827 . . . . 0.0 111.162 179.474 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 32.9 p-10 -92.85 10.63 30.24 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 120.878 0.37 . . . . 0.0 111.419 -175.147 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . 0.525 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 90.51 -11.66 70.78 Favored Glycine 0 N--CA 1.449 -0.433 0 N-CA-C 111.707 -0.557 . . . . 0.0 111.707 179.715 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' TYR . . . . . 0.581 ' CE1' ' HB3' ' A' ' 58' ' ' ASP . 0.6 OUTLIER -111.9 162.07 15.72 Favored 'General case' 0 N--CA 1.446 -0.644 0 N-CA-C 106.541 -1.652 . . . . 0.0 106.541 177.671 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' TYR . . . . . 0.749 ' HB2' ' HB3' ' A' ' 74' ' ' ALA . 39.3 m-85 -125.85 169.68 12.38 Favored 'General case' 0 C--N 1.31 -1.114 0 C-N-CA 119.82 -0.752 . . . . 0.0 112.028 -168.313 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.949 ' HA2' HG22 ' A' ' 45' ' ' ILE . . . -60.52 160.04 24.59 Favored Glycine 0 CA--C 1.5 -0.893 0 CA-C-N 115.121 -0.945 . . . . 0.0 113.54 -175.045 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.629 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 92.15 -109.55 3.77 Favored Glycine 0 N--CA 1.437 -1.267 0 C-N-CA 120.515 -0.85 . . . . 0.0 111.615 -177.751 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.581 HG12 ' NE1' ' A' ' 98' ' ' TRP . 3.9 t -87.15 13.18 1.03 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-O 121.378 0.609 . . . . 0.0 110.466 -174.266 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 56' ' ' GLN . . . . . 0.478 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 0.0 OUTLIER 51.07 33.85 9.88 Favored 'General case' 0 N--CA 1.473 0.689 0 N-CA-C 114.454 1.279 . . . . 0.0 114.454 164.975 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 4.7 p90 -113.77 168.95 9.35 Favored 'General case' 0 C--N 1.325 -0.475 0 C-N-CA 119.348 -0.941 . . . . 0.0 112.169 178.593 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.581 ' HB3' ' CE1' ' A' ' 51' ' ' TYR . 5.5 p-10 -83.83 164.53 19.44 Favored 'General case' 0 CA--C 1.517 -0.311 0 N-CA-C 113.887 1.069 . . . . 0.0 113.887 -163.379 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.421 ' HB2' ' HE1' ' A' ' 52' ' ' TYR . 5.2 tp-100 -63.38 -39.58 94.92 Favored 'General case' 0 N--CA 1.449 -0.481 0 CA-C-N 113.553 -1.658 . . . . 0.0 111.969 179.695 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -65.52 -48.03 72.25 Favored Glycine 0 C--N 1.317 -0.504 0 C-N-CA 121.124 -0.56 . . . . 0.0 111.991 -176.217 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 98.4 m -64.85 -42.05 95.21 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-O 120.936 0.398 . . . . 0.0 110.85 176.052 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 62' ' ' TRP . . . . . 0.437 ' CH2' ' HA ' ' A' ' 82' ' ' GLN . 53.4 t-105 -56.91 -49.76 74.6 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 121.733 0.778 . . . . 0.0 109.871 176.764 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . 0.522 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 1.8 tm-20 -67.68 -33.48 75.0 Favored 'General case' 0 C--N 1.318 -0.802 0 CA-C-N 114.677 -1.147 . . . . 0.0 110.656 -178.246 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -66.86 -40.8 87.98 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.923 -179.581 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . 0.405 HD21 ' NH1' ' A' ' 92' ' ' ARG . 8.2 m120 -82.93 -1.78 53.22 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 121.056 0.455 . . . . 0.0 110.328 177.163 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 80.17 48.93 6.18 Favored Glycine 0 C--N 1.334 0.446 0 CA-C-N 115.6 -0.727 . . . . 0.0 112.413 173.686 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.545 ' HA2' ' HD1' ' A' ' 70' ' ' TYR . . . -80.25 -18.71 71.01 Favored Glycine 0 N--CA 1.442 -0.953 0 C-N-CA 120.828 -0.701 . . . . 0.0 112.959 -176.338 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.729 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 6.5 mp -60.84 -28.47 68.85 Favored 'General case' 0 C--N 1.322 -0.616 0 N-CA-C 112.379 0.511 . . . . 0.0 112.379 -172.364 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 16.3 ptm180 -67.85 -28.79 67.85 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 121.457 0.646 . . . . 0.0 110.188 176.206 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 70' ' ' TYR . . . . . 0.627 ' HB3' ' HG3' ' A' ' 81' ' ' GLU . 86.4 m-85 -79.4 -34.11 42.12 Favored 'General case' 0 N--CA 1.442 -0.838 0 N-CA-C 107.419 -1.326 . . . . 0.0 107.419 175.708 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.68 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 159.13 128.39 0.0 OUTLIER Pre-proline 0 CA--C 1.51 -0.589 0 CA-C-N 112.473 -2.149 . . . . 0.0 106.539 -179.474 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 72' ' ' PRO . . . . . 0.729 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 23.3 Cg_exo -55.64 -6.08 0.94 Allowed 'Trans proline' 0 CA--C 1.527 0.166 0 C-N-CA 122.829 2.353 . . . . 0.0 113.808 -176.824 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 12.8 ptm180 -146.84 138.49 24.38 Favored 'General case' 0 C--N 1.322 -0.597 0 N-CA-C 109.521 -0.548 . . . . 0.0 109.521 177.927 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . 0.749 ' HB3' ' HB2' ' A' ' 52' ' ' TYR . . . -61.7 -23.0 65.82 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 113.052 0.76 . . . . 0.0 113.052 -176.168 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . 0.677 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 5.5 p-10 -84.86 -7.68 59.08 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 121.191 0.52 . . . . 0.0 110.65 -179.051 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 54.6 tp -97.68 -31.47 12.25 Favored 'General case' 0 C--N 1.322 -0.623 0 N-CA-C 109.249 -0.648 . . . . 0.0 109.249 173.591 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . 0.727 ' HB1' ' HB3' ' A' ' 81' ' ' GLU . . . -78.55 155.22 29.82 Favored 'General case' 0 N--CA 1.444 -0.757 0 CA-C-N 115.267 -0.879 . . . . 0.0 109.562 176.277 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 48.0 p -97.86 -173.9 2.74 Favored 'General case' 0 C--N 1.311 -1.093 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.539 -176.766 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . 0.764 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 2.1 mtp180 -51.44 -53.62 35.19 Favored 'General case' 0 C--O 1.219 -0.518 0 O-C-N 123.184 0.302 . . . . 0.0 111.073 -178.044 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 80' ' ' GLU . . . . . 0.615 ' HB3' ' CG2' ' A' ' 22' ' ' VAL . 1.6 pm0 -62.47 -45.47 92.89 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-O 120.949 0.404 . . . . 0.0 111.6 -176.5 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 81' ' ' GLU . . . . . 0.727 ' HB3' ' HB1' ' A' ' 77' ' ' ALA . 0.4 OUTLIER -60.88 -52.3 65.66 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 121.204 0.526 . . . . 0.0 112.332 178.194 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 82' ' ' GLN . . . . . 0.513 ' HG2' HG23 ' A' ' 55' ' ' VAL . 6.0 tt0 -69.84 -33.94 72.97 Favored 'General case' 0 C--N 1.316 -0.876 0 CA-C-N 115.449 -0.796 . . . . 0.0 110.735 -175.305 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.568 ' O ' ' HG2' ' A' ' 87' ' ' GLU . 24.3 mt -60.52 -43.18 93.82 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.638 0 CA-C-N 115.535 -0.757 . . . . 0.0 109.905 174.155 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . 0.579 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -64.51 -39.29 93.51 Favored 'General case' 0 C--O 1.237 0.411 0 CA-C-O 121.421 0.629 . . . . 0.0 111.076 -174.867 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 51.5 t -68.29 -49.28 68.2 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.618 0 CA-C-N 115.645 -0.707 . . . . 0.0 111.162 177.761 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -58.69 -29.82 66.93 Favored 'General case' 0 C--O 1.234 0.267 0 CA-C-O 120.955 0.407 . . . . 0.0 110.532 174.232 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 87' ' ' GLU . . . . . 0.724 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 8.8 mm-40 -59.36 -44.42 92.69 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.467 -0.788 . . . . 0.0 109.766 179.279 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.442 ' O ' ' HG3' ' A' ' 92' ' ' ARG . 70.4 t -62.03 -46.26 96.89 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.209 0 CA-C-O 120.933 0.397 . . . . 0.0 109.938 176.473 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . 0.938 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 0.2 OUTLIER -60.03 -48.61 81.02 Favored 'General case' 0 N--CA 1.447 -0.59 0 CA-C-N 115.67 -0.695 . . . . 0.0 112.004 -175.141 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . 0.69 ' HA ' ' OE1' ' A' ' 93' ' ' GLN . 0.2 OUTLIER -60.46 -33.41 72.51 Favored 'General case' 0 CA--C 1.518 -0.28 0 CA-C-N 116.036 -0.529 . . . . 0.0 111.349 -173.433 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . 0.724 ' HG ' ' O ' ' A' ' 87' ' ' GLU . 24.4 mt -66.53 -26.26 67.07 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 121.364 0.602 . . . . 0.0 110.139 -175.039 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . 0.442 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 10.3 mtm180 -89.13 -49.94 6.45 Favored 'General case' 0 C--N 1.317 -0.84 0 CA-C-N 114.957 -1.02 . . . . 0.0 110.377 -172.18 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 93' ' ' GLN . . . . . 0.69 ' OE1' ' HA ' ' A' ' 90' ' ' ARG . 0.0 OUTLIER -99.05 -22.94 15.46 Favored 'General case' 0 CA--C 1.54 0.582 0 N-CA-C 113.457 0.91 . . . . 0.0 113.457 -171.599 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 81.7 47.19 6.42 Favored Glycine 0 C--N 1.335 0.522 0 C-N-CA 120.81 -0.709 . . . . 0.0 111.921 173.225 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 95' ' ' TRP . . . . . 0.443 ' HH2' ' HB3' ' A' ' 27' ' ' ASP . 4.9 m95 59.34 21.15 9.4 Favored 'General case' 0 C--O 1.221 -0.404 0 CA-C-O 121.567 0.698 . . . . 0.0 109.674 -179.02 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.538 ' H ' ' HG2' ' A' ' 93' ' ' GLN . . . -78.09 -18.62 76.3 Favored Glycine 0 N--CA 1.452 -0.262 0 CA-C-N 115.4 -0.818 . . . . 0.0 112.11 174.645 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -81.79 -31.84 31.65 Favored 'General case' 0 C--N 1.326 -0.421 0 N-CA-C 109.541 -0.54 . . . . 0.0 109.541 176.421 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 98' ' ' TRP . . . . . 0.938 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 17.2 m-90 -105.68 103.9 45.88 Favored Pre-proline 0 C--N 1.323 -0.577 0 CA-C-N 115.286 -0.87 . . . . 0.0 109.143 177.265 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . 0.414 ' HD3' ' HA ' ' A' ' 98' ' ' TRP . 11.3 Cg_exo -77.2 -90.85 0.0 OUTLIER 'Trans proline' 0 CA--C 1.536 0.589 0 C-N-CA 122.789 2.326 . . . . 0.0 114.543 -173.467 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . 0.473 ' O ' ' HD2' ' A' ' 104' ' ' ARG . 4.5 p -69.77 -29.37 40.6 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.349 0 CA-C-O 121.962 0.887 . . . . 0.0 110.196 -172.525 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 78.0 m -73.39 -38.8 65.52 Favored 'General case' 0 C--N 1.312 -1.061 0 CA-C-N 114.281 -1.327 . . . . 0.0 111.564 -174.05 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 102' ' ' ALA . . . . . 0.447 ' HB2' ' HB2' ' A' ' 98' ' ' TRP . . . -70.27 -42.37 72.22 Favored 'General case' 0 C--N 1.326 -0.441 0 C-N-CA 120.761 -0.376 . . . . 0.0 110.499 178.494 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -59.3 -45.47 91.19 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 121.2 0.524 . . . . 0.0 110.59 178.552 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 104' ' ' ARG . . . . . 0.473 ' HD2' ' O ' ' A' ' 100' ' ' VAL . 0.0 OUTLIER -71.82 -18.5 62.08 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 115.566 -0.743 . . . . 0.0 111.888 179.512 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 105' ' ' ALA . . . . . 0.431 ' HB3' HG22 ' A' ' 30' ' ' ILE . . . -92.16 -21.35 20.45 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 121.001 0.429 . . . . 0.0 111.45 179.508 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 110.5 63.06 0.51 Allowed Glycine 0 N--CA 1.451 -0.353 0 CA-C-N 116.005 -0.543 . . . . 0.0 112.018 -177.885 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -65.13 149.39 49.99 Favored 'General case' 0 C--N 1.33 -0.244 0 C-N-CA 122.806 0.442 . . . . 0.0 110.908 -178.25 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 71.7 mtp180 . . . . . 0 C--O 1.246 0.884 0 CA-C-O 118.638 -0.696 . . . . 0.0 110.195 -170.995 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 17.2 m120 . . . . . 0 N--CA 1.476 0.844 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 24.4 t 56.26 87.88 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.449 -0.522 0 CA-C-O 122.211 1.005 . . . . 0.0 110.445 -174.988 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 87.2 t -64.72 120.59 11.92 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.641 0 CA-C-N 114.51 -1.223 . . . . 0.0 112.466 -174.618 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 10.8 t -106.87 140.85 23.64 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.524 0 N-CA-C 107.873 -1.158 . . . . 0.0 107.873 167.262 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 3.3 t -90.11 117.65 68.23 Favored Pre-proline 0 C--N 1.313 -0.986 0 CA-C-O 121.361 0.6 . . . . 0.0 112.429 -171.992 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 1.7 Cg_endo -85.25 165.23 11.11 Favored 'Trans proline' 0 N--CA 1.445 -1.328 0 C-N-CA 123.317 2.678 . . . . 0.0 110.339 171.619 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . 54.96 21.73 3.89 Favored 'General case' 0 C--N 1.316 -0.882 0 CA-C-N 115.06 -0.973 . . . . 0.0 112.305 -176.739 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 33.4 t-80 -80.92 -5.78 57.87 Favored 'General case' 0 C--N 1.322 -0.619 0 N-CA-C 108.285 -1.005 . . . . 0.0 108.285 169.937 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 12.2 pt-20 -63.84 145.5 55.68 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 114.712 -1.131 . . . . 0.0 111.453 -175.68 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -104.29 64.15 0.76 Allowed 'General case' 0 C--N 1.319 -0.739 0 CA-C-O 121.934 0.873 . . . . 0.0 109.608 -178.835 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 7.2 p -57.83 -27.83 31.51 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.896 0 CA-C-N 113.781 -1.554 . . . . 0.0 111.245 178.687 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 38.4 t 41.65 90.49 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.445 -0.698 0 CA-C-O 122.558 1.17 . . . . 0.0 112.425 -179.527 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . 0.409 HH11 ' HD3' ' A' ' 13' ' ' ARG . 12.6 ptp180 -88.81 114.41 25.4 Favored 'General case' 0 C--N 1.306 -1.312 0 CA-C-N 114.107 -1.406 . . . . 0.0 108.871 178.069 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.4 HG12 ' N ' ' A' ' 15' ' ' GLY . 3.3 t -79.88 161.11 4.11 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.347 0 CA-C-N 114.656 -1.156 . . . . 0.0 110.559 -175.445 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . 0.4 ' N ' HG12 ' A' ' 14' ' ' VAL . . . 153.31 86.23 0.05 OUTLIER Glycine 0 N--CA 1.431 -1.673 0 CA-C-N 114.053 -1.431 . . . . 0.0 111.308 -178.704 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 8.6 m -65.53 -35.94 82.36 Favored 'General case' 0 N--CA 1.446 -0.655 0 CA-C-O 121.113 0.482 . . . . 0.0 110.147 -179.231 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 34.1 mmtp 37.63 78.76 0.34 Allowed Pre-proline 0 C--N 1.327 -0.384 0 CA-C-N 114.028 -1.442 . . . . 0.0 113.007 175.456 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 27.2 Cg_exo -64.29 163.45 26.35 Favored 'Trans proline' 0 N--CA 1.457 -0.675 0 C-N-CA 122.65 2.233 . . . . 0.0 112.162 177.843 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 133.69 -52.06 0.83 Allowed Glycine 0 C--N 1.304 -1.244 0 CA-C-N 114.295 -1.32 . . . . 0.0 110.417 -174.007 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 51.4 m -67.31 -30.02 69.76 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 121.957 0.884 . . . . 0.0 108.949 168.688 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 42.4 mt-10 -126.71 137.35 53.24 Favored 'General case' 0 N--CA 1.437 -1.085 0 CA-C-N 114.545 -1.207 . . . . 0.0 108.004 177.103 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 93.3 t -80.23 125.62 80.97 Favored Pre-proline 0 C--N 1.31 -1.142 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.987 -176.362 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_exo -53.74 140.1 67.25 Favored 'Trans proline' 0 C--N 1.347 0.478 0 C-N-CA 123.328 2.685 . . . . 0.0 112.03 178.737 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 10.9 Cg_endo -55.58 139.33 82.6 Favored 'Trans proline' 0 N--CA 1.455 -0.785 0 C-N-CA 123.332 2.688 . . . . 0.0 112.953 -177.936 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.955 HG11 HD13 ' A' ' 83' ' ' ILE . 9.1 p -95.36 130.21 44.43 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.038 0 CA-C-N 114.311 -1.313 . . . . 0.0 110.158 178.142 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 49.9 mm -82.14 -30.22 9.77 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 CA-C-O 121.142 0.496 . . . . 0.0 110.513 178.499 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.424 ' O ' HG13 ' A' ' 30' ' ' ILE . 15.0 m-20 -86.21 -3.67 59.02 Favored 'General case' 0 CA--C 1.498 -1.036 0 CA-C-O 121.88 0.848 . . . . 0.0 109.791 -178.438 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . 0.607 ' HA2' ' HB2' ' A' ' 31' ' ' TRP . . . -70.66 -7.44 61.36 Favored Glycine 0 N--CA 1.438 -1.228 0 CA-C-N 114.659 -1.155 . . . . 0.0 110.295 -179.12 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 41.7 m -77.05 -38.35 52.9 Favored 'General case' 0 C--N 1.32 -0.717 0 N-CA-C 109.029 -0.73 . . . . 0.0 109.029 173.997 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.576 ' HA ' ' HB1' ' A' ' 105' ' ' ALA . 0.2 OUTLIER -71.92 -37.1 60.07 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.692 0 N-CA-C 107.844 -1.169 . . . . 0.0 107.844 175.929 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' TRP . . . . . 0.607 ' HB2' ' HA2' ' A' ' 28' ' ' GLY . 38.9 m95 -71.38 -38.29 71.55 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 114.611 -1.177 . . . . 0.0 110.391 -178.377 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 28.3 t70 -78.31 -30.14 48.17 Favored 'General case' 0 N--CA 1.442 -0.846 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.041 178.599 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . 0.481 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -70.6 -33.78 71.43 Favored 'General case' 0 N--CA 1.452 -0.371 0 O-C-N 122.012 -0.43 . . . . 0.0 110.177 176.389 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . 0.534 ' HA ' ' HB3' ' A' ' 101' ' ' CYS . 70.3 mt -64.73 -46.14 93.07 Favored 'Isoleucine or valine' 0 C--O 1.234 0.239 0 CA-C-O 121.241 0.544 . . . . 0.0 109.804 171.473 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . 0.486 ' HA ' ' O ' ' A' ' 54' ' ' GLY . . . -58.61 -39.45 80.48 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.547 -0.751 . . . . 0.0 110.453 176.177 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -76.51 -7.25 85.33 Favored Glycine 0 C--N 1.319 -0.363 0 CA-C-N 115.462 -0.79 . . . . 0.0 111.763 179.923 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 9.3 t -92.47 -64.78 1.06 Allowed 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 115.428 -0.386 . . . . 0.0 110.972 -178.981 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . 0.806 ' HG3' ' SG ' ' A' ' 101' ' ' CYS . 25.7 mt-10 -90.49 -33.64 15.87 Favored 'General case' 0 C--N 1.325 -0.473 0 C-N-CA 120.522 -0.471 . . . . 0.0 111.419 -175.684 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . 0.438 ' HB3' ' O ' ' A' ' 35' ' ' ALA . . . -89.62 -11.86 41.37 Favored 'General case' 0 C--N 1.325 -0.495 0 C-N-CA 120.697 -0.401 . . . . 0.0 111.641 -176.033 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 76.32 13.36 83.41 Favored Glycine 0 CA--C 1.505 -0.556 0 N-CA-C 110.225 -1.15 . . . . 0.0 110.225 -179.672 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 79.64 57.45 3.1 Favored Glycine 0 N--CA 1.433 -1.549 0 CA-C-N 113.915 -1.143 . . . . 0.0 111.759 -176.038 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . 0.413 ' OD1' ' HB ' ' A' ' 45' ' ' ILE . 2.4 t-20 -147.8 106.12 3.77 Favored 'General case' 0 N--CA 1.448 -0.548 0 N-CA-C 108.76 -0.83 . . . . 0.0 108.76 -177.752 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' TRP . . . . . 0.753 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 35.2 m95 -83.92 -12.38 55.49 Favored 'General case' 0 C--N 1.311 -1.07 0 CA-C-N 115.643 -0.708 . . . . 0.0 110.315 -174.031 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -106.67 13.98 27.46 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 115.346 -0.843 . . . . 0.0 110.895 -179.508 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.566 HG22 ' HA3' ' A' ' 53' ' ' GLY . 7.0 tt -77.51 144.38 11.56 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.01 0 N-CA-C 109.239 -0.652 . . . . 0.0 109.239 177.412 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 41.1 t-20 -156.59 100.67 1.96 Allowed 'General case' 0 C--N 1.313 -1.022 0 CA-C-O 121.213 0.53 . . . . 0.0 109.614 -177.625 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 14.6 p -72.59 -24.75 61.13 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.298 -0.864 . . . . 0.0 110.383 179.527 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 96.12 17.77 33.65 Favored Glycine 0 N--CA 1.441 -1.013 0 CA-C-N 115.413 -0.812 . . . . 0.0 111.181 178.537 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 1.6 p-10 -90.34 9.47 28.76 Favored 'General case' 0 C--N 1.329 -0.32 0 C-N-CA 120.56 -0.456 . . . . 0.0 111.356 -173.141 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . 0.452 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 95.42 -11.55 68.66 Favored Glycine 0 N--CA 1.454 -0.154 0 C-N-CA 120.88 -0.676 . . . . 0.0 111.774 -179.194 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' TYR . . . . . 0.658 ' HA ' ' HA ' ' A' ' 58' ' ' ASP . 0.1 OUTLIER -113.67 159.82 19.28 Favored 'General case' 0 N--CA 1.447 -0.62 0 N-CA-C 106.655 -1.609 . . . . 0.0 106.655 174.186 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' TYR . . . . . 0.835 ' O ' ' HA ' ' A' ' 56' ' ' GLN . 50.8 m-85 -123.67 170.67 10.24 Favored 'General case' 0 C--N 1.311 -1.104 0 C-N-CA 120.639 -0.425 . . . . 0.0 111.116 -169.336 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.566 ' HA3' HG22 ' A' ' 45' ' ' ILE . . . -69.88 -168.27 6.56 Favored Glycine 0 N--CA 1.445 -0.753 0 N-CA-C 114.373 0.509 . . . . 0.0 114.373 -172.851 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.653 ' CA ' ' HA ' ' A' ' 43' ' ' TRP . . . 73.46 -107.84 2.34 Favored Glycine 0 N--CA 1.441 -0.977 0 N-CA-C 111.335 -0.706 . . . . 0.0 111.335 -179.466 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.533 HG22 ' HB3' ' A' ' 82' ' ' GLN . 1.7 m -83.73 -0.43 5.39 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-O 121.464 0.649 . . . . 0.0 110.702 179.413 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 56' ' ' GLN . . . . . 0.835 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 7.8 tp-100 57.97 52.98 7.22 Favored 'General case' 0 CA--C 1.535 0.393 0 CA-C-N 114.157 -1.383 . . . . 0.0 114.546 164.404 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -126.73 171.92 10.78 Favored 'General case' 0 C--O 1.233 0.233 0 C-N-CA 118.969 -1.092 . . . . 0.0 112.806 172.512 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.658 ' HA ' ' HA ' ' A' ' 51' ' ' TYR . 7.9 p-10 -77.72 162.34 27.05 Favored 'General case' 0 CA--C 1.515 -0.393 0 N-CA-C 113.945 1.091 . . . . 0.0 113.945 -163.756 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.785 ' HA ' HE21 ' A' ' 59' ' ' GLN . 0.0 OUTLIER -57.67 -41.98 82.62 Favored 'General case' 0 N--CA 1.445 -0.719 0 CA-C-N 114.367 -1.288 . . . . 0.0 111.137 177.194 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -67.61 -49.44 50.16 Favored Glycine 0 CA--C 1.507 -0.431 0 C-N-CA 120.993 -0.622 . . . . 0.0 112.22 -171.787 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 38.8 m -64.97 -42.03 94.92 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-O 120.904 0.383 . . . . 0.0 111.029 177.804 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 62' ' ' TRP . . . . . 0.484 ' CZ3' ' HA ' ' A' ' 82' ' ' GLN . 47.7 t-105 -56.63 -48.2 78.03 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 121.775 0.798 . . . . 0.0 109.514 175.29 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . 0.659 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 36.9 tt0 -65.74 -37.56 86.72 Favored 'General case' 0 N--CA 1.443 -0.791 0 CA-C-N 114.738 -1.119 . . . . 0.0 110.892 -179.151 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -66.02 -41.39 91.04 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.857 -177.941 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . 0.447 ' HB2' HG13 ' A' ' 85' ' ' VAL . 9.4 m120 -76.8 -13.04 60.05 Favored 'General case' 0 N--CA 1.45 -0.445 0 CA-C-O 120.883 0.373 . . . . 0.0 110.261 177.493 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . 0.532 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 92.11 45.43 3.85 Favored Glycine 0 C--N 1.333 0.393 0 CA-C-N 115.846 -0.616 . . . . 0.0 112.642 175.327 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.573 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -79.91 -20.31 68.26 Favored Glycine 0 N--CA 1.443 -0.89 0 C-N-CA 120.807 -0.711 . . . . 0.0 112.848 -174.495 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 1.0 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 6.7 mp -64.37 -23.47 67.3 Favored 'General case' 0 C--N 1.319 -0.756 0 N-CA-C 112.424 0.527 . . . . 0.0 112.424 -172.933 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . 0.532 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 13.2 ptp180 -65.26 -31.16 72.17 Favored 'General case' 0 C--N 1.324 -0.509 0 N-CA-C 109.113 -0.699 . . . . 0.0 109.113 175.884 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 70' ' ' TYR . . . . . 0.588 ' HB3' ' HB3' ' A' ' 81' ' ' GLU . 92.4 m-85 -81.12 -36.05 30.82 Favored 'General case' 0 N--CA 1.439 -0.992 0 CA-C-N 114.683 -1.144 . . . . 0.0 107.94 177.394 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.52 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 164.72 127.55 0.02 OUTLIER Pre-proline 0 N--CA 1.448 -0.567 0 CA-C-N 112.626 -2.079 . . . . 0.0 107.342 -178.364 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 72' ' ' PRO . . . . . 1.0 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 17.4 Cg_exo -59.03 -3.44 1.6 Allowed 'Trans proline' 0 C--N 1.334 -0.217 0 C-N-CA 122.724 2.282 . . . . 0.0 113.586 -178.557 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 13.0 ptm180 -144.05 133.74 23.66 Favored 'General case' 0 C--N 1.315 -0.913 0 N-CA-C 108.127 -1.064 . . . . 0.0 108.127 175.986 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . 0.658 ' HB3' ' HB2' ' A' ' 52' ' ' TYR . . . -57.99 -28.8 64.74 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 115.578 -0.737 . . . . 0.0 112.372 -175.897 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 20.9 p-10 -84.24 -2.86 57.68 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 121.111 0.481 . . . . 0.0 111.499 -175.944 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.477 ' HB3' ' HB1' ' A' ' 71' ' ' ALA . 62.5 tp -96.38 -28.01 14.66 Favored 'General case' 0 C--N 1.322 -0.624 0 N-CA-C 108.413 -0.958 . . . . 0.0 108.413 170.342 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . 0.754 ' HB1' ' HB2' ' A' ' 81' ' ' GLU . . . -80.18 154.4 28.0 Favored 'General case' 0 N--CA 1.444 -0.77 0 CA-C-N 114.413 -1.267 . . . . 0.0 110.093 173.443 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 44.6 p -100.03 -172.5 2.24 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-N 116.392 -0.367 . . . . 0.0 110.136 179.291 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . 0.753 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 19.2 mtt180 -48.73 -53.28 19.59 Favored 'General case' 0 CA--C 1.509 -0.605 0 CA-C-O 121.205 0.526 . . . . 0.0 111.277 -177.924 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 80' ' ' GLU . . . . . 0.586 ' HG3' ' OE2' ' A' ' 81' ' ' GLU . 3.4 pt-20 -59.88 -41.04 90.68 Favored 'General case' 0 C--N 1.312 -1.04 0 CA-C-N 114.958 -1.019 . . . . 0.0 112.086 -175.553 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 81' ' ' GLU . . . . . 0.754 ' HB2' ' HB1' ' A' ' 77' ' ' ALA . 4.6 mp0 -67.46 -51.99 44.8 Favored 'General case' 0 C--O 1.232 0.181 0 N-CA-C 112.132 0.419 . . . . 0.0 112.132 174.444 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 82' ' ' GLN . . . . . 0.533 ' HB3' HG22 ' A' ' 55' ' ' VAL . 54.3 mt-30 -59.98 -43.44 95.12 Favored 'General case' 0 CA--C 1.512 -0.501 0 CA-C-O 121.116 0.484 . . . . 0.0 110.54 -175.73 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.955 HD13 HG11 ' A' ' 25' ' ' VAL . 15.4 mt -60.69 -40.81 85.98 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.787 0 CA-C-N 114.947 -1.024 . . . . 0.0 110.568 178.851 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . 0.585 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -63.6 -42.13 98.26 Favored 'General case' 0 C--O 1.239 0.524 0 CA-C-O 121.428 0.632 . . . . 0.0 111.366 -177.917 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.447 HG13 ' HB2' ' A' ' 65' ' ' ASN . 44.5 t -69.05 -48.01 72.05 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.675 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.243 178.99 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . 0.476 ' HB1' ' CH2' ' A' ' 31' ' ' TRP . . . -57.85 -29.69 65.19 Favored 'General case' 0 N--CA 1.452 -0.34 0 CA-C-N 115.603 -0.726 . . . . 0.0 110.594 174.062 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 87' ' ' GLU . . . . . 0.631 ' HG2' ' O ' ' A' ' 83' ' ' ILE . 15.9 mm-40 -60.81 -40.64 93.5 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.193 178.738 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.504 ' O ' ' HG3' ' A' ' 92' ' ' ARG . 59.0 t -63.08 -48.06 89.61 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-O 121.276 0.56 . . . . 0.0 109.716 173.546 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . 0.741 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 0.3 OUTLIER -63.41 -47.47 81.85 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 115.559 -0.746 . . . . 0.0 112.224 -174.832 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . 0.547 ' HB3' ' CH2' ' A' ' 31' ' ' TRP . 4.8 ptt180 -62.54 -32.82 73.84 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 121.519 0.676 . . . . 0.0 109.216 -176.276 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . 0.537 ' N ' ' HG3' ' A' ' 90' ' ' ARG . 64.3 tp -66.09 -32.18 73.5 Favored 'General case' 0 C--N 1.313 -1.01 0 CA-C-N 114.029 -1.441 . . . . 0.0 111.622 -173.236 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . 0.504 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 3.5 mtm180 -84.98 -46.46 11.2 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-O 121.507 0.67 . . . . 0.0 110.077 -175.116 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 93' ' ' GLN . . . . . 0.499 HE22 HG22 ' A' ' 89' ' ' THR . 4.5 pt20 -101.89 -27.31 13.06 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 115.218 -0.901 . . . . 0.0 113.155 -168.5 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 92.3 39.62 5.33 Favored Glycine 0 CA--C 1.505 -0.555 0 C-N-CA 120.416 -0.897 . . . . 0.0 111.926 174.547 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 95' ' ' TRP . . . . . 0.499 ' CH2' ' HB ' ' A' ' 30' ' ' ILE . 38.7 m95 71.37 6.91 5.92 Favored 'General case' 0 C--O 1.218 -0.589 0 C-N-CA 123.399 0.68 . . . . 0.0 109.6 -178.462 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -58.46 -37.56 88.58 Favored Glycine 0 CA--C 1.521 0.44 0 CA-C-N 115.595 -0.73 . . . . 0.0 113.741 -179.826 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -68.92 -22.2 64.16 Favored 'General case' 0 CA--C 1.519 -0.241 0 CA-C-N 117.219 0.51 . . . . 0.0 110.657 179.139 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 98' ' ' TRP . . . . . 0.741 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 27.7 m-90 -100.9 104.09 29.45 Favored Pre-proline 0 N--CA 1.449 -0.483 0 N-CA-C 109.05 -0.722 . . . . 0.0 109.05 175.918 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . 0.408 ' HD3' ' HA ' ' A' ' 98' ' ' TRP . 16.5 Cg_exo -72.85 -89.96 0.01 OUTLIER 'Trans proline' 0 CA--C 1.533 0.427 0 C-N-CA 122.872 2.382 . . . . 0.0 114.738 -171.509 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 49.0 t -71.68 -30.28 37.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-O 121.811 0.815 . . . . 0.0 110.103 -173.122 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 101' ' ' CYS . . . . . 0.806 ' SG ' ' HG3' ' A' ' 38' ' ' GLU . 70.4 m -76.77 -27.57 55.36 Favored 'General case' 0 C--N 1.317 -0.835 0 CA-C-N 115.099 -0.955 . . . . 0.0 111.869 -169.713 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -69.68 -46.0 67.05 Favored 'General case' 0 C--N 1.329 -0.317 0 C-N-CA 120.75 -0.38 . . . . 0.0 110.753 -179.628 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -67.62 -32.12 72.61 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 120.856 0.36 . . . . 0.0 110.647 -179.946 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -74.1 -21.94 59.69 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.85 177.261 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 105' ' ' ALA . . . . . 0.576 ' HB1' ' HA ' ' A' ' 30' ' ' ILE . . . -96.17 -22.07 17.51 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.815 -0.629 . . . . 0.0 112.057 -176.26 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 108.62 57.08 0.56 Allowed Glycine 0 CA--C 1.522 0.492 0 C-N-CA 120.871 -0.681 . . . . 0.0 112.186 -177.517 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -61.54 149.73 38.09 Favored 'General case' 0 C--N 1.329 -0.321 0 C-N-CA 123.253 0.621 . . . . 0.0 111.551 -175.674 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 72.9 mtp180 . . . . . 0 C--O 1.245 0.859 0 CA-C-O 118.686 -0.673 . . . . 0.0 110.419 -173.855 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 90.8 m-20 . . . . . 0 N--CA 1.478 0.946 0 CA-C-O 120.857 0.36 . . . . 0.0 110.141 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 10.0 p -91.36 34.85 0.1 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.513 0 CA-C-O 122.232 1.015 . . . . 0.0 109.887 -177.354 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 6.0 p -66.39 121.51 15.61 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.67 0 CA-C-N 114.845 -1.07 . . . . 0.0 112.35 -176.898 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 15.7 t -104.24 144.54 14.24 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.628 0 N-CA-C 108.715 -0.846 . . . . 0.0 108.715 171.155 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 35.6 p -89.72 123.13 67.22 Favored Pre-proline 0 C--N 1.313 -0.986 0 CA-C-N 116.45 -0.341 . . . . 0.0 110.378 -178.829 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -77.61 152.84 29.86 Favored 'Trans proline' 0 N--CA 1.449 -1.101 0 C-N-CA 122.777 2.318 . . . . 0.0 110.979 177.33 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -70.25 101.46 1.9 Allowed 'General case' 0 C--N 1.307 -1.24 0 CA-C-O 122.12 0.962 . . . . 0.0 110.314 -178.496 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . 0.441 ' H ' ' H ' ' A' ' 9' ' ' GLU . 45.6 t-80 164.66 -11.03 0.0 OUTLIER 'General case' 0 C--N 1.309 -1.182 0 CA-C-N 112.651 -2.068 . . . . 0.0 105.678 -170.249 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . 0.441 ' H ' ' H ' ' A' ' 8' ' ' HIS . 13.7 pt-20 -62.73 135.67 57.48 Favored 'General case' 0 C--O 1.234 0.241 0 CA-C-N 114.372 -1.286 . . . . 0.0 109.757 178.215 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -124.92 68.51 1.11 Allowed 'General case' 0 C--N 1.318 -0.789 0 CA-C-O 121.536 0.684 . . . . 0.0 110.748 -175.164 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 12.0 p -66.46 -31.09 52.01 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.743 0 CA-C-N 114.37 -1.286 . . . . 0.0 109.703 176.162 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 98.4 t 11.74 84.78 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.448 -0.574 0 C-N-CA 126.34 1.856 . . . . 0.0 114.235 175.111 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . 0.522 ' HG3' ' O ' ' A' ' 13' ' ' ARG . 4.2 ptp180 -99.58 112.03 24.3 Favored 'General case' 0 C--N 1.302 -1.465 0 CA-C-N 113.989 -1.459 . . . . 0.0 109.36 173.664 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 3.0 t -91.09 160.1 2.74 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.484 0 CA-C-N 114.487 -1.233 . . . . 0.0 109.035 179.235 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 88.79 72.34 1.27 Allowed Glycine 0 C--N 1.303 -1.288 0 N-CA-C 110.384 -1.087 . . . . 0.0 110.384 -175.842 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.48 ' O ' ' HD3' ' A' ' 18' ' ' PRO . 25.5 m -74.85 -34.49 62.3 Favored 'General case' 0 N--CA 1.438 -1.056 0 CA-C-O 121.577 0.703 . . . . 0.0 110.55 -175.681 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 11.4 mmmm -102.27 101.25 18.4 Favored Pre-proline 0 C--N 1.316 -0.866 0 CA-C-N 114.649 -1.16 . . . . 0.0 110.604 178.011 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . 0.48 ' HD3' ' O ' ' A' ' 16' ' ' THR . 5.2 Cg_exo -78.94 172.02 15.6 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 C-N-CA 123.067 2.511 . . . . 0.0 112.02 177.0 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 120.19 47.6 0.34 Allowed Glycine 0 C--N 1.308 -1.02 0 CA-C-N 114.522 -1.217 . . . . 0.0 111.864 -178.492 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 27.5 m -68.86 -31.02 69.68 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-O 121.571 0.7 . . . . 0.0 110.707 178.898 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 44.1 mt-10 -117.88 143.75 46.03 Favored 'General case' 0 N--CA 1.433 -1.284 0 CA-C-N 115.348 -0.842 . . . . 0.0 109.062 -176.854 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 38.8 t -85.36 114.17 54.78 Favored Pre-proline 0 C--N 1.305 -1.341 0 CA-C-N 115.374 -0.83 . . . . 0.0 110.392 -178.53 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.432 ' HA ' ' HD2' ' A' ' 24' ' ' PRO . 36.4 Cg_exo -59.74 130.88 37.04 Favored 'Trans proline' 0 N--CA 1.462 -0.342 0 C-N-CA 123.055 2.503 . . . . 0.0 112.394 -178.642 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . 0.432 ' HD2' ' HA ' ' A' ' 23' ' ' PRO . 9.6 Cg_endo -55.0 140.96 79.93 Favored 'Trans proline' 0 N--CA 1.456 -0.724 0 C-N-CA 123.275 2.65 . . . . 0.0 112.069 177.195 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.617 ' HB ' HG21 ' A' ' 83' ' ' ILE . 26.8 t -113.77 140.62 33.24 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.143 0 CA-C-N 114.729 -1.123 . . . . 0.0 109.513 -177.683 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.403 HD12 ' N ' ' A' ' 26' ' ' ILE . 2.7 mp -61.85 -25.37 36.93 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.353 0 CA-C-N 115.48 -0.782 . . . . 0.0 111.913 -173.876 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 8.7 m-20 -88.03 1.69 53.62 Favored 'General case' 0 CA--C 1.502 -0.889 0 CA-C-O 121.511 0.672 . . . . 0.0 109.774 -177.952 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . 0.483 ' HA2' ' HB2' ' A' ' 31' ' ' TRP . . . -64.62 -11.62 49.48 Favored Glycine 0 N--CA 1.44 -1.073 0 CA-C-N 114.893 -1.049 . . . . 0.0 110.64 176.536 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 11.9 m -76.92 -36.88 56.3 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-O 121.854 0.835 . . . . 0.0 109.592 176.511 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.536 ' HA ' ' HB1' ' A' ' 105' ' ' ALA . 1.2 mm -71.34 -40.79 73.71 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 N-CA-C 107.088 -1.449 . . . . 0.0 107.088 176.701 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' TRP . . . . . 0.557 ' HA ' ' CE3' ' A' ' 31' ' ' TRP . 14.3 m95 -67.93 -35.83 79.09 Favored 'General case' 0 C--N 1.315 -0.898 0 CA-C-N 113.711 -1.586 . . . . 0.0 110.536 -175.528 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.607 ' HB2' HH21 ' A' ' 79' ' ' ARG . 12.4 t70 -77.18 -36.6 54.91 Favored 'General case' 0 N--CA 1.44 -0.937 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.712 -179.532 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . 0.476 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -70.65 -34.02 71.59 Favored 'General case' 0 N--CA 1.448 -0.558 0 C-N-CA 120.692 -0.403 . . . . 0.0 110.789 177.124 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . 0.527 HG13 ' O ' ' A' ' 30' ' ' ILE . 60.5 mt -64.94 -46.83 90.48 Favored 'Isoleucine or valine' 0 C--O 1.234 0.25 0 CA-C-O 120.889 0.376 . . . . 0.0 110.559 175.359 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . 0.44 ' O ' ' HB3' ' A' ' 39' ' ' ALA . . . -61.75 -34.67 76.25 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 121.328 0.585 . . . . 0.0 110.285 176.761 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . 0.469 ' HA2' ' N ' ' A' ' 41' ' ' GLY . . . -75.58 -9.47 84.69 Favored Glycine 0 N--CA 1.449 -0.462 0 CA-C-N 115.525 -0.762 . . . . 0.0 111.47 178.117 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.459 ' HB3' ' O ' ' A' ' 34' ' ' ILE . 1.7 t -91.03 -63.13 1.31 Allowed 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 115.399 -0.401 . . . . 0.0 111.409 -177.508 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . 0.731 ' HG3' ' SG ' ' A' ' 101' ' ' CYS . 13.9 mt-10 -89.27 -33.9 16.8 Favored 'General case' 0 C--N 1.327 -0.381 0 C-N-CA 120.405 -0.518 . . . . 0.0 111.39 -175.262 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . 0.44 ' HB3' ' O ' ' A' ' 35' ' ' ALA . . . -88.93 -9.02 53.06 Favored 'General case' 0 C--N 1.323 -0.567 0 C-N-CA 120.706 -0.398 . . . . 0.0 111.367 -177.335 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 75.5 15.92 80.94 Favored Glycine 0 CA--C 1.504 -0.637 0 N-CA-C 110.033 -1.227 . . . . 0.0 110.033 -178.689 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . 0.469 ' N ' ' HA2' ' A' ' 36' ' ' GLY . . . 75.76 60.39 3.19 Favored Glycine 0 N--CA 1.434 -1.491 0 CA-C-N 114.047 -1.076 . . . . 0.0 111.25 -174.273 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 2.1 t-20 -142.71 95.42 2.78 Favored 'General case' 0 N--CA 1.448 -0.538 0 N-CA-C 109.242 -0.651 . . . . 0.0 109.242 -178.759 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' TRP . . . . . 0.699 ' HA ' ' N ' ' A' ' 54' ' ' GLY . 36.8 m95 -79.96 -4.03 50.78 Favored 'General case' 0 C--N 1.317 -0.824 0 CA-C-N 115.516 -0.765 . . . . 0.0 110.319 -176.465 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -111.78 15.07 21.07 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 114.893 -1.049 . . . . 0.0 111.416 179.548 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.841 HG22 ' HA2' ' A' ' 53' ' ' GLY . 10.8 tt -76.64 141.44 15.67 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.719 0 CA-C-O 121.297 0.57 . . . . 0.0 110.398 179.612 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 19.1 m120 -142.01 95.93 2.88 Favored 'General case' 0 C--N 1.312 -1.053 0 CA-C-O 121.34 0.59 . . . . 0.0 109.513 -177.927 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 34.3 p -66.47 -23.7 66.31 Favored 'General case' 0 C--N 1.318 -0.791 0 CA-C-N 114.959 -1.019 . . . . 0.0 110.52 -179.097 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 88.55 14.54 61.44 Favored Glycine 0 N--CA 1.441 -0.989 0 N-CA-C 110.135 -1.186 . . . . 0.0 110.135 -178.408 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 2.6 t30 -96.16 5.25 51.49 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.423 0.63 . . . . 0.0 110.67 -173.229 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 95.53 -1.34 64.0 Favored Glycine 0 N--CA 1.447 -0.618 0 C-N-CA 120.612 -0.804 . . . . 0.0 111.103 -176.223 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' TYR . . . . . 0.528 ' HA ' ' O ' ' A' ' 57' ' ' PHE . 0.7 OUTLIER -110.88 161.36 15.9 Favored 'General case' 0 N--CA 1.444 -0.77 0 N-CA-C 107.724 -1.213 . . . . 0.0 107.724 179.077 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' TYR . . . . . 0.543 ' HB2' ' HB3' ' A' ' 74' ' ' ALA . 43.8 m-85 -129.62 170.05 14.27 Favored 'General case' 0 C--N 1.313 -1.013 0 CA-C-O 120.877 0.37 . . . . 0.0 111.823 -170.092 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.841 ' HA2' HG22 ' A' ' 45' ' ' ILE . . . -60.61 164.8 15.32 Favored Glycine 0 N--CA 1.448 -0.562 0 N-CA-C 115.127 0.811 . . . . 0.0 115.127 -168.663 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.699 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 90.22 -96.29 2.19 Favored Glycine 0 N--CA 1.439 -1.152 0 CA-C-N 114.659 -0.77 . . . . 0.0 112.258 177.652 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -102.21 12.46 7.09 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.672 0 CA-C-O 120.77 0.319 . . . . 0.0 111.49 -175.803 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 56' ' ' GLN . . . . . . . . . . . . . 21.4 mm-40 60.24 43.64 13.6 Favored 'General case' 0 N--CA 1.47 0.557 0 CA-C-N 115.427 -0.806 . . . . 0.0 112.417 173.903 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . 0.528 ' O ' ' HA ' ' A' ' 51' ' ' TYR . 24.3 m-85 -63.38 127.09 29.72 Favored 'General case' 0 CA--C 1.505 -0.757 0 CA-C-N 115.306 -0.861 . . . . 0.0 112.173 172.847 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.512 ' HA ' ' HA ' ' A' ' 51' ' ' TYR . 6.7 p-10 -72.62 156.77 38.63 Favored 'General case' 0 C--N 1.317 -0.84 0 N-CA-C 108.414 -0.958 . . . . 0.0 108.414 163.522 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.854 ' HA ' HE21 ' A' ' 59' ' ' GLN . 0.0 OUTLIER -58.44 -35.2 71.76 Favored 'General case' 0 C--N 1.316 -0.89 0 CA-C-O 120.733 0.301 . . . . 0.0 111.039 -177.221 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -68.13 -49.69 45.08 Favored Glycine 0 N--CA 1.451 -0.349 0 CA-C-N 116.045 -0.525 . . . . 0.0 112.494 -175.945 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 82.0 m -67.7 -40.97 84.28 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 120.933 0.397 . . . . 0.0 110.735 178.767 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 62' ' ' TRP . . . . . 0.518 ' HB2' ' HB3' ' A' ' 57' ' ' PHE . 65.6 t-105 -58.05 -47.56 82.77 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-O 121.547 0.689 . . . . 0.0 109.416 176.436 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . 0.4 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 33.8 tt0 -67.4 -32.51 73.45 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 115.182 -0.917 . . . . 0.0 110.924 -179.979 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -66.42 -42.37 87.85 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.71 -175.832 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . 0.78 ' HB2' HG13 ' A' ' 85' ' ' VAL . 26.1 m-80 -82.86 -5.9 59.2 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.874 0.368 . . . . 0.0 110.292 176.031 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . 0.593 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 90.61 48.15 3.53 Favored Glycine 0 C--N 1.332 0.327 0 CA-C-N 115.928 -0.578 . . . . 0.0 112.931 171.056 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.58 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -79.8 -29.48 47.33 Favored Glycine 0 N--CA 1.438 -1.203 0 C-N-CA 120.684 -0.77 . . . . 0.0 112.43 -176.053 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 1.046 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 8.2 mp -56.78 -22.0 32.71 Favored 'General case' 0 N--CA 1.447 -0.605 0 N-CA-C 112.997 0.74 . . . . 0.0 112.997 -175.189 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . 0.593 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 12.3 ptm180 -70.76 -30.26 66.71 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-O 121.431 0.634 . . . . 0.0 110.076 177.744 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 70' ' ' TYR . . . . . 0.984 ' HB3' ' HG2' ' A' ' 81' ' ' GLU . 46.7 m-85 -85.41 -36.0 20.95 Favored 'General case' 0 N--CA 1.443 -0.817 0 N-CA-C 107.447 -1.316 . . . . 0.0 107.447 177.037 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.644 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 170.74 126.23 0.05 OUTLIER Pre-proline 0 N--CA 1.445 -0.722 0 CA-C-N 112.863 -1.972 . . . . 0.0 107.522 -176.24 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 72' ' ' PRO . . . . . 1.046 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 26.4 Cg_exo -56.43 -6.15 1.37 Allowed 'Trans proline' 0 C--N 1.333 -0.28 0 C-N-CA 123.005 2.47 . . . . 0.0 113.785 -178.289 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 73' ' ' ARG . . . . . 0.432 ' HB2' ' CD1' ' A' ' 52' ' ' TYR . 13.5 ptm180 -147.53 138.67 23.64 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-O 121.28 0.562 . . . . 0.0 109.559 176.155 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . 0.543 ' HB3' ' HB2' ' A' ' 52' ' ' TYR . . . -56.33 -30.22 62.31 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 114.861 -1.063 . . . . 0.0 113.307 -176.289 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 5.4 p-10 -80.47 -11.82 59.63 Favored 'General case' 0 C--N 1.327 -0.379 0 C-N-CA 120.428 -0.509 . . . . 0.0 110.899 -176.988 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.542 ' HB3' ' HB1' ' A' ' 71' ' ' ALA . 46.4 tp -90.16 -31.8 16.92 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-O 121.937 0.875 . . . . 0.0 108.76 173.621 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . 0.644 ' HB2' ' HB3' ' A' ' 71' ' ' ALA . . . -79.68 162.98 24.9 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 114.489 -1.232 . . . . 0.0 110.255 174.122 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 64.1 p -102.11 176.59 5.15 Favored 'General case' 0 C--N 1.318 -0.782 0 CA-C-N 116.399 -0.364 . . . . 0.0 110.721 179.155 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . 0.632 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 41.8 mtp180 -47.37 -50.84 21.35 Favored 'General case' 0 CA--C 1.511 -0.549 0 C-N-CA 123.103 0.561 . . . . 0.0 111.255 -174.75 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 80' ' ' GLU . . . . . 0.537 ' HA ' HD12 ' A' ' 83' ' ' ILE . 3.4 pm0 -60.01 -31.78 70.26 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-N 115.729 -0.669 . . . . 0.0 111.52 -176.815 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 81' ' ' GLU . . . . . 0.984 ' HG2' ' HB3' ' A' ' 70' ' ' TYR . 5.4 mt-10 -71.72 -47.4 54.16 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 116.619 -0.264 . . . . 0.0 111.524 176.302 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 82' ' ' GLN . . . . . 0.582 ' HB2' ' HZ3' ' A' ' 43' ' ' TRP . 5.9 mp0 -60.78 -36.52 79.18 Favored 'General case' 0 CA--C 1.514 -0.428 0 C-N-CA 120.213 -0.595 . . . . 0.0 109.447 175.466 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.617 HG21 ' HB ' ' A' ' 25' ' ' VAL . 53.7 mt -60.7 -49.28 85.15 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.635 0 CA-C-N 115.104 -0.953 . . . . 0.0 110.47 178.111 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . 0.484 ' O ' ' HG3' ' A' ' 87' ' ' GLU . . . -60.35 -45.76 92.32 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-O 120.957 0.408 . . . . 0.0 111.517 -179.53 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.78 HG13 ' HB2' ' A' ' 65' ' ' ASN . 63.6 t -69.1 -49.26 63.87 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.554 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.551 -178.588 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . 0.526 ' CA ' ' HZ ' ' A' ' 57' ' ' PHE . . . -64.56 -32.05 73.53 Favored 'General case' 0 CA--C 1.509 -0.619 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.897 179.645 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 87' ' ' GLU . . . . . 0.575 ' O ' ' HG3' ' A' ' 90' ' ' ARG . 1.3 pp20? -70.83 -29.65 65.85 Favored 'General case' 0 C--N 1.321 -0.665 0 C-N-CA 120.271 -0.572 . . . . 0.0 110.117 -177.624 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.722 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 61.2 t -64.74 -41.47 92.28 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.285 0 N-CA-C 109.136 -0.69 . . . . 0.0 109.136 168.093 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . 0.942 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 1.8 m -65.02 -47.01 78.98 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 115.66 -0.7 . . . . 0.0 111.166 -177.906 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . 0.684 ' HA ' ' OE1' ' A' ' 93' ' ' GLN . 3.0 ppt_? -60.69 -34.1 73.85 Favored 'General case' 0 CA--C 1.516 -0.365 0 CA-C-N 115.801 -0.636 . . . . 0.0 111.598 -175.774 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . 0.722 ' HG ' ' O ' ' A' ' 88' ' ' VAL . 4.5 pp -72.51 -22.22 61.07 Favored 'General case' 0 C--N 1.319 -0.758 0 CA-C-O 121.222 0.534 . . . . 0.0 110.185 -175.035 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . 0.591 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 10.4 mtm180 -84.57 -51.59 6.76 Favored 'General case' 0 CA--C 1.51 -0.574 0 CA-C-N 115.699 -0.682 . . . . 0.0 110.069 -177.713 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 93' ' ' GLN . . . . . 0.684 ' OE1' ' HA ' ' A' ' 90' ' ' ARG . 0.0 OUTLIER -99.17 -22.91 15.43 Favored 'General case' 0 C--N 1.325 -0.474 0 N-CA-C 113.148 0.795 . . . . 0.0 113.148 -171.127 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 94.52 35.04 6.07 Favored Glycine 0 CA--C 1.508 -0.397 0 C-N-CA 120.849 -0.691 . . . . 0.0 112.439 171.254 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 95' ' ' TRP . . . . . 0.425 ' HE1' ' HB2' ' A' ' 108' ' ' ARG . 20.1 m95 66.27 7.87 5.2 Favored 'General case' 0 C--O 1.22 -0.472 0 C-N-CA 123.602 0.761 . . . . 0.0 109.542 -177.146 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -65.55 -32.55 83.66 Favored Glycine 0 C--N 1.332 0.337 0 C-N-CA 121.083 -0.58 . . . . 0.0 112.169 -179.996 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -67.44 -28.92 68.29 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.792 0.329 . . . . 0.0 110.639 178.998 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 98' ' ' TRP . . . . . 0.942 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 26.5 m-90 -100.1 104.44 29.25 Favored Pre-proline 0 N--CA 1.448 -0.55 0 N-CA-C 108.923 -0.769 . . . . 0.0 108.923 176.246 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . 0.427 ' HB2' ' H ' ' A' ' 100' ' ' VAL . 17.0 Cg_exo -72.53 -91.29 0.01 OUTLIER 'Trans proline' 0 CA--C 1.533 0.434 0 C-N-CA 123.101 2.534 . . . . 0.0 114.682 -171.884 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . 0.427 ' H ' ' HB2' ' A' ' 99' ' ' PRO . 41.5 t -70.67 -28.05 32.98 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-O 121.764 0.792 . . . . 0.0 110.234 -172.938 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 101' ' ' CYS . . . . . 0.731 ' SG ' ' HG3' ' A' ' 38' ' ' GLU . 84.7 m -75.66 -38.4 58.81 Favored 'General case' 0 C--N 1.315 -0.906 0 CA-C-N 115.063 -0.971 . . . . 0.0 111.881 -171.588 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -68.05 -44.48 76.28 Favored 'General case' 0 C--N 1.327 -0.398 0 C-N-CA 120.591 -0.444 . . . . 0.0 110.309 -179.861 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -59.49 -37.44 78.25 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 121.081 0.467 . . . . 0.0 111.053 179.075 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 15.9 tpp180 -73.98 -34.33 64.17 Favored 'General case' 0 N--CA 1.431 -1.398 0 CA-C-N 115.578 -0.737 . . . . 0.0 111.429 179.323 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 105' ' ' ALA . . . . . 0.536 ' HB1' ' HA ' ' A' ' 30' ' ' ILE . . . -88.12 -22.65 23.98 Favored 'General case' 0 C--N 1.326 -0.416 0 N-CA-C 112.667 0.617 . . . . 0.0 112.667 -172.878 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 120.33 58.42 0.24 Allowed Glycine 0 CA--C 1.521 0.415 0 C-N-CA 120.661 -0.781 . . . . 0.0 112.527 -177.927 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -66.68 148.8 51.42 Favored 'General case' 0 C--N 1.325 -0.478 0 C-N-CA 122.771 0.428 . . . . 0.0 110.519 -179.355 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 108' ' ' ARG . . . . . 0.425 ' HB2' ' HE1' ' A' ' 95' ' ' TRP . 72.3 mtp180 . . . . . 0 C--O 1.247 0.949 0 CA-C-O 117.946 -1.026 . . . . 0.0 110.777 -171.924 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 26.8 p-10 . . . . . 0 N--CA 1.476 0.827 0 CA-C-O 121.218 0.532 . . . . 0.0 110.721 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 9.5 p -102.59 15.94 5.29 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-O 121.973 0.892 . . . . 0.0 109.518 175.406 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 60.0 t -60.51 114.04 1.01 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.375 0 CA-C-N 114.692 -1.14 . . . . 0.0 112.206 -176.753 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 24.4 t -102.24 150.13 6.47 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 N-CA-C 108.577 -0.897 . . . . 0.0 108.577 173.54 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 21.4 p -81.26 113.61 42.77 Favored Pre-proline 0 C--N 1.316 -0.855 0 CA-C-N 116.406 -0.361 . . . . 0.0 111.089 -177.34 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_exo -61.2 106.42 0.39 Allowed 'Trans proline' 0 CA--C 1.505 -0.946 0 C-N-CA 123.212 2.608 . . . . 0.0 111.822 178.955 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -112.52 36.47 3.4 Favored 'General case' 0 C--N 1.293 -1.87 0 CA-C-N 113.283 -1.78 . . . . 0.0 111.115 -175.883 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 98.3 m-70 -72.52 -11.37 60.63 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-N 114.867 -1.06 . . . . 0.0 109.006 169.776 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -114.11 133.77 55.33 Favored 'General case' 0 N--CA 1.442 -0.864 0 CA-C-N 115.157 -0.928 . . . . 0.0 109.464 178.368 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -150.33 69.03 0.99 Allowed 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 121.839 0.828 . . . . 0.0 110.523 -178.518 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 11.8 p -85.57 -28.29 6.33 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.923 0 CA-C-N 114.703 -1.135 . . . . 0.0 110.404 179.923 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.456 ' O ' ' HG2' ' A' ' 13' ' ' ARG . 7.1 p 31.34 79.75 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.342 0.254 0 C-N-CA 124.699 1.2 . . . . 0.0 112.601 -176.851 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . 0.456 ' HG2' ' O ' ' A' ' 12' ' ' VAL . 14.7 ptp180 47.73 124.33 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.658 0 CA-C-N 113.102 -1.863 . . . . 0.0 113.528 -172.725 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 3.5 t -66.69 152.12 9.8 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.895 0 N-CA-C 108.395 -0.965 . . . . 0.0 108.395 174.855 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -127.45 66.71 0.56 Allowed Glycine 0 N--CA 1.426 -1.973 0 CA-C-N 115.313 -0.858 . . . . 0.0 112.927 -173.549 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 9.8 m -84.24 -32.4 24.48 Favored 'General case' 0 N--CA 1.439 -1.014 0 CA-C-O 121.714 0.768 . . . . 0.0 109.72 175.154 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . 0.434 ' HA ' ' HD3' ' A' ' 18' ' ' PRO . 70.4 mmtt -65.7 113.22 10.98 Favored Pre-proline 0 C--N 1.317 -0.819 0 CA-C-N 114.369 -1.287 . . . . 0.0 110.967 179.016 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . 0.434 ' HD3' ' HA ' ' A' ' 17' ' ' LYS . 22.3 Cg_exo -67.85 161.51 43.66 Favored 'Trans proline' 0 N--CA 1.455 -0.779 0 C-N-CA 123.387 2.724 . . . . 0.0 112.352 178.885 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 103.94 -26.5 22.97 Favored Glycine 0 C--N 1.303 -1.28 0 CA-C-N 114.248 -1.342 . . . . 0.0 110.261 -177.379 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 21.6 m -59.06 -35.64 73.69 Favored 'General case' 0 C--N 1.313 -1.01 0 CA-C-N 113.527 -1.337 . . . . 0.0 110.983 176.84 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . 0.513 ' O ' ' HD3' ' A' ' 23' ' ' PRO . 1.5 mp0 -64.46 107.9 1.5 Allowed 'General case' 0 CA--C 1.506 -0.72 0 CA-C-O 121.521 0.677 . . . . 0.0 109.835 178.892 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 37.8 t -81.73 114.29 49.01 Favored Pre-proline 0 C--N 1.305 -1.352 0 CA-C-N 114.428 -1.26 . . . . 0.0 110.77 -179.331 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.513 ' HD3' ' O ' ' A' ' 21' ' ' GLU . 35.8 Cg_exo -60.68 154.82 52.19 Favored 'Trans proline' 0 N--CA 1.459 -0.551 0 C-N-CA 123.005 2.47 . . . . 0.0 110.979 170.605 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 7.7 Cg_endo -52.27 140.14 52.66 Favored 'Trans proline' 0 N--CA 1.451 -0.981 0 C-N-CA 122.193 1.929 . . . . 0.0 110.643 178.004 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.557 ' HB ' HG21 ' A' ' 83' ' ' ILE . 93.5 t -79.17 124.96 38.19 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.296 0 CA-C-N 114.683 -1.144 . . . . 0.0 112.301 -163.675 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 43.0 mm -67.65 -30.0 47.18 Favored 'Isoleucine or valine' 0 C--O 1.235 0.297 0 CA-C-N 114.114 -1.403 . . . . 0.0 112.689 -171.376 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.609 ' O ' HG12 ' A' ' 30' ' ' ILE . 16.1 m-20 -83.6 2.43 37.37 Favored 'General case' 0 CA--C 1.499 -1.006 0 CA-C-O 121.998 0.904 . . . . 0.0 108.919 -176.939 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . 0.775 ' HA3' HD13 ' A' ' 83' ' ' ILE . . . -67.55 -1.25 15.12 Favored Glycine 0 N--CA 1.433 -1.534 0 CA-C-N 114.143 -1.39 . . . . 0.0 110.844 172.693 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 19.0 m -73.71 -38.31 64.89 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-O 121.46 0.648 . . . . 0.0 109.405 173.203 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.609 HG12 ' O ' ' A' ' 27' ' ' ASP . 0.3 OUTLIER -71.69 -38.84 67.93 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.551 0 N-CA-C 107.179 -1.415 . . . . 0.0 107.179 175.595 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' TRP . . . . . 0.764 ' CD1' HG23 ' A' ' 83' ' ' ILE . 38.8 m95 -69.2 -36.69 77.56 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 114.359 -1.292 . . . . 0.0 110.667 -176.828 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 18.1 t70 -75.33 -33.93 61.17 Favored 'General case' 0 N--CA 1.444 -0.726 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.444 179.775 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . 0.468 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -70.42 -35.26 73.31 Favored 'General case' 0 N--CA 1.444 -0.739 0 C-N-CA 120.441 -0.503 . . . . 0.0 109.965 175.307 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . 0.554 HG13 ' O ' ' A' ' 30' ' ' ILE . 64.6 mt -64.59 -42.59 95.55 Favored 'Isoleucine or valine' 0 C--O 1.234 0.243 0 CA-C-O 120.996 0.427 . . . . 0.0 109.949 172.947 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . 0.432 ' HA ' ' O ' ' A' ' 54' ' ' GLY . . . -57.22 -38.02 73.11 Favored 'General case' 0 N--CA 1.451 -0.418 0 CA-C-N 115.78 -0.646 . . . . 0.0 109.997 174.608 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -73.49 -13.39 80.08 Favored Glycine 0 N--CA 1.45 -0.431 0 CA-C-N 115.375 -0.829 . . . . 0.0 112.051 179.456 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 37.3 t -94.19 -60.11 1.81 Allowed 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 120.702 0.286 . . . . 0.0 111.291 -178.999 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 9.0 tp10 -88.04 -34.32 18.03 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 121.099 0.476 . . . . 0.0 110.223 -170.972 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . 0.419 ' HB3' ' O ' ' A' ' 35' ' ' ALA . . . -92.76 -16.28 25.6 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.99 -0.55 . . . . 0.0 111.268 -177.528 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 83.52 5.33 88.57 Favored Glycine 0 CA--C 1.507 -0.461 0 N-CA-C 110.118 -1.193 . . . . 0.0 110.118 -176.124 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 90.28 59.23 1.48 Allowed Glycine 0 N--CA 1.434 -1.44 0 CA-C-N 114.095 -1.053 . . . . 0.0 112.034 -178.912 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . 0.486 HD22 ' HB ' ' A' ' 45' ' ' ILE . 66.0 t30 -152.44 126.32 9.01 Favored 'General case' 0 CA--C 1.507 -0.674 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 178.12 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' TRP . . . . . 0.768 ' HA ' ' N ' ' A' ' 54' ' ' GLY . 37.4 m95 -98.16 -12.89 21.25 Favored 'General case' 0 C--N 1.307 -1.263 0 CA-C-N 115.769 -0.65 . . . . 0.0 110.475 -174.171 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -102.95 5.23 38.24 Favored 'General case' 0 C--N 1.316 -0.875 0 CA-C-N 114.922 -1.036 . . . . 0.0 110.729 -179.113 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.486 ' HB ' HD22 ' A' ' 42' ' ' ASN . 9.8 tt -73.57 142.15 15.3 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.981 0 CA-C-N 115.921 -0.581 . . . . 0.0 109.876 -178.55 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 40.3 t-20 -154.63 99.15 2.14 Favored 'General case' 0 C--N 1.307 -1.281 0 N-CA-C 109.446 -0.576 . . . . 0.0 109.446 179.611 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 34.8 p -74.58 -15.79 60.83 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 115.626 -0.716 . . . . 0.0 110.937 -177.33 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 94.84 19.76 30.57 Favored Glycine 0 N--CA 1.448 -0.559 0 N-CA-C 111.431 -0.668 . . . . 0.0 111.431 178.932 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 32.5 p-10 -95.64 2.68 54.23 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-O 120.987 0.423 . . . . 0.0 111.421 -176.374 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 95.49 -11.33 68.72 Favored Glycine 0 N--CA 1.448 -0.553 0 N-CA-C 111.425 -0.67 . . . . 0.0 111.425 179.108 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' TYR . . . . . 0.625 ' CD1' ' HB2' ' A' ' 58' ' ' ASP . 0.5 OUTLIER -106.69 132.64 52.45 Favored 'General case' 0 CA--C 1.505 -0.752 0 N-CA-C 107.283 -1.377 . . . . 0.0 107.283 178.46 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' TYR . . . . . 0.716 ' HB2' ' HB3' ' A' ' 74' ' ' ALA . 30.9 m-85 -103.07 169.44 8.56 Favored 'General case' 0 C--N 1.304 -1.371 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.972 -168.433 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.427 ' HA2' HG22 ' A' ' 45' ' ' ILE . . . -59.53 173.54 4.34 Favored Glycine 0 N--CA 1.448 -0.526 0 N-CA-C 115.086 0.794 . . . . 0.0 115.086 -169.151 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.768 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 82.13 -99.58 2.04 Favored Glycine 0 N--CA 1.436 -1.329 0 CA-C-N 114.872 -0.664 . . . . 0.0 111.698 178.944 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.571 ' HB ' ' CD1' ' A' ' 57' ' ' PHE . 2.0 t -84.25 -3.41 7.83 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-O 121.774 0.797 . . . . 0.0 109.938 -177.511 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 56' ' ' GLN . . . . . 0.891 ' HA ' HE21 ' A' ' 56' ' ' GLN . 0.0 OUTLIER 55.81 50.36 14.27 Favored 'General case' 0 N--CA 1.46 0.04 0 CA-C-N 114.058 -1.428 . . . . 0.0 112.479 171.429 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . 0.571 ' CD1' ' HB ' ' A' ' 55' ' ' VAL . 3.8 p90 -124.62 165.36 18.01 Favored 'General case' 0 C--N 1.323 -0.546 0 C-N-CA 119.912 -0.715 . . . . 0.0 111.859 177.453 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.625 ' HB2' ' CD1' ' A' ' 51' ' ' TYR . 0.0 OUTLIER -77.12 152.04 35.11 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 114.382 -1.281 . . . . 0.0 113.758 -163.169 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.713 ' HA ' HE21 ' A' ' 59' ' ' GLN . 0.0 OUTLIER -50.82 -41.55 57.57 Favored 'General case' 0 N--CA 1.451 -0.393 0 CA-C-N 113.225 -1.807 . . . . 0.0 112.122 177.699 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -67.6 -49.1 52.67 Favored Glycine 0 C--N 1.315 -0.616 0 CA-C-N 115.507 -0.769 . . . . 0.0 112.013 -176.38 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 89.0 m -64.88 -41.16 95.87 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-O 120.919 0.39 . . . . 0.0 110.631 176.99 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 62' ' ' TRP . . . . . 0.524 ' CZ3' ' HA ' ' A' ' 82' ' ' GLN . 40.9 t-105 -57.0 -47.79 79.99 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 121.622 0.725 . . . . 0.0 109.617 174.725 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . 0.521 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 20.2 tt0 -65.28 -36.79 85.16 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-N 114.872 -1.058 . . . . 0.0 110.792 -179.932 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -67.57 -35.47 79.07 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 115.427 -0.806 . . . . 0.0 110.518 -177.672 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . 0.542 ' HB2' HG13 ' A' ' 85' ' ' VAL . 10.7 m120 -78.51 -12.9 60.04 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.249 175.823 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . 0.579 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 87.81 44.11 5.54 Favored Glycine 0 N--CA 1.447 -0.569 0 CA-C-N 115.411 -0.813 . . . . 0.0 112.035 177.345 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.603 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -78.74 -22.04 67.48 Favored Glycine 0 N--CA 1.439 -1.117 0 C-N-CA 120.595 -0.812 . . . . 0.0 112.361 -173.52 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.929 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 7.1 mp -60.68 -21.25 62.64 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 112.592 0.59 . . . . 0.0 112.592 -174.334 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . 0.579 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 10.0 ptp180 -70.56 -32.9 70.49 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-O 121.253 0.549 . . . . 0.0 109.835 175.185 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 70' ' ' TYR . . . . . 0.662 ' HB3' ' CG ' ' A' ' 81' ' ' GLU . 73.2 m-85 -80.53 -34.59 35.42 Favored 'General case' 0 N--CA 1.443 -0.812 0 N-CA-C 107.47 -1.308 . . . . 0.0 107.47 178.502 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.683 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 164.12 129.12 0.02 OUTLIER Pre-proline 0 CA--C 1.511 -0.551 0 CA-C-N 112.616 -2.084 . . . . 0.0 106.759 -179.49 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 72' ' ' PRO . . . . . 0.929 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 20.4 Cg_exo -57.14 -4.75 1.12 Allowed 'Trans proline' 0 C--N 1.333 -0.244 0 C-N-CA 122.84 2.36 . . . . 0.0 113.932 -177.2 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 13.8 ptm180 -148.11 141.09 24.86 Favored 'General case' 0 C--N 1.317 -0.815 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 176.259 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . 0.716 ' HB3' ' HB2' ' A' ' 52' ' ' TYR . . . -59.12 -31.7 69.17 Favored 'General case' 0 C--O 1.219 -0.509 0 CA-C-N 115.615 -0.72 . . . . 0.0 112.298 -177.109 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 8.4 p-10 -85.17 9.68 14.35 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 121.282 0.563 . . . . 0.0 111.263 -174.673 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 50.2 tp -112.13 -33.01 6.37 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.519 -0.764 . . . . 0.0 109.182 173.667 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . 0.683 ' HB2' ' HB3' ' A' ' 71' ' ' ALA . . . -79.6 164.71 23.61 Favored 'General case' 0 N--CA 1.448 -0.548 0 CA-C-N 115.065 -0.97 . . . . 0.0 109.449 173.029 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 19.4 p -100.5 -176.99 3.36 Favored 'General case' 0 C--N 1.322 -0.626 0 C-N-CA 120.429 -0.509 . . . . 0.0 110.292 -179.997 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . 0.606 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 2.5 mtp180 -49.3 -52.63 26.47 Favored 'General case' 0 CA--C 1.512 -0.517 0 O-C-N 123.403 0.439 . . . . 0.0 111.178 -174.505 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 80' ' ' GLU . . . . . 0.562 ' HG3' ' OE2' ' A' ' 81' ' ' GLU . 11.7 pt-20 -58.39 -42.26 86.67 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.892 -174.806 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 81' ' ' GLU . . . . . 0.662 ' CG ' ' HB3' ' A' ' 70' ' ' TYR . 5.2 mp0 -63.5 -52.71 60.08 Favored 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 111.956 0.354 . . . . 0.0 111.956 174.186 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 82' ' ' GLN . . . . . 0.524 ' HA ' ' CZ3' ' A' ' 62' ' ' TRP . 40.7 mt-30 -59.7 -38.11 80.69 Favored 'General case' 0 CA--C 1.518 -0.268 0 CA-C-O 121.54 0.686 . . . . 0.0 110.097 -176.577 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.775 HD13 ' HA3' ' A' ' 28' ' ' GLY . 31.7 mt -61.57 -49.51 84.09 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.843 0 CA-C-N 114.276 -1.329 . . . . 0.0 111.082 173.832 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . 0.647 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -62.67 -38.79 91.72 Favored 'General case' 0 N--CA 1.466 0.342 0 CA-C-O 121.195 0.522 . . . . 0.0 111.886 -176.08 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.542 HG13 ' HB2' ' A' ' 65' ' ' ASN . 60.5 t -64.45 -47.73 88.13 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.495 175.853 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -59.44 -30.86 68.79 Favored 'General case' 0 N--CA 1.453 -0.282 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.051 174.497 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 87' ' ' GLU . . . . . 0.804 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 14.4 mm-40 -59.51 -44.31 93.17 Favored 'General case' 0 C--O 1.219 -0.51 0 CA-C-N 115.344 -0.844 . . . . 0.0 110.484 179.736 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.473 ' HB ' ' HB3' ' A' ' 65' ' ' ASN . 70.7 t -61.48 -49.92 82.46 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.404 0 CA-C-O 121.049 0.452 . . . . 0.0 110.574 -176.414 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . 0.624 HG23 ' CH2' ' A' ' 98' ' ' TRP . 13.7 t -72.64 -33.76 66.82 Favored 'General case' 0 N--CA 1.438 -1.027 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.074 -176.482 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . 0.567 ' HG2' ' HA ' ' A' ' 87' ' ' GLU . 0.8 OUTLIER -60.33 -32.1 70.93 Favored 'General case' 0 N--CA 1.472 0.644 0 CA-C-O 121.176 0.512 . . . . 0.0 110.229 175.982 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . 0.804 ' HG ' ' O ' ' A' ' 87' ' ' GLU . 19.4 mt -62.51 -33.08 74.17 Favored 'General case' 0 C--N 1.317 -0.805 0 CA-C-O 121.428 0.632 . . . . 0.0 109.733 177.312 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . 0.487 ' NE ' ' HA ' ' A' ' 89' ' ' THR . 2.8 mtm180 -86.29 -52.63 5.51 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-N 115.068 -0.969 . . . . 0.0 110.911 -172.975 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 93' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -117.05 2.95 12.73 Favored 'General case' 0 N--CA 1.448 -0.533 0 C-N-CA 119.862 -0.735 . . . . 0.0 112.461 -174.076 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.429 ' HA2' ' O ' ' A' ' 90' ' ' ARG . . . 74.64 -119.98 6.27 Favored Glycine 0 CA--C 1.485 -1.786 0 N-CA-C 111.02 -0.832 . . . . 0.0 111.02 171.943 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 95' ' ' TRP . . . . . 0.457 ' HB3' ' CB ' ' A' ' 102' ' ' ALA . 3.4 m95 -127.57 31.65 5.13 Favored 'General case' 0 C--N 1.299 -1.62 0 N-CA-C 106.338 -1.727 . . . . 0.0 106.338 179.834 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -82.17 -25.92 50.15 Favored Glycine 0 N--CA 1.446 -0.666 0 CA-C-N 114.027 -1.442 . . . . 0.0 110.915 171.539 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -81.14 -23.3 38.41 Favored 'General case' 0 CA--C 1.515 -0.372 0 N-CA-C 109.663 -0.495 . . . . 0.0 109.663 174.352 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 98' ' ' TRP . . . . . 0.624 ' CH2' HG23 ' A' ' 89' ' ' THR . 23.7 m-90 -107.93 107.35 60.17 Favored Pre-proline 0 N--CA 1.448 -0.547 0 CA-C-N 115.776 -0.647 . . . . 0.0 109.909 177.071 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_exo -62.34 -137.01 0.0 OUTLIER 'Trans proline' 0 CA--C 1.535 0.526 0 C-N-CA 123.647 2.898 . . . . 0.0 114.119 -177.044 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 2.9 m -54.54 -28.24 18.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 115.88 -0.6 . . . . 0.0 112.152 -177.787 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 82.5 m -56.8 -39.23 73.75 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.263 178.933 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 102' ' ' ALA . . . . . 0.457 ' CB ' ' HB3' ' A' ' 95' ' ' TRP . . . -71.41 -43.94 65.84 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.845 0.355 . . . . 0.0 111.008 178.118 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -61.54 -44.57 96.8 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.851 -179.649 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -67.33 -19.41 65.45 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.728 -0.669 . . . . 0.0 111.159 177.279 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 105' ' ' ALA . . . . . 0.468 ' CB ' ' HB3' ' A' ' 33' ' ' ALA . . . -91.03 -21.15 21.4 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.913 -0.585 . . . . 0.0 111.606 -178.547 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 111.37 61.52 0.47 Allowed Glycine 0 CA--C 1.519 0.344 0 C-N-CA 121.087 -0.577 . . . . 0.0 111.967 -176.481 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -64.11 149.42 47.69 Favored 'General case' 0 C--N 1.328 -0.355 0 C-N-CA 122.878 0.471 . . . . 0.0 111.006 -176.716 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 74.0 mtp180 . . . . . 0 C--O 1.247 0.946 0 CA-C-O 118.503 -0.761 . . . . 0.0 109.912 -173.899 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 18.3 p-10 . . . . . 0 N--CA 1.48 1.063 0 CA-C-O 121.296 0.57 . . . . 0.0 110.562 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 46.3 t -86.85 -41.51 14.84 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 CA-C-N 115.784 -0.644 . . . . 0.0 109.487 179.027 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 11.6 p -72.21 138.51 21.4 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.856 0 CA-C-N 115.226 -0.897 . . . . 0.0 110.516 176.094 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.526 ' O ' ' HD3' ' A' ' 6' ' ' PRO . 9.3 t -85.38 141.66 14.25 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.577 0 N-CA-C 108.911 -0.774 . . . . 0.0 108.911 176.255 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 16.4 p -104.22 101.94 29.64 Favored Pre-proline 0 C--N 1.318 -0.794 0 CA-C-O 121.057 0.456 . . . . 0.0 111.116 -177.465 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.526 ' HD3' ' O ' ' A' ' 4' ' ' VAL . 61.6 Cg_endo -103.2 169.15 0.22 Allowed 'Trans proline' 0 N--CA 1.444 -1.395 0 C-N-CA 124.09 3.193 . . . . 0.0 112.238 178.785 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -121.36 73.06 1.02 Allowed 'General case' 0 C--N 1.312 -1.027 0 CA-C-N 115.345 -0.843 . . . . 0.0 110.488 173.889 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 32.5 m170 -86.26 -14.79 42.74 Favored 'General case' 0 C--N 1.314 -0.949 0 CA-C-N 114.518 -1.219 . . . . 0.0 107.786 172.366 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 4.8 mt-10 -73.32 121.2 20.04 Favored 'General case' 0 CA--C 1.513 -0.477 0 CA-C-N 114.507 -1.224 . . . . 0.0 111.618 -177.337 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . 0.481 ' O ' HG12 ' A' ' 12' ' ' VAL . . . -153.05 65.24 0.78 Allowed 'General case' 0 C--N 1.316 -0.884 0 CA-C-N 115.272 -0.876 . . . . 0.0 109.152 173.466 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.41 HG13 ' N ' ' A' ' 12' ' ' VAL . 7.1 p -52.92 -49.67 47.43 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.692 0 CA-C-N 114.701 -1.136 . . . . 0.0 111.319 179.789 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.481 HG12 ' O ' ' A' ' 10' ' ' ALA . 7.6 p 29.68 85.26 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.344 0.35 0 C-N-CA 125.099 1.359 . . . . 0.0 113.74 177.676 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 9.5 ptm180 -85.37 112.22 20.64 Favored 'General case' 0 C--N 1.306 -1.286 0 CA-C-N 114.204 -1.362 . . . . 0.0 110.059 -179.403 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 3.0 t -115.97 161.9 14.38 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.5 0 CA-C-N 114.435 -1.257 . . . . 0.0 109.79 -178.261 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 109.3 53.79 0.59 Allowed Glycine 0 N--CA 1.441 -1.029 0 CA-C-N 114.867 -1.06 . . . . 0.0 111.581 178.975 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 8.8 m -91.27 -27.21 18.57 Favored 'General case' 0 C--N 1.31 -1.115 0 CA-C-N 114.075 -1.063 . . . . 0.0 110.254 179.895 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . 0.409 ' HA ' ' HD3' ' A' ' 18' ' ' PRO . 0.1 OUTLIER -74.77 116.31 52.49 Favored Pre-proline 0 C--N 1.314 -0.945 0 CA-C-N 113.972 -1.467 . . . . 0.0 110.987 -176.775 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . 0.409 ' HD3' ' HA ' ' A' ' 17' ' ' LYS . 5.2 Cg_exo -81.8 169.45 14.97 Favored 'Trans proline' 0 N--CA 1.453 -0.876 0 C-N-CA 123.502 2.801 . . . . 0.0 111.563 172.653 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -111.3 -33.5 2.31 Favored Glycine 0 C--N 1.306 -1.097 0 CA-C-N 114.337 -1.301 . . . . 0.0 111.028 178.953 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 23.1 m -64.43 -32.94 74.77 Favored 'General case' 0 C--N 1.315 -0.917 0 CA-C-N 114.281 -0.96 . . . . 0.0 111.174 178.669 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 45.2 mt-10 -131.87 138.82 48.59 Favored 'General case' 0 N--CA 1.441 -0.92 0 CA-C-N 115.885 -0.598 . . . . 0.0 109.921 -175.596 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 61.6 t -85.42 124.34 71.74 Favored Pre-proline 0 C--N 1.312 -1.062 0 CA-C-N 115.458 -0.792 . . . . 0.0 109.159 175.315 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -53.62 128.54 29.87 Favored 'Trans proline' 0 C--N 1.346 0.421 0 C-N-CA 122.887 2.391 . . . . 0.0 112.665 -176.198 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 10.6 Cg_endo -55.43 144.16 74.13 Favored 'Trans proline' 0 N--CA 1.459 -0.55 0 C-N-CA 123.725 2.95 . . . . 0.0 112.698 -179.285 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.861 HG21 HG21 ' A' ' 83' ' ' ILE . 14.8 p -85.0 125.69 40.34 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.981 0 CA-C-N 114.749 -1.114 . . . . 0.0 111.146 -177.253 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 42.9 mm -82.85 -31.42 9.15 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.638 0 CA-C-N 115.419 -0.809 . . . . 0.0 111.35 -179.11 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.603 ' O ' HG12 ' A' ' 30' ' ' ILE . 4.5 m-20 -106.9 6.27 29.13 Favored 'General case' 0 CA--C 1.507 -0.711 0 CA-C-O 121.62 0.724 . . . . 0.0 109.745 -172.947 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . 0.712 ' HA2' ' HB2' ' A' ' 31' ' ' TRP . . . -81.24 3.45 77.19 Favored Glycine 0 CA--C 1.494 -1.259 0 N-CA-C 110.863 -0.895 . . . . 0.0 110.863 -174.504 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 5.8 m -76.39 -48.2 20.65 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-O 121.727 0.775 . . . . 0.0 109.069 176.864 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.797 HG22 ' O ' ' A' ' 105' ' ' ALA . 4.0 pt -71.77 -34.78 52.92 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.182 0 CA-C-N 114.626 -1.17 . . . . 0.0 109.675 175.807 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' TRP . . . . . 0.712 ' HB2' ' HA2' ' A' ' 28' ' ' GLY . 6.5 m95 -66.26 -35.46 80.46 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.311 -0.858 . . . . 0.0 110.085 177.54 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.763 ' HB2' HH21 ' A' ' 79' ' ' ARG . 13.9 t70 -76.37 -34.42 58.92 Favored 'General case' 0 N--CA 1.449 -0.496 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.215 177.135 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -65.67 -36.0 82.4 Favored 'General case' 0 N--CA 1.445 -0.683 0 C-N-CA 120.775 -0.37 . . . . 0.0 110.328 176.794 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . 0.497 HD12 ' CZ3' ' A' ' 31' ' ' TRP . 10.0 mt -67.4 -44.09 87.24 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-O 120.895 0.379 . . . . 0.0 110.706 174.28 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . 0.501 ' O ' ' HB3' ' A' ' 39' ' ' ALA . . . -60.22 -34.13 73.23 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-O 121.464 0.65 . . . . 0.0 110.334 177.023 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -76.35 -18.97 78.81 Favored Glycine 0 N--CA 1.448 -0.551 0 CA-C-N 115.306 -0.861 . . . . 0.0 111.231 177.117 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 7.9 t -86.72 -57.1 3.11 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.238 -0.481 . . . . 0.0 111.536 -176.743 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . 0.878 ' HG2' ' SG ' ' A' ' 101' ' ' CYS . 15.6 mm-40 -87.77 -33.61 18.6 Favored 'General case' 0 CA--C 1.515 -0.39 0 CA-C-O 120.821 0.343 . . . . 0.0 111.078 -174.933 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . 0.501 ' HB3' ' O ' ' A' ' 35' ' ' ALA . . . -96.66 -11.31 25.37 Favored 'General case' 0 C--N 1.324 -0.511 0 C-N-CA 120.424 -0.511 . . . . 0.0 112.124 -173.891 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 80.3 8.28 87.73 Favored Glycine 0 CA--C 1.506 -0.53 0 N-CA-C 110.125 -1.19 . . . . 0.0 110.125 -177.291 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 87.62 56.24 2.16 Favored Glycine 0 N--CA 1.434 -1.455 0 CA-C-N 114.129 -1.036 . . . . 0.0 112.595 179.706 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 50.7 t30 -154.44 122.77 6.06 Favored 'General case' 0 CA--C 1.507 -0.71 0 N-CA-C 109.413 -0.588 . . . . 0.0 109.413 176.993 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' TRP . . . . . 0.712 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 26.3 m95 -96.25 -12.64 24.25 Favored 'General case' 0 C--N 1.308 -1.231 0 CA-C-N 115.055 -0.975 . . . . 0.0 110.415 -173.298 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -101.95 8.97 40.91 Favored 'General case' 0 C--N 1.318 -0.782 0 CA-C-N 115.367 -0.833 . . . . 0.0 110.786 -178.36 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.738 HG22 ' CA ' ' A' ' 53' ' ' GLY . 2.0 tt -72.87 144.22 13.12 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.769 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.006 179.249 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 47.6 t-20 -160.42 101.37 1.36 Allowed 'General case' 0 C--N 1.314 -0.972 0 N-CA-C 109.432 -0.581 . . . . 0.0 109.432 -179.525 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 23.4 p -82.89 -17.13 44.85 Favored 'General case' 0 N--CA 1.445 -0.724 0 CA-C-N 115.559 -0.746 . . . . 0.0 111.222 -178.974 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 91.33 22.19 32.77 Favored Glycine 0 N--CA 1.445 -0.745 0 N-CA-C 111.141 -0.784 . . . . 0.0 111.141 178.398 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 28.7 p-10 -93.67 11.38 29.18 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 121.2 0.524 . . . . 0.0 111.385 -175.904 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . 0.461 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 94.36 -11.38 70.41 Favored Glycine 0 N--CA 1.447 -0.576 0 C-N-CA 120.874 -0.679 . . . . 0.0 111.524 -178.486 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 51' ' ' TYR . . . . . 0.601 ' HA ' ' HA ' ' A' ' 58' ' ' ASP . 0.2 OUTLIER -114.64 162.62 16.54 Favored 'General case' 0 N--CA 1.447 -0.591 0 N-CA-C 107.787 -1.19 . . . . 0.0 107.787 176.94 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 52' ' ' TYR . . . . . 0.635 ' HB2' ' HB3' ' A' ' 74' ' ' ALA . 26.9 m-85 -127.9 169.68 13.67 Favored 'General case' 0 C--N 1.309 -1.191 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.046 -172.717 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.738 ' CA ' HG22 ' A' ' 45' ' ' ILE . . . -68.85 -170.68 6.56 Favored Glycine 0 N--CA 1.445 -0.719 0 N-CA-C 114.342 0.497 . . . . 0.0 114.342 -170.944 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.689 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 75.49 -107.3 2.28 Favored Glycine 0 N--CA 1.44 -1.057 0 C-N-CA 120.984 -0.627 . . . . 0.0 111.856 179.248 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.492 HG12 ' HE1' ' A' ' 98' ' ' TRP . 2.1 t -88.56 9.61 2.29 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.655 0 CA-C-O 121.203 0.525 . . . . 0.0 110.357 -177.403 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 56' ' ' GLN . . . . . 0.659 ' HG3' ' HB3' ' A' ' 38' ' ' GLU . 7.7 mm-40 60.02 50.42 6.66 Favored 'General case' 0 N--CA 1.468 0.426 0 CA-C-N 115.197 -0.911 . . . . 0.0 112.66 174.513 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . 0.502 ' HZ ' ' CA ' ' A' ' 86' ' ' ALA . 49.9 m-85 -76.2 132.24 39.82 Favored 'General case' 0 CA--C 1.503 -0.861 0 CA-C-N 115.126 -0.943 . . . . 0.0 112.301 176.345 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.601 ' HA ' ' HA ' ' A' ' 51' ' ' TYR . 5.6 p-10 -72.54 153.76 41.15 Favored 'General case' 0 C--N 1.315 -0.897 0 C-N-CA 119.542 -0.863 . . . . 0.0 108.707 159.644 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.748 ' HA ' HE21 ' A' ' 59' ' ' GLN . 0.0 OUTLIER -54.92 -36.33 65.13 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-O 120.67 0.271 . . . . 0.0 111.482 -178.187 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -67.63 -49.67 48.33 Favored Glycine 0 C--O 1.226 -0.372 0 CA-C-N 116.046 -0.525 . . . . 0.0 112.445 -174.289 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 88.4 m -65.68 -41.4 92.46 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 121.366 0.603 . . . . 0.0 110.894 179.084 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 62' ' ' TRP . . . . . 0.466 ' CE2' ' HA3' ' A' ' 67' ' ' GLY . 56.5 t-105 -59.07 -48.91 79.87 Favored 'General case' 0 N--CA 1.444 -0.762 0 CA-C-N 115.104 -0.953 . . . . 0.0 109.467 177.144 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . 0.439 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 34.8 tt0 -68.18 -34.64 76.68 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 115.051 -0.977 . . . . 0.0 111.05 -178.604 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -64.43 -41.34 96.64 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.942 -0.572 . . . . 0.0 111.394 -175.914 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . 0.649 HD22 ' N ' ' A' ' 65' ' ' ASN . 0.7 OUTLIER -84.99 -8.63 58.65 Favored 'General case' 0 N--CA 1.451 -0.384 0 CA-C-O 121.109 0.48 . . . . 0.0 110.21 177.394 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 91.76 52.85 2.2 Favored Glycine 0 N--CA 1.451 -0.36 0 CA-C-N 115.762 -0.653 . . . . 0.0 113.15 172.627 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.538 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -80.02 -26.46 55.57 Favored Glycine 0 N--CA 1.439 -1.121 0 C-N-CA 120.669 -0.777 . . . . 0.0 112.338 -178.599 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.962 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 7.6 mp -57.56 -23.0 48.14 Favored 'General case' 0 N--CA 1.45 -0.463 0 N-CA-C 113.272 0.841 . . . . 0.0 113.272 -173.256 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . 0.435 ' HG3' ' N ' ' A' ' 70' ' ' TYR . 1.1 ptp180 -70.39 -31.89 69.31 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-O 121.005 0.431 . . . . 0.0 110.044 176.829 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 70' ' ' TYR . . . . . 1.022 ' HB3' ' HG3' ' A' ' 81' ' ' GLU . 67.5 m-85 -81.39 -34.53 31.58 Favored 'General case' 0 CA--C 1.505 -0.766 0 N-CA-C 107.457 -1.312 . . . . 0.0 107.457 177.274 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.592 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 165.77 129.6 0.03 OUTLIER Pre-proline 0 C--O 1.218 -0.572 0 CA-C-N 112.272 -2.24 . . . . 0.0 107.259 -178.225 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 72' ' ' PRO . . . . . 0.962 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 7.0 Cg_exo -61.02 0.22 0.96 Allowed 'Trans proline' 0 C--N 1.331 -0.367 0 C-N-CA 122.786 2.324 . . . . 0.0 113.536 -177.318 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 73' ' ' ARG . . . . . 0.476 ' HB2' ' CD2' ' A' ' 52' ' ' TYR . 3.4 ptt180 -151.79 136.65 17.19 Favored 'General case' 0 N--CA 1.441 -0.923 0 N-CA-C 108.968 -0.753 . . . . 0.0 108.968 178.817 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . 0.635 ' HB3' ' HB2' ' A' ' 52' ' ' TYR . . . -56.05 -29.55 60.65 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 115.064 -0.971 . . . . 0.0 113.136 -177.081 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . 0.544 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 11.6 p-10 -83.54 -2.26 55.59 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 121.014 0.435 . . . . 0.0 111.205 -175.729 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.487 ' HB3' ' HB1' ' A' ' 71' ' ' ALA . 61.6 tp -101.51 -31.48 10.86 Favored 'General case' 0 C--N 1.322 -0.604 0 N-CA-C 108.536 -0.913 . . . . 0.0 108.536 172.103 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . 0.695 ' HB1' ' HB3' ' A' ' 81' ' ' GLU . . . -78.82 163.26 25.48 Favored 'General case' 0 N--CA 1.443 -0.825 0 CA-C-N 114.739 -1.118 . . . . 0.0 109.86 174.963 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 61.2 p -101.33 -174.59 2.64 Favored 'General case' 0 C--N 1.31 -1.149 0 CA-C-N 115.934 -0.575 . . . . 0.0 111.072 -176.956 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . 0.763 HH21 ' HB2' ' A' ' 32' ' ' ASP . 46.2 mtp180 -54.07 -54.44 39.29 Favored 'General case' 0 CA--C 1.515 -0.374 0 CA-C-O 120.759 0.314 . . . . 0.0 110.437 179.256 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 1.9 pm0 -60.19 -40.37 89.81 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.275 -0.875 . . . . 0.0 111.289 -176.52 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 81' ' ' GLU . . . . . 1.022 ' HG3' ' HB3' ' A' ' 70' ' ' TYR . 0.3 OUTLIER -62.62 -51.19 68.28 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.921 -0.582 . . . . 0.0 112.272 175.94 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 82' ' ' GLN . . . . . 0.62 ' HB2' ' HZ3' ' A' ' 43' ' ' TRP . 53.4 mt-30 -64.07 -35.83 82.01 Favored 'General case' 0 CA--C 1.515 -0.4 0 CA-C-O 121.103 0.478 . . . . 0.0 109.715 179.973 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.861 HG21 HG21 ' A' ' 25' ' ' VAL . 14.7 mt -59.8 -45.43 94.79 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 CA-C-N 115.239 -0.891 . . . . 0.0 110.526 176.636 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . 0.485 ' O ' HG23 ' A' ' 88' ' ' VAL . . . -60.15 -44.29 95.08 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-O 121.209 0.528 . . . . 0.0 110.511 -178.449 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 67.5 t -69.1 -48.58 68.53 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.604 0 CA-C-N 115.428 -0.806 . . . . 0.0 111.493 179.341 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . 0.502 ' CA ' ' HZ ' ' A' ' 57' ' ' PHE . . . -62.6 -34.63 77.4 Favored 'General case' 0 CA--C 1.51 -0.584 0 CA-C-O 121.378 0.608 . . . . 0.0 110.536 179.891 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 87' ' ' GLU . . . . . 0.634 ' HA ' ' HG2' ' A' ' 90' ' ' ARG . 0.7 OUTLIER -71.49 -28.99 64.3 Favored 'General case' 0 C--N 1.315 -0.892 0 CA-C-N 115.525 -0.761 . . . . 0.0 109.965 -176.46 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.636 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 59.9 t -62.47 -42.56 96.19 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.191 0 N-CA-C 109.212 -0.662 . . . . 0.0 109.212 168.969 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . 0.71 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 0.2 OUTLIER -71.96 -41.23 68.0 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 115.869 -0.605 . . . . 0.0 111.54 -174.445 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . 0.634 ' HG2' ' HA ' ' A' ' 87' ' ' GLU . 30.3 ptt180 -59.27 -36.87 76.3 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.657 -175.775 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . 0.636 ' HG ' ' O ' ' A' ' 88' ' ' VAL . 4.6 pp -74.88 -25.25 58.82 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 115.616 -0.72 . . . . 0.0 111.388 -170.087 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . 0.457 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 1.7 mtm180 -85.01 -46.24 11.38 Favored 'General case' 0 CA--C 1.511 -0.533 0 CA-C-O 121.513 0.673 . . . . 0.0 109.796 -176.113 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 93' ' ' GLN . . . . . 0.439 ' NE2' HG22 ' A' ' 89' ' ' THR . 16.6 pt20 -98.71 -29.45 13.01 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.15 -0.932 . . . . 0.0 113.01 -168.592 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 91.86 35.85 6.64 Favored Glycine 0 N--CA 1.446 -0.637 0 C-N-CA 120.167 -1.016 . . . . 0.0 111.355 175.459 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 95' ' ' TRP . . . . . 0.504 ' HA ' ' HE3' ' A' ' 98' ' ' TRP . 31.2 m95 68.3 22.66 7.97 Favored 'General case' 0 C--O 1.222 -0.378 0 CA-C-O 121.486 0.66 . . . . 0.0 110.027 177.186 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -70.11 -27.15 73.32 Favored Glycine 0 N--CA 1.449 -0.454 0 CA-C-N 115.135 -0.938 . . . . 0.0 112.35 175.519 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -75.45 -30.49 59.98 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.782 0.325 . . . . 0.0 110.58 177.242 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 98' ' ' TRP . . . . . 0.71 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 16.5 m-90 -103.8 104.76 44.55 Favored Pre-proline 0 C--N 1.324 -0.527 0 N-CA-C 109.706 -0.479 . . . . 0.0 109.706 179.972 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . 0.405 ' HD3' ' HA ' ' A' ' 98' ' ' TRP . 17.5 Cg_exo -71.09 -93.12 0.01 OUTLIER 'Trans proline' 0 CA--C 1.537 0.645 0 C-N-CA 123.192 2.594 . . . . 0.0 114.523 -173.341 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . 0.472 ' O ' ' HD2' ' A' ' 104' ' ' ARG . 1.3 p -71.68 -27.57 28.54 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.391 0 CA-C-O 121.89 0.852 . . . . 0.0 109.781 -172.686 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 101' ' ' CYS . . . . . 0.878 ' SG ' ' HG2' ' A' ' 38' ' ' GLU . 33.2 m -65.74 -34.76 78.92 Favored 'General case' 0 C--N 1.318 -0.772 0 CA-C-N 114.313 -1.312 . . . . 0.0 111.056 -175.712 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 102' ' ' ALA . . . . . 0.668 ' HB1' ' HB2' ' A' ' 107' ' ' ALA . . . -65.53 -46.55 79.16 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-O 120.945 0.403 . . . . 0.0 110.146 -179.782 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -63.7 -40.59 97.16 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.282 0.563 . . . . 0.0 110.545 179.352 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 104' ' ' ARG . . . . . 0.472 ' HD2' ' O ' ' A' ' 100' ' ' VAL . 0.0 OUTLIER -71.9 -37.89 70.02 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.661 -0.7 . . . . 0.0 111.918 -179.346 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 105' ' ' ALA . . . . . 0.797 ' O ' HG22 ' A' ' 30' ' ' ILE . . . -82.37 -27.84 31.88 Favored 'General case' 0 C--N 1.329 -0.313 0 N-CA-C 112.009 0.374 . . . . 0.0 112.009 -176.166 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 109.4 67.02 0.58 Allowed Glycine 0 CA--C 1.522 0.486 0 C-N-CA 120.64 -0.791 . . . . 0.0 112.277 -173.741 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 107' ' ' ALA . . . . . 0.668 ' HB2' ' HB1' ' A' ' 102' ' ' ALA . . . -58.4 149.81 23.92 Favored 'General case' 0 C--N 1.324 -0.516 0 C-N-CA 123.586 0.754 . . . . 0.0 111.664 178.808 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 8.9 ptm180 . . . . . 0 C--O 1.247 0.945 0 CA-C-N 115.476 -0.783 . . . . 0.0 110.165 -173.168 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 16.0 m120 . . . . . 0 N--CA 1.474 0.752 0 CA-C-O 121.142 0.496 . . . . 0.0 109.847 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 10.5 p -81.94 -15.63 12.12 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.05 0 CA-C-N 115.505 -0.771 . . . . 0.0 109.851 178.696 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . 0.407 ' O ' HG13 ' A' ' 3' ' ' VAL . 5.4 p -66.07 96.96 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.788 0 CA-C-N 115.221 -0.899 . . . . 0.0 111.811 178.351 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 12.0 t -99.04 139.7 20.23 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.659 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 171.895 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . 0.429 ' HA ' ' HD3' ' A' ' 6' ' ' PRO . 8.7 p -113.92 132.19 22.77 Favored Pre-proline 0 C--N 1.309 -1.177 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.599 -173.805 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.429 ' HD3' ' HA ' ' A' ' 5' ' ' THR . 9.4 Cg_exo -74.63 166.31 29.65 Favored 'Trans proline' 0 N--CA 1.45 -1.084 0 C-N-CA 123.24 2.627 . . . . 0.0 110.099 170.182 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . 57.79 -166.01 0.15 Allowed 'General case' 0 C--N 1.312 -1.023 0 CA-C-N 115.069 -0.969 . . . . 0.0 110.412 -172.742 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 18.9 t-80 64.11 10.42 5.43 Favored 'General case' 0 N--CA 1.465 0.293 0 CA-C-O 122.309 1.052 . . . . 0.0 108.764 -172.911 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 10.9 pt-20 -64.35 158.56 23.24 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-N 113.913 -1.494 . . . . 0.0 112.258 -178.918 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -150.17 81.06 1.37 Allowed 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 114.713 -1.13 . . . . 0.0 109.438 178.477 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 14.6 p -58.86 -31.82 45.81 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 CA-C-N 115.182 -0.917 . . . . 0.0 111.871 -178.333 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 6.0 p 34.27 84.11 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.343 0.309 0 CA-C-O 122.823 1.296 . . . . 0.0 113.119 -179.631 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 44.2 mtm180 -89.04 112.98 24.05 Favored 'General case' 0 N--CA 1.432 -1.352 0 CA-C-N 114.01 -1.45 . . . . 0.0 110.833 -177.475 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.8 t -97.55 162.09 2.73 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.204 0 CA-C-N 114.683 -1.144 . . . . 0.0 109.251 178.069 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 129.21 93.99 0.74 Allowed Glycine 0 C--N 1.305 -1.151 0 CA-C-N 115.158 -0.928 . . . . 0.0 111.672 179.66 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.521 ' HB ' ' HD3' ' A' ' 17' ' ' LYS . 36.9 m -81.54 -33.5 31.71 Favored 'General case' 0 N--CA 1.442 -0.833 0 CA-C-O 121.388 0.613 . . . . 0.0 111.675 -176.926 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . 0.521 ' HD3' ' HB ' ' A' ' 16' ' ' THR . 2.5 mppt? -112.59 97.52 40.9 Favored Pre-proline 0 C--N 1.315 -0.924 0 CA-C-N 115.541 -0.754 . . . . 0.0 110.599 -177.772 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . 0.45 ' HD3' ' O ' ' A' ' 16' ' ' THR . 2.2 Cg_endo -86.86 174.4 5.57 Favored 'Trans proline' 0 N--CA 1.449 -1.14 0 C-N-CA 123.204 2.603 . . . . 0.0 111.862 176.06 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 87.8 32.55 12.71 Favored Glycine 0 C--N 1.309 -0.924 0 CA-C-N 114.699 -1.137 . . . . 0.0 111.5 177.729 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 29.8 m -70.07 -30.29 67.5 Favored 'General case' 0 C--N 1.312 -1.054 0 CA-C-N 114.267 -0.966 . . . . 0.0 109.539 175.718 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 31.2 mt-10 -138.91 141.48 38.52 Favored 'General case' 0 N--CA 1.438 -1.043 0 N-CA-C 107.591 -1.263 . . . . 0.0 107.591 -179.678 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.75 HG11 ' HG3' ' A' ' 80' ' ' GLU . 30.3 t -73.32 125.01 91.08 Favored Pre-proline 0 C--N 1.312 -1.063 0 N-CA-C 109.464 -0.569 . . . . 0.0 109.464 178.366 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.437 ' HA ' ' HD2' ' A' ' 24' ' ' PRO . 51.0 Cg_exo -53.26 129.86 35.58 Favored 'Trans proline' 0 C--N 1.346 0.423 0 C-N-CA 123.223 2.615 . . . . 0.0 112.822 -173.729 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . 0.437 ' HD2' ' HA ' ' A' ' 23' ' ' PRO . 10.7 Cg_endo -55.05 141.2 79.84 Favored 'Trans proline' 0 N--CA 1.457 -0.643 0 C-N-CA 123.576 2.851 . . . . 0.0 112.539 -178.853 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.796 HG21 HG21 ' A' ' 83' ' ' ILE . 13.3 p -89.09 127.83 41.56 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.082 0 CA-C-N 114.613 -1.176 . . . . 0.0 111.004 -177.89 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 37.2 mm -83.64 -26.13 7.61 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-N 115.788 -0.642 . . . . 0.0 111.643 -179.879 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.654 ' O ' HG12 ' A' ' 30' ' ' ILE . 2.5 m-20 -110.27 6.39 22.48 Favored 'General case' 0 CA--C 1.506 -0.737 0 CA-C-O 121.86 0.838 . . . . 0.0 109.297 -172.553 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . 0.556 ' HA2' ' HB2' ' A' ' 31' ' ' TRP . . . -79.81 3.81 68.12 Favored Glycine 0 N--CA 1.434 -1.45 0 CA-C-N 114.841 -1.072 . . . . 0.0 110.496 -174.829 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 19.9 t -77.06 -38.86 51.77 Favored 'General case' 0 C--N 1.318 -0.798 0 N-CA-C 108.701 -0.851 . . . . 0.0 108.701 173.456 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.806 ' HA ' ' HB1' ' A' ' 105' ' ' ALA . 0.0 OUTLIER -71.48 -36.66 61.39 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.669 0 N-CA-C 107.166 -1.42 . . . . 0.0 107.166 177.167 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' TRP . . . . . 0.556 ' HB2' ' HA2' ' A' ' 28' ' ' GLY . 14.6 m95 -75.05 -37.91 61.55 Favored 'General case' 0 N--CA 1.442 -0.826 0 CA-C-N 114.447 -1.252 . . . . 0.0 110.726 -176.863 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 23.2 t70 -78.44 -33.28 48.62 Favored 'General case' 0 N--CA 1.442 -0.846 0 CA-C-N 116.445 -0.343 . . . . 0.0 110.933 178.365 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . 0.443 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -68.52 -36.74 79.28 Favored 'General case' 0 N--CA 1.454 -0.26 0 C-N-CA 120.18 -0.608 . . . . 0.0 110.561 176.37 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . 0.504 HG21 ' CD1' ' A' ' 98' ' ' TRP . 79.7 mt -66.63 -46.22 86.54 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-O 120.761 0.315 . . . . 0.0 110.169 174.494 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . 0.439 ' O ' ' HB3' ' A' ' 39' ' ' ALA . . . -58.05 -34.62 70.29 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 121.292 0.568 . . . . 0.0 110.448 176.13 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . 0.519 ' HA2' ' N ' ' A' ' 41' ' ' GLY . . . -80.47 -11.23 84.38 Favored Glycine 0 N--CA 1.45 -0.429 0 CA-C-N 115.616 -0.72 . . . . 0.0 111.975 179.27 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 44.3 t -97.96 -50.75 4.29 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 120.643 0.259 . . . . 0.0 111.309 -176.991 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . 0.601 ' HG2' ' SG ' ' A' ' 101' ' ' CYS . 13.7 mt-10 -88.02 -31.85 19.1 Favored 'General case' 0 CA--C 1.513 -0.474 0 CA-C-O 120.906 0.384 . . . . 0.0 110.346 -175.403 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . 0.439 ' HB3' ' O ' ' A' ' 35' ' ' ALA . . . -103.17 -9.18 19.85 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.828 -177.904 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 77.97 9.92 86.59 Favored Glycine 0 CA--C 1.507 -0.432 0 N-CA-C 110.011 -1.236 . . . . 0.0 110.011 -177.586 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . 0.519 ' N ' ' HA2' ' A' ' 36' ' ' GLY . . . 85.9 59.25 1.9 Allowed Glycine 0 N--CA 1.435 -1.384 0 CA-C-N 114.049 -1.076 . . . . 0.0 111.337 -176.398 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . 0.604 ' HB3' ' HB ' ' A' ' 45' ' ' ILE . 1.8 t30 -140.46 89.3 2.27 Favored 'General case' 0 N--CA 1.448 -0.535 0 N-CA-C 109.215 -0.661 . . . . 0.0 109.215 -176.105 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' TRP . . . . . 0.631 ' HA ' ' N ' ' A' ' 54' ' ' GLY . 50.0 m95 -75.19 -7.83 54.92 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-O 121.563 0.697 . . . . 0.0 110.135 -176.506 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -104.73 9.51 35.01 Favored 'General case' 0 C--N 1.316 -0.867 0 CA-C-N 114.851 -1.068 . . . . 0.0 111.473 -179.637 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.916 HG22 ' HA2' ' A' ' 53' ' ' GLY . 9.7 tt -74.41 143.21 13.74 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.794 0 CA-C-O 121.194 0.521 . . . . 0.0 110.699 -176.862 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 15.3 t-20 -148.37 88.07 1.62 Allowed 'General case' 0 C--N 1.314 -0.958 0 CA-C-O 121.145 0.497 . . . . 0.0 109.681 179.177 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 5.1 p -72.45 -23.95 61.13 Favored 'General case' 0 C--N 1.319 -0.752 0 CA-C-N 115.297 -0.865 . . . . 0.0 111.129 -179.342 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 96.8 16.71 35.26 Favored Glycine 0 N--CA 1.448 -0.513 0 C-N-CA 120.951 -0.642 . . . . 0.0 111.552 178.79 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 12.0 m120 -79.93 2.72 22.36 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.807 0.337 . . . . 0.0 111.006 -175.397 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . 0.45 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 85.7 -3.87 86.55 Favored Glycine 0 N--CA 1.446 -0.678 0 N-CA-C 109.905 -1.278 . . . . 0.0 109.905 -168.396 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 51' ' ' TYR . . . . . 0.506 ' CE1' ' HB3' ' A' ' 58' ' ' ASP . 0.4 OUTLIER -109.09 155.72 20.64 Favored 'General case' 0 N--CA 1.45 -0.453 0 N-CA-C 107.036 -1.468 . . . . 0.0 107.036 177.94 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 52' ' ' TYR . . . . . 0.828 ' O ' ' HA ' ' A' ' 56' ' ' GLN . 47.3 m-85 -129.55 171.32 12.71 Favored 'General case' 0 C--N 1.317 -0.823 0 C-N-CA 120.266 -0.574 . . . . 0.0 112.536 -170.303 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.916 ' HA2' HG22 ' A' ' 45' ' ' ILE . . . -47.97 154.69 1.4 Allowed Glycine 0 N--CA 1.453 -0.172 0 N-CA-C 115.583 0.993 . . . . 0.0 115.583 -171.459 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.631 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 97.79 -109.8 3.89 Favored Glycine 0 N--CA 1.442 -0.923 0 CA-C-N 114.653 -0.774 . . . . 0.0 111.708 176.631 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.432 HG23 ' CD1' ' A' ' 57' ' ' PHE . 1.9 m -84.58 -3.22 7.82 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 CA-C-O 121.681 0.753 . . . . 0.0 110.924 178.403 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 56' ' ' GLN . . . . . 0.828 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 6.1 tt0 55.29 51.4 13.14 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 113.855 -1.521 . . . . 0.0 113.803 168.12 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . 0.432 ' CD1' HG23 ' A' ' 55' ' ' VAL . 1.6 p90 -109.85 172.53 6.8 Favored 'General case' 0 C--O 1.236 0.349 0 C-N-CA 119.731 -0.787 . . . . 0.0 111.533 173.928 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.506 ' HB3' ' CE1' ' A' ' 51' ' ' TYR . 6.8 p-10 -79.0 156.48 28.42 Favored 'General case' 0 C--N 1.329 -0.308 0 N-CA-C 113.733 1.012 . . . . 0.0 113.733 -161.499 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.667 ' HA ' HE21 ' A' ' 59' ' ' GLN . 0.0 OUTLIER -57.03 -38.58 73.38 Favored 'General case' 0 N--CA 1.449 -0.48 0 CA-C-N 113.492 -1.685 . . . . 0.0 111.579 178.805 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -67.38 -49.67 50.02 Favored Glycine 0 N--CA 1.44 -1.089 0 CA-C-N 115.881 -0.6 . . . . 0.0 112.182 -174.256 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 91.6 m -65.8 -41.64 91.67 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 121.37 0.605 . . . . 0.0 110.425 176.405 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 62' ' ' TRP . . . . . 0.594 ' CH2' ' HA ' ' A' ' 74' ' ' ALA . 44.8 t-105 -56.27 -49.49 74.07 Favored 'General case' 0 N--CA 1.447 -0.615 0 CA-C-N 115.129 -0.941 . . . . 0.0 109.958 177.485 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . 0.671 ' HG3' HD11 ' A' ' 68' ' ' LEU . 18.3 tt0 -67.45 -36.47 81.25 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-N 114.907 -1.042 . . . . 0.0 110.77 -179.226 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -64.95 -41.52 95.41 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.657 -0.701 . . . . 0.0 111.059 -177.578 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . 0.633 ' HB2' HG13 ' A' ' 85' ' ' VAL . 8.4 m120 -81.68 -16.44 51.28 Favored 'General case' 0 C--N 1.325 -0.473 0 N-CA-C 109.557 -0.534 . . . . 0.0 109.557 177.991 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 97.01 45.48 2.61 Favored Glycine 0 N--CA 1.449 -0.442 0 CA-C-N 115.784 -0.643 . . . . 0.0 113.538 170.648 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.402 ' HA2' ' CD2' ' A' ' 70' ' ' TYR . . . -79.42 -24.47 60.85 Favored Glycine 0 N--CA 1.44 -1.037 0 N-CA-C 110.762 -0.935 . . . . 0.0 110.762 -179.543 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.683 ' HA ' ' HA ' ' A' ' 72' ' ' PRO . 19.1 mt -54.63 -25.77 28.75 Favored 'General case' 0 N--CA 1.449 -0.503 0 CA-C-O 121.365 0.602 . . . . 0.0 110.728 -176.3 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 8.4 ptm180 -71.98 -27.79 63.0 Favored 'General case' 0 N--CA 1.439 -0.996 0 CA-C-N 115.132 -0.94 . . . . 0.0 109.922 -175.835 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 70' ' ' TYR . . . . . 0.801 ' HB2' ' OE2' ' A' ' 81' ' ' GLU . 10.4 m-85 -94.13 -33.25 13.41 Favored 'General case' 0 N--CA 1.433 -1.308 0 N-CA-C 106.625 -1.62 . . . . 0.0 106.625 177.566 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.933 ' HB1' ' HB3' ' A' ' 76' ' ' LEU . . . 179.16 122.38 0.21 Allowed Pre-proline 0 N--CA 1.447 -0.621 0 CA-C-N 113.422 -1.717 . . . . 0.0 108.754 -178.589 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 72' ' ' PRO . . . . . 0.683 ' HA ' ' HA ' ' A' ' 68' ' ' LEU . 11.9 Cg_exo -61.2 1.58 0.62 Allowed 'Trans proline' 0 CA--C 1.528 0.216 0 C-N-CA 122.683 2.255 . . . . 0.0 113.293 179.417 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 73' ' ' ARG . . . . . 0.522 ' HB2' ' CD2' ' A' ' 52' ' ' TYR . 15.1 ptm180 -151.28 138.2 19.02 Favored 'General case' 0 C--N 1.316 -0.889 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 175.236 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . 0.672 ' HB3' ' HB2' ' A' ' 52' ' ' TYR . . . -58.36 -28.53 65.22 Favored 'General case' 0 C--O 1.218 -0.561 0 CA-C-N 115.543 -0.753 . . . . 0.0 112.584 -174.082 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 11.3 p-10 -87.95 10.15 19.81 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-O 121.062 0.458 . . . . 0.0 111.009 -176.393 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.933 ' HB3' ' HB1' ' A' ' 71' ' ' ALA . 41.6 tp -101.03 -40.16 7.36 Favored 'General case' 0 N--CA 1.45 -0.447 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.121 176.352 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . 0.847 ' HB3' ' HG2' ' A' ' 81' ' ' GLU . . . -103.84 168.81 8.89 Favored 'General case' 0 N--CA 1.447 -0.596 0 CA-C-O 121.108 0.48 . . . . 0.0 110.467 176.757 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 43.6 p -90.17 -177.96 5.28 Favored 'General case' 0 C--N 1.315 -0.918 0 CA-C-N 115.676 -0.693 . . . . 0.0 112.785 -167.303 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . 0.576 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 5.0 mtp180 -49.27 -48.83 45.68 Favored 'General case' 0 CA--C 1.513 -0.457 0 C-N-CA 123.94 0.896 . . . . 0.0 111.782 -171.899 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 80' ' ' GLU . . . . . 0.75 ' HG3' HG11 ' A' ' 22' ' ' VAL . 2.3 pm0 -60.53 -30.31 69.67 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.567 -0.742 . . . . 0.0 111.74 -175.957 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 81' ' ' GLU . . . . . 0.847 ' HG2' ' HB3' ' A' ' 77' ' ' ALA . 0.0 OUTLIER -71.71 -50.38 30.8 Favored 'General case' 0 N--CA 1.449 -0.485 0 C-N-CA 120.934 -0.306 . . . . 0.0 110.311 176.011 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 82' ' ' GLN . . . . . 0.747 ' N ' ' HG3' ' A' ' 81' ' ' GLU . 4.6 mt-30 -59.64 -35.47 74.47 Favored 'General case' 0 CA--C 1.508 -0.661 0 N-CA-C 109.336 -0.616 . . . . 0.0 109.336 -179.851 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.796 HG21 HG21 ' A' ' 25' ' ' VAL . 21.8 mt -61.37 -47.2 94.53 Favored 'Isoleucine or valine' 0 C--O 1.212 -0.92 0 CA-C-N 114.824 -1.08 . . . . 0.0 110.527 175.755 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . 0.643 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -61.03 -43.92 98.17 Favored 'General case' 0 C--O 1.239 0.527 0 CA-C-O 121.378 0.608 . . . . 0.0 111.462 -176.555 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.633 HG13 ' HB2' ' A' ' 65' ' ' ASN . 22.1 t -69.1 -48.47 69.06 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-N 115.927 -0.578 . . . . 0.0 110.549 179.551 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -57.66 -28.68 63.96 Favored 'General case' 0 C--O 1.223 -0.311 0 CA-C-N 115.868 -0.606 . . . . 0.0 110.618 173.925 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 87' ' ' GLU . . . . . 0.675 ' HG2' ' O ' ' A' ' 83' ' ' ILE . 6.6 mm-40 -59.76 -44.87 93.65 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.955 -0.566 . . . . 0.0 109.65 178.166 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.712 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 46.4 t -69.59 -42.34 80.57 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 C-N-CA 120.573 -0.451 . . . . 0.0 110.02 175.58 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . 0.845 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 2.6 m -59.81 -48.09 83.07 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 116.43 -0.35 . . . . 0.0 111.443 -178.898 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . 0.654 ' HA ' ' OE1' ' A' ' 93' ' ' GLN . 7.9 ptt180 -65.67 -34.19 77.64 Favored 'General case' 0 CA--C 1.517 -0.31 0 CA-C-O 120.941 0.4 . . . . 0.0 111.421 -174.874 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . 0.712 ' HG ' ' O ' ' A' ' 88' ' ' VAL . 4.6 pp -70.52 -22.26 62.65 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.892 -174.143 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . 0.562 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 9.8 mtm180 -84.98 -52.28 6.09 Favored 'General case' 0 N--CA 1.449 -0.509 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 -178.698 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 93' ' ' GLN . . . . . 0.732 ' HG2' ' H ' ' A' ' 96' ' ' GLY . 0.0 OUTLIER -96.78 -24.75 15.77 Favored 'General case' 0 CA--C 1.539 0.53 0 N-CA-C 113.602 0.964 . . . . 0.0 113.602 -169.275 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 80.51 50.83 5.17 Favored Glycine 0 CA--C 1.507 -0.414 0 C-N-CA 120.728 -0.749 . . . . 0.0 111.783 176.762 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 95' ' ' TRP . . . . . 0.461 ' HA ' ' HE3' ' A' ' 98' ' ' TRP . 1.4 m95 56.61 29.2 15.21 Favored 'General case' 0 C--O 1.223 -0.3 0 CA-C-O 121.582 0.706 . . . . 0.0 109.754 177.355 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.732 ' H ' ' HG2' ' A' ' 93' ' ' GLN . . . -83.93 -24.78 47.74 Favored Glycine 0 N--CA 1.449 -0.439 0 CA-C-N 115.314 -0.857 . . . . 0.0 111.87 174.912 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -80.9 -23.88 38.65 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 121.238 0.542 . . . . 0.0 109.685 176.423 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 98' ' ' TRP . . . . . 0.845 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 23.4 m-90 -101.01 108.01 52.52 Favored Pre-proline 0 N--CA 1.445 -0.708 0 N-CA-C 108.59 -0.893 . . . . 0.0 108.59 175.63 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . 0.43 ' HD3' ' HA ' ' A' ' 98' ' ' TRP . 45.0 Cg_exo -63.7 -133.68 0.0 OUTLIER 'Trans proline' 0 CA--C 1.541 0.828 0 C-N-CA 123.654 2.903 . . . . 0.0 113.991 -175.928 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 41.8 t -55.22 -25.56 16.99 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.287 0 CA-C-O 120.886 0.374 . . . . 0.0 111.637 -175.116 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 101' ' ' CYS . . . . . 0.601 ' SG ' ' HG2' ' A' ' 38' ' ' GLU . 85.1 m -63.99 -25.66 68.23 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 116.315 -0.402 . . . . 0.0 111.686 -178.25 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -69.36 -44.63 71.17 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.922 0.392 . . . . 0.0 110.368 177.704 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -67.42 -36.63 81.63 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 121.19 0.519 . . . . 0.0 110.142 178.554 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 104' ' ' ARG . . . . . 0.416 HH11 ' HD3' ' A' ' 104' ' ' ARG . 9.8 mmm180 -64.73 -32.56 74.29 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.352 -0.84 . . . . 0.0 110.937 176.844 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 105' ' ' ALA . . . . . 0.806 ' HB1' ' HA ' ' A' ' 30' ' ' ILE . . . -89.01 -22.46 22.97 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 116.136 -0.484 . . . . 0.0 112.085 -176.076 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 103.18 68.04 0.77 Allowed Glycine 0 CA--C 1.521 0.445 0 C-N-CA 120.97 -0.633 . . . . 0.0 112.313 -177.794 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -64.45 152.71 40.88 Favored 'General case' 0 N--CA 1.45 -0.452 0 C-N-CA 122.856 0.462 . . . . 0.0 111.256 -176.063 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 25.5 mmt180 . . . . . 0 C--O 1.248 0.987 0 CA-C-O 118.289 -0.862 . . . . 0.0 111.56 177.64 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 26.2 p-10 . . . . . 0 N--CA 1.473 0.683 0 CA-C-O 121.909 0.862 . . . . 0.0 110.849 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 48.9 t -73.59 -49.37 36.36 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.981 0 N-CA-C 108.434 -0.95 . . . . 0.0 108.434 173.301 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 62.1 t -97.19 132.74 41.05 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.033 0 CA-C-N 115.001 -1.0 . . . . 0.0 109.14 172.671 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 8.0 t -85.39 142.61 12.98 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 CA-C-O 120.766 0.317 . . . . 0.0 110.165 -178.669 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . 0.445 ' HA ' ' HD3' ' A' ' 6' ' ' PRO . 11.8 p -105.76 109.12 62.87 Favored Pre-proline 0 C--N 1.318 -0.804 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.926 -179.613 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.445 ' HD3' ' HA ' ' A' ' 5' ' ' THR . 17.9 Cg_endo -92.4 160.04 3.03 Favored 'Trans proline' 0 N--CA 1.441 -1.561 0 C-N-CA 123.223 2.615 . . . . 0.0 111.746 178.644 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . 0.512 ' C ' ' H ' ' A' ' 9' ' ' GLU . . . 53.33 -157.42 0.17 Allowed 'General case' 0 C--N 1.317 -0.811 0 CA-C-N 114.739 -1.119 . . . . 0.0 111.579 -178.297 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . 0.441 ' HB3' ' O ' ' A' ' 7' ' ' ALA . 80.2 t60 71.52 -21.16 0.22 Allowed 'General case' 0 C--O 1.235 0.293 0 O-C-N 123.703 0.627 . . . . 0.0 110.092 -171.772 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . 0.512 ' H ' ' C ' ' A' ' 7' ' ' ALA . 12.7 pt-20 -104.47 147.26 27.77 Favored 'General case' 0 N--CA 1.442 -0.873 0 CA-C-O 121.084 0.468 . . . . 0.0 110.819 -179.276 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -126.0 74.35 1.42 Allowed 'General case' 0 C--N 1.32 -0.679 0 CA-C-O 121.664 0.745 . . . . 0.0 109.808 -177.191 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.666 HG12 ' HG3' ' A' ' 13' ' ' ARG . 53.9 t -59.93 -57.36 12.06 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.97 0 CA-C-N 114.243 -1.344 . . . . 0.0 111.026 179.306 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 4.9 p 34.33 86.7 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.237 0.443 0 CA-C-O 122.73 1.252 . . . . 0.0 113.445 -179.211 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . 0.666 ' HG3' HG12 ' A' ' 11' ' ' VAL . 23.0 mtm180 -112.12 112.03 23.35 Favored 'General case' 0 C--N 1.312 -1.041 0 CA-C-N 114.105 -1.407 . . . . 0.0 110.824 -179.209 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 3.4 t -112.38 165.0 7.65 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.924 0 CA-C-N 114.856 -1.065 . . . . 0.0 108.744 178.576 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 143.43 94.71 0.2 Allowed Glycine 0 N--CA 1.439 -1.104 0 CA-C-N 115.674 -0.694 . . . . 0.0 112.406 178.97 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -64.52 -67.31 0.44 Allowed 'General case' 0 N--CA 1.446 -0.644 0 CA-C-O 121.025 0.441 . . . . 0.0 110.495 179.16 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 40.5 mmtm 33.83 79.06 0.29 Allowed Pre-proline 0 C--N 1.326 -0.455 0 CA-C-N 113.829 -1.532 . . . . 0.0 113.386 177.754 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 5.7 Cg_exo -75.32 164.56 32.53 Favored 'Trans proline' 0 N--CA 1.455 -0.746 0 C-N-CA 122.654 2.236 . . . . 0.0 111.666 177.765 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 67.59 43.69 84.96 Favored Glycine 0 C--N 1.307 -1.033 0 CA-C-N 114.499 -1.228 . . . . 0.0 111.256 -177.233 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -62.3 -50.63 70.91 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 114.7 -0.75 . . . . 0.0 110.814 -177.11 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 44.6 mt-10 -140.67 135.7 31.91 Favored 'General case' 0 N--CA 1.445 -0.702 0 N-CA-C 108.688 -0.856 . . . . 0.0 108.688 177.025 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 60.7 t -94.5 118.52 66.94 Favored Pre-proline 0 C--N 1.316 -0.852 0 CA-C-N 115.924 -0.58 . . . . 0.0 111.255 -175.284 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_exo -55.22 142.95 77.35 Favored 'Trans proline' 0 C--N 1.345 0.363 0 C-N-CA 123.341 2.694 . . . . 0.0 112.174 176.064 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 9.6 Cg_endo -54.84 148.28 47.11 Favored 'Trans proline' 0 C--N 1.346 0.401 0 C-N-CA 123.815 3.01 . . . . 0.0 113.916 -178.958 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.553 ' HB ' ' HA3' ' A' ' 28' ' ' GLY . 78.3 t -111.22 158.6 11.66 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.82 0 CA-C-N 113.722 -1.581 . . . . 0.0 109.207 -178.395 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 48.1 mm -54.98 -36.7 39.37 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-O 120.739 0.304 . . . . 0.0 111.812 -175.939 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.449 ' O ' HG13 ' A' ' 30' ' ' ILE . 48.6 m-20 -104.14 -12.25 16.83 Favored 'General case' 0 CA--C 1.503 -0.838 0 CA-C-O 122.316 1.055 . . . . 0.0 108.817 175.386 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . 0.625 ' HA2' ' HB2' ' A' ' 31' ' ' TRP . . . -72.15 -2.7 54.29 Favored Glycine 0 N--CA 1.442 -0.923 0 CA-C-N 113.677 -1.602 . . . . 0.0 111.555 -176.637 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 6.3 p -78.02 -48.09 16.96 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-O 122.049 0.928 . . . . 0.0 109.568 174.677 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.741 ' HA ' ' HB1' ' A' ' 105' ' ' ALA . 0.1 OUTLIER -62.89 -35.64 72.11 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.971 0 CA-C-N 113.392 -1.731 . . . . 0.0 107.713 175.691 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' TRP . . . . . 0.625 ' HB2' ' HA2' ' A' ' 28' ' ' GLY . 18.5 m95 -73.58 -36.91 65.61 Favored 'General case' 0 C--N 1.317 -0.817 0 CA-C-N 114.301 -1.318 . . . . 0.0 110.821 -178.092 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 1.6 t70 -77.92 -34.39 51.37 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.596 179.671 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . 0.448 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -70.07 -34.28 72.98 Favored 'General case' 0 N--CA 1.45 -0.474 0 C-N-CA 120.877 -0.329 . . . . 0.0 110.339 176.584 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . 0.504 HG13 ' O ' ' A' ' 30' ' ' ILE . 54.0 mt -65.12 -45.1 95.19 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.225 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 172.311 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . 0.552 ' HA ' ' O ' ' A' ' 54' ' ' GLY . . . -57.59 -36.41 71.68 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.228 176.613 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -73.92 -21.12 79.57 Favored Glycine 0 N--CA 1.451 -0.328 0 CA-C-N 115.574 -0.739 . . . . 0.0 112.237 178.886 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 18.5 t -93.75 -52.9 4.24 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-O 121.038 0.447 . . . . 0.0 111.811 -176.593 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 9.3 tp10 -87.58 -32.3 19.41 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 121.399 0.619 . . . . 0.0 110.107 -171.667 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . 0.448 ' HB3' ' O ' ' A' ' 35' ' ' ALA . . . -101.51 -13.57 17.85 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 115.644 -0.707 . . . . 0.0 111.616 -177.805 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 80.1 13.08 82.54 Favored Glycine 0 CA--C 1.505 -0.555 0 N-CA-C 110.282 -1.127 . . . . 0.0 110.282 -176.808 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 81.03 58.83 2.55 Favored Glycine 0 N--CA 1.436 -1.319 0 CA-C-N 114.143 -1.028 . . . . 0.0 111.965 -177.569 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . 0.81 ' HB3' ' HB ' ' A' ' 45' ' ' ILE . 2.0 t30 -151.44 97.34 2.39 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 108.73 -0.841 . . . . 0.0 108.73 -178.229 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' TRP . . . . . 0.731 ' HZ3' ' HB2' ' A' ' 82' ' ' GLN . 49.8 m95 -75.51 -17.03 60.22 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-O 121.49 0.662 . . . . 0.0 110.495 -176.348 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -101.2 14.31 32.36 Favored 'General case' 0 C--N 1.313 -0.995 0 CA-C-N 115.007 -0.997 . . . . 0.0 110.693 -179.451 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.81 ' HB ' ' HB3' ' A' ' 42' ' ' ASN . 6.2 tt -77.44 143.26 13.1 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.951 0 CA-C-O 121.083 0.468 . . . . 0.0 109.759 -178.487 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . 0.598 ' ND2' HH21 ' A' ' 73' ' ' ARG . 29.3 t-20 -145.54 89.1 1.89 Allowed 'General case' 0 C--N 1.304 -1.399 0 CA-C-O 121.814 0.816 . . . . 0.0 108.994 179.369 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 2.6 p -67.98 -22.03 65.03 Favored 'General case' 0 N--CA 1.443 -0.81 0 CA-C-N 114.091 -1.413 . . . . 0.0 111.142 -178.418 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 90.03 23.45 32.45 Favored Glycine 0 N--CA 1.441 -0.984 0 N-CA-C 111.112 -0.795 . . . . 0.0 111.112 178.109 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . 0.615 HD22 ' H ' ' A' ' 51' ' ' TYR . 0.3 OUTLIER -101.58 15.42 28.95 Favored 'General case' 0 C--N 1.326 -0.426 0 N-CA-C 112.384 0.513 . . . . 0.0 112.384 -177.214 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 93.48 -10.91 72.39 Favored Glycine 0 CA--C 1.509 -0.309 0 N-CA-C 111.401 -0.68 . . . . 0.0 111.401 177.608 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 51' ' ' TYR . . . . . 0.615 ' H ' HD22 ' A' ' 49' ' ' ASN . 0.1 OUTLIER -118.79 149.28 41.76 Favored 'General case' 0 N--CA 1.445 -0.713 0 N-CA-C 106.434 -1.691 . . . . 0.0 106.434 -177.566 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 52' ' ' TYR . . . . . 0.711 ' HB2' ' HB3' ' A' ' 74' ' ' ALA . 22.4 m-85 -119.56 170.9 8.76 Favored 'General case' 0 C--N 1.309 -1.18 0 C-N-CA 119.921 -0.711 . . . . 0.0 112.183 -169.298 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.794 ' HA2' HG22 ' A' ' 45' ' ' ILE . . . -57.56 167.64 5.07 Favored Glycine 0 N--CA 1.449 -0.493 0 N-CA-C 115.939 1.136 . . . . 0.0 115.939 -166.115 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.652 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 86.62 -102.08 2.7 Favored Glycine 0 N--CA 1.437 -1.296 0 CA-C-N 114.202 -0.999 . . . . 0.0 111.541 178.247 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.584 HG22 ' HB3' ' A' ' 82' ' ' GLN . 3.1 m -85.4 -2.85 7.91 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.737 0 CA-C-O 120.434 0.159 . . . . 0.0 111.329 -179.586 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 56' ' ' GLN . . . . . 0.666 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 8.9 tp-100 52.78 52.94 12.96 Favored 'General case' 0 CA--C 1.534 0.339 0 N-CA-C 113.481 0.919 . . . . 0.0 113.481 166.17 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . 0.407 ' CD1' HG23 ' A' ' 55' ' ' VAL . 1.0 OUTLIER -120.57 163.33 18.16 Favored 'General case' 0 C--N 1.327 -0.379 0 C-N-CA 119.862 -0.735 . . . . 0.0 111.366 170.996 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.562 ' HB2' ' CD1' ' A' ' 51' ' ' TYR . 0.0 OUTLIER -73.6 155.1 39.44 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 114.799 -1.092 . . . . 0.0 113.365 -164.565 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.764 ' HA ' HE21 ' A' ' 59' ' ' GLN . 0.0 OUTLIER -53.3 -39.98 64.4 Favored 'General case' 0 N--CA 1.451 -0.402 0 CA-C-N 114.078 -1.419 . . . . 0.0 112.303 -179.905 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -68.39 -49.45 45.04 Favored Glycine 0 C--O 1.225 -0.441 0 CA-C-N 115.921 -0.582 . . . . 0.0 112.03 -177.264 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 32.8 m -65.64 -38.18 88.63 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-O 121.461 0.648 . . . . 0.0 110.26 176.105 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 62' ' ' TRP . . . . . 0.559 ' CH2' ' HA ' ' A' ' 74' ' ' ALA . 39.1 t-105 -56.67 -48.89 76.61 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 115.32 -0.854 . . . . 0.0 109.643 173.9 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . 0.575 ' CB ' HD11 ' A' ' 68' ' ' LEU . 60.6 tt0 -67.07 -33.97 76.66 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-N 114.876 -1.056 . . . . 0.0 110.943 179.359 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -63.04 -42.03 99.65 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.796 -0.638 . . . . 0.0 111.366 -177.81 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 33.0 m-80 -86.64 -11.76 50.44 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.977 0.418 . . . . 0.0 110.303 177.809 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . 0.418 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 92.93 52.38 2.1 Favored Glycine 0 C--O 1.22 -0.743 0 CA-C-N 115.858 -0.61 . . . . 0.0 114.043 170.533 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.475 ' HA3' ' CE2' ' A' ' 62' ' ' TRP . . . -80.28 -27.95 50.43 Favored Glycine 0 N--CA 1.441 -0.967 0 C-N-CA 120.666 -0.778 . . . . 0.0 112.629 179.694 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.652 ' HA ' ' HA ' ' A' ' 72' ' ' PRO . 2.4 mp -59.3 -20.51 55.04 Favored 'General case' 0 CA--C 1.519 -0.241 0 CA-C-O 120.864 0.364 . . . . 0.0 111.923 -170.084 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . 0.418 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 9.1 ptp180 -72.55 -28.1 62.63 Favored 'General case' 0 N--CA 1.44 -0.944 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.225 -179.155 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 70' ' ' TYR . . . . . 0.717 ' HB2' ' CD ' ' A' ' 81' ' ' GLU . 10.5 m-85 -92.26 -33.29 14.71 Favored 'General case' 0 N--CA 1.433 -1.316 0 N-CA-C 106.683 -1.599 . . . . 0.0 106.683 176.894 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.667 ' HB1' ' HB3' ' A' ' 76' ' ' LEU . . . 175.34 126.86 0.13 Allowed Pre-proline 0 N--CA 1.45 -0.443 0 CA-C-N 113.005 -1.907 . . . . 0.0 108.494 179.107 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 72' ' ' PRO . . . . . 0.652 ' HA ' ' HA ' ' A' ' 68' ' ' LEU . 6.1 Cg_exo -62.46 3.86 0.42 Allowed 'Trans proline' 0 C--N 1.333 -0.272 0 C-N-CA 122.717 2.278 . . . . 0.0 113.709 -178.987 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 73' ' ' ARG . . . . . 0.598 HH21 ' ND2' ' A' ' 46' ' ' ASN . 11.0 ptm180 -154.53 142.51 20.17 Favored 'General case' 0 C--N 1.316 -0.877 0 N-CA-C 108.988 -0.745 . . . . 0.0 108.988 177.302 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . 0.711 ' HB3' ' HB2' ' A' ' 52' ' ' TYR . . . -61.69 -29.45 70.1 Favored 'General case' 0 C--O 1.219 -0.508 0 CA-C-N 115.935 -0.575 . . . . 0.0 112.284 -176.675 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 18.6 p-10 -86.44 12.01 11.2 Favored 'General case' 0 C--N 1.317 -0.836 0 CA-C-O 121.168 0.508 . . . . 0.0 111.032 -175.091 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.667 ' HB3' ' HB1' ' A' ' 71' ' ' ALA . 39.6 tp -108.38 -43.58 4.3 Favored 'General case' 0 N--CA 1.449 -0.5 0 CA-C-N 115.586 -0.734 . . . . 0.0 110.429 175.39 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . 0.654 ' HB3' ' HG2' ' A' ' 81' ' ' GLU . . . -99.06 167.85 10.45 Favored 'General case' 0 N--CA 1.449 -0.475 0 CA-C-O 121.58 0.705 . . . . 0.0 111.079 178.767 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . 0.435 ' OG1' ' HG2' ' A' ' 80' ' ' GLU . 27.6 p -91.78 178.73 5.82 Favored 'General case' 0 C--N 1.316 -0.877 0 CA-C-N 115.002 -0.999 . . . . 0.0 112.69 -167.564 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . 0.667 ' HG2' ' CE2' ' A' ' 43' ' ' TRP . 64.5 mtp180 -45.89 -42.9 13.2 Favored 'General case' 0 N--CA 1.469 0.501 0 C-N-CA 123.523 0.729 . . . . 0.0 111.88 -174.779 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 80' ' ' GLU . . . . . 0.435 ' HG2' ' OG1' ' A' ' 78' ' ' THR . 7.4 pt-20 -57.19 -37.57 72.37 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 115.738 -0.665 . . . . 0.0 111.002 -177.423 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 81' ' ' GLU . . . . . 0.717 ' CD ' ' HB2' ' A' ' 70' ' ' TYR . 0.0 OUTLIER -72.03 -49.48 36.49 Favored 'General case' 0 N--CA 1.444 -0.731 0 CA-C-N 116.665 -0.243 . . . . 0.0 110.65 -179.238 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 82' ' ' GLN . . . . . 0.731 ' HB2' ' HZ3' ' A' ' 43' ' ' TRP . 9.4 mp0 -61.97 -32.38 72.82 Favored 'General case' 0 CA--C 1.509 -0.61 0 C-N-CA 120.343 -0.543 . . . . 0.0 110.198 -179.276 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.67 ' O ' ' HB3' ' A' ' 87' ' ' GLU . 40.7 mt -64.37 -46.05 94.17 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.753 0 CA-C-N 115.459 -0.791 . . . . 0.0 109.788 176.598 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . 0.484 ' O ' ' HG3' ' A' ' 87' ' ' GLU . . . -66.12 -48.22 71.57 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 121.038 0.447 . . . . 0.0 111.649 -176.7 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 47.2 t -69.58 -48.35 66.42 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.577 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.874 -175.414 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . 0.431 ' HB1' ' CZ2' ' A' ' 98' ' ' TRP . . . -66.56 -30.15 70.38 Favored 'General case' 0 N--CA 1.444 -0.728 0 CA-C-O 121.026 0.441 . . . . 0.0 110.234 179.682 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 87' ' ' GLU . . . . . 0.67 ' HB3' ' O ' ' A' ' 83' ' ' ILE . 0.4 OUTLIER -70.44 -30.19 66.97 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.774 -177.138 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.671 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 59.1 t -61.29 -42.38 93.34 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.284 0 N-CA-C 108.812 -0.81 . . . . 0.0 108.812 170.732 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . 0.855 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 0.2 OUTLIER -67.25 -43.83 80.91 Favored 'General case' 0 C--N 1.316 -0.872 0 CA-C-N 115.517 -0.765 . . . . 0.0 110.631 -179.45 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . 0.599 ' HG3' ' O ' ' A' ' 87' ' ' GLU . 3.0 ppt_? -63.25 -34.37 77.52 Favored 'General case' 0 CA--C 1.517 -0.295 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.764 -177.512 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . 0.671 ' HG ' ' O ' ' A' ' 88' ' ' VAL . 4.4 pp -73.5 -23.7 60.08 Favored 'General case' 0 C--N 1.322 -0.588 0 O-C-N 123.312 0.383 . . . . 0.0 110.949 -171.387 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . 0.543 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 4.6 mtm180 -84.3 -48.5 9.66 Favored 'General case' 0 CA--C 1.512 -0.511 0 CA-C-O 121.516 0.674 . . . . 0.0 109.628 -178.386 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 93' ' ' GLN . . . . . 0.581 ' NE2' HG22 ' A' ' 89' ' ' THR . 21.7 pt20 -98.47 -28.47 13.59 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 114.967 -1.015 . . . . 0.0 113.285 -169.1 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 92.54 40.1 5.13 Favored Glycine 0 CA--C 1.509 -0.323 0 C-N-CA 120.504 -0.855 . . . . 0.0 111.759 176.013 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 95' ' ' TRP . . . . . 0.587 ' CZ2' HD12 ' A' ' 30' ' ' ILE . 34.4 m95 68.7 11.53 8.38 Favored 'General case' 0 C--O 1.216 -0.671 0 C-N-CA 123.316 0.646 . . . . 0.0 110.165 178.536 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -58.85 -29.51 64.82 Favored Glycine 0 CA--C 1.522 0.49 0 CA-C-N 115.523 -0.762 . . . . 0.0 113.463 178.795 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -80.83 -17.64 50.12 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.938 0.399 . . . . 0.0 110.884 178.031 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 98' ' ' TRP . . . . . 0.855 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 30.0 m-90 -104.93 108.02 60.13 Favored Pre-proline 0 C--N 1.324 -0.51 0 CA-C-N 116.052 -0.522 . . . . 0.0 109.736 178.517 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . . . . . . . . . 39.5 Cg_exo -64.43 -134.63 0.0 OUTLIER 'Trans proline' 0 CA--C 1.537 0.631 0 C-N-CA 123.95 3.1 . . . . 0.0 114.148 -175.845 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 3.8 m -54.14 -27.48 16.55 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.229 0 N-CA-C 112.442 0.534 . . . . 0.0 112.442 -176.813 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 77.1 m -60.81 -40.36 92.41 Favored 'General case' 0 C--N 1.317 -0.847 0 CA-C-N 115.887 -0.597 . . . . 0.0 111.37 179.183 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 102' ' ' ALA . . . . . 0.422 ' HB2' ' CB ' ' A' ' 98' ' ' TRP . . . -72.03 -41.6 67.31 Favored 'General case' 0 CA--C 1.517 -0.295 0 CA-C-O 121.092 0.473 . . . . 0.0 110.26 177.302 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -59.27 -46.21 89.15 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.577 -0.738 . . . . 0.0 110.917 179.128 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 3.0 mpp_? -73.71 -22.08 60.03 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.816 -0.629 . . . . 0.0 111.423 179.854 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 105' ' ' ALA . . . . . 0.741 ' HB1' ' HA ' ' A' ' 30' ' ' ILE . . . -83.06 -20.89 34.09 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.397 179.433 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 104.52 60.72 0.66 Allowed Glycine 0 CA--C 1.519 0.305 0 C-N-CA 121.111 -0.566 . . . . 0.0 112.142 -179.178 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -64.11 141.53 58.74 Favored 'General case' 0 C--O 1.235 0.295 0 C-N-CA 122.659 0.384 . . . . 0.0 111.939 -176.574 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 108' ' ' ARG . . . . . 0.658 ' OXT' ' HD3' ' A' ' 108' ' ' ARG . 0.0 OUTLIER . . . . . 0 C--O 1.246 0.903 0 CA-C-O 118.567 -0.73 . . . . 0.0 110.726 -177.491 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 70.5 m-20 . . . . . 0 N--CA 1.474 0.773 0 CA-C-O 121.338 0.59 . . . . 0.0 110.496 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 46.2 t -116.3 80.71 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.799 0 N-CA-C 108.441 -0.948 . . . . 0.0 108.441 178.018 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 7.5 p -30.68 122.93 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.47 0.529 0 CA-C-N 114.537 -1.211 . . . . 0.0 112.813 179.499 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 6.4 t -89.69 146.05 6.66 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.575 0 CA-C-N 115.367 -0.833 . . . . 0.0 110.174 -175.951 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . 0.472 ' HA ' ' HD3' ' A' ' 6' ' ' PRO . 14.1 p -89.97 125.68 59.83 Favored Pre-proline 0 C--N 1.317 -0.822 0 CA-C-N 115.624 -0.716 . . . . 0.0 111.17 -178.044 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.472 ' HD3' ' HA ' ' A' ' 5' ' ' THR . 37.6 Cg_endo -88.72 156.01 6.2 Favored 'Trans proline' 0 N--CA 1.439 -1.695 0 C-N-CA 123.164 2.576 . . . . 0.0 110.595 176.65 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . 50.42 46.47 25.21 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-O 122.155 0.979 . . . . 0.0 110.442 -174.067 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 54.7 t-80 -77.6 -8.14 57.41 Favored 'General case' 0 C--N 1.314 -0.953 0 CA-C-N 113.766 -1.561 . . . . 0.0 108.855 176.075 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 3.8 mm-40 -56.03 138.5 49.1 Favored 'General case' 0 CA--C 1.515 -0.391 0 CA-C-N 115.453 -0.794 . . . . 0.0 112.532 -177.138 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -121.66 59.71 0.97 Allowed 'General case' 0 C--N 1.316 -0.875 0 CA-C-N 114.584 -1.189 . . . . 0.0 108.794 173.929 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 85.7 t -61.61 -46.35 96.74 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.734 0 CA-C-N 113.92 -1.491 . . . . 0.0 110.79 -179.992 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 6.0 p 34.9 82.14 0.01 OUTLIER 'Isoleucine or valine' 0 C--O 1.234 0.278 0 O-C-N 124.728 1.267 . . . . 0.0 112.731 -176.758 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . 0.453 ' HD2' ' HA ' ' A' ' 13' ' ' ARG . 0.2 OUTLIER 64.17 133.29 0.02 OUTLIER 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 113.404 -1.725 . . . . 0.0 113.221 -176.911 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.7 t -88.76 158.45 3.0 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.089 0 N-CA-C 108.651 -0.87 . . . . 0.0 108.651 175.767 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -163.81 84.87 0.11 Allowed Glycine 0 N--CA 1.428 -1.839 0 CA-C-N 115.309 -0.86 . . . . 0.0 112.483 -177.871 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.683 ' HB ' ' HD3' ' A' ' 17' ' ' LYS . 3.5 m -63.1 -38.04 89.59 Favored 'General case' 0 N--CA 1.447 -0.601 0 CA-C-O 121.852 0.834 . . . . 0.0 110.176 176.726 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . 0.683 ' HD3' ' HB ' ' A' ' 16' ' ' THR . 0.0 OUTLIER -123.71 85.06 53.48 Favored Pre-proline 0 C--N 1.316 -0.879 0 CA-C-N 114.439 -1.255 . . . . 0.0 109.592 176.668 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_exo -61.62 117.12 3.91 Favored 'Trans proline' 0 CA--C 1.506 -0.877 0 C-N-CA 122.784 2.323 . . . . 0.0 112.167 177.195 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 144.44 53.09 0.03 OUTLIER Glycine 0 C--N 1.299 -1.514 0 CA-C-N 113.667 -1.606 . . . . 0.0 113.471 178.184 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 35.5 m -69.94 -33.76 72.56 Favored 'General case' 0 C--N 1.32 -0.698 0 N-CA-C 108.879 -0.786 . . . . 0.0 108.879 170.092 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 48.1 mt-10 -123.71 125.84 45.48 Favored 'General case' 0 N--CA 1.439 -0.996 0 CA-C-N 115.089 -0.959 . . . . 0.0 108.853 176.754 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 31.6 t -71.24 131.04 87.15 Favored Pre-proline 0 C--N 1.313 -0.987 0 CA-C-N 115.522 -0.763 . . . . 0.0 110.295 -177.24 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.438 ' HA ' ' HD2' ' A' ' 24' ' ' PRO . 50.0 Cg_exo -53.71 129.37 33.64 Favored 'Trans proline' 0 C--N 1.348 0.538 0 C-N-CA 123.135 2.557 . . . . 0.0 112.588 -179.002 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . 0.438 ' HD2' ' HA ' ' A' ' 23' ' ' PRO . 11.0 Cg_endo -55.46 141.46 82.38 Favored 'Trans proline' 0 N--CA 1.458 -0.583 0 C-N-CA 123.844 3.03 . . . . 0.0 113.093 -179.36 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.451 ' CG2' HD13 ' A' ' 83' ' ' ILE . 1.5 p -80.21 119.24 29.32 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.984 0 CA-C-N 114.623 -1.171 . . . . 0.0 111.238 179.895 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 42.1 mm -88.82 -54.44 7.79 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-N 115.356 -0.838 . . . . 0.0 111.692 177.414 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.726 ' O ' HG12 ' A' ' 30' ' ' ILE . 33.5 m-20 -128.2 34.88 4.5 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 114.735 -1.12 . . . . 0.0 108.553 -170.688 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . 0.487 ' HA2' ' CD1' ' A' ' 31' ' ' TRP . . . -72.22 -2.6 54.33 Favored Glycine 0 CA--C 1.5 -0.856 0 N-CA-C 110.605 -0.998 . . . . 0.0 110.605 177.482 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 16.4 m -69.63 -37.41 76.8 Favored 'General case' 0 C--N 1.317 -0.828 0 CA-C-O 121.499 0.666 . . . . 0.0 109.352 173.564 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.726 HG12 ' O ' ' A' ' 27' ' ' ASP . 0.3 OUTLIER -69.55 -35.97 68.9 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.672 0 N-CA-C 107.159 -1.422 . . . . 0.0 107.159 176.364 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' TRP . . . . . 0.537 ' CZ2' ' HD3' ' A' ' 90' ' ' ARG . 21.7 m95 -71.45 -36.45 71.23 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 114.255 -1.339 . . . . 0.0 110.776 -177.394 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 27.1 t70 -76.82 -33.39 57.96 Favored 'General case' 0 N--CA 1.445 -0.713 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.167 177.904 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . 0.468 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -70.69 -34.07 71.58 Favored 'General case' 0 N--CA 1.447 -0.592 0 C-N-CA 120.432 -0.507 . . . . 0.0 110.138 176.529 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . 0.527 ' HA ' ' HB3' ' A' ' 101' ' ' CYS . 56.9 mt -67.38 -41.7 86.58 Favored 'Isoleucine or valine' 0 C--O 1.234 0.28 0 CA-C-N 115.851 -0.613 . . . . 0.0 109.99 172.647 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . 0.5 ' HA ' ' O ' ' A' ' 54' ' ' GLY . . . -58.75 -38.68 78.97 Favored 'General case' 0 CA--C 1.515 -0.379 0 CA-C-O 121.448 0.642 . . . . 0.0 110.112 174.045 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -75.29 -10.1 84.34 Favored Glycine 0 N--CA 1.449 -0.443 0 CA-C-N 115.192 -0.913 . . . . 0.0 111.343 179.22 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.427 ' HB3' ' O ' ' A' ' 34' ' ' ILE . 14.4 t -90.87 -66.72 0.9 Allowed 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.174 -0.513 . . . . 0.0 111.327 -178.607 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . 0.872 ' HG3' ' SG ' ' A' ' 101' ' ' CYS . 53.7 mt-10 -89.7 -34.48 16.22 Favored 'General case' 0 CA--C 1.513 -0.45 0 C-N-CA 120.399 -0.521 . . . . 0.0 110.918 -174.023 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . 0.493 ' HB3' ' O ' ' A' ' 35' ' ' ALA . . . -84.15 -18.32 37.12 Favored 'General case' 0 N--CA 1.445 -0.685 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.227 -176.363 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 80.35 12.57 82.96 Favored Glycine 0 CA--C 1.503 -0.701 0 N-CA-C 109.991 -1.243 . . . . 0.0 109.991 -177.351 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 82.81 61.47 1.94 Allowed Glycine 0 N--CA 1.434 -1.44 0 CA-C-N 114.066 -1.067 . . . . 0.0 111.866 -176.689 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . 0.473 ' HB3' ' HB ' ' A' ' 45' ' ' ILE . 52.8 t-20 -155.1 124.37 6.32 Favored 'General case' 0 N--CA 1.442 -0.835 0 N-CA-C 108.624 -0.88 . . . . 0.0 108.624 -179.215 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 43' ' ' TRP . . . . . 0.764 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 44.9 m95 -97.27 -10.41 25.78 Favored 'General case' 0 C--N 1.308 -1.217 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.9 -174.207 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . 0.424 ' HA ' ' HB2' ' A' ' 75' ' ' ASP . . . -110.16 9.34 23.95 Favored 'General case' 0 C--N 1.315 -0.91 0 CA-C-N 115.115 -0.948 . . . . 0.0 110.982 179.938 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.473 ' HB ' ' HB3' ' A' ' 42' ' ' ASN . 11.5 tt -73.78 143.27 13.84 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.875 0 CA-C-O 121.462 0.649 . . . . 0.0 110.959 -178.438 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -135.11 94.71 3.18 Favored 'General case' 0 C--N 1.311 -1.097 0 N-CA-C 109.028 -0.73 . . . . 0.0 109.028 179.46 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 1.7 p -73.79 -12.19 60.62 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-N 115.628 -0.714 . . . . 0.0 110.933 -178.269 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 85.29 21.84 53.42 Favored Glycine 0 N--CA 1.443 -0.878 0 N-CA-C 111.179 -0.769 . . . . 0.0 111.179 174.1 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 33.4 p-10 -103.44 10.17 37.4 Favored 'General case' 0 C--N 1.322 -0.612 0 C-N-CA 120.894 -0.322 . . . . 0.0 111.562 -174.944 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . 0.524 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 87.32 -2.66 86.68 Favored Glycine 0 N--CA 1.454 -0.149 0 C-N-CA 120.87 -0.681 . . . . 0.0 111.658 -178.252 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 51' ' ' TYR . . . . . 0.666 ' HA ' ' HA ' ' A' ' 58' ' ' ASP . 0.3 OUTLIER -116.51 147.7 41.52 Favored 'General case' 0 CA--C 1.508 -0.643 0 N-CA-C 106.5 -1.667 . . . . 0.0 106.5 178.649 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 52' ' ' TYR . . . . . 0.729 ' O ' ' HA ' ' A' ' 56' ' ' GLN . 47.9 m-85 -114.7 163.79 14.97 Favored 'General case' 0 C--N 1.304 -1.376 0 C-N-CA 119.821 -0.751 . . . . 0.0 111.688 -170.247 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.427 ' CA ' HG22 ' A' ' 45' ' ' ILE . . . -60.56 177.95 3.41 Favored Glycine 0 N--CA 1.448 -0.54 0 O-C-N 124.047 0.842 . . . . 0.0 114.849 -167.801 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.674 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 85.87 -108.7 3.27 Favored Glycine 0 N--CA 1.436 -1.359 0 N-CA-C 111.121 -0.792 . . . . 0.0 111.121 -178.417 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.433 HG22 ' HB3' ' A' ' 82' ' ' GLN . 0.2 OUTLIER -83.2 -1.03 5.54 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.69 0 CA-C-O 121.437 0.637 . . . . 0.0 110.067 178.713 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 56' ' ' GLN . . . . . 0.729 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 20.0 tp60 56.12 50.43 13.61 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 114.265 -1.334 . . . . 0.0 113.28 164.678 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -118.72 169.5 9.78 Favored 'General case' 0 C--N 1.329 -0.317 0 C-N-CA 119.44 -0.904 . . . . 0.0 111.478 172.209 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.666 ' HA ' ' HA ' ' A' ' 51' ' ' TYR . 8.3 p-10 -74.38 162.13 29.17 Favored 'General case' 0 C--N 1.327 -0.382 0 N-CA-C 113.995 1.109 . . . . 0.0 113.995 -163.992 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.427 ' HB2' ' CE2' ' A' ' 52' ' ' TYR . 20.6 tp60 -56.06 -42.61 76.89 Favored 'General case' 0 N--CA 1.443 -0.813 0 CA-C-N 114.085 -1.416 . . . . 0.0 111.084 177.256 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -67.77 -49.68 47.44 Favored Glycine 0 N--CA 1.451 -0.365 0 CA-C-N 115.056 -0.974 . . . . 0.0 112.667 -173.896 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 92.3 m -64.63 -40.24 95.12 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-O 120.644 0.259 . . . . 0.0 110.958 177.91 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 62' ' ' TRP . . . . . 0.472 ' CZ3' ' HA ' ' A' ' 82' ' ' GLN . 54.4 t-105 -56.64 -49.3 75.41 Favored 'General case' 0 N--CA 1.45 -0.454 0 CA-C-O 121.809 0.814 . . . . 0.0 109.102 175.008 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . 0.532 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 29.5 tt0 -64.83 -35.67 81.85 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 114.653 -1.158 . . . . 0.0 111.319 -179.979 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -64.93 -42.4 94.72 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.976 -0.556 . . . . 0.0 111.335 -174.606 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 33.8 m-80 -81.49 -9.24 59.75 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.981 0.42 . . . . 0.0 110.369 176.815 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . 0.569 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 92.29 50.38 2.61 Favored Glycine 0 C--N 1.332 0.309 0 CA-C-N 115.865 -0.607 . . . . 0.0 112.658 173.288 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.564 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -80.03 -23.59 61.24 Favored Glycine 0 N--CA 1.438 -1.205 0 C-N-CA 120.887 -0.673 . . . . 0.0 112.781 -176.48 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.908 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 6.9 mp -60.87 -22.9 64.73 Favored 'General case' 0 N--CA 1.448 -0.552 0 N-CA-C 112.139 0.422 . . . . 0.0 112.139 -172.893 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . 0.569 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 3.7 ptp180 -68.37 -32.81 73.16 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-O 121.12 0.486 . . . . 0.0 109.928 177.002 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 70' ' ' TYR . . . . . 0.622 ' HB3' ' CG ' ' A' ' 81' ' ' GLU . 65.6 m-85 -82.26 -34.23 28.85 Favored 'General case' 0 N--CA 1.44 -0.948 0 N-CA-C 107.564 -1.273 . . . . 0.0 107.564 178.915 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.659 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 168.35 124.35 0.04 OUTLIER Pre-proline 0 N--CA 1.448 -0.528 0 CA-C-N 112.868 -1.969 . . . . 0.0 107.319 -178.835 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 72' ' ' PRO . . . . . 0.908 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 24.8 Cg_exo -54.98 -7.38 0.95 Allowed 'Trans proline' 0 C--N 1.335 -0.174 0 C-N-CA 123.003 2.468 . . . . 0.0 114.11 -177.534 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 12.8 ptm180 -146.42 137.16 24.13 Favored 'General case' 0 C--N 1.319 -0.754 0 N-CA-C 108.853 -0.795 . . . . 0.0 108.853 176.472 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . 0.608 ' HB3' ' HB2' ' A' ' 52' ' ' TYR . . . -56.26 -32.0 64.11 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.151 -0.931 . . . . 0.0 112.574 -176.992 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . 0.611 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 4.9 p-10 -78.81 -8.14 58.51 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 121.108 0.48 . . . . 0.0 110.93 -175.312 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 64.5 tp -93.61 -32.04 14.26 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 108.781 -0.822 . . . . 0.0 108.781 173.605 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . 0.79 ' HB1' ' HB2' ' A' ' 81' ' ' GLU . . . -79.68 157.96 27.1 Favored 'General case' 0 N--CA 1.445 -0.713 0 CA-C-N 114.964 -1.016 . . . . 0.0 110.487 176.092 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 40.6 p -100.62 -172.48 2.2 Favored 'General case' 0 C--N 1.315 -0.906 0 CA-C-N 115.937 -0.574 . . . . 0.0 109.918 179.698 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . 0.764 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 10.9 mtt180 -51.14 -52.71 41.33 Favored 'General case' 0 CA--C 1.51 -0.579 0 O-C-N 123.432 0.457 . . . . 0.0 111.029 -175.433 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 1.3 pm0 -57.71 -48.31 79.93 Favored 'General case' 0 C--N 1.314 -0.943 0 CA-C-N 115.135 -0.938 . . . . 0.0 112.142 -176.374 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 81' ' ' GLU . . . . . 0.79 ' HB2' ' HB1' ' A' ' 77' ' ' ALA . 6.5 mp0 -61.31 -50.48 72.79 Favored 'General case' 0 C--O 1.233 0.221 0 N-CA-C 111.9 0.333 . . . . 0.0 111.9 176.491 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 82' ' ' GLN . . . . . 0.472 ' HA ' ' CZ3' ' A' ' 62' ' ' TRP . 51.4 mt-30 -59.93 -39.94 87.22 Favored 'General case' 0 CA--C 1.516 -0.355 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.229 -177.819 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.682 ' O ' ' HG2' ' A' ' 87' ' ' GLU . 28.3 mt -61.78 -45.54 98.46 Favored 'Isoleucine or valine' 0 C--O 1.212 -0.886 0 CA-C-N 115.36 -0.836 . . . . 0.0 110.151 178.601 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . 0.541 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -59.48 -43.4 93.28 Favored 'General case' 0 C--O 1.239 0.509 0 CA-C-O 121.154 0.502 . . . . 0.0 111.336 -178.347 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 60.5 t -68.66 -48.11 73.28 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.649 179.517 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -59.8 -30.08 68.66 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.63 -0.714 . . . . 0.0 110.518 176.08 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 87' ' ' GLU . . . . . 0.682 ' HG2' ' O ' ' A' ' 83' ' ' ILE . 40.1 mm-40 -60.22 -45.81 91.92 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.371 -0.831 . . . . 0.0 110.396 -179.998 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.571 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 24.6 t -64.58 -41.74 93.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 121.392 0.615 . . . . 0.0 109.645 177.823 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . 0.777 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 0.5 OUTLIER -67.56 -46.7 71.95 Favored 'General case' 0 C--N 1.318 -0.791 0 CA-C-N 115.635 -0.711 . . . . 0.0 111.581 -175.662 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . 0.537 ' HD3' ' CZ2' ' A' ' 31' ' ' TRP . 13.8 ptt180 -64.55 -34.16 77.59 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.494 -0.321 . . . . 0.0 111.192 -175.247 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . 0.571 ' HG ' ' O ' ' A' ' 88' ' ' VAL . 4.4 pp -72.63 -23.74 60.96 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.289 -171.92 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . 0.525 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 6.6 mtm180 -83.93 -48.53 9.89 Favored 'General case' 0 CA--C 1.511 -0.53 0 CA-C-O 121.437 0.636 . . . . 0.0 109.734 -178.638 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 93' ' ' GLN . . . . . 0.669 ' NE2' HG22 ' A' ' 89' ' ' THR . 28.9 pt20 -98.44 -28.98 13.38 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 114.773 -1.103 . . . . 0.0 113.741 -168.135 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 82.99 48.5 5.41 Favored Glycine 0 N--CA 1.448 -0.502 0 C-N-CA 120.11 -1.043 . . . . 0.0 111.357 178.784 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 95' ' ' TRP . . . . . 0.511 ' HA ' ' HE3' ' A' ' 98' ' ' TRP . 2.4 m95 62.59 24.12 14.35 Favored 'General case' 0 C--O 1.224 -0.274 0 C-N-CA 123.176 0.591 . . . . 0.0 110.288 176.103 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -69.19 -24.51 75.93 Favored Glycine 0 CA--C 1.52 0.359 0 CA-C-N 115.706 -0.679 . . . . 0.0 112.433 175.977 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . 0.407 ' O ' ' HD3' ' A' ' 99' ' ' PRO . . . -82.05 -34.14 29.61 Favored 'General case' 0 CA--C 1.516 -0.355 0 CA-C-O 120.888 0.375 . . . . 0.0 110.474 176.289 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 98' ' ' TRP . . . . . 0.777 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 22.4 m-90 -96.37 103.55 14.41 Favored Pre-proline 0 N--CA 1.451 -0.414 0 CA-C-N 115.713 -0.676 . . . . 0.0 109.202 -179.62 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . 0.487 ' HB2' ' H ' ' A' ' 100' ' ' VAL . 16.4 Cg_exo -73.44 -98.72 0.01 OUTLIER 'Trans proline' 0 CA--C 1.537 0.656 0 C-N-CA 123.27 2.646 . . . . 0.0 114.869 -170.682 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . 0.487 ' H ' ' HB2' ' A' ' 99' ' ' PRO . 32.8 t -70.22 -27.27 31.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-O 121.702 0.763 . . . . 0.0 110.01 -172.853 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 101' ' ' CYS . . . . . 0.872 ' SG ' ' HG3' ' A' ' 38' ' ' GLU . 38.7 m -67.08 -33.98 76.66 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-N 114.755 -1.111 . . . . 0.0 111.13 -174.77 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 102' ' ' ALA . . . . . 0.503 ' HB1' ' HB2' ' A' ' 107' ' ' ALA . . . -65.38 -45.44 84.03 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.817 0.342 . . . . 0.0 110.69 179.839 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -64.76 -36.28 83.79 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 121.102 0.477 . . . . 0.0 110.545 178.824 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 21.1 mmm180 -74.03 -23.35 59.39 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.553 -0.749 . . . . 0.0 111.693 179.057 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 105' ' ' ALA . . . . . 0.626 ' HB1' ' HA ' ' A' ' 30' ' ' ILE . . . -96.91 -21.53 17.41 Favored 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 112.496 0.554 . . . . 0.0 112.496 -174.472 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 103.94 65.15 0.69 Allowed Glycine 0 CA--C 1.518 0.253 0 C-N-CA 120.827 -0.702 . . . . 0.0 111.919 -177.753 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 107' ' ' ALA . . . . . 0.503 ' HB2' ' HB1' ' A' ' 102' ' ' ALA . . . -71.93 152.75 42.3 Favored 'General case' 0 C--N 1.326 -0.433 0 C-N-CA 122.877 0.471 . . . . 0.0 111.674 -174.912 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 10.7 mmm180 . . . . . 0 C--O 1.25 1.081 0 CA-C-O 117.926 -1.035 . . . . 0.0 111.408 175.043 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 6.0 p30 . . . . . 0 N--CA 1.473 0.676 0 CA-C-O 121.928 0.871 . . . . 0.0 109.722 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 11.2 p -77.8 -18.63 13.93 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.979 0 CA-C-N 114.851 -1.068 . . . . 0.0 110.347 179.881 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 7.9 p -62.53 128.52 24.45 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.618 0 CA-C-N 115.657 -0.701 . . . . 0.0 110.922 177.956 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 25.1 t -96.78 155.06 3.55 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.735 0 CA-C-N 115.555 -0.748 . . . . 0.0 109.01 178.178 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . 0.464 ' HA ' ' HD3' ' A' ' 6' ' ' PRO . 14.6 p -77.38 112.84 26.42 Favored Pre-proline 0 C--N 1.317 -0.837 0 CA-C-N 115.929 -0.578 . . . . 0.0 111.528 -176.807 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.464 ' HD3' ' HA ' ' A' ' 5' ' ' THR . 11.2 Cg_endo -92.66 170.96 2.39 Favored 'Trans proline' 0 N--CA 1.446 -1.31 0 C-N-CA 123.502 2.801 . . . . 0.0 111.518 178.091 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -91.53 63.26 4.74 Favored 'General case' 0 C--N 1.31 -1.121 0 CA-C-O 122.056 0.932 . . . . 0.0 110.569 178.785 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 65.1 m170 -95.9 -1.31 49.59 Favored 'General case' 0 C--N 1.31 -1.129 0 CA-C-N 114.079 -1.419 . . . . 0.0 108.796 173.451 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 6.0 pt-20 -56.71 143.46 36.35 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 114.693 -1.139 . . . . 0.0 111.662 -177.296 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -145.45 71.07 1.27 Allowed 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 115.206 -0.906 . . . . 0.0 109.0 176.541 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 8.9 p -73.14 -22.91 19.71 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.554 0 CA-C-N 114.981 -1.009 . . . . 0.0 111.305 -173.328 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 7.1 p 29.61 77.92 0.01 OUTLIER 'Isoleucine or valine' 0 C--O 1.238 0.471 0 CA-C-O 122.988 1.375 . . . . 0.0 112.745 -177.749 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 31.5 ptt180 -103.28 106.96 17.6 Favored 'General case' 0 C--N 1.306 -1.313 0 CA-C-N 113.66 -1.609 . . . . 0.0 110.617 -176.203 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.406 HG12 ' N ' ' A' ' 15' ' ' GLY . 4.1 t -136.06 163.93 33.12 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.387 0 CA-C-N 114.016 -1.447 . . . . 0.0 109.151 -179.446 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . 0.406 ' N ' HG12 ' A' ' 14' ' ' VAL . . . -171.12 64.47 0.16 Allowed Glycine 0 N--CA 1.432 -1.58 0 CA-C-N 115.499 -0.773 . . . . 0.0 111.694 176.755 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 4.5 m -75.59 -31.11 59.83 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-N 114.788 -0.706 . . . . 0.0 111.592 -175.278 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . 0.475 ' HA ' ' HD3' ' A' ' 18' ' ' PRO . 63.8 mmtt -58.18 110.16 2.35 Favored Pre-proline 0 C--N 1.318 -0.793 0 CA-C-N 114.731 -1.122 . . . . 0.0 111.379 -175.823 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . 0.475 ' HD3' ' HA ' ' A' ' 17' ' ' LYS . 1.9 Cg_endo -86.36 168.73 8.67 Favored 'Trans proline' 0 N--CA 1.45 -1.086 0 C-N-CA 123.76 2.973 . . . . 0.0 112.066 177.747 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -106.38 27.98 15.09 Favored Glycine 0 C--N 1.309 -0.966 0 CA-C-N 114.637 -1.165 . . . . 0.0 111.175 178.972 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 18.1 m -69.54 -39.5 77.43 Favored 'General case' 0 C--N 1.314 -0.958 0 CA-C-N 114.182 -1.009 . . . . 0.0 110.44 179.397 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 46.8 mt-10 -115.42 121.78 43.79 Favored 'General case' 0 N--CA 1.438 -1.062 0 N-CA-C 108.714 -0.847 . . . . 0.0 108.714 177.877 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 45.9 t -71.65 118.81 69.83 Favored Pre-proline 0 C--N 1.314 -0.964 0 CA-C-N 115.557 -0.747 . . . . 0.0 111.057 -175.963 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -55.85 139.74 84.43 Favored 'Trans proline' 0 N--CA 1.459 -0.534 0 C-N-CA 123.31 2.673 . . . . 0.0 112.021 177.085 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 10.3 Cg_endo -54.65 140.12 76.36 Favored 'Trans proline' 0 N--CA 1.455 -0.739 0 C-N-CA 123.373 2.715 . . . . 0.0 112.874 -176.675 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.469 ' HB ' HG21 ' A' ' 83' ' ' ILE . 46.4 t -89.22 137.82 20.49 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.095 0 CA-C-N 114.17 -1.377 . . . . 0.0 109.49 -178.348 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 46.1 mm -63.03 -25.46 38.61 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.615 0 CA-C-N 115.289 -0.868 . . . . 0.0 111.804 -172.374 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.535 ' O ' HG12 ' A' ' 30' ' ' ILE . 7.3 m-20 -104.22 -0.02 28.89 Favored 'General case' 0 CA--C 1.504 -0.794 0 CA-C-O 121.669 0.747 . . . . 0.0 109.498 -179.605 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . 0.551 ' HA2' ' HD1' ' A' ' 31' ' ' TRP . . . -67.49 -8.02 49.46 Favored Glycine 0 N--CA 1.445 -0.748 0 CA-C-N 114.786 -1.097 . . . . 0.0 110.715 179.484 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 6.1 m -76.72 -39.05 53.13 Favored 'General case' 0 C--N 1.318 -0.779 0 CA-C-O 121.652 0.739 . . . . 0.0 109.239 176.388 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.605 ' HA ' ' HB1' ' A' ' 105' ' ' ALA . 0.7 OUTLIER -68.58 -38.49 79.15 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.592 0 N-CA-C 107.35 -1.352 . . . . 0.0 107.35 177.429 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' TRP . . . . . 0.58 ' CD1' HG23 ' A' ' 83' ' ' ILE . 34.8 m95 -68.52 -36.68 79.2 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 114.535 -1.212 . . . . 0.0 110.378 -177.296 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.723 ' HB2' HH21 ' A' ' 79' ' ' ARG . 33.5 t70 -73.77 -41.23 62.74 Favored 'General case' 0 N--CA 1.445 -0.703 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.1 179.043 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . 0.457 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -70.1 -33.11 71.45 Favored 'General case' 0 N--CA 1.448 -0.55 0 CA-C-N 116.405 -0.361 . . . . 0.0 110.912 -179.966 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . 0.608 ' HA ' ' HB3' ' A' ' 101' ' ' CYS . 50.9 mt -64.23 -49.28 81.88 Favored 'Isoleucine or valine' 0 C--O 1.234 0.256 0 CA-C-O 120.777 0.322 . . . . 0.0 110.56 174.893 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . 0.514 ' O ' ' HB3' ' A' ' 39' ' ' ALA . . . -66.02 -33.7 76.4 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-O 121.296 0.57 . . . . 0.0 110.218 178.528 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . 0.425 ' HA2' ' N ' ' A' ' 41' ' ' GLY . . . -71.61 -21.98 78.72 Favored Glycine 0 N--CA 1.448 -0.526 0 N-CA-C 111.101 -0.799 . . . . 0.0 111.101 176.892 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -76.19 -69.33 0.51 Allowed 'General case' 0 N--CA 1.448 -0.551 0 CA-C-N 115.291 -0.455 . . . . 0.0 111.536 -178.574 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . 0.678 ' HB2' ' SG ' ' A' ' 101' ' ' CYS . 15.3 tt0 -90.9 -32.99 15.79 Favored 'General case' 0 C--N 1.323 -0.572 0 C-N-CA 119.743 -0.783 . . . . 0.0 110.871 -171.455 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . 0.514 ' HB3' ' O ' ' A' ' 35' ' ' ALA . . . -84.46 -13.85 50.87 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.996 -178.855 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 74.89 20.5 79.44 Favored Glycine 0 CA--C 1.501 -0.839 0 N-CA-C 109.853 -1.299 . . . . 0.0 109.853 -179.472 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . 0.425 ' N ' ' HA2' ' A' ' 36' ' ' GLY . . . 72.2 64.03 2.77 Favored Glycine 0 N--CA 1.433 -1.564 0 CA-C-N 114.108 -1.046 . . . . 0.0 111.093 -172.837 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . 0.702 ' HB3' ' HB ' ' A' ' 45' ' ' ILE . 0.2 OUTLIER -140.99 84.21 1.92 Allowed 'General case' 0 C--N 1.322 -0.595 0 N-CA-C 108.815 -0.809 . . . . 0.0 108.815 -177.193 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 43' ' ' TRP . . . . . 0.762 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 37.0 m95 -73.65 -11.59 60.46 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 115.741 -0.663 . . . . 0.0 109.973 -177.922 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -106.6 14.38 27.08 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 115.37 -0.832 . . . . 0.0 111.406 179.583 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.732 HG22 ' HA2' ' A' ' 53' ' ' GLY . 9.0 tt -75.86 144.62 11.7 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.812 0 N-CA-C 109.695 -0.483 . . . . 0.0 109.695 179.83 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 21.7 t-20 -153.99 94.65 1.77 Allowed 'General case' 0 C--N 1.308 -1.208 0 CA-C-O 121.302 0.572 . . . . 0.0 110.38 -178.867 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 16.3 p -76.57 -19.56 57.76 Favored 'General case' 0 N--CA 1.445 -0.709 0 CA-C-N 115.225 -0.898 . . . . 0.0 110.718 178.925 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 87.85 24.02 36.78 Favored Glycine 0 N--CA 1.445 -0.759 0 N-CA-C 110.954 -0.859 . . . . 0.0 110.954 179.256 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 3.8 m-20 -97.54 14.4 26.66 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 121.065 0.459 . . . . 0.0 111.52 -174.259 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . 0.446 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 87.46 -16.03 51.4 Favored Glycine 0 N--CA 1.452 -0.28 0 CA-C-N 115.717 -0.674 . . . . 0.0 111.772 179.631 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 51' ' ' TYR . . . . . 0.748 ' CE1' ' HB2' ' A' ' 58' ' ' ASP . 0.3 OUTLIER -102.72 131.89 49.23 Favored 'General case' 0 N--CA 1.446 -0.66 0 N-CA-C 107.805 -1.183 . . . . 0.0 107.805 169.623 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 52' ' ' TYR . . . . . 0.735 ' CE1' ' HB2' ' A' ' 59' ' ' GLN . 15.0 m-85 -104.26 169.64 8.37 Favored 'General case' 0 C--N 1.311 -1.096 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.85 -173.184 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.732 ' HA2' HG22 ' A' ' 45' ' ' ILE . . . -51.91 158.09 3.1 Favored Glycine 0 CA--C 1.509 -0.326 0 N-CA-C 115.613 1.005 . . . . 0.0 115.613 -169.361 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.582 ' CA ' ' HA ' ' A' ' 43' ' ' TRP . . . 98.49 -113.05 4.62 Favored Glycine 0 N--CA 1.438 -1.168 0 CA-C-N 114.486 -0.857 . . . . 0.0 111.369 175.444 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.427 HG23 ' CD1' ' A' ' 57' ' ' PHE . 1.3 m -86.91 -6.09 10.45 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.73 0 CA-C-O 120.442 0.163 . . . . 0.0 110.82 178.38 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 56' ' ' GLN . . . . . 0.578 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 10.5 pt20 45.52 51.71 9.64 Favored 'General case' 0 N--CA 1.479 1.003 0 N-CA-C 114.502 1.297 . . . . 0.0 114.502 167.483 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . 0.578 ' O ' ' HB3' ' A' ' 58' ' ' ASP . 19.7 p90 -103.67 21.62 15.84 Favored 'General case' 0 C--N 1.328 -0.344 0 N-CA-C 113.25 0.833 . . . . 0.0 113.25 -176.071 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.748 ' HB2' ' CE1' ' A' ' 51' ' ' TYR . 0.4 OUTLIER 89.06 135.82 0.04 OUTLIER 'General case' 0 C--N 1.317 -0.838 0 C-N-CA 124.615 1.166 . . . . 0.0 111.953 168.399 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.735 ' HB2' ' CE1' ' A' ' 52' ' ' TYR . 0.0 OUTLIER -58.81 -34.23 71.27 Favored 'General case' 0 CA--C 1.512 -0.493 0 CA-C-N 114.195 -1.366 . . . . 0.0 110.932 -179.332 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -67.06 -44.05 89.05 Favored Glycine 0 N--CA 1.449 -0.463 0 C-N-CA 120.717 -0.754 . . . . 0.0 111.619 177.667 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . 0.577 ' HB ' ' O ' ' A' ' 57' ' ' PHE . 89.5 m -71.02 -41.2 71.16 Favored 'General case' 0 N--CA 1.445 -0.685 0 CA-C-O 121.048 0.452 . . . . 0.0 110.324 178.023 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 62' ' ' TRP . . . . . 0.453 ' CH2' ' HA ' ' A' ' 74' ' ' ALA . 41.1 t-105 -55.57 -49.98 71.27 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.455 -0.793 . . . . 0.0 110.215 172.71 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . 0.485 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 3.7 tp10 -63.54 -40.34 96.75 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 115.437 -0.801 . . . . 0.0 110.555 179.512 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -61.39 -41.37 97.02 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.753 -0.658 . . . . 0.0 110.804 -177.486 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . 0.441 ' HB3' ' HB ' ' A' ' 88' ' ' VAL . 9.3 m120 -80.55 -9.6 59.77 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.439 178.358 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . 0.498 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 85.32 46.8 5.43 Favored Glycine 0 N--CA 1.449 -0.445 0 CA-C-N 115.736 -0.665 . . . . 0.0 112.689 175.716 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.613 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -78.95 -18.53 74.78 Favored Glycine 0 N--CA 1.442 -0.961 0 C-N-CA 120.868 -0.682 . . . . 0.0 112.429 -174.668 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.988 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 7.0 mp -60.12 -24.11 64.41 Favored 'General case' 0 N--CA 1.445 -0.688 0 N-CA-C 112.545 0.572 . . . . 0.0 112.545 -175.0 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . 0.498 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 9.1 ptp180 -67.2 -31.85 72.52 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 121.405 0.622 . . . . 0.0 109.771 175.933 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 70' ' ' TYR . . . . . 0.815 ' HB3' ' HB3' ' A' ' 81' ' ' GLU . 74.5 m-85 -81.47 -33.91 31.72 Favored 'General case' 0 N--CA 1.443 -0.814 0 N-CA-C 107.728 -1.212 . . . . 0.0 107.728 178.199 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.573 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 165.9 126.01 0.03 OUTLIER Pre-proline 0 CA--C 1.512 -0.517 0 CA-C-N 112.897 -1.956 . . . . 0.0 107.325 -179.011 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 72' ' ' PRO . . . . . 0.988 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 21.2 Cg_exo -56.91 -6.66 1.87 Allowed 'Trans proline' 0 C--N 1.333 -0.242 0 C-N-CA 122.495 2.13 . . . . 0.0 113.587 -179.412 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 13.9 ptm180 -143.85 137.49 27.97 Favored 'General case' 0 C--N 1.321 -0.671 0 N-CA-C 109.228 -0.656 . . . . 0.0 109.228 177.752 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . 0.473 ' HB3' ' HB2' ' A' ' 52' ' ' TYR . . . -60.14 -28.06 67.58 Favored 'General case' 0 C--O 1.218 -0.569 0 CA-C-N 114.999 -1.0 . . . . 0.0 111.916 -176.96 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . 0.538 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 20.7 p-10 -88.13 3.56 48.69 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 121.186 0.517 . . . . 0.0 111.761 -176.449 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 66.9 tp -100.57 -30.67 11.65 Favored 'General case' 0 C--N 1.321 -0.64 0 N-CA-C 108.29 -1.004 . . . . 0.0 108.29 168.637 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . 0.921 ' HB1' ' HB2' ' A' ' 81' ' ' GLU . . . -78.89 143.87 35.48 Favored 'General case' 0 N--CA 1.441 -0.914 0 CA-C-N 114.617 -1.174 . . . . 0.0 110.704 176.486 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 27.7 p -93.88 -170.55 2.35 Favored 'General case' 0 C--N 1.314 -0.969 0 CA-C-N 115.417 -0.811 . . . . 0.0 109.117 178.93 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . 0.762 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 57.0 mtp180 -48.53 -51.38 27.79 Favored 'General case' 0 C--N 1.33 -0.262 0 O-C-N 123.196 0.31 . . . . 0.0 111.001 -178.512 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 10.2 pt-20 -57.64 -48.28 79.9 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.856 -0.611 . . . . 0.0 112.264 -173.776 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 81' ' ' GLU . . . . . 0.921 ' HB2' ' HB1' ' A' ' 77' ' ' ALA . 16.9 mp0 -65.25 -51.09 63.04 Favored 'General case' 0 N--CA 1.452 -0.358 0 N-CA-C 112.056 0.391 . . . . 0.0 112.056 177.339 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 82' ' ' GLN . . . . . 0.661 ' HB2' ' HZ3' ' A' ' 43' ' ' TRP . 46.0 mt-30 -61.6 -38.64 88.34 Favored 'General case' 0 CA--C 1.51 -0.561 0 CA-C-O 120.754 0.312 . . . . 0.0 110.833 -175.426 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.641 ' O ' ' HG2' ' A' ' 87' ' ' GLU . 50.2 mt -59.34 -44.46 92.43 Favored 'Isoleucine or valine' 0 C--O 1.215 -0.715 0 CA-C-N 115.512 -0.767 . . . . 0.0 109.865 176.889 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . 0.684 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -66.01 -41.92 90.4 Favored 'General case' 0 C--O 1.237 0.441 0 CA-C-O 121.29 0.567 . . . . 0.0 111.571 -176.841 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.539 HG23 ' O ' ' A' ' 81' ' ' GLU . 14.8 t -69.12 -47.94 71.89 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.696 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.454 178.969 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -58.23 -28.67 65.09 Favored 'General case' 0 C--O 1.232 0.143 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.431 173.389 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 87' ' ' GLU . . . . . 0.773 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 20.2 mm-40 -59.15 -43.87 92.07 Favored 'General case' 0 CA--C 1.51 -0.589 0 CA-C-N 115.32 -0.855 . . . . 0.0 109.619 178.926 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.584 ' O ' ' HG3' ' A' ' 92' ' ' ARG . 40.6 t -63.1 -43.55 99.0 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 CA-C-O 121.293 0.568 . . . . 0.0 109.933 175.572 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . 1.005 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 0.2 OUTLIER -62.61 -47.12 85.16 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.746 -0.661 . . . . 0.0 111.982 -176.016 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . 0.491 ' HB3' ' CH2' ' A' ' 31' ' ' TRP . 30.4 ptt85 -60.16 -29.39 68.63 Favored 'General case' 0 N--CA 1.467 0.381 0 CA-C-O 121.313 0.578 . . . . 0.0 110.448 -178.996 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . 0.773 ' HG ' ' O ' ' A' ' 87' ' ' GLU . 33.4 mt -66.97 -35.01 79.01 Favored 'General case' 0 C--N 1.314 -0.948 0 CA-C-O 121.406 0.622 . . . . 0.0 109.885 -179.918 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . 0.584 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 4.7 mtm180 -89.11 -51.54 5.54 Favored 'General case' 0 N--CA 1.443 -0.78 0 CA-C-N 115.348 -0.842 . . . . 0.0 110.13 -171.807 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 93' ' ' GLN . . . . . 0.51 HE22 ' HZ3' ' A' ' 98' ' ' TRP . 0.0 OUTLIER -108.72 -15.85 14.31 Favored 'General case' 0 N--CA 1.44 -0.946 0 CA-C-N 115.087 -0.96 . . . . 0.0 111.942 -173.151 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.478 ' HA2' ' O ' ' A' ' 90' ' ' ARG . . . 83.6 -107.41 2.93 Favored Glycine 0 CA--C 1.494 -1.232 0 N-CA-C 111.082 -0.807 . . . . 0.0 111.082 177.911 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 95' ' ' TRP . . . . . . . . . . . . . 3.5 m95 -142.81 27.32 1.66 Allowed 'General case' 0 C--N 1.313 -0.994 0 N-CA-C 106.901 -1.518 . . . . 0.0 106.901 179.813 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -79.19 -22.46 65.38 Favored Glycine 0 N--CA 1.448 -0.546 0 CA-C-N 114.457 -1.247 . . . . 0.0 111.079 173.195 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . 0.418 ' O ' ' HD3' ' A' ' 99' ' ' PRO . . . -85.12 -32.16 22.92 Favored 'General case' 0 C--N 1.327 -0.373 0 N-CA-C 109.378 -0.601 . . . . 0.0 109.378 174.419 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 98' ' ' TRP . . . . . 1.005 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 16.9 m-90 -101.14 100.72 13.94 Favored Pre-proline 0 C--O 1.221 -0.441 0 N-CA-C 109.009 -0.737 . . . . 0.0 109.009 174.027 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . 0.418 ' HD3' ' O ' ' A' ' 97' ' ' ALA . 10.3 Cg_exo -79.33 -88.49 0.0 OUTLIER 'Trans proline' 0 CA--C 1.532 0.411 0 C-N-CA 122.848 2.365 . . . . 0.0 115.085 -171.828 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 63.3 t -69.96 -28.32 36.06 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.349 0 CA-C-O 121.679 0.752 . . . . 0.0 110.047 -172.461 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 101' ' ' CYS . . . . . 0.678 ' SG ' ' HB2' ' A' ' 38' ' ' GLU . 87.4 m -72.21 -27.25 62.42 Favored 'General case' 0 C--N 1.317 -0.84 0 CA-C-N 115.25 -0.887 . . . . 0.0 111.084 -176.759 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 102' ' ' ALA . . . . . 0.679 ' HB1' ' HB2' ' A' ' 107' ' ' ALA . . . -69.93 -40.41 75.55 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.808 0.337 . . . . 0.0 110.333 175.658 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -63.08 -37.81 88.68 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 121.432 0.634 . . . . 0.0 110.336 177.591 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -72.88 -30.62 64.1 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.243 -0.89 . . . . 0.0 111.686 177.363 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 105' ' ' ALA . . . . . 0.605 ' HB1' ' HA ' ' A' ' 30' ' ' ILE . . . -96.32 -22.58 17.11 Favored 'General case' 0 C--N 1.325 -0.457 0 N-CA-C 113.001 0.741 . . . . 0.0 113.001 -172.271 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 104.13 69.85 0.8 Allowed Glycine 0 CA--C 1.52 0.376 0 C-N-CA 120.832 -0.699 . . . . 0.0 112.134 -177.302 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 107' ' ' ALA . . . . . 0.679 ' HB2' ' HB1' ' A' ' 102' ' ' ALA . . . -60.02 146.7 41.78 Favored 'General case' 0 CA--C 1.517 -0.325 0 C-N-CA 122.709 0.403 . . . . 0.0 110.912 -179.899 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 97.3 mtt180 . . . . . 0 C--O 1.248 1.013 0 CA-C-O 118.323 -0.846 . . . . 0.0 111.021 -170.482 . . . . . . . . 0 0 . 1 . 021 nuclear nobuild full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 93.5 m-20 . . . . . 0 N--CA 1.476 0.865 0 CA-C-O 121.562 0.696 . . . . 0.0 110.536 . . . . . . . . . 0 0 . 1 . 021 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 6.5 p -112.64 0.65 8.97 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.149 0 CA-C-N 114.976 -1.011 . . . . 0.0 109.599 176.441 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 9.0 p -58.07 139.14 18.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 115.116 -0.947 . . . . 0.0 111.144 176.937 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 2.8 p -61.11 142.53 15.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 121.362 0.601 . . . . 0.0 111.172 178.624 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . 0.462 ' HA ' ' HD3' ' A' ' 6' ' ' PRO . 8.9 t -95.02 132.73 27.54 Favored Pre-proline 0 C--N 1.313 -1.001 0 CA-C-N 115.211 -0.904 . . . . 0.0 111.119 -174.107 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.462 ' HD3' ' HA ' ' A' ' 5' ' ' THR . 0.9 OUTLIER -83.6 179.48 4.88 Favored 'Trans proline' 0 N--CA 1.456 -0.682 0 C-N-CA 123.768 2.979 . . . . 0.0 111.945 175.614 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . 58.26 55.15 5.24 Favored 'General case' 0 C--N 1.318 -0.778 0 CA-C-N 114.632 -1.167 . . . . 0.0 111.664 -179.812 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 79.3 t60 -83.98 -9.59 58.56 Favored 'General case' 0 C--N 1.31 -1.113 0 CA-C-N 114.034 -1.439 . . . . 0.0 108.724 172.484 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 17.2 pt-20 -64.71 135.92 56.38 Favored 'General case' 0 N--CA 1.453 -0.304 0 CA-C-N 115.289 -0.869 . . . . 0.0 110.056 -179.601 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -104.13 66.88 0.84 Allowed 'General case' 0 C--N 1.319 -0.72 0 CA-C-O 122.035 0.921 . . . . 0.0 110.737 -173.388 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 47.9 t -82.83 -61.32 1.79 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.179 0 CA-C-N 114.215 -1.357 . . . . 0.0 109.449 173.431 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 5.9 p 32.74 84.09 0.01 OUTLIER 'Isoleucine or valine' 0 C--O 1.237 0.419 0 C-N-CA 124.953 1.301 . . . . 0.0 113.677 178.87 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 7.1 ttm180 63.68 140.77 0.02 OUTLIER 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 113.597 -1.638 . . . . 0.0 113.298 177.689 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.56 HG23 HG23 ' A' ' 20' ' ' THR . 3.0 t -103.72 160.38 4.67 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.981 0 N-CA-C 108.174 -1.047 . . . . 0.0 108.174 173.447 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -121.49 -54.71 0.22 Allowed Glycine 0 N--CA 1.433 -1.565 0 CA-C-N 115.423 -0.808 . . . . 0.0 111.638 -176.032 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.443 ' O ' ' HD3' ' A' ' 18' ' ' PRO . 20.8 m -65.51 -39.17 91.55 Favored 'General case' 0 C--N 1.312 -1.036 0 CA-C-N 114.555 -0.823 . . . . 0.0 110.755 178.722 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . 0.424 ' O ' ' HB ' ' A' ' 14' ' ' VAL . 27.1 mmtm -104.09 99.4 16.72 Favored Pre-proline 0 C--N 1.314 -0.969 0 CA-C-N 115.034 -0.985 . . . . 0.0 109.689 175.476 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . 0.443 ' HD3' ' O ' ' A' ' 16' ' ' THR . 14.8 Cg_exo -71.46 155.48 59.69 Favored 'Trans proline' 0 N--CA 1.452 -0.954 0 C-N-CA 122.352 2.035 . . . . 0.0 110.964 176.051 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 84.61 51.2 3.94 Favored Glycine 0 C--N 1.299 -1.503 0 CA-C-N 114.86 -1.064 . . . . 0.0 110.895 -178.001 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . 0.56 HG23 HG23 ' A' ' 14' ' ' VAL . 26.5 m -58.42 -41.35 84.79 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 121.697 0.76 . . . . 0.0 110.034 179.514 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 48.5 mt-10 -144.75 140.06 28.27 Favored 'General case' 0 N--CA 1.439 -0.98 0 N-CA-C 106.59 -1.633 . . . . 0.0 106.59 175.053 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.442 ' HA ' ' HD3' ' A' ' 23' ' ' PRO . 41.0 t -71.2 113.89 22.97 Favored Pre-proline 0 C--N 1.314 -0.961 0 N-CA-C 107.99 -1.115 . . . . 0.0 107.99 176.731 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.469 ' HA ' ' HD2' ' A' ' 24' ' ' PRO . 51.7 Cg_exo -53.74 125.89 20.09 Favored 'Trans proline' 0 C--N 1.345 0.362 0 C-N-CA 122.871 2.381 . . . . 0.0 113.672 -163.522 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . 0.469 ' HD2' ' HA ' ' A' ' 23' ' ' PRO . 10.3 Cg_endo -57.12 140.13 91.89 Favored 'Trans proline' 0 N--CA 1.447 -1.22 0 C-N-CA 123.186 2.591 . . . . 0.0 111.538 172.93 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.616 ' HB ' ' CG2' ' A' ' 83' ' ' ILE . 60.4 t -115.2 137.0 50.12 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.359 0 CA-C-N 114.722 -1.126 . . . . 0.0 109.119 179.567 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 34.9 mm -61.08 -23.81 31.12 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-N 115.409 -0.814 . . . . 0.0 112.171 -170.65 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.446 ' O ' HG12 ' A' ' 30' ' ' ILE . 19.4 m-20 -99.05 2.94 46.64 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-O 121.441 0.639 . . . . 0.0 109.791 -177.196 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . 0.412 ' HA3' HD13 ' A' ' 83' ' ' ILE . . . -64.3 -11.54 47.05 Favored Glycine 0 CA--C 1.503 -0.656 0 CA-C-N 114.961 -1.018 . . . . 0.0 111.051 179.635 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 4.4 m -75.73 -41.27 53.85 Favored 'General case' 0 C--N 1.318 -0.794 0 CA-C-O 121.956 0.884 . . . . 0.0 109.116 177.225 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.547 ' HA ' ' HB1' ' A' ' 105' ' ' ALA . 0.9 OUTLIER -67.91 -38.99 80.94 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.726 0 CA-C-N 113.898 -1.501 . . . . 0.0 107.735 178.423 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 31' ' ' TRP . . . . . 0.522 ' HB2' HG12 ' A' ' 83' ' ' ILE . 32.6 m95 -67.98 -35.96 79.23 Favored 'General case' 0 C--N 1.317 -0.845 0 CA-C-N 114.472 -1.24 . . . . 0.0 110.619 -177.684 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.84 ' HB2' HH21 ' A' ' 79' ' ' ARG . 23.3 t70 -73.07 -37.59 66.74 Favored 'General case' 0 N--CA 1.446 -0.654 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.44 -179.349 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . 0.513 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -70.99 -34.15 71.1 Favored 'General case' 0 N--CA 1.446 -0.632 0 C-N-CA 120.707 -0.397 . . . . 0.0 110.787 176.494 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . 0.53 HG13 ' O ' ' A' ' 30' ' ' ILE . 61.1 mt -67.34 -46.89 82.76 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.283 0 CA-C-O 121.108 0.48 . . . . 0.0 110.701 175.201 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . 0.468 ' O ' ' HB3' ' A' ' 39' ' ' ALA . . . -63.19 -34.39 77.54 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.408 178.108 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -72.63 -15.01 77.67 Favored Glycine 0 N--CA 1.449 -0.491 0 N-CA-C 111.181 -0.768 . . . . 0.0 111.181 176.729 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.448 ' HB3' ' O ' ' A' ' 34' ' ' ILE . 41.3 t -87.18 -64.5 1.14 Allowed 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.296 -0.452 . . . . 0.0 111.292 -176.702 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . 0.803 ' HG3' ' SG ' ' A' ' 101' ' ' CYS . 40.8 mt-10 -88.94 -29.62 19.42 Favored 'General case' 0 CA--C 1.516 -0.357 0 CA-C-O 120.813 0.34 . . . . 0.0 111.784 -173.277 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . 0.468 ' HB3' ' O ' ' A' ' 35' ' ' ALA . . . -92.72 -11.33 34.26 Favored 'General case' 0 C--N 1.322 -0.619 0 C-N-CA 120.455 -0.498 . . . . 0.0 111.316 -176.956 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 76.24 15.52 81.39 Favored Glycine 0 N--CA 1.446 -0.664 0 N-CA-C 109.782 -1.327 . . . . 0.0 109.782 -176.229 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 75.11 51.68 7.4 Favored Glycine 0 N--CA 1.436 -1.339 0 CA-C-N 114.268 -0.966 . . . . 0.0 111.939 -176.449 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 2.2 t-20 -140.67 100.1 3.78 Favored 'General case' 0 N--CA 1.448 -0.542 0 N-CA-C 108.855 -0.795 . . . . 0.0 108.855 179.947 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 43' ' ' TRP . . . . . 0.729 ' CE3' ' HA ' ' A' ' 79' ' ' ARG . 30.9 m95 -82.78 -12.69 57.31 Favored 'General case' 0 C--N 1.313 -1.009 0 CA-C-N 115.241 -0.891 . . . . 0.0 110.529 -172.846 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -104.61 10.99 34.7 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 115.455 -0.793 . . . . 0.0 111.272 -178.145 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.699 HG22 ' HA2' ' A' ' 53' ' ' GLY . 4.0 tt -74.04 143.72 13.28 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.655 0 CA-C-O 121.0 0.429 . . . . 0.0 109.915 179.507 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 17.6 t-20 -142.75 87.22 1.98 Allowed 'General case' 0 C--N 1.313 -0.989 0 CA-C-O 121.286 0.565 . . . . 0.0 109.567 -179.171 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 22.7 p -74.12 -24.57 59.47 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.648 179.983 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 92.43 19.57 37.94 Favored Glycine 0 N--CA 1.445 -0.709 0 N-CA-C 110.824 -0.91 . . . . 0.0 110.824 -177.913 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 64.8 t30 -74.94 -7.31 53.19 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 121.384 0.611 . . . . 0.0 111.12 -174.635 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . 0.498 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 95.73 -12.94 67.03 Favored Glycine 0 CA--C 1.504 -0.643 0 N-CA-C 109.47 -1.452 . . . . 0.0 109.47 -173.252 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 51' ' ' TYR . . . . . 0.629 ' HA ' ' HA ' ' A' ' 58' ' ' ASP . 0.5 OUTLIER -114.74 160.9 18.86 Favored 'General case' 0 N--CA 1.439 -0.984 0 N-CA-C 106.132 -1.803 . . . . 0.0 106.132 173.187 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 52' ' ' TYR . . . . . 0.687 ' HB2' ' HB3' ' A' ' 74' ' ' ALA . 55.5 m-85 -123.51 169.4 11.44 Favored 'General case' 0 C--N 1.308 -1.207 0 C-N-CA 120.085 -0.646 . . . . 0.0 111.403 -169.702 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.699 ' HA2' HG22 ' A' ' 45' ' ' ILE . . . -59.31 171.34 5.25 Favored Glycine 0 N--CA 1.445 -0.724 0 O-C-N 123.778 0.674 . . . . 0.0 113.821 -173.212 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.707 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 87.79 -107.78 3.33 Favored Glycine 0 N--CA 1.44 -1.09 0 C-N-CA 120.708 -0.758 . . . . 0.0 111.77 -179.391 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.524 ' HB ' ' CD1' ' A' ' 57' ' ' PHE . 2.0 t -84.6 0.58 5.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.542 0 CA-C-O 121.276 0.56 . . . . 0.0 110.277 -177.555 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 56' ' ' GLN . . . . . 0.585 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 79.3 mm-40 58.05 44.59 19.16 Favored 'General case' 0 N--CA 1.462 0.164 0 CA-C-N 114.971 -1.013 . . . . 0.0 113.169 170.886 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . 0.524 ' CD1' ' HB ' ' A' ' 55' ' ' VAL . 1.6 p90 -118.98 164.26 15.72 Favored 'General case' 0 C--N 1.325 -0.472 0 C-N-CA 119.435 -0.906 . . . . 0.0 111.914 177.301 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.629 ' HA ' ' HA ' ' A' ' 51' ' ' TYR . 7.9 p-10 -74.81 165.57 25.03 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 114.985 -1.007 . . . . 0.0 113.685 -163.512 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.439 ' HB2' ' HE1' ' A' ' 52' ' ' TYR . 19.5 tp60 -59.26 -41.95 90.04 Favored 'General case' 0 N--CA 1.438 -1.044 0 CA-C-N 114.538 -1.21 . . . . 0.0 110.945 178.184 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -68.1 -49.45 46.89 Favored Glycine 0 C--O 1.225 -0.45 0 CA-C-N 115.617 -0.719 . . . . 0.0 112.614 -172.35 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 86.7 m -62.25 -42.37 99.26 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-O 121.098 0.475 . . . . 0.0 110.761 178.624 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 62' ' ' TRP . . . . . 0.501 ' CH2' ' HA ' ' A' ' 74' ' ' ALA . 53.4 t-105 -56.62 -51.25 69.41 Favored 'General case' 0 N--CA 1.448 -0.565 0 CA-C-N 115.133 -0.94 . . . . 0.0 109.39 175.323 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . 1.033 ' HG3' HD11 ' A' ' 68' ' ' LEU . 24.0 tt0 -64.43 -38.36 90.75 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-N 114.544 -1.207 . . . . 0.0 111.275 -177.606 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -67.71 -42.39 82.03 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.935 -0.575 . . . . 0.0 111.424 -175.027 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . 0.624 HD22 ' N ' ' A' ' 65' ' ' ASN . 0.7 OUTLIER -77.96 -8.85 58.69 Favored 'General case' 0 N--CA 1.451 -0.405 0 CA-C-O 121.316 0.579 . . . . 0.0 109.672 176.812 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . 0.524 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 90.17 47.71 3.76 Favored Glycine 0 N--CA 1.449 -0.498 0 CA-C-N 115.438 -0.801 . . . . 0.0 112.417 173.386 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.545 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -80.47 -16.39 76.01 Favored Glycine 0 N--CA 1.444 -0.813 0 C-N-CA 120.876 -0.678 . . . . 0.0 112.065 -177.14 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 1.033 HD11 ' HG3' ' A' ' 63' ' ' GLU . 20.8 mt -65.53 -28.58 69.27 Favored 'General case' 0 C--N 1.314 -0.937 0 CA-C-O 120.999 0.428 . . . . 0.0 111.351 -171.06 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . 0.524 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 11.7 ptm180 -65.04 -31.69 73.04 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.217 175.379 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 70' ' ' TYR . . . . . 0.796 ' HB3' ' HB3' ' A' ' 81' ' ' GLU . 89.9 m-85 -77.4 -34.61 54.79 Favored 'General case' 0 CA--C 1.505 -0.755 0 N-CA-C 107.723 -1.214 . . . . 0.0 107.723 178.328 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.582 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 164.65 123.57 0.02 OUTLIER Pre-proline 0 C--N 1.319 -0.724 0 CA-C-N 112.125 -2.307 . . . . 0.0 106.859 -178.232 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 72' ' ' PRO . . . . . 0.59 ' HA ' ' HA ' ' A' ' 68' ' ' LEU . 38.6 Cg_exo -51.76 -6.48 0.17 Allowed 'Trans proline' 0 CA--C 1.53 0.282 0 C-N-CA 123.16 2.573 . . . . 0.0 114.393 -178.513 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 9.2 ptm180 -146.85 142.67 27.91 Favored 'General case' 0 C--N 1.315 -0.91 0 N-CA-C 108.825 -0.805 . . . . 0.0 108.825 174.905 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . 0.687 ' HB3' ' HB2' ' A' ' 52' ' ' TYR . . . -58.35 -33.08 69.15 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.679 -0.691 . . . . 0.0 112.753 -177.129 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . 0.572 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 4.3 p-10 -80.28 -10.22 59.75 Favored 'General case' 0 C--N 1.331 -0.231 0 C-N-CA 120.668 -0.413 . . . . 0.0 111.247 -173.931 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.477 ' HB3' ' HB1' ' A' ' 71' ' ' ALA . 62.5 tp -87.23 -32.49 19.74 Favored 'General case' 0 C--N 1.323 -0.552 0 N-CA-C 108.869 -0.789 . . . . 0.0 108.869 173.66 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . 0.837 ' HB1' ' HB2' ' A' ' 81' ' ' GLU . . . -82.22 161.08 22.84 Favored 'General case' 0 N--CA 1.442 -0.853 0 CA-C-N 114.98 -1.009 . . . . 0.0 110.371 176.171 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 20.0 p -100.59 -170.59 1.88 Allowed 'General case' 0 C--N 1.316 -0.876 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.088 179.127 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . 0.84 HH21 ' HB2' ' A' ' 32' ' ' ASP . 39.1 mtp180 -48.98 -53.48 19.66 Favored 'General case' 0 CA--C 1.515 -0.391 0 O-C-N 123.498 0.499 . . . . 0.0 111.005 -177.044 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 2.5 pt-20 -60.91 -42.47 98.16 Favored 'General case' 0 C--N 1.315 -0.928 0 CA-C-N 114.972 -1.013 . . . . 0.0 112.895 -171.486 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 81' ' ' GLU . . . . . 0.837 ' HB2' ' HB1' ' A' ' 77' ' ' ALA . 9.1 mp0 -63.38 -50.67 68.99 Favored 'General case' 0 N--CA 1.455 -0.196 0 CA-C-N 118.194 0.452 . . . . 0.0 111.491 175.163 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 82' ' ' GLN . . . . . 0.6 ' HB2' ' HZ3' ' A' ' 43' ' ' TRP . 48.0 mt-30 -61.87 -36.79 82.3 Favored 'General case' 0 CA--C 1.515 -0.369 0 CA-C-O 121.122 0.487 . . . . 0.0 110.309 -177.673 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.616 ' CG2' ' HB ' ' A' ' 25' ' ' VAL . 33.8 mt -59.4 -44.0 91.61 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.686 0 CA-C-N 114.982 -1.008 . . . . 0.0 109.973 177.119 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . 0.616 ' O ' ' HG3' ' A' ' 87' ' ' GLU . . . -66.57 -45.38 79.49 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 116.038 -0.528 . . . . 0.0 111.47 -179.503 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.518 HG23 ' O ' ' A' ' 81' ' ' GLU . 40.1 t -67.73 -50.21 62.56 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-N 116.305 -0.407 . . . . 0.0 112.018 -179.343 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -63.67 -30.96 71.99 Favored 'General case' 0 N--CA 1.449 -0.502 0 CA-C-O 121.002 0.43 . . . . 0.0 110.542 178.962 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 87' ' ' GLU . . . . . 0.616 ' HG3' ' O ' ' A' ' 84' ' ' ALA . 0.1 OUTLIER -70.36 -29.97 66.78 Favored 'General case' 0 C--N 1.325 -0.489 0 C-N-CA 120.418 -0.513 . . . . 0.0 110.438 -177.788 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 53.8 t -62.31 -43.31 97.92 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.258 0 N-CA-C 108.831 -0.803 . . . . 0.0 108.831 170.479 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . 0.704 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 0.6 OUTLIER -65.67 -43.22 89.98 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 115.232 -0.895 . . . . 0.0 110.689 -177.971 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . 0.601 ' HG3' ' O ' ' A' ' 87' ' ' GLU . 4.2 ppt_? -66.37 -33.52 75.89 Favored 'General case' 0 CA--C 1.513 -0.47 0 N-CA-C 109.213 -0.662 . . . . 0.0 109.213 -178.929 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . 0.464 ' HB2' ' O ' ' A' ' 87' ' ' GLU . 2.2 tm? -57.21 -34.8 68.91 Favored 'General case' 0 C--N 1.318 -0.786 0 CA-C-N 114.386 -1.279 . . . . 0.0 110.095 -174.931 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . 0.497 ' HE ' ' HB2' ' A' ' 92' ' ' ARG . 3.4 mtm180 -92.49 -39.9 11.13 Favored 'General case' 0 C--N 1.315 -0.934 0 CA-C-N 115.18 -0.918 . . . . 0.0 109.91 -172.227 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 93' ' ' GLN . . . . . 0.49 ' NE2' HG22 ' A' ' 89' ' ' THR . 7.5 pt20 -94.63 -30.73 14.18 Favored 'General case' 0 C--N 1.316 -0.871 0 CA-C-N 114.27 -1.332 . . . . 0.0 113.777 -169.335 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 86.17 32.46 17.03 Favored Glycine 0 CA--C 1.52 0.345 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.619 178.207 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 95' ' ' TRP . . . . . 0.453 ' CE2' ' HD3' ' A' ' 90' ' ' ARG . 13.5 m95 66.82 16.27 10.33 Favored 'General case' 0 N--CA 1.466 0.355 0 C-N-CA 123.395 0.678 . . . . 0.0 110.085 178.095 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -63.94 -41.69 98.59 Favored Glycine 0 CA--C 1.519 0.326 0 CA-C-N 115.461 -0.79 . . . . 0.0 113.65 -179.852 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . 0.47 ' O ' ' HD3' ' A' ' 99' ' ' PRO . . . -78.59 -21.62 48.3 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 117.072 0.436 . . . . 0.0 111.259 -178.456 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 98' ' ' TRP . . . . . 0.704 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 16.3 m-90 -85.54 104.53 5.2 Favored Pre-proline 0 C--O 1.225 -0.226 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 170.118 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . 0.47 ' HD3' ' O ' ' A' ' 97' ' ' ALA . 11.7 Cg_exo -76.28 -95.59 0.01 OUTLIER 'Trans proline' 0 N--CA 1.457 -0.648 0 C-N-CA 122.435 2.09 . . . . 0.0 115.087 -171.275 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . 0.424 ' H ' ' HB2' ' A' ' 99' ' ' PRO . 38.3 t -71.32 -30.09 38.49 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.445 0 CA-C-O 121.72 0.771 . . . . 0.0 110.411 -169.07 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 101' ' ' CYS . . . . . 0.803 ' SG ' ' HG3' ' A' ' 38' ' ' GLU . 60.8 m -81.8 -25.66 35.04 Favored 'General case' 0 C--N 1.316 -0.855 0 CA-C-N 115.193 -0.912 . . . . 0.0 111.363 -169.722 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 102' ' ' ALA . . . . . 0.453 ' HB1' ' HB2' ' A' ' 107' ' ' ALA . . . -69.82 -45.21 68.39 Favored 'General case' 0 C--N 1.33 -0.276 0 N-CA-C 110.04 -0.355 . . . . 0.0 110.04 176.502 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -61.96 -39.34 91.78 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 121.307 0.575 . . . . 0.0 110.63 177.512 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 12.5 mtp180 -66.09 -39.02 89.66 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.438 -0.801 . . . . 0.0 111.476 177.405 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 105' ' ' ALA . . . . . 0.547 ' HB1' ' HA ' ' A' ' 30' ' ' ILE . . . -83.56 -22.07 32.47 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 112.583 0.586 . . . . 0.0 112.583 -174.026 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 107.71 61.05 0.56 Allowed Glycine 0 CA--C 1.521 0.459 0 C-N-CA 121.035 -0.602 . . . . 0.0 112.506 -179.56 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 107' ' ' ALA . . . . . 0.453 ' HB2' ' HB1' ' A' ' 102' ' ' ALA . . . -62.45 149.22 43.28 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 121.037 0.446 . . . . 0.0 111.528 -176.342 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 108' ' ' ARG . . . . . 0.405 ' CZ ' HD11 ' A' ' 30' ' ' ILE . 92.6 mtt180 . . . . . 0 C--O 1.249 1.067 0 CA-C-N 115.628 -0.715 . . . . 0.0 110.57 -172.596 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 13.4 m120 . . . . . 0 N--CA 1.479 1.019 0 N-CA-C 110.045 -0.354 . . . . 0.0 110.045 . . . . . . . . . 0 0 . 1 . 022 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 54.2 t -82.33 -54.73 8.98 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.508 178.804 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . 0.465 ' O ' HG12 ' A' ' 4' ' ' VAL . 56.7 t -92.91 107.03 18.58 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.797 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.324 -179.254 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.476 HG22 ' H ' ' A' ' 5' ' ' THR . 2.4 p 50.97 165.97 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.535 0.366 0 N-CA-C 115.08 1.511 . . . . 0.0 115.08 176.081 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . 0.509 ' HA ' ' HD3' ' A' ' 6' ' ' PRO . 2.5 p -104.71 126.73 30.5 Favored Pre-proline 0 C--N 1.314 -0.943 0 CA-C-N 113.552 -1.658 . . . . 0.0 109.91 175.965 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.509 ' HD3' ' HA ' ' A' ' 5' ' ' THR . 16.9 Cg_exo -68.21 173.94 8.78 Favored 'Trans proline' 0 CA--C 1.513 -0.526 0 C-N-CA 123.231 2.621 . . . . 0.0 112.436 -178.34 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . 61.3 76.84 0.35 Allowed 'General case' 0 C--N 1.315 -0.924 0 CA-C-N 114.031 -1.44 . . . . 0.0 111.73 -177.297 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 9.9 t-160 -105.89 8.1 32.49 Favored 'General case' 0 C--N 1.314 -0.97 0 CA-C-N 114.12 -1.4 . . . . 0.0 107.796 171.981 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 10.5 pt-20 -47.88 147.28 2.06 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 113.871 -1.513 . . . . 0.0 112.419 178.913 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -109.08 67.97 0.67 Allowed 'General case' 0 C--N 1.318 -0.767 0 CA-C-O 122.049 0.928 . . . . 0.0 110.183 -176.18 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 12.0 p -65.11 -27.11 41.46 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.017 0 CA-C-N 113.953 -1.476 . . . . 0.0 109.929 174.844 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 6.1 p 35.21 91.7 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.239 0.514 0 C-N-CA 125.43 1.492 . . . . 0.0 114.675 173.986 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . 0.407 HH11 ' HD2' ' A' ' 13' ' ' ARG . 47.8 mtm180 -71.72 113.19 8.5 Favored 'General case' 0 N--CA 1.429 -1.525 0 CA-C-N 113.748 -1.569 . . . . 0.0 108.1 170.791 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.5 p -37.81 119.0 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.813 0 CA-C-N 114.039 -1.437 . . . . 0.0 113.87 -172.27 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -145.68 60.34 0.49 Allowed Glycine 0 N--CA 1.43 -1.703 0 CA-C-N 113.531 -1.668 . . . . 0.0 111.008 177.406 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 90.1 m -98.48 -22.14 16.17 Favored 'General case' 0 C--N 1.312 -1.046 0 CA-C-N 114.458 -0.871 . . . . 0.0 110.404 -175.902 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . 0.565 ' HG2' ' O ' ' A' ' 76' ' ' LEU . 0.0 OUTLIER 50.81 87.47 0.13 Allowed Pre-proline 0 C--N 1.321 -0.674 0 CA-C-N 115.001 -1.0 . . . . 0.0 112.008 -178.763 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 26.2 Cg_exo -42.45 111.43 0.2 Allowed 'Trans proline' 0 CA--C 1.508 -0.788 0 C-N-CA 123.595 2.864 . . . . 0.0 112.741 176.084 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 154.18 55.76 0.01 OUTLIER Glycine 0 C--N 1.299 -1.478 0 CA-C-N 113.058 -1.883 . . . . 0.0 110.178 -174.028 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 3.9 m -57.2 -40.3 77.16 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 114.525 -0.837 . . . . 0.0 111.912 -173.734 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 42.1 mt-10 -117.33 82.28 1.79 Allowed 'General case' 0 CA--C 1.512 -0.499 0 CA-C-O 121.708 0.766 . . . . 0.0 111.634 177.863 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 3.3 p -75.65 123.97 88.62 Favored Pre-proline 0 C--N 1.307 -1.272 0 CA-C-N 114.282 -1.326 . . . . 0.0 110.017 174.471 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_exo -55.19 126.82 23.83 Favored 'Trans proline' 0 C--O 1.235 0.348 0 C-N-CA 122.6 2.2 . . . . 0.0 112.699 -178.554 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_exo -57.26 141.28 94.58 Favored 'Trans proline' 0 N--CA 1.443 -1.497 0 C-N-CA 123.263 2.642 . . . . 0.0 112.851 175.487 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 33.6 t -100.75 157.59 4.12 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.171 0 CA-C-N 114.665 -1.152 . . . . 0.0 108.68 176.782 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 49.6 mm -55.32 -39.27 51.45 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-O 121.013 0.435 . . . . 0.0 111.586 -170.874 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.479 ' O ' HG12 ' A' ' 30' ' ' ILE . 7.6 m-20 -111.25 9.08 21.72 Favored 'General case' 0 C--N 1.318 -0.785 0 CA-C-O 121.749 0.785 . . . . 0.0 109.397 -178.908 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -69.92 -5.31 51.9 Favored Glycine 0 N--CA 1.441 -1.004 0 CA-C-N 114.702 -1.136 . . . . 0.0 110.802 178.701 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 12.5 m -76.86 -42.95 38.0 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-O 121.813 0.816 . . . . 0.0 109.11 174.512 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.695 ' HA ' ' HB1' ' A' ' 105' ' ' ALA . 0.4 OUTLIER -66.58 -38.75 82.3 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-N 114.274 -1.33 . . . . 0.0 107.728 178.426 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 31' ' ' TRP . . . . . 0.455 ' CZ2' ' HD3' ' A' ' 90' ' ' ARG . 26.3 m95 -70.05 -35.0 73.94 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 114.572 -1.195 . . . . 0.0 110.516 -178.395 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.401 ' HB2' HH21 ' A' ' 79' ' ' ARG . 32.5 t70 -76.14 -37.63 57.77 Favored 'General case' 0 N--CA 1.449 -0.518 0 CA-C-N 116.024 -0.534 . . . . 0.0 110.349 -179.095 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . 0.511 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -70.59 -34.06 71.75 Favored 'General case' 0 N--CA 1.45 -0.441 0 C-N-CA 120.792 -0.363 . . . . 0.0 110.647 177.417 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . 0.494 HG13 ' O ' ' A' ' 30' ' ' ILE . 74.6 mt -65.55 -45.11 93.48 Favored 'Isoleucine or valine' 0 C--O 1.234 0.252 0 CA-C-O 121.168 0.509 . . . . 0.0 109.841 173.113 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -58.45 -38.3 77.22 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.611 -0.722 . . . . 0.0 110.014 175.074 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . 0.408 ' HA2' ' N ' ' A' ' 41' ' ' GLY . . . -72.2 -12.31 76.0 Favored Glycine 0 N--CA 1.449 -0.456 0 CA-C-N 115.399 -0.819 . . . . 0.0 111.835 179.139 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 46.8 t -88.78 -62.77 1.41 Allowed 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 115.614 -0.293 . . . . 0.0 111.118 -178.249 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . 0.416 ' HG3' ' SG ' ' A' ' 101' ' ' CYS . 34.2 mt-10 -90.0 -33.37 16.39 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 120.969 0.414 . . . . 0.0 111.185 -174.107 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -93.78 -8.57 40.24 Favored 'General case' 0 N--CA 1.45 -0.471 0 C-N-CA 120.547 -0.461 . . . . 0.0 111.763 -174.755 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 79.71 7.16 88.71 Favored Glycine 0 CA--C 1.505 -0.579 0 N-CA-C 110.26 -1.136 . . . . 0.0 110.26 -178.106 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . 0.408 ' N ' ' HA2' ' A' ' 36' ' ' GLY . . . 81.76 50.78 4.81 Favored Glycine 0 N--CA 1.435 -1.374 0 CA-C-N 114.324 -0.938 . . . . 0.0 112.656 -178.537 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . . . . . . . . . 44.7 t-20 -144.26 128.56 17.82 Favored 'General case' 0 N--CA 1.441 -0.9 0 N-CA-C 107.871 -1.159 . . . . 0.0 107.871 178.256 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 43' ' ' TRP . . . . . 0.791 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 17.6 m95 -103.38 0.41 31.25 Favored 'General case' 0 C--N 1.306 -1.304 0 CA-C-N 115.589 -0.732 . . . . 0.0 110.313 -173.549 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -112.55 -2.47 14.61 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-N 115.4 -0.818 . . . . 0.0 111.011 178.396 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 10.0 tt -66.6 143.4 15.63 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.79 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.078 177.991 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 17.7 t-20 -143.59 91.68 2.27 Favored 'General case' 0 C--N 1.317 -0.83 0 CA-C-O 121.471 0.653 . . . . 0.0 109.334 -179.077 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -73.69 -19.17 60.9 Favored 'General case' 0 N--CA 1.437 -1.085 0 CA-C-N 115.065 -0.971 . . . . 0.0 110.555 177.51 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 82.88 23.01 56.82 Favored Glycine 0 N--CA 1.445 -0.732 0 CA-C-N 115.51 -0.768 . . . . 0.0 111.247 174.315 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 4.6 p-10 -93.5 15.38 16.11 Favored 'General case' 0 C--N 1.325 -0.5 0 N-CA-C 112.247 0.462 . . . . 0.0 112.247 -172.073 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . 0.498 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 95.06 -13.51 66.91 Favored Glycine 0 CA--C 1.508 -0.358 0 N-CA-C 110.789 -0.925 . . . . 0.0 110.789 178.859 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 51' ' ' TYR . . . . . 0.498 ' HD1' ' C ' ' A' ' 50' ' ' GLY . 0.1 OUTLIER -121.52 161.58 22.06 Favored 'General case' 0 N--CA 1.441 -0.881 0 N-CA-C 105.286 -2.116 . . . . 0.0 105.286 174.483 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 52' ' ' TYR . . . . . 0.736 ' O ' ' HA ' ' A' ' 56' ' ' GLN . 20.8 m-85 -126.97 167.85 15.33 Favored 'General case' 0 C--N 1.302 -1.487 0 C-N-CA 119.621 -0.832 . . . . 0.0 111.231 -169.827 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -55.31 164.18 4.1 Favored Glycine 0 N--CA 1.446 -0.689 0 O-C-N 123.881 0.738 . . . . 0.0 114.105 -175.852 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.616 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 97.1 -112.99 4.59 Favored Glycine 0 N--CA 1.439 -1.155 0 N-CA-C 111.421 -0.672 . . . . 0.0 111.421 -176.423 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.59 HG12 ' HE1' ' A' ' 98' ' ' TRP . 2.2 t -84.81 -3.5 8.13 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 CA-C-O 121.826 0.822 . . . . 0.0 109.783 -178.418 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 56' ' ' GLN . . . . . 0.736 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 6.4 tt0 50.36 50.57 18.47 Favored 'General case' 0 N--CA 1.463 0.213 0 CA-C-N 113.774 -1.557 . . . . 0.0 113.498 173.314 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . 0.458 ' CD1' ' HB ' ' A' ' 55' ' ' VAL . 2.8 p90 -113.41 159.35 19.55 Favored 'General case' 0 C--N 1.321 -0.64 0 C-N-CA 119.925 -0.71 . . . . 0.0 110.684 171.668 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.433 ' HA ' ' HA ' ' A' ' 51' ' ' TYR . 5.9 p-10 -71.29 157.75 37.57 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-O 121.75 0.786 . . . . 0.0 112.869 -163.922 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.71 ' HA ' HE21 ' A' ' 59' ' ' GLN . 0.0 OUTLIER -55.8 -35.75 66.65 Favored 'General case' 0 N--CA 1.447 -0.603 0 CA-C-N 114.193 -1.367 . . . . 0.0 111.371 178.944 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -68.12 -49.75 44.7 Favored Glycine 0 N--CA 1.45 -0.407 0 CA-C-N 115.572 -0.74 . . . . 0.0 112.155 -175.896 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 51.3 m -65.19 -41.23 94.76 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-O 121.113 0.482 . . . . 0.0 110.595 176.447 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 62' ' ' TRP . . . . . 0.611 ' CZ3' ' HG2' ' A' ' 82' ' ' GLN . 54.5 t-105 -56.5 -48.89 76.23 Favored 'General case' 0 N--CA 1.448 -0.531 0 CA-C-N 115.493 -0.776 . . . . 0.0 109.389 175.833 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . 0.457 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 34.9 tt0 -68.25 -32.49 72.71 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 115.105 -0.952 . . . . 0.0 111.217 -179.505 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -65.53 -41.21 93.34 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.991 -0.549 . . . . 0.0 110.711 -178.552 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . 0.52 ' HB2' HG13 ' A' ' 85' ' ' VAL . 5.9 m120 -81.13 -8.07 59.69 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.45 0.643 . . . . 0.0 109.862 175.239 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . 0.412 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 80.74 50.26 5.34 Favored Glycine 0 N--CA 1.449 -0.454 0 CA-C-N 115.031 -0.986 . . . . 0.0 112.828 174.903 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.602 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -78.58 -18.55 75.46 Favored Glycine 0 N--CA 1.442 -0.966 0 C-N-CA 120.957 -0.64 . . . . 0.0 112.086 -176.499 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.933 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 7.0 mp -60.34 -20.2 58.4 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 111.994 0.368 . . . . 0.0 111.994 -176.09 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . 0.412 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 9.9 ptm180 -70.57 -31.86 69.05 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-O 121.253 0.549 . . . . 0.0 109.823 177.238 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 70' ' ' TYR . . . . . 0.602 ' HD2' ' HA2' ' A' ' 67' ' ' GLY . 43.8 m-85 -85.3 -34.0 21.99 Favored 'General case' 0 N--CA 1.438 -1.04 0 N-CA-C 107.71 -1.218 . . . . 0.0 107.71 178.239 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.511 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 170.69 122.06 0.05 OUTLIER Pre-proline 0 N--CA 1.45 -0.454 0 CA-C-N 113.247 -1.797 . . . . 0.0 107.83 -177.301 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 72' ' ' PRO . . . . . 0.933 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 25.1 Cg_exo -55.34 -7.94 1.48 Allowed 'Trans proline' 0 C--N 1.334 -0.192 0 C-N-CA 123.01 2.473 . . . . 0.0 113.789 -178.737 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 13.4 ptm180 -142.99 136.86 28.88 Favored 'General case' 0 C--N 1.317 -0.825 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 177.461 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . 0.618 ' HB3' ' HB2' ' A' ' 52' ' ' TYR . . . -60.22 -28.11 67.74 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.199 -0.91 . . . . 0.0 112.238 -175.351 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . 0.587 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 19.5 p-10 -84.79 -8.99 58.6 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 121.072 0.463 . . . . 0.0 111.344 -176.712 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.565 ' O ' ' HG2' ' A' ' 17' ' ' LYS . 57.2 tp -84.96 -32.36 23.07 Favored 'General case' 0 C--N 1.32 -0.682 0 N-CA-C 108.107 -1.071 . . . . 0.0 108.107 169.361 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . 0.953 ' HB1' ' HB2' ' A' ' 81' ' ' GLU . . . -77.93 154.23 31.82 Favored 'General case' 0 N--CA 1.44 -0.935 0 CA-C-N 114.953 -1.021 . . . . 0.0 110.851 177.071 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . 0.562 ' H ' ' CD ' ' A' ' 81' ' ' GLU . 19.5 p -99.91 -169.89 1.81 Allowed 'General case' 0 C--N 1.315 -0.895 0 CA-C-N 115.656 -0.702 . . . . 0.0 109.552 176.786 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . 0.791 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 79.8 mtp180 -49.66 -51.41 38.22 Favored 'General case' 0 C--N 1.329 -0.31 0 O-C-N 123.418 0.449 . . . . 0.0 111.305 -176.974 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 80' ' ' GLU . . . . . 0.448 ' HG3' ' N ' ' A' ' 81' ' ' GLU . 10.0 pt-20 -60.87 -47.56 85.82 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 112.457 0.54 . . . . 0.0 112.457 -173.361 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 81' ' ' GLU . . . . . 0.953 ' HB2' ' HB1' ' A' ' 77' ' ' ALA . 4.4 mp0 -60.96 -50.64 72.59 Favored 'General case' 0 CA--C 1.518 -0.26 0 CA-C-O 121.064 0.459 . . . . 0.0 111.03 178.382 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 82' ' ' GLN . . . . . 0.611 ' HG2' ' CZ3' ' A' ' 62' ' ' TRP . 34.2 mt-30 -63.65 -37.05 85.88 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.789 -0.641 . . . . 0.0 111.421 -176.682 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.685 ' O ' ' HG2' ' A' ' 87' ' ' GLU . 40.0 mt -60.14 -44.47 95.27 Favored 'Isoleucine or valine' 0 C--O 1.213 -0.841 0 N-CA-C 109.461 -0.57 . . . . 0.0 109.461 174.211 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . 0.612 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -62.7 -43.6 98.39 Favored 'General case' 0 C--O 1.236 0.346 0 CA-C-O 121.208 0.528 . . . . 0.0 111.792 -177.023 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.52 HG13 ' HB2' ' A' ' 65' ' ' ASN . 32.4 t -67.5 -47.86 79.07 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.332 178.845 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . 0.416 ' HB1' ' CH2' ' A' ' 31' ' ' TRP . . . -59.07 -29.75 67.56 Favored 'General case' 0 N--CA 1.455 -0.225 0 CA-C-N 115.531 -0.759 . . . . 0.0 110.468 174.859 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 87' ' ' GLU . . . . . 0.685 ' HG2' ' O ' ' A' ' 83' ' ' ILE . 25.9 mm-40 -59.51 -43.42 93.38 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.605 -0.725 . . . . 0.0 110.115 178.649 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.691 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 96.9 t -62.64 -48.47 88.04 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.322 0 CA-C-O 121.127 0.489 . . . . 0.0 110.124 176.454 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . 0.766 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 0.2 OUTLIER -64.56 -47.62 78.07 Favored 'General case' 0 C--N 1.317 -0.84 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.989 -175.433 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . 0.455 ' HD3' ' CZ2' ' A' ' 31' ' ' TRP . 7.9 ptt180 -62.52 -33.06 74.14 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.858 -175.84 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . 0.691 ' HG ' ' O ' ' A' ' 88' ' ' VAL . 4.4 pp -73.57 -23.45 59.95 Favored 'General case' 0 C--N 1.321 -0.637 0 C-N-CA 120.623 -0.431 . . . . 0.0 111.069 -172.013 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . 0.553 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 6.1 mtm180 -84.2 -45.86 12.48 Favored 'General case' 0 N--CA 1.45 -0.468 0 CA-C-O 121.369 0.605 . . . . 0.0 109.654 -178.487 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 93' ' ' GLN . . . . . 0.423 HE21 ' HZ3' ' A' ' 98' ' ' TRP . 9.1 pt20 -102.89 -27.98 12.32 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 113.924 1.083 . . . . 0.0 113.924 -169.603 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 83.68 50.95 4.23 Favored Glycine 0 CA--C 1.507 -0.448 0 C-N-CA 120.699 -0.762 . . . . 0.0 111.834 178.735 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 95' ' ' TRP . . . . . 0.492 ' HA ' ' HE3' ' A' ' 98' ' ' TRP . 2.5 m95 60.47 22.77 12.41 Favored 'General case' 0 C--O 1.224 -0.251 0 CA-C-O 121.282 0.563 . . . . 0.0 109.674 177.098 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -75.53 -20.77 78.23 Favored Glycine 0 N--CA 1.447 -0.586 0 CA-C-N 115.368 -0.833 . . . . 0.0 112.569 178.454 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -89.77 -17.49 28.12 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 121.096 0.475 . . . . 0.0 110.173 176.253 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 98' ' ' TRP . . . . . 0.766 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 23.3 m-90 -100.09 113.14 65.14 Favored Pre-proline 0 N--CA 1.444 -0.738 0 CA-C-N 115.73 -0.668 . . . . 0.0 109.433 178.748 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . 0.43 ' HD3' ' HA ' ' A' ' 98' ' ' TRP . 52.8 Cg_exo -61.93 -145.33 0.01 OUTLIER 'Trans proline' 0 CA--C 1.535 0.542 0 C-N-CA 123.954 3.103 . . . . 0.0 114.315 -173.738 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . 0.421 HG12 ' HG3' ' A' ' 104' ' ' ARG . 58.5 t -55.84 -24.4 16.88 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.307 0 CA-C-N 115.919 -0.582 . . . . 0.0 111.032 -179.791 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 101' ' ' CYS . . . . . 0.416 ' SG ' ' HG3' ' A' ' 38' ' ' GLU . 56.6 m -56.44 -36.36 68.91 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.003 177.436 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -69.77 -42.88 73.23 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.834 0.349 . . . . 0.0 110.639 178.891 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -64.37 -42.78 96.0 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.51 178.837 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 104' ' ' ARG . . . . . 0.421 ' HG3' HG12 ' A' ' 100' ' ' VAL . 68.4 mtp180 -60.14 -39.49 86.5 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.389 -0.823 . . . . 0.0 110.916 176.262 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 105' ' ' ALA . . . . . 0.695 ' HB1' ' HA ' ' A' ' 30' ' ' ILE . . . -78.07 -22.05 49.63 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.628 -0.714 . . . . 0.0 112.114 -175.997 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 102.51 64.41 0.73 Allowed Glycine 0 CA--C 1.519 0.318 0 C-N-CA 120.935 -0.65 . . . . 0.0 112.188 -178.23 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -71.1 152.34 43.57 Favored 'General case' 0 C--N 1.324 -0.527 0 C-N-CA 122.649 0.379 . . . . 0.0 111.491 -175.29 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 27.6 mtt180 . . . . . 0 C--O 1.247 0.971 0 CA-C-O 117.702 -1.142 . . . . 0.0 112.464 174.618 . . . . . . . . 0 0 . 1 . 023 nuclear nobuild full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 17.0 p-10 . . . . . 0 N--CA 1.478 0.965 0 CA-C-O 121.192 0.52 . . . . 0.0 110.693 . . . . . . . . . 0 0 . 1 . 023 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 11.0 p -97.37 -19.99 5.82 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 115.744 -0.662 . . . . 0.0 110.417 177.367 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 57.9 t -73.89 126.15 34.17 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.698 0 CA-C-N 115.642 -0.708 . . . . 0.0 111.394 -177.263 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 9.4 t -81.03 135.9 24.22 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 N-CA-C 109.025 -0.732 . . . . 0.0 109.025 174.131 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . 0.465 ' HA ' ' HD3' ' A' ' 6' ' ' PRO . 4.3 p -128.52 120.19 20.74 Favored Pre-proline 0 C--N 1.31 -1.143 0 CA-C-N 115.834 -0.621 . . . . 0.0 111.38 -172.354 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.465 ' HD3' ' HA ' ' A' ' 5' ' ' THR . 4.9 Cg_exo -78.58 164.61 25.83 Favored 'Trans proline' 0 N--CA 1.451 -1.012 0 C-N-CA 122.961 2.44 . . . . 0.0 111.094 175.96 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . 0.507 ' C ' ' H ' ' A' ' 9' ' ' GLU . . . 57.5 -177.48 0.06 Allowed 'General case' 0 C--N 1.316 -0.876 0 CA-C-N 114.504 -1.225 . . . . 0.0 111.267 -175.881 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . 0.456 ' HB3' ' O ' ' A' ' 7' ' ' ALA . 53.7 t-80 69.49 -9.72 0.63 Allowed 'General case' 0 CA--C 1.531 0.239 0 CA-C-O 121.533 0.682 . . . . 0.0 109.7 -173.225 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . 0.507 ' H ' ' C ' ' A' ' 7' ' ' ALA . 10.1 pt-20 -78.87 141.85 37.32 Favored 'General case' 0 N--CA 1.45 -0.471 0 CA-C-N 115.384 -0.825 . . . . 0.0 110.185 -179.092 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -117.7 67.62 0.75 Allowed 'General case' 0 C--N 1.319 -0.731 0 CA-C-O 121.683 0.754 . . . . 0.0 109.497 -177.84 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 60.7 t -57.59 -59.06 3.76 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.792 0 CA-C-N 114.076 -1.42 . . . . 0.0 111.002 -179.835 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 6.0 p 31.2 81.96 0.01 OUTLIER 'Isoleucine or valine' 0 C--O 1.236 0.353 0 CA-C-O 122.733 1.254 . . . . 0.0 113.041 -178.593 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 37.1 ptt180 -130.68 137.03 49.36 Favored 'General case' 0 N--CA 1.433 -1.303 0 CA-C-N 113.917 -1.492 . . . . 0.0 109.709 -178.533 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 3.5 t -92.65 156.49 3.03 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.179 0 N-CA-C 108.078 -1.082 . . . . 0.0 108.078 170.341 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 175.15 75.66 0.05 OUTLIER Glycine 0 N--CA 1.429 -1.786 0 CA-C-N 115.479 -0.782 . . . . 0.0 112.831 -177.543 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 60.9 m -94.5 -22.56 18.16 Favored 'General case' 0 N--CA 1.436 -1.142 0 CA-C-O 121.828 0.823 . . . . 0.0 108.846 173.834 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 27.1 mmmt -61.94 110.2 2.99 Favored Pre-proline 0 C--N 1.322 -0.598 0 CA-C-N 114.122 -1.399 . . . . 0.0 111.395 175.597 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 1.2 Cg_endo -85.21 173.39 7.85 Favored 'Trans proline' 0 N--CA 1.455 -0.768 0 C-N-CA 123.638 2.892 . . . . 0.0 111.778 176.159 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -86.81 34.25 3.58 Favored Glycine 0 C--N 1.313 -0.702 0 CA-C-N 114.753 -1.112 . . . . 0.0 111.244 -179.163 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 2.4 m -61.34 -42.91 99.47 Favored 'General case' 0 C--N 1.316 -0.862 0 CA-C-N 113.985 -1.108 . . . . 0.0 110.725 -179.002 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 7.7 pt-20 -84.65 72.95 10.64 Favored 'General case' 0 N--CA 1.448 -0.562 0 CA-C-O 122.779 1.276 . . . . 0.0 110.196 177.052 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 5.4 p -72.13 137.3 81.77 Favored Pre-proline 0 C--N 1.298 -1.636 0 CA-C-N 113.028 -1.896 . . . . 0.0 110.504 -178.094 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 52.2 Cg_exo -54.04 133.95 57.56 Favored 'Trans proline' 0 C--N 1.347 0.454 0 C-N-CA 122.797 2.331 . . . . 0.0 111.575 175.744 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 10.6 Cg_endo -54.65 141.38 75.21 Favored 'Trans proline' 0 N--CA 1.458 -0.564 0 C-N-CA 123.508 2.805 . . . . 0.0 112.915 -176.663 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.602 ' HB ' HD13 ' A' ' 83' ' ' ILE . 68.5 t -80.75 128.69 38.49 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.006 0 CA-C-N 114.772 -1.104 . . . . 0.0 109.656 -178.154 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 41.1 mm -56.83 -39.89 67.6 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.432 0 CA-C-N 114.719 -1.128 . . . . 0.0 113.572 -167.133 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.655 ' O ' HG12 ' A' ' 30' ' ' ILE . 26.0 t0 -80.55 -16.77 53.36 Favored 'General case' 0 CA--C 1.498 -1.037 0 CA-C-O 122.725 1.25 . . . . 0.0 108.8 -174.512 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . 0.803 ' HA2' ' HB2' ' A' ' 31' ' ' TRP . . . -75.02 6.58 26.64 Favored Glycine 0 N--CA 1.435 -1.418 0 CA-C-N 113.081 -1.872 . . . . 0.0 111.638 -178.162 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 59.6 m -76.69 -42.3 42.09 Favored 'General case' 0 C--N 1.315 -0.904 0 CA-C-O 121.508 0.67 . . . . 0.0 109.346 172.941 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.655 HG12 ' O ' ' A' ' 27' ' ' ASP . 0.0 OUTLIER -71.23 -38.85 71.87 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 N-CA-C 107.517 -1.29 . . . . 0.0 107.517 174.939 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 31' ' ' TRP . . . . . 0.803 ' HB2' ' HA2' ' A' ' 28' ' ' GLY . 20.8 m95 -67.91 -35.15 77.96 Favored 'General case' 0 N--CA 1.445 -0.714 0 CA-C-N 114.543 -1.208 . . . . 0.0 110.686 -177.231 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 6.3 t70 -73.62 -43.12 60.42 Favored 'General case' 0 N--CA 1.446 -0.627 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.951 177.531 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . 0.504 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -68.82 -33.56 74.04 Favored 'General case' 0 N--CA 1.446 -0.639 0 C-N-CA 120.331 -0.548 . . . . 0.0 110.394 -179.497 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . 0.445 HG13 ' O ' ' A' ' 30' ' ' ILE . 65.1 mt -66.89 -43.89 89.19 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.172 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.128 173.066 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -58.04 -35.76 71.78 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 121.299 0.571 . . . . 0.0 110.288 176.375 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . 0.429 ' HA2' ' N ' ' A' ' 41' ' ' GLY . . . -74.02 -22.21 78.19 Favored Glycine 0 N--CA 1.45 -0.383 0 CA-C-N 115.52 -0.764 . . . . 0.0 111.725 178.617 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 11.9 t -87.41 -52.82 5.16 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 115.377 -0.411 . . . . 0.0 111.87 -176.939 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 10.2 tp10 -87.77 -34.01 18.46 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-O 121.071 0.462 . . . . 0.0 110.161 -172.955 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -103.76 -7.81 20.32 Favored 'General case' 0 C--N 1.323 -0.544 0 C-N-CA 120.437 -0.505 . . . . 0.0 112.186 -175.099 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 77.75 13.26 83.64 Favored Glycine 0 CA--C 1.505 -0.58 0 N-CA-C 109.985 -1.246 . . . . 0.0 109.985 -177.666 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . 0.429 ' N ' ' HA2' ' A' ' 36' ' ' GLY . . . 76.74 58.28 3.55 Favored Glycine 0 N--CA 1.434 -1.488 0 CA-C-N 114.236 -0.982 . . . . 0.0 111.975 -177.236 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . 0.57 ' HB3' ' HB ' ' A' ' 45' ' ' ILE . 2.9 t30 -145.88 103.37 3.75 Favored 'General case' 0 N--CA 1.447 -0.593 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 179.901 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 43' ' ' TRP . . . . . 0.76 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 35.6 m95 -82.63 -6.58 59.44 Favored 'General case' 0 C--N 1.314 -0.972 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.649 -172.887 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -111.86 14.7 20.99 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 115.259 -0.882 . . . . 0.0 111.33 179.417 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.57 ' HB ' ' HB3' ' A' ' 42' ' ' ASN . 10.2 tt -79.93 140.54 16.59 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.773 0 N-CA-C 109.138 -0.69 . . . . 0.0 109.138 -179.599 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 10.0 t-20 -149.14 107.22 3.72 Favored 'General case' 0 C--N 1.307 -1.281 0 CA-C-O 121.289 0.566 . . . . 0.0 109.716 -174.861 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 24.5 p -82.45 -22.96 35.02 Favored 'General case' 0 N--CA 1.437 -1.109 0 CA-C-N 115.185 -0.916 . . . . 0.0 109.997 178.946 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 90.63 20.57 40.12 Favored Glycine 0 N--CA 1.443 -0.88 0 N-CA-C 110.902 -0.879 . . . . 0.0 110.902 178.702 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 27.5 p-10 -93.64 11.39 29.06 Favored 'General case' 0 C--N 1.327 -0.379 0 C-N-CA 120.656 -0.418 . . . . 0.0 111.684 -173.359 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 93.97 -12.31 69.44 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.699 -0.763 . . . . 0.0 111.431 -177.95 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 51' ' ' TYR . . . . . 0.771 ' CE1' ' HB2' ' A' ' 58' ' ' ASP . 0.2 OUTLIER -108.02 160.66 15.62 Favored 'General case' 0 N--CA 1.446 -0.673 0 N-CA-C 106.982 -1.488 . . . . 0.0 106.982 172.811 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 52' ' ' TYR . . . . . 0.873 ' O ' ' HA ' ' A' ' 56' ' ' GLN . 31.6 m-85 -130.35 170.57 13.98 Favored 'General case' 0 C--N 1.318 -0.783 0 C-N-CA 120.668 -0.413 . . . . 0.0 111.045 -171.298 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.495 ' HA2' HG22 ' A' ' 45' ' ' ILE . . . -61.63 177.91 4.61 Favored Glycine 0 N--CA 1.452 -0.28 0 N-CA-C 114.833 0.693 . . . . 0.0 114.833 -171.717 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.685 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 82.61 -104.96 2.57 Favored Glycine 0 N--CA 1.445 -0.702 0 C-N-CA 121.039 -0.6 . . . . 0.0 111.718 -179.877 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.569 HG12 ' HE1' ' A' ' 98' ' ' TRP . 2.1 t -83.84 -2.66 7.08 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.657 0 CA-C-O 121.902 0.858 . . . . 0.0 109.616 -179.385 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 56' ' ' GLN . . . . . 0.873 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 5.7 tt0 53.3 52.54 13.35 Favored 'General case' 0 N--CA 1.462 0.149 0 CA-C-N 113.681 -1.599 . . . . 0.0 113.3 171.981 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . 0.497 ' CZ ' ' HE3' ' A' ' 62' ' ' TRP . 16.5 p90 -121.13 173.34 7.35 Favored 'General case' 0 C--N 1.324 -0.519 0 C-N-CA 119.849 -0.74 . . . . 0.0 112.657 176.09 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.771 ' HB2' ' CE1' ' A' ' 51' ' ' TYR . 0.0 OUTLIER -83.97 153.63 23.79 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 114.534 -1.212 . . . . 0.0 114.091 -161.854 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.461 ' HB2' ' HE1' ' A' ' 52' ' ' TYR . 6.3 tp-100 -56.38 -41.91 76.99 Favored 'General case' 0 N--CA 1.447 -0.597 0 CA-C-N 113.656 -1.611 . . . . 0.0 111.985 178.973 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -64.97 -48.42 71.39 Favored Glycine 0 N--CA 1.445 -0.747 0 C-N-CA 120.944 -0.645 . . . . 0.0 111.574 -176.747 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 67.6 m -65.89 -43.83 87.09 Favored 'General case' 0 C--N 1.318 -0.779 0 C-N-CA 122.696 0.398 . . . . 0.0 111.069 176.443 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 62' ' ' TRP . . . . . 0.497 ' HE3' ' CZ ' ' A' ' 57' ' ' PHE . 45.5 t-105 -56.98 -48.21 78.93 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 121.397 0.618 . . . . 0.0 109.729 177.008 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . 0.429 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 3.6 tm-20 -68.05 -32.82 73.44 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 115.143 -0.935 . . . . 0.0 110.39 -178.401 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -66.62 -41.81 87.77 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.717 -0.674 . . . . 0.0 111.493 -178.009 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . 0.66 ' HB2' HG13 ' A' ' 85' ' ' VAL . 50.6 m-20 -76.43 -15.41 59.93 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.002 0.429 . . . . 0.0 110.511 175.839 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . 0.537 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 94.36 48.09 2.66 Favored Glycine 0 C--N 1.333 0.379 0 CA-C-N 115.735 -0.666 . . . . 0.0 112.199 176.966 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.599 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -79.98 -26.24 56.13 Favored Glycine 0 N--CA 1.44 -1.081 0 C-N-CA 121.12 -0.562 . . . . 0.0 112.907 -174.699 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 1.035 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 7.5 mp -60.5 -25.44 66.08 Favored 'General case' 0 N--CA 1.445 -0.705 0 N-CA-C 112.814 0.672 . . . . 0.0 112.814 -173.761 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . 0.537 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 1.3 ptm180 -65.07 -33.64 76.52 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 121.35 0.595 . . . . 0.0 109.615 175.242 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 70' ' ' TYR . . . . . 0.618 ' HB3' ' CG ' ' A' ' 81' ' ' GLU . 84.3 m-85 -78.08 -35.43 49.4 Favored 'General case' 0 N--CA 1.438 -1.059 0 N-CA-C 107.483 -1.303 . . . . 0.0 107.483 178.159 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.592 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 162.03 130.15 0.01 OUTLIER Pre-proline 0 N--CA 1.447 -0.588 0 CA-C-N 112.676 -2.057 . . . . 0.0 106.756 -179.106 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 72' ' ' PRO . . . . . 1.035 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 26.5 Cg_exo -56.41 -6.54 1.52 Allowed 'Trans proline' 0 C--N 1.334 -0.226 0 C-N-CA 122.955 2.436 . . . . 0.0 113.862 -176.894 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 73' ' ' ARG . . . . . 0.493 ' HB2' ' CD2' ' A' ' 52' ' ' TYR . 0.2 OUTLIER -147.0 143.08 28.15 Favored 'General case' 0 C--N 1.317 -0.811 0 N-CA-C 109.533 -0.543 . . . . 0.0 109.533 176.523 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . 0.589 ' HB3' ' HB2' ' A' ' 52' ' ' TYR . . . -58.94 -26.5 64.44 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.413 -0.812 . . . . 0.0 112.722 -177.05 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . 0.479 ' HB2' ' NH2' ' A' ' 73' ' ' ARG . 0.0 OUTLIER -74.27 -25.43 59.61 Favored 'General case' 0 CA--C 1.518 -0.265 0 CA-C-O 121.096 0.474 . . . . 0.0 110.704 -177.258 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.528 ' HB3' ' HB1' ' A' ' 71' ' ' ALA . 55.3 tp -86.76 -30.22 21.76 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-O 121.342 0.591 . . . . 0.0 109.972 -178.635 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . 0.664 ' HB1' ' CB ' ' A' ' 81' ' ' GLU . . . -82.97 161.05 21.9 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 115.383 -0.826 . . . . 0.0 109.66 172.992 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 18.7 p -101.32 -171.78 2.05 Favored 'General case' 0 C--N 1.32 -0.714 0 C-N-CA 120.611 -0.435 . . . . 0.0 110.054 -179.359 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . 0.76 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 2.8 mtt85 -49.36 -53.12 23.99 Favored 'General case' 0 C--N 1.326 -0.436 0 O-C-N 123.487 0.492 . . . . 0.0 111.916 -177.69 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 80' ' ' GLU . . . . . 0.766 ' HA ' HD12 ' A' ' 83' ' ' ILE . 0.0 OUTLIER -61.4 -40.35 94.05 Favored 'General case' 0 C--N 1.324 -0.534 0 O-C-N 123.206 0.316 . . . . 0.0 111.578 -172.275 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 81' ' ' GLU . . . . . 0.664 ' CB ' ' HB1' ' A' ' 77' ' ' ALA . 47.0 mp0 -61.9 -51.48 67.97 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.724 0.297 . . . . 0.0 111.343 175.505 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 82' ' ' GLN . . . . . 0.424 ' HB2' ' HZ3' ' A' ' 43' ' ' TRP . 46.7 mt-30 -59.71 -35.51 74.66 Favored 'General case' 0 CA--C 1.513 -0.473 0 CA-C-O 121.141 0.496 . . . . 0.0 110.198 -178.83 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.766 HD12 ' HA ' ' A' ' 80' ' ' GLU . 35.4 mt -59.47 -49.53 83.27 Favored 'Isoleucine or valine' 0 C--O 1.212 -0.896 0 CA-C-N 114.95 -1.023 . . . . 0.0 109.955 176.905 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . 0.571 ' O ' ' HG3' ' A' ' 87' ' ' GLU . . . -61.27 -44.26 97.52 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-O 121.199 0.523 . . . . 0.0 111.162 -176.188 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.66 HG13 ' HB2' ' A' ' 65' ' ' ASN . 21.8 t -69.33 -49.02 64.34 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.823 179.776 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -66.2 -32.15 73.42 Favored 'General case' 0 CA--C 1.515 -0.379 0 CA-C-O 121.137 0.494 . . . . 0.0 110.888 -179.912 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 87' ' ' GLU . . . . . 0.752 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 0.0 OUTLIER -70.5 -31.52 68.66 Favored 'General case' 0 C--N 1.317 -0.817 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.255 -176.054 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.463 ' O ' ' HG3' ' A' ' 92' ' ' ARG . 71.8 t -60.63 -42.51 92.02 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.373 0 N-CA-C 108.892 -0.781 . . . . 0.0 108.892 172.399 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . 0.816 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 1.1 m -67.42 -43.7 80.57 Favored 'General case' 0 N--CA 1.441 -0.879 0 CA-C-N 114.766 -1.106 . . . . 0.0 111.023 -176.139 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . 0.647 ' HA ' ' OE1' ' A' ' 93' ' ' GLN . 36.2 ptt85 -60.51 -32.46 71.47 Favored 'General case' 0 N--CA 1.461 0.102 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.472 -174.677 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . 0.752 ' HG ' ' O ' ' A' ' 87' ' ' GLU . 18.4 mt -67.7 -25.42 65.66 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-O 121.559 0.695 . . . . 0.0 110.197 -176.804 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . 0.463 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 11.4 mtm180 -90.15 -51.48 5.43 Favored 'General case' 0 C--N 1.317 -0.838 0 CA-C-N 114.992 -1.004 . . . . 0.0 110.44 -171.253 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 93' ' ' GLN . . . . . 0.647 ' OE1' ' HA ' ' A' ' 90' ' ' ARG . 0.0 OUTLIER -96.52 -23.59 16.47 Favored 'General case' 0 C--N 1.32 -0.689 0 N-CA-C 113.047 0.758 . . . . 0.0 113.047 -172.088 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 78.38 51.29 5.72 Favored Glycine 0 CA--C 1.506 -0.53 0 C-N-CA 120.507 -0.854 . . . . 0.0 111.565 176.695 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 95' ' ' TRP . . . . . 0.572 ' CZ2' ' HD2' ' A' ' 90' ' ' ARG . 2.6 m95 59.79 23.5 12.44 Favored 'General case' 0 C--N 1.329 -0.317 0 C-N-CA 123.361 0.665 . . . . 0.0 110.685 175.217 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.643 ' H ' ' HG2' ' A' ' 93' ' ' GLN . . . -77.75 -17.73 78.33 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.935 -0.65 . . . . 0.0 111.682 173.64 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -87.52 -23.09 24.5 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 121.301 0.572 . . . . 0.0 110.137 176.618 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 98' ' ' TRP . . . . . 0.816 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 20.8 m-90 -110.44 108.68 58.43 Favored Pre-proline 0 N--CA 1.448 -0.55 0 CA-C-N 115.417 -0.811 . . . . 0.0 109.797 179.315 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . 0.423 ' HD3' ' HA ' ' A' ' 98' ' ' TRP . 52.6 Cg_exo -61.48 -135.43 0.0 OUTLIER 'Trans proline' 0 CA--C 1.538 0.711 0 C-N-CA 124.083 3.189 . . . . 0.0 114.16 -175.151 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 21.2 t -56.42 -23.21 16.23 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.249 0 CA-C-N 116.397 -0.365 . . . . 0.0 110.95 -178.409 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 68.5 m -54.79 -38.12 66.9 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.013 -0.54 . . . . 0.0 111.024 178.011 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -69.44 -45.89 68.06 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.827 0.346 . . . . 0.0 110.757 -179.163 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -63.56 -35.82 81.77 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.514 179.365 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 4.7 mmp_? -70.79 -31.56 68.37 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.561 -0.745 . . . . 0.0 111.356 177.821 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 105' ' ' ALA . . . . . 0.644 ' HB1' ' HA ' ' A' ' 30' ' ' ILE . . . -89.0 -22.51 22.96 Favored 'General case' 0 C--N 1.326 -0.438 0 N-CA-C 112.664 0.616 . . . . 0.0 112.664 -173.079 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 113.23 58.52 0.41 Allowed Glycine 0 CA--C 1.521 0.437 0 C-N-CA 120.569 -0.824 . . . . 0.0 112.473 -178.333 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -66.69 154.36 40.83 Favored 'General case' 0 C--N 1.325 -0.472 0 C-N-CA 123.402 0.681 . . . . 0.0 111.775 -175.763 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 23.5 mmt180 . . . . . 0 C--O 1.247 0.95 0 CA-C-O 118.09 -0.957 . . . . 0.0 111.346 177.353 . . . . . . . . 0 0 . 1 . 024 nuclear nobuild full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 71.5 m-20 . . . . . 0 N--CA 1.484 1.246 0 CA-C-O 121.245 0.545 . . . . 0.0 111.275 . . . . . . . . . 0 0 . 1 . 024 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 7.2 p -93.72 -12.73 8.69 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.643 0 CA-C-O 121.65 0.738 . . . . 0.0 109.235 175.401 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 7.2 p -66.79 141.48 17.9 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.581 0 CA-C-N 115.094 -0.957 . . . . 0.0 110.902 176.887 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 21.7 t -113.32 146.55 17.8 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 N-CA-C 109.478 -0.564 . . . . 0.0 109.478 176.124 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 15.6 p -121.66 102.72 41.55 Favored Pre-proline 0 C--N 1.314 -0.974 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.323 -178.165 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 98.6 Cg_endo -75.79 96.67 1.06 Allowed 'Trans proline' 0 N--CA 1.459 -0.537 0 C-N-CA 122.613 2.208 . . . . 0.0 112.114 -179.206 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . 0.459 ' C ' ' H ' ' A' ' 9' ' ' GLU . . . -163.51 -168.4 1.66 Allowed 'General case' 0 C--N 1.29 -1.984 0 CA-C-N 113.323 -1.762 . . . . 0.0 109.64 -177.57 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 31.3 t60 70.56 -9.23 0.81 Allowed 'General case' 0 CA--C 1.532 0.282 0 O-C-N 123.878 0.736 . . . . 0.0 109.891 -174.83 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . 0.459 ' H ' ' C ' ' A' ' 7' ' ' ALA . 13.9 pt-20 -71.18 137.92 49.14 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.574 -179.547 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -143.21 79.76 1.65 Allowed 'General case' 0 N--CA 1.447 -0.595 0 CA-C-N 115.7 -0.682 . . . . 0.0 110.245 -176.885 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.404 HG12 ' HG2' ' A' ' 13' ' ' ARG . 61.7 t -67.07 -56.92 11.81 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.838 0 CA-C-N 115.089 -0.96 . . . . 0.0 109.915 176.443 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 75.8 t 25.18 80.31 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.448 -0.532 0 C-N-CA 125.52 1.528 . . . . 0.0 113.371 177.258 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . 0.404 ' HG2' HG12 ' A' ' 11' ' ' VAL . 40.5 ptt180 -144.43 128.33 17.41 Favored 'General case' 0 C--N 1.304 -1.404 0 CA-C-N 114.031 -1.441 . . . . 0.0 110.246 178.541 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 3.7 t -128.21 161.39 36.69 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.894 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 176.116 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 138.83 101.66 0.53 Allowed Glycine 0 N--CA 1.434 -1.435 0 CA-C-N 115.609 -0.723 . . . . 0.0 112.985 177.928 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 17.6 m -80.94 -43.8 19.2 Favored 'General case' 0 N--CA 1.445 -0.687 0 CA-C-O 121.191 0.519 . . . . 0.0 110.274 175.313 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER 41.12 65.98 3.99 Favored Pre-proline 0 C--N 1.322 -0.589 0 CA-C-N 114.353 -1.294 . . . . 0.0 114.032 178.244 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 2.2 Cg_endo -83.08 163.97 15.36 Favored 'Trans proline' 0 N--CA 1.447 -1.258 0 C-N-CA 122.445 2.097 . . . . 0.0 110.534 170.721 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 94.45 -39.89 2.82 Favored Glycine 0 C--N 1.304 -1.237 0 N-CA-C 109.243 -1.543 . . . . 0.0 109.243 -176.918 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 38.4 m -68.19 -44.34 76.08 Favored 'General case' 0 N--CA 1.44 -0.963 0 CA-C-N 113.772 -1.214 . . . . 0.0 109.138 169.3 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 42.9 mt-10 -116.01 114.27 24.36 Favored 'General case' 0 N--CA 1.443 -0.787 0 CA-C-N 114.942 -1.026 . . . . 0.0 109.575 175.805 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 55.3 t -72.74 119.88 77.71 Favored Pre-proline 0 C--N 1.317 -0.817 0 N-CA-C 108.441 -0.948 . . . . 0.0 108.441 174.022 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.48 ' HA ' ' HD2' ' A' ' 24' ' ' PRO . 50.7 Cg_exo -54.5 125.88 20.44 Favored 'Trans proline' 0 N--CA 1.461 -0.387 0 C-N-CA 122.497 2.132 . . . . 0.0 112.991 -173.205 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . 0.48 ' HD2' ' HA ' ' A' ' 23' ' ' PRO . 15.1 Cg_endo -58.03 163.36 9.8 Favored 'Trans proline' 0 N--CA 1.456 -0.734 0 C-N-CA 124.189 3.259 . . . . 0.0 112.042 172.264 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.538 ' HB ' HG21 ' A' ' 83' ' ' ILE . 89.9 t -76.9 158.19 5.33 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.948 0 N-CA-C 107.837 -1.172 . . . . 0.0 107.837 178.597 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 42.8 mm -53.54 -25.52 11.26 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.875 0 N-CA-C 114.38 1.252 . . . . 0.0 114.38 -157.267 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.515 ' O ' HG12 ' A' ' 30' ' ' ILE . 46.5 m-20 -127.07 15.93 7.3 Favored 'General case' 0 C--N 1.313 -0.978 0 CA-C-O 121.542 0.687 . . . . 0.0 109.741 -177.803 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . 0.669 ' HA2' HG12 ' A' ' 83' ' ' ILE . . . -68.24 -6.51 47.49 Favored Glycine 0 N--CA 1.438 -1.203 0 CA-C-N 115.029 -0.987 . . . . 0.0 111.896 -178.878 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 4.9 m -74.47 -46.27 40.78 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-O 122.064 0.935 . . . . 0.0 109.105 176.623 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.606 ' HA ' ' HB1' ' A' ' 105' ' ' ALA . 0.0 OUTLIER -69.77 -38.47 76.11 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.777 0 CA-C-N 114.129 -1.396 . . . . 0.0 108.263 179.242 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 31' ' ' TRP . . . . . 0.573 ' HD1' HG23 ' A' ' 83' ' ' ILE . 9.0 m95 -70.55 -36.29 73.57 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 114.86 -1.063 . . . . 0.0 110.861 -177.589 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 4.4 t70 -72.79 -39.37 66.78 Favored 'General case' 0 N--CA 1.446 -0.663 0 CA-C-N 116.481 -0.327 . . . . 0.0 110.521 178.174 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . 0.437 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -69.54 -37.43 77.08 Favored 'General case' 0 N--CA 1.445 -0.69 0 C-N-CA 120.637 -0.425 . . . . 0.0 110.782 179.294 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . 0.477 HG13 ' O ' ' A' ' 30' ' ' ILE . 75.5 mt -67.46 -44.42 86.79 Favored 'Isoleucine or valine' 0 C--O 1.232 0.177 0 CA-C-O 120.809 0.338 . . . . 0.0 110.454 175.524 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -60.86 -31.83 71.28 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 121.252 0.549 . . . . 0.0 110.229 176.907 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -77.42 -22.78 69.52 Favored Glycine 0 N--CA 1.45 -0.395 0 CA-C-N 115.596 -0.729 . . . . 0.0 111.516 177.54 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 40.9 t -76.83 -58.36 3.32 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 115.367 -0.417 . . . . 0.0 111.041 -179.055 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . . . . . . . . . 17.5 mt-10 -89.1 -32.9 17.31 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 116.353 -0.385 . . . . 0.0 111.3 -171.365 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -102.05 -17.61 15.98 Favored 'General case' 0 C--N 1.323 -0.576 0 C-N-CA 120.507 -0.477 . . . . 0.0 112.183 -177.562 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 81.36 9.99 85.2 Favored Glycine 0 N--CA 1.448 -0.535 0 N-CA-C 109.805 -1.318 . . . . 0.0 109.805 -175.709 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 88.39 62.71 1.39 Allowed Glycine 0 N--CA 1.438 -1.199 0 CA-C-N 114.156 -1.022 . . . . 0.0 111.713 -176.931 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . 0.727 HD22 ' HB ' ' A' ' 45' ' ' ILE . 3.3 t30 -139.31 87.98 2.23 Favored 'General case' 0 C--N 1.326 -0.418 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 -177.142 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 43' ' ' TRP . . . . . 0.778 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 37.9 m95 -76.41 -11.47 59.9 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-O 121.171 0.51 . . . . 0.0 111.259 -172.669 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -102.66 15.56 28.95 Favored 'General case' 0 C--N 1.314 -0.955 0 CA-C-N 115.793 -0.64 . . . . 0.0 110.447 -179.94 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.727 ' HB ' HD22 ' A' ' 42' ' ' ASN . 10.1 tt -77.53 139.94 17.86 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.003 0 CA-C-N 115.861 -0.609 . . . . 0.0 110.799 -177.771 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 34.1 t-20 -150.59 92.35 1.84 Allowed 'General case' 0 C--N 1.314 -0.957 0 CA-C-N 115.522 -0.763 . . . . 0.0 109.363 179.578 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 8.9 p -76.19 -15.67 60.0 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 115.581 -0.736 . . . . 0.0 111.668 -176.279 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 93.43 21.95 28.07 Favored Glycine 0 N--CA 1.448 -0.561 0 N-CA-C 111.149 -0.78 . . . . 0.0 111.149 -179.904 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 4.9 m-20 -90.7 -0.57 57.74 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 120.857 0.361 . . . . 0.0 111.434 -177.005 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . 0.492 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 86.53 -8.42 75.01 Favored Glycine 0 N--CA 1.449 -0.478 0 N-CA-C 110.888 -0.885 . . . . 0.0 110.888 -172.775 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 51' ' ' TYR . . . . . 0.566 ' CE1' ' HB3' ' A' ' 58' ' ' ASP . 0.1 OUTLIER -114.27 140.47 48.57 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 107.459 -1.312 . . . . 0.0 107.459 175.434 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 52' ' ' TYR . . . . . 0.505 ' O ' ' HA ' ' A' ' 56' ' ' GLN . 0.1 OUTLIER -140.33 163.82 31.75 Favored 'General case' 0 C--N 1.319 -0.748 0 N-CA-C 112.7 0.63 . . . . 0.0 112.7 -170.991 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.413 ' HA2' ' O ' ' A' ' 43' ' ' TRP . . . 65.45 105.66 0.01 OUTLIER Glycine 0 C--O 1.221 -0.684 0 N-CA-C 116.287 1.275 . . . . 0.0 116.287 164.198 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.479 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 57.99 -83.45 0.01 OUTLIER Glycine 0 C--N 1.339 0.696 0 N-CA-C 114.579 0.591 . . . . 0.0 114.579 165.226 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.478 HG23 ' HD1' ' A' ' 57' ' ' PHE . 3.7 m -83.16 -6.29 9.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-O 120.932 0.396 . . . . 0.0 110.282 178.337 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 56' ' ' GLN . . . . . 0.505 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 9.8 mt-30 50.19 51.84 15.93 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 114.934 -1.03 . . . . 0.0 113.203 166.788 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . 0.478 ' HD1' HG23 ' A' ' 55' ' ' VAL . 5.5 p90 -102.13 166.68 10.47 Favored 'General case' 0 C--N 1.323 -0.572 0 C-N-CA 119.382 -0.927 . . . . 0.0 110.705 174.926 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.566 ' HB3' ' CE1' ' A' ' 51' ' ' TYR . 4.9 p-10 -74.48 155.99 37.41 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 122.223 1.011 . . . . 0.0 113.548 -163.276 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.413 ' HB2' ' CE1' ' A' ' 52' ' ' TYR . 23.3 tp60 -57.06 -39.58 75.17 Favored 'General case' 0 N--CA 1.441 -0.877 0 CA-C-N 113.175 -1.829 . . . . 0.0 111.633 179.813 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -67.74 -49.29 50.41 Favored Glycine 0 N--CA 1.451 -0.352 0 CA-C-N 115.422 -0.808 . . . . 0.0 112.248 -176.332 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 97.8 m -64.15 -40.83 96.98 Favored 'General case' 0 C--N 1.322 -0.602 0 C-N-CA 122.829 0.451 . . . . 0.0 110.827 176.761 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 62' ' ' TRP . . . . . 0.545 ' CH2' ' HA ' ' A' ' 74' ' ' ALA . 45.6 t-105 -55.92 -48.58 75.42 Favored 'General case' 0 N--CA 1.45 -0.471 0 CA-C-O 121.71 0.767 . . . . 0.0 109.221 174.859 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . 0.515 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 33.2 tt0 -64.64 -36.57 84.67 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-N 114.821 -1.081 . . . . 0.0 110.989 179.187 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -65.47 -41.16 93.64 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.75 -0.659 . . . . 0.0 110.948 -177.282 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . 0.443 ' HB3' ' HB ' ' A' ' 88' ' ' VAL . 8.2 m120 -80.79 -7.76 59.49 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 121.043 0.449 . . . . 0.0 110.339 177.968 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . 0.595 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 87.64 46.8 4.77 Favored Glycine 0 N--CA 1.447 -0.582 0 CA-C-N 115.622 -0.717 . . . . 0.0 112.511 174.207 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.588 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -78.68 -25.05 61.28 Favored Glycine 0 N--CA 1.44 -1.095 0 C-N-CA 120.579 -0.819 . . . . 0.0 112.007 -175.435 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.922 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 7.3 mp -57.78 -23.27 51.46 Favored 'General case' 0 N--CA 1.446 -0.628 0 N-CA-C 112.671 0.619 . . . . 0.0 112.671 -175.38 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . 0.595 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 5.6 ptp180 -70.74 -29.39 65.63 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-O 121.327 0.584 . . . . 0.0 109.761 178.281 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 70' ' ' TYR . . . . . 0.749 ' HB3' ' CG ' ' A' ' 81' ' ' GLU . 43.5 m-85 -87.24 -34.62 18.89 Favored 'General case' 0 N--CA 1.439 -1.005 0 N-CA-C 107.373 -1.343 . . . . 0.0 107.373 177.724 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.526 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 170.12 125.31 0.05 OUTLIER Pre-proline 0 N--CA 1.449 -0.51 0 CA-C-N 113.198 -1.819 . . . . 0.0 107.89 -177.39 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 72' ' ' PRO . . . . . 0.922 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 15.9 Cg_exo -59.79 -2.8 1.73 Allowed 'Trans proline' 0 C--N 1.333 -0.27 0 C-N-CA 122.803 2.335 . . . . 0.0 113.562 -179.044 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 15.5 ptm180 -143.48 138.19 29.07 Favored 'General case' 0 C--N 1.316 -0.851 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 176.614 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . 0.594 ' HB1' ' OE1' ' A' ' 82' ' ' GLN . . . -59.09 -31.24 68.73 Favored 'General case' 0 C--N 1.316 -0.863 0 CA-C-N 114.952 -1.022 . . . . 0.0 112.393 -176.206 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 20.7 p-10 -88.93 9.0 26.51 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 120.961 0.41 . . . . 0.0 112.014 -175.956 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.505 ' HB3' ' HB1' ' A' ' 71' ' ' ALA . 68.3 tp -103.79 -28.93 11.34 Favored 'General case' 0 C--N 1.321 -0.634 0 N-CA-C 108.614 -0.884 . . . . 0.0 108.614 169.974 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . 0.72 ' HB1' ' CB ' ' A' ' 81' ' ' GLU . . . -79.91 153.68 28.82 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-N 114.545 -1.207 . . . . 0.0 110.39 176.553 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 21.9 p -99.79 -171.81 2.12 Favored 'General case' 0 C--N 1.32 -0.712 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.854 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . 0.778 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 4.0 mtp180 -50.65 -52.91 35.29 Favored 'General case' 0 C--O 1.222 -0.367 0 O-C-N 123.356 0.41 . . . . 0.0 110.779 -175.999 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 80' ' ' GLU . . . . . 0.438 ' HG3' ' OE2' ' A' ' 81' ' ' GLU . 10.5 pt-20 -58.92 -40.03 83.32 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.726 -0.67 . . . . 0.0 111.688 -174.154 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 81' ' ' GLU . . . . . 0.749 ' CG ' ' HB3' ' A' ' 70' ' ' TYR . 8.8 mp0 -67.8 -52.36 37.95 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 120.815 0.34 . . . . 0.0 111.812 176.397 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 82' ' ' GLN . . . . . 0.594 ' OE1' ' HB1' ' A' ' 74' ' ' ALA . 31.3 mt-30 -64.37 -31.28 72.43 Favored 'General case' 0 CA--C 1.514 -0.434 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.724 -175.7 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.669 HG12 ' HA2' ' A' ' 28' ' ' GLY . 27.9 mt -59.58 -48.16 88.37 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 CA-C-N 115.413 -0.812 . . . . 0.0 109.771 172.66 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . 0.542 ' HA ' ' HG2' ' A' ' 87' ' ' GLU . . . -62.57 -43.27 99.24 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.989 -0.55 . . . . 0.0 112.056 -177.465 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.417 HG23 ' O ' ' A' ' 81' ' ' GLU . 21.3 t -69.85 -49.76 54.57 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.69 0 O-C-N 122.112 -0.368 . . . . 0.0 111.346 -178.939 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -66.77 -31.17 71.63 Favored 'General case' 0 N--CA 1.446 -0.632 0 CA-C-N 115.947 -0.569 . . . . 0.0 110.403 -179.463 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 87' ' ' GLU . . . . . 0.816 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 6.5 pt-20 -67.62 -32.2 72.74 Favored 'General case' 0 C--O 1.219 -0.551 0 C-N-CA 120.272 -0.571 . . . . 0.0 109.72 -177.637 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.452 ' O ' ' HG3' ' A' ' 92' ' ' ARG . 87.3 t -61.77 -46.95 95.42 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.273 0 CA-C-O 121.421 0.629 . . . . 0.0 109.394 172.625 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . 0.699 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 0.2 OUTLIER -60.8 -45.43 94.44 Favored 'General case' 0 N--CA 1.443 -0.794 0 CA-C-N 115.289 -0.869 . . . . 0.0 111.377 -178.184 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . 0.688 ' HG3' ' O ' ' A' ' 87' ' ' GLU . 5.6 ppt_? -60.35 -32.63 71.44 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.478 -177.095 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . 0.816 ' HG ' ' O ' ' A' ' 87' ' ' GLU . 38.6 mt -61.88 -43.01 99.72 Favored 'General case' 0 N--CA 1.473 0.676 0 CA-C-O 122.165 0.983 . . . . 0.0 110.047 -176.706 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . 0.462 ' HE ' ' HB2' ' A' ' 92' ' ' ARG . 4.4 mtm180 -78.24 -45.17 23.62 Favored 'General case' 0 C--N 1.316 -0.864 0 CA-C-N 113.828 -1.533 . . . . 0.0 110.083 -167.327 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 93' ' ' GLN . . . . . 0.423 HE21 ' HZ3' ' A' ' 98' ' ' TRP . 13.9 pt20 -100.99 -26.74 13.62 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-N 114.605 -1.179 . . . . 0.0 112.857 -170.094 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 87.56 40.19 6.91 Favored Glycine 0 CA--C 1.508 -0.378 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.176 174.775 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 95' ' ' TRP . . . . . 0.494 ' CZ2' ' HD3' ' A' ' 90' ' ' ARG . 18.5 m95 64.54 18.66 11.49 Favored 'General case' 0 C--O 1.219 -0.527 0 CA-C-O 121.455 0.645 . . . . 0.0 109.815 179.912 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -66.41 -29.8 75.46 Favored Glycine 0 CA--C 1.519 0.299 0 CA-C-N 115.163 -0.926 . . . . 0.0 112.862 175.462 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -81.83 -21.21 37.75 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.879 0.371 . . . . 0.0 110.625 178.692 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 98' ' ' TRP . . . . . 0.699 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 24.6 m-90 -99.3 109.06 53.31 Favored Pre-proline 0 N--CA 1.446 -0.625 0 N-CA-C 109.245 -0.65 . . . . 0.0 109.245 177.637 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . 0.42 ' HD3' ' HA ' ' A' ' 98' ' ' TRP . 44.8 Cg_exo -63.24 -139.48 0.0 OUTLIER 'Trans proline' 0 CA--C 1.535 0.541 0 C-N-CA 123.578 2.852 . . . . 0.0 114.331 -174.909 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . 0.422 ' O ' ' HD2' ' A' ' 104' ' ' ARG . 45.0 t -54.98 -23.98 13.64 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.315 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.682 -174.185 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 101' ' ' CYS . . . . . . . . . . . . . 60.7 m -63.42 -31.66 72.88 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.549 -179.847 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -69.72 -46.03 66.88 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.617 0.246 . . . . 0.0 111.124 -177.364 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -66.09 -36.56 83.52 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 121.019 0.438 . . . . 0.0 110.652 179.896 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 104' ' ' ARG . . . . . 0.422 ' HD2' ' O ' ' A' ' 100' ' ' VAL . 0.0 OUTLIER -70.78 -24.13 62.52 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.78 -0.646 . . . . 0.0 111.23 177.194 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 105' ' ' ALA . . . . . 0.606 ' HB1' ' HA ' ' A' ' 30' ' ' ILE . . . -88.83 -21.46 23.71 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.583 -178.386 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . 0.457 ' O ' ' HG2' ' A' ' 108' ' ' ARG . . . 112.29 63.09 0.46 Allowed Glycine 0 CA--C 1.52 0.354 0 C-N-CA 120.996 -0.621 . . . . 0.0 112.129 -178.0 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -57.91 142.06 47.35 Favored 'General case' 0 C--N 1.329 -0.321 0 C-N-CA 122.679 0.392 . . . . 0.0 111.084 -179.321 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 108' ' ' ARG . . . . . 0.457 ' HG2' ' O ' ' A' ' 106' ' ' GLY . 4.6 ptp180 . . . . . 0 C--O 1.247 0.961 0 CA-C-O 118.484 -0.769 . . . . 0.0 111.093 -170.195 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 1' ' ' ASN . . . . . 0.527 ' HB3' HG12 ' A' ' 3' ' ' VAL . 77.8 m-20 . . . . . 0 N--CA 1.479 0.985 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 . . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 8.8 p -89.21 -6.92 10.86 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-O 121.019 0.438 . . . . 0.0 110.589 -177.424 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . 0.527 HG12 ' HB3' ' A' ' 1' ' ' ASN . 7.7 p -58.26 123.61 10.51 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.481 0 CA-C-O 121.413 0.625 . . . . 0.0 111.681 -179.952 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.486 ' O ' ' HD3' ' A' ' 6' ' ' PRO . 17.2 t -100.11 154.24 4.41 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 CA-C-N 115.621 -0.718 . . . . 0.0 109.357 179.511 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 2.0 p -90.18 107.78 21.88 Favored Pre-proline 0 C--N 1.319 -0.728 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.129 179.192 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.486 ' HD3' ' O ' ' A' ' 4' ' ' VAL . 24.6 Cg_exo -68.8 97.54 0.56 Allowed 'Trans proline' 0 CA--C 1.505 -0.974 0 C-N-CA 123.062 2.508 . . . . 0.0 111.922 177.565 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -124.55 47.7 2.07 Favored 'General case' 0 C--N 1.291 -1.97 0 CA-C-N 113.012 -1.903 . . . . 0.0 111.058 -175.706 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 41.8 t60 -85.65 -7.84 58.58 Favored 'General case' 0 C--N 1.308 -1.198 0 CA-C-N 114.497 -1.229 . . . . 0.0 108.481 172.133 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 13.7 pt-20 -118.41 159.78 22.85 Favored 'General case' 0 N--CA 1.446 -0.657 0 CA-C-N 114.634 -1.166 . . . . 0.0 110.222 -179.183 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -139.64 64.5 1.46 Allowed 'General case' 0 C--N 1.318 -0.774 0 CA-C-O 121.948 0.88 . . . . 0.0 110.998 176.884 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 60.4 t -105.39 -72.56 0.64 Allowed 'Isoleucine or valine' 0 C--N 1.314 -0.952 0 CA-C-N 114.687 -1.142 . . . . 0.0 109.597 177.219 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 6.8 p 27.7 78.66 0.01 OUTLIER 'Isoleucine or valine' 0 C--O 1.236 0.383 0 O-C-N 124.91 1.382 . . . . 0.0 113.284 176.598 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 26.7 ptt180 -93.58 94.94 8.91 Favored 'General case' 0 C--N 1.306 -1.284 0 CA-C-O 122.903 1.335 . . . . 0.0 110.73 -178.232 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 7.4 t -124.23 163.28 24.35 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.655 0 CA-C-N 113.134 -1.848 . . . . 0.0 108.039 -179.501 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 88.8 78.71 1.3 Allowed Glycine 0 C--N 1.305 -1.189 0 N-CA-C 110.567 -1.013 . . . . 0.0 110.567 -175.792 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.494 ' HB ' ' HD2' ' A' ' 17' ' ' LYS . 4.0 m -62.8 -36.99 84.96 Favored 'General case' 0 N--CA 1.444 -0.756 0 CA-C-O 121.709 0.766 . . . . 0.0 111.158 -174.902 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . 0.494 ' HD2' ' HB ' ' A' ' 16' ' ' THR . 0.0 OUTLIER -122.12 99.51 43.52 Favored Pre-proline 0 C--N 1.313 -0.985 0 CA-C-N 114.856 -1.066 . . . . 0.0 110.045 177.523 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 10.8 Cg_exo -72.95 165.86 31.63 Favored 'Trans proline' 0 CA--C 1.511 -0.648 0 C-N-CA 123.197 2.598 . . . . 0.0 112.639 -179.316 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -100.24 35.78 4.57 Favored Glycine 0 C--N 1.308 -0.982 0 CA-C-N 114.036 -1.438 . . . . 0.0 110.65 -178.346 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 6.2 m -62.52 -49.13 76.56 Favored 'General case' 0 C--N 1.316 -0.891 0 CA-C-N 114.26 -0.97 . . . . 0.0 111.339 -177.949 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 49.5 mt-10 -131.91 114.66 14.92 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.823 -179.491 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 57.0 t -87.01 112.72 49.48 Favored Pre-proline 0 C--N 1.322 -0.617 0 N-CA-C 109.328 -0.619 . . . . 0.0 109.328 174.378 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 51.9 Cg_exo -54.7 131.84 48.21 Favored 'Trans proline' 0 N--CA 1.46 -0.474 0 C-N-CA 122.845 2.363 . . . . 0.0 111.877 179.413 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 10.3 Cg_endo -54.52 139.25 75.37 Favored 'Trans proline' 0 N--CA 1.456 -0.707 0 C-N-CA 123.23 2.62 . . . . 0.0 112.274 -176.478 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 1.039 HG11 HD13 ' A' ' 83' ' ' ILE . 7.5 p -90.16 127.9 42.42 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.243 0 CA-C-N 114.501 -1.227 . . . . 0.0 111.459 -175.859 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 47.5 mm -76.86 -25.31 15.7 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.714 0 CA-C-N 115.254 -0.884 . . . . 0.0 111.074 -178.658 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.445 ' O ' HG12 ' A' ' 30' ' ' ILE . 50.0 m-20 -111.07 17.96 19.89 Favored 'General case' 0 CA--C 1.506 -0.713 0 CA-C-O 121.392 0.615 . . . . 0.0 109.693 -177.508 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . 0.501 ' HA3' HG13 ' A' ' 25' ' ' VAL . . . -70.34 -7.84 61.19 Favored Glycine 0 N--CA 1.44 -1.066 0 N-CA-C 110.024 -1.231 . . . . 0.0 110.024 176.577 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 8.7 m -74.39 -39.42 62.7 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 114.644 -0.778 . . . . 0.0 109.122 174.621 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.622 ' HA ' ' HB1' ' A' ' 105' ' ' ALA . 1.0 OUTLIER -68.18 -39.58 81.45 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 N-CA-C 107.402 -1.333 . . . . 0.0 107.402 177.771 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 31' ' ' TRP . . . . . 0.588 ' CZ2' ' HD3' ' A' ' 90' ' ' ARG . 27.2 m95 -70.61 -37.35 73.85 Favored 'General case' 0 N--CA 1.443 -0.795 0 CA-C-N 114.301 -1.318 . . . . 0.0 110.345 -177.051 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.671 ' HB2' HH21 ' A' ' 79' ' ' ARG . 21.8 t70 -79.34 -33.85 42.69 Favored 'General case' 0 N--CA 1.448 -0.549 0 CA-C-N 115.965 -0.561 . . . . 0.0 111.258 -179.55 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . 0.466 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -68.63 -32.97 73.21 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 176.713 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . 0.541 HG13 ' O ' ' A' ' 30' ' ' ILE . 66.3 mt -61.07 -45.39 98.66 Favored 'Isoleucine or valine' 0 C--O 1.234 0.289 0 CA-C-N 116.172 -0.467 . . . . 0.0 109.85 171.315 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . 0.767 ' HA ' ' NE2' ' A' ' 56' ' ' GLN . . . -61.34 -36.03 79.05 Favored 'General case' 0 CA--C 1.513 -0.475 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.684 177.6 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -73.56 -18.13 79.32 Favored Glycine 0 N--CA 1.448 -0.509 0 N-CA-C 111.025 -0.83 . . . . 0.0 111.025 179.44 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . 0.509 ' HB3' ' O ' ' A' ' 34' ' ' ILE . 8.3 t -77.14 -70.64 0.45 Allowed 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 115.102 -0.549 . . . . 0.0 111.587 -178.065 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . 0.728 ' HG2' ' SG ' ' A' ' 101' ' ' CYS . 4.5 mm-40 -90.44 -33.54 15.96 Favored 'General case' 0 CA--C 1.511 -0.554 0 C-N-CA 120.435 -0.506 . . . . 0.0 111.133 -172.65 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . 0.501 ' HB3' ' O ' ' A' ' 35' ' ' ALA . . . -84.57 -15.69 44.79 Favored 'General case' 0 N--CA 1.443 -0.8 0 CA-C-N 115.997 -0.547 . . . . 0.0 111.125 -177.182 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 75.84 13.29 83.23 Favored Glycine 0 CA--C 1.504 -0.607 0 N-CA-C 109.687 -1.365 . . . . 0.0 109.687 -177.456 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 88.62 63.33 1.35 Allowed Glycine 0 N--CA 1.432 -1.583 0 CA-C-N 113.957 -1.121 . . . . 0.0 111.436 -175.424 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . 0.823 ' HB3' ' HB ' ' A' ' 45' ' ' ILE . 6.6 m120 -146.59 103.32 3.65 Favored 'General case' 0 CA--C 1.513 -0.456 0 CA-C-O 121.125 0.488 . . . . 0.0 110.003 -177.962 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 43' ' ' TRP . . . . . 0.704 ' HA ' ' N ' ' A' ' 54' ' ' GLY . 44.5 m95 -84.97 -6.87 59.33 Favored 'General case' 0 C--N 1.311 -1.066 0 CA-C-O 121.642 0.734 . . . . 0.0 110.128 178.155 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -109.72 13.96 23.51 Favored 'General case' 0 C--N 1.318 -0.773 0 CA-C-N 114.924 -1.034 . . . . 0.0 111.546 178.449 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.823 ' HB ' ' HB3' ' A' ' 42' ' ' ASN . 11.2 tt -87.23 143.67 10.85 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.712 0 CA-C-O 120.85 0.357 . . . . 0.0 110.595 -177.833 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 4.8 p30 -161.71 113.55 1.75 Allowed 'General case' 0 C--N 1.315 -0.916 0 CA-C-O 121.375 0.607 . . . . 0.0 110.482 175.974 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 30.5 p -82.32 -20.17 37.91 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 115.739 -0.664 . . . . 0.0 111.684 -175.22 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 102.66 25.01 7.87 Favored Glycine 0 N--CA 1.445 -0.757 0 N-CA-C 110.703 -0.959 . . . . 0.0 110.703 -175.204 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 3.4 t30 -95.01 -2.91 49.36 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 121.533 0.682 . . . . 0.0 110.346 -178.64 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 96.3 -13.81 65.23 Favored Glycine 0 C--O 1.227 -0.314 0 CA-C-N 115.548 -0.751 . . . . 0.0 111.526 179.202 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 51' ' ' TYR . . . . . 0.6 ' HA ' ' HA ' ' A' ' 58' ' ' ASP . 0.3 OUTLIER -99.55 137.94 37.33 Favored 'General case' 0 CA--C 1.511 -0.541 0 N-CA-C 108.234 -1.024 . . . . 0.0 108.234 174.543 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 52' ' ' TYR . . . . . 0.673 ' CE1' ' HB2' ' A' ' 59' ' ' GLN . 15.9 m-85 -107.62 169.5 8.55 Favored 'General case' 0 C--N 1.312 -1.065 0 C-N-CA 120.685 -0.406 . . . . 0.0 111.698 -172.199 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -63.01 169.59 16.49 Favored Glycine 0 N--CA 1.449 -0.484 0 N-CA-C 115.256 0.862 . . . . 0.0 115.256 -166.613 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.704 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 85.11 -93.17 1.81 Allowed Glycine 0 N--CA 1.44 -1.086 0 CA-C-N 114.508 -0.846 . . . . 0.0 112.01 177.983 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.528 HG22 ' HB3' ' A' ' 82' ' ' GLN . 0.4 OUTLIER -90.95 -2.15 10.14 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.764 0 CA-C-O 121.017 0.437 . . . . 0.0 111.403 -177.447 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 56' ' ' GLN . . . . . 0.767 ' NE2' ' HA ' ' A' ' 35' ' ' ALA . 9.2 mt-30 58.02 46.94 15.58 Favored 'General case' 0 N--CA 1.472 0.625 0 N-CA-C 113.849 1.055 . . . . 0.0 113.849 164.645 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -125.3 157.77 35.83 Favored 'General case' 0 C--N 1.318 -0.765 0 C-N-CA 119.221 -0.992 . . . . 0.0 111.296 174.87 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.6 ' HA ' ' HA ' ' A' ' 51' ' ' TYR . 24.1 t70 -65.21 144.12 57.39 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 114.33 -1.304 . . . . 0.0 112.052 -167.709 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.673 ' HB2' ' CE1' ' A' ' 52' ' ' TYR . 0.0 OUTLIER -51.87 -36.15 47.5 Favored 'General case' 0 N--CA 1.448 -0.562 0 CA-C-N 114.131 -1.395 . . . . 0.0 111.807 179.017 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -67.43 -41.98 90.04 Favored Glycine 0 N--CA 1.449 -0.438 0 N-CA-C 111.453 -0.659 . . . . 0.0 111.453 179.386 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 64.1 m -71.47 -38.69 71.23 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 120.759 0.314 . . . . 0.0 110.434 176.368 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 62' ' ' TRP . . . . . 0.563 ' CH2' ' HA ' ' A' ' 74' ' ' ALA . 43.3 t-105 -55.59 -47.57 76.26 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 121.64 0.733 . . . . 0.0 109.089 172.571 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . 0.503 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 27.6 tt0 -64.67 -33.53 76.16 Favored 'General case' 0 N--CA 1.443 -0.775 0 CA-C-N 114.784 -1.098 . . . . 0.0 110.711 178.127 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -64.36 -42.84 96.0 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 115.928 -0.578 . . . . 0.0 111.624 -176.598 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . 0.455 ' HB2' HG13 ' A' ' 85' ' ' VAL . 10.2 m-80 -74.16 -19.31 60.6 Favored 'General case' 0 N--CA 1.462 0.173 0 CA-C-O 121.254 0.549 . . . . 0.0 109.892 174.01 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . 0.422 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 94.02 48.12 2.73 Favored Glycine 0 N--CA 1.448 -0.514 0 CA-C-N 115.536 -0.756 . . . . 0.0 111.814 179.309 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.524 ' HA2' ' HD1' ' A' ' 70' ' ' TYR . . . -79.59 -17.37 75.76 Favored Glycine 0 N--CA 1.44 -1.068 0 C-N-CA 120.992 -0.623 . . . . 0.0 113.044 -173.377 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.817 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 6.5 mp -61.68 -23.3 66.0 Favored 'General case' 0 N--CA 1.45 -0.441 0 N-CA-C 112.179 0.437 . . . . 0.0 112.179 -173.372 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . 0.422 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 4.8 ptt180 -70.52 -29.49 66.0 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 121.04 0.448 . . . . 0.0 110.604 175.552 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 70' ' ' TYR . . . . . 0.567 ' HB3' ' HB3' ' A' ' 81' ' ' GLU . 74.7 m-85 -79.27 -33.65 43.25 Favored 'General case' 0 N--CA 1.446 -0.642 0 N-CA-C 107.185 -1.413 . . . . 0.0 107.185 175.891 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.616 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 163.02 127.69 0.01 OUTLIER Pre-proline 0 C--O 1.22 -0.452 0 CA-C-N 112.662 -2.063 . . . . 0.0 107.044 -179.709 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 72' ' ' PRO . . . . . 0.817 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 16.6 Cg_exo -56.92 -4.77 1.02 Allowed 'Trans proline' 0 C--N 1.334 -0.194 0 C-N-CA 122.605 2.203 . . . . 0.0 113.774 -177.97 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 14.4 ptm180 -145.38 140.19 27.5 Favored 'General case' 0 C--N 1.318 -0.798 0 N-CA-C 108.501 -0.925 . . . . 0.0 108.501 175.888 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . 0.563 ' HA ' ' CH2' ' A' ' 62' ' ' TRP . . . -57.68 -36.03 71.38 Favored 'General case' 0 C--O 1.219 -0.535 0 CA-C-N 115.448 -0.796 . . . . 0.0 111.691 -176.77 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . 0.457 ' OD1' ' HD2' ' A' ' 52' ' ' TYR . 11.6 p-10 -84.03 2.58 38.43 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 120.935 0.398 . . . . 0.0 111.455 -173.08 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.468 ' HB3' ' HB1' ' A' ' 71' ' ' ALA . 49.2 tp -98.13 -33.96 10.94 Favored 'General case' 0 C--N 1.323 -0.568 0 N-CA-C 108.419 -0.956 . . . . 0.0 108.419 170.893 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . 0.793 ' HB1' ' HB2' ' A' ' 81' ' ' GLU . . . -79.32 163.27 25.02 Favored 'General case' 0 N--CA 1.444 -0.768 0 CA-C-N 114.785 -1.098 . . . . 0.0 109.959 175.242 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 38.3 p -101.0 178.23 4.73 Favored 'General case' 0 C--N 1.316 -0.887 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.121 179.491 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . 0.671 HH21 ' HB2' ' A' ' 32' ' ' ASP . 60.4 mtp180 -46.1 -48.37 17.18 Favored 'General case' 0 N--CA 1.467 0.399 0 O-C-N 123.693 0.621 . . . . 0.0 111.32 -176.06 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 80' ' ' GLU . . . . . 0.403 ' HG3' ' OE2' ' A' ' 81' ' ' GLU . 6.0 pt-20 -61.7 -42.03 98.4 Favored 'General case' 0 C--N 1.315 -0.915 0 CA-C-N 115.756 -0.656 . . . . 0.0 112.659 -177.375 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 81' ' ' GLU . . . . . 0.793 ' HB2' ' HB1' ' A' ' 77' ' ' ALA . 5.7 mp0 -65.68 -50.48 64.74 Favored 'General case' 0 C--O 1.231 0.121 0 CA-C-N 118.369 0.531 . . . . 0.0 111.824 172.936 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 82' ' ' GLN . . . . . 0.528 ' HB3' HG22 ' A' ' 55' ' ' VAL . 4.0 mt-30 -57.76 -40.78 80.55 Favored 'General case' 0 CA--C 1.515 -0.379 0 CA-C-O 121.217 0.532 . . . . 0.0 110.26 -177.707 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 1.039 HD13 HG11 ' A' ' 25' ' ' VAL . 11.6 mt -61.82 -45.49 98.59 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.696 0 CA-C-N 114.898 -1.047 . . . . 0.0 110.593 178.045 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . 0.565 ' O ' ' HG3' ' A' ' 87' ' ' GLU . . . -62.33 -44.49 96.37 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.911 0.386 . . . . 0.0 111.513 -177.575 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.486 HG23 ' O ' ' A' ' 81' ' ' GLU . 21.7 t -67.27 -48.84 76.88 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 CA-C-N 116.535 -0.302 . . . . 0.0 111.457 179.291 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -65.04 -30.97 71.98 Favored 'General case' 0 N--CA 1.451 -0.423 0 CA-C-O 121.148 0.499 . . . . 0.0 110.558 179.145 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 87' ' ' GLU . . . . . 0.657 ' O ' ' HG2' ' A' ' 90' ' ' ARG . 0.7 OUTLIER -71.86 -27.71 63.05 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.876 -177.526 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.718 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 88.8 t -62.21 -40.1 86.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 N-CA-C 108.805 -0.813 . . . . 0.0 108.805 166.805 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . 0.786 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 2.7 m -67.86 -43.05 80.33 Favored 'General case' 0 C--N 1.318 -0.772 0 CA-C-N 115.524 -0.762 . . . . 0.0 111.005 -178.89 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . 0.657 ' HG2' ' O ' ' A' ' 87' ' ' GLU . 26.3 ptt180 -60.08 -34.34 73.31 Favored 'General case' 0 N--CA 1.47 0.54 0 C-N-CA 122.761 0.424 . . . . 0.0 111.447 -175.906 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . 0.718 ' HG ' ' O ' ' A' ' 88' ' ' VAL . 4.3 pp -73.15 -21.83 60.63 Favored 'General case' 0 C--N 1.318 -0.774 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.588 -174.361 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . 0.475 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 6.7 mtm180 -86.61 -51.1 6.35 Favored 'General case' 0 CA--C 1.511 -0.538 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.135 -176.607 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 93' ' ' GLN . . . . . 0.627 ' OE1' ' HA ' ' A' ' 90' ' ' ARG . 0.0 OUTLIER -98.03 -25.43 14.96 Favored 'General case' 0 CA--C 1.538 0.487 0 N-CA-C 113.311 0.856 . . . . 0.0 113.311 -170.779 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 90.47 40.1 5.79 Favored Glycine 0 CA--C 1.507 -0.447 0 C-N-CA 120.672 -0.775 . . . . 0.0 111.99 173.462 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 95' ' ' TRP . . . . . 0.48 ' HB3' ' HB1' ' A' ' 102' ' ' ALA . 10.2 m95 64.35 11.71 6.66 Favored 'General case' 0 C--O 1.223 -0.328 0 C-N-CA 123.678 0.791 . . . . 0.0 110.142 -179.131 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -71.66 -28.33 69.43 Favored Glycine 0 C--N 1.33 0.2 0 C-N-CA 121.114 -0.565 . . . . 0.0 112.433 177.982 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -70.0 -29.2 66.23 Favored 'General case' 0 CA--C 1.516 -0.334 0 CA-C-O 121.183 0.516 . . . . 0.0 110.2 178.667 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 98' ' ' TRP . . . . . 0.786 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 26.2 m-90 -98.74 103.84 21.35 Favored Pre-proline 0 N--CA 1.446 -0.638 0 N-CA-C 108.299 -1.0 . . . . 0.0 108.299 174.948 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . 0.465 ' HB2' ' H ' ' A' ' 100' ' ' VAL . 22.9 Cg_exo -69.25 -94.23 0.01 OUTLIER 'Trans proline' 0 CA--C 1.532 0.424 0 C-N-CA 123.176 2.584 . . . . 0.0 114.727 -170.438 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . 0.465 ' H ' ' HB2' ' A' ' 99' ' ' PRO . 47.9 t -70.92 -29.74 38.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-O 121.702 0.763 . . . . 0.0 110.013 -174.385 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 101' ' ' CYS . . . . . 0.728 ' SG ' ' HG2' ' A' ' 38' ' ' GLU . 64.0 m -71.13 -38.41 72.27 Favored 'General case' 0 C--N 1.317 -0.807 0 CA-C-N 114.789 -1.096 . . . . 0.0 111.794 -170.895 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 102' ' ' ALA . . . . . 0.48 ' HB1' ' HB3' ' A' ' 95' ' ' TRP . . . -69.99 -43.14 72.06 Favored 'General case' 0 C--N 1.327 -0.401 0 C-N-CA 120.698 -0.401 . . . . 0.0 110.704 179.86 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -61.67 -37.19 83.18 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 121.355 0.598 . . . . 0.0 110.464 178.42 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 104' ' ' ARG . . . . . 0.57 ' HA ' ' NE ' ' A' ' 104' ' ' ARG . 4.8 mmp_? -71.33 -34.84 70.91 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.495 -0.775 . . . . 0.0 111.563 176.323 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 105' ' ' ALA . . . . . 0.622 ' HB1' ' HA ' ' A' ' 30' ' ' ILE . . . -83.4 -22.33 32.77 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.158 -0.474 . . . . 0.0 112.208 -174.775 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 114.81 59.23 0.36 Allowed Glycine 0 CA--C 1.521 0.425 0 C-N-CA 120.818 -0.706 . . . . 0.0 112.37 -178.611 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -61.65 148.03 43.9 Favored 'General case' 0 CA--C 1.515 -0.367 0 C-N-CA 122.91 0.484 . . . . 0.0 110.635 179.478 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.245 0.845 0 CA-C-O 118.29 -0.862 . . . . 0.0 110.059 -173.013 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 5.6 m-20 . . . . . 0 N--CA 1.48 1.051 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 . . . . . . . . . 0 0 . 1 . 026 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 14.7 p 35.1 57.87 0.15 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.514 0 O-C-N 124.424 1.077 . . . . 0.0 111.851 -174.134 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 6.3 p -64.18 100.06 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.522 0 CA-C-N 114.798 -1.092 . . . . 0.0 112.436 -176.537 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 14.3 p -117.75 148.84 20.28 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.764 0 CA-C-N 115.699 -0.682 . . . . 0.0 110.583 173.472 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 4.6 p -129.37 113.2 18.17 Favored Pre-proline 0 C--N 1.308 -1.207 0 CA-C-N 115.169 -0.923 . . . . 0.0 110.473 178.331 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 62.4 Cg_exo -45.99 107.56 0.12 Allowed 'Trans proline' 0 CA--C 1.505 -0.943 0 C-N-CA 123.809 3.006 . . . . 0.0 113.507 -178.547 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -111.27 171.45 7.47 Favored 'General case' 0 C--N 1.297 -1.704 0 CA-C-N 113.357 -1.747 . . . . 0.0 110.656 -178.706 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 31.0 t-80 68.55 6.04 5.19 Favored 'General case' 0 N--CA 1.456 -0.153 0 O-C-N 124.23 0.956 . . . . 0.0 109.345 -174.149 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 11.4 pt-20 -52.66 135.0 35.68 Favored 'General case' 0 C--O 1.235 0.309 0 CA-C-N 115.099 -0.955 . . . . 0.0 110.778 177.175 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -120.92 65.7 0.86 Allowed 'General case' 0 C--N 1.32 -0.681 0 CA-C-O 121.873 0.844 . . . . 0.0 110.668 -176.787 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 58.2 t -78.63 -40.96 24.48 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.021 0 CA-C-N 114.404 -1.271 . . . . 0.0 109.57 176.408 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 6.2 p 31.7 80.83 0.01 OUTLIER 'Isoleucine or valine' 0 C--O 1.235 0.341 0 O-C-N 124.729 1.268 . . . . 0.0 113.163 178.26 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . 0.465 ' HG3' ' O ' ' A' ' 13' ' ' ARG . 10.3 ptp180 -102.85 114.03 27.96 Favored 'General case' 0 C--N 1.307 -1.271 0 CA-C-N 114.016 -1.447 . . . . 0.0 109.323 179.79 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.9 t -110.01 161.32 8.47 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.421 0 CA-C-N 115.09 -0.959 . . . . 0.0 109.456 -179.98 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 137.61 71.63 0.05 OUTLIER Glycine 0 N--CA 1.436 -1.366 0 CA-C-N 115.075 -0.966 . . . . 0.0 111.978 179.542 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 41.9 m -82.85 -21.99 34.22 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-O 121.591 0.71 . . . . 0.0 110.392 179.993 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 26.1 mmtp -56.29 108.93 1.36 Allowed Pre-proline 0 C--N 1.322 -0.615 0 CA-C-N 114.393 -1.276 . . . . 0.0 111.703 178.003 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -79.42 162.96 24.86 Favored 'Trans proline' 0 N--CA 1.451 -0.987 0 C-N-CA 123.476 2.784 . . . . 0.0 112.231 178.014 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -123.82 35.79 3.17 Favored Glycine 0 C--N 1.306 -1.09 0 CA-C-N 114.088 -1.415 . . . . 0.0 111.359 179.224 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 7.1 m -61.12 -41.93 97.6 Favored 'General case' 0 C--N 1.317 -0.807 0 CA-C-N 114.49 -0.855 . . . . 0.0 110.509 177.768 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 43.2 mt-10 -135.14 103.85 5.7 Favored 'General case' 0 N--CA 1.442 -0.873 0 N-CA-C 108.279 -1.008 . . . . 0.0 108.279 -179.318 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 4.6 p -71.84 115.53 38.92 Favored Pre-proline 0 C--N 1.315 -0.895 0 CA-C-N 115.019 -0.991 . . . . 0.0 112.491 -169.472 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_exo -68.2 151.59 76.73 Favored 'Trans proline' 0 N--CA 1.456 -0.702 0 C-N-CA 123.078 2.518 . . . . 0.0 111.57 172.686 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 9.9 Cg_endo -55.4 140.76 82.63 Favored 'Trans proline' 0 N--CA 1.454 -0.836 0 C-N-CA 122.546 2.164 . . . . 0.0 111.185 173.714 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.575 HG11 HG21 ' A' ' 83' ' ' ILE . 14.0 t -107.15 133.05 52.94 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.074 0 CA-C-N 115.232 -0.895 . . . . 0.0 111.024 -173.399 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 44.6 mm -73.08 -23.87 20.45 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 CA-C-N 115.224 -0.898 . . . . 0.0 111.736 -173.524 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 7.9 m-20 -81.28 -5.33 57.68 Favored 'General case' 0 CA--C 1.503 -0.856 0 CA-C-O 121.656 0.741 . . . . 0.0 109.395 -177.374 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . 0.53 ' HA2' ' HB2' ' A' ' 31' ' ' TRP . . . -66.83 -5.78 33.59 Favored Glycine 0 N--CA 1.439 -1.131 0 CA-C-N 114.229 -1.35 . . . . 0.0 110.902 179.94 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 12.7 m -76.38 -44.66 35.27 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-O 121.419 0.628 . . . . 0.0 109.813 175.792 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.581 ' HB ' ' CH2' ' A' ' 95' ' ' TRP . 0.1 OUTLIER -71.01 -35.94 61.39 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.594 0 N-CA-C 108.113 -1.069 . . . . 0.0 108.113 178.078 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 31' ' ' TRP . . . . . 0.72 ' CD1' HG13 ' A' ' 83' ' ' ILE . 48.9 m95 -71.75 -35.64 70.18 Favored 'General case' 0 N--CA 1.442 -0.865 0 CA-C-N 114.658 -1.156 . . . . 0.0 110.19 -178.975 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 20.4 t70 -77.0 -29.31 55.41 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.342 178.908 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -68.55 -35.06 76.9 Favored 'General case' 0 N--CA 1.444 -0.732 0 N-CA-C 109.671 -0.492 . . . . 0.0 109.671 175.215 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . 0.581 ' HA ' ' HB3' ' A' ' 101' ' ' CYS . 58.0 mt -67.64 -49.34 71.15 Favored 'Isoleucine or valine' 0 C--O 1.233 0.199 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.402 173.908 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . 0.455 ' O ' ' HB3' ' A' ' 39' ' ' ALA . . . -59.08 -41.26 87.6 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.778 -0.646 . . . . 0.0 110.454 178.951 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . 0.4 ' HA2' ' N ' ' A' ' 41' ' ' GLY . . . -72.09 -18.95 78.2 Favored Glycine 0 N--CA 1.449 -0.484 0 CA-C-N 115.453 -0.794 . . . . 0.0 111.649 179.069 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 3.6 t -84.24 -62.93 1.44 Allowed 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.433 -0.383 . . . . 0.0 111.463 -178.088 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . 0.575 ' HB2' ' SG ' ' A' ' 101' ' ' CYS . 15.9 tt0 -89.06 -33.2 17.21 Favored 'General case' 0 C--N 1.324 -0.517 0 C-N-CA 120.532 -0.467 . . . . 0.0 110.602 -170.908 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . 0.455 ' HB3' ' O ' ' A' ' 35' ' ' ALA . . . -91.18 -12.36 35.62 Favored 'General case' 0 N--CA 1.453 -0.286 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.301 -178.857 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 82.0 4.93 90.11 Favored Glycine 0 CA--C 1.505 -0.552 0 N-CA-C 109.923 -1.271 . . . . 0.0 109.923 -178.857 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . 0.4 ' N ' ' HA2' ' A' ' 36' ' ' GLY . . . 87.3 61.56 1.55 Allowed Glycine 0 N--CA 1.434 -1.482 0 CA-C-N 113.946 -1.127 . . . . 0.0 111.369 -175.291 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . 0.64 ' HB3' ' HB ' ' A' ' 45' ' ' ILE . 0.3 OUTLIER -144.96 96.57 2.88 Favored 'General case' 0 N--CA 1.448 -0.559 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 -177.217 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 43' ' ' TRP . . . . . 0.749 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 46.3 m95 -79.04 -14.1 59.37 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.968 -175.223 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -107.49 14.24 26.03 Favored 'General case' 0 C--N 1.316 -0.861 0 CA-C-N 115.525 -0.761 . . . . 0.0 111.399 179.962 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.64 ' HB ' ' HB3' ' A' ' 42' ' ' ASN . 8.6 tt -78.13 144.56 11.11 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.738 0 CA-C-O 120.994 0.426 . . . . 0.0 110.181 -178.612 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 29.0 t-20 -150.26 86.74 1.43 Allowed 'General case' 0 C--N 1.31 -1.141 0 CA-C-O 121.437 0.637 . . . . 0.0 109.664 178.952 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 6.1 p -68.7 -25.79 64.96 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.122 -0.945 . . . . 0.0 111.464 -178.342 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 100.98 21.01 12.44 Favored Glycine 0 N--CA 1.445 -0.712 0 C-N-CA 120.985 -0.626 . . . . 0.0 111.545 -179.652 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 4.3 m-20 -81.42 -4.05 54.67 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-O 121.229 0.538 . . . . 0.0 111.029 -179.243 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 95.91 -13.6 65.9 Favored Glycine 0 N--CA 1.446 -0.635 0 N-CA-C 110.038 -1.225 . . . . 0.0 110.038 -176.592 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 51' ' ' TYR . . . . . 0.671 ' CD1' ' HB2' ' A' ' 58' ' ' ASP . 0.1 OUTLIER -102.81 144.99 30.43 Favored 'General case' 0 N--CA 1.446 -0.643 0 N-CA-C 107.631 -1.248 . . . . 0.0 107.631 174.048 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 52' ' ' TYR . . . . . 0.842 ' O ' ' HA ' ' A' ' 56' ' ' GLN . 10.3 m-85 -108.61 164.81 12.03 Favored 'General case' 0 C--N 1.308 -1.205 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.717 -172.147 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.463 ' HA2' HG22 ' A' ' 45' ' ' ILE . . . -58.13 172.73 3.27 Favored Glycine 0 C--O 1.229 -0.182 0 N-CA-C 115.702 1.041 . . . . 0.0 115.702 -166.107 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.64 ' CA ' ' HA ' ' A' ' 43' ' ' TRP . . . 91.55 -111.02 3.93 Favored Glycine 0 N--CA 1.446 -0.671 0 CA-C-N 114.86 -0.67 . . . . 0.0 111.509 -178.799 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.4 HG23 ' CD1' ' A' ' 57' ' ' PHE . 1.9 m -83.23 -2.64 6.79 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 CA-C-O 122.077 0.942 . . . . 0.0 110.454 176.22 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 56' ' ' GLN . . . . . 0.842 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 5.9 tt0 50.49 52.1 15.51 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 113.436 -1.711 . . . . 0.0 114.18 168.921 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . 0.453 ' HZ ' HG13 ' A' ' 85' ' ' VAL . 7.2 p90 -105.74 158.49 16.69 Favored 'General case' 0 C--N 1.321 -0.652 0 C-N-CA 119.123 -1.031 . . . . 0.0 110.368 170.788 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.671 ' HB2' ' CD1' ' A' ' 51' ' ' TYR . 0.5 OUTLIER -64.54 144.19 57.38 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 114.888 -1.051 . . . . 0.0 112.016 -168.793 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.713 ' HB2' ' CE1' ' A' ' 52' ' ' TYR . 4.6 tp-100 -63.1 -30.29 71.48 Favored 'General case' 0 C--O 1.218 -0.555 0 CA-C-N 114.841 -1.072 . . . . 0.0 111.54 -178.562 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -64.83 -44.17 95.08 Favored Glycine 0 C--N 1.316 -0.529 0 N-CA-C 110.84 -0.904 . . . . 0.0 110.84 174.949 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 88.6 m -71.36 -40.18 70.82 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-O 121.093 0.473 . . . . 0.0 111.207 175.299 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 62' ' ' TRP . . . . . 0.761 ' CZ3' HG11 ' A' ' 85' ' ' VAL . 29.5 t-105 -55.12 -46.59 75.62 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-O 121.492 0.663 . . . . 0.0 109.694 173.229 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . 0.562 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 32.0 tt0 -67.24 -35.2 79.05 Favored 'General case' 0 C--N 1.316 -0.876 0 CA-C-N 114.957 -1.019 . . . . 0.0 111.01 179.305 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -64.89 -40.85 95.74 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.936 -0.574 . . . . 0.0 110.958 -178.509 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . 0.44 ' HB3' ' HB ' ' A' ' 88' ' ' VAL . 34.8 m-80 -81.68 -7.29 59.58 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.045 -0.525 . . . . 0.0 111.085 177.039 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 87.14 45.1 5.45 Favored Glycine 0 C--N 1.331 0.269 0 C-N-CA 121.022 -0.609 . . . . 0.0 112.812 173.639 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.581 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -79.67 -22.34 64.49 Favored Glycine 0 N--CA 1.441 -0.973 0 C-N-CA 121.184 -0.532 . . . . 0.0 112.783 -175.861 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.798 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 6.7 mp -60.66 -23.67 64.98 Favored 'General case' 0 C--N 1.328 -0.341 0 N-CA-C 112.345 0.498 . . . . 0.0 112.345 -172.338 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 35.7 ptt180 -71.56 -27.02 62.87 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-O 120.933 0.397 . . . . 0.0 110.374 178.882 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 70' ' ' TYR . . . . . 1.012 ' HB3' ' HG2' ' A' ' 81' ' ' GLU . 51.8 m-85 -82.98 -34.41 26.38 Favored 'General case' 0 N--CA 1.444 -0.746 0 N-CA-C 107.09 -1.448 . . . . 0.0 107.09 174.056 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.554 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 167.25 130.12 0.04 OUTLIER Pre-proline 0 C--N 1.327 -0.397 0 CA-C-N 112.456 -2.157 . . . . 0.0 108.866 -178.783 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 72' ' ' PRO . . . . . 0.798 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 36.6 Cg_endo -67.97 29.58 0.14 Allowed 'Trans proline' 0 N--CA 1.476 0.487 0 C-N-CA 122.862 2.374 . . . . 0.0 113.877 179.311 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 73' ' ' ARG . . . . . 0.465 ' H ' ' C ' ' A' ' 71' ' ' ALA . 14.7 ptm180 -176.27 140.15 0.38 Allowed 'General case' 0 C--N 1.321 -0.66 0 N-CA-C 108.665 -0.865 . . . . 0.0 108.665 178.136 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . 0.544 ' HA ' ' CH2' ' A' ' 62' ' ' TRP . . . -66.47 -27.15 67.57 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.788 -0.642 . . . . 0.0 111.795 -174.949 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . 0.462 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 21.1 p-10 -86.57 -4.92 59.24 Favored 'General case' 0 C--N 1.324 -0.532 0 C-N-CA 120.832 -0.347 . . . . 0.0 111.61 -174.825 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 65.2 tp -97.85 -28.61 13.77 Favored 'General case' 0 C--N 1.322 -0.604 0 N-CA-C 108.97 -0.752 . . . . 0.0 108.97 171.31 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . 0.685 ' HB1' ' HB3' ' A' ' 81' ' ' GLU . . . -78.05 148.54 34.24 Favored 'General case' 0 N--CA 1.441 -0.919 0 CA-C-N 115.12 -0.946 . . . . 0.0 109.934 175.309 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 47.0 p -91.79 -175.61 4.2 Favored 'General case' 0 C--N 1.31 -1.135 0 CA-C-N 115.608 -0.724 . . . . 0.0 109.982 -178.617 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . 0.749 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 43.1 mtp-105 -53.7 -54.84 32.2 Favored 'General case' 0 CA--C 1.515 -0.382 0 CA-C-O 120.979 0.419 . . . . 0.0 110.167 -178.31 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 2.6 pm0 -56.85 -39.02 73.52 Favored 'General case' 0 C--N 1.318 -0.787 0 CA-C-N 115.454 -0.794 . . . . 0.0 111.486 -176.362 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 81' ' ' GLU . . . . . 1.012 ' HG2' ' HB3' ' A' ' 70' ' ' TYR . 1.0 OUTLIER -66.93 -50.8 61.23 Favored 'General case' 0 C--N 1.323 -0.582 0 N-CA-C 112.419 0.526 . . . . 0.0 112.419 175.188 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 82' ' ' GLN . . . . . 0.614 ' HB2' ' HZ3' ' A' ' 43' ' ' TRP . 56.1 mt-30 -61.45 -34.89 76.18 Favored 'General case' 0 CA--C 1.514 -0.417 0 C-N-CA 121.023 -0.271 . . . . 0.0 110.318 -178.402 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.72 HG13 ' CD1' ' A' ' 31' ' ' TRP . 1.4 mp -60.12 -46.19 94.78 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.089 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.76 173.518 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . 0.616 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -62.6 -44.75 95.53 Favored 'General case' 0 C--O 1.238 0.498 0 CA-C-O 121.533 0.683 . . . . 0.0 111.663 -172.813 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.761 HG11 ' CZ3' ' A' ' 62' ' ' TRP . 2.7 p -70.68 -43.66 77.24 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.721 0 CA-C-N 115.949 -0.569 . . . . 0.0 111.027 -179.91 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . 0.463 ' HB1' ' CH2' ' A' ' 31' ' ' TRP . . . -61.04 -28.4 69.03 Favored 'General case' 0 N--CA 1.451 -0.415 0 CA-C-N 115.764 -0.653 . . . . 0.0 109.69 174.396 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 87' ' ' GLU . . . . . 0.687 ' HG3' ' O ' ' A' ' 83' ' ' ILE . 30.6 mt-10 -61.18 -43.84 98.25 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.398 -0.819 . . . . 0.0 109.888 179.203 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.675 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 41.2 t -61.81 -46.08 97.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-O 121.178 0.513 . . . . 0.0 109.799 176.244 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . 0.798 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 0.2 OUTLIER -67.42 -45.95 74.6 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 115.961 -0.563 . . . . 0.0 111.499 -175.25 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . 0.636 ' HD3' ' HZ2' ' A' ' 31' ' ' TRP . 23.2 ptt180 -62.87 -34.23 76.94 Favored 'General case' 0 C--O 1.221 -0.418 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.742 -177.259 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . 0.675 ' HG ' ' O ' ' A' ' 88' ' ' VAL . 4.2 pp -73.55 -23.78 60.02 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-O 120.951 0.405 . . . . 0.0 110.904 -171.82 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . 0.573 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 4.7 mtm180 -82.06 -46.91 13.26 Favored 'General case' 0 CA--C 1.51 -0.588 0 CA-C-O 121.426 0.632 . . . . 0.0 109.608 -179.11 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 93' ' ' GLN . . . . . 0.573 ' NE2' HG22 ' A' ' 89' ' ' THR . 13.2 pt20 -103.42 -27.95 12.1 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 114.759 -1.109 . . . . 0.0 113.965 -168.344 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 92.02 39.98 5.32 Favored Glycine 0 C--N 1.332 0.338 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.436 175.983 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 95' ' ' TRP . . . . . 0.603 ' HZ2' HH11 ' A' ' 90' ' ' ARG . 33.2 m95 70.06 9.62 7.13 Favored 'General case' 0 C--O 1.219 -0.55 0 C-N-CA 123.338 0.655 . . . . 0.0 109.609 -179.933 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -59.44 -41.78 97.23 Favored Glycine 0 N--CA 1.453 -0.223 0 CA-C-N 115.28 -0.873 . . . . 0.0 113.476 -178.68 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . 0.403 ' O ' ' HD3' ' A' ' 99' ' ' PRO . . . -70.03 -17.87 63.28 Favored 'General case' 0 N--CA 1.464 0.275 0 CA-C-N 117.117 0.459 . . . . 0.0 110.793 179.772 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 98' ' ' TRP . . . . . 0.798 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 24.6 m-90 -95.65 107.84 36.12 Favored Pre-proline 0 N--CA 1.448 -0.564 0 N-CA-C 108.794 -0.817 . . . . 0.0 108.794 176.171 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . 0.424 ' HD3' ' HA ' ' A' ' 98' ' ' TRP . 41.7 Cg_exo -63.77 -132.46 0.0 OUTLIER 'Trans proline' 0 CA--C 1.539 0.746 0 C-N-CA 123.857 3.038 . . . . 0.0 114.408 -173.804 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 18.3 t -55.48 -26.24 19.0 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.252 0 CA-C-O 120.82 0.343 . . . . 0.0 111.497 -174.623 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 101' ' ' CYS . . . . . 0.581 ' HB3' ' HA ' ' A' ' 34' ' ' ILE . 75.0 m -64.75 -34.41 78.27 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 116.339 -0.392 . . . . 0.0 111.528 -178.553 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -70.03 -40.78 74.97 Favored 'General case' 0 CA--C 1.519 -0.232 0 CA-C-O 120.971 0.415 . . . . 0.0 110.226 177.642 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -63.09 -39.38 94.52 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.353 176.904 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 104' ' ' ARG . . . . . 0.452 ' HA ' ' NE ' ' A' ' 104' ' ' ARG . 14.9 mmp_? -71.69 -31.49 66.82 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.605 -0.725 . . . . 0.0 111.003 178.844 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 105' ' ' ALA . . . . . 0.486 ' CB ' HG22 ' A' ' 30' ' ' ILE . . . -80.71 -23.95 39.14 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 120.989 0.423 . . . . 0.0 111.735 -177.356 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 97.98 59.3 0.95 Allowed Glycine 0 CA--C 1.522 0.471 0 C-N-CA 120.983 -0.627 . . . . 0.0 112.096 -176.707 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -57.62 146.72 29.56 Favored 'General case' 0 C--N 1.329 -0.311 0 C-N-CA 123.274 0.629 . . . . 0.0 112.356 -177.612 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 108' ' ' ARG . . . . . 0.694 ' O ' ' HD3' ' A' ' 108' ' ' ARG . 0.0 OUTLIER . . . . . 0 C--O 1.25 1.09 0 CA-C-O 118.545 -0.74 . . . . 0.0 110.594 -175.899 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 33.4 m-80 . . . . . 0 N--CA 1.476 0.866 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 . . . . . . . . . 0 0 . 1 . 027 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 12.1 p -75.79 -16.81 15.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-O 121.243 0.544 . . . . 0.0 110.192 -179.628 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 79.5 t -70.93 120.21 18.5 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.557 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.923 176.671 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 15.8 t -90.31 147.0 5.51 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 N-CA-C 109.626 -0.509 . . . . 0.0 109.626 178.069 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 8.8 p -103.14 108.3 58.31 Favored Pre-proline 0 C--N 1.317 -0.811 0 CA-C-N 115.94 -0.573 . . . . 0.0 111.292 -178.722 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 43.1 Cg_endo -98.7 165.71 0.64 Allowed 'Trans proline' 0 N--CA 1.442 -1.529 0 C-N-CA 123.585 2.857 . . . . 0.0 111.856 175.812 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -84.02 48.22 1.43 Allowed 'General case' 0 C--N 1.315 -0.929 0 CA-C-O 122.104 0.954 . . . . 0.0 110.045 176.338 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 9.7 t60 -77.29 -3.75 41.46 Favored 'General case' 0 C--N 1.314 -0.963 0 CA-C-N 113.745 -1.57 . . . . 0.0 108.86 176.23 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 11.8 pt-20 -53.46 133.53 40.68 Favored 'General case' 0 C--O 1.234 0.242 0 CA-C-N 115.249 -0.887 . . . . 0.0 111.028 -178.999 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -149.74 73.94 1.2 Allowed 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 115.529 -0.759 . . . . 0.0 109.796 179.46 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 59.0 t -71.61 -50.01 42.39 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.729 0 CA-C-N 114.876 -1.056 . . . . 0.0 111.041 -176.905 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 5.2 p 32.93 82.88 0.01 OUTLIER 'Isoleucine or valine' 0 C--O 1.235 0.334 0 CA-C-O 122.765 1.269 . . . . 0.0 112.761 -176.913 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . 0.466 ' HG3' ' O ' ' A' ' 13' ' ' ARG . 2.5 ptp180 -82.6 118.33 23.22 Favored 'General case' 0 C--N 1.309 -1.165 0 CA-C-N 113.993 -1.458 . . . . 0.0 110.24 -177.329 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 3.3 t -107.45 164.45 4.89 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.36 0 CA-C-N 114.442 -1.254 . . . . 0.0 109.12 175.66 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 139.99 71.1 0.04 OUTLIER Glycine 0 N--CA 1.437 -1.296 0 CA-C-N 115.26 -0.882 . . . . 0.0 111.471 178.914 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 86.3 m -115.12 -26.25 7.76 Favored 'General case' 0 N--CA 1.44 -0.96 0 CA-C-N 115.001 -0.599 . . . . 0.0 111.261 -175.945 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . 0.472 ' HA ' ' HD3' ' A' ' 18' ' ' PRO . 28.1 mmtp -66.14 108.33 2.19 Favored Pre-proline 0 C--N 1.322 -0.59 0 CA-C-N 115.594 -0.73 . . . . 0.0 111.186 -175.661 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . 0.472 ' HD3' ' HA ' ' A' ' 17' ' ' LYS . 5.3 Cg_endo -88.67 173.76 4.27 Favored 'Trans proline' 0 N--CA 1.45 -1.04 0 C-N-CA 123.889 3.059 . . . . 0.0 112.104 178.483 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -122.38 19.68 8.06 Favored Glycine 0 CA--C 1.5 -0.874 0 CA-C-N 114.915 -1.038 . . . . 0.0 112.015 177.499 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 16.2 m -70.34 -38.32 74.82 Favored 'General case' 0 C--N 1.308 -1.216 0 CA-C-N 114.161 -1.02 . . . . 0.0 109.742 177.126 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 7.9 pt-20 -133.63 157.59 45.37 Favored 'General case' 0 N--CA 1.431 -1.395 0 CA-C-N 114.802 -1.09 . . . . 0.0 108.225 176.464 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 64.0 t -107.87 107.5 60.35 Favored Pre-proline 0 C--N 1.3 -1.56 0 CA-C-N 115.741 -0.663 . . . . 0.0 109.501 174.897 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.428 ' HA ' ' HD2' ' A' ' 24' ' ' PRO . 53.2 Cg_exo -55.13 129.59 36.09 Favored 'Trans proline' 0 N--CA 1.46 -0.461 0 C-N-CA 122.677 2.251 . . . . 0.0 111.063 175.234 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . 0.428 ' HD2' ' HA ' ' A' ' 23' ' ' PRO . 10.1 Cg_endo -54.34 139.5 73.59 Favored 'Trans proline' 0 N--CA 1.453 -0.864 0 C-N-CA 123.06 2.507 . . . . 0.0 112.004 -176.823 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.546 HG12 ' H ' ' A' ' 27' ' ' ASP . 41.7 t -112.99 125.39 70.24 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.227 0 CA-C-N 114.665 -1.152 . . . . 0.0 110.611 -173.527 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 43.6 mm -66.76 -23.28 30.88 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-N 115.401 -0.818 . . . . 0.0 110.278 -177.885 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.546 ' H ' HG12 ' A' ' 25' ' ' VAL . 5.8 m-20 -79.2 -1.63 37.22 Favored 'General case' 0 CA--C 1.504 -0.804 0 CA-C-N 115.237 -0.892 . . . . 0.0 109.523 -178.84 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . 0.572 ' HA2' ' HB2' ' A' ' 31' ' ' TRP . . . -69.1 -9.31 60.01 Favored Glycine 0 N--CA 1.437 -1.266 0 N-CA-C 110.302 -1.119 . . . . 0.0 110.302 176.222 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 17.6 m -76.97 -47.83 19.72 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 121.405 0.622 . . . . 0.0 110.073 177.12 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.773 HG22 ' O ' ' A' ' 105' ' ' ALA . 4.2 pt -71.67 -34.64 52.9 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.923 0 CA-C-N 115.087 -0.96 . . . . 0.0 109.641 176.844 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 31' ' ' TRP . . . . . 0.673 ' CZ2' ' HD3' ' A' ' 90' ' ' ARG . 12.1 m95 -63.75 -37.18 86.41 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 115.334 -0.848 . . . . 0.0 109.528 175.652 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 36.2 t70 -77.63 -31.32 52.7 Favored 'General case' 0 N--CA 1.448 -0.54 0 CA-C-N 115.837 -0.62 . . . . 0.0 111.133 179.793 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . 0.468 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -69.0 -33.75 74.17 Favored 'General case' 0 N--CA 1.446 -0.642 0 C-N-CA 120.409 -0.516 . . . . 0.0 109.727 176.706 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . 0.471 HG13 ' O ' ' A' ' 30' ' ' ILE . 74.1 mt -67.43 -42.81 87.66 Favored 'Isoleucine or valine' 0 C--O 1.233 0.215 0 CA-C-O 121.132 0.491 . . . . 0.0 109.722 171.72 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . 0.604 ' HA ' ' O ' ' A' ' 54' ' ' GLY . . . -57.76 -35.25 70.48 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.574 -0.739 . . . . 0.0 110.452 175.917 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . 0.491 ' HA2' ' N ' ' A' ' 41' ' ' GLY . . . -78.67 -5.44 88.29 Favored Glycine 0 N--CA 1.449 -0.46 0 CA-C-N 115.267 -0.879 . . . . 0.0 112.138 179.412 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 42.6 t -103.07 -54.17 2.67 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 120.742 0.306 . . . . 0.0 110.892 -178.483 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . 0.461 ' HG2' ' SG ' ' A' ' 101' ' ' CYS . 30.1 mm-40 -87.06 -31.05 20.72 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 121.162 0.506 . . . . 0.0 110.758 -174.717 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -103.22 -10.51 18.71 Favored 'General case' 0 N--CA 1.447 -0.6 0 CA-C-N 116.029 -0.532 . . . . 0.0 111.262 -179.043 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 76.22 14.23 82.52 Favored Glycine 0 CA--C 1.503 -0.7 0 N-CA-C 109.864 -1.294 . . . . 0.0 109.864 -178.455 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . 0.491 ' N ' ' HA2' ' A' ' 36' ' ' GLY . . . 81.66 62.53 1.93 Allowed Glycine 0 N--CA 1.432 -1.596 0 CA-C-N 113.94 -1.13 . . . . 0.0 111.82 -176.568 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . 0.565 ' HB3' ' HB ' ' A' ' 45' ' ' ILE . 3.4 t30 -155.87 96.97 1.78 Allowed 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 109.136 -0.69 . . . . 0.0 109.136 -178.557 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 43' ' ' TRP . . . . . 0.725 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 33.0 m95 -73.35 -11.04 60.35 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-O 121.285 0.564 . . . . 0.0 111.007 -175.319 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -106.25 14.91 26.91 Favored 'General case' 0 C--N 1.314 -0.952 0 CA-C-N 115.575 -0.739 . . . . 0.0 111.432 -179.059 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.851 HG22 ' HA2' ' A' ' 53' ' ' GLY . 7.0 tt -78.86 142.92 13.39 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.793 0 CA-C-O 121.138 0.494 . . . . 0.0 110.121 -178.106 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . 0.562 ' ND2' HH21 ' A' ' 73' ' ' ARG . 9.3 t-20 -148.29 90.05 1.77 Allowed 'General case' 0 C--N 1.312 -1.027 0 CA-C-O 121.114 0.483 . . . . 0.0 109.958 178.923 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 13.9 p -76.48 -16.65 59.6 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 115.87 -0.605 . . . . 0.0 111.724 -176.92 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 94.93 21.99 24.31 Favored Glycine 0 N--CA 1.447 -0.625 0 N-CA-C 110.942 -0.863 . . . . 0.0 110.942 -177.931 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 10.4 t-20 -86.1 -12.27 50.48 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 121.302 0.573 . . . . 0.0 110.964 -175.098 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . 0.402 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 95.21 -9.47 69.83 Favored Glycine 0 N--CA 1.448 -0.517 0 N-CA-C 110.184 -1.166 . . . . 0.0 110.184 -175.386 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 51' ' ' TYR . . . . . 0.545 ' HA ' ' HA ' ' A' ' 58' ' ' ASP . 0.5 OUTLIER -110.73 146.68 35.87 Favored 'General case' 0 CA--C 1.505 -0.777 0 N-CA-C 105.914 -1.884 . . . . 0.0 105.914 175.373 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 52' ' ' TYR . . . . . 0.788 ' HB2' ' HB3' ' A' ' 74' ' ' ALA . 45.0 m-85 -112.9 167.58 10.39 Favored 'General case' 0 C--N 1.304 -1.412 0 C-N-CA 119.623 -0.831 . . . . 0.0 112.905 -167.835 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.851 ' HA2' HG22 ' A' ' 45' ' ' ILE . . . -54.86 157.15 7.19 Favored Glycine 0 N--CA 1.446 -0.682 0 CA-C-N 114.787 -1.097 . . . . 0.0 114.105 -171.698 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.689 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 97.03 -109.86 3.93 Favored Glycine 0 N--CA 1.437 -1.244 0 C-N-CA 120.803 -0.713 . . . . 0.0 111.72 -178.411 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.546 HG23 ' HG2' ' A' ' 82' ' ' GLN . 3.1 t -84.83 -0.46 5.94 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 CA-C-O 121.771 0.796 . . . . 0.0 110.354 -176.344 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 56' ' ' GLN . . . . . 0.587 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 8.1 tp-100 56.66 50.49 12.61 Favored 'General case' 0 C--N 1.339 0.141 0 CA-C-N 114.195 -1.366 . . . . 0.0 112.685 168.289 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . 0.47 ' CE1' ' HB2' ' A' ' 86' ' ' ALA . 7.8 p90 -116.98 162.76 17.26 Favored 'General case' 0 C--N 1.321 -0.659 0 C-N-CA 120.105 -0.638 . . . . 0.0 111.083 175.287 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.545 ' HA ' ' HA ' ' A' ' 51' ' ' TYR . 6.4 p-10 -76.28 160.17 29.9 Favored 'General case' 0 C--N 1.324 -0.511 0 N-CA-C 113.594 0.961 . . . . 0.0 113.594 -162.957 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 13.1 tp60 -57.24 -39.45 75.59 Favored 'General case' 0 N--CA 1.443 -0.808 0 CA-C-N 114.036 -1.438 . . . . 0.0 111.563 178.888 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -66.74 -49.89 51.99 Favored Glycine 0 C--O 1.225 -0.436 0 CA-C-N 115.653 -0.703 . . . . 0.0 112.468 -175.746 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 93.6 m -60.68 -44.06 96.96 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 121.15 0.5 . . . . 0.0 110.681 176.051 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 62' ' ' TRP . . . . . 0.433 ' HE3' ' CZ ' ' A' ' 57' ' ' PHE . 52.3 t-105 -57.05 -48.61 78.11 Favored 'General case' 0 N--CA 1.445 -0.68 0 CA-C-N 115.331 -0.849 . . . . 0.0 109.895 176.667 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . 0.503 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 31.4 tt0 -67.48 -35.09 78.48 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-N 115.141 -0.936 . . . . 0.0 110.875 -177.593 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -67.03 -41.67 86.16 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.76 -0.655 . . . . 0.0 111.04 -176.639 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . 0.441 ' HB2' HG13 ' A' ' 85' ' ' VAL . 8.1 m120 -77.69 -9.06 58.78 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 121.112 0.482 . . . . 0.0 110.156 176.137 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 88.35 45.2 5.07 Favored Glycine 0 C--N 1.332 0.341 0 CA-C-N 115.734 -0.666 . . . . 0.0 112.395 174.05 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.518 ' HA2' ' CD1' ' A' ' 70' ' ' TYR . . . -79.02 -20.28 70.62 Favored Glycine 0 N--CA 1.442 -0.964 0 C-N-CA 120.883 -0.675 . . . . 0.0 112.879 -172.937 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.818 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 6.7 mp -61.27 -24.05 66.12 Favored 'General case' 0 N--CA 1.45 -0.434 0 N-CA-C 112.281 0.475 . . . . 0.0 112.281 -173.72 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . 0.497 ' HG3' ' N ' ' A' ' 70' ' ' TYR . 0.7 OUTLIER -70.62 -29.42 65.8 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 121.206 0.527 . . . . 0.0 110.135 176.143 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 70' ' ' TYR . . . . . 0.842 ' HB3' ' HB3' ' A' ' 81' ' ' GLU . 71.7 m-85 -79.7 -34.35 40.23 Favored 'General case' 0 N--CA 1.446 -0.655 0 N-CA-C 107.329 -1.36 . . . . 0.0 107.329 176.449 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.675 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 162.51 127.57 0.01 OUTLIER Pre-proline 0 C--O 1.218 -0.558 0 CA-C-N 112.401 -2.182 . . . . 0.0 107.098 -178.286 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 72' ' ' PRO . . . . . 0.818 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 17.9 Cg_exo -57.13 -1.97 0.47 Allowed 'Trans proline' 0 C--N 1.332 -0.34 0 C-N-CA 122.991 2.46 . . . . 0.0 114.058 -177.453 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 73' ' ' ARG . . . . . 0.562 HH21 ' ND2' ' A' ' 46' ' ' ASN . 12.5 ptm180 -152.56 141.89 21.55 Favored 'General case' 0 C--N 1.319 -0.726 0 N-CA-C 109.64 -0.504 . . . . 0.0 109.64 176.998 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . 0.788 ' HB3' ' HB2' ' A' ' 52' ' ' TYR . . . -63.44 -22.07 66.67 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.509 -0.769 . . . . 0.0 113.028 -176.798 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . 0.517 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 5.2 p-10 -88.29 2.92 51.38 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 121.328 0.585 . . . . 0.0 110.847 -179.781 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.435 ' HB3' ' HB1' ' A' ' 71' ' ' ALA . 53.5 tp -106.27 -34.86 7.35 Favored 'General case' 0 C--N 1.321 -0.654 0 N-CA-C 108.858 -0.793 . . . . 0.0 108.858 174.246 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . 0.815 ' HB1' ' HB2' ' A' ' 81' ' ' GLU . . . -79.83 158.12 26.85 Favored 'General case' 0 N--CA 1.446 -0.627 0 CA-C-N 114.99 -1.005 . . . . 0.0 110.057 174.512 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 25.4 p -100.77 -171.64 2.04 Favored 'General case' 0 C--N 1.314 -0.965 0 CA-C-N 116.2 -0.455 . . . . 0.0 109.8 -179.435 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . 0.725 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 35.9 mtt85 -49.21 -51.95 29.91 Favored 'General case' 0 C--O 1.218 -0.559 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.79 -179.959 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -57.45 -47.61 81.35 Favored 'General case' 0 C--N 1.321 -0.666 0 N-CA-C 112.148 0.425 . . . . 0.0 112.148 -174.854 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 81' ' ' GLU . . . . . 0.842 ' HB3' ' HB3' ' A' ' 70' ' ' TYR . 60.6 mp0 -65.6 -51.23 61.28 Favored 'General case' 0 CA--C 1.517 -0.318 0 CA-C-O 120.983 0.421 . . . . 0.0 111.403 177.228 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 82' ' ' GLN . . . . . 0.546 ' HG2' HG23 ' A' ' 55' ' ' VAL . 4.2 tt0 -65.0 -34.35 78.24 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.606 -0.724 . . . . 0.0 111.361 -173.657 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.582 ' O ' ' HB3' ' A' ' 87' ' ' GLU . 8.1 mt -61.63 -46.13 97.2 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 N-CA-C 109.471 -0.566 . . . . 0.0 109.471 174.193 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . . . . . . . . . . . -61.37 -47.48 85.68 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.205 -176.825 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.441 HG13 ' HB2' ' A' ' 65' ' ' ASN . 46.5 t -65.97 -50.28 70.85 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-N 116.137 -0.483 . . . . 0.0 112.207 -179.997 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . 0.47 ' HB2' ' CE1' ' A' ' 57' ' ' PHE . . . -63.87 -32.05 73.44 Favored 'General case' 0 CA--C 1.515 -0.394 0 CA-C-O 121.397 0.618 . . . . 0.0 110.437 179.702 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 87' ' ' GLU . . . . . 0.675 ' HA ' ' HG2' ' A' ' 90' ' ' ARG . 0.4 OUTLIER -71.32 -27.28 63.28 Favored 'General case' 0 C--N 1.317 -0.844 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.871 -178.136 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.672 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 94.6 t -61.22 -44.17 97.85 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.254 0 N-CA-C 108.701 -0.852 . . . . 0.0 108.701 169.295 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . 0.677 ' HB ' ' HH2' ' A' ' 98' ' ' TRP . 0.3 OUTLIER -66.81 -43.81 82.87 Favored 'General case' 0 C--N 1.316 -0.852 0 CA-C-N 115.582 -0.735 . . . . 0.0 111.375 -179.778 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . 0.675 ' HG2' ' HA ' ' A' ' 87' ' ' GLU . 20.7 ptt180 -59.88 -35.11 74.13 Favored 'General case' 0 C--O 1.222 -0.392 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.707 -176.197 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . 0.672 ' HG ' ' O ' ' A' ' 88' ' ' VAL . 4.6 pp -74.44 -24.77 59.12 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 121.042 0.448 . . . . 0.0 111.102 -171.678 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . 0.501 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 2.5 mtm180 -81.79 -45.24 15.87 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-O 121.568 0.699 . . . . 0.0 109.514 -178.044 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 93' ' ' GLN . . . . . 0.42 HE21 ' HZ3' ' A' ' 98' ' ' TRP . 6.6 pt20 -104.27 -28.06 11.63 Favored 'General case' 0 C--N 1.322 -0.618 0 N-CA-C 113.59 0.959 . . . . 0.0 113.59 -169.696 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 88.35 44.23 5.35 Favored Glycine 0 CA--C 1.507 -0.419 0 C-N-CA 120.625 -0.797 . . . . 0.0 112.136 176.195 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 95' ' ' TRP . . . . . 0.531 ' HZ2' HH11 ' A' ' 90' ' ' ARG . 23.6 m95 66.87 13.63 9.5 Favored 'General case' 0 C--O 1.218 -0.6 0 CA-C-O 121.173 0.511 . . . . 0.0 109.812 178.396 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -65.53 -31.62 80.74 Favored Glycine 0 N--CA 1.451 -0.304 0 CA-C-N 115.588 -0.733 . . . . 0.0 113.132 177.289 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -76.49 -21.52 55.72 Favored 'General case' 0 CA--C 1.515 -0.385 0 CA-C-O 121.152 0.501 . . . . 0.0 110.411 178.508 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 98' ' ' TRP . . . . . 0.677 ' HH2' ' HB ' ' A' ' 89' ' ' THR . 25.1 m-90 -100.26 108.62 53.41 Favored Pre-proline 0 N--CA 1.443 -0.803 0 CA-C-N 115.521 -0.763 . . . . 0.0 109.202 178.42 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . 0.45 ' HD3' ' HA ' ' A' ' 98' ' ' TRP . 52.5 Cg_exo -62.25 -138.46 0.0 OUTLIER 'Trans proline' 0 CA--C 1.535 0.56 0 C-N-CA 123.831 3.021 . . . . 0.0 114.265 -174.026 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 3.4 m -54.11 -26.3 14.6 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.915 -177.882 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 101' ' ' CYS . . . . . 0.461 ' SG ' ' HG2' ' A' ' 38' ' ' GLU . 62.0 m -56.69 -39.64 74.16 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-N 115.75 -0.659 . . . . 0.0 111.525 178.035 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -70.8 -44.24 67.0 Favored 'General case' 0 CA--C 1.519 -0.23 0 CA-C-O 121.008 0.432 . . . . 0.0 110.716 179.871 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -60.68 -44.15 96.85 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.634 179.724 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -66.87 -34.03 76.91 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.712 -0.676 . . . . 0.0 111.049 176.957 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 105' ' ' ALA . . . . . 0.773 ' O ' HG22 ' A' ' 30' ' ' ILE . . . -76.51 -26.77 55.6 Favored 'General case' 0 C--N 1.331 -0.238 0 N-CA-C 111.895 0.332 . . . . 0.0 111.895 -175.285 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 111.62 60.28 0.46 Allowed Glycine 0 CA--C 1.521 0.415 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.234 -175.31 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -70.11 148.61 48.52 Favored 'General case' 0 C--N 1.327 -0.375 0 C-N-CA 122.579 0.351 . . . . 0.0 110.891 -178.94 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 108' ' ' ARG . . . . . 0.434 ' O ' ' HD3' ' A' ' 108' ' ' ARG . 0.0 OUTLIER . . . . . 0 C--O 1.245 0.825 0 CA-C-O 118.559 -0.734 . . . . 0.0 110.318 -177.082 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 91.0 m-20 . . . . . 0 N--CA 1.48 1.061 0 CA-C-O 120.965 0.412 . . . . 0.0 110.437 . . . . . . . . . 0 0 . 1 . 028 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 8.0 p -75.3 -42.87 43.71 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.13 178.635 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 7.4 p -76.44 115.09 17.56 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.893 0 CA-C-O 121.418 0.628 . . . . 0.0 110.69 175.754 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 11.1 t -97.26 148.75 5.37 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.14 -179.396 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . 0.457 ' HA ' ' HD3' ' A' ' 6' ' ' PRO . 1.2 p -82.09 113.75 45.73 Favored Pre-proline 0 C--N 1.319 -0.729 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.641 178.948 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.457 ' HD3' ' HA ' ' A' ' 5' ' ' THR . 3.4 Cg_exo -75.78 170.23 20.6 Favored 'Trans proline' 0 N--CA 1.456 -0.735 0 C-N-CA 122.97 2.447 . . . . 0.0 112.004 -177.519 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -96.54 35.72 1.46 Allowed 'General case' 0 C--N 1.31 -1.147 0 CA-C-N 114.623 -1.171 . . . . 0.0 110.997 -177.672 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 31.3 t-80 -76.27 -7.42 54.87 Favored 'General case' 0 C--N 1.315 -0.91 0 CA-C-N 114.854 -1.066 . . . . 0.0 108.345 169.733 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 12.8 pt-20 -67.85 157.4 34.94 Favored 'General case' 0 N--CA 1.45 -0.433 0 CA-C-N 114.745 -1.116 . . . . 0.0 110.409 177.52 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -144.36 78.55 1.58 Allowed 'General case' 0 C--N 1.315 -0.906 0 CA-C-N 115.472 -0.785 . . . . 0.0 110.061 -178.862 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 57.8 t -68.84 -75.12 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 CA-C-N 114.98 -1.009 . . . . 0.0 109.48 177.125 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 5.1 p 25.15 82.49 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.343 0.325 0 C-N-CA 125.078 1.351 . . . . 0.0 113.554 172.489 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 54.9 mtm180 -87.84 100.72 13.08 Favored 'General case' 0 C--N 1.305 -1.355 0 CA-C-N 114.202 -1.363 . . . . 0.0 111.377 -177.817 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.433 HG12 ' N ' ' A' ' 15' ' ' GLY . 7.0 t -133.32 166.41 29.34 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.144 0 CA-C-N 113.915 -1.493 . . . . 0.0 108.636 178.82 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . 0.433 ' N ' HG12 ' A' ' 14' ' ' VAL . . . 141.7 68.41 0.03 OUTLIER Glycine 0 N--CA 1.439 -1.111 0 CA-C-N 115.598 -0.728 . . . . 0.0 111.94 177.381 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 19.9 m -95.85 -25.47 16.0 Favored 'General case' 0 N--CA 1.442 -0.837 0 CA-C-N 114.992 -0.604 . . . . 0.0 110.945 -177.192 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . 0.42 ' HA ' ' HD3' ' A' ' 18' ' ' PRO . 29.6 mmmt -46.37 114.68 2.74 Favored Pre-proline 0 C--N 1.322 -0.626 0 CA-C-N 114.215 -1.357 . . . . 0.0 112.633 -176.003 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . 0.42 ' HD3' ' HA ' ' A' ' 17' ' ' LYS . 17.1 Cg_exo -70.41 162.78 41.14 Favored 'Trans proline' 0 CA--C 1.509 -0.726 0 C-N-CA 123.668 2.912 . . . . 0.0 112.066 175.039 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -131.4 33.06 2.84 Favored Glycine 0 C--N 1.305 -1.153 0 CA-C-N 114.318 -1.31 . . . . 0.0 111.825 -177.405 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 10.5 m -64.82 -53.24 49.95 Favored 'General case' 0 C--N 1.314 -0.953 0 CA-C-N 114.57 -0.815 . . . . 0.0 109.744 177.591 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . 0.54 ' O ' ' HD3' ' A' ' 23' ' ' PRO . 33.5 mt-10 -144.65 107.43 4.46 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 108.57 -0.9 . . . . 0.0 108.57 173.387 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 7.4 p -92.24 110.58 45.42 Favored Pre-proline 0 C--N 1.317 -0.823 0 CA-C-O 121.569 0.7 . . . . 0.0 111.465 -175.717 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.54 ' HD3' ' O ' ' A' ' 21' ' ' GLU . 27.3 Cg_exo -62.95 155.01 63.06 Favored 'Trans proline' 0 N--CA 1.46 -0.458 0 C-N-CA 123.52 2.813 . . . . 0.0 111.789 175.824 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 8.0 Cg_endo -52.78 140.91 56.29 Favored 'Trans proline' 0 N--CA 1.451 -1.012 0 C-N-CA 122.302 2.001 . . . . 0.0 109.865 172.091 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.97 HG11 HG21 ' A' ' 83' ' ' ILE . 97.2 t -79.83 124.57 38.11 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.243 0 CA-C-O 122.143 0.973 . . . . 0.0 113.254 -161.896 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 48.4 mm -81.24 -25.84 10.43 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 CA-C-N 113.89 -1.505 . . . . 0.0 110.873 -179.372 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.514 ' O ' HG12 ' A' ' 30' ' ' ILE . 7.0 m-20 -84.8 1.3 47.43 Favored 'General case' 0 CA--C 1.504 -0.803 0 CA-C-O 121.791 0.805 . . . . 0.0 108.849 -177.235 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . 0.599 ' HA2' ' HB2' ' A' ' 31' ' ' TRP . . . -66.25 -5.05 25.93 Favored Glycine 0 N--CA 1.44 -1.092 0 CA-C-N 114.488 -1.233 . . . . 0.0 110.581 176.721 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 22.3 m -77.2 -40.44 45.15 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 120.989 0.423 . . . . 0.0 109.98 174.053 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.514 HG12 ' O ' ' A' ' 27' ' ' ASP . 0.6 OUTLIER -65.25 -38.92 83.82 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.513 0 N-CA-C 107.038 -1.467 . . . . 0.0 107.038 174.108 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 31' ' ' TRP . . . . . 0.684 ' CD1' HG13 ' A' ' 83' ' ' ILE . 31.7 m95 -72.1 -36.49 69.48 Favored 'General case' 0 N--CA 1.438 -1.075 0 CA-C-N 113.598 -1.637 . . . . 0.0 111.031 -175.998 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 6.6 t70 -72.63 -34.65 67.46 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.016 178.203 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -67.3 -37.01 82.67 Favored 'General case' 0 N--CA 1.445 -0.685 0 C-N-CA 120.64 -0.424 . . . . 0.0 109.923 177.119 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . 0.509 HG13 ' O ' ' A' ' 30' ' ' ILE . 74.2 mt -67.66 -46.43 82.79 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.171 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.523 174.491 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -58.91 -34.22 71.45 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 121.215 0.531 . . . . 0.0 110.516 177.563 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . 0.528 ' HA2' ' N ' ' A' ' 41' ' ' GLY . . . -78.83 -7.03 88.51 Favored Glycine 0 N--CA 1.45 -0.418 0 CA-C-N 115.617 -0.72 . . . . 0.0 111.719 178.616 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 46.0 t -94.81 -58.1 2.27 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-O 120.775 0.321 . . . . 0.0 110.607 -179.221 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . 0.436 ' HG3' ' SG ' ' A' ' 101' ' ' CYS . 40.2 mt-10 -89.29 -25.61 21.58 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.379 -0.373 . . . . 0.0 111.345 -173.52 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -107.53 -12.95 15.18 Favored 'General case' 0 C--N 1.324 -0.527 0 C-N-CA 120.444 -0.502 . . . . 0.0 111.869 -179.011 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 78.72 13.57 83.01 Favored Glycine 0 CA--C 1.503 -0.665 0 N-CA-C 109.789 -1.324 . . . . 0.0 109.789 -177.371 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . 0.528 ' N ' ' HA2' ' A' ' 36' ' ' GLY . . . 78.87 61.52 2.39 Favored Glycine 0 N--CA 1.435 -1.391 0 CA-C-N 114.069 -1.066 . . . . 0.0 111.855 -177.053 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . 0.599 HD22 ' HB ' ' A' ' 45' ' ' ILE . 4.1 t30 -145.66 96.98 2.9 Favored 'General case' 0 N--CA 1.45 -0.449 0 N-CA-C 109.044 -0.724 . . . . 0.0 109.044 -177.968 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 43' ' ' TRP . . . . . 0.867 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 16.1 m95 -82.72 -1.42 51.34 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-O 121.554 0.692 . . . . 0.0 111.156 -170.412 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -113.62 9.55 17.89 Favored 'General case' 0 C--N 1.314 -0.967 0 CA-C-N 115.039 -0.982 . . . . 0.0 111.095 178.713 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.952 HG22 ' HA2' ' A' ' 53' ' ' GLY . 9.5 tt -72.65 143.22 14.2 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.68 0 CA-C-O 121.177 0.513 . . . . 0.0 110.654 -175.603 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 15.3 t-20 -150.8 97.05 2.43 Favored 'General case' 0 C--N 1.311 -1.1 0 N-CA-C 109.399 -0.593 . . . . 0.0 109.399 177.732 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 11.1 p -74.89 -16.67 60.66 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 115.798 -0.637 . . . . 0.0 111.006 -177.7 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 101.4 13.03 34.09 Favored Glycine 0 N--CA 1.445 -0.705 0 CA-C-N 115.818 -0.628 . . . . 0.0 111.612 178.059 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 31.7 p-10 -91.65 3.01 56.07 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.801 0.334 . . . . 0.0 111.4 -176.381 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 94.9 -2.54 66.55 Favored Glycine 0 N--CA 1.449 -0.494 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.265 179.909 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 51' ' ' TYR . . . . . 0.571 ' HA ' ' HA ' ' A' ' 58' ' ' ASP . 0.4 OUTLIER -108.59 162.6 13.99 Favored 'General case' 0 CA--C 1.515 -0.374 0 N-CA-C 108.464 -0.939 . . . . 0.0 108.464 176.874 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 52' ' ' TYR . . . . . 0.627 ' O ' ' HA ' ' A' ' 56' ' ' GLN . 61.6 m-85 -123.32 169.73 11.03 Favored 'General case' 0 C--N 1.315 -0.927 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.617 -170.874 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.952 ' HA2' HG22 ' A' ' 45' ' ' ILE . . . -64.58 157.89 44.24 Favored Glycine 0 N--CA 1.445 -0.765 0 CA-C-N 115.585 -0.734 . . . . 0.0 114.105 -169.913 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.669 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 107.1 -111.73 3.57 Favored Glycine 0 N--CA 1.442 -0.964 0 N-CA-C 111.653 -0.579 . . . . 0.0 111.653 179.3 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 3.1 m -93.42 12.9 2.75 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 CA-C-O 121.906 0.86 . . . . 0.0 110.385 176.69 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 56' ' ' GLN . . . . . 0.627 ' HA ' ' O ' ' A' ' 52' ' ' TYR . 4.1 tt0 60.8 49.85 5.83 Favored 'General case' 0 C--N 1.317 -0.845 0 CA-C-N 113.673 -1.603 . . . . 0.0 112.178 172.652 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . 0.416 ' HZ ' ' CA ' ' A' ' 86' ' ' ALA . 27.3 m-85 -60.97 133.93 56.59 Favored 'General case' 0 CA--C 1.506 -0.717 0 CA-C-N 115.35 -0.841 . . . . 0.0 111.547 169.626 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.571 ' HA ' ' HA ' ' A' ' 51' ' ' TYR . 6.2 p-10 -74.01 156.13 37.85 Favored 'General case' 0 C--N 1.315 -0.932 0 C-N-CA 119.509 -0.877 . . . . 0.0 108.831 163.928 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 21.0 tp60 -52.52 -39.06 60.93 Favored 'General case' 0 N--CA 1.443 -0.778 0 CA-C-O 121.098 0.475 . . . . 0.0 111.039 -179.082 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -69.7 -50.95 27.62 Favored Glycine 0 C--O 1.222 -0.599 0 CA-C-N 115.127 -0.942 . . . . 0.0 113.237 -174.005 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 95.6 m -64.8 -35.24 80.46 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 121.201 0.524 . . . . 0.0 110.771 179.369 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 62' ' ' TRP . . . . . 0.698 ' CZ3' ' HA ' ' A' ' 82' ' ' GLN . 59.8 t-105 -60.99 -49.04 79.07 Favored 'General case' 0 N--CA 1.443 -0.779 0 CA-C-O 121.579 0.704 . . . . 0.0 109.258 174.768 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . 0.469 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 40.8 tt0 -67.24 -33.96 76.44 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-N 114.858 -1.064 . . . . 0.0 110.858 -179.017 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -63.36 -42.65 98.89 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.815 -0.63 . . . . 0.0 112.057 -175.341 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . 0.634 ' HB2' HG13 ' A' ' 85' ' ' VAL . 37.1 m-80 -83.43 -10.41 58.41 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.826 0.346 . . . . 0.0 110.409 176.209 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . 0.459 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 94.09 51.44 2.08 Favored Glycine 0 C--N 1.332 0.35 0 C-N-CA 121.007 -0.616 . . . . 0.0 112.839 173.831 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.596 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -79.73 -23.96 61.19 Favored Glycine 0 N--CA 1.439 -1.116 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.821 -176.49 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.824 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 6.9 mp -59.47 -26.8 65.54 Favored 'General case' 0 C--N 1.323 -0.545 0 N-CA-C 112.553 0.575 . . . . 0.0 112.553 -172.748 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . 0.459 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 3.4 ptm180 -65.5 -33.15 75.27 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 121.36 0.6 . . . . 0.0 109.877 177.335 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 70' ' ' TYR . . . . . 1.067 ' HB3' ' HG2' ' A' ' 81' ' ' GLU . 74.1 m-85 -81.26 -34.79 31.83 Favored 'General case' 0 N--CA 1.439 -0.98 0 N-CA-C 107.956 -1.127 . . . . 0.0 107.956 179.389 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.681 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 164.63 126.12 0.02 OUTLIER Pre-proline 0 N--CA 1.448 -0.552 0 CA-C-N 112.63 -2.077 . . . . 0.0 106.989 -178.766 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 72' ' ' PRO . . . . . 0.824 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 26.5 Cg_exo -55.17 -5.88 0.66 Allowed 'Trans proline' 0 C--N 1.332 -0.3 0 C-N-CA 123.216 2.61 . . . . 0.0 114.076 -177.808 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 73' ' ' ARG . . . . . 0.423 HH11 ' HD2' ' A' ' 73' ' ' ARG . 9.9 ptm180 -146.97 138.37 24.14 Favored 'General case' 0 C--N 1.318 -0.795 0 CA-C-O 121.459 0.647 . . . . 0.0 110.402 175.776 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . 0.407 ' HB2' ' CE3' ' A' ' 62' ' ' TRP . . . -60.12 -20.68 59.46 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 114.839 -1.073 . . . . 0.0 112.6 -178.889 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . 0.615 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 0.0 OUTLIER -76.83 -22.17 53.97 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 121.262 0.553 . . . . 0.0 110.602 -178.536 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 57.9 tp -92.66 -33.36 14.4 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.643 -0.708 . . . . 0.0 110.022 177.766 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . 0.715 ' HB1' ' HB3' ' A' ' 81' ' ' GLU . . . -77.8 154.84 31.51 Favored 'General case' 0 N--CA 1.447 -0.581 0 CA-C-N 115.48 -0.782 . . . . 0.0 110.66 178.657 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 72.9 p -96.41 -174.39 3.04 Favored 'General case' 0 C--N 1.314 -0.955 0 CA-C-N 115.214 -0.903 . . . . 0.0 110.84 -176.65 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . 0.867 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 0.1 OUTLIER -50.9 -54.75 21.35 Favored 'General case' 0 C--O 1.216 -0.668 0 CA-C-O 120.699 0.285 . . . . 0.0 110.376 -179.093 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -60.35 -38.22 83.14 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-O 121.261 0.553 . . . . 0.0 111.289 -174.086 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 81' ' ' GLU . . . . . 1.067 ' HG2' ' HB3' ' A' ' 70' ' ' TYR . 2.9 mt-10 -72.32 -52.99 13.7 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 115.505 -0.771 . . . . 0.0 112.297 -179.98 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 82' ' ' GLN . . . . . 0.698 ' HA ' ' CZ3' ' A' ' 62' ' ' TRP . 3.7 tt0 -63.78 -34.47 77.97 Favored 'General case' 0 C--N 1.317 -0.841 0 CA-C-N 115.28 -0.873 . . . . 0.0 109.621 -178.441 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.97 HG21 HG11 ' A' ' 25' ' ' VAL . 0.5 OUTLIER -70.02 -39.56 77.47 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.235 0 CA-C-N 114.632 -1.167 . . . . 0.0 110.965 177.907 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . 0.427 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -58.98 -36.19 74.46 Favored 'General case' 0 C--O 1.237 0.418 0 CA-C-O 121.587 0.708 . . . . 0.0 110.321 -178.272 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.634 HG13 ' HB2' ' A' ' 65' ' ' ASN . 44.6 t -67.21 -46.89 83.14 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-N 115.173 -0.921 . . . . 0.0 110.187 176.57 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . 0.416 ' CA ' ' HZ ' ' A' ' 57' ' ' PHE . . . -61.67 -31.92 72.07 Favored 'General case' 0 N--CA 1.451 -0.378 0 CA-C-N 115.465 -0.789 . . . . 0.0 110.641 175.813 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 87' ' ' GLU . . . . . 0.631 ' HA ' ' HG2' ' A' ' 90' ' ' ARG . 21.4 mm-40 -60.53 -44.29 96.22 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.616 -177.809 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.568 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 96.8 t -62.52 -51.78 68.03 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.425 0 C-N-CA 120.431 -0.508 . . . . 0.0 110.553 -179.13 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . 0.56 ' HA ' ' NE ' ' A' ' 92' ' ' ARG . 14.8 t -74.09 -35.08 64.17 Favored 'General case' 0 N--CA 1.439 -0.99 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.505 -175.278 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . 0.631 ' HG2' ' HA ' ' A' ' 87' ' ' GLU . 3.3 ptt180 -62.26 -36.84 83.3 Favored 'General case' 0 N--CA 1.471 0.595 0 O-C-N 122.252 -0.28 . . . . 0.0 111.165 -178.337 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . 0.6 ' N ' ' HG3' ' A' ' 90' ' ' ARG . 4.5 pp -73.03 -23.75 60.63 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.311 -172.964 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . 0.56 ' NE ' ' HA ' ' A' ' 89' ' ' THR . 4.4 mtm180 -82.08 -43.09 18.31 Favored 'General case' 0 CA--C 1.51 -0.581 0 CA-C-O 121.797 0.808 . . . . 0.0 109.652 -178.274 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 93' ' ' GLN . . . . . 0.424 ' OE1' ' HB2' ' A' ' 97' ' ' ALA . 19.0 pt20 -99.98 -27.35 13.62 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 114.764 -1.107 . . . . 0.0 113.111 -170.485 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 84.14 47.75 5.39 Favored Glycine 0 CA--C 1.502 -0.772 0 C-N-CA 120.698 -0.763 . . . . 0.0 111.616 174.795 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 95' ' ' TRP . . . . . 0.514 ' HA ' ' HE3' ' A' ' 98' ' ' TRP . 2.9 m95 63.27 17.4 10.21 Favored 'General case' 0 C--O 1.219 -0.512 0 C-N-CA 123.148 0.579 . . . . 0.0 109.647 177.71 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -66.79 -36.64 91.47 Favored Glycine 0 C--N 1.333 0.372 0 CA-C-N 115.896 -0.593 . . . . 0.0 112.253 179.586 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . 0.424 ' HB2' ' OE1' ' A' ' 93' ' ' GLN . . . -69.94 -23.45 63.2 Favored 'General case' 0 CA--C 1.517 -0.296 0 CA-C-O 120.709 0.29 . . . . 0.0 110.577 177.768 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 98' ' ' TRP . . . . . 0.514 ' HE3' ' HA ' ' A' ' 95' ' ' TRP . 25.1 m-90 -98.94 108.11 47.4 Favored Pre-proline 0 N--CA 1.447 -0.6 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 179.095 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . 0.469 ' HD3' ' HA ' ' A' ' 98' ' ' TRP . 43.6 Cg_exo -63.36 -136.13 0.0 OUTLIER 'Trans proline' 0 CA--C 1.537 0.665 0 C-N-CA 123.671 2.914 . . . . 0.0 114.083 -174.275 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 44.3 t -55.19 -24.77 15.61 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.259 0 CA-C-O 121.241 0.543 . . . . 0.0 111.49 -176.106 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 101' ' ' CYS . . . . . 0.436 ' SG ' ' HG3' ' A' ' 38' ' ' GLU . 61.0 m -62.84 -34.81 78.12 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 116.064 -0.516 . . . . 0.0 111.502 -179.217 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -70.34 -41.05 73.71 Favored 'General case' 0 C--N 1.333 -0.136 0 CA-C-O 121.014 0.435 . . . . 0.0 110.775 177.975 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -64.72 -34.74 79.02 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.002 -0.544 . . . . 0.0 110.272 178.235 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 55.7 mtp180 -73.87 -19.08 60.83 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.505 -0.77 . . . . 0.0 111.864 176.468 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 105' ' ' ALA . . . . . . . . . . . . . . . -95.76 -21.69 17.99 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 116.094 -0.503 . . . . 0.0 112.096 -172.951 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 99.93 67.13 0.84 Allowed Glycine 0 N--CA 1.454 -0.161 0 C-N-CA 120.777 -0.725 . . . . 0.0 111.88 -177.03 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -64.67 152.02 43.42 Favored 'General case' 0 N--CA 1.45 -0.468 0 C-N-CA 122.67 0.388 . . . . 0.0 111.022 -174.147 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 18.0 mmt180 . . . . . 0 C--O 1.241 0.656 0 O-C-N 124.019 0.824 . . . . 0.0 111.416 177.948 . . . . . . . . 0 0 . 1 . 029 nuclear nobuild full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 89.8 m-20 . . . . . 0 N--CA 1.479 0.989 0 CA-C-O 120.73 0.3 . . . . 0.0 110.301 . . . . . . . . . 0 0 . 1 . 029 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 47.8 t -98.8 -34.92 4.66 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 CA-C-O 121.283 0.563 . . . . 0.0 110.318 179.475 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 39.3 t -83.54 134.12 27.64 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.757 0 CA-C-N 115.563 -0.744 . . . . 0.0 110.976 -179.099 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 9.3 t -87.3 138.59 18.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 N-CA-C 109.382 -0.599 . . . . 0.0 109.382 175.838 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 22.1 p -129.73 105.98 17.02 Favored Pre-proline 0 C--N 1.314 -0.957 0 CA-C-N 115.971 -0.559 . . . . 0.0 111.4 -174.58 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 3.4 Cg_exo -80.98 168.41 17.29 Favored 'Trans proline' 0 N--CA 1.452 -0.945 0 C-N-CA 122.805 2.337 . . . . 0.0 111.644 178.279 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -141.09 -171.98 3.39 Favored 'General case' 0 C--N 1.307 -1.26 0 CA-C-N 114.769 -1.105 . . . . 0.0 110.457 -178.714 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 26.4 t-80 69.33 6.3 5.61 Favored 'General case' 0 C--O 1.232 0.167 0 O-C-N 124.068 0.855 . . . . 0.0 109.481 -173.23 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -50.45 135.03 22.99 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.016 -0.993 . . . . 0.0 109.974 174.819 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -123.7 70.88 1.07 Allowed 'General case' 0 C--N 1.318 -0.778 0 CA-C-O 121.674 0.749 . . . . 0.0 110.911 -171.63 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.476 ' O ' ' HG3' ' A' ' 13' ' ' ARG . 99.5 t -65.18 -48.33 84.03 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.015 0 CA-C-N 114.314 -1.312 . . . . 0.0 109.809 174.955 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 3.6 p -31.34 95.34 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.436 -1.144 0 C-N-CA 125.358 1.463 . . . . 0.0 113.376 170.98 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . 0.476 ' HG3' ' O ' ' A' ' 11' ' ' VAL . 22.7 mtm180 -127.33 114.45 17.6 Favored 'General case' 0 C--N 1.302 -1.471 0 CA-C-N 113.543 -1.662 . . . . 0.0 110.304 176.487 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.7 t -98.28 160.37 3.14 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.872 0 CA-C-N 115.492 -0.776 . . . . 0.0 109.634 179.341 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 145.02 97.01 0.21 Allowed Glycine 0 N--CA 1.439 -1.122 0 CA-C-N 115.124 -0.943 . . . . 0.0 111.924 -179.561 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 24.1 m -86.23 -33.72 20.65 Favored 'General case' 0 N--CA 1.446 -0.672 0 CA-C-O 120.655 0.264 . . . . 0.0 111.496 -176.924 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . 0.46 ' HE3' ' HB2' ' A' ' 17' ' ' LYS . 0.0 OUTLIER 42.66 75.64 0.61 Allowed Pre-proline 0 C--N 1.321 -0.673 0 CA-C-N 115.406 -0.815 . . . . 0.0 111.491 -175.304 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 7.0 Cg_exo -74.62 165.88 30.62 Favored 'Trans proline' 0 N--CA 1.458 -0.606 0 C-N-CA 122.75 2.3 . . . . 0.0 112.034 -179.543 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -99.3 23.43 36.33 Favored Glycine 0 C--N 1.309 -0.937 0 CA-C-N 114.598 -1.183 . . . . 0.0 112.439 -176.753 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 2.6 m -70.05 -44.25 69.57 Favored 'General case' 0 C--N 1.307 -1.246 0 CA-C-O 122.164 0.983 . . . . 0.0 109.264 177.122 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . 0.404 ' O ' ' HD3' ' A' ' 23' ' ' PRO . 11.9 pt-20 -130.56 150.84 51.57 Favored 'General case' 0 N--CA 1.42 -1.938 0 N-CA-C 106.789 -1.56 . . . . 0.0 106.789 178.511 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 30.1 t -72.86 114.99 35.62 Favored Pre-proline 0 C--N 1.3 -1.56 0 CA-C-N 115.947 -0.57 . . . . 0.0 110.506 -177.414 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.404 ' HD3' ' O ' ' A' ' 21' ' ' GLU . 47.9 Cg_exo -55.99 152.45 36.68 Favored 'Trans proline' 0 C--N 1.346 0.417 0 C-N-CA 122.919 2.412 . . . . 0.0 111.264 175.921 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 9.9 Cg_endo -54.07 138.49 70.82 Favored 'Trans proline' 0 N--CA 1.452 -0.946 0 C-N-CA 122.64 2.226 . . . . 0.0 111.439 -178.914 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.417 HG12 ' H ' ' A' ' 27' ' ' ASP . 20.9 t -103.4 131.37 52.03 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.243 0 CA-C-N 114.723 -1.126 . . . . 0.0 109.603 -174.106 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 45.1 mm -65.34 -26.01 38.47 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 CA-C-N 115.601 -0.727 . . . . 0.0 110.918 -174.506 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.42 ' O ' HG12 ' A' ' 30' ' ' ILE . 14.2 m-20 -89.97 -12.84 37.56 Favored 'General case' 0 CA--C 1.498 -1.049 0 CA-C-O 121.729 0.776 . . . . 0.0 109.598 179.27 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -63.09 -16.52 57.75 Favored Glycine 0 C--N 1.309 -0.963 0 CA-C-N 114.321 -1.309 . . . . 0.0 111.247 -177.047 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 15.5 m -77.66 -39.84 43.67 Favored 'General case' 0 C--N 1.315 -0.909 0 CA-C-O 121.811 0.815 . . . . 0.0 109.359 178.397 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.571 ' O ' HG13 ' A' ' 34' ' ' ILE . 0.5 OUTLIER -69.76 -39.73 78.29 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.706 0 CA-C-N 114.111 -1.404 . . . . 0.0 107.497 179.194 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 31' ' ' TRP . . . . . 0.519 ' CE3' HG11 ' A' ' 55' ' ' VAL . 18.1 m95 -68.35 -37.42 80.48 Favored 'General case' 0 C--N 1.317 -0.828 0 CA-C-N 114.195 -1.366 . . . . 0.0 110.809 -177.017 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 7.7 t70 -76.38 -32.32 58.52 Favored 'General case' 0 N--CA 1.447 -0.621 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.74 179.335 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . 0.484 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -71.05 -37.19 72.52 Favored 'General case' 0 N--CA 1.448 -0.527 0 C-N-CA 120.684 -0.406 . . . . 0.0 110.691 176.48 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . 0.571 HG13 ' O ' ' A' ' 30' ' ' ILE . 82.3 mt -67.16 -41.81 87.37 Favored 'Isoleucine or valine' 0 C--O 1.234 0.262 0 CA-C-O 121.212 0.53 . . . . 0.0 109.892 175.032 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . 0.651 ' HA ' ' O ' ' A' ' 54' ' ' GLY . . . -57.44 -37.91 73.58 Favored 'General case' 0 CA--C 1.515 -0.382 0 CA-C-N 115.511 -0.768 . . . . 0.0 110.317 175.997 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -78.38 -3.91 86.47 Favored Glycine 0 N--CA 1.45 -0.374 0 CA-C-N 115.246 -0.888 . . . . 0.0 111.638 179.883 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 41.0 t -97.51 -60.14 1.63 Allowed 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 115.689 -0.256 . . . . 0.0 111.055 -178.415 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . 0.637 ' HG3' ' SG ' ' A' ' 101' ' ' CYS . 39.2 mt-10 -89.28 -33.78 16.83 Favored 'General case' 0 CA--C 1.516 -0.356 0 CA-C-O 120.715 0.293 . . . . 0.0 111.388 -173.418 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -95.42 -14.06 24.11 Favored 'General case' 0 C--N 1.324 -0.534 0 C-N-CA 120.676 -0.409 . . . . 0.0 111.693 -176.819 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 77.97 20.22 73.63 Favored Glycine 0 N--CA 1.445 -0.745 0 N-CA-C 109.754 -1.338 . . . . 0.0 109.754 -175.799 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 71.07 56.47 7.0 Favored Glycine 0 N--CA 1.437 -1.28 0 CA-C-N 114.185 -1.008 . . . . 0.0 112.036 -176.412 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . 0.607 HD22 ' HB ' ' A' ' 45' ' ' ILE . 3.7 t30 -141.23 88.03 2.13 Favored 'General case' 0 N--CA 1.447 -0.597 0 N-CA-C 108.89 -0.782 . . . . 0.0 108.89 -177.592 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 43' ' ' TRP . . . . . 0.735 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 22.1 m95 -70.37 -13.03 61.97 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.515 -0.766 . . . . 0.0 111.176 -173.31 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -102.94 14.05 32.87 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 115.959 -0.564 . . . . 0.0 111.543 -177.624 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.819 HG22 ' HA2' ' A' ' 53' ' ' GLY . 3.6 tt -82.82 144.29 10.44 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.598 0 CA-C-O 120.915 0.388 . . . . 0.0 110.171 -177.955 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 44.5 t-20 -158.24 90.51 1.04 Allowed 'General case' 0 C--N 1.314 -0.95 0 N-CA-C 109.67 -0.493 . . . . 0.0 109.67 178.708 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 35.2 p -76.8 -24.05 52.81 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 115.622 -0.717 . . . . 0.0 110.92 -179.849 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 99.36 23.94 10.72 Favored Glycine 0 N--CA 1.442 -0.921 0 CA-C-N 115.458 -0.792 . . . . 0.0 111.377 -179.346 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 35.2 p30 -85.4 5.41 31.04 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.986 0.422 . . . . 0.0 111.559 179.656 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . 0.432 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 96.28 -10.63 67.42 Favored Glycine 0 N--CA 1.446 -0.653 0 N-CA-C 111.625 -0.59 . . . . 0.0 111.625 179.153 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 51' ' ' TYR . . . . . 0.6 ' HA ' ' HA ' ' A' ' 58' ' ' ASP . 0.2 OUTLIER -117.84 156.2 28.8 Favored 'General case' 0 CA--C 1.505 -0.75 0 N-CA-C 106.593 -1.632 . . . . 0.0 106.593 179.393 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 52' ' ' TYR . . . . . 0.651 ' HB2' ' HB3' ' A' ' 74' ' ' ALA . 46.2 m-85 -120.35 165.44 14.88 Favored 'General case' 0 C--N 1.307 -1.258 0 C-N-CA 119.69 -0.804 . . . . 0.0 112.466 -170.415 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.819 ' HA2' HG22 ' A' ' 45' ' ' ILE . . . -57.93 157.81 16.14 Favored Glycine 0 CA--C 1.502 -0.752 0 CA-C-N 114.854 -1.067 . . . . 0.0 114.41 -169.901 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.667 ' N ' ' HA ' ' A' ' 43' ' ' TRP . . . 99.52 -109.23 3.7 Favored Glycine 0 N--CA 1.436 -1.314 0 N-CA-C 111.246 -0.741 . . . . 0.0 111.246 -178.693 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.53 HG12 ' NE1' ' A' ' 98' ' ' TRP . 3.2 t -84.31 -2.11 6.88 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.67 0 CA-C-O 121.791 0.805 . . . . 0.0 110.025 -177.151 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 56' ' ' GLN . . . . . 0.802 ' HA ' HE21 ' A' ' 56' ' ' GLN . 0.0 OUTLIER 57.97 50.51 10.17 Favored 'General case' 0 N--CA 1.461 0.088 0 CA-C-N 114.141 -1.391 . . . . 0.0 112.833 166.598 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . 0.416 ' CE1' ' HB2' ' A' ' 86' ' ' ALA . 10.3 p90 -117.34 162.38 18.01 Favored 'General case' 0 C--N 1.324 -0.511 0 C-N-CA 120.443 -0.503 . . . . 0.0 111.071 175.166 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.6 ' HA ' ' HA ' ' A' ' 51' ' ' TYR . 5.0 p-10 -77.01 163.19 26.92 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 113.667 0.988 . . . . 0.0 113.667 -163.733 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.824 ' HA ' HE21 ' A' ' 59' ' ' GLN . 0.0 OUTLIER -60.57 -40.45 91.71 Favored 'General case' 0 N--CA 1.446 -0.653 0 CA-C-N 113.714 -1.585 . . . . 0.0 111.883 -179.934 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -65.41 -45.2 91.45 Favored Glycine 0 C--N 1.321 -0.286 0 C-N-CA 121.077 -0.582 . . . . 0.0 111.953 -176.952 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . 0.555 ' CG2' HG21 ' A' ' 89' ' ' THR . 95.0 m -66.61 -43.98 83.31 Favored 'General case' 0 C--N 1.32 -0.701 0 C-N-CA 122.558 0.343 . . . . 0.0 111.077 176.524 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 62' ' ' TRP . . . . . . . . . . . . . 50.3 t-105 -57.63 -47.3 82.6 Favored 'General case' 0 N--CA 1.45 -0.426 0 CA-C-O 121.62 0.724 . . . . 0.0 109.876 176.539 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . 0.447 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 29.2 tt0 -67.31 -33.35 75.09 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 115.09 -0.959 . . . . 0.0 110.614 -178.336 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -66.54 -42.87 86.51 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.76 -0.655 . . . . 0.0 110.745 -176.806 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . 0.486 ' HB2' HG13 ' A' ' 85' ' ' VAL . 7.2 m120 -75.22 -13.97 60.49 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 121.041 0.448 . . . . 0.0 110.387 176.655 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . 91.98 46.64 3.57 Favored Glycine 0 N--CA 1.448 -0.533 0 CA-C-N 115.675 -0.693 . . . . 0.0 111.855 176.114 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.478 ' O ' ' HB2' ' A' ' 70' ' ' TYR . . . -79.52 -21.81 65.97 Favored Glycine 0 N--CA 1.439 -1.142 0 C-N-CA 120.882 -0.675 . . . . 0.0 112.835 -172.648 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.858 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 7.4 mp -58.98 -29.93 67.57 Favored 'General case' 0 C--N 1.319 -0.73 0 N-CA-C 112.764 0.653 . . . . 0.0 112.764 -173.191 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 12.3 ptm180 -66.02 -29.36 69.72 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-O 121.491 0.662 . . . . 0.0 110.105 176.324 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 70' ' ' TYR . . . . . 0.81 ' HB3' ' HG2' ' A' ' 81' ' ' GLU . 86.8 m-85 -78.14 -36.2 48.02 Favored 'General case' 0 N--CA 1.445 -0.717 0 N-CA-C 107.366 -1.346 . . . . 0.0 107.366 175.493 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.656 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 158.26 130.67 0.0 OUTLIER Pre-proline 0 CA--C 1.508 -0.659 0 CA-C-N 112.096 -2.32 . . . . 0.0 106.262 -177.949 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 72' ' ' PRO . . . . . 0.858 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 18.4 Cg_exo -56.89 -4.45 0.92 Allowed 'Trans proline' 0 C--N 1.331 -0.343 0 C-N-CA 122.988 2.459 . . . . 0.0 114.103 -174.655 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 3.4 ptt180 -154.48 143.78 21.29 Favored 'General case' 0 C--N 1.318 -0.766 0 CA-C-O 121.308 0.575 . . . . 0.0 110.759 176.894 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . 0.651 ' HB3' ' HB2' ' A' ' 52' ' ' TYR . . . -57.95 -21.97 46.68 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.635 -175.514 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . 0.66 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 5.0 p-10 -87.57 -9.88 53.14 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 121.357 0.598 . . . . 0.0 110.672 -178.642 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.542 HD23 ' HD2' ' A' ' 72' ' ' PRO . 57.6 tp -99.86 -30.5 12.0 Favored 'General case' 0 C--N 1.319 -0.73 0 N-CA-C 108.846 -0.798 . . . . 0.0 108.846 175.301 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . 0.656 ' HB2' ' HB3' ' A' ' 71' ' ' ALA . . . -79.63 160.71 26.27 Favored 'General case' 0 N--CA 1.442 -0.846 0 CA-C-N 115.041 -0.982 . . . . 0.0 109.789 173.118 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 36.0 p -100.48 -178.92 3.95 Favored 'General case' 0 C--N 1.309 -1.188 0 CA-C-N 115.564 -0.744 . . . . 0.0 110.914 -178.023 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . 0.735 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 5.5 mtt180 -51.17 -53.75 31.8 Favored 'General case' 0 CA--C 1.511 -0.525 0 CA-C-O 120.871 0.367 . . . . 0.0 111.031 -179.516 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 1.9 pm0 -58.36 -39.65 80.1 Favored 'General case' 0 C--N 1.314 -0.938 0 CA-C-N 115.393 -0.821 . . . . 0.0 111.602 -177.888 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 81' ' ' GLU . . . . . 0.81 ' HG2' ' HB3' ' A' ' 70' ' ' TYR . 4.1 mt-10 -70.01 -51.54 31.48 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 121.13 0.49 . . . . 0.0 111.923 178.014 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 82' ' ' GLN . . . . . 0.467 HE21 ' HE3' ' A' ' 43' ' ' TRP . 5.3 tt0 -65.69 -33.9 76.94 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-N 115.377 -0.829 . . . . 0.0 110.591 -176.904 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.445 HG23 ' CD1' ' A' ' 31' ' ' TRP . 24.4 mt -61.56 -45.06 99.44 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.678 0 CA-C-N 115.708 -0.678 . . . . 0.0 109.849 174.073 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . 0.654 ' O ' ' HG3' ' A' ' 87' ' ' GLU . . . -64.54 -41.1 96.56 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.945 0.403 . . . . 0.0 111.59 -176.804 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.486 HG13 ' HB2' ' A' ' 65' ' ' ASN . 50.2 t -69.05 -48.99 66.58 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-O 120.968 0.413 . . . . 0.0 111.127 179.255 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . 0.416 ' HB2' ' CE1' ' A' ' 57' ' ' PHE . . . -65.7 -31.79 72.99 Favored 'General case' 0 N--CA 1.449 -0.484 0 CA-C-N 115.914 -0.584 . . . . 0.0 110.76 -179.893 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 87' ' ' GLU . . . . . 0.654 ' HG3' ' O ' ' A' ' 84' ' ' ALA . 0.1 OUTLIER -70.1 -28.93 65.8 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.228 -177.373 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.56 ' O ' ' HG3' ' A' ' 92' ' ' ARG . 85.9 t -61.11 -48.64 88.11 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.177 0 N-CA-C 109.241 -0.651 . . . . 0.0 109.241 169.703 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . 0.562 ' HB ' ' CH2' ' A' ' 98' ' ' TRP . 0.1 OUTLIER -64.9 -44.18 90.43 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 115.647 -0.706 . . . . 0.0 112.143 -176.257 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . 0.478 ' HB3' ' CZ2' ' A' ' 31' ' ' TRP . 0.0 OUTLIER -61.2 -32.23 71.99 Favored 'General case' 0 CA--C 1.511 -0.535 0 CA-C-O 121.727 0.775 . . . . 0.0 108.974 -177.068 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . 0.42 HD13 HH12 ' A' ' 90' ' ' ARG . 48.4 tp -69.48 -27.42 65.2 Favored 'General case' 0 C--N 1.313 -0.984 0 CA-C-N 113.966 -1.47 . . . . 0.0 111.276 -174.418 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . 0.56 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 4.1 mtm180 -90.59 -48.29 7.17 Favored 'General case' 0 C--N 1.317 -0.805 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.293 -175.832 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 93' ' ' GLN . . . . . 0.474 ' HG3' ' H ' ' A' ' 96' ' ' GLY . 15.3 pt20 -99.07 -27.78 13.68 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-N 114.965 -1.016 . . . . 0.0 113.006 -168.995 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 89.17 41.15 5.92 Favored Glycine 0 CA--C 1.501 -0.842 0 C-N-CA 119.971 -1.109 . . . . 0.0 110.796 178.926 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 95' ' ' TRP . . . . . 0.525 ' HA ' ' HE3' ' A' ' 98' ' ' TRP . 6.1 m95 67.16 19.8 10.33 Favored 'General case' 0 C--O 1.216 -0.674 0 CA-C-N 114.893 -0.654 . . . . 0.0 109.288 176.455 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.474 ' H ' ' HG3' ' A' ' 93' ' ' GLN . . . -64.1 -30.44 77.77 Favored Glycine 0 N--CA 1.452 -0.286 0 CA-C-N 115.465 -0.789 . . . . 0.0 112.886 178.462 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -75.14 -20.68 59.28 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 121.006 0.431 . . . . 0.0 110.142 176.584 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 98' ' ' TRP . . . . . 0.562 ' CH2' ' HB ' ' A' ' 89' ' ' THR . 22.3 m-90 -104.31 111.67 65.24 Favored Pre-proline 0 N--CA 1.446 -0.631 0 CA-C-N 115.72 -0.673 . . . . 0.0 110.335 -177.905 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . 0.412 ' HD3' ' HA ' ' A' ' 98' ' ' TRP . 52.5 Cg_exo -61.48 -140.2 0.0 OUTLIER 'Trans proline' 0 CA--C 1.534 0.487 0 C-N-CA 123.644 2.896 . . . . 0.0 114.444 -175.31 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . 0.477 ' O ' ' HD2' ' A' ' 104' ' ' ARG . 12.6 m -54.7 -29.52 21.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.654 -0.703 . . . . 0.0 111.26 -178.363 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 101' ' ' CYS . . . . . 0.637 ' SG ' ' HG3' ' A' ' 38' ' ' GLU . 59.3 m -56.34 -35.56 67.76 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-N 115.205 -0.907 . . . . 0.0 111.706 -179.591 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -69.62 -42.56 74.19 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 121.072 0.463 . . . . 0.0 110.51 179.117 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -66.76 -37.72 85.18 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.656 179.42 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 104' ' ' ARG . . . . . 0.477 ' HD2' ' O ' ' A' ' 100' ' ' VAL . 0.0 OUTLIER -72.6 -20.54 61.28 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.804 -0.635 . . . . 0.0 111.009 178.373 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 105' ' ' ALA . . . . . 0.562 ' HB1' ' HA ' ' A' ' 30' ' ' ILE . . . -91.38 -20.91 21.31 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 115.821 -0.627 . . . . 0.0 111.694 -177.392 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 103.82 54.46 0.81 Allowed Glycine 0 CA--C 1.518 0.244 0 C-N-CA 121.005 -0.617 . . . . 0.0 112.188 179.987 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -67.74 151.25 47.54 Favored 'General case' 0 N--CA 1.449 -0.522 0 C-N-CA 122.385 0.274 . . . . 0.0 111.691 -175.44 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 108' ' ' ARG . . . . . . . . . . . . . 14.5 mtt180 . . . . . 0 C--O 1.252 1.2 0 O-C-N 124.211 0.944 . . . . 0.0 111.673 174.85 . . . . . . . . 0 0 . 1 . 030 nuclear nobuild full ' A' A ' 1' ' ' ASN . . . . . . . . . . . . . 13.3 m120 . . . . . 0 N--CA 1.479 0.988 0 CA-C-O 121.266 0.555 . . . . 0.0 110.311 . . . . . . . . . 0 0 . 1 . 030 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 9.9 p -99.92 -16.19 7.21 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.815 0 CA-C-N 115.503 -0.771 . . . . 0.0 110.651 -176.275 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 59.2 t -61.06 116.18 1.87 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.376 0 CA-C-N 115.804 -0.635 . . . . 0.0 110.796 178.826 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 11.5 t -70.27 141.15 17.4 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.535 0 N-CA-C 109.354 -0.609 . . . . 0.0 109.354 177.292 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 38.7 p -83.01 124.57 76.48 Favored Pre-proline 0 C--N 1.313 -0.986 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.605 -176.707 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 40.1 Cg_endo -63.41 131.0 30.16 Favored 'Trans proline' 0 N--CA 1.452 -0.924 0 C-N-CA 123.219 2.613 . . . . 0.0 111.722 179.869 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . 0.431 ' C ' ' H ' ' A' ' 9' ' ' GLU . . . -141.14 -170.62 3.1 Favored 'General case' 0 C--N 1.295 -1.772 0 CA-C-N 113.754 -1.567 . . . . 0.0 110.407 -179.554 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 8' ' ' HIS . . . . . . . . . . . . . 45.2 t-80 71.75 -10.45 0.84 Allowed 'General case' 0 C--O 1.231 0.106 0 O-C-N 124.053 0.845 . . . . 0.0 110.125 -172.925 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . 0.431 ' H ' ' C ' ' A' ' 7' ' ' ALA . 12.5 pt-20 -90.76 133.55 35.09 Favored 'General case' 0 N--CA 1.448 -0.554 0 CA-C-N 116.164 -0.471 . . . . 0.0 109.914 -179.703 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -151.06 68.46 0.94 Allowed 'General case' 0 C--N 1.317 -0.836 0 CA-C-O 121.534 0.683 . . . . 0.0 109.43 176.22 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 65.6 t -65.87 -60.03 3.21 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.846 0 CA-C-N 114.758 -1.11 . . . . 0.0 110.395 -178.395 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 7.1 p 26.24 76.12 0.01 OUTLIER 'Isoleucine or valine' 0 C--O 1.238 0.48 0 CA-C-O 123.067 1.413 . . . . 0.0 112.95 179.868 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 28.3 mtp180 -89.19 97.57 11.28 Favored 'General case' 0 C--N 1.304 -1.377 0 CA-C-N 113.691 -1.595 . . . . 0.0 111.282 -176.796 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 3.4 t -117.14 157.3 18.22 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.607 0 CA-C-N 114.861 -1.063 . . . . 0.0 108.311 177.13 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 179.28 81.17 0.06 OUTLIER Glycine 0 N--CA 1.424 -2.149 0 CA-C-N 115.405 -0.816 . . . . 0.0 112.583 -178.228 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 6.7 m -79.9 -44.08 21.05 Favored 'General case' 0 N--CA 1.437 -1.076 0 N-CA-C 109.612 -0.514 . . . . 0.0 109.612 176.181 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER 34.73 64.9 1.71 Allowed Pre-proline 0 N--CA 1.471 0.583 0 CA-C-N 114.2 -1.364 . . . . 0.0 112.104 179.661 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 5.8 Cg_exo -78.88 161.48 27.07 Favored 'Trans proline' 0 N--CA 1.451 -1.002 0 C-N-CA 122.91 2.407 . . . . 0.0 113.193 -173.022 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -125.44 37.38 2.54 Favored Glycine 0 C--N 1.304 -1.196 0 CA-C-N 113.597 -1.638 . . . . 0.0 110.472 176.183 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 3.7 m -58.64 -43.57 89.81 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 114.206 -0.997 . . . . 0.0 110.67 -178.888 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 50.5 mt-10 -138.28 124.1 19.93 Favored 'General case' 0 N--CA 1.448 -0.553 0 N-CA-C 108.947 -0.76 . . . . 0.0 108.947 175.718 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 79.2 t -72.57 130.57 85.53 Favored Pre-proline 0 C--N 1.32 -0.699 0 N-CA-C 109.045 -0.724 . . . . 0.0 109.045 176.385 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.437 ' HA ' ' HD2' ' A' ' 24' ' ' PRO . 59.6 Cg_exo -52.39 127.99 26.01 Favored 'Trans proline' 0 C--N 1.347 0.488 0 C-N-CA 122.506 2.138 . . . . 0.0 111.446 -177.905 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . 0.437 ' HD2' ' HA ' ' A' ' 23' ' ' PRO . 11.2 Cg_endo -55.42 141.29 82.41 Favored 'Trans proline' 0 N--CA 1.452 -0.912 0 C-N-CA 123.755 2.97 . . . . 0.0 113.593 -172.553 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.427 ' HB ' HG21 ' A' ' 83' ' ' ILE . 60.2 t -80.0 138.95 18.97 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.206 0 CA-C-N 113.765 -1.561 . . . . 0.0 107.618 174.687 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 43.8 mm -63.29 -25.57 38.76 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-N 115.749 -0.659 . . . . 0.0 111.771 -169.816 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.535 ' O ' HG12 ' A' ' 30' ' ' ILE . 71.8 m-20 -94.21 -1.01 54.78 Favored 'General case' 0 CA--C 1.505 -0.767 0 CA-C-O 122.075 0.941 . . . . 0.0 108.869 -179.674 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . 0.576 ' HA2' ' HB2' ' A' ' 31' ' ' TRP . . . -71.58 -3.0 52.89 Favored Glycine 0 N--CA 1.439 -1.123 0 CA-C-N 113.899 -1.5 . . . . 0.0 110.219 174.958 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 5.6 m -76.34 -37.57 57.15 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 108.655 -0.868 . . . . 0.0 108.655 174.086 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.535 HG12 ' O ' ' A' ' 27' ' ' ASP . 0.9 OUTLIER -70.15 -37.99 73.47 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 N-CA-C 106.943 -1.503 . . . . 0.0 106.943 175.683 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 31' ' ' TRP . . . . . 0.576 ' HB2' ' HA2' ' A' ' 28' ' ' GLY . 22.8 m95 -70.27 -36.41 74.41 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 114.122 -1.399 . . . . 0.0 110.754 -177.079 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.735 ' HB2' HH21 ' A' ' 79' ' ' ARG . 26.5 t70 -76.8 -36.17 57.13 Favored 'General case' 0 N--CA 1.444 -0.73 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.385 179.643 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . 0.415 ' HB3' ' CB ' ' A' ' 105' ' ' ALA . . . -70.77 -36.66 73.17 Favored 'General case' 0 N--CA 1.448 -0.526 0 CA-C-O 120.768 0.318 . . . . 0.0 110.809 176.944 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . 0.496 HG13 ' O ' ' A' ' 30' ' ' ILE . 59.3 mt -63.97 -43.91 97.78 Favored 'Isoleucine or valine' 0 C--O 1.234 0.267 0 CA-C-O 121.041 0.448 . . . . 0.0 110.006 173.789 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . 0.46 ' HA ' ' O ' ' A' ' 54' ' ' GLY . . . -57.1 -39.39 74.96 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.551 -0.75 . . . . 0.0 110.151 176.584 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -73.0 -17.68 78.73 Favored Glycine 0 N--CA 1.452 -0.283 0 CA-C-N 115.299 -0.864 . . . . 0.0 111.813 -179.528 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 37' ' ' CYS . . . . . . . . . . . . . 11.1 t -88.24 -60.9 1.84 Allowed 'General case' 0 C--N 1.322 -0.63 0 CA-C-O 120.778 0.323 . . . . 0.0 111.404 -178.783 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 38' ' ' GLU . . . . . 0.806 ' HG3' ' HG2' ' A' ' 56' ' ' GLN . 8.8 tp10 -88.06 -33.49 18.3 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-O 121.009 0.433 . . . . 0.0 110.509 -169.513 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -96.85 -7.46 33.45 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.086 -0.506 . . . . 0.0 111.605 -176.468 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 76.2 17.2 80.16 Favored Glycine 0 N--CA 1.448 -0.523 0 N-CA-C 109.987 -1.245 . . . . 0.0 109.987 -177.322 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 72.81 55.29 6.6 Favored Glycine 0 N--CA 1.436 -1.306 0 CA-C-N 114.084 -1.058 . . . . 0.0 112.034 -177.334 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 42' ' ' ASN . . . . . 0.74 ' HB3' ' HB ' ' A' ' 45' ' ' ILE . 2.2 t30 -148.17 105.83 3.68 Favored 'General case' 0 CA--C 1.511 -0.521 0 N-CA-C 108.396 -0.964 . . . . 0.0 108.396 -176.444 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 43' ' ' TRP . . . . . 0.876 ' CZ3' ' HA ' ' A' ' 79' ' ' ARG . 30.4 m95 -83.26 -6.87 59.62 Favored 'General case' 0 C--N 1.309 -1.161 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.551 -173.125 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -111.08 15.03 21.84 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.594 -0.73 . . . . 0.0 111.698 177.792 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.74 ' HB ' ' HB3' ' A' ' 42' ' ' ASN . 11.0 tt -86.73 144.78 8.66 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.624 0 CA-C-O 120.835 0.35 . . . . 0.0 110.868 -176.545 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 45.6 t30 -153.62 111.29 3.52 Favored 'General case' 0 C--N 1.316 -0.89 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 174.178 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 6.9 p -82.4 -15.81 51.33 Favored 'General case' 0 C--N 1.315 -0.896 0 CA-C-N 115.809 -0.632 . . . . 0.0 111.342 -179.679 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 95.92 20.53 25.89 Favored Glycine 0 N--CA 1.446 -0.673 0 N-CA-C 111.174 -0.77 . . . . 0.0 111.174 -177.555 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 8.8 p30 -85.73 -5.29 59.28 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 121.136 0.493 . . . . 0.0 111.221 -176.16 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . 0.454 ' C ' ' HD1' ' A' ' 51' ' ' TYR . . . 96.87 -12.99 65.61 Favored Glycine 0 N--CA 1.448 -0.5 0 CA-C-N 115.945 -0.57 . . . . 0.0 111.832 178.411 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 51' ' ' TYR . . . . . 0.608 ' HA ' ' HA ' ' A' ' 58' ' ' ASP . 0.9 OUTLIER -108.82 137.19 47.14 Favored 'General case' 0 CA--C 1.511 -0.529 0 N-CA-C 107.376 -1.342 . . . . 0.0 107.376 172.609 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 52' ' ' TYR . . . . . 0.697 ' CE1' ' HB2' ' A' ' 59' ' ' GLN . 26.6 m-85 -99.83 156.54 17.06 Favored 'General case' 0 C--N 1.307 -1.243 0 C-N-CA 120.607 -0.437 . . . . 0.0 111.255 -167.892 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -61.16 -176.07 1.74 Allowed Glycine 0 C--N 1.329 0.19 0 N-CA-C 115.387 0.915 . . . . 0.0 115.387 -167.632 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.732 ' CA ' ' HA ' ' A' ' 43' ' ' TRP . . . 86.84 -105.12 3.0 Favored Glycine 0 N--CA 1.446 -0.646 0 N-CA-C 111.318 -0.713 . . . . 0.0 111.318 -174.768 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.516 ' HB ' ' CD1' ' A' ' 57' ' ' PHE . 3.1 t -83.58 -4.47 8.44 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.751 0 N-CA-C 108.53 -0.915 . . . . 0.0 108.53 176.857 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 56' ' ' GLN . . . . . 0.806 ' HG2' ' HG3' ' A' ' 38' ' ' GLU . 14.8 tp60 58.38 43.56 19.64 Favored 'General case' 0 C--O 1.231 0.115 0 CA-C-N 114.021 -1.445 . . . . 0.0 112.377 169.651 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 57' ' ' PHE . . . . . 0.516 ' CD1' ' HB ' ' A' ' 55' ' ' VAL . 3.7 p90 -111.44 168.92 9.16 Favored 'General case' 0 C--N 1.323 -0.546 0 C-N-CA 120.181 -0.608 . . . . 0.0 110.888 174.829 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.608 ' HA ' ' HA ' ' A' ' 51' ' ' TYR . 7.7 p-10 -78.07 153.77 31.96 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 122.014 0.912 . . . . 0.0 112.38 -165.514 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.697 ' HB2' ' CE1' ' A' ' 52' ' ' TYR . 4.9 tp-100 -63.77 -30.69 71.75 Favored 'General case' 0 N--CA 1.444 -0.737 0 CA-C-N 113.827 -1.533 . . . . 0.0 111.098 -179.804 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -62.96 -50.29 64.88 Favored Glycine 0 C--N 1.314 -0.689 0 C-N-CA 120.743 -0.741 . . . . 0.0 111.676 178.195 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 99.4 m -65.85 -41.86 91.17 Favored 'General case' 0 C--N 1.321 -0.674 0 C-N-CA 122.707 0.403 . . . . 0.0 111.065 175.697 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 62' ' ' TRP . . . . . 0.522 ' CH2' ' HA ' ' A' ' 74' ' ' ALA . 50.0 t-105 -56.33 -48.74 76.14 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-O 121.617 0.722 . . . . 0.0 109.546 177.487 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . 0.538 ' HA ' ' CD1' ' A' ' 68' ' ' LEU . 55.7 tt0 -67.76 -34.78 77.49 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 114.901 -1.045 . . . . 0.0 110.712 -179.76 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -62.66 -41.09 98.88 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.773 -179.398 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . 0.655 ' OD1' ' HB ' ' A' ' 89' ' ' THR . 7.9 m120 -79.96 -11.16 59.81 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.536 177.9 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . 0.562 ' O ' ' HG2' ' A' ' 69' ' ' ARG . . . 84.03 49.0 4.93 Favored Glycine 0 N--CA 1.448 -0.528 0 CA-C-N 115.47 -0.786 . . . . 0.0 112.105 178.485 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.604 ' HA2' ' HD2' ' A' ' 70' ' ' TYR . . . -80.17 -18.93 70.7 Favored Glycine 0 N--CA 1.439 -1.124 0 C-N-CA 121.104 -0.57 . . . . 0.0 112.725 -176.214 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.696 ' HG ' ' HA ' ' A' ' 72' ' ' PRO . 6.4 mp -62.31 -23.1 66.55 Favored 'General case' 0 N--CA 1.45 -0.425 0 N-CA-C 112.035 0.383 . . . . 0.0 112.035 -172.578 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . 0.562 ' HG2' ' O ' ' A' ' 66' ' ' GLY . 13.9 ptp180 -68.69 -32.19 71.83 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-O 121.259 0.552 . . . . 0.0 110.118 176.84 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 70' ' ' TYR . . . . . 0.653 ' HB3' ' HB3' ' A' ' 81' ' ' GLU . 67.7 m-85 -82.18 -33.99 29.22 Favored 'General case' 0 N--CA 1.442 -0.834 0 N-CA-C 107.436 -1.32 . . . . 0.0 107.436 178.443 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 71' ' ' ALA . . . . . 0.546 ' HB3' ' HB2' ' A' ' 77' ' ' ALA . . . 169.14 122.86 0.04 OUTLIER Pre-proline 0 N--CA 1.447 -0.61 0 CA-C-N 112.654 -2.066 . . . . 0.0 107.445 -178.423 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 72' ' ' PRO . . . . . 0.696 ' HA ' ' HG ' ' A' ' 68' ' ' LEU . 20.9 Cg_exo -55.28 -7.02 0.98 Allowed 'Trans proline' 0 CA--C 1.527 0.138 0 C-N-CA 122.807 2.338 . . . . 0.0 113.76 -178.81 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 73' ' ' ARG . . . . . 0.437 ' HE ' ' CG ' ' A' ' 75' ' ' ASP . 12.1 ptm180 -145.39 137.98 25.96 Favored 'General case' 0 C--N 1.318 -0.772 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 177.491 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . 0.522 ' HA ' ' CH2' ' A' ' 62' ' ' TRP . . . -55.76 -35.43 66.19 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 114.802 -1.09 . . . . 0.0 112.248 -176.005 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . 0.673 ' HA ' ' O ' ' A' ' 43' ' ' TRP . 14.9 p-10 -80.95 -7.35 59.49 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 121.092 0.472 . . . . 0.0 111.531 -173.782 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.517 ' HB3' ' HB1' ' A' ' 71' ' ' ALA . 60.2 tp -87.7 -33.06 18.87 Favored 'General case' 0 C--N 1.318 -0.773 0 N-CA-C 108.688 -0.856 . . . . 0.0 108.688 171.776 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . 0.943 ' HB1' ' HB2' ' A' ' 81' ' ' GLU . . . -79.29 153.37 29.92 Favored 'General case' 0 N--CA 1.446 -0.659 0 CA-C-N 115.01 -0.995 . . . . 0.0 111.012 176.444 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 22.8 p -101.16 -170.3 1.82 Allowed 'General case' 0 C--N 1.315 -0.929 0 CA-C-N 115.77 -0.65 . . . . 0.0 109.517 179.131 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . 0.876 ' HA ' ' CZ3' ' A' ' 43' ' ' TRP . 53.1 mtp180 -50.67 -48.66 58.35 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.903 0.382 . . . . 0.0 111.341 -176.808 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 80' ' ' GLU . . . . . . . . . . . . . 7.3 pt-20 -57.88 -49.29 77.21 Favored 'General case' 0 C--N 1.319 -0.75 0 CA-C-N 115.391 -0.822 . . . . 0.0 112.432 -175.517 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 81' ' ' GLU . . . . . 0.943 ' HB2' ' HB1' ' A' ' 77' ' ' ALA . 26.1 mp0 -66.29 -50.46 63.58 Favored 'General case' 0 CA--C 1.52 -0.208 0 O-C-N 122.06 -0.4 . . . . 0.0 111.559 178.0 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 82' ' ' GLN . . . . . 0.68 ' HB2' ' HZ3' ' A' ' 43' ' ' TRP . 52.0 mt-30 -62.44 -33.67 75.27 Favored 'General case' 0 CA--C 1.513 -0.448 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.003 -174.576 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.643 ' O ' ' HG2' ' A' ' 87' ' ' GLU . 27.2 mt -60.53 -49.11 85.67 Favored 'Isoleucine or valine' 0 C--O 1.216 -0.663 0 N-CA-C 109.188 -0.671 . . . . 0.0 109.188 174.986 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . 0.598 ' O ' ' HB2' ' A' ' 87' ' ' GLU . . . -57.12 -47.68 80.51 Favored 'General case' 0 C--O 1.239 0.53 0 CA-C-O 121.522 0.677 . . . . 0.0 111.821 -178.281 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.431 HG13 ' HB2' ' A' ' 65' ' ' ASN . 45.7 t -65.97 -48.82 80.48 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.587 0 CA-C-N 115.827 -0.624 . . . . 0.0 111.284 -179.458 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . 0.42 ' HB1' ' CH2' ' A' ' 31' ' ' TRP . . . -59.21 -30.31 68.14 Favored 'General case' 0 N--CA 1.45 -0.468 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.439 175.572 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 87' ' ' GLU . . . . . 0.643 ' HG2' ' O ' ' A' ' 83' ' ' ILE . 21.1 mm-40 -59.58 -43.97 93.48 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.957 -179.111 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.632 ' O ' ' HG ' ' A' ' 91' ' ' LEU . 94.2 t -64.9 -50.98 72.52 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 C-N-CA 120.56 -0.456 . . . . 0.0 110.915 179.289 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 89' ' ' THR . . . . . 0.655 ' HB ' ' OD1' ' A' ' 65' ' ' ASN . 14.7 t -72.8 -34.89 67.2 Favored 'General case' 0 C--N 1.317 -0.843 0 C-N-CA 120.495 -0.482 . . . . 0.0 111.499 -173.599 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . 0.623 ' HG3' ' N ' ' A' ' 91' ' ' LEU . 4.3 ptt180 -60.45 -39.31 87.08 Favored 'General case' 0 N--CA 1.466 0.338 0 O-C-N 122.291 -0.256 . . . . 0.0 110.978 -178.267 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . 0.632 ' HG ' ' O ' ' A' ' 88' ' ' VAL . 4.5 pp -72.72 -23.91 60.91 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 115.956 -0.566 . . . . 0.0 111.479 -173.28 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . 0.559 ' HG3' ' O ' ' A' ' 88' ' ' VAL . 10.8 mtm180 -79.28 -48.17 14.61 Favored 'General case' 0 CA--C 1.509 -0.61 0 CA-C-O 121.803 0.811 . . . . 0.0 109.456 -176.882 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 93' ' ' GLN . . . . . 0.501 ' OE1' ' HB2' ' A' ' 97' ' ' ALA . 14.8 pt20 -97.37 -28.38 14.05 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 114.413 -1.267 . . . . 0.0 113.149 -169.773 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 96.89 39.92 3.96 Favored Glycine 0 CA--C 1.503 -0.682 0 C-N-CA 120.215 -0.993 . . . . 0.0 111.119 172.892 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 95' ' ' TRP . . . . . 0.517 ' HA ' ' HE3' ' A' ' 98' ' ' TRP . 12.3 m95 68.11 9.3 7.1 Favored 'General case' 0 C--O 1.218 -0.592 0 N-CA-C 108.953 -0.758 . . . . 0.0 108.953 -178.151 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -62.39 -32.13 81.86 Favored Glycine 0 C--N 1.334 0.451 0 CA-C-N 115.592 -0.731 . . . . 0.0 113.14 -177.814 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . 0.501 ' HB2' ' OE1' ' A' ' 93' ' ' GLN . . . -64.45 -24.26 67.56 Favored 'General case' 0 CA--C 1.514 -0.406 0 CA-C-O 120.902 0.382 . . . . 0.0 110.073 176.312 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 98' ' ' TRP . . . . . 0.581 ' HB2' ' HB2' ' A' ' 102' ' ' ALA . 19.6 m-90 -108.63 105.07 56.25 Favored Pre-proline 0 C--N 1.324 -0.522 0 CA-C-N 115.829 -0.623 . . . . 0.0 109.976 178.893 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 99' ' ' PRO . . . . . 0.439 ' HB2' ' H ' ' A' ' 100' ' ' VAL . 19.1 Cg_exo -72.14 -94.08 0.01 OUTLIER 'Trans proline' 0 CA--C 1.536 0.604 0 C-N-CA 122.888 2.392 . . . . 0.0 113.851 -175.59 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . 0.439 ' H ' ' HB2' ' A' ' 99' ' ' PRO . 46.5 t -71.44 -26.78 27.1 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.176 0 CA-C-O 121.637 0.732 . . . . 0.0 110.324 -174.799 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 101' ' ' CYS . . . . . 0.446 ' SG ' ' HB2' ' A' ' 38' ' ' GLU . 80.2 m -73.02 -37.48 66.91 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 115.217 -0.901 . . . . 0.0 111.742 -172.987 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 102' ' ' ALA . . . . . 0.581 ' HB2' ' HB2' ' A' ' 98' ' ' TRP . . . -69.7 -44.14 71.01 Favored 'General case' 0 C--N 1.327 -0.382 0 C-N-CA 120.811 -0.356 . . . . 0.0 110.267 179.258 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -61.27 -37.41 83.03 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 121.193 0.521 . . . . 0.0 110.92 179.715 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -72.11 -23.84 61.38 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.731 -0.668 . . . . 0.0 111.818 177.526 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 105' ' ' ALA . . . . . 0.48 ' HB1' ' HA ' ' A' ' 30' ' ' ILE . . . -95.63 -22.78 17.37 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 116.1 -0.5 . . . . 0.0 112.154 -174.619 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 121.55 58.47 0.22 Allowed Glycine 0 CA--C 1.521 0.437 0 C-N-CA 121.05 -0.595 . . . . 0.0 112.189 -176.765 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 107' ' ' ALA . . . . . . . . . . . . . . . -72.21 150.4 43.73 Favored 'General case' 0 C--N 1.327 -0.386 0 C-N-CA 122.871 0.469 . . . . 0.0 111.079 -176.494 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 108' ' ' ARG . . . . . 0.476 ' HB2' ' HE1' ' A' ' 95' ' ' TRP . 93.1 mtt180 . . . . . 0 C--O 1.25 1.09 0 CA-C-O 118.303 -0.855 . . . . 0.0 110.636 -174.644 . . . . . . . . 1 1 . 1 stop_ save_